



International  
Classification  
of Diseases  
for  
Mortality and  
Morbidity Statistics

---

Eleventh Revision

---



World Health  
Organization



## Copyright page

International Classification of Diseases, Eleventh Revision (ICD-11)

### © World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NoDerivatives 3.0 IGO license (CC BY-ND 3.0 IGO; <https://creativecommons.org/licenses/by-nd/3.0/igo/>).

Under the terms of this license, you may copy and redistribute the work, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. This license does not allow you to produce adaptations of the work (including translations) without permission from WHO.

Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

This PDF version of ICD-11 was generated to support the user preference for viewing ICD-11 in a portable format. The definitive version of ICD-11 is available from <https://icd.who.int/browse11/l-m/en>.

**Suggested citation.** International Classification of Diseases, Eleventh Revision (ICD-11). Geneva: World Health Organization; 2022. License: [CC BY-ND 3.0 IGO](https://creativecommons.org/licenses/by-nd/3.0/igo/).

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

## Correct use of ICD-11

Please refer to the reference guide for the correct use of ICD-11 (<https://iccdn.who.int/icd11referenceguide/en/html/index.html> ).

To prevent the dilution of ICD's purpose to provide a definitive standard for identifying health information, ICD-11 may not be used for the purpose of developing or promoting a different standard.

The use of ICD-11 in software products is subject to the following license: <https://icd.who.int/en/docs/ICD11-license.pdf>. Under the terms of this license, users may not:

- reproduce ICD-11 in part or whole and distribute it under a different name or without attribution;
- reproduce and distribute ICD-11 in part or whole without the ICD-11 codes;
- reproduce ICD-11 in part or whole without the ICD-11 URIs (not applicable for print publications).

Mappings or crosslinks between other classifications and terminologies and ICD-11 and/or translations are not covered by the ICD-11 license and are subject to a separate written agreement from WHO.

Adding data fields to ICD-11 concepts is permitted, provided such additions are clearly identified as additions that do not originate from WHO.

Suggestions for changes to ICD-11 should be submitted as a proposal to the ICD-11 maintenance platform (<https://icd.who.int/en>).

## TABLE OF CONTENTS

CHAPTER 01 .....	44
Certain infectious or parasitic diseases .....	44
Gastroenteritis or colitis of infectious origin (1A00-1A40.Z) .....	45
Bacterial intestinal infections (1A00-1A0Z) .....	45
Bacterial foodborne intoxications (1A10-1A1Z) .....	47
Viral intestinal infections (1A20-1A2Z) .....	48
Protozoal intestinal infections (1A30-1A3Z) .....	49
Predominantly sexually transmitted infections (1A60-1A9Z).....	51
Syphilis (1A60-1A6Z) .....	51
Gonococcal infection (1A70-1A7Z) .....	54
Sexually transmissible infections due to chlamydia (1A80-1A8Z) .....	55
Mycobacterial diseases (1B10-1B2Z).....	58
Tuberculosis (1B10-1B1Z) .....	58
Certain staphylococcal or streptococcal diseases (1B40-1B5Z).....	63
Acute rheumatic fever (1B40-1B42) .....	63
Pyogenic bacterial infections of the skin or subcutaneous tissues (1B70-1B7Z).....	66
Certain zoonotic bacterial diseases (1B90-1B9Z) .....	70
Other bacterial diseases (1C10-1C4Z).....	73
Other diseases due to chlamydiae (1C20-1C2Z).....	83
Rickettsioses (1C30-1C3Z).....	84
Human immunodeficiency virus disease (1C60-1C62.Z) .....	87
Viral infections of the central nervous system (1C80-1C8Z) .....	92
Non-viral and unspecified infections of the central nervous system (1D00-1D0Z).....	95
Dengue (1D20-1D2Z) .....	101
Certain arthropod-borne viral fevers (1D40-1D4Z) .....	101
Certain zoonotic viral diseases (1D60-1D6Z) .....	104
Certain other viral diseases (1D80-1E1Z).....	108
Viral infection of unspecified site (1D90-1D9Z).....	111
Influenza (1E30-1E32) .....	112
Viral hepatitis (1E50-1E5Z).....	113
Viral infections characterised by skin or mucous membrane lesions (1E70-1F0Z) .....	116
Infections due to poxvirus (1E70-1E7Z) .....	116
Human papillomavirus infection of skin or mucous membrane (1E80-1E8Z) .....	118

Varicella zoster virus infections (1E90-1E91.Z) .....	119
Mycoses (1F20-1F2Z) .....	124
Parasitic diseases (1F40-1G2Z) .....	137
Malaria (1F40-1F4Z) .....	137
Nonintestinal protozoal diseases (1F50-1F5Z).....	139
Helminthiases (1F60-1F9Z) .....	144
Diseases due to nematodes (1F60-1F6Z).....	144
Diseases due to cestodes (1F70-1F7Z).....	150
Diseases due to trematodes (1F80-1F8Z) .....	153
Infestations by ectoparasites (1G00-1G0Z) .....	156
Sepsis (1G40-1G41).....	159
Sequelae of infectious diseases (1G80-1G8Y) .....	161
CHAPTER 02 .....	162
Neoplasms.....	162
Neoplasms of brain or central nervous system (2A00-2A0Z) .....	162
Neoplasms of haematopoietic or lymphoid tissues (2A20-2B3Z) .....	165
Myeloproliferative neoplasms (2A20-2A2Z).....	165
Myelodysplastic syndromes (2A30-2A3Z).....	167
Myelodysplastic and myeloproliferative neoplasms (2A40-2A4Z) .....	168
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 (2A50-2A5Z) .....	169
Precursor lymphoid neoplasms (2A70-2A7Z) .....	172
Mature B-cell neoplasms (2A80-2A8Z) .....	173
Mature T-cell or NK-cell neoplasms (2A90-2B2Z).....	180
Mature T-cell or NK-cell lymphomas and lymphoproliferative disorders, primary cutaneous specified types (2B00-2B0Z) .....	182
Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues (2B50-2E2Z) .....	187
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues (2B50-2D3Z) .....	187
Malignant mesenchymal neoplasms (2B50-2B5Z) .....	187
Malignant neoplasms of lip, oral cavity or pharynx (2B60-2B6Y).....	192
Malignant neoplasms of digestive organs (2B70-2C1Z) .....	198
Malignant neoplasms of intestine (2B80-2C0Z) .....	200
Malignant neoplasms of large intestine (2B90-2B9Y) .....	201

Malignant neoplasms of middle ear, respiratory or intrathoracic organs (2C20-2C2Z).....	208
Malignant neoplasms of skin (2C30-2C3Z) .....	212
Malignant neoplasms of peripheral nerves or autonomic nervous system (2C40-2C4Z) .....	215
Malignant neoplasms of retroperitoneum, peritoneum or omentum (2C50-2C5Z) .....	216
Malignant neoplasms of breast (2C60-2C6Z) .....	217
Malignant neoplasms of female genital organs (2C70-2C7Z).....	219
Malignant neoplasms of male genital organs (2C80-2C8Z) .....	224
Malignant neoplasms of urinary tract (2C90-2C9Z).....	226
Malignant neoplasms of eye or ocular adnexa (2D00-2D0Z) .....	228
Malignant neoplasms of endocrine glands (2D10-2D1Z) .....	231
Malignant neoplasms of ill-defined or unspecified primary sites (2D40-2D4Z) .....	233
Malignant neoplasm metastases (2D50-2E2Z) .....	234
Malignant neoplasm metastasis in lymph nodes (2D60-2D6Z) .....	234
Malignant neoplasm metastasis in thoracic or respiratory organs (2D70-2D7Z).....	235
Malignant neoplasm metastasis in digestive system (2D80-2D8Z) .....	235
Malignant neoplasm metastasis in retroperitoneum or peritoneum (2D90-2D91).....	236
Malignant neoplasm metastasis in other sites (2E00-2E0Y).....	236
In situ neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues (2E60-2E6Z).....	237
Benign neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues (2E80-2F5Z) .....	242
Benign mesenchymal neoplasms (2E80-2E8Z) .....	242
Benign non-mesenchymal neoplasms (2E90-2F3Z) .....	247
Benign neoplasm of respiratory or intrathoracic organs (2F00-2F0Z) .....	249
Benign cutaneous neoplasms (2F20-2F2Z) .....	250
Neoplasms of uncertain behaviour, except of lymphoid, haematopoietic, central nervous system or related tissues (2F70-2F7Z) .....	256
Neoplasms of unknown behaviour, except of lymphoid, haematopoietic, central nervous system or related tissues (2F90-2F9Z) .....	258
CHAPTER 03 .....	259
Diseases of the blood or blood-forming organs .....	259
Anaemias or other erythrocyte disorders (3A00-3A9Z) .....	260
Nutritional or metabolic anaemias (3A00-3A03.Y).....	260
Haemolytic anaemias (3A10-3A4Z).....	264
Congenital haemolytic anaemia (3A10-3A1Y) .....	264

Acquired haemolytic anaemia (3A20-3A2Z) .....	265
Pure red cell aplasia (3A60-3A6Z).....	271
Polycythaemia (3A80-3A8Z).....	275
Coagulation defects, purpura or other haemorrhagic or related conditions (3B10-3B6Z) .....	277
Coagulation defects (3B10-3B4Z) .....	277
Congenital or constitutional haemorrhagic condition (3B10-3B1Z).....	277
Haemorrhagic diseases due to acquired coagulation factor defects (3B20-3B2Y) .....	279
Fibrinolytic defects (3B50-3B51).....	280
Diseases of spleen (3B80-3B8Z).....	286
CHAPTER 04 .....	290
Diseases of the immune system .....	290
Primary immunodeficiencies (4A00-4A0Z) .....	290
Nonorgan specific systemic autoimmune disorders (4A40-4A4Z) .....	294
Autoinflammatory disorders (4A60-4A6Z) .....	303
Allergic or hypersensitivity conditions (4A80-4A8Z).....	305
Immune system disorders involving white cell lineages (4B00-4B0Z).....	312
Certain disorders involving the immune system (4B20-4B2Y) .....	314
CHAPTER 05 .....	317
Endocrine, nutritional or metabolic diseases .....	317
Endocrine diseases (5A00-5B3Z).....	317
Disorders of the thyroid gland or thyroid hormones system (5A00-5A0Z) .....	317
Diabetes mellitus (5A10-5A2Y) .....	322
Acute complications of diabetes mellitus (5A20-5A2Y).....	324
Other disorders of glucose regulation or pancreatic internal secretion (5A40-5A4Z) .....	326
Disorders of the parathyroids or parathyroid hormone system (5A50-5A5Z) .....	327
Disorders of the pituitary hormone system (5A60-5A6Z) .....	329
Disorders of the adrenal glands or adrenal hormone system (5A70-5A7Z).....	332
Disorders of the gonadal hormone system (5A80-5A8Z) .....	335
Certain disorders of puberty (5A90-5A9Z).....	337
Polyglandular dysfunction (5B00-5B0Z).....	338
Endocrine disorders, not elsewhere classified (5B10-5B1Y) .....	338
Nutritional disorders (5B50-5C3Z).....	339
Undernutrition (5B50-5B7Z) .....	339
Sequelae of malnutrition or certain specified nutritional deficiencies (5B60-5B6Z) .....	350

Overweight, obesity or specific nutrient excesses (5B80-5C1Z).....	351
Overweight or obesity (5B80-5B81.Z).....	351
Certain specified nutrient excesses (5B90-5B9Z) .....	353
Metabolic disorders (5C50-5D2Z).....	356
Inborn errors of metabolism (5C50-5C5Z).....	356
Disorders of metabolite absorption or transport (5C60-5C6Z) .....	373
Disorders of fluid, electrolyte or acid-base balance (5C70-5C7Z) .....	379
Disorders of lipoprotein metabolism or certain specified lipidaemias (5C80-5C8Z).....	381
Other metabolic disorders (5D00-5D0Y) .....	384
Postprocedural endocrine or metabolic disorders (5D40-5D46) .....	386
CHAPTER 06 .....	388
Mental, behavioural or neurodevelopmental disorders .....	388
Neurodevelopmental disorders (6A00-6A0Z).....	389
Schizophrenia or other primary psychotic disorders (6A20-6A2Z).....	400
Catatonia (6A40-6A4Z).....	409
Mood disorders (6A60-6A8Z).....	411
Bipolar or related disorders (6A60-6A6Z) .....	411
Depressive disorders (6A70-6A7Z).....	420
Anxiety or fear-related disorders (6B00-6B0Z).....	429
Obsessive-compulsive or related disorders (6B20-6B2Z) .....	432
Disorders specifically associated with stress (6B40-6B4Z) .....	437
Dissociative disorders (6B60-6B6Z) .....	440
Feeding or eating disorders (6B80-6B8Z) .....	446
Elimination disorders (6C00-6C0Z) .....	450
Disorders of bodily distress or bodily experience (6C20-6C2Z).....	452
Disorders due to substance use or addictive behaviours (6C40-6C5Z) .....	454
Disorders due to substance use (6C40-6C4Z) .....	454
Disorders due to addictive behaviours (6C50-6C5Z) .....	555
Impulse control disorders (6C70-6C7Z) .....	558
Disruptive behaviour or dissociative disorders (6C90-6C9Z).....	560
Personality disorders and related traits (6D10-6D11.5).....	563
Paraphilic disorders (6D30-6D3Z) .....	566
Factitious disorders (6D50-6D5Z) .....	568
Neurocognitive disorders (6D70-6E0Z).....	569

Dementia (6D80-6D8Z) .....	574
Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium (6E20-6E2Z) .....	584
Secondary mental or behavioural syndromes associated with disorders or diseases classified elsewhere (6E60-6E6Z) .....	587
CHAPTER 07 .....	595
Sleep-wake disorders .....	595
Insomnia disorders (7A00-7A0Z) .....	596
Hypersomnolence disorders (7A20-7A2Z) .....	597
Sleep-related breathing disorders (7A40-7A4Z) .....	600
Circadian rhythm sleep-wake disorders (7A60-7A6Z) .....	606
Sleep-related movement disorders (7A80-7A8Z) .....	608
Parasomnia disorders (7B00-7B0Z) .....	610
CHAPTER 08 .....	614
Diseases of the nervous system .....	614
Movement disorders (8A00-8A0Z) .....	615
Disorders with neurocognitive impairment as a major feature (8A20-8A2Z) .....	626
Multiple sclerosis or other white matter disorders (8A40-8A4Z) .....	627
Epilepsy or seizures (8A60-8A6Z) .....	634
Headache disorders (8A80-8A8Z) .....	642
Cerebrovascular diseases (8B00-8B2Z) .....	645
Intracranial haemorrhage (8B00-8B0Z) .....	645
Cerebral ischaemia (8B10-8B1Z) .....	647
Spinal cord disorders excluding trauma (8B40-8B4Z) .....	656
Motor neuron diseases or related disorders (8B60-8B6Z) .....	658
Disorders of nerve root, plexus or peripheral nerves (8B80-8C4Z) .....	661
Disorders of cranial nerves (8B80-8B8Z) .....	661
Nerve root or plexus disorders (8B90-8B9Z) .....	663
Polyneuropathy (8C00-8C0Z) .....	664
Mononeuropathy (8C10-8C1Z) .....	666
Hereditary neuropathy (8C20-8C2Z) .....	668
Diseases of neuromuscular junction or muscle (8C60-8D0Z) .....	670
Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z) .....	670
Primary disorders of muscles (8C70-8C7Z) .....	671

Secondary myopathies (8C80-8C8Z).....	678
Cerebral palsy (8D20-8D2Z).....	680
Nutritional or toxic disorders of the nervous system (8D40-8D4Z).....	682
Disorders of cerebrospinal fluid pressure or flow (8D60-8D6Z).....	685
Disorders of autonomic nervous system (8D80-8D8Z).....	688
Human prion diseases (8E00-8E0Z) .....	691
Disorders of consciousness (8E20-8E2Z) .....	692
Other disorders of the nervous system (8E40-8E4Y).....	693
Postprocedural disorders of the nervous system (8E60-8E66) .....	698
CHAPTER 09 .....	700
Diseases of the visual system.....	700
Disorders of the ocular adnexa or orbit (9A00-9A4Z).....	701
Disorders of eyelid or peri-ocular area (9A00-9A0Z).....	701
Disorders of lacrimal apparatus (9A10-9A1Z).....	707
Disorders of orbit (9A20-9A2Z).....	708
Disorders of the eyeball - anterior segment (9A60-9B3Z).....	711
Disorders of conjunctiva (9A60-9A6Z) .....	711
Disorders of the cornea (9A70-9A7Z) .....	714
Disorders of the anterior chamber (9A80-9A8Z) .....	717
Disorders of the anterior uvea (9A90-9A9Z).....	717
Functional disorders of the pupil (9B00-9B0Z) .....	719
Disorders of lens (9B10-9B1Z) .....	720
Disorders of the eyeball - posterior segment (9B50-9C0Z) .....	722
Disorders of sclera (9B50-9B5Z).....	722
Disorders of the choroid (9B60-9B6Z) .....	723
Disorders of the retina (9B70-9B7Z) .....	724
Disorders of the vitreous body (9B80-9B8Z) .....	731
Disorders of the eyeball affecting both anterior and posterior segments (9C20-9C2Z) .....	731
Disorders of the visual pathways or centres (9C40-9C4Z).....	732
Glaucoma or glaucoma suspect (9C60-9C6Z) .....	734
Strabismus or ocular motility disorders (9C80-9C8Z).....	739
Disorders of refraction or accommodation (9D00-9D0Z).....	744
Postprocedural disorders of eye or ocular adnexa (9D20-9D25) .....	745
Impairment of visual functions (9D41-9D7Z).....	746

Subjective visual experiences (9D50-9D5Z).....	748
Vision impairment (9D90-9D9Z) .....	749
CHAPTER 10 .....	752
Diseases of the ear or mastoid process .....	752
Diseases of external ear (AA00-AA6Z).....	753
Infectious diseases of external ear (AA00-AA0Z).....	753
Otitis externa (AA10-AA3Z).....	754
Noninfectious inflammation of external ear (AA10-AA1Z).....	754
Noninflammatory disorders of the external ear (AA40-AA4Z) .....	755
Diseases of middle ear or mastoid (AA80-AB1Z).....	756
Otitis media (AA80-AB0Z) .....	756
Nonsuppurative otitis media (AA80-AA8Z).....	756
Suppurative otitis media (AA90-AA9Z) .....	756
Diseases of inner ear (AB30-AB3Z) .....	760
Disorders with hearing impairment (AB50-AB5Z) .....	764
Disorders of ear, not elsewhere classified (AB70-AB7Y) .....	765
Postprocedural disorders of ear or mastoid process (AB90-AB93).....	766
CHAPTER 11 .....	767
Diseases of the circulatory system.....	767
Hypertensive diseases (BA00-BA04.Z) .....	768
Hypotension (BA20-BA2Z) .....	770
Ischaemic heart diseases (BA40-BA6Z).....	770
Acute ischaemic heart disease (BA40-BA4Z) .....	770
Chronic ischaemic heart disease (BA50-BA5Z) .....	772
Diseases of coronary artery (BA81-BA8Z).....	775
Pulmonary heart disease or diseases of pulmonary circulation (BB00-BB0Z).....	776
Pericarditis (BB20-BB2Z) .....	779
Acute or subacute endocarditis (BB40-BB4Z).....	780
Heart valve diseases (BB60-BC0Z) .....	781
Mitral valve disease (BB60-BB6Z) .....	781
Aortic valve disease (BB70-BB7Z) .....	783
Tricuspid valve disease (BB80-BB8Z) .....	784
Pulmonary valve disease (BB90-BB9Z) .....	785
Diseases of the myocardium or cardiac chambers (BC40-BC4Z).....	789

Cardiac arrhythmia (BC60-BC9Z) .....	794
Ventricular rhythm disturbance (BC70-BC7Z) .....	797
Supraventricular rhythm disturbance (BC80-BC8Z).....	798
Heart failure (BD10-BD1Z) .....	802
Diseases of arteries or arterioles (BD30-BD5Z) .....	803
Chronic arterial occlusive disease (BD40-BD4Z) .....	804
Diseases of veins (BD70-BD7Z) .....	810
Disorders of lymphatic vessels or lymph nodes (BD90-BD9Z).....	815
Postprocedural disorders of circulatory system (BE10-BE1F.1) .....	818
CHAPTER 12 .....	823
Diseases of the respiratory system .....	823
Upper respiratory tract disorders (CA00-CA0Z).....	824
Certain lower respiratory tract diseases (CA20-CA2Z) .....	834
Lung infections (CA40-CA4Z) .....	841
Lung diseases due to external agents (CA60-CA8Z).....	848
Pneumonitis (CA70-CA7Z).....	850
Respiratory diseases principally affecting the lung interstitium (CB00-CB0Z) .....	854
Pleural, diaphragm or mediastinal disorders (CB20-CB2Z).....	860
Postprocedural disorders of the respiratory system (CB60-CB64).....	866
CHAPTER 13 .....	867
Diseases of the digestive system .....	867
Diseases or disorders of orofacial complex (DA00-DA0Z) .....	868
Diseases of oesophagus (DA20-DA2Z).....	885
Diseases of the stomach or the duodenum (DA40-DA7Z).....	893
Diseases of stomach (DA40-DA4Z) .....	893
Diseases of duodenum (DA50-DA5Z).....	898
Ulcer of stomach or duodenum (DA60-DA63.Z).....	902
Diseases of small intestine (DA90-DA9Z).....	906
Diseases of appendix (DB10-DB1Z).....	914
Diseases of large intestine (DB30-DB3Z) .....	916
Diseases of anal canal (DB50-DB7Z) .....	923
Acquired anatomical alterations of the anal canal (DB50-DB5Z) .....	923
Haemorrhoids or perianal venous conditions (DB60-DB6Z).....	925
Diseases of liver (DB90-DB9Z).....	928

Diseases of gallbladder or biliary tract (DC10-DC1Z).....	940
Diseases of pancreas (DC30-DC3Z) .....	943
Diseases of peritoneum (DC50-DC5Z) .....	946
Diverticular disease of intestine (DC70-DD1Z) .....	948
Diverticular disease of small intestine (DC70-DC72.Z) .....	948
Diverticular disease of large intestine (DC80-DC82.Z).....	949
Diverticular disease of intestine of overlapping sites (DC90-DC90) .....	951
Diverticular disease of unspecified part of intestine (DD00-DD02.Z).....	951
Ischaemic vascular disorders of intestine (DD30-DD3Z).....	952
Hernias (DD50-DD5Z).....	953
Inflammatory bowel diseases (DD70-DD7Z).....	955
Functional gastrointestinal disorders (DD90-DD9Z) .....	957
Postprocedural disorders of digestive system (DE10-DE13) .....	962
<b>CHAPTER 14 .....</b>	<b>964</b>
Diseases of the skin.....	964
Certain skin disorders attributable to infection or infestation (EA00-EA6Y).....	965
Certain skin disorders attributable to viral infection (EA00-EA3Z) .....	965
Viral exanthems (EA00-EAOY) .....	965
Certain dermatoses with suspected viral aetiology (EA10-EA12) .....	966
Dermatoses from distant or systemic viral infection (EA20-EA20) .....	966
Certain skin disorders attributable to bacterial infection (EA40-EA5Z).....	967
Predominantly tropical or subtropical bacterial infections affecting skin (EA40-EA40).....	967
Inflammatory dermatoses (EA80-EB7Y) .....	970
Dermatitis and eczema (EA80-EA8Z) .....	970
Papulosquamous dermatoses (EA90-EA95) .....	976
Urticaria, angioedema and other urticarial disorders (EB00-EB0Y) .....	980
Inflammatory erythemas and other reactive inflammatory dermatoses (EB10-EB31).....	982
Neutrophilic dermatoses (EB20-EB2Y).....	984
Immunobullous diseases of the skin (EB40-EB4Y) .....	985
Cutaneous lupus erythematosus (EB50-EB5Z).....	988
Scarring or sclerosing inflammatory dermatoses (EB60-EB61.Z) .....	989
Metabolic and nutritional disorders affecting the skin (EB90-EB9Y) .....	990
Genetic and developmental disorders affecting the skin (EC10-EC7Y) .....	994
Genetic syndromes affecting the skin (EC10-EC1Y).....	994

Genetically-determined epidermolysis bullosa (EC30-EC3Z).....	998
Genetic disorders affecting dermal collagen, elastin or other matrix proteins (EC40-EC4Y).....	999
Specified developmental anomalies affecting the skin (EC50-EC5Y) .....	1000
Sensory and psychological disorders affecting the skin (EC90-ED3Y) .....	1000
Disturbances of cutaneous sensation (EC90-EC9Y) .....	1000
Mental conditions affecting the skin (ED00-ED2Y).....	1003
Self-inflicted skin disorders (ED00-ED0Y) .....	1003
Neurological conditions affecting the skin (ED30-ED3Y) .....	1004
Skin disorders involving specific cutaneous structures (ED50-EG02).....	1005
Disorders of the epidermis and epidermal appendages (ED50-EE21).....	1005
Disorders of epidermal keratinisation (ED50-ED5Y).....	1005
Disorders of skin colour (ED60-ED6Y) .....	1007
Disorders of hair (ED70-ED7Y) .....	1010
Disorders of the hair follicle (ED80-ED9Y) .....	1014
Acne and related disorders (ED80-ED81.Y) .....	1014
Disorders of eccrine sweat glands or sweating (EE00-EEOY) .....	1018
Disorders of the nail or perionychium (EE10-EE1Z).....	1019
Disorders of epidermal integrity (EE20-EE21) .....	1022
Disorders of the dermis and subcutis (EE40-EFOY).....	1023
Disorders of cutaneous connective tissue (EE40-EE7Y).....	1023
Poikiloderma (EE50-EE50).....	1024
Fibromatoses and keloids (EE60-EE6Y).....	1025
Histiocytic-granulomatous disorders of the skin (EE80-EE8Y).....	1026
Benign dermal lymphocytic or lymphoplasmacytic infiltrations or proliferations (EE90-EE91) .....	1027
Disorders of subcutaneous fat (EF00-EFOY).....	1027
Disorders of cutaneous blood and lymphatic vessels (EF20-EG02).....	1029
Malformations involving cutaneous blood vessels (EF20-EF2Z).....	1029
Purpura or bruising (EF30-EF3Z) .....	1030
Dermatoses attributable to hyperviscosity or microvascular occlusion (EF50-EF5Y) .....	1031
Dermatoses resulting from vascular insufficiency (EF60-EF9Y).....	1031
Dermatoses due to venous disease (EF70-EF7Z) .....	1032
Functional vascular disorders of the skin (EG00-EG02) .....	1032
Skin disorders involving certain specific body regions (EG30-EG9Z).....	1033

Skin disorders involving the head and neck (EG30-EG4Z) .....	1033
Disorders of the external ear involving the skin (EG40-EG4Z).....	1034
Inflammatory disorders of the external ear (EG40-EG4Z).....	1034
Skin disorders involving the genital and perianal regions (EG60-EG7Y).....	1034
Dermatoses of the anus, perianal area or perineum (EG60-EG63.Z) .....	1034
Skin disorders associated with pregnancy, the neonatal period and infancy (EH10-EH40.Z).....	1036
Skin disorders specific to the perinatal or neonatal period (EH10-EH3Y) .....	1036
Neonatal skin infection (EH10-EH1Z).....	1036
Adverse cutaneous reactions to medication (EH60-EH7Z).....	1038
Drug eruptions (EH60-EH6Z).....	1038
Skin disorders provoked by external factors (EH90-EK5Y) .....	1043
Dermatoses provoked or exacerbated by exposure to cold (EJ0Y-EJ0Y).....	1046
Dermatoses provoked by heat or electricity (EJ10-EJ1Y) .....	1046
Dermatoses provoked by light or UV radiation (EJ20-EJ6Y) .....	1047
Chronic effects of ultraviolet radiation on the skin (EJ20-EJ2Y) .....	1047
Acute effects of ultraviolet radiation on normal skin (EJ40-EJ4Z).....	1048
Dermatoses due to ionizing radiation (EJ71-EJ7Z).....	1049
Phototoxic reactions to skin contact with photoactive agents (EK20-EK2Z) .....	1054
Benign proliferations, neoplasms and cysts of the skin (EK70-EK71.Z).....	1055
Disorders of the skin of uncertain or unpredictable malignant potential (EK90-EK92) .....	1057
Cutaneous markers of internal disorders (EL10-EL3Y) .....	1059
Cutaneous markers of internal malignancy (EL10-EL1Y) .....	1059
Postprocedural disorders of the skin (EL50-EL80) .....	1059
Adverse cutaneous effects of therapeutic ionizing irradiation (EL60-EL63).....	1060
Complications of cutaneous cosmetic procedures (EL73-EL73.6).....	1061
CHAPTER 15 .....	1063
Diseases of the musculoskeletal system or connective tissue .....	1063
Arthropathies (FA00-FA5Z) .....	1064
Osteoarthritis (FA00-FA0Z) .....	1064
Infection related arthropathies (FA10-FA1Z).....	1065
Inflammatory arthropathies (FA20-FA2Z).....	1067
Certain specified joint disorders or deformities of limbs (FA30-FA3Z).....	1072
Conditions associated with the spine (FA70-FB1Z).....	1077
Structural disorders of spine (FA70-FA7Z) .....	1077

Degenerative condition of spine (FA80-FA8Z).....	1079
Inflammation of spine (FA90-FA9Z).....	1081
Spondylopathies (FB00-FB0Z).....	1082
Soft tissue disorders (FB30-FB6Z).....	1083
Disorders of muscles (FB30-FB3Z) .....	1083
Disorders of synovium or tendon (FB40-FB4Z).....	1085
Miscellaneous specified soft tissue disorders (FB50-FB56.6).....	1087
Osteopathies or chondropathies (FB80-FB8Z).....	1091
CHAPTER 16 .....	1098
Diseases of the genitourinary system.....	1098
Diseases of the female genital system (GA00-GA6Z) .....	1099
Inflammatory disorders of the female genital tract (GA00-GA0Z) .....	1099
Noninflammatory disorders of female genital tract (GA12-GA1Z).....	1105
Abnormal uterine or vaginal bleeding (GA20-GA2Z) .....	1111
Dermatoses of female genitalia (GA40-GA4Y).....	1121
Diseases of the male genital system (GA80-GB0Z).....	1122
Dermatoses of male genitalia (GA80-GA81.Y).....	1122
Diseases of prostate (GA90-GA91.Z) .....	1123
Disorders of breast (GB20-GB2Z).....	1130
Diseases of the urinary system (GB40-GC2Z) .....	1132
Glomerular diseases (GB40-GB4Z).....	1132
Renal tubulo-interstitial diseases (GB50-GB5Z).....	1134
Kidney failure (GB60-GB6Z) .....	1137
Urolithiasis (GB70-GB7Z) .....	1139
Cystic or dysplastic kidney disease (GB80-GB8Z) .....	1141
Certain specified diseases of urinary system (GC00-GC0Y) .....	1146
Other conditions of the genitourinary system (GC40-GC51.Z).....	1152
Female pelvic floor dysfunction (GC40-GC4Z).....	1152
Postprocedural disorders of genitourinary system (GC70-GC7B) .....	1158
CHAPTER 17 .....	1160
Conditions related to sexual health .....	1160
Sexual dysfunctions (HA00-HA0Z) .....	1160
Sexual pain disorders (HA20-HA2Z) .....	1166
Gender incongruence (HA60-HA6Z) .....	1168

CHAPTER 18 .....	1170
Pregnancy, childbirth or the puerperium .....	1170
Abortive outcome of pregnancy (JA00-JA0Z) .....	1170
Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium (JA20-JA2Z).....	1176
Obstetric haemorrhage (JA40-JA4Z) .....	1179
Certain specified maternal disorders predominantly related to pregnancy (JA60-JA6Z).....	1182
Maternal care related to the fetus, amniotic cavity or possible delivery problems (JA80-JA8Z).1187	
Complications of labour or delivery (JB00-JB0Z) .....	1193
Delivery (JB20-JB2Z).....	1202
Complications predominantly related to the puerperium (JB40-JB4Z) .....	1204
Certain obstetric conditions, not elsewhere classified (JB60-JB6Z) .....	1208
CHAPTER 19 .....	1213
Certain conditions originating in the perinatal period .....	1213
Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery (KA00-KA0Z) .....	1214
Disorders of newborn related to length of gestation or fetal growth (KA20-KA2Z) .....	1224
Birth injury (KA40-KA4Z) .....	1230
Infections of the fetus or newborn (KA60-KA6Z).....	1236
Haemorrhagic or haematological disorders of fetus or newborn (KA80-KA8Z).....	1240
Neurological disorders specific to the perinatal or neonatal period (KB00-KB0Z).....	1247
Respiratory disorders specific to the perinatal or neonatal period (KB20-KB2Z).....	1249
Cardiovascular disorders present in the perinatal or neonatal period (KB40-KB4Z) .....	1255
Transitory endocrine or metabolic disorders specific to fetus or newborn (KB60-KB6Z) .....	1256
Digestive system disorders of fetus or newborn (KB80-KB8Z) .....	1260
Genitourinary system disorders specific to the perinatal or neonatal period (KC00-KC0Z) .....	1264
Disorders involving the integument of fetus or newborn (KC20-KC9Z) .....	1264
Skin disorders associated with prematurity (KC30-KC3Y) .....	1266
Iatrogenic injuries involving the skin of the neonate (KC50-KC7Y) .....	1267
Postnatal iatrogenic skin injury (KC50-KC5Z).....	1267
Disturbances of temperature regulation of newborn (KD10-KD1Z).....	1268
Certain disorders originating in the perinatal period (KD30-KD3Y).....	1268
CHAPTER 20 .....	1274
Developmental anomalies .....	1274

Structural developmental anomalies primarily affecting one body system (LA00-LD0Z) .....	1274
Structural developmental anomalies of the nervous system (LA00-LA0Z) .....	1274
Structural developmental anomalies of the eye, eyelid or lacrimal apparatus (LA10-LA1Z) ...	1281
Structural developmental anomalies of the ear (LA20-LA2Z) .....	1286
Structural developmental anomalies of the face, mouth or teeth (LA30-LA5Z) .....	1288
Clefts of lip, alveolus or palate (LA40-LA4Z) .....	1291
Structural developmental anomalies of the neck (LA60-LA6Z) .....	1293
Structural developmental anomalies of the respiratory system (LA70-LA7Z).....	1293
Structural developmental anomalies of the circulatory system (LA80-LA9Z) .....	1297
Structural developmental anomaly of heart or great vessels (LA80-LA8Z) .....	1297
Structural developmental anomalies of the diaphragm, abdominal wall or umbilical cord (LB00-LB0Z) .....	1319
Structural developmental anomalies of the digestive tract (LB10-LB1Z).....	1320
Structural developmental anomalies of the liver, biliary tract, pancreas or spleen (LB20-LB2Z) .....	1326
Structural developmental anomalies of the urinary system (LB30-LB3Z) .....	1328
Structural developmental anomalies of the female genital system (LB40-LB4Z).....	1332
Structural developmental anomalies of the male genital system (LB50-LB5Z) .....	1337
Structural developmental anomalies of the breast (LB60-LB6Z).....	1340
Structural developmental anomalies of the skeleton (LB70-LB9Z) .....	1340
Congenital deformities of fingers or toes (LB80-LB81.Z).....	1347
Structural developmental anomalies of the skin (LC00-LC7Z).....	1353
Developmental hamartomata of the epidermis and epidermal appendages (LC00-LC0Y) ..	1353
Developmental anomalies of skin pigmentation (LC10-LC1Y).....	1354
Hamartomata derived from dermal connective tissue (LC20-LC2Y) .....	1354
Developmental defects of hair or nails (LC30-LC31).....	1354
Developmental anomalies of cutaneous vasculature (LC50-LC5Z).....	1354
Congenital anomalies of skin development (LC60-LC60) .....	1355
Structural developmental anomalies of the adrenal glands (LC80-LC8Z) .....	1355
Multiple developmental anomalies or syndromes (LD20-LD2Z) .....	1356
Chromosomal anomalies, excluding gene mutations (LD40-LD7Z) .....	1380
Sex chromosome anomalies (LD50-LD5Z) .....	1390
CHAPTER 21 .....	1396
Symptoms, signs or clinical findings, not elsewhere classified.....	1396

Symptoms of blood, blood-forming organs, or the immune system (MA00-MA0Y) .....	1397
Symptoms, signs or clinical findings of blood, blood-forming organs, or the immune system (MA10-MA3Y) .....	1397
Clinical findings in blood, blood-forming organs, or the immune system (MA10-MA1Y).....	1397
Symptoms, signs or clinical findings of endocrine, nutritional or metabolic diseases (MA50-MA6Y)	
.....	1402
Results of function studies of the endocrine, nutritional or metabolic diseases (MA50-MA51)	
.....	1402
Symptoms, signs or clinical findings of speech or voice (MA80-MB0Y) .....	1403
Symptoms or signs involving speech or voice (MA80-MA8Y).....	1403
Mental or behavioural symptoms, signs or clinical findings (MB20-MB2Y).....	1405
Symptoms, signs or clinical findings of the nervous system (MB40-MB9Y).....	1423
Symptoms or signs involving the nervous system (MB40-MB6Y) .....	1423
Paralytic symptoms (MB50-MB5Z) .....	1429
Clinical findings in the nervous system (MB70-MB7Y).....	1432
Symptoms, signs or clinical findings of the visual system (MC10-MC2Y).....	1433
Symptoms or signs involving the visual system (MC10-MC1Y) .....	1433
Symptoms, signs or clinical findings of ear or mastoid process (MC40-MC6Y).....	1434
Symptoms or signs involving the ear or mastoid process (MC40-MC4Y).....	1434
Symptoms, signs or clinical findings of the circulatory system (MC80-MC9Y).....	1435
Symptoms or signs involving the circulatory system (MC80-MC8Y) .....	1435
Symptoms, signs or clinical findings of the respiratory system (MD10-MD6Y) .....	1438
Symptoms or signs involving the respiratory system (MD10-MD3Y) .....	1438
Haemorrhage from respiratory passages (MD20-MD2Z) .....	1440
Clinical findings in the respiratory system (MD40-MD4Y).....	1443
Symptoms, signs or clinical findings of the digestive system or abdomen (MD80-ME4Y).....	1444
Symptoms or signs involving the digestive system or abdomen (MD80-ME1Y) .....	1444
Symptoms related to the upper gastrointestinal tract (MD90-MD9Y).....	1446
Symptoms related to the lower gastrointestinal tract or abdomen (ME00-ME0Y) .....	1447
Clinical findings in the digestive system (ME20-ME2Y) .....	1450
Symptoms, signs or clinical findings involving the skin (ME60-ME6Y) .....	1454
Symptoms or signs involving the skin (ME60-ME6Y).....	1454
Symptoms, signs or clinical findings of the musculoskeletal system (ME80-MF1Y) .....	1460
Symptoms or signs of the musculoskeletal system (ME80-ME8Y) .....	1460
Clinical findings in the musculoskeletal system (ME90-ME9Y).....	1465

Symptoms, signs or clinical findings of the genitourinary system (MF30-MG0Y) .....	1467
Symptoms, signs or clinical findings involving the female genital system (MF30-MF3Y) .....	1467
Symptoms, signs or clinical findings involving the male genital system (MF40-MF4Y).....	1468
Symptoms, signs or clinical findings involving the urinary system (MF50-MF5Y).....	1469
Clinical findings in specimens from female genital organs (MF60-MF6Z).....	1473
Clinical findings in specimens from male genital organs (MF70-MF7Z) .....	1473
Clinical findings in specimens from the urinary system (MF80-MF8Z).....	1474
Clinical findings on examination of urine, without diagnosis (MF90-MF9Y) .....	1475
General symptoms, signs or clinical findings (MG20-MG9Y).....	1478
General symptoms (MG20-MG4Y) .....	1478
Pain (MG30-MG3Z) .....	1482
Finding of microorganism resistant to antimicrobial drugs (MG50-MG5Z) .....	1500
Clinical findings in specimens from other specified organs, systems and tissues (MG60-MG6Y)	
.....	1515
Abnormal results, not elsewhere classified (MG70-MG7Z).....	1515
III-defined and unknown causes of mortality (MH10-MH15).....	1516
CHAPTER 22 .....	1518
Injury, poisoning or certain other consequences of external causes .....	1518
Injuries to the head (NA00-NA0Z) .....	1519
Injuries to the neck (NA20-NA6Z) .....	1534
Injury of nerves or spinal cord at neck level (NA30-NA4Z).....	1537
Injury of spinal cord at neck level (NA30-NA3Z).....	1537
Injury of nerves at neck level (NA40-NA4Z).....	1537
Injuries to the thorax (NA80-NB3Z) .....	1540
Injury of nerves or spinal cord at thorax level (NA90-NB2Z).....	1543
Injury of spinal cord at thorax level (NA90-NA9Z) .....	1543
Injury of nerves at thorax level (NB00-NB0Y) .....	1543
Injuries to the abdomen, lower back, lumbar spine or pelvis (NB50-NB9Z) .....	1549
Injury of nerves or lumbar spinal cord at abdomen, lower back or pelvis level (NB60-NB7Z).1551	
Injury of spinal cord at abdomen, lower back or pelvis level (NB60-NB6Z) .....	1551
Injury of nerves at abdomen, lower back or pelvis level (NB70-NB7Z) .....	1552
Injuries to the shoulder or upper arm (NC10-NC1Z) .....	1562
Injuries to the elbow or forearm (NC30-NC3Z).....	1567
Injuries to the wrist or hand (NC50-NC5Z) .....	1572

Injuries to the hip or thigh (NC70-NC7Z) .....	1581
Injuries to the knee or lower leg (NC90-NC9Z).....	1587
Injuries to the ankle or foot (ND10-ND1Z).....	1594
Injuries involving multiple body regions (ND30-ND37) .....	1601
Injuries to unspecified part of trunk, limb or body region (ND50-ND5Z).....	1602
Effects of foreign body entering through natural orifice (ND70-ND7Z) .....	1604
Burns (ND90-NE2Z) .....	1607
Burns of external body surface, specified by site (ND90-ND9Z).....	1607
Burns of eye or internal organs (NE00-NE0Z).....	1610
Burns of multiple or unspecified body regions (NE10-NE11) .....	1611
Frostbite (NE40-NE4Z) .....	1611
Harmful effects of substances (NE60-NE6Z).....	1612
Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z) ....	1613
Other or unspecified effects of external causes (NF00-NF0Z).....	1618
CHAPTER 23 .....	1623
External causes of morbidity or mortality .....	1623
Unintentional causes (PA00-PB6Z) .....	1623
Unintentional transport injury event (PA00-PA5Z) .....	1623
Unintentional land transport road traffic injury event (PA00-PA0Z).....	1624
Unintentional land transport off-road nontraffic injury event (PA10-PA1Z).....	1625
Unintentional land transport injury event unknown whether road traffic or off-road nontraffic (PA20-PA2Z).....	1626
Unintentional railway transport injury event (PA30-PA3Z).....	1627
Unintentional water transport injury event (PA40-PA4Z) .....	1627
Unintentional fall (PA60-PA6Z) .....	1628
Unintentional contact with person, animal or plant (PA70-PA7Z) .....	1628
Unintentional exposure to object, not elsewhere classified (PA80-PA8Z).....	1629
Unintentional immersion, submersion or falling into water (PA90-PA9Z).....	1629
Unintentional threat to breathing (PB00-PB0Z) .....	1630
Unintentional exposure to thermal mechanism (PB10-PB1Z).....	1630
Unintentional exposure to or harmful effects of substances (PB20-PB36) .....	1631
Unintentional exposure to or harmful effects of drugs, medicaments or biological substances (PB20-PB29) .....	1631
Unintentional exposure to or harmful effects of substances chiefly nonmedicinal as to source (PB30-PB36) .....	1632

Unintentional exposure to other mechanism (PB50-PB5B) .....	1632
Intentional self-harm (PB80-PD3Z) .....	1633
Intentional self-harm by transport injury event (PB80-PC2Z) .....	1633
Intentional self-harm by water transport injury event (PB90-PB9Z).....	1633
Intentional self-harm by air or space transport injury event (PC00-PC0Z).....	1634
Intentional self-harm by fall or jump (PC30-PC3Z) .....	1634
Intentional self-harm by contact with person, animal or plant (PC40-PC4Z).....	1634
Intentional self-harm by exposure to object, not elsewhere classified (PC50-PC5Z).....	1635
Intentional self-harm by immersion, submersion or falling into water (PC60-PC6Z).....	1635
Intentional self-harm by threat to breathing (PC70-PC7Z).....	1636
Intentional self-harm by exposure to thermal mechanism (PC80-PC8Z) .....	1636
Intentional self-harm by exposure to or harmful effects of substances (PC90-PD05) .....	1637
Intentional self-harm by exposure to or harmful effects of drugs, medicaments or biological substances (PC90-PC99).....	1637
Intentional self-harm by exposure to or harmful effects of substances chiefly nonmedicinal as to source (PD00-PD05).....	1637
Intentional self-harm by exposure to other mechanism (PD20-PD29) .....	1638
Assault (PD50-PF2Z).....	1638
Assault by transport events (PD50-PD9Z).....	1638
Assault by water transport injury event (PD60-PD6Z).....	1639
Assault by air or space transport injury event (PD70-PD7Z) .....	1639
Assault by causing a fall or jump (PE00-PE0Z) .....	1639
Assault by contact with person, animal or plant (PE10-PE1Z).....	1640
Assault by exposure to object not elsewhere classified (PE20-PE4Z) .....	1640
Assault by being cut or pierced by sharp object (PE30-PE3Z) .....	1640
Assault by immersion, submersion or falling into water (PE50-PE5Z) .....	1641
Assault by threat to breathing (PE60-PE6Z).....	1641
Assault by exposure to thermal mechanism (PE70-PE7Z) .....	1641
Assault by exposure to or harmful effects of substances (PE80-PE95) .....	1642
Assault by exposure to or harmful effects of drugs, medicaments or biological substances (PE80-PE8Z).....	1642
Assault by exposure to or harmful effects of substances chiefly nonmedicinal as to source (PE90-PE95).....	1643
Assault by exposure to other mechanism (PF10-PF1B).....	1643
Undetermined intent (PF40-PH8Z) .....	1644

Transport injury event of undetermined intent (PF40-PG4Z) .....	1644
Land transport road traffic injury event of undetermined intent (PF40-PF4Z) .....	1644
Land transport off-road nontraffic injury event of undetermined intent (PF50-PF5Z) .....	1645
Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic (PF60-PF6Z) .....	1646
Railway transport injury event of undetermined intent (PF70-PF7Z) .....	1647
Water transport injury event of undetermined intent (PF80-PG1Z) .....	1647
Water transport injury event of undetermined intent with water vessel damaged, disabled or destroyed (PF80-PF8Z) .....	1647
Water transport injury event of undetermined intent with water vessel not damaged, disabled or destroyed (PF90-PF9Z) .....	1648
Air or space transport injury event of undetermined intent (PG20-PG2Z) .....	1648
Fall or jump with undetermined intent (PG50-PG5Z).....	1648
Contact with person, animal or plant with undetermined intent (PG60-PG6Z).....	1648
Contact with object, not elsewhere classified with undetermined intent (PG70-PH0Z) .....	1649
Struck by projectile from firearm of undetermined intent (PG70-PG7Z).....	1649
Cut or pierced by sharp object of undetermined intent (PG90-PG9Z).....	1649
Immersion, submersion or falling into water with undetermined intent (PH10-PH1Z) .....	1650
Threat to breathing with undetermined intent (PH20-PH2Z) .....	1650
Exposure to thermal mechanism with undetermined intent (PH30-PH3Z).....	1651
Exposure to or harmful effects of substances, undetermined intent (PH40-PH56).....	1651
Exposure to or harmful effects of undetermined intent of drugs, medicaments or biological substances (PH40-PH49).....	1651
Exposure to or harmful effects of undetermined intent of substances chiefly nonmedicinal as to source (PH50-PH56).....	1652
Exposure to other mechanism with undetermined intent (PH70-PH7B) .....	1652
Exposure to extreme forces of nature (PJ00-PJ0Z).....	1653
Maltreatment (PJ20-PJ2Z) .....	1654
Legal intervention (PJ40-PJ4Z) .....	1654
Armed conflict (PJ60-PK6Z).....	1655
Explosion of marine weapons during armed conflict (PJ60-PJ6Z) .....	1655
Attack on or destruction of aircraft during armed conflict (PJ70-PJ7Z) .....	1655
Other explosions or fragments during armed conflict (PJ80-PJ8Z) .....	1655
Fires, conflagrations or hot substances during armed conflict (PJ90-PJ9Z) .....	1656

Firearm discharge or other forms of conventional warfare during armed conflict (PK00-PK0Z) .....	1656
Use of nuclear weapons during armed conflict (PK10-PK1Z) .....	1656
Use of biological weapons during armed conflict (PK20-PK2Z).....	1656
Chemical weapons or other forms of unconventional warfare during armed conflict (PK30-PK3Z) .....	1656
Injury event occurring after cessation of armed conflict (PK40-PK4Z).....	1657
Causes of healthcare related harm or injury (PK80-PL14.Z).....	1657
Surgical or other medical procedures associated with injury or harm in diagnostic or therapeutic use (PK80-PK8Z).....	1657
Surgical or other medical devices, implants or grafts associated with injury or harm in therapeutic use (PK90-PK9C.4) .....	1673
Substances associated with injury or harm in therapeutic use (PL00-PL0Z) .....	1693
CHAPTER 24 .....	1703
Factors influencing health status or contact with health services .....	1703
Reasons for contact with the health services (QA00-QD3Z) .....	1703
Contact with health services for purposes of examination or investigation (QA00-QA0Z) ....	1703
Contact with health services for counselling (QA10-QA1Z).....	1710
Contact with health services for reasons associated with reproduction (QA20-QA4Z) .....	1712
Contact with health services for procreative management (QA30-QA3Z).....	1712
Health care related circumstances influencing the episode of care without injury or harm (QA50-QB0Z) .....	1721
Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z) .....	1721
Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z) .....	1722
Circumstances associated with exposure to a drug, medicament or biological substance influencing the episode of care without injury or harm (QA70-QA7Z) .....	1723
Circumstances associated with other aspects of care influencing the episode of care without injury or harm (QA80-QA8Z).....	1725
Factors related to medical facilities and other health care (QB10-QB1Z).....	1727
Donors of organs or tissues (QB20-QB2Z) .....	1728
Fitting, adjustment or management of devices (QB30-QB3Z) .....	1728
Dependence on enabling machines or devices (QB40-QB4Z) .....	1730
Presence of device, implants or grafts (QB50-QB5Z) .....	1731
Surgical or postsurgical states (QB60-QB6Z) .....	1732

Convalescence (QB70-QB7Z) .....	1734
Contact with health services for specific surgical interventions (QB80-QB8Z) .....	1734
Contact with health services for nonsurgical interventions not involving devices (QB90-QB9Z) .....	1735
Contact with health services related to immunizations or certain other prophylactic measures (QC00-QC0Z) .....	1738
Interventions not carried out (QC10-QC1Z) .....	1740
Contact with health services associated with the health of others (QC20-QC2Z) .....	1740
Personal or family history or late effect of prior health problems (QC40-QC8Z).....	1741
Personal history of health problems (QC40-QC4Z) .....	1741
Family history of health problems (QC60-QC6Z) .....	1743
Risk factors associated with infectious or certain other conditions (QC90-QD2Z) .....	1744
Carrier of infectious disease agent (QD00-QD0Z).....	1745
Concern about body appearance (QD30-QD3Z).....	1746
Factors influencing health status (QD50-QF2Z).....	1746
Problems associated with finances (QD50-QD5Z).....	1746
Problems associated with drinking water or nutrition (QD60-QD6Z) .....	1746
Problems associated with the environment (QD70-QD7Z) .....	1746
Problems associated with employment or unemployment (QD80-QD8Z).....	1747
Problems associated with education (QD90-QD9Z) .....	1749
Problems associated with social or cultural environment (QE00-QE0Z).....	1749
Problems associated with health behaviours (QE10-QE2Z) .....	1750
Hazardous substance use (QE10-QE1Z).....	1750
Problems associated with social insurance or welfare (QE30-QE3Z) .....	1755
Problems associated with the justice system (QE40-QE4Z) .....	1756
Problems associated with relationships (QE50-QE5Z).....	1756
Problems associated with absence, loss or death of others (QE60-QE6Z).....	1758
Problems associated with harmful or traumatic events (QE80-QE8Z) .....	1759
Problems associated with upbringing (QE90-QE9Z) .....	1760
Acquired absence of body structure (QF00-QF0Z) .....	1761
Difficulty or need for assistance with activities (QF20-QF2Z).....	1762
CHAPTER 25 .....	1764
Codes for special purposes .....	1764
International provisional assignment of new diseases of uncertain aetiology and emergency use (RA00-RA09).....	1764

National provisional assignment of new diseases of uncertain aetiology (RA20-RA26) .....	1765
CHAPTER 26 .....	1767
Supplementary Chapter Traditional Medicine Conditions .....	1767
CHAPTER V .....	1790
Supplementary section for functioning assessment.....	1790
WHODAS 2.0 36-item version.....	1790
Cognition [WHODAS] .....	1791
Mobility [WHODAS] .....	1791
Self-care [WHODAS].....	1792
Getting along [WHODAS] .....	1792
Life activities [WHODAS].....	1793
Participation and impact of health problems [WHODAS].....	1794
Brief Model Disability Survey.....	1794
Mental functions [BMDS].....	1795
Sensory functions and pain [BMDS].....	1795
Generic functioning domains.....	1795
Mental functions.....	1795
Sensory functions and pain.....	1797
Voice and speech functions .....	1798
Functions of the cardiovascular, haematological, immunological and respiratory systems....	1798
Functions of the digestive, metabolic and endocrine systems.....	1798
Genitourinary and reproductive functions .....	1799
Neuromusculoskeletal and movement-related functions .....	1799
Functions of the skin and related structures .....	1800
Learning and applying knowledge .....	1800
General tasks and demands.....	1800
Communication.....	1801
Mobility .....	1801
Self-care .....	1802
Domestic life .....	1804
Interpersonal interactions and relationships.....	1805
Major life areas .....	1805
Community, social and civic life.....	1806
CHAPTER X .....	1807

Extension Codes .....	1807
Severity Scale Value .....	1808
Generic Severity Scale Value.....	1808
Mild Moderate Severe Scale Value.....	1808
Clinical Staging Scale Value .....	1808
Grading Scale Value .....	1809
Phase Scale Value.....	1809
Problem Scale Value .....	1809
Disease Specific Severity Scale Value.....	1810
Tumour spread simplified Scale Value.....	1810
Tumour spread staging Scale Value .....	1810
Histological Grading Scale Value.....	1810
NYHA Functional Classification: Class I-IV.....	1811
Chronic Obstructive Lung Disease Criteria: GOLD 1-4 .....	1811
Peripheral arterial disease (PAD) Severity Classification by Fontaine .....	1811
Endometriosis Severity Scale Value .....	1811
Vocal Cord Paralysis Severity Scale Value.....	1812
Sepsis Severity Scale Value .....	1812
Peripheral arterial disease (PAD) Severity Classification by Rutherford .....	1812
Pain Severity Scale Value .....	1813
Pain intensity.....	1813
Pain-related distress .....	1813
Pain-related interference.....	1814
Presence of psychosocial factors Scale Value.....	1814
Adult Nutritional Status Scale Value .....	1814
Coronary atherosclerosis Severity Scale Value .....	1815
Anaphylaxis Severity Scale Value .....	1815
Temporality .....	1815
Course of the Condition .....	1815
Pattern, Activity, or Clinical Status.....	1815
Intermittent-Persistent Scale Value.....	1815
Course .....	1816
Acute-Subacute-Chronic Scale Value.....	1816
Onset.....	1816

Time in Life .....	1816
Duration of pregnancy .....	1818
Aetiology .....	1818
Causality .....	1818
Occupational relevance .....	1818
Infectious Agents .....	1819
Other Pathogens .....	1854
Topology Scale Value .....	1855
Relational .....	1855
Distribution .....	1855
Laterality .....	1856
Regional.....	1856
Anatomy and topography .....	1856
Functional anatomy .....	1856
Haematopoietic system .....	1856
Immune system.....	1857
Lymphoid organs.....	1857
Endocrine system.....	1862
Nervous system.....	1863
Nerve.....	1879
Number of Nerves.....	1884
Visual system .....	1884
Auditory system .....	1886
Circulatory system .....	1888
Lymphatic system .....	1912
Respiratory system.....	1915
Digestive system .....	1919
Integumentary system .....	1927
Musculoskeletal system.....	1928
Bones.....	1928
Joints and ligaments.....	1941
Number of joints .....	1950
Number of Ligaments.....	1950
Cartilage .....	1951

Muscles .....	1951
Tendons.....	1959
Genitourinary system.....	1966
Urinary system .....	1966
Reproductive system.....	1968
Surface topography.....	1971
Partonomic view .....	1986
Walls in the Body .....	1986
Body Tissues.....	1987
Body Cavities.....	1988
Histopathology.....	1989
Acinar cell neoplasms .....	1989
Acinar cell neoplasms, benign.....	1989
Acinar cell neoplasms, malignant .....	1990
Acinar cell neoplasms, uncertain whether benign or malignant .....	1990
Adenomas and adenocarcinomas.....	1990
Adenomas, benign .....	1990
Adenocarcinomas in situ.....	1994
Adenocarcinomas, malignant .....	1995
Adenomas and adenocarcinomas, uncertain whether benign or malignant .....	2003
Adnexal and skin appendage neoplasms.....	2004
Adnexal and skin appendage neoplasms, benign.....	2004
Adnexal and skin appendage neoplasms, in situ .....	2005
Adnexal and skin appendage neoplasms, malignant.....	2005
Adnexal and skin appendage neoplasms, uncertain whether benign or malignant .....	2006
Basal cell neoplasms .....	2006
Basal cell neoplasms, benign .....	2006
Basal cell neoplasms, malignant .....	2006
Basal cell neoplasms, uncertain whether benign or malignant .....	2007
Blood vessel tumours.....	2008
Blood vessel tumours, benign.....	2008
Blood vessel tumours, malignant.....	2009
Blood vessel tumours, uncertain whether benign or malignant .....	2009
Complex epithelial neoplasms .....	2010

Complex epithelial neoplasms, benign .....	2010
Complex epithelial neoplasms, malignant.....	2010
Complex mixed and stromal neoplasms.....	2010
Complex mixed and stromal neoplasms, benign .....	2010
Complex mixed and stromal neoplasms, malignant.....	2011
Complex mixed and stromal neoplasms, uncertain whether benign or malignant .....	2013
Cystic, mucinous and serous neoplasms.....	2013
Cystic, mucinous and serous neoplasms, benign.....	2013
Cystic, mucinous and serous neoplasms, in situ.....	2014
Cystic, mucinous and serous neoplasms, malignant .....	2015
Cystic, mucinous and serous neoplasms, uncertain whether benign or malignant .....	2016
Ductal and lobular neoplasms .....	2016
Ductal and lobular neoplasms, benign.....	2016
Ductal and lobular neoplasms, in situ.....	2017
Ductal and lobular neoplasms, malignant .....	2018
Epithelial neoplasms, NOS .....	2020
Epithelial neoplasms, benign .....	2020
Epithelial neoplasms, in situ .....	2020
Epithelial neoplasms, malignant .....	2020
Epithelial neoplasms, uncertain whether benign or malignant.....	2022
Fibroepithelial neoplasms.....	2022
Fibroepithelial neoplasms, benign.....	2022
Fibroepithelial neoplasms, malignant.....	2023
Fibroepithelial neoplasms, uncertain whether benign or malignant .....	2023
Fibromatous neoplasms.....	2023
Fibromatous neoplasms, benign.....	2023
Fibromatous neoplasms, malignant.....	2025
Fibromatous neoplasms, uncertain whether benign or malignant .....	2026
Germ cell neoplasms.....	2027
Germ cell neoplasms, benign.....	2027
Germ cell neoplasms, in situ .....	2027
Germ cell neoplasms, malignant.....	2027
Germ cell neoplasms, uncertain whether benign or malignant .....	2028
Giant cell tumours.....	2029

Giant cell tumours, benign.....	2029
Giant cell tumours, malignant.....	2029
Giant cell tumours, uncertain whether benign or malignant.....	2029
Gliomas .....	2029
Gliomas, benign .....	2029
Gliomas, malignant .....	2029
Gliomas, uncertain whether benign or malignant .....	2033
Granular cell tumours and alveolar soft part sarcomas .....	2033
Granular cell tumours and alveolar soft part sarcomas, benign .....	2033
Granular cell tumours and alveolar soft part sarcomas, malignant .....	2034
Lipomatous neoplasms .....	2034
Lipomatous neoplasms, benign .....	2034
Lipomatous neoplasms, malignant .....	2034
Lipomatous neoplasms, uncertain whether benign or malignant.....	2035
Lymphatic vessel tumours .....	2035
Lymphatic vessel tumours, benign .....	2035
Lymphatic vessel tumours, malignant .....	2036
Lymphatic vessel tumours, uncertain whether benign or malignant.....	2036
Meningiomas .....	2036
Meningiomas, benign .....	2036
Meningiomas, malignant .....	2037
Meningiomas, uncertain whether benign or malignant.....	2037
Mesonephromas .....	2037
Mesonephromas, benign .....	2037
Mesonephromas, malignant.....	2037
Mesonephromas, uncertain whether benign or malignant .....	2037
Mesothelial neoplasms .....	2038
Mesothelial neoplasms, benign .....	2038
Mesothelial neoplasms, malignant .....	2038
Mesothelial neoplasms, uncertain whether benign or malignant.....	2038
Miscellaneous bone tumours.....	2038
Miscellaneous bone tumours, benign.....	2038
Miscellaneous bone tumours, malignant .....	2039
Miscellaneous tumours.....	2039

Miscellaneous tumours, benign.....	2039
Miscellaneous tumours, malignant.....	2039
Miscellaneous tumours, uncertain whether benign or malignant .....	2040
Mucoepidermoid neoplasms .....	2040
Mucoepidermoid neoplasms, malignant.....	2040
Mucoepidermoid neoplasms, uncertain whether benign or malignant.....	2040
Myomatous neoplasms.....	2040
Myomatous neoplasms, benign.....	2040
Myomatous neoplasms, malignant.....	2041
Myomatous neoplasms, uncertain whether benign or malignant .....	2042
Myxomatous neoplasms.....	2042
Myxomatous neoplasms, benign .....	2042
Myxomatous neoplasms, malignant.....	2042
Nerve sheath tumours .....	2043
Nerve sheath tumours, benign .....	2043
Nerve sheath tumours, malignant .....	2044
Nerve sheath tumours, uncertain whether benign or malignant.....	2044
Neuroepitheliomatous neoplasms.....	2044
Neuroepitheliomatous neoplasms, benign.....	2044
Neuroepitheliomatous neoplasms, malignant .....	2045
Neuroepitheliomatous neoplasms, uncertain whether benign or malignant .....	2046
Nevi and melanomas .....	2046
Nevi and melanomas, benign.....	2046
Nevi and melanomas, in situ.....	2048
Nevi and melanomas, malignant .....	2048
Nevi and melanomas, uncertain whether benign or malignant .....	2049
Odontogenic tumours .....	2049
Odontogenic tumours, benign.....	2049
Odontogenic tumours, malignant.....	2050
Odontogenic tumours, uncertain whether benign or malignant .....	2051
Osseous and chondromatous neoplasms .....	2051
Osseous and chondromatous neoplasms, benign .....	2051
Osseous and chondromatous neoplasms, malignant .....	2052
Osseous and chondromatous neoplasms, uncertain whether benign or malignant.....	2053

Paragangliomas and glomus tumours.....	2053
Paragangliomas and glomus tumours, benign.....	2053
Paragangliomas and glomus tumours, malignant .....	2053
Paragangliomas and glomus tumours, uncertain whether benign or malignant .....	2054
Soft tissue tumours and sarcomas, NOS.....	2054
Soft tissue tumours and sarcomas, NOS, benign .....	2054
Soft tissue tumours and sarcomas, NOS, malignant.....	2055
Soft tissue tumours and sarcomas, NOS, uncertain whether benign or malignant .....	2055
Specialized gonadal neoplasms .....	2055
Specialized gonadal neoplasms, benign.....	2055
Specialized gonadal neoplasms, malignant .....	2056
Specialized gonadal neoplasms, uncertain whether benign or malignant .....	2056
Squamous cell neoplasms.....	2058
Squamous cell neoplasms, benign .....	2058
Squamous cell neoplasms, in situ .....	2058
Squamous cell neoplasms, malignant.....	2059
Synovial-like neoplasms .....	2061
Synovial-like neoplasms, benign .....	2061
Synovial-like neoplasms, malignant .....	2061
Thymic epithelial neoplasms.....	2061
Thymic epithelial neoplasms, benign.....	2061
Thymic epithelial neoplasms, malignant .....	2061
Thymic epithelial neoplasms, uncertain whether benign or malignant .....	2062
Transitional cell papillomas and carcinomas .....	2062
Transitional cell papillomas and carcinomas, benign .....	2062
Transitional cell papillomas and carcinomas, in situ .....	2063
Transitional cell papillomas and carcinomas, malignant .....	2063
Transitional cell papillomas and carcinomas, uncertain whether benign or malignant.....	2063
Trophoblastic neoplasms .....	2064
Trophoblastic neoplasms, benign .....	2064
Trophoblastic neoplasms, malignant.....	2064
Trophoblastic neoplasms, uncertain whether benign or malignant.....	2064
Myelodysplastic syndromes.....	2064
Myelodysplastic syndromes, malignant.....	2064

Other haematologic disorders .....	2065
Other haematologic disorders, malignant.....	2065
Other haematologic disorders, uncertain whether benign or malignant.....	2065
Chronic myeloproliferative disorders .....	2065
Chronic myeloproliferative disorders, malignant.....	2065
Leukaemias .....	2066
leukaemias, NOS, malignant .....	2066
Lymphoid leukaemias, malignant .....	2067
Myeloid leukaemias, malignant .....	2068
Myeloid leukaemias, uncertain whether benign or malignant.....	2070
Other leukaemias, malignant.....	2070
Hodgkin and non-Hodgkin lymphomas.....	2070
Malignant lymphomas, NOS or diffuse .....	2070
Hodgkin lymphoma.....	2071
Non-Hodgkin lymphomas .....	2073
Immunoproliferative diseases .....	2077
Immunoproliferative diseases, malignant .....	2077
Immunoproliferative diseases, uncertain whether benign or malignant.....	2077
Plasma cell tumours.....	2078
Mast cell tumours .....	2078
Mast cell tumours, malignant .....	2078
Mast cell tumours, uncertain whether benign or malignant.....	2079
Neoplasms of histiocytes and accessory lymphoid cells.....	2079
Neoplasms of histiocytes and accessory lymphoid cells, malignant .....	2079
Neoplasms of histiocytes and accessory lymphoid cells, uncertain whether benign or malignant .....	2080
Dimensions of injury .....	2080
Dimensions of Burns .....	2080
Burns classified according to extent of body surface involved.....	2080
Extent of body surface with full thickness or deep full thickness burn .....	2081
Outcome of deep full thickness or complex burn.....	2081
Joint involvement in fracture .....	2082
Open fracture or closed fracture .....	2082
Fracture types .....	2082

Types of superficial injuries .....	2083
Dimensions of external causes .....	2084
Additional aspects of mechanism .....	2084
Exposure to other mechanism .....	2085
Activity when injured .....	2086
Sports, recreation or leisure activity .....	2087
Being taken care of .....	2087
Aspects of place of injury occurrence .....	2088
Type of place .....	2088
Part of place .....	2091
Objects, living things or substances involved in causing injury .....	2092
Land vehicle or means of land transport .....	2092
Mobile machinery or special purpose vehicle .....	2094
Watercraft or means of water transport .....	2094
Aircraft or means of air transport .....	2095
Utensil or container .....	2100
Item mainly for personal use .....	2100
Equipment mainly used in sports or recreational activity .....	2103
Weapon .....	2106
Person, animal or plant .....	2106
Building, building component, or related fitting .....	2109
Ground surface or surface conformation .....	2111
Material, not elsewhere classified .....	2111
Food, drink .....	2113
Alcohol use in injury event .....	2114
Psychoactive drug use in injury event .....	2115
Aspects of transport injury events .....	2115
Mode of transport of person injured in transport event .....	2115
Vehicle user role of person injured in transport event .....	2121
Counterpart in land transport crash .....	2122
Other mechanisms of transport injury without counterpart .....	2127
Aspects of sports injury events .....	2127
Type of sport or exercise activity .....	2127
Phase of sport or exercise activity .....	2135

Personal countermeasures in sport or exercise .....	2136
Environmental countermeasures in sport or exercise.....	2136
Aspects of occupational injury events .....	2137
Economic activity .....	2137
Occupation.....	2138
Aspects of assault and maltreatment .....	2138
Perpetrator-victim relationship .....	2138
Gender of perpetrator .....	2140
Context of assault and maltreatment.....	2140
Aspects of intentional self-harm events .....	2142
Proximal risk-factors for intentional self-harm.....	2142
Previous non-fatal intentional self harm .....	2143
Intention to die aspect of self-harm .....	2144
Aspects of armed conflict .....	2144
Type of armed conflict .....	2144
Role of injured person in armed conflict .....	2144
Type of legal intervention.....	2144
Aspects of incidents related to devices .....	2145
Investigation conclusion of events related to devices.....	2180
Findings of investigations related to devices.....	2180
Cause investigation and type of investigation.....	2191
Medical device component.....	2194
Biological and chemical medical device component .....	2194
Electrical and magnetic medical device component .....	2195
Measurement medical device component .....	2200
Mechanical medical device component .....	2202
Optical medical device component .....	2213
Safety medical device component.....	2214
Other component of medical device .....	2215
Consciousness .....	2215
Glasgow Coma Scale Eye opening score .....	2215
Glasgow Coma Scale Motor score .....	2216
Glasgow Coma Scale Verbal score .....	2216
Pupil reaction score .....	2216

Substances .....	2217
Medicaments .....	2217
Agents primarily affecting the gastrointestinal system .....	2217
Gastric acid secretion suppressants.....	2217
Histamine H <sub>2</sub> -receptor antagonists.....	2217
Other drugs for peptic ulcer and gastro-oesophageal reflux disease.....	2218
Drugs for functional gastrointestinal disorders .....	2219
Antidiarrhoeal drugs .....	2220
Digestants .....	2221
Antinauseants, antiemetics and emetics.....	2222
Other agents primarily affecting gastrointestinal system .....	2222
Other antacids and anti-gastric-secretion drugs .....	2223
Other laxatives .....	2224
Saline and osmotic laxatives .....	2225
Drugs for constipation .....	2226
Laxatives.....	2226
Propulsives .....	2228
Antipropulsives .....	2229
Agents primarily affecting blood constituents and immune system .....	2229
Antineoplastic agents.....	2229
Antineoplastic antimetabolites.....	2230
Antineoplastic natural products and derivatives .....	2231
Monoclonal antibodies .....	2232
Other antineoplastic drugs .....	2234
Immunostimulants .....	2241
Immunosuppressive agents .....	2243
Anticoagulants and antithrombotics .....	2246
Platelet aggregation inhibitors.....	2246
Anticoagulants .....	2248
Other fibrinolysis-affecting drugs .....	2249
Anticoagulant antagonists, vitamin K and other coagulants .....	2249
Natural blood and blood products.....	2250
Iron and its compounds .....	2252
Vitamin B12, folic acid and other anti-megaloblastic-anaemia preparations .....	2254

Enzymes .....	2254
Drugs used in hereditary angioedema.....	2255
Local hemostatics.....	2255
Other haematological agents.....	2256
Agents affecting genitourinary system, sex and anabolic hormones .....	2256
Other gynaecologicals.....	2256
Intrauterine and intravaginal contraceptives .....	2256
Estrogens and progestogens.....	2256
Estrogen receptor modulators.....	2259
Progesterone receptor modulators .....	2260
Androgens and anabolic congeners.....	2260
Other urologicals.....	2261
Drugs used in benign prostatic hypertrophy .....	2262
Hormones and their synthetic substitutes and antagonists, not elsewhere classified .....	2262
Anterior pituitary [adenohypophyseal] hormones and analogues.....	2262
Posterior pituitary hormones and analogues .....	2263
Hypothalamic hormones and analogues .....	2264
Gonadotropin releasing hormones and analogues.....	2264
Prolactin inhibitors.....	2265
Glucocorticoids and synthetic analogues .....	2265
Anticorticosteroids.....	2266
Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified .....	2266
Thyroid hormones and substitutes .....	2268
Antithyroid drugs .....	2268
Iodine therapy.....	2269
Parathyroid hormones and analogues.....	2269
Antiparathyroid agents .....	2269
Insulin and antidiabetic drugs.....	2269
Sulfonamides (heterocyclic).....	2271
Agents affecting bones, joints and other connective tissue, not elsewhere classified .....	2274
Bisphosphonates.....	2274
Bone morphogenetic proteins .....	2274
Enzymes affecting bones, joints and other connective tissue, not elsewhere classified .	2274
Agents primarily affecting water and nutrition-balance and metabolism .....	2275

Drugs affecting uric acid metabolism and other antigout preparations .....	2275
Mineral salts and supplements, not elsewhere classified .....	2276
Electrolytic, caloric and water-balance agents .....	2279
Diuretics .....	2281
Loop [high-ceiling] diuretics.....	2283
Mineralocorticoids .....	2284
Vitamins and antioxidants .....	2284
Enzymes and digestants .....	2286
Agents in bile and liver therapy .....	2287
Antiobesity preparations .....	2288
Drugs used to treat enzyme deficiencies and disorders of aminoacid, glycolipid and glycoprotein metabolism .....	2289
Agents primarily affecting the cardiovascular system.....	2290
Agents acting on the renin-angiotensin system .....	2290
Antihyperlipidemic and antiarteriosclerotic drugs .....	2291
Calcium-channel blockers .....	2294
Cardiac stimulants.....	2295
Predominantly beta-adrenoreceptor agonists .....	2296
Antiarrhythmics .....	2299
Other antihypertensive drugs.....	2300
Vasodilators used in cardiac diseases .....	2303
Peripheral vasodilators .....	2305
Other agents primarily affecting the cardiovascular system .....	2307
Vasoprotectives .....	2308
Agents used in antivaricose therapy.....	2309
Drugs primarily affecting the autonomic nervous system.....	2309
Adrenergic agonists.....	2309
Adrenergic antagonists .....	2311
Alpha-adrenoreceptor antagonists.....	2311
Beta-adrenoreceptor antagonists.....	2311
Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics .....	2313
Parasympathomimetics [cholinergics] .....	2319
Anticholinesterase agents.....	2319
Ganglionic blocking drugs .....	2320

Drugs used in addictive disorders .....	2321
Antivertigo and motion sickness preparations .....	2321
Agents primarily acting on smooth and skeletal muscles and the respiratory system .....	2321
Oxytocic drugs.....	2321
Muscle relaxants .....	2322
Other drugs acting on muscles .....	2324
Expectorants and mucolytics .....	2326
Antitussives .....	2328
Respiratory stimulants .....	2332
Systemic antibiotics, anti-infectives and antiparasitics .....	2333
Systemic antibiotics and antibacterials.....	2333
Penicillins .....	2333
Cephalosporins and other beta-lactam antibiotics.....	2335
Macrolides.....	2339
Aminoglycosides .....	2340
Other antibacterials .....	2343
Tetracyclines .....	2344
Antimycobacterials .....	2344
Antifungal agents .....	2347
Antiviral drugs .....	2347
Antivenin, antivenom (sera), Immunoglobulin .....	2352
Vaccines .....	2354
Other specified systemic anti-infectives and antiparasitics.....	2369
Antiprotozoal drugs .....	2369
Antimalarials and drugs acting on other blood protozoa .....	2370
Other agents against amoebiasis and other protozoal diseases .....	2373
Anthelmintics.....	2374
Neuroprotective agents, not elsewhere classified .....	2376
Analgesics, antipyretics and anti-inflammatory drugs.....	2377
Specific antirheumatic agents.....	2380
Acetylsalicylic acid and other salicylates .....	2381
Pyrazolone derivatives .....	2381
Paracetamol (acetaminophen) and 4-aminophenol derivatives .....	2382
Other nonopioid analgesics and antipyretics, not elsewhere classified.....	2382

Antiepileptics and antiparkinsonism drugs.....	2384
Antipsychotics [neuroleptics] .....	2387
Phenothiazine antipsychotics and neuroleptics .....	2387
Butyrophenone derivatives.....	2389
Lithium .....	2390
Other antipsychotics and neuroleptics .....	2390
Antidepressants .....	2392
Monoamine oxidase-inhibitor, non-selective .....	2392
Selective serotonin reuptake inhibitors.....	2392
Serotonin-norepinephrine reuptake inhibitors .....	2393
Other antidepressants .....	2393
Cannabinoids & hallucinogens.....	2395
Other psychodysleptics [hallucinogens] .....	2397
Synthetic cannabinoids .....	2398
Unspecified psychodysleptics [hallucinogens].....	2398
Opioids .....	2398
Opioids or related analgesics and agents affecting opioid receptors.....	2398
Opioid receptor antagonists .....	2400
Psychostimulants .....	2403
Cathinone.....	2403
Other specified amphetamines.....	2403
Unspecified psychostimulant drug .....	2403
Sedative hypnotic drugs and other central nervous system depressants .....	2403
Anaesthetics and therapeutic gases .....	2403
General anaesthetics .....	2403
Sedative-hypnotic and anxiolytic drugs .....	2409
Benzodiazepines .....	2409
Bromine compounds.....	2413
Other sedatives, hypnotics and antianxiety drugs.....	2413
Other and unspecified drugs, medicaments and biological substances.....	2417
Antidotes.....	2417
Iron chelating agents.....	2419
Drugs for treatment of hyperkalaemia, hypercalcaemia and hyperphosphataemia .....	2419
Detoxifying agents for antineoplastic treatment.....	2419

Protectives against UV-radiation for systemic use .....	2420
Antipsoriatics for systemic use .....	2420
Vitamin A derivative and other anti-acne preparations for systemic use .....	2420
Agents used in diagnostic tests, not elsewhere classified .....	2420
Tests for bile duct patency.....	2421
Tests for pituitary function .....	2421
Medical gases.....	2423
Contrast media.....	2423
X-ray contrast media, non-iodinated.....	2424
Topical agents primarily affecting skin and mucous membrane and ophthalmological, otorhinolaryngological and dental drugs.....	2428
Antipruritics .....	2428
Camphor.....	2428
Emollients, demulcents and protectants.....	2428
Fluoride preparations .....	2431
Iodine (antiseptic) .....	2431
Keratolytics, keratoplastics, and other hair treatment drugs and preparations .....	2431
Ophthalmological drugs and preparations .....	2433
Other dental drugs, topically applied .....	2437
Other local antifungal, anti-infective and anti-inflammatory drugs.....	2437
Other local astringents and local detergents.....	2448
Other topical agents.....	2448
Otorhinolaryngological drugs and preparations.....	2451
Topical corticosteroid preparations.....	2452
Retinoids topical .....	2453
Substances, chiefly nonmedicinal .....	2454
Animal toxin, venom, or poison.....	2464
Corrosive substance .....	2472
Explosive chemical .....	2475
Gas, fumes or vapour .....	2476
Halogen derivative of aliphatic and aromatic hydrocarbons.....	2479
Inorganic substance .....	2482
Metal.....	2483
Organic solvent .....	2487

Paint or dye .....	2493
Substance of plant origin .....	2495
Substance of human origin .....	2506
Adhesive, not elsewhere classified .....	2506
Chemical compounds not elsewhere classified .....	2506
Chemicals used as process regulators .....	2506
Cleaning agent, not elsewhere classified.....	2507
Food additives not elsewhere classified .....	2507
Organic compounds not elsewhere classified .....	2507
Preservative nonmedicinal, not elsewhere classified.....	2508
Substance eaten as food, nonbacterial, not elsewhere classified.....	2508
Synthetic fragrances not elsewhere classified.....	2510
 Diagnosis code descriptors .....	 2511
Discharge diagnosis types.....	2511
Diagnosis timing.....	2511
Diagnosis timing in relation to surgical procedure .....	2511
Diagnosis method of confirmation .....	2511
Diagnosis certainty.....	2511
Obstetrical diagnosis timing.....	2512
Encounter descriptors.....	2512
Capacity or context .....	2512
Biological sex.....	2512
Health Devices, Equipment and Supplies .....	2512
Devices for administration, collecting and picking .....	2512
Hematology and hemotransfusion devices .....	2512
Cardiocirculatory devices.....	2512
Disinfectants, antiseptics and proteolytics for medical devices (D. Lgs. 46/97).....	2513
Dialysis devices.....	2513
Gastrointestinal devices.....	2516
Suture devices.....	2516
Active-implantable devices.....	2516
Endotherapy and electrosurgical devices .....	2516
Reusable surgical instruments .....	2516
Devices for generic and specialistic medication .....	2516

Devices for nervous and medullary systems .....	2516
Implantable prosthetic devices and osteosynthesis devices.....	2516
Dental, ophthalmologic and ear, nose and throat devices.....	2516
Respiratory and anaesthesia devices.....	2516
Sterilization devices .....	2517
Protection devices and incontinence aids (D. Lgs. 46/97) .....	2517
Medical devices, urogenital apparatus .....	2517
Medical devices - various.....	2517
In vitro diagnostic devices (D. Lgs. 332/2000) .....	2517
Supports or technical aids for disabled persons.....	2518
Medical equipment and related accessories and materials .....	2518

# CHAPTER 01

---

## Certain infectious or parasitic diseases

This chapter has 342 four-character categories.

Code range starts with 1A00

This chapter includes certain conditions caused by pathogenic organisms or microorganisms, such as bacteria, viruses, parasites or fungi.

**Exclusions:** Infection arising from device, implant or graft, not elsewhere classified (NE83.1)

**Coded Elsewhere:** Infections of the fetus or newborn (KA60-KA6Z)

Human prion diseases (8E00-8E0Z)

Pneumonia (CA40)

This chapter contains the following top level blocks:

- Gastroenteritis or colitis of infectious origin
- Predominantly sexually transmitted infections
- Mycobacterial diseases
- Certain staphylococcal or streptococcal diseases
- Pyogenic bacterial infections of the skin or subcutaneous tissues
- Certain zoonotic bacterial diseases
- Other bacterial diseases
- Human immunodeficiency virus disease
- Viral infections of the central nervous system
- Non-viral and unspecified infections of the central nervous system
- Dengue
- Certain arthropod-borne viral fevers
- Certain zoonotic viral diseases
- Certain other viral diseases
- Influenza
- Viral hepatitis
- Viral infections characterised by skin or mucous membrane lesions
- Mycoses
- Parasitic diseases
- Sepsis
- Sequelae of infectious diseases

## Gastroenteritis or colitis of infectious origin (1A00-1A40.Z)

**Coded Elsewhere:** Intestinal fungal infections

### Bacterial intestinal infections (1A00-1A0Z)

Any condition of the intestines, caused by an infection with a bacterial source.

**Exclusions:** Bacterial foodborne intoxications (1A10-1A1Z)

**Coded Elsewhere:** Abdominal actinomycosis (1C10.1)

Listerial gastroenteritis (1C1A.Y)

**1A00**

#### **Cholera**

Cholera is a potentially epidemic and life-threatening infection of the intestine, characterised by extreme watery (secretory) diarrhoea often accompanied by vomiting, with rapid depletion of body fluids and salt that may result in hypovolemic shock and acidosis. Cholera outbreaks are caused by toxigenic strains of *Vibrio cholerae* serogroups O1 and O139. Serogroup O1 has two biovars; classical and eltor. *Vibrio cholerae* O1, biovar cholerae is classical type. *Vibrio cholerae* O1, biovar eltor is eltor type.

**Inclusions:** cholera syndrome

**1A01**

#### **Intestinal infection due to other Vibrio**

**1A02**

#### **Intestinal infections due to Shigella**

A disease caused by an infection with the gram-negative bacteria genus *Shigella*. This disease is characterised by an acute onset of small volume diarrhoea, accompanied by fever and nausea. This disease may also present with toxæmia, vomiting, cramps, and tenesmus. Transmission is by ingestion of contaminated food, or direct contact. Confirmation is by identification of *Shigella* in a faecal sample.

**Coded Elsewhere:** Sepsis due to shigella with septic shock (1C41)

**1A03**

#### **Intestinal infections due to Escherichia coli**

Any condition of the gastrointestinal system, caused by an infection with the gram-negative bacteria *Escherichia coli*.

**1A03.0**

#### **Enteropathogenic *Escherichia coli* infection**

An infection of the gastrointestinal system, caused by the gram-negative bacteria *Escherichia coli*. It is characterised by acute, profuse, watery diarrhoea. Transmission is by the faecal-oral route from contaminated food, water, or fomites. Confirmation is by identification of enteropathogenic *Escherichia coli* (EPEC) in a faecal sample.

**1A03.1**

#### **Enterotoxigenic *Escherichia coli* infection**

A condition of the gastrointestinal system, caused by an infection with the gram-negative bacteria *Escherichia coli*. This condition is characterised by acute, watery diarrhoea due to toxins released from the bacteria. Transmission is by the faecal-oral route from ingestion of contaminated food, water, or fomites. Confirmation is by identification of the *Escherichia coli* in faecal sample.

- 1A03.2 Enteroinvasive Escherichia coli infection**  
A condition of the gastrointestinal system, caused by an infection with the gram-negative bacteria Escherichia coli. This condition is characterised by acute and profuse diarrhoea (that may be haemorrhagic), fever, and abdominal cramps. Transmission is by the faecal-oral route from ingestion of contaminated food or water. Confirmation is by identification of the Escherichia coli in a faecal sample.
- 1A03.3 Enterohaemorrhagic Escherichia coli infection**
- 1A03.Y Intestinal infections due to other specified Escherichia coli**
- 1A03.Z Intestinal infections due to Escherichia coli, unspecified**
- 1A04 Intestinal infections due to Clostridioides difficile**  
A disease of the colon, caused by an infection with the gram-positive bacteria Clostridioides difficile (formerly known as Clostridium difficile). This disease is characterised by colitis, diarrhoea, abdominal pain, and fever. Transmission is commonly by direct or indirect contact, or from a disturbance of the normal bacterial flora of the colon. Confirmation is by identification of Clostridioides difficile in a faecal sample.
- Exclusions:** Necrotising enterocolitis of newborn (KB88)
- 1A05 Intestinal infections due to Yersinia enterocolitica**  
A disease of the intestinal tract, caused by an infection with the gram-negative bacteria Yersinia enterocolitica. This disease commonly presents with a fever, diarrhoea, or abdominal pain. This disease may also lead to a systemic infection. Transmission is by the faecal-oral route from the ingestion of contaminated food or water, or direct contact with infected individuals or animal. Confirmation is by identification of Yersinia enterocolitica in a faecal sample.
- Exclusions:** Extraintestinal yersiniosis (1B9A)
- Coded Elsewhere:** Postinfectious arthropathy in enteritis due to Yersinia enterocolitica (1A05)
- 1A06 Gastroenteritis due to Campylobacter**
- 1A07 Typhoid fever**  
A condition caused by an infection with the gram-negative bacteria Salmonella typhi. This condition is characterised by an acute sustained fever. This condition may present with weakness, stomach pains, headache, loss of appetite, or flat, rose-coloured spots. Transmission is by the faecal-oral route from the ingestion of contaminated food or water. Confirmation is by identification of Salmonella typhi in a faecal or blood sample.
- 1A07.0 Typhoid peritonitis**
- 1A07.Y Other specified typhoid fever**
- 1A07.Z Typhoid fever, unspecified**

**1A08****Paratyphoid fever**

A condition caused by an infection with the gram-negative bacteria *Salmonella paratyphi*. This condition is characterised by an acute sustained fever. The individual may feel weak, have stomach pains, headache, loss of appetite, or a rash of flat, rose-coloured spots. Transmission is by ingestion of contaminated food or water. Confirmation is by identification of *Salmonella paratyphi* in a faecal or blood sample.

**1A09****Infections due to other *Salmonella*****Coding Note:**

Infection or foodborne intoxication due to any *Salmonella* species other than *S. typhi* and *S. paratyphi*

**1A09.0*****Salmonella enteritis***

This refers to inflammation of the small intestine due to infection with bacteria of the genus *Salmonella*, a member of the family Enterobacteriaceae. Bacteria of the genus *Salmonella* are rod-shaped, Gram-negative, non-spore-forming and predominantly motile.

**1A09.Y****Infections due to other *Salmonella* in other organs****Coding Note:**

Infection or foodborne intoxication due to any *Salmonella* species other than *S. typhi* and *S. paratyphi*

**1A09.Z*****Salmonella infection, unspecified*****Coding Note:**

Infection or foodborne intoxication due to any *Salmonella* species other than *S. typhi* and *S. paratyphi*

**1A0Y****Other specified bacterial intestinal infections****1A0Z****Bacterial intestinal infections, unspecified**

Bacterial foodborne intoxications (1A10-1A1Z)

Any condition caused by an infection with a bacterial source. Transmission is by ingestion of contaminated food.

**Exclusions:**

*salmonella* foodborne intoxication and infection (1A09)

*Listeriosis* (1C1A)

Harmful effects of or exposure to noxious substances, Substances chiefly nonmedicinal as to source, Other noxious substances eaten as food (NE61)

*Ichthyotoxicosis* not specified as bacterial (NE61)

**1A10****Foodborne staphylococcal intoxication****1A11****Botulism**

A disease caused by an infection with the gram-positive bacteria *Clostridium botulinum*. This disease commonly presents with abdominal pain, vomiting, acute paralysis, blurred vision, diplopia, and may be fatal. Transmission is by ingestion of contaminated food, direct contact, or from accidental overdose. Confirmation is by identification of *Clostridium botulinum* in a faecal or food sample.

- 1A11.0** **Foodborne intoxication by botulinum toxin**
- 1A11.1** **Other forms of botulism**
- 1A11.Z** **Botulism, unspecified**
- 1A12** **Foodborne Clostridium perfringens intoxication**
  - Inclusions:** enteritis necroticans
  - foodborne Clostridium welchii intoxication
- 1A13** **Foodborne Bacillus cereus intoxication**
- 1A1Y** **Other specified bacterial foodborne intoxications**
- 1A1Z** **Bacterial foodborne intoxications, unspecified**

**Viral intestinal infections (1A20-1A2Z)**

Any condition of the intestines, caused by an infection with a viral source.

- Exclusions:** influenza with involvement of gastrointestinal tract (1E32)
- Coded Elsewhere:** Herpes simplex virus duodenitis (1F00.Y)
- Human immunodeficiency virus disease enteritis (1C62.2)

- 1A20** **Enteritis due to Adenovirus**

A disease of the intestinal tract, caused by an infection with adenovirus. This disease is characterised by a fever, diarrhoea, or vomiting. Transmission is by the faecal-oral route.
- 1A21** **Gastroenteritis due to Astrovirus**
- 1A22** **Gastroenteritis due to Rotavirus**

A disease of the gastrointestinal tract, caused by an infection with rotavirus. This disease is characterised by acute onset of vomiting, non-haemorrhagic diarrhoea, and abdominal pain. Transmission is by ingestion of contaminated food or water, direct contact, or through fomites. Confirmation is by identification of rotavirus.
- 1A23** **Enteritis due to Norovirus**

A disease of the gastrointestinal tract, caused by an infection with norovirus. This disease is characterised by acute onset of vomiting, non-haemorrhagic diarrhoea, and abdominal pain. Transmission is by ingestion of contaminated food or water, direct contact, or through fomites. Confirmation is by identification of norovirus.
- 1A24** **Intestinal infections due to Cytomegalovirus**

A condition of the intestinal tract, caused by an infection with cytomegalovirus. The condition is characterised by diarrhoea, fever, abdominal pain, or haematochezia. Transmission is by direct contact with infected body fluids.
- 1A2Y** **Other specified viral intestinal infections**
- 1A2Z** **Viral intestinal infections, unspecified**

**Protozoal intestinal infections (1A30-1A3Z)**

Any condition of the intestines, caused by an infection with a protozoal parasitic source.

**1A30**

**Infections due to *Balantidium coli***

Any condition caused by an infection with the protozoan parasite *Balantidium coli*.

**1A31**

**Giardiasis**

A condition caused by an infection with the protozoan parasite *Giardia*. This condition is characterised by gastroenteritis, or may be asymptomatic. Transmission is by the faecal-oral route from the ingestion of contaminated food or water. Confirmation is by identification of *Giardia* in a faecal sample.

**1A32**

**Cryptosporidiosis**

Any condition caused by an infection with the protozoan parasite *Cryptosporidium*.

**1A33**

**Cystoisosporiasis**

A disease caused by the protozoan parasite *Cystoisospora belli*. This disease is characterised by watery diarrhoea, fever, abdominal pain, nausea, or malaise. Transmission is by the faecal-oral route, commonly through the ingestion of contaminated food or water. Confirmation is by identification of *Cystoisospora belli* in a faecal sample.

**1A33.0**

**Cystoisosporiasis of small intestine**

*Inclusions:*            Infection due to *Isopora belli*  
                            Infection due to *Isopora hominis*

**1A33.1**

**Cystoisosporiasis of colon**

*Isosporiasis* of colon is a large intestinal inflammation caused by the protozoan *Isospora belli*.

**1A33.Y**

**Other specified cystoisosporiasis**

**1A33.Z**

**Cystoisosporiasis, unspecified**

**1A34**

**Sarcocystosis**

Any condition caused by an infection with the protozoan parasite *Sarcocystis*.

*Inclusions:*            Sarcosporidiosis

**1A35**

**Blastocystosis**

**1A36**

**Amoebiasis**

*Inclusions:*            Infection due to *Entamoeba histolytica*

**1A36.0**

**Intestinal infections due to *Entamoeba***

<b>1A36.00</b>	Acute amoebiasis A disease caused by an infection with the protozoan parasite Entamoeba histolytica. This disease is characterised by fever, abdominal pain, tenesmus, or diarrhoea containing blood. Transmission is by the faecal-oral route or ingestion of contaminated food or water. Confirmation is by identification of Entamoeba histolytica in a faecal or blood sample.
	<b>Inclusions:</b> amoebic dysentery
<b>1A36.01</b>	Amoeboma of intestine <b>Coded Elsewhere:</b> Amoeboma of large intestine (1A36.0Z)
<b>1A36.0Z</b>	Intestinal infections due to Entamoeba, unspecified
<b>1A36.1</b>	<b>Extraintestinal infections due to Entamoeba</b>
<b>1A36.10</b>	Amoebic liver abscess <b>Inclusions:</b> Hepatic amoebiasis
<b>1A36.11</b>	Amoebic lung abscess
<b>1A36.12</b>	Cutaneous amoebiasis
<b>1A36.1Y</b>	Amoebiasis of other specified sites
<b>1A36.Z</b>	Amoebiasis, unspecified
<b>1A3Y</b>	<b>Other specified protozoal intestinal infections</b>
<b>1A3Z</b>	<b>Protozoal intestinal infections, unspecified</b>
<b>1A40</b>	<b>Gastroenteritis or colitis without specification of infectious agent</b> <b>Inclusions:</b> enteritis septic gastroenteritis septic <b>Exclusions:</b> Noninfectious neonatal diarrhoea (KB8C) noninfective diarrhoea (ME05.1)
<b>1A40.0</b>	<b>Gastroenteritis or colitis without specification of origin</b> There is no mention whether the gastroenteritis or colitis is infectious or non-infectious.
<b>1A40.Z</b>	<b>Infectious gastroenteritis or colitis without specification of infectious agent</b>

## Predominantly sexually transmitted infections (1A60-1A9Z)

**Exclusions:** Nonspecific and nongonococcal urethritis (GC02.1)  
Arthropathy following genitourinary infection (FA11.2)

**Coded Elsewhere:** Sexually transmissible viral hepatitis  
Herpes simplex labialis (1F00.01)  
Herpes simplex gingivostomatitis (1F00.02)  
Vulvovaginal candidosis (1F23.10)  
Candida balanoposthitis (1F23.11)  
Human immunodeficiency virus disease (1C60-1C62.Z)  
Other infections with a predominantly sexual mode of transmission complicating pregnancy, childbirth or the puerperium (JB63.3)  
Candidosis of external genitalia (1F23.1Z)  
Anogenital molluscum contagiosum (1E76)

## Syphilis (1A60-1A6Z)

A predominantly sexually transmitted infection caused by *Treponema pallidum* ssp. *pallidum*.

**Coded Elsewhere:** Syphilis complicating pregnancy, childbirth or the puerperium (JB63.1)

### 1A60

#### **Congenital syphilis**

A disease caused by an infection with the gram-negative bacteria *Treponema pallidum pallidum* in utero. This disease may present with clinical signs depending on the stage of disease. Transmission is by vertical transmission.

### 1A60.0

#### **Early congenital syphilis, symptomatic**

A disease affecting newborns or children up to 2 years of age, caused by an infection with the gram-negative bacteria *Treponema pallidum pallidum* in utero. This disease is characterised by premature birth, hepatosplenomegaly, skeletal abnormalities, and bullous skin disease. Transmission is by vertical transmission.

### 1A60.1

#### **Early congenital syphilis, latent**

### 1A60.2

#### **Late congenital syphilitic oculopathy**

This is a late congenital, sexually transmitted infection caused by the spirochete bacterium *Treponema pallidum* subspecies *pallidum*. This diagnosis is with oculopathy.

### 1A60.3

#### **Late congenital neurosyphilis**

Neurological sequelae of longstanding (> 2 years) untreated congenital neurosyphilis include mental delay, hydrocephalus, seizures, cerebral infarction and cranial nerve palsies.

### 1A60.4

#### **Other late congenital syphilis, symptomatic**

### 1A60.5

#### **Late congenital syphilis, latent**

### 1A60.Z

#### **Congenital syphilis, unspecified**

**1A61****Early syphilis**

A disease caused by an infection with the gram-negative bacteria *Treponema pallidum pallidum*, including primary and secondary stages of syphilis, and early latent syphilis of less than 2 years duration. This disease is characterised by a single chancre in the primary stage, and diffuse rash in the secondary stage. Transmission is commonly by sexual contact.

**Exclusions:** Early congenital syphilis (1A60)

**1A61.0****Primary genital syphilis**

A disease caused by an infection with the gram-negative bacteria *Treponema pallidum pallidum*. This disease is characterised by a single chancre in the genital region. Transmission is commonly by sexual contact.

**1A61.1****Primary anal syphilis****1A61.2****Primary syphilis of other sites****1A61.3****Secondary syphilis of skin or mucous membranes**

A disease caused by an infection with *Treponema pallidum pallidum*. This disease is characterised by lesions of the skin and mucous membranes. Transmission is commonly by sexual contact.

**1A61.4****Secondary syphilis of other sites**

A disease caused by an infection with the gram-negative bacteria *Treponema pallidum pallidum*. This disease is characterised by less common symptoms of syphilis, including hepatitis, kidney disease, arthritis, periostitis, optic neuritis, uveitis, or interstitial keratitis. Transmission is commonly by sexual contact.

**1A61.5****Latent early syphilis**

A disease caused by an infection with the gram-negative bacteria *Treponema pallidum pallidum*. This disease is characterised by serologic proof of infection without symptoms of disease less than 1 year after secondary syphilis. Transmission is commonly by sexual contact.

**1A61.Y****Other specified early syphilis****1A61.Z****Early syphilis, unspecified****1A62****Late syphilis**

A disease caused by an infection with the gram-negative bacteria *Treponema pallidum pallidum*. This disease is characterised by gummas, neurological abnormalities, or cardiac abnormalities. Clinical signs normally manifest approximately 3-15 years after initial infection. Transmission is commonly by sexual contact.

**Exclusions:** Late congenital syphilis (1A60)

<b>1A62.0</b>	<b>Neurosyphilis</b> A disease of the brain or spinal cord caused by an infection with the gram-negative bacteria <i>Treponema pallidum pallidum</i> . This disease is characterised by four different forms: meningovascular, tabes dorsalis, general paresis, or may be asymptomatic. Clinical signs normally manifest approximately 4-25 years after initial infection. Transmission is commonly by sexual contact.
<b>1A62.00</b>	Asymptomatic neurosyphilis
<b>1A62.01</b>	Symptomatic late neurosyphilis A diverse constellation of neuropsychiatric signs resulting from prolonged untreated or inadequately treated syphilis. The protean clinical manifestations include chronic, insidious meningeal inflammation with cranial nerve palsy, cognitive and/or behavioural impairment, ataxia, stroke, seizures and visual or auditory impairment.
	<b>Coded Elsewhere:</b> Dementia due to neurosyphilis (6D85.Y) Meningitis due to <i>Treponema pallidum</i> (1D01.0Y)
<b>1A62.0Z</b>	Neurosyphilis, unspecified
<b>1A62.1</b>	<b>Cardiovascular late syphilis</b> This is a late, sexually transmitted infection caused by the spirochete bacterium <i>Treponema pallidum</i> subspecies <i>pallidum</i> . This diagnosis is involving the cardiovascular area.
<b>1A62.2</b>	<b>Symptomatic late syphilis of other sites</b>
<b>1A62.20</b>	Ocular late syphilis This is a late, sexually transmitted infection caused by the spirochete bacterium <i>Treponema pallidum</i> subspecies <i>pallidum</i> . This diagnosis is with ocular.
<b>1A62.21</b>	Late syphilis involving the musculoskeletal system This is a late, sexually transmitted infection caused by the spirochete bacterium <i>Treponema pallidum</i> subspecies <i>pallidum</i> . This diagnosis is involving the musculoskeletal system.
<b>1A62.22</b>	Late syphilis of skin or mucous membranes This is a late, sexually transmitted infection caused by the spirochete bacterium <i>Treponema pallidum</i> subspecies <i>pallidum</i> . This diagnosis is involving the skin and mucous membranes.
<b>1A62.2Y</b>	Symptomatic late syphilis of other specified sites
<b>1A62.2Z</b>	Symptomatic late syphilis of unspecified site
<b>1A62.Y</b>	<b>Other specified late syphilis</b>
<b>1A62.Z</b>	<b>Late syphilis, unspecified</b>

**1A63****Latent syphilis, unspecified as early or late**

A disease caused by an infection with the gram-negative bacteria *Treponema pallidum pallidum*. This disease is characterised by serologic proof of infection without symptoms of disease. Transmission is commonly by sexual contact.

*Inclusions:* Positive serological reaction for syphilis

**1A6Z****Syphilis, unspecified**

Gonococcal infection (1A70-1A7Z)

A condition caused by an infection with the gram-negative bacteria *Neisseria gonorrhoeae*. Transmission is by sexual contact. Confirmation is by identification of *Neisseria gonorrhoeae*.

**Coded Elsewhere:** Gonorrhoea complicating pregnancy, childbirth or the puerperium (JB63.2)

**1A70****Gonococcal genitourinary infection****1A70.0****Gonococcal infection of lower genitourinary tract without periurethral or accessory gland abscess**

*Exclusions:* Gonococcal infection of lower genitourinary tract with periurethral or accessory gland abscess (1A70.1)

**1A70.00**

Gonorrhoea of penis

**1A70.0Y**

Other specified gonococcal infection of lower genitourinary tract without periurethral or accessory gland abscess

**1A70.0Z**

Gonococcal infection of lower genitourinary tract without periurethral or accessory gland abscess, unspecified

**1A70.1****Gonococcal infection of lower genitourinary tract with periurethral or accessory gland abscess****1A70.Y****Gonococcal infection of other specified genitourinary organ****1A70.Z****Gonococcal genitourinary infection, unspecified****1A71****Gonococcal pelviperitonitis**

This is an inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs.

**1A72****Gonococcal infection of other sites****1A72.0****Gonococcal infection of musculoskeletal system**

This is a species of Gram-negative coffee bean-shaped diplococci bacteria responsible for the sexually transmitted infection gonorrhoea. This diagnosis is of the musculoskeletal system.

**1A72.1****Gonococcal infection of rectum**

This is a species of Gram-negative coffee bean-shaped diplococci bacteria responsible for the sexually transmitted infection gonorrhoea of the rectum.

- 1A72.2 Gonococcal infection of anus**  
This is a species of Gram-negative coffee bean-shaped diplococci bacteria responsible for the sexually transmitted infection gonorrhoea. This diagnosis is of the anus.
- 1A72.3 Gonococcal pharyngitis**
- 1A72.4 Gonococcal infection of eye**  
This is a species of Gram-negative coffee bean-shaped diplococci bacteria responsible for the sexually transmitted infection gonorrhoea. This diagnosis is of the eye.
- Coded Elsewhere:** Neonatal conjunctivitis or dacryocystitis due to Neisseria gonorrhoeae (KA65.0)
- 1A72.Y Gonococcal infection of other specified sites**
- 1A73 Disseminated gonococcal infection**  
Disseminated gonococcal infection occurs when there is bacteremic dissemination of Neisseria gonorrhoeae from its initial focus of infection in female pelvic organs. It manifests as pain and swelling around one or more joints, intermittent crops of erythematous papules and pustules on the limbs, fever and rigors. Blood cultures may be but are not always positive.
- 1A7Z Gonococcal infection, unspecified**

#### Sexually transmissible infections due to chlamydia (1A80-1A8Z)

An infection with the gram-negative bacteria Chlamydia trachomatis. This infection may be asymptomatic or characterised by fever, painful urination, urinary urgency, dyspareunia, vaginal bleeding or discharge, pain in the abdomen in females and by fever, urethritis, painful urination, discharge from the penis, swollen or tender testicles in males. Transmission is by anal, vaginal, or oral sex. Confirmation is by identification of Chlamydia trachomatis.

- 1A80 Chlamydial lymphogranuloma**  
A disease of the inguinal lymph glands, caused by an infection with the gram-negative bacteria Chlamydia trachomatis. This disease is characterised by a genital ulcer, buboes, abscesses in the groin, blood in faeces, tenesmus, or proctocolitis. Transmission is by sexual contact. Confirmation is by identification of Chlamydia trachomatis in a blood sample or by polymerase chain reaction tests.
- Inclusions:** Durand-Nicolas-Favre disease
- 1A81 Non-ulcerative sexually transmitted chlamydial infection**
- Exclusions:** Neonatal chlamydial pneumonia (KB24)  
Neonatal conjunctivitis due to Chlamydia (KA65.0)  
Chlamydial lymphogranuloma (1A80)  
Chlamydial peritonitis (1C21)  
Trachoma (1C23)

- 1A81.0 Chlamydial infection of lower genitourinary tract**

- 1A81.1** **Chlamydial infection of internal reproductive organs**
- 1A81.Y** **Non-ulcerative sexually transmitted chlamydial infection of other specified site**
- 1A81.Z** **Non-ulcerative sexually transmitted chlamydial infection of unspecified site**
- 1A8Y** **Other specified sexually transmissible infections due to chlamydia**
- 1A8Z** **Sexually transmissible infections due to chlamydia, unspecified**
- 1A90** **Chancroid**  
A disease caused by an infection with the gram-negative bacteria *Haemophilus ducreyi*. This disease is characterised by painful ulcer(s) on the genitalia. Transmission is by sexual contact. Confirmation is by identification of *Haemophilus ducreyi* from the ulcer exudate.
- Inclusions:** Ulcus molle
- 1A91** **Granuloma inguinale**  
A disease caused by infection with the gram-negative bacterium *Klebsiella granulomatis*. It commonly presents with painless genital ulceration following contact with an infected sexual partner. Small, painless nodules appear after an incubation period of about 10–40 days; later the nodules break down to create open, fleshy, oozing ulcers which gradually extend, mutilating the infected tissue. The lesions occur at the region of contact and are typically found on the shaft of the penis, the labia, or the perineum.
- Inclusions:** Donovanosis
- 1A92** **Trichomoniasis**  
A disease caused by an infection with the protozoan parasite *Trichomonas*. This disease presents with symptoms depending on the site of infection.
- Coded Elsewhere:** Intestinal trichomoniasis (1A3Y)
- 1A93** **Sexually transmissible infestations**  
**Coded Elsewhere:** Scabies (1G04)  
Pubic infestation by *Pthirus pubis* (1G03)
- 1A94** **Anogenital herpes simplex infection**  
A condition of the anogenital region, caused by an infection with herpes simplex virus type 1 or 2. This condition is characterised by vesicles, or may be asymptomatic. Transmission is by sexual contact. Confirmation is by identification of herpes simplex virus type 1 or 2.
- 1A94.0** **Herpes simplex infection of genitalia or urogenital tract**  
Herpes simplex infection affecting the vulva and vagina in women and the penis in men. It is more commonly due to infection with Herpes simplex type 2 virus than with type 1 virus.

- 1A94.1**      **Herpes simplex infection of perianal skin or rectum**  
Herpes simplex infection of perianal skin and rectum. This is commonly due to Herpes simplex virus type 2 and acquired through anal sexual contact.
- 1A94.Z**      **Anogenital herpes simplex infection without further specification**
- 1A95**      **Anogenital warts**  
Anogenital warts are due to an infection of anogenital skin and mucous membranes by certain human papilloma viruses, most commonly HPV subtypes 6, 11, 16 and 18. Transmission is predominantly by sexual contact. They manifest typically as flat plaques or papillomatous, keratinous growths on and adjacent to the external genitalia and anus. Some HPV subtypes, including types 16 and 18, are oncogenic and predispose to the development of anogenital cancers.  
**Coded Elsewhere:** Anogenital verrucous carcinoma of Buschke and Lowenstein (2C31.0)
- 1A95.0**      **Anal warts**  
Infection of the anus or perianal skin by human papillomavirus (HPV). Although the majority of such infections are sexually transmitted and caused by HPV subtypes responsible for genital warts, autoinoculation from common warts, especially on the hands in children, may also cause perianal warts.  
**Inclusions:**      Condylomata acuminata of anus
- 1A95.1**      **Genital warts**  
Infection of anogenital mucosa or skin by the human papillomavirus. The infection is commonly asymptomatic but manifests typically as flat, papular or pedunculated growths depending on the site of infection. Transmission is normally by sexual contact.
- 1A95.2**      **Extragenital condylomata acuminata**  
Anogenital warts transmitted to extragenital sites (i.e. beyond the anogenital region). This may be through autoinoculation of anogenital wart virus to moist, intertriginous sites on the abdomen or under the breasts, or as a result of sexual activity, particularly to the lips and oral cavity.  
**Inclusions:**      Anogenital warts affecting sites other than the anogenital area
- 1A95.Z**      **Anogenital warts, unspecified**
- 1A9Y**      **Other specified predominantly sexually transmitted infections**
- 1A9Z**      **Predominantly sexually transmitted infections, unspecified**

## Mycobacterial diseases (1B10-1B2Z)

### Tuberculosis (1B10-1B1Z)

A disease caused by an infection with bacteria of the *Mycobacterium tuberculosis* complex. This disease presents with symptoms depending on the site of infection. Transmission is commonly by inhalation of infected respiratory secretions.

**Inclusions:** Infections due to *Mycobacterium tuberculosis* and *Mycobacterium bovis*

**Exclusions:** Pneumoconiosis associated with tuberculosis (CA60.3)

**Coded Elsewhere:** Congenital tuberculosis (KA61.0)

Tuberculosis complicating pregnancy, childbirth or the puerperium (JB63.0)

HIV disease clinical stage 1 associated with tuberculosis (1C60.0)

HIV disease clinical stage 2 associated with tuberculosis (1C60.1)

HIV disease clinical stage 3 associated with tuberculosis (1C60.2)

HIV disease clinical stage 4 associated with tuberculosis (1C60.3)

Human immunodeficiency virus disease associated with tuberculosis (1C60)

Tuberculosis of orbit (9A22.2)

#### 1B10

### Tuberculosis of the respiratory system

This is a progressive or chronic disease resulting from infection with the bacterium *Mycobacterium tuberculosis* or other bacteria in the *M. tuberculosis* complex: *M. bovis*, *M. africanum*, *M. canetti*, *M. microti* and *M. pinnipedii*. The infection is limited to the respiratory system.

#### 1B10.0

### Respiratory tuberculosis, confirmed

A disease of the respiratory tract, caused by an infection with the bacteria *Mycobacterium tuberculosis*, which has been confirmed by laboratory testing. This disease is characterised by chronic cough, and sputum production that may be haemorrhagic. Transmission is commonly by inhalation of infected respiratory secretions. Confirmation is by identification of *Mycobacterium tuberculosis* in clinical samples.

#### 1B10.1

### Respiratory tuberculosis, not confirmed

A disease of the respiratory tract, caused by an infection with the bacteria *Mycobacterium tuberculosis*, which has not been confirmed. This disease is characterised by a chronic cough, and sputum production that may be haemorrhagic. Transmission is commonly by inhalation of infected respiratory secretions.

#### 1B10.Z

### Respiratory tuberculosis, without mention of bacteriological or histological confirmation

**1B11****Tuberculosis of the nervous system**

A disease of the central nervous system, caused by an infection with bacteria of the Mycobacterium tuberculosis complex. This disease is characterised by neurological deficits depending on the site affected. Transmission is through haematogenous spread to the nervous system after inhalation of infected respiratory secretions. Confirmation is by identification of bacteria of the Mycobacterium tuberculosis complex in the cerebrospinal fluid.

**1B11.0****Tuberculous meningitis**

A disease of the meninges, caused by an infection with the bacteria Mycobacterium tuberculosis. This disease is characterised by fever, headache, or neurological deficits. Transmission is through haematogenous spread to the meninges after inhalation of infected respiratory secretions. Confirmation is by identification of Mycobacterium tuberculosis in the cerebrospinal fluid.

**Inclusions:**      Tuberculous leptomeningitis

**1B11.1****Tuberculous meningoencephalitis****1B11.2****Meningeal tuberculoma**

Meningeal tuberculomas are conglomerate caseous foci within the meninges of the brain, caused by dissemination of tuberculosis to the central nervous system.

**Inclusions:**      Tuberculoma of meninges

**1B11.3****Tuberculous granuloma of brain****1B11.Y****Tuberculosis of other specified part of nervous system****1B11.Z****Tuberculosis of the nervous system, unspecified****1B12****Tuberculosis of other systems and organs****1B12.0****Tuberculosis of heart**

Mycobacterium tuberculosis infection involving the heart and pericardium

**1B12.1****Tuberculosis of eye**

Tuberculosis involving the eye. This may manifest in multiple different ways including keratoconjunctivitis, episcleritis, anterior uveitis and posterior uveitis

**Exclusions:**      lupus vulgaris of eyelid (1B12.8)

**1B12.2****Tuberculosis of ear**

This is a common, and in many cases lethal, infectious disease caused by various strains of mycobacteria, usually Mycobacterium tuberculosis. This diagnosis is of the ear.

**Exclusions:**      tuberculosis of skin of external ear (1B12.8)

    Tuberculous mastoiditis (1B12.40)

**1B12.3****Tuberculosis of endocrine glands**

Infection of endocrine glands by Mycobacterium tuberculosis with resultant endocrine disturbances including adrenal or pituitary failure.

**Coded Elsewhere:** Tuberculous Addison disease (1B12.3)

- 1B12.4** **Tuberculosis of the musculoskeletal system**  
**Coded Elsewhere:** Mycobacterial infection of vertebra (FA90.1)
- 1B12.40** Tuberculosis of bones or joints  
A disease of the bones and joints, caused by an infection with the bacteria *Mycobacterium tuberculosis*. This disease commonly presents with bone pain, joint inflammation, loss of movement or feeling in the affected bone or joint, and weak bones prone to fracture. Transmission is through haematogenous spread to the bones and joints after inhalation of infected respiratory secretions. Confirmation is by identification of *Mycobacterium tuberculosis* in biopsy samples of the affected site.
- 1B12.41** Tuberculous myositis
- 1B12.4Y** Tuberculosis of other specified part of the musculoskeletal system
- 1B12.4Z** Tuberculosis of the musculoskeletal system, unspecified
- 1B12.5** **Tuberculosis of the genitourinary system**  
Tuberculosis involving the urinary tract and/or reproductive organs. The primary site of infection is most commonly the kidney as a result of haematogenous spread from distant sites: infection may then spread further down the urinary tract and/or to the reproductive organs. Genital infection may be sexually transmitted.
- 1B12.6** **Tuberculous peripheral lymphadenopathy**  
A disease of the peripheral lymph nodes, caused by an infection with the bacteria *Mycobacterium tuberculosis*. This disease is characterised by inflammation of the peripheral lymph nodes, typically the cervical lymph nodes. Transmission is through haematogenous spread to the peripheral lymph nodes after inhalation of infected respiratory secretions. Confirmation is by identification of *Mycobacterium tuberculosis* from lymph node biopsies.
- Inclusions:** Tuberculous adenitis
- Exclusions:** Tuberculosis of intrathoracic lymph nodes, confirmed bacteriologically or histologically (1B10.0)  
Tuberculosis of intrathoracic lymph nodes, without mention of bacteriological or histological confirmation (1B10)
- 1B12.7** **Tuberculosis of the digestive system**  
Tuberculosis of the digestive tract or hepatobiliary system
- 1B12.8** **Cutaneous tuberculosis**  
Tuberculosis involving the skin and mucous membranes including lupus vulgaris, scrofuloderma and periorificial tuberculosis.
- Exclusions:** Tuberculids (EA40-EA5Z)  
Skin complications of BCG immunisation (EA51)
- Coded Elsewhere:** Acute miliary cutaneous tuberculosis (1B13.0)
- 1B12.Y** **Tuberculosis of other specified organ or site**
- 1B13** **Miliary tuberculosis**

- 1B13.0 Acute miliary tuberculosis of a single specified site**  
A disease caused by an infection with the bacteria Mycobacterium tuberculosis that is disseminated through the body, and affecting a specific body site. This disease is characterised by numerous small lesions of 1-5 millimetre(s) in any organ, and fever. Transmission is commonly by inhalation of infected respiratory secretions. Confirmation is by radiography, CT, ultrasonography, and identification of Mycobacterium tuberculosis, depending on the site affected.
- 1B13.1 Acute miliary tuberculosis of multiple sites**  
A disease caused by an infection with the bacteria Mycobacterium tuberculosis that is disseminated through the body, and affecting multiple body sites. This disease is characterised by numerous small lesions of 1-5 millimetre(s) in more than one organ, and fever. Transmission is commonly by inhalation of infected respiratory secretions. Confirmation is by radiography, advanced imaging, ultrasonography, and identification of Mycobacterium tuberculosis, depending on the sites affected.
- 1B13.2 Acute miliary tuberculosis, unspecified site**
- 1B13.Y Other specified miliary tuberculosis**
- 1B13.Z Miliary tuberculosis, unspecified**
- 1B14 Latent tuberculosis**
- 1B1Y Other specified tuberculosis**
- 1B1Z Tuberculosis, unspecified**
- 1B20 Leprosy**  
A disease caused by an infection with Mycobacterium leprae. This disease commonly presents with a long asymptomatic period followed by granulomatous lesions of the skin, respiratory tract, and peripheral nerves. Transmission is commonly by droplet transmission. Confirmation is by identification of Mycobacterium leprae with skin biopsy.  
*Inclusions:* Infection due to Mycobacterium leprae
- 1B20.0 Paucibacillary leprosy**
- 1B20.1 Multibacillary leprosy**
- 1B20.2 Leprosy reactions**
- 1B20.20 Type I leprosy reaction**  
This phenomenon, also named “upgrading reaction,” occurs in borderline leprosy states and is associated with an increase in cell-mediated immunity. It occurs typically within the first 6 months of treatment in previously untreated patients but may be related to stress, intercurrent infections, or pregnancy. Clinical features include inflammatory swelling, erythema and occasionally ulceration of existing lesions, constitutional symptoms and neuritis. If the neuritis is not treated promptly permanent motor nerve damage may ensue.

- 1B20.21** Type II leprosy reaction  
This phenomenon, also named downgrading reaction, occurs in borderline leprosy states and is associated with a decrease in cell-mediated immunity with a shift towards the lepromatous end of the clinical spectrum.
- 1B20.3** **Complications of leprosy**
- 1B20.Z** **Leprosy, unspecified**
- 1B21** **Infections due to non-tuberculous mycobacteria**  
Any condition caused by an infection with Mycobacteria excluding infections due to *Mycobacterium tuberculosis* complex and *Mycobacterium leprae*. These conditions commonly present with lung disease; however, symptoms are dependent on the site of infection. Transmission is by direct contact with non-tuberculous Mycobacteria in the environment. Confirmation is by identification of non-tuberculous Mycobacteria from the affected site(s).
- Exclusions:** Leprosy (1B20)  
Tuberculosis (1B10-1B1Z)
- 1B21.0** **Pulmonary infection due to non-tuberculous mycobacterium**  
A condition of the pulmonary system, caused by an infection with the bacteria *Mycobacterium* (excluding infections due to *Mycobacterium tuberculosis* and *Mycobacterium leprae*). This disease is characterised by cough, fever, weight loss, and fatigue. Transmission is by direct contact with *Mycobacterium* in the environment.
- 1B21.1** **Non-tuberculous mycobacterial lymphadenitis**
- 1B21.2** **Cutaneous non-tuberculous mycobacterial infection**  
**Exclusions:** Leprosy (1B20)  
Tuberculosis (1B10-1B1Z)
- 1B21.20** ***Mycobacterium ulcerans* infection**  
*Mycobacterium ulcerans* infection (Buruli ulcer) typically presents as a subcutaneous nodule which breaks down to form a deep painless ulcer which commonly reaches a size of 15 cm in diameter but may extend further to cause extensive tissue damage. The organism is found in wetlands of tropical and subtropical regions of the world, particularly Africa [Dermatology TAG].
- 1B21.2Y** Cutaneous infection due to other specified non-tuberculous mycobacteria
- 1B21.2Z** Cutaneous infection due to unspecified non-tuberculous mycobacteria
- 1B21.3** **Disseminated non-tuberculous mycobacterial infection**
- 1B21.4** **Gastrointestinal non-tuberculous mycobacterial infection**
- 1B21.Y** **Non-tuberculous mycobacterial infection of other specified site**
- 1B21.Z** **Non-tuberculous mycobacterial infection of unspecified site**
- 1B2Y** **Other specified mycobacterial diseases**

**1B2Z**

**Mycobacterial diseases, unspecified**

Certain staphylococcal or streptococcal diseases (1B40-1B5Z)

**Coded Elsewhere:** Toxic shock syndrome (1C45)

Streptococcal tonsillitis (CA03.0)

Rheumatic myocarditis (BC42.3)

Chronic rheumatic pericarditis (BB21)

Acute staphylococcal tonsillitis (CA03.Y)

Acute rheumatic fever (1B40-1B42)

A disease of the connective tissue, caused by an infection with the gram-positive bacteria Streptococcus pyogenes (the disease may also affect the heart, joints, central nervous system, subcutaneous tissues, or skin). This disease is characterised by fever, polyarthritis, carditis, subcutaneous nodules, or erythema marginatum. Transmission is through haematogenous spread to other parts of the body after direct or indirect contact. Confirmation is by electrocardiography, sedimentation rate, or identification of Streptococcus pyogenes in a blood sample.

**Coded Elsewhere:** Erythema marginatum rheumaticum (EA50.0)

**1B40**

**Acute rheumatic fever without mention of heart involvement**

**1B40.0**

**Rheumatic arthritis, acute or subacute**

**1B40.Y**

**Other specified acute rheumatic fever without mention of heart involvement**

**1B40.Z**

**Acute rheumatic fever without mention of heart involvement, unspecified**

**1B41**

### **Acute rheumatic fever with heart involvement**

A disease of the cardiovascular system, caused as a result of rheumatic fever. Rheumatic heart disease is characterised by repeated inflammation with fibrinous repair. This disease may present with cardinal anatomic changes of the valve including leaflet thickening, commissural fusion, and shortening and thickening of the tendinous cords. Inflammation and valve scarring may also occur. Confirmation is by a thoracic radiography or echocardiography.

- Exclusions:**
- Rheumatic mitral valve stenosis (BB60.0)
  - Rheumatic mitral valve insufficiency (BB61.0)
  - Rheumatic mitral valve prolapse (BB62.0)
  - Rheumatic mitral stenosis with insufficiency (BB63.0)
  - Rheumatic aortic valve stenosis (BB70.0)
  - Rheumatic aortic valve insufficiency (BB71.0)
  - Rheumatic aortic stenosis with insufficiency (BB72.0)
  - Rheumatic tricuspid valve stenosis (BB80.0)
  - Rheumatic tricuspid valve insufficiency (BB81.0)
  - Rheumatic tricuspid valve stenosis with insufficiency (BB82.0)
  - Rheumatic pulmonary valve stenosis (BB90.0)
  - Rheumatic pulmonary valve insufficiency (BB91.0)
  - Rheumatic pulmonary valve stenosis with insufficiency (BB92.0)

**1B41.0**

### **Acute rheumatic pericarditis**

A disease of the pericardium, caused by acute rheumatic fever. This disease is characterised by fever, dry cough, rapid heart rate, fatigue, or low blood pressure. Confirmation is by echocardiography, or thoracic radiography.

**1B41.1**

### **Acute rheumatic endocarditis**

A disease of the endocardium, caused as a result of acute rheumatic fever. This disease is characterised by a high fever, chills, shortness of breath, rapid or irregular heartbeat, coughing up of blood, abdominal pain or septicaemia. This disease commonly presents with valvular involvement. Confirmation is by echocardiography.

**1B41.10**

Rheumatic aortitis

**1B41.1Y**

Other specified acute rheumatic endocarditis

**1B41.1Z**

Acute rheumatic endocarditis, unspecified

**1B41.2**

### **Acute rheumatic myocarditis**

Acute rheumatic myocarditis is cardiac inflammation associated with acute rheumatic fever triggered by an autoimmune reaction to group A streptococci infection resulting in pancarditis involving inflammation of the myocardium, endocardium, and epicardium, usually with left-sided valvar involvement.

**1B41.Y**

### **Other acute rheumatic heart disease**

**1B41.Z      Acute rheumatic heart disease, unspecified**

**1B42      Rheumatic chorea**

***Exclusions:***      Huntington chorea (8A01.10)

**1B50      Scarlet fever**

A disease caused by an infection with the gram-positive bacteria Streptococcus pyogenes. This disease is characterised by a sore throat, fever, and a red rash. Transmission is commonly by inhalation of infected respiratory secretions, direct skin contact, or indirect contact.

***Inclusions:***      Scarlatina NOS

***Exclusions:***      streptococcal sore throat (1B51)

Staphylococcal scarlatina (EA50.3)

**1B51      Streptococcal pharyngitis**

A disease of the pharynx, caused by an infection with the gram-positive bacteria Streptococcus pyogenes. This disease is characterised by fever, sore throat, tonsillar exudates, or large cervical lymph nodes. Transmission is commonly by inhalation of infected respiratory secretions, or indirect contact. Confirmation is by identification of Streptococcus pyogenes from a throat swab.

***Inclusions:***      Streptococcal sore throat

***Exclusions:***      Scarlet fever (1B50)

**1B53      Meningitis due to Streptococcus**

A disease of the meninges, caused by an infection with the gram-positive bacteria genus Streptococcus. This disease commonly presents with nausea, vomiting, photophobia, and confusion. Transmission is through haematogenous spread to the meninges after inhalation of infected respiratory secretions. Confirmation is by identification of Streptococcus in the cerebrospinal fluid.

***Inclusions:***      Streptococcal meningitis

**1B54      Meningitis due to Staphylococcus**

A disease of the meninges, caused by an infection with the gram-positive bacteria genus Staphylococcus. This disease commonly presents with acute inflammation of the meninges causing headache, fever, stiff neck, or neurological deficits. Confirmation is by identification of Staphylococcus in the cerebrospinal fluid.

***Inclusions:***      Staphylococcal meningitis

**1B5Y      Other specified staphylococcal or streptococcal diseases**

**1B5Z      Staphylococcal or streptococcal diseases, unspecified**

## Pyogenic bacterial infections of the skin or subcutaneous tissues (1B70-1B7Z)

**Coded Elsewhere:** Acute bacterial paronychia (EE12.0)

**1B70**

### **Bacterial cellulitis, erysipelas or lymphangitis**

Diffuse, spreading infections of skin and soft tissues by a range of bacterial organisms, most commonly beta-haemolytic streptococci and *Staphylococcus aureus*. The clinical presentation is dependent not only on the organism but also on the manner in which it invades the tissues.

**Exclusions:** Eosinophilic cellulitis (EB30)

**1B70.0**

#### **Erysipelas**

**Exclusions:** postpartum or puerperal erysipelas (JB40)

**1B70.00**

Erysipelas of face

**1B70.01**

Erysipelas of external ear

A rapidly expanding diffuse superficial dermal streptococcal infection involving the external ear. In contrast with infective otitis externa, the skin of the auricle is often initially healthy except at a point of entry for beta-haemolytic streptococci (commonly at a fissure behind the ear or where the ear lobe is attached to the side of the head) and systemic features including fever and malaise are common.

**1B70.02**

Erysipelas of lower limb

**1B70.0Y**

Erysipelas of other specified site

**1B70.0Z**

Erysipelas, unspecified

**1B70.1**

### **Streptococcal cellulitis of skin**

**Exclusions:** Orbital cellulitis (9A21.0)

Cellulitis of external ear (AA01)

anal cellulitis (DB70.00)

vulvar cellulitis (GA00.0)

Cellulitis of penis (GB06)

Inflammatory disorders of scrotum (GB07.2)

perirectal cellulitis (DB36.10)

Superficial incisional site infection (NE81.20)

**1B70.2**

### **Staphylococcal cellulitis of skin**

**Exclusions:** Orbital cellulitis (9A21.0)

Cellulitis of external ear (AA01)

anal cellulitis (DB70.00)

vulvar cellulitis (GA00.0)

Cellulitis of penis (GB06)

Inflammatory disorders of scrotum (GB07.2)

perirectal cellulitis (DB36.10)

Superficial incisional site infection (NE81.20)

- 1B70.3 Ascending bacterial lymphangitis**  
A complication of a focal acute pyogenic bacterial infection in which the draining lymphatics become red, inflamed and tender as the result of ascending infection. It is most commonly caused by *Streptococcus pyogenes*.
- 1B70.Y Bacterial cellulitis or lymphangitis due to other specified bacterium**
- 1B70.Z Bacterial cellulitis or lymphangitis due to unspecified bacterium**
- 1B71 Necrotising fasciitis**
- 1B71.0 Streptococcal necrotising fasciitis**  
**Exclusions:** Neonatal necrotising fasciitis (1B71.2)  
**Coded Elsewhere:** Neonatal streptococcal necrotising fasciitis (1B71.2)
- 1B71.1 Polymicrobial necrotising fasciitis**  
**Exclusions:** Neonatal necrotising fasciitis (1B71.2)
- 1B71.2 Neonatal necrotising fasciitis**  
Neonatal necrotising fasciitis is a life-threatening acute necrotising infection of fascia, subcutaneous tissues, and overlying skin similar to the condition seen in adults. It is rare in neonates but, in contrast to the adult form, tends to affect otherwise healthy babies. It has followed omphalitis, mastitis and postoperative wound infection, though preceding sites of infection are not always found. It has more commonly been associated with *Staphylococcus aureus* than with streptococcal infection. Gram-negative organisms have also been implicated. It may cause extensive tissue destruction and mortality is high.
- 1B71.Y Necrotising fasciitis due to other specified bacterial infection**
- 1B71.Z Necrotising fasciitis, unspecified**
- 1B72 Impetigo**  
A condition of the skin, commonly caused by a secondary infection with the gram-positive bacteria *Staphylococcus aureus* or group A beta haemolytic streptococci. This condition is characterised by bullous or non-bullous symptoms. Transmission is by direct contact with an infected individual. Confirmation is by identification of the infectious agent in a skin sample.  
**Exclusions:** impetigo herpetiformis (EA90.40)  
Staphylococcal scalded skin syndrome (EA50.2)  
**Coded Elsewhere:** Otitis externa in impetigo (AA3Y)

- 1B72.0** **Bullous impetigo**  
Bullous impetigo is a contagious superficial infection of the skin caused by certain strains of *Staphylococcus aureus* which release toxins into the local environment which are capable of cleaving desmoglein I, a protein involved in intercellular adhesion of epidermal keratinocytes. In contrast to the very superficial, rapidly shed and rarely observed blisters of non-bullous impetigo, the bullae of bullous impetigo are tense and well demarcated, sometimes reaching several centimetres in diameter before rupture.
- Coded Elsewhere:** Neonatal bullous impetigo (EH11)
- 1B72.1** **Non-bullous impetigo**  
Non-bullous impetigo is due to superficial skin infection with either *Streptococcus pyogenes* or *Staphylococcus aureus* or both. The very superficial blisters which form in the upper epidermis are soon shed and rarely seen (cf. bullous impetigo) so that it normally presents with areas of superficial oozing and crusting on the skin surface. It often follows minor skin injury or on skin damaged by a preexisting dermatosis such as atopic eczema or scabies.
- 1B72.2** **Secondary impetiginisation of the skin**  
Secondary infection of dermatoses such as atopic eczema by streptococci or staphylococci.
- Coding Note:** Code also the causing condition
- 1B72.Y** **Other specified impetigo**
- 1B72.Z** **Impetigo, unspecified**
- 1B73** **Ecthyma**  
Ecthyma is a superficial ulcerative bacterial pyoderma. It is characterised by small, purulent, shallow, punched-out ulcers with thick, brown-black crusts and surrounding erythema. The commonest form is caused by beta-haemolytic streptococci, often in association with *Staphylococcus aureus*. It is associated with poor hygiene and malnutrition. Ecthyma gangrenosum is an uncommon severe variant caused by *Pseudomonas aeruginosa*.
- 1B73.0** **Streptococcal ecthyma**
- 1B73.1** **Staphylococcal ecthyma**  
Ecthyma due to a monoinfection with *Staphylococcus aureus*. It is less common than streptococcal ecthyma.
- 1B73.2** **Ecthyma gangrenosum**  
Ecthyma gangrenosum is a potentially life-threatening infection of skin in patients who are immunocompromised through disease or immunosuppressive therapy. It is most commonly caused by *Pseudomonas aeruginosa* though a variety of other organisms may be implicated. It is characterised by usually painless erythematous macules or plaques which progress to haemorrhagic blistering and necrosis of the skin. Lesions may be multiple and widely disseminated, though the anogenital area is a common site. *Pseudomonas* can frequently be cultured from the blood.
- Coded Elsewhere:** Neonatal ecthyma gangrenosum (EH11)

- 1B73.Y**      **Other specified ecthyma**
- 1B73.Z**      **Ecthyma, unspecified**
- 1B74**      **Superficial bacterial folliculitis**  
Bacterial infection of the follicular ostium manifested as follicular papules and pustules with perifollicular erythema. The most commonly isolated organisms are coagulase-negative staphylococci and *Staphylococcus aureus*. The infection may be acute but is more commonly subacute or chronic; individual lesions heal without scarring. Commonly affected sites include the scalp, beard area, thighs and buttocks.
- 1B74.0**      ***Staphylococcus aureus* superficial folliculitis**  
Infection of the follicular ostium with *Staphylococcus aureus*. There is a predilection for hairy areas including the scalp, beard and thighs.
- 1B74.Y**      **Superficial bacterial folliculitis due to other specified organism**
- 1B74.Z**      **Superficial bacterial folliculitis due to unspecified organism**
- 1B75**      **Deep bacterial folliculitis or pyogenic abscess of the skin**  
Single or multiple focal infections of skin and soft tissues most commonly centred on the hair follicle and most commonly due to *Staphylococcus aureus*. Pyogenic abscesses may develop in other locations in skin which has been injured as a result of either trauma or surgery.
- 1B75.0**      **Furuncle**  
A localised infection of a hair follicle by *Staphylococcus aureus*. It manifests as a painful swollen purulent mass centred on a hair follicle.
- 1B75.1**      **Carbuncle**  
A deep follicular pyogenic staphylococcal skin infection involving a group of adjacent hair follicles. It manifests as a painful boggy mass containing multiple purulent discharging sinuses.
- 1B75.2**      **Furunculosis**  
The presence of multiple furuncles, this condition is associated with disorders such as malnutrition and diabetes mellitus. Treatment-resistant furunculosis may be associated with Panton-Valentine leucocidin-producing *Staphylococcus aureus*.
- 1B75.3**      **Pyogenic abscess of the skin**  
A pus-producing abscess of the skin most commonly due to bacterial infection by *Staphylococcus aureus*. It is prone to develop where the normal anatomy is disturbed as in pilonidal disease, an epidermoid cyst or around foreign bodies such as surgical sutures.
- Coded Elsewhere:** Sacrococcygeal pilonidal abscess (EG63.2)  
Infected epidermoid cyst (EK70.00)

<b>1B75.4</b>	<b>Chronic deep bacterial folliculitis</b> A chronic pyogenic infection by <i>Staphylococcus aureus</i> involving the whole depth of the hair follicle. Sycosis occurs mostly in males after puberty, and commonly involves the follicles of the beard. Most cases begin in the third or fourth decade. Unknown host factors appear to be important in the chronicity of the infection. Extensive follicular destruction and scarring may ensue (lupoid sycosis).
	<b>Coded Elsewhere:</b> Folliculitis cruris pustulosa atrophicans (ED81.0)
<b>1B75.Z</b>	<b>Deep bacterial folliculitis or pyogenic abscess of the skin, unspecified</b>
<b>1B7Y</b>	<b>Other specified pyogenic bacterial infection of skin or subcutaneous tissue</b>
<b>1B7Z</b>	<b>Pyogenic bacterial infection of skin or subcutaneous tissue, unspecified</b>

### Certain zoonotic bacterial diseases (1B90-1B9Z)

This is a group of bacterial diseases that are transmitted to humans by contact with infected vertebrate animals.

<b>1B90</b>	<b>Rat-bite fevers</b> Any disease caused by an infection with the gram-negative bacteria <i>Streptobacillus moniliformis</i> or gram-negative bacteria <i>Spirillum minus</i> . This disease presents with symptoms depending on the bacterial agent. Transmission is through the bite of an infected rat or rodent.
<b>1B90.0</b>	<b>Spirillosis</b> A disease caused by an infection with the gram-negative bacteria <i>Spirillum minus</i> . This disease is initially characterised by local inflammation, followed by fever, lymphadenitis, and headache. Transmission is commonly by direct contact through the bite or scratch of an infected rat. Confirmation is by identification of <i>Spirillum</i> in blood or tissue samples.  <b>Inclusions:</b> Sodoku
<b>1B90.1</b>	<b>Streptobacillosis</b> A disease caused by an infection with the gram-negative bacteria <i>Streptobacillus moniliformis</i> . This disease is characterised by systemic illness with fever, chills, rash, and polyarthralgias. Transmission is commonly by direct contact through the bite or scratch of an infected rat. Confirmation is by identification of <i>Streptobacillus</i> in blood or joint samples.  <b>Inclusions:</b> Epidemic arthritic erythema Haverhill fever Streptobacillary rat-bite fever

**1B91**

### **Leptospirosis**

A disease caused by an infection with the gram-negative bacteria Leptospira. In the first phase, this disease is characterised by generalised illness (fever, chills, or myalgias) or individuals may be asymptomatic; in the second phase, the heart, liver, kidneys, or brain may be affected by the infection (symptoms are dependent on the site affected). Transmission is by ingestion of contaminated food or water, droplet transmission, or direct cutaneous contact. Confirmation is by identification of Leptospira in samples from the affected individual.

**1B92**

### **Glanders**

A disease caused by an infection with the gram-negative bacteria Burkholderia mallei. This disease presents with symptoms depending on the route of infection. Transmission is by contact with tissues or body fluids from infected animals (typically horses), or inhalation of infected aerosol. Confirmation is by identification of Burkholderia mallei in blood, sputum, urine, or skin samples.

**Inclusions:** Infection due to Pseudomonas mallei

**1B93**

### **Plague**

A disease caused by an infection with the gram-negative bacteria Yersinia pestis. This disease presents with symptoms depending on the site of infection, and may be fatal. Transmission is through the bite of an infected flea, by direct contact, or by droplet transmission.

**1B93.0**

#### **Bubonic plague**

A disease caused by an infection with the gram-negative bacteria Yersinia pestis. This disease commonly presents with an infection of the lymph nodes leading to swelling and pain. This disease may also present with gangrene of the extremities, chills, malaise, high fever, muscle cramps, or seizures. Transmission is through the bite of an infected flea, by direct contact, or by droplet transmission.

**1B93.1**

#### **Cellulocutaneous plague**

Cellulocutaneous plague is a zoonotic disease caused by Yersinia pestis (formerly known as Pasteurella pestis) involving the skin around the flea bite which transmitted the pathogen.

**1B93.2**

#### **Pneumonic plague**

Pneumonic plague is a zoonotic disease caused by Yersinia pestis (formerly known as Pasteurella pestis) involving the lung. The lungs are seeded by hematogenous spread or from inhalation of the pathogen.

**1B93.3**

#### **Plague meningitis**

Plague meningitis is a zoonotic disease caused by Yersinia pestis (formerly known as Pasteurella pestis) that involves the central nervous system.

**1B93.Y**

#### **Other specified plague**

**1B93.Z**

#### **Plague, unspecified**

**1B94**

### **Tularaemia**

A disease caused by an infection with *Francisella tularensis*. This disease is characterised by fever, chills, headache, and weakness, as well as other symptoms depending on the route of infection. Transmission is through the bite of an infected tick or deer fly, by ingestion of contaminated water or food, airborne transmission, or by direct contact with infected animals. Confirmation is by identification of *Francisella tularensis*, or the presence of antibodies to *Francisella tularensis*, in a blood or sputum sample.

**Inclusions:**

- deer-fly fever
- rabbit fever
- infection due to *Francisella tularensis*

**1B94.0**

### **Ulceroglandular tularaemia**

**1B94.Y**

### **Other specified tularaemia**

**1B94.Z**

### **Tularaemia, unspecified**

**1B95**

### **Brucellosis**

A disease caused by an infection with the gram-negative bacteria *Brucella*. This disease is characterised by fever, muscular pain, or sweating. Transmission is by ingestion of unpasteurized milk and soft cheeses made from infected animals. Confirmation is by identification of *Brucella* or antibodies to *Brucella*.

**Inclusions:**

- Malta fever
- Mediterranean fever
- undulant fever

**Coded Elsewhere:** Spondylitis in brucellosis (FA13)

**1B96**

### **Erysipeloid**

A disease caused by an infection with the gram-positive bacteria *Erysipelothrix rhusiopathiae*. This disease is characterised by localised cellulitis. Transmission is by direct cutaneous contact with *Erysipelothrix rhusiopathiae*, often in individuals handling seafood and raw meat.

**1B97**

### **Anthrax**

A disease caused by an infection with the gram-positive bacteria *Bacillus anthracis*. This disease presents with clinical signs depending on the route of infection. Transmission is by inhalation, ingestion, or cutaneous contact with *Bacillus anthracis* spores. Confirmation is by identification of *Bacillus anthracis* in a sample, or detection of antibodies or toxins.

**1B98**

### **Cat-scratch disease**

A disease commonly caused by an infection with the gram-negative bacteria *Bartonella henselae*. This disease is characterised by regional lymphadenopathy, or fever. Transmission is commonly from the scratch or bite of a cat infested with fleas infected with *Bartonella henselae*.

**Inclusions:**

- Cat-scratch fever
- Rochalimaea henselae* infection

**1B99**

### **Pasteurellosis**

A disease caused by an infection with the gram-negative bacteria Pasteurella. This disease is characterised by local cellulitis and may lead to other clinical signs depending on the route of infection. Transmission is commonly by direct contact through the bite, scratch, or lick from an infected animal, inhalation of infected respiratory secretions, or ingestion of contaminated meat. Confirmation is by identification of Pasteurella from the affected individual.

**1B9A**

### **Extraintestinal yersiniosis**

A disease caused by an infection with the gram-negative bacteria Yersinia enterocolitica, excluding infections in the intestinal tract. This disease presents with symptoms depending on the site of infection, and may lead to a systemic infection. Transmission is by the faecal-oral route from the ingestion of contaminated food or water, or direct contact with infected animals or humans. Confirmation is by identification of Yersinia enterocolitica from affected tissues.

**Exclusions:** Enteritis due to Yersinia enterocolitica (1A05)  
Plague (1B93)

**1B9Z**

### **Unspecified zoonotic bacterial disease**

## **Other bacterial diseases (1C10-1C4Z)**

**Coded Elsewhere:** Other bacterial infections of the fetus or newborn (KA61)

Bacterial duodenitis (DA51.6Y)

**1C10**

### **Actinomycosis**

A disease commonly caused by an infection with the gram-positive bacteria Actinomyces. This disease is characterised by painful abscesses in the mouth, lungs, and gastrointestinal tract. Actinomycosis is an endogenous infection whose causative bacteria originate from the patient's oral and pharyngeal flora. It can spread by continuity and hematogenously. Confirmation is by identification of Actinomyces in infected tissue or fluid samples.

**Exclusions:** Actinomycetoma (1C43)

**1C10.0**

### **Pulmonary actinomycosis**

This is a pulmonary infectious bacterial disease caused by Actinomyces species such as *Actinomyces israelii* or *A. gerencseriae*. It can also be caused by *Propionibacterium propionicus*, and the condition is likely to be polymicrobial aerobic-anaerobic infection.

**1C10.1**

### **Abdominal actinomycosis**

This is a cervicofacial infectious bacterial disease caused by Actinomyces species such as *Actinomyces israelii* or *A. gerencseriae*. It can also be caused by *Propionibacterium propionicus*, and the condition is likely to be polymicrobial aerobic anaerobic infection.

<b>1C10.2</b>	<b>Cervicofacial actinomycosis</b> Cervicofacial actinomycosis is the commonest clinical form of actinomycosis, a sporadically occurring endogenous polymicrobial inflammatory process in which fermentative actinomycetes of the genera <i>Actinomyces</i> (especially <i>A. israelii</i> and <i>A. gerencseriae</i> ), <i>Propionibacterium</i> and <i>Bifidobacterium</i> act as the principal pathogens. The typical presentation is a slowly progressive development from painless tissue infiltration and induration of soft tissues of the face and neck to multiple abscesses and draining sinus tracts discharging pus. Actinomycosis is a major factor and indicator of poor prognosis in infected osteoradionecrosis of the jaws following radiation therapy for head and neck cancer.
<b>1C10.3</b>	<b>Primary cutaneous actinomycosis</b>
<b>1C10.Y</b>	<b>Other specified forms of actinomycosis</b>
<b>1C10.Z</b>	<b>Actinomycosis, unspecified</b>
<b>1C11</b>	<p><b>Bartonellosis</b> Any infection caused by the gram-negative bacteria <i>Bartonella</i>. <b>Coded Elsewhere:</b> Cat-scratch disease (1B98)</p>
<b>1C11.0</b>	<b>Carrion disease</b> Infection by <i>Bartonella bacilliformis</i> which can present as a systemic illness, Oroya fever, or as a benign skin eruption, verruga peruana.
<b>1C11.00</b>	Oroya fever A disease commonly caused by an infection with the gram-negative bacteria <i>Bartonella bacilliformis</i> . This disease is characterised by severe haemolytic anaemia and transient immunosuppression. This disease may present with fever, malaise, or jaundice. Transmission is through the bite of infected sandflies from the genus <i>Lutzomyia</i> . Confirmation is by identification of <i>Bartonella bacilliformis</i> in a blood sample.
<b>1C11.01</b>	Verruga peruana A disease caused by an infection with the gram-negative bacteria <i>Bartonella bacilliformis</i> . This disease is characterised by multiple nodular and red-to-purple vascular skin lesions, subsequent to Oroya fever. Transmission is through the bite of infected sandflies from the genus <i>Lutzomyia</i> .
<b>1C11.1</b>	<b>Trench fever</b> A disease caused by an infection with the gram-negative bacteria <i>Bartonella quintana</i> . This disease is characterised by fever, headache, rash, bone pain, or may be asymptomatic. Transmission is through the bite of infected body lice. Confirmation is by identification of <i>Bartonella quintana</i> in a blood sample. <i>Bartonella quintana</i> was formerly known as <i>Rickettsia quintana</i> . <b>Inclusions:</b> Quintan fever
<b>1C11.Y</b>	<b>Other forms of bartonellosis</b>
<b>1C11.Z</b>	<b>Bartonellosis, unspecified</b>

**1C12****Whooping cough**

A disease of the upper respiratory tract, caused by an infection with the gram-negative bacteria *Bordetella*. This disease typically presents with paroxysmal cough, inspiratory whoop, and fainting or vomiting after coughing. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of *Bordetella* from nasopharyngeal samples or sputum, or detection of antibodies against *Bordetella*.

**1C12.0****Whooping cough due to *Bordetella pertussis***

A disease of the upper respiratory tract, caused by an infection of the gram-negative bacteria *Bordetella pertussis*. This disease typically presents with paroxysmal cough, inspiratory whoop, and fainting or vomiting after coughing. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of *Bordetella pertussis* from nasopharyngeal samples or sputum, or detection of antibodies against *Bordetella pertussis*.

**1C12.1****Whooping cough due to *Bordetella parapertussis***

A disease of the upper respiratory tract, caused by an infection of the gram-negative bacteria *Bordetella parapertussis*. This disease typically presents with a mild clinical presentation of paroxysmal cough, inspiratory whoop, and fainting or vomiting after coughing. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of *Bordetella parapertussis* from nasopharyngeal samples or sputum, or detection of antibodies against *Bordetella parapertussis*.

**1C12.Y****Other specified whooping cough****1C12.Z****Whooping cough, unspecified****1C13****Tetanus**

A disease of the skeletal muscle fibres, caused by an infection with the gram-positive bacteria *Clostridium tetani*. This disease is characterised by muscle spasms. Transmission is by direct contact of an open wound.

**Exclusions:**      Obstetrical tetanus (1C14)

                          Tetanus neonatorum (1C15)

**1C14****Obstetrical tetanus**

A disease caused by an infection with the gram-positive bacteria *Clostridium tetani*. This disease is characterised by a prolonged contraction of skeletal muscle fibres during pregnancy or within six weeks of termination of pregnancy. Transmission is by direct contact.

**1C15****Tetanus neonatorum**

A disease affecting neonates, caused by an infection with the gram-positive bacteria *Clostridium tetani*. This disease is characterised by systemic muscle spasms that arise within the first few days after delivery. Transmission is commonly by direct contact or lack of maternal immunity.

**1C16****Gas gangrene**

Gas gangrene or clostridial myonecrosis is a potentially fatal, rapidly progressive necrotizing infection of muscle and soft tissue resulting from bacterial invasion of healthy muscle from adjacent traumatized muscle or soft tissue. The infection originates in a wound contaminated with bacteria of the genus Clostridium. *C. perfringens* accounts for the majority of cases (over eighty percent), while *C. novyi*, *C. septicum*, and *C. histolyticum* cause most of the other cases.

**1C17****Diphtheria**

A disease commonly of the respiratory system, caused by an infection of the gram-positive bacteria *Corynebacterium diphtheriae*. This disease is characterised by sore throat, fever, and a pseudomembrane on the tonsils, pharynx, or nasal cavity. Transmission is by inhalation of infected respiratory secretions, or direct cutaneous contact. Confirmation is by identification of *Corynebacterium diphtheriae* from a throat swab or infected tissue, and by clinical signs.

**1C17.0****Pharyngeal or tonsillar diphtheria**

**Inclusions:** Diphtheritic membranous angina

**1C17.00**

Postdiphtheritic paralysis of uvula

**1C17.0Y**

Other specified pharyngeal or tonsillar diphtheria

**1C17.0Z**

Pharyngeal or tonsillar diphtheria, unspecified

**1C17.1****Nasal diphtheria****1C17.2****Laryngeal diphtheria**

localised infection of mucous membranes of the larynx caused by toxigenic strains of *Corynebacterium diphtheriae*; it is characterised by the presence of a pseudomembrane at the site of infection; diphtheria toxin, produced by *C. diphtheriae*, can cause myocarditis, polyneuritis, and other systemic toxic effects.

**Inclusions:** Diphtheritic laryngotracheitis

**1C17.3****Cutaneous diphtheria**

**Exclusions:** Erythrasma (1C44)

**1C17.Y**

Other specified diphtheria

**1C17.Z**

Diphtheria, unspecified

**1C18****Brazilian purpuric fever**

A disease affecting children, caused by an infection with the gram-negative bacteria *Haemophilus aegyptius*. This disease is characterised by fever, nausea, vomiting, purpuric lesions, and sepsis, that is preceded by conjunctivitis. Transmission may be by mechanical transmission from infected eye gnats, contact with discharge from infected individuals, or fomites used near the eyes. Confirmation is by identification of *Haemophilus influenzae* from blood.

**Inclusions:** Systemic *Haemophilus aegyptius* infection

**1C19**

### **Legionellosis**

Legionellosis varies in severity from a mild febrile illness to a serious and sometimes fatal form of pneumonia and is caused by exposure to Legionella species found in water, and potting mixes.

Legionellosis is a generic term describing the pneumonic and non-pneumonic forms of infection with Legionella.

**1C19.0**

### **Nonpneumonic Legionnaires' disease**

The non-pneumonic form (Pontiac fever) is an acute, self-limiting flu-like illness usually lasting 2–5 days. The incubation period is from a few and up to 48 hours. The main symptoms are fever, chills, headache, malaise and muscle pain (myalgia).

**1C19.1**

### **Legionnaires' disease**

Legionnaires' disease, the pneumonic form, has an incubation period of 2 to 10 days (but up to 16 days has been recorded in some outbreaks). Initially, symptoms are fever, loss of appetite, headache, malaise and lethargy. Some patients may also have muscle pain, diarrhoea and confusion. There is also usually an initial mild cough, but as many as 50% of patients can present phlegm. Blood-streaked phlegm or hemoptysis occurs in about one-third of the patients. The severity of disease ranges from a mild cough to a rapidly fatal pneumonia. Death occurs through progressive pneumonia with respiratory failure and/or shock and multi-organ failure.

**1C19.Z**

### **Legionellosis, unspecified**

**1C1A**

### **Listeriosis**

A disease caused by an infection with the gram-positive bacteria Listeria. This disease commonly presents with fever and muscle aches, followed by gastrointestinal symptoms.

**Inclusions:** listerial foodborne infection

**Coded Elsewhere:** Neonatal listeriosis (KA61.1)

**1C1A.0**

### **Cutaneous listeriosis**

This is a bacterial infection caused by a Gram-positive, motile bacterium, Listeria monocytogenes. Listeriosis occurs primarily in newborn infants, elderly patients, and patients who are immunocompromised.

**1C1A.1**

### **Listerial meningitis or meningoencephalitis**

A disease of the meninges or brain, caused by an infection with the gram-positive bacteria Listeria. This disease is characterised by fever, headache, or neurological deficits. Transmission is through haematogenous spread to the meninges from ingestion of contaminated food. Confirmation is by identification of Listeria from cerebrospinal fluid.

**1C1A.Y**

### **Other specified listeriosis**

**1C1A.Z**

### **Listeriosis, unspecified**

**1C1B****Nocardiosis**

A disease caused by an infection with the gram-positive bacteria Nocardia. This disease presents with symptoms depending on the site of infection (commonly lung, brain, or skin). Transmission is by inhalation of Nocardia from soil or water, or by direct cutaneous contact. Confirmation is by identification of Nocardia in samples from affected sites.

**1C1B.0****Pulmonary nocardiosis**

A disease of the respiratory system, caused by an infection with the gram-positive bacteria Nocardia. This disease is characterised by chest pain, haemoptysis, fever, weight loss, and cough. Transmission is by inhalation of Nocardia from soil or water. Confirmation is by identification of Nocardia in sputum samples, or lung biopsy.

**1C1B.1****Cutaneous nocardiosis**

Cutaneous nocardiosis may be due to direct infection of the skin where it presents either as a solitary cold abscess or as a lymphangitic process in which infection spreads up lymphatic channels to form a linear array of suppurative nodules. Skin involvement is also present in a third of cases of systemic nocardiosis.

***Inclusions:***      Actinomycetoma due to Nocardia species (1C43)

**1C1B.Y****Other specified forms of nocardiosis****1C1B.Z****Nocardiosis, unspecified****1C1C****Meningococcal disease**

This illness is severe and includes infections of the lining of the brain and spinal cord (meningitis) and generalised bloodstream infections (bacteraemia or septicaemia).

Meningococcus bacteria are spread through the exchange of respiratory and throat secretions like spit (e.g., by living in close quarters, kissing). Meningococcal disease can be treated with antibiotics, but quick medical attention is extremely important. Keeping up to date with recommended vaccines is the best defence against meningococcal disease.

***Inclusions:***      Meningococcal infection

**1C1C.0****Meningococcal meningitis**

A condition of the meninges, caused by an infection with the gram-negative bacteria Neisseria meningitidis. This condition is characterised by high fever, stiff neck, severe headache, vomiting, purpura, photophobia, and sometimes chills, altered mental status, or seizures. Transmission is through haematogenous spread to the meninges after droplet transmission or direct contact. Confirmation is by identification of Neisseria meningitidis in CSF (cerebrospinal fluid), for example, by agglutination test or polymerase chain reaction.

***Inclusions:***      Meningitis due to Neisseria meningitidis

<b>1C1C.1</b>	<b>Waterhouse-Friderichsen syndrome</b> A syndrome characterised by adrenal insufficiency due to bleeding into the adrenal glands (mostly bilateral but sometimes also unilateral) due to the severe infection, commonly caused by an infection with meningococcus ( <i>Neisseria meningitidis</i> ). However, it can also be caused by infections with other bacteria such as <i>Streptococcus pneumoniae</i> or <i>Haemophilus influenzae</i> or even due to some severe viral infections.  This syndrome may present with fever, chills, vomiting, myalgia, or rash, with progression to disseminated intravascular coagulation. Transmission of the underlying infections is by direct contact or droplet transmission.  <i>Inclusions:</i> meningococcal haemorrhagic adrenalitis
<b>1C1C.2</b>	<b>Meningococcaemia</b> A condition caused by an infection with the gram-negative bacteria <i>Neisseria meningitidis</i> that leads to a severe systemic inflammatory response. This condition is characterised by fever, rash, and myalgia. Transmission is by direct contact or droplet transmission. Confirmation is by identification of <i>Neisseria meningitidis</i> in blood samples.
<b>1C1C.20</b>	Acute meningococcaemia A condition caused by an infection with the gram-negative bacteria <i>Neisseria meningitidis</i> that leads to a severe systemic inflammatory response. This condition is characterised by fever, chills, myalgia, nausea, or petechial rash, with progression to shock and disseminated intravascular coagulation. Transmission is by direct contact or droplet transmission. Confirmation is by identification of <i>Neisseria meningitidis</i> in blood samples.
<b>1C1C.2Y</b>	Other specified meningococcaemia
<b>1C1C.2Z</b>	Meningococcaemia, unspecified
<b>1C1C.Y</b>	<b>Other specified meningococcal disease</b>
<b>1C1C.Z</b>	<b>Meningococcal disease, unspecified</b>
<b>1C1D</b>	<b>Yaws</b> An infectious disease caused by <i>Treponema pallidum</i> subsp. <i>pertenue</i> which mainly affects children in rural communities in the humid tropics. It affects the skin and bones, is spread by skin to skin contact, and is not sexually transmitted, but cannot be distinguished serologically from syphilis.

<b>1C1D.0</b>	<b>Primary yaws</b> Primary yaws results from primary inoculation of <i>Treponema pallidum</i> subsp. <i>pertenue</i> into the skin, manifesting 2-12 weeks later as a localised papule (initial, primary or 'mother' yaw) before developing into a large non-tender ulcerating nodule, often resembling a raspberry (hence the name 'framboesia'). The primary lesion is most commonly located on the legs and ankles may also be found on the buttocks, arms, hands, and face. It usually heals after 3–6 months and is still present at the onset of the secondary stage in only a minority (9-15%).
	<b>Inclusions:</b> Chancre of yaws Primary framboesia
<b>1C1D.1</b>	<b>Secondary yaws</b> Secondary yaws results from lymphatic and haematogenous spread of <i>Treponema pallidum</i> subsp. <i>pertenue</i> spirochaetes from the initial inoculation site and appears from a few weeks to 2 years after the primary infection. The commonest initial symptoms are non-specific and include arthralgia and malaise. Secondary skin lesions consist of multiple papules and nodules similar to the initial lesion but smaller. They may be localised, regional or generalised; they may ulcerate and on moist areas may mimic syphilitic condylomata lata. Hyperkeratotic plaques on the palms and soles may develop painful fissures and secondary infection, resulting in a characteristic 'crab-like' gait.
<b>1C1D.2</b>	<b>Tertiary yaws</b> Tertiary yaws develops in <10% of untreated infected individuals after an interval of 5 years or more. The late stage skin lesions are characterised by gummatous nodules with necrotic tissue destruction, followed by debilitating scarring and contracture. Destructive osteitis can result in ulceration of the palate and nasopharynx ('gangosa'), or bowing of the tibia (sabre shins). Hypertrophic periostitis at periarticular sites can lead to exostosis of the paranasal maxillae ('goundou').
<b>1C1D.3</b>	<b>Latent yaws</b> Latent yaws is defined as yaws with no clinical signs and only serological evidence of infection (reactive treponemal and non-treponemal tests). Infectious relapses may occur in latent cases for up to 5 and, rarely, 10 years. The total duration of infectivity for an untreated yaws patient, including relapses, is thought to be about 12-18 months.
	<b>Inclusions:</b> Yaws without clinical manifestations, with positive serology
<b>1C1D.Z</b>	<b>Yaws, unspecified</b>
<b>1C1E</b>	<b>Pinta</b> A disease of the skin, caused by an infection with the gram-negative bacteria <i>Treponema pallidum</i> carateum. This disease is characterised by hyperkeratosis and hyperpigmentation. Transmission may be by direct contact.
<b>1C1E.0</b>	<b>Primary lesions of pinta</b> The primary stage of pinta is characterised by a sparse eruption of cutaneous papules and erythematous scaly plaques. This stage may last for months to years.
	<b>Inclusions:</b> Primary chancre of pinta

- 1C1E.1** **Intermediate lesions of pinta**  
The intermediate stage of pinta develops months to years after the primary stage and is characterised by more extensive lesions (known as pintids) which gradually change from pink to blue, black or grey and become atrophic.
- Inclusions:** Pintids
- 1C1E.2** **Late lesions of pinta**  
Late lesions of pinta are confined to the skin and are characterised by dyschromia and atrophy. They typically take between two and four years to develop following initial infection. The skin appears mottled and atrophic with numerous irregular and variegated hypermelanotic, hypomelanotic and amelanotic patches typically involving the wrists, palms, ankles, and elbows, as well as the skin around and within old lesions.
- Inclusions:** Hypomelanosis due to late pinta
- 1C1E.3** **Mixed lesions of pinta**
- 1C1E.Z** **Pinta, unspecified**
- 1C1F** **Endemic non-venereal syphilis**  
Endemic non-venereal syphilis is caused by *Treponema pallidum* subspecies *endemicum* and is transmitted by skin-to-skin or mouth-to-mouth contact rather than sexual contact. Children are at greatest risk of infection. Clinical features are similar to venereal syphilis with a primary ulcer (usually in the mouth or on the nipples of breast-feeding women nursing infected children) and, in the secondary stage, a generalised papular rash, oral mucous patches, condylomata lata and generalised lymphadenopathy. Late stage infection is characterised by destructive gummatous (gangosa), bones and skin.
- Inclusions:** Bejel  
Endemic syphilis  
Njovera
- 1C1G** **Lyme borreliosis**  
A tick-borne infection by the spirochaete *Borrelia burgdorferi*. Lyme borreliosis typically presents with a characteristic rash, erythema chronicum migrans, at an average of seven days after a bite from an infected tick. The rash may be accompanied by flu-like symptoms. Disseminated infection may cause meningitis, cranial neuropathies and carditis amongst other manifestations. Late disease, months to years after initial infection, may present with a pauciarticular arthritis or with encephalomyelitis.
- Coding Note:** Use additional code if desired, to identify any associated condition.  
Use additional code, if desired, to identify any sequelae. The extension code 'Cause of late effect' is used in addition to both codes to show the relationship between the causative condition and the resulting sequelae.
- 1C1G.0** **Early cutaneous Lyme borreliosis**  
*Borrelia burgdorferi* infection involving the skin, typically as erythema migrans, the commonest presentation of Lyme disease.
- Coding Note:** Use additional code if desired, to identify any associated condition.

<b>1C1G.1</b>	<b>Disseminated Lyme borreliosis</b>
<b>Coding Note:</b>	Use additional code if desired, to identify any associated condition.
<b>1C1G.10</b>	Lyme neuroborreliosis
<b>1C1G.11</b>	Lyme carditis
<b>1C1G.12</b>	Ophthalmic Lyme borreliosis
<b>1C1G.13</b>	Lyme arthritis
<b>1C1G.14</b>	Late cutaneous Lyme borreliosis
<b>1C1G.1Y</b>	Other specified disseminated Lyme borreliosis
<b>Coding Note:</b>	Use additional code if desired, to identify any associated condition.
<b>1C1G.1Z</b>	Disseminated Lyme borreliosis, unspecified
<b>Coding Note:</b>	Use additional code if desired, to identify any associated condition.
<b>1C1G.Y</b>	<b>Other specified Lyme borreliosis</b>
<b>Coding Note:</b>	Use additional code if desired, to identify any associated condition.
	Use additional code, if desired, to identify any sequelae. The extension code 'Cause of late effect' is used in addition to both codes to show the relationship between the causative condition and the resulting sequelae.
<b>1C1G.Z</b>	<b>Lyme borreliosis, unspecified</b>
<b>Coding Note:</b>	Use additional code if desired, to identify any associated condition.
	Use additional code, if desired, to identify any sequelae. The extension code 'Cause of late effect' is used in addition to both codes to show the relationship between the causative condition and the resulting sequelae.
<b>1C1H</b>	<b>Necrotising ulcerative gingivitis</b>
	Necrotising ulcerative gingivitis (NUG) is a condition affecting the gums that is caused by a bacterial infection. It is a form of periodontal (gum) disease. But unlike other forms, it typically develops quickly and causes moderate to severe pain. "Necrotising" means that the condition destroys tissue. "Ulcerative" refers to sores that can appear on the gums.
	<b>Inclusions:</b> Fusospirochaetal gangrene
<b>1C1H.0</b>	<b>Other Vincent infections</b>
<b>1C1H.Y</b>	<b>Other specified necrotising ulcerative gingivitis</b>
<b>1C1H.Z</b>	<b>Necrotising ulcerative gingivitis, unspecified</b>
<b>1C1J</b>	<b>Relapsing fever</b>

<b>1C1J.0</b>	<b>Tick-borne relapsing fever</b> A disease caused by an infection with the bacteria Borrelia. This disease is characterised by repeated episodes of fever, with the febrile episode lasting for approximately 3 days, followed by the afebrile state of approximately 7 days. Transmission is through the bite of an infected soft tick (from the genus <i>Ornithodoros</i> ). Confirmation is by identification of spirochete bacteria from a blood smear, bone marrow, or cerebrospinal fluid.  <b>Inclusions:</b> Relapsing fever due to any <i>Borrelia</i> species other than <i>Borrelia recurrentis</i>
<b>1C1J.1</b>	<b>Louse-borne relapsing fever</b> A spirochaetal infection caused by the human to human transmission of <i>Borrelia recurrentis</i> by the human body louse. Epidemics are associated with poor living conditions as may result from famine or war. Episodic fever may progress to severe jaundice, haemorrhage, confusion and death. Confirmation is by identification of <i>Borrelia</i> in blood films.  <b>Inclusions:</b> Relapsing fever due to <i>Borrelia recurrentis</i>
<b>1C1J.Z</b>	<b>Relapsing fever, unspecified</b>
Other diseases due to chlamydiae (1C20-1C2Z)	
<b>1C20</b>	<b>Chlamydial conjunctivitis</b> Chlamydial conjunctivitis is a sexually transmitted infection of conjunctiva caused by bacteria <i>Chlamydia trachomatis</i> . Bacteria can be passed from an infected mother to baby during vaginal childbirth. The symptoms include that one or both eyes will be red with a sticky discharge and swollen eyelids.  <b>Inclusions:</b> Paratrachoma
<b>1C21</b>	<b>Chlamydial peritonitis</b> This is a sexually transmitted infection that causes an inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs.
<b>1C22</b>	<b>Infections due to Chlamydia psittaci</b> Any condition caused by an infection with the gram-negative bacteria <i>Chlamydia psittaci</i> . These conditions are characterised by variable clinical presentations such as fever, cough, headaches, chills, fatigue, nausea, vomiting, diarrhoea, or pneumonia. Transmission is commonly by inhalation of aerosol contaminated with body fluids from infected birds, or direct contact with infected birds. Confirmation is by identification of <i>Chlamydia psittaci</i> .  <b>Inclusions:</b> Psittacosis Ornithosis Parrot fever  <b>Coded Elsewhere:</b> Pneumonia in chlamydia psittaci infection (CA40.0Y)

**1C23****Trachoma**

A disease caused by an infection with the gram-negative bacteria Chlamydia trachomatis. This disease is characterised by a roughening of the inner surfaces of the eyes, and inflammation that may lead to superficial vascularization of the cornea (pannus) and scarring of the conjunctiva. Long term effects include blindness or other visual impairments. Transmission is by direct or indirect contact with the eyes or nose of an infected individual.

**1C23.0****Initial stage of trachoma**

This refers to the initial stage of an infectious disease caused by the Chlamydia trachomatis bacterium which produces a characteristic roughening of the inner surface of the eyelids.

**Inclusions:** Trachoma dubium

**1C23.1****Active stage of trachoma**

This refers to the active stage of an infectious disease caused by the Chlamydia trachomatis bacterium which produces a characteristic roughening of the inner surface of the eyelids.

**1C23.Y****Other specified trachoma****1C23.Z****Trachoma, unspecified****1C2Y****Other specified diseases due to chlamydiae****1C2Z****Diseases due to chlamydiae, unspecified****Rickettsioses (1C30-1C3Z)**

Any disease caused by an infection with the gram-negative bacteria Rickettsia. These diseases commonly present with fever, malaise, and rash. Transmission is commonly through the bite of an infected flea, louse, mite, or tick.

**Coded Elsewhere:** Trench fever (1C11.1)

**1C30****Typhus fever**

A disease caused by an infection with the gram-negative bacteria Rickettsia. This disease is characterised by fever, delirium, back pain, or arthralgia. Transmission is commonly through the bite of an infected flea, louse, mite, or tick.

**Exclusions:** Rickettsiosis due to Ehrlichia sennetsu (1C30-1C3Z)

**1C30.0****Epidemic louse-borne typhus fever due to Rickettsia prowazekii**

This is a form of typhus so named because the disease often causes epidemics following wars and natural disasters. The causative organism is Rickettsia prowazekii, transmitted by the human body louse (*Pediculus humanus corporis*). This diagnosis is due to a species of gram-negative, obligate intracellular parasitic, aerobic bacteria (belonging to the class Alphaproteobacteria) that is the aetiological agent of epidemic typhus, transmitted in the faeces of lice.

- 1C30.1 Recrudescent typhus**  
This is a form of typhus so named because the disease often causes epidemics following wars and natural disasters. The causative organism is Rickettsia prowazekii, transmitted by the human body louse (*Pediculus humanus corporis*).  
*Inclusions:* Brill-Zinsser disease
- 1C30.2 Typhus fever due to *Rickettsia typhi***
- 1C30.3 Typhus fever due to *Orientia tsutsugamushi***  
*Inclusions:* Tsutsugamushi fever
- 1C30.Y Other specified typhus fever**
- 1C30.Z Typhus fever, unspecified**
- 1C31 Spotted fever**  
A disease caused by an infection with the gram-negative bacteria Rickettsia. This disease is characterised by fever, eschar, or rash. Transmission is commonly through the bite of an infected tick.
- 1C31.0 Spotted fever due to *Rickettsia rickettsii***  
*Inclusions:* Rocky Mountain spotted fever  
Sao Paulo fever
- 1C31.1 Spotted fever due to *Rickettsia conorii***  
*Inclusions:* Boutonneuse fever  
Mediterranean tick fever  
African tick typhus  
Kenya tick typhus
- 1C31.2 Spotted fever due to *Rickettsia sibirica***  
*Inclusions:* North Asian tick fever  
Siberian tick typhus
- 1C31.3 Spotted fever due to *Rickettsia australis***  
*Inclusions:* Queensland tick typhus
- 1C31.Y Other specified spotted fever**
- 1C31.Z Spotted fever, unspecified**
- 1C32 Rickettsialpox**  
An acute febrile disease caused by *Rickettsia akari*, which is transmitted from its rodent host by the house-mouse mite *Liponyssoides sanguineus*. An initial skin lesion at the site of a mite bite, often associated with lymphadenopathy, is followed by fever; a disseminated skin rash appears, which generally does not involve the palms and the soles, and lasts only a few days. Death is uncommon.  
*Inclusions:* Kew Gardens spotted fever

**1C33****Q fever**

A disease caused by an infection with the gram-negative bacteria *Coxiella burnetti*. This disease is characterised by fever, or may be asymptomatic. Transmission is by inhalation of the bacteria, contact with contaminated milk, urine, faeces, vaginal mucus, or semen of infected animals, or through the bite of an infected tick.

**Inclusions:** Nine Mile fever

Infection due to *Coxiella burnetii*

Quadrilateral fever

**1C3Y****Other specified rickettsioses****1C3Z****Rickettsioses, unspecified****1C40****Campylobacteriosis**

Campylobacteriosis is caused by *Campylobacter* bacteria (curved or spiral, motile, non-spore-forming, Gram-negative rods). The disease is usually caused by *C. jejuni*, a spiral and comma shaped bacterium normally found in cattle, swine, and birds, where it is nonpathogenic, but the illness can also be caused by *C. coli* (also found in cattle, swine, and birds), *C. upsaliensis* (found in cats and dogs) and *C. lari* (present in seabirds in particular).

**1C41****Bacterial infection of unspecified site**

**Exclusions:** meningococcal infection NOS (1C1C)

chlamydial infection NOS (1C20-1C2Z)

rickettsial infection NOS (1C30-1C3Z)

spirochaetal infection NOS (1C10-1C4Z)

Infection arising from device, implant or graft, not elsewhere classified (NE83.1)

**Coded Elsewhere:** Acute meningococcaemia (1C1C.20)

Disseminated gonococcal infection (1A73)

**1C42****Melioidosis**

A disease caused by the saprophytic environmental gram-negative bacterium *Burkholderia pseudomallei* which is found in soil or water in humid tropical regions of the world, especially South-East Asia and northern Australia. It has protean manifestations ranging from fulminant septicaemia with fatal outcome to chronic low grade infection.

**1C43****Actinomycetoma**

Actinomycetoma is a chronic progressive subcutaneous infection caused by implantation of aerobic branching actinomycetes through a skin wound. These organisms are filamentous bacteria which live as saprophytes in soil or on plants; the commonest infecting agents are Nocardia brasiliensis, Actinomadura madurae and Streptomyces somaliensis. The earliest stage of infection is a firm painless nodule but with time the whole area becomes hard and swollen with multiple papules, pustules and draining sinuses on the skin surface. Extension to underlying bones and joints can result in gross deformity.

**Inclusions:** Mycetoma due to filamentous bacteria

**Exclusions:** Eumycetoma (1F29)

**1C44****Non-pyogenic bacterial infections of the skin**

Skin infection by bacteria which do not characteristically induce pus formation.

**1C45****Toxic shock syndrome**

**Exclusions:** endotoxic shock NOS (1G41)

**1C45.0 Streptococcal toxic shock syndrome****1C45.1 Staphylococcal toxic shock syndrome****1C45.Y Toxic shock syndrome due to other specified infectious agent****1C45.Z Toxic shock syndrome without specified infectious agent****1C4Y****Other specified bacterial diseases****1C4Z****Unspecified bacterial disease****Human immunodeficiency virus disease (1C60-1C62.Z)**

A case of HIV infection is defined as an individual with HIV infection irrespective of clinical stage including severe or stage 4 clinical disease (also known as AIDS) confirmed by laboratory criteria according to country definitions and requirements.

**Coded Elsewhere:** Congenital human immunodeficiency virus infection (KA62.6)

**1C60****Human immunodeficiency virus disease associated with tuberculosis**

**Coded Elsewhere:** Human immunodeficiency disease complicating pregnancy, childbirth or the puerperium (JB63.7)

**1C60.0****HIV disease clinical stage 1 associated with tuberculosis**

**Coded Elsewhere:** Human immunodeficiency virus disease associated with generalised lymphadenopathy (1C62.0)

Acute human immunodeficiency virus infection syndrome  
(1C62.0)

<b>1C60.1</b>	<b>HIV disease clinical stage 2 associated with tuberculosis</b>
	<b>Coded Elsewhere:</b> HIV-associated immune reconstitution inflammatory syndrome (4B23)
	Herpes resulting from human immunodeficiency virus disease (1C62.1)
	Human immunodeficiency virus disease associated with mycosis classified elsewhere (1C62.1)
<b>1C60.2</b>	<b>HIV disease clinical stage 3 associated with tuberculosis</b>
	<b>Coded Elsewhere:</b> Human immunodeficiency virus disease associated with haematological or immunological abnormalities (1C62.2)
	Human immunodeficiency virus disease associated with lymphoid interstitial pneumonitis (1C62.2)
	Human immunodeficiency virus disease enteritis (1C62.2)
	Gastritis due to human immunodeficiency virus disease (1C62.2)
	Myelitis due to Human immunodeficiency virus (1C62.2)
	Meningitis due to human immunodeficiency virus (1C62.2)
	HIV disease resulting in candidosis classified elsewhere (1C62.2)
	HIV disease resulting in cytomegaloviral disease (1C62.2)
<b>1C60.3</b>	<b>HIV disease clinical stage 4 associated with tuberculosis</b>
	<b>Coded Elsewhere:</b> Dementia due to human immunodeficiency virus (6D85.3)
	HIV retinitis (9B72.01)
	HIV - [human immunodeficiency virus] disease associated with Burkitt lymphoma (1C62.3Y)
	Human immunodeficiency virus disease associated with other types of non-Hodgkin lymphoma (1C62.3Y)
	Human immunodeficiency virus disease associated with other malignant neoplasms of lymphoid, haematopoietic or related tissue (1C62.3Y)
	Human immunodeficiency virus disease associated with multiple malignant neoplasms (1C62.3Y)
	Human immunodeficiency virus disease associated with encephalopathy (1C62.3Y)
	Human immunodeficiency virus disease associated with wasting syndrome (1C62.3Y)
	Oesophagitis associated with human immunodeficiency virus disease (DA24.Y)
	HIV or AIDS vacuolar myelopathy (8A45.0Y)
<b>1C60.30</b>	Kaposi sarcoma associated with human immunodeficiency virus disease associated with tuberculosis
<b>1C60.3Y</b>	Other specified HIV disease clinical stage 4 associated with tuberculosis
<b>1C60.3Z</b>	HIV disease clinical stage 4 associated with tuberculosis, unspecified

1C60.Z	<b>Human immunodeficiency virus disease associated with tuberculosis, clinical stage unspecified</b>
1C61	<b>Human immunodeficiency virus disease associated with malaria</b>
	<b>Coded Elsewhere:</b> Human immunodeficiency disease complicating pregnancy, childbirth or the puerperium (JB63.7)
1C61.0	<b>HIV disease clinical stage 1 associated with malaria</b>
	<b>Coded Elsewhere:</b> Human immunodeficiency virus disease associated with generalised lymphadenopathy (1C62.0)
	Acute human immunodeficiency virus infection syndrome (1C62.0)
1C61.1	<b>HIV disease clinical stage 2 associated with malaria</b>
	<b>Coded Elsewhere:</b> HIV-associated immune reconstitution inflammatory syndrome (4B23)
	Herpes resulting from human immunodeficiency virus disease (1C62.1)
	Human immunodeficiency virus disease associated with mycosis classified elsewhere (1C62.1)
1C61.2	<b>HIV disease clinical stage 3 associated with malaria</b>
	<b>Coded Elsewhere:</b> Human immunodeficiency virus disease associated with haematological or immunological abnormalities (1C62.2)
	Human immunodeficiency virus disease associated with lymphoid interstitial pneumonitis (1C62.2)
	Human immunodeficiency virus disease enteritis (1C62.2)
	Gastritis due to human immunodeficiency virus disease (1C62.2)
	Myelitis due to Human immunodeficiency virus (1C62.2)
	Meningitis due to human immunodeficiency virus (1C62.2)
	HIV disease resulting in candidosis classified elsewhere (1C62.2)
	HIV disease resulting in cytomegaloviral disease (1C62.2)

<b>1C61.3</b>	<b>HIV disease clinical stage 4 associated with malaria</b>
	<b>Coded Elsewhere:</b> Dementia due to human immunodeficiency virus (6D85.3)
	HIV retinitis (9B72.01)
	HIV - [human immunodeficiency virus] disease associated with Burkitt lymphoma (1C62.3Y)
	Human immunodeficiency virus disease associated with other types of non-Hodgkin lymphoma (1C62.3Y)
	Human immunodeficiency virus disease associated with other malignant neoplasms of lymphoid, haematopoietic or related tissue (1C62.3Y)
	Human immunodeficiency virus disease associated with multiple malignant neoplasms (1C62.3Y)
	Human immunodeficiency virus disease associated with encephalopathy (1C62.3Y)
	Human immunodeficiency virus disease associated with wasting syndrome (1C62.3Y)
	Oesophagitis associated with human immunodeficiency virus disease (DA24.Y)
	HIV or AIDS vacuolar myelopathy (8A45.0Y)
<b>1C61.30</b>	Kaposi sarcoma associated with human immunodeficiency virus disease associated with malaria
<b>1C61.3Y</b>	Other specified HIV disease clinical stage 4 associated with malaria
<b>1C61.3Z</b>	HIV disease clinical stage 4 associated with malaria, unspecified
<b>1C61.Z</b>	<b>Human immunodeficiency virus disease associated with malaria, clinical stage unspecified</b>
<b>1C62</b>	<b>Human immunodeficiency virus disease without mention of tuberculosis or malaria</b>
	<b>Coded Elsewhere:</b> Human immunodeficiency disease complicating pregnancy, childbirth or the puerperium (JB63.7)
<b>1C62.0</b>	<b>HIV disease clinical stage 1 without mention of tuberculosis or malaria</b>
<b>1C62.1</b>	<b>HIV disease clinical stage 2 without mention of tuberculosis or malaria</b>
	<b>Coded Elsewhere:</b> HIV-associated immune reconstitution inflammatory syndrome (4B23)
<b>1C62.2</b>	<b>HIV disease clinical stage 3 without mention of tuberculosis or malaria</b>
<b>1C62.3</b>	<b>HIV disease clinical stage 4 without mention of tuberculosis or malaria</b>
	<b>Coded Elsewhere:</b> Dementia due to human immunodeficiency virus (6D85.3)
	HIV retinitis (9B72.01)
	Oesophagitis associated with human immunodeficiency virus disease (DA24.Y)
	HIV or AIDS vacuolar myelopathy (8A45.0Y)

- 1C62.30** Kaposi sarcoma associated with human immunodeficiency virus disease without mention of tuberculosis or malaria
- 1C62.3Y** Other specified HIV disease clinical stage 4 without mention of tuberculosis or malaria
- 1C62.3Z** HIV disease clinical stage 4 without mention of tuberculosis or malaria, unspecified
- 1C62.Z** **Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified**

## Viral infections of the central nervous system (1C80-1C8Z)

Any disease of the central nervous system, caused by an infection with a viral source.

**Coded Elsewhere:** Progressive multifocal leukoencephalopathy (8A45.02)

- Enteroviral exanthematous fever (1F05.2)
- Herpes simplex meningitis (1F00.20)
- Subacute sclerosing panencephalitis (8A45.01)
- West Nile virus infection (1D46)
- Colorado tick fever (1D41)
- Zoster meningitis (1E91.3)

### 1C80

#### **Viral encephalitis, not elsewhere classified**

**Coded Elsewhere:** Western equine encephalitis (1C83)

- Eastern equine encephalitis (1C84)
- Venezuelan equine encephalitis (1C8C)
- Argentinian haemorrhagic fever (1D61.0)
- Bolivian haemorrhagic fever (1D61.1)
- Lassa fever (1D61.2)
- La Crosse encephalitis (1C8D)
- Oropouche virus disease (1D43)
- Japanese encephalitis (1C85)
- St Louis encephalitis (1C86)
- Rocio viral encephalitis (1C87)
- Murray Valley encephalitis (1C88)
- Tick-borne encephalitis (1C8G)
- Encephalitis due to herpes simplex virus (1F00.21)
- Encephalitis due to mumps virus (1D80.3)
- Varicella encephalitis (1E90.2)
- Measles complicated by encephalitis (1F03.1)
- Sequelae of viral encephalitis (1G84)
- California encephalitis (1C8B)
- Encephalitis due to Arenavirus (1D61.Y)
- Encephalitis due to Filovirus (1D60.Y)
- Encephalitis due to Influenza virus (1E32)
- Encephalitis due to Rubella virus (1F02.0)

### 1C81

#### **Acute poliomyelitis**

A disease of the nervous system, caused by human poliovirus. This disease commonly presents with a fever, sore throat, headache, vomiting, or stiffness of the neck and back. This disease may present with an acute onset of flaccid paralysis. Transmission is commonly by the faecal-oral route or direct contact. Confirmation is by identification of poliovirus in a faecal sample or by a lumbar puncture.

**1C82**

### **Rabies**

A disease caused by infection with the rabies virus. This disease is characterised by fever, and headache, followed by neurological symptoms dominated by a furious or paralytic form.

**1C83**

### **Western equine encephalitis**

**1C84**

### **Eastern equine encephalitis**

**1C85**

### **Japanese encephalitis**

A disease of the brain, caused by an infection with flavivirus. This disease is characterised by fever, headache, meningism, hyperexcitability, or decreased consciousness. This disease may also present with neurological signs such as cranial nerve palsies, tremor and ataxia, parkinsonism, or upper limb paralysis. Transmission is through the bite of an infected mosquito. Confirmation is by identification of flavivirus in a serum sample or cerebrospinal fluid.

**1C86**

### **St Louis encephalitis**

**1C87**

### **Rocio viral encephalitis**

A disease of the brain, caused by an infection with Rocio virus. In the first phase, this disease is characterised by a fever, headache, vomiting, or conjunctivitis; in the second phase, this disease is characterised by neurological symptoms and muscle weakness. Transmission is through the bite of an infected mosquito. Confirmation is by identification of Rocio virus in a serum or cerebrospinal fluid sample.

**1C88**

### **Murray Valley encephalitis**

A disease of the brain, caused by an infection with Murray Valley encephalitis virus. This disease is characterised by fever, headache, nausea, vomiting, tiredness, or may be asymptomatic. Severe cases may present with confusion, fatigue, lack of coordination, or encephalitis. Transmission is through the bite of an infected mosquito. Confirmation is by detection of anti-Murray Valley encephalitis antibodies in a serum sample.

**Inclusions:** Australian encephalitis

**1C8B**

### **California encephalitis**

**Inclusions:** California meningoencephalitis

**1C8C**

### **Venezuelan equine encephalitis**

**1C8D**

### **La Crosse encephalitis**

**1C8E****Viral meningitis, not elsewhere classified**

Any disease of the meninges, caused by an infection with a viral source.

**Coded Elsewhere:** Meningitis due to mumps virus (1D80.2)

Measles complicated by meningitis (1F03.2)

Herpes simplex meningitis (1F00.20)

Varicella meningitis (1E90.1)

Neonatal meningitis (KA65.4)

Meningitis due to human immunodeficiency virus (1C62.2)

Meningitis due to rubella virus (1F02.0)

Meningitis due to Arenavirus (1D61.Y)

Zoster meningitis (1E91.3)

Viral meningitis due to Epstein-Barr virus (1D81.0)

Viral meningitis due to Cytomegalovirus (1D82.Y)

**1C8E.1****Enteroviral meningitis**

A disease of the meninges, caused by an infection with enterovirus. This disease is characterised by high fever, headache, vomiting, nausea, stiff neck, photophobia, drowsiness, skin rash, confusion, seizures, or loss of consciousness. This disease may be asymptomatic in older adults. Transmission is through haematogenous spread to the meninges. Confirmation is by identification of enterovirus through a lumbar puncture, by agglutination tests, or by polymerase chain reaction.

**1C8E.2****Meningitis due to adenovirus**

A disease of the meninges, caused by an infection with adenovirus. This disease is characterised by high fever, headache, vomiting, nausea, stiff neck, photophobia, drowsiness, skin rash, confusion, seizures, or loss of consciousness. This disease may be asymptomatic in older adults. Transmission is through haematogenous spread to the meninges. Confirmation is by identification of adenovirus through a lumbar puncture, by agglutination tests, or by polymerase chain reaction.

**1C8E.Y****Other specified viral meningitis, not elsewhere classified****1C8E.Z****Viral meningitis, unspecified****1C8F****Lymphocytic choriomeningitis**

A disease of the meninges, caused by an infection with lymphocytic choriomeningitis virus. This disease is characterised by fever, stiffness of the neck, malaise, lack of appetite, myalgia, headache, nausea, vomiting, or is asymptomatic. This disease may also present with cough, sore throat, arthralgia, testicular pain, or parotid pain. Transmission is by direct contact with body fluids from an infected rodent, through the bite of an infected rodent, or by droplet transmission. Confirmation is by identification of lymphocytic choriomeningitis virus in a blood or tissue sample.

**Exclusions:** Encephalitis due to Lymphocytic choriomeningitis virus (1D61)  
meningoencephalitis due to Lymphocytic choriomeningitis virus (1D61)

**1C8G****Tick-borne encephalitis**

<b>1C8G.0</b>	<b>Far Eastern tick-borne encephalitis</b>
<b>1C8G.1</b>	<b>Central European tick-borne encephalitis</b>
<b>1C8G.2</b>	<b>Siberian tick-borne encephalitis</b>
<b>1C8G.Z</b>	<b>Tick-borne encephalitis, unspecified</b>
<b>1C8Y</b>	<b>Other specified viral infections of the central nervous system</b>
<b>1C8Z</b>	<b>Viral infections of the central nervous system, unspecified</b>

### Non-viral and unspecified infections of the central nervous system (1D00-1D0Z)

Any condition of the nervous system, caused by an infection with a bacterial, fungal, parasitic or unspecified source.

**Coded Elsewhere:** Meningitis due to other and unspecified causes (1D01.Z)

<b>1D00</b>	<b>Infectious encephalitis, not elsewhere classified</b>
	A disease of the brain, caused by an infection.

**Coding Note:** Code also the causing condition

<b>1D00.0</b>	<b>Bacterial encephalitis</b>
---------------	-------------------------------

**Coded Elsewhere:** Tuberculous meningoencephalitis (1B11.1)

Meningococcal encephalitis (1C1C.Y)

Encephalitis due to Listeria monocytogenes (1C1A.1)

Encephalitis due to Leptospira species (1B91)

Encephalitis due to Nocardia species (1C1B.Y)

Encephalitis due to Borrelia species (1C1G.10)

Burkholderia encephalomyelitis (1B92)

Tuberculous encephalitis (1B11.Y)

<b>1D00.1</b>	<b>Fungal encephalitis</b>
---------------	----------------------------

<b>1D00.2</b>	<b>Parasitic or protozoal encephalitis</b>
---------------	--

A disease of the brain, caused by an infection with a parasitic or protozoal source.

**Coded Elsewhere:** Meningoencephalitis due to Toxoplasma gondii (1F57.1)

Encephalitis in African trypanosomiasis (1F51.Z)

Encephalitis due to malaria (1F40.0)

Encephalitis in Gambiense trypanosomiasis (1F51.0Y)

Encephalitis in Rhodesiense trypanosomiasis (1F51.1Y)

Encephalitis in Chagas disease (1F53.Y)

Encephalitis due to Acanthamoeba (1F50)

Encephalitis due to coenurus cerebralis (1F76.Y)

**1D00.Y**      **Other specified infectious encephalitis, not elsewhere classified**

**Coding Note:** Code also the causing condition

**1D00.Z**      **Infectious encephalitis, unspecified**

**Coding Note:** Code also the causing condition

**1D01**      **Infectious meningitis, not elsewhere classified**

A disease of the meninges, caused by an infection.

**Coding Note:** Code also the causing condition

**1D01.0**      **Bacterial meningitis**

Any disease of the meninges, caused by an infection with a bacterial source.

**Coding Note:** Code also the causing condition

**Inclusions:** arachnoiditis bacterial

leptomeningitis bacterial

pachymeningitis bacterial

**Exclusions:** bacterial: meningoencephalitis (1D00.0)

bacterial meningomyelitis (1D02.0)

**Coded Elsewhere:** Pachymeningitis (8E41)

**1D01.00** Meningitis due to Haemophilus influenzae

**1D01.0Y** Other specified bacterial meningitis

**Coding Note:** Code also the causing condition

**1D01.0Z** Bacterial meningitis, unspecified

**Coding Note:** Code also the causing condition

**1D01.1** **Fungal meningitis**

A disease of the meninges, caused by an infection with a fungal agent.

**Coded Elsewhere:** Meningitis due to Cryptococcus neoformans (1F27.10)

Coccidioides meningitis (1F25.12)

Candida meningitis (1F23.30)

Meningitis due to Histoplasma capsulatum (1F2A.Y)

Meningitis due to Mucormycosis (1F2C)

Aspergillus meningitis (1F20.01)

**1D01.2** **Parasitic or protozoal meningitis**

**Coded Elsewhere:** Meningitis due to Cysticercosis (1F70.00)

Eosinophilic meningitis due to Angiostrongylus cantonensis (1F60.0)

Meningitis in Chagas disease (1F53.4)

Meningitis in African trypanosomiasis (1F51.Z)

Meningitis due to Strongyloides stercoralis (1F6B)

<b>1D01.3</b>	<b>Benign recurrent meningitis</b>
<b>1D01.Y</b>	<b>Other specified infectious meningitis, not elsewhere classified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>1D01.Z</b>	<b>Infectious meningitis, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>1D02</b>	<b>Infectious myelitis, not elsewhere classified</b>
	A disease of the spinal cord, caused by an infection.
<b>Coding Note:</b>	Code also the causing condition
<b>1D02.0</b>	<b>Bacterial myelitis</b>
	Inflammation of the spinal cord caused by a bacterial organism. Common agents causing bacterial myelitis include <i>Mycoplasma pneumoniae</i> , <i>Mycobacterium tuberculosis</i> , <i>Treponema pallidum</i> , and <i>Brucella</i> .
<b>Coding Note:</b>	Code also the causing condition
<b>1D02.1</b>	<b>Viral myelitis</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Myelitis due to human immunodeficiency disease (1C60-1C62.Z)
<b>1D02.2</b>	<b>Fungal myelitis</b>
	Inflammation of the spinal cord caused by fungal agents. Primary pathogens include <i>Cryptococcus neoformans</i> , <i>Coccidioides immitis</i> , <i>Blastomyces dermatitidis</i> , <i>Histoplasma capsulatum</i> , <i>Candida</i> , and <i>Aspergillus</i> .
<b>Coding Note:</b>	Code also the causing condition
<b>1D02.3</b>	<b>Parasitic myelitis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>1D02.Y</b>	<b>Other specified infectious myelitis, not elsewhere classified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>1D02.Z</b>	<b>Infectious myelitis, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition

**1D03****Infectious abscess of the central nervous system**

A focal suppurative process of the brain parenchyma, the intracranial or spinal epidural or subdural space, and less commonly the spinal cord parenchyma. The suppurative process is most commonly associated with bacterial infection, and occasionally with fungal, protozoal, or parasitic infection. Brain abscesses develop most commonly by spread from a contiguous infected site (ear, paranasal sinuses, mastoid air cells, teeth), craniofacial osteomyelitis, and following open head trauma or previous neurosurgical procedure. Haematogenous spread from purulent pulmonary infections, bacterial endocarditis, or other sites of infection can also cause brain abscess. Patients with intracranial abscess present with variable combinations of headache, altered mental status, focal deficits, and seizures. Fever may be present. Patients with intraspinal abscess present with variable degrees of paraparesis or quadripareisis, sensory impairment below the level of the lesion, altered sphincter function, and back pain. The diagnosis is made by CT or MRI imaging, and may be confirmed by histological examination and culture of the abscess material following neurosurgical drainage. Lumbar puncture is usually contraindicated.

**Coding Note:** Code also the causing condition

**1D03.0           Intraspinal intramedullary abscess**

**Coding Note:** Code also the causing condition

**1D03.1           Intraspinal subdural abscess**

**Coding Note:** Code also the causing condition

**1D03.2           Intraspinal extradural abscess**

**Coding Note:** Code also the causing condition

**1D03.3           Intracranial abscess**

A condition of the cranial cavity, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by a focal accumulation of purulent material within the cranial cavity. This condition may present with fever, headache, and focal neurological deficits.

**Coding Note:** Code also the causing condition

**1D03.30          Deep cerebral hemispheric abscess**

**Coding Note:** Code also the causing condition

**1D03.31          Abscess of the corpus callosum**

**Coding Note:** Code also the causing condition

**1D03.32          Pituitary abscess**

**Coding Note:** Code also the causing condition

**1D03.33** Multiple or widespread intracranial abscess  
Multiple focal suppurative infections within the cranial cavity, including the epidural and subdural spaces, or in the brain, brainstem or cerebellum. The abscesses are typically surrounded by a vascularised capsule. Cerebritis describes nonencapsulated brain abscesses. The infective agent may be bacterial, fungal, or parasitic. The signs and symptoms are variable but typically present as an expanding mass lesion, over a variable period of time, with headache, fever, and a focal neurologic deficit. Seizures may occur. Diagnosis is made by neuroimaging and microbiological testings as Gram stain and culture of abscess material.

**Coding Note:** Code also the causing condition

**1D03.3Y** Other specified intracranial abscess

**Coding Note:** Code also the causing condition

**1D03.3Z** Intracranial abscess, unspecified

**Coding Note:** Code also the causing condition

**1D03.4** **Intraspinal epidural abscess**

A condition of the epidural space, caused by an infection with a bacterial, viral, fungal, or parasitic source. This condition is characterised by a focal accumulation of purulent material within the epidural space. This condition presents with symptoms depending on the location of the abscess. Transmission is through haematogenous spread of the infectious agent commonly from a cutaneous or mucosal source.

**Coding Note:** Code also the causing condition

**1D03.5** **Spinal cord abscess**

A condition of the spinal cord, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by a focal accumulation of purulent material within the spinal cord. This condition may present with fever, back pain, and neurological deficits. Transmission is through haematogenous spread of the infectious agent.

**Coding Note:** Code also the causing condition

**1D03.Y** **Other specified site of infectious abscess of the central nervous system**

**Coding Note:** Code also the causing condition

**1D03.Z** **Infectious abscess of the central nervous system, site unspecified**

**Coding Note:** Code also the causing condition

**1D04** **Infectious granulomas of the central nervous system**

**Coded Elsewhere:** Tuberculous granuloma of brain (1B11.3)

**1D04.0** **Parasitic intracerebral granuloma**

<b>1D04.1</b>	<b>Intracranial granuloma</b> A condition of the cranial cavity, caused by an infection with a bacterial, viral, fungal, or parasitic source. This condition is characterised by an organised collection of macrophages within the cranial cavity. This condition may present with neurological deficits.
<b>1D04.10</b>	Fungal intracranial granuloma
<b>1D04.1Y</b>	Other specified intracranial granuloma
<b>1D04.1Z</b>	Intracranial granuloma, unspecified
<b>1D04.2</b>	<b>Intraspinal intramedullary granuloma</b>
<b>1D04.3</b>	<b>Intraspinal subdural granuloma</b>
<b>1D04.4</b>	<b>Intraspinal extradural granuloma</b>
<b>1D04.5</b>	<b>Intraspinal epidural granuloma</b> A condition of the epidural space, caused by an infection with a bacterial, viral, fungal, or parasitic source. This condition is characterised by an organised collection of macrophages within the epidural space. This condition may present with neurological deficits.
<b>1D04.Y</b>	<b>Other specified site of infectious granulomas of the central nervous system</b>
<b>1D04.Z</b>	<b>Infectious granulomas of the central nervous system, site unspecified</b>
<b>1D05</b>	<b>Infectious cysts of the central nervous system</b>
<b>1D05.0</b>	<b>Epidural infectious cyst</b> A condition of the epidural space, caused by an infection with a bacterial, viral, fungal, or parasitic source. This condition is characterised by a membranous sac that may be filled with gas, fluid, or semi solid material within the epidural space. This condition may present with neurological deficits.
<b>1D05.1</b>	<b>Subdural infectious cyst</b> A condition of the subdural space, caused by an infection with a bacterial, viral, fungal, or parasitic source. This condition is characterised by a membranous sac that may be filled with gas, fluid, or semi solid material between the dura mater and the arachnoid mater. This condition may present with neurological deficits.
<b>1D05.Y</b>	<b>Other specified infectious cysts of the central nervous system</b>
<b>1D05.Z</b>	<b>Infectious cysts of the central nervous system, unspecified</b>
<b>1D0Y</b>	<b>Other specified non-viral and unspecified infections of the central nervous system</b>
<b>1D0Z</b>	<b>Non-viral and unspecified infections of the central nervous system, unspecified</b>

## Dengue (1D20-1D2Z)

Dengue is a viral disease transmitted by the bite of a mosquito infected by dengue viruses. It is one disease entity with different clinical presentations and often with unpredictable clinical evolution and outcome. Most patients recover following a self-limiting non-severe clinical course like nausea, vomiting, rash, aches and pains, but a small proportion progress to severe disease, mostly characterised by plasma leakage with or without haemorrhage, although severe haemorrhages or severe organ impairment can occur, with or without dengue shock.

**1D20**

### Dengue without warning signs

*Inclusions:* Dengue haemorrhagic fever Grade 1

Dengue fever without warning signs

Dengue haemorrhagic fever without warning signs

**1D21**

### Dengue with warning signs

Clinical warning signs are: abdominal pain or tenderness, mucosal bleeding, lethargy and/or restlessness, rapid decrease in platelet count, increase in haematocrit. Other signs can include: persistent vomiting, visible fluid accumulation, liver enlargement more than 2 cm.

**1D22**

### Severe dengue

Clinical signs include: 1. Severe plasma leakage leading to shock (dengue shock syndrome - DSS) and/or fluid accumulation with respiratory distress; 2. severe bleeding as evaluated by clinician, 3. severe organ involvement: Liver AST or ALT  $\geq$  1000, CNS: impaired consciousness, involvement of other organs, as myocarditis or nephritis.

**1D2Z**

### Dengue fever, unspecified

## Certain arthropod-borne viral fevers (1D40-1D4Z)

*Coded Elsewhere:* Dengue (1D20-1D2Z)

Far Eastern tick-borne encephalitis (1C8G.0)

Central European tick-borne encephalitis (1C8G.1)

Western equine encephalitis (1C83)

Eastern equine encephalitis (1C84)

Japanese encephalitis (1C85)

St Louis encephalitis (1C86)

Rocio viral encephalitis (1C87)

Murray Valley encephalitis (1C88)

California encephalitis (1C8B)

Venezuelan equine encephalitis (1C8C)

La Crosse encephalitis (1C8D)

Siberian tick-borne encephalitis (1C8G.2)

**1D40**

### Chikungunya virus disease

**1D41****Colorado tick fever****1D42****O'nyong-nyong fever****1D43****Oropouche virus disease**

A disease caused by an infection with Oropouche virus. This disease is characterised by fever, headache, neck and back pain, joint pain, or photophobia. This disease may also present with bronchitis, nausea, diarrhoea, abdominal pain or burning sensations all over the body. Transmission is through the bite of an infected mosquito or midge. Confirmation is by detection of the Oropouche virus specific antibodies in a serum sample.

*Inclusions:*           Oropouche fever

**1D44****Rift Valley fever**

A disease caused by an infection with Rift Valley fever virus. This disease is commonly asymptomatic. This disease may also present with fever, liver abnormalities, weakness, back pain, or dizziness. Transmission is through the bite of an infected mosquito. Confirmation is commonly by detection of Rift Valley fever virus specific IgM or IgG antibodies in a blood sample.

**1D45****Sandfly fever**

*Inclusions:*           pappataci fever  
                          phlebotomus fever

**1D46****West Nile virus infection**

A condition caused by an infection with West Nile virus. This condition is commonly asymptomatic. This condition may present with fever, headache, stiffness of the neck, stupor, disorientation, coma, tremors, convulsions, muscle weakness, or paralysis. Transmission is through the bite of an infected mosquito. Confirmation is by detection of IgG or IgM anti-West Nile virus antibodies in a serum sample.

*Inclusions:*           West Nile fever

**1D47****Yellow fever**

A condition caused by an infection with yellow fever virus. This condition is characterised by fever, chills, headache, myalgia, conjunctival congestion, or relative bradycardia. Severe conditions may also present with increasing fever, jaundice, renal failure, or bleeding. Transmission is through the bite of an infected mosquito. Confirmation is by detection of IgM anti-yellow fever virus antibodies in a serum sample.

**1D48****Zika virus disease**

Zika virus infection is caused by the bite of an infected Aedes mosquito. The most common symptoms of Zika virus infection are mild fever and exanthema (skin rash), usually accompanied by conjunctivitis, muscle or joint pain, and general malaise that begins 2-7 days after the bite of the infected mosquito.

**Coded Elsewhere:** Congenital Zika virus infection (KA62.0)

**1D49****Crimean-Congo haemorrhagic fever**

A disease caused by an infection with Crimean-Congo haemorrhagic fever virus. The incubation period ranges from 2 to 9 days. Symptoms/signs typically include high fever, headache, malaise, arthralgia, myalgia, nausea, abdominal pain, and rarely diarrhoea. Early signs typically include fever, hypotension, conjunctivitis, and cutaneous flushing or a skin rash. Later, patients may develop signs of progressive haemorrhagic diathesis, such as petechiae, mucous membrane and conjunctival haemorrhage, haematuria, hematemesis, and melena. Lethality may reach 30%. Transmission occurs via bites of infected ticks, by direct contact with infected animal blood, or iatrogenic transmission. Laboratory diagnosis of the infection during the acute phase of illness consists of detection of viral nucleic acid or by isolation of the virus or by demonstration of viral antigen by enzyme-linked immunoassay from serum or plasma samples. In samples collected later during the illness, diagnosis is confirmed by demonstration of specific IgG and IgM antibodies.

**1D4A****Omsk haemorrhagic fever**

A disease caused by an infection with the Omsk haemorrhagic fever virus. This disease is characterised by fever, chills, headache, gastrointestinal symptoms and bleeding, or muscle pain with vomiting. In severe cases, this disease may also present with encephalitis. Transmission is through the bite of an infected tick, by direct contact with an infected animal, by the faecal-oral route from an infected animal, or by ingestion of milk from infected goats or sheep. Confirmation is by detection of anti-Omsk haemorrhagic fever virus antibodies in a serum sample.

**1D4B****Kyasanur Forest disease**

A disease caused by an infection with Kyasanur Forest disease virus. This disease commonly presents with fever, chills, headache, muscle pain and vomiting, or gastrointestinal symptoms and bleeding. This disease may also present with neurological manifestations such as a severe headache, mental disturbances, tremors, or vision deficits. Transmission is through the bite of an infected tick or by direct contact with an infected animal. Confirmation is by identification of Kyasanur Forest disease virus in a serum sample.

**1D4C****Alkhurma haemorrhagic fever****1D4D****Ross River disease**

A disease caused by an infection with Ross River disease virus. This disease is characterised by arthralgia, with or without arthritis. This disease may also present with fever, fatigue, headache, swollen glands, arthralgia, or maculopapular rash commonly affecting the limbs and trunks. Transmission is through the bite of an infected mosquito. Confirmation is by detection of IgM or IgG anti-Ross River disease virus antibodies in a serum sample.

**Inclusions:**      Epidemic polyarthritis and exanthema

                          Ross River fever

**1D4E****Severe fever with thrombocytopenia syndrome****1D4Y****Other specified arthropod-borne viral fevers****1D4Z****Arthropod-borne viral fever, virus unspecified**

## Certain zoonotic viral diseases (1D60-1D6Z)

**Coded Elsewhere:** COVID-19, virus identified (RA01.0)

Encephalitis due to Arenavirus (1D61.Y)

**1D60**

### Filovirus disease

A severe disease with high lethality caused by filovirus infection. Filovirus disease is typically characterised by acute onset of fever with non-specific symptoms/signs (e.g., abdominal pain, anorexia, fatigue, malaise, myalgia, sore throat) usually followed several days later by nausea, vomiting, diarrhoea, and occasionally a variable rash. Hiccups may occur. Severe illness may include haemorrhagic manifestations (e.g., bleeding from puncture sites, ecchymoses, petechiae, visceral effusions), encephalopathy, shock/hypotension, multi-organ failure, spontaneous abortion in pregnant women when infected. Common laboratory findings include thrombocytopenia, elevated transaminase concentrations, electrolyte abnormalities, and signs of renal dysfunction. Individuals who recover may experience prolonged sequelae (e.g., arthralgia, neurocognitive dysfunction, uveitis sometimes followed by cataract formation), and clinical and subclinical persistent infection may occur in immune-privileged compartments (e.g., CNS, eyes, testes). Person-to-person transmission occurs by direct contact with blood, other bodily fluids, organs, or contaminated surfaces and materials with risk beginning at the onset of clinical signs and increasing with disease severity. Family members, sexual contacts, healthcare providers, and participants in burial ceremonies with direct contact with the deceased are at particular risk. The incubation period typically is 7–11 days (range ≈2–21 days).

**1D60.0**

### Ebola disease

A severe disease with high case fatality caused by infection with Ebola virus or a closely related virus. Ebola disease is typically characterised by acute onset of fever with non-specific symptoms/signs (e.g., abdominal pain, anorexia, fatigue, malaise, myalgia, sore throat) usually followed several days later by nausea, vomiting, diarrhoea, and occasionally a variable rash. Hiccups may occur. Severe illness may include haemorrhagic manifestations (e.g., bleeding from puncture sites, ecchymoses, petechiae, visceral effusions), encephalopathy, shock/hypotension, multi-organ failure, spontaneous abortion in infected pregnant women. Common laboratory findings include thrombocytopenia, elevated transaminase concentrations, electrolyte abnormalities, and signs of renal dysfunction. Individuals who recover may experience prolonged sequelae (e.g., arthralgia, neurocognitive dysfunction, uveitis sometimes followed by cataract formation), and clinical and subclinical persistent infection may occur in immune-privileged compartments (e.g., CNS, eyes, testes). Person-to-person transmission occurs by direct contact with blood, other bodily fluids, organs, or contaminated surfaces and materials with risk beginning at the onset of clinical signs and increasing with disease severity. Family members, sexual contacts, healthcare providers, and participants in burial ceremonies with direct contact with the deceased are at particular risk. The incubation period typically is 7–11 days (range ≈2–21 days).

**1D60.00**

#### Bundibugyo virus disease

Ebola disease caused by Bundibugyo virus.

**1D60.01**

#### Ebola virus disease

Ebola disease caused by Ebola virus.

<b>1D60.02</b>	Sudan virus disease Ebola disease caused by Sudan virus.
<b>1D60.03</b>	Atypical Ebola disease
<b>Coding Note:</b>	This code should be used in conjunction with codes that identify the causative virus. Unusual manifestations of disease include organ-specific (e.g. meningoencephalitis) or systemic inflammatory syndromes associated with viral recrudescence occurring after clinical recovery from acute disease. These manifestations may occur several months following infection. Additionally, this code may be used for unusual presentations of acute disease not included in the general description of Ebola disease.
<b>1D60.0Y</b>	Other specified Ebola disease
<b>1D60.0Z</b>	Ebola disease, virus unspecified
<b>1D60.1</b>	<b>Marburg disease</b>  A severe disease with high case fatality caused by infection with Marburg virus or a closely related virus. Marburg disease is typically characterised by acute onset of fever with non-specific symptoms/signs (e.g., abdominal pain, anorexia, fatigue, malaise, myalgia, sore throat) usually followed several days later by nausea, vomiting, diarrhoea, and occasionally a variable rash. Severe illness may include haemorrhagic manifestations (e.g., bleeding from puncture sites, ecchymoses, petechiae, visceral effusions), encephalopathy, shock/hypotension, multi-organ failure. Common laboratory findings include thrombocytopenia, elevated transaminase concentrations, electrolyte abnormalities, and signs of renal dysfunction. Individuals who recover may experience prolonged sequelae (e.g., arthralgia, neurocognitive dysfunction, uveitis), and clinical and subclinical persistent infection may occur in immune-privileged compartments (e.g., CNS, eyes, testes). Person-to-person transmission occurs by direct contact with blood, other bodily fluids, organs, or contaminated surfaces and materials with risk beginning at the onset of clinical signs and increasing with disease severity. Family members, sexual contacts, healthcare providers, and participants in burial ceremonies with direct contact with the deceased are at particular risk. The incubation period typically is 7–11 days (range ≈2–21 days).
<b>1D60.10</b>	Marburg virus disease Marburg disease caused by Marburg virus or Ravn virus.
<b>1D60.11</b>	Atypical Marburg disease
<b>Coding Note:</b>	This code should be used in conjunction with codes that identify the causative virus. Unusual manifestations of disease include organ-specific (e.g. orchitis, uveitis) or systemic inflammatory syndromes associated with viral recrudescence occurring after clinical recovery from acute disease. These manifestations may occur several months following infection. Additionally, this code may be used for unusual presentations of acute disease not included in the general description of Marburg disease.
<b>1D60.1Y</b>	Other specified Marburg disease
<b>1D60.1Z</b>	Marburg disease, virus unspecified
<b>1D60.Y</b>	<b>Other specified filovirus disease</b>

- 1D60.Z** **Filovirus disease, virus unspecified**
- 1D61** **Arenavirus disease**  
*Coded Elsewhere:* Lymphocytic choriomeningitis (1C8F)
- 1D61.0** **Argentinian haemorrhagic fever**  
A disease endemic to the Argentine Pampas that is caused by an infection with Junín virus and that is characterised by haemorrhagic and neurological manifestations and high lethality (10-30%). The disease begins with a 6-14 day-lasting prodromic phase. Argentinian haemorrhagic fever presents with fever, myalgia, erythema, conjunctival injection, non-menstrual uterine bleeding, epistaxis, haematemesis, melena, haematuria, or shock. Around 20-30% of patients advance to a neurological and haemorrhagic phase. Survivors have a long convalescence period. Transmission occurs by inhalation, consumption, or direct contact with excretions and bodily fluids from infected rodents. Diagnosis occurs by identification of Junín virus from blood or mucosal secretions samples.
- 1D61.1** **Bolivian haemorrhagic fever**  
A disease endemic to Bolivia that is caused by an infection with Machupo virus. Early disease symptoms/signs include fever, mild hypertension, headache, bleeding gums, and fatigue. Advanced signs include mucous membrane haemorrhage, epistaxis, melaena, and neurological damage such as tremors, seizures, loss of muscle control, and coma. Onset of disease symptoms occurs usually within seven days of infection. The lethality ranges from 18% to 22%. Transmission occurs by inhalation, consumption, or direct contact with excretions and bodily fluids from infected rodents. Diagnosis occurs by identification of Machupo virus from blood or mucosal secretions samples.
- 1D61.2** **Lassa fever**  
A disease endemic in large parts of sub-Saharan Western Africa caused by infection with Lassa virus. Infection is mild or asymptomatic in most cases, but can cause severe illness or death. After a prodromal period of 7-10 days (sometimes longer), initial symptoms/signs include fever, malaise, headache, sore throat, vomiting, abdominal pain, and diarrhoea. Subsequently, patients develop high fever, extreme lethargy, oedema of head/neck, encephalopathy, pleural effusion, and ascites. Bleeding into the skin, mucosae and underlying tissues occurs in the severest cases. Deafness occurs in many patients, and the disease is often particularly severe in pregnancy. The overall lethality can reach 15% even among hospitalized patients receiving supportive care. Transmission occurs by inhalation, consumption, or direct contact with excretions and bodily fluids from infected rodents. Diagnosis occurs by identification of Lassa virus in blood samples by molecular or serologic methods.

- 1D61.3 Venezuelan haemorrhagic fever**  
A disease mainly found in rural areas of central Venezuela that is caused by an infection with Guanarito virus. Symptoms/signs among patients include fever, malaise, headache, arthralgia, sore throat, vomiting, abdominal pain, diarrhoea, convulsions, and a variety of haemorrhagic manifestations. The majority of patients also develop leukopenia and thrombocytopenia. The overall lethality may reach 30% even in hospitalised patients receiving supportive care. Transmission occurs by inhalation, consumption, or direct contact with excretions and bodily fluids from infected rodents. Diagnosis occurs by identification of Guanarito virus from blood or mucosal secretions samples.
- 1D61.Y Other specified arenavirus disease**
- 1D61.Z Arenavirus disease, unspecified**
- 1D62 Hantavirus disease**  
An acute zoonotic viral disease characterised by abrupt onset of fever, influenza-like clinical signs (e.g., chills, headache, myalgia, dry cough), gastrointestinal signs (e.g., diffuse abdominal pain, vomiting, diarrhoea), transient troubled vision (acute myopia), lumbalgia due to renal swelling, haemorrhagic manifestations to various degrees sometimes followed by rapidly increasing dyspnoea due to non-cardiogenic acute lung oedema, and/or renal involvement. The latter is characterised by initial, often massive proteinuria and microhaematuria sometimes accompanied by transient renal function impediment. All hantavirus infections are heralded by varying degrees of transient thrombocytopenia, which may serve as an indicator of clinical severity.
- 1D62.0 Haemorrhagic fever with renal syndrome**  
Acute zoonotic viral disease with abrupt onset of fever, lower back pain, varying degrees of haemorrhagic manifestations, and renal involvement caused by certain hantaviruses.  
*Inclusions:* Nephropathia epidemica
- 1D62.1 Hantavirus pulmonary syndrome**  
A disease of the respiratory system, caused by infection with certain hantaviruses. This disease is characterised by fever, fatigue, myalgia, headache, chills, nausea, vomiting, diarrhoea, or abdominal pain. This disease may also present with coughing and dyspnoea. Transmission is by the faecal-oral route or airborne transmission.
- 1D62.2 Atypical hantavirus disease**
- 1D62.Y Other specified hantavirus disease**
- 1D62.Z Hantavirus disease, unspecified**
- 1D63 Henipavirus encephalitis**  
Acute bat-borne disease characterised by fever and headaches. The disease may progress to drowsiness, disorientation, mental confusion, and finally encephalitis (brain swelling) in less than a week. This progression may occur with or without an acute respiratory distress component. The incubation period ranges from 4 to 14 days. Lethality is high.

**1D64****Middle East respiratory syndrome**

A disease caused by an infection with Middle East Respiratory Syndrome coronavirus (MERS-CoA). This disease is characterised by severe acute respiratory illness with fever, cough, and shortness of breath. Confirmation is by identification of Middle East Respiratory Syndrome coronavirus from genetic material.

**1D65****Severe acute respiratory syndrome**

A disease of the respiratory system, caused by an infection with coronavirus. This disease is characterised by fever, headache, cough, myalgia, tachycardia, or diarrhoea. This disease may also lead to pneumonia. Transmission is by direct contact, inhalation of infected respiratory secretions, or airborne transmission. Confirmation is by identification of coronavirus in a blood, stool, respiratory secretions, or body tissue sample.

***Inclusions:*** COVID-19, virus identified (RA01.0)

COVID-19, virus not identified (RA01.1)

**1D6Y****Other specified zoonotic viral diseases****1D6Z****Zoonotic viral disease, virus unspecified****Certain other viral diseases (1D80-1E1Z)**

***Coded Elsewhere:*** Congenital Varicella Zoster virus infection (KA62.2)

Other viral diseases complicating pregnancy, childbirth or the puerperium (JB63.5)

Viral duodenitis (DA51.6Y)

Tahyna fever (1D4Y)

**1D80****Mumps**

A disease caused by an infection with mumps virus. This disease commonly presents with fever, headache, fatigue, or eventually parotitis. Transmission is by contact with respiratory secretions, directly or indirectly.

**1D80.0****Mumps without complication****1D80.1****Orchitis due to mumps virus**

Within a few days of infection the mumps virus can attack the testicular glands leading to abrupt onset of fever ranging from 39 to 41 °C, severe testicular pain, scrotal swelling and erythema. Mumps induced orchitis typically presents 1-2 weeks after parotitis. The virus' infiltration into the testicular glands can cause parenchymal inflammation, separation of seminiferous tubules and perivasculär interstitial lymphocyte infiltration. Testicular atrophy can result from a rise in intratesticular pressure. Complications include oligospermia, azoospermia, and asthenospermia, which can contribute to subfertility. Infertility is more common in patients with bilateral mumps orchitis and is estimated to occur in approximately 13% of all patients. Sterility is rarely induced by mumps orchitis.

***Inclusions:*** Mumps orchitis

- 1D80.2 Meningitis due to mumps virus**  
A disease of the meninges, caused by an infection with mumps virus. This disease is characterised by photophobia, vomiting, fever, arthralgia, headache, stiff neck, convulsions, or seizures. This disease may also present with pale, blotchy skin or a distinctive rash. Transmission is by haematogenous spread to the meninges after inhalation of infected respiratory secretions or droplet transmission. Confirmation is by identification of mumps virus in a buccal swab or blood sample.
- Inclusions:* mumps meningitis
- 1D80.3 Encephalitis due to mumps virus**  
An inflammatory process of the brain, frequently with evidence of meningeal involvement, due to infection by mumps virus. The clinical manifestations are usually acute, with fever and variable combinations of convulsions, impaired mental state, and focal deficits. The spinal fluid may show a cellular reaction and elevated protein. Diagnosis is by neuroimaging, spinal fluid analysis and culture, PCR, and serologic tests.
- Inclusions:* Mumps encephalitis
- 1D80.4 Pancreatitis due to mumps virus**  
*Inclusions:* mumps pancreatitis
- 1D80.Y Other specified mumps**
- 1D81 Infectious mononucleosis**  
A disease typically caused by an infection with Epstein-Barr virus or cytomegalovirus. This disease commonly presents with extreme fatigue, fever, acute pharyngitis, body aches, or lymphadenopathy. Transmission is by direct contact with infected body fluids, commonly through saliva.
- Inclusions:* Glandular fever  
Gammaherpesviral mononucleosis
- 1D81.0 Mononucleosis due to Epstein-Barr virus**  
A disease typically caused by an infection with Epstein-Barr virus. This disease commonly presents with extreme fatigue, fever, acute pharyngitis, body aches, or lymphadenopathy. Transmission is by direct contact with infected body fluids, commonly through saliva.
- 1D81.1 Mononucleosis due to cytomegalovirus**  
A disease typically caused by an infection with cytomegalovirus. This disease commonly presents with extreme fatigue, fever, acute pharyngitis, body aches, or lymphadenopathy. Transmission is by direct contact with infected body fluids, commonly through saliva.
- 1D81.Y Other specified infectious mononucleosis**
- 1D81.Z Infectious mononucleosis, unspecified**

**1D82**

### **Cytomegaloviral disease**

Any condition caused by an infection with cytomegalovirus. These conditions are commonly asymptomatic. Transmission is by direct contact with infected body fluids.

**Coded Elsewhere:** Mononucleosis due to cytomegalovirus (1D81.1)

Congenital cytomegalovirus infection (KA62.3)

Intestinal infections due to Cytomegalovirus (1A24)

Cytomegaloviral retinitis (9B72.00)

**1D82.0**

### **Cytomegaloviral hepatitis**

A disease of the hepatic system, caused by an infection with human cytomegalovirus. This disease is characterised by fever, acute pharyngitis, fatigue, lymphadenopathy, or jaundice. Transmission is by direct contact with infected body fluids. Confirmation of an active infection is by identification of human cytomegalovirus in blood, saliva, urine, or other body tissue samples.

**1D82.1**

### **Cytomegaloviral pancreatitis**

**1D82.Y**

### **Other specified cytomegaloviral disease**

**1D82.Z**

### **Cytomegaloviral disease, unspecified**

**1D83**

### **Epidemic myalgia**

A disease caused by an infection with the group B Coxsackie virus. This disease is characterised by pleuritic pain, fever, or muscle swelling. Transmission is by the faecal-oral route.

**Inclusions:** Bornholm disease

**1D84**

### **Viral conjunctivitis**

Inflammation, often mild, of the conjunctiva caused by a variety of viral agents. Conjunctival involvement may be part of a systemic infection.

**Coding Note:**

Code also the causing condition

**Exclusions:** ocular disease herpesviral [herpes simplex] (1F00.1)

Ophthalmic zoster (1E91.1)

**Coded Elsewhere:** Zoster conjunctivitis (1E91.1)

**1D84.0**

### **Conjunctivitis due to adenovirus**

A condition of the conjunctiva, caused by an infection with adenovirus. This condition is characterised by itchy eyes, tearing, redness, discharge, or photophobia (with corneal involvement). Transmission is by direct contact, indirect contact, or droplet transmission.

**Inclusions:** Acute adenoviral follicular conjunctivitis

Swimming-pool conjunctivitis

<b>1D84.1</b>	<b>Acute epidemic haemorrhagic conjunctivitis</b>
	A disease of the conjunctiva, caused by an infection with enterovirus. This disease is characterised by painful and red eyes, swollen lids, conjunctival follicles, chemosis, or subconjunctival haemorrhage. Transmission is by direct contact, or contact with contaminated water.
<b>1D84.Y</b>	<b>Other specified viral conjunctivitis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>1D84.Z</b>	<b>Viral conjunctivitis, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>1D85</b>	<b>Viral carditis</b>
	A disease of the heart, caused by an infection with a viral source. This disease is characterised by fatigue, dyspnoea, palpitations, malaise, or atypical chest discomfort. This disease may also present with sinus tachycardia, cardiomyopathy, idiopathic ventricular arrhythmias, or cardiovascular collapse. Transmission is by endogenous spread or iatrogenic transmission. Confirmation is identification of the viral source in advanced imaging or cardiac biopsy.
	<b>Exclusions:</b> Influenza myocarditis, other influenza virus identified (1E30)
<b>1D85.0</b>	<b>Dilated cardiomyopathy secondary to viral myocarditis</b>
<b>1D85.1</b>	<b>Acute viral carditis</b>
<b>1D85.2</b>	<b>Chronic viral carditis</b>
<b>1D85.3</b>	<b>Aseptic myocarditis of newborn</b>
<b>1D85.4</b>	<b>Coxsackie carditis</b>
<b>1D85.Y</b>	<b>Other specified viral carditis</b>
<b>1D85.Z</b>	<b>Viral carditis, unspecified</b>
<b>1D86</b>	<b>Viral haemorrhagic fever, not elsewhere classified</b>
	<b>Exclusions:</b> Certain arthropod-borne viral fevers (1D40-1D4Z)
	Certain zoonotic viral diseases (1D60-1D6Z)
	Viral infection of unspecified site (1D90-1D9Z)
<b>Exclusions:</b>	Cytomegaloviral disease (1D82) Herpes simplex infections (1F00)
<b>1D90</b>	<b>Adenovirus infection of unspecified site</b>
	Adenovirus infections most commonly cause illness of the respiratory system; however, depending on the infecting serotype, they may also cause various other illnesses and presentations.

**1D91**

**Enterovirus infection of unspecified site**

**Coded Elsewhere:** Congenital echovirus infection (KA62.4)  
Congenital enterovirus infection (KA62.5)

**1D92**

**Coronavirus infection, unspecified site**

**Exclusions:** Severe acute respiratory syndrome (1D65)  
COVID-19, virus not identified (RA01.1)  
COVID-19, virus identified (RA01.0)

**1D93**

**Parvovirus infection of unspecified site**

**Coded Elsewhere:** Congenital parvovirus syndrome (KA62.7)

**1D9Y**

**Other viral infections of unspecified site**

**1D9Z**

**Unspecified viral infection of unspecified site**

**1E1Y**

**Other specified viral diseases**

**1E1Z**

**Unspecified viral disease**

**Influenza (1E30-1E32)**

Any disease of the respiratory system, caused by an infection with influenza virus. These diseases are characterised by fever, cough, headache, myalgia, arthralgia, or malaise. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of influenza virus from a nasopharyngeal, nose, or throat swab.

**1E30**

**Influenza due to identified seasonal influenza virus**

**Exclusions:** Haemophilus influenzae [H. influenzae] meningitis (1D01.00)  
Haemophilus influenzae [H. influenzae] pneumonia (CA40.02)

**1E31**

**Influenza due to identified zoonotic or pandemic influenza virus**

Influenza, caused by influenza virus strains of special epidemiological importance with an animal-human or inter-human transmission.

For use of this category, reference must be made to the guidelines of the Global Influenza Programme (GIP, [www.who.int/influenza/](http://www.who.int/influenza/)) of WHO.

**Coding Note:**

Influenza caused by influenza virus strains of special epidemiological importance with an animal-human or inter-human transmission limited to the inclusions

**Exclusions:** Haemophilus influenzae [H. influenzae] meningitis (1D01.00)  
Haemophilus influenzae [H. influenzae] pneumonia (CA40.02)

**1E32**

### **Influenza, virus not identified**

Any disease of the respiratory system, caused by an unidentified strain of influenza virus. These diseases are characterised by fever, cough, headache, myalgia, arthralgia, or malaise. Transmission is by inhalation of infected respiratory secretions.

**Inclusions:** Influenza specific virus not stated to have been identified

Viral influenza specific virus not stated to have been identified

**Exclusions:** Haemophilus influenzae [H. influenzae] meningitis (1D01.00)

Haemophilus influenzae [H. influenzae] pneumonia (CA40.02)

## **Viral hepatitis (1E50-1E5Z)**

A group of liver diseases caused by infection with one or more of the five hepatitis viruses, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E viruses. The infection may be recent and present for less than 6 months (acute hepatitis) or present for more than 6 months (chronic hepatitis), in which case progression to cirrhosis and liver cancer can occur. Transmission is by the faecal-oral route including water contamination, sexual transmission, blood and body fluid contamination (parenteral spread) and from mother to baby at the time of birth (vertical transmission). Depending on the virus, diagnosis is confirmed by detection of specific viral antigens, anti-viral antibodies or viral nucleic acids in serum.

**Exclusions:** Herpes simplex hepatitis (1F00)

Autoimmune hepatitis (DB96.0)

Non-alcoholic steatohepatitis (DB92.1)

**Coded Elsewhere:** Viral hepatitis complicating pregnancy, childbirth or the puerperium (JB63.4)

Congenital viral hepatitis (KA62.9)

**1E50**

### **Acute viral hepatitis**

A group of liver diseases characterised by liver inflammation and fibrosis, caused by more than 6 months of infection with one or more of hepatitis B virus, hepatitis C virus and hepatitis D virus, with or without HIV. Even at stage of cirrhosis there are often no symptoms. Otherwise, clinical features include fatigue, hard liver edge and complications of cirrhosis (muscle wasting, ascites, splenomegaly/portal hypertension). Transmission of hepatitis B and C viruses is by blood and body fluid contamination, sexual transmission, and from mother to baby at the time of birth (vertical transmission). In addition to detection of specific antigens (HBsAg) and antibodies (anti-HCV), diagnostic assessment requires assay of viral nucleic acids (HBV DNA, HCV RNA etc).

**Exclusions:** Infectious liver disease (DB90)

Acute or subacute hepatic failure (DB91)

Chronic viral hepatitis (1E51)

**Coded Elsewhere:** Cytomegaloviral hepatitis (1D82.0)

Epstein-Barr viral hepatitis (DB90.Y)

- 1E50.0      Acute hepatitis A**  
Acute liver injury and inflammation caused by recent and short-term (less than 6 months) infection with hepatitis A virus (HAV). Transmission is by the faecal-oral route. Diagnosis is confirmed by presence of IgM-anti-HAV in serum. Clinical features, if they occur, are characterised by anorexia, nausea and fever, with jaundice in severer cases.
- Exclusions:** Infectious liver disease (DB90)  
Acute or subacute hepatic failure (DB91)
- 1E50.1      Acute hepatitis B**  
Acute liver injury and inflammation caused by recent and short-term (less than 6 months) infection with hepatitis B virus (HBV). Transmission is by sexual, blood and body fluid contamination (parenteral spread), and from mother to baby at the time of birth (vertical transmission). Diagnosis is confirmed by presence of recent acquisition of HBsAg, ideally with IgM-anti-HBc in serum. Clinical features, if they occur, are characterised by anorexia, nausea and fever, with jaundice in severe cases.
- 1E50.2      Acute hepatitis C**  
Acute liver injury and inflammation caused by recent and short-term (less than 6 months) infection with hepatitis C virus (HCV). Transmission is by blood and body fluid contamination (parenteral spread) in most cases, and rarely by sexual spread or from mother to baby at the time of birth (vertical transmission). Diagnosis is confirmed by presence of recent acquisition of anti-HCV with presence of HCV RNA in serum. Clinical features occur in a minority of cases and are characterised by anorexia, nausea and fever, rarely with jaundice. A high proportion of cases (>70%) develop chronic HCV infection, with liver disease of varying severity.
- Coded Elsewhere:** Necrolytic acral erythema (EA20)
- 1E50.3      Acute hepatitis D**  
Acute liver injury and inflammation caused by recent and short-term (less than 6 months) infection with hepatitis D virus (HDV). Transmission only occurs in someone with chronic HBV infection (super-infection) or at the same time as acute hepatitis B (co-infection), and is by blood and body fluid contamination (parenteral spread), and sexual spread. Diagnosis is confirmed by serum IgM-anti-HDV. Clinical features, if they occur, are characterised by anorexia, nausea and fever, with jaundice in severe cases. Acute liver failure occurs in some cases, and a high proportion of cases develops chronic HDV infection.
- Coded Elsewhere:** Acute hepatitis B with Hepatitis D virus co-infection (1E50.1)
- 1E50.4      Acute hepatitis E**  
A disease of the liver, caused by an acute infection with hepatitis E virus. This disease is characterised by nausea. Transmission is commonly by the faecal-oral route. Confirmation is by detection of anti-hepatitis E virus IgM antibodies in an individual's serum.
- 1E50.Y      Other specified acute viral hepatitis**
- 1E50.Z      Acute viral hepatitis, unspecified**

**1E51****Chronic viral hepatitis**

A disease of the liver, caused by a chronic infection with a hepatotropic virus such as hepatitis B, C, D virus, with or without HIV (for six months or longer). This disease is characterised by fatigue, joint and muscle pain, jaundice, or urine of dark yellow colour. Transmission is by sexual contact, or direct contact with contaminated blood or body fluids. Confirmation is by detection of anti-hepatitis antibodies in the individual's serum.

**Exclusions:**

- Alcoholic liver disease (DB94)
- Autoimmune hepatitis (DB96.0)
- Non-alcoholic fatty liver disease (DB92)

**1E51.0****Chronic hepatitis B**

A liver disease characterised by liver inflammation and fibrosis caused by more than 6 months of infection with the hepatitis B virus. Even at stage of cirrhosis there are often no symptoms. Otherwise, clinical features include fatigue, hard liver edge and complications of cirrhosis (muscle wasting, ascites, splenomegaly/portal hypertension). Transmission is by blood and body fluid contamination, sexual transmission, and from mother to baby at the time of birth (vertical transmission). Confirmation of the diagnosis is by detection of HBsAg, but assessment of severity, prognosis and indication for treatment requires quantification of HBV DNA in serum.

**Coded Elsewhere:** Chronic hepatitis B, co-infected with hepatitis D virus (1E51.2)  
Hepatitis B surface antigen [HBsAg] carrier (1E51.Y)

**1E51.00**

## Chronic hepatitis B with human immunodeficiency virus co-infection

A liver disease characterised by liver inflammation and fibrosis caused by more than 6 months of infection with the hepatitis B virus and with the human immunodeficiency virus (HIV). Clinical features include fatigue, hard liver edge and complications of cirrhosis (muscle wasting, ascites, splenomegaly/portal hypertension), and outcomes, including hepatocellular carcinoma are worse than for hepatitis B without HIV infection.

**1E51.0Y**

## Other specified chronic hepatitis B

**1E51.0Z**

## Chronic hepatitis B, unspecified

<b>1E51.1</b>	<b>Chronic hepatitis C</b>
	A liver disease characterised by liver inflammation and fibrosis caused by more than 6 months of infection with the hepatitis C virus. Even at stage of cirrhosis there may be no symptoms. Otherwise, clinical features include fatigue and impaired quality of life, hard liver edge and complications of cirrhosis (muscle wasting, ascites, splenomegaly/portal hypertension). Chronic hepatitis C increases the risks of type 2 diabetes mellitus and cardiovascular disease, which contribute to increased all-cause mortality. Transmission is by blood and body fluid contamination, rarely by sexual transmission and from mother to baby at the time of birth (vertical transmission). Confirmation of the diagnosis is by detection of HCV RNA in the presence of a positive anti-HCV in serum.
	<b><i>Exclusions:</i></b> Non-alcoholic fatty liver disease (DB92)
	<b><i>Coded Elsewhere:</i></b> Chronic hepatitis B, co-infected with hepatitis C virus (1E51.0Y)
	Chronic hepatitis B, co-infected with hepatitis C virus and hepatitis D virus (1E51.0Y)
<b>1E51.2</b>	<b>Chronic hepatitis D</b>
	<b><i>Coded Elsewhere:</i></b> Chronic hepatitis B, co-infected with hepatitis C virus and hepatitis D virus (1E51.0Y)
<b>1E51.3</b>	<b>Chronic hepatitis E</b>
<b>1E51.Y</b>	<b>Other specified chronic viral hepatitis</b>
<b>1E51.Z</b>	<b>Chronic viral hepatitis, unspecified</b>
<b>1E5Z</b>	<b>Viral hepatitis, unspecified</b>

Viral infections characterised by skin or mucous membrane lesions (1E70-1F0Z)

Infections due to poxvirus (1E70-1E7Z)

<b>1E70</b>	<b>Smallpox</b>
	A disease caused by an infection with variola virus. This disease is characterised by a maculopapular rash that progresses to vesicles (commonly on the face, arms, and legs), and fever. Transmission is by direct contact. Confirmation is by identification of the variola virus in a skin sample of the rash.
	In 1980 the 33rd World Health Assembly declared that smallpox had been eradicated. The classification is maintained for surveillance purposes.

***Inclusions:*** Variola

**1E71**

### **Mpox**

A disease caused by an infection with monkeypox virus. In the first phase, this disease is characterised by lymphadenopathy, fever, headache, or malaise; in the second phase, this disease is characterised by a rash that starts as maculopapules and progresses to vesicles, then pustules, followed by crusts (may occur on the face, palms of the hands, soles of the feet, body, and mucous membranes). Transmission is by direct contact with infected animals (including body fluids or lesions), direct contact with body fluid from infected individuals, or through fomites. Confirmation is by identification of monkeypox virus.

**Inclusions:** monkeypox

**1E72**

### **Cowpox**

Cowpox is due to infection by an orthopoxvirus. Human disease is caused by cutaneous inoculation from an infected host. Cowpox is endemic in Europe amongst small rodents, particularly wood mice and wood voles. After a seven day incubation it causes a systemic febrile flu-like illness. Lesions are solitary or few, mainly affecting the face and

hands. An initial erythematous papula or blister later forms a crusted eschar which heals slowly leaving a deep pock-like scar.

**1E73**

### **Vaccinia**

A poxvirus which was formerly used to protect against smallpox. Its use as a vaccine can be complicated by a generalised rash secondary to viraemia, accidental infection of other sites or other individuals, progressive infection at the site of vaccination or, rarely, encephalomyelitis and myopericarditis.

**1E74**

### **Buffalopox**

Buffalopox is caused by an orthopox virus related to vaccinia virus. It is acquired in humans by direct inoculation from infected water buffalo. It is generally a mild illness similar to cowpox with just a few lesions on the hands and arms. It leaves minor pock-like scars.

**1E75**

### **Orf**

Orf is a virus infection of the skin contracted from sheep and goats. Orf is caused by a parapox virus which infects mainly young lambs and goats. Human lesions are caused by direct inoculation of infected material. Orf is not uncommon among sheep farmers, shearers, freezing workers, vets and farmers' wives or their children who bottle-feed lambs. They occur most commonly on the fingers, hands or forearms but can appear on the face.

**1E76**

### **Molluscum contagiosum**

A disease of the skin and mucous membranes, caused by an infection with molluscum contagiosum virus. This disease is characterised by papular skin eruptions, commonly 2-3 millimetres in diameter. Transmission is by direct contact.

**Exclusions:** Viral warts (1E80)

**1E7Y**

### **Other specified infections due to poxvirus**

**1E7Z**

### **Infections due to poxvirus, unspecified**

**Human papillomavirus infection of skin or mucous membrane (1E80-1E8Z)**

Infection of the skin and mucous membranes by the human papillomavirus (HPV), the agent responsible for viral warts in humans. Clinical manifestations depend on the virus subtype and the anatomical site involved.

**Coded Elsewhere:** Anogenital warts (1A95)

**1E80**

**Common warts**

Common warts are due to an infection of the epidermis by certain human papilloma viruses, most commonly HPV subtypes 1, 2, 4, 27 and 57. They manifest typically as papillomatous, keratinous growths on the hands and feet but may affect any part of the skin (and also adjacent mucous epithelia). They are very common during childhood and adolescence.

**Exclusions:** Warts of lips or oral cavity (1E82)

**1E80.0**

**Digital or periungual warts**

Viral warts affecting the fingers, thumbs or non-plantar (or non-weight-bearing) skin of the toes. They are often difficult to eradicate, particularly if the nail folds are involved, but most will eventually resolve spontaneously.

**Exclusions:** Plantar warts (1E80.1)

**1E80.1**

**Plantar warts**

Viral warts affecting the plantar surfaces of the feet including the weight-bearing skin of the toes. They are often painful and are difficult to eradicate. In most cases, however, they do eventually resolve spontaneously.

**1E80.Y**

**Other specified common warts**

**1E80.Z**

**Common warts, unspecified**

**1E81**

**Plane warts**

Plane warts (flat warts) are clinically distinct from common warts and manifest as multiple small flat-topped, often lightly pigmented papules on the face or extremities. They are caused by human papillomavirus (HPV) subtypes 3 and 10.

**1E82**

**Warts of lips or oral cavity**

Infection of the lips and/or oral cavity, particularly the keratinized surfaces of the gingiva and palate, with "skin" type human papillomavirus (types 2 and 4). Focal epithelial hyperplasia (Heck disease) is a specific form of oral human papillomavirus infection caused by types 13 or 32 and of high prevalence in certain communities in the Americas.

**1E82.0**

**Focal epithelial hyperplasia of oral mucous membranes**

Otherwise known as Heck disease, this is due to infection of the oral mucosa by human papillomavirus types 13 or 32. It most commonly presents as multiple smooth mucosal papules, giving rise to a cobblestone appearance. It is particularly common in children from native communities of the Americas with incidence rates of up to 30% reported.

**1E83****Wart virus proliferation in immune-deficient states**

Enhanced proliferation of human papillomavirus as a result of a failure of immune surveillance. This may be due to a genetic defect, disease or iatrogenic immunosuppression.

**1E8Z****Viral warts, not elsewhere classified**

Varicella zoster virus infections (1E90-1E91.Z)

**1E90****Varicella**

A disease caused by an infection with varicella zoster virus. This disease is characterised by a vesicular rash and fever. Transmission is by inhalation of infected respiratory secretions, or direct contact with fluid from vesicles.

**Coded Elsewhere:** Fetal varicella syndrome (KA62.2)

Congenital varicella (KA62.2)

**1E90.0****Varicella without complication**

A disease caused by an infection with varicella zoster virus. This disease is characterised by a vesicular rash and fever. Transmission is by inhalation of infected respiratory secretions, or direct contact with fluid from vesicles.

**1E90.1****Varicella meningitis**

A disease of the meninges, caused by an infection with varicella zoster virus. This infection is characterised by fever, stiff neck, headache, vomiting, photophobia, and sometimes an altered mental status or body aches. Transmission is through hematogenous spread to the meninges after inhalation of infected respiratory secretions, or direct contact with fluid from vesicles. Confirmation is by identification of varicella zoster viral DNA or anti-varicella zoster IgG in cerebrospinal fluid.

**1E90.2****Varicella encephalitis**

**Inclusions:** Postchickenpox encephalitis

Varicella encephalomyelitis

**1E90.Y****Varicella with other specified complication****1E90.Z****Varicella, unspecified****1E91****Zoster**

A disease caused by the reactivation of a latent infection with varicella zoster virus. This disease commonly presents with a rash (typically within one or two adjacent dermatomes), cutaneous hyperesthesia, or fever.

**1E91.0****Zoster without complications**

A painful blistering skin eruption following a dermatomal distribution resulting from reactivation of Varicella zoster virus in dorsal nerve root ganglia.

- 1E91.1** **Ophthalmic zoster**  
A disease of the eyes, caused by the reactivation of a latent infection with varicella zoster virus in the trigeminal nerve. This disease is characterised by a periorbital rash (typically within one dermatome), and conjunctivitis.
- 1E91.2** **Disseminated zoster**  
Disseminated herpes zoster indicates the presence of widespread cutaneous involvement extending beyond the primarily affected and directly adjacent dermatomes. It may be associated with impaired immunity resulting from disease or from therapy.
- 1E91.3** **Zoster with central nervous system involvement**
- 1E91.4** **Acute neuropathy of cranial nerve due to zoster**
- 1E91.40** Acute trigeminal zoster neuropathy
- 1E91.41** Acute herpetic geniculate ganglionitis
- 1E91.4Y** Other specified acute neuropathy of cranial nerve due to zoster
- 1E91.4Z** Acute neuropathy of cranial nerve due to zoster, unspecified
- 1E91.5** **Postherpetic polyneuropathy**
- 1E91.Y** **Zoster with other specified complications**
- 1E91.Z** **Zoster, unspecified**
- 1F00** **Herpes simplex infections**  
Any condition caused by an infection with herpes simplex virus (human herpesviruses 1 and 2). Confirmation is by identification of herpes simplex virus type 1 or 2.
- Exclusions:** Herpangina (1F05.1)
- Coded Elsewhere:** Perinatal Herpes simplex infection (KA62.A)  
Anogenital herpes simplex infection (1A94)  
Sexually transmissible infections due to Herpes simplex virus (1A9Z)
- 1F00.0** **Herpes simplex infection of skin or mucous membrane**  
A disease of the skin and mucous membranes, caused by an infection with herpes simplex virus type 1 or 2. This disease is characterised by vesicles, or may be asymptomatic. Transmission is by direct contact. Confirmation is by identification of herpes simplex virus type 1 or 2.
- Coded Elsewhere:** Anogenital herpes simplex infection (1A94)
- 1F00.00** Herpes simplex infection of skin  
Herpes simplex infection affecting skin and commonly arising from person-to-person inoculation of virus from contact sports such as Rugby football or wrestling.
- 1F00.01** Herpes simplex labialis  
**Inclusions:** cold sore

- 1F00.02** Herpes simplex gingivostomatitis
- 1F00.03** Disseminated cutaneous herpes simplex infection complicating other skin diseases
- 1F00.0Y** Other specified herpes simplex infection of skin or mucous membrane
- 1F00.1** **Herpes simplex infection of the eye**  
A condition of the eye, caused by an infection with herpes simplex virus type 1 or 2. The condition is characterised by blepharoconjunctivitis or keratitis. Transmission is by direct contact. Confirmation is by identification of herpes simplex virus type 1 or 2.  
**Coded Elsewhere:** Herpes simplex conjunctivitis (1D84.Y)
- 1F00.10** Herpes simplex keratitis  
This is a viral disease from the herpesviridae family caused by both Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). Infection with the herpes virus is categorized into one of several distinct disorders based on the site of infection. This diagnosis is a condition in which the eye's cornea, the front part of the eye, becomes infected and inflamed.  
**Coded Elsewhere:** Herpetic ulcer of cornea (9A76)
- 1F00.11** Herpes simplex infection of eyelid
- 1F00.1Y** Other specified herpes simplex infection of the eye
- 1F00.1Z** Herpes simplex infection of the eye, unspecified
- 1F00.2** **Herpes simplex infection of central nervous system**  
A condition of the central nervous system, caused by an infection with herpes simplex virus (human herpesviruses 1 and 2). This condition is characterised by fever, headache, or other clinical symptoms depending on the site of infection. Confirmation is by identification of herpes simplex virus type 1 or 2.
- 1F00.20** Herpes simplex meningitis
- 1F00.21** Encephalitis due to herpes simplex virus  
Herpetic encephalitis is a cerebral infection caused by herpes simplex virus type 1 (HSV1). It presents as acute necrosing temporal encephalitis. Onset is rapid (less than 48 hours) with a fever of 40 °C, headaches, and behavioural, language and memory problems. These initial manifestations are followed by numbness and coma, which may be accompanied by convulsions and paralysis. This disease, which affects only a small minority of HSV1-infected individuals, results from a primary immune deficiency.  
**Inclusions:** Simian B disease
- 1F00.2Y** Other specified herpes simplex infection of central nervous system
- 1F00.3** **Disseminated herpes simplex infection**
- 1F00.Y** **Other specified herpes simplex infections**
- 1F00.Z** **Herpes simplex infections, unspecified**

**1F01**

### **Roseola infantum**

A disease caused by an infection with roseolovirus (human herpesvirus type 6 or 7). This disease is characterised by acute fever, followed by macular or maculopapular exanthem in some individuals. Transmission is by inhalation of infected respiratory secretions or direct contact.

**1F02**

### **Rubella**

A disease caused by an infection with the rubella virus. This disease commonly presents with lymphadenopathy, or an exanthem that starts on the face and spreads to the limbs and trunk. Transmission is commonly by inhalation of infected respiratory secretions, or direct contact.

**Coded Elsewhere:** Congenital rubella syndrome (KA62.8)

**1F02.0**

#### **Rubella with neurological complications**

**1F02.1**

#### **Rubella arthritis**

A disease of the joints, caused by an infection with the rubella virus. This disease is characterised by inflammation of the joints leading to arthralgia or difficulties moving the joints. Transmission is by inhalation of infected respiratory secretions, or direct contact. Confirmation is by identification of rubella virus (in nasal or throat swab samples, blood, urine, or cerebrospinal fluid), or detection of rubella virus specific IgM antibodies.

**1F02.2**

#### **Rubella without complication**

Rubella was a common childhood viral infection until the advent of mass immunization programmes. It is characterised by a short-lived maculopapular exanthem, lymphadenopathy and mild fever: the majority of infections are not associated with significant morbidity. Transmission is by inhalation of infected respiratory secretions or by direct contact. Confirmation is by identification of rubella virus in nasal swab, throat swab or blood samples, or by detection of rubella virus specific IgM antibodies. Its public health importance lies in its potential to cause devastating harm to the fetus of an infected mother (congenital rubella syndrome).

**1F02.Y**

#### **Rubella with other specified complication**

**1F03**

### **Measles**

A disease of the respiratory system, caused by an infection with Morbillivirus. This disease is characterised by a blotchy rash, fever, cough, conjunctivitis, or malaise. This disease may also present with tiny white spots with bluish-white centres inside the mouth. Transmission is by inhalation of infected respiratory secretions, airborne transmission or direct contact. Confirmation is by detection of Morbillivirus RNA or measles-specific IgM antibodies.

**Inclusions:** morbilli

**Coded Elsewhere:** Subacute sclerosing panencephalitis (8A45.01)

- 1F03.0 Measles without complication**  
A disease caused by an infection with Morbillivirus. This disease is characterised by fever, cough, coryza, conjunctivitis, enanthema, or maculopapular rash, without any additional secondary pathological conditions. Transmission is by inhalation of infected respiratory secretions, or direct contact. Confirmation is by detection of Morbillivirus RNA, or detection measles-specific IgM antibodies.
- 1F03.1 Measles complicated by encephalitis**  
A disease caused by an infection with Morbillivirus that is complicated by an infection of the brain. This disease is characterised by symptoms of measles as well as inflammation of the brain. This disease may also present with fever, headache, poor appetite, vomiting, confusion, lethargy, or photophobia. Transmission is by haematogenous spread to the brain after inhalation of infected respiratory secretions, by airborne transmission, or by direct contact. Confirmation is by detection of Morbillivirus RNA or measles-specific IgM antibodies.
- 1F03.2 Measles complicated by meningitis**  
A disease caused by an infection with Morbillivirus that is complicated by an infection of the meninges. This disease is characterised by symptoms of measles as well as inflammation of the meninges. This disease may also present with a fever, vomiting, lethargy, confusion, muscle pain, photophobia, or convulsions. Transmission is by haematogenous spread to the meninges after inhalation of infected respiratory secretions, airborne transmission, or direct contact. Confirmation is by detection of Morbillivirus RNA or measles-specific IgM antibodies.
- Inclusions:** Postmeasles meningitis
- 1F03.Y Measles with other complications**
- 1F04 Erythema infectiosum**  
A condition caused by infection with parvovirus B19 (member of the Erythroparvovirus genus). In children, this condition is characterised by fever and cold-like symptoms initially, followed by a skin rash typically in the facial region. In adolescents and adults, this condition may present with painful and swollen joints. Transmission is by droplet transmission, or vertical transmission.
- Inclusions:** Slapped cheek syndrome
- 1F05 Picornavirus infections presenting in the skin or mucous membranes**
- 1F05.0 Enteroviral vesicular stomatitis**  
Enteroviral vesicular stomatitis, commonly called hand, foot and mouth disease, is a highly contagious enterovirus infection (usually Coxsackievirus A16 or Enterovirus 71). It typically causes a mild febrile illness with sore throat and loss of appetite followed by an eruption of vesicles on the lips, hands and feet. The majority of cases occur in children under the age of five.
- Inclusions:** Hand, foot and mouth disease
- 1F05.1 Enteroviral vesicular pharyngitis**

<b>1F05.2</b>	<b>Enteroviral exanthematous fever</b> An acute febrile, characteristically morbilliform exanthem due to infection by one of many different enteroviruses, especially Coxsackievirus and Echovirus.
	<b><i>Exclusions:</i></b> Enteroviral vesicular pharyngitis (1F05.1) Enteroviral vesicular stomatitis (1F05.0)
<b>1F05.3</b>	<b>Foot and mouth disease</b> A rare infection in humans due to the Aphthovirus Foot-and-mouth-disease virus (FMDV), which is responsible for a highly contagious epidemic infection of cloven-hoofed animals, particularly cattle. It manifests in humans with prodromal fever and malaise followed by vesiculation and ulceration of oral mucous membranes and lips. Vesicles may sometimes involve the digits and palmoplantar skin.
	<b><i>Exclusions:</i></b> Hand, foot and mouth disease (1F05.0)
<b>1F05.Y</b>	<b>Other specified picornavirus infections presenting in the skin or mucous membranes</b>
<b>1F0Y</b>	<b>Other specified viral infections characterised by skin or mucous membrane lesions</b>
<b>1F0Z</b>	<b>Viral infections characterised by skin or mucous membrane lesions, unspecified</b>

## Mycoses (1F20-1F2Z)

***Exclusions:*** Mycosis fungoides (2B01)  
Hypersensitivity pneumonitis due to organic dust (CA70)

***Coded Elsewhere:*** Intestinal fungal infections  
Fungal infection of fetus or newborn (KA63)

<b>1F20</b>	<b>Aspergillosis</b> Aspergillosis is a disease caused by fungi of the genus Aspergillus. The organism is ubiquitous, being found in soil and water or in decaying vegetation. While Aspergillus is entirely harmless for most individuals, the spores can cause various forms of mycosis in people with lung diseases or weakened immune system.
	<b><i>Inclusions:</i></b> aspergilloma <b><i>Coded Elsewhere:</i></b> Aspergillus-induced allergic or hypersensitivity conditions (CA82.4) Neonatal aspergillosis (KA63.1)

<b>1F20.0</b>	<b>Invasive aspergillosis</b> A disease caused by an infection with the fungi Aspergillus. This disease is characterised by colonization and invasion of tissue by Aspergillus in one part of the body and may spread to other parts of the body. Transmission is commonly by inhalation of Aspergillus spores.
<b>1F20.00</b>	Invasive aspergillosis of the digestive tract
<b>1F20.01</b>	Invasive cerebral aspergillosis

- 1F20.02** Disseminated aspergillosis  
Invasive aspergillosis affecting three or more organs.
- 1F20.0Y** Invasive aspergillosis of other specified site
- 1F20.0Z** Invasive aspergillosis, unspecified
- 1F20.1** **Non-invasive aspergillosis**
- 1F20.10** Aspergillus otomycosis  
Chronic superficial fungal infection of the external auditory canal and auricle due to saprophytic fungi of the genus Aspergillus.
- 1F20.11** Chronic aspergillosis of the paranasal sinuses  
*Inclusions:* Chronic granulomatous Aspergillus rhinosinusitis
- 1F20.12** Chronic pulmonary aspergillosis  
Chronic pulmonary aspergillosis (CPA) presents as nodular or cavitary lesion(s) in the lungs, of at least three months duration. It is caused by Aspergillus species as demonstrated on histological staining, by positive culture of biopsy, or positive Aspergillus IgG antibodies.  
The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA). Untreated it may progress to chronic fibrosing pulmonary aspergillosis (CFPA). Less common manifestations of CPA include Aspergillus nodule and single aspergilloma. All these entities are found in non-immunocompromised patients with prior or current lung disease. Subacute invasive pulmonary aspergillosis (formerly called chronic necrotising pulmonary aspergillosis) is a more rapidly progressive infection (<3 months) usually found in moderately immunocompromised patients.
- 1F20.13** Tonsillar aspergillosis
- 1F20.14** Aspergillus bronchitis
- 1F20.15** Obstructing aspergillus tracheobronchitis
- 1F20.1Y** Other specified non-invasive aspergillosis
- 1F20.1Z** Non-invasive aspergillosis, unspecified
- 1F20.Z** **Aspergillosis, unspecified**
- 1F21** **Basidiobolomycosis**  
Basidiobolomycosis is characterised by a slowly spreading, painless, non-pitting subcutaneous swelling without other obvious clinical signs. It may be single, or there may be multiple satellite lesions. The disc-shaped masses have a uniform hard consistency. It usually involves the limbs or limb-girdle areas and the infection is most often seen in children.  
*Inclusions:* Subcutaneous mucormycosis due to Basidiobolus ranarum

**1F22**

### **Blastomycosis**

A disease caused by an infection with the fungi *Blastomyces dermatitidis*. This disease is characterised by fever, chills, cough, myalgia, arthralgia, or chest pain. This disease may also present in the skin and bones. Transmission is by inhalation of fungal spores. Confirmation is by identification of *Blastomyces dermatitidis* in a urine, cerebrospinal fluid, or blood sample.

**Exclusions:**      Brazilian blastomycosis (1F2E)  
                      keloidal blastomycosis (1F2B)

**1F23**

### **Candidosis**

Candidosis is an infection caused by yeasts of the genus *Candida*. Superficial infections of the mucous membranes and skin are common, but deep invasive disease including fungal sepsis, endocarditis and meningitis may also occur.

**Inclusions:**      moniliasis  
                      candidiasis

**Coded Elsewhere:** Neonatal candidosis (KA63.2)  
                      Invasive neonatal candidosis (KA63.2)

**1F23.0**

### **Candidosis of lips or oral mucous membranes**

A disease of the lips and oral mucous membranes, caused by an infection with the fungi *Candida*. This disease commonly presents with white patches or plaques on the oral mucous membranes, angular cheilitis, or dysphagia. Transmission is by opportunistic transmission. Confirmation is by identification of *Candida* in an oral or skin sample.

**Exclusions:**      Neonatal candidosis (KA63.2)

**1F23.1**

### **Candidosis of skin or mucous membranes**

**Coded Elsewhere:** Neonatal mucocutaneous candidosis (EH12)

**1F23.10**

### **Vulvovaginal candidosis**

A disease caused by an infection with the fungi *Candida*. This disease is characterised by genital itching, burning, or vaginal discharge. Transmission is by endogenous spread, or sexual contact. Confirmation is commonly by identification of *Candida* in a vaginal swab.

**1F23.11**

### ***Candida* balanoposthitis**

A disease caused by an infection with the fungi *Candida* (commonly *Candida albicans*). This disease is characterised by inflammation of the glans or prepuce. This disease may also present with eroded white papules, or white discharge. Transmission is by sexual contact. Confirmation is by identification of *Candida* in a sub-preputial swab or urine sample.

**Inclusions:**      Candidosis of penis  
                      Penile thrush

**1F23.12**

### **Flexural or intertriginous candidosis**

Candidosis of flexural and intertriginous skin, where the warm, moist conditions favour the growth of *Candida* yeasts.

- 1F23.13** Candidosis of nail or paronychium  
Infection of the nail and/or paronychium (nail fold) with Candida yeasts
- 1F23.14** Chronic mucocutaneous candidosis  
Chronic Mucocutaneous Candidiasis is a primary immune deficiency characterised by persistent and/or recurrent infections of skin, nails and mucous membranes, caused by organisms of the genus *Candida*, mainly *C. albicans*.
- 1F23.15** Disseminated cutaneous candidosis
- 1F23.16** Candida otomycosis  
Infection of the external auditory canal with *Candida* yeasts, especially *Candida parapsilosis*. The infection may present with whitish greasy debris in, or discharge from the external auditory canal, or with erythema, oedema and pain. *Candida otomycosis* is less common than otomycosis due to *Aspergillus*. Chronic infection may be associated with perforation of the eardrum.
- 1F23.1Y** Candidosis of skin or mucous membrane of other specified site
- 1F23.1Z** Candidosis of skin or mucous membranes, unspecified
- 1F23.2** **Candidosis of gastrointestinal tract**
- 1F23.3** **Systemic or invasive candidosis**  
Invasion of internal organs by *Candida* yeasts. Risk factors include acute leukemia, haematopoietic stem cell or solid organ transplantation, and acute critical illness. *Candida* species other than *Candida albicans* are commonly implicated.
- Coded Elsewhere:** Invasive neonatal candidosis (KA63.2)  
Candidaemia (MA15.1)
- 1F23.30** Candida meningitis
- 1F23.31** Pulmonary candidosis  
A disease of the pulmonary system, caused by an infection with the fungi *Candida*. This disease is characterised by fever, chills, cough, nausea, vomiting, tachypnoea, tachycardia, or dyspnoea. Transmission is by opportunistic transmission. Confirmation is by identification of *Candida* from a sputum sample.
- 1F23.3Y** Other specified systemic or invasive candidosis
- 1F23.3Z** Systemic or invasive candidosis, unspecified
- 1F23.Y** **Other specified candidosis**
- 1F23.Z** **Candidosis, unspecified**

**1F24**

### **Chromoblastomycosis**

Chromoblastomycosis is a chronic fungal infection of the skin and subcutaneous tissues caused by a variety of pigmented fungi including *Phialophora verrucosa*, *Fonsecaea pedrosoi*, *Fonsecaea compacta* and *Cladophialophora carrionii*, which can be found in soil and wood. The infection usually follows trauma, such as a puncture from a splinter of wood and tends to affect exposed sites such as the feet and ankles. Chromoblastomycosis manifests initially as a warty papule which slowly enlarges to form a hypertrophic, warty plaque. Eventually, after months or many years, large hyperkeratotic masses may form, sometimes with secondary ulceration.

**1F25**

### **Coccidioidomycosis**

A disease caused by an infection with the fungi *Coccidioides*. This disease presents with symptoms depending on the site of infection, or may be asymptomatic. Transmission is commonly by inhalation of fungal spores. Confirmation is by identification or culture of *Coccidioides* from affected tissue or samples, or detection of antibodies against *coccidioides* in serum or cerebrospinal fluid.

**1F25.0**

#### **Pulmonary coccidioidomycosis**

A disease of the pulmonary system, caused by an infection with the fungi *Coccidioides*. This disease is characterised by cough, myalgia, fatigue, chest pain, pneumonia, or pleural effusion. Transmission is commonly by inhalation of fungal spores. Confirmation is by direct examination or culture of *Coccidioides* in a sputum, bronchoalveolar lavage fluid, or tissue sample.

**1F25.00**

#### **Acute pulmonary coccidioidomycosis**

Forty per cent of coccidioidal infections result in symptomatic pulmonary disease that may be indistinguishable from a bacterial community-acquired pneumonia. Radiographically these are usually focal alveolar infiltrates. Infection may be associated with the development of a rash, particularly erythema nodosum and erythema multiforme. Occasionally, there may be symmetric arthralgias or arthritis. Peripheral blood eosinophilia is not uncommon. Acute primary pulmonary coccidioidomycosis, particularly when associated with erythema nodosum and/or erythema multiforme, is frequently called "Valley fever." When associated with arthralgias or arthritis, it has been termed "desert rheumatism."

**1F25.01**

#### **Chronic pulmonary coccidioidomycosis**

A chronic form of pulmonary coccidioidomycosis. Pulmonary sequelae occur in approximately 5% of all cases of acute pulmonary coccidioidomycosis.

**1F25.1**

#### **Extrathoracic coccidioidomycosis**

Coccidioidomycosis involving sites other than the lungs and thoracic cavity. Recognised sites include lymph nodes, bones, joints, central nervous system and skin. Transmission is through haematogenous spread to other body sites after inhalation of fungal spores or by direct inoculation.

- 1F25.10** Disseminated coccidioidomycosis  
Diffuse pulmonary coccidioidomycosis occurs either when there is inhalation of a massive number of arthroconidia, such as may occur during archeological excavations, or among individuals with severely depressed cellular immunity (e.g., late HIV-1 infection [AIDS]; cancer chemotherapy; allogeneic transplant recipients, treatment with corticosteroids; and during the second, third trimesters and postpartum pregnancy). The radiographic appearance often is a mixture of small nodules and interstitial findings, sometimes called "reticulonodular" or, because it may resemble overwhelming pulmonary tuberculosis, "miliary."
- 1F25.11** Primary cutaneous coccidioidomycosis  
Coccidioidomycosis may rarely result from direct inoculation, usually through a puncture of the skin by a thorn or other vegetative structure. The infection generally remains confined to this area with local lymphangitic spread and is not considered indicative of disseminated disease. Coccidioidal serology tests may be positive.
- 1F25.12** Coccidioides meningitis  
An uncommon but often lethal form of coccidioidomycosis due to dissemination of Coccidioides fungi from the primary site of infection, principally the lungs, to the central nervous system.  
*Inclusions:* Coccidioidomycosis meningitis
- 1F25.1Y** Other specified extrathoracic coccidioidomycosis
- 1F25.1Z** Extrathoracic coccidioidomycosis, unspecified
- 1F25.Z** **Coccidioidomycosis, unspecified**
- 1F26** **Conidiobolomycosis**  
Conidiobolomycosis is a subcutaneous infection involving nasal mucosa and paranasal sinuses, leading to formation of firm, subcutaneous nodules or polyps. The infection may be acquired via inhalation of spores or a minor trauma such as an insect bite. The infected host is frequently an otherwise healthy individual working outdoors in tropical areas. Conidiobolomycosis can, however, cause major facial disfigurement. In individuals with impaired immune responses more invasive and potentially fatal infections may occur: such infections are not usually associated with skin lesions.  
*Inclusions:* Rhinoentomophthoromycosis
- 1F27** **Cryptococcosis**  
A disease caused by an infection with the fungi Cryptococcus neoformans or Cryptococcus gattii. This disease commonly presents with shortness of breath, cough, fever, fatigue, or headache. Transmission is by inhalation of fungal spores. Confirmation is by identification of Cryptococcus neoformans or Cryptococcus gattii in a blood, sputum, or cerebrospinal fluid sample.

- 1F27.0      Pulmonary cryptococcosis**  
The pattern of cryptococcal pulmonary disease ranges from asymptomatic airway colonization to pneumonia to acute respiratory distress syndrome. If present, symptoms include cough, dyspnoea or chest pain. Common chest X-ray appearances include nodules or infiltrates. In the immunocompetent host, focal lesions are more commonly seen with infection due to *C. gattii*.
- 1F27.1      Cerebral cryptococcosis**  
A disease of the central nervous system, caused by an infection with the fungi *Cryptococcus neoformans* or *Cryptococcus gattii*. This disease is characterised by fever, headache, lethargy, or neurological deficits. Transmission is by inhalation of fungal spores. Confirmation is by identification of *Cryptococcus neoformans* or *Cryptococcus gattii* in a blood, sputum, or cerebrospinal fluid sample.
- 1F27.10     Meningitis due to *Cryptococcus neoformans***  
Inflammation of the pia and arachnoid and spinal fluid associated with the fungus *Cryptococcus neoformans*. The respiratory tract is the usual portal of entry and meningitis may occur after dissemination to the meninges from the lungs. *C. neoformans* meningitis tends to occur in patients with defective cellular immunity. The meningitis usually evolves subacutely, but may be acute. Clinical features include headache, fever, nausea and vomiting, meningismus, visual disturbances, abnormal mental status, seizures, and raised intracranial pressure. Headache, fever, and stiff neck may be absent. The diagnosis is made by microscopic examination of the spinal fluid, culture of CSF and blood, and the latex agglutination test to detect the capsular polysaccharide antigen in CSF and blood. The organism may be seen on Gram stain or India ink stain of the CSF. The spinal fluid usually shows variable lymphocytic pleocytosis, a low glucose content, and a high protein level.
- 1F27.2      Disseminated cryptococcosis**  
Disseminated cryptococcosis is most common in immunocompromised hosts, with involvement with any organ and predilection for the central nervous system. It may manifest as systemic illness with fever, night sweats and malaise. Blood cultures may be positive (cryptococcaemia).
- 1F27.Y      Other specified cryptococcosis**
- 1F27.Z      Cryptococcosis, unspecified**

**1F28**

### **Dermatophytosis**

Dermatophytosis (tinea, ringworm) is a superficial infection of the skin, hair or nails by dermatophyte fungi of the genera *Trichophyton*, *Epidermophyton* or *Microsporum*. These fungi normally invade only the outer keratinous layer of the epidermis (stratum corneum), the hair shaft and the nail. They count amongst the commonest infections in man. Some species (e.g. *Trichophyton rubrum*) are essentially anthropophilic and infect only man whereas others are zoophilic (e.g. *Trichophyton verrucosum*) but may cause human infection from contact with infected animals.

**Inclusions:** Infections due to species of *Epidermophyton*, *Microsporum* and *Trichophyton*

**Exclusions:** *Tinea nigra* (1F2D.4)

*Tinea versicolor* (1F2D.0)

**1F28.0**

### **Dermatophytosis of scalp**

Dermatophytosis (tinea) affecting scalp and scalp hair. Clinical features range from limited patchy alopecia and scaling to widespread inflammation and suppuration with occipital lymphadenopathy. The scalp is a typical site for a kerion (q.v.), often due to a zoophilic dermatophyte acquired from an infected animal.

**Inclusions:** *Tinea capitis*  
*Scalp ringworm*

**1F28.1**

### **Dermatophytosis of nail**

Fungal infection of the nail plate due to dermatophyte fungi (*tinea unguium*). Infection results in a range of clinical signs including white or yellow discolouration, detachment of the plate from the nail bed (onycholysis), keratinous thickening under the nail plate (subungual hyperkeratosis) and fragility and fragmentation of the abnormal nail plate.

**Inclusions:** *Onychomycosis* due to dermatophyte  
*Tinea unguium*  
*Ringworm of nails*

**Exclusions:** *Onychomycosis* due to non-dermatophyte mould (1F2D.5)  
*Candida onychomycosis* (1F23.13)

**1F28.2**

### **Dermatophytosis of foot**

Dermatophytosis of the skin of the foot (tinea pedis). The lateral interdigital toe clefts are the most common initial site of infection. Longstanding infection with *Trichophyton rubrum*, the most commonly implicated organism in Europe and North America, characteristically causes dry scaling over the sole of the foot. Other species which regularly invade the skin of the foot include *Epidermophyton floccosum* and *Trichophyton interdigitale*.

**Inclusions:** *Moccasin foot*  
*Tinea pedis*  
*Athlete's foot*  
*Ringworm of foot*

- 1F28.3** **Genitocrural dermatophytosis**  
Dermatophyte infection of the inguinocrural folds and adjacent external genitalia (tinea cruris). It presents as erythema and inflammation of affected skin with an advancing scaly edge. It is typically itchy and affects adult men much more commonly than women or children. Dermatophyte infection of the toe clefts commonly co-exists.
- Inclusions:** Tinea cruris  
Ringworm of groin  
Dermatophytosis of groin
- 1F28.4** **Kerion**  
Kerion results from a severe host inflammatory response to dermatophyte infection of the hair follicles of the scalp or beard. It typically presents as a single painful, severely inflammatory, suppurating boggy mass and is most commonly a reaction to a zoophilic dermatophyte infection especially *Trichophyton verrucosum* (cattle ringworm) or *Trichophyton mentagrophytes*.
- 1F28.5** **Disseminated dermatophytosis**  
Extensive and invasive dermatophyte infection due either to a specific genetic anergy to dermatophytes or to profound immunosuppression. Dermal nodules, abscesses or draining sinuses may occur; rarely bone, central nervous system and lymph nodes may be involved.
- 1F28.Y** **Other specified dermatophytosis**
- 1F28.Z** **Dermatophytosis, unspecified**
- 1F29** **Eumycetoma**  
A localised chronic infection caused by various species of fungi and characterised by the formation of aggregates of the causative organisms (grains) within abscesses. This results in severe damage to skin, subcutaneous tissues and bones of the feet, hands and other parts of the body, with draining sinuses which discharge grains to the surface. Recognised agents include *Madurella mycetomatis*, *Madurella grisea*, *Leptosphaeria senegalensis*, *Curvularia lunata*, *Scedosporium apiospermum*, *Neotestudina rosati*,  
*Acremonium* spp. and *Fusarium* spp.  
**Inclusions:** Mycetoma due to fungal infection  
**Exclusions:** Actinomycetoma (1C43)
- 1F2A** **Histoplasmosis**  
Histoplasmosis is a disease caused by the fungus *Histoplasma* that exists worldwide with two significant variants: *Histoplasma capsulatum* and *Histoplasma duboisii*.  
**Coded Elsewhere:** Histoplasmosis-related fibrosing mediastinitis (CB22.0)

- 1F2A.0      Pulmonary histoplasmosis capsulati**  
A disease of the pulmonary system, caused by an infection with the fungi *Histoplasma capsulatum*. This disease is characterised by fever, chest pains, or a dry, nonproductive cough. Transmission is by inhalation of fungal spores, commonly from contaminated soil, or bat or bird faeces. Confirmation is by identification of *Histoplasma capsulatum* from affected tissue or body fluids, detection of antibodies against *Histoplasma capsulatum*, or detection of *Histoplasma capsulatum* antigen.
- 1F2A.1      Histoplasmosis due to *Histoplasma duboisii***  
This form of histoplasmosis is endemic to Sub-Saharan Africa and is generally less virulent than histoplasmosis due to *H. capsulatum*, the classical form which occurs predominantly in tropical and subtropical regions of the Americas but is also seen in Africa and Asia. Otherwise known as African histoplasmosis, histoplasmosis due to *Histoplasma duboisii* usually involves the skin and subcutaneous tissue, lymph nodes and bones and rarely the lungs and other internal organs.
- 1F2A.Y      Other specified histoplasmosis**
- 1F2A.Z      Histoplasmosis, unspecified**
- 1F2B      Lobomycosis**  
A disease of the skin, caused by an infection with the fungi *Lacazia lbooi*. This disease commonly presents with dermal nodules (either lenticular or in plaques), keloids, subcutaneous mycoses, or malignant tumours. Transmission is commonly by direct contact with contaminated water, soil, vegetation, or may be by direct contact with an infected dolphin. Confirmation is by identification of *Lacazia lbooi* in a lesion exudate or tissue sample.
- Inclusions:**      Lobo disease
- 1F2C      Mucormycosis**  
A disease caused by an infection with the fungi from the order Mucorales. This disease presents with symptoms depending on the site of the infection. Transmission is by direct contact with infected soil or decaying matter. Confirmation is by identification of fungi from the order Mucorales from a tissue sample.
- 1F2D      Non-dermatophyte superficial dermatomycoses**  
Any condition of the skin and mucous membranes, caused by an infection with fungi other than *Candida* and dermatophytes.
- Exclusions:**      Candidosis (1F23)  
                        Dermatophytosis (1F28)
- 1F2D.0      Pityriasis versicolor**  
A disease of the skin, caused by an infection with the fungi *Malassezia*. This disease is characterised by white, pink, fawn, brown, or often coalescing lesions that may be covered with thin furfuraceous scales. This disease commonly presents on the trunk, shoulders and arms, or neck and face. Transmission is by opportunistic transmission. Confirmation is by identification of *Malassezia* in a skin sample.

- 1F2D.1** **Malassezia folliculitis**  
Malassezia folliculitis is caused by the invasion of the hair follicle by Malassezia yeasts. Although Malassezia yeasts are a part of the normal human microflora, under certain conditions they can cause superficial dermatological conditions. The invasion results in the development of erythematous papules, and sometimes pustules, which may be either asymptomatic or itchy. Usually Malassezia yeasts are present along with staphylococci and propionibacteria in the follicles.
- Inclusions:** Seborrhoeic folliculitis  
**Exclusions:** Seborrhoea (ED91.2)
- 1F2D.2** **White piedra**  
A disease of the hair shaft, caused by an infection with the fungi Trichosporon beigelii. This disease is characterised by irregular, soft, white, or light brown nodules which adhere to the hair follicle. Transmission is by direct contact with contaminated soil or water, or by airborne transmission. Confirmation is by identification of Trichosporon beigelii in a hair follicle sample.
- Inclusions:** Trichosporosis nodosa
- 1F2D.3** **Black piedra**  
**Inclusions:** Trichomycosis nodularis
- 1F2D.4** **Tinea nigra**  
A disease of the skin, caused by an infection with the fungi Tinea nigra. This disease is characterised by brown to black macules; small, flat circumscribed changes in the colour of skin. This disease commonly presents on the palmar surfaces, soles, or other skin surfaces. Transmission is by direct contact with contaminated soil, wood, or vegetation. Confirmation is identification of Tinea nigra in a skin sample.
- Inclusions:** Keratomycosis nigricans palmaris
- 1F2D.5** **Onychomycosis due to non-dermatophyte mould**  
Fungal nail infection due to organisms other than Candida and dermatophytes. These include Scopulariopsis brevicaulis, Neoscytalidium dimidiatum, Fusarium spp., and Aspergillus spp., which may not respond to therapies directed at the more common causes of onychomycosis.
- Exclusions:** Candidosis of nail or paronychium (1F23.13)
- 1F2D.Y** **Other specified non-dermatophyte superficial dermatomycoses**
- 1F2D.Z** **Non-dermatophyte superficial dermatomycoses, unspecified**
- 1F2E** **Paracoccidioidomycosis**  
A disease caused by an infection with the fungi Paracoccidioides brasiliensis. This disease commonly presents with fever, toxæmia, weight loss, adenopathy, hepatosplenomegaly, anaemia, or eosinophilia. This disease may present with symptoms similar to tuberculosis, leukaemia, or lymphoma. Transmission is by inhalation of fungal spores. Confirmation is by identification of Paracoccidioides brasiliensis in a blood, sputum, or skin sample.

- 1F2E.0** **Pulmonary paracoccidioidomycosis**  
A disease of the pulmonary system, caused by an infection with the fungi Paracoccidioides brasiliensis. This disease is characterised by fever, cough, dyspnoea, or malaise. Transmission is by inhalation of fungal spores. Confirmation is by identification of Paracoccidioides brasiliensis in a blood or sputum sample.
- 1F2E.1** **Disseminated paracoccidioidomycosis**  
Disseminated paracoccidioidomycosis results from haematogenous and lymphatic dissemination of yeasts from the lungs and aerodigestive tract. Cutaneous involvement, seen in 25% of cases, presents as crusted papules, ulcers, nodules, and verrucous plaques. Lymphadenopathy occurs commonly in the cervical region, but all lymph node chains can be involved. Adrenal glands are commonly affected with a significant risk of adrenal insufficiency and Addisonian crisis. Long bones such as ribs, humeri, and clavicles can be involved. Mesenteric lymph node involvement can lead to bowel obstruction. Meningoencephalitis occurs in up to one quarter of cases.
- 1F2E.Y** **Other specified paracoccidioidomycosis**
- 1F2E.Z** **Paracoccidioidomycosis, unspecified**
- 1F2F** **Phaeohyphomycosis**
- 1F2G** **Pneumocystosis**  
*Coded Elsewhere:* HIV disease resulting in Pneumocystis jirovecii pneumonia (1C62.2)
- 1F2G.0** **Pulmonary pneumocystosis**  
An opportunistic pulmonary infection by the fungus Pneumocystis jirovecii. It is strongly associated with HIV and AIDS.  
*Coded Elsewhere:* Pneumonia due to pneumocystis (CA40.20)
- 1F2G.Z** **Pneumocystosis, unspecified**
- 1F2H** **Scedosporiosis**  
An opportunistic infection caused by fungal species of the genus Scedosporium. The most common clinical presentation is disseminated infection, which is associated with underlying disease, especially haematological malignancy, or with organ transplantation, especially of the lung. Infections of lung, bones or joints are also well recognised.
- 1F2J** **Sporotrichosis**  
A disease caused by an infection with the fungi Sporothrix schenckii. This disease presents with symptoms depending on the site of infection. Transmission is by direct contact with infected thorny plants, sphagnum moss, soil, bales of hays, or infected plant material. Confirmation is by identification of Sporothrix schenckii from a tissue or skin sample.

- 1F2J.0 Lymphocutaneous sporotrichosis**  
This is the most common type of sporotrichosis and follows implantation of *Sporothrix schenckii* spores into a cutaneous wound, most commonly on the upper extremity. In addition to a localised nodule or pustule, a chain of nodules develops along draining lymphatics. In longstanding cases regional lymph nodes may become involved.
- 1F2J.1 Fixed cutaneous sporotrichosis**  
Cutaneous sporotrichosis which remains localised to the area of inoculation.
- 1F2J.2 Pulmonary sporotrichosis**  
Pulmonary forms of infection, although uncommon, can occur when *Sporothrix schenckii* conidia are inhaled.  
Symptoms of pulmonary sporotrichosis mimic those of tuberculosis including constitutional complaints of fever, night sweats, weight loss, and fatigue as well as respiratory complaints including dyspnoea, cough, purulent sputum, and haemoptysis.
- 1F2J.3 Disseminated sporotrichosis**
- 1F2J.Y Other specified sporotrichosis**
- 1F2J.Z Sporotrichosis, unspecified**
- 1F2K Talaromycosis**  
Talaromycosis is an infection due to *Talaromyces marneffei*, an ubiquitous saprophyte of soil and decomposing organic matter. This dimorphic fungus, formerly known as *Penicillium marneffei*, is endemic to Southeast Asia and the southern part of China. Once considered rare, its occurrence has increased due to AIDS. It is now the third most common opportunistic infection in HIV-positive individuals. The most common symptoms are fever, skin lesions, anaemia, generalised lymphadenopathy, and hepatomegaly.
- 1F2L Emmonsiosis**  
An opportunistic infection caused by a variety of *Emmonsia* and *Emmonsia*-like fungal species. It was historically seen as a rare lung pathogen but is now increasingly reported as a disseminated infection in persons immunosuppressed, particularly as the result of HIV infection.
- 1F2L.0 Disseminated adiaspiromycosis**  
An increasingly reported fulminant fungal infection caused by *Emmonsia* and *Emmonsia*-like fungal species. It is seen in the context of profound immunosuppression, especially from HIV infection. This is in contrast with pulmonary adiaspiromycosis, which is also caused by *Emmonsia* species but typically affects immunocompetent individuals. Its clinical presentation is similar to those of histoplasmosis and blastomycosis. Skin and lung involvement is characteristic but the CNS and blood may also be affected.
- Exclusions:** Pulmonary adiaspiromycosis (1F2L.1)

**1F2L.1** **Pulmonary adiaspiromycosis**  
Pulmonary adiaspiromycosis is an infection of the lungs due to inhalation of spores of the saprophytic soil fungus Chrysosporium parvum (formerly Emmonsia parva). The fungus affects many species of rodents but may occasionally infect humans. It is characterised by the presence of huge spherules (adiaspores) in the lungs.

**Inclusions:** Adiaspiromycosis

**1F2L.Y** **Other specified emmonsiosis**

**1F2L.Z** **Emmonsiosis, unspecified**

**1F2Y** **Other specified mycoses**

**1F2Z** **Mycoses, unspecified**

## Parasitic diseases (1F40-1G2Z)

**Coded Elsewhere:** Parasitic diseases in the fetus or newborn (KA64)

### Malaria (1F40-1F4Z)

A disease caused by an infection with a protozoan parasite from the Plasmodium genus. This disease commonly presents with fever, chills, headache, nausea and vomiting, or malaise. Transmission is through the bite of an infected mosquito. Confirmation is commonly by identification of the Plasmodium genus in a blood sample.

**Coding Note:** In cases of mixed malaria code all relevant types separately.

**Coded Elsewhere:** HIV disease clinical stage 4 associated with malaria (1C61.3)

HIV disease clinical stage 3 associated with malaria (1C61.2)

HIV disease clinical stage 2 associated with malaria (1C61.1)

HIV disease clinical stage 1 associated with malaria (1C61.0)

Human immunodeficiency virus disease associated with malaria (1C61)

Malaria complicating pregnancy, childbirth, or the puerperium (JB63.60)

Other congenital malaria (KA64.Y)

**1F40** **Malaria due to Plasmodium falciparum**

A disease caused by an infection with the protozoan parasite Plasmodium falciparum. This disease is characterised by fever, chills, headache, myalgia, arthralgia, weakness, vomiting, or diarrhoea. This disease may also present with splenomegaly, anaemia, thrombocytopenia, hypoglycaemia, pulmonary or renal dysfunction, or neurologic changes. Transmission is through the bite of an infected mosquito. Confirmation is by identification of Plasmodium falciparum in a blood sample.

**Coding Note:** Includes mixed infections of Plasmodium falciparum with any other Plasmodium species.

**Coded Elsewhere:** Congenital falciparum malaria (KA64.1)

<b>1F40.0</b>	<b>Plasmodium falciparum malaria with cerebral complications</b> A disease of the cerebrum, caused by an infection with the protozoan parasite Plasmodium falciparum. This disease commonly presents with retinal whitening, splenomegaly, anaemia, thrombocytopenia, hypoglycaemia, pulmonary dysfunction, renal dysfunction, or neurologic changes. This disease may also present with fever, chills, headache, myalgia, arthralgia, weakness, vomiting, or diarrhoea. Transmission is through the bite of an infected mosquito. Confirmation is by identification of Plasmodium falciparum in a blood sample.
<b>1F40.Y</b>	<b>Other severe and complicated Plasmodium falciparum malaria</b>
<b>Coding Note:</b>	Includes mixed infections of Plasmodium falciparum with any other Plasmodium species.
<b>1F40.Z</b>	<b>Malaria due to Plasmodium falciparum, unspecified</b>
<b>Coding Note:</b>	Includes mixed infections of Plasmodium falciparum with any other Plasmodium species.
<b>1F41</b>	<b>Malaria due to Plasmodium vivax</b> A disease caused by an infection with the protozoan parasite Plasmodium vivax. This disease is characterised by fever, chills, headache, nausea and vomiting, body aches, or general malaise. Transmission is through the bite of an infected mosquito. Confirmation is by identification of Plasmodium vivax in a blood sample.  <b>Exclusions:</b> when mixed with Plasmodium falciparum (1F40)
<b>1F41.0</b>	<b>Plasmodium vivax malaria with rupture of spleen</b>
<b>1F41.Y</b>	<b>Malaria due to Plasmodium vivax with other complications</b>
<b>1F41.Z</b>	<b>Plasmodium vivax malaria without complication</b>
<b>1F42</b>	<b>Malaria due to Plasmodium malariae</b> A disease caused by an infection with the protozoan parasite Plasmodium malariae. This disease is characterised by fever, chills, headache, nausea and vomiting, body aches, or general malaise. Transmission is through the bite of an infected mosquito. Confirmation is by identification of Plasmodium malariae in a blood sample.  <b>Exclusions:</b> when mixed with Plasmodium vivax (1F41) when mixed with Plasmodium falciparum (1F40)
<b>1F42.0</b>	<b>Plasmodium malariae malaria with nephropathy</b> Quartan malarial nephropathy is a rare complication of malariae (quartan) malaria, especially occurring in children; it is a glomerulonephritis, usually fatal.
<b>1F42.Y</b>	<b>Malaria due to Plasmodium malariae with other complications</b>
<b>1F42.Z</b>	<b>Plasmodium malariae malaria without complication</b>

**1F43**

### **Malaria due to Plasmodium ovale**

A disease caused by an infection with the protozoan parasite Plasmodium ovale. This disease is characterised by fever, chills, headache, nausea and vomiting, body aches, or general malaise. Transmission is through the bite of an infected mosquito. Confirmation is by identification of Plasmodium ovale in a blood sample.

- Exclusions:**
- when mixed with Plasmodium malariae (1F42)
  - when mixed with Plasmodium falciparum (1F40)
  - when mixed with Plasmodium vivax (1F41)

**1F44**

### **Other parasitologically confirmed malaria**

**1F45**

### **Malaria without parasitological confirmation**

Clinically diagnosed malaria without parasitological confirmation

- Inclusions:**
- Clinically diagnosed malaria without parasitological confirmation

**1F4Z**

### **Malaria, unspecified**

**Coding Note:** In cases of mixed malaria code all relevant types separately.

Nonintestinal protozoal diseases (1F50-1F5Z)

Infections with unicellular organisms of the subkingdom Protozoa.

**Exclusions:** Protozoal intestinal infections (1A30-1A3Z)

**Coded Elsewhere:** Amoebiasis (1A36)

Malaria without parasitological confirmation (1F45)

Protozoal diseases complicating pregnancy, childbirth or the puerperium (JB63.6)

**1F50**

### **Acanthamoebiasis**

**1F51**

### **African trypanosomiasis**

A disease caused by an infection with the protozoan parasite Trypanosoma brucei. This disease presents with symptoms depending on the form of the protozoan parasite (Trypanosoma brucei rhodesiense or Trypanosoma brucei gambiense). Transmission is through the bite of an infected tsetse fly. Confirmation is by identification of Trypanosoma brucei in a blood or tissue sample.

**1F51.0**

### **Gambiense trypanosomiasis**

A disease caused by an infection with the protozoan parasite Trypanosoma brucei gambiense. This disease is characterised by fever, headache, muscle and joint aches, or malaise. This disease may also present with lymphadenopathy, weight loss, or neurological deficits. Transmission is through the bite of an infected tsetse fly. Confirmation is by identification of Trypanosoma brucei gambiense in a biopsy of the lymph node.

**Inclusions:** West African sleeping sickness

Infection due to Trypanosoma brucei gambiense

- 1F51.00** Meningitis in Gambiense trypanosomiasis
- 1F51.0Y** Other specified gambiense trypanosomiasis
- 1F51.0Z** Gambiense trypanosomiasis, unspecified
- 1F51.1** **Rhodesiense trypanosomiasis**  
A disease caused by an infection with the protozoan parasite *Trypanosoma brucei rhodesiense*. This disease is characterised by a chancre at the site of the bite. This disease may also present with fever, headache, muscle and joint aches, or lymphadenopathy. Transmission is through the bite of an infected tsetse fly. Confirmation is by identification of *Trypanosoma brucei rhodesiense* in a blood sample, lymph node fluid, or biopsy of the chancre.
- Inclusions:**
- East African sleeping sickness
  - Infection due to *Trypanosoma brucei rhodesiense*
- 1F51.10** Meningitis in Rhodesiense trypanosomiasis
- 1F51.1Y** Other specified rhodesiense trypanosomiasis
- 1F51.1Z** Rhodesiense trypanosomiasis, unspecified
- 1F51.Y** **Other specified african trypanosomiasis**
- 1F51.Z** **African trypanosomiasis, unspecified**
- 1F52** **Babesiosis**  
A disease caused by the protozoan parasite *Babesia*. This disease is characterised by reproduction and lysis of erythrocytes leading to symptoms that depend on the level of parasitaemia and immune status of the infected individual. This disease may present with fever, chills, malaise, myalgia, haemolytic anaemia, shock, or may be asymptomatic. Transmission is through the bite of an infected tick (*Ixodes*), or vertical transmission. Confirmation is by identification of *Babesia* in a blood smear, or detection of antibodies against *Babesia*.
- Inclusions:**
- Piroplasmosis
- 1F53** **Chagas disease**  
A disease caused by an infection with the protozoan parasite *Trypanosoma cruzi*. This disease is characterised by fever, headache, lymphadenopathy, pallor, muscle pain, dyspnoea, swelling, or abdominal or chest pain. This disease may also be asymptomatic. Transmission is by direct contact with faeces from an infected triatomine bug, vertical transmission, iatrogenic transmission, or ingestion of contaminated food or water. Confirmation is by identification of *Trypanosoma cruzi* in a blood sample.
- Inclusions:**
- American trypanosomiasis
  - infection due to *Trypanosoma cruzi*

- 1F53.1 Acute Chagas disease without heart involvement**  
A disease caused by an acute infection with the protozoan parasite Trypanosoma cruzi. This disease is characterised by fever, headache, lymphadenopathy, pallor, muscle pain, dyspnoea, swelling, or abdominal or chest pain. This disease presents with no cardiac involvement. Transmission is by direct contact with faeces from an infected triatomine bug, vertical transmission, iatrogenic transmission, or ingestion of contaminated food or water. Confirmation is by identification of Trypanosoma cruzi in a blood sample.
- 1F53.2 Chronic Chagas disease with heart involvement**  
A disease caused by a chronic infection with the protozoan parasite Trypanosoma cruzi. This disease commonly presents with severe malaise or cardiac involvement (such as cardiomyopathy, cardiac failure, thromboembolism, bradyarrhythmias, tachyarrhythmias, apical aneurysms, or cardiac arrest). Transmission is by direct contact with faeces from an infected triatomine bug, vertical transmission, iatrogenic transmission, or ingestion of contaminated food or water. Confirmation is by identification of Trypanosoma cruzi in a blood sample.
- 1F53.3 Chagas disease with digestive system involvement**  
A disease caused by an infection with the protozoan parasite Trypanosoma cruzi. This disease is characterised by severe malaise or digestive system involvement (such as megaoesophagus or megacolon). Transmission is by direct contact with faeces from an infected triatomine bug, vertical transmission, iatrogenic transmission, or ingestion of contaminated food or water. Confirmation is by identification of Trypanosoma cruzi in a blood sample.
- 1F53.4 Meningitis in Chagas disease**
- 1F53.Y Other specified Chagas disease**
- 1F53.Z Chagas disease, unspecified**
- 1F54 Leishmaniasis**  
Leishmaniasis is due to infection by vector-borne protozoa from the genus Leishmania. These protozoa exist as obligate intracellular parasites in human and mammalian hosts and are transmitted from host to host by certain species of sandfly. Depending on the Leishmania species involved, the resultant disease picture may range from a localised cutaneous ulcer through extensive mucocutaneous destruction to severe systemic disease.
- 1F54.0 Visceral leishmaniasis**  
A disease caused by an infection with the protozoan parasite Leishmania. This disease is characterised by biphasic fever, hepatosplenomegaly, pancytopenia, wasting, darkening of the skin, or may be asymptomatic. Transmission is through the bite of an infected female phlebotomine sandfly. Confirmation is by identification of Leishmania from a tissue or blood sample, or detection of antibodies against Leishmania.
- Inclusions:** Kala-azar

**1F54.1****Cutaneous leishmaniasis**

Cutaneous leishmaniasis results from bites by sandflies infected by protozoan parasites of the genus *Leishmania*. *Phlebotomus* is the principal vector in the Old World (Mediterranean, North Africa, Ethiopia and Asia), where *L. major*, *L. tropica*, *L. aethiopica* and *L. donovani* infantum predominate. Other sandflies are responsible for transmitting the New World species, *L. mexicana* and *L. brasiliensis*. The commonest presentation is with one or more crusted nodules or ulcers on exposed sites which gradually heal with scarring. Mexican and Ethiopian forms have a tendency to cause diffuse infiltration of the skin; South American forms frequently progress to mucocutaneous leishmaniasis.

**Coded Elsewhere:** Post-kala-azar dermal leishmaniasis (1F54.0)

**1F54.2****Mucocutaneous leishmaniasis**

Mucocutaneous leishmaniasis is a secondary infection of nasal and oral mucosae, predominantly by *Leishmania brasiliensis*. It usually first manifests within two years of initial cutaneous infection but often after the latter has healed. It results from lymphatic or haematogenous spread of infection and can cause severe local tissue destruction.

**Inclusions:** *Leishmania brasiliensis* infection

**1F54.Z****Leishmaniasis, unspecified****1F55****Naegleriasis**

Any condition caused by an infection with the protozoan parasite *Naegleria*.

**1F56****Rhinosporidiosis**

Rhinosporidiosis is a chronic, usually painless localised infection of the mucous membranes. Formerly believed to be a fungus, the causative agent, *Rhinosporidium seeberi*, has also never been cultured. With 18S rDNA sequencing, this organism has been shown to be a protistan parasite. Rhinosporidiosis occurs worldwide, and the greatest numbers of cases are found in southern India and Sri Lanka.

**1F57****Toxoplasmosis**

A disease caused by an infection with the protozoan parasite *Toxoplasma gondii*. This disease is characterised by fever, lymphadenitis, sore throat, or rash. Transmission is by direct ingestion of contaminated food, indirectly by food or water contaminated with infected cat faeces, or vertical transmission. Confirmation is by detection of antibodies against *Toxoplasma gondii*, or identification of *Toxoplasma gondii* in tissue, cerebrospinal fluid, blood, or other body fluids.

**Coded Elsewhere:** Congenital toxoplasmosis (KA64.0)

**1F57.0****Hepatitis due to *Toxoplasma gondii***

A disease of the liver, caused by an infection with the protozoan parasite *Toxoplasma gondii*. This disease is characterised by jaundice. Transmission is by haematogenous spread to the liver after direct ingestion of contaminated food, or indirect transmission by consumption of food or water contaminated with infected cat faeces. Confirmation is by detection of antibodies against *Toxoplasma gondii* in a blood sample or identification of *Toxoplasma gondii* in hepatic tissue.

- 1F57.1 Meningoencephalitis due to *Toxoplasma gondii***  
A disease of the meninges and brain, caused by an infection with the protozoan parasite *Toxoplasma gondii*. This disease is characterised by seizures, neck pain, neurological deficits, or alterations in behaviour, cognition, or consciousness. Transmission is by haematogenous spread to the meninges and brain after direct ingestion of contaminated food, or indirect transmission by consumption of food or water contaminated with infected cat faeces. Confirmation is by detection of antibodies against *Toxoplasma gondii* in cerebrospinal fluid or identification of *Toxoplasma gondii* in cerebrospinal fluid, and advanced imaging of the nervous system.
- Inclusions:** Toxoplasma meningoencephalitis
- 1F57.2 Pulmonary toxoplasmosis due to *Toxoplasma gondii***  
In immunodeficient patients, toxoplasmosis most often occurs in persons with defects in T cell-mediated immunity such as those receiving corticosteroids, anti-tumour necrosis factor (TNF) therapies, or cytotoxic drugs and those with hematologic malignancies, organ transplants, or acquired immunodeficiency syndrome (AIDS).  
Pulmonary toxoplasmosis in the immunodeficient patient may appear in the form of interstitial pneumonitis, necrotizing pneumonitis, consolidation, pleural effusion, or empyema, or all of these.  
AIDS patients with *Toxoplasma* pneumonia present with cough, dyspnoea, and fever. As toxoplasmosis is generally seen only in advanced HIV infection with CD4 counts below 100, the majority of AIDS patients who develop toxoplasma pneumonia already have had previous HIV-associated opportunistic infections. In solid organ transplant patients, this is most commonly due to transplantation of a toxoplasma-seropositive lung or heart into a seronegative recipient, resulting in primary pulmonary disease. In bone marrow transplant patients, pulmonary toxoplasmosis occurs in 0.28% to 0.45% of patients. Unlike solid organ transplant patients, most of these patients have reactivation, not primary disease.
- Inclusions:** Pulmonary toxoplasmosis
- 1F57.3 Eye disease due to *Toxoplasma gondii***  
Chorioretinitis or ocular toxoplasmosis is a relatively common manifestation of *T. gondii* infection. Ocular toxoplasmosis occurs when cysts deposited in or near the retina become active, producing tachyzoites. Focal necrotizing retinitis is the characteristic lesion, but retinal scars from prior reactivation are typically present.
- Inclusions:** Toxoplasma oculopathy
- 1F57.Y Other specified toxoplasmosis**
- 1F57.Z Toxoplasmosis, unspecified**
- 1F58 Microsporidiosis**
- 1F5Z Unspecified protozoal disease**

## Helminthiases (1F60-1F9Z)

**Coded Elsewhere:** Parasitic duodenitis (DA51.6Y)

## Diseases due to nematodes (1F60-1F6Z)

**1F60**

### **Angiostrongyliasis**

A disease caused by an infection with the parasitic worm *Angiostrongylus*. This disease commonly presents with fever, headache, stiffness of the neck and back, tingling or painful feelings in the skin, nausea and vomiting, or may be asymptomatic. Transmission is by ingestion of larvae in contaminated food.

**1F60.0**

### **Eosinophilic meningitis due to *Angiostrongylus cantonensis***

A disease of the meninges caused by an infection with *Angiostrongylus cantonensis*. This disease is characterised by fever, headache, stiffness of the neck, nausea, vomiting, muscular weakness, or paraesthesia. This disease may also present with abscesses, cerebral oedema, haemorrhage, diplopia, ataxia, or blindness. Transmission is by ingestion of infected undercooked snails, slugs, or transport hosts (such as frogs, fresh water shrimp, or land crabs). Confirmation is by identification of *Angiostrongylus cantonensis* from a cerebrospinal fluid sample, blood sample, or from a food history.

**1F60.1**

### **Intestinal angiostrongyliasis**

A disease of the intestines caused by an infection with the parasitic worm *Angiostrongylus costaricensis*. This disease is characterised by abdominal pain, fever, nausea, or vomiting. This disease may also present with intestinal obstruction or perforation. Transmission is by ingestion of infected undercooked slugs, or food contaminated by infected slugs or their slime. Confirmation is by identification of *Angiostrongylus costaricensis* from a cerebrospinal fluid sample, blood sample or from a food history.

**1F60.Y**

### **Other specified angiostrongyliasis**

**1F60.Z**

### **Angiostrongyliasis, unspecified**

**1F61**

### **Anisakiasis**

A disease caused by an infection with the parasitic worm *Anisakis*. This disease presents with severe abdominal pain, nausea, vomiting, or a hypersensitivity reaction. Transmission is by ingestion of undercooked contaminated fish or squid. Confirmation is by a history of consumption of undercooked fish or squid, or identification of *Anisakis* in the intestines or in a vomit sample.

**Inclusions:** Infection due to *Anisakis* larvae

**1F62**

### **Ascariasis**

A disease caused by an infection with the parasitic worm *Ascaris lumbricoides*. This disease presents with symptoms depending on the extent of the infection, ranging from asymptomatic to intestinal blockage. Transmission is by the faecal-oral route from the ingestion of *Ascaris* eggs in contaminated food or water. Confirmation is by identification of *Ascaris* eggs in a faecal sample.

**1F63**

### **Capillariasis**

**Coded Elsewhere:** Capillariasis due to Capillaria hepatica (DB90.0)

**1F63.0**

### **Capillariasis of the intestine**

A condition caused by an infection with the parasitic worm Capillaria philippinensis. This condition is characterised by abdominal pain, diarrhoea, nausea, vomiting, or weight loss. Transmission is by ingestion of infected undercooked fish, or autoinfection. Confirmation is by identification of Capillaria philippinensis in a tissue biopsy of the small intestines or faecal sample.

**Inclusions:** Capillariasis due to Capillaria hepatica (DB90.0)

**1F63.Y**

### **Other specified capillariasis**

**1F63.Z**

### **Capillariasis, unspecified**

**1F64**

### **Dracunculiasis**

A disease resulting from drinking water contaminated with water fleas infected with larvae of the nematode Dracunculus medinensis. It may take up to a year from ingestion of larvae for a mature gravid female worm to migrate to the skin and discharge immature larvae on contact with water. Dracunculiasis typically manifests as an intensely pruritic papule on a lower extremity from which part of the worm may emerge. Secondary pyogenic infection is common. This may be preceded by generalised symptoms such as fever, pruritus, urticaria and oedema.

**Inclusions:** Guinea worm infestation

**1F65**

### **Enterobiasis**

A disease of the intestine, caused by an infection with the parasitic worm Enterobius. This disease is characterised by inflammation of the anus, pruritus, rectal pain, or may be asymptomatic. Transmission is by the faecal-oral route or airborne transmission of the eggs from the parasitic worm. Confirmation is by identification of Enterobius eggs around the perianal region.

**Inclusions:** Pinworm infection

Threadworm infection

Oxyuriasis

**1F66**

### **Filariasis**

infections with nematodes of the superfamily Filarioidea; presence of living worms in the body is mainly asymptomatic but the death of adult worms leads to granulomatous inflammation and permanent fibrosis; organisms of the genus Elaeophora infect wild elk and domestic sheep causing ischaemic necrosis of the brain, blindness, and dermatosis of the face.

**Exclusions:** Onchocerciasis (1F6A)

- 1F66.0 Loiasis**  
A disease caused by an infection with the parasitic worm *Loa loa*. This disease is characterised by Calabar swellings found anywhere on the body (commonly found near joints). This disease may also present with generalised itching, muscle pain, joint pain, fatigue or may be asymptomatic. Transmission is through the bite of an infected fly (genus *Chrysops*). Confirmation is by identification of adult *Loa loa* in the skin or eye, *Loa loa* microfilariae in a blood sample obtained in the day (1000 - 1400), or detection of antibodies against *Loa loa* in a blood sample.
- Inclusions:**
- Eye worm disease of Africa
  - Loa loa* infestation
  - Calabar swelling
- 1F66.1 Mansoneliasis**  
A disease caused by an infection with the parasitic worm *Mansonella*. This disease is characterised by pruritus, dermal pigmentary changes, fever, or lymphadenopathy, or may be asymptomatic. Transmission is through the bite of an infected midge (genus *Culicoides*) or blackfly (genus *Simulium*). Confirmation is by identification of *Mansonella* microfilariae in a skin or blood sample.
- 1F66.2 Filariasis due to *Brugia* species**  
**Coded Elsewhere:** Filariasis due to *Brugia timori* (1F66.32)  
Filariasis due to *Brugia malayi* (1F66.31)
- 1F66.3 Lymphatic filariasis**  
Infestation by filarial nematodes of the genera *Wuchereria* and *Brugia*. It is acquired via transcutaneous injection of larvae by mosquitoes previously infested with microfilariae from the blood of a human host. The adult worms live in the lymphatics but release microfilariae into the bloodstream to complete the life cycle of the parasite. Clinical disease occurs in only a minority of those infected. In the acute stage this may present as an acute painful adenolymphangitis with fever. Chronic infestation causes progressive obstruction of lymphatic vessels and can result in disfiguring lymphoedema (elephantiasis), particularly of the genitalia and lower extremities.
- Exclusions:**
- Lymphoedema due to lymphatic filariasis (BD93.13)
- 1F66.30 Filariasis due to *Wuchereria bancrofti***  
This is a parasitic disease (usually an infectious tropical disease) that is caused by thread-like nematodes (roundworms) belonging to the superfamily *Filarioidea*, also known as "filariae".
- Inclusions:**
- Bancroftian filariasis
- 1F66.31 Filariasis due to *Brugia malayi***  
This is a parasitic disease (usually an infectious tropical disease) that is caused by thread-like nematodes (roundworms) belonging to the superfamily *Filarioidea*, also known as "filariae". This diagnosis is due to a nematode (roundworm), one of the three causative agents of lymphatic filariasis in humans.

- 1F66.32** Filariasis due to Brugia timori  
This is a parasitic disease (usually an infectious tropical disease) that is caused by thread-like nematodes (roundworms) belonging to the superfamily Filarioidea, also known as "filariae". This diagnosis is due to a human filarial parasitic nematode (roundworm) which causes the disease "Timor filariasis."
- 1F66.3Z** Lymphatic filariasis, unspecified
- 1F66.4** **Subcutaneous dirofilariasis**  
Subcutaneous dirofilariasis normally results from the transmission of microfilariae of *Dirofilaria repens* from the latter's natural animal host to man via a mosquito bite. The adult worm cannot develop fully in man but typically manifests as a subcutaneous nodule, commonly located on or around the eyelids.
- 1F66.Y** **Other specified filariasis**
- 1F66.Z** **Filariasis, unspecified**
- 1F67** **Gnathostomiasis**  
A disease caused by an infection with the parasitic worm *Gnathostoma*. This disease is characterised by painful, itchy swelling under the skin from movement of the parasite under the skin. This disease may also initially present with fever, lethargy, abdominal pain, vomiting, or diarrhoea, and may infect other parts of the body (lungs, bladder, eyes, ears, nervous system). Transmission is commonly by ingestion of undercooked contaminated freshwater fish, eels, frogs, birds, or reptiles, or ingestion of contaminated water. Confirmation is commonly by detection of antibodies against *Gnathostoma*, identification of migratory skin lesions, eosinophilia, and history of potential exposure.
- Inclusions:** Wandering swelling
- 1F68** **Hookworm diseases**  
A disease caused by an infection with the parasitic worm *Ancylostoma*. This disease is characterised by pruritus at the site of larval penetration. In mild infections, this disease may be asymptomatic; in moderate to severe infections, this disease may present with cough, pharyngeal irritation during larval migration in airways, iron-deficiency anaemia, abdominal pain, nausea, bloody diarrhoea, fatigue, or delayed development (mental or physical). Transmission is by direct contact with larvae from soil or sand contaminated with dog or cat faeces (by percutaneous migration of larvae), ingestion of larvae, or vertical transmission. Confirmation is by identification of *Ancylostoma* in a faecal sample.
- Inclusions:** Hook-worm infestation by *Ancylostoma*
- Coded Elsewhere:** Eosinophilic enteritis due to *Ancylostoma* (1F9Z)

**1F68.0**

### **Ancylostomiasis**

A disease caused by an infection with the parasitic hookworm *Ancylostoma duodenale*. This disease is characterised by pruritus at the site of larval penetration. In mild infections, this disease may be asymptomatic; in moderate to severe infections, this disease may present with cough, pharyngeal irritation during larval migration in airways, iron-deficiency anaemia, abdominal pain, nausea, bloody diarrhoea, fatigue, or delayed development (mental or physical). Transmission is by direct contact with larvae from soil or sand contaminated with dog or cat faeces (by percutaneous migration of larvae), ingestion of larvae, or vertical transmission. Confirmation is by identification of *Ancylostoma duodenale* in a faecal sample.

**1F68.1**

### **Necatoriasis**

A disease caused by an infection with the parasitic worm *Necator americanus*. This disease is characterised by pruritus at the site of larval penetration. In mild infections, this disease may be asymptomatic; in moderate to severe infections, this disease may present with cough, pharyngeal irritation during larval migration in airways, iron-deficiency anaemia, abdominal pain, nausea, arthralgia, or delayed development (mental or physical). Transmission is by direct contact with larvae from soil or sand contaminated with dog or cat faeces (by percutaneous migration of larvae). Confirmation is by identification of *Necator americanus* in a faecal sample.

**Inclusions:** Infection due to *Necator americanus*

**1F68.2**

### **Cutaneous larva migrans**

A disease caused by an infection with the parasitic worm larvae, commonly *Ancylostoma braziliense*, *A. caninum*, or *Uncinaria stenocephala*. This disease is characterised by intense pruritus and erythematous, serpiginous lesions due to migration of parasitic larvae in the upper dermis where the larvae penetrate the skin. Transmission is by direct contact with larvae from soil or sand contaminated with dog or cat faeces (by percutaneous migration of larvae).

**1F69**

### **Oesophagostomiasis**

This refers to an inflammation of small intestine caused by infection due to a nematode called *Oesophagostomum bifurcum*.

**1F6A**

### **Onchocerciasis**

Any condition caused by an infection with the parasitic worm *Onchocerca volvulus*. These conditions are characterised by the presence of firm subcutaneous nodules filled with adult worms, pruritus, long-term corneal inflammation (keratitis), or thickening of the corneal stroma. If untreated, these infections will lead to blindness. Transmission is through the bite of an infected *Simulium* fly.

**1F6A.0**

### **Onchocerciasis of the eye**

A disease of the eye, caused by an infection with the parasitic worm *Onchocerca volvulus*. This disease is characterised by transient punctate keratitis, or potentially blinding conditions (such as sclerosing keratitis, iridocyclitis, or optic atrophy). Transmission is through the bite of an infected *Simulium* fly. Confirmation is by identification of *Onchocerca volvulus* from the anterior chamber of the eye.

**Inclusions:** Ocular onchocerciasis

- 1F6A.1** **Onchocerciasis of the skin**  
A disease of the skin, caused by an infection with the parasitic worm *Onchocerca volvulus*. This disease is characterised by subcutaneous nodules on the skin (commonly affecting the iliac crests, ribs, knees, or trochanters). Transmission is through the bite of an infected *Simulium* fly. Confirmation is by identification of *Onchocerca volvulus* in a skin sample.
- Inclusions:** Cutaneous onchocerciasis
- 1F6A.Y** **Other specified onchocerciasis**
- 1F6A.Z** **Onchocerciasis, unspecified**
- 1F6B** **Strongyloidiasis**  
A disease caused by the parasitic worm *Strongyloides*. This disease presents with symptoms depending on the site of infection (gastrointestinal tract, pulmonary system, dermis, or systemic), or may be asymptomatic. Transmission is by direct contact through penetration of the skin (generally the feet) with larvae from faecally contaminated soil, or autoinfection of an established infection. Confirmation is by identification of *Strongyloides* larvae in faecal samples, duodenal fluid samples, sputum, pleural fluid, or tissue samples.
- Exclusions:** Trichostrongyliasis (1F6F)
- 1F6C** **Syngamosis**  
A disease caused by an infection with the parasitic worm *Mammomonogamus*. This disease is characterised by chronic nonproductive cough, crawling sensation in the throat, wheezing, or difficulties breathing. Transmission may be by ingestion of adult worms or eggs in contaminated food or water. Confirmation is by identification of adult *Mammomonogamus* by direct visualization, or identification of *Mammomonogamus* eggs in sputum or faecal samples.
- 1F6D** **Toxocariasis**  
A condition caused by an infection with the parasitic worm *Toxocara*. In ocular infections, this condition is characterised by vision loss or inflammation of the eye; in visceral infections, this condition is characterised by fever, coughing, enlarged liver, or pneumonia. This condition may also be asymptomatic. Transmission is by the faecal-oral route through the ingestion of food, water, or soil that contains *Toxocara* eggs (contaminated by faeces from an infected dog or cat). Confirmation is by detection of antibodies against *Toxocara* in a blood sample.
- Inclusions:** Toxocara infestation
- 1F6E** **Trichinosis**  
A disease caused by an infection with the parasitic worm *Trichinella*. This disease is characterised by fever, nausea, diarrhoea, vomiting, fatigue, or abdominal discomfort. This disease may also present with headache, chills, cough, swelling of the face and eyes, or aching joints and muscle pains. Transmission is by ingestion of contaminated meat. Confirmation is by detection of antibodies against *Trichinella* in a blood sample.

**1F6F****Trichostrongyliasis**

A disease caused by an infection with the parasitic worm Trichostrongylus. This disease is characterised by abdominal pain, diarrhoea, weight loss, or may be asymptomatic. Transmission is by ingestion of contaminated food or water. Confirmation is by identification of Trichostrongylus eggs in a faecal sample.

**1F6G****Trichuriasis**

A disease of the small intestine, caused by an infection with the parasitic worm Trichuris trichiura. This disease is commonly asymptomatic. This disease may also present with painful diarrhoea (containing a mixture of mucus, water, or blood). Transmission is by the faecal-oral route. Confirmation is by identification of Trichuris trichiura eggs in a faecal sample.

**Inclusions:** Trichocephaliasis

**1F6H****Uncinariasis**

A disease caused by an infection with the parasitic worm Uncinaria stenocephala. This disease is characterised by pruritus at the site of larval penetration. In mild infections, this disease may be asymptomatic; in moderate to severe infections, this disease may present with cough, pharyngeal irritation during larval migration in airways, iron-deficiency anaemia, abdominal pain, nausea, arthralgia, or delayed development (mental or physical). Transmission is by direct contact with larvae from soil or sand contaminated with dog or cat faeces (by percutaneous migration of larvae). Confirmation is by identification of Uncinaria stenocephala in a faecal sample.

**1F6Y****Other specified diseases due to nematodes****1F6Z****Diseases due to nematodes, unspecified****Diseases due to cestodes (1F70-1F7Z)****1F70****Cysticercosis**

A disease caused by an infection of tissue with larval cysts from the parasitic worm Taenia solium. This disease presents with symptoms depending on the site of infection (central nervous system, eye, or muscle). Transmission is through haematogenous spread of larvae to affected tissue after ingestion of Taenia solium eggs (or proglottids) in contaminated food or water. Confirmation is commonly by detection of antibodies against Taenia solium in a blood sample, cerebrospinal fluid, or faeces, and by advanced imaging of affected tissue.

**Inclusions:** cysticerciasis infection due to larval form of Taenia solium

**Coded Elsewhere:** Encephalitis due to cysticercosis (1F70.0Y)

Cysticercosis of orbit (9A21.Y)

- 1F70.0** **Cysticercosis of central nervous system**  
A disease of the central nervous system, caused by an infection of tissue with larval cysts from the parasitic worm *Taenia solium*. This disease presents with symptoms depending on the site of infection, the number and size of cysts, and the individual's immune status. This disease may present with epilepsy, chronic headache, hydrocephalus, neurological deficits, or may be asymptomatic. Transmission is by haematogenous spread of larvae to the central nervous system after ingestion of *Taenia solium* eggs in contaminated food or water. Confirmation is by detection of antibodies against *Taenia solium* in a blood sample, or cerebrospinal fluid and advanced imaging of the brain.
- 1F70.00** Meningitis due to Cysticercosis  
A disease of the meninges, caused by an infection with larval cysts from the parasitic worm *Taenia solium*. This disease is characterised by headache, fever, seizures, or neurological deficits. Transmission is through hematogenous spread of larvae to the meninges after ingestion of *Taenia solium* eggs (or proglottids) in contaminated food or water. Confirmation is by advanced imaging and detection of antibodies against *Taenia solium* from serum or cerebrospinal fluid.
- 1F70.0Y** Other specified cysticercosis of central nervous system
- 1F70.1** **Cysticercosis of eye**  
A disease of the eye, caused by an infection of tissue with larval cysts from the parasitic worm *Taenia solium*. This disease is characterised by cysts floating in the vitreous humour of the eye leading to impaired vision. Transmission is by haematogenous spread of larvae to the eye after ingestion of *Taenia solium* eggs in contaminated food or water. Confirmation is commonly by history of travel in parasite endemic regions and advanced imaging of the eye.
- 1F70.Y** Other specified cysticercosis
- 1F70.Z** Cysticercosis, unspecified
- 1F71** **Diphyllobothriasis**  
A disease caused by an infection with the parasitic worm *Diphyllobothrium*. This disease is characterised by abdominal discomfort, diarrhoea, vomiting, or weight loss. This disease may be asymptomatic. Transmission is by ingestion of infected undercooked fish. Confirmation is by identification of *Diphyllobothriasis* eggs in a faecal sample.  
*Inclusions:* larval diphyllobothriasis (1F75)
- 1F72** **Dipylidiasis**  
A condition caused by an infection with the parasitic worm *Dipylidium caninum*. This condition is commonly present with abdominal pain, diarrhoea, anal pruritus, or may be asymptomatic. Transmission is by ingestion of an infected flea. Confirmation is by identification of *Dipylidium caninum* eggs in a faecal sample.
- 1F73** **Echinococcosis**  
*Inclusions:* Hydatidosis
- 1F73.0** **Echinococcus infection of liver**

- 1F73.1**      **Echinococcus infection of lung**
- 1F73.2**      **Echinococcus infection of bone**
- 1F73.3**      **Echinococcus infection of central nervous system**
- 1F73.Y**      **Other specified echinococcosis**
- 1F73.Z**      **Echinococcosis, unspecified**

**1F74**

**Hymenolepiasis**

A disease caused by an infection with the parasitic worm Hymenolepis. This disease is commonly asymptomatic. This disease may present with nausea, weakness, abdominal pain, diarrhoea, or vomiting. Transmission is by the ingestion of eggs commonly in contaminated food or water, or ingestion of infected arthropods. Confirmation is by identification of Hymenolepis eggs in a faecal sample.

**1F75**

**Sparganosis**

A disease caused by an infection with the parasitic worm Spirometra. This disease presents with symptoms depending on the site of the infection. Transmission is by ingestion of contaminated water or ingestion of infected undercooked second intermediate hosts (such as fish, reptiles or amphibians). Confirmation is by identification of Spirometra eggs in a faecal sample.

**Inclusions:**      Larval diphyllobothriasis  
                          Spirometrosis

**1F76**

**Taeniasis**

A disease of the intestines, caused by an infection with the adult parasitic worm Taenia. This disease is characterised by abdominal pain, weight loss, diarrhoea, constipation, or may be asymptomatic. Transmission is by ingestion of larval cysts in undercooked beef or pork. Confirmation is by identification of Taenia eggs or proglottids in faecal samples (samples from multiple days).

**Exclusions:**      Cysticercosis (1F70)

**1F76.0**

**Taeniasis due to Taenia solium**

A disease of the intestines, caused by an infection with the adult parasitic worm Taenia solium. This disease is characterised by abdominal pain, weight loss, diarrhoea, constipation, or may be asymptomatic. Transmission is by ingestion of larval cysts in undercooked pork. Confirmation is by identification of Taenia solium eggs or proglottids in faecal samples (samples from multiple days).

**Inclusions:**      Taenia solium taeniasis

<b>1F76.1</b>	<b>Taeniasis due to <i>Taenia saginata</i></b>
	A disease of the intestines, caused by an infection with the adult parasitic worm <i>Taenia saginata</i> . This disease is characterised by abdominal pain, weight loss, diarrhoea, constipation, or may be asymptomatic. Transmission is by ingestion of larval cysts in undercooked beef. Confirmation is by identification of <i>Taenia saginata</i> eggs or proglottids in faecal samples (samples from multiple days).
	<b>Inclusions:</b> Infection due to adult tapeworm <i>Taenia saginata</i>
	<i>Taenia saginata</i> taeniasis
<b>1F76.Y</b>	<b>Other specified taeniasis</b>
<b>1F76.Z</b>	<b>Taeniasis, unspecified</b>
<b>1F7Y</b>	<b>Other specified diseases due to cestodes</b>
<b>1F7Z</b>	<b>Diseases due to cestodes, unspecified</b>

### Diseases due to trematodes (1F80-1F8Z)

<b>1F80</b>	<b>Clonorchiasis</b>
	A condition caused by an infection with the parasitic worm <i>Clonorchis sinensis</i> . This condition commonly presents with inflammation and obstruction of the biliary ducts. This condition may also present with abdominal pain, nausea, or diarrhoea. Transmission is commonly by ingestion of undercooked fish infected with parasitic cysts. Confirmation is by identification of <i>Clonorchis sinensis</i> eggs in a faecal sample.
	<b>Inclusions:</b> Chinese liver fluke disease
	Oriental liver fluke disease
	Infection due to <i>Clonorchis sinensis</i>
<b>1F81</b>	<b>Dicrocoeliasis</b>
	A disease caused by an infection with the parasitic worm <i>Dicrocoelium dendriticum</i> . This disease is commonly asymptomatic. This disease may present with cholecystitis, liver abscesses, or upper abdominal pain. Transmission is by ingestion of infected ants. Confirmation is by identification of <i>Dicrocoelium dendriticum</i> eggs in a faecal sample or duodenal fluid.
	<b>Inclusions:</b> Lancet fluke infection

**1F82**

### **Fascioliasis**

A disease of the hepatic system, caused by an infection with the parasitic worm *Fasciola*. In the acute phase, this disease is characterised by upper abdominal pain, fever, urticaria, shortness of breath, nausea, or vomiting due to migration of the parasite from the intestines to the liver. In the chronic phase, this disease is characterised by cholestasis, cholangitis, pancreatitis, or gallstones. This disease may be asymptomatic. Transmission is by ingestion of undercooked contaminated aquatic plants or contaminated water. Confirmation is commonly by identification of *Fasciola* eggs in a faecal sample (after the individual has followed a liver-free diet prior to testing), or detection of antibodies against *Fasciola*.

**Inclusions:**      Sheep liver fluke disease

**1F83**

### **Fasciolopsiasis**

A disease caused by an infection with the parasitic worm *Fasciolopsis buski*. This disease is characterised by abdominal pain or diarrhoea, or may be asymptomatic. This disease may also present with oedema of the face, abdomen, or legs, vomiting, anorexia, or intestinal obstruction. Transmission is by ingestion of undercooked contaminated aquatic plants. Confirmation is by identification of *Fasciolopsis buski* eggs in a faecal sample.

**1F84**

### **Opisthorchiasis**

A disease caused by an infection with the parasitic worm *Opisthorchis*. This disease is commonly asymptomatic. In mild cases, this disease may present with dyspepsia, abdominal pain, diarrhoea, or constipation; in severe cases, this disease may present with hepatomegaly and malnutrition; in rare cases, this disease may present with cholangitis, cholecystitis, and cholangiocarcinoma. Transmission is by ingestion of infected undercooked freshwater fish. Confirmation is by identification of *Opisthorchis* in a faecal sample.

**1F85**

### **Paragonimiasis**

A disease caused by an infection with the parasitic worm *Paragonimus*. This disease is characterised by cough or haemoptysis, or may be asymptomatic. This disease may present with other symptoms depending on the site where the parasite migrates to. Transmission is commonly by ingestion of undercooked contaminated crustaceans (crab or crayfish). Confirmation is commonly by identification of *Paragonimus* eggs in a sputum or faecal sample.

**Inclusions:**      lung fluke disease  
                        infection due to *paragonimus* species  
                        Infestation due to *Paragonimus* species

**1F86**

### **Schistosomiasis**

An infestation caused by helminths of the genus *Schistosoma*. The clinical features vary according to the species involved but the principal organs affected are the gastrointestinal tract and bladder.

**Inclusions:**      snail fever

- 1F86.0 Schistosomiasis due to *Schistosoma haematobium***  
A disease caused by an infection with the parasitic worm *Schistosoma haematobium*. This disease is characterised by haematuria, scarring, calcification, or squamous cell carcinoma. This disease may also present with embolic egg granulomas in the brain or spinal cord. Transmission is by direct contact with freshwater that has been contaminated with *Schistosoma haematobium* eggs or snails that carry *Schistosoma haematobium*.
- 1F86.1 Schistosomiasis due to *Schistosoma mansoni***  
A disease caused by an infection with the parasitic worm *Schistosoma mansoni*. This disease commonly presents with Katayama fever, hepatic perisinusoidal egg granulomas, Symmers' pipe stem periportal fibrosis, or portal hypertension. This disease may also present with embolic egg granulomas in the brain or spinal cord. Transmission is by direct contact with freshwater that has been contaminated with *Schistosoma mansoni* eggs or snails that carry *Schistosoma mansoni*. Confirmation is by identification of the *Schistosoma mansoni* eggs in a faecal sample.
- 1F86.2 Schistosomiasis due to *Schistosoma japonicum***  
A disease caused by an infection with the parasitic worm *Schistosoma japonicum*. This disease is characterised by Katayama fever, hepatic perisinusoidal egg granulomas, Symmers' pipe stem periportal fibrosis, or portal hypertension. This disease may also present with embolic egg granulomas in the brain or spinal cord. Transmission is by direct contact with freshwater that has been contaminated with *Schistosoma japonicum* eggs or snails that carry *Schistosoma japonicum*. Confirmation is by identification of the *Schistosoma japonicum* eggs in a faecal sample.
- Inclusions:** Asiatic schistosomiasis
- 1F86.3 Other schistosomiases**
- 1F86.4 Cercarial dermatitis**  
A disease caused by an infection with the parasitic worm *Schistosoma*. This disease is characterised by tingling, burning, itching of the skin, small reddish pimples, or small blisters. Transmission is by direct contact with contaminated water. Confirmation is by identification of *Schistosoma* eggs in a faecal, urine, or blood sample.
- 1F86.5 Schistosomal pneumonitis**
- 1F86.Z Schistosomiasis due to unspecified or unknown *Schistosoma* species**
- 1F8Y Other specified diseases due to trematodes**
- 1F8Z Diseases due to trematodes, unspecified**
- 1F90 Other and unspecified infestation by parasitic worms**
- 1F90.0 Mixed intestinal helminthiases**
- 1F90.1 Intestinal parasitic infestation not otherwise specified**  
This concept should be used for parasitic infestation of the intestine only when no more precise details are available.

- 1F90.2** **Intestinal helminthiasis, unspecified**
- 1F90.Y** **Other specified other and unspecified infestation by parasitic worms**
- 1F90.Z** **Other and unspecified infestation by parasitic worms, unspecified**
- 1F91** **Diphyllobothriasis and sparganosis**  
Diphyllobothriasis is defined as infection with the cestode *Diphyllobothrium latum* or other *Diphyllobothrium* species, which occurs accidentally in humans who ingest water containing infected cyclops, eating raw or inadequately cooked flesh. Manifestations may include abdominal discomfort, diarrhoea, vomiting and megaloblastic anaemia. Massive infections may result in intestinal obstruction.
- 1F9Z** **Helminthiases, unspecified**  
Infestations by ectoparasites (1G00-1G0Z)  
Diseases caused by parasitic organisms which normally live on the surface of the host.  
**Coded Elsewhere:** Epidemic louse-borne typhus fever due to *Rickettsia prowazekii* (1C30.0)  
    Recrudescence typhus (1C30.1)
- 1G00** **Pediculosis**  
A condition of the skin, hair, or genital region caused by an infection with the parasite *Pediculus*. This disease is characterised by pruritus. This condition also presents with symptoms depending on the site of infection. Transmission is by direct or indirect contact with an infected individual or animal. Confirmation is by identification of *Pediculus*.
- 1G00.0** **Pediculosis capitis**  
A condition of the scalp and hair shaft, caused by an infection with the parasite *Pediculus humanus capitis*. This condition is characterised by pruritus which may lead to sores or thickened discoloured skin. Transmission is by direct or indirect contact with an infected individual or animal. Confirmation is by identification of *Pediculus humanus capitis* eggs or *Pediculus humanus capitis*.
- 1G00.1** **Pediculosis corporis**  
A condition of the skin, caused by an infection with the parasite *Pediculus humanus corporis*. This condition is characterised by pruritus which may lead to sores or thickened discoloured skin. Transmission is by direct or indirect contact with an infected individual or animal. Confirmation is by identification of *Pediculus humanus corporis* eggs or *Pediculus humanus corporis*.
- 1G00.Z** **Pediculosis of unspecified site or type**

**1G01****Myiasis**

A disease of the tissues, caused by an infection with fly larvae from the order Diptera. This disease is characterised by a lump developing in the tissue. Transmission is by ingestion of contaminated larvae, direct contact with an infected mosquito, tick, fly, or indirect contact with infected fly eggs. Confirmation is by identification of Diptera from a tissue sample.

**Inclusions:** infestation by larvae of flies

**1G01.0****Ocular myiasis**

A disease of the eye, caused by an infection with fly larvae from the order Diptera. This disease is characterised by a lump developing in the tissue. Transmission is by ingestion of contaminated larvae, direct contact with an infected mosquito, tick, fly, or indirect contact with infected fly eggs. Confirmation is by identification of Diptera.

**1G01.1****Nasopharyngeal myiasis****1G01.2****Laryngeal myiasis****1G01.3****Cutaneous myiasis**

The infestation of the skin or subcutaneous tissues by the larvae of certain flies (*Phormia regina*, *Cordylobia anthropophaga*, *Cochliomyia hominivorax*, *C. macellaria*, *Wohlfahrtia vigil*, *W. meigeni*, *W. opaca*, *Dermatobia hominis*, *Sarcophaga krameri*), characterised by a painful boil-like lesion containing one or more larvae with severe pruritus and local destruction of tissue.

**1G01.Y****Other specified myiasis****1G01.Z****Myiasis, unspecified****1G02****External hirudiniasis**

Infestation of the skin by leeches. Sensitisation to antigenic substances deposited in the skin can result in urticarial weals and bullae.

**Exclusions:** Internal hirudiniasis (1F60-1F9Z)

**1G03****Pthiriasis**

Infestation most commonly of pubic hair and less commonly of body hair or eyelashes by the crab louse, *Pthirus pubis*. Transmission is by direct, typically sexual contact with an infected individual. Confirmation is by identification of *Pthirus pubis* or its eggs.

**Inclusions:** Infestation by crab lice

**1G04****Scabies**

A highly contagious infestation of the skin by the mite *Sarcoptes scabiei* var. *hominis*. It may result in epidemics when introduced into institutions such as schools and nursing homes. The mites burrow into the skin, favouring the extremities, genitalia and, in infants, the axillae. The characteristic widespread intensely pruritic papulovesicular rash results largely from the host response rather than directly to burrowing by mites. Where such a response is absent as in immunosuppressed or debilitated patients, unchecked proliferation of mites results in crusted scabies. Sarcoptic mites from other mammals such as dogs may cause a transient pruritic eruption.

**1G04.0****Classical scabies****1G04.1****Crusted scabies**

Crusted scabies results from unchecked proliferation of the human scabies mite in individuals who are unable to mount an adequate immune response to infestation. Extensive thick crusts containing vast numbers of mites form over the skin, particularly of the extremities. Because itching is usually absent, the diagnosis is frequently overlooked. Patients with crusted scabies may serve as the source for widespread outbreaks of scabies in institutions such as hospitals and care homes.

**1G04.Y****Other and unspecified scabies****1G05****Tungiasis**

A disease of the skin, caused by an infection with the parasite *Tunga penetrans*. This disease is characterised by lesions (white patch with a black dot in the middle), skin inflammation, or pruritus surrounding the lesion. This disease may also be asymptomatic. Transmission is through the bite of an infected flea, or by direct contact with an infected animal. Confirmation is by identification of *Tunga penetrans* or travel history.

**1G06****Cimicosis**

Infestation by bedbugs, which are blood-sucking temporary ectoparasites. The most common species to attack humans is *Cimex lectularius*. In individuals who are not sensitized by previous exposure, there may be no symptoms or signs other than purpuric macules at the sites of bites. Weals, papules or bullae may occur in sensitized individuals.

**1G07****Infestation by mites**

**Coded Elsewhere:** Scabies (1G04)

Cutaneous reactions to zoonotic mites (NE61)

**1G07.0****Infestation by Demodex**

Infestation with *Demodex* mites. *Demodex folliculorum* is a saprophytic mite of the human pilosebaceous unit with a predilection for facial skin and eyelashes. *Demodex brevis* is found in the sebaceous glands of the eyelash follicle and in the lobules of eyelid meibomian glands. Although infestation is very common and normally symptomless, the mites have been linked to papulopustular rosacea and chronic blepharitis.

**1G07.Y****Infestation of the skin by other specified parasitic mites**

<b>1G0Y</b>	<b>Infestation by other specified ectoparasite</b>
<b>1G0Z</b>	<b>Infestation by unknown or unspecified ectoparasite</b>
<b>1G2Y</b>	<b>Other specified parasitic diseases</b>
<b>1G2Z</b>	<b>Unspecified parasitic diseases</b>

## Sepsis (1G40-1G41)

**Coding Note:** Any type of infection - bacterial, viral, fungal or protozoal, can cause sepsis and must be coded as well. When the site of infection is unknown, select a code for Infection of unspecified site by organism followed by the appropriate code for sepsis.

- Exclusions:**
- Plague (1B93)
  - Acute or fulminant melioidosis (1C42)
  - Tularaemia (1B94)
  - Other infection during labour (JB0D)
  - Injury or harm arising following infusion, transfusion or therapeutic injection, not elsewhere classified (NE80)
  - Genital tract or pelvic infection following abortion, ectopic or molar pregnancy (JA05.0)
  - Disseminated gonococcal infection (1A73)
  - Extraintestinal yersiniosis (1B9A)
  - Injury or harm arising from a procedure, not elsewhere classified (NE81)
  - Meningococcal disease (1C1C)
  - Systemic inflammatory response syndrome of noninfectious origin (MG46)

**Coded Elsewhere:** Puerperal sepsis (JB40.0)

- Sepsis of fetus or newborn (KA60)
- Obstetric pyaemic or septic embolism (JB42.3)

**1G40**

### **Sepsis without septic shock**

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection.

**Coding Note:** Any type of infection - bacterial, viral, fungal or protozoal, can cause sepsis and must be coded as well. When the site of infection is unknown, select a code for Infection of unspecified site by organism followed by the appropriate code for sepsis.

- Exclusions:**
- Septicaemia (MA15.0)
  - Sepsis of fetus or newborn (KA60)

**1G41**

### **Sepsis with septic shock**

Septic shock is a subset of sepsis in which circulatory, cellular and metabolic abnormalities are profound enough to substantially increase mortality.

**Coding Note:**

Any type of infection - bacterial, viral, fungal or protozoal, can cause sepsis and must be coded as well. When the site of infection is unknown, select a code for Infection of unspecified site by organism followed by the appropriate code for sepsis.

**Exclusions:**      Sepsis of fetus or newborn (KA60)  
                         Septicaemia (MA15.0)

**1G60**

### **Certain other disorders of infectious origin**

Miscellaneous disorders of infectious origin not classifiable elsewhere including those due to algae and oomycetes

**1G60.0**

#### **Mycetoma of unknown or unspecified type**

Mycetoma is a destructive localised chronic infection of skin, subcutaneous tissue and bone, most commonly affecting the foot. It can be caused by either fungi (eumycetoma) or filamentous bacteria (actinomycetoma). Where possible it should be classified more precisely as either actinomycetoma, the commonest type, or eumycetoma

**Exclusions:**      Actinomycetoma (1C43)  
                         Eumycetoma (1F29)

**1G60.1**

#### **Pythiosis**

Pythiosis is a life-threatening infection by the oomycete *Pythium insidiosum*. Although infection in animals occurs widely across the world, human pythiosis is largely confined to Thailand and, with the exception of ocular disease, is closely associated with underlying haematological disease, especially thalassaemia. There is a high mortality in patients with disseminated or vascular disease. In the latter form, invasion of arterial wall results in vascular occlusion and a frequent need for amputation. Patients with ocular pythiosis commonly require enucleation. A small proportion of infections are limited to the skin and subcutaneous tissues.

**1G60.2**

#### **Protothecosis**

Protothecosis is a rare opportunistic infection in humans caused by achloric algae of the genus *Prototheca*. The infection is usually localised and may be associated with antecedent local trauma. It is generally located on exposed sites and remains confined to skin and subcutaneous tissues. In immunocompromised patients, however, widespread cutaneous, subcutaneous or deep infection may occur.

**1G60.Y**

#### **Other specified disorders of infectious origin not elsewhere classified**

## **Sequelae of infectious diseases (1G80-1G8Y)**

A sequela is a chronic condition resulting from an acute condition and begins during that acute condition. The acute condition is no longer present. The sequela continues after the acute phase of the condition is resolved. For infectious diseases, the original infection is no longer present.

The sequelae categories indicate infections as the cause of sequelae which are themselves classified elsewhere.

Not to be used for chronic infections. Code the chronic infection to chronic or active infectious disease as appropriate.

Use an additional code, if desired, to identify the specific sequelae.

**Coded Elsewhere:** Sequelae of inflammatory diseases of central nervous system (1D0Y)

**1G80**

### **Sequelae of tuberculosis**

Sequela of tuberculosis is a chronic condition resulting from acute tuberculosis. *Mycobacterium tuberculosis* is no longer active. The sequela continues after the acute phase is resolved.

**1G81**

### **Sequelae of trachoma**

This refers to a pathological condition resulting from an infectious disease caused by the *Chlamydia trachomatis* bacterium which produces a characteristic roughening of the inner surface of the eyelids.

**1G82**

### **Sequelae of leprosy**

This refers to a pathological condition resulting from a chronic disease caused by the bacteria *Mycobacterium leprae* and *Mycobacterium lepromatosis*.

**1G83**

### **Sequelae of poliomyelitis**

Sequelae of poliomyelitis refers to the residuals of acute poliomyelitis as well as other disorders that have an etiological link to either the acute polio infection or to chronic deficits resulting from the acute infection. Disorders that may manifest late in the lives of polio survivors include early advanced degenerative arthritis, sleep disorders, respiratory insufficiency, and a variety of mental disorders.

**Exclusions:** Post polio progressive muscular atrophy (8B62)

**1G84**

### **Sequelae of viral encephalitis**

**1G85**

### **Sequelae of diphtheria**

This refers to conditions that develop as a consequence of a bacterial infection of the respiratory tract with *Corynebacterium diphtheriae*.

**1G8Y**

### **Sequelae of other specified infectious diseases**

**1H0Z**

### **Infection, unspecified**

# CHAPTER 02

---

## Neoplasms

This chapter has 325 four-character categories.

Code range starts with 2A00

An abnormal or uncontrolled cellular proliferation which is not coordinated with an organism's requirements for normal tissue growth, replacement or repair.

**Coded Elsewhere:** Inherited cancer-predisposing syndromes

This chapter contains the following top level blocks:

- Neoplasms of brain or central nervous system
- Neoplasms of haematopoietic or lymphoid tissues
- Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues
- In situ neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
- Benign neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
- Neoplasms of uncertain behaviour, except of lymphoid, haematopoietic, central nervous system or related tissues
- Neoplasms of unknown behaviour, except of lymphoid, haematopoietic, central nervous system or related tissues
- Inherited cancer-predisposing syndromes

### Neoplasms of brain or central nervous system (2A00-2A0Z)

A benign or malignant neoplasm that affects the brain, meninges, or spinal cord. Representative examples of primary neoplasms include astrocytoma, oligodendrogloma, ependymoma, and meningioma.

<b>2A00</b>	<b>Primary neoplasms of brain</b>
<b>2A00.0</b>	<b>Gliomas of brain</b>
<b>2A00.00</b>	Glioblastoma of brain  Glioblastomas are malignant astrocytic tumours (grade IV according to the WHO classification). They represent the most frequent brain tumours in adults. They may occur at any age, but 70% of cases are seen in patients between 45 and 70 years of age. The tumours are usually located in the brain hemispheres, but can be found anywhere in the central nervous system.
	<b>Inclusions:</b> glioblastoma NOS
<b>2A00.0Y</b>	Other specified gliomas of brain

- 2A00.0Z** Gliomas of brain, unspecified
- 2A00.1** **Embryonal tumours of brain**
- 2A00.10** Medulloblastoma of brain  
A malignant, invasive embryonal neoplasm arising from the cerebellum. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, large cell medulloblastoma, and medulloblastoma with extensive nodularity.
- 2A00.11** Central primitive neuroectodermal tumour  
A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.
- 2A00.1Y** Other specified embryonal tumours of brain
- 2A00.1Z** Embryonal tumours of brain, unspecified
- 2A00.2** **Tumours of neuroepithelial tissue of brain**
- 2A00.20** Tumours of the pineal gland or pineal region
- 2A00.21** Mixed neuronal-glial tumours
- 2A00.22** Choroid plexus tumours
- 2A00.2Y** Other specified tumours of neuroepithelial tissue of brain
- 2A00.2Z** Tumours of neuroepithelial tissue of brain, unspecified
- 2A00.3** **Central neurocytoma of brain**  
Central neurocytoma is a very rare brain tumour of young adults. It is typically found in the lateral ventricles and occasionally in the third ventricle. Symptoms are those of increased intracranial pressure.
- 2A00.4** **Astroblastoma of the brain**  
A rare glial neoplasm more commonly found in young adults. It is characterised by tumour cells with characteristics suggestive of an astrocytic origin (positive for GFAP), arranged perivascularly. The cells have broad, non-tapering processes radiating towards a central blood vessel. The biologic behaviour of astroblastomas is variable, so no WHO grade has been established, yet.
- 2A00.5** **Primary neoplasm of brain of unknown or unspecified type**
- 2A01** **Primary neoplasms of meninges**
- 2A01.0** **Meningiomas**
- 2A01.00** Primary malignant meningioma
- 2A01.0Y** Other specified meningiomas

<b>2A01.0Z</b>	Meningiomas, unspecified
<b>2A01.1</b>	<b>Mesenchymal tumours of meninges</b>
<b>2A01.2</b>	<b>Primary neoplasm of meninges of unknown or unspecified type</b>
<b>2A02</b>	<b>Primary neoplasm of spinal cord, cranial nerves or remaining parts of central nervous system</b>
<b>2A02.0</b>	<b>Gliomas of spinal cord, cranial nerves or other parts of the central nervous system</b>
<b>2A02.00</b>	Glioblastoma of spinal cord, cranial nerves or other parts of central nervous system
<b>2A02.0Y</b>	Other specified gliomas of spinal cord, cranial nerves or other parts of the central nervous system
<b>2A02.0Z</b>	Gliomas of spinal cord, cranial nerves or other parts of the central nervous system, unspecified
<b>2A02.1</b>	<b>Tumours of cranial or paraspinal nerves</b>
<b>2A02.10</b>	Malignant peripheral nerve sheath tumour of cranial or paraspinal nerves Malignant schwannoma is a tumour of the peripheral nervous system that arises in the nerve sheath.  <b>Exclusions:</b> Malignant nerve sheath tumour of peripheral nerves or autonomic nervous system, primary site (2B5E)
<b>2A02.11</b>	Paraspinal neuroblastoma
<b>2A02.12</b>	Malignant neoplasm of the optic nerve
<b>2A02.1Y</b>	Other specified tumours of cranial or paraspinal nerves
<b>2A02.1Z</b>	Tumours of cranial or paraspinal nerves, unspecified
<b>2A02.2</b>	<b>Primary neoplasm of spinal cord of unknown or unspecified type</b>
<b>2A02.3</b>	<b>Benign neoplasm of cranial nerves</b> This is a tumour of cranial nerves having none of the characteristics of a malignant neoplasm.
<b>2A02.4</b>	<b>Benign neoplasm of spinal cord</b>
<b>2A0Z</b>	<b>Other and unspecified neoplasms of brain or central nervous system</b>

## Neoplasms of haematopoietic or lymphoid tissues (2A20-2B3Z)

A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by haematogenous spread, direct tumour infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukaemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms and myelodysplastic syndromes.

### Myeloproliferative neoplasms (2A20-2A22)

<b>2A20</b>	<b>Non mast cell myeloproliferative neoplasms</b>
	<b>Coded Elsewhere:</b> Acquired thrombocytosis (3B63.1)
<b>2A20.0</b>	<b>Chronic myelogenous leukaemia, BCR-ABL1-positive</b>
	<b>Inclusions:</b> Atypical chronic myeloid leukaemia, BCR-ABL1-negative (2A41)
	Chronic myelomonocytic leukaemia (2A40)
	Other and unspecified myeloproliferative neoplasms (2A22)
	Chronic myeloid leukaemia, not elsewhere classified (2B33.2)
<b>2A20.00</b>	Chronic myelogenous leukaemia with blast crisis
<b>2A20.01</b>	Chronic myelogenous leukaemia, Philadelphia chromosome (Ph1) positive
<b>2A20.02</b>	Chronic myelogenous leukaemia, t(9;22)(q34; q11)
<b>2A20.03</b>	Naegeli-type monocytic leukaemia
<b>2A20.0Y</b>	Other specified chronic myelogenous leukaemia, BCR-ABL1-positive
<b>2A20.0Z</b>	Chronic myelogenous leukaemia, BCR-ABL1-positive, unspecified
<b>2A20.1</b>	<b>Chronic neutrophilic leukaemia</b>
	A rare chronic myeloproliferative neoplasm characterised by sustained peripheral blood neutrophilia, bone marrow hypercellularity due to neutrophilic granulocyte proliferation, and hepatosplenomegaly. The neutrophils lack dysplasia and often show toxic granulations. There is no detectable Philadelphia chromosome or BCR/ABL1 fusion gene.
<b>2A20.2</b>	<b>Primary myelofibrosis</b>
	<b>Inclusions:</b> chronic idiopathic myelofibrosis
	<b>Exclusions:</b> Acute panmyelosis with myelofibrosis (2A60.38)
<b>2A20.3</b>	<b>Chronic eosinophilic leukaemia, not elsewhere classified</b>
	A chronic myeloproliferative neoplasm characterised by persistent eosinophilia in the blood, bone marrow and peripheral tissues. Organ damage occurs as a result of leukaemic infiltration or the release of cytokines, enzymes or other proteins by the eosinophils. Chronic eosinophilic leukaemia, not otherwise specified excludes patients with a Ph chromosome, BCR-ABL1 fusion gene or rearrangement of PDGFRA, PDGFRB or FGFR1.

<b>2A20.4</b>	<b>Polycythaemia vera</b>
<b>2A20.5</b>	<b>Non mast cell myeloproliferative neoplasm, unclassifiable</b> Cases that have definite features of myeloproliferative neoplasms (MPN), but fail to meet the criteria of a specific MPN subtype.
<b>2A20.Y</b>	<b>Other specified non mast cell myeloproliferative neoplasms</b>
<b>2A20.Z</b>	<b>Non mast cell myeloproliferative neoplasms, unspecified</b>
<b>2A21</b>	<p><b>Mastocytosis</b></p> <p>Mastocytosis is due to a clonal, neoplastic proliferation of mast cells that accumulate in one or more organ systems. Activating mutations of KIT are frequently found. It is characterised by the presence of multifocal compact clusters or cohesive aggregates/infiltrates of abnormal mast cells. The disorder is heterogeneous, ranging from skin lesions that may spontaneously regress to highly aggressive neoplasms associated with multiorgan failure and short survival. Subtypes of mastocytosis are recognised mainly by the distribution of the disease and clinical manifestations. In cutaneous mastocytosis (CM), the mast cell infiltration remains confined to the skin, whereas systemic mastocytosis (SM) is characterised by involvement of at least one extracutaneous organ with or without evidence of skin lesions. Mastocytosis should be strictly separated from mast cell hyperplasia or mast cell activation states without morphological and/or molecular abnormalities that characterize the neoplastic proliferation.</p>
<b>2A21.0</b>	<p><b>Systemic mastocytosis</b></p> <p>Systemic mastocytosis (SM) comprises a heterogeneous group of rare acquired and chronic haematological malignancies that are related to an abnormal proliferation of mast cells in tissue, including bone marrow, with or without skin involvement. SM can be divided into indolent SM (ISM) and aggressive SM (ASM).</p>
<b>2A21.00</b>	Mast cell leukaemia
<b>2A21.0Y</b>	Other specified systemic mastocytosis
<b>2A21.0Z</b>	Systemic mastocytosis, unspecified
<b>2A21.1</b>	<p><b>Cutaneous mastocytosis</b></p> <p>Cutaneous mastocytosis is characterised by abnormal accumulation and proliferation of cutaneous mast cells. Most types are isolated but cutaneous mastocytosis can occur in association with systemic disease. Clinical forms include cutaneous mastocytoma, urticaria pigmentosa (the most frequent form), pseudoxanthomatous nodular cutaneous mastocytosis, telangiectasia macularis eruptiva perstans and diffuse cutaneous mastocytosis.</p>
<b>2A21.10</b>	Urticaria pigmentosa <i>Inclusions:</i> Maculopapular cutaneous mastocytosis
<b>2A21.1Y</b>	Other specified cutaneous mastocytosis
<b>2A21.1Z</b>	Cutaneous mastocytosis, unspecified

<b>2A21.2</b>	<b>Mast cell sarcoma</b> A rare entity characterised by localised but destructive growth of a tumour consisting of highly atypical, immature mast cells.
<b>2A21.3</b>	<b>Extracutaneous mastocytoma</b> A localised tumour consisting of mature mast cells.
<b>2A21.Y</b>	<b>Other specified mastocytosis</b>
<b>2A21.Z</b>	<b>Mastocytosis, unspecified</b>
<b>2A22</b>	<b>Other and unspecified myeloproliferative neoplasms</b>
	<b><i>Exclusions:</i></b> Chronic myelogenous leukaemia, BCR-ABL1-positive (2A20.0) Atypical chronic myeloid leukaemia, BCR-ABL1-negative (2A41)

#### Myelodysplastic syndromes (2A30-2A3Z)

Clonal hematopoietic disorders characterised by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20% in marrow and blood, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukaemia.

***Exclusions:***      Therapy-related myeloid neoplasms (2A60.2)  
                          Drug-induced aplastic anaemia (3A70.10)

#### **2A30**                **Refractory anaemia**

#### **2A31**                **Refractory neutropaenia**

A myelodysplastic syndrome characterised by the presence of at least 10% dysplastic neutrophils in the bone marrow or the peripheral blood.

#### **2A32**                **Refractory thrombocytopenia**

A myelodysplastic syndrome characterised by the presence of at least 10% dysplastic megakaryocytes, found within at least 30 megakaryocytes examined in the bone marrow.

#### **2A33**                **Refractory anaemia with ring sideroblasts**

A myelodysplastic syndrome characterised by an anaemia in which 15% or more of the erythroid precursors are ringed sideroblasts. The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain.

#### **2A34**                **Refractory cytopenia with multi-lineage dysplasia**

A myelodysplastic syndrome characterised by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines.

**2A35****Refractory anaemia with excess of blasts**

A myelodysplastic syndrome characterised by bi-cytopenia or pancytopenia and dysplastic changes in one or multiple lineages, with 5-19% myeloblasts in the bone marrow, 2-19% blasts in the blood, or <20% blasts with the presence of Auer rods.

**2A36****Myelodysplastic syndrome with isolated del(5q)**

A myelodysplastic syndrome characterised by anaemia with or without other cytopenias and/or thrombocytosis and in which the sole cytogenetic abnormality is del(5q). Myeloblasts are <5% in the bone marrow and <1% in the blood.

**Inclusions:** 5 q- syndrome

**2A37****Myelodysplastic syndrome, unclassifiable**

A subtype of myelodysplastic syndrome which at disease presentation lacks findings appropriate for classification into any other MDS category, or has an MDS-associated cytogenetic abnormality and cytopenia, but lack sufficient dysplastic changes in any lineage and have <15% ring sideroblasts.

**2A38****Refractory cytopenia of childhood**

The most common subtype of the myelodysplastic syndromes affecting children. It is characterised by persistent cytopenia with less than 5% blasts in the bone marrow and less than 2% blasts in the peripheral blood.

**2A3Y****Other specified myelodysplastic syndromes****2A3Z****Myelodysplastic syndromes, unspecified****Myelodysplastic and myeloproliferative neoplasms (2A40-2A4Z)**

A category of clonal haematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.

**2A40****Chronic myelomonocytic leukaemia**

A myelodysplastic/myeloproliferative neoplasm which is characterised by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL1 fusion gene, fewer than 20 percent blasts in the bone marrow and blood, often myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.

**Inclusions:** Chronic monocytic leukaemia

**Exclusions:** Myeloid/lymphoid neoplasm associated with PDGFRA rearrangement (2A50)

Myeloid neoplasm associated with PDGFRB rearrangement (2A51)

**2A41****Atypical chronic myeloid leukaemia, BCR-ABL1-negative**

A myelodysplastic/myeloproliferative neoplasm characterised by the principal involvement of the neutrophil series with leukocytosis with circulating immature myeloid cells, fewer than 20 percent blasts in the bone marrow and blood, and severe dysgranulopoiesis. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL1 fusion gene.

**2A42**

**Juvenile myelomonocytic leukaemia**

A myelodysplastic/myeloproliferative neoplasm of childhood that is characterised by proliferation principally of the granulocytic and monocytic lineages. Myelomonocytic proliferation is seen in the bone marrow and the blood. The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.

**2A42.0**

**Juvenile myelomonocytic leukaemia in complete remission**

**2A42.Y**

**Other specified juvenile myelomonocytic leukaemia**

**2A42.Z**

**Juvenile myelomonocytic leukaemia, unspecified**

**2A43**

**Refractory anaemia with ring sideroblasts associated with marked thrombocytosis**

A provisional entity that encompasses cases with morphologic and clinical characteristics of refractory anaemia with ring sideroblasts, marked thrombocytosis, and abnormal megakaryocytes.

**2A44**

**Myeloproliferative and myelodysplastic disease, unclassifiable**

This entity includes cases that have clinical, laboratory, and morphologic features that support the diagnosis of both a myelodysplastic syndrome and a myeloproliferative neoplasm, but do not meet the criteria for any of the other entities included in the myelodysplastic/myeloproliferative neoplasm category.

**2A4Y**

**Other specified myelodysplastic and myeloproliferative neoplasms**

**2A4Z**

**Myelodysplastic and myeloproliferative neoplasms, unspecified**

Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 (2A50-2A5Z)

A group of rare myeloid and lymphoid neoplasms characterised by rearrangement of the PDGFRA, PDGFRB, or FGFR1 genes, resulting in the formation of fusion transcripts and aberrant tyrosine kinase activity. Eosinophilia is a characteristic finding but it is not always present.

**2A50**

**Myeloid/lymphoid neoplasm associated with PDGFRA rearrangement**

**2A51**

**Myeloid neoplasm associated with PDGFRB rearrangement**

A distinct type of myeloid neoplasm that occurs in association with rearrangement of PDGFRB gene at 5q32. Patients usually present with a picture resembling chronic myelomonocytic leukaemia and, less often atypical chronic myeloid leukaemia or chronic eosinophilic leukaemia.

**2A52**

**Myeloid or lymphoid neoplasms with FGFR1 abnormalities**

Hematologic neoplasms characterised by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients may present with a myeloproliferative neoplasm, acute myeloid leukaemia, lymphoblastic lymphoma/leukaemia of T or B-cell lineage, or acute leukaemia of mixed phenotype.

**2A5Z**

**Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1, unspecified**

**2A60**

**Acute myeloid leukaemias and related precursor neoplasms**

Acute myeloid leukaemia is characterised by clonal expansion of myeloid blasts in the peripheral blood and bone marrow. Clinical manifestations are fever, pallor, anaemia, hemorrhages and recurrent infections.

**2A60.0**

**Acute myeloid leukaemia with recurrent genetic abnormalities**

**2A60.1**

**Acute myeloid leukaemia with myelodysplasia-related changes**

An acute myeloid leukaemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or typical myelodysplastic syndrome-related cytogenetic abnormalities. There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the genetic abnormalities that are present in acute myeloid leukaemia with recurrent genetic abnormalities.

**2A60.2**

**Therapy-related myeloid neoplasms**

**Inclusions:** therapy-related myelodysplastic syndromes

**2A60.20**

Therapy related acute myeloid leukaemia or myelodysplastic syndrome

**2A60.2Y**

Other specified therapy-related myeloid neoplasms

**2A60.2Z**

Therapy-related myeloid neoplasms, unspecified

**2A60.3**

**Acute myeloid leukaemia, not elsewhere classified by criteria of other types**

Acute myeloid leukaemias specified by morphological criteria should only be classified as such, if recurrent genetic abnormalities, prior history of a myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm, or history of cytotoxic chemotherapy and/or radiotherapy are absent.

**Exclusions:** Acute myeloid leukaemia with recurrent genetic abnormalities (2A60.0)

Therapy-related myeloid neoplasms (2A60.2)

Acute myeloid leukaemia with myelodysplasia-related changes (2A60.1)

**2A60.30**

Acute myeloid leukaemia with minimal differentiation

An acute myeloid leukaemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry.

**2A60.31**

Acute myeloid leukaemia without maturation

An acute myeloid leukaemia (AML) characterised by blasts without evidence of maturation to more mature neutrophils.

**2A60.32**

Acute myeloid leukaemia with maturation

An acute myeloid leukaemia (AML) characterised by blasts with evidence of maturation to more mature neutrophils.

- 2A60.33** Acute myelomonocytic leukaemia  
An acute leukaemia characterised by the proliferation of both neutrophil and monocyte precursors.
- 2A60.34** Acute monoblastic or monocytic leukaemia  
Acute monoblastic leukaemia and acute monocytic leukaemia are myeloid leukaemias in which 80% or more of the leukaemic cells are of monocytic lineage including monoblasts, promonocytes and monocytes; a minor neutrophil component, <20%, may be present.
- 2A60.35** Acute erythroid leukaemia  
**Inclusions:** Erythroleukaemia
- 2A60.36** Acute megakaryoblastic leukaemia  
An acute myeloid leukaemia in which at least 50% of the blasts are of megakaryocytic lineage.  
**Inclusions:** Acute myeloid leukaemia, M7  
Acute megakaryocytic leukaemia
- 2A60.37** Acute basophilic leukaemia  
An acute myeloid leukaemia in which the immature cells differentiate towards basophils. This is a rare leukaemia.
- 2A60.38** Acute panmyelosis with myelofibrosis  
An acute myeloid leukaemia characterised by bone marrow fibrosis without preexisting primary myelofibrosis.  
**Inclusions:** Acute myelofibrosis  
**Exclusions:** Cases that meet criteria for AML with myelodysplasia related changes (2A60.1)
- 2A60.39** Myeloid sarcoma  
Myeloid sarcoma is a rare solid tumour of the myelogenous cells occurring in an extramedullary site.  
**Inclusions:** Chloroma  
Granulocytic sarcoma
- 2A60.3Y** Other specified acute myeloid leukaemia, not elsewhere classified by criteria of other types
- 2A60.3Z** Acute myeloid leukaemia, unspecified
- 2A60.4** **Myeloid proliferation associated with Down syndrome**  
Myeloid neoplasms occurring in individuals with Down syndrome. There is an increased risk of acute leukaemias in both children and adults with Down syndrome. In particular, the incidence of acute myeloid leukaemia in Down syndrome children of less than five years of age is particularly high, it is usually an acute megakaryoblastic leukaemia, and is associated with GATA1 gene mutation. This group of disorders also includes the entity transient abnormal myelopoiesis which occurs in neonates and is associated with GATA1 gene mutation.

- 2A60.40** Transient abnormal myelopoiesis  
 A myeloid proliferation occurring in newborns with Down syndrome. It is clinically and morphologically indistinguishable from acute myeloid leukaemia and is associated with GATA1 mutations. The blasts display morphologic and immunophenotypic features of megakaryocytic lineage. In the majority of patients the myeloid proliferation undergoes spontaneous remission.
- 2A60.41** Myeloid leukaemia associated with Down syndrome  
 Leukaemia of children with Down syndrome. Encompasses both MDS and AML
- 2A60.4Y** Other specified myeloid proliferation associated with Down syndrome
- 2A60.4Z** Myeloid proliferation associated with Down syndrome, unspecified
- 2A60.5** **Blastic plasmacytoid dendritic cell neoplasm**  
 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive tumour derived from the precursors of plasmacytoid dendritic cells (PDCs, also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukaemic dissemination.  
 There are currently no clues to the etiology of BPDCN, but its association with myelodysplastic syndrome (MDS) in some cases may suggest a related pathogenesis. Gene expression profiling studies have revealed that the neoplastic cells show a gene expression signature similar to that of resting normal PDCs and closer to that of myeloid than of lymphoid precursors.  
*Inclusions:* blastic NK-cell lymphoma
- 2A60.Y** **Other specified acute myeloid leukaemias and related precursor neoplasms**
- 2A60.Z** **Acute myeloid leukaemias and related precursor neoplasms, unspecified**
- 2A61** **Acute leukaemias of ambiguous lineage**  
 An acute leukaemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells.

#### Precursor lymphoid neoplasms (2A70-2A7Z)

Neoplasms of immature malignant lymphocytes (lymphoblasts) committed to the B-cell or T-cell lineage. Neoplasms involving the bone marrow and the peripheral blood are called precursor lymphoblastic leukaemias or acute lymphoblastic leukaemias. Neoplasms involving primarily lymph nodes or extranodal sites are called lymphoblastic lymphomas.

- 2A70** **Precursor B-lymphoblastic neoplasms**  
 Neoplasms of lymphoblasts committed to the B-cell lineage.
- 2A70.0** **B lymphoblastic leukaemia or lymphoma, not elsewhere classified**  
 Precursor B cell neoplasm without defined recurrent genetic abnormality despite appropriate diagnostics

**2A70.1** **B lymphoblastic leukaemia or lymphoma with t(9;22) (q34;q11.2); BCR-ABL1**  
A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.

**2A70.Y** **Other B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities**

**2A71** **Precursor T-lymphoblastic neoplasms**

A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.

**2A7Z** **Precursor lymphoid neoplasms, unspecified**

Mature B-cell neoplasms (2A80-2A8Z)

Non-Hodgkin lymphomas that originate from mature B lymphocytes. May reside in lymph nodes, lymphatic tissue of different organs or bone marrow and blood (then frequently called leukaemia).

**2A80** **Follicular lymphoma**

Follicular lymphoma (FL) is a neoplasm composed of follicle centre (germinal centre) B-cells (typically both centrocytes and centroblasts/large transformed cells), which usually has at least a partially follicular pattern. t(14;18) with BCL2 rearrangement is frequently observed. If diffuse areas of any size comprised predominantly or entirely of blastic cells are present in any case of follicular lymphoma, a diagnosis of diffuse large B-cell lymphoma is also made. Lymphomas composed of centrocytes and centroblasts with an entirely diffuse pattern in the sampled tissue may be included in this category.

**Inclusions:** follicular lymphoma with or without diffuse areas

**Exclusions:** Mature T-cell or NK-cell neoplasms (2A90-2B2Z)

**2A80.0** **Follicular lymphoma grade 1**

**2A80.1** **Follicular lymphoma grade 2**

**2A80.2** **Follicular lymphoma grade 3**

**2A80.3** **Primary cutaneous follicle centre lymphoma**

A primary lymphoma of the skin composed of various numbers of small and large irregular neoplastic follicle center cells. Its morphologic pattern can be nodular, diffuse, or nodular and diffuse. It presents with solitary or grouped plaques and tumours, and it usually involves the scalp, forehead, or trunk. It rarely involves the legs. This type of cutaneous lymphoma tends to remain localised to the skin, and it has a favorable prognosis.

- 2A80.4 Paediatric type follicular lymphoma**  
A variant of follicular lymphoma often involving cervical or other peripheral lymph nodes and the Waldeyer ring. It is frequently localised, and often lacks BCL-2 protein expression and never has a BCL2 translocation. It is usually but not exclusively seen in the pediatric population. The prognosis is usually favorable.
- 2A80.5 Follicular lymphoma in situ**
- 2A80.6 Follicular lymphoma of small intestine**
- 2A80.Y Other specified follicular lymphoma**
- 2A80.Z Follicular lymphoma, unspecified**
- 2A81 Diffuse large B-cell lymphomas**  
Non-Hodgkin lymphomas are characterised by a proliferation of predominantly large neoplastic B lymphocytes.  
**Coded Elsewhere:** Diffuse large B-cell lymphoma of small intestine (2B33.5)
- 2A81.0 Primary mediastinal large B-cell lymphoma**  
A large B-cell non-Hodgkin lymphoma arising in the mediastinum. Morphologically it is characterised by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.
- 2A81.1 Intravascular large B-cell lymphoma**
- 2A81.2 Plasmablastic lymphoma**  
An aggressive diffuse large B-cell lymphoma frequently arising in the setting of HIV infection and characterised by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells. Sites of involvement include the oral cavity and other extranodal sites
- 2A81.3 Lymphomatoid granulomatosis**
- 2A81.4 T-cell/histiocyte rich large B-cell lymphoma**  
A large B-cell lymphoma characterised by the presence of a limited number of scattered neoplastic large B-lymphocytes which are admixed with numerous non-neoplastic T-lymphocytes and frequently histiocytes.
- 2A81.5 Primary diffuse large B-cell lymphoma of central nervous system**
- 2A81.6 Epstein-Barr Virus-positive diffuse large B-cell lymphoma of the elderly**  
An aggressive diffuse large B-cell lymphoma affecting patients older than 50 years. Epstein-Barr virus is present in all cases. There is no known history of immunodeficiency or prior lymphoma. The majority of patients present with extranodal disease.
- 2A81.7 Diffuse large B-cell lymphoma associated with chronic inflammation**  
A diffuse large B-cell lymphoma arising in body cavities or narrow spaces of long standing chronic inflammation. The classic example is the pyothorax-associated lymphoma that arises in the pleural cavity of patients with a history of long standing pyothorax.

- 2A81.8 ALK-positive large B-cell lymphoma**  
A usually aggressive large B-cell lymphoma characterised by the presence of monomorphic immunoblast-like neoplastic B-lymphocytes in a sinusoidal growth pattern. The neoplastic B-lymphocytes express the ALK kinase but they lack the 2;5 translocation.
- 2A81.9 Primary effusion lymphoma**  
An aggressive non-Hodgkin B-cell lymphoma composed of large cells, presenting as a serous effusion without detectable tumour masses. It is universally associated with human herpes virus 8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV) [HHV-8/KSHV]. It mostly occurs in the setting of immunodeficiency; most cases have been reported in HIV positive patients. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. The prognosis is extremely unfavorable.
- 2A81.A Primary cutaneous diffuse large B-cell lymphoma, leg type**  
An aggressive primary cutaneous B-cell lymphoma, usually involving the lower leg. It is composed of a generally monotonous proliferation of immunoblasts, or less frequently centroblasts, with few admixed reactive cells. This type of lymphoma occurs most often in the elderly who present with rapidly growing tumours, usually on one or both legs. Dissemination to extracutaneous sites is frequent.
- 2A81.Y Other specified diffuse large B-cell lymphomas**
- 2A81.Z Diffuse large B-cell lymphoma, not otherwise specified**
- 2A82 Mature B-cell neoplasm with leukaemic behaviour**
- 2A82.0 Chronic lymphocytic leukaemia or small lymphocytic lymphoma**  
An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukaemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.
- Inclusions:** Small cell B-cell lymphoma

<b>2A82.00</b>	Chronic lymphocytic leukaemia of B-cell type Chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is a neoplasm composed of monomorphic small, round to slightly irregular B lymphocytes in the peripheral blood (PB), bone marrow (BM), spleen and lymph nodes, admixed with prolymphocytes and paraimmunoblasts forming proliferation centres in tissue infiltrates. The CLL/SLL cells usually coexpress CD5 and CD23. In the absence of extramedullary tissue involvement, there must be $<5 \times 10^9/L$ monoclonal lymphocytes with a CLL phenotype in the PB. The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) report requires that the lymphocytosis be present for at least 3 months and also allows for the diagnosis of CLL to be made with lower lymphocyte counts in patients with cytopenias or disease-related symptoms. Whether patients who would have fulfilled the criteria in the past for CLL but who fulfill the criteria only for monoclonal B lymphocytosis (MBL) are better considered to have low stage CLL or MBL remains to be determined. Some may prefer to still consider many of these cases more like CLL. The term SLL is used for non-leukaemic cases with the tissue morphology and immunophenotype of CLL. The IWCLL definition of SLL requires lymphadenopathy, no cytopenias due to BM infiltration by CLL/SLL and $<5 \times 10^9/L$ PB B-cells.
	<b>Inclusions:</b> Lymphoplasmacytic leukaemia
	<b>Exclusions:</b> Lymphoplasmacytic lymphoma (2A85.4)
	<b>Coded Elsewhere:</b> Richter syndrome (2A81.Y)
<b>2A82.0Y</b>	Other specified chronic lymphocytic leukaemia or small lymphocytic lymphoma
<b>2A82.0Z</b>	Chronic lymphocytic leukaemia or small lymphocytic lymphoma, unspecified
<b>2A82.1</b>	<b>B-cell prolymphocytic leukaemia</b>
<b>2A82.10</b>	B-cell prolymphocytic leukaemia in complete remission
<b>2A82.1Y</b>	Other specified b-cell prolymphocytic leukaemia
<b>2A82.1Z</b>	B-cell prolymphocytic leukaemia, unspecified
<b>2A82.2</b>	<b>Hairy-cell leukaemia</b>
	A neoplasm of small B-lymphocytes with hairy projections in bone marrow, spleen, and peripheral blood. Most patients present with splenomegaly and pancytopenia.
	<b>Inclusions:</b> Leukaemic reticuloendotheliosis
<b>2A82.3</b>	<b>Splenic B-cell lymphoma or leukaemia, unclassifiable</b>
	A small B-cell clonal lymphoproliferative disorder of the spleen that does not fall into any of the other categories of mature B-cell neoplasms.
<b>2A82.Y</b>	<b>Other specified mature B-cell neoplasm with leukaemic behaviour</b>
<b>2A82.Z</b>	<b>Mature B-cell neoplasm with leukaemic behaviour, unspecified</b>
<b>2A83</b>	<b>Plasma cell neoplasms</b>
	Plasma cells, usually secreting monoclonal immunoglobulin (M-protein) and/or immunoglobulin light chains.
<b>2A83.0</b>	<b>Monoclonal gammopathy of undetermined significance</b>

- 2A83.1      Plasma cell myeloma**  
A bone marrow-based plasma cell neoplasm usually characterised by presence of a serum monoclonal protein and/or urinary light chains. "CRAB" criteria (calcium elevation (hypercalcaemia), renal failure, anaemia and bone lesions) separate symptomatic plasma cell myeloma from asymptomatic (smoldering) myeloma.
- Inclusions:**      Kahler disease  
                        Myelomatosis  
                        Medullary plasmacytoma  
                        multiple myeloma
- Exclusions:**      Solitary plasmacytoma (2A83.2)
- 2A83.2      Solitary plasmacytoma**  
A single focus of clonal (malignant) plasma cells either in the bone or in another anatomic site without peripheral blood involvement.
- Inclusions:**      Solitary myeloma
- 2A83.3      Extraosseous plasmacytoma**
- 2A83.4      Plasma cell leukaemia**  
An aggressive plasma cell neoplasm. It is characterised by the presence of neoplastic plasma cells in the peripheral blood (PB). The neoplastic plasma cells comprise more than 20% of the white cells in the PB or the number of clonal plasma cells in the PB exceeds  $2 \times 10^9/L$ .
- 2A83.5      Monoclonal immunoglobulin deposition disease**
- 2A83.50      Heavy chain deposition disease**  
A disease of the kidney, caused by proliferation and deposition of pieces of truncated or abnormal alpha, gamma, delta, or mu immunoglobulin heavy chain segments of white blood cells. This disease is characterised by fibrillar or granular tissue deposits and renal dysfunction, which may lead to organ failure. Confirmation is by identifying heavy chain deposition tissue biopsy using immunofluorescence under a microscope.
- Exclusions:**      Heavy chain diseases or malignant immunoproliferative diseases (2A84)  
                        Immunoglobulin heavy chain deficiency (4A01.04)
- 2A83.51      Light and heavy chain deposition disease**  
A disease of the kidney, caused by proliferation and deposition of pieces of truncated or abnormal light and heavy chain segments of white blood cells. This disease is characterised by fibrillar or granular tissue deposits and renal dysfunction, which may lead to organ failure. Confirmation is by identification of light and heavy chain deposition tissue biopsy under a microscope.

- 2A83.52** Light chain deposition disease  
 A disease of the kidney, caused by the deposition of pieces of truncated or abnormal light chain segments of white blood cells. This disease is characterised by fibrillar or granular tissue deposits and renal dysfunction, which may lead to organ failure. Confirmation is by identification of light chain deposition tissue biopsy under an electron microscope.
- Exclusions:** Immunodeficiencies with isotype or light chain deficiencies with normal number of B cells (4A01.04)
- 2A83.Y** Other specified multiple myeloma and plasma cell neoplasms
- 2A83.Z** Plasma cell neoplasm, unspecified
- 2A84** Heavy chain diseases or malignant immunoproliferative diseases  
 A group of rare disorders of immunoglobulin synthesis associated with B-cell proliferative disorders that produce monoclonal heavy chains and typically no light chains.
- 2A84.0** Alpha heavy chain disease  
 The small intestinal morphologic changes are consistent with a mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).
- 2A84.1** Gamma heavy chain disease  
 A clonal disorder characterised by the secretion of a truncated gamma chain. In most cases, it is associated with morphologic changes also seen in lymphoplasmacytic lymphomas, but the clinical course is typically more aggressive than in lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia.
- Inclusions:** Franklin disease
- 2A84.2** Mu heavy chain disease
- 2A84.Y** Other specified malignant immunoproliferative diseases
- 2A84.Z** Heavy chain diseases, unspecified
- 2A85** Other specified mature B-cell neoplasms or lymphoma  
**2A85.0** Nodal marginal zone lymphoma  
 A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease. This is a rare entity, and most patients present with localised or generalised lymphadenopathy. The clinical course is indolent.
- 2A85.1** Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of stomach  
 A low grade, indolent B-cell lymphoma, usually associated with Helicobacter pylori infection. Morphologically it is characterised by a dense mucosal atypical lymphocytic (centrocyte-like cell) infiltrate with often prominent lymphoepithelial lesions and plasmacytic differentiation. Some of gastric MALT lymphomas carry the t(11;18)(q21;q21). Such cases are resistant to Helicobacter pylori therapy.

<b>2A85.2</b>	<b>Extranodal marginal zone B-cell lymphoma, primary site skin</b> A low-grade, extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue that arises from the skin. It usually presents with multifocal papular or nodular lesions in the arms or trunk. It rarely disseminates to internal organs or progresses to high grade lymphoma.
<b>2A85.3</b>	<b>Extranodal marginal zone B-cell lymphoma, primary site excluding stomach or skin</b>
<b>2A85.4</b>	<b>Lymphoplasmacytic lymphoma</b> Neoplasm of small B lymphocytes and plasma cells, mostly residing in the bone marrow. Frequently associated with the production of an IgM serum monoclonal protein, then called Waldenström macroglobulinemia (WM).  <i>Inclusions:</i> primary macroglobulinaemia Waldenström macroglobulinaemia Waldenström macroglobulinaemia without mention of remission  <i>Exclusions:</i> small cell B-cell lymphoma (2A82.0) Chronic lymphocytic leukaemia or small lymphocytic lymphoma (2A82.0)
<b>2A85.5</b>	<b>Mantle cell lymphoma</b> Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma affecting B lymphocytes in the lymph nodes in a region called the ``mantle zone''. It accounts for 2-10% of lymphomas.  <i>Inclusions:</i> Small cell mantle cell lymphoma
<b>2A85.6</b>	<b>Burkitt lymphoma including Burkitt leukaemia</b> A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures. It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients. Three morphologic variants are recognised: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma. All cases express the MYC translocation [t(8;14)].  <i>Inclusions:</i> "Burkitt-like" lymphoma <i>Coded Elsewhere:</i> HIV - [human immunodeficiency virus] disease associated with Burkitt lymphoma (1C62.3Y)
<b>2A85.Y</b>	<b>Further specified mature B-cell neoplasms or lymphoma</b>
<b>2A86</b>	<b>B-cell lymphoma, mixed features</b>
<b>2A86.0</b>	<b>Malignant lymphoma of B cell type, not elsewhere classified</b>
<b>Coding Note:</b>	If B-cell lineage or involvement is mentioned in conjunction with a specific lymphoma, code to the more specific description.
<b>2A86.1</b>	<b>B-cell lymphoma unclassifiable with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma</b>

- 2A86.2**      **B-cell lymphoma unclassifiable with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma**
- 2A86.Y**      **Other specified B-cell lymphoma, mixed features**
- 2A86.Z**      **B-cell lymphoma, mixed features, unspecified**
- 2A8Z**      **Mature B-cell neoplasms, unspecified**

Mature T-cell or NK-cell neoplasms (2A90-2B2Z)

A group of neoplasms composed of T-lymphocytes with a mature (peripheral/post-thymic) immunophenotypic profile and/or NK-cells.

- 2A90**      **Mature T-cell lymphoma, specified types, nodal or systemic**
- 2A90.0**      **T-cell prolymphocytic leukaemia**  
An aggressive T-cell leukaemia, characterised by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.
- 2A90.1**      **T-cell large granular lymphocytic leukaemia**  
A T-cell peripheral neoplasm characterised by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause.
- 2A90.2**      **Chronic lymphoproliferative disorders of NK-cells**  
Heterogeneous disorders with a chronic clinical course affecting predominantly adults and characterised by the proliferation of large granular lymphocytes with natural killer cell immunophenotype.
- 2A90.3**      **Aggressive NK cell leukaemia**  
A rare, highly aggressive, Epstein-Barr virus-associated leukaemia, also known as aggressive NK-cell leukaemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterised by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.
- 2A90.4**      **Systemic Epstein-Barr Virus-positive T-cell lymphoma of childhood**  
This neoplasm of childhood is characterised by a clonal proliferation of EBV-infected T-cells with an activated cytotoxic phenotype. It can occur shortly after primary acute EBV infection or in the setting of chronic active EBV infection (CAEBV).
- 2A90.5**      **Adult T-cell lymphoma or leukaemia, human T-cell lymphotropic virus type 1-associated**  
A peripheral (mature) T-cell neoplasm linked to the human T-cell leukaemia virus type 1 (HTLV-1). Adult T-cell leukaemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.
- Coded Elsewhere:** Adult T-cell leukaemia or lymphoma, skin (2B0Y)

- 2A90.6 Extranodal NK/T-cell lymphoma, nasal type**  
An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma. It is characterised by an often angiocentric and angiodesctructive cellular infiltrate composed of EBV positive NK/T cells. The nasal cavity is the most common site of involvement. Patients often present with midfacial destructive lesions (lethal midline granuloma). The disease may disseminate rapidly to various anatomic sites including the gastrointestinal tract, skin, testis, and cervical lymph nodes. It is also known as angiocentric T-cell lymphoma. The term polymorphic reticulosis has been widely used to describe the morphologic changes seen in this type of lymphoma. However, the latter term may also apply to lymphomatoid granulomatosis, which is an angiocentric and angiodesctructive EBV positive B-cell lymphoproliferative disorder.
- 2A90.7 Enteropathy associated T-cell lymphoma**  
An uncommon mature T-cell lymphoma of intraepithelial lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum. Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. Type II of this lymphoma may occur sporadically outside the context of celiac disease.
- Inclusions:*      Enteropathy type intestinal T-cell lymphoma  
                          Intestinal T-cell lymphoma
- 2A90.8 Hepatosplenic T-cell lymphoma**  
An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type. It is characterised by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids. A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.
- 2A90.9 Angioimmunoblastic T-cell lymphoma**  
A mature T-cell non-Hodgkin lymphoma, characterised by systemic disease and a polymorphous infiltrate involving lymph nodes and extranodal sites. The clinical course is typically aggressive.
- Inclusions:*      AILD - [angioimmunoblastic lymphadenopathy with dysproteinaemia]
- 2A90.A Anaplastic large cell lymphoma, ALK-positive**  
A T-cell peripheral lymphoma composed of usually large, pleomorphic, CD30 positive T-lymphocytes with abundant cytoplasm characterised by the presence of a translocation involving the ALK gene and expression of ALK fusion protein. Most patients present with peripheral and/or abdominal lymphadenopathy, and often have advanced disease and extranodal involvement.
- Inclusions:*      Anaplastic large cell lymphoma, CD30-positive

**2A90.B Anaplastic large cell lymphoma, ALK-negative**  
A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive. It is characterised by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein.

**Exclusions:** Primary cutaneous CD30-positive T-cell lymphoproliferative disorders (2B03)

**2A90.C Peripheral T-cell lymphoma, not otherwise specified**  
A heterogeneous category of nodal and extranodal mature T-cell lymphomas, which do not correspond to any of the specifically defined entities of mature T-cell lymphoma in the current classification.

**Inclusions:** T-zone variant Peripheral T-cell lymphoma  
Lymphoepithelioid lymphoma  
Follicular variant Peripheral T-cell lymphoma

Mature T-cell or NK-cell lymphomas and lymphoproliferative disorders, primary cutaneous specified types (2B00-2B0Z)

Primary cutaneous T-cell lymphomas (CTCL) and NK-cell lymphomas are malignant lymphoproliferative diseases of unknown cause that are thought to originate from T-lymphocytes in the lymphoid tissue of the skin and by definition are confined to the skin at initial diagnosis. Included in the class is also a small number of lymphoma-like primary cutaneous lymphoproliferative disorders which are not considered to be truly malignant.

**Inclusions:** Primary cutaneous peripheral T-cell lymphoma

**Exclusions:** Skin infiltration by nodal or non-cutaneous extranodal lymphoma (2E08)

**2B00**

#### **Subcutaneous panniculitis-like T-cell lymphoma**

Subcutaneous panniculitis-like T-cell lymphoma is a neoplasm of alpha/beta, usually CD8+ T-cells, mainly confined to the subcutis, presenting clinically as subcutaneous nodules which are usually not ulcerated.

**2B01**

#### **Mycosis fungoides**

A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques or less commonly with tumours or erythroderma. It is characterised by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.

**2B02**

#### **Sézary syndrome**

A generalised peripheral (mature) T-cell neoplasm characterised by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood. Sézary syndrome is an aggressive disease.

**2B03**

#### **Primary cutaneous CD30-positive T-cell lymphoproliferative disorders**

Primary skin disorders characterised immunohistologically by infiltration by neoplastic CD30+ lymphocytes.

- 2B03.0 Primary cutaneous CD30-positive anaplastic large cell lymphoma**  
An anaplastic large cell lymphoma that is limited to the skin at the time of diagnosis. Most patients present with solitary or localised skin lesions in a form of nodules or papules, which may be tumours. The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma is not found in this disease.
- 2B03.1 Lymphomatoid papulosis**  
Lymphomatoid papulosis is a proliferation of T-cells, often clonal, characterised clinically by the appearance of crops of dome-shaped papules and nodules which tend to ulcerate and then heal with scarring.
- 2B0Y Other specified primary cutaneous mature T-cell or NK-cell lymphomas and lymphoproliferative disorders**
- 2B0Z Primary cutaneous T-cell lymphoma of undetermined or unspecified type**
- 2B2Y Other specified mature T-cell or NK-cell neoplasms**
- 2B2Z Mature T-cell or NK-cell neoplasms, unspecified**
- 2B30 Hodgkin lymphoma**  
Malignant lymphomas, previously known as Hodgkin's disease, characterised by the presence of large tumour cells in an abundant admixture of nonneoplastic cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.
- 2B30.0 Nodular lymphocyte predominant Hodgkin lymphoma**  
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is characterised by a nodular, or a nodular and diffuse proliferation of scattered large neoplastic cells known as popcorn or lymphocyte predominant cells (LP cells)—formerly called L&H cells for lymphocytic and/or histiocytic Reed-Sternberg cell variants. At present an overlap between NLPHL and T-cell-rich large B-cell lymphoma cannot be excluded.
- 2B30.1 Classical Hodgkin lymphoma**  
Classical Hodgkin lymphoma is a B-cell lymphoma characterised histologically by the presence of large mononuclear Hodgkin cells and multinucleated Reed-Sternberg (HRS) cells.  
  
A monoclonal B-cell lymphoproliferation in the vast majority of cases. It is characterised by a bimodal age distribution (15-30 years of life and late life) and is often associated with EBV infection. In less than 5% of cases it is a monoclonal proliferation of T-lymphocytes. Morphologically, it is characterised by the presence of Reed-Sternberg cells and mononuclear Hodgkin cells. The Reed-Sternberg and mononuclear Hodgkin cells are CD30 positive in nearly all cases and CD15 positive in the majority of cases.
- Inclusions:**      Classical Hodgkin lymphoma, type not specified

- 2B30.10** Nodular sclerosis classical Hodgkin lymphoma  
A subtype of classical Hodgkin lymphoma characterised by collagen bands surrounding lymphoid nodules. The lymphoid nodules contain lacunar and Reed-Sternberg cells. Mediastinal involvement occurs in 80% of patients. The prognosis of nodular sclerosis Hodgkin lymphoma is slightly better than that of mixed cellularity or lymphocyte depleted subtype.
- 2B30.11** Lymphocyte-rich classical Hodgkin lymphoma
- 2B30.12** Mixed cellularity classical Hodgkin lymphoma  
A subtype of classical Hodgkin lymphoma with a mixed inflammatory stroma containing Hodgkin and Reed-Sternberg cells.
- 2B30.13** Lymphocyte depleted classical Hodgkin lymphoma
- 2B30.1Z** Classical Hodgkin lymphoma, unspecified
- 2B30.Z** **Hodgkin lymphoma, unspecified**
- 2B31** **Histiocytic or dendritic cell neoplasms**  
True histiocytic malignancies are vanishing diagnoses due to improved understanding of the provenance of malignant cells.
- 2B31.0** **Juvenile xanthogranuloma**  
It is characterised by the presence of lipid-laden, foamy histiocytes and Touton-type giant cells in the dermis.
- 2B31.1** **Histiocytic sarcoma**  
*Inclusions:* Malignant Histiocytosis
- 2B31.2** **Langerhans cell histiocytosis**  
A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognised: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation.  
*Inclusions:* Histiocytosis X
- 2B31.20** Langerhans cell histiocytosis involving the skin
- 2B31.2Y** Other specified Langerhans cell histiocytosis
- 2B31.2Z** Langerhans cell histiocytosis, unspecified
- 2B31.3** **Langerhans cell sarcoma**  
A neoplastic proliferation of Langerhans cells with overtly malignant cytologic features. It can be considered a higher grade variant of Langerhans cell histiocytosis (LCH) and it can present de novo or progress from antecedent LCH.

- 2B31.4 Interdigitating dendritic cell sarcoma**  
A neoplastic proliferation of spindle to ovoid cells which show phenotypic features similar to those of interdigitating dendritic cells. The clinical course is generally aggressive.
- 2B31.5 Follicular dendritic cell sarcoma**  
A neoplasm composed of spindle to ovoid cells which have morphologic and immunophenotypic characteristics of follicular dendritic cells. It affects lymph nodes and other sites including the tonsils, gastrointestinal tract, spleen, liver, soft tissues, skin, and oral cavity. It usually behaves as a low grade sarcoma. Recurrences have been reported in up to half of the cases.
- 2B31.6 Indeterminate cell histiocytosis**  
A very rare dendritic cell tumour composed of spindle to ovoid cells with a phenotype that is similar to the Langerhans cells. Patients usually present with cutaneous papules, nodules, and plaques. Systemic symptoms are usually absent. The clinical course is variable.
- 2B31.7 Fibroblastic reticular cell tumour**  
A very rare dendritic cell tumour affecting the lymph nodes, spleen, and soft tissues. Morphologically it is similar to the interdigitating dendritic cell sarcoma or follicular dendritic cell sarcoma. The tumour cells are positive for cytokeratin and CD68. Clinical outcome is variable.
- 2B31.Y Other specified histiocytic or dendritic cell neoplasms**
- 2B31.Z Histiocytic or dendritic cell neoplasms, unspecified**
- 2B32 Immunodeficiency-associated lymphoproliferative disorders**  
Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV-negative lymphomas of predominantly B-cell or less often T-cell type. In other immunodeficiency-associated lymphoproliferative disorders, association with EBV is less pronounced.
- Inclusions:** PTLD - [Post transplant lymphoproliferative disorder]
- 2B32.0 Post-transplant lymphoproliferative disorder, early lesion**  
A lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterised by the lack of tissue destruction and the architectural preservation of the involved tissues. It includes two morphologic variants: plasmacytic hyperplasia and infectious mononucleosis-like lymphoproliferative disorders.
- 2B32.1 Reactive plasmacytic hyperplasia**
- 2B32.2 Post-transplant lymphoproliferative disorder, Infectious mononucleosis-like**
- 2B32.3 Polymorphic post-transplant lymphoproliferative disorder**
- 2B32.Y Other specified immunodeficiency-associated lymphoproliferative disorders**

**2B32.Z**      **Immunodeficiency-associated lymphoproliferative disorders, unspecified**

**2B33**      **Malignant haematopoietic neoplasms without further specification**

**Coding Note:** Only to be designated in cases with incomplete diagnostics.

**2B33.0**      **Acute leukaemia, not elsewhere classified**

**Coding Note:** Only to be designated in cases with incomplete diagnostics.

**2B33.1**      **Myeloid leukaemia**

**2B33.2**      **Chronic myeloid leukaemia, not elsewhere classified**

**Coding Note:** Only to be designated in cases with incomplete diagnostics

**2B33.3**      **Lymphoid leukaemia, not elsewhere classified**

**Coding Note:** Only to be designated in cases with incomplete diagnostics.

**2B33.4**      **Leukaemia, unspecified**

**Coding Note:** Only to be designated in cases with incomplete diagnostics.

**2B33.5**      **Malignant lymphoma, not elsewhere classified**

**Coding Note:** Only to be designated in cases with incomplete diagnostics.

**Coded Elsewhere:** Enteropathy associated T-cell lymphoma (2A90.7)

**2B33.Y**      **Other malignant haematopoietic neoplasms without further specification**

**Coding Note:** Only to be designated in cases with incomplete diagnostics.

**2B3Z**      **Neoplasms of haematopoietic or lymphoid tissues, unspecified**

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues (2B50-2E2Z)

**Coding Note:** For use of this category, reference should be made to the mortality coding rules and guidelines in the Reference Guide.

**Exclusions:** Neoplasms of brain or central nervous system (2A00-2A0Z)

Neoplasms of haematopoietic or lymphoid tissues (2A20-2B3Z)

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues (2B50-2D3Z)

### Malignant mesenchymal neoplasms (2B50-2B5Z)

A usually aggressive malignant mesenchymal cell tumour most commonly arising from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the tumour. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.

**Exclusions:** Mesenchymal tumours of meninges (2A01.1)

Tumours of cranial or paraspinal nerves (2A02.1)

#### **2B50 Chondrosarcoma, primary site**

**Exclusions:** Osteosarcoma, primary site (2B51)

#### **2B50.0 Chondrosarcoma of bone or articular cartilage of limbs**

#### **2B50.1 Chondrosarcoma of bone or articular cartilage of pelvis**

#### **2B50.2 Chondrosarcoma of bone or articular cartilage of ribs, sternum or clavicle**

#### **2B50.Y Chondrosarcoma of bone or articular cartilage of other specified sites**

#### **2B50.Z Chondrosarcoma of bone or articular cartilage of unspecified sites**

#### **2B51 Osteosarcoma, primary site**

A usually aggressive malignant bone-forming mesenchymal tumour, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.

#### **2B51.0 Osteosarcoma of bone or articular cartilage of jaw**

#### **2B51.1 Osteosarcoma of bone or articular cartilage of limbs**

#### **2B51.2 Osteosarcoma of bone or articular cartilage of pelvis**

#### **2B51.Y Osteosarcoma of bone and articular cartilage of other specified sites**

#### **2B51.Z Osteosarcoma of bone and articular cartilage of unspecified sites**

**2B52****Ewing sarcoma, primary site**

A small round cell tumour that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing's sarcoma/peripheral neuroectodermal tumour. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.

**2B52.0****Ewing sarcoma of bone or articular cartilage of limbs****2B52.1****Ewing sarcoma of bone or articular cartilage of pelvis****2B52.2****Ewing sarcoma of bone or articular cartilage of ribs****2B52.3****Ewing sarcoma of soft tissue**

A rare malignant neoplasm of the soft tissues. It is typically a disease of children and young adults. It is characterised by t(11:22) (q24: q12) resulting in the expression of EWS/FLI-1 chimeric transcript. Most commonly occurs in the paravertebral region, chest wall, pelvis and lower extremities.

**2B52.Y****Ewing sarcoma of bone and articular cartilage of other specified sites****2B52.Z****Ewing sarcoma of bone and articular cartilage of unspecified sites****2B53****Fibroblastic or myofibroblastic tumour, primary site****2B53.0****Myxofibrosarcoma, primary site****2B53.1****Fibroblastic or myofibroblastic tumour of skin****2B53.Y****Other specified fibroblastic or myofibroblastic tumour, primary site****2B53.Z****Fibroblastic or myofibroblastic tumour, primary site, unspecified****2B54****Unclassified pleomorphic sarcoma, primary site**

A pleomorphic sarcoma characterised by the presence of fibrohistiocytic cells and spindle cells arranged in a storiform pattern.

**2B54.0****Unclassified pleomorphic sarcoma of skin**

A rare malignant neoplasm arising from the skin. It is characterised by the presence of spindle cells in a storiform pattern and histiocytes with abundant cytoplasm.

*Inclusions:* malignant fibrous histiocytoma of skin

**2B54.1****Unclassified pleomorphic sarcoma of retroperitoneum or peritoneum****2B54.Y****Unclassified pleomorphic sarcoma, primary site, other specified site****2B54.Z****Unclassified pleomorphic sarcoma, primary site, unspecified site****2B55****Rhabdomyosarcoma, primary site**

Rhabdomyosarcoma is a malignant soft tissue tumour which develops from cells of striated muscle. It is the most common form of tumour found in children and adolescents.

**2B55.0****Rhabdomyosarcoma of the oral cavity or pharynx**

- 2B55.1** **Rhabdomyosarcoma of respiratory or intrathoracic organs**
- 2B55.2** **Rhabdomyosarcoma of male genital organs**
- 2B55.Y** **Rhabdomyosarcoma, other specified primary site**
- 2B55.Z** **Rhabdomyosarcoma, unspecified primary site**
- 2B56** **Angiosarcoma, primary site**
- 2B56.0** **Angiosarcoma of heart**
- 2B56.1** **Angiosarcoma of skin**  
A malignant tumour arising from the endothelial cells of the blood vessels. Microscopically, it is characterised by frequently open vascular anastomosing and branching channels. The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei. Angiosarcomas most frequently occur in the skin and breast. Patients with long-standing lymphoedema are at increased risk of developing angiosarcoma.
- 2B56.2** **Angiosarcoma of breast**  
A malignant vascular neoplasm arising from the breast.
- 2B56.3** **Angiosarcoma of liver**  
A malignant vascular neoplasm arising from the liver.  
*Inclusions:* Kupffer cell sarcoma of liver
- 2B56.Y** **Angiosarcoma, other specified primary site**
- 2B56.Z** **Angiosarcoma, unspecified primary site**
- 2B57** **Kaposi sarcoma, primary site**  
A malignant neoplasm characterised by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).
- 2B57.0** **Kaposi sarcoma of lung**
- 2B57.1** **Kaposi sarcoma of skin**  
A Kaposi sarcoma arising from the skin. It presents with patches, plaques, or nodules.
- 2B57.2** **Kaposi sarcoma of gastrointestinal sites**
- 2B57.Y** **Kaposi sarcoma of other specified primary sites**
- 2B57.Z** **Kaposi sarcoma of unspecified primary site**
- 2B58** **Leiomyosarcoma, primary site**
- 2B58.0** **Leiomyosarcoma of retroperitoneum or peritoneum**

- 2B58.1** **Leiomyosarcoma of uterus**
- 2B58.2** **Leiomyosarcoma of stomach**  
This is a malignant nonepithelial tumour that arises from cells lining the stomach that develop into smooth-muscle.
- 2B58.Y** **Leiomyosarcoma, other specified primary site**
- 2B58.Z** **Leiomyosarcoma, unspecified primary site**
- 2B59** **Liposarcoma, primary site**  
Liposarcoma, a type of soft tissue sarcoma, describes a group of lipomatous tumours of varying severity ranging from slow-growing to aggressive and metastatic. Liposarcomas are most often located in the lower extremities or retroperitoneum, but they can also occur in the upper extremities, neck, peritoneal cavity, spermatic cord, breast, vulva and axilla.
- 2B59.0** **Liposarcoma of soft tissue of limb**
- 2B59.1** **Liposarcoma of retroperitoneum or peritoneum**
- 2B59.2** **Liposarcoma of male genital organs**
- 2B59.Y** **Liposarcoma, other specified primary site**
- 2B59.Z** **Liposarcoma, unspecified primary site**
- 2B5A** **Synovial sarcoma, primary site**  
A malignant neoplasm characterised by the chromosomal translocation t(X;18)(p11;q11). It can occur at any age, but mainly affects young adults, more commonly males. Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee. Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components). Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes.
- 2B5A.0** **Synovial sarcoma of soft tissues of limb**
- 2B5A.1** **Synovial sarcoma of respiratory or intra-thoracic organs**
- 2B5A.Y** **Synovial sarcoma, other specified primary site**
- 2B5A.Z** **Synovial sarcoma, unspecified primary site**
- 2B5B** **Gastrointestinal stromal tumour, primary site**  
This is the most common mesenchymal tumour that arises in the gastrointestinal tract. It is generally immunohistochemically positive for CD117 (KIT), phenotypically paralleling Cajal-cell differentiation, and most examples contain KIT- or PDGFRA-activating mutations. It is most frequent in the stomach and to a lesser degree in the small intestine. The prognosis depends on the tumour size and the mitotic activity.

- 2B5B.0 Gastrointestinal stromal tumour of stomach**  
A gastrointestinal stromal tumour that arises from the stomach. It covers a spectrum of benign to malignant mesenchymal neoplasms and includes most gastric smooth muscle tumours, leiomyoblastomas, and tumours formerly called gastrointestinal autonomic nerve tumours.
- 2B5B.1 Gastrointestinal stromal tumour of small intestine**  
A gastrointestinal stromal tumour that arises from the small intestine. It usually affects adults over fifty years of age. The majority of cases have spindle cell morphology. The prognosis depends on the tumour size and the mitotic activity.
- 2B5B.Y Gastrointestinal stromal tumour of other gastrointestinal sites**
- 2B5B.Z Gastrointestinal stromal tumour of unspecified gastrointestinal sites**
- 2B5C Endometrial stromal sarcoma, primary site**  
A malignant, infiltrating mesenchymal tumour arising from the uterine corpus, cervix, vagina, and the ovary. Based on its morphologic characteristics, it is classified as either a low grade or an undifferentiated (high grade) stromal sarcoma. The low grade endometrioid stromal sarcoma is characterised by the presence of oval to spindle-shape cells that resemble the cells of the endometrial stroma, without evidence of significant atypia and pleomorphism. Numerous small vessels are also present. The undifferentiated stromal sarcoma is characterised by an aggressive clinical course, the presence of significant cellular atypia, pleomorphism, and high mitotic activity.
- 2B5D Malignant mixed epithelial mesenchymal tumour, primary site**
- 2B5D.0 Malignant mixed epithelial mesenchymal tumour of ovary**  
Malignant mixed epithelial mesenchymal tumour of the ovary is a rare and very aggressive neoplasm presenting most commonly in postmenopausal women and is composed of adenocarcinomatous and sarcomatous elements and, depending on the types of these elements, can be classified as homologous or heterologous. It often has a poor prognosis.
- 2B5D.1 Malignant mixed epithelial and mesenchymal tumour of corpus uteri**  
A primary malignant neoplasm of the uterine corpus characterised by the presence of an epithelial and a mesenchymal component. This category includes carcinosarcoma, carcinofibroma, and adenosarcoma.
- 2B5D.Y Malignant mixed epithelial mesenchymal tumour, other specified primary site**
- 2B5D.Z Malignant mixed epithelial mesenchymal tumour, unspecified primary site**
- 2B5E Malignant nerve sheath tumour of peripheral nerves or autonomic nervous system, primary site**  
**Exclusions:** Malignant peripheral nerve sheath tumour of cranial or paraspinal nerves (2A02.10)
- 2B5F Sarcoma, not elsewhere classified, primary site**

<b>2B5F.0</b>	<b>Sarcoma, not elsewhere classified of uterus</b>
	<b>Coded Elsewhere:</b> Endometrial stromal sarcoma, primary site (2B5C)
	Leiomyosarcoma of uterus (2B58.1)
	Rhabdomyosarcoma of corpus uteri (2B55.Y)
<b>2B5F.1</b>	<b>Sarcoma, not elsewhere classified of retroperitoneum or peritoneum</b>
<b>2B5F.10</b>	Myosarcomas of omentum
<b>2B5F.1Y</b>	Other specified sarcoma, not elsewhere classified of retroperitoneum or peritoneum
<b>2B5F.1Z</b>	Sarcoma, not elsewhere classified of retroperitoneum or peritoneum, unspecified
<b>2B5F.2</b>	<b>Sarcoma, not elsewhere classified of other specified sites</b>
<b>2B5F.3</b>	<b>Sarcoma, not elsewhere classified, primary site unknown</b>
<b>2B5G</b>	<b>Myosarcoma of uterus, part not specified</b>
	<b>Coded Elsewhere:</b> Leiomyosarcoma of uterus (2B58.1)
	Rhabdomyosarcoma of corpus uteri (2B55.Y)
<b>2B5H</b>	<b>Well differentiated lipomatous tumour, primary site</b>
<b>2B5J</b>	<b>Malignant miscellaneous tumours of bone or articular cartilage of other or unspecified sites</b>
	<b>Exclusions:</b> Neoplasms of haematopoietic or lymphoid tissues (2A20-2B3Z)
<b>2B5K</b>	<b>Unspecified malignant soft tissue tumours or sarcomas of bone or articular cartilage of other or unspecified sites</b>
<b>2B5Y</b>	<b>Other specified malignant mesenchymal neoplasms</b>
<b>2B5Z</b>	<b>Malignant mesenchymal neoplasm of unspecified type</b>

### Malignant neoplasms of lip, oral cavity or pharynx (2B60-2B6Y)

Squamous cell carcinomas amount to more than 90% of malignant tumours of the oral cavity and oropharynx. As in other parts of the upper aerodigestive tract, there is a strong and synergistic association with tobacco smoking and alcohol abuse. In some regions, particularly the Indian subcontinent, oral cancer is among the most frequent malignancies, largely due to tobacco chewing.

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

#### **2B60      Malignant neoplasms of lip**

Malignant neoplasms originating from the transitional epithelium of the lip (excluding oral mucosa and skin of the outer lip) or from the underlying anatomical structures (e.g. orbicularis oris muscle).

**Exclusions:** Malignant neoplasm of skin of lip (2C30-2C3Z)

Malignant mesenchymal neoplasms (2B50-2B5Z)

<b>2B60.0</b>	<b>Basal cell carcinoma of lip</b> A basal cell carcinoma arising from the lip.
<b>2B60.1</b>	<b>Squamous cell carcinoma of lip</b> Squamous cell carcinoma located on or originating in the mucosa or vermillion of the lip, including the vermillion border but excluding the skin of the lip.  <b>Exclusions:</b> Squamous cell carcinoma of skin of lip (2C31)
<b>2B60.Y</b>	<b>Other specified malignant neoplasms of lip</b>
<b>2B60.Z</b>	<b>Malignant neoplasms of lip, unspecified</b>
<b>2B61</b>	<b>Malignant neoplasms of base of tongue</b> A primary neoplasm involving the base of the tongue, often associated with chronic alcohol and tobacco use, older age, certain geographic locations, a family history of upper aerodigestive tract cancers and/or certain nutritional deficiencies and infectious agents.  <b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B61.0</b>	<b>Squamous cell carcinoma of the base of the tongue</b> A carcinoma that arises from the base of the tongue. Representative examples include squamous cell carcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.
<b>2B61.Y</b>	<b>Other specified malignant neoplasms of base of tongue</b>
<b>2B61.Z</b>	<b>Malignant neoplasms of base of tongue, unspecified</b>
<b>2B62</b>	<b>Malignant neoplasms of other or unspecified parts of tongue</b>  <b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B62.0</b>	<b>Squamous cell carcinoma of other or unspecified parts of tongue</b>
<b>2B62.1</b>	<b>Malignant neoplasms of lingual tonsil</b>
<b>2B62.10</b>	Squamous cell carcinoma of lingual tonsil
<b>2B62.1Z</b>	Malignant neoplasms of lingual tonsil, unspecified
<b>2B62.Y</b>	<b>Other specified malignant neoplasms of other and unspecified parts of tongue</b>
<b>2B62.Z</b>	<b>Malignant neoplasms of other or unspecified parts of tongue, unspecified</b>
<b>2B63</b>	<b>Malignant neoplasms of gum</b>  <b>Exclusions:</b> Benign osteogenic tumours of bone or articular cartilage of skull or face (2E83.0) Benign osteogenic tumours of bone or articular cartilage of lower jaw (2E83.1) Malignant mesenchymal neoplasms (2B50-2B5Z)

<b>2B63.0</b>	<b>Squamous cell carcinoma of gum</b>
<b>2B63.Y</b>	<b>Other specified malignant neoplasm of gum</b>
<b>2B63.Z</b>	<b>Malignant neoplasms of gum, unspecified</b>
<b>2B64</b>	<b>Malignant neoplasms of floor of mouth</b>
	<i><b>Exclusions:</b></i> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B64.0</b>	<b>Squamous cell carcinoma of floor of mouth</b>
<b>2B64.Y</b>	<b>Other specified malignant neoplasm of floor of mouth</b>
<b>2B64.Z</b>	<b>Malignant neoplasms of floor of mouth, unspecified</b>
<b>2B65</b>	<b>Malignant neoplasms of palate</b>
	<i><b>Exclusions:</b></i> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B65.0</b>	<b>Adenocarcinoma of palate</b>
<b>2B65.1</b>	<b>Squamous cell carcinoma of palate</b>
<b>2B65.Y</b>	<b>Other specified malignant neoplasm of palate</b>
<b>2B65.Z</b>	<b>Malignant neoplasms of palate, unspecified</b>
<b>2B66</b>	<b>Malignant neoplasms of other or unspecified parts of mouth</b>
	<i><b>Exclusions:</b></i> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B66.0</b>	<b>Squamous cell carcinoma of other or unspecified parts of mouth</b>
<b>2B66.Y</b>	<b>Other specified malignant neoplasms of other and unspecified parts of mouth</b>
<b>2B66.Z</b>	<b>Malignant neoplasms of other or unspecified parts of mouth, unspecified</b>
<b>2B67</b>	<b>Malignant neoplasms of parotid gland</b>
	Salivary gland tumours can show a striking range of morphological diversity between different tumour types and sometimes within an individual tumour mass. In addition, hybrid tumours, dedifferentiation and the propensity for some benign tumours to progress to malignancy can confound histopathological interpretation. These features, together with the relative rarity of a number of tumours, can sometimes make diagnosis difficult, despite the abundance of named tumour entities. The increasing use of pre-operative fine needle aspiration biopsies also needs to be taken into account, as artifactual changes may be superimposed on the tumours. Unfortunately, the morphological variability of these tumours is mirrored by the immunocytochemical profiles, so that special stains are rarely useful in routine diagnosis of salivary gland epithelial neoplasms.
	<i><b>Exclusions:</b></i> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B67.0</b>	<b>Adenocarcinoma of parotid gland</b>
<b>2B67.1</b>	<b>Squamous cell carcinoma of parotid gland</b>

<b>2B67.Y</b>	<b>Other specified malignant neoplasms of parotid gland</b>
<b>2B67.Z</b>	<b>Malignant neoplasms of parotid gland, unspecified</b>
<b>2B68</b>	<b>Malignant neoplasms of submandibular or sublingual glands</b> Salivary gland tumours can show a striking range of morphological diversity between different tumour types and sometimes within an individual tumour mass. In addition, hybrid tumours, dedifferentiation and the propensity for some benign tumours to progress to malignancy can confound histopathological interpretation. These features, together with the relative rarity of a number of tumours, can sometimes make diagnosis difficult, despite the abundance of named tumour entities. The increasing use of pre-operative fine needle aspiration biopsies also needs to be taken into account, as artifactual changes may be superimposed on the tumours. Unfortunately, the morphological variability of these tumours is mirrored by the immunocytochemical profiles, so that special stains are rarely useful in routine diagnosis of salivary gland epithelial neoplasms.
	<b>Exclusions:</b> Malignant neoplasms of parotid gland (2B67) Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B68.0</b>	<b>Adenocarcinoma of submandibular or sublingual glands</b>
<b>2B68.1</b>	<b>Squamous cell carcinoma of submandibular or sublingual glands</b>
<b>2B68.2</b>	<b>Other specified malignant neoplasms of submandibular or sublingual glands</b>
<b>2B68.Z</b>	<b>Malignant neoplasms of submandibular or sublingual glands, unspecified</b>
<b>2B69</b>	<b>Malignant neoplasms of tonsil</b> <b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z) <b>Coded Elsewhere:</b> Malignant neoplasms of pharyngeal tonsil (2B6B.2) Malignant neoplasms of lingual tonsil (2B62.1)
<b>2B69.0</b>	<b>Squamous cell carcinoma of tonsil</b>
<b>2B69.1</b>	<b>Other specified malignant neoplasms of tonsil</b>
<b>2B69.Z</b>	<b>Malignant neoplasms of tonsil, unspecified</b>
<b>2B6A</b>	<b>Malignant neoplasms of oropharynx</b> Malignant neoplasms of the oral cavity and pharynx <b>Exclusions:</b> Malignant neoplasms of palate (2B65) Malignant neoplasms of tonsil (2B69) Malignant mesenchymal neoplasms (2B50-2B5Z)

<b>2B6A.0</b>	<b>Squamous cell carcinoma of oropharynx</b> A squamous cell carcinoma arising from the oropharynx. It predominantly affects adults in their fifth and sixth decades of life and is associated with alcohol and tobacco use. Human papillomavirus is present in approximately half of the cases. It is characterised by a tendency to metastasize early to the lymph nodes. When the tumour is small, patients are often asymptomatic. Physical examination may reveal erythematous or white lesions or plaques. The majority of patients present with locally advanced disease. Signs and symptoms include mucosal ulceration, pain, bleeding, weight loss, neck swelling, and difficulty speaking, chewing, and swallowing. Patients may also present with swollen neck lymph nodes without any symptoms from the oropharyngeal tumour. The most significant prognostic factors are the size of the tumour and the lymph nodes status.
<b>2B6A.Y</b>	<b>Other specified malignant neoplasms of oropharynx</b>
<b>2B6A.Z</b>	<b>Malignant neoplasms of oropharynx, unspecified</b>
<b>2B6B</b>	<b>Malignant neoplasms of nasopharynx</b> A wide variety of tumours can arise in the nasopharynx, but it is nasopharyngeal carcinoma that has fascinated generations of oncologists, pathologists, scientists and epidemiologists. It shows marked geographic differences, with highest incidence rates in Southern China. In some endemic areas, the incidence has declined by about 30% over the past two decades, suggesting that environmental or lifestyle factors may play a major role and that the disease is, to some extent, preventable. Nasopharyngeal carcinoma shows a very strong association with Epstein-Barr virus (EBV) infection, irrespective of the ethnic origin of the patients. This association has pioneered a new paradigm of utilizing viral serological tests for the diagnosis of cancer and for screening in high-risk populations. Nasopharyngeal carcinoma is generally responsive to radiation therapy, and the clinical outcome has greatly improved over the years, due to refinements in staging and to improved therapy protocols. The unusual and often deceptive histological features of nasopharyngeal carcinoma have generated controversies over the nature of the tumour and still pose a challenge to surgical pathologists. There have possibly been more names invented for the various histological subtypes of nasopharyngeal carcinoma than any other tumour type.
	<b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B6B.0</b>	<b>Squamous cell carcinoma of nasopharynx</b>
<b>2B6B.1</b>	<b>Malignant epithelial neoplasms of nasopharynx, unspecified type</b>
<b>2B6B.2</b>	<b>Malignant neoplasms of pharyngeal tonsil</b>
<b>2B6B.20</b>	Squamous cell carcinoma of pharyngeal tonsil
<b>2B6B.21</b>	Other or unspecified malignant epithelial neoplasm of pharyngeal tonsil
<b>2B6B.2Y</b>	Other specified malignant neoplasms of pharyngeal tonsil
<b>2B6B.2Z</b>	Malignant neoplasm of pharyngeal tonsil without mention of type
<b>2B6B.Y</b>	<b>Other specified malignant neoplasms of nasopharynx</b>
<b>2B6B.Z</b>	<b>Malignant neoplasms of nasopharynx, unspecified</b>

<b>2B6C</b>	<b>Malignant neoplasms of piriform sinus</b>
	<b><i>Exclusions:</i></b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B6C.0</b>	<b>Squamous cell carcinoma of piriform sinus</b>
<b>2B6C.Y</b>	<b>Other specified malignant neoplasms of piriform sinus</b>
<b>2B6C.Z</b>	<b>Malignant neoplasms of piriform sinus, unspecified</b>
<b>2B6D</b>	<b>Malignant neoplasms of hypopharynx</b>
	A malignant neoplasm arising in the hypopharynx.
	<b><i>Exclusions:</i></b> Malignant neoplasms of piriform sinus (2B6C)
	Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B6D.0</b>	<b>Squamous cell carcinoma of hypopharynx and variants</b>
	A squamous cell carcinoma arising from the hypopharynx. Signs and symptoms include dysphagia, hemoptysis, and the presence of a neck mass.
<b>2B6D.Y</b>	<b>Other specified malignant neoplasms of hypopharynx</b>
<b>2B6D.Z</b>	<b>Malignant neoplasms of hypopharynx, unspecified</b>
<b>2B6E</b>	<b>Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx</b>
	<b><i>Exclusions:</i></b> Malignant neoplasm of oral cavity NOS (2B66)
	Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2B6E.0</b>	<b>Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx</b>
<b>2B6E.Y</b>	<b>Other specified malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx</b>
<b>2B6E.Z</b>	<b>Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx, unspecified</b>
<b>2B6Y</b>	<b>Other specified malignant neoplasms of lip, oral cavity or pharynx</b>

## Malignant neoplasms of digestive organs (2B70-2C1Z)

A primary malignant neoplasm involving any part of the gastrointestinal system.

**Exclusions:** Malignant neoplasm metastasis in digestive system (2D80-2D8Z)

Malignant mesenchymal neoplasms (2B50-2B5Z)

Malignant neoplasms of lip, oral cavity or pharynx (2B60-2B6Y)

**2B70**

### **Malignant neoplasms of oesophagus**

A primary malignant neoplasm involving the oesophagus

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**2B70.0**

### **Adenocarcinoma of oesophagus**

A malignant tumour with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus. Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas. Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular. The prognosis is poor.

**2B70.00**

#### Barrett adenocarcinoma

Barrett adenocarcinoma is defined as adenocarcinoma of lower oesophagus and gastroesophageal junction associated with Barrett's oesophagus.

**2B70.0Y**

#### Other specified adenocarcinoma of oesophagus

**2B70.0Z**

#### Adenocarcinoma of oesophagus, unspecified

**2B70.1**

### **Squamous cell carcinoma of oesophagus**

A squamous cell carcinoma arising from the esophagus. It can be associated with a long history of tobacco and alcohol abuse and is exceedingly rare before the age of 30. The median age is around 65 in both males and females, but the incidence in males is much higher than in females. It is located mostly in the middle and lower third of the esophagus. Grossly, polypoid, ulcerated, plaque-like and occult lesions have been described. The microscopic features are the same as in other squamous cell carcinomas. Any degree of differentiation may occur, and variation within a single tumour is common. The prognosis is poor.

**2B70.Y**

#### Other specified malignant neoplasms of oesophagus

**2B70.Z**

#### Malignant neoplasms of oesophagus, unspecified

**2B71**

### **Malignant neoplasms of oesophagogastric junction**

Malignant neoplasms that arise from the cells of the oesophagogastric junction (OGJ), which is defined as the point at which the oesophagus ends and the stomach begins. This mainly defines adenocarcinomas that straddle the junction of the oesophagus and stomach. This definition includes many tumours formally called cancers of the gastric cardia.

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

<b>2B71.0</b>	<b>Adenocarcinoma of oesophagogastric junction</b> An adenocarcinoma that arises from and straddles the junction of the stomach and esophagus. The category of adenocarcinomas of the gastroesophageal junction also includes the majority of adenocarcinomas previously called gastric cardia adenocarcinomas. Squamous cell carcinomas that affect or cross the junction of the stomach and esophagus are classified as carcinomas of the distal esophagus. Adenocarcinoma of the gastroesophageal junction occurs more often in Caucasian middle aged and elderly males. Clinical signs and symptoms include dysphagia, abdominal pain, and weight loss. The prognosis depends on the completeness of the surgical resection, the number of lymph nodes involved by cancer, and the presence or absence of postoperative complications.
<b>2B71.Y</b>	<b>Other specified malignant neoplasm of oesophagogastric junction</b>
<b>2B71.Z</b>	<b>Malignant neoplasms of oesophagogastric junction, unspecified</b>
<b>2B72</b>	<p><b>Malignant neoplasms of stomach</b> A primary or metastatic malignant neoplasm involving the stomach.</p> <p><b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)</p> <p><b>Coded Elsewhere:</b> Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of stomach (2A85.1) Leiomyosarcoma of stomach (2B58.2) Gastrointestinal stromal tumour of stomach (2B5B.0) Gastric malignant lymphoma (2B33.5)</p>
<b>2B72.0</b>	<b>Adenocarcinoma of stomach</b> An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals. It most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumours which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognised: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a curative resection.
<b>2B72.1</b>	<b>Malignant neuroendocrine neoplasm of stomach</b> A neoplasm with neuroendocrine differentiation that arises from the stomach. It includes well differentiated neuroendocrine tumours (low and intermediate grade) and poorly differentiated neuroendocrine carcinomas (high grade).
	<p><b>Inclusions:</b> carcinoid and other malignant neuroendocrine neoplasms</p> <p><b>Coded Elsewhere:</b> Neuroendocrine neoplasm of duodenum (2B80.01) Neuroendocrine neoplasms of appendix (2B81.2)</p>
<b>2B72.Y</b>	<b>Other specified malignant neoplasms of stomach</b>
<b>2B72.Z</b>	<b>Malignant neoplasms of stomach, unspecified</b>

Malignant neoplasms of intestine (2B80-2C0Z)

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**2B80**

**Malignant neoplasms of small intestine**

A primary malignant neoplasm involving the small intestine.

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**Coded Elsewhere:** Enteropathy associated T-cell lymphoma (2A90.7)

Gastrointestinal stromal tumour of small intestine (2B5B.1)

Malignant lymphoma of small intestine (2B33.5)

Malignant neoplasm of jejunum (2B80.1Z)

Malignant neoplasm of ileum (2B80.1Z)

Small intestinal leiomyosarcoma (2B58.Y)

**2B80.0**

**Malignant neoplasms of duodenum**

A primary malignant neoplasm that affects the duodenum. Representative examples include carcinoma, lymphoma, and sarcoma.

**Coded Elsewhere:** Lymphoma of duodenum (2B33.5)

Malignant mesenchymal tumour of the duodenum (2B5F.2)

**2B80.00**

Adenocarcinoma of duodenum

An adenocarcinoma that arises from the duodenum.

**2B80.01**

Neuroendocrine neoplasm of duodenum

Neoplasms that arise from the cells of neuroendocrine system lining the duodenum.

**2B80.0Y**

Other specified malignant neoplasms of the duodenum

**2B80.0Z**

Malignant neoplasms of duodenum, unspecified

**2B80.1**

**Malignant neoplasms of jejunum or ileum**

**2B80.10**

Adenocarcinoma of jejunum or ileum

**2B80.11**

Neuroendocrine neoplasms of jejunum or ileum

Neoplasms that arise from the cells of neuroendocrine system lining the jejunum or ileum including well-differentiated (low- to intermediate grade) neuroendocrine tumours. These include carcinoid tumour.

**2B80.1Y**

Other specified malignant neoplasms of jejunum or ileum

**2B80.1Z**

Malignant neoplasms of jejunum or ileum, unspecified

**2B80.2**

**Malignant neoplasms of small intestine, site unspecified**

**2B80.20**

Adenocarcinoma of small intestine, site unspecified

A malignant tumour with glandular differentiation arising from epithelium of small intestine.

**Exclusions:** Neuroendocrine neoplasms of small intestine, site unspecified (2B80.21)

- 2B80.21** Neuroendocrine neoplasms of small intestine, site unspecified  
Neoplasms that arise from the cells of neuroendocrine system lining the small intestine.
- 2B80.2Y** Other specified malignant neoplasms of small intestine, site unspecified
- 2B80.Y** **Other specified malignant neoplasms of small intestine**
- 2B80.Z** **Malignant neoplasms of small intestine, unspecified**
- 2B81** **Malignant neoplasms of appendix**  
A primary malignant neoplasm that affects the appendix.
- Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)
- Coded Elsewhere:** Lymphoma of the appendix (2B33.5)
- 2B81.0** **Adenocarcinoma of appendix**  
A malignant neoplasm arising from the glandular epithelium of the appendix. Most are mucinous adenocarcinomas.
- 2B81.00** Mucinous adenocarcinoma of appendix  
An adenocarcinoma, often cystic, with large amounts of extracellular mucin
- 2B81.2** **Neuroendocrine neoplasms of appendix**  
Malignant neoplasms with neuroendocrine differentiation that arise in the appendix. Most are well differentiated neuroendocrine tumours (low and intermediate grade), i.e. carcinoids. Poorly differentiated neuroendocrine carcinomas (high grade) are exceedingly rare.
- 2B81.Y** **Other specified malignant neoplasms of appendix**
- 2B81.Z** **Malignant neoplasms of appendix, unspecified**
- Malignant neoplasms of large intestine (2B90-2B9Y)**
- Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)
- 2B90** **Malignant neoplasms of colon**  
Primary malignant neoplasms arising in the colon.
- Exclusions:** Malignant neoplasms of appendix (2B81)
- Coded Elsewhere:** Gardner syndrome (LD2D.3)  
Malignant Lymphoma of colon (2B33.5)  
Gastrointestinal stromal tumour of colon (2B5B.Y)  
Kaposi sarcoma of colon (2B57.2)  
Leiomyosarcoma of colon (2B58.Y)
- 2B90.0** **Malignant neoplasm of ascending colon and right flexure of colon**

<b>2B90.00</b>	Adenocarcinoma of ascending colon or right flexure of colon A malignant tumour with glandular differentiation arising from epithelium of ascending colon and right flexure.
<b>2B90.0Y</b>	Other specified malignant neoplasm of ascending colon and right flexure of colon
<b>2B90.0Z</b>	Malignant neoplasm of ascending colon and right flexure of colon, unspecified
<b>2B90.1</b>	<b>Malignant neoplasm of descending colon and splenic flexure of colon</b>
<b>2B90.10</b>	Adenocarcinoma of descending colon or splenic flexure of colon A malignant tumour with glandular differentiation arising from epithelium of descending colon and splenic flexure.
<b>2B90.1Y</b>	Other specified malignant neoplasm of descending colon and splenic flexure of colon
<b>2B90.1Z</b>	Malignant neoplasm of descending colon and splenic flexure of colon, unspecified
<b>2B90.2</b>	<b>Malignant neoplasm of transverse colon</b>
<b>2B90.20</b>	Adenocarcinoma of transverse colon A malignant tumour with glandular differentiation arising from epithelium of transverse colon.
<b>2B90.2Y</b>	Other specified malignant neoplasm of transverse colon
<b>2B90.2Z</b>	Malignant neoplasm of transverse colon, unspecified
<b>2B90.3</b>	<b>Malignant neoplasm of sigmoid colon</b>
	<b>Exclusions:</b> Malignant neoplasms of rectosigmoid junction (2B91)
<b>2B90.30</b>	Adenocarcinoma of sigmoid colon A malignant tumour with glandular differentiation arising from epithelium of descending colon and splenic flexure.
<b>2B90.3Y</b>	Other specified malignant neoplasm of sigmoid colon
<b>2B90.3Z</b>	Malignant neoplasm of sigmoid colon, unspecified
<b>2B90.Y</b>	<b>Other specified malignant neoplasms of colon</b>
<b>2B90.Z</b>	<b>Malignant neoplasms of colon, unspecified</b>
<b>2B91</b>	<b>Malignant neoplasms of rectosigmoid junction</b>
<b>2B91.0</b>	<b>Adenocarcinoma of rectosigmoid junction</b> A malignant tumour with glandular differentiation arising from epithelium of rectosigmoid junction
<b>2B91.Y</b>	<b>Other specified malignant neoplasms of rectosigmoid junction</b>
<b>2B91.Z</b>	<b>Malignant neoplasms of rectosigmoid junction, unspecified</b>

**2B92**

**Malignant neoplasms of rectum**

**Coded Elsewhere:** Malignant mesenchymal tumour of rectum (2B5F.2)

**2B92.0**

**Adenocarcinomas of rectum**

An adenocarcinoma arising from the rectum. It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.

**2B92.1**

**Neuroendocrine neoplasms of rectum**

Malignant neoplasms with neuroendocrine differentiation that arise in the rectum. Most are well differentiated neuroendocrine tumours (low and intermediate grade), i.e. carcinoids. Poorly differentiated neuroendocrine carcinomas (high grade) are rare.

**2B92.Y**

**Other specified malignant neoplasms of rectum**

**2B92.Z**

**Malignant neoplasms of rectum, unspecified**

**2B93**

**Malignant neoplasms of large intestine, site unspecified**

**2B93.0**

**Adenocarcinoma of large intestine, site unspecified**

**2B93.Y**

**Other specified malignant neoplasms of large intestine, site unspecified**

**2B93.Z**

**Malignant neoplasms of large intestine, site and type unspecified**

**2B9Y**

**Other specified malignant neoplasms of large intestine**

**2C00**

**Malignant neoplasms of anus or anal canal**

A primary malignant neoplasm that arises in the anal canal up to the junction with perianal, hair-bearing skin. Representative examples include carcinomas and melanomas. Tumours of the anal margin are classified with skin tumours.

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C00.0**

**Adenocarcinoma of anus or anal canal**

An adenocarcinoma arising in the anal canal epithelium, including the mucosal surface, the anal glands, and the lining of fistulous tracts.

**2C00.1**

**Melanoma of anus or anal canal**

A form of cancer that develops in melanocytes, the cells that produce pigment melanin in the skin.

**2C00.2**

**Neuroendocrine neoplasm of anus or anal canal**

Neoplasms that arise from the cells of the neuroendocrine system lining the anus and anal canal.

<b>2C00.3</b>	<b>Squamous cell carcinoma of anus or anal canal</b> A squamous cell carcinoma (SCC) arising from the anal canal up to the junction with the anal margin (perianal, hair-bearing skin). Human papillomavirus is detected in the majority of cases. Homosexual HIV-positive men have an increased risk of developing anal squamous cell carcinoma in comparison to the general male population. The prognosis is generally better for anal margin SCC than for anal canal SCC. The former are classified with skin tumours.
<b>2C00.Y</b>	<b>Other specified malignant neoplasms of anus and anal canal</b>
<b>2C00.Z</b>	<b>Malignant neoplasms of anus or anal canal, unspecified</b>
<b>2C0Y</b>	<b>Other specified malignant neoplasms of intestine</b>
<b>2C0Z</b>	<b>Malignant neoplasms of intestine, unspecified</b>
<b>2C10</b>	<b>Malignant neoplasm of pancreas</b> A primary malignant tumour of the pancreas. Most are adenocarcinomas.  <b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C10.0</b>	<b>Adenocarcinoma of pancreas</b> An adenocarcinoma which arises from the exocrine pancreas. Ductal adenocarcinoma and its variants are the most common types of pancreatic adenocarcinoma.
<b>2C10.1</b>	<b>Neuroendocrine neoplasms of pancreas</b> A neoplasm with neuroendocrine differentiation that arises from the pancreas. It includes neuroendocrine tumours (low and intermediate grade) and neuroendocrine carcinomas (high grade).
<b>2C10.Y</b>	<b>Other specified malignant neoplasms of pancreas</b>
<b>2C10.Z</b>	<b>Malignant neoplasm of pancreas, unspecified</b>
<b>2C11</b>	<b>Malignant neoplasms of other or ill-defined digestive organs</b> A primary malignant tumour involving a digestive organ or organs not coded elsewhere (including intestinal tract [part unspecified], overlapping lesions of the digestive tract and other ill-defined sites within the digestive system)  <b>Exclusions:</b> Malignant neoplasms of retroperitoneum (2C50) Malignant neoplasms of peritoneum (2C51) Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C11.0</b>	<b>Adenocarcinoma of other or ill-defined digestive organs</b>
<b>2C11.1</b>	<b>Mucinous carcinoma of other or ill-defined digestive organs</b>
<b>2C11.2</b>	<b>Other specified malignant neoplasms of other or ill-defined digestive organs</b>
<b>2C11.Z</b>	<b>Malignant neoplasms of other or ill-defined digestive organs, unspecified</b>

**2C12****Malignant neoplasms of liver or intrahepatic bile ducts**

The most frequent and important hepatic neoplasm is the primary hepatocellular carcinoma (HCC). In many parts of the world, in particular Africa and Asia, it poses a significant disease burden. In these high incidence regions, chronic infection with hepatitis B virus (HBV) is the principal underlying cause, with the exception of Japan which has a high prevalence of hepatitis C infection. HBV vaccination has become a powerful tool in reducing cirrhosis and HCC, but implementation is still suboptimal in several high risk regions. In Western countries, chronic alcohol abuse is a major aetiological factor. Hepatic cholangiocarcinoma has a different geographical distribution, with peak incidences in Northern Thailand. Here, it is caused by chronic infection with the liver fluke, *Opisthorchis viverrini*, which is ingested through infected raw fish.

**Exclusions:** Secondary malignant neoplasm of liver (2D80)  
Malignant neoplasm of biliary tract NOS (2C17)

**2C12.0****Malignant neoplasm of liver****2C12.00**

Combined hepatocellular-cholangiocarcinoma

Combined hepatocellular-cholangiocarcinoma is a tumour containing unequivocal, intimately mixed elements of both hepatocellular carcinoma and cholangiocarcinoma.

**Inclusions:** Hepatocholangiocarcinoma

**2C12.01**

Hepatoblastoma

A malignant liver neoplasm that occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Grossly, hepatoblastoma is solid, well circumscribed, and more often solitary than multiple. Microscopically, most of the tumours are composed exclusively of immature hepatocytic elements. About a fourth of hepatoblastomas contain a stromal component that may be undifferentiated or develop into bone or cartilage.

**2C12.02**

Hepatocellular carcinoma of liver

A carcinoma that arises from the hepatocytes.

**2C12.03**

Mesothelial carcinoma of liver

**2C12.0Y**

Other specified malignant neoplasm of liver

**2C12.0Z**

Malignant neoplasm of liver, unspecified

**2C12.1****Malignant neoplasm of intrahepatic bile ducts****2C12.10**

Intrahepatic cholangiocarcinoma

A carcinoma that arises from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree. Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas. Early detection is difficult and the prognosis is generally poor.

**2C12.1Y**

Other specified malignant neoplasms of intrahepatic bile ducts

**2C12.1Z**

Malignant neoplasm of intrahepatic bile ducts, unspecified

**2C13****Malignant neoplasms of gallbladder**

A malignant tumour arising from the epithelium of the gallbladder. It is usually associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, adenocarcinoma is the most common type, however squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur.

**2C13.0****Adenocarcinoma of the gallbladder**

An adenocarcinoma arising from the gallbladder. It is the most common malignant tumour of the gallbladder, typically in the fundus; it is usually well to moderately differentiated. The incidence is higher in patients with gallstones than in patients without gallstones. Signs and symptoms usually present late in the course of the disease and are reminiscent of those of chronic cholecystitis including right upper quadrant pain. Histologic variants include adenocarcinoma of the intestinal type, clear cell adenocarcinoma, mucinous adenocarcinoma, papillary adenocarcinoma, and signet ring adenocarcinoma.

**2C13.Y****Other specified malignant neoplasm of gallbladder****2C13.Z****Malignant neoplasms of gallbladder, unspecified****2C14****Malignant neoplasms of proximal biliary tract, cystic duct****2C14.0****Adenocarcinoma of proximal biliary tract, cystic duct****2C14.1****Mucinous cystic neoplasm with associated invasive carcinoma of cystic duct****2C14.2****Neuroendocrine neoplasms of cystic duct****2C14.Y****Other specified malignant neoplasms of biliary tract, cystic duct****2C14.Z****Malignant neoplasms of proximal biliary tract, cystic duct, unspecified****2C15****Malignant neoplasms of biliary tract, distal bile duct****2C15.0****Adenocarcinoma of biliary tract, distal bile duct**

An adenocarcinoma that arises from the common bile duct distal to the insertion of the cystic duct.

**2C15.1****Mucinous cystic neoplasm with associated invasive carcinoma of distal bile duct****2C15.2****Neuroendocrine neoplasms of distal bile duct****2C15.Y****Other specified malignant neoplasms of biliary tract, distal bile duct****2C15.Z****Malignant neoplasms of biliary tract, distal bile duct, unspecified****2C16****Malignant neoplasms of ampulla of Vater****2C16.0****Adenocarcinoma of ampulla of Vater**

A malignant glandular epithelial tumour arising in the ampulla of Vater

**2C16.1****Neuroendocrine neoplasms of ampulla of Vater**

- 2C16.Y**      **Other specified malignant neoplasms of ampulla of Vater**
- 2C16.Z**      **Malignant neoplasms of ampulla of Vater, unspecified**
- 2C17**      **Malignant neoplasms of other or unspecified parts of biliary tract**
- Exclusions:**      Malignant neoplasm of intrahepatic bile duct (2C12)
- Coded Elsewhere:** Malignant mesenchymal tumours of gallbladder or bile ducts (2B5F.2)
- 2C17.0**      **Adenocarcinoma of other or unspecified parts of biliary tract**
- 2C17.1**      **Mucinous cystic neoplasm with associated invasive carcinoma of other or unspecified parts of biliary tract**
- 2C17.2**      **Neuroendocrine neoplasms of other or unspecified parts of biliary tract**
- 2C17.Y**      **Other specified malignant neoplasms of overlapping lesion of biliary tract**
- 2C17.Z**      **Malignant neoplasms of other or unspecified parts of biliary tract, unspecified**
- 2C18**      **Malignant neoplasms of perihilar bile duct**  
 "Includes left, right and common hepatic ducts to the origin of the cystic duct"
- 2C18.0**      **Hilar cholangiocarcinoma**  
 Klatskin tumour is an extra-hepatic cholangiocarcinoma arising in the junction of the main right or left hepatic ducts to form the common hepatic duct.
- 2C18.1**      **Mucinous cystic neoplasm with associated invasive carcinoma of perihilar bile duct**
- 2C18.2**      **Neuroendocrine neoplasm of perihilar bile duct**
- 2C18.Y**      **Other specified malignant neoplasms of perihilar bile duct**
- 2C18.Z**      **Malignant neoplasms of perihilar bile duct, unspecified**
- 2C1Z**      **Malignant neoplasms of digestive organs, unspecified**

## Malignant neoplasms of middle ear, respiratory or intrathoracic organs (2C20-2C2Z)

- Exclusions:**
- Mesotheliomas of peritoneum (2C51.2)
  - Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C20**

### **Malignant neoplasms of nasal cavity**

From the chapter on Nasal Cavity (H&N BB) Although the nasal cavity and paranasal sinuses occupy a relatively small anatomical space, they are the site of origin of some of the more complex, histologically diverse group of tumours in the entire human body. These include neoplasms derived from mucosal epithelium, seromucinous glands, soft tissues, bone, cartilage, neural/neuroectodermal tissue, haematolymphoid cells and the odontogenic apparatus. Many of the tumours are similar to those found elsewhere in the body but a few, such as the olfactory neuroblastoma, are unique to this site.

- Exclusions:**
- Malignant neoplasm of nose NOS (2C29)
  - Malignant neoplasm of olfactory bulb (2A02)
  - Malignant neoplasm of posterior margin of nasal septum and choana (2B6B)
  - Malignant neoplasm of skin of nose (2C30-2C3Z)
  - Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C20.0**

#### **Adenocarcinoma of nasal cavity**

**2C20.1**

#### **Malignant neuroepitheliomatous neoplasm of nasal cavity**

**2C20.2**

#### **Melanoma of nasal cavity**

**2C20.3**

#### **Olfactory neuroblastoma**

**2C20.4**

#### **Squamous cell carcinoma of nasal cavity**

**2C20.Y**

#### **Other specified malignant neoplasm of nasal cavity**

**2C20.Z**

#### **Malignant neoplasms of nasal cavity, unspecified**

**2C21**

### **Malignant neoplasms of middle ear**

Malignant neoplasm originating in the middle ear.

- Exclusions:**
- malignant neoplasm of skin of (external) ear (2C30-2C3Z)
  - malignant neoplasm of bone of ear (meatus) (2B50-2B5Z)
  - malignant neoplasm of cartilage of ear (2B50-2B5Z)
  - Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C21.0**

#### **Adenocarcinoma of middle ear**

**2C21.1**

#### **Squamous cell carcinoma of middle ear**

**2C21.2**

#### **Unspecified malignant epithelial neoplasm of middle ear**

**2C21.Y**

#### **Other specified malignant neoplasm of middle ear**

<b>2C21.Z</b>	<b>Malignant neoplasms of middle ear, unspecified</b>
<b>2C22</b>	<b>Malignant neoplasms of accessory sinuses</b>
	<b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C22.0</b>	<b>Adenocarcinoma of accessory sinuses</b>
<b>2C22.1</b>	<b>Squamous cell carcinoma of accessory sinuses</b>
<b>2C22.10</b>	Squamous cell carcinoma of sphenoidal sinus
<b>2C22.1Y</b>	Squamous cell carcinoma of other specified accessory sinuses
<b>2C22.2</b>	<b>Malignant epithelial neoplasms of accessory sinuses, unspecified type</b>
<b>2C22.3</b>	<b>Melanomas of accessory sinuses</b>
<b>2C22.Y</b>	<b>Other specified malignant neoplasms of accessory sinuses</b>
<b>2C22.Z</b>	<b>Malignant neoplasms of accessory sinuses, unspecified</b>
<b>2C23</b>	<b>Malignant neoplasms of larynx</b>
	<b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C23.1</b>	<b>Malignant neoplasms of glottis of larynx</b>
<b>2C23.10</b>	Squamous cell carcinoma of larynx, glottis A squamous cell carcinoma of the larynx that arises from the glottic area. It may remain localised for a long period then in late disease stage, it may spread to the opposite true vocal cord, supraglottic and subglottic areas, and the soft tissues of the neck. Hoarseness is the presenting symptom.
<b>2C23.1Y</b>	Other specified malignant neoplasms of larynx, glottis
<b>2C23.2</b>	<b>Malignant neoplasms of supraglottis of larynx</b>
	<b>Exclusions:</b> Malignant neoplasm of anterior surface of epiglottis (2B6A)
<b>2C23.20</b>	Squamous cell carcinoma of larynx, supraglottis A squamous cell carcinoma of the larynx that arises from the supraglottic area. Signs and symptoms include dysphagia, a sensation of foreign body in the throat, and hemoptysis. It spreads to the space anterior to the epiglottis, pyriform sinus, and base of the tongue.
<b>2C23.2Y</b>	Other specified malignant neoplasms of larynx, supraglottis
<b>2C23.3</b>	<b>Malignant neoplasms of subglottis of larynx</b>
	A primary or metastatic malignant neoplasm involving the subglottis.
<b>2C23.30</b>	Squamous cell carcinoma of larynx, subglottis A squamous cell carcinoma of the larynx that arises from the subglottic area. Symptoms include dyspnea and stridor. It spreads to the hypopharynx, trachea, and thyroid gland.

<b>2C23.31</b>	Adenocarcinoma of larynx, subglottis
<b>2C23.3Y</b>	Other specified malignant neoplasms of larynx, subglottis
<b>2C23.4</b>	<b>Malignant neoplasm of laryngeal cartilage</b>
<b>2C23.5</b>	<b>Malignant neoplasm of overlapping lesion of larynx</b>
<b>2C23.Z</b>	<b>Malignant neoplasms of larynx, unspecified</b>
<b>2C24</b>	<p><b>Malignant neoplasms of trachea</b></p> <p>A primary or metastatic malignant neoplasm involving the trachea</p> <p><b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z) trachea carina cancer (2C25)</p>
<b>2C24.0</b>	<b>Adenocarcinoma of trachea</b>
<b>2C24.1</b>	<b>Squamous cell carcinoma of trachea</b>
<b>2C24.2</b>	<b>Malignant epithelial neoplasms of trachea, unspecified type</b>
<b>2C24.Y</b>	<b>Other specified malignant neoplasms of trachea</b>
<b>2C24.Z</b>	<b>Malignant neoplasms of trachea, unspecified</b>
<b>2C25</b>	<p><b>Malignant neoplasms of bronchus or lung</b></p> <p>Primary malignant neoplasm originating from tissues of bronchus or lung.</p> <p><b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)</p>
<b>2C25.0</b>	<p><b>Adenocarcinoma of bronchus or lung</b></p> <p>A carcinoma that arises from the lung and is characterised by the presence of malignant glandular epithelial cells. There is a male predilection with a male to female ratio of 2:1. Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding. If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever. Tobacco smoke is a known risk factor.</p>
<b>2C25.1</b>	<p><b>Small cell carcinoma of bronchus or lung</b></p> <p>A highly aggressive subtype of lung carcinoma characterised by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.</p>
<b>2C25.2</b>	<p><b>Squamous cell carcinoma of bronchus or lung</b></p> <p>A carcinoma arising from malignant squamous bronchial epithelial cells and characterised by the presence of keratinization and/or intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.</p>
<b>2C25.3</b>	<b>Large cell carcinoma of bronchus or lung</b>
<b>2C25.4</b>	<b>Carcinoid or other malignant neuroendocrine neoplasms of bronchus or lung</b>

**2C25.5      Unspecified malignant epithelial neoplasm of bronchus or lung**

**2C25.Y      Other specified malignant neoplasms of bronchus or lung**

**2C25.Z      Malignant neoplasms of bronchus or lung, unspecified**

**2C26**

**Malignant neoplasms of the pleura**

A primary or metastatic malignant neoplasm affecting the pleura. A representative example of primary malignant pleural neoplasm is the malignant pleural mesothelioma. A representative example of metastatic malignant neoplasm to the pleura is when a metastatic carcinoma has spread to the pleura from another anatomic site.

**Exclusions:**      Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C26.0      Mesothelioma of pleura**

Malignant mesothelioma is a fatal asbestos-associated malignancy arising in the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as in the pericardium and the tunica vaginalis.

**2C26.Y      Other specified malignant neoplasms of the pleura**

**2C26.Z      Malignant neoplasms of the pleura, unspecified**

**2C27**

**Malignant neoplasms of thymus**

Primary malignant neoplasm involving the thymus. This category includes malignant thymomas, primary thymic carcinomas and carcinoid tumour or other neuroendocrine neoplasms of thymus.

**Exclusions:**      Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C27.0      Carcinoma of thymus**

A diverse group of carcinomas of the thymus gland, previously known as thymoma type C. It includes morphologic variants derived from purely epithelial cells, as well as from cells with neuroendocrine differentiation.

**2C27.1      Carcinoid tumour or other neuroendocrine neoplasms of thymus**

Thymic neuroendocrine carcinoma is a type of thymic epithelial neoplasm displaying evidence of neuroendocrine differentiation.

**2C27.2      Malignant thymoma**

A thymoma that has an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize. Although any morphologic subtype of thymoma may eventually have a malignant clinical course, this term is most often associated with thymoma types B3 and C.

**2C27.Y      Other specified malignant neoplasms of thymus**

**2C27.Z      Malignant neoplasms of thymus, unspecified**

<b>2C28</b>	<b>Malignant neoplasms of heart, mediastinum or non-mesothelioma of pleura</b>
	<b><i>Exclusions:</i></b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C28.0</b>	<b>Malignant germ cell neoplasms of heart, mediastinum or non-mesothelioma of pleura</b>
<b>2C28.1</b>	<b>Other specified malignant neoplasms of heart, mediastinum or non-mesothelioma of pleura</b>
<b>2C28.Z</b>	<b>Malignant neoplasms of heart, mediastinum or non-mesothelioma of pleura, unspecified</b>
<b>2C29</b>	<b>Malignant neoplasms of other or ill-defined sites in the respiratory system or intrathoracic organs</b>
	<b><i>Exclusions:</i></b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C29.0</b>	<b>Squamous cell carcinomas of other and ill-defined sites in the respiratory system and intrathoracic organs</b>
<b>2C29.1</b>	<b>Other specified malignant neoplasms of other or ill-defined sites in the respiratory system or intrathoracic organs</b>
<b>2C29.Z</b>	<b>Malignant neoplasms of other or ill-defined sites in the respiratory system or intrathoracic organs, unspecified</b>
<b>2C2Y</b>	<b>Other specified malignant neoplasms of middle ear, respiratory or intrathoracic organs</b>
<b>2C2Z</b>	<b>Malignant neoplasms of middle ear, respiratory or intrathoracic organs, unspecified</b>

### Malignant neoplasms of skin (2C30-2C3Z)

A primary or metastatic tumour involving the skin. Primary malignant skin tumours most often are carcinomas (either basal cell or squamous cell carcinomas that arise from cells in the epidermis) or melanomas that arise from pigment-containing skin melanocytes. Metastatic tumours to the skin include carcinomas and lymphomas.

- Exclusions:***
- Carcinoma in situ of skin (2E64)
  - Metastatic malignant neoplasm involving skin (2E08)
  - Malignant mesenchymal neoplasms (2B50-2B5Z)

<b>2C30</b>	<b>Melanoma of skin</b>
	A primary melanoma arising from atypical melanocytes in the skin. Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi. Several histologic variants have been recognised, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.

- Exclusions:***
- Melanoma of penis (2C81.1)
  - Melanoma of vulva (2C70.1)

- 2C30.0      Superficial spreading melanoma, primary**  
The commonest form of melanoma, superficial spreading malignant melanoma accounts for about 70 per cent of all melanomas. It characteristically presents as an asymptomatic pigmented cutaneous macule which is asymmetrical in shape and displays variability in both hue and pigment intensity. It has a relatively long phase of progressive superficial extension (radial growth) before penetrating deeper into the dermis and entering an invasive vertical growth phase.
- 2C30.1      Nodular melanoma, primary**  
Variant of melanoma carrying a poor prognosis due to the fact that there is little or no prodromal radial (superficial) growth phase before deep invasion (vertical growth). The lesion presents as an elevated, reddish, bluish or dark brown coloured, dome-shaped tumour. Ulceration or bleeding from the lesion occurs frequently. It occurs most frequently in the fifth or sixth decade.
- 2C30.2      Lentigo maligna melanoma, primary**  
Lentigo maligna malignant melanoma is a form of melanoma which occurs within a lentigo maligna when neoplastic cells no longer remain confined to the epidermis (in situ radial growth) but invade the dermis (vertical growth). The lentigo maligna from which it arises may have been present as an irregularly pigmented macule on sun-exposed skin for many years before dermal invasion supervenes. Clinical differentiation from lentigo maligna may not be possible in the early stages of invasion but as the tumour progresses a focal thickening or nodule within the lentigo maligna will become apparent.
- Exclusions:**      Lentigo maligna (2E63.00)
- 2C30.3      Acral lentiginous melanoma, primary**  
Acral lentiginous malignant melanoma is a distinct and uncommon form of melanoma affecting either palmar and plantar skin or the nail apparatus. It is usually preceded by a slowly progressive in situ phase which may be overlooked. It typically presents either as an enlarging area of macular pigmentation on the palms and soles or as a longitudinal pigmented band within the nail plate. More aggressive tumours present as ulcerated nodules which, when involving the nail apparatus, can destroy the nail plate. Acral lentiginous malignant melanoma accounts for a high proportion of melanomas seen in dark-skinned people.
- 2C30.Y      Other specified melanoma of skin**
- 2C30.Z      Melanoma of skin, unspecified**
- 2C31      Squamous cell carcinoma of skin**  
A carcinoma arising from the squamous cells of the epidermis. Skin squamous cell carcinoma is most commonly found on sun-exposed areas. The majority of the tumours are well-differentiated.
- Coded Elsewhere:** Squamous cell carcinoma of penis (2C81.0)

- 2C31.0** **Verrucous squamous cell carcinoma of skin**  
Verrucous squamous cell carcinoma is a rare variant of well-differentiated squamous cell carcinoma with low malignant potential. It occurs principally on the glans and prepuce of the penis and on the sole of the foot.
- Exclusions:** Verrucous squamous cell carcinoma of vulva (2C70.2)
- 2C31.1** **Keratoacanthoma**  
Keratoacanthoma is a relatively common keratinocytic epidermal tumour which shows resemblances to squamous cell carcinoma of the skin, from which it may be difficult to distinguish either clinically or histopathologically. It is characterised by rapid growth over a few weeks to months, followed by spontaneous resolution over 4-6 months. Because it is not possible to predict its benign behaviour with complete certainty during its initial growth phase, the designation "Well-differentiated squamous cell carcinoma (keratoacanthoma type)" is also used.
- 2C31.Z** **Cutaneous squamous cell carcinoma**
- 2C32** **Basal cell carcinoma of skin**  
Basal cell carcinoma or BCC is the most common malignancy in humans. It is believed that BCCs arise from pluripotential cells in the basal layer of the epidermis or, less commonly, hair follicle. BCCs typically occur in areas of chronic sun exposure and present as slowly enlarging reddish papules, plaques or nodules on the head and neck, although the superficial variant is often located on the trunk. BCCs frequently ulcerate and become crusted. Although they rarely metastasize, they can cause significant local destruction and disfigurement if neglected or inadequately treated, particularly if of the sclerosing or infiltrative subtype.
- 2C32.0** **Nodular basal cell carcinoma of skin**  
This is the most common form of basal cell carcinoma and is typically located on the head or neck. It starts as a small translucent nodule which will frequently necrose and ulcerate as it enlarges. Telangiectatic blood vessels can often be detected just under the tumour surface. A minority may be pigmented and give rise to difficulty in distinguishing them from melanoma.
- 2C32.1** **Sclerosing basal cell carcinoma of skin**  
This form of basal cell carcinoma is composed of thin strands, cords and columns of malignant cells which infiltrate between collagen bundles of the dermis. It may infiltrate widely and deeply before it becomes clinically obvious. It typically starts as a pale, poorly-defined indurated plaque which may not come to medical attention until it starts to bleed and crust.
- 2C32.2** **Superficial basal cell carcinoma of skin**  
Superficial basal cell carcinomas are often multiple and appear as pink or red barely elevated patches varying in size from a few mm to over 10 cm in diameter. A fine pearly border can usually be seen on careful inspection. They occur most frequently on the trunk.
- 2C32.Y** **Other specified basal cell carcinoma of skin**
- 2C32.Z** **Basal cell carcinoma of skin, unspecified**

**2C33**

### **Adnexal carcinoma of skin**

A carcinoma arising from the sebaceous glands, sweat glands, or the hair follicles. Representative examples include sebaceous carcinoma, apocrine carcinoma, eccrine carcinoma, and pilomatrical carcinoma.

- Inclusions:**
- Primary cutaneous mucinous carcinoma
  - Primary cutaneous adenoid cystic carcinoma
  - Appendageal carcinoma of skin

**2C34**

### **Cutaneous neuroendocrine carcinoma**

Cutaneous neuroendocrine carcinoma is a primary cutaneous cancer arising from a subset of skin neuroendocrine cells (Merkel cells, giving the name Merkel cell carcinoma (MCC)).

**2C35**

### **Cutaneous sarcoma**

A group of generally rare malignant neoplasms arising from mesenchymal elements in the dermis including fibroblasts, pilar smooth muscle and vascular endothelium.

- Coded Elsewhere:**
- Angiosarcoma of skin (2B56.1)
  - Kaposi sarcoma of skin (2B57.1)
  - Cutaneous leiomyosarcoma (2B58.Y)
  - Dermatofibrosarcoma protuberans (2B53.Y)

**2C3Y**

### **Other specified malignant neoplasms of skin**

**2C3Z**

### **Malignant neoplasm of skin of unknown or unspecified type**

## **Malignant neoplasms of peripheral nerves or autonomic nervous system (2C40-2C4Z)**

- Exclusions:**
- Malignant nerve sheath tumour of peripheral nerves or autonomic nervous system, primary site (2B5E)
  - Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C40**

### **Malignant neuroepitheliomatous neoplasms of peripheral nerves or autonomic nervous system**

**2C41**

### **Malignant perineurioma**

**2C4Y**

### **Other specified malignant neoplasms of peripheral nerves and autonomic nervous system**

**2C4Z**

### **Malignant neoplasms of peripheral nerves or autonomic nervous system, unspecified**

## Malignant neoplasms of retroperitoneum, peritoneum or omentum (2C50-2C5Z)

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C50**

### **Malignant neoplasms of retroperitoneum**

A primary or metastatic malignant neoplasm involving the retroperitoneum. The vast majority of cases are carcinomas, lymphomas, or sarcomas.

**Exclusions:** Malignant neoplasms of omentum (2C52)

Malignant neoplasms of peritoneum (2C51)

Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C50.0 Cystic, mucinous or serous carcinoma of retroperitoneum**

**2C50.Y Other specified malignant neoplasms of retroperitoneum**

**2C50.Z Malignant neoplasms of retroperitoneum, unspecified**

**2C51**

### **Malignant neoplasms of peritoneum**

**Exclusions:** Malignant neoplasms of retroperitoneum (2C50)

Malignant neoplasms of omentum (2C52)

Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C51.0 Adenocarcinomas of peritoneum**

**2C51.1 Cystic, mucinous or serous carcinoma of peritoneum**

**2C51.2 Mesotheliomas of peritoneum**

A benign or malignant mesothelial neoplasm that arises from the peritoneum.

**2C51.20 Mesothelioma of mesocolon**

**2C51.21 Mesothelioma of mesentery**

**2C51.2Y Mesotheliomas of other specified sites of peritoneum**

**2C51.2Z Mesotheliomas of peritoneum, site unspecified**

**2C51.Y Other specified malignant neoplasms of peritoneum**

**2C51.Z Malignant neoplasms of peritoneum, unspecified**

**2C52**

### **Malignant neoplasms of omentum**

**Exclusions:** Malignant neoplasms of retroperitoneum (2C50)

Malignant neoplasms of peritoneum (2C51)

Malignant mesenchymal neoplasms (2B50-2B5Z)

**Coded Elsewhere:** Myosarcomas of omentum (2B5F.10)

**2C52.0 Cystic, mucinous or serous carcinoma of omentum**

**2C52.Y Other specified malignant neoplasms of omentum**

<b>2C52.Z</b>	<b>Malignant neoplasms of omentum, unspecified</b>
<b>2C53</b>	<b>Malignant neoplasm involving overlapping sites of retroperitoneum, peritoneum or omentum</b>
	<b><i>Inclusions:</i></b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C53.0</b>	<b>Adenocarcinoma involving overlapping sites of retroperitoneum, peritoneum or omentum</b>
<b>2C53.1</b>	<b>Mesothelioma involving overlapping sites of retroperitoneum, peritoneum or omentum</b>
<b>2C53.Y</b>	<b>Other specified malignant neoplasm involving overlapping sites of retroperitoneum, peritoneum or omentum</b>
<b>2C53.Z</b>	<b>Malignant neoplasm involving overlapping sites of retroperitoneum, peritoneum or omentum, unspecified</b>
<b>2C5Y</b>	<b>Other specified malignant neoplasms of retroperitoneum, peritoneum or omentum</b>
<b>2C5Z</b>	<b>Malignant neoplasms of retroperitoneum, peritoneum or omentum, unspecified</b>

### **Malignant neoplasms of breast (2C60-2C6Z)**

The category refers to primary malignant neoplasms of parenchyma, connective, and soft tissue of the breast, including nipple and areola.

<b><i>Inclusions:</i></b>	malignant neoplasm of connective tissue of breast
<b><i>Exclusions:</i></b>	Malignant neoplasm of skin of breast (2C30-2C3Z) Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C60</b>	<b>Carcinoma of breast, specialised type</b>
<b>2C61</b>	<b>Invasive carcinoma of breast</b>
<b>2C61.0</b>	<b>Invasive ductal carcinoma of breast</b>
<b>2C61.1</b>	<b>Invasive lobular carcinoma of breast</b> An infiltrating lobular adenocarcinoma. The malignant cells lack cohesion and are arranged individually or in a linear manner (Indian files), or as narrow trabeculae within the stroma. The malignant cells are usually smaller than those of ductal carcinoma, are less pleomorphic, and have fewer mitotic figures.
<b>2C61.2</b>	<b>Invasive pleomorphic lobular carcinoma of breast</b> A grade II invasive lobular carcinoma of the breast, characterised by the presence of neoplastic cells with large and atypical nuclei.
<b>2C61.3</b>	<b>Invasive carcinoma of breast with mixed ductal and lobular features</b> An invasive ductal breast carcinoma associated with a lobular carcinomatous component. The lobular carcinomatous component may be in situ or invasive.

- 2C61.4 Invasive carcinoma of breast, unidentifiable type**  
A carcinoma that infiltrates the breast parenchyma and where the histopathological type could not be identified.
- 2C62 Inflammatory carcinoma of breast**  
An advanced, invasive breast adenocarcinoma characterised by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma.
- 2C63 Malignant phyllodes tumour of breast**  
A phyllodes tumour of the breast characterised by infiltrative margins and a sarcomatous stromal component. The sarcomatous stroma usually displays features of fibrosarcoma. Liposarcomatous, osteosarcomatous, or rhabdomyosarcomatous elements may also be present.
- 2C64 Solid papillary carcinoma of breast with evidence of invasion**
- 2C65 Hereditary breast and ovarian cancer syndrome**
- 2C6Y Other specified malignant neoplasms of breast**
- 2C6Z Malignant neoplasms of breast, unspecified**

## Malignant neoplasms of female genital organs (2C70-2C7Z)

A primary or metastatic malignant neoplasm involving the female reproductive system. Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumour, and gestational choriocarcinoma.

**Coding Note:** Includes Malignant neoplasm of skin of female genital organs

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C70**

### **Malignant neoplasms of vulva**

Squamous cell carcinoma of the vulva occurs predominantly in the older age group. Although the incidence rate of vulvar intraepithelial neoplasia is increasing, that of squamous cell carcinoma of the vulva is declining, reflecting earlier detection and more successful treatment. In addition to human papillomavirus infection, cigarette smoking is a putative risk factor for vulvar squamous cell carcinoma. There are three known precursor lesions: vulvar intraepithelial neoplasia, lichen sclerosus and chronic granulomatous disease. Other important epithelial malignancies of the vulva are Paget disease and Bartholin gland carcinoma. They are much less common than squamous lesions, and the risk factors are largely unknown. Prominent non-epithelial tumours are malignant melanoma and sarcoma botryoides.

**Coding Note:** Includes skin of vulva.

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C70.0**

### **Basal cell carcinoma of vulva**

A slow growing, locally infiltrating carcinoma that arises from the vulva. It is characterised by the presence of malignant cells that resemble the basal cells that are present in the epidermis.

**2C70.1**

### **Melanoma of vulva**

**2C70.2**

### **Squamous cell carcinoma of vulva**

An invasive squamous cell carcinoma arising from the vulva. Risk factors include the human papilloma virus and cigarette smoking. Precursor lesions include the vulvar intraepithelial neoplasia, lichen sclerosus with associated squamous cell hyperplasia, and chronic granulomatous vulvar disease such as granuloma inguinale. Symptoms include vulvar pruritus or irritation, discharge, bleeding, and pain. The following morphologic variants have been identified: keratinizing, non-keratinizing, basaloid, warty, verrucous, keratoacanthoma-like, and squamous cell carcinoma with tumour giant cells. Risk factors for recurrence include advanced stage, tumour diameter greater than 2.5 cm, multifocality, capillary-like space involvement, associated vulvar intraepithelial neoplasia grades 2 or 3, and margins of resection involved by tumour.

**Coded Elsewhere:** Verrucous squamous cell carcinoma of vulva (2C31.0)

**2C70.Y**

### **Other specified malignant neoplasms of vulva**

**Coding Note:** Includes skin of vulva.

**2C70.Z**

### **Malignant neoplasms of vulva, unspecified**

**Coding Note:** Includes skin of vulva.

**2C71****Malignant neoplasms of vagina**

A primary or metastatic malignant tumour involving the vagina. Representative examples include carcinomas and sarcomas.

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C71.0****Adenocarcinoma of vagina**

An adenocarcinoma arising from the vagina. Morphologic variants include the clear cell, endometrioid, mesonephric, and mucinous adenocarcinoma.

**2C71.1****Melanoma of vagina**

A primary malignant neoplasm of the vagina composed of malignant melanocytes.

**2C71.2****Squamous cell carcinoma of vagina**

A squamous cell carcinoma arising from the vagina. Human papillomavirus infection is associated with the development of vaginal intraepithelial neoplasia and invasive squamous cell carcinoma. Signs and symptoms include painless bleeding, postcoital bleeding, and urinary tract symptoms. Morphologically it resembles squamous cell carcinomas in other anatomic sites.

**2C71.Y****Other specified malignant neoplasms of vagina****2C71.Z****Malignant neoplasms of vagina, unspecified****2C72****Malignant neoplasms of uterine ligament, parametrium, or uterine adnexa**

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**2C72.0****Adenocarcinoma of uterine ligament, parametrium, or uterine adnexa****2C72.1****Mucinous or serous carcinoma of uterine ligament, parametrium, or uterine adnexa****2C72.3****Carcinosarcomas of uterine ligament, parametrium, or uterine adnexa****2C72.Y****Other specified malignant neoplasms of uterine ligament, parametrium, and uterine adnexa****2C72.Z****Malignant neoplasms of uterine ligament, parametrium, or uterine adnexa, unspecified****2C73****Malignant neoplasms of ovary**

A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumours. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**Coded Elsewhere:** Hereditary breast and ovarian cancer syndrome (2C65)

**2C73.0****Carcinomas of ovary**

- 2C73.00** Clear cell adenocarcinoma of ovary  
A malignant glandular epithelial tumour characterised by the presence of clear and hobnail cells. The tumour is highly associated with ovarian endometriosis, pelvic endometriosis and paraendocrine hypercalcemia.
- 2C73.01** Endometrioid adenocarcinoma of ovary  
An endometrioid adenocarcinoma arising from the ovary. It comprises 10% to 25% of all primary ovarian carcinomas. Grossly, endometrioid carcinoma may present as a cystic or solid mass. Microscopically, the tumour greatly resembles the appearance of the ordinary type of endometrial adenocarcinoma. As a group, endometrioid carcinoma has a prognosis twice as good as that of serous or mucinous carcinoma.
- 2C73.02** Low grade serous adenocarcinoma of ovary  
A slow-growing serous adenocarcinoma that arises from the ovary. It usually originates from borderline neoplastic processes or adenofibromas. It is characterised by the presence of low grade cytologic features and infrequent mitotic figures.
- 2C73.03** High grade serous adenocarcinoma of ovary
- 2C73.04** Mucinous adenocarcinoma of ovary  
An invasive adenocarcinoma that arises from the ovary and is characterised by the presence of malignant epithelial cells that contain intracytoplasmic mucin. There is cellular atypia, increased layering of cells, complexity of glands, and papillary formations.
- 2C73.0Y** Other specified carcinomas of ovary
- 2C73.0Z** Carcinomas of ovary, unspecified
- 2C73.1** **Dysgerminoma of ovary**  
A malignant germ cell tumour arising from the ovary. Morphologically, it is identical to seminoma and consists of a monotonous population of germ cells with abundant pale cytoplasm and uniform nuclei. The stroma invariably contains chronic inflammatory cells, mostly T-lymphocytes. It responds to chemotherapy or radiotherapy and the prognosis relates to the tumour stage.  
**Inclusions:** Malignant dysgerminomatous germ cell tumour of ovary
- 2C73.2** **Granulosa cell malignant tumour of ovary**  
An aggressive granulosa cell tumour that arises from the ovary and metastasizes to other anatomic sites.

- 2C73.3 Malignant teratoma of ovary**  
A malignant germ cell tumour arising from the ovary. It usually affects females in their first two decades of life. It contains variable amounts of immature embryonal tissues. Based on the amount of immature neuroepithelial component, immature teratomas are graded from 1 to 3. The stage and grade of the tumour and the grade of the metastatic tumour are the important factors that predict prognosis. The use of cisplatin-based combination chemotherapy has significantly improved the survival rates of the patients.
- Coded Elsewhere:** Struma ovarii (5A02.Y)
- 2C73.4 Serous cystadenoma, borderline malignancy of ovary**
- 2C73.5 Endodermal sinus tumour, unspecified site, female**
- 2C73.Y Other specified malignant neoplasms of the ovary**
- 2C73.Z Malignant neoplasms of ovary, unspecified**
- 2C74 Malignant neoplasms of fallopian tube**  
Tumours of the fallopian tube are much less common than the corresponding ovarian neoplasms; however, histologically the same surface epithelial-stromal tumour subtypes are recognised. Sex cord-stromal and germ cell tumours are rare. Hydatidiform moles and gestational choriocarcinoma are uncommon complications of tubal ectopic pregnancy. The wolffian adnexal tumour is also infrequent and typically occurs in the leaves of the broad ligament. The risk factors appear similar to those of the ovary. Fallopian tube carcinomas are a component of the hereditary breast-ovarian cancer syndrome caused by BRCA1 and BRCA2 germline mutations.
- Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)
- 2C74.0 Adenocarcinoma of fallopian tube**  
An adenocarcinoma that arises from the fallopian tube. Histologic subtypes include clear cell, endometrioid, serous, and mucinous adenocarcinoma. It spreads to adjacent organs, regional lymph nodes, and peritoneum.
- 2C74.Y Other specified malignant neoplasms of fallopian tube**
- 2C74.Z Malignant neoplasms of fallopian tube, unspecified**
- 2C75 Malignant neoplasms of placenta**  
**Exclusions:** hydatidiform mole, NOS (JA02)  
Malignant mesenchymal neoplasms (2B50-2B5Z)
- 2C75.0 Malignant trophoblastic neoplasms of placenta**  
A diverse group of pregnancy-related tumours characterised by excessive proliferation of trophoblasts. Representative examples include hydatidiform mole, gestational choriocarcinoma, and placental site trophoblastic tumour.
- 2C75.Y Other specified malignant neoplasms of placenta**
- 2C75.Z Malignant neoplasms of placenta, unspecified**

**2C76****Malignant neoplasms of corpus uteri**

A malignant neoplasm that affects the uterine corpus. Representative examples include endometrial carcinoma, carcinosarcoma, leiomyosarcoma, and adenosarcoma.

**Exclusions:** Endometrial stromal sarcoma, primary site (2B5C)

**2C76.0****Endometrial endometrioid adenocarcinoma****2C76.1****Endometrial mucinous adenocarcinoma****2C76.2****Endometrial clear cell adenocarcinoma****2C76.3****Endometrial serous adenocarcinoma****2C76.4****Endometrial mixed adenocarcinoma****2C76.40**

Endometrial squamous cell carcinoma

**2C76.41**

Endometrial small cell carcinoma

**2C76.42**

Endometrial undifferentiated carcinoma

**2C76.43**

Carcinosarcoma of uterus

**2C76.4Z**

Endometrial mixed adenocarcinoma, unspecified

**2C76.Y****Other specified malignant neoplasms of corpus uteri****2C76.Z****Malignant neoplasms of corpus uteri, unspecified****2C77****Malignant neoplasms of cervix uteri**

Primary or metastatic malignant neoplasm involving the cervix.

**2C77.0****Squamous cell carcinoma of cervix uteri**

A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. The following histologic patterns have been described: Conventional squamous cell carcinoma, papillary squamous cell carcinoma, transitional cell carcinoma, lymphoepithelioma-like carcinoma, verrucous carcinoma, condylomatous carcinoma and spindle cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis.

**2C77.1****Adenocarcinoma of cervix uteri**

An adenocarcinoma arising from the cervical epithelium. It accounts for approximately 15% of invasive cervical carcinomas. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors. Grossly, advanced cervical adenocarcinoma may present as an exophytic mass, an ulcerated lesion, or diffuse cervical enlargement. Microscopically, the majority of cervical adenocarcinomas are of the endocervical (mucinous) type.

**2C77.2****Adenosquamous carcinoma of cervix uteri****2C77.3****Neuroendocrine carcinoma of cervix uteri**

<b>2C77.Y</b>	<b>Other specified malignant neoplasms of cervix uteri</b>
<b>2C77.Z</b>	<b>Malignant neoplasms of cervix uteri, unspecified</b>
<b>2C78</b>	<b>Malignant neoplasms of uterus, part not specified</b>
<b>2C79</b>	<b>Malignant neoplasm involving overlapping sites of female genital organs</b>
	<b>Inclusions:</b> Malignant neoplasm of female genital organs whose point of origin cannot be classified to any other existing entity
<b>2C7Y</b>	<b>Other specified malignant neoplasms of female genital organs</b>
<b>Coding Note:</b>	Includes Malignant neoplasm of skin of female genital organs
<b>2C7Z</b>	<b>Malignant neoplasms of female genital organs, unspecified</b>
<b>Coding Note:</b>	Includes Malignant neoplasm of skin of female genital organs

### Malignant neoplasms of male genital organs (2C80-2C8Z)

A primary or metastatic malignant neoplasm involving the male reproductive system. Representative examples include prostate carcinoma, penile carcinoma, testicular seminoma, and testicular embryonal carcinoma.

<b>2C80</b>	<b>Malignant neoplasms of testis</b>
	A primary or metastatic malignant neoplasm that affects the testis. Representative examples include seminoma, embryonal carcinoma, sarcoma, leukaemia, and lymphoma.
	<b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C80.2</b>	<b>Germ cell tumour of testis</b>
	A germ cell tumour arising from the testis. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumour.
<b>2C80.Y</b>	<b>Other specified malignant neoplasms of testis</b>
<b>2C80.Z</b>	<b>Malignant neoplasms of testis, unspecified</b>
<b>2C81</b>	<b>Malignant neoplasms of penis</b>
	A primary or metastatic malignant neoplasm that affects the penis. Representative examples include penile carcinoma and penile sarcoma.
	<b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
	<b>Coded Elsewhere:</b> Verrucous squamous cell carcinoma of penis (2C31.0)

- 2C81.0** **Squamous cell carcinoma of penis**  
A squamous cell carcinoma arising from the penis. It occurs chiefly in the squamous epithelium of the glans, coronal sulcus, and foreskin. Etiologic factors include phimosis, lichen sclerosus, smoking, ultraviolet irradiation, history of warts or condylomas, and lack of circumcision. Human papilloma virus is present in a subset of penile squamous cell carcinomas. Patients may present with an exophytic or flat ulcerative mass in the glans or a large primary tumour with inguinal nodal and skin metastases. Morphologic variants include the basaloid carcinoma, warty (condylomatous) carcinoma, verrucous carcinoma, and sarcomatoid (spindle cell) carcinoma.
- Coded Elsewhere:** Verrucous squamous cell carcinoma of penis (2C31.0)
- 2C81.1** **Melanoma of penis**
- Inclusions:** Melanoma of skin of penis  
Melanoma of mucocutaneous epithelium of penis
- 2C81.Y** **Other specified malignant neoplasm of penis**
- 2C81.Z** **Malignant neoplasms of penis, unspecified**
- 2C82** **Malignant neoplasms of prostate**  
Prostate cancer contributes significantly to the overall cancer burden, being the most frequent malignant neoplasia in men. The number of cases has continuously increased over the past decades, partly due to the higher life expectancy. An additional factor is the Western lifestyle, characterised by a highly caloric diet and lack of physical exercise. Epidemiological data indicates that black people are most susceptible, followed by white people, while Asian people have the lowest risk. The extent to which prostate cancer mortality can be reduced by PSA screening is currently being evaluated. Histopathological diagnosis and grading play a major role in the management of prostate cancer.
- Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)
- 2C82.0** **Adenocarcinoma of prostate**  
An adenocarcinoma arising from the prostate gland. It is one of the most common malignant tumours afflicting men. The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland. Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival. Several grading systems have been proposed, of which the Gleason system is the most commonly used. Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma.
- 2C82.Y** **Other specified malignant neoplasms of prostate**
- 2C82.Z** **Malignant neoplasms of prostate, unspecified**
- 2C83** **Malignant neoplasms of scrotum**
- Inclusions:** malignant neoplasm of skin of scrotum
- Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

<b>2C83.0</b>	<b>Squamous cell carcinoma of scrotum</b>
<b>2C83.Y</b>	<b>Other specified malignant neoplasms of scrotum</b>
<b>2C83.Z</b>	<b>Malignant neoplasms of scrotum, unspecified</b>
<b>2C84</b>	<b>Malignant neoplasms of other specified male genital organs</b>
	<b><i>Exclusions:</i></b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C8Z</b>	<b>Malignant neoplasms of male genital organs, unspecified</b>

**Coding Note:** Includes malignant neoplasm of skin of male genital organs

### Malignant neoplasms of urinary tract (2C90-2C9Z)

A primary or metastatic malignant tumour involving the urinary system. Common tumour types include carcinomas, lymphomas, and sarcomas.

***Exclusions:*** Malignant mesenchymal neoplasms (2B50-2B5Z)

#### **2C90 Malignant neoplasms of kidney, except renal pelvis**

Cancer of the kidney amounts to 2% of the total human cancer burden, with approximately 190,000 new cases diagnosed each year. They occur in all world regions, with a preference for developed countries. Etiological factors include environmental carcinogens (tobacco smoking) and lifestyle factors, in particular obesity. Although renal tumours can be completely removed surgically, haematogeneous metastasis is frequent and may occur already at an early stage of the disease. The pattern of somatic mutations in kidney tumours has been extensively investigated and has become, in addition to histopathology, a major criterion for classification. Kidney tumours also occur in the setting of several inherited cancer syndromes, including von Hippel-Lindau disease.

***Exclusions:*** Malignant neoplasm of renal calyces (2C91)

Malignant neoplasms of renal pelvis (2C91)

Malignant mesenchymal neoplasms (2B50-2B5Z)

#### **2C90.0 Renal cell carcinoma of kidney, except renal pelvis**

A carcinoma arising from the renal parenchyma. The incidence of renal cell carcinoma has increased by 35% from 1973 to 1991. There is a strong correlation between cigarette smoking and the development of renal cell carcinoma. The clinical presentation includes: haematuria, flank pain and a palpable lumbar mass. A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes. Diagnostic procedures include: ultrasound, intravenous pyelography and computed tomography (CT).

#### **2C90.Y Other specified malignant neoplasms of kidney, except renal pelvis**

#### **2C90.Z Malignant neoplasms of kidney, except renal pelvis, unspecified**

<b>2C91</b>	<b>Malignant neoplasms of renal pelvis</b> Abnormal malignant growth of the cells within the renal pelvis.  <b>Inclusions:</b> malignant neoplasm of pelviureteric junction malignant neoplasm of renal calyces  <b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C91.0</b>	<b>Urothelial carcinoma of renal pelvis</b>
<b>2C91.Y</b>	<b>Other specified malignant neoplasms of renal pelvis</b>
<b>2C91.Z</b>	<b>Malignant neoplasms of renal pelvis, unspecified</b>
<b>2C92</b>	<b>Malignant neoplasms of ureter</b> A primary or metastatic malignant tumour involving the ureter. The majority are carcinomas.  <b>Exclusions:</b> malignant neoplasm of ureteric orifice of bladder (2C94) Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C92.0</b>	<b>Urothelial carcinoma of ureter</b>
<b>2C92.Y</b>	<b>Other specified malignant neoplasms of ureter</b>
<b>2C92.Z</b>	<b>Malignant neoplasms of ureter, unspecified</b>
<b>2C93</b>	<b>Malignant neoplasms of urethra or paraurethral gland</b>  <b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C93.0</b>	<b>Adenocarcinoma of urethra or paraurethral gland</b>
<b>2C93.1</b>	<b>Squamous cell carcinoma of urethra or paraurethral gland</b>
<b>2C93.2</b>	<b>Urothelial carcinoma of urethra or paraurethral gland</b>
<b>2C93.Y</b>	<b>Other specified malignant neoplasms of urethra and paraurethral gland</b>
<b>2C93.Z</b>	<b>Malignant neoplasms of urethra or paraurethral gland, unspecified</b>
<b>2C94</b>	<b>Malignant neoplasms of bladder</b> A primary or metastatic malignant neoplasm involving the bladder.  <b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C94.0</b>	<b>Adenocarcinoma of urinary bladder</b> A rare adenocarcinoma arising from metaplastic bladder epithelium. It is frequently associated with long-standing local irritation. The majority of cases originate from the trigone and the posterior wall of the bladder.

<b>2C94.1</b>	<b>Squamous cell carcinoma of urinary bladder</b> A squamous cell carcinoma of the bladder arising from metaplastic epithelium. It represents less than 10% of bladder carcinomas. The exception is the Middle East along the Nile Valley, where it represents the most common form of carcinoma because of the endemic nature of schistosomiasis. Bladder squamous cell carcinoma is often associated with long-standing chronic inflammation of the bladder and usually has a poor prognosis. The diagnosis of squamous cell carcinoma of the bladder should be reserved for those tumours that are predominantly keratin forming.
<b>2C94.2</b>	<b>Urothelial carcinoma of bladder</b>
<b>2C94.Y</b>	<b>Other specified malignant neoplasms of bladder</b>
<b>2C94.Z</b>	<b>Malignant neoplasms of bladder, unspecified</b>
<b>2C95</b>	<b>Malignant neoplasm involving overlapping sites of urinary organs</b> Malignant neoplasm of urinary organs whose point of origin cannot be classified to any other existing category  <b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2C95.0</b>	<b>Adenocarcinoma involving overlapping sites of urinary organs</b>
<b>2C95.1</b>	<b>Squamous cell carcinomas involving overlapping sites of urinary organs</b>
<b>2C95.2</b>	<b>Urothelial carcinoma involving overlapping sites of urinary organs</b>
<b>2C95.Y</b>	<b>Other specified malignant neoplasms of overlapping lesion of urinary organs</b>
<b>2C95.Z</b>	<b>Malignant neoplasm involving overlapping sites of urinary organs, unspecified</b>
<b>2C9Y</b>	<b>Other specified malignant neoplasms of urinary tract</b>
<b>2C9Z</b>	<b>Malignant neoplasms of urinary tract, unspecified</b>

### Malignant neoplasms of eye or ocular adnexa (2D00-2D0Z)

A malignant neoplasm affecting the structures of the eye.

<b>Exclusions:</b>	Malignant neoplasm of optic nerve (2A02) Malignant neoplasm of skin of eyelid (2C30-2C3Z) Malignant mesenchymal neoplasms (2B50-2B5Z)
--------------------	---

**Coded Elsewhere:** Melanoma of uvea (2D0Y)

<b>2D00</b>	<b>Malignant neoplasm of conjunctiva</b> A malignant growth of cells within the conjunctiva of the eye.  <b>Exclusions:</b> Malignant mesenchymal neoplasms (2B50-2B5Z)
-------------	--

- 2D00.0** **Melanoma of conjunctiva**  
A malignant melanoma within the conjunctiva of the eye.
- 2D00.1** **Malignant neoplasm of caruncle**  
This is a broad group of diseases involving unregulated cell growth of a small, red portion of the corner of the eye that contains modified sebaceous and sweat glands.
- 2D00.2** **Squamous cell carcinoma of conjunctiva**
- 2D00.Y** **Other specified malignant neoplasm of conjunctiva**
- 2D00.Z** **Malignant neoplasm of conjunctiva, unspecified**
- 2D01** **Malignant neoplasm of cornea**  
A malignant growth of cells within the cornea of the eye.  
**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)
- 2D01.0** **Melanoma of cornea**  
A melanoma within the cornea of the eye.
- 2D01.1** **Squamous cell carcinoma of cornea**
- 2D01.Y** **Other specified malignant neoplasms of cornea**
- 2D01.Z** **Malignant neoplasm of cornea, unspecified**
- 2D02** **Malignant neoplasm of retina**  
Abnormal growth of cells comprising the retina with malignant characteristics.  
**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)
- 2D02.0** **Adenocarcinoma of retinal pigment epithelium**  
This is a cancer of an epithelium that originates in glandular tissue. Epithelial tissue includes, but is not limited to, the surface layer of skin, glands, and a variety of other tissue that lines the cavities and organs of the body. This diagnosis is with the pigmented cell layer just outside the neurosensory retina that nourishes retinal visual cells, and is firmly attached to the underlying choroid and overlying retinal visual cells.
- 2D02.1** **Malignant neuroepithelial tumours of retina**
- 2D02.2** **Retinoblastoma**  
Retinoblastoma is the most common intraocular malignancy in children. It is a life threatening condition but is potentially curable. It can be hereditary or non-hereditary, unilateral or bilateral (unilateral retinoblastoma, bilateral retinoblastoma, see these terms).
- 2D02.Y** **Other specified malignant neoplasm of retina**
- 2D02.Z** **Malignant neoplasm of retina, unspecified**

<b>2D03</b>	<b>Malignant neoplasm of lacrimal apparatus</b>
	<b><i>Exclusions:</i></b> Malignant mesenchymal neoplasms (2B50-2B5Z)
<b>2D03.0</b>	<b>Adenocarcinoma of the lacrimal apparatus</b>
<b>2D03.1</b>	<b>Mucoepidermoid carcinoma of lacrimal apparatus</b>
<b>2D03.2</b>	<b>Squamous cell carcinoma of the lacrimal apparatus</b>
<b>2D03.Y</b>	<b>Other specified malignant neoplasm of lacrimal apparatus</b>
<b>2D03.Z</b>	<b>Malignant neoplasm of lacrimal apparatus, unspecified</b>
<b>2D04</b>	<b>Malignant neoplasm of orbit</b>
	A primary or metastatic malignant neoplasm involving the orbit.
	<b><i>Exclusions:</i></b> Benign neoplasm of orbital bone (2E83.0)
	malignant neoplasm of orbital bone (2B50-2B5Z)
<b>2D05</b>	<b>Malignant neoplasm of choroid</b>
<b>2D05.0</b>	<b>Melanoma of choroid</b>
<b>2D05.Y</b>	<b>Other specified malignant neoplasm of choroid</b>
<b>2D05.Z</b>	<b>Malignant neoplasm of choroid, unspecified</b>
<b>2D06</b>	<b>Malignant neoplasm of ciliary body</b>
	<b><i>Inclusions:</i></b> Malignant neoplasm of eyeball
<b>2D06.0</b>	<b>Adenocarcinoma of ciliary epithelium</b>
<b>2D06.1</b>	<b>Malignant medulloepithelioma of ciliary body</b>
<b>2D06.3</b>	<b>Malignant neuroepithelial tumours of ciliary body</b>
<b>2D06.4</b>	<b>Melanoma of ciliary body</b>
<b>2D06.Y</b>	<b>Other specified malignant neoplasm of ciliary body</b>
<b>2D06.Z</b>	<b>Malignant neoplasm of ciliary body, unspecified</b>
<b>2D07</b>	<b>Malignant neoplasm of iris</b>
<b>2D07.0</b>	<b>Adenocarcinoma of iris epithelium</b>
<b>2D07.1</b>	<b>Malignant neuroepithelial tumours of iris</b>
<b>2D07.2</b>	<b>Melanoma of iris</b>
<b>2D07.Y</b>	<b>Other specified malignant neoplasm of iris</b>
<b>2D07.Z</b>	<b>Malignant neoplasm of iris, unspecified</b>
<b>2D0Y</b>	<b>Other specified malignant neoplasms of eye and ocular adnexa</b>

**2D0Z**

**Malignant neoplasms of eye or ocular adnexa, unspecified**

**Malignant neoplasms of endocrine glands (2D10-2D1Z)**

A malignant neoplasm affecting the endocrine glands. Representative examples include thyroid gland carcinoma, parathyroid gland carcinoma, pituitary gland carcinoma, and adrenal cortex carcinoma.

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**2D10**

**Malignant neoplasms of thyroid gland**

A primary or metastatic malignant neoplasm affecting the thyroid gland.

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**Coded Elsewhere:** Thyroid lymphoma (2B33.5)

**2D10.0**

**Follicular carcinoma of thyroid gland**

A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. The nuclear features which characterise the thyroid gland papillary carcinoma are absent. Radiation exposure is a risk factor and it comprises approximately 10% to 15% of thyroid cancers. Clinically, it usually presents as a solitary mass in the thyroid gland. It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels. Diagnostic procedures include: thyroid ultrasound and fine needle biopsy.

**2D10.1**

**Papillary carcinoma of thyroid gland**

A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries. Diagnostic procedures include: thyroid ultrasound, and fine needle biopsy. Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei. The nuclei also display clearing or have a ground glass appearance.

**2D10.2**

**Poorly differentiated carcinoma of thyroid gland**

**2D10.3**

**Undifferentiated carcinoma of thyroid gland**

A primary carcinoma of the thyroid gland composed of undifferentiated cells. The malignant cells demonstrate evidence of epithelial differentiation, either by immunohistochemistry or electron microscopic studies. Microscopically, in the majority of cases there is a mixture of spindle, epithelioid, and giant cells. The vast majority of the patients present with a rapidly enlarging neck mass. The clinical course is invariably aggressive.

**Inclusions:** anaplastic carcinoma of thyroid gland

- 2D10.4 Medullary carcinoma of thyroid gland**  
A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis.
- 2D10.Y Other specified malignant neoplasms of thyroid gland**
- 2D10.Z Malignant neoplasms of thyroid gland, unspecified**
- 2D11 Malignant neoplasms of adrenal gland**  
Tumours arising from the adrenal cortex include adenomas and carcinomas. These are rare neoplasms but may cause a variety of hormonal symptoms, including hyperaldosteronism, Cushing syndrome, and virilisation. A small fraction of adrenocortical tumours are associated with an inherited tumour syndrome, including Li-Fraumeni syndrome and Carney complex.  
Benign and malignant phaeochromocytomas arise in the adrenal medulla and are derived from chromaffin cells of neural crest origin. Phaeochromocytomas may occur in the setting of several hereditary conditions, including multiple endocrine neoplasia types 2a and 2b, von Hippel Lindau disease and neurofibromatosis.  
Extra adrenal paragangliomas arise from chromaffin cells in sympathoadrenal and parasympathetic paraganglia. They occur in many parts of the body and can pose a significant challenge to surgeons and oncologists. Some function as chemoreceptors, others are endocrinologically active. Familial paragangliomas are associated with mutations of the mitochondrial complex II genes.  
**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)
- 2D11.0 Adenocarcinoma of adrenal gland**
- 2D11.1 Malignant phaeochromocytoma of adrenal gland**
- 2D11.2 Neuroblastoma of adrenal gland**  
Neuroblastomas are malignant tumours that form in certain types of the nerve tissue. It most often begins in the adrenal gland. About 1 out of 3 neuroblastomas start in the adrenal glands and about 1 out of 4 begin in sympathetic nerve ganglia in the abdomen. Most of the rest start in sympathetic ganglia near the spine in the chest or neck, or in the pelvis.
- 2D11.Y Other specified malignant neoplasms of adrenal gland**
- 2D11.Z Malignant neoplasms of adrenal gland, unspecified**

**2D12 Malignant neoplasms of other endocrine glands or related structures**

**Exclusions:** Malignant neoplasms of adrenal gland (2D11)

Malignant neoplasms of testis (2C80)

Malignant neoplasms of ovary (2C73)

Malignant neoplasm of pancreas (2C10)

Malignant neoplasms of thyroid gland (2D10)

Malignant neoplasms of thymus (2C27)

Malignant mesenchymal neoplasms (2B50-2B5Z)

**2D12.0 Malignant epithelial neoplasms of other endocrine glands or related structures, unspecified type**

**2D12.1 Adenocarcinoma of other endocrine glands or related structures**

**2D12.Y Other specified malignant neoplasms of other endocrine glands or related structures**

**2D12.Z Malignant neoplasms of other endocrine glands or related structures, unspecified**

**2D1Z Malignant neoplasms of endocrine glands, unspecified**

---

**2D3Y Other specified malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues**

**2D3Z Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues, unspecified**

Malignant neoplasms of ill-defined or unspecified primary sites (2D40-2D4Z)

**Exclusions:** Malignant mesenchymal neoplasms (2B50-2B5Z)

**2D40 Adenocarcinoma of unspecified site**

A common cancer characterised by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.

**2D41 Unspecified carcinoma of unspecified site**

**2D42 Malignant neoplasms of ill-defined sites**

Malignant neoplasms of ill defined sites is used for cases where the documentation refers to a site that includes multiple organ systems and tissue types that should be coded separately.

<b>2D43</b>	<b>Malignant neoplasms of independent, multiple primary sites</b>
<b>Coding Note:</b>	Use additional codes to identify individual neoplasms.
<b>2D44</b>	<b>Malignant neoplasm, primary site unknown, so stated</b>
<b>2D4Y</b>	<b>Other specified malignant neoplasms of unspecified primary sites</b>
<b>2D4Z</b>	<b>Unspecified malignant neoplasms of unspecified sites</b>

Malignant neoplasm metastases (2D50-2E2Z)

Spread of a malignant neoplasm into secondary sites.

<b>2D50</b>	<b>Malignant neoplasm metastasis in brain</b>
	A malignant neoplasm that has spread to the brain from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).
<b>2D51</b>	<b>Malignant neoplasm metastasis in meninges</b>
<b>2D52</b>	<b>Malignant neoplasm metastasis in spinal cord, cranial nerves or remaining parts of central nervous system</b>

Malignant neoplasm metastasis in lymph nodes (2D60-2D6Z)

**Exclusions:** Neoplasms of haematopoietic or lymphoid tissues (2A20-2B3Z)

<b>2D60</b>	<b>Malignant neoplasm metastasis in lymph node of a single region</b>
<b>2D60.0</b>	<b>Malignant neoplasm metastasis in lymph nodes of head, face or neck</b>
<b>2D60.1</b>	<b>Malignant neoplasm metastasis in intrathoracic lymph nodes</b>
<b>2D60.2</b>	<b>Malignant neoplasm metastasis in intra-abdominal lymph nodes</b>
<b>2D60.3</b>	<b>Malignant neoplasm metastasis in axillary lymph nodes</b>
<b>2D60.4</b>	<b>Malignant neoplasm metastasis in inguinal lymph nodes</b>
<b>2D60.5</b>	<b>Malignant neoplasm metastasis in intrapelvic lymph nodes</b>
<b>2D60.Y</b>	<b>Other specified malignant neoplasm metastasis in lymph node of a single region</b>
<b>2D60.Z</b>	<b>Malignant neoplasm metastasis in lymph node of a single region, unspecified</b>
<b>2D61</b>	<b>Malignant neoplasm metastases in lymph nodes of multiple regions</b>
<b>2D6Z</b>	<b>Metastatic malignant neoplasm to unspecified lymph node</b>

## Malignant neoplasm metastasis in thoracic or respiratory organs (2D70-2D7Z)

**2D70**

### **Malignant neoplasm metastasis in lung**

**Exclusions:** Malignant neoplasms of bronchus or lung (2C25)

**2D71**

### **Malignant neoplasm metastasis in mediastinum**

The spread of cancer to the mediastinum from an adjacent or distant anatomic site.

**2D72**

### **Malignant neoplasm metastasis in pleura**

The spread of cancer to the pleura from an adjacent or distant anatomic site.

**2D73**

### **Malignant neoplasm metastasis in upper respiratory tract organs**

**2D7Y**

### **Malignant neoplasm metastasis in other specified thoracic organs**

**2D7Z**

### **Malignant neoplasm metastasis in thoracic or respiratory organs, unspecified**

## Malignant neoplasm metastasis in digestive system (2D80-2D8Z)

**2D80**

### **Malignant neoplasm metastasis in liver or intrahepatic bile duct**

Malignant neoplasms that have metastasized to the liver from extrahepatic primary tumours.

**2D80.0**

### **Malignant neoplasm metastasis in liver**

**2D80.1**

### **Malignant neoplasm metastasis in intrahepatic bile duct**

**2D81**

### **Malignant neoplasm metastasis in pancreas**

A malignant neoplasm that has spread to the pancreas from another anatomic site. Representative examples include metastatic carcinomas from the gastrointestinal tract, metastatic melanomas, and renal cell carcinomas.

**2D82**

### **Malignant neoplasm metastasis in extrahepatic bile ducts**

**2D83**

### **Malignant neoplasm metastasis in ampulla of Vater**

**2D84**

### **Malignant neoplasm metastasis in the small intestine**

The spread of cancer to the small intestine. This may be from a primary intestinal cancer, or from a cancer at a distant site.

**2D85**

### **Malignant neoplasm metastasis in large intestine**

The spread of cancer to the large intestine; this may be from a primary colon or rectal cancer to another location in the large intestine, or from a cancer at a distant site or organ.

**2D86**

### **Malignant neoplasm metastasis in anus**

Malignant tumour that metastasized in the anus and anal canal.

**2D8Y**

### **Malignant neoplasm metastasis in other specified digestive system organ**

**2D8Z**

**Malignant neoplasm metastasis in unspecified digestive system organ**

Malignant neoplasm metastasis in retroperitoneum or peritoneum (2D90-2D91)

**2D90**

**Malignant neoplasm metastasis in retroperitoneum**

**2D91**

**Malignant neoplasm metastasis in peritoneum**

Malignant neoplasm metastasis in other sites (2E00-2E0Y)

**2E00**

**Malignant neoplasm metastasis in kidney or renal pelvis**

The spread of the cancer to the kidney. This may be from a primary kidney cancer involving the opposite kidney, or from a cancer at a distant site.

**2E01**

**Malignant neoplasm metastasis in bladder**

Tumours of the urinary bladder that originate from an extravesical, non-urothelial tract neoplasm

**2E02**

**Malignant neoplasm metastasis in other or unspecified urinary system organs**

**2E03**

**Malignant neoplasm metastasis in bone or bone marrow**

The spread of a malignant neoplasm from a primary site to the skeletal system. The majority of metastatic neoplasms to the bone are carcinomas.

**2E04**

**Malignant neoplasm metastasis in soft tissue**

**2E05**

**Malignant neoplasm metastasis in female reproductive system**

**2E05.0**

**Malignant neoplasm metastasis in ovary**

The spread of the cancer to the ovary. This may be from a primary ovarian cancer involving the opposite ovary, or from a cancer at a distant site.

**2E05.Y**

**Malignant neoplasm metastasis in other female reproductive system organs**

**2E05.Z**

**Malignant neoplasm metastasis in female reproductive system, unspecified**

**2E06**

**Malignant neoplasm metastasis in male genital organs**

**2E07**

**Malignant neoplasm metastasis in adrenal gland**

A malignant tumour that has spread to the adrenal gland from an adjacent or distant anatomic site. The majority of cases are metastatic carcinomas, and less frequently lymphomas. (NCI05)

**2E08**

**Metastatic malignant neoplasm involving skin**

Involvement of the skin by metastatic spread from a known or unknown primary malignant neoplasm. The secondary deposit may result from local migration of malignant cells, or from regional lymphatic or haematogenous spread from more distant sites.

<b>2E09</b>	<b>Malignant neoplasm metastasis in peripheral nervous system</b>
<b>2E0Y</b>	<b>Malignant neoplasm metastasis in other specified sites</b>
<b>2E2Z</b>	<b>Malignant neoplasm metastasis, unspecified</b>

In situ neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues (2E60-2E6Z)

**2E60**      **Carcinoma in situ of oral cavity, oesophagus or stomach**

**Exclusions:**      Melanoma in situ neoplasms (2E63)

**2E60.0**      **Carcinoma in situ of lip, oral cavity or pharynx**

**Exclusions:**      Carcinoma in situ of aryepiglottic fold, laryngeal aspect (2E62.0)

                          Carcinoma in situ of epiglottis nos (2E62.0)

                          Carcinoma in situ of epiglottis, suprathyroid portion (2E62.0)

                          Carcinoma in situ of skin of lip (2E64)

**2E60.1**      **Carcinoma in situ of oesophagus**

Stage 0 includes: For squamous cell carcinoma: Tis (HGD), N0, M0, G1, GX, tumour location: Any. For adenocarcinoma: Tis (HGD), N0, M0, G1, GX. Tis: High-grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated. GX: Grade cannot be assessed-stage grouping as G1. tumour location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumour in the esophagus.

**Coded Elsewhere:** Oesophageal adenocarcinoma in situ (2E60.1)

**2E60.2**      **Carcinoma in situ of stomach**

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ: intraepithelial tumour without invasion of the lamina propria. N0: No regional lymph node metastasis. M0: No distant metastasis.

**2E61**      **Carcinoma in situ of other or unspecified digestive organs**

**Exclusions:**      Melanoma in situ neoplasms (2E63)

**2E61.0**      **Carcinoma in situ of colon**

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ: intraepithelial or invasion of lamina propria. N0: No regional lymph node metastasis. M0: No distant metastasis.

**2E61.1**      **Carcinoma in situ of rectum**

Malignant epithelial tumour of rectum that has not invaded adjacent tissue of the large intestine.

- 2E61.2** **Carcinoma in situ of anal canal**  
Malignant epithelial tumour that has not invaded beyond the epithelium of the anal canal.
- Exclusions:**      Carcinoma in situ of anal margin (2E64.2)  
                      Carcinoma in situ of anal skin (2E64)  
                      Carcinoma in situ of perianal skin (2E64.2)
- 2E61.3** **Carcinoma in situ of gallbladder, biliary tract or ampulla of Vater**  
an early form of cancer without invasion of tumour cells into the surrounding tissue, usually before penetration through the basement membrane.
- 2E61.Y** **Carcinoma in situ of other specified digestive organs**
- 2E61.Z** **Carcinoma in situ of unspecified digestive organs**
- 2E62** **Carcinoma in situ of middle ear or respiratory system**
- Exclusions:**      Melanoma in situ neoplasms (2E63)
- 2E62.0** **Carcinoma in situ of larynx**
- Exclusions:**      Carcinoma in situ of aryepiglottic fold, hypopharyngeal aspect (2E60.0)  
                      Carcinoma in situ of aryepiglottic fold, marginal zone (2E60.0)  
                      Carcinoma in situ of aryepiglottic fold, NOS (2E60.0)
- 2E62.1** **Carcinoma in situ of trachea**
- 2E62.2** **Carcinoma in situ of bronchus or lung**
- 2E62.Y** **Carcinoma in situ of other specified sites of middle ear and respiratory system**
- 2E62.Z** **Carcinoma in situ of unspecified sites of middle ear and respiratory system**
- 2E63** **Melanoma in situ neoplasms**  
Stage 0 includes: Tis, N0, M0. Tis: Melanoma in situ. N0: No regional lymph node metastases. M0: No detectable evidence of distant metastases.
- 2E63.0** **Melanoma in situ of skin**  
Malignant melanoma confined to the epidermis and described as being in radial growth phase.
- 2E63.00** **Lentigo maligna**  
An atypical proliferation of atypical melanocytes in the dermal-epidermal junction, without infiltration of the papillary or reticular dermis. The melanocytic proliferation is associated with actinic damage and epidermal atrophy. It usually occurs in the sun-exposed skin of elderly people. It is a form of melanoma in situ and in approximately 5% of cases it progresses to lentigo maligna melanoma.
- 2E63.0Z** **Melanoma in situ of skin, unspecified**
- 2E63.1** **Melanoma in situ of conjunctiva**

<b>2E63.Y</b>	<b>Melanoma in situ neoplasms, other specified site</b>
<b>2E63.Z</b>	<b>Melanoma in situ neoplasms, unspecified site</b>
<b>2E64</b>	<p><b>Carcinoma in situ of skin</b></p> <p>Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis.</p> <p><b>Exclusions:</b> Melanoma in situ neoplasms (2E63)</p> <p><b>Coded Elsewhere:</b> Carcinoma in situ of vulva (2E67.1) Carcinoma in situ of penis (2E67.4)</p>
<b>2E64.0</b>	<p><b>Intraepidermal squamous cell carcinoma</b></p> <p>Malignant squamous neoplasia confined to the epidermis of extragenital skin and known commonly as Bowen disease. It arises most frequently on chronically sun-exposed glabrous skin of the head and neck or lower legs. It typically presents as single or multiple well-demarcated scaly erythematous patches, nodules or plaques which histologically show extensive keratinocytic atypia. It may develop from preexisting actinic keratosis (Actinic intraepidermal squamous cell carcinoma). Although it is most commonly associated with exposure to ultraviolet radiation, other carcinogens such as arsenic and tar may be implicated. Human papilloma virus may represent an additional risk factor in immunosuppressed patients.</p>
<b>2E64.00</b>	<p>Bowen disease of skin</p> <p>Intraepidermal squamous cell carcinoma due to predisposing factors including chronic human papilloma virus infection, arsenic ingestion, ionising radiation and chronic immunosuppression.</p>
<b>2E64.01</b>	<p>Actinic intraepidermal squamous cell carcinoma</p> <p>Intraepidermal squamous cell carcinoma attributable to chronic exposure to ultraviolet radiation and typically developing from a pre-existing actinic keratosis</p>
<b>2E64.0Y</b>	Other specified intraepidermal squamous cell carcinoma
<b>2E64.0Z</b>	Intraepidermal squamous cell carcinoma, unspecified
<b>2E64.1</b>	<p><b>Extramammary Paget disease of skin</b></p> <p>An intraepithelial adenocarcinoma of apocrine gland-bearing skin and mucous membrane. Clinically it presents as sharply demarcated erythematous plaques most commonly affecting the vulva in women and perianal skin in men.</p> <p><b>Coded Elsewhere:</b> Vulvar Paget disease (2E67.11)</p>
<b>2E64.2</b>	<p><b>Carcinoma in situ of anal margin or perianal skin</b></p> <p>Carcinoma in situ of anal margin or perianal skin is most commonly squamous and related to oncogenic HPV strains, HIV infection or both. It may present as warty pigmented patches (Bowenoid papulosis).</p>
<b>2E64.Y</b>	<b>Other specified carcinoma in situ of skin</b>
<b>2E64.Z</b>	<b>Carcinoma in situ of skin, unspecified</b>

<b>2E65</b>	<b>Carcinoma in situ of breast</b>
	<b><i>Exclusions:</i></b> carcinoma in situ of skin of breast (2E64) melanoma in situ of breast (skin) (2E63)
<b>2E65.0</b>	<b>Lobular carcinoma in situ of breast</b>
<b>2E65.1</b>	<b>Lobular carcinoma in situ of breast, pleomorphic subtype</b>
<b>2E65.2</b>	<b>Ductal carcinoma in situ of breast</b>
	<b><i>Exclusions:</i></b> Atypical ductal hyperplasia of breast (2F75)
<b>2E65.3</b>	<b>Ductal carcinoma in situ of breast, comedo subtype</b>
<b>2E65.4</b>	<b>Mixed ductal and lobular carcinoma in situ of breast</b> The co-existence of ductal and lobular carcinoma in situ in the breast, without evidence of stromal invasion.
<b>2E65.5</b>	<b>Paget disease of nipple</b> Paget disease of the nipple describes a rare presentation of breast cancer, seen most frequently in women aged 50-60, manifesting with nipple drainage and itching, erythema, crusty, excoriated nipple, thickened plaques and hyperpigmentation (less frequently). It is due to tumour cells invading the nipple-areola complex and represents 1%-3% of all new breast cancer diagnoses.
<b>2E65.Y</b>	<b>Other specified carcinoma in situ of breast</b>
<b>2E65.Z</b>	<b>Carcinoma in situ of breast, unspecified</b>
<b>2E66</b>	<b>Carcinoma in situ of cervix uteri</b>
	<b><i>Exclusions:</i></b> melanoma in situ of cervix (2E63) Low grade squamous intraepithelial lesion of cervix uteri (GA15.7)
<b>2E66.2</b>	<b>High grade squamous intraepithelial lesion of cervix uteri</b>
<b>2E66.Y</b>	<b>Other specified carcinoma in situ of cervix uteri</b>
<b>2E66.Z</b>	<b>Carcinoma in situ of cervix uteri, unspecified</b>
<b>2E67</b>	<b>Carcinoma in situ of other or unspecified genital organs</b>
	<b><i>Exclusions:</i></b> Melanoma in situ neoplasms (2E63)
<b>2E67.0</b>	<b>Carcinoma in situ of endometrium</b>
<b>2E67.1</b>	<b>Carcinoma in situ of vulva</b>
	<b><i>Exclusions:</i></b> Low grade squamous intraepithelial lesion of vulva (GA13.1)

- 2E67.11** Vulvar Paget disease  
 An uncommon intraepithelial malignant neoplasm of eccrine or apocrine origin, arising from the vulva. It usually affects post-menopausal women. In approximately 10-20% of the cases there is an associated anorectal, or urothelial carcinoma or a skin appendage adenocarcinoma identified. It presents as a red, eczematous lesion. Microscopically, it is characterised by the presence of the typical Paget cells which are large, round cells with abundant cytoplasm and prominent nuclei.
- 2E67.12** Vulvar intraepithelial neoplasia, HPV-independent  
 Vulvar intraepithelial neoplasia (VIN), HPV-independent, is a non-invasive precursor of HPV-independent squamous cell carcinoma of the vulva, characterized by atypia of the basal and parabasal keratinocytes in an otherwise well-differentiated epithelium.
- Exclusions:** Low grade squamous intraepithelial lesion of vulva (GA13.1)
- 2E67.13** High grade squamous intraepithelial lesion of vulva, HPV-associated  
 Squamous intraepithelial lesions (SILs) of the vulva (also known as vulvar intraepithelial neoplasia [VIN]), HPV-associated, are proliferations of squamous cells driven by HPV infection, showing maturation abnormalities and nuclear hyperchromasia that do not extend beyond the basement membrane.
- Coded Elsewhere:** Bowenoid papulosis of the vulva (1A95.1)
- 2E67.2** **Carcinoma in situ of vagina**
- 2E67.22** High grade squamous intraepithelial lesion of vagina
- 2E67.2Y** Other specified carcinoma in situ of vagina
- 2E67.2Z** Carcinoma in situ of vagina, unspecified
- 2E67.3** **Carcinoma in situ of other or unspecified female genital organs**
- 2E67.4** **Carcinoma in situ of penis**  
 This comprises both squamous carcinoma in situ and extramammary Paget disease of the penis. The former is an uncommon precancerous disease of penile skin. Lesions usually appear on the glans or inner aspect of the foreskin and are almost always found in uncircumcised men. If left untreated, 10-30% of cases develop into invasive squamous cell carcinoma of the penis. When it affects the skin of the shaft or prepuce it is commonly called Bowen disease. If it affects the glans or inner surface of the prepuce it may also be referred to as penile intraepithelial neoplasia (or in the past as erythroplasia of Queyrat). Extramammary Paget disease of penis is a rare form of carcinoma in situ involving penile skin or glans penis.
- Coded Elsewhere:** Extramammary Paget disease of penis (2E64.1)
- 2E67.40** Squamous cell carcinoma in situ of skin of penis  
 Squamous cell carcinoma affecting the skin of the prepuce or of the shaft of the penis and commonly called Bowen disease. HPV infection and chronic exposure to psoralen photochemotherapy are predisposing factors.
- Inclusions:** Bowen disease of skin of penis

<b>2E67.41</b>	Squamous cell carcinoma in situ of mucocutaneous epithelium of penis
	<b>Inclusions:</b> Penile intraepithelial neoplasia of inner preputial epithelium Penile intraepithelial neoplasia of glans penis
<b>2E67.5</b>	<b>High grade intraepithelial lesion of prostate</b> High grade prostatic intraepithelial neoplasia characterised by the presence of severe architectural and cytologic abnormalities.
	<b>Inclusions:</b> high grade prostatic intraepithelial neoplasia <b>Exclusions:</b> low grade dysplasia of prostate (GA91.6)
<b>2E67.6</b>	<b>Carcinoma in situ of other or unspecified male genital organs</b>
<b>2E68</b>	<b>Carcinoma in situ of bladder</b> Stage 0is includes: Tis, N0, M0. Tis: Carcinoma in situ: flat tumour. N0: No regional lymph node metastasis. M0: No distant metastasis.
<b>2E69</b>	<b>Carcinoma in situ of other or unspecified urinary organs</b>
<b>2E6A</b>	<b>Carcinoma in situ of the eye or ocular adnexa</b>
<b>2E6A.0</b>	<b>Carcinoma in situ of the conjunctiva</b> <b>Exclusions:</b> Melanoma in situ of conjunctiva (2E63.1)
<b>2E6A.1</b>	<b>Carcinoma in situ of the cornea</b>
<b>2E6A.Y</b>	<b>Carcinoma in situ of other and unspecified part of the eye and adnexa</b>
<b>2E6B</b>	<b>Carcinoma in situ of thyroid and other endocrine glands</b> <b>Exclusions:</b> Carcinoma in situ of ovary (2E67.3) Carcinoma in situ of testis (2E67.6)
<b>2E6Y</b>	<b>Carcinoma in situ of other specified site</b>
<b>2E6Z</b>	<b>Carcinoma in situ of unspecified site</b>

Benign neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues (2E80-2F5Z)

A neoplasm which is characterised by the absence of morphologic features associated with malignancy (severe cytologic atypia, tumour cell necrosis, and high mitotic rate). Benign neoplasms remain confined to the original site of growth and only rarely metastasize to other anatomic sites.

Benign mesenchymal neoplasms (2E80-2E8Z)

Benign neoplasms of muscle, fat, fibrous tissue, bone, cartilage, and blood vessels.

<b>2E80</b>	<b>Benign lipomatous neoplasm</b> A benign tumour composed of adipose (fatty) tissue. The most common representative of this category is the lipoma.
-------------	---

<b>2E80.0</b>	<b>Lipoma</b>
<b>2E80.00</b>	<p>Superficial subcutaneous lipoma</p> <p>A benign well-circumscribed mesenchymal neoplasm composed of mature adipocytes and commonly known as a lipoma.</p>
<b>2E80.01</b>	<p>Deep subfascial lipoma</p> <p>Deep subfascial lipomata are benign neoplasms of adipose tissue which arise deep to the deep fascia and have a tendency to infiltrate between and into muscle. They may occur at any body site and may cause diagnostic difficulty. They are well recognised to occur on the forehead beneath the frontalis muscle (frontalis-associated lipoma).</p>
	<p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Frontalis-associated lipoma</li> <li>Infiltrating lipoma of soft tissue</li> <li>Intramuscular lipoma of soft tissue</li> </ul>
<b>2E80.02</b>	Deep internal or visceral lipoma
<b>2E80.0Y</b>	Lipoma, other specified site
<b>2E80.0Z</b>	Lipoma, unspecified site
<b>2E80.1</b>	<b>Lipoblastoma</b>
<b>2E80.Y</b>	<b>Other specified benign lipomatous neoplasm</b>
<b>2E80.Z</b>	<b>Benign lipomatous neoplasm, unspecified</b>
<b>2E81</b>	<b>Benign vascular neoplasms</b>
	<p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Blue naevus (2F20)</li> <li>Pigmented naevus (2F20)</li> </ul>
	<p><b>Coded Elsewhere:</b> Lobular capillary haemangioma (2F26)</p>
<b>2E81.0</b>	<b>Neoplastic haemangioma</b>
	<p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Benign vascular neoplasms of infancy and childhood (2E81.2)</li> <li>Infantile haemangioma (2E81.2)</li> </ul>
	<p><b>Coded Elsewhere:</b> Pulmonary sclerosing haemangioma (2F00.Y)</p>
<b>2E81.00</b>	<p>Umbilical cord haemangioma</p> <p>tumour composed of thin walled blood vessels lined by endothelium present within the cord</p>
<b>2E81.01</b>	Conjunctival haemangioma or haemolymphangioma
<b>2E81.0Y</b>	Neoplastic haemangioma of other specified site
<b>2E81.0Z</b>	Neoplastic haemangioma, unspecified site

- 2E81.1** **Benign lymphatic neoplasms**  
 Benign circumscribed or diffuse neoplasms of lymphatic vessels. They are much less common than lymphatic malformations and are distinguished from the latter by proliferative growth and the potential to become widely disseminated.
- Exclusions:** Lymphatic malformations (LA90.1)
- 2E81.10** Disseminated lymphangiomatosis  
 A rare disorder characterised by widespread proliferation of aberrant lymphatic vessels which typically infiltrate vital organs in the thorax and abdomen.
- 2E81.11** Acquired progressive lymphangioma  
 Acquired progressive lymphangioma is a benign localised but slowly progressive tumour of lymphatic vessels that typically presents as reddish or bruise-like plaques on the abdominal wall, thigh or calf of young adolescents.
- Exclusions:** Lymphatic malformations (LA90.1)
- 2E81.1Y** Other specified benign lymphatic neoplasms
- 2E81.1Z** Benign lymphatic neoplasms, unspecified
- 2E81.2** **Benign vascular neoplasms of infancy and childhood**  
 The commonest benign vascular neoplasm of infancy is infantile haemangioma. Less common neoplasms are congenital haemangioma, spindle cell haemangioma, tufted angioma and kaposiform haemangioendothelioma.
- 2E81.20** Focal infantile haemangioma  
 Infantile haemangioma is a common benign vascular neoplasm which develops in about 4% of infants. It appears within weeks of birth as a blanched, blushed, or telangiectatic area that then rapidly proliferates for several months before entering a prolonged process of involution lasting up to 12 years, leaving a residual variably prominent scar. A solitary focal tumour is seen in about 85% of cases. Over half of cases are located on the head and neck. Complications include bleeding, infection, ulceration and, in tumours situated close to the eye, amblyopia.
- Inclusions:** Strawberry naevus
- 2E81.21** Multifocal infantile haemangioma  
 Infantile haemangioma is multifocal in up to 25% of cases with numbers ranging from a few to many dozens. If more than 5 cutaneous tumours are present there is an increased risk of associated internal haemangiomatosis, especially of the liver.
- 2E81.2Y** Other specified benign vascular neoplasms of infancy and childhood
- 2E81.2Z** Benign vascular neoplasms of infancy and childhood, unspecified
- 2E81.Y** **Other specified benign vascular neoplasms**
- 2E81.Z** **Benign vascular neoplasms, unspecified**
- 2E82** **Benign chondrogenic tumours**
- 2E82.0** **Benign chondrogenic tumours of bone or articular cartilage of limbs**

- 2E82.1** **Benign chondrogenic tumours of bone or articular cartilage of other specified sites**
- 2E82.Z** **Benign chondrogenic tumours, site unspecified**
- 2E83** **Benign osteogenic tumours**  
A neoplasm arising from the bone or articular cartilage that does not invade adjacent tissues or metastasize to other anatomic sites. Representative examples include benign fibrous histiocytoma of bone, osteoma, osteoblastoma, chondroblastoma, and enchondroma.
- 2E83.0** **Benign osteogenic tumours of bone or articular cartilage of skull or face**
- 2E83.1** **Benign osteogenic tumours of bone or articular cartilage of lower jaw**
- 2E83.2** **Benign osteogenic tumours of bone or articular cartilage of vertebral column**  
**Exclusions:** Benign osteogenic tumour of sacrum (2E83.4)
- 2E83.3** **Benign osteogenic tumours of bone or articular cartilage of ribs, sternum or clavicle**
- 2E83.4** **Benign osteogenic tumours of bone or articular cartilage of pelvic bones, sacrum or coccyx**
- 2E83.5** **Benign osteogenic tumours of bone or articular cartilage of limbs**
- 2E83.Y** **Benign osteogenic tumour of other specified site**
- 2E83.Z** **Benign osteogenic tumour of unspecified site**
- 2E84** **Benign fibrogenic or myofibrogenic tumour**
- 2E84.0** **Benign fibrogenic or myofibrogenic tumour of skin**
- 2E84.Y** **Benign fibrogenic or myofibrogenic tumour of other specified sites**
- 2E84.Z** **Benign fibrogenic or myofibrogenic tumour, site unknown**
- 2E85** **Benign fibrohistiocytic tumour**  
**Exclusions:** Benign neoplasm of peripheral nerves or autonomic nervous system (2E90-2F3Z)  
Benign lymphatic neoplasms (2E81.1)  
Benign lipomatous neoplasm (2E80)  
Haemangioma (2E81)  
Benign neoplasm of uterine ligament, any (2F31)  
Benign vascular neoplasms (2E81)  
Leiomyoma of uterus (2E86.0)  
Benign neoplasm of connective tissue of breast (2F30)
- 2E85.0** **Benign fibrohistiocytic tumour of soft tissues of limbs**

- 2E85.1** **Benign fibrohistiocytic tumour of retroperitoneum or peritoneum**
- Exclusions:** Benign lipomatous neoplasm (2E80)  
Benign neoplasm of mesothelial tissue (2F10)
- 2E85.2** **Benign fibrohistiocytic tumour of skin**
- 2E85.Y** **Benign fibrohistiocytic tumour of other specified sites**
- 2E85.Z** **Benign fibrohistiocytic tumour, site unspecified**
- 2E86** **Benign smooth muscle or skeletal muscle tumour**
- 2E86.0** **Leiomyoma of uterus**  
A well-circumscribed benign smooth muscle neoplasm characterised by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.
- Exclusions:** Leiomyoma of ovary (2E86.1)  
Leiomyoma of fallopian tube (2E86.1)  
Leiomyoma of broad ligament (2E86.1)  
Leiomyoma of vagina (2E86.1)  
Leiomyoma of vulva (2E86.1)  
Benign non-mesenchymal neoplasms of uterus (2F31)
- 2E86.1** **Leiomyoma of other or unspecified sites**
- 2E86.2** **Rhabdomyoma**
- 2E86.Y** **Other specified benign smooth muscle or skeletal muscle tumour**
- 2E86.Z** **Benign smooth muscle or skeletal muscle tumour, unspecified**
- 2E87** **Benign gastrointestinal stromal tumour**
- 2E88** **Benign endometrial stromal nodule**
- 2E89** **Benign mesenchymal tumours of uncertain differentiation**
- 2E89.0** **Benign tumours of uncertain differentiation, bone or cartilage**
- 2E89.1** **Benign tumours of uncertain differentiation, soft tissue**
- 2E89.Y** **Benign mesenchymal tumours of uncertain differentiation of other specified site**
- 2E89.Z** **Benign mesenchymal tumours of uncertain differentiation of unspecified site**
- 2E8A** **Other mixed or unspecified benign mesenchymal tumours**
- 2E8Y** **Other specified benign mesenchymal neoplasm**
- 2E8Z** **Benign mesenchymal neoplasms, unspecified**

Benign non-mesenchymal neoplasms (2E90-2F3Z)

- 2E90**      **Benign neoplasm of lip, oral cavity or pharynx**
- 2E90.0**      **Benign neoplasm of lip**  
A neoplasm without malignant characteristics arising from the lip.
- Exclusions:**      Benign neoplasm of skin of lip (2F20-2F2Z)
- 2E90.1**      **Benign neoplasm of tongue**  
Abnormal growth, without malignant characteristics, of the cells that comprise the tongue.
- 2E90.2**      **Benign neoplasm of floor of mouth**
- 2E90.3**      **Benign neoplasm of other or unspecified parts of mouth**  
**Exclusions:**      Benign neoplasm of nasopharyngeal surface of soft palate (2E90.6)  
benign odontogenic neoplasms (2E83.0)  
mucosa of lip (2E90.0)
- 2E90.4**      **Benign neoplasm of tonsil**  
**Exclusions:**      benign neoplasm of pharyngeal tonsil (2E90.6)  
benign neoplasm of lingual tonsil (2E90.1)  
benign neoplasm of tonsillar pillars (2E90.5)  
benign neoplasm of tonsillar fossa (2E90.5)
- 2E90.5**      **Benign neoplasm of oropharynx**  
A neoplasm of the oropharynx which is characterised by the absence of morphologic features associated with malignancy (severe cytologic atypia, tumour cell necrosis, and high mitotic rate). Benign neoplasms remain confined to the original site of growth and only rarely metastasize to other anatomic sites.  
**Exclusions:**      Benign neoplasm of epiglottis, NOS (2F00)  
Benign neoplasm of epiglottis, suprathyroid portion (2F00)
- 2E90.6**      **Benign neoplasm of nasopharynx**  
A neoplasm of the nasopharynx which is characterised by the absence of morphologic features associated with malignancy (severe cytologic atypia, tumour cell necrosis, and high mitotic rate). Benign neoplasms remain confined to the original site of growth and only rarely metastasize to other anatomic sites.
- 2E90.7**      **Benign neoplasm of hypopharynx**
- 2E90.8**      **Benign neoplasm of pharynx, unspecified**
- 2E91**      **Benign neoplasm of major salivary glands**  
**Exclusions:**      Benign neoplasms of minor salivary glands NOS (2E90.3)
- 2E91.0**      **Benign neoplasm of parotid gland**
- 2E91.1**      **Benign neoplasm of other specified major salivary glands**

<b>2E91.Z</b>	<b>Benign neoplasm of unspecified major salivary glands</b>
<b>2E92</b>	<p><b>Benign neoplasm of digestive organs</b></p> <p>A neoplasm of other and/or ill-defined parts of the digestive system which is characterised by the absence of morphologic features associated with malignancy (severe cytologic atypia, tumour cell necrosis, and high mitotic rate). Benign neoplasms remain confined to the original site of growth and only rarely metastasize to other anatomic sites.</p>
<b>2E92.0</b>	<p><b>Benign neoplasm of oesophagus</b></p> <p>A non-metastasizing neoplasm arising from the esophageal wall.</p> <p><b>Coded Elsewhere:</b> Benign mesenchymal tumour of oesophagus (2E8Z)</p>
<b>2E92.1</b>	<p><b>Benign neoplasm of stomach</b></p> <p>A non-metastasizing neoplasm arising from the gastric wall.</p> <p><b>Coded Elsewhere:</b> Benign mesenchymal tumour of stomach (2E8Y)</p>
<b>2E92.2</b>	<p><b>Benign neoplasm of duodenum</b></p> <p>A non-metastasizing neoplasm arising from the wall of the duodenum.</p> <p><b>Coded Elsewhere:</b> Benign mesenchymal tumour of duodenum (2E8Z)</p>
<b>2E92.3</b>	<p><b>Benign neoplasm of other or unspecified parts of small intestine</b></p> <p><b>Exclusions:</b> Benign neoplasm of duodenum (2E92.2)</p> <p><b>Coded Elsewhere:</b> Benign mesenchymal tumour of small intestine (2E8Z)</p>
<b>2E92.4</b>	<p><b>Benign neoplasm of the large intestine</b></p> <p>A non-metastasizing neoplasm arising from the wall of the colon and rectum.</p> <p><b>Coded Elsewhere:</b> Benign mesenchymal tumour of large intestine (2E8Z)</p>
<b>2E92.40</b>	<p>Polyposis syndrome</p> <p>Intestinal polyposis syndromes can be divided, based on histology, into the broad categories of familial adenomatous polyposis (FAP), hamartomatous polyposis syndromes, and other rare polyposis syndromes, such as hereditary-mixed polyposis syndrome (HMPS).</p> <p><b>Coded Elsewhere:</b> Gardner syndrome (LD2D.3)</p> <ul style="list-style-type: none"> <li>Peutz-Jeghers syndrome (LD2D.0)</li> <li>Cronkhite-Canada syndrome (LD27.01)</li> <li>Familial adenomatous polyposis (2B90.Y)</li> <li>Juvenile gastrointestinal polyposis (2B90.Y)</li> </ul>
<b>2E92.4Y</b>	Other specified benign neoplasm of the large intestine
<b>2E92.4Z</b>	Benign neoplasm of the large intestine, unspecified

- 2E92.5 Benign neoplasm of anus or anal canal**  
 Primary benign tumour that forms in tissues lining the anus and anal canal.
- Exclusions:**
- Benign neoplasm of perianal skin (2F20-2F2Z)
  - Benign neoplasm of anal margin (2F20-2F2Z)
  - Benign neoplasm of anal skin (2F20-2F2Z)
- 2E92.6 Benign neoplasm of gallbladder, extrahepatic bile ducts or ampulla of Vater**  
**Coded Elsewhere:** Benign mesenchymal tumour of gallbladder, extrahepatic bile ducts or ampulla of Vater (2E8Z)  
 Adenoma of bile ducts (2E92.6)
- 2E92.7 Benign neoplasm of liver or intrahepatic bile ducts**  
**Coded Elsewhere:** Focal nodular hyperplasia of liver (DB99.Y)  
 Angiomyolipoma of liver (2E80.02)  
 Haemangioma of liver (2E81.0Y)
- 2E92.8 Benign neoplasm of pancreas**  
 A non-metastasizing neoplasm arising from the pancreas.  
**Exclusions:** Benign neoplasm of endocrine pancreas (2E92.9)
- 2E92.9 Benign neoplasm of endocrine pancreas**  
**Inclusions:**
- Islet cell tumour
  - benign neoplasm of islets of Langerhans
- 2E92.Y Benign neoplasm of other specified digestive organs**
- 2E92.Z Benign neoplasm of unspecified digestive organs**
- Benign neoplasm of respiratory or intrathoracic organs (2F00-2F0Z)
- 2F00 Benign neoplasm of middle ear or respiratory system**
- 2F00.0 Middle ear endocrine tumour**
- 2F00.1 Recurrent respiratory papillomatosis**  
 Recurrent respiratory papillomatosis is a rare respiratory disease characterised by the development of exophytic papillomas, affecting the mucosa of the upper aerodigestive tract (with a strong predilection for the larynx), caused by an infection with human papilloma virus. Symptoms at presentation may include hoarseness, chronic cough, dyspnoea, recurrent upper respiratory tract infections, pneumonia, dysphagia, stridor, and/or failure to thrive.
- 2F00.2 Laryngeal endocrine tumour**
- 2F00.Y Other specified benign neoplasm of middle ear or respiratory system**
- 2F00.Z Benign neoplasm of middle ear or respiratory system, unspecified**

<b>2F01</b>	<b>Benign neoplasm of intrathoracic organs</b>
<b>2F0Y</b>	<b>Benign neoplasms of other specified respiratory and intrathoracic organs</b>
<b>2F0Z</b>	<b>Benign neoplasms of unspecified respiratory and intrathoracic organs</b>
<b>2F10</b>	<b>Benign neoplasm of mesothelial tissue</b> A benign neoplasm arising from mesothelial cells. It is characterised by the formation of glandular and tubular patterns. It can occur in several anatomic sites including the pleura, peritoneum, and epididymis.

### Benign cutaneous neoplasms (2F20-2F2Z)

Abnormal growth of the cells that comprise the tissues of the skin, without any evidence of malignancy.

**Coded Elsewhere:** Benign vascular neoplasms of infancy and childhood (2E81.2)

<b>2F20</b>	<b>Benign cutaneous melanocytic neoplasms</b>
	<i>Inclusions:</i>
	Mole
	Pigmented naevus
	Benign melanocytic naevus
<b>2F20.0</b>	<b>Common acquired melanocytic naevus</b>
<b>2F20.00</b>	Multiple benign melanocytic naevi The presence of multiple benign melanocytic naevi (often taken as more than 20 naevi >2mm in diameter), an independent risk factor for the development of melanoma with highest risk associated with highest numbers of naevi (>100).
<b>2F20.0Y</b>	Other specified common acquired melanocytic naevus
<b>2F20.0Z</b>	Common acquired melanocytic naevus, unspecified
<b>2F20.1</b>	<b>Atypical melanocytic naevus</b> Solitary or multiple, slightly raised, pigmented lesions with irregular borders, usually measuring more than 0.6cm in greatest dimension. Morphologically, there is melanocytic atypia and the differential diagnosis from melanoma may be difficult. Patients are at an increased risk for the development of melanoma.
	<i>Inclusions:</i>
	Dysplastic naevus, unspecified
<b>2F20.2</b>	<b>Congenital melanocytic naevus</b> Congenital melanocytic naevi are circumscribed areas of skin pigmentation present at birth as a result of abnormal intrauterine proliferation of melanocytes within the dermis, the epidermis or both. They may range in size from a few millimetres to many centimetres in diameter. If their projected or final adult maximal diameter is greater than 20 cm they are termed giant congenital melanocytic naevi.

- 2F20.20** Giant congenital melanocytic naevus  
A congenital melanocytic naevus (CMN) with a predicted or final adult maximal diameter of 400 mm or more. Giant CMNs are commonly centred on the dorsal surface of the body between the vertex and the buttocks but may occur elsewhere; they may be associated with multiple smaller satellite naevi (congenital or tardive), hypertrichosis, lipomas or benign proliferative nodules. There is a risk of pre-pubertal melanoma within giant CMN or the central nervous system (CNS). Leptomeningeal melanocytosis or focal neuromelanosis, found in 10-15% of cases, is often associated with other CNS tumours, hydrocephalus, epilepsy, arachnoid cysts, or Dandy-Walker malformation.
- 2F20.2Y** Other specified congenital melanocytic naevus
- 2F20.2Z** Congenital melanocytic naevus, unspecified
- 2F20.3** **Generalised eruptive melanocytic naevi**  
This phenomenon describes the rapid simultaneous appearance of multiple melanocytic naevi, often hundreds in number, on previously uninvolved sun-exposed skin. The phenomenon has been linked to immunosuppression, particularly in renal transplant recipients and in individuals receiving cancer chemotherapy, and may be considered a more advanced counterpart of generalised eruptive lentiginosis.
- Inclusions:**
- Multiple benign melanocytic naevi (2F20.00)
  - Generalized eruptive lentiginosis (ED61)
- 2F20.Y** Other specific types of melanocytic naevus
- 2F20.Z** Melanocytic naevus, unspecified
- 2F21** **Benign keratinocytic acanthomas**  
A group of benign discrete epidermal proliferative disorders including seborrhoeic keratosis and clear cell acanthoma.
- 2F21.0** **Seborrhoeic keratosis**  
Seborrhoeic keratoses are very common benign neoplasms of epidermal keratinocytes which increase in prevalence and number with age. They are commonly multiple and are very variable in shape and colour. Because of the sometimes intense pigmentation they are frequently mistaken for melanocytic tumours.
- Inclusions:**
- Basal cell papilloma
  - Seborrheic wart
- 2F21.Y** Other specified benign keratinocytic acanthomas
- 2F22** **Benign neoplasms of epidermal appendages**  
A range of benign neoplasms arising from the hair follicle, its associated glands or from sweat glands.

**2F23**

**Benign dermal fibrous or fibrohistiocytic neoplasms**

Benign dermal neoplasms due to abnormal proliferation of fibroblasts, myofibroblasts or primitive mesenchymal cells.

**2F23.0**

**Dermatofibroma**

A common benign skin tumour which presents as a firm dermal papule or nodule, most commonly on the lower limbs. Histologically it is characterised by coarse, haphazardly arranged collagen bundles and a variable cellular infiltrate including fibrocytes.

**2F23.Y**

**Other specified benign dermal fibrous or fibrohistiocytic neoplasms**

**2F24**

**Benign cutaneous neoplasms of neural or nerve sheath origin**

**2F25**

**Cherry angioma**

*Inclusions:*      Campbell de Morgan spot

Senile angioma

**2F26**

**Lobular capillary haemangioma**

Historically called pyogenic granuloma, this is a common benign proliferation of capillary blood vessels which may be induced by trauma or by certain drugs. It presents as one or more bright red papules or nodules often located around the mouth or on a terminal phalanx in relation to the nail. Bleeding, ulceration and crusting frequently occur. BRAF mutations within vascular endothelial cells may be present, indicating that this is, in at least a proportion of cases, a true neoplastic process.

*Inclusions:*      Lobular capillary haemangioma of skin

**2F2Y**

**Other specified benign cutaneous neoplasms**

**2F2Z**

**Benign cutaneous neoplasm of unspecified type**

**2F30**

**Benign neoplasm of breast**

A non-metastasizing neoplasm arising from the breast parenchyma.

*Exclusions:*      Benign neoplasm of skin of breast (2F20-2F2Z)

Lipoma (2E80.0)

**2F30.0**

**Tubular adenoma of breast**

A benign, well circumscribed neoplasm that arises from the breast. It is composed entirely of tubular structures that contain epithelial and myoepithelial cells.

**2F30.1**

**Lactating adenoma of breast**

A tubular type adenoma of the breast in which, during pregnancy and lactation, the epithelial cells show extensive secretory changes.

- 2F30.2      Intraductal papilloma of breast**  
A benign papillary neoplasm that arises anywhere in the ductal system of the breast. It is characterised by fibrovascular structures lined by benign epithelial and myoepithelial proliferations. Intraductal breast papillomas are classified as central, when they arise in large ducts, or peripheral, when they arise in the terminal ductal lobular units.
- 2F30.3      Benign phyllodes tumour of breast**  
A usually unilateral, benign and well circumscribed biphasic neoplasm that arises from the breast. It usually affects middle-aged women. It is characterised by the presence of a double layer of epithelial cells that are arranged in clefts, surrounded by a cellular, monomorphic spindle cell mesenchymal component. Mitoses are rare. Necrotic changes may be present in large tumours.
- 2F30.4      Fibromatosis of breast**
- 2F30.5      Fibroadenoma of breast**  
A benign tumour of the breast characterised by the presence of stromal and epithelial elements. It presents as a painless, solitary, slow growing, firm, and mobile mass. It is the most common benign breast lesion. It usually occurs in women of childbearing age. The majority of fibroadenomas do not recur after complete excision. A slightly increased risk of developing cancer within fibroadenomas or in the breast tissue of patients previously treated for fibroadenomas has been reported.
- 2F30.6      Extensive adenomatosis of nipple**  
Rare benign nipple condition presenting as pruritus, burning or pain symptoms with clinical signs showing a nipple which appears ulcerated, crusting, scaling, indurated and erythematous. Differential diagnosis are Paget, psoriasis, etc.
- 2F30.Y      Other specified benign neoplasm of breast**
- 2F30.Z      Benign neoplasm of breast, unspecified**
- 2F31      Benign non-mesenchymal neoplasms of uterus**  
Other non-malignant tumours of the uterus not detailed elsewhere.  
**Exclusions:**      Leiomyoma of uterus (2E86.0)
- 2F31.0      Benign non-mesenchymal neoplasm of uterus, cervix uteri**  
**Exclusions:**      Low grade squamous intraepithelial lesion of cervix uteri (GA15.7)
- 2F31.1      Benign non-mesenchymal neoplasm of uterus, corpus uteri**
- 2F31.2      Benign non-mesenchymal neoplasms of uterus, other parts**
- 2F32      Benign neoplasm of ovary**  
A non-metastasizing neoplasm that arises from the ovary. Representative examples include serous cystadenoma, mucinous cystadenoma, clear cell adenofibroma, benign Brenner tumour, thecoma, and fibroma.  
**Coded Elsewhere:** Struma ovarii (5A02.Y)

- 2F32.0 Cystic teratoma**  
A condition of the ovary, caused by abnormal proliferation due to genetic mutations, abnormal growth or division of germ cells. This condition is characterised by a benign ovarian neoplasm, and abdominal pain, mass or swelling, or abnormal uterine bleeding, and may lead to ovarian torsion or cystic rupture. Confirmation is by imaging.
- 2F32.1 Ovarian fibroma**  
A condition of the ovary, caused by abnormal proliferation due to genetic mutations, abnormal growth or division of cells. This condition is characterised by a benign sex chord ovarian tumour. Confirmation is by imaging.
- 2F32.2 Meigs' syndrome**  
Meigs' syndrome is classically defined as the triad of ascites, pleural effusion, and benign ovarian fibroma. A key feature found in patients with Meigs' syndrome is the resolution of symptoms after tumor resection. Meigs' syndrome is a rare condition that can only be diagnosed after ovarian carcinoma is ruled out.
- 2F32.3 Serous ovarian cystadenoma**
- 2F32.Y Other specified benign neoplasm of ovary**
- 2F32.Z Benign neoplasm of ovary, unspecified**
- 2F33 Benign neoplasm of other or unspecified female genital organs**  
A non-metastasizing neoplasm that arises from the female reproductive system. Representative examples include uterine corpus leiomyoma, endocervical polyp, and benign ovarian germ cell tumour.
- 2F34 Benign neoplasm of male genital organs**  
A non-metastasizing neoplasm that arises from the male reproductive system. Representative examples include benign prostate phyllodes tumour, benign Sertoli cell tumour, seminal vesicle cystadenoma, and epididymal adenomatoid tumour.
- 2F35 Benign neoplasm of urinary organs**  
A non-metastasizing neoplasm that arises from the organs that comprise the urinary system. Representative examples include renal oncocytoma, bladder inverted papilloma, and urothelial papilloma.
- 2F36 Benign neoplasm of eye or ocular adnexa**
- Exclusions:** Benign neoplasm of optic nerve (2A02.3)  
Benign neoplasm of skin of eyelid (2F20-2F2Z)
- Coded Elsewhere:** Epibulbar choristoma (LA14.06)  
Seborrhoeic keratosis (2F21.0)
- 2F36.0 Benign neoplasm of choroid**  
Abnormal growth of the cells of the choroid without malignant characteristics.
- Coded Elsewhere:** Haemangioma of choroid (2E81.0Y)

- 2F36.1**      **Benign neoplasm of iris**
- 2F36.2**      **Benign neoplasm of ciliary body**
- 2F36.3**      **Teratoma of orbit**  
This is an encapsulated tumour with tissue or organ components resembling normal derivatives of all three germ layers. This diagnosis is of the cavity or socket of the skull in which the eye and its appendages are situated.
- 2F36.4**      **Cysts of eyelid**  
**Coded Elsewhere:** Epidermoid cyst (EK70.0)
- 2F36.Y**      **Other specified benign neoplasm of eye or ocular adnexa**
- 2F36.Z**      **Benign neoplasm of eye or ocular adnexa, unspecified**
- 2F37**      **Benign neoplasm of endocrine glands**  
**Exclusions:**    Benign neoplasm of endocrine pancreas (2E92.9)  
                      Benign neoplasm of thymus (2F01)  
                      Benign neoplasm of ovary (2F32)  
                      Benign neoplasm of testis (2F34)  
                      Benign neoplasm of hypothalamus (2A00.5)
- 2F37.0**      **Non-secreting pituitary adenoma**
- 2F37.Y**      **Other specified benign neoplasm of endocrine glands**
- 2F37.Z**      **Benign neoplasm of endocrine glands, unspecified**
- 2F3Y**      **Benign non-mesenchymal neoplasms of other specified site**
- 2F3Z**      **Benign non-mesenchymal neoplasms of unspecified site**
- 
- 2F5Y**      **Other specified benign neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues**
- 2F5Z**      **Benign neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues, unspecified**

## **Neoplasms of uncertain behaviour, except of lymphoid, haematopoietic, central nervous system or related tissues (2F70-2F7Z)**

A neoplasm displaying morphologic, phenotypic, or genotypic characteristics that are clearly not benign but do not permit the establishment of a definitive diagnosis of malignancy. Such neoplasms may or may not eventually have a more aggressive clinical course. Representative examples include lymphoproliferations of uncertain malignant potential (e.g., lymphomatoid granulomatosis and lymphomatoid papulosis), borderline ovarian epithelial neoplasms (e.g., borderline ovarian endometrioid tumour and borderline ovarian mucinous tumour), borderline exocrine pancreatic neoplasm (e.g., pancreatic borderline intraductal papillary-mucinous neoplasm), and primary borderline peritoneal epithelial neoplasm.

**Coded Elsewhere:** Pathological fracture in neoplastic disease of uncertain behaviour (FB80.B)

<b>2F70</b>	<b>Neoplasms of uncertain behaviour of oral cavity or digestive organs</b>
2F70.0	<b>Neoplasms of uncertain behaviour of lip, oral cavity or pharynx</b>
2F70.1	<b>Neoplasms of uncertain behaviour of stomach</b>
2F70.2	<b>Neoplasms of uncertain behaviour of small intestine</b>
2F70.3	<b>Neoplasms of uncertain behaviour of colon</b>
2F70.4	<b>Neoplasms of uncertain behaviour of rectum</b>
2F70.5	<b>Neoplasms of uncertain behaviour of liver, gallbladder or bile ducts</b>
2F70.Y	<b>Neoplasms of uncertain behaviour of oral cavity and digestive organs, other specified site</b>
2F70.Z	<b>Neoplasms of uncertain behaviour of oral cavity and digestive organs, unspecified site</b>
<b>2F71</b>	<b>Neoplasms of uncertain behaviour of middle ear, respiratory or intrathoracic organs</b>
2F71.0	<b>Neoplasms of uncertain behaviour of thymus</b>
2F71.1	<b>Neoplasms of uncertain behaviour of larynx</b>
2F71.2	<b>Neoplasms of uncertain behaviour of pleura</b>
2F71.3	<b>Neoplasms of uncertain behaviour of trachea, bronchus or lung</b>
2F71.4	<b>Neoplasms of uncertain behaviour of mediastinum</b>
2F71.Y	<b>Neoplasms of uncertain behaviour of middle ear, respiratory and intrathoracic organs, other specified site</b>
2F71.Z	<b>Neoplasms of uncertain behaviour of middle ear, respiratory and intrathoracic organs, unspecified site</b>
<b>2F72</b>	<b>Neoplasms of uncertain behaviour of skin</b>

2F72.1	<b>Spitzoid tumour of uncertain malignant potential</b> A spindle cell and epithelioid cell melanocytic neoplasm in which there are sufficient features distinguishing it from a benign Spitz naevus to cast doubt on its benign nature. These atypical features include development in adult life, asymmetry, large diameter (>6 and especially >10 mm), significant thickness (particularly subcutaneous extension), lack of "maturation" and nodule formation, cytological atypia and a high mitotic rate.
2F72.2	<b>Melanocytic naevus with severe melanocytic dysplasia</b> Melanocytic naevus with severe melanocytic dysplasia is a histopathological diagnosis based on the presence of severe cytological atypia, defined as enlarged, spindle- and epithelioid-shaped melanocytes with hyperchromatic nuclei (typically at least twice the size of those of basal keratinocytes) and distinct nucleoli. Such naevi tend to be irregular in size and pigmentation and to have been excised because of concern that they may represent early melanoma.
2F72.Y	<b>Other specified neoplasms of uncertain behaviour of skin</b>
2F73	<b>Neoplasms of uncertain behaviour of retroperitoneum</b>
2F74	<b>Neoplasms of uncertain behaviour of peritoneum</b>
2F75	<b>Neoplasms of uncertain behaviour of breast</b>
2F76	<b>Neoplasms of uncertain behaviour of female genital organs</b>
2F77	<b>Neoplasms of uncertain behaviour of male genital organs</b>
2F78	<b>Neoplasms of uncertain behaviour of urinary organs</b>
2F79	<b>Neoplasms of uncertain behaviour of eye or ocular adnexa</b>
2F7A	<b>Neoplasms of uncertain behaviour of endocrine glands</b>
2F7A.0	<b>Multiple polyglandular tumours</b> <i>Coded Elsewhere:</i> Carney complex (5A70.Y) Von Hippel-Lindau disease (5A75)
2F7A.Y	<b>Other specified neoplasms of uncertain behaviour of endocrine glands</b>
2F7A.Z	<b>Neoplasms of uncertain behaviour of endocrine glands, unspecified</b>
2F7B	<b>Neoplasms of uncertain behaviour of bone or articular cartilage</b>
2F7C	<b>Neoplasms of uncertain behaviour of connective or other soft tissue</b>
2F7Y	<b>Neoplasms of uncertain behaviour of other specified site</b>
2F7Z	<b>Neoplasms of uncertain behaviour of unspecified site</b>

**Neoplasms of unknown behaviour, except of lymphoid, haematopoietic, central nervous system or related tissues (2F90-2F9Z)**

**Coded Elsewhere:** Pathological fracture in neoplastic disease of unknown behaviour (FB80.B)

<b>2F90</b>	<b>Neoplasms of unknown behaviour of oral cavity or digestive organs</b>
<b>2F90.0</b>	<b>Neoplasms of unknown behaviour of colon</b>
<b>2F90.1</b>	<b>Neoplasms of unknown behaviour of rectum</b>
<b>2F90.Y</b>	<b>Neoplasms of unknown behaviour of oral cavity and digestive organs, other specified site</b>
<b>2F90.Z</b>	<b>Neoplasms of unknown behaviour of oral cavity and digestive organs, unspecified site</b>
<b>2F91</b>	<b>Neoplasms of unknown behaviour of middle ear, respiratory or intrathoracic organs</b>
<b>2F91.0</b>	<b>Neoplasms of unknown behaviour of larynx</b>
<b>2F91.1</b>	<b>Neoplasms of unknown behaviour of trachea, bronchus or lung</b>
<b>2F91.Y</b>	<b>Neoplasms of unknown behaviour of other specified respiratory organ, intrathoracic organ or middle ear</b>
<b>2F91.Z</b>	<b>Neoplasms of unknown behaviour of unspecified respiratory organ or intrathoracic organ</b>
<b>2F92</b>	<b>Neoplasms of unknown behaviour of skin</b>
<b>2F93</b>	<b>Neoplasms of unknown behaviour of retroperitoneum</b>
<b>2F94</b>	<b>Neoplasms of unknown behaviour of peritoneum</b>
<b>2F95</b>	<b>Neoplasms of unknown behaviour of breast</b>
<b>2F96</b>	<b>Neoplasms of unknown behaviour of female genital organs</b>
<b>2F97</b>	<b>Neoplasms of unknown behaviour of male genital organs</b>
<b>2F98</b>	<b>Neoplasms of unknown behaviour of urinary organs</b>
<b>2F99</b>	<b>Neoplasms of unknown behaviour of eye or ocular adnexa</b>
<b>2F9A</b>	<b>Neoplasms of unknown behaviour of endocrine glands</b>
<b>2F9B</b>	<b>Neoplasms of unknown behaviour of bone or articular cartilage</b>
<b>2F9C</b>	<b>Neoplasms of unknown behaviour of connective or other soft tissue</b>
<b>2F9Y</b>	<b>Neoplasms of unknown behaviour of other specified site</b>
<b>2F9Z</b>	<b>Neoplasms of unknown behaviour of unspecified site</b>

# CHAPTER 03

---

## Diseases of the blood or blood-forming organs

This chapter has 56 four-character categories.

Code range starts with 3A00

This chapter includes diseases of the blood as well as diseases of blood forming organs.

- Exclusions:**
- Complications of pregnancy, childbirth or the puerperium (Chapter 18)
  - Diseases of the immune system (Chapter 04)
  - Certain conditions originating in the perinatal period (Chapter 19)
  - Injury, poisoning or certain other consequences of external causes (Chapter 22)
  - Human immunodeficiency virus disease (1C60-1C62.Z)
  - Endocrine, nutritional or metabolic diseases (Chapter 05)
  - Congenital malformations, deformations or chromosomal abnormalities (Chapter 20)
  - Other diseases of the blood or blood-forming organs or certain disorders involving the immune mechanism complicating pregnancy, childbirth or the puerperium (JB64.1)

**Coded Elsewhere:** Neoplasms of haematopoietic or lymphoid tissues (2A20-2B3Z)

Symptoms, signs or clinical findings of blood, blood-forming organs, or the immune system (MA10-MA3Y)

This chapter contains the following top level blocks:

- Anaemias or other erythrocyte disorders
- Coagulation defects, purpura or other haemorrhagic or related conditions
- Diseases of spleen

## Anaemias or other erythrocyte disorders (3A00-3A9Z)

**Inclusions:** Anaemia, unspecified

**Coded Elsewhere:** Anaemia complicating pregnancy, childbirth or the puerperium (JB64.0)  
Anaemia of prematurity (KA8B)

### Nutritional or metabolic anaemias (3A00-3A03.Y)

**3A00**

#### **Iron deficiency anaemia**

A disease caused by chronic or acute bleeding, excessive menstrual bleeding, inadequate intake, substances (in diet or drugs) interfering with iron absorption, malabsorption syndromes, inflammation, infection or blood donation. This disease is characterised by decreased levels of iron present in the body. This disease may present with fatigue, pallor or dizziness. Confirmation is by identification of decreased levels of iron in a blood sample.

**3A00.0**

#### **Acquired iron deficiency anaemia due to blood loss**

Chronic blood loss is a possible cause in every case of iron-deficiency anaemia. Iron deficiency anaemia may be caused by acute bleeding in gastrointestinal tract, uterus or genitourinary system, copious menstrual blood losses (menorrhagia) and multiple blood donations. In many tropical countries, infestations with hookworms lead to intestinal blood losses that in some individuals can be considerable. Iron deficiency may also be caused by several circumstances related to "chronic posthaemorrhagic anaemia". A diagnosis of iron deficiency should always lead to a search for pathologic causes of blood loss (e.g. tumours in the gastrointestinal tract or uterus, especially if uterine bleedings have increased or changed in regularity).

**Exclusions:** congenital anaemia from fetal blood loss (KA8C)

**3A00.01**

#### Chronic posthaemorrhagic anaemia

Chronic iron-deficiency anaemia from bleeding may be caused by colon cancer, gastric cancer, peptic ulcer, Meckel diverticulum, hiatal hernia with linear erosions, colonic vascular ectasia, colonic polyps, haemangioma, inflammatory bowel disease, tumours in the gastrointestinal tract or uterus, and chronic menorrhagia. Some infants with severe iron deficiency have chronic intestinal blood loss induced by exposure to cow's milk protein. Repeated phlebotomy for blood tests is a cause of anaemia of prematurity.

**3A00.02**

Acquired iron deficiency anaemia due to blood loss, unspecified

**3A00.1**

#### **Acquired iron deficiency anaemia due to low intake**

Iron deficiency is probably the most common nutritional deficiency disorder in the world. Iron deficiency anaemia during pregnancy increases perinatal risks for mothers and neonates; and increases overall infant mortality. Severe anaemia is a major risk factor associated with greatly increased morbidity and mortality for young children and pregnant women. Prompt recognition of the condition, treatment and clinical follow-up of individuals are crucial in avoiding complications such as high-output heart failure. Maternal iron deficiency during pregnancy increases the risk of iron deficiency in the infant. In less developed countries, the prevalence of iron deficiency during pregnancy is higher than in developed countries, and iron supplementation during pregnancy is beneficial.

- 3A00.2**      **Acquired iron deficiency anaemia due to decreased absorption**
- 3A00.3**      **Acquired iron deficiency anaemia due to increased requirement**
- 3A00.Y**      **Other specified iron deficiency anaemia**
- 3A00.Z**      **Iron deficiency anaemia, unspecified**

**3A01**

**Megaloblastic anaemia due to vitamin B12 deficiency**

A disease caused by inadequate dietary intake of vitamin B12, impaired absorption of vitamin B12, surgical removal of the small bowel, coeliac disease or inherited mutations affecting absorption of vitamin B12. This disease is characterised by decreased levels of vitamin B12 in the body presenting with or without anaemia. This disease may present with fatigue, pallor, dizziness, seizures, or symptoms of dementia. Confirmation is by identification of decreased levels of vitamin B12 in a blood sample.

- 3A01.0**      **Hereditary vitamin B12 deficiency anaemia**

This is a hereditary low blood level of vitamin B12. It can cause permanent damage to nervous tissue if left untreated long enough. Vitamin B12 itself was discovered through investigation of pernicious anaemia, which is an autoimmune disease that destroys parietal cells in the stomach that secrete intrinsic factor.

- 3A01.1**      **Neonatal vitamin B12 deficiency anaemia**

A disease caused by a lack of vitamin B12 in the mother, which is passed onto the fetus in the antenatal period or to the neonate during breast feeding. This disease is characterised by decreased levels of vitamin B12. This disease may present with increased risk of birth defects or preterm delivery, anaemia, irritability, failure to thrive or apathy. Confirmation is by identification of low levels of vitamin B12 in a blood sample.

**Exclusions:**      Hereditary vitamin B12 deficiency anaemia (3A01.0)

- 3A01.2**      **Vitamin B12 deficiency anaemia due to low intake**

A disease caused by insufficient intake of vitamin B12 into the body. This disease is characterised by low levels of vitamin B12 leading to low levels of red blood cells. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of low levels of vitamin B12 and red blood cell count in a blood sample.

- 3A01.3**      **Vitamin B12 deficiency anaemia due to intrinsic factor deficiency**

**Exclusions:**      Vitamin B12 deficiency anaemia due to congenital intrinsic factor deficiency (3A01)

- 3A01.30**      Pernicious anaemia

Acquired pernicious anaemia, also called Biermer's disease, is a disorder in vitamin B12 (cobalamin) absorption characterised by megaloblastic anaemia and gastrointestinal symptoms, and that can lead to neurological abnormalities.

- 3A01.3Y**      Other specified vitamin B12 deficiency anaemia due to intrinsic factor deficiency

<b>3A01.4</b>	<b>Vitamin B12 deficiency anaemia due to intestinal disease</b>
	A number of intestinal disorders can also cause vitamin B12 (cobalamin) deficiency. These include severe pancreatic diseases and small bowel diseases such as malabsorption, ileal disease (including tuberculous ileitis, lymphoma, amyloid, long-term survivors of pelvic irradiation), extensive small bowel resection or bypass, gastric surgery/reconstruction for obesity (bariatric surgery) and Crohn's disease. When jejunal blind loops are present, bacterial overgrowth within the loops competes for cobalamin, leading to cobalamin deficiency. Although not as common currently, infestation with the fish tapeworm, <i>Diphyllobothrium latum</i> , was once a classic cause of cobalamin deficiency.
<b>Coding Note:</b>	Code also the causing condition
<b>3A01.5</b>	<b>Drug-induced vitamin B12 deficiency anaemia</b>
<b>3A01.Y</b>	<b>Other specified megaloblastic anaemia due to vitamin B12 deficiency</b>
<b>3A01.Z</b>	<b>Megaloblastic anaemia due to vitamin B12 deficiency, unspecified</b>
<b>3A02</b>	<b>Folate deficiency anaemia</b>
<b>3A02.0</b>	<b>Hereditary folate deficiency anaemia</b>
<b>3A02.1</b>	<b>Folate deficiency anaemia due to low intake</b>
<b>3A02.2</b>	<b>Folate deficiency anaemia due to increased requirements</b>
<b>3A02.3</b>	<b>Folate deficiency anaemia due to decreased intestinal absorption</b> A disease caused by determinants affecting intestinal absorption of folate arising after birth. This disease is characterised by low levels of folate in the body leading to incomplete formation of red blood cells resulting in large numbers of immature and incompletely developed red blood cells. This disease may present with fatigue, muscle weakness, loss of appetite, weight loss, diarrhoea, nausea, tachycardia or extremity paraesthesia. Confirmation is by identification of low folate levels in a blood sample.
<b>Coding Note:</b>	Code also the causing condition
<b>3A02.4</b>	<b>Drug-induced folate deficiency anaemia</b>
<b>3A02.Y</b>	<b>Other specified folate deficiency anaemia</b>
<b>3A02.Z</b>	<b>Folate deficiency anaemia, unspecified</b>
<b>3A03</b>	<b>Other nutritional or metabolic anaemias</b> A disease caused by nutritional and metabolic determinants leading to anaemia. This disease is characterised by decreased levels of red blood cells within the body. This disease may present with fatigue, pallor or dizziness. Confirmation is by identification of a decreased red blood cell count in a blood sample.
	<b>Coded Elsewhere:</b> Disorders of pyrimidine metabolism (5C55.1)
	Lesch-Nyhan syndrome (5C55.01)

- 3A03.0      Hereditary orotic aciduria**  
Hereditary orotic aciduria is an extremely rare (less than 20 cases identified worldwide) autosomal recessive disorder characterised by retarded growth, anaemia and excessive urinary excretion of orotic acid. It is due to a severe deficiency in the activity of the pyrimidine pathway enzyme uridine 5'-monophosphate (UMP) synthase (bifunctional enzyme containing two activities: orotate phosphoribosyltransferase and orotidine 5'-monophosphate decarboxylase), coded by a single gene (UMPS) localised to chromosome 3q13.
- 3A03.1      Protein deficiency anaemia**  
A disease caused by low levels of protein within the body. This disease is characterised by a low red blood cell count in the blood. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of a low red blood cell count in a blood sample.  
**Exclusions:**      Lesch-Nyhan syndrome (5C55.01)
- 3A03.2      Scorbutic anaemia**  
Scorbutic anaemia is a common finding in infants and young children with scurvy and is related to impaired iron absorption and coexistent haematopoietic nutrient deficiencies including iron, vitamin B12 and folate.
- 3A03.3      Copper deficiency anaemia**  
Anaemia due to copper deficiency arises from impaired utilization of iron and is therefore a conditioned form of iron deficiency anaemia.
- 3A03.4      Acquired other vitamin B deficiency anaemia**  
A disease caused by a lack of B vitamins in the body arising after birth. This disease is characterised by low levels of B vitamins leading to low levels of red blood cells in the body. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of low red blood cell count and low B vitamin counts in a blood sample.
- 3A03.40      Acquired pyridoxine deficiency anaemia**  
A disease caused by determinants arising after birth. This disease is characterised by low levels of pyridoxine (vitamin B6) leading to low levels of red blood cells in the body. This disease may present with fatigue, muscle weakness, loss of appetite, weight loss, diarrhoea, nausea, fast heartbeat or numbness in extremities. Confirmation is by identification of low levels of pyridoxine and low red blood cell count in a blood sample.
- 3A03.41      Acquired riboflavin deficiency anaemia**  
A disease caused by determinants arising after birth. This disease is characterised by low levels of riboflavin (vitamin B2) leading to low levels of red blood cells in the body. This disease may present with fatigue, muscle weakness, loss of appetite, weight loss, diarrhoea, nausea, fast heartbeat or numbness in extremities. Confirmation is by identification of low levels of riboflavin and low red blood cell count in a blood sample.

<b>3A03.42</b>	Acquired thiamine deficiency anaemia A disease caused by a lack of thiamine arising after birth. This disease is characterised low levels of thiamine in the body leading to low levels of red blood cells. This disease may present with fatigue, muscle weakness, loss of appetite, weight loss, diarrhoea, nausea, fast heartbeat or numbness in extremities. Confirmation is by identification of low levels of thiamine and low red blood cell count in a blood sample.
<b>3A03.4Y</b>	Other specified acquired other vitamin B deficiency anaemia
<b>3A03.5</b>	<b>Acquired vitamin A deficiency anaemia</b>
<b>3A03.6</b>	<b>Acquired vitamin E deficiency anaemia</b> <i>Inclusions:</i> Haemolytic anaemia due to vitamin E deficiency
<b>3A03.Y</b>	<b>Other and unspecified nutritional or metabolic anaemia</b>

#### Haemolytic anaemias (3A10-3A4Z)

A disease caused by determinants arising after birth, during the antenatal period or genetically inherited factors leading to premature haemolysis of red blood cells. This disease is characterised by low levels of red blood cells in the body due to abnormal breakdown of the cells. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of low red blood cell count in a blood sample.

#### Congenital haemolytic anaemia (3A10-3A1Y)

A disease caused by determinants arising in the antenatal period. This disease is characterised by low levels of red blood cells in the body due to abnormal destruction of the red blood cells. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of low red blood cell count in a blood sample.

**Coded Elsewhere:** Haemolytic disease of fetus or newborn (KA84)

<b>3A10</b>	<b>Hereditary haemolytic anaemia</b>
<b>3A10.0</b>	<b>Haemolytic anaemias due to hexose monophosphate shunt or glutathione metabolism anomalies</b> This is a form of anaemia due to haemolysis, the abnormal breakdown of red blood cells (RBCs), either in the blood vessels (intravascular haemolysis) or elsewhere in the human body (extravascular). This diagnosis is due to a process that generates NADPH and pentoses (5-carbon sugars) and glutathione metabolism anomalies.
<b>3A10.00</b>	Haemolytic anaemia due to glucose-6-phosphate dehydrogenase deficiency Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common hereditary erythrocyte enzyme deficiency that can manifest with severe neonatal jaundice which can lead to serious neurological consequences, or, most often, with acute haemolytic anaemia following ingestion of certain foods (fava beans), common drugs (some antimalaria drugs, sulphonamides, analgesics), or in the course of an infection, in otherwise asymptomatic individuals.

- 3A10.0Y** Other specified haemolytic anaemias due to hexose monophosphate shunt or glutathione metabolism anomalies
- 3A10.0Z** Haemolytic anaemias due to hexose monophosphate shunt or glutathione metabolism anomalies, unspecified
- 3A10.1** **Haemolytic anaemia due to adenosine deaminase excess**
- 3A10.2** **Hereditary elliptocytosis**  
Hereditary elliptocytosis is a group of rare conditions caused by abnormalities in the red cell cytoskeleton and marked by the presence on blood smears of numerous elliptical red blood cells, called elliptocytes. Clinical presentations are highly heterogeneous ranging from asymptomatic forms to more severe forms associated with variable anaemia, from moderate to severe and with pyropoikilocytosis including fragmented red cells, microelliptocytes and microspherocytes.
- 3A10.3** **Familial pseudohyperkalaemia**  
A disease caused by a genetically inherited mutation. This disease is characterised by a temperature-dependent defect in red cell membrane permeability to potassium that leads to high in vitro potassium levels in samples stored below 37°C leading to elevated potassium levels in the blood that does not reflect the true potassium level. Confirmation is by identification of genetic mutation through genetic testing.
- 3A10.Y** **Other specified hereditary haemolytic anaemia**
- 3A10.Z** **Hereditary haemolytic anaemia, unspecified**
- 3A1Y** **Other specified congenital haemolytic anaemia**

### Acquired haemolytic anaemia (3A20-3A2Z)

A disease characterised by premature destruction of red blood cells arising after birth. This disease is further characterised by low levels of red blood cells in the body due to abnormal destruction of the cells. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of low red blood cell count in a blood sample.

- 3A20** **Acquired haemolytic anaemia, immune**  
A condition characterised by antibodies that are directed against red blood cells in an autoimmune reaction leading to low levels of red blood cells. This condition may present with pallor, fatigue, shortness of breath. Confirmation is by identification of antibodies in a blood sample and positive Coombs test result.

**3A20.0****Autoimmune haemolytic anaemia, warm type**

Autoimmune haemolytic anaemia (AIHA) is an autoimmune disorder in which various types of auto-antibodies are directed against red blood cells causing their survival to be shortened and resulting in haemolytic anaemia. AIHA can be primary (idiopathic), secondary to infection or associated with diseases such as B-cell lymphomas, other systemic or organ-specific autoimmune diseases, Hodgkin's disease, hepatitis or primary immunodeficiencies, or, in the case of drug-induced AIHA, caused by a reaction to drugs.

- Exclusions:**
- Evans syndrome (3A20.5)
  - Haemolytic disease of fetus or newborn (KA84)
  - Paroxysmal cold haemoglobinuria (3A20.3)

**3A20.1****Autoimmune haemolytic anaemia, cold type**

Cold autoimmune haemolytic anaemia comprises two types of autoimmune haemolytic anaemia (AIHA) defined by the presence of cold autoantibodies (autoantibodies which are active at temperatures below 30°C): cold agglutinin disease (CAD), which is the more common, and paroxysmal cold haemoglobinuria (PCH). CAD is more common in people over the age of 55 years, while PCH typically presents in young children. CAD is caused by IgM autoantibodies while PCH is caused by an IgG immunoglobulin.

- Exclusions:**
- Immune thrombocytopenic purpura (3B64.10)
  - Haemolytic disease of fetus or newborn (KA84)

**3A20.2****Autoimmune haemolytic anaemia, mixed type, cold and warm**

Mixed autoimmune haemolytic anaemia is a type of autoimmune haemolytic anaemia (AIHA) defined by the presence of both warm and cold autoantibodies, which have a deleterious effect on red blood cells at either body temperature or at lower temperatures.

**3A20.3****Paroxysmal cold haemoglobinuria**

Paroxysmal cold hemoglobinuria is a very rare subtype of autoimmune haemolytic anaemia (AIHA), caused by the presence of cold-reacting autoantibodies in the blood and characterised by the sudden presence of hemoglobinuria, typically after exposure to cold temperatures. PCH is thought to account for at most 2-10% of cases of AIHA.

**3A20.4****Alloimmune haemolytic anaemia**

A disease caused by determinants such as a blood transfusion that lead to an immune response directed against the person's own red blood cells. This disease is characterised by low levels of red blood cells in the body due to abnormal destruction of the red blood cells. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of low red blood cell count in a blood sample.

- Exclusions:**
- Haemolytic disease of fetus or newborn (KA84)

<b>3A20.5</b>	<b>Evans syndrome</b> Evans syndrome is characterised by the association of autoimmune haemolytic anaemia with another haematological anomaly. The thrombocytopenia may precede, occur concurrently with, or secondary to the autoimmune haemolytic anaemia.
<b>3A20.Y</b>	<b>Other specified acquired haemolytic anaemia, immune</b>
<b>3A21</b>	<b>Acquired haemolytic anaemia, non-immune</b> A disease caused by determinants such as infection, toxic chemicals, drugs and trauma arising after birth. This disease is characterised by haemolysis of red blood cells. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of decreased red blood cell count in a blood sample and negative Coombs test result.
<b>3A21.0</b>	<b>Paroxysmal nocturnal haemoglobinuria</b> Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic stem cell disorder characterised by corpuscular haemolytic anaemia, bone marrow failure and frequent thrombotic events.  <i>Exclusions:</i> haemoglobinuria NOS (MF94) Aplastic anaemia with paroxysmal nocturnal haemoglobinuria (3A70.1)
<b>3A21.1</b>	<b>Microangiopathic haemolytic anaemia</b> This is a microangiopathic subgroup of haemolytic anaemia (loss of red blood cells through destruction) caused by factors in the small blood vessels. It is identified by the finding of anaemia and schistocytes on microscopy of the blood film.
<b>3A21.2</b>	<b>Haemolytic uraemic syndrome</b> <i>Exclusions:</i> Hereditary haemolytic uraemic syndrome (3A10)
<b>3A21.Y</b>	<b>Other specified acquired haemolytic anaemia, non-immune</b>
<b>3A2Z</b>	<b>Acquired haemolytic anaemia, unspecified</b>
<b>3A4Z</b>	<b>Haemolytic anaemias, unspecified</b>
<b>3A50</b>	<b>Thalassaemias</b> A disease caused by genetically inherited autosomal recessive mutations leading to abnormal production of haemoglobin. This disease is characterised by destruction of red blood cells leading to anaemia and abnormal production of haemoglobin. This disease may present with pallor, jaundice, iron overload, fatigue, or shortness of breath. Confirmation is by identification of mutations through genetic testing.
<b>3A50.0</b>	<b>Alpha thalassaemia</b> Alpha-thalassemia is an inherited haemoglobinopathy characterised by impaired synthesis of alpha-globin chains leading to a variable clinical picture depending on the number of affected alleles, and encompassing the alpha thalassaemia trait, haemoglobin H disease (HbH) and Bart's hydrops fetalis.  <i>Exclusions:</i> Hydrops fetalis due to haemolytic disease (KA85)

- 3A50.00** Mild alpha thalassaemia diseases  
 A disease caused by genetically inherited factors affecting the alpha chain of the haemoglobin molecule. This disease is characterised by structural abnormalities of the haemoglobin molecule. This disease may present with mild anaemia: pallor, fatigue, shortness of breath. Confirmation is by identification of changes to the alpha chain by genetic testing.
- 3A50.01** Thalassaemic alpha-chain variants
- 3A50.02** Haemoglobin H disease (- α/- – included)  
 Haemoglobin H (HbH) disease is a moderate to severe form of alpha-thalassemia characterised by pronounced microcytic hypochromic haemolytic anaemia.
- 3A50.03** Homozygous or compound heterozygous alpha0 thalassaemia  
 Hb Bart's hydrops fetalis is the most severe form of alpha-thalassemia and is almost always lethal. It is characterised by fetal onset of generalised oedema, pleural and pericardial effusions, and severe hypochromic anaemia.
- 3A50.0Y** Other specified alpha thalassaemia
- 3A50.0Z** Alpha thalassaemia, unspecified
- 3A50.1** **Alpha thalassaemia related syndromes**  
 Alpha-thalassemia-related diseases refers to a group of diseases characterised by alpha-thalassemia and an associated disorder. Three conditions are included in this group: alpha-thalassemia-intellectual deficit syndrome, X-linked (or ATR-X syndrome), alpha-thalassemia-intellectual deficit syndrome and alpha-thalassemia-myelodysplastic disease or ATMDS.
- 3A50.2** **Beta thalassaemia**  
 Beta-thalassemia (BT) is a haemoglobinopathy characterised by deficiency (Beta+) or absence (Beta0) of synthesis of the beta globin chains of haemoglobin (Hb). Three main types of BT have been described: minor, intermedia and major with clinical presentation ranging from asymptomatic forms to microcytic anaemia and splenomegaly due to defective erythropoiesis and haemolysis.
- 3A50.3** **Delta, delta-beta or gamma-delta-beta thalassaemia**  
 Delta-beta-thalassemia is a form of beta-thalassemia characterised by decreased or absent synthesis of the delta- and beta-globin chains with a compensatory increase in expression of fetal gamma-chain synthesis.
- 3A50.4** **Hereditary persistence of fetal haemoglobin**  
 Hereditary persistence of fetal haemoglobin (HPFH) associated with beta-thalassaemia is a haemoglobinopathy characterised by high haemoglobin (Hb)F levels and an increased number of fetal-Hb-containing cells. The association of HPFH with beta-thalassaemia mitigates the clinical manifestations which vary from a normal state to beta-thalassaemia intermedia.
- 3A50.Y** **Other specified thalassaemias**
- 3A50.Z** **Thalassaemias, unspecified**

**3A51**

### **Sickle cell disorders or other haemoglobinopathies**

Any disorder caused by a HbS mutation in the haemoglobin gene. This disorder is characterised by abnormal rigid sickle-shaped red blood cells decreasing its ability to carry oxygen. This disorder may present with fatigue, shortness of breath, dizziness, headaches, pallor of skin or mucous membranes, and jaundice. This disorder is confirmed by identification of HbS mutation by genetic testing.

**Coded Elsewhere:** Osteonecrosis due to haemoglobinopathy (FB81.4)

Other sickle-cell disorders with retinopathy (9B71.Y)

**3A51.0**

#### **Sickle cell trait**

A disease caused by genetic inheritance of one abnormal allele of the haemoglobin gene. This disease does not display the severe symptoms of sickle cell disease that occurs in homozygous individuals. Confirmation is by identification of mutation through genetic testing.

**3A51.1**

#### **Sickle cell disease without crisis**

A disorder caused by a HbS mutation in the haemoglobin gene. This disorder is characterised by abnormal rigid sickle-shaped red blood cells decreasing its ability to carry oxygen. This disorder may present with fatigue, shortness of breath, dizziness, headaches, pallor of skin or mucous membranes, and jaundice. This disorder is confirmed by identification of HbS mutation by genetic testing.

**3A51.2**

#### **Sickle cell disease with crisis**

Sickle cell crisis occurs when the sickle cells block blood flow, thus decreasing oxygen delivery to the tissues. This results in intense to severe pain in the extremities, lower back, abdomen, and chest. A crisis can be brought on by illness, stress, dehydration, exposure to temperature changes or high altitudes.

**Inclusions:** Hb-SS disease with crisis

**3A51.3**

#### **Compound heterozygous sickling disorders without crisis**

A disease caused by genetic inheritance of two heterozygous recessive alleles of the haemoglobin gene leading to abnormal formation of haemoglobin molecule. This disease is characterised by rigid, sickle shaped red blood cells. Confirmation is by identification of mutations through genetic testing.

**3A51.4**

#### **Compound heterozygous sickling disorders with crisis**

Compound heterozygous sickling disorders with crisis may present with acute chest syndrome, splenic sequestration, haemolytic crisis, and pain.

**3A51.5**

#### **Haemoglobin C disease**

A disease caused by the bi-parental gene that encodes for haemoglobin C. This disease is characterised by abnormal structure of one of the globin chains of the haemoglobin molecule. This disease may present with mild haemolytic anaemia, increased risk for gallstones, enlarged spleen, episodes of joint pain, and increased risk of infection. This disease is confirmed by identification of the haemoglobin C gene by genetic testing.

**Exclusions:** Hereditary persistence of fetal haemoglobin (3A50.4)

- 3A51.6      Haemoglobin D disease**  
Haemoglobin D (Hb D) disease is characterised by mild haemolytic anaemia and mild to moderate splenomegaly. Prevalence is unknown. Heterozygous forms of Hb D are clinically silent. Molecular testing can be useful to distinguish Hb D homozygosity from cases of heterozygous Hb D in association with beta-(0) thalassaemia.
- 3A51.7      High affinity haemoglobin**  
A disease caused by determinants arising after birth, in the antenatal period or by genetically inherited factors leading to high oxygen affinity haemoglobin. This disease is characterised by abnormalities in the globin chains that alter the affinity of the haemoglobin molecule for oxygen, affecting the normal loading of oxygen in the lungs and delivery of oxygen to the tissues.
- 3A51.8      Low affinity haemoglobin**  
A disease caused by determinants arising after birth, in the antenatal period or by genetically inherited factors leading to low oxygen affinity haemoglobin. This disease is characterised by abnormalities in the globin chains that alter the affinity of the haemoglobin molecule for oxygen, affecting the normal loading of oxygen in the lungs and delivery of oxygen to the tissues. This disease may present with fatigue, muscle weakness, loss of appetite, weight loss, diarrhoea, nausea, fast heartbeat or numbness in extremities.
- 3A51.9      Haemoglobin O disease**  
A disease caused by the bi-parental inheritance of the gene that encodes for haemoglobin O. This disease is characterised by abnormal structure of one of the globin chains of the haemoglobin molecule. This disease may present with mild haemolytic anaemia, increased risk for gallstones, enlarged spleen, episodes of joint pain, and increased risk of infection. This disease is confirmed by identification of the haemoglobin O gene by genetic testing.
- 3A51.A      Haemoglobin E disease**  
Haemoglobin E disease is characterised by the synthesis of an abnormal haemoglobin called haemoglobin E (HbE), instead of the normal haemoglobin A (HbA). Subjects heterozygous for HbE (AE) have an asymptomatic condition with no clinical relevance, except for the risk of transmitting E/beta thalassemia if the other parent carries beta thalassemia. The severity of these E/beta thalassemia forms is very variable, the clinical picture ranging from that of beta thalassemia minor through to thalassemia intermedia to thalassemia major. Subjects homozygous for HbE (EE) are asymptomatic.
- 3A51.B      Haemoglobin C/beta thalassaemia compound heterozygosity**  
Haemoglobin C/beta thalassaemia is a condition resulting from coinheritance of haemoglobin C and beta thalassaemia, both beta globin genes being mutated.
- 3A51.Y      Other specified sickle cell disorders or other haemoglobinopathies**
- 3A51.Z      Sickle cell disorders or other haemoglobinopathies, unspecified**

Pure red cell aplasia (3A60-3A6Z)

A condition caused by determinates arising during the antenatal period, after birth or genetically inherited factors, leading to a change in the formation of erythrocytes. This condition is characterised by maturation arrest occurring in the formation of erythrocytes. This condition may present with severe anaemia. Confirmation is by identification of abnormally formed erythrocytes in a blood sample.

**3A60**

**Congenital pure red cell aplasia**

A condition caused by determinants arising during the antenatal period, leading to a change in the formation of erythrocytes. This condition is characterised by maturation arrest occurring in the formation of erythrocytes. This condition may present with severe anaemia. Confirmation is by identification of decreased red blood cell count in a blood sample.

**3A60.0**

**Congenital non-inherited pure red cell aplasia**

A condition caused by determinates arising during the antenatal period, leading to a change in the formation of erythrocytes. This condition is characterised by maturation arrest occurring in the formation of erythrocytes. This condition may present with severe anaemia. Confirmation is by identification of decreased levels of red blood cells in a blood sample.

**3A60.1**

**Hereditary pure red cell aplasia**

A condition caused by determinates arising during the antenatal period, leading to a change in the formation of erythrocytes. This condition is characterised by maturation arrest occurring in the formation of erythrocytes. This condition may present with severe anaemia. Confirmation is by identification of decreased red blood cell count in a blood sample.

**3A60.Z**

**Congenital pure red cell aplasia, unspecified**

**3A61**

**Acquired pure red cell aplasia**

A condition characterised by the near absence of red blood cell precursors in bone marrow, often associated with thymomas and autoimmune disorders

**Exclusions:**      Aplastic anaemia with paroxysmal nocturnal haemoglobinuria (3A70.1)

**3A61.0**

**Acute acquired pure red cell aplasia**

This refers to transient (acute) and acquired type of anaemia affecting the precursors to red blood cells but not to white blood cells. In PRCA, the bone marrow ceases to produce red blood cells.

**3A61.1**

**Chronic acquired pure red cell aplasia**

This refers to a chronic and acquired type of anaemia affecting the precursors to red blood cells but not to white blood cells. In PRCA, the bone marrow ceases to produce red blood cells.

**3A61.Y**

**Other specified acquired pure red cell aplasia**

**3A61.Z**

**Acquired pure red cell aplasia, unspecified**

**3A6Z**

**Pure red cell aplasia, unspecified**

**3A70**

**Aplastic anaemia**

A disease caused by determinants arising after birth, in the antenatal period or genetically inherited factors leading to the inability of stem cells to generate new mature cells. This disease is characterised by low levels of red blood cells, white blood cells, and platelets. This disease may present with pallor, fatigue, dizziness, increased risk of infection or increased bruising or bleeding.

**Inclusions:** Medullary hypoplasia  
Panmyelophthisis

**3A70.0**

**Congenital aplastic anaemia**

A disease caused by determinants in the antenatal period leading to the inability of stem cells to generate new mature cells. This disease is characterised by low levels of red blood cells, white blood cells, platelets. This disease may present with pallor, fatigue, dizziness, increased risk of infection or increased bruising or bleeding.

**Inclusions:** familial hypoplastic anaemia  
Constitutional medullar aplasia

**Exclusions:** Congenital amegakaryocytic thrombocytopenia (3B64.01)

**Coded Elsewhere:** Congenital hypoplastic anaemia (KA8C)  
Noonan syndrome (LD2F.15)

**3A70.1**

**Acquired aplastic anaemias**

A condition occurring secondary to other disorders or via an auto-immune response directed to the bone marrow arising after birth. This disease is characterised by an almost complete absence of hematopoietic stem cells resulting in low levels of red and white blood cells and platelets. This condition may present with fatigue, chronic infections, dizziness, weakness, headaches, and episodes of bleeding, usually in the skin and mucous membranes.

**Inclusions:** Acquired medullar aplasia

**Coded Elsewhere:** Paroxysmal nocturnal haemoglobinuria (3A21.0)  
Myelofibrosis with myeloid metaplasia (2A20.2)

**3A70.10**

Drug-induced aplastic anaemia

A disease caused by drug intake. This disease is characterised by inability of stem cells to generate new mature cells leading to low levels of red blood cells, white blood cells, platelets. This disease may present with pallor, fatigue, dizziness, increased risk of infection or increased bruising/bleeding.

**3A70.11**

Aplastic anaemia due to other external agents

**3A70.12**

Idiopathic aplastic anaemia

**3A70.1Y**

Other specified acquired aplastic anaemias

**3A70.1Z**

Acquired aplastic anaemias, unspecified

**3A70.Z**

**Aplastic anaemia, unspecified**

**3A71****Anaemia due to chronic disease**

A disease caused by chronic diseases such as chronic infection. This disease is characterised by inflammatory responses targeted at red blood cells leading to low levels of red blood cells in the body. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of low levels of red blood cells in a blood sample.

**Coding Note:** Code also the causing condition

**3A71.0****Anaemia in neoplastic disease**

A disease caused by chronic neoplastic diseases. This disease is characterised by inflammatory responses targeted at red blood cell leading to low levels of red blood cells in the body. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of low levels of red blood cells in a blood sample

**Coding Note:** Code also the causing condition

**3A71.1****Anaemia in chronic infectious diseases**

A disease caused by chronic infectious diseases leading to decreased levels of red blood cells in the blood. This disease is characterised by a low red blood cell count in the body. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of low red blood cell count in a blood sample.

**Coding Note:** Code also the causing condition

**3A71.2****Anaemia in chronic kidney disease**

A disease caused by chronic kidney disease. This disease is characterised by a low red blood cell count in the blood. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of a low red blood cell count in a blood sample.

**Coding Note:** Code also the causing condition

**3A71.Y****Anaemia due to other specified chronic disease**

**Coding Note:** Code also the causing condition

**3A71.Z****Anaemia due to chronic disease, unspecified****3A72****Sideroblastic anaemia**

Sideroblastic anaemias are a group of disorders in which haemoglobin is insufficiently synthesized, because of defective use of iron (although plasmatic iron levels may be normal or elevated). They are said to be sideroblastic because of the presence of ringed sideroblasts in the blood due to accumulated ferritin in mitochondria. Anaemias may be microcytic hypochromic (in thalassemia and hereditary sideroblastic anaemias), or macrocytic (in idiopathic acquired sideroblastic anaemias).

<b>3A72.0</b>	<b>Congenital sideroblastic anaemias</b>
	A disease caused by determinants arising in the antenatal period leading to the production of ringed sideroblasts; abnormal nucleated erythroblasts. This disease is characterised by the inability to incorporate haemoglobin, which red blood cells need to transport oxygen efficiently. This disease may present with pallor, fatigue, dizziness, and enlarged spleen and liver, heart disease, liver damage, or kidney failure.
<b>3A72.00</b>	Hereditary sideroblastic anaemias
	<b>Inclusions:</b> Sex-linked hypochromic sideroblastic anaemia
<b>3A72.01</b>	Hereditary syndromic sideroblastic anaemia
	<b>Coded Elsewhere:</b> Thiamine-responsive megaloblastic anaemia syndrome (5C63.Y)
<b>3A72.0Y</b>	Other specified congenital sideroblastic anaemias
<b>3A72.0Z</b>	Congenital sideroblastic anaemias, unspecified
<b>3A72.1</b>	<b>Acquired sideroblastic anaemias</b>
	A disease caused by determinants arising after birth such as myelodysplastic syndromes, antimicrobials, pyridoxine deficiency, lead poisoning, or copper deficiency. Zinc can indirectly cause sideroblastic anaemia by decreasing absorption and increasing excretion of copper. This disease is characterised by the inability to incorporate haemoglobin, which red blood cells need to transport oxygen efficiently. This disease may present with pallor, fatigue, dizziness, and enlarged spleen and liver, heart disease, liver damage, or kidney failure.
	<b>Coded Elsewhere:</b> Refractory anaemia with ring sideroblasts (2A33)
<b>3A72.Z</b>	Sideroblastic anaemia, unspecified
<b>3A73</b>	<b>Congenital dyserythropoietic anaemia</b>
	Congenital dyserythropoietic anaemias (CDA) result from diverse erythropoietic disorders; they lead to the defective production of red blood cells (RBC) and often mild haemolysis that attests to a qualitative defect of these RBC released into the circulation. Three forms of CDA have been characterised: types I, II and III. The shared symptoms include anaemia of variable severity, intermittent jaundice, splenomegaly and hepatomegaly.
	<b>Exclusions:</b> Blackfan-Diamond syndrome (3A60.1) Di Guglielmo disease (2A60.35)

Polycythaemia (3A80-3A8Z)

**Coded Elsewhere:** Polycythaemia vera (2A20.4)

Polycythaemia neonatorum (KA8A)

3A80

### **Congenital polycythaemia**

A disease caused by determinants occurring in the antenatal period leading to changes in the concentration of red blood cells. This disease is characterised by having a high concentration of red blood cells in the body leading to slow flow of blood. This disease may present with headaches, blurred vision, red skin, tiredness, high blood pressure, dizziness, periods of confusion, bleeding problems, gout or itchy skin. Confirmation is by identification of increased levels of red blood cells in a blood sample.

**Coded Elsewhere:** Polycythaemia neonatorum (KA8A)

3A80.0

### **Primary inherited erythrocytosis**

A disease caused by genetically inherited factors leading to changes in the concentration of red blood cells. This disease is characterised by having a high concentration of red blood cells in the body leading to slow flow of blood. Confirmation is by identification of mutations by genetic testing.

3A80.Y

### **Other specified congenital polycythaemia**

3A80.Z

### **Congenital polycythaemia, unspecified**

3A81

### **Acquired polycythaemia**

Secondary polycythaemia is acquired and caused by either natural or artificial increases in the production of erythropoietin, hence an increased production of erythrocytes.

3A81.0

### **Polycythaemia due to hypoxia, including high altitude**

3A81.1

### **Polycythaemia due to over-transfusion or blood doping**

3A81.2

### **Relative polycythaemia**

A disease caused by loss of body fluids leading to apparent increased levels of red blood cells in the blood. This disease may present with headache, vertigo, abnormally enlarged spleen or liver, high blood pressure, or formation of blood clots. Confirmation is by identification of relative blood cell counts in a blood sample.

3A81.Y

### **Other specified acquired polycythaemia**

3A81.Z

### **Acquired polycythaemia, unspecified**

3A8Z

### **Polycythaemia, unspecified**

3A90

### **Anaemia due to acute disease**

**Exclusions:** Acute posthaemorrhagic anaemia (3A94)

**3A91****Congenital methaemoglobinaemia**

A disease caused by determinants in the antenatal period leading to lack of the enzyme cytochrome b5 reductase. This disease is characterised by elevated levels of methemoglobin within the blood leading to haemoglobin ineffectively releasing oxygen to body tissues. This disease may present with shortness of breath, cyanosis, headache, fatigue, exercise intolerance, dizziness and loss of consciousness. Confirmation is by identification of mutation by genetic testing.

**3A92****Hereditary methaemoglobinaemia**

Hereditary methemoglobinemia (HM) is a rare red cell disorder classified principally into two clinical phenotypes: autosomal recessive congenital (or hereditary) methemoglobinemia types I and II (RCM/RHM type 1; RCM/RHM type 2). In RCM type 1, well-tolerated cyanosis from birth is the only symptom. RCM type 2, with global loss of Cb5R function, is much more severe; the cyanosis is accompanied by neurological dysfunction (with intellectual deficit, microcephaly, growth retardation, opisthotonus, strabismus and hypertonia), which usually becomes evident during the first four months of life.

**3A93****Acquired methaemoglobinaemia****3A94****Acute posthaemorrhagic anaemia**

A disease caused by blood loss such as subsequent to trauma. This disease is characterised by loss of blood from the body leading to low levels of red blood cells/blood in the body. This disease may present with pallor, fatigue, or shortness of breath. Confirmation is by identification of low levels of red blood cells in a blood sample.

***Exclusions:***

congenital anaemia from fetal blood loss (KA8C)

Anaemia due to acute disease (3A90)

**3A9Y****Other specified anaemias or erythrocyte disorders****3A9Z****Anaemias or other erythrocyte disorders, unspecified**

## Coagulation defects, purpura or other haemorrhagic or related conditions (3B10-3B6Z)

A condition caused by determinants arising during the antenatal period, after birth or by genetically inherited factors, leading to coagulation defects. This condition is characterised by increased bruising and bleeding.

**Exclusions:** Postpartum coagulation defects (JA43.3)

### Coagulation defects (3B10-3B4Z)

## Congenital or constitutional haemorrhagic condition (3B10-3B1Z)

A condition caused by determinants arising during the antenatal period or genetically inherited factors, leading to defects in clotting mechanisms or abnormalities causing structural flaws in the blood vessels. This disease is characterised by spontaneous bleeding or bruising.

**Coded Elsewhere:** Congenital non-inherited haemorrhagic condition

**3B10**

### Hereditary factor VIII deficiency

A disease caused by a genetically inherited mutation leading to a deficiency in clotting due to lack of factor VIII. This disease is characterised by increasing haemorrhaging and bruising. Confirmation is by identification of mutations by genetic testing.

**3B10.0**

### Haemophilia A

Haemophilia A is the most common form of haemophilia characterised by spontaneous or prolonged haemorrhages due to factor VIII deficiency. Depending on the extent of the factor VIII deficiency, it can be severe (biological activity of factor VIII below 1%), moderately severe (activity of factor VIII between 1% and 5%), or mild (activity of factor VIII between 5 and 40%).

**Exclusions:** factor VIII deficiency with vascular defect (3B12)

**3B10.1**

### Hereditary factor VIII deficiency with anti-factor VIII inhibitor

A disease caused by a genetically inherited mutation leading to a deficiency in clotting due to lack of factor VIII. This disease also causes anti-factor VIII inhibitor antibodies to be produced when receiving transfusions. Anti-factor VIII inhibitor antibodies develop as the body recognises the factor VIII as foreign, therefore deeming factor VIII infusions ineffective. This disease is characterised by increasing haemorrhaging and bruising. Confirmation is by identification of mutations by genetic testing.

**3B10.Y**

### Other specified hereditary factor VIII deficiency

**3B10.Z**

### Hereditary factor VIII deficiency, unspecified

**3B11**

### Hereditary factor IX deficiency

A disease caused by a genetically inherited X-linked recessive trait leading to a defective gene located on the X chromosome. This disease is characterised by low levels of the protein factor IX in the body leading to increased haemorrhaging and bruising due to clotting abnormalities. Confirmation is by identification of recessive trait by genetic testing.

<b>3B11.0</b>	<b>Haemophilia B</b> Haemophilia B is a form of haemophilia characterised by spontaneous or prolonged haemorrhages due to factor IX deficiency. Depending on the extent of the factor IX deficiency, it can be severe (biological activity of factor IX below 1%), moderately severe (activity of factor IX between 1% and 5%), or mild (activity of factor IX between 5 and 40%).
	<b>Inclusions:</b> PTC - [plasma thromboplastin component] deficiency
<b>3B11.Y</b>	<b>Other specified hereditary factor IX deficiency</b>
<b>3B11.Z</b>	<b>Hereditary factor IX deficiency, unspecified</b>
<b>3B12</b>	<b>Von Willebrand disease</b> A disease caused by inherited genetic mutations. This disease is characterised by quantitative, structural or function abnormalities of von Willebrand factor leading to abnormalities in coagulation of the blood. This disease may present with prolonged bleeding, easy bruising or bleeding gums. Confirmation is by identification of mutation through genetic testing.
	<b>Inclusions:</b> Factor VIII deficiency with vascular defect Vascular haemophilia Angiohaemophilia
	<b>Exclusions:</b> factor VIII deficiency with functional defect (3B10) factor VIII deficiency NOS (3B10) Acquired von Willebrand disease or syndrome (3B20-3B2Y)
<b>3B13</b>	<b>Haemophilia C</b> A disease caused by genetically inherited mutations. This disease is characterised by decreased levels of factor XI leading to abnormalities in coagulation of the blood. This disease may present with prolonged bleeding, easy bruising or bleeding gums. Confirmation is by identification of mutation through genetic testing.
<b>3B14</b>	<b>Other inherited coagulation factor deficiency with bleeding tendency</b> Any disease caused by genetically inherited mutations leading to lack of coagulation factors in the blood not elsewhere classified. These diseases are characterised by increased haemorrhaging and bruising as the blood cannot clot properly to control bleeding. Confirmation is identification of mutations by genetic testing.
<b>3B14.0</b>	<b>Hereditary deficiency of factor I</b> Congenital deficiencies of fibrinogen are coagulation disorders characterised by bleeding symptoms ranging from mild to severe resulting from reduced quantity and/or quality of circulating fibrinogen. Afibrinogenaemia (complete absence of fibrinogen) and hypofibrinogenaemia (reduced plasma fibrinogen concentration) correspond to quantitative anomalies of fibrinogen while dysfibrinogenaemia corresponds to a functional anomaly of fibrinogen. Hypo- and dysfibrinogenaemia may be frequently combined (hypodysfibrinogenaemia).

- 3B14.1      Hereditary factor X deficiency**  
Congenital factor X deficiency is an inherited bleeding disorder with a decreased antigen and/or activity of factor X (FX) and characterised by mild to severe bleeding symptoms.
- 3B14.2      Combined deficiency of vitamin K-dependent clotting factors**  
Hereditary combined vitamin K-dependent clotting factors deficiency (VKCFD) is a congenital bleeding disorder resulting from variably decreased levels of coagulation factors II, VII, IX and X, as well as natural anticoagulants protein C, protein S and protein Z.
- 3B14.Z      Other inherited coagulation factor deficiency with bleeding tendency, unspecified**
- 3B15      Inherited coagulation factor deficiency without bleeding tendency**  
A disease caused by a genetically inherited mutation leading to decreased levels of coagulation factor. This disease is characterised by decreased levels of coagulation factor without leading to increased haemorrhaging. Confirmation is by identification of decreased levels of coagulation factor in a blood sample.
- 3B1Z      Congenital or constitutional haemorrhagic condition, unspecified**

## Haemorrhagic diseases due to acquired coagulation factor defects (3B20-3B2Y)

Any disease caused by determinants arising after birth. These diseases are characterised by abnormal coagulation of the blood.

**Exclusions:**      vitamin K deficiency of newborn (KA8F.0)

**3B20      Disseminated intravascular coagulation**

A disorder that is characterised by the systemic intravascular activation of the coagulation system, simultaneously leading to intravascular thrombi, compromising an adequate blood supply to the organs, and to bleeding as the consequence of consumption of platelets and coagulation factors. It may be provoked by a wide range of disorders including infections, inflammatory disorders and malignancy.

**Coded Elsewhere:** Disseminated intravascular coagulation of fetus or newborn (KA88)

**3B21      Haemorrhagic disorder due to circulating anticoagulants and coagulation factors**

A disease caused by anticoagulants present in the body that prevent the blood from clotting normally. This disease is characterised by abnormalities in blood clotting. This disease may present with prolonged bleeding, easy bruising or bleeding gums. Confirmation is by identification of anticoagulants present in a blood sample.

**Exclusions:**      long-term use of anticoagulants without haemorrhage (QC48.0)

- 3B21.0** **Haemorrhage due to thrombin inhibitor other than heparin**  
A disease caused by any thrombin inhibitors other than heparin that affects normal coagulation of the blood. This disease is characterised by inability of the blood to coagulate leading to bleeding. Confirmation is by identification of thrombin inhibitors in a blood sample.
- 3B21.1** **Haemorrhage due to factor Xa inhibitor**  
A disease caused by factor Xa inhibitor that affects normal coagulation of the blood. This disease is characterised by inability of the blood to coagulate leading to bleeding. Confirmation is by identification of factor Xa inhibitor in a blood sample.
- 3B21.Y** **Haemorrhagic disorder due to other specified circulating anticoagulants**
- 3B21.Z** **Haemorrhagic disorder due to unspecified circulating anticoagulants**
- 3B22** **Acquired haemophilia**  
Acquired haemophilia is a rare haemorrhagic disease caused by production of anti-factor VIII antibodies and is sometimes associated with other autoimmune disorders, cancers, lymphoproliferative syndromes and multiple transfusions during the postpartum period.
- 3B2Y** **Other specified haemorrhagic diseases due to acquired coagulation factor defects**
- 3B4Z** **Coagulation defects, unspecified**

#### Fibrinolytic defects (3B50-3B51)

A disease caused by determinants arising during the antenatal period, after birth or genetically inherited factors, affecting the fibrinolysis system which prevents blood clots from growing and becoming problematic. This disease is characterised by defects in the fibrinolysis system leading to coagulation of the blood. This disease may present with thrombosis.

- 3B50** **Inherited fibrinolytic defects**  
A disease caused by genetically inherited mutations affecting the fibrinolysis system which prevents blood clots from growing and becoming problematic. This disease is characterised by defects in the fibrinolysis system leading to coagulation of the blood. This disease may present with thrombosis.  
*Coded Elsewhere:* Hypoplasminogenaemia (DA0D.3)
- 3B50.0** **Congenital alpha-2 antiplasmin deficiency**
- 3B50.1** **Congenital plasminogen activator inhibitor type 1 deficiency**  
Congenital plasminogen activator inhibitor type 1 (PAI-1) deficiency is a disorder that causes premature lysis of haemostatic clots and a moderate bleeding syndrome. Spontaneous bleeding is rarely observed, whereas moderate haemorrhages of the knees, elbows, nose and gingiva are usually triggered by mild trauma. However, menstrual bleeding may be severe and a prolonged bleeding after surgery is common. The PAI-1 deficiency may be qualitative or quantitative, total or partial.

**3B50.Y Other specified inherited fibrinolytic defects**

**3B50.Z Inherited fibrinolytic defects, unspecified**

**3B51 Acquired fibrinolytic defects**

A disease caused by determinants arising after birth, affecting the fibrinolysis system which prevents blood clots from growing and becoming problematic. This disease is characterised by defects in the fibrinolysis system leading to coagulation of the blood. This disease may present with thrombosis.

**3B60 Non-thrombocytopenic purpura**

A descriptive term for purpura caused by determinants other than low platelet count. This should be used for coding only when a more precise diagnosis is not available.

**Exclusions:** Antineutrophil cytoplasmic antibody-associated vasculitis (4A44.A)  
Antiphospholipid syndrome (4A45)  
Drug-associated immune complex vasculitis (4A85.03)  
Immune complex small vessel vasculitis (4A44.9)  
Leukocytoclastic vasculitis (4A44.B)  
Purpura or bruising due to vascular fragility (EE40.32)  
Thrombotic thrombocytopenic purpura (3B64.14)  
Traumatic purpura (EF31)

**3B60.0 Hereditary vascular purpura**

**3B60.1 Acquired vascular purpura**

Purpura resulting from vascular factors rather than from abnormalities in the blood such as dysproteinemias and disorders of platelets and coagulation.

**Exclusions:** Antineutrophil cytoplasmic antibody-associated vasculitis (4A44.A)  
Antiphospholipid syndrome (4A45)  
Capillaritis (EF40.0)  
Drug-associated immune complex vasculitis (4A85.03)  
IgA vasculitis (4A44.92)  
Leukocytoclastic vasculitis (4A44.B)  
Purpura or bruising due to vascular fragility (EE40.32)  
Thrombotic thrombocytopenic purpura (3B64.14)  
Traumatic purpura (EF31)

**3B61 Thrombophilia**

A disease caused by determinants arising after birth or genetically inherited factors leading to abnormalities in blood. This disease is characterised by abnormality of blood coagulation that increases the risk of thrombosis, clots in blood vessels. This disease may present with deep vein thrombosis or pulmonary embolism. Confirmation is identification of abnormal blood coagulation in a blood sample.

<b>3B61.0</b>	<b>Hereditary thrombophilia</b> A disease caused by hereditary factors leading to abnormalities in blood. This disease is characterised by abnormality of blood coagulation that increases the risk of thrombosis, clots in blood vessels. This disease may present with deep vein thrombosis or pulmonary embolism. Confirmation is identification of abnormal blood coagulation in a blood sample.
<b>3B61.00</b>	<b>Hyperhomocysteinaemia</b> A disease caused by deficiencies of vitamin B6, folic acid, or vitamin B12. Genetic defects in 5-MTHF reductase can consequently lead to hyperhomocysteinaemia. This disease is characterised by abnormally high level of homocysteine in the blood. This disease may present with cardiovascular disease, thrombosis, schizophrenia and osteoporosis. Confirmation is by identification of deficiency in a blood sample.
<b>3B61.0Y</b>	<b>Other specified hereditary thrombophilia</b>
<b>3B61.0Z</b>	<b>Hereditary thrombophilia, unspecified</b>
<b>3B61.1</b>	<b>Acquired thrombophilia</b> A disease caused by determinants arising after birth. This disease is characterised by abnormality of blood coagulation that increases the risk of thrombosis, clots in blood vessels. This disease may present with deep vein thrombosis or pulmonary embolism. Confirmation is identification of abnormal blood coagulation in a blood sample.  <b>Coded Elsewhere:</b> Antiphospholipid syndrome (4A45)
<b>3B61.Y</b>	<b>Other specified thrombophilia</b>
<b>3B61.Z</b>	<b>Thrombophilia, unspecified</b>
<b>3B62</b>	<b>Qualitative platelet defects</b> A disease caused by determinants arising after birth, during the antenatal period or genetically inherited factors. This disease is characterised by abnormalities in coagulation of the blood due to defective platelets. This condition may present with easy bruising, prolonged bleeding or bleeding gums. Confirmation is by identification of decreased platelets in a blood sample.  <b>Inclusions:</b> Thrombocytopathy <b>Exclusions:</b> Von Willebrand disease (3B12)
<b>3B62.0</b>	<b>Inherited qualitative platelet defects</b> A disease caused by genetically inherited mutations leading to abnormalities in platelets. This disease is characterised by abnormal platelet formation or function. Confirmation is by identification of mutations by genetic testing.  <b>Coded Elsewhere:</b> Dense granule disease (3B62.3) Alpha-delta dense granule deficiency (3B62.4)

- 3B62.00** Alpha-granule diseases  
A condition caused by determinants arising after birth, in the antenatal period. This condition is characterised by defects in the alpha granules in platelets leading to abnormalities in coagulation mechanisms. This condition may present with prolonged bleeding, epistaxis, menorrhagia, easy bruising, anaemia, fatigue or shortness of breath. Confirmation is by identification of platelet defects in a blood sample.
- 3B62.01** Inherited giant platelet disorder  
A disease caused by genetically inherited mutations. This disease is characterised by abnormally large platelets, low platelet count and a bleeding tendency. Confirmation is by identification of mutations through genetic testing.  
**Coded Elsewhere:** MYH9 macrothrombocytopenia syndromes (3B64.01)
- 3B62.0Y** Other specified inherited qualitative platelet defects
- 3B62.0Z** Inherited qualitative platelet defects, unspecified
- 3B62.1** **Bleeding diathesis due to thromboxane synthesis deficiency**  
A disease caused by thromboxane synthesis deficiency. This disease is characterised by low levels of eicosanoids (lipids), abnormalities in coagulation leading to haemorrhaging. Confirmation is by identification of low levels of eicosanoids in a blood sample.
- 3B62.2** **Isolated thrombocytopenia**
- 3B62.3** **Dense granule disease**  
A condition caused by determinants arising after birth, in the antenatal period. This condition is characterised by defects in the dense granules in platelets leading to abnormalities in coagulation mechanisms. This condition may present with prolonged bleeding, epistaxis, menorrhagia, easy bruising, anaemia, fatigue or shortness of breath. Confirmation is by identification of platelet defects in a blood sample.  
**Coded Elsewhere:** Hermansky-Pudlak syndrome (EC23.20)  
Chédiak-Higashi syndrome (EC23.20)
- 3B62.4** **Alpha-delta dense granule deficiency**  
A condition caused by determinants arising after birth, in the antenatal period. This condition is characterised by defects in the alpha delta dense granules in platelets, leading to abnormalities in coagulation mechanisms. This condition may present with prolonged bleeding, epistaxis, menorrhagia, easy bruising, anaemia, fatigue or shortness of breath. Confirmation is by identification of low levels of alpha delta dense granules in a blood sample.
- 3B62.5** **Haemophagocytic syndrome associated with infection**  
This is an uncommon hematologic disorder that, typically, clinically manifests as fever, hepatosplenomegaly, lymphadenopathy, jaundice and rash, with laboratory findings of histiocytosis, and the pathologic finding of haemophagocytosis, infection-associated.
- 3B62.Y** **Other specified qualitative platelet defects**

3B62.Z	<b>Qualitative platelet defects, unspecified</b>
3B63	<b>Thrombocytosis</b> A disease caused by essential thrombocytosis or other myelo-proliferative disorders such as chronic myelogenous leukaemia, polycythaemia, myelofibrosis. This disease can also have secondary causes such as inflammation, surgery, hypoplasia, splenectomy, asplenia, iron deficiency anaemia or haemorrhage. This disease is characterised by elevated platelet count in the blood. Confirmation is by identification of increased platelet count in a blood sample.
3B63.0	<b>Congenital thrombocytosis</b> Familial thrombocytosis is a type of thrombocytosis, a sustained elevation of platelet numbers, which affects the platelet/megakaryocyte lineage and may create a tendency for thrombosis and haemorrhage but does not cause myeloproliferation.  <b>Inclusions:</b> Hereditary thrombocytosis <b>Exclusions:</b> Essential thrombocythaemia (3B63.1)
3B63.1	<b>Acquired thrombocytosis</b> A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterised by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or haemorrhage. Progression to a post essential thrombocythaemia myelofibrosis stage or transformation to acute myeloid leukaemia is rarely observed.  <b>Inclusions:</b> Idiopathic haemorrhagic thrombocythaemia
3B63.10	Secondary thrombocytosis
<b>Coding Note:</b>	Code also the causing condition
3B63.1Y	Other specified acquired thrombocytosis
3B63.1Z	Acquired thrombocytosis, unspecified
3B63.Y	<b>Other specified thrombocytosis</b>
3B63.Z	<b>Thrombocytosis, unspecified</b>
3B64	<b>Thrombocytopenia</b> This disease is characterised by decreased levels of platelets within the blood. This disease may present with increased bruising or haemorrhaging. Confirmation is by identification of decreased platelet count in a blood sample.  <b>Coded Elsewhere:</b> Isolated thrombocytopenia (3B62.2)
3B64.0	<b>Congenital thrombocytopenia</b> A disease caused by determinants arising during the antenatal period leading to low platelet count. This disease is characterised by decreased levels of platelets within the blood. This disease may present with increased bruising or haemorrhaging. Confirmation is by identification of a decreased platelet count in a blood sample.

<b>3B64.00</b>	Congenital non-inherited thrombocytopenia  <b>Coded Elsewhere:</b> Transient neonatal thrombocytopaenia (KA89)
<b>3B64.01</b>	Hereditary thrombocytopenia A disease caused by a genetically inherited mutation leading to decreased platelet count. This disease is characterised by decreased levels of platelets within the blood. This disease may present with increased bruising or haemorrhaging. Confirmation is by identification of decreased platelet count in a blood sample.  <b>Coded Elsewhere:</b> Thrombocytopaenia - absent radius (LD2F.1Y)  Familial platelet syndrome with predisposition to acute myelogenous leukaemia (3B62.3)  Congenital thrombotic thrombocytopenic purpura due to ADAMTS-13 deficiency (3B64.14)  Macrothrombocytopenia with mitral valve insufficiency (3B62.01)
<b>3B64.0Z</b>	Congenital thrombocytopenia, unspecified
<b>3B64.1</b>	<b>Acquired thrombocytopenia</b> A disease caused by determinants arising after birth, leading to low platelet count. This disease is characterised by low levels of platelets within the blood. This disease may present with increased bruising or haemorrhaging. Confirmation is by identification of decreased platelet count in a blood sample.
<b>3B64.10</b>	Immune thrombocytopenic purpura Immune thrombocytopenic purpura (or immune thrombocytopenia; ITP) is an autoimmune coagulation disorder characterised by isolated thrombocytopenia (a platelet count <100,000/microL), in the absence of any underlying disorder that may be associated with thrombocytopenia.  <b>Coded Elsewhere:</b> Evans syndrome (3A20.5)
<b>3B64.11</b>	Secondary thrombocytopenic purpura This disease is characterised by a relative decrease in levels of platelets within the blood. This disease may present with increased bruising or haemorrhaging. Confirmation is by identification of decreased platelets in a blood sample.
<b>Coding Note:</b>	Code also the causing condition
<b>3B64.12</b>	Drug-induced thrombocytopenic purpura Thrombocytopenic purpura attributable to drug toxicity (e.g. cytotoxic chemotherapeutic or immunosuppressive agents) or to an idiosyncratic drug-associated allergic thrombocytopenia (e.g. quinine, thiazides).
<b>3B64.13</b>	Alloimmune thrombocytopenia A disease caused by determinants such as a blood transfusion that lead to an immune response to the foreign antigens. This disease is characterised by low levels of platelets in the body due to an immune reactive response to the foreign platelet antigens. This disease may present with increased bruising or haemorrhaging. Confirmation is by identification of decreased platelet count and presence of autoantibodies in a blood sample.

<b>3B64.14</b>	Thrombotic thrombocytopenic purpura This condition is idiopathic. This condition is characterised by abnormality of blood coagulation causing extensive microscopic clots to form in the small blood vessels throughout the body resulting in low platelet count. This condition may present with seizures, hemiplegia, paresthesias, visual disturbance, and aphasia or anaemia. Confirmation is by identification of thromboses.
<b>3B64.1Y</b>	Other specified acquired thrombocytopenia
<b>3B64.Z</b>	<b>Thrombocytopenia, unspecified</b>
<b>3B65</b>	<p><b>Thrombotic microangiopathy, not elsewhere classified</b></p> <p>Thrombotic microangiopathies are microvascular occlusive disorders characterised by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes. Thrombotic thrombocytopenic purpura (TTP) and haemolytic–uremic syndrome (HUS) represent a spectrum of thrombotic microangiopathies. In TTP, systemic microvascular aggregation of platelets causes ischemia in the brain and other organs. In HUS, platelet–fibrin thrombi predominantly occlude the renal circulation.</p> <p><b>Coded Elsewhere:</b> Thrombotic thrombocytopenic purpura (3B64.14)</p> <ul style="list-style-type: none"> <li>Haemolytic uraemic syndrome (3A21.2)</li> <li>Methylcobalamin deficiency type cbl G (5C50.B)</li> <li>Hereditary haemolytic uraemic syndrome (3A10.Y)</li> </ul>
<b>3B6Y</b>	<b>Other specified coagulation defects, purpura or other haemorrhagic or related conditions</b>
<b>3B6Z</b>	<b>Coagulation defects, purpura or other haemorrhagic or related conditions, unspecified</b>

## Diseases of spleen (3B80-3B8Z)

<b>3B80</b>	<b>Congenital disorders of spleen</b> Any condition caused by a failure of the spleen to correctly develop in the antenatal period.  <b>Coded Elsewhere:</b> Structural developmental anomalies of spleen (LB22)
<b>3B80.0</b>	<b>Splenomegaly in storage diseases</b> A disease caused by storage diseases; genetically inherited metabolic disorders that result from defects in lysosomal, lipid or glycogen function, of the spleen. This disease is characterised by enlargement of the spleen. This disease may present with abdominal pain, chest pain, pallor, shortness of breath fatigue. Confirmation is through medical imaging.

**3B81**

**Acquired disorders of spleen**

Any condition caused by determinants acquired after birth, leading to dysfunction of the spleen.

**Coded Elsewhere:** Injury of spleen (NB91.0)

Malignant neoplasms of the spleen (2C11.Z)

**3B81.0**

**Tumour-like conditions of spleen**

Any condition caused by determinants acquired after birth, in the antenatal period or genetically inherited factors, leading to tumour-like conditions of the spleen. Confirmation is through medical imaging.

**3B81.1**

**Postsurgical asplenia**

A disease caused by underlying diseases, splenectomy or splenic rupture from trauma. This disease is characterised by absence of normal spleen function. This disease may present with increased susceptibility to infection. Confirmation is through medical imaging.

**3B81.2**

**Atrophy of spleen**

A disease caused by determinants arising after birth, during the antenatal period or by genetically inherited factors. This disease is characterised by partial or complete degradation of the spleen. This disease may present with increased susceptibility to infection. Confirmation is through medical imaging.

**3B81.3**

**Nontraumatic laceration or rupture of spleen**

A disease caused by non-traumatic determinants such as infectious diseases, medical procedures such as colonoscopy, haematological diseases, medications, or pregnancy. This disease is characterised by laceration or rupturing of the spleen leading to lack of function. This disease may present with bleeding and increased susceptibility of infection. Confirmation is through medical imaging.

**3B81.4**

**Splenosis**

A disease caused by determinants arising after birth such as physical trauma or splenectomy . This disease is characterised by autoimplantation of one or more focal deposits of splenic tissue in various compartments of the body. Confirmation is through medical imaging.

**3B81.5**

**Splenic cyst or pseudocyst**

**3B81.50**

**Pseudocyst of spleen**

A disease caused by determinants arising after birth, during the antenatal period or by genetically inherited factors. This disease is characterised by a noncancerous fluid-filled sac, pseudocysts are like cysts, but lack epithelial or endothelial cells. This disease is often asymptomatic but may present with abdominal pain, nausea and vomiting. Confirmation is through medical imaging.

**3B81.51**

**Epithelial cyst of spleen**

**3B81.5Y**

**Other specified splenic cyst**

**3B81.5Z**

**Splenic cyst, unspecified**

<b>3B81.6</b>	<b>Infarction of spleen</b> A disease caused by determinants such as trauma, infection, or inherited factors leading to a shortage of oxygen in the spleen. This disease is characterised by death of spleen tissue and loss of function. Confirmation is by medical imaging.  <b>Exclusions:</b> traumatic rupture of spleen (NB91.0) <b>Coded Elsewhere:</b> Neonatal haemorrhage originating in spleen (KA83.5)
<b>3B81.7</b>	<b>Infection of spleen</b> Any condition of the spleen, caused by an infection with a bacterial, viral, fungal, or parasitic source.
<b>3B81.70</b>	Acute septic splenitis  <b>Inclusions:</b> septic spleen
<b>3B81.71</b>	Abscess of spleen This is a collection of pus (neutrophils) that has accumulated within a tissue because of an inflammatory process in response to either an infectious process (usually caused by bacteria or parasites) or other foreign materials (e.g., splinters, bullet wounds, or injecting needles), in the spleen.
<b>3B81.7Y</b>	Other specified infection of spleen
<b>3B81.7Z</b>	Infection of spleen, unspecified
<b>3B81.8</b>	<b>Torsion of spleen</b> A disease caused by abnormal development of splenic suspensory ligaments. This disease is characterised by twisting of the spleen leading to splenic infarction. This disease may present with abdominal pain. Confirmation is through medical imaging.
<b>3B81.9</b>	<b>Fibrosis of spleen</b> A disease caused by determinants arising after birth, during the antenatal period or by genetically inherited factors. This disease is characterised by formation of excess fibrous connective tissue leading to partial or complete degradation of the spleen. This disease may present with increased susceptibility to infection. Confirmation is through medical imaging.  <b>Coding Note:</b> Code also the causing condition
<b>3B81.A</b>	<b>Perisplenitis</b> A disease caused by bacterial or viral infection, parasite infestation, or cysts. This disease is characterised by inflammation of the peritoneal surface of the spleen. This disease may present with abdominal pain, susceptibility to infection and enlargement of the spleen. Confirmation is by identification of infection in a blood sample.

**3B81.B**      **Hypersplenism**  
A disease caused by determinants such as cirrhosis, malaria, tuberculosis or inflammatory disorders leading overactive spleen function. This disease is characterised by the presence of an enlarged spleen. Confirmation is by identification through medical imaging.

**Exclusions:**      Splenomegaly, not elsewhere classified (ME10.01)  
congenital splenomegaly (LB22)

**3B81.C**      **Chronic congestive splenomegaly**  
A form of exaggerated spleen function characterised by splenic enlargement secondary to splenic vein thrombosis and/or portal hypertension

**3B81.Y**      **Other specified acquired disorders of spleen**

**3B81.Z**      **Acquired disorders of spleen, unspecified**

**3B8Z**      **Diseases of spleen, unspecified**

---

**3C0Y**      **Other specified diseases of the blood or blood-forming organs**

**3C0Z**      **Diseases of the blood or blood-forming organs, unspecified**

# CHAPTER 04

---

## Diseases of the immune system

This chapter has 45 four-character categories.

Code range starts with 4A00

**Exclusions:** Complications of pregnancy, childbirth and the puerperium (Chapter 18)

Neoplasms (Chapter 02)

Developmental anomalies (Chapter 20)

**Coded Elsewhere:** Organ specific autoimmune disorders

Symptoms, signs or clinical findings of blood, blood-forming organs, or the immune system (MA10-MA3Y)

This chapter contains the following top level blocks:

- Primary immunodeficiencies
- Nonorgan specific systemic autoimmune disorders
- Autoinflammatory disorders
- Allergic or hypersensitivity conditions
- Immune system disorders involving white cell lineages
- Certain disorders involving the immune system
- Organ specific autoimmune disorders

### Primary immunodeficiencies (4A00-4A0Z)

#### **4A00 Primary immunodeficiencies due to disorders of innate immunity**

**Coded Elsewhere:** Constitutional neutropaenia (4B00.00)

#### **4A00.0 Functional neutrophil defects**

**Inclusions:** Congenital dysphagocytosis

**Coded Elsewhere:** Haemolytic anaemia due to glucose-6-phosphate dehydrogenase deficiency (3A10.00)

Papillon-Lefèvre syndrome (EC20.30)

#### **4A00.00 Neutrophil immunodeficiency syndrome**

Neutrophil immunodeficiency syndrome is a primary immunodeficiency characterised by neutrophilia with severe neutrophil dysfunction, leukocytosis, a predisposition to bacterial infections and poor wound healing, including an absence of pus in infected areas.

#### **4A00.0Y Other specified functional neutrophil defects**

- 4A00.0Z** Functional neutrophil defects, unspecified
- 4A00.1** **Defects in the complement system**
- Exclusions:** Atypical haemolytic uraemic syndrome (3A10)  
Paroxysmal nocturnal haemoglobinuria (3A21.0)
- 4A00.10** Immunodeficiency with an early component of complement deficiency
- 4A00.11** Immunodeficiency with a late component of complement deficiency
- 4A00.12** Immunodeficiency with factor B deficiency
- 4A00.13** Immunodeficiency with factor D anomaly  
Factor D deficiency is an autosomal recessive immunologic disorder characterised by increased susceptibility to bacterial infections, particularly *Neisseria* infections, due to a defect in the alternative complement pathway.
- 4A00.14** Hereditary angioedema  
Hereditary angioedema is caused in the majority of cases by genetically determined low absolute (type I) or functional (type II) levels of C1 inhibitor, a plasma proteinase inhibitor involved in regulation of complement activation. It is characterised clinically by recurrent subcutaneous and/or submucosal oedema and can result in life-threatening laryngeal obstruction. Involvement of the digestive tract commonly causes abdominal pain. This and the absence of accompanying urticarial weals or itch distinguish it from the common form of angioedema, which is part of the spectrum of urticaria.
- 4A00.15** Acquired angioedema  
Acquired angioedema is clinically similar to hereditary angioedema and is not associated with urticaria. It may be associated with a lymphoproliferative disorder (type I) or may be an isolated phenomenon due to an autoantibody directed against C1 inhibitor (type II).
- 4A00.1Y** Other specified defects in the complement system
- 4A00.1Z** Defects in the complement system, unspecified
- 4A00.2** **Genetic susceptibility to particular pathogens**
- Coded Elsewhere:** Encephalitis due to herpes simplex virus (1F00.21)  
Chronic mucocutaneous candidosis (1F23.14)
- 4A00.3** **Immunodeficiency with natural-killer cell deficiency**
- 4A00.Y** Other specified primary immunodeficiencies due to disorders of innate immunity
- 4A00.Z** Primary immunodeficiencies due to disorders of innate immunity, unspecified
- 4A01** **Primary immunodeficiencies due to disorders of adaptive immunity**
- 4A01.0** **Immunodeficiencies with predominantly antibody defects**  
A disorder characterised by an inability to mount a normal immune response due to antibody (i.e. immunoglobulin) defects

- 4A01.00** Hereditary agammaglobulinaemia with profoundly reduced or absent B cells  
 This refers to a hereditary type of primary immune deficiency disease characterised by a reduction in all types of gamma globulins, and rare X-linked genetic disorder that affects the body's ability to fight infection.
- 4A01.01** Immunodeficiencies with severe reduction in at least two serum immunoglobulin isotypes with normal or low numbers of B cells  
 This refers to a nonfamilial type of primary immune deficiency disease characterised by a reduction in at least two serum immunoglobulin isotypes. Circulating B cells may be normal or low.
- 4A01.02** Specific antibody deficiency with normal immunoglobulin concentrations or normal number of B cells
- 4A01.03** Transient hypogammaglobulinaemia of infancy
- 4A01.04** Immunodeficiencies with isotype or light chain deficiencies with normal number of B cells
- 4A01.05** Immunodeficiencies with severe reduction in serum IgG or IgA with normal or elevated IgM and normal numbers of B-cells  
**Coded Elsewhere:** Hyper-IgM syndrome due to CD40 ligand deficiency (4A01.1Y)  
 Hyper-IgM syndrome due to CD40 deficiency (4A01.1Y)
- 4A01.0Y** Other specified immunodeficiencies with predominantly antibody defects
- 4A01.0Z** Immunodeficiencies with predominantly antibody defects, unspecified
- 4A01.1** **Combined immunodeficiencies**  
**Exclusions:** autosomal recessive agammaglobulinaemia (Swiss type) (4A01.00)  
**Coded Elsewhere:** Laron syndrome with immunodeficiency (5A61.0)
- 4A01.10** Severe combined immunodeficiencies  
 Severe combined immunodeficiency (SCID) comprises a group of rare monogenic primary immunodeficiency disorders characterised by a lack of functional peripheral T lymphocytes resulting in early-onset severe respiratory infections and failure to thrive.
- 4A01.11** Major histocompatibility complex class I deficiency
- 4A01.12** Major histocompatibility complex class II deficiency  
 Immunodeficiency by defective expression of HLA class II is an autosomal recessive primary immune deficiency, manifesting by recurrent viral and bacterial infections, often leading to chronic diarrhoea and growth retardation.
- 4A01.1Y** Other specified combined immunodeficiencies
- 4A01.1Z** Combined immunodeficiencies, unspecified
- 4A01.2** **Diseases of immune dysregulation**

- 4A01.20** Immune dysregulation syndromes with hypopigmentation  
**Coded Elsewhere:** Hermansky-Pudlak syndrome (EC23.20)  
Chédiak-Higashi syndrome (EC23.20)  
Griselli syndrome type 2 (4A01.23)
- 4A01.21** Immune dysregulation syndromes presenting primarily with autoimmunity  
**Coded Elsewhere:** Autoimmune polyendocrinopathy type 1 (5B00)  
Syndromic multisystem autoimmune disease due to ITCH deficiency (4A43.Y)  
Aicardi-Goutières syndrome (5C55.2)  
Spondyloepiphyseal dysplasia with combined immunodeficiency (LD24.4)
- 4A01.22** Immune dysregulation syndromes presenting primarily with lymphoproliferation
- 4A01.23** Primary haemophagocytic lymphohistiocytosis  
A disease caused by determinants arising after birth, during the antenatal period or genetically inherited factors leading to uncontrolled proliferation of activated lymphocytes and macrophages. This disease is characterised by increased proliferation of morphologically benign lymphocytes and macrophages that secrete high amounts of inflammatory cytokines. This disease may present with fever, rash, jaundice, splenomegaly, lymphadenopathy, histiocytosis, haemophagocytosis, or cytopenia.  
**Inclusions:** Histiocytoses of mononuclear phagocytes  
**Coded Elsewhere:** Hermansky-Pudlak syndrome (EC23.20)  
Chédiak-Higashi syndrome (EC23.20)
- 4A01.2Y** Other specified diseases of immune dysregulation
- 4A01.2Z** Diseases of immune dysregulation, unspecified
- 4A01.3** **Other well-defined immunodeficiency syndromes due to defects in adaptive immunity**  
This refers to other defects in the highly specialized, systemic cells and processes that eliminate or prevent pathogen growth.  
**Coded Elsewhere:** Wiskott-Aldrich syndrome (3B62.0Y)  
Netherton syndrome (LD27.2)  
Dyskeratosis congenita (3A70.0)
- 4A01.30** Immunodeficiency due to defects of the thymus  
**Coded Elsewhere:** CATCH 22 phenotype (LD44.N0)
- 4A01.31** DNA repair defects other than combined T-cell or B-cell immunodeficiencies
- 4A01.32** Immuno-osseous dysplasia  
This is an autosomal recessive disorder with the diagnostic features of spondyloepiphyseal dysplasia, renal dysfunction, and T-cell immunodeficiency.  
**Coded Elsewhere:** Cartilage-hair hypoplasia (LD27.0Y)

- 4A01.33** Hepatic veno-occlusive disease - immunodeficiency syndrome  
 Hepatic veno-occlusive disease - immunodeficiency syndrome is characterised by the association of severe hypogammaglobulinemia, combined T and B cell immunodeficiency, absent lymph node germinal centres, absent tissue plasma cells and hepatic veno-occlusive disease.
- 4A01.34** Hyperimmunoglobulin E syndromes
- 4A01.Z** Primary immunodeficiencies due to disorders of adaptive immunity, unspecified
- 4A0Y** Other specified primary immunodeficiencies
- 4A0Z** Primary immunodeficiencies, unspecified
- 4A20** Acquired immunodeficiencies
- Coded Elsewhere:** Human immunodeficiency virus disease (1C60-1C62.Z)  
 Acquired neutropaenia (4B00.01)
- 4A20.0** Adult-onset immunodeficiency  
 Adults with disseminated mycobacterial infections and/or other AIDS-defining infections, often involving concomitant neutrophilic dermatoses. All patients have high titres of anti-interferon-gamma and normal CD4 T helper cell counts.
- 4A20.1** Acquired immunodeficiency due to loss of immunoglobulin  
 Acquired immunodeficiency due to loss of immunoglobulins (protein loss) may occur via the GI tract (protein losing enteropathy), via the kidney (nephrotic syndrome) or via the skin (in severe skin damage).
- 4A20.Y** Other specified acquired immunodeficiencies
- 4A20.Z** Acquired immunodeficiencies, unspecified

## Nonorgan specific systemic autoimmune disorders (4A40-4A4Z)

**Coded Elsewhere:** Rheumatoid arthritis (FA20)

- 4A40** Lupus erythematosus  
 An autoimmune non-organ specific inflammatory disease characterised by the presence of antibodies to DNA, RNA and other components of the nucleus. It has a very variable clinical presentation and course ranging from an acute fulminant life-threatening disorder with involvement of heart, central nervous system and kidneys to an indolent chronic scarring skin disorder.
- Coded Elsewhere:** Subacute cutaneous lupus erythematosus (EB50)  
 Chronic cutaneous lupus erythematosus (EB51)  
 Neonatal lupus erythematosus (KA07.0)

- 4A40.0** **Systemic lupus erythematosus**  
Systemic lupus erythematosus (SLE) is a clinically multisystem disease, which is autoimmune in origin and is characterised by the presence of autoantibodies directed against nuclear antigens. Manifestations include rash, arthritis and fatigue, nephritis, neurological problems, anaemia and thrombocytopenia at the more severe end of the spectrum.
- 4A40.00** Systemic lupus erythematosus with skin involvement  
Systemic lupus erythematosus (SLE) involving the skin. This may present with a malar "butterfly" erythema or with extensive necrolysis of sun-exposed skin, particularly on the head, neck and upper torso.  
**Coded Elsewhere:** Immunobullous systemic lupus erythematosus (EB4Y)
- 4A40.0Y** Other specified systemic lupus erythematosus
- 4A40.0Z** Systemic lupus erythematosus, unspecified
- 4A40.1** **Drug-induced lupus erythematosus**  
Drug-induced lupus erythematosus is a syndrome in which positive antinuclear antibodies are associated with symptoms, such as fever, malaise, arthritis, intense arthralgia/myalgia, serositis, and/or rash. The syndrome appears during therapy with certain medications (e.g., procainamide, hydralazine, phenytoin) and tumour necrosis factor inhibitors. It occurs predominantly in Caucasians, has less female predilection than SLE, rarely involves kidneys or brain, is rarely associated with anti-dsDNA, is commonly associated with antibodies to histones, and usually resolves over several weeks after discontinuation of the offending medication.
- 4A40.Y** Other specified lupus erythematosus
- 4A40.Z** Lupus erythematosus, unspecified
- 4A41** **Idiopathic inflammatory myopathy**  
These comprise a diverse group of syndromes that have in common persistent muscle inflammation of unknown pathophysiology, resulting in damage that affects muscle function. The inflammatory muscle disease can either be acute or chronic in nature.  
**Coded Elsewhere:** Extraocular myositis (9C82.3)
- 4A41.0** **Dermatomyositis**  
Dermatomyositis is an inflammatory myopathy, showing progressive, symmetrical muscle weakness, low muscle endurance, and cutaneous manifestations such as Gottron's papules, heliotrope rash, shawl sign, V-sign and mechanic's hand. Internal organ manifestations such as interstitial pneumonia (pneumonitis) and myocarditis sometimes develop. The skin rash may precede the muscle symptoms and may be the only clinical sign of dermatomyositis in some patients (clinically, amyopathic dermatomyositis).

<b>4A41.00</b>	Adult dermatomyositis Adult dermatomyositis is a systemic inflammatory disorder affecting the skeletal muscles, the skin, and other organs. It is characterised by symmetric proximal muscle weakness, increased serum muscle enzymes, myopathic changes upon electromyography, typical histological findings on muscle biopsy, and typical dermatologic manifestations such as heliotrope rash or Gottron's papules.
	<b>Exclusions:</b> Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)
<b>4A41.01</b>	Juvenile dermatomyositis Juvenile dermatomyositis is the early-onset form of dermatomyositis, a systemic autoimmune inflammatory muscle disorder, characterised by proximal muscle weakness, evocative skin lesion, and systemic manifestations.
<b>4A41.0Z</b>	Dermatomyositis, unspecified
<b>4A41.1</b>	<b>Polymyositis</b> Polymyositis is an inflammatory muscle disease of unknown aetiology occurring predominantly in adults and characterised clinically by proximal muscle weakness (shoulders, arms, thighs), often with associated myalgia. Involvement of pharyngeal and oesophageal muscles may result in dysphagia and a risk of aspiration pneumonia. Myocarditis with rhythm disturbances or cardiomyopathy is a rare but serious complication. Polymyositis may be associated with other autoimmune diseases, malignancy or viral infection. Although serum muscle enzyme concentrations and electromyography are usually abnormal, definitive diagnosis requires demonstration of characteristic histological changes, including muscle necrosis, muscle fibre regeneration and diffuse infiltration by CD8+ T lymphocytes, on muscle biopsy.
<b>4A41.10</b>	Juvenile polymyositis Juvenile polymyositis is a rare childhood idiopathic inflammatory myopathy. It is frequently misdiagnosed, as it lacks a unique clinical phenotype. Traditionally, it presents with weakness of the proximal muscles that evolves over weeks to months. The primary histologic features are fibre size variability, scattered necrotic and regenerating fibres, and perivascular and endomysial cellular infiltrates.
	<b>Exclusions:</b> Systemic sclerosis (4A42) Overlap or undifferentiated nonorgan specific systemic autoimmune disease (4A43) Antiphospholipid syndrome (4A45) Vasculitis (4A44) Lupus erythematosus (4A40)

<b>4A41.11</b>	Paraneoplastic polymyositis Paraneoplastic is a rare cancer associated entity. It presents sub-, or acutely with proximal weakness, often including the neck flexors, dysphagia, rarely the respiratory muscles and the heart are involved. Sometimes muscle pain or myalgia occur. Myopathology shows a targeted, cell-mediated lymphocyte toxicity against muscle fibres in focal areas of inflammation within perimysial connective tissue and surrounding blood vessels. Muscle fibres may be destroyed by cytotoxic T cells. Non-Hodgkin's lymphoma, lung, and bladder carcinoma are the most frequently observed associated cancer types.
<b>Coding Note:</b>	Code also the causing condition
<b>4A41.1Y</b>	Other specified polymyositis
<b>4A41.1Z</b>	Polymyositis, unspecified
<b>4A41.2</b>	<p><b>Inclusion body myopathy</b></p> <p>Inclusion body myopathy (IBM) is distinguished from polymyositis (PM) and dermatomyositis (DM) on the basis of clinical and histopathological features. A characteristic clinical phenotype is characterised by insidious onset of muscle weakness over months to years, muscle weakness localised predominantly in the thigh muscles and finger flexors, and resistance to glucocorticoid treatment. Typical histopathologic features include sarcoplasmic and nuclear inclusions and rimmed vacuoles.</p>
<b>4A41.20</b>	<p><b>Inflammatory inclusion body myositis</b></p> <p>Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy after age 50. It typically presents with chronic insidious proximal leg and/or distal arm asymmetric muscle weakness leading to recurrent falls and loss of dexterity. Creatine kinase is up to 15 times elevated in IBM and needle electromyography mostly shows a chronic irritative myopathy. Muscle histopathology demonstrates endomysial inflammatory exudates surrounding and invading non-necrotic muscle fibres often times accompanied by rimmed vacuoles and protein deposits. Despite inflammatory muscle pathology, it is likely that IBM has a prominent degenerative component as supported by refractoriness to immunosuppressive therapy.</p> <p><b>Exclusions:</b>      Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)</p>
<b>4A41.21</b>	<p><b>Noninflammatory inclusion body myopathy</b></p> <p>Noninflammatory inclusion body myopathy (IBM) is an idiopathic muscle disorder without inflammatory exudates and expression of class I major histocompatibility complex. Rimmed vacuoles and "IBM-like" filaments without inflammatory cells are described in muscle biopsy.</p> <p><b>Exclusions:</b>      Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)</p>
<b>4A41.2Z</b>	Inclusion body myopathy, unspecified
<b>4A41.Y</b>	<b>Other specified idiopathic inflammatory myopathy</b>

**4A41.Z Idiopathic inflammatory myopathy, unspecified**

**4A42 Systemic sclerosis**

Systemic sclerosis is a systemic disorder of the connective tissue; manifested by hardening and thickening of the skin, by abnormalities involving the microvasculature and larger vessels, and by fibrotic degenerative changes in various body organs including the heart, lungs, kidneys, and gastrointestinal tract. (Arthritis Rheum 1980;23:581-590)

**Inclusions:** Systemic scleroderma

**Exclusions:** Circumscribed scleroderma (EB61.0)

**4A42.0 Paediatric onset systemic sclerosis**

Systemic sclerosis arising before the age of 16. Involvement of internal organs is less common but arthritis and myositis are more common than in adults.

**4A42.1 Diffuse systemic sclerosis**

Diffuse cutaneous systemic sclerosis (dcSSc) is a subtype of Systemic Sclerosis (SSc) characterised by truncal and acral skin fibrosis with an early and significant incidence of diffuse involvement (interstitial lung disease, oliguric renal failure, diffuse gastrointestinal disease, and myocardial involvement).

**4A42.2 Limited systemic sclerosis**

Combination of calcinosis, Raynaud phenomenon, oesophageal dysfunction, sclerodactyly and telangiectasia.

**4A42.Z Systemic sclerosis, unspecified**

**4A43 Overlap or undifferentiated nonorgan specific systemic autoimmune disease**

Nonorgan specific systemic autoimmune diseases which do not fulfil the diagnostic criteria for any single recognised disease entity.

**4A43.0 IgG4 related disease**

IgG4 related syndrome (IgG4-related disease: IgG4-RD) is a clinical disease characterised by elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4-positive plasma cells. The diagnostic criteria for IgG4 related syndrome have been proposed, and it may be present in a certain population of patients with a wide variety of diseases, including Mikulicz disease, autoimmune pancreatitis, hypophysitis, Riedel thyroiditis, interstitial pneumonitis, interstitial nephritis, prostatitis, lymphadenopathy, retroperitoneal fibrosis, inflammatory aortic aneurysm, and inflammatory pseudo tumour.

**Coded Elsewhere:** Primary cutaneous plasmacytosis (EK91.2)

Benign dermal lymphocytic or lymphoplasmacytic infiltrations or proliferations (EE90-EE91)

Type 1 IgG4 related autoimmune pancreatitis (DC33)

- 4A43.1 Mikulicz disease**  
Mikulicz disease is a disorder first reported by Johann von Mikulicz in 1892 and characterised by symmetrical swelling of the lachrymal, submandibular, and parotid glands, with massive infiltration of these glands by mononuclear cells. Serum autoantibodies, such as anti-Ro/SS-A, are usually negative and serum IgG4 concentration may be increased. Unlike Sjögren disease, IgG4-Mikulicz disease is characterised by the formation of lymphoid follicles, but shows lower levels of lymphocytic infiltration into salivary ducts, such that their structure remains intact.
- 4A43.2 Sjögren syndrome**  
Sjögren syndrome is a slowly progressive, systemic inflammatory autoimmune disease affecting primarily the exocrine glands. Lymphocytic infiltrates replace functional epithelium, leading to oral and ocular dryness. Characteristic autoantibodies (e.g., anti-Ro/SS-A and/or anti-La/SS-B) are produced. The disorder can occur alone (it is then known as "primary SS") or in association with another autoimmune disease (it is then known as "secondary SS").  
**Coded Elsewhere:** Keratoconjunctivitis sicca (9A79)
- 4A43.20 Primary Sjögren syndrome**
- 4A43.21 Secondary Sjögren syndrome**  
Secondary Sjögren syndrome is a progressive inflammatory autoimmune disease affecting the exocrine glands in the presence of other systemic autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. Lymphocytic infiltrates replace functional epithelium, leading to oral and ocular dryness.
- Coding Note:** Code also the causing condition
- 4A43.22 Paediatric onset Sjögren syndrome**
- 4A43.2Y Other specified sjögren syndrome**
- 4A43.2Z Sjögren syndrome, unspecified**
- 4A43.3 Mixed connective tissue disease**  
Mixed connective tissue disease is an overlapping syndrome combining features of systemic lupus erythematosus, systemic sclerosis, and polymyositis with the presence of autoantibodies to U1-ribonucleoprotein. Raynaud's phenomenon is seen in nearly all patients and pulmonary arterial hypertension is the most common cause of death in MCTD patients.
- 4A43.4 Diffuse eosinophilic fasciitis**  
Also called Shulman disease/diffuse fasciitis, diffuse eosinophilic fasciitis is a rare idiopathic disorder associated with induration of the skin (orange-peel sign) that generally develops rapidly. It is a dermal and hypodermal sclerosis associated with fibrotic thickening of the subcutaneous adipose lobular septa, superficial fascia, and perimysium. Full thickness excisional biopsy of skin lesions revealing fibrosis of the subcutaneous fascia is generally required for diagnosis. Onset follows unusual physical exertion and trauma, especially in males.
- 4A43.Y Other specified overlap non-organ specific systemic autoimmune disease**

**4A43.Z Undifferentiated non-organ specific systemic autoimmune disease**

**4A44**

### **Vasculitis**

Vasculitides represent a heterogenous group of diseases of multifactorial aetiology characterised by inflammatory lesions of vessels. These lesions consist of fibrinoid necrosis (necrotizing arteritis), giant cell infiltration without necrosis, immunoglobulins deposit or leukocytoclastic infiltration. The spectrum and severity of the systemic vasculitides is broad, from life or sight threatening fulminant disease to relatively minor skin disease.

**Coded Elsewhere:** Behçet disease (4A62)

Thrombotic microangiopathy, not elsewhere classified (3B65)

**4A44.0 Rhizomelic pseudopolyarthritits**

**4A44.1 Aortic arch syndrome**

Arteritis, often granulomatous, predominantly affecting the aorta and/or its major branches. Onset usually in patients younger than 50.

**4A44.2 Giant cell arteritis**

Arteritis, often granulomatous, usually affecting the aorta and/or its major branches, with a predilection for the branches of the carotid artery. Often involves the temporal artery. Onset usually in patients older than 50 and often associated with polymyalgia rheumatica.

**4A44.3 Single organ vasculitis**

Vasculitis in arteries or veins of any size in a single organ that has no features that indicate that it is a limited expression of a systemic vasculitis. The involved organ and vessel type should be included in the name (e.g. cutaneous SVV, testicular arteritis, central nervous system vasculitis). Vasculitis distribution may be unifocal or multifocal (diffuse) within an organ. Some patients originally diagnosed with SOV will develop additional disease manifestations that warrant re-defining the case as one of the systemic vasculitides (e.g. cutaneous arteritis later becoming systemic polyarteritis nodosa, etc.). Chapel Hill Consensus Conference, 2011)

**4A44.4 Polyarteritis nodosa**

Polyarteritis nodosa is an immunologically mediated systemic necrotising vasculitis affecting medium-sized vessels. In a few cases, the disease appears after viral infection but in the majority of cases there is no known triggering event. The clinical manifestations involve numerous organs and lead to a general alteration in the health status including rapid weight loss, paralysis of the peripheral nerves, renal disease, and digestive problems such as haemorrhages, perforation, appendicitis and pancreatitis. Arthralgia is almost always present and myalgia occurs in half of patients. Cardiac and cerebral anomalies (cephalalgia) are also reported, as well as ocular and genital (orchitis) manifestations.

- 4A44.5 Mucocutaneous lymph node syndrome**  
Mucocutaneous lymph node syndrome (Kawasaki disease) is a globally distributed acute vasculitis of young children affecting medium to small calibre arteries and if untreated leads to coronary artery aneurysms in about a quarter of cases. Cardinal signs include cervical lymphadenopathy, conjunctival injection, rash (maculopapular, erythrodermic or erythema multiforme-like), strawberry tongue, oropharyngeal erythema, erythema and swelling of hands and feet and periungual desquamation. The cause is unknown but thought to be environmental, possibly from viral infection. A variant of the disease has been linked to SARS CoV-2 infection.
- Inclusions:** Kawasaki syndrome
- 4A44.6 Sneddon syndrome**  
Sneddon syndrome associates livedo reticularis and neurological signs. Livedo is permanent, cyanotic, with no infiltration, and affects the limbs, trunk and sometimes the face. Neurological signs appear later and include cerebrovascular accidents, epilepsy, vertigo and more rarely a pseudobulbar syndrome, chorea, episodes of amnesia or transient amaurosis.
- 4A44.7 Primary angiitis of the central nervous system**  
In primary angiitis of the central nervous system, vasculitis is limited to the central nervous system. Primary angiitis of the central nervous system is a very rare disease, and its manifestation can be mimicked by many other diseases. Patients with primary angiitis commonly show headache, waxing and waning altered mental status, and transient ischemic attack-like events. Diagnosis is often based on angiography, although brain biopsy remains the only definitive diagnostic test.
- 4A44.8 Thromboangiitis obliterans**  
Thromboangiitis obliterans (TAO), or Buerger's disease, is a segmental occlusive inflammatory condition of arteries and veins, with thrombosis and recanalization of the affected vessels. It is a nonatherosclerotic inflammatory disease affecting small and medium sized arteries and veins of upper and lower extremities. TAO can be distinguished from other types of vasculitis based on its tendency to occur in young male subjects. The etiology and pathogenesis of TAO remains unknown; however, tobacco consumption plays a key role in the initiation and persistence of the disease.
- 4A44.9 Immune complex small vessel vasculitis**  
**Coded Elsewhere:** Anti-glomerular basement membrane antibody mediated disease (MF85)  
Susac syndrome (8A45.2Y)
- 4A44.90 Cryoglobulinaemic vasculitis**  
Vasculitis with cryoglobulin immune deposits affecting small vessels (predominantly capillaries, venules, or arterioles) and associated with cryoglobulins in serum. Skin and glomeruli are often involved.

<b>4A44.91</b>	Hypocomplementaemic urticarial vasculitis Vasculitis accompanied by urticaria and hypocomplementemia affecting small vessels (i.e., capillaries, venules, or arterioles), and associated with anti-C1q antibodies. Glomerulonephritis, arthritis, obstructive pulmonary disease, and ocular inflammation are common.(Chapel Hill Consensus Conference, 2011)
<b>4A44.92</b>	IgA vasculitis Vasculitis, with IgA1-dominant immune deposits, affecting small vessels (predominantly capillaries, venules, or arterioles). Often involves skin and gut, and frequently causes arthritis. Glomerulonephritis indistinguishable from IgA nephropathy may occur.  <b>Inclusions:</b> Henoch-Schönlein purpura <b>Coded Elsewhere:</b> Respiratory disorders in IgA vasculitis (CB05.4Y) Noninfectious enteritis or ulcer due to IgA vasculitis (DA94.Y)
<b>4A44.9Y</b>	Other specified immune complex small vessel vasculitis
<b>4A44.9Z</b>	Immune complex small vessel vasculitis, unspecified
<b>4A44.A</b>	<b>Antineutrophil cytoplasmic antibody-associated vasculitis</b> Necrotizing vasculitis, with few or no immune deposits, predominantly affecting small vessels (i.e., capillaries, venules, arterioles and small arteries), associated with MPO-ANCA or PR3-ANCA. Not all patients have ANCA. Add a prefix indicating ANCA reactivity, e.g. PR3-ANCA, MPO-ANCA, ANCA-negative.
<b>4A44.A0</b>	Microscopic polyangiitis Necrotizing vasculitis, with few or no immune deposits, predominantly affecting small vessels (i.e., capillaries, venules, or arterioles). Necrotizing arteritis involving small and medium sized arteries may be present. Necrotizing glomerulonephritis is very common. Pulmonary capillaritis often occurs. Granulomatous inflammation is absent.  <b>Inclusions:</b> Microscopic polyarteritis <b>Exclusions:</b> Polyarteritis nodosa (4A44.4)
<b>4A44.A1</b>	Granulomatosis with polyangiitis Necrotizing granulomatous inflammation usually involving the upper and lower respiratory tract, and necrotizing vasculitis affecting predominantly small to medium-sized vessels (e.g., capillaries, venules, arterioles, arteries and veins). Necrotizing glomerulonephritis is common. (Arthritis Rheum 1990;33:1101-1107)  <b>Inclusions:</b> Wegener granulomatosis
<b>4A44.A2</b>	Eosinophilic granulomatosis with polyangiitis Eosinophil-rich and necrotizing granulomatous inflammation often involving the respiratory tract, and necrotizing vasculitis predominantly affecting small to medium-sized vessels, and associated with asthma and eosinophilia. ANCA is most frequent when glomerulonephritis is present. (Arthritis Rheum 1990;33:1094-1100)  <b>Inclusions:</b> Churg-Strauss syndrome
<b>4A44.AY</b>	Other specified antineutrophil cytoplasmic antibody-associated vasculitis

- 4A44.AZ** Antineutrophil cytoplasmic antibody-associated vasculitis, unspecified
- 4A44.B** **Leukocytoclastic vasculitis**  
Leukocytoclastic vasculitis (hypersensitivity vasculitis; hypersensitivity angiitis) is a histopathological term commonly used to denote a small-vessel vasculitis. It may be localised to the skin or may manifest in other organs. The internal organs affected most commonly include the joints, the gastrointestinal tract, and the kidneys. The prognosis is good in the absence of internal involvement. Leukocytoclastic vasculitis has many causes including infections, drugs and systemic autoimmune diseases but no cause is identified in up to 50% of patients with this condition.
- 4A44.B0** Cutaneous leukocytoclastic vasculitis  
Skin-limited small vessel leucocytoclastic vasculitis of unspecified or unknown aetiology
- 4A44.BY** Other specified leukocytoclastic vasculitis
- 4A44.BZ** Leukocytoclastic vasculitis, unspecified
- 4A44.Y** **Other specified vasculitis**
- 4A44.Z** **Vasculitis, unspecified**
- 4A45** **Antiphospholipid syndrome**  
Antiphospholipid syndrome, also known as Hughes syndrome, is a systemic autoimmune condition characterised by the presence of antiphospholipid antibodies (aPL) in the serum of patients with thrombotic events and/or recurrent pregnancy complications.
- 4A45.0** **Primary antiphospholipid syndrome**
- 4A45.1** **Secondary antiphospholipid syndrome**
- Coding Note:** Code also the causing condition
- 4A45.2** **Antiphospholipid syndrome in pregnancy**
- 4A45.3** **Lupus anticoagulant-hypoprothrombinaemia syndrome**
- 4A45.Z** **Antiphospholipid syndrome, unspecified**
- 4A4Y** **Other specified nonorgan specific systemic autoimmune disorders**
- 4A4Z** **Nonorgan specific systemic autoimmune disorders, unspecified**

## Autoinflammatory disorders (4A60-4A6Z)

**Coded Elsewhere:** Schnitzler syndrome (EB03)

- 4A60** **Monogenic autoinflammatory syndromes**  
Monogenic hereditary autoinflammatory diseases characterised by apparently unprovoked generalised inflammation in the absence of infection or high titre autoantibodies.

**4A60.0** **Familial Mediterranean fever**  
FMF is an autoinflammatory disease associated with mutations in pyrin resulting in enhanced IL1 beta production. This results in clinical attacks of inflammation in the form of fever and serositis in the form of peritoneal, pleural or synovial inflammation along with increased acute phase reactants.

**4A60.1** **Cryopyrin-associated periodic syndromes**  
CAPS is an autoinflammatory disease associated with gain of function changes in the cryopyrin protein, resulting in inflammasome activation and enhanced IL1 beta production. This results in clinical signs and symptoms of inflammation in the form of rash, fever, joint and eye symptoms with increased acute phase reactants.

*Inclusions:* Cryopyrinopathies

**4A60.2** **Tumour necrosis factor receptor 1 associated periodic syndrome**  
TRAPS is an autoinflammatory disease associated with heterozygous mutations in the gene coding for tumour necrosis factor (TNF) receptor 1 (TNFR1). This results in clinical attacks of inflammation in the form of fever and serositis in the form of peritoneal, pleural or synovial inflammation along with increased acute phase reactants.

**4A60.Y** **Other specified monogenic autoinflammatory syndromes**

**4A60.Z** **Autoinflammatory syndrome, unspecified**

**4A61** **SAPHO syndrome**  
SAPHO syndrome is characterised by a constellation of symptoms and signs including synovitis, acne conglobata or fulminans, palmoplantar pustulosis, hyperostosis and osteitis. Its aetiology is poorly understood.

**4A62** **Behçet disease**  
Behçet disease is a disease of incompletely understood aetiopathogenesis characterised by recurrent oral and/or genital aphthous ulcers accompanied by cutaneous, ocular, articular, gastrointestinal, and/or central nervous system inflammatory lesions. Small vessel vasculitis, thrombotic vasculopathy, arteritis and arterial aneurysms may occur. It has a high prevalence from the Eastern Mediterranean across Central Asia to China and Japan.

*Inclusions:* Adamantiades-Behçet disease

*Coded Elsewhere:* Transient neonatal Behçet disease (KA07.Y)

**4A6Y** **Other specified autoinflammatory disorders**

**4A6Z** **Autoinflammatory disorders, unspecified**

## Allergic or hypersensitivity conditions (4A80-4A8Z)

Allergy is a hypersensitivity reaction initiated by proven immunologic mechanisms.

Hypersensitivity is defined as conditions clinically resembling allergy that cause objectively reproducible symptoms or signs, initiated by exposure to a defined stimulus at a dose tolerated by normal subjects.

**Coded Elsewhere:** Eosinophilia (4B03)

Hypersensitivity reactions of unspecified nature (4B07)

**4A80**

### **Allergic or hypersensitivity disorders involving the respiratory tract**

Allergic or hypersensitivity disorders involving the respiratory tract includes several clinically different conditions that can be considered as hypersensitivity disorders of the upper and lower respiratory tract. The classification of these conditions is complex.

**Coded Elsewhere:** Vasomotor or allergic rhinitis (CA08)

Aspergillus-induced allergic or hypersensitivity conditions  
(CA82.4)

Chronic rhinosinusitis (CA0A)

Asthma (CA23)

Nasal polyp (CA0J)

Hypersensitivity pneumonitis due to organic dust (CA70)

**4A80.0**

#### **Drug-induced bronchospasm**

Drug-induced bronchospasm is a common clinical manifestation triggered by various drugs. It ranges in severity from mild to severe, and even fatal from post-anoxic brain damage. It can be manifested as an isolated event or in combination with other symptoms as representation of drug-induced anaphylaxis.

**4A80.1**

#### **Bronchospasm provoked by allergy to food substance**

Bronchospasm provoked by allergy to food allergens is clinical manifestation triggered by various foods as a phenotype of food hypersensitivity. It is more frequent in the youngest atopic patients and the most common foods responsible for these reactions are cow milk, peanut, egg and tree nuts. This clinical presentation can be manifested as an isolated event or in combination with other symptoms as representation of drug-induced anaphylaxis.

**4A80.Y**

#### **Other specified allergic or hypersensitivity disorders involving the respiratory tract**

**4A80.Z**

#### **Allergic or hypersensitivity disorders involving the respiratory tract, unspecified**

**4A81**

### **Allergic or hypersensitivity disorders involving the eye**

Allergic or hypersensitivity disorders involving the eye includes several clinically different conditions that can be considered as hypersensitivity disorders of the ocular surface. The classification of these conditions is complex.

**Coded Elsewhere:** Allergic conjunctivitis (9A60.02)

Vernal keratoconjunctivitis (9A60.5)

Giant papillary conjunctivitis (9A60.00)

Irritant contact blepharoconjunctivitis (EK02.11)

Acute atopic conjunctivitis (9A60.01)

Allergic contact blepharoconjunctivitis (9A06.72)

Atopic keratoconjunctivitis (9A60.0Y)

Vernal conjunctivitis (9A60.0Y)

**4A82**

### **Allergic or hypersensitivity disorders involving skin or mucous membranes**

Allergic or hypersensitivity disorders involving the skin and mucous includes a heterogeneous group of disorders involving skin and mucous membranes in which either allergy or hypersensitivity play a part.

**Coded Elsewhere:** Allergic contact dermatitis (EK00)

Photo-allergic contact dermatitis (EK01)

Allergic contact urticaria (EK10)

Protein contact dermatitis (EK11)

Allergic contact sensitisation (EK12)

Urticaria, angioedema and other urticarial disorders (EB00-EB0Y)

Atopic eczema (EA80)

Allergy to substances in contact with the skin (EK5Y)

**4A83**

### **Allergic or hypersensitivity disorders involving the gastrointestinal tract**

**Coded Elsewhere:** Allergic gastritis (DA42.4)

Allergic duodenitis (DA51.3)

Allergic or dietetic colitis (DB33.2)

Allergic or dietetic enteritis of small intestine (DA94.2)

**4A83.0**

### **Food-induced eosinophilic gastroenteritis**

A disease characterised by eosinophilic infiltration of various layers of stomach and intestine induced by specific food intake in the absence of any known cause of eosinophilia. It can occur in any age and the symptoms vary depending on the site of the intestinal tract involved and degree of eosinophilic inflammation, might include ascites, weight loss, oedema, obstruction.

- 4A83.1 Food-induced eosinophilic oesophagitis**  
A chronic, immune or antigen-mediated oesophageal disease characterised by eosinophilic infiltration of oesophageal wall induced by specific food intake in the absence of any known cause of eosinophilia. The symptoms are related to oesophageal dysfunction, including feeding disorders, reflux symptoms, vomiting, dysphagia, and food impaction.
- 4A83.Y Other specified allergic or hypersensitivity disorders involving the gastrointestinal tract**
- 4A83.Z Allergic or hypersensitivity disorders involving the gastrointestinal tract, unspecified**
- 4A84 Anaphylaxis**  
Anaphylaxis is a severe, life-threatening systemic hypersensitivity reaction characterised by being rapid in onset with potentially life-threatening airway, breathing, or circulatory problems and is usually, although not always, associated with skin and mucosal changes.
- 4A84.0 Anaphylaxis due to allergic reaction to food**  
Rapidly progressive, multi-system and potentially life-threatening reaction to exposure to a food allergen to which the affected individual has previously been sensitized.  
**Exclusions:** obstruction from food aspiration (ND72)  
food intolerance (DA96.02)
- 4A84.1 Drug-induced anaphylaxis**  
Anaphylaxis attributable to a drug. When severe it may be fatal. This systemic reaction usually develops within minutes to hours of administration of the drug, is often severe and may be fatal. The most frequent drugs causing anaphylaxis are antibiotics, particularly penicillins. Clinically there may be premonitory dizziness or faintness, skin tingling and erythema, followed by urticaria, angio-oedema, bronchospasm, abdominal pain and vasomotor collapse.  
**Coded Elsewhere:** Anaphylaxis due to radiocontrast media (EL80)
- 4A84.2 Anaphylaxis due to insect venom**  
Anaphylaxis due to insect venom is a severe systemic hypersensitivity reaction with rapid onset of cutaneous, vascular or respiratory symptoms and signs, either singly or in any combination after exposure (mainly by sting) to an insect venom in a sensitized patient.  
**Exclusions:** Harmful effects of or exposure to noxious substances,  
Substances chiefly nonmedicinal as to source, Venoms  
or toxins (NE61)
- 4A84.3 Anaphylaxis provoked by physical factors**  
Anaphylaxis provoked by physical factors covers a group of anaphylaxis phenotypes in which physical factors are the main triggers. The most relevant are: exercise-induced anaphylaxis, exercise-induced anaphylaxis dependent on food, cold-induced anaphylaxis.

- 4A84.30** Exercise-induced anaphylaxis  
Exercise-induced anaphylaxis is disorder in which anaphylaxis occurs after physical activity. The clinical features may include pruritus, urticarial weals, flushing, wheezing, and gastrointestinal disturbance including nausea, abdominal cramping, and diarrhoea. If physical activity continues, angioedema, laryngeal oedema, hypotension, and, ultimately, cardiovascular collapse may occur. Exercise-induced anaphylaxis is most commonly associated with IgE-mediated allergy to food whereby anaphylaxis occurs only if ingestion is followed temporally by exercise. Cessation of physical activity usually results in immediate improvement of symptoms.
- 4A84.31** Cold-induced anaphylaxis  
Cold-induced anaphylaxis is triggered by skin cooling. The deaths are directly caused by the anaphylactic reaction due to drowning when swimming in cold water.
- 4A84.3Y** Anaphylaxis provoked by other specified physical factors
- 4A84.3Z** Anaphylaxis provoked by unspecified physical factors
- 4A84.4** **Anaphylaxis due to inhaled allergens**  
Rapid progressive, multisystem life-threatening reaction due to the exposure to a sensitized inhaled allergen, such as particles from rubber gloves or latex products, animal dander and dust mite.  
Use additional external cause code, if desired, to identify agent.  
**Exclusions:** Allergic asthma with exacerbation (CA23.00)
- 4A84.5** **Anaphylaxis due to contact with allergens**  
Anaphylaxis resulting from skin or mucosal contact with a substance or substances capable of inducing IgE-mediated response in patients previously sensitized.  
Use additional external cause code, if desired, to identify agent.
- 4A84.6** **Anaphylaxis secondary to mast cell disorder**  
Symptoms of anaphylaxis secondary to mast cell disorders result from excessive mast cell mediator release, especially histamine, and may include pruritus and flushing, abdominal pain, diarrhea, dyspnoea, tachycardia, or profound hypotension. It happens in both children and adults, but in adults it can occur even without urticaria pigmentosa lesions. Levels of basal tryptase are constantly high. Fatal anaphylaxis has been described following hymenoptera stings and in the preoperative period.
- 4A84.Y** Other specified anaphylaxis
- 4A84.Z** Anaphylaxis, unspecified
- 4A85** **Complex allergic or hypersensitivity conditions**

- 4A85.0** **Drug or pharmacological agents hypersensitivity**  
Drug hypersensitivity reactions are the adverse effects of pharmaceutical formulations (including active drugs and excipients) that clinically resemble allergy. It belongs to type B adverse drug reactions, which are defined by the World Health Organization as the dose-independent, unpredictable, noxious, and unintended response to a drug taken at a dose normally used in humans. It covers many different clinical phenotypes with variable onset and severity.
- Coded Elsewhere:** Drug eruptions (EH60-EH6Z)
- Drug-induced bronchospasm (4A80.0)
  - Drug-induced aplastic anaemia (3A70.10)
  - Aspirin-induced asthma (CA23.20)
  - Samter syndrome (CA0A.0)
  - Photoallergic drug reaction (EH75)
  - Pseudolymphomatous drug hypersensitivity syndrome (EH6Y)
  - Anaphylaxis due to radiocontrast media (EL80)
- 4A85.00** Drug-induced liver hypersensitivity disease  
Drug-induced liver hypersensitivity disease is a relatively rare condition, but can have serious consequences for the individual patient, public health, regulatory agencies and the pharmaceutical industry. It is characterised by elevation in serum alanine-aminotransferase (ALT), conjugated bilirubin, or combined bilirubin, ALT and alkaline phosphatase (AP) levels > 2 times the upper limit of normal (ULN) and the most frequent related drugs are halothane, tienilic acid, dihydralazine, diclofenac, and carbamazepine.
- 4A85.01** Drug-induced kidney hypersensitivity  
Drug-induced kidney hypersensitivity constitutes an important cause of acute renal failure and chronic kidney disease in present day clinical practice. Different classes of drugs, by virtue of immunological mechanisms, initiate specific inflammatory renal responses, which are manifested by different clinical patterns, such as drug-induced interstitial nephritis. The drug-induced kidney hypersensitivity can manifest alone or in combination with other drug-induced organ or system hypersensitivity disorders.
- Coded Elsewhere:** Acute renal papillary necrosis due to drugs, biological agents or environmental toxins (GB53)
- 4A85.02** Drug-induced cytopenia  
Drug-induced cytopenia is a relatively common immune-mediated cytopenia and the target cells include erythrocytes, leukocytes, platelets and hematopoietic precursor cells in the marrow. The most frequent condition is the drug-induced immune thrombocytopenia and the most frequent implicated drugs are penicillin and structurally related drugs, quinine, quinidine, sulfonamide antibiotics, non-steroidal anti-inflammatory drugs and anticonvulsants.
- Coded Elsewhere:** Drug-induced immune thrombocytopenia (3B64.12)
- Drug-induced secondary agranulocytosis (4B00.01)

- 4A85.03** Drug-induced vasculitis  
Drug-induced vasculitis is an inflammatory vasculopathy associated with drugs of almost every class and accounting for approximately 3% of the vasculitides. Although small vessel disease limited to the skin is the most common form, involvement of blood vessels in virtually every organ system may occur. It can present multiorgan involvement and the mortality is described in up to 10% of cases.
- 4A85.04** Multiple drug hypersensitivity syndrome  
Multiple drug hypersensitivity syndrome is defined as drug allergies to two or more chemically different drugs. It differs from cross-reactivity (due to structural similarities, common metabolic pathways, or pharmacological mechanisms), flare-up reactions (exacerbation of an existing drug allergy by the early switch of therapy to a novel drug), and multiple drug intolerance syndrome.
- 4A85.0Y** Drug hypersensitivity of other specified type
- 4A85.0Z** Drug hypersensitivity of unspecified type
- 4A85.1** **Hypersensitivity to herbal and alternative medical therapies**  
Hypersensitivity to herbal and alternative medical therapies refers to unpredictable conditions clinically resembling allergy that cause objectively reproducible symptoms or signs, initiated by exposure to herbal and other alternative medical therapies, such as homeopathy, cupping or acupuncture. Herbal and alternative medical therapies are not customarily regarded as drugs, but can trigger immune and non-immune mediated reactions, which occur in susceptible individuals. These reactions are triggered by doses and procedures usually tolerated by normal subjects.
- Exclusions:** Adverse cutaneous reactions to herbal, homoeopathic or other alternative therapies (EH78)
- 4A85.2** **Food hypersensitivity**  
Food hypersensitivity reactions are adverse effects of food or food additives that clinically resemble allergy. Food allergy is an adverse reaction to food mediated by an immunologic mechanism, involving specific IgE (IgE-mediated), cell-mediated mechanisms (non-IgE-mediated) or both IgE- and cell-mediated mechanisms (mixed IgE- and non-IgE-mediated).
- Exclusions:** food intolerance (DA96.02)
- Coded Elsewhere:** Oral allergy syndrome (EK10.0)  
Contact urticaria due to food allergen (EK10.1)  
Anaphylaxis due to allergic reaction to food (4A84.0)  
Bronchospasm provoked by allergy to food substance (4A80.1)

- 4A85.20** Food-induced gastrointestinal hypersensitivity  
 Food-induced gastrointestinal hypersensitivity covers a group of gastrointestinal hypersensitivity disorders due to food allergens with variable onset, severity, clinical presentation and mechanisms.
- Coded Elsewhere:** Food-induced eosinophilic gastroenteritis (4A83.0)  
 Allergic or dietetic colitis (DB33.2)  
 Food-induced eosinophilic oesophagitis (4A83.1)  
 Allergic or dietetic enteritis of small intestine (DA94.2)  
 Food-induced non-IgE-mediated gastrointestinal hypersensitivity (DA42.41)
- 4A85.21** Food-induced urticaria or angioedema  
 Urticaria and/or angioedema triggered by ingestion or direct contact of food allergen in sensitized patient.
- 4A85.22** Allergic contact dermatitis due to food allergen  
 Allergic contact dermatitis, of which most common causal foods are spices, fruits, vegetables. Often occupational because of contact with chemical moieties, oleoresins. Systemic contact dermatitis is a rare variant because of ingestion.  
 Use additional external cause code, if desired, to identify agent.
- Coded Elsewhere:** Allergic contact dermatitis due to food flavours or additives (EK00.3)
- 4A85.2Y** Other specified food hypersensitivity
- 4A85.2Z** Food hypersensitivity, unspecified
- 4A85.3** **Allergic or hypersensitivity reactions to arthropods**  
 This includes both local cutaneous and systemic allergic and hypersensitivity reactions to contact with insects (e.g. bees, wasps and fire ants) and other arthropods (e.g. scorpions and spiders). Reactions are usually mediated via the immune system (IgE-mediated or non-IgE-mediated allergy).
- 4A85.30** Systemic allergic reaction due to Hymenoptera venom  
 Systemic Allergic Reaction due to Hymenoptera venom due to insect venom is a severe hypersensitivity reaction with rapid onset of cutaneous, vascular or respiratory symptoms and signs, either singly or in any combination after exposure (mainly by sting) to an insect venom in a sensitized patient.
- Coded Elsewhere:** Anaphylaxis due to insect venom (4A84.2)
- 4A85.31** Cutaneous allergic or hypersensitivity reactions to Hymenoptera venom  
 Cutaneous reactions to Hymenoptera venom are hypersensitivity reactions classified into normal local reactions and large local reactions. Large local reaction is defined as a swelling exceeding a diameter of 10 cm which lasts longer than 24 h; blisters may rarely be present.
- 4A85.32** Cutaneous allergic or hypersensitivity reactions to arthropods
- 4A85.Y** **Other specified complex allergic or hypersensitivity conditions**

<b>4A85.Z</b>	<b>Complex allergic or hypersensitivity conditions, unspecified</b>
<b>4A8Y</b>	<b>Allergic or hypersensitivity conditions of other specified type</b>
<b>4A8Z</b>	<b>Allergic or hypersensitivity conditions of unspecified type</b>

## Immune system disorders involving white cell lineages (4B00-4B0Z)

**Coded Elsewhere:** Immunodeficiencies with predominantly antibody defects (4A01.0)

- Combined immunodeficiencies (4A01.1)
- Defects in the complement system (4A00.1)
- Diseases of immune dysregulation (4A01.2)
- Other well-defined immunodeficiency syndromes due to defects in adaptive immunity (4A01.3)

### **4B00 Disorders of neutrophil number**

**Exclusions:** Decreased white blood cell count (MA16.10)

#### **4B00.0 Neutropaenia**

**Coded Elsewhere:** Transient neonatal neutropaenia (KA8D)  
Alloimmune neonatal neutropaenia (KA8E)

##### **4B00.00 Constitutional neutropaenia**

This is a granulocyte disorder characterised by an abnormally low number of neutrophils. Neutrophils usually make up 50-70% of circulating white blood cells and serve as the primary defence against infections by destroying bacteria in the blood.

**Exclusions:** Cartilage-hair hypoplasia (LD27.0)

##### **4B00.01 Acquired neutropaenia**

##### **4B00.0Z Neutropaenia, unspecified**

#### **4B00.1 Neutrophilia**

##### **4B00.10 Constitutional neutrophilia**

##### **4B00.11 Acquired neutrophilia**

**Coding Note:** Code also the causing condition

**Exclusions:** Non mast cell myeloproliferative neoplasms (2A20)

##### **4B00.1Z Neutrophilia, unspecified**

#### **4B00.Y Other specified disorders of neutrophil number**

### **4B01 Disorders of neutrophil function**

**Coded Elsewhere:** Functional neutrophil defects (4A00.0)

#### **4B01.0 Constitutional disorders of neutrophil function**

##### **4B01.00 Disorders of neutrophil adhesion**

- 4B01.01** Disorders of neutrophil chemotaxis
- 4B01.02** Disorders of neutrophil granule formation or release
- 4B01.03** Disorders of neutrophil oxidative metabolism
- 4B01.0Y** Other specified constitutional disorders of neutrophil function
- 4B01.0Z** Constitutional disorders of neutrophil function, unspecified
- 4B01.1** **Acquired disorders of neutrophil function**
- 4B01.Z** **Disorders of neutrophil function, unspecified**
- 4B02** **Eosinopenia**
- 4B02.0** **Constitutional decrease in eosinophil number**
- 4B02.1** **Acquired decrease in eosinophil number**
- 4B02.Z** **Eosinopenia, unspecified**
- 4B03** **Eosinophilia**
- 4B03.0** **Constitutional eosinophilia**
- 4B03.1** **Acquired eosinophilia**
- 4B03.Z** **Eosinophilia, unspecified**
- 4B04** **Disorders with decreased monocyte counts**
- 4B05** **Disorders with increased monocyte counts**
- 4B06** **Acquired lymphopenia**
- 4B07** **Acquired lymphocytosis**
  - Exclusions:** Chronic lymphocytic leukaemia or small lymphocytic lymphoma (2A82.0)
  - Coded Elsewhere:** Infectious mononucleosis (1D81)
- 4B0Y** **Other specified immune system disorders involving white cell lineages**
- 4B0Z** **Immune system disorders involving white cell lineages, unspecified**

## Certain disorders involving the immune system (4B20-4B2Y)

Disorders in which disturbed immune regulation plays an important part but which cannot be more precisely located elsewhere in the classification.

- Exclusions:**
- Failure or rejection of transplanted organs or tissues (NE84)
  - Monoclonal gammopathy of undetermined significance (2A83.0)

**Coded Elsewhere:** Hereditary angioedema (4A00.14)

**4B20**

### Sarcoidosis

Sarcoidosis is a multisystem disorder of unknown cause characterised by the formation of immune granulomas in involved organs. The lung and the lymphatic system are predominantly affected, but virtually every organ may be involved. Other severe manifestations result from cardiac, neurological, ocular, kidney or laryngeal localizations.

**4B20.0**

### Sarcoidosis of lung

**4B20.1**

### Sarcoidosis of lymph nodes

Lymphadenopathy is very common in sarcoidosis. Intrathoracic nodes are enlarged in 75 to 90% of all patients; usually this involves the hilar nodes, but the paratracheal nodes are commonly involved. Peripheral lymphadenopathy is very common, particularly involving the cervical (the most common head and neck manifestation of the disease), axillary, epitrochlear, and inguinal nodes.

**4B20.2**

### Sarcoidosis of the digestive system

This is a syndrome involving abnormal collections of chronic inflammatory cells (granulomas) that can form as nodules in the digestive system.

**Coded Elsewhere:** Gastritis due to sarcoidosis (DA42.Y)

Oesophagitis due to sarcoidosis (DA24.Y)

**4B20.3**

### Neurosarcoidosis

This refers to sarcoidosis, a condition of unknown cause featuring granulomas in various tissues, involving the central nervous system (brain and spinal cord). It can have many manifestations, but abnormalities of the cranial nerves (a group of twelve nerves supplying the head and neck area) are the most common.

**4B20.4**

### Ocular sarcoidosis

This is a syndrome involving abnormal collections of chronic inflammatory cells (granulomas) that can form as nodules in multiple organs.

**Coded Elsewhere:** Uveoparotid fever (4B20.Y)

**4B20.5**

### Cutaneous sarcoidosis

**4B20.Y**

### Other specified sarcoidosis

**4B20.Z**

### Sarcoidosis, unspecified

**4B21**

### Polyclonal hypergammaglobulinaemia

**4B22**

### **Cryoglobulinaemia**

**Coded Elsewhere:** Cryoglobulinaemic vasculitis (4A44.90)

Cutaneous microvascular disturbances due to monoclonal cryoglobulins (EF5Y)

**4B23**

### **Immune reconstitution inflammatory syndrome**

This is a condition seen in some cases of AIDS or immunosuppression, in which the immune system begins to recover, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse.

**4B24**

### **Graft-versus-host disease**

Graft-versus-host disease (GVHD) occurs when lymphoid cells from an immunocompetent donor are introduced into a histo-incompatible recipient incapable of rejecting them. This usually occurs as a result of haematopoietic stem cell transplantation. The main targets attacked by the donor lymphocytes are the recipient's skin, gastrointestinal tract and liver. Acute GVHD, normally occurring within the first 100 days following transplantation, has a high mortality. The acute phase may be followed by chronic GVHD, which can also arise de novo. This usually presents as a lichenoid rash but can develop into a severe fibrosing disease affecting skin, lungs and liver.

**4B24.0**

#### **Acute graft-versus-host disease**

Graft-versus-host disease presenting normally within the first 100 days of engraftment. It presents most commonly with a maculopapular rash accompanied by fever. The prognosis correlates with the extent of skin involvement, which may progress to widespread epidermal necrolysis, and the severity of gastrointestinal and liver involvement which may manifest as diarrhoea and jaundice respectively. There is a high mortality in severe acute graft-versus-host disease.

**4B24.1**

#### **Chronic graft-versus-host disease**

Chronic graft-versus-host disease (GVHD) presents more than 100 days after engraftment of immunocompetent donor lymphoid cells. It has specific clinical features by which it can be distinguished from acute GVHD. It may arise de novo but frequently follows acute GVHD. Less commonly, it occurs concurrently with acute GVHD. The earlier stages of chronic GVHD are characterised by a widespread lichenoid rash, poikiloderma and involvement of nails and oral mucous membranes. If the disease remains active, progressive sclerosis of the skin and deeper tissues may result in joint contractures, fibrosis of internal organs and severe malabsorption.

**4B24.Y**

#### **Other specified graft-versus-host disease**

**4B24.Z**

#### **Graft-versus-host disease, unspecified**

**4B2Y**

### **Other specified disorders involving the immune system**

**4B40**

**Diseases of thymus**

**Exclusions:** thymic aplasia or hypoplasia with immunodeficiency (LD44.N0)  
Myasthenia gravis (8C60)

**Coded Elsewhere:** Thymic tumours

**4B40.0**

**Persistent hyperplasia of thymus**

This refers to a persistent enlargement ("hyperplasia") of the thymus.

**4B40.1**

**Abscess of thymus**

**4B40.2**

**Good syndrome**

This is a condition that occurs in adults in whom hypogammaglobulinemia, deficient cell-mediated immunity, and benign thymoma may develop almost simultaneously.

**4B40.Y**

**Other specified diseases of thymus**

**4B40.Z**

**Diseases of thymus, unspecified**

**4B4Y**

**Other specified diseases of the immune system**

**4B4Z**

**Diseases of the immune system, unspecified**

# CHAPTER 05

---

## Endocrine, nutritional or metabolic diseases

This chapter has 148 four-character categories.

Code range starts with 5A00

This chapter includes endocrine diseases, nutritional diseases as well as metabolic diseases.

**Exclusions:** Transitory endocrine or metabolic disorders specific to fetus or newborn  
(KB60-KB6Z)

Pregnancy, childbirth or the puerperium (Chapter 18)

**Coded Elsewhere:** Symptoms, signs or clinical findings of endocrine, nutritional or metabolic diseases (MA50-MA6Y)

Endocrine, nutritional or metabolic diseases complicating pregnancy, childbirth or the puerperium (JB64.2)

This chapter contains the following top level blocks:

- Endocrine diseases
- Nutritional disorders
- Metabolic disorders
- Postprocedural endocrine or metabolic disorders

### Endocrine diseases (5A00-5B3Z)

**Coded Elsewhere:** Neoplasms of the endocrine system

Endocrine tumours

### Disorders of the thyroid gland or thyroid hormones system (5A00-5A0Z)

Disorders due to dysfunction of thyroid gland and regulation systems of thyroid hormone actions including dysfunction of the pituitary, hypothalamus, or thyroid hormone receptors.

#### **5A00                    Hypothyroidism**

##### **5A00.0                  Congenital hypothyroidism**

Hypothyroidism is a condition where the thyroid gland produces too little or no thyroid hormone, and the condition arises at birth. Common clinical features include decreased activity and increased sleep, feeding difficulty and constipation, prolonged jaundice, myxedematous facies, large fontanelles (especially posterior), macroglossia, a distended abdomen with umbilical hernia, and hypotonia.

**Coded Elsewhere:** Congenital central hypothyroidism (5A61.41)

<b>5A00.00</b>	Permanent congenital hypothyroidism with diffuse goitre A condition caused by a partial or complete loss of thyroid function due to failure of the thyroid to correctly develop during the antenatal period. This condition is characterised by a swollen, smooth thyroid gland, and in infants by a dull look, puffy face, and thick tongue that sticks out. This condition may also present with choking episodes, constipation, dry brittle hair, jaundice, lack of muscle tone, low hairline, poor feeding, short height, sleepiness, or sluggishness.  <b>Exclusions:</b> transitory congenital goitre with normal function (KB62)
<b>5A00.01</b>	Permanent congenital hypothyroidism without goitre This is a permanent congenital state in which the thyroid gland does not make enough thyroid hormone. This diagnosis is without swelling of the thyroid gland.
<b>5A00.02</b>	Pendred syndrome Pendred syndrome is characterised by the association of congenital bilateral neurosensory deafness, thyroid goitre, cochleovestibular malformation and potential vestibular dysfunction.
<b>5A00.03</b>	Transient congenital hypothyroidism Transient congenital hypothyroidism is defined as transient thyroid dysfunction with mildly elevated thyroid-stimulating hormone (TSH) and low thyroxine (FT4) levels which return to normal either very promptly and spontaneously, or after several months of thyroxine therapy. The disorder is due to a variety of causes including iodine deficiency or exposure to iodine-containing compounds, transplacental passage of blocking maternal antibodies, and dyshormonogenesis.  <b>Exclusions:</b> Transitory congenital goitre with normal function (KB62)
<b>5A00.04</b>	Congenital hypothyroidism due to iodine deficiency Hypothyroidism is a condition which arises at birth where the thyroid gland produces too little or no thyroid hormone and it can be induced by iodine-deficiency.  <b>Exclusions:</b> Subclinical iodine-deficiency hypothyroidism (5A00.22)
<b>5A00.0Y</b>	Other specified congenital hypothyroidism
<b>5A00.0Z</b>	Congenital hypothyroidism, unspecified
<b>5A00.1</b>	<b>Iodine-deficiency-related thyroid disorders or allied conditions</b> Any condition caused by aberrant thyroid function due to a deficiency of iodine. Confirmation is by blood test.  <b>Exclusions:</b> congenital iodine-deficiency syndrome (5A00.04) Subclinical iodine-deficiency hypothyroidism (5A00.22)
<b>5A00.10</b>	Iodine-deficiency-related diffuse goitre Diffuse enlargement of the thyroid gland due to iodine deficiency.
<b>5A00.11</b>	Iodine-deficiency-related multinodular goitre Multinodular enlargement of the thyroid gland due to iodine deficiency.  <b>Inclusions:</b> Iodine-deficiency-related nodular goitre

- 5A00.1Z** Iodine-deficiency-related thyroid disorders or allied conditions, unspecified
- 5A00.2** **Acquired hypothyroidism**  
Acquired hypothyroidism is a condition where the thyroid gland produces too little or no thyroid hormone, and the condition arises only after birth.  
**Exclusions:** Postprocedural hypothyroidism (5D40)  
iodine-deficiency-related hypothyroidism (5A00.1)  
**Coded Elsewhere:** Acquired central hypothyroidism (5A61.40)  
Dementia due to acquired hypothyroidism (6D85.Y)
- 5A00.20** Hypothyroidism due to medicaments or other exogenous substances  
A condition caused by an underactive thyroid due to a medicaments or other exogenous substances. This condition may present with fatigue, increased sensitivity to cold, constipation, dry skin, weight gain, muscle weakness, elevated blood cholesterol, muscle aches, joint pain or swelling, heavier or irregular menstrual periods, thinning hair, depression, or impaired memory.
- 5A00.21** Myxoedema coma  
A life-threatening hypothyroid condition with long-standing severe untreated hypothyroidism in whom adaptive mechanisms fail to maintain homeostasis.
- 5A00.22** Subclinical iodine-deficiency hypothyroidism  
A condition with elevated serum TSH level, but with normal thyroid hormone levels, which is induced by iodine-deficiency
- 5A00.2Y** Other specified acquired hypothyroidism
- 5A00.2Z** Acquired hypothyroidism, unspecified
- 5A00.Z** **Hypothyroidism, unspecified**
- 5A01** **Nontoxic goitre**  
Enlargement of the thyroid gland due to follicular multiplication, unaccompanied by hyperthyroidism or thyrotoxicosis  
**Exclusions:** congenital goitre NOS (5A00.00)  
congenital parenchymatous goitre (5A00.00)  
iodine-deficiency-related goitre (5A00.1)  
congenital diffuse goitre (5A00.00)
- 5A01.0** **Nontoxic diffuse goitre**  
Diffuse enlargement of the thyroid gland due to follicular multiplication, unaccompanied by hyperthyroidism or thyrotoxicosis
- 5A01.1** **Nontoxic single thyroid nodule**  
Single tumour of the thyroid gland due to follicular multiplication, unaccompanied by hyperthyroidism or thyrotoxicosis

<b>5A01.2</b>	<b>Nontoxic multinodular goitre</b> Multiple nodules of the thyroid gland due to follicular multiplication, unaccompanied by hyperthyroidism or thyrotoxicosis
<b>5A01.Z</b>	<b>Nontoxic goitre, unspecified</b>
<b>5A02</b>	<p><b>Thyrotoxicosis</b> A hypermetabolic condition associated with elevated levels of free thyroxine and/or free triiodothyronine resulting in excess synthesis and secretion of thyroid hormone</p> <p><b>Exclusions:</b> Transitory neonatal hyperthyroidism (KB62.0)</p> <p><b>Coded Elsewhere:</b> Dysthyroid exophthalmos (9A20.00)</p>
<b>5A02.0</b>	<p><b>Thyrotoxicosis with diffuse goitre</b> Thyrotoxicosis occurs by the ingestion of excessive amounts of exogenous thyroid hormone in the form of thyroid hormone supplements such as the most widely used supplement levothyroxine.</p> <p><b>Inclusions:</b> Toxic diffuse goitre Graves disease</p>
<b>5A02.1</b>	<p><b>Thyrotoxicosis with toxic single thyroid nodule</b> <b>Inclusions:</b> Thyrotoxicosis with toxic uninodular goitre</p>
<b>5A02.2</b>	<p><b>Thyrotoxicosis with toxic multinodular goitre</b> Thyrotoxicosis caused by functioning thyroid multinodules</p>
<b>5A02.3</b>	<b>Thyrotoxicosis from ectopic thyroid tissue</b>
<b>5A02.4</b>	<p><b>Thyrotoxicosis factitia</b> A condition of thyrotoxicosis caused by the ingestion of exogenous thyroid hormone</p>
<b>5A02.5</b>	<p><b>Thyroid crisis</b> Thyrotoxic crisis (or thyroid storm) is a rare but severe complication of hyperthyroidism, which may occur when a thyrotoxic patient becomes very sick or physically stressed.</p> <p><b>Inclusions:</b> Thyroid storm</p>
<b>5A02.6</b>	<p><b>Secondary hyperthyroidism</b> Overproduction of thyroid hormone in the thyroid gland induced by dysfunction of the pituitary gland or hypothalamus.</p>
<b>Coding Note:</b>	Code also the causing condition
	<p><b>Exclusions:</b> Generalised resistance to thyroid hormone (5A05) Selective pituitary resistance to thyroid hormone (5A02)</p>
<b>5A02.Y</b>	<b>Other specified thyrotoxicosis</b>
<b>5A02.Z</b>	<b>Thyrotoxicosis, unspecified</b>

**5A03**

### **Thyroiditis**

Thyroiditis is the inflammation of the thyroid gland. It includes acute and chronic forms of thyroiditis. Thyroiditis is usually caused by autoimmune reaction to the thyroid, resulting in inflammation and damage to the thyroid cells. The symptoms include fatigue, weight gain, depression, dry skin, and constipation.

**Inclusions:** Acquired hypothyroidism (5A00.2)

Thyrotoxicosis (5A02)

**Coded Elsewhere:** Postpartum thyroiditis (JB44.5)

**5A03.0**

#### **Acute thyroiditis**

Acute thyroiditis is a rare form of thyroiditis directly caused by an infection, frequently bacterial.

**5A03.1**

#### **Subacute thyroiditis**

A self-limited thyroiditis associated with a triphasic clinical course of hyperthyroidism, hypothyroidism, and return to normal thyroid function. It is thought to be caused by a viral infection.

**Inclusions:** de Quervain thyroiditis

giant-cell thyroiditis

granulomatous thyroiditis

**Exclusions:** Autoimmune thyroiditis (5A03.2)

**5A03.2**

#### **Autoimmune thyroiditis**

A chronic inflammatory disorder of the thyroid gland associated with abnormal circulatory antibodies.

**5A03.20**

Hashimoto thyroiditis

**5A03.21**

Painless thyroiditis

A destructive thyroiditis which has an autoimmune basis in the non-postpartum period. An inflammation of the thyroid gland characterised by transient hyperthyroidism, followed by hypothyroidism and then recovery.

**5A03.2Y**

Other specified autoimmune thyroiditis

**5A03.2Z**

Autoimmune thyroiditis, unspecified

**5A03.Y**

**Other specified thyroiditis**

**5A03.Z**

**Thyroiditis, unspecified**

**5A04**

### **Hypersecretion of calcitonin**

This is the process of elaborating, releasing, and oozing a 32-amino acid linear polypeptide hormone that is produced in humans primarily by the parafollicular cells (also known as C-cells) of the thyroid, and in many other animals in the ultimobranchial body.

**Inclusions:** Hypersecretion of thyrocalcitonin

C-cell hyperplasia of thyroid

**5A05**

**Generalised resistance to thyroid hormone**

Decreased thyroid hormone action, generally induced by mutation of thyroid hormone receptors.

**5A06**

**Sick-euthyroid syndrome**

**5A0Y**

**Other specified disorders of the thyroid gland or thyroid hormones system**

**5A0Z**

**Disorders of the thyroid gland or thyroid hormones system, unspecified**

Diabetes mellitus (5A10-5A2Y)

A metabolic disorder with heterogenous aetiologies which is characterised by chronic hyperglycaemia and disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.

**Coded Elsewhere:** Diabetes mellitus in pregnancy (JA63)

Neonatal diabetes mellitus (KB60.2)

**5A10**

**Type 1 diabetes mellitus**

Diabetes mellitus type 1 (type 1 diabetes, T1DM, formerly insulin dependent or juvenile diabetes) is a form of diabetes mellitus that results from destruction of insulin-producing beta cells, mostly by autoimmune mechanisms. The subsequent lack of insulin leads to increased blood and urine glucose.

**Exclusions:** Type 2 diabetes mellitus (5A11)

Diabetes mellitus, other specified type (5A13)

Diabetes mellitus in pregnancy (JA63)

**Coded Elsewhere:** Pre-existing type 1 diabetes mellitus in pregnancy (JA63.0)

**5A11**

**Type 2 diabetes mellitus**

Diabetes mellitus type 2 (formerly noninsulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes) is a metabolic disorder that is characterised by high blood glucose in the context of insulin resistance and relative insulin deficiency.

**Inclusions:** non-insulin-dependent diabetes of the young

**Exclusions:** Diabetes mellitus in pregnancy (JA63)

Diabetes mellitus, other specified type (5A13)

Idiopathic Type 1 diabetes mellitus (5A10)

**Coded Elsewhere:** Pre-existing type 2 diabetes mellitus in pregnancy (JA63.1)

**5A12**

**Malnutrition-related diabetes mellitus**

**5A13**

**Diabetes mellitus, other specified type**

Diabetes mellitus which cannot be classified as either Type 1 or Type 2 diabetes mellitus.

**Exclusions:** Diabetes mellitus in pregnancy (JA63)

Type 2 diabetes mellitus (5A11)

Idiopathic Type 1 diabetes mellitus (5A10)

**5A13.0**

**Diabetes mellitus due to genetic defects of beta cell function**

Other specified diabetes mellitus due to genetic defects of beta cell function is a form of diabetes, which is associated with monogenetic defects in beta-cell function.

**5A13.1**

**Diabetes mellitus due to genetic defects in insulin action**

Other specified diabetes mellitus due to genetic defects in insulin action is a form of diabetes, which results from genetically determined abnormalities of insulin action. The metabolic abnormalities associated with mutations of the insulin receptor may range from hyperinsulinemia and modest hyperglycaemia to severe diabetes.

**5A13.2**

**Diabetes mellitus due to diseases of the exocrine pancreas**

Other specified diabetes mellitus due to diseases of the exocrine pancreas is a form of diabetes which caused by any process that diffusely injures the pancreas. Acquired processes include pancreatitis, trauma, infection, pancreatectomy, and pancreatic carcinoma. With the exception of that caused by cancer, damage to the pancreas must be extensive for diabetes to occur.

**5A13.3**

**Diabetes mellitus due to endocrinopathies**

Other specified diabetes mellitus due to endocrinopathies is a form of diabetes caused by several hormones (e.g., growth hormone, cortisol, glucagon, epinephrine), which antagonize insulin action. Excess amounts of these hormones (e.g., acromegaly, Cushing's syndrome, glucagonoma, pheochromocytoma, respectively) can cause diabetes. This generally occurs in individuals with preexisting defects in insulin secretion, and hyperglycaemia typically resolves when the hormone excess is resolved.

**5A13.4**

**Diabetes mellitus due to drug or chemical**

Other specified diabetes mellitus due to drug or chemical is a form of diabetes, which is caused by drug or chemical substance that impairs insulin secretion and insulin action.

**5A13.5**

**Diabetes mellitus due to uncommon forms of immune-mediated diabetes**

Other specified diabetes mellitus due to uncommon forms of immune-mediated diabetes is a form of diabetes, which is caused by two known conditions. The stiff-man syndrome is an autoimmune disorder of the central nervous system characterised by stiffness of the axial muscles with painful spasms. Patients usually have high titres of the GAD autoantibodies, and approximately one-third will develop diabetes.

<b>5A13.6</b>	<b>Diabetes mellitus due to other genetic syndromes</b> Other specified diabetes mellitus due to other genetic syndromes is a form of diabetes, which is associated with genetic syndromes.
<b>Coding Note:</b>	Use additional code, if desired, to identify any associated genetic syndrome
	<b>Coded Elsewhere:</b> Wolfram syndrome (5A61.5)
	Maternally inherited diabetes and deafness (LD2H.Y)
	Thiamine-responsive megaloblastic anaemia syndrome (5C63.Y)
	Woodhouse-Sakati syndrome (5A61.0)
	Mitochondrial myopathy with diabetes mellitus (8C73.Y)
<b>5A13.7</b>	<b>Diabetes mellitus due to clinically defined subtypes or syndromes</b> Diabetes mellitus that has clinically defined subtypes or associated syndromes
<b>5A13.Y</b>	<b>Diabetes mellitus due to other specified cause</b>
<b>5A14</b>	<b>Diabetes mellitus, type unspecified</b>
	<b>Exclusions:</b> Idiopathic Type 1 diabetes mellitus (5A10)
	Type 2 diabetes mellitus (5A11)
	Diabetes mellitus, other specified type (5A13)
	Diabetes mellitus in pregnancy (JA63)

### Acute complications of diabetes mellitus (5A20-5A2Y)

<b>5A20</b>	<b>Diabetic hyperosmolar hyperglycaemic state</b>
<b>Coding Note:</b>	Code also the causing condition
<b>5A20.0</b>	<b>Hyperosmolar hyperglycaemic state without coma</b>
<b>Coding Note:</b>	Code also the causing condition
<b>5A20.1</b>	<b>Hyperosmolar hyperglycaemic state with coma</b>
<b>Coding Note:</b>	Code also the causing condition
<b>5A20.Z</b>	<b>Diabetic hyperosmolar hyperglycaemic state, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>5A21</b>	<b>Hypoglycaemia in the context of diabetes mellitus</b>
<b>Coding Note:</b>	Code also the causing condition
<b>5A21.0</b>	<b>Hypoglycaemia in the context of diabetes mellitus without coma</b>
<b>Coding Note:</b>	Code also the causing condition
<b>5A21.1</b>	<b>Hypoglycaemia in the context of diabetes mellitus with coma</b>
<b>Coding Note:</b>	Code also the causing condition

**5A21.Z** **Hypoglycaemia in the context of diabetes, unspecified**

**Coding Note:** Code also the causing condition

**5A22** **Diabetic acidosis**

**Coding Note:** Code also the causing condition

**5A22.0** **Diabetic ketoacidosis without coma**

**Coding Note:** Code also the causing condition

**5A22.1** **Diabetic lactic acidosis**

**Coding Note:** Code also the causing condition

**5A22.2** **Diabetic metabolic acidosis**

**Coding Note:** Always assign an additional code for diabetes mellitus

**5A22.3** **Diabetic ketoacidosis with coma**

**Coding Note:** Code also the causing condition

**5A22.Y** **Other specified diabetic acidosis**

**Coding Note:** Code also the causing condition

**5A22.Z** **Diabetic acidosis, unspecified**

**Coding Note:** Code also the causing condition

**5A23** **Diabetic coma**

**Coding Note:** Code also the causing condition

**5A24** **Uncontrolled or unstable diabetes mellitus**

Brittle diabetes mellitus is a term used to describe particularly hard-to-control Type 1 or Type 2 diabetes mellitus. It results in frequent, extreme swings in blood glucose levels, causing hyperglycaemia that could lead to ketoacidosis or hypoglycaemia.

**Coding Note:** Code also the causing condition

**5A2Y** **Other specified acute complications of diabetes mellitus**

**Coding Note:** Code also the causing condition

Other disorders of glucose regulation or pancreatic internal secretion (5A40-5A4Z)

**Exclusions:** Benign neoplasm of endocrine pancreas (2E92.9)

Multiple endocrine neoplasia type 1 (2F7A.0)

Malignant neoplasm of pancreas (2C10)

**Coded Elsewhere:** Somatostatinoma (2C10.1)

VIPoma (2C10.1)

PPoma (2C10.1)

GRFoma (2C10.1)

**5A40**

### **Intermediate hyperglycaemia**

A metabolic disorder characterised by glucose levels too high to be considered normal, though not high enough to meet the criteria for diabetes.

**Inclusions:** prediabetes

Impaired glucose regulation

**Exclusions:** Diabetes mellitus, other specified type (5A13)

Idiopathic Type 1 diabetes mellitus (5A10)

Type 2 diabetes mellitus (5A11)

Diabetes mellitus, type unspecified (5A14)

Elevated blood glucose level (MA18.0)

**Coded Elsewhere:** Neonatal hyperglycaemia (KB60.3)

**5A40.0**

### **Impaired fasting glucose**

Impaired glucose tolerance is a metabolic disorder with FPG 110–125 mg/dl (6.1–6.9 mmol/l).

**5A40.1**

### **Impaired glucose tolerance**

Impaired glucose tolerance (IGT) is a metabolic disorder, which is characterised by 2-h postload glucose 140–199 mg/dl (7.8–11.1 mmol/l).

**5A40.Y**

### **Other specified intermediate hyperglycaemia**

**5A40.Z**

### **Intermediate hyperglycaemia, unspecified**

**5A41**

### **Hypoglycaemia without associated diabetes**

**Exclusions:** Hypoglycaemia in the context of diabetes mellitus (5A21)

**Coded Elsewhere:** Neonatal hypoglycaemia (KB60.4)

**5A42**

### **Increased secretion of glucagon**

**Exclusions:** Multiple endocrine neoplasia type 1 (2F7A.0)

**Coded Elsewhere:** Glucagonoma (2C10.1)

**5A43**

### **Abnormal secretion of gastrin**

**Coded Elsewhere:** Gastrinoma (2C10.1)

**5A43.0**

### **Drug-induced hypergastrinaemia**

A form of hypergastrinaemia that can be induced by drugs.

<b>5A43.1</b>	<b>Zollinger-Ellison syndrome</b> A syndrome characterised by the presence of a gastrin-secreting tumour, usually in the pancreas or duodenum, resulting in increased gastric acidity and formation of gastric ulcers. Signs and symptoms include abdominal pain and diarrhea. It may be sporadic or a manifestation of multiple endocrine neoplasia type 1.
	<b>Coded Elsewhere:</b> Anastomotic ulcer due to Zollinger-Ellison syndrome (DA62.Y) Gastric ulcer due to Zollinger-Ellison syndrome (DA60.Y) Duodenal ulcer due to Zollinger-Ellison syndrome (DA63.Y)
<b>5A43.Y</b>	<b>Other specified abnormal secretion of gastrin</b>
<b>5A43.Z</b>	<b>Abnormal secretion of gastrin, unspecified</b>
<b>5A44</b>	<b>Insulin-resistance syndromes</b>
	<b>Coding Note:</b> Code also the causing condition
<b>5A45</b>	<b>Persistent hyperinsulinaemic hypoglycaemia of infancy</b> Congenital isolated hyperinsulinism, or Persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI) is defined by an inappropriate oversecretion of insulin by the endocrine pancreas that is responsible for profound hypoglycaemia, which requires aggressive medical and/or surgical treatment to prevent severe and irreversible brain damage. PHHI is a genetically heterogeneous disorder with two types of histological lesions: diffuse (DiPHHI) and focal (FoPHHI) which are clinically indistinguishable.
<b>5A4Y</b>	<b>Other specified disorders of glucose regulation or pancreatic internal secretion</b>
<b>5A4Z</b>	<b>Disorders of glucose regulation or pancreatic internal secretion, unspecified</b>
Disorders of the parathyroids or parathyroid hormone system (5A50-5A5Z)	
Disorders of the parathyroids and parathyroid hormone system generally refer to conditions with inappropriate secretion and/or actions of parathyroid hormone that cause dysregulation of calcium metabolism.	
	<b>Exclusions:</b> Hypocalcaemic vitamin D dependent rickets (5C63.20) Hypovitaminosis D (5B57) Hyperphosphataemic familial tumoural calcinosis (5C54.1) Hypocalcaemic vitamin D resistant rickets (5C63.21)
<b>5A50</b>	<b>Hypoparathyroidism</b> Hypoparathyroidism is a condition with insufficient biological actions of parathyroid hormone due to impaired secretion of parathyroid hormone or refractoriness of target tissues to parathyroid hormone.
	<b>Exclusions:</b> Postprocedural hypoparathyroidism (5D42) tetany NOS (MB47.D)
	<b>Coded Elsewhere:</b> Transitory neonatal hypoparathyroidism (KB64)

<b>5A50.0</b>	<b>Hypoparathyroidism due to impaired parathyroid hormone secretion</b> Hypoparathyroidism due to impaired PTH secretion is a condition with low circulating PTH level and hypocalcaemia caused by being unable to secrete PTH from parathyroids in response to hypocalcaemia with pathological or functional defects in parathyroids.
	<b>Coded Elsewhere:</b> CATCH 22 phenotype (LD44.N0)
<b>5A50.00</b>	Idiopathic hypoparathyroidism <b>Exclusions:</b> Autoimmune polyendocrinopathy type 1 (5B00)
<b>5A50.01</b>	Secondary hypoparathyroidism <b>Coding Note:</b> Code also the causing condition
<b>5A50.02</b>	Hypoparathyroidism due to destruction of the parathyroid glands Dysfunction of parathyroid glands can be caused by several etiologies such as radiation, destruction of parathyroid glands by granulomatous disease or cancer infiltration, and deposition of iron or copper.
<b>5A50.03</b>	Autoimmune hypoparathyroidism
<b>5A50.0Y</b>	Other specified hypoparathyroidism due to impaired parathyroid hormone secretion
<b>5A50.0Z</b>	Hypoparathyroidism due to impaired parathyroid hormone secretion, unspecified
<b>5A50.1</b>	<b>Pseudohypoparathyroidism</b> Pseudohypoparathyroidism is a condition with refractoriness to parathyroid hormone of its target tissues especially kidney that causes hypocalcaemia and hyperphosphataemia even in the presence of high circulating levels of biologically active parathyroid hormone.
<b>5A50.Y</b>	<b>Other specified hypoparathyroidism</b>
<b>5A50.Z</b>	<b>Hypoparathyroidism, unspecified</b>
<b>5A51</b>	<b>Hyperparathyroidism</b> Hyperparathyroidism refers to overproduction of parathormone and is most frequently due to a tumour in one of the parathyroid glands. It may also occur in response to low calcium levels, as encountered in various situations such as vitamin D deficiency or chronic kidney disease. Hyperparathyroidism results in weakening of the bones through loss of calcium. <b>Exclusions:</b> Adult osteomalacia (FB83.2) infantile and juvenile osteomalacia (5B57.0)
<b>5A51.0</b>	<b>Primary hyperparathyroidism</b> Primary hyperparathyroidism is a condition with enhanced PTH secretion and high circulatory PTH level caused by abnormal parathyroid pathology such as adenoma, hyperplasia and cancer. Primary hyperparathyroidism usually causes hypercalcaemia by enhanced PTH actions.

<b>5A51.1</b>	<b>Secondary hyperparathyroidism</b> Secondary hyperparathyroidism is a condition with enhanced parathyroid hormone (PTH) secretion and high circulatory PTH level caused by metabolic changes such as hypocalcaemia, hyperphosphataemia and low 1,25-dihydroxyvitamin D.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> secondary hyperparathyroidism of renal origin (GB90.4)
<b>5A51.2</b>	<b>Familial hypocalciuric hypercalcaemia</b> Familial Hypocalciuric Hypercalcaemia (FHH) or benign familial hypercalcaemia is an autosomal dominant disorder of calcium metabolism that is often asymptomatic and that is biologically characterised by a significant but moderate hypercalcaemia. Serum levels of parathyroid hormone are normal or slightly increased, and urinary calcium excretion is relatively low for hypercalcaemia. CASR, GNA11 and AP2S1 have been identified as causative genes.
<b>5A51.Y</b>	<b>Other specified hyperparathyroidism</b>
<b>5A51.Z</b>	<b>Hyperparathyroidism, unspecified</b>
<b>5A5Y</b>	<b>Other specified disorders of the parathyroids or parathyroid hormone system</b>
<b>5A5Z</b>	<b>Disorders of the parathyroids or parathyroid hormone system, unspecified</b>

#### Disorders of the pituitary hormone system (5A60-5A6Z)

Clinical status with increased, decreased, or dysregulated secretion of pituitary hormones, which is caused by a variety of tumourous, non-tumourous, and genetic disorders.

<b>5A60</b>	<b>Hyperfunction of pituitary gland</b> A disease characterised by hypersecretion of adenohypophyseal hormones such as growth hormone, prolactin, thyrotropin, luteinising hormone, follicle stimulating hormone or adrenocorticotropic hormone.  Clinical status with excessive production of one or more pituitary hormones, which is mostly caused by hormone-producing pituitary adenomas.
	<b>Exclusions:</b> Nelson syndrome (5A70.3) overproduction of pituitary ACTH (5A70.0) overproduction of thyroid-stimulating hormone (5A02) Cushing syndrome (5A70) Multiple endocrine neoplasia type 1 (2F7A.0) Multiple endocrine neoplasia type 4 (2F7A.0)

<b>5A60.0</b>	<b>Acromegaly or pituitary gigantism</b> Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and characterised by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations. The main clinical features are broadened extremities (hands and feet), widened thickened and stubby fingers, and thickened soft tissue. The disease also has rheumatologic, cardiovascular, respiratory and metabolic consequences which determine its prognosis. In the majority of cases, acromegaly is related to a pituitary adenoma, either purely GH-secreting (60%) or mixed. Transsphenoidal surgery is often the first-line treatment. When surgery fails to correct GH/IGF-I hypersecretion, medical treatment with somatostatin analogs and/or radiotherapy can be used.
	<b>Inclusions:</b> Overproduction of growth hormone
	<b>Exclusions:</b> constitutional gigantism (5B12) increased secretion from endocrine pancreas of growth hormone-releasing hormone (5A40-5A4Z) Constitutional tall stature (5B12)
<b>5A60.1</b>	<b>Hyperprolactinaemia</b> Increased peripheral blood levels of prolactin often associated with galactorrhoea, sometimes associated with normal ovarian function, but often resulting in a spectrum of ovulatory dysfunction varying between short luteal phase (inadequate preovulatory follicular development), anovulatory cycles, amenorrhoea and hypogonadotropic hypogonadism
	<b>Coded Elsewhere:</b> Prolactinoma of pituitary gland (2F37.Y)
<b>5A60.2</b>	<b>Syndrome of inappropriate secretion of antidiuretic hormone</b> Syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) is characterised by continued ADH secretion, leading to hyponatraemia, hypoosmolality and natriuresis. Exact prevalence is unknown. The disease has been described in all age groups. SIADH is often associated with tumours, pulmonary disease, central nervous system disorders or exposure to drugs. Occasionally, it is found in patients with adrenal, thyroid or pituitary insufficiency. The disorder is caused by gain-of-function mutations in the gene encoding the vasopressin V2 receptor. Fluid restriction is the most common treatment. The outcome is related to the underlying and associated disorders.
<b>5A60.20</b>	Nephrogenic syndrome of inappropriate antidiuresis
<b>5A60.2Y</b>	Other specified syndrome of inappropriate secretion of antidiuretic hormone
<b>5A60.2Z</b>	Syndrome of inappropriate secretion of antidiuretic hormone, unspecified
<b>5A60.3</b>	<b>Central precocious puberty</b> Central precocious puberty is defined as the onset of pubertal changes before 8 years of age in girls and before 9.5 years of age in boys due to the overproduction of gonadotropin-releasing hormone (GnRH) by the hypothalamus. It may be idiopathic with no apparent cause (90% of cases in girls, 50% of cases in boys) or secondary to a lesion (tumour or malformation) in the hypothalamus. Other causes may include traumatic brain injury, or genetic disorders, affecting behavioural and psychological development, and final body height.

- 5A60.Y**           **Other specified hyperfunction of pituitary gland**
- 5A60.Z**           **Hyperfunction of pituitary gland, unspecified**
- 5A61**           **Hypofunction or certain other specified disorders of pituitary gland**  
 Clinical status with disordered function of the pituitary gland without excessive pituitary hormone production, which is caused by a variety of diseases
- Inclusions:**       Postprocedural hypopituitarism (5D43)  
                          Craniopharyngioma (2A00)
- Coded Elsewhere:** Non-secreting pituitary adenoma (2F37.0)
- 5A61.0**           **Hypopituitarism**  
 A disorder manifesting a deficiency or decrease of one or more pituitary hormones, which is caused by a variety of diseases such as tumour, trauma/surgery, irradiation, inflammation and haemorrhage/infarction.
- Inclusions:**       pituitary cachexia  
                          pituitary short stature
- Coded Elsewhere:** Prader-Willi syndrome (LD90.3)  
                          Argonz-del Castillo Syndrome (5A60.1)
- 5A61.1**           **Adrenocorticotrophic hormone deficiency**  
 Deficiency of adrenocorticotrophic hormone (ACTH) resulting in functional hypocortisolism. Includes deficiency of corticotropin releasing hormone (CRH, CRF).
- 5A61.2**           **Gonadotropin deficiency**  
 Deficiency of Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) resulting in hypogonadism (male and female). Includes deficiency of Gonadotropin Releasing Hormone (GnRH, LHRH).
- Inclusions:**       Ovarian dysfunction (5A80)  
                          Testicular hypofunction (5A81.1)
- 5A61.3**           **Growth hormone deficiency**  
 Deficiency of growth hormone in children, adolescents and adults. Includes deficiency of growth hormone releasing hormone (GHRH) and excess of central somatostatin, leading to growth hormone deficiency. Includes idiopathic, inborn and acquired forms of growth hormone deficiency.
- Inclusions:**       Hypopituitarism (5A61.0)
- 5A61.4**           **Thyroid stimulating hormone deficiency**  
 Deficiency of thyroid stimulating hormone (TSH), leading to secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. Includes deficiency of TSH releasing hormone (TRH).
- 5A61.40**          Acquired central hypothyroidism  
 Central Hypothyroidism is a condition where the thyroid gland produces too little or no thyroid hormone, induced by dysfunction of either hypothalamus or pituitary.

- 5A61.41** Congenital central hypothyroidism
- 5A61.4Y** Other specified thyroid stimulating hormone deficiency
- 5A61.4Z** Thyroid stimulating hormone deficiency, unspecified
- 5A61.5** **Central diabetes insipidus**  
Central diabetes insipidus (CDI) is a hypothalamus-pituitary disease characterised by polyuria and polydipsia due to a vasopressin (AVP) deficiency. The condition may be associated with deficient secretion of antidiuretic hormone (ADH) and is most frequently idiopathic (possibly due to autoimmune injury to the ADH-producing cells), or may be induced by trauma, pituitary surgery, or hypoxic or ischaemic encephalopathy.  
**Inclusions:** ADH - [antidiuretic hormone secretion] deficiency  
**Exclusions:** Nephrogenic diabetes insipidus (GB90.4A)
- 5A61.6** **Oxytocin deficiency**  
Isolated oxytocin deficiency or oxytocin deficiency in combination with anterior and/or posterior pituitary deficiencies.
- 5A61.Y** **Other specified hypofunction or disorders of pituitary gland**
- 5A6Z** **Disorders of the pituitary hormone system, unspecified**
- Disorders of the adrenal glands or adrenal hormone system (5A70-5A7Z)
- Coded Elsewhere:** Gonadotropin deficiency (5A61.2)  
Growth hormone deficiency (5A61.3)  
Thyroid stimulating hormone deficiency (5A61.4)  
Oxytocin deficiency (5A61.6)  
Adrenal incidentaloma (2F37.Y)
- 5A70** **Cushing syndrome**  
Cushing syndrome results from excess of corticosteroid hormones in the body due to overstimulation of the adrenal glands by excessive amounts of the hormone ACTH, secreted either by a tumor of the pituitary gland (Cushing's disease) or by a malignant tumour in the lung or elsewhere. Symptoms include weight gain, reddening of the face and neck, excess growth of body and facial hair, raised blood pressure, loss of mineral from the bones (osteoporosis), raised blood glucose levels, and sometimes mental disturbances.
- 5A70.0** **Pituitary-dependent Cushing disease**  
Pituitary-dependent Cushing disease is caused by a pituitary tumour, generally benign (adenoma) but rarely malignant (carcinoma), which secretes adrenocorticotropin (ACTH) autonomously, leading to hypercortisolism. The condition is associated with increased morbidity and mortality that can be mitigated by treatments that result in sustained endocrine remission. Transsphenoidal pituitary surgery (TSS) remains the mainstay of treatment for this disease but requires considerable neurosurgical expertise and experience in order to optimize patient outcomes.

- 5A70.1** **Ectopic ACTH syndrome**
- 5A70.2** **Pseudo-Cushing syndrome**  
This is a condition in which patients display the signs, symptoms, and abnormal hormone levels seen in Cushing's syndrome. However, pseudo-Cushing's syndrome is not caused by a problem with the hypothalamic-pituitary-adrenal axis as Cushing's is; it is an idiopathic condition.
- 5A70.3** **Nelson syndrome**
- 5A70.Y** **Other specified Cushing syndrome**
- 5A70.Z** **Cushing syndrome, unspecified**
- 5A71** **Adrenogenital disorders**  
Disorders of the reproductive system resulting from pathologic androgen production secondary to abnormalities in cortisol and/or aldosterone production
- 5A71.0** **46,XX disorders of sex development induced by androgens of fetal origin**  
This refers to 46,XX disorders of sex development induced by any natural or synthetic compound, usually a steroid hormone, that stimulates or controls the development and maintenance of male characteristics in vertebrates by binding to androgen receptors, of fetal origin.
- 5A71.00** **Glucocorticoid resistance**  
Glucocorticoid resistance is a rare genetic endocrine condition characterised by generalised, partial, target tissue resistance to glucocorticoids. The clinical spectrum of the condition is broad, ranging from asymptomatic to severe cases of hyperandrogenism, fatigue and/or mineralocorticoid excess.
- 5A71.01** **Congenital adrenal hyperplasia**  
Congenital adrenal hyperplasia (CAH) refers to a group of conditions associated with either complete (classical form) or partial (non-classical) anomalies in the biosynthesis of adrenal hormones. The condition is characterised by insufficient production of cortisol, or of aldosterone (classical form with salt wasting), associated with overproduction of adrenal androgens. In the classical form, metabolic decompensation (dehydration with hyponatraemia, hyperkalaemia and acidosis associated with mineralocorticoid deficiency, and hypoglycaemia associated with glucocorticoid deficiency) may be life-threatening from the neonatal period onwards. Genital variations may be noted at birth in affected females. Chronic hyperandrogenism may lead to accelerated growth during childhood, but advanced bone maturation may lead to a deficit in final height. Adults tend to be overweight and metabolic disturbances, bone anomalies and fertility problems may also be present. Non-classical forms are associated with later onset, during the peri- or postpubertal period, and manifest with signs of hyperandrogenism (acne, hirsutism, menstrual problems and infertility).
- 5A71.0Y** **Other specified 46,XX disorders of sex development induced by androgens of fetal origin**
- 5A71.0Z** **46,XX disorders of sex development induced by androgens of fetal origin, unspecified**

- 5A71.1** **46,XX disorders of sex development induced by androgens of maternal origin**  
This refers to 46,XX disorders of sex development induced by any natural or synthetic compound, usually a steroid hormone, that stimulates or controls the development and maintenance of male characteristics in vertebrates by binding to androgen receptors, of maternal origin.
- 5A71.Y** **Other specified adrenogenital disorders**
- 5A71.Z** **Adrenogenital disorders, unspecified**
- 5A72** **Hyperaldosteronism**
- 5A72.0** **Primary hyperaldosteronism**
- 5A72.1** **Secondary hyperaldosteronism**
- Coding Note:** Code also the causing condition
- 5A72.Z** **Hyperaldosteronism, unspecified**
- 5A73** **Hypoaldosteronism**  
**Exclusions:** Congenital adrenal hyperplasia (5A71.01)
- 5A74** **Adrenocortical insufficiency**  
A condition in which the adrenal glands do not produce adequate amounts of steroid hormones, primarily cortisol. It may also include impaired production of aldosterone (a mineralocorticoid), which regulates sodium conservation, potassium secretion, and water retention and also accompanies impaired production of adrenal androgens.  
**Coded Elsewhere:** Neonatal haemorrhage originating in adrenal gland (KA83.4)  
X-linked adrenoleukodystrophy (5C57.1)
- 5A74.0** **Acquired adrenocortical insufficiency**  
This is a acquired condition in which the adrenal glands do not produce adequate amounts of steroid hormones, primarily cortisol; but may also include impaired production of aldosterone (a mineralocorticoid), which regulates sodium conservation, potassium secretion, and water retention.  
**Exclusions:** Amyloidosis (5D00)  
**Coded Elsewhere:** Adrenocorticotrophic hormone deficiency (5A61.1)  
Tuberculous Addison disease (1B12.3)
- 5A74.1** **Adrenal crisis**  
Adrenal crisis is a life-threatening condition that indicates severe adrenal insufficiency caused by insufficient levels of cortisol.  
**Coded Elsewhere:** Waterhouse-Friderichsen syndrome (1C1C.1)
- 5A74.Y** **Other specified adrenocortical insufficiency**
- 5A74.Z** **Adrenocortical insufficiency, unspecified**

**5A75**

**Adrenomedullary hyperfunction**

Idiopathic overstimulation of the adrenal medulla resulting in pathologic epinephrine/norepinephrine-mediated sympathetic output

**5A76**

**Certain specified disorders of adrenal gland**

**5A76.0**

**Premature adrenarche**

Premature development of pubic and/or axillary hair without central or peripheral precocious puberty. Children show premature clinical and/or laboratory signs of androgen action without estrogen action.

**Exclusions:**      Central precocious puberty (5A60.3)

                        Congenital adrenal hyperplasia (5A71.01)

                        Peripheral precocious puberty (5A92)

**5A76.Y**

**Other specified disorders of adrenal gland**

**5A7Z**

**Disorders of the adrenal glands or adrenal hormone system, unspecified**

Disorders of the gonadal hormone system (5A80-5A8Z)

Gonad has a capability to produce androgen and estrogen under the control by hypothalamic–pituitary–gonadal axis. Gonadal dysfunction is caused by either insufficient actions of gonadotropin or resistance to gonadotropin.

**5A80**

**Ovarian dysfunction**

Pathological processes of the ovary.

**Exclusions:**      isolated gonadotropin deficiency (5A61.0)

                        Postprocedural ovarian failure (5D44)

**Coded Elsewhere:** Premature ovarian failure (GA30.6)

                        Hirsutism associated with hyperandrogenaemia (ED72.1)

                        Ovarian hyperstimulation syndrome (GA32.0)

                        HAIR-AN syndrome (5A44)

**5A80.0**

**Clinical hyperandrogenism**

Presence of hirsutism, acne or androgenic alopecia (scalp hair loss in women)

**5A80.1**

**Polycystic ovary syndrome**

Condition defined by the presence of at least 2 of the following 3 criteria: oligo/anovulation; clinical or biochemical signs of hyperandrogenism; presence of polycystic ovaries as identified by ultrasound.

**Inclusions:**      Sclerocystic ovary syndrome

**Exclusions:**      Polycystic ovary NOS (5A80.2)

<b>5A80.2</b>	<b>Polycystic ovary</b> Ovary with increased size (> 7 mL) and stromal volume, and with increased number of follicles (12 or more measuring 2-9 mm in diameter), that may be present in women with PCOS, but also in women with normal ovulatory function and normal fertility (unilaterally or bilaterally).
	<b>Exclusions:</b> Polycystic ovary syndrome (5A80.1)
<b>5A80.3</b>	<b>Anovulation</b> lack of ovulation in the last 12 months, leading to amenorrhea, irregular or infrequent cycles
<b>5A80.4</b>	<b>Oligo-ovulation</b> Oligo-ovulation (less than 4 ovulations in the last 12 months) not related to described categories of endocrine dysfunction. Excludes anovulation related to PCOS, hyperprolactinaemia or amenorrhea.
<b>5A80.5</b>	<b>Diminished ovarian reserve</b> Condition characterised by ovaries with lower number of oocytes than expected for female chronologic age, marked by biochemical abnormalities (increased serum FSH levels, decreased serum AMH levels) and/or ultrasound findings (low antral follicle count) associated with ovarian ageing, reduced response to ovarian stimulation, and female infertility
<b>5A80.Y</b>	<b>Other specified ovarian dysfunction</b>
<b>5A80.Z</b>	<b>Ovarian dysfunction, unspecified</b>
<b>5A81</b>	<b>Testicular dysfunction or testosterone-related disorders</b>
	<b>Exclusions:</b> isolated gonadotropin deficiency (5A61.0) Klinefelter syndrome (LD50.3) Postprocedural testicular hypofunction (5D45) Azoospermia (GB04.0) Oligospermia (GB04)
	<b>Coded Elsewhere:</b> 46,XY gonadal dysgenesis (LD2A.1) Testicular agenesis (LD2A.2) 46,XY disorder of sex development due to a defect in testosterone metabolism (LD2A.3) 46,XY disorder of sex development due to androgen resistance (LD2A.4) 46, XY disorders of sex development (LD2A.Z)
<b>5A81.0</b>	<b>Testicular hyperfunction</b> A hypersecretion of testicular hormones.
	<b>Exclusions:</b> McCune-Albright syndrome (FB80.0)

<b>5A81.1</b>	<b>Testicular hypofunction</b>
	In pre-puberty, a disorder characterised by atrophied testes and sterility, abnormal height and absence of secondary sex characteristics. In post-puberty, a disorder characterised by depressed sexual function, loss of sex drive and sterility, muscle weakness and osteoporosis (due to loss of the androgen anabolic effect).
<b>5A81.Y</b>	<b>Other specified testicular dysfunction or testosterone-related disorders</b>
<b>5A81.Z</b>	<b>Testicular dysfunction or testosterone-related disorders, unspecified</b>
<b>5A8Z</b>	<b>Disorders of the gonadal hormone system, unspecified</b>

Certain disorders of puberty (5A90-5A9Z)

**Exclusions:** Central precocious puberty (5A60.3)

<b>5A90</b>	<b>Disorder of puberty due to oestrogen resistance</b>
-------------	--

<b>5A91</b>	<b>Delayed puberty</b>
-------------	------------------------

This is when an organism has passed the usual age of onset of puberty with no physical or hormonal signs that it is beginning. Puberty may be delayed for several years and still occur normally, in which case it is considered constitutional delay, a variation of healthy physical development. Delay of puberty may also occur due to malnutrition, many forms of systemic disease, or to defects of the reproductive system (hypogonadism) or the body's responsiveness to sex hormones.

**Inclusions:** Delayed sexual development

Constitutional delay of puberty

<b>5A92</b>	<b>Peripheral precocious puberty</b>
-------------	--------------------------------------

Precocious puberty without activation of the GnRH-gonadotropin axis. It includes gonadal tumours with sex hormone production and it may be part of McCune-Albright's syndrome.

**Inclusions:** Precocious menstruation

**Exclusions:** female heterosexual precocious pseudopuberty (5A71)

male isosexual precocious pseudopuberty (5A71)

Central precocious puberty (5A60.3)

Congenital adrenal hyperplasia (5A71.01)

**Coded Elsewhere:** Testotoxicosis (5A81.0)

McCune-Albright syndrome (FB80.0)

<b>5A9Y</b>	<b>Other disorders of puberty</b>
-------------	-----------------------------------

<b>5A9Z</b>	<b>Disorders of puberty, unspecified</b>
-------------	--

Polyglandular dysfunction (5B00-5B0Z)

- Exclusions:** Ataxia-telangiectasia (4A01.31)  
Pseudohypoparathyroidism (5A50.1)  
dystrophia myotonica [Steinert] (8C71.0)

**Coded Elsewhere:** Multiple polyglandular tumours (2F7A.0)

**5B00**

### **Autoimmune polyendocrinopathy**

This is a subtype of autoimmune polyendocrine syndrome, in which multiple endocrine glands dysfunction as a result of autoimmunity. It is a genetic disorder attributed to a defect in the AIRE gene that normally confers immune tolerance. It is inherited in a recessive fashion.

**Coded Elsewhere:** X-linked immune dysregulation – polyendocrinopathy – enteropathy (4A01.21)

**5B01**

### **Polyglandular hyperfunction**

**5B0Y**

### **Other specified polyglandular dysfunction**

**5B0Z**

### **Polyglandular dysfunction, unspecified**

Endocrine disorders, not elsewhere classified (5B10-5B1Y)

- Exclusions:** Pseudohypoparathyroidism (5A50.1)

**5B10**

### **Carcinoid syndrome**

**5B11**

### **Short stature, not elsewhere classified**

- Exclusions:** Progeria (LD2B)

Silver-Russell syndrome (LD2F.1)

short-limbed stature with immunodeficiency (4A01.10)

short stature hypochondroplastic (LD24.01)

short stature achondroplastic (LD24.00)

renal short stature (GB61)

pituitary related short stature (5A61.0)

**Coded Elsewhere:** Short stature due to growth hormone resistance (5A61.0)

**5B12**

### **Constitutional tall stature**

Constitutional (familial) tall stature, a variant of the normal pattern of childhood growth and development, is defined as a condition in which the height of an individual is more than 2 SD above the corresponding mean height for a normal subject of the same age and gender. Distinguishing features are a family history of tall stature and lack of dimorphism or other clinical features suggesting pathologic causes of abnormally rapid growth.

**Inclusions:** Constitutional gigantism

**5B1Y**

### **Other specified endocrine disorders, not elsewhere classified**

---

**5B3Y**      **Other specified endocrine diseases**

**5B3Z**      **Endocrine diseases, unspecified**

### Nutritional disorders (5B50-5C3Z)

Nutritional disorders in all their forms result from imbalances (excess or deficiency) in energy and/or specific macro and micronutrients. They occur when the intake of essential macronutrients and micronutrients does not meet or exceeds the metabolic demands for those nutrients. Metabolic demands vary with age and other physiological conditions, they are also affected by environmental circumstances, including poor hygiene and sanitation, which lead to diarrhea and other infections.

**Coded Elsewhere:** Nutritional or toxic disorders of the nervous system (8D40-8D4Z)

#### Undernutrition (5B50-5B7Z)

Undernutrition is a condition in which the body's requirements are unmet due to underconsumption or to impaired absorption and use of nutrients. It can be produced by lack of access to food, or as a consequence of illness. Undernutrition commonly refers to a deficit in energy intake, but can also refer to deficiencies of specific nutrients, and can be either acute or chronic.

**Inclusions:**      Malnutrition NOS

**Exclusions:**      slim disease (1C62.3)

starvation (NF07.0)

Intestinal malabsorption (DA96.0)

Anorexia Nervosa (6B80)

**Coded Elsewhere:** Malnutrition in pregnancy (JA64)

Fetal intrauterine malnutrition without mention of small for gestational age  
(KA20.2)

Undernutrition-dehydration cataract (9B10.2Y)

**5B50**      **Underweight in infants, children or adolescents**

**5B51**      **Wasting in infants, children or adolescents**

**5B52**      **Acute malnutrition in infants, children or adolescents**

**5B53**      **Stunting in infants, children or adolescents**

**5B54**      **Underweight in adults**

Body mass index (BMI) <18.5 kg/m<sup>2</sup>

**5B55**

### **Vitamin A deficiency**

Vitamin A deficiency (VAD) is defined as a state in which tissue concentrations of vitamin A are low enough to have adverse health consequences even if there is no evidence of clinical xerophthalmia. The term xerophthalmia encompasses the clinical spectrum of ocular manifestations of vitamin A deficiency, from milder stages of night blindness and Bitot's spots, to potentially blinding stages of corneal xerosis, ulceration and necrosis (keratomalacia). In addition to the specific signs and symptoms of xerophthalmia and the risk of irreversible blindness, nonspecific symptoms include increased morbidity and mortality, poor reproductive health, increased risk of anaemia, and contributions to slowed growth and development.

**Inclusions:** Hypovitaminosis A

**Coded Elsewhere:** Acquired vitamin A deficiency anaemia (3A03.5)

**5B55.0**

### **Vitamin A deficiency with night blindness**

Night blindness (poor adaptation to darkness) is generally the earliest manifestation of vitamin A deficiency. In mild cases, night blindness is apparent only after photic stress. Affected children no longer move around after dusk and prefer to sit in a secure corner, often unable to find their food or toys. Night blindness of recent onset in a preschool child is practically pathognomonic of vitamin A deficiency. All patients respond rapidly to therapy with vitamin A, usually within 48 hours.

**5B55.1**

### **Vitamin A deficiency with conjunctival xerosis**

In conjunctival xerosis the epithelium of the conjunctiva is transformed from the normal columnar to the stratified squamous type, with a resultant loss of goblet cells, formation of a granular cell layer, and keratinization of the surface. Clinically, these changes are expressed as marked dryness or unwettability, the affected area appearing roughened, with fine droplets or bubbles on the surface, rather than smooth and glistening. Conjunctival xerosis first appears in the temporal quadrant, as an isolated oval or triangular patch adjacent to the limbus in the interpalpebral fissure. It is almost always present in both eyes.

**5B55.2**

### **Vitamin A deficiency with conjunctival xerosis and Bitot's spots**

Generalised conjunctival xerosis suggests advanced vitamin A deficiency. The entire conjunctiva appears dry, roughened, and corrugated, sometimes skin-like. In some individuals keratin and saprophytic bacilli accumulate on the xerotic surface, giving it a foamy or cheesy appearance. Such lesions are known as Bitot's spot. With treatment active conjunctival xerosis and Bitot's spot begin to resolve within 2-5 days. Most will disappear within 2 weeks, though a significant proportion of temporal lesions may persist, in shrunken form, for months.

**5B55.3**

**Vitamin A deficiency with corneal xerosis**

Clinically, the cornea develops classical xerosis, a hazy, lustreless, dry appearance, first apparent near the inferior limbus. Many children have characteristic superficial punctate lesions of the inferior-nasal aspects of their cornea that stain brightly with fluorescein. Early in the disease they are visible only through a slit-lamp examination. With more severe disease the punctate lesions become more numerous and spread upwards over the central cornea, and the corneal stroma becomes oedematous. Thick, keratinized plaques resembling Bitot's spot may form on the corneal surface. These are often densest in the interpalpebral zone. With treatment, these corneal plaques peel off, sometimes leaving superficial erosion which quickly heals. Corneal xerosis responds within 2-5 days to vitamin A therapy, the cornea regaining its normal appearance in 1-2 weeks.

**5B55.4**

**Vitamin A deficiency with corneal ulceration or keratomalacia**

Ulceration/keratomalacia indicates permanent destruction of part or all of the corneal stroma, resulting in permanent structural alteration. Ulcers are classically round to oval "punched-out" defects, as if a trephine or cork-borer had been applied to the eye. The surrounding cornea is generally xerotic but otherwise clear, and typically lacks the grey, infiltrated appearance of ulcers of bacterial origin. There may be more than one ulcer. Small ulcers are almost invariably confined to the periphery of the cornea, especially its inferior and nasal aspects. The ulceration may be shallow, but is commonly deep. Perforations become plugged with iris, thereby preserving the anterior chamber. In more advanced disease the necrotic stroma sloughs, leaving a large ulcer or descemetocele. As with smaller ulcers, this is usually peripheral and heals as a dense, white, adherent leukoma. With therapy, superficial ulcers often heal with surprisingly little scarring; deeper ulcers, especially perforations, form dense peripheral adherent leukomas.

**5B55.5**

**Vitamin A deficiency with xerophthalmic scars of cornea or blindness**

Xerophthalmia or "dry eye" remains the most important cause of childhood blindness in many developing countries. Healed sequelae of prior corneal disease related to vitamin A deficiency include opacities or scars of varying density (nebula, macula, leukoma), weakening and outpouching of the remaining corneal layers (staphylooma and descemetocele) and, where loss of intraocular contents has occurred, phthisis bulbi, a scarred shrunken globe. Such end-stage lesions are not specific for xerophthalmia and may arise from numerous other conditions, notably trauma and infection.

**5B55.Y**

**Vitamin A deficiency with other specified manifestations**

**5B55.Z**

**Vitamin A deficiency, unspecified**

**5B56**

**Vitamin C deficiency**

This condition groups several clinical consequences secondary to vitamin C deficiency with scurvy being the most severe presentation. The populations at risk of vitamin C deficiency are those for whom the fruit and vegetable supply is minimal. Epidemics of scurvy are associated with famine and war, when food supply is small and irregular. Children fed predominantly heat-treated (ultra-high-temperature or pasteurized) milk or unfortified formulas and not receiving fruits and fruit juices are at significant risk for symptomatic disease.

<b>5B56.0</b>	<b>Scurvy</b> Scurvy is a disease caused by a lack of vitamin C (ascorbic acid) in the diet. Vitamin C plays a central role in collagen and ground-substance formation, metabolism of aromatic amino acids (phenylalanine, tyrosine), reduction of folic acid to folinic acid and a broad range of biochemical redox reactions. Clinical features include perifollicular haemorrhages, ecchymoses, swollen bleeding gums, stomatitis and epistaxis.  <i>Coded Elsewhere:</i> Scorbutic anaemia (3A03.2)
<b>5B56.Y</b>	<b>Other specified vitamin C deficiency</b>
<b>5B56.Z</b>	<b>Vitamin C deficiency, unspecified</b>
<b>5B57</b>	<b>Vitamin D deficiency</b> Vitamin D is a fat-soluble vitamin contained naturally in very few foods, added to milk, available as a supplement, and produced endogenously with exposure to sunlight. Vitamin D deficiency can be caused by inadequate intake due to dietary factors (e.g., special diets (veganism), lactose intolerance or allergies) and/or limited exposure to sunlight due to geographic location, sun avoidance, or shiftwork. Severe deficiency results in disordered bone modelling called rickets in childhood (open growth plates), and osteomalacia in adults (fused growth plates).
<b>5B57.0</b>	<b>Vitamin D deficiency rickets</b> Rickets is a disease of growing bone that is due to unmineralized matrix at the growth plates and occurs in children only before fusion of the epiphyses. There are many causes of rickets, including vitamin D disorders, calcium deficiency, phosphorous deficiency, and distal renal tubular acidosis. With the increased survival rate of very low birthweight infants, rickets in this age group has become a significant problem.
<b>5B57.1</b>	<b>Vitamin D deficiency osteomalacia</b> Osteomalacia is a disorder of defective mineralization of newly formed osteoid at sites of bone turnover. Several different disorders cause osteomalacia via mechanisms that result in hypocalcaemia, hypophosphatemia, or direct inhibition of the mineralization process. Severe vitamin D deficiency, secondary to inadequate dietary intake, lack of sun exposure, gastric bypass or malabsorption (celiac disease), is the most common cause of osteomalacia in adults.
<b>5B57.Y</b>	<b>Other specified vitamin D deficiency</b>
<b>5B57.Z</b>	<b>Vitamin D deficiency, unspecified</b>

**5B58**

### **Vitamin E deficiency**

Vitamin E deficiency is a condition that causes haemolysis and/or neurologic manifestations. Red blood cell fragility occurs and can produce a haemolytic anaemia. Neuronal degeneration produces peripheral neuropathies, ophthalmoplegia, and destruction of posterior columns of spinal cord. Neurologic disease is frequently irreversible if deficiency is not corrected early enough. Vitamin E deficiency may also contribute to the haemolytic anaemia and retrorenal fibroplasia seen in premature infants.

**Coded Elsewhere:** Acquired vitamin E deficiency anaemia (3A03.6)

Dementia due to vitamin E deficiency (6D85.Y)

**5B59**

### **Vitamin K deficiency**

Vitamin K is necessary for the synthesis of clotting factors II, VII, IX, and X, and deficiency of vitamin K can result in clinically significant bleeding. Vitamin K deficiency typically affects infants, who experience a transient deficiency related to inadequate intake, or patients of any age who have decreased vitamin K absorption. Mild vitamin K deficiency can affect long-term bone and vascular health.

**Coded Elsewhere:** Neonatal vitamin K deficiency (KA8F)

**5B5A**

### **Vitamin B1 deficiency**

Vitamin B1 deficiency manifests itself principally with changes involving the nervous system (polyneuritis and paralysis of the peripheral nerves), the cardiovascular system (cardiac insufficiency and generalised oedema), and also the gastrointestinal tract (constipation, vomiting, and abdominal pain).

**5B5A.0**

#### **Beriberi**

The clinical picture of Beriberi is usually divided into a dry (neuritic) type and a wet (cardiac) type. The disease is wet or dry depending on the amount of fluid which accumulates in the body due to factors like cardiac function, kidney lesions and others; even though the exact cause for this oedema has never been successfully explained. Many cases of thiamine deficiency show a mixture of the two main features and are more properly termed thiamine deficiency with cardiopathy and peripheral neuropathy. The infant shows signs of cyanosis and an acute cardiac attack can follow with the infant usually dying within 2 to 4 hours. The common age for this form of the deficiency disease is one month up through the third month. This type of deficiency responds very dramatically to thiamine.

**5B5A.00**

Dry beriberi

Neuritic form of Beri Beri

**5B5A.01**

Wet beriberi

Cardiac form of Beri Beri.

**5B5A.0Z**

Beriberi, unspecified

<b>5B5A.1</b>	<b>Wernicke-Korsakoff Syndrome</b> A thiamine-deficiency syndrome characterised by symmetric hyperaemic lesions of the brainstem, hypothalamus, thalamus, and mammillary bodies with glial proliferation, capillary dilatation, and perivascular haemorrhage. The syndrome is manifested by a confusional state, disorientation, ophthalmoplegia, nystagmus, diplopia, and ataxia (Wernicke encephalopathy), with severe loss of memory for recent events and confabulation (the invention of accounts of events to cover the loss of memory) (Korsakoff psychosis) occurring following recovery. Defective binding of thiamine diphosphate by transketolase has been found. It appears that the disorder is of autosomal recessive inheritance but is expressed as clinical disease only in the event of thiamine deficiency.
<b>Coding Note:</b>	Chronic alcohol use may be associated with thiamine deficiency, but alcohol may also have effects on the brain via other mechanisms. This category should be used to describe cognitive symptoms due to chronic alcohol use if there is evidence of thiamine deficiency.
	<b>Exclusions:</b> Amnestic disorder due to use of alcohol (6D72.10)
<b>5B5A.10</b>	<b>Wernicke encephalopathy</b> Wernicke's encephalopathy is an acute neuropsychiatric syndrome characterised by nystagmus, ophthalmoplegia, changes in the mental status, an uncoordinated gait and truncal ataxia. Wernicke's encephalopathy is usually accompanied or followed by Korsakoff's syndrome/Korsakoff's dementia (a continuum of Wernicke's encephalopathy characterised by severe memory defects, ataxia, apathy, disorientation, confabulations, hallucinations, paralysis of muscles controlling the eye and coma). The disorder results from a deficiency in vitamin B1, and mostly occurs in adults with a history of alcohol abuse or in patients with AIDS.
<b>5B5A.11</b>	<b>Korsakoff syndrome</b> A disease of the nervous system, caused by deficiency of vitamin B1 in the brain. This disease commonly follows Wernicke encephalopathy, and may present with inability to form new memories, amnesia, confabulation, or hallucinations.
<b>Coding Note:</b>	Chronic alcohol use may be associated with thiamine deficiency, but alcohol may also have effects on the brain via other mechanisms. This category should be used to describe cognitive symptoms due to chronic alcohol use if there is evidence of thiamine deficiency.
	<b>Exclusions:</b> Amnestic disorder due to use of alcohol (6D72.10)
<b>5B5A.1Y</b>	<b>Other specified Wernicke-Korsakoff Syndrome</b>
<b>Coding Note:</b>	Chronic alcohol use may be associated with thiamine deficiency, but alcohol may also have effects on the brain via other mechanisms. This category should be used to describe cognitive symptoms due to chronic alcohol use if there is evidence of thiamine deficiency.
<b>5B5A.1Z</b>	<b>Wernicke-Korsakoff Syndrome, unspecified</b>
<b>Coding Note:</b>	Chronic alcohol use may be associated with thiamine deficiency, but alcohol may also have effects on the brain via other mechanisms. This category should be used to describe cognitive symptoms due to chronic alcohol use if there is evidence of thiamine deficiency.
<b>5B5A.Y</b>	<b>Other specified vitamin B1 deficiency</b>
<b>5B5A.Z</b>	<b>Vitamin B1 deficiency, unspecified</b>

**5B5B**

### **Vitamin B2 deficiency**

The signs of riboflavin deficiency are sore throat, hyperaemia, oedema of the pharyngeal and oral mucous membranes, cheilosis, angular stomatitis, glossitis, seborrheic dermatitis, and normochromic normocytic anaemia associated with pure red cell cytoplasia of the bone marrow. The major cause of hyporiboflavinosis is inadequate dietary intake as a result of limited food supply, which is sometimes exacerbated by poor food storage or processing. Children in developing countries will commonly demonstrate clinical signs of riboflavin deficiency during periods of the year when gastrointestinal infections are prevalent. Decreased assimilation of riboflavin also results from abnormal digestion, such as that which occurs with lactose intolerance.

**Inclusions:** Riboflavin deficiency

**Coded Elsewhere:** Acquired riboflavin deficiency anaemia (3A03.41)

**5B5C**

### **Vitamin B3 deficiency**

Niacin deficiency classically results in pellagra, which is a chronic wasting disease associated with a characteristic erythematous dermatitis that is bilateral and symmetrical, a dementia after mental changes including insomnia and apathy preceding an overt encephalopathy, and diarrhoea resulting from inflammation of the intestinal mucous surfaces. Pellagra occurs endemically in poorer areas of Africa, China and India.

**Inclusions:** niacin deficiency NOS

**5B5C.0**

#### **Pellagra**

Pellagra is a potentially life-threatening disorder due to niacin deficiency and is observed in malnourished individuals, especially alcoholics, and as a complication of isoniazid therapy. The diagnosis is often overlooked or delayed. Pellagra manifests as diarrhoea, dermatitis, dementia, which usually appear in this order. Gastrointestinal tract symptoms always precede skin involvement, which presents initially with a sunburn-like blistering erythema, typically affecting the dorsal surfaces of the hands, face, neck, arms, and feet. With time the skin becomes thickened, scaly and pigmented.

**5B5C.Y**

#### **Other specified vitamin B3 deficiency**

**5B5C.Z**

#### **Vitamin B3 deficiency, unspecified**

**5B5D**

### **Vitamin B6 deficiency**

A deficiency of vitamin B6 alone is uncommon because it usually occurs in association with a deficit in other B-complex vitamins. Hypovitaminosis B6 may often occur with riboflavin (vitamin B2) deficiency. The classical clinical symptoms of vitamin B6 deficiency are a seborrheic dermatitis, microcytic anaemia, epileptiform convulsions, and depression and confusion. Infants are especially susceptible to insufficient intakes, which can lead to epileptiform convulsions. Moreover, there is usually a decrease in circulating lymphocytes and sometimes a normocytic, microcytic, or sideroblastic anaemia as well. As is the case with other micronutrient deficiencies, vitamin B6 deficiency results in an impairment of the immune system. Several medical conditions can also affect vitamin B6 metabolism and thus lead to deficiency symptoms.

**Exclusions:** Pyridoxine-responsive sideroblastic anaemia, not elsewhere classified (3A72.1)

**Coded Elsewhere:** Acquired pyridoxine deficiency anaemia (3A03.40)

Pyridoxine dependent epilepsy with antiquitin mutations  
(8A61.0Y)

**5B5E**

### **Folate deficiency**

Nutritional deficiency of folate is common in people consuming a limited diet. This can be exacerbated by malabsorption conditions, including coeliac disease and tropical sprue. Pregnant women are at risk for folate deficiency because pregnancy significantly increases the folate requirement, especially during periods of rapid fetal growth (i.e. in the second and third trimester). During lactation, losses of folate in milk also increase the folate requirement. During pregnancy, there is an increased risk of fetal neural tube defects (NTDs), with risk increasing 10-fold as folate status goes from adequate to poor. Between days 21 and 27 post-conception, the neural plate closes to form what will eventually be the spinal cord and cranium. Spina bifida, anencephaly, and other similar conditions are collectively called NTDs. They result from improper closure of the spinal cord and cranium, respectively, and are the most common congenital abnormalities associated with folate deficiency.

**5B5F**

### **Vitamin B12 deficiency**

Vegetarianism and poverty-imposed near-vegetarianism are the most common causes of nutritional cobalamin insufficiency worldwide in all age groups. In such populations, low maternal cobalamin status is associated with adverse pregnancy outcomes (preterm birth, intrauterine growth retardation, early recurrent miscarriage), neural tube defects, reduced neurocognitive performance in children, accelerated bone turnover, and low bone mineral density with fractures. Insufficient cobalamin intake is also seen in breast-fed infants of mothers with pernicious anaemia.

**Inclusions:** cobalamin deficiency

cyanocobalamin deficiency

**Coded Elsewhere:** Vitamin B12 deficiency anaemia due to low intake (3A01.2)

Vitamin B12 deficiency anaemia due to intrinsic factor deficiency (3A01.3)

Vitamin B12 deficiency anaemia due to intestinal disease (3A01.4)

Drug-induced vitamin B12 deficiency anaemia (3A01.5)

Acquired vitamin B12 deficiency anaemia (3A01.Z)

Dementia due to vitamin B12 deficiency (6D85.Y)

**5B5G**

### **Biotin deficiency**

Isolated biotin deficiency is rare. Signs of biotin deficiency in humans have been demonstrated in individuals who consume raw egg white over long periods and in total parenteral nutrition (TPN) before biotin supplementation in patients with malabsorption. The clinical findings of biotin deficiency include dermatitis, conjunctivitis, alopecia, and central nervous system abnormalities. In adults fed raw egg white (which contains avidin, a protein that binds biotin with such high affinity that it renders it biounavailable) or receiving biotin-free TPN for months to years, thinning of hair, frequently with loss of hair colour, has been reported. Most adults with the deficiency demonstrate a red, scaly, skin rash, frequently around the eyes, nose, and mouth. Most of the adults have neurological symptoms, including depression, lethargy, hallucinations, and paraesthesia of the extremities.

**5B5H**

### **Pantothenic acid deficiency**

Pantothenic deficiency is rare: only reported as a result of feeding semisynthetic diets or an antagonist to the vitamin. Experimental, isolated deficiency in humans produces fatigue, abdominal pain, vomiting, insomnia, and paraesthesiae of the extremities.

**5B5J**

### **Choline deficiency**

Choline deficiency is rare. Individuals fed with total parenteral nutrition (TPN) solutions lacking choline develop fatty liver and liver damage.

**5B5K**

### **Mineral deficiencies**

**Exclusions:** Disorders of mineral absorption or transport (5C64)

**Coded Elsewhere:** Hypokalaemia (5C77)

Hypomagnesaemia (5C64.41)

**5B5K.0**

**Iron deficiency**

Iron deficiency is a state in which there is insufficient iron to maintain the normal physiological function of blood, brain and muscles. It can exist in the absence of anaemia if it has not lasted long enough or if it has not been severe enough to cause the haemoglobin concentration to fall below the threshold for the specific sex and age group. Iron deficiency is the most common nutritional deficiency.

**Exclusions:** Iron deficiency anaemia (3A00)

**Coded Elsewhere:** Acquired iron deficiency anaemia due to blood loss (3A00.0)

Acquired iron deficiency anaemia due to low intake (3A00.1)

Acquired iron deficiency anaemia due to decreased absorption  
(3A00.2)

Acquired iron deficiency anaemia due to increased  
requirement (3A00.3)

Acquired iron deficiency anaemia (3A00.Z)

Dementia due to iron deficiency (6D85.Y)

**5B5K.1**

**Calcium deficiency**

Hypocalcaemia is defined as a total serum calcium concentration of less than 8.4 mg/dl (2.1 mmol/litre) or an ionized calcium concentration of less than 4.48 mg/dl (1.12 mmol/litre). There are numerous causes of hypocalcaemia, chronic kidney disease being the most common cause. Other causes are: vitamin D deficiency, disorders associated with acquired or genetic hypoparathyroidism, including intravenous bisphosphonate therapy, post-thyroidectomy and post-parathyroidectomy, and acute pancreatitis. Hypocalcaemia may be associated with a spectrum of clinical manifestations, ranging from few symptoms if the hypocalcaemia is mild, to life-threatening seizures, refractory heart failure, or laryngospasm if it is severe. In addition to severity, the rate of development of hypocalcaemia and chronicity determine the clinical manifestations.

**Exclusions:** Disorders of calcium metabolism (5C64.5)

**Coded Elsewhere:** Neonatal hypocalcaemia (KB61.2)

Neonatal osteopenia (KB61.3)

Myopathy due to calcium deficiency (8D40.2)

**5B5K.10**

Tetany due to acute calcium deficiency

The hallmark of acute hypocalcaemia is tetany, which is characterised by neuromuscular irritability. The symptoms of tetany may be mild (peri-oral numbness, paresthesias of the hands and feet, muscle cramps) or severe (carpopedal spasm, laryngospasm, and focal or generalised seizures, which must be distinguished from the generalised tonic muscle contractions that occur in severe tetany). Other patients have less specific symptoms such as fatigue, hyperirritability, anxiety, and depression, and some patients, even with severe hypocalcaemia, have no neuromuscular symptoms. Factors that determine the variation in frequency and severity of symptoms include acid-base status (hypocalcaemia and alkalosis act synergistically to cause tetany), hypomagnesaemia, and potassium balance.

**5B5K.1Y**

Other specified calcium deficiency

**5B5K.1Z**

Calcium deficiency, unspecified

**5B5K.2****Zinc deficiency**

The clinical features of severe zinc deficiency in humans are growth retardation, delayed sexual and bone maturation, skin lesions, diarrhoea, alopecia, impaired appetite, increased susceptibility to infections mediated via defects in the immune system, and the appearance of behavioural changes. The effects of marginal or mild zinc deficiency are less clear. A reduced growth rate and impairments of immune defence are so far the only clearly demonstrated signs of mild zinc deficiency in humans. Other effects, such as impaired taste and wound healing, which have been claimed to result from a low zinc intake, are less consistently observed.

**Coded Elsewhere:** Neonatal nutritional zinc deficiency (5C64.21)

**5B5K.3****Iodine deficiency**

Iodine deficiency disorders (IDD), caused mainly by a low dietary supply of iodine, refer to all of the consequences of iodine deficiency in a population that can be prevented by ensuring that the population has an adequate intake of iodine. Iodine deficiency is the most frequent cause of preventable brain damage in childhood.

**Coded Elsewhere:** Iodine-deficiency-related thyroid disorders or allied conditions (5A00.1)

Acquired hypothyroidism (5A00.2)

Congenital hypothyroidism due to iodine deficiency (5A00.04)

**5B5K.4****Fluorine deficiency**

A condition caused by a deficiency of fluoride. Low fluorine concentrations in an individual's dental plaque and enamel may result in an increased risk for dental caries at any age. Fluorine deficiencies might also show negative effects on human's bone health.

**5B5K.5****Sodium chloride deficiency**

Sodium and chloride are usually found together in most foods as sodium chloride, also termed salt. For that reason, the effects of sodium and chloride deficiency are considered together. Deficiency can be caused by poor intake or increased losses (e.g., diuretics increase the urinary excretion of water, sodium, and chloride; in cystic fibrosis the sodium and chloride content of sweat is very high; gastrointestinal losses are associated with diarrhoeal diseases, emesis, ostomy output and other causes).

**5B5K.6****Copper deficiency**

Dietary deficiency is rare; it has been observed in premature and low birthweight infants fed exclusively a cow's milk diet and in individuals on long-term total parenteral nutrition without copper. Clinical manifestations include depigmentation of skin and hair, neurologic disturbances, leukopenia, hypochromic microcytic anaemia, and skeletal abnormalities.

**Coded Elsewhere:** Copper deficiency anaemia (3A03.3)

- 5B5K.7      Selenium deficiency**  
Selenium deficiency is rare but has been observed in individuals on long-term total parenteral nutrition lacking selenium. Clinical manifestations of deficiency arising from such situations are uncommon and poorly defined. They include muscular weakness and myalgia with, in several instances, the development of congestive heart failure. The importance of selenium for thyroid hormone metabolism is evident from changes in the T<sub>3</sub>–T<sub>4</sub> ratio which develop after relatively mild selenium depletion in infants and elderly subjects.
- 5B5K.8      Chromium deficiency**  
Deficiency in humans is only described in long-term total parenteral nutrition patients receiving insufficient chromium. Hyperglycaemia or impaired glucose tolerance occurs. Elevated plasma free fatty acid concentrations, neuropathy, encephalopathy, and abnormalities in nitrogen metabolism are also reported.
- 5B5K.9      Manganese deficiency**
- 5B5K.A      Molybdenum deficiency**  
Molybdenum functions as a cofactor for a limited number of enzymes in humans: sulphite oxidase, xanthine oxidase and aldehyde oxidase. A rare severe metabolic defect causing molybdenum cofactor deficiency and preventing these enzymes from being synthesized has been described. Few infants with such defects survive the first days of life, and those who survive have severe neurological abnormalities. Although molybdenum deficiency related to a dietary deficiency is extremely rare in humans, it has been described in long-term total parenteral nutrition as being secondary to the administration of sulphite. Symptoms include: tachycardia, headache, night blindness, irritability and coma. Biochemical changes can consist of elevated plasma and methionine concentration, low serum uric acid concentration, high urinary thiosulfate and low urinary uric acid and sulphate levels.
- 5B5K.B      Vanadium deficiency**  
A biological role of vanadium in humans has not yet been identified.
- 5B5K.Y      Other specified mineral deficiency**
- 5B5K.Z      Mineral deficiency, unspecified**

## Sequelae of malnutrition or certain specified nutritional deficiencies (5B60-5B6Z)

This refers to sequelae of malnutrition or certain specified nutritional deficiencies.

- 5B60      Sequelae of protein-energy malnutrition**  
This refers to a pathological condition resulting from protein-energy malnutrition.
- 5B61      Sequelae of vitamin A deficiency**  
This refers to a pathological condition resulting from vitamin A deficiency.
- 5B62      Sequelae of vitamin C deficiency**  
This refers to a pathological condition resulting from vitamin C deficiency.

**5B63**

**Sequelae of rickets**

Bowed legs and/or arms, knock-knees, deformities of the thoracic cage and/or spine and/or skeletal dysplasia secondary to chronic or advanced rickets

**5B6Y**

**Other specified sequelae of malnutrition or certain specified nutritional deficiencies**

**5B6Z**

**Sequelae of malnutrition or certain specified nutritional deficiencies, unspecified**

**5B70**

**Essential fatty acid deficiency**

Deficiency of EFA (linoleic acid, linolenic acid, arachidonic acid, docosapentaenoic acid, docosahexaenoic acid and eicosapentaenoic acid) can be caused by deficient intake, particularly, in rapidly growing infants (as preterm infants), in patients receiving parenteral nutrition without an adequate source of EFA, and in diseases with fat malabsorption. Clinical findings are: dermatitis, alopecia, and thrombocytopenia. The role of EFA during pregnancy and lactation has been highlighted, and the role of long-chain n-3 fatty acids as structural components for the development of the retinal function and central nervous system is now accepted. The prenatal period is a time of increased risk for omega-3 deficiency, as maternal tissue stores tend to decline as they are used for the developing fetus. Deficiency of n-3 EFA can affect growth, and cognitive and visual function in infants. The characteristic signs of deficiency attributed to the n-6 fatty acids are scaly skin rash, increased transepidermal water loss, reduced growth, and elevation of the plasma ratio of eicosatrienoic acid: arachidonic acid. EFA deficiency in special populations has been linked to hematologic disturbances and diminished immune response. Long-chain n-3 and n-6 fatty acids are essential nutrients and also, as part of the overall fat supply may affect the prevalence and severity of cardiovascular disease, diabetes, cancer and age-related functional decline.

**5B71**

**Protein deficiency**

**5B7Y**

**Other specified undernutrition**

**5B7Z**

**Unspecified undernutrition**

Overweight, obesity or specific nutrient excesses (5B80-5C1Z)

Overweight or obesity (5B80-5B81.Z)

**5B80**

**Overweight or localised adiposity**

Overweight is a condition characterized by excessive adiposity. Overweight is assessed by the body mass index (BMI), which is a surrogate marker of adiposity calculated as weight (kg)/height<sup>2</sup> (m<sup>2</sup>). The BMI categories for defining overweight vary by age and gender in infants, children and adolescents. For adults, overweight (or pre-obesity) is defined by a BMI ranging from 25.00 to 29.99 kg/m<sup>2</sup>. Localized adiposity is a condition characterized by accumulation of adipose tissue in specific regions of the body independently of BMI.

<b>5B80.0</b>	<b>Overweight</b> Overweight is a condition characterized by excessive adiposity. Overweight is assessed by the body mass index (BMI), which is a surrogate marker of adiposity calculated as weight (kg)/height <sup>2</sup> (m <sup>2</sup> ). The BMI categories for defining overweight vary by age and gender in infants, children and adolescents. For adults, overweight (or pre-obesity) is defined by a BMI ranging from 25.00 to 29.99 kg/m <sup>2</sup> .
<b>5B80.00</b>	Overweight in infants, children or adolescents Overweight is a condition characterised by excessive adiposity. Overweight is assessed by the body mass index (BMI), which is a surrogate marker of adiposity calculated as weight (kg)/height <sup>2</sup> (m <sup>2</sup> ). In infants, children and adolescents, BMI categories for defining overweight vary by age and gender based on WHO growth charts. Children 0 to 5 years are overweight if weight-for-length/height or BMI-for-age is above 2 and less than or equal to 3 standard deviations of the median of the WHO Child Growth Standards. Children 5 to 19 years are overweight if BMI-for-age is above 1 and less than or equal to 2 standard deviations of the median of WHO Growth Reference for School-aged Children and Adolescents.
<b>5B80.01</b>	Overweight in adults
<b>5B80.0Z</b>	Overweight, unspecified
<b>5B80.1</b>	<b>Localised adiposity</b> A condition characterised by accumulation of adipose tissue in specific regions of the body. <b>Coded Elsewhere:</b> Benign symmetrical lipomatosis (EF02.1)
<b>5B81</b>	<b>Obesity</b> Obesity is a chronic complex disease defined by excessive adiposity that can impair health. It is in most cases a multifactorial disease due to obesogenic environments, psycho-social factors and genetic variants. In a subgroup of patients, single major etiological factors can be identified (medications, diseases, immobilization, iatrogenic procedures, monogenic disease/genetic syndrome). Body mass index (BMI) is a surrogate marker of adiposity calculated as weight (kg)/height <sup>2</sup> (m <sup>2</sup> ). The BMI categories for defining obesity vary by age and gender in infants, children and adolescents. For adults, obesity is defined by a BMI greater than or equal to 30.00 kg/m <sup>2</sup> and there are three levels of severity in recognition of different management options. <b>Coded Elsewhere:</b> Obesity hypoventilation syndrome (7A42.0) Syndromes with obesity as a major feature (LD29)
<b>5B81.0</b>	<b>Obesity due to energy imbalance</b> Obesity is a chronic complex disease defined by excessive adiposity that can impair health. It is in most cases a multifactorial disease due to obesogenic environments, psycho-social factors and genetic variants. In a subgroup of patients, single major etiological factors can be identified (diseases, immobilization, iatrogenic procedures, monogenic disease/genetic syndrome).

<b>5B81.00</b>	Obesity in children or adolescents  In infants, children and adolescents, BMI categories for defining obesity vary by age and gender based on WHO growth charts. Children 0 to 5 years have obesity if weight-for-length/height or BMI-for-age is above 3 standard deviations of the median of the WHO Child Growth Standards.  Children aged 5 to 19 years have obesity if BMI-for-age is above 2 standard deviations of the median of WHO Growth Reference for School-aged Children and Adolescents.
<b>5B81.01</b>	Obesity in adults  Obesity is defined as a body mass index (BMI) greater than or equal to 30.00 kg/m <sup>2</sup> . There are three levels of severity in recognition of different management options.
<b>5B81.1</b>	<b>Drug-induced obesity</b>
<b>5B81.Y</b>	<b>Other specified obesity</b>
<b>5B81.Z</b>	<b>Obesity, unspecified</b>

### Certain specified nutrient excesses (5B90-5B9Z)

Any disease caused by an excess of specific nutrients. Confirmation is by blood test.

<b>5B90</b>	<b>Vitamin excesses</b>
<b>5B90.0</b>	<b>Hypervitaminosis A</b>  Because vitamin A is fat soluble and can be stored, primarily in the liver, routine consumption of large amounts of vitamin A over a period of time can result in toxic symptoms, including liver damage, bone abnormalities and joint pain, alopecia, headaches, vomiting, and skin desquamation. Hypervitaminosis A appears to be due to abnormal transport and distribution of vitamin A and retinoids caused by overloading of the plasma transport mechanisms. Very high single doses can cause transient acute toxic symptoms that may include bulging fontanelles in infants; headaches in older children and adults; and vomiting, diarrhoea, loss of appetite, and irritability in all age groups. Rarely does toxicity occur from ingestion of food sources of preformed vitamin A. When this occurs, it usually results from very frequent consumption of liver products.
	<b>Coded Elsewhere:</b> Pseudotumour Cerebri related to Hypervitaminosis A (8D41.2)
<b>5B90.1</b>	<b>Hypercarotenaemia</b>  Excessive intake of carotenoids is not associated with toxicity but can cause yellow coloration of the skin that disappears when intake is reduced. This disorder is especially likely to occur in children with liver disease, diabetes mellitus or hypothyroidism, and in those who do not have enzymes that metabolize carotenoids.

5B90.2	<b>Hypervitaminosis D</b> Hypervitaminosis D is secondary to excessive intake of vitamin D. It can occur with long-term high intake or with a substantial, acute ingestion. Excess amounts result in abnormally high concentrations of calcium and phosphate in the serum. The signs and symptoms of vitamin D intoxication are secondary to hypercalcaemia. Gastrointestinal manifestations include nausea, vomiting, constipation, abdominal pain and pancreatitis. Possible cardiac findings are hypertension, decreased Q-T interval and arrhythmias. The central nervous system effects of hypercalcaemia include lethargy, hypotonia, confusion, disorientation, depression, psychosis, hallucinations and coma. Hypercalcaemia impairs renal concentrating mechanisms, which can lead to polyuria, dehydration and hypernatremia. Hypercalcaemia can also lead to acute renal failure, nephrolithiasis and nephrocalcinosis, which can result in chronic renal insufficiency. Deaths are usually associated with arrhythmias or dehydration.
5B90.3	<b>Megavitamin-B6 syndrome</b> A disease caused by an excess of vitamin B6. This disease is characterised by progressive sensory ataxia, diminished or absent tendon reflexes, and impaired sense of touch, temperature and pain. Confirmation is by blood test.
5B90.Y	<b>Other specified vitamin excess</b>
5B90.Z	<b>Unspecified vitamin excesses</b>
<b>5B91</b>	<b>Mineral excesses</b> <i>Coded Elsewhere:</i> Hyperkalaemia (5C76) Iron overload diseases (5C64.10)
5B91.0	<b>Hypercalcaemia</b> Hypercalcaemia is a condition caused by increased calcium levels. The higher the calcium levels and the faster its level rises, the more severe will be the symptoms. When present, symptoms are caused by dehydration secondary to urinary losses of calcium, water and other electrolytes, and to an increase in membrane potential caused by the elevation in extracellular fluid ionized calcium concentration. Patients with moderate to severe hypercalcaemia often complain of nausea and vomiting, symptoms likely related to dehydration as well as to the effects of the hypercalcaemia on central nervous system function. Because hypercalcaemia tends to hyperpolarize membranes, a range of neurologic and neuromuscular signs and symptoms can occur. Patients with mild hypercalcaemia often complain of fatigue, depressed mood and asthenia. Gastrointestinal motility is impaired; this commonly results in constipation. <i>Coded Elsewhere:</i> Myopathy due to hypercalcaemia (8D41.1)

- 5B91.1 Zinc excess**  
Adverse effects associated with chronic intake of supplemental zinc include suppression of immune response, decrease in high-density lipoprotein (HDL) cholesterol and reduced copper status. Acute adverse effects of excess zinc include epigastric pain, nausea, vomiting, loss of appetite, abdominal cramps, diarrhoea, headaches and gastrointestinal distress.
- Coded Elsewhere:** Myelopathy due to excess of zinc (8D41.Y)
- 5B91.2 Sodium chloride excess**  
The main adverse effect of increased sodium chloride in the diet is increased blood pressure, which is a major risk factor for cardiovascular-renal diseases. However, evidence from a variety of studies, including observational studies and clinical trials, has demonstrated heterogeneity in the blood pressure responses to sodium intake. Those individuals with the greatest reductions in blood pressure in response to decreased sodium intake are termed “salt sensitive”.
- 5B91.3 Fluorine excess**  
The primary adverse effects associated with chronic, excess fluoride intake are enamel and skeletal fluorosis. Enamel fluorosis is a dose-response effect caused by fluoride intake during the pre-eruptive development of teeth. The development of skeletal fluorosis and its severity is directly related to the level and duration of exposure. The clinical signs in advanced stages may include dose-related calcification of ligaments, osteosclerosis, exostoses, possibly osteoporosis of long bones, muscle wasting and neurological defects due to hypercalcification of vertebrae.
- Coded Elsewhere:** Dental enamel fluorosis (DA07.0)
- 5B91.4 Aluminium excess**  
Patients receiving long-term parenteral nutrition are at increased risk of aluminium toxicity because of bypass of the gastrointestinal tract during parenteral nutrition infusion. Complications of aluminium toxicity include metabolic bone disease, aluminium-associated encephalopathy in adults and impaired neurological development in preterm infants.
- 5B91.5 Manganese excess**  
Manganese toxicity in humans is a well-recognised occupational hazard for people who inhale manganese dust. High concentrations of circulating manganese as a result of total parenteral nutrition have also been associated with manganese toxicity. People with chronic liver disease have neurological pathology and behavioural signs of manganese neurotoxicity, probably because elimination of manganese in bile is impaired. The most prominent effect is central nervous system pathology, especially in the extra-pyramidal motor system. The lesions and symptoms are similar to those of Parkinson's disease.
- Coded Elsewhere:** Dementia or parkinsonism due to manganese toxicity (6D84.Y)
- 5B91.Y Other specified mineral excess**
- 5B91.Z Unspecified mineral excess**
- 5B9Y Other specified nutrient excesses**

<b>5B9Z</b>	<b>Certain specified nutrient excesses, unspecified</b>
<b>5C1Y</b>	<b>Other specified overweight, obesity or specific nutrient excesses</b>
<b>5C1Z</b>	<b>Overweight, obesity or specific nutrient excesses, unspecified</b>
<b>5C3Y</b>	<b>Other specified nutritional disorders</b>
<b>5C3Z</b>	<b>Nutritional disorders, unspecified</b>

### Metabolic disorders (5C50-5D2Z)

**Exclusions:** androgen resistance syndrome (LD2A.4)  
Congenital adrenal hyperplasia (5A71.01)  
Ehlers-Danlos syndrome (LD28.1)  
Hereditary haemolytic anaemia due to enzyme deficiency (3A10)  
Marfan syndrome (LD28.01)  
5-alpha-reductase deficiency (5A81.1)

**Coded Elsewhere:** Cystic fibrosis (CA25)  
Metabolic disorders following abortion, ectopic or molar pregnancy (JA05.5)

### Inborn errors of metabolism (5C50-5C5Z)

Inborn errors of metabolism comprise a large class of genetic diseases involving disorders of metabolism. The majority are due to defects of single genes that code for enzymes that facilitate conversion of various substances (substrates) into others (products).

**Exclusions:** Disorders of lipoprotein metabolism or certain specified lipidaemias  
(5C80-5C8Z)

#### **5C50 Inborn errors of amino acid or other organic acid metabolism**

##### **5C50.0 Phenylketonuria**

Phenylketonuria is a hereditary metabolic disease, characterised by deficiency of phenylalanine hydroxylase, an enzyme necessary for the transformation of phenylalanine into tyrosine. Untreated, phenylketonuria leads to mental retardation, sometimes profound, as well as hypopigmentation. Dietary phenylalanine restriction allows patients to lead almost normal lives.

##### **5C50.00 Classical phenylketonuria**

Classical phenylketonuria is a severe form of phenylketonuria (PKU) an inborn error of amino acid metabolism characterised in untreated patients by severe intellectual deficit and neuropsychiatric complications.

- 5C50.01** Nonclassical phenylketonuria  
Mild phenylketonuria is a rare form of phenylketonuria (PKU), an inborn error of amino acid metabolism, characterised by symptoms of PKU of mild to moderate severity.
- 5C50.02** Embryofetopathy due to maternal phenylketonuria  
Maternal phenylalaninaemia refers to developmental anomalies that may occur in offspring of women affected by phenylketonuria (PKU), and include fetal development disorders, including microcephaly, intrauterine growth retardation, and subsequent intellectual deficit, and embryo development disorders such as heart defects (usually conotruncal), corpus callosum agenesis, neuronal migration disorders, facial dysmorphism and more rarely cleft palate, tracheo-oesophageal abnormalities.
- 5C50.0Y** Other specified phenylketonuria
- 5C50.0Z** Phenylketonuria, unspecified
- 5C50.1** Disorders of tyrosine metabolism  
**Coded Elsewhere:** Transitory tyrosinaemia of newborn (KB63.4)  
Autosomal recessive dopa-responsive dystonia (8A02.11)  
Oculocutaneous albinism type 1A (EC23.20)  
Oculocutaneous albinism type 1B (EC23.20)
- 5C50.10** Alkaptonuria  
Alkaptonuria is characterised by the accumulation of homogentisic acid (HGA) and its oxidised product benzoquinone acetic acid (BQA), leading to a darkening of the urine when it is left exposed to air, grey-blue colouration of the eye sclerae and the ear helix (ochronosis), and a disabling joint disease involving both the axial and peripheral joints (ochronotic arthropathy).
- 5C50.11** Tyrosinaemia type 1  
Tyrosinemia type 1 is an inborn error of amino acid metabolism characterised by hepatorenal manifestations. The early-onset acute form of the disorder manifests between 15 days and 3 months after birth with hepatocellular necrosis. Septicaemia is a frequent complication. Renal tubular dysfunction occurs and is associated with phosphate loss and hypophosphatemic rickets. A later onset form has also been described and manifests with vitamin-resistant rickets caused by renal tubular dysfunction.
- 5C50.12** Tyrosinaemia type 2  
Tyrosinemia type 2 is an inborn error of tyrosine metabolism characterised by hypertyrosinemia with oculocutaneous manifestations (eye redness, photophobia, excessive tearing and pain, palmoplantar hyperkeratosis) and, in some cases, intellectual deficit.
- 5C50.1Y** Other specified disorders of tyrosine metabolism
- 5C50.1Z** Disorders of tyrosine metabolism, unspecified

- 5C50.2** **Disorders of histidine metabolism**  
**Coded Elsewhere:** Formiminoglutamic aciduria (3A02.Y)
- 5C50.20** Histidinaemia  
Histidinemia is a disorder of histidine metabolism caused by a defect in histidase, and seems to be benign in most affected individuals.
- 5C50.21** Urocanic aciduria  
This is an autosomal recessive metabolic disorder caused by a deficiency of the enzyme urocanase. It is a secondary disorder of histidine metabolism.
- 5C50.2Y** Other specified disorders of histidine metabolism
- 5C50.2Z** Disorders of histidine metabolism, unspecified
- 5C50.3** **Disorders of tryptophan metabolism**  
**Exclusions:** Hartnup disease (5C60)
- 5C50.4** **Disorders of lysine or hydroxylysine metabolism**  
**Exclusions:** Refsum disease (5C57.1)  
Zellweger syndrome (5C57.0)  
Glutaryl-CoA dehydrogenase deficiency (5C50.E1)
- 5C50.5** **Disorders of the gamma-glutamyl cycle**  
**Coded Elsewhere:** Haemolytic anaemia due to glutathione synthetase deficiency (3A10.0Y)  
Haemolytic anaemia due to gamma-glutamylcysteine synthetase deficiency (3A10.0Y)
- 5C50.6** **Disorders of serine metabolism**
- 5C50.7** **Disorders of glycine metabolism**
- 5C50.70** Glycine encephalopathy  
Isolated nonketotic hyperglycinemia is an inborn disorder of glycine metabolism whose onset is generally neonatal with coma, severe hypotonia, myoclonic seizures, and microcephaly, usually progressing to severe intellectual deficit and tetrapyrimal syndrome.
- 5C50.71** Sarcosinaemia  
Sarcosinaemia is a metabolic disorder characterised by an increased concentration of sarcosine in plasma and urine due to sarcosine dehydrogenase deficiency. Prevalence has been estimated at 1:28,000 to 1:350,000 in newborn screening programs. Sarcosinaemia is most probably a benign condition without significant clinical problems. It is transmitted in an autosomal recessive manner. Mutations in the gene for sarcosine dehydrogenase, located on chromosome 9q34, have been associated with this deficiency.
- 5C50.7Y** Other specified disorders of glycine metabolism
- 5C50.7Z** Disorders of glycine metabolism, unspecified

- 5C50.8**           **Disorders of proline or hydroxyproline metabolism**
- 5C50.9**           **Disorders of ornithine metabolism**
- Coded Elsewhere:** Hyperornithinaemia-hyperammonaemia-homocitrullinuria (5C50.AY)
- Ornithine carbamoyltransferase deficiency (5C50.AY)
- 5C50.A**           **Disorders of urea cycle metabolism**
- Exclusions:** Disorders of ornithine metabolism (5C50.9)  
Lysinuric protein intolerance (5C60)
- 5C50.A0**          Argininosuccinic aciduria  
 Argininosuccinic aciduria is an autosomal recessive inherited deficiency of argininosuccinate lyase, an enzyme involved in the urea cycle that leads to severe hyperammonemic coma in neonates or, in childhood, to hypotonia, growth failure, anorexia and chronic vomiting or behavioural disorders. Onset can also occur later with hyperammonemic coma or behavioural disorders that simulate psychiatric disorders.
- 5C50.A1**          Carbamoylphosphate synthetase deficiency  
 Carbamyl phosphate synthetase deficiency is an urea cycle disorder strictly limited to the liver and intestine that results in congenital hyperammonemia and defective citrulline synthesis.
- 5C50.A2**          Argininaemia  
 Arginase deficiency is a rare autosomal recessive amino acid metabolism disorder characterised clinically by variable degrees of hyperammonemia, developing from about 3 years of age, and leading to progressive loss of developmental milestones and spasticity in the absence of treatment.
- 5C50.A3**          Citrullinaemia
- 5C50.AY**          Other specified disorders of urea cycle metabolism
- 5C50.AZ**          Disorders of urea cycle metabolism, unspecified
- 5C50.B**           **Disorders of methionine cycle or sulphur amino acid metabolism**
- Coded Elsewhere:** Hereditary megaloblastic anaemia due to transcobalamin deficiency (3A01.0)
- 5C50.C**           **Disorders of beta or omega amino acid metabolism**
- Exclusions:** 4-hydroxybutyric aciduria (5C50.E1)
- Coded Elsewhere:** Gamma aminobutyric acid transaminase deficiency (5C59.1)

<b>5C50.D</b>	<b>Disorders of branched-chain amino acid metabolism</b>
	<p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Methylmalonic acidaemia (5C50.E0)</li> <li>Propionic acidaemia (5C50.E0)</li> <li>Isovaleric acidaemia (5C50.E0)</li> <li>3-methylglutaconic aciduria (5C50.E0)</li> <li>Developmental delay due to 2-methylbutyryl-CoA dehydrogenase deficiency (5C50.E0)</li> <li>3-hydroxyisobutyric aciduria (5C50.E0)</li> </ul>
<b>5C50.D0</b>	Maple-syrup-urine disease  Maple syrup urine disease (MSUD) is a disorder of branched-chain amino acids metabolism. Four forms are described. The early onset classic form manifests after birth by lethargy, poor feeding and neurological signs of intoxication. Clinical course without treatment is characterised by deepening coma with maple syrup odour of urine. Subacute MSUD manifests later with encephalopathy, mental disability, major hypotonia, opisthotonus and cerebral atrophy with severe outcome. The intermittent form of MSUD may manifest at any age and presents with repeated ketoacidotic coma. Thiamine-responsive MSUD is a very rare form characterised by improvement of the biochemical profile with thiamine therapy.
<b>5C50.DY</b>	Other specified disorders of branched-chain amino acid metabolism
<b>5C50.DZ</b>	Disorders of branched-chain amino acid metabolism, unspecified
<b>5C50.E</b>	<b>Organic aciduria</b>  An inborn error of metabolism disrupting normal amino acid metabolism, particularly branched-chain amino acids, causing a buildup of acids, which are usually not present
<b>5C50.E0</b>	Classical organic aciduria  This a term used to classify a group of metabolic disorders which disrupt normal amino acid metabolism, particularly branched-chain amino acids, causing a buildup of acids which are usually not present.  <b>Coded Elsewhere:</b> Ketoacidosis due to beta-ketothiolase deficiency (5C50.DY)
<b>5C50.E1</b>	Cerebral organic aciduria  This is a term used to classify a group of metabolic disorders which disrupt normal amino acid metabolism, particularly branched-chain amino acids, causing a buildup of acids which are usually not present.
<b>5C50.EY</b>	Other specified organic aciduria
<b>5C50.EZ</b>	Organic aciduria, unspecified
<b>5C50.F</b>	<b>Disorders of peptide metabolism</b>  A condition which refers to inborn errors in peptide metabolism.
	<p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Disorders of gamma aminobutyric acid metabolism (5C59.1)</li> </ul>

<b>5C50.F0</b>	Polidase deficiency Polidase deficiency is a very rare inborn error of metabolism characterised by mild to severe skin lesions particularly on the face, palms, lower legs and soles, together with other variable features.
<b>5C50.F1</b>	Carnosinaemia Carnosinaemia is a very rare inherited disorder of the metabolism of peptides that presents with serum carnosinase deficiency, variable degrees of intellectual deficit, sometimes with seizures, while a few patients are asymptomatic.
<b>5C50.F2</b>	Homocarnosinosis Homocarnosinosis is a metabolic defect characterised by progressive spastic diplegia, intellectual deficit and retinitis pigmentosa. This extremely rare disorder has been reported in only one family, namely a woman and three of her children. The latter showed but their mother was symptom free. It is therefore uncertain whether there is a relationship between the biochemical defect and the clinical symptoms. Inheritance in the reported family seems to be autosomal dominant.
<b>5C50.FY</b>	Other specified disorders of peptide metabolism
<b>5C50.FZ</b>	Disorders of peptide metabolism, unspecified
<b>5C50.G</b>	<b>Trimethylaminuria</b> Trimethylaminuria is a metabolic disorder characterised by a body malodour similar to that of decaying fish.  <i>Inclusions:</i> Fish odour syndrome
<b>5C50.Y</b>	<b>Other specified inborn errors of amino acid or other organic acid metabolism</b>
<b>5C50.Z</b>	<b>Inborn errors of amino acid or other organic acid metabolism, unspecified</b>
<b>5C51</b>	<b>Inborn errors of carbohydrate metabolism</b>  <i>Exclusions:</i> Increased secretion of glucagon (5A42) Diabetes mellitus (5A10-5A2Y) hypoglycaemia NOS (5A41) Mucopolysaccharidosis (5C56.3)  <i>Coded Elsewhere:</i> Transitory disorders of carbohydrate metabolism specific to fetus or newborn (KB60)
<b>5C51.0</b>	<b>Disorders of the pentose phosphate pathway</b>  <i>Coded Elsewhere:</i> Haemolytic anaemia due to glucose-6-phosphate dehydrogenase deficiency (3A10.00)
<b>5C51.1</b>	<b>Disorders of glycerol metabolism</b>

- 5C51.2** **Disorders of glyoxylate metabolism**  
Primary hyperoxaluria, or oxalosis, is a rare metabolic disorder transmitted as an autosomal recessive disease, including both type 1, the most frequent, and type 2, extremely rare. Hyperoxaluria type 1 is due to a defect of the peroxysomal hepatic enzyme L-alanine: glyoxylate aminotransferase (AGT). Hyperoxaluria type 2 is extremely rare and is due to glycerate dehydrogenase deficiency.
- 5C51.20** Primary hyperoxaluria type 1  
Primary hyperoxaluria type 1 is a rare metabolic disorder due to a defect of the peroxysomal hepatic enzyme L-alanine: glyoxylate aminotransferase (AGT). The infantile form is characterised by chronic renal failure due to massive oxalate deposition. In other patients, urolithiasis develops with infections, haematuria, renal colic or acute renal failure due to complete obstruction. End-stage renal failure occurs before 15 years of age in half the cases and the resulting increase of circulating oxalate leads to its deposition in tissues causing cardiac conduction defects, hypertension, distal gangrene, and reduced joint mobility and pain.
- 5C51.2Y** Other specified disorders of glyoxylate metabolism
- 5C51.2Z** Disorders of glyoxylate metabolism, unspecified
- 5C51.3** **Glycogen storage disease**  
The term Glycogen storage disease characterises a group of heterogeneous diseases resulting from defects in the process of glycogen synthesis or breakdown within muscles, liver, and other cell types.
- 5C51.4** **Disorders of galactose metabolism**
- 5C51.40** Galactose-1-phosphate uridylyltransferase deficiency  
Classic galactosemia is a life-threatening metabolic disease with onset in the neonatal period. Infants usually develop feeding difficulties, lethargy, and severe liver disease.
- 5C51.41** Galactokinase deficiency  
Galactokinase deficiency is a rare mild form of galactosemia characterised by early onset of cataract and an absence of the usual signs of classic galactosemia, i.e. feeding difficulties, poor weight gain and growth, lethargy, and jaundice.
- 5C51.42** Glucose or galactose intolerance of newborn
- 5C51.4Y** Other specified disorders of galactose metabolism
- 5C51.4Z** Disorders of galactose metabolism, unspecified
- 5C51.5** **Disorders of fructose metabolism**  
This refers to disorders of the metabolism of fructose in the phosphorylation of fructose to fructose 1-phosphate by fructokinase, thus trapping fructose for metabolism in the liver.
- Coded Elsewhere:** Fructose malabsorption (5C61.40)

<b>5C51.50</b>	Hereditary fructose intolerance Hereditary fructose intolerance is an autosomal recessive disorder due to a deficiency of fructose-1-phosphate aldolase activity, which results in an accumulation of fructose-1-phosphate in the liver, kidney, and small intestine, and is characterised by severe abdominal pain, vomiting, and hypoglycaemia following ingestion of fructose or other sugars metabolised through fructose-1-phosphate.
	<b><i>Exclusions:</i></b> Fructose malabsorption (5C61.40)
<b>5C51.5Y</b>	Other specified disorders of fructose metabolism
<b>5C51.5Z</b>	Disorders of fructose metabolism, unspecified
<b>5C51.Y</b>	<b>Other specified inborn errors of carbohydrate metabolism</b>
<b>5C51.Z</b>	<b>Inborn errors of carbohydrate metabolism, unspecified</b>
<b>5C52</b>	<b>Inborn errors of lipid metabolism</b>
	<b><i>Coded Elsewhere:</i></b> Retinal dystrophy in lipid storage disorders (9B71.Y)
<b>5C52.0</b>	<b>Inborn errors of fatty acid oxidation or ketone body metabolism</b>
	<b><i>Coded Elsewhere:</i></b> Adrenoleukodystrophy (8A44.1)
<b>5C52.00</b>	Disorders of carnitine transport or the carnitine cycle
<b>5C52.01</b>	Disorders of mitochondrial fatty acid oxidation
<b>5C52.02</b>	Disorders of ketone body metabolism <b><i>Coded Elsewhere:</i></b> Cytosolic acetoacetyl-CoA thiolase deficiency (5C50.DY)
<b>5C52.03</b>	Sjögren-Larsson syndrome Sjögren-Larsson syndrome is a neurocutaneous disorder caused by an inborn error of lipid metabolism and characterised by congenital ichthyosis, intellectual deficit, and spasticity.
<b>5C52.0Y</b>	Other specified inborn errors of fatty acid oxidation or ketone body metabolism
<b>5C52.0Z</b>	Inborn errors of fatty acid oxidation or ketone body metabolism, unspecified
<b>5C52.1</b>	<b>Inborn errors of sterol metabolism</b>
	<b><i>Coded Elsewhere:</i></b> X-linked ichthyosis (EC20.01)
<b>5C52.10</b>	Disorders of cholesterol synthesis <b><i>Coded Elsewhere:</i></b> Chondrodysplasia punctata, X-linked dominant (LD24.04) Greenberg dysplasia (LD24.04) Congenital hemidysplasia with ichthyosiform erythroderma and limbs defects (LD24.04) Hyperalphalipoproteinæmia due to cholesteryl ester transfer protein deficiency (5C80.3)

<b>5C52.11</b>	Bile acid synthesis defect with cholestasis Anomalies of bile acid synthesis are a group of sterol metabolism disorders due to enzyme deficiencies of bile acid synthesis in infants, children and adults, with variable manifestations that include cholestasis, neurological disease, and fat malabsorption. Eight inborn errors have been clearly identified, 7 of which lead to liver cholestasis and include: 3 $\beta$ -hydroxy-C27-steroid oxidoreductase deficiency (type 1), $\Delta$ 4-3-oxosteroid 5 $\beta$ -reductase deficiency (type 2), oxysterol 7 $\alpha$ -hydroxylase deficiency (type 3), 2-methylacyl-CoA racemase deficiency (type 4), bile acid CoA ligase deficiency, and cerebrotendinous xanthomatosis. Cholesterol 7 $\alpha$ -hydroxylase deficiency leads to hypercholesterolaemia without liver cholestasis.
<b>5C52.1Y</b>	Other specified inborn errors of sterol metabolism
<b>5C52.1Z</b>	Inborn errors of sterol metabolism, unspecified
<b>5C52.2</b>	<b>Neutral lipid storage disease</b> Neutral lipid storage disease (NLSD) refers to a group of diseases characterised by a deficit in the degradation of cytoplasmic triglycerides and their accumulation in cytoplasmic lipid vacuoles in most tissues of the body. The group is heterogeneous: NLSD with ichthyosis (NLSDI/Dorfman-Chanarin disease) and NLSD with myopathy (NLSDM/neutral lipid storage myopathy) can be distinguished.
<b>5C52.Y</b>	<b>Other specified inborn errors of lipid metabolism</b>
<b>5C52.Z</b>	<b>Inborn errors of lipid metabolism, unspecified</b>
<b>5C53</b>	<b>Inborn errors of energy metabolism</b>
<b>5C53.0</b>	<b>Disorders of pyruvate metabolism</b>
<b>5C53.00</b>	Pyruvate kinase deficiency This refers to an enzyme involved in glycolysis. It catalyzes the transfer of a phosphate group from phosphoenolpyruvate (PEP) to ADP, yielding one molecule of pyruvate and one molecule of ATP. <b>Coded Elsewhere:</b> Glycogen storage disease due to muscle pyruvate kinase deficiency (5C51.3) Haemolytic anaemia due to red cell pyruvate kinase deficiency (3A10.Y)
<b>5C53.01</b>	Lactate dehydrogenase deficiency This refers to a deficiency in the enzyme present in a wide variety of organisms, including plants and animals. This exists in four distinct enzyme classes. Two of them are cytochrome c-dependent enzymes, each acting on either D-lactate (EC 1.1.2.4) or L-lactate (EC 1.1.2.3). The other two are NAD(P)-dependent enzymes, each acting on either D-lactate (EC 1.1.1.28) or L-lactate (EC 1.1.1.27). This article is about the NAD(P)-dependent L-lactate dehydrogenase.
<b>5C53.02</b>	Pyruvate dehydrogenase complex deficiency Pyruvate dehydrogenase deficiency (PDHD) is a rare neurometabolic disorder characterised by a wide range of clinical signs with metabolic and neurological components of varying severity. Manifestations range from often fatal, severe, neonatal to later-onset neurological disorders.

- 5C53.03** Pyruvate carboxylase deficiency  
 This is a deficiency in the enzyme of the ligase class that catalyzes the (depending on the species) irreversible carboxylation of pyruvate to form oxaloacetate (OAA).
- 5C53.0Y** Other specified disorders of pyruvate metabolism
- 5C53.0Z** Disorders of pyruvate metabolism, unspecified
- 5C53.1** **Disorders of the citric acid cycle**
- 5C53.2** **Disorders of mitochondrial oxidative phosphorylation**  
 An inborn error of metabolism in cellular respiration (oxidative phosphorylation) in the mitochondria, where a series of enzymes catalyze the transfer of electrons to molecular oxygen and the generation of energy-storing ATP  
*Coded Elsewhere:* Neuropathy, ataxia, and retinitis pigmentosa (8C73.1)
- 5C53.20** Mitochondrial DNA depletion syndromes  
 The mitochondrial DNA (mtDNA) depletion syndrome (MDS) is a clinically heterogeneous group of mitochondrial disorders characterised by a reduction of the mtDNA copy number in affected tissues without mutations or rearrangements in the mtDNA. MDS is phenotypically heterogeneous, manifesting either as a hepatocerebral form, a myopathic form, a benign 'later-onset' myopathic form or a cardiomyopathic form.  
*Coded Elsewhere:* Childhood-onset autosomal dominant optic atrophy (9C40.8)
- 5C53.21** Multiple mitochondrial DNA deletion syndromes  
 This is the multiple DNA located in organelles called mitochondria, structures within eukaryotic cells that convert the chemical energy from food into a form that cells can use, adenosine triphosphate (ATP).  
*Coded Elsewhere:* Progressive external ophthalmoplegia, autosomal dominant (9C82.0)  
     Progressive external ophthalmoplegia, autosomal recessive (9C82.0)  
     Autosomal dominant optic atrophy plus syndrome (9C40.8)  
     Deafness - optic atrophy syndrome (LD2H.Y)  
     Autosomal dominant optic atrophy and cataract (9C40.8)
- 5C53.22** Coenzyme Q10 deficiency  
 This is a deficiency in a 1,4-benzoquinone, where Q refers to the quinone chemical group, and 10 refers to the number of isoprenyl chemical subunits in its tail. This oil-soluble, vitamin-like substance is present in most eukaryotic cells, primarily in the mitochondria. It is a component of the electron transport chain and participates in aerobic cellular respiration, generating energy in the form of ATP.  
*Coded Elsewhere:* Cerebellar atrophy - ataxia - seizures (LD90.Y)

<b>5C53.23</b>	Mitochondrial protein translation defects This refers to defects in the enzyme that belongs to the family of hydrolases, specifically those acting on acid anhydrides to catalyse transmembrane movement of substances.  <b>Coded Elsewhere:</b> Pontocerebellar hypoplasia type 6 (LD20.01) Mitochondrial myopathy with sideroblastic anaemia (3A72.0Y)
<b>5C53.24</b>	Leigh syndrome Leigh syndrome or subacute necrotizing encephalomyopathy is a progressive neurological disease defined by specific neuropathological features associating brainstem and basal ganglia lesions. Loss of motor milestones, hypotonia with poor head control, recurrent vomiting, and a movement disorder are common initial symptoms. Pyramidal and extrapyramidal signs, nystagmus, breathing disorders, ophthalmoplegia and peripheral neuropathy are often noted later. Epilepsy is relatively uncommon. Leigh syndrome has multiple causes, all of which imply a defect in aerobic energy production, ranging from the pyruvate dehydrogenase complex to the oxidative phosphorylation pathway.  <b>Coded Elsewhere:</b> Maternally inherited Leigh syndrome (8C73.Y)
<b>5C53.25</b>	Isolated ATP synthase deficiency
<b>5C53.2Y</b>	Other specified disorders of mitochondrial oxidative phosphorylation
<b>5C53.2Z</b>	Disorders of mitochondrial oxidative phosphorylation, unspecified
<b>5C53.3</b>	<b>Disorders of mitochondrial membrane transport</b> An inborn error of metabolism in proteins in the membranes of mitochondria, which serve to transport molecules and other factors such as ions into or out of the organelles
<b>5C53.30</b>	Mitochondrial substrate carrier disorders  <b>Coded Elsewhere:</b> Autosomal recessive sideroblastic anaemia, pyridoxine-refractory (3A72.00)
<b>5C53.31</b>	Mitochondrial protein import disorders This refers to disorders in the enzyme that belongs to the family of hydrolases, specifically those acting on acid anhydrides to catalyse transmembrane movement of substances.  <b>Coded Elsewhere:</b> Deafness-dystonia optic atrophy syndrome (8A02.12)
<b>5C53.3Y</b>	Other specified disorders of mitochondrial membrane transport
<b>5C53.3Z</b>	Disorders of mitochondrial membrane transport, unspecified
<b>5C53.4</b>	<b>Disorders of creatine metabolism</b> An inborn error of metabolism in creatine which serves as an energy shuttle between the mitochondrial sites of ATP production and the cytosol where ATP is utilized
<b>5C53.Y</b>	<b>Other specified inborn errors of energy metabolism</b>

- 5C53.Z**           **Inborn errors of energy metabolism, unspecified**
- 5C54**           **Inborn errors of glycosylation or other specified protein modification**  
Congenital Disorders of Glycosylation (CDG) syndromes are a group of glycoprotein synthesis disorders characterised by neurological manifestations that can be associated with multivisceral involvement. The CDG syndromes are associated with different enzymatic deficits.
- 5C54.0**           **Disorders of protein N-glycosylation**  
Congenital disorders involving defective N-glycosylation of proteins (the addition of glycans linked to the polypeptide chain by a beta-linkage between the anomeric carbon of N-acetylglucosamine and the amido group of L-asparagine).
- 5C54.1**           **Disorders of protein O-glycosylation**  
Congenital disorders involving defective O-linked glycosylation, which typically occurs via an alpha linkage of the glycan to the hydroxyl group of a serine or threonine residue on a protein  
*Coded Elsewhere:* Multiple osteochondromas (LD24.20)
- 5C54.2**           **Disorders of multiple glycosylation or other pathways**  
*Coded Elsewhere:* Hereditary inclusion body myositis (4A41.20)
- 5C54.Y**           **Other specified congenital disorders of glycosylation and protein modification**
- 5C54.Z**           **Congenital disorders of glycosylation and protein modification, unspecified**
- 5C55**           **Inborn errors of purine, pyrimidine or nucleotide metabolism**  
*Exclusions:*       Xeroderma pigmentosum (LD27.1)  
                        Calculus of kidney (GB70.0)
- 5C55.0**           **Disorders of purine metabolism**  
*Coded Elsewhere:* Primary gout (FA25.0)  
                        Haemolytic anaemia due to adenosine deaminase excess (3A10.1)  
                        Immunodeficiency due to purine nucleoside phosphorylase deficiency (4A01.1Y)  
                        Severe combined immunodeficiency T- B- due to adenosine deaminase deficiency (4A01.10)
- 5C55.00**           Xanthinuria

<b>5C55.01</b>	Lesch-Nyhan syndrome Lesch-Nyhan syndrome (LNS) is the most severe form of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency, a hereditary disorder of purine metabolism, and is associated with uric acid overproduction (UAO), neurological troubles, and behavioural problems. Patients are normal at birth. Psychomotor delay becomes evident within 3 to 6 months with a delay in head support and sitting, hypotonia and athetoid movements. Sandy urine in diapers or crystalluria with urinary tract obstruction are common forms of presentation. Patients usually show mild to moderate intellectual deficit. Diagnosis is suspected when psychomotor delay occurs in a patient with elevated UA in blood and urine. Undetectable HPRT enzyme activity in peripheral blood or in intact cells (erythrocyte, fibroblast) and molecular genetic testing confirm the diagnosis. Inheritance is X-linked recessive.
<b>5C55.0Y</b>	Other specified disorders of purine metabolism
<b>5C55.0Z</b>	Disorders of purine metabolism, unspecified
<b>5C55.1</b>	<b>Disorders of pyrimidine metabolism</b> <i>Coded Elsewhere:</i> Hereditary orotic aciduria (3A03.0) Haemolytic anaemia due to pyrimidine 5' nucleotidase deficiency (3A10.Y)
<b>5C55.2</b>	<b>Disorders of nucleotide metabolism</b> <i>Coded Elsewhere:</i> Haemolytic anaemia due to adenosine triphosphatase deficiency (3A10.Y)
<b>5C55.Y</b>	<b>Other specified inborn errors of purine, pyrimidine or nucleotide metabolism</b>
<b>5C55.Z</b>	<b>Inborn errors of purine, pyrimidine or nucleotide metabolism, unspecified</b>
<b>5C56</b>	<b>Lysosomal diseases</b> <i>Exclusions:</i> Glycogen storage disease due to LAMP-2 deficiency (5C51.3)
<b>5C56.0</b>	<b>Sphingolipidosis</b> <i>Coded Elsewhere:</i> Krabbe disease (8A44.4)
<b>5C56.00</b>	Gangliosidosis
<b>5C56.01</b>	Fabry disease Fabry disease (FD) is a progressive, inherited, multisystemic lysosomal storage disease characterised by specific neurological, cutaneous, renal, cardiovascular, cochleo-vestibular and cerebrovascular manifestations. <i>Coded Elsewhere:</i> Glomerular disease associated with Fabry disease (GB4Z)
<b>5C56.02</b>	Metachromatic leukodystrophy Metachromatic leukodystrophy is a neurodegenerative disease characterised by an accumulation of sulfatides (sulphated glycosphingolipids, especially sulfogalactosylceramides or sulfogalactocerebrosides) in the nervous system and kidneys. Three forms of the disease exist: late infantile, juvenile and adult.
<b>5C56.0Y</b>	Other specified sphingolipidosis

- 5C56.0Z** Sphingolipidosis, unspecified
- 5C56.1** **Neuronal ceroid lipofuscinosis**  
Neuronal ceroid lipofuscinoses (NCLs) are a group of inherited progressive degenerative brain diseases characterised clinically by a decline of mental and other capacities, epilepsy, and vision loss through retinal degeneration, and histopathologically by intracellular accumulation of an autofluorescent material, ceroid lipofuscin, in the neuronal cells in the brain and in the retina.
- 5C56.2** **Glycoproteinosis**  
These are lysosomal storage diseases affecting glycoproteins, resulting from defects in lysosomal function. The term is sometimes reserved for conditions involving degradation of glycoproteins.
- 5C56.20** Mucolipidosis  
**Exclusions:** Sialidosis (mucolipidosis type 1) (5C56.21)  
**Coded Elsewhere:** Mucolipidosis type 4 (5C56.0Y)  
Wolman disease (5C56.0Y)
- 5C56.21** Oligosaccharidosis
- 5C56.2Y** Other specified glycoproteinosis
- 5C56.2Z** Glycoproteinosis, unspecified
- 5C56.3** **Mucopolysaccharidosis**  
**Inclusions:** Disorders of glycosaminoglycan metabolism
- 5C56.30** Mucopolysaccharidosis type 1  
Mucopolysaccharidosis type 1 (MPS 1) is a rare lysosomal storage disease belonging to the group of mucopolysaccharidoses. There are three variants, differing widely in their severity, with Hurler syndrome (57% of cases) being the most severe, Scheie syndrome (20% of cases) the mildest and Hurler-Scheie syndrome (23% of cases) giving an intermediate phenotype.
- 5C56.31** Mucopolysaccharidosis type 2  
Mucopolysaccharidosis type 2 (MPS 2) is a lysosomal storage disease belonging to the group of mucopolysaccharidoses. The clinical picture ranges from severe (the most frequent form) with early psychomotor regression, facial dysmorphism (macroglossia, constantly opened mouth, coarse features), hepatosplenomegaly, limited joint motion, carpal tunnel syndrome, dysostosis multiplex, small size, behavioural disorders and psychomotor regression leading to intellectual deficit, deafness, cardiac and respiratory disorders, and cutaneous signs, to mild (normal intelligence, milder dysmorphism and dysostoses).  
**Inclusions:** Hunter syndrome

- 5C56.32** Mucopolysaccharidosis type 4  
Mucopolysaccharidosis type IV (MPS IV) is a lysosomal storage disease belonging to the group of mucopolysaccharidoses, and characterised by spondylo-epiphysometaphyseal dysplasia. It exists in two clinically indistinguishable forms, A and B. A deficiency in one of the two enzymes required for the degradation of keratan sulfate (KS) is responsible for the MPS IV subtypes: N-acetylgalactosamine-6-sulfate sulfatase in MPS IVA, and beta-D-galactosidase in MPS IVB.
- 5C56.33** Mucopolysaccharidosis type 6  
Mucopolysaccharidosis type 6 (MPS VI) is a lysosomal storage disease with progressive multisystem involvement, associated with a deficiency of arylsulfatase B (ASB) leading to the accumulation of dermatan sulfate. The disorder shows a wide spectrum of symptoms from slowly to rapidly progressing forms.
- 5C56.3Y** Other specified mucopolysaccharidosis
- 5C56.3Z** Mucopolysaccharidosis, unspecified
- 5C56.4** **Disorders of sialic acid metabolism**  
This refers to any disorders of the N- or O-substituted derivatives of neuraminic acid, a monosaccharide with a nine-carbon backbone.
- 5C56.Y** **Other specified lysosomal diseases**
- 5C56.Z** **Lysosomal diseases, unspecified**
- 5C57** **Peroxisomal diseases**  
Peroxisomal disorders represent a class of medical conditions caused by defects in peroxisome functions. This may be due to defects in single enzymes important for peroxisome function or in peroxins, proteins encoded by PEX genes that are critical for normal peroxisome assembly and biogenesis.
- Coded Elsewhere:** Primary hyperoxaluria type 1 (5C51.20)  
Adrenoleukodystrophy (8A44.1)  
Rhizomelic chondrodysplasia punctata (LD24.04)  
Glutaric aciduria type 3 (5C50.E0)
- 5C57.0** **Disorders of peroxisome biogenesis**  
Peroxisome biogenesis disorders (PBDs) include the Zellweger syndrome spectrum (PBD-ZSD) and rhizomelic chondrodysplasia punctata type 1 (RCDP1). PBD-ZSD represents a continuum of disorders including infantile Refsum disease, neonatal adrenoleukodystrophy, and Zellweger syndrome. Collectively, PBDs are autosomal recessive developmental brain disorders that also result in skeletal and craniofacial dysmorphism, liver dysfunction, progressive sensorineural hearing loss, and retinopathy.
- 5C57.1** **Disorders of peroxisomal alpha-, beta- or omega-oxidation**  
**Coded Elsewhere:** Congenital bile acid synthesis defect type 4 (5C52.11)
- 5C57.Y** **Other specified peroxisomal diseases**
- 5C57.Z** **Peroxisomal diseases, unspecified**

**5C58**

**Inborn errors of porphyrin or heme metabolism**

**Inclusions:** defects of catalase and peroxidase

**Coded Elsewhere:** X-linked sideroblastic anaemia, pyridoxine-responsive  
(3A72.00)

**5C58.0**

**Disorders of bilirubin metabolism or excretion**

**Coded Elsewhere:** Neonatal hyperbilirubinaemia (KA87)

**5C58.00**

**Crigler-Najjar syndrome**

Crigler-Najjar syndrome is an autosomal recessive disorder of bilirubin metabolism characterised by unconjugated hyperbilirubinemia due to a hepatic deficit of bilirubin glucuronosyltransferase activity. Two types have been described, CNS types 1 and 2, depending on whether the enzymatic deficit is complete or partial: clinical manifestations vary accordingly. Patients present with isolated jaundice that appears early in life. Biological analyses detect severe unconjugated hyperbilirubinemia with normal liver function tests. Abdominal imaging studies (plain X-rays, CT scans or ultrasonograms) and liver histology findings are normal. Diagnosis is generally confirmed by genomic DNA analysis.

**5C58.01**

**Gilbert syndrome**

Gilbert's syndrome is an inherited liver disorder characterised by jaundice due to unconjugated hyperbilirubinemia, resulting from a partial deficiency in hepatic bilirubin glucuronosyltransferase activity.

**5C58.02**

**Dubin-Johnson syndrome**

Dubin-Johnson syndrome (DJS) is a benign, inherited liver disorder characterised clinically by chronic, predominantly conjugated, hyperbilirubinemia and histopathologically by black-brown pigment deposition in parenchymal liver cells.

**5C58.03**

**Progressive familial intrahepatic cholestasis**

Progressive familial intrahepatic cholestasis (PFIC) refers to a heterogeneous group of autosomal recessive disorders of childhood that disrupt bile formation and present with cholestasis of hepatocellular origin. Three types of PFIC have been identified and are related to mutations in hepatocellular transport system genes involved in bile formation. PFIC1 and PFIC2 usually appear in the first months of life, whereas onset of PFIC3 may also occur later in infancy, in childhood or even during young adulthood.

**5C58.04**

**Benign recurrent intrahepatic cholestasis**

**5C58.0Y**

**Other specified disorders of bilirubin metabolism or excretion**

**5C58.0Z**

**Disorders of bilirubin metabolism or excretion, unspecified**

<b>5C58.1</b>	<b>Porphyrias</b> Porphyrias constitute a group of diseases characterised by intermittent neurovisceral manifestations, cutaneous lesions or by the combination of both. All porphyrias are caused by a deficiency in one of the enzymes of the heme biosynthesis pathway resulting in an accumulation of porphyrins and/or their precursors in the liver or bone marrow. Clinical signs of the disease usually appear in adulthood, but some porphyrias affect children. Porphyrias can be classified according to the main location of the metabolic anomaly. Direct or indirect neurotoxicity may cause neurological manifestations. Transmission of hereditary porphyrias is autosomal and either dominant with weak penetrance or recessive with complete penetrance. Diagnosis is mainly based on the measurement of porphyrins and their precursors in biological samples.
	<b>Coded Elsewhere:</b> Liver diseases due to porphyria (5C90.1)
<b>5C58.10</b>	Porphyria cutanea tarda Porphyria cutanea tarda (PCT) is due to an accumulation of uroporphyrins in plasma from blockage of the normal haem synthetic pathway in the liver at the level of uroporphyrinogen decarboxylase (URO-D). The majority of cases are sporadic and frequently associated with iron overload. PCT manifests as skin fragility and blistering in light-exposed skin, particularly on the dorsa of the hands, together with hypertrichosis.
<b>5C58.12</b>	Erythropoietic porphyrias Erythropoietic porphyrias are associated clinically with photosensitivity and biochemically with abnormal accumulation of porphyrins in erythrocytes. They include erythropoietic protoporphyrina and the very rare congenital erythropoietic porphyria.
<b>5C58.13</b>	Variegate porphyria Variegate porphyria is a form of acute hepatic porphyria characterised by the occurrence of neuro-visceral attacks with or without the presence of cutaneous lesions (bullous photodermatitis).
<b>5C58.1Y</b>	Other specified porphyrias
<b>5C58.1Z</b>	Porphyrias, unspecified
<b>5C58.Y</b>	<b>Other specified inborn errors of porphyrin or heme metabolism</b>
<b>5C58.Z</b>	<b>Inborn errors of porphyrin or heme metabolism, unspecified</b>
<b>5C59</b>	<b>Inborn errors of neurotransmitter metabolism</b>
<b>5C59.0</b>	<b>Disorders of biogenic amine metabolism</b>
<b>5C59.00</b>	Disorders of catecholamine synthesis Any condition caused by failure to correctly synthesize catecholamines. Confirmation is by blood test.
<b>5C59.01</b>	Disorders of pterin metabolism Any condition caused by failure to correctly metabolize pterin.
	<b>Coded Elsewhere:</b> Dopa-responsive dystonia (8A02.11)

- 5C59.0Y** Other specified disorders of biogenic amine metabolism
- 5C59.0Z** Disorders of biogenic amine metabolism, unspecified
- 5C59.1** **Disorders of gamma aminobutyric acid metabolism**  
**Coded Elsewhere:** 4-hydroxybutyric aciduria (5C50.E1)
- 5C59.2** **Disorders of pyridoxine metabolism**  
**Coded Elsewhere:** Pyridoxal dependent epilepsy (8A61.00)  
Pyridoxine dependent epilepsy with antiquitin mutations  
(8A61.0Y)
- 5C59.Y** **Other specified inborn errors of neurotransmitter metabolism**
- 5C59.Z** **Inborn errors of neurotransmitter metabolism, unspecified**
- 5C5A** **Alpha-1-antitrypsin deficiency**  
Alpha-1-antitrypsin deficiency (AATD) is a genetic disorder that manifests as pulmonary emphysema, liver cirrhosis and, rarely, as the skin disease panniculitis, and is characterised by low serum levels of AAT, the main protease inhibitor (PI) in human serum.
- 5C5Y** **Other specified inborn errors of metabolism**
- 5C5Z** **Inborn errors of metabolism, unspecified**
- Disorders of metabolite absorption or transport (5C60-5C6Z)
- 5C60** **Disorders of amino acid absorption or transport**  
Any condition caused by deficiencies in amino acid absorption and transport.  
**Exclusions:** Disorders of tryptophan metabolism (5C50.3)  
**Coded Elsewhere:** Fanconi syndrome (GB90.42)
- 5C60.0** **Oculocerebrorenal syndrome**  
Oculocerebrorenal syndrome of Lowe (OCRL) is a multisystem disorder characterised by congenital cataracts, glaucoma, intellectual disabilities, postnatal growth retardation and renal tubular dysfunction with chronic renal failure.
- 5C60.1** **Cystinosis**  
Cystinosis is a metabolic disease characterised by an accumulation of cystine inside the lysosomes of different tissues due to a defect in cystine transport out of lysosomes. There are three clinical forms : infantile, juvenile and ocular. The infantile form is severe, multisystem disease, with impaired proximal tubular reabsorptive capacity, with severe fluid-electrolyte balance alterations, cystine deposits in various organs and progression towards renal failure after 6 years of age. Juvenile cystinosis appear around 8 years of age and has an intermediate clinical picture with end-stage renal disease occurring after the age of 15. The ocular, adult form presents with photophobia.

<b>5C60.2</b>	<b>Cystinuria</b> Cystinuria is a renal tubular aminoacid transport disorder characterised by recurrent formation of kidneys cystine stones.
<b>5C60.Y</b>	<b>Other specified disorders of amino acid absorption or transport</b>
<b>5C60.Z</b>	<b>Disorders of amino acid absorption or transport, unspecified</b>
<b>5C61</b>	<b>Disorders of carbohydrate absorption or transport</b>
<b>5C61.0</b>	<b>Glucose-galactose malabsorption</b> Glucose-galactose malabsorption is characterised by diarrhoea and severe neonatal dehydration. Around 300 cases have been described to date. Moderate glucosuria has also been reported, but fructose absorption is normal. Glucose-galactose malabsorption is caused by a mutation in the SLC5A1 gene, encoding the glucose-sodium cotransporter, SGTL1. The mode of transmission is autosomal recessive. The fatal consequences of this syndrome can be avoided by following a glucose and galactose restricted diet.  <i><b>Exclusions:</b></i> Glucose or galactose intolerance of newborn (5C51.42)
<b>5C61.1</b>	<b>Maltase-glucoamylase deficiency</b> Chronic diarrhea due to glucoamylase deficiency is characterised by chronic diarrhoea in infancy or childhood in association with intestinal glucoamylase deficiency.
<b>5C61.2</b>	<b>Congenital sucrase-isomaltase deficiency</b> Congenital sucrase-isomaltase deficiency (CSID) is a carbohydrate intolerance disorder characterised by malabsorption of oligosaccharides and disaccharides. CSID is transmitted as an autosomal recessive trait and is caused by mutations in the brush-border membrane complex sucrase-isomaltase (SI), which is required for the breakdown of sucrose and starch into monosaccharides. The SI deficiency results in an accumulation of disaccharides in the lumen, causing osmotic diarrhoea. The prognosis for patients is good as the starch intolerance usually resolves during the first few years of life and sucrose intolerance usually improves with age.
<b>5C61.3</b>	<b>Alpha, alpha trehalase deficiency</b> Alpha, alpha trehalase deficiency is characterised by diarrhoea and vomiting after ingestion of trehalose, a disaccharide found mainly in mushrooms. The disease is very rare in most populations but the incidence has been estimated at least 1 in 13 in Greenland. Isolated trehalose intolerance is due to a deficiency of trehalase (TREH; 11q23.3), a brush-border membrane glycoprotein.
<b>5C61.4</b>	<b>Acquired monosaccharide malabsorption</b> This is an acquired condition in which the cells lining the intestine cannot take in one or all of the sugars glucose, galactose or fructose, which prevents proper digestion of these molecules and larger molecules made from them.  It may cause osmotic diarrhoea.
<b>5C61.40</b>	Fructose malabsorption

- 5C61.4Y** Other specified acquired monosaccharide malabsorption
- 5C61.4Z** Acquired monosaccharide malabsorption, unspecified
- 5C61.5** **Disorders of facilitated glucose transport**
- Coded Elsewhere:** Glycogen storage disease due to GLUT2 deficiency (5C51.3)
- 5C61.6** **Lactose intolerance**
- Lactose intolerance is the inability to digest lactose, a sugar found in milk and some dairy products, due to a deficiency of lactase, the enzyme that metabolizes lactose. Lactose intolerance occurs when lactose is not completely broken down and consequently the sugar cannot be absorbed into the blood.
- 5C61.60** Primary lactase deficiency
- 5C61.61** Congenital lactase deficiency
- This is a congenital deficiency of lactase (EC 3.2.1.108), inherited as an autosomal recessive trait, presenting in infancy and manifested by profuse watery diarrhoea in response to dietary milk, due to inability to digest lactose, a sugar found in milk and to a lesser extent milk-derived dairy products. The condition may lead to marasmus and death if lactose is not eliminated from the diet.
- 5C61.62** Secondary lactase deficiency
- This form of lactase deficiency results from some sort of damage to the intestines either due to a disease or surgery.
- Coding Note:** Code also the causing condition
- 5C61.6Z** Lactose intolerance, unspecified
- 5C61.Y** **Other specified disorders of carbohydrate absorption or transport**
- 5C61.Z** **Disorders of carbohydrate absorption or transport, unspecified**
- 5C62** **Disorders of lipid absorption or transport**
- 5C63** **Disorders of vitamin or non-protein cofactor absorption or transport**
- Coded Elsewhere:** Hereditary factor X deficiency (3B14.1)
- Combined deficiency of vitamin K-dependent clotting factors (3B14.2)
- 5C63.0** **Disorders of cobalamin metabolism or transport**
- Coded Elsewhere:** Hereditary vitamin B12 deficiency anaemia (3A01.0)
- Neonatal vitamin B12 deficiency anaemia (3A01.1)
- Methylmalonic aciduria, vitamin B12 responsive (5C50.E0)
- Congenital or neonatal vitamin B12 deficiency anaemia (3A01.Z)
- 5C63.1** **Disorders of folate metabolism or transport**
- Coded Elsewhere:** Formiminoglutamic aciduria (3A02.Y)
- 5C63.2** **Disorders of vitamin D metabolism or transport**

- 5C63.20** Hypocalcaemic vitamin D dependent rickets  
Hypocalcaemic vitamin D-dependent rickets (VDDR-I) is an early-onset hereditary vitamin D metabolism disorder characterised by severe hypocalcaemia leading to osteomalacia and rachitic bone deformations, and moderate hypophosphatemia.
- 5C63.21** Hypocalcaemic vitamin D resistant rickets  
Hypocalcaemic vitamin D-resistant rickets is a hereditary disorder of vitamin D action characterised by hypocalcaemia, severe rickets and in many cases alopecia.
- 5C63.22** Hypophosphataemic rickets  
Hypophosphatemic rickets is a group of genetic diseases characterised by hypophosphatemia, rickets, and normal serum levels of calcium.
- 5C63.2Y** Other specified disorders of vitamin D metabolism or transport
- 5C63.2Z** Disorders of vitamin D metabolism or transport, unspecified
- 5C63.Y** **Other specified disorders of vitamin or non-protein cofactor absorption or transport**
- 5C63.Z** **Disorders of vitamin or non-protein cofactor absorption or transport, unspecified**

## 5C64

### **Disorders of mineral absorption or transport**

A condition in which there is a deviation or interruption in the processing of a specific mineral in the body: its absorption, transport, storage, and utilization

- Exclusions:** Disorders of the parathyroids or parathyroid hormone system (5A50-5A5Z)
- Vitamin D deficiency (5B57)  
dietary mineral deficiency (5B5K)

- 5C64.0** **Disorders of copper metabolism**  
Any condition caused by failure to correctly metabolize copper.  
**Coded Elsewhere:** X-linked cutis laxa (LD28.2)
- 5C64.00** Wilson disease  
Wilson disease is an autosomal recessive disorder of copper metabolism characterised by the toxic accumulation of copper, mainly in the liver and central nervous system that may present as hepatic, neurologic or psychiatric forms.
- 5C64.0Y** Other specified disorders of copper metabolism
- 5C64.0Z** Disorders of copper metabolism, unspecified
- 5C64.1** **Disorders of iron metabolism**  
This refers to any disorders of the set of chemical reactions maintaining human homeostasis of iron. The control of this necessary but potentially toxic substance is an important part of many aspects of human health and disease.
- Exclusions:** Sideroblastic anaemia (3A72)  
Iron deficiency anaemia (3A00)

- 5C64.10** Iron overload diseases  
 Iron overload is the accumulation of excess iron in body tissues. Iron overload usually occurs as a result of a genetic predisposition to absorb and store iron in excess amounts, the most common form of which is hereditary hemochromatosis. Iron overload can also occur as a complication of other hematologic disorders that require chronic transfusion therapy, repeated injections of parenteral iron, or excessive iron ingestion. Excessive iron stores usually accumulate in the reticuloendothelial tissues and cause little damage (" hemosiderosis"). If overload continues, iron eventually begins to accumulate in tissues such as hepatic parenchyma, pancreas, heart and synovium, causing hemochromatosis.
- Coded Elsewhere:** Friedreich ataxia (8A03.10)  
 Atransferrinaemia (3A00.Y)  
 Microcytic anaemia with liver iron overload (3A00.Y)
- 5C64.1Y** Other specified disorders of iron metabolism
- 5C64.1Z** Disorders of iron metabolism, unspecified
- 5C64.2** **Disorders of zinc metabolism**  
 Any condition caused by failure to correctly metabolize zinc. These conditions may present with dermatitis, diarrhoea, alopecia, loss of appetite, growth impairment, neuropsychological changes, or immune deficiency syndromes.
- 5C64.20** Acrodermatitis enteropathica  
 Acrodermatitis enteropathica is an uncommon autosomal recessive disorder of intestinal zinc absorption. Signs usually appear within the first months of life with an exudative and crusted erythema located predominantly around body orifices (mouth, anogenital) and on the scalp and distal extremities. The signs are often misdiagnosed as being due to infection. The condition responds rapidly to zinc supplementation which must be continued throughout life.
- 5C64.21** Zinc deficiency syndromes  
**Coded Elsewhere:** Acrodermatitis enteropathica (5C64.20)
- 5C64.2Y** Other specified disorders of zinc metabolism
- 5C64.2Z** Disorders of zinc metabolism, unspecified
- 5C64.3** **Disorders of phosphorus metabolism or phosphatases**  
 Any condition caused by errors in phosphorus metabolism, or in phosphatase activity.
- Exclusions:** Adult osteomalacia (FB83.2)  
 Osteoporosis (FB83.1)
- Coded Elsewhere:** Hypophosphataemic rickets (5C63.22)  
 Phosphate losing hypophosphataemia (GB90.48)

<b>5C64.4</b>	<b>Disorders of magnesium metabolism</b> Any condition caused by failure to correctly metabolize magnesium.  <b>Coded Elsewhere:</b> Transitory neonatal disorders of calcium or magnesium metabolism (KB61)
<b>5C64.40</b>	Hypermagnesaemia This is an electrolyte disturbance in which there is an abnormally elevated level of magnesium in the blood. Usually this results in excess of magnesium in the body.
<b>5C64.41</b>	Hypomagnesaemia This is an electrolyte disturbance in which there is an abnormally low level of magnesium in the blood. Normal magnesium levels in humans fall between 1.5 - 2.5 mg/dL. Usually a serum level less than 0.7 mmol/L is used as reference for hypomagnesemia (not hypomagnesia which refers to low magnesium content in food/supplement sources).  <b>Coded Elsewhere:</b> Neonatal hypomagnesaemia (KB61.0)
<b>5C64.4Z</b>	Disorders of magnesium metabolism, unspecified
<b>5C64.5</b>	<b>Disorders of calcium metabolism</b> This refers to disorders in the mechanism by which the body maintains adequate calcium levels. Derangements of this mechanism lead to hypercalcaemia or hypocalcaemia, both of which can have important consequences for health.  <b>Exclusions:</b> Hyperparathyroidism (5A51) Chondrocalcinosis (FA26.2)  <b>Coded Elsewhere:</b> Familial hypocalciuric hypercalcaemia (5A51.2) Hypercalciuria (MF98.0) Nephrocalcinosis (GB57) Hypercalcaemia (5B91.0) Transitory neonatal disorders of calcium or magnesium metabolism (KB61)
<b>5C64.6</b>	<b>Disorders of sodium metabolism</b> <b>Coded Elsewhere:</b> Tubular disorders of sodium or potassium transport (GB90.46) Congenital sodium diarrhoea (DA90.1)
<b>5C64.7</b>	<b>Disorders of chloride metabolism</b> <b>Coded Elsewhere:</b> Congenital chloride diarrhoea (DA90.1)
<b>5C64.Y</b>	<b>Disorders of other specified mineral absorption and transport</b>
<b>5C64.Z</b>	<b>Disorders of mineral absorption or transport, unspecified</b>
<b>5C6Y</b>	<b>Other specified disorders of metabolite absorption or transport</b>
<b>5C6Z</b>	<b>Disorders of metabolite absorption or transport, unspecified</b>

Disorders of fluid, electrolyte or acid-base balance (5C70-5C7Z)

**5C70**

### **Volume depletion**

**Exclusions:** Hypovolaemic shock (MG40.1)

**5C70.0**

### **Dehydration**

Dehydration occurs when there is an insufficient amount or excessive loss of water in the body. This can be caused by vomiting, diarrhoea, fever, use of diuretics, profuse sweating, or decreased water intake.

**Coded Elsewhere:** Dehydration of newborn (KB63.1)

**5C70.1**

### **Hypovolaemia**

This is a state of decreased blood volume; more specifically, decrease in volume of blood plasma. It is thus the intravascular component of volume contraction (or loss of blood volume due to things such as haemorrhaging or dehydration), but, as it also is the most essential one, hypovolemia and volume contraction are sometimes used synonymously.

**Exclusions:** Traumatic shock, not elsewhere classified (NF0A.4)

Hypovolaemic shock (MG40.1)

**5C70.Y**

### **Other specified volume depletion**

**5C70.Z**

### **Volume depletion, unspecified**

**5C71**

### **Hyperosmolality or hypernatraemia**

Serum sodium concentrations in excess of 145 mmol/L; increased serum concentration of osmotically active particles

**Coded Elsewhere:** Hypernatremia of newborn (KB63.21)

**5C72**

### **Hypo-osmolality or hyponatraemia**

Serum sodium concentrations of less than 135 mEq/L; decreased serum concentration of osmotically active particles

**Inclusions:** sodium [na] deficiency

**Exclusions:** Syndrome of inappropriate secretion of antidiuretic hormone (5A60.2)

**Coded Elsewhere:** Hyponatremia of newborn (KB63.20)

**5C73**

### **Acidosis**

Acidosis is an abnormally acidic state of the blood and tissues.

**Exclusions:** diabetic acidosis (5A10-5A2Y)

**Coded Elsewhere:** Late metabolic acidosis of newborn (KB63.0)

Kussmaul respiration (5A22.Y)

- 5C73.0 Acute respiratory acidosis**  
This is an acute condition in which decreased ventilation (hypoventilation) causes increased blood carbon dioxide concentration and decreased pH (a condition generally called acidosis). Carbon dioxide is produced continuously as the body's cells respire, and this CO<sub>2</sub> will accumulate rapidly if the lungs do not adequately expel it through alveolar ventilation. Alveolar hypoventilation thus leads to an increased PaCO<sub>2</sub> (called hypercapnia). The increase in PaCO<sub>2</sub> in turn decreases the HCO<sub>3</sub><sup>-</sup>/PaCO<sub>2</sub> ratio and decreases pH.
- 5C73.1 Chronic respiratory acidosis**  
This is a chronic condition in which decreased ventilation (hypoventilation) causes increased blood carbon dioxide concentration and decreased pH (a condition generally called acidosis). Carbon dioxide is produced continuously as the body's cells respire, and this CO<sub>2</sub> will accumulate rapidly if the lungs do not adequately expel it through alveolar ventilation. Alveolar hypoventilation thus leads to an increased PaCO<sub>2</sub> (called hypercapnia). The increase in PaCO<sub>2</sub> in turn decreases the HCO<sub>3</sub><sup>-</sup>/PaCO<sub>2</sub> ratio and decreases pH.
- 5C73.2 Anion gap metabolic acidosis**  
This is a form of metabolic acidosis characterised by a high anion gap. The list of agents that cause high anion gap metabolic acidosis is similar to but broader than the list of agents that cause a serum osmolal gap.
- 5C73.Y Other specified acidosis**
- 5C73.Z Acidosis, unspecified**
- 5C74 Alkalosis**  
Alkalosis is an abnormally basic state of the blood and tissues.
- 5C75 Mixed disorder of acid-base balance**  
This is a condition where more than one of the normal mechanisms that regulate the amount of acid or base content in the body are dysfunctional.
- 5C76 Hyperkalaemia**  
*Inclusions:* Potassium [K] excess  
Potassium [K] overload  
*Coded Elsewhere:* Hyperkalaemia of newborn (KB63.31)
- 5C77 Hypokalaemia**  
*Coded Elsewhere:* Hypokalaemia of newborn (KB63.30)

**5C78**

### **Fluid overload**

This is the condition where there is too much fluid in the blood. The opposite condition is hypovolemia, which is too little fluid volume in the blood. Fluid volume excess in the intravascular compartment occurs due to an increase in total body sodium content and a consequent increase in extracellular body water. The mechanism usually stems from compromised regulatory mechanisms for sodium handling as seen in congestive heart failure (CHF), kidney failure, and liver failure. It may also be caused by excessive intake of sodium from foods, intravenous (IV) solutions and blood transfusions, medications, or diagnostic contrast dyes.

**5C7Y**

### **Other specified disorders of fluid, electrolyte or acid-base balance**

**5C7Z**

### **Disorders of fluid, electrolyte or acid-base balance, unspecified**

Disorders of lipoprotein metabolism or certain specified lipidaemias (5C80-5C8Z)

Elevated levels of lipoprotein(a), or Lp(a), in the blood. It is associated with an elevated risk of cardiovascular diseases.

**Exclusions:** Sphingolipidosis (5C56.0)

**Coded Elsewhere:** Lipoid dermatopathology (FA38.Y)

Multicentric reticulohistiocytosis (EE8Y)

Lipoid proteinosis (LD27.Y)

**5C80**

### **Hyperlipoproteinaemia**

Disorders of lipoprotein metabolism that result in high levels of lipoproteins in the circulating blood

**5C80.0**

### **Hypercholesterolaemia**

**5C80.00**

Primary hypercholesterolaemia

This is a genetic disorder characterised by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL, "bad cholesterol"), in the blood and early cardiovascular disease.

**Coded Elsewhere:** Sitosterolaemia (5C52.1Y)

**5C80.01**

Secondary hypercholesterolaemia

**Coding Note:**

Code also the causing condition

**5C80.0Z**

Hypercholesterolaemia, unspecified

**5C80.1**

### **Hypertriglyceridaemia**

A form of hyperlipidaemia characterised by abnormally elevated levels of triglyceride-rich lipoproteins in the blood. It is associated with an elevated risk of cardiovascular morbidity.

**Inclusions:** Hyperlipidaemia, group B

Endogenous hypertriglyceridaemia

<b>5C80.2</b>	<b>Mixed hyperlipidaemia</b> Elevated levels of both LDL cholesterol and triglycerides in the blood
	<b>Inclusions:</b> Hyperbetalipoproteinaemia with prebetalipoproteinaemia Hypercholesterolaemia with endogenous hyperglyceridaemia Hyperlipidaemia, group C
	<b>Exclusions:</b> cerebrotendinous cholesterosis [van Bogaert-Scherer-Epstein] (5C52.11)
<b>5C80.3</b>	<b>Hyperalphalipoproteinaemia</b> A condition in which high-density lipoprotein is elevated in the blood.
<b>5C80.Y</b>	<b>Other specified hyperlipoproteinaemia</b>
<b>5C80.Z</b>	<b>Hyperlipoproteinaemia, unspecified</b>
<b>5C81</b>	<b>Hypolipoproteinaemia</b> Disorders characterised by low level of lipoproteins of any type in the blood
	<b>Inclusions:</b> High-density lipoprotein deficiency
<b>5C81.0</b>	<b>Hypoalphalipoproteinaemia</b> A disorder characterised by low levels of high-density lipoprotein in the blood.
<b>5C81.1</b>	<b>Hypobetalipoproteinaemia</b> Hypobetalipoproteinemia (HBL) constitutes a group of lipoprotein metabolism disorders that are characterised by permanently low levels (below the 5th percentile) of apolipoprotein B and LDL cholesterol. There are two types of HBL: familial hypobetalipoproteinemia and chylomicron retention disease (CMRD; see these terms). The familial form can be severe with early onset (abetalipoproteinemia/homozygous familial hypobetalipoproteinemia; see this term) or benign (benign familial hypobetalipoproteinemia; see this term). (Please add the sentence). Severe familial HBL and CMRD appear in infancy or childhood. As a result they are often associated with growth delay, diarrhoea with steatorrhoea, and fat malabsorption. Benign familial hypobetalipoproteinemia is generally asymptomatic, but in adults is occasionally associated with dietary intolerance to fat. HBL disorders are caused by mutations in proteins involved in the synthesis, secretion and catabolism of lipoproteins containing apolipoprotein B (LDL, VLDL and chylomicrons).
<b>5C81.Y</b>	<b>Other specified hypolipoproteinaemia</b>
<b>5C81.Z</b>	<b>Hypolipoproteinaemia, unspecified</b>
<b>5C8Y</b>	<b>Other specified disorders of lipoprotein metabolism or lipidaemias</b>
<b>5C8Z</b>	<b>Unspecified disorders of lipoprotein metabolism or lipidaemias</b>

**5C90**

**Metabolic or transporter liver disease**

- Exclusions:**
- Alcoholic liver disease (DB94)
  - Non-alcoholic fatty liver disease (DB92)
  - Drug-induced or toxic liver disease (DB95)
  - Acute fatty liver of pregnancy (JA65.0)
- Coded Elsewhere:**
- Bile acid synthesis defect with cholestasis (5C52.11)
  - Progressive familial intrahepatic cholestasis (5C58.03)
  - Benign recurrent intrahepatic cholestasis (5C58.04)
  - Glycogen storage disease (5C51.3)
  - Disorders of galactose metabolism (5C51.4)
  - Disorders of fructose metabolism (5C51.5)
  - Alpha-1-antitrypsin deficiency (5C5A)
  - Reye syndrome (8E46)

**5C90.0**

**Liver diseases due to urea cycle defects**

This is a group of liver diseases due to defects in the urea cycle, which is a metabolic cycle of nitrogen-containing compounds that produces the waste product urea.

- Coded Elsewhere:**
- Argininosuccinic aciduria (5C50.A0)
  - Carbamoylphosphate synthetase deficiency (5C50.A1)
  - Argininaemia (5C50.A2)
  - Ornithine carbamoyltransferase deficiency (5C50.AY)

**5C90.1**

**Liver diseases due to disorders of porphyrin or bilirubin metabolism or transport**

These are liver diseases due to disorders of porphyrin and bilirubin metabolism and transport

- Exclusions:**
- Defects of catalase and peroxidase (5C58)
- Coded Elsewhere:**
- Porphyria cutanea tarda (5C58.10)
  - Variegate porphyria (5C58.13)
  - Crigler-Najjar syndrome (5C58.00)
  - Gilbert syndrome (5C58.01)
  - Dubin-Johnson syndrome (5C58.02)
  - Rotor syndrome (5C58.0Y)

**5C90.2**

**Liver diseases due to disorders of amino acid metabolism**

This is liver disease due to the disorder of the various biochemical processes responsible for the synthesis of proteins and amino acids, and the breakdown of proteins (and other large molecules, too) by catabolism.

- Coded Elsewhere:**
- Disorders of tyrosine metabolism (5C50.1)
  - Citrullinaemia (5C50.A3)

<b>5C90.3</b>	<b>Liver disease due to disorders of lysosomal storage</b> This is liver disease due to a group of approximately 50 rare inherited metabolic disorders that result from defects in lysosomal function.  <b>Coded Elsewhere:</b> Gaucher disease (5C56.0Y) Niemann-Pick disease (5C56.0Y) Wolman disease (5C56.0Y) Cholesteryl ester storage disease (5C56.0Y)
<b>5C90.4</b>	<b>Liver diseases due to mitochondrial disorders</b> This is liver disease due to a group of disorders caused by dysfunctional mitochondria, the organelles that generate energy for the cell.
<b>5C90.5</b>	<b>Liver diseases due to disorders of mineral metabolism</b> This is a liver disease due to a disorder of the organic compound required by an organism as a vital nutrient in limited amounts.
<b>Coding Note:</b>	Code also the causing condition
<b>5C90.Y</b>	<b>Other specified metabolic or transporter liver disease</b>
<b>5C90.Z</b>	<b>Metabolic or transporter liver disease, unspecified</b>
Other metabolic disorders (5D00-5D0Y)	
<b>Exclusions:</b>	histiocytosis X (chronic) (2B31.2)
<b>Coded Elsewhere:</b>	Tophaceous gout (FA25.20)
<b>5D00</b>	<b>Amyloidosis</b> Amyloidosis is a vast group of diseases defined by the presence of insoluble protein deposits in tissues. Its diagnosis is based on histological findings. Amyloidoses are classified according to clinical signs and biochemical type of amyloid protein involved. Most amyloidoses are multisystemic, 'generalised' or 'diffuse'. There are a few forms of localised amylosis. The most frequent forms are AL amyloidosis (immunoglobulins), AA (inflammatory), and ATTR (transthyretin accumulation).  <b>Exclusions:</b> Dementia due to Alzheimer disease (6D80)
<b>5D00.0</b>	<b>AL amyloidosis</b> AL amyloid is due to the deposition of immunoglobulin light chains in glomeruli where they are seen as Congo red binding fibrils and immuno-stain specifically for kappa or lambda light chains. By light microscopy there is amorphous hyaline material in the mesangium and capillary walls. A light chain producing plasma cell or B-cell dysplasia is responsible. Other organs are also involved in this systemic disease.  <b>Coded Elsewhere:</b> Isolated cerebral amyloid angiopathy (8B22.3)

<b>5D00.1</b>	<b>AA amyloidosis</b> AA amyloid is due to the deposition of the acute phase reactant serum amyloid A protein (SAA) in glomeruli where they are seen as Congo red binding fibrils which immunostain specifically for SAA. Chronic inflammation is responsible. Other organs are also involved in this systemic disease.
<b>5D00.2</b>	<b>Hereditary amyloidosis</b> Hereditary amyloidosis (familial amyloidosis) is an inherited disorder that often affects the liver, nerves, heart and kidneys. Many different types of gene abnormalities present at birth are associated with an increased risk of amyloid disease. The type and location of an amyloid gene abnormality can affect the risk of certain complications, the age at which symptoms first appear, and the way the disease progresses over time.
<b>5D00.20</b>	Hereditary ATTR amyloidosis
<b>5D00.21</b>	<b>Non-neuropathic heredofamilial amyloidosis</b> This is an amyloidosis (the formation of insoluble proteins, or amyloids) of inherited origin that does not affect the peripheral nerves. The most common sites of deposits are associated with the kidney and heart. <b>Coded Elsewhere:</b> Familial Mediterranean fever with amyloidosis (4A60.0)
<b>5D00.2Y</b>	Other specified hereditary amyloidosis
<b>5D00.2Z</b>	Hereditary amyloidosis, unspecified
<b>5D00.3</b>	<b>Dialysis-associated amyloidosis</b> Dialysis-related amyloidosis develops when proteins in blood are deposited in joints and tendons — causing pain, stiffness and fluid in the joints, as well as carpal tunnel syndrome. This type generally affects people on long-term dialysis.
<b>5D00.Y</b>	<b>Other specified amyloidosis</b>
<b>5D00.Z</b>	<b>Amyloidosis, unspecified</b>
<b>5D01</b>	<b>Tumour lysis syndrome</b> This is a group of metabolic complications that can occur after treatment of cancer, usually lymphomas and leukaemias, and sometimes even without treatment. These complications are caused by the breakdown products of dying cancer cells and include hyperkalaemia, hyperphosphataemia, hyperuricaemia and hyperuricosuria, hypocalcaemia, and consequent acute uric acid nephropathy and acute renal failure.
<b>Coding Note:</b>	Code also the causing condition
<b>5D0Y</b>	<b>Other specified metabolic disorders</b>
<b>5D2Z</b>	<b>Metabolic disorders, unspecified</b>

## Postprocedural endocrine or metabolic disorders (5D40-5D46)

Any endocrine or metabolic disorder caused by or subsequent to any medical procedure.

**Coded Elsewhere:** Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)

### 5D40 Postprocedural hypothyroidism

#### 5D40.0 Postirradiation hypothyroidism

5D40.00 Hypothyroidism postradioactive iodine ablation

5D40.0Y Other specified postirradiation hypothyroidism

5D40.0Z Postirradiation hypothyroidism, unspecified

#### 5D40.Y Other specified postprocedural hypothyroidism

#### 5D40.Z Postprocedural hypothyroidism, unspecified

### 5D41 Postprocedural hypoinsulinaemia

This is a low level of insulin that can result after medical procedures, including radiation, and it carries a risk of developing diabetes mellitus.

**Inclusions:** Postpancreatectomy hyperglycaemia  
Postsurgical hypoinsulinaemia

### 5D42 Postprocedural hypoparathyroidism

This refers to a postprocedural decreased function of the parathyroid glands with underproduction of parathyroid hormone. This can lead to low levels of calcium in the blood, often causing cramping and twitching of muscles or tetany (involuntary muscle contraction), and several other symptoms.

**Inclusions:** Parathyroprival tetany

### 5D43 Postprocedural hypopituitarism

This is the postprocedural decreased (hypo) secretion of one or more of the eight hormones normally produced by the pituitary gland at the base of the brain. If there is decreased secretion of most pituitary hormones, the term panhypopituitarism (pan meaning "all") is used.

### 5D44 Postprocedural ovarian failure

A condition in women characterised by amenorrhea, caused by or subsequent to any intervention. This condition may also present with hot flashes, night sweats, irritability, poor concentration, decreased sex drive, pain during sex, vaginal dryness.

### 5D45 Postprocedural testicular hypofunction

A condition in men characterised by testosterone deficiency, caused by or subsequent to any intervention. This condition may present with fatigue, decreased libido, erectile dysfunction, negative mood states, decreased lean body mass, increased fat mass, or decreased bone mineral density.

**5D46**

**Postprocedural adrenocortical hypofunction**

A condition caused by or subsequent to any medical procedure. This condition is characterised by adrenocortical hormone deficiency. This condition may present with chronic fatigue, muscle weakness, loss of appetite, weight loss or abdominal pain.

# CHAPTER 06

---

## Mental, behavioural or neurodevelopmental disorders

This chapter has 162 four-character categories.

Code range starts with 6A00

Mental, behavioural and neurodevelopmental disorders are syndromes characterised by clinically significant disturbance in an individual's cognition, emotional regulation, or behaviour that reflects a dysfunction in the psychological, biological, or developmental processes that underlie mental and behavioural functioning. These disturbances are usually associated with distress or impairment in personal, family, social, educational, occupational, or other important areas of functioning.

- Exclusions:**      Acute stress reaction (QE84)  
                        Uncomplicated bereavement (QE62)
- Coded Elsewhere:** Sleep-wake disorders (7A00-7B2Z)  
                        Sexual dysfunctions (HA00-HA0Z)  
                        Gender incongruence (HA60-HA6Z)

This chapter contains the following top level blocks:

- Neurodevelopmental disorders
- Schizophrenia or other primary psychotic disorders
- Catatonia
- Mood disorders
- Anxiety or fear-related disorders
- Obsessive-compulsive or related disorders
- Disorders specifically associated with stress
- Dissociative disorders
- Feeding or eating disorders
- Elimination disorders
- Disorders of bodily distress or bodily experience
- Disorders due to substance use or addictive behaviours
- Impulse control disorders
- Disruptive behaviour or dissociative disorders
- Personality disorders and related traits
- Paraphilic disorders
- Factitious disorders
- Neurocognitive disorders

- Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium
- Secondary mental or behavioural syndromes associated with disorders or diseases classified elsewhere

## Neurodevelopmental disorders (6A00-6A0Z)

Neurodevelopmental disorders are behavioural and cognitive disorders that arise during the developmental period that involve significant difficulties in the acquisition and execution of specific intellectual, motor, language, or social functions. Although behavioural and cognitive deficits are present in many mental and behavioural disorders that can arise during the developmental period (e.g., Schizophrenia, Bipolar disorder), only disorders whose core features are neurodevelopmental are included in this grouping. The presumptive etiology for neurodevelopmental disorders is complex, and in many individual cases is unknown.

**Coded Elsewhere:** Primary tics or tic disorders (8A05.0)

Secondary neurodevelopmental syndrome (6E60)

**6A00**

### Disorders of intellectual development

Disorders of intellectual development are a group of etiologically diverse conditions originating during the developmental period characterised by significantly below average intellectual functioning and adaptive behaviour that are approximately two or more standard deviations below the mean (approximately less than the 2.3rd percentile), based on appropriately normed, individually administered standardized tests. Where appropriately normed and standardized tests are not available, diagnosis of disorders of intellectual development requires greater reliance on clinical judgment based on appropriate assessment of comparable behavioural indicators.

**Coding Note:** Use additional code, if desired, to identify any known aetiology.

**Exclusions:** Dementia (6D80-6D8Z)

**6A00.0**

### Disorder of intellectual development, mild

A mild disorder of intellectual development is a condition originating during the developmental period characterised by significantly below average intellectual functioning and adaptive behaviour that are approximately two to three standard deviations below the mean (approximately 0.1 – 2.3 percentile), based on appropriately normed, individually administered standardized tests or by comparable behavioural indicators when standardized testing is unavailable. Affected persons often exhibit difficulties in the acquisition and comprehension of complex language concepts and academic skills. Most master basic self-care, domestic, and practical activities. Persons affected by a mild disorder of intellectual development can generally achieve relatively independent living and employment as adults but may require appropriate support.

**6A00.1**

**Disorder of intellectual development, moderate**

A moderate disorder of intellectual development is a condition originating during the developmental period characterised by significantly below average intellectual functioning and adaptive behaviour that are approximately three to four standard deviations below the mean (approximately 0.003 – 0.1 percentile), based on appropriately normed, individually administered standardized tests or by comparable behavioural indicators when standardized testing is unavailable. Language and capacity for acquisition of academic skills of persons affected by a moderate disorder of intellectual development vary but are generally limited to basic skills. Some may master basic self-care, domestic, and practical activities. Most affected persons require considerable and consistent support in order to achieve independent living and employment as adults.

**6A00.2**

**Disorder of intellectual development, severe**

A severe disorder of intellectual development is a condition originating during the developmental period characterised by significantly below average intellectual functioning and adaptive behaviour that are approximately four or more standard deviations below the mean (less than approximately the 0.003rd percentile), based on appropriately normed, individually administered standardized tests or by comparable behavioural indicators when standardized testing is unavailable. Affected persons exhibit very limited language and capacity for acquisition of academic skills. They may also have motor impairments and typically require daily support in a supervised environment for adequate care, but may acquire basic self-care skills with intensive training. Severe and profound disorders of intellectual development are differentiated exclusively on the basis of adaptive behaviour differences because existing standardized tests of intelligence cannot reliably or validly distinguish among individuals with intellectual functioning below the 0.003rd percentile.

**6A00.3**

**Disorder of intellectual development, profound**

A profound disorder of intellectual development is a condition originating during the developmental period characterised by significantly below average intellectual functioning and adaptive behaviour that are approximately four or more standard deviations below the mean (approximately less than the 0.003rd percentile), based on individually administered appropriately normed, standardized tests or by comparable behavioural indicators when standardized testing is unavailable. Affected persons possess very limited communication abilities and capacity for acquisition of academic skills is restricted to basic concrete skills. They may also have co-occurring motor and sensory impairments and typically require daily support in a supervised environment for adequate care. Severe and profound disorders of intellectual development are differentiated exclusively on the basis of adaptive behaviour differences because existing standardized tests of intelligence cannot reliably or validly distinguish among individuals with intellectual functioning below the 0.003rd percentile.

**6A00.4      Disorder of intellectual development, provisional**

Disorder of intellectual development, provisional is assigned when there is evidence of a disorder of intellectual development but the individual is an infant or child under the age of four or it is not possible to conduct a valid assessment of intellectual functioning and adaptive behaviour because of sensory or physical impairments (e.g., blindness, pre-lingual deafness), motor or communication impairments, severe problem behaviours or co-occurring mental and behavioural disorders.

**6A00.Z      Disorders of intellectual development, unspecified**

**Coding Note:** Use additional code, if desired, to identify any known aetiology.

**6A01**

**Developmental speech or language disorders**

Developmental speech or language disorders arise during the developmental period and are characterised by difficulties in understanding or producing speech and language or in using language in context for the purposes of communication that are outside the limits of normal variation expected for age and level of intellectual functioning. The observed speech and language problems are not attributable to regional, social, or cultural/ethnic language variations and are not fully explained by anatomical or neurological abnormalities. The presumptive aetiology for Developmental speech or language disorders is complex, and in many individual cases, is unknown.

**6A01.0      Developmental speech sound disorder**

Developmental speech sound disorder is characterised by difficulties in the acquisition, production and perception of speech that result in errors of pronunciation, either in number or types of speech errors made or the overall quality of speech production, that are outside the limits of normal variation expected for age and level of intellectual functioning and result in reduced intelligibility and significantly affect communication. The errors in pronunciation arise during the early developmental period and cannot be explained by social, cultural, and other environmental variations (e.g., regional dialects). The speech errors are not fully explained by a hearing impairment or a structural or neurological abnormality.

**Inclusions:** Functional speech articulation disorder

**Exclusions:** Deafness not otherwise specified (AB52)

Diseases of the nervous system (Chapter 08)

Dysarthria (MA80.2)

Verbal apraxia (MB4A)

6A01.1	<b>Developmental speech fluency disorder</b>
	<p>Developmental speech fluency disorder is characterised by frequent or pervasive disruption of the normal rhythmic flow and rate of speech characterised by repetitions and prolongations in sounds, syllables, words, and phrases, as well as blocking and word avoidance or substitutions. The speech dysfluency is persistent over time. The onset of speech dysfluency occurs during the developmental period and speech fluency is markedly below what would be expected for age. Speech dysfluency results in significant impairment in social communication, personal, family, social, educational, occupational or other important areas of functioning. The speech dysfluency is not better accounted for by a Disorder of Intellectual Development, a Disease of the Nervous System, a sensory impairment, or a structural abnormality, or other speech or voice disorder.</p>
	<p><b>Exclusions:</b> Tic disorders (8A05)</p>
6A01.2	<b>Developmental language disorder</b>
	<p>Developmental language disorder is characterised by persistent deficits in the acquisition, understanding, production or use of language (spoken or signed), that arise during the developmental period, typically during early childhood, and cause significant limitations in the individual's ability to communicate. The individual's ability to understand, produce or use language is markedly below what would be expected given the individual's age. The language deficits are not explained by another neurodevelopmental disorder or a sensory impairment or neurological condition, including the effects of brain injury or infection.</p>
	<p><b>Exclusions:</b> Autism spectrum disorder (6A02)</p>
	<p>Diseases of the nervous system (Chapter 08)</p>
	<p>Deafness not otherwise specified (AB52)</p>
	<p>Selective mutism (6B06)</p>
6A01.20	<p>Developmental language disorder with impairment of receptive and expressive language</p>
	<p>Developmental language disorder with impairment of receptive and expressive language is characterised by persistent difficulties in the acquisition, understanding, production, and use of language that arise during the developmental period, typically during early childhood, and cause significant limitations in the individual's ability to communicate. The ability to understand spoken or signed language (i.e., receptive language) is markedly below the expected level given the individual's age and level of intellectual functioning, and is accompanied by persistent impairment in the ability to produce and use spoken or signed language (i.e., expressive language).</p>
	<p><b>Inclusions:</b> developmental dysphasia or aphasia, receptive type</p>
	<p><b>Exclusions:</b> acquired aphasia with epilepsy [Landau-Kleffner] (8A62.2)</p>
	<p>Autism spectrum disorder (6A02)</p>
	<p>Selective mutism (6B06)</p>
	<p>dysphasia NOS (MA80.1)</p>
	<p>Diseases of the nervous system (Chapter 08)</p>
	<p>Deafness not otherwise specified (AB52)</p>

<b>6A01.21</b>	<p>Developmental language disorder with impairment of mainly expressive language</p> <p>Developmental language disorder with impairment of mainly expressive language is characterised by persistent difficulties in the acquisition, production, and use of language that arise during the developmental period, typically during early childhood, and cause significant limitations in the individual's ability to communicate. The ability to produce and use spoken or signed language (i.e., expressive language) is markedly below the expected level given the individual's age and level of intellectual functioning, but the ability to understand spoken or signed language (i.e., receptive language) is relatively intact.</p> <p><b>Inclusions:</b> Developmental dysphasia or aphasia, expressive type</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>acquired aphasia with epilepsy [Landau-Kleffner] (8A62.2)</li> <li>Selective mutism (6B06)</li> <li>dysphasia and aphasia: developmental, receptive type (6A01.20)</li> <li>dysphasia NOS (MA80.1)</li> <li>aphasia NOS (MA80.0)</li> <li>Diseases of the nervous system (Chapter 08)</li> <li>Deafness not otherwise specified (AB52)</li> </ul>
<b>6A01.22</b>	<p>Developmental language disorder with impairment of mainly pragmatic language</p> <p>Developmental language disorder with impairment of mainly pragmatic language is characterised by persistent and marked difficulties with the understanding and use of language in social contexts, for example making inferences, understanding verbal humour, and resolving ambiguous meaning. These difficulties arise during the developmental period, typically during early childhood, and cause significant limitations in the individual's ability to communicate. Pragmatic language abilities are markedly below the expected level given the individual's age and level of intellectual functioning, but the other components of receptive and expressive language are relatively intact. This qualifier should not be used if the pragmatic language impairment is better explained by Autism Spectrum Disorder or by impairments in other components of receptive or expressive language.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Diseases of the nervous system (Chapter 08)</li> <li>Selective mutism (6B06)</li> </ul>
<b>6A01.23</b>	<p>Developmental language disorder, with other specified language impairment</p> <p>Developmental language disorder with other specified language impairment is characterised by persistent difficulties in the acquisition, understanding, production or use of language (spoken or signed), that arise during the developmental period and cause significant limitations in the individual's ability to communicate. The pattern of specific deficits in language abilities is not adequately captured by any of the other developmental language disorder categories.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Autism spectrum disorder (6A02)</li> <li>Diseases of the nervous system (Chapter 08)</li> <li>Disorders of intellectual development (6A00)</li> <li>Selective mutism (6B06)</li> </ul>

**6A01.Y Other specified developmental speech or language disorders**

**6A01.Z Developmental speech or language disorders, unspecified**

**6A02**

**Autism spectrum disorder**

Autism spectrum disorder is characterised by persistent deficits in the ability to initiate and to sustain reciprocal social interaction and social communication, and by a range of restricted, repetitive, and inflexible patterns of behaviour, interests or activities that are clearly atypical or excessive for the individual's age and sociocultural context. The onset of the disorder occurs during the developmental period, typically in early childhood, but symptoms may not become fully manifest until later, when social demands exceed limited capacities. Deficits are sufficiently severe to cause impairment in personal, family, social, educational, occupational or other important areas of functioning and are usually a pervasive feature of the individual's functioning observable in all settings, although they may vary according to social, educational, or other context. Individuals along the spectrum exhibit a full range of intellectual functioning and language abilities.

**Inclusions:** Autistic disorder

**Exclusions:** Rett syndrome (LD90.4)

**6A02.0 Autism spectrum disorder without disorder of intellectual development and with mild or no impairment of functional language**

All definitional requirements for autism spectrum disorder are met, intellectual functioning and adaptive behaviour are found to be at least within the average range (approximately greater than the 2.3rd percentile), and there is only mild or no impairment in the individual's capacity to use functional language (spoken or signed) for instrumental purposes, such as to express personal needs and desires.

**6A02.1 Autism spectrum disorder with disorder of intellectual development and with mild or no impairment of functional language**

All definitional requirements for both autism spectrum disorder and disorder of intellectual development are met and there is only mild or no impairment in the individual's capacity to use functional language (spoken or signed) for instrumental purposes, such as to express personal needs and desires.

**6A02.2 Autism spectrum disorder without disorder of intellectual development and with impaired functional language**

All definitional requirements for autism spectrum disorder are met, intellectual functioning and adaptive behaviour are found to be at least within the average range (approximately greater than the 2.3rd percentile), and there is marked impairment in functional language (spoken or signed) relative to the individual's age, with the individual not able to use more than single words or simple phrases for instrumental purposes, such as to express personal needs and desires.

**6A02.3 Autism spectrum disorder with disorder of intellectual development and with impaired functional language**

All definitional requirements for both autism spectrum disorder and disorder of intellectual development are met and there is marked impairment in functional language (spoken or signed) relative to the individual's age, with the individual not able to use more than single words or simple phrases for instrumental purposes, such as to express personal needs and desires.

<b>6A02.5</b>	<b>Autism spectrum disorder with disorder of intellectual development and with absence of functional language</b> All definitional requirements for both autism spectrum disorder and disorder of intellectual development are met and there is complete, or almost complete, absence of ability relative to the individual's age to use functional language (spoken or signed) for instrumental purposes, such as to express personal needs and desires
<b>6A02.Y</b>	<b>Other specified autism spectrum disorder</b>
<b>6A02.Z</b>	<b>Autism spectrum disorder, unspecified</b>
<b>6A03</b>	<b>Developmental learning disorder</b> Developmental learning disorder is characterised by significant and persistent difficulties in learning academic skills, which may include reading, writing, or arithmetic. The individual's performance in the affected academic skill(s) is markedly below what would be expected for chronological age and general level of intellectual functioning, and results in significant impairment in the individual's academic or occupational functioning. Developmental learning disorder first manifests when academic skills are taught during the early school years. Developmental learning disorder is not due to a disorder of intellectual development, sensory impairment (vision or hearing), neurological or motor disorder, lack of availability of education, lack of proficiency in the language of academic instruction, or psychosocial adversity. <i><b>Exclusions:</b></i> Symbolic dysfunctions (MB4B)
<b>6A03.0</b>	<b>Developmental learning disorder with impairment in reading</b> Developmental learning disorder with impairment in reading is characterised by significant and persistent difficulties in learning academic skills related to reading, such as word reading accuracy, reading fluency, and reading comprehension. The individual's performance in reading is markedly below what would be expected for chronological age and level of intellectual functioning and results in significant impairment in the individual's academic or occupational functioning. Developmental learning disorder with impairment in reading is not due to a disorder of intellectual development, sensory impairment (vision or hearing), neurological disorder, lack of availability of education, lack of proficiency in the language of academic instruction, or psychosocial adversity. <i><b>Exclusions:</b></i> Disorders of intellectual development (6A00)

- 6A03.1      Developmental learning disorder with impairment in written expression**  
Developmental learning disorder with impairment in written expression is characterised by significant and persistent difficulties in learning academic skills related to writing, such as spelling accuracy, grammar and punctuation accuracy, and organisation and coherence of ideas in writing. The individual's performance in written expression is markedly below what would be expected for chronological age and level of intellectual functioning and results in significant impairment in the individual's academic or occupational functioning. Developmental learning disorder with impairment in written expression is not due to a disorder of intellectual development, sensory impairment (vision or hearing), a neurological or motor disorder, lack of availability of education, lack of proficiency in the language of academic instruction, or psychosocial adversity.
- Exclusions:**      Disorders of intellectual development (6A00)
- 6A03.2      Developmental learning disorder with impairment in mathematics**  
Developmental learning disorder with impairment in mathematics is characterised by significant and persistent difficulties in learning academic skills related to mathematics or arithmetic, such as number sense, memorization of number facts, accurate calculation, fluent calculation, and accurate mathematic reasoning. The individual's performance in mathematics or arithmetic is markedly below what would be expected for chronological or developmental age and level of intellectual functioning and results in significant impairment in the individual's academic or occupational functioning. Developmental learning disorder with impairment in mathematics is not due to a disorder of intellectual development, sensory impairment (vision or hearing), a neurological disorder, lack of availability of education, lack of proficiency in the language of academic instruction, or psychosocial adversity.
- Exclusions:**      Disorders of intellectual development (6A00)
- 6A03.3      Developmental learning disorder with other specified impairment of learning**  
Developmental learning disorder with other specified impairment of learning is characterised by significant and persistent difficulties in learning academic skills other than reading, mathematics, and written expression. The individual's performance in the relevant academic skill is markedly below what would be expected for chronological age and level of intellectual functioning and results in significant impairment in the individual's academic or occupational functioning. Developmental learning disorder with other specified impairment of learning is not due to a disorder of intellectual development, sensory impairment (vision or hearing), neurological disorder, lack of availability of education, lack of proficiency in the language of academic instruction, or psychosocial adversity.
- Exclusions:**      Disorders of intellectual development (6A00)
- 6A03.Z      Developmental learning disorder, unspecified**

**6A04****Developmental motor coordination disorder**

Developmental motor coordination disorder is characterised by a significant delay in the acquisition of gross and fine motor skills and impairment in the execution of coordinated motor skills that manifest in clumsiness, slowness, or inaccuracy of motor performance. Coordinated motor skills are markedly below that expected given the individual's chronological age and level of intellectual functioning. Onset of coordinated motor skills difficulties occurs during the developmental period and is typically apparent from early childhood. Coordinated motor skills difficulties cause significant and persistent limitations in functioning (e.g. in activities of daily living, school work, and vocational and leisure activities). Difficulties with coordinated motor skills are not solely attributable to a Disease of the Nervous System, Disease of the Musculoskeletal System or Connective Tissue, sensory impairment, and not better explained by a Disorder of Intellectual Development.

***Exclusions:***

Abnormalities of gait and mobility (MB44)

Diseases of the musculoskeletal system or connective tissue  
(Chapter 15)

Diseases of the nervous system (Chapter 08)

**6A05****Attention deficit hyperactivity disorder**

Attention deficit hyperactivity disorder is characterised by a persistent pattern (at least 6 months) of inattention and/or hyperactivity-impulsivity that has a direct negative impact on academic, occupational, or social functioning. There is evidence of significant inattention and/or hyperactivity-impulsivity symptoms prior to age 12, typically by early to mid-childhood, though some individuals may first come to clinical attention later. The degree of inattention and hyperactivity-impulsivity is outside the limits of normal variation expected for age and level of intellectual functioning. Inattention refers to significant difficulty in sustaining attention to tasks that do not provide a high level of stimulation or frequent rewards, distractibility and problems with organisation. Hyperactivity refers to excessive motor activity and difficulties with remaining still, most evident in structured situations that require behavioural self-control. Impulsivity is a tendency to act in response to immediate stimuli, without deliberation or consideration of the risks and consequences. The relative balance and the specific manifestations of inattentive and hyperactive-impulsive characteristics varies across individuals and may change over the course of development. In order for a diagnosis to be made, manifestations of inattention and/or hyperactivity-impulsivity must be evident across multiple situations or settings (e.g., home, school, work, with friends or relatives), but are likely to vary according to the structure and demands of the setting. Symptoms are not better accounted for by another mental, behavioural, or neurodevelopmental disorder and are not due to the effect of a substance or medication.

***Inclusions:***

attention deficit disorder with hyperactivity

attention deficit syndrome with hyperactivity

- 6A05.0** **Attention deficit hyperactivity disorder, predominantly inattentive presentation**  
All definitional requirements for attention deficit hyperactivity disorder are met and inattentive symptoms are predominant in the clinical presentation. Inattention refers to significant difficulty in sustaining attention to tasks that do not provide a high level of stimulation or frequent rewards, distractibility and problems with organisation. Some hyperactive-impulsive symptoms may also be present, but these are not clinically significant in relation to the inattentive symptoms.
- 6A05.1** **Attention deficit hyperactivity disorder, predominantly hyperactive-impulsive presentation**  
All definitional requirements for attention deficit hyperactivity disorder are met and hyperactive-impulsive symptoms are predominant in the clinical presentation. Hyperactivity refers to excessive motor activity and difficulties with remaining still, most evident in structured situations that require behavioural self-control. Impulsivity is a tendency to act in response to immediate stimuli, without deliberation or consideration of the risks and consequences. Some inattentive symptoms may also be present, but these are not clinically significant in relation to the hyperactive-impulsive symptoms.
- 6A05.2** **Attention deficit hyperactivity disorder, combined presentation**  
All definitional requirements for attention deficit hyperactivity disorder are met. Both inattentive and hyperactive-impulsive symptoms are clinically significant, with neither predominating in the clinical presentation. Inattention refers to significant difficulty in sustaining attention to tasks that do not provide a high level of stimulation or frequent rewards, distractibility and problems with organisation. Hyperactivity refers to excessive motor activity and difficulties with remaining still, most evident in structured situations that require behavioural self-control. Impulsivity is a tendency to act in response to immediate stimuli, without deliberation or consideration of the risks and consequences.
- 6A05.Y** **Attention deficit hyperactivity disorder, other specified presentation**
- 6A05.Z** **Attention deficit hyperactivity disorder, presentation unspecified**
- 6A06** **Stereotyped movement disorder**  
Stereotyped movement disorder is characterised by the persistent (e.g., lasting several months) presence of voluntary, repetitive, stereotyped, apparently purposeless (and often rhythmic) movements that arise during the early developmental period, are not caused by the direct physiological effects of a substance or medication (including withdrawal), and markedly interfere with normal activities or result in self-inflicted bodily injury. Stereotyped movements that are non-injurious can include body rocking, head rocking, finger-flicking mannerisms, and hand flapping. Stereotyped self-injurious behaviours can include repetitive head banging, face slapping, eye poking, and biting of the hands, lips, or other body parts.
- Exclusions:** Tic disorders (8A05)  
Trichotillomania (6B25.0)  
Abnormal involuntary movements (MB46)

**6A06.0      Stereotyped movement disorder without self-injury**

This category should be applied to forms of Stereotyped movement disorder in which stereotyped behaviours markedly interfere with normal activities, but do not result in self-inflicted bodily injury. Stereotyped movement disorder without self-injury is characterised by voluntary, repetitive, stereotyped, apparently purposeless (and often rhythmic) movements that arise during the early developmental period, are not caused by the direct physiological effects of a substance or medication (including withdrawal), and markedly interfere with normal activities. Stereotyped movements that are non-injurious can include body rocking, head rocking, finger-flicking mannerisms, and hand flapping.

**6A06.1      Stereotyped movement disorder with self-injury**

This category should be applied to forms of Stereotyped movement disorder in which stereotyped behaviours result in self-inflicted bodily injury that is significant enough to require medical treatment, or would result in such injury if protective measures (e.g., helmet to prevent head injury) were not employed. Stereotyped movement disorder with self-injury is characterised by voluntary, repetitive, stereotyped, apparently purposeless (and often rhythmic) movements that arise during the early developmental period, are not caused by the direct physiological effects of a substance or medication (including withdrawal). Stereotyped movements that are self-injurious can include head banging, face slapping, eye poking, and biting of the hands, lips, or other body parts.

**6A06.Z      Stereotyped movement disorder, unspecified**

**6A0Y      Other specified neurodevelopmental disorders**

**6A0Z      Neurodevelopmental disorders, unspecified**

## Schizophrenia or other primary psychotic disorders (6A20-6A2Z)

Schizophrenia and other primary psychotic disorders are characterised by significant impairments in reality testing and alterations in behaviour manifest in positive symptoms such as persistent delusions, persistent hallucinations, disorganised thinking (typically manifest as disorganized speech), grossly disorganized behaviour, and experiences of passivity and control, negative symptoms such as blunted or flat affect and avolition, and psychomotor disturbances. The symptoms occur with sufficient frequency and intensity to deviate from expected cultural or subcultural norms. These symptoms do not arise as a feature of another mental and behavioural disorder (e.g., a mood disorder, delirium, or a disorder due to substance use). The categories in this grouping should not be used to classify the expression of ideas, beliefs, or behaviours that are culturally sanctioned.

**Coded Elsewhere:** Substance-induced psychotic disorders

Secondary psychotic syndrome (6E61)

**6A20**

### Schizophrenia

Schizophrenia is characterised by disturbances in multiple mental modalities, including thinking (e.g., delusions, disorganisation in the form of thought), perception (e.g., hallucinations), self-experience (e.g., the experience that one's feelings, impulses, thoughts, or behaviour are under the control of an external force), cognition (e.g., impaired attention, verbal memory, and social cognition), volition (e.g., loss of motivation), affect (e.g., blunted emotional expression), and behaviour (e.g., behaviour that appears bizarre or purposeless, unpredictable or inappropriate emotional responses that interfere with the organisation of behaviour). Psychomotor disturbances, including catatonia, may be present. Persistent delusions, persistent hallucinations, thought disorder, and experiences of influence, passivity, or control are considered core symptoms. Symptoms must have persisted for at least one month in order for a diagnosis of schizophrenia to be assigned. The symptoms are not a manifestation of another health condition (e.g., a brain tumour) and are not due to the effect of a substance or medication on the central nervous system (e.g., corticosteroids), including withdrawal (e.g., alcohol withdrawal).

**Exclusions:** Schizotypal disorder (6A22)  
schizophrenic reaction (6A22)  
Acute and transient psychotic disorder (6A23)

**6A20.0**

### Schizophrenia, first episode

Schizophrenia, first episode should be used to identify individuals experiencing symptoms that meet the diagnostic requirements for Schizophrenia (including duration) but who have never before experienced an episode during which diagnostic requirements for Schizophrenia were met.

**6A20.00**

#### Schizophrenia, first episode, currently symptomatic

All definitional requirements for Schizophrenia, first episode in terms of symptoms and duration are currently met, or have been met within the past one month.

- 6A20.01** Schizophrenia, first episode, in partial remission  
All definitional requirements for Schizophrenia, first episode in terms of symptoms and duration were previously met. Symptoms have ameliorated such that the diagnostic requirements for the disorder have not been met for at least one month, but some clinically significant symptoms remain, which may or may not be associated with functional impairment. The partial remission may have occurred in response to medication or other treatment.
- 6A20.02** Schizophrenia, first episode, in full remission  
All definitional requirements for Schizophrenia, first episode in terms of symptoms and duration were previously met. Symptoms have ameliorated such that no significant symptoms remain. The remission may have occurred in response to medication or other treatment.
- 6A20.0Z** Schizophrenia, first episode, unspecified
- 6A20.1** **Schizophrenia, multiple episodes**  
Schizophrenia, multiple episodes should be used to identify individuals experiencing symptoms that meet the diagnostic requirements for Schizophrenia and who have also previously experienced episodes during which diagnostic requirements were met, with substantial remission of symptoms between episodes. Some attenuated symptoms may remain during periods of remission, and remissions may have occurred in response to medication or other treatment.
- 6A20.10** Schizophrenia, multiple episodes, currently symptomatic  
All definitional requirements for Schizophrenia, multiple episodes in terms of symptoms and duration are currently met, or have been met within the past one month.
- 6A20.11** Schizophrenia, multiple episodes, in partial remission  
All definitional requirements for Schizophrenia, multiple episodes in terms of symptoms and duration were previously met. Symptoms have ameliorated such that the diagnostic requirements for the disorder have not been met for at least one month, but some clinically significant symptoms remain, which may or may not be associated with functional impairment. The partial remission may have occurred in response to medication or other treatment.
- 6A20.12** Schizophrenia, multiple episodes, in full remission  
All definitional requirements for Schizophrenia, multiple episodes in terms of symptoms and duration were previously met. Symptoms have ameliorated such that no significant symptoms remain. The remission may have occurred in response to medication or other treatment.
- 6A20.1Z** Schizophrenia, multiple episodes, unspecified
- 6A20.2** **Schizophrenia, continuous**  
Symptoms fulfilling all definitional requirements of Schizophrenia have been present for almost all of the illness course over a period of at least one year, with periods of subthreshold symptoms being very brief relative to the overall course.

- 6A20.20** Schizophrenia, continuous, currently symptomatic  
All definitional requirements for Schizophrenia, continuous in terms of symptoms and duration are currently met, or have been met within the past one month.
- 6A20.21** Schizophrenia, continuous, in partial remission  
All definitional requirements for Schizophrenia, continuous in terms of symptoms and duration were previously met. Symptoms have ameliorated such that the diagnostic requirements for the disorder have not been met for at least one month, but some clinically significant symptoms remain, which may or may not be associated with functional impairment. The partial remission may have occurred in response to medication or other treatment.
- 6A20.22** Schizophrenia, continuous, in full remission  
All definitional requirements for Schizophrenia, continuous in terms of symptoms and duration were previously met. Symptoms have ameliorated such that no significant symptoms remain. The remission may have occurred in response to medication or other treatment.
- 6A20.2Z** Schizophrenia, continuous, unspecified
- 6A20.Y** Other specified episode of schizophrenia
- 6A20.Z** Schizophrenia, episode unspecified

## 6A21

### Schizoaffective disorder

Schizoaffective disorder is an episodic disorder in which the diagnostic requirements of schizophrenia and a manic, mixed, or moderate or severe depressive episode are met within the same episode of illness, either simultaneously or within a few days of each other. Prominent symptoms of schizophrenia (e.g. delusions, hallucinations, disorganisation in the form of thought, experiences of influence, passivity and control) are accompanied by typical symptoms of a moderate or severe depressive episode (e.g. depressed mood, loss of interest, reduced energy), a manic episode (e.g. an extreme mood state characterised by euphoria, irritability, or expansiveness; increased activity or a subjective experience of increased energy) or a mixed episode. Psychomotor disturbances, including catatonia, may be present. Symptoms must have persisted for at least one month. The symptoms are not a manifestation of another medical condition (e.g. a brain tumor) and are not due to the effect of a substance or medication on the central nervous system (e.g. corticosteroids), including withdrawal (e.g. alcohol withdrawal).

## 6A21.0

### Schizoaffective disorder, first episode

Schizoaffective disorder, first episode should be used to identify individuals experiencing symptoms that meet the diagnostic requirements for Schizoaffective disorder (including duration) but who have never before experienced an episode during which diagnostic requirements for Schizoaffective disorder or Schizophrenia were met.

- 6A21.00** Schizoaffective disorder, first episode, currently symptomatic  
All definitional requirements for Schizoaffective disorder, first episode in terms of symptoms and duration are currently met, or have been met within the past one month.
- 6A21.01** Schizoaffective disorder, first episode, in partial remission  
All definitional requirements for Schizoaffective disorder, first episode in terms of symptoms and duration were previously met. Symptoms have ameliorated such that the diagnostic requirements for the disorder have not been met for at least one month, but some clinically significant symptoms remain, which may or may not be associated with functional impairment. The partial remission may have occurred in response to medication or other treatment.
- 6A21.02** Schizoaffective disorder, first episode, in full remission  
All definitional requirements for Schizoaffective disorder, first episode in terms of symptoms and duration were previously met. Symptoms have ameliorated such that no significant symptoms remain. The remission may have occurred in response to medication or other treatment.
- 6A21.0Z** Schizoaffective disorder, first episode, unspecified
- 6A21.1** **Schizoaffective disorder, multiple episodes**  
Schizoaffective disorder, multiple episodes should be used to identify individuals experiencing symptoms that meet the diagnostic requirements for Schizoaffective disorder and who have also previously experienced episodes during which diagnostic requirements for Schizoaffective disorder or Schizophrenia were met, with substantial remission of symptoms between episodes. Some attenuated symptoms may remain during period of remission, and remissions may have occurred in response to medication or other treatment.
- 6A21.10** Schizoaffective disorder, multiple episodes, currently symptomatic  
All definitional requirements for Schizoaffective disorder, multiple episodes in terms of symptoms and duration are currently met, or have been met within the past one month.
- 6A21.11** Schizoaffective disorder, multiple episodes, in partial remission  
All definitional requirements for Schizoaffective disorder, multiple episodes in terms of symptoms and duration were previously met. Symptoms have ameliorated such that the diagnostic requirements for the disorder have not been met for at least one month, but some clinically significant symptoms remain, which may or may not be associated with functional impairment. The partial remission may have occurred in response to medication or other treatment.
- 6A21.12** Schizoaffective disorder, multiple episodes, in full remission  
All definitional requirements for Schizoaffective disorder, multiple episodes in terms of symptoms and duration were previously met. Symptoms have ameliorated such that no significant symptoms remain. The remission may have occurred in response to medication or other treatment.
- 6A21.1Z** Schizoaffective disorder, multiple episodes, unspecified

- 6A21.2** **Schizoaffective disorder, continuous**  
Symptoms fulfilling all definitional requirements of Schizoaffective disorder have been present for almost all of the illness course over a period of at least one year, with periods of subthreshold symptoms being very brief relative to the overall course.
- 6A21.20** Schizoaffective disorder, continuous, currently symptomatic  
All definitional requirements for Schizoaffective disorder, continuous in terms of symptoms and duration are currently met, or have been met within the past one month.
- 6A21.21** Schizoaffective disorder, continuous, in partial remission  
All definitional requirements for Schizoaffective disorder, continuous in terms of symptoms and duration were previously met. Symptoms have ameliorated such that the diagnostic requirements for the disorder have not been met for at least one month, but some clinically significant symptoms remain, which may or may not be associated with functional impairment. The partial remission may have occurred in response to medication or other treatment.
- 6A21.22** Schizoaffective disorder, continuous, in full remission  
All definitional requirements for Schizoaffective disorder, continuous in terms of symptoms and duration were previously met. Symptoms have ameliorated such that no significant symptoms remain. The remission may have occurred in response to medication or other treatment.
- 6A21.2Z** Schizoaffective disorder, continuous, unspecified
- 6A21.Y** Other specified schizoaffective disorder
- 6A21.Z** Schizoaffective disorder, unspecified
- 6A22** **Schizotypal disorder**  
Schizotypal disorder is characterised by an enduring pattern (i.e. characteristic of the person's functioning over a period of at least several years) of eccentricities in behaviour, appearance and speech, accompanied by cognitive and perceptual distortions, unusual beliefs, and discomfort with—and often reduced capacity for—interpersonal relationships. Symptoms may include constricted or inappropriate affect and anhedonia. Paranoid ideas, ideas of reference, or other psychotic symptoms, including hallucinations in any modality, may occur, but are not of sufficient intensity or duration to meet the diagnostic requirements of schizophrenia, schizoaffective disorder, or delusional disorder. The symptoms cause distress or impairment in personal, family, social, educational, occupational or other important areas of functioning.
- Inclusions:** Schizotypal personality disorder
- Exclusions:** Autism spectrum disorder (6A02)  
Personality disorder (6D10)

**6A23**

**Acute and transient psychotic disorder**

Acute and transient psychotic disorder is characterised by acute onset of psychotic symptoms that emerge without a prodrome and reach their maximal severity within two weeks. Symptoms may include delusions, hallucinations, disorganisation of thought processes, perplexity or confusion, and disturbances of affect and mood. Catatonia-like psychomotor disturbances may be present. Symptoms typically change rapidly, both in nature and intensity, from day to day, or even within a single day. The duration of the episode does not exceed 3 months, and most commonly lasts from a few days to 1 month. The symptoms are not a manifestation of another medical condition (e.g. a brain tumour) and are not due to the effect of a substance or medication on the central nervous system (e.g. corticosteroids), including withdrawal (e.g. alcohol withdrawal).

**6A23.0**

**Acute and transient psychotic disorder, first episode**

Acute and transient psychotic disorder, first episode should be used to identify individuals experiencing symptoms that meet the diagnostic requirements for acute and transient psychotic disorder but who have never before experienced a similar episode.

**6A23.00**

Acute and transient psychotic disorder, first episode, currently symptomatic

All definitional requirements for Acute and transient psychotic disorder, first episode in terms of symptoms and duration are currently met, or have been met within the past one month.

**6A23.01**

Acute and transient psychotic disorder, first episode, in partial remission

All definitional requirements for Acute and transient psychotic disorder, first episode in terms of symptoms and duration were previously met. Symptoms have ameliorated such that the diagnostic requirements for the disorder have not been met for at least one month, but some clinically significant symptoms remain, which may or may not be associated with functional impairment. The partial remission may have occurred in response to medication or other treatment.

**6A23.02**

Acute and transient psychotic disorder, first episode, in full remission

All definitional requirements for Acute and transient psychotic disorder, first episode in terms of symptoms and duration were previously met. Symptoms have ameliorated such that no significant symptoms remain. The remission may have occurred in response to medication or other treatment.

**6A23.0Z**

Acute and transient psychotic disorder, first episode, unspecified

**6A23.1**

**Acute and transient psychotic disorder, multiple episodes**

Acute and transient psychotic disorder, multiple episodes should be used to identify individuals experiencing symptoms that meet the diagnostic requirements for acute and transient psychotic disorder and who have experienced similar episodes in the past.

**6A23.10**

Acute and transient psychotic disorder, multiple episodes, currently symptomatic

All definitional requirements for Acute and transient psychotic disorder, multiple episodes in terms of symptoms and duration are currently met, or have been met within the past one month.

- 6A23.11** Acute and transient psychotic disorder, multiple episodes, in partial remission  
All definitional requirements for Acute and transient psychotic disorder, multiple episodes in terms of symptoms and duration were previously met. Symptoms have ameliorated such that the diagnostic requirements for the disorder have not been met for at least one month, but some clinically significant symptoms remain, which may or may not be associated with functional impairment. The partial remission may have occurred in response to medication or other treatment.
- 6A23.12** Acute and transient psychotic disorder, multiple episodes, in full remission  
All definitional requirements for Acute and transient psychotic disorder, multiple episodes in terms of symptoms and duration were previously met. Symptoms have ameliorated such that no significant symptoms remain. The remission may have occurred in response to medication or other treatment.
- 6A23.1Z** Acute and transient psychotic disorder, multiple episodes, unspecified
- 6A23.Y** **Other specified acute and transient psychotic disorder**
- 6A23.Z** **Acute and transient psychotic disorder, unspecified**
- 6A24**
- Delusional disorder**
- Delusional disorder is characterised by the development of a delusion or set of related delusions, typically persisting for at least 3 months and often much longer, in the absence of a Depressive, Manic, or Mixed mood episode. The delusions are variable in content across individuals, but typically stable within individuals, although they may evolve over time. Other characteristic symptoms of Schizophrenia (i.e. clear and persistent hallucinations, negative symptoms, disorganized thinking, or experiences of influence, passivity, or control) are not present, although various forms of perceptual disturbances (e.g. hallucinations, illusions, misidentifications of persons) thematically related to the delusion are still consistent with the diagnosis. Apart from actions and attitudes directly related to the delusion or delusional system, affect, speech, and behavior are typically unaffected. The symptoms are not a manifestation of another medical condition (e.g., a brain tumour) and are not due to the effect of a substance or medication on the central nervous system (e.g. corticosteroids), including withdrawal effects (e.g. alcohol withdrawal).
- 6A24.0** **Delusional disorder, currently symptomatic**  
All definitional requirements for Delusional disorder in terms of symptoms and duration are currently met, or have been met within the past one month.
- 6A24.1** **Delusional disorder, in partial remission**  
All definitional requirements for Delusional disorder in terms of symptoms and duration were previously met. Symptoms have ameliorated such that the diagnostic requirements for the disorder have not been met for at least one month, but some clinically significant symptoms remain, which may or may not be associated with functional impairment. The partial remission may have occurred in response to medication or other treatment.

<b>6A24.2</b>	<b>Delusional disorder, in full remission</b> All definitional requirements for Delusional disorder in terms of symptoms and duration were previously met. Symptoms have ameliorated such that no significant symptoms remain. The remission may have occurred in response to medication or other treatment.
<b>6A24.Z</b>	<b>Delusional disorder, unspecified</b>
<b>6A25</b>	<p><b>Symptomatic manifestations of primary psychotic disorders</b></p> <p>These categories may be used to characterize the current clinical presentation in individuals diagnosed with Schizophrenia or another primary psychotic disorder, and should not be used in individuals without such a diagnosis. Multiple categories may be applied. Symptoms attributable to the direct pathophysiological consequences of a health condition or injury not classified under Mental, behavioural or neurodevelopmental disorders (e.g., a brain tumour or traumatic brain injury), or to the direct effects of a substance or medication on the central nervous system, including withdrawal effects, should not be considered as examples of the respective types of symptoms.</p> <p><b>Coding Note:</b> These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of these symptoms in primary psychotic disorders.</p>
<b>6A25.0</b>	<p><b>Positive symptoms in primary psychotic disorders</b></p> <p>Positive symptoms in primary psychotic disorders include persistent delusions, persistent hallucinations (most commonly verbal auditory hallucinations), disorganized thinking (formal thought disorder such as loose associations, thought derailment, or incoherence), grossly disorganized behaviour (behaviour that appears bizarre, purposeless and not goal-directed) and experiences of passivity and control (the experience that one's feelings, impulses, or thoughts are under the control of an external force). The rating should be made based on the severity of positive symptoms during the past week.</p> <p><b>Coding Note:</b> These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of these symptoms in primary psychotic disorders.</p>
<b>6A25.1</b>	<p><b>Negative symptoms in primary psychotic disorders</b></p> <p>Negative symptoms in primary psychotic disorders include constricted, blunted, or flat affect, alogia or paucity of speech, avolition (general lack of drive, or lack of motivation to pursue meaningful goals), asociality (reduced or absent engagement with others and interest in social interaction) and anhedonia (inability to experience pleasure from normally pleasurable activities). To be considered negative psychotic symptoms, relevant symptoms should not be entirely attributable to antipsychotic drug treatment, a depressive disorder, or an under-stimulating environment, and should not be a direct consequence of a positive symptom (e.g., persecutory delusions causing a person to become socially isolated due to fear of harm). The rating should be made based on the severity of negative symptoms during the past week.</p> <p><b>Coding Note:</b> These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of these symptoms in primary psychotic disorders.</p>

- 6A25.2 Depressive mood symptoms in primary psychotic disorders**  
Depressive mood symptoms in primary psychotic disorders refer to depressed mood as reported by the individual (feeling down, sad) or manifested as a sign (e.g. tearful, defeated appearance). If only non-mood symptoms of a depressive episode are present (e.g., anhedonia, psychomotor slowing), this descriptor should not be used. This descriptor may be used whether or not depressive symptoms meet the diagnostic requirements of a separately diagnosed Depressive disorder. The rating should be made based on the severity of depressive mood symptoms during the past week.
- Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of these symptoms in primary psychotic disorders.
- 6A25.3 Manic mood symptoms in primary psychotic disorders**  
Manic mood symptoms in primary psychotic disorders refer to elevated, euphoric, irritable, or expansive mood states, including rapid changes among different mood states (i.e., mood lability). It also includes increased subjective experience of energy, which may be accompanied by increased goal-directed activity. The severity of associated non-mood symptoms of a Manic or Hypomanic Episode (e.g., decreased need for sleep, distractibility) should not be considered in making a rating. Increased non-goal-directed psychomotor activity should be considered as part of the rating of the 'psychomotor symptoms in primary psychotic disorders' rather than here. This descriptor may be used whether or not the manic symptoms meet the diagnostic requirements of a separately diagnosed bipolar disorder. The rating should be made based on the severity of manic mood symptoms during the past week.
- Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of these symptoms in primary psychotic disorders.
- 6A25.4 Psychomotor symptoms in primary psychotic disorders**  
Psychomotor symptoms in primary psychotic disorders include psychomotor agitation or excessive motor activity, usually manifested by purposeless behaviours such as fidgeting, shifting, fiddling, inability to sit or stand still, wringing of the hands, psychomotor retardation, or a visible generalised slowing of movements and speech, and catatonic symptoms such as excitement, posturing, waxy flexibility, negativism, mutism, or stupor. The rating should be made based on the severity of psychomotor symptoms during the past week.
- Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of these symptoms in primary psychotic disorders.

**6A25.5 Cognitive symptoms in primary psychotic disorders**

Cognitive symptoms in primary psychotic disorders refer to cognitive impairment in any of the following domains: speed of processing, attention/concentration, orientation, judgment, abstraction, verbal or visual learning, and working memory. The cognitive impairment is not attributable to a neurodevelopmental disorder, a delirium or other neurocognitive disorder, or the direct effects of a substance or medication on the central nervous system, including withdrawal effects. Ideally, use of this category should be based on the results of locally validated, standardized neuropsychological assessments, although such measures may not be available in all settings. The rating should be made based on the severity of cognitive symptoms during the past week.

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of these symptoms in primary psychotic disorders.

**Exclusions:**      Neurocognitive disorders (6D70-6E0Z)  
                        Neurodevelopmental disorders (6A00-6A0Z)

**6A2Y Other specified primary psychotic disorder**

**6A2Z Schizophrenia or other primary psychotic disorders, unspecified**

### Catatonia (6A40-6A4Z)

Catatonia is a syndrome of primarily psychomotor disturbances, characterized by the co-occurrence of several symptoms of decreased, increased, or abnormal psychomotor activity. The assessment of catatonia is complex and requires observation, interview and physical exam. Catatonia can occur in the context of another mental disorder, such as Schizophrenia or Other Primary Psychotic Disorders, Mood Disorders, and Neurodevelopmental Disorders, especially Autism Spectrum Disorder. Catatonia can also develop during or soon after intoxication or withdrawal from certain psychoactive substances, including phencyclidine (PCP), cannabis, hallucinogens such as mescaline or LSD, cocaine and MDMA or related drugs, or during the use of certain psychoactive and non-psychoactive medications (e.g. antipsychotic medications, benzodiazepines, steroids, disulfiram, ciprofloxacin). Finally, Catatonia can occur as a direct pathophysiological consequence of a medical condition not classified under Mental, Behavioural or Neurodevelopmental Disorders. Examples of medical conditions that may be associated with Catatonia include diabetic ketoacidosis, hypercalcemia, hepatic encephalopathy, homocystinuria, neoplasms head trauma, cerebrovascular disease, and encephalitis.

**Exclusions:**      Harmful effects of drugs, medicaments or biological substances, not elsewhere classified (NE60)

**Coded Elsewhere:** Secondary catatonia syndrome (6E69)

**6A40 Catatonia associated with another mental disorder**

Catatonia associated with another mental disorder is a syndrome of primarily psychomotor disturbances, characterized by the co-occurrence of several symptoms of decreased, increased, or abnormal psychomotor activity, which occurs in the context of another mental disorder, such as Schizophrenia or Other Primary Psychotic Disorders, Mood Disorders, and Neurodevelopmental Disorders, especially Autism Spectrum Disorder.

**6A41**

**Catatonia induced by substances or medications**

Catatonia induced by substances or medications is a syndrome of primarily psychomotor disturbances, characterized by the co-occurrence of several symptoms of decreased, increased, or abnormal psychomotor activity, which develops during or soon after intoxication or withdrawal from certain psychoactive substances, including phencyclidine (PCP), cannabis, hallucinogens such as mescaline or LSD, cocaine and MDMA or related drugs, or during the use of certain psychoactive and non-psychoactive medications (e.g. antipsychotic medications, benzodiazepines, steroids, disulfiram, ciprofloxacin).

**Exclusions:** Neuroleptic malignant syndrome (8A00-8A0Z)

Serotonin syndrome (8D85)

**6A4Z**

**Catatonia, unspecified**

**Coding Note:** Code also the causing condition

## Mood disorders (6A60-6A8Z)

Mood Disorders refers to a superordinate grouping of Bipolar and Depressive Disorders. Mood disorders are defined according to particular types of mood episodes and their pattern over time. The primary types of mood episodes are Depressive episode, Manic episode, Mixed episode, and Hypomanic episode. Mood episodes are not independently diagnosable entities, and therefore do not have their own diagnostic codes. Rather, mood episodes make up the primary components of most of the Depressive and Bipolar Disorders.

**Coded Elsewhere:** Substance-induced mood disorders  
Secondary mood syndrome (6E62)

## Bipolar or related disorders (6A60-6A6Z)

Bipolar and related disorders are episodic mood disorders defined by the occurrence of Manic, Mixed or Hypomanic episodes or symptoms. These episodes typically alternate over the course of these disorders with Depressive episodes or periods of depressive symptoms.

**6A60**

### **Bipolar type I disorder**

Bipolar type I disorder is an episodic mood disorder defined by the occurrence of one or more manic or mixed episodes. A manic episode is an extreme mood state lasting at least one week unless shortened by a treatment intervention characterised by euphoria, irritability, or expansiveness, and by increased activity or a subjective experience of increased energy, accompanied by other characteristic symptoms such as rapid or pressured speech, flight of ideas, increased self-esteem or grandiosity, decreased need for sleep, distractibility, impulsive or reckless behaviour, and rapid changes among different mood states (i.e., mood lability). A mixed episode is characterised by the presence of several prominent manic and several prominent depressive symptoms consistent with those observed in manic episodes and depressive episodes, which either occur simultaneously or alternate very rapidly (from day to day or within the same day). Symptoms must include an altered mood state consistent with a manic and/or depressive episode (i.e., depressed, dysphoric, euphoric or expansive mood), and be present most of the day, nearly every day, during a period of at least 2 weeks, unless shortened by a treatment intervention. Although the diagnosis can be made based on evidence of a single manic or mixed episode, typically manic or mixed episodes alternate with depressive episodes over the course of the disorder.

**Exclusions:** Cyclothymia (6A62)  
Bipolar type II disorder (6A61)

**6A60.0**

**Bipolar type I disorder, current episode manic, without psychotic symptoms**

Bipolar type I disorder, current episode manic, without psychotic symptoms is diagnosed when the definitional requirements for Bipolar type I disorder are met, the current episode is manic, and there are no delusions or hallucinations present during the episode. A manic episode is an extreme mood state lasting at least one week unless shortened by a treatment intervention characterised by euphoria, irritability, or expansiveness, and by increased activity or a subjective experience of increased energy, accompanied by other characteristic symptoms such as rapid or pressured speech, flight of ideas, increased self-esteem or grandiosity, decreased need for sleep, distractibility, impulsive or reckless behaviour, and rapid changes among different mood states (i.e., mood lability). If the individual has experienced Manic or Mixed Episodes in the past, a duration of one week is not required in order to diagnose a current episode if all other diagnostic requirements are met.

**6A60.1**

**Bipolar type I disorder, current episode manic, with psychotic symptoms**

Bipolar type I disorder, current episode manic with psychotic symptoms is diagnosed when the definitional requirements for Bipolar type I Disorder have been met, the current episode is Manic and there are delusions or hallucinations present during the episode. A manic episode is an extreme mood state lasting at least one week unless shortened by a treatment intervention characterised by euphoria, irritability, or expansiveness, and by increased activity or a subjective experience of increased energy, accompanied by other characteristic symptoms such as rapid or pressured speech, flight of ideas, increased self-esteem or grandiosity, decreased need for sleep, distractibility, impulsive or reckless behaviour, and rapid changes among different mood states (i.e., mood lability). If the individual has experienced Manic or Mixed Episodes in the past, a duration of one week is not required in order to diagnose a current episode if all other diagnostic requirements are met.

**6A60.2**

**Bipolar type I disorder, current episode hypomanic**

Bipolar type I disorder, current episode hypomanic is diagnosed when the definitional requirements for Bipolar type I disorder have been met and the current episode is hypomanic. A hypomanic episode is a persistent mood state lasting at least several days characterised by mild elevation of mood or increased irritability and increased activity or a subjective experience of increased energy, accompanied by other characteristic symptoms such as rapid speech, rapid or racing thoughts, increased self-esteem, an increase in sexual drive or sociability, decreased need for sleep, distractibility, or impulsive or reckless behaviour. The symptoms are not severe enough to cause marked impairment in occupational functioning or in usual social activities or relationships with others, does not necessitate hospitalization, and there are no accompanying delusions or hallucinations.

**6A60.3**

**Bipolar type I disorder, current episode depressive, mild**

Bipolar type I disorder, current episode depressive, mild is diagnosed when the definitional requirements for Bipolar type I disorder have been met and the current episode is depressive at a mild level of severity. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a mild depressive episode, the individual is usually distressed by the symptoms and has some difficulty in continuing to function in one or more domains (personal, family, social, educational, occupational, or other important domains). There are no delusions or hallucinations during the episode.

**6A60.4**

**Bipolar type I disorder, current episode depressive, moderate without psychotic symptoms**

Bipolar type I disorder, current episode depressive, moderate, without psychotic symptoms is diagnosed when the definitional requirements for Bipolar type I disorder have been met and the current episode is depressive at a moderate level of severity and there are no delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a moderate depressive episode, several symptoms of a depressive episode are present to a marked degree, or a large number of depressive symptoms of lesser severity are present overall. The individual typically has considerable difficulty functioning in multiple domains (personal, family, social, educational, occupational, or other important domains).

**6A60.5**

**Bipolar type I disorder, current episode depressive, moderate with psychotic symptoms**

Bipolar type I disorder, current episode depressive, moderate, with psychotic symptoms diagnosed when the definitional requirements for Bipolar type I disorder have been met and the current episode is depressive at a moderate level of severity and there are delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a moderate depressive episode, several symptoms of a depressive episode are present to a marked degree, or a large number of depressive symptoms of lesser severity are present overall. The individual typically has considerable difficulty functioning in multiple domains (personal, family, social, educational, occupational, or other important domains).

**6A60.6**

**Bipolar type I disorder, current episode depressive, severe without psychotic symptoms**

Bipolar type I disorder, current episode depressive, severe, without psychotic symptoms is diagnosed when the definitional requirements for Bipolar type I disorder are met and the current episode is severe and there are no delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a severe depressive episode, many or most symptoms of a Depressive Episode are present to a marked degree, or a smaller number of symptoms are present and manifest to an intense degree. The individual has serious difficulty continuing to function in most domains (personal, family, social, educational, occupational, or other important domains).

**6A60.7**

**Bipolar type I disorder, current episode depressive, severe with psychotic symptoms**

Bipolar type I disorder, current episode depressive, severe, with psychotic symptoms is diagnosed when the definitional requirements for Bipolar type I disorder are met and the current episode is severe and there are delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a severe depressive episode, many or most symptoms of a Depressive Episode are present to a marked degree, or a smaller number of symptoms are present and manifest to an intense degree. The individual has serious difficulty continuing to function in most domains (personal, family, social, educational, occupational, or other important domains).

**6A60.8**

**Bipolar type I disorder, current episode depressive, unspecified severity**

Bipolar type I disorder, current episode depressive, unspecified severity is diagnosed when the definitional requirements for Bipolar type I disorder have been met and the current episode is depressive, but there is insufficient information to determine the severity of the current depressive episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. The symptoms are associated with at least some difficulty in continuing with ordinary work, social, or domestic activities.

- 6A60.9 Bipolar type I disorder, current episode mixed, without psychotic symptoms**  
Bipolar type I disorder, current episode mixed, without psychotic symptoms is diagnosed when the definitional requirements for Bipolar type I disorder are met and the current episode is mixed and there are no delusions or hallucinations present during the episode. A mixed episode is characterised by the presence of several prominent manic and several prominent depressive symptoms consistent with those observed in manic episodes and depressive episodes, which either occur simultaneously or alternate very rapidly (from day to day or within the same day). Symptoms must include an altered mood state consistent with a manic and/or depressive episode (i.e., depressed, dysphoric, euphoric or expansive mood), and be present most of the day, nearly every day, during a period of at least 2 weeks, unless shortened by a treatment intervention. If the individual has experienced Manic or Mixed Episodes in the past, a duration of 2 weeks is not required in order to diagnose a current episode if all other diagnostic requirements are met.
- 6A60.A Bipolar type I disorder, current episode mixed, with psychotic symptoms**  
Bipolar type I disorder, current episode mixed, with psychotic symptoms is diagnosed when the definitional requirements for Bipolar type I disorder are met and the current episode is mixed and there are delusions or hallucinations present during the episode. A mixed episode is characterised by the presence of several prominent manic and several prominent depressive symptoms consistent with those observed in manic episodes and depressive episodes, which either occur simultaneously or alternate very rapidly (from day to day or within the same day). Symptoms must include an altered mood state consistent with a manic and/or depressive episode (i.e., depressed, dysphoric, euphoric or expansive mood), and be present most of the day, nearly every day, during a period of at least 2 weeks, unless shortened by a treatment intervention. If the individual has experienced Manic or Mixed Episodes in the past, a duration of 2 weeks is not required in order to diagnose a current episode if all other diagnostic requirements are met.
- 6A60.B Bipolar type I disorder, currently in partial remission, most recent episode manic or hypomanic**  
Bipolar type I disorder, currently in partial remission, most recent episode manic or hypomanic is diagnosed when the definitional requirements for Bipolar type I disorder have been met and the most recent episode was a manic or hypomanic episode. The full definitional requirements for a manic or hypomanic episode are no longer met but some significant mood symptoms remain. In some cases, residual mood symptoms may be depressive rather than manic or hypomanic, but do not satisfy the definitional requirements for a depressive episode.
- 6A60.C Bipolar type I disorder, currently in partial remission, most recent episode depressive**  
Bipolar type I disorder, currently in partial remission, most recent episode depressive is diagnosed when the definitional requirements for Bipolar type I disorder have been met and the most recent episode was a depressive episode. The full definitional requirements for the episode are no longer met but some significant depressive symptoms remain.

- 6A60.D** **Bipolar type I disorder, currently in partial remission, most recent episode mixed**  
Bipolar type I disorder, currently in partial remission, most recent episode mixed is diagnosed when the definitional requirements for Bipolar type I disorder have been met and the most recent episode was a mixed episode. The full definitional requirements for the episode are no longer met but some significant mood symptoms remain.
- 6A60.E** **Bipolar type I disorder, currently in partial remission, most recent episode unspecified**  
Bipolar type I disorder, currently in partial remission, most recent episode unspecified is diagnosed when the definitional requirements for Bipolar type I disorder have been met but there is insufficient information to determine the nature of the most recent mood episode. The full definitional requirements for a mood episode are no longer met but some significant mood symptoms remain.
- 6A60.F** **Bipolar type I disorder, currently in full remission**  
Bipolar type I disorder, currently in full remission is diagnosed when the full definitional requirements for Bipolar I disorder have been met in the past but there are no longer any significant mood symptoms.
- 6A60.Y** **Other specified bipolar type I disorder**
- 6A60.Z** **Bipolar type I disorder, unspecified**
- 6A61** **Bipolar type II disorder**  
Bipolar type II disorder is an episodic mood disorder defined by the occurrence of one or more hypomanic episodes and at least one depressive episode. A hypomanic episode is a persistent mood state lasting for at least several days characterised by persistent elevation of mood or increased irritability as well as increased activity or a subjective experience of increased energy, accompanied by other characteristic symptoms such as increased talkativeness, rapid or racing thoughts, increased self-esteem, decreased need for sleep, distractability, and impulsive or reckless behavior. The symptoms represent a change from the individual's typical mood, energy level, and behavior but are not severe enough to cause marked impairment in functioning. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as changes in appetite or sleep, psychomotor agitation or retardation, fatigue, feelings of worthless or excessive or inappropriate guilt, feelings or hopelessness, difficulty concentrating, and suicidality. There is no history of manic or mixed episodes.

**6A61.0**

**Bipolar type II disorder, current episode hypomanic**

Bipolar type II disorder, current episode hypomanic is diagnosed when the definitional requirements for Bipolar type II disorder have been met and the current episode is hypomanic. A hypomanic episode is a persistent mood state lasting at least several days characterised by mild elevation of mood or increased irritability and increased activity or a subjective experience of increased energy, accompanied by other characteristic symptoms such as rapid speech, rapid or racing thoughts, increased self-esteem, an increase in sexual drive or sociability, decreased need for sleep, distractibility, or impulsive or reckless behaviour. The symptoms are not severe enough to cause marked impairment in occupational functioning or in usual social activities or relationships with others, does not necessitate hospitalization, and there are no accompanying delusions or hallucinations.

**6A61.1**

**Bipolar type II disorder, current episode depressive, mild**

Bipolar type II disorder, current episode depressive, mild is diagnosed when the definitional requirements for Bipolar type II disorder have been met and the current episode is depressive at a mild level of severity. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a mild depressive episode, the individual is usually distressed by the symptoms and has some difficulty in continuing to function in one or more domains (personal, family, social, educational, occupational, or other important domains). There are no delusions or hallucinations during the episode.

**6A61.2**

**Bipolar type II disorder, current episode depressive, moderate without psychotic symptoms**

Bipolar type II disorder, current episode depressive, moderate, without psychotic symptoms is diagnosed when the definitional requirements for Bipolar type II disorder have been met and the current episode is depressive at a moderate level of severity and there are no delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a moderate depressive episode, several symptoms of a depressive episode are present to a marked degree, or a large number of depressive symptoms of lesser severity are present overall. The individual typically has considerable difficulty functioning in multiple domains (personal, family, social, educational, occupational, or other important domains).

- 6A61.3 Bipolar type II disorder, current episode depressive, moderate with psychotic symptoms**
- Bipolar type II disorder, current episode depressive, moderate, with psychotic symptoms diagnosed when the definitional requirements for Bipolar type II disorder have been met and the current episode is depressive at a moderate level of severity and there are delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a moderate depressive episode, several symptoms of a depressive episode are present to a marked degree, or a large number of depressive symptoms of lesser severity are present overall. The individual typically has considerable difficulty functioning in multiple domains (personal, family, social, educational, occupational, or other important domains).
- 6A61.4 Bipolar type II disorder, current episode depressive, severe without psychotic symptoms**
- Bipolar type II disorder, current episode depressive, severe, without psychotic symptoms is diagnosed when the definitional requirements for Bipolar type II disorder are met and the current episode is severe and there are no delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a severe depressive episode, many or most symptoms of a Depressive Episode are present to a marked degree, or a smaller number of symptoms are present and manifest to an intense degree. The individual has serious difficulty continuing to function in most domains (personal, family, social, educational, occupational, or other important domains).
- 6A61.5 Bipolar type II disorder, current episode depressive, severe with psychotic symptoms**
- Bipolar type II disorder, current episode depressive, severe, with psychotic symptoms is diagnosed when the definitional requirements for Bipolar type II disorder are met and the current episode is severe and there are delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a severe depressive episode, many or most symptoms of a Depressive Episode are present to a marked degree, or a smaller number of symptoms are present and manifest to an intense degree. The individual has serious difficulty continuing to function in most domains (personal, family, social, educational, occupational, or other important domains).

- 6A61.6 Bipolar type II disorder, current episode depressive, unspecified severity**  
Bipolar type II disorder, current episode depressive, unspecified severity is diagnosed when the definitional requirements for Bipolar type II disorder have been met and the current episode is depressive, but there is insufficient information to determine the severity of the current depressive episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. The symptoms are associated with at least some difficulty in continuing with ordinary work, social, or domestic activities.
- 6A61.7 Bipolar type II disorder, currently in partial remission, most recent episode hypomanic**  
Bipolar type II disorder, currently in partial remission, most recent episode hypomanic is diagnosed when the definitional requirements for Bipolar type II disorder have been met and the most recent episode was a hypomanic episode. The full definitional requirements for a hypomanic episode are no longer met but some significant mood symptoms remain. In some cases, residual mood symptoms may be depressive rather than hypomanic, but do not satisfy the definitional requirements for a depressive episode.
- 6A61.8 Bipolar type II disorder, currently in partial remission, most recent episode depressive**  
Bipolar type II disorder, currently in partial remission, most recent episode depressive is diagnosed when the definitional requirements for Bipolar type II disorder have been met and the most recent episode was a depressive episode. The full definitional requirements for the episode are no longer met but some significant depressive symptoms remain.
- 6A61.9 Bipolar type II disorder, currently in partial remission, most recent episode unspecified**  
Bipolar type II disorder, currently in partial remission, most recent episode unspecified is diagnosed when the definitional requirements for Bipolar type II disorder have been met but there is insufficient information to determine the nature of the most recent mood episode. The full definitional requirements for a mood episode are no longer met but some significant mood symptoms remain.
- 6A61.A Bipolar type II disorder, currently in full remission**  
Bipolar type II disorder, currently in full remission, is diagnosed when the definitional requirements for Bipolar type II disorder have been met but there are no longer any significant mood symptoms.
- 6A61.Y Other specified bipolar type II disorder**
- 6A61.Z Bipolar type II disorder, unspecified**

**6A62**

### **Cyclothymic disorder**

Cyclothymic disorder is characterised by a persistent instability of mood over a period of at least 2 years, involving numerous periods of hypomanic (e.g., euphoria, irritability, or expansiveness, psychomotor activation) and depressive (e.g., feeling down, diminished interest in activities, fatigue) symptoms that are present during more of the time than not. The hypomanic symptomatology may or may not be sufficiently severe or prolonged to meet the full definitional requirements of a hypomanic episode (see Bipolar type II disorder), but there is no history of manic or mixed episodes (see Bipolar type I disorder). The depressive symptomatology has never been sufficiently severe or prolonged to meet the diagnostic requirements for a depressive episode (see Bipolar type II disorder). The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**Inclusions:**      Cycloid personality  
                         Cyclothymic personality

**6A6Y**

### **Other specified bipolar or related disorders**

**6A6Z**

### **Bipolar or related disorders, unspecified**

Depressive disorders (6A70-6A7Z)

Depressive disorders are characterised by depressive mood (e.g., sad, irritable, empty) or loss of pleasure accompanied by other cognitive, behavioural, or neurovegetative symptoms that significantly affect the individual's ability to function. A depressive disorder should not be diagnosed in individuals who have ever experienced a manic, mixed or hypomanic episode, which would indicate the presence of a bipolar disorder.

**Coded Elsewhere:** Premenstrual dysphoric disorder (GA34.41)

**6A70**

### **Single episode depressive disorder**

Single episode depressive disorder is characterised by the presence or history of one depressive episode when there is no history of prior depressive episodes. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. There have never been any prior manic, hypomanic, or mixed episodes, which would indicate the presence of a bipolar disorder.

**Exclusions:**      recurrent depressive disorder (6A71)  
                         Adjustment disorder (6B43)  
                         Bipolar or related disorders (6A60-6A6Z)

**6A70.0**

**Single episode depressive disorder, mild**

Single episode depressive disorder, mild, is diagnosed when the definitional requirements of a Depressive episode are met and the episode is of mild severity. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a mild depressive episode, the individual is usually distressed by the symptoms and has some difficulty in continuing to function in one or more domains (personal, family, social, educational, occupational, or other important domains). There are no delusions or hallucinations during the episode.

**6A70.1**

**Single episode depressive disorder, moderate, without psychotic symptoms**

Single episode depressive disorder, moderate, without psychotic symptoms is diagnosed when the definitional requirements of a depressive episode have been met, there is no history of prior depressive episodes, the episode is of moderate severity, and there are no delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a moderate depressive episode, several symptoms of a depressive episode are present to a marked degree, or a large number of depressive symptoms of lesser severity are present overall. The individual typically has considerable difficulty functioning in multiple domains (personal, family, social, educational, occupational, or other important domains).

**6A70.2**

**Single episode depressive disorder, moderate, with psychotic symptoms**

Single episode depressive disorder, moderate, with psychotic symptoms is diagnosed when the definitional requirements of a depressive episode have been met, there is no history of prior depressive episodes, the episode is of moderate severity, and there are delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a moderate depressive episode, several symptoms of a depressive episode are present to a marked degree, or a large number of depressive symptoms of lesser severity are present overall. The individual typically has considerable difficulty functioning in multiple domains (personal, family, social, educational, occupational, or other important domains).

**6A70.3**

**Single episode depressive disorder, severe, without psychotic symptoms**

Single episode depressive disorder, severe, without psychotic symptoms is diagnosed when the definitional requirements for Single episode depressive disorder are met and the current episode is severe and there are no delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a severe depressive episode, many or most symptoms of a Depressive Episode are present to a marked degree, or a smaller number of symptoms are present and manifest to an intense degree. The individual has serious difficulty continuing to function in most domains (personal, family, social, educational, occupational, or other important domains).

**Inclusions:**      Major depression single episode without psychotic symptoms  
                          Vital depression single episode without psychotic symptoms

**6A70.4**

**Single episode depressive disorder, severe, with psychotic symptoms**

Single episode depressive disorder, severe, with psychotic symptoms is diagnosed when the definitional requirements for Single episode depressive disorder are met and the current episode is severe and there are delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a severe depressive episode, many or most symptoms of a Depressive Episode are present to a marked degree, or a smaller number of symptoms are present and manifest to an intense degree. The individual has serious difficulty continuing to function in most domains (personal, family, social, educational, occupational, or other important domains). In a severe depressive episode, many or most symptoms of a Depressive Episode are present to a marked degree, or a smaller number of symptoms are present and manifest to an intense degree. The individual has serious difficulty continuing to function in most domains (personal, family, social, educational, occupational, or other important domains).

**6A70.5**

**Single episode depressive disorder, unspecified severity**

Single episode depressive disorder, unspecified severity is diagnosed when the definitional requirements of a depressive episode have been met, there is no history of prior depressive episodes, and there is insufficient information to determine the severity of the current depressive episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. The symptoms are associated with at least some difficulty in continuing with ordinary work, social, or domestic activities.

- 6A70.6 Single episode depressive disorder, currently in partial remission**  
Single episode depressive disorder, currently in partial remission, is diagnosed when the full definitional requirements for a depressive episode have been met and there is no history of prior depressive episodes. The full definitional requirements for a depressive episode are no longer met but some significant mood symptoms remain.
- 6A70.7 Single episode depressive disorder, currently in full remission**  
Single episode depressive disorder, currently in full remission is diagnosed when the full definitional requirements for one depressive episode have been met in the past and there are no longer any significant mood symptoms. There is no history of depressive episodes preceding the episode under consideration.
- 6A70.Y Other specified single episode depressive disorder**
- 6A70.Z Single episode depressive disorder, unspecified**
- 6A71 Recurrent depressive disorder**  
Recurrent depressive disorder is characterised by a history of at least two depressive episodes separated by at least several months without significant mood disturbance. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. There have never been any prior manic, hypomanic, or mixed episodes, which would indicate the presence of a Bipolar disorder.
- Inclusions:** seasonal depressive disorder
- Exclusions:** Adjustment disorder (6B43)  
Bipolar or related disorders (6A60-6A6Z)  
Single episode depressive disorder (6A70)
- 6A71.0 Recurrent depressive disorder, current episode mild**  
Recurrent depressive disorder, current episode mild is diagnosed when the definitional requirements for Recurrent depressive disorder have been met and there is currently a depressive episode of mild severity. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a mild depressive episode, the individual is usually distressed by the symptoms and has some difficulty in continuing to function in one or more domains (personal, family, social, educational, occupational, or other important domains). There are no delusions or hallucinations during the episode.

**6A71.1**

**Recurrent depressive disorder, current episode moderate, without psychotic symptoms**

Recurrent depressive disorder, current episode moderate, without psychotic symptoms is diagnosed when the definitional requirements for recurrent depressive disorder have been met and there is currently a depressive episode of moderate severity, and there are no delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a moderate depressive episode, several symptoms of a depressive episode are present to a marked degree, or a large number of depressive symptoms of lesser severity are present overall. The individual typically has considerable difficulty functioning in multiple domains (personal, family, social, educational, occupational, or other important domains).

**6A71.2**

**Recurrent depressive disorder, current episode moderate, with psychotic symptoms**

Recurrent depressive disorder, current episode moderate, with psychotic symptoms is diagnosed when the definitional requirements for Recurrent depressive disorder have been met and there is currently a depressive episode of moderate severity, and there are delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a moderate depressive episode, several symptoms of a depressive episode are present to a marked degree, or a large number of depressive symptoms of lesser severity are present overall. The individual typically has considerable difficulty functioning in multiple domains (personal, family, social, educational, occupational, or other important domains).

**6A71.3**

**Recurrent depressive disorder, current episode severe, without psychotic symptoms**

Recurrent depressive disorder, current episode severe, without psychotic symptoms is diagnosed when the definitional requirements for Recurrent depressive disorder are met and the current episode is severe and there are no delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a severe depressive episode, many or most symptoms of a Depressive Episode are present to a marked degree, or a smaller number of symptoms are present and manifest to an intense degree. The individual has serious difficulty continuing to function in most domains (personal, family, social, educational, occupational, or other important domains).

- Inclusions:**
- Endogenous depression without psychotic symptoms
  - Major depression, recurrent without psychotic symptoms
  - Manic-depressive psychosis, depressed type without psychotic symptoms
  - Vital depression, recurrent without psychotic symptoms

**6A71.4**

**Recurrent depressive disorder, current episode severe, with psychotic symptoms**

Recurrent depressive disorder, current episode severe, with psychotic symptoms is diagnosed when the definitional requirements for Recurrent depressive disorder are met and the current episode is severe and there are delusions or hallucinations during the episode. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. In a severe depressive episode, many or most symptoms of a Depressive Episode are present to a marked degree, or a smaller number of symptoms are present and manifest to an intense degree. The individual has serious difficulty continuing to function in most domains (personal, family, social, educational, occupational, or other important domains). In a severe depressive episode, many or most symptoms of a Depressive Episode are present to a marked degree, or a smaller number of symptoms are present and manifest to an intense degree. The individual has serious difficulty continuing to function in most domains (personal, family, social, educational, occupational, or other important domains).

- Inclusions:**
- Endogenous depression with psychotic symptoms
  - Manic-depressive psychosis, depressed type with psychotic symptoms

- 6A71.5 Recurrent depressive disorder, current episode, unspecified severity**  
Recurrent depressive disorder current episode, unspecified severity is diagnosed when the definitional requirements of a depressive episode have been met and there is a history of prior depressive episodes, but there is insufficient information to determine the severity of the current depressive episode. A depressive episode is characterised by a period of almost daily depressed mood or diminished interest in activities lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. The symptoms are associated with at least some difficulty in continuing with ordinary work, social, or domestic activities.
- 6A71.6 Recurrent depressive disorder, currently in partial remission**  
Recurrent depressive disorder, currently in partial remission, is diagnosed when the definitional requirements for Recurrent depressive disorder have been met; the full definitional requirements for a depressive episode are no longer met but some significant mood symptoms remain.
- 6A71.7 Recurrent depressive disorder, currently in full remission**  
Recurrent depressive disorder, currently in full remission is diagnosed when the definitional requirements for recurrent depressive disorder have been met but currently there are no significant mood symptoms.
- 6A71.Y Other specified recurrent depressive disorder**
- 6A71.Z Recurrent depressive disorder, unspecified**
- 6A72 Dysthymic disorder**  
Dysthymic disorder is characterised by a persistent depressive mood (i.e., lasting 2 years or more), for most of the day, for more days than not. In children and adolescents depressed mood can manifest as pervasive irritability. The depressed mood is accompanied by additional symptoms such as markedly diminished interest or pleasure in activities, reduced concentration and attention or indecisiveness, low self-worth or excessive or inappropriate guilt, hopelessness about the future, disturbed sleep or increased sleep, diminished or increased appetite, or low energy or fatigue. During the first 2 years of the disorder, there has never been a 2-week period during which the number and duration of symptoms were sufficient to meet the diagnostic requirements for a Depressive Episode. There is no history of Manic, Mixed, or Hypomanic Episodes.
- Inclusions:** Dysthymia
- Exclusions:** anxiety depression (mild or not persistent) (6A73)

**6A73****Mixed depressive and anxiety disorder**

Mixed depressive and anxiety disorder is characterised by symptoms of both anxiety and depression more days than not for a period of two weeks or more. Depressive symptoms include depressed mood or markedly diminished interest or pleasure in activities. There are multiple anxiety symptoms, which may include feeling nervous, anxious, or on edge, not being able to control worrying thoughts, fear that something awful will happen, having trouble relaxing, muscle tension, or sympathetic autonomic symptoms. Neither set of symptoms, considered separately, is sufficiently severe, numerous, or persistent to justify a diagnosis of another depressive disorder or an anxiety or fear-related disorder. The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning. There is no history of manic or mixed episodes, which would indicate the presence of a bipolar disorder.

**6A7Y****Other specified depressive disorders****6A7Z****Depressive disorders, unspecified****6A80****Symptomatic and course presentations for mood episodes in mood disorders**

These categories may be applied to describe the presentation and characteristics of mood episodes in the context of single episode depressive disorder, recurrent depressive disorder, bipolar type I disorder, or bipolar type II disorder. These categories indicate the presence of specific, important features of the clinical presentation or of the course, onset, and pattern of mood episodes. These categories are not mutually exclusive, and as many may be added as apply.

**Coding Note:**

These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify specific clinically important features of mood episodes in mood disorders.

**Coded Elsewhere:** Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms (6E20)

Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, with psychotic symptoms (6E21)

**6A80.0****Prominent anxiety symptoms in mood episodes**

In the context of a current depressive, manic, mixed, or hypomanic episode, prominent and clinically significant anxiety symptoms (e.g., feeling nervous, anxious or on edge, not being able to control worrying thoughts, fear that something awful will happen, having trouble relaxing, motor tension, autonomic symptoms) have been present for most of the time during the episode. If there have been panic attacks during a current depressive or mixed episode, these should be recorded separately.

When the diagnostic requirements for both a mood disorder and an anxiety or fear-related disorder are met, the anxiety or fear-related disorder should also be diagnosed.

**Coding Note:**

These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify specific clinically important features of mood episodes in mood disorders.

<b>6A80.1</b>	<b>Panic attacks in mood episodes</b> In the context of a current mood episode (manic, depressive, mixed, or hypomanic), there have been recurrent panic attacks (i.e., at least two) during the past month that occur specifically in response to anxiety-provoking cognitions that are features of the mood episode. If panic attacks occur exclusively in response to such thoughts, panic attacks should be recorded using this qualifier rather than assigning an additional co-occurring diagnosis of panic disorder.  If some panic attacks over the course of the depressive or mixed episode have been unexpected and not exclusively in response to depressive or anxiety-provoking thoughts, a separate diagnosis of panic disorder should be assigned.
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify specific clinically important features of mood episodes in mood disorders.
	<b>Exclusions:</b> Panic disorder (6B01)
<b>6A80.2</b>	<b>Current depressive episode persistent</b> The diagnostic requirements for a depressive episode are currently met and have been met continuously for at least the past 2 years.
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify specific clinically important features of mood episodes in mood disorders.
<b>6A80.3</b>	<b>Current depressive episode with melancholia</b> In the context of a current Depressive Episode, several of the following symptoms have been present during the worst period of the current episode: loss of interest or pleasure in most activities that are normally enjoyable to the individual (i.e., pervasive anhedonia); lack of emotional reactivity to normally pleasurable stimuli or circumstances (i.e., mood does not lift even transiently with exposure); terminal insomnia (i.e., waking in the morning two hours or more before the usual time); depressive symptoms are worse in the morning; marked psychomotor retardation or agitation; marked loss of appetite or loss of weight.
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify specific clinically important features of mood episodes in mood disorders.
<b>6A80.4</b>	<b>Seasonal pattern of mood episode onset</b> In the context of recurrent depressive disorder, bipolar type I or bipolar type II disorder, there has been a regular seasonal pattern of onset and remission of at least one type of episode (i.e., depressive, manic, mixed, or hypomanic episodes), with a substantial majority of the relevant mood episodes corresponding to the seasonal pattern. (In bipolar type I and bipolar type II disorder, all types of mood episodes may not follow this pattern.) A seasonal pattern should be differentiated from an episode that is coincidental with a particular season but predominantly related to a psychological stressor that regularly occurs at that time of the year (e.g., seasonal unemployment).
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify specific clinically important features of mood episodes in mood disorders.

**6A80.5      Rapid cycling**

In the context of bipolar type I or bipolar type II disorder, there has been a high frequency of mood episodes (at least four) over the past 12 months. There may be a switch from one polarity of mood to the other, or the mood episodes may be demarcated by a period of remission. In individuals with a high frequency of mood episodes, some may have a shorter duration than those usually observed in bipolar type I or bipolar type II disorder. In particular, depressive periods may only last several days. If depressive and manic symptoms alternate very rapidly (i.e., from day to day or within the same day), a mixed episode should be diagnosed rather than rapid cycling.

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify specific clinically important features of mood episodes in mood disorders.

**6A8Y      Other specified mood disorders**

**6A8Z      Mood disorders, unspecified**

## Anxiety or fear-related disorders (6B00-6B0Z)

Anxiety and fear-related disorders are characterised by excessive fear and anxiety and related behavioural disturbances, with symptoms that are severe enough to result in significant distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. Fear and anxiety are closely related phenomena; fear represents a reaction to perceived imminent threat in the present, whereas anxiety is more future-oriented, referring to perceived anticipated threat. A key differentiating feature among the Anxiety and fear-related disorders are disorder-specific foci of apprehension, that is, the stimulus or situation that triggers the fear or anxiety. The clinical presentation of Anxiety and fear-related disorders typically includes specific associated cognitions that can assist in differentiating among the disorders by clarifying the focus of apprehension.

**Coded Elsewhere:** Substance-induced anxiety disorders

Hypochondriasis (6B23)

Secondary anxiety syndrome (6E63)

**6B00**

### Generalised anxiety disorder

Generalised anxiety disorder is characterised by marked symptoms of anxiety that persist for at least several months, for more days than not, manifested by either general apprehension (i.e. 'free-floating anxiety') or excessive worry focused on multiple everyday events, most often concerning family, health, finances, and school or work, together with additional symptoms such as muscular tension or motor restlessness, sympathetic autonomic over-activity, subjective experience of nervousness, difficulty maintaining concentration, irritability, or sleep disturbance. The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. The symptoms are not a manifestation of another health condition and are not due to the effects of a substance or medication on the central nervous system.

**6B01****Panic disorder**

Panic disorder is characterised by recurrent unexpected panic attacks that are not restricted to particular stimuli or situations. Panic attacks are discrete episodes of intense fear or apprehension accompanied by the rapid and concurrent onset of several characteristic symptoms (e.g. palpitations or increased heart rate, sweating, trembling, shortness of breath, chest pain, dizziness or lightheadedness, chills, hot flushes, fear of imminent death). In addition, panic disorder is characterised by persistent concern about the recurrence or significance of panic attacks, or behaviours intended to avoid their recurrence, that results in significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. The symptoms are not a manifestation of another medical condition and are not due to the effects of a substance or medication on the central nervous system.

**Exclusions:**      Panic attack (MB23.H)

**6B02****Agoraphobia**

Agoraphobia is characterised by marked and excessive fear or anxiety that occurs in response to multiple situations where escape might be difficult or help might not be available, such as using public transportation, being in crowds, being outside the home alone (e.g., in shops, theatres, standing in line). The individual is consistently anxious about these situations due to a fear of specific negative outcomes (e.g., panic attacks, other incapacitating or embarrassing physical symptoms). The situations are actively avoided, entered only under specific circumstances such as in the presence of a trusted companion, or endured with intense fear or anxiety. The symptoms persist for at least several months, and are sufficiently severe to result in significant distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning.

**6B03****Specific phobia**

Specific phobia is characterised by a marked and excessive fear or anxiety that consistently occurs upon exposure or anticipation of exposure to one or more specific objects or situations (e.g., proximity to certain animals, flying, heights, closed spaces, sight of blood or injury) that is out of proportion to actual danger. The phobic objects or situations are avoided or else endured with intense fear or anxiety. Symptoms persist for at least several months and are sufficiently severe to result in significant distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning.

**Inclusions:**      Simple phobia

**Exclusions:**      Body dysmorphic disorder (6B21)

Hypochondriasis (6B23)

**6B04**

### **Social anxiety disorder**

Social anxiety disorder is characterised by marked and excessive fear or anxiety that consistently occurs in one or more social situations such as social interactions (e.g. having a conversation), doing something while feeling observed (e.g. eating or drinking in the presence of others), or performing in front of others (e.g. giving a speech). The individual is concerned that he or she will act in a way, or show anxiety symptoms, that will be negatively evaluated by others. Relevant social situations are consistently avoided or else endured with intense fear or anxiety. The symptoms persist for at least several months and are sufficiently severe to result in significant distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning.

**6B05**

### **Separation anxiety disorder**

Separation anxiety disorder is characterised by marked and excessive fear or anxiety about separation from specific attachment figures. In children and adolescents, separation anxiety typically focuses on caregivers, parents or other family members and the fear or anxiety is beyond what would be considered developmentally normative. In adults, the focus is typically a romantic partner or children. Manifestations of separation anxiety may include thoughts of harm or untoward events befalling the attachment figure, reluctance to go to school or work, recurrent excessive distress upon separation, reluctance or refusal to sleep away from the attachment figure, and recurrent nightmares about separation. The symptoms persist for at least several months and are sufficiently severe to result in significant distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning.

- Exclusions:**
- mood [affective] disorders (6A60-6A8Z)
  - Selective mutism (6B06)
  - Social anxiety disorder (6B04)

**6B06**

### **Selective mutism**

Selective mutism is characterised by consistent selectivity in speaking, such that a child demonstrates adequate language competence in specific social situations, typically at home, but consistently fails to speak in others, typically at school. The disturbance lasts for at least one month, is not limited to the first month of school, and is of sufficient severity to interfere with educational achievement or with social communication. Failure to speak is not due to a lack of knowledge of, or comfort with, the spoken language required in the social situation (e.g. a different language spoken at school than at home).

- Exclusions:**
- Schizophrenia (6A20)
  - transient mutism as part of separation anxiety in young children (6B05)
  - Autism spectrum disorder (6A02)

**6B0Y**

### **Other specified anxiety or fear-related disorders**

**6B0Z**

### **Anxiety or fear-related disorders, unspecified**

## **Obsessive-compulsive or related disorders (6B20-6B2Z)**

Obsessive-compulsive and related disorders is a group of disorders characterised by repetitive thoughts and behaviours that are believed to share similarities in aetiology and key diagnostic validators. Cognitive phenomena such as obsessions, intrusive thoughts and preoccupations are central to a subset of these conditions (i.e., obsessive-compulsive disorder, body dysmorphic disorder, hypochondriasis, and olfactory reference disorder) and are accompanied by related repetitive behaviours. Hoarding Disorder is not associated with intrusive unwanted thoughts but rather is characterised by a compulsive need to accumulate possessions and distress related to discarding them. Also included in the grouping are body-focused repetitive behaviour disorders, which are primarily characterised by recurrent and habitual actions directed at the integument (e.g., hair-pulling, skin-picking) and lack a prominent cognitive aspect. The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning.

**Coded Elsewhere:** Substance-induced obsessive-compulsive or related disorders

Secondary obsessive-compulsive or related syndrome (6E64)

Tourette syndrome (8A05.00)

**6B20**

### **Obsessive-compulsive disorder**

Obsessive-Compulsive Disorder is characterised by the presence of persistent obsessions or compulsions, or most commonly both. Obsessions are repetitive and persistent thoughts, images, or impulses/urges that are intrusive, unwanted, and are commonly associated with anxiety. The individual attempts to ignore or suppress obsessions or to neutralize them by performing compulsions. Compulsions are repetitive behaviours including repetitive mental acts that the individual feels driven to perform in response to an obsession, according to rigid rules, or to achieve a sense of 'completeness'. In order for obsessive-compulsive disorder to be diagnosed, obsessions and compulsions must be time consuming (e.g. taking more than an hour per day) or result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**Inclusions:** anankastic neurosis

obsessive-compulsive neurosis

**Exclusions:** obsessive compulsive behaviour (MB23.4)

**6B20.0**

### **Obsessive-compulsive disorder with fair to good insight**

All definitional requirements of obsessive-compulsive disorder are met. Much of the time, the individual is able to entertain the possibility that his or her disorder-specific beliefs may not be true and is willing to accept an alternative explanation for his or her experience. At circumscribed times (e.g., when highly anxious), the individual may demonstrate no insight.

**6B20.1**

### **Obsessive-compulsive disorder with poor to absent insight**

All definitional requirements of obsessive-compulsive disorder are met. Most or all of the time, the individual is convinced that the disorder-specific beliefs are true and cannot accept an alternative explanation for their experience. The lack of insight exhibited by the individual does not vary markedly as a function of anxiety level.

**6B20.Z**

### **Obsessive-compulsive disorder, unspecified**

**6B21****Body dysmorphic disorder**

Body Dysmorphic Disorder is characterised by persistent preoccupation with one or more perceived defects or flaws in appearance that are either unnoticeable or only slightly noticeable to others. Individuals experience excessive self-consciousness, often with ideas of reference (i.e., the conviction that people are taking notice, judging, or talking about the perceived defect or flaw). In response to their preoccupation, individuals engage in repetitive and excessive behaviours that include repeated examination of the appearance or severity of the perceived defect or flaw, excessive attempts to camouflage or alter the perceived defect, or marked avoidance of social situations or triggers that increase distress about the perceived defect or flaw. The symptoms are sufficiently severe to result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**Exclusions:** Anorexia Nervosa (6B80)  
Bodily distress disorder (6C20)  
Concern about body appearance (QD30-QD3Z)

**6B21.0****Body dysmorphic disorder with fair to good insight**

All definitional requirements of body dysmorphic disorder are met. Much of the time, the individual is able to entertain the possibility that his or her disorder-specific beliefs may not be true and is willing to accept an alternative explanation for his or her experience. At circumscribed times (e.g., when highly anxious), the individual may demonstrate no insight.

**6B21.1****Body dysmorphic disorder with poor to absent insight**

All definitional requirements of body dysmorphic disorder are met. Most or all of the time, the individual is convinced that the disorder-specific beliefs are true and cannot accept an alternative explanation for their experience. The lack of insight exhibited by the individual does not vary markedly as a function of anxiety level.

**6B21.Z****Body dysmorphic disorder, unspecified****6B22****Olfactory reference disorder**

Olfactory Reference Disorder is characterised by persistent preoccupation with the belief that one is emitting a perceived foul or offensive body odour or breath that is either unnoticeable or only slightly noticeable to others. Individuals experience excessive self-consciousness about the perceived odour, often with ideas of reference (i.e., the conviction that people are taking notice, judging, or talking about the odour). In response to their preoccupation, individuals engage in repetitive and excessive behaviours such as repeatedly checking for body odour or checking the perceived source of the smell, or repeatedly seeking reassurance, excessive attempts to camouflage, alter, or prevent the perceived odour, or marked avoidance of social situations or triggers that increase distress about the perceived foul or offensive odour. The symptoms are sufficiently severe to result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

- 6B22.0 Olfactory reference disorder with fair to good insight**  
All definitional requirements of olfactory reference disorder are met. Much of the time, the individual is able to entertain the possibility that his or her disorder-specific beliefs may not be true and is willing to accept an alternative explanation for his or her experience. At circumscribed times (e.g., when highly anxious), the individual may demonstrate no insight.
- 6B22.1 Olfactory reference disorder with poor to absent insight**  
All definitional requirements of olfactory reference disorder are met. Most or all of the time, the individual is convinced that the disorder-specific beliefs are true and cannot accept an alternative explanation for their experience. The lack of insight exhibited by the individual does not vary markedly as a function of anxiety level.
- 6B22.Z Olfactory reference disorder, unspecified**
- 6B23 Hypochondriasis**  
Hypochondriasis is characterised by persistent preoccupation or fear about the possibility of having one or more serious, progressive or life-threatening illnesses. The preoccupation is accompanied by either: 1) repetitive and excessive health-related behaviours, such as repeatedly checking the body for evidence of illness, spending inordinate amounts of time searching for information about the feared illness, repeatedly seeking reassurance (e.g. arranging multiple medical consultations); or 2) maladaptive avoidance behaviour related to health (e.g. avoids medical appointments). The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.
- Inclusions:** Hypochondriacal neurosis  
Illness anxiety disorder
- Exclusions:** Body dysmorphic disorder (6B21)  
Bodily distress disorder (6C20)  
Fear of cancer (MG24.0)
- 6B23.0 Hypochondriasis with fair to good insight**  
All definitional requirements of hypochondriasis are met. Much of the time, the individual is able to entertain the possibility that his or her disorder-specific beliefs may not be true and is willing to accept an alternative explanation for his or her experience. At circumscribed times (e.g., when highly anxious), the individual may demonstrate no insight.
- 6B23.1 Hypochondriasis with poor to absent insight**  
All definitional requirements of hypochondriasis are met. Most or all of the time, the individual is convinced that the disorder-specific beliefs are true and cannot accept an alternative explanation for their experience. The lack of insight exhibited by the individual does not vary markedly as a function of anxiety level.
- 6B23.Z Hypochondriasis, unspecified**

**6B24**

### **Hoarding disorder**

Hoarding disorder is characterised by accumulation of possessions that results in living spaces becoming cluttered to the point that their use or safety is compromised. Accumulation occurs due to both repetitive urges or behaviours related to amassing items and difficulty discarding possessions due to a perceived need to save items and distress associated with discarding them. If living areas are uncluttered this is only due to the intervention of third parties (e.g., family members, cleaners, authorities). Amassment may be passive (e.g. accumulation of incoming flyers or mail) or active (e.g. excessive acquisition of free, purchased, or stolen items). The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**6B24.0**

#### **Hoarding disorder with fair to good insight**

All definitional requirements of hoarding disorder are met. The individual recognizes that hoarding-related beliefs and behaviours (pertaining to excessive acquisition, difficulty discarding, or clutter) are problematic. This qualifier level may still be applied if, at circumscribed times (e.g., when being forced to discard items), the individual demonstrates no insight.

**6B24.1**

#### **Hoarding disorder with poor to absent insight**

All definitional requirements of hoarding disorder are met. Most or all of the time, the individual is convinced that that hoarding-related beliefs and behaviours (pertaining to excessive acquisition, difficulty discarding, or clutter) are not problematic, despite evidence to the contrary. The lack of insight exhibited by the individual does not vary markedly as a function of anxiety level.

**6B24.Z**

#### **Hoarding disorder, unspecified**

**6B25**

### **Body-focused repetitive behaviour disorders**

Body focused repetitive behaviour disorders are characterised by recurrent and habitual actions directed at the integument (e.g. hair-pulling, skin-picking, lip-biting), typically accompanied by unsuccessful attempts to decrease or stop the behaviour involved, and which lead to dermatological sequelae (e.g., hair loss, skin lesions, lip abrasions). The behaviour may occur in brief episodes scattered throughout the day or in less frequent but more sustained periods. The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**6B25.0**

### **Trichotillomania**

Trichotillomania is characterised by recurrent pulling of one's own hair leading to significant hair loss, accompanied by unsuccessful attempts to decrease or stop the behaviour. Hair pulling may occur from any region of the body in which hair grows but the most common sites are the scalp, eyebrows, and eyelids. Hair pulling may occur in brief episodes scattered throughout the day or in less frequent but more sustained periods. The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**Inclusions:** Compulsive hair plucking

**Exclusions:** stereotyped movement disorder with hair-plucking (6A06)

<b>6B25.1</b>	<b>Excoriation disorder</b> Excoriation disorder is characterised by recurrent picking of one's own skin leading to skin lesions, accompanied by unsuccessful attempts to decrease or stop the behaviour. The most commonly picked sites are the face, arms and hands, but many individuals pick from multiple body sites. Skin picking may occur in brief episodes scattered throughout the day or in less frequent but more sustained periods. The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.
	<b>Inclusions:</b> skin picking disorder
	<b>Exclusions:</b> Stereotyped movement disorder (6A06) Acute excoriation of skin (ME62.9) Chronic excoriation of skin (ME63.7)
<b>6B25.Y</b>	<b>Other specified body-focused repetitive behaviour disorders</b>
<b>6B25.Z</b>	<b>Body-focused repetitive behaviour disorders, unspecified</b>
<b>6B2Y</b>	<b>Other specified obsessive-compulsive or related disorders</b>
<b>6B2Z</b>	<b>Obsessive-compulsive or related disorders, unspecified</b>

## Disorders specifically associated with stress (6B40-6B4Z)

Disorders specifically associated with stress are directly related to exposure to a stressful or traumatic event, or a series of such events or adverse experiences. For each of the disorders in this grouping, an identifiable stressor is a necessary, though not sufficient, causal factor. Although not all individuals exposed to an identified stressor will develop a disorder, the disorders in this grouping would not have occurred without experiencing the stressor. Stressful events for some disorders in this grouping are within the normal range of life experiences (e.g., divorce, socio-economic problems, bereavement). Other disorders require the experience of a stressor of an extremely threatening or horrific nature (i.e., potentially traumatic events). With all disorders in this grouping, it is the nature, pattern, and duration of the symptoms that arise in response to the stressful events—together with associated functional impairment—that distinguishes the disorders.

- Exclusions:**      Burnout (QD85)  
                        Acute stress reaction (QE84)

**6B40**

### **Post traumatic stress disorder**

Post traumatic stress disorder (PTSD) may develop following exposure to an extremely threatening or horrific event or series of events. It is characterised by all of the following: 1) re-experiencing the traumatic event or events in the present in the form of vivid intrusive memories, flashbacks, or nightmares. Re-experiencing may occur via one or multiple sensory modalities and is typically accompanied by strong or overwhelming emotions, particularly fear or horror, and strong physical sensations; 2) avoidance of thoughts and memories of the event or events, or avoidance of activities, situations, or people reminiscent of the event(s); and 3) persistent perceptions of heightened current threat, for example as indicated by hypervigilance or an enhanced startle reaction to stimuli such as unexpected noises. The symptoms persist for at least several weeks and cause significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

- Inclusions:**      Traumatic neurosis  
**Exclusions:**      Acute stress reaction (QE84)  
                        Complex post traumatic stress disorder (6B41)

**6B41**

### **Complex post traumatic stress disorder**

Complex post traumatic stress disorder (Complex PTSD) is a disorder that may develop following exposure to an event or series of events of an extremely threatening or horrific nature, most commonly prolonged or repetitive events from which escape is difficult or impossible (e.g. torture, slavery, genocide campaigns, prolonged domestic violence, repeated childhood sexual or physical abuse). All diagnostic requirements for PTSD are met. In addition, Complex PTSD is characterised by severe and persistent 1) problems in affect regulation; 2) beliefs about oneself as diminished, defeated or worthless, accompanied by feelings of shame, guilt or failure related to the traumatic event; and 3) difficulties in sustaining relationships and in feeling close to others. These symptoms cause significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

- Exclusions:**      Post traumatic stress disorder (6B40)  
                        Personality disorder (6D10)

**6B42**

### **Prolonged grief disorder**

Prolonged grief disorder is a disturbance in which, following the death of a partner, parent, child, or other person close to the bereaved, there is persistent and pervasive grief response characterised by longing for the deceased or persistent preoccupation with the deceased accompanied by intense emotional pain (e.g. sadness, guilt, anger, denial, blame, difficulty accepting the death, feeling one has lost a part of one's self, an inability to experience positive mood, emotional numbness, difficulty in engaging with social or other activities). The grief response has persisted for an atypically long period of time following the loss (more than 6 months at a minimum) and clearly exceeds expected social, cultural or religious norms for the individual's culture and context. Grief reactions that have persisted for longer periods that are within a normative period of grieving given the person's cultural and religious context are viewed as normal bereavement responses and are not assigned a diagnosis. The disturbance causes significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**6B43**

### **Adjustment disorder**

Adjustment disorder is a maladaptive reaction to an identifiable psychosocial stressor or multiple stressors (e.g. divorce, illness or disability, socio-economic problems, conflicts at home or work) that usually emerges within a month of the stressor. The disorder is characterised by preoccupation with the stressor or its consequences, including excessive worry, recurrent and distressing thoughts about the stressor, or constant rumination about its implications, as well as by failure to adapt to the stressor that causes significant impairment in personal, family, social, educational, occupational or other important areas of functioning. The symptoms are not better explained by another mental disorder (e.g., Mood Disorder, another Disorder Specifically Associated with Stress) and typically resolve within 6 months, unless the stressor persists for a longer duration.

- Exclusions:**
- separation anxiety disorder of childhood (6B05)
  - Recurrent depressive disorder (6A71)
  - Single episode depressive disorder (6A70)
  - Prolonged grief disorder (6B42)
  - Uncomplicated bereavement (QE62)
  - Burnout (QD85)
  - Acute stress reaction (QE84)

**6B44****Reactive attachment disorder**

Reactive attachment disorder is characterised by grossly abnormal attachment behaviours in early childhood, occurring in the context of a history of grossly inadequate child care (e.g., severe neglect, maltreatment, institutional deprivation). Even when an adequate primary caregiver is newly available, the child does not turn to the primary caregiver for comfort, support and nurture, rarely displays security-seeking behaviours towards any adult, and does not respond when comfort is offered. Reactive attachment disorder can only be diagnosed in children, and features of the disorder develop within the first 5 years of life. However, the disorder cannot be diagnosed before the age of 1 year (or a developmental age of less than 9 months), when the capacity for selective attachments may not be fully developed, or in the context of Autism spectrum disorder.

**Exclusions:** Asperger syndrome (6A02)  
disinhibited attachment disorder of childhood (6B45)

**6B45****Disinhibited social engagement disorder**

Disinhibited social engagement disorder is characterised by grossly abnormal social behaviour, occurring in the context of a history of grossly inadequate child care (e.g., severe neglect, institutional deprivation). The child approaches adults indiscriminately, lacks reticence to approach, will go away with unfamiliar adults, and exhibits overly familiar behaviour towards strangers. Disinhibited social engagement disorder can only be diagnosed in children, and features of the disorder develop within the first 5 years of life. However, the disorder cannot be diagnosed before the age of 1 year (or a developmental age of less than 9 months), when the capacity for selective attachments may not be fully developed, or in the context of Autism spectrum disorder.

**Exclusions:** Asperger syndrome (6A02)  
Adjustment disorder (6B43)  
Attention deficit hyperactivity disorder (6A05)  
reactive attachment disorder of childhood (6B44)

**6B4Y****Other specified disorders specifically associated with stress****6B4Z****Disorders specifically associated with stress, unspecified**

## Dissociative disorders (6B60-6B6Z)

Dissociative disorders are characterised by involuntary disruption or discontinuity in the normal integration of one or more of the following: identity, sensations, perceptions, affects, thoughts, memories, control over bodily movements, or behaviour. Disruption or discontinuity may be complete, but is more commonly partial, and can vary from day to day or even from hour to hour. The symptoms of dissociative disorders are not due to the direct effects of a medication or substance, including withdrawal effects, are not better explained by another Mental, behavioural, or neurodevelopmental disorder, a Sleep-wake disorder, a Disease of the nervous system or other health condition, and are not part of an accepted cultural, religious, or spiritual practice. Dissociative symptoms in dissociative disorders are sufficiently severe to result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**Coded Elsewhere:** Secondary dissociative syndrome (6E65)

**6B60**

### **Dissociative neurological symptom disorder**

Dissociative neurological symptom disorder is characterised by the presentation of motor, sensory, or cognitive symptoms that imply an involuntary discontinuity in the normal integration of motor, sensory, or cognitive functions and are not consistent with a recognised disease of the nervous system, other mental or behavioural disorder, or other medical condition. The symptoms do not occur exclusively during another dissociative disorder and are not due to the effects of a substance or medication on the central nervous system, including withdrawal effects, or a Sleep-Wake disorder.

**Exclusions:** Factitious disorders (6D50-6D5Z)

**6B60.0**

### **Dissociative neurological symptom disorder, with visual disturbance**

Dissociative neurological symptom disorder, with visual disturbance is characterised by visual symptoms such as blindness, tunnel vision, diplopia, visual distortions or hallucinations that are not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and do not occur exclusively during another dissociative disorder.

**6B60.1**

### **Dissociative neurological symptom disorder, with auditory disturbance**

Dissociative neurological symptom disorder, with auditory disturbance is characterised by auditory symptoms such as loss of hearing or auditory hallucinations that are not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and do not occur exclusively during another dissociative disorder.

**6B60.2**

### **Dissociative neurological symptom disorder, with vertigo or dizziness**

Dissociative neurological symptom disorder, with vertigo or dizziness is characterised by a sensation of spinning while stationary (vertigo) or dizziness that is not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and does not occur exclusively during another dissociative disorder.

- 6B60.3 Dissociative neurological symptom disorder, with other sensory disturbance**  
Dissociative neurological symptom disorder, with other sensory disturbance is characterised by sensory symptoms not identified in other specific categories in this grouping such as numbness, tightness, tingling, burning, pain, or other symptoms related to touch, smell, taste, balance, proprioception, kinesthesia, or thermoception. The symptoms are not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and do not occur exclusively during another dissociative disorder.
- 6B60.4 Dissociative neurological symptom disorder, with non-epileptic seizures**  
Dissociative neurological symptom disorder, with non-epileptic seizures is characterised by a symptomatic presentation of seizures or convulsions that are not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and do not occur exclusively during another dissociative disorder.
- 6B60.5 Dissociative neurological symptom disorder, with speech disturbance**  
Dissociative neurological symptom disorder, with speech disturbance is characterised by symptoms such as difficulty with speaking (dysphonia), loss of the ability to speak (aphonia) or difficult or unclear articulation of speech (dysarthria) that are not consistent with a recognised disease of the nervous system, a neurodevelopmental or neurocognitive disorder, other mental, behavioural or neurodevelopmental disorder, or other medical condition and do not occur exclusively during another dissociative disorder.
- 6B60.6 Dissociative neurological symptom disorder, with paresis or weakness**  
Dissociative neurological symptom disorder, with paresis or weakness is characterised by a difficulty or inability to intentionally move parts of the body or to coordinate movements that is not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and does not occur exclusively during another dissociative disorder.
- 6B60.7 Dissociative neurological symptom disorder, with gait disturbance**  
Dissociative neurological symptom disorder, with gait disturbance is characterised by symptoms involving the individual's ability or manner of walking, including ataxia and the inability to stand unaided, that are not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and do not occur exclusively during another dissociative disorder.
- 6B60.8 Dissociative neurological symptom disorder, with movement disturbance**  
Dissociative neurological symptom disorder, with movement disturbance is characterised by symptoms such as chorea, myoclonus, tremor, dystonia, facial spasm, parkinsonism, or dyskinesia that are not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and do not occur exclusively during another dissociative disorder.

- 6B60.80** Dissociative neurological symptom disorder, with chorea  
Dissociative neurological symptom disorder, with chorea is characterised by irregular, non-repetitive, brief, jerky, flowing movements that move randomly from one part of the body to another that are not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and do not occur exclusively during another dissociative disorder.
- 6B60.81** Dissociative neurological symptom disorder, with myoclonus  
Dissociative neurological symptom disorder, with myoclonus is characterised by sudden rapid jerks that may be focal, multifocal or generalised that are not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and do not occur exclusively during another dissociative disorder.
- 6B60.82** Dissociative neurological symptom disorder, with tremor  
Dissociative neurological symptom disorder, with tremor is characterised by involuntary oscillation of a body part that is not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and does not occur exclusively during another dissociative disorder.
- 6B60.83** Dissociative neurological symptom disorder, with dystonia  
Dissociative neurological symptom disorder, with dystonia is characterised by sustained muscle contractions that frequently cause twisting and repetitive movements or abnormal postures that are not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and do not occur exclusively during another dissociative disorder.
- 6B60.84** Dissociative neurological symptom disorder, with facial spasm  
Dissociative neurological symptom disorder, with facial spasm is characterised by involuntary muscle contractions or twitching of the face that is not consistent with a recognised disease of the nervous system, other mental, behavioural or neurodevelopmental disorder, or other medical condition and does not occur exclusively during another dissociative disorder.
- 6B60.85** Dissociative neurological symptom disorder, with Parkinsonism  
Dissociative neurological symptom disorder, with Parkinsonism is characterised by a symptomatic presentation of a Parkinson-like syndrome in the absence of confirmed Parkinson disease that does not occur exclusively during another mental, behavioural or neurodevelopmental disorder, other medical condition, or another dissociative disorder. Dissociative neurological symptom disorder, with Parkinsonism can be distinguished from Parkinson disease by features such as abrupt onset, early disability, bilateral shaking and slowness, nondecremental slowness when performing repetitive movements, voluntary resistance against passive movement without cogwheel rigidity, distractability, 'give-way' weakness, stuttering speech, bizarre gait, and a variety of behavioural symptoms.
- 6B60.8Y** Dissociative neurological symptom disorder, with other specified movement disturbance

<b>6B60.8Z</b>	Dissociative neurological symptom disorder, with unspecified movement disturbance
<b>6B60.9</b>	<b>Dissociative neurological symptom disorder, with cognitive symptoms</b> Dissociative neurological symptom disorder, with cognitive symptoms is characterised by impaired cognitive performance in memory, language or other cognitive domains that is internally inconsistent and not consistent with a recognised disease of the nervous system, a neurodevelopmental or neurocognitive disorder, other mental, behavioural or neurodevelopmental disorder, or another medical condition and does not occur exclusively during another dissociative disorder.
	<b>Exclusions:</b> Dissociative amnesia (6B61)
<b>6B60.Y</b>	<b>Dissociative neurological symptom disorder, with other specified symptoms</b>
<b>6B60.Z</b>	<b>Dissociative neurological symptom disorder, with unspecified symptoms</b>
<b>6B61</b>	<p><b>Dissociative amnesia</b></p> <p>Dissociative amnesia is characterised by an inability to recall important autobiographical memories, typically of recent traumatic or stressful events, that is inconsistent with ordinary forgetting. The amnesia does not occur exclusively during another dissociative disorder and is not better explained by another mental, behavioural or neurodevelopmental disorder. The amnesia is not due to the direct effects of a substance or medication on the central nervous system, including withdrawal effects, and is not due to a disease of the nervous system or to head trauma. The amnesia results in significant impairment in personal, family, social, educational, occupational or other important areas of functioning.</p> <p><b>Exclusions:</b> amnesia NOS (MB21.1) Amnestic disorder due to use of alcohol (6D72.10) Anterograde amnesia (MB21.10) Retrograde amnesia (MB21.11) nonalcoholic organic amnesic syndrome (6D72.0) postictal amnesia in epilepsy (8A60-8A6Z)</p>
<b>6B61.0</b>	<p><b>Dissociative amnesia with dissociative fugue</b></p> <p>Dissociative amnesia with dissociative fugue is characterised by all of the features of Dissociative Amnesia, accompanied by dissociative fugue, i.e., a loss of a sense of personal identity and sudden travel away from home, work, or significant others for an extended period of time (days or weeks). A new identity may be assumed.</p> <p><b>Exclusions:</b> postictal fugue in epilepsy (8A60-8A6Z)</p>
<b>6B61.1</b>	<p><b>Dissociative amnesia without dissociative fugue</b></p> <p>Dissociative amnesia without dissociative fugue is characterised by all of the features of dissociative amnesia occurring in the absence of symptoms of dissociative fugue.</p>
<b>6B61.Z</b>	<b>Dissociative amnesia, unspecified</b>

**6B62**

### **Trance disorder**

Trance disorder is characterised by trance states in which there is a marked alteration in the individual's state of consciousness or a loss of the individual's customary sense of personal identity in which the individual experiences a narrowing of awareness of immediate surroundings or unusually narrow and selective focusing on environmental stimuli and restriction of movements, postures, and speech to repetition of a small repertoire that is experienced as being outside of one's control. The trance state is not characterised by the experience of being replaced by an alternate identity. Trance episodes are recurrent or, if the diagnosis is based on a single episode, the episode has lasted for at least several days. The trance state is involuntary and unwanted and is not accepted as a part of a collective cultural or religious practice. The symptoms do not occur exclusively during another dissociative disorder and are not better explained by another mental, behavioural or neurodevelopmental disorder. The symptoms are not due to the direct effects of a substance or medication on the central nervous system, including withdrawal effects, exhaustion, or to hypnagogic or hypnopompic states, and are not due to a disease of the nervous system, head trauma, or a sleep-wake disorder. The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**6B63**

### **Possession trance disorder**

Possession trance disorder is characterised by trance states in which there is a marked alteration in the individual's state of consciousness and the individual's customary sense of personal identity is replaced by an external 'possessing' identity and in which the individual's behaviours or movements are experienced as being controlled by the possessing agent. Possession trance episodes are recurrent or, if the diagnosis is based on a single episode, the episode has lasted for at least several days. The possession trance state is involuntary and unwanted and is not accepted as a part of a collective cultural or religious practice. The symptoms do not occur exclusively during another dissociative disorder and are not better explained by another mental, behavioural or neurodevelopmental disorder. The symptoms are not due to the direct effects of a substance or medication on the central nervous system, including withdrawal effects, exhaustion, or to hypnagogic or hypnopompic states, and are not due to a disease of the nervous system or a sleep-wake disorder. The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

- Exclusions:**
- Schizophrenia (6A20)
  - Disorders due to use of other specified psychoactive substances, including medications (6C4E)
  - Acute and transient psychotic disorder (6A23)
  - Secondary personality change (6E68)

**6B64**

### **Dissociative identity disorder**

Dissociative identity disorder is characterised by disruption of identity in which there are two or more distinct personality states (dissociative identities) associated with marked discontinuities in the sense of self and agency. Each personality state includes its own pattern of experiencing, perceiving, conceiving, and relating to self, the body, and the environment. At least two distinct personality states recurrently take executive control of the individual's consciousness and functioning in interacting with others or with the environment, such as in the performance of specific aspects of daily life such as parenting, or work, or in response to specific situations (e.g., those that are perceived as threatening). Changes in personality state are accompanied by related alterations in sensation, perception, affect, cognition, memory, motor control, and behaviour. There are typically episodes of amnesia, which may be severe. The symptoms are not better explained by another mental, behavioural or neurodevelopmental disorder and are not due to the direct effects of a substance or medication on the central nervous system, including withdrawal effects, and are not due to a disease of the nervous system or a sleep-wake disorder. The symptoms result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**6B65**

### **Partial dissociative identity disorder**

Partial dissociative identity disorder is characterised by disruption of identity in which there are two or more distinct personality states (dissociative identities) associated with marked discontinuities in the sense of self and agency. Each personality state includes its own pattern of experiencing, perceiving, conceiving, and relating to self, the body, and the environment. One personality state is dominant and normally functions in daily life, but is intruded upon by one or more non-dominant personality states (dissociative intrusions). These intrusions may be cognitive, affective, perceptual, motor, or behavioural. They are experienced as interfering with the functioning of the dominant personality state and are typically aversive. The non-dominant personality states do not recurrently take executive control of the individual's consciousness and functioning, but there may be occasional, limited and transient episodes in which a distinct personality state assumes executive control to engage in circumscribed behaviours, such as in response to extreme emotional states or during episodes of self-harm or the reenactment of traumatic memories. The symptoms are not better explained by another mental, behavioural or neurodevelopmental disorder and are not due to the direct effects of a substance or medication on the central nervous system, including withdrawal effects, and are not due to a disease of the nervous system or a sleep-wake disorder. The symptoms result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**6B66****Depersonalization-derealization disorder**

Depersonalization-derealization disorder is characterised by persistent or recurrent experiences of depersonalization, derealization, or both. Depersonalization is characterised by experiencing the self as strange or unreal, or feeling detached from, or as though one were an outside observer of, one's thoughts, feelings, sensations, body, or actions. Derealization is characterised by experiencing other persons, objects, or the world as strange or unreal (e.g., dreamlike, distant, foggy, lifeless, colourless, or visually distorted) or feeling detached from one's surroundings. During experiences of depersonalization or derealization, reality testing remains intact. The experiences of depersonalization or derealization do not occur exclusively during another dissociative disorder and are not better explained by another mental, behavioural or neurodevelopmental disorder. The experiences of depersonalization or derealization are not due to the direct effects of a substance or medication on the central nervous system, including withdrawal effects, and are not due to a disease of the nervous system or to head trauma. The symptoms result in significant distress or impairment in personal, family, social, educational, occupational or other important areas of functioning.

**6B6Y****Other specified dissociative disorders****6B6Z****Dissociative disorders, unspecified****Feeding or eating disorders (6B80-6B8Z)**

Feeding and Eating Disorders involve abnormal eating or feeding behaviours that are not explained by another health condition and are not developmentally appropriate or culturally sanctioned. Feeding disorders involve behavioural disturbances that are not related to body weight and shape concerns, such as eating of non-edible substances or voluntary regurgitation of foods. Eating disorders involve abnormal eating behaviour and preoccupation with food as well as prominent body weight and shape concerns.

**6B80****Anorexia Nervosa**

Anorexia Nervosa is characterised by significantly low body weight for the individual's height, age and developmental stage that is not due to another health condition or to the unavailability of food. A commonly used threshold is body mass index (BMI) less than 18.5 kg/m<sup>2</sup> in adults and BMI-for-age under 5th percentile in children and adolescents. Rapid weight loss (e.g. more than 20% of total body weight within 6 months) may replace the low body weight guideline as long as other diagnostic requirements are met. Children and adolescents may exhibit failure to gain weight as expected based on the individual developmental trajectory rather than weight loss. Low body weight is accompanied by a persistent pattern of behaviours to prevent restoration of normal weight, which may include behaviours aimed at reducing energy intake (restricted eating), purging behaviours (e.g. self-induced vomiting, misuse of laxatives), and behaviours aimed at increasing energy expenditure (e.g. excessive exercise), typically associated with a fear of weight gain. Low body weight or shape is central to the person's self-evaluation or is inaccurately perceived to be normal or even excessive.

- 6B80.0** **Anorexia Nervosa with significantly low body weight**  
Anorexia Nervosa with significantly low body weight meets all definitional requirements for Anorexia Nervosa, with BMI between 18.5 kg/m<sup>2</sup> and 14.0 kg/m<sup>2</sup> for adults or between the fifth percentile and the 0.3 percentile for BMI-for-age in children and adolescents.
- 6B80.00** Anorexia Nervosa with significantly low body weight, restricting pattern  
Anorexia Nervosa with significantly low body weight, restricting pattern refers to individuals who meet the definitional requirements of Anorexia Nervosa with significantly low body weight and who induce weight loss and maintain low body weight through restricted food intake or fasting alone or in combination with increased energy expenditure (such as through excessive exercise) but who do not engage in binge eating or purging behaviours.
- 6B80.01** Anorexia Nervosa with significantly low body weight, binge-purge pattern  
Anorexia Nervosa with significantly low body weight, binge-purge pattern refers to individuals who meet the definitional requirements of Anorexia Nervosa with significantly low body weight and who present with episodes of binge eating or purging behaviours. These individuals induce weight loss and maintain low body weight through restricted food intake, commonly accompanied by significant purging behaviours aimed at getting rid of ingested food (e.g. self-induced vomiting, laxative abuse or enemas). This pattern also includes individuals who exhibit binge eating episodes but do not purge.
- 6B80.0Z** Anorexia Nervosa with significantly low body weight, unspecified
- 6B80.1** **Anorexia Nervosa with dangerously low body weight**  
Anorexia Nervosa with dangerously low body weight meets all definitional requirements for Anorexia Nervosa, with BMI under 14.0 kg/m<sup>2</sup> in adults or under the 0.3rd percentile for BMI-for-age in children and adolescents. In the context of Anorexia Nervosa, severe underweight status is an important prognostic factor that is associated with high risk of physical complications and substantially increased mortality.
- 6B80.10** Anorexia Nervosa with dangerously low body weight, restricting pattern  
Anorexia Nervosa with dangerously low body weight, restricting pattern refers to individuals who meet the definitional requirements of Anorexia Nervosa with dangerously low body weight and who induce weight loss and maintain low body weight through restricted food intake or fasting alone or in combination with increased energy expenditure (such as through excessive exercise) but who do not engage in binge eating or purging behaviours.
- 6B80.11** Anorexia Nervosa with dangerously low body weight, binge-purge pattern  
Anorexia Nervosa with dangerously low body weight, binge-purge pattern refers to individuals who meet the definitional requirements of Anorexia Nervosa with dangerously low body weight and who present with episodes of binge eating or purging behaviours. These individuals induce weight loss and maintain low body weight through restricted food intake, commonly accompanied by significant purging behaviours aimed at getting rid of ingested food (e.g. self-induced vomiting, laxative abuse or enemas). This pattern also includes individuals who exhibit binge eating episodes but do not purge.

**6B80.1Z** Anorexia Nervosa with dangerously low body weight, unspecified

**6B80.2** **Anorexia Nervosa in recovery with normal body weight**

Among individuals who are recovering from Anorexia Nervosa and whose body weight is more than 18.5 kg/m<sup>2</sup> for adults or over the fifth percentile for BMI-for-age for children and adolescents, the diagnosis should be retained until a full and lasting recovery is achieved, as indicated by the maintenance of a healthy weight and the cessation of behaviours aimed at reducing body weight independent of the provision of treatment (e.g., for at least 1 year after intensive treatment is withdrawn).

**6B80.Y** **Other specified anorexia Nervosa**

**6B80.Z** **Anorexia Nervosa, unspecified**

**6B81** **Bulimia Nervosa**

Bulimia Nervosa is characterised by frequent, recurrent episodes of binge eating (e.g. once a week or more over a period of at least one month). A binge eating episode is a distinct period of time during which the individual experiences a subjective loss of control over eating, eating notably more or differently than usual, and feels unable to stop eating or limit the type or amount of food eaten. Binge eating is accompanied by repeated inappropriate compensatory behaviours aimed at preventing weight gain (e.g. self-induced vomiting, misuse of laxatives or enemas, strenuous exercise). The individual is preoccupied with body shape or weight, which strongly influences self-evaluation. There is marked distress about the pattern of binge eating and inappropriate compensatory behaviour or significant impairment in personal, family, social, educational, occupational or other important areas of functioning. The individual does not meet the diagnostic requirements of Anorexia Nervosa.

**Exclusions:** Binge eating disorder (6B82)

**6B82** **Binge eating disorder**

Binge eating disorder is characterised by frequent, recurrent episodes of binge eating (e.g. once a week or more over a period of several months). A binge eating episode is a distinct period of time during which the individual experiences a subjective loss of control over eating, eating notably more or differently than usual, and feels unable to stop eating or limit the type or amount of food eaten. Binge eating is experienced as very distressing, and is often accompanied by negative emotions such as guilt or disgust. However, unlike in Bulimia Nervosa, binge eating episodes are not regularly followed by inappropriate compensatory behaviours aimed at preventing weight gain (e.g. self-induced vomiting, misuse of laxatives or enemas, strenuous exercise). There is marked distress about the pattern of binge eating or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**Exclusions:** Bulimia Nervosa (6B81)

**6B83**

### Avoidant-restrictive food intake disorder

Avoidant-restrictive food intake disorder (ARFID) is characterised by avoidance or restriction of food intake that results in: 1) the intake of an insufficient quantity or variety of food to meet adequate energy or nutritional requirements that has resulted in significant weight loss, clinically significant nutritional deficiencies, dependence on oral nutritional supplements or tube feeding, or has otherwise negatively affected the physical health of the individual; or 2) significant impairment in personal, family, social, educational, occupational or other important areas of functioning (e.g., due to avoidance or distress related to participating in social experiences involving eating). The pattern of eating behaviour is not motivated by preoccupation with body weight or shape. Restricted food intake and its effects on weight, other aspects of health, or functioning are not due to unavailability of food, not a manifestation of another medical condition (e.g. food allergies, hyperthyroidism) or mental disorder, and are not due to the effect of a substance or medication on the central nervous system including withdrawal effects.

**Exclusions:** Anorexia Nervosa (6B80)  
Feeding problem of infant (MG43.30)  
Feeding problems of newborn (KD32)

**6B84**

### Pica

Pica is characterised by the regular consumption of non-nutritive substances, such as non-food objects and materials (e.g., clay, soil, chalk, plaster, plastic, metal and paper) or raw food ingredients (e.g., large quantities of salt or corn flour) that is persistent or severe enough to require clinical attention in an individual who has reached a developmental age at which they would be expected to distinguish between edible and non-edible substances (approximately 2 years). That is, the behaviour causes damage to health, impairment in functioning, or significant risk due to the frequency, amount or nature of the substances or objects ingested.

**6B85**

### Rumination-regurgitation disorder

Rumination-regurgitation disorder is characterised by the intentional and repeated bringing up of previously swallowed food back to the mouth (i.e., regurgitation), which may be re-chewed and re-swallowed (i.e. rumination), or may be deliberately spat out (but not as in vomiting). The regurgitation behaviour is frequent (at least several times per week) and sustained over a period of at least several weeks. The regurgitation behaviour is not fully accounted for by another medical condition that directly causes regurgitation (e.g., oesophageal strictures or neuromuscular disorders affecting oesophageal functioning) or causes nausea or vomiting (e.g. pyloric stenosis). Rumination-regurgitation disorder should only be diagnosed in individuals who have reached a developmental age of at least 2 years.

**Exclusions:** Adult rumination syndrome (DD90.6)  
Nausea or vomiting (MD90)

**6B8Y**

### Other specified feeding or eating disorders

**6B8Z**

### Feeding or eating disorders, unspecified

## Elimination disorders (6C00-6C0Z)

Elimination disorders include the repeated voiding of urine into clothes or bed (enuresis) and the repeated passage of faeces in inappropriate places (encopresis). Elimination disorders should only be diagnosed after the individual has reached a developmental age when continence is ordinarily expected (5 years for enuresis and 4 years for encopresis). The urinary or faecal incontinence may have been present from birth (i.e., an atypical extension of normal infantile incontinence), or may have arisen following a period of acquired bladder or bowel control. An Elimination disorder should not be diagnosed if the behaviour is fully attributable to another health condition that causes incontinence, congenital or acquired abnormalities of the urinary tract or bowel, or excessive use of laxatives or diuretics.

### 6C00

#### Enuresis

Enuresis is the repeated voiding of urine into clothes or bed, which may occur during the day or at night, in an individual who has reached a developmental age when urinary continence is ordinarily expected (5 years). The urinary incontinence may have been present from birth (i.e., an atypical extension of normal infantile incontinence), or may have arisen following a period of acquired bladder control. In most cases, the behaviour is involuntary but in some cases it appears intentional. Enuresis should not be diagnosed if unintentional voiding of urine is due to a health condition that interferes with continence (e.g., diseases of the nervous system or musculoskeletal disorders) or by congenital or acquired abnormalities of the urinary tract.

- Inclusions:**
- Functional enuresis
  - Psychogenic enuresis
  - Urinary incontinence of nonorganic origin
- Exclusions:**
- Stress incontinence (MF50.20)
  - Urge Incontinence (MF50.21)
  - Functional urinary incontinence (MF50.23)
  - Overflow Incontinence (MF50.2)
  - Reflex incontinence (MF50.24)
  - Extraurethral urinary incontinence (MF50.2)

### 6C00.0

#### Nocturnal enuresis

Nocturnal enuresis refers to repeated voiding of urine into clothes or bed that occurs only during sleep (i.e., during the night) in an individual who has reached a developmental age when urinary continence is ordinarily expected (5 years). The urinary incontinence may have been present from birth (i.e., an atypical extension of normal infantile incontinence), or may have arisen following a period of acquired bladder control. In most cases, the behaviour is involuntary but in some cases it appears intentional.

### 6C00.1

#### Diurnal enuresis

Diurnal enuresis refers to repeated voiding of urine into clothes that occurs only during waking hours in an individual who has reached a developmental age when urinary continence is ordinarily expected (5 years). The urinary incontinence may have been present from birth (i.e., an atypical extension of normal infantile incontinence), or may have arisen following a period of acquired bladder control. In most cases, the behaviour is involuntary but in some cases it appears intentional.

- 6C00.2 Nocturnal and diurnal enuresis**  
Nocturnal and diurnal enuresis refers to repeated voiding of urine into clothes or bed that occurs both during sleep (i.e., during the night) and during waking hours in an individual who has reached a developmental age when urinary continence is ordinarily expected (5 years). The urinary incontinence may have been present from birth (i.e., an atypical extension of normal infantile incontinence), or may have arisen following a period of acquired bladder control. In most cases, the behaviour is involuntary but in some cases it appears intentional.
- 6C00.Z Enuresis, unspecified**
- 6C01 Encopresis**  
Encopresis is the repeated passage of faeces in inappropriate places. Encopresis should be diagnosed if inappropriate passage of faeces occurs repeatedly (e.g., at least once per month over a period of several months) in an individual who has reached the developmental age when faecal continence is ordinarily expected (4 years). The faecal incontinence may have been present from birth (i.e., an atypical extension of normal infantile incontinence), or may have arisen following a period of acquired bowel control. Encopresis should not be diagnosed if faecal soiling is fully attributable to another health condition (e.g., aganglionic megacolon, spina bifida, dementia), congenital or acquired abnormalities of the bowel, gastrointestinal infection, or excessive use of laxatives.
- 6C01.0 Encopresis with constipation or overflow incontinence**  
Encopresis is the repeated passage of faeces in inappropriate places occurring repeatedly (e.g., at least once per month over a period of several months) in an individual who has reached the developmental age when faecal continence is ordinarily expected (4 years). The faecal incontinence may have been present from birth (i.e., an atypical extension of normal infantile incontinence), or may have arisen following a period of acquired bowel control. Encopresis with constipation and overflow incontinence is the most common form of faecal soiling, and involves retention and impaction of faeces. Stools are typically — but not always — poorly formed (loose or liquid) and leakage may range from occasional to continuous. There is often a history of toilet avoidance leading to constipation.
- 6C01.1 Encopresis without constipation or overflow incontinence**  
Encopresis is the repeated passage of faeces in inappropriate places occurring repeatedly (e.g., at least once per month over a period of several months) in an individual who has reached the developmental age when faecal continence is ordinarily expected (4 years). The faecal incontinence may have been present from birth (i.e., an atypical extension of normal infantile incontinence), or may have arisen following a period of acquired bowel control. Encopresis without constipation and overflow is not associated with retention and impaction of faeces, but rather reflects reluctance, resistance or failure to conform to social norms in defecating in acceptable places in the context of normal physiological control over defecation. Stools are typically of normal consistency and inappropriate defecation is likely to be intermittent.
- 6C01.Z Encopresis, unspecified**
- 6C0Z Elimination disorders, unspecified**

## Disorders of bodily distress or bodily experience (6C20-6C2Z)

Disorders of bodily distress and bodily experience are characterised by disturbances in the person's experience of his or her body. Bodily distress disorder involves bodily symptoms that the individual finds distressing and to which excessive attention is directed. Body integrity dysphoria involves a disturbance in the person's experience of the body manifested by the persistent desire to have a specific physical disability accompanied by persistent discomfort, or intense feelings of inappropriateness concerning current non-disabled body configuration.

- Exclusions:**
- Dissociative neurological symptom disorder (6B60)
  - Concern about body appearance (QD30-QD3Z)

**6C20**

### Bodily distress disorder

Bodily distress disorder is characterised by the presence of bodily symptoms that are distressing to the individual and excessive attention directed toward the symptoms, which may be manifest by repeated contact with health care providers. If another health condition is causing or contributing to the symptoms, the degree of attention is clearly excessive in relation to its nature and progression. Excessive attention is not alleviated by appropriate clinical examination and investigations and appropriate reassurance. Bodily symptoms are persistent, being present on most days for at least several months. Typically, bodily distress disorder involves multiple bodily symptoms that may vary over time. Occasionally there is a single symptom—usually pain or fatigue—that is associated with the other features of the disorder. The symptoms and associated distress and preoccupation have at least some impact on the individual's functioning (e.g. strain in relationships, less effective academic or occupational functioning, abandonment of specific leisure activities).

- Exclusions:**
- Tourette syndrome (8A05.00)
  - Hair pulling disorder (6B25.0)
  - Dissociative disorders (6B60-6B6Z)
  - hair-plucking (6B25.0)
  - Hypochondriasis (6B23)
  - Body dysmorphic disorder (6B21)
  - Excoriation disorder (6B25.1)
  - Gender incongruence (HA60-HA6Z)
  - Sexual dysfunctions (HA00-HA0Z)
  - Tic disorders (8A05)
  - Sexual pain-penetration disorder (HA20)
  - Postviral fatigue syndrome (8E49)
  - Chronic fatigue syndrome (8E49)
  - Myalgic encephalomyelitis (8E49)

- 6C20.0      Mild bodily distress disorder**  
All definitional requirements of bodily distress disorder are present. There is excessive attention to distressing symptoms and their consequences, which may result in frequent medical visits, but the person is not preoccupied with the symptoms (e.g., the individual spends less than an hour per day focusing on them). Although the individual expresses distress about the symptoms and they may have some impact on his or her life (e.g., strain in relationships, less effective academic or occupational functioning, abandonment of specific leisure activities), there is no substantial impairment in the person's personal, family, social, educational, occupational, or other important areas of functioning.
- 6C20.1      Moderate bodily distress disorder**  
All definitional requirements of bodily distress disorder are present. There is persistent preoccupation with the distressing symptoms and their consequences (e.g., the individual spends more than an hour a day thinking about them), typically associated with frequent medical visits. The person devotes much of his or her energy to focusing on the symptoms and their consequences. The symptoms and associated distress and preoccupation cause moderate impairment in personal, family, social, educational, occupational, or other important areas of functioning (e.g., relationship conflict, performance problems at work, abandonment of a range of social and leisure activities).
- 6C20.2      Severe bodily distress disorder**  
All definitional requirements of Bodily distress disorder are present. There is pervasive and persistent preoccupation with the symptoms and their consequences to the extent that these may become the focal point of the person's life, typically resulting in extensive interactions with the health care system. The symptoms and associated distress and preoccupation cause serious impairment in personal, family, social, educational, occupational, or other important areas of functioning (e.g., unable to work, alienation of friends and family, abandonment of nearly all social and leisure activities). The person's interests may become so narrow as to focus almost exclusively on his or her bodily symptoms and their negative consequences.
- 6C20.Z      Bodily distress disorder, unspecified**
- 6C21      Body integrity dysphoria**  
Body integrity dysphoria is characterised by an intense and persistent desire to become physically disabled in a significant way (e.g. major limb amputee, paraplegic, blind), with onset by early adolescence accompanied by persistent discomfort, or intense feelings of inappropriateness concerning current non-disabled body configuration. The desire to become physically disabled results in harmful consequences, as manifested by either the preoccupation with the desire (including time spent pretending to be disabled) significantly interfering with productivity, with leisure activities, or with social functioning (e.g. person is unwilling to have a close relationship because it would make it difficult to pretend) or by attempts to actually become disabled having resulted in the person putting his or her health or life in significant jeopardy. The disturbance is not better accounted for by another mental, behavioural or neurodevelopmental disorder, by a Disease of the Nervous System or by another medical condition, or by Malingering.

**Exclusions:**      Gender incongruence of adolescence or adulthood (HA60)

**6C2Y****Other specified disorders of bodily distress or bodily experience****6C2Z****Disorders of bodily distress or bodily experience, unspecified**

## Disorders due to substance use or addictive behaviours (6C40-6C5Z)

Disorders due to substance use and addictive behaviours are mental and behavioural disorders that develop as a result of the use of predominantly psychoactive substances, including medications, or specific repetitive rewarding and reinforcing behaviours.

### Disorders due to substance use (6C40-6C4Z)

Disorders due to substance use include disorders that result from a single occasion or repeated use of substances that have psychoactive properties, including certain medications. Disorders related to fourteen classes or groups of psychoactive substances are included. Typically, initial use of these substances produces pleasant or appealing psychoactive effects that are rewarding and reinforcing with repeated use. With continued use, many of the included substances have the capacity to produce dependence. They also have the potential to cause numerous forms of harm, both to mental and physical health. Disorders due to harmful non-medical use of non-psychoactive substances are also included in this grouping.

**Coded Elsewhere:** Catatonia induced by substances or medications (6A41)

**6C40**

### Disorders due to use of alcohol

Disorders due to use of alcohol are characterised by the pattern and consequences of alcohol use. Alcohol—more specifically termed ethyl alcohol or ethanol—is an intoxicating compound produced by fermentation of sugars usually in agricultural products such as fruits, cereals, and vegetables with or without subsequent distillation. There are a wide variety of alcoholic drinks, with alcohol concentrations typically ranging from 1.5% to 60%. Alcohol is predominantly a central nervous system depressant. In addition to ability to produce Alcohol Intoxication, alcohol has dependence-producing properties, resulting in Alcohol Dependence in some people and Alcohol Withdrawal when alcohol use is reduced or discontinued. Unlike most other substances, elimination of alcohol from the body occurs at a constant rate, such that its clearance follows a linear rather than a logarithmic course. Alcohol is implicated in a wide range of harms affecting most organs and systems of the body (e.g., cirrhosis of the liver, gastrointestinal cancers, pancreatitis). Harm to others resulting from behaviour during Alcohol Intoxication is well recognized and is included in the definitions of harmful use of alcohol (i.e., Episode of Harmful Use of Alcohol and Harmful Pattern of Use of Alcohol). Several alcohol-induced mental disorders (e.g., Alcohol-Induced Psychotic Disorder) and alcohol-related forms of neurocognitive impairment (e.g., Dementia Due to Use of Alcohol) are recognized.

**Exclusions:** Hazardous alcohol use (QE10)

- 6C40.0      Episode of harmful use of alcohol**
- An episode of use of alcohol that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to alcohol intoxication on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of alcohol use.
- Exclusions:**      Harmful pattern of use of alcohol (6C40.1)  
Alcohol dependence (6C40.2)
- 6C40.1      Harmful pattern of use of alcohol**
- A pattern of alcohol use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of alcohol use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to alcohol intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of alcohol applies.
- Exclusions:**      Alcohol dependence (6C40.2)  
Episode of harmful use of alcohol (6C40.0)
- 6C40.10     Harmful pattern of use of alcohol, episodic**
- A pattern of episodic or intermittent alcohol use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic alcohol use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to alcohol intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of alcohol applies.
- Exclusions:**      Episode of harmful use of alcohol (6C40.0)  
Alcohol dependence (6C40.2)

<b>6C40.11</b>	Harmful pattern of use of alcohol, continuous  A pattern of continuous (daily or almost daily) alcohol use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous alcohol use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to alcohol intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of alcohol applies.
	<b><i>Exclusions:</i></b> Episode of harmful use of alcohol (6C40.0) Alcohol dependence (6C40.2)
<b>6C40.1Z</b>	Harmful pattern of use of alcohol, unspecified
<b>6C40.2</b>	<p><b>Alcohol dependence</b></p> <p>Alcohol dependence is a disorder of regulation of alcohol use arising from repeated or continuous use of alcohol. The characteristic feature is a strong internal drive to use alcohol, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use alcohol. Physiological features of dependence may also be present, including tolerance to the effects of alcohol, withdrawal symptoms following cessation or reduction in use of alcohol, or repeated use of alcohol or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if alcohol use is continuous (daily or almost daily) for at least 3 months.</p> <p><b><i>Inclusions:</i></b> Chronic alcoholism Dipsomania</p> <p><b><i>Exclusions:</i></b> Episode of harmful use of alcohol (6C40.0) Harmful pattern of use of alcohol (6C40.1)</p>
<b>6C40.20</b>	<p>Alcohol dependence, current use, continuous</p> <p>Alcohol dependence with continuous consumption of alcohol (daily or almost daily) over a period of at least 1 month.</p> <p><b><i>Exclusions:</i></b> Episode of harmful use of alcohol (6C40.0) Harmful pattern of use of alcohol (6C40.1)</p>
<b>6C40.21</b>	<p>Alcohol dependence, current use, episodic</p> <p>During the past 12 months, there has been alcohol dependence with intermittent heavy drinking, with periods of abstinence from alcohol. If current use is continuous (daily or almost daily over at least the past 1 month), the diagnosis of Alcohol dependence, current use, continuous should be made instead.</p> <p><b><i>Exclusions:</i></b> Episode of harmful use of alcohol (6C40.0) Harmful pattern of use of alcohol (6C40.1)</p>

- 6C40.22** Alcohol dependence, early full remission  
After a diagnosis of alcohol dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from alcohol during a period lasting between 1 and 12 months.
- Exclusions:** Episode of harmful use of alcohol (6C40.0)  
Harmful pattern of use of alcohol (6C40.1)
- 6C40.23** Alcohol dependence, sustained partial remission  
After a diagnosis of alcohol dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in alcohol consumption for more than 12 months, such that even though intermittent or continuing drinking has occurred during this period, the definitional requirements for dependence have not been met.
- Exclusions:** Episode of harmful use of alcohol (6C40.0)  
Harmful pattern of use of alcohol (6C40.1)
- 6C40.24** Alcohol dependence, sustained full remission  
After a diagnosis of alcohol dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from alcohol for 12 months or longer.
- Exclusions:** Episode of harmful use of alcohol (6C40.0)  
Harmful pattern of use of alcohol (6C40.1)
- 6C40.2Z** Alcohol dependence, unspecified
- 6C40.3** **Alcohol intoxication**  
Alcohol intoxication is a clinically significant transient condition that develops during or shortly after the consumption of alcohol that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of alcohol and their intensity is closely related to the amount of alcohol consumed. They are time-limited and abate as alcohol is cleared from the body. Presenting features may include impaired attention, inappropriate or aggressive behaviour, lability of mood and emotions, impaired judgment, poor coordination, unsteady gait, fine nystagmus and slurred speech. At more severe levels of intoxication, stupor or coma may occur. Alcohol intoxication may facilitate suicidal ideation or behaviour.
- Coding Note:** Code also the causing condition
- Exclusions:** alcohol poisoning (NE61)  
Possession trance disorder (6B63)

<b>6C40.4</b>	<b>Alcohol withdrawal</b> Alcohol withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of alcohol in individuals who have developed Alcohol dependence or have used alcohol for a prolonged period or in large amounts. Presenting features of Alcohol withdrawal may include autonomic hyperactivity (e.g. tachycardia, hypertension, perspiration), increased hand tremor, nausea, retching or vomiting, insomnia, anxiety, psychomotor agitation, depressed or dysphoric mood, transient visual, tactile or auditory illusions or hallucinations, and distractability. Less commonly, the withdrawal state is complicated by generalised tonic-clonic seizures. The withdrawal state may progress to a very severe form of delirium characterised by confusion and disorientation, delusions, and prolonged visual, tactile or auditory hallucinations. In such cases, a separate diagnosis of Alcohol-induced delirium should also be assigned.
<b>Coding Note:</b>	Code also the causing condition
<b>6C40.40</b>	Alcohol withdrawal, uncomplicated All diagnostic requirements for Alcohol Withdrawal are met and the withdrawal state is not accompanied by perceptual disturbances or seizures.
<b>Coding Note:</b>	Code also the causing condition
<b>6C40.41</b>	Alcohol withdrawal with perceptual disturbances All diagnostic requirements for Alcohol withdrawal are met and the withdrawal state is accompanied by perceptual disturbances (e.g., visual or tactile hallucinations or illusions) with intact reality testing. There is no evidence of confusion and other diagnostic requirements for Delirium are not met. The withdrawal state is not accompanied by seizures.
<b>Coding Note:</b>	Code also the causing condition
<b>6C40.42</b>	Alcohol withdrawal with seizures All diagnostic requirements for Alcohol withdrawal are met and the withdrawal state is accompanied by seizures (i.e., generalised tonic-clonic seizures) but not by perceptual disturbances.
<b>Coding Note:</b>	Code also the causing condition
<b>6C40.43</b>	Alcohol withdrawal with perceptual disturbances and seizures All diagnostic requirements for Alcohol withdrawal are met and the withdrawal state is accompanied by both seizures (i.e., generalised tonic-clonic seizures) and perceptual disturbances (e.g., visual or tactile hallucinations or illusions) with intact reality testing. Diagnostic requirements for Delirium are not met.
<b>Coding Note:</b>	Code also the causing condition
<b>6C40.4Z</b>	Alcohol withdrawal, unspecified <b>Coding Note:</b> Code also the causing condition

<b>6C40.5</b>	<b>Alcohol-induced delirium</b> Alcohol-induced delirium is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of alcohol. The amount and duration of alcohol use must be capable of producing delirium. Specific features of alcohol-induced delirium may include impaired consciousness with disorientation, vivid hallucinations and illusions, insomnia, delusions, agitation, disturbances of attention, and accompanying tremor and physiological symptoms of alcohol withdrawal. In some cases of alcohol withdrawal, the withdrawal state may progress to a very severe form of Alcohol-induced delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> Delirium tremens (alcohol-induced) Delirium induced by alcohol withdrawal
<b>6C40.6</b>	<b>Alcohol-induced psychotic disorder</b> Alcohol-induced psychotic disorder is characterised by psychotic symptoms (e.g. delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from alcohol. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Alcohol intoxication or Alcohol withdrawal. The amount and duration of alcohol use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g. Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the alcohol use, if the symptoms persist for a substantial period of time after cessation of the alcohol use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g. a history of prior episodes not associated with alcohol use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C40.60</b>	Alcohol-induced psychotic disorder with hallucinations Alcohol-induced psychotic disorder with hallucinations is characterised by the presence of hallucinations that are judged to be the direct consequence of alcohol use. Neither delusions nor other psychotic symptoms are present. The symptoms do not occur exclusively during hypnagogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).
<b>Coding Note:</b>	Code also the causing condition

- 6C40.61** Alcohol-induced psychotic disorder with delusions  
Alcohol-induced psychotic disorder with delusions is characterised by the presence of delusions that are judged to be the direct consequence of alcohol use. Neither hallucinations nor other psychotic symptoms are present. The symptoms do not occur exclusively during hypnogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).
- Coding Note:** Code also the causing condition
- 6C40.62** Alcohol-induced psychotic disorder with mixed psychotic symptoms  
Alcohol-induced psychotic disorder with mixed psychotic symptoms is characterised by the presence of multiple psychotic symptoms, primarily hallucinations and delusions, when these are judged to be the direct consequence of alcohol use. The symptoms do not occur exclusively during hypnogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).
- Coding Note:** Code also the causing condition
- 6C40.6Z** Alcohol-induced psychotic disorder, unspecified  
**Coding Note:** Code also the causing condition
- 6C40.7** **Certain specified alcohol-induced mental or behavioural disorders**
- Coding Note:** Code also the causing condition
- Coded Elsewhere:** Amnestic disorder due to use of alcohol (6D72.10)  
Dementia due to use of alcohol (6D84.0)
- 6C40.70** Alcohol-induced mood disorder  
Alcohol-induced mood disorder is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from alcohol. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Alcohol intoxication or Alcohol withdrawal. The amount and duration of alcohol use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the alcohol use, if the symptoms persist for a substantial period of time after cessation of the alcohol use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with alcohol use).
- Coding Note:** Code also the causing condition

**6C40.71** Alcohol-induced anxiety disorder  
Alcohol-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from alcohol. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Alcohol intoxication or Alcohol withdrawal. The amount and duration of alcohol use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and Fear-Related Disorder, a Depressive Disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the alcohol use, if the symptoms persist for a substantial period of time after cessation of the alcohol use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with alcohol use).

**Coding Note:** Code also the causing condition

**6C40.Y** Other specified disorders due to use of alcohol

**6C40.Z** Disorders due to use of alcohol, unspecified

**6C41**

**Disorders due to use of cannabis**

Disorders due to use of cannabis are characterised by the pattern and consequences of cannabis use. Cannabis is the collective term for a range of psychoactive preparations of the cannabis plant, *Cannabis sativa*, and related species and hybrids. Cannabis contains cannabinoids, a class of diverse chemical compounds that act on endogenous cannabinoid receptors that modulate neurotransmitter release in the brain. The principal psychoactive cannabinoid is δ-9-tetrahydrocannabinol (THC). Cannabis is typically smoked in the form of the flowering heads or leaves of the marijuana plant; tobacco is often mixed with cannabis when smoked. There are also cannabis oils that are prepared from these same sources. These preparations vary considerably in their THC potency. Cannabis has predominantly central nervous system depressant effects and produces a characteristic euphoria that may be part of the presenting features of Cannabis Intoxication, which may also include impairment in cognitive and psychomotor functioning. Cannabis has dependence-producing properties resulting in Cannabis Dependence in some people and Cannabis Withdrawal when use is reduced or discontinued. Cannabis is associated with a range of Cannabis-Induced Mental Disorders.

**Exclusions:** Disorders due to use of synthetic cannabinoids (6C42)

Hazardous use of cannabis (QE11.1)

- 6C41.0      Episode of harmful use of cannabis**
- An episode of use of cannabis that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to cannabis intoxication on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of cannabis use.
- Exclusions:**      Cannabis dependence (6C41.2)  
                          Harmful pattern of use of cannabis (6C41.1)
- 6C41.1      Harmful pattern of use of cannabis**
- A pattern of cannabis use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of cannabis use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to cannabis intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of cannabis applies.
- Exclusions:**      Cannabis dependence (6C41.2)  
                          Episode of harmful use of cannabis (6C41.0)
- 6C41.10     Harmful pattern of use of cannabis, episodic**
- A pattern of episodic or intermittent cannabis use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic cannabis use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to cannabis intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of cannabis applies.
- Exclusions:**      Episode of harmful use of cannabis (6C41.0)  
                          Cannabis dependence (6C41.2)

- 6C41.11** Harmful pattern of use of cannabis, continuous  
A pattern of continuous (daily or almost daily) cannabis use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous cannabis use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to cannabis intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of cannabis applies.
- Exclusions:** Episode of harmful use of cannabis (6C41.0)  
Cannabis dependence (6C41.2)
- 6C41.1Z** Harmful pattern of use of cannabis, unspecified
- 6C41.2** **Cannabis dependence**  
Cannabis dependence is a disorder of regulation of cannabis use arising from repeated or continuous use of cannabis. The characteristic feature is a strong internal drive to use cannabis, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use cannabis. Physiological features of dependence may also be present, including tolerance to the effects of cannabis, withdrawal symptoms following cessation or reduction in use of cannabis, or repeated use of cannabis or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if cannabis use is continuous (daily or almost daily) for at least 3 months.
- Exclusions:** Episode of harmful use of cannabis (6C41.0)  
Harmful pattern of use of cannabis (6C41.1)
- 6C41.20** Cannabis dependence, current use  
Current cannabis dependence with use of cannabis within the past month.
- Exclusions:** Episode of harmful use of cannabis (6C41.0)  
Harmful pattern of use of cannabis (6C41.1)
- 6C41.21** Cannabis dependence, early full remission  
After a diagnosis of cannabis dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from cannabis during a period lasting between 1 and 12 months.
- Exclusions:** Episode of harmful use of cannabis (6C41.0)  
Harmful pattern of use of cannabis (6C41.1)

<b>6C41.22</b>	Cannabis dependence, sustained partial remission  After a diagnosis of cannabis dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in cannabis consumption for more than 12 months, such that even though cannabis use has occurred during this period, the definitional requirements for dependence have not been met.
	<b><i>Exclusions:</i></b> Episode of harmful use of cannabis (6C41.0) Harmful pattern of use of cannabis (6C41.1)
<b>6C41.23</b>	Cannabis dependence, sustained full remission  After a diagnosis of cannabis dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from cannabis for 12 months or longer.
	<b><i>Exclusions:</i></b> Episode of harmful use of cannabis (6C41.0) Harmful pattern of use of cannabis (6C41.1)
<b>6C41.2Z</b>	Cannabis dependence, unspecified
<b>6C41.3</b>	<b>Cannabis intoxication</b>  Cannabis intoxication is a clinically significant transient condition that develops during or shortly after the consumption of cannabis that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of cannabis and their intensity is closely related to the amount of cannabis consumed. They are time-limited and abate as cannabis is cleared from the body. Presenting features may include inappropriate euphoria, impaired attention, impaired judgment, perceptual alterations (such as the sensation of floating, altered perception of time), changes in sociability, increased appetite, anxiety, intensification of ordinary experiences, impaired short-term memory, and sluggishness. Physical signs include conjunctival injection (red or bloodshot eyes) and tachycardia.
	<b><i>Coding Note:</i></b> Code also the causing condition  <b><i>Inclusions:</i></b> "Bad trips" due to cannabinoids <b><i>Exclusions:</i></b> cannabinoid poisoning (NE60) Possession trance disorder (6B63)
<b>6C41.4</b>	<b>Cannabis withdrawal</b>  Cannabis withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of cannabis in individuals who have developed Cannabis dependence or have used cannabis for a prolonged period or in large amounts. Presenting features of Cannabis withdrawal may include irritability, anger or aggressive behaviour, shakiness, insomnia, restlessness, anxiety, depressed or dysphoric mood, decreased appetite and weight loss, headache, sweating or chills, abdominal cramps and muscle aches.
	<b><i>Coding Note:</i></b> Code also the causing condition

<b>6C41.5</b>	<b>Cannabis-induced delirium</b>
	Cannabis-induced delirium is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of cannabis. The amount and duration of cannabis use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.
<b>Coding Note:</b>	Code also the causing condition
<b>6C41.6</b>	<b>Cannabis-induced psychotic disorder</b>
	Cannabis-induced psychotic disorder is characterised by psychotic symptoms (e.g. delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from cannabis. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Cannabis intoxication or Cannabis withdrawal. The amount and duration of cannabis use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g. Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the cannabis use, if the symptoms persist for a substantial period of time after cessation of the cannabis use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g. a history of prior episodes not associated with cannabis use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C41.7</b>	<b>Certain specified cannabis-induced mental or behavioural disorders</b>
<b>Coding Note:</b>	Code also the causing condition
<b>6C41.70</b>	Cannabis-induced mood disorder
	Cannabis-induced mood disorder is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from cannabis. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Cannabis intoxication or Cannabis withdrawal. The amount and duration of cannabis use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the cannabis use, if the symptoms persist for a substantial period of time after cessation of the cannabis use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with cannabis use).
<b>Coding Note:</b>	Code also the causing condition

<b>6C41.71</b>	Cannabis-induced anxiety disorder Cannabis-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from cannabis. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Cannabis intoxication or Cannabis withdrawal. The amount and duration of cannabis use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and Fear-Related Disorder, a Depressive Disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the cannabis use, if the symptoms persist for a substantial period of time after cessation of the cannabis use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with cannabis use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C41.Y</b>	<b>Other specified disorders due to use of cannabis</b>
<b>6C41.Z</b>	<b>Disorders due to use of cannabis, unspecified</b>
<b>6C42</b>	<p><b>Disorders due to use of synthetic cannabinoids</b></p> <p>Disorders due to use of synthetic cannabinoids are characterised by the pattern and consequences of synthetic cannabinoid use. Synthetic cannabinoids are synthesized diverse chemical compounds that are potent agonists for endogenous cannabinoid receptors. There are several hundred such compounds. The synthetic compound is typically sprayed onto a vehicle such as cannabis or tea leaves and then smoked. The effect of these compounds is distinctly different from smoking naturally cultivated cannabis in that the euphoric effects are typically accompanied or dominated by psychotic-like symptoms (e.g., paranoia, hallucinations, and disorganized behavior). Synthetic Cannabinoid Intoxication may therefore present more frequently with psychotic symptoms in addition to the more typical effects of cannabis. Synthetic cannabinoids are also dependence-producing and Synthetic Cannabinoid Dependence and Synthetic Cannabinoid Withdrawal are recognized. Synthetic Cannabinoid-Induced Mental Disorders also occur; in particular Synthetic Cannabinoid-Induced Psychotic Disorder is recognized.</p> <p><b>Exclusions:</b> Disorders due to use of cannabis (6C41)</p> <p><b>6C42.0</b> <b>Episode of harmful use of synthetic cannabinoids</b></p> <p>An episode of use of a synthetic cannabinoid that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to synthetic cannabinoid intoxication on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of synthetic cannabinoid use.</p> <p><b>Exclusions:</b> Harmful pattern of use of synthetic cannabinoids (6C42.1) Synthetic cannabinoid dependence (6C42.2)</p>

<b>6C42.1</b>	<b>Harmful pattern of use of synthetic cannabinoids</b> A pattern of use of synthetic cannabinoids that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of synthetic cannabinoid use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to synthetic cannabinoid intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of synthetic cannabinoids applies.
	<b>Exclusions:</b> Episode of harmful use of synthetic cannabinoids (6C42.0) Synthetic cannabinoid dependence (6C42.2)
<b>6C42.10</b>	Harmful pattern of use of synthetic cannabinoids, episodic A pattern of episodic or intermittent use of synthetic cannabinoids that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic synthetic cannabinoid use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to synthetic cannabinoid intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of synthetic cannabinoids applies.
	<b>Exclusions:</b> Episode of harmful use of synthetic cannabinoids (6C42.0) Synthetic cannabinoid dependence (6C42.2)
<b>6C42.11</b>	Harmful pattern of use of synthetic cannabinoids, continuous A pattern of continuous (daily or almost daily) use of synthetic cannabinoids that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous synthetic cannabinoid use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to synthetic cannabinoid intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of synthetic cannabinoids applies.
	<b>Exclusions:</b> Episode of harmful use of synthetic cannabinoids (6C42.0) Synthetic cannabinoid dependence (6C42.2)
<b>6C42.1Y</b>	Other specified harmful pattern of use of synthetic cannabinoids
<b>6C42.1Z</b>	Harmful pattern of use of synthetic cannabinoids, unspecified

<b>6C42.2</b>	<b>Synthetic cannabinoid dependence</b> Synthetic cannabinoid dependence is a disorder of regulation of synthetic cannabinoid use arising from repeated or continuous use of synthetic cannabinoids. The characteristic feature is a strong internal drive to use synthetic cannabinoids, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use synthetic cannabinoids. Physiological features of dependence may also be present, including tolerance to the effects of synthetic cannabinoids, withdrawal symptoms following cessation or reduction in use of synthetic cannabinoids, or repeated use of synthetic cannabinoids or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if synthetic cannabinoid use is continuous (daily or almost daily) for at least 3 months.
	<b>Exclusions:</b> Episode of harmful use of synthetic cannabinoids (6C42.0) Harmful pattern of use of synthetic cannabinoids (6C42.1)
<b>6C42.20</b>	Synthetic cannabinoid dependence, current use Current synthetic cannabinoid dependence with use of synthetic cannabinoids within the past month.  <b>Exclusions:</b> Episode of harmful use of synthetic cannabinoids (6C42.0) Harmful pattern of use of synthetic cannabinoids (6C42.1)
<b>6C42.21</b>	Synthetic cannabinoid dependence, early full remission After a diagnosis of synthetic cannabinoid dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from synthetic cannabinoid use during a period lasting between 1 and 12 months.  <b>Exclusions:</b> Episode of harmful use of synthetic cannabinoids (6C42.0) Harmful pattern of use of synthetic cannabinoids (6C42.1)
<b>6C42.22</b>	Synthetic cannabinoid dependence, sustained partial remission After a diagnosis of synthetic cannabinoid dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in synthetic cannabinoid consumption for more than 12 months, such that even though synthetic cannabinoid use has occurred during this period, the definitional requirements for dependence have not been met.  <b>Exclusions:</b> Episode of harmful use of synthetic cannabinoids (6C42.0) Harmful pattern of use of synthetic cannabinoids (6C42.1)
<b>6C42.23</b>	Synthetic cannabinoid dependence, sustained full remission After a diagnosis of synthetic cannabinoid dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from synthetic cannabinoid use for 12 months or longer.  <b>Exclusions:</b> Episode of harmful use of synthetic cannabinoids (6C42.0) Harmful pattern of use of synthetic cannabinoids (6C42.1)

- 6C42.2Y** Other specified synthetic cannabinoid dependence
- 6C42.2Z** Synthetic cannabinoid dependence, unspecified
- 6C42.3** **Synthetic cannabinoid intoxication**  
Synthetic cannabinoid intoxication is a clinically significant transient condition that develops during or shortly after the consumption of synthetic cannabinoids that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of synthetic cannabinoids and their intensity is closely related to the amount of synthetic cannabinoid consumed. They are time-limited and abate as synthetic cannabinoid is cleared from the body. Presenting features may include inappropriate euphoria, impaired attention, impaired judgment, perceptual alterations (such as the sensation of floating, altered perception of time), changes in sociability, increased appetite, anxiety, intensification of ordinary experiences, impaired short-term memory, and sluggishness. Physical signs include conjunctival injection (red or bloodshot eyes) and tachycardia. Intoxication with synthetic cannabinoids may also cause delirium or acute psychosis.
- Coding Note:** Code also the causing condition
- 6C42.4** **Synthetic cannabinoid withdrawal**  
Synthetic cannabinoid withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of synthetic cannabinoids in individuals who have developed Synthetic cannabinoid dependence or have used synthetic cannabinoids for a prolonged period or in large amounts. Presenting features of Synthetic cannabinoid withdrawal may include irritability, anger, aggression, shakiness, insomnia and disturbing dreams, restlessness, anxiety, depressed mood and appetite disturbance. In the early phase, Synthetic cannabinoid withdrawal may be accompanied by residual features of intoxication from the drug, such as paranoid ideation and auditory and visual hallucinations.
- Coding Note:** Code also the causing condition
- 6C42.5** **Synthetic cannabinoid-induced delirium**  
Synthetic cannabinoid-induced delirium is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of synthetic cannabinoids. The amount and duration of synthetic cannabinoid use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.
- Coding Note:** Code also the causing condition

<b>6C42.6</b>	<b>Synthetic cannabinoid-induced psychotic disorder</b> Synthetic cannabinoid-induced psychotic disorder is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from synthetic cannabinoids. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Synthetic cannabinoid intoxication or Synthetic cannabinoid withdrawal. The amount and duration of synthetic cannabinoid use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the synthetic cannabinoid use, if the symptoms persist for a substantial period of time after cessation of the synthetic cannabinoid use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with synthetic cannabinoid use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C42.7</b>	<b>Certain specified synthetic cannabinoids-induced mental or behavioural disorders</b>
<b>Coding Note:</b>	Code also the causing condition
<b>6C42.70</b>	<b>Synthetic cannabinoid-induced mood disorder</b> Synthetic cannabinoid-induced mood disorder is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from synthetic cannabinoids. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Synthetic cannabinoid intoxication or Synthetic cannabinoid withdrawal. The amount and duration of synthetic cannabinoid use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the synthetic cannabinoid use, if the symptoms persist for a substantial period of time after cessation of the synthetic cannabinoid use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with synthetic cannabinoid use).
<b>Coding Note:</b>	Code also the causing condition

<b>6C42.71</b>	Synthetic cannabinoid-induced anxiety disorder Synthetic cannabinoid-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from synthetic cannabinoids. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Synthetic cannabinoid intoxication or Synthetic cannabinoid withdrawal. The amount and duration of synthetic cannabinoid use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and Fear-Related Disorder, a Depressive Disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the synthetic cannabinoid use, if the symptoms persist for a substantial period of time after cessation of the synthetic cannabinoid use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with synthetic cannabinoid use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C42.Y</b>	<b>Other specified disorders due to use of synthetic cannabinoids</b>
<b>6C42.Z</b>	<b>Disorders due to use of synthetic cannabinoids, unspecified</b>
<b>6C43</b>	<b>Disorders due to use of opioids</b> Disorders due to use of opioids are characterised by the pattern and consequences of opioid use. Opioids is a generic term that encompasses the constituents or derivatives of the opium poppy Papaver somniferum as well as a range of synthetic and semisynthetic compounds, some related to morphine and others chemically distinct but all having their primary actions on the $\mu$ opioid receptor. Examples of opioids include morphine, diacetylmorphine (heroin), fentanyl, pethidine, oxycodone, hydromorphone, methadone, buprenorphine, codeine and d-propoxyphene. The opioids all have analgesic properties of different potencies and are primarily central nervous system depressants. They suppress respiration as well as other vital functions and are a common cause of overdose and related deaths. Certain opioids are used or administered parenterally, including heroin, a common and potent opioid that is primarily used non-medically. Therapeutic opioids are prescribed for a range of indications worldwide, and are essential for pain management in cancer pain and palliative care, although they are also used for non-therapeutic reasons. In some countries morbidity and mortality related to therapeutic opioids is greater than that related to heroin. All opioids may result in Opioid Intoxication, Opioid Dependence and Opioid Withdrawal. A range of Opioid-Induced Disorders occur, some of which occur following Opioid Withdrawal.

**Exclusions:** Hazardous use of opioids (QE11.0)

**6C43.0**

**Episode of harmful use of opioids**

An episode of opioid use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to opioid intoxication on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of opioid use.

**Exclusions:**      Harmful pattern of use of opioids (6C43.1)  
                          Opioid dependence (6C43.2)

**6C43.1**

**Harmful pattern of use of opioids**

A pattern of use of opioids that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of opioid use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to opioid intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of opioids applies.

**Exclusions:**      Episode of harmful use of opioids (6C43.0)  
                          Opioid dependence (6C43.2)

**6C43.10**

**Harmful pattern of use of opioids, episodic**

A pattern of episodic or intermittent use of opioids that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic opioid use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to opioid intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of opioids applies.

**Exclusions:**      Episode of harmful use of opioids (6C43.0)  
                          Opioid dependence (6C43.2)

- 6C43.11** Harmful pattern of use of opioids, continuous  
A pattern of continuous (daily or almost daily) use of opioids that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous opioid use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to opioid intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of opioids applies.
- Exclusions:** Episode of harmful use of opioids (6C43.0)  
Opioid dependence (6C43.2)
- 6C43.1Z** Harmful pattern of use of opioids, unspecified
- 6C43.2** **Opioid dependence**  
Opioid dependence is a disorder of regulation of opioid use arising from repeated or continuous use of opioids. The characteristic feature is a strong internal drive to use opioids, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use opioids. Physiological features of dependence may also be present, including tolerance to the effects of opioids, withdrawal symptoms following cessation or reduction in use of opioids, or repeated use of opioids or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if opioid use is continuous (daily or almost daily) for at least 3 months.
- Exclusions:** Episode of harmful use of opioids (6C43.0)  
Harmful pattern of use of opioids (6C43.1)
- 6C43.20** Opioid dependence, current use  
Opioid dependence, with use of an opioid within the past month.  
**Exclusions:** Episode of harmful use of opioids (6C43.0)  
Harmful pattern of use of opioids (6C43.1)
- 6C43.21** Opioid dependence, early full remission  
After a diagnosis of opioid dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from opioid use during a period lasting between 1 and 12 months.  
**Exclusions:** Episode of harmful use of opioids (6C43.0)  
Harmful pattern of use of opioids (6C43.1)

<b>6C43.22</b>	Opioid dependence, sustained partial remission After a diagnosis of Opioid dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in opioid consumption for more than 12 months, such that even though opioid use has occurred during this period, the definitional requirements for dependence have not been met.
	<b>Exclusions:</b> Episode of harmful use of opioids (6C43.0) Harmful pattern of use of opioids (6C43.1)
<b>6C43.23</b>	Opioid dependence, sustained full remission After a diagnosis of Opioid dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from opioids for 12 months or longer.
	<b>Exclusions:</b> Episode of harmful use of opioids (6C43.0) Harmful pattern of use of opioids (6C43.1)
<b>6C43.2Z</b>	Opioid dependence, unspecified
<b>6C43.3</b>	<b>Opioid intoxication</b> Opioid intoxication is a clinically significant transient condition that develops during or shortly after the consumption of opioids that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of opioids and their intensity is closely related to the amount of opioids consumed. They are time-limited and abate as opioids are cleared from the body. Presenting features may include somnolence, stupor, mood changes (e.g. euphoria followed by apathy and dysphoria), psychomotor retardation, impaired judgment, respiratory depression, slurred speech, and impairment of memory and attention. In severe intoxication coma may ensue. A characteristic physical sign is pupillary constriction but this sign may be absent when intoxication is due to synthetic opioids. Severe opioid intoxication can lead to death due to respiratory depression.
	<b>Coding Note:</b> Code also the causing condition
	<b>Exclusions:</b> opioid poisoning (NE60) Possession trance disorder (6B63) fentanyl poisoning (NE60) oxycodone poisoning (NE60)

<b>6C43.4</b>	<b>Opioid withdrawal</b> Opioid withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of opioids in individuals who have developed Opioid dependence or have used opioids for a prolonged period or in large amounts. Opioid withdrawal can also occur when prescribed opioids have been used in standard therapeutic doses. Presenting features of Opioid withdrawal may include dysphoric mood, craving for an opioid, anxiety, nausea or vomiting, abdominal cramps, muscle aches, yawning, perspiration, hot and cold flushes, lacrimation, rhinorrhea, hypersomnia (typically in the initial phase) or insomnia, diarrhea, piloerection, and pupillary dilatation.
<b>Coding Note:</b>	Code also the causing condition
<b>6C43.5</b>	<b>Opioid-induced delirium</b> Opioid-induced delirium is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of opioids. The amount and duration of opioid use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, Behavioural, and Neurodevelopmental Disorders.
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> Delirium induced by opioid withdrawal
<b>6C43.6</b>	<b>Opioid-induced psychotic disorder</b> Opioid-induced psychotic disorder is characterised by psychotic symptoms (e.g. delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from opioids. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Opioid intoxication or Opioid withdrawal. The amount and duration of opioid use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g. Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the opioid use, if the symptoms persist for a substantial period of time after cessation of the opioid use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g. a history of prior episodes not associated with opioid use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C43.7</b>	<b>Certain specified opioid-induced mental or behavioural disorders</b>
<b>Coding Note:</b>	Code also the causing condition

<b>6C43.70</b>	Opioid-induced mood disorder Opioid-induced mood disorder is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from opioids. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Opioid intoxication or Opioid withdrawal. The amount and duration of opioid use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the opioid use, if the symptoms persist for a substantial period of time after cessation of the opioid use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with opioid use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C43.71</b>	Opioid-induced anxiety disorder Opioid-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from opioids. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Opioid intoxication or Opioid withdrawal. The amount and duration of opioid use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and Fear-Related Disorder, a Depressive Disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the opioid use, if the symptoms persist for a substantial period of time after cessation of the opioid use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with opioid use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C43.Y</b>	<b>Other specified disorders due to use of opioids</b>
<b>6C43.Z</b>	<b>Disorders due to use of opioids, unspecified</b>
<b>6C44</b>	<b>Disorders due to use of sedatives, hypnotics or anxiolytics</b> Disorders due to use of sedatives, hypnotics or anxiolytics are characterised by the pattern and consequences of use of these substances. Sedatives, hypnotics, and anxiolytics are typically prescribed for the short-term treatment of anxiety or insomnia and are also employed to provide sedation for medical procedures. They include the benzodiazepines and the non-benzodiazepine positive allosteric modulators of GABA receptors (i.e., 'Z-drugs') as well as many other compounds. Sedatives, hypnotics, and anxiolytics include barbiturates, which are available much less commonly now than in previous decades. Sedatives, hypnotics, and anxiolytics have dependence-inducing properties that are related to the dose and duration of their use. They may cause intoxication, dependence and withdrawal. Several other mental disorders induced by sedatives, hypnotics, or anxiolytics are recognized. <b>Exclusions:</b> Hazardous use of sedatives, hypnotics or anxiolytics (QE11.2)

- 6C44.0      Episode of harmful use of sedatives, hypnotics or anxiolytics**
- An episode of use of a sedative, hypnotic or anxiolytic that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to sedative, hypnotic or anxiolytic intoxication on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of sedative, hypnotic or anxiolytic use.
- Exclusions:**
- Sedative, hypnotic or anxiolytic dependence (6C44.2)
- Harmful pattern of use of sedatives, hypnotics or anxiolytics  
(6C44.1)
- 6C44.1      Harmful pattern of use of sedatives, hypnotics or anxiolytics**
- A pattern of sedative, hypnotic, or anxiolytic use that has caused clinically significant harm to a person's physical or mental health or in which behaviour induced by sedatives, hypnotics or anxiolytics has caused clinically significant harm to the health of other people. The pattern of sedative, hypnotic, or anxiolytic use is evident over a period of at least 12 months if use is episodic and at least one month if use is continuous (i.e., daily or almost daily). Harm may be caused by the intoxicating effects of sedatives, hypnotics or anxiolytics, the direct or secondary toxic effects on body organs and systems, or a harmful route of administration.
- Exclusions:**
- Sedative, hypnotic or anxiolytic dependence (6C44.2)
- Episode of harmful use of sedatives, hypnotics or anxiolytics  
(6C44.0)
- 6C44.10      Harmful pattern of use of sedatives, hypnotics or anxiolytics, episodic**
- A pattern of episodic or intermittent use of sedatives, hypnotics or anxiolytics that has caused clinically significant harm to a person's physical or mental health or in which behaviour induced by sedatives, hypnotics or anxiolytics has caused clinically significant harm to the health of other people. The pattern of episodic or intermittent use of sedatives, hypnotics or anxiolytics is evident over a period of at least 12 months. Harm may be caused by the intoxicating effects of sedatives, hypnotics or anxiolytics, the direct or secondary toxic effects on body organs and systems, or a harmful route of administration.
- Exclusions:**
- Episode of harmful use of sedatives, hypnotics or anxiolytics  
(6C44.0)
- Sedative, hypnotic or anxiolytic dependence (6C44.2)

- 6C44.11** Harmful pattern of use of sedatives, hypnotics or anxiolytics, continuous  
A pattern of continuous use of sedatives, hypnotics or anxiolytics (daily or almost daily) that has caused clinically significant harm to a person's physical or mental health or in which behaviour induced by sedatives, hypnotics or anxiolytics has caused clinically significant harm to the health of other people. The pattern of continuous use of sedatives, hypnotics or anxiolytics is evident over a period of at least one month. Harm may be caused by the intoxicating effects of sedatives, hypnotics or anxiolytics, the direct or secondary toxic effects on body organs and systems, or a harmful route of administration.
- Exclusions:** Episode of harmful use of sedatives, hypnotics or anxiolytics (6C44.0)  
Sedative, hypnotic or anxiolytic dependence (6C44.2)
- 6C44.1Z** Harmful pattern of use of sedatives, hypnotics or anxiolytics, unspecified
- 6C44.2** **Sedative, hypnotic or anxiolytic dependence**  
Sedative, hypnotic or anxiolytic dependence is a disorder of regulation of sedative use arising from repeated or continuous use of these substances. The characteristic feature is a strong internal drive to use sedatives, hypnotics, or anxiolytics, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use these substances. Physiological features of dependence may also be present, including tolerance to the effects of sedatives, hypnotics or anxiolytics, withdrawal symptoms following cessation or reduction in use, or repeated use of sedatives or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if sedative use is continuous (daily or almost daily) for at least 3 months.
- Exclusions:** Episode of harmful use of sedatives, hypnotics or anxiolytics (6C44.0)  
Harmful pattern of use of sedatives, hypnotics or anxiolytics (6C44.1)
- 6C44.20** Sedative, hypnotic or anxiolytic dependence, current use  
Current Sedative, hypnotic or anxiolytic dependence with use of a sedative, hypnotic or anxiolytic drug within the past month.
- Exclusions:** Episode of harmful use of sedatives, hypnotics or anxiolytics (6C44.0)  
Harmful pattern of use of sedatives, hypnotics or anxiolytics (6C44.1)

- 6C44.21** Sedative, hypnotic or anxiolytic dependence, early full remission  
After a diagnosis of Sedative, hypnotic or anxiolytic dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from sedatives, hypnotics or anxiolytics during a period lasting between 1 and 12 months.
- Exclusions:**
- Episode of harmful use of sedatives, hypnotics or anxiolytics (6C44.0)
  - Harmful pattern of use of sedatives, hypnotics or anxiolytics (6C44.1)
- 6C44.22** Sedative, hypnotic or anxiolytic dependence, sustained partial remission  
After a diagnosis of Sedative, hypnotic or anxiolytic dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in sedative, hypnotic or anxiolytic consumption for more than 12 months, such that even though sedative, hypnotic or anxiolytic use has occurred during this period, the definitional requirements for dependence have not been met.
- Exclusions:**
- Episode of harmful use of sedatives, hypnotics or anxiolytics (6C44.0)
  - Harmful pattern of use of sedatives, hypnotics or anxiolytics (6C44.1)
- 6C44.23** Sedative, hypnotic or anxiolytic dependence, sustained full remission  
After a diagnosis of sedative, hypnotic or anxiolytic dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from sedative, hypnotic or anxiolytic for 12 months or longer.
- Exclusions:**
- Episode of harmful use of sedatives, hypnotics or anxiolytics (6C44.0)
  - Harmful pattern of use of sedatives, hypnotics or anxiolytics (6C44.1)
- 6C44.2Z** Sedative, hypnotic or anxiolytic dependence, unspecified

<b>6C44.3</b>	<b>Sedative, hypnotic or anxiolytic intoxication</b> Sedative, hypnotic or anxiolytic intoxication is a clinically significant transient condition that develops during or shortly after the consumption of sedatives, hypnotics or anxiolytics that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of sedatives, hypnotics or anxiolytics and their intensity is closely related to the amount of sedatives, hypnotics or anxiolytics consumed. They are time-limited and abate as sedatives, hypnotics or anxiolytics are cleared from the body. Presenting features may include somnolence, impaired judgment, inappropriate behavior (including sexual behavior or aggression), slurred speech, impaired motor coordination, unsteady gait, mood changes, as well as impaired memory, attention and concentration. Nystagmus (repetitive, uncontrolled eye movements) is a common physical sign. In severe cases stupor or coma may occur.
<b>Coding Note:</b>	Code also the causing condition
<b>Inclusions:</b>	"Bad trips" due to sedatives, hypnotics or anxiolytics
<b>Exclusions:</b>	sedative, hypnotic drugs and other CNS depressants poisoning (NE60)
	Possession trance disorder (6B63)
<b>6C44.4</b>	<b>Sedative, hypnotic or anxiolytic withdrawal</b> Sedative, hypnotic or anxiolytic withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of sedatives, hypnotics or anxiolytics in individuals who have developed dependence or have used sedatives, hypnotics or anxiolytics for a prolonged period or in large amounts. Sedative, hypnotic or anxiolytic withdrawal can also occur when prescribed sedatives, hypnotics or anxiolytics have been used in standard therapeutic doses. Presenting features of Sedative, hypnotic or anxiolytic withdrawal may include anxiety, psychomotor agitation, insomnia, increased hand tremor, nausea or vomiting, and transient visual, tactile or auditory illusions or hallucinations. There may be signs of autonomic hyperactivity (e.g., tachycardia, hypertension, sweating), or postural hypotension. The withdrawal state may be complicated by seizures. Less commonly, there may be progression to a more severe withdrawal state characterised by confusion and disorientation, delusions, and more prolonged visual, tactile or auditory hallucinations. In such cases, a separate diagnosis of Sedative, hypnotic, or anxiolytic-induced delirium should be assigned.
<b>Coding Note:</b>	Code also the causing condition
<b>6C44.40</b>	Sedative, hypnotic or anxiolytic withdrawal, uncomplicated All diagnostic requirements for Sedative, hypnotic or anxiolytic withdrawal are met and the withdrawal state is not accompanied by perceptual disturbances or seizures.
<b>Coding Note:</b>	Code also the causing condition

- 6C44.41** Sedative, hypnotic or anxiolytic withdrawal, with perceptual disturbances  
All diagnostic requirements for Sedative, hypnotic or anxiolytic withdrawal are met and the withdrawal state is accompanied by perceptual disturbances (e.g., visual or tactile hallucinations or illusions) with intact reality testing. There is no evidence of confusion and other diagnostic requirements for Delirium are not met. The withdrawal state is not accompanied by seizures.
- Coding Note:** Code also the causing condition
- 6C44.42** Sedative, hypnotic or anxiolytic withdrawal, with seizures  
All diagnostic requirements for Sedative, hypnotic or anxiolytic withdrawal are met and the withdrawal state is accompanied by seizures (i.e., generalised tonic-clonic seizures) but not by perceptual disturbances.
- Coding Note:** Code also the causing condition
- 6C44.43** Sedative, hypnotic or anxiolytic withdrawal, with perceptual disturbances and seizures  
All diagnostic requirements for Sedative, hypnotic or anxiolytic withdrawal are met and the withdrawal state is accompanied by both seizures (i.e., generalised tonic-clonic seizures) and perceptual disturbances (e.g., visual or tactile hallucinations or illusions) with intact reality testing. Diagnostic requirements for Delirium are not met.
- Coding Note:** Code also the causing condition
- 6C44.4Z** Sedative, hypnotic or anxiolytic withdrawal, unspecified
- Coding Note:** Code also the causing condition
- 6C44.5** **Sedative, hypnotic or anxiolytic-induced delirium**  
Sedative, hypnotic or anxiolytic-induced delirium is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of sedatives, hypnotics, or anxiolytics. Specific features of Sedative, hypnotic or anxiolytic-induced delirium may include confusion and disorientation, paranoid delusions, and recurrent visual, tactile or auditory hallucinations. The amount and duration of sedative, hypnotic, or anxiolytic use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.
- Coding Note:** Code also the causing condition
- Inclusions:** Delirium induced by sedative, hypnotic or anxiolytic withdrawal

<b>6C44.6</b>	<b>Sedative, hypnotic or anxiolytic-induced psychotic disorder</b> Sedative, hypnotic or anxiolytic-induced psychotic disorder is characterised by psychotic symptoms (e.g. delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from sedatives, hypnotics or anxiolytics. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of intoxication or withdrawal due to sedatives, hypnotics or anxiolytics. The amount and duration of sedative, hypnotic or anxiolytic use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g. Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the sedative, hypnotic or anxiolytic use, if the symptoms persist for a substantial period of time after cessation of the sedative, hypnotic or anxiolytic use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g. a history of prior episodes not associated with sedative, hypnotic or anxiolytic use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C44.7</b>	<b>Certain specified sedatives, hypnotics or anxiolytic-induced mental or behavioural disorders</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Coded Elsewhere:</b> Amnestic disorder due to use of sedatives, hypnotics or anxiolytics (6D72.11)
	Dementia due to use of sedatives, hypnotics or anxiolytics (6D84.1)
<b>6C44.70</b>	<b>Sedative, hypnotic or anxiolytic-induced mood disorder</b> Sedative, hypnotic or anxiolytic-induced mood disorder is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from sedatives, hypnotics or anxiolytics. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of intoxication or withdrawal due to sedatives, hypnotics or anxiolytics. The amount and duration of sedative, hypnotic or anxiolytic use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the sedative, hypnotic or anxiolytic use, if the symptoms persist for a substantial period of time after cessation of the sedative, hypnotic or anxiolytic use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with sedative, hypnotic or anxiolytic use).
<b>Coding Note:</b>	Code also the causing condition

<b>6C44.71</b>	Sedative, hypnotic or anxiolytic-induced anxiety disorder Sedative, hypnotic or anxiolytic-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from sedatives, hypnotics or anxiolytics. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of intoxication or withdrawal due to sedatives, hypnotics or anxiolytics. The amount and duration of sedative, hypnotic or anxiolytic use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and Fear-Related Disorder, a Depressive Disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the sedative, hypnotic or anxiolytic use, if the symptoms persist for a substantial period of time after cessation of the sedative, hypnotic or anxiolytic use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with sedative, hypnotic or anxiolytic use).
----------------	--

**Coding Note:** Code also the causing condition

**6C44.Y** **Other specified disorders due to use of sedatives, hypnotics or anxiolytics**

**6C44.Z** **Disorders due to use of sedatives, hypnotics or anxiolytics, unspecified**

## **6C45**

### **Disorders due to use of cocaine**

Disorders due to use of cocaine are characterised by the pattern and consequences of cocaine use. Cocaine is a compound found in the leaves of the coca plant, *Erythroxylum coca*, which is indigenous to countries in northern regions of South America. Cocaine has a limited place in medical treatment as an anaesthetic and vasoconstrictive agent. It is commonly used illicitly and widely available across the world, where it is found in two main forms: cocaine hydrochloride and cocaine freebase (also known as 'crack'). Cocaine is a central nervous system stimulant, and Cocaine Intoxication typically includes a state of euphoria and hyperactivity. Cocaine has potent dependence-producing properties and Cocaine Dependence is a common cause of morbidity and of clinical presentations. Cocaine Withdrawal has a characteristic course that includes lethargy and depressed mood. A range of Cocaine-Induced Mental Disorders is described.

**Exclusions:** Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone (6C46)

Hazardous use of cocaine (QE11.3)

- 6C45.0      Episode of harmful use of cocaine**
- An episode of use of cocaine that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to cocaine intoxication on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of cocaine use.
- Exclusions:**      Cocaine dependence (6C45.2)  
                          Harmful pattern of use of cocaine (6C45.1)
- 6C45.1      Harmful pattern of use of cocaine**
- A pattern of use of cocaine that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of cocaine use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to cocaine intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of cocaine applies.
- Exclusions:**      Cocaine dependence (6C45.2)  
                          Episode of harmful use of cocaine (6C45.0)
- 6C45.10     Harmful pattern of use of cocaine, episodic**
- A pattern of episodic or intermittent cocaine use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic cocaine use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to cocaine intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of cocaine applies.
- Exclusions:**      Episode of harmful use of cocaine (6C45.0)  
                          Cocaine dependence (6C45.2)

- 6C45.11** Harmful pattern of use of cocaine, continuous  
A pattern of continuous (daily or almost daily) cocaine use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous cocaine use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to cocaine intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of cocaine applies.
- Exclusions:** Episode of harmful use of cocaine (6C45.0)  
Cocaine dependence (6C45.2)
- 6C45.1Z** Harmful pattern of use of cocaine, unspecified
- 6C45.2** **Cocaine dependence**  
Cocaine dependence is a disorder of regulation of cocaine use arising from repeated or continuous use of cocaine. The characteristic feature is a strong internal drive to use cocaine, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use cocaine. Physiological features of dependence may also be present, including tolerance to the effects of cocaine, withdrawal symptoms following cessation or reduction in use of cocaine, or repeated use of cocaine or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if cocaine use is continuous (daily or almost daily) for at least 3 months.
- Exclusions:** Episode of harmful use of cocaine (6C45.0)  
Harmful pattern of use of cocaine (6C45.1)
- 6C45.20** Cocaine dependence, current use  
Current cocaine dependence with cocaine use within the past month.
- Exclusions:** Episode of harmful use of cocaine (6C45.0)  
Harmful pattern of use of cocaine (6C45.1)
- 6C45.21** Cocaine dependence, early full remission  
After a diagnosis of Cocaine dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from cocaine during a period lasting between 1 and 12 months.
- Exclusions:** Episode of harmful use of cocaine (6C45.0)  
Harmful pattern of use of cocaine (6C45.1)

<b>6C45.22</b>	Cocaine dependence, sustained partial remission  After a diagnosis of Cocaine dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in cocaine consumption for more than 12 months, such that even though cocaine use has occurred during this period, the definitional requirements for dependence have not been met.
	<b>Exclusions:</b> Episode of harmful use of cocaine (6C45.0) Harmful pattern of use of cocaine (6C45.1)
<b>6C45.23</b>	Cocaine dependence, sustained full remission  After a diagnosis of cocaine dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from cocaine for 12 months or longer.
	<b>Exclusions:</b> Episode of harmful use of cocaine (6C45.0) Harmful pattern of use of cocaine (6C45.1)
<b>6C45.2Z</b>	Cocaine dependence, unspecified
<b>6C45.3</b>	<b>Cocaine intoxication</b>  Cocaine intoxication is a clinically significant transient condition that develops during or shortly after the consumption of cocaine that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of cocaine and their intensity is closely related to the amount of cocaine consumed. They are time-limited and abate as cocaine is cleared from the body. Presenting features may include inappropriate euphoria, anxiety, anger, impaired attention, hypervigilance, psychomotor agitation, paranoid ideation (sometimes of delusional intensity), auditory hallucinations, confusion, and changes in sociability. Perspiration or chills, nausea or vomiting, and palpitations and chest pain may be experienced. Physical signs may include tachycardia, elevated blood pressure, and pupillary dilatation. In rare instances, usually in severe intoxication, cocaine use can result in seizures, muscle weakness, dyskinesia, or dystonia.
	<b>Coding Note:</b> Code also the causing condition
	<b>Exclusions:</b> cocaine poisoning (NE60) Possession trance disorder (6B63)
<b>6C45.4</b>	<b>Cocaine withdrawal</b>  Cocaine withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of cocaine in individuals who have developed Cocaine dependence or have used cocaine for a prolonged period or in large amounts. Presenting features of Cocaine withdrawal may include dysphoric mood, irritability, fatigue, psychomotor retardation, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite, anxiety, psychomotor agitation or retardation, and craving for cocaine.
	<b>Coding Note:</b> Code also the causing condition

- 6C45.5 Cocaine-induced delirium**  
Cocaine-induced delirium is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of cocaine. The amount and duration of cocaine use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural, and neurodevelopmental disorders.
- Coding Note:** Code also the causing condition
- 6C45.6 Cocaine-induced psychotic disorder**  
Cocaine-induced psychotic disorder is characterised by psychotic symptoms (e.g. delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from cocaine. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Cocaine intoxication or Cocaine withdrawal. The amount and duration of cocaine use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g. Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the cocaine use, if the symptoms persist for a substantial period of time after cessation of the cocaine use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g. a history of prior episodes not associated with cocaine use).
- Coding Note:** Code also the causing condition
- 6C45.60 Cocaine-induced psychotic disorder with hallucinations**  
Cocaine-induced psychotic disorder with hallucinations is characterised by the presence of hallucinations that are judged to be the direct consequence of cocaine use. Neither delusions nor other psychotic symptoms are present. The symptoms do not occur exclusively during hypnagogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).
- Coding Note:** Code also the causing condition
- 6C45.61 Cocaine-induced psychotic disorder with delusions**  
Cocaine-induced psychotic disorder with delusions is characterised by the presence of delusions that are judged to be the direct consequence of cocaine use. Neither hallucinations nor other psychotic symptoms are present. The symptoms do not occur exclusively during hypnagogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).
- Coding Note:** Code also the causing condition

<b>6C45.62</b>	Cocaine-induced psychotic disorder with mixed psychotic symptoms Cocaine-induced psychotic disorder with mixed psychotic symptoms is characterised by the presence of multiple psychotic symptoms, primarily hallucinations and delusions, when these are judged to be the direct consequence of cocaine use. The symptoms do not occur exclusively during hypnagogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., Schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).
<b>Coding Note:</b>	Code also the causing condition
<b>6C45.6Z</b>	Cocaine-induced psychotic disorder, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>6C45.7</b>	<b>Certain specified cocaine-induced mental or behavioural disorders</b>
<b>Coding Note:</b>	Code also the causing condition
<b>6C45.70</b>	Cocaine-induced mood disorder Cocaine-induced mood disorder is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from cocaine. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Cocaine intoxication or Cocaine withdrawal. The amount and duration of cocaine use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the cocaine use, if the symptoms persist for a substantial period of time after cessation of the cocaine use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with cocaine use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C45.71</b>	Cocaine-induced anxiety disorder Cocaine-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from cocaine. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Cocaine intoxication or Cocaine withdrawal. The amount and duration of cocaine use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the cocaine use, if the symptoms persist for a substantial period of time after cessation of the cocaine use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with cocaine use).
<b>Coding Note:</b>	Code also the causing condition

<b>6C45.72</b>	Cocaine-induced obsessive-compulsive or related disorder Cocaine-induced obsessive-compulsive or related disorder is characterised by either repetitive intrusive thoughts or preoccupations, normally associated with anxiety and typically accompanied by repetitive behaviours performed in response, or by recurrent and habitual actions directed at the integument (e.g., hair pulling, skin picking) that develop during or soon after intoxication with or withdrawal from cocaine. The intensity or duration of the symptoms is substantially in excess of analogous disturbances that are characteristic of Cocaine intoxication or Cocaine withdrawal. The amount and duration of cocaine use must be capable of producing obsessive-compulsive or related symptoms. The symptoms are not better explained by a primary mental disorder (in particular an Obsessive-compulsive or related disorder), as might be the case if the symptoms preceded the onset of the cocaine use, if the symptoms persist for a substantial period of time after cessation of the cocaine use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with obsessive-compulsive or related symptoms (e.g., a history of prior episodes not associated with cocaine use).
<b><i>Coding Note:</i></b>	Code also the causing condition
<b>6C45.73</b>	Cocaine-induced impulse control disorder Cocaine-induced impulse control disorder is characterised by persistently repeated behaviours in which there is recurrent failure to resist an impulse, drive, or urge to perform an act that is rewarding to the person, at least in the short-term, despite longer-term harm either to the individual or to others (e.g., fire setting or stealing without apparent motive, repetitive sexual behaviour, aggressive outbursts) that develop during or soon after intoxication with or withdrawal from cocaine. The intensity or duration of the symptoms is substantially in excess of disturbances of impulse control that are characteristic of Cocaine intoxication or Cocaine withdrawal. The amount and duration of cocaine use must be capable of producing disturbances of impulse control. The symptoms are not better explained by a primary mental disorder (e.g., an Impulse control disorder, a Disorder due to addictive behaviours), as might be the case if the impulse control disturbances preceded the onset of the cocaine use, if the symptoms persist for a substantial period of time after cessation of the cocaine use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with impulse control symptoms (e.g., a history of prior episodes not associated with cocaine use).
<b><i>Coding Note:</i></b>	Code also the causing condition
<b>6C45.Y</b>	<b>Other specified disorders due to use of cocaine</b>
<b>6C45.Z</b>	<b>Disorders due to use of cocaine, unspecified</b>

**6C46**

**Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone**

Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone are characterised by the pattern and consequences of use of these substances. There is a wide array of naturally occurring and synthetically produced psychostimulants other than cocaine. The most numerous of this group are the amphetamine-type substances, including methamphetamine. Prescribed stimulants including dexamphetamine are indicated for a limited number of conditions such as for Attention Deficit Hyperactivity Disorder. Methcathinone, known in many countries as ephedrone, is a synthetic potent stimulant that is a structural analogue of methamphetamine and is related to cathinone. All these drugs have primarily psychostimulant properties and are also vasoconstrictors to a varying degree. They induce euphoria and hyperactivity as may be seen in Stimulant Intoxication. They have potent dependence-producing properties, which may lead to the diagnosis of Stimulant Dependence and Stimulant Withdrawal following the cessation of use. Several Stimulant-Induced Mental Disorders are described.

- Exclusions:**
- Disorders due to use of synthetic cathinones (6C47)
  - Disorders due to use of caffeine (6C48)
  - Disorders due to use of cocaine (6C45)
  - Hazardous use of stimulants including amphetamines or methamphetamine (QE11.4)

**6C46.0**

**Episode of harmful use of stimulants including amphetamines, methamphetamine or methcathinone**

An episode of use of a stimulant including amphetamines, methamphetamine and methcathinone that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to stimulant intoxication on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of stimulant including amphetamines, methamphetamine and methcathinone use.

- Exclusions:**
- Harmful pattern of use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.1)
  - Stimulant dependence including amphetamines, methamphetamine or methcathinone (6C46.2)

**6C46.1**

**Harmful pattern of use of stimulants including amphetamines, methamphetamine or methcathinone**

A pattern of use of stimulants including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of stimulant use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to stimulant intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of stimulants including amphetamines, methamphetamine and methcathinone applies.

***Exclusions:***

- Harmful pattern of use of caffeine (6C48.1)
- Harmful pattern of use of cocaine (6C45.1)
- Harmful pattern of use of synthetic cathinones (6C47.1)
- Episode of harmful use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.0)
- Stimulant dependence including amphetamines, methamphetamine or methcathinone (6C46.2)

**6C46.10**

**Harmful pattern of use of stimulants including amphetamines, methamphetamine or methcathinone, episodic**

A pattern of episodic or intermittent use of stimulants including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic stimulant use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to stimulant intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of stimulants including amphetamines, methamphetamine and methcathinone applies.

***Exclusions:***

- Episode of harmful use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.0)
- Stimulant dependence including amphetamines, methamphetamine or methcathinone (6C46.2)

<b>6C46.11</b>	<p>Harmful pattern of use of stimulants including amphetamines, methamphetamine or methcathinone, continuous</p> <p>A pattern of use of stimulants including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of stimulant use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to stimulant intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of stimulants including amphetamines, methamphetamine and methcathinone applies.</p>
	<p><b><i>Exclusions:</i></b> Episode of harmful use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.0)</p> <p>Stimulant dependence including amphetamines, methamphetamine or methcathinone (6C46.2)</p>
<b>6C46.1Z</b>	Harmful pattern of use of stimulants including amphetamines, methamphetamine and methcathinone, unspecified
<b>6C46.2</b>	<p><b>Stimulant dependence including amphetamines, methamphetamine or methcathinone</b></p> <p>Stimulant dependence including amphetamines, methamphetamine or methcathinone is a disorder of regulation of stimulant use arising from repeated or continuous use of stimulants. The characteristic feature is a strong internal drive to use stimulants, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use stimulants. Physiological features of dependence may also be present, including tolerance to the effects of stimulants, withdrawal symptoms following cessation or reduction in use of stimulants, or repeated use of stimulants or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if stimulant use is continuous (daily or almost daily) for at least 3 months.</p> <p><b><i>Exclusions:</i></b> Cocaine dependence (6C45.2)</p> <p>Synthetic cathinone dependence (6C47.2)</p> <p>Episode of harmful use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.0)</p> <p>Harmful pattern of use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.1)</p>

<b>6C46.20</b>	<p>Stimulant dependence including amphetamines, methamphetamine or methcathinone, current use</p> <p>Stimulant dependence including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones refers to amphetamine or other stimulant use within the past month.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Harmful pattern of use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.1)</li> <li>Episode of harmful use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.0)</li> </ul>
<b>6C46.21</b>	<p>Stimulant dependence including amphetamines, methamphetamine or methcathinone, early full remission</p> <p>After a diagnosis of Stimulant dependence including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from stimulants during a period lasting between 1 and 12 months.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Episode of harmful use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.0)</li> <li>Harmful pattern of use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.1)</li> </ul>
<b>6C46.22</b>	<p>Stimulant dependence including amphetamines, methamphetamine or methcathinone, sustained partial remission</p> <p>After a diagnosis of Stimulant dependence including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in amphetamine or other stimulant consumption for more than 12 months, such that even though amphetamine or other stimulant use has occurred during this period, the definitional requirements for dependence have not been met.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Episode of harmful use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.0)</li> <li>Harmful pattern of use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.1)</li> </ul>
<b>6C46.23</b>	<p>Stimulant dependence including amphetamines, methamphetamine or methcathinone, sustained full remission</p> <p>After a diagnosis of Stimulant dependence including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from amphetamine or other stimulants for 12 months or longer.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Episode of harmful use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.0)</li> <li>Harmful pattern of use of stimulants including amphetamines, methamphetamine or methcathinone (6C46.1)</li> </ul>
<b>6C46.2Z</b>	Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified

**6C46.3 Stimulant intoxication including amphetamines, methamphetamine or methcathinone**

Stimulant intoxication including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones is a clinically significant transient condition that develops during or shortly after the consumption of amphetamine or other stimulants that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of amphetamine or other stimulants and their intensity is closely related to the amount of amphetamine or other stimulant consumed. They are time-limited and abate as amphetamine or another stimulant is cleared from the body. Presenting features may include anxiety, anger, impaired attention, hypervigilance, psychomotor agitation, paranoid ideation (possibly of delusional intensity), transient auditory hallucinations, transitory confusion, and changes in sociability. Perspiration or chills, nausea or vomiting, and palpitations may be experienced. Physical signs may include tachycardia, elevated blood pressure, pupillary dilatation, dyskinesias and dystonias, and skin sores. In rare instances, usually in severe intoxication, use of stimulants including amphetamines, methamphetamine and methcathinone can result in seizures.

**Coding Note:** Code also the causing condition

**Exclusions:**

- amphetamine poisoning (NE60)
- Caffeine intoxication (6C48.2)
- Cocaine intoxication (6C45.3)
- Synthetic cathinone intoxication (6C47.3)
- Possession trance disorder (6B63)

**6C46.4 Stimulant withdrawal including amphetamines, methamphetamine or methcathinone**

Stimulant withdrawal including amphetamines, methamphetamine and methcathinone is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of stimulants in individuals who have developed Stimulant dependence or have used stimulants for a prolonged period or in large amounts. Stimulant withdrawal can also occur when prescribed stimulants have been used in standard therapeutic doses. Presenting features of stimulant withdrawal may include dysphoric mood, irritability, fatigue, insomnia or (more commonly) hypersomnia, vivid and unpleasant dreams, increased appetite, psychomotor agitation or retardation, and craving for amphetamine or related stimulants.

**Coding Note:** Code also the causing condition

**Exclusions:**

- Cocaine withdrawal (6C45.4)
- Caffeine withdrawal (6C48.3)
- Synthetic cathinone withdrawal (6C47.4)

<b>6C46.5</b>	<b>Stimulant-induced delirium including amphetamines, methamphetamine or methcathinone</b>  Stimulant-induced delirium including amphetamines, methamphetamine and methcathinone is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of stimulants. The amount and duration of stimulant use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.
<b>Coding Note:</b>	Code also the causing condition
<b>Exclusions:</b>	Cocaine-induced delirium (6C45.5)  Synthetic cathinone-induced delirium (6C47.5)  Disorders due to use of caffeine (6C48)
<b>6C46.6</b>	<b>Stimulant-induced psychotic disorder including amphetamines, methamphetamine or methcathinone</b>  Stimulant-induced psychotic disorder including amphetamines, methamphetamine and methcathinone is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication or withdrawal due to stimulants. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Stimulant intoxication or Stimulant withdrawal. The amount and duration of stimulant use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the stimulant use, if the symptoms persist for a substantial period of time after cessation of the stimulant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with use of stimulants).
<b>Coding Note:</b>	Code also the causing condition
<b>Exclusions:</b>	Cocaine-induced psychotic disorder (6C45.6)  Synthetic cathinone-induced psychotic disorder (6C47.6)  Disorders due to use of caffeine (6C48)

<b>6C46.60</b>	<p>Stimulant-induced psychotic disorder including amphetamines, methamphetamine or methcathinone with hallucinations</p> <p>Stimulant-induced psychotic disorder with hallucinations is characterised by the presence of hallucinations that are judged to be the direct consequence of stimulant use. Neither delusions nor other psychotic symptoms are present. The symptoms do not occur exclusively during hypnagogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).</p>
	<p><b>Coding Note:</b> Code also the causing condition</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Cocaine-induced psychotic disorder with hallucinations (6C45.60)</li> <li>Disorders due to use of caffeine (6C48)</li> <li>Synthetic cathinone-induced psychotic disorder with hallucinations (6C47.60)</li> </ul>
<b>6C46.61</b>	<p>Stimulant-induced psychotic disorder including amphetamines, methamphetamine or methcathinone with delusions</p> <p>Stimulant-induced psychotic disorder including amphetamines, methamphetamine and methcathinone is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication or withdrawal due to stimulants. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Stimulant intoxication or Stimulant withdrawal. The amount and duration of stimulant use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the stimulant use, if the symptoms persist for a substantial period of time after cessation of the stimulant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with use of stimulants).</p>
	<p><b>Coding Note:</b> Code also the causing condition</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Disorders due to use of caffeine (6C48)</li> <li>Cocaine-induced psychotic disorder with delusions (6C45.61)</li> <li>Synthetic cathinone-induced psychotic disorder with delusions (6C47.61)</li> </ul>

<b>6C46.62</b>	<p>Stimulant-induced psychotic disorder including amphetamines but excluding caffeine or cocaine with mixed psychotic symptoms</p> <p>Stimulant-induced psychotic disorder with mixed psychotic symptoms is characterised by the presence of multiple psychotic symptoms, primarily hallucinations and delusions, when these are judged to be the direct consequence of stimulant use. The symptoms do not occur exclusively during hypnagogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., Schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).</p>
<b>Coding Note:</b>	Code also the causing condition
<b>Exclusions:</b>	<p>Disorders due to use of caffeine (6C48)</p> <p>Cocaine-induced psychotic disorder with mixed psychotic symptoms (6C45.62)</p> <p>Synthetic cathinone-induced psychotic disorder with mixed psychotic symptoms (6C47.62)</p>
<b>6C46.6Z</b>	Stimulant-induced psychotic disorder including amphetamines, methamphetamine or methcathinone, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>6C46.7</b>	<b>Certain specified stimulant-induced mental or behavioural disorders including amphetamines, methamphetamine or methcathinone</b>
<b>Coding Note:</b>	Code also the causing condition
<b>6C46.70</b>	<p>Stimulant-induced mood disorder including amphetamines, methamphetamine or methcathinone</p> <p>Stimulant-induced mood disorder including amphetamines, methamphetamine and methcathinone is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication or withdrawal due to stimulants. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Stimulant intoxication or Stimulant withdrawal. The amount and duration of stimulant use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the stimulant use, if the symptoms persist for a substantial period of time after cessation of the stimulant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with use of stimulants).</p>
<b>Coding Note:</b>	Code also the causing condition
<b>Exclusions:</b>	<p>Synthetic cathinone-induced mood disorder (6C47.70)</p> <p>Cocaine-induced mood disorder (6C45.70)</p> <p>Disorders due to use of caffeine (6C48)</p>

<b>6C46.71</b>	<p>Stimulant-induced anxiety disorder including amphetamines, methamphetamine or methcathinone</p> <p>Stimulant-induced anxiety disorder including amphetamines, methamphetamine and methcathinone is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication or withdrawal due to stimulants. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Stimulant intoxication or Stimulant withdrawal. The amount and duration of stimulant use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the stimulant use, if the symptoms persist for a substantial period of time after cessation of the stimulant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with use of stimulants).</p>
<b>Coding Note:</b>	Code also the causing condition
<b>Exclusions:</b>	<p>Cocaine-induced anxiety disorder (6C45.71)</p> <p>Caffeine-induced anxiety disorder (6C48.40)</p> <p>Synthetic cathinone-induced anxiety disorder (6C47.71)</p>
<b>6C46.72</b>	<p>Stimulant-induced obsessive-compulsive or related disorder including amphetamines, methamphetamine or methcathinone</p> <p>Stimulant-induced obsessive-compulsive or related disorder including amphetamines, methamphetamine and methcathinone is characterised by either repetitive intrusive thoughts or preoccupations, normally associated with anxiety and typically accompanied by repetitive behaviours performed in response, or by recurrent and habitual actions directed at the integument (e.g., hair pulling, skin picking) that develop during or soon after intoxication with or withdrawal from stimulants. The intensity or duration of the symptoms is substantially in excess of analogous disturbances that are characteristic of Stimulant intoxication or Stimulant withdrawal. The amount and duration of stimulant use must be capable of producing obsessive-compulsive or related symptoms. The symptoms are not better explained by a primary mental disorder (in particular an Obsessive-compulsive or related disorder), as might be the case if the symptoms preceded the onset of the stimulant use, if the symptoms persist for a substantial period of time after cessation of the stimulant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with obsessive-compulsive or related symptoms (e.g., a history of prior episodes not associated with stimulant use).</p>
<b>Coding Note:</b>	Code also the causing condition
<b>Exclusions:</b>	<p>Cocaine-induced obsessive-compulsive or related disorder (6C45.72)</p> <p>Synthetic cathinone-induced obsessive-compulsive or related syndrome (6C47.72)</p> <p>Disorders due to use of caffeine (6C48)</p>

<b>6C46.73</b>	<p>Stimulant-induced impulse control disorder including amphetamines, methamphetamine or methcathinone</p> <p>Stimulant-induced impulse control disorder including amphetamines, methamphetamine and methcathinone is characterised by persistently repeated behaviours in which there is recurrent failure to resist an impulse, drive, or urge to perform an act that is rewarding to the person, at least in the short-term, despite longer-term harm either to the individual or to others (e.g., fire setting or stealing without apparent motive, repetitive sexual behaviour, aggressive outbursts) that develop during or soon after intoxication with or withdrawal from stimulants. The intensity or duration of the symptoms is substantially in excess of disturbances of impulse control that are characteristic of Stimulant intoxication or Stimulant withdrawal. The amount and duration of stimulant use must be capable of producing disturbances of impulse control. The symptoms are not better explained by a primary mental disorder (e.g., an Impulse control disorder, a Disorder due to addictive behaviours), as might be the case if the impulse control disturbances preceded the onset of the stimulant use, if the symptoms persist for a substantial period of time after cessation of the stimulant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with impulse control symptoms (e.g., a history of prior episodes not associated with stimulant use).</p>
----------------	---

**Coding Note:** Code also the causing condition

**6C46.Y** **Other specified disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone**

**6C46.Z** **Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone, unspecified**

## **6C47**

### **Disorders due to use of synthetic cathinones**

Disorders due to use of synthetic cathinones are characterised by the pattern and consequences of synthetic cathinone use. Synthetic cathinones (also known as 'bath salts') are synthetic compounds with stimulant properties related to cathinone found in the khat plant, Catha edulis. The use of synthetic cathinones is common in young populations in many countries. They may produce a range of disorders including Synthetic Cathinone Intoxication, Synthetic Cathinone Dependence and Synthetic Cathinone Withdrawal. Several synthetic cathinone-induced mental disorders are recognised.

**6C47.0** **Episode of harmful use of synthetic cathinones**

An episode of synthetic cathinone use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to synthetic cathinone intoxication on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of synthetic cathinone use.

**Exclusions:** Harmful pattern of use of synthetic cathinones (6C47.1)  
Synthetic cathinone dependence (6C47.2)

- 6C47.1** **Harmful pattern of use of synthetic cathinones**  
A pattern of use of synthetic cathinones that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of synthetic cathinone use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to synthetic cathinone intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of synthetic cathinones applies.
- Exclusions:** Episode of harmful use of synthetic cathinones (6C47.0)  
Synthetic cathinone dependence (6C47.2)
- 6C47.10** Harmful pattern of use of synthetic cathinones, episodic  
A pattern of episodic or intermittent use of synthetic cathinones that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic synthetic cathinone use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to synthetic cathinone intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of synthetic cathinones applies.
- Exclusions:** Episode of harmful use of synthetic cathinones (6C47.0)  
Synthetic cathinone dependence (6C47.2)
- 6C47.11** Harmful use of synthetic cathinones, continuous  
A pattern of continuous (daily or almost daily) use of synthetic cathinones that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous synthetic cathinone use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to synthetic cathinone intoxication on the part of the person to whom the diagnosis of Harmful use of synthetic cathinones applies.
- Exclusions:** Episode of harmful use of synthetic cathinones (6C47.0)  
Synthetic cathinone dependence (6C47.2)
- 6C47.1Y** Other specified harmful pattern of use of synthetic cathinones
- 6C47.1Z** Harmful pattern of use of synthetic cathinones, unspecified

<b>6C47.2</b>	<b>Synthetic cathinone dependence</b> Synthetic cathinone dependence is a disorder of regulation of synthetic cathinone use arising from repeated or continuous use of synthetic cathinones. The characteristic feature is a strong internal drive to use synthetic cathinones, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use synthetic cathinones. Physiological features of dependence may also be present, including tolerance to the effects of synthetic cathinones, withdrawal symptoms following cessation or reduction in use of synthetic cathinones, or repeated use of synthetic cathinones or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if synthetic cathinone use is continuous (daily or almost daily) for at least 3 months.
	<b>Exclusions:</b> Harmful pattern of use of synthetic cathinones (6C47.1) Episode of harmful use of synthetic cathinones (6C47.0)
<b>6C47.20</b>	Synthetic cathinone dependence, current use Current synthetic cathinone dependence with use of synthetic cathinones within the past month.
	<b>Exclusions:</b> Episode of harmful use of synthetic cathinones (6C47.0) Harmful pattern of use of synthetic cathinones (6C47.1)
<b>6C47.21</b>	Synthetic cathinone dependence, early full remission After a diagnosis of synthetic cathinone dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from synthetic cathinone use during a period lasting between 1 and 12 months.
	<b>Exclusions:</b> Episode of harmful use of synthetic cathinones (6C47.0) Harmful pattern of use of synthetic cathinones (6C47.1)
<b>6C47.22</b>	Synthetic cathinone dependence, sustained partial remission After a diagnosis of synthetic cathinone dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in synthetic cathinone consumption for more than 12 months, such that even though synthetic cathinone use has occurred during this period, the definitional requirements for dependence have not been met.
	<b>Exclusions:</b> Episode of harmful use of synthetic cathinones (6C47.0) Harmful pattern of use of synthetic cathinones (6C47.1)
<b>6C47.23</b>	Synthetic cathinone dependence, sustained full remission After a diagnosis of synthetic cathinone dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from synthetic cathinone use for 12 months or longer.
	<b>Exclusions:</b> Episode of harmful use of synthetic cathinones (6C47.0) Harmful pattern of use of synthetic cathinones (6C47.1)
<b>6C47.2Y</b>	Other specified synthetic cathinone dependence

- 6C47.2Z** Synthetic cathinone dependence, unspecified
- 6C47.3** **Synthetic cathinone intoxication**  
Synthetic cathinone intoxication is a clinically significant transient condition that develops during or shortly after the consumption of synthetic cathinones that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of synthetic cathinones and their intensity is closely related to the amount of synthetic cathinones consumed. They are time-limited and abate as the synthetic cathinone is cleared from the body. Presenting features may include anxiety, anger, impaired attention, hypervigilance, psychomotor agitation, paranoid ideation (possibly of delusional intensity), transient auditory hallucinations, transitory confusion, and changes in sociability. Perspiration or chills, nausea or vomiting, and palpitations may be experienced. Physical signs may include tachycardia, elevated blood pressure, pupillary dilatation, dyskinesias and dystonias, and skin sores. In rare instances, usually in severe intoxication, use of synthetic cathinones can result in seizures.
- Coding Note:** Code also the causing condition
- 6C47.4** **Synthetic cathinone withdrawal**  
Synthetic cathinone withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of synthetic cathinones in individuals who have developed Synthetic cathinone dependence or have used synthetic cathinones for a prolonged period or in large amounts. Presenting features of Synthetic cathinone withdrawal may include dysphoric mood, irritability, fatigue, insomnia or (more commonly) hypersomnia, vivid and unpleasant dreams, increased appetite, psychomotor agitation or retardation, and craving for stimulants, including synthetic cathinones.
- Coding Note:** Code also the causing condition
- 6C47.5** **Synthetic cathinone-induced delirium**  
Synthetic cathinone-induced delirium is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of synthetic cathinones. The amount and duration of synthetic cathinone use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.
- Coding Note:** Code also the causing condition

<b>6C47.6</b>	<b>Synthetic cathinone-induced psychotic disorder</b> Synthetic cathinone-induced psychotic disorder is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from synthetic cathinones. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Synthetic cathinone intoxication or Synthetic cathinone withdrawal. The amount and duration of synthetic cathinone use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the synthetic cathinone use, if the symptoms persist for a substantial period of time after cessation of the synthetic cathinone use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with synthetic cathinone use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C47.60</b>	Synthetic cathinone-induced psychotic disorder with hallucinations Synthetic cathinone-induced psychotic disorder with hallucinations is characterised by the presence of hallucinations that are judged to be the direct consequence of synthetic cathinone use. Neither delusions nor other psychotic symptoms are present. The symptoms do not occur exclusively during hypnagogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).
<b>Coding Note:</b>	Code also the causing condition
<b>6C47.61</b>	Synthetic cathinone-induced psychotic disorder with delusions Synthetic cathinone psychotic disorder with delusions is characterised by the presence of delusions that are judged to be the direct consequence of synthetic cathinone use. Neither hallucinations nor other psychotic symptoms are present. The symptoms do not occur exclusively during hypnagogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).
<b>Coding Note:</b>	Code also the causing condition
<b>6C47.62</b>	Synthetic cathinone-induced psychotic disorder with mixed psychotic symptoms Synthetic cathinone-induced psychotic disorder with mixed psychotic symptoms is characterised by the presence of multiple psychotic symptoms, primarily hallucinations and delusions, when these are judged to be the direct consequence of synthetic cathinone use. The symptoms do not occur exclusively during hypnagogic or hypnopompic states, are not better accounted for by another mental and behavioural disorder (e.g., Schizophrenia), and are not due to another disorder or disease classified elsewhere (e.g., epilepsies with visual symptoms).
<b>Coding Note:</b>	Code also the causing condition
<b>6C47.6Z</b>	Synthetic cathinone-induced psychotic disorder, unspecified <b>Coding Note:</b> Code also the causing condition

<b>6C47.7</b>	<b>Certain specified synthetic cathinone-induced mental or behavioural disorders</b>
<b>Coding Note:</b>	Code also the causing condition
<b>6C47.70</b>	<p>Synthetic cathinone-induced mood disorder</p> <p>Synthetic cathinone-induced mood disorder is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from synthetic cathinones. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Synthetic cathinone intoxication or Synthetic cathinone withdrawal. The amount and duration of synthetic cathinone use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the synthetic cathinone use, if the symptoms persist for a substantial period of time after cessation of the synthetic cathinone use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with synthetic cathinone use).</p>
<b>Coding Note:</b>	Code also the causing condition
<b>6C47.71</b>	<p>Synthetic cathinone-induced anxiety disorder</p> <p>Synthetic cathinone-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from synthetic cathinones. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Synthetic cathinone intoxication or Synthetic cathinone withdrawal. The amount and duration of synthetic cathinone use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the synthetic cathinone use, if the symptoms persist for a substantial period of time after cessation of the synthetic cathinone use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with synthetic cathinone use).</p>
<b>Coding Note:</b>	Code also the causing condition

<b>6C47.72</b>	Synthetic cathinone-induced obsessive-compulsive or related syndrome Synthetic cathinone-induced obsessive-compulsive or related disorder is characterised by either repetitive intrusive thoughts or preoccupations, normally associated with anxiety and typically accompanied by repetitive behaviours performed in response, or by recurrent and habitual actions directed at the integument (e.g., hair pulling, skin picking) that develop during or soon after intoxication with or withdrawal from synthetic cathinones. The intensity or duration of the symptoms is substantially in excess of analogous disturbances that are characteristic of Synthetic cathinone intoxication or Synthetic cathinone withdrawal. The amount and duration of synthetic cathinone use must be capable of producing obsessive-compulsive or related symptoms. The symptoms are not better explained by a primary mental disorder (in particular an Obsessive-compulsive or related disorder), as might be the case if the symptoms preceded the onset of the synthetic cathinone use, if the symptoms persist for a substantial period of time after cessation of the synthetic cathinone use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with obsessive-compulsive or related symptoms (e.g., a history of prior episodes not associated with synthetic cathinone use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C47.73</b>	Synthetic cathinone-induced impulse control disorder Synthetic cathinone-induced impulse control disorder is characterised by persistently repeated behaviours in which there is recurrent failure to resist an impulse, drive, or urge to perform an act that is rewarding to the person, at least in the short-term, despite longer-term harm either to the individual or to others (e.g., fire setting or stealing without apparent motive, repetitive sexual behaviour, aggressive outbursts) that develop during or soon after intoxication with or withdrawal from synthetic cathinones. The intensity or duration of the symptoms is substantially in excess of disturbances of impulse control that are characteristic of Synthetic cathinone intoxication or Synthetic cathinone withdrawal. The amount and duration of synthetic cathinone use must be capable of producing disturbances of impulse control. The symptoms are not better explained by a primary mental disorder (e.g., an Impulse control disorder, a Disorder due to addictive behaviours), as might be the case if the impulse control disturbances preceded the onset of the synthetic cathinone use, if the symptoms persist for a substantial period of time after cessation of the synthetic cathinone use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with impulse control symptoms (e.g., a history of prior episodes not associated with synthetic cathinone use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C47.Y</b>	<b>Other specified disorders due to use of synthetic cathinones</b>
<b>6C47.Z</b>	<b>Disorders due to use of synthetic cathinones, unspecified</b>

**6C48**

## **Disorders due to use of caffeine**

Disorders due to use of caffeine are characterised by the pattern and consequences of caffeine use. Caffeine is a mild psychostimulant and diuretic that is found in the beans of the coffee plant (*Coffea* species) and is a constituent of coffee, cola drinks, chocolate, a range of proprietary 'energy drinks' and weight-loss aids. It is the most commonly used psychoactive substance worldwide and several clinical conditions related to its use are described, although severe disorders are comparatively rare considering its ubiquity. Caffeine Intoxication related to consumption of relatively higher doses (i.e., > 1 g per day) is described. Caffeine Withdrawal is common upon cessation of use among individuals who have used caffeine for a prolonged period or in large amounts. Caffeine-Induced Anxiety Disorder has been described, often following intoxication or heavy use.

**Exclusions:** Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone (6C46)  
Hazardous use of caffeine (QE11.5)

**6C48.0**

### **Episode of harmful use of caffeine**

An episode of caffeine use that has caused damage to a person's physical or mental health. Harm to health of the individual occurs due to one or more of the following: (1) direct or secondary toxic effects on body organs and systems; or (2) a harmful route of administration. This diagnosis should not be made if the harm is attributed to a known pattern of caffeine use.

**Exclusions:** Harmful pattern of use of caffeine (6C48.1)

**6C48.1**

### **Harmful pattern of use of caffeine**

A pattern of caffeine use that has caused clinically significant harm to a person's physical or mental health or in which caffeine-induced behaviour has caused clinically significant harm to the health of other people. The pattern of caffeine use is evident over a period of at least 12 months if use is episodic and at least one month if use is continuous (i.e., daily or almost daily). Harm may be caused by the intoxicating effects of caffeine, the direct or secondary toxic effects on body organs and systems, or a harmful route of administration.

**Exclusions:** Episode of harmful use of caffeine (6C48.0)

**6C48.10**

### **Harmful pattern of use of caffeine, episodic**

A pattern of episodic or intermittent caffeine use that has caused damage to a person's physical or mental health. The pattern of episodic caffeine use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) direct or secondary toxic effects on body organs and systems; or (2) a harmful route of administration.

**Exclusions:** Episode of harmful use of caffeine (6C48.0)

**6C48.11**

### **Harmful pattern of use of caffeine, continuous**

A pattern of continuous (daily or almost daily) caffeine use that has caused damage to a person's physical or mental health. The pattern of continuous caffeine use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) direct or secondary toxic effects on body organs and systems; or (2) a harmful route of administration.

**Exclusions:** Episode of harmful use of caffeine (6C48.0)

<b>6C48.1Z</b>	Harmful pattern of use of caffeine, unspecified
<b>6C48.2</b>	<p><b>Caffeine intoxication</b></p> <p>Caffeine intoxication is a clinically significant transient condition that develops during or shortly after the consumption of caffeine that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of caffeine and their intensity is closely related to the amount of caffeine consumed. They are time-limited and abate as caffeine is cleared from the body. Presenting features may include restlessness, anxiety, excitement, insomnia, flushed face, tachycardia, diuresis, gastrointestinal disturbances, muscle twitching, psychomotor agitation, perspiration or chills, and nausea or vomiting. Cardiac arrhythmias may occur. Disturbances typical of intoxication tend to occur at relatively higher doses (e.g., &gt; 1 g per day). Very high doses of caffeine (e.g., &gt; 5 g) can result in respiratory distress or seizures and can be fatal.</p>
<b>Coding Note:</b>	Code also the causing condition
<b>6C48.3</b>	<p><b>Caffeine withdrawal</b></p> <p>Caffeine withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of caffeine (typically in the form of coffee, caffeinated drinks, or as an ingredient in certain over-the-counter medications) in individuals who have used caffeine for a prolonged period or in large amounts. Presenting features of Caffeine withdrawal may include headache, marked fatigue or drowsiness, irritability, depressed or dysphoric mood, nausea or vomiting, and difficulty concentrating.</p>
<b>Coding Note:</b>	Code also the causing condition
<b>6C48.4</b>	<b>Certain specified caffeine-induced mental or behavioural disorders</b>
<b>Coding Note:</b>	Code also the causing condition
<b>6C48.40</b>	<p>Caffeine-induced anxiety disorder</p> <p>Caffeine-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from caffeine. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Caffeine intoxication or Caffeine withdrawal. The amount and duration of caffeine use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the caffeine use, if the symptoms persist for a substantial period of time after cessation of the caffeine use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with caffeine use).</p>
<b>Coding Note:</b>	Code also the causing condition
<b>6C48.Y</b>	<b>Other specified disorders due to use of caffeine</b>
<b>6C48.Z</b>	<b>Disorders due to use of caffeine, unspecified</b>

**6C49**

### **Disorders due to use of hallucinogens**

Disorders due to use of hallucinogens are characterised by the pattern and consequences of hallucinogen use. Several thousand compounds have hallucinogenic properties, many of which are found in plants (e.g., mescaline) and fungi (e.g., psilocybin) or are chemically synthesized (e.g., lysergic acid diethylamide [LSD]). These compounds have primarily hallucinogenic properties, but some may also be stimulants. Much of the morbidity associated with these compounds arises from the acute effects related to Hallucinogen Intoxication. Hallucinogen Dependence is rare and Hallucinogen Withdrawal is not described. Among the mental disorders related to hallucinogen use, Hallucinogen-Induced Psychotic Disorder is the most frequently seen, although worldwide it is still fairly uncommon.

**6C49.0**

### **Episode of harmful use of hallucinogens**

An episode of hallucinogen use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to hallucinogen intoxication on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of hallucinogen use.

**Exclusions:**      Hallucinogen dependence (6C49.2)

                          Harmful pattern of use of hallucinogens (6C49.1)

**6C49.1**

### **Harmful pattern of use of hallucinogens**

A pattern of use of hallucinogens that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of hallucinogen use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to hallucinogen intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of hallucinogens applies.

**Exclusions:**      Hallucinogen dependence (6C49.2)

                          Episode of harmful use of hallucinogens (6C49.0)

- 6C49.10** Harmful pattern of use of hallucinogens, episodic  
A pattern of episodic or intermittent use of hallucinogens that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic hallucinogen use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to hallucinogen intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of hallucinogens applies.
- Exclusions:** Episode of harmful use of hallucinogens (6C49.0)  
Hallucinogen dependence (6C49.2)
- 6C49.11** Harmful pattern of use of hallucinogens, continuous  
A pattern of continuous (daily or almost daily) use of hallucinogens that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous hallucinogen use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to hallucinogen intoxication on the part of the person to whom the diagnosis of Harmful use of hallucinogens applies.
- Exclusions:** Episode of harmful use of hallucinogens (6C49.0)  
Hallucinogen dependence (6C49.2)
- 6C49.1Z** Harmful pattern of use of hallucinogens, unspecified
- 6C49.2** **Hallucinogen dependence**  
Hallucinogen dependence is a disorder of regulation of hallucinogen use arising from repeated or continuous use of hallucinogens. The characteristic feature is a strong internal drive to use hallucinogens, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use hallucinogens. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if hallucinogens use is continuous (daily or almost daily) for at least 3 months.
- Exclusions:** Episode of harmful use of hallucinogens (6C49.0)  
Harmful pattern of use of hallucinogens (6C49.1)
- 6C49.20** Hallucinogen dependence, current use  
Current hallucinogen dependence with hallucinogen use within the past month.
- Exclusions:** Episode of harmful use of hallucinogens (6C49.0)  
Harmful pattern of use of hallucinogens (6C49.1)

<b>6C49.21</b>	Hallucinogen dependence, early full remission  After a diagnosis of Hallucinogen dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from hallucinogens during a period lasting between 1 and 12 months.
	<b>Exclusions:</b> Episode of harmful use of hallucinogens (6C49.0) Harmful pattern of use of hallucinogens (6C49.1)
<b>6C49.22</b>	Hallucinogen dependence, sustained partial remission  After a diagnosis of Hallucinogen dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in hallucinogen consumption for more than 12 months, such that even though intermittent or continuing hallucinogen use has occurred during this period, the definitional requirements for dependence have not been met.
	<b>Exclusions:</b> Episode of harmful use of hallucinogens (6C49.0) Harmful pattern of use of hallucinogens (6C49.1)
<b>6C49.23</b>	Hallucinogen dependence, sustained full remission  After a diagnosis of Hallucinogen dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from hallucinogens for 12 months or longer.
	<b>Exclusions:</b> Episode of harmful use of hallucinogens (6C49.0) Harmful pattern of use of hallucinogens (6C49.1)
<b>6C49.2Z</b>	Hallucinogen dependence, unspecified
<b>6C49.3</b>	<b>Hallucinogen intoxication</b>  Hallucinogen intoxication is a clinically significant transient condition that develops during or shortly after the consumption of hallucinogens that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of hallucinogens and their intensity is closely related to the amount of hallucinogen consumed. They are time-limited and abate as the hallucinogen is cleared from the body. Presenting features may include hallucinations, illusions, perceptual changes such as depersonalisation, derealization, or synesthesias (blending of senses, such as a visual stimulus evoking a smell), anxiety, depressed or dysphoric mood, ideas of reference, paranoid ideation, impaired judgment, palpitations, sweating, blurred vision, tremors and incoordination. Physical signs may include tachycardia, elevated blood pressure, and pupillary dilatation. In rare instances, hallucinogen intoxication may facilitate suicidal ideation and behaviour.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> hallucinogens poisoning (NE60) Possession trance disorder (6B63)

<b>6C49.4</b>	<b>Hallucinogen-induced delirium</b> Hallucinogen-induced delirium is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or during the use of hallucinogens. The amount and duration of hallucinogen use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.
<b>Coding Note:</b>	Code also the causing condition
<b>6C49.5</b>	<b>Hallucinogen-induced psychotic disorder</b> Hallucinogen-induced psychotic disorder is characterised by psychotic symptoms (e.g. delusions, hallucinations, disorganised thinking, grossly disorganized behaviour) that develop during or soon after intoxication with hallucinogens. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of hallucinogen intoxication. The amount and duration of hallucinogen use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g. Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the hallucinogen use, if the symptoms persist for a substantial period of time after cessation of the hallucinogen use, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g. a history of prior episodes not associated with hallucinogen use).
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Psychotic disorder induced by other specified psychoactive substance (6C4E.6) Alcohol-induced psychotic disorder (6C40.6)
<b>6C49.6</b>	<b>Certain specified hallucinogen-induced mental or behavioural disorders</b>
<b>Coding Note:</b>	Code also the causing condition
<b>6C49.60</b>	Hallucinogen-induced mood disorder Hallucinogen-induced mood disorder is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with hallucinogens. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of hallucinogen intoxication. The amount and duration of hallucinogen use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the hallucinogen use, if the symptoms persist for a substantial period of time after cessation of the hallucinogen use, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with hallucinogen use).
<b>Coding Note:</b>	Code also the causing condition

<b>6C49.61</b>	Hallucinogen-induced anxiety disorder Hallucinogen-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with hallucinogens. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of hallucinogen intoxication. The amount and duration of hallucinogen use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and Fear-Related Disorder, a Depressive Disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the hallucinogen use, if the symptoms persist for a substantial period of time after cessation of the hallucinogen use, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with hallucinogen use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C49.Y</b>	<b>Other specified disorders due to use of hallucinogens</b>
<b>6C49.Z</b>	<b>Disorders due to use of hallucinogens, unspecified</b>
<b>6C4A</b>	<p><b>Disorders due to use of nicotine</b></p> <p>Disorders due to use of nicotine are characterised by the pattern and consequences of nicotine use. Nicotine is the active dependence-producing constituent of the tobacco plant, <i>Nicotiana tabacum</i>. Nicotine is used overwhelmingly through smoking cigarettes. Increasingly, it is also used in electronic cigarettes that vaporize nicotine dissolved in a carrier solvent for inhalation (i.e., “vaping”). Pipe smoking, chewing tobacco and inhaling snuff are minor forms of use. Nicotine is a highly potent addictive compound and is the third most common psychoactive substance used worldwide after caffeine and alcohol. Nicotine Dependence and Nicotine Withdrawal are well described and Nicotine-Induced Mental Disorders are recognized.</p>
<b>6C4A.0</b>	<p><b>Episode of harmful use of nicotine</b></p> <p>An episode of nicotine use that has caused damage to a person's physical or mental health. Harm to health of the individual occurs due to one or more of the following: (1) direct or secondary toxic effects on body organs and systems; or (2) a harmful route of administration. This diagnosis should not be made if the harm is attributed to a known pattern of nicotine use.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Nicotine dependence (6C4A.2)</li> <li>Harmful pattern of use of nicotine (6C4A.1)</li> <li>Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified (NE61)</li> </ul>

- 6C4A.1** **Harmful pattern of use of nicotine**  
A pattern of nicotine use that has caused damage to a person's physical or mental health. The pattern of nicotine use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) direct or secondary toxic effects on body organs and systems; or (2) a harmful route of administration.
- Exclusions:** Nicotine dependence (6C4A.2)  
Episode of harmful use of nicotine (6C4A.0)
- 6C4A.10** Harmful pattern of use of nicotine, episodic  
A pattern of episodic or intermittent nicotine use that has caused damage to a person's physical or mental health. The pattern of episodic nicotine use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) direct or secondary toxic effects on body organs and systems; or (2) a harmful route of administration.
- Exclusions:** Episode of harmful use of nicotine (6C4A.0)  
Nicotine dependence (6C4A.2)
- 6C4A.11** Harmful pattern of use of nicotine, continuous  
A pattern of continuous (daily or almost daily) nicotine use that has caused damage to a person's physical or mental health. The pattern of continuous nicotine use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) direct or secondary toxic effects on body organs and systems; or (2) a harmful route of administration.
- Exclusions:** Episode of harmful use of nicotine (6C4A.0)  
Nicotine dependence (6C4A.2)
- 6C4A.1Z** Harmful pattern of use of nicotine, unspecified
- 6C4A.2** **Nicotine dependence**  
Nicotine dependence is a disorder of regulation of nicotine use arising from repeated or continuous use of nicotine. The characteristic feature is a strong internal drive to use nicotine, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use nicotine. Physiological features of dependence may also be present, including tolerance to the effects of nicotine, withdrawal symptoms following cessation or reduction in use of nicotine, or repeated use of nicotine or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if nicotine use is continuous (daily or almost daily) for at least 3 months.
- Exclusions:** Episode of harmful use of nicotine (6C4A.0)  
Harmful pattern of use of nicotine (6C4A.1)

- 6C4A.20** Nicotine dependence, current use  
Current nicotine dependence with nicotine use within the past month.
- Exclusions:** Episode of harmful use of nicotine (6C4A.0)  
Harmful pattern of use of nicotine (6C4A.1)
- 6C4A.21** Nicotine dependence, early full remission  
After a diagnosis of nicotine dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from nicotine during a period lasting between 1 and 12 months.
- Exclusions:** Episode of harmful use of nicotine (6C4A.0)  
Harmful pattern of use of nicotine (6C4A.1)
- 6C4A.22** Nicotine dependence, sustained partial remission  
After a diagnosis of nicotine dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in nicotine consumption for more than 12 months, such that even though intermittent or continuing nicotine use has occurred during this period, the definitional requirements for dependence have not been met.
- Exclusions:** Episode of harmful use of nicotine (6C4A.0)  
Harmful pattern of use of nicotine (6C4A.1)
- 6C4A.23** Nicotine dependence, sustained full remission  
After a diagnosis of nicotine dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from nicotine for 12 months or longer.
- Exclusions:** Episode of harmful use of nicotine (6C4A.0)  
Harmful pattern of use of nicotine (6C4A.1)
- 6C4A.2Z** Nicotine dependence, unspecified
- 6C4A.3 Nicotine intoxication**  
Nicotine intoxication is a clinically significant transient condition that develops during or shortly after the consumption of nicotine that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of nicotine and their intensity is closely related to the amount of nicotine consumed. They are time-limited and abate as nicotine is cleared from the body. Presenting features may include restlessness, psychomotor agitation, anxiety, cold sweats, headache, insomnia, palpitations, paresthesias, nausea or vomiting, abdominal cramps, confusion, bizarre dreams, burning sensations in the mouth, and salivation. In rare instances, paranoid ideation, perceptual disturbances, convulsions or coma may occur. Nicotine intoxication occurs more commonly in naïve (non-tolerant) users or among those taking higher than accustomed doses.
- Coding Note:** Code also the causing condition
- Inclusions:** "Bad trips" due to nicotine
- Exclusions:** intoxication meaning poisoning (NE61)  
Possession trance disorder (6B63)

<b>6C4A.4</b>	<b>Nicotine withdrawal</b> Nicotine withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of nicotine (typically used as a constituent of tobacco) in individuals who have developed Nicotine dependence or have used nicotine for a prolonged period or in large amounts. Presenting features of Nicotine withdrawal may include dysphoric or depressed mood, insomnia, irritability, anger, anxiety, difficulty concentrating, restlessness, bradycardia, increased appetite, and craving for tobacco (or other nicotine-containing products). Other physical symptoms may include increased cough and mouth ulceration.
<b>Coding Note:</b>	Code also the causing condition
<b>6C4A.Y</b>	<b>Other specified disorders due to use of nicotine</b>
<b>6C4A.Z</b>	<b>Disorders due to use of nicotine, unspecified</b>
<b>6C4B</b>	<p><b>Disorders due to use of volatile inhalants</b></p> <p>Disorders due to use of volatile inhalants are characterised by the pattern and consequences of volatile inhalant use. Volatile inhalants include a range of compounds that are in the gaseous or vapour phase at ambient temperatures and include various organic solvents, glues, gasoline (petrol), nitrites and gases such as nitrous oxide, trichloroethane, butane, toluene, fluorocarbons, ether and halothane. They have a range of pharmacological properties but are predominantly central nervous system depressants, with many also having vasoactive effects. They tend to be used by younger persons and may be used when access to alternative psychoactive substances is difficult or impossible. Volatile Inhalant Intoxication is well recognized. Volatile inhalants have dependence-producing properties and Volatile Inhalant Dependence and Volatile Inhalant Withdrawal is recognized although comparatively uncommon worldwide. Volatile Inhalant-Induced Mental Disorders are described. They may also cause neurocognitive impairment, including Dementia.</p>
<b>6C4B.0</b>	<p><b>Episode of harmful use of volatile inhalants</b></p> <p>An episode of volatile inhalant use or unintentional exposure (e.g., occupational exposure) that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to volatile inhalant intoxication on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of volatile inhalant use.</p>
<b>Exclusions:</b>	Harmful pattern of use of volatile inhalants (6C4B.1) Volatile inhalant dependence (6C4B.2)

- 6C4B.1**           **Harmful pattern of use of volatile inhalants**  
A pattern of volatile inhalant use that has caused damage to a person's physical or mental health. The pattern of volatile inhalant use is evident over a period of at least 12 months if substance use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (1) direct or secondary toxic effects on body organs and systems; or (2) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to volatile inhalant intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of volatile inhalants applies.
- Exclusions:**       Volatile inhalant dependence (6C4B.2)  
                        Episode of harmful use of volatile inhalants (6C4B.0)
- 6C4B.10**           Harmful pattern of use of volatile inhalants, episodic  
A pattern of episodic or intermittent volatile inhalant use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic volatile inhalant use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to volatile inhalant intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of volatile inhalants applies.
- Exclusions:**       Episode of harmful use of volatile inhalants (6C4B.0)  
                        Volatile inhalant dependence (6C4B.2)
- 6C4B.11**           Harmful pattern of use of volatile inhalants, continuous  
A pattern of continuous (daily or almost daily) volatile inhalant use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous volatile inhalant use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to volatile inhalant intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of volatile inhalants applies.
- Exclusions:**       Episode of harmful use of volatile inhalants (6C4B.0)  
                        Volatile inhalant dependence (6C4B.2)
- 6C4B.1Z**           Harmful pattern of use of volatile inhalants, unspecified

<b>6C4B.2</b>	<b>Volatile inhalant dependence</b> Volatile inhalant dependence is a disorder of regulation of volatile inhalant use arising from repeated or continuous use of volatile inhalants. The characteristic feature is a strong internal drive to use volatile inhalants, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use volatile inhalants. Physiological features of dependence may also be present, including tolerance to the effects of volatile inhalants, withdrawal symptoms following cessation or reduction in use of volatile inhalants, or repeated use of volatile inhalants or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if volatile inhalant use is continuous (daily or almost daily) for at least 3 months.
	<b>Exclusions:</b> Episode of harmful use of volatile inhalants (6C4B.0) Harmful pattern of use of volatile inhalants (6C4B.1)
<b>6C4B.20</b>	Volatile inhalant dependence, current use Current volatile inhalant dependence with volatile inhalant use within the past month. <b>Exclusions:</b> Episode of harmful use of volatile inhalants (6C4B.0) Harmful pattern of use of volatile inhalants (6C4B.1)
<b>6C4B.21</b>	Volatile inhalant dependence, early full remission After a diagnosis of volatile inhalant dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from volatile inhalants during a period lasting between 1 and 12 months. <b>Exclusions:</b> Episode of harmful use of volatile inhalants (6C4B.0) Harmful pattern of use of volatile inhalants (6C4B.1)
<b>6C4B.22</b>	Volatile inhalant dependence, sustained partial remission After a diagnosis of Volatile inhalant dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in volatile inhalant consumption for more than 12 months, such that even though intermittent or continuing volatile inhalant use has occurred during this period, the definitional requirements for dependence have not been met. <b>Exclusions:</b> Episode of harmful use of volatile inhalants (6C4B.0) Harmful pattern of use of volatile inhalants (6C4B.1)
<b>6C4B.23</b>	Volatile inhalant dependence, sustained full remission After a diagnosis of Volatile inhalant dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from volatile inhalants for 12 months or longer. <b>Exclusions:</b> Episode of harmful use of volatile inhalants (6C4B.0) Harmful pattern of use of volatile inhalants (6C4B.1)
<b>6C4B.2Z</b>	Volatile inhalant dependence, unspecified

<b>6C4B.3</b>	<b>Volatile inhalant intoxication</b>
	<p>Volatile inhalant intoxication is a clinically significant transient condition that develops during or shortly after the consumption of a volatile inhalant that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of volatile inhalants and their intensity is closely related to the amount of volatile inhalant consumed. They are time-limited and abate as the volatile inhalant is cleared from the body. Presenting features may include euphoria, impaired judgment, aggression, somnolence, stupor or coma, dizziness, tremor, lack of coordination, slurred speech, unsteady gait, lethargy and apathy, psychomotor retardation, and visual disturbances. Muscle weakness and diplopia may occur. Use of volatile inhalants may cause cardiac arrhythmia, cardiac arrest, and death. Inhalants containing lead (e.g. some forms of petrol/gasoline) may cause confusion, irritability, coma and seizures.</p>
<b>Coding Note:</b>	Code also the causing condition
<b>Exclusions:</b>	Possession trance disorder (6B63)
<b>6C4B.4</b>	<b>Volatile inhalant withdrawal</b>
	<p>Volatile inhalant withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of volatile inhalants in individuals who have developed Volatile inhalant dependence or have used volatile inhalants for a prolonged period or in large amounts. Presenting features of Volatile inhalant withdrawal may include insomnia, anxiety, irritability, dysphoric mood, shakiness, perspiration, nausea, and transient illusions.</p>
<b>Coding Note:</b>	Code also the causing condition
<b>6C4B.5</b>	<b>Volatile inhalant-induced delirium</b>
	<p>Volatile inhalant-induced delirium is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of volatile inhalants. The amount and duration of volatile inhalant use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.</p>
<b>Coding Note:</b>	<p>This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.</p> <p>When dementia is due to multiple aetiologies, code all that apply.</p>

<b>6C4B.6</b>	<b>Volatile inhalant-induced psychotic disorder</b>
	Volatile inhalant-induced psychotic disorder is characterised by psychotic symptoms (e.g. delusions, hallucinations, disorganized thinking, grossly disorganized behaviour) that develop during or soon after intoxication with or withdrawal from volatile inhalants. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Volatile inhalant intoxication or Volatile inhalant withdrawal. The amount and duration of volatile inhalant use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g. Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the volatile inhalant use, if the symptoms persist for a substantial period of time after cessation of the volatile inhalant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g. a history of prior episodes not associated with volatile inhalant use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C4B.7</b>	<b>Certain specified volatile inhalants-induced mental or behavioural disorders</b>
<b>Coding Note:</b>	Code also the causing condition
<b>6C4B.70</b>	Volatile inhalant-induced mood disorder
	Volatile inhalant-induced mood disorder is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from volatile inhalants. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Volatile inhalant intoxication or Volatile inhalant withdrawal. The amount and duration of volatile inhalant use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the volatile inhalant use, if the symptoms persist for a substantial period of time after cessation of the volatile inhalant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with volatile inhalant use).
<b>Coding Note:</b>	Code also the causing condition

<b>6C4B.71</b>	Volatile inhalant-induced anxiety disorder Volatile inhalant-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from volatile inhalants. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Volatile inhalant intoxication or Volatile inhalant withdrawal. The amount and duration of volatile inhalant use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and Fear-Related Disorder, a Depressive Disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the volatile inhalant use, if the symptoms persist for a substantial period of time after cessation of the volatile inhalant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with volatile inhalant use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C4B.Y</b>	<b>Other specified disorders due to use of volatile inhalants</b>
<b>6C4B.Z</b>	<b>Disorders due to use of volatile inhalants, unspecified</b>
<b>6C4C</b>	<p><b>Disorders due to use of MDMA or related drugs, including MDA</b></p> <p>Disorders due to use of MDMA or related drugs, including MDA are characterised by the pattern and consequences of MDMA or related drug use. MDMA is methylene-dioxymethamphetamine and is a common drug of abuse in many countries especially among young people. It is predominantly available in tablet form known as 'ecstasy'. Pharmacologically, MDMA has stimulant and empathogenic properties and these encourage its use among young people for social and other interactions. Considering its wide prevalence in many countries and among many sub-groups of young people, MDMA and Related Drug Dependence and MDMA and Related Drug Withdrawal are comparatively uncommon. Substance-Induced Mental Disorders may arise from its use. Several analogues of MDMA exist, including MDA (methylene-dioxyamphetamine).</p> <p><b>Exclusions:</b> Hazardous use of MDMA or related drugs (QE11.6)</p> <p><b>6C4C.0</b> <b>Episode of harmful use of MDMA or related drugs, including MDA</b></p> <p>An episode of use of MDMA or related drugs, including MDA, that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to intoxication with MDMA or related drugs, including MDA, on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of use of MDMA or related drugs, including MDA.</p> <p><b>Exclusions:</b> Harmful pattern of use of MDMA or related drugs, including MDA (6C4C.1)</p> <p>MDMA or related drug dependence, including MDA (6C4C.2)</p>

- 6C4C.1** **Harmful pattern of use of MDMA or related drugs, including MDA**  
A pattern of use of MDMA or related drugs, including MDA, that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of use of MDMA or related drugs is evident over a period of at least 12 months if use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to MDMA or related drug intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of MDMA or related drugs, including MDA applies.
- Exclusions:**     MDMA or related drug dependence, including MDA (6C4C.2)  
                    Episode of harmful use of MDMA or related drugs, including MDA (6C4C.0)
- 6C4C.10** **Harmful use of MDMA or related drugs, including MDA, episodic**  
A pattern of episodic or intermittent use of MDMA or related drugs, including MDA, that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic use of MDMA or related drugs is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to MDMA or related drug intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of MDMA or related drugs, including MDA applies.
- Exclusions:**     Episode of harmful use of MDMA or related drugs, including MDA (6C4C.0)  
                    MDMA or related drug dependence, including MDA (6C4C.2)
- 6C4C.11** **Harmful use of MDMA or related drugs, including MDA, continuous**  
A pattern of continuous (daily or almost daily) use of MDMA or related drugs, including MDA, that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous use of MDMA or related drugs is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to MDMA or related drug intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of MDMA or related drugs, including MDA applies.
- Exclusions:**     Episode of harmful use of MDMA or related drugs, including MDA (6C4C.0)  
                    MDMA or related drug dependence, including MDA (6C4C.2)
- 6C4C.1Z** **Harmful pattern of use of MDMA or related drugs, including MDA, unspecified**

<b>6C4C.2</b>	<b>MDMA or related drug dependence, including MDA</b> MDMA or related drug dependence, including MDA is a disorder of regulation of MDMA or related drug use arising from repeated or continuous use of MDMA or related drugs. The characteristic feature is a strong internal drive to use MDMA or related drugs, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use MDMA or related drugs. Physiological features of dependence may also be present, including tolerance to the effects of MDMA or related drugs, withdrawal symptoms following cessation or reduction in use of MDMA or related drugs, or repeated use of MDMA or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if MDMA or related drug use is continuous (daily or almost daily) for at least 3 months.
	<p><b>Exclusions:</b> Episode of harmful use of MDMA or related drugs, including MDA (6C4C.0)</p> <p>Harmful pattern of use of MDMA or related drugs, including MDA (6C4C.1)</p>
<b>6C4C.20</b>	MDMA or related drug dependence, including MDA, current use Current MDMA or related drug dependence, including MDA, with MDMA or related drug use within the past month.
	<p><b>Exclusions:</b> Episode of harmful use of MDMA or related drugs, including MDA (6C4C.0)</p> <p>Harmful pattern of use of MDMA or related drugs, including MDA (6C4C.1)</p>
<b>6C4C.21</b>	MDMA or related drug dependence, including MDA, early full remission After a diagnosis of MDMA or related drug dependence, including MDA, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from MDMA or related drug dependence, including MDA, during a period lasting from between 1 and 12 months.
	<p><b>Exclusions:</b> Episode of harmful use of MDMA or related drugs, including MDA (6C4C.0)</p> <p>Harmful pattern of use of MDMA or related drugs, including MDA (6C4C.1)</p>
<b>6C4C.22</b>	MDMA or related drug dependence, including MDA, sustained partial remission After a diagnosis of MDMA or related drug dependence, including MDA, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in consumption of MDMA or related drugs, including MDA, for more than 12 months, such that even though intermittent or continuing use of MDMA or related drugs, including MDA, has occurred during this period, the definitional requirements for dependence have not been met.
	<p><b>Exclusions:</b> Episode of harmful use of MDMA or related drugs, including MDA (6C4C.0)</p> <p>Harmful pattern of use of MDMA or related drugs, including MDA (6C4C.1)</p>

**6C4C.23** MDMA or related drug dependence, including MDA, sustained full remission  
After a diagnosis of MDMA or related drug dependence, including MDA, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from MDMA or related drugs, including MDA, for 12 months or longer.

***Exclusions:*** Episode of harmful use of MDMA or related drugs, including MDA (6C4C.0)

Harmful pattern of use of MDMA or related drugs, including MDA (6C4C.1)

**6C4C.2Z** MDMA or related drug dependence, including MDA, unspecified

**6C4C.3** **MDMA or related drug intoxication, including MDA**

MDMA or related drug intoxication, including MDA is a clinically significant transient condition that develops during or shortly after the consumption of MDMA or related drugs that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of MDMA or related drugs and their intensity is closely related to the amount of MDMA or a related drug consumed. They are time-limited and abate as MDMA or a related drug is cleared from the body. Presenting features may include increased or inappropriate sexual interest and activity, anxiety, restlessness, agitation, and sweating. In rare instances, usually in severe intoxication, use of MDMA or related drugs, including MDA can result in dystonia and seizures. Sudden death is a rare but recognised complication.

***Coding Note:*** Code also the causing condition

**6C4C.4** **MDMA or related drug withdrawal, including MDA**

MDMA or related drug withdrawal, including MDA is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of MDMA or related drugs in individuals who have developed MDMA or related drug dependence or have used MDMA or related drugs for a prolonged period or in large amounts. Presenting features of MDMA or related drug withdrawal may include fatigue, lethargy, hypersomnia or insomnia, depressed mood, anxiety, irritability, craving, difficulty in concentrating, and appetite disturbance.

***Coding Note:*** Code also the causing condition

**6C4C.5** **MDMA or related drug-induced delirium, including MDA**

MDMA or related drug-induced delirium, including MDA is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or during the use of MDMA or related drugs. The amount and duration of MDMA or related drug use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.

***Coding Note:*** Code also the causing condition

- 6C4C.6 MDMA or related drug-induced psychotic disorder, including MDA**  
MDMA or related drug-induced psychotic disorder, including MDA is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with MDMA or related drugs. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of MDMA or related drug intoxication. The amount and duration of MDMA or related drug use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the MDMA or related drug use, if the symptoms persist for a substantial period of time after cessation of the MDMA or related drug use, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with MDMA or related drug use, including MDA).
- Coding Note:** Code also the causing condition
- 6C4C.7 Certain specified MDMA or related drug-induced mental or behavioural disorders, including MDA**  
**Coding Note:** Code also the causing condition
- 6C4C.70 MDMA or related drug-induced mood disorder, including MDA**  
MDMA or related drug-induced mood disorder, including MDA is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with MDMA or related drugs. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of MDMA or related drug intoxication, including MDA. The amount and duration of MDMA or related drug use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the MDMA or related drug use, if the symptoms persist for a substantial period of time after cessation of the MDMA or related drug use, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with MDMA or related drug use).
- Coding Note:** Code also the causing condition

<b>6C4C.71</b>	MDMA or related drug-induced anxiety disorder MDMA or related drug-induced anxiety disorder, including MDA is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with MDMA or related drugs. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of MDMA or related drug intoxication, including MDA. The amount and duration of MDMA or related drug use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the MDMA or related drug use, if the symptoms persist for a substantial period of time after cessation of the MDMA or related drug use, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with MDMA or related drug use).
----------------	---

**Coding Note:** Code also the causing condition

<b>6C4C.Y</b>	<b>Other specified disorders due to use of MDMA or related drugs, including MDA</b>
---------------	---

<b>6C4C.Z</b>	<b>Disorders due to use of MDMA or related drugs, including MDA, unspecified</b>
---------------	--

<b>6C4D</b>	<b>Disorders due to use of dissociative drugs including ketamine and phencyclidine [PCP]</b>
-------------	--

Disorders due to use of dissociative drugs including ketamine and phencyclidine [PCP] are characterised by the pattern and consequences of dissociative drug use. Dissociative drugs include ketamine and phencyclidine (PCP) and their (comparatively rare) chemical analogues. Ketamine is an intravenous anaesthetic widely used in low- and middle-income countries, particularly in Africa, and in emergency situations. Ketamine is also undergoing evaluation for treatment of some mental disorders (e.g., treatment resistant Depressive Disorders). It is also a widespread drug of nonmedical use in many countries and may be taken by the oral or nasal routes or injected. It produces a sense of euphoria but depending on the dose, emergent hallucinations and dissociation are recognised as unpleasant side effects. Phencyclidine has a more restricted worldwide distribution and also has euphoric and dissociative effects. Its use may result in bizarre behaviour uncharacteristic for the individual, including self-harm. Dissociative Drug Dependence is described but a withdrawal syndrome is not recognized by most authorities. Several Dissociative Drug-Induced Mental Disorders are recognised.

**Exclusions:** Hazardous use of dissociative drugs including ketamine or PCP (QE11.7)

6C4D.0

#### **Episode of harmful use of dissociative drugs including ketamine or PCP**

An episode of use of a dissociative drug, including Ketamine and PCP, that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to intoxication with a dissociative drug, including Ketamine and PCP, on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of use of dissociative drugs, including Ketamine and PCP.

**Exclusions:** Dissociative drug dependence including ketamine or PCP (6C4D.2)

Harmful pattern of use of dissociative drugs, including ketamine or PCP (6C4D.1)

6C4D.1

**Harmful pattern of use of dissociative drugs, including ketamine or PCP**

A pattern of use of dissociative drugs, including ketamine and phencyclidine (PCP), that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of dissociative drug use is evident over a period of at least 12 months if use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to dissociative drug intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of dissociative drugs, including ketamine and PCP applies.

**Exclusions:** Dissociative drug dependence including ketamine or PCP (6C4D.2)

Episode of harmful use of dissociative drugs including ketamine or PCP (6C4D.0)

- 6C4D.10** Harmful pattern of use of dissociative drugs including ketamine or PCP, episodic  
A pattern of episodic or intermittent use of dissociative drugs, including ketamine and phencyclidine (PCP), that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic use of dissociative drugs is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to dissociative drug intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of dissociative drugs, including ketamine and PCP applies.
- Exclusions:**
- Episode of harmful use of dissociative drugs including ketamine or PCP (6C4D.0)
  - Dissociative drug dependence including ketamine or PCP (6C4D.2)
- 6C4D.11** Harmful pattern of use of dissociative drugs including ketamine or PCP, continuous  
A pattern of continuous (daily or almost daily) use of dissociative drugs, including ketamine and phencyclidine (PCP), that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous use of dissociative drugs is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to dissociative drug intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of dissociative drugs, including ketamine and PCP applies.
- Exclusions:**
- Episode of harmful use of dissociative drugs including ketamine or PCP (6C4D.0)
  - Dissociative drug dependence including ketamine or PCP (6C4D.2)
- 6C4D.1Z** Harmful pattern of use of dissociative drugs, including ketamine or PCP, unspecified

<b>6C4D.2</b>	<b>Dissociative drug dependence including ketamine or PCP</b> Dissociative drug dependence including ketamine or PCP is a disorder of regulation of dissociative drug use arising from repeated or continuous use of dissociative drugs. The characteristic feature is a strong internal drive to use dissociative drugs, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use dissociative drugs. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if dissociative drugs use is continuous (daily or almost daily) for at least 3 months.
	<b><i>Exclusions:</i></b> Episode of harmful use of dissociative drugs including ketamine or PCP (6C4D.0)  Harmful pattern of use of dissociative drugs, including ketamine or PCP (6C4D.1)
<b>6C4D.20</b>	Dissociative drug dependence including Ketamine or PCP, current use Dissociative drug dependence including Ketamine and PCP, current use refers to use of dissociative drugs within the past month.
	<b><i>Exclusions:</i></b> Episode of harmful use of dissociative drugs including ketamine or PCP (6C4D.0)  Harmful pattern of use of dissociative drugs, including ketamine or PCP (6C4D.1)
<b>6C4D.21</b>	Dissociative drug dependence including ketamine or PCP, early full remission After a diagnosis of Dissociative drug dependence including ketamine and PCP, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from dissociative drugs during a period lasting between 1 and 12 months.
	<b><i>Exclusions:</i></b> Episode of harmful use of dissociative drugs including ketamine or PCP (6C4D.0)  Harmful pattern of use of dissociative drugs, including ketamine or PCP (6C4D.1)
<b>6C4D.22</b>	Dissociative drug dependence including Ketamine or PCP, sustained partial remission After a diagnosis of Dissociative drug dependence including Ketamine and PCP, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in dissociative drug consumption for more than 12 months, such that even though intermittent or continuing dissociative drug use has occurred during this period, the definitional requirements for dependence have not been met.
	<b><i>Exclusions:</i></b> Episode of harmful use of dissociative drugs including ketamine or PCP (6C4D.0)  Harmful pattern of use of dissociative drugs, including ketamine or PCP (6C4D.1)

<b>6C4D.23</b>	Dissociative drug dependence including Ketamine or PCP, sustained full remission After a diagnosis of Dissociative drug dependence including Ketamine and PCP, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from dissociative drugs for 12 months or longer.
<b>Exclusions:</b>	Episode of harmful use of dissociative drugs including ketamine or PCP (6C4D.0) Harmful pattern of use of dissociative drugs, including ketamine or PCP (6C4D.1)
<b>6C4D.2Z</b>	Dissociative drug dependence including ketamine or PCP, unspecified
<b>6C4D.3</b>	<b>Dissociative drug intoxication including Ketamine or PCP</b> Dissociative drug intoxication including Ketamine and PCP is a clinically significant transient condition that develops during or shortly after the consumption of a dissociative drug that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of a dissociative drug and their intensity is closely related to the amount of the dissociative drug consumed. They are time-limited and abate as the dissociative drug is cleared from the body. Presenting features may include aggression, impulsiveness, unpredictability, anxiety, psychomotor agitation, impaired judgment, numbness or diminished responsiveness to pain, slurred speech, and dystonia. Physical signs include nystagmus (repetitive, uncontrolled eye movements), tachycardia, elevated blood pressure, numbness, ataxia, dysarthria, and muscle rigidity. In rare instances, use of dissociative drugs including Ketamine and PCP can result in seizures.
<b>Coding Note:</b>	Code also the causing condition
<b>6C4D.4</b>	<b>Dissociative drug-induced delirium including ketamine or PCP</b> Dissociative drug-induced delirium including Ketamine or PCP is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or during the use of dissociative drugs. The amount and duration of dissociative drug use must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.
<b>Coding Note:</b>	Code also the causing condition

<b>6C4D.5</b>	<b>Dissociative drug-induced psychotic disorder including Ketamine or PCP</b>
	Dissociative drug-induced psychotic disorder including Ketamine or PCP is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganized behaviour) that develop during or soon after intoxication with dissociative drugs. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Dissociative drug intoxication. The amount and duration of Dissociative drug use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the dissociative drug use, if the symptoms persist for a substantial period of time after cessation of the dissociative drug use, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with dissociative drug use).
<b>Coding Note:</b>	Code also the causing condition
<b>6C4D.6</b>	<b>Certain specified dissociative drug-induced mental or behavioural disorders, including ketamine and phencyclidine [PCP]</b>
<b>Coding Note:</b>	Code also the causing condition
<b>6C4D.60</b>	Dissociative drug-induced mood disorder including Ketamine or PCP Dissociative drug-induced mood disorder including Ketamine or PCP is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with dissociative drugs. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Dissociative drug intoxication. The amount and duration of Dissociative drug use must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the dissociative drug use, if the symptoms persist for a substantial period of time after cessation of the dissociative drug use, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with dissociative drug use).
<b>Coding Note:</b>	Code also the causing condition

**6C4D.61** Dissociative drug-induced anxiety disorder including Ketamine or PCP  
Dissociative drug-induced anxiety disorder including Ketamine or PCP is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with dissociative drugs. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Dissociative drug intoxication. The amount and duration of Dissociative drug use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and Fear-Related Disorder, a Depressive Disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the dissociative drug use, if the symptoms persist for a substantial period of time after cessation of the dissociative drug use, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with dissociative drug use).

**Coding Note:** Code also the causing condition

**6C4D.Y** Other specified disorders due to use of dissociative drugs including ketamine and phencyclidine [PCP]

**6C4D.Z** Disorders due to use of dissociative drugs including ketamine and phencyclidine [PCP], unspecified

**6C4E** Disorders due to use of other specified psychoactive substances, including medications

Disorders due to use of other specified psychoactive substances, including medications are characterised by the pattern and consequences of psychoactive substances that are not included among the major substance classes specifically identified. Examples include khat, antidepressants, medications with anticholinergic properties (e.g., benztropine), and some antihistamines.

**6C4E.0** Episode of harmful use of other specified psychoactive substance

An episode of use of a specified psychoactive substance or medication that is not included in the other substance classes specifically identified under Disorders Due to Substance Use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to substance intoxication or psychoactive medication use; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to substance intoxication or psychoactive medication use on the part of the person to whom the diagnosis of single episode of harmful use of other specified psychoactive substance applies. This diagnosis should not be made if the harm is attributed to a known pattern of use of the specified psychoactive substance.

**Exclusions:** Harmful pattern of use of other specified psychoactive substance (6C4E.1)

Other specified psychoactive substance dependence (6C4E.2)

**6C4E.1****Harmful pattern of use of other specified psychoactive substance**

A pattern of use of a specified psychoactive substance or medication that is not included in the other substance classes specifically identified under Disorders Due to Substance Use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of substance use is evident over a period of at least 12 months if use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to intoxication due to the specified substance or medication on the part of the person to whom the diagnosis of Harmful pattern of use of other specified psychoactive substance applies.

- Exclusions:**
- Other specified psychoactive substance dependence (6C4E.2)
  - Episode of harmful use of other specified psychoactive substance (6C4E.0)

**6C4E.10****Harmful pattern of use of other specified psychoactive substance, episodic**

A pattern of episodic or intermittent use of a specified psychoactive substance or medication that is not included in the other substance classes specifically identified under Disorders Due to Substance Abuse that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic substance use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to intoxication due to the specified substance or medication on the part of the person to whom the diagnosis of Harmful pattern of use of other specified psychoactive substance applies.

- Exclusions:**
- Episode of harmful use of other specified psychoactive substance (6C4E.0)
  - Other specified psychoactive substance dependence (6C4E.2)

- 6C4E.11** Harmful pattern of use of other specified psychoactive substance, continuous  
A pattern of continuous (daily or almost daily) use of a specified psychoactive substance or medication that is not included in the other substance classes specifically identified under Disorders Due to Substance Use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous substance use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to intoxication due to the specified substance or medication on the part of the person to whom the diagnosis of Harmful pattern of use of other specified psychoactive substance applies.
- Exclusions:** Episode of harmful use of other specified psychoactive substance (6C4E.0)  
Other specified psychoactive substance dependence (6C4E.2)
- 6C4E.1Z** Harmful pattern of use of other specified psychoactive substance, unspecified
- 6C4E.2** **Other specified psychoactive substance dependence**  
Other specified psychoactive substance dependence is a disorder of regulation of use of a specified substance arising from repeated or continuous use of the specified substance. The characteristic feature is a strong internal drive to use the specified substance, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use the specified substance. Physiological features of dependence may also be present, including tolerance to the effects of the specified substance, withdrawal symptoms following cessation or reduction in use of the specified substance, or repeated use of the specified substance or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if use of the specified substance is continuous (daily or almost daily) for at least 3 months.
- Exclusions:** Episode of harmful use of other specified psychoactive substance (6C4E.0)  
Harmful pattern of use of other specified psychoactive substance (6C4E.1)
- 6C4E.20** Other specified psychoactive substance dependence, current use  
Current Other specified psychoactive substance dependence, with use of the specified psychoactive substance within the past month.
- Exclusions:** Episode of harmful use of other specified psychoactive substance (6C4E.0)  
Harmful pattern of use of other specified psychoactive substance (6C4E.1)

- 6C4E.21** Other specified psychoactive substance dependence, early full remission  
 After a diagnosis of Other specified psychoactive substance dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from the specified substance during a period lasting between 1 and 12 months.
- Exclusions:**
- Episode of harmful use of other specified psychoactive substance (6C4E.0)
  - Harmful pattern of use of other specified psychoactive substance (6C4E.1)
- 6C4E.22** Other specified psychoactive substance dependence, sustained partial remission  
 After a diagnosis of Other specified psychoactive substance dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in consumption of the specified substance for more than 12 months, such that even though intermittent or continuing substance use has occurred during this period, the definitional requirements for dependence have not been met.
- Exclusions:**
- Episode of harmful use of other specified psychoactive substance (6C4E.0)
  - Harmful pattern of use of other specified psychoactive substance (6C4E.1)
- 6C4E.23** Other specified psychoactive substance dependence, sustained full remission  
 After a diagnosis of Other specified psychoactive substance dependence, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from the specified substance for 12 months or longer.
- Exclusions:**
- Episode of harmful use of other specified psychoactive substance (6C4E.0)
  - Harmful pattern of use of other specified psychoactive substance (6C4E.1)
- 6C4E.2Z** Other specified psychoactive substance dependence, unspecified
- 6C4E.3** **Other specified psychoactive substance intoxication**  
 Other specified psychoactive substance intoxication is a clinically significant transient condition that develops during or shortly after the consumption of a specified psychoactive substance or medication that is characterised by disturbances in level of consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of the specified psychoactive substance and their intensity is closely related to the amount of the specified psychoactive substance consumed. They are time-limited and abate as the specified substance is cleared from the body.
- Coding Note:** Code also the causing condition

- 6C4E.4 Other specified psychoactive substance withdrawal**  
Other specified psychoactive substance withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of the specified substance in individuals who have developed dependence or have used the specified substance for a prolonged period or in large amounts. Other specified psychoactive substance withdrawal can also occur when prescribed psychoactive medications have been used in standard therapeutic doses. The specific features of the withdrawal state depend on the pharmacological properties of the specified substance.
- Coding Note:** Code also the causing condition
- 6C4E.40 Other specified psychoactive substance withdrawal, uncomplicated**  
The development of a withdrawal state not accompanied by perceptual disturbances or seizures following cessation or reduction of use of the specified substance.
- Coding Note:** Code also the causing condition
- 6C4E.41 Other specified psychoactive substance withdrawal, with perceptual disturbances**  
The development of a withdrawal state accompanied by perceptual disturbances but not by seizures following cessation or reduction of use of the specified substance.
- Coding Note:** Code also the causing condition
- 6C4E.42 Other specified psychoactive substance withdrawal, with seizures**  
The development of a withdrawal state accompanied by seizures but not by perceptual disturbances following cessation or reduction of use of the specified substance.
- Coding Note:** Code also the causing condition
- 6C4E.43 Other specified psychoactive substance withdrawal, with perceptual disturbances and seizures**  
The development of a withdrawal state accompanied by both perceptual disturbances and seizures following cessation or reduction of use of the specified substance.
- Coding Note:** Code also the causing condition
- 6C4E.4Z Other specified psychoactive substance withdrawal, unspecified**
- Coding Note:** Code also the causing condition

<b>6C4E.5</b>	<b>Delirium induced by other specified psychoactive substance including medications</b> Delirium induced by other specified psychoactive substance is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of a specified psychoactive substance. The amount and duration of use of the specified substance must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a different substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.
<b>Coding Note:</b>	Code also the causing condition
<b>6C4E.6</b>	<b>Psychotic disorder induced by other specified psychoactive substance</b> Psychotic disorder induced by other specified psychoactive substance is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganized thinking, grossly disorganized behaviour) that develop during or soon after intoxication with or withdrawal from a specified psychoactive substance. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of intoxication with or withdrawal from a specified psychoactive substance. The amount and duration of use of the specified psychoactive substance must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the use of the specified psychoactive substance, if the symptoms persist for a substantial period of time after cessation of the use of the specified psychoactive substance or withdrawal from the specified psychoactive substance, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with the use of the specified psychoactive substance).
<b>Coding Note:</b>	Code also the causing condition
<b>6C4E.7</b>	<b>Certain other specified psychoactive substance-induced mental or behavioural disorders</b>
<b>Coding Note:</b>	Code also the causing condition

**6C4E.70** Mood disorder induced by other specified psychoactive substance  
Mood disorder induced by other specified psychoactive substance is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from a specified psychoactive substance. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of intoxication with or withdrawal from a specified psychoactive substance. The amount and duration of use of the specified psychoactive substance must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the use of the specified psychoactive substance, if the symptoms persist for a substantial period of time after cessation of the use of the specified psychoactive substance or withdrawal from the specified psychoactive substance, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with the use of the specified psychoactive substance).

**Coding Note:** Code also the causing condition

**6C4E.71** Anxiety disorder induced by other specified psychoactive substance  
Anxiety disorder induced by other specified psychoactive substance is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from a specified psychoactive substance. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of intoxication with or withdrawal from a specified psychoactive substance. The amount and duration of use of the specified psychoactive substance must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the use of the specified psychoactive substance, if the symptoms persist for a substantial period of time after cessation of the use of the specified psychoactive substance or withdrawal from the specified psychoactive substance, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with the use of the specified psychoactive substance).

**Coding Note:** Code also the causing condition

<b>6C4E.72</b>	<p><b>Obsessive-compulsive or related disorder induced by other specified psychoactive substance</b></p> <p>Obsessive-compulsive or related disorder induced by other specified psychoactive substance is characterised by either repetitive intrusive thoughts or preoccupations, normally associated with anxiety and typically accompanied by repetitive behaviours performed in response, or by recurrent and habitual actions directed at the integument (e.g., hair pulling, skin picking) that develop during or soon after intoxication with or withdrawal from a specified psychoactive substance. The intensity or duration of the symptoms is substantially in excess of analogous disturbances that are characteristic of intoxication with or withdrawal from the specified psychoactive substance. The amount and duration of the specified psychoactive substance use must be capable of producing obsessive-compulsive or related symptoms. The symptoms are not better explained by a primary mental disorder (in particular an Obsessive-compulsive or related disorder), as might be the case if the symptoms preceded the onset of the specified psychoactive substance use, if the symptoms persist for a substantial period of time after cessation of use or withdrawal of the specified psychoactive substance, or if there is other evidence of a pre-existing primary mental disorder with obsessive-compulsive or related symptoms (e.g., a history of prior episodes not associated with specified psychoactive substance use).</p>
<b>Coding Note:</b>	Code also the causing condition
<b>6C4E.73</b>	<p><b>Impulse control disorder induced by other specified psychoactive substance</b></p> <p>Impulse control disorder induced by other specified psychoactive substance is characterised by persistently repeated behaviours in which there is recurrent failure to resist an impulse, drive, or urge to perform an act that is rewarding to the person, at least in the short-term, despite longer-term harm either to the individual or to others (e.g., fire setting or stealing without apparent motive, repetitive sexual behaviour, aggressive outbursts) that develop during or soon after intoxication with or withdrawal from a specified psychoactive substance. The intensity or duration of the symptoms is substantially in excess of disturbances of impulse control that are characteristic of intoxication with or withdrawal from the specified psychoactive substance. The amount and duration of the specified psychoactive substance use must be capable of producing disturbances of impulse control. The symptoms are not better explained by a primary mental disorder (e.g., an Impulse control disorder, a Disorder due to addictive behaviours), as might be the case if the impulse control disturbances preceded the onset of the specified psychoactive substance use, if the symptoms persist for a substantial period of time after cessation of use or withdrawal of the specified psychoactive substance, or if there is other evidence of a pre-existing primary mental disorder with impulse control symptoms (e.g., a history of prior episodes not associated with specified psychoactive substance use).</p>
<b>Coding Note:</b>	Code also the causing condition
<b>6C4E.Y</b>	<b>Other specified disorders due to use of other specified psychoactive substances, including medications</b>
<b>6C4E.Z</b>	<b>Disorders due to use of other specified psychoactive substances, including medications, unspecified</b>

**6C4F****Disorders due to use of multiple specified psychoactive substances, including medications**

Disorders due to use of multiple specified psychoactive substances, including medications are characterised by the pattern and consequences of multiple psychoactive substances. Although this grouping is provided for coding purposes, in most clinical situations it is recommended that multiple specific disorders due to substance use be assigned rather than using categories from this grouping.

**6C4F.0****Episode of harmful use of multiple specified psychoactive substances**

An episode of use of multiple specified psychoactive substances or medications that are not included in the other substance classes specifically identified under Disorder Due to Substance Use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to multiple substance intoxication or psychoactive medication use; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to multiple substance intoxication or psychoactive medication use on the part of the person to whom the diagnosis of single episode of harmful use of multiple specified psychoactive substances applies. This diagnosis should not be made if the harm is attributed to a known pattern of use of the multiple psychoactive substances.

**Exclusions:** Harmful pattern of use of multiple specified psychoactive substances (6C4F.1)

Multiple specified psychoactive substances dependence  
(6C4F.2)

**6C4F.1****Harmful pattern of use of multiple specified psychoactive substances**

A pattern of use of multiple specified psychoactive substances or medications that are not included in the other substance classes specifically identified under Disorders Due to Substance Use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of substance use is evident over a period of at least 12 months if use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to multiple substance intoxication or psychoactive medication use; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to multiple substance intoxication or psychoactive medication use on the part of the person to whom the diagnosis of Harmful pattern of use of multiple specified psychoactive substances applies.

**Exclusions:** Episode of harmful use of multiple specified psychoactive substances (6C4F.0)

Multiple specified psychoactive substances dependence  
(6C4F.2)

- 6C4F.10** Harmful pattern of use of multiple specified psychoactive substances, episodic  
A pattern of episodic or intermittent use of a specified psychoactive substance or medication that is not included in the other substance classes specifically identified under Disorders Due to Substance Use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic substance use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to intoxication due to the specified substance or medication on the part of the person to whom the diagnosis of Harmful pattern of use of other specified psychoactive substance applies.
- Exclusions:**
- Episode of harmful use of multiple specified psychoactive substances (6C4F.0)
  - Multiple specified psychoactive substances dependence (6C4F.2)
- 6C4F.11** Harmful pattern of use of multiple specified psychoactive substances, continuous  
A pattern of continuous (daily or almost daily) use of multiple specified psychoactive substances or medications that are not included in the other substance classes specifically identified under Disorders Due to Substance Use that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous substance use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to multiple substance intoxication or psychoactive medication use; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to multiple substance intoxication or psychoactive medication use on the part of the person to whom the diagnosis of Harmful pattern of multiple specified psychoactive substances applies.
- Exclusions:**
- Episode of harmful use of multiple specified psychoactive substances (6C4F.0)
  - Multiple specified psychoactive substances dependence (6C4F.2)
- 6C4F.1Z** Harmful pattern of use of multiple specified psychoactive substances, unspecified

<b>6C4F.2</b>	<b>Multiple specified psychoactive substances dependence</b> Multiple specified psychoactive substance dependence is a disorder of regulation of use of multiple specified substances arising from repeated or continuous use of the specified substances. The characteristic feature is a strong internal drive to use the specified substances, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use the specified substances. Physiological features of dependence may also be present, including tolerance to the effects of the specified substances, withdrawal symptoms following cessation or reduction in use of the specified substances, or repeated use of the specified substances or pharmacologically similar substances to prevent or alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if use of the specified substances is continuous (daily or almost daily) for at least 3 months.
	<b>Exclusions:</b> Episode of harmful use of multiple specified psychoactive substances (6C4F.0)  Harmful pattern of use of multiple specified psychoactive substances (6C4F.1)
<b>6C4F.20</b>	Multiple specified psychoactive substances dependence, current use <b>Exclusions:</b> Episode of harmful use of multiple specified psychoactive substances (6C4F.0)  Harmful pattern of use of multiple specified psychoactive substances (6C4F.1)
<b>6C4F.21</b>	Multiple specified psychoactive substances dependence, early full remission <b>Exclusions:</b> Episode of harmful use of multiple specified psychoactive substances (6C4F.0)  Harmful pattern of use of multiple specified psychoactive substances (6C4F.1)
<b>6C4F.22</b>	Multiple specified psychoactive substances dependence, sustained partial remission <b>Exclusions:</b> Episode of harmful use of multiple specified psychoactive substances (6C4F.0)  Harmful pattern of use of multiple specified psychoactive substances (6C4F.1)
<b>6C4F.23</b>	Multiple specified psychoactive substances dependence, sustained full remission <b>Exclusions:</b> Episode of harmful use of multiple specified psychoactive substances (6C4F.0)  Harmful pattern of use of multiple specified psychoactive substances (6C4F.1)
<b>6C4F.2Z</b>	Multiple specified psychoactive substances dependence, unspecified

- 6C4F.3      Intoxication due to multiple specified psychoactive substances**  
Intoxication due to multiple specified psychoactive substances is a clinically significant transient condition that develops during or shortly after the consumption of multiple specified substances or medications that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of the multiple specified psychoactive substances and their intensity is closely related to the amount of the substances consumed. They are time-limited and abate as the multiple specified substances are cleared from the body.
- Coding Note:** Code also the causing condition
- 6C4F.4      Multiple specified psychoactive substances withdrawal**  
Multiple specified psychoactive substance withdrawal is a clinically significant cluster of symptoms, behaviours and physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of multiple specified substances in individuals who have developed dependence or have used the specified substances for a prolonged period or in large amounts. Multiple specified psychoactive substance withdrawal can also occur when prescribed psychoactive medications have been used in standard therapeutic doses. The specific features of the withdrawal state depend on the pharmacological properties of the specified substances and their interactions.
- Coding Note:** Code also the causing condition
- 6C4F.40     Multiple specified psychoactive substances withdrawal, uncomplicated**  
**Coding Note:** Code also the causing condition
- 6C4F.41     Multiple specified psychoactive substances withdrawal, with perceptual disturbances**  
**Coding Note:** Code also the causing condition
- 6C4F.42     Multiple specified psychoactive substances withdrawal, with seizures**  
**Coding Note:** Code also the causing condition
- 6C4F.43     Multiple specified psychoactive substances withdrawal, with perceptual disturbances and seizures**  
**Coding Note:** Code also the causing condition
- 6C4F.4Y     Other specified multiple specified psychoactive substances withdrawal**  
**Coding Note:** Code also the causing condition
- 6C4F.4Z     Multiple specified psychoactive substances withdrawal, unspecified**  
**Coding Note:** Code also the causing condition

**6C4F.5 Delirium induced by multiple specified psychoactive substances including medications**

Delirium induced by multiple specified psychoactive substances is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of multiple specified substances. The amount and duration of use of the multiple specified substances must be capable of producing delirium. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from a substance other than those specified, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders. Note that this diagnosis applies only to those situations in which delirium is present but it cannot be determined which of multiple psychoactive substances is the cause of the delirium. In cases of multiple psychoactive substance use in which more than one specific substance can be identified as a cause of the delirium, the corresponding specific substance-induced delirium diagnoses should be given instead.

**Coding Note:** Code also the causing condition

**6C4F.6 Psychotic disorder induced by multiple specified psychoactive substances**

Psychotic disorder induced by multiple specified psychoactive substances is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganized thinking, grossly disorganized behaviour) that develop during or soon after intoxication with or withdrawal from multiple specified psychoactive substances. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of intoxication with or withdrawal from multiple specified psychoactive substances. The amount and duration of use of the multiple specified psychoactive substances must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the use of the multiple specified psychoactive substances, if the symptoms persist for a substantial period of time after cessation of the use of the multiple specified psychoactive substances or withdrawal from the multiple specified psychoactive substances, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with the use of the multiple specified psychoactive substances).

**Coding Note:** Code also the causing condition

**6C4F.7 Certain multiple specified psychoactive substances-induced mental or behavioural disorders**

**Coding Note:** Code also the causing condition

<b>6C4F.70</b>	Mood disorder induced by multiple specified psychoactive substances  Mood disorder induced by multiple specified psychoactive substances is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from multiple specified psychoactive substances. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of intoxication with or withdrawal from multiple specified psychoactive substances. The amount and duration of use of the multiple specified psychoactive substances must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the use of the multiple specified psychoactive substances, if the symptoms persist for a substantial period of time after cessation of the use of the multiple specified psychoactive substances or withdrawal from the multiple specified psychoactive substances, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with the use of the multiple specified psychoactive substances).
<b>Coding Note:</b>	Code also the causing condition
<b>6C4F.71</b>	Anxiety disorder induced by multiple specified psychoactive substances  Anxiety disorder induced by multiple specified psychoactive substances is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from multiple specified psychoactive substances. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of intoxication with or withdrawal from multiple specified psychoactive substances. The amount and duration of use of the multiple specified psychoactive substances must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the use of the multiple specified psychoactive substances, if the symptoms persist for a substantial period of time after cessation of the use of the multiple specified psychoactive substances or withdrawal from the multiple specified psychoactive substances, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with the use of the multiple specified psychoactive substances).
<b>Coding Note:</b>	Code also the causing condition

<b>6C4F.72</b>	<p><b>Obsessive-compulsive or related disorder induced by multiple specified psychoactive substances</b></p> <p>Obsessive-compulsive or related disorder induced by multiple specified psychoactive substances is characterised by either repetitive intrusive thoughts or preoccupations, normally associated with anxiety and typically accompanied by repetitive behaviours performed in response, or by recurrent and habitual actions directed at the integument (e.g., hair pulling, skin picking) that develop during or soon after intoxication with or withdrawal from multiple specified psychoactive substances. The intensity or duration of the symptoms is substantially in excess of analogous disturbances that are characteristic of intoxication with or withdrawal from the multiple specified psychoactive substances. The amount and duration of the multiple specified psychoactive substances use must be capable of producing obsessive-compulsive or related symptoms. The symptoms are not better explained by a primary mental disorder (in particular an Obsessive-compulsive or related disorder), as might be the case if the symptoms preceded the onset of the use of multiple specified psychoactive substances, if the symptoms persist for a substantial period of time after cessation of the multiple specified psychoactive substance use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with obsessive-compulsive or related symptoms (e.g., a history of prior episodes not associated with multiple specified psychoactive substances use).</p>
<b>Coding Note:</b>	Code also the causing condition
<b>6C4F.73</b>	<p><b>Impulse control syndrome induced by multiple specified psychoactive substances</b></p> <p>Impulse control disorder induced by multiple specified psychoactive substances is characterised by persistently repeated behaviours in which there is recurrent failure to resist an impulse, drive, or urge to perform an act that is rewarding to the person, at least in the short-term, despite longer-term harm either to the individual or to others (e.g., fire setting or stealing without apparent motive, repetitive sexual behaviour, aggressive outbursts) that develop during or soon after intoxication with or withdrawal from multiple specified psychoactive substances. The intensity or duration of the symptoms is substantially in excess of disturbances of impulse control that are characteristic of intoxication with or withdrawal from the multiple specified psychoactive substances. The amount and duration of the multiple specified psychoactive substances use must be capable of producing disturbances of impulse control. The symptoms are not better explained by a primary mental disorder (e.g., an Impulse control disorder, a Disorder due to addictive behaviours), as might be the case if the impulse control disturbances preceded the onset of the use of multiple specified psychoactive substances, if the symptoms persist for a substantial period of time after cessation of the multiple specified psychoactive substance use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with impulse control symptoms (e.g., a history of prior episodes not associated with multiple specified psychoactive substances use).</p>
<b>Coding Note:</b>	Code also the causing condition
<b>6C4F.Y</b>	<b>Other specified disorders due to use of multiple specified psychoactive substances, including medications</b>
<b>6C4F.Z</b>	<b>Disorders due to use of multiple specified psychoactive substances, including medications, unspecified</b>

**6C4G****Disorders due to use of unknown or unspecified psychoactive substances**

Disorders due to use of unknown or unspecified psychoactive substances are characterised by the pattern and consequences of psychoactive substance use when the specific substance is unknown or unspecified. These categories may be used in clinical situations in which it is clear that the disturbance is due to substance use but the specific class of substance is unknown. Once the relevant substance is identified, the disturbance should be recoded under the appropriate substance class.

**6C4G.0****Episode of harmful use of unknown or unspecified psychoactive substances**

An episode of use of an unknown or unspecified psychoactive substance that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication or withdrawal; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour due to substance intoxication or withdrawal on the part of the person to whom the diagnosis of single episode of harmful use applies. This diagnosis should not be made if the harm is attributed to a known pattern of use of the unknown or unspecified psychoactive substance.

**Exclusions:**      Harmful pattern of use of unknown or unspecified psychoactive substance (6C4G.1)

Unknown or unspecified psychoactive substance dependence  
(6C4G.2)

**6C4G.1****Harmful pattern of use of unknown or unspecified psychoactive substance**

A pattern of use of an unknown or unspecified psychoactive substance that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of substance use is evident over a period of at least 12 months if use is episodic or at least one month if use is continuous (i.e., daily or almost daily). Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to substance intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of unknown or unspecified psychoactive substance applies.

**Exclusions:**      Episode of harmful use of unknown or unspecified psychoactive substances (6C4G.0)

Unknown or unspecified psychoactive substance dependence  
(6C4G.2)

- 6C4G.10** Harmful pattern of use of unknown or unspecified psychoactive substance, episodic  
A pattern of episodic or intermittent use of an unknown or unspecified psychoactive substance that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of episodic substance use is evident over a period of at least 12 months. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to substance intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of unknown or unspecified psychoactive substance applies.
- Exclusions:**
- Episode of harmful use of unknown or unspecified psychoactive substances (6C4G.0)
  - Unknown or unspecified psychoactive substance dependence (6C4G.2)
- 6C4G.11** Harmful pattern of use of unknown or unspecified psychoactive substance, continuous  
A pattern of continuous (daily or almost daily) use of an unknown or unspecified psychoactive substance that has caused damage to a person's physical or mental health or has resulted in behaviour leading to harm to the health of others. The pattern of continuous substance use is evident over a period of at least one month. Harm to health of the individual occurs due to one or more of the following: (1) behaviour related to intoxication; (2) direct or secondary toxic effects on body organs and systems; or (3) a harmful route of administration. Harm to health of others includes any form of physical harm, including trauma, or mental disorder that is directly attributable to behaviour related to substance intoxication on the part of the person to whom the diagnosis of Harmful pattern of use of unknown or unspecified psychoactive substance applies.
- Exclusions:**
- Episode of harmful use of unknown or unspecified psychoactive substances (6C4G.0)
  - Unknown or unspecified psychoactive substance dependence (6C4G.2)
- 6C4G.1Z** Harmful pattern of use of unknown or unspecified psychoactive substance, unspecified

<b>6C4G.2</b>	<b>Unknown or unspecified psychoactive substance dependence</b> Unknown or unspecified psychoactive substance dependence is a disorder of regulation of use of an unknown or unspecified substance arising from repeated or continuous use of the substance. The characteristic feature is a strong internal drive to use the unknown or unspecified substance, which is manifested by impaired ability to control use, increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to use the unknown or unspecified substance. The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if use of the unknown or unspecified substance is continuous (daily or almost daily) for at least 3 months.
	<b>Exclusions:</b> Episode of harmful use of unknown or unspecified psychoactive substances (6C4G.0)  Harmful pattern of use of unknown or unspecified psychoactive substance (6C4G.1)
<b>6C4G.20</b>	Unknown or unspecified psychoactive substance dependence, current use Current dependence on an unknown or unspecified psychoactive substance, with use of the substance within the past month.  <b>Exclusions:</b> Episode of harmful use of unknown or unspecified psychoactive substances (6C4G.0)  Harmful pattern of use of unknown or unspecified psychoactive substance (6C4G.1)
<b>6C4G.21</b>	Unknown or unspecified psychoactive substance dependence, early full remission After a diagnosis of Unknown or unspecified psychoactive substance dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from the substance during a period lasting between 1 and 12 months.  <b>Exclusions:</b> Episode of harmful use of unknown or unspecified psychoactive substances (6C4G.0)  Harmful pattern of use of unknown or unspecified psychoactive substance (6C4G.1)
<b>6C4G.22</b>	Unknown or unspecified psychoactive substance dependence, sustained partial remission After a diagnosis of Unknown or unspecified psychoactive substance dependence, and often following a treatment episode or other intervention (including self-help intervention), there is a significant reduction in consumption of the substance for more than 12 months, such that even though intermittent or continuing use of the substance has occurred during this period, the definitional requirements for dependence have not been met.  <b>Exclusions:</b> Episode of harmful use of unknown or unspecified psychoactive substances (6C4G.0)  Harmful pattern of use of unknown or unspecified psychoactive substance (6C4G.1)

<b>6C4G.23</b>	Unknown or unspecified psychoactive substance dependence, sustained full remission  After a diagnosis of Unknown or unspecified psychoactive substance dependence, sustained full remission, and often following a treatment episode or other intervention (including self-intervention), the person has been abstinent from the substance for 12 months or longer.
	<b><i>Exclusions:</i></b> Episode of harmful use of unknown or unspecified psychoactive substances (6C4G.0)  Harmful pattern of use of unknown or unspecified psychoactive substance (6C4G.1)
<b>6C4G.2Z</b>	Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified
<b>6C4G.3</b>	<b>Intoxication due to unknown or unspecified psychoactive substance</b>  Intoxication due to unknown or unspecified psychoactive substance is a transient condition that develops during or shortly after the administration of an unknown or unspecified psychoactive substance that is characterised by disturbances in level of consciousness, cognition, perception, affect or behaviour, or other psychophysiological functions and responses. This diagnosis should be made only when there is strong evidence that an unidentified substance has been taken and the features cannot be accounted for by another disorder or disease.
<b>Coding Note:</b>	Code also the causing condition
<b>6C4G.4</b>	<b>Withdrawal due to unknown or unspecified psychoactive substance</b>  Withdrawal due to unknown or unspecified psychoactive substance is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of an unknown or unspecified substance in individuals who have developed dependence or have used the unknown or unspecified substance for a prolonged period or in large amounts. Withdrawal due to unknown or unspecified psychoactive substance can also occur when prescribed psychoactive medications have been used in standard therapeutic doses. The specific features of the withdrawal state depend on the pharmacological properties of the unknown or unspecified substance.
<b>Coding Note:</b>	Code also the causing condition
<b>6C4G.40</b>	Withdrawal due to unknown or unspecified psychoactive substance, uncomplicated  All diagnostic requirements for Withdrawal due to unknown or unspecified psychoactive substance are met and the withdrawal state is not accompanied by perceptual disturbances or seizures.
<b>Coding Note:</b>	Code also the causing condition

- 6C4G.41** Withdrawal due to unknown or unspecified psychoactive substance, with perceptual disturbances  
All diagnostic requirements for Withdrawal due to unknown or unspecified psychoactive substance are met and the withdrawal state is accompanied by perceptual disturbances (e.g., visual or tactile hallucinations or illusions) with intact reality testing. There is no evidence of confusion and other diagnostic requirements for Delirium are not met. The withdrawal state is not accompanied by seizures.
- Coding Note:** Code also the causing condition
- 6C4G.42** Withdrawal due to unknown or unspecified psychoactive substance, with seizures  
All diagnostic requirements for Withdrawal due to unknown or unspecified psychoactive substance are met and the withdrawal state is accompanied by seizures (i.e., generalised tonic-clonic seizures) but not by perceptual disturbances.
- Coding Note:** Code also the causing condition
- 6C4G.43** Withdrawal due to unknown or unspecified psychoactive, with perceptual disturbances and seizures  
The development of a withdrawal syndrome accompanied by both perceptual disturbances and seizures following cessation or reduction of use of the unknown or unspecified substance.
- Coding Note:** Code also the causing condition
- 6C4G.4Z** Withdrawal due to unknown or unspecified psychoactive substance, unspecified
- Coding Note:** Code also the causing condition
- 6C4G.5** **Delirium induced by unknown or unspecified psychoactive substance**  
Delirium induced by unknown or unspecified psychoactive substance is characterised by an acute state of disturbed attention and awareness with specific features of delirium that develops during or soon after substance intoxication or withdrawal or during the use of an unknown or unspecified substance. The symptoms are not better explained by a primary mental disorder, by use of or withdrawal from another substance, or by another health condition that is not classified under Mental, behavioural and neurodevelopmental disorders.
- Coding Note:** Code also the causing condition

- 6C4G.6      Psychotic disorder induced by unknown or unspecified psychoactive substance**
- Psychotic disorder induced by unknown or unspecified psychoactive substance is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from an unknown or unspecified psychoactive substance. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the use of the unknown or unspecified psychoactive substance, if the symptoms persist for a substantial period of time after cessation of the use of the unknown or unspecified psychoactive substance or withdrawal from the unknown or unspecified psychoactive substance, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with the use of the unknown or unspecified psychoactive substance).
- Coding Note:** Code also the causing condition
- 6C4G.7      Certain unknown or unspecified psychoactive substance-induced mental or behavioural disorders**
- Coding Note:** Code also the causing condition
- 6C4G.70      Mood disorder induced by unknown or unspecified psychoactive substance**
- Mood disorder induced by unknown or unspecified psychoactive substance is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxication with or withdrawal from a specified psychoactive substance. The symptoms are not better explained by a primary mental disorder (e.g., a Depressive disorder, a Bipolar disorder, Schizoaffective disorder), as might be the case if the mood symptoms preceded the onset of the use of the unknown or unspecified psychoactive substance, if the symptoms persist for a substantial period of time after cessation of the use of the unknown or unspecified psychoactive substance or withdrawal from the unknown or unspecified psychoactive substance, or if there is other evidence of a pre-existing primary mental disorder with mood symptoms (e.g., a history of prior episodes not associated with the use of the unknown or unspecified psychoactive substance).
- Coding Note:** Code also the causing condition

**6C4G.71** Anxiety disorder induced by unknown or unspecified psychoactive substance  
Anxiety disorder induced by unknown or unspecified psychoactive substance is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with or withdrawal from an unknown or unspecified psychoactive substance. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the use of the unknown or unspecified psychoactive substance, if the symptoms persist for a substantial period of time after cessation of the use of the unknown or unspecified psychoactive substance or withdrawal from the unknown or unspecified psychoactive substance, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with the use of the unknown or unspecified psychoactive substance).

**Coding Note:** Code also the causing condition

**6C4G.72** Obsessive-compulsive or related disorder induced by unknown or unspecified psychoactive substance  
Obsessive-compulsive or related disorder induced by unknown or unspecified psychoactive substance is characterised by either repetitive intrusive thoughts or preoccupations, normally associated with anxiety and typically accompanied by repetitive behaviours performed in response, or by recurrent and habitual actions directed at the integument (e.g., hair pulling, skin picking) that develop during or soon after intoxication with or withdrawal from an unknown or unspecified psychoactive substance. The symptoms are not better explained by a primary mental disorder (in particular an Obsessive-compulsive or related disorder), as might be the case if the symptoms preceded the onset of the unknown or unspecified psychoactive substance use, if the symptoms persist for a substantial period of time after cessation of use or withdrawal of the unknown or unspecified psychoactive substance, or if there is other evidence of a pre-existing primary mental disorder with obsessive-compulsive or related symptoms (e.g., a history of prior episodes not associated with the unknown or unspecified psychoactive substance use).

**Coding Note:** Code also the causing condition

<b>6C4G.73</b>	Impulse control disorder induced by unknown or unspecified psychoactive substance  Impulse control disorder induced by unknown or unspecified psychoactive substance is characterised by persistently repeated behaviours in which there is recurrent failure to resist an impulse, drive, or urge to perform an act that is rewarding to the person, at least in the short-term, despite longer-term harm either to the individual or to others (e.g., fire setting or stealing without apparent motive, repetitive sexual behaviour, aggressive outbursts) that develop during or soon after intoxication with or withdrawal from an unknown or unspecified psychoactive substance. The symptoms are not better explained by a primary mental disorder (e.g., an Impulse control disorder, a Disorder due to addictive behaviours), as might be the case if the impulse control disturbances preceded the onset of the unknown or unspecified psychoactive substance use, if the symptoms persist for a substantial period of time after cessation of use or withdrawal of the unknown or unspecified psychoactive substance, or if there is other evidence of a pre-existing primary mental disorder with impulse control symptoms (e.g., a history of prior episodes not associated with the unknown or unspecified psychoactive substance use).
----------------	--

**Coding Note:** Code also the causing condition

**6C4G.Y** **Other specified disorders due to use of unknown or unspecified psychoactive substances**

**6C4G.Z** **Disorders due to use of unknown or unspecified psychoactive substances, unspecified**

## **6C4H Disorders due to use of non-psychoactive substances**

Disorders due to use of non-psychoactive substances are characterised by the pattern and consequences of non-medical use of non-psychoactive substances. Non-psychoactive substances include laxatives, anabolic steroids, growth hormone, erythropoietin, and non-steroidal anti-inflammatory drugs. They may also include proprietary or over-the-counter medicines and folk remedies. Non-medical use of these substances may be associated with harm to the individual due to the direct or secondary toxic effects of the non-psychoactive substance on body organs and systems, or a harmful route of administration (e.g., infections due to intravenous self-administration). They are not associated with intoxication or with a dependence or withdrawal syndrome and are not recognized causes of substance-induced mental disorders.

### **6C4H.0 Episode of harmful use of non-psychoactive substances**

An episode of use of a non-psychoactive substance that has caused damage to a person's physical or mental health. Harm to health of the individual occurs due to direct or secondary toxic effects on body organs and systems or a harmful route of administration. This diagnosis should not be made if the harm is attributed to a known pattern of non-psychoactive substance use.

**Exclusions:** Harmful pattern of use of non-psychoactive substances  
(6C4H.1)

- 6C4H.1** **Harmful pattern of use of non-psychoactive substances**  
A pattern of use of non-psychoactive substances that has caused clinically significant harm to a person's physical or mental health. The pattern of use is evident over a period of at least 12 months if use is episodic and at least one month if use is continuous (i.e., daily or almost daily). Harm may be caused by the direct or secondary toxic effects of the substance on body organs and systems, or a harmful route of administration.
- Exclusions:**
- Harmful pattern of use of other specified psychoactive substance (6C4E.1)
  - Episode of harmful use of non-psychoactive substances (6C4H.0)
- 6C4H.10** Harmful pattern of use of non-psychoactive substances, episodic  
A pattern of episodic or intermittent use of a non-psychoactive substance that has caused damage to a person's physical or mental health. The pattern of episodic or intermittent use of the non-psychoactive substance is evident over a period of at least 12 months. Harm may be caused by the direct or secondary toxic effects on body organs and systems, or a harmful route of administration.
- 6C4H.11** Harmful pattern of use of non-psychoactive substances, continuous  
A pattern of continuous use of a non-psychoactive substance (daily or almost daily) that has caused damage to a person's physical or mental health. The pattern of continuous use of the non-psychoactive substance is evident over a period of at least one month. Harm may be caused by the direct or secondary toxic effects on body organs and systems, or a harmful route of administration.
- 6C4H.1Z** Harmful pattern of use of non-psychoactive substances, unspecified
- 6C4H.Y** **Other specified disorders due to use of non-psychoactive substances**
- 6C4H.Z** **Disorders due to use of non-psychoactive substances, unspecified**
- 6C4Y** **Other specified disorders due to substance use**
- 6C4Z** **Disorders due to substance use, unspecified**

## Disorders due to addictive behaviours (6C50-6C5Z)

Disorders due to addictive behaviours are recognizable and clinically significant syndromes associated with distress or interference with personal functions that develop as a result of repetitive rewarding behaviours other than the use of dependence-producing substances. Disorders due to addictive behaviours include gambling disorder and gaming disorder, which may involve both online and offline behaviour.

- Exclusions:** Compulsive sexual behaviour disorder (6C72)  
Paraphilic disorders (6D30-6D3Z)

**6C50**

### Gambling disorder

Gambling disorder is characterised by a pattern of persistent or recurrent gambling behaviour, which may be online (i.e., over the internet) or offline, manifested by:

1. impaired control over gambling (e.g., onset, frequency, intensity, duration, termination, context);
2. increasing priority given to gambling to the extent that gambling takes precedence over other life interests and daily activities; and
3. continuation or escalation of gambling despite the occurrence of negative consequences.

The pattern of gambling behaviour may be continuous or episodic and recurrent. The pattern of gambling behaviour results in significant distress or in significant impairment in personal, family, social, educational, occupational or other important areas of functioning. The gambling behaviour and other features are normally evident over a period of at least 12 months in order for a diagnosis to be assigned, although the required duration may be shortened if all diagnostic requirements are met and symptoms are severe.

- Inclusions:** Compulsive gambling  
**Exclusions:** Bipolar type I disorder (6A60)  
Bipolar type II disorder (6A61)  
Hazardous gambling or betting (QE21)

### 6C50.0      Gambling disorder, predominantly offline

Gambling disorder, predominantly offline is characterised by a pattern of persistent or recurrent gambling behaviour that is not primarily conducted over the internet and is manifested by:

1. impaired control over gambling (e.g., onset, frequency, intensity, duration, termination, context);
2. increasing priority given to gambling to the extent that gambling takes precedence over other life interests and daily activities; and
3. continuation or escalation of gambling despite the occurrence of negative consequences. The behaviour pattern is of sufficient severity to result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

The pattern of gambling behaviour may be continuous or episodic and recurrent. The gambling behaviour and other features are normally evident over a period of at least 12 months in order for a diagnosis to be assigned, although the required duration may be shortened if all diagnostic requirements are met and symptoms are severe.

- Exclusions:** Hazardous gambling or betting (QE21)

## **6C50.1                  Gambling disorder, predominantly online**

Gambling disorder, predominantly online is characterised by a pattern of persistent or recurrent gambling behaviour that is primarily conducted over the internet and is manifested by:

1. impaired control over gambling (e.g., onset, frequency, intensity, duration, termination, context);
2. increasing priority given to gambling to the extent that gambling takes precedence over other life interests and daily activities; and
3. continuation or escalation of gambling despite the occurrence of negative consequences. The behaviour pattern is of sufficient severity to result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

The pattern of gambling behaviour may be continuous or episodic and recurrent. The gambling behaviour and other features are normally evident over a period of at least 12 months in order for a diagnosis to be assigned, although the required duration may be shortened if all diagnostic requirements are met and symptoms are severe.

***Exclusions:***              Hazardous gambling or betting (QE21)

## **6C50.Z                  Gambling disorder, unspecified**

### **6C51                  Gaming disorder**

Gaming disorder is characterised by a pattern of persistent or recurrent gaming behaviour ('digital gaming' or 'video-gaming'), which may be online (i.e., over the internet) or offline, manifested by:

1. impaired control over gaming (e.g., onset, frequency, intensity, duration, termination, context);
2. increasing priority given to gaming to the extent that gaming takes precedence over other life interests and daily activities; and
3. continuation or escalation of gaming despite the occurrence of negative consequences.

The pattern of gaming behaviour may be continuous or episodic and recurrent. The pattern of gaming behaviour results in marked distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. The gaming behaviour and other features are normally evident over a period of at least 12 months in order for a diagnosis to be assigned, although the required duration may be shortened if all diagnostic requirements are met and symptoms are severe.

***Exclusions:***              Hazardous gaming (QE22)

                                  Bipolar type I disorder (6A60)

                                  Bipolar type II disorder (6A61)

## **6C51.0                  Gaming disorder, predominantly online**

Gaming disorder, predominantly online is characterised by a pattern of persistent or recurrent gaming behaviour ('digital gaming' or 'video-gaming') that is primarily conducted over the internet and is manifested by:

1. impaired control over gaming (e.g., onset, frequency, intensity, duration, termination, context);
2. increasing priority given to gaming to the extent that gaming takes precedence over other life interests and daily activities; and

3. continuation or escalation of gaming despite the occurrence of negative consequences. The behaviour pattern is of sufficient severity to result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

The pattern of gaming behaviour may be continuous or episodic and recurrent. The gaming behaviour and other features are normally evident over a period of at least 12 months in order for a diagnosis to be assigned, although the required duration may be shortened if all diagnostic requirements are met and symptoms are severe.

**6C51.1                  Gaming disorder, predominantly offline**

Gaming disorder, predominantly offline is characterised by a pattern of persistent or recurrent gaming behaviour ('digital gaming' or 'video-gaming') that is not primarily conducted over the internet and is manifested by:

1. impaired control over gaming (e.g., onset, frequency, intensity, duration, termination, context);
2. increasing priority given to gaming to the extent that gaming takes precedence over other life interests and daily activities; and
3. continuation or escalation of gaming despite the occurrence of negative consequences. The behaviour pattern is of sufficient severity to result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

The pattern of gaming behaviour may be continuous or episodic and recurrent. The gaming behaviour and other features are normally evident over a period of at least 12 months in order for a diagnosis to be assigned, although the required duration may be shortened if all diagnostic requirements are met and symptoms are severe.

**6C51.Z                  Gaming disorder, unspecified**

**6C5Y                  Other specified disorders due to addictive behaviours**

**6C5Z                  Disorders due to addictive behaviours, unspecified**

## Impulse control disorders (6C70-6C7Z)

Impulse control disorders are characterised by the repeated failure to resist an impulse, drive, or urge to perform an act that is rewarding to the person, at least in the short-term, despite consequences such as longer-term harm either to the individual or to others, marked distress about the behaviour pattern, or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. Impulse Control Disorders involve a range of specific behaviours, including fire-setting, stealing, sexual behaviour, and explosive outbursts.

**Coded Elsewhere:** Substance-induced impulse control disorders

- Gambling disorder (6C50)
- Gaming disorder (6C51)
- Secondary impulse control syndrome (6E66)
- Body-focused repetitive behaviour disorders (6B25)

**6C70**

### Pyromania

Pyromania is characterised by a recurrent failure to control strong impulses to set fires, resulting in multiple acts of, or attempts at, setting fire to property or other objects, in the absence of an apparent motive (e.g., monetary gain, revenge, sabotage, political statement, attracting attention or recognition). There is an increasing sense of tension or affective arousal prior to instances of fire setting, persistent fascination or preoccupation with fire and related stimuli (e.g., watching fires, building fires, fascination with firefighting equipment), and a sense of pleasure, excitement, relief or gratification during, and immediately after the act of setting the fire, witnessing its effects, or participating in its aftermath. The behaviour is not better explained by intellectual impairment, another mental and behavioural disorder, or substance intoxication.

**Inclusions:** pathological fire-setting

**Exclusions:** Conduct-dissocial disorder (6C91)

Bipolar type I disorder (6A60)

Schizophrenia or other primary psychotic disorders  
(6A20-6A2Z)

Fire-setting as the reason for observation for suspected mental or behavioural disorders, ruled out (QA02.3)

**6C71**

### Kleptomania

Kleptomania is characterised by a recurrent failure to control strong impulses to steal objects in the absence of an apparent motive (e.g., objects are not acquired for personal use or monetary gain). There is an increasing sense of tension or affective arousal before instances of theft and a sense of pleasure, excitement, relief, or gratification during and immediately after the act of stealing. The behaviour is not better explained by intellectual impairment, another mental and behavioural disorder, or substance intoxication.

**Coding Note:** If stealing occurs within the context of conduct-dissocial disorder or a manic episode, Kleptomania should not be diagnosed separately.

**Inclusions:** pathological stealing

**Exclusions:** shoplifting as the reason for observation for suspected mental disorder, ruled out (QA02.3)

**6C72****Compulsive sexual behaviour disorder**

Compulsive sexual behaviour disorder is characterised by a persistent pattern of failure to control intense, repetitive sexual impulses or urges resulting in repetitive sexual behaviour. Symptoms may include repetitive sexual activities becoming a central focus of the person's life to the point of neglecting health and personal care or other interests, activities and responsibilities; numerous unsuccessful efforts to significantly reduce repetitive sexual behaviour; and continued repetitive sexual behaviour despite adverse consequences or deriving little or no satisfaction from it. The pattern of failure to control intense, sexual impulses or urges and resulting repetitive sexual behaviour is manifested over an extended period of time (e.g., 6 months or more), and causes marked distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. Distress that is entirely related to moral judgments and disapproval about sexual impulses, urges, or behaviours is not sufficient to meet this requirement.

**Exclusions:** Paraphilic disorders (6D30-6D3Z)

**6C73****Intermittent explosive disorder**

Intermittent explosive disorder is characterised by repeated brief episodes of verbal or physical aggression or destruction of property that represent a failure to control aggressive impulses, with the intensity of the outburst or degree of aggressiveness being grossly out of proportion to the provocation or precipitating psychosocial stressors. The symptoms are not better explained by another mental, behavioural, or neurodevelopmental disorder and are not part of a pattern of chronic anger and irritability (e.g., in oppositional defiant disorder). The behaviour pattern is of sufficient severity to result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**Exclusions:** Oppositional defiant disorder (6C90)

**6C7Y****Other specified impulse control disorders****6C7Z****Impulse control disorders, unspecified**

## **Disruptive behaviour or dissocial disorders (6C90-6C9Z)**

Disruptive behaviour and dissocial disorders are characterised by persistent behaviour problems that range from markedly and persistently defiant, disobedient, provocative or spiteful (i.e., disruptive) behaviours to those that persistently violate the basic rights of others or major age-appropriate societal norms, rules, or laws (i.e., dissocial). Onset of Disruptive and dissocial disorders is commonly, though not always, during childhood.

**6C90**

### **Oppositional defiant disorder**

Oppositional defiant disorder is a persistent pattern (e.g., 6 months or more) of markedly defiant, disobedient, provocative or spiteful behaviour that occurs more frequently than is typically observed in individuals of comparable age and developmental level and that is not restricted to interaction with siblings. Oppositional defiant disorder may be manifest in prevailing, persistent angry or irritable mood, often accompanied by severe temper outbursts or in headstrong, argumentative and defiant behaviour. The behaviour pattern is of sufficient severity to result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning

**6C90.0**

### **Oppositional defiant disorder with chronic irritability-anger**

All definitional requirements for oppositional defiant disorder are met. This form of oppositional defiant disorder is characterised by prevailing, persistent angry or irritable mood that may be present independent of any apparent provocation. The negative mood is often accompanied by regularly occurring severe temper outbursts that are grossly out of proportion in intensity or duration to the provocation. Chronic irritability and anger are characteristic of the individual's functioning nearly every day, are observable across multiple settings or domains of functioning (e.g., home, school, social relationships), and are not restricted to the individual's relationship with his/her parents or guardians. The pattern of chronic irritability and anger is not limited to occasional episodes (e.g., developmentally typical irritability) or discrete periods (e.g., irritable mood in the context of manic or depressive episodes).

**6C90.00**

Oppositional defiant disorder with chronic irritability-anger with limited prosocial emotions

All definitional requirements for oppositional defiant disorder with chronic irritability-anger are met. In addition, the individual exhibits characteristics that are sometimes referred to as 'callous and unemotional'. These characteristics include a lack of empathy or sensitivity to the feelings of others and a lack of concern for others' distress; a lack of remorse, shame or guilt over their own behaviour (unless prompted by being apprehended), a relative indifference to the probability of punishment; a lack of concern over poor performance in school or work; and limited expression of emotions, particularly positive or loving feelings toward others, or only doing so in ways that seem shallow, insincere, or instrumental.

**6C90.01**

Oppositional defiant disorder with chronic irritability-anger with typical prosocial emotions

All definitional requirements for oppositional defiant disorder with chronic irritability-anger are met. The individual does not exhibit characteristics referred to as 'callous and unemotional', such as lack of empathy or sensitivity to the feelings of others and a lack of concern for others' distress.

**6C90.0Z**

Oppositional defiant disorder with chronic irritability-anger, unspecified

- 6C90.1** **Oppositional defiant disorder without chronic irritability-anger**  
Meets all definitional requirements for oppositional defiant disorder. This form of oppositional defiant disorder is not characterised by prevailing, persistent, angry or irritable mood, but does feature headstrong, argumentative, and defiant behaviour.
- 6C90.10** Oppositional defiant disorder without chronic irritability-anger with limited prosocial emotions  
All definitional requirements for oppositional defiant disorder without chronic irritability-anger are met. In addition, the individual exhibits characteristics that are sometimes referred to as 'callous and unemotional'. These characteristics include a lack of empathy or sensitivity to the feelings of others and a lack of concern for others' distress; a lack of remorse, shame or guilt over their own behaviour (unless prompted by being apprehended), a relative indifference to the probability of punishment; a lack of concern over poor performance in school or work; and limited expression of emotions, particularly positive or loving feelings toward others, or only doing so in ways that seem shallow, insincere, or instrumental. This pattern is pervasive across situations and relationships (i.e., the qualifier should not be applied based on a single characteristic, a single relationship, or a single instance of behaviour) and is persistent over time (e.g., at least 1 year).
- 6C90.11** Oppositional defiant disorder without chronic irritability-anger with typical prosocial emotions  
All definitional requirements for oppositional defiant disorder without chronic irritability-anger are met. The individual does not exhibit characteristics referred to as 'callous and unemotional', such as lack of empathy or sensitivity to the feelings of others and a lack of concern for others' distress.
- 6C90.1Z** Oppositional defiant disorder without chronic irritability-anger, unspecified
- 6C90.Z** **Oppositional defiant disorder, unspecified**
- 6C91** **Conduct-dissocial disorder**  
Conduct-dissocial disorder is characterised by a repetitive and persistent pattern of behaviour in which the basic rights of others or major age-appropriate societal norms, rules, or laws are violated such as aggression towards people or animals; destruction of property; deceitfulness or theft; and serious violations of rules. The behaviour pattern is of sufficient severity to result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning. To be diagnosed, the behaviour pattern must be enduring over a significant period of time (e.g., 12 months or more). Isolated dissocial or criminal acts are thus not in themselves grounds for the diagnosis.
- 6C91.0** **Conduct-dissocial disorder, childhood onset**  
Conduct-dissocial disorder, childhood onset is characterised by a repetitive and persistent pattern of behaviour in which the basic rights of others or major age-appropriate societal norms, rules, or laws are violated such as aggression towards people or animals; destruction of property; deceitfulness or theft; and serious violations of rules. To be diagnosed, features of the disorder must be present during childhood prior to adolescence (e.g., before 10 years of age) and the behaviour pattern must be enduring over a significant period of time (e.g., 12 months or more). Isolated dissocial or criminal acts are thus not in themselves grounds for the diagnosis.

<b>6C91.00</b>	Conduct-dissocial disorder, childhood onset with limited prosocial emotions Meets all definitional requirements for Conduct-dissocial disorder, childhood onset. In addition, the individual exhibits characteristics that are sometimes referred to as 'callous and unemotional'. These characteristics include a lack of empathy or sensitivity to the feelings of others and a lack of concern for others' distress; a lack of remorse, shame or guilt over their own behaviour (unless prompted by being apprehended), a relative indifference to the probability of punishment; a lack of concern over poor performance in school or work; and limited expression of emotions, particularly positive or loving feelings toward others, or only doing so in ways that seem shallow, insincere, or instrumental.
<b>6C91.01</b>	Conduct-dissocial disorder, childhood onset with typical prosocial emotions All definitional requirements for conduct-dissocial disorder, childhood onset are met. The individual does not exhibit characteristics referred to as 'callous and unemotional', such as lack of empathy or sensitivity to the feelings of others and a lack of concern for others' distress.
<b>6C91.0Z</b>	Conduct-dissocial disorder, childhood onset, unspecified
<b>6C91.1</b>	<b>Conduct-dissocial disorder, adolescent onset</b> Conduct-dissocial disorder, adolescent onset is characterised by a repetitive and persistent pattern of behaviour in which the basic rights of others or major age-appropriate societal norms, rules, or laws are violated such as aggression towards people or animals; destruction of property; deceitfulness or theft; and serious violations of rules. No features of the disorder are present during childhood prior to adolescence (e.g., before 10 years of age). To be diagnosed, the behaviour pattern must be enduring over a significant period of time (e.g., 12 months or more). Isolated dissocial or criminal acts are thus not in themselves grounds for the diagnosis.
<b>6C91.10</b>	Conduct-dissocial disorder, adolescent onset with limited prosocial emotions All definitional requirements for conduct-dissocial disorder, adolescent onset are met. In addition, the individual exhibits characteristics that are sometimes referred to as 'callous and unemotional'. These characteristics include a lack of empathy or sensitivity to the feelings of others and a lack of concern for others' distress; a lack of remorse, shame or guilt over their own behaviour (unless prompted by being apprehended), a relative indifference to the probability of punishment; a lack of concern over poor performance in school or work; and limited expression of emotions, particularly positive or loving feelings toward others, or only doing so in ways that seem shallow, insincere, or instrumental.
<b>6C91.11</b>	Conduct-dissocial disorder, adolescent onset with typical prosocial emotions All definitional requirements for conduct-dissocial disorder, adolescent onset are met. The individual does not exhibit characteristics referred to as 'callous and unemotional', such as lack of empathy or sensitivity to the feelings of others and a lack of concern for others' distress.
<b>6C91.1Y</b>	Other specified conduct-dissocial disorder, adolescent onset
<b>6C91.Z</b>	<b>Conduct-dissocial disorder, unspecified</b>
<b>6C9Y</b>	<b>Other specified disruptive behaviour or dissocial disorders</b>

**6C9Z**

**Disruptive behaviour or dissocial disorders, unspecified**

**Personality disorders and related traits (6D10-6D11.5)**

**Coded Elsewhere:** Secondary personality change (6E68)

**6D10**

**Personality disorder**

Personality disorder is characterised by problems in functioning of aspects of the self (e.g., identity, self-worth, accuracy of self-view, self-direction), and/or interpersonal dysfunction (e.g., ability to develop and maintain close and mutually satisfying relationships, ability to understand others' perspectives and to manage conflict in relationships) that have persisted over an extended period of time (e.g., 2 years or more). The disturbance is manifest in patterns of cognition, emotional experience, emotional expression, and behaviour that are maladaptive (e.g., inflexible or poorly regulated) and is manifest across a range of personal and social situations (i.e., is not limited to specific relationships or social roles). The patterns of behaviour characterizing the disturbance are not developmentally appropriate and cannot be explained primarily by social or cultural factors, including socio-political conflict. The disturbance is associated with substantial distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning.

**6D10.0**

**Mild personality disorder**

All general diagnostic requirements for Personality Disorder are met. Disturbances affect some areas of personality functioning but not others (e.g., problems with self-direction in the absence of problems with stability and coherence of identity or self-worth), and may not be apparent in some contexts. There are problems in many interpersonal relationships and/or in performance of expected occupational and social roles, but some relationships are maintained and/or some roles carried out. Specific manifestations of personality disturbances are generally of mild severity. Mild Personality Disorder is typically not associated with substantial harm to self or others, but may be associated with substantial distress or with impairment in personal, family, social, educational, occupational or other important areas of functioning that is either limited to circumscribed areas (e.g., romantic relationships; employment) or present in more areas but milder.

**6D10.1**

**Moderate personality disorder**

All general diagnostic requirements for Personality Disorder are met. Disturbances affect multiple areas of personality functioning (e.g., identity or sense of self, ability to form intimate relationships, ability to control impulses and modulate behaviour). However, some areas of personality functioning may be relatively less affected. There are marked problems in most interpersonal relationships and the performance of most expected social and occupational roles is compromised to some degree. Relationships are likely to be characterised by conflict, avoidance, withdrawal, or extreme dependency (e.g., few friendships maintained, persistent conflict in work relationships and consequent occupational problems, romantic relationships characterised by serious disruption or inappropriate submissiveness). Specific manifestations of personality disturbance are generally of moderate severity. Moderate Personality Disorder is sometimes associated with harm to self or others, and is associated with marked impairment in personal, family, social, educational, occupational or other important areas of functioning, although functioning in circumscribed areas may be maintained.

**6D10.2**

**Severe personality disorder**

All general diagnostic requirements for Personality Disorder are met. There are severe disturbances in functioning of the self (e.g., sense of self may be so unstable that individuals report not having a sense of who they are or so rigid that they refuse to participate in any but an extremely narrow range of situations; self view may be characterised by self-contempt or be grandiose or highly eccentric). Problems in interpersonal functioning seriously affect virtually all relationships and the ability and willingness to perform expected social and occupational roles is absent or severely compromised. Specific manifestations of personality disturbance are severe and affect most, if not all, areas of personality functioning. Severe Personality Disorder is often associated with harm to self or others, and is associated with severe impairment in all or nearly all areas of life, including personal, family, social, educational, occupational, and other important areas of functioning.

**6D10.Z**

**Personality disorder, severity unspecified**

**6D11**

**Prominent personality traits or patterns**

Trait domain qualifiers may be applied to Personality Disorders or Personality Difficulty to describe the characteristics of the individual's personality that are most prominent and that contribute to personality disturbance. Trait domains are continuous with normal personality characteristics in individuals who do not have Personality Disorder or Personality Difficulty. Trait domains are not diagnostic categories, but rather represent a set of dimensions that correspond to the underlying structure of personality. As many trait domain qualifiers may be applied as necessary to describe personality functioning. Individuals with more severe personality disturbance tend to have a greater number of prominent trait domains.

- 6D11.0      Negative affectivity in personality disorder or personality difficulty**
- The core feature of the Negative Affectivity trait domain is the tendency to experience a broad range of negative emotions. Common manifestations of Negative Affectivity, not all of which may be present in a given individual at a given time, include: experiencing a broad range of negative emotions with a frequency and intensity out of proportion to the situation; emotional lability and poor emotion regulation; negativistic attitudes; low self-esteem and self-confidence; and mistrustfulness.
- Coding Note:** This category should ONLY be used in combination with a Personality disorder category (Mild, Moderate, or Severe) or Personality difficulty.
- 6D11.1      Detachment in personality disorder or personality difficulty**
- The core feature of the Detachment trait domain is the tendency to maintain interpersonal distance (social detachment) and emotional distance (emotional detachment). Common manifestations of Detachment, not all of which may be present in a given individual at a given time, include: social detachment (avoidance of social interactions, lack of friendships, and avoidance of intimacy); and emotional detachment (reserve, aloofness, and limited emotional expression and experience).
- Coding Note:** This category should ONLY be used in combination with a Personality disorder category (Mild, Moderate, or Severe) or Personality difficulty.
- 6D11.2      Dissociality in personality disorder or personality difficulty**
- The core feature of the Dissociality trait domain is disregard for the rights and feelings of others, encompassing both self-centeredness and lack of empathy. Common manifestations of Dissociality, not all of which may be present in a given individual at a given time, include: self-centeredness (e.g., sense of entitlement, expectation of others' admiration, positive or negative attention-seeking behaviours, concern with one's own needs, desires and comfort and not those of others); and lack of empathy (i.e., indifference to whether one's actions inconvenience or hurt others, which may include being deceptive, manipulative, and exploitative of others, being mean and physically aggressive, callousness in response to others' suffering, and ruthlessness in obtaining one's goals).
- Coding Note:** This category should ONLY be used in combination with a Personality disorder category (Mild, Moderate, or Severe) or Personality difficulty.
- 6D11.3      Disinhibition in personality disorder or personality difficulty**
- The core feature of the Disinhibition trait domain is the tendency to act rashly based on immediate external or internal stimuli (i.e., sensations, emotions, thoughts), without consideration of potential negative consequences. Common manifestations of Disinhibition, not all of which may be present in a given individual at a given time, include: impulsivity; distractibility; irresponsibility; recklessness; and lack of planning.
- Coding Note:** This category should ONLY be used in combination with a Personality disorder category (Mild, Moderate, or Severe) or Personality difficulty.

<b>6D11.4</b>	<b>Anankastia in personality disorder or personality difficulty</b> The core feature of the Anankastia trait domain is a narrow focus on one's rigid standard of perfection and of right and wrong, and on controlling one's own and others' behaviour and controlling situations to ensure conformity to these standards. Common manifestations of Anankastia, not all of which may be present in a given individual at a given time, include: perfectionism (e.g., concern with social rules, obligations, and norms of right and wrong, scrupulous attention to detail, rigid, systematic, day-to-day routines, hyper-scheduling and planfulness, emphasis on organisation, orderliness, and neatness); and emotional and behavioural constraint (e.g., rigid control over emotional expression, stubbornness and inflexibility, risk-avoidance, perseveration, and deliberativeness).
<b>Coding Note:</b>	This category should ONLY be used in combination with a Personality disorder category (Mild, Moderate, or Severe) or Personality difficulty.
<b>6D11.5</b>	<b>Borderline pattern</b> The Borderline pattern specifier may be applied to individuals whose pattern of personality disturbance is characterised by a pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity, as indicated by many of the following: Frantic efforts to avoid real or imagined abandonment; A pattern of unstable and intense interpersonal relationships; Identity disturbance, manifested in markedly and persistently unstable self-image or sense of self; A tendency to act rashly in states of high negative affect, leading to potentially self-damaging behaviours; Recurrent episodes of self-harm; Emotional instability due to marked reactivity of mood; Chronic feelings of emptiness; Inappropriate intense anger or difficulty controlling anger; Transient dissociative symptoms or psychotic-like features in situations of high affective arousal.
<b>Coding Note:</b>	This category should ONLY be used in combination with a Personality disorder category (Mild, Moderate, or Severe) or Personality difficulty.

## Paraphilic disorders (6D30-6D3Z)

Paraphilic disorders are characterised by persistent and intense patterns of atypical sexual arousal, manifested by sexual thoughts, fantasies, urges, or behaviours, the focus of which involves others whose age or status renders them unwilling or unable to consent and on which the person has acted or by which he or she is markedly distressed. Paraphilic disorders may include arousal patterns involving solitary behaviours or consenting individuals only when these are associated with marked distress that is not simply a result of rejection or feared rejection of the arousal pattern by others or with significant risk of injury or death.

**Inclusions:** paraphilias

### **6D30      Exhibitionistic disorder**

Exhibitionistic disorder is characterised by a sustained, focused and intense pattern of sexual arousal—as manifested by persistent sexual thoughts, fantasies, urges, or behaviours—that involves exposing one's genitals to an unsuspecting individual in public places, usually without inviting or intending closer contact. In addition, in order for Exhibitionistic Disorder to be diagnosed, the individual must have acted on these thoughts, fantasies or urges or be markedly distressed by them. Exhibitionistic Disorder specifically excludes consensual exhibitionistic behaviours that occur with the consent of the person or persons involved as well as socially sanctioned forms of exhibitionism.

**6D31****Voyeuristic disorder**

Voyeuristic disorder is characterised by a sustained, focused and intense pattern of sexual arousal—as manifested by persistent sexual thoughts, fantasies, urges, or behaviours—that involves observing an unsuspecting individual who is naked, in the process of disrobing, or engaging in sexual activity. In addition, in order for Voyeuristic Disorder to be diagnosed, the individual must have acted on these thoughts, fantasies or urges or be markedly distressed by them. Voyeuristic Disorder specifically excludes consensual voyeuristic behaviours that occur with the consent of the person or persons being observed.

**6D32****Pedophilic disorder**

Pedophilic disorder is characterised by a sustained, focused, and intense pattern of sexual arousal—as manifested by persistent sexual thoughts, fantasies, urges, or behaviours—Involving pre-pubertal children. In addition, in order for Pedophilic Disorder to be diagnosed, the individual must have acted on these thoughts, fantasies or urges or be markedly distressed by them. This diagnosis does not apply to sexual behaviours among pre- or post-pubertal children with peers who are close in age.

**6D33****Coercive sexual sadism disorder**

Coercive sexual sadism disorder is characterised by a sustained, focused and intense pattern of sexual arousal—as manifested by persistent sexual thoughts, fantasies, urges or behaviours—that involves the infliction of physical or psychological suffering on a non-consenting person. In addition, in order for Coercive Sexual Sadism Disorder to be diagnosed, the individual must have acted on these thoughts, fantasies or urges or be markedly distressed by them. Coercive Sexual Sadism Disorder specifically excludes consensual sexual sadism and masochism.

**6D34****Frotteuristic disorder**

Frotteuristic disorder is characterised by a sustained, focused and intense pattern of sexual arousal—as manifested by persistent sexual thoughts, fantasies, urges, or behaviours—that involves touching or rubbing against a non-consenting person in crowded public places. In addition, in order for Frotteuristic Disorder to be diagnosed, the individual must have acted on these thoughts, fantasies or urges or be markedly distressed by them. Frotteuristic Disorder specifically excludes consensual touching or rubbing that occurs with the consent of the person or persons involved.

**6D35****Other paraphilic disorder involving non-consenting individuals**

Other paraphilic disorder involving non-consenting individuals is characterised by a persistent and intense pattern of atypical sexual arousal — manifested by sexual thoughts, fantasies, urges, or behaviours — in which the focus of the arousal pattern involves others who are unwilling or unable to consent but that is not specifically described in any of the other named Paraphilic Disorders categories (e.g., arousal patterns involving corpses or animals). The individual must have acted on these thoughts, fantasies or urges or be markedly distressed by them. The disorder specifically excludes sexual behaviours that occur with the consent of the person or persons involved, provided that they are considered able to provide such consent.

**6D36**

### **Paraphilic disorder involving solitary behaviour or consenting individuals**

Paraphilic disorder involving solitary behaviour or consenting individuals is characterised by a persistent and intense pattern of atypical sexual arousal — manifested by sexual thoughts, fantasies, urges, or behaviours — that involves consenting adults or solitary behaviours. One of the following two elements must be present: 1) the person is markedly distressed by the nature of the arousal pattern and the distress is not simply a consequence of rejection or feared rejection of the arousal pattern by others; or 2) the nature of the paraphilic behaviour involves significant risk of injury or death either to the individual or to the partner (e.g., asphyxophilia).

**6D3Z**

### **Paraphilic disorders, unspecified**

## **Factitious disorders (6D50-6D5Z)**

Factitious disorders are characterised by intentionally feigning, falsifying, inducing, or aggravating medical, psychological, or behavioural signs and symptoms or injury in oneself or in another person, most commonly a child dependent, associated with identified deception. A pre-existing disorder or disease may be present, but the individual intentionally aggravates existing symptoms or falsifies or induces additional symptoms. Individuals with factitious disorder seek treatment or otherwise present themselves or another person as ill, injured, or impaired based on the feigned, falsified, or self-induced signs, symptoms, or injuries. The deceptive behaviour is not solely motivated by obvious external rewards or incentives (e.g., obtaining disability payments or evading criminal prosecution). This is in contrast to Malingering, in which obvious external rewards or incentives motivate the behaviour.

**Exclusions:** Malingering (QC30)

**6D50**

### **Factitious disorder imposed on self**

Factitious disorder imposed on self is characterised by feigning, falsifying, or inducing medical, psychological, or behavioural signs and symptoms or injury associated with identified deception. If a pre-existing disorder or disease is present, the individual intentionally aggravates existing symptoms or falsifies or induces additional symptoms. The individual seeks treatment or otherwise presents himself or herself as ill, injured, or impaired based on the feigned, falsified, or self-induced signs, symptoms, or injuries. The deceptive behaviour is not solely motivated by obvious external rewards or incentives (e.g., obtaining disability payments or evading criminal prosecution). This is in contrast to Malingering, in which obvious external rewards or incentives motivate the behaviour

**Inclusions:** Münchhausen syndrome

**Exclusions:** Excoriation disorder (6B25.1)

Malingering (QC30)

**6D51****Factitious disorder imposed on another**

Factitious disorder imposed on another is characterised by feigning, falsifying, or inducing medical, psychological, or behavioural signs and symptoms or injury in another person, most commonly a child dependent, associated with identified deception. If a pre-existing disorder or disease is present in the other person, the individual intentionally aggravates existing symptoms or falsifies or induces additional symptoms. The individual seeks treatment for the other person or otherwise presents him or her as ill, injured, or impaired based on the feigned, falsified, or induced signs, symptoms, or injuries. The deceptive behaviour is not solely motivated by obvious external rewards or incentives (e.g., obtaining disability payments or avoiding criminal prosecution for child or elder abuse).

**Coding Note:**

The diagnosis of Factitious Disorder Imposed on Another is assigned to the individual who is feigning, falsifying or inducing the symptoms in another person, not to the person who is presented as having the symptoms. Occasionally the individual induces or falsifies symptoms in a pet rather than in another person.

**Exclusions:** Malingering (QC30)

**6D5Z****Factitious disorders, unspecified****Neurocognitive disorders (6D70-6E0Z)**

Neurocognitive disorders are characterised by primary clinical deficits in cognitive functioning that are acquired rather than developmental. That is, neurocognitive disorders do not include disorders characterised by deficits in cognitive function that are present from birth or that typically arise during the developmental period, which are classified in the grouping neurodevelopmental disorders. Rather, neurocognitive disorders represent a decline from a previously attained level of functioning. Although cognitive deficits are present in many mental disorders (e.g., schizophrenia, bipolar disorders), only disorders whose core features are cognitive are included in the neurocognitive disorders grouping. In cases where the underlying pathology and aetiology for neurocognitive disorders can be determined, the identified etiology should be classified separately.

**Exclusions:** Neurodevelopmental disorders (6A00-6A0Z)

**Coded Elsewhere:** Secondary neurocognitive syndrome (6E67)

**6D70****Delirium**

Delirium is characterized by a disturbance of attention, orientation, and awareness that develops within a short period of time, typically presenting as significant confusion or global neurocognitive impairment, with transient symptoms that may fluctuate depending on the underlying causal condition or etiology. Delirium often includes disturbance of behaviour and emotion, and may include impairment in multiple cognitive domains. A disturbance of the sleep-wake cycle, including reduced arousal of acute onset or total sleep loss with reversal of the sleep-wake cycle, may also be present. Delirium may be caused by the direct physiological effects of a medical condition not classified under mental, behavioural or neurodevelopmental disorders, by the direct physiological effects of a substance or medication, including withdrawal, or by multiple or unknown etiological factors.

<b>6D70.0</b>	<b>Delirium due to disease classified elsewhere</b> All definitional requirements for delirium are met. There is evidence from history, physical examination, or laboratory findings that Delirium is caused by the direct physiological consequences of a disorder or disease classified elsewhere.
<b>Coding Note:</b>	Identified etiology should be classified separately.
<b>6D70.1</b>	<b>Delirium due to psychoactive substances including medications</b> All definitional requirements for delirium are met. There is evidence from history, physical examination, or laboratory findings that the delirium is caused by the direct physiological effects of a substance or medication (including withdrawal). If the specific substance inducing the delirium has been identified, it should be classified using the appropriate subcategory (e.g., alcohol-induced delirium).
<b>Coded Elsewhere:</b>	Alcohol-induced delirium (6C40.5) <ul style="list-style-type: none"> <li>Cannabis-induced delirium (6C41.5)</li> <li>Synthetic cannabinoid-induced delirium (6C42.5)</li> <li>Opioid-induced delirium (6C43.5)</li> <li>Sedative, hypnotic or anxiolytic-induced delirium (6C44.5)</li> <li>Cocaine-induced delirium (6C45.5)</li> <li>Stimulant-induced delirium including amphetamines, methamphetamine or methcathinone (6C46.5)</li> <li>Synthetic cathinone-induced delirium (6C47.5)</li> <li>Hallucinogen-induced delirium (6C49.4)</li> <li>Volatile inhalant-induced delirium (6C4B.5)</li> <li>MDMA or related drug-induced delirium, including MDA (6C4C.5)</li> <li>Dissociative drug-induced delirium including ketamine or PCP (6C4D.4)</li> <li>Delirium induced by other specified psychoactive substance including medications (6C4E.5)</li> <li>Delirium induced by multiple specified psychoactive substances including medications (6C4F.5)</li> <li>Delirium induced by unknown or unspecified psychoactive substance (6C4G.5)</li> </ul>
<b>6D70.2</b>	<b>Delirium due to multiple etiological factors</b> All definitional requirements for delirium are met. There is evidence from history, physical examination, or laboratory findings that the delirium is attributable to multiple etiological factors, which may include disorders or diseases not classified under mental and behavioural disorders, substance intoxication or withdrawal, or a medication.
<b>Coding Note:</b>	Identified etiologies should be classified separately.
<b>6D70.Y</b>	<b>Delirium, other specified cause</b>
<b>6D70.Z</b>	<b>Delirium, unspecified or unknown cause</b>

**6D71****Mild neurocognitive disorder**

Mild neurocognitive disorder is characterized by mild impairment in one or more cognitive domains relative to that expected given the individual's age and general premorbid level of cognitive functioning, which represents a decline from the individual's previous level of functioning. Diagnosis is based on report from the patient, informant, or clinical observation, and is accompanied by objective evidence of impairment by quantified clinical assessment or standardized cognitive testing. Cognitive impairment is not severe enough to significantly interfere with an individual's ability to perform activities related to personal, family, social, educational, and/or occupational functioning or other important functional areas. Cognitive impairment is not attributable to normal aging and may be static, progressive, or may resolve or improve depending on underlying cause or treatment. Cognitive impairment may be attributable to an underlying acquired disease of the nervous system, a trauma, an infection or other disease process affecting the brain, use of specific substances or medications, nutritional deficiency or exposure to toxins, or the etiology may be undetermined. The impairment is not due to current substance intoxication or withdrawal.

**Coding Note:**

Code also the causing condition

**6D72****Amnestic disorder**

Amnestic disorder is characterised by prominent memory impairment relative to expectations for age and general premorbid level of cognitive functioning, which represents a decline from the individual's previous level of functioning, in the absence of other significant cognitive impairment. It is manifested by a deficit in acquiring, learning, and/or retaining new information, and may include the inability to recall previously learned information, without disturbance of consciousness, altered mental status, or delirium. Recent memory is typically more disturbed than remote memory, and the ability to immediately recall a limited amount of information is usually relatively preserved. The memory impairment is severe enough to result in significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. It is presumed to be attributable to an underlying acquired disease of the nervous system, a trauma, an infection or other disease process affecting the brain, to use of specific substances or medications, nutritional deficiency or exposure to toxins, or the etiology may be undetermined. The impairment is not due to current substance intoxication or withdrawal.

**Exclusions:**

Delirium (6D70)

Dementia (6D80-6D8Z)

Mild neurocognitive disorder (6D71)

<b>6D72.0</b>	<b>Amnestic disorder due to diseases classified elsewhere</b> All definitional requirements for amnestic disorder are met. The memory symptoms are judged to be the direct pathophysiological consequence of a medical condition not classified under mental, behavioural and neurodevelopmental disorders, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not better explained by Delirium, Dementia, another mental disorder (e.g., Schizophrenia or Other Primary Psychotic Disorder, a Mood Disorder) or the effects of a medication or substance, including withdrawal effects. The symptoms are sufficiently severe to be a specific focus of clinical attention. The identified etiological medical condition should be classified separately.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> amnesia: retrograde (MB21.11) Korsakoff syndrome, alcohol-induced or unspecified (8D44) Dissociative amnesia (6B61) Anterograde amnesia (MB21.10) amnesia NOS (MB21.1)
<b>6D72.1</b>	<b>Amnestic disorder due to psychoactive substances including medications</b> All definitional requirements for amnestic disorder are met. The memory symptoms are judged to be the direct consequence of psychoactive substance use. The intensity and duration of substance use must be known to be capable of producing memory impairment. The memory impairment may develop during or soon after substance intoxication or withdrawal, but its intensity and duration are substantially in excess of those normally associated with these conditions. The symptoms are not better accounted for by another disorder or medical condition, as might be the case if the amnestic symptoms preceded the onset of substance use.
<b>Coding Note:</b>	Code also the causing condition
<b>6D72.10</b>	<b>Amnestic disorder due to use of alcohol</b> All definitional requirements for amnestic disorder are met. The memory symptoms are judged to be the direct consequence of alcohol use. The intensity and duration of alcohol use must be known to be capable of producing memory impairment. The memory impairment may develop during or soon after alcohol intoxication or withdrawal, but its intensity and duration are substantially in excess of those normally associated with these conditions. The symptoms are not better accounted for by another disorder or medical condition, as might be the case if the amnestic symptoms preceded the onset of the alcohol use.
<b>Coding Note:</b>	This category should not be used to describe cognitive changes due to thiamine deficiency associated with chronic alcohol use.
	<b>Exclusions:</b> Korsakoff syndrome (5B5A.11) Wernicke-Korsakoff Syndrome (5B5A.1)

- 6D72.11** Amnestic disorder due to use of sedatives, hypnotics or anxiolytics  
All definitional requirements for amnestic disorder are met. The memory symptoms are judged to be the direct consequence of use of sedatives, hypnotics or anxiolytics. The intensity and duration of use of sedatives, hypnotics or anxiolytics must be known to be capable of producing memory impairment. The memory impairment may develop during or soon after sedative, hypnotic or anxiolytic intoxication or withdrawal, but its intensity and duration are substantially in excess of those normally associated with these conditions. The symptoms are not better accounted for by another disorder or medical condition, as might be the case if the amnestic symptoms preceded the onset of use of sedatives, hypnotics or anxiolytics.
- Coding Note:** Code also the causing condition
- 6D72.12** Amnestic disorder due to other specified psychoactive substance including medications  
All definitional requirements for amnestic disorder are met. The memory symptoms are judged to be the direct consequence of use of a specified psychoactive substance other than alcohol; sedatives, hypnotics or anxiolytics; or volatile inhalants. The intensity and duration of use of the specified psychoactive substance must be known to be capable of producing memory impairment. The memory impairment may develop during or soon after specified psychoactive substance intoxication or withdrawal, but its intensity and duration are substantially in excess of those normally associated with these conditions. The symptoms are not better accounted for by another disorder or medical condition, as might be the case if the amnestic symptoms preceded the onset of the specified psychoactive substance.
- 6D72.13** Amnestic disorder due to use of volatile inhalants  
All definitional requirements for amnestic disorder are met. The memory symptoms are judged to be the direct consequence of use of volatile inhalants. The intensity and duration of use of volatile inhalants must be known to be capable of producing memory impairment. The memory impairment may develop during or soon after volatile inhalant intoxication or withdrawal, but its intensity and duration are substantially in excess of those normally associated with these conditions. The symptoms are not better accounted for by another disorder or medical condition, as might be the case if the amnestic symptoms preceded the onset of use of volatile inhalants.
- 6D72.Y** **Amnestic disorder, other specified cause**
- 6D72.Z** **Amnestic disorder, unknown or unspecified cause**

## Dementia (6D80-6D8Z)

Dementia is characterized by the presence of marked impairment in two or more cognitive domains relative to that expected given the individual's age and general premorbid level of cognitive functioning, which represents a decline from the individual's previous level of functioning. Memory impairment is present in most forms of dementia, but cognitive impairment is not restricted to memory (i.e., there is impairment in other areas such as executive functions, attention, language, social cognition and judgment, psychomotor speed, visuoperceptual or visuospatial abilities). Neurobehavioural changes may also be present and, in some forms of dementia, may be the presenting symptom. Cognitive impairment is not attributable to normal aging and is severe enough to significantly interfere with independence in an individual's performance of activities of daily living. The cognitive impairment is presumed to be attributable to an underlying acquired disease of the nervous system, a trauma, an infection or other disease process affecting the brain, or to use of specific substances or medications, nutritional deficiency or exposure to toxins, or the etiology may be undetermined. The impairment is not due to current substance intoxication or withdrawal.

**Coding Note:** This category should only be used for primary tabulation, if the aetiology of the dementia is unknown. If the aetiology of the dementia is known code to the aetiology of the dementia for primary tabulation.

When dementia is due to multiple aetiologies, code all that apply.

**Inclusions:** Dementia NOS

**Exclusions:** Coma (MB20.1)

Delirium (6D70)

Disorders of intellectual development (6A00)

Neurodevelopmental disorders (6A00-6A0Z)

Stupor (MB20.0)

Ageing associated decline in intrinsic capacity (MG2A)

## 6D80

### Dementia due to Alzheimer disease

Dementia due to Alzheimer disease is the most common form of dementia. Onset is insidious with memory impairment typically reported as the initial presenting complaint. The characteristic course is a slow but steady decline from a previous level of cognitive functioning with impairment in additional cognitive domains (such as executive functions, attention, language, social cognition and judgment, psychomotor speed, visuoperceptual or visuospatial abilities) emerging with disease progression. Dementia due to Alzheimer disease may be accompanied by mental and behavioural symptoms such as depressed mood and apathy in the initial stages of the disease and may be accompanied by psychotic symptoms, irritability, aggression, confusion, abnormalities of gait and mobility, and seizures at later stages. Positive genetic testing, family history and gradual cognitive decline are suggestive of Dementia due to Alzheimer disease.

**Coding Note:** This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.

<b>6D80.0</b>	<b>Dementia due to Alzheimer disease with early onset</b> Dementia due to Alzheimer disease in which symptoms emerge before the age of 65 years. It is relatively rare, representing less than 5% of all cases, and may be genetically determined (autosomal dominant Alzheimer disease). Clinical presentation may be similar to cases with later onset, but progression of cognitive deficits may be more rapid.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
<b>6D80.1</b>	<b>Dementia due to Alzheimer disease with late onset</b> Dementia due to Alzheimer disease that develops at the age of 65 years or above. This is the most common pattern, representing more than 95% of all cases.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
<b>6D80.2</b>	<b>Alzheimer disease dementia, mixed type, with cerebrovascular disease</b> Dementia due to Alzheimer disease and concomitant cerebrovascular disease.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
<b>6D80.3</b>	<b>Alzheimer disease dementia, mixed type, with other nonvascular aetiologies</b> Dementia due to Alzheimer disease with other concomitant pathology, not including cerebrovascular disease.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
<b>6D80.Z</b>	<b>Dementia due to Alzheimer disease, onset unknown or unspecified</b> This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.

**6D81****Dementia due to cerebrovascular disease**

Dementia due to brain parenchyma injury resulting from cerebrovascular disease (ischemic or haemorrhagic). The onset of the cognitive deficits is temporally related to one or more vascular events. Cognitive decline is typically most prominent in speed of information processing, complex attention, and frontal-executive functioning. There is evidence of the presence of cerebrovascular disease considered to be sufficient to account for the neurocognitive deficits from history, physical examination and neuroimaging.

**Coding Note:**

This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.

**Exclusions:**      Alzheimer disease dementia, mixed type, with cerebrovascular disease (6D80.2)

**6D82****Dementia due to Lewy body disease**

Dementia preceding or occurring within one year after the onset of motor parkinsonian signs in the setting of Lewy body disease. Characterized by presence of Lewy bodies, which are intraneuronal inclusions containing  $\alpha$ -synuclein and ubiquitin in the brain stem, limbic area, forebrain, and neocortex. Onset is insidious with attentional and executive functioning deficits often present. These cognitive deficits are often accompanied by visual hallucinations and symptoms of REM sleep behaviour disorder. Hallucinations in other sensory modalities, depressive symptoms, and delusions may also be present. The symptom presentation usually varies significantly over the course of days necessitating longitudinal assessment and differentiation from delirium. Spontaneous onset of Parkinsonism within approximately 1 year of the onset of cognitive symptoms is common.

**Coding Note:**

This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.

When dementia is due to multiple aetiologies, code all that apply.

**6D83****Frontotemporal dementia**

Frontotemporal dementia (FTD) is a group of primary neurodegenerative disorders primarily affecting the frontal and temporal lobes. Onset is typically insidious with a gradual and worsening course. Several syndromic variants (some with an identified genetic basis or familiality) are described that include presentations with predominantly marked personality and behavioral changes (such as executive dysfunction, apathy, deterioration of social cognition, repetitive behaviours, and dietary changes), predominantly language deficits (that include semantic, agrammatic/nonfluent, and logopenic forms), predominantly movement-related deficits (progressive supranuclear palsy, corticobasal degeneration, multiple systems atrophy, or amyotrophic lateral sclerosis), or a combination of these deficits. Memory function often remains relatively intact, particularly during the early stages of the disorder.

**Coding Note:**

This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.

When dementia is due to multiple aetiologies, code all that apply.

**6D84**

**Dementia due to psychoactive substances including medications**

Dementia due to psychoactive substances including medications includes forms of dementia that are judged to be a direct consequence of substance use and that persist beyond the usual duration of action or withdrawal syndrome associated with the substance. The amount and duration of substance use must be sufficient to produce the cognitive impairment. The cognitive impairment is not better accounted for by a disorder that is not induced by substances such as a dementia due to another medical condition.

**Coding Note:** This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.

When dementia is due to multiple aetiologies, code all that apply.

**Inclusions:** Dementia due to exposure to heavy metals and other toxins  
(6D85.2)

**6D84.0**

**Dementia due to use of alcohol**

Dementia due to use of alcohol is characterised by the development of persistent cognitive impairments (e.g., memory problems, language impairment, and an inability to perform complex motor tasks) that meet the definitional requirements of Dementia that are judged to be a direct consequence of alcohol use and that persist beyond the usual duration of alcohol intoxication or acute withdrawal. The intensity and duration of alcohol use must have been sufficient to produce the cognitive impairment. The cognitive impairment is not better accounted for by a disorder or disease that is not induced by alcohol such as a dementia due to another disorder or disease classified elsewhere.

**Coding Note:** This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.

When dementia is due to multiple aetiologies, code all that apply.

This category should not be used to describe cognitive changes due to thiamine deficiency associated with chronic alcohol use.

**Inclusions:** Alcohol-induced dementia

**Exclusions:** Wernicke-Korsakoff Syndrome (5B5A.1)  
Korsakoff syndrome (5B5A.11)

<b>6D84.1</b>	<b>Dementia due to use of sedatives, hypnotics or anxiolytics</b> Dementia due to use of sedatives, hypnotics or anxiolytics is characterised by the development of persistent cognitive impairments (e.g., memory problems, language impairment, and an inability to perform complex motor tasks) that meet the definitional requirements of Dementia that are judged to be a direct consequence of sedative, hypnotic, or anxiolytic use and that persist beyond the usual duration of action or withdrawal syndrome associated with the substance. The amount and duration of sedative, hypnotic, or anxiolytic use must be sufficient to produce the cognitive impairment. The cognitive impairment is not better accounted for by a disorder that is not induced by sedatives, hypnotics, or anxiolytics such as a dementia due to another medical condition.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
	<b>Inclusions:</b> Late-onset psychoactive substance-induced psychotic disorder
<b>6D84.2</b>	<b>Dementia due to use of volatile inhalants</b> Dementia due to use of volatile inhalants is characterised by the development of persistent cognitive impairments (e.g., memory problems, language impairment, and an inability to perform complex motor tasks) that meet the definitional requirements of Dementia that are judged to be a direct consequence of inhalant use or exposure and that persist beyond the usual duration of action or withdrawal syndrome associated with the substance. The amount and duration of inhalant use or exposure must be sufficient to be capable of producing the cognitive impairment. The cognitive impairment is not better accounted for by a disorder that is not induced by volatile inhalants such as a dementia due to another medical condition.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
<b>6D84.Y</b>	<b>Dementia due to other specified psychoactive substance</b> This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
<b>6D85</b>	<b>Dementia due to diseases classified elsewhere</b> This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.

6D85.0	<b>Dementia due to Parkinson disease</b>
	Dementia due to Parkinson disease develops among individuals with idiopathic Parkinson disease and is characterized by impairment in attention, memory, executive and visuo-spatial functions. Mental and behavioral symptoms such as changes in affect, apathy and hallucinations may also be present. Onset is insidious and the course is one of gradual worsening of symptoms.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.
	When dementia is due to multiple aetiologies, code all that apply.
6D85.1	<b>Dementia due to Huntington disease</b>
	Dementia due to Huntington disease occurs as part of a widespread degeneration of the brain due to a trinucleotide repeat expansion in the HTT gene, which is transmitted through autosomal dominance. Onset of symptoms is insidious typically in the third and fourth decade of life with gradual and slow progression. Initial symptoms typically include impairments in executive functions with relative sparing of memory, prior to the onset of motor deficits (bradykinesia and chorea) characteristic of Huntington disease.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.
	When dementia is due to multiple aetiologies, code all that apply.
	<b>Inclusions:</b> Dementia in Huntington chorea
6D85.2	<b>Dementia due to exposure to heavy metals and other toxins</b>
	Dementia due to exposure to heavy metals and other toxins caused by toxic exposure to specific heavy metals such as aluminium from dialysis water, lead, mercury or manganese. The characteristic cognitive impairments in Dementia due to exposure to heavy metals and other toxins depend on the specific heavy metal or toxin that the individual has been exposed to but can affect any cognitive domain. Onset of symptoms is related to exposure and progression can be rapid especially with acute exposure. In many cases, symptoms are reversible when exposure is identified and ceases. Investigations such as brain imaging or neurophysiological testing may be abnormal. Lead poisoning is associated with abnormalities on brain imaging including widespread calcification and increased signal on MRI T2-weighted images of periventricular white matter, basal ganglia hypothalamus and pons. Dementia due to aluminium toxicity may demonstrate characteristic paroxysmal high-voltage delta EEG changes. Examination may make evident other features such as peripheral neuropathy in the case of lead, arsenic, or mercury.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.
	When dementia is due to multiple aetiologies, code all that apply.
	<b>Exclusions:</b> Dementia due to psychoactive substances including medications (6D84)

<b>6D85.3</b>	<b>Dementia due to human immunodeficiency virus</b> Dementia due to human immunodeficiency virus develops during the course of confirmed HIV disease, in the absence of a concurrent illness or condition other than HIV infection that could explain the clinical features. Although a variety of patterns of cognitive deficit are possible depending on where the HIV pathogenic processes have occurred, typically deficits follow a subcortical pattern with impairments in executive function, processing speed, attention, and learning new information. The course of Dementia due to human immunodeficiency virus varies including resolution of symptoms, gradual decline in functioning, improvement, or fluctuation in symptoms. Rapid decline in cognitive functioning is rare with the advent of antiretroviral medications.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
<b>6D85.4</b>	<b>Dementia due to multiple sclerosis</b> Dementia due to multiple sclerosis is a neurodegenerative disease due to the cerebral effects of multiple sclerosis, a demyelinating disease. Onset of symptoms is insidious and not secondary to the functional impairment attributable to the primary disease (i.e., multiple sclerosis). Cognitive impairments vary according to the location of demyelination but typically include deficits in processing speed, memory, attention, and aspects of executive functioning.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
<b>6D85.5</b>	<b>Dementia due to prion disease</b> Dementia due to prion disease is a primary neurodegenerative disease caused by a group of spongiform encephalopathies resulting from abnormal prion protein accumulation in the brain. These can be sporadic, genetic (caused by mutations in the prion-protein gene), or transmissible (acquired from an infected individual). Onset is insidious and there is a rapid progression of symptoms and impairment characterised by cognitive deficits, ataxia, and motor symptoms (myoclonus, chorea, or dystonia). Diagnosis is typically made on the basis of brain imaging studies, presence of characteristic proteins in spinal fluid, EEG, or genetic testing.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.

<b>6D85.6</b>	<b>Dementia due to normal pressure hydrocephalus</b> Dementia due to normal pressure hydrocephalus results from excess accumulation of cerebrospinal fluid in the brain as a result of idiopathic, non-obstructive causes but can also be secondary to haemorrhage, infection or inflammation. Progression is gradual but intervention (e.g., shunt) may result in improvement of symptoms, especially if administered earlier in the course of the condition. Typically, cognitive impairments include reduced processing speed and deficits in executive functioning and attention. These symptoms are also typically accompanied by gait abnormalities and urinary incontinence. Brain imaging to reveal ventricular volume and characterize brain displacement is often necessary to confirm the diagnosis.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
<b>6D85.7</b>	<b>Dementia due to injury to the head</b> Dementia due to injury to the head is caused by damage inflicted on the tissues of the brain as the direct or indirect result of an external force. Trauma to the brain is known to have resulted in loss of consciousness, amnesia, disorientation and confusion, or neurological signs. The symptoms characteristic of Dementia due to injury to the head must arise immediately following the trauma or after the individual gains consciousness and must persist beyond the acute post-injury period. Cognitive deficits vary depending on the specific brain areas affected and the severity of the injury but can include impairments in attention, memory, executive functioning, personality, processing speed, social cognition, and language abilities.
<b>Coding Note:</b>	This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
<b>6D85.8</b>	<b>Dementia due to pellagra</b> Dementia due to pellagra is caused by persistent lack of vitamin B3 (niacin) or tryptophan either in the diet or due to poor absorption in the gastrointestinal tract due to disease (e.g., Crohn disease) or due to the effects of some medications (e.g., isoniazid). Core signs of pellagra include dermatological changes (sensitivity to sunlight, lesions, alopecia, and oedema) and diarrhoea. With prolonged nutritional deficiency cognitive symptoms that include aggressivity, motor disturbances (ataxia and restlessness), confusion, and weakness are observed. Treatment with nutritional supplementation (e.g., niacin) typically results in reversal of symptoms.
<b>Coding Note:</b>	Code also the causing condition

6D85.9	<b>Dementia due to Down syndrome</b> Dementia due to Down syndrome is a neurodegenerative disorder related to the impact of abnormal increased production and accumulation of amyloid precursor protein (APP) leading to formation of beta-amyloid plaques and tau tangles. APP gene expression is increased due to its location on chromosome 21, which is abnormally triplicated in Down syndrome. Cognitive deficits and neuropathological features are similar to those observed in Alzheimer disease. Onset is typically after the fourth decade of life with a gradual decline in functioning, and may impact 50% or more of individuals with Down syndrome.
	<b>Coding Note:</b> This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
6D85.Y	<b>Dementia due to other specified diseases classified elsewhere</b>
	<b>Coding Note:</b> This category should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of dementia in diseases classified elsewhere.  When dementia is due to multiple aetiologies, code all that apply.
6D86	<b>Behavioural or psychological disturbances in dementia</b> In addition to the cognitive disturbances characteristic of dementia, the current clinical picture includes clinically significant behavioural or psychological disturbances.
	<b>Coding Note:</b> These categories should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of behavioural or psychological disturbance in dementia.  Code all that apply.
	<b>Exclusions:</b> Secondary mental or behavioural syndromes associated with disorders or diseases classified elsewhere (6E60-6E6Z)
6D86.0	<b>Psychotic symptoms in dementia</b> In addition to the cognitive disturbances characteristic of dementia, the current clinical picture includes clinically significant delusions or hallucinations.
	<b>Exclusions:</b> Schizophrenia or other primary psychotic disorders (6A20-6A2Z)  Secondary psychotic syndrome (6E61)
6D86.1	<b>Mood symptoms in dementia</b> In addition to the cognitive disturbances characteristic of dementia, the current clinical picture includes clinically significant mood symptoms such as depressed mood, elevated mood, or irritable mood.
	<b>Exclusions:</b> Mood disorders (6A60-6A8Z)  Secondary mood syndrome (6E62)

- 6D86.2 Anxiety symptoms in dementia**  
In addition to the cognitive disturbances characteristic of dementia, the current clinical picture includes clinically significant symptoms of anxiety or worry.
- Exclusions:**
- Anxiety or fear-related disorders (6B00-6B0Z)
  - Secondary anxiety syndrome (6E63)
- 6D86.3 Apathy in dementia**  
In addition to the cognitive disturbances characteristic of dementia, the current clinical picture includes clinically significant indifference or lack of interest.
- Exclusions:**
- Mood disorders (6A60-6A8Z)
  - Secondary mood syndrome (6E62)
- 6D86.4 Agitation or aggression in dementia**  
In addition to the cognitive disturbances characteristic of dementia, the current clinical picture includes: 1) clinically significant excessive psychomotor activity accompanied by increased tension; or 2) hostile or violent behaviour.
- 6D86.5 Disinhibition in dementia**  
In addition to the cognitive disturbances characteristic of dementia, the current clinical picture includes clinically significant lack of restraint manifested in disregard for social conventions, impulsivity, and poor risk assessment.
- 6D86.6 Wandering in dementia**  
In addition to the cognitive disturbances characteristic of dementia, the current clinical picture includes clinically significant wandering that puts the person at risk of harm.
- 6D86.Y Other specified behavioural or psychological disturbances in dementia**
- Coding Note:** These categories should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of behavioural or psychological disturbance in dementia.  
Code all that apply.
- 6D86.Z Behavioural or psychological disturbances in dementia, unspecified**
- Coding Note:** These categories should never be used in primary tabulation. The codes are provided for use as supplementary or additional codes when it is desired to identify the presence of behavioural or psychological disturbance in dementia.  
Code all that apply.
- 6D8Y Dementia, other specified cause**
- Coding Note:** This category should only be used for primary tabulation, if the aetiology of the dementia is unknown. If the aetiology of the dementia is known code to the aetiology of the dementia for primary tabulation.  
When dementia is due to multiple aetiologies, code all that apply.

**6D8Z****Dementia, unknown or unspecified cause****Coding Note:**

This category should only be used for primary tabulation, if the aetiology of the dementia is unknown. If the aetiology of the dementia is known code to the aetiology of the dementia for primary tabulation.

When dementia is due to multiple aetiologies, code all that apply.

**6E0Y****Other specified neurocognitive disorders****6E0Z****Neurocognitive disorders, unspecified**

Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium (6E20-6E2Z)

Syndromes associated with pregnancy or the puerperium (commencing within about 6 weeks after delivery) that involve significant mental and behavioural features. If the symptoms meet the diagnostic requirements for a specific mental disorder, that diagnosis should also be assigned.

**Coded Elsewhere:** Psychological disorder related to obstetric fistula (GC04.1Y)

**6E20****Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms**

A syndrome associated with pregnancy or the puerperium (commencing within about 6 weeks after delivery) that involves significant mental and behavioural features, most commonly depressive symptoms. The syndrome does not include delusions, hallucinations, or other psychotic symptoms. If the symptoms meet the diagnostic requirements for a specific mental disorder, that diagnosis should also be assigned. This designation should not be used to describe mild and transient depressive symptoms that do not meet the diagnostic requirements for a depressive episode, which may occur soon after delivery (so-called postpartum blues).

**Coding Note:**

Code also the causing condition

**6E21****Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, with psychotic symptoms**

A syndrome associated with pregnancy or the puerperium (commencing within about 6 weeks after delivery) that involves significant mental and behavioural features, including delusions, hallucinations, or other psychotic symptoms. Mood symptoms (depressive and/or manic) are also typically present. If the symptoms meet the diagnostic requirements for a specific mental disorder, that diagnosis should also be assigned.

**Coding Note:**

Code also the causing condition

**6E2Z****Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, unspecified**

**6E40**

**Psychological or behavioural factors affecting disorders or diseases classified elsewhere**

Psychological and behavioural factors affecting disorders or diseases classified elsewhere are those that may adversely affect the manifestation, treatment, or course of a condition classified in another chapter of the ICD. These factors may adversely affect the manifestation, treatment, or course of the disorder or disease classified in another chapter by: interfering with the treatment of the disorder or disease by affecting treatment adherence or care seeking; constituting an additional health risk; or influencing the underlying pathophysiology to precipitate or exacerbate symptoms or otherwise necessitate medical attention. This diagnosis should be assigned only when the factors increase the risk of suffering, disability, or death and represent a focus of clinical attention, and should be assigned together with the diagnosis for the relevant other condition.

**Inclusions:** Psychological factors affecting physical conditions

**Exclusions:** Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium (6E20-6E2Z)

**6E40.0**

**Mental disorder affecting disorders or diseases classified elsewhere**

All diagnostic requirements for Psychological or behavioural factors affecting disorders or diseases classified elsewhere are met. The individual is diagnosed with a mental, behavioural, or neurodevelopmental disorder that adversely affects the manifestation, treatment, or course of a disorder or disease classified in another chapter (e.g., a woman with Bulimia Nervosa and Type 1 diabetes mellitus who skips insulin doses as a way to avoid weight gain that would otherwise be caused by her binge eating).

**6E40.1**

**Psychological symptoms affecting disorders or diseases classified elsewhere**

All diagnostic requirements for Psychological or behavioural factors affecting disorders or diseases classified elsewhere are met. The individual exhibits psychological symptoms that do not meet the diagnostic requirements for a mental, behavioural, or neurodevelopmental disorder that adversely affect the manifestation, treatment, or course of a disorder or disease classified in another chapter (e.g., depressive symptoms interfering with rehabilitation following surgery).

**6E40.2**

**Personality traits or coping style affecting disorders or diseases classified elsewhere**

All diagnostic requirements for Psychological or behavioural factors affecting disorders or diseases classified elsewhere are met. The individual exhibits personality traits or coping styles that do not meet the diagnostic requirements for a mental, behavioural, or neurodevelopmental disorder that adversely affect the manifestation, treatment, or course of a disorder or disease classified in another chapter (e.g., pathological denial of the need for surgery in a patient with cancer; hostile, pressured behaviour contributing to heart disease).

- 6E40.3 Maladaptive health behaviours affecting disorders or diseases classified elsewhere**  
All diagnostic requirements for Psychological or behavioural factors affecting disorders or diseases classified elsewhere are met. The individual exhibits maladaptive health behaviours that adversely affect the manifestation, treatment, or course of a disorder or disease classified in another chapter (e.g., overeating, lack of exercise).
- 6E40.4 Stress-related physiological response affecting disorders or diseases classified elsewhere**  
All diagnostic requirements for Psychological or behavioural factors affecting disorders or diseases classified elsewhere are met. The individual exhibits stress-related physiological responses that adversely affect the manifestation, treatment, or course of a disorder or disease classified in another chapter (e.g., stress-related exacerbation of ulcer, hypertension, arrhythmia, or tension headache).
- 6E40.Y Other specified psychological or behavioural factors affecting disorders or diseases classified elsewhere**
- 6E40.Z Psychological or behavioural factors affecting disorders or diseases classified elsewhere, unspecified**

## Secondary mental or behavioural syndromes associated with disorders or diseases classified elsewhere (6E60-6E6Z)

This grouping includes syndromes characterised by the presence of prominent psychological or behavioural symptoms judged to be direct pathophysiological consequences of a medical condition not classified under mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., adjustment disorder or anxiety symptoms in response to being diagnosed with a life-threatening illness). These categories should be used in addition to the diagnosis for the presumed underlying disorder or disease when the psychological and behavioural symptoms are sufficiently severe to warrant specific clinical attention.

- Exclusions:**
- Acute pain (MG31)
  - Bodily distress disorder (6C20)
  - Chronic pain (MG30)

**Coded Elsewhere:** Delirium due to disease classified elsewhere (6D70.0)

**6E60**

### Secondary neurodevelopmental syndrome

A syndrome that involves significant neurodevelopmental features that do not fulfill the diagnostic requirements of any of the specific neurodevelopmental disorders that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders (e.g., autistic-like features in Rett syndrome; aggression and self-mutilation in Lesch-Nyhan syndrome, abnormalities in language development in Williams syndrome), based on evidence from the history, physical examination, or laboratory findings.

This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the neurodevelopmental problems are sufficiently severe to warrant specific clinical attention.

**Coding Note:** Code also the causing condition

- Exclusions:**
- Autism spectrum disorder (6A02)
  - Disorders of intellectual development (6A00)
  - Stereotyped movement disorder (6A06)

**6E60.0**

### Secondary speech or language syndrome

A syndrome that involves significant features related to speech or language development that do not fulfill the diagnostic requirements of any of the specific developmental speech or language disorders that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. Possible etiologies include a disease of the nervous system, sensory impairment, brain injury or infection.

**Coding Note:** This diagnosis should be assigned in addition to the diagnosis for the presumed underlying disorder or disease when the neurodevelopmental problems are sufficiently severe to warrant specific clinical attention.

**6E60.Y**

### Other specified secondary neurodevelopmental syndrome

**Coding Note:** Code also the causing condition

**6E60.Z              Secondary neurodevelopmental syndrome, unspecified**

**Coding Note:** Code also the causing condition

**6E61              Secondary psychotic syndrome**

A syndrome characterised by the presence of prominent hallucinations or delusions judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., an acute stress reaction in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the psychotic symptoms are sufficiently severe to warrant specific clinical attention.

**Coding Note:** Code also the causing condition

**Exclusions:**        Acute and transient psychotic disorder (6A23)

                        Delirium (6D70)

                        Mood disorders (6A60-6A8Z)

**6E61.0              Secondary psychotic syndrome, with hallucinations**

A syndrome characterised by the presence of prominent hallucinations that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. Delusions are not a prominent aspect of the clinical presentation. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., an acute stress reaction in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the psychotic symptoms are sufficiently severe to warrant specific clinical attention.

**Coding Note:** Code also the causing condition

**Exclusions:**        Delirium (6D70)

                        Mood disorders (6A60-6A8Z)

<b>6E61.1</b>	<b>Secondary psychotic syndrome, with delusions</b> A syndrome characterised by the presence of prominent delusions that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. Hallucinations are not a prominent aspect of the clinical presentation. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., an acute stress reaction in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the psychotic symptoms are sufficiently severe to warrant specific clinical attention.
	<b>Coding Note:</b> Code also the causing condition
	<b>Exclusions:</b> Delirium (6D70) Mood disorders (6A60-6A8Z)
<b>6E61.2</b>	<b>Secondary psychotic syndrome, with hallucinations and delusions</b> A syndrome characterised by the presence of both prominent hallucinations and prominent delusions that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., an acute stress reaction in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the psychotic symptoms are sufficiently severe to warrant specific clinical attention.
	<b>Coding Note:</b> Code also the causing condition
	<b>Exclusions:</b> Delirium (6D70) Mood disorders (6A60-6A8Z)
<b>6E61.3</b>	<b>Secondary psychotic syndrome, with unspecified symptoms</b>
	<b>Coding Note:</b> Code also the causing condition
<b>6E62</b>	<b>Secondary mood syndrome</b> A syndrome characterised by the presence of prominent mood symptoms (i.e., depression, elevated mood, irritability) judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., depressive symptoms in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the mood symptoms are sufficiently severe to warrant specific clinical attention.
	<b>Coding Note:</b> Code also the causing condition
	<b>Exclusions:</b> Adjustment disorder (6B43) Delirium (6D70)

6E62.0	<p><b>Secondary mood syndrome, with depressive symptoms</b></p> <p>A syndrome characterised by the presence of prominent depressive symptoms such as persistently depressed mood, loss of interest in previously enjoyable activities, or signs such as tearful and downtrodden appearance that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., depressive symptoms in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the mood symptoms are sufficiently severe to warrant specific clinical attention.</p>
	<p><b>Coding Note:</b> Code also the causing condition</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Adjustment disorder (6B43)</li> <li>Delirium (6D70)</li> </ul>
6E62.1	<p><b>Secondary mood syndrome, with manic symptoms</b></p> <p>A syndrome characterised by the presence of prominent manic symptoms such as elevated, euphoric, irritable, or expansive mood states, rapid changes among different mood states (i.e., mood lability), or increased energy or activity that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders based on evidence from the history, physical examination, or laboratory findings.</p>
	<p><b>Coding Note:</b> Code also the causing condition</p> <p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>mood syndrome due to disorders or diseases not classified under Mental and behavioural disorders, with manic symptoms</li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Adjustment disorder (6B43)</li> <li>Delirium (6D70)</li> </ul>

**6E62.2**

**Secondary mood syndrome, with mixed symptoms**

A syndrome characterised by the presence of both manic and depressive symptoms, either occurring together or alternating from day to day or over the course of a day that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders based on evidence from the history, physical examination, or laboratory findings. Manic symptoms may include elevated, euphoric, irritable, or expansive mood states, rapid changes among different mood states (i.e., mood lability), or increased energy or activity. Depressive symptoms may include persistently depressed mood, loss of interest in previously enjoyable activities, or signs such as tearful or downtrodden appearance. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., depressive symptoms in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the mood symptoms are sufficiently severe to warrant specific clinical attention.

**Coding Note:**

Code also the causing condition

**Exclusions:**

Adjustment disorder (6B43)

Delirium (6D70)

**6E62.3**

**Secondary mood syndrome, with unspecified symptoms**

**Coding Note:**

Code also the causing condition

**Exclusions:**

Adjustment disorder (6B43)

Delirium (6D70)

**6E63**

**Secondary anxiety syndrome**

A syndrome characterised by the presence of prominent anxiety symptoms judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., anxiety symptoms or panic attacks in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the anxiety symptoms are sufficiently severe to warrant specific clinical attention.

**Coding Note:**

Code also the causing condition

**Exclusions:**

Adjustment disorder (6B43)

Delirium (6D70)

**6E64**

### **Secondary obsessive-compulsive or related syndrome**

A syndrome characterised by the presence of prominent obsessions, compulsions, hoarding, skin picking, hair pulling, other body-focused repetitive behaviours, or other symptoms characteristic of obsessive-compulsive and related disorder that is judged to be the direct pathophysiological consequence of a disorder or disease not classified under Mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by Delirium or by another Mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., repetitive ruminations in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the obsessive-compulsive or related symptoms are sufficiently severe to warrant specific clinical attention.

**Coding Note:**

Code also the causing condition

**Exclusions:**

Delirium (6D70)

Obsessive-compulsive or related disorder induced by other specified psychoactive substance (6C4E.72)

Tic disorders (8A05)

**6E65**

### **Secondary dissociative syndrome**

A syndrome characterised by the presence of prominent dissociative symptoms (e.g., depersonalization, derealization) that is judged to be the direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., as part of an acute stress reaction in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the dissociative symptoms are sufficiently severe to warrant specific clinical attention.

**Coding Note:**

Code also the causing condition

**Exclusions:**

Delirium (6D70)

Acute stress reaction (QE84)

**6E66**

### **Secondary impulse control syndrome**

A syndrome characterised by the presence of prominent symptoms that are characteristic of Impulse Control Disorders or Disorders Due to Addictive Behaviours (e.g., stealing, fire-setting, aggressive outbursts, compulsive sexual behaviour, excessive gambling) that are judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., as part of an adjustment disorder in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the impulse control symptoms are sufficiently severe to warrant specific clinical attention.

**Coding Note:**

Code also the causing condition

**Exclusions:** Delirium (6D70)

**6E67**

### **Secondary neurocognitive syndrome**

A syndrome that involves significant cognitive features that do not fulfill the diagnostic requirements of any of the specific neurocognitive disorders and are judged to be a direct pathophysiological consequence of a health condition or injury not classified under mental and behavioural disorders (e.g., cognitive changes due to a brain tumour), based on evidence from the history, physical examination, or laboratory findings. This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the cognitive symptoms are sufficiently severe to warrant specific clinical attention.

**Coding Note:**

Code also the causing condition

**Exclusions:** Disorders with neurocognitive impairment as a major feature (8A20-8A2Z)

**Coded Elsewhere:** Delirium (6D70)

**6E68**

### **Secondary personality change**

A syndrome characterised by a persistent personality disturbance that represents a change from the individual's previous characteristic personality pattern that is judged to be a direct pathophysiological consequence of a health condition not classified under Mental and behavioural disorders, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by delirium or by another mental and behavioural disorder, and are not a psychologically mediated response to a severe medical condition (e.g., social withdrawal, avoidance, or dependence in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying disorder or disease when the personality symptoms are sufficiently severe to warrant specific clinical attention.

**Coding Note:**

Code also the causing condition

**Exclusions:** Personality difficulty (QE50.7)

Personality disorder (6D10)

Delirium (6D70)

**6E69**

**Secondary catatonia syndrome**

Secondary catatonia syndrome is a syndrome of primarily psychomotor disturbances, characterized by the co-occurrence of several symptoms of decreased, increased, or abnormal psychomotor activity, which occurs as a direct pathophysiological consequence of a medical condition not classified under Mental, Behavioural or Neurodevelopmental Disorders. Examples of medical conditions that may be associated with Catatonia include diabetic ketoacidosis, hypercalcaemia, hepatic encephalopathy, homocystinuria, neoplasms head trauma, cerebrovascular disease, and encephalitis.

**Coding Note:** Use additional code, if desired, for any underlying disorder if known.

**6E6Y**

**Other specified secondary mental or behavioural syndrome**

**Coding Note:** Code also the causing condition

**6E6Z**

**Secondary mental or behavioural syndrome, unspecified**

**Coding Note:** Code also the causing condition

**6E8Y**

**Other specified mental, behavioural or neurodevelopmental disorders**

**6E8Z**

**Mental, behavioural or neurodevelopmental disorders, unspecified**

# **CHAPTER 07**

---

## **Sleep-wake disorders**

This chapter has 42 four-character categories.

Code range starts with 7A00

Sleep-wake disorders are characterised by difficulty initiating or maintaining sleep (insomnia disorders), excessive sleepiness (hypersomnolence disorders), respiratory disturbance during sleep (sleep-related breathing disorders), disorders of the sleep-wake schedule (circadian rhythm sleep-wake disorders), abnormal movements during sleep (sleep-related movement disorders), or problematic behavioural or physiological events that occur while falling asleep, during sleep, or upon arousal from sleep (parasomnia disorders).

This chapter contains the following top level blocks:

- Insomnia disorders
- Hypersomnolence disorders
- Sleep-related breathing disorders
- Circadian rhythm sleep-wake disorders
- Sleep-related movement disorders
- Parasomnia disorders

## **Insomnia disorders (7A00-7A0Z)**

Insomnia disorders are characterised by the complaint of persistent difficulty with sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunity and circumstances for sleep, and results in some form of daytime impairment. Daytime symptoms typically include fatigue, depressed mood or irritability, general malaise, and cognitive impairment. Individuals who report sleep related symptoms in the absence of daytime impairment are not regarded as having an insomnia disorder.

**7A00**

### **Chronic insomnia**

Chronic insomnia is a frequent and persistent difficulty initiating or maintaining sleep that occurs despite adequate opportunity and circumstances for sleep and that results in general sleep dissatisfaction and some form of daytime impairment. Daytime symptoms typically include fatigue, depressed mood or irritability, general malaise, and cognitive impairment. The sleep disturbance and associated daytime symptoms occur at least several times per week for at least 3 months. Some individuals with chronic insomnia may show a more episodic course, with recurrent episodes of sleep/wake difficulties lasting several weeks at a time over several years. Individuals who report sleep related symptoms in the absence of daytime impairment are not regarded as having an insomnia disorder. If the insomnia is due to another sleep-wake disorder, a mental disorder, another medical condition, or a substance or medication, chronic insomnia should only be diagnosed if the insomnia is an independent focus of clinical attention.

**7A01**

### **Short-term insomnia**

Short-term insomnia is characterised by difficulty initiating or maintaining sleep of less than 3 months duration that occurs despite adequate opportunity and circumstances for sleep and results in general sleep dissatisfaction and some form of daytime impairment. Daytime symptoms typically include fatigue, depressed mood or irritability, general malaise, and cognitive impairment. Individuals who report sleep related symptoms in the absence of daytime impairment are not regarded as having an insomnia disorder. If the insomnia is due to another sleep-wake disorder, a mental disorder, another medical condition, or a substance or medication, short-term insomnia should only be diagnosed if the insomnia is an independent focus of clinical attention.

**7A0Z**

### **Insomnia disorders, unspecified**

## Hypersomnolence disorders (7A20-7A2Z)

Hypersomnolence disorders are characterised by a complaint of daytime sleepiness that is not due to another sleep-wake disorder (e.g. disturbed nocturnal sleep, misaligned circadian rhythm, or breathing disorder). Individuals with excessive sleepiness may show irritability, concentration and attention deficits, reduced vigilance, distractibility, reduced motivation, anergia, dysphoria, fatigue, restlessness, and lack of coordination.

**7A20**

### **Narcolepsy**

Narcolepsy is a disorder characterised by daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least several months, accompanied by abnormal manifestations of REM sleep. Multiple sleep latency testing (MSLT) demonstrates a mean sleep latency of <8 minutes and two or more sleep-onset REM periods (SOREMP's), or one or more SOREMP's on MSLT and a SOREMP on the preceding overnight polysomnography (PSG). Nighttime sleep is often disturbed, and brief daytime naps are typically refreshing.

**7A20.0**

#### **Narcolepsy, Type 1**

Type 1 narcolepsy is a disorder of excessive sleepiness due to a deficiency of hypothalamic hypocretin (orexin) signaling. In addition to daily periods of irrepressible need to sleep or daytime lapses into sleep, type 1 narcolepsy is characterised by symptoms of REM sleep dissociation, most importantly cataplexy. Cataplexy is a sudden and uncontrollable loss of muscle tone arising during wakefulness that is typically triggered by a strong emotion, such as excitement or laughter. Although cataplexy is a pathognomonic symptom of type 1 narcolepsy, it may not manifest until years following onset of the sleepiness. In such cases, a diagnosis of narcolepsy, type 1 may be made based on cerebrospinal fluid (CSF)-hypocretin levels < 110 picograms per milliliter. Episodes of sleep paralysis and hypnagogic or hypnopompic hallucinations may also be present. The disorder is not attributable to a disease of the nervous system or other medical condition.

Note: A definitive diagnosis requires daily periods of irrepressible need to sleep or daytime lapses into sleep plus either: a) cataplexy and multiple sleep latency test/polysomnography (MSLT/PSG) findings characteristic of narcolepsy; or b) demonstrated CSF hypocretin deficiency.

**7A20.1**

#### **Narcolepsy, Type 2**

Type 2 narcolepsy is a disorder of excessive sleepiness characterised by daily periods of irrepressible need to sleep or daytime lapses into sleep and abnormal manifestations of REM sleep as demonstrated by multiple sleep latency test (MSLT/PSG) findings in the context of normal hypothalamic hypocretin (orexin) signaling. That is, cerebrospinal fluid (CSF) hypocretin determinations are > 110 picograms per milliliter. Cataplexy is not present. The disorder is not attributable to a disease of the nervous system or other medical condition.

Note: A definitive diagnosis requires daily periods of irrepressible need to sleep or daytime lapses into sleep and multiple sleep latency test/polysomnography (MSLT/PSG) findings characteristic of narcolepsy. There should be no evidence of cataplexy or CSF hypocretin deficiency (if testing is performed).

**7A20.Z**

#### **Narcolepsy, unspecified**

**7A21**

### **Idiopathic hypersomnia**

Idiopathic hypersomnia is characterised by daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least several months in the absence of cataplexy or hypocretin deficiency (if determined). Polysomnography/multiple sleep latency test (MSLT) findings characteristic of narcolepsy (i.e., two or more sleep-onset REM periods (SOREMP's), or one or more SOREMP's on MSLT and a SOREMP on the preceding overnight polysomnography) should also be absent. The daytime sleepiness is not better explained by another disorder (e.g., insufficient sleep syndrome, obstructive sleep apnoea, circadian rhythm sleep-wake disorder), a substance or medication, or a medical condition). Objective evidence of hypersomnolence is indicated by an MSLT showing a mean sleep latency of ≤ 8 minutes or by polysomnography or wrist actigraphy showing a total 24-hour sleep time of 11 hours or more. Prolonged and severe sleep inertia is often observed and consists of sustained difficulty waking up with repeated returns to sleep, irritability, automatic behaviour, and confusion. In contrast to narcolepsy, naps are generally long, often more than 60 minutes, and unrefreshing.

Note: A definitive diagnosis requires daily periods of irrepressible need to sleep or daytime lapses into sleep, objective demonstration of excessive sleepiness and absence of REM-related findings by multiple sleep latency test (MSLT/PSG).

**7A22**

### **Kleine-Levin syndrome**

Kleine-Levin syndrome is characterised by recurrent episodes of severe sleepiness in association with cognitive, psychiatric, and behavioural disturbances. A typical episode lasts a median of 10 days (range 2.5–80 days), with rare episodes lasting several weeks to months. During episodes, patients may sleep as long as 16 to 20 hours per day, waking or getting up only to eat and void. When awake during episodes, most patients are exhausted, apathetic, confused, and slow in speaking and answering. Hyperphagia, hypersexuality, childish behaviour, depression, anxiety, hallucinations and delusions are often observed during the episodes. Patients are normal between episodes with regard to sleep, cognition, mood, and eating. Rarely, Kleine Levin syndrome may occur exclusively during menstrual periods.

**Inclusions:** recurrent hypersomnolence

**7A23**

### **Hypersomnia due to a medical condition**

Hypersomnia due to a medical condition is characterised by excessive nocturnal sleep, daytime sleepiness, or excessive napping of at least several months duration that is attributable to a coexisting medical or neurological disorder (e.g. head trauma, Parkinson disease, certain genetic conditions, metabolic, neurologic or endocrine disorders) and is sufficiently severe to require an independent focus of clinical attention. Hypersomnia due to a medical condition is only diagnosed if the hypersomnia is a direct physiological consequence of the medical condition. Residual sleepiness in patients with adequately-treated obstructive sleep apnoea is classified here under the assumption that it is due to central nervous system damage from recurrent hypoxemia.

Note: A definitive diagnosis requires use of polysomnography and multiple sleep latency test (MSLT) to rule out other hypersomnolence disorders or other sleep disorders (e.g. obstructive sleep apnea) which might better explain the sleepiness.

**7A24****Hypersomnia due to a medication or substance**

Hypersomnia due to a medication or substance is characterised by excessive nocturnal sleep, daytime sleepiness, or excessive napping that is attributable to the sedating effects of medications, alcohol, or other psychoactive substances, including withdrawal syndromes (e.g., from stimulants) and is sufficiently severe to constitute an independent focus of clinical attention.

Note: A definitive diagnosis requires use of polysomnography and multiple sleep latency test (MSLT) to rule out other hypersomnolence disorders or other sleep disorders (e.g. obstructive sleep apnea) which might better explain the sleepiness.

**Inclusions:** Hypersomnia due to substances including medications

**7A25****Hypersomnia associated with a mental disorder**

Hypersomnia associated with a mental disorder is characterised by excessive nocturnal sleep, daytime sleepiness, or excessive napping that is sufficiently severe to constitute an independent focus of clinical attention. This is most typical of depressive disorders or the depressed phase of bipolar disorders. Patients often feel that their sleep is of poor quality and nonrestorative and may be intensely focused on their hypersomnolence. Objective evidence of excessive sleepiness on MSLT is often absent.

Note: A definitive diagnosis requires use of polysomnography and multiple sleep latency test (MSLT) to rule out other hypersomnolence disorders or other sleep disorders (e.g. obstructive sleep apnea) which might better explain the sleepiness.

**7A26****Insufficient sleep syndrome**

Insufficient sleep syndrome occurs when an individual persistently fails to obtain the amount of sleep required relative to their own physiological sleep requirements to maintain normal levels of alertness and wakefulness and is thus chronically sleep deprived. The curtailed sleep pattern is present most days for at least several months.

The person's ability to initiate and maintain sleep is unimpaired. Sleep time is often markedly extended on weekend nights or during holidays compared to weekday. Extension of total sleep time results in resolution of the symptoms of sleepiness.

**Inclusions:** Behaviourally induced hypersomnia

**Exclusions:** Narcolepsy (7A20)

**7A2Y****Other specified hypersomnolence disorders****7A2Z****Hypersomnolence disorders, unspecified**

## Sleep-related breathing disorders (7A40-7A4Z)

Sleep related breathing disorders are characterised by abnormalities of respiration during sleep. In some of these disorders, respiration is also abnormal during wakefulness. The disorders are grouped into central sleep apnoeas, obstructive sleep apnoea, and sleep related hypoventilation or hypoxemia disorders.

**Exclusions:** Apnoea of newborn (KB2A)

**Coded Elsewhere:** Sleep related Cheyne-Stokes respiration (MD11.4)

**7A40**

### **Central sleep apnoeas**

Central sleep apnoeas are characterised by reduction or cessation of airflow due to absent or reduced respiratory effort. Central apnoea (cessation of airflow) or hypopnea (reduction in airflow) may occur in a cyclical or intermittent fashion. Patients with central sleep apnoea of various etiologies may also exhibit obstructive events, in which case diagnoses of both central sleep apnoea and obstructive sleep apnoea may be given.

Note: A definitive diagnosis requires objective evidence based on polysomnography.

**Exclusions:** Central neonatal apnoea (KB2A.0)

**7A40.0**

### **Primary central sleep apnoea**

Primary central sleep apnoea is of unknown etiology (idiopathic) and is characterised by recurrent, predominantly central apnoeas. Airflow and respiratory effort cease simultaneously in a repetitive fashion over the course of the night. The recurrent episodes of apnoea (more than five per hour) and associated arousals are sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring.

Note: A definitive diagnosis requires objective evidence based on polysomnography.

**Exclusions:** Primary central sleep apnoea of infancy (7A40.1)

Primary central sleep apnoea of prematurity (7A40.2)

**7A40.1**

### **Primary central sleep apnoea of infancy**

Primary central sleep apnoea of infancy is characterised by prolonged (> 20 seconds), predominantly central apnoeas or periodic breathing during more than 5% of total sleep time in an infant of at least 37 weeks conceptional age. These events are typically associated with physiological compromise (hypoxemia, bradycardia), or the need for intervention such as stimulation or resuscitation. This diagnosis should be assigned when central events are the predominant finding, even if obstructive or mixed apnoeas or hypopneas are also present.

Note: A definitive diagnosis requires objective evidence based on polysomnography or alternative monitoring such as hospital or home monitoring.

**Exclusions:** Primary central sleep apnoea of prematurity (7A40.2)

**7A40.2**

**Primary central sleep apnoea of prematurity**

Primary central sleep apnoea of prematurity is characterised by prolonged (> 20 seconds), predominantly central apnoeas or periodic breathing during more than 5% of total sleep time in an infant of less than 37 weeks conceptional age. These events are typically associated with physiological compromise (hypoxemia, bradycardia), or the need for intervention such as stimulation or resuscitation. This diagnosis should be assigned when central events are the predominant finding, even if obstructive or mixed apnoeas or hypopneas are also present.

Note: A definitive diagnosis requires objective evidence based on polysomnography or alternative monitoring such as hospital or home monitoring.

**Exclusions:** Primary central sleep apnoea of infancy (7A40.1)

**7A40.3**

**Central sleep apnea with Cheyne-Stokes breathing**

Central sleep apnoea with Cheyne-Stokes breathing is characterised by recurrent, predominantly central apnoeas or central hypopneas (more than five per hour) alternating with a respiratory phase exhibiting a crescendo-decrescendo pattern of flow (or tidal volume). The longer cycle length (> 40 seconds) distinguishes central sleep apnoea with Cheyne-Stokes breathing from other central sleep apnoea types. The vast majority of patients with Central sleep apnoea with Cheyne-Stokes breathing have either systolic or diastolic heart failure. Patients with Central sleep apnoea with Cheyne-Stokes breathing have normal or low daytime arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>). The disturbance is typically associated with atrial fibrillation/flutter, congestive heart failure, or a neurological disorder and is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring.

Note: A definitive diagnosis requires objective evidence based on polysomnography.

**7A40.4**

**Central sleep apnoea due to a medical condition without Cheyne-Stokes breathing**

Central sleep apnoea due to a medical condition without Cheyne-Stokes breathing (CSB) is characterised by recurrent, predominantly central apnoeas or central hypopneas (more than five per hour) that are attributed to a medical condition (and do not have the pattern of CSB). The majority of these patients have brainstem lesions of developmental, vascular, neoplastic, degenerative, demyelinating, or traumatic origin. The disturbance is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnea, or snoring.

Note: A definitive diagnosis requires objective evidence based on polysomnography in the presence of a medical condition that is judged to be causing the symptoms.

**Exclusions:** Central sleep apnoea due to a medication or substance (7A40.6)

- 7A40.5 Central sleep apnoea due to high-altitude periodic breathing**  
High-altitude periodic breathing is characterised by alternating periods of central apnoea and hyperpnoea associated with recent ascent to high altitude (typically > 2500 meters). The pattern of periodic breathing is an expected response to ascent to elevation. The disturbance is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring. The cycle length of this respiratory pattern is commonly less than 40 seconds and often as short as 12 to 20 seconds.
- Note: This diagnosis can be made clinically based on symptoms and recent ascent to high altitude.
- 7A40.6 Central sleep apnoea due to a medication or substance**  
Central sleep apnoea due to a medication is characterised by a pattern of recurring, predominantly central sleep apnoea or hypopnoea (more than five per hour) that is attributable to a medication or substance, most commonly long-acting opioids (e.g. methadone, long-acting morphine or oxycodone, fentanyl patches). The disturbance is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring. Obstructive apnoeas and hypoventilation may be present, but central sleep apnoea is the predominant finding.
- Note: A definitive diagnosis requires objective evidence based on polysomnography in the context of medication or substance use that is judged to be causing the symptoms.
- 7A40.7 Treatment-emergent central sleep apnoea**  
Treatment-emergent central sleep apnoea is characterised by persistence or emergence of recurrent, predominantly central sleep apnoea (more than five per hour) during effective treatment for obstructive apnoea (obstructive or mixed apnoea or hypopnea) with positive airway pressure. Central apnoeas must be the predominant finding (>50% of total respiratory events). The disturbance is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring. If the reduction or cessation of airflow due to absent or reduced respiratory effort is better explained by another central sleep apnoea disorder (e.g., Central sleep apnoea due to a medication or substance), that diagnosis along with a diagnosis of Obstructive sleep apnoea should be given, rather than a diagnosis of treatment-emergent central sleep apnoea.
- Note: A definitive diagnosis requires objective evidence based on polysomnography.
- 7A40.Y Other specified central sleep apnoeas**
- 7A40.Z Central sleep apnoeas, unspecified**

**7A41**

### **Obstructive sleep apnoea**

Obstructive sleep apnoea is characterised by repetitive episodes of apnoea or hypopnea that are caused by upper airway obstruction occurring during sleep. These events often result in reductions in blood oxygen saturation and are usually terminated by brief arousals from sleep. Excessive sleepiness is a major presenting complaint in many but not all cases. Reports of insomnia, poor sleep quality, and fatigue are also common. Upper airway resistance syndrome shares the same pathophysiology and should be classified here. In adults (> 18 years), obstructive sleep apnoea is diagnosed when the frequency of obstructive events (apnoeas, hypopneas or respiratory event-related arousals) is greater than 15 per hour. The disorder may also be diagnosed when the frequency is greater than five per hour and: a) symptoms attributable to the disorder (e.g., sleepiness or sleep disruption) are present; or b) nocturnal respiratory distress or observed apnoea/habitual snoring are reported; or c) when hypertension, a mood disorder, cognitive dysfunction, coronary artery disease, stroke, congestive heart failure, atrial fibrillation, or type 2 diabetes mellitus are present. In children, the disorder is diagnosed when the frequency of obstructive events is greater than one per hour, accompanied by signs or symptoms related to the breathing disorder.

Note: A definitive diagnosis requires objective evidence based on polysomnography.

***Inclusions:*** Obstructive neonatal apnoea (KB2A.1)

**7A42**

### **Sleep-related hypoventilation or hypoxemia disorders**

The primary feature of these disorders is insufficient sleep related ventilation, resulting in abnormally elevated arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>) during sleep. Sleep-related hypoxemia is diagnosed when overnight monitoring reveals sustained (> 5 minutes) decline in oxygen saturation to ≤ 88% in adults (or ≤ 90% in children) for ≥ 5 minutes.

Note: A definitive diagnosis requires objective evidence based on polysomnography as well as carbon dioxide (CO<sub>2</sub>) monitoring during sleep (by arterial, end-tidal or transcutaneous measures).

**7A42.0**

### **Obesity hypoventilation syndrome**

Obesity hypoventilation syndrome is characterised by obesity (in adults, Body-Mass-Index > 30 kg/m<sup>2</sup>) and daytime hypercapnia indicated by arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>) > 45 mm Hg that cannot be fully attributed to an underlying cardiopulmonary or neurologic disease. Hypercapnia worsens during sleep and is often associated with severe arterial oxygen desaturation. Obstructive sleep apnoea is also present in the majority of cases and should be diagnosed in addition to obesity hypoventilation.

Note: A definitive diagnosis requires demonstration of daytime hypercapnia and objective evidence based on polysomnography, with carbon dioxide (CO<sub>2</sub>) monitoring (by arterial, end-tidal or transcutaneous measures).

***Inclusions:*** Pickwickian syndrome

**7A42.1****Congenital central alveolar sleep-related hypoventilation**

Congenital central alveolar hypoventilation syndrome (CCHS) is a disorder of autonomic dysfunction, primarily the failure of automatic central control of breathing, caused by a mutation of the PHOX2B gene. CCHS is characterised by hypoventilation, which is worse during sleep than wakefulness. Onset is usually at birth, and CCHS most commonly presents in an otherwise normal-appearing infant who is noted to have cyanosis, feeding difficulties, hypotonia or, less commonly, central apnoea. Severity is related to the specific mutation present. Individuals with milder variants of the disorder may not present for clinical attention until adulthood.

Note: A definitive diagnosis requires demonstration of PHOX2B mutation and objective evidence based on polysomnography with carbon dioxide (CO<sub>2</sub>) monitoring (by arterial, end-tidal or transcutaneous measures).

**7A42.2****Non-congenital central hypoventilation with hypothalamic abnormalities**

Non-congenital central hypoventilation with hypothalamic dysfunction is a disorder of central control of ventilation. Patients are usually healthy until early childhood (often 2-3 years of age) when they develop hyperphagia and severe obesity, followed by central hypoventilation, which often presents as respiratory failure. Hypothalamic endocrine dysfunction may be characterised by increased or decreased hormone levels and may include one or more of the following: diabetes insipidus, inappropriate antidiuretic hormone hypersecretion, precocious puberty, hypogonadism, hyperprolactinemia, hypothyroidism, and decreased growth hormone secretion, or tumours of neural origin. Mood and behaviour abnormalities, sometimes severe, are often present. Developmental delay or autistic features may be present, but many patients are cognitively normal.

Note: A definitive diagnosis requires objective evidence based on polysomnography with carbon dioxide (CO<sub>2</sub>) monitoring (by arterial, end-tidal or transcutaneous measures).

**7A42.3****Idiopathic central alveolar hypoventilation**

Idiopathic central alveolar hypoventilation is defined as the presence of decreased alveolar ventilation resulting in sleep related hypercapnia and hypoxemia in individuals with presumed normal mechanical properties of the lung and respiratory pump. Chronic hypoventilation during sleep exists without any readily identifiable impairments of respiration, such as pulmonary airway or parenchymal conditions, neurologic, neuromuscular or chest wall abnormalities, severe obesity, other sleep related breathing disorder, or use of respiratory depressant medications or substances. Diurnal as well as nocturnal hypoventilation is believed to be due primarily to blunted chemoresponsiveness to carbon dioxide (CO<sub>2</sub>) and oxygen (O<sub>2</sub>). Patients may complain of morning headaches, fatigue, neurocognitive decline and sleep disturbance, or may be entirely asymptomatic.

Note: A definitive diagnosis requires objective evidence based on polysomnography with carbon dioxide (CO<sub>2</sub>) monitoring (by arterial, end-tidal or transcutaneous measures).

- 7A42.4 Sleep-related hypoventilation due to a medication or substance**  
Sleep-related hypoventilation due to a medication or substance is characterised primarily by chronic hypoventilation and hypercapnia due to prolonged use of medications or substances known to depress ventilatory drive and/or impair respiratory muscle mechanics (e.g. long-acting narcotics, anesthetics, sedative compounds, and muscle relaxants). Hypoxemia is commonly present as well. Hypercapnia may also be present during wakefulness in some patients. Patients can either be asymptomatic or present with complaints of dyspnea, chest tightness, or fatigue.  
Note: A definitive diagnosis requires objective evidence based on polysomnography with carbon dioxide (CO<sub>2</sub>) monitoring (by arterial, end-tidal or transcutaneous measures) in the context of medication or substance use that is judged to be causing the symptoms.
- 7A42.5 Sleep-related hypoventilation due to medical condition**  
Sleep-related hypoventilation due to medical condition is characterised by sleep-related hypoventilation due to lung airway or parenchymal disease, chest wall disorders, pulmonary hypertension, or neurologic and neuromuscular disorders. Daytime hypercapnia may also be present. Sleep related hypoxemia may be severe. Patients can either be asymptomatic or present with complaints of dyspnea, chest tightness, or fatigue.  
Note: A definitive diagnosis requires objective evidence based on polysomnography with carbon dioxide (CO<sub>2</sub>) monitoring (by arterial, end-tidal or transcutaneous measures) in the presence of a medical condition that is judged to be causing the symptoms.
- Exclusions:**
- Obesity hypoventilation syndrome (7A42.0)
  - Congenital central alveolar sleep-related hypoventilation (7A42.1)
- 7A42.6 Sleep-related hypoxemia due to a medical condition**  
Sleep related hypoxemia due to a medical condition is characterised by sustained declines in SpO<sub>2</sub> (oxygen saturation measured by pulse oximeter) ( $\leq 88\%$  in adults or  $\leq 90\%$  in children for  $\geq 5$  minutes) during sleep. The condition is attributable to a medical or neurological disorder. The presence of hypoxemia is not better explained by another sleep related breathing disorder (e.g., obstructive sleep apnoea). Although some amount of obstructive or central apnoea may be present, these disorders are not thought to be primarily responsible for the hypoxemia during sleep. Some patients with sleep related hypoxemia also exhibit hypoxemia during wakefulness. If the presence of hypercapnia has been established, a diagnosis of sleep-related hypoventilation should be made, rather than sleep-related hypoxemia.  
Note: A definitive diagnosis requires objective evidence based on polysomnographic monitoring of oxygen saturation in arterial blood (SaO<sub>2</sub>) in the presence of a medical condition that is judged to be causing the declines in SaO<sub>2</sub>.
- 7A42.Y Other specified sleep-related hypoventilation or hypoxemia disorders**
- 7A42.Z Sleep-related hypoventilation or hypoxemia disorders, unspecified**
- 7A4Y Other specified sleep-related breathing disorders**

**7A4Z****Sleep-related breathing disorders, unspecified****Circadian rhythm sleep-wake disorders (7A60-7A6Z)**

Circadian rhythm sleep-wake disorders are disturbances of the sleep-wake cycle (typically manifest as insomnia, excessive sleepiness, or both) due to alterations of the circadian time-keeping system, its entrainment mechanisms, or a misalignment of the endogenous circadian rhythm and the external environment. Sleep logs and, if possible, actigraphy for a minimum of one week should be utilized to define the specific sleep-wake schedule disturbance.

- Inclusions:**
- Delayed sleep phase syndrome
  - Irregular sleep-wake pattern

**7A60****Delayed sleep-wake phase disorder**

Delayed sleep-wake phase disorder is a recurrent pattern of disturbance of the sleep-wake schedule characterised by persistent delay in the major sleep period compared to conventional or desired sleep times. The disorder results in difficulty falling asleep and difficulty awakening at desired or required times. When sleep is allowed to occur on the delayed schedule, it is essentially normal in quality and duration. The symptoms should have persisted for at least several months and result in significant distress or mental, physical, social, occupational or academic impairment.

**7A61****Advanced sleep-wake phase disorder**

Advanced sleep-wake phase disorder is a recurrent pattern of disturbance of the sleep-wake schedule characterised by persistent advance (to an earlier time) of the major sleep period compared to conventional or desired sleep times. The disorder results in evening sleepiness (prior to the desired bedtime) and awakening earlier than the desired or required times. When sleep is allowed to occur on the advanced schedule, it is essentially normal in quality and duration. The symptoms should have persisted for at least several months and result in significant distress or mental, physical, social, occupational or academic impairment.

**7A62****Irregular sleep-wake rhythm disorder**

Irregular sleep-wake rhythm disorder is characterised by absence of a clearly-defined cycle of sleep and wake. Sleep becomes distributed in multiple episodes of variable duration throughout the 24-hour period. Patients typically complain of insomnia and/or excessive daytime sleepiness as a result of the condition. The symptoms should have persisted for at least several months and result in significant distress or mental, physical, social, occupational or academic impairment.

**7A63**

### **Non-24 hour sleep-wake rhythm disorder**

Non-24 hour sleep-wake rhythm disorder is characterised by periods of insomnia and/or daytime sleepiness, alternating with periods of relatively normal sleep, due to a lack of entrainment of the circadian clock to the 24-hour environmental cycle. The period length of the circadian/sleep-wake cycle is typically longer than 24 hours. Symptoms occur as the circadian-controlled sleep-wake propensity cycles in and out of phase with the environmental day-night cycle. The disorder is seen most commonly in individuals with complete blindness. The symptoms should have persisted for at least several months and result in significant distress or mental, physical, social, occupational or academic impairment.

**7A64**

### **Circadian rhythm sleep-wake disorder, shift work type**

Circadian rhythm sleep-wake disorder, shift work type is characterised by complaints of insomnia and/or excessive sleepiness that occur as a result of work shifts that overlap with all or a portion of conventional nighttime sleep periods. The disorder is also associated with a reduction in total sleep time. The symptoms should have persisted for at least several months and result in significant distress or mental, physical, social, occupational or academic impairment.

**7A65**

### **Circadian rhythm sleep-wake disorder, jet lag type**

Circadian rhythm sleep-wake disorder, jet lag type is characterised by a temporary mismatch between the timing of the sleep and wake cycle generated by the endogenous circadian clock and that of the sleep and wake pattern required by transmeridian travel across at least two time zones. Individuals complain of disturbed sleep, sleepiness and fatigue, somatic symptoms (e.g. gastrointestinal distress) or impaired daytime function. The severity and duration of symptoms is dependent on the number of time zones traveled, the ability to sleep while traveling, exposure to appropriate circadian times cues in the new environment, tolerance to circadian misalignment when awake during the biological night, and the direction of the travel. The symptoms result in significant distress or mental, physical, social, occupational or academic impairment.

**7A6Z**

### **Circadian rhythm sleep-wake disorders, unspecified**

## Sleep-related movement disorders (7A80-7A8Z)

Sleep related movement disorders are primarily characterised by relatively simple, usually stereotyped, movements that disturb sleep or its onset. An exception is Restless legs syndrome, which is primarily a waking, sensorimotor experience but is included in Sleep-related movement disorders because it almost always also involves periodic limb movements during sleep.

**Coded Elsewhere:** REM sleep behaviour disorder (7B01.0)

**7A80**

### **Restless legs syndrome**

Restless legs syndrome is a waking sensorimotor disorder characterised by a complaint of a strong, nearly irresistible urge to move the limbs. This urge to move is often but not always accompanied by other uncomfortable sensations felt deep inside the limbs. Although the legs are most prominently affected, a significant percentage of individuals with Restless legs syndrome describe some arm sensations. The symptoms of Restless legs syndrome are worse at rest, alleviated with movement, and predominant in the evening or night. The symptoms are sufficiently severe to result in significant distress or impairment in personal, family, social, educational, occupational or other important areas of functioning (e.g., due to frequent disruptions in sleep). The vast majority of individuals with Restless legs syndrome also exhibit periodic limb movements during sleep. A separate diagnosis of Periodic limb movement disorder is not warranted in such cases because the limb movements during sleep are considered to be an expected part of Restless legs syndrome.

**7A81**

### **Periodic limb movement disorder**

Periodic limb movement disorder is characterised by periodic episodes of repetitive (> 5/hour in children or > 15/hour in adults), highly stereotyped limb movements that occur during sleep, in conjunction with significant difficulties with sleep initiation or maintenance or fatigue that cannot be accounted for by another primary sleep disorder or other etiology. Specifically, when periodic limb movements are associated with Restless legs syndrome, narcolepsy or REM sleep behaviour disorder, a separate diagnosis of Periodic limb movement disorder is not warranted because the limb movements during sleep are considered an expected part of these disorders. Periodic limb movements occur most frequently in the lower extremities but may be seen in the arms as well. They may be associated with recurrent arousal from sleep, which gives rise to sleep disruption. The symptoms are sufficiently severe to result in significant distress or impairment in personal, family, social, educational, occupational or other important areas of functioning (e.g., due to frequent disruptions in sleep).

Note: A definitive diagnosis requires objective evidence based on polysomnography.

**7A82**

### **Sleep-related leg cramps**

Sleep related leg cramps are painful sensations in the leg or foot associated with sudden, involuntary muscle hardness or tightness, indicating a strong muscle contraction. They typically last from a few seconds to several minutes. The symptoms are sufficiently severe to result in significant distress or impairment in personal, family, social, educational, occupational or other important areas of functioning (e.g., due to frequent disruptions in sleep).

**7A83**

### **Sleep-related bruxism**

Sleep-related bruxism is characterised by repetitive, rhythmic jaw muscle contractions that occur during sleep. These contractions can take the form of repetitive phasic muscle contractions or isolated sustained jaw clenching (tonic contractions). These contractions during sleep produce tooth-grinding sounds. The symptoms are sufficiently severe to result in significant distress or impairment in personal, family, social, educational, occupational or other important areas of functioning (e.g., due to frequent disruptions in sleep) or significant damage to the teeth.

**7A84**

### **Sleep-related rhythmic movement disorder**

Sleep related rhythmic movement disorder is characterised by repetitive, stereotyped, and rhythmic motor behaviours that involve large muscle groups (e.g., banging head against pillow or mattress, head rolling, body rocking, body rolling). The symptoms are sufficiently severe to result in significant distress or impairment in personal, family, social, educational, occupational or other important areas of functioning (e.g., due to frequent disruptions in sleep) or result in bodily injury (e.g., due to falling out of bed).

**7A85**

### **Benign sleep myoclonus of infancy**

Benign sleep myoclonus of infancy is characterised by repetitive myoclonic jerks that occur during sleep in neonates and infants. Benign sleep myoclonus of infancy is commonly confused with epilepsy. However, unlike the jerks of myoclonic seizures and myoclonic encephalopathy, the jerks of Benign sleep myoclonus of infancy occur exclusively during sleep. The jerks are often bilateral and massive, typically involving large muscle groups.

**7A86**

### **Propriospinal myoclonus at sleep onset**

Propriospinal myoclonus at sleep onset consists of sudden myoclonic jerks of the trunk, hips, and knees in a fixed pattern that occur during the transition from wakefulness to sleep and, more rarely, during nighttime awakenings or upon awakening in the morning. The jerks arise mainly in spinally innervated muscles and thereafter propagate to rostral and caudal muscles at a low speed, typical of propriospinal pathways. The movements result in clinically significant difficulty with sleep initiation or maintenance.

**7A87**

### **Sleep-related movement disorder due to a medical condition**

Sleep-related movement disorder due to a medical condition is characterised by sleep-related movement abnormalities that are directly attributable to an underlying neurological or medical condition. Many medical conditions, particularly diseases of the nervous system, may be associated with movement abnormalities that are evident in wake and sleep. In some cases, the nocturnal manifestations of the movement abnormalities may be apparent before establishment of a firm neurological diagnosis. Once the presence of a medical or neurological condition is clearly established, this diagnosis should only be assigned if the sleep-related aspects of the movement abnormality or its sequelae are the focus of independent clinical attention.

**Coding Note:** Code also the causing condition

**7A88****Sleep-related movement disorder due to a medication or substance**

Sleep-related movement disorder due to a medication or substance is characterised by sleep-related movement abnormalities that are directly attributable to the effect of a medication or substance. Many substances may be associated with movement abnormalities that are evident in wake and sleep. To the extent that the movement abnormality is an expected complication of the substance(s) involved (e.g., tardive dyskinesia or akathisia associated with neuroleptic usage), this diagnosis should only be assigned if the sleep-related aspects of the movement abnormality or its sequelae are the focus of independent clinical attention.

**7A8Y****Other specified sleep-related movement disorders****7A8Z****Sleep-related movement disorders, unspecified****Parasomnia disorders (7B00-7B0Z)**

Parasomnias are problematic behavioural or physiological events that occur while falling asleep, during sleep, or upon arousal from sleep. Parasomnias may occur during non-rapid eye movement sleep (NREM), rapid eye movement sleep (REM), or during transitions to and from sleep. They encompass abnormal sleep related complex movements, behaviours, emotions, perceptions, dreams, and autonomic nervous system activity.

**7B00****Disorders of arousal from non-REM sleep**

Disorders of arousal from non-REM sleep are characterised by experiences or behaviours such as confusion, ambulation, terror, or extreme autonomic arousal that typically arise as a result of incomplete arousals from deep non-REM (N3) sleep. An exception is sleep-related eating disorder, which has been observed to arise during all stages of non-REM sleep. This group of disorders is also characterised by partial or complete amnesia for the event, inappropriate or absent responsiveness to efforts by others to intervene or redirect the person during the episode, and limited (e.g., a single visual scene) or no associated cognition or dream imagery. The experiences or behaviours are sufficiently severe to result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning or significant risk of injury to the individual or to others (e.g., thrashing or striking out in response to efforts to restrain the individual).

**7B00.0****Confusional arousals**

Confusional arousals are characterised by mental confusion or confused behaviour (e.g., disorientation, being unresponsive, impaired or slow speech, poor memory) during a partial arousal from deep sleep. There is partial or complete amnesia for the events. The experiences or behaviours are sufficiently severe to result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning or significant risk of injury to the individual or to others.

**7B00.1****Sleepwalking disorder**

Sleepwalking disorder is characterised by ambulation and other complex behaviours during a partial arousal from deep sleep.

- 7B00.2 Sleep terrors**  
Sleep terrors are characterised by episodes of abrupt terror during a partial arousal from deep sleep, typically beginning with a vocalization such as a frightening scream. The individual experiences intense fear accompanied by signs of autonomic arousal, such as mydriasis, tachycardia, tachypnea, and diaphoresis.
- 7B00.3 Sleep-related eating disorder**  
Sleep-related eating disorder is characterised by recurrent episodes of involuntary excessive or dangerous eating or drinking that occur during the main sleep period that are not attributable to the effects of a medication or substance. Episodes may involve consumption of peculiar forms or combinations of food or inedible or toxic substances or injurious or potentially injurious behaviours performed while in pursuit of food or while cooking food. There may be adverse health consequences from recurrent nocturnal binge eating of high calorie foods. There is partial or complete amnesia for the events.
- 7B00.Y Other specified disorders of arousal from non-REM sleep**
- 7B00.Z Disorders of arousal from non-REM sleep, unspecified**
- 7B01 Parasomnias related to REM sleep**  
Parasomnias related to REM (rapid eye movement) sleep are characterised by experiences or behaviours such as vocalization or complex motor behaviours, sleep paralysis, or nightmares that are associated with REM sleep. The experiences are sufficiently severe to result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning or significant risk of injury to the individual or to others.
- 7B01.0 REM sleep behaviour disorder**  
REM sleep behaviour disorder is characterised by repeated episodes of sleep related vocalization or complex motor behaviours that are either documented by polysomnography to occur during REM (rapid eye movement) sleep or are presumed to occur during REM sleep due to a clinical history of dream enactment. Polysomnographic recording (when performed) demonstrates REM sleep without atonia. The disorder may occur as an isolated, idiopathic form but is frequently associated with latent or manifest disease of the nervous system, especially alpha-synucleinopathies.  
  
Note: A provisional diagnosis may be established on clinical grounds but definitive diagnosis requires polysomnographic demonstration of REM sleep without atonia.
- 7B01.1 Recurrent isolated sleep paralysis**  
Recurrent isolated sleep paralysis consists of recurrent inability to move the trunk and all of the limbs at sleep onset (hypnagogic) or upon awakening (hypnopompic) from sleep. Episodes typically last from a few seconds to a few minutes and cause clinically significant distress including bedtime anxiety or fear of sleep.

7B01.2	<b>Nightmare disorder</b> Nightmare disorder is characterised by recurrent, vivid and highly dysphoric dreams, often involving threat to the individual, that generally occur during REM sleep and that often result in awakening with anxiety. The person is rapidly oriented and alert upon awakening.
	<b>Inclusions:</b> Dream anxiety disorder
7B01.Y	<b>Other specified parasomnias related to REM sleep</b>
7B01.Z	<b>Parasomnias related to REM sleep, unspecified</b>
7B02	<b>Other parasomnias</b> Other parasomnias include Hypnagogic exploding head syndrome, Sleep-related hallucinations, and abnormal sleep related complex movements, behaviours, emotions, perceptions, dreams, or autonomic nervous system activity related to a medical condition or due to a medication or substance. The experiences are sufficiently severe to result in significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning or significant risk of injury to the individual or to others.
	<b>Coded Elsewhere:</b> Nocturnal enuresis (6C00.0)
7B02.0	<b>Hypnagogic exploding head syndrome</b> Hypnagogic exploding head syndrome is characterised by the perception of a sudden, loud noise or sense of a violent explosion in the head that typically occurs as the individual is falling asleep. On occasion, these episodes may occur with awakening during the night. They are associated with abrupt arousal following the event, often with a sense of fright.
	<b>Inclusions:</b> Hypnagogic sensory disturbance
7B02.1	<b>Sleep-related hallucinations</b> Sleep related hallucinations are hallucinatory experiences that occur at sleep onset (hypnagogic hallucinations) or on awakening from sleep (hypnopompic hallucinations). Sleep related hallucinations are predominantly visual but may include auditory, tactile, or kinetic phenomena.
7B02.2	<b>Parasomnia disorder due to a medical condition</b> Parasomnia disorder due to a medical condition is characterised by abnormal sleep related complex movements, behaviours, emotions, perceptions, dreams, or autonomic nervous system activity that are directly attributable to an underlying neurological or medical condition.
7B02.3	<b>Parasomnia disorder due to a medication or substance</b> Parasomnia disorder due to a medication or substance is characterised by abnormal sleep related complex movements, behaviours, emotions, perceptions, dreams, and autonomic nervous system activity that are directly attributable to the effect of a medication or substance.
7B0Y	<b>Other specified parasomnia disorders</b>
7B0Z	<b>Parasomnia disorders, unspecified</b>

---

**7B2Y**

**Other specified sleep-wake disorders**

**7B2Z**

**Sleep-wake disorders, unspecified**

# CHAPTER 08

---

## Diseases of the nervous system

This chapter has 204 four-character categories.

Code range starts with 8A00

This is a group of conditions characterised as being in or associated with the nervous system.

- Exclusions:**
- Endocrine, nutritional or metabolic diseases (Chapter 05)
  - Complications of pregnancy, childbirth and the puerperium (Chapter 18)
  - Certain conditions originating in the perinatal period (Chapter 19)
  - Injury, poisoning or certain other consequences of external causes (Chapter 22)

- Coded Elsewhere:**
- Injuries of the nervous system
  - Neoplasms of the nervous system
  - Structural developmental anomalies of the nervous system (LA00-LA0Z)
  - Syndromes with central nervous system anomalies as a major feature (LD20)
  - Non-viral and unspecified infections of the central nervous system (1D00-1D0Z)
  - Symptoms, signs or clinical findings of the nervous system (MB40-MB9Y)
  - Paralytic symptoms (MB50-MB5Z)
  - Dissociative neurological symptom disorder (6B60)
  - Diseases of the nervous system complicating pregnancy, childbirth or the puerperium (JB64.3)

This chapter contains the following top level blocks:

- Movement disorders
- Disorders with neurocognitive impairment as a major feature
- Multiple sclerosis or other white matter disorders
- Epilepsy or seizures
- Headache disorders
- Cerebrovascular diseases
- Spinal cord disorders excluding trauma
- Motor neuron diseases or related disorders
- Disorders of nerve root, plexus or peripheral nerves
- Diseases of neuromuscular junction or muscle
- Cerebral palsy
- Nutritional or toxic disorders of the nervous system
- Disorders of cerebrospinal fluid pressure or flow

- Disorders of autonomic nervous system
- Human prion diseases
- Disorders of consciousness
- Other disorders of the nervous system
- Postprocedural disorders of the nervous system
- Injuries of the nervous system
- Neoplasms of the nervous system

## Movement disorders (8A00-8A0Z)

This is a group of involuntary movement disorders.

**Coded Elsewhere:** Restless legs syndrome (7A80)

Periodic limb movement disorder (7A81)

Hemifacial spasm (8B88.2)

**8A00**

### Parkinsonism

Parkinsonism is a clinical syndrome characterised by four cardinal features: rest tremor, muscular rigidity, akinesia or bradykinesia, and postural disturbances which include shuffling gait and flexed posture and loss of postural reflexes. Bradykinesia and one other clinical feature is required to make a diagnosis of Parkinsonism. Parkinsonism may result from a variety of conditions including progressive neurodegenerative disorders such as Parkinson Disease or Atypical Parkinsonism where the progressive degeneration of nigral and other neurons leads to dopamine deficiency. Parkinsonism may also be a result of structural lesions such as strokes or tumours or blockage of dopamine receptors in the striatum by drugs such as neuroleptics.

**Exclusions:** Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)

Arthropathies (FA00-FA5Z)

**8A00.0**

### Parkinson disease

Parkinson Disease is a gradual onset progressive degenerative disease whose cardinal manifestations include bradykinesia plus one of the following-tremor, rigidity or postural instability. Nonmotor manifestations include autonomic dysfunction and neuropsychiatric features.

**8A00.00**

#### Sporadic Parkinson disease

This is defined as Parkinson Disease occurring sporadically with no apparent mode of inheritance.

**8A00.01**

#### Familial Parkinson disease

Familial subtype of Parkinson Disease, a disorder caused by progressive dopaminergic neuron degeneration of the substantia nigra that is characterized by resting tremor, bradykinesia, and rigidity. Familial cases can be caused by mutations in LRRK2, PARK7, PINK1, PRKN, or SNCA genes.

<b>8A00.0Y</b>	Other specified Parkinson disease
<b>8A00.0Z</b>	Parkinson disease, unspecified
<b>8A00.1</b>	<p><b>Atypical parkinsonism</b></p> <p>Atypical parkinsonism is a term used to describe several neurodegenerative conditions where the degeneration extends beyond the substantia nigra and is more extensive than seen in conditions like Parkinson disease. The clinical picture is often more complex than PD and patients may have apraxia, supranuclear ophthalmoplegia or autonomic failure.</p> <p><b>Coded Elsewhere:</b> Multiple system atrophy, Parkinsonism (8D87.01) Lewy body disease (8A22)</p>
<b>8A00.10</b>	<p>Progressive supranuclear palsy</p> <p>Progressive supranuclear palsy (PSP) is a late-onset neurodegenerative disease characterised by supranuclear gaze palsy, postural instability, progressive rigidity, and mild dementia. Five clinical variants have been described with clinicopathological correlations: Classical PSP (Richardson's syndrome), and four atypical variants of PSP including PSP-Parkinsonism (PSP-P), PSP-Pure akinesia with gait freezing (PSP-PAGF), PSP-corticobasal syndrome (PSP-CBS), and PSP-progressive non fluent aphasia (PSP-PNFA).</p>
<b>8A00.1Y</b>	Other specified atypical parkinsonism
<b>8A00.1Z</b>	Atypical parkinsonism, unspecified
<b>8A00.2</b>	<p><b>Secondary parkinsonism</b></p> <p>Secondary parkinsonism is a term used to describe Parkinsonism due to a known agent such as drugs, infections, toxins or structural lesions.</p> <p><b>Coding Note:</b> Code also the causing condition</p>
<b>8A00.20</b>	<p>Parkinsonism due to heredodegenerative disorders</p> <p>Parkinsonism may occur as a result of more widespread heredodegenerative disorders. It is accompanied by other neurological findings such as dystonia, ataxia and dementia. Other family members may be affected.</p> <p><b>Coding Note:</b> Code also the causing condition</p>
<b>8A00.21</b>	<p>Hemiparkinsonism hemiatrophy syndrome</p> <p>Hemiparkinsonism may follow hemiatrophy of the body due to an intrauterine or early neonatal cerebral damage.</p>
<b>8A00.22</b>	<p>Infectious or postinfectious parkinsonism</p> <p>A syndrome caused by an infection with a bacterial, viral, fungal, or parasitic source, which occurs during or after the acute phase of the infection. This condition is characterised by tremors, slow movement, or stiffness of the arms and legs, similar to symptoms seen in Parkinson disease.</p>

- 8A00.23** Vascular parkinsonism  
Multiple lacunar infarcts or diffuse vascular disease of the brain can result in Parkinsonism- imaging often shows multiple lacunar infarcts or diffuse white matter change. The dopamine transporter scan may be normal or abnormal depending upon the site of the infarcts.
- 8A00.24** Drug-induced parkinsonism  
Parkinsonism due to prescription medications.
- 8A00.25** Post traumatic Parkinsonism  
Parkinsonism may be a result of a major head trauma where it occurs in combination with other neurological findings such as weakness and pyramidal signs. It may also occur as a result of multiple blows to the head and may be associated with dementia. It is also called chronic traumatic encephalopathy.
- 8A00.26** Parkinsonism due to structural lesions  
Parkinsonism occurring in the setting of a demonstrable structural lesion such as subdural hematoma and brain tumours. Neuroimaging such as Magnetic Resonance Imaging is very helpful. It has to be emphasized that small brain tumours such as meningioma may be an incidental finding in cases of otherwise typical PD.
- 8A00.2Y** Other specified secondary parkinsonism  
**Coding Note:** Code also the causing condition
- 8A00.2Z** Secondary parkinsonism, unspecified  
**Coding Note:** Code also the causing condition
- 8A00.3** **Functional parkinsonism**  
Functional movement disorder with mixed features of functional tremor but also slowness and stiffness which can be demonstrated to be variable and internally inconsistent. No cause has been identified after investigation.  
**Inclusions:** Psychogenic parkinsonism
- 8A00.Y** Other specified parkinsonism
- 8A00.Z** Parkinsonism, unspecified
- 8A01** **Choreiform disorders**  
Chorea consists of irregular, non-repetitive, brief, jerky, flowing movements that move randomly from one part of the body to another.
- 8A01.0** **Benign hereditary chorea**  
Benign hereditary chorea should be considered in people with a relatively stable, nonprogressive chorea, in whom childhood onset and an autosomal dominant family history are present. Benign hereditary chorea can be associated with short stature and developmental delay. Larger deletions of causative gene, TITF-1, can cause a multisystem disorder with congenital hypothyroidism, hypotonia, and pulmonary problems.

<b>8A01.1</b>	<b>Secondary Chorea</b> Chorea consists of irregular, non-repetitive, brief, jerky, flowing movements that move randomly from one part of the body to another. Chorea can be seen in a variety of metabolic, immunological and other disorders and is termed secondary chorea.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Benign hereditary chorea (8A01.0)
<b>8A01.10</b>	Huntington disease Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system. HD is an autosomal dominant disorder due to a mutation resulting in an increased number of triplicate cytosine-adenine-guanine repeats on chromosome 4. The manifestations include chorea, dementia and personality changes. In the Westphal variant dystonia and parkinsonism are prominent. Neuroimaging reveals caudate atrophy. A genetic test is available and may facilitate presymptomatic detection.
	<b>Inclusions:</b> Huntington chorea
<b>8A01.11</b>	Chorea due to Huntington disease-like conditions The clinical picture of Huntington Disease (HD) is closely mimicked by disorders with an autosomal dominant inheritance. The gene test for HDS is negative prompting the consideration of other disorders. These are called HD like (HDL diseases).
<b>8A01.12</b>	Chorea due to Dentatorubral pallidoluysian atrophy Dentatorubropallidoluysian atrophy patients may have chorea as a major manifestation.
<b>8A01.13</b>	Chorea due to Wilson disease
<b>Coding Note:</b>	Code also the causing condition
<b>8A01.14</b>	Chorea due to infectious or para-infectious causes
<b>Coding Note:</b>	Code also the causing condition
<b>8A01.15</b>	Chorea due to systemic lupus erythematosus Chorea may be a presenting manifestation of systemic lupus erythematosus (SLE) or may occur in established disease. It is associated with the presence of antiphospholipid antibodies.
<b>8A01.16</b>	Drug-induced chorea Chorea may be due to prescribed and illicit drugs.
<b>8A01.1Y</b>	Other specified secondary chorea
<b>Coding Note:</b>	Code also the causing condition
<b>8A01.1Z</b>	Secondary chorea, unspecified
<b>Coding Note:</b>	Code also the causing condition

- 8A01.2** **Hemichorea or hemiballismus**  
 Ballism (“ballismós” meaning ‘jumping around’ in Ancient Greek) refers to violent, irregular flinging movements of the limbs primarily due to contractions of the proximal muscles. Hemiballism refers to movements involving upper and lower extremities on the same side with or without involvement of the face.
- Hemichorea refers to hemibody chorea with brief non repetitive jerks affecting arm and leg on one side with or without involvement of the face.
- 8A01.20** **Hemichorea**  
 Hemichorea refers to hemibody chorea with brief non repetitive jerks affecting arm and leg on one side with or without involvement of the face.
- 8A01.21** **Ballism**  
 Ballism (“ballismós” meaning ‘jumping around’ in Ancient Greek) refers to violent, irregular flinging movements of the limbs primarily due to contractions of the proximal muscles.
- 8A01.22** **Hemiballism**  
 Hemiballism refers to movements involving upper and lower extremities on the same side with or without involvement of the face.
- 8A01.2Y** **Other specified hemichorea or hemiballismus**
- 8A01.2Z** **Hemichorea or hemiballismus, unspecified**
- 8A01.Y** **Other specified choreiform disorders**
- 8A01.Z** **Choreiform disorders, unspecified**
- 8A02** **Dystonic disorders**  
*Exclusions:*      athetoid cerebral palsy (8D21)
- 8A02.0** **Primary dystonia**  
 Primary dystonias (primary torsion dystonias) are disorders where dystonia is the sole neurological manifestation. These disorders are slowly progressive and may be familial/genetic or sporadic in origin.
- 8A02.00** **Benign essential blepharospasm**  
 This is a neurological condition characterised by forcible closure of the eyelids due to involuntary and sustained contraction of the muscles around the eyes.
- 8A02.0Y** **Other specified primary dystonia**
- 8A02.0Z** **Primary dystonia, unspecified**
- 8A02.1** **Secondary dystonia**  
 This is dystonia – a disorder of involuntary muscle contractions – of an acquired nature. Causes include substance toxicity, injury, hypoxia and tumours.
- Coding Note:** Code also the causing condition

- 8A02.10** Drug-induced dystonia  
 This is dystonia due to medications either as an idiosyncratic side effect or due to overdose of medications.
- 8A02.11** Dystonia-plus  
 This is a group of heterogenous syndromes present with dystonia – a disorder of involuntary muscle contractions – along with other clinical features, but not in tandem with a neurodegenerative disease. Examples include myoclonus dystonia and dopa responsive dystonia.
- 8A02.12** Dystonia associated with heredodegenerative disorders  
 Dystonia occurring as a part of a more complex heredodegenerative disorder. It is not a pure dystonia and other neurological findings such as ataxia, pyramidal signs and cognitive issues may be seen.
- 8A02.1Y** Other specified secondary dystonia  
**Coding Note:** Code also the causing condition
- 8A02.1Z** Secondary dystonia, unspecified  
**Coding Note:** Code also the causing condition
- 8A02.2** **Paroxysmal dystonia**  
 Paroxysmal dyskinesias are a group of rare movement disorders characterised by their recurrent and episodic nature, arising from a background of normal motor activity and behaviour. These abnormal movements can manifest in the form of ballism, dystonia, chorea and athetosis or a combination of these.
- 8A02.3** **Functional dystonia or spasms**  
 Functional movement disorder presenting predominantly with mobile or fixed dystonic posturing which is incongruous with other causes of dystonia and may be responsive to placebo therapy or psychotherapy. Typically a clenched fist, inverted ankle or orbicularis oculis/platysma contraction with onset as a teenager or adult.  
 Functional dystonia or spasms where no cause has been identified after investigation.
- 8A02.Y** Other specified dystonic disorders
- 8A02.Z** Dystonic disorders, unspecified
- 8A03** **Ataxic disorders**  
 Disorders associated with ataxia. The word "ataxia" comes from a Greek word meaning "lack of order, indiscipline". People with ataxia have problems with coordination because parts of the nervous system that control movement and balance are affected. Ataxia may affect the fingers, hands, arms, legs, body, speech, and eye movements.
- 8A03.0** **Congenital ataxia**  
 Congenital Ataxia is defined as a lack of coordination due to congenital abnormalities in the cerebellum. It is usually nonprogressive.

- 8A03.1** **Hereditary ataxia**  
 A group of genetic disorders characterised by slowly progressive incoordination of gait and often associated with poor coordination of hands, speech, and eye movements
- Exclusions:** Metabolic disorders (5C50-5D2Z)  
 Cerebral palsy (8D20-8D2Z)
- 8A03.10** Friedreich ataxia  
 Friedreich ataxia is an autosomal recessive ataxia characterised by difficulties to coordinate movements, associated with neurological signs (dysarthria, loss of reflexes, decrease of deep sensation, pes cavus and scoliosis), cardiomyopathy and sometimes diabetes mellitus. It is due to a mutation in the frataxin gene.
- Coded Elsewhere:** Hereditary optic neuropathy associated with hereditary ataxias (8A03.15)
- 8A03.11** Ataxia due to Cerebrotendinous xanthomatosis  
 Ataxia in the setting of cerebrotendinous xanthomatosis, a rare autosomal recessive disorder of bile acid metabolism caused by a mutation in the CYP27A1 gene encoding mitochondrial enzyme sterol 27-hydroxylase. Accumulation of sterols in multiple tissues leads to premature cataracts and tendon xanthomas in late childhood, followed by progressive neurological dysfunction such as ataxia, dementia, and polyneuropathy.
- 8A03.12** Ataxia due to Refsum disease  
 Ataxia in the setting of Refsum disease, a rare autosomal recessive disorder caused by a mutation in the PHYH gene coding for peroxisomal phytanoyl-CoA hydroxylase or PEX7, coding for peroxin 7 receptor protein. Onset is usually in late childhood, initially presenting with retinitis pigmentosa, with progression to ataxia and chronic polyneuropathy.
- 8A03.13** Ataxia due to abetalipoproteinemia  
 Ataxia in the setting of abetalipoproteinemia, a rare autosomal recessive disorder caused by a mutation of the MTP gene coding for microsomal triglyceride transfer protein which impairs the ability to produce very low density lipoprotein. All patients have fat malabsorption, acanthocytosis, hypocholesterolemia, and absent apolipoprotein B.
- 8A03.14** Hereditary episodic ataxia  
 Autosomal dominant disorders associated with intermittent episodes of cerebellar dysfunction, with normal functioning or minimal ataxia and nystagmus between episodes. The two major subtypes include EA1 and EA2. EA1 is caused by a mutation of the KCNA1 gene coding and characterized by episodes triggered by exercise and muscle myokymia. EA2 is caused by a mutation in CACNA1A gene and involves more prolonged attacks of ataxia (lasting hours to days), and interictal residual ataxia with nystagmus.
- 8A03.15** Ataxia due to mitochondrial mutations

- 8A03.16** Spinocerebellar ataxia  
Autosomal dominantly inherited ataxias associated with over 37 gene loci that involve progressive degeneration of the cerebellum and spinocerebellar tracts of the spinal cord, presenting with characteristic sensory loss, diminished tendon reflexes, Romberg sign, and positive Babinski sign(s).
- 8A03.1Y** Other specified hereditary ataxia
- 8A03.1Z** Hereditary ataxia, unspecified
- 8A03.2** **Non-hereditary degenerative ataxia**  
Ataxia is characterized by incoordination, due to lesions in the cerebellum and efferent or afferent connections. Sporadic forms of ataxia that present without any family history or known genetic cause. Diagnosis is made after ruling out other causes of ataxia.
- 8A03.20** Late onset cerebellar cortical atrophy  
This is a sporadic late onset cerebellar cortical atrophy with progressive ataxia. Neuropathologically it is characterised by diffuse cerebellar cortical lesions and absence of neuronal loss in the dorsomedial part of the inferior olives.  
**Exclusions:** Hereditary ataxia (8A03.1)
- 8A03.2Y** Other specified non-hereditary degenerative ataxia
- 8A03.2Z** Non-hereditary degenerative ataxia, unspecified
- 8A03.3** **Acquired ataxia**  
Ataxia that is caused by a variety of exogenous and endogenous factors and is not clearly hereditary. May be seen in the setting of drug toxicity, post-viral cerebellitis, acute disseminated encephalomyelitis, traumatic brain injury, hypoxia, heat stroke, Wernicke's encephalopathy, Miller Fisher syndrome, basilar migraine, or conversion reaction.
- 8A03.30** Ataxia due to alcoholic cerebellar degeneration  
This is the most common form of acquired ataxia and occurs among people suffering from degeneration of the cerebellum as a result of chronic alcohol use.
- 8A03.3Y** Other specified acquired ataxia
- 8A03.3Z** Acquired ataxia, unspecified
- 8A03.Y** **Other specified ataxic disorders**
- 8A03.Z** **Ataxic disorders, unspecified**
- 8A04** **Disorders associated with tremor**  
Tremor is an involuntary oscillation of a body part and is commonly classified according to the behavioural circumstances in which it occurs. Tremor may occur during attempted relaxation (rest tremor), during a voluntarily held posture (postural tremor), or during a voluntary movement (kinetic tremor).

<b>8A04.0</b>	<b>Enhanced physiological tremor</b> This is a high frequency, low amplitude tremor present with posture or action. It represents an exacerbation of a physiologic tremor which may have been worsened by drugs, stress, anxiety, etc.
<b>8A04.1</b>	<b>Essential tremor or related tremors</b> Essential tremor is the most common form of tremor of moderate frequency ranging from 7-12 Hz and presents as a postural and kinetic tremor of the hands. It may also be present in the head/neck, and voice.  <b>Exclusions:</b> tremor NOS (8A04)
<b>8A04.2</b>	<b>Rest tremor</b> Resting tremors happen while the patient is sitting or lying down and relaxed. People who have a resting tremor can usually stop the tremor by deliberately moving the affected body part. It usually occurs in the setting of Parkinsonism.
<b>8A04.3</b>	<b>Secondary tremor</b> <b>Coding Note:</b> Code also the causing condition
<b>8A04.30</b>	Tremor due to metabolic disorders Involuntary oscillation of a body part due to metabolic disorders.  <b>Coding Note:</b> Code also the causing condition
<b>8A04.31</b>	Tremor due to chronic or acute substance use Drug use can cause tremor or exacerbate an existing tremor.  <b>Coding Note:</b> Code also the causing condition
<b>8A04.32</b>	Tremor due to drug withdrawal <b>Coding Note:</b> Code also the causing condition
<b>8A04.33</b>	Tremor due to certain specified central nervous system diseases <b>Coding Note:</b> Code also the causing condition
<b>8A04.3Y</b>	Other specified secondary tremor <b>Coding Note:</b> Code also the causing condition
<b>8A04.3Z</b>	Secondary tremor, unspecified <b>Coding Note:</b> Code also the causing condition
<b>8A04.4</b>	<b>Functional tremor</b> Functional movement disorder presenting predominantly with tremor. The tremor might be variable in frequency and distractible on testing, either entraining or ceasing in response to contralateral externally cued rhythmical movements provided by the examiner.  Functional tremor is that in which no cause has been identified after investigation.
<b>8A04.Y</b>	<b>Other specified disorders associated with tremor</b>
<b>8A04.Z</b>	<b>Disorders associated with tremor, unspecified</b>

**8A05**

### **Tic disorders**

Disorders characterized by brief, sudden, repetitive movements (motor tics) or utterances (phonic or vocal tics) that are temporarily suppressible and are usually preceded by a strong urge to perform the tic. The most common cause of childhood-onset tics is Tourette Syndrome.

**8A05.0**

### **Primary tics or tic disorders**

Primary tics or tic disorders are characterised by the presence of chronic motor and/or vocal (phonic) tics. Motor and vocal tics are defined as sudden, rapid, non-rhythmic, and recurrent movements or vocalizations, respectively. In order to be diagnosed, tics must have been present for at least one year, although they may not manifest consistently.

**8A05.00**

#### Tourette syndrome

Tourette syndrome is a chronic tic disorder characterised by the presence of both chronic motor tics and vocal (phonic) tics, with onset during the developmental period. Motor and vocal tics are defined as sudden, rapid, non-rhythmic, and recurrent movements or vocalizations, respectively. In order to be diagnosed as Tourette syndrome, both motor and vocal tics must have been present for at least one year, although they may not manifest concurrently or consistently throughout the symptomatic course.

**Inclusions:** Combined vocal and multiple motor tic disorder

**8A05.01**

#### Chronic motor tic disorder

Chronic motor tic disorder is characterised by the presence of motor tics over a period of at least one year, although they may not manifest consistently. Motor tics are defined as sudden, rapid, non-rhythmic, and recurrent movements.

**Exclusions:** Tourette syndrome (8A05.00)

**8A05.02**

#### Chronic phonic tic disorder

Chronic phonic tic disorder is characterised by the presence of phonic (vocal) tics over a period of at least one year, although they may not manifest consistently. Phonic tics are defined as sudden, rapid, non-rhythmic, and recurrent vocalizations.

**Exclusions:** Tourette syndrome (8A05.00)

**8A05.03**

#### Transient motor tics

Tics are sudden, non-rhythmic stereotyped movements such as blinking, sniffing, tapping, etc. They should have been present for less than 1 year.

**8A05.0Y**

#### Other specified primary tics or tic disorders

**8A05.0Z**

#### Primary tics or tic disorders, unspecified

**8A05.1**

### **Secondary tics**

A tic disorder as a direct physiologic consequence of an antecedent infection, drugs or illness.

**Coding Note:**

Code also the causing condition

**8A05.10** Infectious or postinfectious tics  
A tic disorder as a direct physiologic consequence of an antecedent infection.

**8A05.11** Tics associated with developmental disorders  
A tic disorder as a direct consequence of a developmental disorder.

**8A05.1Y** Other specified secondary tics  
**Coding Note:** Code also the causing condition

**8A05.1Z** Secondary tics, unspecified  
**Coding Note:** Code also the causing condition

**8A05.Y** **Other specified tic disorders**

**8A05.Z** **Tic disorders, unspecified**

## **8A06 Myoclonic disorders**

**Exclusions:** myoclonic epilepsy (8A60-8A6Z)

Facial myokymia (8B88.1)

Dystonia-plus (8A02.11)

### **8A06.0 Essential myoclonus**

This is a hereditary form of myoclonus, which is not usually associated with epilepsy or any other medical condition. Essential myoclonus tends to be stable without increasing in severity over time. More recently, it is believed that essential myoclonus may be the same as myoclonus-dystonia caused by a mutation in the sarcoglycan gene.

### **8A06.1 Segmental myoclonus**

Rhythmic or semi-rhythmic involuntary contractions of muscle groups supplied by one or more contiguous segments of the brainstem and/or spinal cord.

### **8A06.2 Focal myoclonus**

Sudden, involuntary twitching or jerking of a muscle or group of muscles which effects a localised area of the body.

### **8A06.20 Palatal myoclonus**

Palatal myoclonus is usually a rhythmic, continuous movement of the muscles of the middle ear or palate, but can also include muscle of the eye, tongue, neck and diaphragm. The movement may be present in sleep or with distraction with a frequency of 1.5 to 3 Hz. Essential palatal myoclonus is more likely to have an associated rhythmic clicking noise compared to symptomatic palatal myoclonus.

### **8A06.21 Chronic hiccups**

Chronic hiccup is a rare disorder causing repeated inspiratory spasms over periods of 48 hours or more.

### **8A06.2Y Other specified focal myoclonus**

### **8A06.2Z Focal myoclonus, unspecified**

<b>8A06.Y</b>	<b>Other specified myoclonic disorders</b>
<b>8A06.Z</b>	<b>Myoclonic disorders, unspecified</b>
<b>8A07</b>	<p><b>Certain specified movement disorder</b></p> <p>Neurologic motor disorders that present with slowness of movement (bradykinesia or hypokinesia) or abnormal involuntary movements (hyperkinesias) as a result of genetic, infectious, toxic, metabolic, inflammatory, or vascular abnormalities.</p> <p><b>Coded Elsewhere:</b> Sleep-related movement disorders (7A80-7A8Z)</p> <p style="padding-left: 20px;">Hereditary spastic paraparesis (8B44.0)</p>
<b>8A07.0</b>	<p><b>Stereotypies</b></p> <p>Stereotypy refers to simple or complex movements that repeat themselves continually and identically. These are usually not preceded by an uncomfortable feeling.</p> <p><b>Coded Elsewhere:</b> Autism spectrum disorder (6A02)</p> <p style="padding-left: 20px;">Rett syndrome (LD90.4)</p>
<b>8A07.00</b>	<p>Primary stereotypy</p> <p>A stereotypy that occurs in typically developing child.</p>
<b>8A07.01</b>	<p>Secondary stereotypy</p> <p>A constellation of repetitive stereotyped movements such as hand flapping, that occur in association with a genetic, metabolic, neurodevelopmental, neurodegenerative, paraneoplastic, or infectious disorder.</p>
<b>Coding Note:</b>	Code also the causing condition
<b>8A07.0Y</b>	Other specified stereotypies
<b>8A07.0Z</b>	Stereotypies, unspecified
<b>8A07.1</b>	<b>Akathisia</b>
<b>8A07.2</b>	<p><b>Excessive startle reflex</b></p> <p>Exaggerated startle reaction (eye blinking, muscle jerks, body spasms) that occur in response to unexpected stimuli. May be secondary to hyperkplexia, myoclonic neurological diseases, or neuropsychiatric disorders.</p>
<b>8A0Y</b>	<b>Other specified movement disorders</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8A0Z</b>	<b>Movement disorders, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition

Disorders with neurocognitive impairment as a major feature (8A20-8A2Z)

<b>8A20</b>	<b>Alzheimer disease</b>
-------------	--------------------------

**8A21****Progressive focal atrophies**

Progressive cortical atrophies are neurodegenerative diseases with progressive impairment in a single cognitive domain secondary to circumscribed cerebral atrophy.

**8A21.0****Posterior cortical atrophy**

Benson's syndrome or Posterior Cortical Atrophy (PCA) refers to a clinical syndrome in which higher order visual processing is disrupted owing to a neurodegenerative disorder. The patients present with progressive and severe visual agnosia (inability to recognize and identify familiar objects or persons) and apraxia (loss in the ability to execute or perform skilled familiar movements).

**8A21.Y****Other specified progressive focal atrophies****8A21.Z****Progressive focal atrophies, unspecified****8A22****Lewy body disease**

Lewy body disease is a neurodegenerative disorder and the second most common form of dementia in the elderly after Alzheimer disease. Lewy bodies are histologically defined as intracytoplasmic eosinophilic neuronal inclusions in the cortex or brainstem.

**8A23****Frontotemporal lobar degeneration****8A2Y****Other specified disorders with neurocognitive impairment as a major feature****8A2Z****Disorders with neurocognitive impairment as a major feature, unspecified****Multiple sclerosis or other white matter disorders (8A40-8A4Z)**

This is a group of conditions involving demyelination, damage to the myelin sheath which protects nerve axons and is responsible for neurotransmission.

**8A40****Multiple sclerosis**

Multiple Sclerosis (MS) is a chronic, inflammatory demyelinating disease of the central nervous system. Three categories of multiple sclerosis have been outlined: Relapsing/remitting, secondary progressive and primary progressive multiple sclerosis.

**Coded Elsewhere:** Retrobulbar neuritis in multiple sclerosis (9C40.1Y)

**8A40.0****Relapsing-remitting multiple sclerosis**

Clearly defined disease relapses with full recovery or with sequelae and residual deficit upon recovery. The periods between disease relapses are characterised by a lack of disease progression.

<b>8A40.1</b>	<b>Primary progressive multiple sclerosis</b> Disease progression from onset, with occasional plateaus and temporary minor improvements allowed.
<b>Coding Note:</b>	This category is to be used to indicate Primary progressive multiple sclerosis which is progressive from onset but includes progressive - relapsing, or is progressive from onset with a single relapse
<b>8A40.2</b>	<b>Secondary progressive multiple sclerosis</b>
<b>Coding Note:</b>	This category is to be used to indicate Secondary progressive multiple sclerosis, after an initially relapsing/remitting course (includes remitting relapsing progressive, may have superimposed relapses)
<b>8A40.Y</b>	<b>Other specified multiple sclerosis</b>
<b>8A40.Z</b>	<b>Multiple sclerosis, unspecified</b>
<b>8A41</b>	<b>Isolated demyelinating syndromes of the central nervous system</b> Clinically isolated syndrome (CIS) is the first clinical inflammatory demyelinating event of the central nervous system, lasting more than 24 hours. CIS is now recognised as the first clinical presentation of a disease that shows characteristics of inflammatory demyelination that could be MS, but has yet to fulfill criteria of dissemination in time.  <b>Coded Elsewhere:</b> Optic neuritis (9C40.1) Idiopathic inflammatory optic neuropathy (9C40.1Y)
<b>8A41.0</b>	<b>Transverse myelitis</b> Focal inflammatory and demyelinating disorder of the spinal cord, resulting in motor, sensory and autonomic dysfunction. Symptoms include Lhermitte's, numbness of the limbs, progressive spastic paraparesis, urinary urgency, incontinence and sexual dysfunction.  <b>Coding Note:</b> Code also the causing condition
<b>8A41.1</b>	<b>Neuromyelitis optica myelin oligodendrocyte glycoprotein antibody-positive</b> MOG antibody associated spectrum disorders are inflammatory demyelinating diseases of the central nervous system with a predilection for optic nerve that include a subgroup of patients with bilateral optic neuritis (ON), longitudinally extensive (> 3 vertebral segments) myelitis (often recurrent) and rarely patients with an NMO like presentation. The clinical and immunopathological phenotype is under active investigation
<b>8A41.Y</b>	<b>Other specified isolated demyelinating syndromes of the central nervous system</b>
<b>8A41.Z</b>	<b>Isolated demyelinating syndromes of the central nervous system, unspecified</b>

**8A42**

**Acute disseminated encephalomyelitis**

Acute disseminated encephalomyelitis is a demyelinating disorder of the central nervous system. It usually develops after acute viral or bacterial infection or vaccination, with a sudden onset of irritability and lethargy after a prodromal period of 1-4 weeks. Major symptoms include fever, headache, drowsiness, changes in mental status, seizures and coma. Weakness, vomiting, weight loss, stiff neck, ataxia, bilateral optic neuritis and delirium are common. Peripheral nervous system involvement (paralysis of a single limb or hemiplegia) may occur.

**8A42.0**

**Acute haemorrhagic leukoencephalitis**

Rare, severe, rapidly progressive inflammatory and haemorrhagic demyelinating disorder of the central nervous system, considered a variant of ADEM.

**8A42.Y**

**Other specified acute disseminated encephalomyelitis**

**8A42.Z**

**Acute disseminated encephalomyelitis, unspecified**

**8A43**

**Neuromyelitis optica**

**Coded Elsewhere:** Neuromyelitis optica myelin oligodendrocyte glycoprotein antibody-positive (8A41.1)

**8A43.0**

**Neuromyelitis optica aquaporin-4 antibody positive**

Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system characterised mainly by attacks of uni- or bilateral optic neuritis (ON) and acute longitudinally extensive (> 3 vertebral segments) myelitis. This form is seropositive for aquaporin-4 antibodies.

**8A43.1**

**Neuromyelitis optica aquaporin-4 antibody negative**

Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system characterised mainly by attacks of uni- or bilateral optic neuritis (ON) and acute longitudinally extensive (> 3 vertebral segments) myelitis. This form is seronegative for aquaporin-4 antibodies.

Some patients may be myelin oligodendrocyte glycoprotein (MOG) antibody positive.

**8A43.2**

**Single transverse myelitis aquaporin-4 antibody positive**

A single episode of transverse myelitis which is typically longitudinally extensive (>3 vertebral segments) associated with seropositivity for aquaporin-4 antibodies but without sufficient features to fulfill the 2006 NMO diagnostic criteria.

**8A43.3**

**Recurrent transverse myelitis aquaporin-4 antibody positive**

Two or more episodes of transverse myelitis which is typically longitudinally extensive (>3 vertebral segments) associated with seropositivity for aquaporin-4 antibodies but without sufficient features to fulfill the 2006 NMO diagnostic criteria.

**8A43.4**

**Single optic neuritis aquaporin-4 antibody positive**

A single episode of optic neuritis associated with seropositivity for aquaporin-4 antibodies but without sufficient features to fulfill the 2006 NMO diagnostic criteria.

<b>8A43.5</b>	<b>Recurrent optic neuritis aquaporin-4 antibody positive</b> Two or more episodes of optic neuritis associated with seropositivity for aquaporin-4 antibodies but without sufficient features to fulfill the 2006 NMO diagnostic criteria.
<b>8A43.Y</b>	<b>Other specified neuromyelitis optica</b>
<b>8A43.Z</b>	<b>Neuromyelitis optica, unspecified</b>
<b>8A44</b>	<p><b>Leukodystrophies</b></p> <p>Group of rare progressive genetic diseases that are caused by mutations in genes that lead to destruction of white matter of the brain by disrupting development of the myelin sheath. More than 50 different leukodystrophies have been identified, including Alexander disease, Canavan disease, cerebrotendinous xanthomatosis, metachromatic leukodystrophy, Pelizaeus-Merzbacher disease, and Refsum disease.</p> <p><b>Coded Elsewhere:</b> Metachromatic leukodystrophy (5C56.02)            Canavan disease (5C50.E1)            Leukoencephalopathy with brainstem - spinal cord involvement - lactate elevation (5C53.23)</p>
<b>8A44.0</b>	<p><b>Pelizaeus-Merzbacher disease</b></p> <p>Pelizaeus-Merzbacher disease (PMD) is an X-linked leukodystrophy characterised by developmental delay, nystagmus, hypotonia, spasticity, and variable intellectual deficit. It is classified into three sub-forms based on the age of onset and severity: connatal, transitional, and classic PMD.</p> <p><b>Coded Elsewhere:</b> Pelizaeus-Merzbacher-like disease (LD90.2)</p>
<b>8A44.1</b>	<p><b>Adrenoleukodystrophy</b></p> <p>X-linked genetic disorder associated with accumulation of very-long-chain fatty acids in the brain and adrenal cortex due to a mutation in the ABCD1 gene causing defects in peroxisomal oxidation. Neurological symptoms can present in childhood or adulthood with almost all patients having concurrent adrenal insufficiency.</p> <p><b>Coded Elsewhere:</b> Zellweger syndrome (5C57.0)            Neonatal adrenoleukodystrophy (5A74.Y)            X-linked adrenoleukodystrophy (5C57.1)</p>
<b>8A44.2</b>	<p><b>Alexander disease</b></p> <p>Alexander's disease is a neurodegenerative disorder encompassing different clinical forms: the infantile form (birth to 2 years), the most common, is characterised by its early onset and severe evolution with progressive megalecephaly (sometimes hydrocephaly), retarded psychomotor development or mental deterioration, pyramidal signs, ataxia and convulsive seizures. The juvenile forms start in school-aged children and associate spastic paraparesis and progressive bulbar signs. Adult forms are heterogeneous and difficult to diagnose.</p>

- 8A44.3 Certain specified leukodystrophies**
- Coded Elsewhere:** Phenylketonuria (5C50.0)  
Refsum disease (5C57.1)  
Cerebrotendinous xanthomatosis (5C52.11)  
Leber hereditary optic neuropathy (8C73.Y)  
Cystic leukoencephalopathy without megalecephaly (5C55.2)  
Gaucher disease (5C56.0Y)  
Niemann-Pick disease (5C56.0Y)  
Tay-Sachs disease (5C56.00)  
Oculo-dento-digital dysplasia (LD27.0Y)
- 8A44.4 Krabbe disease**
- Krabbe disease, also called globoid cell leukodystrophy, is a sphingolipidosis resulting from galactosylceramidase (or galactocerebrosidase) deficiency, a lysosomal enzyme that catabolizes a major lipid component of myelin. The disease leads to demyelination of the central and peripheral nervous system which is rapidly progressive from the first year of life, but juvenile, adolescent or adult onset forms have also been reported, with a more variable rate of progression.
- 8A44.Z Leukodystrophies, unspecified**
- 8A45 Secondary white matter disorders**
- Coding Note:** Code also the causing condition
- 8A45.0 White matter disorders due to infections**
- Coded Elsewhere:** Tabes dorsalis (1A62.01)
- 8A45.00 Human T-cell lymphotropic virus-associated myelopathy**
- Human T-cell lymphotropic virus (HTLV) is a retrovirus and causes immune mediated diseases of the nervous system. Human T-cell lymphotropic virus type 1 (HTLV-1) and Human T-cell lymphotropic virus type 2 (HTLV-2) are closely related retroviruses with similar biological properties and common modes of transport.
- Coded Elsewhere:** Myelitis due to Human T-lymphotropic virus type 1 (1D02.1)
- 8A45.01 Subacute sclerosing panencephalitis**
- Inclusions:** Dawson inclusion body encephalitis  
Van Bogaert sclerosing leukoencephalopathy
- 8A45.02 Progressive multifocal leukoencephalopathy**
- 8A45.0Y Other specified white matter disorders due to infections**
- 8A45.0Z White matter disorders due to infections, unspecified**
- 8A45.1 White matter disorders due to toxicity**
- Coded Elsewhere:** Myelopathy due to radiation injury (8B42)
- 8A45.2 White matter disorders due to vascular abnormality or ischemia**

- 8A45.20** White matter disorder due to CADASIL
- 8A45.21** Subacute necrotising myelitis  
Foix-Alajouanine syndrome, also called subacute ascending necrotising myelitis, results from chronic congestion of the extrinsic pial veins of the spinal cord and of the intrinsic subpial network. It is characterised by progressive ascending deficit over a period of several months or years.
- 8A45.2Y** Other specified white matter disorders due to vascular abnormality or ischemia
- 8A45.2Z** White matter disorders due to vascular abnormality or ischemia, unspecified
- 8A45.3** **White matter disorders due to nutritional deficiency**  
Damage to the white matter due to nutritional deficiency.
- 8A45.30** White matter disorder due to vitamin B12 deficiency  
Neurological features occur in 40% of patients with B12 deficiency. Subacute combined degeneration is a potentially reversible neurological complication of a vitamin B12 deficiency. Symptoms develop insidiously and neuropathic manifestations include progressive paraesthesia distally, numbness, gait ataxia and diminished proprioception in the lower limbs, while the myelopathic component leads to variable motor impairment due to pyramidal tract dysfunction. Incontinence of bowel and bladder with impotence and postural hypotension occur as part of the myelopathy. Central manifestations include confusion, depression, progressive hallucination and mental slowing. There may also be optic neuropathy present.
- 8A45.31** Central pontine myelinolysis
- 8A45.3Y** Other specified white matter disorders due to nutritional deficiency
- 8A45.3Z** White matter disorders due to nutritional deficiency, unspecified
- 8A45.4** **White matter disorders due to certain specified systemic disease**
- 8A45.40** Demyelination due to sarcoidosis  
Sarcoidosis can affect any part of the nervous system. It is estimated that about 5-15% of cases develop evidence of central nervous system involvement. Neurosarcoidosis may manifest in many different ways, diagnosis may be difficult. Neurosarcoidosis can appear in an acute explosive fashion or as a slow, chronic illness. Any part of the central nervous system can be attacked by sarcoidosis but chronic neurosarcoidosis can cause multiple cranial nerve palsies, parenchymatous cerebral involvement, hydrocephalus and encephalopathy or peripheral nervous system manifestations.
- 8A45.41** Demyelination due to systemic lupus erythematosus  
Among the 12 systemic lupus erythematosus (SLE)-related central nervous system (CNS) syndromes defined by the American College of Rheumatology (ACR), demyelinating syndrome and myelopathy are two of the less prevalent and more poorly understood ones. One important issue concerning demyelinating disease in SLE is that it can be easily misdiagnosed with other central nervous system demyelinating disorders such as multiple sclerosis (MS).
- 8A45.42** Demyelination due to Sjögren disease

- 8A45.43** Demyelination due to Behcet disease
- 8A45.44** Demyelination due to systemic vasculitis  
The CNS vasculature can be targeted by systemic vasculitis and include the following conditions;  
Small-Medium Vessel Vasculitis - Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, Cryoglobulinemic vasculitis and Behçet's disease.  
Medium Vessel Vasculitis - Polyarteritis nodosa  
Large Vessel Vasculitis - Giant-cell arteritis, Takayasu's arteritis (Neurologic complications are mainly due to involvement of extracranial vessels).  
Usually CNS involvement coexists with other clearly apparent systemic manifestations but some patients may present primarily with prominent symptoms of CNS dysfunction
- 8A45.45** Demyelination due to mitochondrial disease  
Mitochondrial disorders can cause multifocal and relapsing central nervous system syndromes. Mitochondrial disorders which can cause such syndromes include Mitochondrial Encephalopathy with Lactic Acidosis and Stroke (MELAS), and Leigh's disease. MELAS is a progressive neurodegenerative disorder associated with headache, treatment resistant partial seizures, short stature, muscle weakness, exercise intolerance, deafness, diabetes, and slow progressive dementia. Leigh syndrome or subacute necrotizing encephalomyopathy is the prototype mitochondrial disease, with hallmark neuroimaging findings.
- 8A45.4Z** White matter disorders due to certain specified systemic disease, unspecified
- 8A45.Y** **Other specified secondary white matter disorders**
- Coding Note:** Code also the causing condition
- 8A45.Z** **Secondary white matter disorders, unspecified**
- Coding Note:** Code also the causing condition
- 8A46** **Central demyelination of corpus callosum**  
This is demyelination, damage to the myelin sheath of neurons, in the corpus callosum.
- 8A4Y** **Other specified multiple sclerosis or other white matter disorders**
- 8A4Z** **Multiple sclerosis or other white matter disorders, unspecified**

## Epilepsy or seizures (8A60-8A6Z)

At least 2 unprovoked (or reflex) seizures occurring more than 24 hours apart.

**Coding Note:** Use additional code, if desired, to identify the type of seizure.

**Exclusions:** Syncope (MG45)

**Coded Elsewhere:** Sudden unexpected death in epilepsy (MH15)

Neonatal seizures (KB06)

**8A60**

### **Epilepsy due to structural or metabolic conditions or diseases**

Epilepsy occurring in relation to a distinct other structural or metabolic condition or disease that has been demonstrated to be associated with a substantially increased risk of developing epilepsy.

**8A60.0**

### **Epilepsy due to prenatal or perinatal brain insults**

Epilepsy occurring in relation to a distinct structural or metabolic condition or disease that has been demonstrated to be associated with a substantially increased risk of developing epilepsy, with the insult occurring before birth [prenatal] or between 22 weeks of gestation and 7 days after birth. Onset of epilepsy may be in infancy, childhood, or adulthood.

**Coding Note:**

Code also the causing condition

**Exclusions:** Neonatal seizures (KB06)

**8A60.00**

### Epilepsy due to prenatal or perinatal vascular insults

Epilepsy occurring in relation to an ischemic stroke or haemorrhagic stroke, with the stroke occurring or presumed to occur before birth [prenatal] or between 22 weeks of gestation and 7 days after birth [perinatal]. No other conditions associated with a substantially increased risk of developing epilepsy are present. Onset of epilepsy may be in infancy, childhood, or adulthood.

**Coding Note:**

Code also the causing condition

**8A60.01**

### Epilepsy due to neonatal hypoxic ischemic encephalopathy

**8A60.0Y**

### Epilepsy due to other prenatal or perinatal brain insults

**Coding Note:**

Code also the causing condition

**8A60.0Z**

### Epilepsy due to unspecified prenatal or perinatal brain insults

**Coding Note:**

Code also the causing condition

**8A60.1**

### **Epilepsy due to cerebrovascular disorders**

Epilepsy occurring in relation to a stroke, with onset at least one week following an ischemic or haemorrhagic stroke.

**Coding Note:**

Code also the causing condition

**8A60.2**

### **Epilepsy due to degenerative brain disorders**

Epilepsy in relation to a degenerative brain disorder known to be associated with seizures, such as certain neuronal storage disorders (e.g. adult neuronal ceroid lipofuscinosis), and certain mitochondrial disorders.

**Coding Note:**

Code also the causing condition

- 8A60.3      Epilepsy due to dementias**  
Epilepsy with onset in a patient with established diagnosis of dementia. Seizures may occur at any time after the disease onset. Focal onset seizures are the prevailing type in Alzheimer's disease while seizures with bilateral convulsive activity predominate in other dementing disorders. Myoclonus is another common finding in patients with Alzheimer's disease.
- Coding Note:** Code also the causing condition
- 8A60.4      Epilepsy due to central nervous system infections or infestations**  
Epilepsy with onset in a patient with a documented CNS infection or infestation after the acute phase of the disease.
- Coding Note:** Code also the causing condition
- 8A60.5      Epilepsy due to injuries to the head**  
Epilepsy occurring in relation to a traumatic brain injury. Onset is more than 1 week following the trauma, with risk increasing with the severity of brain injury.
- Coding Note:** Code also the causing condition
- 8A60.6      Epilepsy due to tumours of the nervous system**  
Epilepsy occurring in relation to intracranial tumours. The epilepsy may be the presenting symptom of the tumour, which is located within or affects the cerebral cortex. The tumour may be a primary intracranial tumour or a metastatic tumour.
- Coding Note:** Code also the causing condition
- 8A60.7      Epilepsy with mesial temporal sclerosis**  
Epilepsy associated with imaging and/or pathologic findings of mesial temporal sclerosis. Onset of epilepsy may be in childhood or adulthood. A history of prolonged febrile seizures is common.
- 8A60.8      Epilepsy due to immune disorders**  
Epilepsy in relation to immunological or autoimmune disorders, such as systemic lupus erythematosus [1], inflammatory bowel disease [2], and antibody associated encephalitis (e.g. NMDA receptors) [3]. Antibody associated encephalitis is often a limbic encephalitis, and is sometimes paraneoplastic. Excludes multiple sclerosis and other demyelinating disorders.
- Coding Note:** Code also the causing condition
- 8A60.9      Epilepsy due to abnormalities of brain development**  
Epilepsy due to disorders of cortical development encompassing a wide range of etiologies, with effects that depend on the stage of brain development. Seizure types usually reflect the topology of the malformation.
- Coding Note:** Code also the causing condition
- 8A60.A      Epilepsy due to genetic syndromes with widespread or progressive effects**  
Epilepsy due to genetically determined conditions in which, as we currently understand it, there is a separate disorder interposed between the genetic defect and the epilepsy, for example, as in tuberous sclerosis. Includes epilepsy due to documented autosomal, X-linked, mitochondrial or chromosomal abnormalities.

<b>8A60.B</b>	<b>Epilepsy due to multiple sclerosis or other demyelinating disorders</b> Epilepsy with onset in a patient with established diagnosis of multiple sclerosis (MS) or other demyelinating disorder. Seizures must occur during the disease course, but not in close temporal relationship with an acute phase. The duration of MS symptoms prior to first seizure is generally several years.
<b>Coding Note:</b>	Code also the causing condition
<b>8A60.Y</b>	<b>Epilepsy due to other structural or metabolic condition or disease</b>
<b>8A60.Z</b>	<b>Epilepsy due to unspecified structural or metabolic condition or disease</b>
<b>8A61</b>	<b>Genetic or presumed genetic syndromes primarily expressed as epilepsy</b> The epilepsy is, as best as understood, the direct result of one or more known or presumed genetic defects in which seizures are the core symptom of the disorder.
<b>8A61.0</b>	<b>Genetic epileptic syndromes with neonatal onset</b> Epilepsy with onset in the first 30 days of life resulting from one or more known or presumed genetic defects in which seizures are the core symptom of the disorder.
	<b>Exclusions:</b> Neonatal seizures (KB06) Epilepsy due to prenatal or perinatal brain insults (8A60.0)
<b>8A61.00</b>	Pyridoxal dependent epilepsy Pyridoxal 5-phosphate dependent epilepsy usually presents with neonatal intractable seizures and is diagnosed by cerebrospinal fluid (CSF) analysis, gene testing, and clinical response. The majority of patients have pyridoxamine 5'-phosphate oxidase (PNPO) gene disease causing mutations. Early diagnosis and effective treatment can lead to a relatively favourable neurodevelopmental outcome.
<b>8A61.0Y</b>	Other specified genetic epileptic syndromes with neonatal onset
<b>8A61.0Z</b>	Genetic epileptic syndromes with neonatal onset, unspecified
<b>8A61.1</b>	<b>Genetic epileptic syndromes with onset in infancy</b> Include a vast spectrum of phenotypes having in common a genetic background and the onset in infancy. They range from benign self-remitting to severe drug resistant syndromes. Family history of epilepsy is common in some syndromic entities and exceptional in others.
<b>8A61.10</b>	Benign familial infantile epilepsy Epilepsy characterised by the occurrence of repeated seizures in healthy infants with no prior medical history during the first year of life. The seizures manifest with motor arrest, impairment of consciousness, staring, eye and head deviation, and mild unilateral clonic convulsions. A family history of the same epilepsy is a constant finding. The pattern of inheritance is most probably autosomal dominant.

- 8A61.11** Dravet syndrome  
A refractory epileptic encephalopathy occurring in otherwise healthy infants during the first year of life with clonic/tonic-clonic, generalised and unilateral seizures, hemiclonic or generalised status epilepticus. The interictal EEG may initially be normal but with time background activity deteriorates and bilateral asymmetric, focal or multifocal paroxysms of polyspike and slow-waves appear. Mutations in the voltage-gated sodium channel gene SCN1A are commonly found.
- 8A61.12** Epilepsy of infancy with migrating focal seizures  
Epilepsy syndrome with onset between the first week of life and seven months of intractable, polymorphous focal seizures. Psychomotor development progressively deteriorates. A mutation of SCN1A may be found. The EEG shows multifocal, varying sites of seizure onset, and diffuse slowing.
- 8A61.1Y** Other specified genetic epileptic syndromes with onset in infancy
- 8A61.1Z** Genetic epileptic syndromes with onset in infancy, unspecified
- 8A61.2** **Genetic epileptic syndromes with childhood onset**
- 8A61.20** Benign childhood epilepsy with centro-temporal spikes  
Epilepsy characterised by focal seizures, mainly during sleep, often with involvement of the mouth and face. Convulsive seizures may occur. A history of febrile seizures is common. Onset is maximal between 7 and 10 years of age. The electroencephalogram typically shows focal epileptiform discharges over one or both centrot temporal areas. Remission occurs before age 16 years.
- 8A61.21** Childhood absence epilepsy  
Epilepsy with onset in an otherwise normal child of 2 to 12 years of age, often with multiple daily brief staring episodes lasting an average of 10 seconds. Absence seizures are usually provoked by hyperventilation. The electroencephalogram shows ictal and interictal diffuse 2.5-3 cycles per second spike and wave discharges. The genetic pattern is probably polygenic.
- 8A61.22** Epilepsy with myoclonic-astatic seizures  
Epilepsy beginning between the second and fifth year of life in a previously normal child with family history of seizures, that initially manifests as tonic-clonic seizures with myoclonic-astatic seizures beginning several weeks later. These seizures are characterised by a sudden loss of muscular tonus associated with forward or backward propulsion that may result in injury to the face and head if the patient falls.
- 8A61.23** Myoclonic absences or absences with myoclonias  
Childhood epileptic syndrome characterised by absence seizures associated with severe rhythmic bilateral myoclonic jerks. The EEG pattern shows rhythmic, bilateral, synchronous, symmetric 3-Hz spike and slow-waves discharges associated with EMG myoclonic bursts at 3 Hz, superimposed to a progressively increasing tonic contraction.
- 8A61.2Y** Other specified genetic epileptic syndromes with childhood onset
- 8A61.2Z** Genetic epileptic syndromes with childhood onset, unspecified

- 8A61.3** **Genetic epileptic syndrome with adolescent or adult onset**  
Includes a wide array of epilepsy syndromes having a (presumed) genetic origin, with onset in adolescence or in adult life. The developmental background is usually normal. Family history of epilepsy is frequently present. Focal and generalised seizures may be present most frequently in isolation to mark the diagnostic category, and rarely in combination. The interictal and ictal EEG may show typical, sometimes pathognomonic, patterns. Neuroimaging is normal although focal abnormalities are occasionally reported.
- 8A61.30** Juvenile myoclonic epilepsy  
Epilepsy with onset between the ages of 6 and 25 years with myoclonic jerks without loss of consciousness predominantly occurring early in the morning. Intelligence is not affected. Jerks may be facilitated by sleep deprivation, stress, or certain visual stimuli. Convulsive seizures may occur and may be preceded by myoclonic jerks.
- 8A61.31** Juvenile absence epilepsy  
Juvenile absence epilepsy is one of the age-related idiopathic generalised epilepsies (IGE) with an age at onset between 10 and 17 years of age, and is characterised by sporadic (non-pyknoleptic) occurrence of absence seizures frequently associated with generalised tonic-clonic seizures (GTCS) predominantly on awakening. Interictal and ictal EEG shows generalised spike and wave discharges with normal background activity.
- 8A61.32** Benign adult familial myoclonus epilepsy  
Benign adult familial myoclonic epilepsy (BAFME) is an inherited epileptic syndrome characterised by cortical hand tremors, myoclonic jerks and occasional generalised or focal seizures with a non-progressive or very slowly progressive disease course, and no signs of early dementia or cerebellar ataxia.
- 8A61.3Y** Other specified genetic epileptic syndrome with adolescent or adult onset
- 8A61.3Z** Genetic epileptic syndrome with adolescent or adult onset, unspecified
- 8A61.4** **Genetic epileptic syndromes with variable age of onset**  
Epilepsies occurring in an otherwise normal child or adult. Seizures may occur spontaneously or may be provoked by external stimuli. Family history of seizures is not uncommon and is frequently reported in selected epilepsy syndromes.  
Genetic aspects may follow differing features ranging from complex hereditary patterns to classic Mendelian features or to focused defects.
- 8A61.40** Reflex epilepsies  
Reflex epilepsies are rare epileptic syndromes with seizures induced by specific triggering factors (either by visual, auditory, somato-sensitive or somato-motor stimulation, or by higher cortical function activities). Photosensitive epilepsies are the most frequent form. Spontaneous seizures may also occur. "Reflex seizures" can be classified into a simple "pure" reflex epilepsy and a complex group. The former comprises seizure triggered by simple sensory stimuli or by movements (photosensitive epilepsies). The latter are triggered by complex mental and emotional processes (verbal and non-verbal epilepsies).

<b>8A61.41</b>	Progressive myoclonic epilepsy
<b>8A61.4Y</b>	Other specified genetic epileptic syndromes with variable age of onset
<b>8A61.4Z</b>	Genetic epileptic syndromes with variable age of onset, unspecified
<b>8A61.Y</b>	<b>Other specified genetic or presumed genetic syndromes primarily expressed as epilepsy</b>
<b>8A61.Z</b>	<b>Genetic or presumed genetic syndromes primarily expressed as epilepsy, unspecified</b>

## **8A62**

### **Epileptic encephalopathies**

Epilepsies for which no clear etiology can be detected or occurring at the presence of two or more static structural or metabolic conditions increasing the risk for epileptic seizures. The epileptic activity itself may contribute to severe cognitive and behavioural impairments above and beyond what might be expected from the underlying pathology alone.

## **8A62.0**

### **Infantile spasms**

Syndrome characterised by the subacute onset of brief, repeated seizures with axial or limb flexion, occurring in clusters. EEG shows hypsarrhythmia, i.e., chaotic, high voltage slowing multifocal spikes, with ictal abrupt decremental pattern. Various structural brain pathologies may be present, or no cause may be found. Two-thirds of children have subsequent cognitive deficits.

## **8A62.1**

### **Lennox-Gastaut syndrome**

Syndrome defined as a cryptogenic or symptomatic generalised epilepsy, which is characterised by the following symptomatic triad: several epileptic seizures (atypical absences, axial tonic seizures and sudden atonic or myoclonic falls); diffuse slow interictal spike waves in the waking EEG (< 3 Hz) and fast rhythmic bursts (10 Hz) during sleep; slow mental development associated with personality disturbances.

## **8A62.2**

### **Acquired epileptic aphasia**

Epilepsy with onset in a previously normal child characterised by acquired aphasia, variable seizure types, focal bitemporal EEG epileptiform abnormalities (1.5-5 Hz spike and slow-waves), frequently activated by sleep, with or without seizures. Behavioural disorders such as hyperactivity and attention deficit are common. There is no documented brain pathology.

## **8A62.Y**

### **Other specified epileptic encephalopathies**

## **8A62.Z**

### **Epileptic encephalopathies, unspecified**

## **8A63**

### **Seizure due to acute causes**

A clinical seizure occurring at the time of a systemic insult or in close temporal association with a documented brain insult.

#### **Coding Note:**

Code also the causing condition

**Exclusions:** Migraine aura-triggered seizures (8A80.3)

<b>8A63.0</b>	<b>Febrile seizures</b> Seizures associated with a rise of the body temperature in the absence of intracranial infection, metabolic disturbance, or history of afebrile seizures. They most commonly occur in children between the ages of 6 months and 5 years.
<b>8A63.00</b>	Simple febrile seizures Febrile seizures lasting less than 15 minutes, with no focal features and no occurrence in series.
<b>8A63.01</b>	Complex febrile seizures Febrile seizures lasting longer than 15 minutes and/or multiple episodes occurring within 24 hours and/or seizures with focal features.
<b>8A63.0Y</b>	Other specified febrile seizures
<b>8A63.0Z</b>	Febrile seizures, unspecified
<b>8A63.Y</b>	<b>Seizure due to other acute cause</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8A63.Z</b>	<b>Seizure due to unspecified acute cause</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8A64</b>	<b>Single seizure due to remote causes</b> An unprovoked seizure occurring in a patient with no history of antecedent seizures but with abnormalities of brain development or a potentially responsible clinical condition (metabolic, structural, toxic). The temporal relationship with the CNS insult is beyond the interval estimated for the occurrence of acute symptomatic seizures. The CNS insult may be static or progressive.  <b>Coding Note:</b> Code also the causing condition
<b>8A65</b>	<b>Single unprovoked seizure</b> A seizure occurring in the absence of a potentially responsible structural or metabolic condition or beyond the interval estimated for the occurrence of an acute symptomatic seizure.
<b>8A66</b>	<b>Status epilepticus</b> Status epilepticus is defined as 5 min or more of (i) continuous clinical and/or electrographic seizure activity or (ii) recurrent seizure activity without recovery (returning to baseline) between seizures.
<b>8A66.0</b>	<b>Convulsive status epilepticus</b> Convulsive status epilepticus is defined as 5 min or more of (i) continuous clinical convulsive seizure activity or (ii) recurrent seizure activity without recovery (returning to baseline) between seizures.
<b>8A66.1</b>	<b>Non-convulsive status epilepticus</b> Non-convulsive status epilepticus is defined as 5 min or more of (i) continuous clinical and/or electrographic seizure activity or (ii) recurrent seizure activity without recovery (returning to baseline) between seizures.

<b>8A66.10</b>	Absence status epilepticus An absence seizure (see absence seizures, typical and atypical) lasting >10 min (on average 10-15 min).
<b>8A66.1Y</b>	Other specified non-convulsive status epilepticus
<b>8A66.1Z</b>	Non-convulsive status epilepticus, unspecified
<b>8A66.Y</b>	<b>Other specified status epilepticus</b>
<b>8A66.Z</b>	<b>Status epilepticus, unspecified</b>
<b>8A67</b>	<b>Acute repetitive seizures</b> Acute repetitive seizures are multiple seizures, with a distinct time of onset, with recovery between each seizure, occurring within 24 hours in adults, or 12 hours in children.
<b>8A68</b>	<b>Types of seizures</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Dissociative neurological symptom disorder, with non-epileptic seizures (6B60.4) Neonatal seizures (KB06)
<b>8A68.0</b>	<b>Focal unaware seizure</b> Previously termed “complex partial seizures”, define seizures originating within networks limited to one hemisphere and accompanied by loss of awareness (i.e., knowledge of self or environment).
<b>8A68.1</b>	<b>Absence seizures, atypical</b> Absence seizures with changes in tone more pronounced than in typical absences or with non-abrupt onset and/or cessation, often associated with slow, irregular, generalised spike-wave activity.
<b>8A68.2</b>	<b>Absence seizures, typical</b> Seizures characterised by sudden onset, interruption of ongoing activities, blank stare, possibly brief upward gaze deviation, unresponsiveness, duration from few seconds to half a minute, and rapid recovery. An EEG would show generalised epileptiform discharges during the event.
<b>8A68.3</b>	<b>Focal aware seizure</b> Focal aware seizures define seizures originating within networks limited to one hemisphere and accompanied by awareness (i.e., knowledge of self or environment).
<b>8A68.4</b>	<b>Generalised tonic-clonic seizure</b> A seizure characterized by an abrupt onset with loss of consciousness and bilateral tonic extension of the trunk and limbs (tonic phase) followed by synchronous muscle jerking (clonic phase). Usually followed by a postictal phase, lasting for several minutes up to hours, characterized by initial mydriasis, body relaxation, hypotonia, and sleep.

<b>8A68.5</b>	<b>Generalised myoclonic seizure</b> Seizure characterized by sudden, rapid brief (<100msec) involuntary muscle jerks that may involve just one muscle or the entire trunk musculature and are associated with an ictal EEG discharge. Can occur bilaterally, unilaterally, synchronously or asynchronously.
<b>8A68.6</b>	<b>Generalised tonic seizure</b> A seizure characterised by sustained increase in muscle contraction lasting a few seconds to minutes.
<b>8A68.7</b>	<b>Generalised atonic seizure</b> Seizure characterised by sudden loss or diminution of muscle tone without apparent preceding myoclonic or tonic event lasting 1-2 sec, involving head, trunk, jaw, or limb muscles.
<b>8A68.Y</b>	<b>Other specified type of seizure</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8A68.Z</b>	<b>Type of seizure, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8A6Y</b>	<b>Other specified epilepsy or seizures</b>
<b>Coding Note:</b>	Use additional code, if desired, to identify the type of seizure.
<b>8A6Z</b>	<b>Epilepsy or seizures, unspecified</b>
<b>Coding Note:</b>	Use additional code, if desired, to identify the type of seizure.

## Headache disorders (8A80-8A8Z)

**Exclusions:** Headache, not elsewhere classified (MB4D)

<b>8A80</b>	<b>Migraine</b> A primary headache disorder, in most cases episodic. Disabling attacks lasting 4-72 hours are characterised by moderate or severe headache, usually accompanied by nausea, vomiting and/or photophobia and phonophobia, and sometimes preceded by a short-lasting aura of unilateral fully-reversible visual, sensory or other central nervous system symptoms. In a small minority of cases headache, but not necessarily the associated symptoms, becomes very frequent, with loss of episodicity.
<b>Exclusions:</b>	Headache, not elsewhere classified (MB4D)

<b>8A80.0</b>	<b>Migraine without aura</b> Recurrent headache disorder manifesting in attacks lasting 4-72 hours. The duration of attacks may be shorter in children. Typical characteristics of the headache are unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity and association with nausea and/or photophobia and phonophobia.
---------------	---

- 8A80.1** **Migraine with aura**  
Recurrent attacks, lasting minutes, of unilateral fully-reversible visual, sensory or other central nervous system symptoms that usually develop gradually and are usually followed by headache and associated migraine symptoms.
- 8A80.10** **Hemiplegic migraine**  
Migraine with aura including motor weakness.
- 8A80.1Y** **Other specified migraine with aura**
- 8A80.1Z** **Migraine with aura, unspecified**
- 8A80.2** **Chronic migraine**  
Headache occurring on 15 or more days per month for more than three months, which, on at least eight days per month, has the features of migraine headache and is not associated with medication overuse.
- 8A80.3** **Complications related to migraine**
- 8A80.30** **Status migrainosus**  
A debilitating migraine attack lasting for more than 72 hours
- 8A80.3Y** **Other specified complications related to migraine**
- 8A80.4** **Cyclic vomiting syndrome**  
Recurrent episodic attacks, usually stereotypical in the individual patient, of vomiting and intense nausea. Attacks are associated with pallor and lethargy. There is complete resolution of symptoms between attacks.
- 8A80.Y** **Other specified migraine**
- 8A80.Z** **Migraine, unspecified**
- 8A81** **Tension-type headache**  
A primary and highly prevalent headache disorder, in most cases episodic. Attacks of highly variable frequency and duration are characterised by mild-to-moderate headache without associated symptoms, although pericranial tenderness may be present. In a minority of cases the disorder evolves, with increasingly frequent headache and sometimes loss of episodicity.
- Exclusions:** New daily-persistent headache (8A83)
- 8A81.0** **Infrequent episodic tension-type headache**  
Infrequent episodes of headache, typically bilateral, pressing or tightening in quality and of mild to moderate intensity, lasting minutes to days. The pain does not worsen with routine physical activity and is not associated with nausea, but photophobia or phonophobia may be present.
- 8A81.1** **Frequent episodic tension-type headache**  
Frequent episodes of headache, typically bilateral, pressing or tightening in quality and of mild to moderate intensity, lasting minutes to days. The pain does not worsen with routine physical activity and is not associated with nausea, but photophobia or phonophobia may be present.

- 8A81.2      Chronic tension-type headache**  
A disorder evolving from frequent episodic tension-type headache, with daily or very frequent episodes of headache, typically bilateral, pressing or tightening in quality and of mild to moderate intensity, lasting hours to days, or unremitting. The pain does not worsen with routine physical activity, but may be associated with mild nausea, photophobia or phonophobia.
- 8A81.Y      Other specified tension-type headache**
- 8A81.Z      Tension-type headache, unspecified**
- 8A82      Trigeminal autonomic cephalgias**  
A group of related primary headache disorders essentially characterised by unilateral headache and trigeminal autonomic activation. In most but not all of these disorders, the headache is short-lasting and very frequently recurring, but sometimes remitting for long periods.
- 8A83      Other primary headache disorder**  
A group of clinically heterogeneous headache disorders, believed to be primary. Although largely unrelated, they fall into four categories: headaches associated with physical exertion; headaches attributed to direct physical but innocuous stimuli; epicranial headaches; and other miscellaneous primary headache disorders.
- 8A84      Secondary headache**  
**Coding Note:** Code also the causing condition
- 8A84.0      Acute headache associated with traumatic injury to the head**  
Headache of less than three months' duration associated with traumatic injury to the head.
- 8A84.1      Persistent headache associated with traumatic injury to the head**  
Headache of greater than three months' duration caused by traumatic injury to the head.
- 8A84.Y      Other specified secondary headache**  
**Coding Note:** Code also the causing condition
- 8A84.Z      Secondary headache, unspecified**
- 8A85      Painful cranial neuropathies or other facial pains**  
A group of disorders characterised by head and/or facial pain, presenting variably as a neuralgia or as pain of neuropathic or central origin.  
**Coded Elsewhere:** Trigeminal neuralgia (8B82.0)  
Burning mouth syndrome (DA0F.0)
- 8A8Y      Other specified headache disorders**
- 8A8Z      Headache disorders, unspecified**

## Cerebrovascular diseases (8B00-8B2Z)

This is a group of brain dysfunctions related to disease of the blood vessels supplying the brain. This includes "stroke", which includes the following entities: Intracerebral haemorrhage; Subarachnoid haemorrhage; Cerebral ischaemic stroke; and Stroke not known if ischaemic or haemorrhagic.

**Inclusions:** Cerebrovascular disease with mention of hypertension

**Exclusions:** Intracranial injury (NA07)

**Coded Elsewhere:** Asymptomatic stenosis of intracranial or extracranial artery (BD55)

Asymptomatic occlusion of intracranial or extracranial artery (BD56)

### Intracranial haemorrhage (8B00-8B0Z)

**Coded Elsewhere:** Intracranial nontraumatic haemorrhage of fetus or newborn (KA82)

**8B00**

#### **Intracerebral haemorrhage**

Acute neurological dysfunction caused by haemorrhage within the brain parenchyma or in the ventricular system.

**Coding Note:** Code also the causing condition

**Exclusions:** sequelae of intracerebral haemorrhage (8B25.1)

Traumatic intracerebral haemorrhage (NA07.1)

**Coded Elsewhere:** Intracerebral nontraumatic haemorrhage of fetus or newborn (KA82.4)

**8B00.0**

#### **Deep hemispheric haemorrhage**

Acute neurological dysfunction caused by haemorrhage localised to the subcortex, basal ganglia, and the diencephalon (thalamus).

**Coding Note:** Code also the causing condition

**Inclusions:** Deep intracerebral haemorrhage

**8B00.1**

#### **Lobar haemorrhage**

Acute neurological dysfunction caused by haemorrhage within the lobes of the brain and outside the subcortex, basal ganglia, and the diencephalon (thalamus).

**Coding Note:** Code also the causing condition

**Inclusions:** Cerebral lobe haemorrhage

Superficial intracerebral haemorrhage

**8B00.2**

#### **Brainstem haemorrhage**

**Coding Note:** Code also the causing condition

**8B00.3**

#### **Cerebellar haemorrhage**

**Coding Note:** Code also the causing condition

**Coded Elsewhere:** Cerebellar nontraumatic, hemispheres or vermis or posterior fossa haemorrhage of fetus or newborn (KA82.6)

- 8B00.4**      **Intraventricular haemorrhage without parenchymal haemorrhage**  
                   Acute neurological dysfunction caused by haemorrhage within the ventricular system, without a component of parenchymal haemorrhage.
- Coding Note:** Code also the causing condition
- 8B00.5**      **Haemorrhage of multiple sites**  
                   Acute neurological dysfunction caused by haemorrhage of multiple sites, within the brain parenchyma, or in the ventricular system combined with haemorrhage in the brain parenchyma.
- Coding Note:** Code also the causing condition
- 8B00.Z**      **Intracerebral haemorrhage, site unspecified**  
**Coding Note:** Code also the causing condition
- 8B01**      **Subarachnoid haemorrhage**  
                   Acute neurological dysfunction caused by subarachnoid haemorrhage.  
**Exclusions:**    sequelae of subarachnoid haemorrhage (8B25.2)  
                   Traumatic subarachnoid haemorrhage (NA07.7)  
**Coded Elsewhere:** Subarachnoid nontraumatic haemorrhage of fetus or newborn (KA82.5)
- 8B01.0**      **Aneurysmal subarachnoid haemorrhage**  
**Inclusions:**    ruptured cerebral aneurysm NOS
- 8B01.1**      **Non-aneurysmal subarachnoid haemorrhage**
- 8B01.2**      **Subarachnoid haemorrhage not known if aneurysmal or non-aneurysmal**
- 8B02**      **Nontraumatic subdural haemorrhage**  
**Coding Note:** This entity is not part of the definition of stroke.  
**Exclusions:**    Traumatic subdural haemorrhage (NA07.6)  
**Coded Elsewhere:** Subdural nontraumatic haemorrhage of fetus or newborn (KA82.7)
- 8B03**      **Nontraumatic epidural haemorrhage**  
**Coding Note:** This entity is not part of the definition of stroke.
- 8B0Z**      **Intracranial haemorrhage, unspecified**

Cerebral ischaemia (8B10-8B1Z)

**Coded Elsewhere:** Neonatal cerebral ischaemia (KB00)

**8B10**

**Transient ischaemic attack**

Transient episode of focal neurological dysfunction caused by focal brain ischemia without acute infarction in the clinically relevant area of the brain or transient monocular visual loss due to retinal ischemia. Symptoms should resolve completely within 24 hours.

**Exclusions:** Neonatal cerebral ischaemia (KB00)

Transient global amnesia (MB21.12)

**8B10.0**

**Amaurosis fugax**

A transient episode of acute visual dysfunction caused by retinal ischaemia. Symptoms should resolve completely within 24 hours.

**Coding Note:** Code also the causing condition

**8B10.Y**

**Other specified transient ischaemic attack**

**8B10.Z**

**Transient ischaemic attack, unspecified**

**8B11**

**Cerebral ischaemic stroke**

Acute focal neurological dysfunction caused by focal infarction at single or multiple sites of the brain. Evidence of acute infarction may come either from a) symptom duration lasting more than 24 hours, or b) neuroimaging or other technique in the clinically relevant area of the brain. The term does not include infarction of the retina.

**Coding Note:** When the cause of ischaemic stroke is known, code to the cause. When the cause of ischaemic stroke is not known, code to 8B11.5-. When the cause of stroke is not known, code to 8B20 Stroke not known if ischaemic or haemorrhagic.

**Exclusions:** sequelae of cerebral infarction (8B25.0)

Silent cerebral infarct (8B21.0)

**8B11.0**

**Cerebral ischaemic stroke due to extracranial large artery atherosclerosis**

**Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.

**8B11.1**

**Cerebral ischaemic stroke due to intracranial large artery atherosclerosis**

**Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.

**8B11.2**

**Cerebral ischaemic stroke due to embolic occlusion**

**Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.

**8B11.20**

**Cerebral ischaemic stroke due to cardiac embolism**

**Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.

- 8B11.21** Cerebral ischaemic stroke due to aortic arch embolism
- Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.
- 8B11.22** Cerebral ischaemic stroke due to paradoxical embolism  
This is a sudden loss of brain function due to a lack of adequate blood flow. It is the result of a thromboembolism – a blood clot that detached and travelled through the blood vessels – that originated in the venous system. Because of a heart defect, it passes through to the systemic circulation system, instead of becoming lodged in the lungs.
- Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.
- 8B11.2Y** Cerebral ischaemic stroke due to other specified embolic occlusion
- Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.
- 8B11.2Z** Cerebral ischaemic stroke due to embolic occlusion, unspecified
- Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.
- 8B11.3** **Cerebral ischaemic stroke due to small artery occlusion**  
This is a sudden loss of brain function due to a lack of adequate blood flow of the small arteries.
- Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.
- 8B11.4** **Cerebral ischaemic stroke due to other known cause**
- Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.
- 8B11.40** Cerebral ischaemic stroke due to global hypoperfusion with watershed infarct  
This is a sudden loss of brain function due to a lack of adequate blood flow. It occurs in association with a low state of blood flow to the brain. The "watershed" regions of the brain, regions that are supplied by the branching ends of two large arteries, are particularly sensitive to low oxygen supply when arteries do not maintain the appropriate tension.
- Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.
- 8B11.41** Cerebral ischaemic stroke due to other non-atherosclerotic arteriopathy  
This is a sudden loss of brain function due to a lack of adequate blood flow. It is due to a disorder of the arteries, but it is neither associated with atherosclerosis nor classified elsewhere.
- Coding Note:** If an additional code is used for anatomy, the artery affected by the stroke should be selected.

<b>8B11.42</b>	Cerebral ischaemic stroke due to hypercoagulable state This is a sudden loss of brain function due to a lack of adequate blood flow. It is associated with a blood clot and a risk factor that increases blood clotting.
<b>Coding Note:</b>	If an additional code is used for anatomy, the artery affected by the stroke should be selected.
<b>8B11.43</b>	Cerebral ischaemic stroke in association with subarachnoid haemorrhage
<b>Coding Note:</b>	If an additional code is used for anatomy, the artery affected by the stroke should be selected.
<b>8B11.44</b>	Cerebral ischemic stroke from dissection
<b>Coding Note:</b>	If an additional code is used for anatomy, the artery affected by the stroke should be selected.
<b>8B11.5</b>	<b>Cerebral ischaemic stroke of unknown cause</b> This is a sudden loss of brain function due to a lack of adequate blood flow. It is of an uncertain nature, and approximately 30% of examined events fall into this category.
<b>Coding Note:</b>	If an additional code is used for anatomy, the artery affected by the stroke should be selected.
	<b>Inclusions:</b> cryptogenic stroke
<b>8B11.50</b>	Cerebral ischaemic stroke due to unspecified occlusion or stenosis of extracranial large artery This is a sudden loss of brain function due to a lack of adequate blood flow of the large extracranial arteries.
<b>Coding Note:</b>	If an additional code is used for anatomy, the artery affected by the stroke should be selected.
	<b>Exclusions:</b> Cerebral ischaemic stroke due to embolic occlusion (8B11.2) Cerebral ischaemic stroke due to other known cause (8B11.4) Cerebral ischaemic stroke due to extracranial large artery atherosclerosis (8B11.0)
<b>8B11.51</b>	Cerebral ischaemic stroke due to unspecified occlusion or stenosis of intracranial large artery This is a sudden loss of brain function due to a lack of adequate blood flow of the large intracranial arteries.
<b>Coding Note:</b>	If an additional code is used for anatomy, the artery affected by the stroke should be selected.
	<b>Exclusions:</b> Cerebral ischaemic stroke due to intracranial large artery atherosclerosis (8B11.1) Cerebral ischaemic stroke due to embolic occlusion (8B11.2) Cerebral ischaemic stroke due to other known cause (8B11.4)
<b>8B11.5Z</b>	Cerebral ischaemic stroke, unspecified
<b>Coding Note:</b>	If an additional code is used for anatomy, the artery affected by the stroke should be selected.

<b>8B1Y</b>	<b>Other specified cerebral ischaemia</b>
<b>8B1Z</b>	<b>Cerebral ischaemia, unspecified</b>
<b>8B20</b>	<b>Stroke not known if ischaemic or haemorrhagic</b> Fulfils criteria for stroke in acute symptoms of focal brain injury that have lasted 24 hours or more (or led to death before 24 hours), but subtype of stroke (ischemic or haemorrhagic) has not been determined by neuroimaging or other techniques.  <b>Exclusions:</b> sequelae of stroke (8B25.4)
<b>8B21</b>	<b>Cerebrovascular disease with no acute cerebral symptom</b> Silent cerebral infarct is defined as an infarct demonstrated on neuroimaging or at autopsy that has not caused acute dysfunction of the brain (i.e. does not qualify for diagnoses of TIA or cerebral ischemic stroke). The term "silent" denotes lack of acute symptoms.  <b>Exclusions:</b> Transient ischaemic attack (8B10) Cerebral ischaemic stroke (8B11) Intracerebral haemorrhage (8B00) Subarachnoid haemorrhage (8B01) Stroke not known if ischaemic or haemorrhagic (8B20)
<b>8B21.0</b>	<b>Silent cerebral infarct</b> Cerebral infarct that has not caused acute focal dysfunction of the brain.
<b>8B21.1</b>	<b>Silent cerebral microbleed</b> Small bleeding in the brain parenchyma that has not caused acute focal dysfunction of the brain.
<b>8B21.Y</b>	<b>Other specified cerebrovascular disease with no acute cerebral symptom</b>
<b>8B21.Z</b>	<b>Cerebrovascular disease with no acute cerebral symptom, unspecified</b>
<b>8B22</b>	<b>Certain specified cerebrovascular diseases</b> Specified other abnormalities of intracranial or extracranial arteries or veins. Entities in this section may be used in combination with other diagnostic codes in this block. Several of the entities may each cause different types of cerebrovascular disease such as TIA, cerebral ischemic stroke or intracerebral haemorrhage; may be associated with other clinical syndromes; or may be asymptomatic (not having caused acute focal dysfunction of the brain).  Section on Intracranial vascular malformations has been much revised compared to ICD-10 based on major scientific progress in this field.  Cerebral vasoconstriction syndromes and Posterior reversible encephalopathy are considered to be separate entities (as vasoconstriction is not always present in the latter).  "Progressive vascular leukoencephalopathy (Binswanger's disease)" has been removed as a separate entity.  <b>Exclusions:</b> Late effects of cerebrovascular disease (8B25)

- 8B22.0** **Dissection of cerebral arteries**  
**Exclusions:** ruptured cerebral arteries (8B01)
- 8B22.1** **Cerebral venous thrombosis**  
Thrombosis (blood clot) of the cerebral venous sinuses, which drain blood from brain  
**Exclusions:** Cerebral ischaemic stroke (8B11)  
Cerebral venous thrombosis in the puerperium (JB41.3)  
**Coded Elsewhere:** Cerebral venous thrombosis in pregnancy (JA61.5)  
Neonatal cerebral sinovenous thrombosis (KB00.1)
- 8B22.2** **Cerebral vasoconstriction syndromes**  
Cerebral vasoconstriction syndrome is characterised by severe headaches, with or without other acute neurological symptoms, and diffuse segmental constriction of cerebral arteries
- 8B22.3** **Isolated cerebral amyloid angiopathy**  
Cerebral amyloid angiopathy is characterised by the progressive accumulation of amyloid protein in the walls of small-to-medium-sized arteries and arterioles predominantly located in the leptomeningeal space, the cortex, and, to a lesser extent, also in the capillaries and veins.
- 8B22.4** **Intracranial vascular malformation**
- 8B22.40** Arteriovenous malformation of cerebral vessels
- 8B22.41** Cerebral cavernous malformation  
Cerebral cavernomas, still called cavernous angiomas, angioma cavernosum or cavernous hemangiomas, are vascular malformations in the brain that are asymptomatic or lead to seizures and/or cerebral haemorrhages. These are often found in an inheritable disorder with autosomal dominant inheritance.
- 8B22.42** Dural arteriovenous fistula  
Dural arteriovenous fistulas are formed by an abnormal connection between arteries within the dura mater and veins that normally drain the brain.
- 8B22.43** Carotid cavernous fistula  
A carotid-cavernous fistula results from an abnormal communication between the arterial and venous systems within the cavernous sinus in the skull.
- 8B22.4Y** Other specified intracranial vascular malformation
- 8B22.4Z** Intracranial vascular malformation, unspecified
- 8B22.5** **Cerebral aneurysm, nonruptured**  
**Exclusions:** Congenital cerebral nonruptured aneurysm (LA90.42)  
ruptured cerebral aneurysm (8B01.0)
- 8B22.6** **Familial cerebral saccular aneurysm**  
These are pouch-like expansions of arteries inside the skull that are familial.

<b>8B22.7</b>	<b>Cerebral arteritis, not elsewhere classified</b>
<b>8B22.70</b>	<p>Primary cerebral arteritis</p> <p>Primary cerebral arteritis (or "angiitis") results from inflammation and destruction of central nervous system (CNS) vessels without evidence of vasculitis outside the CNS</p>
<b>8B22.7Y</b>	Other specified cerebral arteritis, not elsewhere classified
<b>8B22.7Z</b>	Cerebral arteritis, not elsewhere classified, unspecified
<b>8B22.8</b>	<b>Hypertensive encephalopathy</b>
<b>8B22.9</b>	<b>Migraine-induced stroke</b>
<b>8B22.A</b>	<p><b>Subclavian steal syndrome</b></p> <p>Retrograde blood flow in the vertebral artery in the setting of ipsilateral proximal subclavian artery stenosis or occlusion leading to symptoms of basilar insufficiency.</p>
<b>8B22.B</b>	<p><b>Moyamoya syndrome</b></p> <p>A cerebrovascular disease caused by stenotic arteries at the base of the brain in the basal ganglia. Moyamoya, meaning "puff of smoke" refers to the appearance of the anastomotic vessel network formed at the base of the brain distal to the circle of Willis to compensate for the blockage.</p>
<b>8B22.C</b>	<p><b>Hereditary cerebrovascular diseases</b></p> <p>Hereditary cerebrovascular disease does not include effects from abnormalities due other vascular diseases which are independent of the nervous system.</p>
<b>8B22.C0</b>	<p>CADASIL - [cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy] syndrome</p> <p>CADASIL is the acronym for Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. CADASIL is a genetic disease transmitted in an autosomal dominant pattern. It is associated with ischemic stroke, migraine, dementia, psychological disturbances.</p>
<b>8B22.C1</b>	<p>CARASIL - [cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy] syndrome</p> <p>CARASIL is the acronym for cerebral autosomal recessive arteriopathy with subcortical ischaemic strokes and leukoencephalopathy.</p>
<b>8B22.CY</b>	Other specified hereditary cerebrovascular diseases
<b>8B22.CZ</b>	Hereditary cerebrovascular diseases, unspecified
<b>8B22.Y</b>	<b>Other specified cerebrovascular disease</b>

**8B23****Cerebrovascular abnormalities**

Cerebrovascular abnormalities in diseases that also involve other parts of the vascular system than intracranial and extracranial arteries, or other body systems than the nervous system.

**Coding Note:**

Code also the causing condition

**Coded Elsewhere:** Vein of Galen aneurysm (LA90.20)

Cerebral arteritis in infectious or parasitic diseases (8B22.7Y)

**8B24****Hypoxic-ischaemic encephalopathy**

Brain damage due to hypoxia-ischemia: Previous term Anoxic brain damage has been changed. The new term is now widely accepted, and better describes the pathophysiology, i.e., the combination of complete and incomplete transitory global cerebral ischemia together with a combination of anoxia and hypoxia. In a surviving patient, pure anoxic encephalopathy is very uncommon.

**Exclusions:**

complicating: surgical and medical care (NE80-NE8Z)

neonatal anoxia (KB21)

Central nervous system complications of anaesthesia during pregnancy (JA67.2)

complicating: abortion or ectopic or molar pregnancy (JA00-JA0Z)

Central nervous system complications of anaesthesia during labour or delivery (JB0C.3)

Central nervous system complications of anaesthesia during the puerperium (JB43.2)

**Coded Elsewhere:** Hypoxic ischaemic encephalopathy of newborn (KB04)

**8B24.0****Anoxic-ischaemic encephalopathy****8B24.Y****Other specified hypoxic-ischaemic encephalopathy****8B24.Z****Hypoxic-ischaemic encephalopathy, unspecified****8B25****Late effects of cerebrovascular disease**

Effects of cerebrovascular disease 1 month or later after the onset of the disease. Codes for acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.

**Coding Note:**

Use of the code "Late effects of cerebrovascular disease" requires that there are residual (still persisting) symptoms or signs after a previous cerebrovascular event. Codes for neurological symptoms may be added. Code first, the specific residual condition(s) resulting from a previous cerebrovascular event.

Codes for acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.

<b>8B25.0</b>	<b>Late effects of cerebral ischemic stroke</b> Late effects of cerebral ischaemic stroke 1 month or later after the onset of the disease. Codes for the acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.
<b>Coding Note:</b>	Use of the code "Late effects of cerebrovascular disease" requires that there are residual (still persisting) symptoms or signs after a previous cerebrovascular event. Codes for neurological symptoms may be added. Code first, the specific residual condition(s) resulting from a previous cerebrovascular event.  Codes for acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.
<b>8B25.1</b>	<b>Late effects of intracerebral haemorrhage</b>
<b>Coding Note:</b>	Use of the code "Late effects of cerebrovascular disease" requires that there are residual (still persisting) symptoms or signs after a previous cerebrovascular event. Codes for neurological symptoms may be added. Code first, the specific residual condition(s) resulting from a previous cerebrovascular event.  Codes for acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.
<b>8B25.2</b>	<b>Late effects of subarachnoid haemorrhage</b> Late effects of non-traumatic subarachnoid haemorrhage 1 month or later after the onset of the disease. Codes for acute haemorrhage should be exclusively used for the acute haemorrhage and immediately related hospitalisation episodes.
<b>Coding Note:</b>	Use of the code "Late effects of cerebrovascular disease" requires that there are residual (still persisting) symptoms or signs after a previous cerebrovascular event. Codes for neurological symptoms may be added.  Code first, the specific residual condition(s) resulting from a previous cerebrovascular event.  Codes for acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.
<b>8B25.3</b>	<b>Late effects of other nontraumatic intracranial haemorrhage</b> Late effects of other non-traumatic intracranial haemorrhage 1 month or later after the onset of the disease. Codes for acute episode should be exclusively used for the acute haemorrhage and immediately related hospitalisation episodes.
<b>Coding Note:</b>	Use of the code "Late effects of cerebrovascular disease" requires that there are residual (still persisting) symptoms or signs after a previous cerebrovascular event. Codes for neurological symptoms may be added.  Code first, the specific residual condition(s) resulting from a previous cerebrovascular event.  Codes for acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.

<b>8B25.4</b>	<b>Late effects of stroke not known if ischaemic or haemorrhagic</b> Late effects occurring 1 month or later after the onset of the disease. Codes for acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.
<b>Coding Note:</b>	Use of the code "Late effects of cerebrovascular disease" requires that there are residual (still persisting) symptoms or signs after a previous cerebrovascular event. Codes for neurological symptoms may be added.  Code first, the specific residual condition(s) resulting from a previous cerebrovascular event.  Codes for acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.
<b>8B25.Y</b>	<b>Late effects of other specified cerebrovascular disease</b>
<b>Coding Note:</b>	Use of the code "Late effects of cerebrovascular disease" requires that there are residual (still persisting) symptoms or signs after a previous cerebrovascular event. Codes for neurological symptoms may be added. Code first, the specific residual condition(s) resulting from a previous cerebrovascular event.  Codes for acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.
<b>8B25.Z</b>	<b>Late effects of cerebrovascular disease, unspecified</b>
<b>Coding Note:</b>	Use of the code "Late effects of cerebrovascular disease" requires that there are residual (still persisting) symptoms or signs after a previous cerebrovascular event. Codes for neurological symptoms may be added. Code first, the specific residual condition(s) resulting from a previous cerebrovascular event.  Codes for acute stroke should be exclusively used for the acute stroke and immediately related hospitalisation episodes.
<b>8B26</b>	<b>Vascular syndromes of brain in cerebrovascular diseases</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8B26.0</b>	<b>Brainstem stroke syndrome</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8B26.1</b>	<b>Cerebellar stroke syndrome</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8B26.2</b>	<b>Middle cerebral artery syndrome</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8B26.3</b>	<b>Anterior cerebral artery syndrome</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8B26.4</b>	<b>Posterior cerebral artery syndrome</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8B26.5</b>	<b>Lacunar syndromes</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8B26.50</b>	Pure motor lacunar syndrome

<b>8B26.51</b>	Pure sensory lacunar syndrome
<b>8B26.5Y</b>	Other specified lacunar syndromes
<b>Coding Note:</b>	Code also the causing condition
<b>8B26.5Z</b>	Lacunar syndromes, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>8B26.Y</b>	<b>Other specified vascular syndromes of brain in cerebrovascular diseases</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8B26.Z</b>	<b>Vascular syndromes of brain in cerebrovascular diseases, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8B2Z</b>	<b>Cerebrovascular diseases, unspecified</b>

### Spinal cord disorders excluding trauma (8B40-8B4Z)

**Coded Elsewhere:** Dural arteriovenous fistula (8B22.42)

Intervertebral disc degeneration (FA80)

<b>8B40</b>	<b>Cauda equina syndrome</b>
-------------	------------------------------

<b>8B41</b>	<b>Myelitis</b>
-------------	-----------------

**Coding Note:** Code also the causing condition

<b>8B42</b>	<b>Myelopathy</b>
-------------	-------------------

**Coding Note:** Code also the causing condition

**Coded Elsewhere:** Myelopathy due to nutritional deficiency (8D40.Y)

<b>8B43</b>	<b>Non-compressive vascular myelopathies</b>
-------------	--

Non-compressive spinal cord syndromes due to arterial or venous circulation anomalies.

<b>8B43.0</b>	<b>Acute arterial infarction of the spinal cord</b>
---------------	---

Acute arterial infarction of the spinal cord is due to occlusion of the anterior or posterior spinal arteries or their branches. Classical anterior spinal artery occlusion in the watershed zone in the lower cervical cord causes a specific cord syndrome with sparing of the posterior segment of the cord. Associated aortic atherosclerotic disease as well as dissection should not be overlooked.

<b>8B43.1</b>	<b>Acute venous infarction of the spinal cord</b>
---------------	---

Loss of blood flow in the venous system, leading to spinal cord infarction, commonly associated with dural fistula and dural arteriovenous malformation.

<b>8B43.2</b>	<b>Chronic venous infarction of the spinal cord</b>
---------------	---

Loss of blood flow to the spinal cord due to venous flow abnormality, leading to spinal cord infarction development over a longer period of time.

**8B43.Y**      **Other specified non-compressive vascular myelopathies**

**8B43.Z**      **Non-compressive vascular myelopathies, unspecified**

**8B44**      **Degenerative myelopathic disorders**

**Coded Elsewhere:** Friedreich ataxia (8A03.10)

Primary lateral sclerosis (8B60.4)

**8B44.0**      **Hereditary spastic paraplegia**

Hereditary spastic paraplegias (HSP) comprise a genetically and clinically heterogeneous group of neurodegenerative disorders characterised by varying degrees of lower limb spasticity, pyramidal weakness, hyperreflexia and hypertonic bladder involvement. Clinically, HSPs can be divided into two main groups: uncomplicated (pure) and complicated (complex) forms depending on the presence of other neurological features including ataxia, peripheral neuropathy, cognitive impairment, epilepsy, amyotrophy, retinopathy, deafness, ichthyosis and extrapyramidal involvement, in addition to spastic paraparesis. Pure HSPs are characterised by slowly progressive lower extremity spasticity and weakness, often associated with hypertonic urinary disturbances, mild reduction of lower extremity vibration sense and, occasionally, of joint position sensation. Complex HSP forms are characterised by the presence of additional neurological or non-neurological features. A positive family history particularly in autosomal dominant cases is often but not always present. The diagnosis may be aided by neuroimaging and genetic testing.

**Coded Elsewhere:** Spastic paraplegia - nephritis - deafness (LD2H.Y)

**8B44.00**      Autosomal dominant hereditary spastic paraplegia

**8B44.01**      Autosomal recessive hereditary spastic paraplegia

**8B44.02**      X-linked hereditary spastic paraplegia

**8B44.0Y**      Other specified hereditary spastic paraplegia

**8B44.0Z**      Hereditary spastic paraplegia, unspecified

**8B44.Y**      **Other specified degenerative myelopathic disorders**

**8B44.Z**      **Degenerative myelopathic disorders, unspecified**

**8B4Y**      **Other specified spinal cord disorders excluding trauma**

**8B4Z**      **Spinal cord disorders excluding trauma, unspecified**

## **Motor neuron diseases or related disorders (8B60-8B6Z)**

A group of genetic disorders characterised by progressive weakness secondary to degeneration of the lower motor neurons

**8B60**

### **Motor neuron disease**

Motor neuron disease is a neurodegenerative disorder of undetermined etiology, characterised by degeneration of upper motor neurons (cortical Betz cells and corticospinal tract) or lower motor neurons (ventral horns of spinal cord and cranial nerve motor nuclei) or both. Features of involvement of lower motor neurons (LMN) are atrophy, weakness, fasciculations, hypotonia, decreased or absent deep tendon reflexes. Features of involvement of upper motor neurons (UMN) are spasticity, exaggerated deep tendon reflexes, and extensor plantar responses. Depending on the site of onset and the presence of UMN or LMN features or both, MND has varying patterns and distributions of signs and symptoms.

**Coded Elsewhere:** Brown-Vialetto-van Laere syndrome (LD2H.Y)

**8B60.0**

### **Amyotrophic lateral sclerosis**

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal disorder in which progressive signs of LMN and UMN degeneration are seen within one or more of the four regions: bulbar, cervical, thoracic and lumbosacral. Electrophysiological studies may be required to confirm lower motor neuron degeneration and to exclude alternative causes. Neuroimaging may be performed to exclude other causes, which might explain the clinical and electrophysiological features. Familial ALS (FALS) of autosomal dominant inheritance constitutes 5 to 10% of ALS. The clinical profile of FALS and sporadic ALS is similar. Mutations in the C9ORF72 and Cu/Zn superoxide dismutase (SOD1) genes constitute 50-60% of FALS.

**8B60.1**

### **Progressive bulbar palsy**

Progressive bulbar palsy (PBP) is a variant of amyotrophic lateral sclerosis that initially presents with symptoms of bulbar weakness such as dysarthria and dysphagia. Symptoms may remain relatively confined to the bulbar region. PBP more commonly affects females than males. Patients typically progress to develop limb weakness and features consistent with more typical ALS at a later stage of disease.

**8B60.2**

### **Progressive pseudobulbar palsy**

Spastic speech, difficulty in swallowing, emotional lability, brisk jaw jerk, release reflexes such as palmonental reflex due to involvement of craniobulbar tracts are the common features of progressive pseudobulbar palsy. Usually mild lower motor neuron signs observed in progressive bulbar palsy may also co-exist or may develop during the progression of the disorder.

- 8B60.3** **Progressive muscular atrophy**  
In progressive muscular atrophy, lower motor neuron signs in limb and trunk muscles are present without upper motor neuron involvement. Over time, some patients may progress to develop upper motor neuron signs, of which pathological evidence is common even in patients who never displayed clinical upper motor neuron signs, suggesting that progressive muscular atrophy is a form of ALS.
- Exclusions:** Fazio-Londe syndrome (8B60)  
Amyotrophic lateral sclerosis (8B60.0)
- 8B60.4** **Primary lateral sclerosis**  
Primary lateral sclerosis (PLS) is a rare motor neuron disease variant which presents with slowly progressive UMN signs, such as spastic gait, brisk deep tendon jerks, and extensor plantar responses. Onset is most commonly with spastic paraparesis, but patients typically progress to develop upper limb and bulbar involvement. The characteristic feature of PLS is the complete absence of involvement of lower motor neuron involvement. When LMN signs develop during the course of the disease, the diagnosis will change to ALS, and they are considered a spectrum of the same disorder.
- 8B60.5** **Amyotrophic lateral sclerosis-Plus**  
This category represents a group of disorders with motor symptoms of ALS and superimposed features of dysfunction of other neurological systems, such as extrapyramidal, cerebellar or cognitive dysfunction.
- 8B60.6** **Monomelic amyotrophy**  
Atrophy and weakness restricted to one upper or lower limb, onset in the second or third decade, male predominance, and sporadic occurrence are characteristic features of MMA. Other typical features include: insidious onset of lower motor neuron signs due to anterior horn cell involvement, absence of upper motor neuron signs, slow progression followed by stabilization within a few years,, and a benign symptomatic disease course. MMA is particularly prevalent in Asia although it is encountered worldwide.
- 8B60.7** **Madras type motor neuron disease**
- 8B60.Y** **Other specified motor neuron disease**
- 8B60.Z** **Motor neuron disease, unspecified**
- 8B61** **Spinal muscular atrophy**  
Spinal muscular atrophy (SMA) is a progressive disorder with loss of anterior horn cells leading to muscle weakness and wasting. The weakness is typically symmetrical. Typically, upper motor neuron signs are absent and there is no sensory deficit. Feeding and swallowing can be affected, and involvement of respiratory muscles may occur. SMA is an autosomal recessive disorder linked to chromosome 5q13 and the disorder is caused by deletion or mutation of SMN 1 (spinal motor neuron 1) gene. The four types of SMA I, II, III and IV are categorised based on the age of onset of the disease and the ability to achieve motor milestones.

- 8B61.0 Infantile spinal muscular atrophy, Type I**  
In SMA type 1, onset of weakness may be prenatal (decreased fetal movements toward the end of pregnancy) or within the first six months of life. Infants demonstrate a characteristic frog position with the thighs externally rotated and abducted and the knees flexed (floppy infant). Bulbar weakness causes feeding difficulty. Children are never able to sit without support, and the average survival is 9 months; survival beyond 2 years is rare.
- 8B61.1 Late infantile spinal muscular atrophy, Type II**  
In SMA type 2, muscle weakness is seen between the ages of 6 to 18 months. The child can sit unsupported, but cannot stand or walk independently. Death usually occurs between 2 years of age and young adulthood.
- 8B61.2 Juvenile form spinal muscular dystrophy, Type III**  
In SMA type 3, weakness of muscles is seen after 18 months of age. The child is able to sit and stand independently. There is a limb girdle-type of distribution of weakness causing waddling gait, falls, and difficulty with running. The ability to walk may be lost, requiring a wheelchair as the disease progresses. The life expectancy may be normal.
- 8B61.3 Adult onset spinal muscular atrophy, Type IV**  
In SMA type 4 weakness, most commonly develops after 35 years of age (less commonly between 18 to 35 years old). Weakness of proximal muscles is more prominent in the legs than in the arms. Insidious onset and very slow progression are the characteristic features, and life span is normal.
- 8B61.4 Localised spinal muscular atrophy**  
This category comprises a group of disorders with a varied pattern of weakness and autosomal dominant or X-linked recessive inheritance with specific genetic profiles.
- 8B61.Y Other specified spinal muscular atrophy**
- 8B61.Z Spinal muscular atrophy, unspecified**
- 8B62 Post polio progressive muscular atrophy**  
The diagnostic criteria for Post-polio progressive muscular atrophy (PPMA) are: a credible history of poliomyelitis with partial recovery of function, a minimum 10-year period of stabilization, and the subsequent development of progressive muscle weakness. Symptoms of weakness, atrophy, and fatigue of previously affected muscles may be seen. These symptoms may also be newly noted in muscles that were apparently unaffected by the poliomyelitis episode. Muscle cramps and fasciculations may accompany the new weakness.
- Inclusions:** Post polio myelitic syndrome
- 8B6Y Other specified motor neuron diseases or related disorders**
- 8B6Z Motor neuron diseases or related disorders, unspecified**

## Disorders of nerve root, plexus or peripheral nerves (8B80-8C4Z)

- Exclusions:**
- neuritis NOS (FB56)
  - Injury of cranial nerves (NA04)
  - Injury of nerves or spinal cord at neck level (NA30-NA4Z)
  - Injury of nerves or lumbar spinal cord at abdomen, lower back or pelvis level (NB60-NB7Z)
  - Injury of nerves at shoulder or upper arm level (NC14)
  - Injury of nerves at forearm level (NC34)
  - Injury of nerves at wrist or hand level (NC55)
  - Injury of nerves at hip or thigh level (NC74)
  - Injury of nerves at lower leg level (NC94)
  - Injury of nerves at ankle or foot level (ND15)
- Coded Elsewhere:**
- Neuromyotonia (8C71.4)
  - Disorder of the optic nerve (9C40)
  - Ocular motor nerve palsies (9C81)
  - Infections of the peripheral nerves (1D0Y)

## Disorders of cranial nerves (8B80-8B8Z)

- Exclusions:**
- Disorders of acoustic nerve (AB72)
  - Disorder of the optic nerve (9C40)
- Coded Elsewhere:**
- Acute neuropathy of cranial nerve due to zoster (1E91.4)
  - Ocular motor nerve palsies (9C81)

**8B80**

### Disorders of olfactory nerve

- Inclusions:**
- Disorder of 1st cranial nerve
- Exclusions:**
- Idiopathic anosmia (MB41.0)
  - Idiopathic parosmia (MB41.1)
- Coded Elsewhere:**
- Injury of olfactory nerve (NA04.0)

**8B81**

### Disorders of vestibulocochlear nerve

- Coded Elsewhere:**
- Vestibular neuritis (AB30.0)
  - Meniere disease (AB31.0)
  - Acquired hearing impairment (AB51)
  - Acute vestibular syndrome (AB30)
  - Episodic vestibular syndrome (AB31)
  - Chronic vestibular syndrome (AB32)

**8B81.0**      **Brainstem lesion**

**8B81.Y**      **Other specified disorders of vestibulocochlear nerve**

**8B81.Z**      **Disorders of vestibulocochlear nerve, unspecified**

**8B82****Disorders of trigeminal nerve**

The trigeminal nerve is a mixed nerve with three divisions, ophthalmic, maxillary and mandibular divisions, that provides sensory innervation to the face and mucous membrane of the oral and nasal cavities and motor innervations to the muscle of mastication, tensor tympani, tensor veli palatine, mylohyoid and anterior belly of the digastric muscle. The trigeminal nuclear complex extends throughout the brainstem, hence it is susceptible to many pathologic processes including demyelination, ischemia, haemorrhage, infectious and non-infectious inflammation and neoplasm leading to symptoms of trigeminal nerve involvement. Compression of the sensory nerve root outside the brain stem by a vascular loop leads to trigeminal neuralgia. Symptoms and signs depend on the site of the lesion. In general, a trigeminal nerve disorder is associated with hemisensory facial loss, deviation of the jaw to paralysed side on opening of the mouth, and loss of the corneal reflex.

**Coded Elsewhere:** Atypical facial pain (8A85)

**8B82.0****Trigeminal neuralgia**

Trigeminal neuralgia is a manifestation of orofacial neuropathic pain restricted to one or more divisions of the trigeminal nerve. The pain is recurrent, abrupt in onset and termination, triggered by innocuous stimuli and typically compared to an electric shock or described as shooting or stabbing. Some patients experience continuous pain between these painful paroxysms.

**8B82.Z****Disorders of trigeminal nerve, unspecified****8B83****Disorders of spinal accessory nerve**

**Coded Elsewhere:** Injury of accessory nerve (NA04.A)

Lesion in jugular foramen (8B87)

**8B84****Disorders of hypoglossal nerve****8B85****Disorders of multiple cranial nerves**

This is a group of disorders of multiple cranial nerves, the twelve nerves that emerge from the brain and brainstem.

**Inclusions:** Cranial polyneuritis

**8B86****Disorders of vagus nerve**

**Exclusions:** Paralysis of vocal cords or larynx (CA0H.0)

**Coded Elsewhere:** Lesion in jugular foramen (8B87)

**8B87****Disorders of glossopharyngeal nerve**

**Inclusions:** Disorders of 9th cranial nerve

**8B88****Disorders of facial nerve****8B88.0**

**Bell palsy**

**8B88.1**

**Facial myokymia**

<b>8B88.2</b>	<b>Hemifacial spasm</b>
	Hemifacial spasm (HFS) is a movement disorder most commonly caused by vascular compression of the VII cranial nerve at its root exit zone from the brainstem. It manifests as involuntary contractions and twitching on ipsilateral side of the face.
<b>8B88.3</b>	<b>Facial neuritis</b>
<b>8B88.Y</b>	<b>Other specified disorders of facial nerve</b>
<b>8B88.Z</b>	<b>Disorders of facial nerve, unspecified</b>
<b>8B8Y</b>	<b>Other specified disorders of cranial nerves</b>
<b>8B8Z</b>	<b>Disorders of cranial nerves, unspecified</b>

Nerve root or plexus disorders (8B90-8B9Z)

**Exclusions:** intervertebral disc disorders (FA80-FA8Z)

Spondylolysis (FA81)

<b>8B90</b>	<b>Nerve root and plexus compressions</b>
-------------	---

**Coding Note:** Code also the causing condition

<b>8B91</b>	<b>Brachial plexus disorders</b>
-------------	----------------------------------

<b>8B91.0</b>	<b>Neuralgic shoulder amyotrophy</b>
---------------	--------------------------------------

Parsonage-Turner syndrome is a rare condition of unknown etiology that presents with a characteristic pattern of sudden and acute pain across the top of the shoulder, lasting a few hours to a fortnight, followed by flaccid paralysis of some muscles of the shoulder girdle.

<b>8B91.1</b>	<b>Thoracic outlet syndrome due to cervical rib</b>
---------------	---

<b>8B91.Y</b>	<b>Other specified brachial plexus disorders</b>
---------------	--

<b>8B91.Z</b>	<b>Brachial plexus disorders, unspecified</b>
---------------	---

<b>8B92</b>	<b>Lumbosacral plexus disorders</b>
-------------	-------------------------------------

<b>8B92.0</b>	<b>Post radiation lumbosacral plexopathy</b>
---------------	--

<b>8B92.1</b>	<b>Vasculitic lumbosacral plexopathy</b>
---------------	--

<b>8B92.2</b>	<b>Diabetic lumbosacral plexopathy</b>
---------------	--

**Coding Note:** Always assign an additional code for diabetes mellitus

<b>8B92.3</b>	<b>Lumbosacral radiculoplexopathy</b>
---------------	---------------------------------------

<b>8B92.Y</b>	<b>Other specified lumbosacral plexus disorders</b>
---------------	---

<b>8B92.Z</b>	<b>Lumbosacral plexus disorders, unspecified</b>
---------------	--

<b>8B93</b>	<b>Radiculopathy</b>
	<b>Exclusions:</b> Neuritis (FB56) Intervertebral disc degeneration (FA80)
<b>8B93.0</b>	<b>Radiculopathy due to compression</b>
<b>8B93.1</b>	<b>Radiculopathy due to metabolic disorders</b>
<b>8B93.2</b>	<b>Radiculopathy due to electric shock or lightning</b>
<b>8B93.3</b>	<b>Radiculopathy due to radiation injury</b>
<b>8B93.4</b>	<b>Radiculopathy due to nutritional deficiencies</b>
<b>8B93.5</b>	<b>Radiculopathy due to toxicity</b>
<b>8B93.6</b>	<b>Radiculopathy due to intervertebral disc disorders</b>
<b>8B93.7</b>	<b>Radiculopathy due to neoplastic disease</b>
<b>8B93.8</b>	<b>Radiculopathy due to spondylosis</b>
<b>8B93.Y</b>	<b>Other specified radiculopathy</b>
<b>8B93.Z</b>	<b>Radiculopathy, unspecified</b>
<b>8B94</b>	<b>Diabetic radiculoplexoneuropathy</b>
	Diabetic radiculoplexoneuropathy is a rare, but established complication of a focal neuropathy occurring in patients with diabetes type 2. Etiologically inflammatory changes of microvasculitis are assumed. It is independent on the stage of diabetes and often occurs usually in association of weight loss, not before the 4th or 5th decade. It presents with acute severe pain, and predominant motor involvement of the lumbar plexus often asymmetric and usually unilateral. Muscle atrophy occurs early. It is self limiting, but disability may persist.
	Always assign an additional code for the type of diabetes mellitus.
<b>Coding Note:</b>	Code also the causing condition
<b>8B95</b>	<b>Secondary brachial plexus lesion due to certain specified disorders</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8B9Y</b>	<b>Other specified nerve root or plexus disorders</b>
<b>8B9Z</b>	<b>Nerve root or plexus disorders, unspecified</b>
Polyneuropathy (8C00-8C0Z)	
<b>8C00</b>	<b>Idiopathic progressive neuropathy</b>

**8C01****Inflammatory polyneuropathy**

Acquired inflammatory peripheral neuropathies are of a presumed immune etiology and are classified on the basis of their clinical course: acute inflammatory demyelinating polyneuropathy (AIDP or Guillain-Barré syndrome) with the motor deficit reaching a maximal level by 28 days, and chronic inflammatory demyelinating polyneuropathy (CIDP) which has a slowly progressive course of two or more months or a relapsing remitting course. There are many variants of AIDP and CIDP.

**8C01.0****Acute inflammatory demyelinating polyneuropathy**

Progressive weakness of the limbs over a few days to 28 days, symmetrical deficit, areflexia, absent or mild sensory disturbance, elevated cerebrospinal fluid protein, and slowing of nerve conduction velocities are the cardinal features. The disorder may be preceded by upper respiratory or gastrointestinal infection or immunization 1 to 4 weeks prior to onset of the illness. Bifacial palsy may be present.

**Inclusions:** Acute Inflammatory Demyelinating Polyradiculoneuropathy

**8C01.1****Post vaccinal neuropathy****8C01.2****Subacute inflammatory demyelinating polyneuropathy**

Subacute inflammatory demyelinating polyneuropathy (SIDP) is a subacute progressive symmetric sensorial and/or motor disorder characterised by muscular weakness with impaired sensation, absent or diminished tendon reflexes and elevated cerebrospinal fluid (CSF) proteins. SIDP is an intermediate form between Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP).

**8C01.3****Chronic inflammatory demyelinating polyneuropathy**

Chronic inflammatory demyelinating polyneuropathy is a chronic monophasic, progressive or relapsing symmetric sensorimotor disorder characterised by progressive muscular weakness with impaired sensation, absent or diminished tendon reflexes and elevated cerebrospinal fluid proteins.

**8C01.Y****Other specified inflammatory polyneuropathy****8C01.Z****Inflammatory polyneuropathy, unspecified****8C03****Other secondary polyneuropathy****Coding Note:**

Code also the causing condition

**8C03.0****Diabetic polyneuropathy****Coding Note:**

Always assign an additional code for diabetes mellitus.

**Coded Elsewhere:** Diabetic foot ulcer (BD54)

**8C03.1****Polyneuropathy due to infectious diseases****Coding Note:**

Code also the causing condition

**8C03.2****Polyneuropathy in neoplastic disease****Coding Note:**

Code also the causing condition

<b>8C03.3</b>	<b>Polyneuropathy in nutritional deficiency</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8C03.4</b>	<b>Polyneuropathy in systemic connective tissue disorders</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8C03.Y</b>	<b>Other specified secondary polyneuropathy</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8C03.Z</b>	<b>Other secondary polyneuropathy, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8C0Y</b>	<b>Other specified polyneuropathy</b>
<b>8C0Z</b>	<b>Polyneuropathy, unspecified</b>

#### Mononeuropathy (8C10-8C1Z)

<b>8C10</b>	<b>Mononeuropathies of upper limb</b>
	Damage to a single nerve or nerve group of the upper limb (not including central nervous structures such as the brain, brainstem or spinal cord), resulting in a loss of movement, sensation and/or autonomic function.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> current traumatic nerve disorder - see nerve injury by body region (Chapter 22)
<b>8C10.0</b>	<b>Carpal tunnel syndrome</b>
	A compression neuropathy due to entrapment of the median nerve within the carpal tunnel at the wrist.
<b>Coding Note:</b>	Code also the causing condition
<b>8C10.1</b>	<b>Lesion of ulnar nerve</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> Tardy ulnar nerve palsy
	<b>Exclusions:</b> Injury of ulnar nerve at upper arm level (NC14.0) Injury of ulnar nerve at forearm level (NC34.0) Injury of ulnar nerve at wrist or hand level (NC55.0)
<b>8C10.2</b>	<b>Lesion of radial nerve</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Injury of radial nerve at upper arm level (NC14.2) Injury of radial nerve at forearm level (NC34.2) Injury of radial nerve at wrist or hand level (NC55.2)
<b>8C10.Y</b>	<b>Other specified mononeuropathies of upper limb</b>
<b>Coding Note:</b>	Code also the causing condition

**8C10.Z** **Mononeuropathies of upper limb, unspecified**

**Coding Note:** Code also the causing condition

**8C11**

**Mononeuropathies of lower limb**

Damage to a single nerve or nerve group of the lower limb (not including central nervous structures such as the brain, brainstem or spinal cord), resulting in a loss of movement, sensation and/or autonomic function.

**Coding Note:** Code also the causing condition

**Inclusions:** Mononeuritis of lower limb

**Exclusions:** current traumatic nerve disorder - see nerve injury by body region (Chapter 22)

**8C11.0** **Lesion of sciatic nerve**

Disease or damage involving the SCIATIC NERVE, which divides into the PERONEAL NERVE and TIBIAL NERVE (see also PERONEAL NEUROPATHIES and TIBIAL NEUROPATHY). Clinical manifestations may include SCIATICA or pain localised to the hip, PARESIS or PARALYSIS of posterior thigh muscles and muscles innervated by the peroneal and tibial nerves, and sensory loss involving the lateral and posterior thigh, posterior and lateral leg, and sole of the foot. The sciatic nerve may be affected by trauma; ISCHEMIA; COLLAGEN DISEASES; and other conditions.

**Coding Note:** Code also the causing condition

**Exclusions:** sciatica attributed to intervertebral disc disorder (FA80)

sciatica NOS (ME84.3)

Injury of sciatic nerve at hip or thigh level (NC74.0)

**8C11.00** Sciatic nerve piriformis syndrome

**8C11.0Y** Other specified lesion of sciatic nerve

**Coding Note:** Code also the causing condition

**8C11.0Z** Lesion of sciatic nerve, unspecified

**Coding Note:** Code also the causing condition

**8C11.1** **Meralgia paraesthetica**

**Coding Note:** Code also the causing condition

**8C11.2** **Lesion of femoral nerve**

**Coding Note:** Code also the causing condition

**Exclusions:** Injury of femoral nerve at hip or thigh level (NC74.1)

**8C11.3** **Lesion of common peroneal nerve**

**Coding Note:** Code also the causing condition

**Exclusions:** Injury of peroneal nerve at lower leg level (NC94.1)

<b>8C11.4</b>	<b>Lesion of tibial nerve</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Injury of tibial nerve at lower leg level (NC94.0)
<b>8C11.5</b>	<b>Tarsal tunnel syndrome</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8C11.6</b>	<b>Lesion of plantar nerve</b>
	Disease or damage to the medial and/or lateral plantar nerves, branches of the tibial nerve below the level of the tarsal tunnel secondary to insult.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Tarsal tunnel syndrome (8C11.5) Injury of lateral plantar nerve (ND15.0) Injury of medial plantar nerve (ND15.1)
<b>8C11.Y</b>	<b>Other specified mononeuropathies of lower limb</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8C11.Z</b>	<b>Mononeuropathies of lower limb, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8C12</b>	<b>Certain specified mononeuropathies</b>
<b>8C12.0</b>	<b>Intercostal neuropathy</b> Peripheral neuropathy of the intercostal nerves
<b>8C12.1</b>	<b>Mononeuritis multiplex</b>
<b>8C12.2</b>	<b>Lesion of suprascapular nerve</b>
<b>8C12.3</b>	<b>Lesion of axillary nerve</b>
<b>8C12.4</b>	<b>Lesion of long thoracic nerve</b>
<b>8C12.5</b>	<b>Traumatic neuroma, not otherwise specified</b> <b>Exclusions:</b> Neuroma of amputation stump (NE85.3)
<b>8C12.Y</b>	<b>Mononeuropathy of other specified nerve</b>
<b>8C1Y</b>	<b>Mononeuropathy of other specified site</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8C1Z</b>	<b>Mononeuropathy of unspecified site</b>
<b>Coding Note:</b>	Code also the causing condition

Hereditary neuropathy (8C20-8C2Z)

<b>8C20</b>	<b>Hereditary motor and sensory neuropathy</b>
	<b>Inclusions:</b> Hereditary motor and sensory neuropathy, types I-IV

- 8C20.0** **Charcot-Marie-Tooth disease 1 demyelinating**
- 8C20.1** **Charcot-Marie-Tooth disease 2 axonal**
- 8C20.2** **Intermediate Charcot-Marie-Tooth disease**
- 8C20.Y** **Other specified hereditary motor and sensory neuropathy**
- 8C20.Z** **Hereditary motor and sensory neuropathy, unspecified**
- 8C21** **Hereditary sensory or autonomic neuropathy**  
*Coded Elsewhere:* Primary erythromelalgia (EG00)
- 8C21.0** **Hereditary sensory and autonomic neuropathy type I**  
Hereditary sensory autonomic type I neuropathies are autosomal dominant sensory-autonomic sensory polyneuropathies
- 8C21.1** **Hereditary sensory and autonomic neuropathy type III**  
Hereditary sensory and autonomic neuropathy, type 3 (HSAN3) is an autosomal recessive disorder seen primarily in Ashkenazi Jewish children caused by a mutation in the I-kappa B kinase associated protein.  
It is characterised by sensory dysfunction and severe impairment of the autonomic nervous system activity, resulting in multisystem dysfunction.  
Symptoms can include insensitivity to pain and temperature, intact visceral pain, alacrima, hypoactive corneal and tendon reflexes and absence of lingual fungiform papillae.
- 8C21.2** **Hereditary sensory and autonomic neuropathy type IV**  
Hereditary sensory and autonomic neuropathy, type 4 (HSAN4) is an inherited disorder characterised by anhidrosis, insensitivity to pain, self-mutilating behaviour and episodes of fever.
- 8C21.3** **Hereditary sensory and autonomic neuropathy type V**  
Hereditary sensory and autonomic neuropathy, type 5 (HSAN5) is characterised by loss of pain perception and impaired temperature sensitivity, in the absence of any other major neurological anomalies.
- 8C21.Y** **Other specified hereditary sensory or autonomic neuropathy**
- 8C21.Z** **Hereditary sensory or autonomic neuropathy, unspecified**
- 8C2Y** **Other specified hereditary neuropathy**
- 8C2Z** **Hereditary neuropathy, unspecified**
- 
- 8C4Y** **Other specified disorders of nerve root, plexus or peripheral nerves**
- 8C4Z** **Disorders of nerve root, plexus or peripheral nerves, unspecified**

## Diseases of neuromuscular junction or muscle (8C60-8D0Z)

Diseases resulting from destruction or malfunction of the neuromuscular junction, a chemical synapse formed between the end of the motor nerve terminal and the voluntary muscle. Pathology can occur at the presynaptic or postsynaptic membrane and leads to dysfunction of neuromuscular transmission. Common diseases of this category include Myasthenia Gravis and Lambert Eaton Myasthenic Syndrome.

### Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)

Myasthenia gravis is the most common autoimmune disease affecting the neuromuscular junction and is characterised by painless fatigable muscle weakness. It is caused by autoantibodies against neuromuscular junction proteins, either the nicotinic acetylcholine receptor (AChR) or the muscle specific tyrosine kinase (MuSK). Mutations in neuromuscular junction proteins cause congenital myasthenic syndromes. Other antibodies mediated conditions affecting the neuromuscular junction, including Lambert Eaton myasthenic syndrome and neuromyotonia.

**Coded Elsewhere:** Botulism (1A11)

Neuromuscular junction disorders due to toxicity (NE61)

**8C60**

### Myasthenia gravis

Myasthenia gravis is the most common acquired auto-antibody mediated neuromuscular transmission disorder. Prevalence is 1–2 per 10,000 persons. Fluctuating weakness increasing with repeated activity and improving after a period of rest is the hallmark. Myasthenia Gravis with antibodies directed against postsynaptic proteins, usually the nicotinic acetylcholine receptor are the most prevalent. Other types are Myasthenia Gravis associated with muscle-specific kinase antibodies and MG with unknown autoantibodies (seronegative) Myasthenia Gravis.

There are three groups: 1. Purely ocular Myasthenia Gravis

2. Early-onset (<40-50 years) generalised Myasthenia Gravis

3. Late-onset generalised MG.

In about 15%, the disease can be classified as paraneoplastic, usually associated with a thymoma.

**Coded Elsewhere:** Transient neonatal myasthenia gravis (KB08.0)

**8C60.0**

### Drug-induced myasthenia gravis

Some drugs can have clear effects on Myasthenia Gravis, including Neuromuscular junction blockers, antibiotics, prednisone, chloroquine, D-penicillamine, interferons, and others. In rapid-onset drug-induced Myasthenia Gravis, myasthenic signs develop within days which rapidly disappear after drug withdrawal. Anti-Acetylcholinesterase antibodies are absent. This disorder may unmask a pre-existing neuromuscular transmission disorder or may exacerbate pre-existing Myasthenia Gravis, i.e. subclinical Myasthenia Gravis becomes manifest after drug treatment, or known MG becomes more severe. Certain drugs are linked with aggravation of Myasthenia Gravis, including pain management medications, tricyclic antidepressants and some antiepileptic medications, and should be used with caution.

**8C60.Y**

### Other specified myasthenia gravis

8C60.Z	<b>Myasthenia gravis, unspecified</b>
8C61	<b>Congenital myasthenic syndromes</b> Congenital myasthenic syndrome is a heterogeneous group of genetically determined diseases. There are four well-defined categories: Congenital myasthenic syndrome with presynaptic defect, Synaptic basal lamina-associated CMS, Congenital myasthenia with postsynaptic defect, CMS with glycosylation deficiency, and the remaining category is that of unidentified CMS.
8C62	<b>Lambert-Eaton syndrome</b> Lambert-Eaton myasthenic syndrome, 20 times as rare as acetylcholine receptor positive myasthenia gravis with a prevalence of 3.42 per million, is an immune-mediated disease of the neuromuscular junction. Clinically the disease is characterised by proximal weakness of the legs. In most patients, the weakness extends to other muscles including the oculobulbar ones. Autonomic symptoms (dry mouth, erectile dysfunction, constipation) are frequent. Tendon reflexes are reduced. Repetitive nerve stimulation shows low compound muscle action potentials, decrement > 10% at low frequency and increment > 100% after maximum voluntary contraction at high frequency.
8C6Y	<b>Other specified myasthenia gravis and neuromuscular junction disorders</b>
8C6Z	<b>Unspecified myasthenia gravis or neuromuscular junction disorders</b>

Primary disorders of muscles (8C70-8C7Z)

Disorders in which the primary symptom of muscle weakness is secondary to a specific dysfunction of a muscle fiber.

**Exclusions:** Metabolic disorders (5C50-5D2Z)

Arthrogryposis multiplex congenita (LD26.41)

**Coded Elsewhere:** Idiopathic rhabdomyolysis (FB32.20)

Idiopathic inflammatory myopathy (4A41)

8C70	<b>Muscular dystrophy</b> Progressive, hereditary skeletal muscle diseases characterised by muscle weakness, wasting, defects in muscle proteins, necrosis of muscle tissue and replacement of muscle tissue with connective and fatty tissue.
	<b>Coded Elsewhere:</b> Muscular dystrophy affecting extraocular muscle (9C82.1) Barth syndrome (5C50.E0) Epidermolysis bullosa simplex with muscular dystrophy (EC30)

8C70.0	<b>Becker muscular dystrophy</b>
--------	----------------------------------

- 8C70.1 Duchenne muscular dystrophy**  
Duchenne muscular dystrophy (DMD) is a severe X-linked myopathy caused by mutation in the dystrophin gene with symptoms appearing before the age of 6 with a rapid disease progression. Symptoms may include fatigue, learning difficulties (the IQ can be below 75), Muscle weakness, problems with motor skills, frequent falls and progressive difficulty walking.
- 8C70.2 Emery-Dreifuss muscular dystrophy**  
Emery-Dreifuss muscular dystrophy (EDMD) is a muscle disease characterised by muscular weakness and atrophy, with early contractures of the tendons and cardiac involvement (arrhythmias, cardiomyopathy).
- 8C70.3 Facioscapulohumeral muscular dystrophy**  
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominantly inherited muscle disease characterised by progressive muscle weakness with initial focal involvement of the facial, shoulder and arm muscles.
- 8C70.4 Limb-girdle muscular dystrophy**  
Limb-girdle muscular dystrophy (LGMD) constitutes a group of genetically determined, progressive disorders of muscles, in which the pelvic or shoulder girdle musculature is predominantly or primarily involved. It may be inherited in an autosomal recessive or dominant fashion.
- 8C70.40 Dominant limb-girdle muscular dystrophy**  
The Limb Girdle Muscular Dystrophies (LGMD) are a group of genetic disorders characterised predominantly by progressive wasting and weakness of proximal limb girdle muscles, including pelvic, shoulder, upper arm and thigh muscles. The onset symptoms usually vary from early childhood to late adulthood, and the progression rate and distribution of weakness and wasting also varies considerably among individuals and genetic subtypes. There are currently 8 autosomal dominant LGMDs (LGMD1), linked to specific gene mutations. Dominant LGMDs are often allelic with other clinical disorders, including the myofibrillar myopathies or dilated cardiomyopathy.
- Exclusions:** Secondary myopathies (8C80-8C8Z)  
Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)

- 8C70.41** Recessive limb-girdle muscular dystrophy  
 Autosomal recessive limb girdle muscular dystrophies (LGMD2) are a group of genetically heterogeneous diseases that are typically characterised by progressive weakness and wasting of the shoulder and pelvic girdle muscles. Many of the more than 20 different conditions show overlapping clinical features with other forms of muscular dystrophy, congenital, myofibrillar or even distal myopathies and also with acquired muscle diseases. Although individually extremely rare, all types of LGMD2 together form an important differential diagnostic group among neuromuscular diseases.
- Exclusions:** Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)  
 Secondary myopathies (8C80-8C8Z)
- 8C70.4Y** Other specified limb-girdle muscular dystrophy
- 8C70.4Z** Limb-girdle muscular dystrophy, unspecified
- 8C70.5** **Scapuloperoneal muscular dystrophy**  
 Scapuloperoneal muscular dystrophies are a group of genetically heterogeneous myopathies characterised by progressive weakness and wasting of scapular and anterior leg muscles. Emery-Dreifuss muscular dystrophy is a classic scapuloperoneal muscular dystrophy associated with early contractures and cardiac arrhythmia, but other muscle disorders can also present with a scapuloperoneal phenotype.
- Exclusions:** Secondary myopathies (8C80-8C8Z)  
 Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)
- 8C70.6** **Congenital muscular dystrophy**  
 Congenital muscular dystrophies with central nervous system abnormalities are a heterogeneous group of autosomal recessively inherited degenerative muscle disorders associated with cerebral and cerebellar dysplasia, white matter abnormalities and ocular abnormalities in some subtypes.
- 8C70.Y** Other specified muscular dystrophy
- 8C70.Z** Muscular dystrophy, unspecified
- 8C71** **Myotonic disorders**  
 Group of inherited muscular disorders associated with clinical and/or electrical myotonia. Myotonia is defined clinically as the occurrence of “delayed relaxation of muscle after voluntary contraction or percussion.”

**8C71.0**

**Myotonic dystrophy**

Myotonic dystrophy is a group of inherited muscular disorders. It is the most common form of muscular dystrophy that begins in adulthood. Myotonic dystrophy is characterised by progressive muscle wasting and weakness, and prolonged muscle contractions (myotonia) that are not able to relax after use. Other signs and symptoms of myotonic dystrophy include slurred speech or temporary locking of their jaw, cataracts and cardiac conduction defects. In affected men, hormonal changes may lead to early balding and infertility. The clinical severity varies widely among affected patients, even among members of the same family.

**Exclusions:** Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)

Secondary myopathies (8C80-8C8Z)

**Coded Elsewhere:** Myotonic cataract (9B10.2Y)

**8C71.1**

**Chondrodystrophic myotonia**

Schwartz-Jampel syndrome is a congenital myotonic syndrome characterised by myotonia that results in a characteristic facies with blepharophimosis and a puckered facial appearance, and osteoarticular abnormalities leading to limited joint mobility.

**8C71.2**

**Myotonia congenita**

Thomsen and Becker disease are myotonic disorders characterised by slow muscle relaxation associated with hyperexcitation of the muscle fibres occurring within the first few months after birth. The myotonia is unusual in that it is relieved by exercise (warm-up effect). Autosomal dominant myotonia congenita (Thomsen disease) is a non-dystrophic muscle disorder caused by mutation in the gene encoding skeletal muscle chloride channel-1 (CLCN1). It is clinically characterised by muscle stiffness and an inability of the muscle to relax after voluntary contraction. Autosomal recessive myotonia congenita (Becker disease) is caused by mutation in the gene encoding skeletal muscle chloride channel-1 (CLCN1). It is a non-dystrophic skeletal muscle disorder characterised by muscle stiffness and an inability of the muscle to relax after voluntary contraction. Most patients have symptom onset in the legs, which later progresses to the arms, neck, and facial muscles. Many patients show marked hypertrophy of the lower limb muscles. Transient muscle weakness is a characteristic feature.

**8C71.3**

**Drug-induced myotonia**

Drug-induced myotonia refers to the myotonia-inducing effects of certain drugs. Hypocholesterolaemic agents may induce myotonia by altering the sterol composition of the muscle cell membrane, while other drugs including beta-adrenergic blockers and agonists, succinylcholine and diuretics may exacerbate or unmask pre-existing myotonia.

**Exclusions:** Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)

Secondary myopathies (8C80-8C8Z)

<b>8C71.4</b>	<b>Neuromyotonia</b> Neuromyotonia or Isaac's syndrome is an immune-mediated peripheral nerve disorder characterised by continuous muscle fibre activity at rest resulting in muscle stiffness, cramps, myokymia, and pseudomyotonia.
<b>8C71.5</b>	<b>Pseudomyotonia</b> The term pseudomyotonia (slow relaxation of muscles after voluntary contraction) describes the clinical appearance of myotonia in the absence of myotonic discharges on the electromyography. Pseudomyotonia is most commonly observed as the slow-relaxing or "hung-up" tendon reflexes of hypothyroidism, although other causes are described. Pseudomyotonia is seen in about one-third of patients with Isaacs syndrome, particularly with handgrip, but also after eye and jaw closure; rarely, this can be the first symptom.  <b>Exclusions:</b> Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)  Secondary myopathies (8C80-8C8Z)
<b>8C71.Y</b>	<b>Other specified myotonic disorders</b>
<b>8C71.Z</b>	<b>Myotonic disorders, unspecified</b>
<b>8C72</b>	<b>Congenital myopathies</b>
<b>8C72.0</b>	<b>Congenital myopathy with structural abnormalities</b> Distinct group of inherited disorders of skeletal muscles which have characteristic structural abnormalities on muscle immuno-histochemistry.  <b>Coding Note:</b> Code also the causing condition  <b>Exclusions:</b> Secondary myopathies (8C80-8C8Z)  Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)
<b>8C72.00</b>	Nemaline myopathy Nemaline myopathy encompasses a large spectrum of congenital myopathies characterised by hypotonia, weakness and depressed or absent deep tendon reflexes, with pathologic evidence of nemaline bodies (rods) on muscle biopsy.
<b>8C72.01</b>	Centronuclear myopathy Centronuclear myopathy (CNM) is an inherited neuromuscular disorder characterised by clinical features of a congenital myopathy and centrally placed nuclei on muscle biopsy. It encompasses the X-linked form, the autosomal recessive form and the autosomal dominant form with a highly variable clinical presentation.
<b>8C72.02</b>	Central core disease Central core disease (CCD) is an inherited neuromuscular disorder characterised by central cores on muscle biopsy and clinical features of a congenital myopathy (hypotonia and motor developmental delay) and is characterised by predominantly proximal weakness, pronounced in the hip girdle.

<b>8C72.0Y</b>	Other specified congenital myopathy with structural abnormalities
<b>Coding Note:</b>	Code also the causing condition
<b>8C72.0Z</b>	Congenital myopathy with structural abnormalities, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>8C72.1</b>	<b>Congenital myopathy with no structural abnormalities</b>
	<b>Exclusions:</b> Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)
	Secondary myopathies (8C80-8C8Z)
<b>8C72.Y</b>	<b>Other specified congenital myopathies</b>
<b>8C72.Z</b>	<b>Congenital myopathies, unspecified</b>
<b>8C73</b>	<b>Mitochondrial myopathies</b>
	Mitochondrial myopathies are heterogeneous group of disorders caused by dysfunction of mitochondrial oxidative phosphorylation and can be classified according to the associated biochemical, genetic defects (in the mitochondrial DNA or in nuclear encoded proteins) or clinical phenotype. Exclude: defects of mitochondrial respiratory chain, Kearns-Sayre syndrome, myoclonic epilepsy with ragged red fibres (MERRF)
	<b>Coded Elsewhere:</b> Leigh syndrome (5C53.24)
	Progressive external ophthalmoplegia (9C82.0)
<b>8C73.0</b>	<b>Autosomal recessive cardiomyopathy or ophthalmoplegia</b>
	Autosomal recessive cardiomyopathy and ophthalmoplegia is a childhood-onset disease characterised by progressive external ophthalmoplegia, mild facial and proximal limb weakness, and severe cardiomyopathy. Muscle biopsies show ragged-red and cytochrome C oxidase-negative fibres; the activities of several complexes in the electron-transport chain are decreased. The combination of progressive external ophthalmoplegia, cardiomyopathy, and multiple mtDNA deletions is thought to be due to a defect of communication between the nuclear and mitochondrial genomes.
	<b>Exclusions:</b> Secondary myopathies (8C80-8C8Z)
	Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)
<b>8C73.1</b>	<b>Neuropathy, ataxia, and retinitis pigmentosa</b>
	Neuropathy, Ataxia, and Retinitis Pigmentosa (NARP) syndrome is a clinically heterogeneous oxidative phosphorylation disorder often characterised by a combination of sensory-motor neuropathy, cerebellar ataxia, and night blindness.
<b>8C73.Y</b>	<b>Other specified mitochondrial myopathies</b>
<b>8C73.Z</b>	<b>Mitochondrial myopathies, unspecified</b>

**8C74****Periodic paralyses or disorders of muscle membrane excitability**

These are a group of disorders caused by malfunctioning of the ion channels in skeletal muscle membranes causing the cells to depolarize leading to weakness or paralysis. The common triggers include cold, heat, high carbohydrate meals, stress, excitement, physical exertion etc.

**8C74.0****Paramyotonia congenita**

Paramyotonia congenita of Von Eulenburg is a skeletal muscle disease characterised by exercise- or cold-induced myotonia and muscle weakness.

**8C74.1****Periodic paralysis**

Rare group of neuromuscular disorders that are associated with defects in ion channels. Characterized by intermittent episodes of severe weakness of the limbs usually after heavy exercise, fasting, or high carbohydrate meals. The three major types of inherited periodic paralysis include hypokalemic periodic paralysis, hyperkalemic periodic paralysis, and Andersen–Tawil syndrome.

**8C74.10****Hypokalaemic periodic paralysis**

Hypokalaemic periodic paralysis (hypoPP) is a muscle channelopathy characterised by episodes of muscle paralysis lasting from a few to 24-48 hours and associated with a fall in blood potassium levels.

**Coded Elsewhere:** Thyrotoxic periodic paralysis (5A02.Y)

**8C74.11****Hyperkalaemic periodic paralysis**

Hyperkalaemic periodic paralysis (HyperPP) is a muscle disorder characterised by episodic attacks of muscle weakness associated with an increase in serum potassium concentration.

**Coded Elsewhere:** Long QT syndrome type 7 (BC65.0)

**8C74.1Y****Other specified periodic paralysis****8C74.1Z****Periodic paralysis, unspecified****8C74.Y****Other specified periodic paralyses or disorders of muscle membrane excitability****8C74.Z****Periodic paralyses or disorders of muscle membrane excitability, unspecified****8C75****Distal myopathies**

Distal myopathies are heterogeneous group of myopathies characterised clinically by progressive weakness and atrophy starting in distal muscles and progressing to proximal ones, and histologically by nonspecific myopathic features on muscle biopsy.

**8C76**

### **Myofibrillar myopathy**

Myofibrillar myopathies are a heterogeneous group of disorders, characterised by the pathologic finding of myofibrillar disruption on electron microscope with a spectrum of histological abnormalities including excessive desmin accumulation in muscle fibres.

**Exclusions:** Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)

Secondary myopathies (8C80-8C8Z)

**8C77**

### **Ocular myopathy**

Slowly progressive weakness of ocular muscles, usually characterised by decreased mobility of the eye and drooping of the upper lid. The disorder may be unilateral or bilateral, and may be caused by central or peripheral nervous system lesion or by a neuromuscular disease.

**Exclusions:** Ocular myopathy with mitochondrial abnormalities (9C82.0)  
oculopharyngeal muscular dystrophy (9C82.1)  
Ocular muscular dystrophy (9C82.1)

**8C78**

### **Malignant hyperthermia or hyperpyrexia**

Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anaesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely in humans, to stresses such as vigorous exercise and heat. May be caused by a mutation in the Ryonadine Receptor 1 gene.

**8C7Y**

### **Other specified primary disorders of muscles**

**8C7Z**

### **Primary disorders of muscles, unspecified**

Secondary myopathies (8C80-8C8Z)

This is a group of conditions in which the muscle fibres are dysfunctional, resulting in muscle weakness. The myopathy is caused by an underlying disorder.

**Exclusions:** Arthrogryposis multiplex congenita (LD26.41)  
Ischaemic infarction of muscle (FB32.2)

**Coded Elsewhere:** Alcoholic myopathy (8D44.1)

Myopathy due to toxicity (8D43.3)

**8C80**

### **Drug-induced myopathy**

Myopathy caused by drugs that ranges from mild myalgias with or without mild weakness to chronic myopathy with severe weakness, to massive rhabdomyolysis with acute renal failure. It could be due to several different mechanisms including direct myotoxicity, immune mediated and indirect muscle damage through drug-induced coma, drug-induced hypokalaemia, drug-induced hyperkinetic states or dystonic states.

**8C81****Autoimmune myopathy**

Autoimmune myopathy is a subgroup of idiopathic inflammatory myopathies, which, despite diverse causes, have the common histopathological features of myocyte necrosis without significant inflammation. Patients present with a subacute severe symmetrical proximal myopathy, associated with a markedly elevated creatine kinase level. These are most likely immune-mediated, as they respond to immunotherapy. It is often accompanied by statin therapy, connective tissue diseases, cancer, and autoantibodies specific for signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR).

**Coding Note:**

Code also the causing condition

**Exclusions:** Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)

Primary disorders of muscles (8C70-8C7Z)

**8C82****Myopathy in certain specified infectious or parasitic disease**

Myopathy in certain specified infectious or parasitic disease is an uncommon group of muscle diseases caused by a broad range of bacterial, fungal, parasitic, and viral agents. Bacterial organisms cause pyomyositis, psoas abscess, Staphylococcus aureus myositis, group A streptococcal necrotizing myositis, group B streptococcal myositis, clostridial gas gangrene, and nonclostridial myositis. Fungal myositis is rare and usually occurs among immunocompromised hosts. Parasitic myositis is most commonly a result of trichinosis or cysticercosis, but other protozoa or helminths may be involved. Viruses may cause benign acute myositis, pleurodynia, acute rhabdomyolysis, or an immune-mediated polymyositis.

**Coding Note:**

Code also the causing condition

**Exclusions:** Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)

Primary disorders of muscles (8C70-8C7Z)

**8C83****Myopathy in certain specified endocrine disease**

Myopathy in certain specified endocrine disease refers to muscle disorders associated with adrenal dysfunction (as steroid myopathy), thyroid dysfunction (as in myxoedema coma or thyrotoxic myopathy), parathyroid dysfunction (as in multiple endocrine neoplasia), pituitary dysfunction, and islands of Langerhans dysfunction (as in diabetic myopathy from ischemic infarction of the femoral muscles). Steroid myopathy is the most common endocrine myopathy. These conditions are usually reversible with correction of the underlying endocrine disturbance.

**Coding Note:**

Code also the causing condition

**Exclusions:** Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)

Primary disorders of muscles (8C70-8C7Z)

**8C84****Secondary rhabdomyolysis**

Secondary rhabdomyolysis occurs when the primary effect of a aetiological factor results in a functional or biochemical state which is conducive to the development of ischemic, degenerative, necrotic or membrane destabilizing changes in muscle, producing the clinical and biochemical features of rhabdomyolysis. Most frequently, rhabdomyolysis is secondary to a metabolic derangement often genetic in nature, as result of abnormally excessive movement, excessive isometric tension by attempted movement against resistance, or coma leading to increased intramuscular pressure, ischemia, hypoxia and necrosis. Secondary rhabdomyolysis can also be caused by a mutation in various genes (RYR1, LPIN).

**Coding Note:** Code also the causing condition

**Exclusions:** Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)

Primary disorders of muscles (8C70-8C7Z)

**8C8Y****Other specified secondary myopathies**

**Coding Note:** Code also the causing condition

**8C8Z****Secondary myopathies, unspecified**

**Coding Note:** Code also the causing condition

**8D0Y****Other specified diseases of neuromuscular junction or muscle****8D0Z****Diseases of neuromuscular junction or muscle, unspecified****Cerebral palsy (8D20-8D2Z)**

**Exclusions:** Hereditary spastic paraplegia (8B44.0)

**8D20****Spastic cerebral palsy**

Spastic cerebral palsy is characterised by increased muscle tone associated with hyperactive muscle stretch reflexes (deep tendon reflexes) and an increase in resistance to rapid muscle stretch. Extensor plantar responses are commonly present.

**8D20.0****Spastic unilateral cerebral palsy**

Spastic unilateral cerebral palsy is a form of cerebral palsy in which the spasticity is confined to one side; it is often accompanied by cortical sensory impairment and varying degrees of hemineglect, demonstrable by testing stereognosis and graphesthesia. Early hand preference is often the first sign of this disorder, and may be apparent in the first months of life.

**8D20.1****Spastic bilateral cerebral palsy**

- 8D20.10** Spastic quadriplegic cerebral palsy  
Spastic quadriplegic cerebral palsy is a form of cerebral palsy in which spasticity is generalised, yet most marked in the legs. Opisthotonic posturing is often apparent in infancy, and head movement may elicit forced extension of the arms and legs. Suprabulbar palsy is often present, causing impaired swallowing and articulation ('spastic dysarthria').
- Inclusions:* Spastic tetraplegic cerebral palsy
- 8D20.11** Spastic diplegic cerebral palsy  
Spastic diplegic cerebral palsy is a form of cerebral palsy in which spasticity is most marked in the legs, with mild, if any, involvement of the arms.
- 8D20.1Z** Spastic bilateral cerebral palsy, unspecified
- 8D20.Y** Other specified spastic cerebral palsy
- 8D20.Z** Spastic cerebral palsy, unspecified
- 8D21** **Dyskinetic cerebral palsy**  
Dyskinetic cerebral palsy, also known as extrapyramidal cerebral palsy is characterised by impairment of voluntary movement because of the presence of interfering involuntary movements, and inappropriate co-contraction of agonist and antagonist muscles (dystonia). This group of disorders includes choreoathetotic cerebral palsy and dystonic cerebral palsy. The former is characterised by large amplitude, involuntary movements of mainly distal limbs (athetosis) with or without small amplitude, fleeting, asymmetric contractions of individual muscle groups (chorea).
- Dystonic cerebral palsy predominantly affects proximal trunk and limb muscles, which may show slow, persistent movements, leading to the adoption of unusual postures, such as torticollis.
- Inclusions:* Athetoid cerebral palsy
- 8D22** **Ataxic cerebral palsy**  
Ataxic cerebral palsy is dominated by signs of cerebellar dysfunction, including hypotonia, ataxia, dysdiadochokinesis, dysmetria, dysarthria and nystagmus. Reflexes may be pendular, although there are often also signs of spasticity.
- 8D23** **Worster-Drought syndrome**  
Worster-Drought syndrome (WDS) is a form of cerebral palsy characterised by congenital pseudobulbar (suprabulbar) paresis manifesting as selective weakness of the lips, tongue and soft palate, dysphagia, dysphonia, drooling and jaw jerking.
- 8D2Y** Other specified cerebral palsy
- 8D2Z** Cerebral palsy, unspecified

**Nutritional or toxic disorders of the nervous system (8D40-8D4Z)**

**8D40      Neurological disorders due to nutrient deficiency**

**Coding Note:** Code also the causing condition

**Coded Elsewhere:** Dementia due to pellagra (6D85.8)

White matter disorders due to nutritional deficiency (8A45.3)

Dementia due to nutritional deficiency (6D85.Y)

**8D40.0      Encephalopathy due to nutritional deficiency**

**Coding Note:** Code also the causing condition

**8D40.1      Neuropathy due to nutritional deficiency**

**Coding Note:** Code also the causing condition

**8D40.2      Myopathy due to nutritional deficiency**

**Coding Note:** Code also the causing condition

**8D40.3      Intellectual developmental disorder due to nutritional deficiency**

**Coding Note:** Code also the causing condition

**8D40.Y      Other specified neurological disorders due to nutrient deficiency**

**Coding Note:** Code also the causing condition

**8D40.Z      Neurological disorders due to nutrient deficiency, unspecified**

**Coding Note:** Code also the causing condition

**8D41      Neurological disorders due to an excess of micro or macro nutrients**

**Coding Note:** Code also the causing condition

**8D41.0      Peripheral neuropathy due to vitamin B6 hyperalimentation**

**8D41.1      Myopathy due to hypercalcaemia**

**8D41.2      Pseudotumour Cerebri related to Hypervitaminosis A**

**8D41.Y      Other specified neurological disorders due to an excess of micro or macro nutrients**

**Coding Note:** Code also the causing condition

**8D41.Z      Neurological disorders due to an excess of micro or macro nutrients, unspecified**

**Coding Note:** Code also the causing condition

**8D42****Neurological disorders due to overweight or obesity in adults or children**

Neurological disorders that arise from the metabolic dysfunction, inflammation, and dyslipidemia caused by overweight ( $BMI > 25$ ) or obese ( $BMI > 30$ ) status. Examples include mild cognitive impairment secondary to hippocampal alteration, hypothalamic dysfunction, autonomic dysfunction, peripheral polyneuropathy, and obstructive sleep apnea.

**Coding Note:**

Code also the causing condition

**8D43****Neurological disorders due to toxicity**

**Coded Elsewhere:** Neuromuscular junction disorders due to toxicity (NE61)

Intracranial hypertension associated with medication or toxin exposure (8D60.Y)

Myelopathy due to toxicity (8B42)

**8D43.0****Encephalopathy due to toxicity****8D43.00**

Encephalopathy due to ammonia

**8D43.0Y**

Other specified encephalopathy due to toxicity

**8D43.0Z**

Encephalopathy due to toxicity, unspecified

**8D43.1****Cognitive impairment due to toxicity**

These are conditions of impaired cognition due to the toxicity of substances.

**Coded Elsewhere:** Dementia due to exposure to heavy metals and other toxins (6D85.2)

Dementia due to carbon monoxide poisoning (6D84.Y)

Post radiation dementia (6D84.Y)

Dementia or parkinsonism due to manganese toxicity (6D84.Y)

**8D43.2****Neuropathy due to toxicity**

In considering the diagnosis of toxic neuropathy, two criteria should be met: (1) Exposure can be verified and temporally related to the onset of clinical symptoms. Neuropathic symptoms usually occur concurrently with the exposure or following a variable latency of up to several months. (2) There must be neurological signs and abnormal electrodiagnostic studies, because many toxic neuropathies are subclinical, subjective symptoms may or may not occur. Removal from exposure results in cessation of progression of symptoms and the deficit. Most toxins produce symmetrical axonal degeneration in a length-dependent pattern, beginning in the distal segments of the long and large-calibre nerve fibres eventually spreading proximally with continued exposure. In addition to motor and/or sensory deficits, severe pain may be a characteristic feature.

**Coded Elsewhere:** Alcoholic polyneuropathy (8D44.0)

**8D43.20**

Drug-induced polyneuropathy

**8D43.21**

Post radiation polyneuropathy

**8D43.2Y**

Other specified neuropathy due to toxicity

- 8D43.2Z** Neuropathy due to toxicity, unspecified
- 8D43.3** **Myopathy due to toxicity**  
*Coded Elsewhere:* Alcoholic myopathy (8D44.1)  
Myopathy due to other toxic agents (8C8Y)
- 8D43.4** **Movement disorders due to toxicity**  
Movements of the body such as hyperkinesias, dyskinesias, myoclonus, chorea, tremor and tics produced by toxicity either by toxin or drug, e.g. toxicity by manganese, neuroleptic drugs, calcium channel blockers, gastrointestinal prokinetics, antiarrhythmics and antidepressants that may induce Parkinsonism.  
*Coded Elsewhere:* Toxin-induced parkinsonism (8A00.2Y)  
Chorea due to toxins (8A01.1Y)  
Dystonia due to toxins (8A02.1Y)  
Ataxia due to certain specified toxins (8A03.3Y)
- 8D43.5** **Cassava poisoning**  
Symmetrical, non-progressive, non-remitting spastic paraparesia occurring in epidemic and endemic forms with a predilection for children and young women. The unknown aetiology is related to consumption of bitter cassava roots with very minimal protein supplementation.  
*Coded Elsewhere:* Myelopathy due to konzo (8B42)
- 8D43.Y** **Other specified neurological disorders due to toxicity**
- 8D43.Z** **Neurological disorders due to toxicity, unspecified**
- 8D44** **Alcohol-related neurological disorders**  
*Coded Elsewhere:* Dementia due to use of alcohol (6D84.0)
- 8D44.0** **Alcoholic polyneuropathy**
- 8D44.1** **Alcoholic myopathy**  
Myopathy secondary to alcohol use and includes acute and chronic alcoholic myopathy. Several forms have been described: acute necrotizing myopathy, acute hypokalaemic myopathy, chronic alcoholic myopathy, asymptomatic alcoholic myopathy, and alcoholic cardiomyopathy.
- 8D44.Y** **Other specified alcohol-related neurological disorders**
- 8D44.Z** **Alcohol-related neurological disorders, unspecified**
- 8D4Y** **Other specified nutritional or toxic disorders of the nervous system**
- 8D4Z** **Nutritional or toxic disorders of the nervous system, unspecified**

## Disorders of cerebrospinal fluid pressure or flow (8D60-8D6Z)

- 8D60** **Increased intracranial pressure**  
An increase in pressure within the skull caused by changes in the volumes of the intracranial components, such as brain matter, CSF and blood, or by the presence of a pathological mass entity.
- 8D60.0** **Brain herniation syndromes**  
The shift or displacement of brain tissue due to mass effect from its normal location to a region it does not occupy.
- 8D60.1** **Cerebral oedema**  
Is an excess accumulation of fluid in the intracellular and/or extracellular spaces of the brain.  
**Exclusions:** Traumatic cerebral oedema (NA07.2)  
Cerebral oedema due to birth injury (KA40.1)
- 8D60.Y** **Other specified increased intracranial pressure**
- 8D60.Z** **Increased intracranial pressure, unspecified**
- 8D61** **Intracranial hypotension**  
The syndrome of intracranial hypotension is a single pathophysiological entity of diverse origin. Usually it is characterised by an orthostatic headache, one that occurs or worsens with upright posture. Patients with chronic headaches and asymptomatic patients have been described.
- 8D61.0** **Spontaneous intracranial hypotension**  
The exact cause of spontaneous spinal CSF leaks usually remains unknown, but a combination of an underlying weakness of the spinal meninges and a trivial precipitating event is generally suspected.
- 8D61.1** **Secondary intracranial hypotension**  
**Coding Note:** Code also the causing condition
- 8D61.Y** **Other specified intracranial hypotension**
- 8D61.Z** **Intracranial hypotension, unspecified**
- 8D62** **Cerebrospinal fluid rhinorrhoea**
- 8D63** **Cerebrospinal fluid otorrhoea**
- 8D64** **Hydrocephalus**  
**Coded Elsewhere:** Neonatal hydrocephalus (KB05)
- 8D64.0** **Communicating hydrocephalus**  
Communicating hydrocephalus, also known as non-obstructive hydrocephalus, is a disorder characterised by impaired cerebrospinal fluid reabsorption in the absence of any CSF-flow obstruction between the ventricles and subarachnoid space.

- 8D64.00** Increased cerebrospinal fluid production  
Is a type of communicating hydrocephalus caused by increased CSF production.
- 8D64.01** Congenital agenesis of arachnoid villi
- 8D64.02** Post haemorrhagic hydrocephalus
- 8D64.03** Post traumatic hydrocephalus
- 8D64.04** Normal-pressure hydrocephalus  
A clinical syndrome mainly comprising gait disturbance, dementia, and urinary incontinence, and associated with dilatation of the ventricular system of the brain. Most of the times demonstrating normal cerebrospinal fluid (CSF) pressure at lumbar puncture.
- 8D64.0Y** Other specified communicating hydrocephalus
- 8D64.0Z** Communicating hydrocephalus, unspecified
- 8D64.1** **Non-communicating hydrocephalus**  
It represents a form of hydrocephalus where there is an excessive accumulation of CSF within the ventricles caused by blockage of its pathway and due to several causes.  
**Coded Elsewhere:** Neonatal obstructive hydrocephalus (KB05.0)
- 8D64.10** Hydrocephalus due to structural malformations  
Ventricular enlargement due to an accumulation of cerebrospinal fluid secondary to obstruction caused by a structural abnormality such as Chiari malformations or aqueductal stenosis.  
**Coded Elsewhere:** Dandy-Walker malformation with hydrocephalus (LA06.0)
- 8D64.1Y** Other specified non-communicating hydrocephalus
- 8D64.1Z** Non-communicating hydrocephalus, unspecified
- 8D64.2** **Ex-vacuo hydrocephalus**  
Hydrocephalus ex-vacuo occurs when there is damage to the brain caused by stroke, injury, or radiation, and there may be an actual shrinkage of brain substance. Although there is more CSF than usual, the CSF pressure itself is normal in hydrocephalus ex-vacuo.
- 8D64.Z** **Hydrocephalus, unspecified**
- 8D65** **Cerebrospinal fluid fistula**  
Cerebrospinal fluid fistula is a condition in which the cerebrospinal fluid (CSF) held in and around the human brain and spinal cord leaks out of the surrounding protective sac, the dura, for no apparent reason or due to several pathological processes.

**8D66****Syringomyelia or syringobulbia**

In syringomyelia, there is fluid-filled tubular cavitation (syrinx formation) within the central spinal cord. The syrinx can elongate, enlarge and expand into the grey and white matter and, as it does so, it compresses the nervous tissue of the corticospinal and spinothalamic tracts and the anterior horn cells. This leads to the various neurological symptoms and signs. If the syrinx extends into the brainstem, syringobulbia results.

**Exclusions:** Congenital hydromyelia (LA07.3)

**8D66.0****Idiopathic syringomyelia**

A condition in which the syrinx has no identifiable cause and which is difficult to treat. Most large and/or symptomatic syrinxes can be treated with syrinx shunting.

**8D66.1****Syringomyelia due to certain specified cause**

A condition when the syrinx is associated with an underlying cause.

**Coding Note:**

Code also the causing condition

**8D66.2****Syringobulbia**

Chronic progressive degenerative disorder of the CNS characterized by the formation of a fluid filled cavity known as a syrinx in the spinal cord that extends upwards to involve the medulla and pons. May occur in isolation or may also occur secondary to neoplasms, traumas, deformities of the craniocervical junction or meningitis.

**8D66.Y****Other specified syringomyelia or syringobulbia****8D66.Z****Syringomyelia or syringobulbia, unspecified****8D67****Intracranial arachnoid cyst**

A fluid filled cavity within the arachnoid membrane which may be congenital or acquired. Acquired causes include trauma, infection and surgery. The most common site is the middle cranial fossa. Factors that influence whether the cyst causes symptoms include its size and location. Symptoms if present may include headache, dizziness, nausea and vomiting, seizures, developmental delay

**8D68****Porencephalic cyst**

Cavity within the cerebral hemisphere that communicates directly with the ventricular system. Ischemic necrosis in utero or later in life can cause the adjacent ventricular region to expand into the stroke cavity forming, forming a cyst.

**8D6Y****Other specified disorders of cerebrospinal fluid pressure or flow****8D6Z****Disorders of cerebrospinal fluid pressure or flow, unspecified**

## Disorders of autonomic nervous system (8D80-8D8Z)

This is a group of conditions characterised as being in or associated with the autonomic nervous system, the

component of the peripheral nervous system that regulates involuntary physiologic processes.

**Inclusions:** Disorder of parasympathetic nervous system

**Coded Elsewhere:** Paroxysmal autonomic disorders

Hypohidrosis (EE01)

**8D80** **Congenital malformations of the autonomic nervous system**

**8D81** **Inherited autonomic nervous system disorders**

**8D82** **Autoimmune disorders involving the autonomic nervous system**

**8D83** **Autonomic nervous system disorder due to infection**

**Coding Note:** Code also the causing condition

**8D84** **Pure autonomic nervous system failure**

Pure autonomic failure is a sporadic, adult onset, slowly progressive disorder associated with accumulation of synuclein in peripheral autonomic neurons resulting in orthostatic hypotension, bladder and sexual dysfunction.

**8D85** **Autonomic nervous system disorder due to substances**

**Coded Elsewhere:** Neuroleptic malignant syndrome (8A0Y)

**8D86** **Autonomic nervous system hyperactivity**

**8D87** **Autonomic nervous system disorder due to certain specified neurodegenerative disorder**

**8D87.0** **Multiple system atrophy**

Multiple system atrophy (MSA) is a rare neurodegenerative disorder characterised by varied combinations of parkinsonian, cerebellar, autonomic (erectile dysfunction, bladder dysfunction, orthostatic hypotension) and pyramidal features. The disease belongs to the group of alpha-synucleinopathies, a group of diseases characterised by aggregation of alpha-synuclein in affected brain regions. There are two different types: MSA-P (with parkinsonism) and MSA-C (with cerebellar dysfunction).

**8D87.00** Multiple system atrophy, Cerebellar type

**8D87.01** Multiple system atrophy, Parkinsonism

This is a progressive disorder of the central and autonomic nervous systems, characterised by orthostatic hypotension (an excessive drop in blood pressure when standing up), which causes dizziness or fainting. It can occur without orthostatic hypotension, but instead have urinary involvement (urgency/incontinence). This type includes symptoms of Parkinson's disease such as slow movement, rigidity, and tremor.

**Exclusions:** Spinocerebellar ataxia (8A03.16)

Pure autonomic nervous system failure (8D84)

<b>8D87.0Y</b>	Other specified multiple system atrophy
<b>8D87.0Z</b>	Multiple system atrophy, unspecified
<b>8D87.Y</b>	<b>Other specified autonomic nervous system disorder due to specified neurodegenerative disorder</b>
<b>8D88</b>	<b>Autonomic neuropathies</b>
	<b>Coded Elsewhere:</b> Hereditary sensory or autonomic neuropathy (8C21)
<b>8D88.0</b>	<b>Autonomic neuropathy due to sodium channelopathies</b>
	<b>Coded Elsewhere:</b> Paroxysmal extreme pain disorder (8E43.Y)
	Primary erythromelalgia (EG00)
	Secondary erythromelalgia (EG00)
<b>8D88.1</b>	<b>Autonomic neuropathy due to diabetes mellitus</b>
	Dysfunction of the autonomic nervous system due to diabetes mellitus that presents as functional complications such as resting tachycardia, exercise intolerance, orthostatic hypotension, constipation, gastroparesis, sweating, bladder distention, and impotence.
<b>Coding Note:</b>	Always assign an additional code for diabetes mellitus.
<b>8D88.2</b>	<b>Immune mediated autonomic neuropathy</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8D88.3</b>	<b>Autonomic disorder due to toxins</b>
<b>8D88.4</b>	<b>Autonomic neuropathy in endocrine and metabolic diseases</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8D88.Y</b>	<b>Other specified autonomic neuropathies</b>
<b>8D88.Z</b>	<b>Autonomic neuropathies, unspecified</b>
<b>8D89</b>	<b>Disorders of orthostatic tolerance</b>
	Disorders characterized by symptomatic arterial hypotension (lightheadedness, fatigue) when assuming an upright position usually due to dysfunction of adrenergic regulation.
	<b>Coded Elsewhere:</b> Orthostatic hypotension (BA21)
<b>8D89.0</b>	<b>Reflex syncope</b>
	Reflex syncope is a transient loss of consciousness with spontaneous recovery and associated with loss of postural tone. Reflex syncope is the most common form of syncope and can occur in individuals with normal autonomic function. The mechanism is believed to be related to blood pooling in the legs followed by reduction in blood return to the heart which triggers a sympathetic tone increase. Vigorous cardiac contractions with an underfilled ventricle are hypothesized to cause reflex loss of sympathetic tone and vagotonia.
<b>8D89.1</b>	<b>Syncope due to autonomic failure</b>

- 8D89.2 Postural orthostatic tachycardia syndrome**  
Postural Orthostatic Tachycardia Syndrome is a type of chronic orthostatic intolerance lasting three months or longer associated with excessive upright tachycardia in the absence of orthostatic hypotension, plus a constellation of typically daily symptoms which may include lightheadedness, dizziness, nausea, dyspnoea, diaphoresis, headache, fatigue and other symptoms of autonomic dysfunction. Excessive tachycardia is defined by present consensus as a heart rate increase of at least 30 beats per minute in adults (40 beats per minute for adolescents), or a heart rate greater than 120 beats per minute, within 10 minutes of upright tilt table testing.
- 8D89.3 Baroreflex failure**
- 8D89.Y Other specified disorders of orthostatic tolerance**
- 8D89.Z Disorders of orthostatic tolerance, unspecified**
- 8D8A Focal or segmental autonomic disorders**  
*Coded Elsewhere:* Trigeminal autonomic cephalgias (8A82)  
Hyperlacrimation (9A10.3)  
Underproduction of tears (9A10.4)
- 8D8A.1 Horner syndrome**
- 8D8A.2 Episodic anisocoria**  
This is a group of disorders in which periodic pupillary movements lead to changes in size. These are due to abnormal parasympathetic or sympathetic tone.
- 8D8A.Y Other specified focal or segmental autonomic disorders**
- 8D8A.Z Focal or segmental autonomic disorders, unspecified**
- 8D8B Disorders affecting autonomic synaptic neurotransmission**  
*Coded Elsewhere:* Aromatic L-amino acid decarboxylase deficiency (5C59.00)  
Dopamine beta-hydroxylase deficiency (5C59.00)  
Autosomal recessive dopa-responsive dystonia (8A02.11)  
Menkes disease (5C64.0Y)
- 8D8C Autonomic dysreflexia**  
This is a potentially dangerous disorder associated with damage to the spinal cord above the sixth thoracic level characterized by a marked increase in the sympathetic response to minor stimuli. It leads to sudden severe hypertension which can be life-threatening.
- 8D8D Hypoglycaemia unawareness**  
Hypoglycemia unawareness is defined at the onset of neuroglycopenia before the appearance of autonomic warning symptoms
- 8D8Y Other specified disorders of autonomic nervous system**
- 8D8Z Disorders of autonomic nervous system, unspecified**

## **Human prion diseases (8E00-8E0Z)**

Human prion diseases or transmissible spongiform encephalopathies are rare transmissible diseases affecting the central nervous system. The infectious agents are composed of an abnormal isoform of a host membrane protein called 'prion protein' (PrP). Their common features are a long duration of incubation and lesions limited to the central nervous system without inflammatory or immunologic reaction but with accumulation of an abnormal form of prion protein (PrPsc).

**8E00**

### **Sporadic Creutzfeldt-Jakob Disease**

A disease of the brain, that is associated with a mutation of normal prion protein genes or spontaneous transformation of prion proteins. This disease is characterised by a long incubation period, progressive dementia, neurological deficits, and is fatal. Transmission may be by direct contact with infected nervous tissue or blood. Confirmation is by pathological examination of the brain.

**8E01**

### **Acquired prion disease**

Environmentally acquired prion diseases are prion diseases caused by a known source of abnormal prion protein.

**8E01.0**

### **Iatrogenically acquired Creutzfeldt-Jakob Disease**

Iatrogenically acquired Creutzfeldt-Jakob Disease (iCJD) is CJD acquired by medical procedures, medicines, medicinal materials, or devices.

**8E01.1**

### **Kuru**

A disease of the nervous system, caused by a prion. This disease is characterised by limb pain, ataxia, tremors, decreased coordination, or emotional changes, and is fatal. Transmission is by ingestion of infected human brain, or direct contact. Confirmation is commonly by clinical signs, or pathological examination of the brain.

**8E01.2**

### **Variant Creutzfeldt-Jakob Disease**

A disease of the brain, that is suspected to be caused by a prion associated with Bovine Spongiform Encephalopathy. This disease is characterised by a long incubation period, psychiatric symptoms followed by neurological deficits, and is fatal. Transmission may be by ingestion of food (with a bovine origin) contaminated with infected brain or spinal cord from an infected cow, or blood transfusion. Confirmation is by pathological examination of the brain.

**8E01.3**

### **Other acquired Creutzfeldt-Jakob Disease**

There have been cases of Creutzfeldt-Jakob Disease (CJD) associated with neurosurgical procedures and stereotactic electroencephalogram (EEG) electrode placement on the brain, particularly in the 1950s to 1970s when the transmissibility of prions was not yet recognised.

**8E01.Z**

### **Acquired prion disease, unspecified**

**8E02**

### **Genetic prion diseases**

**8E02.0**

### **Genetic Creutzfeldt-Jakob disease**

A disease of the brain, that is associated with a prion. This disease is characterised by neurological deficits, and is fatal. Confirmation is by pathological examination of the brain.

- 8E02.1**           **Gerstmann-Straussler-Scheinker syndrome**  
A disease caused by inheritance of mutation(s) in normal prion protein genes. This disease is characterised by cerebellar ataxia, decreased coordination, dysmetria, or dysarthria, and is fatal. Confirmation is by pathological examination of the brain and genetic testing.
- Exclusions:**       Gerstmann syndrome (MB4C)
- 8E02.2**           **Fatal familial insomnia**  
A disease of the brain, caused by inheritance of mutation(s) of normal prion protein genes. This disease is characterised by severe insomnia and autonomic system dysfunction, and is fatal. Confirmation is by pathological examination of the brain and genetic testing.
- 8E02.3**           **Other genetic prion diseases**
- 8E02.Y**           **Other specified Creutzfeldt-Jakob disease**
- 8E02.Z**           **Creutzfeldt-Jakob disease, unspecified**
- 8E03**           **Variably protease sensitive prionopathy**  
A disease of the brain, caused by a mutation(s) in prion protein genes. This disease is characterised by deposition of abnormal prions in the brain leading to behavioural and mood changes, speech deficits, and progressive motor impairments. Confirmation is by pathological examination of the brain or identification of protease-sensitive prion proteins in a brain sample.
- 8E0Y**           **Other specified human prion diseases**
- 8E0Z**           **Human prion diseases, unspecified**

## Disorders of consciousness (8E20-8E2Z)

**Coded Elsewhere:** Delirium (6D70)

Coma (MB20.1)

- 8E20**           **Persistent vegetative state**  
Subacute or chronic state of severe disturbance of consciousness lasting at least a month, characterised by the recovery of cyclic arousal states mimicking sleep/wake cycles after a severe brain injury. Patients with this condition are unresponsive and show no evidence of awareness of themselves or their environment. Cardiopulmonary and visceral autonomic regulation is maintained by the brainstem.

- 8E21**           **Permanent vegetative state**  
Prognostic term applied to patients in a persistent vegetative state for whom no recovery is expected.

<b>8E22</b>	<b>Minimally conscious state</b> Subacute or chronic state of severely disturbed consciousness in which patients show minimal yet definite signs of consciousness, such as visual pursuit or command following, occurring after a severe brain injury. These patients do not show functional communication or functional use of objects.
<b>8E22.0</b>	<b>Minimally conscious state plus</b> Subcategory of patients in a minimally conscious state who show signs of command following.
<b>8E22.1</b>	<b>Minimally conscious state minus</b> Subcategory of patients in a minimally conscious state who show signs of non-reflex behaviour such as eye tracking, orientation to pain, or contingent responses to specific emotional stimuli but without command following.
<b>8E22.Y</b>	<b>Other specified minimally conscious state</b>
<b>8E22.Z</b>	<b>Minimally conscious state, unspecified</b>
<b>8E2Y</b>	<b>Other specified disorders of consciousness</b>
<b>8E2Z</b>	<b>Disorders of consciousness, unspecified</b>

## Other disorders of the nervous system (8E40-8E4Y)

**Coded Elsewhere:** Brain death (MH10)

Neurosarcoidosis (4B20.3)

<b>8E40</b>	<b>Disorders of the meninges excluding infection</b>
	<b>Coded Elsewhere:</b> Postprocedural meningitis (8E62)

<b>8E40.0</b>	<b>Neoplastic meningitis</b>
	Inflammation of the meninges due to malignant infiltration from carcinomas, leukaemias and lymphomas. The syndrome is clinically characterised by headache, neck stiffness, fever and photophobia with potential progression to stupor and coma. The presentation may be acute, subacute or chronic. Diagnosis may be aided by neuroimaging and spinal fluid analysis which may reveal a lymphocytic pleocytosis, raised protein and the presence of malignant cells on cytology.

**Coding Note:** Code also the causing condition

<b>8E40.1</b>	<b>Chemical meningitis</b>
<b>8E40.2</b>	<b>Inflammatory meningitis</b>

A general term to describe a group of disorders in which there is Inflammation of the meninges due to an underlying inflammatory disorder. The syndrome is clinically characterised by headache, neck stiffness, fever and photophobia. Other central and peripheral nervous system manifestations may be present. Non-neurological features, including skin, eye and organ involvement may also be present. Diagnosis may be aided by serological testing, neuroimaging and if appropriate a tissue biopsy. Spinal fluid analysis may reveal a lymphocytic pleocytosis, a raised protein and the presence of oligoclonal bands.

- 8E40.3 Arachnoiditis**  
Arachnoiditis is a chronic inflammation of the arachnoid layer of the meninges, of which adhesive arachnoiditis is the most severe form, characterised by debilitating, intractable neurogenic back and limb pain and a range of other neurological problems.
- 8E40.Y Other specified disorders of the meninges excluding infection**
- 8E40.Z Disorders of the meninges excluding infection, unspecified**
- 8E41 Pachymeningitis**  
Inflammation of the pachymeninges resulting in localised or diffuse thickening of the dura mater which can be caused by chronic infection, inflammatory and immune-mediated disorders and malignancies. The cranial and/or the spinal dura may be affected. Neurological features include headache, visual disturbance, cranial nerve palsies, ataxia and with spinal involvement, limb weakness, sensory impairment and sphincter disturbances . Diagnosis may be aided by neuroimaging and spinal fluid analysis.
- 8E41.0 Pachymeningitis due to infection**  
Inflammation of the pachymeninges resulting in localised or diffuse thickening of the dura mater caused by chronic infection such as tuberculosis. The cranial and/or the spinal dura may be affected. Neurological features include headache, visual disturbance, cranial nerve palsies, ataxia and, with spinal involvement, limb weakness, sensory impairment and sphincter disturbances. Diagnosis may be aided by neuroimaging, spinal fluid analysis and dural biopsy.
- 8E41.1 Idiopathic hypertrophic pachymeningitis**  
Inflammation of the pachymeninges resulting in localised or diffuse thickening of the dura mater for which no identifiable cause is found. The cranial and/or the spinal dura may be affected. Neurological features include headache, visual disturbance, cranial nerve palsies, ataxia and with spinal involvement, limb weakness, sensory impairment and sphincter disturbances. Diagnosis may be aided by neuroimaging and spinal fluid analysis and dural biopsy.
- 8E41.Y Other specified pachymeningitis**
- 8E41.Z Pachymeningitis, unspecified**
- 8E42 Superficial siderosis of the nervous system**  
Superficial siderosis is the deposition of haemosiderin in the central nervous system as a result of chronic or recurrent subarachnoid haemorrhage due to vascular anomalies, aneurysms, vascular tumours, neurosurgery, cervical root lesions, head injury and trauma. Clinical feature of Superficial siderosis include sensorineural deafness, cerebellar ataxia, pyramidal weakness and less frequently dementia, loss of sphincter control, anosmia, anisocoria, sensory disturbance, extra-ocular motor palsies, sciatica and lower motor neuron signs. The diagnosis may be confirmed by pure tone audiometry, neuroimaging, spinal fluid analysis, angiography to identify a potential bleeding source and where appropriate genetic testing.

**8E43****Pain disorders**

**Exclusions:** Chronic neuropathic pain (MG30.5)

**8E43.0****Neuropathic pain**

Neuropathic pain is described as electric, burning, or shock like, caused by metabolic, nutritional, infectious, genetic, autoimmune, and/or vasculitic processes. The pain may occur spontaneously, without provocation, or be provoked by noxious or nonnoxious stimuli. Pain is characteristic of small fibre neuropathy, but even in large fibre neuropathies, a sufficient number of small fibres may be damaged to cause pain. Neuropathic pain usually affects distal skin and subcutaneous structures. The pain may be constant or intermittent, and may be described as searing, burning, or icy cold.

Complex regional pain syndrome follows trauma and comprises regional pain, sensory changes, abnormalities of temperature, sudomotor activity, colour changes of the skin, and oedema.

**Exclusions:** Chronic neuropathic pain (MG30.5)

**8E43.00****Phantom limb syndrome**

Phantom limb pain is the perception of sensations, including pain, in a limb that has been amputated or a body part that has been removed. These sensations may include a specific position, shape, or movement of the phantom, feelings of warmth or cold, itching, tingling, or electric sensations, and other paraesthesiae.

**8E43.0Y****Other specified neuropathic pain****8E43.0Z****Neuropathic pain, unspecified****8E43.Y****Other specified pain disorders****8E43.Z****Pain disorders, unspecified****8E44****Post anoxic brain damage**

Post anoxic brain damage refers to the variable severity of encephalopathy that results from circulatory arrest, hypotension or asphyxia.

**8E45****Locked-in syndrome****8E46****Reye syndrome**

Reye syndrome is sudden (acute) brain damage (encephalopathy) and liver function problems of unknown cause. The syndrome has occurred with the use of aspirin to treat chickenpox or the flu in children. However, it has become very uncommon since aspirin is no longer recommended for routine use in children. Reye syndrome often begins with vomiting, which lasts for many hours. The vomiting is quickly followed by irritable and aggressive behaviour. There is no specific treatment for this condition. The health care provider will monitor the pressure in the brain, blood gases, and blood acid-base balance (pH).

**8E47**

**Encephalopathy, not elsewhere classified**

Global brain dysfunction

**Coding Note:**

Code also the causing condition

**Coded Elsewhere:** Neonatal encephalopathy (KB03)

**8E48**

**Encephalitis, not elsewhere classified**

**8E49**

**Postviral fatigue syndrome**

**Inclusions:** chronic fatigue syndrome

myalgic encephalomyelitis

**Exclusions:** Fatigue (MG22)

**8E4A**

**Paraneoplastic or autoimmune disorders of the nervous system**

Paraneoplastic and autoimmune disorders of the nervous system result from a targeted immune attack on neurons or glial cells in the central (e.g. encephalopathy, ataxia, myelitis) or peripheral nervous systems (peripheral or autonomic neuropathies, neuromuscular junction disorders or myopathy). In the paraneoplastic context, this attack is a consequence of a potentially effective tumour immune response initiated by onco-neural antigens derived from a systemic cancer. In the non-paraneoplastic context termed autoimmune the etiology remains elusive though increasing evidence indicates a preceding infectious trigger in at least some cases. These disorders are commonly multifocal causing injury and symptoms arising from involvement at many levels of the nervous system. A personal or family history of autoimmunity is often found. Accompanying neural and non-organ specific (thyroid peroxidase [TPO] antibodies) autoantibodies may be found. The neural autoantibody profile may be predictive of a specific cancer type and may be associated with a particular neurological phenotype. Exclusion of alternative etiologies (e.g. infections) is important. Response to immunotherapy may support the diagnosis.

**Coding Note:**

Code also the causing condition

**8E4A.0 Paraneoplastic or autoimmune disorders of the central nervous system, brain or spinal cord**

Paraneoplastic and autoimmune disorders of the central nervous system, brain and spinal cord nervous system result from a targeted immune attack on neurons or glial cells in the central (e.g. encephalopathy, ataxia, myelopathy, myelitis) nervous system. In the paraneoplastic context, this attack is a consequence of a potentially effective tumour immune response initiated by onco-neural antigens derived from a systemic cancer. In the non-paraneoplastic context termed 'autoimmune' the etiology remains elusive though increasing evidence indicates a preceding infectious trigger in at least some cases. These disorders are commonly multifocal causing injury and symptoms arising from involvement at many levels of the central nervous system. A personal or family history of autoimmunity is often found. Accompanying neural and non-organ specific (thyroid peroxidase [TPO] antibodies) autoantibodies may be found. The neural autoantibody profile may be predictive of a specific cancer type and may be associated with a particular neurological phenotype. Exclusion of alternative etiologies (e.g. infections) is important. Response to immunotherapy may support the diagnosis.

**Coding Note:** Code also the causing condition

**Coded Elsewhere:** Paraneoplastic retinopathy (9B71.4)

Autoimmune retinopathy (9B71.5)

Opsoclonus-myoclonus (9C85.02)

**8E4A.1 Paraneoplastic or autoimmune disorders of the peripheral or autonomic nervous system**

Paraneoplastic and autoimmune disorders of the peripheral and autonomic nervous system result from a targeted immune attack on neurons or glial cells in the peripheral nervous systems (peripheral or autonomic neuropathies). In the paraneoplastic context, this attack is a consequence of a potentially effective tumour immune response initiated by onco-neural antigens derived from a systemic cancer. In the non-paraneoplastic context termed autoimmune the etiology remains elusive though increasing evidence indicates a preceding infectious trigger in at least some cases. Onset may be subacute or insidious and these disorders may be limited, multifocal or generalised. Autoimmune somatic peripheral nerve disorders may affect the nerve at multiple levels including root, nerve and plexus and may be axonal, demyelinating or both. Autoimmune autonomic disorders result in autonomic failure that can be partial or generalised. The prototypic autonomic neuropathy is the autoimmune ganglionopathy associated with

antibodies targeting the ganglionic nicotinic acetylcholine receptor ( $\alpha$ 3 gAChR). Screening for cancer is appropriate for those with specific neural antibody profiles and other risk factors.

Associated neural antibodies in peripheral neuropathies include anti neuronal nuclear antibody type 1 or anti-Hu, CASPR2, gAChR, ganglioside (GM1 IgG and IGM) antibodies.

**Coding Note:** Code also the causing condition

<b>8E4A.2</b>	<b>Paraneoplastic or autoimmune neuromuscular transmission disorders</b>
	NMT disorders are defined by a variable disturbance of the function of the neuromuscular transmission, resulting in fluctuating muscle weakness and fatigue. These are usually classified into pre- and postsynaptic disorders.
	Presynaptic disorders, mainly the Lambert Eaton Myasthenic Syndrome (LEMS) is associated with antibodies targeting the voltage gated calcium channels (PQ and N type). LEMS is associated with malignancy (pulmonary or extra-pulmonary small cell carcinoma) in about 50% of cases. In the context of LEMS the detection of SOX 1 (anti glial nuclear) antibodies is highly predictive of cancer.
	Postsynaptically, myasthenia gravis is mostly (> 90%) associated with antibodies targeting the muscle acetylcholine receptor (AChR) or rarely other proteins (including muscle -specific kinase -MuSK). Myasthenia is usually not considered a paraneoplastic disease, with the exception of thymoma in about 10% cases.
<b>Coding Note:</b>	Code also the causing condition
	<b>Coded Elsewhere:</b> Lambert-Eaton syndrome (8C62)
	Myasthenia gravis (8C60)
<b>8E4A.3</b>	<b>Paraneoplastic or autoimmune disorders of the muscle</b>
	Paraneoplastic and autoimmune diseases of muscle present with weakness and can be caused by a variety of causes, either by undefined remote effects or autoimmune effects in cancer, or autoimmune mechanisms in non cancer related conditions. The presentation is variable, usually presenting with a proximal myopathic pattern.
<b>Coding Note:</b>	Code also the causing condition
<b>8E4A.Y</b>	<b>Other specified paraneoplastic or autoimmune disorders of the nervous system</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8E4A.Z</b>	<b>Paraneoplastic or autoimmune disorders of the nervous system, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>8E4Y</b>	<b>Other specified disorders of the nervous system</b>

### Postprocedural disorders of the nervous system (8E60-8E66)

<b>Coded Elsewhere:</b>	Anoxic-ischaemic encephalopathy (8B24.0)
	Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)
	Post dural puncture headache (8A84.Y)
	Dural graft-associated Creutzfeldt-Jakob Disease (8E01.0)

### **8E60 Post ventricular shunting leak**

**8E61**

**Post radiation injury of the nervous system**

**Coded Elsewhere:** Post radiation lumbosacral plexopathy (8B92.0)

Post radiation polyneuropathy (8D43.21)

Post radiation brachial plexopathy (8B91.Y)

**8E61.0**

**Radiation-induced brain injury**

Injury to the brain from therapeutic cranial irradiation which may be divided temporally into three syndromes: Acute or early toxicity which is consequent upon immediate exposure to radiation, early-delayed injury and late-delayed injury although the three may overlap.

**8E61.1**

**Spinal cord irradiation**

**8E61.Z**

**Post radiation injury of the nervous system, unspecified**

**8E62**

**Postprocedural meningitis**

Inflammation of the meninges due to a procedure. The syndrome is clinically characterised by headache, neck stiffness, fever and photophobia. Diagnosis may be aided by neuroimaging and spinal fluid analysis which may reveal a lymphocytic pleocytosis and raised protein.

**8E63**

**Post pump encephalopathy**

**8E64**

**Multifocal cerebral infarctions**

**8E66**

**Intracranial hypotension due to lumbar puncture**

---

**8E7Y**

**Other specified diseases of the nervous system**

**8E7Z**

**Diseases of the nervous system, unspecified**

# CHAPTER 09

---

## Diseases of the visual system

This chapter has 160 four-character categories.

Code range starts with 9A00

This refers to any diseases of the visual system, which includes the eyes and adnexa, the visual pathways and brain areas, which initiate and control visual perception and visually guided behaviour.

- Exclusions:**
- Certain conditions originating in the perinatal period (Chapter 19)
  - Certain infectious or parasitic diseases (Chapter 01)
  - Complications of pregnancy, childbirth and the puerperium (Chapter 18)
  - Endocrine, nutritional or metabolic diseases (Chapter 05)
  - Injury, poisoning or certain other consequences of external causes (Chapter 22)
  - Posterior cortical atrophy (8A21.0)

- Coded Elsewhere:**
- Neoplasms of the eye or ocular adnexa
  - Reasons for contact with the health care system in relation to eyes or vision
  - Contusion of eyeball or orbital tissues (NA06.9)
  - Foreign body in multiple parts of external eye (ND70.2)
  - Oculocutaneous albinism (EC23.20)
  - Traumatic injury to eyeball (NA06.8)
  - Birth injury to eye (KA41)
  - Late congenital syphilitic oculopathy (1A60.2)
  - Symptoms, signs or clinical findings of the visual system (MC10-MC2Y)
  - Structural developmental anomalies of the eye, eyelid or lacrimal apparatus (LA10-LA1Z)

This chapter contains the following top level blocks:

- Disorders of the ocular adnexa or orbit
- Disorders of the eyeball - anterior segment
- Disorders of the eyeball - posterior segment
- Disorders of the eyeball affecting both anterior and posterior segments
- Disorders of the visual pathways or centres
- Glaucoma or glaucoma suspect
- Strabismus or ocular motility disorders
- Disorders of refraction or accommodation
- Postprocedural disorders of eye or ocular adnexa

- Impairment of visual functions
- Vision impairment
- Neoplasms of the eye or ocular adnexa
- Reasons for contact with the health care system in relation to eyes or vision

## Disorders of the ocular adnexa or orbit (9A00-9A4Z)

**Coded Elsewhere:** Ocular myiasis (1G01.0)

### Disorders of eyelid or peri-ocular area (9A00-9A0Z)

**Coded Elsewhere:** Congenital malformations of the eyelid

- Seborrhoeic keratosis (2F21.0)
- Cysts of eyelid (2F36.4)
- Eyelid trauma (NA06.0)
- Benign cutaneous neoplasm or cyst of eyelid (2F36.Z)

**9A00**

### Congenital malposition of eyelids

- Coded Elsewhere:** Congenital entropion (LA14.02)  
 Congenital ectropion (LA14.03)  
 Congenital ptosis (LA14.04)  
 Hypotelorism (LB71.0)  
 Hypertelorism (LB71.1)  
 Epiblepharon (LA14.0Y)

**9A00.0**

### Dystopia canthorum

**Coded Elsewhere:** Waardenburg syndrome (EC23.2Y)

**9A00.1**

### Telecanthus

**9A00.Y**

### Other specified congenital malposition of eyelids

**9A00.Z**

### Congenital malposition of eyelids, unspecified

**9A01**

### Infectious disorders of eyelid

- Coded Elsewhere:** Trachoma (1C23)  
 Involvement of eyelid in tuberculosis (1B12.1)  
 Involvement of eyelid in leprosy (1B20.3)  
 Verruca vulgaris of eyelid (1E80.Y)

**9A01.0**

### Preseptal cellulitis

**9A01.1**

### Abscess of eyelid

- 9A01.2** **Hordeolum**  
An acute focal infection usually by *Staphylococcus aureus* involving the eyelash follicle and its associated meibomian and Zeis glands. If the principal focus of infection is the follicle, it presents with a painful boil which discharges pus at the eyelid margin (external hordeolum or stye). If the infection is centred on the meibomian gland (internal hordeolum) then suppuration onto the conjunctival surface occurs.
- 9A01.20** **Hordeolum externum**  
An acute focal pyogenic infection of the eyelash follicle commonly known as a stye and caused predominantly by *Staphylococcus aureus*. It presents as an acute painful inflammatory eyelid swelling which subsequently discharges at the eyelid margin.
- 9A01.21** **Hordeolum internum**  
A focal acute pyogenic infection, usually by *Staphylococcus aureus*, of a meibomian gland, the normal secretion from which into the eyelash follicle is blocked. It presents as an acute inflammatory swelling which may discharge onto the conjunctival surface of the eyelid, or rarely anteriorly through the eyelid skin. It may predispose to formation of a chalazion.
- Exclusions:** Chalazion (9A02.0)
- 9A01.2Z** **Hordeolum, unspecified**
- 9A01.3** **Infectious blepharitis**  
A condition of the eyelid, commonly caused by an infection with a bacterial source. This condition is characterised by pruritus, burning, scratchiness, excessive tearing, or crusty debris around the eyelashes. This condition may also present with lid erythema, collarettes, madarosis, trichiasis, or plugged meibomian glands. Transmission is by direct or indirect contact with an infected individual, endogenous spread, or through fomites.
- Exclusions:** Blepharoconjunctivitis (9A60.4)
- Coded Elsewhere:** Herpes simplex infection of eyelid (1F00.11)  
Molluscum contagiosum of eyelid (1E76)  
Zoster infection of eyelid (1E91.1)
- 9A01.4** **Infestation of eyelid**
- Coding Note:** Code also the causing condition
- Coded Elsewhere:** Parasitic infestation of eyelid in loiasis (1F66.0)  
Parasitic infestation of eyelid in leishmaniasis (1F54.Z)
- 9A01.Y** **Other specified infectious disorders of eyelid**
- 9A01.Z** **Unspecified infectious disorders of eyelid**
- 9A02** **Inflammatory disorders of eyelid**
- Coded Elsewhere:** Atopic eczema of eyelids (9A06.70)  
Seborrhoeic dermatitis of eyelids (9A06.71)

<b>9A02.0</b>	<b>Chalazion</b> A chalazion is a small cyst on the eyelid caused by blockage of a meibomian gland.
<b>9A02.00</b>	Chalazion externum
<b>9A02.01</b>	Chalazion internum
<b>9A02.0Y</b>	Other specified chalazion
<b>9A02.0Z</b>	Chalazion, unspecified
<b>9A02.1</b>	<b>Posterior blepharitis</b> Posterior blepharitis is inflammation of the eyelids secondary to dysfunction of the meibomian glands. Like anterior blepharitis it is a bilateral chronic condition and manifested by a broad spectrum of symptoms involving the lids including inflammation and plugging of the meibomian orifices and production of abnormal secretion upon pressure over the glands. It may be associated with skin rosacea.
<b>9A02.2</b>	<b>Ligneous conjunctivitis</b> Ligneous conjunctivitis (LC) is a rare form of chronic conjunctivitis characterised by the recurrent formation of pseudomembranous lesions most commonly on the palpebral surfaces. It is most frequently reported as a clinical manifestation of severe homozygous or compound-heterozygous hypoplasminogenaemia. Most cases involve infants and children.
<b>9A02.4</b>	<b>Meibomian gland dysfunction</b> This refers to the dysfunction of a special kind of sebaceous gland at the rim of the eyelids inside the tarsal plate, responsible for the supply of meibum, an oily substance that prevents evaporation of the eye's tear film. Meibum prevents tear spillage onto the cheek, trapping tears between the oiled edge and the eyeball, and makes the closed lids airtight.
<b>9A02.Y</b>	<b>Other specified inflammatory disorders of eyelid</b>
<b>9A02.Z</b>	<b>Inflammatory disorders of eyelid, unspecified</b>
<b>9A03</b>	<b>Acquired malposition of eyelid</b>
<b>9A03.0</b>	<b>Blepharoptosis</b> Drooping of the upper lid due to deficient development or paralysis of the levator palpebrae muscle.
<b>9A03.00</b>	Marcus-Gunn syndrome Marcus-Gunn syndrome is characterised by ptosis associated with maxillopalpebral synkinesis. The syndrome is generally unilateral and sporadic, but bilateral and autosomal dominant inherited cases have been reported.
<b>9A03.01</b>	Mechanical ptosis of eyelid

<b>9A03.02</b>	Myogenic ptosis of eyelid This refers to a contraction initiated by the myocyte cell itself instead of an outside occurrence or stimulus such as nerve innervation, causing drooping or falling of the eyelid. The drooping may be worse after being awake longer, when the individual's muscles are tired.
<b>9A03.03</b>	Paralytic ptosis of eyelid
<b>9A03.0Y</b>	Other specified blepharoptosis
<b>9A03.0Z</b>	Blepharoptosis, unspecified
<b>9A03.1</b>	<b>Entropion of eyelid</b>
<b>9A03.10</b>	Cicatricial entropion of eyelid
<b>9A03.11</b>	Mechanical entropion of eyelid
<b>9A03.12</b>	Senile entropion of eyelid This is a senile condition in which the eyelid (usually the lower lid) folds inward. It is very uncomfortable, as the eyelashes constantly rub against the cornea and irritate it. Entropion is usually caused by genetic factors and very rarely it may be congenital when an extra fold of skin grows with the lower eyelid (epiblepharon). Entropion can also create secondary pain of the eye (leading to self trauma, scarring of the eyelid, or nerve damage).
<b>9A03.13</b>	Spastic entropion of eyelid This is a spastic condition in which the eyelid (usually the lower lid) folds inward. It is very uncomfortable, as the eyelashes constantly rub against the cornea and irritate it. Entropion is usually caused by genetic factors and very rarely it may be congenital when an extra fold of skin grows with the lower eyelid (epiblepharon). Entropion can also create secondary pain of the eye (leading to self trauma, scarring of the eyelid, or nerve damage).
<b>9A03.1Y</b>	Other specified entropion of eyelid
<b>9A03.1Z</b>	Entropion of eyelid, unspecified
<b>9A03.2</b>	<b>Ectropion of eyelid</b> The turning outward (eversion) of the edge of the eyelid, resulting in the exposure of the palpebral conjunctiva.
<b>9A03.20</b>	Cicatricial ectropion of eyelid
<b>9A03.21</b>	Mechanical ectropion of eyelid
<b>9A03.22</b>	Senile ectropion of eyelid
<b>9A03.23</b>	Spastic ectropion of eyelid

- 9A03.24** Floppy eyelid syndrome  
 Acquired disorder of unknown origin, manifested by an easily everted floppy upper eyelid and papillary conjunctivitis of the upper palpebral conjunctiva. It is primarily associated with obese men and obstructive sleep apnoea. The tarsus of the upper eyelid becomes softer and looser probably due to mechanical forces and enzymatical changes. The upper eyelid everts during sleep, resulting in irritation, papillary conjunctivitis, and conjunctival keratinization. Effective treatment consists of preventing the upper eyelid from everting while the patient is sleeping.
- 9A03.2Y** Other specified ectropion of eyelid
- 9A03.2Z** Ectropion of eyelid, unspecified
- 9A03.3** **Eyelid retraction**
- 9A03.4** **Lagophthalmos**
- 9A03.40** Cicatricial lagophthalmos
- 9A03.41** Mechanical lagophthalmos
- 9A03.42** Paralytic lagophthalmos
- 9A03.4Y** Other specified lagophthalmos
- 9A03.4Z** Lagophthalmos, unspecified
- 9A03.5** **Dermatochalasis of eyelid**
- 9A03.Y** **Other specified acquired malposition of eyelid**
- 9A03.Z** **Acquired malposition of eyelid, unspecified**
- 9A04** **Acquired disorders of eyelashes**
- Exclusions:** Distichiasis (LA14.0)  
 Structural developmental anomalies of eyelids (LA14.0)
- 9A04.0** **Trichiasis without entropion**  
 This refers to abnormally positioned eyelashes that grow back toward the eye, touching the cornea or conjunctiva. This can be caused by infection, inflammation, autoimmune conditions, congenital defects, eyelid agenesis and trauma such as burns or eyelid injury. This diagnosis is without a condition in which the eyelid (usually the lower lid) folds inward. It is very uncomfortable, as the eyelashes constantly rub against the cornea and irritate it.
- 9A04.1** **Madarosis of eyelid or periocular area**  
 Partial or complete loss of eyelashes and/or eyebrow hairs. Alopecia areata and chronic cutaneous lupus erythematosus are well recognised causes. If the underlying cause is known this should be coded as well.
- 9A04.Y** **Other specified acquired disorders of eyelashes**
- 9A04.Z** **Acquired disorders of eyelashes, unspecified**

**9A05****Movement disorders of eyelid**

**Exclusions:** Tic disorders (8A05)

**Coded Elsewhere:** Benign essential blepharospasm (8A02.00)

Hemifacial spasm (8B88.2)

Facial tic (8A05.03)

**9A05.0****Myokymia of eyelid**

Myokymia is used to describe an involuntary eyelid muscle contraction, typically involving the lower eyelid or less often the upper eyelid. It occurs in normal individuals and typically starts and disappears spontaneously. However, it can sometimes last up to three weeks. Since the condition typically resolves itself, medical professionals do not consider it to be serious or a cause for concern.

**Exclusions:** Facial myokymia (8B88.1)

Myokymia (MB47.5)

**9A05.1****Eyelid apraxia****9A05.Y****Other specified movement disorders of eyelid****9A05.Z****Movement disorders of eyelid, unspecified****9A06****Certain specified disorders of eyelid****9A06.0****Involvement of eyelid by dermatosis classified elsewhere**

Involvement of eyelid by skin diseases such as psoriasis or lichen planus.

**9A06.1****Vitiligo of eyelid or periocular area****9A06.2****Sympblepharon, acquired****9A06.3****Traumatic scar of eyelid****9A06.4****Xanthelasma of eyelid**

Xanthelasmata are a form of plane xanthoma which manifest as sharply demarcated yellowish deposits of lipid within the skin of the eyelid. While they are neither harmful nor painful, these minor growths may be disfiguring and may be the presenting sign of hypercholesterolaemia. They are common in people of Asian origin and those from the Mediterranean region.

**9A06.5****Tear Trough Deformity****9A06.6****Sunken Sulcus Deformity****9A06.7****Dermatitis or eczema of eyelids**

Eczematous blepharitis and contact dermatitis affecting the eyelids.

**Coded Elsewhere:** Irritant contact blepharoconjunctivitis (EK02.11)

**9A06.70****Atopic eczema of eyelids**

Atopic eczema affecting the eyelids. This is a common manifestation of atopic eczema and can result in a significant impact on normal vision and on well-being.

- 9A06.71** Seborrhoeic dermatitis of eyelids  
 Seborrhoeic dermatitis of eyelids (seborrhoeic blepharitis) is common. It is characterised by redness and scaling on the skin of the eyelids with variable involvement of the eyelid margins.  
**Exclusions:** Seborrhoea (ED91.2)
- 9A06.72** Allergic contact blepharoconjunctivitis  
 Allergic contact dermatitis affecting the eyelid and conjunctivae.
- 9A06.7Y** Other specified dermatitis or eczema of eyelids
- 9A06.7Z** Dermatitis or eczema of eyelids, type unspecified
- 9A06.8** **Blepharochalasis**  
 This is a malposition of the eyelid caused either by involution or by inflammation of the eyelid. The inflammation is characterised by exacerbations and remissions of eyelid oedema, which results in a stretching and subsequent atrophy of the eyelid tissue resulting in redundant folds over the lid margins. It typically affects only the upper eyelids, and may be unilateral as well as bilateral.
- 9A06.Y** Other specified disorders of eyelid
- 9A0Y** Other specified disorders of eyelid or peri-ocular area
- 9A0Z** Disorders of eyelid or peri-ocular area, unspecified

Disorders of lacrimal apparatus (9A10-9A1Z)

- Exclusions:** congenital malformations of lacrimal system (LA14.1)
- 9A10** **Disorders of lacrimal gland**
- 9A10.0** **Infections of the lacrimal gland**
- 9A10.1** **Orbital inflammatory syndrome**  
 This refers to a marginated mass-like enhancing soft tissue involving any area of the orbit. It is the most common painful orbital mass in the adult population, and is associated with proptosis, cranial nerve palsy (Tolosa-Hunt syndrome), uveitis, and retinal detachment.
- 9A10.2** **Benign lymphoepithelial lesion of lacrimal gland**  
 This is a type of benign enlargement of the parotid and/or lacrimal glands. This pathologic state is sometimes, but not always, associated with Sjögren's syndrome. This diagnosis is of paired almond-shaped glands, one for each eye, that secrete the aqueous layer of the tear film.
- 9A10.3** **Hyperlacrimation**
- 9A10.4** **Underproduction of tears**  
 Underproduction of tears causes keratoconjunctivitis sicca and can be caused by disorders that interrupt the neural control of lachrymation.

<b>9A10.Y</b>	<b>Other specified disorders of lacrimal gland</b>
<b>9A10.Z</b>	<b>Disorders of lacrimal gland, unspecified</b>
<b>9A11</b>	<b>Disorders of lacrimal drainage system</b>
	<b>Coded Elsewhere:</b> Agenesis of lacrimal ducts (LA14.11)
	Congenital dacryocele (LA14.12)
	Congenital agenesis of lacrimal punctum (LA14.13)
	Congenital stenosis or stricture of lacrimal duct (LA14.14)
<b>9A11.0</b>	<b>Eversion of lacrimal punctum</b>
	<b>Inclusions:</b> Punctal ectropion
<b>9A11.1</b>	<b>Canaliculitis</b>
<b>9A11.2</b>	<b>Dacryocystitis</b>
<b>9A11.3</b>	<b>Conjunctivochalasis</b>
<b>9A11.4</b>	<b>Punctal stenosis</b>
<b>9A11.5</b>	<b>Nasolacrimal canicular stenosis</b>
<b>9A11.6</b>	<b>Dacryolith</b>
<b>9A11.7</b>	<b>Nasolacrimal sac stenosis</b>
<b>9A11.8</b>	<b>Nasolacrimal duct obstruction</b>
	<b>Coded Elsewhere:</b> Congenital stenosis or stricture of lacrimal duct (LA14.14)
<b>9A11.Y</b>	<b>Other specified disorders of lacrimal drainage system</b>
<b>9A11.Z</b>	<b>Disorders of lacrimal drainage system, unspecified</b>
<b>9A1Y</b>	<b>Other specified disorders of lacrimal apparatus</b>
<b>9A1Z</b>	<b>Disorders of lacrimal apparatus, unspecified</b>

#### Disorders of orbit (9A20-9A2Z)

This refers to disorders of the cavity or socket of the skull in which the eye and its appendages are situated. "Orbit" can refer to the bony socket, or it can also be used to imply the contents.

<b>Coded Elsewhere:</b> Neoplasms of orbit	
Orbital trauma	
Structural developmental anomalies of orbit (LA14.2)	
<b>9A20</b>	<b>Displacement of eyeball</b>
<b>9A20.0</b>	<b>Axial displacement of eyeball</b>

- 9A20.00** Outward displacement of eyeball
- Coding Note:** Code also the causing condition
- Inclusions:**
- Proptosis
  - Exophthalmos
- 9A20.01** Inward displacement of eyeball
- Inclusions:**
- Enophthalmos
- 9A20.0Y** Other specified axial displacement of eyeball
- 9A20.0Z** Axial displacement of eyeball, unspecified
- 9A20.1** **Non-axial displacement of eyeball**
- 9A20.Y** **Other specified displacement of eyeball**
- 9A20.Z** **Displacement of eyeball, unspecified**
- 9A21** **Orbital infection**
- Coded Elsewhere:**
- Osteomyelitis of orbit (FB84.Y)
  - Hydatic cyst (9A23.1)
  - Echinococcus infection of orbit (1F73.Y)
  - Myiasis of orbit (1G01.0)
- 9A21.0** **Orbital cellulitis**
- Exclusions:**
- Streptococcal cellulitis of skin (1B70.1)
  - Staphylococcal cellulitis of skin (1B70.2)
- 9A21.1** **Orbital subperiosteal abscess**
- A condition of the eye and adnexa, caused by an infection with a bacterial source. This condition is characterised by a focal accumulation of purulent material in the bones that support the globe, fever, crusting of the eye, swelling of the eye, or proptosis. Confirmation is by identification of the bacterial agent.
- 9A21.2** **Orbital abscess**
- 9A21.3** **Periostitis of orbit**
- 9A21.Y** **Other specified orbital infection**
- 9A21.Z** **Orbital infection, unspecified**
- 9A22** **Orbital inflammation**
- 9A22.0** **Dysthyroid orbitopathy**
- 9A22.1** **Diffuse orbital inflammation**
- 9A22.2** **Granulomatous orbital inflammation**
- 9A22.Y** **Other specified orbital inflammation**
- 9A22.Z** **Orbital inflammation, unspecified**

<b>9A23</b>	<b>Orbital cyst</b>
<b>9A23.0</b>	<b>Congenital orbital cyst</b>
	<i>Coded Elsewhere:</i> Teratoma of orbit (2F36.3)
	Dermoid cyst of eyelid (2F36.4)
<b>9A23.1</b>	<b>Acquired orbital cyst</b>
	<i>Coded Elsewhere:</i> Epidermoid cyst (EK70.0)
<b>9A23.Z</b>	<b>Orbital cyst, unspecified</b>
<b>9A24</b>	<b>Bony deformity of orbit</b>
<b>9A24.0</b>	<b>Contraction of orbit</b>
<b>9A24.1</b>	<b>Expansion of orbit</b>
<b>9A24.2</b>	<b>Distortion of orbit</b>
<b>9A24.3</b>	<b>Enlargement of bony orbit</b>
<b>9A24.4</b>	<b>Exostosis of orbit</b>
<b>9A24.Y</b>	<b>Other specified bony deformity of orbit</b>
<b>9A24.Z</b>	<b>Bony deformity of orbit, unspecified</b>
<b>9A25</b>	<b>Soft tissue deformity of orbit</b>
<b>9A25.0</b>	<b>Anophthalmic socket</b>
<b>9A25.1</b>	<b>Microphthalmic socket</b>
<b>9A25.2</b>	<b>Contracted socket</b>
<b>9A25.3</b>	<b>Oedema of orbit</b>
<b>9A25.4</b>	<b>Haemorrhage of orbit</b> This is the loss of blood or blood escaping from the circulatory system. This diagnosis is of the cavity or socket of the skull in which the eye and its appendages are situated. "Orbit" can refer to the bony socket, or it can also be used to imply the contents.
<b>9A25.5</b>	<b>Atrophy of soft tissue of orbit</b>
<b>9A25.Y</b>	<b>Other specified soft tissue deformity of orbit</b>
<b>9A25.Z</b>	<b>Soft tissue deformity of orbit, unspecified</b>
<b>9A26</b>	<b>Combined bony and soft tissue deformity of orbit</b>
	<i>Coded Elsewhere:</i> Hypertelorism (LB71.1)
<b>9A2Y</b>	<b>Other specified disorders of orbit</b>
<b>9A2Z</b>	<b>Disorders of orbit, unspecified</b>

---

**9A4Y      Other specified disorders of the ocular adnexa or orbit**

**9A4Z      Disorders of the ocular adnexa or orbit, unspecified**

### Disorders of the eyeball - anterior segment (9A60-9B3Z)

This refers to any disorders of the front third of the eye that includes the structures in front of the vitreous humour: the cornea, iris, ciliary body, and lens.

**Coded Elsewhere:** Structural disorders of the pupil (LA11.6)

Developmental anomalies of anterior segment (LA11.Y)

### Disorders of conjunctiva (9A60-9A6Z)

This is a group of conditions associated with the conjunctiva which lines the inside of the eyelids and covers the sclera.

**Coded Elsewhere:** Neoplasms of conjunctiva

**9A60      Conjunctivitis**

**Exclusions:**      keratoconjunctivitis (9A70-9A7Z)

**Coded Elsewhere:** Trachoma (1C23)

Viral conjunctivitis (1D84)

Neonatal conjunctivitis or dacryocystitis (KA65.0)

**9A60.0      Papillary conjunctivitis**

**9A60.00**      Giant papillary conjunctivitis

Giant papillary conjunctivitis is a nonallergic hypersensitivity inflammation of the ocular surface, most frequently to contact lenses, ocular prostheses, postoperative sutures, and scleral buckles.

**9A60.01**      Acute atopic conjunctivitis

This is the allergic inflammation of the conjunctiva (mucous membrane that covers the posterior surface of the eyelids and the anterior pericorneal surface of the eyeball) of the immediate type, due to airborne allergens such as pollens, dusts, spores, and animal hair.

**9A60.02**      Allergic conjunctivitis

Allergic conjunctivitis is an IgE-mediated response due to the exposure of seasonal or perennial allergens in sensitized patients. The allergen-induced inflammatory response of the conjunctiva results in the release of histamine and other mediators. Symptoms consist of redness (mainly due to vasodilation of the peripheral small blood vessels), oedema (swelling) of the conjunctiva, itching, and increased lacrimation (production of tears).

**9A60.0Y**      Other specified papillary conjunctivitis

**9A60.0Z**      Papillary conjunctivitis, unspecified

- 9A60.1** **Follicular conjunctivitis**  
**Coded Elsewhere:** Chlamydial conjunctivitis (1C20)  
Herpes simplex keratoconjunctivitis (1F00.1Y)  
Zoster keratoconjunctivitis (1E91.1)  
Keratoconjunctivitis due to adenovirus (1D84.0)  
Keratoconjunctivitis due to Acanthamoeba (1F50)
- 9A60.2** **Cicatrizing conjunctivitis**
- 9A60.3** **Mucopurulent conjunctivitis**  
These are infections of the conjunctiva, containing mucus and pus, by several species such as Haemophilus, Streptococcus, Neisseria, and Chlamydia.
- 9A60.30** Ulceration of conjunctiva  
**9A60.31** Abscess of conjunctiva  
**9A60.32** Conjunctivitis due to Koch-Weeks bacillus  
**9A60.33** Acute epidemic conjunctivitis  
**9A60.3Y** Other specified mucopurulent conjunctivitis  
**9A60.3Z** Mucopurulent conjunctivitis, unspecified
- 9A60.4** **Blepharoconjunctivitis**
- 9A60.5** **Vernal keratoconjunctivitis**  
Vernal keratoconjunctivitis is a persistent and severe form of ocular allergy that affects children and young adults, usually in warm climates. Vernal keratoconjunctivitis typically appears in boys between the ages of 4–12 years. The typical symptoms are intense itching, tearing, and photophobia. Disease exacerbation can be triggered either by allergen re-exposure or by nonspecific stimuli such as sunlight, wind, and dust. The tarsal form is characterised by irregularly sized hypertrophic papillae, leading to a cobblestone appearance of the upper tarsal plate. The limbal form is characterised by transient, multiple limbal, or conjunctival gelatinous yellow-grey infiltrates superposed with white points or deposits, known as Horner-Trantas dots and papillae at the limbus.
- 9A60.6** **Serous conjunctivitis, except viral**  
**9A60.Y** Other specified conjunctivitis  
**9A60.Z** Conjunctivitis, unspecified

**9A61**

**Certain specified disorders of conjunctiva**

**Exclusions:** keratoconjunctivitis (9A70-9A7Z)

**Coded Elsewhere:** Conjunctival blebitis after glaucoma surgery (9D23)

Complications with glaucoma drainage devices (9D24)

Injury of conjunctiva or corneal abrasion without mention of foreign body (NA06.4)

Foreign body in conjunctival sac (ND70.1)

**9A61.0** **Pingueculae**

**9A61.1** **Pterygium**

**Exclusions:** Pseudopterygium of conjunctiva (9A61.2)

**9A61.2** **Pseudopterygium of conjunctiva**

**9A61.3** **Conjunctival scars**

These are cicatrices of the mucous membrane that lines the inner surface of the eyelid and the exposed surface of the eyeball that occur due to various reasons such as trauma, infection or allergy.

**9A61.4** **Conjunctival vascular disorders**

Benign cysts which often appear as small, clear, fluid-filled inclusions of conjunctival epithelium whose goblet cells secrete into the cyst and not onto the surface.

**9A61.40** Vascular abnormalities of conjunctiva

**Coded Elsewhere:** Conjunctival haemangioma or haemolymphangioma (2E81.01)

**9A61.4Y** Other specified conjunctival vascular disorders

**9A61.4Z** Conjunctival vascular disorders, unspecified

**9A61.5** **Conjunctival or subconjunctival haemorrhage**

A conjunctival haemorrhage is a small haematoma clearly delimited on the conjunctiva itself resulting from a direct blow on the eye. Subconjunctival haemorrhage extends from the orbit, forward and deep to the conjunctiva with no posterior limit.

**9A61.6** **Conjunctival or subconjunctival degenerations or deposits**

These are the conjunctival/subconjunctival accumulation of some materials and gradual deterioration with impairment or loss of function, caused by injury, disease, or aging.

**Coded Elsewhere:** Vitamin A deficiency with conjunctival xerosis (5B55.1)

Vitamin A deficiency with conjunctival xerosis and Bitot's spots (5B55.2)

**9A61.Z** **Certain specified disorders of conjunctiva, unspecified**

**9A62****Mucous membrane pemphigoid with ocular involvement**

Mucous membrane pemphigoid (MMP) involving the conjunctivae is also known as ocular pemphigoid. This may be confined to the conjunctivae or may be associated with involvement of other sites as well. Its importance lies in its potential to cause loss of vision and it may thus warrant more aggressive therapy than would be considered for MMP of other sites.

**Coded Elsewhere:** Chronic cicatrizing conjunctivitis, ocular cicatricial pemphigoid (9A60.2)

**9A6Y****Other specified disorders of conjunctiva****9A6Z****Disorders of conjunctiva, unspecified**

Disorders of the cornea (9A70-9A7Z)

This refers to disorders of the transparent front part of the eye that covers the iris, pupil, and anterior chamber. The cornea, with the anterior chamber and lens, refracts light, with the cornea accounting for approximately two-thirds of the eye's total optical power.

**Coded Elsewhere:** Neoplasms of the cornea

**9A70****Hereditary corneal dystrophies**

The term corneal dystrophy embraces a heterogeneous group of bilateral genetically determined non-inflammatory corneal diseases that are usually restricted to the cornea. The designation is imprecise but remains in vogue because of its clinical value.

**Coded Elsewhere:** X-linked ichthyosis (EC20.01)

Cornea plana (LA11.1)

Megalocornea (LA11.1)

Microcornea (LA11.1)

**9A70.0****Endothelial corneal dystrophy****9A70.Y****Other specified hereditary corneal dystrophies****9A70.Z****Hereditary corneal dystrophies, unspecified****9A71****Infectious keratitis**

**Coded Elsewhere:** Herpes simplex keratitis (1F00.10)

**9A72****Traumatic keratitis**

**Exclusions:** Foreign body in cornea (ND70.0)

**9A73****Exposure keratitis**

This is an exposure condition in which the eye's cornea, the front part of the eye, becomes inflamed. The condition is often marked by moderate to intense pain and usually involves impaired eyesight. May cause feelings of scratching each time individual blinks eye.

<b>9A74</b>	<b>Neurotrophic keratitis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>9A75</b>	<b>Autoimmune keratitis</b>
<b>9A76</b>	<b>Corneal ulcer</b>  Loss of epithelial tissue from the surface of the cornea due to progressive erosion and necrosis of the tissue. It is often caused by bacterial, fungal, or viral infection.
<b>9A77</b>	<b>Corneal scars or opacities</b>  Corneal opacity occurs when the cornea is scarred by a variety of infectious and inflammatory eye diseases. These scars stop light from passing through the cornea to the retina and may cause the cornea which is normally transparent to appear white or clouded over.  <b>Coded Elsewhere:</b> Anterior corneal pigmentations (9A78.1) Posterior corneal pigmentations (9A78.1) Stromal corneal pigmentations (9A78.1)
<b>9A77.0</b>	<b>Contact lens-associated corneal infiltrates</b>
<b>9A77.1</b>	<b>Adherent leukoma</b>  This is a white tumour of the cornea enclosing a prolapsed adherent iris.
<b>9A77.Y</b>	<b>Other specified corneal scars or opacities</b>
<b>9A77.Z</b>	<b>Corneal scars or opacities, unspecified</b>
<b>9A78</b>	<b>Certain specified disorders of cornea</b>  <b>Coded Elsewhere:</b> Injury of conjunctiva or corneal abrasion without mention of foreign body (NA06.4)  Ocular laceration or rupture with prolapse or loss of intraocular tissue, unilateral (NA06.87) Ocular laceration without prolapse or loss of intraocular tissue, unilateral (NA06.8D) Ocular laceration or rupture with prolapse or loss of intraocular tissue, bilateral (NA06.88) Ocular laceration without prolapse or loss of intraocular tissue, bilateral (NA06.8E) Foreign body in cornea (ND70.0) Chemical burn of cornea or conjunctival sac (NE00)
<b>9A78.0</b>	<b>Corneal neovascularization</b>
<b>9A78.1</b>	<b>Corneal pigmentations or deposits</b>
<b>9A78.2</b>	<b>Corneal oedema</b>

- 9A78.20** Bullous keratopathy  
This is the maximum stage of corneal oedema.  
It is a pathological condition in which small vesicles, or bullae, are formed in the cornea due to endothelial dysfunction. In a healthy cornea, endothelial cells keep the tissue from excess fluid absorption, pumping it back into the aqueous humour. When affected by some reason, such as Fuchs' dystrophy or a trauma during cataract removal, endothelial cells suffer mortality or damage. The corneal endothelial cells normally do not undergo mitotic cell division, and cell loss results in permanent loss of function.
- 9A78.21** Secondary corneal oedema
- 9A78.2Y** Other specified corneal oedema
- 9A78.2Z** Corneal oedema, unspecified
- 9A78.3** **Changes in corneal membranes**
- 9A78.4** **Corneal degeneration**  
*Exclusions:* Mooren ulcer (9A76)  
*Coded Elsewhere:* Vitamin A deficiency with corneal xerosis (5B55.3)  
Vitamin A deficiency with corneal ulceration or keratomalacia (5B55.4)  
Vitamin A deficiency with xerophthalmic scars of cornea or blindness (5B55.5)
- 9A78.5** **Corneal deformities**  
*Coded Elsewhere:* Structural developmental anomalies of cornea (LA11.1)
- 9A78.50** Keratoconus  
Keratoconus is a noninflammatory, often bilateral, corneal dystrophy characterised by progressive cone-shaped bulging and thinning of the cornea.
- Coding Note:** Code also the causing condition
- 9A78.51** Corneal staphyloma
- 9A78.5Y** Other specified corneal deformities
- 9A78.5Z** Corneal deformities, unspecified
- 9A78.6** **Anaesthesia of cornea**  
This is the condition of having sensation (including the feeling of pain) blocked or temporarily taken away, of the transparent front part of the eye that covers the iris, pupil, and anterior chamber.
- 9A78.7** **Hypoesthesia of cornea**  
This refers to a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli, of the transparent front part of the eye that covers the iris, pupil, and anterior chamber.
- 9A78.8** **Recurrent erosion of cornea**

<b>9A78.9</b>	<b>Corneal abscess</b>
<b>9A78.A</b>	<b>Sclerosing keratitis</b>
<b>9A78.Z</b>	<b>Certain specified disorders of cornea, unspecified</b>
<b>9A79</b>	<b>Keratoconjunctivitis sicca</b>
<b>9A7Y</b>	<b>Other specified disorders of the cornea</b>
<b>9A7Z</b>	<b>Disorders of the cornea, unspecified</b>

Disorders of the anterior chamber (9A80-9A8Z)

**Coded Elsewhere:** Retained foreign body in anterior chamber of eye (NA06.2)

<b>9A80</b>	<b>Hyphaema</b>
	<b><i>Exclusions:</i></b> traumatic hyphaema (NA06.9)
<b>9A81</b>	<b>Parasites in the anterior chamber of the eye</b>
<b>Coding Note:</b>	Code also the causing condition
<b>9A82</b>	<b>Cyst in the anterior chamber of the eye</b>
<b>9A83</b>	<b>Flat anterior chamber hypotony of eye</b>
<b>9A8Y</b>	<b>Other specified disorders of the anterior chamber</b>
<b>9A8Z</b>	<b>Disorders of the anterior chamber, unspecified</b>

Disorders of the anterior uvea (9A90-9A9Z)

**Coded Elsewhere:** Congenital malformations of the uvea

- Neoplasms of the iris
- Neoplasms of the ciliary body
- Corectopia (LA11.Y)
- Polycoria (LA11.Y)
- Atresia iridis (LA11.Y)

<b>9A90</b>	<b>Degeneration of iris or ciliary body</b>
-------------	---

<b>9A90.0</b>	<b>Disorders of chamber angle</b>
---------------	-----------------------------------

This refers to the change of tissue to a lower or less functionally active form, of the fluid-filled space inside the eye between the iris and the cornea's innermost surface, the endothelium.

<b>9A90.1</b>	<b>Degeneration of iris</b>
---------------	-----------------------------

This refers to the change of tissue to a lower or less functionally active form, of the thin, circular structure in the eye, responsible for controlling the diameter and size of the pupil and thus the amount of light reaching the retina. The color of the iris is often referred to as "eye color."

<b>9A90.2</b>	<b>Iris atrophy</b>
<b>9A90.Y</b>	<b>Other specified degeneration of iris or ciliary body</b>
<b>9A90.Z</b>	<b>Degeneration of iris or ciliary body, unspecified</b>
<b>9A91</b>	<b>Cyst of iris or ciliary body</b>
<b>9A92</b>	<b>Persistent pupillary membranes</b>
<b>9A93</b>	<b>Adhesions or disruptions of iris or ciliary body</b> This refers to adhesions and disruptions of the thin, circular structure in the eye, responsible for controlling the diameter and size of the pupil and thus the amount of light reaching the retina. The colour of the iris is often referred to as "eye colour." It is also of the circumferential tissue inside the eye composed of the ciliary muscle and ciliary processes. It is triangular in horizontal section and is coated by a double layer, the ciliary epithelium.
	<b>Exclusions:</b> Corectopia (LA11)
<b>9A94</b>	<b>Certain specified disorders of iris or ciliary body</b>
<b>9A94.0</b>	<b>Rubeosis of iris</b>
<b>9A94.1</b>	<b>Floppy iris syndrome</b> This is a complication that may occur during cataract extraction in certain patients. This syndrome is characterised by a flaccid iris which billows in response to ordinary intraocular fluid currents, a propensity for this floppy iris to prolapse towards the area of cataract extraction during surgery, and progressive intraoperative pupil constriction despite standard procedures to prevent this.
<b>9A94.2</b>	<b>Plateau iris syndrome</b>
<b>9A94.Y</b>	<b>Other disorders of iris and ciliary body</b>
<b>9A96</b>	<b>Anterior uveitis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>9A96.0</b>	<b>Anterior uveitis not associated with systemic conditions</b>
<b>9A96.1</b>	<b>Anterior uveitis associated with systemic conditions</b>
<b>Coding Note:</b>	Code also the causing condition <b>Coded Elsewhere:</b> Sarcoid associated anterior uveitis (4B20.4)
<b>9A96.2</b>	<b>Infection-associated anterior uveitis</b>
<b>Coding Note:</b>	Code also the causing condition <b>Coded Elsewhere:</b> Gonococcal anterior uveitis (1A72.4) Zoster anterior uveitis (1E91.1) Secondary syphilitic anterior uveitis (1A61.4) Tuberculous anterior uveitis (1B12.1) Chronic tuberculous iridocyclitis (1B12.1) Syphilitic uveitis (1A62.20)

<b>9A96.3</b>	<b>Primary anterior uveitis</b>
	This refers to primary inflammation of the uvea. The uvea consists of the middle, pigmented, vascular structures of the eye and includes the iris, ciliary body, and choroid.
<b>9A96.Y</b>	<b>Other specified anterior uveitis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>9A96.Z</b>	<b>Anterior uveitis, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>9A9Y</b>	<b>Other specified disorders of the anterior uvea</b>
<b>9A9Z</b>	<b>Disorders of the anterior uvea, unspecified</b>

Functional disorders of the pupil (9B00-9B0Z)

<b>9B00</b>	<b>Disorders of the afferent pupillary system</b>
<b>9B00.0</b>	<b>Relative afferent pupillary defects</b>
<b>9B00.1</b>	<b>Amaurotic pupillary reaction</b>
<b>9B00.2</b>	<b>Paradoxical pupillary reaction to light or darkness</b>
<b>9B00.3</b>	<b>Wernicke pupils</b>
<b>9B00.Y</b>	<b>Other specified disorders of the afferent pupillary system</b>
<b>9B00.Z</b>	<b>Disorders of the afferent pupillary system, unspecified</b>
<b>9B01</b>	<b>Disorders of the efferent pupillary system</b>
	<b>Coded Elsewhere:</b> Horner syndrome (8D8A.1)
	Horner syndrome, acquired (8D8A.1)
	Horner syndrome, congenital (8D8A.1)
<b>9B01.0</b>	<b>Physiologic anisocoria</b>
<b>9B01.1</b>	<b>Parasympathoparetic pupils</b> Damage to the parasympathetic outflow to the iris sphincter muscle <b>Coded Elsewhere:</b> Third nerve palsy (9C81.0)
<b>9B01.2</b>	<b>Pharmacologic inhibition of the parasympathetic pathway</b>
<b>9B01.3</b>	<b>Iris sphincter disorders</b> This refers to disorders of the muscle in the part of the eye called the iris. It encircles the pupil of the iris, appropriate to its function as a constrictor of the pupil.
<b>9B01.4</b>	<b>Pharmacologic parasympathomimetic pupils</b> Pharmacologic stimulation of the parasympathetic pathway
<b>9B01.5</b>	<b>Pharmacologic sympathoparetic pupils</b>

<b>9B01.6</b>	<b>Sympathometic pupils</b>
<b>9B01.7</b>	<b>Episodic unilateral mydriasis</b>
<b>9B01.Y</b>	<b>Other specified disorders of the efferent pupillary system</b>
<b>9B01.Z</b>	<b>Disorders of the efferent pupillary system, unspecified</b>
<b>9B02</b>	<b>Light-near dissociations</b>
<b>9B02.0</b>	<b>Argyll Robertson pupil</b> These are bilateral small pupils that constrict when the patient focuses on a near object but do not constrict when exposed to bright light (they do not "react" to light).
<b>Coding Note:</b>	Code also the causing condition
	<b>Coded Elsewhere:</b> Syphilitic Argyll Robertson pupil (1A62.01)
<b>9B02.1</b>	<b>Pregeniculate light-near dissociations</b>
<b>9B02.2</b>	<b>Mesencephalic light-near dissociations</b>
<b>9B02.Y</b>	<b>Other specified light-near dissociations</b>
<b>9B02.Z</b>	<b>Light-near dissociations, unspecified</b>
<b>9B0Y</b>	<b>Other specified functional disorders of the pupil</b>
<b>9B0Z</b>	<b>Functional disorders of the pupil, unspecified</b>

Disorders of lens (9B10-9B1Z)

**Coded Elsewhere:** Structural developmental anomalies of lens or zonula (LA12)

Presence of intraocular lens (QB51.2)

<b>9B10</b>	<b>Cataract</b>
<b>9B10.0</b>	<b>Age-related cataract</b> A senile cataract is a clouding of the lens of the eye, which impedes the passage of light, related to ageing, and that occurs usually starting from the age of 40. <b>Exclusions:</b> capsular glaucoma with pseudoexfoliation of lens (9C61.0)
<b>9B10.00</b>	Coronary age-related cataract
<b>9B10.01</b>	Punctate age-related cataract
<b>9B10.02</b>	Mature age-related cataract This is a mature age-related clouding of the lens inside the eye which leads to a decrease in vision. It is the most common cause of blindness and is conventionally treated with surgery. Visual loss occurs because opacification of the lens obstructs light from passing and being focused on to the retina at the back of the eye.
<b>9B10.0Y</b>	Other specified age-related cataract
<b>9B10.0Z</b>	Age-related cataract, unspecified

<b>9B10.1</b>	<b>Infantile or juvenile cataract</b> A cataract is clouding of the lens of the eye, which impedes the passage of light.  <b>Exclusions:</b> Congenital cataract (LA12.1)
<b>9B10.10</b>	Combined forms of infantile and juvenile cataract
<b>9B10.1Y</b>	Other specified infantile or juvenile cataract
<b>9B10.1Z</b>	Infantile or juvenile cataract, unspecified
<b>9B10.2</b>	<b>Certain specified cataracts</b> A cataract is clouding of the lens of the eye, which impedes the passage of light.  <b>Coding Note:</b> Code also the causing condition  <b>Exclusions:</b> Congenital cataract (LA12.1)  <b>Coded Elsewhere:</b> Myotonic cataract (9B10.2Y) Undernutrition-dehydration cataract (9B10.2Y)
<b>9B10.20</b>	Traumatic cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence) resulting from or following injury.
<b>9B10.21</b>	Diabetic cataract This refers to an unspecified group of metabolic diseases in which a person has high blood sugar, either because the pancreas does not produce enough insulin, or because cells do not respond to the insulin that is produced. This diagnosis is with diabetic cataract.  <b>Coding Note:</b> Always assign an additional code for diabetes mellitus.
<b>9B10.22</b>	After-cataract This is a clouding of the lens of the eye, which impedes the passage of light resulting from disease, degeneration, or from surgery.  <b>Inclusions:</b> Secondary cataract Soemmerring ring
<b>9B10.23</b>	Subcapsular glaucomatous flecks  <b>Coding Note:</b> Code also the causing condition
<b>9B10.2Y</b>	Other specified cataracts  <b>Coding Note:</b> Code also the causing condition
<b>9B10.Z</b>	<b>Cataract, unspecified</b>

**9B11****Certain specified disorders of lens**

**Exclusions:** congenital lens malformations (LA12)  
Cataract lens fragments in eye following cataract surgery  
(9D21)

**Coded Elsewhere:** Presence of intraocular lens (QB51.2)

**9B11.0****Aphakia****9B11.1****Dislocation of lens****9B11.Y****Other disorders of lens****9B1Z****Disorders of lens, unspecified****9B3Y****Other specified disorders of the eyeball - anterior segment****9B3Z****Disorders of the eyeball - anterior segment, unspecified****Disorders of the eyeball - posterior segment (9B50-9C0Z)**

This refers to disorders of the back two-thirds of the eye that includes the anterior hyaloid membrane and all of the optical structures behind it: the vitreous humour, retina, choroid, and optic nerve.

**Disorders of sclera (9B50-9B5Z)**

**Coded Elsewhere:** Blue sclera (LA11.0)

**9B50****Episcleritis**

Episcleritis is a benign, self-limiting inflammatory disease affecting part of the eye called the episclera. The episclera is a thin layer of tissue that lies between the conjunctiva and the connective tissue layer that forms the white of the eye (sclera). Episcleritis is a common condition, and is characterised by the abrupt onset of mild eye pain and redness.

**Coded Elsewhere:** Tuberculous episcleritis (1B12.1)

Late syphilitic episcleritis (1A62.20)

**9B51****Scleritis**

Inflammation of the white, opaque, fibrous, outer tunic of the eyeball. Can be associated with uveitis.

**Coded Elsewhere:** Zoster scleritis (1E91.1)

**9B52****Scleral staphyloma**

**Exclusions:** degenerative myopia (9B76)

**9B5Y****Other specified disorders of sclera****9B5Z****Disorders of sclera, unspecified**

Disorders of the choroid (9B60-9B6Z)

**Inclusions:** Disorders of posterior uvea

**Coded Elsewhere:** Neoplasms of choroid

Congenital malformations of choroid (LA13.6)

**9B60**

**Choroidal degeneration**

**Exclusions:** angioid streaks (9B78.3)

**9B61**

**Choroidal dystrophy**

**Exclusions:** ornithinaemia (5C50.9)

**9B62**

**Chorioretinal scars**

**9B63**

**Choroidal haemorrhage or rupture**

**Coded Elsewhere:** Choroidal rupture (NA06.61)

**9B64**

**Choroidal detachment**

**9B65**

**Choroiditis**

**Inclusions:** Posterior uveitis

**9B65.0**

**Noninfectious posterior choroiditis**

**Coded Elsewhere:** Ocular Behçet disease (4A62)

**9B65.1**

**Infectious posterior choroiditis**

**Coding Note:**

Code also the causing condition

**Coded Elsewhere:** Late syphilitic posterior uveitis (1A62.20)

Toxoplasma posterior uveitis (1F57.3)

Tuberculous posterior uveitis (1B12.1)

**9B65.2**

**Chorioretinal inflammation**

**Coded Elsewhere:** Toxoplasma chorioretinitis (1F57.3)

Tuberculous chorioretinitis (1B12.1)

Late congenital syphilitic chorioretinitis (1A60.2)

**9B65.Z**

**Choroiditis, unspecified**

**9B66**

**Intermediate choroiditis**

This is a form of uveitis localised to the vitreous and peripheral retina. Primary sites of inflammation include the vitreous of which other such entities as pars planitis, posterior cyclitis, and hyalitis are encompassed. Intermediate uveitis may either be an isolated eye disease or associated with the development of a systemic disease such as multiple sclerosis or sarcoidosis.

**9B66.0** **Noninfectious intermediate choroiditis**  
This is a non-infectious form of uveitis localised to the vitreous and peripheral retina. Primary sites of inflammation include the vitreous of which other such entities as pars planitis, posterior cyclitis, and hyalitis are encompassed. Intermediate uveitis may either be an isolated eye disease or associated with the development of a systemic disease such as multiple sclerosis or sarcoidosis.

**9B66.1** **Infectious intermediate choroiditis**  
This is a infectious form of uveitis localised to the vitreous and peripheral retina. Primary sites of inflammation include the vitreous of which other such entities as pars planitis, posterior cyclitis, and hyalitis are encompassed. Intermediate uveitis may either be an isolated eye disease or associated with the development of a systemic disease such as multiple sclerosis or sarcoidosis.

**9B66.Z** **Intermediate choroiditis, unspecified**

**9B6Y** **Other specified disorders of the choroid**

**9B6Z** **Disorders of the choroid, unspecified**

Disorders of the retina (9B70-9B7Z)

**Coded Elsewhere:** Certain congenital malformations of posterior segment of eye (LA13.8)

Neoplasms of retina

Traumatic injuries of the retina (NA06.6)

Renal retinitis in chronic kidney disease, stage 5 (GB61.5)

Presence of retina Implant (QB51.Y)

Coats disease (LD21.Y)

**9B70** **Inherited retinal dystrophies**

**Coded Elsewhere:** Sjögren-Larsson syndrome (5C52.03)

Usher syndrome (LD2H.4)

Asphyxiating thoracic dystrophy (LD24.B1)

**9B71** **Retinopathy**

**Coding Note:** Code also the causing condition

**9B71.0** **Diabetic retinopathy**

A condition characterised as a disease of the retina (retinopathy) involving damage to the small blood vessels in the retina which is due to chronically high blood glucose levels in people with diabetes.

**Coding Note:** Always assign an additional code for diabetes mellitus.

**9B71.00** Nonproliferative diabetic retinopathy

**Coding Note:** Code also the causing condition

<b>9B71.01</b>	Proliferative diabetic retinopathy This is proliferative retinopathy (damage to the retina) caused by complications of diabetes, which can eventually lead to blindness. It is an ocular manifestation of diabetes, a systemic disease, which affects up to 80 percent of all patients who have had diabetes for 10 years or more. Always assign an additional code for the type of diabetes mellitus.
<b>Coding Note:</b>	Code also the causing condition
<b>9B71.02</b>	Diabetic macular oedema
<b>Coding Note:</b>	Code also the causing condition
<b>9B71.0Z</b>	Diabetic retinopathy, unspecified
<b>Coding Note:</b>	Always assign an additional code for diabetes mellitus.
<b>9B71.1</b>	<b>Hypertensive retinopathy</b>
<b>Coding Note:</b>	Code also the causing condition
<b>9B71.2</b>	<b>Radiation retinopathy</b> Radiation retinopathy is damage to retina due to exposure to ionizing radiation. Radiation retinopathy has a delayed onset, typically after months or years of radiation, and is slowly progressive. In general, radiation retinopathy is seen around 18 months after treatment with external-beam radiation and with brachytherapy.
<b>9B71.3</b>	<b>Retinopathy of prematurity</b> Retinopathy of prematurity is a vasoproliferative disorder that affects extremely premature infants potentially leading to severe visual impairment or blindness. Exposure of newborn premature infants to hyperoxia down regulates retinal vascular endothelial growth factor. Blood vessels constrict and can become obliterated, resulting in delays of normal retinal vascular development. Low birth weight, young gestational age, and severity of illness (e.g. respiratory distress syndrome, bronchopulmonary dysplasia, sepsis) are associated factors. It primarily occurs in extremely low birth weight infants because of the cessation of normal retinal vascular maturation.
<b>Coding Note:</b>	Code also the causing condition
<b>Inclusions:</b>	Retrothalental fibroplasia

<b>9B71.4</b>	<b>Paraneoplastic retinopathy</b>
	Paraneoplastic retinopathies result from a targeted attack on the retina due to a tumour immune response initiated by onco-neural antigens derived from systemic cancer. Patients usually present after cancer diagnosis with progressive visual dimming and photopsias but dysfunction of rods (impaired dark adaption and peripheral vision loss) and cones (decreased visual acuity, colour dysfunction, photosensitivity and glare) may also occur. Symptoms are often worse than clinical signs. Other causes of retinopathy should be excluded. Multiple anti-retinal autoantibodies (e.g. anti-recoverin antibodies) are described although their significance is uncertain. Two major subsets are recognised: cancer-associated retinopathy (most commonly small-cell lung cancer) and melanoma-associated retinopathy.
	Associated neural autoantibodies include:
	CRMP5 (anti-CV2) (collapsin response mediator protein 5 - anti CV2); anti-recoverin autoantibodies; and alpha-enolase autoantibodies.
<b>Coding Note:</b>	Code also the causing condition
<b>9B71.40</b>	Melanoma associated retinopathy
<b>9B71.4Y</b>	Other specified paraneoplastic retinopathy
<b>Coding Note:</b>	Code also the causing condition
<b>9B71.4Z</b>	Paraneoplastic retinopathy, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>9B71.5</b>	<b>Autoimmune retinopathy</b>
	Autoimmune retinopathies are immune-mediated inflammatory disorders of the retina that differ from paraneoplastic retinopathies in the lack of association with cancer. Patients present with progressive visual loss and dysfunction of rods (impaired dark adaption and peripheral vision problems) and cones (visual acuity, colour dysfunction, photosensitivity and glare) may occur. The symptoms are often worse than the clinical signs on fundoscopy. Multiple anti-retinal autoantibodies (e.g. anti-recoverin antibodies) are described although their significance is uncertain. Autoimmune retinopathy is a diagnosis of exclusion and other causes of retinopathy need to be ruled out, while the potential role of immunotherapy remains uncertain.
	Associated neural autoantibodies include:
	anti-recoverin autoantibodies; alpha-enolase autoantibodies; anti-transducin autoantibodies.
<b>Coding Note:</b>	Code also the causing condition
<b>9B71.Y</b>	<b>Other specified retinopathy</b>
<b>Coding Note:</b>	Code also the causing condition
<b>9B71.Z</b>	<b>Retinopathy, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition

**9B72****Inflammatory diseases of the retina**

This refers to inflammatory diseases of light-sensitive layer of tissue, lining the inner surface of the eye. The optics of the eye create an image of the visual world on the retina, which serves much the same function as the film in a camera.

**Coded Elsewhere:** Retinal vasculitis (9B78.12)

**9B72.0****Viral retinitis****9B72.00****Cytomegaloviral retinitis**

This is an inflammation of the eye's retina that can lead to blindness. This is a DNA virus in the family Herpesviridae known for producing large cells with nuclear and cytoplasmic inclusions. Such inclusions are called an "owl's eye" effect.

**9B72.01****HIV retinitis****9B72.0Y****Other specified viral retinitis****9B72.0Z****Viral retinitis, unspecified****9B72.Y****Other specified inflammatory diseases of the retina****9B72.Z****Inflammatory diseases of the retina, unspecified****9B73****Retinal detachments or breaks**

Retinal breaks are full thickness openings in the neurosensory retina that can be in the form of a hole, a tear or a retinal dialysis. Retinal detachment is a condition in which the retina peels away from its underlying layer of support tissue.

**Exclusions:** detachment of retinal pigment epithelium (9B78.6)

**9B73.0****Retinal detachment with retinal break**

**Inclusions:** Rhegmatogenous retinal detachment

**9B73.1****Retinoschisis**

Retinoschisis is an eye disease characterised by the abnormal splitting of the retina's neurosensory layers.

**9B73.10****Adult retinoschisis****9B73.11****Juvenile retinoschisis**

X-linked retinoschisis is a genetic ocular disease that is characterised by reduced visual acuity in males due to juvenile macular degeneration.

**9B73.1Y****Other specified retinoschisis****9B73.1Z****Retinoschisis, unspecified****9B73.2****Retinal cysts**

A retinal cyst is a closed sac, having a distinct membrane and division compared to the nearby tissue in retina that can either be congenital or acquired.

**Exclusions:** congenital retinoschisis (LA13.3)

Microcystoid degeneration of retina (9B78.4)

<b>9B73.3</b>	<b>Serous retinal detachment</b> This occurs due to inflammation, injury or vascular abnormalities that results in fluid accumulating underneath the retina without the presence of a hole, tear, or break.  <b>Exclusions:</b> Central serous chorioretinopathy (9B75.2)
<b>9B73.4</b>	<b>Retinal breaks without detachment</b>  <b>Exclusions:</b> Chorioretinal scars after surgery for detachment (9D22) peripheral retinal degeneration without break (9B78.4)
<b>9B73.Y</b>	<b>Other specified retinal detachments or breaks</b>
<b>9B73.Z</b>	<b>Retinal detachments or breaks, unspecified</b>
<b>9B74</b>	<b>Retinal vascular occlusions</b> These are obstruction or closure of retinal vascular structures.  <b>Exclusions:</b> amaurosis fugax (9D51)
<b>9B74.0</b>	<b>Retinal artery occlusions</b>
<b>9B74.1</b>	<b>Retinal venous occlusions</b>
<b>9B74.2</b>	<b>Combined retinal arterial and vein occlusion</b>
<b>9B74.Y</b>	<b>Other specified retinal vascular occlusions</b>
<b>9B74.Z</b>	<b>Retinal vascular occlusions, unspecified</b>
<b>9B75</b>	<b>Macular disorders</b>
<b>9B75.0</b>	<b>Age-related macular degeneration</b> Age-related macular degeneration (ARMD) is defined as an ocular disease leading to loss of central vision in the elderly, and characterised by primary and secondary damage of macular retinal pigment epithelial (RPE) cells, resulting in formation of drusen (deposits lying beneath the RPE), choroidal neovascularization (CNV), and atrophy of photoreceptors and choriocapillaris layer of the choroidea.  <b>Coded Elsewhere:</b> Small drusen of the macula (MC20.1)
<b>9B75.00</b>	Early age-related macular degeneration consists of a combination of multiple small drusen, few intermediate drusen (63 to 124 microns in diameter), or RPE abnormalities.
<b>9B75.01</b>	Intermediate age-related macular degeneration consists of extensive intermediate drusen, at least one large druse (>=125 microns in diameter), or geographic atrophy not involving the centre of the fovea
<b>9B75.03</b>	Atrophic late-stage age-related macular degeneration
<b>9B75.04</b>	Neovascular late-stage age-related macular degeneration
<b>9B75.0Y</b>	Other specified age-related macular degeneration
<b>9B75.0Z</b>	Age-related macular degeneration, unspecified

- 9B75.1** **Non-traumatic macular hole**
- 9B75.2** **Central serous chorioretinopathy**  
This is an eye disease which causes visual impairment, often temporary, usually in one eye. When the disorder is active it is characterised by leakage of fluid under the retina that has a propensity to accumulate under the central macula.
- 9B75.3** **Macular telangiectasia**
- 9B75.Y** **Other specified macular disorders**
- 9B75.Z** **Macular disorders, unspecified**
- 9B76** **Degenerative high myopia**  
Macular lesions occurring in people with myopia, usually high myopia, causing a decrease of the best corrected visual acuity and comprising myopic chorioretinal atrophy, myopic choroidal neovascularization and myopic retinoschisis
- 9B77** **Eales disease**  
Eales disease is a retinal vasculopathy that presents as an inflammatory stage with retinal periphlebitis affecting especially peripheral retina, then an ischemic stage with sclerosis of retinal veins, and finally a proliferative stage characterised by neovascularization, haemorrhage and retinal detachment.
- 9B78** **Certain specified retinal disorders**  
*Coded Elsewhere:* Double heterozygous sickling disorders with retinopathy (3A51.3)  
Retinal dystrophy in GM2 gangliosidosis (5C56.00)
- 9B78.0** **Retinal vasculopathy and cerebral leukodystrophy**  
Retinal vasculopathy and cerebral leukodystrophy is an inherited group of small vessel diseases comprised of cerebroretinal vasculopathy, hereditary vascular retinopathy and hereditary endotheliopathy with retinopathy, nephropathy and stroke (HERNS); all exhibiting progressive visual impairment as well as variable cerebral dysfunction.  
*Coded Elsewhere:* HERNS syndrome (LD2F.1Y)
- 9B78.1** **Background retinopathy and retinal vascular changes**  
Background retinopathy is the earliest visible change to the retina in diabetes, characterised by some retinal vascular changes, e.g. the capillaries in the retina may become blocked, they may bulge slightly (microaneurysm) and may leak blood or fluid.
- 9B78.10** Changes in retinal vascular appearance
- 9B78.11** Exudative retinopathy
- 9B78.12** Retinal vasculitis
- 9B78.13** Retinal telangiectasis
- 9B78.1Y** Other specified background retinopathy and retinal vascular changes

- 9B78.1Z** Background retinopathy and retinal vascular changes, unspecified
- 9B78.2** **Other proliferative retinopathy**
- Exclusions:** proliferative vitreo-retinopathy with retinal detachment (9B73)  
Proliferative diabetic retinopathy (9B71.01)
- 9B78.3** **Degeneration of macula or posterior pole**
- Exclusions:** Age-related macular degeneration (9B75.0)
- 9B78.30** Reticular pseudodrusen  
Histologically located above the retinal pigment epithelium, this finding is often associated with other retinal disease.
- 9B78.3Y** Other specified degeneration of macula or posterior pole
- 9B78.3Z** Degeneration of macula or posterior pole, unspecified
- 9B78.4** **Peripheral retinal degeneration**
- Exclusions:** with retinal break (9B73.4)
- 9B78.5** **Retinal haemorrhage**
- Exclusions:** Traumatic retinal haemorrhage (NA06.7)
- 9B78.6** **Separation of retinal layers**
- Inclusions:** Detachment of retinal pigment epithelium
- 9B78.60** Serous detachment of retinal pigment epithelium  
This refers to the serous detachment of the pigmented cell layer just outside the neurosensory retina that nourishes retinal visual cells, and is firmly attached to the underlying choroid and overlying retinal visual cells.
- 9B78.61** Haemorrhagic detachment of retinal pigment epithelium  
This refers to the haemorrhagic detachment of the pigmented cell layer just outside the neurosensory retina that nourishes retinal visual cells, and is firmly attached to the underlying choroid and overlying retinal visual cells.
- 9B78.6Y** Other specified separation of retinal layers
- 9B78.6Z** Separation of retinal layers, unspecified
- 9B78.7** **Retinal oedema**
- 9B78.8** **Retinal ischaemia**
- Coding Note:** Code also the causing condition
- 9B78.9** **Retinal atrophy**  
This is a group of genetic diseases and is characterised by the bilateral degeneration of the retina, causing progressive vision loss culminating in blindness.
- 9B7Y** **Other specified disorders of the retina**
- 9B7Z** **Disorders of the retina, unspecified**

Disorders of the vitreous body (9B80-9B8Z)

Any condition of the transparent, semigelatinous substance that fills the cavity behind the crystalline lens of the eye and in front of the retina.

**Coded Elsewhere:** Congenital anomalies of the vitreous (LA13.0)

**9B80            Inherited vitreoretinal disorders**

**Coded Elsewhere:** Stickler syndrome (LD2F.1Y)

**9B81            Posterior vitreous detachment**

**9B82            Vitreous prolapse**

**Exclusions:** vitreous syndrome following cataract surgery (9D20)

**9B83            Vitreous haemorrhage**

**9B84            Vitreous opacities, membranes or strands**

**9B8Y            Other specified disorders of the vitreous body**

**9B8Z            Disorders of the vitreous body, unspecified**

---

**9C0Y            Other specified disorders of the eyeball - posterior segment**

**9C0Z            Disorders of the eyeball - posterior segment, unspecified**

Disorders of the eyeball affecting both anterior and posterior segments (9C20-9C2Z)

**9C20            Panuveitis**

**9C20.0          Noninfectious panuveitis**

**Coded Elsewhere:** Multifocal choroiditis (9B65.0)

**9C20.1          Infectious panuveitis**

**Coded Elsewhere:** Tuberculous panuveitis (1B12.1)

Infectious panuveitis in Lyme disease (1C1G.12)

**9C20.2          Purulent endophthalmitis**

Suppurative inflammation of the tissues of the internal structures of the eye; often caused by fungi, necrosis of intraocular tumours, or retained intraocular foreign bodies. Other aetiology can be any infectious uveitis.

**9C20.Y          Other specified panuveitis**

**9C20.Z          Panuveitis, unspecified**

**9C21            Endophthalmitis**

**Coded Elsewhere:** Purulent endophthalmitis (9C20.2)

**9C21.0          Sympathetic uveitis**

<b>9C21.Y</b>	<b>Other specified endophthalmitis</b>
<b>9C21.Z</b>	<b>Endophthalmitis, unspecified</b>
<b>9C22</b>	<b>Eyeball deformity</b>
	<b>Coded Elsewhere:</b> Microphthalmos (LA10.0)
	Clinical anophthalmos (LA10.1)
	Microphthalmos associated with syndromes (LD21.0)
<b>9C22.0</b>	<b>Atrophy bulbi</b>
<b>9C22.1</b>	<b>Phthisis bulbi</b>
<b>9C22.Y</b>	<b>Other specified eyeball deformity</b>
<b>9C22.Z</b>	<b>Eyeball deformity, unspecified</b>
<b>9C2Y</b>	<b>Other specified disorders of the eyeball affecting both anterior and posterior segments</b>
<b>9C2Z</b>	<b>Disorders of the eyeball affecting both anterior and posterior segments, unspecified</b>

### Disorders of the visual pathways or centres (9C40-9C4Z)

This refers to disorders part of the central nervous system which gives organisms the ability to process visual detail, as well as enabling the formation of several non-image photo response functions.

<b>9C40</b>	<b>Disorder of the optic nerve</b>
	<b>Coded Elsewhere:</b> Congenital malformation of optic disc (LA13.7)
	Injury of optic nerve, unilateral (NA04.10)
	Malignant neoplasm of the optic nerve (2A02.12)
<b>9C40.0</b>	<b>Infectious optic neuropathy</b>
	<b>Coded Elsewhere:</b> Late syphilitic retrobulbar neuritis (1A62.20)
<b>9C40.1</b>	<b>Optic neuritis</b>
	Optic neuritis is a condition related to immune mediated inflammation of the optic nerve. It is commoner in women and can be the first presenting symptom of MS. The symptoms are those of blurred vision, pain on moving the eye and in the vast majority it is self limiting.
	<b>Coded Elsewhere:</b> Neuromyelitis optica (8A43)
<b>9C40.10</b>	Retrobulbar neuritis
<b>9C40.1Y</b>	Other specified optic neuritis
<b>9C40.1Z</b>	Optic neuritis, unspecified
<b>9C40.2</b>	<b>Neuroretinitis</b>

- 9C40.3**      **Perineuritis of optic nerve**  
                 Inflammation of the optic nerve sheath without inflammation of the nerve itself
- 9C40.4**      **Ischaemic optic neuropathy**  
                 Optic nerve disorders caused by an ischaemic process of the optic nerve
- 9C40.40**     Anterior ischemic optic neuropathy  
                 This refers to anterior ischemic damage to the optic nerve due to any cause. Damage and death of these nerve cells, or neurons, leads to characteristic features of optic neuropathy.
- 9C40.41**     Posterior ischemic optic neuropathy  
                 This refers to posterior ischemic damage to the optic nerve due to any cause. Damage and death of these nerve cells, or neurons, leads to characteristic features of optic neuropathy.
- 9C40.4Y**     Other specified ischaemic optic neuropathy
- 9C40.4Z**     Ischaemic optic neuropathy, unspecified
- 9C40.5**      **Compressive optic neuropathy**  
                 Optic nerve disorders caused by the compression of the optic nerve
- 9C40.6**      **Infiltrative optic neuropathy**  
                 Optic nerve disorders caused by an infiltrative process of the optic nerve
- 9C40.7**      **Traumatic optic neuropathy**  
                 Optic nerve disorders due to trauma to the optic nerve
- 9C40.8**      **Hereditary optic neuropathy**  
                 Optic nerve disorders caused by genetic abnormalities  
*Coded Elsewhere:* Leber hereditary optic neuropathy (8C73.Y)
- 9C40.9**      **Glaucomatous optic neuropathy**  
*Inclusions:*      Glaucomatous optic atrophy
- 9C40.A**      **Optic disc swelling**  
                 This refers to swelling in the location where ganglion cell axons exit the eye to form the optic nerve. There are no light sensitive rods or cones to respond to a light stimulus at this point.
- 9C40.A0**     Papilloedema  
                 Optic disc swelling that results from increased intracranial pressure  
*Inclusions:*      Optic disc swelling that results from increased intracranial pressure
- 9C40.A1**     Optic disc swelling associated with uveitis
- 9C40.AY**     Other specified optic disc swelling
- 9C40.AZ**     Optic disc swelling, unspecified

**9C40.B**      **Optic atrophy**  
Optic atrophies (OA) refer to a specific group of hereditary optic neuropathies in which the cause of the optic nerve dysfunction is inherited either in an autosomal dominant or autosomal recessive pattern. Autosomal dominant optic atrophy (ADOA), type Kjer, is the most common OA, whereas autosomal recessive optic atrophy (AROA) is a rare form.

**Coded Elsewhere:** Leber hereditary optic neuropathy (8C73.Y)

**9C40.B0**      Congenital optic atrophy

**9C40.B1**      Acquired optic atrophy

**Coding Note:** Code also the causing condition

**9C40.BZ**      Optic atrophy, unspecified

**9C40.Y**      **Other specified disorder of the optic nerve**

**9C40.Z**      **Disorder of the optic nerve, unspecified**

**9C41**      **Disorder of optic chiasm**

This is a group of conditions associated with the optic chiasm, the part of the brain where the optic nerves (CN II) partially cross.

**Coding Note:** Use additional code, if desired, to identify underlying condition.

**9C42**      **Disorder of post chiasmal visual pathways**

**Coding Note:** Use additional code, if desired, to identify underlying condition.

**Inclusions:** Disorders of optic tracts, geniculate nuclei and optic radiations

**9C43**      **Disorder of visual cortex**

**Coding Note:** Use additional code, if desired, to identify underlying condition.

**9C44**      **Disorder of higher visual centres**

**Coding Note:** Use additional code, if desired, to identify underlying condition.

**9C4Y**      **Other specified disorders of the visual pathways or centres**

**9C4Z**      **Disorders of the visual pathways or centres, unspecified**

Glaucoma or glaucoma suspect (9C60-9C6Z)

**9C60**      **Glaucoma suspect**

**9C61**      **Glaucoma**

**Exclusions:** Traumatic glaucoma due to birth injury (KA41)

**Coded Elsewhere:** Glaucomatous optic neuropathy (9C40.9)

<b>9C61.0</b>	<b>Primary open-angle glaucoma</b> Primary open-angle glaucoma is a chronic progressive optic neuropathy with characteristic morphological changes at the optic nerve head and retinal nerve fibre layer in the absence of other ocular disease or congenital anomalies. Progressive retinal ganglion cell death and visual field loss are associated with these changes. Anterior chamber angle appearance is normal and major risk factors include level of intraocular pressure and older age.
<b>9C61.00</b>	Normal tension glaucoma Normal tension glaucoma is a condition considered to be within the continuum of primary open-angle glaucoma; the term is used when intraocular pressure is within the statistically normal range (10-21 mmHg).
<b>9C61.01</b>	Ocular hypertension Ocular hypertension is a condition of elevated intraocular pressure in the absence of optic nerve, nerve fibre layer or visual field abnormalities.
<b>9C61.0Y</b>	Other specified primary open-angle glaucoma
<b>9C61.0Z</b>	Primary open-angle glaucoma, unspecified
<b>9C61.1</b>	<b>Primary angle closure and angle closure glaucoma</b> Primary angle closure glaucoma is a condition described as angle closure or/and peripheral anterior synechiae with elevated intraocular pressure and evidence of optic nerve damage.
<b>9C61.10</b>	Primary angle closure suspect or anatomical narrow angle Primary angle closure glaucoma suspect is a condition of narrow anterior chamber angle, suspicious for future closure, with no signs of trabecular meshwork or optic nerve damage.
<b>9C61.11</b>	Primary angle-closure Primary angle closure is a condition defined by the presence of iridotrabecular contact with elevated intraocular pressure or peripheral anterior synechiae but no signs of optic nerve damage.
<b>9C61.12</b>	Primary angle closure glaucoma Primary angle closure glaucoma is a condition described as angle closure or/and peripheral anterior synechiae with elevated intraocular pressure and evidence of optic nerve damage.
<b>9C61.13</b>	Primary angle closure without pupillary block Primary angle closure without pupillary block is a condition described as anatomical variation in the iris root in which narrowing of the anterior chamber angle occurs independent of pupillary block causing angle closure.
<b>9C61.14</b>	Acute angle closure with pupillary block Acute Angle Closure (AAC) with pupillary block is a condition described as circumferential iris apposition to the trabecular meshwork with rapid and excessive increase in intraocular pressure that does not resolve spontaneously.

<b>9C61.15</b>	Intermittent angle-closure Intermittent Angle Closure is a milder clinical manifestation of acute angle closure that resolves spontaneously.
<b>9C61.16</b>	Chronic angle-closure Chronic angle closure is a condition when intraocular pressure elevation is due to variable portions of anterior chamber angle being permanently closed by peripheral anterior synechiae.
<b>9C61.17</b>	Condition after acute angle-closure glaucoma attack Condition after acute angle closure glaucoma attack refers to a condition after a previous episode of acute angle-closure attack, usually with secondary alterations of the iris (sphincter lesions) and lens ("Glaukomflecken", cataract).
<b>9C61.1Y</b>	Other specified primary angle closure and angle closure glaucoma
<b>9C61.1Z</b>	Primary angle closure and angle closure glaucoma, unspecified
<b>9C61.2</b>	<b>Secondary open-angle glaucoma</b>
<b>Coding Note:</b>	Code also the causing condition <b>Coded Elsewhere:</b> Glaucoma due to ocular surgery or laser (9D25)
<b>9C61.20</b>	Pseudoexfoliative open-angle glaucoma Pseudoexfoliative Open-Angle glaucoma is a condition where fibrillar pseudoexfoliative material is produced by various ocular tissues and is deposited on the trabecular meshwork, lens, and other structures of the anterior segment leading to intraocular pressure elevation and subsequent optic nerve damage.
<b>9C61.21</b>	Pigmentary open-angle glaucoma Pigmentary open-angle glaucoma is a condition where pigment is liberated due to rubbing of the zonules against the posterior iris sheath that leads to obstruction of the trabecular meshwork causing intraocular pressure elevation and subsequent optic nerve damage.
<b>9C61.22</b>	Lens-induced secondary open-angle glaucoma
<b>9C61.23</b>	Glaucoma associated with intraocular haemorrhage Ghost cell glaucoma is a condition where bleeding into the vitreous body or anterior chamber can lead to intraocular pressure elevation when stiffer red blood cells that have lost their haemoglobin obstruct the trabecular meshwork. <b>Inclusions:</b> ghost cell glaucoma
<b>9C61.24</b>	Glaucoma due to eye inflammation <b>Coding Note:</b> Code also the causing condition
<b>9C61.25</b>	Glaucomato-cyclitic crisis A glaucomato-cyclitic crisis presents with mild keratic precipitates and aqueous flare, acute intraocular pressure elevation and optic nerve damage when repeated attacks occur.

<b>9C61.26</b>	Secondary open-angle glaucoma due to parasitic eye disease
<b>Coding Note:</b>	Code also the causing condition
<b>9C61.27</b>	Glaucoma due to intraocular tumours
<b>Coding Note:</b>	Code also the causing condition
<b>9C61.28</b>	Glaucoma associated with retinal detachment
<b>Coding Note:</b>	Code also the causing condition
<b>9C61.29</b>	Glaucoma due to eye trauma
<b>Coding Note:</b>	Code also the causing condition
<b>9C61.2A</b>	Glaucoma due to drugs
<b>9C61.2B</b>	Glaucoma caused by increased episcleral venous pressure
<b>Coding Note:</b>	Code also the causing condition
<b>9C61.2C</b>	Secondary glaucoma due to extra-ocular mass
<b>Coding Note:</b>	Code also the causing condition
<b>9C61.2Y</b>	Other specified secondary open-angle glaucoma
<b>Coding Note:</b>	Code also the causing condition
<b>9C61.2Z</b>	Secondary open-angle glaucoma, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>9C61.3</b>	<b>Secondary angle closure glaucoma</b>
<b>9C61.30</b>	Secondary angle closure glaucoma with pupillary block Secondary angle closure glaucoma with pupillary block is a condition where an anteriorly subluxated lens occludes the pupil causing acute secondary angle closure and intraocular pressure elevation.
<b>Coding Note:</b>	Code also the causing condition
<b>9C61.31</b>	Secondary angle closure glaucoma without pupillary block
<b>9C61.32</b>	Neovascular secondary angle closure glaucoma Neovascular secondary angle-closure glaucoma is a frequent condition where neovascular membranes occlude and close the chamber angle by fibrovascular contraction leading to intraocular pressure elevation and subsequent optic nerve damage. Neovascularization can be due to retinal venous occlusion, diabetic retinopathy, ocular ischemia, long-standing retinal detachment and other ischemic conditions of the eye.
<b>Coding Note:</b>	Code also the causing condition
<b>9C61.33</b>	Secondary angle closure glaucoma due to endothelial overgrowth Secondary angle-closure glaucoma due to endothelial overgrowth is a condition where corneal endothelial cells overgrow the trabecular meshwork and iris, closing the angle by tissue contraction leading to intraocular pressure elevation and subsequent optic nerve damage.

- 9C61.34** Secondary angle closure glaucoma due to epithelial ingrowth  
 Epithelial ingrowth is a condition after open globe trauma or surgery where conjunctival or corneal epithelial cells get access to the anterior chamber and overgrow the trabecular meshwork with subsequent intraocular pressure elevation and optic nerve damage.
- 9C61.35** Ciliary block glaucoma  
 Ciliary block glaucoma is a condition where aqueous misdirection into the vitreous cavity displaces the lens-iris diaphragm anteriorly thus causing angle closure with subsequent intraocular pressure elevation and optic nerve damage.
- 9C61.36** Secondary angle closure glaucoma due to other anterior displacement of the lens-iris diaphragm  
 Iris and ciliary body cysts, intraocular tumours, posterior scleritis, uveal effusion, or Silicon Oil or gas in the vitreous cavity can cause IOP elevation by angle closure.
- 9C61.3Y** Other specified secondary angle closure glaucoma
- 9C61.3Z** Secondary angle closure glaucoma, unspecified
- 9C61.4** **Developmental glaucoma**
- Inclusions:**
- Glaucoma of newborn
  - Hydrocephalus
- 9C61.40** Primary congenital glaucoma  
 Primary Congenital Glaucoma is a condition during early infancy where delayed development and malformation of the trabecular meshwork blocks the outflow routes leading to elevated intraocular pressure that causes enlargement of the eyeball (Buphthalmus), corneal oedema, Descemet tears, myopia, and damage to the optic nerve, often resulting in severe visual impairment or blindness
- 9C61.41** Primary infantile glaucoma  
 Primary infantile glaucoma is a condition after 2 years of age where malformation of the trabecular meshwork causes elevated intraocular pressure without enlargement of the eyeball but damage to the optic nerve similar to congenital glaucoma.
- 9C61.42** Secondary childhood glaucoma
- Coding Note:** Code also the causing condition
- Coded Elsewhere:** Aniridia (LA11.3)
- Marfan syndrome (LD28.01)
  - Rubella (1F02)
  - Oculocerebrorenal syndrome (5C60.0)
  - Neurofibromatosis (LD2D.1)
- 9C61.4Y** Other specified developmental glaucoma
- 9C61.4Z** Developmental glaucoma, unspecified
- 9C61.Z** **Glaucoma, unspecified**

**9C6Y**      **Other specified glaucoma or glaucoma suspect**

**9C6Z**      **Glaucoma or glaucoma suspect, unspecified**

## Strabismus or ocular motility disorders (9C80-9C8Z)

Disorder due to abnormalities of extraocular muscles or ocular motor abnormalities.

**Coded Elsewhere:** Diseases of neuromuscular junction or muscle (8C60-8D0Z)

**9C80**      **Non paralytic strabismus**

Non-paralytic strabismus is an abnormal binocular alignment in which one of the eyes is deviated. There are full ocular movements in each eye. The condition can alternate between eyes or only involve one eye. Strabismus may be intermittent or constant. The abnormal alignment may be present at distance fixation, near fixation or both.

**9C80.0**      **Esotropia**

Esotropia is an abnormal binocular alignment in which one of the eyes has an inward deviation. Fixation can be alternating or monocular. Esotropia is present in all distances. Squint angles can vary with distances.

**9C80.1**      **Exotropia**

Exotropia is an abnormal binocular alignment in which one of the eyes has an outward deviation. Fixation can be alternating or monocular. Exotropia is present in all distances.

**9C80.2**      **Vertical or torsional strabismus**

An abnormal binocular alignment which may be constant or intermittent, that is not horizontal, but vertical or torsional (rotational) around the pupillary axis.

**9C80.3**      **Intermittent strabismus**

An abnormal binocular alignment which is present intermittently, with normal alignment at other times with binocular single vision.

**9C80.30**      Intermittent divergent exotropia

**9C80.31**      Intermittent convergent esotropia

**9C80.3Y**      Other specified intermittent strabismus

**9C80.3Z**      Intermittent strabismus, unspecified

**9C80.4**      **Heterophoria**

A temporary deviation of the eyes from normal binocular alignment when there is disruption of the visual input from one eye. The alignment is normal when there is binocular visual input.

<b>9C80.5</b>	<b>Mechanical strabismus</b> An abnormal binocular alignment caused by abnormalities of ocular movement in one or both eyes caused by damage to the extraocular muscles and/or other orbital structures. Mechanical strabismus is characterised by limitation of movements in one or more directions and variable strabismus.
<b>9C80.Y</b>	<b>Other specified non paralytic strabismus</b>
<b>9C80.Z</b>	<b>Non paralytic strabismus, unspecified</b>
<b>9C81</b>	<b>Ocular motor nerve palsies</b>
	<b><i>Exclusions:</i></b> Internuclear ophthalmoplegia (9C83.5) Internal ophthalmoplegia (9D01.0) ophthalmoplegia progressive supranuclear (8A00.10)
<b>9C81.0</b>	<b>Third nerve palsy</b> <b><i>Inclusions:</i></b> isolated oculomotor nerve palsy
<b>9C81.00</b>	External bilateral paralysis of oculomotor nerve
<b>9C81.0Y</b>	Other specified third nerve palsy
<b>9C81.0Z</b>	Third nerve palsy, unspecified
<b>9C81.1</b>	<b>Fourth nerve palsy</b> <b><i>Inclusions:</i></b> isolated trochlear nerve palsy
<b>9C81.2</b>	<b>Sixth nerve palsy</b> <b><i>Inclusions:</i></b> isolated abducent nerve palsy
<b>9C81.3</b>	<b>Total external ophthalmoplegia</b>
<b>9C81.4</b>	<b>Cavernous sinus syndromes</b>
<b>9C81.Y</b>	<b>Palsy of other specified ocular motor nerve</b>
<b>9C81.Z</b>	<b>Palsy of unspecified ocular motor nerve</b>
<b>9C82</b>	<b>Disorders of extraocular muscles</b> <b><i>Coded Elsewhere:</i></b> Certain paralytic strabismus (9C81.Y)

<b>9C82.0</b>	<b>Progressive external ophthalmoplegia</b> Chronic ophthalmoplegia is characterised by progressive weakness of ocular muscles and levator muscle of the upper eyelid. The condition is mainly manifested in adults. It may be totally and permanently isolated, however in a minority of cases it is associated with skeletal myopathy, which causes abnormal fatigability and even permanent muscle weakness. In this case the affection is still termed isolated progressive external ophthalmoplegia. A large proportion of chronic ophthalmoplegias presents with multisystemic pattern of signs: neurological signs (hearing loss, retinopathy, cerebellar disorders, peripheral neuropathy, etc.), endocrine (diabetes, hypogonadism, hypoparathyroidism, etc.), kidney (kidney failure, tubulopathy, etc.), and heart disorders (conduction disorders, myocardiopathy, etc.).
<b>9C82.1</b>	<b>Muscular dystrophy affecting extraocular muscle</b> Non-specific term that is used to describe a range of primary myopathies that affect the extraocular muscles.  <b>Exclusions:</b> Secondary myopathies (8C80-8C8Z)  <b>Coded Elsewhere:</b> Congenital fibrosis of extraocular muscles (9C82.2)
<b>9C82.2</b>	<b>Congenital cranial dysinnervation syndrome</b>
<b>9C82.3</b>	<b>Restrictive ophthalmopathy</b>
<b>Coding Note:</b>	Code also the causing condition
<b>9C82.4</b>	<b>Oculomotor apraxia</b>
<b>9C82.Y</b>	<b>Other specified disorders of extraocular muscles</b>
<b>9C82.Z</b>	<b>Disorders of extraocular muscles, unspecified</b>
<b>9C83</b>	<b>Disorders of binocular movement</b> Other disorders of binocular movement in which the movement of the two eyes is abnormal.
<b>9C83.0</b>	<b>Palsy of conjugate gaze</b> A palsy of conjugate gaze is an incomplete or absent movement of the two eyes in a particular direction of gaze.  <b>Coded Elsewhere:</b> Progressive supranuclear palsy (8A00.10)
<b>9C83.00</b>	Horizontal gaze palsy A palsy of horizontal gaze is an incomplete or absent movement of the two eyes in a horizontal direction of gaze. May be in one or both directions
<b>9C83.01</b>	Vertical gaze palsy A palsy of vertical gaze is an incomplete or absent movement of the two eyes in the vertical direction of gaze.

<b>9C83.02</b>	Monocular elevator palsy Monocular elevator palsy is an incomplete or absent movement of one eye in upgaze. May be due to pathology in the orbit, as well as infranuclear, internuclear, or supranuclear in origin.
<b>9C83.0Y</b>	Other specified palsy of conjugate gaze
<b>9C83.0Z</b>	Palsy of conjugate gaze, unspecified
<b>9C83.1</b>	<b>Spasm of conjugate gaze</b>
<b>9C83.10</b>	Horizontal conjugate gaze deviation
<b>9C83.11</b>	Upward gaze deviation
<b>9C83.12</b>	Downward gaze deviation
<b>9C83.13</b>	Oculogyric crisis Episodic spells of tonic upward and sometimes lateral deviation of the eyes, rarely downward.
<b>9C83.1Y</b>	Other specified spasm of conjugate gaze
<b>9C83.1Z</b>	Spasm of conjugate gaze, unspecified
<b>9C83.2</b>	<b>Convergence insufficiency</b>
<b>9C83.3</b>	<b>Convergence excess</b>
<b>9C83.4</b>	<b>Spasm of the near reflex</b>
<b>9C83.5</b>	<b>Internuclear ophthalmoplegia</b> This is a disorder of conjugate lateral gaze in which the affected eye shows impairment of adduction.
<b>9C83.6</b>	<b>Anomalies of divergence or deviation of eye movement</b>
<b>9C83.60</b>	Divergence insufficiency
<b>9C83.61</b>	Divergence paralysis
<b>9C83.62</b>	Divergence excess
<b>9C83.63</b>	Synergistic divergence Anomalous innervation of muscle normally supplied by the oculomotor nerve. In congenital unilateral adduction palsy, when adduction is attempted, the affected eye abducts rather than adducts.
<b>9C83.64</b>	Skew deviation a vertical misalignment of the visual axes caused by a disturbance of prenuclear inputs

<b>9C83.65</b>	Ocular tilt reaction skew deviation associated with ocular torsion (cyclodeviation) and a head tilt (ear to shoulder)
<b>9C83.66</b>	Alternating skew deviation
<b>9C83.67</b>	Dissociative vertical divergence
<b>9C83.6Y</b>	Other specified anomalies of divergence or deviation of eye movement
<b>9C83.6Z</b>	Anomalies of divergence or deviation of eye movement, unspecified
<b>9C83.Y</b>	<b>Other specified disorders of binocular movement</b>
<b>9C83.Z</b>	<b>Disorders of binocular movement, unspecified</b>
<b>9C84</b>	<b>Nystagmus</b>
<b>9C84.0</b>	<b>Physiological nystagmus</b>
<b>9C84.1</b>	<b>Congenital forms of nystagmus</b>
<b>9C84.2</b>	<b>Vestibular nystagmus</b>
<b>9C84.20</b>	Downbeat nystagmus
<b>9C84.21</b>	Upbeat nystagmus
<b>9C84.22</b>	Torsional nystagmus
<b>9C84.23</b>	Perverted nystagmus
<b>9C84.2Y</b>	Other specified vestibular nystagmus
<b>9C84.2Z</b>	Vestibular nystagmus, unspecified
<b>9C84.3</b>	<b>Seesaw nystagmus</b>
<b>9C84.4</b>	<b>Gaze-evoked nystagmus</b>
<b>9C84.5</b>	<b>Nystagmus occurring in visual system disorders</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Coded Elsewhere:</b> Spasmus nutans (8A04.Y)
<b>9C84.50</b>	Visual deprivation nystagmus
<b>9C84.51</b>	Divergence nystagmus
<b>9C84.52</b>	Convergence-retraction nystagmus
<b>9C84.5Y</b>	Other specified nystagmus occurring in visual system disorders
<b>Coding Note:</b>	Code also the causing condition
<b>9C84.5Z</b>	Nystagmus occurring in visual system disorders, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>9C84.6</b>	<b>Eyelid nystagmus</b>

<b>9C84.Y</b>	<b>Other specified nystagmus</b>
<b>9C84.Z</b>	<b>Nystagmus, unspecified</b>
<b>9C85</b>	<b>Certain specified irregular eye movements</b>
<b>9C85.0</b>	<b>Anomalies of saccadic eye movements</b>
<b>9C85.00</b>	Disorders of the saccadic pulse
<b>9C85.01</b>	Disorders of the saccadic step
	<b>Coded Elsewhere:</b> Gaze-evoked nystagmus (9C84.4)
<b>9C85.02</b>	Inappropriate saccades
	<b>Inclusions:</b> Saccadic intrusions and oscillations
<b>9C85.0Y</b>	Other specified anomalies of saccadic eye movements
<b>9C85.0Z</b>	Anomalies of saccadic eye movements, unspecified
<b>9C85.1</b>	<b>Anomalies of smooth pursuit movements</b>
<b>9C85.2</b>	<b>Nonorganic eye movement disorders</b>
<b>9C85.Y</b>	<b>Other specified irregular eye movements</b>
<b>9C85.Z</b>	<b>Irregular eye movements, unspecified</b>
<b>9C8Y</b>	<b>Other specified strabismus or ocular motility disorders</b>
<b>9C8Z</b>	<b>Strabismus or ocular motility disorders, unspecified</b>

#### Disorders of refraction or accommodation (9D00-9D0Z)

<b>9D00</b>	<b>Disorders of refraction</b>
<b>9D00.0</b>	<p><b>Myopia</b></p> <p>A refractive error in which rays of light entering the eye parallel to the optic axis are brought to a focus in front of the retina when ocular accommodation is relaxed. This usually results from the eyeball being too long from front to back, but can be caused by an overly curved cornea, a lens with increased optical power, or both. It is also called nearsightedness.</p> <p><b>Exclusions:</b> degenerative myopia (9B76)</p>
<b>9D00.1</b>	<p><b>Hypermetropia</b></p> <p>A refractive error in which rays of light entering the eye parallel to the optic axis are brought to a focus behind the retina, as a result of the eyeball being too short from front to back. It is also called farsightedness because the near point is more distant than it is in emmetropia with an equal amplitude of accommodation.</p>

<b>9D00.2</b>	<b>Astigmatism</b> Unequal curvature of the refractive surfaces of the eye. Thus a point source of light cannot be brought to a point focus on the retina but is spread over a more or less diffuse area. This results from the radius of curvature in one plane being longer or shorter than the radius at right angles to it.
<b>9D00.3</b>	<b>Presbyopia</b> The normal decreasing elasticity of the crystalline lens that leads to loss of accommodation.
<b>9D00.4</b>	<b>Anisometropia</b>
<b>9D00.5</b>	<b>Aniseikonia</b>
<b>9D00.6</b>	<b>Transient refractive change</b>
<b>9D00.Y</b>	<b>Other specified disorders of refraction</b>
<b>9D00.Z</b>	<b>Disorders of refraction, unspecified</b>
<b>9D01</b>	<b>Disorders of accommodation</b>
<b>9D01.0</b>	<b>Internal ophthalmoplegia</b>
<b>9D01.1</b>	<b>Paresis of accommodation</b>
<b>9D01.2</b>	<b>Spasm of accommodation</b>
<b>9D01.Y</b>	<b>Other specified disorders of accommodation</b>
<b>9D01.Z</b>	<b>Disorders of accommodation, unspecified</b>
<b>9D0Y</b>	<b>Other specified disorders of refraction or accommodation</b>
<b>9D0Z</b>	<b>Disorders of refraction or accommodation, unspecified</b>

### Postprocedural disorders of eye or ocular adnexa (9D20-9D25)

**Exclusions:** pseudophakia (QB51.2)

**Coded Elsewhere:** Haemorrhage and haematoma of eye or ocular adnexa complicating a procedure (NE81.01)

Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)

<b>9D20</b>	<b>Bullous aphakic keratopathy following cataract surgery</b> <i>Inclusions:</i> Vitreal corneal syndrome
<b>9D21</b>	<b>Cataract lens fragments in eye following cataract surgery</b>
<b>9D22</b>	<b>Chorioretinal scars after surgery for detachment</b>
<b>9D23</b>	<b>Conjunctival blebitis after glaucoma surgery</b>
<b>9D24</b>	<b>Complications with glaucoma drainage devices</b>

**9D25**

**Glaucoma due to ocular surgery or laser**

Impairment of visual functions (9D41-9D7Z)

**Coded Elsewhere:** Impairment of electrophysiological functions (MC21)

Polyopia (9D53)

**9D41**

**Impairment of visual field**

Ranges of visual field impairment refer to the extent of peripheral vision outside fixation. The extent should be measured for each eye separately.

**9D42**

**Patterns of visual field impairment**

Patterns of visual field impairment are often indicative for certain disease conditions.

**9D42.0**

**Visual field loss, pattern not specified**

**9D42.2**

**Peripheral field deficit**

**9D42.20**

Enlarged blind spot

**Inclusions:**              Scotoma of blind spot area

**9D42.21**

Arcuate scotoma

A Bjerrum or arcuate scotoma follows the pattern of the retinal nerve fibres. It is typical for glaucomatous defects and can also be caused by juxta-papillary lesions.

**9D42.22**

Nasal step

A nasal step is a discontinuity of the nasal field limit at the horizontal meridian. It is typical for glaucoma.

**9D42.23**

Ring scotoma

A ring scotoma is a scotoma that surrounds the central field. Initially, it may consist of several smaller scotomas that gradually coalesce.

**9D42.24**

Isolated peripheral scotoma

Isolated scotomas may be the result of scarring from infections or surgery.

**9D42.2Y**

Other specified peripheral field deficit

**9D42.2Z**

Peripheral field deficit, unspecified

**9D42.3**

**Hemianopic or quadrantic loss**

Defects that cover a hemi-field or a quadrant in one eye may be the result of optic nerve involvement.

**9D42.4**

**Central scotoma**

A central scotoma is a defect that covers the fovea. It therefore causes visual acuity loss and may necessitate eccentric fixation.

- 9D42.5** **Para-central scotoma**  
A para-central scotoma is a scotoma adjacent to the fovea. Both may minimally affect letter chart acuity, but may interfere significantly with reading and other activities.
- 9D42.6** **Homonymous hemianopia or quadrant anopia**  
Homonymous, binocular field defects present the same or similar patterns in both eyes. They are caused by lesions of the retro-chiasmal pathways.
- 9D42.60** Right hemi-field homonymous hemianopia or quadrant anopia
- 9D42.61** Left hemi-field homonymous hemianopia or quadrant anopia
- 9D42.6Y** Other specified homonymous hemianopia or quadrant anopia
- 9D42.6Z** Homonymous hemianopia or quadrant anopia, unspecified
- 9D42.7** **Heteronymous hemianopia or quadrant anopia**  
Heteronymous field defects present opposite patterns in the two eyes. They may be caused by chiasmal lesions.
- 9D42.70** Bi-nasal defects heteronymous hemianopia or quadrant anopia
- 9D42.71** Bi-temporal defects heteronymous hemianopia or quadrant anopia
- 9D42.7Y** Other specified heteronymous hemianopia or quadrant anopia
- 9D42.7Z** Heteronymous hemianopia or quadrant anopia, unspecified
- 9D42.8** **Visual field loss, other specified forms**
- 9D42.Y** **Other specified patterns of visual field impairment**
- 9D42.Z** **Patterns of visual field impairment, unspecified**
- 9D43** **Impairment of contrast vision**  
Contrast sensitivity refers to the ability to distinguish small differences in brightness between adjacent surfaces.  
Peak Contrast sensitivity refers to the smallest differences that are discernible for large stimuli.  
For smaller objects, such as those involved in many Activities of Daily Living, contrast sensitivity interacts with visual acuity and visual field. Better contrast makes smaller details visible. The visual field is larger for stronger stimuli.
- 9D44** **Impairment of colour vision**  
Colour vision refers to the ability to distinguish colour differences. True colour "blindness" is extremely rare. Most colour vision deficiencies are minor, and congenital, with X-linked recessive inheritance (more prevalent among men). Some drugs and optic neuritis may also cause colour vision deficiencies.
- Inclusions:** achromatopsia  
acquired colour vision deficiency  
colour blindness

9D45	<b>Impairment of light sensitivity</b>
	<b>Coded Elsewhere:</b> Vitamin A deficiency with night blindness (5B55.0)
9D46	<b>Impairment of binocular functions</b>
	Subjective visual experiences (9D50-9D5Z)
	Subjective Visual Experiences are experiences reported by patients, whose presence or absence cannot be verified objectively.
9D50	<b>Visual discomfort</b>
	<b>Inclusions:</b> Asthenopia
9D51	<b>Transient visual loss</b>
	<b>Coded Elsewhere:</b> Amaurosis fugax (8B10.0)
9D52	<b>Hemifield losses</b>
9D53	<b>Entoptic phenomena</b>
	Entoptic phenomena are visual phenomena caused by changes within the eye.
	<b>Coded Elsewhere:</b> Visual floaters (MC1A)
9D54	<b>Visual illusions</b>
	Visual illusions refer to percepts based on an erroneous interpretation of visual input.
9D55	<b>Nonorganic visual loss</b>
9D56	<b>Visual release hallucinations</b>
	Visual release hallucinations, also called Charles Bonnet syndrome, refer to the experience of complex visual hallucinations in a person who has experienced partial or complete loss of vision. Hallucinations are exclusively visual, usually temporary, and unrelated to mental and behavioural disorders.
	<b>Exclusions:</b> Schizophrenia or other primary psychotic disorders (6A20-6A2Z)
9D5Y	<b>Other specified subjective visual experiences</b>
9D5Z	<b>Subjective visual experiences, unspecified</b>
9D7Y	<b>Other specified impairment of visual functions</b>
9D7Z	<b>Impairment of visual functions, unspecified</b>

## Vision impairment (9D90-9D9Z)

A vision impairment results when an eye condition affects the visual system and one or more of its vision functions. Typically, population-based surveys measure visual impairment using exclusively visual acuity, with severity categorized as mild, moderate or severe distance vision impairment or blindness, and near vision impairment. However, in the clinical setting, other visual functions are also often assessed, such as a person's field of vision, contrast sensitivity and colour vision.

**9D90**

### **Vision impairment including blindness**

The table below gives a classification of severity of vision impairment based on visual acuity. For epidemiological studies, it is recommended to collect the following information on visual acuity for each eye, for both eyes open and for distance and near.

- a. Uncorrected visual acuity
- b. Presenting visual acuity
- c. Best corrected visual acuity

Blindness is also categorized according to the degree of constriction of the central visual field in the better eye to less than 10 degrees.

For capturing and coding of "No vision impairment", use QA00.62 (QA00.6 Examination of eyes or vision).

Category	Visual acuity *1	
	Worse than:	Equal to or better than:
No vision impairment		<ul style="list-style-type: none"><li>• 6/12</li><li>• 5/10 (0.5)</li><li>• 20/40</li><li>• 0.3</li></ul>
1 Mild vision impairment	<ul style="list-style-type: none"><li>• 6/12</li><li>• 5/10 (0.5)</li><li>• 20/40</li><li>• 0.3</li></ul>	<ul style="list-style-type: none"><li>• 6/18</li><li>• 3/10 (0.3)</li><li>• 20/70</li><li>• 0.5</li></ul>
2 Moderate vision impairment	<ul style="list-style-type: none"><li>• 6/18</li><li>• 3/10 (0.3)</li><li>• 20/70</li><li>• 0.5</li></ul>	<ul style="list-style-type: none"><li>• 6/60</li><li>• 1/10 (0.1)</li><li>• 20/200</li><li>• 1.0</li></ul>
3 Severe vision impairment	<ul style="list-style-type: none"><li>• 6/60</li><li>• 1/10 (0.1)</li><li>• 20/200</li><li>• 1.0</li></ul>	<ul style="list-style-type: none"><li>• 3/60</li><li>• 1/20 (0.05)</li><li>• 20/400</li><li>• 1.3</li></ul>

Category	<b>Visual acuity *1</b>	
	<b>Worse than:</b>	<b>Equal to or better than:</b>
4 Blindness	<ul style="list-style-type: none"> <li>• 3/60</li> <li>• 1/20 (0.05)</li> <li>• 20/400</li> <li>• 1.3</li> </ul>	<ul style="list-style-type: none"> <li>• 1/60 or counts fingers (CF)</li> <li>• at 1 metre</li> <li>• 1/50 (0.02)</li> <li>• 20/1200 or counts fingers (CF)</li> <li>• at 1 metre</li> <li>• 1.8</li> </ul>
5 Blindness	<ul style="list-style-type: none"> <li>• 1/60</li> <li>• 1/50 (0.02)</li> <li>• 5/300 (20/1200)</li> <li>• 1.8</li> </ul>	Light perception
6 Blindness	No light perception	
9	Undetermined or unspecified	
Near vision impairment	N6 or M 0.8 at 40cms	

\*1 Presented in metres, decimals, feet and logMar

**Coded Elsewhere:** No vision impairment (QA00.62)

- 9D90.1      Mild vision impairment**
- 9D90.2      Moderate vision impairment**
- Inclusions:* visual impairment category 2, in both eyes
- 9D90.3      Severe vision impairment**
- Inclusions:* visual impairment category 3 in one eye, with categories 1 or 2 in the other eye
- 9D90.6      Blindness**
- The numerical definition used for WHO statistics refers to profound, near-total or total loss. The functional definition refers to individuals who have little or no residual vision and who have to rely predominantly on vision substitution skills, i.e. on using senses other than vision (Braille or talking books for reading, a long cane or guide dog for mobility, or touch for manipulation).
- Inclusions:*
- visual impairment category 5
  - visual impairment categories 4, 5, 6 in both eyes
  - visual impairment categories 4, 5, 6 in one eye and categories 1, 2, 3 or 9 in the other eye
  - visual impairment categories 4, 5, 6 in one eye [normal vision in other eye]

**9D90.7      Near vision impairment**

Near vision refers to the ability to perform tasks that require detailed vision at a close distance. It should be measured with both eyes open at the subject's preferred viewing distance and with the subject's habitual near vision correction (if any). Near vision impairment is characterised by a presenting near visual acuity worse than N6.

**9D92      Specific vision dysfunctions**

Specific visual dysfunctions refer to functional deficits in higher cerebral centres. Such dysfunctions may exist with or without visual impairment of the eyes and the lower visual system.

**9D93      Complex vision-related dysfunctions**

Complex Vision-Related Dysfunctions involve interactions with other sensory and motor systems. They reflect the combined effects at all stages of processing.

**9D94      Impairment of presenting visual acuity**

**9D95      Impairment of best corrected visual acuity**

**9D96      Impairment of uncorrected visual acuity**

**9D9Y      Other specified vision impairment**

**9D9Z      Vision impairment, unspecified**

---

**9E1Y      Other specified diseases of the visual system**

**9E1Z      Diseases of the visual system, unspecified**

# CHAPTER 10

---

## Diseases of the ear or mastoid process

This chapter has 78 four-character categories.

Code range starts with AA00

This chapter contains diseases of the ear and diseases of the mastoid process.

- Exclusions:**
- Complications of pregnancy, childbirth and the puerperium (Chapter 18)
  - Certain infectious or parasitic diseases (Chapter 01)
  - Certain conditions originating in the perinatal period (Chapter 19)
  - Injury, poisoning or certain other consequences of external causes (Chapter 22)
  - Neoplasms (Chapter 02)
  - Endocrine, nutritional or metabolic diseases (Chapter 05)

- Coded Elsewhere:**
- Structural developmental anomalies of the ear (LA20-LA2Z)
  - Symptoms, signs or clinical findings of ear or mastoid process (MC40-MC6Y)

This chapter contains the following top level blocks:

- Diseases of external ear
- Diseases of middle ear or mastoid
- Diseases of inner ear
- Disorders with hearing impairment
- Disorders of ear, not elsewhere classified
- Postprocedural disorders of ear or mastoid process

## Diseases of external ear (AA00-AA6Z)

**Coded Elsewhere:** Inflammatory disorders of the external ear (EG40-EG4Z)

Infectious diseases of external ear (AA00-AA0Z)

**Coded Elsewhere:** Erysipelas of external ear (1B70.01)

Candida otomycosis (1F23.16)

Herpes simplex infection of external ear (1F00.0Y)

Otitis externa due to zoster (1E91.Y)

**AA00**

### Abscess of external ear

A fluctuant collection of purulent exudate and necrotic tissue located in the external auditory canal or in the soft tissues of the pinna, most commonly due to *Staphylococcus aureus*.

**AA01**

### Cellulitis of external ear

A diffuse subacute bacterial infection of the soft tissues of the external ear, most commonly due to beta-haemolytic streptococci. It may arise within an apparently healthy external ear but may complicate both inflammatory and infective forms of otitis externa.

**Exclusions:** Erysipelas of external ear (1B70.01)

Staphylococcal cellulitis of skin (1B70.2)

Streptococcal cellulitis of skin (1B70.1)

**AA02**

### Malignant otitis externa

Malignant otitis externa is a rare life-threatening infective complication of otitis externa. It is due in the majority of cases to *Pseudomonas aeruginosa*. Organisms penetrate from the external ear canal into the surrounding deeper tissues resulting in osteomyelitis of the temporal bone and risks of damage to adjacent cranial nerves and septic thrombo-emboli to the brain. Advanced age, uncontrolled diabetes mellitus and immunosuppression are risk factors.

**AA03**

### Otomycosis

Fungal infection of the ear. Otomycosis is due to *Aspergillus* spp., especially *A. niger*, in 75% or more of cases and *Candida* in most of the remainder.

**Coded Elsewhere:** *Aspergillus* otomycosis (1F20.10)

Candida otomycosis (1F23.16)

**AA04**

### Perichondritis of external ear

Perichondritis is an infection of the tissue surrounding the cartilage of the outer ear, the perichondrium. It usually results from injury to the ear from ear surgery, ear piercing (especially piercing of the cartilage), or trauma from contact sports. The most common bacterium causing perichondritis is *Pseudomonas aeruginosa*. Presenting features include pain, redness and swelling of the auricle, and fever.

**AA0Y**

### Other specified infectious diseases of external ear

**AA0Z**

### Infectious diseases of external ear, unspecified

## Otitis externa (AA10-AA3Z)

Inflammation of the outer ear including the external ear canal, cartilages of the auricle, and the tympanic membrane.

## Noninfectious inflammation of external ear (AA10-AA1Z)

**Coded Elsewhere:** Contact dermatitis of external ear (EG40)

Juvenile spring eruption (EJ30.0)

**AA10**

### **Seborrhoeic otitis externa**

Seborrhoeic dermatitis affecting the skin of the external ear. It is usually accompanied by evidence of seborrhoeic dermatitis at other sites. In mild cases it may be asymptomatic but it can present acutely with severe pain, oedema and exudation. Longstanding cases may be complicated by chronic lymphoedema and occlusion of the external auditory canal.

**Exclusions:** Seborrhoea (ED91.2)

**AA11**

### **Acute noninfectious otitis externa**

Rapid onset of eczematous inflammation of the outer ear the cause of which cannot be more precisely classified.

**Exclusions:** Acute seborrhoeic otitis externa (AA10)

Allergic contact dermatitis of external ear (EG40.0)

Irritant contact dermatitis of external ear (EK02.10)

**AA12**

### **Chondrodermatitis nodularis**

A common pressure-induced painful nodule or ulcer affecting the external ear. It results from ischaemia of skin and underlying cartilage from a focal point of high pressure from the weight of the recumbent head. The site of involvement is dependent on the shape of the pinna (most commonly the helix is involved but in some individuals it is the antihelix which is more prominent) and whether the sufferer is limited to sleeping on one side and is thus unable to spare the ear from constant pressure when lying in bed.

**AA13**

### **Chronic otitis externa**

**AA1Y**

### **Other specified noninfectious inflammation of external ear**

**AA1Z**

### **Noninfectious inflammation of external ear, unspecified**

---

**AA3Y**

### **Other specified otitis externa**

**Coding Note:** Code also the causing condition

**AA3Z**

### **Otitis externa, unspecified**

**Coding Note:** Code also the causing condition

Noninflammatory disorders of the external ear (AA40-AA4Z)

Miscellaneous noninflammatory disorders involving the external ear.

**Coded Elsewhere:** Ear-lobe keloid (EE60.00)

Acanthoma fissuratum (EH92.Y)

**AA40 Acquired deformity of external auditory canal**

**AA40.0 Exostosis of external auditory canal**

**AA40.1 Acquired stenosis of external auditory canal**

Acquired stenosis of external auditory canal was described as resulting from a number of different causes. Since then, histology and imaging studies of this disease have shown that a common cascade of inflammatory changes resulting from these different causes is the primary pathogenesis leading to medial canal fibrosis. Once there is complete obstruction of the external auditory canal, surgery is the primary treatment.

**AA40.2 Cholesteatoma of external auditory canal**

**AA40.Y Other specified acquired deformity of external auditory canal**

**AA41 Acquired deformity of pinna**

Acquired deformities involving the external ear.

*Inclusions:* Acquired deformity of auricle

**AA41.0 Cauliflower ear**

Cauliflower ear is the end result of fibrosis of the skin and soft tissues of the pinna following a traumatic subperichondrial haematoma, usually due to trauma. It manifests as permanent swelling and deformity of the ear, described as resembling a cauliflower. It is found most commonly amongst men involved in contact sports such as boxing, wrestling, martial arts and rugby football.

**AA41.Y Other specified acquired deformity of pinna**

**AA42 Impacted cerumen**

Impacted cerumen is the presence of occlusive aural wax in the external ear canal. Wax may cause tinnitus or otalgia and removal may be required to allow adequate otoscopic examination and/or alleviate symptoms.

**AA4Y Other specified noninflammatory disorders of the external ear**

**AA4Z Noninflammatory disorders of the external ear, unspecified**

---

**AA6Z Diseases of external ear, unspecified**

## Diseases of middle ear or mastoid (AA80-AB1Z)

Middle ear, derived from the first pharyngeal (branchial) pouch; has the malleus and incus and stapes and includes the spaces of the epitympanum and mesotympanum and hypotympanum. The mastoid; normally contains "air"; the lateral boundary of the mesotympanum is where the tympanic membrane is, or normally would be located.

**Coded Elsewhere:** Congenital conductive hearing loss (AB50.0)

Otosclerosis (AB33)

Congenital mixed conductive and sensorineural hearing loss (AB50.2)

## Otitis media (AA80-AA0Z)

### Non-suppurative otitis media (AA80-AA8Z)

**AA80**

#### **Acute serous or mucoid otitis media**

Acute serous or mucoid otitis media is a collection of non-infected fluid in the middle ear that has developed as a result of an upper respiratory infection.

**AA81**

#### **Acute nonserous nonsuppurative otitis media**

**Exclusions:** Otitic barotrauma (NF04.0)

**AA82**

#### **Chronic serous or mucoid otitis media**

Chronic serous or mucoid otitis media is probably the most common form of subacute middle ear disease found in the developed world. It typically lingers following otitis media, when the fluid in the ear, formed by the infection, does not clear spontaneously. The tympanic membrane is intact but the middle ear is liquid-fluid filled. This presumably puts the middle ear at risk for further infection and often worsens hearing by about 30 dB. This is most frequently found in children and can interfere with language acquisition and learning.

**AA83**

#### **Noninfected otitis media with effusion**

**AA8Z**

#### **Nonsuppurative otitis media, unspecified**

### Suppurative otitis media (AA90-AA9Z)

This involves a perforation (hole) in the tympanic membrane and active bacterial infection within the middle ear space for several weeks or more. There may be enough pus that it drains to the outside of the ear (otorrhea), or the purulence may be minimal enough to only be seen on examination using a binocular microscope, unspecified.

**AA90**

#### **Acute suppurative otitis media**

Acute suppurative otitis media is defined as an inflammation of the middle ear which erupts suddenly and passes quickly. It is characteristic to have a middle-ear infection behind a reddened eardrum.

**AA91**

#### **Chronic suppurative otitis media**

<b>AA91.0</b>	<b>Chronic tubotympanic suppurative otitis media</b> Having a tympanic membrane perforation for at least three months, chronic suppurative otitis media has traditionally been classified into safe and unsafe type. Chronic tubotympanic suppurative otitis media is considered "safe" (meaning it is unlikely to become a worse problem for the patient) if it involves a central perforation of the pars tensa with the inflammatory process affecting the mucosa of the middle ear cleft.
	<b>Inclusions:</b> Benign chronic suppurative otitis media Chronic tubotympanic disease
<b>AA91.1</b>	<b>Chronic atticoantral suppurative otitis media</b> Chronic suppurative otitis media has traditionally been classified into safe and unsafe type. Chronic atticoantral suppurative otitis media which is unsafe type is typified by a marginal perforation of the posterosuperior pars tensa or pars flaccida.
	<b>Inclusions:</b> Chronic atticoantral disease
<b>AA91.2</b>	<b>Other chronic suppurative otitis media</b> This involves a perforation (hole) in the tympanic membrane and active bacterial infection within the middle ear space for several weeks or more. There may be enough pus that it drains to the outside of the ear (otorrhea), or the purulence may be minimal enough to only be seen on examination using a binocular microscope.
<b>AA91.Z</b>	<b>Chronic suppurative otitis media, unspecified</b>
<b>AA9Z</b>	<b>Suppurative otitis media, unspecified whether acute or chronic</b>
<b>AB00</b>	<b>Acute otitis media</b> <b>Coded Elsewhere:</b> Acute nonserous nonsuppurative otitis media (AA81) Acute suppurative otitis media (AA90)
<b>AB01</b>	<b>Chronic otitis media</b> <b>Coded Elsewhere:</b> Chronic serous or mucoid otitis media (AA82) Chronic suppurative otitis media (AA91)
<b>AB0Y</b>	<b>Other specified otitis media</b> <b>Coding Note:</b> Code also the causing condition
<b>AB0Z</b>	<b>Otitis media, unspecified</b> <b>Coding Note:</b> Code also the causing condition
<b>AB10</b>	<b>Disorders of Eustachian tube</b>
<b>AB10.0</b>	<b>Diverticulum of Eustachian tube</b>
<b>AB10.1</b>	<b>Patulous Eustachian tube</b>
<b>AB10.2</b>	<b>Eustachian salpingitis</b>

<b>AB10.3</b>	<b>Obstruction of Eustachian tube</b>
	<p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Compression of Eustachian tube</li> <li>Stricture of Eustachian tube</li> </ul>
<b>AB10.Y</b>	<b>Other specified disorders of Eustachian tube</b>
<b>AB10.Z</b>	<b>Disorders of Eustachian tube, unspecified</b>
<b>AB11</b>	<b>Mastoiditis or related conditions</b>
<b>AB11.0</b>	<b>Acute mastoiditis</b> Rapid onset inflammation of the mastoid bone, located in the skull just behind the ear. It is often a complication of otitis media.
<b>AB11.1</b>	<b>Chronic mastoiditis</b> Persistent or recurrent inflammation of the space in the mastoid bone. It is often a complication of otitis media.
<b>AB11.2</b>	<b>Petrositis</b>
<b>AB11.3</b>	<b>Mastoiditis, not elsewhere classified</b>
<b>AB11.Y</b>	<b>Other specified mastoiditis or related conditions</b>
<b>AB12</b>	<b>Cholesteatoma of middle ear</b>
	<p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Recurrent cholesteatoma of postmastoidectomy cavity (AB90)</li> <li>Cholesteatoma of external auditory canal (AA40.2)</li> </ul>
<b>AB13</b>	<b>Perforation of tympanic membrane</b>
	<p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Traumatic rupture of ear drum (NA0A.2)</li> </ul>
<b>AB13.0</b>	<b>Central perforation of tympanic membrane</b> A temporary or persistent opening in the central portion of the tympanic membrane. Clinical signs depend on the size, location, and associated pathological condition.
<b>AB13.1</b>	<b>Attic perforation of tympanic membrane</b>
	<p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Perforation of pars flaccida</li> </ul>
<b>AB13.2</b>	<b>Other marginal perforations of tympanic membrane</b>
<b>AB13.Y</b>	<b>Other specified perforation of tympanic membrane</b>
<b>AB13.Z</b>	<b>Perforation of tympanic membrane, unspecified</b>

**AB14****Acute myringitis**

Myringitis is the inflammation of the tympanic membrane, often involving painful blisters on the tympanic membrane. It can develop as self-maintained primary disease of the TM (primary myringitis) or as an effect of an inflammatory process of adjacent tissues of the external or middle ear (secondary myringitis). Myringitis may be accompanied by hearing impairment and a sensation of congestion and earache. It is generally a viral or bacterial infection and may occur with otitis media. After 3 weeks, acute myringitis becomes subacute and, within 3 months, chronic.

**Inclusions:** Acute tympanitis

**Exclusions:** Acute myringitis with otitis media (AB00)

**AB15****Chronic myringitis**

Persistent or recurrent inflammation of the tympanic membrane.

**Inclusions:** Chronic tympanitis

**Exclusions:** Chronic myringitis with otitis media (AB01)

**AB16****Tympanosclerosis**

Tympanosclerosis is a scarring process with a remarkable variability in its localization within the middle ear. It can lead to conductive hearing loss.

**AB17****Adhesive middle ear disease**

**Inclusions:** Adhesive otitis

**Exclusions:** glue ear (AA82)

**AB18****Discontinuity or dislocation of ear ossicles****AB19****Acquired abnormalities of ear ossicles not related to discontinuity or dislocation****AB1A****Polyp of middle ear****AB1A.0****Aural polyp****AB1A.Y****Other specified polyp of middle ear****AB1A.Z****Polyp of middle ear, unspecified****AB1B****Middle ear cicatrix****AB1Y****Other specified diseases of middle ear or mastoid****AB1Z****Diseases of middle ear or mastoid, unspecified**

## Diseases of inner ear (AB30-AB3Z)

**Coded Elsewhere:** Congenital mixed conductive and sensorineural hearing loss (AB50.2)

Congenital sensorineural hearing loss (AB50.1)

**AB30**

### **Acute vestibular syndrome**

A clinical syndrome of acute-onset, continuous vertigo, dizziness, or unsteadiness lasting days to weeks, and generally including features suggestive of new, ongoing vestibular system dysfunction (e.g., vomiting, nystagmus, severe postural instability). There may also be symptoms or signs suggesting cochlear or central nervous system dysfunction. Acute vestibular syndrome usually connotes a single, monophasic event, often caused by a one-time disorder, but it may instead punctuate a relapsing-and-remitting or stepwise, progressive illness course. Disorders typically presenting this syndrome include vestibular neuritis, acute labyrinthitis, traumatic vestibulopathy, demyelinating disease with vestibular involvement, and strokes affecting central or peripheral vestibular structures.

**Coding Note:** Code also the causing condition

**AB30.0      Vestibular neuritis**

Vestibular neuritis (also known as vestibular neuronitis) may be described as acute, sustained dysfunction of the peripheral vestibular system with secondary nausea, vomiting, and vertigo. Important negative features include aural fullness and hearing loss.

**AB30.1      Labyrinthitis**

Labyrinthitis is an inflammatory disorder of the inner ear (labyrinth) producing disturbances of balance and hearing to varying degrees. It can be caused by bacterial or viral infections and autoimmune processes.

**AB30.Y      Other specified acute vestibular syndrome**

**Coding Note:** Code also the causing condition

**AB30.Z      Acute vestibular syndrome, unspecified**

**Coding Note:** Code also the causing condition

**AB31**

### **Episodic vestibular syndrome**

A clinical syndrome of transient vertigo, dizziness, or unsteadiness lasting seconds to hours, occasionally days, and generally including features suggestive of temporary, short-lived vestibular system dysfunction (e.g., nausea, nystagmus, sudden falls). There may also be symptoms or signs suggesting cochlear or central nervous system dysfunction. Episodic vestibular syndrome usually connotes multiple, recurrent events caused by an episodic disorder with repeated spells (triggered or spontaneous), but may initially present after the first event.

**Coded Elsewhere:** Benign paroxysmal vertigo of childhood (8A80.Y)

- AB31.0 Meniere disease**  
Meniere Disease (MD) is a chronic progressive inner ear disease, with endolymphatic hydrops. It is characterised by recurrent attacks of debilitating spontaneous vertigo lasting from 20 minutes to up to 12 hours, accompanied by a sense of fullness and tinnitus in the affected ear, and ipsilateral fluctuating sensorineural hearing loss (SNHL) in the low or low and middle frequencies. There may be nystagmus during attacks and falls are frequent. When known, etiology should be added.
- Inclusions:** Labyrinthine hydrops
- AB31.1 Vestibular migraine**  
Recurrent attacks of moderate to severe vestibular symptoms lasting from 5 minutes to 72 hours in patients with a past or ongoing history of migraine headaches. Vestibular symptoms are usually spontaneous and positional vertigo, head motion-induced and visual vertigo as well as head motion-induced dizziness with nausea. Attacks of vestibular symptoms may occur together or independently of migraine symptoms like headache, photophobia, phonophobia or visual aura.
- AB31.2 Benign positional paroxysmal vertigo**  
Benign paroxysmal positional vertigo is defined as an abnormal sensation of motion that is elicited by certain critical provocative physical positions of the patient (e.g. becoming dorsal recumbent). The provocative positions usually trigger specific eye movements (e.g. nystagmus). The character and direction of the nystagmus is specific to the part of the inner ear affected and the underlying pathophysiology.
- AB31.3 Superior canal dehiscence syndrome**  
Superior canal dehiscence syndrome (SCDS) occurs when thin or dehiscent bone over the superior semicircular canal, best demonstrated on CT, allows pressure transmission between the canal and the intracranial space. Vertigo and nystagmus may occur when the canal is stimulated by loud sounds or changes in middle ear or intracranial pressure. Hyperacusis to bone-conducted sounds can cause conductive hearing loss, pulsatile tinnitus, or autophony (hearing one's own body sounds as loud or distorted). While the bony defect may be congenital, head trauma can be the final step that opens a functionally mobile labyrinthine window.
- AB31.4 Disembarkment syndrome**  
Disembarkment syndrome, or Mal de débarquement (MdD) occurs when habituation to unfamiliar motion patterns like traveling on a boat, train, or airplane, becomes resistant to re-adaption on return to stable conditions. It results in an illusion of self motion typically described as rocking, bobbing, or swaying. Brief periods of MdD (hours) are common in healthy individuals, this otherwise natural phenomenon can become persistent in some individuals.
- AB31.5 Autoimmune inner ear disease**  
Autoimmune inner ear disease (AIID) is a clinical syndrome of bilateral sensorineural hearing loss (SNHL) >30dB at one or more frequencies progressing over a period of 3-90 days. Progression of SNLH >15dB at one frequency or >10dB in two frequencies in at least one ear should be demonstrated. Vestibular symptoms may be present in 50% of patients and systemic autoimmune disease (SAD) coexists in 30% of patients.

<b>AB31.6</b>	<b>Vestibular paroxysmia</b> Vestibular paroxysmia (VP) is characterised by recurrent spells of vertigo or dizziness, lasting seconds to minutes, often many times a day. Attacks usually occur spontaneously but may occasionally be induced by changes of head position (which then needs to be distinguished from benign paroxysmal positioning vertigo). Possible accompanying symptoms are short attacks of tinnitus or changes in hearing. In the attack-free interval mild to moderate impairments of vestibular or audiological function may be found. Neurovascular cross-compression of the eighth nerve is the assumed mechanism.
<b>AB31.7</b>	<b>Vertiginous syndromes</b>
<b>AB31.Y</b>	<b>Other specified episodic vestibular syndrome</b>
<b>AB31.Z</b>	<b>Episodic vestibular syndrome, unspecified</b>
<b>AB32</b>	<b>Chronic vestibular syndrome</b> A clinical syndrome of chronic vertigo, dizziness, or unsteadiness lasting months to years and generally including features suggestive of persistent vestibular system dysfunction (e.g., oscillopsia, nystagmus, gait unsteadiness). There may also be symptoms or signs suggesting cochlear or central nervous system dysfunction. Chronic vestibular syndrome often connotes a progressive, deteriorating course, but sometimes instead reflects a stable, incomplete recovery after an acute vestibular event, or persistent, lingering symptoms between episodic vestibular events.
<b>AB32.0</b>	<b>Persistent Postural-Perceptual Dizziness</b> Persistent non-vertiginous dizziness, unsteadiness, or both lasting three months or more. Symptoms are present most days, often increasing throughout the day, but may wax and wane. Momentary flares may occur spontaneously or with sudden movement. Affected individuals feel worst when upright, exposed to moving or complex visual stimuli, and during active or passive head motion. These situations may not be equally provocative. Typically, the disorder follows occurrences of acute or episodic vestibular or balance-related problems. Symptoms may begin intermittently, and then consolidate. Gradual onset is uncommon.
<b>AB32.1</b>	<b>Chronic unilateral idiopathic vestibulopathy</b>
<b>AB32.2</b>	<b>Persistent unilateral vestibulopathy after vestibular neuritis</b>
<b>AB32.3</b>	<b>Unilateral vestibulopathy due to schwannoma</b>
<b>AB32.4</b>	<b>Unilateral vestibulopathy after medical intervention</b>
<b>AB32.5</b>	<b>Chronic bilateral vestibulopathy</b> Bilateral vestibulopathy (BVP) results from impaired vestibular function of both inner ears. It is clinically characterised by postural imbalance and unsteadiness of gait that worsens in darkness and on uneven ground, head or body movement-induced oscillopsia. If known, the etiology should be added to the diagnosis.
<b>AB32.Y</b>	<b>Other specified chronic vestibular syndrome</b>
<b>AB32.Z</b>	<b>Chronic vestibular syndrome, unspecified</b>

**AB33****Otosclerosis**

Otosclerosis is a genetically mediated metabolic bone disease that affects the otic capsule and stapes. It is an autosomal dominant disorder with varying penetrance and expressivity. Usually symptomatic hearing loss from otosclerosis develops early in the third decade of life, although onset in the teenage years does occur.

*Inclusions:*            otospongiosis

**AB34****Disorders of vestibular function**

*Exclusions:*            vertigo: NOS (MB48.0)

vertigo: epidemic (1C80-1C8Z)

**AB34.0****Idiopathic bilateral vestibulopathy**

This results as the culmination of damage done to both inner ears and causes problems in vision, hearing and motor coordination.

**AB34.1****Other peripheral vertigo****AB34.Y****Other specified disorders of vestibular function****AB34.Z****Disorders of vestibular function, unspecified****AB35****Labyrinthine fistula**

Labyrinthine fistula is a condition in which an abnormal communication is present between the perilymphatic space of the inner ear and the middle ear (usually at or adjacent to the round or oval window). The manifestations of this disease vary in severity and complexity, commonly ranging from very mild to incapacitating.

**AB36****Labyrinthine dysfunction****AB37****Noise effects on inner ear**

Noise toxicity can cause hearing loss, either transient or permanent, and impairment. Noise-induced hearing loss typically begins in the high-pitched frequency range of human voices communication.

*Inclusions:*            Noise-induced hearing loss

**AB3Y****Other specified diseases of inner ear****AB3Z****Diseases of inner ear, unspecified**

## Disorders with hearing impairment (AB50-AB5Z)

**Exclusions:** Otosclerosis (AB33)

**AB50**

### **Congenital hearing impairment**

Both dominant and recessive genes exist which can cause mild to profound impairment. If a family has a dominant gene for deafness it will persist across generations because it will manifest itself in the offspring even if it is inherited from only one parent. If a family had genetic hearing impairment caused by a recessive gene it will not always be apparent as it will have to be passed onto offspring from both parents. Hearing impairment is sustained before the acquisition of language, which occurs due to a congenital condition.

**AB50.0** **Congenital conductive hearing loss**

**AB50.1** **Congenital sensorineural hearing loss**

**AB50.2** **Congenital mixed conductive and sensorineural hearing loss**

**AB50.Y** **Other specified congenital hearing impairment**

**AB50.Z** **Congenital hearing impairment, unspecified**

**AB51**

### **Acquired hearing impairment**

Loss of hearing that occurs sometime the course of life and is not present at birth. The hearing impairment is sustained after the acquisition of language, which can occur due to disease, trauma, or as a side-effect of a medicine. Conductive hearing loss may occur as a result of a problem in the outer or middle ear such as an obstruction (cerumen, foreign body), damage to the ossicles, middle ear infections, and/or perforation of the tympanic membrane. Sensorineural hearing loss is a type of hearing loss in which the root cause lies in the vestibulocochlear nerve (Cranial nerve VIII), the inner ear, or central processing centres of the brain. Mixed conductive and sensorineural hearing loss refers to a mix of both conductive and sensorineural hearing loss.

**Exclusions:** noise-induced hearing loss (AB37)

Ototoxic hearing loss (AB53)

Sudden idiopathic hearing loss (AB55)

deafness NOS (AB52)

Deaf mutism, not elsewhere classified (AB50-AB5Z)

**AB51.0** **Acquired conductive hearing loss**

Conductive hearing loss occurs when there is a problem conducting sound waves anywhere along the route through the outer ear, tympanic membrane (eardrum), or middle ear (ossicles), bilateral.

**AB51.1** **Acquired sensorineural hearing loss**

Sensorineural hearing loss is a type of hearing loss in which the root cause lies in the vestibulocochlear nerve (Cranial nerve VIII), the inner ear, or central processing centres of the brain.

<b>AB51.2</b>	<b>Acquired mixed conductive and sensorineural hearing loss</b>
	Conductive hearing loss occurs when there is a problem conducting sound waves anywhere along the route through the outer ear, tympanic membrane (eardrum), or middle ear (ossicles). Sensorineural hearing loss is a type of hearing loss in which the root cause lies in the vestibulocochlear nerve (Cranial nerve VIII), the inner ear, or central processing centres of the brain. This diagnosis refers to a mix of both conductive and sensorineural hearing loss.
<b>AB51.Y</b>	<b>Other specified acquired hearing impairment</b>
<b>AB51.Z</b>	<b>Acquired hearing impairment, unspecified</b>
<b>AB52</b>	<b>Deafness not otherwise specified</b>
<b>AB53</b>	<b>Ototoxic hearing loss</b>
<b>AB54</b>	<b>Presbycusis</b>
	The term presbycusis refers to sensorineural hearing impairment in elderly individuals. Characteristically, presbycusis involves bilateral high-frequency hearing loss associated with difficulty in speech discrimination and central auditory processing of information.
	<i>Inclusions:</i> Presbyacusia
<b>AB55</b>	<b>Sudden idiopathic hearing loss</b>
<b>AB56</b>	<b>Hereditary hearing loss</b>
	<i>Exclusions:</i> Congenital hearing impairment (AB50)
	Acquired hearing impairment (AB51)
<b>AB57</b>	<b>Auditory synaptopathy or neuropathy</b>
	Normal outer hair cell function but lacking synchrony of neural transmission of auditory information due to damage of inner hair cells or their synapses or of the spiral ganglion cells or of the auditory nerve
<b>AB5Y</b>	<b>Other specified disorders with hearing impairment</b>
<b>AB5Z</b>	<b>Disorders with hearing impairment, unspecified</b>

Disorders of ear, not elsewhere classified (AB70-AB7Y)	
<i>Exclusions:</i>	Tinnitus (MC41)
<b>AB70</b>	<b>Otalgia or effusion of ear</b>
<i>Exclusions:</i>	Otitis media (AA80-AB0Z)
	Chronic primary orofacial pain (MG30.03)
	Chronic secondary headache or orofacial pain (MG30.6)

<b>AB70.0</b>	<b>Otorrhoea</b>
	<b><i>Exclusions:</i></b> leakage of cerebrospinal fluid through ear (8D63) Otorrhagia (AB70.1)
<b>AB70.1</b>	<b>Otorrhagia</b>
	<b><i>Exclusions:</i></b> traumatic otorrhagia - code by type of injury (Chapter 22)
<b>AB70.2</b>	<b>Otalgia</b> Pain in one or both ears.
	<b><i>Exclusions:</i></b> Chronic primary orofacial pain (MG30.03) Chronic secondary headache or orofacial pain (MG30.6)
<b>AB71</b>	<b>Degenerative or vascular disorders of ear</b>
	<b><i>Exclusions:</i></b> Presbycusis (AB54)
<b>AB72</b>	<b>Disorders of acoustic nerve</b>
	<b><i>Inclusions:</i></b> Disorder of 8th cranial nerve
<b>AB72.0</b>	<b>Acoustic neuritis</b>
	<b><i>Coding Note:</i></b> Code also the causing condition
<b>AB72.Y</b>	<b>Other specified disorders of acoustic nerve</b>
<b>AB72.Z</b>	<b>Disorders of acoustic nerve, unspecified</b>
<b>AB73</b>	<b>Atrophy ear</b>
<b>AB7Y</b>	<b>Other specified disorders of ear, not elsewhere classified</b>

Postprocedural disorders of ear or mastoid process (AB90-AB93)

<b>AB90</b>	<b>Recurrent cholesteatoma of postmastoidectomy cavity</b>
<b>AB91</b>	<b>Mucosal cyst of postmastoidectomy cavity</b>
<b>AB92</b>	<b>Granulation of postmastoidectomy cavity</b>
<b>AB93</b>	<b>Chronic inflammation of postmastoidectomy cavity</b>

---

<b>AC0Y</b>	<b>Other specified diseases of the ear or mastoid process</b>
<b>AC0Z</b>	<b>Diseases of the ear or mastoid process, unspecified</b>

# CHAPTER 11

---

## Diseases of the circulatory system

This chapter has 161 four-character categories.

Code range starts with BA00

This refers to diseases of the organ system that passes nutrients (such as amino acids, electrolytes and lymph), gases, hormones, blood cells, etc. to and from cells in the body to help fight diseases, stabilize body temperature and pH, and to maintain homeostasis.

- Exclusions:**
- Certain infectious or parasitic diseases (Chapter 01)
  - Certain conditions originating in the perinatal period (Chapter 19)
  - Congenital malformations, deformations and chromosomal abnormalities (Chapter 20)
  - Complications of pregnancy, childbirth and the puerperium (Chapter 18)
  - Injury, poisoning or certain other consequences of external causes (Chapter 22)
  - Endocrine, nutritional or metabolic diseases (Chapter 05)

- Coded Elsewhere:**
- Neoplasms of the circulatory system
  - Developmental anomalies of the circulatory system
  - Infections of the circulatory system
  - Symptoms, signs or clinical findings of the circulatory system (MC80-MC9Y)
  - Cerebrovascular diseases (8B00-8B2Z)
  - Functional vascular disorders of the skin (EG00-EG02)
  - Diseases of the circulatory system complicating pregnancy, childbirth or the puerperium (JB64.4)

This chapter contains the following top level blocks:

- Hypertensive diseases
- Hypotension
- Ischaemic heart diseases
- Diseases of coronary artery
- Pulmonary heart disease or diseases of pulmonary circulation
- Pericarditis
- Acute or subacute endocarditis
- Heart valve diseases
- Diseases of the myocardium or cardiac chambers
- Cardiac arrhythmia

- Heart failure
- Diseases of arteries or arterioles
- Diseases of veins
- Disorders of lymphatic vessels or lymph nodes
- Postprocedural disorders of circulatory system
- Neoplasms of the circulatory system
- Developmental anomalies of the circulatory system
- Infections of the circulatory system

## Hypertensive diseases (BA00-BA04.Z)

Although a continuous association exists between higher BP and increased cardiovascular disease risk, it is useful to categorize BP levels for clinical and public health decision making. Recent guidelines categorise systemic hypertension into 4 levels on the basis of average BP measured in a healthcare setting (office pressures):

- Normal: systolic BP < 120 mmHg and diastolic BP < 80 mmHg
- Elevated: systolic BP 120-129 mmHg and diastolic BP < 80 mmHg
- Stage 1 hypertension: systolic BP 130-139 mmHg or diastolic BP 80-89 mmHg
- Stage 2 hypertension: systolic BP 140 mmHg or more, diastolic BP 90 mmHg or more

In children, systemic hypertension is defined as an average systolic or diastolic blood pressure equal or higher than the 95th percentile appropriate for the sex, age and height of the child.

The complications of uncontrolled or prolonged hypertension include damage to the blood vessels, heart, kidneys and brain.

- Exclusions:**
- Pulmonary hypertension (BB01)
  - involving coronary vessels (BA40-BA6Z)
  - Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium (JA20-JA2Z)
  - White coat hypertension (MC80.00)

**Coded Elsewhere:** Neonatal hypertension (KB45)

<b>BA00</b>	<b>Essential hypertension</b>
	Essential (primary) hypertension, accounting for 95% of all cases of hypertension, is defined as high blood pressure for which a secondary cause cannot be found.
	<b>Inclusions:</b> high blood pressure
	<b>Exclusions:</b> Cerebrovascular diseases (8B00-8B2Z)

Background retinopathy and retinal vascular changes (9B78.1)

**Coded Elsewhere:** Pre-existing essential hypertension complicating pregnancy, childbirth or the puerperium (JA20.0)

<b>BA00.0</b>	<b>Combined diastolic and systolic hypertension</b>
---------------	---

- BA00.1**      **Isolated diastolic hypertension**
- BA00.2**      **Isolated systolic hypertension**
- BA00.Y**      **Other specified essential hypertension**
- BA00.Z**      **Essential hypertension, unspecified**

### **BA01      Hypertensive heart disease**

Uncontrolled and prolonged hypertension can lead to a variety of changes in the myocardial structure, coronary vasculature, and conduction system of the heart. Hypertensive heart disease is a term applied generally to heart diseases, such as left ventricular hypertrophy, coronary artery disease, cardiac arrhythmias, and congestive heart failure, that are caused by direct or indirect effects hypertension.

**Coded Elsewhere:** Pre-existing hypertensive heart disease complicating pregnancy, childbirth or the puerperium (JA20.1)

Pre-existing hypertensive heart and renal disease complicating pregnancy, childbirth or the puerperium (JA20.3)

### **BA02      Hypertensive renal disease**

Hypertensive renal disease is a medical condition referring to damage to the kidney due to chronic high blood pressure.

**Inclusions:**      hypertensive nephropathy

**Exclusions:**      Secondary hypertension (BA04)

**Coded Elsewhere:** Pre-existing hypertensive renal disease complicating pregnancy, childbirth or the puerperium (JA20.2)

Pre-existing hypertensive heart and renal disease complicating pregnancy, childbirth or the puerperium (JA20.3)

### **BA03      Hypertensive crisis**

**Coding Note:** Code also the causing condition

### **BA04      Secondary hypertension**

Defined through the measurement of the blood pressure using cuff method with a sitting systolic blood pressure above 140 mmHg or a sitting diastolic blood pressure above 90 mmHg in three consequent measurements with an identifiable cause.

**Coding Note:** Code also the causing condition

**Exclusions:**      involving vessels of brain (8B00-8B2Z)

                        involving vessels of eye (9B78.1)

**Coded Elsewhere:** Congenital renal artery stenosis (LA90.40)

                        Hyperaldosteronism (5A72)

Pre-existing secondary hypertension complicating pregnancy, childbirth or the puerperium (JA20.4)

### **BA04.0      Combined diastolic and systolic secondary hypertension**

### **BA04.1      Isolated diastolic secondary hypertension**

### **BA04.2      Isolated systolic secondary hypertension**

**BA04.Y**      **Other specified secondary hypertension**

**Coding Note:** Code also the causing condition

**BA04.Z**      **Secondary hypertension, unspecified**

**Coding Note:** Code also the causing condition

## Hypotension (BA20-BA2Z)

**Exclusions:**     cardiovascular collapse (MG40)  
                  Nonspecific low blood-pressure reading (MC80.1)  
                  Maternal hypotension syndrome (JA65.6)

**Coded Elsewhere:** Intracranial hypotension (8D61)

Neonatal hypotension (KB46)

**BA20**      **Idiopathic hypotension**

**BA21**      **Orthostatic hypotension**

**Exclusions:**     Shy-Drager syndrome (8D87.0)

**BA2Y**      **Other specified hypotension**

**BA2Z**      **Hypotension, unspecified**

## Ischaemic heart diseases (BA40-BA6Z)

Acute ischaemic heart disease (BA40-BA4Z)

**Inclusions:**     acute coronary syndrome

**BA40**      **Angina pectoris**

**Inclusions:**     Anginal syndrome  
                  Ischaemic chest pain  
                  Angina NOS

**Exclusions:**     Otocephaly (LA23)

**Coded Elsewhere:** Microvascular angina (BA86)

**BA40.0**      **Unstable angina**

**Inclusions:**     Preinfarction syndrome  
                  worsening effort angina

**BA40.1**      **Stable angina**

**BA40.Y**      **Other specified angina pectoris**

**BA40.Z**      **Angina pectoris, unspecified**

**BA41**

### **Acute myocardial infarction**

The term acute myocardial infarction (MI) should be used when there is evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Under these conditions any one of the following criteria meets the diagnosis for MI;

Detection of a rise and/or fall of cardiac biomarker values with at least one value above the 99th percentile upper reference limit and with at least one of the following;

- a. Symptoms of ischaemia.
- b. New or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch block (LBBB) in the electrocardiogram (ECG).
- c. Development of pathologic Q waves in the electrocardiogram (ECG).
- d. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
- e. Identification of an intracoronary thrombus by angiography or autopsy.

Infarction of any myocardial site, occurring within 4 weeks (28 days) from onset of a previous infarction (WHO)

***Inclusions:***

postmyocardial infarction syndrome (BA60.0)

Subsequent myocardial infarction (BA42)

Certain current complications following acute myocardial infarction (BA60)

Old myocardial infarction (BA50)

**BA41.0**

### **Acute ST elevation myocardial infarction**

STEMI is an acute myocardial infarction with developing ST elevation in two contiguous leads. The criteria of ST elevation are as follows: New ST elevation at the J point in two contiguous leads where these cut points apply: 0.2mV in men > 40 years, > 0.25mV in men < 40 years, and > 0.15 mV in women.

**BA41.1**

### **Acute non-ST elevation myocardial infarction**

**BA41.Z**

### **Acute myocardial infarction, unspecified**

**BA42**

### **Subsequent myocardial infarction**

Infarction of any myocardial site, occurring within 4 weeks (28 days) from onset of a previous infarction

***Inclusions:***

extension of myocardial infarction

recurrent myocardial infarction

***Exclusions:***

specified as chronic or with a stated duration of more than 4 weeks (more than 28 days) from onset (BA50)

**BA42.0**

### **Subsequent myocardial infarction, ST elevation myocardial infarction**

Extension or recurrent myocardial infarction. This category should be assigned for infarction of any myocardial site, occurring within 4 weeks (28 days) from onset of a previous infarction. This most commonly results from total occlusion of the culprit coronary artery.

<b>BA42.1</b>	<b>Subsequent myocardial infarction, non-ST elevation myocardial infarction</b> Extension or recurrent myocardial infarction. For morbidity coding, this category should be assigned for infarction of any myocardial site, occurring within 4 weeks (28 days) from onset of a previous infarction. This most commonly results from severe obstruction, but not total occlusion, of the culprit coronary artery.
<b>BA42.Z</b>	<b>Subsequent myocardial infarction, unspecified</b>
<b>BA43</b>	<b>Coronary thrombosis not resulting in myocardial infarction</b> Superimposed thrombus associated with plaque rupture or erosion which does not obstruct the coronary flow to cause myocardial infarction.  <i>Inclusions:</i> Occlusion of coronary artery or vein not resulting in myocardial infarction Embolism of coronary artery or vein not resulting in myocardial infarction Thromboembolism of coronary artery or vein not resulting in myocardial infarction
<b>BA4Z</b>	<b>Acute ischaemic heart disease, unspecified</b>
	Chronic ischaemic heart disease (BA50-BA5Z) Chronic heart disease is seen due to the atherosclerosis of coronary arteries. It is characterised by angina pectoris and unstable angina.
<b>BA50</b>	<b>Old myocardial infarction</b> Past myocardial infarction diagnosed by electrocardiogram (ECG) or other special investigation, but currently presenting no symptoms.  <i>Inclusions:</i> healed myocardial infarction
<b>BA51</b>	<b>Ischaemic cardiomyopathy</b> Ischaemic cardiomyopathy has been defined as left ventricular systolic dysfunction with one or more of the following: a history of prior myocardial revascularisation or myocardial infarction, more than 75% stenosis in the left main stem or left anterior descending artery, or two vessels or more with a greater than 75% stenosis. It consists of a spectrum of pathophysiological states that relate to perfusion contraction matching and mismatching, including myocardial infarction, stunning, hibernation and scarring.
<b>BA51.0</b>	<b>Dilated cardiomyopathy due to congenital anomaly of coronary artery</b> Dilated cardiomyopathy due to a congenital anomaly of one or more coronary arteries, such as anomalous left coronary artery from pulmonary artery (ALCAPA), coronary ostial stenosis or atresia, right ventricular dependent coronary circulation in pulmonary atresia with an intact ventricular septum. It is a form of ischaemic cardiomyopathy causing systolic ventricular dysfunction that relates to a spectrum of perfusion contraction matching and mismatching, including myocardial infarction, stunning, hibernation and scarring.
<b>BA51.Y</b>	<b>Other specified ischaemic cardiomyopathy</b>

<b>BA51.Z</b>	<b>Ischaemic cardiomyopathy, unspecified</b>
<b>BA52</b>	<p><b>Coronary atherosclerosis</b></p> <p>Atherosclerosis is the build up inside the coronary arteries of cholesterol, fatty acids, calcium, fibrous connective tissue and cells (mostly macrophages), referred to as plaque. The effect of this is to reduce the blood flow through the coronary arteries to heart muscle and when marked results in heart damage often with symptoms such as chest pain.</p> <p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Coronary artery atherosclerosis</li> <li>Coronary artery atheroma</li> <li>Coronary artery sclerosis</li> <li>coronary artery ostial stenosis due to atherosclerosis</li> </ul>
<b>BA52.0</b>	<p><b>Coronary atherosclerosis of native coronary artery</b></p> <p>Atherosclerotic lesions, or atherosclerotic plaques of native coronary artery.</p> <p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Coronary atherosclerosis without significant ischaemia of native coronary artery</li> </ul>
<b>BA52.1</b>	<p><b>Coronary atherosclerosis of autologous bypass graft</b></p> <p>Atherosclerotic lesions, or atherosclerotic plaques of autologous bypass graft.</p> <p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Coronary atherosclerosis of autologous bypass graft without significant ischaemia</li> </ul>
<b>BA52.10</b>	Coronary atherosclerosis of arterial autologous bypass graft
<b>BA52.11</b>	Coronary atherosclerosis of venous autologous bypass graft
<b>BA52.1Z</b>	Coronary atherosclerosis of unspecified autologous bypass graft
<b>BA52.2</b>	<p><b>Coronary atherosclerosis of non-autologous bypass graft</b></p> <p>Atherosclerotic lesions, or atherosclerotic plaques of non-autologous bypass graft.</p> <p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Coronary atherosclerosis without significant ischaemia of non-autologous bypass graft</li> </ul>
<b>BA52.Z</b>	<b>Coronary atherosclerosis, unspecified site</b>
<b>BA5Y</b>	<b>Other specified chronic ischaemic heart disease</b>
<b>BA5Z</b>	<b>Chronic ischaemic heart disease, unspecified</b>
<b>BA60</b>	<p><b>Certain current complications following acute myocardial infarction</b></p> <p>Secondary conditions which may occur in the course after the heart attack. They include pericarditis, arrhythmia, cardiogenic shock, heart failure, ventricular rupture, ventricular aneurysm (with thrombus) and recurrent infarction.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>the listed conditions, when: not specified as current complications following acute myocardial infarction (Chapter 11)</li> <li>the listed conditions, when: concurrent with acute myocardial infarction (BA41)</li> </ul>

<b>BA60.0</b>	<b>Dressler syndrome</b> A condition of postmyocardial infarction (1 to 8 weeks), characterised by a set of associated symptom, including malaise, fever, pericardial discomfort, leukocytosis, an elevated sedimentation rate, and a pericardial effusion. Patients with this syndrome usually demonstrate localised fibrous pericarditis containing polymorphonuclear leukocytes.  <b>Inclusions:</b> Postmyocardial infarction syndrome
<b>BA60.1</b>	<b>Other pericarditis as current complication following acute myocardial infarction</b> An inflammation of the pericardium that can produce chest pain, which occurs as early as the first day and as late as 6 weeks after acute myocardial infarction. The pain of pericarditis radiates to either trapezius ridge. Transmural myocardial infarction is responsible for local pericardial inflammation. Transient pericardial friction rubs are relatively common in patients with transmural infarction within the first 48 hours. An acute fibrinous pericarditis occurs commonly after transmural infarction, whereas the risk of haemorrhagic pericarditis is increased by anticoagulation.
<b>BA60.2</b>	<b>Ventricular aneurysm as current complication following acute myocardial infarction</b> A discrete dyskinetic area of the left ventricular wall with a broad neck after acute myocardial infarction. The wall of the true aneurysm is thinner than the rest of the left ventricle; it is usually composed of fibrous tissue and necrotic muscle, occasionally mixed with viable myocardium. In contrast, pseudoaneurysms are composed of organised hematoma and pericardium and lack any elements of the original myocardial wall.
<b>BA60.3</b>	<b>Ventricular septal defect as current complication following acute myocardial infarction</b> A mechanical rupture of the interventricular septum after ST elevation myocardial infarction resulting in the left-to-right shunt to deteriorate hemodynamic, which confers a high 30-day mortality. Rupture of the septum with an anterior infarction tends to be apical in location, whereas inferior infarctions are associated with perforation of the basal septum.
<b>BA60.4</b>	<b>Cardiac rupture as current complication following acute myocardial infarction</b> A tearing of acutely infarcted tissue after acute myocardial infarction, which may involve the papillary muscles, interventricular septum, or free wall of either ventricle.
<b>BA60.5</b>	<b>Pulmonary embolism as current complication following acute myocardial infarction</b> A pulmonary embolism that resulted from thrombi in the veins of the lower extremities (e.g. after prolonged periods of bed rest) or mural thrombi overlying an area of right ventricular infarction after acute myocardial infarction.  <b>Exclusions:</b> Mural thrombus as current complication following acute myocardial infarction (BA60.7)
<b>BA60.6</b>	<b>Rupture of papillary muscle or chordae tendineae as current complication following acute myocardial infarction</b>

<b>BA60.7</b>	<b>Mural thrombus as current complication following acute myocardial infarction</b> A blood clot formed on the endoventricle or endoatrium, usually overlying dyskinetic or akinetic area of the ventricular infarction after acute myocardial infarction.
	<b><i>Exclusions:</i></b> Pulmonary embolism as current complication following acute myocardial infarction (BA60.5)
<b>BA60.8</b>	<b>Arrhythmia as current complication following acute myocardial infarction</b> A large and heterogeneous group of conditions in which the heart beats with an irregular or abnormal rhythm that can complicate the course of patients with acute myocardial infarction.
<b>BA60.9</b>	<b>Cardiogenic shock, unrelated to mechanical complications, as current complication following acute myocardial infarction</b> The most severe clinical expression of left ventricular failure and is associated with extensive damage to the left ventricular myocardium after acute myocardial infarction, unrelated to a mechanical defect such as ventricular septal or papillary muscle rupture. Shock is defined as systolic blood pressure (BP) < 90 mmHg and organ hypoperfusion.
<b>BA60.Y</b>	<b>Other specified current complications following acute myocardial infarction</b>
<b>BA60.Z</b>	<b>Certain current complications following acute myocardial infarction, unspecified</b>
<b>BA6Z</b>	<b>Ischaemic heart diseases, unspecified</b>

### Diseases of coronary artery (BA81-BA8Z)

Conditions affecting the blood perfusion of the heart.

***Coded Elsewhere:*** Coronary atherosclerosis (BA52)

Cardiac transplant associated coronary allograft vasculopathy (BE1A)

<b>BA81</b>	<b>Coronary artery aneurysm</b> Coronary dilatation which exceeds the diameter of normal adjacent segments or the diameter of the patient's largest coronary vessel by 1.5 times.
	<b><i>Exclusions:</i></b> Congenital coronary arterial aneurysm (LA8C) Mucocutaneous lymph node syndrome (4A44.5)
<b>BA81.0</b>	<b>Coronary artery aneurysm with perforation</b>
<b>BA81.1</b>	<b>Coronary artery aneurysm with rupture</b>
<b>BA81.2</b>	<b>Coronary artery aneurysm without mention of perforation or rupture</b>

**BA82****Coronary artery dissection**

Coronary artery dissection results from a tear in the inner layer of the coronary artery, the tunica intima. This allows blood to penetrate and cause an intramural hematoma in the central layer, the tunica media, and restriction in the size of lumen.

**Inclusions:** spontaneous coronary artery dissection

**Exclusions:** Injury or harm arising from a procedure, not elsewhere classified (NE81)

Injury of blood vessels of thorax (NB30)

**BA83****Coronary artery fistula, acquired**

Abnormal communication between a coronary artery and a cardiac chamber or major vessels, acquired after coronary or heart surgery, coronary angioplasty, rupture or coronary artery aneurysm or injury to the heart.

**BA84****Chronic total occlusion of coronary artery**

A chronic total occlusion of coronary artery is defined as the complete obstruction of a coronary artery or coronary arteries, exhibiting a TIMI flow score of zero or one, with an occlusion duration of greater than 3 months.

**Coding Note:**

Code also the causing condition

**Exclusions:** Acute myocardial infarction (BA41)

**BA85****Coronary vasospastic disease**

The term coronary vasospastic disease refers to a sudden, intense vasoconstriction of an epicardial coronary artery that causes vessel occlusion or near occlusion. Although it may be involved in other coronary syndromes, it represents the usual cause of variant angina.

**BA85.0****Silent coronary vasospastic disease**

The feature of this is the frequency of asymptomatic ischemic episodes in coronary vasospastic disease.

**BA85.Y****Other specified coronary vasospastic disease****BA85.Z****Coronary vasospastic disease, unspecified****BA86****Coronary microvascular disease****BA8Y****Other specified diseases of coronary artery****BA8Z****Diseases of coronary artery, unspecified**

Pulmonary heart disease or diseases of pulmonary circulation (BB00-BB0Z)

**BB00****Pulmonary thromboembolism**

**Exclusions:** Complications following abortion, ectopic or molar pregnancy (JA05)

Diseases of the circulatory system complicating pregnancy, childbirth or the puerperium (JB64.4)

<b>BB00.0</b>	<b>Acute pulmonary thromboembolism</b> Acute pulmonary thromboembolism is defined as a partial or complete occlusion of a pulmonary arterial branch with the abrupt onset of related symptoms, such as dyspnoea, tachypnoea, chest pain, cough and blood-tinged sputum. However, acute pulmonary embolism may also occur in the absence of any symptoms.
<b>BB00.1</b>	<b>Chronic pulmonary thromboembolism</b> Chronic pulmonary thromboembolism is defined as a partial or complete occlusion of at least one major pulmonary arterial branch in the presence of a mean pulmonary artery pressure 25mmHg at rest, and normal left ventricular filling pressures, despite effective coagulation over at least three months.
	<b>Coded Elsewhere:</b> Chronic thromboembolic pulmonary hypertension (BB01.3)
<b>BB00.Z</b>	<b>Pulmonary thromboembolism, unspecified</b>
<b>BB01</b>	<p><b>Pulmonary hypertension</b></p> <p>Pulmonary hypertension (PH) is a haemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure (PAP) 25 mmHg at rest as assessed by right heart catheterization. PH can be found in multiple clinical conditions.</p> <p><b>Coded Elsewhere:</b> Persistent pulmonary hypertension of the newborn (KB42)</p>
<b>BB01.0</b>	<p><b>Pulmonary arterial hypertension</b></p> <p>Pulmonary arterial hypertension is a clinical condition characterised by the presence of pre-capillary pulmonary hypertension in the absence of other causes of pre-capillary pulmonary hypertension, such as due to lung diseases, chronic thromboembolic pulmonary hypertension, or other rare diseases. It includes different forms that share a similar clinical picture and virtually identical pathological changes of the lung microcirculation.</p> <p><b>Inclusions:</b> primary pulmonary hypertension</p>
<b>BB01.1</b>	<b>Pulmonary hypertension due to left heart disease</b>
<b>BB01.2</b>	<b>Pulmonary hypertension due to lung disease or hypoxia</b>
<b>BB01.3</b>	<p><b>Chronic thromboembolic pulmonary hypertension</b></p> <p>Chronic thromboembolic pulmonary hypertension (CTEPH) is characterised by the persistence of thromboemboli in the form of organised tissue obstructing the pulmonary arteries. The consequence is an increase in pulmonary vascular resistance (PVR) resulting in pulmonary hypertension (PH) and progressive right heart failure.</p>
<b>BB01.4</b>	<b>Pulmonary hypertension with multifactorial mechanism</b>
<b>Coding Note:</b>	Code also the causing condition
<b>BB01.5</b>	<p><b>Cor pulmonale</b></p> <p>Cor pulmonale refers to the altered structure and/or impaired function of the right ventricle that results from pulmonary hypertension associated with diseases of the lung, upper airway, or chest wall.</p> <p><b>Coding Note:</b> Code also the causing condition</p>

- BB01.Z** **Pulmonary hypertension, unspecified**
- BB02** **Certain specified diseases of pulmonary vessels**  
This definition includes Arteriovenous fistula of pulmonary vessels, Aneurysm of pulmonary artery and Other specified diseases of pulmonary vessels.
- BB02.0** **Arteriovenous fistula of pulmonary vessels**
- BB02.1** **Aneurysm of pulmonary artery**  
Aneurysm of pulmonary artery is an abnormal dilatation of part of the pulmonary artery
- BB02.10** Aneurysm of pulmonary artery with perforation
- BB02.11** Aneurysm of pulmonary artery with rupture
- BB02.12** Aneurysm of pulmonary artery without mention of perforation or rupture
- BB02.1Y** Other specified aneurysm of pulmonary artery
- BB02.1Z** Aneurysm of pulmonary artery, unspecified
- BB02.2** **Rupture of pulmonary vessels**  
This is defined as the tearing apart of the pulmonary vessels allowing blood to escape outside.
- BB02.3** **Acquired pulmonary arterial tree abnormality**  
A postnatal pathological change in form or function of the pulmonary arterial tree.  
**Coded Elsewhere:** Postprocedural pulmonary trunk stenosis (BE15.0)  
Postprocedural right pulmonary artery stenosis (BE15.1)  
Postprocedural pulmonary arterial tree disorder (BE15)
- BB03** **Acquired pulmonary venous abnormality**  
A postnatal pathological change in form or function of one or more pulmonary veins.  
**Coded Elsewhere:** Postprocedural pulmonary venous disorder (BE16)
- BB03.0** **Acquired pulmonary venous obstruction**  
A postnatal pathologic condition of one or more pulmonary vein(s) in which flow is impeded or blocked due to narrowing or atresia.
- BB03.Y** Other specified acquired pulmonary venous abnormality
- BB03.Z** Acquired pulmonary venous abnormality, unspecified
- BB0Y** Other specified pulmonary heart disease or diseases of pulmonary circulation
- BB0Z** Pulmonary heart disease or diseases of pulmonary circulation, unspecified

## Pericarditis (BB20-BB2Z)

**Coded Elsewhere:** Pneumopericardium originating in the perinatal period (KB27.3)

Acute rheumatic pericarditis (1B41.0)

**BB20**

### Acute pericarditis

Acute pericarditis is defined as pericardial inflammation of no more than 1 to 2 weeks duration.

**Coding Note:** Code also the causing condition

**Inclusions:** acute pericardial effusion

**Exclusions:** Acute rheumatic pericarditis (1B41.0)

**BB20.0**

### Infectious pericarditis

A disease of the pericardium, caused by a secondary infection with a bacterial, viral, or fungal source. This disease is characterised by fever, odynophagia, cough, fatigue, or chest pain. Confirmation is by identification of the bacterial, viral, or fungal agent in a blood sample.

**Coding Note:** Code also the causing condition

**Inclusions:** Pyopericarditis

**BB20.1**

### Neoplastic pericarditis

**Coding Note:** Code also the causing condition

**BB20.2**

### Myopericarditis

**Inclusions:** Perimyocarditis

**BB20.Y**

### Other specified acute pericarditis

**Coding Note:** Code also the causing condition

**BB20.Z**

### Acute pericarditis, unspecified

**Coding Note:** Code also the causing condition

**BB21**

### Chronic rheumatic pericarditis

Inflammation of the pericardium and of the surrounding mediastinal cellular tissue resulted from rheumatic etiology.

**BB22**

### Constrictive pericarditis

Chronic fibrous pericarditis due to the presence of dense fibrous tissue between the parietal and visceral layers of pericardium and neighbouring structures.

**Inclusions:** concretio cordis

**BB23**

### Cardiac tamponade

Cardiac tamponade is a clinical syndrome caused by the accumulation of fluid in the pericardial space, resulting in reduced ventricular filling and subsequent hemodynamic compromise. Cardiac tamponade is a medical emergency, the complications of which include shock, and death.

**BB24****Haemopericardium**

This is hemopericardium caused by diseases not elsewhere classified. Hemopericardium generally refers to blood in the pericardial sac of the heart. It is clinically similar to a pericardial effusion, and, depending on the volume and rapidity with which it develops, may cause cardiac tamponade.

**BB25****Pericardial effusion**

Pericardial effusion is an abnormal accumulation of fluid in the pericardial sac. Noninflammatory diseases such as chronic renal failure, circulatory congestion, hypothyroidism and amyloidosis can cause pericardial effusion.

**BB2Y****Other specified pericarditis**

**Coding Note:** Code also the causing condition

**BB2Z****Pericarditis, unspecified**

**Coding Note:** Code also the causing condition

**Acute or subacute endocarditis (BB40-BB4Z)**

A condition characterised by inflammation of endocardium

**Coded Elsewhere:** Acute rheumatic endocarditis (1B41.1)

Systemic lupus erythematosus with cardiac involvement (4A40.0Y)

Typhoid fever with heart involvement (1A07.Y)

**BB40****Acute or subacute infectious endocarditis**

**Coding Note:** Code also the causing condition

**Exclusions:** Infectious myocarditis (BC42.1)

**Coded Elsewhere:** Endocardial fibroelastosis (BC43.3)

Syphilitic endocarditis (1A62.1)

Tuberculosis of endocardium (1B12.0)

**BB41****Myoendocarditis**

**Exclusions:** Infectious myocarditis (BC42.1)

**BB42****Periendocarditis****BB4Y****Other specified acute or subacute endocarditis**

**Coding Note:** Code also the causing condition

**BB4Z****Acute or subacute endocarditis, unspecified**

**Coding Note:** Code also the causing condition

## Heart valve diseases (BB60-BC0Z)

- Exclusions:**
- Congenital anomaly of a ventriculo-arterial valve or adjacent regions (LA8A)
  - Atypical truncal valve (LA85.4)
  - Acute rheumatic fever (1B40-1B42)
  - Structural developmental anomalies of the circulatory system (LA80-LA9Z)

### Mitral valve disease (BB60-BB6Z)

This is a disorder of the heart in which the mitral valve does not close properly when the heart pumps out blood. It is the abnormal leaking of blood from the left ventricle through the mitral valve into the left atrium when the left ventricle contracts. Simply put, there is regurgitation of blood back into the left atrium.

- Exclusions:** Congenital anomaly of mitral valve (LA87.1)

- Coded Elsewhere:** Injury to mitral valve (NB31.40)

**BB60**

#### Mitral valve stenosis

- Exclusions:** Mitral valve stenosis with insufficiency (BB63)

- Coded Elsewhere:** Postprocedural mitral valve stenosis (BE12.0)

**BB60.0**

#### Rheumatic mitral valve stenosis

Mitral stenosis refers to narrowing of the mitral valve orifice, resulting in impedance of filling of the left ventricle in diastole. It is usually caused by rheumatic heart disease.

**BB60.1**

#### Nonrheumatic mitral valve stenosis

Mitral stenosis is narrowing of the passage through the mitral valve due to fibrosis, and calcinosis in the leaflets and chordal areas.

The most common reason of mitral stenosis is rheumatic fever. Except rheumatic fever; SLE, Malignant Sarcoid, Active Infective Endocarditis, Gout Whipple's Disease, Massive Annular calcification cause to the mitral stenosis.

- Exclusions:** Postprocedural mitral valve stenosis (BE12.0)

**BB60.Z**

#### Mitral valve stenosis, unspecified

**BB61**

#### Mitral valve insufficiency

Mitral insufficiency is a clinical condition which mitral valve can't close properly. It is the antidiromic leaking of blood from the left ventricle through the mitral valve, and into the left atrium.

- Exclusions:** Mitral valve stenosis with insufficiency (BB63)

- Coded Elsewhere:** Postprocedural mitral valve insufficiency (BE12.1)

Mitral valve insufficiency due to acute myocardial infarction (BA60.6)

- BB61.0** **Rheumatic mitral valve insufficiency**  
Mitral insufficiency can be caused by conditions such as rheumatic fever.  
Mitral insufficiency is leakage of blood from the left ventricle into the left atrium during systole.  
**Exclusions:** Active or acute endocarditis of mitral valve (1B41.1)
- BB61.Y** **Other specified mitral valve insufficiency**
- BB61.Z** **Mitral valve insufficiency, unspecified**
- BB62** **Mitral valve prolapse**  
**Inclusions:** floppy mitral valve syndrome  
**Exclusions:** Marfan syndrome (LD28.01)
- BB62.0** **Rheumatic mitral valve prolapse**  
This is a rheumatic valvular heart disease characterised by the displacement of an abnormally thickened mitral valve leaflet into the left atrium during systole.
- BB62.1** **Degenerative mitral valve prolapse**  
This is a degenerative valvular heart disease characterised by the displacement of an abnormally thickened mitral valve leaflet into the left atrium during systole.
- BB62.Y** **Other specified nonrheumatic mitral valve prolapse**
- BB62.Z** **Mitral valve prolapse, unspecified**
- BB63** **Mitral valve stenosis with insufficiency**  
This is a valvular heart disease characterised by the narrowing of the orifice of the mitral valve of the heart, with regurgitation.
- BB63.0** **Rheumatic mitral stenosis with insufficiency**  
Mitral stenosis and mitral insufficiency occur in patients with rheumatic heart disease.
- BB63.1** **Nonrheumatic mitral stenosis with insufficiency**  
This is a non-rheumatic valvular heart disease characterised by the narrowing of the orifice of the mitral valve of the heart, with regurgitation.
- BB63.Z** **Mitral valve stenosis with insufficiency, unspecified**
- BB64** **Mitral valvar abscess**
- BB65** **Mitral valve rupture**  
**Exclusions:** Rupture of papillary muscle or chordae tendineae as current complication following acute myocardial infarction (BA60.6)
- BB6Y** **Other specified mitral valve disease**
- BB6Z** **Mitral valve disease, unspecified**

Aortic valve disease (BB70-BB7Z)

**Exclusions:** Congenital anomaly of aortic valve (LA8A.2)

**Coded Elsewhere:** Traumatic injury to aortic valve (NB31.4Y)

Dysplasia of aortic valve (LA8A.2Y)

**BB70**

### **Aortic valve stenosis**

Aortic valve stenosis is abnormal narrowing of the aortic valve. This decreases the blood flow from heart to organs.

**Exclusions:** Congenital supravalvar aortic stenosis (LA8A.3)

Congenital subaortic stenosis (LA8A.5)

**Coded Elsewhere:** Postprocedural aortic valve stenosis (BE12.2)

**BB70.0**

### **Rheumatic aortic valve stenosis**

Aortic stenosis caused by scarring of the aortic valve due to rheumatic fever as a child or young adult. In aortic stenosis, the aortic valve does not open fully. This decreases blood flow from the heart.

**BB70.1**

### **Nonrheumatic aortic valve stenosis**

**Exclusions:** Postprocedural aortic valve stenosis (BE12.2)

**Coded Elsewhere:** Stenosis of the neoaortic valve of pulmonary origin (BC02.30)

**BB70.Y**

### **Other specified aortic valve stenosis**

**BB70.Z**

### **Aortic valve stenosis, unspecified**

**BB71**

### **Aortic valve insufficiency**

Aortic valve insufficiency results from leakage and backflow of blood that is ejected from the left ventricle into the ascending aorta back into the left ventricle.

**Coding Note:**

Code also the causing condition

**Coded Elsewhere:** Postprocedural aortic valve insufficiency (BE12.3)

Insufficiency of the neoaortic valve of pulmonary origin  
(BC02.31)

**BB71.0**

### **Rheumatic aortic valve insufficiency**

Aortic insufficiency is the leaking of the aortic valve of the heart that causes blood to flow in the reverse direction during ventricular diastole, from the aorta into the left ventricle. Rheumatic fever causes the valve cusps to retract.

**Inclusions:** rheumatic aortic incompetence

rheumatic aortic regurgitation

**Exclusions:** Active or acute rheumatic endocarditis of aortic valve (1B41.1)

**BB71.Y**

### **Other specified nonrheumatic aortic valve insufficiency**

**Coding Note:**

Code also the causing condition

**BB71.Z**

### **Aortic valve insufficiency, unspecified**

**Coding Note:**

Code also the causing condition

<b>BB72</b>	<b>Aortic valve stenosis with insufficiency</b>
<b>BB72.0</b>	<b>Rheumatic aortic stenosis with insufficiency</b> Aortic stenosis from chronic rheumatic heart disease is typically associated with aortic insufficiency. The valve commissures and cusps become adherent and fused, and the valve orifice becomes small. Upon auscultation, S2 may be single because the aortic leaflets are immobile and do not produce an aortic closure sound
<b>BB72.1</b>	<b>Nonrheumatic aortic valve stenosis with insufficiency</b> This is a non-rheumatic disease of the heart valves in which the opening of the aortic valve is narrowed, with regurgitation.
<b>BB72.Z</b>	<b>Aortic valve stenosis with insufficiency, unspecified</b>
<b>BB73</b>	<b>Aortic valvar abscess</b>
<b>BB74</b>	<b>Aortic valvar prolapse</b> A congenital cardiovascular malformation of the aortic valve in which part or all of one or more of the aortic valve leaflets is on the ventricular side of the plane of the inferior aspect of the attachments of the aortic valve leaflets.
<b>BB7Y</b>	<b>Other specified aortic valve disease</b>
<b>BB7Z</b>	<b>Aortic valve disease, unspecified</b>

Tricuspid valve disease (BB80-BB8Z)

**Exclusions:** Congenital anomaly of tricuspid valve (LA87.0)

**Coded Elsewhere:** Traumatic injury to tricuspid valve (NB31.4Y)

<b>BB80</b>	<b>Tricuspid valve stenosis</b> This is a valvular heart disease which results in the narrowing of the orifice of the tricuspid valve of the heart. It is a relatively rare condition that causes stenosis-increased resistance to blood flow through the valve.  <b>Coded Elsewhere:</b> Postprocedural tricuspid valve stenosis (BE12.4)
<b>BB80.0</b>	<b>Rheumatic tricuspid valve stenosis</b> Tricuspid stenosis is almost always rheumatic in origin. Tricuspid stenosis results in the narrowing of the orifice of the tricuspid valve of the heart.
<b>BB80.Y</b>	<b>Other specified nonrheumatic tricuspid valve stenosis</b>
<b>BB80.Z</b>	<b>Tricuspid valve stenosis, unspecified</b>
<b>BB81</b>	<b>Tricuspid valve insufficiency</b> This refers to the failure of the heart's tricuspid valve to close properly during systole. As a result, with each heart beat some blood passes from the right ventricle to the right atrium, the opposite of the normal direction.  <b>Coded Elsewhere:</b> Postprocedural tricuspid valve insufficiency (BE12.5)
<b>BB81.0</b>	<b>Rheumatic tricuspid valve insufficiency</b>

<b>BB81.Y</b>	<b>Other specified nonrheumatic tricuspid valve insufficiency</b>
<b>BB81.Z</b>	<b>Tricuspid valve insufficiency, unspecified</b>
<b>BB82</b>	<b>Tricuspid valve stenosis with insufficiency</b> This is a valvular heart disease which results in the narrowing of the orifice of the tricuspid valve of the heart. It is a relatively rare condition that causes stenosis-increased resistance to blood flow through the valve, with regurgitation.
<b>BB82.0</b>	<b>Rheumatic tricuspid valve stenosis with insufficiency</b> Tricuspid valve insufficiency due to leaflet abnormalities may be secondary to rheumatic heart disease. When due to the latter, it generally occurs in combination with tricuspid stenosis
<b>BB82.Y</b>	<b>Other specified nonrheumatic tricuspid valve stenosis with insufficiency</b>
<b>BB82.Z</b>	<b>Tricuspid valve stenosis with insufficiency, unspecified</b>
<b>BB83</b>	<b>Tricuspid valvular abscess</b>
<b>BB84</b>	<b>Tricuspid valve rupture</b>
<b>BB8Y</b>	<b>Other specified tricuspid valve disease</b>
<b>BB8Z</b>	<b>Tricuspid valve disease, unspecified</b>

Pulmonary valve disease (BB90-BB9Z)

**Exclusions:** Congenital anomaly of pulmonary valve (LA8A.0)

**Coded Elsewhere:** Traumatic injury to pulmonary valve (NB31.4Y)

<b>BB90</b>	<b>Pulmonary valve stenosis</b> Pulmonary valve stenosis is an obstruction at the level of pulmonary valve which impedes the outflow of blood from right ventricle to pulmonary artery. <b>Coded Elsewhere:</b> Postprocedural pulmonary valve stenosis (BE12.6)
<b>BB90.0</b>	<b>Rheumatic pulmonary valve stenosis</b> This is a rheumatic heart valve disorder in which outflow of blood from the right ventricle of the heart is obstructed at the level of the pulmonic valve.
<b>BB90.Y</b>	<b>Other specified nonrheumatic pulmonary valve stenosis</b>
<b>BB90.Z</b>	<b>Pulmonary valve stenosis, unspecified</b>
<b>BB91</b>	<b>Pulmonary valve insufficiency</b> Pulmonary valve insufficiency which is an incomplete closure of the pulmonary valve allows blood to return from pulmonary artery into the right ventricle. <b>Coded Elsewhere:</b> Postprocedural pulmonary valve insufficiency (BE12.7) Neopulmonary valve regurgitation (BE14.41)

- BB91.0** **Rheumatic pulmonary valve insufficiency**  
This is a rheumatic condition where the pulmonary valve is not strong enough to prevent backflow to the right ventricle.
- BB91.Y** **Other specified nonrheumatic pulmonary valve insufficiency**
- BB91.Z** **Pulmonary valve insufficiency, unspecified**
- BB92** **Pulmonary valve stenosis with insufficiency**  
This is a clinical condition in which pulmonary valve stenosis and pulmonary insufficiency are seen together.
- BB92.0** **Rheumatic pulmonary valve stenosis with insufficiency**  
This is a rheumatic heart valve disorder in which outflow of blood from the right ventricle of the heart is obstructed at the level of the pulmonic valve, with regurgitation.
- BB92.1** **Nonrheumatic pulmonary valve stenosis with insufficiency**  
This is a non-rheumatic heart valve disorder in which outflow of blood from the right ventricle of the heart is obstructed at the level of the pulmonic valve, with regurgitation.
- BB92.Z** **Pulmonary valve stenosis with insufficiency, unspecified**
- BB93** **Pulmonary valvar abscess**
- BB9Y** **Other specified pulmonary valve disease**
- BB9Z** **Pulmonary valve disease, unspecified**
- BC00** **Multiple valve disease**
- Coding Note:** When specific type of valve disease is known, assign codes for the specific conditions.
- BC01** **Prosthetic valve disease**
- Coding Note:** When specific type of valve disease is known, assign codes for the specific conditions.
- Coded Elsewhere:** Infection or inflammatory reaction of heart valve prosthesis NOS (NE83.1)

**BC02****Acquired abnormality of congenitally malformed valve**

A postnatal pathological change in form or function of a congenitally malformed valve.

- Exclusions:**
- Congenital anomaly of aortic valve (LA8A.2)
  - Congenital anomaly of mitral valve (LA87.1)
  - Congenital anomaly of pulmonary valve (LA8A.0)
  - Congenital anomaly of tricuspid valve (LA87.0)
- Coded Elsewhere:**
- Endocarditis of common atrioventricular valve (BB40)
  - Endocarditis of right atrioventricular valve (BB40)
  - Endocarditis of left atrioventricular valve (BB40)
  - Endocarditis of the neoaortic valve of pulmonary origin (BB40)
  - Endocarditis of neopulmonary valve (BB40)

**BC02.0****Acquired common atrioventricular valvar abnormality in biventricular connections**

A postnatal pathological change in form or function of the common atrioventricular valve in the presence of biventricular atrioventricular connections.

**BC02.1****Acquired truncal valvar abnormality**

A postnatal pathological change in form or function of the truncal valve when the truncal valve supplies both the systemic and pulmonary circulations.

- Coded Elsewhere:** Endocarditis of truncal valve or neo-aortic valve of truncal origin (BB40)

**BC02.2****Acquired common atrioventricular valvar abnormality in double inlet ventricle**

**Coded Elsewhere:** Postprocedural common atrioventricular valvar abnormality in double-inlet ventricle (BE14.7)

- Postprocedural right-sided atrioventricular valvar abnormality in double-inlet ventricle (BE14.5)
- Postprocedural left-sided atrioventricular valvar abnormality in double-inlet ventricle (BE14.6)

**BC02.3****Acquired abnormality of neoaortic valve of pulmonary origin****BC02.30**

Stenosis of the neoaortic valve of pulmonary origin

Acquired obstruction to flow through the neo-aortic valve of pulmonary origin, that is, the native pulmonary valve that has become the functional neo-aortic valve.

Examples of hearts in which a neo-aortic valve has been created include the aortopulmonary anastomosis (Damus-Kaye-Stansel, Norwood procedures), pulmonary valve autograft (Ross procedure), and arterial switch operation

**BC02.31**

Insufficiency of the neoaortic valve of pulmonary origin

Acquired backward flow through the neo-aortic valve of pulmonary origin, that is, the native pulmonary valve that has become the functional neo-aortic valve.

Examples of hearts in which a neo-aortic valve has been created include the aortopulmonary anastomosis (Damus-Kaye-Stansel, Norwood procedures), pulmonary valve autograft (Ross procedure), and arterial switch operation.

<b>BC02.3Y</b>	Other specified acquired abnormality of neoaortic valve of pulmonary origin
<b>BC02.3Z</b>	Acquired abnormality of neoaortic valve of pulmonary origin, unspecified
<b>BC02.4</b>	<b>Acquired abnormality of the neoaortic valve of truncal origin</b> A postnatal pathological change in form or function of the neo-aortic valve that results from biventricular repair of common arterial trunk (truncus arteriosus)
<b>BC02.40</b>	Acquired stenosis of the neoaortic valve of truncal origin Acquired obstruction to flow through the neo-aortic valve, when the neo-aortic valve results from biventricular repair of common arterial trunk (truncus arteriosus)
<b>BC02.41</b>	Acquired regurgitation of the neoaortic valve of truncal origin Acquired backward flow through the neo-aortic valve, when the neo-aortic valve results from biventricular repair of common arterial trunk (truncus arteriosus)
<b>BC02.4Y</b>	Other specified acquired abnormality of the neoaortic valve of truncal origin
<b>BC02.4Z</b>	Acquired abnormality of the neoaortic valve of truncal origin, unspecified
<b>BC02.Y</b>	<b>Other specified acquired abnormality of congenitally malformed valve</b>
<b>BC02.Z</b>	<b>Acquired abnormality of congenitally malformed valve, unspecified</b>
<b>BC0Z</b>	<b>Heart valve diseases, unspecified</b>
<b>BC20</b>	<b>Chronic rheumatic heart diseases, not elsewhere classified</b>
	<b>Coded Elsewhere:</b> Acute rheumatic fever with heart involvement (1B41)
	Rheumatic mitral valve stenosis (BB60.0)
	Rheumatic mitral valve insufficiency (BB61.0)
	Rheumatic mitral valve prolapse (BB62.0)
	Rheumatic mitral stenosis with insufficiency (BB63.0)
	Rheumatic aortic valve stenosis (BB70.0)
	Rheumatic aortic valve insufficiency (BB71.0)
	Rheumatic aortic stenosis with insufficiency (BB72.0)
	Rheumatic tricuspid valve stenosis (BB80.0)
	Rheumatic tricuspid valve insufficiency (BB81.0)
	Rheumatic tricuspid valve stenosis with insufficiency (BB82.0)
	Rheumatic pulmonary valve stenosis (BB90.0)
	Rheumatic pulmonary valve insufficiency (BB91.0)
	Rheumatic pulmonary valve stenosis with insufficiency (BB92.0)
<b>BC20.0</b>	<b>Rheumatic diseases of endocardium, valve unspecified</b> Endocardium and valves are affected to varying degrees due to rheumatic process.
<b>BC20.1</b>	<b>Rheumatic heart disease, unspecified</b>
<b>BC20.Y</b>	<b>Other specified chronic rheumatic heart disease</b>

**BC20.Z                   Chronic rheumatic heart disease, unspecified**

**Diseases of the myocardium or cardiac chambers (BC40-BC4Z)**

This refers to diseases of a type of involuntary striated muscle found in the walls and histological foundation of the heart, with specific reference to the atrial and ventricular chambers, as well as the myocardium itself.

**BC40                   Acquired atrial abnormality**

A postnatal pathological change in form or function of one or both atriums.

**Coded Elsewhere:** Postprocedural residual or recurrent interatrial communication (BE17)

Postprocedural right atrial complication (BE1E)

Postprocedural left atrial complication (BE1F)

**BC40.0                   Acquired interatrial communication**

A postnatal pathological hole or pathway between the atrial chambers.

**BC40.Y                   Other specified acquired atrial abnormality**

**BC40.Z                   Acquired atrial abnormality, unspecified**

**BC41                   Acquired ventricular abnormality**

A postnatal pathological change in form or function of a ventricle.

**Coded Elsewhere:** Postprocedural ventricular septal defect disorder (BE14.8)

**BC41.0                   Acquired interventricular communication**

Hole or pathway between the ventricular chambers not present at birth.

**Coded Elsewhere:** Ventricular septal defect as current complication following acute myocardial infarction (BA60.3)

**BC41.Y                   Other specified acquired ventricular abnormality**

**BC41.Z                   Acquired ventricular abnormality, unspecified**

**BC42                   Myocarditis**

Myocarditis (inflammatory cardiomyopathy) is inflammation of the heart muscle generally in the presence of a dilated cardiomyopathy that results from exposure to either discrete infectious external antigens such as viruses, bacteria, fungal or parasites; non-infectious external antigens such as hypersensitivity to drugs; or internal non-infectious triggers such as autoimmune or hypersensitive activation against self-antigens.

**Coding Note:** Code also the causing condition

**Coded Elsewhere:** Acute rheumatic myocarditis (1B41.2)

Sarcoid myocarditis (4B20.Y)

Loeffler endocarditis (BC43.20)

<b>BC42.0</b>	<b>Giant cell myocarditis</b>
	Giant cell myocarditis is a form of dilated cardiomyopathy secondary to myocardial inflammation that is characterised by widespread infiltration of giant cells (abnormal masses produced by the fusion of macrophages) associated with other inflammatory cells and heart muscle cell destruction.
<b>BC42.1</b>	<b>Infectious myocarditis</b>
	Infectious myocarditis (infectious inflammatory cardiomyopathy) is inflammation of the heart muscle generally in the presence of a dilated cardiomyopathy that results from exposure to discrete infectious external antigens such as a virus, bacteria or parasite.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b>
	Acute rheumatic myocarditis (1B41.2)
	Myoendocarditis (BB41)
	Acute or subacute infectious endocarditis (BB40)
<b>BC42.2</b>	<b>Hypersensitivity myocarditis</b>
	Hypersensitivity myocarditis is the presence of dilated cardiomyopathy in association with a known related disorder (hypereosinophilic syndrome (usually a restrictive cardiomyopathy), Churg-Strauss syndrome, malignancy, parasite infection, drugs, or vaccines) and findings of interstitial lymphocytic and eosinophilic infiltration, giant cell, and possible myocardial necrosis on biopsy, usually with peripheral eosinophilia.
	<b>Inclusions:</b>
	eosinophilic myocarditis
<b>BC42.3</b>	<b>Rheumatic myocarditis</b>
	Rheumatic myocarditis is cardiac inflammation and scarring triggered by an autoimmune reaction to group A streptococci infection resulting acutely in pancarditis involving inflammation of the myocardium, endocardium, and epicardium and chronically by valve fibrosis.
<b>Coding Note:</b>	Code also the causing condition
<b>BC42.Y</b>	<b>Other specific myocarditis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>BC42.Z</b>	<b>Myocarditis, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition

**BC43**

### **Cardiomyopathy**

These are myocardial disorders in which the heart muscle is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension, valvular disease and congenital heart disease sufficient to cause the observed myocardial abnormality.

**Coding Note:** Code also the causing condition

**Exclusions:** Inflammatory cardiomyopathy (BC42)

Myocarditis (BC42)

**Coded Elsewhere:** Ischaemic cardiomyopathy (BA51)

Pacing-induced cardiomyopathy (NE82.03)

Cardiomyopathy in the puerperium (JB44.3)

**BC43.0**

### **Dilated cardiomyopathy**

Dilated cardiomyopathy is a myocardial disorder in which there is systolic dysfunction and chamber dilation of one or both ventricles in the absence of a haemodynamic cause that can produce the existent dilation and dysfunction, including physiological (such as sepsis) or anatomic causes with either abnormal loading conditions (such as coarctation of the aorta) or ischaemia (such as coronary artery disease or anomalies).

Additional information: Physiological and anatomic conditions can affect the dilated cardiomyopathy morphofunctional phenotype. If this morphofunctional phenotype is retained after appropriate intervention, then a dilated cardiomyopathy is established.

**Inclusions:** Congestive cardiomyopathy

**BC43.00**

Familial-genetic dilated cardiomyopathy

Familial-genetic dilated cardiomyopathy is the presence of dilated cardiomyopathy that is present in multiple members of a pedigree, or in the presence of a genetic mutation known to be significantly associated with dilated cardiomyopathy.

Additional information: Candidate cytoskeletal and Z disk-encoding genes, most of whom are hypothesized to lead to abnormalities in force transmission, include  $\delta$ -sarcoglycan,  $\beta$ -sarcoglycan, desmin, lamin A/C, metavinculin, muscle LIM protein, titin,  $\alpha$ -actinin-2, nebulin, myopalladin, and ZASP (Z band alternatively spliced PDZ domain protein)

**Coded Elsewhere:** Dilated cardiomyopathy due to glycogen branching enzyme deficiency (5C51.3)

**BC43.01**

Nonfamilial dilated cardiomyopathy

Nonfamilial dilated cardiomyopathy is dilated cardiomyopathy secondary to an acquired systemic disorder that is known to be associated with dilated or inflammatory cardiomyopathy such as infectious myocarditis, exposure to toxins such as alcohol or anthracycline therapy, nutritional disorders, autoimmune disease, and many others.

**Exclusions:** Pacing-induced cardiomyopathy (NE82.03)

**BC43.0Z**

Dilated cardiomyopathy, unspecified

<b>BC43.1</b>	<b>Hypertrophic cardiomyopathy</b> Hypertrophic cardiomyopathy is the presence of a hypertrophied, non-dilated ventricle in the absence of a hemodynamic cause that is capable of producing the existent magnitude of wall thickening excluding both physiologic hypertrophy secondary to physical activity, and pathologic hypertrophy due to systemic hypertension, aortic valvar stenosis, and coarctation.
	<b>Coded Elsewhere:</b> Syndrome of infant of a diabetic mother, type 1 or 2, nongestational, insulin dependent (KB60.1)
<b>BC43.10</b>	Familial-genetic hypertrophic cardiomyopathy Familial isolated hypertrophic cardiomyopathy is the presence of non-syndromic hypertrophic cardiomyopathy in multiple members of a pedigree, or in the presence of a genetic mutation known to be significantly associated with hypertrophic cardiomyopathy.
<b>BC43.11</b>	Non-obstructive hypertrophic cardiomyopathy Non-obstructive hypertrophic cardiomyopathy is hypertrophic cardiomyopathy that has no fixed or dynamic intraventricular narrowing sufficient to result in a significant pressure gradient between the ventricular apex and the outflow valve (aortic or pulmonary).
<b>BC43.12</b>	Obstructive hypertrophic cardiomyopathy Obstructive hypertrophic cardiomyopathy is hypertrophic cardiomyopathy that manifests sufficient fixed or dynamic narrowing within one or both ventricles to result in a significant pressure gradient between the ventricular apex and the outflow valve (aortic or pulmonary).
<b>BC43.1Y</b>	Other specified hypertrophic cardiomyopathy
<b>BC43.1Z</b>	Hypertrophic cardiomyopathy, unspecified
<b>BC43.2</b>	<b>Restrictive cardiomyopathy</b> Restrictive cardiomyopathy is the presence of impaired ventricular diastolic function related to reduced rate and/or extent of relaxation and/or compliance in the absence of another predominant phenotype of dilated or hypertrophic cardiomyopathy.
<b>BC43.20</b>	Nonfamilial restrictive cardiomyopathy Nonfamilial restrictive cardiomyopathy is restrictive cardiomyopathy secondary to an acquired systemic disorder that is known to be associated with restrictive cardiomyopathy such as amyloidosis, scleroderma, sarcoidosis, or anthracycline therapy.
<b>BC43.2Y</b>	Other specified restrictive cardiomyopathy
<b>BC43.2Z</b>	Restrictive cardiomyopathy, unspecified

- BC43.3 Endocardial fibroelastosis**  
Endocardial fibroelastosis is the formation of a marked fibro-elastic thickening of the subendocardium in one or both cardiac ventricles. A disorder of fetuses and infants, secondary causes include congenital left-sided obstructive cardiac lesions, metabolic disorders, autoimmune disease (anti-Ro/anti-La antibodies), and transplacental viral infection such as mumps. Primary endocardial fibroelastosis has been linked to recessive and x-linked inheritance, such as with Barth syndrome.
- BC43.4 Cardiomyopathy due to drugs or other external agents**  
This is one type of cardiomyopathy due to drugs and other external agents. Causing agents are alcohol, cocaine chemotherapeutic agents, psychotherapeutic agents and chemical toxins.
- BC43.5 Stress-induced cardiomyopathy**  
Stress-induced or Takotsubo cardiomyopathy is a disease of the myocardium characterised by episodes of acute onset, reversible left ventricular apical wall motion abnormalities mimicking acute myocardial infarction, but with non-specific electrocardiographic ST elevation and T wave changes, and minimal myocardial enzymatic release, in the absence of coronary stenosis.  
**Inclusions:**      Takotsubo cardiomyopathy
- BC43.6 Arrhythmogenic ventricular cardiomyopathy**  
Arrhythmogenic ventricular cardiomyopathy is a cardiomyopathy characterised by myocardial cell loss with partial or total replacement of right ventricular muscle by adipose and fibrous tissue, beginning subepicardially to become transmural in time, sparing the papillary muscles and trabeculae, and often associated with aneurysms particularly of the right ventricular outflow tract. There is progressive systolic impairment with ventricular dilation and marked propensity for ventricular arrhythmias of right, as well as left, ventricular origin. Classically a disease of the right ventricle, more recent evidence suggests left ventricular involvement to a varying extent in up to 75% of cases, as well as isolated left ventricular disease.
- BC43.7 Diabetic cardiomyopathy**  
Diabetic cardiomyopathy is the presence of myocardial dysfunction in the absence of overt clinical coronary artery disease, valvar disease, and other conventional cardiovascular risk factors, such as hypertension and dyslipidemia. It is initially characterised by myocardial fibrosis, dysfunctional remodeling, and diastolic dysfunction, progressing to systolic dysfunction and heart failure.  
Additional information. The development and progression of diabetic cardiomyopathy has been linked to impaired cardiac insulin metabolic signaling, increases in oxidative stress, reduced nitric oxide bioavailability, collagen-based cardiomyocyte and extracellular matrix stiffness, impaired mitochondrial and cardiomyocyte calcium handling, inflammation, renin–angiotensin–aldosterone system activation, cardiac autonomic neuropathy, endoplasmic reticulum stress, microvascular dysfunction, and a myriad of cardiac metabolic abnormalities.
- Coding Note:** Always assign an additional code for diabetes mellitus.
- BC43.Y Other specified cardiomyopathy**  
**Coding Note:** Code also the causing condition

**BC43.Z**      **Cardiomyopathy, unspecified**

**Coding Note:** Code also the causing condition

**BC44**      **Noncompaction cardiomyopathy**

Noncompaction cardiomyopathy is a morphologic abnormality of the myocardium predominantly affecting the apex of the ventricle characterised by hypertrabeculation and deep inter-trabecular recesses, usually accompanied by an abnormally thin subepicardial layer of compacted myocardium, that is generally but not always associated with ventricular dysfunction.

Additional information. Noncompaction cardiomyopathy classically involves the left ventricle but can also involve only the right ventricle or both. It can occur as an isolated finding or in association with a dilated, hypertrophic, or mixed cardiomyopathic phenotype. It has been described in association with complex congenital heart disease, coronary artery anomalies and as an isolated finding, with and without musculoskeletal and other system abnormalities.

**BC45**      **Cardiomegaly**

**BC46**      **Intracardiac thrombosis**

**Exclusions:**      Acute myocardial infarction, without specification of ST elevation (BA41)

**BC4Y**      **Other specified diseases of the myocardium or cardiac chambers**

**BC4Z**      **Diseases of the myocardium or cardiac chambers, unspecified**

**Cardiac arrhythmia (BC60-BC9Z)**

This is any of a large and heterogeneous group of conditions in which there is abnormal electrical activity in the heart. The heartbeat may be too fast or too slow, and may be regular or irregular.

**Coded Elsewhere:** Cardiac arrest (MC82)

Cardiac arrhythmias in the neonate (KB41)

Dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified (NE82)

**BC60**      **Atrial premature depolarization**

Cardiac electrical depolarization arising from the atria, occurring earlier than the expected sinus beat

**BC61**      **Junctional premature depolarization**

Cardiac electrical depolarization arising from the compact atrioventricular node or His bundle occurring earlier than the expected sinus beat.

**BC62**      **Accessory pathway**

An additional electrical connection which typically bypasses the AV node, typically inserting directly into atrial and ventricular myocardium, but may also connect to the specialised conduction system (e.g., the bundle of His, right or left bundles, or one of the fascicles).

<b>BC63</b>	<b>Conduction disorders</b> Any abnormal alteration of atrio-ventricular conduction. <b>Coded Elsewhere:</b> Congenital heart block (LA8Y)
<b>BC63.0</b>	<b>Atrioventricular block, first degree</b> Disorder of the atrioventricular conduction system in which the PR interval is greater than the 97th percentile for age or > 200 ms in adults
<b>BC63.1</b>	<b>Atrioventricular block, second degree</b> Disorder of the atrioventricular conduction system in which some but not all atrial impulses fail to propagate to the ventricles. Electrocardiographically, some P waves are not followed by a QRS complex.
<b>BC63.10</b>	High-grade second degree atrioventricular block Form of second degree atrioventricular block in which either multiple consecutive P-waves are not conducted or there are transient periods of atrioventricular dissociation
<b>BC63.1Y</b>	Other specified atrioventricular block, second degree
<b>BC63.1Z</b>	Atrioventricular block, second degree, unspecified
<b>BC63.2</b>	<b>Complete atrioventricular block</b> Disorder of the atrioventricular conduction system in which there is failure of all atrial impulses to propagate to the ventricle <b>Inclusions:</b> Third-degree block
<b>BC63.20</b>	Congenital complete atrioventricular block Third degree atrioventricular block is defined as the absence of atrioventricular node conduction and here it is congenital, that is, it has been present since birth and is not acquired, although it may be first detected later. <b>Exclusions:</b> Congenital complete heart block (LA80-LA8Z)
<b>BC63.21</b>	Acquired complete atrioventricular block Complete atrioventricular block in which the onset of the conduction disorder is recognised after birth
<b>BC63.2Z</b>	Complete atrioventricular block, unspecified
<b>BC63.3</b>	<b>Right bundle branch block</b> Disorder of the atrioventricular conduction system characterised by prolonged QRS duration (greater than or equal to 120 ms in adults, greater than 100 ms in children ages 4 to 16 years, and greater than 90 ms in children less than 4 years of age), rsr, rsR, or rSR in leads V1 or V2, S wave of greater duration than R wave (or greater than 40 ms in leads I and V6 in adults)

<b>BC63.4</b>	<b>Left bundle branch block</b> Disorder of the atrioventricular conduction system in which the QRS duration is greater than or equal to 120 ms in adults, greater than 100 ms in children 4 to 16 years of age, and greater than 90 ms in children less than 4 years of age; there is a QS or rS pattern in lead V1 and a wide slurred R wave in leads I and V6.
<b>BC63.40</b>	Left anterior fascicular block Disorder of the atrioventricular conduction system characterised by left axis deviation for age (frontal plane axis between -45° and -90°), qR pattern in lead aVL, R-peak time in lead aVL of 45 ms or more, and a QRS duration that does not meet age dependent criteria for complete bundle branch block (less than 120 ms in adults, less than 100 ms in children 4 to 16 years of age, and less than 90 ms in children less than 4 years of age)
<b>BC63.41</b>	Left posterior fascicular block Disorder of the atrioventricular conduction system characterised by right axis deviation for age (between 90° and 180° in adults), with a qR pattern in inferior leads, rS pattern in leftward leads (I and aVL), and a QRS duration that does not meet age dependent criteria for complete bundle branch block (less than 120 ms in adults, less than 100 ms in children 4 to 16 years of age, and less than 90 ms in children less than 4 years of age)
<b>BC63.4Z</b>	Left bundle branch block, fascicle unspecified
<b>BC63.5</b>	<b>Nonspecific intraventricular conduction delay</b> Disorder of the atrioventricular conduction system characterised by a prolonged QRS duration (QRS duration greater than 110 ms in adults, greater than 90 ms in children 8 to 16 years of age, and greater than 80 ms in children less than 8 years of age) without criteria for right or left bundle branch block.
<b>BC63.Y</b>	<b>Other specified conduction disorders</b>
<b>BC63.Z</b>	<b>Conduction disorders, unspecified</b>
<b>BC64</b>	<b>Sudden arrhythmic death syndrome</b>
<b>BC65</b>	<b>Cardiac arrhythmia associated with genetic disorder</b>
<b>BC65.0</b>	<b>Long QT syndrome</b> A congenital disorder of ventricular myocardial repolarization characterised by a prolonged QT interval on the electrocardiogram (ECG) that can lead to symptomatic ventricular arrhythmias and an increased risk of sudden cardiac death.
<b>BC65.1</b>	<b>Brugada syndrome</b> Clinical manifestations of cardiac syncope, ventricular tachycardia, ventricular fibrillation, or sudden death in conjunction with a genetic mutation associated with Brugada Syndrome and/or a Brugada pattern ECG (spontaneous or provoked).
<b>BC65.2</b>	<b>Short QT syndrome</b> Familial short QT syndrome is a rare cardiac rhythm disorder that associates a short QT interval (QT and QTc 300 ms) on the surface electrocardiogram (ECG) with a high risk of syncope or sudden death due to malignant ventricular arrhythmia.

- BC65.3 Early repolarisation syndrome**  
Genetic arrhythmia disorder characterised by inferolateral J wave elevation noted on ECG in conjunction with ventricular fibrillation not explained by other causes.
- BC65.4 Idiopathic ventricular fibrillation**  
Genetic arrhythmia disorder characterised by occurrence of ventricular fibrillation in the absence of other underlying causes, including absence of electrocardiogram (ECG) findings of Brugada syndrome, bidirectional ventricular tachycardia, and inferolateral J wave elevation.
- BC65.5 Catecholaminergic polymorphic ventricular tachycardia**  
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe genetic arrhythmogenic disorder of childhood characterised by adrenergically-induced ventricular tachycardia (bidirectional ventricular tachycardia and, less frequently, supraventricular tachycardia and atrial fibrillation) manifesting as syncope and sudden death.
- BC65.Y Other specified cardiac arrhythmia associated with genetic disorder**
- BC65.Z Cardiac arrhythmia associated with genetic disorder, unspecified**

Ventricular rhythm disturbance (BC70-BC7Z)

Any cardiac rhythm anomaly arising from the ventricles.

- BC70 Ventricular premature depolarization**  
Ventricular depolarization occurring earlier than the expected ventricular depolarization initiated by the sinoatrial node or another supraventricular pacemaker.
- BC71 Ventricular tachyarrhythmia**  
Any ventricular rhythm disturbance with a rate faster than the normal age dependent ventricular escape rate.
- BC71.0 Ventricular tachycardia**  
Ventricular tachycardia is a cardiac arrhythmia of three or more consecutive complexes in duration emanating from the ventricles at a rate of greater than 120 bpm in adolescents or adults and a rate greater than 150 bpm in child. Ventricular tachycardia may occur with or without loss of cardiac output.
- BC71.00 Right outflow tract ventricular tachycardia**  
Monomorphic ventricular tachycardia with focal activity originating from the right ventricular outflow tract, having a left bundle branch block (LBBB) morphology and inferior axis.
- BC71.01 Polymorphic ventricular tachycardia**  
Ventricular tachycardia with 2 or more QRS morphologies.

<b>BC71.02</b>	Sustained ventricular tachycardia Ventricular tachycardia that has a duration of >30 seconds or causes haemodynamic instability.
<b>BC71.03</b>	Non-sustained ventricular tachycardia Ventricular tachycardia lasting less than or equal to 30 seconds
<b>BC71.0Y</b>	Other specified ventricular tachycardia
<b>BC71.0Z</b>	Ventricular tachycardia, unspecified
<b>BC71.1</b>	<b>Ventricular fibrillation</b> Ventricular fibrillation is a rapid grossly irregular ventricular rhythm, usually more than 300 bpm/200 ms (cycle length 180 ms or less), with marked variability in QRS cycle length, morphology, and amplitude, associated with loss of cardiac output, and is usually sustained, requiring intervention to terminate.
<b>BC71.2</b>	<b>Re-entry ventricular arrhythmia</b>
<b>BC71.Y</b>	<b>Other specified ventricular tachyarrhythmia</b>
<b>BC71.Z</b>	<b>Ventricular tachyarrhythmia, unspecified</b>
<b>BC7Y</b>	<b>Other specified ventricular rhythm disturbance</b>
<b>BC7Z</b>	<b>Ventricular rhythm disturbance, unspecified</b>

Supraventricular rhythm disturbance (BC80-BC8Z)

<b>BC80</b>	<b>Supraventricular bradycardia</b> Any of a number of possible arrhythmias originating at or above the level of bundle of His in which the heart beats slower than the age-dependent lower limits of normal.
<b>BC80.0</b>	<b>Sinus pause</b> An interruption in the typical sinus cadence where the p-p interval > sum of 2 previous p-p (excludes sinus arrhythmia).
<b>BC80.1</b>	<b>Sinus bradycardia</b> Resting sinus rates below the 97% for age (<60 bpm in adults).
<b>BC80.2</b>	<b>Sinus node dysfunction</b> Non-specific term that refers to abnormalities in sinus node impulse formation and propagation and includes sinus bradycardia, sinus pause/arrest, chronotropic incompetence, and sinoatrial exit block.
<b>BC80.20</b>	Sick sinus syndrome Sick sinus syndrome may be defined as inappropriate sinus rates (either resting bradycardia or chronotropic incompetence) which may be associated with episodes of atrial tachycardia.

<b>BC80.21</b>	Sinoatrial block Delay or block of the electrical impulse from the sinus node to the atria
<b>BC80.2Y</b>	Other specified sinus node dysfunction
<b>BC80.2Z</b>	Sinus node dysfunction, unspecified
<b>BC80.Y</b>	<b>Other specified supraventricular bradyarrhythmia</b>
<b>BC80.Z</b>	<b>Supraventricular bradyarrhythmia, unspecified</b>
<b>BC81</b>	<b>Supraventricular tachyarrhythmia</b> Tachycardia originating at or above the atrioventricular (AV) node, usually with a narrow QRS or QRS complex similar to the sinus QRS morphology.
<b>BC81.0</b>	<b>Ectopic atrial tachycardia</b> Ectopic atrial tachycardia originates from a small area (focus) in the atrium and spreading centrifugally.
<b>BC81.1</b>	<b>Junctional ectopic tachycardia</b> Narrow or usual complex tachycardia originates from a focus at or near the atrioventricular junction.
<b>BC81.2</b>	<b>Macro reentrant atrial tachycardia</b> An atrial arrhythmia in which there is intra-atrial reentry or circus movement around a fixed or functional central obstacle. The central obstacle may consist of normal (e.g. valves) or abnormal (e.g. scar) structures.  This form of SVT originates in the atrium; conduction to the ventricles is not necessary for the tachycardia to continue. An organised atrial rhythm with a rate typically between 250 and 350 bpm, including tachycardias using a variety of reentry circuits that often occupy large areas of the atrium ("macro-reentrant"). Here the arrhythmia involves the cavotricuspid isthmus.
<b>BC81.20</b>	Cavotricuspid isthmus dependent macroreentry tachycardia A macro re-entrant atrial tachycardia that rotates around the tricuspid annulus.
<b>BC81.21</b>	Non-scar, non-isthmus dependent macro reentrant atrial tachycardia A macro re-entrant atrial tachycardia coursing around a normal cardiac structure (except the cavotricuspid isthmus) such as the mitral valve annulus, or superior caval vein.
<b>BC81.22</b>	Scar mediated macro reentrant atrial tachycardia A macro re-entrant atrial tachycardia in which the central obstacle and/or the zone of slow conduction sustaining the tachycardia is due to scar. In this context scar generally refers to surgical or ischaemic heart disease mediated scarring rather than the fibrosis that can accompany other disease states or aging.
<b>BC81.2Y</b>	Other specified macro reentrant atrial tachycardia
<b>BC81.2Z</b>	Macro reentrant atrial tachycardia, unspecified

- BC81.3** **Atrial fibrillation**  
An atrial tachyarrhythmia characterised by rapid (usually faster than 300 bpm), irregular and uncoordinated atrial impulse generation, usually manifesting on ECG with indistinct P-waves and an irregularly irregular ventricular response.
- BC81.30** **Paroxysmal atrial fibrillation**  
Recurrent AF (>=2 episodes) that terminates spontaneously within 7 days or less (usually within 24 hours).
- BC81.31** **Persistent atrial fibrillation**  
Atrial fibrillation (AF) which is sustained beyond seven days, or lasting less than seven days but necessitating pharmacologic or electrical cardioversion to restore normal sinus rhythm.
- BC81.32** **Permanent atrial fibrillation**  
A term used to identify individuals with persistent AF where a decision has been made to no longer pursue a rhythm control strategy, or where cardioversion has either failed or not been attempted.
- BC81.33** **Preexcited atrial fibrillation**  
Atrial fibrillation that occurs in the setting of a preexcitation syndrome such a Wolff-Parkinson-White syndrome, resulting in an erratic wide-complex rhythm that can degenerate into ventricular fibrillation, and sudden cardiac death.
- BC81.3Y** **Other specified atrial fibrillation**
- BC81.3Z** **Atrial fibrillation, unspecified**
- BC81.4** **Wolff-Parkinson-White syndrome**  
Arrhythmia symptoms, documented supraventricular tachycardia, and/or cardiac arrest due to rapidly conducted atrial fibrillation associated with preexcitation on electrocardiogram. Includes latent preexcitation identified during electrophysiology study.
- BC81.5** **Sinus node reentrant tachycardia**  
A reentrant tachycardia within the sinus node/perinodal tissue characterised by abrupt onset/termination, regular cadence, and P-waves consistent with sinus node origin
- BC81.6** **Inappropriate sinus tachycardia**  
Heart rate which is elevated with regard to level of activity; usually exhibits features of automaticity.
- BC81.7** **Atrioventricular reciprocating tachycardia**  
A macro-reentrant tachycardia involving the atria and ventricles in series that uses the atrioventricular node or an accessory pathway for one limb of the circuit and an accessory pathway for the other.

- BC81.70** Atrioventricular reciprocating tachycardia, orthodromic  
An atrioventricular reciprocating tachycardia that uses an accessory pathway for retrograde conduction and the atrioventricular node for anterograde conduction resulting in a narrow or usual complex tachycardia.
- BC81.71** Atrioventricular reciprocating tachycardia, antidromic  
An atrioventricular reciprocating tachycardia that uses the atrioventricular node for retrograde conduction and the accessory pathway for anterograde conduction resulting in a wide complex tachycardia.
- BC81.7Y** Other specified atrioventricular reciprocating tachycardia
- BC81.7Z** Atrioventricular reciprocating tachycardia, unspecified
- BC81.8** **Atrioventricular nodal reentry tachycardia**  
A reentrant supraventricular tachycardia that uses multiple slow atrioventricular nodal pathways or a slow atrioventricular nodal pathway in conjunction with a fast atrioventricular nodal pathway in a reentry circuit.
- BC81.Y** **Other specified supraventricular tachyarrhythmia**
- BC81.Z** **Supraventricular tachyarrhythmia, unspecified**
- BC8Y** **Other specified supraventricular rhythm disturbance**
- BC8Z** **Supraventricular rhythm disturbance, unspecified**
- BC90** **Rhythm disturbance at level of atrioventricular junction**
- BC91** **Pacemaker or implantable cardioverter defibrillator battery at end of battery life**  
Pacemaker or implantable cardioverter defibrillator (ICD) battery at or near complete exhaustion.
- BC9Y** **Other specified cardiac arrhythmia**
- BC9Z** **Cardiac arrhythmia, unspecified**

## Heart failure (BD10-BD1Z)

**Exclusions:** Heart failure following cardiac surgery or due to presence of cardiac prosthesis (BE11)  
complicating abortion or ectopic or molar pregnancy (JA05)  
complicating obstetric surgery and procedures (JB0D.3)

**Coded Elsewhere:** Neonatal cardiac failure (KB40)

**BD10**

### **Congestive heart failure**

A clinical syndrome characterised by abnormalities of ventricular function and neurohormonal regulation which are accompanied by effort intolerance and fluid retention.

**Coding Note:** Code also the causing condition

**Inclusions:** Congestive heart disease

**BD11**

### **Left ventricular failure**

A clinical syndrome characterised by abnormalities of left ventricular function resulting in pulmonary congestion and fluid retention.

**Coding Note:** Code also the causing condition

**Inclusions:** Left heart failure

**BD11.0**

### **Left ventricular failure with preserved ejection fraction**

A syndrome of left ventricular dysfunction occurring with normal or relatively preserved ejection fraction

**Coding Note:** Code also the causing condition

**BD11.1**

### **Left ventricular failure with mid range ejection fraction**

**Coding Note:** Code also the causing condition

**BD11.2**

### **Left ventricular failure with reduced ejection fraction**

A syndrome of left ventricular dysfunction associated with reduced ejection fraction.

**Coding Note:** Code also the causing condition

**BD11.Z**

### **Left ventricular failure, unspecified**

**Coding Note:** Code also the causing condition

**BD12**

### **High output syndromes**

Increased cardiac output above normal associated with anaemia, arteriovenous fistulas, thyrotoxicosis and other syndromes. May result in heart failure.

**BD13**

### **Right ventricular failure**

Heart failure associated with right ventricular dysfunction manifest by distention of the neck veins, enlargement of the liver, and dependent oedema.

**Coding Note:** Code also the causing condition

**BD14**

### **Biventricular failure**

**Coding Note:** Code also the causing condition

**BD1Y**      **Other specified heart failure**

**Coding Note:** Code also the causing condition

**BD1Z**      **Heart failure, unspecified**

**Coding Note:** Code also the causing condition

## Diseases of arteries or arterioles (BD30-BD5Z)

**Exclusions:** Diseases of coronary artery (BA81-BA8Z)

**BD30**      **Acute arterial occlusion**

**Coding Note:** Code also the causing condition

**BD30.0**      **Acute upper limb arterial occlusion**

**BD30.00**      Acute thromboembolic upper limb arterial occlusion

**BD30.01**      Acute thrombotic upper limb arterial occlusion

**BD30.0Y**      Other specified acute upper limb arterial occlusion

**BD30.0Z**      Acute upper limb arterial occlusion, unspecified

**BD30.1**      **Acute aortoiliac occlusion**

**BD30.10**      Acute thromboembolic aortoiliac occlusion

**BD30.11**      Acute thrombotic aortoiliac occlusion

**BD30.1Y**      Other specified acute aortoiliac occlusion

**BD30.1Z**      Acute aortoiliac occlusion, unspecified

**BD30.2**      **Acute lower limb arterial occlusion**

**BD30.20**      Acute thromboembolic lower limb arterial occlusion

**BD30.21**      Acute thrombotic lower limb arterial occlusion

**BD30.2Y**      Other specified acute lower limb arterial occlusion

**BD30.2Z**      Acute lower limb arterial occlusion, unspecified

**BD30.Y**      **Other specified acute arterial occlusion**

**Coding Note:** Code also the causing condition

**BD30.Z**      **Acute arterial occlusion, unspecified**

**Coding Note:** Code also the causing condition

Chronic arterial occlusive disease (BD40-BD4Z)

**Coded Elsewhere:** Secondary peripheral angiopathy (BD53.Y)

**BD40**

**Atherosclerotic chronic arterial occlusive disease**

**Inclusions:** endarteritis deformans

senile arteritis

senile endarteritis

**Exclusions:** Chronic vascular disorders of intestine (DD31)

Cerebral ischaemic stroke due to intracranial large artery atherosclerosis (8B11.1)

Coronary atherosclerosis (BA52)

Chilblains (NF03.0)

Frostbite (NE40-NE4Z)

Cerebral ischaemic stroke due to extracranial large artery atherosclerosis (8B11.0)

Asymptomatic stenosis of intracranial or extracranial artery (BD55)

**Coded Elsewhere:** Atherosclerotic retinopathy (BD40.Y)

**BD40.0**

**Lower limb atherosclerosis**

This is a condition in which an artery wall thickens as a result of the accumulation of fatty materials such as cholesterol, of the lower limb.

**BD40.1**

**Atherosclerosis of aorta**

**BD40.2**

**Atherosclerosis of renal artery**

**Exclusions:** atherosclerosis of renal arterioles (BA02)

**BD40.3**

**Aortic bifurcation syndrome**

**BD40.Y**

**Other specified atherosclerotic chronic arterial occlusive disease**

**BD40.Z**

**Atherosclerotic chronic arterial occlusive disease, unspecified**

**BD41**

**Non-atherosclerotic chronic arterial occlusive disease**

A heterogeneous group of disorders which may present with symptoms suggestive of atherosclerotic peripheral arterial disease (e.g. intermittent claudication) but in which arterial or arteriolar occlusion is due to other causes such as fibromuscular dysplasia, thromboarteritis obliterans and calcific arteriolopathy.

**Coded Elsewhere:** Thromboangiitis obliterans (4A44.8)

Calcific arteriolopathy (EB90.42)

**BD41.0**

**Arterial fibromuscular dysplasia**

Fibromuscular dysplasia, formerly called fibromuscular fibroplasia, is a group of nonatherosclerotic, noninflammatory arterial diseases that most commonly involve the renal and carotid arteries.

**BD41.Y**

**Other specified non-atherosclerotic chronic arterial occlusive disease**

**BD41.Z** **Non-atherosclerotic chronic arterial occlusive disease, unspecified**

**BD42** **Raynaud phenomenon**

Raynaud phenomenon describes an exaggerated vascular response to cold temperature or emotional stimuli resulting in episodic digital ischaemia. It is characterised by paroxysmal vasoconstriction producing initially pallor, an essential component for the diagnosis, followed by cyanosis and erythema. Primary Raynaud disease is an isolated innocuous disorder. Secondary Raynaud phenomenon occurs in association with a wide range of different disorders including dysproteinaemias and non-organ-specific systemic autoimmune diseases.

**BD42.0** **Primary Raynaud disease**

Raynaud phenomenon unassociated with any concomitant disease, drug or other provoking trauma. Criteria for diagnosis include: bilateral symmetrical episodic attacks without evidence of peripheral vascular disease or tissue injury, normal nail fold capillaroscopy, negative antinuclear antibody and normal erythrocyte sedimentation rate.

**Inclusions:** Raynaud disease

**BD42.1** **Secondary Raynaud phenomenon**

**Coding Note:** Code also the causing condition

**BD42.Z** **Raynaud phenomenon, unspecified**

**BD4Y** **Other specified chronic arterial occlusive disease**

**BD4Z** **Chronic arterial occlusive disease, unspecified**

**BD50** **Aortic aneurysm or dissection**

Aortic aneurysm is a term for any swelling (dilation or aneurysm) of the aorta to greater than 1.5 times normal, usually representing an underlying weakness in the wall of the aorta at that location. Aortic dissection occurs when a tear in the inner wall of the aorta causes blood to flow between the layers of the wall of the aorta, forcing the layers apart.

**Coded Elsewhere:** Postprocedural true or false aortic aneurysm (BE13)

Aortic aneurysm due to congenital heart disease (LA8Y)

**BD50.0** **Thoracic aortic dissection, ascending aorta dissection and propagation beyond arch**

This occurs when a tear in the inner wall of the aorta causes blood to flow between the layers of the wall of the aorta, forcing the layers apart: ascending aorta dissection and propagation beyond arch.

**BD50.00** Thoracic aortic dissection, ascending aorta dissection and propagation beyond arch with perforation

**BD50.01** Thoracic aortic dissection, ascending aorta dissection and propagation beyond arch with rupture

**BD50.02** Thoracic aortic dissection, ascending aorta dissection and propagation beyond arch without mention of perforation or rupture

<b>BD50.0Y</b>	Other specified thoracic aortic dissection, ascending aorta dissection and propagation beyond arch
<b>BD50.0Z</b>	Thoracic aortic dissection, ascending aorta dissection and propagation beyond arch, unspecified
<b>BD50.1</b>	<b>Ascending aorta dissection not beyond arch</b>
<b>BD50.10</b>	Ascending aorta dissection not beyond arch with perforation
<b>BD50.11</b>	Ascending aorta dissection not beyond arch with rupture
<b>BD50.12</b>	Ascending aorta dissection not beyond arch without mention of perforation or rupture
<b>BD50.1Y</b>	Other specified ascending aorta dissection not beyond arch
<b>BD50.1Z</b>	Ascending aorta dissection not beyond arch, unspecified
<b>BD50.2</b>	<b>Descending aorta dissection and distal propagation</b>
	This occurs when a tear in the inner wall of the aorta causes blood to flow between the layers of the wall of the aorta, forcing the layers apart, and distal propagation.
<b>BD50.20</b>	Descending aorta dissection and distal propagation with perforation
<b>BD50.21</b>	Descending aorta dissection and distal propagation with rupture
<b>BD50.22</b>	Descending aorta dissection and distal propagation without mention of perforation or rupture
<b>BD50.2Y</b>	Other specified descending aorta dissection and distal propagation
<b>BD50.2Z</b>	Descending aorta dissection and distal propagation, unspecified
<b>BD50.3</b>	<b>Thoracic aortic aneurysm</b>
<b>BD50.30</b>	Thoracic aortic aneurysm with perforation
<b>BD50.31</b>	Thoracic aortic aneurysm with rupture
<b>BD50.32</b>	Thoracic aortic aneurysm without mention of perforation or rupture
<b>BD50.3Y</b>	Other specified thoracic aortic aneurysm
<b>BD50.3Z</b>	Thoracic aortic aneurysm, unspecified
<b>BD50.4</b>	<b>Abdominal aortic aneurysm</b>
<b>BD50.40</b>	Abdominal aortic aneurysm with perforation
<b>BD50.41</b>	Abdominal aortic aneurysm with rupture
<b>BD50.4Y</b>	Other specified abdominal aortic aneurysm
<b>BD50.4Z</b>	Abdominal aortic aneurysm, unspecified
<b>BD50.5</b>	<b>Thoracoabdominal aortic aneurysm</b>
<b>BD50.50</b>	Thoracoabdominal aortic aneurysm with perforation

<b>BD50.51</b>	Thoracoabdominal aortic aneurysm with rupture
<b>BD50.52</b>	Thoracoabdominal aortic aneurysm without mention of perforation or rupture
<b>BD50.5Y</b>	Other specified thoracoabdominal aortic aneurysm
<b>BD50.5Z</b>	Thoracoabdominal aortic aneurysm, unspecified
<b>BD50.Z</b>	<b>Aortic aneurysm or dissection, unspecified</b>
<b>BD51</b>	<b>Arterial aneurysm or dissection, excluding aorta</b>
	<i><b>Exclusions:</b></i>
	Aneurysm of pulmonary artery (BB02.1)
	aneurysm of heart (BA41)
	aneurysm of varicose (BD52.1)
	aneurysm of retinal (9B78.1)
	dissection of precerebral artery, congenital (nonruptured) (LA90.41)
	aneurysm (of): aorta (BD50)
	aneurysm (of): arteriovenous NOS acquired (BD52.1)
	Cerebral aneurysm, nonruptured (8B22.5)
	Coronary artery aneurysm (BA81)
	ruptured cerebral aneurysm (8B01.0)
<b>BD51.0</b>	<b>Aneurysm or dissection of carotid artery</b>
<b>BD51.1</b>	<b>Aneurysm or dissection of vertebral artery</b>
<b>BD51.2</b>	<b>Aneurysm or dissection of other precerebral arteries</b>
	<i><b>Exclusions:</b></i>
	Aneurysm or dissection of carotid artery (BD51.0)
	Aneurysm or dissection of vertebral artery (BD51.1)
<b>BD51.3</b>	<b>Aneurysm or dissection of artery of upper extremity</b>
<b>BD51.4</b>	<b>Aneurysm or dissection of renal artery</b>
<b>BD51.5</b>	<b>Aneurysm or dissection of iliac artery</b>
<b>BD51.6</b>	<b>Aneurysm or dissection of artery of lower extremity</b>
<b>BD51.Y</b>	<b>Aneurysm and dissection of other artery, excluding aorta</b>
<b>BD51.Z</b>	<b>Aneurysm and dissection of unspecified artery</b>
<b>BD52</b>	<b>Certain specified disorders of arteries or arterioles</b>
	<i><b>Exclusions:</b></i>
	collagen (vascular) diseases (4A40-4A4Z)
	Hypersensitivity angiitis (4A44.B)
	Acute arterial occlusion (BD30)
	Chronic arterial occlusive disease (BD40-BD4Z)

<b>BD52.0</b>	<b>Segmental arterial mediolysis</b> Segmental arterial mediolysis is a rare noninflammatory vascular disease of the abdominal splanchnic arteries, characterised by disruption of the arterial medial layer. It will induce multiple aneurysms in mesenteric arteries with susceptibility to vessel dissection, haemorrhage and mesenteric ischemia.
<b>BD52.1</b>	<b>Arteriovenous fistula, acquired</b> <b>Exclusions:</b> Cerebral aneurysm, nonruptured (8B22.5) traumatic - see injury of blood vessel by body region (Chapter 22) Coronary artery aneurysm (BA81)
<b>BD52.2</b>	<b>Stricture of artery</b>
<b>BD52.3</b>	<b>Rupture of artery</b> <b>Exclusions:</b> traumatic rupture of artery - see injury of blood vessel by body region (Chapter 22)
<b>BD52.4</b>	<b>Necrosis of artery</b>
<b>BD52.5</b>	<b>Coeliac artery compression syndrome</b>
<b>BD52.6</b>	<b>Congenital great vessel related acquired abnormality</b> Any postnatal pathological change in form or function of the heart and/or great vessels consequent to the presence of congenital cardiovascular disease. <b>Exclusions:</b> Acquired systemic vein abnormality (BD73) Acquired pulmonary venous abnormality (BB03) Acquired pulmonary arterial tree abnormality (BB02.3) <b>Coded Elsewhere:</b> Acquired abnormality of congenitally malformed valve (BC02) Postprocedural arterial duct disorder (BE14.A) Acquired narrowing of constructed cardiac intraventricular tunnel (BE14.B) Acquired subaortic stenosis (BB70.Y) Acquired pulmonary atresia (BB90.Y) Cardiac conduit related disorder (BE14.B) Superior cavopulmonary anastomosis related disorder (BE14.B) Systemic-to-pulmonary arterial shunt related disorder (BE14.B)
<b>BD52.7</b>	<b>Certain acquired abnormalities of aorta</b> A pathological change in form or function of the aorta that develops after birth. <b>Coded Elsewhere:</b> Recoarctation of the aorta (BE14.9)
<b>BD52.70</b>	Acquired abnormality of aortic arch branch A postnatal pathological change in form or function of one or more branches of the aortic arch.

<b>BD52.71</b>	Acquired ascending aorta or root dilation Enlargement of the luminal diameter of the aorta between the ventriculo-aortic junction and the origin of the first brachiocephalic branch above the upper limit of normal adjusted for body size that develops after birth  <b>Coded Elsewhere:</b> Postprocedural ascending aorta dilation (BE14.9)
<b>BD52.7Y</b>	Other specified certain acquired abnormalities of aorta
<b>BD52.7Z</b>	Certain acquired abnormalities of aorta, unspecified
<b>BD53</b>	<b>Secondary disorders of arteries and arterioles</b>
<b>Coding Note:</b>	Code also the causing condition
<b>BD53.0</b>	<b>Arterial cystic medial diseases</b>
<b>Coding Note:</b>	Code also the causing condition
<b>BD53.1</b>	<b>Hypothenar hammer syndrome</b>
<b>BD53.2</b>	<b>Iliac artery arteriopathy</b>
<b>BD53.3</b>	<b>Popliteal entrapment syndrome</b>
<b>BD53.4</b>	<b>Cholesterol atheroembolism</b>  Embolic occlusion of distal small arteries and arterioles by cholesterol crystals released from atherosclerotic plaque in larger more central arteries. The resultant microvascular ischaemia is accompanied by an inflammatory response to the presence of cholesterol crystals. This may occur spontaneously or as a complication of angiography or vascular surgery. Organs most commonly affected include the skin, kidneys, gastrointestinal tract, and brain. Cutaneous manifestations, present in the majority of cases, include livedo reticularis and focal ischaemic necrosis and ulceration; these are commonly associated with acute kidney injury.
<b>BD53.40</b>	Cholesterol atheroembolism to kidneys  This occurs when cholesterol is released, usually from an atherosclerotic plaque, and travels along with the bloodstream (embolism) to other places in the kidneys, where it obstructs blood vessels.
<b>BD53.4Y</b>	Cholesterol atheroembolism to other specified sites
<b>BD53.4Z</b>	Cholesterol atheroembolism to unspecified site
<b>BD53.Y</b>	<b>Other specified secondary disorders of arteries and arterioles</b>
<b>Coding Note:</b>	Code also the causing condition
<b>BD53.Z</b>	<b>Secondary disorders of arteries and arterioles, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition

**BD54****Diabetic foot ulcer**

Chronic foot ulcers occur in as many as 15–25% of diabetic patients. The underlying aetiology is a combination of disturbed sensation from diabetic neuropathy and impaired perfusion from diabetic vasculopathy. Poor foot care, abnormal foot structure, or poorly fitting shoes increase the risk of diabetic foot ulcers. The ulcers typically occur in areas of increased plantar pressure, especially beneath the metatarsal heads.

**Coding Note:**

Always assign an additional code for diabetes mellitus.

**BD55****Asymptomatic stenosis of intracranial or extracranial artery**

Stenosis of intracranial or extracranial artery that has not caused TIA or cerebral ischemic stroke.

**Inclusions:** narrowing of basilar, carotid or vertebral arteries, not resulting in cerebral infarction

**Exclusions:** Transient ischaemic attack (8B10)  
Cerebral ischaemic stroke (8B11)

**BD56****Asymptomatic occlusion of intracranial or extracranial artery**

Occlusion of intracranial or extracranial artery that has not caused TIA or cerebral ischemic stroke.

**Exclusions:** Transient ischaemic attack (8B10)  
Cerebral ischaemic stroke (8B11)

**BD5Y****Other specified diseases of arteries or arterioles****BD5Z****Diseases of arteries or arterioles, unspecified****Diseases of veins (BD70-BD7Z)**

**Coded Elsewhere:** Other venous complications following abortion, ectopic or molar pregnancy (JA05.7)

Venous complications in pregnancy (JA61)

**BD70****Superficial thrombophlebitis**

**Coded Elsewhere:** Superficial thrombophlebitis in pregnancy (JA61.2)

Superficial thrombophlebitis in the puerperium (JB41.0)

**BD70.0****Superficial thrombophlebitis of lower limbs**

Inflammation and thrombosis of the superficial veins of the lower limbs affecting particularly varicose superficial leg veins.

**BD70.1****Superficial thrombophlebitis of upper limbs****BD70.2****Thrombophlebitis migrans**

Thrombophlebitis migrans is characterised by the development of recurrent and migratory superficial thrombophlebitis. It is an acquired coagulopathy that is strongly associated with malignancy, especially solid tumours of the adenocarcinoma type.

**Coding Note:**

Code also the causing condition

<b>BD70.3</b>	<b>Mondor disease</b> A form of localised superficial venous thrombophlebitis typically affecting the chest wall and manifesting as a fibrous cord with surrounding skin retraction and an absence of overlying cutaneous inflammation. No cause is found in many cases but trauma and breast surgery are often implicated.
	<b>Coded Elsewhere:</b> Mondor disease of the penis (GB06.3)
<b>BD70.Y</b>	<b>Other specified superficial thrombophlebitis</b>
<b>BD70.Z</b>	<b>Superficial thrombophlebitis, unspecified</b>
<b>BD71</b>	<p><b>Deep vein thrombosis</b> The process whereby thrombus (blood clot) forms in the large veins of the peripheral venous system. In addition to obstructing venous return it possesses a hazard whereby thrombus may detach and embolize to the pulmonary circulation.</p> <p><b>Coded Elsewhere:</b> Deep phlebothrombosis in pregnancy (JA61.3) Deep phlebothrombosis in the puerperium (JB41.1)</p>
<b>BD71.0</b>	<b>Upper limb deep vein thrombosis</b> Venous thrombosis within the deep veins of the upper limb.
<b>BD71.1</b>	<b>Vena caval thrombosis</b> Venous thrombosis within the vena cava.
<b>BD71.2</b>	<b>Renal vein thrombosis</b> Venous thrombosis within the renal vein
<b>BD71.3</b>	<b>Iliac vein thrombosis</b> Venous thrombosis within the iliac veins.
<b>BD71.4</b>	<b>Lower limb deep vein thrombosis</b> Thrombosis within the deep venous system of the lower limb. <b>Inclusions:</b> deep vein thrombosis NOS
<b>BD71.Y</b>	<b>Other specified deep vein thrombosis</b>
<b>BD72</b>	<b>Venous thromboembolism</b>
<b>BD73</b>	<p><b>Acquired systemic vein abnormality</b> A postnatal pathological change in form or function of a systemic vein.</p> <p><b>BD73.0</b> <b>Acquired inferior caval vein abnormality</b> A postnatal pathological change in form or function of the inferior caval vein (inferior vena cava).</p> <p><b>Coded Elsewhere:</b> Inferior caval vein obstruction due to foreign body (BE1C)</p>

- BD73.1** **Acquired superior caval vein abnormality**  
A postnatal pathological change in form or function of the superior caval vein (superior vena cava).  
**Coded Elsewhere:** Superior caval vein obstruction due to foreign body (BE1D)
- BD73.2** **Systemic vein obstruction**  
A postnatal pathologic condition of a systemic vein in which flow is impeded or blocked due to narrowing or atresia.
- BD73.20** Obstruction of peripheral vein  
A postnatal pathologic condition of a peripheral vein in which flow is impeded or blocked due to narrowing or atresia.
- BD73.21** Obstruction of visceral vein  
A postnatal pathologic condition of a visceral vein in which flow is impeded or blocked due to narrowing or atresia.
- BD73.2Y** Other specified systemic vein obstruction
- BD73.2Z** Systemic vein obstruction, unspecified
- BD73.3** **Acquired coronary sinus abnormality**  
A postnatal pathologic change in form or function of the coronary sinus.
- BD73.Y** Other specified acquired systemic vein abnormality
- BD73.Z** Acquired systemic vein abnormality, unspecified
- BD74** **Chronic peripheral venous insufficiency of lower extremities**  
The presence of increased pressure in the peripheral venous system, particularly of the lower extremities. Peripheral venous hypertension may be due to incompetence of venous valves following deep vein thrombosis but other factors including obesity may also impair venous return. The consequences of chronic peripheral venous insufficiency include varicose veins, venous ulceration and lymphoedema.  
**Coded Elsewhere:** Lymphoedema due to venous insufficiency (BD93.10)
- BD74.0** **Uncomplicated lower limb venous hypertension**  
The presence of lower limb venous incompetence or hypertension as may be manifest by the presence of haemosiderin pigmentation of the skin, telangiectasia or finely dilated superficial veins.  
**Coded Elsewhere:** Lower limb venous telangiectases (EF20.2)

- BD74.1**      **Lower limb varicose veins**  
The commonest manifestation of chronic peripheral venous insufficiency, varicose veins present as dilatation and tortuosity of the superficial veins of the lower extremities. Incompetence of the superficial venous valve system impedes the return of venous blood to the heart. Chronically increased venous pressure causes symptoms like heaviness, discomfort, extremity fatigue, itching, and dull or burning pain.
- Inclusions:**      complicating: puerperium (JB41)
- Coded Elsewhere:** Varicose veins of lower extremity in pregnancy (JA61.0)
- BD74.10**      Varicose veins with great saphenous reflux  
Varicose veins associated with reflux within the great saphenous vein, normally as the result of valve incompetence: this can be due to congenitally weak valves or following injury from direct trauma or venous thrombosis.
- BD74.11**      Varicose veins with small saphenous reflux  
Varicose veins associated with reflux within the small saphenous vein, normally as the result of valve incompetence: this can be due to congenitally weak valves or following injury from direct trauma or venous thrombosis.
- BD74.12**      Varicose veins with non-truncal reflux  
Varicose veins associated with reflux sparing the main truncal veins of the lower limb.
- BD74.1Z**      Lower limb varicose veins, not further specified
- BD74.2**      **Lipodermatosclerosis**  
Lipodermatosclerosis is a form of panniculitis of the lower legs that develops in the context of venous insufficiency, giving rise to features that include oedema, erythema, hyperpigmentation and induration. In the acute phase tenderness, erythema and oedema predominate and may mimic cellulitis. As the condition becomes chronic, post-inflammatory pigmentation, fibrosis and lymphoedema predominate, sometimes resulting in the lower leg assuming an “inverted champagne bottle” appearance.
- BD74.3**      **Venous leg ulcer**  
Venous leg ulcers are chronic skin ulcers of the gaiter area (ankle and lower leg) due to chronic peripheral venous hypertension. They are often associated with other manifestations of chronic peripheral venous insufficiency of the lower extremities including lower limb varicose veins and lipodermatosclerosis.
- Inclusions:**      Gravitational ulcer  
                        Varicose ulcer
- BD74.30**      Primary venous leg ulcer  
A venous leg ulcer developing in skin without preceding episodes of ulceration.

<b>BD74.31</b>	Recurrent venous leg ulcer A venous leg ulcer developing in skin which has been damaged by previous episodes of ulceration. The chances of long-term healing are reduced in comparison with primary venous leg ulcers.
<b>BD74.32</b>	Healed venous leg ulcer
<b>BD74.3Z</b>	Venous leg ulcer, unspecified
<b>BD74.Z</b>	<b>Chronic peripheral venous insufficiency of lower extremities, unspecified</b>
<b>BD75</b>	<p><b>Venous varicosities of sites other than lower extremity</b></p> <p><b>Exclusions:</b>      retinal varices (9B78.1)                                  Duodenal varices (DA52.0)</p> <p><b>Coded Elsewhere:</b> Gastric varices (DA43.0)                                  Oesophageal varices (DA26.0)</p>
<b>BD75.0</b>	<p><b>Sublingual varices</b>           Varicose veins on the underside of the tongue</p>
<b>BD75.1</b>	<p><b>Scrotal varices</b>  <b>Inclusions:</b>      Varicocele of scrotum</p>
<b>BD75.2</b>	<p><b>Vulval varices</b>           Congested and dilated vulval veins, occurring particularly in association with pregnancy.</p> <p><b>Exclusions:</b>      complicating: childbirth and the puerperium (JB41)                                  Genital varices in pregnancy (JA61.1)</p>
<b>BD75.3</b>	<p><b>Pelvic varices</b>           The presence of dilated and incompetent ovarian and pelvic veins in women. These may cause no symptoms but may be associated with chronic pelvic pain (pelvic congestion syndrome) or with externally apparent vulvovaginal varicosities.</p>
<b>BD75.Y</b>	<b>Venous varicosities of other specified sites</b>
<b>BD75.Z</b>	<b>Venous varicosities of unspecified site</b>
<b>BD7Y</b>	<b>Other specified diseases of veins</b>
<b>BD7Z</b>	<b>Diseases of veins, unspecified</b>

## Disorders of lymphatic vessels or lymph nodes (BD90-BD9Z)

Disorders due to developmental and acquired disturbances of lymph circulation and drainage and to infective disorders of lymph vessels and nodes.

**Exclusions:** Enlarged lymph nodes (MA01)

**Coded Elsewhere:** Lymphatic malformations (LA90.1)

**BD90**

### Lymphadenitis

**Exclusions:** human immunodeficiency virus [HIV] disease resulting in generalized lymphadenopathy (1C60-1C62.Z)

Enlarged lymph nodes (MA01)

lymphadenopathy (MA01)

Malignant neoplasm metastasis in lymph nodes (2D60-2D6Z)

**BD90.0**

### Acute lymphadenitis

**Exclusions:** Nonspecific mesenteric lymphadenitis (BD90.1)

Chronic lymphadenitis (BD90.2)

human immunodeficiency virus [HIV] disease resulting in generalized lymphadenopathy (1C60-1C62.Z)

enlarged lymph nodes (MA01)

**BD90.1**

### Nonspecific mesenteric lymphadenitis

**BD90.2**

### Chronic lymphadenitis

**Exclusions:** Enlarged lymph nodes (MA01)

Nonspecific mesenteric lymphadenitis (BD90.1)

Tuberculosis of intrathoracic lymph nodes, confirmed bacteriologically or histologically (1B10.0)

Tuberculosis of intrathoracic lymph nodes, without mention of bacteriological or histological confirmation (1B10)

Tuberculous peripheral lymphadenopathy (1B12.6)

**BD90.20**

Chronic cervical lymphadenitis

**BD90.21**

Chronic axillary lymphadenitis

**BD90.22**

Chronic inguinal lymphadenitis

**BD90.2Y**

Other specified chronic lymphadenitis

**BD90.2Z**

Chronic lymphadenitis, unspecified

**BD90.Y**

Other specified lymphadenitis

**BD90.Z**

Lymphadenitis, unspecified

**BD91****Lymphangitis**

Lymphangitis is an inflammation of lymphatic vessels. It is most often caused by infection from bacteria, virus or fungus or infiltration by cancer cells.

**Coding Note:**

Code first any underlying infection.

**Exclusions:** Lymphocutaneous sporotrichosis (1F2J.0)

**Coded Elsewhere:** Ascending bacterial lymphangitis (1B70.3)

Sclerosing lymphangitis of penis (GB06.5)

**BD92****Lymphangiectasia****BD92.0****Intestinal lymphangiectasia**

Intestinal lymphangiectasia is a pathologic dilation of lymph vessels of intestinal mucosa. This results in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy.

**Coded Elsewhere:** Primary intestinal lymphangiectasia (LB15.Y)

**BD92.1****Cutaneous lymphangiectasia****BD92.Z****Lymphangiectasia, unspecified****BD93****Lymphoedema**

Swelling due to the excess accumulation of lymph in the tissues caused by inadequate lymph drainage. It typically affects the extremities but may involve any body site. It is disfiguring and increases susceptibility to recurrent infection and local malignancy.

**BD93.0****Primary lymphoedema**

Lymphoedema as a result of lymphatic vessel hypoplasia

**Coded Elsewhere:** Yellow nail syndrome (EE11.1)

Noonan syndrome (LD2F.15)

**BD93.1****Secondary lymphoedema**

Lymphoedema as a result of an identifiable cause that renders insufficient the function of existing lymphatic vessels.

**Coding Note:**

Code also the causing condition

**BD93.10****Lymphoedema due to venous insufficiency**

Permanent lymphoedema, usually of the lower extremities, resulting from venous hypertension and chronic gravitational oedema.

**Coding Note:**

Code also the causing condition

**BD93.11****Lymphoedema due to dependency and immobility**

Lymphoedema occurring in immobile individuals with reduced muscle pump activity as a result of paralysis or infirmity. It is particularly liable to develop in those who are unable to sleep recumbent.

**Coding Note:**

Code also the causing condition

<b>BD93.12</b>	Lymphoedema due to obesity Lymphoedema resulting from morbid obesity. Lymphoedema of the lower limbs and lymphoedema of the abdominal apron fold are common sequelae of chronic morbid obesity.
<b>Coding Note:</b>	Code also the causing condition
<b>BD93.13</b>	Lymphoedema due to lymphatic filariasis Lymphoedema resulting from infestation of lymphatics by nematode worms of the genera Wuchereria and Brugia. This is the commonest cause of lymphoedema worldwide. The lymphoedema may present years after initial infection and most commonly affects the legs and male genitalia.
<b>Coding Note:</b>	Code also the causing condition
<b>BD93.14</b>	Lymphoedema due to podoconiosis Lymphoedema of the lower limbs resulting from an inflammatory response within lymphatic vessels to mineral particles from soil in genetically susceptible individuals. It is a leading cause of lower limb lymphoedema in farmers in Africa, Central America and India.
<b>Coding Note:</b>	Code also the causing condition
<b>BD93.15</b>	Lymphoedema due to malignant infiltration Lymphoedema resulting from obstruction of draining lymphatics as a result of infiltration by malignant, usually metastatic cells.
<b>Coding Note:</b>	Code also the causing condition
<b>BD93.1Y</b>	Lymphoedema secondary to other specified cause
<b>Coding Note:</b>	Code also the causing condition
<b>BD93.1Z</b>	Secondary lymphoedema, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>BD93.Y</b>	<b>Other specified forms of lymphoedema</b>
<b>BD93.Z</b>	<b>Lymphoedema, unspecified</b>
<b>BD9Y</b>	<b>Other specified disorders of lymphatic vessels or lymph nodes</b>
<b>BD9Z</b>	<b>Disorders of lymphatic vessels or lymph nodes, unspecified</b>

## Postprocedural disorders of circulatory system (BE10-BE1F.1)

This refers to postprocedural disorders of the organ system that passes nutrients (such as amino acids, electrolytes and lymph), gases, hormones, blood cells, etc. to and from cells in the body to help fight diseases, stabilize body temperature and pH, and to maintain homeostasis, not elsewhere classified.

**Coded Elsewhere:** Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)

- Prosthetic valve disease (BC01)
- Coronary artery fistula, acquired (BA83)
- Dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified (NE82)
- Postprocedural complete atrioventricular block (BC63.21)
- Postprocedural obstructed systemic venous pathway (BD73.2Y)
- Postprocedural left pulmonary artery stenosis (BB02.3)
- Postprocedural inferior caval vein complication (BD73.0)
- Postprocedural superior caval vein complication (BD73.1)
- Postoperative junctional ectopic tachycardia (BC81.1)

### BE10

#### **Postcardiotomy syndrome**

Postcardiotomy syndrome is a hypersensitivity reaction to antigen derived from injured myocardium 3 weeks to 2 months after myocardial infarction, cardiac surgery, or penetrating and non penetrating heart injury. The diagnosis is made by history of heart injury, and exclusion of other diseases such as congestive heart failure, recurrent myocardial infarction, endocarditis, myocarditis, and pericarditis.

### BE11

#### **Other functional disturbances following cardiac surgery**

### BE12

#### **Postprocedural valve disorders**

##### BE12.0

#### **Postprocedural mitral valve stenosis**

##### BE12.1

#### **Postprocedural mitral valve insufficiency**

This is a postprocedural disorder of the heart in which the mitral valve does not close properly when the heart pumps out blood. It is the abnormal leaking of blood from the left ventricle, through the mitral valve, and into the left atrium, when the left ventricle contracts, i.e. there is regurgitation of blood back into the left atrium.

##### BE12.2

#### **Postprocedural aortic valve stenosis**

**Coded Elsewhere:** Stenosis of the neoaortic valve of pulmonary origin (BC02.30)

##### BE12.3

#### **Postprocedural aortic valve insufficiency**

This refers to postprocedural aortic valve of the heart that causes blood to flow in the reverse direction during ventricular diastole, from the aorta into the left ventricle.

**Coded Elsewhere:** Insufficiency of the neoaortic valve of pulmonary origin (BC02.31)

##### BE12.4

#### **Postprocedural tricuspid valve stenosis**

- BE12.5 Postprocedural tricuspid valve insufficiency**  
This refers to the postprocedural failure of the heart's tricuspid valve to close properly during systole. As a result, with each heart beat some blood passes from the right ventricle to the right atrium, the opposite of the normal direction.
- BE12.6 Postprocedural pulmonary valve stenosis**
- BE12.7 Postprocedural pulmonary valve insufficiency**
- BE13 Postprocedural true or false aortic aneurysm**  
This refers to postprocedural true and false swelling (dilation or aneurysm) of the aorta to greater than 1.5 times normal, usually representing an underlying weakness in the wall of the aorta at that location.
- BE14 Postprocedural disorder of circulatory system following repair of congenital heart or great vessel anomaly**
- BE14.4 Acquired abnormality of the neopulmonary valve**  
A postnatal pathological change in form or function of the neopulmonary valve, that is, the native aortic valve that has become the functional neopulmonary valve after the arterial switch operation.
- BE14.40 Neopulmonary valve stenosis**  
Acquired obstruction to flow through the neopulmonary valve, that is, the native aortic valve that has become the functional neopulmonary valve after the arterial switch operation.  
**Exclusions:** Postprocedural pulmonary valve stenosis (BE12.6)
- BE14.41 Neopulmonary valve regurgitation**  
Acquired backward flow through the neopulmonary valve, that is, the native aortic valve that has become the functional neopulmonary valve after the arterial switch operation.  
**Exclusions:** Postprocedural pulmonary valve insufficiency (BE12.7)
- BE14.5 Postprocedural right-sided atrioventricular valvar abnormality in double-inlet ventricle**  
A postnatal pathological change in form or function of the right-sided atrioventricular valve in double inlet ventricle that occurred during or after an intervention.
- Coding Note:** Includes: right ventricular component and right-sided atrioventricular valve within a common atrioventricular junction (atrioventricular septal defect).  
**Exclusions:** Congenital anomaly of an atrioventricular valve or atrioventricular septum (LA87)

BE14.6	<b>Postprocedural left-sided atrioventricular valvar abnormality in double-inlet ventricle</b> A postnatal pathological change in form or function of the left-sided atrioventricular valve in double inlet ventricle that occurred during or after an intervention.
<b>Coding Note:</b>	Includes: left ventricular component and left-sided atrioventricular valve within a common atrioventricular junction (atrioventricular septal defect) in the setting of double inlet ventricle
	<b>Exclusions:</b> Congenital anomaly of an atrioventricular valve or atrioventricular septum (LA87)
BE14.7	<b>Postprocedural common atrioventricular valvar abnormality in double-inlet ventricle</b> A postnatal pathological change in form or function of the common atrioventricular valve in double inlet ventricle that occurred during or after an intervention.
BE14.8	<b>Postprocedural ventricular septal defect disorder</b> An event or occurrence affecting a ventricular septal defect that is associated with a healthcare intervention, is a departure from the desired course of events, and may cause, or be associated with, a suboptimal outcome.
BE14.9	<b>Postprocedural aortic disorder related to congenital heart anomaly</b> An event or occurrence affecting the aorta consequent to the presence of congenital cardiovascular disease, that is associated with a healthcare intervention, is a departure from the desired course of events, and may cause, or be associated with, a suboptimal outcome.
BE14.A	<b>Postprocedural arterial duct disorder</b> An event or occurrence affecting the arterial duct (ductus arteriosus) that is associated with a healthcare intervention, is a departure from the desired course of events, and may cause, or be associated with, a suboptimal outcome.
BE14.B	<b>Postprocedural disorder following cardiovascular conduit or shunt procedure</b>
<b>BE15</b>	<b>Postprocedural pulmonary arterial tree disorder</b> An event or occurrence affecting the pulmonary arterial tree that is associated with a healthcare intervention, is a departure from the desired course of events, and may cause, or be associated with, a suboptimal outcome.
BE15.0	<b>Postprocedural pulmonary trunk stenosis</b> Discrete narrowing of the luminal diameter of the pulmonary trunk (main pulmonary artery) (below the lower limit of normal adjusted for body size) that occurs during or after an intervention.
BE15.1	<b>Postprocedural right pulmonary artery stenosis</b> Discrete narrowing of the luminal diameter of one or more segments of the right pulmonary artery (below the lower limit of normal adjusted for body size) that occurs during or after an intervention.

**BE16****Postprocedural pulmonary venous disorder**

An event or occurrence affecting one or more pulmonary vein(s) that is associated with a healthcare intervention, is a departure from the desired course of events, and may cause, or be associated with, a suboptimal outcome.

**BE17****Postprocedural residual or recurrent interatrial communication**

A persistent or recurrent hole or pathway between the atrial chambers, including intentional residual communications.

**BE19****Postprocedural ventricular abnormality****BE1A****Cardiac transplant associated coronary allograft vasculopathy**

Coronary artery intimal proliferation following cardiac transplantation, defined based on a combination of visual angiographic vessel descriptors in concert with measures of cardiac allograft function, according to the International Society for Heart and Lung Transplantation.

**BE1B****Lymphoedema due to surgery or radiotherapy**

Lymphoedema resulting from damage to draining lymphatics as a result of surgery or radiotherapy.

**BE1B.0****Postmastectomy lymphoedema syndrome****BE1B.1****Lymphoedema due to other medical or surgical procedures****BE1C****Inferior caval vein obstruction due to foreign body**

A postnatal pathologic condition of the inferior caval vein (inferior vena cava) in which flow is impeded or blocked by a foreign body.

**BE1D****Superior caval vein obstruction due to foreign body**

A postnatal pathologic condition of the superior caval vein (superior vena cava) in which flow is impeded or blocked by a foreign body.

**BE1E****Postprocedural right atrial complication**

An event or occurrence affecting the morphologically right atrium that is associated with a healthcare intervention, is a departure from the desired course of events, and may cause, or be associated with, a suboptimal outcome

**BE1E.0****Postprocedural right atrial perforation**

Perforation of the morphologically right atrial wall that occurred during or after an intervention

**BE1E.1****Right atrial erosion due to implanted device**

Injury of the morphologically right atrial wall occurring as a direct result of chronic friction from an implanted device or wire

**BE1F****Postprocedural left atrial complication**

An event or occurrence affecting the morphologically left atrium that is associated with a healthcare intervention, is a departure from the desired course of events, and may cause, or be associated with, a suboptimal outcome

- BE1F.0**      **Postprocedural left atrial perforation**  
Perforation of the morphologically left atrial wall that occurred during or after an intervention
- BE1F.1**      **Left atrial erosion due to implanted device**  
Injury of the morphologically left atrial wall occurring as a direct result of chronic friction from an implanted device or wire
- BE2Y**      **Other specified diseases of the circulatory system**
- BE2Z**      **Diseases of the circulatory system, unspecified**

# CHAPTER 12

---

## Diseases of the respiratory system

This chapter has 79 four-character categories.

Code range starts with CA00

- Exclusions:**
- Endocrine, nutritional or metabolic diseases (Chapter 05)
  - Congenital malformations, deformations and chromosomal abnormalities (Chapter 20)
  - Injury, poisoning or certain other consequences of external causes (Chapter 22)
  - Certain conditions originating in the perinatal period (Chapter 19)
  - Certain infectious or parasitic diseases (Chapter 01)
  - Complications of pregnancy, childbirth and the puerperium (Chapter 18)

- Coded Elsewhere:**
- Neoplasms of the respiratory system
  - Developmental respiratory diseases
  - Symptoms, signs or clinical findings of the respiratory system (MD10-MD6Y)
  - Pulmonary heart disease or diseases of pulmonary circulation (BB00-BB0Z)
  - Sleep-related breathing disorders (7A40-7A4Z)
  - Diseases of the respiratory system complicating pregnancy, childbirth or the puerperium (JB64.5)

This chapter contains the following top level blocks:

- Upper respiratory tract disorders
- Certain lower respiratory tract diseases
- Lung infections
- Lung diseases due to external agents
- Respiratory diseases principally affecting the lung interstitium
- Pleural, diaphragm or mediastinal disorders
- Postprocedural disorders of the respiratory system
- Neoplasms of the respiratory system
- Developmental respiratory diseases

## Upper respiratory tract disorders (CA00-CA0Z)

This group of disorders refers to diseases of the upper airways (upper respiratory tract). The upper airways anatomically are complicated structures which extend from the airway openings at the nares and lips to the trachea. The term upper airways includes several anatomically distinct regions. The nose constitutes the upper segment, followed by the nasopharyngeal and oropharyngeal airways, which extend from the nasal choanae and oral cavity to the supraglottic space. The paranasal sinuses drain into the nasal cavities and are attached to the lateral, posterior, and superior aspects of the nose. The larynx divides the upper and lower airways, although some place it in the thoracic inlet.

**Exclusions:** Chronic obstructive pulmonary disease with acute exacerbation, unspecified (CA22.0)

**CA00**

### Acute nasopharyngitis

A disease of the upper respiratory tract, caused by an infection with rhinovirus. This disease is characterised by pharyngitis, runny nose, stuffy nose, or cough. Transmission is by inhalation of infected respiratory secretions, or direct contact.

**Exclusions:** Chronic nasopharyngitis (CA09.1)  
pharyngitis NOS (CA02)  
Acute pharyngitis (CA02)  
Chronic pharyngitis (CA09.2)  
rhinitis NOS (CA09.0)  
sore throat NOS (CA00-CA0Z)  
Vasomotor rhinitis (CA08.3)  
Chronic rhinitis (CA09.0)  
Allergic rhinitis (CA08.0)  
acute sore throat (CA02)  
chronic sore throat (CA09.2)

**CA01**

### Acute sinusitis

Recent onset and/or short duration inflammation of the mucosa in one or more of the paranasal sinuses (maxillary, ethmoid, frontal and sphenoid) arising from infection or other causes such as caries or injury to the teeth. Purulent discharge can be seen at the middle meatus and olfactory cleavage and patients complain of dysosmia, stuffy nose, fever, or localised tenderness or pain. Allergic rhinitis, nasal septum deformity or hypertrophic rhinitis are underlying diseases that may induce acute sinusitis.

**Exclusions:** sinusitis, chronic or NOS (CA0A)

**CA02**

### **Acute pharyngitis**

Acute pharyngitis is defined as an infection or irritation of the pharynx and/or tonsils and is a part of the common cold symptoms. The etiology is usually infectious, with most cases being of viral origin. Although virus infection is the primary cause, it is also caused by bacterial infection. The discomfort of a throat, a throat pain and swallowing pain often occur. Headache, general fatigueness, radiating pain to the ear and a cervical lymphadenitis also occur. Local finding demonstrates hyperaemic palatine tonsils and swelling of lymphoid follicles of posterior wall of pharynx. Patients with acute pharyngitis present most commonly with a sore throat. Other various symptoms can rise in these patients depending on their causing organisms.

**Inclusions:** acute sore throat

**Exclusions:** Acute laryngopharyngitis (CA04)

Peritonsillar abscess (CA0K.1)

Chronic pharyngitis (CA09.2)

Retropharyngeal or parapharyngeal abscess (CA0K.0)

**Coded Elsewhere:** Streptococcal pharyngitis (1B51)

Meningococcal pharyngitis (1C1C.Y)

**CA02.0**

### **Acute pharyngitis due to other bacteria**

Rapid onset inflammation of the pharynx, (back of the throat, between the tonsils and the voicebox (larynx)) due to a specifically identified organism not classified elsewhere.

**Exclusions:** Viral infections characterised by skin or mucous membrane lesions (1E70-1F0Z)

**Coded Elsewhere:** Gonococcal pharyngitis (1A72.3)

**CA02.1**

### **Acute viral pharyngitis**

**Coded Elsewhere:** Enteroviral vesicular pharyngitis (1F05.1)

**CA02.10**

### **Pharyngitis due to Adenovirus**

Pharyngitis is an inflammation of the mucous membranes and underlying structures of the throat. Adenoviral pharyngitis is a self-limiting disease associated with fever, erythema of the pharynx, enlarged tonsils with exudate and enlarged cervical lymph nodes accompanied by fever, malaise, myalgia and abdominal pain. Frequently occurs with self-limiting conjunctivitis (refer to pharyngoconjunctival fever), laryngotracheitis, bronchitis and pneumonia.

**CA02.1Y**

Other specified acute viral pharyngitis

**CA02.1Z**

Acute viral pharyngitis, unspecified

**CA02.Y**

**Other specified acute pharyngitis**

**CA02.Z**

**Acute pharyngitis, unspecified**

<b>CA03</b>	<b>Acute tonsillitis</b>
	<p><b>Exclusions:</b> Streptococcal pharyngitis (1B51)            Acute pharyngitis (CA02)            Peritonsillar abscess (CA0K.1)</p>
<b>CA03.0</b>	<b>Streptococcal tonsillitis</b>
	A disease of the tonsils, caused by an infection with the gram-positive bacteria Streptococcus pyogenes (Streptococcus group A). This disease is characterised by a sore throat, fever, tonsillar exudates, or cervical adenopathy. This disease may also present with odynophagia, dysphagia, otalgia, dry tongue, erythematous, enlarged tonsils, or yellowish white spots on the tonsils. Transmission is commonly by inhalation of infected respiratory secretions or indirect contact. Confirmation is by identification of Streptococcus group A from a throat swab.
<b>CA03.Y</b>	<b>Other specified acute tonsillitis</b>
<b>CA03.Z</b>	<b>Acute tonsillitis, unspecified</b>
<b>CA04</b>	<b>Acute laryngopharyngitis</b>
	The most common upper respiratory tract infection is the common cold however, infections of laryngopharynx is also considered upper respiratory tract infections, of multiple sites.
<b>CA05</b>	<b>Acute laryngitis or tracheitis</b>
	Acute laryngitis and tracheitis are defined respectively as acute inflammation of larynx and trachea, with local findings of erythema, and oedema of laryngeal and tracheal mucosa. Acute laryngitis and tracheitis are induced by upper respiratory tract viral infections or voice abuse.
	<p><b>Exclusions:</b> Laryngismus (stridulus) (CA0H.4)            Acute obstructive laryngitis or epiglottitis (CA06)</p>
<b>CA05.0</b>	<b>Acute laryngitis</b>
	Rapid onset inflammation of the laryngeal mucosa, including the vocal cords. It is frequently characterised by irritation, oedema, and reduced pliability of the mucosa.
	<p><b>Exclusions:</b> Chronic laryngitis (CA0G)            Acute obstructive laryngitis or epiglottitis (CA06)</p>
<b>CA05.1</b>	<b>Acute tracheitis</b>
	This condition refers to the acute inflammation of the trachea.
	<p><b>Exclusions:</b> Chronic tracheitis (CA20.1)  <b>Coded Elsewhere:</b> Neonatal tracheitis (KB25)</p>
<b>CA05.2</b>	<b>Acute laryngotracheitis</b>
	Acute laryngotracheitis refers to the acute inflammation of both the larynx (laryngitis) and trachea (tracheitis).
	<p><b>Exclusions:</b> Chronic laryngitis or laryngotracheitis (CA0G)</p>
<b>CA06</b>	<b>Acute obstructive laryngitis or epiglottitis</b>

<b>CA06.0</b>	<b>Acute obstructive laryngitis</b> A condition commonly caused by an acute viral infection of the upper airway. This condition is characterised by a barking cough, stridor, hoarseness, or difficulty breathing. Transmission is commonly by inhalation of infected respiratory secretions.
	<b>Inclusions:</b> croup
<b>CA06.1</b>	<b>Acute epiglottitis</b> Acute epiglottitis is a special type of laryngeal inflammation, being characterised with a local swelling of epiglottis mucosa. Haemophilus influenzae type B infection is considered an important causative factor. Particularly in children, rapid exacerbation of dyspnoea can occur a couple of hours after the onset of this disease.
<b>CA06.Z</b>	<b>Acute obstructive laryngitis or epiglottitis, unspecified</b>
<b>CA07</b>	<b>Acute upper respiratory infections of multiple and unspecified sites</b>
	<b>Exclusions:</b> Influenza, virus not identified (1E32) influenza virus, identified (1E30)
<b>CA07.0</b>	<b>Acute upper respiratory infection, site unspecified</b>
<b>CA07.1</b>	<b>Acute upper respiratory infections of multiple sites</b>
<b>Coding Note:</b>	Assign additional codes for the specific infections.
<b>CA08</b>	<b>Vasomotor or allergic rhinitis</b> Rhinitis is inflammation of the nasal mucosa clinically characterised by major symptoms: sneezing, nasal pruritus, running nose, and stuffy nose.  Allergic rhinitis is an inflammation of nasal airway triggered by allergens to which the affected individual has previously been sensitized. Pathogenesis of allergic rhinitis is type I allergy on the nasal mucosa. Antigens inhaled into sensitized nasal mucosa bind to IgE antibodies on mast cells, which release chemical mediators such as histamine and peptide leukotriene. Consequently terminal of sensory neurons and vessels react to induce sneezing, running nose, and stuffy nose (immediate phase reaction). In late phase reaction, various chemical mediators are produced by mast cells, cytokines are produced by Th2 and mast cells, and chemokines are produced by epithelial cells, endothelium of blood vessels, and fibrocytes, respectively. These cell-derived transmitters actually induce various cell types of inflammatory cell infiltration to nasal mucosa. Among them, activated eosinophils is the main player of mucosal swelling and hyperreactivity.  Non-allergic rhinitis is an inflammation of nasal mucosa in which allergic mechanisms are not involved. It covers many different phenotypes.  <b>Exclusions:</b> rhinitis NOS (CA09.0)

<b>CA08.0</b>	<b>Allergic rhinitis</b> Allergic rhinitis is an inflammation of nasal airway triggered by allergens to which the affected individual has previously been sensitized. Pathogenesis of allergic rhinitis is type I allergy on the nasal mucosa. Antigens inhaled into sensitized nasal mucosa bind to IgE antibodies on mast cells, which release chemical mediators such as histamine and peptide leukotriene. Consequently terminal of sensory neurons and vessels react to induce sneezing, running nose, and stuffy nose (immediate phase reaction). In late phase reaction, various chemical mediators are produced by mast cells, cytokines are produced by Th2 and mast cells, and chemokines are produced by epithelial cells, endothelium of blood vessels, and fibrocytes, respectively. These cell-derived transmitters actually induce various cell types of inflammatory cell infiltration to nasal mucosa. Among them, activated eosinophils is the main player of mucosal swelling and hyperreactivity.
<b>CA08.00</b>	Allergic rhinitis due to pollen This condition is an allergic inflammation of the nasal airways. It occurs when an allergen, such as pollen, is inhaled by an individual with a sensitized immune system.
	<b>Inclusions:</b> Pollinosis
<b>CA08.01</b>	Allergic rhinitis due to other seasonal allergens This refers to other allergic inflammation of the nasal airways in patients with proven allergy to other allergens besides pollens and house dust mite, with multiple sensitization or as a component of complex conditions such as latex allergy. Clinically characterised by major symptoms: sneezing, nasal pruritus, running nose, and stuffy nose. It occurs when an allergen, such as animal dander (particles of shed skin and hair), insect (cockroach body particles), fungal particles, is inhaled by an individual with a sensitized immune system.
<b>CA08.02</b>	Allergic rhinitis due to house dust mite Allergic rhinitis triggered by the exposure to house dust mite allergens to which the affected individual has previously been sensitized.
<b>CA08.03</b>	Other allergic rhinitis This refers to other allergic inflammation of the nasal airways. It occurs when an allergen, such as pollen, dust or animal dander (particles of shed skin and hair) is inhaled by an individual with a sensitized immune system.
<b>CA08.0Z</b>	Allergic rhinitis, unspecified
<b>CA08.1</b>	<b>Non-allergic rhinitis</b> Non-allergic rhinitis is an inflammation of nasal mucosa in which allergic mechanisms are not involved. It covers many different phenotypes. <b>Coded Elsewhere:</b> Drug-induced rhinitis (4A85.0Y)

- CA08.10** Non-allergic rhinitis with eosinophils  
The non-allergic rhinitis with eosinophils is characterised by large numbers (inconsistently defined as >5% to >20%) of eosinophils on nasal smear. Patients usually have paroxysmal exacerbations of symptoms, including sneezing, profuse watery rhinorrhoea, nasal pruritus, nasal congestion, and occasional anosmia. It may precede the development of nasal polyposis and aspirin hypersensitivity. Patients with non-allergic rhinitis with eosinophils are at increased risk for the development of obstructive sleep apnoea.
- CA08.1Y** Other specified non-allergic rhinitis
- CA08.1Z** Non-allergic rhinitis, unspecified
- CA08.2** **Mixed rhinitis**  
Mixed rhinitis is a specific rhinitis subtype that combines characters of allergic rhinitis and non-infectious non-allergic rhinitis. It may represent between 50 and 70% of all allergic rhinitis cases.
- CA08.3** **Vasomotor rhinitis**  
Vasomotor rhinitis is a form of non-allergic inflammation of the nasal mucosa that is characterised by nasal congestion and posterior pharyngeal drainage. The non-allergic triggers cause dilation of the blood vessels in the lining of the nose, which results in swelling, and drainage.
- CA08.Y** **Mixed allergic and non-allergic rhinitis**
- CA08.Z** **Rhinitis, unspecified whether allergic or nonallergic**
- CA09** **Chronic rhinitis, nasopharyngitis or pharyngitis**  
The pathological condition of chronic rhinitis is a continuation of persistent inflammation on nasal turbinate mucosae, which is induced by microbial infection, irritation with inhaled substances and abnormal structure of nasal cavity. This condition induces nasal obstruction and increased nasal discharge. Pharyngitis is an inflammation of whole pharyngeal mucosa and lymphatic tissues and its acute symptoms are a part of the common cold symptoms. Although viral infection is the primary cause, it is also caused by bacterial infections. The discomfort of throat, throat pain and swallowing pain occur. Headache, general fatigueness, radiating pain to the ear and a cervical lymphadenitis also occur. Local finding demonstrates hyperaemic palatine tonsils and swelling of lymphoid follicles of posterior wall of pharynx. Chronic pharyngitis can be considered as a consequence of acute pharyngitis or effect of continuous stimuli, with symptoms of abnormal sensation of throat, discomfort, and foreign body sensation.
- CA09.0** **Chronic rhinitis**  
Persistent or recurrent inflammation of the nasal mucosa.  
**Exclusions:** Vasomotor rhinitis (CA08.3)  
Allergic rhinitis (CA08.0)

<b>CA09.1</b>	<b>Chronic nasopharyngitis</b> Persistent or recurrent inflammation of the top portion of the pharynx situated posterior to the nose and superior to the soft palate, usually including its mucosa, related lymphoid structure, and glands.  <b>Exclusions:</b> Acute nasopharyngitis (CA00)
<b>CA09.2</b>	<b>Chronic pharyngitis</b> Persistent or recurrent inflammation of the pharynx; the funnel-shaped fibromuscular tube which conducts food to the oesophagus and air to the larynx.  <b>Inclusions:</b> Chronic sore throat  <b>Exclusions:</b> Acute pharyngitis (CA02)
<b>CA0A</b>	<b>Chronic rhinosinusitis</b> Sinusitis is an inflammation of the mucosal lining of the paranasal sinuses secondary to both infectious and allergic mechanisms. The retention of sinus secretions is the most important event in the development of sinusitis. This creates a favourable milieu for the growth of infection agents and may be caused by the obstruction or narrowing of sinus ostia, mucociliary dysfunction and changes in mucus composition. 90% of sinus infections involve the maxillary sinus. Chronic sinusitis refers to symptom duration lasting 3 months or more. Diagnosis of sinusitis is based on past history and physical examination findings. The CT scan is the most sensitive technique in evaluating sinus disease. The goals of management of chronic sinusitis are to eradicate infection, to relieve ostiomeatal obstruction, to normalize mucociliary clearance, and to prevent complications. When pharmaceutical treatment does not have any remarkable improvement or when a surgical approach can be chosen as patient's complication, surgical intervention should be aimed to establish an effective sinus drainage from the ostium. Functional endoscopic sinus surgery (FESS) describes endoscopic techniques that have revolutionized the approach to sinus disease. The procedure is aimed at restoring the functional physiology of sinus aeration and drainage via the expanded ostiomeatal complex while minimizing surgical alteration of the normal anatomic pathways.  <b>Exclusions:</b> Acute sinusitis (CA01)
<b>CA0A.0</b>	<b>Samter syndrome</b> Samter syndrome is composed of asthma, aspirin intolerance, nasal polyps and chronic rhinosinusitis.
<b>CA0A.Y</b>	<b>Other specified chronic rhinosinusitis</b>
<b>CA0A.Z</b>	<b>Chronic rhinosinusitis, unspecified</b>
<b>CA0B</b>	<b>Silent sinus syndrome</b> Silent sinus syndrome is a spontaneous, asymptomatic collapse of the maxillary sinus and orbital floor associated with negative sinus pressures.

**CA0C****Cyst or mucocele of nose or nasal sinus**

A condition which refers to diseases of the nose and nasal sinus that cause a cyst or mucocele.

A mucocele is any dilatation (typically pathologic) with accumulation of mucus. Mucoceles are benign, epithelium-lined cysts filled with mucus, which can form in the paranasal sinuses. These structures may cause symptoms if sufficiently large or if exerting pressure on surrounding anatomic structures. Symptomatic mucoceles typically require surgical intervention. Mucoceles should be differentiated from sinus retention cysts. Unlike mucoceles, sinus retention cysts do not result in expansion and thinning of the bony sinus walls.

**CA0D****Deviated nasal septum****CA0E****Hypertrophy of nasal turbinates****CA0F****Chronic diseases of tonsils or adenoids**

Any persistent or recurrent disease affecting the round-to-oval mass of lymphoid tissue embedded in the lateral wall of the pharynx (tonsils) or the collection of lymphoid nodules on the posterior wall and roof of the nasopharynx (adenoids)

*Exclusions:* Recurrent acute tonsillitis (CA03)

**CA0F.0****Hypertrophy of tonsils**

*Inclusions:* Enlargement of tonsils

**CA0F.1****Hypertrophy of adenoids**

*Inclusions:* Enlargement of adenoids

**CA0F.3****Hypertrophy of tonsils with hypertrophy of adenoids**

This is an excessive growth ("hypertrophy") of the tissue of tonsils and adenoids.

**CA0F.Y****Other specified chronic diseases of tonsils or adenoids****CA0F.Z****Chronic diseases of tonsils or adenoids, unspecified****CA0G****Chronic laryngitis or laryngotracheitis**

Persistent or recurrent inflammation of the larynx (airway) and/or the larynx and the cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi (trachea).

**CA0H****Diseases of vocal cords or larynx, not elsewhere classified**

*Exclusions:* stridor: NOS (MD11.B)

laryngitis: ulcerative (CA05.0)

Acute obstructive laryngitis (CA06.0)

Postprocedural subglottic stenosis (CB62)

<b>CA0H.0</b>	<b>Paralysis of vocal cords or larynx</b> Loss of function or feeling of one or both of the vocal folds, often caused by injury or disease to the nerves of the larynx.  <b>Coded Elsewhere:</b> Acquired vocal cord paralysis in newborn (KB2H) Congenital laryngeal palsy (LA71.Y)
<b>CA0H.1</b>	<b>Polyp of vocal cord or larynx</b> A polyp is an abnormal growth of tissue projecting from a mucous membrane, in this condition it is of the vocal cord and larynx.  <b>Exclusions:</b> adenomatous polyps (2F00)
<b>CA0H.2</b>	<b>Nodules of vocal cords</b>
<b>CA0H.3</b>	<b>Oedema of larynx</b> Laryngeal oedema is oedema (accumulation of fluid) which may occur for example in asaryepiglottic folds, epiglottis, the arytenoid region or submucosal of the subglottic region. It may occur due to anaphylaxis, angioneurotic oedema, larynx infection, foreign body or substance, or injury.  <b>Exclusions:</b> oedematous laryngitis (CA05.0) laryngitis: acute obstructive [croup] (CA06.0)
<b>CA0H.4</b>	<b>Laryngeal spasm</b> Laryngeal spasm is a pathological condition that is mainly a spasmodic closure (spasm) of the inlet portion of the larynx or the glottic region. There is an adult-onset and childhood (infant)-onset generally in this disease. There is a difference in the pattern of expression for these two types. In the infant, respiratory arrest is associated with this condition and spasmodic closure of the glottis occurs suddenly, and then breathing returns to original quite rapidly within a few minutes. In adults, the main symptoms of this condition are difficulty breathing or inspiratory stridor rather than a complete respiratory arrest.  <b>Inclusions:</b> laryngospasm
<b>CA0H.5</b>	<b>Stenosis of larynx</b> Laryngeal stenosis is an abnormal narrowing within the cavity of the larynx.
<b>CA0H.Y</b>	<b>Other specified diseases of vocal cords or larynx, not elsewhere classified</b>
<b>CA0H.Z</b>	<b>Diseases of vocal cords or larynx, not elsewhere classified, unspecified</b>
<b>CA0J</b>	<b>Nasal polyp</b> Nasal polyp is an inflammatory and proliferating mass arising from the epithelial linings of nasal cavity and paranasal sinuses. In general, nasal polyp appears to be greyish white, smoothly surfaced, and glutinous and agar-like mass. The pathogenesis is thought to be multifactorial.  <b>Exclusions:</b> adenomatous polyps (2F00)

<b>CA0J.0</b>	<b>Polypoid sinus degeneration</b>
	Also referred to as Woakes' syndrome or ethmoiditis. Woakes' syndrome is characterised by severe recurrent nasal polyps, often without eosinophils on histological examination and with broadening of the nose.
<b>CA0J.Y</b>	<b>Other specified nasal polyp</b>
<b>CA0J.Z</b>	<b>Nasal polyp, unspecified</b>
<b>CA0K</b>	<p><b>Abscess of upper respiratory tract</b></p> <p>Abscess of upper respiratory tract is defined as abscess formation which occurs from nose to pharynx and larynx. Abscess, furuncle and carbuncle of nose, retropharyngeal, parapharyngeal abscess and other abscess of pharynx are included in this classification.</p>
<b>CA0K.0</b>	<p><b>Retropharyngeal or parapharyngeal abscess</b></p> <p>A retropharyngeal abscess is an abscess located in the tissues in the back of the throat behind the posterior pharyngeal wall (the retropharyngeal space). A parapharyngeal abscess is an abscess developing in the potential space in the head and the neck.</p> <p><b>Exclusions:</b> Peritonsillar abscess (CA0K.1)</p>
<b>CA0K.1</b>	<p><b>Peritonsillar abscess</b></p> <p>Peritonsillar abscess is defined with abscess formation between the tonsillar capsule and the tonsillar constrictor muscles. Peritonsillar abscess mostly comes from peritonsillitis. Fever rise, pharyngeal pain and swallowing pain are the main symptoms, but, it also causes a muffled voice. Uvula is deviated to the unaffected side and swelling and redness around the affected tonsil is remarkable. Bacterial examination from the peritonsillar pus often reveal streptococcus group A beta-haemolytic as the aerobic bacteria and the detection rate of anaerobic bacteria also amounted to more than half. The treatment consists of antimicrobial therapy and incision and drainage of the abscess. The symptoms improve with above treatment in the most cases, while in some cases the abscess proceeds to a deadly deep neck infection and mediastinal abscess. If there are systemic complications such as diabetes mellitus, special attention is required.</p> <p><b>Inclusions:</b> Quinsy</p> <p><b>Exclusions:</b> Acute tonsillitis (CA03) Chronic tonsillitis (CA0F) tonsillitis, NOS (CA03) retropharyngeal abscess (CA0K.0)</p>
<b>CA0K.Y</b>	<b>Other specified abscess of upper respiratory tract</b>
<b>CA0K.Z</b>	<b>Abscess of upper respiratory tract, unspecified</b>
<b>CA0Y</b>	<b>Other specified upper respiratory tract disorders</b>
<b>CA0Z</b>	<b>Upper respiratory tract disorders, unspecified</b>

## Certain lower respiratory tract diseases (CA20-CA2Z)

This group refers to diseases of airways that forms the connection between the outside world and the terminal respiratory unit. Intrapulmonary airways are divided into three major groups; bronchi, membranous bronchiole, and respiratory bronchiole/gas exchange ducts.

**Coded Elsewhere:** Acute tracheitis (CA05.1)

Whooping cough (1C12)

Chronic respiratory disease originating in the perinatal period (KB29)

**CA20**

### **Bronchitis**

Bronchitis is inflammation of the main air passages to the lungs.

**Coding Note:** Excludes acute infectious bronchitis

**Exclusions:** bronchitis, asthmatic NOS (CA23.3)

bronchitis, chemical (acute) (CA81)

**Coded Elsewhere:** Acute bronchitis (CA42)

**CA20.0** **Acute noninfectious bronchitis**

**CA20.1** **Chronic bronchitis**

**Exclusions:** chronic asthmatic bronchitis (CA22.1)

chronic: bronchitis: with airways obstruction (CA22)

chronic: emphysematous bronchitis (CA22.1)

chronic: obstructive pulmonary disease NOS (CA22)

**CA20.10** Simple chronic bronchitis

**CA20.11** Mucopurulent chronic bronchitis

**CA20.12** Mixed simple and mucopurulent chronic bronchitis

**CA20.13** Protracted bacterial bronchitis

Protracted bacterial bronchitis (PBB) is a disease caused by the chronic infection of the conducting airways. The condition causes a persistent wet cough lasting more than four weeks that responds to antibiotic treatment.

**CA20.1Y** Other specified chronic bronchitis

**CA20.1Z** Chronic bronchitis, unspecified

**CA20.Y** **Other specified bronchitis**

**Coding Note:** Excludes acute infectious bronchitis

**CA20.Z** **Bronchitis, unspecified**

**Coding Note:** Excludes acute infectious bronchitis

**CA21**

## **Emphysema**

Emphysema is defined by abnormal and permanent enlargement of the airspaces that are distal to the terminal bronchioles. This is accompanied by destruction of the airspace walls, without obvious fibrosis (i.e. there is no fibrosis visible to the naked eye). Emphysema can exist in individuals who do not have airflow obstruction; however, it is more common among patients who have moderate or severe airflow obstruction.

- Inclusions:***
- Compensatory emphysema (CB40.4)
  - Interstitial emphysema originating in the perinatal period (KB27.0)
  - emphysema due to inhalation of chemicals, gases, fumes or vapours (CA81)
  - emphysema mediastinal (CB40.3)
  - Traumatic subcutaneous emphysema, not elsewhere classified (NF0A.7)
  - emphysema, surgical (subcutaneous) (NE81)
  - emphysema with chronic (obstructive) bronchitis (CA22)
  - emphysematous (obstructive) bronchitis (CA22.1)

**CA21.0**

### **MacLeod syndrome**

Decrease in size of one lung due to obliterating bronchiolitis, a congenital abnormality of other disorder resulting in hyperinflation of the normal lung.

**CA21.1**

### **Panlobular emphysema**

Panlobular (panacinar) emphysema destroys the entire alveolus uniformly and is predominant in the lower half of the lungs. Panlobular emphysema generally is observed in patients with homozygous alpha1-antitrypsin deficiency.

- Inclusions:***
- Panacinar emphysema

**CA21.2**

### **Centrilobular emphysema**

Centrilobular (centriacinar) emphysema begins in the respiratory bronchioles and spreads peripherally. This form is associated with long-standing cigarette smoking and predominantly involves the upper half of the lungs.

**CA21.Y**

### **Other specified emphysema**

**CA21.Z**

### **Emphysema, unspecified**

**CA22****Chronic obstructive pulmonary disease**

Chronic Obstructive Pulmonary disease (COPD), a common preventable and treatable disease, is characterised by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.

***Exclusions:***

- Emphysema (CA21)
- chronic tracheobronchitis (CA20.1)
- chronic tracheitis (CA20.1)
- Simple or mucopurulent chronic bronchitis (CA20.1)
- asthmatic bronchitis NOS (CA23.3)
- Bronchiectasis (CA24)
- Asthma (CA23)
- chronic bronchitis NOS (CA20.1)

**CA22.0****Chronic obstructive pulmonary disease with acute exacerbation, unspecified**

An exacerbation of COPD is an acute event characterised by a worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication. Exacerbations of COPD can be precipitated by several factors. The most common causes appear to be viral upper respiratory tract infections and infection of the tracheobronchial tree. The diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnoea, cough, and/or sputum production) that is beyond normal day-to-day variation.

**CA22.1****Certain specified chronic obstructive pulmonary disease*****Coding Note:***

Use additional code to identify any associated respiratory tract infection.

***Exclusions:***

- Chronic obstructive pulmonary disease with acute exacerbation, unspecified (CA22.0)

**CA22.Z****Chronic obstructive pulmonary disease, unspecified****CA23****Asthma**

Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. It is characterised by an increased responsiveness of the trachea and bronchi to various stimuli and manifested by a widespread narrowing of the airways that change in severity either spontaneously or as a result of therapy. This leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning.

***Inclusions:***

- Idiosyncratic asthma

***Exclusions:***

- wood asthma (CA70)
- asthma with chronic obstructive pulmonary disease (CA22)
- miner's asthma (CA60.1)
- Wheezing (MD11.C)
- chronic obstructive asthma (CA22)
- chronic asthmatic (obstructive) bronchitis (CA22.1)

<b>CA23.0</b>	<b>Allergic asthma</b> Allergic asthma is the most easily recognised asthma phenotype, which often commences in childhood and is associated with a past and/or family history of allergic diseases such as eczema, allergic rhinitis, or food or drug allergy. Examination of the induced sputum of these patients before treatment often reveals eosinophilic airway inflammation. The main trigger is the exposure to inhaled allergens, such as dust mite and pollens, to which the affected individual has previously been sensitized. Patients with this asthma phenotype usually respond well to inhaled corticosteroid (ICS) treatment and specific allergen-immunotherapy.
<b>CA23.00</b>	Allergic asthma with exacerbation This refers to acute or subacute episodes of progressively worsening shortness of breath, cough, wheezing, and chest tightness, or some combination of these symptoms in patients with proven allergic asthma. Allergic asthma can be exacerbated by allergens to which the individual is allergic, other exogenous factors such as respiratory infections, pollutants or climate change, or endogenous co-factors. Exacerbations are characterised by decreases in expiratory airflow that can be documented and quantified by simple measurement of lung function (spirometry or PEF), can vary widely among individuals and within individuals from rare to frequent. The severity of exacerbation of allergic asthma can vary from mild to very severe and life-threatening, but in general respond to standard treatments of bronchodilators (inhalers) and steroid
<b>CA23.01</b>	Allergic asthma with status asthmaticus
<b>CA23.02</b>	Allergic asthma, uncomplicated
<b>CA23.1</b>	<b>Non-allergic asthma</b> Non-allergic asthma occurs in some patients who have asthma that is not associated with allergy. The cellular profile of the sputum of these patients may be neutrophilic, eosinophilic or contain only a few inflammatory cells (paucigranulocytic). Patients with non-allergic asthma often respond less well to inhaled corticosteroids. It can cover different phenotypes.
<b>CA23.10</b>	Non-allergic asthma with exacerbation
<b>CA23.11</b>	Non-allergic asthma with status asthmaticus
<b>CA23.12</b>	Non-allergic asthma, uncomplicated
<b>CA23.2</b>	<b>Other specified forms of asthma or bronchospasm</b> <b>Coded Elsewhere:</b> Asthmatic pulmonary eosinophilia (CB02.0) Samter syndrome (CA0A.0)
<b>CA23.20</b>	Aspirin-induced asthma In some asthma individuals, aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase 1 (COX-1) exacerbate the condition. This distinct clinical syndrome, called aspirin-induced asthma (AIA), is characterised by an eosinophilic rhinosinusitis, nasal polyposis, aspirin hypersensitivity, and asthma.

- CA23.21** Exercise-induced bronchospasm  
Exercise-induced bronchoconstriction (EIB) describes airway narrowing that occurs in association with exercise. EIB occurs in up to 90% of asthmatic patients and is estimated to occur in >10% of the general population. Recent reviews have identified asthma as a risk factor for sudden death and have reported many deaths that have been attributed directly to EIB.
- CA23.22** Cough variant asthma  
Cough variant asthma is an occult form of asthma in which the only sign or symptom is chronic cough.
- CA23.3** **Unspecified asthma**
- CA23.30** Unspecified asthma with exacerbation  
This refers to an unspecified inflammatory disease of the airways characterised by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm, with an acute sudden worsening.
- CA23.31** Unspecified asthma with status asthmaticus  
This refers to an unspecified inflammatory disease of the airways characterised by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm, with an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators (inhalers) and steroids.  
**Exclusions:** acute asthma NOS (CA23.32)  
severe asthma NOS (CA23.32)
- CA23.32** Unspecified asthma, uncomplicated  
**Exclusions:** acute severe asthma (CA23.31)
- CA24** **Bronchiectasis**  
Bronchiectasis is an abnormal widening of one or more airways. Normally, tiny glands in the lining of the airways make a small amount of mucus. Mucus keeps the airways moist and traps any dust and dirt in the inhaled air. Because bronchiectasis creates an abnormal widening of the airways, extra mucus tends to form and pool in parts of the widened airways. Widened airways with extra mucus are prone to infection.  
**Exclusions:** tuberculous bronchiectasis, confirmed (1B10.0)  
Respiratory tuberculosis, not confirmed (1B10.1)

**CA25**

### **Cystic fibrosis**

Cystic fibrosis (CF) is a genetic disorder characterised by the production of sweat with a high salt content and mucus secretions with an abnormal viscosity. The disease is chronic and generally progressive, with onset usually occurring during early childhood or, occasionally, at birth (meconium ileus). Virtually any internal organ may be involved but the principle manifestations concern the breathing apparatus (chronic bronchitis), pancreas (pancreatic insufficiency, adolescent diabetes and occasionally pancreatitis) and, more rarely, the intestine (stercoral obstruction) or liver (cirrhosis). The usual presenting symptoms and signs include persistent pulmonary infection, pancreatic insufficiency, and elevated sweat chloride levels. However, many patients demonstrate mild or atypical symptoms, and clinicians should remain alert to the possibility of CF even when only a few of the usual features are present. Both criteria; clinical symptoms consistent with CF in at least one organ system and evidence of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction must be met to diagnose cystic fibrosis.

**Inclusions:** mucoviscidosis

**CA25.0**

#### **Classical cystic fibrosis**

**Coded Elsewhere:** Exocrine pancreatic manifestations of classical cystic fibrosis  
(DC30.Y)

Endocrine pancreatic manifestations of classical cystic fibrosis  
(DC30.Y)

**CA25.1**

#### **Atypical cystic fibrosis**

**Coded Elsewhere:** Endocrine pancreatic manifestations of atypical cystic fibrosis  
(DC30.Y)

**CA25.2**

#### **Subclinical cystic fibrosis**

**Coding Note:**

Cystic fibrosis with no clinical manifestations is coded here.

**Inclusions:** Asymptomatic cystic fibrosis

**CA25.Z**

#### **Cystic fibrosis, unspecified**

**CA26**

### **Chronic bronchiolitis**

Bronchiolitis and bronchiolitis obliterans are general terms used to describe a nonspecific inflammatory injury that primarily affects the small airways and generally spares the interstitium. Bronchiolitis may be caused by inhalation injury, infection, or drugs; associated with organ transplantation or connective tissue disease; or may be idiopathic. The main pathologic categories of bronchiolitis are: constrictive, proliferative, follicular, airway-centred interstitial fibrosis, and diffuse panbronchiolitis. The constrictive and proliferative patterns may occur together.

<b>CA26.0</b>	<b>Chronic obliterative bronchiolitis</b> Bronchiolitis obliterans is commonly used to describe a number of unrelated conditions whose common end point is functional obstruction of bronchioles. A typical form is constrictive bronchiolitis. Constrictive bronchiolitis is an uncommon histologic finding characterised by alterations in the walls of membranous and respiratory bronchioles, often without extensive changes in alveolar ducts and alveolar walls. These changes lead to concentric narrowing or complete obliteration of the airway lumen. The clinical manifestations of constrictive bronchiolitis usually include progressive airflow obstruction, sometimes in the presence of a relatively normal chest radiograph. The clinical severity depends upon the type, extent, and severity of the initial lung injury.
	<b><i>Exclusions:</i></b> Respiratory conditions due to inhalation of chemicals, gases, fumes or vapours (CA81)
<b>CA26.1</b>	<b>Diffuse panbronchiolitis</b> Diffuse panbronchiolitis (DPB) is an idiopathic inflammatory disease principally affecting the respiratory bronchioles, causing a progressive suppurative and severe obstructive respiratory disorder. Onset occurs in the second to fifth decade of life and manifests by chronic cough, exertional dyspnoea, and sputum production. Most patients also have chronic paranasal sinusitis. If left untreated, DPB progresses to bronchiectasis, respiratory failure and death. A significant improvement in the prognosis has been reported thanks to the use of long-term therapy with macrolide antibiotics, the effect of which is attributed to an anti-inflammatory and immunoregulatory action.
<b>CA26.Y</b>	<b>Other specified chronic bronchiolitis</b>
<b>CA26.Z</b>	<b>Chronic bronchiolitis, unspecified</b>
<b>CA27</b>	<b>Tracheobronchitis</b> Tracheobronchitis is inflammation of the trachea and bronchi. <b>Coded Elsewhere:</b> Relapsing polychondritis (FB82.3)
<b>CA27.0</b>	<b>Tracheobronchopathia osteochondroplastica</b> Tracheobronchopathia osteochondroplastica is a rare disorder of unknown cause, seen with a frequency of 0.4 percent at bronchoscopy, affecting the large airways. It is characterised by the development of multiple osseous and cartilaginous submucosal nodules connected to tracheal cartilage. The abnormality spares the posterior tracheal membranous wall. In spite of marked radiographic changes, patients are only rarely symptomatic since severe airway obstruction is unusual. Linear tracheoplasty may be required in patients with symptomatic airway obstruction.
<b>CA27.1</b>	<b>Tracheobronchomegaly</b> Tracheobronchomegaly is a disorder of unknown cause defined by dilatation of trachea and large bronchi presenting in adults.
<b>CA27.Y</b>	<b>Other specified tracheobronchitis</b>
<b>CA27.Z</b>	<b>Tracheobronchitis, unspecified</b>
<b>CA2Y</b>	<b>Other specified lower respiratory tract disease</b>

**CA2Z**

**Lower respiratory tract disease, unspecified**

**Lung infections (CA40-CA4Z)**

Any condition of the lungs, caused by an infection with a bacterial, viral, fungal, or parasitic source.

**Coded Elsewhere:** Influenza (1E30-1E32)

Pulmonary histoplasmosis capsulati (1F2A.0)

Chronic obstructive pulmonary disease with acute lower respiratory infection (CA22.1)

Influenza with pneumonia, seasonal influenza virus identified (1E30)

**CA40**

**Pneumonia**

A disease of the lungs, frequently but not always caused by an infection with bacteria, virus, fungus, or parasite. This disease is characterised by fever, chills, cough with sputum production, chest pain and shortness of breath. Confirmation is by chest x-ray.

**Inclusions:** infectious pneumonia

**Exclusions:** Pneumonitis (CA70-CA7Z)

**Coded Elsewhere:** Pulmonary toxoplasmosis due to Toxoplasma gondii (1F57.2)

Severe acute respiratory syndrome (1D65)

Congenital pneumonia (KB24)

Abscess of lung with pneumonia (CA43.1)

**CA40.0**

**Bacterial pneumonia**

A disease of the pulmonary system, caused by an infection with a bacterial source. This disease is characterised by fever, lethargy, headache, myalgia, vomiting, or coughing. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of the bacterial source in a sputum sample.

**Coding Note:** Code also the causing condition

**Inclusions:** bronchopneumonia due to bacteria other than *S. pneumoniae* and *H. influenzae*

**Exclusions:** Congenital pneumonia (KB24)

Legionellosis (1C19)

**Coded Elsewhere:** Pulmonary actinomycosis (1C10.0)

Pulmonary nocardiosis (1C1B.0)

Legionnaires disease (1C19.1)

Pneumonia in Q fever (1C33)

Pulmonary anthrax (1B97)

<b>CA40.00</b>	Pneumonia due to Chlamydophila pneumoniae  A disease of the pulmonary system, caused by an infection with the gram-negative bacteria Chlamydia pneumoniae. This disease commonly presents with a gradual onset of cough with low-grade fever. This disease may also present with pharyngitis, laryngitis, and sinusitis. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of Chlamydia pneumoniae in a sputum sample.
	<b>Coded Elsewhere:</b> Congenital pneumonia due to Chlamydia (KB24)
<b>CA40.01</b>	Pneumonia due to Escherichia coli  A disease of the pulmonary system, caused by an infection with the gram-negative bacteria Escherichia coli. This disease is characterised by fever, cough, and dyspnoea. Transmission is commonly by inhalation of infected respiratory secretions. Confirmation is by identification of Escherichia coli in blood, sputum, or pleural fluid samples.
	<b>Coded Elsewhere:</b> Congenital pneumonia due to Escherichia coli (KB24)
<b>CA40.02</b>	Pneumonia due to Haemophilus influenzae  A disease of the pulmonary system, caused by an infection with the gram-negative bacteria Haemophilus influenzae. This disease is characterised by cough, shortness of breath, fever, chills, muscle aches, and chest pain. Transmission is by inhalation of infected respiratory secretions or direct contact. Confirmation is by identification of Haemophilus influenzae in blood or other typically sterile body fluid.
	<b>Inclusions:</b> Bronchopneumonia due to H. influenzae
	<b>Exclusions:</b> Congenital pneumonia (KB24)
<b>CA40.03</b>	Pneumonia due to Klebsiella pneumoniae  A disease of the pulmonary system, caused by an infection with the gram-negative bacteria Klebsiella pneumoniae. This infection commonly presents with thick, haemorrhagic, mucoid sputum. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of Klebsiella pneumoniae in a sputum sample.
<b>CA40.04</b>	Pneumonia due to Mycoplasma pneumoniae  A disease of the pulmonary system, caused by an infection with Mycoplasma pneumoniae. This infection commonly presents with a non-productive cough, chest pain, or fever. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of Mycoplasma pneumoniae in a sputum sample.
<b>CA40.05</b>	Pneumonia due to Pseudomonas aeruginosa  A disease of the pulmonary system, caused by an infection with the gram-negative bacteria Pseudomonas aeruginosa. This disease is characterised by fever, cough, and dyspnoea.
	<b>Coded Elsewhere:</b> Congenital pneumonia due to Pseudomonas aeruginosa (KB24)

<b>CA40.06</b>	Pneumonia due to Staphylococcus A disease of the pulmonary system, caused by an infection with the gram-positive bacteria Staphylococcus. This disease is characterised by fever, cough, dyspnoea, and pulmonary abscesses.
	<b>Coded Elsewhere:</b> Congenital pneumonia due to staphylococcus (KB24)
<b>CA40.07</b>	Pneumonia due to Streptococcus pneumoniae A disease of the pulmonary system, caused by an infection with the gram-positive bacteria Streptococcus pneumoniae. This disease is characterised by an acute onset of fever and chills, or rigors. This disease may also present with chest pain, productive cough, dyspnoea, tachypnoea, hypoxia, or tachycardia. Transmission is by inhalation of infected respiratory secretions, or indirect contact. Confirmation is by identification of Streptococcus pneumoniae in a sputum sample.
	<b>Inclusions:</b> Bronchopneumonia due to S. pneumoniae
	<b>Exclusions:</b> Pneumonia due to other streptococci (CA40.0) congenital pneumonia due to S. pneumoniae (KB24) Pneumonia due to beta-haemolytic streptococcus (CA40.08)
<b>CA40.08</b>	Pneumonia due to beta-haemolytic streptococcus A disease of the lungs, caused by an infection with the gram-positive bacteria beta-haemolytic streptococcus. This disease is characterised by an acute onset of fever and chills, or rigors. This presents with chest pain, productive cough, dyspnoea, tachypnoea, hypoxia, or tachycardia. Transmission is by inhalation of infected inspiratory secretions, or direct contact.
	<b>Inclusions:</b> Pneumonia due to streptococcus, group B
	<b>Coded Elsewhere:</b> Congenital pneumonia due to streptococcus, group B (KB24)
<b>CA40.0Y</b>	Pneumonia due to other specified bacteria
<b>Coding Note:</b>	Code also the causing condition
<b>CA40.0Z</b>	Bacterial pneumonia, unspecified
<b>Coding Note:</b>	Code also the causing condition

<b>CA40.1</b>	<b>Viral pneumonia</b> A disease of the pulmonary system, caused by an infection with a viral source. This disease is characterised by fever, lethargy, headache, myalgia, vomiting, or coughing. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of the viral source in a sputum sample.
<b>Coding Note:</b>	Code also the causing condition
<b>Inclusions:</b>	bronchopneumonia due to viruses other than influenza viruses
<b>Exclusions:</b>	aspiration pneumonia (CA71.0) Influenza with pneumonia, virus not identified (1E32) Severe acute respiratory syndrome (1D65) lipid pneumonia (CA71.1) Idiopathic interstitial pneumonitis (CB03) Aspiration pneumonitis due to anaesthesia during labour or delivery (JB0C.0) Pulmonary complications of anaesthesia during pregnancy (JA67.0) Congenital pneumonia (KB24) Pneumonitis due to solids and liquids (CA71) Pulmonary complications of anaesthesia during the puerperium (JB43.0)
<b>CA40.10</b>	Pneumonia due to Adenovirus A disease of the pulmonary system, caused by an infection with adenovirus. This disease is characterised by fever, chills, or rigors. This disease may also present with chest pain, productive cough, dyspnoea, tachypnoea, hypoxia, and tachycardia. Transmission is by droplet transmission. Confirmation is by identification of adenovirus in a sputum sample.
<b>CA40.11</b>	Pneumonia due to Respiratory syncytial virus A disease caused by an infection with respiratory syncytial virus. This disease is characterised by an inflammatory condition of the lung commonly affecting the alveoli (pneumonia), leading to coughing, sneezing, fever, or wheezing. This disease may be severe in premature babies and those with concurrent disease or immunosuppression. Transmission is by direct contact, droplet transmission, or indirect contact with infected respiratory secretions. Confirmation is by identification of respiratory syncytial virus, commonly through antigen detection or cell culture.
<b>CA40.12</b>	Pneumonia due to parainfluenza virus A disease of the pulmonary system, caused by an infection with parainfluenza virus. This disease is characterised by fever, malaise, cough, or tachypnoea. Transmission is by inhalation of infected respiratory secretions, direct contact, or through fomites. Confirmation is by identification of the parainfluenza virus in respiratory secretions, detection of a significant rise in parainfluenza specific IgG antibodies in paired serum, or detection of parainfluenza specific IgM antibodies in a single serum sample.

<b>CA40.13</b>	Pneumonia due to Human metapneumovirus A disease of the pulmonary system, caused by an infection with Human metapneumovirus. This disease is characterised by fever, myalgia, rhinorrhoea, dyspnoea, tachypnoea, or wheezing. This disease also presents with symptoms of pneumonia. Transmission is by direct or indirect contact, inhalation of infected respiratory secretions, or through fomites. Confirmation is by identification of Human metapneumovirus in a nasopharyngeal, nose, or throat swab or blood sample.
<b>CA40.1Y</b>	Pneumonia due to other specified virus
<b>Coding Note:</b>	Code also the causing condition
<b>CA40.1Z</b>	Viral pneumonia, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>CA40.2</b>	<b>Fungal pneumonia</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Coded Elsewhere:</b> Pulmonary adiaspiromycosis (1F2L.1)
	Pulmonary candidosis (1F23.31)
	Pulmonary cryptococcosis (1F27.0)
	Chronic pulmonary aspergillosis (1F20.12)
	Disseminated histoplasmosis capsulati (1F2A.Y)
	Early-onset pneumonia due to Candida (1F23.31)
<b>CA40.20</b>	Pneumonia due to pneumocystis A disease of the pulmonary system, caused by an infection with the fungi Pneumocystis jirovecii. This disease is characterised by fever, dry cough, shortness of breath, or fatigue. Transmission is by opportunistic infection. Confirmation is by identification of Pneumocystis jirovecii in a lung fluid or tissue sample.
<b>CA40.2Y</b>	Other specified fungal pneumonia
<b>Coding Note:</b>	Code also the causing condition
<b>CA40.2Z</b>	Fungal pneumonia, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>CA40.Y</b>	<b>Other specified pneumonia</b>
<b>CA40.Z</b>	<b>Pneumonia, organism unspecified</b>
<b>CA41</b>	<b>Acute bronchiolitis</b> An acute disease of the bronchioles, commonly caused by an infection with a bacteria or viral source. This disease is characterised by inflammation of the bronchioles and coryza. This disease presents with cough, wheezing, tachypnoea, fever, or chest retraction. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of the infectious agent in a sputum or blood sample.

CA41.0	<b>Acute bronchiolitis due to respiratory syncytial virus</b> A disease of the bronchioles, caused by an infection with respiratory syncytial virus. This disease is characterised by inflammation of the bronchioles. This disease may present with cough, wheezing, or shortness of breath. Transmission is by direct contact, droplet transmission, or indirect contact with infected respiratory secretions. Confirmation is by identification of respiratory syncytial virus from nasopharyngeal swabs.
CA41.Y	<b>Other specified acute bronchiolitis</b>
CA41.Z	<b>Acute bronchiolitis, unspecified</b>
<b>CA42</b>	<b>Acute bronchitis</b> An acute disease of the bronchi, commonly caused by an infection with a bacterial or viral source. This disease is characterised by inflammation of the bronchi. This disease presents with cough, wheezing, chest pain or discomfort, fever, or dyspnoea. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of the infectious agent in a sputum sample.  <b><i>Exclusions:</i></b> tracheobronchitis: chronic obstructive (CA22) tracheobronchitis: chronic (CA22) Tracheobronchitis, NOS (CA27) bronchitis, chronic: obstructive (CA22.1) Simple chronic bronchitis (CA20.10) Chronic bronchitis, NOS (CA20.1) Mucopurulent chronic bronchitis (CA20.11)
CA42.0	<b>Acute bronchitis due to Streptococcus</b> A disease of the bronchi, caused by an infection with the gram-positive bacteria Streptococcus. This disease is characterised by inflammation of the bronchi leading to cough, sputum production, or shortness of breath and wheezing. Transmission is by inhalation of infected respiratory secretions. Confirmation is by identification of Streptococcus in a sputum sample.
CA42.1	<b>Acute bronchitis due to Rhinovirus</b> A disease of the pulmonary system, caused by an infection with rhinovirus. This disease is characterised by cough, with or without production of sputum. Transmission is by inhalation of infected respiratory secretions, or direct contact.
CA42.2	<b>Acute bronchitis due to Respiratory syncytial virus</b> Rapid onset inflammation of the large airways in the lung, including any part of the bronchi due to infection with respiratory syncytial virus.

- CA42.3      Acute bronchitis due to Parainfluenza virus**  
A disease of the bronchi, caused by an acute infection with parainfluenza virus. This disease is characterised by acute inflammation of the bronchi leading to cough, sputum production, wheezing, or shortness of breath. Transmission is by inhalation of infected respiratory secretions, direct contact, or through fomites. Confirmation is by identification of the parainfluenza virus in respiratory secretions, detection of a significant rise in parainfluenza specific IgG antibodies in paired serum, or detection of parainfluenza specific IgM antibodies in a single serum sample.
- CA42.4      Acute bronchitis due to Haemophilus influenzae**  
A disease of the bronchi, caused by an infection with the gram-negative bacteria Haemophilus influenzae. This disease is characterised by acute inflammation of the bronchi leading to cough, sputum production, wheezing or shortness of breath. Transmission is by inhalation of infected respiratory secretions, or direct contact. Confirmation is by identification of Haemophilus influenzae in blood or other typically sterile body fluid.
- CA42.5      Acute bronchitis due to Coxsackievirus**  
A disease of the pulmonary system, caused by an infection with Coxsackie virus. This disease is characterised by cough, fever, or tachypnoea. Transmission is by the faecal-oral route, or vertical transmission. Confirmation is by identification of coxsackievirus in upper respiratory secretion samples.
- CA42.Y      Other specified acute bronchitis**
- CA42.Z      Acute bronchitis, unspecified**
- CA43      Abscess of lung or mediastinum**  
*Coded Elsewhere:* Amoebic lung abscess (1A36.11)
- CA43.0      Gangrene or necrosis of lung**  
The term "necrotizing pneumonia" or "lung gangrene" is used to distinguish pulmonary necrosis with multiple small abscesses from a larger cavitary lesion (lung abscess).
- CA43.1      Abscess of lung with pneumonia**
- CA43.2      Abscess of lung without pneumonia**
- CA43.3      Abscess of mediastinum**
- CA43.Y      Other specified abscess of lung or mediastinum**
- CA43.Z      Abscess of lung or mediastinum, unspecified**

**CA44**

### **Pyothorax**

Suppurative inflammation of the pleural space, typically due to acute bacterial infection. It can occur as a complication of pneumonia, thoracotomy, abscesses (lung, hepatic, or subdiaphragmatic), or penetrating trauma with a secondary infection.

**Inclusions:** empyema

pyopneumothorax

**Exclusions:** due to tuberculosis (1B10)

**CA45**

### **Respiratory infections, not elsewhere classified**

**Exclusions:** Upper respiratory tract disorders (CA00-CA0Z)

Chronic obstructive pulmonary disease (CA22)

Certain lower respiratory tract diseases (CA20-CA2Z)

**CA4Y**

### **Other specified lung infections**

**CA4Z**

### **Lung infections, unspecified**

Lung diseases due to external agents (CA60-CA8Z)

**Exclusions:** Asthma (CA23)

**CA60**

### **Pneumoconiosis**

Pneumoconiosis is a lung disease due to inhalation of minute particles and characterised pathologically by interstitial fibrosis. The different types of pneumoconiosis vary in relation to the types of inhaled particles, often accompanied by certain occupational environments.

**CA60.0**

### **Pneumoconiosis due to dust containing silica**

Interstitial lung disease due to inhalation of silica dust. The accumulation of silica/silicates in lung leads to fibrosis and formation of opacities in upper lobes of lungs on chest X-ray

**Exclusions:** with tuberculosis (1B10-1B1Z)

**CA60.00**

Pneumoconiosis due to talc dust

**CA60.0Y**

Other specified pneumoconiosis due to dust containing silica

**CA60.0Z**

Pneumoconiosis due to dust containing silica, unspecified

- CA60.1      Coal worker pneumoconiosis**  
Coalworker pneumoconiosis, an interstitial lung disease due to inhalation of coal dust. The accumulation of coal in the lung leads to fibrosis and formation of coal macules which are seen on chest X-ray as opacities and fibrosis.
- Inclusions:**      Black lung  
                         Anthracosis  
                         Anthracosilicosis  
                         Coalworker lung
- Exclusions:**      with tuberculosis (1B10-1B1Z)
- CA60.2      Pneumoconiosis due to mineral fibres including asbestos**  
Asbestosis is pneumoconiosis, an interstitial lung disease due to inhalation of asbestos fibres. The accumulation of fibres in the lung leads to diffuse fibrosis and formation of opacities in lower parts of lungs on chest X-ray. Asbestos bodies may be detected in lungs and sputum.
- Inclusions:**      Asbestosis
- Exclusions:**      Pleural plaque with presence of asbestos (CB20)  
                         with tuberculosis (1B10-1B1Z)
- CA60.3      Pneumoconiosis associated with tuberculosis**  
This is an occupational lung disease and a restrictive lung disease caused by the inhalation of dust, often in mines, associated with a common, and in many cases lethal, infectious disease caused by various strains of mycobacteria, usually Mycobacterium tuberculosis.
- CA60.4      Aluminosis of lung**  
Aluminosis is a lung disease caused by the inhalation of dusts of certain aluminium compounds.
- CA60.5      Bauxite fibrosis of lung**
- CA60.6      Berylliosis**  
Chronic beryllium disease also known as berylliosis is an occupational hypersensitivity disorder caused by beryllium exposure at the workplace. It is characterised by non-caseating, non-necrotising granulomata within affected organs, most frequently lung and skin.
- Coded Elsewhere:** Hepatic berylliosis (DB97.1)
- CA60.7      Graphite fibrosis of lung**  
Graphite fibrosis of lung is the pulmonary damage caused by excessive inhalation of graphite.
- CA60.8      Siderosis**  
Siderosis refers to pneumoconiosis resulting from inhalation of iron from welding fumes or from iron or hematite mine dust.

<b>CA60.9</b>	<b>Stannosis</b>
	Stannosis is a benign non-fibrotic pneumoconiosis caused by exposure to tin oxides including stannous oxide (SnO) and stannic oxide (SnO <sub>2</sub> ).
<b>CA60.Y</b>	<b>Other specified pneumoconiosis</b>
<b>CA60.Z</b>	<b>Pneumoconiosis, unspecified</b>

**Pneumonitis (CA70-CA7Z)**

Pneumonitis is a general term that refers to inflammation of lung tissue. Pneumonitis includes the non-infectious lung diseases that cause inflammation of the interstitium of the lung tissue mainly.

**Exclusions:** Pneumonia (CA40)

**Coded Elsewhere:** Chronic pneumonitis of infancy (CB04.6)

Aspiration pneumonitis due to anaesthesia during labour or delivery (JB0C.0)

**CA70 Hypersensitivity pneumonitis due to organic dust**

Hypersensitivity pneumonitis due to organic dust is an inflammation of the alveoli, terminal bronchioli and the interstitium within caused by hypersensitivity to inhaled organic dusts, such as allergens derived from fungal, bacterial, animal protein.

**Coding Note:** Includes: allergic alveolitis and pneumonitis due to inhaled organic dust and particles of fungal, actinomycetic or other origin

**Exclusions:** pneumonitis due to inhalation of chemicals, gases, fumes or vapours (CA81.0)

**CA70.0 Farmer lung**

Farmer's lung disease is a hypersensitivity pneumonitis, caused by inhalation of organic dust containing spores of microorganisms, often thermophilic actinomycetes and less commonly *Saccharopolyspora rectivirgula*, living in mouldy hay, straw, or grain. Typical symptoms include dyspnoea, cough, tiredness, headaches and occasional fever/night sweats, with acute, sub-acute or chronic clinical course and can result in chronic disability with granulomatous disease.

**CA70.1 Bagassosis**

Bagassosis is hypersensitivity pneumonitis due to inhalation of dust from bagasse (the residue of cane after extraction of sugar).

**CA70.2 Bird fancier lung**

Bird fancier lung, also called Pigeon-breeder's lung disease, is an allergic alveolitis caused by inhalation of particulate avian emanations, sometimes specified by avian species. Presentation can be acute with chills, cough, fever, shortness of breath, chest tightness usually resolving within 24h after cessation of antigen exposure, sub-acute with cough and dyspnoea over several days to weeks, whereas chronic form results in breathlessness, coughing, lack of appetite and weight loss.

<b>CA70.3</b>	<b>Suberosis</b> Suberosis also known as corkhandler disease or corkworker lung is a type of hypersensitivity pneumonitis usually caused by the fungus <i>Penicillium glabrum</i> (formerly called <i>Penicillium frequentans</i> ) from exposure to moldy cork dust. <i>Chrysonilia sitophila</i> , <i>Aspergillus fumigatus</i> , uncontaminated cork dust, and <i>Mucor macedo</i> may also have significant roles in the pathogenesis of the disease.
<b>CA70.4</b>	<b>Malt worker lung</b> A disease of the pulmonary system, caused by the fungi <i>Aspergillus clavatus</i> or <i>Aspergillus fumigatus</i> . This disease commonly presents with fever, chills, fatigue, weight loss, cough, headache, myalgia, or shortness of breath. Transmission is by inhalation of fungal spores. Confirmation is by identification of <i>Aspergillus</i> in a sputum, blood, or skin sample.  <i>Inclusions:</i> Alveolitis due to <i>Aspergillus clavatus</i>
<b>CA70.5</b>	<b>Mushroom worker lung</b> Mushroom-worker's lung is occupational hypersensitivity pneumonitis due to mushroom spores and moldy compost.
<b>CA70.6</b>	<b>Maple bark stripper lung</b> Maple-bark-stripper's lung is occupational hypersensitivity pneumonitis due to moldy maple bark containing <i>Cryptostroma corticale</i> .  <i>Inclusions:</i> Alveolitis due to <i>Cryptostroma corticale</i> Cryptostromosis
<b>CA70.7</b>	<b>Air conditioner or humidifier lung</b> A form of the sick building syndrome caused by organisms that contaminate humidifiers and the piping of air conditioner ducts. The air conditioner blows cold air containing spores of the organisms throughout the building.
<b>CA70.Y</b>	<b>Other specified hypersensitivity pneumonitis due to organic dust</b>
<b>Coding Note:</b>	Includes: allergic alveolitis and pneumonitis due to inhaled organic dust and particles of fungal, actinomycetic or other origin
<b>CA70.Z</b>	<b>Hypersensitivity pneumonitis due to organic dust, unspecified</b>
<b>Coding Note:</b>	Includes: allergic alveolitis and pneumonitis due to inhaled organic dust and particles of fungal, actinomycetic or other origin
<b>CA71</b>	<b>Pneumonitis due to solids and liquids</b> <i>Exclusions:</i> Neonatal aspiration syndromes (KB26)
<b>CA71.0</b>	<b>Pneumonitis due to inhalation of food or vomit</b> Acute inflammation of the lung parenchyma due to inadvertent passage of ingested solids or liquids into the airway from swallowing dysfunction or after an acute vomiting or gastroesophageal reflux episode.  <i>Exclusions:</i> Mendelson syndrome (CA72)

- CA71.1 Pneumonitis due to oils or essences**  
Lipoid pneumonia (pneumonitis) is a rare form of pneumonia (pneumonitis) caused by inhalation or aspiration of fat containing substances like petroleum jelly, mineral oils, few laxatives etc.
- CA71.2 Pneumonitis due to aspiration of blood**
- CA71.3 Lipoid pneumonitis**  
Lipoid pneumonia (pneumonitis) refers to two types lipoid pneumonias (pneumonitises), one is Exogenous lipoid pneumonia (pneumonitis) and another is Endogenous lipoid pneumonia (pneumonitis). Exogenous lipoid pneumonia (pneumonitis) is the accumulation of aspirated oils within the alveoli and subsequent foreign body reaction. Endogenous lipoid pneumonia (pneumonitis), also called cholesterol pneumonia (pneumonitis) or golden pneumonia (pneumonitis), is a localised accumulation of lipid-laden macrophages within alveolar spaces distal to an obstructed airway.
- CA71.Y Other specified pneumonitis due to solids and liquids**
- CA71.Z Pneumonitis due to solids and liquids, unspecified**
- CA72 Mendelson syndrome**  
This is chemical pneumonitis caused by aspiration during anaesthesia, especially during pregnancy. Aspiration contents may include gastric juice, blood, bile, water or an association of them.
- Exclusions:**      Complications of anaesthesia during pregnancy (JA67)  
                        Complications of anaesthesia during labour or delivery (JB0C)  
                        Complications of anaesthesia during the puerperium (JB43)
- CA7Y Other specified pneumonitis**
- CA7Z Pneumonitis, unspecified**
- CA80 Airway disease due to specific organic dust**  
Airway disease due to specific organic dust includes airway diseases due to cotton dust or dusts from other vegetable fibres such as flax, cannabis, hemp, or sisal.
- Exclusions:**      Farmer lung (CA70.0)  
                        reactive airways dysfunction syndrome (CA81)  
                        Hypersensitivity pneumonitis due to organic dust (CA70)  
                        Bagassosis (CA70.1)
- CA80.0 Byssinosis due to exposure to cotton**  
Byssinosis (brown lung disease) is a lung disease caused by exposure to dusts from cotton processing.
- Inclusions:**      airway disease due to cotton dust
- CA80.1 Byssinosis due to exposure to flax**  
A form of chronic obstructive pulmonary disease caused by inhalation of particles of unprocessed flax; a form of byssinosis.

- CA80.2** **Byssinosis due to exposure to cannabis**  
Lung disease caused by exposure to dusts from the processing cannabis.
- CA80.Y** **Other specified airway disease due to specific organic dust**
- CA80.Z** **Airway disease due to specific organic dust, unspecified**
- CA81** **Respiratory conditions due to inhalation of chemicals, gases, fumes or vapours**  
This refers to conditions affecting the organs and tissues that make gas exchange due to inhalation of chemicals, gases, fumes, and vapours.
- CA81.0** **Bronchitis or pneumonitis due to chemicals, gases, fumes or vapours**  
This is an inflammation of the mucous membranes of the bronchi (the larger and medium-sized airways that carry airflow from the trachea into the more distal parts of the lung parenchyma) and inflammation of lung tissue, due to chemicals, gases, fumes and vapours.
- CA81.1** **Pulmonary oedema due to chemicals, gases, fumes or vapours**
- CA81.2** **Upper respiratory inflammation due to chemicals, gases, fumes or vapours, not elsewhere classified**
- CA81.Y** **Other specified respiratory conditions due to inhalation of chemicals, gases, fumes or vapours**
- CA81.Z** **Respiratory conditions due to inhalation of chemicals, gases, fumes or vapours, unspecified**
- CA82** **Respiratory conditions due to other external agents**
- CA82.0** **Acute pulmonary manifestations due to radiation**  
An acute inflammatory reaction of the lung in response to repeated or high dose radiation exposure.
- CA82.1** **Chronic or other pulmonary manifestations due to radiation**  
A chronic inflammatory reaction of the lung ultimately resulting in fibrosis in response to repeated or high dose radiation exposure.
- CA82.2** **Acute drug-induced interstitial lung disorders**  
An acute inflammatory reaction of the lung in response to drugs.
- CA82.3** **Chronic drug-induced interstitial lung disorders**  
A chronic inflammatory reaction of the lung ultimately resulting in fibrosis in response to drugs.
- CA82.4** **Aspergillus-induced allergic or hypersensitivity conditions**  
**Coded Elsewhere:** Malt worker lung (CA70.4)  
Allergic aspergillus rhinosinusitis (CA0A.Y)
- CA82.Y** **Other specified respiratory conditions due to other external agents**
- CA82.Z** **Respiratory conditions due to other external agents, unspecified**

**CA8Y**      **Other specified lung diseases due to external agents**

**CA8Z**      **Lung diseases due to external agents, unspecified**

Respiratory diseases principally affecting the lung interstitium (CB00-CB0Z)

**Coded Elsewhere:** Lipoid pneumonitis (CA71.3)

**CB00**      **Acute respiratory distress syndrome**

Acute respiratory distress syndrome ("ARDS") is a life-threatening inflammation with oedema in the lungs which leads to severe respiratory failure. ARDS is a clinical syndrome of lung injury with hypoxic respiratory failure caused by intense pulmonary inflammation that develops after a severe physiologic insult.

**Coded Elsewhere:** Respiratory distress syndrome of newborn (KB23.0)

**CB01**      **Pulmonary oedema**

Pulmonary oedema is a condition caused by excess fluid in the lungs. This fluid collects in the numerous air sacs in the lungs, making it difficult to breathe.

**Exclusions:**      Pulmonary oedema due to chemicals, gases, fumes or vapours (CA81.1)

Pulmonary oedema with mention of heart disease NOS or heart failure (BD11)

**CB02**      **Pulmonary eosinophilia**

Pulmonary eosinophilia are a heterogeneous group of disorders that share the feature of abnormally increased numbers of eosinophils.

**CB02.0**      **Asthmatic pulmonary eosinophilia**

Asthmatic pulmonary eosinophilia is a form of pulmonary eosinophilia associated with asthma which has been commonly attributed to fungi such as Aspergillus species. Although many cases have not shown any allergen.

**CB02.1**      **Idiopathic eosinophilic pneumonitis**

This is an idiopathic disease in which a certain type of white blood cell called an eosinophil accumulates in the lung. These cells cause disruption of the normal air spaces (alveoli) where oxygen is extracted from the atmosphere.

**Inclusions:**      Idiopathic eosinophilic pneumonia

**CB02.10**      Idiopathic acute eosinophilic pneumonitis

Idiopathic acute eosinophilic pneumonia (pneumonitis) is characterised by acute febrile respiratory failure associated with diffuse radiographic infiltrates and eosinophilia in bronchoalveolar lavage fluid (BAL) in the absence of infection. Patients, who are initially healthy and often young, present with severe hypoxemia.

**Inclusions:**      Idiopathic acute eosinophilic pneumonia

<b>CB02.11</b>	Idiopathic chronic eosinophilic pneumonitis Idiopathic chronic eosinophilic pneumonia (pneumonitis) is a pulmonary disease characterised by subacute or chronic respiratory and general symptoms, alveolar and/or blood eosinophilia, and peripheral pulmonary infiltrates on chest imaging and blood eosinophilia in most cases.
	<b>Inclusions:</b> Idiopathic chronic eosinophilic pneumonia
<b>CB02.1Y</b>	Other specified idiopathic eosinophilic pneumonitis
<b>CB02.1Z</b>	Idiopathic eosinophilic pneumonitis, unspecified
<b>CB02.2</b>	<b>Tropical pulmonary eosinophilia</b> Tropical pulmonary eosinophilia (TPE) is a syndrome of wheezing, fever and eosinophilia seen predominantly in the Indian subcontinent and other tropical areas. The syndrome has been termed tropical eosinophilia, tropical pulmonary eosinophilia (TPE), or tropical filarial pulmonary eosinophilia (TFPE). Tropical filarial pulmonary eosinophilia (TFPE) is a clinical manifestation of lymphatic filariasis, a parasitic infection caused by filarial nematodes ( roundworms) that inhabit the lymphatics and bloodstream.
<b>CB02.Y</b>	<b>Other specified pulmonary eosinophilia</b>
<b>CB02.Z</b>	<b>Pulmonary eosinophilia, unspecified</b>
<b>CB03</b>	<b>Idiopathic interstitial pneumonitis</b> The idiopathic interstitial pneumonias (pneumonitises) are a subset of diffuse interstitial lung diseases of unknown etiology characterised by expansion of the interstitial compartment (i.e. that portion of the lung parenchyma sandwiched between the epithelial and endothelial basement membranes) with an infiltrate of inflammatory cells. The inflammatory infiltrate is sometimes accompanied by fibrosis, either in the form of abnormal collagen deposition or proliferation of fibroblasts capable of collagen synthesis. <b>Inclusions:</b> Idiopathic interstitial pneumonia
<b>CB03.0</b>	<b>Acute interstitial pneumonitis</b> Acute interstitial pneumonia (pneumonitis), also referred to as Hamman-Rich syndrome, is a rapidly progressive and histologically distinct form of idiopathic interstitial pneumonia (pneumonitis).
<b>CB03.1</b>	<b>Combined pulmonary fibrosis and emphysema syndrome</b> Combined pulmonary fibrosis and emphysema (CPFE) is a syndrome of combined emphysema of the upper lobes and fibrosis of the lower lobes defined on chest computed tomography, and characterised by subnormal spirometry, severe impairment of gas exchange, high prevalence of pulmonary hypertension, and poor survival. Characteristic functional profile of CPEF is strongly impaired carbon monoxide diffusing capacity of the lung, and hypoxaemia at exercise, with preserved lung volumes. Despite subnormal spirometry, which may be responsible for its under recognition, CPFE is a severe entity. The presence of pulmonary arterial hypertension at diagnosis is a critical determinant of prognosis.

- CB03.2** **Cryptogenic organizing pneumonitis**  
 Cryptogenic organizing pneumonia (pneumonitis) (COP) or bronchiolitis obliterans with organizing pneumonia (pneumonitis) (BOOP) is an inflammatory, non-infectious lung disease with distinctive clinical, radiological and pathological features, and that responds to corticosteroid therapy.
- CB03.3** **Desquamative interstitial pneumonitis**  
 This is a form of idiopathic interstitial pneumonia (pneumonitis) featuring elevated levels of macrophages.  
*Inclusions:* Desquamative interstitial pneumonia
- CB03.4** **Idiopathic pulmonary fibrosis**  
 Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia (pneumonitis) of unknown cause, occurring primarily in older adults, limited to the lungs, and associated with the histopathologic and/or radiologic pattern of UIP. The definition of IPF requires the exclusion of other forms of interstitial pneumonia (pneumonitis) including other idiopathic interstitial pneumonias (pneumonitis) and Interstitial Lung Disease (ILD) associated with environmental exposure, medication, or systemic disease.
- CB03.5** **Lymphoid interstitial pneumonia**  
 This refers to several conditions in which lymphocytes are produced in excessive quantities. They typically occur in patients who have compromised immune systems. They are sometimes equated with "immunoproliferative disorders", but technically lymphoproliferative disorders are a subset of immunoproliferative disorders, along with hypergammaglobulinemia and paraproteinaemias.
- CB03.6** **Respiratory bronchiolitis - interstitial lung disease**  
 Respiratory bronchiolitis - interstitial lung disease is a mild inflammatory pulmonary disorder developed by cigarette smokers and characterised by shortness of breath and cough, pulmonary function abnormalities of mixed restrictive and obstructive lung disease and high resolution CT scanning showing centrilobular micronodules, ground glass opacities and peribronchiolar thickening.
- CB03.Y** **Other specified idiopathic interstitial pneumonitis**
- CB03.Z** **Idiopathic interstitial pneumonitis, unspecified**
- CB04** **Primary interstitial lung diseases specific to infancy or childhood**
- CB04.0** **Diffuse pulmonary developmental disorders**
- CB04.1** **Pulmonary lymphatic dysplasia syndromes**  
*Coded Elsewhere:* Yellow nail syndrome (EE11.1)  
 Congenital pulmonary lymphangiectasia (LA75.Y)

<b>CB04.2</b>	<b>Disorders of surfactant metabolism</b> Primary interstitial lung disease specific to childhood due to pulmonary surfactant protein anomalies is a group of interstitial lung diseases (ILD) induced by genetic mutations disrupting surfactant function and gas exchange in the lung. The disorders caused by these mutations affect full-term infants and older children and exhibit considerable overlap in their clinical and histologic presentation
<b>CB04.3</b>	<b>Alveolar or peri-alveolar conditions</b>
<b>CB04.30</b>	Idiopathic pulmonary haemosiderosis Idiopathic pulmonary hemosiderosis is a respiratory disease due to repeated episodes of diffuse alveolar haemorrhage without any underlying apparent cause, most often in children. Anaemia, cough, and pulmonary infiltrates on chest radiographs are found in majority of the patients.
<b>CB04.31</b>	Pulmonary alveolar proteinosis This is a rare lung disease in which abnormal accumulation of surfactant occurs within the alveoli, interfering with gas exchange. PAP can occur in a primary form or secondarily in the settings of malignancy (especially in myeloid leukemia), pulmonary infection, or environmental exposure to dusts or chemicals.
<b>CB04.3Y</b>	Other specified alveolar or peri-alveolar conditions
<b>CB04.3Z</b>	Alveolar or peri-alveolar conditions, unspecified
<b>CB04.4</b>	<b>Pulmonary capillaritis</b> Isolated pauciimmune pulmonary capillaritis is a small vessel vasculitis restricted to the lungs that may induce diffuse alveolar haemorrhage with dyspnoea, anaemia, chest pain, haemoptysis, bilateral and diffuse alveolar infiltrates at chest X-rays, without any underlying systemic disease. ANCA are frequently positive but could be negative.
<b>CB04.5</b>	<b>Brain-lung-thyroid syndrome</b> Brain-lung-thyroid syndrome is a rare disorder characterised by congenital hypothyroidism, infant respiratory distress syndrome (IRDS) and benign hereditary chorea.
<b>CB04.6</b>	<b>Chronic pneumonitis of infancy</b> Chronic pneumonitis of infancy is a rare paediatric form of interstitial lung disease (ILD) sharing clinical and radiologic features with other forms of ILD (cough, tachypnoea, and infiltrative opacities on chest imaging) and harbouring specific histological abnormalities including diffuse thickening of alveolar septa, hyperplasia of type 2 alveolar epithelial cells (AEC), and presence of primitive mesenchymal cells within the alveolar septa.
<b>CB04.7</b>	<b>Neuroendocrine cell hyperplasia of infancy</b> Neuroendocrine cell hyperplasia of infancy is a non-lethal paediatric form of interstitial lung disease (ILD) characterised by tachypnoea and respiratory distress without respiratory failure.
<b>CB04.Y</b>	<b>Other specified primary interstitial lung diseases specific to infancy or childhood</b>

**CB04.Z Primary interstitial lung diseases specific to infancy or childhood, unspecified**

**CB05**

**Interstitial lung diseases associated with systemic diseases**

This refers to a group of lung diseases affecting the interstitium (the tissue and space around the air sacs of the lungs). This diagnosis is associated with diseases that affect a number of organs and tissues, or affects the body as a whole.

**Coding Note:** Code also the causing condition

**CB05.0**

**Diffuse alveolar damage**

This is a histological pattern in lung disease. It is seen in acute respiratory distress syndrome (ARDS), transfusion related acute lung injury (TRALI) and acute interstitial pneumonia (pneumonitis) (AIP).

**CB05.1**

**Interstitial lung diseases associated with connective tissue diseases**

Interstitial lung diseases associated with connective tissue diseases refers to a group of lung diseases affecting the interstitium (the tissue and space around the air sacs of the lungs) associated with connective tissue diseases.

**Coding Note:** Code also the causing condition

**Coded Elsewhere:** Respiratory disorders in juvenile dermatomyositis (CB40.Y)

Respiratory disorders in other dermatomyositis (CB40.Y)

Respiratory disorders in polymyositis (CB40.Y)

Respiratory disorders in Sjögren syndrome (CB40.Y)

Respiratory disorders in systemic lupus erythematosus (CB40.Y)

Respiratory disorders in systemic sclerosis (CB40.Y)

**CB05.2**

**Interstitial lung diseases associated with granulomatous diseases**

Interstitial lung diseases associated with granulomatous diseases refers to a group of lung diseases affecting the interstitium (the tissue and space around the air sacs of the lungs) associated with granulomatous diseases, such as sarcoidosis.

**Coded Elsewhere:** Sarcoidosis of lung (4B20.0)

Sarcoidosis of lung with sarcoidosis of lymph nodes (4B20.Y)

**CB05.3**

**Interstitial lung diseases associated with metabolic diseases**

Interstitial lung diseases associated with metabolic diseases refers to a group of lung diseases affecting the interstitium (the tissue and space around the air sacs of the lungs). This diagnosis is associated with a large class of genetic diseases involving disorders of metabolism.

**Coding Note:** Code also the causing condition

**Coded Elsewhere:** Familial hypocalciuric hypercalcaemia (5A51.2)

Hermansky-Pudlak syndrome with pulmonary fibrosis (EC23.20)

<b>CB05.4</b>	<b>Interstitial lung diseases associated with systemic vasculitides</b> Interstitial lung diseases associated with systemic vasculitides refers to a group of lung diseases affecting the interstitium (the tissue and space around the air sacs of the lungs). This diagnosis is associated with a type of small vessel vasculitis. <b>Coded Elsewhere:</b> Respiratory disorders in Wegener's granulomatosis (CB40.Y)
<b>CB05.40</b>	Respiratory disorders in Churg-Strauss syndrome This encompasses pathological conditions affecting the organs and tissues that make gas exchange possible in higher organisms, and includes conditions of the upper respiratory tract, trachea, bronchi, bronchioles, alveoli, pleura and pleural cavity, and the nerves and muscles of breathing. This diagnosis is in a medium and small vessel autoimmune vasculitis, leading to necrosis.
<b>CB05.41</b>	Respiratory disorders in microscopic polyangiitis This encompasses pathological conditions affecting the organs and tissues that make gas exchange possible in higher organisms, and includes conditions of the upper respiratory tract, trachea, bronchi, bronchioles, alveoli, pleura and pleural cavity, and the nerves and muscles of breathing. This diagnosis is in an ill-defined autoimmune disease characterised by a systemic, pauci-immune, necrotizing, small-vessel vasculitis without clinical or pathological evidence of necrotizing granulomatous inflammation.
<b>CB05.4Y</b>	Other specified interstitial lung diseases associated with systemic vasculitides
<b>CB05.4Z</b>	Interstitial lung diseases associated with systemic vasculitides, unspecified
<b>CB05.5</b>	<b>Secondary pulmonary haemosiderosis</b> Secondary pulmonary hemosiderosis is a respiratory disease due to the deposition of hemosiderin-laden macrophages in lungs as a result of repeated alveolar haemorrhage secondary to another disease, especially dysimmune disorders (i.e. Heiner syndrome, autoimmune diseases), thrombotic disorders and cardiovascular disorders such as mitral stenosis. It manifests as a triad of haemoptysis, anaemia and diffuse parenchymal infiltrates on chest radiography
<b>Coding Note:</b>	Code also the causing condition
<b>CB05.Y</b>	<b>Other specified interstitial lung diseases associated with systemic diseases</b>
<b>Coding Note:</b>	Code also the causing condition
<b>CB05.Z</b>	<b>Interstitial lung diseases associated with systemic diseases, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>CB06</b>	<b>Pulmonary alveolar microlithiasis</b> Pulmonary alveolar microlithiasis is an idiopathic rare disease in which concretions composed of calcium and phosphorus collect in alveolar spaces. A systemic disorder of calcium metabolism has not been identified, and the serum calcium and phosphate levels are normal. Cough and dyspnoea are the most common presenting symptoms. Expectorated microliths have been reported. Inspiratory crackles, finger clubbing, and signs of cor pulmonale may be present in more advanced disease.

**CB07**

### **Lymphangioleiomyomatosis**

Lymphangioleiomyomatosis (LAM) is a multiple cystic lung disease characterised by progressive cystic destruction of the lung and lymphatic abnormalities, frequently associated with renal angiomyolipomas (AMLs). LAM occurs either sporadically or as a manifestation of tuberous sclerosis complex (TSC).

**CB07.0**

### **Lymphangioleiomyomatosis associated with tuberous sclerosis complex**

This is a rare lung disease that results in a proliferation of disorderly smooth muscle growth (leiomyoma) throughout the lungs, in the bronchioles, alveolar septa, perivascular spaces, and lymphatics, resulting in the obstruction of small airways (leading to pulmonary cyst formation and pneumothorax) and lymphatics (leading to chylous pleural effusion). This diagnosis is associated with a rare multi-system genetic disease that causes non-malignant tumours to grow in the brain and on other vital organs such as the kidneys, heart, eyes, lungs, and skin.

**CB07.1**

### **Sporadic lymphangioleiomyomatosis**

This is a rare lung disease that results in a proliferation of disorderly smooth muscle growth (leiomyoma) throughout the lungs, in the bronchioles, alveolar septa, perivascular spaces, and lymphatics, resulting in the obstruction of small airways (leading to pulmonary cyst formation and pneumothorax) and lymphatics (leading to chylous pleural effusion). LAM occurs in a sporadic form, which affects only females, usually of childbearing age; LAM also occurs in patients who have tuberous sclerosis.

**CB07.Y**

### **Other specified lymphangioleiomyomatosis**

**CB07.Z**

### **Lymphangioleiomyomatosis, unspecified**

**CB0Y**

### **Other specified respiratory diseases principally affecting the lung interstitium**

**CB0Z**

### **Respiratory diseases principally affecting the lung interstitium, unspecified**

## **Pleural, diaphragm or mediastinal disorders (CB20-CB2Z)**

Pleural, diaphragm and mediastinal disorders are disorders of the potential space between the two pleura (visceral and parietal) of the lungs, disorders of the diaphragm and mediastinum. The mediastinum is an undelineated group of structures in the thorax, surrounded by loose connective tissue. It is the central compartment of the thoracic cavity.

**CB20**

### **Pleural plaque**

Deposits of hyalinized collagen fibres in the parietal pleura that result from chronic inflammation. Most commonly associated with past exposure to asbestos, typically becoming visible years after inhalation of the inciting exposure.

**CB21**

### **Pneumothorax**

Pneumothorax is an abnormal collection of air or gas in the pleural space that separates the lung from the chest wall, and that may interfere with normal breathing.

**Exclusions:**      pyopneumothorax (CA44)  
                        pneumothorax: tuberculous (not confirmed) (1B10.1)  
                        Traumatic pneumothorax (NB32.0)  
                        pneumothorax: tuberculous (confirmed) (1B10.0)

**Coded Elsewhere:** Pneumothorax originating in the perinatal period (KB27.1)

**CB21.0**

### **Spontaneous tension pneumothorax**

A tension pneumothorax is present when the intrapleural pressure is greater than atmospheric throughout expiration and often during inspiration as well. The mechanism responsible for tension pneumothorax is the disruption of the visceral or parietal pleura in such a manner that a one-way valve develops. A tension pneumothorax can occur after any type of pneumothorax; it is independent of the etiology. It can sometimes occur after a spontaneous pneumothorax but is more common after a traumatic pneumothorax, with mechanical ventilation, or during cardiopulmonary resuscitation.

**CB21.1**

### **Other spontaneous pneumothorax**

Spontaneous pneumothorax that is not tension pneumothorax is included in this classification.

They include primary spontaneous pneumothorax without tension and secondary spontaneous pneumothorax without tension. Primary spontaneous pneumothorax occurs in patients without underlying pulmonary disease, classically in tall, thin young men in their teens and 20s. It is thought to be due to spontaneous rupture of subpleural apical blebs or bullae that result from smoking or that are inherited. It generally occurs at rest, although some cases occur during activities involving reaching or stretching. Primary spontaneous pneumothorax also occurs during diving and high-altitude flying because of unequally transmitted pressure changes in the lung. Secondary spontaneous pneumothorax occurs in patients with underlying pulmonary disease. It most often results from rupture of a bleb or bulla in patients with severe COPD, HIV-related *Pneumocystis jirovecii* infection, cystic fibrosis, or any underlying pulmonary parenchymal disease. Secondary spontaneous pneumothorax is more serious than primary spontaneous pneumothorax because it occurs in patients whose underlying lung disease decreases their pulmonary reserve.

**CB21.Y**

### **Other specified pneumothorax**

**CB21.Z**

### **Pneumothorax, unspecified**

**CB22**

### **Diseases of mediastinum, not elsewhere classified**

This refers to diseases of the mediastinum where the mediastinum is an undelineated group of structures in the thorax, surrounded by loose connective tissue. It is the central compartment of the thoracic cavity

**Exclusions:**      Abscess of mediastinum (CA43.3)

- CB22.0 Fibrosing mediastinitis**  
Fibrosing mediastinitis, also known as sclerosing mediastinitis or mediastinal fibrosis, is a disorder characterised by an excessive fibrotic reaction in the mediastinum. It can result in compromise of airways, great vessels, and other mediastinal structures, with morbidity directly related to the location and extent of fibrosis. The commonest cause is histoplasmosis, of which it is a rare late complication, but it may also occur in association with other infections and with systemic autoimmune disorders such as Behçet disease, granulomatosis with polyangiitis and retroperitoneal fibrosis.
- CB22.Y Other specified diseases of mediastinum, not elsewhere classified**
- CB22.Z Diseases of mediastinum, not elsewhere classified, unspecified**
- CB23 Disorders of diaphragm**  
This category includes the abnormalities of diaphragmatic position or motion (paralysis, relaxation, and acquired deformity) and the inflammation of the diaphragm, but neoplasms of the diaphragm, congenital malformation of diaphragm, and diaphragmatic hernias are included in other categories.
- Exclusions:** Congenital diaphragmatic hernia (LB00.0)  
Structural developmental anomalies of diaphragm (LB00)
- CB24 Chyloous effusion**  
A chylothorax (chyloous effusion) signifies leakage of chyle from the thoracic duct. A pleural fluid triglyceride concentration of more than 110 mg per decilitre signifies a high likelihood of chylothorax, whereas a triglyceride concentration below 50 mg per decilitre makes chylothorax highly unlikely.
- Inclusions:** Chyliform effusion
- CB25 Fibrothorax**  
Fibrothorax results from fibrosis of the visceral pleura, and is clinically manifested by decreased respiratory excursion and restrictive pulmonary physiology. There are two distinct mechanisms that can lead to the formation of fibrothorax: 1) Most often, fibrothorax develops as a consequence of pleural inflammation in patients with pleural effusions, including hemothorax, tuberculous effusion, or chronic empyema; 2) Less frequently, fibrothorax results from pulmonary parenchymal disease, and can be seen in patients with tuberculosis, bronchiectasis, or lung abscess.
- CB26 Haemothorax**  
Hemothorax is the presence of blood with or without air in the pleural space. The most common cause is chest trauma. Hemothorax should be considered to be present when the haematocrit of the pleural fluid is more than half that of the peripheral blood. A number of bleeding sites may be responsible for the hemothorax, including pulmonary laceration, intercostal vessel laceration, and rupture of pleural adhesions.

**CB27****Pleural effusion**

Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces.

**Coding Note:**

Code also the causing condition

**Inclusions:** Pleurisy with effusion

**Exclusions:** Tuberculosis of the respiratory system (1B10)

Chylous effusion (CB24)

Pleurisy (MD31)

**CB2Y****Other specified pleural, diaphragm or mediastinal disorders****CB2Z****Pleural, diaphragm or mediastinal disorders, unspecified****CB40****Certain diseases of the respiratory system**

**Coded Elsewhere:** Pulmonary sporotrichosis (1F2J.2)

Alpha-1-antitrypsin deficiency (5C5A)

Airway obstruction in the neonate due to airway abnormality (KB2J)

**CB40.0****Ciliary dyskinesia**

Defective function of the cilia lining the respiratory tract (lower and upper, sinuses, Eustachian tube, middle ear) resulting in altered mucociliary transport and manifesting as recurrent upper and lower respiratory infection, chronic productive cough, chronic rhinosinusitis or persistent otitis media. Acquired forms result from respiratory tract injury associated especially with respiratory infections such as bronchiolitis or chronic obstructive pulmonary disease. The rare primary forms are inherited as autosomal recessive disorders presenting early in life and typically progressing to bronchiectasis; they may be associated with infertility in men and women due to abnormal sperm motility or fallopian tube function respectively.

**Coded Elsewhere:** Primary ciliary dyskinesia (LA75.Y)

Syndromic ciliary dyskinesia (LA75.Y)

**CB40.1****Young syndrome**

Young syndrome is characterised by the association of obstructive azoospermia with recurrent sinobronchial infections.

**CB40.2****Pulmonary collapse**

**Inclusions:** Atelectasis

**Exclusions:** Primary atelectasis of newborn (KB2B)

atelectasis (of): tuberculous (not confirmed) (1B10.1)

atelectasis (of): tuberculous (confirmed) (1B10.0)

<b>CB40.3</b>	<b>Interstitial emphysema</b> This is a collection of air outside of the normal air passages in the body and instead is found inside the connective tissue of the peribronchovascular sheaths, interlobular septa, and visceral pleura. This collection develops as a result of alveolar and terminal bronchiolar rupture.
	<p><b>Exclusions:</b>      emphysema: NOS (CA21)                                  emphysema: surgical (subcutaneous) (NE81)                                  Traumatic subcutaneous emphysema, not elsewhere classified                                  (NF0A.7)</p>
	<p><b>Coded Elsewhere:</b> Pneumomediastinum originating in the perinatal period                                  (KB27.2)</p> <p>Interstitial emphysema originating in the perinatal period                                  (KB27.0)</p>
<b>CB40.4</b>	<b>Compensatory emphysema</b> Compensatory emphysema is a condition in which one portion of the lung increases in size and function, when another portion is destroyed or temporarily useless. It occurs, for instance, in association with pneumonias, pleural effusions and pneumothorax. Anatomically, there is found an enlargement of the normal lung; there are no variations from the normal structure; the unaffected lung, as a result of distention, has an increased vital capacity and is able to perform a greater amount of work than when in its usual condition. The tissues show no similarity to those truly emphysematous. This change is in no way related to true emphysema and the term should not be used, as it creates great confusion in the literature. Its use is no more justified than that of speaking of the compensatory enlargement of a kidney, when the opposite kidney has been removed, as of a compensatory nephritis. True emphysema can never compensate for diseased lung tissue, because the emphysematous lung is totally or almost totally functionless.
<b>CB40.Y</b>	<b>Other specified diseases of the respiratory system</b>
<b>CB41</b>	<p><b>Respiratory failure</b></p> <p>Respiratory failure is a life-threatening impairment of oxygenation or carbon dioxide (CO<sub>2</sub>) elimination. Respiratory failure may occur because of impaired gas exchange, decreased ventilation, or both. The level of oxygen in the blood becomes dangerously low or the level of carbon dioxide becomes dangerously high.</p> <p><b>Coding Note:</b> Code also the causing condition</p> <p><b>Exclusions:</b>      Acute respiratory distress syndrome (CB00)                                  Respiratory arrest (MD33)                                  Respiratory distress of newborn (KB23)</p>
<b>CB41.0</b>	<b>Acute respiratory failure</b> Respiratory failure can be acute (short term) or chronic (ongoing), using time as the main parameter. In acute respiratory failure hypoxemia occurs over a period of hours to days (less than 7 days), and acute respiratory failure can develop quickly and may require emergency treatment.
	<p><b>Coding Note:</b> Code also the causing condition</p>

<b>CB41.00</b>	Acute respiratory failure, Type I When acute respiratory failure causes a low level of oxygen in the blood without a high level of carbon dioxide, it's called hypoxic acute respiratory failure.
<b>Coding Note:</b>	Code also the causing condition
<b>CB41.01</b>	Acute respiratory failure, Type II When acute respiratory failure causes a high level of carbon dioxide in the blood, it's called hypercapnic acute respiratory failure.
<b>Coding Note:</b>	Code also the causing condition
<b>CB41.0Z</b>	Acute respiratory failure, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>CB41.1</b>	<b>Chronic respiratory failure</b> In chronic respiratory failure hypoxemia occurs over a period of weeks to months (more than seven days), and chronic respiratory failure develops more slowly and lasts longer than acute respiratory failure.
<b>Coding Note:</b>	Code also the causing condition
<b>CB41.10</b>	Chronic respiratory failure, Type I When chronic respiratory failure causes a low level of oxygen in the blood without a high level of carbon dioxide, it's called hypoxic chronic respiratory failure.
<b>CB41.11</b>	Chronic respiratory failure, Type II When chronic respiratory failure causes a high level of carbon dioxide in the blood, it's called hypercapnic chronic respiratory failure.
<b>CB41.1Z</b>	Chronic respiratory failure, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>CB41.2</b>	<b>Respiratory failure, unspecified as acute or chronic</b> This is inadequate gas exchange by the respiratory system, with the result that levels of arterial oxygen, carbon dioxide or both cannot be maintained within their normal ranges, unspecified.
<b>Coding Note:</b>	Code also the causing condition
<b>CB41.20</b>	Respiratory failure, unspecified, Type I This is when the PaCO <sub>2</sub> may be normal or low. It is typically caused by a ventilation/perfusion (V/Q) mismatch; the volume of air flowing in and out of the lungs is not matched with the flow of blood to the lungs. The basic defect in type 1 respiratory failure is failure of oxygenation
<b>CB41.21</b>	Respiratory failure, unspecified, Type II Type 2 respiratory failure is caused by inadequate ventilation; both oxygen and carbon dioxide are affected. Defined as the build up of carbon dioxide levels (PaCO <sub>2</sub> ) that has been generated by the body.

**CB41.2Z** Respiratory failure, unspecified

**Coding Note:** Code also the causing condition

### Postprocedural disorders of the respiratory system (CB60-CB64)

**Exclusions:** Acute pulmonary manifestations due to radiation (CA82.0)

**Coded Elsewhere:** Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)

**CB60** **Tracheostomy malfunction**

**CB61** **Chronic pulmonary insufficiency following surgery**

**CB62** **Postprocedural subglottic stenosis**

**CB63** **Postprocedural stenosis of the trachea**

**CB64** **Transfusion related acute lung injury**

This is a serious blood transfusion complication characterised by the acute onset of non-cardiogenic pulmonary oedema following transfusion of blood products.

**CB7Z** **Diseases of the respiratory system, unspecified**

# CHAPTER 13

---

## Diseases of the digestive system

This chapter has 158 four-character categories.

Code range starts with DA00

- Exclusions:**
- Endocrine, nutritional or metabolic diseases (Chapter 05)
  - Injury, poisoning or certain other consequences of external causes (Chapter 22)
  - Neoplasms (Chapter 02)
  - Certain infectious or parasitic diseases (Chapter 01)
  - Complications of pregnancy, childbirth and the puerperium (Chapter 18)
  - Mental, behavioural or neurodevelopmental disorders (Chapter 06)
- Coded Elsewhere:**
- Digestive system disorders of fetus or newborn (KB80-KB8Z)
  - Symptoms, signs or clinical findings of the digestive system or abdomen (MD80-ME4Y)
  - Structural developmental anomalies of the digestive tract (LB10-LB1Z)
  - Diseases of the digestive system complicating pregnancy, childbirth or the puerperium (JB64.6)

This chapter contains the following top level blocks:

- Diseases or disorders of orofacial complex
- Diseases of oesophagus
- Diseases of the stomach or the duodenum
- Diseases of small intestine
- Diseases of appendix
- Diseases of large intestine
- Diseases of anal canal
- Diseases of liver
- Diseases of gallbladder or biliary tract
- Diseases of pancreas
- Diseases of peritoneum
- Diverticular disease of intestine
- Ischaemic vascular disorders of intestine
- Hernias
- Inflammatory bowel diseases
- Functional gastrointestinal disorders

- Postprocedural disorders of digestive system

## Diseases or disorders of orofacial complex (DA00-DA0Z)

Morbid process, derangement or abnormality localised in the mouth or related tissues of the face

**Coded Elsewhere:** Structural developmental anomalies of mouth or tongue (LA31)

Symptoms or signs of the orofacial complex (MD80)

Jaw pain (ME86.9)

**DA00**

### **Disorders of lips**

A group of any derangement or condition affecting the normal structure and function of the lips resulting from developmental or traumatic factors or systemic disease.

**Coded Elsewhere:** Lichen planus of lips (EA91.Y)

**DA00.0**

### **Cheilitis**

Cheilitis is the generic term given to inflammatory conditions of the lip.

**Coded Elsewhere:** Actinic cheilitis (EK90.Y)

**DA00.1**

### **Self-induced lip trauma**

Self-inflicted damage to lips by biting, picking, chewing etc.

**Coded Elsewhere:** Artefactual cheilitis (ED00)

**DA00.2**

### **Pigmentary abnormalities of lips**

This is an abnormality in the material that changes the colour of reflected or transmitted light as the result of wavelength-selective absorption, of the lips.

**DA00.3**

### **Lip fissure**

**DA00.Y**

### **Other specified disorders of lips**

**DA00.Z**

### **Disorder of lips, unspecified**

**DA01**

### **Disorders of oral mucosa**

Inflammation of the soft tissues of the mouth, such as mucosa; palate; gingiva; and/or lip, as well as any associated pathological or traumatic discontinuity of tissue

**Exclusions:** Noma (DA0C.31)

gangrenous stomatitis (1C1H)

Cheilitis (DA00.0)

cancrum oris (DA0C.31)

**Coded Elsewhere:** Lichen planus and lichenoid reactions of oral mucosa (EA91.4)

Oral submucous fibrosis (DA02.2)

Oral allergy syndrome (EK10.0)

Contact gingivostomatitis (DA02.3)

Neonatal disorders of the oral mucosa (KC23)

<b>DA01.0</b>	<b>Disturbances of oral epithelium</b>
	<b>Coded Elsewhere:</b> Cheek-biting (6B25.Y)
<b>DA01.00</b>	Oral leukoplakia Leukoplakia is a condition where areas of keratosis appear as adherent white patches on the mucous membranes of the oral cavity. Leukoplakia may affect other gastrointestinal tract mucosal sites, or mucosal surfaces of the urinary tract and genitals.  <b>Inclusions:</b> Leukoplakia of gingiva <b>Exclusions:</b> Hairy leukoplakia (DA01.01)
<b>DA01.01</b>	Hairy leukoplakia Oral hairy leukoplakia is a focal epithelial hyperplasia of the oral mucosa associated with Epstein-Barr virus. It is closely associated with HIV and occurs in both immunocompromised and immunocompetent HIV-infected individuals. It is also, however, found in uninfected people who are immunosuppressed, e.g. organ transplant recipients. It presents as white patches with a corrugated or hairy appearance affecting particularly the lateral borders of the tongue.
<b>DA01.02</b>	Wandering rash of the mouth The counterpart of geographic tongue affecting other parts of the oral epithelium. It is less common than geographic tongue.
<b>DA01.0Y</b>	Other specified disturbances of oral epithelium
<b>DA01.1</b>	<b>Noninfectious erosive or ulcerative disorders of oral mucosa</b> A group of erosive and ulcerative disorders of oral mucosa without infection.  <b>Coded Elsewhere:</b> Oral pemphigus (EB40.00) Stevens-Johnson syndrome (EB13.0) Pyodermatitis–pyostomatitis vegetans (EL3Y) Lupus erythematosus of oral mucosa (4A40.Y)
<b>DA01.10</b>	Oral aphthae or aphtha-like ulceration This is a frequent small, shallow, painful ulceration in the oral mucosa. Recurrent oral ulceration that clinically resembles recurrent aphthous stomatitis but presents atypically, including commencement after adolescence, with fever, with a strong family history, or failing to resolve with age.  <b>Coded Elsewhere:</b> Oropharyngeal ulceration due to Behçet disease (4A62)
<b>DA01.11</b>	Oral mucositis Ulcerative mucositis is the inflammation of the oral mucosa with inflammation, ulceration and frequently with bleeding.

- DA01.12** Chronic ulcerative stomatitis  
Chronic ulcerative stomatitis (CUS) is a rare disease which presents with chronic oral mucosal erosions and ulceration resembling erosive lichen planus but refractory to standard therapies. It typically occurs in older women. Diagnosis requires the demonstration of speckled granular perinuclear IgG deposits in the basal and parabasal layers of oral epithelium (stratified epithelium-specific antinuclear or SES-ANA pattern). There is increasing evidence that CUS is an autoimmune disease provoked by circulating IgG antibodies directed against delta-Np63, an isoform of the p53 family of nuclear transcription factors which is present around the nuclei of normal oral epithelial basal keratinocytes. CUS normally responds to treatment with hydroxychloroquine.
- DA01.13** Erythema multiforme with oral ulceration  
This is a skin condition of unknown cause, possibly mediated by deposition of immune complex (mostly IgM) in the superficial microvasculature of the skin and oral mucous membrane that usually follows an infection or drug exposure.
- DA01.14** Drug-induced oral ulcer  
Ulceration of the oral mucosa attributable to medication. Non-steroidal anti-inflammatory drugs (NSAIDs) and cytotoxic drugs such as methotrexate are well recognised causes but many others have been incriminated.
- DA01.15** Mouth ulcers  
Oral ulceration of other specified or unspecified type.  
**Exclusions:**      Mechanical oral ulceration (DA01.1)  
                        Drug-induced oral ulcer (DA01.14)
- DA01.1Y** Other specified noninfectious erosive or ulcerative disorders of oral mucosa
- DA01.2** **Granuloma or granuloma-like lesions of oral mucosa**  
This is a specific type of chronic inflammatory response of the oral mucosa characterised by a localised accumulation of epithelioid macrophages, multi nucleate giant cells, and lymphocytes.  
**Inclusions:**      Denture granuloma  
**Coded Elsewhere:** Sarcoidosis of oral cavity (4B20.Y)  
                        Crohn disease of lips or oral mucosa (DD70.0)
- DA01.20** Giant cell granuloma, central  
A benign condition of the jaws. It is twice as likely to affect women and is more likely to occur in individuals between the age of 20 and 40. Central giant cell granulomas are more common in the mandible and often cross the midline.  
**Exclusions:**      peripheral giant cell granuloma (DA0D)

- DA01.21** Orofacial granulomatosis  
Orofacial granulomatosis (OFG) is an uncommon clinicopathological entity characterised by persistent and/or recurrent lymphoedema and fissuring of the lips and oral mucosa (the latter resulting in a "cobblestone" appearance), oral ulceration and the presence on biopsy of non-caseating granulomas. OFG may be an early manifestation of Crohn disease, sometimes presenting months or years before bowel disease. Some cases are associated with dental infections, sarcoidosis, food allergy or contact allergy. Granulomatous cheilitis is a form of OFG confined to the lips. Rarely, OFG may be associated with fissured tongue and facial palsy (Melkersson-Rosenthal syndrome).
- Coded Elsewhere:** Granulomatous cheilitis (DA00.0)
- DA01.2Y** Other specified granuloma or granuloma-like lesions of oral mucosa
- DA01.3** **Infections of lips or oral mucosa**  
A group of conditions characterised by the invasion of lips and oral mucosa by harmful organisms (pathogens), such as bacteria, fungi, protozoa, rickettsiae, or viruses.
- Coded Elsewhere:** Enteroviral vesicular stomatitis (1F05.0)  
Enteroviral vesicular pharyngitis (1F05.1)  
Candidosis of lips or oral mucous membranes (1F23.0)  
Warts of lips or oral cavity (1E82)  
Angular cheilitis due to bacterial infection (DA00.0)
- DA01.30** Cellulitis or abscess of soft tissues of the mouth  
Infection of the soft tissues of the mouth resulting in cellulitis and/or abscess formation.
- Exclusions:** Peritonsillar abscess (CA0K.1)  
Abscess of salivary gland (DA04.3)  
Periapical abscess without sinus (DA09.62)  
Periapical abscess with sinus (DA09.61)  
Periapical abscess with facial involvement (DA09.60)
- Coded Elsewhere:** Abscess of periodontium (DA0C.4)
- DA01.3Y** Other specified infections of lips or oral mucosa
- DA01.4** **Irritative hyperplasia of oral mucosa**  
**Exclusions:** irritative hyperplasia of edentulous ridge [denture hyperplasia] (DA0D.2)
- DA01.40** Papillary hyperplasia of oral mucosa  
This is an oral pathologic condition that appears in the mouth as an overgrowth of tissue usually beneath a denture and is associated with poor denture hygiene, denture overuse, and ill-fitting dentures.
- DA01.41** Denture hyperplasia
- DA01.42** Oral fibroepithelial polyp

<b>DA01.4Z</b>	Irritative hyperplasia of oral mucosa, unspecified
<b>DA01.Y</b>	<b>Other specified disorders of oral mucosa</b>
<b>DA01.Z</b>	<b>Disorder of oral mucosa, unspecified</b>
<b>DA02</b>	<b>Miscellaneous specified disorders of lips or oral mucosa</b>
	<b><i>Exclusions:</i></b> Diseases of tongue (DA03) Cysts of oral or facial-neck region (DA05) Certain specified disorders of gingiva or edentulous alveolar ridge (DA0D)
	<b><i>Coded Elsewhere:</i></b> Drug-induced oral conditions (EH74)
<b>DA02.0</b>	<b>Genetic or developmental disorders involving lips or oral mucosa</b> A group of genetic and developmental disorders characterised by abnormal facial development that particularly involves the lips and oral mucosa.  <b><i>Coded Elsewhere:</i></b> Chronic mucocutaneous candidosis (1F23.14) Peutz-Jeghers syndrome (LD2D.0) Hereditary haemorrhagic telangiectasia (LA90.00) Pachyonychia congenita (LD27.Y) Cowden syndrome (LD2D.Y) Dyskeratosis congenita (3A70.0) Heterotopic sebaceous glands of lips (ED91.0) Heterotopic sebaceous glands of oral mucosa (ED91.0)
<b>DA02.1</b>	<b>Xerostomia</b> Dry mouth. This may result from many causes including dehydration, salivary gland dysfunction, suppression of saliva production by drugs (e.g. anticholinergics) or habitual mouth-breathing.
<b>DA02.2</b>	<b>Oral submucous fibrosis</b>
<b>DA02.3</b>	<b>Contact gingivostomatitis</b> Inflammation of the gingivae and oral mucosa due to contact with irritants or allergens but without specification of which mechanism is involved.
<b>DA02.30</b>	Allergic contact gingivostomatitis Allergic contact dermatitis affecting the gingivae and oral mucosa.
<b>DA02.31</b>	Irritant contact gingivostomatitis Inflammation of gingivae and oral mucosa due to contact with irritants.

**DA03**

**Diseases of tongue**

Any pathological process affecting the structural tissues of the tongue with or without interference of its normal functions.

- Exclusions:**
- leukoplakia of tongue (DA01.00)
  - erythroplakia of tongue (DA01.0)
  - leukoedema of tongue (DA01.0)
  - Hairy leukoplakia (DA01.01)
  - submucous fibrosis of tongue (DA02.2)
  - Ankyloglossia (LA31.2)

**Coded Elsewhere:** Sublingual varices (BD75.0)

**DA03.0**

**Glossitis**

Inflammation of the tongue

- Exclusions:**
- atrophic glossitis (DA03.2)

**DA03.1**

**Geographic tongue**

A condition characterised by migratory glossitis and loss of dorsal papillae with a map-like appearance that gives origin to the name.

- Inclusions:**
- Benign migratory glossitis
  - Glossitis areata exfoliativa
  - Erythema migrans of tongue

**DA03.2**

**Atrophy of tongue papillae**

- Inclusions:**
- Atrophic glossitis
  - Central papillary atrophy of the tongue

**DA03.3**

**Median rhomboid glossitis**

**DA03.4**

**Hypertrophy of tongue papillae**

- Inclusions:**
- Hypertrophy of foliate papillae

**DA03.5**

**Macroglossia**

Macroglossia is the medical term for a large or enlarged tongue. It may be due to a variety of congenital and acquired conditions. Isolated macroglossia has no determinable cause. It is seen commonly in Down syndrome. The most common causes of tongue enlargement are vascular malformations (e.g. lymphangioma or haemangioma) and muscular hypertrophy. It may, however, be due to infiltration, as with primary systemic amyloidosis.

**Coded Elsewhere:** Congenital macroglossia (LA31.0)

Macroglossia due to primary systemic amyloidosis (5D00.Y)

**DA03.Y**

**Other specified diseases of tongue**

**DA03.Z**

**Diseases of tongue, unspecified**

**DA04**

## **Diseases of salivary glands**

A group of diseases with any pathological condition that affects the structural tissues of the salivary glands or the salivary ducts which may or not interfere with the normal production and transport of saliva into the oral cavity.

**Coded Elsewhere:** Aplasia of lacrimal or salivary glands (LA14.10)

Uveoparotid fever (4B20.Y)

**DA04.0**

### **Atrophy of salivary gland**

Salivary gland atrophy is a wasting or decrease in size of salivary gland, which is not sufficient to cause necrosis. It may occur in response to poor nutrition, lack of use (disuse or immobilization), reduction in blood supply, loss of nerve supply, chronic cell injury, or ageing etc. It is including Sjögren's syndrome, irradiation therapy and obstructive sialadenitis.

**DA04.1**

### **Hypertrophy of salivary gland**

**DA04.2**

### **Sialoadenitis**

Sialoadenitis (or Sialadenitis) is an inflammation of the salivary gland. It is often associated with pain, tenderness, redness, and gradual localised swelling of the affected area.

**Exclusions:** epidemic parotitis (1D80.0)

Uveoparotid fever (4B20)

**DA04.3**

### **Abscess of salivary gland**

This is a collection of pus (neutrophils) that has accumulated within the salivary gland because of an inflammatory process in response to either an infectious process (usually caused by bacteria or parasites) or other foreign materials.

**DA04.4**

### **Sialolithiasis**

Sialolithiasis is a condition where a calcified mass forms within a salivary gland, usually in the duct of the submandibular gland. The usual symptoms are pain and swelling of the affected salivary gland, both of which get worse when salivary flow is stimulated.

**Inclusions:** Calculus of salivary gland or duct

Stone of salivary gland or duct

**DA04.5**

### **Mucocele of salivary gland**

This is a clinical term used to describe a bluish, soft, often fluctuant swelling caused by either blockage or rupture of a salivary gland duct.

**DA04.6**

### **Disturbances of salivary secretion**

A group of conditions characterised by an increase or decrease in saliva secretion.

**Exclusions:** Dry mouth (DA02.1)

**Coded Elsewhere:** Xerostomia due to disturbance of salivary secretion (DA02.1)

**DA04.7**

### **Sialophagia**

Excessive swallowing of saliva

<b>DA04.8</b>	<b>Sialoschesis</b> Suppression of the secretion of saliva.
<b>DA04.Y</b>	<b>Other specified diseases of salivary glands</b>
<b>DA04.Z</b>	<b>Diseases of salivary glands, unspecified</b>
<b>DA05</b>	<p><b>Cysts of oral or facial-neck region</b> Cysts of oral or facial-neck region, having a distinct epithelial lining and division compared to the nearby tissue, which may contain air, fluids, or semi-solid material.</p> <p><b>Exclusions:</b> Radicular cyst (DA09.8)</p> <p><b>Coded Elsewhere:</b> Epstein pearl (KC23)</p>
<b>DA05.0</b>	<p><b>Developmental odontogenic cysts</b> Cysts derived from odontogenic (tooth forming) tissue, usually containing fluid or semisolid material, which develop during various stages of odontogenesis.</p>
<b>DA05.1</b>	<p><b>Developmental nonodontogenic cysts of oral region</b> Cysts that arise from non-odontogenic (non-tooth forming) tissue. By definition, the cysts are lined by epithelium. These cysts include for example; nasopalatine duct cyst, palatal cyst of the neonate, globulomaxillary cyst and more.</p>
<b>DA05.Y</b>	<b>Other specified cysts of oral or facial-neck region</b>
<b>DA05.Z</b>	<b>Cysts of oral or facial-neck region, unspecified</b>
<b>DA06</b>	<p><b>Certain specified diseases of jaws</b> A group of diseases which are associated with the jaws and which are not classified elsewhere.</p>
<b>DA06.0</b>	<p><b>Inflammatory conditions of jaws</b> <b>Exclusions:</b> Cervicofacial actinomycosis (1C10.2)</p>
<b>DA06.1</b>	<p><b>Alveolitis of jaw</b> Inflammation of the alveolus.</p> <p><b>Inclusions:</b> Alveolar osteitis Dry socket</p>
<b>DA06.2</b>	<p><b>Exostosis of jaw</b> Formation of bone mass on the vestibular, buccal or facial side of the maxilla or the mandibular jaw where it may affect the lingual aspect; exostoses are more frequent in the maxillary bone.</p>

DA06.3	<b>Stafne mandibular bone cavity</b> Although commonly called a Stafne cyst, this entity is not a true cyst but rather a cavity due to a focal cortical defect of the medial aspect of the mandible. It is found most frequently in middle-aged men and is usually discovered radiologically as an incidental finding. Its importance is that it may be difficult to distinguish from other radiolucent lesions in the mandible such as myeloma or metastatic squamous carcinoma. The cavity is usually filled by part of the submandibular salivary gland or adjacent fat and it is thought to result from remodelling of the bone by adjacent salivary tissue. Stafne cysts are most frequently seen in middle-aged men. The estimated prevalence ranges around 0.10-0.48%. Pathology: Stafne cysts are thought to result from remodelling of the bone by adjacent salivary tissue, and have been noted to regress following resection of the gland nearby. They generally appear in the area between the mandibular first molar and the mandibular angle 6.
DA07	<b>Disorders of tooth development or eruption</b> Alteration of the normal formation process of the tooth, the normal chronology of eruption into the mouth or the proper alignment in the dental arch affecting a single or multiple teeth.  <b><i>Inclusions:</i></b> disorder of tooth development <b><i>Coded Elsewhere:</i></b> Anodontia (LA30.0) Hypodontia (LA30.1) Oligodontia (LA30.2) Hyperdontia (LA30.3) Abnormalities of size or form of teeth (LA30.4) Amelogenesis imperfecta (LA30.6) Dentine dysplasia (LA30.7) Dentinogenesis imperfecta (LA30.8) Odontogenesis imperfecta (LA30.9) Solitary median maxillary central incisor syndrome (LA30.Y) Hereditary disturbances in tooth structure (LA30.Z) Papillon-Lefèvre syndrome (EC20.30)
DA07.0	<b>Fluoride related opacities or lesions</b> This is a fluoride related abnormality in the tissue of an organism (in layman's terms, "damage"), usually caused by disease or trauma.
DA07.1	<b>Nonfluoride enamel opacities</b> This is a condition characterised by enamel opacities, white spots, or visibly lighter areas on a tooth's surface, not attributed to fluorine, which occur in low-fluoride areas.

<b>DA07.3</b>	<b>Disturbances in tooth formation</b> A group of conditions characterised by disturbances in tooth formation.  <b>Inclusions:</b> Dental dysplasia <b>Exclusions:</b> Hutchinson teeth and mulberry molars in congenital syphilis (1A60) mottled teeth (DA07.0)
<b>DA07.4</b>	<b>Root anomaly</b> Common presence of fused roots showed by X-ray film that short or long root, supernumerary root, or fused roots. These root anomalies are commonly seen in permanent molars, especially in third molars which are the most anomaly in one fused root, 2 or 3 fused roots, even 4 fused roots, round apical root or dilacerations.
<b>DA07.5</b>	<b>Cementum dysplasia</b>
<b>DA07.6</b>	<b>Disturbances in tooth eruption</b>
<b>DA07.60</b>	Teething syndrome Gum and jaw discomfort when an infant's teeth emerges. Teething typically starts between 4 and 7 months of age and lasts until about the age of 3 years. Most common symptoms include irritability, crying, lack of appetite, red and swollen gums, drooling, and inability to sleep.
<b>DA07.61</b>	Ankylosis of teeth Tooth ankylosis is the solid fixation of a tooth, resulting from fusion of the cementum and alveolar bone, with obliteration of the periodontal ligament. It is uncommon in deciduous dentition, and very rare in permanent teeth.  <b>Inclusions:</b> Absence of exfoliation of teeth
<b>DA07.6Y</b>	Other specified disturbances in tooth eruption
<b>DA07.6Z</b>	Disturbances in tooth eruption, unspecified
<b>DA07.7</b>	<b>Embedded teeth</b> an unerupted tooth, usually completely covered with bone  <b>Exclusions:</b> embedded teeth with abnormal position of such teeth or adjacent teeth (DA0E.3)
<b>DA07.8</b>	<b>Impacted teeth</b> An impacted tooth is a tooth that is all the way or partially below the gum line and is not able to erupt properly. Wisdom teeth (third molars) are the most commonly impacted teeth  <b>Inclusions:</b> dental impaction impacted tooth <b>Exclusions:</b> impacted teeth with abnormal position of such teeth or adjacent teeth (DA0E.3)
<b>DA07.Y</b>	<b>Other specified disorders of tooth development or eruption</b>
<b>DA07.Z</b>	<b>Disorders of tooth development or eruption, unspecified</b>

**DA08**

**Diseases of hard tissues of teeth**

This is a group of conditions affecting the integrity of tooth enamel, dentine or cementum.

**DA08.0**

**Dental caries**

A condition characterised by localised destruction of calcified tissue, initiated on the tooth surface by decalcification of the enamel, followed by the enzymatic lysis of organic structures, resulting in cavity formation.

**Inclusions:** Dental decay

**DA08.1**

**Certain specified diseases of hard tissues of teeth**

**Exclusions:** Dental caries (DA08.0)

bruxism (DA0E.7)

teeth-grinding NOS (DA0E.7)

**Coded Elsewhere:** Ankylosis of teeth (DA07.61)

**DA08.10**

**Excessive attrition of teeth**

The pathological wearing away of tooth substance as a result of tooth-to-tooth contact.

**DA08.11**

**Abrasion of teeth**

Abrasion is abnormal tooth surface loss resulting from direct friction forces between the teeth and external objects or from frictional forces between contacting teeth components in the presence of an abrasive medium.

**DA08.12**

**Erosion of teeth**

Tooth erosion is a gradual and irreversible loss of the normally hard surface of the tooth due to chemical, not bacterial, processes.

**DA08.13**

**Abfraction**

Theoretical concept of loss of tooth structure not caused by dental caries

**Inclusions:** non-carious cervical lesion

**DA08.14**

**Pathological resorption of teeth**

Tooth resorption, external, resorption of calcified dental tissue, beginning on the external surface, usually at the apex or the lateral surface of the root, as a result of tissue reaction in the periodontal or pericoronal tissue, increasing in severity with age.

**DA08.15**

**Posteruptive colour changes of dental hard tissues**

This is a condition characterised by colour changes of the dental hard tissues after tooth eruption.

**Exclusions:** Deposits on teeth (DA08.4)

**DA08.2**

**Chronic dental injuries**

A group of conditions characterised by persistent or long-lasting damage caused by an external force applied to the tooth resulting from intentional or unintentional means.

- DA08.3 Nontraumatic fracture of tooth**  
 Discontinuity of tooth structure in vertical or horizontal direction of the long axis of a tooth and which may affect enamel and/or dentine. This condition is referred as incomplete fracture and may be related to flexural loads acting on the teeth. In some cases the dental pulp may become affected.
- Inclusions:** Incomplete fracture not involving vital pulp  
 Complete nontraumatic fracture not involving vital pulp
- Exclusions:** traumatic fracture of tooth (NA0D.02)
- DA08.4 Deposits on teeth**  
 In dentistry, calculus or tartar is a form of hardened dental plaque.
- DA08.Y Other specified diseases of hard tissues of teeth**
- DA08.Z Diseases of hard tissues of teeth, unspecified**
- DA09 Diseases of pulp or periapical tissues**  
 Dental pulp is that part of the tooth located in the centre of the coronal portion underneath dentin and composed of connective tissue, blood vessels and nerve endings.  
 Periapical tissues are designated as those located at the tip of the tooth root surrounding the apical foramen.
- DA09.0 Pulpitis**  
 Inflammation of pulpal tissue resulting from irritating factors of diverse nature such as bacterial, hyperaemic, chemical or thermal that act directly or indirectly on the dental pulp.
- DA09.1 Necrosis of pulp**  
 Necrosis of the dental pulp which clinically does not respond to thermal stimulation; the tooth may be asymptomatic or sensitive to percussion and palpation.
- DA09.2 Pulp abscess**  
 This is an acute or chronic inflammation of dental pulp, associated with a circumscribed collection of necrotic tissue and pus arising from breakdown of leukocytes and bacteria, sometimes walled off with connective tissue.
- Inclusions:** Pulpal abscess
- DA09.3 Phoenix abscess**  
 This is an acute condition that results immediately after endodontic therapy or in tooth with necrotic pulp
- DA09.4 Pulp degeneration**
- DA09.5 Abnormal hard tissue formation in pulp**  
 This is a condition affecting the tooth characterised by secondary or irregular dentine in the pulp.
- DA09.6 Periapical abscess**

- DA09.60** Periapical abscess with facial involvement  
Purulent periapical lesion resulting from necrosis of dental pulpal tissues and that has penetrated facial soft and bone tissues.
- DA09.61** Periapical abscess with sinus  
**Inclusions:**  
Dental abscess with sinus  
Dentoalveolar abscess with sinus  
Dental sinus
- DA09.62** Periapical abscess without sinus
- DA09.6Y** Other specified periapical abscess
- DA09.6Z** Periapical abscess, unspecified
- DA09.7** **Periapical periodontitis**
- DA09.70** Acute apical periodontitis of pulpal origin  
Acute, apical periodontitis is a result of inflammation of the periapical tissues following pulpal necrosis.
- DA09.71** Chronic apical periodontitis  
A periapical inflammation characterised by dental granuloma formation.
- DA09.7Y** Other specified periapical periodontitis
- DA09.7Z** Periapical periodontitis, unspecified
- DA09.8** **Radicular cyst**  
The radicular cyst is defined as an area of chronic inflammation exhibiting a closed central cavity surrounded by an epithelial lining.  
**Exclusions:** lateral periodontal cyst (DA05.0)
- DA09.Y** Other specified diseases of pulp or periapical tissues
- DA09.Z** Diseases of pulp or periapical tissues, unspecified
- DA0A** **Certain specified disorders of teeth or supporting structures**
- DA0A.0** **Exfoliation of teeth due to systemic causes**  
Premature loss of teeth associated with systemic disease usually results from some change in the immune system or connective tissue.
- DA0A.1** **Loss of teeth due to accident, extraction or local periodontal disease**
- DA0A.2** **Atrophy of edentulous alveolar ridge**
- DA0A.3** **Retained dental root**  
Complete or fragment of root structure that remains in the jaw usually as result of fracture during the corresponding tooth extraction procedure.
- DA0A.Y** **Other specified disorders of teeth and supporting structures**

<b>DA0A.Z</b>	<b>Unspecified disorders of teeth and supporting structures</b>	
<b>DA0B</b>	<b>Gingival diseases</b>	
	Gingivitis is inflammation of the tissues of the gingiva (gum) without loss of connective tissue.	
	<b>Coded Elsewhere:</b> Periodontal pocket (DA0C.Y)	
<b>DA0B.0</b>	<b>Allergic gingivitis</b>	
<b>DA0B.1</b>	<b>Catarrhal gingivitis</b>	
<b>DA0B.2</b>	<b>Eruptive gingivitis</b>	
<b>DA0B.3</b>	<b>Atrophic senile gingivitis</b>	
<b>DA0B.4</b>	<b>Acute multiple gingival abscesses</b>	
<b>DA0B.5</b>	<b>Developmental or acquired deformities or conditions of gingiva</b> This is a major developmental difference in the shape of a body part or organ compared to the average shape of that part.	
<b>DA0B.6</b>	<b>Pericoronitis</b> A gum condition in which irritation and inflammation are produced by the crown of an incompletely erupted tooth.	
<b>DA0B.Y</b>	<b>Other specified gingival diseases</b>	
<b>DA0B.Z</b>	<b>Gingival diseases, unspecified</b>	
<b>DA0C</b>	<b>Periodontal disease</b>	
	Periodontal disease can refer to any pathological process involving the gum (GINGIVA), the alveolar bone (alveolar process), the dental cementum, and / or the periodontal ligament	
<b>DA0C.0</b>	<b>Acute periodontitis</b> This is an acute disease affecting the tooth-supporting structures, i.e. gingiva, alveolar bone and periodontal membrane.	
	<b>Exclusions:</b>	Periapical abscess without sinus (DA09.62) Acute apical periodontitis of pulpal origin (DA09.70) Periapical abscess with sinus (DA09.61) Periapical abscess with facial involvement (DA09.60)
<b>DA0C.1</b>	<b>Aggressive periodontitis</b> A type of periodontal disease and includes localised aggressive periodontitis (LAP), and Generalised aggressive periodontitis (GAP).	
	<b>Inclusions:</b>	Juvenile periodontitis
<b>DA0C.2</b>	<b>Periodontosis</b> Periodontosis defined as a disease of the periodontium occurring in an otherwise healthy adolescent and characterised by a rapid loss of the alveolar bone around more than one tooth of the permanent dentition.	

<b>DA0C.3</b>	<b>Necrotising periodontal diseases</b> An infection characterised by necrosis of periodontal tissues <b>Coded Elsewhere:</b> Necrotising ulcerative gingivitis (1C1H)
<b>DA0C.30</b>	Necrotising ulcerative periodontitis <b>Inclusions:</b> Necrotising ulcerative gingivo-periodontitis
<b>DA0C.31</b>	Noma This is a devastating infectious disease which destroys the soft and hard tissues of the oral and para-oral structures. <b>Inclusions:</b> Cancrum oris Gangrenous stomatitis Stomatonecrosis
<b>DA0C.3Y</b>	Other specified necrotising periodontal diseases
<b>DA0C.3Z</b>	Necrotising periodontal diseases, unspecified
<b>DA0C.4</b>	<b>Abscess of periodontium</b> localised purulent infection of periodontal tissues; common clinical feature in patients with moderate or advanced periodontitis. <b>Inclusions:</b> Periodontal abscess
<b>DA0C.5</b>	<b>Linear gingival erythema</b>
<b>DA0C.Y</b>	<b>Other specified periodontal disease</b>
<b>DA0C.Z</b>	<b>Periodontal disease, unspecified</b>
<b>DA0D</b>	<b>Certain specified disorders of gingiva or edentulous alveolar ridge</b> A group of diseases which are associated with gingiva or alveolar ridge, which are not classified elsewhere. <b>Exclusions:</b> Chronic gingivitis (DA0B) Atrophy of edentulous alveolar ridge (DA0A.2) gingivitis NOS (DA0B) Acute gingivitis (DA0B)
<b>DA0D.0</b>	<b>Gingival recession</b>
<b>DA0D.1</b>	<b>Gingival enlargement</b> An abnormal overgrowth of gingival tissues.
<b>DA0D.2</b>	<b>Gingival or edentulous alveolar ridge lesions associated with trauma</b> Damage of gingival or mucosal lesions resulting from external stimuli. Common causes of traumatic ulcers include: denture irritation, biting, injuries, burns and friction irritation from sharp or fractured teeth.

<b>DA0D.3</b>	<b>Hypoplasminogenaemia</b> Severe hypoplasminogenaemia or type 1 plasminogen (plg) deficiency is a systemic disease characterised by markedly impaired extracellular fibrinolysis leading to the formation of ligneous (fibrin-rich) pseudomembranes on mucosae during wound healing.
<b>DA0D.4</b>	<b>Cotton-roll gingivitis</b>
<b>DA0D.5</b>	<b>Gingival ulceration</b>
<b>DA0D.Y</b>	<b>Other specified disorders of gingival or edentulous alveolar ridge</b>
<b>DA0E</b>	<p><b>Dentofacial anomalies</b></p> <p>A congenital or acquired abnormality in which the dental and oral structures deviate from normal form, function, or position.</p> <p><b>Exclusions:</b>      hemifacial atrophy or hypertrophy (LA52)                            Robin's syndrome (LA56)                            acromegaly (5A60.0)</p>
<b>DA0E.0</b>	<b>Major anomalies of jaw size</b>
<b>DA0E.00</b>	Micrognathia Apparently reduced length and width of the mandible when viewed from the front but not from the side. This is a bundled term comprising shortening and narrowing of the mandible and chin.
	<b>Exclusions:</b> Pierre Robin syndrome (LA56)
<b>DA0E.0Y</b>	Other specified major anomalies of jaw size
<b>DA0E.0Z</b>	Major anomalies of jaw size, unspecified
<b>DA0E.1</b>	<b>Anomalies of jaw-cranial base relationship</b> This is a congenital or acquired abnormality in which the portion of the skull that holds the upper jaw deviates from the normal form, function, or position.
<b>DA0E.2</b>	<b>Anomalies of dental arch relationship</b> This is a congenital or acquired abnormality in which dental arch relationship deviate from normal form, function, or position. <b>Coded Elsewhere:</b> Crossbite (DA0E.5Y)
<b>DA0E.3</b>	<b>Anomalies of tooth position</b> Dental anomalies are craniofacial abnormalities of form, function, or position of the teeth, bones, and tissues of the jaw and mouth. Anomalies of tooth position can be classified in ectopic, transmigration, transposition, rotation.
<b>DA0E.4</b>	<b>Food impaction</b> The forcible wedging of food between adjacent teeth during mastication, producing gingival recession and pocket formation.

<b>DA0E.5</b>	<b>Malocclusion</b> Malocclusion is the atypical relationship between maxillary and mandibular teeth which may interfere with the efficiency of excursive movements of the mandible that are essential for the effective mastication process.
<b>DA0E.50</b>	Class II division 2 malocclusion This condition relates to Angle's classification of occlusion in which the first permanent maxillary molar position is aligned or in an anterior relationship to that of the mandibular first permanent molar, such that the mesiobuccal cusp of the maxillary molar is mesial to the buccal groove of the mandibular molar and the central incisors are in linguoversion.
<b>DA0E.51</b>	Angle class I malocclusion The maxillary first permanent molar is in slight distoversion in relation to the mandibular first permanent molar, and the mesiobuccal cusp of the maxillary molar is aligned with the buccal groove of the mandibular molar.
<b>DA0E.5Y</b>	Other specified malocclusion
<b>DA0E.5Z</b>	Malocclusion, unspecified
<b>DA0E.6</b>	<b>Dentofacial functional abnormalities</b> Temporomandibular joint disorder (TMJ) is the name given to a group of symptoms that cause pain in the head, face, and jaw. The symptoms include headaches, soreness in the chewing muscles, and clicking or stiffness of the joints. They often have psychological as well as physical causes.  <b>Exclusions:</b> teeth-grinding NOS (DA0E.7) bruxism (DA0E.7) teeth clenching (DA0E.7)
<b>DA0E.7</b>	<b>Dentofacial parafunctional disorders</b> Bruxism is a repetitive jaw-muscle activity characterised by clenching or grinding of the teeth and/or by bracing or thrusting of the mandible. Bruxism has two distinct circadian manifestations: it can occur during sleep (indicated as sleep bruxism) or during wakefulness (indicated as awake bruxism)  <b>Exclusions:</b> Atypical facial pain (8A85) dyskinesia (MB47.4) trismus (DA0E.8)
<b>DA0E.8</b>	<b>Temporomandibular joint disorders</b> This is an umbrella term covering acute or chronic pain, especially in the muscles of mastication and/or inflammation of the temporomandibular joint, which connects the mandible to the skull.  <b>Inclusions:</b> Temporomandibular joint-pain-dysfunction syndrome <b>Exclusions:</b> current temporomandibular joint: strain (NA03.3) current temporomandibular joint: dislocation (NA03.0)
<b>DA0E.Y</b>	<b>Other specified dentofacial anomalies</b>

<b>DA0E.Z</b>	<b>Dentofacial anomalies, unspecified</b>
<b>DA0F</b>	<b>Sensory disturbances affecting orofacial complex</b>
	<i>Coded Elsewhere:</i> Trigeminal neuralgia (8B82.0)
	Dysgeusia (MB41.2)
<b>DA0F.0</b>	<b>Burning mouth syndrome</b>
	Chronic burning mouth pain is chronic orofacial pain with an intraoral burning or dysaesthetic sensation that recurs for more than two hours per day on 50 % of the days over more than three months, without evident causative lesions on clinical investigation and examination. It is characterised by significant emotional distress (anxiety, anger/frustration or depressed mood) or interference with orofacial functions such as eating, yawning, speaking etc. Chronic burning mouth pain is multifactorial: biological, psychological and social factors contribute to the pain condition. The diagnosis is appropriate independently of identified biological or psychological contributors unless another diagnosis would better account for the presenting symptoms.
	<i>Inclusions:</i> Orodynia
<b>DA0F.Y</b>	<b>Other specified sensory disturbances affecting orofacial complex</b>
<b>DA0F.Z</b>	<b>Sensory disturbances affecting orofacial complex, unspecified</b>
<b>DA0Y</b>	<b>Other specified diseases or disorders of orofacial complex</b>
<b>DA0Z</b>	<b>Diseases or disorders of orofacial complex, unspecified</b>

### Diseases of oesophagus (DA20-DA2Z)

	<i>Coded Elsewhere:</i> Neoplasms of the oesophagus
	Structural developmental anomalies of oesophagus (LB12)
	Foreign body in oesophagus (ND73.1)
<b>DA20</b>	<b>Acquired anatomical alterations of the oesophagus</b>
	This group incorporates oesophageal disorders principally due to acquired morphological changes of the oesophagus.
	<i>Exclusions:</i> Structural developmental anomalies of oesophagus (LB12)
<b>DA20.0</b>	<b>Oesophageal obstruction</b>
	Hindrance of the passage of luminal contents in the oesophagus. Obstruction of oesophagus can be partial or complete, and caused by intrinsic or extrinsic factors.
	<i>Exclusions:</i> Congenital stenosis or stricture of oesophagus (LB12.3)
	Anatomical alteration due to gastro-oesophageal reflux disease (DA22)
	Neoplasms of the oesophagus ()
	Foreign body in oesophagus (ND73.1)

<b>DA20.1</b>	<b>Diverticulum of oesophagus, acquired</b> Diverticulum of oesophagus is a disorder having out-pouchings from the oesophageal wall.
	<b>Inclusions:</b> Oesophageal pouch, acquired Rokitansky diverticulum
	<b>Exclusions:</b> Congenital diverticulum of oesophagus (LB12.4)
<b>DA20.2</b>	<b>Oesophageal web</b> Oesophageal web is a thin membrane located in the middle or upper oesophagus, resulting in pain and dysphagia.
	<b>Exclusions:</b> Congenital oesophageal web or ring (LB12.0)
	<b>Coded Elsewhere:</b> Plummer-Vinson syndrome (3A00.Y)
<b>DA20.3</b>	<b>Perforation of oesophagus</b> Perforation of oesophagus is a penetration or hole of the wall of the oesophagus, resulting in luminal contents in oesophagus flowing into the mediastinum and/or thoracic cavity.
	<b>Exclusions:</b> Oesophageal ulcer (DA25)
	<b>Coded Elsewhere:</b> Oesophagitis due to external causes (DA24.2) Foreign body in oesophagus (ND73.1)
<b>DA20.30</b>	Spontaneous rupture of oesophagus Spontaneous perforation of the oesophageal wall. This most commonly results from a sudden increase in intraoesophageal pressure combined with relatively negative intrathoracic pressure caused by straining or vomiting. This is known as effort rupture of the oesophagus or Boerhaave's syndrome.
	<b>Inclusions:</b> Rupture of oesophagus
	<b>Exclusions:</b> traumatic perforation of (thoracic) oesophagus (NB32) Mallory-Weiss syndrome (DA26.3) Perforation due to malignant neoplasm ()
<b>DA20.3Y</b>	Other specified perforation of oesophagus
<b>DA20.3Z</b>	Perforation of oesophagus, unspecified
<b>DA20.Y</b>	<b>Other specified acquired anatomical alterations of the oesophagus</b>
<b>DA20.Z</b>	<b>Acquired anatomical alterations of the oesophagus, unspecified</b>
<b>DA21</b>	<b>Motility disorders of oesophagus</b> This group incorporates oesophageal disorders due to disturbances of oesophageal motor function.
	<b>Coding Note:</b> Code also the causing condition

<b>DA21.0</b>	<b>Achalasia</b> Achalasia is an oesophageal smooth muscle motility disorder characterised by a loss of peristalsis in the distal oesophagus and a failure of lower oesophageal sphincter (LES) relaxation. Basic mechanism is the degeneration of neurons (ganglion cells) in the myenteric plexuses in the oesophageal wall, but the cause is still unclear.  <b>Inclusions:</b> Cardiospasm <b>Exclusions:</b> congenital cardiospasm (LB12) <b>Coded Elsewhere:</b> Achalasia in Chagas disease (1F53.3)
<b>DA21.1</b>	<b>Motility disorder of cervical or upper oesophagus</b> Motility disorder of cervical and upper oesophagus is a condition characterised by choke, swallow air, regurgitate fluid into the nose, or experience discomfort in swallowing food due to incompetence of upper oesophageal sphincter.  <b>Coding Note:</b> Code also the causing condition <b>Inclusions:</b> Dyskinesia of cervical and upper oesophagus
<b>DA21.2</b>	<b>Disorder of oesophageal peristalsis</b> Disorder of oesophageal peristalsis is part of a spectrum of motility disorders in the thoracic oesophagus characterised by dysphagia and chest pain due to incoordination of oesophageal peristaltic contractions. There is no abnormality in lower oesophageal sphincter relaxation.  <b>Coding Note:</b> Code also the causing condition <b>Exclusions:</b> Achalasia (DA21.0) Gastro-oesophageal reflux disease (DA22)
<b>DA21.20</b>	Hypertensive peristalsis This is a motility disorder of oesophagus characterised by hypertensive peristalsis. This motility abnormality includes nutcracker oesophagus that has been reported in association with dysphagia, non-cardiac chest pain, and heartburn.
<b>DA21.21</b>	Hypotensive peristalsis This is a motility disorder of oesophagus characterised by hypotensive peristalsis. The peristaltic dysfunction likely leads to impaired volume clearance.
<b>DA21.22</b>	Spastic peristalsis This is a motility disorder of oesophagus characterised by hypercontractile spastic peristalsis, known as "jackhammer oesophagus" in the presence of normal lower oesophageal sphincter (LES) relaxation. This category also includes diffuse oesophageal spasm (DES) with uncoordinated contraction characterised by reduced distal latency on oesophageal manometry.  <b>Inclusions:</b> Diffuse oesophageal spasm Spasm of oesophagus
<b>DA21.2Y</b>	Other specified disorder of oesophageal peristalsis <b>Coding Note:</b> Code also the causing condition

<b>DA21.2Z</b>	Disorder of oesophageal peristalsis, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>DA21.3</b>	<b>Disorder of lower oesophageal sphincter function</b> Disorder of lower oesophageal sphincter function is a condition characterised by dysphagia, chest pain, heartburn and regurgitation due to incompetence of lower oesophageal sphincter.
<b>Coding Note:</b>	Code also the causing condition
<b>DA21.Y</b>	<b>Other specified motility disorders of oesophagus</b>
<b>Coding Note:</b>	Code also the causing condition
<b>DA21.Z</b>	<b>Motility disorders of oesophagus, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>DA22</b>	<b>Gastro-oesophageal reflux disease</b> A condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications <b>Coded Elsewhere:</b> Gastro-oesophageal reflux disease in newborn (KB80)
<b>DA22.0</b>	<b>Non-erosive gastro-oesophageal reflux disease</b> A disease condition in that patients have classic symptoms of gastro-oesophageal reflux disease (GERD), but do not have apparent esophagitis or oesophageal mucosal injury. <b>Exclusions:</b> Functional heartburn (DD90.2)
<b>DA22.1</b>	<b>Erosive gastro-oesophageal reflux disease</b> Erosive gastro-oesophageal reflux disease is defined endoscopically by visible breaks of the distal oesophageal mucosa. <b>Inclusions:</b> Reflux oesophagitis Peptic oesophagitis
<b>DA22.Z</b>	<b>Gastro-oesophageal reflux disease, unspecified</b>
<b>DA23</b>	<b>Columnar metaplastic epithelium of the oesophagus</b> An acquired condition in which the tissue lining the oesophagus is replaced by tissue that is similar to the lining of the intestine or the stomach following chronic gastro-oesophageal reflux. <b>Coded Elsewhere:</b> Barrett adenocarcinoma (2B70.00)
<b>DA23.0</b>	<b>Barrett epithelium</b> Barrett epithelium is defined as those having circumferential columnar metaplasia of oesophagus from the esophago-gastric junction. Recently, from the view of adenocarcinogenesis of the oesophagus, the term of Barrett epithelium require the histological confirmation of specialized intestinal metaplasia.

<b>DA23.1</b>	<b>Dysplasia of Barrett epithelium</b> Dysplasia of Barrett epithelium is defined as neoplastic epithelium that remains confined within the basement membrane of Barrett oesophagus. Dysplasia of Barrett epithelium is considered as a precursor of adenocarcinoma arising in Barrett Oesophagus.
<b>DA23.2</b>	<b>Barrett ulcer</b> Barrett ulcer is defined as ulceration in columnar epithelium of oesophagus.
<b>DA23.Y</b>	<b>Other specified columnar metaplastic epithelium of the oesophagus</b>
<b>DA23.Z</b>	<b>Columnar metaplastic epithelium of the oesophagus, unspecified</b>
<b>DA24</b>	<p><b>Oesophagitis</b></p> <p>Oesophagitis is inflammation of the oesophagus. Oesophagitis can cause painful, difficult swallowing and chest pain. Oesophagitis has several causes; some common causes include stomach reflux, infection, oral medicines and allergies. Treatment for esophagitis depends on the underlying cause and how badly the tissue lining the esophagus is damaged. If left untreated, this condition can cause ulcers or scarring of the oesophagus causing narrowing of the oesophagus, unintended weight loss and dehydration.</p> <p><b>Exclusions:</b> reflux oesophagitis (DA22.1) Oesophageal erosion (DA25.0) Gastro-oesophageal reflux disease (DA22) Crohn disease (DD70)</p> <p><b>Coded Elsewhere:</b> Oesophagitis in newborn (KB81)</p>
<b>DA24.0</b>	<p><b>Infectious oesophagitis</b></p> <p>Infectious oesophagitis is inflammation, irritation and swelling of the oesophagus due to the infectious agent.</p> <p><b>Coding Note:</b> Code also the causing condition</p>
<b>DA24.00</b>	<p>Oesophageal phlegmon</p> <p>A spreading diffuse inflammatory process with formation of suppurative/purulent exudate or pus in the oesophageal wall. It often develops to a defined pocket of pus, oesophageal abscess. This is mainly due to the result of acute inflammation by bacterial infection.</p> <p><b>Inclusions:</b> Abscess of oesophagus</p>
<b>DA24.0Y</b>	Other specified infectious oesophagitis
<b>Coding Note:</b>	Code also the causing condition
<b>DA24.0Z</b>	Infectious oesophagitis, unspecified
<b>Coding Note:</b>	Code also the causing condition

<b>DA24.1</b>	<b>Eosinophilic oesophagitis</b> Eosinophilic oesophagitis is an inflammatory condition in which the wall of the oesophagus becomes filled with a large number of eosinophils. It is diagnosed based on typical oesophageal symptoms and oesophageal mucosal biopsies demonstrating oesophageal epithelial infiltration with eosinophils.
	<b>Inclusions:</b> Allergic oesophagitis
	<b>Coded Elsewhere:</b> Food-induced eosinophilic oesophagitis (4A83.1) Neonatal eosinophilic oesophagitis (KB81.0)
<b>DA24.2</b>	<b>Oesophagitis due to external causes</b> Inflammation of the oesophagus due to external cause such as radiation, ingestion of the alkali and acid, and swallowed pills or food failing to traverse entire oesophagus. <b>Coded Elsewhere:</b> Thermal injury of oesophagus (NE02)
<b>DA24.20</b>	Chemical oesophagitis This is oesophageal inflammation caused by chemical injury including alkaline or acid solutions.
<b>DA24.21</b>	Drug-induced oesophagitis This refers to a drug-induced inflammation of the oesophagus. Medications can induce oesophageal abnormalities via both systemic effects and by causing direct oesophageal mucosal injury, so-called 'pill-induced' oesophagitis.
<b>DA24.22</b>	Radiation oesophagitis
<b>DA24.2Z</b>	Oesophagitis due to external causes, unspecified
<b>DA24.Y</b>	<b>Other specified oesophagitis</b>
<b>DA24.Z</b>	<b>Oesophagitis, unspecified</b>
<b>DA25</b>	<p><b>Oesophageal ulcer</b> Oesophageal ulcer is tissue defect located in the oesophagus. It causes inflammatory injuries in the oesophageal mucosa, with extension beyond the submucosa into the muscularis mucosa. The oesophageal ulcer due to acidic digestive juices is classified elsewhere in gastro-oesophageal reflux disease, and excluded from here.</p> <p><b>Exclusions:</b> Barrett ulcer (DA23.2) Neoplasms of the oesophagus () Crohn disease (DD70)</p>
<b>DA25.0</b>	<b>Oesophageal erosion</b> Oesophageal erosion represents a mucosal breach extending up to, but not through, the muscularis mucosa. Oesophageal erosion due to gastro-oesophageal reflux disease is excluded from here.

<b>DA25.1</b>	<b>Infectious oesophageal ulcer</b> Infectious oesophageal ulcer is ulceration or erosion in the mucosa of oesophagus due to the infectious agent, such as bacteria, viruses, fungi and parasites.
<b>DA25.10</b>	Bacterial oesophageal ulcer Ulcer in the mucosa of oesophagus due to bacterial infection.
<b>DA25.11</b>	Fungal oesophageal ulcer Ulcer in the mucosa of oesophagus due to fungal infection.
<b>DA25.12</b>	Parasitic oesophageal ulcer Ulcer in the mucosa of oesophagus due to parasitic infection.
<b>DA25.13</b>	Viral oesophageal ulcer Ulcer in the mucosa of oesophagus due to viral infection.
<b>DA25.1Y</b>	Other specified infectious oesophageal ulcer
<b>DA25.1Z</b>	Infectious oesophageal ulcer, unspecified
<b>DA25.2</b>	<b>Oesophageal ulcer due to allergic or immunologic disorder</b> Oesophageal ulcer or erosion due to allergic disorders or systemic immunologic disorders.
<b>Coding Note:</b>	Code also the causing condition
<b>DA25.3</b>	<b>Oesophageal ulcer due to external causes</b> Oesophageal ulcer or erosion due to external causes such as ingestion of certain chemical substances or drugs, radiation and thermal injury, or other external causes.  <b>Coded Elsewhere:</b> Thermal oesophageal ulcer (NE02)
<b>DA25.30</b>	Chemical oesophageal ulcer This is oesophageal ulcer caused by chemical injury including alkaline or acid solutions.  <b>Inclusions:</b> Ulcer of oesophagus due to ingestion of chemicals
<b>DA25.31</b>	Drug-induced oesophageal ulcer <b>Inclusions:</b> Ulcer of oesophagus due to ingestion of drugs and medicaments
<b>DA25.32</b>	Radiation oesophageal ulcer
<b>DA25.3Y</b>	Oesophageal ulcer due to other specified external causes
<b>DA25.3Z</b>	Oesophageal ulcer due to external causes, unspecified
<b>DA25.Y</b>	<b>Other specified oesophageal ulcer</b>
<b>DA25.Z</b>	<b>Oesophageal ulcer, unspecified</b>

**DA26****Vascular disorders of the oesophagus**

This group incorporates vascular disorders principally affecting the blood vessels of the oesophagus. They include vascular disorders of arteries, veins and capillaries that carry blood to and from the oesophagus.

**DA26.0****Oesophageal varices**

Abnormally dilated veins developed as portosystemic shunts in the lining of the lower oesophagus in patients with portal hypertension. Once oesophageal varices develop, they continue to grow, and bleeding from oesophageal varices can be fatal.

**Coding Note:**

Code also the causing condition

**DA26.00**

Oesophageal varices with bleeding

**Coding Note:**

Code also the causing condition

**DA26.01**

Oesophageal varices without bleeding

**Coding Note:**

Code also the causing condition

**DA26.0Z**

Oesophageal varices, unspecified

**Coding Note:**

Code also the causing condition

**DA26.1****Angiodysplasia or arteriovenous malformation of oesophagus**

Enlarged or widened blood vessels with thin walls that are similar to varicose veins. It can be a source of gastrointestinal bleeding and anaemia.

**DA26.2****Intramural haemorrhage of oesophagus**

Hematoma in the oesophageal wall that can be formed spontaneously or as a result of trauma, toxic ingestion, or endoscopic procedures. It is rarely observed.

**Inclusions:** Intramural haematoma of oesophagus

**Exclusions:** Oesophageal varices (DA26.0)

**DA26.3****Gastro-oesophageal laceration-haemorrhage syndrome**

Bleeding from tears in the mucosa at the junction of the stomach and oesophagus, usually caused by severe vomiting, retching or coughing.

**Inclusions:** Mallory-Weiss syndrome

Mallory-Weiss tear

Mallory-Weiss lesion

**DA26.Y****Other specified vascular disorders of the oesophagus****DA26.Z****Vascular disorders of the oesophagus, unspecified****DA2Y****Other specified diseases of oesophagus****DA2Z****Diseases of oesophagus, unspecified**

## Diseases of the stomach or the duodenum (DA40-DA7Z)

### Diseases of stomach (DA40-DA4Z)

This is a group of conditions characterised as being in or associated with the stomach.

- Exclusions:**
- Gastrostomy malfunction (DE12.1)
  - Diaphragmatic hernia (DD50.0)

- Coded Elsewhere:**
- Neoplasms of the stomach
  - Structural developmental anomalies of stomach (LB13)
  - Gastric ulcer (DA60)
  - Peptic ulcer, site unspecified (DA61)
  - Anastomotic ulcer (DA62)
  - Foreign body in stomach (ND73.2)

**DA40**

### **Acquired anatomical alterations of the stomach**

This group incorporates gastric disorders principally due to acquired morphological changes of the stomach.

- Exclusions:**
- Structural developmental anomalies of stomach (LB13)
  - Diaphragmatic hernia (DD50.0)

**DA40.0**

### **Gastric outlet obstruction**

Gastric outlet obstruction is a disorder characterised by epigastric abdominal pain and postprandial vomiting due to mechanical obstruction mostly at the level of the pylorus.

**DA40.1**

### **Gastric fistula, acquired**

Acquired gastric fistula is an opening through the gastric wall and into the peritoneal cavity, into another organ and vessels that normally do not connect, or through the abdominal wall.

**DA40.2**

### **Gastric volvulus**

Gastric volvulus is an uncommon clinical entity defined as an abnormal rotation (twisting) of all or part of the stomach by more than 180 degrees, creating a closed-loop obstruction of the flow of material through the stomach. It can result in incarceration and strangulation, with variable loss of blood supply.

Although rare in childhood, a wandering spleen may also be associated with gastric volvulus, because they share a common etiology: congenital absence of intraperitoneal visceral attachments.

**DA40.3**

### **Gastric diverticulum**

Gastric diverticulum is a disorder having out-pouchings from the gastric wall.

- Exclusions:**
- Congenital diverticulum of stomach (LB13)

<b>DA40.4</b>	<b>Hourglass stricture and stenosis of stomach</b> This is a structural change of stomach in which one more or less completely divided into two parts, resembling an hourglass in shape, due to often scarring which complicates chronic gastric ulcer.
<b>DA40.5</b>	<b>Gastrophtosis</b> This is the abnormal downward displacement of the stomach.
<b>DA40.Y</b>	<b>Other specified acquired anatomical alterations of the stomach</b>
<b>DA40.Z</b>	<b>Acquired anatomical alterations of the stomach, unspecified</b>
<b>DA41</b>	<p><b>Gastroduodenal motor or secretory disorders</b> This group incorporates disorders due to abnormalities of gastroduodenal motor function and gastroduodenal secretory function, often resulting in the disturbance of transportation and/or digestion of foods.</p> <p><b>Coded Elsewhere:</b> Dumping syndrome (DE11)</p>
<b>DA41.0</b>	<b>Abnormal gastric motility</b>
<b>DA41.00</b>	<b>Gastroparesis</b> Gastroparesis is a disorder in which the stomach takes too long to empty its contents principally due to malfunction of vagus nerve.
<b>DA41.0Y</b>	Other specified abnormal gastric motility
<b>DA41.0Z</b>	Abnormal gastric motility, unspecified
<b>DA41.1</b>	<b>Acute dilatation of stomach</b> Acute dilatation of stomach is a disorder due to acute enlargement of the gastric cavity by over-distention, resulting in the retention of food and the products of digestion in the stomach.
	<b>Inclusions:</b> Acute distension of stomach
<b>DA41.2</b>	<b>Acid hypersecretion</b> Acid hypersecretion is a condition due to basal hypersecretion of gastric acid in the stomach, resulting in peptic ulcer and steatorrhoea.
	<b>Exclusions:</b> Zollinger-Ellison syndrome (5A43.1)
<b>DA41.3</b>	<b>Achlorhydria</b> Achlorhydria is a condition due to the absence of gastric acid in the stomach, resulting in indigestion and malabsorption.
<b>DA41.Y</b>	<b>Other specified gastroduodenal motor or secretory disorders</b>
<b>DA41.Z</b>	<b>Gastroduodenal motor or secretory disorders, unspecified</b>

**DA42**

## **Gastritis**

Gastritis is an injury of gastric mucosa that involves epithelial damage, mucosal inflammation, and epithelial cell regeneration except for any epithelial defect. Gastritis is caused by various factors such as infectious agents, drugs, chemical agents, autoimmune reaction and others. Gastritis is diagnosed histopathologically and/or endoscopically. Gastritis is classified as acute and chronic phase by clinical course.

**Inclusions:**      Gastroduodenitis

**DA42.0**

### **Autoimmune gastritis**

A type of chronic atrophic gastritis restricted to gastric body mucosa, and characterised by a severe atrophy of the acid secreting glands and achlorhydria. This is usually associated with serum antiparietal cell antibody, with or without pernicious anaemia.

**Coding Note:**

Code also the causing condition

**DA42.1**

### **Helicobacter pylori induced gastritis**

Gastritis with Helicobacter pylori infection. H. pylori infection causes acute gastritis at first. Lasting the infection the gastric mucosa turns into chronic gastritis and atrophic gastritis, one of the risk factors of gastric adenocarcinoma(CJBAA).

**DA42.2**

### **Eosinophilic gastritis**

**Coded Elsewhere:** Food-induced eosinophilic gastroenteritis (4A83.0)

**DA42.3**

### **Lymphocytic gastritis**

Chronic gastritis characterised by a peculiar infiltration of benign lymphocytes into the glands and surface mucosa. Lymphocytic gastritis is associated with celiac disease, Helicobacter pylori (HP) gastritis, and varioliform gastritis.

**DA42.4**

### **Allergic gastritis**

Gastritis due to allergic disorders, principally meaning acute gastritis that occurs secondary to food allergy. But this also includes allergic gastritis due to non-food substances and allergic gastritis due to non-IgE-mediated hypersensitivity. This includes gastroduodenitis and gastroenteritis.

**Exclusions:**

Allergic eosinophilic gastritis (DA42.2)

Food-induced eosinophilic gastroenteritis (4A83.0)

**DA42.40**

Allergic gastritis due to IgE-mediated hypersensitivity

**DA42.41**

Allergic gastritis due to non-IgE-mediated hypersensitivity

**DA42.4Y**

Other specified allergic gastritis

**DA42.4Z**

Allergic gastritis, unspecified

**DA42.5**

### **Gastritis due to duodenogastric reflux**

Gastritis due to an excessive reflux of duodenal contents including bile into the stomach.

<b>DA42.6</b>	<b>Menetrier disease</b> Gastritis characterised by gastric mucosal hypertrophy, which may cause the giant rugal folds. The thickening of the rugae is predominantly caused by the expansion of the epithelial cell compartment of the gastric mucosa. Patients with Ménétier disease most often present with hypoalbuminemia secondary to a loss of albumin into the gastric lumen.
<b>DA42.7</b>	<b>Gastritis of unknown aetiology with specific endoscopic or pathological features</b>
<b>DA42.70</b>	Acute superficial gastritis of unknown aetiology
<b>DA42.71</b>	Chronic superficial gastritis of unknown aetiology Persistent or recurrent inflammation of the lamina propria, limited to the outer third of the mucosa in the foveolar area.
<b>DA42.72</b>	Acute haemorrhagic gastritis of unknown aetiology Rapid onset inflammation of the mucosal lining of the stomach with associated bleeding or abnormal blood flow.  <b><i>Exclusions:</i></b> Gastric erosion (DA60.0)
<b>DA42.73</b>	Chronic atrophic gastritis of unknown aetiology Persistent or recurrent inflammation of the gastric mucosa with atrophy leading to decreased hydrochloric acid concentration in the gastric juice. Atrophic gastritis frequently progresses from chronic gastritis.  <b><i>Inclusions:</i></b> Gastric atrophy
<b>DA42.74</b>	Metaplastic gastritis of unknown aetiology Gastritis with intestinal metaplastic lesion, endoscopically visualized as an ash-coloured nodular change.  <b><i>Inclusions:</i></b> Intestinal metaplasia
<b>DA42.75</b>	Granulomatous gastritis of unknown aetiology A rare disease characterised by the presence of granulomas within the gastric mucosa or submucosa. Common causes of GG are Crohn's disease (CD), disseminated sarcoidosis and infections (tuberculosis [TB], syphilis, fungal).
<b>DA42.76</b>	Hypertrophic gastritis of unknown aetiology Gastritis with rugal hypertrophy of greater curvature in corpus, in which hypertrophy of glands is observed.  <b><i>Exclusions:</i></b> Menetrier disease (DA42.6)
<b>DA42.7Y</b>	Other specified gastritis of unknown aetiology with specific endoscopic or pathological features
<b>DA42.8</b>	<b>Gastritis due to external causes</b> Gastritis caused by external substances, such as alcohol, radiation, chemical agent and by other external causes.

- DA42.80** Alcoholic gastritis  
Inflammation of the gastric mucosa due to excessive alcohol use.
- DA42.81** Radiation gastritis
- DA42.82** Chemical gastritis
- DA42.83** Drug-induced gastritis  
Acute or chronic gastritis induced by taking some known gastric mucosal damaged agents such as NSAIDs, aspirin and antibiotics.
- DA42.8Z** Gastritis due to external causes, unspecified
- DA42.9** **Gastric phlegmon**  
A spreading diffuse inflammatory process with formation of suppurative/purulent exudate or pus in the gastric wall. It often develops to a defined pocket of pus, gastric abscess. This is mainly due to the result of acute inflammation by bacterial infection.
- Inclusions:**      Gastric abscess  
                         Phlegmonous gastritis
- DA42.Y** Other specified gastritis
- DA42.Z** Gastritis, unspecified
- DA43** **Vascular disorders of the stomach**  
This group incorporates vascular disorders principally affecting the blood vessels of the stomach. They include vascular disorders of arteries, veins and capillaries that carry blood to and from the stomach
- DA43.0** **Gastric varices**  
Abnormally dilated veins developed as portosystemic shunts in the lining of stomach (fundus and/or cardia) in patients with portal hypertension. Once gastric varices develop, they continue to grow, and bleeding from gastric varices can be fatal.
- DA43.1** **Angiodysplasia of stomach**  
Small vascular malformation of the stomach. Most lesions are less than 10mm in size and often observed in multiple sites. It can be a source of gastrointestinal bleeding and anaemia.  
**Coded Elsewhere:** Hereditary haemorrhagic telangiectasia (LA90.00)
- DA43.2** **Arteriovenous malformation of stomach**  
Arteriovenous malformation is a vascular lesion in which arteries and veins are tangled and not connected by capillaries.
- DA43.3** **Portal hypertensive gastropathy**  
Changes in the mucosa of the stomach in patients with portal hypertension; by far the most common cause of this is cirrhosis of the liver.

<b>DA43.4</b>	<b>Diffuse vascular ectasia of stomach</b> Tortuous dilated blood vessels in the pyloric antrum radiating outward from the pylorus (so-called watermelon stomach). It may cause both acute and chronic gastrointestinal haemorrhage.
<b>DA43.Y</b>	<b>Other specified vascular disorders of the stomach</b>
<b>DA43.Z</b>	<b>Vascular disorders of the stomach, unspecified</b>
<b>DA44</b>	<p><b>Gastric polyp</b> Protruding lesion on the gastric epithelium caused by local overgrowth of gastric epithelial cells, classified as pedunculated and sessile type.</p> <p><b>Inclusions:</b> Non-neoplastic gastric polyp  <b>Exclusions:</b> Adenomatous gastric polyp (2E92.1)  Adenoma of stomach (2E92.1)</p>
<b>DA44.0</b>	<b>Hyperplastic polyp of stomach</b> Due to over growth of gastric foveolar epithelial cells. The histological background of hyperplastic polyp is atrophic gastritis, mostly caused by long-term H. pylori infection.
<b>DA44.1</b>	<b>Fundic gland polyp of stomach</b> Due to hyperplasia of fundic gland cells. Fundic polyp rises on fundic gland area without atrophic gastritis. Most cases show H. pylori negative.
<b>DA44.2</b>	<b>Hamartomatous polyp of stomach</b> Formed of dilated oxyntic glands and irregularly deformed oxyntic glands histologically. Most of them are located in the gastric body or the fundus.
<b>DA44.Y</b>	<b>Other specified gastric polyp</b>
<b>DA44.Z</b>	<b>Gastric polyp, unspecified</b>
<b>DA4Y</b>	<b>Other specified diseases of stomach</b>
<b>DA4Z</b>	<b>Diseases of stomach, unspecified</b>

#### Diseases of duodenum (DA50-DA5Z)

This is a group of conditions characterised as being in or associated with the duodenum, the first portion of the small intestine.

**Coded Elsewhere:** Neoplasms of the duodenum

- Structural developmental anomalies of duodenum (LB14)
- Duodenal ulcer (DA63)

#### **DA50** **Acquired anatomical alterations of the duodenum**

This group incorporates duodenal disorders principally due to acquired morphological changes of the duodenum.

<b>DA50.0</b>	<b>Obstruction of duodenum</b> Hindrance of the passage of luminal contents in the duodenum. Obstruction of duodenum can be partial or complete, and caused by intrinsic or extrinsic factors. Simple obstruction is associated with diminished or stopped flow of luminal contents. Strangulating obstruction is associated with impaired blood flow to the duodenum in addition to obstructed flow of luminal contents.
	<b><i>Exclusions:</i></b> congenital stenosis of duodenum (LB14)
<b>DA50.1</b>	<b>Diverticulum of duodenum</b> Diverticulum of duodenum is a disorder having out-pouchings from the duodenal wall.
	<b><i>Exclusions:</i></b> Congenital diverticulum of duodenum (LB14)
<b>DA50.2</b>	<b>Fistula of duodenum</b> Fistula of duodenum is an opening through the duodenal wall and into the peritoneal cavity, into another organ and vessels that normally do not connect, or through the abdominal wall.
<b>DA50.3</b>	<b>Deformity of duodenum, acquired</b> Changes of duodenum in response to the influence by duodenal disease, compression of other organs around the duodenum.
<b>DA50.Y</b>	<b>Other specified acquired anatomical alterations of the duodenum</b>
<b>DA50.Z</b>	<b>Acquired anatomical alterations of the duodenum, unspecified</b>
<b>DA51</b>	<p><b>Duodenitis</b> Duodenitis is an injury of duodenal mucosa that involves epithelial damage and mucosal inflammation except for any epithelial defect. Duodenitis is caused by various factors such as high acid secretion, infectious agents, drugs, chemical agents and others. Gastric metaplasia (GM) is considered adaptive responses to hyperacidity. Helicobacter pylori can be colonized on GM epithelium, and induce duodenitis. Duodenitis is diagnosed histopathologically and/or endoscopically. Duodenitis is classified as acute and chronic phase by clinical course.</p> <p><b><i>Inclusions:</i></b> Inflammation of duodenum  <b><i>Exclusions:</i></b> Crohn disease (DD70)</p>
<b>DA51.0</b>	<b>Helicobacter-pylori associated duodenitis</b> Duodenitis with Helicobacter pylori infection. H. pylori can be colonized on gastric metaplasia epithelium at bulb, and induce duodenitis.
<b>DA51.1</b>	<b>Eosinophilic duodenitis</b> A disease characterised by eosinophilic infiltration of various layers of duodenum in the absence of any known cause of eosinophilia.
<b>DA51.2</b>	<b>Lymphocytic duodenitis</b> Chronic duodenitis characterised by a dense infiltration of benign lymphocytes into the epithelium and lamina propria. Lymphocytic duodenitis may present early gluten-induced damage.

<b>DA51.3</b>	<b>Allergic duodenitis</b> Duodenitis due to allergic disorders.
<b>DA51.4</b>	<b>Duodenitis of unknown aetiology with specific endoscopic or pathologic features</b> Duodenitis of unknown etiology showing specific endoscopic or pathological findings, including acute haemorrhagic duodenitis and Granulomatous duodenitis.
<b>DA51.40</b>	Acute haemorrhagic duodenitis of unknown aetiology
<b>DA51.41</b>	<b>Granulomatous duodenitis of unknown aetiology</b> A rare disease characterised by the presence of granulomas within the duodenal mucosa or submucosa. Common causes are Crohn's disease (CD), disseminated sarcoidosis and infections (tuberculosis [TB], syphilis, fungal).
<b>DA51.4Z</b>	Duodenitis of unknown aetiology with specific endoscopic or pathologic features, unspecified
<b>DA51.5</b>	<b>Duodenitis due to external causes</b> Duodenitis caused by external substances, such as alcohol, radiation, chemical agent and by other external causes.
<b>DA51.50</b>	Alcoholic duodenitis <b>Inclusions:</b> Inflammation of the duodenal mucosa due to alcohol use
<b>DA51.51</b>	Drug-induced duodenitis Acute or chronic duodenitis induced by taking some known duodenal mucosal damaged agents such as NSAIDs and aspirin.
<b>DA51.52</b>	Chemical duodenitis <b>Inclusions:</b> Toxic duodenitis
<b>DA51.53</b>	Radiation duodenitis
<b>DA51.5Y</b>	Duodenitis due to other specified external causes
<b>DA51.5Z</b>	Duodenitis due to external causes, unspecified
<b>DA51.6</b>	<b>Infectious duodenitis</b>
<b>DA51.60</b>	Duodenal phlegmon A spreading diffuse inflammatory process with formation of suppurative/purulent exudate or pus in the duodenal wall. It often develops to a defined pocket of pus, duodenal abscess. This is mainly due to the result of acute inflammation by bacterial infection.
<b>DA51.6Y</b>	Other specified infectious duodenitis
<b>DA51.6Z</b>	Infectious duodenitis, unspecified
<b>DA51.Y</b>	<b>Other specified duodenitis</b>
<b>DA51.Z</b>	<b>Duodenitis, unspecified</b>

**DA52**

### **Vascular disorders of the duodenum**

This group incorporates vascular disorders principally affecting the blood vessels of the duodenum. They include vascular disorders of arteries, veins and capillaries that carry blood to and from the stomach.

**DA52.0**

#### **Duodenal varices**

Abnormally dilated veins developed as portosystemic shunts in the lining of duodenum in patients with portal hypertension. Once duodenal varices develop, they continue to grow, and bleeding from duodenal varices can be fatal.

**DA52.1**

#### **Angiodysplasia of duodenum**

Ectasia of duodenal submucosal veins and overlying mucosal capillaries. Most lesions are less than 10mm in size, and multiple lesions are frequent. On endoscopy, flat or slightly elevated, reddish, roundish or starry lesions are observed.

**DA52.2**

#### **Arteriovenous malformation of duodenum**

Arteriovenous malformation is a vascular lesion in which arteries and veins are tangled and not connected by capillaries. Dilated weak-walled blood vessels in the duodenum usually close to the inside surface. They appear as very red areas, and tend to bleed easily with minimal trauma.

**DA52.Y**

#### **Other specified vascular disorders of the duodenum**

**DA52.Z**

#### **Vascular disorders of the duodenum, unspecified**

**DA53**

### **Duodenal polyp**

Protruding lesion on the duodenal epithelium caused by local overgrowth of duodenal epithelial cells.

***Exclusions:***

Gastric heterotopia of duodenum (LB14)

adenoma or adenomatous polyp of the duodenum (2E92.2)

**DA53.0**

#### **Hyperplastic duodenal polyp**

Due to overgrowth of gastric foveolar type epithelial cells in duodenum.

**DA53.Y**

#### **Other specified duodenal polyp**

**DA53.Z**

#### **Duodenal polyp, unspecified**

**DA5Y**

#### **Other specified diseases of duodenum**

**DA5Z**

#### **Diseases of duodenum, unspecified**

Ulcer of stomach or duodenum (DA60-DA63.Z)

**DA60**

**Gastric ulcer**

Gastric ulcer is defined as a distinct breach in the mucosa of the stomach as a result of caustic effects of acid and pepsin in the lumen. Histologically, gastric ulcer is identified as necrosis of the mucosa extending through the muscularis mucosae into the submucosa. In the endoscopic or radiological view, there is an appreciable depth of the lesion. When the break of epithelial lining is confined to the mucosa without penetrating through the muscularis mucosae, the superficial lesion is called 'erosion'.

**Inclusions:** Mucosal defect of the stomach

Peptic ulcer of stomach

**Exclusions:** acute haemorrhagic erosive gastritis (DA42.72)

Malignant neoplasms of stomach (2B72)

**DA60.0**

**Gastric erosion**

Gastric erosion represents a mucosal breach extending up to, but not through, the muscularis mucosa. Gastric erosion may constitute a phase of ulcer development or accompany some forms of gastric ulcer.

**DA60.1**

**Helicobacter pylori associated gastric ulcer**

Helicobacter pylori (H. pylori) is a gram-negative bacillus that is found in the mucous layer overlying gastric epithelium, within epithelial cells and attached to mucous cells, leading to inflammation. It accounts for the majority of gastric ulcer. H. pylori that involves the acid-producing mucosa of the stomach can lead to hypochlorhydria or achlorhydria, and subsequent gastric ulceration.

**Exclusions:** Helicobacter pylori associated and drug-induced gastric ulcer (DA60.2)

**DA60.2**

**Helicobacter pylori associated and drug-induced gastric ulcer**

**DA60.3**

**Stress ulcer of stomach**

Stress ulcers of stomach are acute mucosal lesions occurring in critically ill patients that may result in acute upper gastrointestinal bleeding. They are usually superficial erosions but can develop into ulcers. Stress ulcers of stomach may develop anywhere within the stomach but are more likely to occur in fundic mucosa, which lines the body and fundus of the stomach.

**DA60.4**

**Eosinophilic gastric ulcer**

Gastric ulcer caused by eosinophilic gastritis.

**DA60.5**

**Lymphocytic gastric ulcer**

Gastric ulcer caused by lymphocytic gastritis.

**DA60.6**

**Gastric ulcer due to external causes**

Gastric ulcer caused by external substances, such as alcohol, radiation, chemical agent and by other external causes.

**DA60.60**

Alcohol-induced gastric ulcer

- DA60.61** Chemical gastric ulcer
- DA60.62** Drug-induced gastric ulcer  
Medications such as NSAIDs can cause gastric ulcer. Other drugs that may increase the risk of ulceration include potassium chloride, concomitant use of steroids with NSAIDs, bisphosphonates, and mycophenolate mofetil.
- Inclusions:** Toxic gastric ulcer
- Exclusions:** Helicobacter pylori associated and drug-induced gastric ulcer (DA60.2)
- DA60.63** Radiation gastric ulcer
- DA60.6Y** Other specified gastric ulcer due to external causes
- DA60.6Z** Gastric ulcer due to external causes, unspecified
- DA60.7** **Infectious secondary gastric ulcer**  
Gastric ulcer due to infectious diseases other than Helicobacter pylori, such as bacteria such as mycobacterium, virus, fungus and parasites.
- Coding Note:** Code also the causing condition
- DA60.Y** Other specified gastric ulcer
- DA60.Z** Gastric ulcer, unspecified
- DA61** **Peptic ulcer, site unspecified**  
Peptic ulcer is defined as a distinct breach in the mucosa of the gastrointestinal tract as a result of caustic effects of acid and pepsin in the lumen. A peptic ulcer may develop in any part of the gastrointestinal tract exposed to acid and pepsin. The most common locations are the stomach and duodenal bulb, but peptic ulcer may also develop in the oesophagus in gastro-oesophageal reflux diseases, and in the distal ileum as a result of a Meckel's diverticulum lined with heterotopic gastric mucosa.
- DA62** **Anastomotic ulcer**  
Anastomotic ulcer develops following gastric resection or other procedures, such as gastroenterostomy, that involve the anastomosis of the stomach to some other portion of the gastrointestinal tract. In such cases an ulcer develops near the stoma; it is almost invariably in the efferent limb of the intestine, not in the stomach.
- Exclusions:** Primary ulcer of small intestine (DA94.0)
- DA62.0** **Anastomotic erosion**  
Anastomotic erosion represents a mucosal breach extending up to, but not through, the muscularis mucosa. Anastomotic erosion may constitute a phase of ulcer development or accompany some forms of anastomotic ulcer.
- DA62.1** **Helicobacter pylori associated anastomotic ulcer**  
Helicobacter pylori associated anastomotic ulcer is an ulcer at the anastomosis that is associated with Helicobacter pylori infection. Helicobacter pylori infection is considered as one of the risk factors for anastomotic ulcer.

<b>DA62.2</b>	<b>Drug-induced anastomotic ulcer</b> Drug-induced anastomotic ulcer is an ulcer at the anastomosis that is caused by drug ingestion. NSAID is considered as one of the risk factors for anastomotic ulcer.
<b>DA62.3</b>	<b>Peptic anastomotic ulcer</b> Anastomotic ulcer, peptic is an ulcer resulting from the effects of gastric acid on the susceptible intestinal mucosa.
<b>DA62.Y</b>	<b>Other specified anastomotic ulcer</b>
<b>DA62.Z</b>	<b>Anastomotic ulcer, unspecified</b>
<b>DA63</b>	<p><b>Duodenal ulcer</b></p> <p>Duodenal ulcer is defined as a distinct breach in the mucosa of the duodenum as a result of caustic effects of acid and pepsin in the lumen. Histologically, duodenal ulcer is identified as necrosis of the mucosa extending through the muscularis mucosae into the submucosa. In the endoscopic or radiological view, there is an appreciable depth of the lesion. When the break of epithelial lining is confined to the mucosa without penetrating through the muscularis mucosae, the superficial lesion is called 'erosion'.</p> <p><b>Exclusions:</b> Anastomotic ulcer (DA62)</p>
<b>DA63.0</b>	<b>Duodenal erosion</b> Duodenal erosion represents a mucosal breach extending up to, but not through, the muscularis mucosa. Duodenal erosion may constitute a phase of ulcer development or accompany some forms of duodenal ulcer.
<b>DA63.1</b>	<b>Helicobacter-pylori associated duodenal ulcer</b> Helicobacter pylori (H. pylori) is a gram-negative bacillus that is found in the mucous layer overlying gastric epithelium, within epithelial cells and attached to mucous cells, leading to inflammation. In the case of duodenal ulcers, H. pylori is believed to infect the gastric antrum or ectopic gastric mucosa in the duodenum. This is associated with increased acid production and duodenal ulceration.
<b>DA63.2</b>	<b>Helicobacter-pylori associated and drug-induced duodenal ulcer</b>
<b>DA63.3</b>	<b>Stress ulcer of duodenum</b> Stress ulcers of duodenum are acute mucosal lesions occurring in critically ill patients that may result in acute upper gastrointestinal bleeding. They are usually superficial erosions but can develop into ulcers.
<b>DA63.4</b>	<b>Eosinophilic duodenal ulcer</b> Duodenal ulcer caused by eosinophilic duodenitis
<b>DA63.5</b>	<b>Duodenal ulcer due to external causes</b> Duodenal ulcer caused by external substances, such as alcohol, radiation, chemical agent and by other external causes.

<b>DA63.50</b>	Drug-induced duodenal ulcer Medications such as NSAIDs can cause duodenal ulcer. Other drugs that may increase the risk of ulceration include potassium chloride, concomitant use of steroids with NSAIDs, bisphosphonates, and mycophenolate mofetil.
	<b>Inclusions:</b> Toxic duodenal ulcer
<b>DA63.51</b>	Radiation duodenal ulcer
<b>DA63.52</b>	Chemical duodenal ulcer
<b>DA63.5Y</b>	Duodenal ulcer due to other specified external causes
<b>DA63.5Z</b>	Duodenal ulcer due to external causes, unspecified
<b>DA63.6</b>	<b>Infectious duodenal ulcer</b> <b>Coded Elsewhere:</b> Parasitic duodenal ulcer (1F61)
<b>DA63.60</b>	Bacterial duodenal ulcer Duodenal ulcer caused by infection with bacteria. This includes mycobacterium, Treponema pallidum (syphilis bacterium) and other bacterial infections in the duodenum. <b>Exclusions:</b> Helicobacter-pylori associated duodenal ulcer (DA63.1)
<b>DA63.61</b>	Viral duodenal ulcer Duodenal ulcer caused by infection with virus. Infectious diseases such as cytomegalovirus and herpes simplex virus are often associated with duodenal ulcer.
<b>DA63.62</b>	Fungal duodenal ulcer Duodenal ulcer caused by infection with fungus. This includes infection with candida and other fungal infections in the duodenum.
<b>DA63.6Z</b>	Infectious duodenal ulcer, unspecified
<b>DA63.Y</b>	<b>Other specified duodenal ulcer</b>
<b>DA63.Z</b>	<b>Duodenal ulcer, unspecified</b>

---

**DA7Z                  Diseases of the stomach or the duodenum, unspecified**

## Diseases of small intestine (DA90-DA9Z)

This is a group of conditions characterised as being in or associated with the small intestine.

**Exclusions:** Ileostomy malfunction (DE12.0)

Diseases of duodenum (DA50-DA5Z)

**Coded Elsewhere:** Neoplasms of the small intestine

Foreign body in small intestine (ND73.3)

Structural developmental anomalies of small intestine (LB15)

**DA90**

### **Nonstructural developmental anomalies of small intestine**

Any congenital defect of small intestine that results from interference with the normal growth and differentiation of the fetus. Such defects can arise at any stage of embryonic development, vary greatly in type and severity, and are caused by a wide variety of determining factors, including genetic mutations, chromosomal aberrations, teratogenic agents, and environmental factors. Most developmental defects are apparent at birth, especially any structural malformation, but some becomes evident later.

**Coded Elsewhere:** Maltase-glucoamylase deficiency (5C61.1)

Congenital sucrase-isomaltase deficiency (5C61.2)

Alpha, alpha trehalase deficiency (5C61.3)

Congenital lactase deficiency (5C61.61)

**DA90.0**

### **Syndromic diarrhoea**

Syndromic diarrhoea (SD), also known as phenotypic diarrhoea (PD) or tricho-hepato-enteric syndrome (THE), is a congenital enteropathy presenting with early-onset of severe diarrhoea requiring parenteral nutrition (PN), associated with facial dysmorphism, woolly and poorly pigmented hair and liver disease, with extensive fibrosis or cirrhosis, in about half of the patients.

**Inclusions:** Phenotypic diarrhoea

DA90.1	<b>Congenital intestinal transport defect</b> This is a congenital disease of the small intestinal mucosa that presents with intractable diarrhoea and malabsorption of nutrients in young children, due to defect of transporter of nutrients in enterocytes.  <b>Coded Elsewhere:</b> Glucose-galactose malabsorption (5C61.0) Fructose malabsorption (5C61.40) Acrodermatitis enteropathica (5C64.20) Idiopathic bile acid malabsorption (DA96.02) Hereditary megaloblastic anaemia due to transcobalamin deficiency (3A01.0) Glycogen storage disease due to GLUT2 deficiency (5C51.3) Lysinuric protein intolerance (5C60.Y) Haptocorrin deficiency (5C63.0) Hereditary folate malabsorption (5C63.1) Vitamin B12 deficiency anaemia due to selective vitamin B12 malabsorption with proteinuria (3A01.Y)
DA90.2	<b>Congenital intestinal motility disorders</b> This is a congenital disorder of the small intestinal intestine that presents severe impairment or change of bowel movement often associated with malabsorption of nutrients in young children.  <b>Coded Elsewhere:</b> Megacystis - microcolon - intestinal hypoperistalsis - hydronephrosis (LD2F.1Y)
DA90.Y	<b>Other specified nonstructural developmental anomalies of small intestine</b>
DA90.Z	<b>Nonstructural developmental anomalies of small intestine, unspecified</b>
<b>DA91</b>	<b>Obstruction of small intestine</b> Hindrance of the passage of luminal contents in the small intestine. Obstruction of the small intestine can be partial or complete, and caused by intrinsic or extrinsic factors. Simple obstruction is associated with diminished or stopped flow of luminal contents. Strangulating obstruction is associated with impaired blood flow to the small intestine in addition to obstructed flow of luminal contents.  <b>Inclusions:</b> Occlusion of small intestine <b>Exclusions:</b> Diverticular disease of small intestine (DC70-DC72.Z) Crohn disease of small intestine (DD70.1) hernia involving small intestine (DD50.2) ischaemic stricture of small intestine (DD31) Paralytic ileus (DA93.0) Intestinal obstruction of newborn (KB87)
DA91.0	<b>Intussusception of small intestine</b> Intussusception occurs when a segment of bowel invaginates, or telescopes, into adjacent distal bowel, leading to obstruction and possibly ischemic injury.

<b>DA91.1</b>	<b>Volvulus of small intestine</b> A volvulus is an abnormal twisting of the intestine around the axis of its own mesentery, resulting in obstruction of the more proximal bowel. Twisting of the mesentery may involve the mesenteric vessels and so make the involved loop particularly susceptible to strangulation and gangrene, with resulting perforation, peritonitis, and sepsis.
<b>DA91.2</b>	<b>Intestinal adhesions or bands of small intestine with obstruction</b> Small bowel obstruction resulting from intraabdominal adhesion due to laparotomy, trauma, and intraabdominal inflammation such as endometriosis.
<b>DA91.3</b>	<b>Obstructive ileus of small intestine due to impaction</b> Small bowel obstruction may result when a substance such as gallstone or enterolith is too large to traverse the small intestine, especially at the ileocecal valve.
<b>DA91.30</b>	Gallstone ileus of small intestine Small bowel obstruction due to stenosis resulting from impaction of gallstones.
<b>DA91.31</b>	Enterolith of small intestine This is a mineral concretion or calculus formed anywhere in the gastrointestinal system, but in this case the small intestine.
<b>DA91.3Y</b>	Other specified obstructive ileus of small intestine due to impaction
<b>DA91.3Z</b>	Obstructive ileus of small intestine due to impaction, unspecified
<b>DA91.Y</b>	<b>Other specified obstruction of small intestine</b>
<b>DA91.Z</b>	<b>Obstruction of small intestine, unspecified</b>
<b>DA92</b>	<p><b>Other acquired anatomical alterations of small intestine</b></p> <p>This group incorporates small intestinal disorders principally due to acquired morphological changes of the small intestine, except for obstruction of small intestine (EC).</p> <p><b>Coded Elsewhere:</b> Diverticular disease of small intestine (DC70-DC72.Z)            Perforation of small intestine (ME24.30)            Endometriosis of small intestine (GA10.C1)</p>
<b>DA92.0</b>	<p><b>Fistula of small intestine</b></p> <p>A small intestinal fistula is defined as an abnormal communication between the small intestine and another epithelialized surface such as the skin or an adjacent loop of bowel.</p> <p><b>Inclusions:</b> Fistula of intestine, site unspecified  <b>Exclusions:</b> Fistula of duodenum (DA50.2)  <b>Coded Elsewhere:</b> Fistula of small intestine to vagina (GC04.11)</p>

DA92.1	<b>Pneumatosis intestinalis of small intestine</b> Pneumatosis intestinalis is a rare condition characterised by multiple, gas-filled cysts, typically within the subserosa and submucosa of the small intestine.
DA92.Y	<b>Other specified other acquired anatomical alterations of small intestine</b>
DA92.Z	<b>Other acquired anatomical alterations of small intestine, unspecified</b>
<b>DA93</b>	<p><b>Motility disorders of small intestine</b></p> <p>Disorders of small intestinal motility due to abnormal contractions, such as weak contractions and disorganised (unsynchronized) contractions. The loss of ability to coordinate motor activity may cause a variety of disorders including small intestinal distention and bacterial overgrowth.</p>
DA93.0	<p><b>Paralytic ileus</b></p> <p>A type of ileus, a functional not mechanical obstruction of the small intestines, and a state of pathophysiologic inhibition of motor activity due to non-mechanical causes. The paralysis does not need to be complete, but the intestinal muscles must be so inactive that it leads to a functional blockage of the intestine.</p> <p><b>Exclusions:</b> Obstructive ileus of small intestine due to impaction (DA91.3) Gallstone ileus of small intestine (DA91.30)</p> <p><b>Coded Elsewhere:</b> Transitory ileus of newborn (KB87.3)</p>
DA93.Y	<b>Other specified motility disorders of small intestine</b>
DA93.Z	<b>Motility disorders of small intestine, unspecified</b>
<b>DA94</b>	<p><b>Noninfectious enteritis or ulcer of small intestine</b></p> <p>Noninfectious enteritis and ulcer of small intestine is inflammation or tissue defect in the small intestine of non-infectious origin, usually due to medication including chemotherapy or radiation therapy side effects; or allergic or systemic disorders. Its severity may vary from mild and inconvenient to severe and life-threatening.</p> <p><b>Inclusions:</b> Noninfectious small intestinal inflammation, erosion, ulcer or ulcer scar</p> <p><b>Exclusions:</b> Crohn disease of small intestine (DD70.1) Functional diarrhoea (DD91.2) Noninfectious neonatal diarrhoea (KB8C)</p>
DA94.0	<p><b>Primary ulcer of small intestine</b></p> <p>Enteritis or ulcer of small intestine of unknown origin</p>
DA94.00	<p>Primary nonspecific ulceration of small intestine</p> <p>Primary or simple ulcer of the small intestine occurring beyond the duodenum is rare. The lesion includes single ulcers within the jejunum and ileum of unknown etiology. Non-specific ulcer accompanied with Behcet disease is classified elsewhere in EGD.</p> <p><b>Inclusions:</b> Simple ulcer of small intestine</p>

- DA94.01** Chronic non-specific multiple ulcers of small intestine  
In CNSU patients chronic non-specific multiple ulcers are predominantly found in the ileum, which are circular or irregular in shape. The margins of ulcers are always clear and the intervening mucosa appears normal. CNSU is often characterised by anaemia and hypoalbuminemia due to bleeding and protein loss from multiple ulcers.
- DA94.02** Cryptogenic multifocal ulcerous stenosing enteritis  
CMUSE is an independent, rare disease characterised by chronic diarrhoea and by non-specific small intestinal ulceration and ulcerative stenosis which responds to corticosteroid therapy.
- DA94.0Y** Other specified primary ulcer of small intestine
- DA94.0Z** Primary ulcer of small intestine, unspecified
- DA94.1** **Drug-induced or toxic enteritis of small intestine**  
Enteritis or ulcer of small intestine due to medication including mucosal damaged agents such as NSAIDs, aspirin and antibiotics, due to chemotherapy and due to chemical toxic substances.
- DA94.2** **Allergic or dietetic enteritis of small intestine**  
Enteritis or ulcer of small intestine due to allergic disorders including food allergy. This category includes both immediate-type (IgE mediated) and non-IgE-mediated intestinal hypersensitivity, and eosinophilic disorders of small intestine. Food protein-induced enterocolitis syndrome (EPIES) is also included here.
- DA94.20** IgE mediated allergic enteritis of small intestine  
Immediate type (IgE-mediated) enteric hypersensitivity due to exposure to an allergen in individuals previously sensitized. The symptoms are acute abdominal pain and diarrhoea and can be combined to other symptoms in cases of anaphylaxis.
- DA94.21** Eosinophilic enteritis  
This refers to a rare and heterogeneous condition of inflammation of small intestine characterised by patchy or diffuse eosinophilic infiltration of the intestinal tissue.
- DA94.22** Food protein-induced enterocolitis syndrome  
A non-IgE-mediated intestinal hypersensitivity cell-mediated persistent chronic inflammation of the enteric tract which primarily affects children. The most common causal foods are: cow's milk, soy, rice, oat, meat. In cases of chronic exposure, the most frequent symptoms are emesis, diarrhoea, poor growth and lethargy. In cases of re-exposure after restriction, the patient can present emesis, diarrhoea, hypotension (15%) 2 hours after ingestion.
- DA94.2Y** Other specified allergic or dietetic enteritis of small intestine
- DA94.2Z** Allergic or dietetic enteritis of small intestine, unspecified

- DA94.3** **Enteritis or ulcer of small intestine due to other external causes**  
Enteritis and ulcer of small intestine induced by external causes, such as foreign body, radiation, trauma, and other external causes. Enteritis due to chemical and toxic substances is excluded from here and classified in EGB.
- DA94.30** Enteritis or ulcer of small intestine due to foreign body
- DA94.31** Enteritis or ulcer of small intestine due to radiation
- DA94.32** Enteritis or ulcer of small intestine due to trauma
- DA94.3Z** Enteritis or ulcer of small intestine due to other external causes, unspecified
- DA94.Y** **Other specified noninfectious enteritis or ulcer of small intestine**
- DA94.Z** **Noninfectious enteritis or ulcer of small intestine, unspecified**
- DA95** **Coeliac disease**  
Coeliac disease is a permanent intolerance to gluten proteins, present in wheat, rye, and barley. It is an autoimmune disorder, characterised by a chronic inflammatory state of the small intestinal mucosa and submucosa, which can impair digestion and absorption of nutrients, leading to malnutrition.
- Inclusions:**      Gluten-sensitive enteropathy  
                        Nontropical sprue  
                        Idiopathic steatorrhoea
- DA96** **Intestinal malabsorption or protein-losing enteropathy**  
Intestinal malabsorption is a diseased condition in which absorption of food nutrients across the intestinal tract is disturbed. Impairment of single or multiple nutrients may lead to malnutrition.  
Protein-losing enteropathy is a diseased condition in which there is excessive loss of plasma protein into the intestine. More loss of proteins than synthesis may lead to hypoalbuminemia.
- Exclusions:**      Crohn disease (DD70)
- DA96.0** **Intestinal malabsorption**  
Intestinal malabsorption (syndrome) occurs due to pathological interference with the normal physiological sequence of digestion (intraluminal process), absorption (mucosal process), and transport (post-mucosal events) of nutrients in the small intestine. The concept of intestinal failure is a life-threatening severe type of intestinal malabsorption due to short bowel, structural enterocyte defects, and intestinal dysmotility etc.
- Coded Elsewhere:** Postsurgical malabsorption, not elsewhere classified (DE13)  
Neonatal malabsorption syndromes (KB89)  
Amyloidosis of small intestine (5D00.0)

<b>DA96.00</b>	Bacterial overgrowth syndrome  Bacterial overgrowth syndrome is a term that describes clinical manifestations that occur when poor movement of intestinal contents allows certain normal intestinal bacteria to grow excessively, causing diarrhoea and poor absorption of nutrients (malabsorption). Various etiological processes can disrupt mechanisms that keep the number of these bacteria low. These include structural abnormalities (congenital or surgical) and disorders that cause decreased gastric acidity, reduced peristaltic activity, and mucosal damage or atrophy.
	<b>Coded Elsewhere:</b> Bowel-associated dermatosis-arthritis syndrome (EB2Y)
<b>DA96.01</b>	Tropical sprue  Tropical sprue is a syndrome involving the entire small intestine that causes acute or chronic diarrhoea and malabsorption of nutrients of progressive severity that results in malnutrition and anaemia due to folic acid deficiency. The disorder occurs only among persons (mostly adults) who visit, or are residents of, certain tropical and subtropical areas. Histological changes consist of lengthening of the crypt area and broadening and shortening of the villi with chronic inflammation of small intestine. The cause of tropical sprue is not known, but excess levels of certain types of bacteria in the small intestines have been suggested, and antimicrobial therapy may result in cure of the intestinal abnormalities.
	<b>Inclusions:</b> Tropical steatorrhoea
<b>DA96.02</b>	Malabsorption or intolerance of specific nutrients  Food intolerance is a term used for difficulty in digesting a food due to various physiological responses associated with a particular food, or compound found. Food intolerance should not be mistaken for food allergy, which is primarily involving the immune reaction against the food.
	<b>Coded Elsewhere:</b> Lactose intolerance (5C61.6)
<b>DA96.04</b>	Short bowel syndrome  Having less than 200 cm of residual small bowel with or without colon in an adult and for children (< 18 yrs), less than 25% of the normal length of intestine for their respective age.
	<b>Exclusions:</b> Congenital short bowel (LB15.2) <b>Coded Elsewhere:</b> Short bowel syndrome in neonate (KB89.1)
<b>DA96.05</b>	Intestinal failure  The reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth.
<b>DA96.0Y</b>	Other specified intestinal malabsorption
<b>DA96.0Z</b>	Intestinal malabsorption, unspecified

DA96.1	<b>Protein-losing enteropathy</b> Protein-losing enteropathy is a syndrome characterised by the severe loss of serum proteins into the intestine. It is not a single disease, but an atypical manifestation of other diseases, which involves intestinal mucosa as well as intestinal blood or lymphatic vessels.  <b>Coded Elsewhere:</b> Intestinal lymphangiectasia (BD92.0)
DA96.Y	<b>Other specified intestinal malabsorption or protein-losing enteropathy</b>
DA96.Z	<b>Intestinal malabsorption or protein-losing enteropathy, unspecified</b>
<b>DA97</b>	<p><b>Certain vascular disorders of small intestine</b></p> <p>The whole small intestine receives its blood supply from the superior mesenteric artery and the venous drainage is through the portal system via the superior mesenteric vein. Vascular disorders includes lesions in these vessels and capillary.</p> <p><b>Exclusions:</b> Ischaemic vascular disorders of intestine (DD30-DD3Z)</p> <p><b>Coded Elsewhere:</b> Non-occlusive mesenteric ischaemia (DD31.0)  Segmental arterial mediolysis (BD52.0)  Vascular abnormality of small intestine due to injury or trauma (NB90.Y)</p>
DA97.0	<b>Angiodysplasia of small intestine</b> Small dilated submucosal vessels of small intestinal mucosa with perforating vessels going through the muscularis mucosae.  <b>Coded Elsewhere:</b> Hereditary haemorrhagic telangiectasia (LA90.00)
DA97.1	<b>Arteriovenous malformation of small intestine</b> Vascular malformations of small intestine that result from a localised maldevelopment of part of the primitive vascular plexus and consist of abnormal arteriovenous communications without intervening capillaries. They vary in size, ranging from massive lesions that are fed by multiple vessels to lesions so small that they are hard to identify at arteriography, surgery, or autopsy, but relatively larger than angiodysplasia.
DA97.2	<b>Vasculitis of mesenteric arteries</b> A part of systemic vasculitis involving the gastrointestinal tract which causes mesenteric ischemia. This includes systemic lupus erythematosus, polyarteritis nodosa, allergic granulomatous vasculitis (Churg-Strauss syndrome), and thromboangiitis obliterans (Buerger's disease).
DA97.3	<b>Varices of small intestine</b> The dilation of venous plexus in the small intestine.  <b>Exclusions:</b> Duodenal varices (DA52.0)
DA97.Z	<b>Certain vascular disorders of small intestine, unspecified</b>

**DA98****Polyps of small intestine**

Polyps of small intestine are benign mushroom-like abnormalities of the small intestine that may have a stalk or be flat with a stalk. (Polyps of small intestine are any mass of tissue that arises from the small intestinal wall and protrudes into the lumen.)

***Exclusions:***

Adenoma of small intestine (2E92.3)

Adenomatous polyp of small intestine (2E92.3)

Polyposis syndrome (2E92.40)

**DA98.0****Hamartoma of small intestine**

Hamartoma of small intestine is a non-neoplastic mass of indigenous tissue in the small intestine.

**DA98.1****Hyperplastic polyp of small intestine**

Hyperplastic/metaplastic polyps of small intestine usually result from the abnormal maturation of the mucosal cells of the small intestines and are usually of small size.

**DA98.2****Inflammatory fibroid polyp of small intestine**

Inflammatory fibroid polyp (IFP) is a rare tumour and it presents either as a solitary large or sessile lesion that arises in the submucosa. It is characterised by spindle and stellate cells set in an inflammatory, myxoid stroma.

**DA98.3****Lymphoid hyperplasia of small intestine**

Lymphoid hyperplasia of small intestine is a formation of well differentiated lymphoid tissue due to enhanced cell division in the small intestinal mucosa.

**DA98.Y****Other specified polyps of small intestine****DA98.Z****Polyps of small intestine, unspecified****DA9Y****Other specified diseases of small intestine****DA9Z****Diseases of small intestine, unspecified****Diseases of appendix (DB10-DB1Z)**

**Coded Elsewhere:** Neoplasms of the appendix

**DB10****Appendicitis**

Appendicitis is a condition characterised by inflammation of the veriform appendix.

**DB10.0****Acute appendicitis**

Acute inflammation and enlargement of the veriform appendix. It has been recognised as one of the most common causes of severe acute abdominal pain worldwide. Most cases require appropriate medical treatment or removal of the inflamed appendix. If untreated, mortality is high, mainly because of the risk of rupture leading to peritonitis and shock. In this category acute appendicitis only due to common bacterial infection is included, and appendicitis due to specific organisms is ruled out from here, and described elsewhere.

- DB10.00** Acute appendicitis with generalised peritonitis  
This is a condition characterised by acute inflammation of the veriform appendix that is extending into the free, not contained, inflammation of the peritoneum. There is usually a free perforation and surgical treatment is recommended.
- Inclusions:**
- Acute appendicitis with free perforation to the abdominal cavity
  - acute appendicitis with diffuse peritonitis following rupture or perforation
- DB10.01** Acute appendicitis with localised peritonitis  
This condition is characterised by acute inflammation of the veriform appendix with peritonitis that is contained into an abscess or phlegmone. There is often an underlying covered perforation of appendix with leakage from the appendix lumen.
- Inclusions:**
- Acute appendicitis with contained perforation to a localised abscess
- DB10.02** Acute appendicitis without localised or generalised peritonitis  
This condition is characterised by acute inflammation of the veriform appendix in that there is no mention about the extent of the peritonitis. Acute appendicitis without peritonitis is included here. Acute appendicitis with no perforation or abscess, and simply phlegmonous or suppurative appendicitis, these can usually be treated conservatively, are also included here.
- DB10.1** **Chronic appendicitis**  
A correctly diagnosed non-acute form of appendicitis. Chronic appendicitis is a disorder caused by inflammation of the appendix over a period of time. While acute appendicitis shows the typical manifestation of an inflamed appendix, chronic appendicitis may cause symptoms related to abdominal discomfort or more generalised symptoms. In this category chronic appendicitis only due to common bacterial infection is included, and appendicitis due to specific organisms is ruled out from here, and described elsewhere.
- DB10.Y** **Other specified appendicitis**
- DB10.Z** **Appendicitis, unspecified**
- DB11** **Certain specified diseases of appendix**  
Diseases of appendix other than appendicitis or neoplasm. This includes intussusception, mucocele, hyperplasia, appendicular concretions, diverticulum, fistula and other specified diseases of appendix.
- Exclusions:**
- Appendicitis (DB10)
  - Neoplasms of the appendix ()
- DB11.0** **Megaloappendix**  
The veriform appendix is an organ that can have variable sizes, locations as well as functional potentials. This refers to the longer and the larger appendix than normal size.

- DB11.1**      **Hyperplasia of appendix**  
                 Hyperplasia of appendix is the rapid growth proliferation of normal lymphoid cells that resemble lymphoid tissue.
- DB11.2**      **Appendicular concretions**  
                 A condition of the appendix filled with calcification
- DB11.3**      **Diverticulum of appendix, acquired**  
                 A condition of an outpouching of a hollow structure of the appendix.
- DB11.4**      **Fistula of appendix**  
                 A condition of an abnormal passageway between the appendix and neighbour organs.
- DB11.5**      **Intussusception of appendix**  
                 A condition in which a part of the appendix has invaginated into another section of the appendix. Complete invagination of the appendix into the caecum may progress to a colo-colic and/or ileo-colic intussusception.
- DB11.6**      **Mucocele of appendix**  
                 Mucocele of the appendix is a cystic, dilated appendix filled with mucin. Simple mucocele is not a neoplasm and results from chronic obstruction of the proximal lumen, usually by fibrous tissue.
- DB1Y**            **Other specified diseases of appendix**
- DB1Z**            **Diseases of appendix, unspecified**

## Diseases of large intestine (DB30-DB3Z)

**Coded Elsewhere:** Neoplasms of the large intestine

- Structural developmental anomalies of large intestine (LB16)
- Diverticular disease of large intestine (DC80-DC82.Z)
- Polyposis syndrome (2E92.40)

**DB30**

### Obstruction of large intestine

Hindrance of the passage of luminal contents in the large intestine. Obstruction of the large intestine can be partial or complete, and caused by intrinsic or extrinsic factors. Simple obstruction is associated with diminished or stopped flow of luminal contents. Strangulating obstruction is associated with impaired blood flow to the large intestine in addition to obstructed flow of luminal contents.

**Exclusions:**      Paralytic ileus of large intestine (DA93.0)

**DB30.0**

### Intussusception of the large intestine

Intussusception occurs when a segment of bowel invaginates, or telescopes, into adjacent distal bowel, leading to obstruction and possibly ischemic injury. Colonic intussusception is a relatively uncommon condition that is most frequent in the early years of life. There are three main varieties: caecocolic, colocolic and sigmoidrectal.

- DB30.1 Volvulus of large intestine**  
A volvulus is an abnormal twisting of the intestine around the axis of its own mesentery, resulting in obstruction of the more proximal bowel. Twisting of the mesentery may involve the mesenteric vessels and so make the involved loop particularly susceptible to strangulation and gangrene, with resulting perforation, peritonitis, and sepsis. The classical sites of large intestinal volvulus are the caecum and the sigmoid colon, although there are reports of volvulus of the transverse colon and the splenic flexure.
- DB30.2 Adhesions of large intestine with obstruction**  
Large bowel obstruction resulting from intraabdominal adhesion due to laparotomy, trauma, and intraabdominal inflammation such as endometriosis.
- DB30.3 Impaction of large intestine**  
Large bowel obstruction may result when a substance such as gallstone, foreign body, or enterolith, but not faecal, is too large to traverse the large intestine.  
**Inclusions:** Impaction of large bowel  
**Exclusions:** faecal impaction (ME05.0)
- DB30.4 Stenosis of the rectum**  
Rectal stenosis is defined as narrowing of the rectum.
- DB30.Y Other specified obstruction of large intestine**
- DB30.Z Obstruction of large intestine, unspecified**
- DB31 Other acquired anatomical alterations of large intestine**  
This group incorporates acquired large intestinal disorders principally due to morphological changes of the colon and rectum. Diverticular diseases and obstruction of large intestine are classified in GB a GD, respectively.  
**Exclusions:** Obstruction of large intestine (DB30)  
Diverticular disease of large intestine (DC80-DC82.Z)  
**Coded Elsewhere:** Perforation of large intestine (ME24.31)  
Endometriosis of large intestine (GA10.C1)
- DB31.0 Fistula of large intestine**  
Fistula of large intestine is defined as an abnormal communication between the large intestine and another epithelialized surface such as the skin, an adjacent organ or an adjacent loop of bowel. Colovesical fistula is the most common, but colovaginal, colocolic, coloileal, colocutaneous, and coloanal fistulae have been described. Fistulas due to Crohn disease are excluded from here.  
**Coded Elsewhere:** Fistula of large intestine to vagina (GC04.12)  
Rectovaginal fistula (GC04.16)
- DB31.1 Pneumatosis intestinalis of large intestine**  
This refers to pneumatosis intestinalis in the large intestine, which is a condition characterised by multiple, gas-filled cysts, typically within the subserosa and submucosa of the intestine.

<b>DB31.2</b>	<b>Rectal prolapse</b> Rectal mucosal prolapse refers to abdominal descent of the rectal mucosa. The best recognised site of the mucosal prolapse is the anterior wall of the rectum.
	<b>Inclusions:</b> Prolapse of rectal mucosa
<b>DB31.Y</b>	<b>Other specified other acquired anatomical alterations of large intestine</b>
<b>DB31.Z</b>	<b>Other acquired anatomical alterations of large intestine, unspecified</b>
<b>DB32</b>	<p><b>Motility disorders of large intestine</b> Disorders of colonic motility due to abnormal contractions, such as spasms and colonic paralysis. The loss of ability to coordinate motor activity may cause a variety of disorders including colonic distention and severe constipation.</p> <p><b>Coded Elsewhere:</b> Paralytic ileus of large intestine (DA93.0) Paralytic ileus of small intestine or colon (DA93.0)</p>
<b>DB32.0</b>	<b>Pseudo-obstruction of colon</b> Colonic pseudo-obstruction is a rare condition with symptoms of decreased ability of the colon to push fluid, food and air through like those caused by a colonic obstruction, or blockage. The clinical and radiological findings are often similar to true obstruction, but no true mechanical blockage is found. The symptoms generally includes dyspepsia, chronic constipation and, in the moments where appear abdominal colic. Ogilvie syndrome: acute pseudoobstruction of the colon in severely ill debilitated patients is included here as acute form.
<b>DB32.1</b>	<b>Slow transit constipation</b> Slow transit constipation (STC) typically involves the unusually slow passage of luminal contents through the large intestine. This can lead to chronic problems, such as constipation and uncontrollable soiling and could require colectomy.
<b>DB32.2</b>	<b>Megacolon</b> Megacolon is a descriptive term indicating an abnormal dilation of large intestine. The dilatation is often accompanied by a paralysis of the peristaltic movements of the bowel.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Congenital megacolon (LB16.1) Hirschsprung disease (LB16.1)
<b>DB32.20</b>	Toxic megacolon Toxic megacolon is an acute form of colonic distension characterised by a very dilated colon, accompanied by abdominal distension (bloating), and sometimes fever, abdominal pain, or shock. "Toxic" means that this complication occurs with inflammation. Toxic megacolon is a rare, life-threatening widening of the large intestine that occurs within a few days, occurring as a complication of inflammatory bowel disease, such as ulcerative colitis and Crohn disease.
<b>Coding Note:</b>	Code also the causing condition
<b>DB32.2Y</b>	Other specified megacolon
<b>Coding Note:</b>	Code also the causing condition

<b>DB32.2Z</b>	Megacolon, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>DB32.3</b>	<b>Acquired hypoganglionosis of large intestine</b> Acquired hypoganglionosis is characterised as a degeneration of ganglion cells and gliosis histologically. The prognosis is usually good following resection of the affected bowel.
	<b>Exclusions:</b> Congenital hypoganglionosis of large intestine (LB16.3)
<b>DB32.Y</b>	<b>Other specified motility disorders of large intestine</b>
<b>DB32.Z</b>	<b>Motility disorders of large intestine, unspecified</b>
<b>DB33</b>	<p><b>Certain noninfectious colitis or proctitis</b> Noninfectious colitis and proctitis is inflammation or tissue defect in the large intestine of non-infectious origin, but not included in inflammatory bowel diseases, including specific type of colitis, colitis due to medication including chemotherapy or radiation therapy side effects; or allergic or systemic disorders.</p> <p><b>Exclusions:</b> Inflammatory bowel diseases (DD70-DD7Z) Gastroenteritis or colitis of infectious origin (1A00-1A40.Z)</p>
<b>DB33.0</b>	<b>Primary ulcer of colon</b> A condition with single or multiple ulcers (mucosal defect) develops in the rectum or colon. Ulcers of the colon can cause bleeding with straining in people with chronic constipation.
	<b>Inclusions:</b> Simple ulcer of colon
<b>DB33.1</b>	<b>Microscopic colitis</b> A condition of inflammation of the colon that is only detectable when the colon's lining is examined under a microscope. The endoscopic appearance of the inner colon lining is normal. There are two types of microscopic colitis: lymphocytic colitis and collagenous colitis.
<b>DB33.10</b>	Collagenous colitis Collagenous colitis is characterised by chronic watery diarrhoea, normal radiological and endoscopic appearance of the colon, and a specific histopathological feature consisting in the presence of a subepithelial collagen band (10 mm or more) adjacent to the basal membrane, together with epithelial lymphocyte infiltration and chronic inflammation of the lamina propria.
<b>DB33.11</b>	Lymphocytic colitis Lymphocytic colitis is an intestinal inflammatory disorder characterised by increased intraepithelial lymphocytes and manifesting as chronic watery diarrhoea, abdominal pain, nausea, incontinence and faecal urgency. Together with collagenous colitis it makes up a group known as microscopic colitis.
<b>DB33.1Y</b>	Other specified microscopic colitis
<b>DB33.1Z</b>	Microscopic colitis, unspecified

- DB33.2** **Allergic or dietetic colitis**  
 Colitis and proctitis due to allergic disorders including food allergy. This category includes both immediate-type (IgE mediated) and non-IgE-mediated colonic hypersensitivity, and eosinophilic disorders of large intestine. Food protein-induced proctitis/colitis of infants is also included here.
- DB33.20** Food protein-induced proctitis or colitis of infants  
 A non-IgE-mediated intestinal hypersensitivity (in the absence of IgE antibodies) induced by food protein that induces inflammatory response mainly to the rectum and distal sigmoid colon. This is a condition in infants that results from an immune response triggered by proteins in the diet mainly milk (through breast-feeding). Patients usually appear healthy and have normal, soft stools that contain flecks or streaks of blood. The diagnosis is usually made based upon the resolution of symptoms upon withdrawal of the presumed food antigen. The usual onset is in the first 2 months of life but it also occurs in infants from 1 day to 6 months of age.
- DB33.2Y** Other specified allergic or dietetic colitis
- DB33.2Z** Allergic or dietetic colitis, unspecified
- DB33.3** **Diversion colitis**  
 An inflammatory condition that occurs in segments of the colon and rectum that are diverted from the faecal stream by surgery.
- DB33.4** **Colitis or proctitis due to external causes**  
 Colitis and proctitis induced by external causes, such as chemical and toxic substances, foreign body, radiation, trauma, and other external causes.
- Inclusions:** Gastroenteritis or colitis of infectious origin (1A00-1A40.Z)
- DB33.40** Chemical colitis or proctitis  
 This refers to condition of inflammation of large intestine caused by chemical or toxic substances.
- DB33.41** Radiation-induced colitis  
 This refers to inflammation of the large intestine and colonic ulcer due to radiation.
- DB33.42** Radiation proctitis  
 Radiation proctitis is a rare rectal disease directly induced by pelvic radiotherapy and characterised by rectal bleeding, change in bowel habits, tenesmus and sepsis.
- DB33.43** Drug-induced colitis  
 Colitis or ulcer of large intestine due to medication including mucosal damaged agents such as NSAIDs, antibiotics, chemotherapy drugs, and other medications.
- Inclusions:** Drug-induced proctitis  
 Drug-induced colonic ulcer
- Coded Elsewhere:** Pseudomembranous colitis (1A04)
- DB33.4Y** Other specified colitis or proctitis due to external causes
- DB33.4Z** Colitis or proctitis due to external causes, unspecified

- DB33.Y**      **Other specified noninfectious colitis or proctitis**
- DB33.Z**      **Certain noninfectious colitis or proctitis, unspecified**
- DB34**      **Certain vascular disorders of large intestine**  
The whole large intestine receives its blood supply from colonic branches of the superior mesenteric artery and the inferior mesenteric artery, and the venous drainage is through the portal system via the superior and inferior mesenteric vein. Vascular disorders includes lesions in these vessels and capillary.
- Exclusions:**      Ischaemic vascular disorders of intestine (DD30-DD3Z)
- Coded Elsewhere:** Ischaemic colitis (DD31.00)  
Vascular disorders of large intestine due to injury or trauma (NB90.Y)
- DB34.0**      **Angiodysplasia of colon**  
Small dilated submucosal vessels of colonic mucosa with perforating vessels going through the muscularis mucosae.
- DB34.1**      **Arteriovenous malformation of large intestine**  
Vascular malformations of large intestine that result from a localised maldevelopment of part of the primitive vascular plexus and consist of abnormal arteriovenous communications without intervening capillaries. They vary in size, ranging from massive lesions that are fed by multiple vessels to lesions so small that they are hard to identify at arteriography, surgery, or autopsy, but relatively larger than angiodysplasia.
- DB34.2**      **Vasculitis of large intestine**
- DB34.3**      **Varices of large intestine**  
Abnormally dilated veins in the lining of large intestine. Intestinal varices represent varices at an unusual site in patients with cirrhosis and portal hypertension.
- DB34.4**      **Acute haemorrhagic rectal ulcer**  
Acute haemorrhagic rectal ulcer is regarded as an acute ischemic mucosal disorder that occurs in elderly patients who are suffering from incipient blood flow reduction due to arteriosclerotic factors. These patients are often bedridden, and this causes a decrease in mucosal blood flow in the lower rectum, which in turn triggers this pathology.
- DB34.Y**      **Other specified vascular disorders of large intestine**
- DB34.Z**      **Vascular disorders of large intestine, unspecified**
- DB35**      **Polyp of large intestine**  
Polyps are abnormal growths rising from the lining of the large intestine that protrude into the intestinal lumen. Polyps can cause bleeding, and over time, can develop into cancers.
- Exclusions:**      Polyposis syndrome (2E92.40)  
Malignant neoplasms of colon (2B90)
- Coded Elsewhere:** Adenomatous polyp of the colon (2E92.4Y)

- DB35.0      Hyperplastic polyp of large intestine**  
Hyperplastic polyps are truly benign growths, possessing no potential for progression to colorectal cancer. Hyperplastic polyps pathologically lack dysplasia.
- Inclusions:**      Hyperplastic nodule of large intestine  
                          Serrated polyp of large intestine
- DB35.1      Inflammatory polyp of large intestine**  
Inflammatory polyps occur as a result of the chronic inflammation that takes place in the colon and rectum.
- Exclusions:**      Crohn disease of large intestine (DD70.3)
- DB35.2      Benign lymphoid polyp of large intestine**  
Benign lymphoid polyps are associated with hyperplasia (enhanced cell division) of lymphoid tissue in the colonic mucosa. It is seen in parts of the intestine where lymphoid tissues are concentrated like the ileum of the small intestine or rectum.
- Inclusions:**      Focal lymphoid hyperplasia
- DB35.3      Hamartomatous polyp**  
The hamartomatous polyp is a non-neoplastic, benign tumour-like malformation resulting from an abnormal formation of normal tissue. It contains mesenchymal elements of excess vascular and/or fibrous stroma and glandular proliferation with cystic dilatation.
- Exclusions:**      PTEN Hamartoma tumour syndrome (LD2D)
- DB35.4      Inflammatory fibroid polyp of large intestine**  
Inflammatory fibroid polyp is a benign, non-encapsulated submucosal lesion, composed mainly of loose connective tissues, vessels and with an eosinophilic inflammatory component.
- DB35.Y      Other specified polyp of large intestine**
- DB35.Z      Polyp of large intestine, unspecified**
- DB36      Certain infections of the large intestine**
- DB36.0      Colonic abscess**  
A condition of the colon, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by focal accumulation of purulent material in colonic tissue. This disease may present with back pain, abdominal pain, fever, rectal bleeding, or diarrhoea. Confirmation is commonly by advanced imaging.
- DB36.1      Rectal abscess**  
A condition of the rectum, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by a focal accumulation of purulent material in the rectal area.

<b>DB36.10</b>	Perirectal abscess A condition of the perirectal region, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by focal accumulation of purulent material within the perirectal region. This condition may present with perirectal pain and swelling, fever, chills, or constipation. Confirmation is commonly by advanced imaging.
	<b>Exclusions:</b> Streptococcal cellulitis of skin (1B70.1) Staphylococcal cellulitis of skin (1B70.2)
<b>DB36.11</b>	Ischiorectal abscess A condition of the rectum, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by a focal accumulation of purulent material in the ischiorectal space. This condition presents with pain in the perianal region, back pain, swelling, or fever. Confirmation is commonly by advanced imaging.
	<b>Inclusions:</b> Abscess of ischiorectal fossa
<b>DB36.12</b>	Rectal cellulitis
<b>DB36.Y</b>	<b>Other specified infections of the large intestine</b>
<b>DB36.Z</b>	<b>Certain infections of the large intestine, unspecified</b>
<b>DB3Y</b>	<b>Other specified diseases of large intestine</b>
<b>DB3Z</b>	<b>Diseases of large intestine, unspecified</b>

### Diseases of anal canal (DB50-DB7Z)

**Coded Elsewhere:** Neoplasms of the anal canal

Structural developmental anomalies of anal canal (LB17)

### Acquired anatomical alterations of the anal canal (DB50-DB5Z)

This group incorporates disorders principally due to morphological changes of the anus and anal canal.

**Exclusions:** congenital anomalies of the anal canal (LB17)  
Anal abscess (DB70.00)

**Coded Elsewhere:** Haemorrhage of anus and rectum (ME24.A1)  
Crohn disease of anal region (DD70.4)  
Open wound of anus (NB51.Z)

### **DB50** **Fissure or fistula of anal regions**

Anal fissure and fistula are the common disorders of anal regions. An anal fissure is a superficial linear tear in the anoderm that is distal to the dentate line. An anal fistula is an inflammatory tract between the anal canal and the skin.

- DB50.0      Anal fissure**  
An anal fissure is a linear break or tear in the mucosa that lines the anal canal. It may occur when hard or large stools are passed after defecation and typically cause pain and bright red anal bleeding.
- DB50.1      Anal fistula**  
Anal fistula is an abnormal communication, hollow tract lined with granulation tissue connecting the primary opening inside the anal canal to a secondary opening in the perineal skin. They are usually associated with anorectal abscesses, and they are thought to be a chronic condition after an abscess evacuation.
- DB50.2      Anorectal fistula**
- DB50.Y      Other specified fissure or fistula of anal regions**
- DB50.Z      Fissure or fistula of anal regions, unspecified**
- DB51           Stenosis of anal canal**
- DB52           Ulcer of anus**  
Ulcer of anus is tissue defect located in the anal regions, extending beyond the submucosa into the muscularis mucosa.  
*Inclusions:*      Ulcer of anus and rectum  
                         Solitary ulcer of anus  
                         Stercoral ulcer of anus  
*Coded Elsewhere:* Drug-induced anal ulceration (EH76.Y)
- DB53           Anal prolapse**  
This is a condition in which the rectal tissue loses its internal support and protrudes from the anus to the exterior of the body.  
*Inclusions:*      Prolapse of anal canal
- DB5Y           Other specified acquired anatomical alterations of the anal canal**
- DB5Z           Acquired anatomical alterations of the anal canal, unspecified**

## Haemorrhoids or perianal venous conditions (DB60-DB6Z)

Haemorrhoids are anatomical structures of swollen veins of the rectal plexus in the walls of the anal canal and/or under the skin around the anus. The term haemorrhoids is usually related to the symptoms caused by haemorrhoids resulting in bleeding and painful swelling when they become enlarged, inflamed, thrombosed, or prolapsed. Haemorrhoids are classified according to the degree of prolapse, although this may not always reflect the severity of symptoms.

**Inclusions:** varicose veins of anus and rectum

**DB60**

### **Haemorrhoids**

A prolapse of vascular cushions resulting in bleeding and painful swelling in the anal canal. Internal haemorrhoids are swollen veins inside the anal canal and one in a vein of the superior rectal plexus, originating above the pectinate line and covered by mucous membrane.

Internal haemorrhoids are classified according to the degree of prolapse, although this may not always reflect the severity of symptoms.

**Inclusions:** piles

**Coded Elsewhere:** Haemorrhoids in pregnancy (JA61.4)

Haemorrhoids in the puerperium (JB41.2)

**DB60.0**

### **First degree haemorrhoids**

(grade I): First-degree haemorrhoids bulge into the anal canal and sometimes bleed, but do not prolapse through the anus.

**Inclusions:** Haemorrhoids (bleeding) without prolapse outside of anal canal

**DB60.1**

### **Second degree haemorrhoids**

(grade II): Second-degree haemorrhoids prolapse from the anus during bowel movements but then withdraw back up into the anal canal, spontaneously.

**Inclusions:** Haemorrhoids (bleeding) that prolapse with straining, but retract spontaneously

**DB60.2**

### **Third degree haemorrhoids**

(grade III): Third-degree haemorrhoids remain prolapsed unless pushed gently back into the anal canal, and they can be reduced manually.

**Inclusions:** Haemorrhoids (bleeding) that prolapse with straining, and require manual reduction back inside the anal canal

**DB60.3**

### **Fourth degree haemorrhoids**

(grade IV): Fourth-degree haemorrhoids cannot be pushed back into the anal canal and permanently prolapsed.

**Inclusions:** Haemorrhoids (bleeding) with prolapsed tissue that cannot be manually reduced

**DB60.Z**

### **Haemorrhoids, unspecified**

**DB61**

### **Perianal venous thrombosis**

Extremely painful cherry like lesions under the perianal skin containing clotted blood have been attributed to rupture of a blood vessel with haematoma. However, histology confirmed that these lesions are thrombi lying within the thin-walled vessels of the external anal plexus.

**Inclusions:** perianal thrombosis

Perianal haematoma (nontraumatic)

**DB62**

### **Residual haemorrhoidal skin tags**

This refers to residual small benign tumours that form primarily in areas where the skin forms creases, especially in the anal canal which help with stool control.

**DB6Y**

### **Other specified haemorrhoids or perianal venous conditions**

**DB6Z**

### **Haemorrhoids or perianal venous conditions, unspecified**

**DB70**

### **Infections of the anal region**

Infections of anal canal caused by various microorganisms including bacteria, virus, fungus, parasite and the other specified agents.

**Coded Elsewhere:** Anal warts (1A95.0)

Primary anal syphilis (1A61.1)

Herpes simplex infection of perianal skin or rectum (1A94.1)

Gonococcal infection of anus (1A72.2)

Infections of the anus or perianal skin (EG61)

Tuberculosis of anal canal (1B12.7)

**DB70.0**

### **Abscess of anal regions**

A condition of the anal and rectal region, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by a focal accumulation of purulent material in the anal or rectal region.

**Coded Elsewhere:** Ischiorectal abscess (DB36.11)

**DB70.00**

### **Anal abscess**

A condition of the anus, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by a focal accumulation of purulent material in the perianal crypts or glands. This condition may present with pain and swelling in the perianal region, or fever. Confirmation is commonly by rectal examination.

**Inclusions:** Perianal abscess

**Exclusions:** Intrasphincteric abscess (DB70.02)

Streptococcal cellulitis of skin (1B70.1)

Staphylococcal cellulitis of skin (1B70.2)

**DB70.01**

### **Anorectal abscess**

- DB70.02** Intrasphincteric abscess  
A condition of the intrasphincteric space, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by a focal accumulation of purulent material between the internal and external anal sphincter. Confirmation is commonly by ultrasonography or advanced imaging.
- DB70.0Y** Other specified abscess of anal regions
- DB70.0Z** Abscess of anal regions, unspecified
- DB70.Y** **Other specified infections of the anal region**
- DB70.Z** **Infections of the anal region, unspecified**
- DB71**
- Anal polyp**  
Abnormal mushroom-like growth sticking out from the epithelium rising from the lining of the anus and anal canal.
- DB71.0** **Inflammatory anal polyp**  
Inflammatory polyp is an abnormal, mushroom-like growth sticking out from the mucous membrane that lines the anus. This mass is a reaction to some type of chronic inflammation in the anus.
- DB71.1** **Lymphoid polyp**  
Lymphoid polyp is a benign, focal or diffuse small polypoid lesion composed of well-differentiated lymphoid tissue.
- DB71.2** **Hypertrophied anal papillae**  
The enlargement of existing anal papillae is a consequence of chronic inflammation and fibrotic proliferation within the anorectal zone, which is known as hypertrophied or fibrous anal polyp.
- DB71.Y** **Other specified anal polyp**
- DB71.Z** **Anal polyp, unspecified**
- DB72**
- Certain specified diseases of anal canal**
- Coded Elsewhere:** Crohn disease of anal region (DD70.4)
- Anal pruritus (EG60)
  - Foreign body in anus or rectum (ND73.5)
- DB72.0** **Anal spasm**  
Spasm of the anal sphincter muscle.
- DB72.Z** **Certain specified diseases of anal canal, unspecified**
- DB7Y** **Other specified diseases of anal canal**
- DB7Z** **Diseases of anal canal, unspecified**

## Diseases of liver (DB90-DB9Z)

**Exclusions:** Unspecified jaundice (ME10.1)

**Coded Elsewhere:** Neoplasms of the liver

Structural developmental anomalies of liver (LB20.0)

Metabolic or transporter liver disease (5C90)

Viral hepatitis (1E50-1E5Z)

**DB90**

### Infectious liver disease

**Exclusions:** Viral hepatitis (1E50-1E5Z)

**Coded Elsewhere:** Dengue (1D20-1D2Z)

Yellow fever (1D47)

Cytomegaloviral hepatitis (1D82.0)

Hepatitis due to Toxoplasma gondii (1F57.0)

Herpes simplex hepatitis (1F00.Y)

**DB90.0**

### Abscess of liver

A condition of the liver, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by a focal accumulation of purulent material in the liver. This condition may present with fever, abdominal pain, or shock. Confirmation is by advanced imaging or ultrasonography.

**Exclusions:** pylephlebitis without liver abscess (DB98.3)

**Coded Elsewhere:** Amoebic liver abscess (1A36.10)

**DB90.Y**

### Other specified infectious liver disease

**DB90.Z**

### Infectious liver disease, unspecified

**DB91****Acute or subacute hepatic failure**

Acute and subacute liver failure is characterised by onset of coagulopathy and/or hepatic encephalopathy within 8 weeks of onset of symptoms in a patient without previously known liver diseases.

- Exclusions:**
- Chronic viral hepatitis (1E51)
  - Alcoholic hepatitis (DB94.1)
  - Alcoholic cirrhosis of liver with hepatic encephalopathy (DB94.3)
  - Hepatic failure complicating abortion, ectopic or molar pregnancy (JA00-JA0Z)
  - Icterus of fetus and newborn (KA87)
  - Non-alcoholic fatty liver disease with hepatic encephalopathy (DB92)
  - Chronic hepatic failure due to portosystemic shunt (DB98)
  - Drug-induced or toxic liver disease (DB95)
  - Hepatic encephalopathy (DB97)
  - Liver disorders in pregnancy, childbirth or the puerperium (JA65.0)

**DB91.0****Acute or subacute hepatic failure due to hepatitis virus**

Acute infection of hepatitis A, B, C, D and E viruses can cause acute and subacute hepatic failure. The prognosis varies depending on the virus.

**DB91.1****Other acute or subacute hepatic failure**

Other causes of acute and subacute hepatic failure are drugs, toxic agents, metabolic diseases (particularly Wilson's disease), ischemic diseases, autoimmune hepatitis, and unknown diseases.

**DB91.Z****Acute or subacute hepatic failure, unspecified****DB92****Non-alcoholic fatty liver disease**

NAFLD is characterised by fatty liver related to insulin resistance in the absence of significant alcohol consumption. It embraces a pathological spectrum from simple steatosis to steatohepatitis. 10-20% of cases have steatohepatitis (non-alcoholic steatohepatitis: NASH), which can progress to cirrhosis and hepatocellular carcinoma.

- Exclusions:**
- Reye syndrome (8E46)
  - Acute fatty liver of pregnancy (JA65.0)
  - Drug-induced or toxic liver disease (DB95)
  - Chronic hepatitis C (1E51.1)
  - Alcoholic liver disease (DB94)
  - inherited defects in mitochondrial metabolism (5C53)

**DB92.0****Non-alcoholic fatty liver disease without non-alcoholic steatohepatitis**

<b>DB92.1</b>	<b>Non-alcoholic steatohepatitis</b> Non-alcoholic steatohepatitis (NASH) is a histological form of Non-alcoholic fatty liver disease (NAFLD) in which the key features are histological evidence of hepatocyte injury (such as ballooning or Mallory hyaline) and substantial lobular inflammation. NASH is often associated with fibrosis in pericentral and perisinusoidal distribution (a portal fibrosis pattern also exists, particularly in children). NASH is the clinically progressive form of NAFLD with clinical outcomes including cardiovascular events, and cirrhosis or hepatocellular carcinoma. While novel biomarkers for NASH have been reported, histology remains the gold standard for diagnosis.
<b>DB92.Y</b>	<b>Other specified non-alcoholic fatty liver disease</b>
<b>DB92.Z</b>	<b>Non-alcoholic fatty liver disease, unspecified</b>
<b>DB93</b>	<p><b>Hepatic fibrosis or cirrhosis</b></p> <p><b>Exclusions:</b> Drug-induced or toxic liver disease with fibrosis or cirrhosis of liver (DB95.5)</p> <p>Alcoholic cirrhosis of liver without hepatitis (DB94.3)</p> <p>Alcoholic liver fibrosis (DB94.2)</p> <p>Fibropolycystic liver disease (LB20.00)</p> <p>Congenital hepatic fibrosis (LB20.00)</p> <p>Chronic viral hepatitis with cirrhosis (1E51)</p> <p>Non-alcoholic steatohepatitis (DB92.1)</p> <p>Non-alcoholic fatty liver disease (DB92)</p> <p>Cardiac cirrhosis (DB98.8)</p>
<b>DB93.0</b>	<p><b>Hepatic fibrosis</b></p> <p>Hepatic Fibrosis is defined as an excess deposition of the components of extracellular matrix (i.e. collagens, glycoproteins, proteoglycans) within the liver. This response to liver injury potentially is reversible. In contrast, in most patients, cirrhosis is not a reversible process.</p> <p><b>Inclusions:</b> hepatic sclerosis hepatic fibrosis with hepatic sclerosis</p> <p><b>Exclusions:</b> Alcoholic liver fibrosis (DB94.2) Congenital hepatic fibrosis (LB20.00) Drug-induced or toxic liver disease with fibrosis or cirrhosis of liver (DB95.5)</p> <p><b>Coded Elsewhere:</b> Hepatic fibrosis due to Schistosomiasis without portal hypertension (1F86.Z)</p>

<b>DB93.1</b>	<b>Hepatic cirrhosis</b>
	Hepatic (liver) cirrhosis is the end stage of fibrosis of the liver caused by many kinds of liver diseases and conditions. Diffuse nodulation of liver due to fibrous bands subdividing liver into regenerative nodules. Blood vessels reach outflow through resistant collagen which contributes to the portal hypertension. Liver cirrhosis is usually irreversible. Some patients with cirrhosis in the early stage are asymptomatic, and other patients in the advanced stage showed signs and symptoms caused by decreased hepatic synthetic function, portal hypertension or decreased detoxification function.
<b>Coding Note:</b>	Code also the causing condition
<b>Exclusions:</b>	Alcoholic cirrhosis of liver without hepatitis (DB94.3) Alcoholic hepatitis with cirrhosis (DB94.10) Congenital cirrhosis of liver (KB80-KB8Z) Secondary biliary cirrhosis (DB93) Cardiac fibrosis and cirrhosis of liver (DB98.8) Drug-induced or toxic liver disease with fibrosis or cirrhosis of liver (DB95.5)
<b>DB93.2</b>	<b>Certain specified fibrosis or cirrhosis of liver</b>
	This is other formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process and chronic liver disease characterised by replacement of liver tissue by fibrosis, scar tissue and regenerative nodules.
<b>Inclusions:</b>	Biliary cirrhosis, unspecified
<b>Coded Elsewhere:</b>	Joubert syndrome with hepatic defect (LD20.0Y)
<b>DB93.20</b>	Hereditary North American Indian childhood cirrhosis
	Hereditary North American Indian childhood cirrhosis is a severe autosomal recessive intrahepatic cholestasis that has only been described in aboriginal children from northwestern Quebec. Manifesting first as transient neonatal jaundice, the disease evolves into periportal fibrosis and cirrhosis during a period ranging from childhood to adolescence.
<b>DB93.21</b>	Idiopathic copper-associated cirrhosis
	Idiopathic copper-associated cirrhosis is a rare copper-overload liver disease characterised by a rapidly progressive liver cirrhosis from the first few years of life leading to hepatic insufficiency and harbouring a specific pathological aspect: pericellular fibrosis, inflammatory infiltration, hepatocyte necrosis, absence of steatosis, poor regeneration and histochemical copper staining.
<b>DB93.Y</b>	<b>Other specified hepatic fibrosis or cirrhosis</b>

**DB94**

### **Alcoholic liver disease**

Alcoholic liver disease is damage to the liver and its function due to excessive intake of alcohol over a prolonged period of time. The diagnosis is made by a history of excessive intake of alcohol and exclusion of other causes of liver disease. However, it is important to note that excessive alcohol intake interacts with other causes of chronic liver disease to worsen the pathological severity and clinical outcome; important (relatively common) examples are with chronic hepatitis C, obesity and diabetes-related fatty liver, and haemochromatosis.

**DB94.0**

### **Alcoholic fatty liver**

Alcoholic fatty liver is abnormal retention of lipids in liver cells evident as stainable fat (steatosis) due to excessive intake of alcohol. It is the earliest stage of alcoholic liver disease. It is difficult to histologically distinguish alcoholic fatty liver from non-alcoholic fatty liver. Diagnosis is dependent on history of level of alcohol intake (see definition of NAFLD).

**DB94.1**

### **Alcoholic hepatitis**

Alcoholic hepatitis is injury and inflammation of the liver caused by excessive intake of alcohol. It is characterised by infiltration by neutrophils, ballooning degeneration of hepatocytes and deposit of Mallory hyaline bodies. Alcoholic hepatitis often occurs concomitantly in patients with other forms of alcoholic liver disease such as fatty liver (alcoholic steatohepatitis), liver fibrosis and cirrhosis.

**DB94.10**

### Alcoholic hepatitis with cirrhosis

This is an inflammation of the liver due to excessive intake of alcohol, consequence of liver disease characterised by replacement of liver tissue by fibrosis, scar tissue and regenerative nodules.

**DB94.1Y**

### Other specified alcoholic hepatitis

**DB94.1Z**

### Alcoholic hepatitis, unspecified

**DB94.2**

### **Alcoholic liver fibrosis**

Alcoholic fibrosis of liver is defined as an excess deposition of the collagens and extracellular matrix within the liver as evident histologically, caused by excessive intake of alcohol.

**Inclusions:**              Alcoholic sclerosis of liver

**DB94.3**

### **Alcoholic cirrhosis of liver without hepatitis**

Alcoholic cirrhosis is an advanced pathological stage of alcoholic liver disease characterised by diffuse fibrosis that links portal tracts and central veins, distortion of the hepatic architecture and the formation of regenerative nodules. It often occurs with alcoholic hepatitis.

**Exclusions:**              Alcoholic hepatitis with cirrhosis (DB94.10)

**DB94.Y**

### **Other specified alcoholic liver disease**

**DB94.Z**

### **Alcoholic liver disease, unspecified**

**DB95**

**Drug-induced or toxic liver disease**

Drug-induced and toxic liver disease is hepatotoxicity as injury to the liver that is associated with impaired liver function caused by exposure to a drug or another noninfectious agent.

**Exclusions:**      Budd-Chiari syndrome (DB98.5)  
                          Alcoholic liver disease (DB94)

**DB95.0**

**Drug-induced or toxic liver disease with acute hepatic necrosis or acute hepatitis**

This is an acute hepatocellular injury that develops within 1 to 20 weeks after starting treatment. The histological lesions consist mainly of focal, zonal or bridging necrosis, but lobular and portal tract inflammation evident with drug hepatitis. Extrahepatic features of drug hypersensitivity, including rash, lymphadenopathy, eosinophilia or other systemic features, are observed in some cases.

**DB95.1**

**Drug-induced or toxic liver disease with chronic hepatitis**

This is the chronic form of drug-induced liver injury that almost always depends on continued exposure to the agent, and is characterised by interface hepatitis, bridging necrosis, and fibrosis.

**DB95.10**

Drug-induced or toxic liver disease with chronic hepatitis with cirrhosis

This is the chronic form of drug-induced liver injury characterised by interface hepatitis, bridging necrosis and fibrosis, with the development of cirrhosis.

**DB95.11**

Drug-induced or toxic liver disease with chronic hepatitis without cirrhosis

**DB95.1Y**

Other specified drug-induced or toxic liver disease with chronic hepatitis

**DB95.1Z**

Drug-induced or toxic liver disease with chronic hepatitis, unspecified

**DB95.2**

**Drug-induced or toxic liver disease with cholestasis**

This is a drug-induced cholestatic liver injury where the symptoms of pruritus and jaundice are often prominent, and elevated serum alkaline phosphatase is the dominant biochemical finding.

**Inclusions:**      Cholestasis with hepatocyte injury

**DB95.20**

Chronic drug-induced or toxic liver disease with cholestasis

This is a chronic cholestasis defined by persistence of drug-induced cholestatic liver injury for more than 3 months.

**DB95.2Y**

Other specified drug-induced or toxic liver disease with cholestasis

**DB95.2Z**

Drug-induced or toxic liver disease with cholestasis, unspecified

**DB95.3**

**Drug-induced or toxic liver disease with fatty liver**

This is a drug-induced fatty liver that consists of three types of steatosis, including microvesicular steatosis, macrovesicular steatosis, and phospholipidosis.

- DB95.30** Drug-induced or toxic liver disease with chronic fatty liver disease  
This is a chronic drug-induced steatosis characterised by relatively large triglyceride globules, which effectively fill the hepatocyte, displace the nucleus and other intracellular constituents to the periphery. Some patients show steatohepatitis, steatosis with focal necrosis and inflammatory cell infiltrate, leading to the development of cirrhosis.
- DB95.3Y** Other specified drug-induced or toxic liver disease with fatty liver
- DB95.3Z** Drug-induced or toxic liver disease with fatty liver, unspecified
- DB95.4** **Drug-induced or toxic liver disease with granulomatous hepatitis**
- DB95.5** **Drug-induced or toxic liver disease with fibrosis or cirrhosis of liver**  
This is a drug-induced hepatic fibrosis as the end result of chronic hepatitis, chronic hepatotoxicity, steatohepatitis, or chronic cholestasis with bile duct injury.
- DB95.6** **Drug-induced or toxic liver disease with vascular disorders of the liver**  
Drug-associated disorders, leading to portal hypertension independent of primary liver disease, include hepatic vein thrombosis, hepatic veno-occlusive disease, non-cirrhotic portal hypertension, and nodular regenerative hyperplasia.
- DB95.7** **Drug-induced or toxic liver disease with liver tumours**  
Medication and chemical exposure have been associated with many forms of hepatic neoplasms, including focal nodular hyperplasia, hepatic adenoma, hepatocellular carcinoma, cholangiocarcinoma and angiosarcoma.
- DB95.Y** Other specified drug-induced or toxic liver disease
- DB95.Z** Drug-induced or toxic liver disease, unspecified
- DB96** **Autoimmune liver disease**  
Autoimmune liver diseases are generally forms of chronic liver disease in which the etiology is unclear but autoimmune mechanisms are evident or postulated for the development of the disease. The primary target organ is the liver and/or biliary system. It can progress to liver cirrhosis.
- DB96.0** **Autoimmune hepatitis**  
Autoimmune hepatitis is a chronic hepatitis, which can progress to liver cirrhosis, generally featured by the presence of circulating autoantibodies and hyperglobulinemia. It has been subdivided into three main categories according to the autoantibodies detected.

<b>DB96.1</b>	<b>Primary biliary cholangitis</b> Primary biliary cholangitis is characterised by progressive destruction and disappearance of the intralobular bile duct epithelial cells leading to cholestasis (high alkaline phosphatase and GGT (gamma glutamyl transferase)) and eventually liver cirrhosis and liver failure, generally associated with the presence of circulating antimitochondrial antibodies and an increase of serum IgM levels.
	<b>Inclusions:</b> chronic nonsuppurative destructive cholangitis
	<b>Exclusions:</b> Hepatic fibrosis or cirrhosis (DB93) Alcoholic cirrhosis of liver without hepatitis (DB94.3) Primary sclerosing cholangitis (DB96.2)
<b>DB96.10</b>	Primary biliary cholangitis with overlap syndrome
<b>DB96.1Y</b>	Other specified primary biliary cholangitis
<b>DB96.1Z</b>	Primary biliary cholangitis, unspecified
<b>DB96.2</b>	<b>Primary sclerosing cholangitis</b> Primary sclerosing cholangitis is a chronic disease which shows focal or multifocal strictures of intra- and/or extra-hepatic bile ducts without any apparent causes, leading to cholestasis and ultimately liver cirrhosis and liver failure.
<b>DB96.20</b>	Primary sclerosing cholangitis with cirrhosis Primary sclerosing cholangitis with cirrhosis is primary sclerosing cholangitis complicated with liver cirrhosis.
<b>DB96.2Y</b>	Other specified primary sclerosing cholangitis
<b>DB96.2Z</b>	Primary sclerosing cholangitis, unspecified
<b>DB96.Y</b>	<b>Other specified autoimmune liver disease</b>
<b>DB96.Z</b>	<b>Autoimmune liver disease, unspecified</b>
<b>DB97</b>	<b>Certain specified inflammatory liver diseases</b>
	<b>Inclusions:</b> Nonspecific reactive hepatitis
	<b>Exclusions:</b> Drug-induced or toxic liver disease (DB95) Acute viral hepatitis (1E50) Acute or subacute hepatic failure (DB91) Chronic viral hepatitis (1E51) Infectious liver disease (DB90) Phlebitis of portal vein (DB98.3)
	<b>Coded Elsewhere:</b> Hepatic sarcoidosis (4B20.2)
<b>DB97.0</b>	<b>Idiopathic granulomatous hepatitis</b>
<b>DB97.1</b>	<b>Hepatic berylliosis</b>

<b>DB97.2</b>	<b>Chronic hepatitis, not elsewhere classified</b>
	<p><b>Inclusions:</b> Chronic hepatitis, unspecified Other specified chronic hepatitis</p>
	<p><b>Exclusions:</b> hepatitis (chronic): granulomatous NEC (DB97.0) Drug-induced or toxic liver disease (DB95) hepatitis (chronic): viral (1E50-1E5Z) hepatitis (chronic): alcoholic (DB94.1)</p>
<b>DB97.Y</b>	<b>Other specified inflammatory liver disease</b>
<b>DB97.Z</b>	<b>Inflammatory liver disease, unspecified</b>
<b>DB98</b>	<p><b>Vascular disorders of the liver</b> Vascular disorders of the liver are conditions where the hepatic blood flow is deranged due to damage, malformation and obstruction of hepatic artery, portal vein and hepatic vein.</p> <p><b>Coded Elsewhere:</b> Hereditary haemorrhagic telangiectasia (LA90.00) Congenital portosystemic shunt (LA90.21)</p>
<b>DB98.0</b>	<p><b>Infarction of liver</b> Infarction of the liver is hepatic damage caused by limited blood supply to the liver due to obstruction or reduced blood flow of hepatic artery, portal vein or both.</p>
<b>DB98.1</b>	<p><b>Peliosis hepatis</b> <b>Inclusions:</b> Hepatic angiomas</p>
<b>DB98.2</b>	<p><b>Nodular regenerative hyperplasia of liver</b> Nodular regenerative hyperplasia of the liver is a rare disorder characterised by diffuse micronodular transformation of the hepatic parenchyma without fibrous septa between the nodules.</p>
<b>DB98.3</b>	<p><b>Portal vein thrombosis</b> Portal vein thrombosis is a condition where the portal vein and/or its branches are obstructed, mainly by a blood clot or malignant tumour invasion.</p> <p><b>Inclusions:</b> Phlebitis of portal vein</p>
<b>DB98.4</b>	<p><b>Splenic vein thrombosis</b> Splenic vein thrombosis is a condition where the splenic vein is obstructed, mainly by a blood clot or malignant tumour invasion.</p>

<b>DB98.5</b>	<b>Budd-Chiari syndrome</b> Budd-Chiari syndrome is caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava and leading to hepatic congestion and ischemic necrosis. Severity depends on the speed of onset and extent of the obstruction.  Obstructions are generally caused by thrombosis in primary BCS, while secondary BCS results from tumour invasion into the lumen or compression of the vein by an expansive lesion. The principle manifestations of BCS are ascites leading to undernutrition and renal insufficiency, gastrointestinal haemorrhage due to portal hypertension, and hepatic insufficiency resulting in encephalopathy and severe infections. Asymptomatic forms have also been reported.
<b>DB98.6</b>	<b>Hepatic veno-occlusive disease</b> Hepatic veno-occlusive disease (hepatic VOD) is a liver disease resulting from toxic injury to the hepatic sinusoidal capillaries that leads to obstruction of the small hepatic veins. The clinical picture is characterised by painful hepatomegaly, jaundice, oedemas, and ascites.  <b>Exclusions:</b> Budd-Chiari syndrome (DB98.5) Hepatic veno-occlusive disease - immunodeficiency syndrome (4A01.33)
<b>DB98.7</b>	<b>Portal hypertension</b> Portal hypertension is abnormal increase of portal vein pressure, which induces development of collateral vessels of portal vein including oesophageal and cardiac varices. It also contributes to development of ascites.
<b>DB98.70</b>	Idiopathic portal hypertension
<b>DB98.71</b>	Non-cirrhotic portal fibrosis
<b>DB98.72</b>	Partial nodular transformation of liver
<b>DB98.73</b>	Splanchnic arteriovenous fistula
<b>DB98.74</b>	Secondary portal hypertension This is secondary hypertension (high blood pressure) in the portal vein system, which is composed by the portal vein, and its branches and tributaries.  <b>Exclusions:</b> Partial nodular transformation of liver (DB98.72) Splanchnic arteriovenous fistula (DB98.73) <b>Coded Elsewhere:</b> Portal hypertension in schistosomiasis (1F86.Z)
<b>DB98.7Y</b>	Other specified portal hypertension
<b>DB98.7Z</b>	Portal hypertension, unspecified
<b>DB98.8</b>	<b>Passive congestion of liver</b> A condition of congestion, due to impaired venous drainage, typically by right heart failure, that affects the liver.  <b>Exclusions:</b> Hepatic veno-occlusive disease (DB98.6) Budd-Chiari syndrome (DB98.5)

<b>DB98.9</b>	<b>Hepatic artery aneurysm</b> An aneurysm which develops on the hepatic artery. Causes of the aneurysm include arteriosclerosis, vasculitis, trauma and infection.
<b>DB98.A</b>	<b>Hepatic haemorrhage</b> Traumatic or nontraumatic spontaneous bleeding in the liver. The most common cause of the latter is the rupture of liver tumours.  <b>Exclusions:</b> Hepatic haemorrhage due to hepatocellular carcinoma (2C12.02)  <b>Coded Elsewhere:</b> Neonatal hepatic haemorrhage (KA83.3)
<b>DB98.B</b>	<b>Ischaemia reperfusion injury of liver</b> Liver injury caused by reperfusion of blood after non-lethal ischaemia of the liver.  <b>Inclusions:</b> Ischaemic hepatitis
<b>DB98.Y</b>	<b>Other specified vascular disorders of the liver</b>
<b>DB98.Z</b>	<b>Vascular disorders of the liver, unspecified</b>
<b>DB99</b>	<b>Certain specified diseases of liver</b> This is a group of conditions characterised as being in or associated with the liver that are not classified elsewhere.  <b>Exclusions:</b> cystic disease of liver (congenital) (LB20.00) hepatic vein thrombosis (BD71) toxic liver disease (DB95) hepatomegaly NOS (ME10.00) portal vein thrombosis (DB98.3) amyloid degeneration of liver (5D00.0) alcoholic liver disease (DB94)  <b>Coded Elsewhere:</b> Liver disorders in pregnancy, childbirth or the puerperium (JA65.0) Cirrhotic cardiomyopathy (BC43.Y)
<b>DB99.0</b>	<b>Chronic liver disease</b>
<b>DB99.1</b>	<b>Hepatic cyst</b> This is a closed sac, having a distinct membrane and division compared to the nearby tissue. It may contain air, fluids, or semi-solid material of the liver.  <b>Inclusions:</b> Simple cyst of liver
<b>DB99.10</b>	<b>Polycystic liver disease</b> Polycystic liver disease is a genetic disorder characterised by the appearance of numerous cysts spread throughout the liver.
<b>DB99.1Y</b>	<b>Other specified hepatic cyst</b>
<b>DB99.1Z</b>	<b>Hepatic cyst, unspecified</b>

<b>DB99.2</b>	<b>Hepatorenal syndrome</b>
	<b><i>Exclusions:</i></b> Hepatorenal syndrome following labour or delivery (JB44.4)
<b>DB99.3</b>	<b>Portopulmonary hypertension</b>
	This is the coexistence of portal and pulmonary hypertension, and is a serious complication of liver disease, present in 0.25 to 4% of all patients suffering from cirrhosis.
<b>DB99.4</b>	<b>Hepatopulmonary syndrome</b>
	This is a syndrome of shortness of breath and hypoxemia (low oxygen levels in the blood of the arteries) caused by vasodilation (broadening of the blood vessels) in the lungs of patients with liver disease.
<b>DB99.5</b>	<b>Hepatic encephalopathy</b>
	Hepatic encephalopathy is a complication of liver cirrhosis and a hallmark of acute liver failure, and is also observed in patients with portosystemic shunts without cirrhosis. Hepatic encephalopathy is characterised by personality changes, intellectual impairment, flapping tremor and a decreased consciousness level. In the advanced stages it is called hepatic coma, which may lead to death. The diagnosis of hepatic encephalopathy is made primarily by recognition of neuropsychiatric changes occurring in a patient with liver disease, after exclusion of brain diseases.
<b>Coding Note:</b>	Code also the causing condition
	<b><i>Exclusions:</i></b> Chronic liver disease (DB99.0)
<b>DB99.6</b>	<b>Intrahepatic cholestasis, not elsewhere classified</b>
	<b><i>Exclusions:</i></b>
	Metabolic liver disease (5C90)
	Neonatal jaundice due to isoimmunization (KA84.0)
	Neonatal hyperbilirubinaemia (KA87)
	Progressive familial intrahepatic cholestasis (5C58.03)
	Benign recurrent intrahepatic cholestasis (5C58.04)
	Chronic cholestasis (DC10.02)
	<b><i>Coded Elsewhere:</i></b> Hepatic amyloidosis with intrahepatic cholestasis (5D00.0)
<b>DB99.60</b>	<b>Cholestasis of parenteral nutrition</b>
	This is a condition where bile cannot flow from the liver to the duodenum, so one must feed a person intravenously, bypassing the usual process of eating and digestion.
<b>DB99.6Y</b>	Other specified intrahepatic cholestasis, not elsewhere classified
<b>DB99.6Z</b>	Intrahepatic cholestasis, not elsewhere classified, unspecified
<b>DB99.7</b>	<b>Hepatic failure without mention whether acute or chronic</b>
<b>DB99.8</b>	<b>Chronic hepatic failure</b>
<b>DB99.Y</b>	<b>Other diseases of liver</b>
<b>DB9Z</b>	<b>Diseases of liver, unspecified</b>

## Diseases of gallbladder or biliary tract (DC10-DC1Z)

This is a group of conditions characterised as being in or associated with the gallbladder (an organ) and the biliary tract (the passageways for bile).

**Coded Elsewhere:** Neoplasms of the gallbladder or biliary tract

Structural developmental anomalies of gallbladder (LB20.1)

Structural developmental anomalies of bile ducts (LB20.2)

Structural developmental anomalies of gallbladder or bile ducts (LB20.Z)

**DC10**

### **Acquired anatomical alterations of gallbladder or bile ducts**

This considers the structure in the alterations of the gall bladder and the long tube-like structures that carry bile.

**Exclusions:** Congenital anomalies of gall bladder and bile ducts (LB20)

**Coded Elsewhere:** Perforation of gallbladder or bile ducts (ME24.35)

**DC10.0**

### **Obstruction of gallbladder or bile ducts**

This is obstruction in the small organ that aids mainly in fat digestion and concentrates bile produced by the liver and in any of a number of long tube-like structures that carry bile.

**Exclusions:** Obstruction of gall bladder and bile ducts: with cholelithiasis (DC11)

**DC10.00**

Obstruction of cystic duct

**DC10.01**

Obstruction of gall bladder

**DC10.02**

Obstruction of bile duct

**Exclusions:** with cholelithiasis (DC11)

**DC10.0Y**

Other specified obstruction of gallbladder or bile ducts

**DC10.0Z**

Obstruction of gallbladder or bile ducts, unspecified

**DC10.1**

### **Hydrops of gallbladder**

Abnormal accumulation of serous fluid in the gallbladder

**DC10.2**

### **Fistula of gallbladder or bile duct**

This is an abnormal connection or passageway between gallbladder or bile duct and other organs.

**DC10.3**

### **Polyp of gallbladder**

The deposits of cholesterol and triglyceride in the gallbladder wall, projecting into the lumen.

**Exclusions:** Adenoma of gallbladder (2E92.6)

**DC10.4**

### **Cholesterolosis of gallbladder**

**Inclusions:** Strawberry gallbladder

**DC10.Y**

### **Other specified acquired anatomical alterations of gallbladder or bile ducts**

**DC10.Z      Acquired anatomical alterations of gallbladder or bile ducts, unspecified**

**DC11      Cholelithiasis**

Cholelithiasis is calculus of gallbladder, cystic duct or bile duct. Most stones in the gallbladder are asymptomatic, but the most common initial symptom is biliary colic before the development of complications, including acute cholecystitis or cholangitis.

**DC11.0      Calculus of gallbladder or cystic duct with acute cholecystitis**

Stones in gallbladder or cystic duct present with acute inflammation of the gall bladder wall typically follows the cystic duct obstruction by the stone.

**DC11.1      Calculus of gallbladder or cystic duct with other cholecystitis**

Stones in gallbladder or cystic duct present with inflammation of the gall bladder wall and bile duct.

**DC11.2      Calculus of gallbladder or cystic duct with cholangitis**

**DC11.3      Calculus of gallbladder or cystic duct without cholecystitis or cholangitis**

Stones in gallbladder present without inflammation of the gall bladder wall and bile duct.

**DC11.4      Calculus of bile duct with cholangitis**

Stones in bile duct present with inflammation of bile duct.

*Inclusions:*      Choledocholithiasis with cholangitis

**DC11.5      Calculus of bile duct with cholecystitis**

Stones in bile duct present with inflammation of gallbladder wall.

**DC11.6      Calculus of bile duct without cholangitis or cholecystitis**

Stones in bile duct present without inflammation of gallbladder wall and bile duct.

**DC11.7      Intrahepatic cholelithiasis**

**DC11.Y      Other specified cholelithiasis**

**DC11.Z      Cholelithiasis, unspecified**

**DC12      Cholecystitis**

Inflammation of gallbladder wall by infection of various organism and/or unspecified disorders.

*Exclusions:*      Cholelithiasis (DC11)

**DC12.0      Acute cholecystitis**

Acute inflammation of the gall bladder wall typically follows the cystic duct obstruction. The inflammation is evoked by mechanical, chemical, vascular, and bacterial inflammatory factors.

*Inclusions:*      acute acalculous cholecystitis

**DC12.00      Acute or chronic cholecystitis**

<b>DC12.0Y</b>	Other specified acute cholecystitis
<b>DC12.0Z</b>	Acute cholecystitis, unspecified
<b>DC12.1</b>	<p><b>Chronic cholecystitis</b></p> <p>Chronic inflammation of the gall bladder wall resulted from repeated acute cholecystitis or from mechanical irritation of the gall bladder wall by unspecified disorders</p> <p><b>Inclusions:</b> chronic acalculous cholecystitis</p>
<b>DC12.Y</b>	<b>Other specified cholecystitis</b>
<b>DC12.Z</b>	<b>Cholecystitis, unspecified</b>
<b>DC13</b>	<p><b>Cholangitis</b></p> <p><b>Exclusions:</b> chronic nonsuppurative destructive cholangitis (DB96.1) cholangitis with cholelithiasis (DC11.4) Primary sclerosing cholangitis (DB96.2)</p>
<b>DC14</b>	<p><b>Certain specified biliary diseases</b></p> <p>This is a group of conditions characterised as being in or associated with the biliary tract, the passageway for bile, which are not classified elsewhere.</p> <p><b>Exclusions:</b> Malignant neoplasms of hepatobiliary system (2B70-2C1Z) Carcinoma in situ of gallbladder, biliary tract or ampulla of Vater (2E61.3) Benign neoplasm of gallbladder, extrahepatic bile ducts or ampulla of Vater (2E92.6)</p>
<b>DC14.0</b>	<p><b>Haemorrhage of bile duct</b></p> <p><b>Inclusions:</b> Haemobilia</p>
<b>DC14.1</b>	<p><b>Postcholecystectomy syndrome</b></p> <p>This describes the presence of abdominal symptoms after surgical removal of the gallbladder. Symptoms may include nausea and vomiting, bloating and diarrhoea, and pain in the upper right abdomen. The pain is often ascribed to discoordination of biliary sphincter of Oddi.</p>
<b>DC14.2</b>	<p><b>Dyskinesia of sphincter of Oddi</b></p> <p>This is a movement disorder which consists of adverse effects including diminished voluntary movements and the presence of involuntary movements in the muscular valve that controls the flow of digestive juices (bile and pancreatic juice) through the ampulla of Vater into the second part of the duodenum.</p> <p><b>Inclusions:</b> Dysfunction of sphincter of Oddi Malfunctioning of sphincter of Oddi</p>
<b>DC14.3</b>	<p><b>Adenomyomatosis of gallbladder</b></p> <p>This is a condition of an abnormal gallbladder wall. There can be overgrowth of mucosa, thickened muscle, and Rokitansky-Aschoff sinuses.</p>

<b>DC14.Y</b>	<b>Other biliary diseases</b>
<b>DC14.Z</b>	<b>Biliary disease, unspecified</b>
<b>DC1Y</b>	<b>Other specified diseases of gallbladder or biliary tract</b>
<b>DC1Z</b>	<b>Diseases of gallbladder or biliary tract, unspecified</b>

## Diseases of pancreas (DC30-DC3Z)

This is a group of conditions characterised as being in or associated with the pancreas.

**Coded Elsewhere:** Neoplasms of pancreas

Structural developmental anomalies of pancreas (LB21)

<b>DC30</b>	<b>Cystic diseases of the pancreas</b> This is a closed sac, having a distinct membrane and division compared to the nearby tissue, which may contain air, fluids, or semi-solid material, of the pancreas.
<b>DC30.0</b>	<b>Cyst of pancreas</b> <b>Coded Elsewhere:</b> Congenital pancreatic cyst (LB21.Y)
<b>DC30.1</b>	<b>Pseudocyst of pancreas</b>
<b>DC30.Y</b>	<b>Other specified cystic diseases of the pancreas</b>
<b>DC30.Z</b>	<b>Cystic diseases of the pancreas, unspecified</b>
<b>DC31</b>	<p><b>Acute pancreatitis</b> Inflammation of the pancreas with sudden onset. Pathological changes range from oedema to necrosis. While mild cases often recover without complications, severe cases have high mortality due to systemic complications despite intensive treatment.</p> <p><b>Coded Elsewhere:</b> Cytomegaloviral pancreatitis (1D82.1) Pancreatitis due to mumps virus (1D80.4)</p>
<b>DC31.0</b>	<b>Acute idiopathic pancreatitis</b> Acute pancreatitis of which etiology cannot be identified. It should be diagnosed by exclusion of alcohol, gallstone, and other possible etiologies.
<b>DC31.1</b>	<b>Acute alcohol-induced pancreatitis</b> Acute pancreatitis associated with alcohol consumption. Although alcohol consumption is a major cause of this disease, the diagnosis should be made after exclusion of other etiologies.
<b>DC31.2</b>	<b>Acute biliary pancreatitis</b> Acute pancreatitis associated with gallstone. Although gallstone is a major etiology, the diagnosis should be made after exclusion of other etiologies. Bile reflux into pancreatic duct caused by an impacted stone at the duodenal papilla is assumed to be a cause.
	<b>Inclusions:</b> Gallstone pancreatitis

- DC31.3      Acute drug-induced pancreatitis**  
Acute pancreatitis caused by drug administration. Some diuretics, anti-tumour or antibiotic drugs, estrogen-containing contraceptives, azathioprine and others have been reported to induce acute pancreatitis.
- DC31.4      Hereditary acute pancreatitis**  
This is a recurrent acute inflammation of pancreas characterised by episodes of severe abdominal pain. Several genetic mutations are associated with this pancreatitis. Onset of the disease is generally under 20 years old, but it can be at any age.
- DC31.5      Acute exacerbation of chronic pancreatitis**
- DC31.Y      Other specified acute pancreatitis**
- DC31.Z      Acute pancreatitis, unspecified**
- DC32      Chronic pancreatitis**
- Exclusions:***      Cystic fibrosis of pancreas with pancreatic insufficiency (DC30)  
Pancreatic steatorrhoea (DC35.2)
- DC32.0      Calcific pancreatitis**  
This is inflammation of the pancreas which requires immediate medical attention and hospitalization during an attack, which calcium salts build up in soft tissue, causing it to harden.
- DC32.1      Groove pancreatitis**
- DC32.2      Hereditary chronic pancreatitis**  
Hereditary chronic pancreatitis is a very rare form of childhood onset chronic pancreatitis. With the exception of an earlier onset and a slower progression the clinical course, the morphological features and laboratory findings of HCP do not differ from those present in patients with alcoholic chronic pancreatitis.
- DC32.3      Chronic alcohol-induced pancreatitis**
- DC32.4      Chronic idiopathic pancreatitis**  
This is an inflammation of the pancreas characterised by recurring or persistent abdominal pain, not associated with known risk factors.
- DC32.5      Tropical pancreatitis**  
Tropical pancreatitis is a rare pancreatic disease of juvenile onset occurring mainly in tropical developing countries and characterised by chronic non-alcoholic pancreatitis manifesting with abdominal pain, steatorrhoea and fibrocalculous pancreatopathy. It is also commonly associated with the development of pancreatic calculi and pancreatic cancer at a much higher frequency than seen in ordinary chronic pancreatitis.
- DC32.Y      Other specified chronic pancreatitis**
- DC32.Z      Chronic pancreatitis, unspecified**

**DC33****Autoimmune pancreatitis**

Autoimmune pancreatitis (AIP) is a rare pancreatic disease characterised by chronic non-alcoholic pancreatitis that presents with abdominal pain, steatorrhoea, obstructive jaundice and responds well to steroid therapy and is seen in two subforms: type 1 AIP which affects elderly males, involves other organs and has increased immunoglobulin G4 (IgG4) levels and type 2 AIP which affects both sexes equally but presents at a younger age and has no other organ involvement or increased IgG4 levels.

**DC34****Obstructive pancreatitis**

This is obstruction in the inflammation of the pancreas which requires immediate medical attention and hospitalization during an attack that has multiple causes and symptoms, which occurs when pancreatic enzymes (especially trypsin) that digest food are activated in the pancreas instead of the small intestine.

**DC35****Certain specified diseases of pancreas**

- DC35.0      **Atrophy of pancreas**
- DC35.1      **Secondary pancreatic insufficiency**
- Coding Note:** Code also the causing condition
- DC35.2      **Pancreatic steatorrhoea**
- DC35.Z      **Certain specified diseases of pancreas, unspecified**
- DC3Y**      **Other specified diseases of pancreas**
- DC3Z**      **Diseases of pancreas, unspecified**

## Diseases of peritoneum (DC50-DC5Z)

This is the serous membrane that forms the lining of the abdominal cavity or the coelom—it covers most of the intra-abdominal (or coelomic) organs—in amniotes and some invertebrates.

**Coded Elsewhere:** Neoplasms of peritoneum or retroperitoneum

**DC50**

### **Peritonitis**

Peritonitis is inflammation of the peritoneum, a condition marked by exudations in the peritoneum of serum, fibrin, cells, and pus.

**Exclusions:** Female pelvic peritonitis, unspecified (GA05.2)

peritonitis with or following: abortion or ectopic or molar pregnancy (JA05.0)

puerperal peritonitis (JB40.0)

peritonitis with or following diverticular disease of small intestine (DC70-DC72.Z)

peritonitis with or following diverticular disease of large intestine (DC80-DC82.Z)

periodic familial peritonitis (5D00.21)

**Coded Elsewhere:** Neonatal peritonitis (KB8B)

**DC50.0**

### **Primary peritonitis**

Peritonitis without surgical source nor the evident source of the infecting and other agent.

**DC50.00**

### Spontaneous bacterial peritonitis

Acute bacterial infection of ascetic fluid without the evident source of the infecting agent in the patient with liver cirrhosis, or in the patient receiving peritoneal dialysis

**DC50.01**

### Other specified primary peritonitis

**DC50.1**

### **Secondary peritonitis**

Peritonitis with evident source of an infecting agent or due to other diseases.

**Coding Note:**

Code also the causing condition

**Exclusions:** Female pelvic peritonitis, unspecified (GA05.2)

Neonatal peritonitis (KB8B)

Genital tract or pelvic infection following abortion, ectopic or molar pregnancy (JA05.0)

Puerperal sepsis (JB40.0)

**DC50.10**

### Eosinophilic peritonitis

10% or more eosinophils in peritoneal effluent at presentation, and its causes are often obscure. However, cases have been reported with allergic reactions, exposure to drugs such as vancomycin, fungal and viral infections, soon after catheter replacement, and icodextrin treatment

**DC50.11**

### Mesenteric peritonitis

peritonitis due to mesenterial fat necrosis or saponification

<b>DC50.12</b>	Chronic proliferative peritonitis Extensive peritoneal fibrosis in response to asbestos, continuous ambulatory peritoneal dialysis. Clinical intestinal obstruction due to massive peritoneal adhesions.
<b>DC50.13</b>	Peritonitis due to <i>Streptococcus pneumoniae</i> This is an inflammation of the peritoneum due to a Gram-positive, alpha-haemolytic, aerotolerant anaerobic member of the genus <i>Streptococcus</i> .
<b>DC50.1Y</b>	Other specified secondary peritonitis
<b>Coding Note:</b>	Code also the causing condition
<b>DC50.1Z</b>	Secondary peritonitis, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>DC50.2</b>	<b>Peritoneal abscess</b> A confined collection of inflammatory exudate in peritonitis.
<b>DC50.Z</b>	<b>Peritonitis, unspecified</b>
<b>DC51</b>	<b>Certain specified disorders of peritoneum or retroperitoneum</b>
	<b>Exclusions:</b> Ascites (ME04)
	<b>Coded Elsewhere:</b> Pneumoperitoneum, originating in the perinatal period, due to primary pulmonary air leak syndromes (KB27.4)
<b>DC51.0</b>	<b>Chylous ascites</b> Chylous ascites is a rare form of ascites caused by accumulation of lymph in the peritoneal cavity, usually due to intra-abdominal malignancy, liver cirrhosis or abdominal surgery complications, and present with painless but progressive abdominal distension, dyspnoea and weight gain.
<b>DC51.1</b>	<b>Peritoneal adhesions</b> Disorders of peritoneum sticking by scar tissue or fibrosis
	<b>Exclusions:</b> Adhesions of large intestine with obstruction (DB30.2) Postprocedural pelvic peritoneal adhesions (GC73) Intestinal adhesions or bands of small intestine with obstruction (DA91.2)
<b>DC51.2</b>	<b>Haemoperitoneum</b> Blood retention in peritoneal cavity
	<b>Exclusions:</b> traumatic retroperitoneal haemorrhage or haematoma (NB97.0)
<b>DC51.Y</b>	<b>Other specified disorders of peritoneum or retroperitoneum</b>
<b>DC5Z</b>	<b>Diseases of peritoneum, unspecified</b>

## Diverticular disease of intestine (DC70-DD1Z)

Diverticula are a major burden of illness in an aging population, presenting with bleeding or in form of a diverticulitis. Many are asymptomatic. Most diverticula (pseudodiverticula) occur in the colon, occurrence in the small intestine is also possible, but less frequent.

- Exclusions:**
- Gastric diverticulum (DA40.3)
  - Diverticulum of oesophagus, acquired (DA20.1)
  - Meckel diverticulum (LB15.0)

## Diverticular disease of small intestine (DC70-DC72.Z)

Diverticula can occur anywhere in the small intestine, but they are most common in the jejunum. They represent herniations through the mesenteric side of the bowel and are usually acquired. This refers to the clinical entity characterised by the presence of sac-like outpocketings of the intestinal mucosa and submucosa through weak points of the muscle layer of the small intestine. This contains both diverticulitis and diverticulosis.

- Exclusions:**
- Meckel diverticulum (LB15.0)
  - Diverticulum of duodenum (DA50.1)

**Coded Elsewhere:** Diverticulum of duodenum, with complication (DA50.1)

### **DC70      Diverticulitis of small intestine**

When the pouches of small intestine (diverticula) become infected or inflamed, the condition is called diverticulitis. Diverticulitis may lead to several serious complications, such as small tears, called perforations and abscess, formation of fistula to adjacent organs, bleeding, or blockages in the lumen, and medical care is needed.

### **DC70.0      Diverticulitis of small intestine with complication**

This develops from diverticulosis, which involves the formation of pouches (diverticula) on the outside of the small intestine and results if one or some of these diverticula becomes inflamed, of the small intestine with complication.

#### **DC70.00      Diverticulitis of small intestine with perforation or abscess**

This develops from diverticulosis, which involves the formation of pouches (diverticula) on the outside of the small intestine and results if one or some of these diverticula becomes inflamed, of the small intestine with perforation or abscess.

#### **DC70.0Y      Diverticulitis of small intestine with other specified complication**

#### **DC70.0Z      Diverticulitis of small intestine with unspecified complication**

### **DC70.1      Diverticulitis of small intestine without complication**

This develops from diverticulosis, which involves the formation of pouches (diverticula) on the outside of the small intestine and results if one or some of these diverticula becomes inflamed, of the small intestine without complication.

### **DC70.Z      Diverticulitis of small intestine without specification of presence of complications**

**DC71**

**Diverticulosis of small intestine**

Diverticulosis of small intestine is a condition characterised by the presence of multiple sack-like mucosal herniations called diverticula through weak points in the wall or lining of the small intestine. Small intestinal diverticula are far less common than colonic diverticula. Most people with diverticulosis do not have any discomfort or symptoms. However, some people may experience pain or discomfort in the abdomen, bloating, and bleeding.

**DC71.0**

**Diverticulosis of small intestine with haemorrhage**

This is the condition of having diverticula in the small intestine, which are outpocketings of the mucosa and submucosa through weaknesses of muscle layers in the wall of the small intestine, with haemorrhage.

**DC71.1**

**Diverticulosis of small intestine without haemorrhage**

This is the condition of having diverticula in the small intestine, which are outpocketings of the mucosa and submucosa through weaknesses of muscle layers in the wall of the small intestine, without haemorrhage.

**DC71.Z**

**Diverticulosis of small intestine, unspecified**

**DC72**

**Diverticulum of small intestine**

This is a morphological condition in which there is a small pouch in the lining of the small intestine, bulging outward through a weak spot. Each pouch is called a diverticulum. The condition of having multiple diverticula with symptoms, or with inflammation is excluded from here.

**DC72.0**

**Diverticulum of small intestine with haemorrhage**

This is a morphological condition in which there is a small pouch called diverticulum in the lining of the small intestine, with haemorrhage.

**DC72.1**

**Diverticulum of small intestine without haemorrhage**

This is a morphological condition in which there is a small pouch called diverticulum in the lining of the small intestine, without haemorrhage.

**DC72.Z**

**Diverticulum of small intestine, no specification about presence or absence of haemorrhage**

**Diverticular disease of large intestine (DC80-DC82.Z)**

This refers to the clinical entity characterised by the presence of sac-like outpocketings of the colonic mucosa and submucosa through weak points of the muscle layer of the large intestine. This contains both diverticulitis and diverticulosis. Diverticular disease is used to describe a specific clinical disorder with defined radiological and pathological appearance, in which there is a characteristic muscle abnormality, usually, but not invariably accompanied by the presence of diverticula which may or may not be inflamed.

**Exclusions:**

Diverticular disease of small and large intestine (DC90)

**DC80**

**Diverticulitis of large intestine**

Diverticulitis is applied when one or more diverticula are the source of visible macroscopic inflammation. It is often accompanied by pericolic abscess formation.

<b>DC80.0</b>	<b>Diverticulitis of large intestine with complication</b> This develops from diverticulosis, which involves the formation of pouches (diverticula) on the outside of the colon and results if one or some of these diverticula becomes inflamed, of the large intestine with complication.
<b>DC80.00</b>	Diverticulitis of large intestine with perforation or abscess This develops from diverticulosis, which involves the formation of pouches (diverticula) on the outside of the colon and results if one of these diverticula becomes inflamed, of the large intestine with perforation or abscess.
<b>DC80.0Z</b>	Diverticulitis of large intestine with complication, unspecified
<b>DC80.1</b>	<b>Diverticulitis of large intestine without complication</b> This develops from diverticulosis, which involves the formation of pouches (diverticula) on the outside of the colon and results if one or some of these diverticula becomes inflamed, of the large intestine without complication.
<b>DC80.Z</b>	<b>Diverticulitis of large intestine without specification of presence of complications</b>
<b>DC81</b>	<p><b>Diverticulosis of large intestine</b> The name diverticulosis is used merely to indicate the presence of multiple diverticula in the large intestine, with or without the accompanying muscle abnormalities found in classical diverticular disease. The condition of having multiple pouches (diverticula) is called diverticulosis. Most people with diverticulosis do not have any discomfort or symptoms. However, some people may experience crampy pain or discomfort in the lower abdomen, bloating, and constipation.</p>
<b>DC81.0</b>	<b>Diverticulosis of large intestine with haemorrhage</b> This is the condition of having diverticula in the large intestine, which are outpocketings of the mucosa and submucosa through weaknesses of muscle layers in the wall of the large intestine, with haemorrhage.
<b>DC81.1</b>	<b>Diverticulosis of large intestine without haemorrhage</b> This is the condition of having diverticula in the large intestine, which are outpocketings of the mucosa and submucosa through weaknesses of muscle layers in the wall of the large intestine, without haemorrhage.
<b>DC81.Z</b>	<b>Diverticulosis of large intestine, unspecified</b>
<b>DC82</b>	<p><b>Diverticulum of large intestine</b> This is a morphological condition in which typical pulsion type of consisting of a pouch of mucous membrane (including muscularis mucosae) projecting through and beyond the circular muscle layers of the bowel wall so that they come to lie in the pericolic fat and appendices epiploicae. Each pouch is called a diverticulum. The condition of having multiple diverticula with symptoms, or with inflammation is excluded from here.</p>
<b>DC82.0</b>	<b>Diverticulum of large intestine with haemorrhage</b> This is a morphological condition in which there is a small pouch called diverticulum in the lining of the large intestine, with haemorrhage.

**DC82.1** **Diverticulum of large intestine without haemorrhage**  
This is a morphological condition in which there is a small pouch called diverticulum in the lining of the large intestine, without haemorrhage.

**DC82.Z** **Diverticulum of large intestine, unspecified**

Diverticular disease of intestine of overlapping sites (DC90-DC90)

**DC90** **Diverticular disease of small and large intestine**

Diverticular disease of unspecified part of intestine (DD00-DD02.Z)

**DD00** **Diverticulitis of unspecified part of intestine**

**DD00.0** **Diverticulitis of unspecified part of intestine with complication**

**DD00.00** Diverticulitis of unspecified part of intestine with perforation or abscess

**DD00.0Y** Other specified diverticulitis of unspecified part of intestine with complication

**DD00.0Z** Diverticulitis of unspecified part of intestine with complication, unspecified

**DD00.1** **Diverticulitis of unspecified part of intestine without complication**

**DD00.Z** **Diverticulitis of unspecified part of intestine without specification of presence or absence of complications**

**DD01** **Diverticulosis of unspecified part of intestine**

**DD01.0** **Diverticulosis of unspecified part of intestine with haemorrhage**

**DD01.1** **Diverticulosis of unspecified part of intestine without haemorrhage**

**DD01.Z** **Diverticulosis of unspecified part of intestine, unspecified**

**DD02** **Diverticulum of unspecified part of intestine**

**DD02.0** **Diverticular disease of unspecified part of intestine with haemorrhage**

**DD02.1** **Diverticulum of unspecified part of intestine without complication**

**DD02.Z** **Diverticulum of unspecified part of intestine, unspecified**

---

**DD1Z** **Diverticular disease of intestine, unspecified**

## Ischaemic vascular disorders of intestine (DD30-DD3Z)

Intestinal ischemia characterised by blood supply to the gastrointestinal tract that is inadequate to meet its metabolic demand

**Exclusions:** necrotizing enterocolitis of fetus or newborn (KB88)

**Coded Elsewhere:** Angiodysplasia of colon (DB34.0)

### DD30

#### Acute vascular disorders of intestine

Intestinal ischaemia has an associated vascular block, usually due to atheroma, thrombus, or embolus but occasionally the result of an arteritis, vasculitis, or other condition.

**Coded Elsewhere:** Non-occlusive mesenteric ischaemia (DD31.0)

### DD30.0

#### Acute mesenteric arterial infarction

Acute mesenteric arterial infarction is an ischemic disorder of sudden interruption of mesenteric arterial flow because of occlusion of mesenteric artery. This may be further subdivided into acute mesenteric arterial embolus (AMAE) and acute mesenteric arterial thrombosis (AMAT).

### DD30.1

#### Acute mesenteric arterial ischaemia

Acute mesenteric ischemia is low flow states of mesenteric circulation, in which inadequate blood flow through the mesenteric circulation causes ischemia and eventual gangrene of the bowel wall. It can be caused by various conditions such as arterial occlusion, venous occlusion, strangulating obstruction, and hypoperfusion associated with nonocclusive vascular diseases.

### DD30.2

#### Acute mesenteric venous occlusion

Acute mesenteric venous occlusion is an ischemic disorder of sudden interruption of mesenteric venous flow because of venous thrombosis.

### DD30.Y

#### Other specified acute vascular disorders of intestine

### DD30.Z

#### Acute vascular disorders of intestine, unspecified

### DD31

#### Chronic vascular disorders of intestine

Chronic mesenteric ischaemia is a clinical syndrome characterised by recurrent abdominal pain and weight loss as a result of repeated transient episodes of insufficient intestinal blood flow, usually related with the increased metabolic demand associated with digestion.

### DD31.0

#### Non-occlusive mesenteric ischaemia

Non-occlusive mesenteric ischaemia causes 20% to 30% of acute mesenteric ischaemia episodes. Mesenteric ischaemia without anatomic arterial or venous obstruction is due to mesenteric vasospasm, which can occur during periods of relatively low mesenteric flow, especially if there is underlying arterial atherosclerotic disease. Such low-flow state can result from heart failure, hypotension, or hypovolemia.

**Coded Elsewhere:** Acute non-occlusive mesenteric arterial ischaemia (DD30.1)

<b>DD31.00</b>	Ischaemic colitis Ischemic colitis is the most common form of ischemic injury to the gut and occurs more frequently in elderly people. The disease can result from either occlusive or nonocclusive events, mainly in the territory of the inferior mesenteric artery, in colonic branches of the superior mesenteric artery, and in the superior and inferior mesenteric veins. The splenic flexure and rectosigmoid junction, where low perfusion exists, are commonly affected.
	<b>Coded Elsewhere:</b> Acute ischaemic colitis (DD30.Z)
	Fulminant ischaemic colitis (DD30.Z)
<b>DD31.0Y</b>	Other specified non-occlusive mesenteric ischaemia
<b>DD31.0Z</b>	Non-occlusive mesenteric ischaemia, unspecified
<b>DD31.Y</b>	<b>Other specified chronic vascular disorders of intestine</b>
<b>DD31.Z</b>	<b>Chronic vascular disorders of intestine, unspecified</b>
<b>DD3Y</b>	<b>Other specified ischaemic vascular disorders of intestine</b>
<b>DD3Z</b>	<b>Ischaemic vascular disorders of intestine, unspecified</b>

## Hernias (DD50-DD5Z)

A hernia is the protrusion of an organ or the fascia of an organ through the wall of the cavity that normally contains it. In this category hernia which relates to gastrointestinal organs is included.

<b>DD50</b>	<b>Non-abdominal wall hernia</b> A hernia occurs through the foramen in the diaphragm, the pelvic wall and the other opening covered by peritoneum not through the abdominal wall.
<b>DD50.0</b>	<b>Diaphragmatic hernia</b> A hernia occurs through the foramen in the diaphragm.  <b>Inclusions:</b> paraoesophageal hernia <b>Exclusions:</b> Congenital diaphragmatic hernia (LB00.0) Congenital hiatus hernia (LB13.1)
<b>DD50.1</b>	<b>Pelvic hernia</b> A hernia occurs through the foramen in the pelvic wall.
<b>DD50.2</b>	<b>Intra-abdominal hernia</b> A hernia occurs intra-abdominally through the opening covered by peritoneum.
<b>DD50.20</b>	Primary intra-abdominal hernia A hernia occurs intra-abdominally and primarily through the opening covered by peritoneum without surgery and trauma.  <b>Exclusions:</b> congenital malpositioning of the intestine (LB18)

**DD50.21** Secondary intra-abdominal hernia  
A hernia occurs intra-abdominally and secondarily through the opening covered by peritoneum after abdominal surgery and trauma.

**Coding Note:** Code also the causing condition

**DD50.2Y** Other specified intra-abdominal hernia

**DD50.2Z** Intra-abdominal hernia, unspecified

**DD50.Y** Other specified non-abdominal wall hernia

**DD50.Z** Non-abdominal wall hernia, unspecified

### **DD51** Inguinal hernia

A hernia occurs when part of an internal organ bulges through a weak area of muscle. Most hernias occur in the abdomen. Inguinal hernia is the most common type and is in the groin.

**Coding Note:** Use additional codes, if desired, to identify complications such as obstruction or gangrene.

**Inclusions:**      bubonocele  
                      scrotal hernia

### **DD52** Femoral hernia

A femoral hernia is a protrusion of a loop of the intestine through a weakened abdominal wall, located in the lower abdomen near the thigh.

A hernia occurs when the contents of the abdomen (usually part of the small intestine) push through a weak point or tear the thin muscular wall of the abdomen, which holds the abdominal organs in place. Femoral hernias tend to occur more often in women than in men.

### **DD53** Umbilical hernia

A hernia occurs when part of an internal organ bulges through a weak area of muscle. An umbilical hernia is a protrusion of the peritoneum and fluid, omentum, or a portion of abdominal organ(s) through the umbilical ring. The umbilical ring is the fibrous and muscle tissue around the navel (belly-button). Small hernias usually close spontaneously without treatment by age 1 or 2. Umbilical hernias are usually painless and are common in infants.

**Exclusions:**      Omphalocele (LB01)  
                      Urachal cyst (LB03.0)

### **DD54** Paraumbilical hernia

Paraumbilical or periumbilical hernias occur next to and supra-umbilical occur just above the navel. Paraumbilical hernias are large abdominal defects through the linea alba in the region of the umbilicus and are usually related to diastasis of the rectus abdominis muscles.

**Inclusions:**      Supraumbilical hernia

**DD55**

### **Epigastric hernia**

A hernia occurs through the weak area of the upper abdomen between the umbilicus and the xiphoid on the linea alba. Although congenital epigastric hernias have been described in infants, they are usually considered an acquired condition.

**DD56**

### **Incisional hernia**

A hernia occurs through the weak area on the incision of the past abdominal surgery or major abdominal trauma.

**DD57**

### **Parastomal hernia**

A hernia occurs through the weak parastomal area after making stoma.

**DD5Y**

### **Other specified hernias**

**DD5Z**

### **Hernias, unspecified**

## **Inflammatory bowel diseases (DD70-DD7Z)**

Inflammatory bowel disease is a group of inflammatory conditions of the intestine of unknown aetiology. Regarding its pathogenesis, it is hypothesized that the mucosal immune system shows an aberrant response towards luminal antigens such as dietary factors and commensal microbiota in genetically susceptible individuals.

**DD70**

### **Crohn disease**

Crohn's disease is characterised by chronic and relapsing transmural inflammation extending through all layers of the small and/or large intestinal walls and has potential to involve the patient's entire gastrointestinal tract.

**Inclusions:** Granulomatous enteritis

Regional enteritis

Intestinal ulcer and erosion due to Crohn disease

**Exclusions:** Ulcerative colitis (DD71)

**Coded Elsewhere:** Cutaneous or mucocutaneous Crohn disease (EE8Y)

**DD70.0**

### **Crohn disease of upper gastrointestinal tract**

Crohn disease involved in upper gastrointestinal tract, such as oral cavity, oesophagus, stomach and duodenum.

**DD70.1**

### **Crohn disease of small intestine**

Crohn disease, which is characterised by chronic and relapsing transmural inflammation, may affect any part of the digestive tract. This refers to Crohn disease involving the small intestine.

**Exclusions:** Crohn disease of both small and large intestine (DD70.5)

**DD70.2**

### **Crohn disease of appendix**

Crohn disease, which is characterised by chronic and relapsing transmural inflammation, may affect any part of the digestive tract. This refers to Crohn disease involving the appendix.

- DD70.3 Crohn disease of large intestine**  
Crohn's disease, which is characterised by chronic and relapsing transmural inflammation, may affect any part of the digestive tract. This refers to Crohn disease involved in the large intestine.  
**Exclusions:** Crohn disease of both small and large intestine (DD70.5)
- DD70.4 Crohn disease of anal region**  
Crohn disease commonly involves the anus and perianal area and may precede any other gut involvement by years. The constellation of symptoms and signs which may occur include pruritus ani, maceration, skin tags, fissures, fistulae, erosions and secondary infection with abscesses.
- DD70.5 Crohn disease of both small and large intestine**  
Crohn disease, which is characterised by chronic and relapsing transmural inflammation, may affect any part of the digestive tract. This refers to Crohn disease involved in both small and large intestine.
- DD70.6 Crohn disease of anastomotic sites**  
Crohn disease, which is characterised by chronic and relapsing transmural inflammation, may affect any part of the digestive tract. This refers to Crohn disease involving anastomotic site of gastrointestinal tract, such as anastomotic ulcer due to Crohn disease.
- DD70.Y Crohn disease of other specified site**
- DD70.Z Crohn disease, unspecified site**
- DD71 Ulcerative colitis**  
Ulcerative colitis is a chronic inflammatory disorder of unknown etiology that continuously causes ulcers in the lining of the rectum and colon. Inflammation is histologically restricted to the mucosa.
- DD71.0 Ulcerative pancolitis**
- DD71.1 Left sided ulcerative colitis**  
**Inclusions:** left hemicolitis
- DD71.2 Ulcerative rectosigmoiditis**
- DD71.3 Ulcerative proctitis**
- DD71.Y Other specified ulcerative colitis**
- DD71.Z Ulcerative colitis, unspecified**
- DD72 Indeterminate colitis**  
Indeterminate colitis is a chronic inflammatory disorder of the colon, for which a definitive diagnosis of either Crohn's disease or ulcerative colitis can be made.
- DD7Y Other specified inflammatory bowel diseases**
- DD7Z Inflammatory bowel diseases, unspecified**

## Functional gastrointestinal disorders (DD90-DD9Z)

Functional gastrointestinal disorder (FGID) is used to define several variable combinations of chronic or recurrent gastrointestinal (GI) symptoms that do not have an identified underlying pathophysiology, and that occur in the absence of underlying structural abnormalities. FGID may include a number of separate idiopathic disorders which affect different parts of the gastrointestinal tract. FGID are the most common problem in gastroenterological practice. The Rome process has helped to define the functional gastrointestinal disorders.

- Exclusions:**
- Bodily distress disorder (6C20)
  - Hypochondriasis (6B23)
  - Symptoms, signs or clinical findings, not elsewhere classified (Chapter 21)

### DD90

#### Functional oesophageal or gastroduodenal disorders

This group incorporates oesophageal and gastroduodenal disorders which principally present unpleasant upper gastrointestinal complaints without apparent morphological changes of oesophagus and gastroduodenum.

- Exclusions:**
- Bodily distress disorder (6C20)
  - Hypochondriasis (6B23)

### DD90.0

#### Globus

Globus is a persistent or intermittent non-painful sensation of a lump or foreign body in the throat unrelated to swallowing without structural or motor disorder of the pharynx and/or oesophagus, often accompanying with acute anxiety or emotional conflicts.

### DD90.1

#### Functional swallowing disorder

Functional dysphagia is a disorder having no structural abnormalities and absence of gastroesophageal reflux for dysphagia, characterised by sense of solid and/or liquid foods sticking, lodging, or passing abnormally through the oesophagus.

- Inclusions:** Functional dysphagia  
**Exclusions:** dysphagia NOS (MD93)

### DD90.2

#### Functional heartburn

Functional heartburn is a disorder having no structural abnormalities and absence of gastroesophageal reflux for heartburn, characterised by burning retrosternal discomfort or pain.

- Exclusions:** heartburn NOS (MD95)

### DD90.3

#### Functional dyspepsia

Functional dyspepsia is a disorder defined as the presence of dyspepsia symptoms thought to originate from the gastroduodenal region, in the absence of any organic, systemic, or metabolic disease that is likely to explain the symptoms such as epigastric pain, epigastric burning, postprandial fullness, and early satiation.

- Inclusions:** Indigestion  
**Exclusions:** Heartburn (MD95)  
Dyspepsia NOS (MD92)

**Coded Elsewhere:** Chronic primary epigastric pain syndrome (MG30.00)

<b>DD90.4</b>	<b>Functional nausea or vomiting</b> Functional nausea and vomiting is a disorder having no structural abnormalities for nausea and vomiting.  <b>Exclusions:</b> Nausea or vomiting NOS (MD90) <b>Coded Elsewhere:</b> Cyclic vomiting syndrome (8A80.4)
<b>DD90.5</b>	<b>Functional belching disorders</b> Functional belching disorders are having troublesome repetitive belching with observed excessive air swallowing and no evidence of excessive air swallowing.  <b>Inclusions:</b> Excessive belching, unspecified Aerophagia <b>Exclusions:</b> Belching NOS (MD91)
<b>DD90.6</b>	<b>Adult rumination syndrome</b> Adult rumination syndrome is a disorder in adulthood characterised by the persistent or recurrent regurgitation of recently ingested food into the mouth with subsequent spitting or remastication and swallowing.  <b>Exclusions:</b> Rumination-regurgitation disorder (6B85) Rumination-regurgitation (MB29.4)
<b>DD90.Y</b>	<b>Other specified functional oesophageal or gastroduodenal disorders</b>
<b>DD90.Z</b>	<b>Functional oesophageal or gastroduodenal disorders, unspecified</b>
<b>DD91</b>	<b>Irritable bowel syndrome or certain specified functional bowel disorders</b> This group incorporates functional bowel disorders which principally present symptoms attributable to the intestinal tract in the absence of specific and unique organic pathology in the small and large intestine.  <b>Inclusions:</b> Functional intestinal disorders NOS <b>Exclusions:</b> Bodily distress disorder (6C20) Hypochondriasis (6B23)
<b>DD91.0</b>	<b>Irritable bowel syndrome</b> Irritable bowel syndrome (IBS) is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit, and with features of disordered defecation.  <b>Inclusions:</b> irritable colon
<b>DD91.00</b>	Irritable bowel syndrome, constipation predominant This is a bowel pattern subtype of irritable bowel syndrome, characterised by alteration of bowel habits with constipation predominant.
<b>DD91.01</b>	Irritable bowel syndrome, diarrhoea predominant This is a bowel pattern subtype of irritable bowel syndrome, characterised by alteration of bowel habits with diarrhoea predominant.

- DD91.02** Irritable bowel syndrome, mixed type  
This is a bowel pattern subtype of irritable bowel syndrome, characterised by alteration of bowel habits having both diarrhoea and constipation. The subtype having diarrhoea and constipation alternatively often varying over time is also considered as synonymous.
- DD91.03** Irritable bowel syndrome, unsubtyped
- DD91.0Z** Irritable bowel syndrome, type unspecified
- DD91.1** **Functional constipation**  
Functional constipation is a functional bowel disorder that presents as persistently difficult, infrequent, or seemingly incomplete defecation, which do not meet IBS criteria.  
**Exclusions:** Constipation NOS (ME05.0)  
**Coded Elsewhere:** Slow transit constipation (DB32.1)
- DD91.2** **Functional diarrhoea**  
Functional diarrhoea is a continuous or recurrent syndrome characterised by the passage of loose (mushy) or watery stools without abdominal pain or discomfort.
- DD91.3** **Functional bloating**  
Functional bloating is a recurrent sensation of abdominal distension, that may or may not be associated with measurable distension, but is not part of another functional bowel or gastroduodenal disorder.
- DD91.4** **Functional abdominal pain syndrome**  
Functional abdominal pain syndrome represents a pain syndrome attributed to the abdomen that is poorly related to gut function, is associated with some loss of daily activities, and has been present at least 6 months. The pain is constant, nearly constant, or at least frequently recurring. Also there is the lack of symptom relationship to food intake or defecation.
- DD91.Y** **Other specified irritable bowel syndrome or functional bowel disorders**
- DD91.Z** **Irritable bowel syndrome or functional bowel disorders, unspecified**
- DD92** **Functional anorectal disorders**  
This group incorporates anorectal disorders which principally present anorectal and defecation complaints without apparent morphological changes of anorectal regions. However, the distinction between organic and functional anorectal disorders may be difficult to make in individual patients.  
**Exclusions:** Bodily distress disorder (6C20)

- DD92.0      Functional faecal incontinence**  
Recurrent uncontrolled passage of faecal material in an individual with a developmental age of at least 4 years and one or more of the following;  
a. Abnormal functioning of normally innervated and structurally intact muscles  
b. Minor abnormalities of sphincter structure and/or innervation  
c. Normal or disordered bowel habits  
d. Psychological causes  
**Exclusions:**      Encopresis (6C01)  
                        Encopresis with constipation or overflow incontinence (6C01.0)  
                        Encopresis without constipation or overflow incontinence (6C01.1)
- DD92.1      Functional anorectal pain**  
This group incorporates functional disorders which principally complaints pain in the anorectal regions. In this category two disorders (chronic proctalgia – Levator ani syndrome and proctalgia fugax) are distinguished on the basis of duration, frequency, and characteristic quality of pain.
- DD92.2      Functional defaecation disorders**  
Functional defaecation disorders are characterised by paradoxical contraction or inadequate relaxation of the pelvic floor muscles during attempted defaecation (dyssynergic defaecation) or inadequate propulsive forces during attempted defaecation (inadequate defaecatory propulsion). The patients must satisfy diagnostic criteria for functional constipation.  
**Exclusions:**      Encopresis (6C01)  
                        Encopresis with constipation or overflow incontinence (6C01.0)  
                        Encopresis without constipation or overflow incontinence (6C01.1)
- DD92.Y      Other specified functional anorectal disorders**
- DD92.Z      Functional anorectal disorders, unspecified**
- DD93      Functional digestive disorders of infants, toddlers or children**  
This group incorporates functional gastrointestinal disorders in infants and toddlers and disorders diagnosed more often in school-aged children and adolescents. These disorders include a variable combination of often age-dependent, chronic or recurrent symptoms not explained by structural or biochemical abnormalities.  
**Exclusions:**      Bodily distress disorder (6C20)  
                        Hypochondriasis (6B23)  
                        Rumination-regurgitation (MB29.4)  
                        Rumination-regurgitation disorder (6B85)

- DD93.0** **Infant regurgitation**  
This is a functional regurgitation that presents frequently (greater than or equal to 2 times/day for greater than equal to 3 weeks) in infants during the first year of life, without retching, haematemesis, aspiration, apnoea, or feeding or swallowing difficulties, or abnormal posturing.
- DD93.1** **Infantile colic**  
This is a condition in which an otherwise healthy baby cries or displays symptoms of distress (cramping, moaning, etc.) frequently and for extended periods, without any discernible reason.
- DD93.2** **Infant dyschezia**
- DD93.Y** **Other functional digestive disorders of infants, neonates or toddlers**
- DD93.Z** **Functional digestive disorders of infants, toddlers or children, unspecified**
- DD94** **Functional gallbladder disorder**  
This is a motility disorder that manifests symptomatically with biliary pain as consequence of either an initial metabolic disorder (supersaturated bile with cholesterol) or a primary motility alteration of gallbladder, at least initially, of any abnormalities of bile composition. There are normal liver enzymes, conjugated bilirubin and amylase/lipase.
- DD95** **Functional sphincter of Oddi disorder**  
This is a functional disorder of the sphincter of Oddi which defines motility abnormalities of sphincter of Oddi associated with prevention of bile and pancreatic juice from flowing through and a backup of the juice. It causes severe abdominal pain with elevated pancreatic enzymes, liver enzymes or both.
- DD9Y** **Other specified functional gastrointestinal disorders**
- DD9Z** **Functional gastrointestinal disorders, unspecified**

## Postprocedural disorders of digestive system (DE10-DE13)

This is a group of disorders associated with the digestive system that occur after medical procedures and are not classified elsewhere.

**Exclusions:** Radiation proctitis (DB33.42)

**Coded Elsewhere:** Postcholecystectomy syndrome (DC14.1)

- Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)
- Chronic dental injuries (DA08.2)
- Radiation oesophageal ulcer (DA25.32)
- Intramural haemorrhage of oesophagus (DA26.2)
- Anastomotic ulcer (DA62)
- Radiation oesophagitis (DA24.22)
- Radiation gastritis (DA42.81)
- Radiation gastric ulcer (DA60.63)
- Radiation duodenal ulcer (DA63.51)
- Radiation duodenitis (DA51.53)
- Enteritis or ulcer of small intestine due to trauma (DA94.32)
- Enteritis or ulcer of small intestine due to radiation (DA94.31)
- Radiation-induced colitis (DB33.41)
- Incisional hernia (DD56)
- Short bowel syndrome (DA96.04)
- Thermal oesophageal ulcer (NE02)

**DE10**

### Vomiting following gastrointestinal surgery

Vomiting occurred following gastrointestinal surgery due to disturbance or inadequate movement of GI tract.

**DE11**

### Dumping syndrome

Dumping syndrome is a group of signs and symptoms that develops most often in people who have had surgery to remove all or part of their stomach, or in whom surgically bypassed. It may occur early (during a meal or within 15-30 minutes after a meal with nausea, vomiting, abdominal pain, cramps, diarrhoea, dizziness, and heart palpitations) or late (1 to 3 hours after eating with sweating, weakness, fatigue, dizziness, lightheadedness, heart palpitations, and fainting).

**DE12**

### Malfunction or complication of external stoma of digestive organs

**Exclusions:** Postsurgical leak (NE81.3)

Acute gastrointestinal bleeding, not elsewhere classified (ME24.90)

Acute postoperative haemorrhage (NE81.0)

**Coded Elsewhere:** Skin problem resulting from external stoma of digestive organs (EM0Y)

**DE12.0**

### Colostomy or enterostomy malfunction or complication

- DE12.1**      **Gastrostomy malfunction**
- DE13**      **Postsurgical malabsorption, not elsewhere classified**
- Inclusions:*      Postsurgical blind loop syndrome
- Exclusions:*      Osteoporosis due to malabsorption (FB83.14)
- 
- DE2Y**      **Other specified diseases of the digestive system**
- DE2Z**      **Diseases of the digestive system, unspecified**

# CHAPTER 14

---

## Diseases of the skin

This chapter has 246 four-character categories.

Code range starts with EA00

Diseases of the skin incorporate conditions affecting the epidermis, its appendages (hair, hair follicle, sebaceous glands, apocrine sweat gland apparatus, eccrine sweat gland apparatus and nails) and associated mucous membranes (conjunctival, oral and genital), the dermis, the cutaneous vasculature and the subcutaneous tissue (subcutis).

- Inclusions:**
- Diseases of the epidermis
  - Diseases of the dermis
  - Diseases of the epidermal appendages (hair, hair follicle, sebaceous glands, apocrine sweat gland apparatus, eccrine sweat gland apparatus and nails)
  - Diseases of subcutaneous tissue
  - Diseases of cutaneous vasculature
- Coded Elsewhere:**
- Malignant neoplasms involving the skin
  - Haematoma of surgical wound of skin (NE81.00)
  - Superficial incisional site infection (NE81.20)
  - Neonatal phototherapy burn (KC50)
  - Symptoms or signs involving the skin (ME60-ME6Y)

This chapter contains the following top level blocks:

- Certain skin disorders attributable to infection or infestation
- Inflammatory dermatoses
- Metabolic and nutritional disorders affecting the skin
- Genetic and developmental disorders affecting the skin
- Sensory and psychological disorders affecting the skin
- Skin disorders involving specific cutaneous structures
- Skin disorders involving certain specific body regions
- Skin disorders associated with pregnancy, the neonatal period and infancy
- Adverse cutaneous reactions to medication
- Skin disorders provoked by external factors
- Benign proliferations, neoplasms and cysts of the skin
- Disorders of the skin of uncertain or unpredictable malignant potential
- Cutaneous markers of internal disorders
- Postprocedural disorders of the skin
- Malignant neoplasms involving the skin

## Certain skin disorders attributable to infection or infestation (EA00-EA6Y)

Infections and infestations affecting the skin incorporate both direct invasion of the skin (including associated mucous membranes, hair and nails) by microorganisms or parasites and dermatoses arising from systemic or other distant infections (e.g. viral exanthems)

**Coded Elsewhere:** Certain parasitic infections or infestations affecting the skin

- Infestation of the skin by ectoparasites
- Pythiosis (1G60.1)
- Protothecosis (1G60.2)
- Mycetoma of unknown or unspecified type (1G60.0)

## Certain skin disorders attributable to viral infection (EA00-EA3Z)

This group incorporates both localised infection of the skin by virus (e.g. viral warts) and systemic or distant viral infections with important skin manifestations (e.g. viral exanthemata).

**Coded Elsewhere:** Pox virus infections of the skin

- Human herpes virus infections involving skin or mucous membrane
- Human papillomavirus infection of skin or mucous membrane (1E80-1E8Z)

## Viral exanthems (EA00-EA0Y)

Acute viral infections characterised by the appearance of a skin rash.

**Coded Elsewhere:** Measles without complication (1F03.0)  
Rubella without complication (1F02.2)  
Roseola infantum (1F01)  
Erythema infectiosum (1F04)  
Enteroviral vesicular stomatitis (1F05.0)  
Foot and mouth disease (1F05.3)  
Picornavirus infections presenting in the skin or mucous membranes (1F05)

**EA00**

### **Viral exanthem due to unknown or unspecified agent**

An exanthematic rash with symptoms suggestive of a viral aetiology where the agent is either unknown or unspecified.

**EA0Y**

### **Viral exanthem due to other specified virus**

## Certain dermatoses with suspected viral aetiology (EA10-EA12)

Skin disorders for which there are indications but no proof that viral infection is responsible.

**EA10**

### **Pityriasis rosea**

Pityriasis rosea is an acute, self-limiting skin disease, probably infective in origin, affecting mainly children and young adults, and characterised by a distinctive skin eruption and minimal constitutional symptoms. The cause of pityriasis rosea is uncertain, but many epidemiological and clinical features suggest that an infective agent may be implicated. In the majority of cases the disease follows a characteristic course whereby a so-called herald patch, larger than subsequent lesions, appears several days before the eruption of multiple oval scaly pink macules over the trunk and proximal limbs predominantly.

**EA11**

### **Papular purpuric gloves and socks syndrome**

This acute acral dermatosis is characterised by an intensely pruritic papular and often purpuric eruption affecting the hands, wrists, feet and ankles. This is frequently accompanied by oral inflammation and ulceration, malaise and fever. It affects adults predominantly and had been linked to a range of viral infections, most commonly to parvovirus B19.

**EA12**

### **Infantile papular acrodermatitis**

Infantile papular acrodermatitis (Gianotti-Crosti syndrome) is a cutaneous reaction pattern to a range of infective agents affecting predominantly young children aged from six months to two years. Agents implicated include hepatitis B virus, Epstein-Barr virus and a number of enteroviruses. The rash consists in a profuse eruption of 5-10 mm diameter dull red flat-topped papules which appear first on the thighs and buttocks, then on the extensor aspects of the arms, and finally on the face. There may be lymphadenopathy but the child is usually otherwise well and the eruption fades over the course of a few weeks.

***Exclusions:***

Acrodermatitis chronica atrophicans (1C1G.14)

Acrodermatitis continua of Hallopeau (EA90.41)

Acrodermatitis enteropathica (5C64.20)

Acrodermatitis perstans (EA90.41)

## Dermatoses from distant or systemic viral infection (EA20-EA20)

**Coded Elsewhere:** Hairy leukoplakia (DA01.01)

Erythema multiforme provoked by viral infection (EB12.Y)

Skin disorders associated with Human immunodeficiency virus infection (EL3Y)

**EA20**

### **Necrolytic acral erythema**

Necrolytic acral erythema is a distinctive acrally-located dermatosis affecting patients with active viral hepatitis C. It manifests principally on the dorsal surfaces of the feet and hands as well circumscribed dusky erythematous areas with flaccid blisters in its early stages and elevated scaly psoriasiform plaques in its chronic form. Microscopically there is keratinocyte necrosis in the upper epidermis.

**EA3Z**

### **Unspecified skin disorder attributable to viral infection**

Certain skin disorders attributable to bacterial infection (EA40-EA5Z)

Disorders of the skin and/or subcutaneous tissues caused by bacteria which a) cause infection normally limited to the skin (e.g. erythrasma); b) characteristically involve the skin at the same time as other organs (e.g. syphilis); c) which may cause disease in the skin as well as in other organs (e.g. cutaneous tuberculosis) or d) which infect other organs but which may manifest in the skin as a result of release of toxins or other indirect mechanism (e.g. streptococcal toxic shock syndrome).

**Exclusions:** Asymptomatic colonization of the skin by virulent or therapy resistant bacteria (QD04)

**Coded Elsewhere:** Certain sexually transmissible bacterial infections affecting skin

Certain zoonotic bacterial infections involving the skin

Dermatoses due to certain filamentous bacteria

Pyogenic bacterial infections of the skin or subcutaneous tissues (1B70-1B7Z)

Non-pyogenic bacterial infections of the skin (1C44)

Yaws (1C1D)

Pinta (1C1E)

Endemic non-venereal syphilis (1C1F)

Cutaneous tuberculosis (1B12.8)

Leprosy (1B20)

Cutaneous non-tuberculous mycobacterial infection (1B21.2)

Acute meningococcaemia (1C1C.20)

Disseminated gonococcal infection (1A73)

Non-venereal treponematoses (1C4Z)

Systemic bacterial infection affecting skin (1C41)

Predominantly tropical or subtropical bacterial infections affecting skin (EA40-EA40)

**Coded Elsewhere:** Cutaneous and subcutaneous melioidosis (1C42)

**EA40**

**Tropical phagedaenic ulcer**

Tropical (phagedaenic) ulcer is an acute or chronic skin disease seen in the tropics and subtropics that is characterised by necrosis of the epidermis and underlying superficial tissue. Ulcers may heal spontaneously, leaving regular depressed scars, but sometimes enlarge to enter a chronic phase. Chronic ulcers are often large and irregular in shape and may involve the whole circumference of a limb. Pseudoepitheliomatous changes can develop which may proceed to the development of frank squamous carcinoma. Vincent's organisms (*Fusobacterium nucleatum* and *Borrelia vincentii*) are thought to play a pathogenic role.

**EA50**

**Toxin-mediated cutaneous reactions to distant or systemic bacterial infection**

**Coded Elsewhere:** Scarlet fever (1B50)

Streptococcal toxic shock syndrome (1C45.0)

Staphylococcal toxic shock syndrome (1C45.1)

Toxic shock syndrome (1C45)

<b>EA50.0</b>	<b>Erythema marginatum rheumaticum</b> A cutaneous exanthem occurring in up to 10% of cases of rheumatic fever. The rash appears as widespread pink or red macules or papules that expand centrifugally with central clearing to form annular or polycyclic erythematous plaques. The exanthem may persist intermittently for weeks to months.
<b>EA50.1</b>	<b>Streptococcal toxin-mediated perineal erythema</b> Streptococcal toxin-mediated perineal erythema is characterised by a striking diffuse macular erythema in the perineum occurring abruptly after a streptococcal pharyngitis. It is often recurrent.
<b>EA50.2</b>	<b>Staphylococcal scalded skin syndrome</b> A syndrome caused by an infection with the gram-positive bacteria Staphylococcus. This syndrome is characterised by fever, blisters, erythema, large areas of skin peel, or Nikolsky's sign. Transmission is by direct or indirect contact with an infected individual, through fomites, or by iatrogenic transmission. Confirmation is by identification of Staphylococcus in a blood or skin sample.  <i>Exclusions:</i> Toxic epidermal necrolysis (EB13.1) <i>Coded Elsewhere:</i> Neonatal staphylococcal scalded skin syndrome (EH11)
<b>EA50.3</b>	<b>Staphylococcal scarlatina</b> An exanthem mediated by staphylococcal toxins from distant <i>Staphylococcus aureus</i> infection but without the systemic complications seen in staphylococcal toxic shock syndrome, of which it may be regarded as a mild form. Clinically it resembles scarlet fever.  <i>Exclusions:</i> Scarlatina NOS (1B50)
<b>EA50.Y</b>	<b>Other specified toxin-mediated cutaneous reactions to distant or systemic bacterial infection</b>
<b>EA50.Z</b>	<b>Toxin-mediated cutaneous reactions to distant or systemic bacterial infection, unspecified</b>
<b>EA51</b>	<b>Skin complications of BCG immunisation</b> Complications secondary to immunization with attenuated <i>Mycobacterium bovis</i> ( <i>Bacillus Calmette-Guérin</i> or BCG).  <i>Exclusions:</i> Cutaneous tuberculosis (1B12.8) <i>Coded Elsewhere:</i> BCG-induced tuberculid (EA5Y) Adverse reaction to BCG immunization (PK81.7)
<b>EA5Y</b>	<b>Cutaneous involvement by other specified bacterial infection</b>
<b>EA5Z</b>	<b>Cutaneous involvement by unspecified bacterial infection</b>

**EA60**

**Certain skin disorders attributable to fungal infection**

This group incorporates both localised infection of the skin by fungus (e.g. pityriasis versicolor) and systemic fungal infections with important skin manifestations (e.g. cutaneous cryptococcosis).

**Coded Elsewhere:** Candidosis of skin or mucous membranes (1F23.1)

Dermatophytosis (1F28)

Non-dermatophyte superficial dermatomycoses (1F2D)

Otomycosis (AA03)

**EA60.0**

**Subcutaneous mycoses**

**Coded Elsewhere:** Lobomycosis (1F2B)

Lymphocutaneous sporotrichosis (1F2J.0)

Fixed cutaneous sporotrichosis (1F2J.1)

Eumycetoma (1F29)

Chromoblastomycosis (1F24)

Conidiobolomycosis (1F26)

Cutaneous mucormycosis (1F2C)

Cutaneous or lymphocutaneous sporotrichosis (1F2J.Z)

Subcutaneous infections due to dematiaceous fungi (1F2Y)

**EA60.1**

**Systemic mycoses affecting skin**

**Coded Elsewhere:** Primary cutaneous coccidioidomycosis (1F25.11)

Disseminated paracoccidioidomycosis (1F2E.1)

Talaromycosis (1F2K)

Histoplasmosis due to Histoplasma duboisii (1F2A.1)

Disseminated adiaspiromycosis (1F2L.0)

Disseminated histoplasmosis capsulati (1F2A.Y)

Primary cutaneous blastomycosis (1F22)

Disseminated blastomycosis (1F22)

Mucocutaneous paracoccidioidomycosis (1F2E.Y)

Cutaneous cryptococcosis (1F27.Y)

**EA60.Y**

**Skin involvement in other specified fungal infection**

**EA60.Z**

**Fungal infection of the skin, unspecified**

**EA6Y**

**Cutaneous involvement by other specified infection or infestation**

## Inflammatory dermatoses (EA80-EB7Y)

A large group of skin disorders in which inflammation plays an important role.

- Exclusions:**
- Napkin candidosis (1F23.12)
  - Bullous impetigo of the napkin area (1B72.0)
  - Dermatoses precipitated by drug therapy (EH71)
  - Dermatoses associated with specific classes of medication (EH76)

- Coded Elsewhere:**
- Nonorgan specific systemic autoimmune disorders involving the skin
  - Autoinflammatory disorders (4A60-4A6Z)

### Dermatitis and eczema (EA80-EA8Z)

Dermatitis and eczema are synonymous and describe an inflammatory reaction pattern in the skin characterised histologically by spongiosis with varying degrees of acanthosis, and a superficial perivascular lympho-histiocytic infiltrate. The clinical features may include itching, redness, scaling and clustered papulo-vesicles. The condition may be induced by a wide range of external and internal factors acting singly or in combination.

- Exclusions:**
- Dermatitis herpetiformis (EB44)
  - Periorificial dermatitis (ED90.1)
  - Cercarial dermatitis (1F86.4)
- Coded Elsewhere:**
- Allergic contact dermatitis (EK00)
  - Photo-allergic contact dermatitis (EK01)
  - Irritant contact dermatitis (EK02)
  - Contact dermatitis of external ear (EG40)
  - Allergic contact blepharoconjunctivitis (9A06.72)
  - Irritant contact blepharoconjunctivitis (EK02.11)
  - Contact gingivostomatitis (DA02.3)
  - Irritant contact dermatitis of hands (EK02.12)
  - Irritant contact dermatitis of vulva (EK02.13)
  - Dermatitis or eczema of eyelids (9A06.7)
  - Dermatitis or eczema of external ear
  - Eczematous nail dystrophy (EE13.5)
  - Dermatitis due to exogenous factors (EK5Y)
  - Eczematous drug eruption (EH6Y)

EA80

### Atopic eczema

A chronic inflammatory genetically-determined eczematous dermatosis associated with an atopic diathesis (elevated circulating IgE levels, Type I allergy, asthma and allergic rhinitis). Filaggrin mutations resulting in impaired epidermal barrier function are important in its pathogenesis. Atopic eczema is manifested by intense pruritus, exudation, crusting, excoriation and lichenification. The face and non-flexural areas are often involved in infants; involvement of the limb flexures may be seen at any age. Although commonly limited in extent and duration, atopic eczema may be generalised and life-long.

**Inclusions:** atopic dermatitis  
**Coded Elsewhere:** Atopic eczema of eyelids (9A06.70)  
Atopic eczema of hands (EA85.20)

**EA80.0 Infantile atopic eczema**

Infantile atopic eczema is defined as atopic eczema present during the first year of life. It typically first manifests between the ages of 2 and 6 months: approximately 50% of people with atopic eczema first present in infancy. The face and non-flexural areas are commonly affected. The napkin area tends to be relatively spared. Involvement of the limb flexures, as is typical in childhood atopic eczema, is also often seen in infancy.

**EA80.1 Childhood atopic eczema**

Atopic eczema in children and adolescents first presenting or continuing after infancy up to age 19 years. Its prevalence is highest in northern latitudes (e.g. nearly 20% in Norwegian children as compared with 0.7% in Tanzanian children). The sites most characteristically involved are the elbow and knee flexures, sides of the neck, wrists and ankles. As the disease progresses, lichenification (skin thickening) becomes a typical clinical feature, especially in areas that can be easily reached and scratched. Discoid variants are more common in children of African and Asian ancestry.

**EA80.2 Adult atopic eczema**

Atopic eczema in adults (19 years or greater) may persist from childhood, recur in adulthood in individuals with a history of atopic eczema in childhood or, less commonly, may develop de novo in adult life.

**EA80.Y Other specified forms of atopic eczema**

**EA80.Z Atopic eczema, unspecified**

**EA81 Seborrhoeic dermatitis and related conditions**

A group of related inflammatory skin disorders affecting predominantly the scalp, face, upper trunk and flexures and characterised by variable amounts of erythema, scale, inflammation and exudation. It is thought that *Malassezia* yeasts play an important role in their pathogenesis. Although these disorders are common, they are seen with increased frequency and severity amongst persons infected with HIV.

**Exclusions:** Seborrhoea (ED91.2)

**Coded Elsewhere:** Infantile seborrhoeic dermatitis (EH40.0)  
Seborrhoeic dermatitis of eyelids (9A06.71)  
Seborrhoeic otitis externa (AA10)  
*Malassezia* folliculitis (1F2D.1)  
HIV-associated seborrhoeic dermatitis (EL3Y)

**EA81.0 Seborrhoeic dermatitis of face**

Seborrhoeic dermatitis affecting the face, most typically the nasolabial folds and chin.

**Exclusions:** Seborrhoea (ED91.2)

<b>EA81.1</b>	<b>Seborrhoeic dermatitis of the scalp</b> Seborrhoeic dermatitis of the scalp is characterised by varying degrees of scaling, inflammation, exudation and crusting affecting the scalp. It may occur in isolation or may be accompanied by seborrhoeic dermatitis of other sites. It may be difficult to differentiate from scalp psoriasis. Pityriasis capitis (dandruff) is considered to represent a mild form of seborrhoeic dermatitis of the scalp.
	<b><i>Inclusions:</i></b> Cradle cap (EH40.00) Seborrhoea (ED91.2)
<b>EA81.Y</b>	<b>Seborrhoeic dermatosis of other specified type or distribution</b>
<b>EA81.Z</b>	<b>Seborrhoeic dermatitis, unspecified</b>
<b>EA82</b>	<b>Nummular dermatitis</b> Cutaneous eruption otherwise known as discoid eczema characterised by discoid or coin-shaped plaques of eczema. The lesions usually occur on the extensor surfaces of the extremities, but the face and trunk may also be involved. The cause is unknown. <b><i>Coded Elsewhere:</i></b> Nummular dermatitis of hands (EA85.2Y)
<b>EA83</b>	<b>Lichen simplex or lichenification</b> If a circumscribed area of skin is subjected to repeated rubbing or scratching, localised epidermal thickening or lichenification will ensue. This may occur as a discrete patch within normal skin (lichen simplex) but frequently complicates eczema or other pruritic dermatoses.
<b>EA83.0</b>	<b>Lichen simplex</b> Circumscribed pruritic lichenification of the skin of any origin. If a circumscribed area of skin is subjected to repeated rubbing or scratching, localised epidermal thickening or lichenification will ensue. The nape of the neck, genitalia, perianal area and lateral calf are commonly affected sites. <b><i>Inclusions:</i></b> Neurodermatitis
<b>EA83.00</b>	Lichen simplex of vulva Circumscribed pruritic lichenification of female external genitalia.
<b>EA83.01</b>	Lichen simplex of male genitalia Circumscribed pruritic lichenification of male genitalia. The scrotum or the base of the penis are commonly affected sites.
<b>EA83.02</b>	Perianal lichen simplex Circumscribed pruritic lichenification of perianal localisation.
<b>EA83.0Y</b>	Lichen simplex of other specified site
<b>EA83.0Z</b>	Lichen simplex of unspecified site

- EA83.1      Secondary lichenification**  
 Thickening of skin affected by a primary dermatosis as the result of repeated rubbing and scratching.
- Coding Note:** Code also the causing condition
- EA84      Asteatotic eczema**  
 Asteatotic eczema develops from asteatosis cutis. In the latter cracking and crazing of the epidermal stratum corneum produces a flaky skin with a reticulate erythema beneath the scales. It occurs particularly on the lower legs. It is more common in the elderly and is provoked by a combination of defatting and desiccation of the epidermis. If inflammation progresses then it may become more pruritic and eczematous, asteatotic eczema.
- EA85      Dermatitis or eczema of hands and feet**  
 Dermatitis (eczema) involving the hands and/or feet.
- Inclusions:**
- Dermatitis of hands and feet
  - Eczema of hands and feet
- EA85.0      Vesicular dermatitis of hands and feet**  
 An eczema of unknown cause affecting principally the palms, soles and sides of the fingers and toes. It is commonly known as pompholyx and is characterised by eruptions of itchy, often multiloculated blisters, which tend to rupture and become secondarily infected. It occurs most commonly in adolescents and young adults. Its relationship to other forms of eczema and to allergic sensitisation, especially to nickel, remains to be adequately elucidated.
- EA85.1      Hyperkeratotic dermatitis of hands and feet**  
 Form of eczema (dermatitis) characterised by highly irritable, scaly, fissured, hyperkeratotic patches on the palms and/or soles. The aetiology is unknown. This disorder takes a chronic course and may be extremely refractory to treatment.
- EA85.2      Dermatitis of hands**  
 Dermatitis or eczema involving predominantly the hands.
- Coded Elsewhere:** Irritant contact dermatitis of hands (EK02.12)
- Vesicular dermatitis of hands (EA85.0)
  - Chronic relapsing vesiculosquamous dermatitis of hands (EA85.0)
  - Hyperkeratotic fissured palmar dermatitis (EA85.1)
- EA85.20      Atopic eczema of hands**  
 Atopic eczema involving predominantly the hands. Individuals with an atopic diathesis are particularly prone to hand eczema. It may be provoked by repeated contact with irritants at work as in hairdressers, cooks and health care workers. It may manifest in a discoid pattern of eczema.
- EA85.2Y      Other specified dermatitis of hands**
- EA85.2Z      Dermatitis of hands, unspecified**

<b>EA85.3</b>	<b>Dermatitis of feet</b> Dermatitis (eczema) involving predominantly the feet.  <b>Coded Elsewhere:</b> Vesicular dermatitis of feet (EA85.0) Hyperkeratotic fissured plantar dermatitis (EA85.1)
<b>EA86</b>	<b>Dermatitis and eczema of lower legs</b> Dermatitis (eczema) affecting the lower legs, most commonly associated with lower limb venous insufficiency, lymphoedema and/or immobility.  <b>Coded Elsewhere:</b> Lower limb venous eczema (EF70)
<b>EA86.0</b>	<b>Stasis dermatitis of the lower legs</b> A chronic eczematous process affecting the skin of the lower legs in association with chronic lower limb lymphoedema and immobility. It is often associated with lipodermatosclerosis. Failure of the normal "muscle pump" to aid venous return is an important component in the aetiology. It is common in the morbidly obese. It is characterised by low grade inflammation with variable scaling and desquamation.
<b>EA87</b>	<b>Dermatitis or eczema of anogenital region</b> Dermatitis (eczema) affecting the external genitalia, crural folds and/or perianal skin.
<b>EA87.0</b>	<b>Dermatitis or eczema of male genitalia</b> Dermatitis (eczema) involving male external genital organs.
<b>EA87.1</b>	<b>Dermatitis or eczema of female genitalia</b> Dermatitis (eczema) affecting the female external genitalia.  <b>Coded Elsewhere:</b> Irritant contact dermatitis of vulva (EK02.13)
<b>EA87.2</b>	<b>Dermatitis or eczema of perianal area</b> Dermatitis (eczema) involving perianal skin.  <b>Coded Elsewhere:</b> Perianal dermatitis of the newborn (KC21.2) Irritant contact dermatitis of perianal skin (EK02.1Y)
<b>EA87.Z</b>	<b>Dermatitis or eczema of anogenital region, unspecified</b>
<b>EA88</b>	<b>Miscellaneous specified eczematous dermatoses</b> A heterogeneous group of eczematous dermatoses not classified elsewhere.
<b>EA88.0</b>	<b>Infectious dermatitis</b> Infective dermatitis (infective eczematoid dermatitis) is an acute exudative dermatitis developing on normal skin surrounding a focus of suppurative infection. Such foci include infected wounds, suppurating sinuses and acute inflammatory fungal and/or bacterial infection of the toe clefts. The dermatitis may spread well beyond the skin directly affected by the suppuration.  <b>Inclusions:</b> Infective eczematoid dermatitis <b>Coded Elsewhere:</b> Infectious dermatitis of the forefeet (EA85.3)

**EA88.00** Human T-cell lymphotropic virus type 1 associated infective dermatitis of childhood  
An inflammatory dermatitis of childhood which develops in a minority of children with HTLV-1 infection, acquired usually via breast milk from an infected mother. Although the disease may clear spontaneously in adolescence, there is a high risk of development of Human T-cell lymphotropic virus-associated myelopathy (tropical spastic paraparesis) in later life. The onset is most frequent between the ages of 2 and 3, but it can manifest from as early as a few months of age to late childhood. Sites of predilection include the scalp, ears, eyelids, nostrils, neck, axillae and groin: erosions and crusting are commonly seen.

**EA88.0Y** Other specified infectious dermatitis

**EA88.0Z** Infectious dermatitis, unspecified

**EA88.1** **Post traumatic eczema**

Eczema localised to skin damaged by physical trauma or by chemical or thermal burns. It may appear months or years after the injury has healed, usually with visible scarring.

**EA88.2** **Disseminated secondary eczema**

The development of eczematous inflammation at sites distant from the primary site of an eczema or dermatitis. The onset of such dissemination may occur days or weeks after the primary dermatitis. The distribution of the secondary eczema tends to be symmetrical. Venous eczema, allergic contact dermatitis, acute irritant contact dermatitis and infective dermatitis are all potential triggers. The precise aetiopathology is as yet poorly understood.

**Coding Note:** Code also the causing condition

**Inclusions:** Eczematid

**EA88.3** **Secondary eczema**

An eczematous reaction to the presence of another, usually inflammatory, skin disorder. This may be observed in some forms of psoriasis when the underlying disease may be obscured by a concurrent eczematous reaction.

**Coding Note:** Code also the causing condition

**EA88.4** **Pityriasis alba**

A common low grade inflammatory dermatosis of unknown aetiology in which multiple small finely scaling macules appear on the face, and less commonly the shoulders and upper arms, of children. These may initially be mildly erythematous but soon become hypopigmented with fine surface scale. Histopathologically there is a mild subacute spongiotic dermatitis with reduction in melanin. It is more prominent in children with pigmented skin and may give rise to concern about vitiligo.

**EA89** **Generalised eczematous dermatitis of unspecified type**

Generalised eczema of uncertain, unknown or unspecified aetiology.

**EA8Y** **Other specified eczematous dermatosis**

**EA8Z** **Dermatitis or eczema, unspecified**

## Papulosquamous dermatoses (EA90-EA95)

A group of skin disorders characterised by epidermal thickening and scaling. The archetypal papulosquamous dermatosis is psoriasis.

### EA90

#### **Psoriasis**

Psoriasis is a common, chronic, relapsing, inflammatory skin disorder characterised by abnormal epidermal keratinization and hyperproliferation. It has a strong genetic component and affects some 2% of the populations of many regions of the world. Up to 10-20% of patients with psoriasis also experience an inflammatory polyarthritis (psoriatic arthritis). Although many people with psoriasis have limited disease, both psoriasis and its associated arthritis often cause major functional and psychosocial disability. The more severe forms of psoriasis are frequently associated with the metabolic syndrome and, as a result, a reduced life expectancy.

### EA90.0

#### **Plaque psoriasis**

The commonest form of psoriasis, which manifests as well-defined red, scaly plaques on the skin. Typical sites of initial involvement are the scalp, the extensor surfaces of the elbows and knees, the lower back and the shins. In severe disease a majority of the skin surface may be involved.

### EA90.1

#### **Guttate psoriasis**

An acute, usually widespread eruption of small (<1cm) papules of psoriasis associated in a majority of cases with preceding streptococcal infection, particularly tonsillitis and streptococcal sore throat. This form of psoriasis is seen typically in children and young adults. If untreated it tends to resolve over a period of four to six months.

### EA90.2

#### **Unstable psoriasis**

Unstable psoriasis is an inflammatory form of psoriasis which may be the precursor of erythrodermic or generalised pustular psoriasis. It is characterised by intense inflammation around the edges of existing plaques and/or the appearance of multiple small fresh inflammatory papules and plaques. Some patients may have a lifelong tendency to unstable psoriasis. It tends to be difficult to control without resort to systemic therapy.

### EA90.3

#### **Erythrodermic psoriasis**

Erythrodermic psoriasis is a severe generalised inflammatory form of psoriasis characterised by confluent intense erythema involving more than 90% of the skin surface. Erythrodermic psoriasis usually develops from preceding extensive, active plaque psoriasis but may arise de novo. Precipitating or trigger factors include withdrawal of systemic glucocorticosteroids, and, less frequently, abrupt discontinuation of methotrexate, phototherapy burns, or intercurrent infections. Patients may develop hypothermia or high output cardiac failure.

### EA90.4

#### **Pustular psoriasis**

Psoriasis characterised by clinically visible pustules. Pustular psoriasis may be localised or generalised and life-threatening.

**Coded Elsewhere:** Infantile pustular psoriasis (EH40.Y)

- EA90.40** Generalised pustular psoriasis  
An inflammatory form of psoriasis characterised by the presence of widely distributed areas of visible sterile pustulation.
- EA90.41** Acropustulosis of Hallopeau  
An uncommon pustular form of psoriasis which may rarely eventuate into generalised pustular psoriasis. It is characterised by pustules and variable scaling occurring in and around the nails and nail-beds of the fingers and toes. It may cause marked nail destruction and may be associated with a distal interphalangeal joint arthritis, with palmoplantar pustulosis or with plaque psoriasis elsewhere.
- Exclusions:** Palmoplantar pustulosis (EA90.42)
- EA90.42** Palmoplantar pustulosis  
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin condition characterised by crops of sterile pustules on the palms and soles which erupt repeatedly over months or years. The affected areas tend to become red and scaly; cracks may form and these are often painful. It is strongly associated with smoking. It is associated with psoriasis elsewhere on the body in up to 24% of patients though appears to have a genetic profile distinct from psoriasis vulgaris. Interleukin-36 receptor gene polymorphisms are strongly associated with generalised pustular psoriasis and have been detected in a minority of patients with PPP.
- Inclusions:** Palmoplantar pustular psoriasis
- EA90.4Y** Other specified pustular psoriasis
- EA90.4Z** Pustular psoriasis, unspecified
- EA90.5** **Psoriasis of specified site or distribution**  
The appearance, management and impact of psoriasis can vary considerably according to its location. Important variants are listed under this heading.
- EA90.50** Scalp psoriasis  
The scalp is frequently the site of initial presentation and is the commonest anatomical site to be involved by psoriasis. Morphologies range from discrete plaques to total scalp involvement with either thick plaques or scaly non-thickened areas almost identical to seborrhoeic dermatitis. Sites of predilection include the immediate post-auricular area and occiput.
- EA90.51** Nail psoriasis  
Psoriasis of the nails manifests as pitting, roughening, thickening or detachment of the nail plate and in its early stages is accompanied by reddening of the distal nail bed.
- EA90.52** Flexural and intertriginous psoriasis  
Psoriasis involving flexures (retro-auricular folds, axillae, crural folds) and/or intertriginous areas (groins, under the breasts and, in obese individuals, abdominal apron fold). It may occur on its own or in association with seborrhoeic psoriasis or chronic plaque psoriasis. Plaques are thin, shiny and beef-red in colour with minimal scale. They may become secondarily fissured and/or macerated.

**EA90.53** Anogenital psoriasis  
Psoriasis involving anogenital skin including the vulva, penis or perianal area.

**EA90.5Y** Psoriasis of other specified site or distribution

**EA90.Y** Other specified forms of psoriasis

**EA90.Z** Psoriasis of unspecified type

**EA91** **Lichen planus**

Lichen planus is an inflammatory disease of skin and mucous membranes characterised by intense inflammation at the interface between epidermis/epithelium and dermis/corium. Its clinical manifestations vary according to how acutely it develops and to where it attacks. On the skin it typically presents as a symmetrical eruption of itchy, flat-topped pink or purple papules or plaques. Involvement of the scalp or nail matrix can produce permanent loss of hair or nails respectively. Although mucous membrane involvement can be asymptomatic, it can cause significant pain and distress, particularly when it is erosive.

**EA91.0** **Acute eruptive lichen planus**

An acute generalised form of lichen planus.

**Exclusions:** Lichenoid drug eruption (EH62)

**EA91.1** **Hypertrophic lichen planus**

A chronic recalcitrant form of lichen planus often localised to the lower legs and ankles and characterised by plaques of markedly thickened skin. It is often extremely pruritic. It can leave permanent pigmentation and scarring.

**EA91.2** **Follicular lichen planus**

Lichen planus involving the hair follicle rather than the epidermis. It typically involves the scalp but may be seen elsewhere. Clinically it presents as grouped small, slightly scaly erythematous follicular papules.

**EA91.3** **Lichen planus of genital skin and mucous membranes**

Lichen planus of genital mucous membranes tends to be mild in men but may give rise to concern about sexually-transmitted infection. Although it may be asymptomatic in women the severe erosive form may cause mark pain and disability.

**EA91.4** **Lichen planus and lichenoid reactions of oral mucosa**

Oral lichenoid reactions represent a common end point in response to extrinsic agents (drugs, allergens), altered self-antigens, or superantigens. Clinical presentation can vary from asymptomatic white reticular striae to painful erythema and erosions. Cutaneous and mucosal involvement of other sites is common. Although oral lichen planus is by definition idiopathic, oral lichenoid reactions may be caused by medications or exogenous agents such as cinnamates and other flavourings.

**EA91.40** Non-erosive lichen planus of oral mucosa

Oral lichen planus in which the epithelium remains intact.

- EA91.41** Erosive oral lichen planus  
Oral lichen planus in which the epithelium is ulcerated.  
**Coded Elsewhere:** Vulvovaginal gingival syndrome (EA91.3)
- EA91.42** Oral lichen planus, unspecified  
Lichen planus of oral mucosa without mention of presence or absence of ulceration.
- EA91.43** Lichenoid mucositis  
Oral lichenoid mucositis is a term describing clinicopathological features of the oral mucosa which represent a common end point in response to extrinsic agents such as drugs or contact allergens, or to presumed altered self-antigens as in lichen planus. Clinical presentation can vary from asymptomatic white reticular striae to painful erythema and erosions. Idiopathic lichen planus cannot always be distinguished from lichenoid reactions to external agents and in such circumstances it is appropriate to label the changes observed as oral lichenoid mucositis until a more definitive diagnosis can be made.
- EA91.4Y** Other specified lichenoid reactions of oral mucosa
- EA91.5** **Lichen planus of the nails**  
Lichen planus of the nail most commonly presents as nail plate thinning with longitudinal grooving and ridging. Hyperpigmentation, subungual hyperkeratosis, onycholysis, and longitudinal melanonychia can also occur. Rarely, the matrix can be permanently destroyed with prominent pterygium formation. Lichen planus has been linked to childhood idiopathic nail atrophy and may overlap with twenty-nail dystrophy of childhood.
- EA91.6** **Subacute lichen planus**  
The commonest form of lichen planus affecting the skin. It may be limited to a few papules or plaques but may be widespread. It may continue to extend over months and may remain active over several years.
- EA91.Y** Other specified lichen planus
- EA91.Z** Lichen planus of unspecified type
- EA92** **Lichenoid dermatoses**  
Conditions other than lichen planus in which there is histological damage to the lower epidermis accompanied by a chronic inflammatory infiltrate in the papillary dermis disturbing the interface between the epidermis and dermis.  
**Coded Elsewhere:** Lichenoid drug eruption (EH62)
- EA93** **Pityriasis lichenoides**  
Pityriasis lichenoides is an uncommon inflammatory skin disease of unknown aetiology. It can range from a relatively mild chronic form to a fulminant form with skin necrosis and severe constitutional symptoms. The disease can last from just weeks to months or years. The chronic form is manifest as multiple small flat asymptomatic scaly papules located predominantly on the trunk and proximal limbs. The acute forms present with the abrupt appearance of multiple papules in the same distribution which rapidly progress to haemorrhagic blisters and ulceration.

**EA94**

### **Pityriasis rubra pilaris**

Pityriasis rubra pilaris (PRP) is the name given to a group of clinically similar papulosquamous dermatoses of unknown aetiology. They initially present with erythematous, hyperkeratotic perifollicular papules, which tend to coalesce into plaques, but may progress to erythroderma, particularly in adults. The distribution, age of onset and speed of onset differ markedly between patients and these differences have been used to classify PRP into a number of clinically distinct subtypes.

**EA95**

### **Small plaque parapsoriasis**

The benign form of parapsoriasis, a chronic multifocal skin disease characterised by atrophic erythematous patches located preferentially on the trunk and proximal extremities. The aetiology is unknown.

**Inclusions:**      Digitate dermatosis

Chronic superficial dermatitis

Urticaria, angioedema and other urticarial disorders (EB00-EBOY)

A heterogeneous group of disorders characterised by dermal and/or subcutaneous and submucosal oedema. The most common underlying mechanism is release of histamine from mast cells with consequent capillary dilatation and tissue oedema. This is responsible for the weals of spontaneous and most physical urticarias. A variety of other mechanisms are involved in other urticarial disorders.

**Exclusions:**      Urticaria pigmentosa (2A21.10)

    Papular urticaria (EK50.00)

**Coded Elsewhere:** Hereditary angioedema (4A00.14)

    Acquired angioedema (4A00.15)

    Urticular vasculitis (EF40.10)

    Food-induced urticaria or angioedema (4A85.21)

    Drug-induced urticaria, angioedema and anaphylaxis (EH61)

    Angioedema due to disordered complement activation or kinin metabolism  
        (4A00.1Z)

**EB00**

### **Spontaneous urticaria**

Spontaneous urticaria is a disease characterised by the daily or almost daily eruption of spontaneous weals, angioedema or both.

**Inclusions:**      ordinary urticaria

**EB00.0**

### **Acute urticaria**

Spontaneous urticaria lasting less than six weeks

**EB00.1**

### **Chronic urticaria**

Spontaneous urticaria lasting six weeks or more.

**Inclusions:**      Chronic spontaneous urticaria

    Chronic ordinary urticaria

**EB00.Z**

### **Spontaneous urticaria, unspecified**

**EB01****Inducible urticaria and angioedema**

The inducible or physical urticarias are a heterogeneous subgroup of urticarias in which pruritic weals, angioedema or both are triggered reproducibly by specific external physical stimuli. The onset of wealing is characteristically rapid with resolution within an hour. The exception is delayed pressure urticaria where weals take longer to develop and resolve. Individual susceptibility to a physical urticaria may be short-lived or may last for years.

**EB01.0****Dermographism**

Dermographism is characterised by the development of short-lived itchy weals in response to stroking of the skin. The weals are typically linear. Symptomatic dermographism is triggered by light skin stroking or friction and is pruritic, whereas simple dermographism is a common physiological response to firm skin stroking and is not pruritic.

**Inclusions:**              Factitious urticaria  
                                  Dermatographic urticaria

**EB01.1****Cold urticaria**

Cold urticaria is triggered by skin cooling. Weals often develop as the skin rewarms afterwards. Cold contact urticaria is triggered by local skin cooling whereas the much less common cold reflex urticaria is triggered by generalised chilling causing a fall in core temperature.

**EB01.2****Delayed pressure urticaria**

Delayed pressure urticaria differs from other forms of physical urticaria in that the appearance of weals is delayed for several hours following the provoking stimulus. It is commonly associated with chronic spontaneous urticaria but tends to respond poorly to antihistamine therapy. The palms and soles, the waist, and the buttocks and thighs are commonly affected areas. Wealing can be induced by a variety of stimuli, including standing, walking, wearing of tight clothes, or sitting on a hard surface.

**EB01.3****Contact urticaria**

Urticaria resulting from skin or mucosal contact with a substance or substances capable of inducing wealing either by immunological or by non-immunological means.

**Coded Elsewhere:** Allergic contact urticaria (EK10)

**EB01.Y****Other specified forms of inducible urticaria and angioedema****EB01.Z****Inducible urticaria and angioedema, unspecified****EB02****Cholinergic urticaria and related conditions**

A range of urticarial disorders associated with heat and activation of sweating.

**Coded Elsewhere:** Exercise-induced anaphylaxis (4A84.30)

<b>EB02.0</b>	<b>Cholinergic urticaria</b> Cholinergic urticaria presents as an eruption of multiple small 2-3 mm monomorphic papular weals in response to sweat-inducing stimuli such as physical exertion, hot baths, spicy foods or sudden emotional stress. The weals tend to be pink in milder cases but white with surrounding macular erythema when the oedema is more intense. Angioedema and systemic manifestations including faintness, headache, palpitations and wheezing may occur in severe cases.
	<b><i>Inclusions:</i></b> Exercise-induced anaphylaxis (4A84.30)
<b>EB02.Y</b>	<b>Other conditions mediated by cholinergic activation</b>
<b>EB03</b>	<b>Syndromes with urticarial reactions or angioedema</b> Periodic and other syndromes in which urticarial reactions or angioedema play an important part.  <b>Coded Elsewhere:</b> Cryopyrin-associated periodic syndromes (4A60.1) Tumour necrosis factor receptor 1 associated periodic syndrome (4A60.2)
<b>EB04</b>	<b>Idiopathic angioedema</b>
<b>EB05</b>	<b>Urticaria of unspecified type</b> <b><i>Inclusions:</i></b> Hives Nettle rash
<b>EB0Y</b>	<b>Other specified urticarial disorders</b>  Inflammatory erythemas and other reactive inflammatory dermatoses (EB10-EB31) A heterogeneous group of disorders characterised by skin inflammation in response to known (usually infections or drugs) or unknown triggers  <b>Coded Elsewhere:</b> Inflammatory dermatoses of the newborn (KC21) Pyodermititis–pyostomatitis vegetans (EL3Y)
<b>EB10</b>	<b>Diffuse inflammatory erythemas</b> A group of disorders characterised by diffuse redness of the skin. They may be due to drugs, viral infections or circulating toxins but frequently a precise aetiology cannot be determined.  <b>Coded Elsewhere:</b> Drug-induced erythroderma (EH64) Neonatal toxic erythema (KC21.1)

**EB11****Annular erythema**

Annular erythema is the term given to a group of chronic annular and gyrate eruptions in which irregular rings and arcs of elevated erythema form from initial inflammatory papules which slowly enlarge whilst clearing centrally. The lesions are usually located on the buttocks, thighs and upper arms, but any area may be involved. The condition may persist for months to years. In the majority of cases the aetiology remains obscure.

**Coded Elsewhere:** Erythema gyratum repens (EL10)

Necrolytic migratory erythema (EL10)

**EB12****Erythema multiforme**

Erythema multiforme is a self-limiting reactive inflammatory dermatosis triggered by cell-mediated hypersensitivity, most commonly to drugs or infection, particularly Herpes simplex. It is characterised by an eruption of macules, papules, nodules, vesicles and/or bullae affecting preferentially the dorsal aspects of the hands and forearms. It may also involve oral and genital mucous membranes.

**Exclusions:** Stevens-Johnson syndrome or toxic epidermal necrolysis (EB13)

**EB12.0****Cutaneous erythema multiforme**

Erythema multiforme confined to the skin and typically triggered by recurrent Herpes simplex infection.

**EB12.1****Mucocutaneous erythema multiforme**

Erythema multiforme with mucosal involvement, usually of oral and/or genital mucous membranes. It causes significantly more morbidity than erythema multiforme confined to the skin.

**Coded Elsewhere:** Erythema multiforme with oral ulceration (DA01.13)

**EB12.Y****Other specified erythema multiforme****EB12.Z****Erythema multiforme, unspecified****EB13****Stevens-Johnson syndrome or toxic epidermal necrolysis**

A spectrum of severe and life-threatening hypersensitivity disorders affecting skin and mucous membranes, most commonly precipitated by an idiosyncratic reaction to medication. Stevens-Johnson syndrome (SJS) always involves mucosal surfaces but the skin involvement is limited by definition to <10% body surface area (BSA). Toxic epidermal necrolysis (TEN) may sometimes spare mucous membranes but skin involvement is by definition >30% BSA. An intermediate form is recognised in which mucosal involvement is accompanied by skin involvement of 10-30% BSA (SJS-TEN overlap syndrome). All forms result in extensive sloughing and ulceration and carry a significant risk of fatal outcome.

**Coded Elsewhere:** Stevens-Johnson syndrome and toxic epidermal necrolysis due to drug (EH63)

EB13.0	<b>Stevens-Johnson syndrome</b> Stevens-Johnson syndrome is an immune-complex–mediated hypersensitivity disorder involving mucous membranes (conjunctivae, oral mucosa and genital mucosa) with, by definition, skin involvement limited to no more than 9% body surface area. It is related to toxic epidermal necrolysis and shares many of the same triggers, notably drugs, but the inflammation is centred on and close to mucosal surfaces. Although mortality is low, acute morbidity is high and conjunctival involvement has the potential to cause blindness.
	<b>Coded Elsewhere:</b> Drug-induced Stevens-Johnson syndrome (EH63.0)
	Acute cicatrizing conjunctivitis, Stevens-Johnson's (9A60.2)
	Chronic cicatrizing conjunctivitis, Stevens-Johnson's (9A60.2)
EB13.1	<b>Toxic epidermal necrolysis</b> Toxic epidermal necrolysis (TEN) is an acute life-threatening skin disease with commonly quoted overall risk of mortality of between 25 and 30%, though the risk of fatal outcome is around 90% in the most severely affected patients (SCORTEN score >5). It is characterised by the rapid onset of extensive erythema, necrosis, and bullous detachment of the epidermis (> 30% body surface area). Commonly, the mucous membranes are also involved. Death may result from a combination of sepsis, fluid depletion and multi-organ failure. In two thirds of cases, TEN is triggered by a clearly identifiable drug allergy.
	<b>Coded Elsewhere:</b> Drug-induced toxic epidermal necrolysis (EH63.1)
EB13.2	<b>Stevens-Johnson and toxic epidermal necrolysis overlap syndrome</b> A severe reactive skin disorder with features of both toxic epidermal necrolysis and Stevens-Johnson syndrome. It is defined by the presence of mucosal involvement and between 10% and 30% body surface area detachment of skin. It may be regarded as an intermediate form of these two disorders and, as with them, it can in most cases be attributed to a drug.
	<b>Coded Elsewhere:</b> Drug-induced Stevens-Johnson and toxic epidermal necrolysis overlap syndrome (EH63.2)

## Neutrophilic dermatoses (EB20-EB2Y)

A group of inflammatory skin disorders characterised by neutrophilic infiltration of the skin.

**Coded Elsewhere:** Disseminated gonococcal infection (1A73)

Behçet disease (4A62)

### EB20

#### Acute febrile neutrophilic dermatosis

Sweet syndrome (the eponym for acute febrile neutrophilic dermatosis) is characterised by a constellation of clinical symptoms, physical features, and pathological findings which include fever, neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis. Sweet syndrome presents in three clinical settings: classical (or idiopathic), malignancy-associated, and drug-induced.

**Inclusions:** Sweet syndrome

**EB21****Pyoderma gangrenosum**

An idiopathic, rapidly evolving, and severely debilitating disease occurring most commonly in association with chronic ulcerative colitis. It is characterised by the presence of boggy, purplish ulcers with undermined borders, appearing mostly on the legs. The majority of cases are in people between 40 and 60 years old. Its etiology is unknown.

**Inclusions:** Phagedenic pyoderma

**EB2Y****Other specified neutrophilic dermatoses****EB30****Eosinophilic cellulitis**

Eosinophilic cellulitis (Wells syndrome) is characterised by a distinctive clinical picture resembling cellulitis, and a typical histology with tissue eosinophilia, oedema and 'flame' figures (clusters of eosinophils and histiocytes around a core of collagen and eosinophilic debris). It can affect either sex, usually in adult life. Any site may be involved, with single or multiple lesions, and recurrences are common. Initially, the lesions are itchy erythematous plaques with features resembling both urticaria and cellulitis but bullous and nodular forms have also been described. It may arise spontaneously but a number of drugs and infections have been implicated.

**EB31****Erythema nodosum**

An erythematous eruption commonly associated with drug reactions or infection and characterised by inflammatory nodules that are usually tender, multiple, and bilateral. These nodules are located predominantly on the shins with less common occurrence on the thighs and forearms. They undergo characteristic colour changes ending in temporary bruise-like areas. This condition usually subsides in 3-6 weeks without scarring or atrophy.

**Coded Elsewhere:** Acute sarcoidosis with erythema nodosum (4B20.5)

Drug-induced erythema nodosum (EH6Y)

**Immunobullous diseases of the skin (EB40-EB4Y)**

A group of disorders characterised by the presence of circulating auto-antibodies directed against specific skin or mucous membrane antigens and resulting in blisters or erosions.

**EB40****Pemphigus**

Pemphigus is a group of chronic autoimmune skin diseases characterised by blister formation on the skin and the mucous membranes. The exact causes of the disease are unknown but the disease is mediated by auto-antibodies to desmosome components. Three clinical forms have been characterised. Pemphigus vulgaris, pemphigus foliaceus and pemphigus vegetans. Other variants exist, namely intercellular IgA dermatosis and paraneoplastic pemphigus.

**Coded Elsewhere:** Neonatal pemphigus (KA07.1)

**EB40.0****Pemphigus vulgaris**

Pemphigus vulgaris is a chronic autoimmune skin disease characterised by blister formation on the skin and the mucous membranes mediated by auto-antibodies to the desmosome components desmoglein 1 and 3.

- EB40.00** Oral pemphigus  
 Oral pemphigus is a variant of pemphigus vulgaris, and is a chronic autoimmune skin disease characterised by blister formation on the oral mucous membrane mediated by auto-antibodies to the desmosome component desmoglein 3.
- EB40.0Y** Other specified pemphigus vulgaris
- EB40.0Z** Pemphigus vulgaris, unspecified
- EB40.1** **Pemphigus foliaceus**  
 Pemphigus foliaceus is a chronic autoimmune skin disease characterised by superficial blister formation on the skin mediated by auto-antibodies to the desmosome component desmoglein 1.
- EB40.2** **Paraneoplastic pemphigus**  
 Paraneoplastic pemphigus is a severe, often fatal autoimmune disease characterised by blisters and erosions not only on the skin and the mucous membranes but also involving other organs including the respiratory system. Auto-antibodies to a variety of plakin components of desmosomes and hemidesmosomes and to the protease inhibitor, Alpha-2-macroglobulin-like-1 protein, have all been implicated in its pathogenesis. It is strongly associated with lymphoproliferative disease.
- Coding Note:** Code also the causing condition
- EB40.Y** Other specified pemphigus
- EB40.Z** Pemphigus, unspecified
- EB41** **Pemphigoid**  
 The pemphigoid group of immunobullous diseases is characterised by the production of IgG antibodies to the epidermal basement membrane zone, leading to subepidermal clefts which are clinically manifest as blisters or erosions of skin or mucous membranes.
- Coded Elsewhere:** Gestational pemphigoid (JA65.10)  
 Neonatal gestational pemphigoid (KA07.Y)
- EB41.0** **Bullous pemphigoid**  
 Bullous pemphigoid is the most common autoimmune blistering disease in the Western world. It chiefly affects the elderly and typically presents with a pruritic urticated erythema which evolves into a widespread eruption of intact tense blisters. It can sometimes involve mucous membranes. It is characterised by IgG antibodies to the basement membrane zone, leading to subepidermal clefts that are clinically manifest as blisters.

<b>EB41.1</b>	<b>Mucous membrane pemphigoid</b> Mucous membrane pemphigoid (MMP) encompasses a heterogeneous group of mucous membrane-dominated autoimmune diseases in which autoantibodies to antigens of the basement membrane zone (BMZ) of mucous membranes and the skin result in subepithelial blistering. MMP may be limited to the conjunctivae (ocular pemphigoid) or to the oral cavity (oral pemphigoid). When the skin is involved, it is generally less extensive and less migratory than in bullous pemphigoid. MMP follows a chronic course and may lead to severe scarring with the attendant risks of loss of vision and oesophageal strictures.
	<b>Coded Elsewhere:</b> Mucous membrane pemphigoid with ocular involvement (9A62)
<b>EB41.Y</b>	<b>Other specified pemphigoid</b>
<b>EB41.Z</b>	<b>Pemphigoid, unspecified</b>
<b>EB42</b>	<b>Linear IgA bullous dermatosis</b> Linear IgA bullous dermatosis is an uncommon immunobullous disorder which occurs in both adults and children. It is characterised by linear deposition of IgA along the epidermal basement membrane. Although the clinical picture may resemble dermatitis herpetiformis, it is not associated with gluten enteropathy and it has different clinical and immunopathological attributes.
<b>EB43</b>	<b>Epidermolysis bullosa acquisita</b> Epidermolysis bullosa acquisita is an acquired non-familial blistering disease characterised by the presence of autoantibodies to collagen VII at the epidermal basement membrane zone, as demonstrated by direct immunofluorescence. There is a wide spectrum of clinical manifestations including a trauma-induced variant and a more inflammatory variant.
	<b>Exclusions:</b> Genetically-determined epidermolysis bullosa (EC30-EC3Z)
	<b>Coded Elsewhere:</b> Transient neonatal epidermolysis bullosa acquisita (KA07.Y)
<b>EB44</b>	<b>Dermatitis herpetiformis</b> Dermatitis herpetiformis is an immunobullous skin characterised by recurrent eruptions of intensely itchy papules, vesicles or bullae, which are typically grouped symmetrically on the extensor surfaces of the limbs and on the buttocks and back. The primary lesions are frequently obscured by excoriation. An incompletely understood abnormal response to dietary gluten provokes the formation of autoantibodies to tissue and epidermal transglutaminases and granular deposition of IgA in dermal papillae. The disease is strongly associated with gluten-sensitive enteropathy, which can range from mild jejunal epithelial inflammation to total villous atrophy (coeliac disease).
<b>EB4Y</b>	<b>Other specified immunobullous disorder</b>

### Cutaneous lupus erythematosus (EB50-EB5Z)

Lupus erythematosus involving the skin. This ranges from acute cutaneous lupus as may accompany a flare of systemic lupus erythematosus to a variety of chronic forms which are in the majority of cases limited to the skin.

**Exclusions:** Systemic lupus erythematosus (4A40.0)

Lupus vulgaris (1B12.8)

**Coded Elsewhere:** Systemic lupus erythematosus with skin involvement (4A40.00)

Neonatal lupus erythematosus (KA07.0)

#### EB50

##### **Subacute cutaneous lupus erythematosus**

Subacute cutaneous lupus erythematosus is a non-scarring form of lupus erythematosus typified by the presence of circulating anti-Ro/SSA antibodies and discoid or annular inflamed red patches with variable fine scaling on sun-exposed skin, especially the sides of the face and neck, the vee of the neck, the extensor surfaces of the upper arms and the upper back: in contrast with systemic lupus erythematosus the cheeks tend to be spared. Visceral disease is less frequent than in systemic lupus erythematosus: renal involvement is rare and mild.

#### EB51

##### **Chronic cutaneous lupus erythematosus**

Chronic cutaneous lupus erythematosus (LE) is characterised by the presence of circumscribed cutaneous plaques showing varying degrees of oedema, erythema, scaling, follicular plugging and atrophy. It most commonly presents as discoid plaques involving the face, ears and scalp but can be widely disseminated or may affect predominantly the extremities (chilblain LE) or subcutaneous fat (lupus panniculitis). It can cause marked disfigurement with prominent facial scarring and permanent hair loss. Most patients remain otherwise in good health but 5-10% may develop systemic lupus erythematosus. Photosensitivity is less apparent than in subacute cutaneous lupus erythematosus.

**Exclusions:** Systemic lupus erythematosus (4A40.0)

#### EB51.0

##### **Discoid lupus erythematosus**

Discoid lupus erythematosus is characterised by the presence of discoid plaques showing varying degrees of oedema, erythema, scaling, follicular plugging and atrophy. It typically involves the face, ears and scalp, but widespread dissemination may occur. It can cause marked disfigurement with prominent facial scarring and permanent hair loss.

#### EB51.Y

##### **Other specified chronic cutaneous lupus erythematosus**

#### EB51.Z

##### **Chronic cutaneous lupus erythematosus, unspecified**

#### EB5Z

##### **Cutaneous lupus erythematosus of unspecified type**

**Scarring or sclerosing inflammatory dermatoses (EB60-EB61.Z)**

A group of inflammatory dermatoses limited to skin and mucous membranes and characterised by variable degrees of sclerosis, fibrosis and atrophy.

**Coded Elsewhere:** Graft-versus-host disease (4B24)

**EB60**

**Lichen sclerosus**

Lichen sclerosus is a chronic inflammatory dermatosis of unknown aetiology. It affects both women and men of all ages. It is characterised by the development of white, smooth, atrophic plaques on vulval and perianal skin in females and on the prepuce and glans penis in males. It often results in scar formation leading to a narrow introitus or phimosis with impairment of urinary and sexual function. The risk of anogenital squamous cell carcinoma is slightly increased. Less commonly other sites of the skin are affected, either independently or in conjunction with anogenital involvement.

**EB60.0**

**Lichen sclerosus of vulva**

Lichen sclerosus of the vulva is an inflammatory disorder of unknown aetiology affecting the skin of the vulva and perianal area. Typically it affects women in the fifth and sixth decades of life though is not uncommon in prepubertal girls. It presents with pruritus, soreness or dyspareunia. The affected skin is white and atrophic, though secondary changes including maceration, purpura and erosion may dominate the clinical picture. In longstanding cases there may be marked shrinkage of the vulva, labial fusion and an increased risk of malignant transformation.

**EB60.1**

**Lichen sclerosus of penis**

Lichen sclerosus of the penis develops almost exclusively in uncircumcised males and is the result of chronic occluded contact of susceptible epithelium to urine. It often causes dyspareunia and difficulties with micturition. It manifests typically as a sclerotic phimosis of the prepuce, which it may not be possible to retract, together with inflammation and sclerosis of the mucocutaneous surface of the prepuce and glans penis. Stenosis and occasionally obliteration of the external meatal orifice may occur in severe cases. Although most commonly recognised in adult men it is a common cause of acquired phimosis in boys.

**Inclusions:**              Balanitis xerotica obliterans

**EB60.Y**

**Lichen sclerosus of other specified sites**

**EB60.Z**

**Lichen sclerosus, unspecified**

**EB61**

**Morphea**

A group of related diseases of poorly understood aetiology affecting principally skin and subcutaneous tissue and characterised by variable fibrosis, sclerosis and cutaneous atrophy.

**Coded Elsewhere:** Extranodal lichen sclerosus with morphea (EB60.Y)

Atrophoderma of Pasini and Pierini (EE7Y)

<b>EB61.0</b>	<b>Plaque morphoea</b>
	The commonest form of morphoea which presents as indurated waxy plaques, often with a violaceous border and commonly affecting the trunk, especially in the submammary folds and around the waist. The cause is unknown. It is commoner in women than men.
	<b>Inclusions:</b> Circumscribed scleroderma
<b>EB61.1</b>	<b>Linear morphoea</b>
	Linear morphoea is a form of morphoea which usually presents in childhood or adolescence and is usually unilateral, affecting a limb with a linear induration of skin, subcutis and occasionally underlying muscle and bone. It may also affect the scalp and forehead ("en coup de sabre") producing a depressed scar likened to a healed sabre wound, with sclerosis of the skin and alopecia of affected scalp.
<b>EB61.Y</b>	<b>Other specified forms of morphoea</b>
<b>EB61.Z</b>	<b>Morphoea, unspecified</b>

---

### **EB7Y      Other specified inflammatory dermatoses**

#### Metabolic and nutritional disorders affecting the skin (EB90-EB9Y)

This group includes dermatoses resulting either from disturbed metabolic processes or from defective nutrition

- Coded Elsewhere:** Disorders of essential minerals or their metabolism affecting the skin  
 Disorders of vitamins or their metabolism which may affect the skin  
 Neonatal nutritional disorders affecting the skin (KC24)  
 Dermatoses resulting from defective nutrition (5C3Y)

### **EB90      Dermatoses resulting from disturbed metabolic processes**

This group comprises dermatoses where abnormal quantities of biological material accumulate in the skin. The effects of such accumulations depend on the particular material involved. Examples include lipid, mucin, amyloid, porphyrins and calcium.

- Coded Elsewhere:** Tophaceous gout (FA25.20)  
 Genetic disorders of amino acid metabolism or transport  
 affecting the skin  
 Cutaneous amyloidosis (5D00.Y)

<b>EB90.0</b>	<b>Diabetic skin lesions</b>
	Unspecified skin changes attributable to diabetes.

**Coding Note:** Always assign an additional code for diabetes mellitus.

<b>EB90.1</b>	<b>Cutaneous mucinosis</b> Skin disorders characterised by accumulation of mucin in the skin <b>Coded Elsewhere:</b> Mucopolysaccharidosis type 1 (5C56.30) Mucopolysaccharidosis type 2 (5C56.31) Mucopolysaccharidosis type 6 (5C56.33)
<b>EB90.10</b>	Pretibial myxoedema  Pretibial myxoedema is a form of diffuse cutaneous mucinosis in which there is an accumulation of excess glycosaminoglycans, especially hyaluronic acid, in the dermis and subcutis. It is most commonly seen on the shins (pretibial areas) but does occur elsewhere on the lower extremities. It manifests as violaceous or brownish, firm, non-pitting, asymmetrical nodules or plaques or nodules which tend to coalesce to produce extensive areas of induration with a "peau d'orange" (orange peel) appearance.  It is nearly always associated with autoimmune thyroiditis (Graves disease) and may be associated with finger clubbing (acropachy) and exophthalmos (thyroid eye disease).
<b>Coding Note:</b>	Code also the causing condition
<b>EB90.11</b>	Lichen myxedematosus  Localised lichen myxedematosus is a group of skin diseases characterised by the development of papules, nodules and/or plaques with mucin deposits and a variable degree of fibrosis in the absence of thyroid disease. The group comprises five sub-forms: nodular lichen myxedematosus, discrete papular lichen myxedematosus, papular mucinosis of infancy, acral persistent papular mucinosis and self-healing papular mucinosis.
<b>EB90.12</b>	Reticular erythematous mucinosis  Reticular erythematous mucinosis comprises areas of reticular infiltrated erythema affecting particularly the upper anterior chest wall. Histologically there is a mucinous and chronic inflammatory cell infiltrate in the dermis. It occurs most frequently in women in middle years of life. The aetiology is not understood though exposure to sunlight may play a part.
<b>EB90.1Y</b>	Other specified forms of cutaneous mucinosis
<b>EB90.2</b>	<b>Cutaneous and subcutaneous xanthomata</b> An abnormal accumulation of lipid in the skin or soft tissues, most frequently due to an associated dyslipidaemia.  <b>Exclusions:</b> Benign cephalic histiocytosis (EE81)

<b>EB90.20</b>	Plane xanthoma Plane (planar) xanthomata are flat cutaneous xanthomata and contrast with eruptive and tuberous xanthomata which present as papules and nodules. They are often completely macular but may develop into elevated plaques. The commonest type is the xanthelasma of the eyelid but also included is the palmar xanthoma and a less common widespread form, diffuse plane xanthoma, which may be mimicked by a clinically similar disorder associated with paraproteinaemia, diffuse normolipidaemic plane xanthomatosis.
<b>Coding Note:</b>	Code also the causing condition
	<b>Coded Elsewhere:</b> Xanthelasma of eyelid (9A06.4)
<b>EB90.21</b>	Tuberous xanthoma Tuberous xanthomas are firm yellow-red nodules that occur over sites of pressure: they usually indicate the presence of hyperlipidaemia type 3 (Type III hyperlipoproteinæmia). They start as small xanthomas, usually over the extensor aspects of the elbows and knees, but can develop into quite exuberant exophytic lesions several centimetres in diameter and height. They can develop over other pressure sites particularly the heels and plantar surfaces of the feet.
<b>Coding Note:</b>	Code also the causing condition
<b>EB90.22</b>	Eruptive xanthoma Eruptive xanthomata manifest as crops of small yellow papules which erupt in large numbers over extensor surfaces, particularly the buttocks, back, legs and arms. They are associated with severe hypertriglyceridaemia and may be associated with uncontrolled diabetes mellitus.
<b>Coding Note:</b>	Code also the causing condition
<b>EB90.23</b>	Tendinous xanthoma Tendinous xanthomata manifest most commonly as subcutaneous nodules attached to the extensor tendons over the knuckles or the Achilles tendon, though other tendons can sometimes be affected. They are most frequently seen in familial hypercholesterolaemia but may also be associated with secondary hypercholesterolaemia due to prolonged cholestasis.
<b>Coding Note:</b>	Code also the causing condition
<b>EB90.24</b>	Xanthoma due to specified disorder of lipid metabolism Lipid accumulations in the skin and soft tissues resulting from disordered lipid metabolism.
<b>Coding Note:</b>	Code also the causing condition
<b>EB90.2Z</b>	Cutaneous and subcutaneous xanthomata of unspecified type
<b>EB90.3</b>	<b>Porphyria or pseudoporphyria affecting the skin</b> Skin disorders resulting from or simulating disorders due to certain disorders of porphyrin metabolism.
	<b>Coded Elsewhere:</b> Porphyria cutanea tarda (5C58.10) Variegate porphyria (5C58.13) Erythropoietic porphyrias (5C58.12)

- EB90.30** Pseudoporphyria  
The development of blistering of exposed skin on the extremities resembling porphyria cutanea tarda without demonstrable abnormalities of porphyrin metabolism.
- EB90.3Y** Other specified porphyria or pseudoporphyria affecting the skin
- EB90.4** **Calcification of skin or subcutaneous tissue**  
A heterogeneous group of disorders which result in deposition of calcium in skin and soft tissues.
- EB90.40** Dystrophic calcification of the skin of uncertain or unspecified aetiology  
Abnormal deposition of calcium in the skin and subcutaneous tissues of unknown (idiopathic) or unspecified cause.  
**Coded Elsewhere:** Scrotal calcinosis (GA81.Y)
- EB90.41** Calcific panniculitis  
Calcific panniculitis presents as discrete, firm subcutaneous masses, often affecting the thighs and hips. It is strongly associated with hyperparathyroidism, particularly in the context of chronic renal failure. It may occur in conjunction with but is clinically distinct from calcific arteriolopathy (calciphylaxis).
- EB90.42** Calcific arteriolopathy  
Calcific arteriolopathy (calciphylaxis) is a life-threatening vasculopathic disorder characterised by painful cutaneous ischaemia and infarction due to calcification, intimal fibroplasia, and thrombosis of subcutaneous arterioles. It is most commonly associated with end-stage kidney disease or renal transplantation, particularly in the context of longstanding diabetes mellitus. Affected skin, commonly on the hips and thighs, appears mottled, grey and devitalized before progressing to full thickness infarction and deep ulceration. These changes may be accompanied by indurated subcutaneous plaques indicating an underlying calcifying panniculitis. The condition may be but is not always associated with hyperparathyroidism or an elevated calcium-phosphate product.  
**Inclusions:** Calciphylaxis
- EB90.4Y** Other specified calcification of skin or subcutaneous tissue
- EB9Y** **Other specified metabolic and nutritional disorders affecting the skin**

## Genetic and developmental disorders affecting the skin (EC10-EC7Y)

A large group of disorders, some limited to the skin but many involving other organ systems, due to heritable genetic defects, chromosomal abnormalities or embryofetal developmental anomalies.

**Coded Elsewhere:** Chromosomal disorders affecting the skin

- DNA instability syndromes affecting the skin
- Genetic disorders of adipose tissue or lipid metabolism affecting the skin
- Genetic disorders of amino acid metabolism or transport affecting the skin
- Sphingolipidoses with skin manifestations
- Genetic hamartoneoplastic syndromes affecting the skin (LD27.5)
- Variegate porphyria (5C58.13)
- Mucopolysaccharidosis type 1 (5C56.30)
- Mucopolysaccharidosis type 2 (5C56.31)
- Mucopolysaccharidosis type 6 (5C56.33)
- Acrodermatitis enteropathica (5C64.20)
- Monogenic autoinflammatory syndromes (4A60)
- Chronic mucocutaneous candidosis (1F23.14)
- Congenital anomalies of skin development (LC60-LC60)
- Developmental hamartomata of the epidermis and epidermal appendages (LC00-LC0Y)
- Developmental anomalies of skin pigmentation (LC10-LC1Y)
- Hamartomata derived from dermal connective tissue (LC20-LC2Y)
- Developmental defects of hair or nails (LC30-LC31)
- Developmental anomalies of cutaneous vasculature (LC50-LC5Z)

## Genetic syndromes affecting the skin (EC10-EC1Y)

**Coded Elsewhere:** Genetic syndromes affecting cutaneous vasculature

- Ectodermal dysplasia syndromes (LD27.0)
- Syndromes with premature ageing appearance as a major feature (LD2B)

**EC10**

### Genetic syndromes with poikiloderma

Hereditary syndromes in which poikiloderma (cutaneous pigmentation, atrophy and telangiectasia) is a conspicuous feature.

**Coded Elsewhere:** Cockayne syndrome (LD2B)

- Rothmund-Thomson syndrome (LD2B)
- Hereditary acrokeratotic poikiloderma, Weary type (LD27.Y)
- Kindler syndrome (LD2B)
- Bloom syndrome (4A01.31)
- Dyskeratosis congenita (3A70.0)

**EC1Y**

### Other specified genetic syndromes affecting the skin

**EC20**

### **Genetic disorders of keratinisation**

Heritable disorders characterised by abnormal epidermal keratinization. They include the ichthyoses and palmoplantar keratodermas.

**Coded Elsewhere:** Syndromic ichthyosis (LD27.2)

Keratosis pilaris (ED56)

**EC20.0**

#### **Non-syndromic ichthyosis**

Hereditary ichthyoses with clinical manifestations limited to the integument.

**EC20.00**

#### **Ichthyosis vulgaris**

Ichthyosis vulgaris accounts for 95% of all cases of hereditary ichthyosis. It is an autosomal dominant condition due to filaggrin gene mutations. At birth the skin may appear normal but it gradually becomes dry, rough and scaly, with most signs and symptoms appearing by the age of 5. Ichthyosis vulgaris can affect all parts of the skin surface including the face and scalp though the limb flexures are usually spared. Hyperlinearity of the palms is a characteristic feature. It is closely associated with the development of atopic eczema.

**EC20.01**

#### **X-linked ichthyosis**

X-linked ichthyosis is an X-linked recessive genodermatosis associated with steroid sulfatase deficiency and elevated plasma cholesterol sulfate. Generalised scaling is present at or shortly after birth, most prominently over the extremities, neck, trunk, and buttocks. It occurs only in males and may be associated with testicular disease and corneal opacities.

**EC20.02**

#### **Autosomal recessive congenital ichthyosis**

A heterogeneous group of genetically-determined ichthyoses with autosomal recessive inheritance.

**EC20.03**

#### **Keratinopathic ichthyoses**

Heritable ichthyoses resulting from mutations in keratin genes.

**EC20.0Y**

#### **Other specified or unclassifiable non-syndromic ichthyosis**

**EC20.1**

#### **Hereditary skin peeling**

A group of uncommon heritable disorders characterised by abnormal skin peeling

**EC20.2**

#### **Hereditary acantholytic dermatoses**

A group of heritable disorders characterised by epidermal acantholysis and loss of epidermal integrity.

**EC20.3**

#### **Hereditary palmoplantar keratodermas**

Heritable disorders of keratinisation of the skin of the palms and soles.

**EC20.30**

#### **Diffuse palmoplantar keratodermas**

Palmoplantar keratoderma in which there is confluent epidermal thickening affecting the palms and soles.

**Coded Elsewhere:** Hidrotic ectodermal dysplasia, Clouston type (LD27.03)

- EC20.31** Focal palmoplantar keratodermas  
 Palmoplantar keratoderma in which there is focal epidermal thickening with areas of normal intervening palmar and plantar skin.
- Coded Elsewhere:** Tyrosinaemia type 2 (5C50.12)
- EC20.32** Papular palmoplantar keratodermas  
 Palmoplantar keratoderma characterised by the presence of multiple small discrete hyperkeratotic papules involving palmar and plantar skin.
- EC20.3Z** Hereditary palmoplantar keratoderma of unspecified type
- EC20.Y** Other specified genetic disorders of keratinisation
- EC21**
- Genetic defects of hair or hair growth**
- Coded Elsewhere:** Genetic syndromes with hypertrichosis (LD27.3)
- EC21.0** Genetic defects of the hair shaft
- Exclusions:** Menkes' kinky hair syndrome (5C64.0)
- EC21.1** Genetic syndromes with abnormalities of the hair shaft
- Coded Elsewhere:** Bamforth-Lazarus syndrome (5A00.0Y)
- Cartilage-hair hypoplasia (LD27.0Y)
  - Netherton syndrome (LD27.2)
  - Woolly hair – palmoplantar keratoderma – dilated cardiomyopathy (BC43.6)
  - Woolly hair – hypotrichosis – everted lower lip – outstanding ears (LD27.0Y)
  - Menkes disease (5C64.0Y)
  - Curly hair – ankyloblepharon – nail dysplasia syndrome (LD27.0Y)
- EC21.2** Hereditary alopecia or hypotrichosis  
 Genetically-determined absence or sparsity of hair.

EC21.3	<p><b>Genetic syndromes with alopecia or hypotrichosis</b></p> <p>Hereditary syndromes in which sparse or absent hair is a component</p> <p><b>Coded Elsewhere:</b> Argininosuccinic aciduria (5C50.A0)</p> <ul style="list-style-type: none"> <li>Hidrotic ectodermal dysplasia, Clouston type (LD27.03)</li> <li>Severe T-cell immunodeficiency - congenital alopecia - nail dystrophy (4A01.1Y)</li> <li>Ichthyosis – hypotrichosis syndrome (LD27.2)</li> <li>Neonatal sclerosing cholangitis – ichthyosis – hypotrichosis syndrome (DB96.2Y)</li> <li>Odonto-onycho-dermal dysplasia (LD27.0Y)</li> <li>Woolly hair – hypotrichosis – everted lower lip – outstanding ears (LD27.0Y)</li> <li>Autosomal dominant palmoplantar keratoderma and congenital alopecia (LD27.0Y)</li> <li>Autosomal recessive palmoplantar keratoderma and congenital alopecia (LD27.0Y)</li> <li>Alopecia - contractures - dwarfism - intellectual deficit (LD27.0Y)</li> <li>Alopecia – psychomotor epilepsy – periodontal pyorrhoea – intellectual disability syndrome (LD90.Y)</li> <li>Cataract - alopecia - sclerodactyly (LD27.0Y)</li> <li>Odonto-onycho dysplasia - alopecia (LD27.0Y)</li> <li>Schöpf-Schulz-Passarge syndrome (LD27.0Y)</li> <li>Macrocephaly – alopecia – cutis laxa – scoliosis syndrome (LD28.2)</li> </ul>
EC21.4	<p><b>Genetically-determined hypertrichosis</b></p> <p>Increased non-androgen-dependent hair growth due to genetic abnormality</p> <p><b>Coded Elsewhere:</b> Hypertrichosis lanuginosa congenita (LD27.0Y)</p> <ul style="list-style-type: none"> <li>Congenital generalised hypertrichosis (LD27.0Y)</li> <li>X-linked dominant congenital generalised hypertrichosis (LD27.0Y)</li> <li>Familial isolated trichomegaly (LD27.0Y)</li> </ul>
EC21.Y	<p><b>Other specified genetic defects of hair or hair growth</b></p>
EC21.Z	<p><b>Genetic defects of hair or hair growth, unspecified</b></p>
<b>EC22</b>	<p><b>Genetic defects of nails or nail growth</b></p> <p><b>Coded Elsewhere:</b> Genetic syndromes affecting nails (LD27.4)</p>
EC22.0	<p><b>Inherited deformities of nails</b></p> <p>Genetically-determined abnormalities of nail development.</p>

<b>EC23</b>	<b>Genetic disorders of skin pigmentation</b> Genetic disorders of the skin characterised by disordered pigmentation, including albinism and inherited forms of lentiginosis.
<b>EC23.0</b>	<b>Non-syndromic genetically-determined hypermelanosis or lentiginosis</b>
<b>EC23.1</b>	<b>Syndromic genetically-determined hypermelanosis or lentiginosis</b>
	<b>Coded Elsewhere:</b> Peutz-Jeghers syndrome (LD2D.0)  Incontinentia pigmenti (LD27.00) Neurofibromatoses (LD2D.1) Arterial dissection - lentiginosis (BD50.Z) McCune-Albright syndrome (FB80.0) LEOPARD syndrome (LD2F.1Y) Carney complex (5A70.Y) Bannayan-Riley-Ruvalcaba syndrome (LD2D.Y) Legius syndrome (LD27.5)
<b>EC23.2</b>	<b>Albinism or other specified genetically-determined hypomelanotic disorders</b> A large group of heritable disorders in which cutaneous melanin production is reduced or absent, mainly as the result of defects in enzymes required for normal melanin biosynthesis.  <b>Coded Elsewhere:</b> Ocular albinism (9E1Y)
<b>EC23.20</b>	Oculocutaneous albinism Oculocutaneous albinism is a genetically heterogeneous congenital disorder characterised by decreased or absent pigmentation in the hair, skin, and eyes.
<b>EC23.2Y</b>	Other specified genetically-determined hypomelanotic disorders
<b>EC23.Y</b>	<b>Other specified genetic disorders of skin pigmentation</b>
<b>EC23.Z</b>	<b>Genetic disorders of skin pigmentation, unspecified</b>

Genetically-determined epidermolysis bullosa (EC30-EC3Z)

Epidermolysis bullosa (EB) is the name given to a heterogeneous group of blistering disorders which in the majority of cases are due to genetically-determined defects in structural proteins of the epidermis and dermo-epidermal junction. The genetic forms are to be distinguished from the immunobullous disorder, epidermolysis bullosa acquisita (qv).

**Exclusions:** Epidermolysis bullosa acquisita (EB43)

<b>EC30</b>	<b>Epidermolysis bullosa simplex</b> Epidermolysis bullosa simplex is the name given to a heterogeneous group of genetically-determined defects in epidermal cell-cell adhesion. These give rise to blistering in response to frictional and shearing stresses.
-------------	--

**EC31**

### **Junctional epidermolysis bullosa**

Junctional (lucidolytic) epidermolysis bullosa is due to defects at the level of the lamina lucida of the epidermal basement membrane. The generalised severe form (Herlitz) is associated with widespread mucosal involvement of internal organs and has a high mortality in infancy.

**EC32**

### **Dystrophic epidermolysis bullosa**

Dystrophic (dermolytic) epidermolysis bullosa is due to defects in or absence of type VII collagen. As a result the anchoring fibrils which secure the epidermal basement membrane to the dermis are defective or absent. The severe recessive form causes extensive scarring and predisposes to aggressive squamous cell carcinoma.

**EC33**

### **Syndromic epidermolysis bullosa**

A small group of disorders including Kindler syndrome in which skin blistering is associated with other defects.

**Coded Elsewhere:** Kindler syndrome (LD2B)

Ectodermal dysplasia – skin fragility syndrome (EC30)

Skin fragility-woolly hair syndrome (EC21.1)

**EC3Z**

### **Epidermolysis bullosa**

Genetic disorders affecting dermal collagen, elastin or other matrix proteins (EC40-EC4Y)

A heterogeneous group of disorders due to genetically-determined abnormalities of dermal structural proteins including collagen and elastin.

**Coded Elsewhere:** Ehlers-Danlos syndrome (LD28.1)

Marfan syndrome (LD28.01)

Genetically-determined cutis laxa (LD28.2)

Familial cutaneous collagenoma (LC2Y)

**EC40**

### **Pseudoxanthoma elasticum**

Pseudoxanthoma elasticum (PXE) is an inherited connective tissue disorder characterised by progressive calcification and fragmentation of elastic fibres in the skin, retina, and arterial walls.

**EC4Y**

### **Other specified genetic disorders affecting dermal matrix proteins**

Specified developmental anomalies affecting the skin (EC50-EC5Y)

**Coded Elsewhere:** Structural developmental anomalies of eyelids (LA14.0)

Structural developmental anomalies of mouth or tongue (LA31)

Facial clefts (LA51)

Minor anomalies of pinnae (LA21)

Amniotic bands (LD2F.1Y)

**EC50**

### **Developmental anomalies of the umbilicus**

**Coded Elsewhere:** Allantoic duct remnants or cysts (LB03.0)

Umbilical sinus (LB03.Y)

Umbilical vitelline cyst or remnants (LB03.Y)

Subcutaneous vitelline cyst or remnants (LB03.Y)

**EC5Y**

### **Other specified developmental anomalies affecting the skin**

**EC7Y**

### **Other specified genetic and developmental disorders affecting the skin**

Sensory and psychological disorders affecting the skin (EC90-ED3Y)

A group of skin disorders due to disturbances of cutaneous sensation including pruritus and pain, psychological disorders including artefact and delusional states, and dermatoses resulting from nerve damage and other neurological conditions.

Disturbances of cutaneous sensation (EC90-EC9Y)

This group includes dermatoses associated with itch, pain and other disturbances of cutaneous sensation.

**Coded Elsewhere:** Lichen simplex (EA83.0)

**EC90**

### **Pruritus**

An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.

**Exclusions:** neurotic excoriation (6B25.1)

**Coded Elsewhere:** Pruritus of pregnancy (JA65.11)

**EC90.0**

### **Pruritus due to skin disorder**

Pruritus due to skin disorder, especially those such as xerosis cutis or psoriasis where itch may occur but is not an inherent component of the disorder.

**EC90.1**

### **Pruritus due to systemic disorder**

Pruritus due to underlying systemic disorder such as renal failure or cholestatic jaundice.

**Coded Elsewhere:** HIV-associated pruritus (EL3Y)

Paraneoplastic pruritus (EL1Y)

- EC90.10** Uraemic pruritus  
Pruritus in patients with chronic renal failure. Although common in untreated chronic kidney disease, it is particularly prevalent in patients receiving peritoneal or haemodialysis. The itch is not due to elevated serum urea levels. The precise mechanisms are not fully understood.
- EC90.11** Cholestatic pruritus  
Pruritus due to defective elimination of bile.  
**Coded Elsewhere:** Intrahepatic cholestasis of pregnancy (JA65.0)
- EC90.12** Haemodialysis-associated pruritus  
Generalised pruritus attributable to haemodialysis rather than to chronic kidney disease. The causes are not well understood.
- EC90.1Y** Pruritus due to other specified systemic disorder
- EC90.2** **Drug-induced pruritus**  
Pruritus attributable to drugs, in particular opioids.
- EC90.3** **Pruritus due to neurological disorder**  
Pruritus resulting from damage or irritation of sensory nerves or their central connections.
- EC90.4** **Psychogenic pruritus**  
Chronic episodic pruritus in the absence of an identifiable organic cause and typically associated with stress and/or depression.
- EC90.5** **Anogenital pruritus**  
Persistent itching of the perianal skin and/or external genitalia.  
**Coded Elsewhere:** Penoscrotal pruritus (GA81.0)  
Vulval pruritus (GA42.0)  
Anal pruritus (EG60)
- EC90.6** **Pruritus of unknown cause**  
Pruritus without identifiable cause despite thorough investigation.
- EC90.Y** **Pruritus of other specified type or aetiology**
- EC90.Z** **Pruritus, unspecified**
- EC91** **Prurigo**  
Prurigo is a cutaneous reaction pattern due to chronic scratching of itchy skin. It is characterised by widespread, symmetrically distributed, itchy, excoriated papules and nodules with focal epidermal acanthosis and hyperkeratosis on histology.  
**Coded Elsewhere:** HIV-associated papular pruritic eruption (EL3Y)

EC91.0	<b>Nodular prurigo</b> A chronic highly pruritic dermatosis of poorly understood aetiology which presents with multiple warty nodules on the skin, particularly on the limbs. Exudation, crusting and scale result from repeated scratching.
EC91.1	<b>Atopic prurigo</b> A clinical variant of atopic eczema characterised by multiple discrete itchy, often excoriated papules, particularly on the limbs.  <b>Coded Elsewhere:</b> Childhood atopic eczema, prurigo pattern (EA80.1) Adult atopic eczema, prurigo pattern (EA80.2)
EC91.Z	<b>Prurigo, unspecified</b>
EC92	<b>Mucocutaneous or cutaneous pain syndromes</b> A range of chronic focal pain disorders affecting skin or mucosal sites, with a predilection for the orocervical and urogenital regions. They are diagnoses of exclusion and should be made only when no other explanation for the symptoms can be found. They are frequently associated with severe psychological distress.  <b>Coded Elsewhere:</b> Burning mouth syndrome (DA0F.0) Vulvodynia (GA34.02)
EC92.0	<b>Penoscrotodynia</b> An uncommon but distressing somatoform disorder affecting men in which there is a clear and precise complaint of genital pain and/or a skin burning sensation for which no underlying cause can be found.
EC92.1	<b>Scalp dysaesthesia</b> An uncommon but distressing somatoform disorder in which there is a clear and precise complaint of scalp pain or burning sensation for which no underlying cause can be found.
EC9Y	<b>Other specified disturbances of cutaneous sensation</b>

## Mental conditions affecting the skin (ED00-ED2Y)

This group includes cutaneous artefacts and disorders of cutaneous image and perception including delusional states and body dysmorphic disorder.

**Coded Elsewhere:** Olfactory reference disorder (6B22)

Body dysmorphic disorder (6B21)

Somatic delusion directed at the skin (MB26.09)

## Self-inflicted skin disorders (ED00-ED0Y)

This heterogeneous group of disorders all result from self-inflicted skin injury or pathomimicry directly induced either by psychopathological behaviour or by intentional deception.

**Coded Elsewhere:** Body-focused repetitive behaviour disorders (6B25)

Trichotillomania (6B25.0)

Self-inflicted hair-damaging disorder (6B25.Z)

**ED00**

### Artefactual skin disorder

Artefactual skin disorder encompasses a diverse range of self-inflicted skin injuries that are provoked by mechanical means or by the application or injection of chemical irritants or caustics. They may simulate other dermatoses but usually have a distinctive, geometric, bizarre configuration which cannot be otherwise explained.

**Inclusions:** Dermatitis artefacta

**Exclusions:** Excoriation disorder (6B25.1)

Factitious disorders (6D50-6D5Z)

Malingering (QC30)

**Coded Elsewhere:** Artefactual panniculitis (EF00.Y)

**ED01**

### Simulated skin disease

Simulated skin disease can present in a variety of ways such as application of glue, dyes or make-up to the skin (particularly by children or adolescent girls) and is usually though not always readily recognised for what it is. The motivation for the simulation can vary but may point to some form of psychopathology or may be purely experimentation.

**Exclusions:** Factitious disorders (6D50-6D5Z)

Malingering (QC30)

**ED02**

### Painful bruising syndrome

Painful bruising syndrome (Gardner-Diamond syndrome, autoerythrocyte sensitization, psychogenic purpura) is a rare and poorly understood clinical presentation of unexplained painful ecchymoses, mostly on the extremities and/or the face. It has been associated with emotional stress or one or more concomitant mental illnesses.

**ED0Y**

### Other specified self-inflicted skin disorders

---

**ED2Y**

**Other specified mental conditions affecting the skin**

Neurological conditions affecting the skin (ED30-ED3Y)

Skin conditions resulting from degeneration of or damage to the nervous system

**Coded Elsewhere:** Pruritus due to neurological disorder (EC90.3)

Hereditary sensory or autonomic neuropathy (8C21)

**ED30**

**Neuropathic skin damage**

Skin changes attributable entirely or in part to sensory or autonomic nerve damage.

**ED30.0**

**Neuropathic skin ulceration**

Ulceration of the skin resulting from impairment of pain sensation due to sensory nerve dysfunction.

**Inclusions:** Neuropathic ulcer

**Coded Elsewhere:** Neuropathic skin ulceration due to leprosy (1B20.3)

**ED30.Y**

**Other specified neuropathic skin damage**

**ED31**

**Burning feet syndrome**

Burning feet syndrome is thought to be due to a specific autonomic neuropathy affecting predominantly small fibre cholinergic nerves. It is characterised by an uncomfortable burning sensation on the feet, often accentuated by heat or cold. It may be sporadic, familial or associated with diabetes mellitus.

**ED3Y**

**Cutaneous involvement in other specified neurological condition**

## Skin disorders involving specific cutaneous structures (ED50-EG02)

### Disorders of the epidermis and epidermal appendages (ED50-EE21)

This group incorporates skin disorders involving principally the epidermis, including abnormalities of keratinization and pigmentation, and the epidermal appendages, namely the hair follicular unit (hair, hair follicle, sebaceous gland, apocrine duct and apocrine gland), the eccrine sweat gland apparatus (eccrine duct and gland) and the nail apparatus.

### Disorders of epidermal keratinisation (ED50-ED5Y)

This group incorporates dermatoses characterised by scaling (ichthyoses and hyperkeratoses), epidermal thickening (acanthoses and keratodermas), loss of cohesion (acantholytic dermatoses and skin peeling) or xeroderma.

**Coded Elsewhere:** Hereditary acantholytic dermatoses (EC20.2)

**ED50**

#### **Ichthyoses**

Genetically-determined and acquired disorders of epidermal keratinization characterised by diffuse scaling and/or thickening of the stratum corneum.

**Coded Elsewhere:** Non-syndromic ichthyosis (EC20.0)

Syndromic ichthyosis (LD27.2)

Hereditary ichthyosis (EC20.Y)

**ED50.0**

#### **Acquired ichthyosis**

Acquired ichthyosis resembles autosomal dominant ichthyosis vulgaris but develops in adult life in individuals without a previous history of ichthyosis. It may be caused by certain drugs but when associated with underlying malignancy (i.e. paraneoplastic) it is strongly associated with Hodgkin lymphoma and may be the presenting sign of that disease. It may less commonly be associated with other lymphoid neoplasms or solid tumours.

**Exclusions:** Hereditary ichthyosis (EC20)

**Coded Elsewhere:** Paraneoplastic acquired ichthyosis (EL10)

**ED50.Z**

#### **Ichthyosis of unspecified type**

**ED51**

#### **Diffuse epidermal hyperkeratosis and acanthosis**

Conditions characterised by diffuse thickening of the horny and/or spinous layers of the epidermis.

**ED51.0**

#### **Acanthosis nigricans**

Acanthosis nigricans is characterised by dark, thick, velvety skin in body folds and creases. It is most commonly encountered in association with obesity and type 2 diabetes though may be a component of a number of genetic syndromes. Hyperinsulinaemia and insulin resistance are important underlying factors. Acanthosis nigricans may rarely be due to underlying malignancy (paraneoplastic acanthosis nigricans).

**Coded Elsewhere:** Paraneoplastic acanthosis nigricans (EL10)

<b>ED51.00</b>	Benign acanthosis nigricans Benign acanthosis nigricans is a thickening and pigmentation affecting predominantly flexural skin, especially the neck, axillae and groins. It is thought to be due to high concentrations of insulin binding to insulin-like growth factor receptors, with resultant keratinocyte proliferation. It is strongly associated with insulin resistance and obesity. Type 2 diabetes and the metabolic syndrome are commonly associated.
	<b><i>Exclusions:</i></b> Paraneoplastic acanthosis nigricans (EL10)
<b>ED51.0Y</b>	Other specified acanthosis nigricans
<b>ED51.0Z</b>	Acanthosis nigricans, unspecified
<b>ED51.Y</b>	<b>Other specified hyperkeratotic and acanthotic dermatoses</b>
<b>ED52</b>	<p><b>Porokeratoses</b></p> <p>Porokeratoses result from a clonal disorder of keratinization. They are characterised by one or more atrophic patches surrounded by a clinically and histologically distinctive ridged hyperkeratotic border (cornoid lamella). Multiple clinical variants of porokeratosis are recognised.</p>
<b>ED53</b>	<p><b>Skin peeling</b></p> <p>A range of hereditary and acquired disorders characterised by an increased tendency to superficial skin peeling.</p> <p><b>Coded Elsewhere:</b> Hereditary skin peeling (EC20.1)</p>
<b>ED54</b>	<p><b>Xerosis cutis or asteatosis</b></p> <p>Dryness of the skin surface commonly due to defatting of the epidermis by excessive exposure to soaps and detergents or desiccation from prolonged exposure to low ambient humidity. It occurs most commonly in the elderly and is seen particularly on the lower legs. It is a major cause of pruritus in the elderly. In more severe cases the skin may become inflamed (asteatotic eczema).</p> <p><b>Coded Elsewhere:</b> Asteatotic eczema (EA84)</p> <p>Xerosis cutis due to leprosy (1B20.3)</p>
<b>ED55</b>	<p><b>Palmoplantar keratodermas</b></p> <p>A range of genetic and acquired disorders in which there is thickening of the epidermal keratin of the skin of the palmar surfaces of the hands and plantar surfaces of the feet.</p> <p><b>Coded Elsewhere:</b> Hereditary palmoplantar keratodermas (EC20.3)</p>
<b>ED55.0</b>	<p><b>Acquired palmoplantar keratodermas</b></p> <p><b><i>Exclusions:</i></b> inherited keratosis palmaris et plantaris (EC50-EC5Y)</p> <p><b>Coded Elsewhere:</b> Arsenical keratosis (EK90.Y)</p>
<b>ED55.Z</b>	<b>Palmoplantar keratoderma, unspecified</b>

**ED56**

### **Keratosis pilaris**

Keratosis pilaris is a very common abnormality of keratinization characterised by keratinous plugging of follicular orifices with varying degrees of perifollicular erythema. It is seen in up to half of normal children and in three quarters of children with ichthyosis vulgaris. The sides of the face and the extensor surfaces of the upper arms are sites of predilection. Autosomal dominant inheritance can often be demonstrated. In some variants atrophy or pigmentation may be more prominent than keratosis.

**ED5Y**

### **Other specified disorders of epidermal keratinisation**

## **Disorders of skin colour (ED60-ED6Y)**

This group includes not only abnormalities of melanin pigmentation (e.g. vitiligo and melasma) but also skin colour changes due to other pigments (e.g. carotenaemia and argyria).

**Coded Elsewhere:** Genetic disorders of skin pigmentation (EC23)

Developmental anomalies of skin pigmentation (LC10-LC1Y)

Late lesions of pinta (1C1E.2)

Pigmentary abnormalities of skin due to drug (EH70)

**ED60**

### **Acquired hypermelanosis**

Increased melanin pigmentation of the skin resulting from disease or from other stimuli including ultraviolet radiation and hormones.

**Coded Elsewhere:** Drug-induced hypermelanosis (EH70)

Labial melanin incontinence (DA00.2)

Oral melanin incontinence (DA01.Y)

Occupational melanosis (EK5Y)

**ED60.0**

### **Physiological hypermelanosis**

The response of normal skin to exposure to natural or artificial ultraviolet radiation.

**ED60.00**

#### Suntan

Increased melanin pigmentation of the skin as a result of exposure to natural sunlight.

**ED60.01**

Tanning due to exposure to artificial sources of ultraviolet radiation

Increased melanin pigmentation as a result of deliberate (sunbeds and tanning booths) or unintentional exposure to UV.

**Exclusions:** Burn from exposure to artificial source of ultraviolet radiation (EJ41)

**ED60.1**

### **Melasma**

A common condition of incompletely understood aetiology characterised by patchy melanin pigmentation of the malar prominences, forehead and perioral skin. The pigmentation is exacerbated by sun exposure. Melasma is common in pregnancy and in women taking oral contraceptive preparations; it may, however, also be seen in men.

<b>ED60.2</b>	<b>Postinflammatory hypermelanosis</b> Melanin pigmentation of the skin resulting from preceding cutaneous inflammation, particularly when this is centred on the dermo-epidermal junction as in lichen planus. Damage to melanocytes results in release of melanin into the dermis (pigmentary incontinence).
<b>ED60.Y</b>	<b>Hypermelanosis of other specified aetiology</b>
<b>ED60.Z</b>	<b>Hypermelanosis of unspecified aetiology</b>
<b>ED61</b>	<p><b>Acquired melanotic macules or lentigines</b> Acquired discrete macules and flat patches of melanin skin pigmentation including freckles and lentigines.</p> <p><b>Coded Elsewhere:</b> Actinic lentigo (EJ20.1) Actinic lentiginosis (EJ20.2) PUVA lentiginosis (EM0Y)</p>
<b>ED61.0</b>	<p><b>Freckles</b> The presence of multiple ephelides (ephelis = freckle) as is commonly seen in sun-exposed skin of individuals with phototype I (sun-sensitive) skin. They occur as a profusion of light brown macules, particularly on the face and upper extremities, and become more prominent after sun exposure. In contrast to lentigines there is no keratinocyte proliferation histologically.</p>
<b>ED61.1</b>	<p><b>Mucosal melanosis</b> Abnormal pigmentation of the mucous membranes</p> <p><b>Coded Elsewhere:</b> Labial melanotic macule (DA00.2) Melanotic macule of oral mucosa (DA01.Y)</p>
<b>ED61.10</b>	<p>Penile melanotic macule Discrete circumscribed area of macular hypermelanosis affecting the glans penis or the shaft of the penis. These are much commoner than melanoma of the penis but may be clinically suspected to be melanoma and thus require biopsy. By definition the cause is unknown.</p>
<b>ED61.11</b>	<p>Vulval melanotic macule Benign genital melanosis affecting the vulva.</p>
<b>ED61.1Y</b>	Other specified mucosal melanosis
<b>ED61.Y</b>	<b>Other specified acquired melanotic macules or lentigines</b>
<b>ED62</b>	<p><b>Endogenous non-melanin pigmentation</b> Pigmentation of the skin resulting from endogenous pigments other than melanin. The most important of these is haemosiderin.</p> <p><b>Coded Elsewhere:</b> Endogenous ochronosis (5C50.10)</p>

<b>ED62.0</b>	<b>Haemosiderin pigmentation of skin</b> Dermal haemosiderin deposition causes a yellowish-brown or bronze discolouration of the skin. The deposition may be focal as seen following repeated extravasation of red blood cells (e.g. in association with venous hypertension or chronic vasculitis) or from generalised iron overload (e.g. haemochromatosis). Haemosiderin may stimulate melanogenesis and thus the colour is due to variable proportions of haemosiderin and melanin.  <i>Coded Elsewhere:</i> Hereditary haemochromatosis (5C64.10)
<b>ED62.Y</b>	<b>Other specified endogenous non-melanin pigmentation</b>
<b>ED63</b>	<b>Acquired hypomelanotic disorders</b> Acquired disorders characterised by diminution or loss of pigment from the skin. The most important of these is vitiligo.
<b>ED63.0</b>	<b>Vitiligo</b> Vitiligo is an acquired pigmentary disorder of the skin and mucous membranes where progressive destruction of melanocytes results in loss of skin pigmentation. Half of all cases first appear before the age of 20. The clinical course is unpredictable but gradual extension of the areas involved is the norm. The disease may have a devastating psychological impact, particularly in people with dark skin.  <i>Coded Elsewhere:</i> Vitiligo of eyelid or periocular area (9A06.1)
<b>ED63.1</b>	<b>Hypomelanosis due to exposure to chemicals</b> Loss of skin pigment due to exposure to depigmenting agents such as hydroquinone, which is frequently employed as a cosmetic skin lightener, and industrial chemicals such as 4-tert-butylcatechol (PTBC) and para-substituted phenols (PSP).  <i>Coded Elsewhere:</i> Occupational leukoderma (EK5Y)
<b>ED63.2</b>	<b>Postinflammatory hypomelanosis</b> A reduction in skin pigmentation apparent following the resolution of skin inflammation. This may be from an inflammatory dermatosis such as dermatitis or lichen planus or may follow trauma or interventional procedures. The loss of pigment may cause significant psychological distress in dark-skinned individuals but in most cases is temporary.  <i>Exclusions:</i> Postinfective hypomelanosis (ED63)
<b>ED63.3</b>	<b>Vogt-Koyanagi-Harada syndrome</b> <i>Coded Elsewhere:</i> Vogt-Koyanagi-Harada syndrome-associated anterior uveitis (9A96.1) Posterior uveitis due to Vogt Koyanagi Harada syndrome (9B65.0)
<b>ED63.Y</b>	<b>Acquired hypomelanosis due to other specified disorder</b>
<b>ED63.Z</b>	<b>Acquired hypomelanosis of unknown or unspecified aetiology</b>
<b>ED64</b>	<b>Abnormal skin pigmentation</b> Abnormal skin pigmentation without specification of type or cause.

**ED6Y****Other specified disorders of skin pigmentation****Disorders of hair (ED70-ED7Y)**

**Coded Elsewhere:** Genetic defects of hair or hair growth (EC21)

Developmental defects of hair or hair growth (LC30)

Trichotillomania (6B25.0)

Drug-induced hair abnormalities (EH72)

Self-inflicted hair-damaging disorder (6B25.Z)

**ED70****Alopecia or hair loss**

Disorders characterised by abnormal temporary or permanent loss of hair, particularly from the scalp and beard.

**Coded Elsewhere:** Madarosis of eyelid or periocular area (9A04.1)

**ED70.0****Male pattern hair loss**

Male pattern hair loss (common baldness; male androgenetic alopecia) is the result of a progressive, patterned hair loss mediated by exposure to androgens. Although over 90% of men demonstrate some degree of frontoparietal recession of the hairline by the age of 20, the extent of hair loss is genetically determined and only 30% of men ever develop extensive hair loss.

**Inclusions:** Common balding

**ED70.1****Female pattern hair loss**

Female pattern hair loss differs from male pattern hair loss not only in being generally less pronounced than in men but also by the fact that the normal frontal hair line is usually preserved. A quarter of women will develop clinically detectable pattern hair loss by the age of 70. In the majority of cases it can be attributed to the effects of androgens.

**ED70.2****Alopecia areata**

A microscopically inflammatory, usually reversible, patchy hair loss occurring in sharply defined areas and usually involving the beard or scalp

**ED70.20****Patchy alopecia areata of scalp**

The commonest form of alopecia areata in which one or more usually circular patches of scalp hair loss develop.

**ED70.21****Alopecia totalis**

Alopecia totalis is a form of alopecia areata in which hair loss extends to the entire scalp

**ED70.2Y****Other specified forms of alopecia areata****ED70.2Z****Alopecia areata, unspecified**

<b>ED70.3</b>	<b>Telogen effluvium</b> Increased shedding of telogen hairs from the scalp. There are numerous triggers of which severe systemic illness and pregnancy are important examples.  <b>Coded Elsewhere:</b> Drug-induced telogen hair loss (EH72.00)
<b>ED70.30</b>	Acute telogen effluvium Acute telogen effluvium is an acute-onset scalp hair loss that occurs two to three months after a triggering, often life-threatening, stress which interrupts normal anagen hair growth. It is commonly seen in survivors who have required intensive care for severe sepsis, blood loss, inflammatory disease or trauma. It may also result from acute starvation. Large numbers of anagen hairs are converted to telogen and are shed two to three months later resulting in a diffuse alopecia.
<b>ED70.31</b>	Postpartum telogen effluvium A physiological phenomenon in which diffuse hair loss occurs two to three months following parturition. It is due to a postponement of the normal cyclical conversion of anagen hairs to telogen during pregnancy. After parturition a large number of anagen hairs are converted simultaneously to telogen and shed two to three months later. Normal hair cycling is then resumed.
<b>ED70.3Y</b>	Telogen hair shedding due to other specified cause
<b>ED70.3Z</b>	Telogen effluvium unspecified
<b>ED70.4</b>	<b>Anagen effluvium</b> Anagen effluvium occurs after any insult to the hair follicle that impairs its mitotic or metabolic activity. Patients present with diffuse hair loss after an exposure to drugs or toxic chemicals. Chemotherapeutic agents are most commonly responsible for hair loss. The most severe hair loss occurs in association with doxorubicin, the nitrosoureas, and cyclophosphamide. Hair loss usually begins 7-14 days after a single pulse of chemotherapy. The hair loss is clinically most apparent after 1-2 months.  <b>Coded Elsewhere:</b> Drug-induced anagen effluvium (EH72.01)
<b>ED70.5</b>	<b>Scarring alopecia</b> Hair loss in which there is irreversible damage to the hair follicle from inflammation, infection, malignant infiltration or trauma, resulting in destruction of the follicle and repair by fibrosis. Regeneration does not occur once the follicle has been destroyed.  <b>Inclusions:</b> Cicatricial alopecia <b>Exclusions:</b> Lichen planopilaris (EA91.2)

<b>ED70.50</b>	Folliculitis decalvans  Folliculitis decalvans is characterised by the progression of scalp folliculitis to extensive inflammation, follicular destruction and scarring. In a variant called tufted folliculitis the hairs become clumped into tufts containing a dozen or more hairs. In contrast to the course in the vast majority of people who develop a bacterial pustular folliculitis of the scalp, individuals with folliculitis decalvans appear unable to eradicate <i>Staphylococcus aureus</i> from the hair follicle even with appropriate antibiotic therapy. Recurrent pustulation with surrounding inflammation and scaling leads to extensive permanent scarring and loss of hair.
<b>ED70.51</b>	Dissecting cellulitis  Dissecting cellulitis is a destructive inflammatory disorder of the scalp characterised by widespread perifolliculitis with dermal abscess and sinus tract formation and extensive scarring. It occurs predominantly in black males aged between 18 and 40 years. It may be associated with hidradenitis suppurativa and acne conglobata (follicular occlusion triad), and with pilonidal sinus. Painful swellings develop around the vertex of the scalp and coalesce to form irregular undulating oedematous ridges and furrows. With time an extensive network of sinuses discharging pus may develop. Progressive scarring and permanent alopecia ensue.  <b>Coded Elsewhere:</b> Follicular occlusion syndrome (ED80.41)
<b>ED70.5Y</b>	Scarring alopecia due to other specified cause
<b>ED70.5Z</b>	Scarring alopecia of unknown or unspecified aetiology
<b>ED70.Y</b>	<b>Other specified alopecia or hair loss</b>
<b>ED70.Z</b>	<b>Alopecia, unspecified</b>
<b>ED71</b>	<p><b>Hypertrichosis</b></p> <p><b>Exclusions:</b> congenital hypertrichosis (9B70) Hirsutism and syndromes with hirsutism (ED72)</p> <p><b>Coded Elsewhere:</b> Hypertrichosis of eyelid (9A04.Y) Naevoid hypertrichosis (LC30) Acquired hypertrichosis lanuginosa (EL10) Drug-induced hypertrichosis (EH72.Y)</p>
<b>ED72</b>	<p><b>Hirsutism and syndromes with hirsutism</b></p> <p><b>Coded Elsewhere:</b> Polycystic ovary syndrome (5A80.1) Congenital adrenal hyperplasia (5A71.01) HAIR-AN syndrome (5A44)</p>
<b>ED72.0</b>	<p><b>Constitutional hirsutism</b></p> <p>Hirsutism in a person with normal endocrine and reproductive function. It is more prevalent in some ethnic groups (e.g. South Asian) than others.</p>

- ED72.1** **Hirsutism associated with hyperandrogenaemia**  
 Excessive male-pattern facial and body hair in women, mostly caused by PCOS, by hyperandrogenemia combined with normal ovulation, or idiopathically, after exclusion of androgen-secreting neoplasm, congenital adrenal hyperplasia and HAIR-AN syndrome. The severity of hirsutism can be assessed by the Ferriman-Gallwey score.
- ED72.Z** **Hirsutism, unspecified**
- ED73** **Acquired disorders of the hair shaft**
- ED73.0** **Weathered hair**  
 Weathered hair results from repetitive damage to the hair shaft from excessive sunlight, excessive wetting, chemical insults including hair cosmetics and physical damage. The hair appears dull and lustreless, fractures readily and may show "split ends".
- ED73.1** **Acquired changes in hair colour**  
 Abnormal diffuse or circumscribed alterations in natural hair colour. Causes include drugs, idiopathic premature greying of the hair, differential shedding of pigmented hair in alopecia areata or hair pigment loss in association with vitiligo or regressing melanocytic naevi.  
**Coded Elsewhere:** Drug-induced hair colour change (EH72.Y)  
 Segmental heterochromia of hair (LC30)
- ED73.10** **Premature canities**  
 Premature greying of the hair, usually taken to mean before the age of 20 in Caucasians and before the age of 30 in Africans.  
**Inclusions:** Premature greying of hair
- ED73.11** **Acquired poliosis**  
 Circumscribed loss of hair pigment. This is most commonly associated with vitiligo (especially segmental vitiligo), alopecia areata or regressing melanocytic naevi. It is also a component of Vogt-Koyanagi-Harada syndrome and Alezzandrini syndrome.  
**Inclusions:** Circumscribed loss of hair pigment  
**Coded Elsewhere:** Acquired poliosis of eyelashes (9A04.Y)
- ED73.Y** **Other specified acquired disorders of the hair shaft**
- ED7Y** **Other specified disorders of hair**

## Disorders of the hair follicle (ED80-ED9Y)

This group incorporates disorders of the hair shaft and hair follicular unit including, for example, hirsutism, alopecia, acne and hidradenitis suppurativa.

**Coded Elsewhere:** Chronic deep bacterial folliculitis (1B75.4)

### Acne and related disorders (ED80-ED81.Y)

A group of related disorders characterised by follicular occlusion and inflammation.

<b>ED80</b>	<b>Acne</b> Acne without further specification.  <b>Coded Elsewhere:</b> Neonatal acne (KC21.0)
<b>ED80.0</b>	<b>Comedonal acne</b> Acne in which the principal manifestation is the presence of open and/or closed comedones, respectively blackheads and whiteheads.  <b>Exclusions:</b> Actinic comedonal plaque (EJ20.0) Comedo naevus (LC01)
<b>ED80.1</b>	<b>Superficial mixed comedonal and papulopustular acne</b> Acne in which comedones are accompanied by small inflammatory papules and pustules
<b>ED80.2</b>	<b>Papulopustular acne</b> Acne in which the principal manifestation is the presence of multiple small inflammatory papules and pustules.
<b>ED80.3</b>	<b>Nodular acne</b> Acne in which large inflammatory nodules and fluid-filled cystic swellings as well as more superficial lesions are present. Systemic therapy with antibiotics or retinoids is usually required.
<b>ED80.4</b>	<b>Severe inflammatory acne</b> Intensely inflammatory acne which may be acute (acne fulminans) or subacute and chronic (acne conglobata).
<b>ED80.40</b>	Acne fulminans Acne fulminans is a severe systemic disease in which acute inflammatory acne with multiple follicular abscesses and skin ulceration is accompanied by fever, weight loss and arthralgia. It typically affects adolescent white males.
<b>ED80.41</b>	Acne conglobata An uncommon chronic severe inflammatory form of acne characterised by the development of multiple abscesses and sinuses followed by extensive hypertrophic and atrophic scarring. It may be associated with spondyloarthropathy or with other follicular occlusive diseases including dissecting cellulitis of the scalp and hidradenitis suppurativa.

- ED80.4Y** Other specified severe inflammatory acne
- ED80.4Z** Severe inflammatory acne, unspecified
- ED80.5** **Acne scarring**  
Scarring resulting from acne, ranging from mild irregularity of the skin surface to highly disfiguring or functionally disabling distortion of normal skin anatomy.  
*Coded Elsewhere:* Keloidal acne (EE60.Y)
- ED80.6** **Infantile acne**  
Infantile acne usually presents at 3–6 months of age but has been reported as late as 16 months. Male infants are affected more commonly than females and there may be a history of severe acne in one or more parents. It may last up to the age of five years. Both comedonal and inflammatory acne with papules, pustules and nodules may be seen; scarring may result.
- ED80.Y** **Other specified acne**
- ED80.Z** **Acne, unspecified**
- ED81** **Acneform inflammatory disorders**  
Disorders characterised by acne-like follicular inflammation.  
*Coded Elsewhere:* Scalp folliculitis (EG30.0)  
Acne or acneform reactions attributable to drugs (EH67)  
Folliculitis keloidalis (EE60.Y)
- ED81.0** **Folliculitis cruris pustulosa atrophicans**  
A folliculitis prevalent in Sub-Saharan Africa due to the custom of applying of greasy ointments to the lower legs. It presents as an inflammatory folliculitis which may result in follicular scarring and atrophy.
- ED81.1** **Acneform reactions to halogenated aromatic hydrocarbons**  
Acne caused by exposure to halogenated hydrocarbons such as chlorinated naphthalene, dioxins and dibenzofurans. Numerous comedones and noninflammatory cysts are a common feature. The course is often chronic. Frequently affected body parts are the face, neck, axillae and groin area.  
*Inclusions:* Chloracne
- ED81.Y** **Other specified acneform inflammatory disorders**
- ED90** **Rosacea and related disorders**

<b>ED90.0</b>	<b>Rosacea</b> The term rosacea encompasses a spectrum of changes that occur mainly in facial skin but may also involve the eyes. Most patients with rosacea have facial erythema and vascular instability which are variably associated with inflammatory papules and pustules, hypertrophic changes and ocular involvement. The cause of rosacea is unknown. It is doubtful that any single aetiological factor is responsible for the diverse features that comprise this disorder.
	<b>Coded Elsewhere:</b> Posterior blepharitis (9A02.1)
	Lymphoedematous rosacea (BD93.1Y)
<b>ED90.00</b>	Erythematotelangiectatic rosacea Erythematotelangiectatic rosacea manifests as facial erythema and a flushing tendency affecting but not confined to the central face and forehead: the lateral cheeks, the ears and the sides of the neck may also be involved. It is commonest in fair-skinned individuals and tends to be made worse by exposure to wind and sunlight. With time permanent telangiectasia develops.
<b>ED90.01</b>	Papulopustular rosacea Papulopustular rosacea is characterised, as the name implies, by erythematous papules and sterile pustules affecting facial skin. These are typically located on the cheeks, central chin, nose and central forehead. The perilesional skin is inflamed and may be oedematous. In contradistinction to papulopustular acne, comedones, nodules and cysts are not a feature.
<b>ED90.02</b>	Phymatous rosacea The hallmark of phymatous rosacea is rhinophyma but the forehead, chin and ears may also be affected. It is characterised by hypertrophy of the affected tissue which can produce gross distortion, particularly of the nose. The pathological changes include a variably severe mixed inflammatory infiltrate, sebaceous gland hyperplasia and dermal fibrosis. The aetiology is poorly understood. It is not always accompanied by other features of rosacea.
<b>ED90.0Y</b>	Other specified rosacea
<b>ED90.0Z</b>	Rosacea, unspecified
<b>ED90.1</b>	<b>Periorificial dermatitis</b> Periorificial dermatitis is a term which links two erythematous and papulopustular facial dermatoses that are strongly linked to prolonged potent topical corticosteroid use, namely perioral dermatitis and periocular dermatitis. It is characterised by the development of erythema, papules and pustules in perioral and periocular skin.
<b>ED90.Y</b>	<b>Other specified rosacea-like disorders</b>
<b>ED90.Z</b>	<b>Rosacea-like disorders unspecified</b>
<b>ED91</b>	<b>Disorders of the sebaceous gland</b> A group of disorders in which sebaceous gland size, location, anatomy or secretion is abnormal.
<b>ED91.0</b>	<b>Heterotopic sebaceous glands</b>

- ED91.1**      **Sebaceous gland hyperplasia**
- ED91.2**      **Seborrhoea**  
The secretion of excessive amounts of sebum resulting in an excessively greasy skin, a situation which may cause considerable distress. It may be associated with a number of conditions including acne, acromegaly and Parkinson disease. It is not normally a prominent component of seborrhoeic dermatitis, which is an inflammatory dermatitis.  
*Exclusions:*      Seborrhoeic dermatitis and related conditions (EA81)
- ED91.Y**      **Other specified disorders of the sebaceous gland**
- ED91.Z**      **Disorders of the sebaceous gland, unspecified**
- ED92**      **Disorders involving the apocrine follicular unit**  
A group of disorders involving apocrine glands and their associated follicular units. The most important of these is hidradenitis suppurativa.
- ED92.0**      **Hidradenitis suppurativa**  
Hidradenitis suppurativa is a chronic disease characterised by recurrent, painful, deep-seated, rounded nodules and abscesses due to follicular occlusion with secondary inflammation and destruction of the pilo-sebaceous-apocrine apparatus and extension to the adjacent subcutaneous tissue. Subsequent hypertrophic scarring and suppuration of apocrine gland-bearing skin (axillae, groins, peri-anal and perineal regions) are the main clinical features. Infection and hormonal influence are described but are not the primary pathogenetic factor: the exact aetiology remains unknown. Obesity is common and is associated with more severe disease. The main complications are fistulae, arthropathy, carcinoma and amyloidosis.
- ED92.1**      **Apocrine sweat disorders**  
Disorders in which apocrine secretion is abnormal or obstructed.  
*Exclusions:*      Hidradenitis suppurativa (ED92.0)
- ED92.Y**      **Other specified disorders involving the apocrine follicular unit**
- ED92.Z**      **Disorders involving the apocrine follicular unit, unspecified**
- ED9Y**      **Other specified disorders involving the hair follicle**

## Disorders of eccrine sweat glands or sweating (EE00-EE0Y)

This group incorporates disorders characterised by increased or reduced sweating (hyper- and hypohidrosis respectively), and by eccrine duct occlusion (miliaria).

**EE00**

### **Hyperhidrosis**

Excessive sweating. In the localised type, the most frequent sites are the palms, soles, axillae, inguinal folds, and the perineal area. Emotional factors may play a part. Generalised hyperhidrosis may be induced by a hot, humid environment, by fever, or by vigorous exercise.

**Inclusions:** Excessive sweating

**EE00.0**

### **Localised hyperhidrosis**

Excessive sweating in specific and localised sites.

**EE00.00**

### Palmoplantar hyperhidrosis

Excessive sweating of palms and soles. This is usually bilateral. Palmar hyperhidrosis may be triggered by emotional stress but, in severe cases, can be continuous and cause major disability by inhibiting normal social interaction and interfering with everyday tasks such as writing, preparing food or handling papers. Plantar hyperhidrosis may accompany palmar hyperhidrosis but may occur independently.

**EE00.01**

### Axillary hyperhidrosis

Excessive axillary sweating, sometimes in response to emotional stress but often persistent and disabling.

**EE00.02**

### Craniofacial hyperhidrosis

Excessive sweating involving the scalp, face and/or neck.

**EE00.0Y**

### Other specified localised hyperhidrosis

**EE00.0Z**

### Localised hyperhidrosis, unspecified

**EE00.1**

### **Primary generalised hyperhidrosis**

Primary generalised hyperhidrosis is characterised by sweating that exceeds the amount necessary to maintain thermal regulation.

**Coded Elsewhere:** Cold-induced sweating syndrome (8C21.Y)

**EE00.Z**

### **Hyperhidrosis, unspecified**

**EE01**

### **Hypohidrosis**

Abnormally diminished or absent perspiration. Both generalised and segmented (reduced or absent sweating in circumscribed locations) forms of the disease are usually associated with other underlying conditions.

**Coding Note:**

Code also the causing condition

**Inclusions:** Impaired sweating

**EE01.0**

### **Hypohidrosis attributable to defective sudomotor innervation or function**

**Coding Note:**

Code also the causing condition

<b>EE01.1</b>	<b>Hypohidrosis due to genetic abnormalities of eccrine gland structure or function</b>
	Hypohidrosis due to a heritable disorder of sweat gland or duct development. Sweating may be severely diminished or absent due to a paucity or absence of eccrine glands or to defective autonomic innervation. An absence of sweating leads to an inability to thermoregulate by evaporative cooling, and hyperthermia can occur with physical exertion or in a warm environment.
<b>Coding Note:</b>	Code also the causing condition
	<b>Coded Elsewhere:</b> Hereditary sensory and autonomic neuropathy type IV (8C21.2)
<b>EE01.2</b>	<b>Hypohidrosis of undetermined aetiology</b>
	Reduced or absent sweating for which no explanation has been found.
<b>EE01.Y</b>	<b>Other specified forms of hypohidrosis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>EE01.Z</b>	<b>Hypohidrosis, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>EE02</b>	<b>Miliaria</b>
	Miliaria is a common skin disorder resulting from occlusion of eccrine sweat ducts. It is precipitated by hot, humid conditions.
<b>EE02.0</b>	<b>Neonatal miliaria</b>
<b>EE02.Y</b>	<b>Other specified forms of miliaria</b>
<b>EE02.Z</b>	<b>Miliaria, unspecified</b>
<b>EE0Y</b>	<b>Other specified disorders of eccrine sweat glands or sweating</b>

## Disorders of the nail or peronychium (EE10-EE1Z)

Disorders affecting the nail and surrounding tissues

**Coded Elsewhere:** Genetic defects of nails or nail growth (EC22)

<b>EE10</b>	<b>Acquired deformities of the nail plate</b>
	Acquired abnormalities of nail shape, surface, thickness or adhesion
<b>EE10.0</b>	<b>Abnormality of nail shape</b>
	<b>Exclusions:</b> Congenital club finger (LB90.5)
<b>EE10.1</b>	<b>Abnormality of nail surface</b>
<b>EE10.10</b>	Nail pitting <b>Coded Elsewhere:</b> Psoriatic nail pitting (EA90.51)
<b>EE10.1Y</b>	Other specified abnormality of nail surface

- EE10.1Z** Abnormality of nail surface, unspecified
- EE10.2** **Onycholysis**
- Coded Elsewhere:* Psoriatic onycholysis (EA90.51)  
Drug-induced onycholysis (EH73)
- EE10.3** **Nail hypertrophy**
- Coded Elsewhere:* Psoriatic nail hypertrophy (EA90.51)  
Drug-induced nail hypertrophy (EH73)
- EE10.4** **Nail atrophy**
- EE10.5** **Nail dystrophy, not otherwise specified**
- EE10.Y** **Other specified acquired deformities of the nail plate**
- EE10.Z** **Acquired deformities of the nail plate, unspecified**
- EE11** **Acquired abnormalities of nail colour**
- Coded Elsewhere:* Pseudomonas infection of nail (EE12.Y)  
Drug-induced nail pigmentation (EH73)
- EE11.0** **Melanonychia**  
Melanin pigmentation of the nail plate. This may be of no significance but may signify the presence of melanoma arising from the nail matrix
- EE11.1** **Yellow nail syndrome**  
Yellow nail syndrome is characterised by yellow, dystrophic, thick and slowly growing nails, associated with lymphoedema and respiratory involvement. Less than 100 cases have been described. Lymphoedema occurs more often in the lower limbs. It can appear at birth or later in life. Onset generally follows the onset of ungual abnormalities. Patients usually suffer from chronic bronchitis and in some cases, from chronic sinusitis, bronchiectasia and recurring pneumonitis. They can also present with pleural effusion (30% of cases) and bronchial hyperreactivity. Most cases are sporadic. However, familial forms have been described. Aetiology is unknown.
- EE11.Y** **Other abnormalities of nail colour**
- EE11.Z** **Acquired abnormalities of nail colour, unspecified**
- EE12** **Infections of the nail or perionychium**  
Infections involving the nail or perionychium for which no information on the infecting organism is available.
- Coded Elsewhere:* Candidosis of nail or paronychium (1F23.13)  
Paronychial herpes simplex infection (1F00.0Y)

<b>EE12.0</b>	<b>Acute bacterial paronychia</b>
	Acute bacterial paronychia is an acute infection, usually by <i>Staphylococcus aureus</i> , of the paronychial tissues of a digit. It may result from local injury, e.g. a thorn prick in a lateral nail groove, a splinter, torn hangnails or nail biting, but also occurs frequently as an episode during the course of chronic paronychia, when other organisms may be involved, including streptococci, <i>Pseudomonas aeruginosa</i> , coliform organisms and <i>Proteus vulgaris</i> .
	<b>Inclusions:</b> Whitlow
	<b>Exclusions:</b> Herpetic whitlow (1F00.0)
<b>EE12.1</b>	<b>Onychomycosis</b>
	Fungal infection of fingernails and/or toenails due most commonly to dermatophytes ( <i>tinea unguium</i> ) or yeasts, especially <i>Candida</i> species.
	<b>Inclusions:</b> Fungal infection of the nails
	<b>Exclusions:</b> Candidosis of nail or paronychium (1F23.13)
	<b>Coded Elsewhere:</b> Onychomycosis due to non-dermatophyte mould (1F2D.5) Dermatophytosis of nail (1F28.1) <i>Candida</i> onychomycosis (1F23.13)
<b>EE12.Y</b>	<b>Other specified infections of the nail or perionychium</b>
<b>EE12.Z</b>	<b>Infections of the nail or perionychium, unspecified</b>
<b>EE13</b>	<b>Certain disorders affecting the nails or perionychium</b>
	Abnormalities of the nails and perionychium (the soft tissues surrounding the nail plate including the matrix, nail folds, eponychium and hyponychium) which are not classified elsewhere.
	<b>Coded Elsewhere:</b> Drug-induced nail abnormalities (EH73) Nail psoriasis (EA90.51) Lichen planus of the nails (EA91.5) Subungual haematoma (NC50) Traumatic injury to nail bed or matrix of nail of foot (ND10) Traumatic injury to nail bed or matrix of nail of hand (NC50) Alopecia areata of the nails (ED70.2Y)
<b>EE13.0</b>	<b>Nail fragility</b>
	A range of nail disorders in which the integrity of the nail plate is disturbed.
	<b>Coded Elsewhere:</b> Drug-induced nail fragility (EH73)
<b>EE13.1</b>	<b>Ingrowing nail</b>
<b>EE13.10</b>	Ingrowing toenail
<b>EE13.11</b>	Infected ingrowing toenail
<b>EE13.1Y</b>	Other specified ingrowing nail
<b>EE13.1Z</b>	Ingrowing nail, unspecified

<b>EE13.2</b>	<b>Chronic paronychia</b>
	<b>Coded Elsewhere:</b> Candida paronychia (1F23.13)
<b>EE13.3</b>	<b>Nail disorder associated with specified dermatosis</b>
	Abnormality of the nail plate attributable to other specified skin disease.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b>
	Lichen planus of the nails (EA91.5)
	Nail psoriasis (EA90.51)
	Alopecia areata of the nails (ED70.2)
<b>EE13.4</b>	<b>Nail disorder associated with specified systemic disease</b>
	Nail dystrophy attributable to systemic disorder. A wide range of systemic disorders may produce abnormalities of the nails.
<b>Coding Note:</b>	Code also the causing condition
<b>EE13.5</b>	<b>Eczematous nail dystrophy</b>
	Nail dystrophy attributable to eczema affecting paronychial tissues.
<b>EE13.Y</b>	<b>Other specified nail disorder</b>
<b>EE1Y</b>	<b>Other specified disorders of the nail or perionychium</b>
<b>EE1Z</b>	<b>Disorders of the nail or perionychium, unspecified</b>

### Disorders of epidermal integrity (EE20-EE21)

**Coded Elsewhere:** Diabetic bullae (EB90.0)

<b>EE20</b>	<b>Acute cutaneous distension syndrome</b>
	A common sequela of acute oedema, especially of the lower extremities. It manifests as blisters, which may be mistaken for an immunobullous disorder, (acute oedema blisters); or as superficial fissuring and inflammation of the skin (eczéma craquelé).
<b>EE21</b>	<b>Epidermal fragility</b>

Epidermal fragility of unknown or unspecified cause resulting in reduced resistance to mechanical stress and manifesting as abnormal fissuring, erosion or blistering of the skin surface.

## Disorders of the dermis and subcutis (EE40-EF0Y)

This group incorporates disorders of dermal connective tissue, dermal histiocytic and granulomatous disorders and disorders affecting subcutaneous fat.

**Coded Elsewhere:** Cutaneous mastocytosis (2A21.1)

## Disorders of cutaneous connective tissue (EE40-EE7Y)

Skin disorders attributable to abnormalities affecting dermal and subcutaneous collagen, elastin and other connective tissue components.

**Coded Elsewhere:** Genetic disorders affecting dermal collagen, elastin or other matrix proteins (EC40-EC4Y)

**EE40**

### **Atrophy or degeneration of dermal or subcutaneous connective tissue**

A heterogeneous group of disorders resulting from atrophic and degenerative changes in dermal and subcutaneous collagen and elastin.

**Coded Elsewhere:** Actinic elastosis (EJ20.0)

**EE40.0**

### **Corticosteroid-induced skin atrophy**

**EE40.1**

### **Stretch marks**

Linear scars attributable to rupture of the normal dermal matrix from distension by abnormal physical forces (pregnancy, obesity, pubertal growth spurt), increased collagenase activity (corticosteroids) or as a result of genetically abnormal dermal matrix proteins.

**EE40.10**

Stretch marks of pregnancy

**EE40.1Y**

Stretch marks of other specified aetiology

**EE40.1Z**

Stretch marks, unspecified

**EE40.2**

### **Atrophic scarring of the skin**

The process whereby healing of damaged skin results in a reduction of dermal thickness as well as scarring, thus the counterpart of hypertrophic scarring.

**Coded Elsewhere:** Atrophic surgical scar (EL50.2)

**EE40.3**

### **Skin fragility**

Fragility of the skin due principally to genetic or acquired abnormalities of dermal matrix proteins.

**Exclusions:** Epidermal fragility (EE21)

**Coded Elsewhere:** Skin fragility of prematurity (KC30)

**EE40.30**

Genetically-determined skin fragility

**Coded Elsewhere:** Purpura or bruising due to genetically-determined skin fragility (EE40.32)

**EE40.31**

Age-related skin fragility

**EE40.32** Purpura or bruising due to vascular fragility  
Purpura due to leakage or rupture of abnormally fragile cutaneous blood vessels.

**Coded Elsewhere:** Scorbutic purpura (5B56.0)

**EE40.Y** Other specified atrophy or degeneration of dermal or subcutaneous connective tissue

**EE40.Z** Atrophy or degeneration of dermal or subcutaneous connective tissue, unspecified type

#### **EE41** Abnormalities of dermal elastin

**Coded Elsewhere:** Blepharochalasis (9A06.8)

Pseudoxanthoma elasticum (EC40)

Granulomatous slack skin (2B01)

**EE41.0** Cutis laxa

Cutis laxa is the term used for a group of inherited and acquired conditions in which abnormalities of elastic fibres result in loose, redundant, hypoelastic skin. Typically, the skin can easily be pulled away from underlying tissue and only slowly returns to its original position. Unlike some conditions in the differential diagnosis, cutis laxa is not characterised by spontaneous bruising or abnormal scarring. Redundant skin is often most noticeable on the neck, hands, and groin, but can also be seen on the face, creating a premature aging appearance.

**Coded Elsewhere:** Genetically-determined cutis laxa (LD28.2)

**EE41.1** Anetoderma

A condition presenting as focal areas of thinned, flaccid skin and resulting from focal defects in dermal elastin. The involved skin is often elevated above the surrounding normal skin but can be depressed. The condition may be primary and without identifiable cause or may be a sequela of a large number of different conditions which may damage elastin in the dermis.

**EE41.Y** Other specified dermatoses characterised by abnormal dermal elastin

**EE41.Z** Abnormalities of dermal elastin, unspecified

#### Poikiloderma (EE50-EE50)

Poikiloderma is defined as a combination of skin atrophy, pigmentation and telangiectasia. It is a component of a number of genetic syndromes, of certain non-organ-specific systemic autoimmune disorders and may follow skin injury including from radiotherapy.

**Coded Elsewhere:** Genetic syndromes with poikiloderma (EC10)

Poikiloderma vasculare atrophicans (EK91.1)

#### **EE50** Acquired poikiloderma

**Coded Elsewhere:** Poikiloderma following radiotherapy (EL61)

Poikiloderma of Civatte (EK20)

## Fibromatoses and keloids (EE60-EE6Y)

A heterogeneous group of disorders characterised by pathologically increased deposition of fibrous tissue in the skin and subcutaneous tissues.

**EE60**

### **Keloid or hypertrophic scars**

Keloid and hypertrophic scars result from the production of excessive amounts of collagen in the dermis during connective tissue repair following inflammation, injury or surgery. Keloid scars often develop apparently spontaneously after minor injury or inflammation and expand beyond the boundary of that initial injury or inflammation. Hypertrophic scars on the other hand remain confined to the area of injury or inflammation and may undergo spontaneous resolution.

**EE60.0**

### **Keloid**

A keloid is a progressively enlarging scar resulting from formation of excessive amounts of collagen in the dermis during connective tissue repair following inflammation, injury or surgery. It differs from a hypertrophic scar in that a keloid expands beyond the boundaries of the initial wound or site of inflammation.

**Coded Elsewhere:** Keloidal surgical scar (EL50.0)

**EE60.00**

### **Ear-lobe keloid**

A common type of keloid which usually follows ear-piercing

**EE60.0Y**

### **Other specified keloid**

**EE60.0Z**

### **Keloid, unspecified**

**EE60.1**

### **Hypertrophic scar**

Hypertrophic scars result from the production of excessive amounts of collagen in the dermis during connective tissue repair following inflammation, injury or surgery. In contrast to keloid scars, they do not expand beyond the boundary of the initial injury or inflammation and may undergo spontaneous resolution.

**Coded Elsewhere:** Hypertrophic surgical scar (EL50.1)

**EE60.Y**

### **Other specified keloidal disorders**

**EE61**

### **Superficial fibromatoses**

**Coded Elsewhere:** Palmar fascial fibromatosis (FB51.0)

Knuckle pads (FB51.1)

Penile fibromatosis (GB06.2)

Plantar fascial fibromatosis (FB51.Y)

Fibro-osseous pseudotumour of the digit (FB51.Y)

**EE6Y**

### **Other specified fibromatous disorders of skin and soft tissue**

**EE70**

### **Perforating dermatoses**

A group of skin disorders characterised by trans-epidermal elimination of abnormal matter, especially collagen or elastin, from the dermis to the exterior.

**Coded Elsewhere:** Perforating granuloma annulare (EE80.0)

<b>EE70.0</b>	<b>Acquired perforating dermatosis</b>
	A condition commonly seen in association with longstanding diabetes mellitus, particularly in association with renal failure, in which multiple large follicular and non-follicular keratotic papules develop on the trunk and limbs. Trauma from scratching pruritic skin may be the initiating event leading to transepidermal elimination of degenerate collagen and elastic fibres from the dermis.
<b>EE70.Y</b>	<b>Other specified perforating dermatoses</b>
<b>EE70.Z</b>	<b>Perforating dermatoses, unspecified</b>
<b>EE7Y</b>	<b>Other specified disorders of cutaneous connective tissue</b>

### Histiocytic-granulomatous disorders of the skin (EE80-EE8Y)

A range of disorders characterised by the presence of increased numbers of histiocytes in the skin as a result of granulomatous inflammation or histiocytic infiltration.

**Coded Elsewhere:** Cutaneous sarcoidosis (4B20.5)

Crohn disease of anal region (DD70.4)

Langerhans cell histiocytosis involving the skin (2B31.20)

Indeterminate cell histiocytosis (2B31.6)

<b>EE80</b>	<b>Necrobiotic granulomatous skin disorders</b>
-------------	---

<b>EE80.0</b>	<b>Granuloma annulare</b>
---------------	---------------------------

A common inflammatory disorder in which granulomatous inflammation surrounds foci of degenerate dermal collagen. It presents clinically as dermal papules and annular plaques. It may be localised, especially over bony prominences, or generalised. The cause is unknown.

<b>EE80.1</b>	<b>Necrobiosis lipoidica</b>
---------------	------------------------------

Necrobiosis lipoidica is an uncommon skin condition in which degenerate dermal collagen is surrounded by a granulomatous inflammatory response to produce shiny, red-brown or yellowish patches in the skin, particularly on the shins. In severe cases the affected skin may ulcerate. It is associated in the majority of but not all cases with underlying diabetes mellitus, the onset of which it may precede.

<b>EE80.Z</b>	<b>Necrobiotic granulomatous skin disorders, unspecified</b>
---------------	--

<b>EE81</b>	<b>Dermal dendrocyte, Class IIa histiocytoses</b>
-------------	---

A sub-class of cutaneous histiocytic disorders involving dermal dendritic cells.

**Inclusions:** Non-Langerhans cell histiocytoses of dermal dendrocyte lineage

**Coded Elsewhere:** Juvenile xanthogranuloma (2B31.0)

Erdheim-Chester disease (2B31.Y)

<b>EE8Y</b>	<b>Other specified histiocytic and granulomatous disorders of the skin</b>
-------------	--

Benign dermal lymphocytic or lymphoplasmacytic infiltrations or proliferations (EE90-EE91)

**EE90**

**Benign lymphocytic infiltration of the skin**

Benign lymphocytic infiltration of Jessner is a chronic benign T-cell lymphoproliferative disorder characterised by the presence of non-scarring red tumid nodules, usually on facial skin. It may be difficult to distinguish from cutaneous lupus erythematosus.

**Inclusions:** Jessner lymphocytic infiltration

**EE91**

**Lymphocytoma cutis**

Lymphocytoma cutis is a benign, cutaneous B-cell lymphoproliferative disorder. It presents as papules, nodules or plaques usually on the head and neck and pursues a chronic course. It occurs as a response to known or unknown antigenic stimuli that result in the accumulation of lymphocytes and other inflammatory cells.

**Inclusions:** Benign cutaneous lymphoid hyperplasia

**Coded Elsewhere:** Borrelial lymphocytoma cutis (1C1G.14)

Disorders of subcutaneous fat (EF00-EF0Y)

**Coded Elsewhere:** Neonatal disorders of subcutaneous fat (KC22)

**EF00**

**Panniculitis**

Panniculitis is the name given to a heterogeneous group of diseases all characterised by inflammation of subcutaneous adipose tissue.

**Exclusions:** Calcific panniculitis (EB90.41)

**Coded Elsewhere:** Erythema nodosum (EB31)

Lipodermatosclerosis (BD74.2)

Cold panniculitis of the newborn (KC22.1)

Alpha-1 antitrypsin deficiency panniculitis (5C5A)

Lupus panniculitis (EB51.Y)

Erythema induratum (EF40.2Y)

Cytophagic histiocytic panniculitis (EE8Y)

Gouty panniculitis (FA25.2Y)

**EF00.0** **Pancreatic enzyme panniculitis**

**EF00.Y** **Panniculitis of other specified aetiology**

**EF00.Z** **Panniculitis of undetermined or unspecified etiology**

**EF01**

**Lipoatrophy or lipodystrophy**

Hereditary or acquired disorders characterised by loss of subcutaneous fat.

**Coded Elsewhere:** Genetic lipodystrophy (LD27.6)

<b>EF01.0</b>	<b>Acquired partial lipodystrophy</b> Acquired partial lipodystrophy, or Barraquer-Simons syndrome, is characterised by the association of lipoatrophy of the upper part of the body and lipohypertrophy of the thighs.
<b>EF01.1</b>	<b>Localised lipoatrophy and lipodystrophy</b> Localised lipodystrophies covers a heterogeneous group of conditions characterised by loss of subcutaneous tissue from small regions of the body.
<b>EF01.Y</b>	<b>Other specified forms of lipodystrophy and lipoatrophy</b>
<b>EF01.Z</b>	<b>Lipodystrophy of unspecified type</b>
<b>EF02</b>	<b>Certain noninflammatory disorders of subcutaneous fat</b>
<b>EF02.0</b>	<b>Fat hypertrophy</b> Focal hypertrophy of subcutaneous adipose tissue. It is a common sequela of long-term insulin injection into the skin.
<b>EF02.1</b>	<b>Subcutaneous lipomatosis</b> Diffuse infiltration of the subcutis by non-encapsulated adipose tissue.
<b>EF02.2</b>	<b>Lipoedema</b> Lipoedema is characterised by non-pitting diffuse "fatty" swelling, usually confined to the legs, thighs, hips and upper arms. It may be confused with lymphoedema. Lipoedema may also occur in the scalp. <i>Coded Elsewhere:</i> Lipo-lymphoedema (BD93.1Y)
<b>EF02.3</b>	<b>Cellulite</b> Cellulite is a common architectural derangement of subcutaneous adipose tissue which results in dimpling and nodularity of the overlying skin. It is seen most commonly in postpubertal women and affects principally the pelvic region, lower limbs, and abdomen. It is thought to result from herniation of multiple small aggregates of subcutaneous fat through the fibrous tissue at the dermohypodermal junction. Obesity predisposes to but is not necessary for its development. The term is in widespread use but is misleading as it has nothing to do with cellulitis. The condition is asymptomatic but may cause considerable embarrassment.
<b>EF02.Y</b>	<b>Other specified noninflammatory disorders of subcutaneous fat</b>
<b>EF02.Z</b>	<b>Noninflammatory disorders of subcutaneous fat, unspecified</b>
<b>EF0Y</b>	<b>Other specified disorders of subcutaneous fat</b>

Disorders of cutaneous blood and lymphatic vessels (EF20-EG02)

**Coded Elsewhere:** Malformations involving cutaneous lymphatic vessels

- Oedema of skin or soft tissues
- Superficial thrombophlebitis (BD70)
- Lower limb deep vein thrombosis (BD71.4)
- Lymphoedema (BD93)
- Venous varicosities of sites other than lower extremity (BD75)

Malformations involving cutaneous blood vessels (EF20-EF2Z)

**Coded Elsewhere:** Genetic syndromes affecting cutaneous vasculature

Developmental anomalies of cutaneous vasculature (LC50-LC5Z)

**EF20**

### **Acquired malformations of cutaneous blood vessels**

**Coded Elsewhere:** Erythematotelangiectatic rosacea (ED90.00)

Actinic telangiectasia (EJ20.3)

Lower limb superficial venous ectasia (BD74.0)

**EF20.0**      **Venous lake**

**EF20.1**      **Angiokeratoma**

Angiokeratomas are acquired vascular lesions that result from the ectatic dilatation of pre-existing vessels in the papillary dermis, accompanied by hyperkeratotic epidermis. There are several clinical variants: solitary papular angiokeratoma, angiokeratoma corporis diffusum, angiokeratoma of Mibelli and angiokeratoma of Fordyce, amongst which the last, in which the lesions are located on the vulva or scrotum, is the most common.

**Coded Elsewhere:** Angiokeratoma corporis diffusum (5C56.01)

**EF20.2**      **Lower limb venous telangiectases**

Finely dilated superficial veins of lower limbs resulting from chronic venous hypertension.

**EF20.3**      **Spider telangiectasis**

A benign vascular ectasia consisting of a central dilated terminal arteriole from which radiate several ectatic capillaries, giving rise to a spider-like appearance. They occur most commonly on the upper trunk and proximal upper limbs. Large numbers may develop in association with pregnancy or liver disease.

**Exclusions:**      Lower limb venous telangiectases (EF20.2)

**EF20.4**      **Generalised essential telangiectasia**

**EF20.Y**      **Other specified acquired malformations of cutaneous blood vessels**

**EF20.Z**      **Acquired malformations of cutaneous blood vessels, unspecified**

**EF2Z**

### **Cutaneous vascular malformation, unspecified**

## Purpura or bruising (EF30-EF3Z)

Purpura is a non-blanchable multifocal purple skin discolouration due to bleeding into the skin and manifested as petechiae (pinpoint foci of intradermal haemorrhage) and ecchymoses (larger areas of intradermal haemorrhage). It has many causes and may be the presenting sign of diseases as diverse as thrombocytopenia, primary amyloidosis, meningococcal septicaemia and scurvy. It will often be accompanied by haemorrhage into the subcutaneous tissues (spontaneous bruising or haematoma).

**Coded Elsewhere:** Purpura due to disorders of platelets

Purpura or bruising due to vascular fragility (EE40.32)

Painful bruising syndrome (ED02)

**EF30**

### Purpura or bruising due to disorders of coagulation

Purpura resulting from genetically-determined or acquired deficiencies or dysfunction of clotting factors.

**EF31**

### Traumatic purpura

Purpura and bruising attributable to trauma which may be self-induced (as from rubbing itchy skin), due to friction from clothing or due to man-handling, particularly of debilitated elderly patients.

**EF3Y**

### Other specified purpura

**EF3Z**

### Purpura of unspecified aetiology

**EF40**

### Vasculitis or capillaritis involving the skin

A range of conditions characterised by inflammation of cutaneous blood vessels with or without extravasation of red blood cells into the interstitium.

**Coded Elsewhere:** Giant cell arteritis (4A44.2)

Mucocutaneous lymph node syndrome (4A44.5)

Sneddon syndrome (4A44.6)

Thromboangiitis obliterans (4A44.8)

Pityriasis lichenoides (EA93)

Vasculitis associated with probable aetiology (4A44.Y)

**EF40.0**

### Capillaritis

Capillaritis results from extravasation of red blood cells from leaky capillaries into the dermis and manifests initially as a finely stippled pink to purple purpura, most commonly affecting the lower limbs. As iron is released and converted into haemosiderin, the skin stains gold or brown. Various patterns of capillaritis have been described and given separate names depending on the distribution, time course, extent and degree of pigmentation and presence or otherwise of epidermal thickening. The underlying processes involved in all these variants are very similar and of unknown cause. Histology may show mild inflammation around capillaries but no vasculitis.

**Inclusions:** Pigmented purpura

**Exclusions:** Pulmonary capillaritis (CB04.4)

<b>EF40.1</b>	<b>Vasculitis affecting small cutaneous blood vessels</b>
	<b>Coded Elsewhere:</b> Antineutrophil cytoplasmic antibody-associated vasculitis (4A44.A)
	Cryoglobulinaemic vasculitis (4A44.90)
	IgA vasculitis (4A44.92)
	Acute haemorrhagic oedema of infancy (EH40.3)
	Cutaneous leukocytoclastic vasculitis (4A44.B0)
<b>EF40.10</b>	<b>Urticular vasculitis</b>
	An uncommon form of cutaneous leucocytoclastic vasculitis manifested by urticarial weals which, in contrast to those of chronic urticaria, are long-lasting and painful rather than itchy. A cause is often not identified. It may be associated with hypocomplementaemia and systemic inflammation (hypocomplementaemic urticarial vasculitis).
	<b>Coded Elsewhere:</b> Hypocomplementaemic urticarial vasculitis (4A44.91)
<b>EF40.1Y</b>	Other specified vasculitis affecting small cutaneous blood vessels
<b>EF40.2</b>	<b>Localised cutaneous vasculitis</b>
	A heterogeneous group of uncommon, predominantly chronic inflammatory dermatoses, each with a characteristic limited distribution, which all exhibit vasculitis on histopathological examination.
<b>EF40.20</b>	Granuloma faciale
<b>EF40.2Y</b>	Other specified localised cutaneous vasculitis
<b>EF40.Z</b>	<b>Cutaneous vasculitis unspecified</b>

### Dermatoses attributable to hyperviscosity or microvascular occlusion (EF50-EF5Y)

A range of disorders characterised by vascular occlusion but attributable not to primary vascular inflammation but to intravascular occlusion.

<b>Coded Elsewhere:</b>	Thrombotic thrombocytopenic purpura (3B64.14)
	Antiphospholipid syndrome (4A45)
	Disseminated intravascular coagulation (3B20)
	Cryoglobulinaemic vasculitis (4A44.90)

<b>EF50</b>	<b>Livedoid vasculopathy</b>
<b>EF5Y</b>	<b>Other specified dermatoses attributable to hyperviscosity or microvascular occlusion</b>

### Dermatoses resulting from vascular insufficiency (EF60-EF9Y)

<b>EF60</b>	<b>Ischaemic ulceration of skin</b>
-------------	-------------------------------------

**Coding Note:** Code also the causing condition

Dermatoses due to venous disease (EF70-EF7Z)

**Coded Elsewhere:** Venous leg ulcer (BD74.3)

Lipodermatosclerosis (BD74.2)

**EF70**

**Lower limb venous eczema**

A pruritic inflammatory dermatitis affecting the lower legs and ankles of individuals with lower limb venous hypertension. It may become acutely exudative, when the possibility of superimposed allergic contact dermatitis should be considered. Treatment of the associated venous hypertension is an important part of management. Venous eczema is not necessarily associated with the presence of varicose leg veins.

**EF7Y**

**Other specified dermatoses due to venous disease**

**EF7Z**

**Dermatoses due to venous disease, unspecified**

**EF9Y**

**Other specified dermatoses resulting from vascular insufficiency**

Functional vascular disorders of the skin (EG00-EG02)

Skin disorders due to disturbances in vascular tone and skin blood flow.

**EG00**

**Vasodilatation of extremities**

Disorders due to failure of normal vasoconstrictive mechanisms in the cutaneous vasculature.

**EG01**

**Vasoconstriction of extremities**

Disorders characterised by peripheral vasospasm including Raynaud disease and ergotism.

**Coded Elsewhere:** Raynaud phenomenon (BD42)

**EG02**

**Flushing disorders**

**Coded Elsewhere:** Carcinoid syndrome (5B10)

Flushing (ME64.4)

Menopausal hot flush (GA30.4)

## Skin disorders involving certain specific body regions (EG30-EG9Z)

### Skin disorders involving the head and neck (EG30-EG4Z)

Dermatoses specific to the scalp; external ear; the eyes, eyelids and eyebrows; the lips and oral cavity; and to dermatoses specific to the skin of the head and neck

**Coded Elsewhere:** Dermatoses of the eye, eyelids or eyebrows

Dermatoses of the lips or oral cavity

**EG30**

#### **Skin disorders localised to the scalp**

Skin disorders affecting preferentially or exclusively the scalp.

**Coded Elsewhere:** Dermatophytosis of scalp (1F28.0)

Seborrhoeic dermatitis of the scalp (EA81.1)

Scalp psoriasis (EA90.50)

Contact dermatitis of scalp (EK5Y)

Lichen planopilaris of scalp (EA91.2)

Chronic cutaneous lupus erythematosus of scalp (EB51.Y)

Scalp pruritus (EC90.Y)

Cutis verticis gyrata (EE7Y)

Lipoedema of the scalp (EF02.2)

Aplasia cutis congenita of scalp (LC60)

Hereditary hypotrichosis of scalp (EC21.2)

**EG30.0**

#### **Scalp folliculitis**

A non-scarring chronic superficial folliculitis of the scalp that is typically characterised by multiple minute, very itchy pustules within the scalp and which has in the past been termed acne necrotica miliaris. The cause is not well understood but an inflammatory response to Propionibacterium acnes has been postulated.

**EG30.1**

#### **Erosive pustular dermatosis of scalp**

Erosive pustular dermatosis of the scalp is a distinctive scalp disorder of the elderly characterised by the development of sterile pustules, erosions and crusts in areas of chronically sun-damaged scalp skin. Local trauma may also play an aetiological role. It normally responds to high-potency topical corticosteroids.

**EG30.2**

#### **Pityriasis amiantacea**

Pityriasis amiantacea refers to a reaction pattern on the scalp where large adherents are attached to the growing hairs and overlap like tiles on a roof. The abnormality may be localised and confined to a small patch or widespread involving the entire scalp. The underlying scalp is often moist and inflamed. The condition may occur on its own or may be associated with inflammatory disorders such as seborrhoeic dermatitis and psoriasis or with underlying dermatophytosis (tinea capitis).

**EG30.Y**

#### **Other specified scalp disorders not elsewhere classifiable**

**EG30.Z**

#### **Skin disorders localised to the scalp, unspecified**

## Disorders of the external ear involving the skin (EG40-EG4Z)

**Coded Elsewhere:** Dermatitis or eczema of external ear

Otitis externa (AA10-AA3Z)

Acquired deformity of pinna (AA41)

## Inflammatory disorders of the external ear (EG40-EG4Z)

**Coded Elsewhere:** Chronic otitis externa (AA13)

Acute noninfectious otitis externa (AA11)

Seborrhoeic otitis externa (AA10)

**EG40**

### **Contact dermatitis of external ear**

Contact dermatitis of external ear may be due to irritants or allergy. Antimicrobial aural preparations are common causes of allergic contact dermatitis.

**Coded Elsewhere:** Irritant contact dermatitis of external ear (EK02.10)

**EG40.0**

### **Allergic contact dermatitis of external ear**

Allergic contact dermatitis affecting the external ear.

**EG4Y**

### **Other specified inflammatory disorder of external ear**

**EG4Z**

### **Inflammatory disorder of external ear, unspecified**

## Skin disorders involving the genital and perianal regions (EG60-EG7Y)

**Coded Elsewhere:** Dermatoses of male genitalia (GA80-GA81.Y)

Dermatoses of female genitalia (GA40-GA4Y)

## Dermatoses of the anus, perianal area or perineum (EG60-EG63.Z)

Disorders affecting the skin of and surrounding the anus including the intergluteal cleft and genitocrural folds.

**Coded Elsewhere:** Perianal lichen simplex (EA83.02)

Herpes simplex infection of perianal skin or rectum (1A94.1)

Anal warts (1A95.0)

Primary anal syphilis (1A61.1)

Drug-induced anal ulceration (EH76.Y)

**EG60**

### **Anal pruritus**

Anal pruritus is irritation of the skin at the anal margin and surrounding perianal skin which results in the desire to scratch.

**EG61**

### **Infections of the anus or perianal skin**

**EG62**

**Inflammatory dermatoses of the perianal area**

**Coded Elsewhere:** Crohn disease of anal region (DD70.4)

Dermatitis or eczema of perianal area (EA87.2)

Perianal psoriasis (EA90.53)

Hidradenitis suppurativa of anogenital region (ED92.0)

**EG63**

**Sacrococcygeal pilonidal disease**

Pilonidal disease describes a spectrum of clinical presentations, ranging from asymptomatic hair-containing cysts and sinuses to large symptomatic abscesses of the sacrococcygeal area which tend to recur. It is found predominantly in white males in their second and third decades and is thought to result from penetration of hair into the tissues with the formation of sinuses and a foreign-body granulomatous response. Risk factors for pilonidal disease include male gender, Caucasian ethnicity, sitting occupations, obesity, a deep natal cleft, and presence of hair within the natal cleft.

**EG63.0      Sacrococcygeal pilonidal sinus**

**EG63.1      Sacrococcygeal pilonidal cyst**

**EG63.2      Sacrococcygeal pilonidal abscess**

**EG63.Z      Sacrococcygeal pilonidal disease, unspecified**

---

**EG7Y**

**Other specified skin disorders involving the genital and perianal regions**

---

**EG9Y**

**Skin disorders involving other specific body regions**

**EG9Z**

**Skin disorders involving certain specific body regions, unspecified**

## Skin disorders associated with pregnancy, the neonatal period and infancy (EH10-EH40.Z)

Dermatoses which are either specific to or occur predominantly in pregnancy, the neonatal period or the first few months of life

**Coded Elsewhere:** Pregnancy dermatoses (JA65.1)

Diseases of the skin complicating pregnancy, childbirth or the puerperium (JB64.7)

### Skin disorders specific to the perinatal or neonatal period (EH10-EH3Y)

This group incorporates both skin disorders of the neonate and other disorders of the neonate with skin manifestations

**Coded Elsewhere:** Prenatally acquired infections with neonatal skin manifestations

Inflammatory dermatoses of the newborn (KC21)

Neonatal dermatoses due to maternal antibodies (KA07)

Neonatal nutritional disorders affecting the skin (KC24)

Neonatal disorders of subcutaneous fat (KC22)

Neonatal disorders of the oral mucosa (KC23)

Skin disorders associated with prematurity (KC30-KC3Y)

Iatrogenic injuries involving the skin of the neonate (KC50-KC7Y)

Miscellaneous skin disorders in the neonate (KC40)

### Neonatal skin infection (EH10-EH1Z)

Any condition of the skin affecting neonates, caused by an infection with a bacterial, viral, fungal, or parasitic source.

**EH10**

#### **Neonatal viral infections involving the skin**

**Coded Elsewhere:** Perinatal Herpes simplex infection (KA62.A)

Disseminated perinatal varicella (KA62.2)

Mucocutaneous perinatal varicella (KA62.2)

**EH11**

#### **Neonatal pyogenic skin infections**

**Coded Elsewhere:** Neonatal necrotising fasciitis (1B71.2)

**EH12**

#### **Neonatal fungal infections involving the skin**

**Exclusions:** Prenatally-acquired mucocutaneous candidosis (KA63.2)

**EH1Z**

#### **Neonatal skin infection, unspecified**

**EH3Y**

#### **Other specified skin disorders specific to the perinatal or neonatal period**

**EH40**

## **Dermatoses of infancy**

**Exclusions:** Syndromes with skin or mucosal anomalies as a major feature (LD27)

Congenital malformations affecting the skin (LC00-LC7Z)

**Coded Elsewhere:** Infantile atopic eczema (EA80.0)

Infantile acne (ED80.6)

Infantile papular acrodermatitis (EA12)

**EH40.0**

### **Infantile seborrhoeic dermatitis**

An inflammatory but usually non-pruritic dermatitis of infants with a similar distribution to adult seborrhoeic dermatitis. Its principal manifestations are a confluent psoriasiform napkin eruption and greasy, adherent scaling over the scalp ("cradle cap"). In disseminated forms the face, retroauricular folds, neck and trunk may be involved. A small proportion of cases represent infantile onset of psoriasis ("napkin psoriasis"). Its onset is characteristically earlier than that of infantile atopic eczema, the subsequent development of which it does not preclude.

**Inclusions:** Neonatal seborrhoeic dermatitis

**Exclusions:** Seborrhoea (ED91.2)

**EH40.00**

#### **Cradle cap**

Cradle cap is a form of seborrhoeic dermatitis that manifests as yellowish, crusty, greasy patches of scaling on the scalp of infants between the second week and sixth month of life. The forehead and eyebrows are frequently affected. It is usually asymptomatic. It may be associated with infantile seborrhoeic dermatitis of other areas including the trunk and napkin area.

**EH40.01**

#### **Disseminated infantile seborrhoeic dermatitis**

A widespread form of infantile seborrhoeic dermatitis affecting the napkin area, scalp, face, neck, axillae and anterior trunk. In contrast to atopic eczema, pruritus is not usually evident and the infant remains otherwise well.

**EH40.02**

#### **Psoriasiform napkin dermatitis**

A napkin eruption characterised by sharply marginated confluent erythema and scale in the napkin area. It is considered a component of infantile seborrhoeic dermatitis, the disseminated form of which may start in the napkin area. In some cases, however, the same clinical picture may eventuate into psoriasis (napkin psoriasis). The clinical picture is essentially identical.

**EH40.0Z**

#### **Infantile seborrhoeic dermatitis, unspecified**

**EH40.1**

### **Infantile napkin dermatoses**

**Coded Elsewhere:** Psoriasiform napkin dermatitis (EH40.02)

Acrodermatitis enteropathica (5C64.20)

<b>EH40.10</b>	Primary irritant napkin dermatitis A type of irritant dermatitis seen most frequently in infants localised to the area in contact with a napkin (diaper) and occurring most often as a reaction to prolonged contact with urine, faeces, or retained soap or detergent.
	<b>Inclusions:</b> Nappy rash Diaper rash
<b>EH40.1Y</b>	Other specified infantile napkin dermatoses
<b>EH40.1Z</b>	Infantile napkin dermatoses, unspecified
<b>EH40.2</b>	<b>Erythrodermas of infancy</b> <b>Coded Elsewhere:</b> Severe combined immunodeficiency with hypereosinophilia (4A01.10) Wiskott-Aldrich syndrome (3B62.0Y) Congenital non-bullous ichthyosiform erythroderma (EC20.02) Netherton syndrome (LD27.2) Multiple carboxylase deficiency due to holocarboxylase synthetase deficiency (5C50.E0)
<b>EH40.3</b>	<b>Acute haemorrhagic oedema of infancy</b> Acute haemorrhagic oedema is an immune complex-mediated cutaneous vasculitis usually associated with respiratory infection or immunization. It affects children between the ages of 4 months and 2 years, with males being affected twice as frequently as females. The dramatic clinical appearance of facial and limb oedema with multiple targetoid purpuric macules belies its generally benign course.
<b>EH40.Y</b>	<b>Other specified dermatoses of infancy</b>
<b>EH40.Z</b>	<b>Dermatoses of infancy, unspecified</b>

### Adverse cutaneous reactions to medication (EH60-EH7Z)

This group incorporates not only drug rashes but also other acute and chronic cutaneous and mucocutaneous effects of topical or systemic medicaments, whether conventional or "alternative".

**Coded Elsewhere:** Drug-induced pruritus (EC90.2)

Drug eruptions (EH60-EH6Z)

**Coded Elsewhere:** Drug-associated immune complex vasculitis (4A85.03)

<b>EH60</b>	<b>Exanthematic drug eruption</b> Acute skin eruption typically resembling viral infections such as measles, rubella or scarlatina attributable to drug. Antibiotics are common causes. <b>Inclusions:</b> Drug-induced toxic erythema
-------------	--

**EH61**

**Drug-induced urticaria, angioedema and anaphylaxis**

Adverse reaction to drugs due to release of histamine or vasoactive kinins.

**Coded Elsewhere:** Drug-induced anaphylaxis (A84.1)

**EH61.0**

**Drug-induced urticaria**

Urticaria provoked by drug. This may be due to immunological or non-immunological mechanisms. Mild anaphylactic reactions may cause little more than urticaria but may serve as a warning of more severe reactions if the responsible agent is encountered again. Aspirin is a well-known cause of non-allergic urticaria.

**EH61.1**

**Drug-induced angioedema**

Non-allergic angioedema due to drugs, in particular angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs.

**EH62**

**Lichenoid drug eruption**

**Coded Elsewhere:** Drug-induced oral lichenoid reaction (A91.4Y)

**EH63**

**Stevens-Johnson syndrome and toxic epidermal necrolysis due to drug**

A spectrum of severe and potentially life-threatening reactions affecting skin and mucous membranes. In the majority of cases a drug can be implicated.

**EH63.0**

**Drug-induced Stevens-Johnson syndrome**

This is one of the four principal forms of severe cutaneous adverse reaction to drugs (SCARs) and is characterised by inflammation, blistering and erosion of skin and mucous membranes. By definition, there is involvement of at least one mucous membrane and skin detachment is limited to less than 10% of body surface area. Most cases occur within the first 8 weeks of drug exposure. The drugs most commonly involved are antimicrobial sulfonamides, anticonvulsants, allopurinol, nevirapine and oxicam–nonsteroidal anti-inflammatory drugs.

**EH63.1**

**Drug-induced toxic epidermal necrolysis**

**EH63.2**

**Drug-induced Stevens-Johnson and toxic epidermal necrolysis overlap syndrome**

**EH64**

### **Drug-induced erythroderma**

Erythroderma (defined as erythema and scaling involving at least 90% of the skin surface) which is attributable to drug administration but which cannot be more precisely categorized, thus excluding more specific severe cutaneous adverse reactions to drugs reaction patterns such as DRESS syndrome, acute generalised exanthematous pustulosis (AGEP) and toxic epidermal necrolysis. Many drugs have been implicated.

***Inclusions:***

DRESS syndrome (EH65)

Stevens-Johnson syndrome and toxic epidermal necrolysis due to drug (EH63)

Drug-induced toxic epidermal necrolysis (EH63.1)

Drug-induced Stevens-Johnson and toxic epidermal necrolysis overlap syndrome (EH63.2)

Drug-induced acute generalised exanthematous pustulosis (EH67.0)

**EH65**

### **DRESS syndrome**

DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms) is a hypersensitivity reaction characterised by a generalised skin rash, fever, eosinophilia, lymphocytosis and visceral involvement (hepatitis, nephritis, pneumonitis, pericarditis and myocarditis) and, in some patients, reactivation of human herpes virus 6.

***Inclusions:***

Drug-induced hypersensitivity syndrome

**EH66**

### **Fixed drug eruption**

The term fixed drug eruption describes the development of one or more annular or oval inflamed erythematous patches on the skin as a result of systemic exposure to a drug. The patches may develop into bullae. The inflamed patches normally resolve with post-inflammatory hyperpigmentation but typically recur at the same site(s), often with progressively more involved sites, following each reexposure to the drug. In extreme cases (generalised bullous fixed drug eruption) the clinical picture may mimic toxic epidermal necrolysis. A large number of drugs have been implicated as triggers.

**EH67**

### **Acne or acneform reactions attributable to drugs**

***Coded Elsewhere:*** Corticosteroid-induced acne (EH76.2)

**EH67.0**

### **Drug-induced acute generalised exanthematous pustulosis**

This uncommon reaction to systemic medication is characterised by fever (generally on the same day as the start of the rash) and multiple, small, non-follicular pustules that arise on a widespread inflammatory erythema centred on the upper trunk and body folds. It may be difficult to differentiate from acute generalised pustular psoriasis. It usually appears within 24 hours of drug exposure. Antibiotics are probably the commonest precipitants although many drugs have been implicated.

***Inclusions:***

Drug-induced toxic pustuloderma

**EH67.Y**

### **Other specified acne or acneform reactions attributable to drugs**

**EH67.Z**

### **Acne or acneform reactions attributable to drugs, unspecified**

- EH6Y** **Drug eruption of other specified type**
- EH6Z** **Drug eruption of unspecified type**
- EH70** **Pigmentary abnormalities of skin due to drug**  
Disturbances of skin colour due to an ingested or injected drug. These may result from a number of different mechanisms including the colour of the drug itself, disturbed melanisation of the skin or deposition of pigments by drug breakdown products.
- Coded Elsewhere:** Non-melanin pigmentation due to drug (ED6Y)
- EH71** **Dermatoses precipitated by drug therapy**  
Specific dermatoses which are not in themselves commonly associated with drugs but which may be precipitated in susceptible individuals by certain drugs.
- Coded Elsewhere:** Drug-induced lupus erythematosus (4A40.1)  
Drug-induced thrombocytopenic purpura (3B64.12)  
Acute febrile neutrophilic dermatosis, drug-induced (EB20)  
Drug-induced capillaritis (EF40.0)  
Drug-induced ichthyosis (ED50.0)
- EH72** **Drug-induced hair abnormalities**
- EH72.0** **Drug-induced alopecia**
- EH72.00** Drug-induced telogen hair loss  
Telogen hair loss due to drug. Many drugs may occasionally cause telogen hair loss. Commonly implicated drugs include retinoids and anticonvulsants.
- Exclusions:** Anagen effluvium (ED70.4)
- EH72.01** Drug-induced anagen effluvium  
Anagen effluvium due to medication, most commonly from cytotoxic cancer chemotherapy.
- EH72.Y** **Other specified drug-induced hair abnormalities**
- EH72.Z** **Drug-induced hair abnormalities, unspecified**
- EH73** **Drug-induced nail abnormalities**  
Abnormalities of nails or nail growth attributable to drugs.
- Coded Elsewhere:** Drug-induced photo-onycholysis (EH75)
- EH74** **Drug-induced oral conditions**
- Coded Elsewhere:** Drug-induced oral ulcer (DA01.14)  
Drug-induced cheilitis (DA00.0)  
Oral mucositis due to cancer chemotherapy (DA01.11)  
Drug-induced gingival hyperplasia (DA0D.1)

**EH75****Photosensitivity due to drug**

A photosensitive skin reaction to a medicament, most commonly a phototoxic reaction to a systemically administered drug, although photoallergy to drugs may rarely occur.

**EH76****Dermatoses associated with specific classes of medication**

A heterogeneous group of adverse skin reactions characteristic for each drug or class of drug involved. Cancer chemotherapeutic agents and systemic corticosteroids are two important examples.

**EH76.0****Dermatoses resulting from cytotoxic or cancer chemotherapy**

**Coded Elsewhere:** Oral mucositis due to cancer chemotherapy (DA01.11)

Neutrophilic eccrine hidradenitis (EB2Y)

**EH76.1****Dermatoses resulting from immunosuppressive therapy****EH76.2****Dermatoses attributable to corticosteroid therapy**

**Coded Elsewhere:** Corticosteroid-induced skin atrophy (EE40.0)

Corticosteroid-modified dermatophytosis (1F28.Y)

Perioral dermatitis (ED90.1)

Corticosteroid-induced stretch marks (EE40.1Y)

Corticosteroid-induced purpura (EE40.32)

**EH76.3****Dermatoses resulting from anticoagulant therapy**

**Coded Elsewhere:** Heparin-induced thrombocytopenia (3B64.12)

**EH76.Y****Other dermatoses associated with specific classes of medication****EH77****Localised adverse cutaneous reactions to administration of drug**

**Coded Elsewhere:** Allergic contact dermatitis due to topical medicaments (EK00.C)

Allergic contact dermatitis due to systemic medicaments (EK00.B)

Localised lipoatrophy due to injected drug (EF01.1)

Insulin-induced localised fat hypertrophy (EF02.0)

Superficial thrombophlebitis resulting from infusion or injection of drug (BD70.1)

**EH78****Adverse cutaneous reactions to herbal, homoeopathic or other alternative therapies**

These may range from "drug" eruptions, phototoxicity, contact allergy to skin infections and scarring. (The primary code should be the adverse cutaneous reaction but this may be used to add supplementary information.)

**EH7Y****Other specified adverse cutaneous reactions to medication****EH7Z****Unspecified adverse cutaneous reactions to medication**

## Skin disorders provoked by external factors (EH90-EK5Y)

A large group of skin disorders due to exposure of the skin to various external physical, chemical or environmental insults including chemical irritants and allergens, poisons, pressure, cold, heat, sunlight, radiation and physical injury.

**Coded Elsewhere:** Miscellaneous specified dermatoses provoked by pressure

- Skin injury due to exposure to corrosive substances
- Hand and arm vibration syndrome (NF08.20)
- Contact dermatitis of external ear (EG40)
- Allergic contact blepharoconjunctivitis (9A06.72)
- Contact gingivostomatitis (DA02.3)
- Haematoma of surgical wound of skin (NE81.00)
- Superficial incisional site infection (NE81.20)
- Cutaneous wounds, injuries or scars (ND56.0)

### EH90

#### Pressure ulceration

Pressure ulcers result from localised injury and ischaemic necrosis of skin and underlying tissues due to prolonged pressure, or pressure in combination with shear; bony prominences of the body are the most frequently affected sites; immobility and debility are major contributing factors.

- Inclusions:**
- pressure injury
  - pressure ulcer
  - bedsore

- Exclusions:**
- decubitus (trophic) ulcer of cervix (uteri) (GA15.1)

### EH90.0

#### Pressure ulceration grade 1

Pressure ulceration grade I is a precursor to skin ulceration. The skin remains intact but there is non-blanchable redness of a localised area, usually over a bony prominence. The area may be painful, firm, soft, warmer or cooler as compared to adjacent tissue. It can be difficult to detect in individuals with dark skin but affected areas may differ in colour from the surrounding skin. The presence of pressure ulceration grade 1 may indicate persons at risk of progressing to frank ulceration.

- Inclusions:**
- pressure injury stage 1 with nonblanchable erythema

### EH90.1

#### Pressure ulceration grade 2

Pressure injury with partial thickness loss of dermis. It presents as a shallow open ulcer with a red or pink wound bed without slough or as a serum-filled or serosanguinous blister which may rupture.

This category should not be used to describe skin tears, tape burns, incontinence associated dermatitis, maceration or excoriation

- Inclusions:**
- pressure injury stage 2 with partial thickness skin loss

<b>EH90.2</b>	<b>Pressure ulceration grade 3</b> Pressure ulcer with full thickness skin loss. Subcutaneous fat may be visible but bone, tendon or muscle are not exposed. Slough may be present but does not obscure the depth of tissue loss. There may be undermining and tunnelling into adjacent structures. The depth varies by anatomical location: grade 3 pressure ulcers can be shallow in areas with little or no subcutaneous fat (e.g. bridge of the nose, ear, occiput and malleolus). In contrast, grade 3 pressure ulcers can be extremely deep in areas of significant adiposity.
	<b>Inclusions:</b> pressure injury stage 3 with full thickness skin loss
<b>EH90.3</b>	<b>Pressure ulceration grade 4</b> Pressure ulcer with visible or directly palpable muscle, tendon or bone as a result of full thickness loss of skin and subcutaneous tissue. Slough or eschar may be present. The depth varies by anatomical location: grade IV pressure ulcers can be shallow in areas with little or no subcutaneous fat (e.g. bridge of the nose, ear, occiput and malleolus) but are typically deep and often undermine or tunnel into adjacent structures.
	<b>Inclusions:</b> pressure injury stage 4 with full thickness tissue loss
<b>EH90.4</b>	<b>Suspected deep pressure-induced tissue damage, depth unknown</b> An area of soft tissue damage due to pressure or shear which is anticipated to evolve into a deep pressure ulcer but has not yet done so. The affected skin is typically discoloured purple or maroon and may display haemorrhagic blistering. It may be painful and oedematous. It can be either warmer or cooler than adjacent tissue. Evolution into a deep ulcer may be rapid even with optimal treatment.
<b>EH90.5</b>	<b>Pressure ulceration, ungradable</b> Pressure ulcer with full thickness skin loss in which actual depth of the ulcer is completely obscured by slough (yellow, tan, grey, green or brown) and/or eschar (tan, brown or black) in the wound bed. Until enough slough and/or eschar are removed to expose the base of the wound, it is not possible to determine whether the ulcer is grade 3 or grade 4.
	<b>Inclusions:</b> pressure injury with depth unknown
<b>EH90.Z</b>	<b>Pressure ulcer of unspecified grade</b>
<b>EH92</b>	<b>Dermatoses provoked by friction or mechanical stress</b> <b>Coded Elsewhere:</b> Contact dermatitis due to skin damage from friction or micro-trauma (EK02.Y)
<b>EH92.0</b>	<b>Corns or callosities</b> Callosities are areas of focal hyperkeratosis due to repeated friction and pressure. A corn is a sharply demarcated callosity occurring over a bony prominence, usually on the foot, and is painful. <b>Coded Elsewhere:</b> Occupational callosities (EK5Y)

<b>EH92.00</b>	Hard corn A discrete area of painful hyperkeratosis resulting from repeated pressure and friction over a bony prominence, most commonly a metatarsal head or an interphalangeal joint of the forefoot.
<b>EH92.01</b>	Soft corn A soft corn is a painful callosity extending from the side of one toe across to the side of the adjacent toe. It is normally caused by lateral pressure from ill-fitting footwear and appears white as a result of maceration of the excess keratin.
<b>EH92.0Z</b>	Callosity, unspecified
<b>EH92.1</b>	<b>Friction blister</b> A blister due to disruption of epidermal integrity as a result of repeated frictional stress. They usually form in areas with a strong, thick epidermis, i.e. the palms, fingers, soles and sides of the feet and toes. Common causes include repetitive heavy manual tasks or ill-fitting footwear.
<b>EH92.Y</b>	<b>Other specified skin damage due to repetitive friction and mechanical trauma</b>
<b>EH93</b>	<b>Dermatoses due to foreign bodies</b> <i>Coded Elsewhere:</i> Sacrococcygeal pilonidal disease (EG63)
<b>EH93.0</b>	<b>Tattoos or tattoo reactions</b> Tattoos are the result of injection into the skin of insoluble coloured pigments as ornamentation of the body, or of inert materials such as coal dust as a result of superficial trauma or blast injury. They may provoke both allergic and foreign body reactions.
<b>EH93.1</b>	<b>Foreign body reaction to inorganic matter in the skin</b> A usually granulomatous, often sarcoidal reaction to the presence in the skin of inorganic foreign material which cannot be degraded or eliminated. Responsible agents include tattoo pigment, suture materials, silica, zirconium, aluminium, paraffin, and silicone.
<b>EH93.2</b>	<b>Foreign body reaction to organic matter in the skin</b>
<b>EH93.3</b>	<b>Foreign body granuloma of skin</b>
<b>EH93.Y</b>	<b>Other specified reaction to foreign body in the skin</b>
<b>EH93.Z</b>	<b>Dermatoses due to foreign bodies, unspecified</b>
<b>EH94</b>	<b>Scar of skin, not elsewhere classified</b>

Dermatoses provoked or exacerbated by exposure to cold (EJ0Y-EJ0Y)

Skin conditions provoked by exposure to low temperatures.

**Coded Elsewhere:** Skin or soft tissue injury due to exposure to cold

Abnormal vascular reactivity to cold

**EJ0Y**

**Other specified dermatoses provoked or exacerbated by exposure to cold**

Dermatoses provoked by heat or electricity (EJ10-EJ1Y)

**Coded Elsewhere:** Burns of external body surface, specified by site (ND90-ND9Z)

Heat contact urticaria (EB01.Y)

Thermal keratosis (EK90.Y)

**EJ10**

**Erythema ab igne**

A characteristic reticular telangiectatic and pigmented dermatosis resulting from repeated or prolonged exposure to infrared radiation (heat) of insufficient energy to produce a burn. It most commonly affects the lower extremities or lower back as a result of habitually sitting too close to a heat source (radiator or open hearth) or from keeping a hot water bottle held against the skin.

**Exclusions:** Burns of external body surface, specified by site  
(ND90-ND9Z)

**EJ1Y**

**Other specified dermatoses provoked by heat or electricity**

Dermatoses provoked by light or UV radiation (EJ20-EJ6Y)

**Coded Elsewhere:** Porphyria or pseudoporphyrina affecting the skin (EB90.3)

Cutaneous lupus erythematosus (EB50-EB5Z)

Dermatomyositis (4A41.0)

Rosacea (ED90.0)

Phototoxic reactions to skin contact with photoactive agents (EK20-EK2Z)

Abnormal sensitivity to light or UV radiation of uncertain or unspecified nature (ME66.0)

Photo-allergic contact dermatitis (EK01)

Chronic effects of ultraviolet radiation on the skin (EJ20-EJ2Y)

**Coded Elsewhere:** Actinic keratosis (EK90.0)

Diffuse actinic keratinocyte dysplasia (EK90.1)

Brachioradial pruritus (EC90.3)

Disseminated superficial actinic porokeratosis (ED52)

Poikiloderma of Civatte (EK20)

Actinic cheilitis (EK90.Y)

## EJ20

### **Photoaging of the skin**

The changes in skin which can be attributed to chronic exposure to ultraviolet radiation and which are clinically manifest principally as actinic elastosis, wrinkles and dyspigmentation.

**Inclusions:** Sun damage due to chronic sun exposure

## EJ20.0

### **Actinic elastosis**

**Inclusions:** Solar elastosis

Rhytides

## EJ20.1

### **Actinic lentigo**

A circumscribed grey or brown macule resulting from chronic exposure to the sun or to artificial sources of ultraviolet such as sun-beds. They are typically located on the backs of the hands and forearms, shoulders, forehead and the scalp (if bald). They often coexist with and may be difficult to differentiate from plane seborrhoeic keratoses, which differ clinically in exhibiting fine scaling and histologically in showing proliferation of keratinocytes as well as melanocytes.

**Inclusions:** Liver spot

## EJ20.2

### **Actinic lentiginosis**

The presence of multiple actinic lentigines. This is a common finding in people with fair skin who have a long history of repeated exposure to the sun where it most commonly affects the upper extremities, upper back, forehead and scalp (if bald). It can be generalised and occur at an earlier age in people with an addiction to sun-bathing and use of sun beds.

## EJ20.3

### **Actinic telangiectasia**

<b>EJ20.Z</b>	<b>Photoaging of the skin, unspecified</b>
<b>EJ2Y</b>	<b>Other specified chronic effects of ultraviolet radiation on the skin</b>
<b>EJ30</b>	<b>Autoimmune or other photodermatoses</b> A heterogeneous group of dermatoses mostly involving an interaction between the immune system and ultraviolet radiation or visible light <b>Coded Elsewhere:</b> Solar urticaria (EB01.Y)
<b>EJ30.0</b>	<b>Polymorphic light eruption</b> Polymorphic light eruption is a common delayed-onset abnormal inflammatory cutaneous reaction to sunlight or other source of ultraviolet radiation. It typically manifests as an eruption of papules and vesicles affecting normally sun-protected skin sites following exposure to sunlight. Tolerance is commonly seen after repeated sunlight or UV exposure.
<b>EJ30.1</b>	<b>Chronic actinic dermatitis</b>
<b>EJ30.Y</b>	<b>Other specified photodermatoses</b>
<b>EJ30.Z</b>	<b>Photodermatoses, unspecified</b>

#### Acute effects of ultraviolet radiation on normal skin (EJ40-EJ4Z)

**Coded Elsewhere:** Photosensitivity due to drug (EH75)

Photo-onycholysis (EE10.2)

<b>EJ40</b>	<b>Sunburn</b> An injury to the skin causing erythema, tenderness, and sometimes blistering and resulting from excessive exposure to the sun. The reaction is produced by the ultraviolet radiation in sunlight.
<b>EJ40.0</b>	<b>Sunburn erythema</b>
<b>EJ40.1</b>	<b>Sunburn with blisters or exudation</b>
<b>EJ40.Z</b>	<b>Sunburn, unspecified</b>
<b>EJ41</b>	<b>Burn from exposure to artificial source of ultraviolet radiation</b> <b>Exclusions:</b> Tanning due to exposure to artificial sources of ultraviolet radiation (ED60.01)
<b>EJ41.0</b>	<b>Burn from exposure to therapeutic ultraviolet radiation</b>
<b>EJ41.Y</b>	<b>Other specified burn from exposure to artificial source of ultraviolet radiation</b>
<b>EJ41.Z</b>	<b>Burn from exposure to artificial source of ultraviolet radiation, unspecified</b>
<b>EJ4Z</b>	<b>Acute effects of ultraviolet radiation on normal skin, unspecified</b>
<b>EJ6Y</b>	<b>Other specified dermatoses provoked by light or UV radiation</b>

Dermatoses due to ionizing radiation (EJ71-EJ7Z)

**Coded Elsewhere:** Acute effects of ionizing radiation on the skin

**EJ71**

**Chronic effects of ionizing radiation on the skin**

The long-term sequelae of prior exposure of skin to ionizing radiation.

**Coded Elsewhere:** Chronic radiodermatitis following radiotherapy (EL61)

Radionecrosis of skin attributable to diagnostic procedure  
(EL80)

Chronic radiation keratosis (EK90.Y)

**EJ7Z**

**Dermatoses due to ionizing radiation, unspecified**

**EK00**

**Allergic contact dermatitis**

Allergic contact dermatitis is an eczematous response provoked by a Type IV delayed immune reaction in the skin to a substance or substances to which the individual has previously been sensitized.

**Exclusions:** Irritant contact dermatitis (EK02)

Allergic contact sensitisation (EK12)

**Coded Elsewhere:** Allergic contact dermatitis of external ear (EG40.0)

Allergic contact gingivostomatitis (DA02.30)

**EK00.0**

**Allergic contact dermatitis due to clothing or footwear**

Allergic contact dermatitis due to exposure to allergens found in clothing and footwear: these include colophony, p-phenylenediamine (PPD), disperse dyes, potassium dichromate and formaldehyde resins.

**EK00.1**

**Allergic contact dermatitis due to cosmetics or fragrances**

Allergic contact dermatitis due to sensitisation to any of a large number of allergens which may be found in cosmetics and other products to which fragrances are added. Common allergens include colophony, fragrances such as hydroxycitronellal, emollients such as lanolin (wool wax alcohols), surfactants such as cocamidopropyl betaine, or preservatives such as isothiazolinones, parabens or formaldehyde-releasing agents. Fragrances are found in many household products as well as in cosmetics.

**EK00.2**

**Allergic contact dermatitis due to dental materials**

Allergic contact dermatitis due to sensitisation to agents used in dentistry. Dentists, dental nurses and dental technicians are generally at greater risk than their clients. Important allergens include acrylates and methacrylates, disinfectant aldehydes and fragrances.

**EK00.3**

**Allergic contact dermatitis due to food flavours or additives**

Allergic contact dermatitis due to flavouring agents (e.g. cinnamyl alcohol) and other food additives (e.g. ammonium persulfate, benzoic acid). Such agents may be encountered at work in food processing or preparation, or may rarely cause allergic contact cheilitis or stomatitis.

- EK00.4 Allergic contact dermatitis due to hairdressing products**  
Allergic contact dermatitis due to hair care products such as dyes, permanent wave and bleaching agents and shampoos. Such allergens may show occupational relevance among hairdressers although consumers are most commonly affected.
- EK00.5 Allergic contact dermatitis due to industrial biocides, cutting oils or disinfectants**  
Allergic contact dermatitis due to any of a large number of potential allergens used to prevent microbial contamination in industrial processes or in commercial, health care and other public environments. These allergens are of predominantly occupational relevance.
- EK00.6 Allergic contact dermatitis due to metals or metal salts**  
Allergic contact dermatitis due to exposure to metals and metal salts such as nickel, cobalt or chromate.
- EK00.7 Allergic contact dermatitis due to allergenic haptens derived from plants or organic matter**  
Allergic contact dermatitis due to low molecular weight allergens from organic matter including plants and woods such as Primula obconica, sesquiterpene lactones and teak.
- EK00.8 Allergic contact dermatitis due to plastics, glues or resin systems**  
Allergic contact dermatitis due to exposure to chemicals used in plastics and resin systems. It is normally the uncured chemicals (e.g. uncured epoxy resin or methacrylates) which are responsible.
- EK00.9 Allergic contact dermatitis due to preservatives or biocides**  
Allergic contact dermatitis due to exposure to preservatives and biocides such as parabens, isothiazolinones, formaldehyde, formaldehyde releasers and phenoxyethanol.
- EK00.A Allergic contact dermatitis due to rubber chemicals**  
Allergic contact dermatitis due to exposure to rubber chemicals such as thiurams, mercaptobenzothiazoles, N-isopropyl-N-phenyl-p-phenylenediamine (IPPD), thiourea derivatives or carbamates.
- EK00.B Allergic contact dermatitis due to systemic medicaments**  
Allergic contact dermatitis due to exposure to systemic medicaments, usually during the manufacturing process. Examples include penicillins, carbamazepine and tetrazepam.
- EK00.C Allergic contact dermatitis due to topical medicaments**  
Allergic contact dermatitis due to exposure to topical medicaments such as corticosteroids, antibiotics, antimycotics, disinfectants, local anaesthetics or NSAIDs.
- EK00.Y Other specified allergic contact dermatitis**
- EK00.Z Allergic contact dermatitis, unspecified**

**EK01**

**Photo-allergic contact dermatitis**

Allergic contact dermatitis caused by sensitisation to a photoproduct of a compound either applied directly to the skin or taken up by the skin via the systemic circulation. The parent compound does not elicit an allergic reaction until it is chemically modified by exposure to ultraviolet radiation.

**EK02**

**Irritant contact dermatitis**

Irritant contact dermatitis is an eczematous reaction provoked by acute or prolonged and repeated contact with a substance or substances which are injurious to the skin. Common irritants include defatting agents (solvents, soaps and detergents), acids (both inorganic and organic) and alkalis (e.g. sodium hydroxide and wet cement).

**Exclusions:** Allergic contact dermatitis (EK00)

**EK02.0**

**Irritant contact dermatitis from specified external agents**

Irritant contact dermatitis from external agents grouped according to the type of causative agent.

**EK02.00**

Irritant contact dermatitis due to wet work

Irritant contact dermatitis caused by prolonged or repetitive wet work. It usually affects predominantly the skin of the hands and wrists but may affect other sites if clothing is repeatedly drenched. Although water and sweat alone (especially from under occlusive protection gloves) may be responsible, the risk is increased by exposure to defatting agents and irritants including soaps, detergents and cooling fluids. It is seen commonly in those looking after dependent relatives, especially young mothers. Professions or occupational sectors where there are substantial risks include health care, hairdressing, cleaning, catering and food-processing.

**EK02.01**

Irritant contact dermatitis due to solvents

Irritant contact dermatitis caused by skin contact with solvents such as tetrachloroethylene, toluene, turpentine, acetone, methyl acetate, ethyl acetate, hexane, citrus terpenes or ethanol. These have numerous uses including in dry-cleaning chemicals, paint thinners, nail polish removers, glue solvents and perfumes. Occupations where there are substantial risks include painters and decorators, construction workers, dry-cleaners, machinists and workers in the chemical industry.

**EK02.02**

Irritant contact dermatitis due to exposure to acids, alkalis or other specified chemical irritants

**EK02.03**

Irritant contact dermatitis due to cosmetics or emollients

Irritant contact dermatitis caused by skin contact with cosmetics and emollients containing substances with irritant capacities such as fragrances, sodium lauryl sulfate, formaldehyde, alcohols, urea, lactic acid, enzymes or peeling particles.

- EK02.04** Irritant contact dermatitis due to topical medicaments or antimicrobials  
 Irritant contact dermatitis caused by repetitive or prolonged skin contact with topical medicaments and antimicrobials containing e.g. benzoyl peroxide, hydrogen peroxide, povidone iodine, formaldehyde, salicylic acid, alcohols, 5-fluorouracil, dithranol, chlorhexidine, quaternary ammonium compounds or tretinoin. Their irritancy is usually mild and sometimes part of their therapeutic action.
- EK02.05** Irritant contact dermatitis due to plants or other vegetable matter  
 Irritant contact dermatitis caused by exposure to plants and other vegetable matter. Irritation may be due to the mechanical (e.g. hairs, thorns, or spines) or chemical (e.g. acids, proteolytic enzymes) properties of the plant. Occupations where there is a substantial risk include agricultural workers, florists and gardeners.
- EK02.06** Irritant contact dermatitis due to foods
- EK02.1** **Irritant contact dermatitis of specified site**  
 Irritant contact dermatitis organised by the body part affected.  
**Exclusions:** Irritant contact dermatitis from specified external agents (EK02.0)  
**Coded Elsewhere:** Irritant contact gingivostomatitis (DA02.31)
- EK02.10** Irritant contact dermatitis of external ear  
 Irritant contact dermatitis affecting skin of external ear. This may result from retention of irritants such as soaps and shampoos in the external auditory canal or from friction and maceration from use of hearing-aids etc. Irritant damage to the skin may predispose to secondary infection.
- EK02.11** Irritant contact blepharoconjunctivitis  
 Irritant contact dermatitis affecting skin of eyelid and/or conjunctiva. Cosmetics are often responsible.
- EK02.12** Irritant contact dermatitis of hands  
 Irritant contact dermatitis affecting skin of hands. This is the commonest site for the development of irritant contact dermatitis. In the early stages the dorsal finger-webs are affected before the inflammation extends to involve the fingers, the dorsa of the hands and frequently the wrists. The palms are usually but not always less severely affected.  
**Inclusions:** Irritant hand dermatitis
- EK02.13** Irritant contact dermatitis of vulva  
 Irritant contact dermatitis affecting the vulva and surrounding skin. It is much more frequent than allergic contact dermatitis in this area. It is commonly due to a combination of occlusion and use of feminine hygiene products in the genital area. Leakage of urine or profuse vaginal discharge are sometimes important factors.  
**Inclusions:** Vulval irritant contact dermatitis
- EK02.1Y** Irritant contact dermatitis of other specified site

- EK02.2** **Irritant contact dermatitis due to friction, sweating or contact with body fluids**  
 Irritant contact dermatitis due to friction, sweating and contact with body fluids. Irritation from body fluids may be due to high or low pH, to proteolytic enzymes or both; the irritant effect may be aggravated or caused solely by sweating and repetitive friction of apposed skin surfaces.
- Coded Elsewhere:** Primary irritant napkin dermatitis (EH40.10)
- EK02.20** Intertriginous dermatitis due to friction, sweating or contact with body fluids  
 Intertriginous dermatitis (intertrigo) is a form of irritant contact dermatitis of the skin folds (axillary, submammary, genitocrural, abdominal apron) caused by repetitive shearing forces of skin on skin. Sweat, other body fluids, occlusion and obesity all contribute to its development.
- EK02.21** Irritant contact dermatitis due to saliva  
 Perioral irritant contact dermatitis caused by repetitive or prolonged contact with saliva.
- EK02.22** Irritant contact dermatitis due to incontinence  
 Irritant contact dermatitis from prolonged contact with urine or faeces as a result of incontinence.  
**Inclusions:** Incontinence-associated dermatitis
- EK02.23** Irritant contact dermatitis related to stoma or fistula  
 Irritant contact dermatitis of skin surrounding stomas or fistulas caused by prolonged or repeated contact with gastrointestinal secretions, faeces, urine, pus, mucus, or cleansing materials.
- EK02.24** Irritant contact dermatitis related to skin contact with prostheses or surgical appliances  
 Irritant contact dermatitis resulting from friction and sweating between the skin surface and a prosthesis or appliance in contact with the skin, especially limb prostheses.
- EK02.Y** **Irritant contact dermatitis due to other specified cause**
- EK02.Z** **Irritant contact dermatitis, unspecified**
- EK10** **Allergic contact urticaria**  
 Allergic contact urticaria is a Type I IgE-mediated immediate immune reaction from cutaneous or mucosal contact to a substance or substances to which the individual has previously been exposed.
- EK10.0** **Oral allergy syndrome**  
 Type I IgE-mediated immediate immune reaction limited to the lips, oral cavity, tongue and throat caused by direct contact with allergen in sensitized patient. Symptoms include mucosal swelling, itching or a burning sensation.  
**Inclusions:** Pollen-food allergy syndrome

**EK10.1** **Contact urticaria due to food allergen**  
Contact urticaria due to food allergen is a IgE-mediated immediate immune reaction from cutaneous or mucosal contact to food allergen in a sensitized patient.

**EK10.Y** **Other specified allergic contact urticaria**

**EK10.Z** **Allergic contact urticaria, unspecified**

**EK11** **Protein contact dermatitis**

Immediate contact dermatitis due to exposure to proteins from plants, animal tissue and other organic matter.

**Exclusions:** Allergic contact dermatitis due to food allergen (4A85.22)

**EK12** **Allergic contact sensitisation**

The presence of specific delayed type IV hypersensitivity of the immune system to a given substance without imputation of past or current disease. Such sensitisation is normally acquired by prior contact of the skin or mucous membranes with the substance or with one chemically closely related to it (cross-reactivity). Subsequent contact with the substance may provoke an allergic reaction. In certain circumstances such sensitisation may prevent an individual from taking up or continuing employment where exposure to the allergen cannot be avoided. Some individuals sensitized to a specific allergen may, however, never experience symptoms on contact with it.

Phototoxic reactions to skin contact with photoactive agents (EK20-EK2Z)

Non-allergic skin inflammation caused by cellular damage from reactive oxygen species in the skin produced by the interaction between ultraviolet or visible light and a photoactive substance in contact with the skin.

**EK20** **Phototoxic reaction to fragrance or cosmetics**

Phototoxic reaction caused by a combination of sun exposure and skin contact with fragrances or cosmetics containing photoactive substances such as oak moss, musk ambrette or bergamot oil.

**EK2Y** **Phototoxic reaction to skin contact with other specified photoactive agent**

**EK2Z** **Phototoxic dermatitis, unspecified**

**EK50** **Cutaneous reactions to venomous or noxious animals**

**Coded Elsewhere:** Cutaneous reactions to arthropods (NE61)

Cutaneous reactions to venomous or noxious aquatic invertebrates (NE61)

Cutaneous reactions to venomous or noxious vertebrates (NE61)

<b>EK50.0</b>	<b>Cutaneous insect bite reactions</b> Skin reactions to known or presumed insect bites. Commonly the nature of the insect responsible is unknown.
	<b>Coded Elsewhere:</b> Cutaneous allergic or hypersensitivity reactions to Hymenoptera venom (4A85.31)
<b>EK50.00</b>	Papular urticaria A reaction pattern to insect bites with the formation of multiple itchy, urticated papules or papulovesicles.
<b>EK50.01</b>	Bullous insect bite reaction Cutaneous blisters resulting from a brisk immune response to insect bites. These are most common around the lower legs and ankles and in children rather than adults.
<b>EK50.02</b>	Persistent insect bite reaction Bite reactions lasting for months as inflamed papules and nodules, this is particularly likely to be seen with tick bites and mosquito bites. These may be confused with lymphoma histologically, with a dense inflammatory infiltrate of lymphoid cells, histiocytes, eosinophils and plasma cells together with the presence of atypical mononuclear cells.  <b>Inclusions:</b> Insect bite granuloma
<b>EK50.0Y</b>	Other specified cutaneous insect bite reactions
<b>EK50.0Z</b>	Cutaneous insect bite reactions, unspecified
<b>EK5Y</b>	<b>Other specified skin disorders provoked by external factors</b>

## Benign proliferations, neoplasms and cysts of the skin (EK70-EK71.Z)

**Coded Elsewhere:** Benign adipocytic neoplasms of skin or soft tissue  
Benign cutaneous neoplasms (2F20-2F2Z)

<b>EK70</b>	<b>Cutaneous cysts</b> <b>Coded Elsewhere:</b> Neonatal milia (KC40.1)
<b>EK70.0</b>	<b>Epidermoid cyst</b> A cutaneous cyst with an epidermoid wall filled with keratin and its breakdown products. It most commonly forms as the result of squamous metaplasia in a damaged sebaceous gland but may result from trauma (traumatic inclusion cyst), especially when situated on the extremities. It typically presents as a spherical skin-coloured or yellowish nodule, often with a central pore opening onto the skin surface.  <b>Inclusions:</b> Epidermal inclusion cyst
<b>EK70.00</b>	Infected epidermoid cyst An epidermoid cyst which has become secondarily infected by, most commonly, <i>Staphylococcus aureus</i> . It manifests as pain, swelling and erythema of a preexisting cyst and is predisposed to rupture.

- EK70.0Z** Epidermoid cyst, unspecified
- EK70.1** **Trichilemmal cyst**  
A trichilemmal (pilar) cyst is a common, typically non-tender, intradermal or subcutaneous cyst. The cysts are typically confined to the scalp and are often multiple. They usually occur sporadically but may be inherited in an autosomal dominant manner. They are derived from the outer root sheath of the hair follicle and as such contain keratin or keratin degradation products. Rarely, they may undergo malignant transformation.  
*Inclusions:* Pilar cyst
- EK70.2** **Digital myxoid pseudocyst**  
Digital myxoid cysts (DMCs) are benign ganglion cysts of the digits, which typically present as a small dome-shaped, often translucent papule on the dorsum of the terminal phalanx and/or as longitudinal "guttering" of the nail plate which is focally compressed by the cyst as it develops from the underlying nail matrix. In the majority of cases a stalk connecting the cyst with the adjacent distal interphalangeal joint can be demonstrated, accounting for the alternative names of digital ganglion cyst and digital synovial cyst.  
*Inclusions:* Digital ganglion cyst
- EK70.3** **Hidrocystoma**  
A hidrocystoma is a cystic cutaneous swelling lined by either apocrine or eccrine ductal epithelium. It presents typically as a small solitary bluish translucent papule on or around the eyelids. It is not always possible to be certain whether it is of apocrine or eccrine origin though the majority show apocrine differentiation.
- EK70.Y** Other specified cutaneous cysts
- EK70.Z** Cutaneous cysts, unspecified
- EK71** **Skin tags or polyps**  
Benign outgrowths of skin consisting of a fibrovascular core covered with normal or thinned epidermis. They may be single or multiple and range in diameter from less than a millimetre to a centimetre or more.
- EK71.0** **Fibroepithelial polyp of skin**  
A common polypoid, often pedunculated non-neoplastic benign skin growth consisting of a fibrovascular core covered with normal or thinned epidermis. If torsion of the stalk occurs they may become painful, swollen and necrotic.
- EK71.1** **Multiple skin tags**  
Very common non-neoplastic fibroepithelial skin growths ranging from less than one to several millimetres in diameter. They favour the neck and intertriginous areas and may be very numerous. They are associated with obesity, type II diabetes, insulin resistance and acanthosis nigricans.
- EK71.Z** **Polyp of skin not elsewhere classified**

## Disorders of the skin of uncertain or unpredictable malignant potential (EK90-EK92)

**Coded Elsewhere:** Neoplasms of uncertain behaviour of skin (2F72)

**EK90**

### **Actinic keratosis and other discrete epidermal dysplasias**

A group of conditions characterised by varying degrees of keratinocytic atypia resulting from damage to keratinocyte DNA. They carry a small propensity to develop into invasive squamous cell carcinoma.

**EK90.0**

#### **Actinic keratosis**

Actinic keratoses (AKs) are focal areas of abnormal keratinocyte proliferation and differentiation induced by chronic exposure to ultraviolet radiation. They are very common on sun-exposed skin of fair-skinned individuals who have had excessive exposure to sunlight. Initially flat scaly papules, they may become significantly elevated from the skin surface by producing dense adherent keratin or as a result of unregulated cellular proliferation which may progress to frank carcinoma in situ or invasive squamous cell carcinoma.

*Inclusions:* Solar keratosis

**EK90.1**

#### **Diffuse actinic keratinocyte dysplasia**

Diffuse actinic dysplasia develops after repeated exposure of skin to ultraviolet radiation, usually over decades, and results from cumulative DNA damage within the nuclei of epidermal keratinocytes. It is characterised initially by subtle diffuse skin changes including mottling, erythema, telangiectasia and irregular fine scaling. It is seen most commonly on the unprotected scalp skin of bald men. Histologically there are early signs of dysplasia in the basal epidermis. As damage accumulates the clinical changes become more pronounced with the formation of discrete actinic keratoses, from which intraepidermal or invasive squamous cell carcinoma may develop.

*Inclusions:* "Field change" due to chronic exposure to ultraviolet radiation

**EK90.Y**

#### **Other discrete epidermal dysplasias**

**EK91**

### **Dermatoses which may presage cutaneous lymphoma**

Dermatoses which may represent the earliest stages of cutaneous lymphoma but where it is not possible to confirm their neoplastic nature.

**EK91.0**

#### **Large plaque parapsoriasis**

Large plaque parapsoriasis is a chronic skin disorder characterised by the indolent development over years or decades of scaly patches or slightly elevated plaques which may be clinically indistinguishable from early mycosis fungoides but in which no evidence of infiltration by abnormal lymphocytes can be found. Approximately 10% of patients will, however, eventually progress to mycosis fungoides.

**EK91.1**

**Poikiloderma vasculare atrophicans**

Poikiloderma vasculare atrophicans is a cutaneous reaction pattern characterised by mottled hyper- and hypomelanosis, telangiectasia and progressive dermal and epidermal atrophy. It may manifest as a component of established mycosis fungoides but may precede the development of the latter by many years and, in some cases, may persist indefinitely without progression to frank lymphoma. It should be distinguished from other causes of poikiloderma such as may be seen with dermatomyositis.

**EK91.2**

**Primary cutaneous plasmacytosis**

A skin disorder resulting from focal or multifocal dense infiltration of the skin by plasma cell aggregates. It may be associated with high levels of serum IgG4. It typically presents as widespread reddish-brown papules, nodules and pigmented indurated plaques involving the trunk and limbs but may present as a single nodule or plaque. The majority of patients with this uncommon skin disorder are of East Asian descent. There is a risk of progression to systemic lymphoproliferative malignancy.

**EK92**

**Histiocytoses of uncertain malignant potential**

Disorders characterised by abnormal proliferation of dendritic cells and macrophages. The proliferation may or may not be clonal and the prognosis is unpredictable.

**Coded Elsewhere:** Langerhans cell histiocytosis (2B31.2)

Indeterminate cell histiocytosis (2B31.6)

## Cutaneous markers of internal disorders (EL10-EL3Y)

A heterogeneous group of skin disorders associated with underlying disease.

**Coded Elsewhere:** Tophaceous gout (FA25.20)

- Diabetic skin lesions (EB90.0)
- Benign acanthosis nigricans (ED51.00)
- Acquired perforating dermatosis (EE70.0)
- Calcific arteriolopathy (EB90.42)
- Pretibial myxoedema (EB90.10)
- Acromegaly or pituitary gigantism (5A60.0)
- Cholestatic pruritus (EC90.11)
- Yellow nail syndrome (EE11.1)
- Uraemic pruritus (EC90.10)
- Nail-patella syndrome (LD24.J0)
- Hairy leukoplakia (DA01.01)
- Immune reconstitution inflammatory syndrome (4B23)

## Cutaneous markers of internal malignancy (EL10-EL1Y)

A range of generally uncommon skin signs which may point to the presence of an internal malignancy

**EL10**

### Paraneoplastic syndromes involving skin

**Coded Elsewhere:** Paraneoplastic pemphigus (EB40.2)

- Thrombophlebitis migrans (BD70.2)
- Paraneoplastic dermatomyositis (4A41.00)
- Paraneoplastic hypertrophic osteoarthropathy (FB86.10)

**EL1Y**

### Other specified cutaneous markers of internal malignancy

---

**EL3Y**

### Other specified cutaneous markers of internal disorders

**Coding Note:** Code also the causing condition

## Postprocedural disorders of the skin (EL50-EL80)

This group of disorders incorporates drug eruptions, other cutaneous side effects of medication and adverse reactions to medical and surgical interventions.

**EL50**

### Unsatisfactory surgical scar of skin

A surgical skin scar with a poor functional or cosmetic outcome.

**EL50.0**

### Keloidal surgical scar

A surgical scar which heals with an overgrowth of fibrous scar tissue which extends beyond the limits of the original surgical wound.

<b>EL50.1</b>	<b>Hypertrophic surgical scar</b> An elevated surgical scar containing an excess of fibrous tissue which, in contrast to a keloidal scar, does tend to flatten with time.
<b>EL50.2</b>	<b>Atrophic surgical scar</b> A surgical scar in which there is thinning of the skin giving it a wrinkled appearance. <b>Exclusions:</b> Postinflammatory atrophic scarring of the skin (EE40.2)
<b>EL50.3</b>	<b>Expanded surgical scar</b> A widened surgical scar, often resulting from inadequate deep suturing or poor surgical technique. They are common in disorders of connective tissue such as Ehlers-Danlos syndrome. <b>Inclusions:</b> Stretched scar
<b>EL50.Z</b>	<b>Unsatisfactory surgical scar of skin, unspecified</b>
<b>EL51</b>	<b>Cutaneous flap necrosis</b> Necrosis of surgical skin flap
<b>EL52</b>	<b>Myocutaneous flap necrosis</b> Necrosis of a surgical flap containing both skin and muscle
<b>EL53</b>	<b>Skin graft failure</b> Failure of skin graft tissue to engraft as intended
<b>EL54</b>	<b>Composite graft failure</b> Failure of composite graft tissue (e.g. skin and cartilage) to engraft as intended
Adverse cutaneous effects of therapeutic ionizing irradiation (EL60-EL63)	
<b>Coded Elsewhere:</b> Oral mucositis due to radiotherapy (DA01.11)	
Radiotherapy-induced xerostomia (DA02.1)	
Scarring alopecia following radiotherapy (ED70.5Y)	
Radiotherapy-induced skin malignancy (2C3Y)	
<b>EL60</b>	<b>Acute radiodermatitis following radiotherapy</b> The reaction of the skin, and in particular the epidermis, to acute exposure to ionising radiation directed at the skin for therapeutic purposes. It manifests as inflammation, erosion and crusting.
<b>EL61</b>	<b>Chronic radiodermatitis following radiotherapy</b> The late cutaneous sequelae of the therapeutic use of ionising radiation. It may take five to ten years to develop and is characterised by cutaneous atrophy, fibrosis, dyspigmentation, alopecia and telangiectasia with associated damage to underlying subcutaneous fat.
<b>EL63</b>	<b>Radionecrosis of skin due to therapeutic ionizing irradiation</b> Necrosis and ulceration of skin attributable to radiotherapy

Complications of cutaneous cosmetic procedures (EL73-EL73.6)

**Coded Elsewhere:** Specified cutaneous complications of cosmetic procedures (EL73)

**EL73**

**Unsatisfactory outcome from cutaneous cosmetic surgical procedure**

The outcome from a surgical intervention designed to improve cosmetic appearance which is considered by the practitioner who performed the procedure to be less satisfactory than anticipated.

**EL73.0**

**Adverse reaction to dermal or deep fillers**

Any adverse event attributable to the use of injected fillers used for soft tissue augmentation.

**Exclusions:** Pyogenic abscess of the skin (1B75.3)

**EL73.1**

**Adverse reaction to chemical peel**

Any adverse reaction attributable to the use of chemical peels on the skin for cosmetic enhancement. Examples include infection, chemical burns, pustular acneform eruptions, dyspigmentation and scarring. The precise adverse reaction should be documented separately.

**EL73.2**

**Adverse reaction to injection of neurotoxin**

Adverse event resulting from use of neurotoxins, especially botulinum toxin, into the skin. This is most commonly administered for aesthetic reasons. Recognised problems include ptosis, diplopia and hypersensitivity to the toxin. Details of the reaction should be coded separately.

**EL73.3**

**Unsatisfactory outcome from cosmetic laser surgery**

The outcome from an intervention using lasers designed to improve cosmetic appearance which is considered by the practitioner who performed the procedure to be less satisfactory than anticipated.

**EL73.4**

**Hypomelanosis resulting from cosmetic procedure**

Loss of skin pigmentation attributable to a cosmetic intervention and particularly associated with chemical peels.

**EL73.5**

**Dyspigmentation resulting from cosmetic procedure**

Disturbed skin pigmentation following a cosmetic procedure

**EL73.6**

**Fibrosis or scarring following cosmetic procedure**

Unsatisfactory scarring and fibrosis following a procedure designed to improve cosmesis.

**EL80**

**Adverse cutaneous effects of diagnostic procedures**

Skin problems arising from diagnostic procedures. Examples would be radiation necrosis from prolonged fluoroscopy or anaphylaxis from use of radiocontrast media.

**Coded Elsewhere:** Nephrogenic systemic fibrosis (FB51.Y)

**EM0Y**

**Other specified diseases of the skin**

**EM0Z**

**Skin disease of unspecified nature**

# CHAPTER 15

---

## Diseases of the musculoskeletal system or connective tissue

This chapter has 90 four-character categories.

Code range starts with FA00

This chapter contains diseases of musculoskeletal system and diseases of connective tissue.

- Exclusions:**
- Injury, poisoning or certain other consequences of external causes (Chapter 22)
  - Endocrine, nutritional or metabolic diseases (Chapter 05)
  - Complications of pregnancy, childbirth and the puerperium (Chapter 18)
  - Certain infectious or parasitic diseases (Chapter 01)
  - Temporomandibular joint disorders (DA0E.8)
  - Certain conditions originating in the perinatal period (Chapter 19)

- Coded Elsewhere:**
- Neoplasms of the musculoskeletal system
  - Monogenic autoinflammatory syndromes (4A60)
  - Nonorgan specific systemic autoimmune disorders (4A40-4A4Z)
  - Symptoms, signs or clinical findings of the musculoskeletal system (ME80-MF1Y)
  - Structural developmental anomalies of the skeleton (LB70-LB9Z)
  - Syndromes with connective tissue involvement as a major feature (LD28)
  - Syndromes with skeletal anomalies as a major feature (LD24)

This chapter contains the following top level blocks:

- Arthropathies
- Conditions associated with the spine
- Soft tissue disorders
- Osteopathies or chondropathies
- Neoplasms of the musculoskeletal system

## Arthropathies (FA00-FA5Z)

### Osteoarthritis (FA00-FA0Z)

Osteoarthritis (OA) can be defined as a group of distinct, but overlapping diseases, which may have different etiologies, but similar biological, morphological, and clinical outcomes affecting the articular cartilage, subchondral bone, ligaments, joint capsule, synovial membrane, and periarticular muscles. OA is the most common joint disease in persons 65 years of age and above. Its etiology is not fully understood, although there are several related factors, such as female gender, genetics, metabolism, and excessive mechanical stress. The diagnosis of OA is primarily based on clinical history and physical examination. The cardinal radiographic features of OA are focal/non-uniform narrowing of the joint space in the areas subjected to the most pressure, subchondral cysts, subchondral sclerosis, and osteophytes.

<b>FA00</b>	<b>Osteoarthritis of hip</b>
<b>FA00.0</b>	<b>Primary osteoarthritis of hip</b>
<b>FA00.1</b>	<b>Post traumatic osteoarthritis of hip</b>
<b>FA00.2</b>	<b>Other secondary osteoarthritis of hip</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FA00.Z</b>	<b>Osteoarthritis of hip, unspecified</b>
<b>FA01</b>	<b>Osteoarthritis of knee</b>
	Primary osteoarthritis occurring in an otherwise intact knee joint, involving genetically related, age-related or use-related degeneration with microscopic and macroscopic anatomical changes, which ultimately limit motion in one or more joints. Changes to the joint include increasing cartilage loss and osseous transformation such as sclerosis, osteophyte formation and cysts as well as potential inflammatory changes in surrounding soft tissue structures.
<b>FA01.0</b>	<b>Primary osteoarthritis of knee</b>
<b>FA01.1</b>	<b>Post traumatic osteoarthritis of knee</b>
<b>FA01.2</b>	<b>Other secondary osteoarthritis of knee</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FA01.Z</b>	<b>Osteoarthritis of knee, unspecified</b>
<b>FA02</b>	<b>Osteoarthritis of wrist or hand</b>
<b>FA02.0</b>	<b>Primary osteoarthritis of wrist or hand</b>
<b>FA02.1</b>	<b>Post traumatic osteoarthritis of wrist or hand</b>
<b>FA02.2</b>	<b>Other secondary osteoarthritis of wrist or hand</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FA02.Z</b>	<b>Osteoarthritis of wrist or hand, unspecified</b>
<b>FA03</b>	<b>Osteoarthritis of other specified joint</b>

<b>FA03.0</b>	<b>Primary osteoarthritis of other specified joint</b>
<b>FA03.1</b>	<b>Post traumatic osteoarthritis of other specified joint</b>
<b>FA03.2</b>	<b>Other secondary osteoarthritis of other specified joint</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FA03.Z</b>	<b>Osteoarthritis of other specified joint, unspecified</b>
<b>FA04</b>	<b>Oligoosteoarthritis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FA05</b>	<b>Polyosteoarthritis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FA0Z</b>	<b>Osteoarthritis, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition

#### Infection related arthropathies (FA10-FA1Z)

A disease of the joints, caused by an infection with a bacterial, viral, fungal, or parasitic source.

Distinction is made between the following types of etiological relationship.

- a) direct infection of joint, where organisms invade synovial tissue and microbial antigen is present in the joint;
- b) indirect infection, which may be of two types: a reactive arthropathy, where microbial infection of the body is established but neither organisms nor antigens can be identified in the joint, and a postinfective arthropathy, where microbial antigen is present but recovery of an organism is inconstant and evidence of local multiplication is lacking.

<b>FA10</b>	<b>Direct infections of joint</b>
	Hematogenic or non-hematogenic infections of joints.
	<b>Exclusions:</b> Reactive arthropathies (FA11) Postinfectious arthropathies (FA12)
<b>FA10.0</b>	<b>Bacterial infection of joint</b>
	<b>Coded Elsewhere:</b> Gonococcal arthritis (1A72.0)
<b>FA10.1</b>	<b>Viral infection of joint</b>
<b>FA10.2</b>	<b>Fungal infection of joint</b>
<b>FA10.Z</b>	<b>Direct infections of joint, unspecified</b>

**FA11****Reactive arthropathies**

A disease of the joints, caused by an infection in another part of the body, auto-immune disease, or post-vaccination. This disease is characterised by a secondary inflammation of the joints in reaction to infection, auto-immune disease, or vaccination. Common previous sites of infection are the enteric or genitourinary system.

**Coding Note:** Code also the underlying disease or aetiology.

**Exclusions:** Acute rheumatic fever (1B40-1B42)

Behçet disease (4A62)

**Coded Elsewhere:** Arthritis mutilans (FA21.Y)

**FA11.0 Arthropathy following intestinal bypass**

**Coded Elsewhere:** Bowel-associated dermatosis-arthritis syndrome (EB2Y)

**FA11.1 Arthropathy following vaccination****FA11.2 Arthropathy following genitourinary infection**

Reactive arthritis (ReA) is an autoimmune disorder belonging to the group of seronegative spondyloarthropathies and is characterised by the classic triad of arthritis, urethritis and conjunctivitis.

**Coding Note:** Code also the causing condition

**FA11.Y Other specified reactive arthropathies**

**Coding Note:** Code also the underlying disease or aetiology.

**FA11.Z Reactive arthropathies, unspecified**

**Coding Note:** Code also the underlying disease or aetiology.

**FA12****Postinfectious arthropathies**

**Coding Note:** Code also the causing condition

**FA12.0 Bacterial postinfectious arthropathy**

**Coding Note:** Code also the causing condition

**FA12.1 Viral postinfectious arthropathies**

**Coding Note:** Code also the causing condition

**FA12.2 Fungal postinfectious arthropathies**

**Coding Note:** Code also the causing condition

**FA12.3 Parasitic postinfectious arthropathies**

**Coding Note:** Code also the causing condition

**FA12.Y Other specified postinfectious arthropathies**

**Coding Note:** Code also the causing condition

**FA12.Z** **Postinfectious arthropathies, unspecified**

**Coding Note:** Code also the causing condition

**FA13** **Infectious spondyloarthritis**

A condition of the spine, caused by an infection with a bacterial, viral, fungal, or parasitic source. This condition is characterised by inflammation of the vertebrae.

**Exclusions:** Inflammatory spondyloarthritis (FA92)

**FA1Y** **Other specified infection related arthropathies**

**FA1Z** **Infection related arthropathies, unspecified**

Inflammatory arthropathies (FA20-FA2Z)

**Coded Elsewhere:** Peripheral spondyloarthritis (FA92.1)

**FA20** **Rheumatoid arthritis**

Rheumatoid arthritis (RA) is persistent and/or erosive disease that is defined as the confirmed presence of synovitis in at least 1 joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in 4 domains: number and site of involved joints, serologic abnormality, elevated acute-phase response, and symptom duration.

**Exclusions:** rheumatoid arthritis, juvenile (FA24.1)

Acute rheumatic fever (1B40-1B42)

**Coded Elsewhere:** Respiratory disorders in rheumatoid arthritis (CB05.1)

**FA20.0** **Seropositive rheumatoid arthritis**

**FA20.1** **Seronegative rheumatoid arthritis**

**FA20.Z** **Rheumatoid arthritis, serology unspecified**

**FA21** **Psoriatic arthritis**

Psoriatic arthritis, a member of the spondyloarthritis family, is defined as an inflammatory arthropathy associated with psoriasis that is usually rheumatic factor negative. It is characterised by various clinical manifestations, including symmetric polyarthritis, asymmetric oligoarthritis or polyarthritis, spinal inflammation similar to ankylosing spondylitis, peripheral enthesitis, anterior chest wall involvement, distal interphalangeal arthritis of the hands and feet, dactylitis (sausage digit or toe), arthritis mutilans and onycho-pachydermo-periostitis. The CASPAR has high sensitivity and specificity.

**Exclusions:** Juvenile psoriatic arthritis (FA24.2)

**FA21.0** **Psoriatic spondyloarthritis**

**Inclusions:** Psoriatic spondylitis

**FA21.Y** **Other specified psoriatic arthritis**

**FA21.Z** **Psoriatic arthritis, unspecified**

**FA22**

### **Polymyalgia rheumatica**

Polymyalgia rheumatica (PMR) is a syndrome characterised by aching of the proximal portions of the extremities and torso. Provisional classification criteria for PMR by the European League Against Rheumatism/American College of Rheumatology Collaborative Initiative should be applied to patients aged 50 years or older with bilateral shoulder aching, and abnormal CRP and/or ESR. The scoring algorithm is based on morning stiffness >45 minutes (2 points), hip pain/limited range of motion (1 point), absence of rheumatoid factor and/or anti-citrullinated protein antibody (1 point), with optional ultrasound criteria. Most commonly, PMR occurs in isolation, but may be seen in 40-50% of patients with giant cell arteritis.

**Exclusions:** Giant cell arteritis with polymyalgia rheumatica (4A44.2)

**FA23**

### **Adult-onset Still disease**

Adult onset Still's disease is a rare rheumatic condition characterised by a combination of symptoms, such as fever higher than 39 degrees C, cutaneous rash during fever peaks, joint or muscle pain, lymph node hypertrophy, increase of white blood cells (especially polymorphonuclear neutrophils) and abnormalities of liver metabolism.

**Exclusions:** Still disease NOS (FA24.4)

**FA24**

### **Juvenile idiopathic arthritis**

Juvenile idiopathic arthritis (JIA) is the term used to describe a group of inflammatory articular disorders of unknown cause that begin before the age of 16 and last over 6 weeks. Six disorders have been defined: systemic-onset juvenile idiopathic arthritis (formerly referred to as Still's disease), oligoarticular arthritis, rheumatoid factor-positive polyarthritis, rheumatoid factor-negative polyarthritis, enthesitis-related arthritis (spondyloarthropathies), and the juvenile form of psoriatic arthritis (see these terms). A seventh category has been defined comprising unclassified types of arthritis (types that do not correspond to any of the defined disease or that correspond to more than one of the disease definitions).

**Coding Note:** Arthritis in children, with onset before 16th birthday and lasting longer than 6 weeks

**Exclusions:** Juvenile dermatomyositis (4A41.01)

Felty syndrome (FA20.0)

**FA24.0**

### **Juvenile idiopathic oligoarthritis**

Oligoarticular juvenile arthritis is the most common form of juvenile idiopathic arthritis, representing nearly 50% of cases. It is more common in girls (80% of cases), with onset occurring between ages 2 and 4. It is usually asymmetrical and affects between one and a maximum of four joints, predominantly those of the lower limbs (knee or foot).

**Coding Note:** Use additional code, if desired, to identify associated uveitis

**FA24.00**

Juvenile idiopathic oligoarthritis, onset persistent

Onset persistent refers to the fact that the child never has more than four joints involved throughout the course of the disease.

<b>FA24.01</b>	Juvenile idiopathic oligoarthritis, onset extended Onset extended refers to the fact that after the initial six month period, the total number of affected joints exceeds four.
<b>FA24.0Z</b>	Juvenile idiopathic oligoarthritis, onset unspecified
<b>Coding Note:</b>	Use additional code, if desired, to identify associated uveitis
<b>FA24.1</b>	<b>Juvenile idiopathic polyarthritis</b> Juvenile idiopathic polyarthritis is a type of juvenile idiopathic arthritis (JIA) that affects five or more joints in the first six months after onset. It often affects the same joints on each side of the body. It is more common in girls.
<b>FA24.2</b>	<b>Juvenile psoriatic arthritis</b> Juvenile psoriatic arthritis is an autoimmune inflammatory disorder representing less than 10% of all juvenile idiopathic arthritis (JIA) cases, and characterised by the association of psoriasis with one of two forms of arthritis: the association of psoriasis with an arthritis that most resembles oligoarticular arthritis with a risk of uveitis is more common in girls with onset at around 6 years of age, whereas the association of psoriasis with a form of arthritis that most resembles a spondyloarthropathy is most common in boys and manifests later.
<b>Coding Note:</b>	Use additional code to identify associated uveitis
<b>FA24.3</b>	<b>Juvenile enthesitis related arthritis</b> Enthesitis-related arthritis is a type of juvenile idiopathic arthritis (JIA) that represents the paediatric form of spondyloarthropathy in adults, but differs from it as the initial manifestations in the paediatric form are asymmetric oligoarticular arthritis of the lower limbs, associated with enthesitis. Axial manifestations (sacroiliac involvement) are present in only 25% of cases at onset but appear several years later in the disease course.
<b>Coding Note:</b>	Use additional code to identify associated uveitis
<b>FA24.4</b>	<b>Juvenile systemic arthritis</b> Systemic-onset juvenile idiopathic arthritis represents 10-11% of cases of juvenile idiopathic arthritis (JIA) and is marked by the severity of the extra-articular manifestations (fever, cutaneous eruptions) and by an equal sex ratio. Fever peaks are associated with transient cutaneous eruptions and diffuse erythematosis or urticarial-like lesions. The presence of arthritis is essential for diagnosis but may appear later in the disease course. The number of sites affected is variable (mono-, oligo- or polyarthritis) affecting both the small and large joints in a nearly symmetrical manner. This characteristic diagnostic triad may also be associated with an adenopathy and hepatosplenomegaly. Visceral complications (pericarditis, pleural effusion or serous peritonitis with abdominal pain) may be present.
<b>Coding Note:</b>	Code also the causing condition
<b>FA24.Y</b>	<b>Other specified juvenile idiopathic arthritis</b>
<b>Coding Note:</b>	Arthritis in children, with onset before 16th birthday and lasting longer than 6 weeks
<b>FA24.Z</b>	<b>Juvenile idiopathic arthritis, unspecified</b>
<b>Coding Note:</b>	Arthritis in children, with onset before 16th birthday and lasting longer than 6 weeks

**FA25**

### **Gout**

Gout is an acute or chronic arthropathy resulting from deposition of monosodium urate monohydrate crystals in joint tissues. It is strongly associated with hyperuricaemia, which may be secondary to certain drugs, poisons or lymphoproliferative disorders. Gout is definitively diagnosed by demonstration of urate crystals in aspirated synovial fluid in the absence of an alternative aetiology for arthritis. It may be associated with focal urate deposition in skin and subcutaneous tissue (tophaceous gout) and with urate nephropathy

**Exclusions:** Hyperuricaemia without signs of inflammatory arthritis or tophaceous disease (5C55)

**FA25.0**

### **Primary gout**

Primary gout refers to those cases that appear to be innate, that are neither secondary to another acquired disorder nor a subordinate manifestation of an inborn error that leads initially to a major disease unlike gout. Although some cases of primary gout have a genetic basis, others do not.

**Inclusions:** Gouty bursitis  
Gouty arthropathy

**FA25.1**

### **Secondary gout**

Secondary gout refers to those cases that develop during the course of another disease, or as a consequence of treatment with drugs. Secondary gout is associated with increased purine biosynthesis de novo, increased nucleic acid turnover, or decreased renal clearance of uric acid.

**Coding Note:** Code also the causing condition

**FA25.10** Lead-induced gout

**FA25.11** Drug-induced gout

**FA25.12** Gouty arthropathy due to enzyme defects or other inherited disorders

**Coding Note:** Code also the causing condition

**FA25.1Y** Other specified secondary gout

**Coding Note:** Code also the causing condition

**FA25.1Z** Secondary gout, unspecified

**Coding Note:** Code also the causing condition

**FA25.2** **Gout without specification whether primary or secondary**

**FA25.20** Tophaceous gout

Tophi are precipitates of monosodium urate in the tissues of patients with hyperuricaemia and may be associated with other manifestations of hyperuricaemia including gouty arthropathy. They present particularly in the skin and subcutaneous tissue. One of the more common sites for them is the helix of the ear.

**FA25.2Y** Other specified gout without specification whether primary or secondary

**FA25.2Z** Gout, unspecified

<b>FA26</b>	<b>Certain specified crystal arthropathies</b>
	<b><i>Exclusions:</i></b> Gout (FA25)
<b>FA26.0</b>	<b>Calcium pyrophosphate dehydrate deposition disease</b> Familial calcium pyrophosphate deposition is a chronic inherited arthropathy characterised by chondrocalcinosis (cartilage calcification), often associated with recurrent acute calcium pyrophosphate crystal arthritis and polyarticular osteoarthritis.
<b>FA26.1</b>	<b>Hydroxyapatite deposition disease</b> Calcium hydroxyapatite crystal deposition disease is characterised by the presence of basic calcium phosphate crystals - predominantly hydroxyapatite - in periarticular soft tissues, especially tendons. This entity is best recognised as "calcific tendinitis" at its most frequent site about the shoulder, but the disease involves numerous other sites and may be more appropriately termed calcific periarthritis.
<b>FA26.2</b>	<b>Chondrocalcinosis</b> Chondrocalcinosis refers to radiographic calcification in hyaline and/or fibrocartilage and is not specific for CPPD or other particular crystal deposition disease. Familial I CPPD deposition disease has been reported from many countries and some kindred have CPPD disease linked to ANKH mutation on chromosome 5p. <b><i>Inclusions:</i></b> Familial chondrocalcinosis
<b>FA26.Y</b>	<b>Other specified crystal arthropathies</b>
<b>FA26.Z</b>	<b>Crystal arthropathies, unspecified</b>
<b>FA27</b>	<b>Certain specified inflammatory arthropathies</b>
	<b><i>Exclusions:</i></b> cricoarytenoid arthropathy (CA0H) arthropathy NOS (FA38)
<b>FA27.0</b>	<b>Kashin-Beck disease</b> Kashin-Beck disease (KBD) is a chronic, endemic osteochondropathy of unknown etiology. The disease is mainly distributed in a diagonal belt ranging from the northeast to the southwest of China, where the soil selenium content is low. Mineral deficiencies (e.g., selenium, iodine), fungal cereal contamination, and water contamination may be contributing factors to its etiology. The disease is manifested by arthritic pain, morning stiffness, enlarged and shortened fingers, deformed and enlarged joints, and limited motion of the joints in the extremities.
<b>FA27.1</b>	<b>Pigmented villonodular synovitis</b> This condition is characterised by outgrowths of synovial membrane composed of villi and fibrous nodules and is histologically characterised by hemosiderin- and lipid-containing macrophages and multinucleated giant cells. It usually occurs in the knee and hip, and is often diagnosed by Magnetic Resonance Imaging.

<b>FA27.2</b>	<b>Palindromic rheumatism</b>
	Palindromic rheumatism causes sudden attacks of joint pain and swelling, typically in the hands and feet. An episode may last from a few hours to several days. The frequency of attacks also varies. Between attacks, pain and swelling completely disappear, and the affected joints look normal on X-rays. It is likely that 30 to 50 percent of patients with palindromic rheumatism go on to develop rheumatoid arthritis, but the progression may take several years.
<b>FA27.3</b>	<b>Transient synovitis</b>
<b>FA27.4</b>	<b>Intermittent hydrarthrosis</b>
<b>FA27.Y</b>	<b>Other specified inflammatory arthropathies</b>
<b>FA2Z</b>	<b>Inflammatory arthropathies, unspecified</b>

Certain specified joint disorders or deformities of limbs (FA30-FA3Z)

**Exclusions:** Conditions associated with the spine (FA70-FB1Z)

<b>FA30</b>	<b>Acquired deformities of fingers or toes</b>
	<b>Exclusions:</b> congenital deformities and malformations of fingers and toes (LB80-LB81.Z)
	Congenital absence of finger (LB99.7)
	Congenital absence of toe (LB9A.5)
	Acquired absence of toe (QF00)
	Acquired absence of finger, including thumb, unilateral (QF00)
	amputation of finger (QF00)
	amputation of toe (QF00)
<b>FA30.0</b>	<b>Acquired hallux valgus</b>
<b>FA30.1</b>	<b>Hallux rigidus</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FA30.2</b>	<b>Acquired hammer toe</b>
	<b>Exclusions:</b> Congenital hammer toe (LB98.5)
<b>FA30.Y</b>	<b>Other specified acquired deformities of fingers or toes</b>
<b>FA30.Z</b>	<b>Acquired deformities of fingers or toes, unspecified</b>

<b>FA31</b>	<b>Other acquired deformities of limbs</b>
	<b>Exclusions:</b> congenital: deformities and malformations of limbs (LB70-LB9Z)
	Acquired deformities of fingers or toes (FA30)
	congenital: absence of limbs (LB70-LB9Z)
	Coxa plana (FB82.1)
	Acquired absence of limb (QF00)
<b>FA31.0</b>	<b>Valgus deformity, not elsewhere classified</b>
	<b>Exclusions:</b> Talipes calcaneovalgus (LB98.22)
	Metatarsus valgus (LB98.21)
<b>FA31.1</b>	<b>Varus deformity, not elsewhere classified</b>
	<b>Exclusions:</b> Metatarsus varus (LB98.02)
	tibia vara (FB82.1)
<b>FA31.2</b>	<b>Flexion deformity</b>
<b>FA31.3</b>	<b>Acquired wrist drop</b>
<b>FA31.4</b>	<b>Acquired foot drop</b>
<b>FA31.5</b>	<b>Acquired pes planus</b>
	<b>Exclusions:</b> Congenital pes planus (LB98.1)
<b>FA31.6</b>	<b>Acquired clawhand or clubhand</b>
<b>FA31.7</b>	<b>Acquired clawfoot or clubfoot</b>
	<b>Exclusions:</b> congenital clubfoot - varus (LB98.0)
	congenital clubfoot - valgus (LB98.22)
<b>FA31.8</b>	<b>Acquired unequal limb length</b>
<b>FA31.Y</b>	<b>Other specified acquired deformities of limbs</b>
<b>FA31.Z</b>	<b>Acquired deformities of limbs, unspecified</b>
<b>FA32</b>	<b>Disorders of patella</b>
	<b>Exclusions:</b> Dislocation of patella (NC93.1)
	<b>Coded Elsewhere:</b> Chondromalacia patellae (FB82.00)
<b>FA32.0</b>	<b>Recurrent instability of patella</b>
<b>FA32.1</b>	<b>Patellofemoral disorders</b>
<b>FA32.Y</b>	<b>Other specified disorders of patella</b>
<b>FA32.Z</b>	<b>Disorders of patella, unspecified</b>

**FA33****Internal derangement of knee**

Internal derangement of the knee (IDK) is a chronic disorder of the knee due to a torn, ruptured or deranged meniscus of the knee, or a partial or complete cruciate rupture, with or without injury to the capsular ligament, resulting in ongoing or intermittent signs and symptoms such as pain, instability, or abnormal mobility of that knee.

If indicated that derangement is due to trauma, code to Injury, poisoning and certain other consequences of external causes, regardless of time past since injury.

**Exclusions:**

- recurrent dislocation or subluxation patella (FA32.0)
- Ankylosis of joint (FA34.4)
- deformity of knee (FA31)
- Injuries to the knee or lower leg (NC90-NC9Z)
- Disorders of patella (FA32)

**FA33.0 Cystic meniscus**

**FA33.1 Discoid meniscus**

**FA33.2 Derangement of meniscus due to old tear or injury**

**Inclusions:** Old bucket-handle tear

**FA33.3 Loose body in knee**

**FA33.4 Chronic instability of knee**

**Exclusions:** Recurrent instability of patella (FA32.0)

**FA33.40** Chronic instability of knee, medial collateral ligament or other or unspecified part of medial meniscus

**FA33.4Y** Other specified chronic instability of knee

**FA33.4Z** Chronic instability of knee, unspecified

**FA33.Y Other specified internal derangement of knee**

**FA33.Z Internal derangement of knee, unspecified**

**FA34****Certain specified joint derangements**

**Exclusions:**

- Temporomandibular joint disorders (DA0E.8)
- current injury - see injury of joint by body region (Chapter 22)

**FA34.0 Loose body in joint**

**Exclusions:** Loose body in knee (FA33.3)

**FA34.1 Disorder of ligament**

**Exclusions:**

- Chronic instability of knee (FA33.4)
- familial ligamentous laxity (LD28.1)

<b>FA34.2</b>	<b>Recurrent instability of joint</b>
	<p><b><i>Exclusions:</i></b> vertebral subluxation (ME93) Recurrent instability of patella (FA32.0)</p>
<b>FA34.3</b>	<b>Contracture of joint</b>
	<p><b><i>Exclusions:</i></b> Dupuytren contracture (FB51.0) contracture of tendon (sheath) without contracture of joint (FB42.1) acquired deformities of limbs (FA31)</p>
<b>FA34.4</b>	<b>Ankylosis of joint</b>
	<p><b><i>Exclusions:</i></b> stiffness of joint without ankylosis (ME85) Ankylosis of spinal joint (FB00)</p>
<b>FA34.5</b>	<b>Impingement syndrome of hip</b>
<b>FA34.Y</b>	<b>Other joint derangements</b>
<b>FA35</b>	<b>Wear of articular bearing surface of joint prosthesis</b>
	<p><b><i>Exclusions:</i></b> Mode of injury or harm associated with a surgical or other medical device, implant or graft (PL12)</p>
<b>FA35.0</b>	<b>Wear of articular bearing surface of joint prosthesis of hip</b>
<b>FA35.1</b>	<b>Wear of articular bearing surface of joint prosthesis of knee</b>
<b>FA35.2</b>	<b>Wear of articular bearing surface of joint prosthesis of other joint</b>
<b>FA35.Z</b>	<b>Wear of articular bearing surface of joint prosthesis of unspecified joint</b>
<b>FA36</b>	<b>Effusion of joint</b>
	Increased intra-articular fluid secondary to trauma and/or other acquired conditions not detailed in other codes.
	<p><b><i>Inclusions:</i></b> hydrarthrosis <b><i>Exclusions:</i></b> hydrarthrosis of yaws (1C1D.2)</p>
<b>FA36.0</b>	<b>Effusion of joint containing blood</b>
	<p><b><i>Inclusions:</i></b> haemarthrosis <b><i>Exclusions:</i></b> Dislocation or strain or sprain of unspecified body region (ND56.3)</p>
<b>FA36.Y</b>	<b>Other specified effusion of joint</b>
<b>FA36.Z</b>	<b>Effusion of joint, unspecified</b>

<b>FA37</b>	<b>Certain joint disorders, not elsewhere classified</b>
	<p><b>Exclusions:</b> calcification of: tendon (FB40.3)            difficulty in walking (MB44.2)            abnormality of gait and mobility (MB44)            Acquired deformities of fingers or toes (FA30)            Other acquired deformities of limbs (FA31)</p>
	<p><b>Coded Elsewhere:</b> Pain in joint (ME82)            Stiffness of joint (ME85)</p>
<b>FA37.0</b>	<b>Osteophyte</b>
<b>FA37.Y</b>	<b>Other specified certain joint disorders, not elsewhere classified</b>
<b>FA37.Z</b>	<b>Certain joint disorders, not elsewhere classified, unspecified</b>
<b>FA38</b>	<b>Arthropathy in diseases classified elsewhere</b>
	<p><b>Coding Note:</b> Code also the causing condition</p>
	<p><b>Exclusions:</b> arthropathy in: haematological disorders (Chapter 03)            neuropathic spondylopathy (FB00-FB0Z)            psoriatic and enteropathic arthropathies juvenile (FA24.2)</p>
<b>FA38.0</b>	<b>Diabetic arthropathy</b>
	<p><b>Coding Note:</b> Code also the causing condition</p>
	<p><b>Exclusions:</b> Diabetic Charcot arthropathy (FA38.10)            Diabetic cheiroarthropathy (EE40-EE7Y)</p>
<b>FA38.1</b>	<b>Neuropathic arthropathy</b>
	<p>Neuropathic arthropathy is a progressive destructive arthritis associated with loss of pain sensation, proprioception, or both. Normal muscular reflexes that modulate joint movement are decreased. Without these protective mechanisms, joints are subjected to repeated trauma, resulting in progressive cartilage and bone damage. Additional symptoms include skin changes, such as erythema, swelling, hyperpigmentation, or purpura and soft tissue ulcers over the affected area, as well as joint loosening or instability and joint deformities.</p>
	<p><b>Coding Note:</b> Use additional code, if desired, to identify neuropathy.</p>
<b>FA38.10</b>	Diabetic Charcot arthropathy
	<p>Joint damage resulting from diabetic sensory polyneuropathy. This most commonly affects the ankle and foot in patients with longstanding diabetes mellitus.</p>
	<p><b>Coding Note:</b> Always assign an additional code for diabetes mellitus.</p>
<b>FA38.1Y</b>	Other specified neuropathic arthropathy
	<p><b>Coding Note:</b> Use additional code, if desired, to identify neuropathy.</p>
<b>FA38.1Z</b>	Neuropathic arthropathy, unspecified
	<p><b>Coding Note:</b> Use additional code, if desired, to identify neuropathy.</p>

**FA38.2** **Arthropathy in hypersensitivity reactions classified elsewhere**

**Coding Note:** Code also the causing condition

**FA38.3** **Haemophilic arthropathy**

Joint destruction in the knees, shoulders, ankles, elbows, and hips is associated with haemophilia. The condition includes acute hemarthrosis, subacute or chronic arthritis, and end-stage haemophilic arthropathy. Nearly all patients with severe haemophilia A or B and half of patients with moderate disease activity experience hemarthrosis. Symptoms include joint pain, joint swelling, joint fibrosis, development of flexion deformities, and erosion of joint cartilage. Joints most commonly affected are knees, ankles, elbows, shoulders, and hips (in order of frequency). Bleeding into muscle and soft tissue also causes musculoskeletal dysfunction.

**Coding Note:** Code also the causing condition

**FA38.Y** **Other specified arthropathy in diseases classified elsewhere**

**Coding Note:** Code also the causing condition

**FA38.Z** **Unspecified arthropathy in diseases classified elsewhere**

**Coding Note:** Code also the causing condition

**FA3Z** **Unspecified joint disorders and deformities of limbs**

**FA5Y** **Other specified arthropathies**

**FA5Z** **Arthropathies, unspecified**

## Conditions associated with the spine (FA70-FB1Z)

This is a group of conditions in which there is a deviation from or interruption of the normal structure or function of the spine.

**Coded Elsewhere:** Spinal pain (ME84)

Neck syndrome (ME86.C)

## Structural disorders of spine (FA70-FA7Z)

**FA70** **Spinal deformities**

**FA70.0** **Kyphosis**

This is a curving of the spine that causes a bowing or rounding of the back, which leads to a hunchback or slouching posture.

**Exclusions:** Post radiation kyphosis (FC01.2)

**FA70.1** **Scoliosis**

**Coded Elsewhere:** Post radiation scoliosis (FC01.5)

Congenital scoliosis due to congenital bony malformation  
(LB73.25)

<b>FA70.2</b>	<b>Lordosis</b> This is the inward curvature of a portion of the lumbar and cervical vertebral column, excessive curvature is called hyperlordosis.  <b>Coded Elsewhere:</b> Postsurgical lordosis (FC01.4)
<b>FA70.Z</b>	<b>Spinal deformities, unspecified</b>
<b>FA71</b>	<b>Torticollis</b>  <b>Exclusions:</b> Cervical dystonia or spasmotic torticollis (8A02.0) Congenital torticollis (LA62) current injury - see injury of spine by body region (NB50-NB9Z)  torticollis: due to birth injury (KA43.3)
<b>FA72</b>	<b>Disorders of vertebra</b> Changes in the structure of the spine causing damage to vertebrae and surrounding tissue secondary to infection, injury, tumours, infections, bone changes that come with age etc. Spinal diseases often limit movement and cause pain when bone changes put pressure on the spinal cord or nerves.
<b>FA72.0</b>	<b>Ankylosing hyperostosis</b>
<b>FA72.1</b>	<b>Kissing spine</b>
<b>FA72.2</b>	<b>Traumatic spondylopathy</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FA72.3</b>	<b>Fatigue fracture of vertebra</b>
<b>Coding Note:</b>	Code also the causing condition  <b>Inclusions:</b> Stress fracture of vertebra
<b>FA72.4</b>	<b>Collapsed vertebra, not elsewhere classified</b>  <b>Exclusions:</b> collapsed vertebra in osteoporosis (FB00-FB0Z) current injury - see injury of spine by body region (NB50-NB9Z)
<b>FA72.Y</b>	<b>Other specified disorders of vertebra</b>
<b>FA72.Z</b>	<b>Disorders of vertebra, unspecified</b>
<b>FA7Y</b>	<b>Other specified structural disorders of spine</b>
<b>FA7Z</b>	<b>Structural disorders of spine, unspecified</b>

Degenerative condition of spine (FA80-FA8Z)

This is a disease characterised by degenerative changes in the intervertebral disc, vertebral end-plates and spinal joints due to aging or structural change.

<b>FA80</b>	<b>Intervertebral disc degeneration</b>
<b>FA80.0</b>	<b>Intervertebral disc degeneration of cervical spine without prolapsed disc</b> This is a disease characterised by degenerative changes in the intervertebral disc and vertebral end-plates without prolapse of the intervertebral disc. <b>Exclusions:</b> Intervertebral disc degeneration of cervical spine with nervous system involvement (FA80.3)
<b>FA80.1</b>	<b>Intervertebral disc degeneration of cervical spine with prolapsed disc</b> <b>Exclusions:</b> Intervertebral disc degeneration of cervical spine with nervous system involvement (FA80.3)
<b>FA80.2</b>	<b>Intervertebral disc degeneration of cervical spine with bony spur at the vertebra</b> <b>Exclusions:</b> Intervertebral disc degeneration of cervical spine with nervous system involvement (FA80.3)
<b>FA80.3</b>	<b>Intervertebral disc degeneration of cervical spine with nervous system involvement</b>
<b>FA80.4</b>	<b>Intervertebral disc degeneration of thoracic spine without prolapsed disc</b> <b>Exclusions:</b> Intervertebral disc degeneration of thoracic spine with nervous system involvement (FA80.7)
<b>FA80.5</b>	<b>Intervertebral disc degeneration of thoracic spine with prolapsed disc</b> <b>Exclusions:</b> Intervertebral disc degeneration of thoracic spine with nervous system involvement (FA80.7)
<b>FA80.6</b>	<b>Intervertebral disc degeneration of thoracic spine with bony spur at the vertebra</b> <b>Exclusions:</b> Intervertebral disc degeneration of thoracic spine with nervous system involvement (FA80.7)
<b>FA80.7</b>	<b>Intervertebral disc degeneration of thoracic spine with nervous system involvement</b>
<b>FA80.8</b>	<b>Intervertebral disc degeneration of lumbar spine without prolapsed disc</b> <b>Exclusions:</b> Intervertebral disc degeneration of lumbar spine with nervous system involvement (FA80.B)
<b>FA80.9</b>	<b>Intervertebral disc degeneration of lumbar spine with prolapsed disc</b> <b>Exclusions:</b> Intervertebral disc degeneration of lumbar spine with nervous system involvement (FA80.B)
<b>FA80.A</b>	<b>Intervertebral disc degeneration of lumbar spine with bony spur at the vertebra</b> <b>Exclusions:</b> Intervertebral disc degeneration of lumbar spine with nervous system involvement (FA80.B)

**FA80.B** **Intervertebral disc degeneration of lumbar spine with nervous system involvement**

**FA80.Y** **Other specified intervertebral disc degeneration**

**FA80.Z** **Intervertebral disc degeneration, unspecified**

**FA81** **Spondylolysis**

This is a condition characterised by degeneration of a portion of the vertebra, usually in the pars interarticularis (the bone bridge between the superior and inferior facet joints of the lumbar vertebra).

**FA81.0** **Spondylolysis with slippage**

This is a condition characterised by degeneration of a portion of the vertebra, usually in the pars interarticularis (the bone bridge between the superior and inferior facet joints of the lumbar vertebra) with forward displacement of a superior vertebral body over the vertebral body below.

**FA81.1** **Spondylolysis without slippage**

This is a condition characterised by degeneration of a portion of the vertebra, usually in the pars interarticularis (the bone bridge between the superior and inferior facet joints of the lumbar vertebra) without slippage of the vertebrae.

**FA81.Z** **Spondylolysis, unspecified**

**FA82** **Spinal stenosis**

This is a condition characterised by narrowing of the spinal canal.

**FA83** **Ossification of spinal ligaments**

**Coding Note:** Code also the causing condition

**Coded Elsewhere:** Ankylosing hyperostosis (FA72.0)

**FA84** **Spondylolisthesis**

This is a forward displacement of a vertebral body (the anterior or front-facing portion of a vertebra), with a higher position over the vertebral body below.

**Coding Note:** Code also the causing condition

**FA84.0** **Spondylolisthesis with pars defect**

**FA84.1** **Spondylolisthesis without pars defect**

This is a condition characterised by forward displacement of a superior vertebral body over the vertebral body below without a defect in the pars interarticularis.

**FA84.Z** **Spondylolisthesis, unspecified**

**Coding Note:** Code also the causing condition

**FA85** **Spinal endplate defects**

**FA85.0** **Spinal epiphysiolopathy with no determinant**

**FA85.1** **Spinal epiphysiolopathy with determinants**

- FA85.10** Localised central endplate defect
- FA85.11** Multiple anterior endplate defect  
Familial Scheuermann disease is an inherited disorder characterised by kyphotic deformity of the spine that develops in adolescence. The spinal deformity includes irregularities of the vertebral endplates, the presence of Schmorl's nodes, disk-space narrowing, and vertebral wedging.
- FA85.12** Separation of ring apophysis
- FA85.1Y** Other specified spinal epiphysiology with determinants
- FA85.1Z** Spinal epiphysiology with determinants, unspecified
- FA85.Y** **Other specified spinal endplate defects**
- FA85.Z** **Spinal endplate defects, unspecified**
- FA8Y** **Other specified degenerative condition of spine**
- FA8Z** **Degenerative condition of spine, unspecified**

Inflammation of spine (FA90-FA9Z)

- FA90** **Infection of vertebra**  
A condition of the vertebrae, caused by an infection with a bacterial, viral, fungal, or parasitic source. This condition commonly presents with fever, chills, headache, weight loss, or may be asymptomatic. Confirmation is by identification of the infectious agent in a blood sample, or radiographic tests.
- FA90.0** **Infection of vertebra with no determinant**
- FA90.1** **Infection of vertebra with determinants**
- FA90.Y** **Other specified infection of vertebra**
- FA90.Z** **Infection of vertebra, unspecified**
- FA91** **Infection of intervertebral disc**  
A condition of the intervertebral discs, caused by an infection with a bacterial, viral, fungal, or parasitic source. This condition commonly presents with fever, chills, headache, stiffness of the neck, or tingling sensations in the arms or legs. Confirmation is by identification of the infectious agent in a blood sample, or radiographic tests.

**FA92****Inflammatory spondyloarthritis**

Inflammatory spondyloarthritis is a rheumatic disease referring to the group of inflammatory disorders affecting the lower limb, enthesitis, dactylitis, and uveitis. Clinical characteristics include typical patterns of peripheral arthritis (i.e., predominantly of the lower limb and asymmetric), absence of rheumatoid factor, absence of subcutaneous nodules and other extra-articular features of rheumatoid arthritis, overlapping extra-articular features of the group (e.g., anterior uveitis), and significant familial aggregation and association with HLA-B27.

**Exclusions:** Infectious spondyloarthritis (FA13)

**FA92.0****Axial spondyloarthritis**

**Inclusions:** Ankylosing spondylitis

**Exclusions:** Behçet disease (4A62)

**FA92.00**

Spinal enthesitis

**FA92.01**

Sacroiliitis, not elsewhere classified

Inflammation of the sacroiliac joint that may be related to local disease or systemic disease.

**FA92.0Y**

Other specified axial spondyloarthritis

**FA92.0Z**

Axial spondyloarthritis, unspecified

**FA92.1****Peripheral spondyloarthritis**

Experts from the Assessment of SpondyloArthritis international Society (ASAS) developed classification criteria for axSpA and peripheral SpA. These criteria were developed for patients with peripheral manifestations without back pain, arthritis, enthesitis or dactylitis plus SpA features.

**FA92.Y**

Other specified inflammatory spondyloarthritis

**FA92.Z**

Inflammatory spondyloarthritis, unspecified

**FA9Y**

Other specified inflammation of spine

**FA9Z**

Inflammation of spine, unspecified

Spondylopathies (FB00-FB0Z)

**Coded Elsewhere:** Infectious spondyloarthritis (FA13)

Collapsed vertebra, not elsewhere classified (FA72.4)

Nonunion after spinal arthrodesis (FC01.70)

**FB00**

Ankylosis of spinal joint

**FB0Y**

Other specified spondylopathies

**FB0Z**

Spondylopathies, unspecified

<b>FB10</b>	<b>Spinal instabilities</b>
	<b>Exclusions:</b> Spondylolysis (FA81)
<b>FB1Y</b>	<b>Other specified conditions associated with the spine</b>
<b>FB1Z</b>	<b>Conditions associated with the spine, unspecified</b>

## Soft tissue disorders (FB30-FB6Z)

**Coded Elsewhere:** Diabetic radiculoplexoneuropathy (8B94)  
**Exclusions:** Autoimmune neuritis (8E4A.1)

## Disorders of muscles (FB30-FB3Z)

**Exclusions:** Muscular dystrophy (8C70)  
**Coded Elsewhere:** Foreign body granuloma of soft tissue, not elsewhere classified (FB56.0)

<b>FB30</b>	<b>Infectious myositis</b>  Infective myositis is an acute, subacute, or chronic infection of skeletal muscle and may be caused by a wide range of infecting organisms. Immunosuppression, particularly as the result of HIV infection, is an important predisposing factor.
<b>FB31</b>	<b>Calcification or ossification of muscle</b>
<b>FB31.0</b>	<b>Progressive osseous heteroplasia</b>
<b>FB31.1</b>	<b>Fibrodysplasia ossificans progressiva</b>  This is an extremely rare disease of the connective tissue where a mutation of the body's repair mechanism causes fibrous tissue (including muscle, tendon, and ligament) to be ossified when damaged.
<b>FB31.Y</b>	<b>Other specified calcification or ossification of muscle</b>
<b>FB31.Z</b>	<b>Calcification or ossification of muscle, unspecified</b>
<b>FB32</b>	<b>Certain specified disorders of muscle</b>  This is an impairment of health or a condition of abnormal functioning of the muscle that does not fit in another category.  <b>Exclusions:</b> Alcoholic myopathy (8D44.1) Myalgia (FB56.2) Cramp or spasm (MB47.3) Stiff person syndrome (8E4A.0) Primary disorders of muscles (8C70-8C7Z)  <b>Coded Elsewhere:</b> Drug-induced myopathy (8C80) Sarcoid myositis (4B20.Y)

<b>FB32.0</b>	<b>Diastasis of muscle</b> This is a pathological separation or tearing of muscle fibres from other muscle fibres, tendons or fascia
<b>FB32.1</b>	<b>Spontaneous rupture of muscle</b> This is a spontaneous tearing or separation of muscle fibres from other muscle fibres and/or tendons in the absence of trauma.  <b>Exclusions:</b> rupture of tendon (Chapter 22)  traumatic rupture of muscle - see injury of muscle by body region (Chapter 22)
<b>FB32.2</b>	<b>Ischaemic infarction of muscle</b> <b>Exclusions:</b> Volkmann ischaemic contracture (NF0A.6)  traumatic ischaemia of muscle (NF0A.6)  compartment syndrome, traumatic (NF0A.6)
<b>FB32.20</b>	<b>Idiopathic rhabdomyolysis</b> Skeletal muscle breakdown with leakage of muscle contents, frequently accompanied by myoglobinuria, occurring in both adult and paediatric populations with no identifiable cause. The attacks are often recurrent. Renal failure due to tubular necrosis is a severe complication.  <b>Exclusions:</b> Myasthenia gravis or certain specified neuromuscular junction disorders (8C60-8C6Z)  Secondary myopathies (8C80-8C8Z)
<b>FB32.2Y</b>	Other specified ischaemic infarction of muscle
<b>FB32.2Z</b>	Ischaemic infarction of muscle, unspecified
<b>FB32.3</b>	<b>Immobility syndrome</b>
<b>FB32.4</b>	<b>Contracture of muscle</b> <b>Exclusions:</b> Contracture of joint (FA34.3)
<b>FB32.5</b>	<b>Muscle strain or sprain</b> <b>Exclusions:</b> current injury - see injury of muscle by body region (Chapter 22)
<b>FB32.Y</b>	<b>Other specified disorders of muscles</b>
<b>FB33</b>	<b>Secondary disorders of muscle</b>
<b>Coding Note:</b>	Code also the causing condition  <b>Exclusions:</b> myopathy in: metabolic diseases (8C80-8C8Z)
<b>FB3Z</b>	<b>Disorders of muscles, unspecified</b>

Disorders of synovium or tendon (FB40-FB4Z)

This is a group of disorders which affect the synovial joint lining (synovium) and also tendons.

**FB40**

**Tenosynovitis**

**Exclusions:** soft tissue disorders related to use, overuse and pressure (FB50.1)

current injury - see injury of ligament or tendon by body region (Chapter 22)

**FB40.0** **Infectious tenosynovitis**

**FB40.1** **Plantar fasciitis**

**FB40.2** **Posterior tibial tendonitis**

**FB40.3** **Calcific tendinitis**

This is a disorder characterised by deposits of hydroxyapatite in any tendon of the body causing inflammation and pain.

**FB40.4** **Trigger finger**

This is a common disorder characterised by catching, snapping or locking of the involved finger flexor tendon, associated with dysfunction and pain.

**Inclusions:** Nodular tendinous disease

**FB40.5** **Radial styloid tenosynovitis**

Inflammation of the flexor and/or extensor tendon synovial sheaths in the hand and wrist that control movement of the thumb.

**FB40.Y** **Other specified tenosynovitis**

**FB40.Z** **Tenosynovitis, unspecified**

**FB41**

**Spontaneous rupture of synovium or tendon**

This is a spontaneous rupture to a fluid-filled sac containing viscous fluid which normally acts to decrease friction and also provides a cushion between bones and tendons and/or muscles around a joint.

**Coding Note:** Includes rupture that occurs when a normal force is applied to tissues that are inferred to have less than normal strength.

**Exclusions:** rupture where an abnormal force is applied to normal tissue - see injury of tendon by body region (Chapter 22)

rotator cuff syndrome (FB53.1)

**FB41.0** **Spontaneous rupture of popliteal cyst**

This is a rupture of the semimembranous or more rarely some other synovial bursa, or fluid filled sac, found behind the knee joint.

<b>FB41.1</b>	<b>Spontaneous rupture of synovium</b>
	This is a rupture to a fluid-filled sac containing viscous fluid which normally acts to decrease friction and also provides a cushion between bones and tendons and/or muscles around a joint.
	<b>Exclusions:</b> Spontaneous rupture of popliteal cyst (FB41.0)
<b>FB41.2</b>	<b>Spontaneous rupture of tendon</b>
<b>FB41.Y</b>	<b>Other specified spontaneous rupture of synovium or tendon</b>
<b>Coding Note:</b>	Includes rupture that occurs when a normal force is applied to tissues that are inferred to have less than normal strength.
<b>FB41.Z</b>	<b>Spontaneous rupture of synovium or tendon, unspecified</b>
<b>Coding Note:</b>	Includes rupture that occurs when a normal force is applied to tissues that are inferred to have less than normal strength.
<b>FB42</b>	<b>Certain specified disorders of synovium or tendon</b>
	<b>Exclusions:</b> Palmar fascial fibromatosis (FB51.0) tendinitis NOS (FB55) xanthomatosis localized to tendons (5C80.2)
<b>FB42.0</b>	<b>Acquired short Achilles tendon</b>
<b>FB42.1</b>	<b>Contracture of tendon sheath</b>
<b>FB42.2</b>	<b>Ganglion</b> This is a nodular tumour-like lesions or mucoid flesh, arising from tendon sheaths, ligaments, or joint capsule, especially of the hands, wrists, or feet. They are not true cysts as they lack epithelial wall. They are distinguished from synovial cysts by the lack of communication with a joint cavity or the synovial membrane.  <b>Inclusions:</b> Ganglion of tendon sheath <b>Exclusions:</b> ganglion in yaws (1C1D.1)
<b>FB42.3</b>	<b>Synovial hypertrophy, not elsewhere classified</b> This is an increase in synovial lining thickness which is not elsewhere classified.
<b>FB43</b>	<b>Secondary disorders of synovium or tendon</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FB4Y</b>	<b>Other specified disorders of synovium or tendon</b>
<b>FB4Z</b>	<b>Disorders of synovium or tendon, unspecified</b>

## Miscellaneous specified soft tissue disorders (FB50-FB56.6)

This is a group of other disorders, which are not defined elsewhere, affecting tissues that connect, support, or surround other structures and organs of the body, not being bone.

### FB50

#### **Bursitis**

This is a disorder of inflammation of one or more bursae (small sacs) of synovial fluid in the body which usually results in pain.

**Exclusions:** Tibial collateral bursitis (FB54.2)

### FB50.0

#### **Infectious bursitis**

This is a disorder of inflammation of one or more bursae (small sacs) of synovial fluid in the body which usually results in pain and is caused by an infectious agent.

**Exclusions:** Tuberculous bursitis (1B12.4)

### FB50.1

#### **Bursitis related to use, overuse or pressure**

This is a disorder of inflammation of one or more bursae (small sacs) of synovial fluid in the body which usually results in pain and is caused by repetitive use, overuse and pressure irritation.

### FB50.2

#### **Synovial cyst of popliteal space**

This is a benign swelling of the semimembranous or more rarely some other synovial bursa found behind the knee joint.

**Exclusions:** Spontaneous rupture of popliteal cyst (FB41.0)

### FB50.3

#### **Calcium deposit in bursa**

**Exclusions:** Calcific tendinitis of shoulder (FB40.3)

### FB50.Y

#### **Other specified bursitis**

### FB50.Z

#### **Bursitis, unspecified**

### FB51

#### **Fibroblastic disorders**

### FB51.0

#### **Palmar fascial fibromatosis**

This is a fixed flexion contracture of the hand where the fingers bend towards the palm and cannot be fully extended (straightened).

**Inclusions:** Dupuytren disease of palm

### FB51.1

#### **Knuckle pads**

These are benign, asymptomatic, well-circumscribed, smooth, firm, skin-coloured papules, nodules, or plaques, located in the skin over the dorsal aspects of the metacarpophalangeal (MCP) and interphalangeal (IP) joints.

### FB51.2

#### **Fasciitis and fibromatosis**

### FB51.3

#### **Fibroblastic rheumatism**

<b>FB51.4</b>	<b>Retroperitoneal fibrosis</b> Retroperitoneal fibrosis (RPF) is a disease characterised by the development of extensive proliferation of fibrous tissue in the retroperitoneum, resulting in entrapment and obstruction of retroperitoneal structures, notably the ureters. RPF can be classified as primary (idiopathic) meaning that the cause is not known or secondary. But its association with various immune-related conditions and response to immunosuppression have led to speculation regarding an autoimmune aetiology of idiopathic RPF. One-third of the cases are secondary to malignancy, medication, trauma, or certain infections.
<b>FB51.40</b>	Primary retroperitoneal fibrosis This is the commonest form of retroperitoneal fibrosis. By definition, no associated trigger (e.g. drugs or malignancy) can be determined, although atherosclerosis of the abdominal aorta is often associated. It has been postulated that such atherosclerosis may be of aetiological significance in some cases.
<b>FB51.4Y</b>	Other specified retroperitoneal fibrosis
<b>FB51.4Z</b>	Retroperitoneal fibrosis, unspecified
<b>FB51.Y</b>	<b>Other specified fibroblastic disorders</b>
<b>FB51.Z</b>	<b>Fibroblastic disorders, unspecified</b>
<b>FB52</b>	<b>Soft tissue disorders in diseases classified elsewhere</b> This is a group of disorders affecting tissues that connect, support, or surround other structures and organs of the body, not being bone and occur in diseases classified elsewhere.
<b>Coding Note:</b>	Code also the causing condition
<b>FB53</b>	<b>Shoulder lesions</b> This is a group of disorders which are normally characterised with shoulder pain and reduced range of motion of the shoulder girdle.  <b>Exclusions:</b> Rotator cuff tendonitis (FB40.3) Shoulder-hand syndrome (MG30.04)
<b>FB53.0</b>	<b>Adhesive capsulitis of shoulder</b> This is a condition characterised by spontaneous onset of shoulder pain accompanied by progressive loss of active and passive ranges of motion.  <b>Inclusions:</b> Frozen shoulder
<b>FB53.1</b>	<b>Rotator cuff syndrome</b> <b>Exclusions:</b> Rotator cuff tendonitis (FB40.3)
<b>FB53.2</b>	<b>Impingement syndrome of shoulder</b> This is a clinical syndrome which occurs when the tendons of the rotator cuff muscles become irritated and inflamed as they pass through the subacromial space, the passage beneath the acromion. This can result in pain, weakness and loss of movement at the shoulder.

<b>FB53.Y</b>	<b>Other specified shoulder lesions</b>
<b>FB53.Z</b>	<b>Shoulder lesions, unspecified</b>
<b>FB54</b>	<b>Enthesopathies of lower limb</b>
	This is a group of disorders which refer to any abnormality of tendon and ligament insertion points of the leg. Abnormalities include inflammation and calcification.
	<b>Exclusions:</b> Bursitis related to use, overuse or pressure (FB50.1)
<b>FB54.0</b>	<b>Iliac crest spur</b>
	This is a disorder characterised by bony exostosis at iliac muscle origins.
<b>FB54.1</b>	<b>Iliotibial band syndrome</b>
	This is the most common running injury of the lateral side of the knee. It is a non-traumatic overuse injury caused by repeated flexion and extension of the knee that causes irritation in the structures around the knee causing knee pain.
<b>FB54.2</b>	<b>Tibial collateral bursitis</b>
<b>FB54.3</b>	<b>Calcaneal spur</b>
	This is a disorder characterised by a bone outgrowth located on the calcaneus (heel bone).
<b>FB54.4</b>	<b>Metatarsalgia</b>
	This is a condition characterised by pain and inflammation in the ball of your foot or at the metatarsal heads.
	<b>Exclusions:</b> Morton metatarsalgia (8C11.6) Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>FB54.Y</b>	<b>Other specified enthesopathies of lower limb</b>
<b>FB54.Z</b>	<b>Enthesopathies of lower limb, unspecified</b>
<b>FB55</b>	<b>Certain specified enthesopathies</b>
	<b>Exclusions:</b> Bursitis related to use, overuse or pressure (FB50.1) spinal enthesopathy (FA92.00) Osteophyte (FA37.0)
<b>FB55.0</b>	<b>Medial epicondylitis of elbow</b>
	This is a common upper extremity disorder which is characterised by degenerative changes in the musculotendonous region of the medial epicondyle, resulting from repetitive stress of flexion and extension movements of the wrist joint.
<b>FB55.1</b>	<b>Lateral epicondylitis of elbow</b>
	This is a common upper extremity disorder which is characterised by degenerative changes in the musculotendonous region of the lateral epicondyle, resulting from repetitive stress of flexion and extension movements of the wrist joint
	<b>Inclusions:</b> Tennis elbow

<b>FB55.2</b>	<b>Periarthritis of wrist</b> This disorder is characterised by inflammation of tissues around the joints of the wrist.
<b>FB55.Z</b>	<b>Enthesopathies, unspecified</b>
<b>FB56</b>	<b>Specified soft tissue disorders, not elsewhere classified</b> This is a group of other disorders, which are not classified elsewhere, affecting tissues that connect, support, or surround other structures and organs of the body, not being bone.  <b>Exclusions:</b> brachial radiculitis NOS (8B93) lumbosacral radiculitis NOS (8B93) Mononeuropathy (8C10-8C1Z) radiculitis NOS (8B93) Sciatica (ME84.3)
<b>FB56.0</b>	<b>Foreign body granuloma of soft tissue, not elsewhere classified</b>  <b>Exclusions:</b> Foreign body granuloma of skin (EH93.3)
<b>FB56.1</b>	<b>Residual foreign body in soft tissue</b>  <b>Exclusions:</b> Foreign body granuloma of skin (EH93.3) Foreign body granuloma of soft tissue, not elsewhere classified (FB56.0)
<b>FB56.2</b>	<b>Myalgia</b> This is a disorder characterised by pain in a muscle or group of muscles.  <b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>FB56.3</b>	<b>Hypertrophy of infrapatellar fat pad</b> This is a hypertrophy of an intracapsular but extrasynovial structure limited by the inferior pole of the patella superiorly, the joint capsule and patellar tendon anteriorly, the proximal tibia and deep infrapatellar bursa inferiorly, and the synovium-lined joint cavity posteriorly.
<b>FB56.4</b>	<b>Pain in limb</b>  <b>Exclusions:</b> Chronic primary limb pain (MG30.02) Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>FB56.6</b>	<b>Other specified soft tissue disorders</b>
<b>FB6Z</b>	<b>Soft tissue disorders, unspecified</b>

## Osteopathies or chondropathies (FB80-FB8Z)

**Coded Elsewhere:** Bone diseases with increased bone density (LD24.1)

- Bone diseases with disorganised development of skeletal components (LD24.2)
- Congenital vascular bone syndromes (LD26.6)
- Tuberculosis of bones or joints (1B12.40)
- Malignant otitis externa (AA02)

**FB80**

### **Certain specified disorders of bone density or structure**

**Exclusions:** Osteopoikilosis (LD24.11)  
Osteopetrosis (LD24.10)

**Coded Elsewhere:** Osteogenesis imperfecta (LD24.K0)

**FB80.0**

#### **Fibrous dysplasia of bone**

Fibrous dysplasia of bone is a congenital non-hereditary benign bone disease, where normal bone is replaced by a fibrous-like tissue with immature osteogenesis. Bone lesions are mono- or polyostotic and may be associated with bone pain and fragility, leading to fractures. In some patients or bone sites, they are hypertrophic, and responsible for neurological complications.

**FB80.1**

#### **Skeletal fluorosis**

**FB80.2**

#### **Osteitis condensans**

**FB80.3**

#### **Hyperostosis of skull**

**FB80.4**

#### **Osteosclerosis**

**FB80.5**

#### **Solitary bone cyst**

A solitary bone cyst is a benign non-epithelial bone cavity that is asymptomatic and that is found most commonly in the second decade of life by chance. The long bones are most often affected, but cases involving the jaw bone have been reported.

**Exclusions:** solitary cyst of jaw (DA05)

**FB80.6**

#### **Aneurysmal bone cyst**

**Exclusions:** aneurysmal cyst of jaw (DA05)

**FB80.7**

#### **Malunion of fracture**

**FB80.8**

#### **Nonunion of fracture**

**Exclusions:** Pseudarthrosis after fusion or arthrodesis (FC01.0)

**FB80.9**

#### **Delayed union of fracture**

**FB80.A**

#### **Stress fracture, not elsewhere classified**

**Exclusions:** stress fracture of vertebra (FA72.3)

**FB80.B**

#### **Pathological fracture**

**Exclusions:** Collapsed vertebra, not elsewhere classified (FA72.4)

<b>FB80.Y</b>	<b>Other specified disorders of bone density and structure</b>
<b>FB80.Z</b>	<b>Disorder of bone density and structure, unspecified</b>
<b>FB81</b>	<b>Osteonecrosis</b>
	Osteonecrosis is the medical term for death of bone tissue that occurs when the supply of blood to the bone is cut off for some reason. Doctors sometimes refer to the condition as avascular necrosis, aseptic necrosis or ischemic bone necrosis
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> avascular necrosis of bone
<b>FB81.0</b>	<b>Idiopathic aseptic osteonecrosis</b>
<b>FB81.1</b>	<b>Osteonecrosis due to dialysis</b>
<b>FB81.2</b>	<b>Drug-induced osteonecrosis</b> Alteration of the normal structure of orofacial tissues resulting from medicinal substances acting locally or systemically.
	<b>Inclusions:</b> Osteonecrosis due to chemical burn of oral mucosa
<b>FB81.3</b>	<b>Osteonecrosis due to trauma</b>
<b>FB81.4</b>	<b>Osteonecrosis due to haemoglobinopathy</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FB81.5</b>	<b>Osteonecrosis due to ionizing radiation</b> Necrosis of bone attributable to ionizing radiation, most commonly seen affecting the mandible following radical radiotherapy for the treatment of head and neck cancer or the chest wall following radiotherapy for breast cancer.
	<b>Coded Elsewhere:</b> Osteoradionecrosis of jaw (DA06.0)
<b>FB81.6</b>	<b>Alcohol induced osteonecrosis</b>
<b>FB81.Y</b>	<b>Other specified osteonecrosis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FB81.Z</b>	<b>Osteonecrosis, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FB82</b>	<b>Chondropathies</b>
	<b>Exclusions:</b> postprocedural chondropathies (FC01)
	<b>Coded Elsewhere:</b> Chondrodysplasia punctata (LD24.04)
<b>FB82.0</b>	<b>Chondromalacia</b>
<b>FB82.00</b>	Chondromalacia patellae A disease of the knee joint, caused by damage to the cartilage under the patella. This disease is characterised by pain in the front of the knee that worsens when walking up or down stairs. This disease may be associated with injury or overuse.
<b>FB82.0Y</b>	Other specified chondromalacia

<b>FB82.0Z</b>	Chondromalacia, unspecified
<b>FB82.1</b>	<p><b>Osteochondrosis or osteochondritis dissecans</b></p> <p>Note: Osteochondroses are typically referred to by eponyms. The most common eponyms are indexed to osteochondrosis with specification identified by the site and time in life.</p> <p><b>Coded Elsewhere:</b> Medial condensing osteitis of clavicle (LB72.Y) Idiopathic aseptic osteonecrosis of carpal lunate (FB81.0)</p>
<b>FB82.2</b>	<b>Slipped upper femoral epiphysis</b>
<b>FB82.3</b>	<p><b>Relapsing polychondritis</b></p> <p>Relapsing polychondritis is a multisystem inflammatory disease of unknown aetiology affecting the cartilage. The disease is characterised by intermittent or fluctuant inflammatory manifestations due to inflammation of the cartilaginous structures, resulting in tissue damage and tissue destruction. Chondritis of auricular, nasal, tracheal cartilage predominates in this disease, suggesting response to tissue-specific antigens such as collagen II and cartilage matrix protein (matrillin-1). In about one third of patients, RP is associated with vasculitis (from isolated cutaneous leucocytoclastic vasculitis to systemic polyangiitis) and autoimmune rheumatic diseases (mainly rheumatoid arthritis and systemic lupus erythematosus). Haematological malignant diseases, gastrointestinal disorders and endocrine diseases may also occur. Functional and anatomical evaluation for upper and lower airway disease is essential in evaluation and management of the disease.</p>
<b>FB82.Y</b>	<b>Other specified chondropathies</b>
<b>FB82.Z</b>	<b>Chondropathies, unspecified</b>
<b>FB83</b>	<p><b>Low bone mass disorders</b></p> <p><b>Coded Elsewhere:</b> Genetic bone diseases with decreased bone density (LD24.K)</p>
<b>FB83.0</b>	<b>Osteopenia</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FB83.00</b>	Premenopausal idiopathic osteopenia
<b>FB83.01</b>	Postmenopausal osteopenia
<b>FB83.02</b>	Senile osteopenia
<b>Coding Note:</b>	Code also the causing condition
<b>FB83.03</b>	Osteopenia of disuse
<b>FB83.04</b>	Drug-induced osteopenia
<b>FB83.0Y</b>	Other specified osteopenia
<b>Coding Note:</b>	Code also the causing condition
<b>FB83.0Z</b>	Osteopenia, unspecified
<b>Coding Note:</b>	Code also the causing condition

<b>FB83.1</b>	<b>Osteoporosis</b>  <b>Coded Elsewhere:</b> Postoophorectomy osteoporosis (FC01.9) Osteoporosis in multiple myelomatosis (2A83.1)
<b>FB83.10</b>	Premenopausal idiopathic osteoporosis
<b>FB83.11</b>	Postmenopausal osteoporosis  Susceptibility to bone fracture secondary to a systemic decrease in bone mass and micro-architectural deterioration of bone tissue related to hormonal changes associated with menopause
<b>FB83.12</b>	Osteoporosis of disuse
<b>FB83.13</b>	Drug-induced osteoporosis
<b>FB83.14</b>	Osteoporosis due to malabsorption  <b>Coded Elsewhere:</b> Osteoporosis in atypical cystic fibrosis (CA25.1) Osteoporosis in classical cystic fibrosis (CA25.0) Osteoporosis in unspecified cystic fibrosis (CA25.Z)
<b>FB83.1Y</b>	Other specified osteoporosis
<b>FB83.1Z</b>	Osteoporosis, unspecified
<b>FB83.2</b>	<b>Adult osteomalacia</b>  A disease characterised by defects in bone mineralization and bone softening secondary to vitamin D deficiency.  <b>Exclusions:</b> renal osteodystrophy (GB61) osteomalacia: vitamin-D-resistant (5C64.3) infantile and juvenile osteomalacia (5B57.0) rickets (active) vitamin-D-resistant (5C64.3)  <b>Coded Elsewhere:</b> Puerperal osteomalacia (JB44.6)
<b>FB83.20</b>	Aluminium bone disease
<b>Coding Note:</b>	Code also the causing condition
<b>FB83.21</b>	Adult osteomalacia due to malnutrition  <b>Coding Note:</b> Code also the causing condition
<b>FB83.22</b>	Drug-induced adult osteomalacia
<b>FB83.2Y</b>	Other specified adult osteomalacia
<b>FB83.2Z</b>	Adult osteomalacia, unspecified
<b>FB84</b>	<b>Osteomyelitis or osteitis</b>  <b>Exclusions:</b> osteomyelitis jaw (DA06.0) osteomyelitis vertebra (FA90)
<b>FB84.0</b>	<b>Acute haematogenous osteomyelitis</b>

<b>FB84.1</b>	<b>Other acute osteomyelitis</b>
<b>FB84.2</b>	<b>Subacute osteomyelitis</b>
<b>FB84.3</b>	<b>Chronic multifocal osteomyelitis</b>
<b>FB84.4</b>	<b>Chronic osteomyelitis with draining sinus</b>
<b>FB84.5</b>	<b>Other chronic haematogenous osteomyelitis</b>
<b>FB84.Y</b>	<b>Other specified osteomyelitis or osteitis</b>
<b>FB84.Z</b>	<b>Osteomyelitis or osteitis, unspecified</b>

**FB85** **Paget disease of bone**

A disorder characterised by pathologically excessive resorption of bone by multinucleated osteoclasts and abnormal modelling of disorganised, woven bone by osteoblasts with resultant bone vascularization, weakness, enlargement and deformity.

**Inclusions:** Osteitis deformans

<b>FB85.0</b>	<b>Juvenile Paget disease</b>
<b>FB85.1</b>	<b>Paget disease of bone in neoplastic disease</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FB85.Y</b>	<b>Other specified Paget disease of bone</b>
<b>FB85.Z</b>	<b>Paget disease of bone, unspecified</b>

**FB86** **Disorders associated with bone growth**

<b>FB86.0</b>	<b>Epiphyseal arrest</b>
<b>FB86.1</b>	<b>Bone hyperplasias</b>
	<b>Coded Elsewhere:</b> Ankylosing hyperostosis (FA72.0)

<b>FB86.10</b>	Hypertrophic osteoarthropathy
	Hypertrophic osteoarthropathy (HOA) is a syndrome of clubbing of the digits, subperiosteal new bone formation (periostitis) affecting the long bones, and arthritis. The primary hereditary form is associated with mutations in the HPGD gene. The secondary form may be secondary to a number of systemic disorders, most commonly as a paraneoplastic phenomenon related to bronchial carcinoma.

**Exclusions:** Isolated congenital club finger (LB90.5)

<b>FB86.11</b>	Hypertrophy of bone
<b>FB86.1Y</b>	Other specified bone hyperplasias
<b>FB86.1Z</b>	Bone hyperplasias, unspecified
<b>FB86.2</b>	<b>Osteolysis</b>
<b>Coding Note:</b>	Code also the causing condition

<b>FB86.Y</b>	<b>Other specified disorders associated with bone growth</b>
<b>FB86.Z</b>	<b>Disorders associated with bone growth, unspecified</b>
<b>FB8Y</b>	<b>Other specified osteopathies or chondropathies</b>
<b>FB8Z</b>	<b>Osteopathies or chondropathies, unspecified</b>
<b>FC00</b>	<b>Certain specified acquired deformities of musculoskeletal system or connective tissue, not elsewhere classified</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Dentofacial anomalies (DA0E) Spinal deformities (FA70) Structural developmental anomalies of the skeleton (LB70-LB9Z)
	acquired deformities of limbs (FA30-FA3Z) acquired absence of limbs (QF00) Postprocedural disorders of the musculoskeletal system (FC01) Acquired absence of organs (QF01)
<b>FC00.0</b>	<b>Acquired deformity of nose</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Deviated nasal septum (CA0D)
<b>FC00.1</b>	<b>Acquired deformity of neck</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FC00.2</b>	<b>Acquired deformity of chest or rib</b>
<b>Coding Note:</b>	Code also the causing condition
<b>FC00.3</b>	<b>Acquired deformity of pelvis</b>
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Maternal care for known or suspected disproportion (JA83) Obstructed labour due to maternal pelvic abnormality (JB05) Obstructed labour due to deformed pelvis (JB05.0)
<b>FC00.4</b>	<b>Acquired deformity of trunk</b>
<b>FC00.Y</b>	<b>Acquired deformities of musculoskeletal system and connective tissue, not classified elsewhere, other specified sites</b>
<b>Coding Note:</b>	Code also the causing condition

**FC01**

**Postprocedural disorders of the musculoskeletal system**

- Exclusions:**
- Osteoporosis (FB83.1)
  - Presence of devices other than cardiac or vascular implants (QB51)
  - Arthropathy following intestinal bypass (FA11.0)
- Coded Elsewhere:**
- Osteonecrosis due to ionizing radiation (FB81.5)
  - Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)
  - Wear of articular bearing surface of joint prosthesis (FA35)
  - Post radiation lordosis (FA70.2)

**FC01.0**

**Pseudarthrosis after fusion or arthrodesis**

**FC01.1**

**Postlaminectomy syndrome, not elsewhere classified**

**FC01.2**

**Post radiation kyphosis**

**FC01.3**

**Postlaminectomy kyphosis**

**FC01.4**

**Postsurgical lordosis**

**FC01.5**

**Post radiation scoliosis**

**FC01.6**

**Fracture of bone following insertion of orthopaedic implant, joint prosthesis, or bone plate**

**FC01.7**

**Nonunion after arthrodesis**

**FC01.70**

**Nonunion after spinal arthrodesis**

- Inclusions:**
- nonunion after spinal fusion

**FC01.7Y**

**Nonunion after arthrodesis of other sites**

**FC01.8**

**Postsurgical osteolysis**

**FC01.9**

**Postoophorectomy osteoporosis**

osteoporosis occurring after oophorectomy

**FC01.A**

**Postsurgical malabsorption osteoporosis**

**FC0Y**

**Other specified diseases of the musculoskeletal system or connective tissue**

**FC0Z**

**Diseases of the musculoskeletal system or connective tissue, unspecified**

# CHAPTER 16

---

## Diseases of the genitourinary system

This chapter has 119 four-character categories.

Code range starts with GA00

Any disease characterised by pathological changes to the genitourinary system.

**Exclusions:** Injury, poisoning or certain other consequences of external causes (Chapter 22)

Endocrine, nutritional or metabolic diseases (Chapter 05)

Complications of pregnancy, childbirth and the puerperium (Chapter 18)

Certain infectious or parasitic diseases (Chapter 01)

**Coded Elsewhere:** Contact with health services for reasons associated with reproduction (QA20-QA4Z)

Predominantly sexually transmitted infections (1A60-1A9Z)

Symptoms, signs or clinical findings of the genitourinary system (MF30-MG0Y)

Female gonococcal pelvic inflammatory disease (1A71)

This chapter contains the following top level blocks:

- Diseases of the female genital system
- Diseases of the male genital system
- Disorders of breast
- Diseases of the urinary system
- Other conditions of the genitourinary system
- Postprocedural disorders of genitourinary system

## Diseases of the female genital system (GA00-GA6Z)

**Coded Elsewhere:** Certain specified disorders of genital development

Neoplasms of the female genital organs

Symptoms, signs or clinical findings involving the female genital system (MF30-MF3Y)

### Inflammatory disorders of the female genital tract (GA00-GA0Z)

**Exclusions:** those complicating: abortion or ectopic or molar pregnancy (JA00-JA0Z)

Infections of genitourinary tract in pregnancy (JA62)

Other infection during labour (JB0D)

Infections in the puerperium (JB40)

**Coded Elsewhere:** Endometriosis (GA10)

Adenomyosis (GA11)

### GA00

#### Vulvitis

**Exclusions:** senile (atrophic) vaginitis (GA30.2)

**Coded Elsewhere:** Irritant contact dermatitis of vulva (EK02.13)

Genital warts of vulva (1A95.1)

Tuberculous ulceration of vulva (1B12.5)

### GA00.0

#### Acute vulvitis

**Exclusions:** Streptococcal cellulitis of skin (1B70.1)

Staphylococcal cellulitis of skin (1B70.2)

### GA00.1

#### Subacute, chronic or recurrent vulvitis

### GA00.2

#### Abscess of vulva

A condition of the vulva, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by a focal accumulation of purulent material in the vulva. This condition may present with pain and swelling of the vulva, pain on sexual intercourse, or fever. Confirmation is by gynaecological examination.

### GA00.3

#### Genital ulcer of vulva

Ulceration of the vulva of unknown or uncertain aetiology but where a sexually transmitted infection, especially Herpes simplex, primary syphilis or chancroid, is suspected. This is a provisional diagnosis which should be amended once the cause of the ulceration is known.

**Coding Note:**

Code also the causing condition

### GA00.4

#### Vulvovaginal ulceration and inflammation

**Coded Elsewhere:** Vulvovaginal candidosis (1F23.10)

### GA00.40

Vulvovaginal ulceration

### GA00.4Y

Other specified vulvovaginal ulceration and inflammation

<b>GA00.4Z</b>	Vulvovaginal ulceration and inflammation, unspecified
<b>GA01</b>	<p><b>Inflammatory disorders of the uterus, except cervix</b></p> <p>A spectrum of inflammations involving the Uterus and the supporting tissues. It is usually caused by an ascending infection of organisms from the endocervix. Such inflammation can lead to functional impairment and infertility.</p>
<b>GA01.0</b>	<b>Acute inflammatory disease of uterus</b>
<b>GA01.00</b>	Acute endometritis
	A disease of the endometrium, caused by an infection with a bacterial or viral source. This condition is characterised by fever, lower abdominal pain, abnormal vaginal bleeding, or vaginal discharge. Confirmation is by a pelvic exam and identification of the bacteria or virus from a cervical swab, endometrial biopsy, or laparoscopy.
	<b>Coded Elsewhere:</b> Tuberculous endometritis (1B12.5)
<b>GA01.01</b>	Acute inflammatory disease of uterus with pyometra
<b>GA01.0Z</b>	Acute inflammatory disease of uterus, unspecified
<b>GA01.1</b>	<b>Chronic inflammatory disease of uterus</b>
	A condition characterised by inflammation of the uterus which lasts for more than 3 months.
<b>GA01.10</b>	Chronic endometritis
	<b>Coded Elsewhere:</b> Tuberculous endometritis (1B12.5)
<b>GA01.11</b>	Chronic inflammatory disease of uterus with pyometra
<b>GA01.1Z</b>	Chronic inflammatory disease of uterus, unspecified
<b>GA01.Y</b>	<b>Other specified inflammatory disorders of the uterus, except cervix</b>
<b>GA01.Z</b>	<b>Inflammatory disorders of the uterus, except cervix, unspecified</b>
<b>GA02</b>	<p><b>Vaginitis</b></p> <p><b>Coded Elsewhere:</b> Vulvovaginal ulceration and inflammation (GA00.4)</p> <p>Genital warts of vagina (1A95.1)</p>
<b>GA02.0</b>	<b>Acute vaginitis</b>
<b>Coding Note:</b>	Code also the causing condition
<b>GA02.1</b>	<b>Inflammatory vaginitis</b>
	Clinical syndrome characterised by diffuse exudative vaginitis, epithelial cell exfoliation and a profuse purulent vaginal discharge, associated with vulvovaginal burning or irritation and dyspareunia. Signs may include vulvovaginal erythema and ecchymotic spots.
<b>Coding Note:</b>	Code also the causing condition

- GA02.2 Subacute or chronic vaginitis**  
Chronic vulvovaginal candidiasis, marked by chronic irritative symptoms of vestibule, vulva and vagina, with burning replacing itching as the prominent symptom. Differential diagnosis with chronic atopic dermatitis or atrophic vulvovaginitis.
- GA02.3 Genital ulcer disease of vagina**
- GA02.Z Vaginitis, unspecified**
- GA03 Diseases of Bartholin gland**  
Any disease characterised by inflammation of the Bartholin gland.
- GA03.0 Abscess of Bartholin gland**  
A condition of the Bartholin gland, caused by an infection with a bacterial, viral, or fungal source. This condition is characterised by focal accumulation of purulent material in the Bartholin gland, located on either side of the vaginal opening. This condition may present with swelling on either side of the vagina, pain on sexual intercourse, or fever. Confirmation is by gynaecological examination.
- GA03.1 Cyst of Bartholin gland**  
A condition of the vagina, caused by growth of a flap of skin, occlusion of the Bartholin duct due to mucus, or infection. This condition is characterised by the accumulation of mucus or clear fluid in a closed sac-like structure that forms on (or from) one of the Bartholin glands or its ducts. This condition is commonly asymptomatic, but may become painful if the cyst becomes enlarged or infected.
- GA03.Y Other specified diseases of Bartholin gland**
- GA03.Z Diseases of Bartholin gland, unspecified**
- GA04 Cervicitis**  
*Coded Elsewhere:* Tuberculosis of cervix uteri (1B12.5)
- GA05 Female pelvic inflammatory diseases**  
*Coded Elsewhere:* Postprocedural acute female pelvic inflammatory disease (GC78)  
Secondary syphilitic female pelvic inflammatory disease (1A61.4)
- GA05.0 Acute female pelvic inflammatory disease**  
*Coded Elsewhere:* Tuberculous female pelvic inflammatory disease (1B12.5)
- GA05.1 Chronic pelvic inflammatory disease**  
*Coded Elsewhere:* Chlamydial female pelvic inflammatory disease (1A81.1)
- GA05.2 Female pelvic peritonitis, unspecified**  
This is an inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs, unspecified.

<b>GA05.3</b>	<b>Tuboovarian abscess</b> End-stage process of acute pelvic inflammatory disease (PID), marked by pelvic mass palpable during bimanual examination. Usually bilateral but can be unilateral.
<b>GA05.Y</b>	<b>Other specified female pelvic inflammatory diseases</b>
<b>GA05.Z</b>	<b>Female pelvic inflammatory diseases, unspecified</b>
<b>GA06</b>	<b>Pelvic peritoneal adhesions of unknown or combined origin</b> A condition characterised by fibrous bands of scar tissue and abnormal connection between pelvic organs or tissues. This condition may also present with pelvic pain or bowel obstruction.
<b>GA07</b>	<b>Salpingitis and oophoritis</b> Inflammation of the fallopian tube, characterised by a typical inflammatory response (redness and oedema). It is usually manifested by lower abdominal pain and tenderness, fever, increased pulse rate, hypermenorrhoea and/or metrorrhagia. The disorder may resolve or result in fibrosis, hydrosalpinx, pyosalpinx, or cyst formation.  <i>Inclusions:</i> salpingo-oophoritis tubo-ovarian inflammatory disease  <i>Exclusions:</i> Salpingitis isthmica nodosa (GA17.4)  <i>Coded Elsewhere:</i> Tuberculous oophoritis or salpingitis (1B12.5) Chlamydial salpingitis (1A81.1)
<b>GA07.0</b>	<b>Acute salpingitis and oophoritis</b> <i>Coded Elsewhere:</i> Acute gonococcal salpingitis (1A71)
<b>GA07.1</b>	<b>Chronic salpingitis and oophoritis</b> <i>Coded Elsewhere:</i> Chronic gonococcal salpingitis (1A71)
<b>GA07.Z</b>	<b>Salpingitis and oophoritis, unspecified</b>
<b>GA0Z</b>	<b>Inflammatory disorders of the female genital tract, unspecified</b>
<b>GA10</b>	<b>Endometriosis</b> A condition of the uterus that is frequently idiopathic. This condition is characterised by ectopic growth and function of endometrial tissue outside the uterine cavity. This condition may be associated with remaining vestigial tissue from the wolffian or mullerian duct, or fragments endometrium refluxed backward into the peritoneal cavity during menstruation. This condition may also present with dysmenorrhoea, dyspareunia, nonmenstrual pelvic pain, infertility, alteration of menses, or may be asymptomatic. Confirmation is by laparoscopy and histological identification of ectopic fragments.  <i>Coded Elsewhere:</i> Salpingitis isthmica nodosa (GA17.4)
<b>GA10.B</b>	<b>Endometriosis of the reproductive system</b> <i>Exclusions:</i> Endometriosis of the uterus (GA11)
<b>GA10.B0</b>	Endometriosis of the uterosacral ligaments

<b>GA10.B1</b>	Endometriosis of the pelvic side wall
<b>GA10.B2</b>	Endometriosis of rectovaginal septum or vagina
<b>GA10.B3</b>	Endometriosis of fallopian tube
<b>GA10.B4</b>	Superficial ovarian endometriosis Endometriosis on the ovarian cortex, containing typical or subtle lesions.
<b>GA10.B5</b>	Deep ovarian endometriosis Ovarian endometriosis cyst containing dark stained blood (chocolate fluid) and lined by a pseudocyst wall covered by ectopic endometrium. This cyst can be subdivided according to its size in the following categories: less than 1 cm, 1-3 cm, > 3 cm
<b>GA10.BY</b>	Endometriosis of other sites of the reproductive system
<b>GA10.BZ</b>	Endometriosis of unspecified site of reproductive system
<b>GA10.C</b>	<b>Endometriosis of the digestive system</b>
<b>GA10.C0</b>	Endometriosis of the gallbladder
<b>GA10.C1</b>	Endometriosis of intestine Endometriosis situated inside the bowel wall at or below the subserosal level, excluding superficial serosal lesions that are still classified as peritoneal endometriosis. Mostly affecting rectosigmoid area, but can be found also in other parts of the bowel system.
<b>GA10.C2</b>	Endometriosis of pelvic peritoneum A condition that is frequently idiopathic. This condition is characterised by ectopic growth and function of endometrial tissue extending 5 millimetres or less under the visceral or parietal pelvic peritoneal surface and appearing as black-brown or light red-orange lesions. This condition may be associated with remaining vestigial tissue from the wolffian or mullerian duct, or fragments endometrium refluxed backward into the peritoneal cavity during menstruation. This condition may also present with dysmenorrhoea, dyspareunia, nonmenstrual pelvic pain, infertility, alteration of menses, or may be asymptomatic. Confirmation is by laparoscopy and histological identification of ectopic fragments.
<b>GA10.C3</b>	Peritoneal pockets due to endometriosis Peritoneal pockets usually observed in the cul-de-sac, may occur in other parts of the female pelvis, also known as Allen-Masters defect. Can be asymptomatic or harbour microscopic endometriosis.
<b>GA10.CY</b>	Endometriosis of other sites within the digestive system
<b>GA10.CZ</b>	Endometriosis of unspecified site within the digestive system
<b>GA10.D</b>	<b>Endometriosis of urinary system</b>
<b>GA10.D0</b>	Endometriosis of the bladder
<b>GA10.DY</b>	Endometriosis of other sites in the urinary system

<b>GA10.DZ</b>	Endometriosis of unspecified site in the urinary system
<b>GA10.E</b>	<b>Endometriosis of the circulatory system</b>
<b>GA10.F</b>	<b>Endometriosis of the nervous system</b>
<b>GA10.G</b>	<p><b>Thoracic endometriosis</b></p> <p>Thoracic endometriosis lesions can affect the diaphragm, pleura, lung and bronchi. There may be a greater affinity for the right hemi thorax, and the parenchyma is more commonly affected in the lower lobes. Macroscopically, the endometriotic implants appear as brown–yellow and sometimes red nodules surrounded by neovascularization. Symptoms include: dyspnea, shortness of breath, rapid heartbeat, coughing up blood and a variety of pain patterns to include scapula, chest, ipsilateral neck and shoulder, upper abdominal and epigastric. Thoracic endometriosis may present with catamenial pneumothorax (recurrent pneumothorax occurring within 72 hours of menstruation), haemoptysis in case of bronchial location, haemothorax, pericardial effusions. A diagnosis of thoracic endometriosis is simple when both endometrial stroma and gland are present. In cases of endometriosis with stroma only, a further classification of “aggregated pattern”, in which immunohistochemistry is ER-, PR- and CD10-positive might be necessary for diagnosis.</p>
	<p><b>Exclusions:</b> Endometriosis of the heart (GA10.E)</p>
<b>GA10.H</b>	<b>Endometriosis in cutaneous scar</b>
<b>GA10.J</b>	<b>Endometriosis-related adhesions</b>
<b>GA10.Y</b>	<b>Endometriosis of other specified sites</b>
<b>GA10.Z</b>	<b>Endometriosis of unspecified site</b>
<b>GA11</b>	<p><b>Adenomyosis</b></p> <p>A condition of the uterus characterised by endometrial tissue growth in the myometrium, hypertrophy of the myometrium, and heavy or prolonged menstrual bleeding, dysmenorrhoea, dyspareunia, bleeding between menstruation, or infertility; it can also be asymptomatic. Confirmation is by histopathology or ultrasound.</p>
	<p><b>Exclusions:</b> Leiomyoma of uterus (2E86.0)</p>

## Noninflammatory disorders of female genital tract (GA12-GA1Z)

Any disorder of the female genital tract, characterised by pathological changes, leading to noninflammatory effects.

**Coded Elsewhere:** Congenital abnormalities of vulva or perineum

- Congenital abnormalities of vagina
- Congenital abnormalities of cervix uteri
- Congenital abnormalities of uterus, except cervix
- Congenital abnormalities of fallopian tube
- Congenital abnormalities of ovary
- Congenital abnormalities of broad ligament
- Endometriosis (GA10)
- Adenomyosis (GA11)

### GA12

#### Dyspareunia

A symptom of the genital system affecting females, caused by physical determinants. This symptom is characterised by recurrent genital pain or discomfort that occurs before, during, or after sexual intercourse, or superficial or deep vaginal penetration that is related to an identifiable physical cause, not including lack of lubrication. Confirmation is by medical assessment of physical causes.

**Exclusions:** Sexual pain-penetration disorder (HA20)

### GA13

#### Acquired abnormalities of vulva or perineum

Any condition of the vulva and perineum, caused by determinants arising after birth. These conditions are characterised by a malfunction, malformation, or another anomaly of the vulva and perineum.

##### GA13.0 Polyp of vulva

##### GA13.1 Low grade squamous intraepithelial lesion of vulva

A condition of the vulva, characterised by lesion of the squamous vulvar intraepithelial cells, leading to unspecified grade or severity of dysplasia and varying degrees of atypia of the cells. This condition is associated with smoking and immunosuppression, or conditions such as human papillomavirus, chronic vulvar irritation, or herpes simplex virus type 2. Confirmation is by tissue biopsy.

**Exclusions:** Genital warts of vulva (1A95.1)

Squamous cell carcinoma of vulva (2C70.2)

High grade squamous intraepithelial lesion of vulva, HPV-associated (2E67.13)

Vulvar intraepithelial neoplasia, HPV-independent (2E67.12)

##### GA13.2 Hypertrophy of vulva

A condition of the vulva that is frequently idiopathic. This condition is characterised by enlargement or thickening of the tissues of all or part of the female external genitalia, such as the clitoris, labia, vestibule, or glands. This condition may also present with a patchy white discolouration, itching, pain or burning of the skin.

<b>GA13.3</b>	<b>Vulvar cyst</b> Closed, fluid filled sac located on or in the vulvar tissue.
<b>GA13.4</b>	<b>Labial agglutination</b> Sign of agglutination of labia minora and/or majora as a result of chronic vulvar inflammation from any cause, usually observed in prepubertal girls.
<b>GA13.5</b>	<b>Skene duct cyst</b> Cystic dilations of the Skene glands, typically located adjacent to the urethral meatus within the vulvar vestibule. Mostly small and often asymptomatic, they may enlarge urinary obstruction, requiring excision.
<b>GA13.6</b>	<b>Vulvar laceration</b> An injury to the vulva, caused by trauma due to childbirth, sexual abuse, or forceful impact. This injury is characterised by tearing of the skin, muscle, or other tissue in the vulvar area.
<b>GA13.7</b>	<b>Vulvar haematoma</b> An injury to the vulvar branches of the internal pudendal or inferior rectal arteries, caused by rupture and trauma due to childbirth, sexual abuse, or forceful impact. This injury is characterised by a localised collection of extravasated blood vessels and significant bruising. This injury may also present with an inability to urinate.
<b>GA13.Y</b>	<b>Other specified acquired abnormalities of vulva or perineum</b>
<b>GA13.Z</b>	<b>Acquired abnormalities of vulva or perineum, unspecified</b>
<b>GA14</b>	<b>Acquired abnormalities of vagina</b> Any condition of the vagina, caused by determinants arising after birth. These conditions are characterised by pathological changes to the vagina.  <b>Coded Elsewhere:</b> Postoperative adhesions of vagina (GC70) Prolapse of vaginal vault after hysterectomy (GC71)
<b>GA14.0</b>	<b>Polyp of vagina</b>
<b>GA14.1</b>	<b>Haematocolpos</b> A condition of the vagina, caused by an outflow vaginal obstruction. This condition is characterised by the presence of blood in the vagina.
<b>GA14.2</b>	<b>Vaginal foreign body</b> A condition of the vagina, caused by foreign bodies lodged into the vaginal canal. This condition is characterised by vaginitis, vaginal bleeding, foul-smelling and purulent vaginal discharge, abdominal pain, and supra-pubic pain. This condition may also present with dysuria or infection.
<b>GA14.3</b>	<b>Vaginal haematoma</b> A condition of the vagina, caused by trauma, commonly subsequent to childbirth, sexual abuse, or forceful impact. This condition is characterised by a localised collection of extravasated blood vessels and significant bruising. This condition may also present with pain, swelling, ecchymosis and urinary retention.

<b>GA14.5</b>	<b>Leukoplakia of vagina</b> A condition of the vagina, caused by hyperkeratinisation of epithelial cells due to human papillomavirus (HPV) infection, chronic trauma, radiotherapy, or premalignant/malignant lesions. This condition is characterised by white, whitish yellow, or grey plaque on the mucosal surfaces in the vagina.
<b>GA14.6</b>	<b>Low grade squamous intraepithelial lesion of vagina</b>
<b>GA14.Y</b>	<b>Other specified acquired abnormalities of vagina</b>
<b>GA14.Z</b>	<b>Acquired abnormalities of vagina, unspecified</b>
<b>GA15</b>	<b>Acquired abnormalities of cervix uteri</b>
<b>GA15.0</b>	<b>Polyp of cervix uteri</b>
<b>GA15.1</b>	<b>Erosion or ectropion of cervix uteri</b> A condition of the cervix uteri, caused by an increase in the total estrogen level in the body. This condition is characterised by protrusion and transformation of the endocervical columnar epithelium to stratified squamous epithelium on the cervix uteri. This condition may also present with non-purulent vaginal discharge, post-coital bleeding, or may be asymptomatic. <i>Exclusions:</i> Cervicitis (GA04)
<b>GA15.2</b>	<b>Nabothian cyst</b>
<b>GA15.3</b>	<b>Old laceration of cervix uteri</b> An injury of the cervix, caused by trauma subsequent to procedures that lacerate the cervix, such as vaginal delivery, induced abortion, or surgery. This condition is characterised by tearing of the cervix uteri tissue. <i>Exclusions:</i> Perineal laceration during delivery (JB09)
<b>GA15.4</b>	<b>Stricture or stenosis of cervix uteri</b> A condition of the cervix uteri, caused by inflammation, trauma, scarring, or atrophy. This condition is characterised by narrowing of the cervical ostium. <i>Exclusions:</i> Obstructed labour due to abnormality of maternal pelvic organs (JB05.5)
<b>GA15.5</b>	<b>Hypertrophic elongation of cervix uteri</b> A condition of the cervix uteri, caused by uterine prolapse. This condition is characterised by hypertrophy, hyperplasia, elongation or strain to the vaginal or supravaginal parts of the cervix uteri. This condition may also present with dyspareunia or infertility. Confirmation is by pelvic examination to differentiate between vaginal or supravaginal elongation.

<b>GA15.6</b>	<b>Incompetence of cervix uteri</b> A condition of the cervix uteri, caused by the weakness of the cervical tissue and intrauterine pressure as pregnancy progresses. This condition is characterised by dilation and effacement of the cervix before reaching a term pregnancy. This condition may lead to a miscarriage during the second trimester, or an early preterm birth during the third trimester.
	<p><b>Exclusions:</b> Fetus or newborn affected by incompetence of cervix uteri (KA01.0)</p> <p>Maternal care for cervical incompetence (JA84.3)</p>
<b>GA15.7</b>	<b>Low grade squamous intraepithelial lesion of cervix uteri</b> A condition of the cervix uteri caused by chronic infection. This condition is characterised by premalignant transformation and abnormal cell growth and behaviour of the cervical squamous epithelial tissue.
	<p><b>Exclusions:</b> Carcinoma in situ of cervix uteri (2E66)</p> <p>High grade squamous intraepithelial lesion of cervix uteri (2E66.2)</p> <p>Cervical Intraepithelial neoplasia grade III (2E66.2)</p> <p>Cervical Intraepithelial neoplasia grade II (2E66.2)</p>
<b>GA15.Y</b>	<b>Other specified acquired abnormalities of cervix uteri</b>
<b>GA15.Z</b>	<b>Acquired abnormalities of cervix uteri, unspecified</b>
<b>GA16</b>	<b>Acquired abnormalities of uterus, except cervix</b> Any condition of the uterus, caused by determinants arising after birth. These conditions are characterised by a malfunction, malformation, or another anomaly of the uterus (excluding the cervix).
	<p><b>Coded Elsewhere:</b> Adenomyosis (GA11)</p> <p>Leiomyoma of uterus (2E86.0)</p> <p>Acquired absence of the uterus (QF01.10)</p>
<b>GA16.0</b>	<b>Endometrial glandular hyperplasia</b> A condition of the uterus, caused by chronic, excess oestrogen stimulation due to obesity, anovulation, or oestrogen therapy. This condition is characterised by excessive proliferation of the endometrial gland cells and a greater gland-to-stroma ratio of endometrial cells. This condition may also present with abnormal uterine bleeding, particularly among postmenopausal women and premenopausal women of increasing age. Confirmation is by sampling endometrial tissue through biopsy or dilation and curettage.

<b>GA16.1</b>	<b>Malposition of uterus</b> A condition of the uterus, caused by weakened pelvic ligaments, enlargement of the uterus, scarred pelvic tissue from pregnancy, tumour, menopause, endometriosis, inflammation, or salpingitis. This condition is characterised by a deviation in the position of the uterus from normal.
	<b>Exclusions:</b> Obstructed labour due to abnormality of maternal pelvic organs (JB05.5)  Maternal care for other abnormalities of pelvic organs (JA84)
<b>GA16.2</b>	<b>Intrauterine synechiae</b> Intrauterine adhesions caused by pelvic inflammatory disease, uterine surgery, or complications related to spontaneous, incomplete or induced abortion. May be asymptomatic or associated with amenorrhea or light menstrual bleeding and subfertility.
<b>GA16.3</b>	<b>Haematometra</b> Presence of blood clots inside the uterus, usually caused by a uterine outflow obstruction.
	<b>Exclusions:</b> haematometra with haematocolpos (GA14.1)
<b>GA16.Y</b>	<b>Other specified acquired abnormalities of uterus, except cervix</b>
<b>GA16.Z</b>	<b>Acquired abnormalities of uterus, except cervix, unspecified</b>
<b>GA17</b>	<b>Acquired abnormalities of fallopian tube</b> A condition of the fallopian tube, caused by determinants arising after birth. This condition is characterised by a malfunction, malformation, or another anomaly.
<b>GA17.0</b>	<b>Acquired parafimbrial cyst of the fallopian tube</b> Cyst located on the fallopian tube at the outside of the fimbrial end.
<b>GA17.1</b>	<b>Fimbrial agglutination</b> Agglutination of fimbriae in the presence of an open or closed fallopian tube
<b>GA17.2</b>	<b>Hydrosalpinx</b> A condition of the fallopian tube, caused by a distal occlusion and the release of purulent material following infection. This condition is characterised by the presence of fluid inside the fallopian tube, and pelvic pressure, pelvic pain, or dyspareunia.
<b>GA17.3</b>	<b>Haematosalpinx</b> A condition of the Fallopian tube, caused by tubal pregnancy, endometriosis, tubal carcinoma, or cryptomenorrhoea. This condition is characterised by bleeding and the presence of blood clots inside the Fallopian tubes, and pelvic pain or uterine bleeding. Confirmation is by imaging.
	<b>Exclusions:</b> haematosalpinx with haematocolpos (GA14.1) haematosalpinx with haematometra (GA16.3)

GA17.4	<b>Salpingitis isthmica nodosa</b> A condition of the fallopian tube caused by infection or inflammation. This condition is characterised by bilateral, nodular thickening of the isthmic and proximal ampullary tunica muscularis. This condition may also present with infertility or ectopic pregnancy. Confirmation is by imaging.
GA17.Y	<b>Other specified acquired abnormalities of fallopian tube</b>
GA17.Z	<b>Acquired abnormalities of fallopian tube, unspecified</b>
<b>GA18</b>	<b>Acquired abnormalities of ovary</b> Any condition of the ovary, caused by determinants arising after birth. These conditions are characterised by a malfunction, malformation, or another anomaly of the ovary. <b>Coded Elsewhere:</b> Polycystic ovary (5A80.2) Cystic teratoma (2F32.0) Ovarian fibroma (2F32.1) Meigs' syndrome (2F32.2) Serous ovarian cystadenoma (2F32.3)
GA18.0	<b>Follicular cyst of ovary</b> A condition of the ovary, caused by a follicular growth or involution due to failure of ovulation. This condition is characterised by the non-neoplastic formation of closed sac-like structures filled with fluid on or in the ovary and lined by layers of granulosa cells. This condition is commonly asymptomatic, but may also present with pelvic pain, irregular menstrual bleeding, dyspareunia, nausea, vomiting, or urgency to urinate. Confirmation is by imaging. <b>Inclusions:</b> Cyst of graafian follicle
GA18.1	<b>Corpus luteum cyst</b> A condition affecting females, caused by the expansion of the corpus luteum with air, blood, or fluid in the ovary after ovulation of a follicle. This condition is characterised by a mass of up to 10 cm in diameter. This condition may also present with pelvic or abdominal pain, haemorrhage, or ovarian torsion.
GA18.2	<b>Theca lutein cyst</b> Least common of functional ovarian cysts, usually bilateral and coexistent with pregnancy, including molar pregnancies. May be quite large (up to 30 cm), are multicystic and disappear spontaneously.
GA18.4	<b>Para ovarian cyst</b>
GA18.5	<b>Torsion of ovary, ovarian pedicle or fallopian tube</b> A condition of the ovary, ovarian pedicle, and fallopian tube, caused by a benign ovarian cyst or ovarian hyperstimulation. This condition is characterised by the partial or complete rotation of the ovarian vascular pedicle and abdominal pain. Confirmation is by imaging.

<b>GA18.6</b>	<b>Other or unspecified ovarian cysts</b> Any collection of fluid, surrounded by a very thin wall, within an ovary, which is not classified elsewhere. This includes any ovarian follicle that is larger than about two centimetres in diameter.
	<b>Exclusions:</b> Polycystic ovary syndrome (5A80.1) ovarian cyst: developmental (LB45.2) ovarian cyst: neoplastic (2C73)
<b>GA18.7</b>	<b>Acquired atrophy of ovary or fallopian tube</b> A condition of the ovary and Fallopian tube, caused by determinants such as infection, chemotherapy or radiation therapy, or shock, arising after birth. This condition is characterised by the partial or complete decrease in size and function of the ovary and the Fallopian tube, premature menopause, fatigue, irregular menstruation, weight gain, and irritability. Confirmation is by identification of elevated levels of oestrogen and follicle stimulating hormone levels in a blood sample.
<b>GA18.Y</b>	<b>Other specified acquired abnormalities of ovary</b>
<b>GA18.Z</b>	<b>Acquired abnormalities of ovary, unspecified</b>
<b>GA19</b>	<b>Acquired abnormalities of broad ligament</b> <b>Coded Elsewhere:</b> Postprocedural pelvic peritoneal adhesions (GC73)
<b>GA19.0</b>	<b>Haematoma of broad ligament</b> A condition affecting females, caused by childbirth, trauma, or surgery. This condition is characterised by a tear in the upper vagina, cervix, or uterus that extends into uterine or vaginal arteries, bleeding (although not always with obvious vaginal bleeding), back pain, pressure in the rectoanal area, dizziness, hypotension, or anaemia. Confirmation is by rectovaginal exam to rule out clotting and expansion of haematoma.
<b>GA19.Y</b>	<b>Other specified acquired abnormalities of broad ligament</b>
<b>GA19.Z</b>	<b>Acquired abnormalities of broad ligament, unspecified</b>
<b>GA1Y</b>	<b>Other specified noninflammatory disorders of female genital tract</b>
<b>GA1Z</b>	<b>Noninflammatory disorders of female genital tract, unspecified</b>

Abnormal uterine or vaginal bleeding (GA20-GA2Z)

A condition of the genital system, caused by hormonal disturbances, weight changes, neoplasms, or use of pharmacological agents. This condition is characterised by irregular or excessive shedding of the uterine lining, or vaginal bleeding during or between menstrual cycles.

**Coded Elsewhere:** Postmenopausal uterine bleeding (GA30.1)  
Neonatal vaginal or uterine haemorrhage (KA83.9)

**GA20** **Menstrual cycle bleeding disorders**

<b>GA20.0</b>	<b>Amenorrhoea</b> A condition of the genital system, caused by hormonal or endocrine disturbances, absence of the uterus, pregnancy, lactation, abnormalities of the genital outflow tract, or failure of the ovaries to retain egg cells during the antenatal period. This condition is characterised by the absence of menstruation by age 16, or the termination of an established menstruation cycle for more than 3-9 months.
	<b>Exclusions:</b> Ovarian dysfunction (5A80)
	<b>Coded Elsewhere:</b> Amenorrhoea related to obstetric fistula (GC04.1Y)
<b>GA20.00</b>	Primary amenorrhoea No menses by age 14 in the absence of growth or development of secondary sexual characteristics; or no menses by age 16 regardless of the presence of normal growth and development of secondary sexual characteristics.
	<b>Coded Elsewhere:</b> 46,XX gonadal dysgenesis (LB45.1)
<b>GA20.01</b>	Secondary amenorrhoea In women who have menstruated previously, no menses for an interval of time equivalent to a total of at least 3 previous cycles, or 6 months
<b>Coding Note:</b>	Code also the causing condition
<b>GA20.02</b>	Lactational amenorrhoea A condition of the genital system affecting females, caused by hormonal disturbances associated with lactation. This condition is characterised by the termination of an established menstruation cycle for more than 3-9 months.
<b>GA20.0Y</b>	Other specified amenorrhoea
<b>GA20.0Z</b>	Amenorrhoea, unspecified
<b>GA20.1</b>	<b>Abnormal frequency of uterine bleeding</b> Any condition of the genital system affecting females, caused by hormonal disturbances. These conditions are characterised by menstrual bleeding episodes that occur with increased frequency or are delayed over several menstrual cycles (within 90 days).
<b>GA20.10</b>	Frequent menstrual bleeding A condition of the genital system affecting females, caused by hormonal change due to pharmacologic or nonpharmacologic agents. This condition is characterised by menstrual bleeding episodes that occur with increased frequency over several menstrual cycles (more than four episodes within 90 days).
<b>GA20.11</b>	Infrequent menstrual bleeding Menstruation with a frequency of 39 days or more
<b>GA20.1Z</b>	Abnormal frequency of uterine bleeding, unspecified
<b>GA20.2</b>	<b>Ovulation bleeding</b> A condition of the genital system affecting females, caused by natural and routine fluctuations in endocrine hormones. This condition is characterised by recurrent and cyclic bleeding of the uterine lining, occurring during the peri-ovulatory period.

- GA20.20** Intermenstrual bleeding  
A condition of the genital system affecting females, caused by a hormonal imbalance, use of an intrauterine device, pregnancy complications, uterine fibroids or polyps, infection, or cancer. This condition is characterised by vaginal bleeding between menstrual periods.
- GA20.2Y** Other specified ovulation bleeding
- GA20.2Z** Ovulation bleeding, unspecified
- GA20.3** **Abnormal regularity of uterine bleeding**  
A condition of the genital system affecting females, caused by hormonal disturbances. This condition is characterised by abnormal menstruation, with a between cycle variation of 2-20 days.
- GA20.4** **Abnormal duration of uterine bleeding**
- GA20.5** **Abnormal volume of uterine bleeding**
- GA20.50** Heavy menstrual bleeding  
Menstruation with heavy (> 80 ml) volume of monthly blood loss
- GA20.51** Light menstrual bleeding  
Menstruation with light (< 5 ml) volume of monthly blood loss
- GA20.5Z** Abnormal volume of uterine bleeding, unspecified
- GA20.Y** **Other specified menstrual cycle bleeding disorders**
- GA20.Z** **Menstrual cycle bleeding disorders, unspecified**
- GA21** **Nonmenstrual bleeding disorders**  
**Coded Elsewhere:** Postprocedural nonmenstrual uterine bleeding (GC77)
- GA21.0** **Postcoital or contact bleeding**  
A condition of the genital system, caused by infection, cervical ectropion, cervical or endometrial polyps, cancer, or trauma to the cervix or vagina. This condition is characterised by non-menstrual bleeding after sexual intercourse. Confirmation is by transvaginal imaging to identify any structural abnormalities.
- GA21.Y** **Other specified nonmenstrual bleeding disorders**
- GA21.Z** **Nonmenstrual bleeding disorders, unspecified**
- GA22** **Excessive menstruation with irregular cycle**  
*Inclusions:* Menometrorrhagia
- GA23** **Anovulatory bleeding**
- GA2Y** **Other specified abnormal uterine or vaginal bleeding**
- GA2Z** **Abnormal uterine or vaginal bleeding, unspecified**

**GA30**

**Menopausal or certain specified perimenopausal disorders**

Any disorder affecting females, characterised by pathological changes during the menopausal and perimenopausal periods.

**Coded Elsewhere:** Postprocedural ovarian failure (5D44)

Menopausal symptom or complaint (MF32)

**GA30.0**

**Menopause**

A condition affecting females, caused by the loss of ovarian follicular function and decline in circulating blood oestrogen levels. This condition is characterised by the cessation of menstruation, hot flushes, atrophic genital changes, psychophysiological effects, and bone loss. Confirmation is by taking a patient history to determine psychophysiological effects such as the presence of amenorrhoea, and identification of hypooestrogenaemia and elevated serum FSH levels in a blood sample.

**Coded Elsewhere:** Contact with health services for menopausal counselling (QA4B)

**GA30.00**

**Menopausal or female climacteric states**

Any condition of the genital system affecting females, caused by pathological changes associated with the perimenopausal period, such as the permanent cessation of menstruation and infertility.

**Coding Note:**

Includes: Symptoms such as flushing, sleeplessness, headache, lack of concentration, associated with menopause

**Exclusions:** States associated with artificial menopause (GA30.3)

**GA30.01**

**Menopausal transition**

A condition affecting females, caused by gradual loss of ovarian follicular function and decline in circulating blood estrogen levels. This condition is characterised by infrequent or irregular menstrual bleeding, alterations in the functioning of the ovary, and gradual atrophic genital changes, psychophysiological effects. Confirmation is by taking a patient history to determine psychophysiological effects.

**GA30.02**

**Excessive bleeding in the premenopausal period**

aka "menorrhagia", excessive uterine bleeding during MENSTRUATION

**GA30.0Y**

**Other specified menopause**

**GA30.0Z**

**Menopause, unspecified**

**GA30.1**

**Postmenopausal uterine bleeding**

A condition of the genital system, caused by polyps, endometrial atrophy, hyperplasia, or cancer. This condition is characterised by abnormal uterine bleeding subsequent to the completion of menopause.

**Exclusions:** that associated with artificial menopause (GA30.3)

<b>GA30.2</b>	<b>Postmenopausal atrophic vaginitis</b> A condition of the vagina, caused by decreased oestrogen levels during the menopausal period. This condition is characterised by inflammation of the vagina and outer urinary tract, thinning and drying of the vaginal tissues, decreased lubrication, vaginal burning or dryness, shortening and tightening of the vaginal canal, or urinary incontinence after menopause.
	<b><i>Exclusions:</i></b> States associated with artificial menopause (GA30.3)
<b>GA30.3</b>	<b>States associated with artificial menopause</b> Any condition caused by the artificial cessation of menstruation induced by surgical or pharmacological effects.
<b>GA30.4</b>	<b>Menopausal hot flush</b> A condition affecting females, caused by hormonal changes associated with menopause. This condition is characterised by recurrent and transient periods of flushing, sweating, and a systemic sensation of heat. This condition may also present with palpitations, anxiety, or periods of heat followed by chills.
<b>GA30.5</b>	<b>Menopausal osteoporosis</b>
<b>GA30.6</b>	<b>Premature ovarian failure</b> Menopause occurring spontaneously before 40 years of age, generally resulting in secondary amenorrhea although some women may exhibit intermittent ovarian function and ovulation, with a minority conceiving and delivering a pregnancy. POF/POI occurs mostly without a known cause, but can be caused by the following conditions: numerical and structural chromosomal abnormalities, Fragile X (FMR1) permutations, autoimmune disorders, radiation therapy, chemotherapy, galactosemia, and other rare enzyme defects or mutations. To be subdivided in 4 categories according to cause: congenital, acquired, iatrogenic and unknown  <b><i>Exclusions:</i></b> Isolated gonadotropin deficiency (5A61.0) Postprocedural ovarian failure (5D44)  <b><i>Coded Elsewhere:</i></b> Primary amenorrhoea (GA20.00) Secondary amenorrhoea (GA20.01)
<b>GA30.Y</b>	<b>Other specified menopausal and perimenopausal disorders</b>
<b>GA30.Z</b>	<b>Menopausal and perimenopausal disorders, unspecified</b>

**GA31**

**Female infertility**

Disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse.

**Inclusions:** inability to achieve a pregnancy

**Exclusions:** relative infertility (GA33)

Male infertility (GB04)

**Coded Elsewhere:** Contact with health services for preconception counselling (QA33)

Contact with health services for fertility preservation counselling (QA34)

Contact with health services by gestational carrier (QA35)

Female hypofertility in classical cystic fibrosis (CA25.0)

Female hypofertility in atypical cystic fibrosis (CA25.1)

Contact with health services for preimplantation genetic diagnosis (QA3Y)

Contact with health services for preimplantation genetic screening (QA3Y)

**GA31.0**

**Primary female infertility**

Infertility in a woman who has never had a clinical pregnancy

**GA31.00**

Primary female infertility of uterine origin

Female infertility caused by uterine abnormalities on the level of the endometrium or myometrium, with more detailed description classified elsewhere, i.e. under genitourinary infections, STDs and noninflammatory benign gynaecological disease

**Coding Note:**

Code also the causing condition

**GA31.01**

Primary female infertility of tubal origin

Female infertility caused by dysfunction of one or both fallopian tubes, usually related to pelvic adhesions or occurring after pelvic surgery, with or without hydrosalpinx

**Coding Note:**

Code also the causing condition

**GA31.0Y**

Primary female infertility of other specified origin

**GA31.0Z**

Primary female infertility of unspecified origin

**GA31.1**

**Secondary female infertility**

Infertility in a woman who has had at least one clinical pregnancy

**GA31.10**

Secondary female infertility of uterine origin

**GA31.11**

Secondary female infertility of tubal origin

**GA31.1Y**

Secondary female infertility of other specified origin

**GA31.1Z**

Secondary female infertility of unspecified origin

**GA31.Z**

**Female infertility without specification whether primary or secondary**

**GA32**

**Complications associated with medically assisted reproduction**

Any complication caused by or subsequent to any intervention used to achieve pregnancy by artificial or partially artificial means.

**GA32.0**

**Ovarian hyperstimulation syndrome**

A disease of the endocrine system, caused by elevated human chorionic gonadotropin hormone, commonly after the use of injectable fertility treatments. This disease is characterised by ovarian enlargement, and hemodynamic or metabolic complications. This disease may also present with abdominal pain, abdominal bloating, or weight gain depending on graded symptoms.

**Inclusions:** Hyperstimulation of ovaries associated with induced ovulation

**GA32.1**

**Bleeding after egg retrieval**

Significant bleeding after egg retrieval requiring hospitalization for blood transfusion, surgical intervention, clinical observation or other medical procedure

**GA32.2**

**Infection associated with medically assisted reproduction**

Significant genital or pelvic infection occurring after egg retrieval or other treatment with medically assisted reproduction

**GA32.3**

**Complications of attempted embryo transfer or medically assisted insemination**

Any complication caused by or subsequent to any attempted embryo transfer or medically assisted sperm insemination procedure.

**GA32.Y**

**Other specified complications associated with medically assisted reproduction**

**GA32.Z**

**Complications associated with medically assisted reproduction, unspecified**

**GA33**

**Recurrent pregnancy loss**

**Exclusions:** currently pregnant (Chapter 18)

with current abortion (JA00-JA0Z)

**GA34**

**Female pelvic pain associated with genital organs or menstrual cycle**

A symptom affecting females, characterised by pain in the pelvic region associated with any of the genital organs or the menstrual cycle.

**Exclusions:** Chronic primary visceral pain (MG30.00)

Chronic secondary visceral pain (MG30.4)

**Coded Elsewhere:** Interstitial cystitis (GC00.3)

**GA34.0**

**Pain related to vulva, vagina or pelvic floor**

A condition affecting females, characterised by any type of pain associated with the vulva, vagina, and pelvic floor tissues, either during sexual intercourse, physical activity, or rest.

**Exclusions:** Chronic primary visceral pain (MG30.00)

Chronic secondary visceral pain (MG30.4)

<b>GA34.00</b>	Vulval pain A symptom of vulval pain affecting females, caused by trauma, infection, injury, inflammation, or hypersensitivity of the nerve fibres. This symptom is characterised by any type of pain in the vulva, during sexual intercourse, physical activity, or rest.
	<b><i>Exclusions:</i></b> Chronic primary visceral pain (MG30.00) Chronic secondary visceral pain (MG30.4)
<b>GA34.01</b>	Perineal pain A symptom of perineal pain affecting females, caused by trauma, infection, injury, inflammation, or hypersensitivity of the nerve fibres. This symptom is characterised by any type of pain in the area between the posterior lip of the vaginal introitus and the anus, during sexual intercourse, physical activity, or rest.
	<b><i>Exclusions:</i></b> Chronic primary visceral pain (MG30.00) Chronic secondary visceral pain (MG30.4)
<b>GA34.02</b>	Vulvodynia Vulvodynia describes a chronic sensation of pain, burning or rawness of vulval skin which cannot be ascribed to any specific cause and persists for at least three months. Symptoms may be diffuse and unprovoked (dysaesthetic vulvodynia) or localised, usually to the vulval vestibule, and provoked by touch (vestibulodynia). Dysaesthetic vulvodynia characteristically occurs in postmenopausal women who are often not sexually active: pain is spontaneous and often occurs independently of touch. Vestibulodynia occurs typically in younger women and is characterised by vestibular tenderness to touch, erythema of the vestibular epithelium and secondary dyspareunia.
<b>GA34.0Y</b>	Other specified pain related to vulva, vagina or pelvic floor
<b>GA34.0Z</b>	Pain related to vulva, vagina or pelvic floor, unspecified
<b>GA34.1</b>	<b>Vaginal laxity</b>
<b>GA34.2</b>	<b>Female pelvic pain</b> Pain in the pelvic region in a female associated with any of the genital organs or the menstrual cycle.  <b><i>Exclusions:</i></b> Pain related to vulva, vagina or pelvic floor (GA34.0) Pelvic or perineal pain (MD81.11) Bladder pain (MF52) Chronic primary bladder pain syndrome (MG30.00) Sexual pain-penetration disorder (HA20) Chronic primary visceral pain (MG30.00) Chronic secondary visceral pain (MG30.4)  <b><i>Coded Elsewhere:</i></b> Vulvodynia (GA34.02) Chronic pelvic pain in females (MG30.00)

<b>GA34.20</b>	Cyclic pelvic pain A symptom affecting females, caused by gynaecological and physiological aspects associated with the menstrual cycle such as dysmenorrhoea or mittelschmetz. This symptom is characterised by recurrent pain in the pelvis, anterior abdominal wall, lower back, or buttocks, associated with a specific moment or period of time.
	<b>Exclusions:</b> Chronic primary visceral pain (MG30.00) Chronic secondary visceral pain (MG30.4)
<b>GA34.21</b>	Noncyclic pelvic pain A symptom affecting females, caused by gynaecological and physiological aspects not associated with the menstrual cycle. This symptom is characterised by chronic pelvic pain in the pelvis, anterior abdominal wall, lower back, or buttocks, not associated with a specific moment or period of time.
	<b>Exclusions:</b> Chronic primary visceral pain (MG30.00) Chronic secondary visceral pain (MG30.4)
<b>GA34.2Z</b>	Female pelvic pain, unspecified
<b>GA34.3</b>	<b>Dysmenorrhoea</b> A condition of the genital system affecting females, caused by endometriosis, adenomyosis, ovarian cysts, or may be idiopathic. This condition is characterised by cyclic pelvic pain preceding or accompanying menstruation that interferes with daily activities, lower, umbilical, or suprapubic abdominal pain, such as sharp, throbbing, burning, or shooting pains that may extend to the thighs and lower back.
<b>GA34.4</b>	<b>Premenstrual disturbances</b>
<b>GA34.40</b>	Premenstrual tension syndrome A syndrome affecting females that is frequently idiopathic. This syndrome is characterised by certain environmental, metabolic, or behavioural factors that occur during the luteal phase of the menstrual cycle, and leads to cyclic emotional, physical, or behavioural symptoms that interfere with an individual's lifestyle. Confirmation is by documentation of specific cyclic symptoms associated with the luteal and menstrual phases of the cycle (from a prospective symptom diary), and evidence of socioeconomic dysfunction.
	<b>Exclusions:</b> Premenstrual dysphoric disorder (GA34.41)
	<b>Coded Elsewhere:</b> Premenstrual symptom or complaint (MF33)

<b>GA34.41</b>	Premenstrual dysphoric disorder During a majority of menstrual cycles within the past year, a pattern of mood symptoms (depressed mood, irritability), somatic symptoms (lethargy, joint pain, overeating), or cognitive symptoms (concentration difficulties, forgetfulness) that begin several days before the onset of menses, start to improve within a few days after the onset of menses, and then become minimal or absent within approximately 1 week following the onset of menses. The temporal relationship of the symptoms and luteal and menstrual phases of the cycle should ideally be confirmed by a prospective symptom diary over at least two symptomatic menstrual cycles. The symptoms are severe enough to cause significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning and do not represent the exacerbation of a mental disorder.
	<b>Inclusions:</b> PMDD - [premenstrual dysphoric disorder]
	<b>Exclusions:</b> Premenstrual tension syndrome (GA34.40)
<b>GA34.4Y</b>	Other specified premenstrual disturbances
<b>GA34.4Z</b>	Premenstrual disturbances, unspecified
<b>GA34.5</b>	<b>Ovarian remnant syndrome</b> Chronic pelvic pain in a patient after bilateral salpingooophorectomy for severe endometriosis or PID, caused by residual ovarian cortical tissue left in situ after difficult dissection. Symptoms may include lateralizing pelvic pain, often cyclic and associated with genitourinary or gastrointestinal symptoms. Signs may include a tender mass in the lateral region of the pelvis.
<b>GA34.6</b>	<b>Female genital pain</b> A symptom of genital pain affecting females that is idiopathic. This symptom is characterised by any type of pain in the genital area tissues, during sexual intercourse, physical activity, or rest.
	<b>Exclusions:</b> Chronic primary visceral pain (MG30.00) Chronic secondary visceral pain (MG30.4)
<b>GA34.Y</b>	<b>Other specified female pelvic pain associated with genital organs or menstrual cycle</b>
<b>GA34.Z</b>	<b>Female pelvic pain associated with genital organs or menstrual cycle, unspecified</b>

Dermatoses of female genitalia (GA40-GA4Y)

**Coded Elsewhere:** Malignant neoplasms of vulva (2C70)

Carcinoma in situ of vulva (2E67.1)

Vulval melanotic macule (ED61.11)

Heterotopic sebaceous glands of vulva (ED91.0)

**GA40**

### **Inflammatory dermatoses of the vulva**

**Coded Elsewhere:** Dermatitis or eczema of female genitalia (EA87.1)

Lichen sclerosus of vulva (EB60.0)

Vulval psoriasis (EA90.53)

**GA41**

### **Ulcerative or erosive disorders of the vulva**

**Coded Elsewhere:** Genital ulcer of vulva (GA00.3)

Herpes simplex infection of vulva (1A94.0)

Erosive lichen planus of vulva or vagina (EA91.3)

Ulceration of vulva due to Behçet disease (4A62)

Vulval pemphigus (EB40.0Y)

Mucous membrane pemphigoid of vulval mucosa (EB41.1)

**GA41.0**

### **Vulval aphthosis**

Vulval aphthae are vulval ulcers not attributable to infection or other identifiable cause. They typically occur on the medial aspects of the labia minora in young females (second decade of life). They may be associated with fever and malaise or with oral aphthae.

**GA41.Y**

### **Other specified ulcerative or erosive disorders of the vulva**

**GA42**

### **Sensory disturbance of the vulva**

Disorders characterised by vulval pruritus, dysaesthesia or pain.

**Coded Elsewhere:** Lichen simplex of vulva (EA83.00)

Vulvodynia (GA34.02)

**GA42.0**

### **Vulval pruritus**

Intense itching of the external female genitalia.

**GA4Y**

### **Other specified dermatoses of female genitalia**

**GA6Y**

### **Other specified diseases of the female genital system**

**GA6Z**

### **Diseases of the female genital system, unspecified**

## Diseases of the male genital system (GA80-GB0Z)

Any disease characterised by pathological changes to the male genital system.

**Coded Elsewhere:** Neoplasms of the male genital organs

- Ejaculatory dysfunctions (HA03)
- Problems of male genital organs (MF40)
- Penoscrotodynia (EC92.0)
- Structural developmental anomalies of the male genital system (LB50-LB5Z)
- Symptoms, signs or clinical findings involving the male genital system (MF40-MF4Y)
- Herpes simplex infection of genitalia or urogenital tract (1A94.0)

## Dermatoses of male genitalia (GA80-GA81.Y)

**Coded Elsewhere:** Inflammatory dermatoses affecting the penis or scrotum

- Premalignant or malignant disorders of the penis or scrotum
- Balanoposthitis (GB06.0)

**GA80**

### **Ulcerative disorders of the penis or scrotum**

**Coded Elsewhere:** Herpes simplex infection of penis (1A94.0)

- Mucous membrane pemphigoid of penile mucosa (EB41.1)
- Ulceration of penis or scrotum due to Behçet disease (4A62)
- Necrotising fasciitis of the scrotum, penis or perineum (1B71.1)
- Amoebiasis of penis (1A36.1Y)

**GA80.0**

### **Aphthosis of penis or scrotum**

Genital aphthosis in men is a non-infective but often painful ulceration of penile, scrotal or perigenital skin. It may be associated with oral ulceration (orogenital aphthosis) or with Behçet disease but may occur on its own. Both genital and orogenital aphthosis may represent forms frustes of Behçet disease.

**Inclusions:** Genital aphthosis in the male

**GA80.1**

### **Ulcer of penis of uncertain nature**

**Exclusions:** Syphilitic chancre of penis (1A61.0)

- Penile chancroid (1A90)
- Herpetic ulcer of penis (1A94.0)
- Penile aphthosis (GA80.0)
- Ulceration of penis or scrotum due to Behçet disease (4A62)

**GA80.Y**

### **Other specified ulcerative disorders of penis and scrotum**

**GA81**

### **Miscellaneous dermatoses of male genitalia**

**Coded Elsewhere:** Lichen simplex of male genitalia (EA83.01)

Penile melanotic macule (ED61.10)

Heterotopic sebaceous glands of penis (ED91.0)

Angiokeratoma of the scrotum (EF20.1)

Burning scrotum (EC92.0)

Genitoperineal median raphe cyst (LB5Y)

**GA81.0**

### **Penoscrotal pruritus**

An intense itching sensation that produces the urge to rub or scratch the skin of the scrotum and/or base of the penis to obtain relief.

**GA81.Y**

### **Other specified dermatoses of male genitalia**

Diseases of prostate (GA90-GA91.Z)

**Coded Elsewhere:** Tuberculosis of prostate (1B12.5)

**GA90**

### **Hyperplasia of prostate**

A condition of the prostate, caused by an increased rate of cellular division of the glandular and stromal cells. This condition is characterised by enlargement of the prostatic tissue, dysuria, urinary urgency, nocturia, weak urine stream, straining while urinating, incomplete bladder emptying during urination, or increased frequency of urinary tract infection.

**Inclusions:** Adenofibromatous hypertrophy of prostate

**Exclusions:** Benign neoplasms of prostate (2F34)

**GA91**

### **Inflammatory and other diseases of prostate**

Any disease caused by obstruction of the prostate gland. These diseases are characterised by a build-up of secretions and inflammation of the prostate.

**Coded Elsewhere:** Gonococcal prostatitis (1A70.Y)

Prostatitis due to Trichomonas vaginalis (1A92)

**GA91.0**

### **Chronic prostatitis**

A condition caused by obstruction of the prostate glands. This condition is characterised by inflammation of the prostate gland, dysuria, pollakiuria, urinary urgency, genital pain, lower back pain, abdominal pain, and repeated bladder infections that last for at least three months.

**GA91.1**

### **Abscess of prostate**

A condition caused by infection with the gram-negative bacteria *Neisseria gonorrhoeae*, *Staphylococcus*, or *Escherichia coli*, or the gram-positive bacteria *Staphylococcus aureus* or *Mycobacterium tuberculosis*. This condition is characterised by a focal accumulation of purulent material and neutrophils within or on the prostatic tissue, dysuria, fever, and suprapubic pain. Confirmation is by a transrectal ultrasound to identify size and location of abscess, and a urine sample to identify leukocytes.

<b>GA91.2</b>	<b>Prostatocystitis</b> A condition characterised by inflammation of the bladder, bladder neck, prostate, and prostatic urethra.
<b>GA91.3</b>	<b>Calculus of prostate</b> A condition characterised by a small, solid calcification commonly composed of calcium carbonate or calcium phosphate that is formed in the prostate. This condition may be associated with diabetes mellitus, infection, cancer, iatrogenic factors, or may be idiopathic. Confirmation is by imaging.  <i>Inclusions:</i> Prostatolithiasis
<b>GA91.4</b>	<b>Haemorrhage of the prostate</b> A condition of the prostate, caused by ruptured vessel walls in the prostate. This condition is characterised by excessive loss of blood from the prostate.  <i>Inclusions:</i> Bleeding of prostate prostatic varicosis
<b>GA91.5</b>	<b>Atrophy of prostate</b> A condition of the prostate, caused by apoptosis of the cells due to diminished cellular proliferation, decreased cellular volume, decreased function, ischemia, malnutrition, disease, mutation, or hormonal changes. This condition is characterised by a partial or complete decrease in size and function of the prostatic tissue.
<b>GA91.6</b>	<b>Low grade intraepithelial lesion of prostate</b> A condition of the prostate, caused by an alteration or mutation in cell growth, or prostatic epithelial cells that are dividing more rapidly than normal epithelium. This condition is characterised by premalignant transformation and abnormal development of the prostatic epithelial tissue.  <i>Inclusions:</i> Low grade prostatic intraepithelial neoplasia <i>Exclusions:</i> high grade dysplasia of prostate (2E67.5) PIN III (2E67.5) high grade PIN (2E67.5)
<b>GA91.Y</b>	<b>Other specified inflammatory and other diseases of prostate</b>
<b>GA91.Z</b>	<b>Inflammatory and other diseases of prostate, unspecified</b>
<b>GB00</b>	<b>Hydrocele or spermatocele</b> A condition characterised by an accumulation of serous fluid in the tunica vaginalis testis or along the spermatic cord, and cystic swelling containing fluid and dead spermatozoa of the testicular epididymis, rete testis or efferent ductuli.  <i>Coded Elsewhere:</i> Congenital hydrocele (KC00)

<b>GB00.0</b>	<b>Encysted hydrocele</b> A condition of the testis, caused by inflammation or testicular epididymis, obstruction to the venous or lymphatic systems through the cord, or an abnormality during the antenatal period. This condition is characterised by a circumscribed accumulation of fluid in the tunica vaginalis testis or along the spermatic cord.
<b>GB00.1</b>	<b>Infected hydrocele</b>
<b>GB00.2</b>	<b>Spermatocele</b> A condition characterised by cystic swelling (containing fluid and dead spermatozoa) of the epididymis, rete testis, or efferent ductuli. This condition may be associated with obstruction of the epididymal ducts due to trauma, infection, or an inflammatory process.
	<b><i>Inclusions:</i></b> Encysted hydrocele (GB00.0) Infected hydrocele (GB00.1)
<b>GB00.Y</b>	<b>Other specified hydrocele or spermatocele</b>
<b>GB00.Z</b>	<b>Hydrocele or spermatocele, unspecified</b>
<b>GB01</b>	<b>Torsion of testis, epididymis or appendices</b> Any condition characterised by a partial or complete rotation and an occlusion to the venous or arterial blood supply of the testis, epididymis or testicular appendix.
<b>GB01.0</b>	<b>Torsion of testis</b> A condition of the testes, caused by determinants arising during the antenatal period, or exposure to cold temperatures. This condition is characterised by twisting of the spermatic cord, ischaemia of the testis, severe pain, tenderness, and decreased or absent cremasteric reflex. Confirmation is by imaging.
	<b><i>Inclusions:</i></b> Torsion of spermatic cord
<b>GB01.1</b>	<b>Torsion of epididymis</b> A condition of the epididymis, caused by determinants arising during the antenatal period. This condition is characterised by twisting of the epididymis around its axis and ischaemia, scrotal pain, or inflammation. This condition may also present with a thickened scrotal wall, a reactive hydrocele, and enlargement of the head of the epididymis. Confirmation is by imaging.
<b>GB01.2</b>	<b>Torsion of hydatids</b> A condition of the testicular appendix, caused by determinants arising during the antenatal period. This condition is characterised by twisting of the hydatid of Morgagni and pedunculated hydatid around its axis and ischaemia, testicular pain, scrotal oedema, and a palpable blue dot discolouration on the scrotum. Confirmation is by imaging.
<b>GB01.Z</b>	<b>Torsion of testis, epididymis or appendices, unspecified</b>

**GB02****Orchitis or epididymitis**

**Coded Elsewhere:** Orchitis due to mumps virus (1D80.1)

Gonococcal epididymitis (1A70.Y)

Gonococcal orchitis (1A70.Y)

Chlamydial epididymitis (1A81.1)

Chlamydial orchitis (1A81.1)

**GB02.0****Orchitis, epididymitis or epididymo-orchitis with abscess**

Inflammation of a testis and / or the epididymitis with an associated abscess, a collection of pus (neutrophils) that has accumulated within a tissue because of an inflammatory process in response to either an infectious process or other foreign materials.

**GB02.1****Orchitis, epididymitis or epididymo-orchitis without abscess**

Inflammation of a testis and / or the epididymitis without associated abscess, a collection of pus (neutrophils) that has accumulated within a tissue because of an inflammatory process in response to either an infectious process or other foreign materials.

**GB02.Y****Other specified orchitis or epididymitis****GB02.Z****Orchitis or epididymitis, unspecified****GB03****Atrophy of testis**

A condition of the testis, caused by apoptosis of the cells due to diminished cellular proliferation, decreased cellular volume, decreased function, ischemia, malnutrition, disease, infection, mutation, or hormonal changes. This condition is characterised by a partial or complete decrease in size and function of the testis tissue.

**GB04****Male infertility**

Any disorder of the reproductive system affecting males, characterised by dysfunctions in the ejection of semen or an abnormal absence in the measurable level of sperm in semen.

**Coded Elsewhere:** Male infertility in classical cystic fibrosis (CA25.0)

Male infertility in atypical cystic fibrosis (CA25.1)

**GB04.0****Azoospermia**

Any condition of the genital system affecting males, caused by obstruction of the reproductive tract, abnormal hormone levels, testicular failure, or inadequate production of spermatozoa. These conditions are characterised by the absence of a measurable level of sperm cells in semen, and very low levels of fertility. Confirmation is by the absence of spermatozoa in the sediment of a centrifuged sample of ejaculate.

**GB04.Y****Other specified male infertility****GB04.Z****Male infertility, unspecified**

**GB05****Redundant prepuce, phimosis or paraphimosis**

Several conditions of the foreskin, caused by abnormalities in the prepuce. This condition is characterised by redundant or tight foreskin and lack of retractability of the foreskin or the inability of the foreskin to be reduced.

**GB05.0****Redundant prepuce**

A condition of the foreskin, caused by determinants arising during the antenatal period. This condition is characterised by the presence of excess foreskin tissue.

**GB05.1****Frenulum breve**

A condition of the frenulum preputii penis, caused by determinants arising during the antenatal period. This condition is characterised by a short frenulum and restricted movement of the prepuce, leading to hindered penetration during sexual intercourse or pain and tearing.

**GB05.2****Phimosis**

A condition of the foreskin, caused by the improper development of the foreskin during the antenatal period, balanitis, lichen sclerosus, inflammation, infection, repeated catheterization, or forcible foreskin retraction. This condition is characterised by constriction of the preputial orifice and restricted movement of the prepuce over the glans. This condition may also present with difficulty urinating or dysfunctions during sexual intercourse.

**GB05.3****Paraphimosis**

A condition of the foreskin, caused by a narrow or inflamed foreskin, improper handling of foreskin, or retraction of the foreskin for an extended duration. This condition is characterised by an inability for the foreskin to return to its normal position after being retracted over the glans, pain, and inflammation, and may lead to gangrene.

**GB05.4****Adherent prepuce**

A condition in which the prepuce is adherent to the prepuce which makes it hard to retract the prepuce.

**GB05.Z****Redundant prepuce, phimosis or paraphimosis, unspecified****GB06****Certain specified disorders of penis**

**Exclusions:** Redundant prepuce, phimosis or paraphimosis (GB05)

**Coded Elsewhere:** Male erectile dysfunction (HA01.1)

**GB06.0****Balanoposthitis**

Inflammation of the foreskin and/or glans penis. It may be associated with specific disorders such as lichen planus, lichen sclerosus, reactive arthritis or contact dermatitis etc. but is most commonly "non-specific".

**GB06.01**

Irritant balanoposthitis

**GB06.02**

Balanoposthitis due to infection

**Coded Elsewhere:** Candida balanoposthitis (1F23.11)

<b>GB06.0Y</b>	Other specified forms of balanitis and balanoposthitis
<b>GB06.0Z</b>	Balanoposthitis, unspecified
<b>GB06.1</b>	<p><b>Priapism</b></p> <p>A condition of the penis, caused by acute leukaemia, sickle cell anaemia, infection, a penile or central nervous system lesion, or the use of certain pharmacological agents. This condition is characterised by prolonged or persistent painful penile erection lasting over four hours without physical or psychological sexual arousal.</p>
	<p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Painful erection</li> </ul>
<b>GB06.2</b>	<p><b>Penile fibromatosis</b></p> <p>A condition characterised by induration of the corpora cavernosa of the penis producing a painful fibrous chordee within the soft tissue of the penis and inflammation of the tunica albuginea. This condition may be associated with trauma or injury to the penis. This condition may also present with pain during erection, erectile dysfunction, shortening, or abnormal curvature of the penis when erect. Confirmation is by ultrasonography.</p>
	<p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Peyronie disease</li> <li>Plastic induration of penis</li> <li>Induratio penis plastica</li> </ul>
<b>GB06.3</b>	<p><b>Mondor disease of the penis</b></p> <p>A well-recognised usually benign and self-limiting entity occurring in sexually active men and presenting with a cord-like thickening of penile veins or lymphatics located around the coronal sulcus or, less commonly, along the dorsal vein of the penis. Infrequently it may be associated with non-sexual trauma or with hypercoagulable states.</p>
<b>GB06.4</b>	<p><b>Chronic penile oedema</b></p> <p>Chronic oedema localised to the penis. Proposed causes include chronic strangulation, low grade streptococcal infection with resultant irreversible lymphatic damage or primary hypoplastic lymphatics.</p>
<b>GB06.5</b>	<p><b>Sclerosing lymphangitis of penis</b></p> <p>This condition presents with a usually painless serpiginous cord-like swelling in the coronal sulcus of the penis. It is typically associated with vigorous sexual intercourse. It normally resolves within a period of weeks.</p>
<b>GB06.Y</b>	<b>Other specified disorders of penis</b>
<b>GB06.Z</b>	<b>Disorders of penis, unspecified</b>

**GB07****Inflammatory disorders of male genital organs, not elsewhere classified**

Any disorder of the male genital organs, characterised by pathological changes and inflammation of the tissue, not classified elsewhere.

- Exclusions:**
- Inflammation of penis (GB06)
  - Orchitis or epididymitis (GB02)
  - Epididymorchitis (GB02)

**GB07.0****Inflammatory disorders of seminal vesicle**

Any disorder of the seminal vesicle, characterised by pathological changes and inflammation of the tissue.

**Coded Elsewhere:** Tuberculosis of seminal vesicle (1B12.5)

**GB07.1****Inflammatory disorders of spermatic cord, tunica vaginalis or vas deferens**

Any disorder of the spermatic cord, tunica vaginalis and vas deferens, characterised by pathological changes and inflammation of the tissue.

**Coded Elsewhere:** Chylocele of tunica vaginalis in loiasis (1F66.0)

Chylocele of tunica vaginalis in filariasis due to Wuchereria bancrofti (1F66.30)

**GB07.2****Inflammatory disorders of scrotum**

Any disorder of the scrotum, caused by poor hygiene or chafing of the skin. This condition is characterised by superficial inflammation of the tissue.

- Exclusions:**
- Streptococcal cellulitis of skin (1B70.1)
  - Staphylococcal cellulitis of skin (1B70.2)

**GB07.Y****Other specified inflammatory disorders of male genital organs, not elsewhere classified****GB08****Vascular disorders of male genital organs**

Any disorder affecting the cardiovascular and genital systems, characterised by pathological changes to the blood vessels of the male genital organs.

**GB0Y****Other specified diseases of the male genital system****GB0Z****Diseases of the male genital system, unspecified**

## Disorders of breast (GB20-GB2Z)

Any disorder characterised by pathological changes to the breast or breast tissue.

**Exclusions:** Certain specified disorders of breast or lactation associated with childbirth (JB46)

**Coded Elsewhere:** Neoplasms of the breast

**GB20**

### **Benign breast disease**

Any disease affecting females, characterised by benign, noncancerous lesions in the breast, leading to pathological changes to (and discomfort of) the breast or breast tissue.

**Coded Elsewhere:** Breast abscess (GB21.0)

Disorders of breast augmentation (GC7A)

Disorders of breast reduction (GC79)

**GB20.0**

### **Fibrocystic change of breast**

A condition characterised by changes to the breast tissue leading to benign, noncancerous lesions in the breast. These conditions may be associated with small or large cyst formation, hyperplasia of the ductal epithelium, apocrine metaplasia of the ductal cells, papillomatosis, duct ectasia, sclerosing adenosis, or fibrosis of the stroma. This condition may also present with breast pain, thickening of breast tissue, or nipple discharge that worsen prior to menstruation, or may be asymptomatic. Confirmation is by clinical breast exam, followed by mammography or ultrasonography to distinguish between abnormal tissue.

**GB20.1**

### **Fibroadenosis of breast**

**Exclusions:** Fibroadenoma of breast (2F30.5)

**GB20.Y**

### **Other specified benign breast disease**

**GB20.Z**

### **Benign breast disease, unspecified**

**GB21**

### **Inflammatory disorders of breast**

Any disorder of the breast or breast tissue, characterised by inflammatory effects, pain, heat, redness, swelling, and loss of function.

**Coded Elsewhere:** Nonpurulent mastitis associated with childbirth (JB45.1)

Neonatal infectious mastitis (KA65.3)

**GB21.0**

### **Breast abscess**

A condition of the breast, caused by inflammation due to infection with a bacterial or parasitic host, or contact with other foreign materials. This condition is characterised by a focal accumulation of purulent material within or on the breast tissue.

**Coded Elsewhere:** Abscess of breast associated with childbirth (JB45.0)

**GB21.Y**

### **Other specified inflammatory disorders of breast**

**GB21.Z**

### **Inflammatory disorders of breast, unspecified**

**GB22****Hypertrophy of breast**

A condition affecting the breast, characterised by unilateral or bilateral enlargement or thickening of the connective tissues that exceeds 3% of the total body weight. This condition may be associated with increased histologic sensitivity to, or abnormally high levels of, prolactin, estrogen, and progesterone in the blood.

**GB23****Certain specified disorders of breast**

Any disorder of the breast or breast tissue, characterised by pathological changes, not classified elsewhere.

**Coded Elsewhere:** Other signs or symptoms in breast (MF3Y)

**GB23.0****Mammary duct ectasia**

A condition of the breast, caused by lipid and cellular debris or secretory (such as colostrum) stasis, or a nonspecific duct widening process. This condition is characterised by obstruction and subsequent dilation of the lactiferous duct, periductal inflammation, periductal fibrosis, nipple retraction, inversion, pain, or bloody discharge from the nipple.

**GB23.1****Fissure or fistula of nipple**

A condition characterised by the formation of a deep furrow or crack-like lesion on the nipple and an abnormal passage between the nipple and adjacent tissues or surfaces.

**GB23.2****Fat necrosis of breast**

A condition of the breast, caused by saponification of fat tissue, commonly subsequent to trauma or radiation therapy. This condition is characterised by damage, death, or inflammation of the fat tissue by blood and tissue digestive enzymes, and the development of scar tissue and lesions. Confirmation is by imaging of the breast and needle aspiration.

**GB23.3****Atrophy of breast**

A condition of the breast, caused by apoptosis of the cells commonly due to prolonged estrogen reduction, diminished cellular proliferation, decreased cellular volume, decreased function, ischaemia, malnutrition, disease, or mutation. This condition is characterised by a partial or complete decrease in size and function of the breast tissue.

**GB23.4****Galactorrhoea not associated with childbirth**

A condition of the breast, characterised by persistent and abnormal secretion of white discharge. In females, the secretions occur between intervals of neonate or infant nursing, or after the infant has stopped breastfeeding. In males and children, these secretions occur spontaneously. This condition is not associated with the physiological changes as part of pregnancy, childbirth, or the puerperium.

**GB23.5****Mastodynia**

The symptom of breast pain. This symptom may be classified as cyclic or non-cyclical depending on the clinical patterns.

**Exclusions:** Chronic pain (MG30)

**GB2Z****Disorders of breast, unspecified**

## Diseases of the urinary system (GB40-GC2Z)

Any disease characterised by pathological changes to the urinary system.

**Coded Elsewhere:** Neoplasms of the urinary system

Clinical findings on examination of urine, without diagnosis (MF90-MF9Y)

Structural developmental anomalies of the urinary system (LB30-LB3Z)

Symptoms, signs or clinical findings involving the urinary system (MF50-MF5Y)

Hypertensive renal disease (BA02)

### Glomerular diseases (GB40-GB4Z)

Any disease characterised by pathological changes to the glomerulus.

**Inclusions:** Hypertensive renal disease (BA02)

**Coded Elsewhere:** Clinical findings in specimens from the urinary system (MF80-MF8Z)

Symptomatic late syphilis of other sites (1A62.2)

Plasmodium malariae malaria with nephropathy (1F42.0)

Glomerular disorders in secondary systemic amyloidosis (5D00.1)

**GB40**

### Nephritic syndrome

Sudden onset of glomerular disease usually with severe (macroscopic/visible) haematuria accompanied by oliguria, elevated blood pressure, mild oedema and albuminuria or proteinuria usually of sub-nephrotic range. May be a cause of acute renal failure in which case the syndrome is termed rapidly progressive nephritis. Nephritic syndrome has many possible causes and is associated with renal light microscopic changes such hypercellularity, necrosis or thrombosis.

**Inclusions:** acute nephritis

**Exclusions:** Tubulo-interstitial nephritis, not specified as acute or chronic (GB54)

**GB41**

### Nephrotic syndrome

A condition characterised by severe proteinuria, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in hypoalbuminaemia and generalised oedema. There is also usually hyperlipidaemia. Other manifestations of glomerular disease may be present. There are many possible causes and renal histological appearances. Possible complications include vascular thrombosis, infections, malnutrition and renal failure.

**GB42****Persistent proteinuria or albuminuria**

Persistent albuminuria >3mg/mmol creatinine or >30mg/day is regarded as abnormal, indicative and often the first manifestation of chronic kidney disease (KDOQI, KDIGO). In surveillance for CKD in “at risk” patients such as diabetics, urinalysis for albuminuria is recommended by most clinical practice guidelines. This diagnosis does not refer to intermittent proteinuria as in orthostatic or exercise induced proteinuria, nor to non-albuminuric proteinuria such as Bence Jones (immunoglobulin light chain) proteinuria.

**Exclusions:**

- Orthostatic proteinuria (MF96.0)
- proteinuria NOS (MF96)
- Gestational proteinuria without hypertension (JA22.0)
- Bence Jones proteinuria (MF96.1)
- Nephrotic syndrome (GB41)
- albuminuria NOS (MF96)

**GB42.0****Albuminuria, Grade A2**

Presence of excessive albumin in the urine, indicating abnormal permeability glomerular filtration. Can be quantitated by either timed collections or spot urine samples with the concentration adjusted to the urine creatinine concentration to correct for variations in overall urine concentration. When persistent and of moderate or greater severity usually indicates overt glomerular disease such as caused by diabetic glomerulosclerosis, glomerulonephritis or amyloid.

**Coding Note:**

Code also the causing condition

**GB42.1****Albuminuria, Grade A3**

Presence of excessive albumin in the urine, indicating abnormal permeability glomerular filtration. Can be quantitated by either timed collections or spot urine samples with the concentration adjusted to the urine creatinine concentration to correct for variations in overall urine concentration. When persistent and of moderate or greater severity usually indicates overt glomerular disease such as caused by diabetic glomerulosclerosis, glomerulonephritis or amyloid.

**Coding Note:**

Code also the causing condition

**GB42.Y****Other specified persistent proteinuria or albuminuria****GB42.Z****Persistent proteinuria or albuminuria, unspecified****GB4Y****Other specified glomerular diseases****GB4Z****Glomerular diseases, unspecified**

## Renal tubulo-interstitial diseases (GB50-GB5Z)

Any disease characterised by pathological changes to the renal tubules and interstitial tissues.

**Exclusions:** pyeloureteritis cystica (GB90)

**Coded Elsewhere:** Renal tubulo-interstitial disorders due to toxoplasma gondii (1F57.Y)

Renal tubulo-interstitial disorders due to salmonella infection (1A09.Y)

**GB50**

### Acute tubulo-interstitial nephritis

A disease characterised by acute inflammation of, and damage to, tubules and the interstitium of the kidney, usually accompanied by acute renal failure (acute kidney injury). Histology shows acute inflammatory infiltrate in the interstitium with oedema and tubular cell necrosis, and often prominent eosinophils and plasma cells. Usually due to an allergic or immunological reaction to an identifiable allergen. Usually accompanied by acute renal failure which may be reversible if the allergen is withdrawn expeditiously with or without corticosteroid administration. Can lead to chronic tubulointerstitial nephritis, particularly if the allergen exposure is not short term. May be associated with other signs of an allergic reaction such as rash or fever.

**GB51**

### Acute pyelonephritis

Acute inflammation of the renal pelvis and parenchyma due to bacterial infection. One of the commonest bacterial infections of adult women. Symptoms include fever, loin (kidney) pain, nausea and vomiting. Co-incident symptoms of acute cystitis with dysuria, frequency and haematuria may occur. Renal failure is not a feature unless there is septicaemia, hypotension or hypovolemia.

**GB52**

### Acute tubular necrosis

Any condition of the kidney, caused by hypotension, hypoperfusion, ischaemia, hypoxia, or use of nephrotoxic drugs. These conditions are characterised by death of tubular epithelial cells and acute kidney injury. Confirmation is by identification of "muddy brown casts" of epithelial cells in a urine sample.

**Coding Note:**

Code also the causing condition

**GB53**

### Acute renal papillary necrosis

A condition of the kidney, caused by ischaemia, liver disease, or analgesic nephropathy. This condition is characterised by death of single or multiple renal papillae, haematuria, flank pain, and tissue fragments in the urine. This condition may also present with fever and chills.

**GB54**

### Tubulo-interstitial nephritis, not specified as acute or chronic

A disease characterised by inflammation of and damage to tubules or the interstitium of the kidney while sparing the glomeruli secondary to immune reaction or toxic agent.

**Exclusions:** calculous pyelonephritis (GB70)

**GB55****Chronic tubulo-interstitial nephritis**

A disease characterised by inflammation of and damage to tubules and/or the interstitium of the kidney, interstitial scarring, fibrosis and tubule atrophy resulting in progressive chronic renal insufficiency

**Coding Note:**

Code also the causing condition

**Exclusions:** calculous pyelonephritis (NFAD) (GB70)

**Coded Elsewhere:** Autosomal dominant polycystic kidney disease (GB81)

**GB55.0****Balkan nephropathy**

Balkan nephropathy is a form of interstitial nephritis characterised by a very localised geographic occurrence. It was first identified in the 1920s among several small, discrete communities along the Danube River and its major tributaries. Now thought to be due to chronic aristolochic acid ingestion (ingestion of Aristolochia clematitis seeds native to the Balkan region), though it has some differences from Chinese herbal nephropathy. This disease is characterised by renal insufficiency, proteinuria, tubulointerstitial nephritis, anaemia, weakness, copper discolouration of the skin, and may lead to end-stage renal disease within 5 years after onset.

**Inclusions:** Balkan endemic nephropathy

**GB55.1****Nephropathy induced by heavy metals**

A disease of the kidney, caused by exposure to heavy, nephrotoxic metals such as cadmium, lead, copper, and mercury. This disease is characterised by tubular damage, renal insufficiency, interstitial fibrosis, necrosis, or renal dysfunction. This disease may also present with hypertension, proteinuria, hyperuricaemia, aminoaciduria, or other symptoms characteristic of chronic kidney disease.

**GB55.2****Chronic urate nephropathy**

A condition characterised by deposition of urate crystals in the tubules and interstitium, partial or complete obstruction of the collecting ducts, renal pelvis, or ureter, hyperuricaemia disproportionate to the degree of renal insufficiency and decreased urate excretion. This condition may lead to inflammation, fibrosis, and renal failure.

**GB55.Y****Other specified chronic tubulo-interstitial nephritis****Coding Note:**

Code also the causing condition

**GB55.Z****Chronic tubulo-interstitial nephritis, unspecified****Coding Note:**

Code also the causing condition

**GB56****Obstructive or reflux nephropathy**

Distention of the pelvis and calices of the kidney with urine as a result of obstruction of the ureter or as a result of a vesicoureteral or vesicoureterorenal reflux of urine. Diffuse or focal cortical scarring and chronic tubulointerstitial nephritis may be present.

**Exclusions:** Calculus of kidney and ureter without hydronephrosis  
(GB70-GB7Z)

Obstructive pyelonephritis (GB55)

- GB56.0 Hydronephrosis with ureteropelvic junction obstruction**  
A condition caused by any obstruction in or stenosis of the ureteropelvic junction. This condition is characterised by distension of the pelvis and calyces of the kidney with a partial or complete obstructed flow of urine. This condition may present with flank pain, haematuria, pyuria, or hyperpyrexia.
- Exclusions:** Congenital ureteropelvic junction occlusion (QJCB) (LB31.8)  
Congenital hydronephrosis (LB31.0)
- GB56.1 Hydronephrosis with ureteral obstruction**  
Intrinsic stenosis or stricture or extrinsic obstruction of the ureter, except at the ureteropelvic junction or at the ureteral orifice, causing distension of the pelvis and calices of the kidney with urine.
- Exclusions:** Congenital hydronephrosis (LB31.0)
- GB56.2 Hydronephrosis with ureteral orifice obstruction**  
Dilatation of the renal pelvis and calyces associated with (and presumably due to) obstruction of the ureter at the insertion into the bladder and hence ascending back pressure.
- Exclusions:** with infection (GB58)
- GB56.3 Hydronephrosis due to bladder obstruction**  
A condition caused by an obstruction in the urinary bladder. It is characterised by distention of the pelvis and calices of one or both kidneys, and lack of free flow of urine from the kidney, and can lead to progressive atrophy of the kidney if untreated. The condition may also present with pain in the flank, haematuria, pyuria, or hyperpyrexia.
- GB56.4 Other or unspecified hydronephrosis**  
This refers to distension and dilation of the renal pelvis and calyces in situations other than those coded elsewhere or when no additional details are available.
- Exclusions:** Pyonephrosis (GB58)
- GB56.5 Hydronephrosis and reflux nephropathy with vesicoureteral or vesico-uretero-renal reflux**  
Distention of the pelvis and calices of the kidney with urine as a result of obstruction of the ureter not caused by strictures or stenoses of the ureter or by ureteral stones.
- Exclusions:** Congenital vesico-uretero-renal reflux (LB31.D)  
Congenital hydronephrosis (LB31.0)
- GB56.Y Other specified obstructive or reflux nephropathy**
- GB56.Z Obstructive or reflux nephropathy, unspecified**
- GB57 Nephrocalcinosis**  
A condition of the kidney, caused by previous inflammation or degeneration when accompanied by previous renal failure. This condition is characterised by renal lithiasis, or calcium-based deposition in the renal parenchyma. This condition may also present with infection, haematuria, anal colic, or decreased renal function. Confirmation is by abdominal medical imaging to determine location of deposits.

**GB58****Pyonephrosis**

A condition caused by complications subsequent to calyces, hydronephrosis, or pyelonephritis, or which may be idiopathic. This condition is characterised by a collection of pus in the renal pelvis, leading to distension of the kidney and possibly kidney failure.

**GB59****Renal or perinephric abscess**

A collection of purulent material in the kidney substance and/or around the kidneys. Usually due to bacterial infection. Minor: Origin can be haematogenous or ascending infection.

**GB5Y****Other specified renal tubulo-interstitial diseases**

**Coding Note:** Code also the causing condition

**GB5Z****Renal tubulo-interstitial diseases, unspecified**

**Coding Note:** Code also the causing condition

Kidney failure (GB60-GB6Z)

Inability of the kidneys to adequately filter the blood of waste products, with a lower than normal glomerular filtration rate (GFR). Can be abrupt and potentially reversible (acute kidney injury) or persistent due to irreversible kidney damage (chronic kidney disease).

**Exclusions:** Hypertensive renal disease (BA02)

**Coded Elsewhere:** Renal failure following abortion, ectopic or molar pregnancy (JA05.4)

Congenital renal failure (KC01)

**GB60****Acute kidney failure**

An increase in serum creatinine by 0.3 mg/dl or greater within 48 hours; or increase in serum creatinine by 1.5-fold or greater above baseline, which is known or presumed to have occurred within 7 days; or urine volume less than 0.5 ml/kg/h for 6 hours or more.

**Coding Note:** Code also the causing condition

**Inclusions:** nontraumatic acute kidney injury

**GB60.0****Acute kidney failure, stage 1**

Rate of change of serum creatinine: Increase 1.5-1.9 times baseline within 7 days OR increase by 0.3 mg/dl increase within 48 h OR Magnitude of urine output: <0.5 ml/kg/h for 6-12 hours

**Coding Note:** Code also the causing condition

**Inclusions:** Acute nontraumatic kidney injury, mild

**GB60.1****Acute kidney failure, stage 2**

Rate of change of serum creatinine: 2.0-2.9 times baseline OR Magnitude of urine output: <0.5 ml/kg/h for >= 12 hours

**Coding Note:** Code also the causing condition

**Inclusions:** Acute nontraumatic kidney injury, moderate

<b>GB60.2</b>	<b>Acute kidney failure, stage 3</b>
	Rate of change of serum creatinine: 3.0 times baseline OR increase to 4.0 mg/dl OR need for renal replacement therapy (i.e. dialysis) or for patients <18 years, decrease in GFR to <35 ml/min per 1.73 m <sup>2</sup> OR Magnitude of urine output: <0.3 ml/kg/h for 24 hours OR anuria for >= 12 hours
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> Acute nontraumatic kidney injury, severe
<b>GB60.Y</b>	<b>Other specified acute kidney failure</b>
<b>Coding Note:</b>	Code also the causing condition
<b>GB60.Z</b>	<b>Acute kidney failure, stage unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>GB61</b>	<b>Chronic kidney disease</b>
	GFR <60 or presence of kidney damage that is present for more than 3 months. Evidence of kidney damage can include structural abnormalities (imaging or histology), albuminuria above normal limits, urinary sediment abnormalities or electrolyte disturbances due to tubular disorders.
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> chronic renal failure Chronic renal insufficiency
	<b>Exclusions:</b> Hypertensive renal disease (BA02)
<b>GB61.0</b>	<b>Chronic kidney disease, stage 1</b>
	Kidney damage with normal or increased GFR (>90 ml/min/1.73m <sup>2</sup> )
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> chronic renal failure, stage 1
<b>GB61.1</b>	<b>Chronic kidney disease, stage 2</b>
	Kidney damage and GFR 60-89 ml/min/1.73m <sup>2</sup>
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> chronic renal failure, stage 2
<b>GB61.2</b>	<b>Chronic kidney disease, stage 3a</b>
	GFR 45-59 ml/min/1.63m <sup>2</sup>
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> chronic renal failure, stage 3a
<b>GB61.3</b>	<b>Chronic kidney disease, stage 3b</b>
	GFR 30-44 ml/min/1.73m <sup>2</sup>
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> chronic renal failure, stage 3b

<b>GB61.4</b>	<b>Chronic kidney disease, stage 4</b> GFR (15-29 ml/min/1.73m <sup>2</sup> )
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> chronic renal failure, stage 4
<b>GB61.5</b>	<b>Chronic kidney disease, stage 5</b> Kidney failure, GFR < 15 ml/min/1.73m <sup>2</sup>
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> chronic renal failure, stage 5
	<b>Coded Elsewhere:</b> Albuminurica retinitis (9B65.Z)
<b>GB61.Z</b>	<b>Chronic kidney disease, stage unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>GB6Z</b>	<b>Kidney failure, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition

#### Urolithiasis (GB70-GB7Z)

A condition of the urinary system, caused by dehydration, decreased urine volume or fluid flow rates, or increased excretion of minerals such as calcium, oxalate, magnesium, cystine, and phosphate. This condition is characterised by the presence of calculi originating in the urinary system or which are located within the urinary system. Confirmation is by abdominal radiography, or intravenous pyelography.

<b>Exclusions:</b>	Hyperoxaluria (5C51.2) Hypercalciuria (MF98.0) Crystalluria (MF90-MF9Y) Cystinuria (5C60.2)
--------------------	--

#### **GB70** **Calculus of upper urinary tract**

A condition of the urinary system, caused by dehydration, decreased urine volume or fluid flow rates, or increased excretion of minerals such as calcium, oxalate, magnesium, cystine, and phosphate. This condition is characterised by urinary calculi located in the upper urinary tract (renal papilla). This condition may present with haematuria, dysuria, or pain in the flank, lower abdomen, or groin. Confirmation is by abdominal radiography to determine the presence and location of calculi.

<b>GB70.0</b>	<b>Calculus of kidney</b>
	A condition of the kidney, caused by dehydration, decreased urine volume or fluid flow rates, or increased excretion of minerals such as calcium, oxalate, magnesium, cystine, and phosphate. This condition is characterised by the urinary calculi located in the kidney, in renal calyces, or in the renal pelvis. This condition may present with haematuria, dysuria, or pain in the flank, lower abdomen, or groin. Confirmation is by abdominal radiography to determine the presence and location of calculi.

<b>Inclusions:</b>	Renal calculus or stone Stone in kidney
--------------------	--

<b>GB70.00</b>	Staghorn calculus A condition of the kidney, characterised by large, branched, struvite or calcium carbonate apatite calculi within the renal pelvis and extending into one or more caliceal extensions, and fever, haematuria, or flank pain, leading to renal failure and life-threatening sepsis. This condition may be associated with urinary tract infection. Confirmation is by imaging of the abdominal region.
<b>GB70.0Y</b>	Other specified calculus of kidney
<b>GB70.0Z</b>	Calculus of kidney, unspecified
<b>GB70.1</b>	<p><b>Calculus of ureter</b></p> <p>A condition of the ureter, caused by dehydration, decreased urine volume or fluid flow rates, or increased excretion of minerals such as calcium, oxalate, magnesium, cystine, and phosphate. This condition is characterised by urinary calculi located in the ureter, and may lead to renal colic. This condition may present with haematuria, dysuria, or pain in the flank, lower abdomen, groin, thighs, or genitalia. Confirmation is by abdominal radiography to determine the presence and location of calculi.</p> <p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Ureteric stone</li> <li>Ureteral calculus or stone</li> <li>Stone in the ureter</li> </ul>
<b>GB70.Z</b>	<b>Calculus of upper urinary tract, unspecified</b>
<b>GB71</b>	<p><b>Calculus of lower urinary tract</b></p> <p>A condition of the urinary system, caused by dehydration, decreased urine volume or fluid flow rates, or increased excretion of minerals such as calcium, oxalate, magnesium, cystine, and phosphate. This condition is characterised by urinary calculi located in the lower urinary tract (urinary bladder and urethra). This condition may also present with haematuria, dysuria, or pain in the flank, lower abdomen, or groin. Confirmation is by abdominal radiography to determine the presence and location of calculi.</p> <p><b>Calculus in bladder</b></p> <p>A condition caused by dehydration, decreased urine volume or fluid flow rates, or increased excretion of minerals such as calcium, oxalate, magnesium, cystine, and phosphate. This condition is characterised by urinary calculi located in the bladder. This condition may also present with haematuria, dysuria, or pain in the flank, lower abdomen, or groin. Confirmation is by abdominal radiography, to determine the presence and location of calculi.</p> <p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Urinary bladder stone</li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Calculus in a bowel segment for urinary diversion (e.g. neobladder, pouch) (NFBC) (GB71.2)</li> </ul>

<b>GB71.1</b>	<b>Calculus in urethra</b>
	A condition caused by dehydration, decreased urine volume or fluid flow rates, or increased excretion of minerals such as calcium, oxalate, magnesium, cystine, and phosphate. This condition is characterised by urinary calculi located in the urethra, where it may lead to renal colic. This condition may also present with haematuria, dysuria, or pain in the flank, lower abdomen, groin, thighs, or genitalia. Confirmation is by abdominal radiography to determine the presence and location of calculi.
	<b><i>Inclusions:</i></b> Calculus of bowel segments for urinary diversion (GB71.2)
<b>GB71.2</b>	<b>Calculus of bowel segments for urinary diversion</b>
	A condition caused by dehydration, decreased urine volume or fluid flow rates, or increased excretion of minerals such as calcium, oxalate, magnesium, cystine, and phosphate. This condition is characterised by urinary calculi located in the bowel segment for urinary diversion (ileal neobladder, ileal conduit, ileocaecal pouch). This condition may also present with haematuria, dysuria, or pain in the flank, lower abdomen, or groin. Confirmation is by abdominal radiography to determine the presence and location of calculi.
<b>GB71.Z</b>	<b>Calculus of lower urinary tract, unspecified</b>
<b>GB7Z</b>	<b>Urolithiasis, unspecified</b>
 <b>Cystic or dysplastic kidney disease (GB80-GB8Z)</b>	
Any disease of the kidney, caused by determinants arising during the antenatal period or after birth. These diseases are characterised by pathological changes to one or both kidneys, and may manifest in other anatomical tissues.	
	<b><i>Coded Elsewhere:</i></b> Tuberous sclerosis (LD2D.2)
	Noonan syndrome (LD2F.15)
	Meckel-Gruber syndrome (LD2F.13)
	Asphyxiating thoracic dystrophy (LD24.B1)
	Multicystic renal dysplasia (LB30.9)
<b>GB80</b>	<b>Nonfamilial nongenetic cystic kidney disease</b>
	Diseases where there are developmental anatomical or pathological changes in the renal substance not occurring in a familial distribution and not known to have a mono-genetic cause.
	<b><i>Coded Elsewhere:</i></b> Medullary sponge kidney (LB30.8)
	Multicystic renal dysplasia (LB30.9)
<b>GB80.0</b>	<b>Simple renal cyst</b>
	A disease of the kidney, caused by obstruction of tubules, anaemia, or detachment of diverticula. This disease is characterised by the formation of thin-walled abnormal sacs filled with hypo-echogenic radiolucent fluid in the kidney. Confirmation is by imaging.
	<b><i>Inclusions:</i></b> Bosniak 1 cyst

<b>GB80.1</b>	<b>Complex renal cyst</b> Renal cyst with high attenuation or mixed contents, septate or thickened wall. May be subclassified by the Bosniak classification Bosniak 2-4 to indicate increasing likelihood of neoplasm.
<b>GB80.2</b>	<b>Subscapular or perirenal urinoma</b> A disease of the kidney, caused by urinary obstruction such as calices in the kidney or ureter, or a breach of the integrity of the pelvis. This disease is characterised by an encapsulated collection of urine located in a fat-lined sac around the kidneys or in the retroperitoneum. Confirmation is by imaging.
<b>GB80.Y</b>	<b>Other specified nonfamilial nongenetic cystic kidney disease</b>
<b>GB80.Z</b>	<b>Nonfamilial nongenetic cystic kidney disease, unspecified</b>
<b>GB81</b>	<b>Autosomal dominant polycystic kidney disease</b> Multiple cysts in both kidneys increasing in number and size from adolescence, associated with development of hypertension and chronic renal failure. Autosomal dominant familial pattern is usual and due to mutations on chromosomes 16 and 4. Non-renal manifestations can include cysts in the liver and less commonly pancreas. Cerebral arterial aneurysms with subarachnoid haemorrhage, and other non-renal vascular abnormalities can also occur.
<b>GB82</b>	<b>Autosomal dominant tubulointerstitial disease</b> Nonglomerular, autosomal dominant kidney diseases characterised by progressive tubulointerstitial fibrosis and progression to end-stage renal disease. Currently there are 4 known genetic defects - in uromodulin, mucin-1, renin and hepatocyte nuclear factor 1-beta. The last is associated with Maturity-Onset Diabetes of the Young (MODY) and thus is classified as MODY-5  <b>Coded Elsewhere:</b> Medullary sponge kidney (LB30.8) MODY 5 syndrome (5A13.6)
<b>GB83</b>	<b>Nephronophthisis</b> Autosomal recessive disease characterised by polyuria, polydipsia, enuresis and chronic kidney disease with end stage renal failure occurring between birth and late adolescence depending on the NPHP gene involved. Extra-renal manifestations occur with associated multisystem genetic disorders (e.g. Senior-Loken, Cogan, Joubert)
<b>GB8Y</b>	<b>Other specified cystic or dysplastic kidney disease</b>
<b>GB8Z</b>	<b>Cystic or dysplastic kidney disease, unspecified</b>

<b>GB90</b>	<b>Certain specified disorders of kidney or ureter</b> Any disorder characterised by pathological changes to the kidney or ureter.
<b>Coding Note:</b>	Code also the causing condition
<b>Exclusions:</b>	Urolithiasis (GB70-GB7Z)
<b>Coded Elsewhere:</b>	Macroscopic changes of size of the kidney (MF54) Ureteral fistula (GC04.2) Postinterventional ischemia or infarction of kidney (GC7B) Neonatal haemorrhage originating in kidney or bladder (KA83.6) Diabetic nephropathy (GB61.Z) Renal late syphilis (1A62.2Y) Disorders of kidney or ureter in tuberculosis (1B1Y)
<b>GB90.0</b>	<b>Nephroptosis</b> Enhanced mobility of the kidney, resulting in ptosis when the patient is upright. More common on the right, associated with a longer renal artery, and debatably associated with fibromuscular hyperplasia and hypertension.
<b>GB90.1</b>	<b>Hydroureter</b> A condition caused by obstruction, stricture, or stenosis of the ureter, which may be due to prostatic hypertrophy, carcinoma, retroperitoneal or pelvic neoplasms, calculi, or a congenital anomaly. This condition is characterised by distention of the ureter with urine.  <b>Exclusions:</b> Congenital primary megaureter (LB31.1)
<b>GB90.2</b>	<b>Ureteral kinking or deviation without obstruction</b> A condition characterised by a sharp twist, curve, or other deviation in the length of the ureter, but without an obstructed flow of urine.  <b>Inclusions:</b> Kinking of the ureter without hydronephrosis <b>Exclusions:</b> with infection (GB58) congenital ureteric stenosis (LB31.8)
<b>GB90.3</b>	<b>Ischaemia or infarction of kidney</b> <b>Exclusions:</b> Atherosclerosis of renal artery (BD40.2) Goldblatt kidney (BD40.2) Congenital renal artery stenosis (LA90.40)
<b>GB90.4</b>	<b>Renal tubular function disorders</b> Disorders primarily due to abnormalities of renal tubular resorption or secretion.  <b>Coded Elsewhere:</b> Cystinuria (5C60.2) Nephrogenic syndrome of inappropriate antidiuresis (5A60.20)

<b>GB90.40</b>	Hypotonia-cystinuria type 1 This is a rare syndrome including neonatal and infantile hypotonia and failure to thrive, cystinuria type 1, nephrolithiasis, growth retardation due to growth hormone deficiency, and minor facial dysmorphism due to a homozygous deletion of two contiguous genes on chromosome 2: SLC3A1 and PREP (2p21). <b>Coded Elsewhere:</b> Hypotonia-cystinuria syndrome (5C60.Y)
<b>GB90.41</b>	Pseudohypoaldosteronism type 1 Pseudohypoaldosteronism type 1 (PHA1) are rare forms of mineralocorticoid resistance. PHA1 presents in the newborn with renal salt wasting, failure to thrive and dehydration. Two clinical forms have been described: i) a renal form (renal PHA1) that improves with age and in which mineralocorticoid resistance is restricted to the kidney, and ii) a generalised severe form (generalised PHA1) that persists into adulthood and in which mineralocorticoid resistance is systemic and salt loss occurs in multiple organs. Inheritance can be autosomal recessive (arPHA1) which is more severe and persistent than the autosomal dominant form (AdPHA1)
<b>GB90.42</b>	Fanconi syndrome Disorder associated with generalised dysfunction of the proximal tubule expressed as amino-aciduria, low molecular weight proteinuria, polyuria with sodium and potassium wasting, hyper-phosphaturia (hence bone disease), renal tubular acidosis, glycosuria and hypercalciuria. <b>Coded Elsewhere:</b> Oculocerebrorenal syndrome (5C60.0)
<b>GB90.43</b>	Bartter syndrome Bartter syndrome is a genetic renal tubular disease characterised by the association of hypokalaemic alkalosis, increased levels of plasma renin and aldosterone, low blood pressure and vascular resistance to angiotensin II. Two forms of the disease can be distinguished according to clinical criteria: an antenatal or infantile Bartter syndrome (most patients with genotypes I, II and IV), characterised by polyhydramnios, premature delivery, polyuria, dehydration, hypercalciuria and nephrocalcinosis; and classical Bartter syndrome (mostly patients with genotype III, but also some type IV patients), manifesting as polyuria-polydipsia in infancy-childhood through to adulthood, dehydration and a variable delay in the height-weight growth curve.
<b>GB90.44</b>	Renal tubular acidosis Conditions characterised by failure of the kidney to excrete acids, or to lose bicarbonate into the urine, which causes the blood to become too acidic. Characteristically hyperchloremic acidosis (low anion gap metabolic acidosis). Has several forms and many causes. <b>Coded Elsewhere:</b> Osteopetrosis with renal tubular acidosis (LD24.10)
<b>GB90.45</b>	Renal glycosuria Glycosuria (glucose in the urine) at normal blood glucose levels due to inadequate renal tubular resorption. Can be due to above normal glomerular filtration as in pregnancy or occurs residual nephrons in renal failure, or reduced tubular resorption.

<b>GB90.46</b>	Tubular disorders of sodium or potassium transport Abnormalities of the renal tubules resorptive or secretory functions, inherited or acquired.
	<b>Exclusions:</b> Fanconi syndrome (GB90.42)
<b>GB90.47</b>	Aminoaciduria Conditions in which amino acids are found in the urine either due to over-production (high blood levels) or failure of tubular resorption
<b>GB90.48</b>	Disorders of calcium or phosphate excretion Conditions in which renal excretion of calcium and / or phosphate is deranged.  <b>Coded Elsewhere:</b> Pseudohypoparathyroidism (5A50.1) Hypophosphataemic rickets (5C63.22)
<b>GB90.49</b>	Renal hypocalciuria A condition of the kidney, caused by renal tubular retention, low dietary calcium intake, or abnormalities in calcium absorption, and which may be associated with thiazide diuretic intake, Gitelman's disease, or familial hypocalciuric hypercalcaemia. This condition is characterised by a decrease in the level of calcium in the urine.  <b>Coded Elsewhere:</b> Familial hypocalciuric hypercalcaemia (5A51.2) Acquired hypocalciuric hypercalcemia (5A51.Y)
<b>GB90.4A</b>	Nephrogenic diabetes insipidus Nephrogenic diabetes insipidus is a condition in which the kidney tubules respond poorly to pituitary secreted anti-diuretic hormone, resulting in a failure to concentrate the urine, and water loss. Polyuria with dilute urine and polydipsia (excessive thirst) are present. It can be congenital or acquired with many causes. The congenital forms may be attributed to vasopressin receptor or aquaporin-2 defects. They are characterised by polyuria with polydipsia, recurrent bouts of fever, constipation, and acute hypernatraemic dehydration after birth that may cause neurological sequelae.  <b>Exclusions:</b> Central diabetes insipidus (5A61.5)
<b>GB90.4Y</b>	Other specified renal tubular function disorders
<b>GB90.4Z</b>	Renal tubular function disorders, unspecified
<b>GB90.Y</b>	<b>Other specified disorders of kidney or ureter</b>
<b>Coding Note:</b>	Code also the causing condition

Certain specified diseases of urinary system (GC00-GC0Y)

**Exclusions:** Infections of genitourinary tract in pregnancy (JA62)  
Urolithiasis (GB70-GB7Z)

**Coded Elsewhere:** Urinary incontinence (MF50.2)  
Tuberculosis of kidney or ureter (1B12.5)  
Tuberculosis of bladder (1B12.5)

## GC00

### **Cystitis**

A condition of the bladder, caused by infection, reaction to pharmacological agents, exposure to radiation therapy, or potential irritants. This condition is characterised by inflammation of the urinary bladder, dysuria, pollakiuria, fever, or flank pain.

**Exclusions:** Prostatocystitis (GA91.2)

**Coded Elsewhere:** Infections of bladder in pregnancy (JA62.1)

## GC00.0

### **Trigonitis**

A condition of the bladder that is frequently idiopathic. This condition is characterised by inflammation of the nonkeratinizing squamous metaplasia in the trigone region of the bladder.

## GC00.1

### **Infectious cystitis**

Inflammation of the urinary bladder caused by microbes

**Exclusions:** tuberculous cystitis (NHEA) (1B12.5)  
bladder disorder in schistosomiasis [bilharziasis] (NHEB) (1F86.0)

## GC00.2

### **Contracted urinary bladder**

A condition characterised by inflammation of the urinary bladder that may lead to progressive shrinkage, fibrosis, contraction, and irreversible end-stage disease with high urination frequency.

## GC00.3

### **Interstitial cystitis**

A condition characterised by inflammation of the urinary bladder and ureters. This condition may be associated with a malformation of, or injury to, the bladder epithelium, infection with toxins, an autoimmune reaction, or an allergy. This condition may also present with Hunner ulcers diffuse glomerulations affecting all quadrants of the bladder mucosa, mild to severe chronic bladder pressure, bladder pain, urgency to urinate, and low volumes of urine.

## GC00.Y

### **Other specified cystitis**

## GC00.Z

### **Cystitis, unspecified**

**GC01**

**Other disorders of bladder**

Any disorder characterised by pathological changes to the urinary bladder.

**Exclusions:** Cystocele (GC40.0)

hernia or prolapse of bladder, female (GC40.0)

Calculus in bladder (GB71.0)

**Coded Elsewhere:** Bladder pain (MF52)

Neonatal haemorrhage originating in kidney or bladder  
(KA83.6)

**GC01.0**

**Bladder neck obstruction**

A condition of the bladder, caused by congenital or acquired abnormalities that impair the muscles that connect the bladder to the urethra. This condition is characterised by obstruction of the bladder neck and constricted opening during urination. This condition may also present with pelvic pain, pollakiuria, incontinence, or incomplete bladder emptying. Confirmation is by video urodynamics to observe the obstruction as the bladder fills and voids.

**GC01.1**

**Vesical fistula, not elsewhere classified**

A condition caused by medical intervention, trauma, inflammation, infection, cancer, or congenital factors. This condition is characterised by the formation of an abnormal passage between the urinary bladder and the skin, bowel, vagina, uterus, or rectum, and suprapubic pain, frequency, dysuria, or tenesmus.

**Coded Elsewhere:** Vesicovaginal fistula (GC04.10)

**GC01.2**

**Diverticulum of bladder**

A condition of the bladder, caused by congenital or acquired obstruction to the bladder outlet, a bladder dysfunction following a nerve injury, or a prior bladder surgery. This condition is characterised by balloon-like protrusions on the bladder lining, leading to an area of weakness in the bladder wall. This condition may be asymptomatic, or present with recurrent bladder infections, difficulty urinating, or abdominal fullness. Confirmation is by contrast radiography or cystoscopy.

**Exclusions:** Congenital diverticulum of urinary bladder (LB31.4)

Urachal diverticulum (LB03.0)

Hutch-diverticulum (LB31.4)

**GC01.3**

**Rupture of bladder, nontraumatic**

A condition of the bladder, caused by determinants not attributable to wound or injury. This condition is characterised by rupture of the bladder.

**GC01.4**

**Neuromuscular dysfunction of bladder, not elsewhere classified**

**Exclusions:** Functional urinary incontinence (MF50.23)

neurogenic bladder due to cauda equina syndrome (8B40)

due to spinal cord lesion (ND51)

Urinary incontinence associated with pelvic organ prolapse  
(GC40.5)

**GC01.Y**

**Other specified disorders of bladder**

GC01.Z	<b>Disorder of bladder, unspecified</b>
GC02	<p><b>Urethritis and urethral syndrome</b></p> <p>A condition of the urethra, caused by non-infectious factors such as trauma, allergies, anatomical malformations, or scarring and adhesions following a medical intervention. This condition is characterised by inflammation of the urethra, chronic recurrent urinary tract infections without bacterial growth, and pyuria.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>urethrotrigonitis (GC00.0)</li> <li>urethritis in diseases with a predominantly sexual mode of transmission (1A60-1A9Z)</li> <li>Reiter disease (FA11.2)</li> </ul> <p><b>Coded Elsewhere:</b> Infections of urethra in pregnancy (JA62.2)</p>
GC02.0	<p><b>Urethral abscess</b></p> <p>A condition of the urethra, caused by an obstruction to the periurethral glands that is commonly the result of frequent infection. This condition is characterised by a focal accumulation of purulent material within or on the urethral tissue.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Urethral caruncle (GC07)</li> </ul>
GC02.1	<p><b>Nonspecific urethritis</b></p> <p>Urethral inflammation for which a specific sexually transmitted infective cause, in particular gonococcal or chlamydial infection, has not been identified. It typically presents in males with dysuria, urethral discharge, itching or urinary urgency. It can occur following urinary tract infection or genital trauma. Historically, before chlamydia infection could be easily identified, chlamydial urethritis was labeled "non-specific".</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Chlamydial infection of lower genitourinary tract (1A81.0)</li> <li>Chlamydial urethritis (1A81.0)</li> <li>Gonococcal genitourinary infection (1A70)</li> </ul>
GC02.Y	<b>Other specified urethritis and urethral syndrome</b>
GC02.Z	<b>Urethritis and urethral syndrome, unspecified</b>
GC03	<p><b>Urethral stricture</b></p> <p>Stenosis of the urethra accompanied by fibrosis and scarring of the spongiosal body</p> <p><b>Coded Elsewhere:</b> Postprocedural urethral stricture (GC72)</p>
GC04	<p><b>Fistula of the genitourinary tract</b></p> <p>Any condition caused by trauma, medical intervention, infection, cancer, or congenital factors. This condition is characterised by the formation of an abnormal passage between any two locations within the genitourinary tract.</p> <p><b>Coded Elsewhere:</b> Fistula of intestinal segments used for urinary diversion (GC01.1)</p>

<b>GC04.0</b>	<b>Urethral fistula</b> A condition of the urethra, caused by surgery, infection, trauma, or congenital factors. This condition is characterised by the formation of an abnormal passage between the urethra and adjacent organs or surfaces.  <b>Coded Elsewhere:</b> Urethrovaginal fistula (GC04.14)
<b>GC04.1</b>	<b>Fistulae involving female genital tract</b> Any condition characterised by the formation of an abnormal passage between the genital tract and another organ, or between a genital organ and an adjacent organ or surface.
<b>GC04.10</b>	Vesicovaginal fistula A condition of the bladder and vagina, caused by and subsequent to childbirth, trauma, hysterectomy, medical intervention, infections, bladder calculi, endometriosis, cone biopsy, or congenital factors. This condition is characterised by the formation of an abnormal passage between the urinary bladder and the vagina, leading to the continuous involuntary discharge of urine into the vagina.  <b>Coded Elsewhere:</b> Vesicosigmoidovaginal fistula (GC04.12)
<b>GC04.11</b>	Fistula of small intestine to vagina  <b>Exclusions:</b> Obstetric Fistula (GC04.1)
<b>GC04.12</b>	Fistula of large intestine to vagina A condition of the large intestine and vagina, caused by damage to the tissue due to childbirth, an inflammatory bowel disease, radiation treatment, cancer, or a complication following pelvic surgery. This condition is characterised by the formation of an abnormal passage between any part of the large bowel and the vagina. This condition may also present with leakage of bowel contents (faeces or gas) through the vagina.  <b>Exclusions:</b> Obstetric Fistula (GC04.1)  <b>Coded Elsewhere:</b> Rectovaginal fistula (GC04.16)
<b>GC04.13</b>	Female genital tract-skin fistulae A condition of the genital system, caused by damage to the tissue between the genital tract and the skin. This condition is characterised by the formation of an abnormal passage between the genital tract and the skin.  <b>Exclusions:</b> Obstetric Fistula (GC04.1)
<b>GC04.14</b>	Urethrovaginal fistula This refers to the abnormal connection or passageway between the female urethra and the vagina without further specification.

<b>GC04.15</b>	Combined urethrovesicovaginal fistula A condition of the bladder, urethra, and vagina, caused by and subsequent to childbirth, trauma, hysterectomy, medical intervention, infection, bladder calculi, endometriosis, cone biopsy, or congenital factors. This condition is characterised by the formation of an abnormal passage between the urinary bladder, urethra, and the vagina, not otherwise specified.
	<b>Inclusions:</b> Urethrovesicovaginal fistula
<b>GC04.16</b>	Rectovaginal fistula A condition of the rectum and vagina, caused by childbirth, trauma, Crohn's disease, medical intervention, or infection. This condition is characterised by the formation of an abnormal passage between the rectum and the vagina, not otherwise specified.
<b>GC04.17</b>	Vesicouterine fistula with severe scar or extensive tissue loss This is a condition characterised by the presence of extensive amounts of fibrous tissue (fibrosis) that have replaced normal tissue associated with a vesicouterine fistula.
<b>GC04.18</b>	Other combined urinary fistula with severe scar or extensive tissue loss Any other condition characterised by the presence of extensive amounts of fibrous tissue (fibrosis) that have replaced normal tissue associated with any other abnormal connection or passageway between any two locations within the urinary tract which do not normally connect.
<b>GC04.19</b>	Combined urinary and rectal fistula including cloaca with severe scar or extensive tissue loss A condition characterised by the presence of extensive amounts of fibrous tissue (fibrosis) that have replaced normal tissue associated with an abnormal connection or passageway between the rectum, including cloaca, and a location within the urinary system.
<b>GC04.1A</b>	Vaginal stenosis or gynatresia related to obstetric fistula A condition of the vagina, caused by congenital or acquired factors. The congenital condition is caused by Mayer-Kustner-Hauser syndrome. The acquired condition is caused by severe or failed childbirth or medical intervention to repair a fistula. This condition is characterised by an abnormal narrowing and foreshortening of the vagina. Confirmation is by pelvic examination.
<b>GC04.1Y</b>	Other specified fistulae involving female genital tract
<b>GC04.1Z</b>	Fistulae involving female genital tract, unspecified
<b>GC04.2</b>	<b>Ureteral fistula</b> Abnormal passage or communication between the ureter and another body organ or cavity or the body surface.
<b>GC04.Y</b>	<b>Other specified fistula of the genitourinary tract</b>
<b>GC04.Z</b>	<b>Fistula of the genitourinary tract, unspecified</b>

**GC05****Prolapsed urethral mucosa**

A condition characterised by a circular protrusion of the distal urethra mucosa through the external urethral meatus. This condition may be associated with congenital or acquired abnormalities such as weakened pelvic floor structures, trauma, or separation of the longitudinal and circular-oblique smooth muscle layers. This condition is commonly asymptomatic in adolescents, or presents with vaginal bleeding and difficulty urinating in postmenopausal individuals.

**Inclusions:** prolapse of urethra

**Exclusions:** Female urethrocele (GC40.0)

**GC06****Urethral diverticulum**

A disease of the urethra, caused by an obstruction to the periurethral glands due to subsequent to frequent infection, or congenitally. This disease is characterised by a localised protrusion of the urethra into the anterior vaginal wall, consisting mostly of fibrous tissue. This disease may also present with urinary frequency, urgency, and dysuria. Confirmation is by imaging to determine the extent and location of the diverticulum.

**GC07****Urethral caruncle**

A condition characterised by small, focal, benign, pink or red polypoid masses of the distal urethral mucosa, which may become painful, bloody, and deep red in colour. This condition may be associated with urogenital atrophy due to estrogen deficiency, and may be aggravated by chronic irritation of urethral mucosa exposure. This condition typically affects postmenopausal women.

**GC08****Urinary tract infection, site not specified**

**Coded Elsewhere:** Urinary tract infection following delivery (JB40.3)

Neonatal urinary tract infection (KA65.2)

Pyuria associated with urinary tract infection (MF97)

**GC08.0****Urinary tract infection, site not specified, due to Escherichia coli****GC08.1****Urinary tract infection, site not specified, due to Klebsiella pneumoniae****GC08.2****Urinary tract infection, site not specified, due to Proteus**

A disease of the urinary tract, caused by an infection with the gram-negative bacteria Proteus. In females, this disease is characterised by dysuria, pyuria, or pollakiuria; in males, this disease may present with urethral discharge. Transmission is unknown. Confirmation is by identification of Proteus in a urinary sample.

**GC08.Y****Urinary tract infection, site not specified due to other agent****GC08.Z****Urinary tract infection, site and agent not specified****GC0Y****Other diseases of urinary system****GC2Z****Diseases of the urinary system, unspecified**

## Other conditions of the genitourinary system (GC40-GC51.Z)

Any disorder characterised by pathological changes to the genitourinary system.

### Female pelvic floor dysfunction (GC40-GC4Z)

Any condition affecting females, caused by an altered or lack of function of the female pelvic floor. These conditions are characterised by weakened or tightened pelvic floor muscles, or an impairment of the sacroiliac joint, lower back, coccyx, or hip joint.

**Coded Elsewhere:** Rectal prolapse (DB31.2)

**GC40**

#### **Pelvic organ prolapse**

The descent of one or more of the anterior vaginal wall, posterior vaginal wall, the uterus (cervix), or the apex of the vagina (vaginal vault) or cuff scar after hysterectomy.

**Exclusions:** Obstructed labour due to abnormality of maternal pelvic organs (JB05.5)

Maternal care for other abnormalities of gravid uterus (JA84)

**GC40.0**

#### **Prolapse of anterior vaginal wall**

**GC40.00**

Incomplete anterior vaginal wall prolapse

Most distal prolapse is 1cm or less proximal or distal to the hymen

**GC40.01**

Complete anterior vaginal wall prolapse

**GC40.0Z**

Prolapse of anterior vaginal wall, unspecified

**GC40.1**

#### **Prolapse of posterior vaginal wall**

**GC40.10**

Incomplete posterior vaginal wall prolapse

**GC40.11**

Complete posterior vaginal wall prolapse

**GC40.1Z**

Prolapse of posterior vaginal wall, unspecified

**GC40.2**

#### **Prolapse of the vaginal apex**

**GC40.20**

Incomplete apical vaginal wall prolapse

**GC40.21**

Complete apical vaginal wall prolapse

**GC40.2Z**

Prolapse of the vaginal apex, unspecified

**GC40.3**

**Uterovaginal prolapse**

<b>GC40.30</b>	<p>Incomplete uterovaginal prolapse</p> <p>A condition caused by weakness, damage, or stretching of the ligaments between the uterus and the vaginal wall, typically subsequent to childbirth. This condition is characterised by stage 1 descensus of the uterus into the vagina, leading to a bulge and distal prolapse greater than 1 centimetre above the hymen or stage 2 descensus with distal prolapse of 1 centimetre or less proximal or distal to the hymen. This condition may also present with urinary incontinence, sensation of heaviness in the pelvis, or difficulty urinating.</p>
	<p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Incomplete uterine prolapse with anterior vaginal wall prolapse (GC40.31)</li> <li>Incomplete uterine prolapse with posterior vaginal wall prolapse (GC40.32)</li> <li>Incomplete uterine prolapse with anterior and posterior vaginal wall prolapse (GC40.33)</li> </ul>
<b>GC40.31</b>	<p>Incomplete uterine prolapse with anterior vaginal wall prolapse</p> <p>A condition characterised by the displacement of the uterus from its normal position into the vaginal area in association with herniation of the bladder into the vagina due to tearing of the tough fibrous wall between a woman's bladder and her vagina (the pubovesical fascia).</p>
<b>GC40.32</b>	<p>Incomplete uterine prolapse with posterior vaginal wall prolapse</p> <p>A condition characterised by the displacement of the uterus from its normal position into the vaginal area in association with herniation of the rectum into the vagina, due to a tear in the rectovaginal septum (which is normally a tough, fibrous, sheet-like divider between the rectum and vagina).</p>
<b>GC40.33</b>	<p>Incomplete uterine prolapse with anterior and posterior vaginal wall prolapse</p> <p>A condition characterised by the displacement of the uterus from its normal position into the vaginal area in association with herniation of both the bladder and the rectum into the vagina, due to tears in the tough fibrous wall between a woman's bladder and her vagina (the pubovesical fascia) and in the rectovaginal septum, a tough, fibrous, sheet-like divider between the rectum and vagina.</p>
<b>GC40.34</b>	<p>Complete uterovaginal prolapse</p> <p>A condition caused by weakness, damage, or stretching of the ligaments between the uterus and the vaginal wall, typically subsequent to childbirth. This condition is characterised by stage 3 descensus of the uterus into the vagina, leading to a bulge and distal prolapse greater than 1 centimetre below the hymen or stage 4 descensus with complete eversion of the total length of the genital tract. This condition may also present with urinary incontinence, sensation of heaviness in the pelvis, or difficulty urinating.</p>
<b>GC40.35</b>	<p>Complete uterine prolapse with anterior vaginal wall prolapse</p> <p>A condition characterised by the displacement of the uterus from its normal position to at least one cm below the hymen, possibly up to complete eversion of the female genital tract, in association with herniation of the bladder into the vagina due to tearing of the tough fibrous wall between a woman's bladder and her vagina (the pubovesical fascia).</p>

<b>GC40.36</b>	Complete uterine prolapse with posterior vaginal wall prolapse A condition characterised by the displacement of the uterus from its normal position to at least one cm below the hymen, possibly up to complete eversion of the female genital tract, in association with herniation of the rectum into the vagina, due to a tear in the rectovaginal septum (which is normally a tough, fibrous, sheet-like divider between the rectum and vagina).
<b>GC40.37</b>	Complete uterine prolapse with anterior and posterior vaginal wall prolapse A condition characterised by the displacement of the uterus from its normal position to at least one cm below the hymen, possibly up to complete eversion of the female genital tract, in association with herniation of both the bladder and the rectum into the vagina, due to tears in the tough fibrous wall between a woman's bladder and her vagina (the pubovesical fascia) and in the rectovaginal septum, a tough, fibrous, sheet-like divider between the rectum and vagina.
<b>GC40.3Z</b>	Uterovaginal prolapse, unspecified
<b>GC40.4</b>	<b>Pelvic floor muscle disruption</b> A condition caused by damage or trauma to the muscles of the pelvic floor. This condition is characterised by weakness and dysfunction of the muscle.
<b>GC40.40</b>	Levator avulsion from symphysis pubis A condition caused by damage or trauma to the pelvic floor, leading to the detachment of the levator ani muscle fibres from the symphysis pubis. This condition is characterised by weakness and dysfunction of the muscle.
<b>GC40.4Y</b>	Other specified pelvic floor muscle disruption
<b>GC40.4Z</b>	Pelvic floor muscle disruption, unspecified
<b>GC40.5</b>	<b>Urinary incontinence associated with pelvic organ prolapse</b> A condition of the urinary system, caused by the abnormal displacement of one or more pelvic organs. This condition is characterised by the involuntary loss of urine. Confirmation is by urinalysis.
<b>GC40.50</b>	Stress incontinence associated with pelvic organ prolapse A condition of the urinary system, caused by weakness of the pelvic floor muscles and an increase in intra-abdominal pressure, leading to pressure on the bladder. This condition is characterised by a shift in the position of the urethra allowing urine to pass easily, and urinary incontinence when coughing, laughing, sneezing, exercising, or other physical activities that increase intra-abdominal pressure.
<b>GC40.51</b>	Urge incontinence associated with pelvic organ prolapse A condition of the urinary system, caused by detrusor dysfunction. This condition is characterised by urinary incontinence that accompanies detrusor hyperreflexia when a specific bladder volume is reached, leakage of urine, lack of urge to urinate, or lack of awareness of bladder filling.

<b>GC40.52</b>	Mixed urinary incontinence associated with pelvic organ prolapse A condition of the urinary system, caused by detrusor overactivity and impaired urethral function. This condition is characterised by a mix of stress and urge incontinence symptoms including involuntary loss of urine, urinary urgency, urinary frequency, or urinary incontinence when coughing, laughing, sneezing, exercising, or other physical activities that increase intra-abdominal pressure.
<b>GC40.53</b>	Overflow incontinence associated with pelvic organ prolapse A condition of the urinary system, caused by the incomplete emptying of urine from the bladder and an acontractile detrusor muscle. This condition is characterised by urinary incontinence and leakage of urine in small volumes. This condition may be associated with obstruction, weak bladder muscles, injury, pharmacological use, diabetes mellitus, nerve damage or nervous system dysfunction.
<b>GC40.54</b>	Urinary incontinence, not otherwise specified with pelvic organ prolapse
<b>GC40.6</b>	<b>Functional bladder disorders associated with pelvic organ prolapse</b> Any condition characterised by urinary postponement, stress incontinence, urge incontinence, urinary urgency, or urinary incontinence, or dysfunctional urinary voiding. These conditions are associated with abnormal displacement of one or more pelvic organs.
	<b>Exclusions:</b> Diurnal enuresis (6C00.1) Enuresis (6C00) Nocturnal and diurnal enuresis (6C00.2) Nocturnal enuresis (6C00.0)
	<b>Coded Elsewhere:</b> Absent or diminished bladder sensation associated with pelvic organ prolapse (GC50.10)
<b>GC40.60</b>	Overactive bladder associated with pelvic organ prolapse A condition of the bladder, caused by impaired kidney function, dysfunctional or absent nerve innervation, involuntary contraction of the bladder muscles, diabetes, pharmacological use, or infection. This condition is characterised by a sudden urge to urinate, urinary frequency, and urge incontinence. This condition may also present with nocturia.
<b>GC40.6Y</b>	Other specified functional bladder disorders associated with pelvic organ prolapse
<b>GC40.6Z</b>	Functional bladder disorders associated with pelvic organ prolapse, unspecified
<b>GC40.Z</b>	<b>Pelvic organ prolapse, unspecified</b>
<b>GC41</b>	<b>Anorectal dysfunction associated with pelvic organ prolapse</b> Any condition characterised by abnormal or absent function of the anus and rectum and dysfunctional defecation or flatus. These conditions are associated with abnormal displacement of one or more pelvic organs.

**GC42**

**Sexual dysfunction associated with pelvic organ prolapse**

A condition affecting women, characterised by difficulties experienced in the sensations or function of the genital system during normal sexual activity. This condition is associated with abnormal displacement of the vagina, introitus, or pelvic floor tissues.

**GC42.0**

**Diminished sensation due to vaginal or introital laxity**

A condition characterised by decreased or absent feeling due to decreased muscle tone in the vaginal muscles or at the vaginal opening (introitus).

**GC42.1**

**Obstructed intercourse**

A condition of the genital system, caused by obstruction or blockage in the vaginal canal, or hypertonicity of the vaginal muscles. This condition is characterised by the inability to engage in vaginal sexual intercourse.

**GC4Z**

**Female pelvic floor dysfunction, unspecified**

**GC50**

**Functional bladder disorders, not otherwise specified**

Any other condition characterised by symptoms that include overactive bladder syndrome, voiding postponement, stress incontinence, giggle incontinence, and dysfunctional voiding in children, without further specification.

**Exclusions:** Diurnal enuresis (6C00.1)

Nocturnal and diurnal enuresis (6C00.2)

Enuresis (6C00)

Nocturnal enuresis (6C00.0)

**GC50.0**

**Overactive bladder**

A urological condition characterised by urgency and frequency, as well as the potential for nocturia, which may or may not be accompanied by incontinence.

**Exclusions:** Diurnal enuresis (6C00.1)

Nocturnal and diurnal enuresis (6C00.2)

Enuresis (6C00)

Nocturnal enuresis (6C00.0)

**Coded Elsewhere:** Overactive bladder associated with pelvic organ prolapse (GC40.60)

**GC50.1**

**Absent or diminished bladder sensation**

A condition of the bladder, caused by lack of muscle tone, dysfunctional or absent innervation, or chronic obstruction. This condition is characterised by a large, dilated bladder and incomplete bladder emptying.

**GC50.10**

Absent or diminished bladder sensation associated with pelvic organ prolapse

**GC50.1Y**

Other specified absent or diminished bladder sensation

**GC50.1Z**

Absent or diminished bladder sensation, unspecified

**GC50.Y**

**Other specified functional bladder disorders, not otherwise specified**

<b>GC50.Z</b>	<b>Functional bladder disorders, not otherwise specified, unspecified</b>
<b>GC51</b>	<b>Female Genital Mutilation</b>
	A condition caused by procedures or other interventions for non-medical purposes. This condition is characterised by the partial or total removal of the external female genitalia or other injury to the female genital organs.
	<b>Exclusions:</b>
	Traumatic amputation of entire vulva (NB93.24)
	Traumatic amputation of part of vulva (NB93.25)
<b>GC51.0</b>	<b>Female Genital Mutilation Type 1</b>
	Vulvar abnormality caused by partial or total removal of the clitoris and/or the prepuce (clitoridectomy).
<b>GC51.00</b>	Female Genital Mutilation Type 1a
	Removal of the clitoral hood or prepuce only.
<b>GC51.01</b>	Female Genital Mutilation Type 1b
	Removal of the clitoris with the prepuce.
<b>GC51.0Z</b>	Female Genital Mutilation Type 1, unspecified
<b>GC51.1</b>	<b>Female Genital Mutilation Type 2</b>
	Vulvar abnormality caused by partial or total removal of the clitoris and the labia minora, with or without excision of the labia majora (excision).
<b>GC51.10</b>	Female Genital Mutilation Type 2a
	Removal of the labia minora only.
<b>GC51.11</b>	Female Genital Mutilation Type 2b
	Partial or total removal of the clitoris and the labia minora.
<b>GC51.12</b>	Female Genital Mutilation Type 2c
	Partial or total removal of the clitoris, the labia minora and the labia majora.
<b>GC51.1Z</b>	Female Genital Mutilation Type 2, unspecified
<b>GC51.2</b>	<b>Female Genital Mutilation Type 3</b>
	Vulvar/vaginal abnormality caused by narrowing of the vaginal orifice with a covering seal, as a result from cutting and appositioning the labia minora and/or the labia majora, with or without excision of the clitoris (infibulation).
<b>GC51.20</b>	Female Genital Mutilation Type 3a
	Removal and apposition of the labia minora.
<b>GC51.21</b>	Female Genital Mutilation Type 3b
	Removal and apposition of the labia majora.
<b>GC51.2Z</b>	Female Genital Mutilation Type 3, unspecified

**GC51.3      Female Genital Mutilation Type 4**  
All other harmful procedures to the female genitalia for non-medical purposes, for example: pricking, piercing, incising, scraping and cauterization.

**GC51.Z      Female Genital Mutilation, unspecified**

### Postprocedural disorders of genitourinary system (GC70-GC7B)

Any disorder caused by or subsequent to any intervention of the genitourinary system.

**Exclusions:**      Irradiation cystitis (GC00)  
States associated with artificial menopause (GA30.3)

**Coded Elsewhere:** Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)

**GC70      Postoperative adhesions of vagina**

A condition caused by or subsequent to any vaginal surgery or intervention. This condition is characterised by fibrous bands of scar tissue between the intravaginal tissues (intravaginal adhesions). This condition may also present with pelvic pain and dyspareunia.

**GC71      Prolapse of vaginal vault after hysterectomy**

A condition of the vagina, caused by or subsequent to hysterectomy. This condition is characterised by descensus of the vaginal vault that may also lead to weakening of the vaginal walls.

**GC72      Postprocedural urethral stricture**

Urethral stricture caused by catheterization, transurethral manipulations (e.g. transurethral resections), urethral instillations, or irradiation exposure

**GC73      Postprocedural pelvic peritoneal adhesions**

A condition caused by or subsequent to any pelvic intervention leading to damage and inflammation of the peritoneum. This condition is characterised by fibrous bands of scar tissue and abnormal connection between pelvic organs or tissues. This condition may also present with pelvic pain or bowel obstruction.

**Exclusions:**      Endometriosis (GA10)

**GC74      Malfunction or complication of external stoma of urinary tract**

A condition caused by a surgically created opening connecting the urinary tract to the external environment. This condition is characterised by dysfunction or decreased function of the incision.

**Exclusions:**      Postsurgical leak (NE81.3)

**GC75      Malfunction of the afferent segment of a continent urinary pouch**

A condition characterised by the dysfunction or lack of function of a surgically created urine reservoir within the body, specifically along the path by which urine enters the pouch.

**GC76**

**Malfunction of the efferent segment of a continent urinary pouch**

A condition characterised by the dysfunction or lack of function of a surgically created urine reservoir within the body, specifically along the path by which urine exits the pouch.

**GC77**

**Postprocedural nonmenstrual uterine bleeding**

Uterine bleeding occurring after procedure (i.e. uterine surgery, induced abortion, ...)

**GC78**

**Postprocedural acute female pelvic inflammatory disease**

**GC79**

**Disorders of breast reduction**

**GC7A**

**Disorders of breast augmentation**

A group of disorders that may arise in concert with or subsequent to the surgical placement of breast implants.

**GC7B**

**Postinterventional ischemia or infarction of kidney**

This refers to a restriction in blood supply to tissues of the kidney due to a health care intervention causing a shortage of oxygen and glucose needed for cellular metabolism resulting in the death of kidney tissue cells.

---

**GC8Y**

**Other specified diseases of the genitourinary system**

**GC8Z**

**Diseases of the genitourinary system, unspecified**

# CHAPTER 17

---

## Conditions related to sexual health

This chapter has 15 four-character categories.

Code range starts with HA00

**Coded Elsewhere:** Changes in female genital anatomy

Changes in male genital anatomy

Paraphilic disorders (6D30-6D3Z)

Adrenogenital disorders (5A71)

Predominantly sexually transmitted infections (1A60-1A9Z)

Contact with health services for contraceptive management (QA21)

This chapter contains the following top level blocks:

- Sexual dysfunctions
- Sexual pain disorders
- Gender incongruence
- Changes in female genital anatomy
- Changes in male genital anatomy

### Sexual dysfunctions (HA00-HA0Z)

Sexual Dysfunctions are syndromes that comprise the various ways in which adult people may have difficulty experiencing personally satisfying, non-coercive sexual activities. Sexual response is a complex interaction of psychological, interpersonal, social, cultural and physiological processes and one or more of these factors may affect any stage of the sexual response. In order to be considered a sexual dysfunction, the dysfunction must: 1) occur frequently, although it may be absent on some occasions; 2) have been present for at least several months; and 3) be associated with clinically significant distress.

**Coded Elsewhere:** Sexual dysfunction associated with pelvic organ prolapse (GC42)

**HA00**

#### **Hypoactive sexual desire dysfunction**

Hypoactive Sexual Desire Dysfunction is characterised by absence or marked reduction in desire or motivation to engage in sexual activity as manifested by any of the following: 1) reduced or absent spontaneous desire (sexual thoughts or fantasies); 2) reduced or absent responsive desire to erotic cues and stimulation; or 3) inability to sustain desire or interest in sexual activity once initiated. The pattern of diminished or absent spontaneous or responsive desire or inability to sustain desire or interest in sexual activity has occurred episodically or persistently over a period at least several months, and is associated with clinically significant distress.

- HA00.0      Hypoactive sexual desire dysfunction, lifelong, generalised**  
The person has always experienced hypoactive sexual desire dysfunction from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in all circumstances, including masturbation.
- HA00.1      Hypoactive sexual desire dysfunction, lifelong, situational**  
The person has always experienced hypoactive sexual desire dysfunction, from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.
- HA00.2      Hypoactive sexual desire dysfunction, acquired, generalised**  
The onset of hypoactive sexual desire dysfunction has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in all circumstances, including masturbation.
- HA00.3      Hypoactive sexual desire dysfunction, acquired, situational**  
The onset of hypoactive sexual desire dysfunction has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.
- HA00.Z      Hypoactive sexual desire dysfunction, unspecified**
- HA01      Sexual arousal dysfunctions**  
Sexual arousal dysfunctions include difficulties with the physiological or the subjective aspects of sexual arousal.
- HA01.0      Female sexual arousal dysfunction**  
Female sexual arousal dysfunction is characterised by absence or marked reduction in response to sexual stimulation in women, as manifested by any of the following: 1) Absence or marked reduction in genital response, including vulvovaginal lubrication, engorgement of the genitalia, and sensitivity of the genitalia; 2) Absence or marked reduction in non-genital responses such as hardening of the nipples, flushing of the skin, increased heart rate, increased blood pressure, and increased respiration rate; 3) Absence or marked reduction in feelings of sexual arousal (sexual excitement and sexual pleasure) from any type of sexual stimulation. The absence or marked reduction in response to sexual stimulation occurs despite the desire for sexual activity and adequate sexual stimulation, has occurred episodically or persistently over a period at least several months, and is associated with clinically significant distress.
- HA01.00      Female sexual arousal dysfunction, lifelong, generalised**  
The person has always experienced female sexual arousal dysfunction from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in all circumstances, including masturbation.

- HA01.01** Female sexual arousal dysfunction, lifelong, situational  
The person has always experienced female sexual arousal dysfunction from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.
- HA01.02** Female sexual arousal dysfunction, acquired, generalised  
The onset of female sexual arousal dysfunction has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in all circumstances, including masturbation.
- HA01.03** Female sexual arousal dysfunction, acquired, situational  
The onset of female sexual arousal dysfunction has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.
- HA01.0Z** Female sexual arousal dysfunction, unspecified
- HA01.1** **Male erectile dysfunction**  
Male erectile dysfunction is characterised by inability or marked reduction in the ability in men to attain or sustain a penile erection of sufficient duration or rigidity to allow for sexual activity. The pattern of erectile difficulty occurs despite the desire for sexual activity and adequate sexual stimulation, has occurred episodically or persistently over a period at least several months, and is associated with clinically significant distress.
- Coding Note:** Code also the causing condition
- HA01.10** Male erectile dysfunction, lifelong, generalised  
The person has always experienced male erectile dysfunction from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in all circumstances, including masturbation.
- HA01.11** Male erectile dysfunction, lifelong, situational  
The person has always experienced male erectile dysfunction from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.
- HA01.12** Male erectile dysfunction, acquired, generalised  
The onset of male erectile dysfunction has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in all circumstances, including masturbation.
- HA01.13** Male erectile dysfunction, acquired, situational  
The onset of male erectile dysfunction has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situation

<b>HA01.1Z</b>	Male erectile dysfunction, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>HA01.Y</b>	<b>Other specified sexual arousal dysfunctions</b>
<b>HA01.Z</b>	<b>Sexual arousal dysfunctions, unspecified</b>
<b>HA02</b>	<b>Orgasmic dysfunctions</b>
	Orgasmic dysfunctions refer to difficulties related to the subjective experience of orgasm.
<b>HA02.0</b>	<b>Anorgasmia</b>
	Anorgasmia is characterised by the absence or marked infrequency of the orgasm experience or markedly diminished intensity of orgasmic sensations. In women, this includes a marked delay in orgasm, which in men would be diagnosed as Male Delayed Ejaculation. The pattern of absence, delay, or diminished frequency or intensity of orgasm occurs despite adequate sexual stimulation, including the desire for sexual activity and orgasm, has occurred episodically or persistently over a period at least several months, and is associated with clinically significant distress.
	<b>Inclusions:</b> Psychogenic anorgasmia
<b>HA02.00</b>	Anorgasmia, lifelong, generalised The person has always experienced anorgasmia from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in all circumstances, including masturbation.
<b>HA02.01</b>	Anorgasmia, lifelong, situational The person has always experienced anorgasmia from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.
<b>HA02.02</b>	Anorgasmia, acquired, generalised The onset of anorgasmia has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in all circumstances, including masturbation.
<b>HA02.03</b>	Anorgasmia, acquired, situational The onset of anorgasmia has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.
<b>HA02.0Z</b>	Anorgasmia, unspecified
<b>HA02.Y</b>	<b>Other specified orgasmic dysfunctions</b>
<b>HA02.Z</b>	<b>Orgasmic dysfunctions, unspecified</b>

**HA03**

### **Ejaculatory dysfunctions**

Ejaculatory dysfunctions refer to difficulties with ejaculation in men, including ejaculatory latencies that are experienced as too short (Male early ejaculation) or too long (Male delayed ejaculation).

**Coded Elsewhere:** Retrograde ejaculation (MF40.3)

**HA03.0**

#### **Male early ejaculation**

Male early ejaculation is characterised by ejaculation that occurs prior to or within a very short duration of the initiation of vaginal penetration or other relevant sexual stimulation, with no or little perceived control over ejaculation. The pattern of early ejaculation has occurred episodically or persistently over a period at least several months, and is associated with clinically significant distress.

**HA03.00**

##### Male early ejaculation, lifelong, generalised

The person has always experienced early ejaculation from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in all circumstances, including masturbation.

**HA03.01**

##### Male early ejaculation, lifelong, situational

The person has always experienced early ejaculation from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.

**HA03.02**

##### Male early ejaculation, acquired, generalised

The onset of early ejaculation has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in all circumstances, including masturbation.

**HA03.03**

##### Male early ejaculation, acquired, situational

The onset of early ejaculation has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.

**HA03.0Z**

##### Male early ejaculation, unspecified

**HA03.1**

#### **Male delayed ejaculation**

Male delayed ejaculation is characterised by an inability to achieve ejaculation or an excessive or increased latency of ejaculation, despite adequate sexual stimulation and the desire to ejaculate. The pattern of delayed ejaculation has occurred episodically or persistently over a period at least several months, and is associated with clinically significant distress.

**HA03.10**

##### Male delayed ejaculation, lifelong, generalised

The person has always experienced delayed ejaculation from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in all circumstances, including masturbation.

- HA03.11** Male delayed ejaculation, lifelong, situational  
The person has always experienced delayed ejaculation from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.
- HA03.12** Male delayed ejaculation, acquired, generalised  
The onset of delayed ejaculation has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in all circumstances, including masturbation.
- HA03.13** Male delayed ejaculation, acquired, situational  
The onset of delayed ejaculation has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.
- HA03.1Z** Male delayed ejaculation, unspecified
- HA03.Y** **Other specified ejaculatory dysfunctions**
- HA03.Z** **Ejaculatory dysfunctions, unspecified**
- HA0Y** **Other specified sexual dysfunctions**
- HA0Z** **Sexual dysfunctions, unspecified**

## Sexual pain disorders (HA20-HA2Z)

Sexual pain disorders refer to marked and persistent or recurrent difficulties related to the experience of pain during sexual activity in adult people, which are not entirely attributable to an underlying medical condition, insufficient lubrication in women, age-related changes, or changes associated with menopause in women and are associated with clinically significant distress.

**Inclusions:** Psychogenic dyspareunia

**Coded Elsewhere:** Dyspareunia (GA12)

**HA20**

### **Sexual pain-penetration disorder**

Sexual pain-penetration disorder is characterised by at least one of the following: 1) marked and persistent or recurrent difficulties with penetration, including due to involuntary tightening or tautness of the pelvic floor muscles during attempted penetration; 2) marked and persistent or recurrent vulvovaginal or pelvic pain during penetration; 3) marked and persistent or recurrent fear or anxiety about vulvovaginal or pelvic pain in anticipation of, during, or as a result of penetration. The symptoms are recurrent during sexual interactions involving or potentially involving penetration, despite adequate sexual desire and stimulation, are not entirely attributable to a medical condition that adversely affects the pelvic area and results in genital and/or penetrative pain or to a mental disorder, are not entirely attributable to insufficient vaginal lubrication or post-menopausal/age-related changes, and are associated with clinically significant distress.

**Exclusions:** Dyspareunia (GA12)

Pain related to vulva, vagina or pelvic floor (GA34.0)

**HA20.0**

### **Sexual pain-penetration disorder, lifelong, generalised**

The person has always experienced genito-pelvic pain or penetration disorder from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in all circumstances, including masturbation.

**HA20.1**

### **Sexual pain-penetration disorder, lifelong, situational**

The person has always experienced genito-pelvic pain or penetration disorder from the time of initiation of relevant sexual activity and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.

**HA20.2**

### **Sexual pain-penetration disorder, acquired, generalised**

The onset of genito-pelvic pain or penetration disorder has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in all circumstances, including masturbation.

**HA20.3**

### **Sexual pain-penetration disorder, acquired, situational**

The onset of genito-pelvic pain or penetration disorder has followed a period of time during which the person did not experience it and the desired response is currently absent or diminished in some circumstances, with some partners, or in response to some stimuli, but not in other situations.

**HA20.Z**

### **Sexual pain-penetration disorder, unspecified**

**HA2Y**

### **Other specified sexual pain disorders**

HA2Z	<b>Sexual pain disorders, unspecified</b>
HA40	<b>Aetiological considerations in sexual dysfunctions and sexual pain disorders</b>
HA40.0	<b>Aetiological considerations associated with a medical condition, injury, or the effects of surgery or radiation treatment</b>  This category should be assigned when there is evidence that an underlying or co-occurring health condition, including hormonal, neurological, and vascular conditions, injuries, and consequences of surgical or radiation treatment is an important contributing factor to a Sexual Dysfunction or a Sexual Pain Disorder. In such cases, the diagnosis corresponding to the underlying or co-occurring health condition should also be assigned. However, underlying or contributory mental disorders should be noted using the qualifier 'Associated with psychological and behavioural factors, including mental disorders', rather than using with this category.
HA40.1	<b>Aetiological considerations associated with psychological or behavioural factors, including mental disorders</b>  This category should be assigned when psychological and behavioural factors or symptoms are important contributing factors to the Sexual Dysfunction or Sexual Pain Disorder. Examples include low self-esteem, negative attitudes toward sexual activity, adverse past sexual experiences, and behavioural patterns such as poor sleep hygiene and overwork. Depressive, anxiety, or cognitive symptoms as well as other symptoms of Mental, Behavioural, or Neurodevelopmental Disorders may also interfere with sexual functioning. If the symptoms reach the level of constituting a diagnosable Mental and Behavioural Disorder and the Sexual Dysfunction or Sexual Pain Disorder is an independent focus of clinical attention, this category should be used and the appropriate Mental and Behavioural Disorder diagnosis should also be assigned. However, underlying or contributory Disorders Due to Substance Use should be noted using the category 'Associated with use of psychoactive substance or medication', rather than using this category.
HA40.2	<b>Aetiological considerations associated with use of psychoactive substance or medication</b>  This category should be assigned when there is evidence that the direct physiological effects of a psychoactive substance or medication are an important contributing factor to the Sexual Dysfunction or Sexual Pain Disorder. Examples include selective serotonin reuptake inhibitors, histamine-2 receptor antagonists (e.g., cimetidine), alcohol, opioids, and amphetamines. If the diagnostic requirements for a Disorder Due to Substance Use are met, the appropriate Disorder Due to Substance Use diagnosis should also be assigned.
HA40.3	<b>Aetiological considerations associated with lack of knowledge or experience</b>  This category should be assigned when, in the clinician's judgment, the individual's lack of knowledge or experience of her or his own body, sexual functioning, and sexual response is an important contributing factor to the Sexual Dysfunction or Sexual Pain Disorder. This includes inaccurate information or myths about sexual functioning.

<b>HA40.4</b>	<b>Aetiological considerations associated with relationship factors</b> This category should be assigned when, in the clinician's judgment, relationship factors are important contributing factors to the Sexual Dysfunction or Sexual Pain Disorder. Examples include relationship conflict or lack of romantic attachment. This category may also be used when the Sexual Dysfunction or Sexual Pain Disorder is associated with a Sexual Dysfunction or Sexual Pain Disorder in the sexual partner.
<b>HA40.5</b>	<b>Aetiological considerations associated with cultural factors</b> This category should be assigned when, in the clinician's judgment, cultural factors are important contributing factors to the Sexual Dysfunction or Sexual Pain Disorder. Cultural factors may influence expectations or provoke inhibitions about the experience of sexual pleasure or other aspects of sexual activity. Other examples include strong culturally shared beliefs about sexual expression, for example a belief that loss of semen can lead to weakness, disease or death.
<b>HA40.Y</b>	<b>Other specified aetiological considerations in sexual dysfunctions and sexual pain disorders</b>

### Gender incongruence (HA60-HA6Z)

Gender incongruence is characterised by a marked and persistent incongruence between an individual's experienced gender and the assigned sex. Gender variant behaviour and preferences alone are not a basis for assigning the diagnoses in this group.

**Exclusions:** Paraphilic disorders (6D30-6D3Z)

**HA60**

#### **Gender incongruence of adolescence or adulthood**

Gender Incongruence of Adolescence and Adulthood is characterised by a marked and persistent incongruence between an individual's experienced gender and the assigned sex, which often leads to a desire to 'transition', in order to live and be accepted as a person of the experienced gender, through hormonal treatment, surgery or other health care services to make the individual's body align, as much as desired and to the extent possible, with the experienced gender. The diagnosis cannot be assigned prior the onset of puberty. Gender variant behaviour and preferences alone are not a basis for assigning the diagnosis.

**Exclusions:** Paraphilic disorders (6D30-6D3Z)

**HA61**

#### **Gender incongruence of childhood**

Gender incongruence of childhood is characterised by a marked incongruence between an individual's experienced/expressed gender and the assigned sex in pre-pubertal children. It includes a strong desire to be a different gender than the assigned sex; a strong dislike on the child's part of his or her sexual anatomy or anticipated secondary sex characteristics and/or a strong desire for the primary and/or anticipated secondary sex characteristics that match the experienced gender; and make-believe or fantasy play, toys, games, or activities and playmates that are typical of the experienced gender rather than the assigned sex. The incongruence must have persisted for about 2 years. Gender variant behaviour and preferences alone are not a basis for assigning the diagnosis.

**Exclusions:** Paraphilic disorders (6D30-6D3Z)

- HA6Z      Gender incongruence, unspecified**
- HA8Y      Other specified conditions related to sexual health**
- HA8Z      Conditions related to sexual health, unspecified**

# CHAPTER 18

---

## Pregnancy, childbirth or the puerperium

This chapter has 83 four-character categories.

Code range starts with JA00

A group of conditions characterised as occurring during the period of time from conception to delivery (pregnancy), during labour and delivery (childbirth) or during the approximately six weeks after delivery during which the uterus returns to the original size (puerperium).

**Coding Note:** The codes included in this chapter are to be used for conditions related to or aggravated by the pregnancy, childbirth or by the puerperium (maternal causes or obstetric causes)

**Exclusions:** Postpartum necrosis of pituitary gland (5A61.0)  
Obstetrical tetanus (1C14)  
Injury, poisoning or certain other consequences of external causes (Chapter 22)

**Coded Elsewhere:** Gestational trophoblastic diseases  
Contact with health services for reasons associated with reproduction (QA20-QA4Z)

This chapter contains the following top level blocks:

- Abortive outcome of pregnancy
- Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium
- Obstetric haemorrhage
- Certain specified maternal disorders predominantly related to pregnancy
- Maternal care related to the fetus, amniotic cavity or possible delivery problems
- Complications of labour or delivery
- Delivery
- Complications predominantly related to the puerperium
- Certain obstetric conditions, not elsewhere classified
- Gestational trophoblastic diseases

### Abortive outcome of pregnancy (JA00-JA0Z)

A group of conditions characterised by pregnancy which does not result in live offspring. These conditions include e.g. abortion, ectopic pregnancy or molar pregnancy.

**Exclusions:** Continuing pregnancy after abortion of one fetus or more (JA81.1)

**JA00**

**Abortion**

<b>JA00.0</b>	<b>Spontaneous abortion</b> Spontaneous abortion (also referred to as miscarriage) is a spontaneous loss of pregnancy (i.e. embryo or fetus) before 22 completed weeks of gestation. When information on gestational age is unavailable, use birthweight less than 500 grams as the criteria.  Spontaneous abortions (miscarriages) are distinct from cases of induced abortion.
<b>JA00.00</b>	Spontaneous abortion, incomplete, complicated by genital tract or pelvic infection A condition caused by immunological factors, abnormal ovum or uterine body, maternal disease or infection, or cervical incompetence and complicated by genital tract or pelvic infection. This condition is characterised by the incomplete passage of products of conception prior to 22 weeks gestation or weighing less than 500 grams.
<b>JA00.01</b>	Spontaneous abortion, incomplete, complicated by delayed or excessive haemorrhage A condition caused by immunological factors, abnormal ovum or uterine body, maternal disease or infection, or cervical incompetence and complicated by delayed or excessive bleeding. This condition is characterised by incomplete passage of products of conception prior to 22 weeks gestation or weighing less than 500 grams.
<b>JA00.02</b>	Spontaneous abortion, incomplete, complicated by embolism A condition caused by immunological factors, abnormal ovum or uterine body, maternal disease or infection, or cervical incompetence and complicated by embolism. This condition is characterised by incomplete passage of products of conception prior to 22 weeks gestation or weighing less than 500 grams.
<b>JA00.03</b>	Spontaneous abortion, incomplete, with other or unspecified complications
<b>JA00.04</b>	Spontaneous abortion, incomplete, without complication A condition caused by immunological factors, abnormal ovum or uterine body, maternal disease or infection, or cervical incompetence without any associated complications. This condition is characterised by incomplete passage of products of conception prior to 22 weeks gestation or weighing less than 500 grams.
<b>JA00.05</b>	Spontaneous abortion, complete or unspecified, complicated by genital tract or pelvic infection
<b>JA00.06</b>	Spontaneous abortion, complete or unspecified, complicated by delayed or excessive haemorrhage A condition caused by immunological factors, abnormal ovum or uterine body, maternal disease or infection, or cervical incompetence, and complicated by delayed or excessive bleeding. This condition is characterised by non-induced embryonic or fetal death or passage of products of conception prior to 22 weeks' gestation or weighing less than 500 grams.

- JA00.07** Spontaneous abortion, complete or unspecified, complicated by embolism  
A condition caused by immunological factors, abnormal ovum or uterine body, maternal disease or infection, or cervical incompetence, and complicated by embolism. This condition is characterised by non-induced embryonic or fetal death or passage of products of conception prior to 22 weeks gestation or weighing less than 500 grams.
- JA00.08** Spontaneous abortion, complete or unspecified, with other or unspecified complications
- JA00.09** Spontaneous abortion, complete or unspecified, without complication
- JA00.1** **Induced abortion**  
Induced abortion (also referred to as Artificial termination of pregnancy) is a complete expulsion or extraction from a woman of an embryo or a fetus (irrespective of the duration of the pregnancy), following a deliberate interruption of an ongoing pregnancy by medical or surgical means, which is not intended to result in a live birth. Induced abortions are distinct from cases of spontaneous abortion and stillbirth.  
*Inclusions:* therapeutic abortion
- JA00.10** Induced abortion, incomplete, complicated by genital tract or pelvic infection
- JA00.11** Induced abortion, incomplete, complicated by delayed or excessive haemorrhage
- JA00.12** Induced abortion, incomplete, complicated by embolism
- JA00.13** Induced abortion, incomplete, with other or unspecified complications
- JA00.14** Induced abortion, incomplete, without complication
- JA00.15** Induced abortion, complete or unspecified, complicated by genital tract or pelvic infection
- JA00.16** Induced abortion, complete or unspecified, complicated by delayed or excessive haemorrhage  
A condition caused by surgical, pharmacological, mechanical, artificial, or other unspecified interventions and complicated by delayed or excessive bleeding. This condition is characterised by termination of pregnancy and intentional embryonic or fetal death with complete or unspecified expulsion of products of conception from the uterus before the fetus is viable.
- JA00.17** Induced abortion, complete or unspecified, complicated by embolism  
A condition caused by surgical, pharmacological, mechanical, artificial, or other unspecified interventions and complicated by embolism. This condition is characterised by termination of pregnancy and intentional embryonic or fetal death with complete or unspecified expulsion of products of conception from the uterus before the fetus is viable.
- JA00.18** Induced abortion, complete or unspecified, with other complication
- JA00.19** Induced abortion, complete or unspecified, without complication
- JA00.2** **Unspecified abortion**

- JA00.20** Unspecified abortion, incomplete, complicated by genital tract or pelvic infection
- JA00.21** Unspecified abortion, incomplete, complicated by delayed or excessive haemorrhage
- JA00.22** Unspecified abortion, incomplete, complicated by embolism
- JA00.23** Unspecified abortion, incomplete, with other or unspecified complications
- JA00.24** Unspecified abortion, incomplete, without complication
- JA00.25** Unspecified abortion, complete or unspecified, complicated by genital tract or pelvic infection
- JA00.26** Unspecified abortion, complete or unspecified, complicated by delayed or excessive haemorrhage
- JA00.27** Unspecified abortion, complete or unspecified, complicated by embolism
- JA00.28** Unspecified abortion, complete or unspecified, with other or unspecified complications
- JA00.29** Unspecified abortion, complete or unspecified, without complication
- JA00.3** **Failed attempted abortion**  
 Ongoing pregnancy after medical or surgical interventions which fail to terminate the pregnancy.  
**Inclusions:** failure of attempted induction of abortion  
**Exclusions:** incomplete abortion (JA00.1)
- JA00.30** Failed medical abortion, complicated by genital tract or pelvic infection  
 Medical interventions which fail to terminate the pregnancy and complicated by genital tract and pelvic infection
- JA00.31** Failed medical abortion, complicated by delayed or excessive haemorrhage  
 Medical interventions which fail to terminate the pregnancy and complicated by delayed or excessive haemorrhage
- JA00.32** Failed medical abortion, complicated by embolism  
 Medical interventions which fail to terminate the pregnancy and complicated by delayed or excessive haemorrhage
- JA00.33** Failed medical abortion, with other or unspecified complications  
 Medical interventions which fail to terminate the pregnancy and associated with other and unspecified complications.
- JA00.34** Failed medical abortion, without complication  
 Medical interventions which fail to terminate the pregnancy without any associated complications.
- JA00.35** Other or unspecified failed attempted abortion, complicated by genital tract or pelvic infection

**JA00.36** Other or unspecified failed attempted abortion, complicated by delayed or excessive haemorrhage

**JA00.37** Other or unspecified failed attempted abortion, complicated by embolism

**JA00.38** Other or unspecified failed attempted abortion, with other or unspecified complications

**JA00.39** Other or unspecified failed attempted abortion, without complication

**JA01**

**Ectopic pregnancy**

Any condition characterised by implantation of the embryo outside the endometrium and endometrial cavity during pregnancy.

*Inclusions:* ruptured ectopic pregnancy

**JA01.0**

**Abdominal pregnancy**

A condition characterised by implantation of the embryo within the peritoneal cavity during pregnancy.

*Exclusions:* Maternal care for viable fetus in abdominal pregnancy (JA86.6)

Delivery of viable fetus in abdominal pregnancy (JB23.3)

**JA01.1**

**Tubal pregnancy**

A condition characterised by implantation of the embryo within the fallopian tube (ampullary, isthmus, interstitium) during pregnancy.

*Inclusions:* Fallopian pregnancy

Tubal abortion

**JA01.2**

**Ovarian pregnancy**

A condition characterised by implantation of the embryo within the ovary during pregnancy.

**JA01.Y**

**Other specified ectopic pregnancy**

**JA01.Z**

**Ectopic pregnancy, unspecified**

**JA02**

**Molar pregnancy**

A condition caused by the over-production of cells arising into the placenta during pregnancy. This condition is characterised by a pregnancy with abnormal placental growth in which the chorionic villi become hydropic, trophoblast proliferation and invasion of the uterine tissue within 10-16 weeks after conception, and a placental mass.

*Exclusions:* malignant hydatidiform mole (2C75.0)

<b>JA02.0</b>	<b>Complete hydatidiform mole</b> A condition caused by the over-production of cells arising into the placenta during pregnancy. This condition is characterised by a pregnancy with abnormal placental growth in which the chorionic villi become hydropic, slight to severe trophoblast proliferation and invasion of the uterine tissue within 10-16 weeks after conception, a placental mass, 25-30% theca lutein cysts, 15-20% persistent trophoblastic disease, 50% uterine size for dates, and vaginal bleeding, nausea, or vomiting. This condition leads to an absent fetus.
	<b>Inclusions:</b> classical hydatidiform mole
<b>JA02.1</b>	<b>Incomplete or partial hydatidiform mole</b> A condition caused by the over-production of cells arising into the placenta during pregnancy. This condition is characterised by a pregnancy with abnormal placental growth in which the chorionic villi become hydropic, slight to moderate trophoblast proliferation and invasion of the uterine tissue within 10-16 weeks after conception, a placental mass, theca lutein cysts, 1-5% persistent trophoblastic disease, small uterine size for dates, and vaginal bleeding, nausea, or vomiting. This condition leads to some fetal development and a missed abortion.
<b>JA02.Y</b>	<b>Other specified molar pregnancy</b>
<b>JA02.Z</b>	<b>Molar pregnancy, unspecified</b>
<b>JA03</b>	<b>Missed abortion</b> A condition caused by genetic abnormality, abnormal cell division, or poor quality ovum or sperm. This condition is characterised by a failed pregnancy, immature fetal or embryonic death that is not expelled from the uterus for at least 8 weeks, and diminished uterine size. This condition may also present with maternal infection, blood clotting, fetal calcification, and resorption of conception products. Confirmation is by imaging.
	<b>Inclusions:</b> Early fetal death with retention of dead fetus
	<b>Exclusions:</b> Blighted ovum or nonhydatidiform mole (JA04) Molar pregnancy (JA02)
<b>JA04</b>	<b>Blighted ovum or nonhydatidiform mole</b> A condition caused by genetic abnormality, abnormal cell division, or poor quality ovum or sperm. This condition is characterised by a failed pregnancy, implantation of a fertilized egg without development into an embryo, haemorrhage into the decidua, and adjacent tissue necrosis.
	<b>Inclusions:</b> Pathological ovum
<b>JA05</b>	<b>Complications following abortion, ectopic or molar pregnancy</b> Any complication affecting pregnant females, caused by or subsequent to abortion, ectopic, and molar pregnancy.
<b>JA05.0</b>	<b>Genital tract or pelvic infection following abortion, ectopic or molar pregnancy</b>
	<b>Exclusions:</b> septic or septicopyaemic embolism (JA05.2) Urinary tract infection, site not specified (GC08)

- JA05.1**      **Delayed or excessive haemorrhage following abortion, ectopic or molar pregnancy**
- JA05.2**      **Embolism following abortion, ectopic or molar pregnancy**
- JA05.3**      **Shock following abortion, ectopic or molar pregnancy**
  - Exclusions:***    septic shock (JA05.0)
- JA05.4**      **Renal failure following abortion, ectopic or molar pregnancy**
- JA05.5**      **Metabolic disorders following abortion, ectopic or molar pregnancy**
- JA05.6**      **Damage to pelvic organs and tissues following abortion, ectopic or molar pregnancy**
- JA05.7**      **Other venous complications following abortion, ectopic or molar pregnancy**
- JA05.Y**      **Other specified complications following abortion, ectopic or molar pregnancy**
- JA05.Z**      **Complications following abortion, ectopic or molar pregnancy, unspecified**
- JA0Z**      **Abortive outcome of pregnancy, unspecified**

Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium (JA20-JA2Z)

Any disorder affecting pregnant females, characterised by excessive systemic fluid build-up, excess serum proteins in the urine, and abnormally elevated blood pressure during pregnancy, childbirth, or the puerperium.

- JA20**      **Pre-existing hypertension complicating pregnancy, childbirth or the puerperium**
  - A condition affecting pregnant females, caused by previously diagnosed maternal hypertension. This condition is characterised by any complication during pregnancy, childbirth, and the puerperium as a result of a blood pressure reading above 140/90 mmHg prior to the 20th week of pregnancy, or persisting longer than 12 weeks postpartum. Confirmation is by sphygmomanometer.
  - Exclusions:***    Pre-eclampsia superimposed on chronic hypertension (JA21)
- JA20.0**      **Pre-existing essential hypertension complicating pregnancy, childbirth or the puerperium**
  - A condition affecting pregnant females, caused by previously diagnosed, or diagnosed within the first 20 weeks, hypertension. This condition is characterised by blood pressure of 140/90 mmHg or greater, leading to a complication during pregnancy, childbirth, and the puerperium. Confirmation is by sphygmomanometer.

- JA20.1 Pre-existing hypertensive heart disease complicating pregnancy, childbirth or the puerperium**  
A condition affecting pregnant females, caused by previously diagnosed, or diagnosed within the first 20 weeks, hypertension and associated heart disease. This condition is characterised by blood pressure of 140/90 mmHg or greater, leading to a complication during pregnancy, childbirth, and the puerperium. Confirmation is by sphygmomanometer.
- Inclusions:** Hypertensive heart disease specified as a reason for obstetric care during pregnancy, childbirth or the puerperium
- JA20.2 Pre-existing hypertensive renal disease complicating pregnancy, childbirth or the puerperium**  
A condition affecting pregnant females, caused by previously diagnosed, or diagnosed within the first 20 weeks, hypertension and associated renal disease. This condition is characterised by blood pressure of 140/90 mmHg or greater, leading to a complication during pregnancy, childbirth, and the puerperium. Confirmation is by sphygmomanometer.
- JA20.3 Pre-existing hypertensive heart and renal disease complicating pregnancy, childbirth or the puerperium**  
Blood pressure of 140 mm Hg or greater systolic and/or 90 mm Hg or greater diastolic diagnosed preconception or in the first 20 weeks of pregnancy with associated heart and renal disease
- Inclusions:** Hypertensive heart and renal disease specified as a reason for obstetric care during pregnancy, childbirth or the puerperium
- JA20.4 Pre-existing secondary hypertension complicating pregnancy, childbirth or the puerperium**  
A condition affecting pregnant females, caused by renal disease, endocrine disorders, or tumours. This condition is characterised by blood pressure greater than 140/90 mmHg prior to the 20th week of pregnancy, or persisting longer than 12 weeks postpartum, leading to a complication during pregnancy, childbirth, and the puerperium. Confirmation is by sphygmomanometer.
- Inclusions:** Secondary hypertension specified as a reason for obstetric care during pregnancy, childbirth or the puerperium
- JA20.Y Other specified pre-existing hypertension complicating pregnancy, childbirth or the puerperium**
- JA20.Z Pre-existing hypertension complicating pregnancy, childbirth or the puerperium, unspecified**

**JA21**

**Pre-eclampsia superimposed on chronic hypertension**

A condition affecting pregnant females over 20 weeks gestation. This condition is characterised by systolic blood pressure greater than 140mmHg and diastolic greater or equal to 90mmHg on two occasions 4 hours apart in the presence of either proteinuria or other new onset maternal organ dysfunction characterised by one thrombocytopenia, elevated serum creatinine or liver transaminases, or neurological conditions or fetal growth restriction in a female diagnosed with pre-existing hypertension.

**Inclusions:** Superimposed pre-eclampsia

**JA22**

**Gestational oedema or proteinuria without hypertension**

A condition affecting pregnant females, characterised by excessive systemic fluid build-up and serum proteins in the urine, without an abnormally elevated blood pressure induced by pregnancy.

**Inclusions:** Pregnancy-induced oedema and proteinuria without hypertension

**JA22.0**

**Gestational proteinuria without hypertension**

**JA22.1**

**Gestational oedema without hypertension**

**JA22.2**

**Gestational oedema with proteinuria without hypertension**

The accumulation of fluid and proteinuria due to the physiological alterations of pregnancy in the absence of hypertension

**JA23**

**Gestational hypertension**

A condition affecting pregnant females, characterised by systolic blood pressure greater than 140mmHg and/or a diastolic blood pressure greater or equal to 90mmHg on two occasions, 4 hours or more apart. Can be newly diagnosed after 20 weeks gestation or before 1 week postpartum. Confirmation is by measurement of blood pressure, liver and kidney functions test, and urine test.

**JA24**

**Pre-eclampsia**

This condition is characterised by systolic blood pressure greater than 140 mmHg and/or diastolic greater or equal to 90 mmHg on two occasions 4 hours or more apart in the presence of either proteinuria or other new onset maternal organ dysfunction characterised by one thrombocytopenia, elevated serum creatinine or liver transaminases, or neurological conditions or fetal growth restriction.

**Exclusions:** Pre-eclampsia superimposed on chronic hypertension (JA21)

**JA24.0**

**Mild to moderate pre-eclampsia**

This condition is characterised by systolic blood pressure greater than 140 mmHg and/or diastolic greater or equal to on two occasions 4 hours or more apart in the presence of either proteinuria or other new onset maternal organ dysfunction characterised by one thrombocytopenia, elevated serum creatinine or liver transaminases, or neurological conditions or fetal growth restriction.

<b>JA24.1</b>	<b>Severe pre-eclampsia</b> This condition is characterised by systolic blood pressure greater than 160 mmHg and/or diastolic greater or equal to 110 mmHg on two occasions 4 hours or more apart in the presence of either proteinuria or other new onset maternal organ dysfunction characterised by one thrombocytopenia, elevated serum creatinine or liver transaminases, or neurological conditions or fetal growth restriction.
<b>JA24.2</b>	<b>HELLP syndrome</b> severe preeclampsia associated with haemolysis, elevated liver enzymes, or low platelets
<b>JA24.Z</b>	<b>Pre-eclampsia, unspecified</b>
<b>JA25</b>	<p><b>Eclampsia</b> Any condition affecting pregnant females, characterised by seizure or convulsions newly arising in pregnancy. The condition is often associated with pregnancy-induced hypertension, convulsions, seizure, anxiety, epigastric pain, severe headache, blurred vision, proteinuria, and oedema that may occur during pregnancy, labour, or the puerperium.</p>
<b>JA25.0</b>	<b>Eclampsia in pregnancy</b> This condition is characterised by seizure or convulsions newly arising in pregnancy. The condition is often associated with pregnancy-induced hypertension, convulsions, seizure, anxiety, epigastric pain, severe headache, blurred vision, proteinuria, and oedema that occurs during pregnancy.
<b>JA25.1</b>	<b>Eclampsia in labour</b> This condition is characterised by seizure or convulsions newly arising in pregnancy. The condition is often associated with pregnancy-induced hypertension, convulsions, seizure, anxiety, epigastric pain, severe headache, blurred vision, proteinuria, and oedema that occurs during labour.
<b>JA25.2</b>	<b>Eclampsia in the puerperium</b> This condition is characterised by seizure or convulsions newly arising in pregnancy. The condition is often associated with pregnancy-induced hypertension, convulsions, seizure, anxiety, epigastric pain, severe headache, blurred vision, proteinuria, and oedema that occurs during the puerperium.
<b>JA25.3</b>	<b>Eclampsia, time period unspecified</b> Onset of convulsions in a woman with pre-eclampsia not attributable to other causes without a specific onset time.
<b>JA2Z</b>	<b>Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium, unspecified</b>

### Obstetric haemorrhage (JA40-JA4Z)

<b>JA40</b>	<b>Haemorrhage in early pregnancy</b> <i>Exclusions:</i> Abortion outcome of pregnancy (JA00-JA0Z)
-------------	---

<b>JA40.0</b>	<b>Threatened abortion</b> A bloody vaginal discharge of bleeding appears through a closed cervical os during the first half of pregnancy.
	<i>Inclusions:</i> Haemorrhage specified as due to threatened abortion
<b>JA40.Y</b>	<b>Other specified haemorrhage in early pregnancy</b>
<b>JA40.Z</b>	<b>Haemorrhage in early pregnancy, unspecified</b>
<b>JA41</b>	<b>Antepartum haemorrhage</b> <i>Exclusions:</i> Haemorrhage in early pregnancy (JA40)
<b>JA41.0</b>	<b>Antepartum haemorrhage with coagulation defect</b>
<b>JA41.Y</b>	<b>Other specified antepartum haemorrhage</b>
<b>JA41.Z</b>	<b>Antepartum haemorrhage, unspecified</b>
<b>JA42</b>	<b>Intrapartum haemorrhage</b> <i>Exclusions:</i> Postpartum haemorrhage (JA43) Maternal care related to premature separation of placenta (JA8C) Antepartum haemorrhage (JA41) Maternal care related to placenta praevia or low lying placenta (JA8B)
<b>JA42.0</b>	<b>Intrapartum haemorrhage with coagulation defect</b> A condition affecting pregnant females, excluding those caused by abruptio placentae and placenta praevia. This condition is characterised by excessive loss of blood with difficulties in blood clotting factors, after 20 weeks gestation until labour and delivery.
<b>JA42.1</b>	<b>Intrapartum haemorrhage resulting from obstructed labour with uterine rupture</b>
<b>Coding Note:</b>	Code also the causing condition
<b>JA42.2</b>	<b>Intrapartum haemorrhage resulting from obstructed labour without mention of uterine rupture</b> Labour and delivery complicated by intrapartum haemorrhage from obstructed labour due to not otherwise specified causes or without mention of uterine rupture
<b>Coding Note:</b>	Code also the causing condition
<b>JA42.Y</b>	<b>Other specified intrapartum haemorrhage</b>
<b>JA42.Z</b>	<b>Intrapartum haemorrhage, unspecified</b>
<b>JA43</b>	<b>Postpartum haemorrhage</b> <b>Coding Note:</b> Code also the causing condition <i>Inclusions:</i> haemorrhage after delivery of fetus or infant

<b>JA43.0</b>	<b>Third-stage haemorrhage</b>
	A condition characterised by excessive loss of blood during the third stage of labour for a vaginal delivery. This condition is caused by uterine atony, trauma, retained placenta, or coagulopathy.
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> third-stage postpartum haemorrhage
<b>JA43.1</b>	<b>Other immediate postpartum haemorrhage</b>
	A condition characterised by excessive loss of blood within the first 24 hours after the completion of the third stage of labour for a vaginal delivery (more than 500 millilitres), or after a caesarean section (more than 1000 millilitres). This condition is caused by uterine atony, trauma, retained placenta, or coagulopathy.
<b>Coding Note:</b>	Code also the causing condition
<b>JA43.2</b>	<b>Delayed or secondary postpartum haemorrhage</b>
	A condition characterised by excessive loss of blood between 24 hours and 12 weeks after delivery. This condition is caused by uterine atony, trauma, retained placenta, or coagulopathy.
<b>Coding Note:</b>	Code also the causing condition
<b>JA43.3</b>	<b>Postpartum coagulation defects</b>
	A condition characterised by excessive loss of blood following a vaginal or caesarean section delivery. This condition is caused by coagulation defects during the postpartum period.
<b>Coding Note:</b>	Code also the causing condition
<b>JA43.4</b>	<b>Postpartum haemorrhage following obstructed labour with uterine rupture</b>
<b>Coding Note:</b>	Code also the causing condition
<b>JA43.5</b>	<b>Postpartum haemorrhage following obstructed labour without mention of uterine rupture</b>
<b>Coding Note:</b>	Code also the causing condition
<b>JA43.Y</b>	<b>Other specified postpartum haemorrhage</b>
<b>Coding Note:</b>	Code also the causing condition
<b>JA43.Z</b>	<b>Postpartum haemorrhage, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>JA4Z</b>	<b>Obstetric haemorrhage, unspecified</b>

## Certain specified maternal disorders predominantly related to pregnancy (JA60-JA6Z)

A group of conditions of the mother which occur during the period of time from conception to delivery (pregnancy).

- Exclusions:** Maternal infectious diseases classifiable elsewhere but complicating pregnancy, childbirth or the puerperium (JB63)  
Maternal care related to the fetus, amniotic cavity or possible delivery problems (JA80-JA8Z)  
Certain maternal diseases classifiable elsewhere but complicating pregnancy, childbirth or the puerperium (JB64)

**Coded Elsewhere:** Pregnancy symptom or complaint (MF34)

<b>JA60</b>	<b>Excessive vomiting in pregnancy</b>
<b>JA60.0</b>	<b>Mild hyperemesis gravidarum</b> Vomiting occurring during pregnancy responsive to dietary modification and antiemetic treatment
	<b>Inclusions:</b> Hyperemesis gravidarum, mild or unspecified, starting before the end of the 22nd week of gestation <b>Exclusions:</b> Hyperemesis gravidarum with metabolic disturbance (JA60.1)
<b>JA60.1</b>	<b>Hyperemesis gravidarum with metabolic disturbance</b> Vomiting in pregnancy, not responsive to dietary modification and antiemetic treatment and associated with electrolyte disturbances and acid-base imbalance
<b>JA60.2</b>	<b>Late vomiting of pregnancy</b> Vomiting occurring after 22 completed weeks of gestation. <b>Inclusions:</b> Excessive vomiting starting after 22 completed weeks of gestation
<b>JA60.Y</b>	<b>Other specified excessive vomiting in pregnancy</b>
<b>JA60.Z</b>	<b>Excessive vomiting in pregnancy, unspecified</b>
<b>JA61</b>	<b>Venous complications in pregnancy</b>
	<b>Exclusions:</b> Complications following abortion, ectopic or molar pregnancy (JA05) obstetric pulmonary embolism (JB42.2) Venous complications in the puerperium (JB41)
<b>JA61.0</b>	<b>Varicose veins of lower extremity in pregnancy</b>
<b>JA61.1</b>	<b>Genital varices in pregnancy</b>
<b>JA61.2</b>	<b>Superficial thrombophlebitis in pregnancy</b> <b>Inclusions:</b> Thrombophlebitis of legs in pregnancy
<b>JA61.3</b>	<b>Deep phlebothrombosis in pregnancy</b>

- JA61.4      Haemorrhoids in pregnancy**  
A condition affecting females during pregnancy, caused by an increase in intra-abdominal pressure and hormonal changes during pregnancy. This condition is characterised by enlarged and varicosed haemorrhoidal veins in the anus and lower rectum. This condition may also present with itching, burning, painful swellings at the anus, dyschezia or rectal bleeding with bowel movements. Confirmation is by digital or visual examination with an anoscope, proctoscope, or sigmoidoscope of the anal canal and rectum to determine the presence of haemorrhoids.
- JA61.5      Cerebral venous thrombosis in pregnancy**  
*Inclusions:*      Cerebrovenous sinus thrombosis in pregnancy
- JA61.Y      Other specified venous complications in pregnancy**
- JA61.Z      Venous complications in pregnancy, unspecified**
- JA62      Infections of genitourinary tract in pregnancy**
- JA62.0      Infections of kidney in pregnancy**  
Kidney infections occurring during pregnancy
- JA62.1      Infections of bladder in pregnancy**  
Bladder infections occurring during pregnancy
- JA62.2      Infections of urethra in pregnancy**  
Urethra infections occurring during pregnancy
- JA62.3      Infections of other parts of urinary tract in pregnancy**  
Infections of urinary tract other than kidney, bladder and urethra occurring during pregnancy
- JA62.4      Infections of the genital tract in pregnancy**
- JA62.Y      Infections of genitourinary tract in pregnancy, other specified site**
- JA62.Z      Infection of genitourinary tract in pregnancy, site unspecified**
- JA63      Diabetes mellitus in pregnancy**  
A condition caused by dysfunctional maternal insulin receptors. This condition is characterised by glucose intolerance with onset or first recognition during pregnancy, with at least one of the following criteria met: fasting plasma glucose greater than or equal to 7.0 millimoles per litre (126 mg/dL); 2-hour plasma glucose greater than or equal to 11.1 millimoles per litre (200 mg/dL) following a 75 gram oral glucose load; random plasma glucose greater than or equal to 11.1 millimoles per litre (200 mg/dL). Confirmation is by an oral glucose tolerance test.
- JA63.0      Pre-existing type 1 diabetes mellitus in pregnancy**
- JA63.1      Pre-existing type 2 diabetes mellitus in pregnancy**

<b>JA63.2</b>	<b>Diabetes mellitus arising in pregnancy</b> Diabetes mellitus arising or diagnosed in pregnancy (per WHO criteria or other national criteria)-Gestational diabetes. Gestational diabetes mellitus is defined as any degree of glucose intolerance with onset or first recognition during pregnancy. The definition applies regardless of whether insulin or only diet modification is used for treatment or whether the condition persists after pregnancy.
<b>JA63.Y</b>	<b>Other specified diabetes mellitus in pregnancy</b>
<b>JA63.Z</b>	<b>Diabetes mellitus in pregnancy, unspecified</b>
<b>JA64</b>	<b>Malnutrition in pregnancy</b> A condition caused by ingestion of a diet in which the nutrients are lacking or are in excess.
<b>JA65</b>	<b>Maternal care for other conditions predominantly related to pregnancy</b> Any reason for encounter to assess (or care for) a mother for other conditions predominantly related to pregnancy.
<b>JA65.0</b>	<b>Liver disorders in pregnancy, childbirth or the puerperium</b> Any disorder affecting females, characterised by pathological changes to the liver that occur during pregnancy, childbirth, and the puerperium.  <b>Exclusions:</b> Hepatorenal syndrome following labour or delivery (JB44.4) Viral hepatitis (1E50-1E5Z)
	<b>Coded Elsewhere:</b> HELLP syndrome (JA24.2)
<b>JA65.1</b>	<b>Pregnancy dermatoses</b> A group of skin disorders which are specific to pregnancy.  <b>Coded Elsewhere:</b> Generalised pustular psoriasis of pregnancy (EA90.40)
<b>JA65.10</b>	Gestational pemphigoid Gestational pemphigoid (pemphigoid gestationis) is an autoimmune skin disease characterised by pruritic plaques and blister formation on the skin in association with pregnancy or the trophoblastic tumours, hydatiform mole and choriocarcinoma. The exact causes of the disease are unknown but the disease is mediated by auto-antibodies to the hemidesmosome component BP180/BPAg2/collagen XVII. The maternal antibodies may cause short lived disease in the neonate, neonatal pemphigoid gestationis.  This disease is not an infection with herpes virus despite its old name, herpes gestationis.  <b>Exclusions:</b> impetigo herpetiformis (EA90.40)

- JA65.11** Pruritus of pregnancy  
Pruritus in pregnancy can usually be attributed to a specific cause such as cholestasis, a pregnancy-specific dermatosis such as pruritic urticarial papules and plaques of pregnancy, or to exacerbation of a preexisting inflammatory dermatosis such as atopic eczema. Not uncommonly, however, a specific cause cannot be identified.  
**Coded Elsewhere:** Intrahepatic cholestasis of pregnancy (JA65.0)
- JA65.12** Polymorphic eruption of pregnancy  
Polymorphic eruption of pregnancy is a dermatosis which occurs almost exclusively in primigravidae or women with multiple pregnancy. It is associated with above average weight gain in pregnancy and it is thought that distension of abdominal skin is important in the pathogenesis: the precise mechanism is not understood. The eruption characteristically first appears in the third trimester of pregnancy as intensely itchy erythematous urticarial papules and plaques in and around the abdominal striae distensae. In some women it may then become more generalised. Onset is sometimes delayed until the immediate postpartum period. It does not usually recur in subsequent pregnancies.
- JA65.1Y** Other specified pregnancy dermatoses
- JA65.2** **Excessive weight gain in pregnancy**  
Any reason for encounter to assess (or care for) a mother for excessive weight gain during pregnancy.  
**Exclusions:** Gestational oedema without hypertension (JA22.1)
- JA65.3** **Low weight gain in pregnancy**  
Any reason for encounter to assess (or care for) a mother for low weight gain during pregnancy.
- JA65.4** **Pregnancy care of habitual aborter**  
Any reason for encounter to assess (or care for) a mother who has a history of habitual aborting.  
**Exclusions:** habitual aborter with current abortion (JA00-JA0Z)  
habitual aborter without current pregnancy (GA33)
- JA65.5** **Retained intrauterine contraceptive device in pregnancy**  
Any reason for encounter to assess (or care for) a mother with a retained intrauterine contraceptive device during pregnancy.  
**Exclusions:** Retained intrauterine device without injury or harm in non-pregnant uterus (QA21.60)
- JA65.6** **Maternal hypotension syndrome**  
Any reason for encounter to assess a mother for low blood pressure during pregnancy.  
**Inclusions:** Supine hypotensive syndrome

JA65.7	<b>Subluxation of symphysis pubis in pregnancy, childbirth or the puerperium</b> Any reason for encounter to assess (or care for) a mother for subluxation of pubis symphysis during pregnancy.
	<b>Exclusions:</b> traumatic separation of symphysis (pubis) during childbirth (JB0A.7)
JA65.Y	<b>Maternal care for other specified conditions predominantly related to pregnancy</b>
JA65.Z	<b>Maternal care for unspecified conditions predominantly related to pregnancy</b>
<b>JA66</b>	<p><b>Clinical findings on antenatal screening of mother</b> Any sign characterised by an abnormality detected during an antenatal screening of the mother.</p> <p><b>Exclusions:</b> Maternal care related to the fetus, amniotic cavity or possible delivery problems (JA80-JA8Z)</p>
JA66.0	<b>Abnormal haematological finding on antenatal screening of mother</b> A sign characterised by an abnormality detected by haematology during an antenatal screening of the mother.
JA66.1	<b>Abnormal biochemical finding on antenatal screening of mother</b> A sign characterised by an abnormality detected by biochemistry during an antenatal screening of the mother.
JA66.2	<b>Abnormal cytological finding on antenatal screening of mother</b> A sign characterised by an abnormality detected by cytology during an antenatal screening of the mother.
JA66.3	<b>Abnormal ultrasonic finding on antenatal screening of mother</b> A sign characterised by an abnormality detected by ultrasound during an antenatal screening of the mother.
JA66.4	<b>Abnormal radiological finding on antenatal screening of mother</b> A sign characterised by an abnormality detected by radiology during an antenatal screening of the mother.
JA66.5	<b>Abnormal chromosomal or genetic finding on antenatal screening of mother</b> A sign characterised by a chromosomal or genetic abnormality detected during an antenatal screening of the mother.
JA66.Y	<b>Other specified clinical findings on antenatal screening of mother</b>
JA66.Z	<b>Clinical findings on antenatal screening of mother, unspecified</b>

**JA67**

**Complications of anaesthesia during pregnancy**

**Exclusions:** Complications of anaesthesia during the puerperium (JB43)  
Complications of anaesthesia during labour or delivery (JB0C)  
complications of anaesthesia during: abortion or ectopic or  
molar pregnancy (JA00-JA0Z)

**JA67.0**

**Pulmonary complications of anaesthesia during pregnancy**

**JA67.1**

**Cardiac complications of anaesthesia during pregnancy**

**JA67.2**

**Central nervous system complications of anaesthesia during pregnancy**

**JA67.3**

**Toxic reaction to local anaesthesia during pregnancy**

A condition affecting females during pregnancy, caused by the properties or the concentration of the anaesthetic agent, or patient factors. This condition is characterised by a local or systemic toxic reaction leading to malfunctioning or failure of the neurovascular, central nervous, respiratory or cardiovascular systems with onset between 30 seconds and 60 minutes after administration of an anaesthetic.

**JA67.4**

**Spinal or epidural anaesthesia-induced headache during pregnancy**

A condition affecting females during pregnancy, caused by the administration of spinal and epidural anaesthesia. This condition is characterised by cephalgia during pregnancy.

**JA67.5**

**Failed or difficult intubation during pregnancy**

A condition affecting females during pregnancy, caused by physiological, pathophysiological, or psychological factors that aggravate the tissues necessary to secure the tube. This condition is characterised by a difficulty or inability to insert a tube into an external or internal orifice of the body during pregnancy.

**JA67.6**

**Awareness under general anaesthesia during pregnancy**

**JA67.Y**

**Other specified complications of anaesthesia during pregnancy**

**JA67.Z**

**Complications of anaesthesia during pregnancy, unspecified**

**JA6Z**

**Maternal disorders predominantly related to pregnancy, unspecified**

Maternal care related to the fetus, amniotic cavity or possible delivery problems (JA80-JA8Z)

A group of conditions characterised by the provision of health interventions to the mother due to conditions associated with the fetus, the amniotic cavity, or to issues associated with labour and delivery.

**JA80**

**Maternal care related to multiple gestation**

**Exclusions:** Maternal care related to complications specific to multiple gestation (JA81)

**JA80.0**

**Twin pregnancy**



JA82.Y	<b>Maternal care for known or suspected other specified malpresentation of fetus</b>
JA82.Z	<b>Maternal care for known or suspected malpresentation of fetus, unspecified</b>
<b>JA83</b>	<b>Maternal care for known or suspected disproportion</b>
	A condition characterised by the provision of health interventions to the mother due to the situation in which the head or body of the fetus is too large to fit through the pelvis of the mother.
	<b>Exclusions:</b> Obstructed labour due to maternal pelvic abnormality (JB05) Obstructed labour due to other causes (JB06)
<b>JA83.0</b>	<b>Maternal care for disproportion due to deformity of maternal pelvic bones</b>
<b>JA83.1</b>	<b>Maternal care for disproportion due to generally contracted pelvis</b>
<b>JA83.2</b>	<b>Maternal care for disproportion due to inlet contraction of pelvis</b>
<b>JA83.3</b>	<b>Maternal care for disproportion due to outlet contraction of pelvis</b>
<b>JA83.4</b>	<b>Maternal care for disproportion of mixed maternal and fetal origin</b>
<b>JA83.5</b>	<b>Maternal care for disproportion due to unusually large fetus</b>
<b>JA83.6</b>	<b>Maternal care for disproportion due to hydrocephalic fetus</b>
<b>JA83.Y</b>	<b>Maternal care for known or suspected other specified disproportion</b>
<b>JA83.Z</b>	<b>Maternal care for known or suspected disproportion, unspecified</b>
<b>JA84</b>	<b>Maternal care for known or suspected abnormality of pelvic organs</b>
	A condition characterised by the provision of health interventions to the mother due to some abnormality that is either suspected or known to be present in one or more of her pelvic organs.
	<b>Exclusions:</b> Obstructed labour due to maternal pelvic abnormality (JB05)
<b>JA84.0</b>	<b>Maternal care for congenital malformation of uterus</b>
	Care provided for the pregnant female necessary due to malformation of the pregnant female's uterus present at or before the time of birth.
<b>JA84.1</b>	<b>Maternal care for tumour of corpus uteri</b>
	Care provided for the pregnant female necessary due to the presence of a uterine tumour at the time of pregnancy.
	<b>Exclusions:</b> maternal care for tumour of cervix (JA84)
<b>JA84.2</b>	<b>Maternal care due to uterine scar from previous surgery</b>
	<b>Inclusions:</b> Maternal care for scar from prior uterine surgery
	<b>Exclusions:</b> Vaginal delivery following previous caesarean section (JB0D.6)
<b>JA84.3</b>	<b>Maternal care for cervical incompetence</b>

- JA84.4** **Maternal care for abnormality of vagina**  
Care provided for the pregnant female necessary due to some abnormality of the vagina.
- Exclusions:** maternal care for vaginal varices in pregnancy (JA61.1)
- JA84.5** **Maternal care for abnormality of vulva or perineum**  
**Exclusions:** maternal care for perineal and vulval varices in pregnancy (JA61.1)
- JA84.Y** **Maternal care for known or suspected other specified abnormality of pelvic organs**
- JA84.Z** **Maternal care for known or suspected abnormality of pelvic organs, unspecified**
- JA85** **Maternal care for known or suspected fetal abnormality or damage**  
A condition characterised by the provision of health interventions to the mother due to some abnormality or damage that is either suspected or known to be present in the fetus.
- Exclusions:** Maternal care for known or suspected disproportion (JA83)
- JA85.0** **Maternal care for known or suspected central nervous system malformation in fetus**  
**Exclusions:** Maternal care for known or suspected chromosomal abnormality in fetus (JA85.1)
- JA85.1** **Maternal care for known or suspected chromosomal abnormality in fetus**
- JA85.2** **Maternal care for known or suspected hereditary disease in fetus**  
**Exclusions:** Maternal care for known or suspected chromosomal abnormality in fetus (JA85.1)
- JA85.3** **Maternal care for known or suspected damage to fetus from viral disease in mother**
- JA85.Y** **Maternal care for known or suspected other specified fetal abnormality or damage**
- JA85.Z** **Maternal care for known or suspected fetal abnormality or damage, unspecified**
- JA86** **Maternal care for other known or suspected fetal problems**  
A condition characterised by the provision of health interventions to the mother due to any other issue that is either suspected or known to be present in the fetus.
- Exclusions:** Labour or delivery complicated by fetal distress (JB07)  
Placental transfusion syndromes (JA8A.0)
- JA86.0** **Maternal care for red cell antibodies**  
Maternal care for rhesus or other isoimmunization
- JA86.1** **Maternal care for hydrops fetalis**

- JA86.2** **Maternal care for signs of fetal hypoxia**
- JA86.3** **Maternal care for intrauterine death**
- Exclusions:** Missed abortion (JA03)
- JA86.4** **Maternal care for fetal growth restriction**
- JA86.5** **Maternal care for suspected macrosomia**
- Inclusions:** Maternal care for known or suspected large-for-dates
- JA86.6** **Maternal care for viable fetus in abdominal pregnancy**
- JA86.Y** **Maternal care for other specified fetal problems**
- JA86.Z** **Maternal care for other known or suspected fetal problems, unspecified**
- JA87** **Maternal care related to polyhydramnios**  
 Excessive amniotic fluid normally diagnosed on ultrasound either subjectively using either single deepest vertical pocket of greater or equal to 8 cm and/or amniotic fluid index greater or equal to 24 cm.
- Inclusions:** Hydramnios
- JA88** **Maternal care related to certain specified disorders of amniotic fluid or membranes**
- Exclusions:** Maternal care related to premature rupture of membranes (JA89)
- JA88.0** **Oligohydramnios**
- JA88.1** **Infection of amniotic sac or membranes**
- JA88.Y** **Other specified disorders of amniotic fluid and membranes**
- JA88.Z** **Disorders of amniotic fluid and membranes, unspecified**
- JA89** **Maternal care related to premature rupture of membranes**  
 Spontaneous rupture of fetal membranes before the onset of labour.
- JA89.0** **Premature rupture of membranes, onset of labour within 24 hours**
- JA89.1** **Premature rupture of membranes, onset of labour after 24 hours**
- Exclusions:** Premature rupture of membranes, labour delayed by therapy (JA89.2)
- JA89.2** **Premature rupture of membranes, labour delayed by therapy**
- JA89.3** **Preterm premature rupture of membranes**
- JA89.Y** **Other specified maternal care related to premature rupture of membranes**
- JA89.Z** **Maternal care related to premature rupture of membranes, unspecified**

**JA8A****Maternal care related to placental disorders**

- Exclusions:**
- Maternal care related to premature separation of placenta (JA8C)
  - Maternal care related to placenta praevia or low lying placenta (JA8B)
  - maternal care for poor fetal growth due to placental insufficiency (JA86.4)

**JA8A.0 Placental transfusion syndromes**

**JA8A.1 Malformation of placenta**

**JA8A.2 Morbidly adherent placenta**

**JA8A.Y Other specified maternal care related to placental disorders**

**JA8A.Z Maternal care related to placental disorders, unspecified**

**JA8B****Maternal care related to placenta praevia or low lying placenta**

A placenta that is implanted over or very near the internal cervical os--total, partial, marginal, low-lying placenta

**JA8B.0 Placenta praevia specified as without haemorrhage**

**Inclusions:** low implantation of placenta specified as without haemorrhage

**JA8B.1 Placenta praevia with haemorrhage**

**Exclusions:** labour and delivery complicated by haemorrhage from vasa praevia (JB08.3)

**JA8B.Z Maternal care related to placenta praevia or low lying placenta, unspecified**

**JA8C****Maternal care related to premature separation of placenta**

**JA8C.0 Premature separation of placenta with coagulation defect**

**JA8C.Y Other specified maternal care related to premature separation of placenta**

**JA8C.Z Maternal care related to premature separation of placenta, unspecified**

**JA8D****Maternal care related to false labour**

Contractions suggestive of labour but which do not lead to cervical dilatation.

**JA8D.0 False labour before 37 completed weeks of gestation**

**JA8D.1 False labour at or after 37 completed weeks of gestation**

**JA8D.Z Maternal care related to false labour, unspecified**

**JA8E****Maternal care related to prolonged pregnancy**

Pregnancy that has exceeded a duration of 42 weeks from the last menstrual period.

**Inclusions:** Post-term

**JA8Y**

**Maternal care related to other specified fetus, amniotic cavity or possible delivery problems**

**JA8Z**

**Maternal care related to unspecified fetus, amniotic cavity or possible delivery problems**

## Complications of labour or delivery (JB00-JB0Z)

Any complication characterised by the adverse evolution of a condition that arises during any one of the three stages of labour and delivery.

**JB00**

**Preterm labour or delivery**

A condition characterised by the onset of labour and delivery before 37 completed weeks.

Assign an additional extension code, if desired, for Duration of pregnancy.

**JB00.0**

**Preterm labour without delivery**

A condition characterised by the onset of labour before 37 completed weeks, without delivery.

**JB00.1**

**Preterm spontaneous labour with preterm delivery**

A condition characterised by the spontaneous onset of labour and delivery before 37 completed weeks.

**JB00.2**

**Preterm labour with term delivery**

A condition characterised by the spontaneous onset of labour before 37 completed weeks followed by a delivery after 39 weeks.

**JB00.3**

**Preterm delivery following iatrogenic induction of labour or caesarean section**

**JB00.Y**

**Other specified preterm labour or delivery**

**JB00.Z**

**Preterm labour or delivery, unspecified**

**JB01**

**Failed induction of labour**

A condition characterised by a failed attempt to stimulate contractions before the spontaneous onset of labour. This condition may occur with or without ruptured membranes.

**JB01.0**

**Failed medical induction of labour**

A condition characterised by a failed attempt to stimulate contractions pharmacologically before the spontaneous onset of labour. This condition may occur with or without ruptured membranes.

**JB01.1**

**Failed instrumental induction of labour**

A condition characterised by a failed attempt to instrumentally stimulate contractions before the spontaneous onset of labour. This condition may occur with or without ruptured membranes.

**JB01.Z**

**Failed induction of labour, unspecified**

**JB02**

**Abnormalities of forces of labour**

Any condition affecting pregnant females, characterised by an anomaly or dysfunction to the tissues or processes associated with the natural progression of labour. These conditions may lead to further complications during labour and childbirth.

**JB02.0**

**Primary uterine inertia**

A condition affecting pregnant females characterised by insufficiently strong or inappropriately coordinated rhythmic activity of the myometrium during labour to efface and dilate the cervix.

- Inclusions:**
- Primary hypotonic uterine dysfunction
  - Uterine inertia during latent phase of labour
  - Primary inadequate contractions

**JB02.1**

**Secondary uterine inertia**

A condition affecting pregnant females that is idiopathic. This condition is characterised by vigorous contractions that decrease in vigour due to exhaustion or dehydration of the individual. This condition leads to lack of labour progress.

- Inclusions:**
- Secondary hypotonic uterine dysfunction
  - Arrested active phase of labour

**JB02.2**

**Other uterine inertia**

A condition affecting pregnant females that is idiopathic. This condition is characterised by the absence of effective uterine contractions during labour and abnormal relaxation of the uterus during labour. This condition leads to lack of labour progress or uterine haemorrhage.

- Inclusions:**
- Atony of uterus, during labour
- Exclusions:**
- atony of uterus, postpartum (JA43.1)

**JB02.3**

**Precipitate labour**

A condition affecting pregnant females that is idiopathic. This condition is characterised by rapid labour and the lack of time for standard obstetric preparations or procedures leading to the delivery of the newborn. This condition leads to vaginal bleeding, frequent strong contractions, feelings of defecation, crowning of the fetus head at the vaginal introitus, or bulging of the amniotic sac.

**JB02.4**

**Hypertonic, incoordinate, or prolonged uterine contractions**

A condition affecting pregnant females that is idiopathic. This condition is characterised by uterine dysfunction leading to hypertonic, uncoordinated, and prolonged rhythmic activity of the myometrium during labour.

- Exclusions:**
- dystocia (fetal)(maternal) NOS (JB06)

**JB02.Y**

**Other specified abnormalities of forces of labour**

**JB02.Z**

**Abnormalities of forces of labour, unspecified**

**JB03**

**Long labour**

Any condition characterised by a longer than average parturition between the initiation of regular, rhythmic, and painful contractions and cervical dilation, to the delivery of the placenta.

**JB03.0**

**Prolonged first stage of labour**

The first stage of labour where cervical dilatation progresses less than 1 centimetre per hour for a minimum of 4 hours. Protracted descent is less than 1 centimetre per hour for nulliparas and less than 2 centimetre per hour for multiparas.

**JB03.1**

**Prolonged second stage of labour**

The fetus has not been delivered after the cervix has become fully dilated within 2 hours for a primipara, or 1 hour for a multipara. Presence of regional anaesthesia will add 1 hour.

**JB03.2**

**Delayed delivery of successive neonates**

A condition affecting pregnant females, characterised by the delayed spontaneous or caesarean section delivery of the successive neonates in a multiple delivery.

**JB03.Z**

**Long labour, unspecified**

**JB04**

**Obstructed labour due to malposition or malpresentation of fetus**

A condition affecting pregnant females, caused by the abnormal position of fetal head or the abnormal presentation of the fetus away from the fetal head in vertex.

**JB04.0**

**Obstructed labour due to incomplete rotation of fetal head**

**JB04.1**

**Obstructed labour due to breech presentation**

**JB04.2**

**Obstructed labour due to face presentation**

**JB04.3**

**Obstructed labour due to brow presentation**

**JB04.4**

**Obstructed labour due to shoulder presentation**

**Inclusions:** Prolapsed arm

**Exclusions:** Obstructed labour due to shoulder dystocia (JB06.0)  
impacted shoulders (JB06.0)

**JB04.5**

**Obstructed labour due to compound presentation**

**JB04.Y**

**Obstructed labour due to other malposition and malpresentation of fetus**

**JB04.Z**

**Obstructed labour due to malposition or malpresentation of fetus, unspecified**

**JB05**

**Obstructed labour due to maternal pelvic abnormality**

Obstructed labour means that, in spite of strong contractions of the uterus, the fetus cannot descend through the pelvis because there is an insurmountable barrier preventing its descent. Obstruction usually occurs at the pelvic brim, but occasionally it may occur in the cavity or at the outlet of the pelvis. Complications resulting from obstructed labour can be avoided if a woman in obstructed labour is identified early and appropriate action is taken.

<b>JB05.0</b>	<b>Obstructed labour due to deformed pelvis</b>
<b>JB05.1</b>	<b>Obstructed labour due to generally contracted pelvis</b>
<b>JB05.2</b>	<b>Obstructed labour due to pelvic inlet contraction</b>
<b>JB05.3</b>	<b>Obstructed labour due to pelvic outlet or mid-cavity contraction</b>
<b>JB05.4</b>	<b>Obstructed labour due to foetopelvic disproportion, unspecified</b>
	<b><i>Exclusions:</i></b> dystocia due to abnormality of fetus (JB06)
<b>JB05.5</b>	<b>Obstructed labour due to abnormality of maternal pelvic organs</b>
	<b><i>Inclusions:</i></b> Obstructed labour due to maternal care for known or suspected abnormality of pelvic organs
<b>JB05.Y</b>	<b>Obstructed labour due to other maternal pelvic abnormalities</b>
<b>JB05.Z</b>	<b>Obstructed labour due to maternal pelvic abnormality, unspecified</b>
<b>JB06</b>	<b>Obstructed labour due to other causes</b> Any other condition characterised by the inability of the presenting part of the fetus to progress into the birth canal for any reason.
<b>JB06.0</b>	<b>Obstructed labour due to shoulder dystocia</b>
	<b><i>Inclusions:</i></b> Impacted shoulders
<b>JB06.1</b>	<b>Obstructed labour due to locked twins</b>
<b>JB06.2</b>	<b>Obstructed labour due to unusually large fetus</b>
<b>JB06.3</b>	<b>Obstructed labour due to other abnormalities of fetus</b>
<b>JB06.Y</b>	<b>Obstructed labour due to other specified causes</b>
<b>JB06.Z</b>	<b>Obstructed labour due to unspecified causes</b>
<b>JB07</b>	<b>Labour or delivery complicated by fetal distress</b>
<b>JB07.0</b>	<b>Labour or delivery complicated by fetal heart rate anomaly</b> A condition characterised by an abnormal fetal heart rate. This condition leads to further difficulties and complications during labour and delivery. Confirmation is by Doppler ultrasound. <b><i>Exclusions:</i></b> Labour or delivery complicated by fetal heart rate anomaly with meconium in amniotic fluid (JB07)
<b>JB07.1</b>	<b>Labour or delivery complicated by meconium in amniotic fluid</b> A condition characterised by complications during labour and delivery that is caused by meconium in amniotic fluid. <b><i>Exclusions:</i></b> Labour or delivery complicated by fetal heart rate anomaly with meconium in amniotic fluid (JB07)

- JB07.2 Labour or delivery complicated by biochemical evidence of fetal stress**  
A condition characterised by complications during labour and delivery that is caused by biochemical evidence of fetal distress. Confirmation is by a fetal blood sample from a scalp prick through the open cervix during labour.
- JB07.Y Other specified labour or delivery complicated by fetal distress**
- JB07.Z Labour or delivery complicated by fetal distress, unspecified**
- JB08 Labour or delivery complicated by umbilical cord complications**
- JB08.0 Labour or delivery complicated by prolapse of cord**  
A condition characterised by complications during labour and delivery that is caused by umbilical cord prolapse.
- JB08.1 Labour or delivery complicated by cord around neck, with compression**  
A condition characterised by complications during labour and delivery that is caused by wrapping of the umbilical cord around the neck of the fetus, with compression.
- JB08.2 Labour or delivery complicated by short cord**  
A condition characterised by complications during labour and delivery that is caused by a short umbilical cord.
- JB08.3 Labour or delivery complicated by vasa praevia**  
A condition characterised by complications during labour and delivery that is caused when the umbilical vessels traverse the membranes of the internal cervical os.  
*Inclusions:* Haemorrhage from vasa praevia
- JB08.4 Labour or delivery complicated by vascular lesion of cord**  
A condition characterised by complications during labour and delivery that is caused by vascular lesion of the umbilical cord.
- JB08.5 Labour or delivery complicated by other cord entanglement, with compression**
- JB08.Y Labour and delivery complicated by other specified umbilical cord complications**
- JB08.Z Labour or delivery complicated by umbilical cord complications, unspecified**
- JB09 Perineal laceration during delivery**  
An injury characterised by a laceration to the maternal perineum during delivery.  
*Inclusions:* episiotomy extended by laceration
- JB09.0 First degree perineal laceration during delivery**  
Perineal lacerations involving the fourchette, perineal skin, and vaginal mucous membrane but not the underlying fascia and muscle.

<b>JB09.1</b>	<b>Second degree perineal laceration during delivery</b> Perineal lacerations involve, in addition, the fascia and muscles of the perineal body but not the anal sphincter.  <b>Exclusions:</b> that involving anal sphincter (JB09.2)
<b>JB09.2</b>	<b>Third degree perineal laceration during delivery</b> Perineal lacerations extending farther to involve the anal sphincter.  <b>Exclusions:</b> that involving anal or rectal mucosa (JB09.3)
<b>JB09.3</b>	<b>Fourth degree perineal laceration during delivery</b> Perineal lacerations extending through the rectum's mucosa to expose its lumen.
<b>JB09.Z</b>	<b>Perineal laceration during delivery, unspecified</b>
<b>JB0A</b>	<p><b>Certain specified obstetric trauma</b></p> <p>Any injury characterised by maternal trauma. These injuries are caused by or subsequent to the process of (or any intervention related to) pregnancy, or labour and delivery.</p> <p><b>Coded Elsewhere:</b></p> <ul style="list-style-type: none"> <li>Vesicovaginal fistula (GC04.10)</li> <li>Urethrovaginal fistula (GC04.14)</li> <li>Combined urethrovesicovaginal fistula (GC04.15)</li> <li>Vesicouterine fistula with severe scar or extensive tissue loss (GC04.17)</li> <li>Other combined urinary fistula with severe scar or extensive tissue loss (GC04.18)</li> <li>Rectovaginal fistula (GC04.16)</li> <li>Combined urinary and rectal fistula including cloaca with severe scar or extensive tissue loss (GC04.19)</li> <li>Vaginal stenosis or gynatresia related to obstetric fistula (GC04.1A)</li> <li>Obstetric Fistula (GC04.1Z)</li> </ul>
<b>JB0A.0</b>	<b>Rupture of uterus before onset of labour</b> An injury characterised by rupture of the myometrial wall of the uterus before the onset of labour. This injury is caused by pregnancy. This injury presents with abdominal pain, haemorrhage, or hypovolemic shock in the mother, or late decelerations, reduced variability, tachycardia, or bradycardia in the fetus.
<b>JB0A.1</b>	<b>Rupture of uterus during labour</b> An injury characterised by rupture of the myometrial wall of the uterus during labour. This injury is caused by or subsequent to the process of (or any intervention related to) pregnancy, or labour and delivery. This injury presents with abdominal pain, haemorrhage, or hypovolemic shock in the mother, or late decelerations, reduced variability, tachycardia, or bradycardia in the fetus.  <b>Inclusions:</b> Rupture of uterus not stated as occurring before onset of labour

- JB0A.2 Postpartum inversion of uterus**  
An injury characterised by uterine inversion and prolapse through the dilated cervix that occurs after the delivery of a neonate. This condition is caused by or subsequent to labour and delivery, commonly as a result of excessive fundal pressure or cord traction. This condition presents with postpartum haemorrhage.
- JB0A.3 Obstetric laceration of cervix**  
An injury characterised by a laceration to the cervix. This injury is caused by or subsequent to the process of (or any intervention related to) pregnancy, or labour and delivery.
- JB0A.4 Obstetric high vaginal laceration**  
An injury characterised by a laceration in the upper third area of the vagina. This injury is caused by or subsequent to the process of (or any intervention related to) pregnancy, or labour and delivery.
- Inclusions:** Laceration of vaginal wall without mention of perineal laceration  
high vaginal obstetrical instrument injury
- JB0A.5 Obstetric uterine laceration or tear**
- JB0A.6 Other obstetric injury to pelvic organs**  
Any injury characterised by damage to the maternal pelvic organs. These injuries are caused by or subsequent to the process of (or any intervention related to) pregnancy, or labour and delivery.
- JB0A.7 Obstetric damage to pelvic joints or ligaments**  
An injury characterised by damage to the pelvic joints and ligaments. This injury is caused by or subsequent to the process of (or any intervention related to) pregnancy, or labour and delivery.
- JB0A.8 Obstetric haematoma of pelvis**  
An injury characterised by a collection of extravasated blood trapped in the pelvic tissues. This injury is caused by or subsequent to the process of (or any intervention related to) pregnancy, or labour and delivery. This condition may also present with bruising or blood clots in the pelvic area.
- JB0A.Y Other specified obstetric trauma**
- JB0A.Z Obstetric trauma, unspecified**
- JB0B Retained placenta or membranes, without haemorrhage**  
A condition characterised by a placenta or membranes that have not been expelled from the uterus during the third stage of labour and up to 30 minutes following delivery, and without haemorrhage. This condition is caused by uterine atony, a trapped placenta, or a placenta accreta. This condition may lead to primary postpartum haemorrhage or infection.

<b>JB0B.0</b>	<b>Retained placenta without haemorrhage</b> A condition characterised by a placenta that has not been expelled from the uterus during the third stage of labour and up to 30 minutes following delivery, and without haemorrhage. This condition is caused by uterine atony, a trapped placenta, or a placenta accreta. This condition may lead to primary postpartum haemorrhage or infection.
<b>Coding Note:</b>	Code also the causing condition
<b>JB0B.1</b>	<b>Retained portions of placenta or membranes, without haemorrhage</b> A condition characterised by portions of a placenta and membranes that have not been expelled from the uterus during the third stage of labour and up to 30 minutes following delivery, and without haemorrhage. This condition is caused by uterine atony, a trapped placenta, or a placenta accreta. This condition may lead to primary postpartum haemorrhage or infection.
<b>Coding Note:</b>	Code also the causing condition
<b>JB0C</b>	<b>Complications of anaesthesia during labour or delivery</b> Any complication caused by or subsequent to any anaesthetic intervention used during labour and delivery.  <b>Inclusions:</b> maternal complications arising from the administration of a general or local anaesthetic, analgesic or other sedation during labour and delivery  <b>Exclusions:</b> Complications of anaesthesia during pregnancy (JA67) Complications of anaesthesia during the puerperium (JB43)
<b>JB0C.0</b>	<b>Aspiration pneumonitis due to anaesthesia during labour or delivery</b> Massive gastric inhalation causing pulmonary insufficiency from aspiration pneumonitis due to anaesthesia during labour and delivery.  <b>Inclusions:</b> Mendelson syndrome due to anaesthesia during labour and delivery
<b>JB0C.1</b>	<b>Other pulmonary complications of anaesthesia during labour or delivery</b>
<b>JB0C.2</b>	<b>Cardiac complications of anaesthesia during labour or delivery</b>
<b>JB0C.3</b>	<b>Central nervous system complications of anaesthesia during labour or delivery</b>
<b>JB0C.4</b>	<b>Toxic reaction to local anaesthesia during labour or delivery</b>
<b>JB0C.5</b>	<b>Spinal or epidural anaesthesia-induced headache during labour or delivery</b>
<b>JB0C.6</b>	<b>Other complications of spinal or epidural anaesthesia during labour or delivery</b>
<b>JB0C.7</b>	<b>Failed or difficult intubation during labour or delivery</b>
<b>JB0C.8</b>	<b>Awareness under general anaesthesia during labour or delivery</b>
<b>JB0C.Y</b>	<b>Other specified complications of anaesthesia during labour or delivery</b>
<b>JB0C.Z</b>	<b>Complications of anaesthesia during labour or delivery, unspecified</b>

<b>JB0D</b>	<b>Certain specified complications of labour or delivery, not elsewhere classified</b>
	<p><b>Exclusions:</b> Infections in the puerperium (JB40) Puerperal sepsis (JB40.0)</p>
<b>JB0D.0</b>	<b>Maternal distress during labour or delivery</b> A condition characterised by maternal anxiety, depression, or stress during labour and delivery.
<b>JB0D.1</b>	<b>Shock during or following labour or delivery</b> A syndrome characterised by systemic cellular hypoxia and organ dysfunction as a result of hypoperfusion following labour and delivery. This syndrome is caused by haemorrhage, vomiting, diarrhoea, inadequate fluid intake, or a systemic inflammatory response to bacteria, endotoxins, or exotoxins.
	<p><b>Inclusions:</b> Obstetric shock</p>
<b>JB0D.2</b>	<b>Pyrexia during labour, not elsewhere classified</b> A complication characterised by maternal fever during labour, and not elsewhere classified.
<b>JB0D.3</b>	<b>Other complications of obstetric surgery or procedures</b> Any complication caused by or subsequent to obstetric surgery and procedures, and not elsewhere classified.
	<p><b>Exclusions:</b> Infection of obstetric surgical wound (JB40.1) Haematoma of obstetric wound (JB44.2) Complications of anaesthesia during labour or delivery (JB0C) Disruption of perineal obstetric wound (JB44.1)</p>
<b>JB0D.4</b>	<b>Delayed delivery after artificial rupture of membranes</b> A complication characterised by a delayed neonatal delivery after the artificial rupture of the membranes.
<b>JB0D.5</b>	<b>Delayed delivery after spontaneous or unspecified rupture of membranes</b> A complication characterised by a delayed neonatal delivery after the spontaneous or unspecified rupture of the membranes.
	<p><b>Exclusions:</b> spontaneous premature rupture of membranes (JA89)</p>
<b>JB0D.6</b>	<b>Vaginal delivery following previous caesarean section</b>
<b>JB0D.7</b>	<b>Failed application of vacuum extractor or forceps, unspecified</b>
	<p><b>Inclusions:</b> Failed application of ventouse or forceps, with subsequent delivery by forceps or caesarean section respectively</p>
<b>JB0D.8</b>	<b>Failed trial of labour, unspecified</b>
<b>JB0D.Y</b>	<b>Other specified complications of labour or delivery, not elsewhere classified</b>
<b>JB0Y</b>	<b>Other specified complications of labour or delivery</b>

**JB0Z****Complications of labour or delivery, unspecified****Delivery (JB20-JB2Z)**

Birth of one or more neonates from the uterus either spontaneously, assisted, or by caesarean section.

**Exclusions:** Disorders of newborn related to length of gestation or fetal growth (KA20-KA2Z)

**JB20****Single spontaneous delivery**

A condition caused by the development of a fetus to the culmination of the pregnancy period. This condition is characterised by spontaneous parturition of a neonate from the uterus.

**Inclusions:** delivery in a completely normal case

**JB20.0****Spontaneous vertex delivery**

A condition caused by the development of a fetus to the culmination of the pregnancy period. This condition is characterised by spontaneous parturition of a neonate in vertex position from the uterus.

**JB20.1****Spontaneous breech delivery**

A condition caused by the development of a fetus to the culmination of the pregnancy period. This condition is characterised by spontaneous parturition of a neonate in breech position from the uterus.

**JB20.Y****Single spontaneous delivery with other specified presentation****JB20.Z****Single spontaneous delivery, unspecified****JB21****Single delivery by forceps or vacuum extractor**

A condition caused by the development of a fetus to the culmination of the pregnancy period. This condition is characterised by parturition of a neonate from the uterus using forceps and vacuum extractor to assist the delivery.

**Exclusions:** Failed application of vacuum extractor or forceps, unspecified (JB0D.7)

**JB22****Single delivery by caesarean section**

A condition caused by the development of a fetus to the culmination of the pregnancy period. This condition is characterised by parturition of a single neonate from the uterus by caesarean section.

**JB22.0****Delivery by elective caesarean section****JB22.1****Delivery by emergency caesarean section****JB22.2****Single delivery by caesarean hysterectomy**

A condition caused by the development of a fetus to the culmination of the pregnancy period. This condition is characterised by parturition of a neonate from the uterus by caesarean section followed by removal of the uterus.

**JB22.Z****Single delivery by caesarean section, unspecified**

**JB23**

**Other assisted single delivery**

**JB23.0**

**Breech extraction**

A condition caused by the development of a fetus to the culmination of the pregnancy period. This condition is characterised by parturition of a neonate in breech position from the uterus using breech extraction interventions or techniques to assist the delivery.

**JB23.1**

**Other assisted breech delivery**

A condition caused by the development of a fetus to the culmination of the pregnancy period. This condition is characterised by parturition of a neonate in breech position from the uterus using other interventions or techniques to assist the delivery.

**JB23.2**

**Other manipulation-assisted delivery**

A condition caused by the development of a fetus to the culmination of the pregnancy period. This condition is characterised by parturition of a neonate from the uterus using other manipulation-assisted interventions or techniques to assist the delivery.

**JB23.3**

**Delivery of viable fetus in abdominal pregnancy**

A condition caused by the development of a viable fetus to the culmination of the pregnancy period. This condition is characterised by parturition of a viable neonate from the abdominal cavity, at the culmination of an abdominal pregnancy.

**JB23.4**

**Destructive operation for delivery**

A condition caused by the development of a fetus to the culmination of the pregnancy period. This condition is characterised by parturition of a neonate using destructive operation interventions or techniques to assist the delivery.

**JB23.Z**

**Other assisted single delivery, unspecified**

**JB24**

**Multiple delivery**

A condition caused by the development of more than one fetus to the culmination of the pregnancy period. This condition is characterised by parturition of more than one neonate from the uterus either spontaneously, assisted, or by caesarean section.

**JB24.0**

**Multiple delivery, all spontaneous**

A condition caused by the development of more than one fetus to the culmination of the pregnancy period. This condition is characterised by parturition of more than one neonate spontaneously from the uterus.

**JB24.1**

**Multiple delivery, all by forceps or vacuum extractor**

A condition caused by the development of more than one fetus to the culmination of the pregnancy period. This condition is characterised by parturition of more than one neonate from the uterus using forceps and vacuum extractor.

<b>JB24.2</b>	<b>Multiple delivery, all by caesarean section</b>
	A condition caused by the development of more than one fetus to the culmination of the pregnancy period. This condition is characterised by parturition of more than one neonate from the uterus by caesarean section.
<b>JB24.3</b>	<b>Multiple delivery by combination of methods with caesarean</b>
<b>JB24.Y</b>	<b>Other specified multiple delivery</b>
<b>JB24.Z</b>	<b>Multiple delivery, unspecified</b>
<b>JB2Z</b>	<b>Delivery, unspecified</b>

### Complications predominantly related to the puerperium (JB40-JB4Z)

A group of conditions characterised as any adverse evolution (complication) which may arise during the approximately six weeks after delivery during which the uterus returns to the original size (puerperium).

**Exclusions:**      Obstetrical tetanus (1C14)

**Coded Elsewhere:** Postpartum symptom or complaint (MF35)

<b>JB40</b>	<b>Infections in the puerperium</b>
	<b>Exclusions:</b> infection during labour (JB0D)

<b>JB40.0</b>	<b>Puerperal sepsis</b>
	<b>Coding Note:</b> Any type of infection - bacterial, viral, fungal or protozoal, can cause sepsis and must be coded as well. When the site of infection is unknown, select a code for Infection of unspecified site by organism followed by the appropriate code for sepsis.

**Exclusions:**      Obstetric pyaemic or septic embolism (JB42.3)  
                          sepsis during labour (JB0D)

<b>JB40.1</b>	<b>Infection of obstetric surgical wound</b>
<b>JB40.2</b>	<b>Other infection of genital tract following delivery</b>
<b>JB40.3</b>	<b>Urinary tract infection following delivery</b>
<b>JB40.4</b>	<b>Pyrexia of unknown origin following delivery</b>

**Exclusions:**      puerperal fever (JB40.0)  
                          Pyrexia during labour, not elsewhere classified (JB0D.2)

<b>JB40.Y</b>	<b>Other specified infections in the puerperium</b>
<b>JB40.Z</b>	<b>Infections in the puerperium, unspecified</b>

<b>JB41</b>	<b>Venous complications in the puerperium</b>
	<b>Exclusions:</b> Venous complications in pregnancy (JA61) Obstetric embolism (JB42)

<b>JB41.0</b>	<b>Superficial thrombophlebitis in the puerperium</b>
---------------	---

- JB41.1 Deep phlebothrombosis in the puerperium**
  - JB41.2 Haemorrhoids in the puerperium**
  - JB41.3 Cerebral venous thrombosis in the puerperium**
  - JB41.Y Other specified venous complications in the puerperium**
  - JB41.Z Venous complications in the puerperium, unspecified**

JB42 Obstetric embolism

A condition characterised by the lodging of a blood clot, a fat globule or a gas bubble (embolus) in the bloodstream, which can cause a blockage associated with the physiological and other changes that occur during the period of time from conception to delivery (pregnancy), during labour and delivery (childbirth) or during the approximately six weeks after delivery during which the uterus returns to the original size (puerperium).

**Exclusions:** Embolism following abortion, ectopic or molar pregnancy (JA05.2)

- JB42.0 Obstetric air embolism

A condition characterised by the lodging of a gas bubble (air embolus) in the bloodstream, which can cause a blockage associated with the physiological and other changes that occur during the period of time from conception to delivery (pregnancy), during labour and delivery (childbirth) or during the approximately six weeks after delivery during which the uterus returns to the original size (puerperium).

- ## JB42-1 Amniotic fluid embolism

Amniotic fluid embolism is a rare obstetric emergency in which it is postulated that amniotic fluid, fetal cells, hair, or other debris enter the maternal circulation, causing cardiorespiratory collapse.

**Inclusions:** Anaphylactoid syndrome of pregnancy

- #### **JB42.2 Obstetric blood-clot embolism**

A condition characterised by the lodging of a blood clot (a specific type of embolus known as a thrombus) in the bloodstream, which can cause a blockage associated with the physiological and other changes that occur during the period of time from conception to delivery (pregnancy), during labour and delivery (childbirth) or during the approximately six weeks after delivery during which the uterus returns to the original size (puerperium).

- #### **JB42.3                    Obstetric pyaemic or septic embolism**

- ## **JB42.Y Other specified obstetric embolism**

- ## **JB42.Z              Obstetric embolism, unspecified**

**JB43****Complications of anaesthesia during the puerperium**

**Coding Note:** Maternal complications arising from the administration of a general or local anaesthetic, analgesic or other sedation during the puerperium

**Inclusions:** Complications of anaesthesia during pregnancy (JA67)  
Complications of anaesthesia during labour or delivery (JB0C)

**JB43.0** **Pulmonary complications of anaesthesia during the puerperium**

**JB43.1** **Cardiac complications of anaesthesia during the puerperium**

**JB43.2** **Central nervous system complications of anaesthesia during the puerperium**

**JB43.3** **Spinal or epidural anaesthesia-induced headache during the puerperium**

**JB43.4** **Other complications of spinal or epidural anaesthesia during the puerperium**

**JB43.5** **Failed or difficult intubation during the puerperium**

**JB43.6** **Awareness under general anaesthesia during the puerperium**

**JB43.Y** **Other specified complications of anaesthesia during the puerperium**

**Coding Note:** Maternal complications arising from the administration of a general or local anaesthetic, analgesic or other sedation during the puerperium

**JB43.Z** **Complications of anaesthesia during the puerperium, unspecified**

**Coding Note:** Maternal complications arising from the administration of a general or local anaesthetic, analgesic or other sedation during the puerperium

**JB44****Certain specified complications of the puerperium**

A group of conditions characterised as any adverse evolution (complication) which may arise during the approximately six weeks after delivery during which the uterus returns to the original size (puerperium) which are not classified elsewhere.

**JB44.0** **Disruption of caesarean section wound**

**JB44.1** **Disruption of perineal obstetric wound**

**Inclusions:** Secondary perineal tear

**JB44.2** **Haematoma of obstetric wound**

**JB44.3** **Cardiomyopathy in the puerperium**

A group of diseases in which the dominant feature is the involvement of the cardiac muscle itself occurring in puerperium, the period of 6-8 weeks after giving birth. Cardiomyopathies are classified according to their predominant pathophysiological features or their etiological/pathological factors.

**JB44.4** **Postpartum acute renal failure**

**JB44.5** **Postpartum thyroiditis**

Postpartum thyroiditis (PPT) is the occurrence, in the postpartum period, of transient hyperthyroidism and/or transient hypothyroidism, with most women returning to the euthyroid state by 1 year postpartum.

<b>JB44.6</b>	<b>Puerperal osteomalacia</b>
<b>Coding Note:</b>	Code also the causing condition
<b>JB44.Y</b>	<b>Other specified complications of the puerperium</b>
<b>JB44.Z</b>	<b>Complications of the puerperium, unspecified</b>
<b>JB45</b>	<b>Infections of breast associated with childbirth</b>
<b>JB45.0</b>	<b>Abscess of breast associated with childbirth</b>
<b>JB45.1</b>	<b>Nonpurulent mastitis associated with childbirth</b>
<b>JB45.Y</b>	<b>Other specified infections of breast associated with childbirth</b>
<b>JB45.Z</b>	<b>Infections of breast associated with childbirth, unspecified</b>
<b>JB46</b>	<b>Certain specified disorders of breast or lactation associated with childbirth</b>
	<b>Coded Elsewhere:</b> Breast or lactation symptom or complaint (MF31)
<b>JB46.0</b>	<b>Retracted nipple associated with childbirth</b> A condition characterised as the abnormal inversion of a nipple that does not return to normal position even when stimulated that has occurred in association with childbirth.
<b>JB46.1</b>	<b>Cracked nipple associated with childbirth</b>
<b>JB46.2</b>	<b>Other or unspecified disorders of breast associated with childbirth</b>
<b>JB46.3</b>	<b>Agalactia</b> <i>Inclusions:</i> Failure of lactation Primary agalactia
<b>JB46.4</b>	<b>Hypogalactia</b> <i>Inclusions:</i> Insufficient milk supply Delayed milk supply
<b>JB46.5</b>	<b>Suppressed lactation</b>
<b>JB46.6</b>	<b>Galactorrhoea</b> Excessive or inappropriate lactation in females or males, and not necessarily related to pregnancy. Galactorrhoea can occur either unilaterally or bilaterally, and be profuse or sparse. Its most common cause is hyperprolactinemia. <i>Inclusions:</i> Oversupply of milk <i>Exclusions:</i> Galactorrhoea not associated with childbirth (GB23.4)
<b>JB46.7</b>	<b>Other or unspecified disorders of lactation</b>
<b>JB4Z</b>	<b>Complications predominantly related to the puerperium, unspecified</b>

## Certain obstetric conditions, not elsewhere classified (JB60-JB6Z)

Any condition characterised by an obstetric complication, condition, disease, or death during pregnancy, labour and delivery, or the puerperium that is not elsewhere classified.

**JB60**

### **Obstetric death of unspecified cause**

A condition characterised by maternal death during pregnancy or within 42 days following delivery. This death may be associated with physiological, obstetrical, or other changes or is provoked by interventions used during pregnancy, childbirth, or puerperium, but has no specified cause.

**JB61**

### **Death from any obstetric cause occurring more than 42 days but less than one year after delivery**

A condition characterised by maternal death between 43 days and one year following delivery. This death is caused by any physiological, obstetrical, or other changes or is provoked by interventions used during pregnancy, childbirth, or puerperium.

**Coding Note:** This category is to be used to indicate death from any obstetric cause (conditions in categories JA00-JB0Z; JB40-JB4Z and JB63-JB6Z), and occurring more than 42 days but less than one year after delivery.

**Exclusions:** Sequelae of complication of pregnancy, childbirth or the puerperium (JB65)

Death from sequelae of obstetric causes (JB62)

**JB61.0**

### **Death from direct obstetric cause occurring more than 42 days but less than one year after delivery**

Any condition directly resulting in death due to any cause associated with the physiological or other changes that occur during the period of time from conception to delivery (pregnancy), during labour and delivery (childbirth) or during the approximately six weeks after delivery during which the uterus returns to the original size (puerperium).

**Coding Note:**

This category is to be used to indicate death from direct obstetric cause and occurring more than 42 days but less than one year after delivery.

**JB61.1**

### **Death from indirect obstetric cause occurring more than 42 days but less than one year after delivery**

Any condition indirectly resulting in death via an intermediate cause due to any issue associated with the physiological or other changes that occur during the period of time from conception to delivery (pregnancy), during labour and delivery (childbirth) or during the approximately six weeks after delivery during which the uterus returns to the original size (puerperium).

**Coding Note:**

This category is to be used to indicate death from indirect obstetric cause and occurring more than 42 days but less than one year after delivery.

**JB61.Z**

### **Death from obstetric cause occurring more than 42 days but less than one year after delivery, unspecified whether direct or indirect**

**Coding Note:**

This category is to be used to indicate death from any obstetric cause (conditions in categories JA00-JB0Z; JB40-JB4Z and JB63-JB6Z), and occurring more than 42 days but less than one year after delivery.

**JB62**

**Death from sequelae of obstetric causes**

A secondary condition of pregnant females, caused by and subsequent to any complications during pregnancy, childbirth, or puerperium. This condition is characterised by maternal death.

**Inclusions:**      Death from any direct obstetric cause occurring one year or more after delivery

**JB62.0**

**Death from sequelae of direct obstetric cause**

Any condition directly resulting in death due to a pathological condition resulting from any adverse evolution (complication) which may arise associated with the period of time from conception to delivery (pregnancy), during labour and delivery (childbirth) or during the approximately six weeks after delivery during which the uterus returns to the original size (puerperium).

**JB62.1**

**Death from sequelae of indirect obstetric cause**

Any condition resulting in death via an intermediate cause due to a pathological condition resulting from any adverse evolution (complication) which may arise associated with the period of time from conception to delivery (pregnancy), during labour and delivery (childbirth) or during the approximately six weeks after delivery during which the uterus returns to the original size (puerperium).

**JB62.Z**

**Death from sequelae of obstetric causes, unspecified**

**JB63**

**Maternal infectious diseases classifiable elsewhere but complicating pregnancy, childbirth or the puerperium**

Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth or the puerperium

**Exclusions:**      Obstetrical tetanus (1C14)  
                        Laboratory evidence of human immunodeficiency virus (MA14.0)  
                        Asymptomatic human immunodeficiency virus infection (1C62.0)  
                        puerperal infection (JB40)  
                        Puerperal sepsis (JB40.0)  
                        when the reason for maternal care is that the disease is known or suspected to have affected the fetus (JA80-JA8Z)

**JB63.0**

**Tuberculosis complicating pregnancy, childbirth or the puerperium**

**JB63.00**

Tuberculous placenta

**JB63.0Y**

Other specified tuberculosis complicating pregnancy, childbirth or the puerperium

**JB63.0Z**

Tuberculosis complicating pregnancy, childbirth or the puerperium, unspecified

**JB63.1**

**Syphilis complicating pregnancy, childbirth or the puerperium**

Syphilis complicating pregnancy, childbirth or the puerperium

**JB63.2**

**Gonorrhoea complicating pregnancy, childbirth or the puerperium**

<b>JB63.3</b>	<b>Other infections with a predominantly sexual mode of transmission complicating pregnancy, childbirth or the puerperium</b>
<b>JB63.4</b>	<b>Viral hepatitis complicating pregnancy, childbirth or the puerperium</b>
<b>JB63.5</b>	<b>Other viral diseases complicating pregnancy, childbirth or the puerperium</b>
<b>JB63.6</b>	<b>Protozoal diseases complicating pregnancy, childbirth or the puerperium</b>
<b>JB63.60</b>	Malaria complicating pregnancy, childbirth, or the puerperium
<b>JB63.6Y</b>	Other specified protozoal diseases complicating pregnancy, childbirth or the puerperium
<b>JB63.6Z</b>	Protozoal diseases complicating pregnancy, childbirth or the puerperium, unspecified
<b>JB63.7</b>	<b>Human immunodeficiency disease complicating pregnancy, childbirth or the puerperium</b>
<b>JB63.Y</b>	<b>Other specified maternal infectious diseases classifiable elsewhere but complicating pregnancy, childbirth or the puerperium</b>
<b>JB63.Z</b>	<b>Maternal infectious diseases classifiable elsewhere but complicating pregnancy, childbirth or the puerperium, unspecified</b>
<b>JB64</b>	<b>Certain maternal diseases classifiable elsewhere but complicating pregnancy, childbirth or the puerperium</b>

**Coding Note:** This category includes conditions which complicate the pregnant state, are aggravated by the pregnancy or are a main reason for obstetric care but no specific category exists in this chapter.

**Exclusions:** when the reason for maternal care is that the condition is known or suspected to have affected the fetus (JA85)  
infectious and parasitic diseases (JB63)  
Injury, poisoning or certain other consequences of external causes (Chapter 22)

**Coded Elsewhere:** Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium (6E20-6E2Z)  
Injury complicating pregnancy (ND56.9)

<b>JB64.0</b>	<b>Anaemia complicating pregnancy, childbirth or the puerperium</b> A condition of the circulatory system affecting pregnant females, characterised by a haemoglobin level below 11 grams per decilitre that complicates pregnancy, childbirth, or the puerperium.
---------------	---

**Coding Note:** This category includes conditions which complicate the pregnant state, are aggravated by the pregnancy or are a main reason for obstetric care but no specific category exists in this chapter.

<b>JB64.1</b>	<b>Other diseases of the blood or blood-forming organs or certain disorders involving the immune mechanism complicating pregnancy, childbirth or the puerperium</b> Any disease affecting pregnant females, characterised by pathological changes to the blood and blood-forming organs and pathological changes involving the immune mechanism that complicate pregnancy, childbirth, or the puerperium not classified elsewhere.
<b>Coding Note:</b>	This category includes conditions which complicate the pregnant state, are aggravated by the pregnancy or are a main reason for obstetric care but no specific category exists in this chapter.
	<b>Exclusions:</b> Antepartum haemorrhage with coagulation defect (JA41.0) Intrapartum haemorrhage with coagulation defect (JA42.0)
<b>JB64.2</b>	<b>Endocrine, nutritional or metabolic diseases complicating pregnancy, childbirth or the puerperium</b> Any disease affecting pregnant females, characterised by endocrine, nutrition, or metabolic manifestations that complicate pregnancy, childbirth, or the puerperium.
<b>Coding Note:</b>	This category includes conditions which complicate the pregnant state, are aggravated by the pregnancy or are a main reason for obstetric care but no specific category exists in this chapter.
	<b>Exclusions:</b> Malnutrition in pregnancy (JA64) Diabetes mellitus in pregnancy (JA63) Postpartum thyroiditis (JB44.5)
<b>JB64.3</b>	<b>Diseases of the nervous system complicating pregnancy, childbirth or the puerperium</b> Any disorder or disease of the nervous system affecting pregnant females leading to complications during pregnancy, childbirth, or puerperium.
<b>Coding Note:</b>	This category includes conditions which complicate the pregnant state, are aggravated by the pregnancy or are a main reason for obstetric care but no specific category exists in this chapter.
	<b>Exclusions:</b> Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium (6E20-6E2Z)
<b>JB64.4</b>	<b>Diseases of the circulatory system complicating pregnancy, childbirth or the puerperium</b>
<b>Coding Note:</b>	This category includes conditions which complicate the pregnant state, are aggravated by the pregnancy or are a main reason for obstetric care but no specific category exists in this chapter.
	<b>Exclusions:</b> Obstetric embolism (JB42) venous complications and cerebrovenous sinus thrombosis in pregnancy (JA61) Venous complications in the puerperium (JB41) Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium (JA20-JA2Z) Cardiomyopathy in the puerperium (JB44.3) Other venous complications following abortion, ectopic or molar pregnancy (JA05.7)

<b>JB64.5</b>	<b>Diseases of the respiratory system complicating pregnancy, childbirth or the puerperium</b>
<b>Coding Note:</b>	This category includes conditions which complicate the pregnant state, are aggravated by the pregnancy or are a main reason for obstetric care but no specific category exists in this chapter.
<b>JB64.6</b>	<b>Diseases of the digestive system complicating pregnancy, childbirth or the puerperium</b>
<b>Coding Note:</b>	This category includes conditions which complicate the pregnant state, are aggravated by the pregnancy or are a main reason for obstetric care but no specific category exists in this chapter.
	<b>Exclusions:</b> Liver disorders in pregnancy, childbirth or the puerperium (JA65.0)
<b>JB64.7</b>	<b>Diseases of the skin complicating pregnancy, childbirth or the puerperium</b>
	Diseases of the skin or subcutaneous tissue not specifically related to pregnancy but which contribute to increased morbidity during pregnancy, childbirth or the puerperium, for example genetic blistering disorders or lichen sclerosus.
<b>Coding Note:</b>	This category includes conditions which complicate the pregnant state, are aggravated by the pregnancy or are a main reason for obstetric care but no specific category exists in this chapter.
	<b>Exclusions:</b> Herpes gestationis (JA65.10) Gestational pemphigoid (JA65.10) Polymorphic eruption of pregnancy (JA65.12) Pregnancy dermatoses (JA65.1) Pruritus of pregnancy (JA65.11)
<b>JB64.8</b>	<b>Congenital anomaly complicating pregnancy</b>
<b>JB64.Y</b>	<b>Other specified maternal diseases classifiable elsewhere but complicating pregnancy, childbirth or the puerperium</b>
<b>Coding Note:</b>	This category includes conditions which complicate the pregnant state, are aggravated by the pregnancy or are a main reason for obstetric care but no specific category exists in this chapter.
<b>JB65</b>	<b>Sequelae of complication of pregnancy, childbirth or the puerperium</b>
	A secondary condition that develops during the period of time from conception to delivery (pregnancy), during labour and delivery (childbirth) or during the six weeks following delivery (puerperium).
	<b>Exclusions:</b> Death from any obstetric cause occurring more than 42 days but less than one year after delivery (JB61) Death from sequelae of obstetric causes (JB62)
<b>JB6Y</b>	<b>Other specified obstetric conditions, not elsewhere classified</b>
<b>JB6Z</b>	<b>Unspecified obstetric condition</b>

# CHAPTER 19

---

## Certain conditions originating in the perinatal period

This chapter has 151 four-character categories.

Code range starts with KA00

This chapter includes conditions that have their origin in the perinatal period even though death or morbidity occurs later.

**Coding Note:** Conditions arising in the perinatal period, even though death or morbidity occurs later, should, as far as possible, be coded to chapter 19, which takes precedence over chapters containing codes for diseases by their anatomical site.

For children less than 28 days old, assume that a reported condition developed in the perinatal period, unless the duration is stated and the onset was after the first completed week of life.

- Exclusions:**
- Endocrine, nutritional or metabolic diseases (Chapter 05)
  - Congenital malformations, deformations and chromosomal abnormalities (Chapter 20)
  - Neoplasms (Chapter 02)
  - Injury, poisoning or certain other consequences of external causes (Chapter 22)
  - Congenital gonococcal infection (1A70-1A7Z)
  - Certain infectious or parasitic diseases - acquired after birth (Chapter 01)
  - Gastroenteritis or colitis of infectious origin (1A00-1A40.Z)
  - Hereditary haemolytic anaemia (3A10)
  - Transient hypogammaglobulinaemia of infancy (4A01.03)
  - Certain congenital diseases of the nervous system (Chapter 08)
  - congenital cardiomyopathy (BC43)
  - Paralytic ileus (DA93.0)
  - Pemphigus neonatorum (EA50)
  - Cradle cap (EH40.00)

This chapter contains the following top level blocks:

- Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery
- Disorders of newborn related to length of gestation or fetal growth
- Birth injury
- Infections of the fetus or newborn
- Haemorrhagic or haematological disorders of fetus or newborn

- Neurological disorders specific to the perinatal or neonatal period
- Respiratory disorders specific to the perinatal or neonatal period
- Cardiovascular disorders present in the perinatal or neonatal period
- Transitory endocrine or metabolic disorders specific to fetus or newborn
- Digestive system disorders of fetus or newborn
- Genitourinary system disorders specific to the perinatal or neonatal period
- Disorders involving the integument of fetus or newborn
- Disturbances of temperature regulation of newborn
- Certain disorders originating in the perinatal period

## Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery (KA00-KA0Z)

A group of conditions characterised by findings in the fetus or newborn due to conditions associated with the mother or by an adverse evolution (complication) which may arise associated with the time period from conception through childbirth.

**Coding Note:** These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.

**KA00**

### **Fetus or newborn affected by maternal conditions that may be unrelated to present pregnancy**

A group of conditions characterised by findings in the fetus or newborn due to conditions associated with the mother which are unrelated to the present pregnancy.

**Coding Note:** These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.

**Exclusions:** Fetus or newborn affected by maternal complications of pregnancy (KA01)

fetus and newborn affected by maternal endocrine and metabolic disorders (KB60-KB6Z)

Fetus or newborn affected by noxious influences transmitted via placenta or breast milk (KA06)

**KA00.0**

### **Fetus or newborn affected by maternal hypertensive disorders**

Maternal hypertensive disorders - chronic hypertension, preeclampsia-eclampsia, preeclampsia superimposed on chronic hypertension, and gestational hypertension.

**KA00.1**

### **Fetus or newborn affected by gestational oedema or proteinuria without hypertension**

**KA00.2**

### **Fetus or newborn affected by maternal renal or urinary tract diseases**

A group of conditions characterised by findings in the fetus or newborn due to conditions in the mother associated with the kidneys and urinary tract.

<b>KA00.3</b>	<b>Fetus or newborn affected by maternal infectious diseases</b> A condition affecting fetuses or newborns, that is (or suspected to be) caused by a maternal infection with a bacterial, viral, fungal, or parasitic source.
	<b><i>Inclusions:</i></b> Infections of the genital tract in pregnancy (JA62.4)
<b>KA00.4</b>	<b>Fetus or newborn affected by periodontal disease in mother</b>
<b>KA00.5</b>	<b>Fetus or newborn affected by maternal respiratory diseases</b>
<b>KA00.6</b>	<b>Fetus or newborn affected by maternal nutritional disorders</b> A group of conditions characterised by findings in the fetus or newborn due to conditions in the mother that are directly or indirectly associated with a lack of essential nutrients in the diet.
<b>KA00.60</b>	Fetus or newborn affected by maternal malnutrition
<b>KA00.61</b>	Fetus or newborn affected by maternal overweight or obesity
<b>KA00.6Y</b>	Other specified fetus or newborn affected by maternal nutritional disorders
<b>KA00.6Z</b>	Fetus or newborn affected by maternal nutritional disorders, unspecified
<b>KA00.7</b>	<b>Fetus or newborn affected by abnormal maternal chemistry</b>
<b>KA00.8</b>	<b>Fetus or newborn affected by maternal injury</b> A group of conditions characterised by findings in the fetus or newborn due to conditions in the mother resulting from physical damage or harm.
	<b><i>Inclusions:</i></b> Fetus or newborn affected by maternal injury, poisoning or certain other consequences of external causes
<b>KA00.9</b>	<b>Fetus or newborn affected by maternal chemotherapy</b>
<b>KA00.A</b>	<b>Fetus or newborn affected by surgical procedure on mother</b> A group of conditions characterised by findings in the fetus or newborn due to conditions in the mother resulting from surgical health intervention.
	<b><i>Exclusions:</i></b> damage to placenta from amniocentesis, caesarean section or surgical induction (KA02) Termination of pregnancy, affecting surviving fetus or newborn (KD3A) previous surgery to uterus or pelvic organs (KA05) Fetus or newborn affected by caesarean delivery (KA05.4)
<b>KA00.B</b>	<b>Fetus or newborn affected by maternal anaemia</b>
<b>KA00.Y</b>	<b>Fetus or newborn affected by other specified maternal condition that may be unrelated to present pregnancy</b>
<b>Coding Note:</b>	These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.

**KA00.Z Fetus or newborn affected by unspecified maternal condition that may be unrelated to present pregnancy**

**Coding Note:** These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.

**KA01**

**Fetus or newborn affected by maternal complications of pregnancy**

Any other condition characterised by findings in the fetus or newborn due to any condition of the mother due to an adverse evolution (complication) which may arise associated with the time period from conception through childbirth.

**Coding Note:** These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.

**KA01.0**

**Fetus or newborn affected by incompetence of cervix uteri**

Cervical incompetence refers to a weakness of the cervix and lower uterine segment, which can lead to recurrent second-trimester or early third-trimester loss of pregnancy due to an inability of the uterine cervix to retain a pregnancy until term. It is associated with a premature shortening of the cervix, dilatation, and opening of the cervical os during pregnancy. Ultrasound changes that suggest cervical incompetence include a cervical length < 1.5 cm, cervical width > 3 cm, and an expanded cervical canal > 8 mm.

**KA01.1**

**Fetus or newborn affected by premature rupture of membranes**

Preterm premature rupture of membranes (PPROM) refers to a patient who is at less than 37 weeks' gestation and has presented with a rupture of membranes prior to the onset of labour. Complications include pre-term delivery, ascending infection, umbilical cord prolapse, oligohydramnios, placental abruption, retained placenta, postpartum haemorrhage, or rupture of the vasa praevia.

**KA01.2**

**Fetus or newborn affected by oligohydramnios**

Oligohydramnios is defined as a decrease in the volume of amniotic fluid. It is diagnosed if the diameter of the largest amniotic fluid depot is < 2 cm, or if the amniotic fluid index (AFI) is < 5 cm.

**Exclusions:** Fetus or newborn affected by premature rupture of membranes (KA01.1)

**KA01.3**

**Fetus or newborn affected by polyhydramnios**

Polyhydramnios is defined as an abnormally large volume of amniotic fluid within the uterus. An amount of 2 L at term, any single pool >8cm or an amniotic fluid index (AFI) > 24 cm is considered to be polyhydramnios.

**Inclusions:** fetus or newborn affected by hydramnios

- KA01.4 Fetus or newborn affected by ectopic pregnancy**  
An ectopic pregnancy occurs when a pregnancy begins outside of the uterus. The most common site is within one of the fallopian tubes, although in rare cases, ectopic pregnancies can occur in the stomach region, cervix, or ovary. It is often caused by a condition that slows or blocks the movement of a fertilised egg through the fallopian tube to the uterus. Ectopic pregnancies cannot continue to term and the developing cells must be removed to prevent rupture of the ectopic area, which can lead to shock and danger the life of the mother.
- Inclusions:** Abdominal pregnancy affecting fetus or newborn
- KA01.5 Fetus or newborn affected by multiple pregnancy**  
A condition characterised by findings in the fetus or newborn due to any condition associated with the presence of a multiple pregnancy.
- KA01.6 Fetus or newborn affected by maternal death**  
A condition characterised by findings in the fetus or newborn due to death of the mother.
- KA01.7 Fetus or newborn affected by malpresentation before labour**  
Malpresentations are all presentations of the fetus other than the vertex, and includes breech, transverse, shoulder, compound, face, and brow presentations. They may pose risks to the fetus and mother and may necessitate operative vaginal or caesarean delivery, or other interventions to accomplish delivery. Breech presentation, the most common malpresentation, results when the fetal buttocks, legs, feet, or a combination of these presents first into the maternal pelvis.
- KA01.8 Fetus or newborn affected by maternal blood loss**
- KA01.Y Fetus or newborn affected by other specified maternal complication of pregnancy**
- Coding Note:** These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.
- KA01.Z Fetus or newborn affected by unspecified maternal complication of pregnancy**
- Coding Note:** These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.
- KA02 Fetus or newborn affected by complications of placenta**  
A group of conditions characterised by findings in the fetus or newborn due to an adverse evolution (complication) associated with the placenta, umbilical cord, or chorioamniotic membranes.
- Coding Note:** These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.

- KA02.0 Fetus or newborn affected by placenta praevia**  
Placenta praevia exists when the placenta lies wholly or in part in the lower segment of the uterus. Diagnosis has evolved from the clinical I-IV grading system, and is determined by ultrasonic imaging techniques relating the leading edge of the placenta to the cervical os. Grade I is a low lying placenta, Grade II is a placenta that meets the edge of the cervical os, Grade III is a placenta that partially covers the os, and Grade IV is a placenta that completely covers the os.
- KA02.1 Fetus or newborn affected by placental oedema or large placenta**  
A large placenta, also known as placentomegaly, is one that weighs > 750 g. Placentomegaly can be seen in the following conditions: fetal hydrops, maternal diabetes mellitus, Rh incompatibility, chronic infections (e.g. syphilis, cytomegalovirus), maternal anaemia, or acute placental oedema with acute chorioamnionitis.
- KA02.2 Fetus or newborn affected by placental infarction**  
Placental infarction is the formation of localised areas of ischemic villous necrosis, usually due to vasospasm of the maternal circulation. The affected regions of the placenta are incompetent, and lead to placental insufficiency if the infarcts are severe.
- KA02.3 Fetus or newborn affected by placental insufficiency or small placenta**  
Placental insufficiency is defined as the inability of the placenta to deliver a sufficient supply of oxygen and nutrients to the fetus, and therefore, is unable to sustain the growth of the developing baby until term. Placental insufficiency can result in intrauterine growth restriction (IUGR), pre-eclampsia, abruption, or preterm labour and delivery. A small placenta is defined as a placenta that weighs less than the lower limit of normal for the gestational period. A low placental weight can be the result of a maternal or fetal conditions. Among maternal conditions belong those causing underperfusion of the placenta, such as pre-eclampsia or maternal hypertension. Among fetal conditions belong fetal malformations or chromosomal anomalies.
- KA02.4 Fetus or newborn affected by placental transfusion syndromes**  
Twin-to-twin transfusion syndrome (TTTS) occurs in monozygotic twins while they are in the uterus. It occurs when blood travels from one twin to the other, and the twin that loses blood is the donor twin, while the twin that receives blood is the recipient twin. Depending on the severity of the transfusion, both infants may experience problems, such as anaemia, paleness, and dehydration in the donor twin, and redness and an increased blood pressure in the recipient twin.
- Inclusions:** Placental and cord abnormalities resulting in twin-to-twin or other transplacental transfusion
- KA02.Y Fetus or newborn affected by other specified complication of placenta**
- Coding Note:** These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.

<b>KA02.Z</b>	<b>Fetus or newborn affected by unspecified complication of placenta</b>
<b>Coding Note:</b>	These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.
<b>KA03</b>	<b>Fetus or newborn affected by complications of umbilical cord</b>
<b>KA03.0</b>	<b>Fetus or newborn affected by prolapsed cord</b>  A prolapsed umbilical cord is when the cord enters the opening cervix and down into the birth canal during labour before the baby has left the uterus. The risk of prolapse is higher if the baby is lying in a transverse position, the mother has had more than one baby, an excess amount of amniotic fluid exists, there is preterm prelabour rupture of membranes, or if membranes are artificially ruptured.
<b>KA03.1</b>	<b>Fetus or newborn affected by other compression of umbilical cord</b>  A group of conditions characterised by findings in the fetus or newborn due obstruction of blood flow through the umbilical cord secondary to pressure from an external object or misalignment of the cord itself not classified elsewhere.  <b>Coded Elsewhere:</b> Fetus or newborn affected by umbilical cord-to-cord entanglements in monoamniotic twins (LB03.Y)  Fetus or newborn affected by umbilical cord knot (LB03.Y) Fetus or newborn affected by umbilical cord loop (LB03.Y)
<b>KA03.2</b>	<b>Fetus or newborn affected by abnormalities of umbilical cord length</b>
<b>KA03.20</b>	Fetus or newborn affected by short umbilical cord  An umbilical cord < 2 SD in length below mean for the gestational age. At term, this is < 35 cm. Often associated with fetal hypokinesia
<b>KA03.21</b>	Fetus or newborn affected by long umbilical cord  An umbilical cord > 2 SD in length above mean for the gestational age. At term, this is > 80 cm.
<b>KA03.2Y</b>	Other specified fetus or newborn affected by abnormalities of umbilical cord length
<b>KA03.2Z</b>	Fetus or newborn affected by abnormalities of umbilical cord length, unspecified
<b>KA03.3</b>	<b>Fetus or newborn affected by vasa praevia</b>  An obstetric complication characterised by fetal vessels crossing or running in close proximity to the internal orifice of the cervix (inner cervical os).  <b>Exclusions:</b> Fetal blood loss from vasa praevia (KA80.0)
<b>KA03.4</b>	<b>Fetus or newborn affected by traumatic injury of the umbilical cord</b>
<b>KA03.Y</b>	<b>Fetus or newborn affected by other specified complication of umbilical cord</b>
<b>KA03.Z</b>	<b>Fetus or newborn affected by unspecified complication of umbilical cord</b>
<b>KA04</b>	<b>Fetus or newborn affected by other abnormalities of membranes</b>

<b>KA04.0</b>	<b>Fetus or newborn affected by chorioamnionitis</b> Chorioamnionitis is an infection of the placental tissues and amniotic fluid. It can lead to bacteraemia in the mother, which is an infection of the blood, and this can cause preterm birth or infection in the newborn. Organisms which are usually responsible for chorioamnionitis include Escherichia coli (E. coli) and Group B streptococcus.
	<b><i>Inclusions:</i></b> Infections of the fetus or newborn (KA60-KA6Z)
<b>KA04.1</b>	<b>Fetus or newborn affected by amniotic band syndrome</b>
<b>KA04.Y</b>	<b>Fetus or newborn affected by other specified abnormality of membranes</b>
<b>KA04.Z</b>	<b>Fetus or newborn affected by unspecified abnormality of membranes</b>
<b>KA05</b>	<b>Fetus or newborn affected by certain complications of labour or delivery</b> A group of conditions characterised by findings in the fetus or newborn due to any other adverse evolution (complication) during labour and delivery.
	<b>Coding Note:</b> These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.
<b>KA05.0</b>	<b>Fetus or newborn affected by breech delivery or extraction</b> Breech presentation refers to a fetus that is lying with its bottom downwards. There are three different types of breech presentation: breech with extended legs (frank), fully flexed legs (complete), or footling (incomplete) with one or both thighs extended. Breech presentation is associated with an increased risk of intrapartum trauma or asphyxia, and caesarean section is a common mode of delivery to reduce birth-related complications.
<b>KA05.1</b>	<b>Fetus or newborn affected by other malpresentation, malposition or disproportion during labour or delivery</b> A condition characterised by findings in the fetus or newborn due to abnormal positions of the vertex of the fetal head (malposition) or any presentation position of the fetus other than vertex of the fetal head, first (malpresentation) during labour and delivery.
<b>KA05.2</b>	<b>Fetus or newborn affected by forceps delivery</b> A condition characterised by findings in the fetus or newborn due to assisted birth in which intervention assistance is provided with smooth metal instruments curved to fit around the head (forceps).
<b>KA05.3</b>	<b>Fetus or newborn affected by delivery by vacuum extractor</b> A condition characterised by findings in the fetus or newborn due to assisted birth in which intervention assistance is provided with a soft or hard plastic or metal cup attached by a tube to a suction device that fits firmly onto the head and attaches with suction (vacuum extractor, ventouse).
	<b><i>Inclusions:</i></b> Fetus and newborn affected by delivery by ventouse

- KA05.4 Fetus or newborn affected by caesarean delivery**  
A condition characterised by findings in the fetus or newborn due to delivery via a surgical procedure in which one or more incisions are made through a mother's abdomen (laparotomy) and uterus (hysterotomy) to deliver one or more babies (Caesarean delivery).
- KA05.5 Fetus or newborn affected by precipitate delivery**  
A precipitate delivery is one that is < 3 hours and where contractions are unusually severe. It commonly occurs in multiparous women or when labour has been induced. Due to the force and speed of delivery, trauma may occur to the mother and newborn. The mother may suffer from haemorrhage, perineal laceration, infection, or uterine rupture, and the newborn may suffer from subdural hematoma, anoxia, or fractures.
- KA05.6 Fetus or newborn affected by abnormal uterine contractions**  
Abnormal uterine contractions can either be hypertonic or hypotonic. Hypertonic contractions are ones that occur more frequently and are marked by an increase in resting tone to more than 15 mm Hg. Hypotonic contractions are ones where the number of contractions is unusually low, the resting tone of the uterus is less than 10 mm Hg, and the strength of contractions is consistently < 26 mm Hg.
- KA05.7 Fetus or newborn affected by abnormality in fetal intrauterine heart rate or rhythm**
- KA05.70** Fetus and newborn affected by abnormality in fetal intrauterine heart rate or rhythm before onset of labour
- KA05.71** Fetus and newborn affected by abnormality in fetal intrauterine heart rate or rhythm during labour
- KA05.7Z** Fetus or newborn affected by abnormality in fetal intrauterine heart rate or rhythm, unspecified
- KA05.8 Meconium passage during delivery**  
Meconium passage by the fetus during labour and/or delivery process.  
**Exclusions:**      Neonatal aspiration of meconium (KB26.0)  
                        Meconium staining (KD38)
- KA05.Y Fetus or newborn affected or suspected to be affected by other specified complications of labour or delivery**  
**Coding Note:** These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.
- KA05.Z Fetus or newborn affected or suspected to be affected by unspecified complications of labour or delivery**  
**Coding Note:** These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.

**KA06**

**Fetus or newborn affected by noxious influences transmitted via placenta or breast milk**

A group of conditions characterised by findings in the fetus or newborn due to the transmission of any harmful or poisonous substance to the fetus or newborn via the placenta or in breast milk.

**Coding Note:**

These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.

**Inclusions:** nonteratogenic effects of substances transmitted via placenta

**Exclusions:** congenital malformations (Chapter 20)

Neonatal hyperbilirubinaemia due to drugs or toxins  
transmitted from mother (KA87.4)

**KA06.0**

**Fetus or newborn affected by maternal anaesthesia or analgesia in pregnancy, labour or delivery**

A condition characterised by findings in the fetus or newborn due to the transmission of anaesthesia or analgesia provided to the mother during the period of time between conception and childbirth.

**Inclusions:** Reactions and intoxications from maternal opiates and tranquillizers administered during labour and delivery

**KA06.1**

**Fetus or newborn affected by maternal use of tobacco**

A condition characterised by findings in the fetus or newborn due to the transmission of any substances derived from tobacco use by the mother to the fetus or newborn.

**Exclusions:** Exposure to tobacco smoke in the perinatal period (KD37)

**KA06.2**

**Fetus or newborn affected by maternal use of alcohol**

A condition characterised by findings in the fetus or newborn due to the transmission of any substances derived from alcohol use by the mother to the fetus or newborn.

**Exclusions:** Fetal alcohol syndrome (LD2F.00)

**KA06.3**

**Fetus or newborn affected by maternal use of drugs of addiction**

A condition characterised by findings in the fetus or newborn due to the transmission of any substances derived from other drug use by the mother to the fetus or newborn.

**Exclusions:** Fetus or newborn affected by maternal anaesthesia or analgesia in pregnancy, labour or delivery (KA06.0)

withdrawal symptoms from maternal use of drugs of addiction  
(KD35)

**KA06.4**

**Fetus or newborn affected by maternal use of nutritional chemical substances**

A condition characterised by findings in the fetus or newborn due to the transmission of any substances derived from nutritional chemical use by the mother to the fetus or newborn.

<b>KA06.5</b>	<b>Fetus or newborn affected by maternal exposure to environmental chemical substances</b> A condition characterised by findings in the fetus or newborn due to the transmission of any substances derived from exposure of the mother to environmental chemicals.
<b>KA06.Y</b>	<b>Fetus or newborn affected by other specified noxious influence transmitted via placenta or breast milk</b>
<b>Coding Note:</b>	These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.
<b>KA06.Z</b>	<b>Fetus or newborn affected by unspecified noxious influence transmitted via placenta or breast milk</b>
<b>Coding Note:</b>	These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.
<b>KA07</b>	<b>Neonatal dermatoses due to maternal antibodies</b> A range of antibody-mediated neonatal skin disorders due to transplacental transfer of maternal antibodies to the fetus. The relevant autoimmune disorder may or may not be apparent in the mother.
<b>KA07.0</b>	<b>Neonatal lupus erythematosus</b> Neonatal lupus erythematosus results from trans-placental transfer of maternal antibodies, in particular anti-Ro/SSA and anti La/SSB. It manifests with an erythematous rash which may be obviously photosensitive and is closely associated with congenital heart block. The mother may have known lupus, especially subacute cutaneous lupus erythematosus, but she may be asymptomatic. The rash normally subsides within the first few months of life.
<b>KA07.1</b>	<b>Neonatal pemphigus</b> Neonatal pemphigus vulgaris is a short lived autoimmune skin disease arising as a result of transplacental transmission to the neonate of maternal antibodies. Neonatal pemphigus is characterised by blister formation on the skin and the mucous membranes mediated by auto-antibodies to the desmosome component desmoglein 3.
<b>KA07.Y</b>	<b>Other specified neonatal dermatoses due to maternal antibodies</b>
<b>KA0Z</b>	<b>Fetus or newborn affected by unspecified maternal factors or by complications of pregnancy, labour or delivery</b>
<b>Coding Note:</b>	These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth). Use additional code to identify the condition in the fetus or newborn.

## Disorders of newborn related to length of gestation or fetal growth (KA20-KA2Z)

A group of conditions related to the length of time that the fetus is carried inside the uterus and develops.

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

### **KA20 Disorders of newborn related to slow fetal growth or fetal malnutrition**

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

#### **KA20.0 Small for gestational age**

Birth weight below – 2 standard deviations of the mean or below the 10th percentile according to local intrauterine growth charts

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

**Inclusions:** Small-for-dates

#### **KA20.00 Small for gestational age, symmetrical**

Growth of the fetus is affected in early pregnancy and growth is slow throughout the duration of the pregnancy. The head circumference is proportional to the rest of the body. Birth weight is 2 standard deviations below the mean, or below the 10th percentile.

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

#### **KA20.01 Small for gestational age, asymmetrical**

This growth restriction leads to a disparity in length and head circumference when compared to birth weight. This condition typically occurs in the third trimester.

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

#### **KA20.0Z Small for gestational age, unspecified**

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

#### **KA20.1 Intrauterine growth restriction**

The fetus does not achieve its predicted genetic potential and infant, not light or small for gestational age, showing signs of fetal malnutrition.

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

#### **KA20.10 Asymmetrical intrauterine growth restriction**

There is restriction of body weight followed by length with general head sparing. This condition occurs late in pregnancy and is caused by extrinsic factors. Fetal malnutrition leading to low ponderal index less than 2 (weight to length ratio) but weight not severe enough to qualify as small for gestational age.

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

<b>KA20.11</b>	Symmetrical intrauterine growth restriction This condition begins earlier in pregnancy and there is a higher incidence of permanent neurologic sequela. It is often associated with either genetic abnormalities or fetal infection, especially 1st trimester viral infections.
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
<b>KA20.12</b>	Intrauterine growth restriction associated with small for gestational age These infants are classified as small for gestational age but have also been subject to intrauterine growth restriction.
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
<b>KA20.1Y</b>	Other specified intrauterine growth restriction
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
<b>KA20.1Z</b>	Intrauterine growth restriction, unspecified
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
<b>KA20.2</b>	<b>Fetal intrauterine malnutrition without mention of small for gestational age</b> Neonate, not light or small for gestational age, showing signs of fetal malnutrition, such as dry, peeling skin and loss of subcutaneous tissue
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
	<b>Exclusions:</b> fetal malnutrition with mention of: light for gestational age (KA21) fetal malnutrition with mention of: small for gestational age (KA20.0)
<b>KA20.Y</b>	<b>Other specified disorders of newborn related to slow fetal growth or fetal malnutrition</b>
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
<b>KA20.Z</b>	<b>Disorders of newborn related to slow fetal growth or fetal malnutrition, unspecified</b>
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

**KA21**

**Disorders of newborn related to short gestation or low birth weight, not elsewhere classified**

Infants whose weight is appropriate for their gestational ages are termed appropriate for gestational age (AGA). Infants that are heavier than expected are large for gestational age (LGA). Conversely, those smaller than expected are considered small for gestational age (SGA).

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

**Exclusions:** Disorders of newborn related to slow fetal growth or fetal malnutrition (KA20)

**KA21.0 Extremely low birth weight of newborn**

Newborn birth weight 999 g or less. Infants have increased morbidity including neurosensory disability, cerebral palsy, retinopathy of prematurity, deafness, pulmonary immaturity, chronic lung disease and subnormal cognitive function.

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

**KA21.00 Extremely low birth weight of newborn, 499g or less**

A paediatric condition in which the infant is born weighing 499 g or less.

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

**KA21.01 Extremely low birth weight of newborn, 500-749g**

A paediatric condition in which the infant is born weighing between 500 and 749 g.

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

**KA21.02 Extremely low birth weight of newborn, 750-999g**

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

**KA21.0Z Extremely low birth weight of newborn, unspecified**

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

**KA21.1 Very low birth weight of newborn**

A paediatric condition in which the infant is born weighing between 1000 and 1499 g.

**Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

**KA21.10 Very low birth weight of newborn, 1000-1249g**

A paediatric condition in which the infant is born weighing between 1000 and 1249 g.

**KA21.11 Very low birth weight of newborn, 1250-1499g**

A paediatric condition in which the infant is born weighing between 1250 and 1499 g.

- KA21.1Z** Very low birth weight of newborn, unspecified
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.2** **Low birth weight of newborn**
- A paediatric condition in which the infant is born weighing between 1500 and 2499 g.
- KA21.20** Low birth weight of newborn, 1500-1999g
- A paediatric condition in which the infant is born weighing between 1500 and 1999 g.
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.21** Low birth weight of newborn, 2000-2499g
- A paediatric condition in which the infant is born weighing between 2000 and 2499 g.
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.2Z** Low birth weight of newborn, unspecified
- KA21.3** **Extreme prematurity of newborn**
- Less than 28 completed weeks (less than 196 completed days) of gestation.
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.30** Extreme prematurity of newborn, gestational age less than 22 completed weeks  
Extreme prematurity of newborn, gestational age less than 22 weeks, 0 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.31** Extreme prematurity of newborn, gestational age 22 completed weeks  
Extreme prematurity of newborn, gestational age 22 weeks, 0 days through 22 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.32** Extreme prematurity of newborn, gestational age 23 completed weeks  
Extreme prematurity of newborn, gestational age 23 weeks, 0 days through 23 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.33** Extreme prematurity of newborn, gestational age 24 completed weeks  
Extreme prematurity of newborn, gestational age 24 weeks, 0 days through 24 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

- KA21.34** Extreme prematurity of newborn, gestational age 25 completed weeks  
Extreme prematurity of newborn, gestational age 25 weeks, 0 days through 25 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.35** Extreme prematurity of newborn, gestational age 26 completed weeks  
Extreme prematurity of newborn, gestational age 26 weeks, 0 days through 26 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.36** Extreme prematurity of newborn, gestational age 27 completed weeks  
Extreme prematurity of newborn, gestational age 27 weeks, 0 days through 27 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.3Z** Extreme prematurity of newborn, unspecified
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.4** **Preterm newborn**  
Preterm: is less than 37 completed weeks (less than 259 days) of gestation.
- Coding Note:** When both birth weight and gestational age are available, priority of assignment must be given to gestational age.
- KA21.40** Preterm newborn, gestational age 28 completed weeks  
Preterm newborn, gestational age 28 weeks, 0 days through 28 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.41** Preterm newborn, gestational age 29 completed weeks  
Preterm newborn, gestational age 29 weeks, 0 days through 29 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.42** Preterm newborn, gestational age 30 completed weeks  
Preterm newborn, gestational age 30 weeks, 0 days through 30 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.43** Preterm newborn, gestational age 31 completed weeks  
Preterm newborn, gestational age 31 weeks, 0 days through 31 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

- KA21.44** Preterm newborn, gestational age 32 completed weeks  
Preterm newborn, gestational age 32 weeks, 0 days through 32 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.45** Preterm newborn, gestational age 33 completed weeks  
Preterm newborn, gestational age 33 weeks, 0 days through 33 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.46** Preterm newborn, gestational age 34 completed weeks  
Preterm newborn, gestational age 34 weeks, 0 days through 34 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.47** Preterm newborn, gestational age 35 completed weeks  
Preterm newborn, gestational age 35 weeks, 0 days through 35 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.48** Preterm newborn, gestational age 36 completed weeks  
Preterm newborn, gestational age 36 weeks, 0 days through 36 weeks, 6 days
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA21.4Z** Preterm newborn, unspecified
- Coding Note:** When both birth weight and gestational age are available, priority of assignment must be given to gestational age.

- KA22** **Disorders of newborn related to long gestation or high birth weight**  
Usually implies gestation > 290 or 294 days (42 weeks); high birthweight = >4000g.
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- KA22.0** **Exceptionally large newborn**  
An exceptionally large baby is defined as having a weight at birth of > 4500 g, regardless of gestational age at birth.
- Coding Note:** When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
- Exclusions:** Syndrome of infant of mother with gestational diabetes (KB60.0)  
Syndrome of infant of a diabetic mother, type 1 or 2, nongestational, insulin dependent (KB60.1)

<b>KA22.1</b>	<b>Large newborn for gestational age</b> A birth weight greater than the 90th percentile for gestational age or birth weight 4000-4499 g at term regardless of period of gestation.
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
	<b>Exclusions:</b> Syndrome of infant of mother with gestational diabetes (KB60.0)  Syndrome of infant of a diabetic mother, type 1 or 2, nongestational, insulin dependent (KB60.1)
<b>KA22.2</b>	<b>Post-term newborn</b> A condition of the newborn characterised by a gestational period that reached or exceeded 42 completed weeks (294 days or more) of gestation.
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
	<b>Exclusions:</b> Postmaturity syndrome (KA22.3)
<b>KA22.3</b>	<b>Postmaturity syndrome</b> Post-term infant with signs of dysmaturity including dry peeling wrinkled skin, yellow staining of the skin, long stained fingernails, abundant scalp hair, thin growth retarded body with long thin limbs and hyperalert behaviours.
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
	<b>Exclusions:</b> Post-term newborn (KA22.2)
<b>KA2Y</b>	<b>Other specified disorders of newborn related to length of gestation or fetal growth</b>
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.
<b>KA2Z</b>	<b>Disorders of newborn related to length of gestation or fetal growth, unspecified</b>
<b>Coding Note:</b>	When both birth weight and gestational age are available, priority of assignment should be given to birth weight.

## Birth injury (KA40-KA4Z)

A group of conditions characterised by the presence of damage of the tissues and organs of a newly delivered child due to physical pressure or injury during delivery.

<b>KA40</b>	<b>Birth injury to central nervous system</b> A condition characterised by the presence of damage to the central nervous system due to physical pressure or injury during delivery.
-------------	--

<b>KA40.0</b>	<b>Intracranial laceration or haemorrhage due to birth injury</b> A group of conditions characterised as a traumatic brain injury occurring when the tissue of the brain is mechanically cut or torn and bleeds in a newly delivered child due to physical pressure or injury during delivery.
	<b>Exclusions:</b> intracranial haemorrhage of fetus or newborn: due to anoxia, hypoxia, or ischaemia (KA82)
	Intracranial nontraumatic haemorrhage of fetus or newborn (KA82)
<b>KA40.00</b>	Subdural haemorrhage due to birth injury Haemorrhage into the subdural space (between the dura and the arachnoid) resulting from traumatic tearing of the bridging veins and venous sinuses due to rotational movement of the brain secondary to a traumatic delivery.
	<b>Exclusions:</b> subdural haemorrhage accompanying tentorial tear (KA40.05)
<b>KA40.01</b>	Cerebral haemorrhage due to birth injury Cerebral haemorrhage due to birth injury refers to haemorrhage occurring into the cerebral parenchyma as a result of birth trauma, and is commonly accompanied by extracerebral contusion and/or bleeding haemorrhage in the scalp. May have associated skull fracture(s).
<b>KA40.02</b>	Cerebellar haemorrhage due to birth injury Haemorrhage into the cerebellum, hemispheres or vermis, due to trauma. Occipitalocephalostasis with breech delivery is the most common cause of this injury.
<b>KA40.03</b>	Intraventricular haemorrhage due to birth injury Traumatic haemorrhage into the intraventricular space as the dominant lesion, usually in a term infant, a result of birth trauma. Usually seen in conjunction with other intracranial bleeding (parenchymal, subdural, subarachnoid) and can be seen in the term or preterm infant.
<b>KA40.04</b>	Subarachnoid haemorrhage due to birth injury Haemorrhage within the subarachnoid space (the area between the arachnoid membrane and the pia matter) due to either leakage from the leptomeningeal plexus or rupture of bridging veins within the subarachnoid space.
<b>KA40.05</b>	Tentorial tear due to birth injury Lacerations of tentorium cerebelli due to birth trauma, usually resulting in infratentorial haemorrhages; lesser degrees of tentorial injury most commonly associated with subdural bleeds.
<b>KA40.06</b>	Cerebellar contusion due to birth injury A bruise of the brain tissue. There is a punctuate haemorrhage which occurs in the long gyri.
<b>KA40.07</b>	Cerebral contusion due to birth injury A bruise of the brain tissue. Focal region of necrosis and haemorrhage, usually involving the cerebral cortex and subcortical white matter

- KA40.08** Extradural or epidural haemorrhage due to birth injury  
Haemorrhage in the plane between the skull bone and the periosteum on the inner surface of the skull from injury to the middle meningeal artery from birth trauma
- KA40.0Y** Other specified intracranial laceration or haemorrhage due to birth injury
- KA40.0Z** Intracranial laceration or haemorrhage due to birth injury, unspecified
- KA40.1** **Cerebral oedema due to birth injury**  
Cerebral oedema is an excessive accumulation of water in the intracellular or extracellular spaces of the brain. There is a breakdown of the tight endothelial junctions which make up the blood brain barrier.
- KA40.2** **Birth injury to spine or spinal cord**  
Injury to the spinal cord incurred during delivery from excessive traction or rotation, principally occurring during breech and rotational forceps during vertex deliveries
- KA40.3** **Birth injury to brainstem**  
Injury to the brain stem occurring during delivery due to excessive longitudinal traction especially when this traction is combined with flexion and torsion of the spine during delivery.
- Exclusions:** Fracture, dislocation or subluxation of spine due to birth injury (KA45.4)
- KA40.Y** Other specified birth injury to central nervous system
- KA40.Z** Birth injury to central nervous system, unspecified
- KA41** **Birth injury to eye**  
Ocular injuries due to birth trauma include lid lacerations, hyphema, rupture of Descemet's membrane of cornea, vitreous haemorrhage, corneal oedema, abrasions and lacerations, orbital haemorrhage and fractures, and intraocular haemorrhages.
- KA42** **Birth injury to scalp**  
A condition characterised by the presence of damage to the scalp due to physical pressure or injury during delivery.
- KA42.0** **Bruising of scalp due to birth injury**  
Erythema of the scalp occurring usually as a result of dystocia or application of forceps
- KA42.1** **Cephalohaematoma due to birth injury**  
Cephalhaematoma is a subperiosteal collection of blood caused by rupture of vessels beneath the periosteum and does not extend across the suture lines.
- KA42.2** **Chignon due to birth injury**  
Chignon is a temporary swelling (oedema of the scalp) secondary to the placement of a ventouse suction cup used in assisted vacuum deliveries. It usually disappears after several hours

- KA42.3 Monitoring injury of scalp of newborn**  
Injuries to the scalp from use of intrapartum fetal monitoring devices including injury following fetal blood sampling.
- KA42.4 Subgaleal epicranial subaponeurotic haemorrhage due to birth injury**  
Subgaleal haemorrhage is a collection of blood in the space between the epicranial aponeurosis of the scalp and the periosteum of the skull.
- KA42.Y Other specified birth injury to scalp**
- KA42.Z Birth injury to scalp, unspecified**
- KA43 Birth injury to skin or soft tissues**  
Superficial injury including abrasions, lacerations and ecchymoses sustained during birth to sites other than scalp face and external genitalia
- Exclusions:** Birth injury to scalp (KA42)
- KA43.0 Birth injury to sternocleidomastoid**  
Injury to the sternomastoid muscle due to birth usually presents with torticollis (tilt and rotation of head) and a firm, spindle-shaped, immobile mass in the midportion of sternomastoid muscle.
- KA43.1 Birth injury to external genitalia**  
Injuries of external genitalia such as oedema, ecchymoses, and haematomas of scrotum and labia majora, haematocoele, and trauma to the testes as a result of trauma during birth, especially after a breech delivery
- KA43.2 Subcutaneous fat necrosis due to birth injury**  
Subcutaneous fat necrosis is a rare acute transient hypodermatitis that develops within first weeks of life in term infants.
- Exclusions:** Subcutaneous fat necrosis of the newborn (KC22.0)
- KA43.3 Birth injury to face**  
Birth injuries to face include injuries sustained to nose (deviations, deformities, and septal damage), ears (abrasions, lacerations, deformities and haematomas).
- KA43.Y Other specified birth injury to skin or soft tissues**
- KA43.Z Birth injury to skin or soft tissues, unspecified**
- KA44 Birth injury to peripheral nervous system**  
A condition characterised by the presence of damage to the nerves and ganglia outside of the brain and spinal cord due to physical pressure or injury during delivery.
- KA44.0 Birth injury to cranial nerves**  
Birth injuries to the cranial nerves include contusion, avulsion, rupture, neuroma and praxis.

- KA44.00** Birth injury to facial nerve  
 Facial palsy involving both upper and lower halves of the face caused by traumatic compression of the facial nerve as it exits the stylomastoid foramen, or as it passes over the ramus of the mandible.
- KA44.0Y** Birth injury to other specified cranial nerve
- KA44.0Z** Birth injury to unspecified cranial nerve
- KA44.1** **Brachial plexus palsy in newborn**  
 Brachial plexus birth palsy occurs when the brachial plexus are damaged during birth. It occurs most typically during a difficult delivery.
- KA44.10** Erb paralysis  
 Erb paralysis is one of the most common brachial plexus birth palsies. The injury occurs in the upper brachial plexus nerves and affects the upper arm.
- KA44.11** Klumpke paralysis  
 Klumpke paralysis is a form of brachial plexus palsy that causes paralysis in the hand.
- KA44.1Z** Brachial plexus palsy in newborn, unspecified
- KA44.2** **Phrenic nerve paralysis due to birth injury**  
 Birth injury to the cervical roots 3 to 5 resulting in the paralysis of the ipsilateral diaphragm usually after a difficult breech delivery
- KA44.Y** **Birth injury to other specified peripheral nerve**
- KA44.Z** **Birth injury to unspecified peripheral nerve**
- KA45** **Birth injury to skeleton**  
 A condition characterised by the presence of damage to the skeleton due to physical pressure or injury during delivery.  
**Exclusions:** Birth injury to spine or spinal cord (KA40.2)
- KA45.0** **Fracture of skull due to birth injury**  
 Linear or depressed fractures of skull bones resulting from injury during birth, including those related to forceps and vacuum assisted delivery
- KA45.00** Linear skull fracture due to birth injury  
 Linear fractures of skull bones resulting from injury during birth, including those related to forceps and vacuum assisted delivery.
- KA45.01** Depressed skull fracture due to birth injury  
 Depressed fractures of skull bones resulting from injury during birth, including those related to forceps and vacuum assisted delivery
- KA45.0Y** Other specified fracture of skull due to birth injury
- KA45.0Z** Fracture of skull due to birth injury, unspecified

- KA45.1      Occipital osteodiastasis due to birth injury**  
Occipital osteodiastasis (OOD) is a form of birth injury characterised by a tear along the innominate (posterior occipital or supraoccipital-exoccipital) synchondrosis with separation of the occipital squama from the lateral or condylar parts of the occipital bone.
- KA45.2      Birth injury to facial bones**
- KA45.20     Mandibular bone fracture due to birth injury**
- KA45.21     Nasal bone fracture due to birth injury**
- KA45.2Y     Birth injury to other specified facial bones**
- KA45.2Z     Birth injury to facial bones, unspecified**
- KA45.3      Birth injury of thorax**  
Fracture of bones of the thorax including ribs, sternum due to birth injury.
- KA45.4      Fracture, dislocation or subluxation of spine due to birth injury**
- KA45.5      Fracture of clavicle due to birth injury**  
This is a greenstick fracture of the clavicle that may occur during the birthing process.
- KA45.6      Birth injury to long bones**
- KA45.Y       Other specified birth injury to skeleton**
- KA45.Z       Birth injury to skeleton, unspecified**
- KA46        Birth injury to other organs**  
A group of conditions characterised by the presence of damage of organs of a newly delivered child due to physical pressure or injury during delivery.
- KA46.0      Birth injury to liver**  
Rupture or subcapsular haemorrhage into the liver parenchyma as a result of birth trauma usually seen in large for gestational age infants, those with hepatomegaly, those born by breech delivery; may present as haemoperitoneum
- KA46.1      Birth injury to spleen**  
Rupture or subcapsular haemorrhage into spleen as a result of birth trauma; may present as haemoperitoneum  
*Inclusions:*      Rupture of spleen due to birth injury
- KA46.2      Adrenal haemorrhage due to birth injury**
- KA46.Y       Birth injury to other specified organ**
- KA46.Z       Birth injury, unspecified**

## Infections of the fetus or newborn (KA60-KA6Z)

- Inclusions:** infections acquired in utero or during birth
- Exclusions:** human immunodeficiency virus [HIV] disease (1C60-1C62.Z)  
Congenital pneumonia (KB24)  
congenital gonococcal infection (1A70-1A7Z)  
Asymptomatic human immunodeficiency virus infection (1C62.0)  
Gastroenteritis or colitis of infectious origin (1A00-1A40.Z)  
Laboratory evidence of human immunodeficiency virus (MA14.0)

**Coded Elsewhere:** Fetus or newborn affected by maternal infectious diseases (KA00.3)  
Congenital syphilis (1A60)

**KA60**

### Sepsis of fetus or newborn

- Coded Elsewhere:** Bacterial infection of fetus or newborn due to other and unspecified streptococci (KA61.Z)  
Bacterial infection of fetus or newborn due to other and unspecified staphylococci (KA61.Z)

**KA61**

### Other bacterial infections of the fetus or newborn

**Coding Note:** Code also the causing condition

- Coded Elsewhere:** Early congenital syphilis, latent (1A60.1)  
Early congenital syphilis, symptomatic (1A60.0)  
Neonatal necrotising fasciitis (1B71.2)  
Tetanus neonatorum (1C15)

**KA61.0**

### Congenital tuberculosis

A disease affecting infants, caused by an infection with the bacteria Mycobacterium tuberculosis in utero. Transmission is by vertical transmission.

**KA61.1**

### Neonatal listeriosis

A condition affecting fetuses or neonates, caused by an infection with the gram-positive bacteria Listeria. This condition is characterised by respiratory distress and shock in the neonate, by stillbirth, or by abortion. Transmission is by vertical transmission. Confirmation is by identification of Listeria in the neonate and mother.

**KA61.Z**

### Bacterial infection of the fetus or newborn, unspecified

**Coding Note:** Code also the causing condition

**KA62**

### Viral infection in the fetus or newborn

Any condition affecting fetuses or newborns, caused by an infection with a virus.

**KA62.0**

### Congenital Zika virus infection

- KA62.1 Congenital Epstein-Barr virus infection**  
There are several forms of Epstein–Barr virus infection. Infectious mononucleosis, nasopharyngeal carcinoma, and Burkitt's lymphoma can all be caused by the Epstein–Barr virus.
- KA62.2 Congenital Varicella Zoster virus infection**  
Transplacentally acquired Varicella zoster virus infection. Both the gestational age at the time of maternal infection and the time interval between maternal infection and birth have major influences on the clinical course.
- KA62.3 Congenital cytomegalovirus infection**  
A condition affecting neonates, caused by an infection with cytomegalovirus in utero. This condition is characterised by jaundice, low birth weight, splenomegaly, hepatomegaly, or pneumonia if symptoms develop shortly after birth, or may be asymptomatic. This condition commonly presents later in life with loss of hearing, loss of vision, or developmental disabilities. Transmission is by vertical transmission. Confirmation is by detection of cytomegalovirus in neonatal urine, saliva, blood, or other body tissues within 2-3 weeks of birth.
- KA62.4 Congenital echovirus infection**  
A disease affecting neonates, caused by an infection with enteric cytopathic human orphan (ECHO) virus in utero. This disease presents with various symptoms depending on the site of the infection, or may be asymptomatic. Transmission is by vertical transmission. Confirmation is by identification of ECHO virus in the neonate.
- KA62.5 Congenital enterovirus infection**  
Congenital viral infections with enteroviruses (including coxsackie viruses and ECHO viruses) are infectious embryofetopathies that have been reported to cause fetal malformations, acute systemic illness in the newborn and long-term neurodevelopmental abnormalities.
- KA62.6 Congenital human immunodeficiency virus infection**  
A disease affecting neonates, caused by an infection with human immunodeficiency virus in utero. Transmission is by vertical transmission. Confirmation is by identification of human immunodeficiency virus in the neonate.
- KA62.7 Congenital parvovirus syndrome**  
Fetal parvovirus syndrome is a fetopathy likely to occur when a pregnant woman is infected by parvovirus B19. Fetal parvovirus infection results in aplastic crisis. Anaemia induces a risk of hydrops and fetal death by cardiac failure in 10 to 20% of cases.
- KA62.8 Congenital rubella syndrome**  
A disease caused by an infection with the rubella virus in utero. This disease presents with symptoms depending on the timing of infection of the fetus and may present with birth defects (such as hearing loss), or intrauterine growth retardation. Transmission is by vertical transmission. Confirmation is by identification of rubella virus or detection of anti-rubella virus IgM antibodies in the neonate or infant.

<b>KA62.9</b>	<b>Congenital viral hepatitis</b> A disease of the liver affecting the neonate, caused by an infection with either hepatitis A, B, C, D, or E virus in utero. This disease is characterised by lethargy, jaundice, abdominal distention, failure to thrive, or clay coloured stools. Transmission is by vertical transmission. Confirmation is by identification of the hepatitis A, B, C, D, or E virus in a blood sample from the neonate.
<b>KA62.A</b>	<b>Perinatal Herpes simplex infection</b> Herpes simplex infection acquired during the perinatal period, normally from active herpes infection of the mother's genital tract, but may also be transmitted in utero.
<b>KA62.Y</b>	<b>Other specified viral infection in the fetus or newborn</b>
<b>KA62.Z</b>	<b>Viral infection in the fetus or newborn, unspecified</b>
<b>KA63</b>	<b>Fungal infection of fetus or newborn</b> Any condition affecting fetuses or newborns, caused by an infection with a fungal agent.
<b>KA63.0</b>	<b>Malassezia infection in newborn</b> A condition affecting newborns, caused by an infection with Malassezia that leads to a severe systemic inflammatory response. This condition is characterised by fever or respiratory distress. Confirmation is by identification of Malassezia in a blood sample.
<b>KA63.1</b>	<b>Neonatal aspergillosis</b> A disease affecting neonates, caused by an infection with the fungi Aspergillus. This disease presents with clinical symptoms depending on the site of infection. Transmission is by inhalation of Aspergillus spores, or direct contact. Confirmation is by identification of Aspergillus from affected sites.
<b>KA63.2</b>	<b>Neonatal candidosis</b> A condition affecting neonates, caused by an infection with the fungi Candida. This condition is characterised by apnoea, thrombocytopenia, or decreasing respiratory function or other symptoms depending on the site of infection. Transmission is vertical (from the mother to the baby). Confirmation is by identification of Candida in a blood or urine sample.
	<b>Coded Elsewhere:</b> Neonatal mucocutaneous candidosis (EH12)
<b>KA63.Y</b>	<b>Other specified fungal infection of fetus or newborn</b>
<b>KA63.Z</b>	<b>Fungal infection of fetus or newborn, unspecified</b>
<b>KA64</b>	<b>Parasitic diseases in the fetus or newborn</b> Any condition affecting fetuses or newborns, caused by an infection with a parasite.  <b>Exclusions:</b> Tetanus neonatorum (1C15) Congenital syphilis (1A60) Necrotising enterocolitis of newborn (KB88)

- KA64.0** **Congenital toxoplasmosis**  
A disease caused by an infection with the protozoan parasite *Toxoplasma gondii* in utero. This disease is characterised by chorioretinitis, hydrocephalus, intracranial calcifications, anaemia, or neurological deficits that develop after birth. This disease may present at birth with jaundice, premature birth, hepatosplenomegaly, myocarditis, pneumonitis, or rash. Transmission is by vertical transmission. In the fetus, confirmation is by identification of *Toxoplasma gondii* in amniotic fluid; in the neonate, confirmation is by identification of *Toxoplasma gondii* in body fluids or tissues, or detection of antibodies against *Toxoplasma gondii*.
- KA64.1** **Congenital falciparum malaria**  
A disease caused by an infection with the protozoan parasite *Plasmodium falciparum* in utero. This disease is characterised by fever, anaemia, splenomegaly, hepatomegaly, jaundice, regurgitation, diarrhoea, or poor feeding. This disease may also present with respiratory distress, drowsiness, or cyanosis. Transmission is by vertical transmission. Confirmation is by identification of the *Plasmodium falciparum* in a blood sample from the neonate.
- KA64.Y** **Other specified parasitic diseases in the fetus or newborn**
- KA64.Z** **Parasitic diseases in the fetus or newborn, unspecified**
- KA65** **Neonatal infections of certain specified sites**  
*Coded Elsewhere:* Neonatal tracheitis (KB25)  
Neonatal skin infection (EH10-EH1Z)
- KA65.0** **Neonatal conjunctivitis or dacryocystitis**  
This refers to inflammation of the conjunctiva (the outermost layer of the eye and the inner surface of the eyelids) and the inflammation of the nasolacrimal sac, frequently caused by nasolacrimal duct obstruction or infection.  
*Exclusions:* Gonococcal conjunctivitis (1A72.4)
- KA65.1** **Omphalitis of newborn**  
A disease of the umbilical cord affecting newborns, commonly caused by an infection with a bacterial source. This disease is characterised by purulent or foul-smelling discharge from the umbilicus or umbilical stump, periumbilical erythema, oedema, or tenderness. This disease may also present with fever, hypothermia, jaundice, tachycardia, hypotension, tachypnoea, respiratory distress, apnoea, or abdominal distention with absent bowel sounds. Transmission is by vertical transmission or iatrogenic transmission. Confirmation is by identification of the infectious agent.
- KA65.2** **Neonatal urinary tract infection**  
A condition of the urinary tract affecting neonates, commonly caused by an infection with a bacterial source. This condition is characterised by fever, pyuria, jaundice, poor appetite, diarrhoea, blood tinged stool, vomiting, or abdominal distention. This condition may also be asymptomatic. Transmission is by vertical transmission. Confirmation is by identification of the infectious agent in a urine sample.

KA65.3	<b>Neonatal infectious mastitis</b> A disease of the breasts in neonates, may be caused by a maternal infection with a bacterial source. This disease is characterised by swelling, erythema, warmth, tenderness, induration of the breast, or purulent discharge from the nipple. It is usually unilateral. This disease may also present with breast abscesses.
	<b>Exclusions:</b> Breast engorgement of newborn (KC41.0) noninfective mastitis of newborn (KC41.0)
	<b>Coded Elsewhere:</b> Neonatal staphylococcal mastitis (EH11) Neonatal streptococcal mastitis (EH11)
KA65.4	<b>Neonatal meningitis</b>
KA65.Y	<b>Neonatal infections of other specified sites</b>
KA6Y	<b>Other specified infections of the fetus or newborn</b>
KA6Z	<b>Infections of the fetus or newborn, unspecified</b>

### Haemorrhagic or haematological disorders of fetus or newborn (KA80-KA8Z)

A group of conditions occurring during the period of time around childbirth, especially the five months before and one month after birth which are associated with bleeding, the blood, and blood forming organs.

<b>Exclusions:</b>	Hereditary haemolytic anaemia (3A10) Gilbert syndrome (5C58.01) Congenital stenosis or stricture of bile ducts (LB20.22) Crigler-Najjar syndrome (5C58.00) Dubin-Johnson syndrome (5C58.02)
<b>Coded Elsewhere:</b>	Hereditary vitamin B12 deficiency anaemia (3A01.0) Neonatal vitamin B12 deficiency anaemia (3A01.1) Congenital or neonatal vitamin B12 deficiency anaemia (3A01.Z)
KA80	<b>Fetal blood loss</b>

Fetal blood loss is a loss of blood from the fetal circulation during pregnancy, labour, or delivery. Due to the small volume of fetal blood that is present, even a small loss can lead to anaemia or fetal death.

KA80.0	<b>Fetal blood loss from vasa praevia</b> In vasa praevia, the fetal blood vessels connecting the placenta and umbilical cord cross the internal cervical os, the entrance to the birth canal, underneath the fetus.
KA80.1	<b>Fetal blood loss from ruptured cord</b> The umbilical cord can rupture during labour and delivery and lead to fetal blood loss. Possible reasons include: traction on an abnormally short cord, a cord that is entangled around the fetus, a thin friable cord, or a cord with vascular abnormalities. Fetal blood loss can also occur following accidental cord puncture during amniocentesis or following in utero cordocentesis or transfusion.

- KA80.2 Fetal blood loss from placenta**  
Fetal blood loss can result from placental abruption, which is when the placenta separates from the uterine wall prior to delivery. Placental abruptions occur under conditions of maternal hypertension and drug use (e.g. cocaine), maternal vascular and collagen vascular disease, maternal clotting disorders, and following direct abdominal trauma. Fetal blood loss can also result from accidental incision of the placenta during a caesarean section.
- KA80.3 Haemorrhage into co-twin**  
Monozygous twins often share a placenta. Vascular anastomoses within the placenta allow for the transfer of blood between the two fetuses. In some cases, the flow is unbalanced and one fetus (larger, plethoric, and polycythaemic twin) has an overload of fluid, while the other (smaller, hydropic twin) becomes anaemic.
- KA80.4 Haemorrhage into maternal circulation**  
Fetal-maternal haemorrhage occurs when the trophoblastic lining of the placenta fails to act as a barrier and allows fetal blood cells to enter the maternal circulation.
- KA80.5 Fetal blood loss from cut end of co-twin cord**  
Sometimes the blood content of monozygotic twins differs considerably, which can occur when anastomoses exist. One twin loses blood through shunts, while the other gains a large quantity of blood. Therefore, following the delivery of one twin, the other may bleed through these anastomoses if the umbilical cord of the delivered twin is not immediately clamped.
- KA80.Y Other specified fetal blood loss**
- KA80.Z Fetal blood loss, unspecified**
- KA81 Umbilical haemorrhage of newborn**  
A condition characterised by bleeding from the umbilical cord stump of a newborn.  
**Exclusions:** omphalitis with mild haemorrhage (KA65.1)
- KA82 Intracranial nontraumatic haemorrhage of fetus or newborn**  
Intraventricular (nontraumatic) haemorrhage of the fetus and newborn is a condition characterised by bleeding within the skull of a newborn that is not due to injury causing physical damage.  
**Exclusions:** intracranial haemorrhage due to birth injury (KA40.0)  
Intracranial haemorrhage due to head trauma (NA00-NA0Z)
- KA82.0 Intraventricular nontraumatic haemorrhage, grade 1, of fetus or newborn**  
A condition characterised by bleeding into the subependymal region or germinal matrix of the ventricular system of the brain of a newborn that is not due to injury causing physical damage.

- KA82.1 Intraventricular nontraumatic haemorrhage, grade 2, of fetus or newborn**  
 Intraventricular (nontraumatic) haemorrhage, grade 2 is a condition of the fetus or newborn characterised by bleeding into the germinal matrix of the ventricular system with bleeding into the lateral ventricles of the brain without ventricular enlargement.
- Inclusions:** Subependymal haemorrhage with intraventricular extension without ventricular dilatation
- KA82.2 Intraventricular nontraumatic haemorrhage, grade 3, of fetus or newborn**  
 Intraventricular (nontraumatic) haemorrhage, grade 3, of the fetus and newborn located in the subependymal region with extension into the lateral ventricles, with ventricular enlargement.
- Inclusions:** Subependymal haemorrhage with both intraventricular and ventricular dilatation
- KA82.3 Intraventricular nontraumatic haemorrhage, grade 4, of fetus or newborn**
- KA82.4 Intracerebral nontraumatic haemorrhage of fetus or newborn**  
 A condition characterised by bleeding within the brain tissue of a fetus or newborn that is not due to injury causing physical damage.
- KA82.5 Subarachnoid nontraumatic haemorrhage of fetus or newborn**  
 A condition characterised by bleeding into the area between the arachnoid membrane and the pia mater (subarachnoid space) surrounding the brain of a fetus or newborn that is not due to injury causing physical damage.
- KA82.6 Cerebellar nontraumatic, hemispheres or vermis or posterior fossa haemorrhage of fetus or newborn**  
 A condition characterised by bleeding within the part of the intracranial cavity located between the foramen magnum and tentorium cerebelli (posterior fossa) including bleeding in tissue of the cerebellum or brain stem, of a fetus or newborn that is not due to injury causing physical damage.
- KA82.7 Subdural nontraumatic haemorrhage of fetus or newborn**
- KA82.Z Intracranial nontraumatic haemorrhage of fetus or newborn, unspecified**
- KA83 Certain specified neonatal haemorrhages**  
 Any other condition characterised by bleeding in a newborn.
- Exclusions:** Pulmonary haemorrhage originating in the perinatal period (KB28)  
 Fetal blood loss (KA80)
- KA83.0 Neonatal bleeding originating in the mouth, nose or pharynx**  
**Exclusions:** Neonatal haematemesis or melaena due to swallowed maternal blood (KB8A)

<b>KA83.1</b>	<b>Neonatal bleeding originating in the oesophagus, stomach, small or large intestine</b> Bleeding in the neonate that originates from the digestive system. Most common causes include enteritis, gastritis, milk protein allergies, intussusception, and/or erosions of mucosa.
	<p><b><i>Exclusions:</i></b>      Neonatal volvulus (LB18)                            Meckel diverticulum with complication (LB15.0)                            Neonatal haematemesis or melaena due to swallowed maternal blood (KB8A)</p>
<b>KA83.2</b>	<b>Neonatal rectal haemorrhage</b> A condition characterised by bleeding in the rectum of a newborn.
<b>KA83.3</b>	<b>Neonatal hepatic haemorrhage</b> Haemorrhage of the liver in the newborn.
<b>KA83.4</b>	<b>Neonatal haemorrhage originating in adrenal gland</b> A condition characterised by bleeding into the adrenal glands in a newborn.
<b>KA83.5</b>	<b>Neonatal haemorrhage originating in spleen</b>
<b>KA83.6</b>	<b>Neonatal haemorrhage originating in kidney or bladder</b>
<b>KA83.7</b>	<b>Neonatal haemorrhage originating in trachea or pulmonary parenchyma</b>
<b>KA83.8</b>	<b>Neonatal cutaneous haemorrhage</b> <p><b><i>Exclusions:</i></b>      Bruising of scalp due to birth injury (KA42.0)                            Cephalohaematoma due to birth injury (KA42.1)</p>
<b>KA83.9</b>	<b>Neonatal vaginal or uterine haemorrhage</b> A condition characterised by bleeding from the vagina of a newborn which is excessive or lasts longer than the first month of life.
	<p><b><i>Inclusions:</i></b>      Pseudomenses</p>
<b>KA83.A</b>	<b>Neonatal epistaxis</b> A condition characterised by bleeding from the nose of a newborn.
<b>KA84</b>	<b>Haemolytic disease of fetus or newborn</b> A paediatric alloimmune condition characterised by the break-down of red blood cells by IgG antibodies which are transmitted from mother to child via the placenta.
<b>KA84.0</b>	<b>Rh isoimmunization of fetus or newborn</b> A condition characterised by the transmission of antibodies from a mother to the child via the placenta against the Rhesus factor of blood. Such antibodies were developed in a Rhesus factor negative mother subsequent to exposure to Rhesus factor positive blood resulting in the break-down of the red blood cells of the fetus.
<b>KA84.1</b>	<b>Isoimmunization due to other red cell factors</b>

- KA84.2 ABO isoimmunization of fetus or newborn**  
A condition of the newborn characterized by the destruction of red blood cells initiated by the transmission of anti-A or anti-B antibodies from a mother to the child via the placenta against A or B antigens of the newborn's blood.
- KA84.3 Haemolytic anaemia due to other unclassified antibodies of fetus or newborn**
- KA84.4 Haemolytic disease due to disease of other neonatal organs**
- KA84.5 Neonatal haemolysis due to systemic bacterial infection with or without concomitant diffuse intravascular coagulation**
- KA84.Z Haemolytic disease of fetus or newborn, unspecified**
- KA85 Hydrops fetalis due to haemolytic disease**  
A fetal condition characterised by an accumulation of fluid or oedema in at least two fetal compartments, including subcutaneous compartments, the pleura, the pericardium, or the abdomen, due to the antibody-mediated break-down of fetal red blood cells.
- Exclusions:** Hydrops fetalis not due to haemolytic disease (KC41.1)
- KA85.0 Hydrops fetalis due to isoimmunization**  
A fetal condition characterised by an accumulation of fluid or oedema in at least two fetal compartments, including subcutaneous compartments, the pleura, the pericardium, or the abdomen, due to the transmission of IgG antibodies against the Rhesus factor of blood from the mother to the child via the placenta that break-down of the red blood cells of the fetus.
- KA85.Y Other specified hydrops fetalis due to haemolytic disease**
- KA85.Z Hydrops fetalis due to haemolytic disease, unspecified**
- KA86 Neonatal kernicterus**  
Kernicterus is a pathologic diagnosis of the neonate that is characterised by yellow staining of the basal ganglia following elevated bilirubin concentrations in the blood and/or a breech in the blood brain barrier more common in the premature infant or the sick term neonate. It is characterised later in infancy and childhood by hearing deficits, choreoathetosis, and varying degrees of cognitive deficit.
- Exclusions:** kernicterus due to inborn errors of metabolism (5C50-5C5Z)
- KA87 Neonatal hyperbilirubinaemia**  
A condition characterised as an increased level of bilirubin above 85 µmol/l (5 mg/dL) which manifests as yellowing of the eyes, skin, and other tissues of a newborn due to excessive break-down of red blood cells for any other reason not classified elsewhere.
- Exclusions:** jaundice due to isoimmunization (KA84.0)
- Coded Elsewhere:** Neonatal hyperbilirubinaemia due to red cell haemolysis with infection (KA6Y)

- KA87.0** **Neonatal hyperbilirubinaemia due to swallowed maternal blood**  
A condition characterised as an increased level of bilirubin above 85 umol/l (5 mg/dL) which manifests as yellowing of the eyes, skin, and other tissues of a newborn due to consumption by the newborn of blood from the mother.
- KA87.1** **Neonatal hyperbilirubinaemia due to enzymatic defect in bilirubin degradation**
- KA87.2** **Neonatal hyperbilirubinaemia due to breast milk inhibitor of bilirubin conjugation**  
A paediatric condition characterised by persistently increased level of bilirubin above 85 umol/l (5 mg/dL) manifesting as yellowing of the eyes, skin, and other tissues of a newborn due to any chemical substance that prevents or decreases the production of breast milk by the mother.
- KA87.3** **Neonatal hyperbilirubinaemia due to total parenteral nutrition**  
A paediatric condition characterised by persistently increased level of bilirubin above 85 umol/l (5 mg/dL) manifesting as yellowing of the eyes, skin, and other tissues of a newborn due to intravenous feeding which bypasses the normal processes of eating and digestion.
- KA87.4** **Neonatal hyperbilirubinaemia due to drugs or toxins transmitted from mother**
- KA87.5** **Neonatal hyperbilirubinaemia due to drugs or toxins given to newborn**
- KA87.6** **Neonatal hyperbilirubinaemia from other or unspecified hepatocellular damage**
- KA87.Y** **Other specified neonatal hyperbilirubinaemia**
- KA87.Z** **Neonatal hyperbilirubinaemia, unspecified**
- KA88** **Disseminated intravascular coagulation of fetus or newborn**  
Neonatal purpura fulminans is a potentially lethal disorder characterised by progressive haemorrhagic necrosis of the skin associated with cutaneous vascular thrombosis. It is usually due to a genetically transmitted thrombophilic disorder: most commonly homozygous deficiency of protein C or, less frequently, protein S.
- KA89** **Transient neonatal thrombocytopaenia**  
A rare paediatric condition characterised by a temporary relative decrease in the number of platelets in the blood associated with either increased destruction or decreased production of platelets in a newborn.
- KA89.0** **Thrombocytopaenia following systemic infection, including diffuse intravascular coagulation**
- KA89.Y** **Other specified transient neonatal thrombocytopaenia**
- KA89.Z** **Transient neonatal thrombocytopaenia, unspecified**
- KA8A** **Polycythaemia neonatorum**  
Polycythaemia of the neonate represents an excessive quality of circulating red blood cells due to excessive marrow production and haematocrits that exceed ~60%.

- KA8A.0** **Polycythaemia neonatorum due to placental insufficiency or fetal intrauterine growth restriction**
- KA8A.1** **Polycythaemia neonatorum due to twin to twin transfusion**
- KA8A.2** **Polycythaemia neonatorum due to inherited disorder of erythropoietin production**
- KA8A.3** **Polycythaemia neonatorum following umbilical cord transfusion or stripping at delivery**
- KA8A.4** **Polycythaemia neonatorum following blood transfusion**
- KA8A.Y** **Other specified polycythaemia neonatorum**
- KA8A.Z** **Polycythaemia neonatorum, unspecified**

**KA8B** **Anaemia of prematurity**

A paediatric condition characterised by a decrease in number of red blood cells (RBCs) or less than the normal quantity of haemoglobin in the blood of a newborn associated with the child being born prior to completing 37 weeks of gestation.

**KA8C** **Congenital hypoplastic anaemia**

A paediatric condition characterised by a decreased number of red blood cells (RBCs) or lower than the normal levels of haemoglobin in the blood of a newborn present at birth due to loss of blood from the circulatory system of the fetus.

**KA8D** **Transient neonatal neutropaenia**

Neonatal neutropaenia can be due to underproduction of the marrow (e.g. hypoxemia due to placental insufficiency, congenital viral disease) or excessive utilization of white blood cells (bacterial sepsis) or due to maternal transfer of antibodies to the fetus

**Coding Note:** Code also the causing condition

**KA8E** **Alloimmune neonatal neutropaenia**

Alloimmune neonatal neutropaenia (ANN) is a disease caused by the passive transfer of neutrophil specific maternal IgG antibodies across the placenta during pregnancy.

**KA8F** **Neonatal vitamin K deficiency**

There are 3 forms of vitamin K-deficiency bleeding (VKDB) of the newborn. Early VKDB (haemorrhagic disease of the newborn) that occurs at 1-14 days of age. The most common sites of bleeding are the gastrointestinal tract, mucosal and cutaneous tissue, the umbilical stump, and the post-circumcision site. Late VKDB most commonly occurs at 2-12 weeks of age, although cases can occur up to 6 months. The most common site of bleeding is intracranial, although cutaneous and gastrointestinal bleeding may be initial manifestation. The third form of VKDB occurs at birth or shortly thereafter. It is secondary to maternal intake of medications (warfarin, phenobarbital, phenytoin) that cross the placenta.

<b>KA8F.0</b>	<b>Diffuse bleeding diathesis due to vitamin K deficient haemorrhagic disease of fetus or newborn</b>
	Haemorrhagic disease of the newborn is a bleeding disorder of the newborn usually seen in the first week after life when vitamin K replacement is not provided to the newborn infant immediately after birth and is primarily characterised by gastrointestinal bleeding. The disorder can also be seen later in the newborn period in breast fed infants of vitamin K deficient mothers.
<b>KA8F.Y</b>	<b>Other specified neonatal vitamin K deficiency</b>
<b>KA8F.Z</b>	<b>Neonatal vitamin K deficiency, unspecified</b>
<b>KA8Y</b>	<b>Other specified haemorrhagic or haematological disorders of fetus or newborn</b>
<b>KA8Z</b>	<b>Haemorrhagic or haematological disorders of fetus or newborn, unspecified</b>

### Neurological disorders specific to the perinatal or neonatal period (KB00-KB0Z)

A group of paediatric conditions characterised by an abnormal change in the cerebral status of a newborn.

**Coded Elsewhere:** Brain cystic malformations (LA05.7)

Neurodevelopmental syndrome due to prenatal alcohol exposure (6A0Y)

#### **KB00** **Neonatal cerebral ischaemia**

A paediatric condition characterised by insufficient blood flow to the brain of a newborn to meet metabolic demand.

##### **KB00.0** **Perinatal arterial stroke**

##### **KB00.1** **Neonatal cerebral sinovenous thrombosis**

##### **KB00.Y** **Other specified neonatal cerebral ischaemia**

##### **KB00.Z** **Neonatal cerebral ischaemia, unspecified**

#### **KB01** **Periventricular cysts of newborn**

A paediatric condition characterised by the development of cysts around the brain ventricles in a newborn.

#### **KB02** **Neonatal cerebral leukomalacia**

A paediatric condition characterised by the death of small areas of brain tissue creating "holes" in the brain of a newborn.

**Exclusions:** Hypoxic-ischaemic encephalopathy (8B24)

#### **KB03** **Neonatal encephalopathy**

Encephalopathy is disorder of the brain. It may be the result of interference in the development of the brain, an infection or other condition in the neonate.

**Exclusions:** Hypoxic ischaemic encephalopathy of newborn (KB04)

**KB04****Hypoxic ischaemic encephalopathy of newborn**

Hypoxic ischaemic encephalopathy (HIE) is when a newborn's brain fails to receive a sufficient amount of oxygen or blood before and during birth that may lead to brain damage or death.

**KB05****Neonatal hydrocephalus**

**Exclusions:** Hydrocephalus due to congenital toxoplasmosis (KA64.0)

**Coded Elsewhere:** Congenital hydrocephalus (LA04)

**KB05.0****Neonatal obstructive hydrocephalus****KB05.Y****Other specified neonatal hydrocephalus****KB05.Z****Neonatal hydrocephalus, unspecified****KB06****Neonatal seizures**

A paediatric condition characterised by rapid and repeated muscle contraction and relaxation, resulting in an uncontrolled shaking of the body of a newborn.

**Exclusions:** Benign familial neonatal epilepsy (8A61.0)

Epilepsy due to prenatal or perinatal vascular insults (8A60.00)

**KB07****Compression of brain in neonate**

**Exclusions:** Crushing injury of brain (NA08.0)

**KB08****Disorders of muscle tone of newborn**

A group of paediatric conditions characterised by abnormal muscle tone in a newborn.

**KB08.0****Transient neonatal myasthenia gravis**

A paediatric condition characterised as a temporary autoimmune neuromuscular disease leading to fluctuating muscle weakness and fatigue in a newborn.

**KB08.1****Congenital hypertonia**

A paediatric condition characterised by abnormally increased muscle tone that is present at birth in a newborn.

**KB08.2****Congenital hypotonia**

A paediatric condition characterised by abnormally decreased muscle tone that is present at birth in a newborn.

**Inclusions:** Nonspecific floppy baby syndrome

**KB08.Y****Other specified disorders of muscle tone of newborn****KB08.Z****Disorders of muscle tone of newborn, unspecified****KB0Y****Other specified neurological disorders specific to the perinatal or neonatal period****KB0Z****Neurological disorders specific to the perinatal or neonatal period, unspecified**

## Respiratory disorders specific to the perinatal or neonatal period (KB20-KB2Z)

A group of conditions occurring during the period of time around childbirth, especially the five months before and one month after birth which are associated with the cardiovascular or respiratory systems.

**Coded Elsewhere:** Choanal atresia (LA70.2)

Congenital hypoplasia of lung (LA75.2)

Primary central sleep apnoea of infancy (7A40.1)

Primary central sleep apnoea of prematurity (7A40.2)

Late acquired pneumonia (CA40.Y)

### KB20

#### Intrauterine hypoxia

Intrauterine hypoxia occurs when the fetus is deprived of an adequate supply of oxygen. This may occur with prolapse or occlusion of the umbilical cord, placental infarction and maternal smoking. This can lead to damage of the central nervous system and neonatal encephalopathy, which increases the risk of mortality.

**Inclusions:** intrauterine distress

**Exclusions:** Intracranial nontraumatic haemorrhage of fetus or newborn (KA82)

Hypoxic ischaemic encephalopathy of newborn (KB04)

Metabolic acidosis in newborn (KB22)

Late metabolic acidosis of newborn (KB63.0)

### KB20.0

#### Intrauterine hypoxia first noted before onset of labour

A condition characterised by deprivation of an adequate supply of oxygen to the fetus during the gestation period which is diagnosed prior to the onset of labour.

### KB20.1

#### Intrauterine hypoxia first noted during labour or delivery

A condition characterised by deprivation of an adequate supply of oxygen to the fetus diagnosed immediately prior to or during labour and delivery.

### KB20.Z

#### Intrauterine hypoxia, unspecified

### KB21

#### Birth asphyxia

**Coding Note:** This category is not to be used for low Apgar score without mention of asphyxia or other respiratory problems.

**Exclusions:** intrauterine hypoxia or asphyxia (KB20)

### KB21.0

#### Severe birth asphyxia

Pulse less than 100 per minute at birth and falling or steady, respiration absent or gasping, colour poor, tone absent.

### KB21.1

#### Mild and moderate birth asphyxia

Normal respiration not established within one minute, but heart rate 100 or above, some muscle tone present, some response to stimulation.

### KB21.Z

#### Birth asphyxia, unspecified

**Coding Note:** This category is not to be used for low Apgar score without mention of asphyxia or other respiratory problems.

**KB22****Metabolic acidaemia in newborn**

Metabolic acidaemia represents an increase in hydrogen ion concentration, usually due to the production of lactic acid following hypoxia or ischemia induced anaerobic metabolism. Acidaemia can also result from inborn errors of metabolism, and disorders of the kidney and liver.

**KB23****Respiratory distress of newborn**

A condition characterised by developmental insufficiency of surfactant associated proteins or surfactant production and structural immaturity in the lungs.

**Exclusions:** Respiratory failure of newborn (KB2D)

**KB23.0****Respiratory distress syndrome of newborn**

Respiratory distress syndrome (RDS) is an acute illness, usually of preterm infants, due to pulmonary surfactant deficiency, developing within 4-6 hours of birth, and is characterised by respiratory distress (tachypnoea, intercostal and sternal retractions, expiratory grunt, and cyanosis) with abnormal chest radiograph showing diffuse reticulogranular densities and air bronchograms, evidence of reduced lung compliance and functional residual capacity, evidence of abnormal gas exchange (hypoxaemia, hypercapnia, cyanosis) of sufficient severity to require oxygen and/or continuous or intermittent positive pressure ventilatory support for more than 24 hours.

**KB23.00**

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

**KB23.01**

Respiratory distress syndrome of the newborn, altered by pulmonary surfactant replacement therapy

**KB23.02**

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy or pulmonary surfactant replacement therapy

**KB23.0Y**

Other specified respiratory distress syndrome of newborn

**KB23.0Z**

Respiratory distress syndrome of newborn, unspecified

**KB23.1****Transient tachypnoea of newborn**

Transient tachypnoea of newborn is usually a benign self-limiting illness of term and near-term infants demonstrating increased respiratory rate and requiring supplementary oxygen after birth.

**KB23.2****Respiratory instability of prematurity**

Infant within the neonatal period who requires continued respiratory life support, including positive pressure ventilation and/or prolonged oxygen therapy, without a clear pathologic diagnosis. This may be caused by inadequate respiratory muscle strength, excessive chest wall compliance, and/or inadequate CNS respiratory drive.

**KB23.Y**

Other specified respiratory distress of newborn

**KB23.Z**

Respiratory distress of newborn, unspecified

**KB24****Congenital pneumonia**

Congenital pneumonia is an acute respiratory infection contracted prenatally or during the intrapartum period that is caused by a virus, bacteria, or fungi.

**Inclusions:** infective pneumonia acquired in utero or during birth

**Exclusions:** Neonatal aspiration syndromes (KB26)

Pneumonitis (CA70-CA7Z)

**KB25****Neonatal tracheitis**

A disease of the trachea in neonates, caused by an infection with a bacterial, viral, or fungal source. This disease is characterised by stridor, or increased respiratory effort. Transmission is commonly by inhalation of the infectious agent. Confirmation is by direct laryngoscopy.

**KB26****Neonatal aspiration syndromes**

Aspiration of meconium, blood, amniotic fluids and gastric contents in a neonate resulting in clinical symptoms from airway obstruction (atelectasis, air trapping and air leaks), parenchymal injury (pneumonitis), right-to-left shunting, and ventilation-perfusion mismatch.

**KB26.0****Neonatal aspiration of meconium**

Meconium Aspiration Syndrome (MAS) is defined as respiratory distress in an infant born through meconium-stained amniotic fluid with roentgenographic findings consistent with MAS and whose symptoms could not be otherwise explained.

**Exclusions:** Meconium passage during delivery (KA05.8)

Meconium staining (KD38)

**KB26.1****Neonatal aspiration of amniotic fluid or mucus**

Clinical symptoms of Neonatal aspiration syndrome due to inhalation of amniotic fluid

**KB26.2****Neonatal aspiration of blood**

Clinical symptoms of Neonatal aspiration syndrome due to inhalation of blood usually during birth process, or through aspiration of gastrointestinal bleeding.

**KB26.3****Neonatal aspiration of milk or regurgitated food**

Clinical symptoms of Neonatal aspiration syndrome due to aspiration of acidic gastric content and/or milk.

**KB26.Y****Other specified neonatal aspiration syndromes****KB26.Z****Neonatal aspiration syndromes, unspecified****KB27****Pulmonary air leak or related conditions originating in the perinatal period**

Clinical syndrome due to free air from rupture of overdistended alveoli tracking into pulmonary interstitium, mediastinum, pleural cavity or subcutaneous tissues.

- KB27.0 Interstitial emphysema originating in the perinatal period**  
Escape of air into the interstitium, lymphatics and venous circulation of the lungs resulting from rupture of small airways associated with a characteristic cystic appearance on chest X-ray, almost exclusively seen in preterm infants receiving mechanical ventilation
- KB27.1 Pneumothorax originating in the perinatal period**  
Abnormal presence of air or other gas in the pleural cavity, usually secondary to tracking of free air from pulmonary interstitial emphysema, or rupture of subpleural blebs.
- KB27.2 Pneumomediastinum originating in the perinatal period**  
Presence of air in the mediastinum usually from tracking of free air from ruptured alveolar ducts along the perivascular sheaths of pulmonary blood vessels, or rupture of subpleural bleb
- KB27.3 Pneumopericardium originating in the perinatal period**  
Presence of air in the pericardial cavity usually from tracking of free air from ruptured alveolar ducts along the perivascular sheaths of pulmonary blood vessels, or rupture of subpleural bleb
- KB27.4 Pneumoperitoneum, originating in the perinatal period, due to primary pulmonary air leak syndromes**
- KB27.Y Other specified pulmonary air leak or related conditions originating in the perinatal period**
- KB27.Z Pulmonary air leak or related conditions originating in the perinatal period, unspecified**
- KB28 Pulmonary haemorrhage originating in the perinatal period**  
A condition characterised by bleeding from the lung which begins during the period of time around childbirth, especially the five months before and one month after birth.
- Exclusions:** Acute idiopathic pulmonary haemorrhage in infants over 28 days of age (MD24)
- KB28.0 Tracheobronchial haemorrhage originating in the perinatal period**  
A condition characterised by bleeding from the trachea or bronchi which begins during the period of time around childbirth, especially the five months before and one month after birth.
- KB28.1 Traumatic pulmonary haemorrhage originating in the perinatal period**  
Pulmonary haemorrhage in neonate as a result of trauma, generally from a respiratory suction catheter following deep suctioning.
- KB28.Y Other specified pulmonary haemorrhage originating in the perinatal period**
- KB28.Z Pulmonary haemorrhage originating in the perinatal period, unspecified**

**KB29****Chronic respiratory disease originating in the perinatal period**

A group of conditions associated with the respiratory system which begin during the period of time around childbirth, especially the five months before and one month after birth, and which lasts for at least 3 months.

**KB29.0****Bronchopulmonary dysplasia originating in the perinatal period**

Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants.

**KB29.Y****Other specified chronic respiratory disease originating in the perinatal period****KB29.Z****Chronic respiratory disease originating in the perinatal period, unspecified****KB2A****Apnoea of newborn**

Any condition characterised by suspension of external breathing in a newborn (premature or term) which is not classified elsewhere

**KB2A.0****Central neonatal apnoea**

Central apnoea is a cessation of airflow > 20 seconds with loss of all respiratory effort. It is due to immaturity of the brainstem to control respiration. It is found in many premature infants and generally resolves by 36 weeks of age.

**KB2A.1****Obstructive neonatal apnoea**

Apnoea that occurs secondary to diminished airway airflow from an obstruction in the airway from the nose and mouth, tongue, hypopharynx, epiglottis, vocal cords or subglottic region. This is characterised by initial increased work of breathing and rapid progression to cyanosis.

**KB2A.2****Mixed neonatal apnoea**

A combination of central apnoea and obstructive apnoea. Most apnoea of prematurity is of the mixed variety, and most often resolves by 36 weeks of age.

**KB2A.3****Apnoea of newborn, due to neurologic injury****KB2A.Y****Other specified apnoea of newborn****KB2A.Z****Apnoea of newborn, unspecified****KB2B****Primary atelectasis of newborn**

Failure of the lungs to expand after birth, as in stillborn infants or in liveborn infants who die before respiration is established

**Inclusions:** Primary failure to expand terminal respiratory units

**KB2C****Cyanotic attacks of newborn**

Sudden attacks of cyanosis, lasting from a few moments up to half an hour, in an infant whose colour was previously normal, and whose colour returns to normal in atmospheric air after the attack

**Exclusions:** Apnoea of newborn (KB2A)

**KB2D****Respiratory failure of newborn**

Acute or chronic respiratory failure in a newborn. Neonates in acute respiratory failure require respiratory support.

**KB2E****Respiratory arrest of newborn****KB2F****Congenital lung or lobar atelectasis**

Collapsed lobe or lobes of the lung that is present at birth and is due to narrowing of the airway, kinking of the airway, compression from a mass in the airway or other congenital abnormality.

**KB2G****Tracheal haemorrhage of newborn due to airway trauma**

Trauma from suction catheters, endotracheal tubes, bronchoscopes that results in tracheal haemorrhage in the newborn.

**KB2H****Acquired vocal cord paralysis in newborn**

Acquired vocal cord paralysis may result from birth trauma, result of the extracorporeal membrane oxygenation cannulation, thoracic surgery, or some infections. Unilateral vocal cord paralysis is more common and the left vocal cord is most frequently involved.

**KB2J****Airway obstruction in the neonate due to airway abnormality**

**Coded Elsewhere:** Congenital macroglossia (LA31.0)

Congenital micrognathia (DA0E.00)

**KB2J.0****Hypotonia of hypopharynx in neonate**

Poor muscle tone of the hypopharynx.

**KB2J.1****Hypopharyngeal mass in neonate****KB2J.2****Tracheo-bronchial malacia in neonate**

Tracheomalacia is a condition characterised by flaccidity of the tracheal support cartilage causing weakness of the tracheobronchial tree and tracheal collapse.

**KB2J.Y****Other specified airway obstruction in the neonate due to airway abnormality****KB2J.Z****Airway obstruction in the neonate due to airway abnormality, unspecified****KB2K****Pulmonary cysts in newborn****KB2K.0****Acquired pulmonary cysts in newborn**

Cysts occurring as a result of infection or trauma from mechanical ventilation resulting in pulmonary interstitial emphysema.

**KB2K.Z****Pulmonary cysts in newborn, unspecified****KB2Y****Other specified respiratory disorders specific to the perinatal or neonatal period****KB2Z****Respiratory disorders specific to the perinatal or neonatal period, unspecified**

## Cardiovascular disorders present in the perinatal or neonatal period (KB40-KB4Z)

A group of conditions which begin during the period of time around childbirth, especially the five months before and one month after birth which are associated with the cardiovascular systems.

**Exclusions:** congenital malformations of the heart and circulatory system (LA80-LA8Z)

**Coded Elsewhere:** Patent arterial duct (LA8B.4)

**KB40**

### **Neonatal cardiac failure**

Cardiac failure originating in the neonatal period

**KB40.0**

### **Neonatal cardiac failure due to pulmonary overperfusion**

Neonatal cardiac failure due to pulmonary overperfusion

**KB40.1**

### **Neonatal cardiac failure due to decreased left ventricular output**

**KB40.Y**

### **Other specified neonatal cardiac failure**

**KB40.Z**

### **Neonatal cardiac failure, unspecified**

**KB41**

### **Cardiac arrhythmias in the neonate**

Abnormal electrical rhythm, both tachyarrhythmias and bradyarrhythmias, in neonate

**KB42**

### **Persistent pulmonary hypertension of the newborn**

Persistent pulmonary hypertension of the newborn is a cardiopulmonary disorder characterised by systemic arterial hypoxemia secondary to pulmonary hypertension and extrapulmonary right-to-left shunting across the foramen ovale and ductus arteriosus.

**KB44**

### **Transient myocardial ischaemia of newborn**

A paediatric condition characterised by an imbalance between the oxygen supply and demand of the heart muscle (myocardium) in a newborn.

**KB45**

### **Neonatal hypertension**

Hypertension is defined by a systolic blood pressure in a neonate which is >95th percentile for age and sex on 3 separate occasions

**KB46**

### **Neonatal hypotension**

Mean Arterial Blood Pressure below gestational age in weeks (corresponds with 10th centile for birth weight and postnatal age 1) or below 30 mmHg as hypotension.

**KB47**

### **Benign or innocent cardiac murmurs in newborn**

A paediatric condition characterised by heart sounds that are produced as a result of turbulent blood flow that is sufficient to produce audible noise primarily due to physiologic conditions outside the heart, as opposed to structural defects in the heart itself in a newborn.

**KB48**

**Patent arterial duct of prematurity**

Patent arterial duct associated with the child being born prior to completing 37 weeks of gestation, in the absence of ductal-dependent congenital heart disease.

**KB4Y**

**Other specified cardiovascular disorders present in the perinatal or neonatal period**

**KB4Z**

**Cardiovascular disorders present in the perinatal or neonatal period, unspecified**

**Transitory endocrine or metabolic disorders specific to fetus or newborn (KB60-KB6Z)**

A group of paediatric conditions in which there is a temporary disorder in a newborn or infant associated with changes in hormone production or utilization (endocrine system) or when abnormal chemical reactions in the body disrupt the normal processes of enzyme catalyzed reactions within tissue cells (metabolism), such as getting or making energy from consumed food.

**KB60**

**Transitory disorders of carbohydrate metabolism specific to fetus or newborn**

A group of paediatric conditions in which there is a temporary disorder in a newborn or infant associated with abnormal chemical reactions in the body disrupting the process of getting or making energy from consumed carbohydrates.

**KB60.0**

**Syndrome of infant of mother with gestational diabetes**

Describes the range of effects on the infant born to a woman with gestational diabetes (onset or first recognition of carbohydrate intolerance of variable severity in pregnancy). Common neonatal effects include macrosomia, intrauterine growth restriction, birth injuries, congenital anomalies, hypoglycaemia, respiratory distress, and hypertrophic cardiomyopathy.

**KB60.1**

**Syndrome of infant of a diabetic mother, type 1 or 2, nongestational, insulin dependent**

Describes the range of effects on the infant born to a woman with pregestational diabetes mellitus (type 1 or type 2). Common neonatal effects include macrosomia, intrauterine growth restriction, birth injuries, congenital anomalies, hypoglycaemia, respiratory distress, caudal regression syndrome and hypertrophic cardiomyopathy.

**KB60.2**

**Neonatal diabetes mellitus**

Neonatal diabetes mellitus (NDM) is a monogenic form of diabetes that occurs in the first 6 months of life. It is a rare condition occurring in only one in 100,000 to 500,000 live births. Infants with NDM do not produce enough insulin, leading to an increase in blood glucose. NDM can be mistaken for the much more common type 1 diabetes, but type 1 diabetes usually occurs later than the first 6 months of life. In about half of those with NDM, the condition is lifelong and is called permanent neonatal diabetes mellitus (PNDM). In the rest of those with NDM, the condition is transient and disappears during infancy but can reappear later in life; this type of NDM is called transient neonatal diabetes mellitus (TNDM).

- KB60.20** Transient neonatal diabetes mellitus  
 Transient neonatal diabetes mellitus (TNDM) is a developmental disorder of insulin production that resolves postnatally within the first year of life. Intrauterine growth restriction is usually present. TNDM infants develop diabetes in the first few weeks of life but may go into remission in a few months, with possible relapse to a permanent diabetes state usually around adolescence or as adults. The pancreatic dysfunction in this condition may be maintained throughout life, with relapse initiated at times of metabolic stress such as puberty or pregnancy.
- KB60.2Y** Other specified neonatal diabetes mellitus
- KB60.2Z** Neonatal diabetes mellitus, unspecified
- KB60.3** **Neonatal hyperglycaemia**
- KB60.30** Neonatal hyperglycaemia due to insulin deficiency
- KB60.31** Neonatal hyperglycaemia due to iatrogenic intravenous therapy
- KB60.3Y** Other specified neonatal hyperglycaemia
- KB60.3Z** Neonatal hyperglycaemia, unspecified
- KB60.4** **Neonatal hypoglycaemia**
- KB60.40** Transient hyperinsulinaemic neonatal hypoglycaemia  
 This refers to transient above normal level of insulin in the blood, and an abnormally diminished content of glucose in the blood, of a newborn.
- KB60.41** Transitory iatrogenic neonatal hypoglycaemia  
 A condition associated with hypoglycemia as a result of therapeutic intervention. Often occurs with insulin therapy, but may also result from inadequate provision of glucose.
- KB60.42** Other transitory neonatal hypoglycaemia
- KB60.4Y** Other specified neonatal hypoglycaemia
- KB60.4Z** Neonatal hypoglycaemia, unspecified
- KB60.Y** **Other specified transitory disorders of carbohydrate metabolism specific to fetus or newborn**
- KB60.Z** **Transitory disorders of carbohydrate metabolism specific to fetus or newborn, unspecified**
- KB61** **Transitory neonatal disorders of calcium or magnesium metabolism**  
 A group of paediatric conditions in which there is a temporary disorder in a newborn associated with abnormal chemical reactions in the body disrupting the normal processes of enzyme catalyzed reactions to utilize calcium and magnesium for other body functions.

<b>KB61.0</b>	<b>Neonatal hypomagnesaemia</b> Defined as serum magnesium levels less than 0.66 mmol/L (1.6 mg/L) in neonates. Symptoms usually do not develop until serum Magnesium (Mg) levels fall below 0.49 mmol/L (1.2 mg/L). This is usually transient but can cause symptoms similar to those of hypocalcaemia.
<b>KB61.1</b>	<b>Neonatal tetany without calcium or magnesium deficiency</b> Features of tetany (hyperexcitability, hyperreflexia, spasms and laryngospasm) not accompanied by low calcium or magnesium levels
<b>KB61.2</b>	<b>Neonatal hypocalcaemia</b> Hypocalcaemia is a common metabolic problem in newborns. In the neonate, hypocalcaemia is defined by birth weight (BW) categories. In infants with BW greater than 1500 g, hypocalcaemia is defined as a total serum calcium (Ca) concentration less than 8 mg/dL (2 mmol/L) or an ionized fraction of less than 4.4 mg/dL (1.1 mmol/L). In very low birth weight premature infants (BW<1500 g), hypocalcaemia is defined as a total serum Ca concentration less than 7 mg/dL (1.75 mmol/L) or an ionized fraction of less than 4 mg/dL (1 mmol/L). Aetiologies of early hypocalcaemia (occurs in the first two to three days after birth) include prematurity, maternal diabetes, birth asphyxia, and intrauterine growth. Causes of late hypocalcaemia (usually occurs at the end of the first week of life) include hypoparathyroidism and high phosphate intake. Most infants with hypocalcaemia are asymptomatic. If symptomatic, neuromuscular irritability is the most common sign with jitteriness and muscle jerking. Less common findings include seizures, and rarely laryngospasm, wheezing, or vomiting.
	<b>Exclusions:</b> Transitory neonatal hypoparathyroidism (KB64)
<b>KB61.3</b>	<b>Neonatal osteopenia</b> Metabolic bone disease is a common complication in very low birthweight (VLBW) preterm infants. The smallest, sickest infants are at greatest risk. Progressive osteopenia with demineralized bones and, occasionally, pathologic fractures may develop. The major cause is inadequate intake of calcium and phosphorus to meet the requirements for growth. Poor intake of vitamin D is an additional risk factor. Contributing factors include prolonged parenteral nutrition, vitamin D and calcium malabsorption, intake of unsupplemented human milk, immobilization, and urinary calcium losses from long-term diuretic use.
<b>KB61.Y</b>	<b>Other specified transitory neonatal disorders of calcium or magnesium metabolism</b>
<b>KB61.Z</b>	<b>Transitory neonatal disorders of calcium or magnesium metabolism, unspecified</b>
<b>KB62</b>	<b>Transitory neonatal disorders of thyroid function</b> A group of paediatric conditions in which there is a temporary disorder in a newborn or infant associated with the thyroid.  <b>Exclusions:</b> Pendred syndrome (5A00.02) Congenital hypothyroidism (5A00.0) dyshormogenetic goitre (5A00.00) <b>Coded Elsewhere:</b> Transient congenital hypothyroidism (5A00.03)

- KB62.0 Transitory neonatal hyperthyroidism**  
A paediatric condition characterised by a temporarily abnormally increased level of thyroid hormones (triiodothyronine (T3) and thyroxine (T4)) in the blood of a newborn.
- Inclusions:** Neonatal thyrotoxicosis
- KB62.1 Other transitory neonatal disorders of thyroid function, not elsewhere classified**  
Any other paediatric condition characterised by abnormal or absent function of the thyroid gland in a newborn.
- Inclusions:** Transitory neonatal hypothyroidism
- KB62.2 Transient hyperthyrotropinaemia**  
Transient hyperthyrotropinaemia is characterised by elevated thyroid-stimulating hormone (TSH) and normal thyroxine (FT4) levels with the elevated TSH levels eventually normalising.
- KB62.3 Transient hypothyroxinaemia**  
Transient hypothyroxinaemia is characterised by low thyroxine (T4, T3 and FT4) levels but normal level of thyroid-stimulating hormone (TSH), and is seen in preterm infants, usually those born before 30 weeks of gestational age.
- KB62.Y Other specified transitory neonatal disorders of thyroid function**
- KB62.Z Transitory neonatal disorders of thyroid function, unspecified**
- KB63 Certain specified transitory neonatal electrolyte or metabolic disturbances**  
A group of paediatric conditions in which there is a temporary abnormality in the normal processes of enzyme catalyzed reactions within tissue cells (metabolism) or with the levels of minerals in the blood or other body fluids.
- KB63.0 Late metabolic acidosis of newborn**  
Mild to moderate metabolic acidosis occurring between 1 to 3 weeks of age in otherwise healthy premature infants fed cow's milk and accompanied by poor growth. This is thought to be due to excessive protein content of the milk.
- KB63.1 Dehydration of newborn**  
A paediatric condition characterised by excessive loss of body water in a newborn.
- KB63.2 Disturbances of sodium balance of newborn**  
A paediatric condition characterised by abnormally high or low levels of sodium in the blood in a newborn, when the normal range is defined as 135 to 150 mEq/L.
- KB63.20 Hyponatremia of newborn**  
Hyponatremia is defined as serum sodium less than 130 mmol/L
- KB63.21 Hypernatremia of newborn**  
Hypernatremia is defined as serum sodium greater than 145 mmol/L.

<b>KB63.2Y</b>	Other specified disturbances of sodium balance of newborn
<b>KB63.2Z</b>	Disturbances of sodium balance of newborn, unspecified
<b>KB63.3</b>	<b>Disturbances of potassium balance of newborn</b> A paediatric condition characterised by abnormally high or low levels of potassium in the blood in a newborn, when the normal range is defined as 3.5 to 5.5 mmol/L.
<b>KB63.30</b>	Hypokalaemia of newborn Hypokalaemia is defined as serum potassium less than 3.5 mmol/L.
<b>KB63.31</b>	Hyperkalaemia of newborn Hyperkalaemia is defined as serum potassium greater than 5.5 mmol/L.
<b>KB63.3Y</b>	Other specified disturbances of potassium balance of newborn
<b>KB63.3Z</b>	Disturbances of potassium balance of newborn, unspecified
<b>KB63.4</b>	<b>Transitory tyrosinaemia of newborn</b> Clinically asymptomatic elevated blood tyrosine level caused by late fetal maturation of 4-hydroxyphenylpyruvate dioxygenase, usually detected on newborn bloodspot screening. Most commonly seen in premature infants receiving milk formulae with high protein content. Generally considered benign and resolves by 4-6 weeks of age.
<b>KB63.5</b>	<b>Metabolic bone disease of prematurity</b> A paediatric condition characterised by bone abnormalities in a newborn due to abnormalities of minerals such as calcium, phosphorus, magnesium or vitamin D associated with the child being born prior to completing 37 weeks of gestation.
<b>KB64</b>	<b>Transitory neonatal hypoparathyroidism</b> Defined as hypocalcaemia, hyperphosphatemia and low serum parathyroid hormone that improves spontaneously but may last from weeks to months.
<b>KB6Z</b>	<b>Transitory endocrine or metabolic disorders specific to fetus or newborn, unspecified</b>

## Digestive system disorders of fetus or newborn (KB80-KB8Z)

**Coded Elsewhere:** Hirschsprung disease (LB16.1)

Meconium ileus in unspecified cystic fibrosis (CA25.Z)

<b>KB80</b>	<b>Gastro-oesophageal reflux disease in newborn</b> A condition which develops when the reflux of stomach contents causes the newborn to vomit with associated discomfort, difficulty feeding and/or weight loss.
-------------	--

<b>KB81</b>	<b>Oesophagitis in newborn</b> Oesophagitis is inflammation of the oesophagus. If left untreated, this condition can cause ulcers or scarring of the oesophagus.
-------------	---

- KB81.0      Neonatal eosinophilic oesophagitis**  
Eosinophilic oesophagitis is an inflammatory condition, possibly caused by food allergy, in which the wall of the oesophagus becomes filled with a large number of eosinophils. It can be confused with acid reflux disease but it can be differentiated if neonate does not respond to anti-reflux medications.
- KB81.Y      Other specified oesophagitis in newborn**
- KB81.Z      Oesophagitis in newborn, unspecified**
- KB82      Prenatal gastric perforation**  
Prenatal gastric perforation is a perforation or hole of the wall of the stomach that occurs while the baby is in utero. This is a rare and life-threatening condition in a neonate.
- KB83      Postnatal gastric perforation**  
Postnatal gastric perforation is a spontaneous or traumatic penetration or hole of the wall of the stomach that occurs after birth. This is a rare and life-threatening condition in a neonate.
- KB84      Postnatal isolated ileal perforation**  
Post natal bowel perforation, generally in the terminal ileum. Can be confused with necrotizing enterocolitis, but generally occurs earlier (2-5 days of age) and does not involve extensive bowel necrosis.
- KB85      Prenatal intrauterine intestinal perforation**  
In-utero or prenatal bowel perforation results in a chemical peritonitis (meconium peritonitis) from peritoneal leakage of sterile meconium. Meconium peritonitis results from prenatal intestinal perforation nearly always involving the small bowel.  
**Exclusions:**      Meconium ileus with perforation (KB87.4)
- KB85.0      Prenatal intrauterine intestinal perforation due to in utero volvulus**
- KB85.1      Prenatal intrauterine intestinal perforation due to intestinal atresia or stenosis**
- KB85.2      Prenatal intrauterine intestinal perforation due to intraluminal obstruction**
- KB85.Y      Other specified prenatal intrauterine intestinal perforation**
- KB85.Z      Prenatal intrauterine intestinal perforation, unspecified**
- KB86      Postnatal intestinal perforation**  
Postnatal intestinal perforation is a complete penetration of wall of the large or small intestine, often resulting in the leakage of luminal contents into the abdominal cavity.
- KB86.0      Postnatal intestinal perforation due to drugs**
- KB86.1      Postnatal intestinal perforation due to in utero volvulus**
- KB86.2      Postnatal intestinal perforation due to intestinal atresia or stenosis**
- KB86.3      Postnatal intestinal perforation due to intraluminal obstruction**

<b>KB86.Y</b>	<b>Other specified postnatal intestinal perforation</b>
<b>KB86.Z</b>	<b>Postnatal intestinal perforation, unspecified</b>
<b>KB87</b>	<b>Intestinal obstruction of newborn</b>
	Any other impairment, arrest, or reversal of the normal flow of intestinal toward the anal canal in a newborn
<b>KB87.0</b>	<b>Intestinal obstruction due to inspissated milk</b>
	Mechanical intestinal obstruction in premature infants due to hard milk curds formed when high-energy formula or powdered milk is fed in the presence of reduced intestinal motility and increased absorption of water from the colon. The site of obstruction is the terminal ileum, the ileocaecal valve, or the colon. The manifestations include constipation, abdominal distension, and vomiting (progressively bilious or faecal).
<b>KB87.1</b>	<b>Meconium plug without ileus</b>
	Meconium plug, also referred to as functional immaturity of the colon, is an obstruction in the newborn colon. It is usually a transient disorder of the newborn and is characterised by delayed passage of meconium and intestinal dilatation.
<b>KB87.2</b>	<b>Meconium ileus without perforation</b>
	The meconium sometimes becomes thickened and congested in the terminal ileum, a condition known as meconium ileus. Meconium ileus is among the most common causes of intestinal obstruction in the newborn, accounting for 9-33% of neonatal intestinal obstructions. A symptom of both Hirschsprung's disease and cystic fibrosis is the failure to pass meconium. Some babies have a blockage in their colon that may look like meconium ileus (a meconium plug), and they have small left colon syndrome. This means the last part of their colon is smaller than normal.
<b>KB87.3</b>	<b>Transitory ileus of newborn</b>
	Transient intestinal obstruction of functional rather than anatomical origin which is not uncommon in the first few days of life. As surgery may be strongly contraindicated in this group, the differential diagnosis is extremely important.
	<b>Exclusions:</b> Hirschsprung disease (LB16.1)
<b>KB87.4</b>	<b>Meconium ileus with perforation</b>
	Complicated meconium ileus with bowel perforation with varying degrees of meconium peritonitis.
<b>KB87.Y</b>	<b>Other specified intestinal obstruction of newborn</b>
<b>KB87.Z</b>	<b>Intestinal obstruction of newborn, unspecified</b>

**KB88****Necrotising enterocolitis of newborn**

This is a fulminating disease of neonates in which there is extensive mucosal ulceration, pseudomembrane formation, submucosal haemorrhage, and necrosis usually of the right colon, caecum, terminal ileum, and appendix (ENTEROCOLITIS), possibly due to perinatal intestinal ischemia and bacterial invasion. The entire colon, small intestine, stomach, and oesophagus may also be affected. Most infants are premature or suffer from respiratory distress syndrome, sepsis, or hypoxia. Symptoms (apparent during the first few weeks of life) include abdominal distension, bilious vomiting, and melaena; there may be apnoea, lethargy, temperature instability, tachycardia, tachypnoea, and a fall in blood pressure. The disorder may progress to perforation and peritonitis.

**KB88.0      Necrotising enterocolitis of newborn, Stage 1A & B****KB88.1      Necrotising enterocolitis of newborn, Stage 2A & B****KB88.2      Necrotising enterocolitis of newborn, Stage 3A****KB88.3      Necrotising enterocolitis of newborn, Stage 3B****KB88.Y      Other specified necrotising enterocolitis of newborn****KB88.Z      Necrotising enterocolitis of newborn, unspecified****KB89****Neonatal malabsorption syndromes**

**Coded Elsewhere:** Glucose or galactose intolerance of newborn (5C51.42)

Hereditary fructose intolerance (5C51.50)

**KB89.0      Neonatal malabsorption due to endocrine secreting tumour****KB89.1      Short bowel syndrome in neonate**

Short bowel syndrome in neonate is a condition originating in the perinatal period in which nutrients are not properly absorbed due to either surgical removal of a large portion of the small intestine or rarely due to the complete dysfunction of a large segment of small intestine.

**Exclusions:**      Congenital short bowel (LB15.2)

**KB89.Y      Other specified neonatal malabsorption syndromes****KB89.Z      Neonatal malabsorption syndromes, unspecified****KB8A****Neonatal haematemesis or melaena due to swallowed maternal blood**

A less serious, self-limiting case of haematemesis and melena which can occur in newborns two to three days after delivery, due to swallowed maternal blood.

**KB8B****Neonatal peritonitis**

Neonatal peritonitis may be bacterial or chemical in origin. The majority of cases of bacterial peritonitis are due to intestinal perforations, ruptured omphaloceles, or ischemic intestinal necrosis. Although most babies had peritonitis secondary to intestinal perforation subsequent to intestinal obstruction, many instances are unexplained perforation, possibly secondary to defects in the intestinal musculature or visceral ischemia. The less common chemical peritonitis is due to prenatal intestinal perforation with extrusion of sterile meconium into the peritoneal cavity. The two types may coexist if an antenatal perforation remains open after birth, allowing bacterial contamination of the previously sterile peritoneum.

**KB8C****Noninfectious neonatal diarrhoea**

Non-infectious causes of diarrhoea in neonates. Childhood diarrhoea is most often caused by infection. Much less often, however, it is due to other causes - e.g., malabsorption or dietary intolerance, endocrine abnormalities, hormone-secreting tumours, pancreatic and liver dysfunction. Non-infectious causes of diarrhoea may have other systemic signs and symptoms. Neonates are at particular risk of dehydration and malnutrition.

**KB8Y****Other specified digestive system disorders of fetus or newborn****KB8Z****Digestive system disorders of fetus or newborn, unspecified****Genitourinary system disorders specific to the perinatal or neonatal period (KC00-KC0Z)**

A group of conditions occurring during the period of time around childbirth, especially the five months before and one month after birth which are associated with the genitourinary system.

**KC00****Congenital hydrocele**

A paediatric condition characterised by the buildup of watery fluid around one or both testicles of a newborn that is present at birth.

**KC01****Congenital renal failure**

A severe irreversible decline in the ability of kidneys to remove wastes, concentrate urine, and maintain electrolyte balance; blood pressure; and calcium metabolism which existed at, or often before, birth.

**Inclusions:** Uraemia of newborn

**KC0Y****Other specified genitourinary system disorders specific to the perinatal or neonatal period****KC0Z****Genitourinary system disorders specific to the perinatal or neonatal period, unspecified****Disorders involving the integument of fetus or newborn (KC20-KC9Z)**

**Coded Elsewhere:** Neonatal dermatoses due to maternal antibodies (KA07)

**KC20****Conditions involving the umbilical cord**

- KC20.0      Delayed separation of umbilical cord**
- KC20.1      Umbilical cutis or polyp of newborn**  
An umbilical cord polyp is a congenital lesion resulting from persistence of the omphalomesenteric duct. It originates from either the omphalomesenteric duct or from urachal remnants. The polyp may contain intestinal mucosa.
- KC20.2      Umbilical granuloma of newborn**
- KC20.Y      Other specified conditions involving the umbilical cord**
- KC20.Z      Conditions involving the umbilical cord, unspecified**
- KC21      Inflammatory dermatoses of the newborn**  
A range of inflammatory skin disorders presenting in the neonatal period.
- KC21.0      Neonatal acne**  
Acne presenting at birth or shortly afterwards, generally with predominantly comedonal lesions of the cheeks and a paucity of inflammatory lesions. It is thought to be due to hyperactivity of the sebaceous glands stimulated by neonatal androgens from the testes in boys and adrenals in girls.
- KC21.1      Neonatal toxic erythema**  
Neonatal toxic erythema is a common rash in neonates, appearing in up to half of newborns carried to term, usually between day 2-5 after birth; it does not occur outside the neonatal period and typically resolves within first two weeks of life. It is characterised by blotchy erythema with crops of evanescent small white or yellow papules or pustules. It is a benign condition and is thought to cause no discomfort to the baby.  
*Inclusions:*      Neonatal erythema toxicum
- KC21.2      Perianal dermatitis of the newborn**  
Perianal dermatitis of the newborn presents with perianal erythema during the first week of life, which in more severe forms may progress to oedema and superficial erosion of perianal skin. Although it usually occurs alone, perianal dermatitis may sometimes be associated with primary irritant napkin dermatitis. It is commoner in infants receiving cow's milk formulations than in breast-fed infants; it is assumed that it represents an irritant response to faecal constituents.
- KC21.Y      Other specified inflammatory dermatoses of the newborn**
- KC22      Neonatal disorders of subcutaneous fat**
- Coding Note:** Code also the causing condition
- KC22.0      Subcutaneous fat necrosis of the newborn**  
*Exclusions:*      Subcutaneous fat necrosis due to birth injury (KA43.2)

<b>KC22.1</b>	<b>Cold panniculitis of the newborn</b> Cold panniculitis resulting either from exposure of neonates to low environmental temperature or from local application of cold objects (e.g. ice packs for management of neonatal supraventricular tachycardia). The newborn are particularly susceptible as a result of a high saturated/unsaturated fat ratio in subcutaneous fat with a consequent elevation of the freezing point of fat.
<b>KC22.2</b>	<b>Sclerema neonatorum</b> Sclerema neonatorum is an uncommon condition which typically affects gravely ill, preterm neonates in the first week of life. It manifests as a diffuse hardening of skin and subcutaneous adipose tissue such that the skin cannot be pitted or picked up and pinched into a fold. Histologically there is minimal inflammation without fat necrosis. It is associated with a high mortality.
<b>KC22.Y</b>	<b>Other specified neonatal disorders of subcutaneous fat</b>
<b>Coding Note:</b>	Code also the causing condition
<b>KC22.Z</b>	<b>Neonatal disorders of subcutaneous fat, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>KC23</b>	<b>Neonatal disorders of the oral mucosa</b>
<b>KC24</b>	<b>Neonatal nutritional disorders affecting the skin</b> A range of nutritional disorders presenting in the neonatal period with skin manifestations. They may result from inadequate maternal nutrition or from problems with neonatal absorption of minerals such as zinc.  <b>Coding Note:</b> Code also the causing condition

Skin disorders associated with prematurity (KC30-KC3Y)

<b>KC30</b>	<b>Skin fragility of prematurity</b> <b>Coding Note:</b> Code also the causing condition
<b>KC31</b>	<b>Congenital erosive or vesicular dermatosis healing with reticulated supple scarring</b> A rare condition reported principally in premature neonates characterised by extensive erosions, vesicles, ulcerations and crusts affecting up to 75% of the body surface. The cause is unknown and the skin heals rapidly leaving faint reticulate scars.  <b>Coding Note:</b> Code also the causing condition
<b>KC3Y</b>	<b>Other specified skin disorders associated with prematurity</b> <b>Coding Note:</b> Code also the causing condition

**KC40**

**Miscellaneous skin disorders in the neonate**

**Coded Elsewhere:** Neonatal miliaria (EE02.0)

Disseminated intravascular coagulation of fetus or newborn  
(KA88)

Neonatal graft-versus-host disease (4B24.Y)

**KC40.0**

**Congenital sucking blisters**

**KC40.1**

**Neonatal milia**

**KC40.Y**

**Other specified skin disorders in the neonate**

**KC41**

**Miscellaneous specified conditions of integument specific to fetus or newborn**

**KC41.0**

**Breast engorgement of newborn**

A paediatric condition characterised by the painful overfilling of the breasts of a newborn with milk.

**KC41.1**

**Hydrops fetalis not due to haemolytic disease**

A fetal condition characterised by an accumulation of fluid or oedema in at least two fetal compartments, including subcutaneous compartments, the pleura, the pericardium, or the abdomen that is not due to the breakdown of red blood cells.

**KC41.Y**

**Other specified conditions of integument specific to fetus and newborn**

Iatrogenic injuries involving the skin of the neonate (KC50-KC7Y)

**Postnatal iatrogenic skin injury (KC50-KC5Z)**

Injuries resulting from perinatal and postnatal medical procedures

**KC50**

**Neonatal phototherapy burn**

Burn resulting from phototherapy administered to neonate, usually for the treatment of neonatal jaundice.

**KC5Y**

**Other specified postnatal iatrogenic skin injury**

**KC5Z**

**Postnatal iatrogenic skin injury, unspecified**

**KC7Y**

**Other specified iatrogenic injuries involving the skin of the neonate**

**KC9Z**

**Disorders involving the integument of fetus or newborn, unspecified**

## Disturbances of temperature regulation of newborn (KD10-KD1Z)

Normal temperature of newborn is 36.5 degrees C (S.D. = 0.6 degrees C). Temperature above 38.0 and below 36.0 may be regarded as unusual and called hyper- or hypothermia.

**KD10**

### **Environmental hyperthermia of newborn**

A paediatric condition characterised by a core body temperature above 37.5 degrees C (99.5 degrees F) in a newborn due to exposure of the newborn to prolonged or extremely high environmental temperature.

**KD11**

### **Fever of newborn**

**KD12**

### **Hypothermia of newborn**

Core body temperature of a newborn below -1SD (36.0 degrees C) compared with mean temperature (36.5 degrees of C).

**KD12.0**

### **Neonatal cold injury syndrome**

Neonatal cold injury syndrome is characterised by a core body temperature below 35°C (95°F) due to exposure of the newborn to prolonged or extremely low environmental temperatures. Clinically it is characterised by coldness to touch, apathy, immobility, decreased urine output and refusal of food. In addition oedema and redness of the extremities, especially the hands, feet, and face, are observed. It is commonly fatal and survivors may have evidence of brain damage.

**KD12.Y**

### **Other specified hypothermia of newborn**

**KD12.Z**

### **Hypothermia of newborn, unspecified**

**KD1Y**

### **Other specified disturbances of temperature regulation of newborn**

**KD1Z**

### **Disturbances of temperature regulation of newborn, unspecified**

## Certain disorders originating in the perinatal period (KD30-KD3Y)

A group of any other paediatric conditions that occur during the period of time around childbirth, especially the five months before and one month after birth.

**Coded Elsewhere:** Abnormal findings on neonatal screening (MG71.0)

Excessive crying of infant (MG44.0)

**KD30**

### **Birth depression**

A condition characterised by cardiorespiratory and neurological depression in a newborn.

**Coding Note:** Code also the causing condition

**KD30.0**

### **Birth depression with 5 minute Apgar score 0-3**

A condition characterised by cardiorespiratory and neurological depression, defined as an Apgar score between 0 to 3 at 5 minutes following birth.

- KD30.1** **Birth depression with 5 minute Apgar score 4-6**  
A condition characterised by cardiorespiratory and neurological depression, defined as an Apgar score between 4 and 6 at 5 minutes following birth.
- KD30.2** **Birth depression with associated metabolic acidaemia of cord blood**
- KD30.Z** **Birth depression, unspecified**
- Coding Note:** Code also the causing condition
- KD31** **Wide cranial sutures of newborn**  
A paediatric condition characterised by abnormally large separation between the bones of the skull of a newborn.
- KD32** **Feeding problems of newborn**  
A lack of interest in feeding or a problem receiving the proper amount of nutrition in a newborn.  
**Exclusions:** Avoidant-restrictive food intake disorder (6B83)
- KD32.0** **Slow feeding of newborn**  
A paediatric condition characterised by a newborn who requires more than approximately 45 minutes per feeding.
- KD32.1** **Underfeeding of newborn**  
A paediatric condition characterised by a newborn who consumes less than average for their age and weight and who seems hungry and unsatisfied after feeding, is fussy or cries a lot, does not produce several wet and soiled diapers each day, and who does not gain weight.
- KD32.2** **Overfeeding of newborn**  
A paediatric condition characterised by a newborn who consumes too much food and has subsequent excessive vomiting or weight gain beyond normal averages.
- KD32.3** **Neonatal difficulty in feeding at breast**  
A paediatric condition characterised by a newborn who has difficulty breastfeeding associated with problematic latching on to the breast, poor sucking reflex, structural anomalies, or other issues.
- KD32.4** **Failure to thrive in newborn**  
When newborn's current weight or rate of weight gain is significantly below that of other newborns of similar age and gender.
- KD32.Y** **Other specified feeding problems of newborn**
- KD32.Z** **Feeding problems of newborn, unspecified**
- KD33** **Jittery baby, not elsewhere classified**  
Jitteriness can occur on the first day of life. It can be caused by hypoglycaemia, hypocalcaemia, drug withdrawal, or other conditions.

**KD34**

### **Reactions or intoxications due to drugs administered to fetus or newborn**

A group of paediatric substance-induced conditions associated with health interventions applied to a fetus or newborn using pharmaceutical products.

**Exclusions:** Withdrawal symptoms from therapeutic use of drugs in newborn (KD36)

Neonatal hyperbilirubinaemia due to drugs or toxins transmitted from mother (KA87.4)

reactions and intoxications from maternal opiates, tranquillizers and other medication (KA06.0)

Neonatal withdrawal syndrome from maternal use of drugs of addiction (KD35)

Neonatal hyperbilirubinaemia due to drugs or toxins given to newborn (KA87.5)

**KD35**

### **Neonatal withdrawal syndrome from maternal use of drugs of addiction**

Intrauterine exposure to addictive drugs can lead to neonatal withdrawal symptoms. Withdrawal symptoms are usually neurological, preventing normal autonomic function. The clinical presentation of drug withdrawal is variable and dependent on several factors, such as, the type and dose of drug used and rate of metabolism and excretion of the mother and infant.

**Inclusions:** Drug withdrawal syndrome in infant of dependent mother  
Neonatal abstinence syndrome

**Exclusions:** Fetus or newborn affected by maternal anaesthesia or analgesia in pregnancy, labour or delivery (KA06.0)

**KD36**

### **Withdrawal symptoms from therapeutic use of drugs in newborn**

A paediatric condition characterised by the presence of symptoms due to drug withdrawal in a newborn.

**KD37**

### **Exposure to tobacco smoke in the perinatal period**

Exposure to tobacco smoke in the perinatal period, both directly or through second hand smoke, can lead to: low birth weight, preterm delivery, Sudden Infant Death Syndrome (SIDS or cot death), spontaneous abortion, or intrauterine growth retardation.

**Exclusions:** Fetus or newborn affected by maternal use of tobacco (KA06.1)

**KD38**

### **Meconium staining**

Green or yellowish appearing amniotic fluid, indicating presence of meconium. The newborn's skin, nail beds or the umbilical cord may be stained.

**Exclusions:** Neonatal aspiration of meconium (KB26.0)  
Meconium passage during delivery (KA05.8)

**KD39**

**Complications of intrauterine procedures, not elsewhere classified**

A group of conditions characterised as an unfavourable evolution of a condition (complication) due to a health intervention applied inside of the uterus.

**Exclusions:**      fetus and newborn affected by placental separation and haemorrhage due to intrauterine procedures (KA02)

**KD39.0**

**Fetus or newborn affected by amniocentesis**

Amniocentesis involves extracting a small sample of amniotic fluid surrounding the fetus. Risks include miscarriage or injury if the needle comes into contact with the fetus or placenta.

**KD39.1**

**Fetus or newborn affected by chorionic villous sampling**

Chorionic villus sampling (CVS) is a procedure where a small sample of the placenta is removed, either through the cervix or abdomen. Risks when performing CVS include: injury to the fetus or mother from the needle, infection to the mother from a punctured bowel or contaminated skin, or Rhesus sensitisation. Injury or infection can lead to miscarriage, although this is rare.

**KD39.2**

**Fetus or newborn affected by fetal blood sampling**

Fetal blood sampling involves extracting a sample of fetal blood from the umbilical cord using a needle and an ultrasound as a guide. It is used to detect fetal abnormalities and is generally performed after the completion of 18 weeks of gestation. Risks to the fetus and newborn include: miscarriage, bleeding from the needle entry site, uterine infection and temporary slowing of the baby's heart rate following the procedure.

**Inclusions:**      Fetus or newborn affected by cordocentesis

**KD39.3**

**Fetus or newborn affected by complications of fetal surgery**

A condition in the fetus due to an unfavourable evolution of a condition (complication) associated with a surgical health intervention applied to the fetus.

**KD39.4**

**Fetus or newborn affected by complications of intrauterine fetal surgery**

Fetal surgery is the surgical treatment of a fetus still present in the uterus. It is performed when the fetus is suffering from a birth defect and is not expected to survive the delivery or live long after birth. It allows for the fetus to survive to birth, so that further corrective surgery can then be performed. Fetal surgery can be done in the following ways: fetoscopic surgery by using a fibrooptic scope to enter the uterus through small surgical openings, open fetal surgery by performing a hysterotomy which is an opening of the uterus, or radiofrequency ablation which cuts off the blood supply to a tumour.

**KD39.Y**

**Other specified complications of intrauterine procedures, not elsewhere classified**

**KD39.Z**

**Complications of intrauterine procedures, not elsewhere classified, unspecified**

**KD3A**

### **Termination of pregnancy, affecting surviving fetus or newborn**

Termination of pregnancy (TOP) refers to a medically directed miscarriage, and this can be performed using pharmacological or surgical methods.

**Inclusions:** termination of pregnancy (affecting mother) (JA00.1)

**KD3B**

### **Fetal death, cause not specified**

Fetal death is death of a fetus prior to its complete expulsion or extraction from a woman, irrespective of the duration of pregnancy. Fetal death may be diagnosed in utero by absence of fetal heart sounds, confirmed by imaging techniques where available, or after delivery by absence of signs of life after the complete expulsion or extraction from the woman.

Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.

**Coding Note:** Not to be used for the underlying cause of death of live births.

Not to be used for the underlying cause of fetal death, if any other cause of fetal mortality is known.

**Inclusions:**

- stillbirth NOS
- stillborn NOS
- osteopiedion fetus
- lithopedion fetus
- fetus maceration
- calcified fetus

**KD3B.0**

### **Antepartum fetal death**

Antepartum fetal death is a fetal death before the onset of labour. If vital status of the fetus at the onset of labour is unknown, consider it was antepartum if there is presence of signs of maceration at the time of delivery.

Macerated stillbirth - is the complete expulsion or extraction from a woman of a fetus following a fetal death at 22 or more completed weeks of gestation; or if gestational age is not available with a birthweight of 500g or more with skin showing signs of maceration.

Antepartum stillbirth - is the complete expulsion or extraction from a woman of a fetus following an antepartum fetal death at 22 or more completed weeks of gestation; or if gestational age is not available with a birthweight of 500 grams or more.

**Coding Note:** Not to be used for the underlying cause of death of live births.

Not to be used for the underlying cause of fetal death, if any other cause of fetal mortality is known.

**Inclusions:**

- macerated stillbirth
- antepartum stillbirth

<b>KD3B.1</b>	<b>Intrapartum fetal death</b> Intrapartum fetal death is a fetal death during labour. If vital status of the fetus at the onset of labour is unknown, consider it was intrapartum if there is fresh skin appearance or no signs of maceration at the time of delivery.  Intrapartum stillbirth - is the complete expulsion or extraction from a woman of a fetus following an intrapartum fetal death at 22 or more completed weeks of gestation; or if gestational age is not available with a birthweight of 500 grams or more.
<b>Coding Note:</b>	Not to be used for the underlying cause of death of live births.  Not to be used for the underlying cause of fetal death, if any other cause of fetal mortality is known.
	<b>Inclusions:</b> intrapartum stillbirth fresh stillbirth
<b>KD3B.Z</b>	<b>Unspecified time of fetal death, cause not specified</b>
<b>Coding Note:</b>	Not to be used for the underlying cause of death of live births.  Not to be used for the underlying cause of fetal death, if any other cause of fetal mortality is known.
<b>KD3C</b>	<b>Vomiting in newborn</b> A paediatric condition characterised by the forceful expulsion of the contents of the stomach through the mouth and sometimes the nose of a newborn.
<b>KD3C.0</b>	<b>Bilious vomiting of newborn</b>
<b>KD3C.Y</b>	<b>Other specified vomiting in newborn</b>
<b>KD3C.Z</b>	<b>Vomiting in newborn, unspecified</b>
<b>KD3Y</b>	<b>Other specified disorders originating in the perinatal period</b>

---

<b>KD5Z</b>	<b>Conditions originating in the perinatal or neonatal period, unspecified</b>
<b>Coding Note:</b>	Conditions arising in the perinatal period, even though death or morbidity occurs later, should, as far as possible, be coded to chapter 19, which takes precedence over chapters containing codes for diseases by their anatomical site.  For children less than 28 days old, assume that a reported condition developed in the perinatal period, unless the duration is stated and the onset was after the first completed week of life.

# CHAPTER 20

---

## Developmental anomalies

This chapter has 221 four-character categories.

Code range starts with LA00

This chapter includes conditions caused by failure of a particular body site or body system to develop correctly during the antenatal period.

**Exclusions:** Inborn errors of metabolism (5C50-5C5Z)

This chapter contains the following top level blocks:

- Structural developmental anomalies primarily affecting one body system
- Multiple developmental anomalies or syndromes
- Chromosomal anomalies, excluding gene mutations

### Structural developmental anomalies primarily affecting one body system (LA00-LD0Z)

A deformation established before birth of an anatomical structure.

#### Structural developmental anomalies of the nervous system (LA00-LA0Z)

Any condition caused by failure of the nervous system to correctly develop during the antenatal period.

**LA00**

#### Anencephaly or similar anomalies

A malformation of the nervous system caused by the failure of neuropore closure. Infants are born with intact spinal cord, cerebellum, and brainstem, but lack formation of neural structures above this level. The skull is only partially formed but the eyes are usually normal.

**LA00.0**

#### Anencephaly

Anencephaly is a neural tube defect, characterised by the total or partial absence of the cranial vault and the covering skin, the brain being missing or reduced to a small mass. Most cases are stillborn, although some infants have been reported to survive for a few hours. In most cases autopsy findings reveal absence of adrenal glands. Anencephaly is likely to be multifactorial, the result of gene-environment interactions. Familial cases with a seemingly autosomal recessive mode of inheritance have been described but most cases are sporadic. Folic acid and zinc deficiencies, as well as maternal obesity, have been shown to be risk factors.

<b>LA00.00</b>	Craniorachischisis A condition caused by failure of the neural tube to close completely during the antenatal period. This condition is characterised by complete absence of the skull, extensive defects in the vertebrae and skin, and absence of the brain.
<b>LA00.0Y</b>	Other specified anencephaly
<b>LA00.0Z</b>	Anencephaly, unspecified
<b>LA00.1</b>	<b>Iniencephaly</b> Iniencephaly is a rare form of neural tube defect in which a malformation of the cervico-occipital junction is associated with a malformation of the central nervous system. The cardinal features are occipital bone defect, partial or total absence of cervicothoracic vertebrae, fetal retroflexion of the head and characteristic absence of the neck. It is associated with malformations of the central nervous (spina bifida and/or anencephaly), gastrointestinal (omphalocele) and cardiovascular systems.
<b>LA00.2</b>	<b>Acephaly</b>
<b>LA00.3</b>	<b>Amyelencephaly</b> Amyelencephaly is the absence of both the brain and spinal cord.
<b>LA00.Y</b>	<b>Other specified anencephaly or similar anomalies</b>
<b>LA00.Z</b>	<b>Anencephaly or similar anomalies, unspecified</b>
<b>LA01</b>	<b>Cephalocele</b> A condition caused by failure of the skull to correctly close during the antenatal period. This condition is characterised by herniation of the meninges. This condition may present with herniation of brain, or developmental delay. Confirmation is through observation of herniated meninges by imaging.
<b>LA02</b>	<b>Spina bifida</b> Spina bifida is the most common of a group of birth defects called neural tube defects. Spina bifida affects the backbone and, sometimes, the spinal cord. Aperta spina bifida defines the dorsal malclosure of vertebrae, associated with various degrees of spine defects. A pocket of skin may form, containing meninges (meningocele) or spinal cord and meninges (myelomeningocele). Different subtypes are distinguished according to the location of the defect. Consequences are paraplegia (paralysed lower limbs), hydrocephaly, Chiari malformation (result of the attached spine during life in utero), urinary and anorectal incontinence. The intensity of signs varies greatly with the level and extent of the lesion.  <b>Inclusions:</b> Rachischisis Spinal dysraphism  <b>Exclusions:</b> Arnold-Chiari malformation type I (LA07.4) Arnold-Chiari malformation type II (LA03) Occult spinal dysraphism (LB73.0)

<b>LA02.0</b>	<b>Spina bifida cystica</b> A condition caused by failure of the neural tube to correctly develop during the antenatal period. This condition is characterised by nerve damage and the presence of meningoceles on the back. This condition may present with physical or mental impairment.
<b>LA02.00</b>	Myelomeningocele with hydrocephalus A condition caused by failure of the neural tube to correctly develop during the antenatal period. This condition is characterised by nerve damage and hydrocephalus. This condition may also present with syringomyelia, hip dislocation, headache, nausea, vomiting, blurry vision, balance problems, bladder control problems, meningitis, or mental impairment.
<b>LA02.01</b>	Myelomeningocele without hydrocephalus A condition caused by failure of the neural tube to close completely during fetal development. This condition is characterised by nerve damage. This condition may also present with syringomyelia, hip dislocation, headache, nausea, vomiting, blurry vision, balance problems, bladder control problems, meningitis, or mental impairment.
<b>LA02.02</b>	Myelocystocele A condition caused by failure of the neural tube to close completely during fetal development. The condition is characterised by skin covered lumbosacral masses, an arachnoid lined meningocele that is directly continuous with the spinal subarachnoid space, and a low lying hydromyelic spinal cord that traverses the meningocele and expands into a large terminal cyst. This condition can present with neural damage and consequent impairment of function below the site of the myelocystocele.
<b>LA02.0Y</b>	Other specified spina bifida cystica
<b>LA02.0Z</b>	Spina bifida cystica, unspecified
<b>LA02.1</b>	<b>Spina bifida aperta</b> A condition caused by failure of the neural tube to correctly develop during the antenatal period. This condition is characterised by nerve damage originating from a known location in the spine, signified by the presence of a meningocele or myelomeningocele. This condition may present with physical or mental impairment.
<b>LA02.Y</b>	Other specified spina bifida
<b>LA02.Z</b>	Spina bifida, unspecified

**LA03****Arnold-Chiari malformation type II**

A condition caused by failure of the brain and spinal cord to correctly develop during the antenatal period. This condition is characterised by extension of both cerebellar and brain stem tissue into the foramen magnum. This condition may present with partial or complete absence of the cerebellar vermis, myelomeningocele, neck pain, balance problems, muscle weakness, limb numbness, dizziness, vision problems, difficulty swallowing, ringing in the ears, hearing loss, vomiting, insomnia, depression, or impairment of motor skills.

**Inclusions:** Arnold-Chiari malformation type I (LA07.4)

**LA04****Congenital hydrocephalus**

A disease caused by failure of the brain to correctly develop during the antenatal period. This condition is characterised by a rapid increase in head circumference or an unusually large head size due to excessive accumulation of cerebrospinal fluid in the brain. This condition may also present with vomiting, sleepiness, irritability, downward deviation of the eyes, or seizures. Confirmation is through observation of cerebrospinal fluid within cerebral ventricles by imaging.

**Inclusions:** Hydrocephalus in newborn

**Exclusions:** Myelomeningocele with hydrocephalus (LA02.00)

Hydrocephalus due to congenital toxoplasmosis (KA64.0)

Arnold-Chiari malformation type I (LA07.4)

Arnold-Chiari malformation type II (LA03)

**LA04.0****Hydrocephalus with stenosis of the aqueduct of Sylvius**

Hydrocephalus with stenosis of aqueduct of Sylvius (HSAS) or Bickers-Adams syndrome is characterised by the association of hydrocephaly, severe intellectual deficit, spasticity and adducted thumbs, and is part of the L1 syndrome (see this term).

**Inclusions:** Stenosis of the aqueduct of Sylvius

**LA04.Y****Other specified congenital hydrocephalus****LA04.Z****Congenital hydrocephalus, unspecified****LA05****Cerebral structural developmental anomalies**

Any condition caused by failure of the brain to correctly develop during the antenatal period.

**Exclusions:** Encephalocele (LA01)

**LA05.0****Microcephaly**

A condition caused by failure of the head to correctly develop during the antenatal period. This condition is characterised by a head size that is significantly smaller than normal for their age and sex. This condition may also present with developmental delays, difficulties with balance and coordination, short stature, hyperactivity, mental retardation, seizures, or other neurological abnormalities.

**Coding Note:**

Code also the causing condition

**Inclusions:** Micrencephaly

**Exclusions:** Syndromes with microcephaly as a major feature (LD20.2)

- LA05.1      Megalencephaly**  
A condition caused by failure of the brain to correctly develop during the antenatal period. This condition is characterised by increased size or weight of an otherwise correctly formed brain. This condition may also present with seizures, motor deficits, mental retardation and mild cognitive impairment.
- LA05.2      Holoprosencephaly**  
Holoprosencephaly is a brain malformation resulting from incomplete cleavage of the prosencephalon, occurring between the 18th and the 28th day of gestation and affecting both the forebrain and the face. In most of the cases, facial anomalies are observed: cyclopia, proboscis and median or bilateral cleft lip/palate in severe forms, and ocular hypotelorism or solitary median maxillary central incisor in minor forms. These latter midline defects can occur without the cerebral malformations (microforms). Children with HPE have many medical problems: developmental delay and feeding difficulties, epilepsy, and instability of temperature, heart rate and respiration. Endocrine disorders like diabetes insipidus, adrenal hypoplasia, hypogonadism, thyroid hypoplasia and growth hormone deficiency are frequent.
- Coded Elsewhere:** Cyclopia (LA10.Y)
- LA05.3      Corpus callosum agenesis**  
Corpus callosum agenesis is the most common brain malformation and is characterised by total or partial absence of the main interhemispheric commissure, the corpus callosum.
- LA05.4      Arrhinencephaly**  
A condition caused by failure of the olfactory organs to correctly develop during the antenatal period. This condition is characterised by absence of the olfactory bulbs and tracts.
- LA05.5      Abnormal neuronal migration**  
Any condition caused by abnormal migration of neuronal cells during the antenatal period. These conditions may present with poor muscle tone and motor function, seizures, developmental delays, mental retardation, failure to grow and thrive, difficulties with feeding, swelling in the extremities or microcephaly.
- Exclusions:** Lissencephaly (LD20.1)
- LA05.50     Polymicrogyria**  
Polymicrogyria (PMG) is a cerebral cortical malformation characterised by excessive cortical folding and by shallow sulci. Microscopic examination reveals abnormal cortical layering. Topographic distribution of PMG is variable, but bilateral symmetrical perisylvian PMG (BPP) is the most frequent form. PMG is manifested by mild intellectual deficit, epilepsy, and pseudobulbar palsy, which causes difficulties with speech learning and feeding. The severity of PMG is highly dependent on the location and size of the affected area.
- LA05.51     Cortical dysplasia**  
A condition caused by failure of the cortex to correctly develop during the antenatal period, or by trauma. This condition is characterised by epileptic seizures. This condition may also present with learning impairments.

<b>LA05.5Y</b>	Other specified abnormal neuronal migration
<b>LA05.5Z</b>	Abnormal neuronal migration, unspecified
<b>LA05.6</b>	<b>Encephaloclastic disorders</b>
<b>LA05.60</b>	<p>Porencephaly</p> <p>Porencephaly is characterised by a circumscribed intracerebral cavity of variable size that may be bordered by abnormal polymicrogyric grey matter. In extreme cases, this cavity may result in a communication between the pial surface and the ventricle; this is termed schizencephaly.</p>
<b>LA05.61</b>	<p>Schizencephaly</p> <p>Schizencephaly is a rare congenital cerebral malformation characterised by the presence of linear clefts in one or both hemispheres of the brain, extending from the lateral ventricles to the pial surface of the cortex, and that lead to a variety of neurological symptoms such as epilepsy, motor deficits, and psychomotor retardation.</p>
<b>LA05.62</b>	<p>Hydranencephaly</p> <p>A condition caused by failure of the cerebral hemispheres to develop during the antenatal period. This condition is characterised by a lack of a forebrain upon imaging. This condition may present with visual impairment, lack of growth, deafness, blindness, spastic quadripareisis, or intellectual deficits.</p>
<b>LA05.6Y</b>	Other specified encephaloclastic disorders
<b>LA05.6Z</b>	Encephaloclastic disorders, unspecified
<b>LA05.7</b>	<b>Brain cystic malformations</b>
	<p>A disease caused by expansion of the roof plate of the brain vesicle, or by extraaxial structures such as an arachnoid membrane or migrating ependymal cells. This disease is characterised by the presence of fluid filled cysts in the brain. This disease may present with asymmetry of the skull, brain compression, raised intracranial pressure, hydrocephalus, bleeding or seizures. This disease may also be asymptomatic. Confirmation is through observation of intracerebral cysts by imaging.</p>
	<p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Acquired porencephalic cysts (8E40)</li> <li>Dandy-Walker malformation with hydrocephalus (LA06.0)</li> <li>Dandy-Walker malformation without hydrocephalus (LA06.0)</li> </ul>
	<p><b>Coded Elsewhere:</b> Intracranial arachnoid cyst (8D67)</p>
<b>LA05.8</b>	<b>Colpocephaly</b>
	<p>A condition caused by the white matter in the posterior cerebrum failing to develop or thicken during the antenatal period. This condition is characterised by the occipital horns – the posterior or rear portion of the lateral ventricles (cavities) of the brain – being larger than normal.</p>
	<p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Porencephaly (LA05.60)</li> <li>stenosis of interventricular foramen (ME93)</li> </ul>
<b>LA05.Y</b>	<b>Other specified cerebral structural developmental anomalies</b>

LA05.Z	<b>Cerebral structural developmental anomalies, unspecified</b>
LA06	<p><b>Cerebellar structural developmental anomalies</b></p> <p>Any condition caused by failure of the brain to correctly develop during the antenatal period.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Arnold-Chiari malformation type I (LA07.4)</li> <li>Arnold-Chiari malformation type II (LA03)</li> </ul>
LA06.0	<p><b>Dandy-Walker malformation</b></p> <p>Dandy-Walker malformation is the association of three signs: hydrocephalus, partial or complete absence of the cerebellar vermis, and posterior fossa cyst contiguous with the fourth ventricle.</p>
LA06.1	<p><b>Hypoplasia or agenesis of cerebellar hemispheres</b></p> <p>Cerebellar hypoplasia corresponds to underdevelopment of cerebellar structures that can involve the vermis and/or the cerebellar hemispheres from partial to total agenesis. It has been described in the context of various clinical entities: chromosomal anomalies, in utero exposure to toxins and infectious agents, metabolic disorders (disorders of glycosylation and CoQ10 deficiencies), and a wide variety of rare genetic neurological diseases. It can be confined to the cerebellum, or affect other CNS structures: the midbrain (molar tooth syndromes), pons and medulla (ponto-cerebellar hypoplasia), cerebral cortex (lissencephaly cerebellar hypoplasia syndromes).</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>PHACE syndrome (LD2F.1)</li> </ul>
LA06.2	<p><b>Focal cerebellar dysplasia</b></p> <p>A condition caused by failure of the cerebellum to correctly develop during the antenatal period. This condition may present with hypotonia, facial deformities, abnormalities in eyes or in ocular motricity, cognitive deficiencies, or motor dysfunction. Confirmation is through observation of a malformed cerebellum by imaging.</p>
LA06.Y	<b>Other specified cerebellar structural developmental anomalies</b>
LA06.Z	<b>Cerebellar structural developmental anomalies, unspecified</b>
LA07	<p><b>Structural developmental anomalies of the neureneric canal, spinal cord or vertebral column</b></p> <p>Any condition caused by failure of the neureneric canal, spinal cord and vertebral column to correctly develop during the antenatal period.</p> <p><b>Coded Elsewhere:</b> Occult spinal dysraphism (LB73.0)</p>
LA07.0	<p><b>Primary tethered cord syndrome</b></p> <p>A condition caused by failure of the spinal cord to correctly develop during the antenatal period. This condition is characterised by tethering of the spinal cord to the spinal canal. This condition may present with lower back skin appendages, radicular pain, weakness, asymmetric hyporeflexia, spasticity, sensory changes, bowel or bladder dysfunction, or motor dysfunction. Confirmation is through observation of a tethered spinal cord by imaging.</p>

<b>LA07.1</b>	<b>Diastematomyelia</b> A condition caused by failure of the spinal cord during the antenatal period. This condition is characterised by separation of the spinal cord into two parts by a rigid or fibrous septum. This condition may present with misformed vertebrae, pain, weakness, impaired gait, sensory changes in the legs, or sphincter disturbance. Confirmation is through observation of a septum-bifurcated spinal cord by imaging.
	<b>Inclusions:</b> Split cord malformation
<b>LA07.2</b>	<b>Amyelia</b> A condition caused by malformation of the spinal cord during the antenatal period. This condition is characterised by absence of sections of the spinal cord.
	<b>Inclusions:</b> Spinal cord agenesis
<b>LA07.3</b>	<b>Primary syringomyelia or hydromyelia</b> A condition caused by failure of the spinal canal to correctly develop during the antenatal period. This condition is characterised by a cavity within the spinal cord in which cerebrospinal fluid can accumulate. Confirmation is through observation of a fluid filled cavity within the spinal cord by imaging.
	<b>Exclusions:</b> Syringomyelia due to certain specified cause (8D66.1)
<b>LA07.4</b>	<b>Arnold-Chiari malformation type I</b> A condition caused by failure of the cerebellum to correctly develop during the antenatal period. This condition is characterised by extension of the cerebellar tonsils into the foramen magnum, without involving the brain stem. This condition may present as asymptomatic. Confirmation is through observation of the cerebellar tonsil extension by imaging.
	<b>Exclusions:</b> Arnold-Chiari malformation type II (LA03)
<b>LA07.Y</b>	<b>Other specified structural developmental anomalies of the neureneric canal, spinal cord or vertebral column</b>
<b>LA07.Z</b>	<b>Structural developmental anomalies of the neureneric canal, spinal cord or vertebral column, unspecified</b>
<b>LA0Y</b>	<b>Other specified structural developmental anomalies of the nervous system</b>
<b>LA0Z</b>	<b>Structural developmental anomalies of the nervous system, unspecified</b>

Structural developmental anomalies of the eye, eyelid or lacrimal apparatus (LA10-LA1Z)

Any condition caused by failure of the eye, eyelid and lacrimal apparatus to correctly develop during the antenatal period.

<b>LA10</b>	<b>Structural developmental anomalies of ocular globes</b> Any condition caused by failure of the ocular globes to correctly develop during the antenatal period.
	<b>Exclusions:</b> Holoprosencephaly with cyclopia or synophthalmia (LA05.2)

<b>LA10.0</b>	<b>Microphtalmos</b>
	<b><i>Inclusions:</i></b>
	Dysplasia of eye
	Hypoplasia of eye
	Rudimentary eye
<b>LA10.1</b>	<b>Clinical anophthalmos</b>
	This refers to the clinical absence of one or both eyes. Both the globe (human eye) and the ocular tissue are missing from the orbit. The absence of the eye will cause a small bony orbit, a constricted mucosal socket, short eyelids, reduced palpebral fissure and malar prominence. Genetic mutations, chromosomal abnormalities, and prenatal environment can all cause anophthalmia. Anophthalmia is an extremely rare disease and is mostly rooted in genetic abnormalities.
	<b><i>Inclusions:</i></b>
	Agenesis of eye
	Aplasia of eye
<b>LA10.2</b>	<b>Buphthalmos</b>
	A condition characterised by enlargement of the globe of the eye.
<b>LA10.3</b>	<b>Congenital macrophtalmos</b>
	A condition caused by failure of the eye to develop correctly during the antenatal period. This condition is characterised by enlargement of the globe of the eye.
	<b><i>Exclusions:</i></b>
	macrophtalmos in congenital glaucoma (9C61.4)
<b>LA10.Y</b>	<b>Other specified structural developmental anomalies of ocular globes</b>
<b>LA10.Z</b>	<b>Structural developmental anomalies of ocular globes, unspecified</b>
<b>LA11</b>	<b>Structural developmental anomalies of the anterior segment of eye</b>
	Any condition caused by failure of the anterior segment of the eye to correctly develop during the antenatal period.
	<b><i>Coded Elsewhere:</i></b> Developmental glaucoma (9C61.4)
<b>LA11.0</b>	<b>Blue sclera</b>
	A condition of the eye, characterised by transparency of the sclera such that the blue uvea is visible.
<b>LA11.1</b>	<b>Structural developmental anomalies of cornea</b>
	Any condition caused by failure of the cornea to correctly develop during the antenatal period.
	<b><i>Coded Elsewhere:</i></b> Corneal staphyloma (9A78.51)
<b>LA11.2</b>	<b>Anterior segment dysgenesis</b>
	A condition caused by failure of the anterior structures of the eye to correctly develop during the antenatal period. This condition may present with iris hypoplasia, irregular and misplaced pupils, hazy corneas, or attachments of the iris to the cornea.

<b>LA11.3</b>	<b>Aniridia</b> Aniridia is a congenital ocular malformation characterised by the complete or partial absence of the iris. It can be isolated or part of a syndrome (isolated and syndromic aniridia).
<b>LA11.4</b>	<b>Coloboma of iris</b> A disease of the eye, caused by trauma or congenital genetic mutation. This disease is characterised by notches or gaps in iris.
<b>LA11.5</b>	<b>Congenital corneal opacity</b> A condition caused by failure of the cornea to correctly develop during the antenatal period. This condition is characterised by opacity of the cornea.  <b>Coded Elsewhere:</b> Peters anomaly (9C61.42) Congenital hereditary endothelial dystrophy type 2 (9A70.0)
<b>LA11.6</b>	<b>Structural disorders of the pupil</b>
<b>LA11.60</b>	Irregular pupil of the eye
<b>LA11.61</b>	Iridoschisis
<b>LA11.62</b>	Anomalies of pupillary function This is a group of conditions associated with pupillary function which is to regulate the amount of light that enters the eye controlled by the muscular structures of the iris.  <b>Coded Elsewhere:</b> Congenital mydriasis (9B01.3)
<b>LA11.6Y</b>	Other specified structural disorders of the pupil
<b>LA11.6Z</b>	Structural disorders of the pupil, unspecified
<b>LA11.Y</b>	<b>Other specified structural developmental anomalies of the anterior segment of eye</b>
<b>LA11.Z</b>	<b>Structural developmental anomalies of the anterior segment of eye, unspecified</b>
<b>LA12</b>	<b>Structural developmental anomalies of lens or zonula</b> Any condition caused by failure of the lens and zonula to correctly develop during the antenatal period.
<b>LA12.0</b>	<b>Coloboma of lens</b>
<b>LA12.1</b>	<b>Congenital cataract</b> Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness; typically diagnosed at birth
<b>LA12.2</b>	<b>Congenital aphakia</b> Congenital primary aphakia is a developmental eye defect characterised by an absence of the lens, and can be associated with variable secondary ocular defects (including aplasia/dysplasia of the anterior segment of the eye, microphthalmia, and in some cases absence of the iris, retinal dysplasia, or sclerocornea).

LA12.3	<b>Spherophakia</b> A disease of the eye, caused by homozygous mutations in the LTBP2 gene (isolated spherophakia), or by other genetic mutations. This disease is characterised by small, spherical lenses. This disease can also present with lenticular myopia, glaucoma, or sublation of the lens into the vitreous cavity.
LA12.Y	<b>Other specified structural developmental anomalies of lens or zonula</b>
LA12.Z	<b>Structural developmental anomalies of lens or zonula, unspecified</b>
<b>LA13</b>	<b>Structural developmental anomalies of the posterior segment of eye</b> Any condition caused by failure of the posterior segment of the eye to correctly develop during the antenatal period. These conditions are characterised by clinical, functional, or morphological changes to the posterior segment of the eye.  <b>Coded Elsewhere:</b> Juvenile retinoschisis (9B73.11) Optic nerve hypoplasia or aplasia (LA13.7Z)
LA13.0	<b>Congenital anomalies of the vitreous</b> <b>Coded Elsewhere:</b> Congenital vitreoretinal dysplasia (LA13.3) Persistent hyperplastic primary vitreous (LA13.Y)
LA13.1	<b>Coloboma of choroid or retina</b> A condition of the eye characterised by absence of the retina in the lower inside corner of the eye.
LA13.2	<b>Coloboma of macula</b> A disease caused by malformation of the macula due to retinal inflammation during the antenatal period or by congenital genetic mutation. This disease is characterised by a clearly delineated defect in the macula.
LA13.3	<b>Congenital vitreoretinal dysplasia</b> Any disease caused by the maldevelopment of the vitreous and retina.  <b>Coded Elsewhere:</b> Incontinentia pigmenti (LD27.00) Walker Warburg syndrome (8C70.6) Norrie disease (LD21.Y)
LA13.5	<b>Congenital retinal aneurysm</b>
LA13.6	<b>Congenital malformations of choroid</b> These are single or multiple defects of the morphogenesis of the choroid, the vascular layer of the eye, identifiable at birth or during the intrauterine life.
LA13.7	<b>Congenital malformation of optic disc</b>
LA13.70	Isolated optic nerve hypoplasia
LA13.71	Optic nerve aplasia
LA13.72	Congenitally elevated optic disc

<b>LA13.73</b>	Optic disc dysplasia deformed optic discs that fail to conform to any recognizable diagnostic category
<b>LA13.74</b>	Megalopapilla
<b>LA13.76</b>	Coloboma of optic disc Congenital abnormal optic disc appearance due to incomplete coaptation of the proximal end of the embryonic fissure in ocular development
<b>LA13.7Y</b>	Other specified congenital malformation of optic disc
<b>LA13.7Z</b>	Congenital malformation of optic disc, unspecified
<b>LA13.8</b>	<b>Certain congenital malformations of posterior segment of eye</b> <b>Coded Elsewhere:</b> Coloboma of choroid or retina (LA13.1)
<b>LA13.80</b>	Anastomosis of retinal or choroidal vessels
<b>LA13.Y</b>	<b>Other specified structural developmental anomalies of the posterior segment of eye</b>
<b>LA13.Z</b>	<b>Structural developmental anomalies of the posterior segment of eye, unspecified</b>
<b>LA14</b>	<b>Structural developmental anomalies of eyelid, lacrimal apparatus or orbit</b> Any condition caused by failure of the eyelid lacrimal apparatus and orbit to correctly develop during the antenatal period. <b>Exclusions:</b> cryptophthalmos NOS (LA10.0)
<b>LA14.0</b>	<b>Structural developmental anomalies of eyelids</b>
<b>Coding Note:</b>	Code also any associated syndrome
<b>LA14.00</b>	Palpebral cleft or coloboma
<b>LA14.01</b>	Cryptophthalmia Isolated cryptophthalmia is a congenital abnormality in which the eyelids are absent and skin covers the ocular bulb, which is often microphthalmic.
<b>LA14.02</b>	Congenital entropion
<b>LA14.03</b>	Congenital ectropion
<b>LA14.04</b>	Congenital ptosis Congenital ptosis is characterised by superior eyelid drop present at birth.
<b>LA14.05</b>	Congenital eyelid retraction
<b>LA14.06</b>	Epibulbar choristoma

- LA14.07** Ankyloblepharon filiforme adnatum  
 Isolated ankyloblepharon filiforme adnatum is characterised by the presence of single or multiple thin bands of connective tissue between the upper and lower eyelids, preventing full opening of the eye.
- LA14.0Y** Other specified structural developmental anomalies of eyelids
- Coding Note:** Code also any associated syndrome
- LA14.1** **Structural developmental anomalies of lacrimal apparatus**  
 This refers to structural developmental anomalies of the physiologic system containing the orbital structures for tear production and drainage.
- LA14.10** Aplasia of lacrimal or salivary glands
- LA14.11** Agenesis of lacrimal ducts  
 Isolated congenital alacrima is characterised by deficient lacrimation (ranging from a complete absence of tears to hyposecretion of tears) that is present from birth.  
**Inclusions:** Absence of punctum lacrimale
- LA14.12** Congenital dacryocele
- LA14.13** Congenital agenesis of lacrimal punctum
- LA14.14** Congenital stenosis or stricture of lacrimal duct
- LA14.1Y** Other specified structural developmental anomalies of lacrimal apparatus
- LA14.1Z** Structural developmental anomalies of lacrimal apparatus, unspecified
- LA14.2** **Structural developmental anomalies of orbit**  
 Any condition caused by failure of the orbit to correctly develop during the antenatal period.
- LA14.Y** **Other specified structural developmental anomalies of eyelid, lacrimal apparatus or orbit**
- LA14.Z** **Structural developmental anomalies of eyelid, lacrimal apparatus or orbit, unspecified**
- LA1Y** **Other specified structural developmental anomalies of the eye, eyelid or lacrimal apparatus**
- LA1Z** **Structural developmental anomalies of the eye, eyelid or lacrimal apparatus, unspecified**

Structural developmental anomalies of the ear (LA20-LA2Z)

Any condition caused by failure of the ear to correctly develop during the antenatal period.

- LA20** **Structural anomaly of eustachian apparatus**

**LA21****Minor anomalies of pinnae**

Any condition caused by failure of the pinna to correctly develop during the antenatal period. These conditions are characterised by asymptomatic abnormalities of the visible part of the ear.

**LA21.0****Macrotia**

- 1) Median longitudinal ear length greater than 2 SD above the mean and median ear width greater than 2 SD above the mean (objective).
- 2) Apparent increase in length and width of the pinna (subjective).

**LA21.1****Protruding ear****LA21.2****Low-set ear**

The upper third of the pinna is not above a plane defined by the lateral canthi and the maximum convexity of the occiput.

**Exclusions:** cervical auricle (LA23)

**LA21.3****Misshapen ear**

A condition caused by the malformation of the ear during the antenatal period.

**Exclusions:** Acquired deformity of pinna (AA41)

**LA21.Y****Other specified minor anomalies of pinnae****LA21.Z****Minor anomalies of pinnae, unspecified****LA22****Structural developmental anomalies of ear causing hearing impairment**

Any condition caused by the failure of the ear to correctly develop during the antenatal period. These conditions are characterised by hearing impairment.

**LA22.0****Microtia**

Microtia is a congenital malformation of variable severity of the external and middle ear. Both hereditary factors (evidence for familial craniofacial microsomia and patterns suggestive of multifactorial inheritance)

and vascular accidents are involved in the etiology of the disease. Specific causative factors also can include maternal rubella during the first trimester of pregnancy. Microtia commonly involves the external canal and middle ear; hence, hearing can be affected. Microtia may present within a spectrum of branchial arch defects (hemifacial microsomia, craniofacial microsomia) or may manifest as an independent malformation. The microtic auricle consists of a disorganised remnant of cartilage attached to a variable amount of soft tissue lobule.

**LA22.1****Anotia**

Complete absence of any auricular structures.

**LA22.2****Aplasia or hypoplasia of external auditory canal**

**Exclusions:** Microtia (LA22.0)  
Anotia (LA22.1)

- LA22.3** **Structural developmental anomalies of ear ossicles**  
Any condition caused by failure of the ear ossicles to correctly develop during the antenatal period.
- LA22.4** **Structural developmental anomalies of inner ear**  
Any condition caused by failure of the inner ear to correctly develop during the antenatal period.
- LA22.Y** **Other specified structural developmental anomalies of ear causing hearing impairment**
- LA22.Z** **Structural developmental anomalies of ear causing hearing impairment, unspecified**
- LA23** **Otocephaly**  
Malplacement of the external ears with or without fusion microstomia, and persistence of the buccopharyngeal membrane likely being secondary effects of absence or hypoplasia of the mandibular arch.
- LA24** **Accessory auricle**  
A condition caused by development of an auricular appendage during the antenatal period.
- LA2Y** **Other specified structural developmental anomalies of the ear**
- LA2Z** **Structural developmental anomalies of the ear, unspecified**

Structural developmental anomalies of the face, mouth or teeth (LA30-LA5Z)  
Any condition caused by failure of the face, mouth and teeth to correctly develop during the antenatal period.

- Coded Elsewhere:** Dermoid cyst (LC40)  
Congenital micrognathia (DA0E.00)
- LA30** **Structural developmental anomalies of teeth and periodontal tissues**  
**Coded Elsewhere:** Disturbances in tooth formation (DA07.3)  
Root anomaly (DA07.4)  
Disturbances in tooth eruption (DA07.6)  
Anomalies of tooth position (DA0E.3)

- LA30.0** **Anodontia**  
Anodontia is a genetic disorder commonly defined as the absence of all teeth, affecting both temporary and permanent dentitions, and is extremely rarely encountered in a pure form without any associated abnormalities. Rare but more common than complete anodontia is hypodontia.

<b>LA30.1</b>	<b>Hypodontia</b> Hypodontia presents as a lack of one or a few (less than 6) permanent teeth, without any systemic disorders.
	<b>Inclusions:</b> Congenital absence of one tooth
<b>LA30.2</b>	<b>Oligodontia</b> A genetic condition characterised by the development of fewer than the normal number of teeth. The diagnosis of Oligodontia is usually made in cases in which more than six teeth are missing.
<b>LA30.3</b>	<b>Hyperdontia</b> Hyperdontia is the condition of having supernumerary teeth, or teeth which appear in addition to the regular number of teeth.
	<b>Inclusions:</b> Supplementary teeth Supernumerary teeth distomolar Fourth molar Mesiodens Paramolar
<b>LA30.4</b>	<b>Abnormalities of size or form of teeth</b> A group of conditions characterised by abnormal size and form of teeth.
<b>LA30.5</b>	<b>Anomalies in tooth resorption or loss</b> <b>Coded Elsewhere:</b> Pathological resorption of teeth (DA08.14)
<b>LA30.50</b>	Early exfoliation of teeth
<b>LA30.51</b>	Late exfoliation of teeth
<b>LA30.5Y</b>	Other specified anomalies in tooth resorption or loss
<b>LA30.5Z</b>	Anomalies in tooth resorption or loss, unspecified
<b>LA30.6</b>	<b>Amelogenesis imperfecta</b> Amelogenesis imperfecta presents with a rare abnormal formation of the enamel or external layer of the crown of teeth. Amelogenesis imperfecta is due to the malfunction of the proteins in the enamel: ameloblastin, enamelin, tuftelin and amelogenin. People afflicted with amelogenesis imperfecta have teeth with abnormal colour: yellow, brown or grey; this disorder can afflict any number of teeth of both dentitions. The teeth have a higher risk for dental cavities and are hypersensitive to temperature changes as well as rapid attrition, excessive calculus deposition, and gingival hyperplasia.
<b>LA30.7</b>	<b>Dentine dysplasia</b>
<b>LA30.8</b>	<b>Dentinogenesis imperfecta</b>
<b>LA30.9</b>	<b>Odontogenesis imperfecta</b>

<b>LA30.Y</b>	<b>Other specified structural developmental anomalies of teeth and periodontal tissues</b>
<b>LA30.Z</b>	<b>Structural developmental anomalies of teeth and periodontal tissues, unspecified</b>
<b>LA31</b>	<b>Structural developmental anomalies of mouth or tongue</b>
	Embryo fetal anomalies affecting structure of maxillo-labial or mandibular tissues or the tongue.
<b>LA31.0</b>	<b>Congenital macroglossia</b>
	A condition caused by failure of the tongue to correctly develop during the antenatal period. This condition is characterised by a larger than normal tongue.
<b>LA31.1</b>	<b>Hypoglossia or aglossia</b>
	Isolated aglossia and hypoglossia are terms covering the spectrum from partial to total absence of the tongue. These congenital malformations have been classified as part of the group of oromandibular-limb hypogenesis syndromes (OLHS).
<b>LA31.2</b>	<b>Ankyloglossia</b>
	A condition of the tongue, caused by short, tight, lingual frenulum or fusion of the tongue to the floor of the mouth. This condition is characterised by difficulty in speech articulation due to limitation or restriction in tongue movement.
	<i>Inclusions:</i> Tongue tie
<b>LA31.3</b>	<b>Macrostomia</b>
	Congenital macrostomia or transverse facial cleft is a rare congenital craniofacial anomaly. It is usually associated with deformities of other structures developed from the first and second branchial arches and is thought to be part of the manifestations of hemifacial microsomia, the second most common congenital craniofacial anomaly.
	<i>Inclusions:</i> Transverse facial cleft
<b>LA31.4</b>	<b>Microstomia</b>
	A condition of the mouth, caused by congenital genetic mutation, burns, or injury. This condition is characterised by reduction in the size of the oral aperture with or without involvement of the entire oral cavity.
<b>LA31.Y</b>	<b>Other specified structural developmental anomalies of mouth or tongue</b>
<b>LA31.Z</b>	<b>Structural developmental anomalies of mouth or tongue, unspecified</b>

## Clefts of lip, alveolus or palate (LA40-LA4Z)

A condition caused by failure of the structures of the mouth to correctly develop during the antenatal period. This condition is characterised by a fissure extending across the upper lip, nasal base, alveolar ridge or the palate. This condition may present with disruption of sucking or swallowing in neonates, recurrent otitis, transmission hypoacusia, or abnormalities of the maxillary lateral incisor.

**LA40**

### **Cleft lip**

Isolated cleft lip is a fissure type embryopathy extending from the upper lip to the nasal base.

**Exclusions:** Cleft lip and alveolus (LA41)

**LA40.0**

### **Cleft lip, unilateral**

**Exclusions:** Cleft lip and alveolus (LA41)

**LA40.1**

### **Cleft lip, bilateral**

A condition caused by failure of the upper lip to correctly develop during the antenatal period. This condition is characterised by two fissures in the upper lip and a collapsed and stretched nose through one side of the upper lip. This condition may present with disruption of sucking or swallowing in neonates.

**Exclusions:** Cleft lip and alveolus (LA41)

**LA40.2**

### **Cleft lip, median**

**Exclusions:** Cleft lip and alveolus (LA41)

**LA40.Z**

### **Cleft lip, unspecified**

**LA41**

### **Cleft lip and alveolus**

Cleft lip and alveolus is a fissure type embryopathy that involves the upper lip, nasal base and alveolar ridge in variable degrees.

**LA41.0**

### **Cleft lip and alveolus, unilateral**

**LA41.1**

### **Cleft lip and alveolus, bilateral**

**LA41.Z**

### **Cleft lip and alveolus, unspecified**

**LA42**

### **Cleft palate**

Cleft palate is a fissure type embryopathy that affects the soft and hard palate to varying degrees.

**LA42.0**

### **Cleft hard palate**

A condition caused by failure of the palate to correctly develop during the antenatal period. This condition is characterised by a fissure extending across the palate, including the bony portion of the palate. This condition may present with disruption of sucking or swallowing in neonates.

**LA42.1**

### **Cleft soft palate**

Cleft velum is a fissure type embryopathy that affects in varying degrees the soft palate.

<b>LA42.2</b>	<b>Cleft uvula</b> Bifid uvula is a fissure type embryopathy affecting the uvula at the back of the soft palate.
<b>LA42.Z</b>	<b>Cleft palate, unspecified</b>
<b>LA4Y</b>	<b>Other specified clefts of lip, alveolus or palate</b>
<b>LA4Z</b>	<b>Clefts of lip, alveolus or palate, unspecified</b>
<b>LA50</b>	<b>Congenital velopharyngeal incompetence</b> A condition caused by failure of the velum to correctly develop during the antenatal period. This condition is characterised by improper closing of the velopharyngeal sphincter, nasal speech, and difficulties in pronouncing certain letters or words.
<b>LA51</b>	<b>Facial clefts</b> Any condition caused by failure of the structures of the face to correctly develop during the antenatal period. These conditions are characterised by a partition in bone, soft tissue, or skin of the face.  <b>Exclusions:</b> Frontofacionasal dysostosis (LD25.3) Frontonasal dysplasia (LD25.3)
<b>LA52</b>	<b>Facial asymmetry</b> A condition caused by failure of the face to develop symmetrically during the antenatal period.
<b>LA53</b>	<b>Macrocheilia</b> A condition characterised by above normal lip volume. This condition may present with difficulties in speaking, drinking, salivary control, or mastication.
<b>LA54</b>	<b>Microcheilia</b> A condition caused by failure of the lips to develop correctly during the antenatal period. This condition is characterised by below normal lip size.
<b>LA55</b>	<b>Compression facies</b> A disease caused by neurovascular compression of the facial nerve. This disease is characterised by facial spasm, and abnormal facial expression.
<b>LA56</b>	<b>Pierre Robin syndrome</b> Pierre-Robin syndrome (or Pierre-Robin sequence) is characterised by triad of orofacial morphological anomalies consisting of retrognathia, glossoptosis and a posterior median velopatatal cleft. This condition is referred to as a sequence because the posterior cleft palate is a secondary defect associated with abnormal mandibular development: mandibular hypoplasia occurring early in gestation causes the tongue to be maintained high-up in the oral cavity, preventing fusion of the palatal shelves.
<b>LA5Y</b>	<b>Other specified structural developmental anomalies of the face</b>
<b>LA5Z</b>	<b>Structural developmental anomalies of the face, unspecified</b>

Structural developmental anomalies of the neck (LA60-LA6Z)

Any condition caused by failure of the neck to correctly develop during the antenatal period.

**Coded Elsewhere:** Thyroglossal cyst (DA05.Y)

**LA60**

**Webbed neck**

A condition caused by failure of the tissues of the neck to correctly develop during the antenatal period. This condition is characterised by a broad neck due to lateral folds of skin. This condition may present with limited range of motion of the neck.

**Inclusions:** Pterygium colli

**LA61**

**Congenital sternomastoid tumour**

**LA62**

**Congenital torticollis**

**LA6Y**

**Other specified structural developmental anomalies of the neck**

**LA6Z**

**Structural developmental anomalies of the neck, unspecified**

Structural developmental anomalies of the respiratory system (LA70-LA7Z)

**LA70**

**Structural developmental anomalies of the nose or cavum**

Any condition caused by failure of the nose and cavum to correctly develop during the antenatal period.

**LA70.0**

**Arrhinia**

Also called nasal agenesis, it is a very rare anomaly in which external nose does not develop and the nasal cavity is totally or partially obliterated.

**LA70.1**

**Bifid nose**

Isolated bifid nose is defined as a median cleft of the nose due to fusion anomalies of the medial nasal processes, that may involve the nasal tip only, or the nose on its length. Bifid nose may also be seen in multiple malformation syndromes like frontonasal dysplasia.

**LA70.2**

**Choanal atresia**

Any condition in neonates, caused by failure of the nose to correctly develop during the antenatal period. This condition is characterised by narrowing or blockage of the nasal airway by tissue. This condition may also present with chest retraction unless child is breathing through mouth or crying, difficulty breathing, cyanosis, and inability to nurse and breathe at same time.

**LA70.3**

**Congenital perforated nasal septum**

A condition caused by trauma during birth or by failure of the nasal septum to correctly develop during the antenatal period. This condition is characterised by the presence of a hole in the nasal septum.

**LA70.Y**

**Other specified structural developmental anomalies of the nose or cavum**

**LA70.Z**

**Structural developmental anomalies of the nose or cavum, unspecified**

**LA71**

### **Structural developmental anomalies of larynx**

Any condition caused by failure of the larynx to correctly develop during the antenatal period.

**Coded Elsewhere:** Airway obstruction in the neonate due to airway abnormality (KB2J)

Laryngeal lymphatic malformation (LA90.12)

**LA71.0**

#### **Congenital laryngomalacia**

A condition caused by failure of the larynx to correctly develop during the antenatal period. This disease is characterised by collapse of the supraglottic structures into the airway during the inspiratory phase of respiration, resulting in inspiratory stridor. This disease may also present with regurgitation, emesis, cough, choking, slow feedings, weight loss, failure to thrive, tachypnoea, suprasternal and substernal retractions, cyanosis, pectus excavatum, or obstructive sleep apnoea. Confirmation is through verification of supraglottic collapse by flexible laryngoscopy.

**LA71.1**

#### **Laryngocele**

A condition of the larynx, characterised by an abnormal saccular dilatation of the appendix of the laryngeal ventricle of Morgagni. This condition may also present with cough, hoarseness, stridor, sore throat, or swelling of the neck. Alternatively this condition may be asymptomatic.

**LA71.2**

#### **Laryngeal hypoplasia**

A condition caused by failure of the pharynx and larynx to correctly develop during the antenatal period. This condition is characterised by a narrowed airway and protrusion of intestines through the belly button. This condition may also present with high pitched voice, spinal curvature, or learning difficulties.

**LA71.3**

#### **Congenital subglottic stenosis**

A condition caused by failure of the tracheal rings to correctly develop during the antenatal period. This condition is characterised by inspiratory stridor. This condition may also present with shortness of breath, difficulty feeding, or failure to thrive. Confirmation is through observation of the stenosis by flexible laryngoscopy.

**LA71.Y**

#### **Other specified structural developmental anomalies of larynx**

**LA71.Z**

#### **Structural developmental anomalies of larynx, unspecified**

**LA72**

### **Laryngotracheo-oesophageal cleft**

A laryngo-tracheo-oesophageal cleft (LC) is a congenital malformation characterised by an abnormal, posterior, sagittal communication between the larynx and the pharynx, possibly extending downward between the trachea and the oesophagus. Five types of laryngo-tracheo-oesophageal cleft have been described based on the downward extension of the cleft, which typically correlates with the severity of symptoms: Type 0 laryngo-tracheo-oesophageal cleft to Type 4 laryngo-tracheo-oesophageal cleft (see these terms).

**LA73**

### **Structural developmental anomalies of trachea**

**Coded Elsewhere:** Congenital tracheobronchomegaly (CA27.1)

- LA73.0      Congenital stenosis of trachea**  
Tracheal stenosis is a fixed intrinsic narrowing of the trachea. The narrowing can be localised to a short or long tracheal segment, often due to a complete tracheal ring. Alternatively, the tracheal lumen may become progressively narrow caudally.  
**Inclusions:**                  Atresia of trachea
- LA73.1      Congenital tracheomalacia**  
Congenital tracheomalacia is a relatively uncommon anomaly that results from an intrinsic weakness of the cartilaginous support of the trachea such that it is prone to collapse especially during expiration.
- LA73.Y      Other specified structural developmental anomalies of trachea**
- LA73.Z      Structural developmental anomalies of trachea, unspecified**
- LA74      Structural developmental anomalies of bronchi**  
This refers to the structural developmental anomalies of the passage of airway in the respiratory tract that conducts air into the lungs.
- LA74.0      Congenital stenosis or atresia of bronchus**  
A condition caused by interruption of a lobar, segmental, or subsegmental bronchus with peripheral mucus impaction, during the antenatal period. This condition is characterised by hyperinflation of the blocked section of lung. This condition may present with respiratory distress, infiltrative pneumonia, or emphysema.
- LA74.1      Congenital bronchomalacia**  
Bronchus characterised by excessive dynamic collapse
- LA74.Y      Other specified structural developmental anomalies of bronchi**
- LA74.Z      Structural developmental anomalies of bronchi, unspecified**
- LA75      Structural developmental anomalies of lungs**  
Any condition caused by failure of the lungs to correctly develop during the antenatal period.
- LA75.0      Accessory lobe of lung**  
An extra lobe of lung beyond the 3 on the right and the 2 on the left
- LA75.1      Agenesis of lung**  
This refers to the absence or rudimentary residua of an undeveloped lung.
- LA75.2      Congenital hypoplasia of lung**
- LA75.3      Congenital hyperplasia of lung**

- LA75.4      Congenital pulmonary airway malformations**  
A disease caused by failure of the bronchial structure to correctly develop during the antenatal period. This disease may present with severe respiratory distress in the newborn period, acute respiratory distress or infection later in life, or may be asymptomatic. This disease can be distinguished from other lesions and normal lung by polypoid projections of the mucosa, an increase in smooth muscle and elastic tissue within the cyst walls, an absence of cartilage in the cystic parenchyma, mucous secreting cells, and the absence of inflammation.
- Inclusions:**      Congenital honeycomb lung  
                        Congenital polycystic disease of lung
- Exclusions:**      Cystic lung disease, acquired or unspecified (CB40)
- LA75.5      Congenital lobar emphysema**  
Congenital lobar emphysema is a developmental lung anomaly characterised by over distension of the affected lobe and leading to compression and displacement of adjacent normal lung tissue and mediastinum. In the majority of cases, symptoms appear during the neonatal period or in early childhood. Clinically, children present with signs of respiratory distress, frequently occurring with a lower respiratory tract infection that aggravates air trapping and renders the patient symptomatic.
- LA75.6      Congenital sequestration of lung**  
A medical condition wherein a piece of tissue that ultimately develops into lung tissue is not attached to the pulmonary arterial blood supply, as is the case in normally developing lung. As a result, this sequestered tissue is not connected to the normal bronchial airway. With intralobar sequestration, the lung tissue lies within the same visceral pleura as the lobe in which it occurs. With extralobar sequestrations, an accessory lung is contained within its own pleura
- LA75.Y      Other specified structural developmental anomalies of lungs**
- LA75.Z      Structural developmental anomalies of lungs, unspecified**
- LA76      Structural developmental anomalies of pleura**  
Anomalies of the lining of the lung (visceral pleura) and thoracic cavity (parietal pleura)
- LA77      Congenital cyst of mediastinum**  
A condition caused by failure of the anterior intestine or coelomic cavity to correctly develop during the antenatal period. This condition may be asymptomatic or may present with adjacent organ compression. Confirmation is observation of the cysts by imaging.
- LA7Y      Other specified structural developmental anomalies of the respiratory system**
- LA7Z      Structural developmental anomalies of the respiratory system, unspecified**

Structural developmental anomalies of the circulatory system (LA80-LA9Z)

## Structural developmental anomaly of heart or great vessels (LA80-LA8Z)

A congenital malformation of the heart and/or great vessels or an acquired abnormality unique to the congenitally malformed heart.

**Coded Elsewhere:** Congenital great vessel related acquired abnormality (BD52.6)

Congenital cardiac tumor, not otherwise specified (2F9Y)

**LA80**

### Anomalous position-orientation of heart

A congenital cardiovascular finding or malformation in which there is an abnormality of the position or orientation of heart.

**LA80.0**

#### **Laevocardia**

A congenital cardiovascular finding in which the heart is predominantly to the left of the thoracic midline.

**Coding Note:** This term should be coded only in the context of complex heart disease. This is independent of the orientation of the cardiac apex.

**LA80.1**

#### **Dextrocardia**

A congenital cardiovascular malformation in which the heart is predominantly to the right of the thoracic midline. This is independent of the orientation of the cardiac apex.

**Exclusions:**

Isomerism of left atrial appendages (LA80-LA8Z)

Isomerism of right atrial appendages (LA80-LA8Z)

Total mirror imagery (LA82)

**LA80.2**

#### **Mesocardia**

A congenital cardiovascular malformation in which the heart is central or midline within the thorax.

**LA80.3**

#### **Extrathoracic heart**

A congenital cardiovascular malformation in which the heart is at least partially outside of the thorax.

**LA80.Y**

#### **Other specified anomalous position-orientation of heart**

**LA80.Z**

#### **Anomalous position-orientation of heart, unspecified**

**LA81**

### **Abnormal ventricular relationships**

A congenital cardiovascular malformation in which the ventricular positions relative to each other or their laterality (sidedness) are abnormal.

**LA82**

### **Total mirror imagery**

A congenital malformation in which there is complete mirror-imaged arrangement of the internal organs along the left-right axis of the body.

**Inclusions:** Situs inversus totalis

**Exclusions:** dextrocardia NOS (LA80.1)

laevocardia (LA80.0)

Primary ciliary dyskinesia, Kartagener type (LA75)

Kartagener triad (LA75)

**LA83**

### **Right isomerism**

A congenital cardiovascular malformation that is a variant of heterotaxy syndrome in which some paired structures on opposite sides of the left-right axis of the body are symmetrical mirror images of each other, and have the morphology of the normal right-sided structures.

**LA84**

### **Left isomerism**

A congenital cardiovascular malformation that is a variant of an heterotaxy syndrome in which some paired structures on opposite sides of the left-right axis of the body are symmetrical mirror images of each other, and have the morphology of the normal left-sided structures.

**LA85**

### **Congenital anomaly of an atrioventricular or ventriculo-arterial connection**

A congenital cardiovascular malformation in which one or more of the following connections is abnormal 1) the morphologically right atrium to the morphologically right ventricle, 2) the morphologically left atrium to the morphologically left ventricle, 3) the morphologically right ventricle to the pulmonary trunk, 4) the morphologically left ventricle to the aorta.

This excludes codes for hearts with a univentricular atrioventricular connection (mitral atresia, tricuspid atresia and double inlet ventricle), as these are listed under Functionally Univentricular Heart.

**Exclusions:** Functionally univentricular heart (LA89)

**LA85.0**

### **Discordant atrioventricular connections**

A congenital cardiovascular malformation in which the morphologically right atrium connects to the morphologically left ventricle and the morphologically left atrium connects to the morphologically right ventricle.

**LA85.00**

### **Congenitally corrected transposition of great arteries**

A congenital cardiac malformation in which the morphologically right atrium connects to the morphologically left ventricle, the morphologically left atrium connects to the morphologically right ventricle, the morphologically right ventricle connects to the aorta, and the morphologically left ventricle connects to the pulmonary trunk.

**Inclusions:** corrected transposition

**LA85.0Y**

### **Other specified discordant atrioventricular connections**

- LA85.0Z** Discordant atrioventricular connections, unspecified
- LA85.1** **Transposition of the great arteries**  
A congenital cardiovascular malformation in which the morphologically right ventricle or its remnant connects to the aorta and the morphologically left ventricle or its remnant connects to the pulmonary trunk.
- LA85.2** **Double outlet right ventricle**  
A congenital cardiovascular malformation in which both great arteries arise entirely or predominantly from the morphologically right ventricle.
- LA85.20** Double outlet right ventricle with subpulmonary ventricular septal defect, transposition type  
A congenital cardiovascular malformation that is a variant of double outlet right ventricle with concordant atrioventricular connections that is associated with a subpulmonary ventricular septal defect (includes Taussig-Bing heart).
- LA85.21** Double outlet right ventricle with non-committed ventricular septal defect  
A congenital cardiovascular malformation that is a variant of double outlet right ventricle with concordant atrioventricular connections that is associated with ventricular septal defect that is remote from the ventricular outflow tracts and usually within the inlet or trabecular muscular septum.
- LA85.22** Double outlet right ventricle with subaortic or doubly committed ventricular septal defect without pulmonary stenosis, ventricular septal defect type  
A congenital cardiovascular malformation that is a variant of double outlet right ventricle with concordant atrioventricular connections, a subaortic or doubly-committed (with absence or deficiency of the conal septum) ventricular septal defect, and unobstructed pulmonary outflow tract.
- LA85.23** Double outlet right ventricle with subaortic or doubly committed ventricular septal defect and pulmonary stenosis, Fallot type  
A congenital cardiovascular malformation that is a variant of double outlet right ventricle with concordant atrioventricular connections, a subaortic or doubly-committed (with absence or deficiency of the conal septum) ventricular septal defect, and pulmonary outflow tract obstruction.
- LA85.2Y** Other specified double outlet right ventricle
- LA85.2Z** Double outlet right ventricle, unspecified
- LA85.3** **Double outlet left ventricle**  
A congenital cardiovascular malformation in which both great arteries arise entirely or predominantly from the morphologically left ventricle.
- LA85.4** **Common arterial trunk**  
A congenital cardiovascular malformation in which a single arterial trunk arises from the heart, giving origin sequentially to the coronary arteries, one or more pulmonary arteries, and the systemic arterial circulation.
- Inclusions:**
- persistent truncus arteriosus
  - truncus arteriosus

<b>LA85.40</b>	Common arterial trunk with aortic dominance A congenital cardiovascular malformation in which a common arterial trunk is associated with an unobstructed aortic arch.
<b>LA85.41</b>	Common arterial trunk with pulmonary dominance and interrupted aortic arch A congenital cardiovascular malformation in which a common arterial trunk is associated with an interrupted aortic arch.
<b>LA85.4Y</b>	Other specified common arterial trunk
<b>LA85.4Z</b>	Common arterial trunk, unspecified
<b>LA85.Y</b>	<b>Other specified congenital anomaly of an atrioventricular or ventriculo-arterial connection</b>
<b>LA85.Z</b>	<b>Congenital anomaly of an atrioventricular or ventriculo-arterial connection, unspecified</b>

## LA86

### **Congenital anomaly of mediastinal vein**

A congenital cardiovascular malformation in which there is an abnormality of a mediastinal vein including but not limited to: pulmonary veins, caval veins, coronary sinus, hepatic veins connecting to the heart, brachiocephalic veins, azygos veins, and/or levo-atrial cardinal veins.

## LA86.0

### **Left superior caval vein**

A congenital cardiovascular malformation in which there is a left superior caval vein (superior vena cava).

**Coding Note:** Unless the code for absent right superior caval vein is used, this term assumes that a right superior caval vein is present and, therefore, there are bilateral superior caval veins with or without a bridging vein.

## LA86.1

### **Unroofed coronary sinus**

A congenital cardiovascular malformation in which there is direct communication between the left atrium and the coronary sinus.

Additional information: this term includes partial and complete unroofing of the coronary sinus in the presence or absence of an interatrial communication. If an interatrial communication is present through the coronary sinus orifice then also select the term 'Interatrial communication through coronary sinus orifice'. If a left superior caval vein (superior vena cava) is present then one should also select the term for 'Left superior caval vein (superior vena cava) to left-sided atrium'.

**Coding Note:** If an interatrial communication is present through the coronary sinus orifice code also interatrial communication through coronary sinus orifice. If a left superior caval vein (superior vena cava) is present code also left superior caval vein (superior vena cava) to left-sided atrium.

## LA86.2

### **Anomalous pulmonary venous connection**

A congenital cardiovascular malformation in which one or more pulmonary vein does not connect normally to the morphologically left atrium.

- LA86.20** Total anomalous pulmonary venous connection  
A congenital cardiovascular malformation in which none of the pulmonary veins connect to the morphologically left atrium.
- LA86.21** Partial anomalous pulmonary venous connection  
A congenital cardiovascular malformation in which one or more (but not all) of the pulmonary veins connect anomalously to the right atrium or to one or more of its venous tributaries and the remaining pulmonary veins connect to the left atrium.
- LA86.22** Scimitar syndrome  
A congenital cardiopulmonary malformation with “partial anomalous pulmonary venous connection of Scimitar type” and one or more of the following: hypoplasia of the right lung with bronchial anomalies, dextrocardia, hypoplasia of the right pulmonary artery, lobar lung sequestration, and anomalous systemic arterial supply to the lower lobe of the right lung directly from the aorta or its main branches.
- LA86.2Y** Other specified anomalous pulmonary venous connection
- LA86.2Z** Anomalous pulmonary venous connection, unspecified
- LA86.3** **Congenital pulmonary venous stenosis or hypoplasia**  
A congenital cardiovascular malformation with a pathologic narrowing of one or more pulmonary veins including diffuse hypoplasia, long segment focal/tubular stenosis and/or discrete stenosis.
- LA86.Y** Other specified congenital anomaly of mediastinal vein
- LA86.Z** Congenital anomaly of mediastinal vein, unspecified
- LA87** **Congenital anomaly of an atrioventricular valve or atrioventricular septum**  
A congenital cardiovascular malformation in which there is an abnormality of the atrioventricular valve or atrioventricular septum.
- LA87.0** **Congenital anomaly of tricuspid valve**  
A congenital cardiovascular malformation in which there is an abnormality of the tricuspid valve.  
**Inclusions:** congenital anomaly of tricuspid subvalvular apparatus  
**Exclusions:** Tricuspid atresia (LA89.1)
- LA87.00** Congenital tricuspid regurgitation  
A congenital cardiovascular finding in which there is backward flow through the tricuspid valve.
- LA87.01** Congenital tricuspid valvar stenosis  
A congenital cardiovascular malformation of the tricuspid valve in which there is narrowing or stricture (obstruction to flow).

<b>LA87.02</b>	Dysplasia of tricuspid valve A congenital cardiovascular malformation of the tricuspid valve, commonly consisting of leaflet thickening and restricted mobility, with normally hinged leaflets.
<b>Coding Note:</b>	This diagnosis is not used for patients with Ebstein malformation of tricuspid valve, which is characterised by abnormally hinged tricuspid valve.
	<b>Exclusions:</b> Ebstein malformation of tricuspid valve (LA87.03)
<b>LA87.03</b>	Ebstein malformation of tricuspid valve A congenital cardiovascular malformation of the tricuspid valve and right ventricle that is characterised by incomplete delamination of the septal and inferior (posterior) tricuspid valvar leaflets from the myocardium of the right ventricle, and varying degrees of downward (apical) rotational displacement of the functional annulus.  Additional information: associated cardiac anomalies include an interatrial communication, the presence of accessory conduction pathways and varying degrees of right ventricular outflow tract obstruction, including pulmonary atresia. In the setting of discordant atrioventricular and ventriculo-arterial connections ['Congenitally corrected transposition of great arteries'], 'Ebstein malformation of tricuspid valve' may be present.
<b>LA87.0Y</b>	Other specified congenital anomaly of tricuspid valve
<b>LA87.0Z</b>	Congenital anomaly of tricuspid valve, unspecified
<b>LA87.1</b>	<b>Congenital anomaly of mitral valve</b> A congenital cardiac malformation in which there is an abnormality of the mitral valve.  <b>Exclusions:</b> Mitral atresia (LA89.2)
<b>LA87.10</b>	Congenital mitral regurgitation A congenital cardiovascular finding in which there is backward flow through the mitral valve.
<b>LA87.11</b>	Congenital mitral valvar stenosis A congenital cardiovascular malformation of the mitral valve in which there is narrowing or stricture of the valvar orifice (obstruction to flow).
<b>LA87.12</b>	Dysplasia of mitral valve A congenital cardiac malformation that includes any structural abnormality of the mitral valvar leaflet(s), commonly consisting of leaflet thickening and restricted mobility.
<b>LA87.13</b>	Congenital anomaly of mitral subvalvar apparatus A congenital cardiac malformation in which the mitral chords, chordal attachments, or papillary muscles are abnormal.
<b>LA87.1Y</b>	Other specified congenital anomaly of mitral valve
<b>LA87.1Z</b>	Congenital anomaly of mitral valve, unspecified

- LA87.3 Common atrioventricular junction without an atrioventricular septal defect**  
A congenital cardiac malformation in which there is a common atrioventricular junction without any communication at the level of the atrioventricular septum.  
Additional information: this code should be used when there is a trifoliate left atrioventricular valve in the setting of a common atrioventricular junction with evidence of obliteration of the atrioventricular septal defect by valve or subvalvar tissue. This should be distinguished from a 'True cleft of anterior mitral leaflet', without evidence of a common atrioventricular junction. Additional defects in the atrial or ventricular septums that do not involve the atrioventricular septum are not excluded by this term and should be coded separately.
- LA87.4 Common atrioventricular junction with atrioventricular septal defect**  
*Inclusions:*      AVC - [atrioventricular canal]
- LA87.40 Atrioventricular septal defect with communication at the atrial level only**  
A congenital cardiac malformation that is a variant of an atrioventricular septal defect (atrioventricular canal defect) with an interatrial communication just above the atrioventricular valve, no interventricular communication just below the atrioventricular valve, separate right and left atrioventricular valvar orifices, and varying degrees of malformation of the left sided component of the common atrioventricular valve.  
Additional information: the bridging leaflets of the common atrioventricular valve are bound down to the crest of the scooped out ventricular septum so that the potential for shunting through the atrioventricular septal defect is possible only at the atrial level and not at the ventricular level.
- LA87.41 Atrioventricular septal defect with communication at the ventricular level only**  
A congenital cardiac malformation that is a variant of an atrioventricular septal defect (atrioventricular canal defect) with an interventricular communication just below the atrioventricular valve, no interatrial communication just above the atrioventricular valve, separate right and left atrioventricular valvar orifices, and varying degrees of malformation of the left sided component of the common atrioventricular valve.  
Additional information: the bridging leaflets of the common atrioventricular valve are bound to the atrial septum so that the potential for shunting through the atrioventricular septal defect is possible only at the ventricular level and not at the atrial level.
- LA87.42 Atrioventricular septal defect with communication at atrial level and restrictive communication at ventricular level**  
A congenital cardiac malformation that is a variant of an atrioventricular septal defect (atrioventricular canal defect) with an interatrial communication immediately above the atrioventricular valve, and a restrictive interventricular communication immediately below the atrioventricular valve.

- LA87.43** Atrioventricular septal defect with communication at atrial level and unrestrictive communication at ventricular level  
A congenital cardiac malformation that is a variant of an atrioventricular septal defect (atrioventricular canal defect) with an interatrial communication just above the atrioventricular valve, an interventricular communication just below the atrioventricular valve, and varying degrees of malformation of the left ventricular component of the common atrioventricular valve.  
Additional information: there is unrestrictive interventricular communication (no interventricular pressure gradient) and the bridging leaflets usually float to varying extent within the atrioventricular septal defect.
- LA87.44** Atrioventricular septal defect with ventricular imbalance  
A congenital cardiac malformation that is a variant of an atrioventricular septal defect (atrioventricular canal defect) with one ventricle significantly larger than the other.  
Additional information: unbalanced ventricular size and unbalanced relation of the common atrioventricular valve to the ventricles are to be distinguished by coding unbalanced ventricular size as 'Atrioventricular septal defect with ventricular imbalance' and the unbalanced relation of the common atrioventricular valve to the ventricles should also be coded as 'Common atrioventricular valve with unbalanced commitment of valve to ventricles'.
- LA87.45** Atrioventricular septal defect and tetralogy of Fallot  
A congenital cardiac malformation with both an atrioventricular septal defect (atrioventricular canal defect) and tetralogy of Fallot.  
Additional information: tetralogy of Fallot with atrioventricular septal defect (common atrioventricular canal defect) is always the complete form (unrestrictive interventricular component) and very few or no attachments of the superior bridging leaflet to the crest of ventricular septum.
- LA87.4Y** Other specified common atrioventricular junction with atrioventricular septal defect
- LA87.4Z** Common atrioventricular junction with atrioventricular septal defect, unspecified
- LA87.Y** **Other specified congenital anomaly of an atrioventricular valve or atrioventricular septum**
- LA87.Z** **Congenital anomaly of an atrioventricular valve or atrioventricular septum, unspecified**
- LA88** **Congenital anomaly of a ventricle or the ventricular septum**  
A congenital cardiac malformation in which there is an abnormality of a ventricle and/or the ventricular septum. The ventricles include the ventricular inlet, ventricular body and ventricular outflow tract.

- LA88.0      Congenital right ventricular outflow tract obstruction**  
A congenital cardiovascular condition in which the flow through the right ventricular outflow tract (proximal to the valve[s] guarding the outflow from the right ventricle) is blocked or impeded.  
Additional information: this code should not be used for obstruction immediately under the arterial valve(s) because specific codes exist for these entities, such as congenital subpulmonary and subaortic stenosis.
- LA88.1      Double chambered right ventricle**  
A congenital cardiovascular malformation in which the right ventricle is divided into two chambers, one inferior including the inlet and trabecular portions of the right ventricle and one superior including the trabecular portion and infundibulum.  
Additional information: Double chamber right ventricle is often associated with one or several closing ventricular septal defects. In some cases, the ventricular septal defect is already closed. Double chamber right ventricle is differentiated from the rare isolated infundibular stenosis that develops more superiorly.
- LA88.2      Tetralogy of Fallot**  
A group of congenital cardiovascular malformations with biventricular atrioventricular alignments or connections characterised by anterosuperior deviation of the conal or outlet septum or its fibrous remnant, narrowing or atresia of the pulmonary outflow, a ventricular septal defect of the malalignment type, and biventricular origin of the aorta.  
Additional information: tetralogy of Fallot will always have a ventricular septal defect, narrowing or atresia of the pulmonary outflow, aortic override, and most often right ventricular hypertrophy.
- LA88.20     Tetralogy of Fallot with absent pulmonary valve syndrome**  
A congenital cardiovascular malformation that is a variant of tetralogy of Fallot in which the ventriculo-arterial junction of the right ventricle with the pulmonary trunk features an atypical valve with absent or rudimentary leaflets (cusps) that do not coapt.  
Additional information: in its usual form there is dilatation of the pulmonary trunk and central right and left pulmonary arteries, which when extreme, is associated with abnormal arborization of lobar and segmental pulmonary artery branches and with compression of the trachea and mainstem bronchi, often with tracheobronchomalacia. The physiologic consequence is usually a combination of variable degrees of both stenosis and regurgitation of the pulmonary valve.
- LA88.21     Tetralogy of Fallot with pulmonary atresia**  
A congenital cardiovascular malformation that is a variant of tetralogy of Fallot in which there is no direct communication between the right ventricle and the pulmonary arterial tree.
- Exclusions:***      Tetralogy of Fallot with pulmonary atresia and systemic-to-pulmonary collateral artery (LA88.22)

- LA88.22**      Tetralogy of Fallot with pulmonary atresia and systemic-to-pulmonary collateral artery  
A congenital cardiovascular malformation that is a variant of tetralogy of Fallot in which there is no direct communication between the right ventricle and the pulmonary arterial tree and there are collateral blood vessels between the systemic and pulmonary arteries.
- Coding Note:** This morphological abnormality usually is an integral part of other congenital cardiovascular anomalies and does not need to be coded separately. It should be coded as secondary to an accompanying congenital cardiovascular anomaly if the left ventricular hypoplasia is not considered an integral and understood part of the primary congenital cardiovascular diagnosis such as hypoplastic left heart syndrome.
- LA88.2Y**      Other specified tetralogy of Fallot
- LA88.2Z**      Tetralogy of Fallot, unspecified
- LA88.3**      **Congenital left ventricular outflow tract obstruction**  
A congenital cardiac condition in which the flow through the left ventricular outflow tract (proximal to the valve[s] guarding the outflow from the left ventricle) is blocked or impeded.  
This code should not be used for obstruction immediately under the arterial valve such as subaortic stenosis due to fibromuscular shelf or tunnel.
- LA88.4**      **Ventricular septal defect**  
A congenital cardiac malformation in which there is a hole or pathway between the ventricular chambers.
- LA88.40**      Trabecular muscular ventricular septal defect  
A congenital cardiac malformation in which there is a ventricular septal defect within the trabeculated component of the ventricular septum.  
Additional information: the codes specifying defects within the trabecular part of the ventricular septum should not be used to code inlet or outlet muscular defects, as there are specific codes for these entities.

**LA88.41****Perimembranous central ventricular septal defect**

A congenital cardiovascular malformation in which there is a ventricular septal defect that 1) occupies the space that is usually closed by the interventricular part of the membranous septum, 2) is usually adjacent to the area of fibrous continuity between the leaflets of an atrioventricular valve and an arterial valve, 3) is adjacent to an area of mitral-tricuspid fibrous continuity, and 4) is located at the center of the base of the ventricular mass.

Additional information: This code is used by some as synonymous with the perimembranous, conoventricular, Type II, or the paramembranous defects. Although best used to describe the perimembranous defect that opens centrally at the base of the right ventricle, this term might be used to code perimembranous defects with inlet or outlet extension. It is recommended, however, that the more precise terms be used whenever possible for coding the latter lesions. It should also not be used to code an inlet ventricular septal defect, or the so-called atrioventricular canal ventricular septal defect. More specific terms exist for coding these entities. It is used by some to describe an isolated perimembranous ventricular septal defect without extension, although it is unlikely that perimembranous defects exist in the absence of deficiency of their muscular perimeter. The conoventricular ventricular septal defect with malalignment should be coded as an outlet defect, as should the perimembranous defect opening to the outlet of the right ventricle. Such defects can also extend to become doubly committed and juxta-arterial (conal septal hypoplasia) when there is also fibrous continuity between the leaflets of the arterial valves or when there is a common arterial valve. Specific codes exist for these variants, which ideally should not be coded using this term.

**Coding Note:**

Although best used to describe the perimembranous defect that opens centrally at the base of the right ventricle, this term might be used to code perimembranous defects with inlet or outlet extension. It is recommended, however, that the more precise terms be used whenever possible for coding the latter lesions. This code is used by some as synonymous with the perimembranous, conoventricular, Type II, or the paramembranous defects. It should not be used to code an inlet VSD, or the so-called atrioventricular canal VSD. More specific terms exist for coding these entities. It is used by some to describe an isolated perimembranous VSD without extension, although it is unlikely that perimembranous defects exist in the absence of deficiency of their muscular perimeter. The conoventricular VSD with malalignment should be coded as an outlet defect, as should the perimembranous defect opening to the outlet of the right ventricle. All perimembranous defects, nonetheless, have part of their margins made up of fibrous continuity either between the leaflets of an atrioventricular and an arterial valve or, in the setting of double outlet right ventricle or overriding of the tricuspid valve, by fibrous continuity between the leaflets of the mitral and tricuspid valves. Such defects can also extend to become doubly committed and juxta-arterial (conal septal hypoplasia) when there is also fibrous continuity between the leaflets of the arterial valves or when there is a common arterial valve. Specific codes exist for these variants, which ideally should not be coded using this term.

<b>LA88.42</b>	Ventricular septal defect haemodynamically insignificant A congenital cardiac malformation in which there is one or more small, clinically insignificant ventricular septal defect(s) in the absence of flow-related cardiac chamber dilation or abnormal elevation of pulmonary arterial pressure.  Additional information: though restrictive ventricular septal defect is listed as a synonym of haemodynamically insignificant VSD, it should be recognised that some pressure restrictive ventricular septal defects will lead to flow-related chamber dilation, and thus would be haemodynamically significant. In such instances, the term haemodynamically insignificant ventricular septal defect should not be coded.
<b>LA88.4Y</b>	Other specified ventricular septal defect
<b>LA88.4Z</b>	Ventricular septal defect, unspecified
<b>LA88.Y</b>	<b>Other specified congenital anomaly of a ventricle or the ventricular septum</b>
<b>LA88.Z</b>	<b>Congenital anomaly of a ventricle or the ventricular septum, unspecified</b>
<b>LA89</b>	<p><b>Functionally univentricular heart</b></p> <p>The term “functionally univentricular heart” describes a spectrum of congenital cardiovascular malformations in which the ventricular mass may not readily lend itself to partitioning that commits one ventricular pump to the systemic circulation, and another to the pulmonary circulation.</p> <p>Additional information: a heart may be functionally univentricular because of its anatomy or because of the lack of feasibility or lack of advisability of surgically partitioning the ventricular mass. Common lesions in this category typically include double inlet right ventricle (DIRV), double inlet left ventricle (DILV), tricuspid atresia, mitral atresia, and hypoplastic left heart syndrome. Other lesions which sometimes may be considered to be a functionally univentricular heart include complex forms of atrioventricular septal defect, double outlet right ventricle, congenitally corrected transposition, pulmonary atresia with intact ventricular septum, and other cardiovascular malformations. Specific diagnostic codes should be used whenever possible, and not the term “functionally univentricular heart”.</p>
<b>LA89.0</b>	<p><b>Double inlet atrioventricular connection</b></p> <p>A congenital cardiovascular malformation with a univentricular atrioventricular connection wherein both atria connect to one ventricle either via two separate atrioventricular valves or a common atrioventricular valve, such that all or nearly all of the total atrioventricular junctional (annular) area is committed to one ventricular chamber.</p>
<b>LA89.1</b>	<p><b>Tricuspid atresia</b></p> <p>A congenital cardiovascular malformation with absence of the tricuspid valvar annulus (connection/junction) or an imperforate tricuspid valve.</p>
<b>LA89.2</b>	<p><b>Mitral atresia</b></p> <p>A congenital cardiovascular malformation with absence of the mitral valvar annulus (connection/junction) or an imperforate mitral valve.</p>

<b>LA89.3</b>	<b>Hypoplastic left heart syndrome</b> A spectrum of congenital cardiovascular malformations with normally aligned great arteries without a common atrioventricular junction, characterised by underdevelopment of the left heart with significant hypoplasia of the left ventricle including atresia, stenosis, or hypoplasia of the aortic or mitral valve, or both valves, and hypoplasia of the ascending aorta and aortic arch.
<b>LA89.Y</b>	<b>Other specified functionally univentricular heart</b>
<b>LA89.Z</b>	<b>Functionally univentricular heart, unspecified</b>
<b>LA8A</b>	<p><b>Congenital anomaly of a ventriculo-arterial valve or adjacent regions</b> A congenital cardiovascular malformation of a ventriculo-arterial valve or its immediate subvalvar and supravalvar regions.</p> <p><b>Exclusions:</b> Common arterial trunk (LA85.4)</p>
<b>LA8A.0</b>	<p><b>Congenital anomaly of pulmonary valve</b> A congenital malformation of the heart where the pulmonary valve is abnormal.</p>
<b>LA8A.00</b>	<p>Congenital pulmonary valvar stenosis A congenital cardiovascular malformation of the pulmonary valve in which there is narrowing or stricture causing obstruction to flow. Additional information: congenital pulmonary valvar stenosis ranges from critical neonatal pulmonic valve stenosis with hypoplasia of the right ventricle to valvar pulmonary stenosis in the infant, child, or adult.</p>
<b>LA8A.01</b>	<p>Congenital pulmonary regurgitation Congenital cardiovascular malformation of the pulmonary valve allowing backward flow into the ventricle. Congenital pulmonary valve regurgitation may be due to primary annular dilation, prolapse and leaflet underdevelopment.</p>
<b>LA8A.0Y</b>	Other specified congenital anomaly of pulmonary valve
<b>LA8A.0Z</b>	Congenital anomaly of pulmonary valve, unspecified
<b>LA8A.1</b>	<p><b>Congenital pulmonary atresia</b> A congenital cardiovascular malformation in which there is no opening between any ventricle and the pulmonary arterial tree.</p> <p><b>Exclusions:</b> Tetralogy of Fallot with pulmonary atresia (LA88.21)</p>

- LA8A.10** Pulmonary atresia with intact ventricular septum  
A congenital cardiovascular malformation in which there are normally aligned great arteries, no opening between the morphologically right ventricle and the pulmonary trunk, and no ventricular level communication.  
Additional information: pulmonary atresia with intact ventricular septum is a duct-dependent congenital malformation that forms a spectrum of lesions including atresia of the pulmonary valve, a varying degree of right ventricle and tricuspid valve hypoplasia, and anomalies of the coronary circulation. A right ventricular dependent coronary artery circulation is present when coronary artery fistulas are associated with a proximal coronary artery stenosis. Associated Ebstein anomaly of the tricuspid valve can be present.
- LA8A.1Y** Other specified congenital pulmonary atresia
- LA8A.1Z** Congenital pulmonary atresia, unspecified
- LA8A.2** **Congenital anomaly of aortic valve**  
A congenital cardiovascular malformation where the aortic valve is abnormal.
- LA8A.20** Congenital aortic valvar stenosis  
A congenital cardiovascular malformation of the aortic valve in which there is narrowing or stricture (obstruction to flow).  
Additional information: 'Congenital aortic valvar stenosis' arises most commonly as a result of partial or complete fusion of one or more commissures, or is due to dysplasia of one or more aortic cusps. These congenital malformations of the aortic valve may not be initially obstructive but may become stenotic later in life due to leaflet thickening, poor relative growth and/or calcification. It is not until the congenitally malformed aortic valve is or becomes stenotic that this term should be used.
- Exclusions:** Congenital subaortic stenosis (LA8A.5)  
that in hypoplastic left heart syndrome (LA89.3)
- LA8A.21** Congenital aortic regurgitation  
Congenital cardiovascular malformation of the aortic valve allowing backward flow into the ventricle.  
Additional information: congenital aortic regurgitation is rare as an isolated entity. Aortic regurgitation is more commonly seen with other associated congenital cardiac anomalies.
- LA8A.22** Bicuspid aortic valve  
A congenital abnormality of the heart where the aortic valve has two commissures and two separate leaflets because of fusion or absence of one of the commissures

<b>LA8A.23</b>	Aortic valvar atresia A congenital cardiovascular malformation in which there is no orifice of the aortic valve.  Additional information: aortic valvar atresia will most often not be coded independently, as it is frequently included within the 'Hypoplastic left heart syndrome' code as part of this spectrum of cardiovascular malformations. However, there is a small subset of patients with aortic valve atresia who have a well developed left ventricle and mitral valve and a large ventricular septal defect (nonrestrictive or restrictive).
<b>Coding Note:</b>	Aortic valve atresia will most often be coded under the hypoplastic left heart syndrome/complex diagnostic codes since it most often occurs as part of a spectrum of cardiovascular malformations. However, there is a small subset of patients with aortic valve atresia who have a well developed left ventricle and mitral valve and a large ventricular septal defect (nonrestrictive or restrictive).
<b>LA8A.24</b>	Unicuspid aortic valve A congenital cardiovascular malformation in which the aortic valve has a single commissure and a single or functionally single leaflet (cusp)
<b>LA8A.2Y</b>	Other specified congenital anomaly of aortic valve
<b>LA8A.2Z</b>	Congenital anomaly of aortic valve, unspecified
<b>LA8A.3</b>	<b>Congenital supravalvar aortic stenosis</b> A congenital cardiovascular malformation with narrowing of the aorta at the level of the sinotubular junction which may extend into the ascending aorta.  Additional information: 'Congenital supravalvar aortic stenosis' is described as three forms: an hourglass deformity, a fibrous membrane, and a diffuse narrowing of the ascending aorta. Supravalvar aortic stenosis may involve the coronary artery ostia, and the aortic leaflets may be tethered. The coronary arteries can become tortuous and dilated due to elevated pressures and early atherosclerosis may ensue.
	<b>Exclusions:</b> Congenital aortic valvar stenosis (LA8A.20)
<b>LA8A.4</b>	<b>Aneurysm of aortic sinus of Valsalva</b> A congenital cardiovascular malformation in which there is dilation of one or more sinuses of Valsalva.  Additional information: the sinus of Valsalva is defined as that portion of the aortic root between the aortic root annulus and the sinotubular junction. Sinus of Valsalva aneurysm most commonly originates from the right sinus, less commonly from the non-coronary sinus and rarely from the left sinus (<5%). The aneurysm may rupture into an adjacent chamber or site (right atrium, right ventricle, left atrium, left ventricle, pulmonary artery, pericardium) and in this case should be coded specifically ('Ruptured aortic sinus of Valsalva aneurysm'). This is to be distinguished from aortic root dilation associated with connective tissue disorders and aortopathies.
<b>LA8A.5</b>	<b>Congenital subaortic stenosis</b> <b>Exclusions:</b> Subaortic stenosis due to fibromuscular tunnel (LA8A) Subaortic stenosis due to fibromuscular shelf (LA8A)

<b>LA8A.6</b>	<b>Congenital subpulmonary stenosis</b> A congenital cardiovascular malformation associated with narrowing within the outflow tract supporting the pulmonary valve.  Additional information: subvalvar (infundibular) pulmonary stenosis is a narrowing of the outflow tract of the ventricle immediately below the pulmonic valve. This term should preferably be used in the setting of abnormal ventriculo-arterial connections, such as double outlet ventricle. Although subvalvar pulmonary stenosis is a type of right ventricular outflow tract obstruction if the ventriculo-arterial connections are normal, in this setting 'Congenital right ventricular outflow tract obstruction' should be used. Subvalvar pulmonary stenosis is also a type of left ventricular outflow tract obstruction in the setting of discordant ventriculo-arterial connections; this term should be used when the obstruction is only apparent immediately below the pulmonary valve, otherwise the term 'Congenital left ventricular outflow tract obstruction' should be used
	<b><i>Exclusions:</i></b> Double chambered right ventricle (LA88.1)
<b>LA8A.Y</b>	<b>Other specified congenital anomaly of a ventriculo-arterial valve or adjacent regions</b>
<b>LA8A.Z</b>	<b>Congenital anomaly of a ventriculo-arterial valve or adjacent regions, unspecified</b>
<b>LA8B</b>	<b>Congenital anomaly of great arteries including arterial duct</b> A congenital cardiovascular malformation of the great arteries (aorta, pulmonary trunk [main pulmonary artery], branch pulmonary arteries) or the arterial duct (ductus arteriosus).  <b><i>Exclusions:</i></b> Common arterial trunk (LA85.4)
<b>LA8B.0</b>	<b>Congenital aortopulmonary window</b> A congenital cardiovascular malformation in which there is side-to-side continuity of the lumens of the ascending aorta and pulmonary trunk in association with separate aortic and pulmonary valves or their atretic remnants.  Additional information: side-to-side continuity of the lumens of the aorta and pulmonary arterial tree, which is distinguished from common arterial trunk (truncus arteriosus) by the presence of two arterial valves or their atretic remnants, and involvement of the pulmonary trunk (main pulmonary artery).  <b><i>Inclusions:</i></b> Aortic septal defect Aortopulmonary window
<b>LA8B.1</b>	<b>Congenital anomaly of pulmonary arterial tree</b> A congenital cardiovascular malformation of the pulmonary trunk (main pulmonary artery) and/or branch pulmonary arteries (right, left, and ramifications).  <b><i>Inclusions:</i></b> Aberrant pulmonary artery Anomaly of pulmonary artery
<b>LA8B.2</b>	<b>Congenital anomaly of aorta or its branches</b> A congenital cardiovascular malformation of the aorta and/or its branches.

<b>LA8B.21</b>	<p>Coarctation of aorta</p> <p>A congenital cardiovascular malformation in which there is a discrete luminal narrowing of the junction between the aortic arch and the descending aorta.</p> <p>Additional information: 'Coarctation of the aorta' generally indicates a narrowing of the descending thoracic aorta just distal to the left subclavian artery. However, the term may also be accurately used to refer to a region of narrowing anywhere in the thoracic or abdominal aorta.</p>
<b>LA8B.22</b>	<p>Interrupted aortic arch</p> <p>A congenital cardiovascular malformation in which there is an absence of luminal continuity between the ascending and descending aorta.</p> <p>Additional information: this includes luminal atresia with discontinuity between the aortic segments and also luminal atresia with fibrous continuity between the aortic segments. Interrupted aortic arch is defined as the loss of luminal continuity between the ascending and descending aorta. In most cases, blood flow to the descending thoracic aorta is through a patent arterial duct, and there is a large ventricular septal defect. Arch interruption is further defined by site of interruption.</p> <p>In type A, interruption is distal to the left subclavian artery; in type B, interruption is between the left carotid and left subclavian arteries; and in type C, interruption occurs between the innominate and left carotid arteries.</p>
<b>LA8B.23</b>	<p>Congenital anomaly of descending thoracic or abdominal aorta</p> <p>A congenital cardiovascular malformation of the aorta distal to the aortic arch</p> <p><b>Coded Elsewhere:</b> Descending thoracic or abdominal aortic coarctation (LA8B.21)</p> <ul style="list-style-type: none"> <li>Coarctation of the descending thoracic aorta (LA8B.21)</li> <li>Coarctation of the abdominal aorta (LA8B.21)</li> </ul>
<b>LA8B.24</b>	<p>Congenital anomaly of aortic arch branch</p> <p>A congenital cardiovascular malformation of one or more branches of the aortic arch (innominate, carotid, or subclavian arteries).</p>
<b>LA8B.2Y</b>	Other specified congenital anomaly of aorta or its branches
<b>LA8B.2Z</b>	Congenital anomaly of aorta or its branches, unspecified
<b>LA8B.3</b>	<p><b>Tracheo-oesophageal compressive syndrome</b></p> <p>A congenital cardiovascular malformation which causes compression of the trachea and/or the oesophagus.</p>
<b>LA8B.4</b>	<p><b>Patent arterial duct</b></p> <p>A congenital cardiovascular finding in which the arterial duct (ductus arteriosus) is open beyond the normal age of spontaneous closure.</p> <p><b>Inclusions:</b> bilateral arterial ducts</p> <p><b>Coded Elsewhere:</b> Patent arterial duct of prematurity (KB48)</p>
<b>LA8B.Y</b>	Other specified congenital anomaly of great arteries including arterial duct
<b>LA8B.Z</b>	Congenital anomaly of great arteries including arterial duct, unspecified

**LA8C****Congenital anomaly of coronary artery**

A congenital cardiovascular malformation of a coronary artery. This includes absence of a coronary, anomalous origin or course, dilation or stenosis, and fistulas.

Additional information: congenital anomalies of the coronary venous system should not be included here but rather under 'Congenital anomaly of mediastinal systemic vein'.

**LA8C.0****Anomalous origin of coronary artery from pulmonary arterial tree**

A congenital cardiovascular malformation in which a coronary artery origin is the pulmonary trunk or one of its branches. Although the most common of these malformations involves the left coronary artery arising from the pulmonary trunk (main pulmonary artery) rather than from the aorta, occasionally the right coronary artery, the circumflex, or both coronary arteries may arise from any of the central pulmonary arteries.

**LA8C.1****Anomalous aortic origin or course of coronary artery**

A congenital cardiovascular malformation in which the origin and/or course of a coronary artery is abnormal.

This is where coronary "anomalies" in the presence of discordant ventriculo-arterial connections should be coded.

**LA8C.2****Congenital coronary arterial fistula**

A congenital cardiovascular malformation in which a coronary artery communicates, through an anomalous channel, with a cardiac chamber or with any segment of the systemic or pulmonary circulation.

Additional information: this communication may be simple and direct or may be tortuous and dilated. In order of frequency the involved coronary artery is the right, the left and, rarely, both coronary arteries. Occasionally multiple fistulas are present.

**Inclusions:** congenital coronary fistula to pulmonary artery

**Exclusions:** anomalous origin of coronary artery from pulmonary arterial tree (LA8C.0)

**LA8C.Y****Other specified congenital anomaly of coronary artery****LA8C.Z****Congenital anomaly of coronary artery, unspecified****LA8D****Congenital pericardial anomaly**

A congenital cardiovascular malformation in which there is a structural and/or functional abnormality of the pericardium.

**LA8E****Congenital anomaly of atrial septum**

A congenital cardiovascular malformation in which there is an abnormality of the atrial septum.

<b>LA8E.0</b>	<b>Patent oval foramen</b> A congenital cardiovascular finding in which there is a small interatrial communication (or potential communication) confined to the region of the oval fossa (fossa ovalis) characterised by no deficiency of the primary atrial septum (septum primum) and a normal limbus with no deficiency of the septum secundum (superior interatrial fold).
<b>LA8E.1</b>	<b>Atrial septal defect within oval fossa</b> A congenital cardiovascular malformation in which there is an interatrial communication confined to the region of the oval fossa (fossa ovalis), most commonly due to a deficiency of the primary atrial septum (septum primum) but deficiency of the septum secundum (superior interatrial fold) may also contribute.
<b>LA8E.2</b>	<b>Sinus venosus defect</b> A congenital cardiovascular malformation in which there is a caval vein (vena cava) and/or pulmonary vein (or veins) that overrides the atrial septum or the septum secundum (superior interatrial fold) producing an interatrial or anomalous veno-atrial communication.  Additional information: although the term sinus venosus atrial septal defect is commonly used, the lesion is more properly termed a sinus venosus communication because, while it functions as an interatrial communication, this lesion is not a defect of the atrial septum.
<b>LA8E.3</b>	<b>Interatrial communication through coronary sinus orifice</b> A congenital cardiovascular malformation in which there is a communication between the left atrium and the coronary sinus allowing interatrial communication through the coronary sinus ostium.  Additional information: 'Interatrial communication through coronary sinus orifice' may or may not be associated with a persistent left superior caval vein (superior vena cava). This occurs in the absence of the coronary sinus (total unroofing of the coronary sinus) or partial unroofing of the coronary sinus.
<b>LA8E.Y</b>	<b>Other specified congenital anomaly of atrial septum</b>
<b>LA8E.Z</b>	<b>Congenital anomaly of atrial septum, unspecified</b>
<b>LA8F</b>	<b>Congenital anomaly of right atrium</b> A congenital cardiovascular malformation in which there is an abnormality of the right atrium.
<b>LA8G</b>	<b>Congenital anomaly of left atrium</b> A congenital cardiovascular malformation in which there is an abnormality of the left atrium.

<b>LA8G.0</b>	<b>Divided left atrium</b> A congenital cardiac malformation in which there is a partition that divides the left atrium into a posterosuperior chamber that receives some or all of the pulmonary veins and an antero-inferior chamber that communicates with the left atrial appendage and atrioventricular junction (usually the mitral valve).  Additional information: in differentiating 'Divided left atrium' from 'Congenital supravalvar or intravalvar mitral ring', in the latter, the antero-inferior compartment contains only the mitral valvar orifice.
<b>LA8G.Y</b>	<b>Other specified congenital anomaly of left atrium</b>
<b>LA8G.Z</b>	<b>Congenital anomaly of left atrium, unspecified</b>
<b>LA8Y</b>	<b>Other specified structural developmental anomaly of heart or great vessels</b>
<b>LA8Z</b>	<b>Structural developmental anomaly of heart or great vessels, unspecified</b>
<b>LA90</b>	<b>Structural developmental anomalies of the peripheral vascular system</b>  <b>Exclusions:</b> Congenital anomaly of coronary artery (LA8C) Congenital anomaly of pulmonary arterial tree (LA8B.1) haemangioma and lymphangioma (2E81) Congenital retinal aneurysm (LA13.5)
<b>LA90.0</b>	<b>Capillary malformations</b> This is a vascular anomaly consisting of superficial and deep dilated capillaries in the skin which produce a reddish to purplish discolouration of the skin.  <b>Exclusions:</b> Macrocephaly - Cutis Marmorata Telangiectatica Congenita (LD2F.1)  <b>Coded Elsewhere:</b> Developmental capillary vascular malformations of the skin (LC50)
<b>LA90.00</b>	Hereditary haemorrhagic telangiectasia Rendu-Osler-Weber disease, also called hereditary haemorrhagic telangiectasia (HHT), is a genetic disorder of angiogenesis leading to arteriovenous dilatations: cutaneo-mucosal haemorrhagic telangiectasias and visceral shunting.
<b>LA90.0Y</b>	Other specified capillary malformations
<b>LA90.0Z</b>	Capillary malformations, unspecified
<b>LA90.1</b>	<b>Lymphatic malformations</b> Lymphatic malformations (LM), formerly referred to by the term lymphangioma, are malformations of the lymphatic system which result in obstructed lymphatic drainage. There are two types of LM: macrocystic LM (including cystic hygroma/lymphangioma) and tissue-infiltrating microcystic LM (lymphangioma circumspectum). The macro and microcystic forms of LM may occur in association.  <b>Coded Elsewhere:</b> Primary lymphoedema (BD93.0)

<b>LA90.10</b>	Macrocystic lymphatic malformation A condition caused by failure of the lymphatic system to correctly develop during the antenatal period. This condition is characterised by large, soft, smooth clear masses under normal or bluish skin. This condition may be associated with cellulitis, bleeding within the malformation, pain, or leakage of lymphatic fluid internally.
<b>LA90.11</b>	Microcystic lymphatic malformation Microcystic lymphatic malformations consist of clusters of dilated lymphatic vessels which have developed without connection to the systemic lymphatic circulation. They present with grouped clear or haemorrhagic vesicles anywhere on the skin or mucous membrane.
	<b>Inclusions:</b> Lymphangioma circumspectum
	<b>Exclusions:</b> Circumscribed lymphatic malformation (LA90.10)
<b>LA90.12</b>	Lymphatic malformations of certain specified sites
<b>LA90.13</b>	Cystic hygroma in fetus Development abnormalities of the lymphoid system that occur at sites of lymphatic-venous connection, most commonly in the posterior neck but may be anterior and may extend into chest. Frequently associated with karyotypic abnormalities, various malformation syndromes, and several teratogenic agents. When diagnosed prenatally, the overall prognosis is poor. Cystic hygroma diagnosed after birth is usually associated with a good prognosis.
<b>LA90.1Y</b>	Other specified lymphatic malformations
<b>LA90.1Z</b>	Lymphatic malformations, unspecified
<b>LA90.2</b>	<b>Peripheral venous malformations</b>
	<b>Coded Elsewhere:</b> Developmental venous malformations involving the skin (LC51) Blue rubber bleb naevus syndrome (LC51)
<b>LA90.20</b>	Vein of Galen aneurysm Vein of Galen aneurysmal malformation (VGAM) is a congenital vascular malformation characterised by dilation of the embryonic precursor of the vein of Galen. It is a sporadic lesion that occurs during embryogenesis. Cardiac insufficiency of variable severity is the principle manifestation that leads to detection of the malformation in newborns.
<b>LA90.21</b>	Congenital portosystemic shunt
<b>LA90.2Y</b>	Other specified peripheral venous malformations
<b>LA90.2Z</b>	Peripheral venous malformations, unspecified

<b>LA90.3</b>	<b>Peripheral arteriovenous malformations</b> This is a peripheral, abnormal connection between arteries and veins, bypassing the capillary system. This vascular anomaly is widely known because of its occurrence in the central nervous system, but can appear in any location.  <b>Inclusions:</b> congenital arteriovenous varices NOS <b>Exclusions:</b> acquired arteriovenous aneurysm (BD52.1) <b>Coded Elsewhere:</b> Arteriovenous malformation of cerebral vessels (8B22.40)
<b>LA90.30</b>	Portal vein-hepatic artery fistula
<b>LA90.31</b>	Arteriovenous malformation of precerebral vessels
<b>LA90.32</b>	Uterine arteriovenous malformations
<b>LA90.3Y</b>	Other specified peripheral arteriovenous malformations
<b>LA90.3Z</b>	Peripheral arteriovenous malformations, unspecified
<b>LA90.4</b>	<b>Peripheral arterial malformations</b> This is a peripheral lesion with a direct connection between an artery and a vein, without an intervening capillary bed, but with an interposed nidus of dysplastic vascular channels in between.  <b>Coded Elsewhere:</b> Hereditary cerebrovascular diseases (8B22.C)
<b>LA90.40</b>	Congenital renal artery stenosis This is the congenital narrowing of the renal artery, most often caused by atherosclerosis or fibromuscular dysplasia. This narrowing of the renal artery can impede blood flow to the target kidney.
<b>LA90.41</b>	Congenital precerebral nonruptured aneurysm
<b>LA90.42</b>	Congenital cerebral nonruptured aneurysm This is a cerebrovascular disorder in which weakness in the wall of a cerebral artery or vein causes a localised dilation or ballooning of the blood vessel (nonruptured).  <b>Coded Elsewhere:</b> Familial cerebral saccular aneurysm (8B22.6)
<b>LA90.4Y</b>	Other specified peripheral arterial malformations
<b>LA90.4Z</b>	Peripheral arterial malformations, unspecified
<b>LA90.5</b>	<b>Pulmonary arteriovenous fistula</b> A congenital cardiovascular malformation in which there is an abnormal, direct connection between a pulmonary artery and pulmonary vein or left atrium without an intervening capillary bed.
<b>LA90.Y</b>	<b>Other specified structural developmental anomalies of the peripheral vascular system</b>
<b>LA90.Z</b>	<b>Structural developmental anomalies of the peripheral vascular system, unspecified</b>

**LA9Y**      **Other specified structural developmental anomalies of the circulatory system**

**LA9Z**      **Structural developmental anomalies of the circulatory system, unspecified**

Structural developmental anomalies of the diaphragm, abdominal wall or umbilical cord (LB00-LB0Z)

Any condition caused by failure of the diaphragm, abdominal wall or umbilical cord to correctly develop during the antenatal period.

**Exclusions:**      Prune belly syndrome (LD2F.10)

**LB00**      **Structural developmental anomalies of diaphragm**

**LB00.0**      **Congenital diaphragmatic hernia**

Congenital diaphragmatic hernia is a posterolateral defect of the diaphragm that allows passage of abdominal viscera into the thorax, leading to respiratory insufficiency and persistent pulmonary hypertension with high mortality.

**Exclusions:**      Congenital hiatus hernia (LB13.1)

**LB00.1**      **Absence of diaphragm**

**LB00.Y**      **Other specified structural developmental anomalies of diaphragm**

**LB00.Z**      **Structural developmental anomalies of diaphragm, unspecified**

**LB01**      **Omphalocele**

Omphalocele is an embryopathy classified in the group of abdominal celosomias and is characterised by a large hernia of the abdominal wall, centred on the umbilical cord, in which the protruding viscera are protected by a sac.

**Exclusions:**      Umbilical hernia (DD53)

**LB02**      **Gastroschisis**

Gastroschisis is a congenital abdominal wall defect characterised by viscera protruding, without a covering sac, from the fetal abdomen on the right lateral base of the umbilicus.

**LB03**      **Structural developmental anomalies of umbilical cord**

Any condition caused by failure of the umbilical cord to correctly develop during the antenatal period.

**Coded Elsewhere:** Umbilical cord haemangioma (2E81.00)

Fetus or newborn affected by short umbilical cord (KA03.20)

Fetus or newborn affected by long umbilical cord (KA03.21)

Developmental anomalies of the umbilicus (EC50)

**LB03.0**      **Allantoic duct remnants or cysts**

Any condition caused by failure of the umbilical cord to correctly develop during the antenatal period. These conditions are characterised by cysts or remnants of allantoic tissue within the umbilical cord, the umbilicus, or the urachus.

<b>LB03.1</b>	<b>Single umbilical cord artery</b>
	A single umbilical artery arising from either the allantoic arterial system (Type I) or vitelline artery (Type II). It has been associated with renal anomalies.
<b>LB03.Y</b>	<b>Other specified structural developmental anomalies of umbilical cord</b>
<b>LB03.Z</b>	<b>Structural developmental anomalies of umbilical cord, unspecified</b>
<b>LB0Y</b>	<b>Other specified structural developmental anomalies of the diaphragm, abdominal wall or umbilical cord</b>
<b>LB0Z</b>	<b>Structural developmental anomalies of the diaphragm, abdominal wall or umbilical cord, unspecified</b>

Structural developmental anomalies of the digestive tract (LB10-LB1Z)

Any condition caused by failure of the digestive tract to correctly develop during the antenatal period.

**Coded Elsewhere:** Genetic or developmental disorders involving lips or oral mucosa (DA02.0)

<b>LB10</b>	<b>Structural developmental anomalies of salivary glands or ducts</b>
	Any condition caused by failure of the salivary glands and ducts to correctly develop during the antenatal period.

<b>LB11</b>	<b>Congenital diverticulum of pharynx</b>
	A condition caused by failure of the pharynx to correctly develop during the antenatal period. This condition may present with difficulty swallowing, or may be asymptomatic. Confirmation is through observation of a diverted pharynx by imaging.

**Exclusions:** pharyngeal pouch syndrome (LD44.N0)

<b>LB12</b>	<b>Structural developmental anomalies of oesophagus</b>
	Any congenital defect of oesophagus that results from interference with the normal growth and differentiation of the fetus. Such defects can arise at any stage of embryonic development, vary greatly in type and severity, and are caused by a wide variety of determining factors, including genetic mutations, chromosomal aberrations, teratogenic agents, and environmental factors. Most developmental defects are apparent at birth, especially any structural malformation, but some become evident later.

**Coded Elsewhere:** Bronchopulmonary foregut malformation (LA74.Y)

<b>LB12.0</b>	<b>Congenital oesophageal web or ring</b>
	A rare form of incomplete oesophageal obstruction due to a developmental defect of the primitive foregut that presents as a mucosal lesion forming an incomplete diaphragm. Symptoms (apparent from birth) include dysphagia, regurgitation, and choking.

**Exclusions:** Oesophageal web (DA20.2)

<b>LB12.1</b>	<b>Atresia of oesophagus</b> Oesophageal atresia encompasses a group of congenital anomalies with an interruption in the continuity of the oesophagus, with or without persistent communication with the trachea. In 86% of cases there is a distal tracheoesophageal fistula, in 7% of cases there is no fistulous connection, while in 4% of cases there is a tracheoesophageal fistula without atresia. The remaining cases are made up of patients with OA with proximal, or both proximal and distal, tracheoesophageal fistula.
	<b>Coded Elsewhere:</b> Laryngotracheooesophageal cleft (LA72)
<b>LB12.10</b>	Atresia of oesophagus with oesophagobronchial fistula
<b>LB12.1Y</b>	Other specified atresia of oesophagus
<b>LB12.1Z</b>	Atresia of oesophagus, unspecified
<b>LB12.2</b>	<b>Oesophageal fistula without atresia</b> This is a birth defect (congenital anomaly) of oesophagus, and one type of EA/TEF, namely isolated "H"-shaped atresia. Tracheoesophageal fistula in which there is no oesophageal atresia because the oesophagus is continuous to the stomach. Fistula is present between the oesophagus and the trachea. Incidence of TE fistula without atresia varies between 1-11% of oesophageal malformations.
<b>LB12.3</b>	<b>Congenital stenosis or stricture of oesophagus</b> A form of incomplete oesophageal obstruction due to a developmental defect of the primitive foregut. Abnormal narrowing of the oesophagus occurs most often at the junction of the middle and lower thirds. Clinical manifestations, apparent 2 to 3 weeks after birth, include dysphagia and progressive vomiting.
<b>LB12.4</b>	<b>Congenital diverticulum of oesophagus</b> A very rare congenital diverticulum which is typically located just above the cricopharyngeal junction. It is usually asymptomatic unless complicated by an inflammatory process. If the diverticulum compresses the trachea or is associated with oesophageal stenosis or fistula, the symptoms of stridor, progressive dysphagia, respiratory distress, severe choking, and regurgitation may be present from birth.  <b>Inclusions:</b> Congenital oesophageal pouch oesophageal pouch  <b>Exclusions:</b> Diverticulum of oesophagus, acquired (DA20.1)
<b>LB12.5</b>	<b>Congenital dilatation of oesophagus</b> This is a congenital abnormal enlargement of the lower portion of the oesophagus, as seen in patients with achalasia.
<b>LB12.Y</b>	<b>Other specified structural developmental anomalies of oesophagus</b>
<b>LB12.Z</b>	<b>Structural developmental anomalies of oesophagus, unspecified</b>

**LB13****Structural developmental anomalies of stomach**

Any congenital defect of stomach that results from interference with the normal growth and differentiation of the fetus. Such defects can arise at any stage of embryonic development, vary greatly in type and severity, and are caused by a wide variety of determining factors, including genetic mutations, chromosomal aberrations, teratogenic agents, and environmental factors. Most developmental defects are apparent at birth, especially any structural malformation, but some become evident later.

**Coded Elsewhere:** Gastric volvulus (DA40.2)

**LB13.0****Congenital hypertrophic pyloric stenosis**

A not uncommon congenital malformation of the stomach of unknown cause in which there is hypertrophy and hyperplasia of the circular muscle of the pylorus. Symptoms of gastric outlet obstruction usually appear between the third and sixth weeks of life. The anomaly is manifested by intermittent vomiting (which increases in frequency and becomes projectile), regurgitation, weight loss, dehydration, electrolyte imbalance, sometimes a small palpable pyloric mass, and visible peristaltic contractions across the epigastrium; there may also be jaundice. Some cases appear to be familial (possibly of autosomal dominant inheritance).

**LB13.1****Congenital hiatus hernia**

Congenital diaphragmatic hernia is an embryopathy which is defined by the absence of development of all or part of the diaphragmatic dome that results in the presence of abdominal viscera in the thorax, with compression of the homolateral lung and impaired development of the contralateral lung.

**Inclusions:** Congenital displacement of cardia through oesophageal hiatus

**Exclusions:** Congenital diaphragmatic hernia (LB00.0)

Diaphragmatic hernia (DD50.0)

**LB13.2****Congenital antral web****LB13.Y****Other specified structural developmental anomalies of stomach****LB13.Z****Structural developmental anomalies of stomach, unspecified****LB14****Structural developmental anomalies of duodenum**

Any congenital defect of duodenum that results from interference with the normal growth and differentiation of the fetus. Such defects can arise at any stage of embryonic development, vary greatly in type and severity, and are caused by a wide variety of determining factors, including genetic mutations, chromosomal aberrations, teratogenic agents, and environmental factors. Most developmental defects are apparent at birth, especially any structural malformation, but some become evident later.

**LB15****Structural developmental anomalies of small intestine**

Congenital gross anatomical structural defect of small intestine that results from interference with the normal growth and differentiation of the fetus, which may be inherited genetically, acquired during gestation, or inflicted during parturition.

<b>LB15.0</b>	<b>Meckel diverticulum</b> A congenital abnormality characterised by the outpouching or sac formation in the ileum. It is a remnant of the embryonic yolk sac in which the vitelline duct failed to close. During early gestation, the omphalomesenteric or vitelline duct connects the fetal yolk sac to the primitive gut. By 7-8 weeks of gestation, this duct is normally completely obliterated. A Meckel diverticulum results when this structure fails to resorb completely.
<b>LB15.1</b>	<b>Atresia of small intestine</b> Jejunoileal atresias and stenoses are major causes of neonatal intestinal obstruction. Atresia refers to a congenital obstruction with complete occlusion of the intestinal lumen. It accounts for 95% of obstructions. Four types of jejunoileal atresias are described. They can range from having a small area of blockage or web to missing large sections of the intestines.  Intestinal atresia is one of the most frequent causes of bowel obstruction in the newborn. The ileal atresia is more common than jejunal atresia, and multiple foci are more common than isolated atresia. The most accepted theory regarding the etiology of jejunoileal atresia is that of an intrauterine vascular accident resulting in necrosis of the affected segment.  Stenosis, on the other hand, refers to a partial occlusion with incomplete obstruction and accounts for the remaining 5% of cases. A stenosis has an intact mesentery and is a localised narrowing of the bowel. No loss of continuity of the lumen exists.  <i>Inclusions:</i> Congenital absence of small intestine Congenital stenosis of small intestine
<b>LB15.2</b>	<b>Congenital short bowel</b> Short bowel syndrome is a condition in which nutrients are not properly absorbed due to a congenital defect where a large part of the small intestine is missing.
<b>LB15.3</b>	<b>Congenital diverticulitis of small intestine</b> This refers to a clinical entity characterised by the presence of sac-like congenital herniations in the wall of the small intestine, in which the pouches of small intestine (diverticula) become infected or inflamed.
<b>LB15.4</b>	<b>Congenital diverticulosis of small intestine</b> This refers to a condition characterised by the presence of congenital multiple sack-like mucosal herniations called diverticula through weak points in the wall or lining of the small intestine. Most people with diverticulosis do not have any discomfort or symptoms. However, some people may experience pain or discomfort in the abdomen, bloating, and bleeding.
<b>LB15.5</b>	<b>Congenital diverticulum of small intestine</b> This refers to a morphological condition in which there is single small congenital pouch in the lining of the small intestine, bulging outward through a weak spot.
<b>LB15.Y</b>	<b>Other specified structural developmental anomalies of small intestine</b>
<b>LB15.Z</b>	<b>Structural developmental anomalies of small intestine, unspecified</b>

**LB16****Structural developmental anomalies of large intestine**

Any congenital defect of large intestine that results from interference with the normal growth and differentiation of the fetus. Such defects can arise at any stage of embryonic development, vary greatly in type and severity, and are caused by a wide variety of determining factors, including genetic mutations, chromosomal aberrations, teratogenic agents, and environmental factors. Most developmental defects are apparent at birth, especially any structural malformation, but some become evident later.

- Exclusions:**
- Congenital atresia of rectum (LB17)
  - Persistent cloaca (LB17.2)
  - Congenital atresia of anus (LB17)

**Coded Elsewhere:** Meconium ileus without perforation (KB87.2)

**LB16.0****Congenital absence, atresia or stenosis of large intestine**

Colonic atresia is a congenital intestinal malformation resulting in a non-latent segment of the colon and characterised by lower intestinal obstruction manifesting with abdominal distention and failure to pass meconium in newborns.

- Exclusions:**
- Congenital atresia of rectum (LB17)
  - Congenital absence of rectum (LB17)

**LB16.1****Hirschsprung disease**

This is a developmental anomaly affecting the intestinal tract characterised by congenital absence of myenteric ganglion cells (aganglionosis) in a segment of the large bowel. Due to the absence of intrinsic innervation of the muscle layers of the affected segment, there is a loss of motor function. This results in an abnormally large or dilated colon (congenital megacolon) with intestinal occlusion or constipation. This condition becomes evident shortly after birth.

**LB16.2****Immature ganglionosis of large intestine**

When the number of ganglion cells is normal but the ganglion cells are prominently immature, the disease is referred to as immature ganglionosis or immaturity of ganglia.

**LB16.3****Congenital hypoganglionosis of large intestine**

The number and size of ganglion cells are small at birth. The size of ganglion cells tends to increase over time, but because their numbers do not increase the symptoms of dysmotility do not improve.

Source: <http://www.ncbi.nlm.nih.gov/pubmed/17161202>

- Exclusions:**
- Acquired hypoganglionosis of large intestine (DB32.3)

**LB16.Y****Other specified structural developmental anomalies of large intestine****LB16.Z****Structural developmental anomalies of large intestine, unspecified****LB17****Structural developmental anomalies of anal canal**

- LB17.0 Anorectal malformations**
- Anorectal malformations (ARMs) are birth defects (due to alterations in embryo development of hindgut or proctodeum) where the anus and rectum (the lower end of the digestive tract) do not develop properly. They occur in approximately 1 in 5000 live births. These comprise a wide spectrum of diseases, which can affect boys and girls, and involve the distal anus and rectum as well as the urinary and genital tracts. Several abnormalities can occur, including the following: A membrane may be present over the anal opening; The rectum may not connect to the anus (imperforate anus); The rectum may connect to a part of the urinary tract or the reproductive system through an abnormal passage called a fistula. The classification of ARMs is mainly based on the position of the rectal pouch relative to the puborectal sling, the presence or absence of fistulas, and the types and locations of the fistulas. The following classification is according to the level of the atretic rectal cul-de-sac with respect to the pubococcygeal line (the radiological landmark for the upper border of the levator ani muscle).
- LB17.1 Ectopic anus**
- While children with imperforate or obviously mislocated anus are identified in the newborn period, some children with a very mild abnormality may escape identification until after the newborn period. This mild mislocation of the anus has been termed anterior ectopic anus. Anterior ectopic anus is different from imperforate anus with perineal fistula in that the anal opening is usually of normal size, and only mildly misplaced. Most of these children come to medical attention due to severe constipation.
- LB17.2 Persistent cloaca**
- A congenital anomaly in which the intestinal, urinary, and reproductive ducts open into a common cavity, a result of the failure of the urorectal septum to form during prenatal development. They occur exclusively in girls and comprise the most complex defect in the spectrum of anorectal malformations.
- LB17.3 Cloacal exstrophy**
- Rare and complex anorectal and genitourinary malformation in which rectum, vagina and urinary tract share a common everted orifice, accompanied by an omphalocele and an imperforate anus.
- Exstrophy of the cloaca is a well-known malformation that includes the persistence and the exstrophy of a cloaca that receives ureters, ileum and a rudimentary hindgut. Cloacal exstrophy is a severe birth defect wherein much of the abdominal organs (the bladder and intestines) are exposed. It often causes the splitting of both male and female genitalia (specifically, the penis and clitoris respectively), and the anus is occasionally sealed.
- LB17.4 Perineal groove**
- The perineal groove describes a normal vestibule but with a groove extending from the vestibule to the anus, which is both normal sized and positioned.
- LB17.Y Other specified structural developmental anomalies of anal canal**
- LB17.Z Structural developmental anomalies of anal canal, unspecified**

**LB18****Congenital anomalies of intestinal fixation**

A condition caused by failure of the intestines to correctly develop during the antenatal period. This condition may present with intermittent abdominal pain, vomiting, or diarrhoea. Confirmation is through observation of intestinal rotation by imaging.

**LB1Y****Other specified structural developmental anomalies of the digestive tract****LB1Z****Structural developmental anomalies of the digestive tract, unspecified**

Structural developmental anomalies of the liver, biliary tract, pancreas or spleen (LB20-LB2Z)

Any condition caused by failure of the liver, biliary tract, pancreas and spleen to correctly develop during the antenatal period.

**LB20****Structural developmental anomalies of gallbladder, bile ducts or liver**

Any condition caused by failure of the gallbladder, bile ducts and liver to correctly develop during the antenatal period.

**LB20.0****Structural developmental anomalies of liver**

**Exclusions:** Non-alcoholic fatty liver disease (DB92)

**Coded Elsewhere:** Biliary atresia (LB20.21)

**LB20.00**

Fibropolycystic liver disease

**Coded Elsewhere:** Choledochal cyst (LB20.20)

**LB20.0Y**

Other specified structural developmental anomalies of liver

**LB20.0Z**

Structural developmental anomalies of liver, unspecified

**LB20.1****Structural developmental anomalies of gallbladder****LB20.10**

Agenesis, aplasia or hypoplasia of gallbladder

**LB20.1Y**

Other specified structural developmental anomalies of gallbladder

**LB20.1Z**

Structural developmental anomalies of gallbladder, unspecified

**LB20.2****Structural developmental anomalies of bile ducts**

**Coded Elsewhere:** Congenital bronchobiliary fistula (LA74.Y)

**LB20.20**

Choledochal cyst

**Inclusions:** Congenital bile duct dilatation

**LB20.21**

Biliary atresia

Biliary atresia is a rare disease characterised by an inflammatory biliary obstruction of unknown origin that presents in the neonatal period. It is the most frequent surgical cause of cholestatic jaundice in this age group. Untreated, this condition leads to cirrhosis and death within the first years of life.

**LB20.22**

Congenital stenosis or stricture of bile ducts

<b>LB20.23</b>	Structural developmental anomalies of cystic duct
<b>LB20.24</b>	Accessory bile duct
<b>LB20.2Y</b>	Other specified structural developmental anomalies of bile ducts
<b>LB20.2Z</b>	Structural developmental anomalies of bile ducts, unspecified
<b>LB20.Y</b>	<b>Other specified structural developmental anomalies of gallbladder, bile ducts or liver</b>
<b>LB20.Z</b>	<b>Structural developmental anomalies of gallbladder, bile ducts or liver, unspecified</b>
<b>LB21</b>	<b>Structural developmental anomalies of pancreas</b>
<b>LB21.0</b>	<b>Annular pancreas</b> Annular pancreas is a distinct form of duodenal atresia in which the head of the pancreas forms a ring around the second portion of the duodenum. During the neonatal period, the clinical picture is dominated by epigastric distension with vomiting, which is nonbilious as the obstruction is usually supra-vaterian. Chromosomal abnormalities are present in one-third of cases of annular pancreas, with trisomy 21 (followed by trisomy 18 and 13) being the most frequently detected anomaly. Annular pancreas is an embryopathy resulting from an anomaly occurring early (towards the fourth week) in development.
<b>LB21.1</b>	<b>Pancreas divisum</b> This is a congenital anomaly in the anatomy of the ducts of the pancreas in which a single pancreatic duct is not formed, but rather remains as two distinct dorsal and ventral ducts.
<b>LB21.2</b>	<b>Accessory pancreas</b> Accessory pancreas is an asymptomatic embryopathy characterised by the presence of pancreatic tissue in other sites of the body such as the splenic pedicle, gonadic pedicles, intestinal mesentery, duodenum wall, upper jejunum, or, more rarely, the gastric wall, ileum, gallbladder or spleen.
<b>LB21.3</b>	<b>Agenesis-aplasia of pancreas</b> This refers to the failure of an organ to develop during embryonic growth and development due to the absence of primordial tissue of the pancreas.
<b>LB21.4</b>	<b>Partial agenesis of pancreas</b> Partial agenesis of the pancreas is characterised by the congenital absence of a critical mass of pancreatic tissue. The severity of the disease depends on the amount of functional pancreatic tissue present. Pancreatic agenesis is commonly associated with other malformations, in particular pancreaticobiliary duct anomalies, leading to acute or chronic pancreatitis, hyperglycaemia (50% of cases), or, more rarely, polysplenia.
<b>LB21.5</b>	<b>Hypoplasia of pancreas</b>
<b>LB21.Y</b>	<b>Other specified structural developmental anomalies of pancreas</b>
<b>LB21.Z</b>	<b>Structural developmental anomalies of pancreas, unspecified</b>

**LB22** **Structural developmental anomalies of spleen**  
Any condition caused by failure of the spleen to correctly develop during the antenatal period.

**Exclusions:** isomerism of atrial appendages (with asplenia or polysplenia) (LA80-LA8Z)

**LB22.0** **Congenital asplenia**  
A condition caused by failure of the spleen to develop during the antenatal period. This condition may present with pneumococcal sepsis. Confirmation is through verification of no spleen by imaging.

**LB22.1** **Polysplenia**  
A condition caused by the development of supernumerary spleens during the antenatal period. This condition may present with cardiac defects, anomalies in abdominal organs, or may be asymptomatic.

**LB22.2** **Ectopic spleen**

**LB22.Y** **Other specified structural developmental anomalies of spleen**

**LB22.Z** **Structural developmental anomalies of spleen, unspecified**

**LB2Y** **Other specified structural developmental anomalies of the liver, biliary tract, pancreas or spleen**

**LB2Z** **Structural developmental anomalies of the liver, biliary tract, pancreas or spleen, unspecified**

## Structural developmental anomalies of the urinary system (LB30-LB32)

Any condition caused by failure of the urinary system to correctly develop during the antenatal period.

LB30	<b>Structural developmental anomalies of kidneys</b> Any condition caused by failure of the kidneys to correctly develop during the antenatal period.
LB30.0	<b>Renal agenesis or other reduction defects of kidney</b> A series of conditions resulting in reduced kidney function including a congenital absence of both kidneys
LB30.00	Renal agenesis A condition where one or both kidneys does not form (or develop) in utero.
LB30.0Y	Other specified renal agenesis or other reduction defects of kidney
LB30.0Z	Renal agenesis or other reduction defects of kidney, unspecified
LB30.1	<b>Renal dysplasia</b> A condition characterised by abnormal development of one or both kidneys. <b>Exclusions:</b> Autosomal dominant polycystic kidney disease (GB81)

- LB30.2**      **Congenital single renal cyst**  
A single cyst in a kidney, noted in utero or from birth. No other structural abnormality of the kidney or urinary tract noted.
- LB30.3**      **Renal tubular dysgenesis**  
Abnormal renal development and kidney formation secondary to an underlying condition or exposure.
- LB30.4**      **Oligomeganephronia**  
Oligomeganephronic renal hypoplasia is a severe developmental defect of both kidneys characterised by a reduced number of nephrons (the functional unit of the kidney), hypertrophic glomeruli with diameters twice the normal size, hypertrophic tubules and thickening of Bowman's capsule, occurring in the absence of a urinary tract malformation.
- LB30.5**      **Accessory kidney**
- LB30.6**      **Fusion anomaly of kidneys**  
The embryological, incomplete fusion of renal lobules and/or kidneys
- LB30.60**      Lobulated kidney  
Any condition caused by incomplete fusion of the developing renal lobules during the antenatal period. This condition may be asymptomatic.
- LB30.61**      Fused pelvic kidney  
A condition caused by failure of the kidneys to correctly develop during the antenatal period. This condition is characterised by the presence of a single kidney, along the midline of the body. This condition may present with kidney stones, hydronephrosis, kidney infection, haematuria, or may be asymptomatic. Confirmation is through observation of a fused kidney by imaging.
- LB30.62**      Horseshoe kidney  
Horseshoe kidney is the most frequent renal fusion anomaly and is characterised by the union of the inferior poles of the two kidneys through an isthmus. Horseshoe kidney is in fact an anatomical anomaly rather than a disease, but it does lead to predisposition to certain conditions such as hydronephrosis, nephrolithiasis or pyelonephritis. One third of individuals with horseshoe kidney are asymptomatic, with the anomaly being discovered fortuitously during a radiological examination. Urogenital or renal vessel anomalies may be associated with the condition. For cases requiring treatment, various therapeutic approaches are available and choice of treatment depends on the associated pathology.
- LB30.6Y**      Other specified fusion anomaly of kidneys
- LB30.6Z**      Fusion anomaly of kidneys, unspecified

- LB30.7      Ectopic or pelvic kidney**  
A birth defect characterised by an abnormally positioned kidney; may be asymptomatic or result in urine blockage, infection or kidney stones  
**Inclusions:**            Congenital displaced kidney  
                                  Malrotation of kidney
- LB30.8      Medullary sponge kidney**  
A condition characterised by cystic or saccular dilatations of the medullary collecting ducts seen with radiocontrast filling. A predisposition to stones and associated often with renal tubular acidosis. There is no clear genetic predisposition.
- LB30.9      Multicystic renal dysplasia**  
A condition characterised by abnormal development of the kidney, specifically in which the abnormal kidney does not form a reniform structure but rather, a collection of non-communicating cysts, with no renal functional tissue.
- LB30.Y      Other specified structural developmental anomalies of kidneys**
- LB30.Z      Structural developmental anomalies of kidneys, unspecified**
- LB31      Structural developmental anomalies of urinary tract**  
Any condition caused by failure of the urinary tract to correctly develop during the antenatal period.  
**Coded Elsewhere:** Allantoic duct remnants or cysts (LB03.0)  
                                  Persistent urogenital sinus (LB42.Y)
- LB31.0      Congenital hydronephrosis**  
Congenital hydronephrosis is a renal urinary disease characterised by distension and dilation of the renal pelvis and calyces secondary to various congenital obstructive malformations of the kidneys and urinary tract that can evolve to renal atrophy.
- LB31.1      Congenital primary megaureter**  
Congenital primary megaureter is an idiopathic condition in which the bladder and bladder outlet are normal but the ureter is dilated to some extent. It may be obstructed, refluxing or unobstructed and not refluxing.
- LB31.2      Fetal lower urinary tract obstruction**  
A disease caused by partial or complete obstruction of the urethra, during the antenatal period. This disease can present with enlarged bladder, oligohydramnios, or pulmonary hypoplasia. Confirmation is through observation of the obstruction by imaging.

- LB31.3      Exstrophy of urinary bladder**  
Bladder exstrophy (or classic bladder exstrophy) is a congenital genitourinary malformation belonging to the spectrum of the exstrophy-epispadias complex and is characterised by an evaginated bladder plate, epispadias and an anterior defect of the pelvis, pelvic floor and abdominal wall.
- Inclusions:**      Ectopia vesicae  
                          Extroversion of bladder
- LB31.4      Congenital diverticulum of urinary bladder**  
A condition caused by failure of the bladder to correctly develop. This condition is characterised by weakness in the bladder wall through which some of the lining of the bladder protrudes. This condition may present with urinary tract infections, difficulty voiding, or abdominal fullness. This condition may also be asymptomatic.
- LB31.5      Duplication of urethra**  
A condition caused by failure of the urethra to correctly develop during the antenatal period. This condition is characterised by the presence of a second passage from the bladder. This condition may present with double urinary stream, urination from the anus, or may be asymptomatic. Confirmation is through observation of a second urethra by imaging.
- LB31.6      Congenital megalourethra**  
A condition caused by failure of the penile corpora cavernosa and spongiosa to correctly develop during the antenatal period. This condition is characterised by dilatation of the penile urethra. This condition may present with poor stream, swelling of the penis, megacystis, oligohydramnios, renal failure, or pulmonary hypoplasia.
- LB31.7      Megacystis-megaureter**  
Megacystic-megaureter syndrome describes the presence of a massive primary non-obstructive vesicoureteral reflux and a large capacity, smooth, thin walled bladder due to the continual recycling of refluxed urine. Recurrent urinary infections are commonly associated with this condition.
- LB31.8      Atresia or stenosis of ureter**  
A condition caused by blockage or narrowing of the ureter due to failure to correctly develop during the antenatal period. This condition may present with bladder outlet obstruction, low amniotic fluid volume, pulmonary hypoplasia, megacystis, hydronephrosis, or renal dysplasia.
- LB31.9      Agenesis of ureter**  
A condition caused by failure of the ureter to develop during the antenatal period. Confirmation verification that one or more ureters are missing by imaging.
- Inclusions:**      Absent ureter

<b>LB31.A</b>	<b>Duplication of ureter</b> A condition caused by failure of the ureter to correctly develop during the antenatal period, resulting in incorrect connection of the ureter to the kidney. This condition may present with ureteroureteral reflux, or ureteropelvic junction obstruction of the lower pole of the kidney in the case of incomplete duplication. Complete duplication may present with vesicoureteral reflux, ectopic ureterocele, or ectopic ureteral insertion. Confirmation is through observation of two ureters on one side by imaging.
	<b>Inclusions:</b> Double ureter Accessory ureter
<b>LB31.B</b>	<b>Malposition of ureter</b> A condition caused by failure of the ureter to correctly develop during the antenatal period, resulting in partial or complete duplication of the ureter. This condition may present with hydronephrosis, urinary tract infection, or incontinence in females. Confirmation is through observation of an incorrectly positioned ureter by imaging.
<b>LB31.C</b>	<b>Congenital absence of bladder or urethra</b> Any condition caused by failure of both the bladder and the urethra to develop during the antenatal period. This condition may result in fetal death, or sepsis and severe complications in cases of live births.
<b>LB31.D</b>	<b>Congenital vesico-uretero-renal reflux</b> A condition caused by failure of the ureter to develop correctly during the antenatal period. This condition may present with urinary tract infection, or may be asymptomatic.
<b>LB31.Y</b>	<b>Other specified structural developmental anomalies of urinary tract</b>
<b>LB31.Z</b>	<b>Structural developmental anomalies of urinary tract, unspecified</b>
<b>LB3Y</b>	<b>Other specified structural developmental anomalies of the urinary system</b>
<b>LB3Z</b>	<b>Structural developmental anomalies of the urinary system, unspecified</b>

Structural developmental anomalies of the female genital system (LB40-LB4Z)

**Exclusions:** Disorders of sex development leading to sexual ambiguity (LD2A)

<b>LB40</b>	<b>Structural developmental anomalies of vulva</b> A deformation established before birth of an anatomical structure of the vulva.
-------------	---

<b>LB40.0</b>	<b>Absence of vulva</b> This is a birth defect or congenital abnormality of the female genitourinary system that manifests itself in the absence of the vulva.
<b>LB40.1</b>	<b>Embryonic cyst of vulva</b> Remnant tissue from embryological development of the pelvic organs presenting as a closed fluid sac in or on the tissue of the vulva.

<b>LB40.2</b>	<b>Fusion of labia</b> A condition of the labia commonly affecting females between 6 months and 6 years of age, caused by skin irritation during infancy. This condition is characterised by the sealing of the labia minor (usually completely) due to a thin membrane that seals the entrance to the vagina, leaving a very small gap for urination.
<b>LB40.Y</b>	<b>Other specified structural developmental anomalies of vulva</b>
<b>LB40.Z</b>	<b>Structural developmental anomalies of vulva, unspecified</b>
<b>LB41</b>	<b>Structural developmental anomalies of clitoris</b> A deformation established before birth of an anatomical structure of the clitoris.
<b>LB41.0</b>	<b>Agenesis of clitoris</b>
<b>LB41.1</b>	<b>Duplication of clitoris</b> An anatomical anomaly present at birth in which there are two clitoral structures present.
<b>LB41.2</b>	<b>Clitoromegaly</b>
<b>LB41.Y</b>	<b>Other specified structural developmental anomalies of clitoris</b>
<b>LB41.Z</b>	<b>Structural developmental anomalies of clitoris, unspecified</b>
<b>LB42</b>	<b>Structural developmental anomalies of vagina</b> A deformation established before birth of an anatomical structure of the vagina.
<b>LB42.0</b>	<b>Absence of vagina</b> A condition of the genitourinary system affecting females, caused by an abnormality arising during the antenatal period. This condition is characterised by vaginal agenesis.
<b>LB42.1</b>	<b>Septate vagina</b> A condition of the genitourinary system affecting females, caused by the absence of Mullerian duct fusion during the antenatal period. This condition is characterised by a transverse or longitudinal septum, partitioning the vagina into two parts. This condition may also present with dyspareunia, abnormal vaginal bleeding, or is asymptomatic. Confirmation is by imaging. <b>Exclusions:</b> doubling of vagina with doubling of uterus and cervix (LB44.3)
<b>LB42.2</b>	<b>Congenital rectovaginal fistula</b> A condition of the genitourinary system affecting females, caused by an abnormality arising during the antenatal period. This condition is characterised by the formation of an abnormal passage between the rectum and the vagina. <b>Exclusions:</b> Persistent cloaca (LB17.2)

- LB42.3 Tight hymenal ring**  
A condition of the vagina, caused by determinants arising during the antenatal period. This condition is characterised by tightening of the hymen and stenosis of the external opening of the vagina, and dyspareunia.
- Inclusions:** Rigid hymen  
Tight introitus
- Exclusions:** Imperforate hymen (LB42.4)
- LB42.4 Imperforate hymen**  
A condition in which the hymen, the membrane that surrounds or partially covers the external vaginal opening, is harder than normal or is complete and sealed without any opening into the vaginal vault.
- LB42.5 Stricture or atresia of vagina**  
A condition of the vagina, caused by an abnormality arising during the antenatal period. This condition is characterised by stenosis and occlusion of the vaginal opening.
- Exclusions:** Postoperative adhesions of vagina (GC70)
- LB42.Y Other specified structural developmental anomalies of vagina**
- LB42.Z Structural developmental anomalies of vagina, unspecified**
- LB43 Structural developmental anomalies of cervix uteri**
- LB43.0 Embryonic cyst of cervix**  
A condition of the cervix, caused by a cluster of cells that have formed a closed sac or structures left behind from development during the antenatal period. This condition is characterised by air, fluid, or semi-solid material surrounded by a distinct membrane of cells with abnormal appearance and behaviour.
- LB43.1 Agenesis or aplasia of cervix**  
A condition of the cervix, caused by the absence of primordial tissue development during the antenatal period. This condition is characterised by improper or lack of development of the cervix.
- LB43.Y Other specified structural developmental anomalies of cervix uteri**
- LB43.Z Structural developmental anomalies of cervix uteri, unspecified**
- LB44 Structural developmental anomalies of uterus, except cervix**
- LB44.0 Agenesis or aplasia of uterine body**  
A condition of the uterus, caused by the absence of primordial tissue development during the antenatal period. This condition is characterised by improper or lack of development of the uterine body.
- LB44.1 Hypoplasia of uterus**

- LB44.2      Unicornuate uterus**  
A uterine malformation where the uterus is formed from one only of the paired Müllerian ducts while the other Müllerian duct does not develop or develops only in a rudimentary fashion.
- LB44.3      Bicornuate uterus**  
A condition of the uterus, caused by malformation in the development of the uterus during the antenatal period. This condition is characterised by a uterus with a bifurcated cephalo, and a unitary caudal part. Confirmation is by imaging.
- LB44.4      Septate uterus**  
Longitudinal septum in uterus, subclassified as complete or partial
- LB44.5      Congenital fistulae between uterus and digestive and urinary tracts**  
A condition caused by abnormal tissue development during the antenatal period. This condition is characterised by the formation of an abnormal passage between the uterus, digestive, and urinary tracts.
- LB44.6      Uterovaginal malformation due to diethylstilbestrol syndrome**  
Fetal diethylstilbestrol syndrome is characterised by a group of symptoms likely to occur in children and grandchildren of a woman who was treated while pregnant with diethylstilbestrol (DES). The drug is a synthetic nonsteroidal oestrogen, used in the US until 1971 and in Europe until 1978 to try and prevent miscarriage, premature delivery, and other pregnancy complications. It has been estimated that 25% of female fetuses exposed to DES in utero during the first trimester have subsequently developed genital tract anomalies including vaginal adenosis, cervical malformations, vaginal septae, uterine cavity anomalies, or fallopian tube anomalies causing subsequent fertility problems.
- LB44.Y      Other specified structural developmental anomalies of uterus, except cervix**
- LB44.Z      Structural developmental anomalies of uterus, except cervix, unspecified**
- LB45      Structural developmental anomalies of ovaries, fallopian tubes or broad ligaments**
- LB45.0      Congenital absence of ovary**  
A condition of the ovary, caused by determinants arising during the antenatal period. This condition is characterised by a female born with fewer than two ovaries.  
**Exclusions:**      Turner syndrome (LD50.0)
- LB45.1      46,XX gonadal dysgenesis**  
Karyotype 46 XX; Gonads: gonadal dysgenesis (streak gonads); Phenotype female with symptoms like primary amenorrhea, hypergonadotropic hypogonadism, normal stature and no other abnormalities.
- LB45.2      Developmental ovarian cyst**  
A condition in which an individual is born with a benign, functional cyst, or cysts, on one or more ovaries which result from enlargement of otherwise normal follicles during third trimester or early neonatal period.

- LB45.3 Congenital torsion of ovary**  
A condition of the ovary, caused by determinants arising during the antenatal period. This condition is characterised by a partial or complete rotation of the ovary, an occlusion to the venous or arterial blood supply of the ovary, severe lower abdominal pain that may radiate to the back, pelvis and thigh, and nausea, vomiting, diarrhoea or constipation.
- LB45.4 Accessory ovary**  
A condition of the ovary, caused by determinants arising during the antenatal period. This condition is characterised by excess ovarian tissue situated near an anatomically correct ovary, which may or may not be connected to the original ovarian tissue.
- LB45.5 Congenital absence of fallopian tube**  
A condition of the fallopian tube, caused by determinants arising during the antenatal period. This condition is characterised by a female born with fewer than two fallopian tubes.
- LB45.6 Atresia of fallopian tube**  
A condition of the fallopian tube, caused by determinants arising during the antenatal period. This condition is characterised by unilateral or bilateral closure or absence of the fallopian tube(s), commonly within the proximal isthmic or proximal ampillary segments.
- LB45.7 Accessory fallopian tube**  
A condition of the fallopian tube, caused by determinants arising during the antenatal period. This condition is characterised by the duplication of one or more fallopian tubes, commonly attached to the ampillary segment.
- LB45.8 Embryonic cyst of fallopian tube**  
A condition of the Fallopian tube, caused by the overgrowth of pelvic tissue during the antenatal period. This condition is characterised by air, fluid, or semi-solid material surrounded by a distinct membrane of cells with abnormal appearance and behaviour.  
*Inclusions:* Fimbrial cyst
- LB45.9 Embryonic cyst of broad ligament**  
Remnant tissue from embryological development of the development of the pelvic organs presenting as a closed fluid sac on the broad ligament.  
*Inclusions:* epoophoron cyst  
parovarian cyst
- LB45.Y Other specified structural developmental anomalies of ovaries, fallopian tubes or broad ligaments**
- LB45.Z Structural developmental anomalies of ovaries, fallopian tubes or broad ligaments, unspecified**
- LB4Y Other specified structural developmental anomalies of the female genital system**

**LB4Z****Structural developmental anomalies of the female genital system, unspecified**

Structural developmental anomalies of the male genital system (LB50-LB5Z)

Any condition affecting the male genital system, caused by determinants arising during the antenatal period. These conditions are characterised by structural developmental anomalies.

**Exclusions:** Disorders of sex development leading to sexual ambiguity (LD2A)

**LB50****Micropenis or penis agenesis**

A condition caused by reduced androgen production during the antenatal period. This condition is characterised by an absent, or unusually small penis. Confirmation is by measuring the length of a dorsal erectile penis.

**LB51****Anorchia or microorchidia**

A disorder affecting males, caused by an abnormality occurring in sex development during the antenatal period. This disorder is characterised by individuals who are born with absence of the testes, or with testes that are deficient in size and function. Confirmation is by physical examination, identification of low testosterone levels but elevated follicle stimulating hormone and luteinizing hormone levels in a blood sample, or imaging.

**Coded Elsewhere:** Testicular agenesis (LD2A.2)

**LB52****Cryptorchidism**

A disorder affecting males, caused by an abnormality occurring in sex development during the antenatal period. This disorder is characterised by the absence of one or both testes from the scrotum. This disorder may also present with reduced fertility, psychological implications, or increased risk of testicular germ cell tumours. Confirmation is by imaging, karyotyping, or identification of male sex hormones in a blood sample.

**Exclusions:** Retractile testis migrans (MF42)

**LB52.0****Ectopic testis**

A condition of the testis, caused by determinants arising during the antenatal period. This condition is characterised by the abnormal location of the testis away from the normal line of descent such as in the superficial inguinal pouch, perineal, abdominal, pelvic, crural, penile or femoral positions, and with normal testis and spermatic cord anatomy. Confirmation is by diagnostic laparoscopy to rule out an intra-abdominal, inguinal or absent/vanishing testis.

**LB52.1****Undescended testicle, unilateral**

The situation in which one of the two testicles in a male has not transitioned from the abdomen, and therefore appears absent from the scrotum.

**LB52.2****Undescended testicle, bilateral**

The situation in which both testicles in a male have not transitioned from the abdomen, and therefore appear absent from the scrotum.

**LB52.Y****Other specified cryptorchidism**

<b>LB52.Z</b>	<b>Cryptorchidism, unspecified</b>
<b>LB53</b>	<b>Hypospadias</b> Any condition of the urethra affecting males, caused by determinants arising during the antenatal period. These conditions are characterised by a malformation of the urethra and an abnormally placed urinary meatus. <b>Exclusions:</b> Epispadias (LB55)
<b>LB53.0</b>	<b>Hypospadias, balanic</b> A condition of the urethra affecting males, caused by determinants arising during the antenatal period. This condition is characterised by a malformation of the urethra and an abnormally placed urinary meatus that opens at the site of the frenulum. This condition may also present with an incomplete foreskin that forms a hood.
<b>LB53.00</b>	<b>Hypospadias, coronal</b> A condition of the urethra affecting males, caused by determinants arising during the antenatal period. This condition is characterised by a malformation of the urethra and the ventral side of the penis, leading to an abnormally placed urinary meatus that opens in the ventral portion of the coronal sulcus. This condition may also present with an incomplete foreskin that forms a hood.
<b>LB53.01</b>	<b>Hypospadias, glandular</b> A condition of the urethra affecting males, caused by determinants arising during the antenatal period. This condition is characterised by a malformation of the urethra and the ventral side of the penis, leading to an abnormally placed urinary meatus that opens at the site of the frenulum. This condition may also present with an incomplete foreskin that forms a hood.
<b>LB53.0Y</b>	<b>Other specified hypospadias, balanic</b>
<b>LB53.0Z</b>	<b>Hypospadias, balanic, unspecified</b>
<b>LB53.1</b>	<b>Hypospadias, penile</b> A condition of the urethra affecting males, caused by determinants arising during the antenatal period. This condition is characterised by a malformation of the urethra and the ventral side of the penis and an abnormally placed urinary meatus that opens along the shaft of the penis. This condition may also present with an incomplete foreskin that forms a hood.
<b>LB53.2</b>	<b>Hypospadias, penoscrotal</b> A condition of the urethra affecting males, caused by determinants arising during the antenatal period. This condition is characterised by a malformation of the urethra and the ventral side of the penis, leading to an abnormally placed urinary meatus that opens where the shaft of the penis meets the scrotum. This condition may also present with an incomplete foreskin that forms a hood.

- LB53.3 Hypospadias, scrotal**  
A condition caused by determinants arising during the antenatal period. This condition is characterised by a malformation of the urethra and the ventral side of the penis, leading to an abnormally placed urinary meatus that opens on the scrotum. This condition may also present with an incomplete foreskin that forms a hood.
- LB53.4 Hypospadias, perineal**  
A condition of the urethra affecting males, caused by determinants arising during the antenatal period. This condition is characterised by a malformation of the urethra and the ventral side of the penis and an abnormally placed urinary meatus that opens in the perineum. This condition may also present with an incomplete foreskin that forms a hood.
- LB53.Y Other specified hypospadias**
- LB53.Z Hypospadias, unspecified**
- LB54 Congenital chordee**  
A condition caused by the development of fibrous bands of tissue along the corpus spongiosum and shortening of the ventral skin during the antenatal period. This condition is characterised by ventral or dorsal curvature of the head of the penis at the junction with the shaft, most apparent during erection. This condition may also present with hypospadias.
- LB55 Epispadias**  
Epispadias is a congenital genitourinary malformation belonging to the spectrum of the exstrophy-epispadias complex and is characterised in males by an ectopic meatus or a mucosal strip in place of the urethra on the penile dorsum and in females by bifid clitoris and a variable cleft of the urethra.
- Exclusions:**      Hypospadias (LB53)
- LB56 Bifid scrotum**  
A condition caused by failure of the scrotum to correctly develop during the antenatal period resulting in incomplete fusion of the labioscrotal folds. This condition is characterised by a deep midline cleft in the scrotum. This condition may be asymptomatic.
- LB57 Agenesis of vas deferens**  
A condition of the vas deferens affecting males, caused by determinants arising during the antenatal period. This condition is characterised by the unilateral or bilateral absence of the vas deferens, azoospermia, and infertility.
- LB58 Polyorchidism**  
A condition of the testes, caused by determinants arising during the antenatal period. This condition is characterised by the presence of more than two testicles. Confirmation is by imaging.

**LB59**

**Hypoplasia of testis or scrotum**

A condition caused by incomplete development of the testis and scrotum during the antenatal period. This condition is characterised by a decrease or destruction in the number or size of cells testis and scrotal tissue.

**LB5Y**

**Other specified structural developmental anomalies of the male genital system**

**LB5Z**

**Structural developmental anomalies of the male genital system, unspecified**

Structural developmental anomalies of the breast (LB60-LB6Z)

A deformation established before birth of an anatomical structure of the breast or breast tissue.

**LB60**

**Breast aplasia**

A condition caused by failure of the breast to develop during the antenatal period. This condition is characterised by a total lack of breast tissue. This condition may also present with absence of the nipple or pectoral muscle.

**LB61**

**Absent nipple**

A condition caused by failure of the nipple to develop during the antenatal period. This condition is characterised by a total lack of a nipple. This condition may also present with absence of the breast or pectoral muscle.

**LB62**

**Supernumerary breasts**

A condition caused by failure of the breasts to correctly develop during the antenatal period. This condition is characterised by supernumerary breasts, with or without nipples. This condition may be asymptomatic.

**LB63**

**Accessory nipple**

A condition caused by development of supernumerary nipples during the antenatal period. This condition is characterised by the presence of nipples or nipple-like structures additional to the normal two. This condition may be asymptomatic.

**Inclusions:**              Supernumerary nipple

**LB6Y**

**Other specified structural developmental anomalies of the breast**

**LB6Z**

**Structural developmental anomalies of the breast, unspecified**

Structural developmental anomalies of the skeleton (LB70-LB9Z)

A deformation established before birth of an anatomical structure of one or more bones.

**LB70**

**Structural developmental anomalies of cranium**

Any condition caused by failure of the cranium to correctly develop during the antenatal period.

**Coded Elsewhere:** Wide cranial sutures of newborn (KD31)

<b>LB70.0</b>	<b>Craniosynostosis</b>
	Craniosynostosis consists of premature fusion of one or more cranial sutures, resulting in an abnormal head shape. It can be divided in several subgroups; the major different types are primary vs secondary craniosynostosis and isolated vs syndromic craniosynostosis.
	<b>Inclusions:</b> Imperfect fusion of skull
<b>LB70.00</b>	<b>Plagiocephaly</b>
	Isolated synostotic plagiocephaly is a form of nonsyndromic craniosynostosis characterised by premature fusion of one coronal or lambdoid suture leading to skull deformity and facial asymmetry.
<b>LB70.0Y</b>	<b>Other specified craniosynostosis</b>
<b>LB70.0Z</b>	<b>Craniosynostosis, unspecified</b>
<b>LB70.1</b>	<b>Wormian bones</b>
	Also known as intrasutural bone, is an additional bony segment interlocked in an existing cranial suture. A special form: Interparietal bone or Inca bone is an interlocked irregular isolated bone at the lambdoid suture. Although harmless it may be associated with craniofacial and other syndromes.
<b>LB70.2</b>	<b>J-shaped sella turcica</b>
<b>LB70.3</b>	<b>Macrocephaly</b>
	A condition characterised by above normal head size.
<b>Coding Note:</b>	Code also the causing condition
<b>LB70.Y</b>	<b>Other specified structural developmental anomalies of cranium</b>
<b>LB70.Z</b>	<b>Structural developmental anomalies of cranium, unspecified</b>
<b>LB71</b>	<b>Structural developmental anomalies of facial bones</b>
	Any condition caused by failure of the facial bones to correctly develop during the antenatal period.
	<b>Exclusions:</b> Facial clefts (LA51) Otomandibular dysplasia (LD2F.16) Agnathia (LA30-LA5Z) Micrognathia (DA0E.00)
<b>LB71.0</b>	<b>Hypotelorism</b>
	A condition caused by failure of the facial bones to correctly develop during the antenatal period. This condition is characterised by lower than normal distance between the eyes.
<b>LB71.1</b>	<b>Hypertelorism</b>
	A condition caused by failure of the facial bones to correctly develop during the antenatal period. This condition is characterised by higher than normal distance between the eyes.

<b>LB71.Y</b>	<b>Other specified structural developmental anomalies of facial bones</b>
<b>LB71.Z</b>	<b>Structural developmental anomalies of facial bones, unspecified</b>
<b>LB72</b>	<b>Structural developmental anomalies of shoulder girdle</b> Any condition caused by failure of the shoulder girdle to correctly develop during the antenatal period.
<b>LB72.0</b>	<b>Cervical rib</b>
<b>LB72.1</b>	<b>Sprengel deformity</b> A condition caused by failure of the pectoral girdle to correctly develop during the antenatal period. This condition is characterised by abnormal descent, and altered position and anatomy of the scapula. This condition may present with muscle hypoplasia.
<b>LB72.2</b>	<b>Deformation of scapula</b>
<b>LB72.Y</b>	<b>Other specified structural developmental anomalies of shoulder girdle</b>
<b>LB72.Z</b>	<b>Structural developmental anomalies of shoulder girdle, unspecified</b>
<b>LB73</b>	<b>Structural developmental anomalies of spine or bony thorax</b> Any condition caused by failure of the spine or bony thorax to correctly develop during the antenatal period.
<b>LB73.0</b>	<b>Occult spinal dysraphism</b> <p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Spina bifida occulta</li> <li>Cryptomerorachischisis</li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>meningocele (spinal) (LA02)</li> <li>Spina bifida aperta (LA02.1)</li> <li>Spina bifida cystica (LA02.0)</li> </ul>
<b>LB73.1</b>	<b>Structural developmental anomalies of chest wall</b> Any condition caused by failure of the chest wall to correctly develop during the antenatal period.
<b>LB73.10</b>	<b>Poland syndrome</b> Poland syndrome is characterised by a unilateral absence or hypoplasia of the pectoralis major muscle (most frequently involving the sternocostal portion), and a variable degree of ipsilateral hand anomalies, including symbrachydactyly.
<b>LB73.11</b>	<b>Bifid rib</b>
<b>LB73.12</b>	<b>Accessory rib</b> A condition caused by failure of the ribs to correctly develop during the antenatal period. This condition is characterised by a supernumerary rib arising from a cervical or lumbar vertebra. This condition may present with thoracic outlet syndrome, or may be asymptomatic.

- LB73.13** Structural developmental anomalies of sternum  
Any condition caused by failure of the sternum to correctly develop during the antenatal period.
- LB73.1Y** Other specified structural developmental anomalies of chest wall
- LB73.1Z** Structural developmental anomalies of chest wall, unspecified
- LB73.2** **Structural developmental anomalies of spine**  
Any condition caused by failure of the spine to correctly develop during the antenatal period.
- LB73.20** Klippel-Feil anomaly  
Klippel-Feil syndrome is characterised by improper segmentation of cervical segments resulting in congenitally fused cervical vertebrae.  
*Inclusions:* Cervical fusion syndrome
- LB73.21** Occipitalisation of atlas  
A condition caused by failure of the atlas and occiput to correctly develop during the antenatal period. This condition is characterised by fusion of the atlas to the base of the occiput. This condition may present with headache, suboccipital stiffness, restricted motion, or dizziness. Confirmation is through observation of the fusion by imaging.
- LB73.22** Atlanto-axial instability or subluxation  
A condition caused by bony or ligamentous abnormality of the upper spinal column. This condition is characterised by excessive movement at the junction between C1 and C2 vertebrae. This condition may present with impaired rotation of the neck, neurological difficulties, or may be asymptomatic.
- LB73.23** Aplasia or hypoplasia of the odontoid process of axis
- LB73.24** Segmentation anomalies of vertebrae  
Any condition caused by failure of the vertebrae to correctly develop during the antenatal period. These conditions are characterised by an abnormal number of fully developed vertebrae. Confirmation is through verification of absent or improperly formed vertebrae by imaging.
- LB73.25** Congenital scoliosis due to congenital bony malformation  
A condition caused by malformation of the ribs or spine. This condition is characterised by abnormal curving of the spine.  
*Exclusions:* congenital scoliosis NOS (LB73.2)
- LB73.26** Sacralisation of the last lumbar vertebra
- LB73.27** Lumbarisation of the first sacral vertebra
- LB73.28** Sacrum agenesis or hypoplasia

<b>LB73.29</b>	Caudal appendage A condition caused by development of a malformation on the lower back during the antenatal period. This condition is characterised by a cutaneous protrusion superior to the buttocks. This condition may be associated with occult spinal dysraphism.  <b>Exclusions:</b> Caudal regression sequence (LD2F.1)
<b>LB73.2A</b>	Congenital spondylolisthesis A condition caused by vertebral malformation, which allows the vertebra to slip forward over the sacrum. This condition may present with lower back pain, or may be asymptomatic.  <b>Exclusions:</b> acquired spondylolisthesis (FA84) acquired spondylolysis (FA81)
<b>LB73.2Y</b>	Other specified structural developmental anomalies of spine
<b>LB73.2Z</b>	Structural developmental anomalies of spine, unspecified
<b>LB73.Y</b>	<b>Other specified structural developmental anomalies of spine or bony thorax</b>
<b>LB73.Z</b>	<b>Structural developmental anomalies of spine or bony thorax, unspecified</b>
<b>LB74</b>	<b>Structural developmental anomalies of pelvic girdle</b> Any condition caused by failure of the pelvic girdle to correctly develop during the antenatal period.  <b>Exclusions:</b> Clicking hip (ME80)
<b>LB74.0</b>	<b>Developmental dysplasia of hip</b> A condition caused by failure of the hip to correctly develop during the antenatal period. This condition is characterised by slippage of the hip from the socket. This condition may present with outward turning of the leg, reduced movement on one side of the body, shortness of one leg, uneven skin folds on thigh or buttocks, walking difficulties, or inward rounding of the lower back.
<b>LB74.1</b>	<b>Congenital subluxation of hip</b>
<b>LB74.2</b>	<b>Unstable hip</b> A condition caused by failure of the hip joint to correctly develop during the antenatal period. This condition is characterised by looseness of the hip joint. This condition may present with dislocation, multidirectional intra-operative instability, abductor insufficiency, or neuromuscular disability.
<b>LB74.3</b>	<b>Congenital coxa vara</b> A condition caused by failure of the hip joint to correctly develop during the antenatal period. This condition is characterised by a decrease in the femoral neck-shaft angle. This condition may present with a shortened leg, or a limp.
<b>LB74.4</b>	<b>Congenital coxa valga</b> A condition caused by failure of the hip joint to correctly develop during the antenatal period. This condition is characterised by an increase in the femoral neck-shaft angle.

- LB74.5** **Wide symphysis pubis**
- LB74.Y** **Other specified structural developmental anomalies of pelvic girdle**
- LB74.Z** **Structural developmental anomalies of pelvic girdle, unspecified**
- LB75** **Brachydactyly**  
Brachydactyly ('short digits') is a general term that refers to disproportionately short fingers and toes, and forms part of the group of limb malformations characterised by bone dysostosis. The various types of isolated brachydactyly are rare, except for types A3 and D.
- LB75.0** **Brachydactyly of fingers**  
A condition caused by failure of the fingers to correctly develop during the antenatal period. This condition is characterised by below normal finger length.
- LB75.1** **Brachydactyly of toes**  
A condition caused by failure of the toes to correctly develop during the antenatal period. This condition is characterised by below normal toe length.
- LB75.2** **Sybrachydactyly of hands or feet**  
A condition caused by failure of the digits to correctly develop during the antenatal period. This condition is characterised by short digits, which may be webbed. This condition may also present with missing digits, shortened metacarpals, or short limb sections.
- LB75.Y** **Other specified brachydactyly**
- LB75.Z** **Brachydactyly, unspecified**
- LB76** **Triphalangeal thumb**  
A condition caused by failure of the thumb to correctly develop during the antenatal period. This condition is characterised by a long, finger-like thumb with three phalanges instead of two. Isolated triphalangeal thumbs may be associated with genetic abnormality in the 7q36 region.
- LB77** **Hyperphalangy**  
Hyperphalangy is a congenital, non-syndromic limb malformation characterized by the presence of an accessory phalanx between metacarpal/metatarsal and proximal phalanx, or between any two other phalanges of a digit, excluding the thumb. Hyperphalangy is almost always bilateral and patients present no more than five digits and no other skeletal anomalies.
- LB78** **Polydactyly**  
Any condition caused by development of supernumerary fingers during the antenatal period.
- LB78.0** **Polydactyly of the thumb**  
A condition caused by development of supernumerary thumbs during the antenatal period.

<b>LB78.1</b>	<b>Polysyndactyly</b> Polysyndactyly is a form of preaxial polydactyly of fingers characterised by the presence of a thumb showing the mildest degree of duplication, being broad, bifid or with radially deviated distal phalanx. Syndactyly of various degrees of third-and-fourth fingers is occasionally present. Two forms have been characterised: unilateral and bilateral.
<b>LB78.2</b>	<b>Postaxial polydactyly of fingers</b> A condition caused by development of supernumerary fingers during the antenatal period. This condition is characterised by fifth digit duplications.
<b>LB78.3</b>	<b>Polydactyly of toes</b> Any condition caused by development of supernumerary toes during the antenatal period.
<b>LB78.Y</b>	<b>Other specified polydactyly</b>
<b>LB78.Z</b>	<b>Polydactyly, unspecified</b>
<b>LB79</b>	<b>Syndactyly</b> A condition caused by failure of the longitudinal interdigital necrosis that normally separates the digits during the antenatal period. This condition is characterised by the presence of two or more digits that are fused together. <i>Coded Elsewhere:</i> Polysyndactyly (LB78.1)
<b>LB79.0</b>	<b>Fused fingers</b> <i>Inclusions:</i> complex syndactyly of fingers with synostosis
<b>LB79.1</b>	<b>Webbed fingers</b> A condition caused by failure of the longitudinal interdigital necrosis that normally separates the fingers to during the antenatal period. This condition is characterised by the presence of two or more fingers that are fused together. <i>Inclusions:</i> Simple syndactyly of fingers without synostosis
<b>LB79.2</b>	<b>Fused toes</b> <i>Inclusions:</i> Complex syndactyly of toes with synostosis
<b>LB79.3</b>	<b>Webbed toes</b> A condition caused by failure of the longitudinal interdigital necrosis that normally separates the toes during the antenatal period. This condition is characterised by the presence of two or more toes that are fused together. <i>Inclusions:</i> Simple syndactyly of toes without synostosis
<b>LB79.Y</b>	<b>Other specified syndactyly</b>
<b>LB79.Z</b>	<b>Syndactyly, unspecified</b>

## Congenital deformities of fingers or toes (LB80-LB81.Z)

<b>LB80</b>	<b>Congenital deformities of fingers</b> Any condition caused by failure of the fingers to develop correctly during the antenatal period.  <b>Inclusions:</b> Congenital deformities of hand
<b>LB80.0</b>	<b>Clinodactyly of fingers</b> A condition caused by failure of the fifth finger to correctly develop during the antenatal period. This condition is characterised by bending of the fifth finger towards the fourth.
<b>LB80.2</b>	<b>Radial deviation of fingers</b>
<b>LB80.Y</b>	<b>Other specified congenital deformities of fingers</b>
<b>LB80.Z</b>	<b>Congenital deformities of fingers, unspecified</b>
<b>LB81</b>	<b>Congenital deformities of toes</b> <b>Coded Elsewhere:</b> Congenital hammer toe (LB98.5)
<b>LB81.0</b>	<b>Clinodactyly of toes</b>
<b>LB81.Y</b>	<b>Other specified congenital deformities of toes</b>
<b>LB81.Z</b>	<b>Congenital deformities of toes, unspecified</b>
<b>LB90</b>	<b>Joint formation defects</b> Any condition of the skeletal system, caused by failure of joints to correctly develop during the antenatal period.
<b>LB90.0</b>	<b>Humero-radio-ulnar synostosis</b> A condition caused by failure of the arm bones to correctly develop during the antenatal period. This condition is characterised by direct fusion of the humerus to the ulnar and radial bones of the arm, and consequent inability to straighten the elbow joint. This condition may be associated with thalidomide embryopathy. Confirmation is through observation of humero-radio-ulnar fusion by imaging.
<b>LB90.1</b>	<b>Humero-radial synostosis</b>
<b>LB90.2</b>	<b>Humero-ulnar synostosis</b> A condition caused by failure of the arm bones to correctly develop during the antenatal period. This condition is characterised by direct fusion of the humerus and radial bones of the arm, and consequent inability to straighten the elbow joint. Confirmation is through observation of humero-ulnar fusion by imaging.
<b>LB90.3</b>	<b>Radio-ulnar synostosis</b> A condition caused by failure of the arm bones to correctly develop during the antenatal period. This condition is characterised by direct fusion of the ulnar and radial bones of the arm, and consequent limitation of rotational movement of the forearm. Confirmation is through observation of radio ulnar fusion by imaging.

<b>LB90.4</b>	<b>Madelung deformity</b> Madelung disease, or deformity is a predominantly bilateral wrist anomaly characterised by shortened and bowed radii and long ulnae leading to dorsal dislocation of the distal ulna and limited mobility of the wrist and elbow.
<b>LB90.5</b>	<b>Congenital digital clubbing</b> Isolated congenital digital clubbing is a rare genodermatosis disorder characterised by enlargement of the terminal segments of fingers and toes with thickened nails without any other abnormality.
<b>LB90.6</b>	<b>Tibio-fibular synostosis</b>
<b>LB90.7</b>	<b>Cubitus valgus</b>
<b>LB90.8</b>	<b>Cubitus varus</b>
<b>LB90.Y</b>	<b>Other specified joint formation defects</b>
<b>LB90.Z</b>	<b>Joint formation defects, unspecified</b>
<b>LB91</b>	<b>Congenital shoulder dislocation</b>
<b>LB92</b>	<b>Congenital elbow dislocation</b>
<b>LB93</b>	<b>Congenital knee dislocation</b> A condition characterised by hyperextension of the knee joint.
<b>LB93.0</b>	<b>Congenital genu recurvatum</b>
<b>LB93.1</b>	<b>Congenital genu flexum</b>
<b>LB93.Y</b>	<b>Other specified congenital knee dislocation</b>
<b>LB93.Z</b>	<b>Congenital knee dislocation, unspecified</b>
<b>LB94</b>	<b>Congenital patella dislocation</b>
<b>LB95</b>	<b>Patella aplasia or hypoplasia</b> Isolated patella aplasia-hypoplasia is an extremely rare genetic condition characterised by congenital absence or marked reduction of the patellar bone. This condition may present with discomfort or abnormal gait. Confirmation is through verification of the reduced or absent patella by imaging
<b>LB96</b>	<b>Congenital bowing of long bones</b> Congenital bowing of long bones is a congenital condition described by the presence of symmetric or asymmetric angular deformity and shortening of the long bones, particularly the femurs, tibiae and ulnae.
<b>LB96.0</b>	<b>Congenital bowing of femur</b> A condition caused by failure of the femur to develop correctly during the antenatal period. This condition is characterised by abnormal angling of the femur. Confirmation is through observation of the bowed femur by imaging.

<b>LB96.1</b>	<b>Congenital bowing of tibia</b> A condition caused by failure of the tibia to develop correctly during the antenatal period. This condition is characterised by abnormal angling of the tibia. Confirmation is through observation of the bowed tibia by imaging.
<b>LB96.Y</b>	<b>Other specified congenital bowing of long bones</b>
<b>LB96.Z</b>	<b>Congenital bowing of long bones, unspecified</b>
<b>LB97</b>	<p><b>Limb overgrowth</b> Disproportionately long or asymmetric upper limbs</p> <p><b>Exclusions:</b> Hemihypertrophy (LD2C)</p>
<b>LB97.0</b>	<b>Macroductyly of fingers</b> A condition caused by failure of the fingers to correctly develop during the antenatal period. This condition is characterised by overgrowth of bone and soft tissue, resulting in larger than normal fingers. This condition may be asymptomatic.
<b>LB97.1</b>	<b>Macroductyly of toes</b>
<b>LB97.2</b>	<b>Upper limb hypertrophy</b>
<b>LB97.3</b>	<b>Lower limb hypertrophy</b>
<b>LB97.Y</b>	<b>Other specified limb overgrowth</b>
<b>LB97.Z</b>	<b>Limb overgrowth, unspecified</b>
<b>LB98</b>	<p><b>Congenital deformities of feet</b> Any condition caused by malformation of the foot during the antenatal period.</p>
<b>LB98.0</b>	<b>Congenital varus deformities of feet</b> Any condition caused by failure of the bones of the foot to correctly develop during the antenatal period. These conditions are characterised by twisting of parts of the foot inward from the centre of the body.
<b>LB98.00</b>	Talipes equinovarus A condition characterised by a foot that is fixated in adduction, in supination, and in varus. This condition may be associated with intrauterine position, genetic mutation, or can be idiopathic.
<b>LB98.01</b>	Talipes calcaneovarus
<b>LB98.02</b>	Metatarsus varus A condition characterised by medial rotation of the cuneiform bones at the midtarsal joint, with associated medial deviation of the metatarsal, resulting in adduction and supination of the forefoot.
<b>LB98.0Y</b>	Other specified congenital varus deformities of feet
<b>LB98.0Z</b>	Congenital varus deformities of feet, unspecified

- LB98.1**      **Congenital pes planus**  
Any condition caused by failure of the foot to correctly develop during the antenatal period. These conditions are characterised by severe rigid flat foot deformity.  
*Inclusions:*            congenital flat foot
- LB98.2**      **Congenital valgus deformities of feet**  
Any condition caused by failure of the bones of the foot to correctly develop during the antenatal period. These conditions are characterised by twisting of parts of the foot outward from the centre of the body.
- LB98.20**     Congenital hallux valgus  
A condition caused by failure of the hallux to correctly develop during the antenatal period. This condition is characterised by angling of the hallux medial to the metatarsophalangeal joint.
- LB98.21**     Metatarsus valgus  
A condition caused by failure of the bones of the foot to correctly develop during the antenatal period. This condition is characterised by rotation of the forepart of the foot outward from the midline of the body.
- LB98.22**     Talipes calcaneovalgus  
A condition caused by tightness of the muscles of the foot due to resting of the foot in a turned up position during the antenatal period. This condition is characterised by a foot that is turned upwards towards the shin.
- LB98.2Y**      Other specified congenital valgus deformities of feet
- LB98.2Z**      Congenital valgus deformities of feet, unspecified
- LB98.3**      **Congenital pes cavus**  
A condition characterised by a high arch of the foot that does not flatten with weight bearing.
- LB98.4**      **Congenital vertical talus**  
Isolated congenital vertical talus is a rare pedal deformity recognizable at birth by a dislocation of the talonavicular joint, resulting in a characteristic radiographic near-vertical orientation of the talus.
- LB98.5**      **Congenital hammer toe**  
A condition characterised by angling downwards of the toe.
- LB98.Y**      **Other specified congenital deformities of feet**
- LB98.Z**      **Congenital deformities of feet, unspecified**
- LB99**      **Reduction defects of upper limb**  
Any condition caused by the failure of an upper limb to correctly develop during the antenatal period. These conditions are characterised by reduction in size or absence of the limb.

- LB99.0      Amelia of upper limb**  
A condition caused by the failure of an upper limb to develop during the antenatal period. This condition is characterised by absence of the upper limb.
- LB99.1      Humeral agenesis or hypoplasia**
- LB99.2      Radial hemimelia**  
Radial hemimelia is a congenital longitudinal deficiency of the radius bone of the forearm characterised by partial or total absence of the radius.  
*Inclusions:*            Radial clubhand
- LB99.3      Ulnar hemimelia**  
Ulnar hemimelia is a congenital ulnar deficiency of the forearm characterised by complete or partial absence of the ulna bone.
- LB99.4      Congenital absence of upper arm or forearm with hand present**  
A condition caused by the failure of the upper arm and forearm to develop during the antenatal period, but with the hand present. This condition is characterised by direct connection of the hand to the shoulder.
- LB99.5      Congenital absence of both forearm and hand**  
A condition caused by the failure of the forearm and hand to develop during the antenatal period.
- LB99.6      Acheiria**  
A condition caused by failure of one or both hands to develop during the antenatal period.
- LB99.7      Adactyly of hands**  
A condition caused by failure of the digits on the hand to correctly develop during the antenatal period. This condition is characterised by absence of digits on the hand.
- LB99.8      Split hand**  
A condition caused by malformation of the hand during the antenatal period. This condition is characterised by a deep median cleft of the hand due to the absence of the central rays.
- LB99.Y      Other specified reduction defects of upper limb**
- LB99.Z      Reduction defects of upper limb, unspecified**
- LB9A      Reduction defects of lower limb**  
Any condition caused by the failure of a lower limb to correctly develop during the antenatal period. These conditions are characterised by reduction in size or absence of the limb.
- LB9A.0      Amelia of lower limb**

- LB9A.1** **Tibial hemimelia**  
Tibial hemimelia is a rare congenital anomaly characterised by deficiency of the tibia with a relatively intact fibula.
- LB9A.2** **Fibular hemimelia**  
Fibular hemimelia is a congenital longitudinal limb deficiency characterised by complete or partial absence of the fibula bone.
- LB9A.3** **Congenital absence of thigh or lower leg with foot present**  
Any condition caused by the failure of the thigh and lower leg to develop during the antenatal period. These conditions are characterised by direct connection of the foot to the hip.
- LB9A.4** **Apodia**  
A condition caused by failure of the foot to develop during the antenatal period.
- LB9A.5** **Adactyly of feet**  
A condition caused by failure of the digits on the foot to correctly develop during the antenatal period. This condition is characterised by absence of digits on the foot.
- LB9A.6** **Split foot**  
A condition caused by malformation of the foot during the antenatal period. This condition is characterised by a deep median cleft of the foot due to the absence of the central rays.
- LB9A.7** **Congenital absence of both lower leg and foot**  
Any condition caused by the failure of the lower leg and foot to develop during the antenatal period.
- LB9A.8** **Femoral agenesis or hypoplasia**  
Femoral agenesis/hypoplasia is a rare malformation of variable severity ranging from mild hypoplasia to complete absence of the femur.
- LB9A.Y** **Other specified reduction defects of lower limb**
- LB9A.Z** **Reduction defects of lower limb, unspecified**
- LB9B** **Reduction defects of upper and lower limbs**
- LB9Y** **Other specified structural developmental anomalies of the skeleton**
- LB9Z** **Structural developmental anomalies of the skeleton, unspecified**

Structural developmental anomalies of the skin (LC00-LC7Z)

A deformation established before birth of an anatomical structure of the skin.

- Exclusions:**
- pilonidal cyst or sinus (EG63)
  - Congenital erythropoietic porphyria (5C58.12)
  - Acrodermatitis enteropathica (5C64.20)

## Developmental hamartomata of the epidermis and epidermal appendages (LC00-LC0Y)

Keratinocytic, pilosebaceous, eccrine, apocrine and other complex hamartomatous malformations of the skin.

<b>LC00</b>	<b>Keratinocytic epidermal hamartoma</b> Keratinocytic epidermal hamartoma or epidermal naevus is a congenital hamartomatous epidermal malformation composed of keratinocytes. It is thought to arise as a result of somatic mutation: early embryonic mutations can give rise to extensive systematised naevi, though typically epidermal naevi are localised linear papillomatous or verrucous plaques. Histologically they exhibit acanthosis, papillomatosis and acanthosis. <b>Coded Elsewhere:</b> Linear porokeratosis (ED52)
<b>LC00.0</b>	<b>Epidermal naevus</b>
<b>LC00.Y</b>	<b>Other specified keratinocytic epidermal hamartoma</b>
<b>LC00.Z</b>	<b>Keratinocytic epidermal hamartoma, unspecified</b>
<b>LC01</b>	<b>Pilosebaceous hamartoma</b> Hamartomatous malformation involving elements originating from the developing pilosebaceous follicle.
<b>LC02</b>	<b>Complex epidermal hamartoma</b> Hamartomatous malformation composed of elements deriving from several components of the developing epidermis and epidermal appendages.
<b>LC0Y</b>	<b>Other specified developmental hamartomata of the epidermis and epidermal appendages</b>

## Developmental anomalies of skin pigmentation (LC10-LC1Y)

Hamartomatous cutaneous malformations involving melanocytes including congenital pigmented naevi.

**Coded Elsewhere:** Congenital melanocytic naevus (2F20.2)

Familial multiple café-au-lait macules (EC23.0)

**LC10**

### **Dermal melanocytosis**

The presence at birth of functional melanocytes within the dermis. Most commonly this is as a result of incomplete migration of melanocytes to the epidermis as in lumbosacral dermal melanocytosis (Mongolian spot). Less commonly it is due to circumscribed hamartomatous proliferation of melanocytes in the dermis (e.g. Naevus of Ota).

**Coded Elsewhere:** Phakomatosis caesioflammea (LD2D.Y)

Phakomatosis caesiomarmorata (LD2D.Y)

**LC1Y**

### **Other specified developmental anomalies of skin pigmentation**

## Hamartomata derived from dermal connective tissue (LC20-LC2Y)

Hamartomatous malformations of dermal collagen and elastin.

**LC20**

### **Connective tissue hamartoma**

**Inclusions:** Connective tissue naevus

**LC2Y**

### **Other specified hamartomata derived from dermal connective tissue**

## Developmental defects of hair or nails (LC30-LC31)

**LC30**

### **Developmental defects of hair or hair growth**

**LC31**

### **Developmental defects of the nail apparatus**

Congenital malformations of the nail apparatus.

**Inclusions:** congenital abnormalities of the nails

**LC40**

### **Dermoid cyst**

**Coded Elsewhere:** Dermoid cyst of eyelid (2F36.4)

## Developmental anomalies of cutaneous vasculature (LC50-LC5Z)

Congenital vascular malformations affecting the skin

**LC50**

### **Developmental capillary vascular malformations of the skin**

**Coded Elsewhere:** Phakomatosis pigmentovascularis (LD2D.Y)

<b>LC50.0</b>	<b>Salmon patch</b> A common skin condition of neonates, characterised by flat, deep-pink localised areas of capillary dilation that occur predominantly on the back of the neck, lower occiput, upper eyelids, upper lip, and bridge of the nose. The areas disappear permanently by about 2 years of age.
<b>LC50.1</b>	<b>Port-wine stain</b> A port-wine stain is defined as a macular telangiectatic area of skin which is present at birth and does not spontaneously involute. Port-wine stains may be localised or extensive and they are often associated with an underlying disorder.  <i>Coded Elsewhere:</i> Sturge-Weber syndrome (LD23)
<b>LC50.Y</b>	<b>Other specified cutaneous capillary vascular malformation</b>
<b>LC51</b>	<b>Developmental venous malformations involving the skin</b> Certain genetically-determined syndromes presenting with venous anomalies in the skin
<b>LC52</b>	<b>Complex or combined developmental vascular malformations involving the skin</b>  <i>Coded Elsewhere:</i> Angio-osteohypertrophic syndrome (LD26.60) Cobb syndrome (LA90.3Y) Maffucci syndrome (LD2F.1Y)
<b>LC5Y</b>	<b>Other specified developmental anomalies of cutaneous vasculature</b>
<b>LC5Z</b>	<b>Developmental anomalies of cutaneous vasculature, unspecified</b>

### Congenital anomalies of skin development (LC60-LC60)

<b>Coded Elsewhere:</b>	Focal dermal hypoplasia (LD27.0Y) Beckwith-Wiedemann syndrome (LD2C)
<b>LC60</b>	<b>Aplasia cutis congenita</b> Congenital absence of skin. The commonest form presents as a defect limited to the scalp. It is also a component of a number of genetic syndromes.
<b>LC7Y</b>	<b>Other specified structural developmental anomalies of the skin</b>
<b>LC7Z</b>	<b>Structural developmental anomalies of the skin, unspecified</b>

### Structural developmental anomalies of the adrenal glands (LC80-LC8Z)

A deformation established before birth of an anatomical structure of the adrenal glands.

<b>Exclusions:</b>	Congenital adrenal hyperplasia (5A71.01)
<b>LC80</b>	<b>Congenital adrenal hypoplasia</b>
	<i>Coded Elsewhere:</i> Congenital adrenocortical insufficiency (5A74.Y)

<b>LC8Y</b>	<b>Other specified structural developmental anomalies of the adrenal glands</b>
<b>LC8Z</b>	<b>Structural developmental anomalies of the adrenal glands, unspecified</b>
<b>LD0Y</b>	<b>Other specified structural developmental anomalies primarily affecting one body system</b>
<b>LD0Z</b>	<b>Structural developmental anomalies primarily affecting one body system, unspecified</b>

## Multiple developmental anomalies or syndromes (LD20-LD2Z)

Complex developmental anomalies involving more than one body system

<b>LD20</b>	<b>Syndromes with central nervous system anomalies as a major feature</b>
	<b><i>Inclusions:</i></b> Meckel syndrome (LD2F.13)
<b>LD20.0</b>	<b>Syndromes with cerebellar anomalies as a major feature</b>
	<b><i>Coded Elsewhere:</i></b> Dysplastic cerebellar gangliocytoma (2A00.21)
<b>LD20.00</b>	Joubert syndrome Joubert syndrome is a genetic midbrain-hindbrain malformation syndrome characterised by congenital malformation of the brainstem and agenesis or hypoplasia of the cerebellar vermis leading to an abnormal respiratory pattern, nystagmus, hypotonia, ataxia, and delay in achieving motor milestones. <b><i>Coded Elsewhere:</i></b> Oral-facial-digital syndrome type 6 (LD25.00)
<b>LD20.01</b>	Pontocerebellar hypoplasia Nonsyndromic pontocerebellar hypoplasias are a rare heterogeneous group of diseases characterised by hypoplasia and atrophy and/or early neurodegeneration of the cerebellum and pons. Eight subtypes named type 1-8 have been described, generally inherited in an autosomal recessive pattern.
<b>LD20.0Y</b>	Other specified syndromes with cerebellar anomalies as a major feature
<b>LD20.0Z</b>	Syndromes with cerebellar anomalies as a major feature, unspecified
<b>LD20.1</b>	<b>Syndromes with lissencephaly as a major feature</b> The term lissencephaly covers a group of rare malformations sharing the common feature of anomalies in the appearance of brain convolutions (characterised by simplification or absence of folding) associated with abnormal organisation of the cortical layers as a result of neuronal migration defects during embryogenesis. Children with lissencephaly have feeding and swallowing problems, muscle tone anomalies (early hypotonia and subsequently limb hypertonia), seizures (in particular, infantile spasms) and severe psychomotor retardation. Two large groups can be distinguished: classical lissencephaly (and its variants) and cobblestone lissencephaly. <b><i>Inclusions:</i></b> Agyria Pachygyria

- LD20.2      Syndromes with microcephaly as a major feature**  
 Developmental syndromes in which an abnormally small head size is a significant feature.
- LD20.3      Syndromes with holoprosencephaly as a major feature**  
 Any syndrome caused by failure of the prosencephalon to divide in two during the antenatal period. These syndromes may present with closely spaced eyes, cyclopia, flat nasal bridge, single maxillary central incisor, small head size, and clefts of the lip and palate.  
*Coded Elsewhere:* Arrhinencephaly (LA05.4)
- LD20.4      Syndromes with brain calcifications as a major feature**  
 A group of rare familial syndromes characterised by abnormal calcification of cerebral tissue and typically first manifesting in adult life with any of a wide range of neuropsychiatric disorders.
- LD20.Y      Other specified syndromes with central nervous system anomalies as a major feature**
- LD20.Z      Syndromes with central nervous system anomalies as a major feature, unspecified**
- LD21      Syndromes with eye anomalies as a major feature**  
 Any syndrome caused by failure of one or both eyes to correctly develop during the antenatal period.  
**Exclusions:** Septo-optic dysplasia (5A61.0)  
 Cat-eye syndrome (LD41.P)  
 Aicardi syndrome (LD20)  
 Papilorenal syndrome (LA13.7)  
 WAGR syndrome (LD2A)
- LD21.0      Syndromes with microphthalmia as a major feature**  
 Syndromes in which abnormally small eyes form an important component.
- LD21.Y      Other specified syndromes with eye anomalies as a major feature**
- LD21.Z      Syndromes with eye anomalies as a major feature, unspecified**
- LD22      Syndromes with dental anomalies as a major feature**  
*Coded Elsewhere:* Amelogenesis imperfecta (LA30.6)  
 Dentine dysplasia (LA30.7)  
 Dentinogenesis imperfecta (LA30.8)
- LD23      Syndromes with vascular anomalies as a major feature**  
*Coded Elsewhere:* Angio-osteohypertrophic syndrome (LD26.60)  
 Primary lymphoedema (BD93.0)  
 Cutis marmorata telangiectatica congenita (LC52)

**LD24**

**Syndromes with skeletal anomalies as a major feature**

**Coded Elsewhere:** Progressive osseous heteroplasia (FB31.0)

Fibrodysplasia ossificans progressiva (FB31.1)

Osteolysis syndromes (FB86.2)

Calcification or ossification of muscles of genetic origin  
(FB31.Z)

**LD24.0**

**Syndromes with micromelia**

Syndromes in which abnormally short limbs are a major feature

**LD24.00**

Achondroplasia

Achondroplasia is the most frequent form of chondrodysplasia and is a type of dwarfism characterised by short limbs, hyperlordosis, short hands, and macrocephaly with high forehead and saddle nose, with normal intellectual development.

**LD24.01**

Hypochondroplasia

Hypochondroplasia is a skeletal dysplasia characterised by disproportionate short stature, mild lumbar lordosis and limited extension of the elbow joints.

**LD24.02**

Thanatophoric dysplasia

Thanatophoric Dysplasia is a severe skeletal disorder that is lethal in the neonatal period. Two clinically defined TD subtypes have been classified: type I (TDI), characterised by micromelia with bowed femurs and, occasionally, by the presence of cloverleaf skull deformity of varying severity and type II (TDII), characterised by micromelia with straight femurs and a moderate to severe cloverleaf skull deformity.

**LD24.03**

Diastrophic dysplasia

Diastrophic dwarfism is a rare autosomal recessive disorder marked by short stature with short extremities (final adult height is 120cm +/- 10cm), and joint malformations leading to multiple joint contractures (principally involving the shoulders, elbows, interphalangeal joints and hips)

**LD24.04**

Chondrodysplasia punctata

**LD24.0Y**

Other specified syndromes with micromelia

**LD24.0Z**

Syndromes with micromelia, unspecified

**LD24.1**

**Bone diseases with increased bone density**

**Coded Elsewhere:** Pycnodysostosis (5C56.Y)

Buschke-Ollendorff syndrome (EC4Y)

<b>LD24.10</b>	Osteopetrosis Osteopetrosis ('marble bone disease') is a descriptive term that refers to a group of rare, heritable disorders of the skeleton characterised by increased bone density on radiographs. Osteopetrotic conditions vary greatly in their presentation and severity, ranging from neonatal onset with life-threatening complications such as bone marrow failure (as in classical or 'malignant' autosomal recessive osteopetrosis) to the incidental finding of osteopetrosis on radiographs (e.g. osteopoikilosis).
	<b>Coded Elsewhere:</b> OL-EDA-ID syndrome (LD27.0Y)
	Osteopetrosis - hypogammaglobulinaemia (4A01.0Y)
<b>LD24.11</b>	Osteopoikilosis
<b>LD24.1Y</b>	Other specified bone diseases with increased bone density
<b>LD24.1Z</b>	Bone diseases with increased bone density, unspecified
<b>LD24.2</b>	<b>Bone diseases with disorganised development of skeletal components</b>
	<b>Coded Elsewhere:</b> Osteogenesis imperfecta (LD24.K0)
	Enchondromatosis (2E83.Z)
	X-linked cutis laxa (LD28.2)
	Maffucci syndrome (LD2F.1Y)
	Inherited bone dysplasia (FB80.Y)
<b>LD24.20</b>	Multiple osteochondromas
	<b>Inclusions:</b> Diaphyseal aclasis
<b>LD24.21</b>	Exostoses with anetodermia and brachydactyly type E
<b>LD24.22</b>	Cherubism Cherubism is a benign fibro-osseous hereditary disorder of childhood, limited to the lower half of the face, the maxilla and particularly the mandible, with bilateral painless swelling of jaws (giving the so-called cherubic look) associated with multicystic bone tumours and eyes-to-heaven appearance. Dentition is also abnormal at the sites concerned: tooth agenesis, noneruption, displacement, root resorption and malocclusions are common.
<b>LD24.23</b>	Yunis-Varon disease A disease caused by failure of multiple body systems to correctly develop during the antenatal period, due to mutation of the FIG4 gene. This disease is characterised by cleidocranial dysplasia, digital anomalies, and severe neurological involvement.
<b>LD24.2Y</b>	Other specified bone diseases with disorganised development of skeletal components
<b>LD24.2Z</b>	Bone diseases with disorganised development of skeletal components, unspecified

<b>LD24.3</b>	<b>Spondyloepiphyseal or spondyloepimetaphyseal dysplasias</b> Spondyloepiphyseal dysplasias (SED) are a heterogeneous group of congenital chondrodysplasias that specifically affect epiphyses and vertebrae. Their most frequent form is characterised by small neonatal size of ovoid vertebrae and overall late growth of bones, more marked in the femoral heads, with a slightly irregular metaphyseal limit. Other clinical forms have been described, some of which were dominant and more or less severe with metaphyseal lesions, while others were recessive and included nephrotic syndrome, lymphopenia, and immune disorders (immune bone dysplasia).
<b>LD24.4</b>	<b>Spondylometaphyseal dysplasias</b> Spondylometaphyseal dysplasias are a heterogeneous group of disorders associated with walking and growth disturbances that become evident during the second year of life. The disorders are characterised by platyspondyly (flattened vertebrae) and marked hip and knee metaphyseal lesions. The different forms of spondylometaphyseal dysplasia are distinguished by the localization and severity of involvement of the affected metaphyses.
<b>LD24.5</b>	<b>Spondylodysplastic dysplasias</b>
<b>LD24.50</b>	Achondrogenesis
<b>LD24.51</b>	Hypochondrogenesis A condition caused by failure of the skeletal system to correctly develop during the antenatal period, due to mutation of the COL2A1 gene. This condition is characterised by a small body, short limbs, underdeveloped lungs, flat and oval-shaped face, hypertelorism, micrognathia, enlarged abdomen, and ossification in the spine and pelvis. This condition may also present with a cleft palate.
<b>LD24.5Y</b>	Other specified spondylodysplastic dysplasias
<b>LD24.5Z</b>	Spondylodysplastic dysplasias, unspecified
<b>LD24.6</b>	<b>Multiple epiphyseal dysplasia or pseudoachondroplasia</b>
<b>LD24.60</b>	Pseudoachondroplasia Pseudoachondroplasia is a chondrodysplasia characterised by severe growth deficiency and deformations such as bow legs and hyperlordosis.
<b>LD24.61</b>	Multiple epiphyseal dysplasias Multiple epiphyseal dysplasias (MED/EDMs) are characterised by epiphyseal anomalies causing joint pain early in life, recurrent osteochondritis and early arthrosis. The EDMs are a heterogeneous group of diseases with variable expression classed as MED/EDMs 1-6.
	<b>Coded Elsewhere:</b> Wolcott-Rallison syndrome (5A13.6)
<b>LD24.6Y</b>	Other specified multiple epiphyseal dysplasia or pseudoachondroplasia
<b>LD24.6Z</b>	Multiple epiphyseal dysplasia or pseudoachondroplasia, unspecified

<b>LD24.7</b>	<b>Multiple metaphyseal dysplasias</b>
	<b><i>Exclusions:</i></b> Pyle disease (LD24.1)
	<b><i>Coded Elsewhere:</i></b> Cartilage-hair hypoplasia (LD27.0Y) Metaphyseal dysostosis - intellectual deficit - conductive deafness (LD2H.Y)
<b>LD24.8</b>	<b>Acromelic dysplasias</b>
	<b><i>Coded Elsewhere:</i></b> Microspherophakia or Weill Marchesani Syndrome (9C61.42) Trichorhinophalangeal syndrome type 1 and 3 (LD27.0Y)
<b>LD24.80</b>	Langer-Giedion syndrome  Langer-Giedion syndrome or trichorhinophalangeal syndrome type 2 is a chromosomal anomaly syndrome characterised by the association of intellectual deficit and numerous other anomalies including redundant skin, multiple cartilaginous exostoses, characteristic facies and cone-shaped phalangeal epiphyses.
<b>LD24.8Y</b>	Other specified acromelic dysplasias
<b>LD24.8Z</b>	Acromelic dysplasias, unspecified
<b>LD24.9</b>	<b>Acromesomelic dysplasias</b>  A group of rare disorders characterised by shortening of the bones of the forearms, lower legs, hands and feet.  <b><i>Exclusions:</i></b> Sensenbrenner syndrome (LD27.0)
<b>LD24.A</b>	<b>Mesomelic or rhizomesomelic dysplasias</b>
<b>LD24.B</b>	<b>Short rib syndromes</b>  <b><i>Exclusions:</i></b> Oral-facial-digital syndrome type 4 (LD25.00) <b><i>Coded Elsewhere:</i></b> Chondroectodermal dysplasia (LD27.0Y)
<b>LD24.B0</b>	Short rib-polydactyly syndrome  Short rib-polydactyly syndromes are a group of bone malformations characterised by a narrow thorax and polydactyly (usually preaxial). Prevalence as a group is unknown. The group is heterogeneous and includes Jeune syndrome and Ellis-Van Creveld syndrome, neither of which are lethal, together with lethal chondrodysplasias: Saldino-Noonan (type 1), Majewski (type 2), Verma-Naumoff (type 3) and Beemer-Langer (type 4).
<b>LD24.B1</b>	Asphyxiating thoracic dystrophy  Asphyxiating thoracic dystrophy, also called Jeune syndrome, is a short-rib dysplasia characterised by a narrow thorax, short limbs and radiological skeletal abnormalities including "trident" aspect of the acetabula and metaphyseal changes.
<b>LD24.BY</b>	Other specified short rib syndromes
<b>LD24.BZ</b>	Short rib syndromes, unspecified

<b>LD24.C</b>	<b>Bent bone dysplasias</b> Any syndromes are characterised by poor mineralization of the skull, craniosynostosis, hypoplastic pubis and clavicles, osteopenia, bent long bones, low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia. These syndromes may be associated with mutation of the FGFR2 gene.  <b>Coded Elsewhere:</b> Campomelic dysplasia (LD2A.Y) Juvenile osteochondrosis of tibia or fibula (FB82.1)
<b>LD24.D</b>	<b>Slender bone dysplasias</b> Any syndrome characterised by dwarfism, thin bones, multiple fractures, and prenatal or early postnatal death.  <b>Coded Elsewhere:</b> IMAGe syndrome (5A74.Y)
<b>LD24.E</b>	<b>Bone dysplasias with multiple joint dislocations</b> Any syndrome characterised by malformation of the musculoskeletal system during the antenatal period, which includes the dislocations of multiple joints.
<b>LD24.F</b>	<b>Progressive ossification of skin, skeletal muscle, fascia, tendons or ligaments</b> <b>Coded Elsewhere:</b> Progressive osseous heteroplasia (FB31.0) Fibrodysplasia ossificans progressiva (FB31.1)
<b>LD24.G</b>	<b>Syndromic craniosynostoses</b> Any syndrome caused by premature fusing of sections of the infant skull. These syndromes are characterised by disfiguring compensatory growth of the skull. These syndromes may also present with frequent worsening morning headache, recurrent vomiting, cephalocranial disproportion, raised intracranial pressure, optic atrophy, blindness, or developmental delay.  <b>Exclusions:</b> Sensenbrenner syndrome (LD27.0) Shprintzen-Goldberg craniosynostosis syndrome (LD28.0) Craniotelencephalic dysplasia (LD20.1)  <b>Coded Elsewhere:</b> Craniofrontonasal dysplasia (LD25.3)
<b>LD24.G0</b>	Pfeiffer syndrome Pfeiffer syndrome (associated with mutations in the FGFR1 and 2 gene) is a syndromic form of craniosynostosis characterised by the association of craniosynostosis. Often pansynostosis. Severe midface hypoplasia. Broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Hydrocephaly may be found occasionally, along with severe ocular proptosis, ankylosed elbows.  <b>Exclusions:</b> Pfeiffer disease (1D81.0)
<b>LD24.G1</b>	Crouzon disease Crouzon disease is a form of syndromic craniosynostosis characterised by craniosynostosis and facial hypoplasia.

<b>LD24.G2</b>	Apert syndrome Apert syndrome is a syndromic craniosynostosis associated with mutations in the FGFR2 gene and characterised by premature closure of coronal suture and a later onset of pansynostosis. Pathognomonic is an osseous and membranous syndactyly of at least Digitus II-IV (fingers and toes). High incidence of midface hypoplasia with orbital and facial stenosis, cleft palate, vertebral fusion. Mental deficits in 30%.
<b>LD24.GY</b>	Other specified syndromic craniosynostoses
<b>LD24.GZ</b>	Syndromic craniosynostoses, unspecified
<b>LD24.H</b>	<b>Dysostoses with predominant vertebral and costal involvement</b> Any syndrome characterised by malformation of the musculoskeletal system during the antenatal period, which includes dysgenesis of the vertebrae and intercostal cartilage.  <b>Exclusions:</b> Spondylocostal dysostosis - anal and genitourinary malformations (LD2F.1)
<b>LD24.J</b>	<b>Patellar dysostoses</b> Any syndrome characterised by malformation of the patella during the antenatal period.
<b>LD24.J0</b>	Nail-patella syndrome Nail patella syndrome is a hereditary osteo-onychodysplasia characterised by nail dysplasia with triangular lunula, hypoplastic or absent patellas, iliac exostoses ('iliac horns') and dysplastic elbows.
<b>LD24.JY</b>	Other specified patellar dysostoses
<b>LD24.JZ</b>	Patellar dysostoses, unspecified
<b>LD24.K</b>	<b>Genetic bone diseases with decreased bone density</b> <b>Coded Elsewhere:</b> Ehlers-Danlos-osteogenesis imperfecta syndrome (LD28.1Y)
<b>LD24.K0</b>	Osteogenesis imperfecta Osteogenesis imperfecta (OI) comprises a heterogeneous group of genetic disorders characterised by increased bone fragility, low bone mass, and susceptibility to bone fractures with variable severity. The most clinically relevant characteristic of all types of OI is bone fragility, which manifests as multiple spontaneous fractures.  <b>Inclusions:</b> Fragilitas ossium Osteopsathyrosis
<b>LD24.KY</b>	Other specified genetic bone diseases with decreased bone density
<b>LD24.KZ</b>	Genetic bone diseases with decreased bone density, unspecified
<b>LD24.Y</b>	<b>Other specified syndromes with skeletal anomalies as a major feature</b>
<b>LD24.Z</b>	<b>Syndromes with skeletal anomalies as a major feature, unspecified</b>

<b>LD25</b>	<b>Syndromes with face or limb anomalies as a major feature</b>
	<b><i>Exclusions:</i></b> Freeman-Sheldon syndrome (LD26.4)
<b>LD25.0</b>	<b>Oromandibular-limb anomaly syndrome</b> A syndrome caused by failure of the face and limbs to correctly develop during the antenatal period. This syndrome is characterised by malformations of the tongue, mandible, and limbs.
	<b><i>Exclusions:</i></b> Ectrodactyly - cleft palate (LD2F.1) Ectrodactyly - ectodermal dysplasia - cleft lip or palate (LD27.0)
<b>LD25.00</b>	<b>Oral-facial-digital syndrome</b> A condition caused by failure of the head and digits to correctly develop during the antenatal period. This condition may be associated with cleft or lobed tongue, noncancerous tumours or nodules of the tongue, abnormal shape or number of teeth, cleft palate, hyperplastic frenula of the lip or gums, cleft lip, hypertelorism, wide nose with broad, flat nasal bridge, syndactyly, brachydactyly, clinodactyly, polydactyly, polycystic kidney disease, neurological problems, bone abnormalities, vision loss, or heart defects.
<b>LD25.0Y</b>	Other specified oromandibular-limb anomaly syndrome
<b>LD25.0Z</b>	Oromandibular-limb anomaly syndrome, unspecified
<b>LD25.1</b>	<b>Fronto-otopalatodigital syndromes</b>
<b>LD25.2</b>	<b>Acrofacial dysostoses</b> Any syndrome caused by failure of the face and limbs to correctly develop during the antenatal period.
<b>LD25.3</b>	<b>Craniofacial dysostoses</b> Syndromes caused by abnormal development of skull and facial bones. They may present with acrocephaly, exophthalmos, hypertelorism, strabismus, parrot-beaked nose, or hypoplastic maxilla. Non-syndromic craniosynostosis, which is predominantly sporadic, is coded elsewhere.
	<b><i>Exclusions:</i></b> Acrofacial dysostosis, Nager type (LD25.2) Postaxial acrofacial dysostosis (LD25.2) Acrofacial dysostosis, Weyers type (LD25.2) Frontometaphyseal dysplasia (LD25.1) Craniosynostosis (LB70.0)
<b>LD25.Y</b>	<b>Other specified syndromes with face or limb anomalies as a major feature</b>
<b>LD25.Z</b>	<b>Syndromes with face or limb anomalies as a major feature, unspecified</b>
<b>LD26</b>	<b>Syndromes with limb anomalies as a major feature</b>
<b>LD26.0</b>	<b>Combined reduction defects of upper and lower limbs</b>

<b>LD26.1</b>	<b>Complex brachydactylies</b> A disease caused by failure of the digits to correctly develop during the antenatal period. This disease is characterised by multiple digits of below normal length. This condition may be associated with mutation in the GDF5 gene.  <b>Exclusions:</b> Catel-Manzke syndrome (LD2F.1)
<b>LD26.2</b>	<b>Syndromes with limb duplication, polydactyly, syndactyly or triphalangism</b> Any syndrome caused by failure of the limbs to correctly develop during the antenatal period. These syndromes are characterised by supernumerary limbs or digits, fused digits, or supernumerary phalanges.  <b>Exclusions:</b> Townes-Brocks syndrome (LD2F.1)
<b>LD26.3</b>	<b>Syndromes with synostoses of limbs</b>
<b>LD26.4</b>	<b>Arthrogryposis syndromes</b> Any syndrome caused by failure of elastic tissue to correctly develop during the antenatal period. These syndromes are characterised by the presence of multiple joint contractures, where elastic tissues are replaced by inelastic tissues, which results in fixation of the joint.  <b>Exclusions:</b> Arthrogryposis due to muscular dystrophy (8C70)
<b>LD26.40</b>	Multiple pterygium syndrome
<b>LD26.41</b>	Arthrogryposis multiplex congenita Arthrogryposis multiplex congenita, comprises nonprogressive congenital conditions characterised by multiple joint contractures. The term is currently used in connection with a very heterogeneous group of disorders that all include multiple congenital joint contractures. The major cause of arthrogryposis is fetal akinesia due to fetal abnormalities (e.g. neurogenic, muscle, or connective tissue abnormalities; mechanical limitations to movement) or maternal disorders (e.g. infection, drugs, trauma, other maternal illnesses). Generalised fetal akinesia can also lead to polyhydramnios, pulmonary hypoplasia, micrognathia, ocular hypertelorism, and short umbilical cord. Lack of fetal movement causes extra connective tissue to develop around the joint, limiting movement and further aggravating the joint contracture.  <b>Exclusions:</b> COFS syndrome (LD2B) Arthrogryposis multiplex congenita - lissencephaly (LD2F.1) <b>Coded Elsewhere:</b> Arthrogryposis - renal dysfunction - cholestasis (5C58.0Y)
<b>LD26.4Y</b>	Other specified arthrogryposis syndromes
<b>LD26.4Z</b>	Arthrogryposis syndromes, unspecified
<b>LD26.5</b>	<b>Constriction rings</b> A condition caused by entangling of fibrous bands of the amniotic sac around a developing fetus. This condition may present with circular indentation around a digit or limb, swelling, restriction of the lymphatic or venous flow, limb development defects, or in utero amputation.
<b>LD26.6</b>	<b>Congenital vascular bone syndromes</b>

<b>LD26.60</b>	Angio-osteohypertrophic syndrome Angio-osteohypertrophic (AOH) syndrome is a congenital vascular bone syndrome characterised by the presence of vascular malformations in a limb resulting in limb overgrowth. Depending on whether the malformations are slow flow venous or fast flow arteriovenous the syndrome may be divided into two subtypes, Klippel-Trénaunay and Parkes-Weber syndromes respectively. Some cases of the latter are associated with mutations in the RASA1 gene.
<b>LD26.6Y</b>	Other specified congenital vascular bone syndromes
<b>LD26.6Z</b>	Congenital vascular bone syndromes, unspecified
<b>LD26.Y</b>	<b>Other specified syndromes with limb anomalies as a major feature</b>
<b>LD26.Z</b>	<b>Syndromes with limb anomalies as a major feature, unspecified</b>
<b>LD27</b>	<b>Syndromes with skin or mucosal anomalies as a major feature</b>
	<b>Coded Elsewhere:</b> Acrodermatitis enteropathica (5C64.20)
	Non-syndromic ichthyosis (EC20.0)
	Pseudoxanthoma elasticum (EC40)
	Xeroderma pigmentosum-Cockayne syndrome complex (LD2B)
	Hereditary ichthyosis (EC20.Y)
	Palmoplantar keratoderma – oral leukokeratosis – oesophageal carcinoma (EC20.31)
<b>LD27.0</b>	<b>Ectodermal dysplasia syndromes</b>
	Ectodermal dysplasias (EDs) are a heterogeneous group of disorders characterised by developmental dystrophies of ectodermal structures, such as hypohidrosis, hypotrichosis, onychodysplasia and hypodontia or anodontia. More than 160 clinically and genetically distinct hereditary ectodermal dysplasias have been catalogued.
	<b>Coded Elsewhere:</b> Langer-Giedion syndrome (LD24.80)
	Oral-facial-digital syndrome (LD25.00)
	Solitary median maxillary central incisor syndrome (LA30.Y)
	Rothmund-Thomson syndrome (LD2B)
	Hallermann-Streiff-François syndrome (LD2B)
	Keratitis – ichthyosis – deafness syndrome (LD27.2)
	Papillon-Lefèvre syndrome (EC20.30)
	Cataract – hypertrichosis – intellectual deficit (LD27.3)
	Hypomelanosis of Ito (EC23.2Y)
	Ectodermal dysplasia – skin fragility syndrome (EC30)
	Dyskeratosis congenita (3A70.0)

- LD27.00** Incontinentia pigmenti  
Incontinentia pigmenti is an X-linked dominant gene disorder due to abnormalities of the NF-kappa-B (NEMO) gene on chromosome Xq28. It is lethal in male fetuses but the presence of a normal second X chromosome in females results in a mosaicism which is compatible with life. Affected females present in infancy with skin blisters in linear arrays (Blaschko lines) typically on the scalp and limbs. Within the first few months of life these are succeeded by warty changes and hyperpigmentation. These tend to resolve over time, often leaving atrophic streaks. Associated features include abnormal dentition, ocular defects and a variety of neurological complications.
- LD27.01** Cronkhite-Canada syndrome  
Cronkhite-Canada syndrome (CCS) is a sporadically occurring, noninherited disorder of generalised gastrointestinal polyps (hamartomas), cutaneous pigmentation, alopecia, and onychodystrophy. The possibility of progression to cancer is considered to be low. Chronic diarrhea and protein-losing enteropathy are often observed.
- LD27.02** Hypohidrotic ectodermal dysplasia  
Hypohidrotic ectodermal dysplasia is a genetic disorder of ectoderm development characterised by malformation of ectodermal structures such as skin, hair, teeth and sweat glands. It comprises three clinically almost indistinguishable subtypes with impaired sweating as the key symptom: Christ-Siemens-Touraine syndrome (X-linked), autosomal recessive and autosomal dominant hypohidrotic ectodermal dysplasia, as well as a fourth rare subtype with immunodeficiency as the key symptom.
- LD27.03** Hidrotic ectodermal dysplasia, Clouston type  
Clouston syndrome (or hidrotic ectodermal dysplasia) is an inherited disorder characterised by the clinical triad of nail dystrophy, alopecia, and palmoplantar hyperkeratosis.
- LD27.0Y** Other specified ectodermal dysplasia syndromes
- LD27.1** **Xeroderma pigmentosum**  
Xeroderma pigmentosum (XP) is a rare genodermatosis characterised by extreme sensitivity to ultraviolet (UV)-induced changes in the skin and eyes, and multiple skin cancers. It is subdivided into 8 complementation groups, according to the affected gene: XPA to XPG, and XP variant (XPV). The severity of the clinical manifestations and the age of onset are extremely variable and are in part dependent on exposure to sunlight and the complementation group.  
**Coded Elsewhere:** Xeroderma pigmentosum variant (LD27.Y)
- LD27.2** **Syndromic ichthyosis**  
Hereditary disorders in which ichthyosis is associated with significant other abnormalities.  
**Coded Elsewhere:** Sjögren-Larsson syndrome (5C52.03)

LD27.3	<b>Genetic syndromes with hypertrichosis</b> Genetic syndromes in which excessive non-androgen-dependent hair growth is associated with other abnormalities.
	<p><b>Coded Elsewhere:</b> Cone-rod type amaurosis congenita – congenital hypertrichosis (9B70)</p> <p>Ramon syndrome (LD2F.1Y)</p>
LD27.4	<b>Genetic syndromes affecting nails</b>
	<p><b>Coded Elsewhere:</b> Wilson disease (5C64.00)</p> <p>Nail-patella syndrome (LD24.J0)</p> <p>Hidrotic ectodermal dysplasia, Clouston type (LD27.03)</p> <p>Severe T-cell immunodeficiency - congenital alopecia - nail dystrophy (4A01.1Y)</p> <p>Odonto-onycho-dermal dysplasia (LD27.0Y)</p> <p>Onycho-tricho-dysplasia – neutropaenia syndrome (LD27.0Y)</p> <p>Knuckle pads – leukonychia – sensorineural deafness (LD2H.Y)</p> <p>Deafness – enamel hypoplasia – nail defects (LD27.0Y)</p> <p>Anonychia with bizarre flexural pigmentation (LD27.0Y)</p> <p>Anonychia or onychodystrophy – hypoplasia or absence of distal phalanges (LD27.0Y)</p> <p>Autosomal dominant hypodontia with nail dysplasia (LD27.0Y)</p> <p>Amelo-onycho-hypohidrotic syndrome (LD27.0Y)</p> <p>Deafness – onychodystrophy (LD27.0Y)</p> <p>Odonto-onycho-hypohidrotic dysplasia - midline scalp defects (LD27.0Y)</p> <p>Tricho-odonto-onycho-dermal syndrome (LD27.0Y)</p> <p>Tricho-odonto-onychodysplasia - dominant syndactyly (LD27.0Y)</p> <p>Pili torti - onychodysplasia (LD27.0Y)</p> <p>Dyskeratosis congenita (3A70.0)</p> <p>Primary hypertrophic osteoarthropathy (FB86.10)</p>
LD27.5	<b>Genetic hamartoneoplastic syndromes affecting the skin</b>
	A heterogeneous group of inherited diseases characterised by the presence of multiple hamartomata and associated with an increased risk of malignancy.
	<p><b>Coded Elsewhere:</b> Neurofibromatoses (LD2D.1)</p> <p>Tuberous sclerosis (LD2D.2)</p> <p>Gardner syndrome (LD2D.3)</p> <p>Gorlin syndrome (LD2D.4)</p> <p>Bannayan-Riley-Ruvalcaba syndrome (LD2D.Y)</p> <p>Cowden syndrome (LD2D.Y)</p> <p>Multiple familial trichoepithelioma (2F22)</p>

<b>LD27.6</b>	<b>Genetic lipodystrophy</b> Genetic lipodystrophies represent a heterogeneous group of rare diseases characterised by a generalised or localised loss of body fat (lipoatrophy).
	<b>Coded Elsewhere:</b> Familial partial lipodystrophy (5A44)
	Wiedemann-Rautenstrauch progeroid syndrome (LD2B)
<b>LD27.60</b>	Congenital generalised lipodystrophy
	<b>Coded Elsewhere:</b> Berardinelli-Seip congenital lipodystrophy (5A44)
<b>LD27.6Z</b>	Genetic lipodystrophy, unspecified
<b>LD27.Y</b>	<b>Other specified syndromes with skin or mucosal anomalies as a major feature</b>
<b>LD27.Z</b>	<b>Syndromes with skin or mucosal anomalies as a major feature, unspecified</b>
<b>LD28</b>	<b>Syndromes with connective tissue involvement as a major feature</b>
	<b>Exclusions:</b> Cutis laxa (EE41.0) Pseudoxanthoma elasticum (EC40)
<b>LD28.0</b>	<b>Marfan syndrome or Marfan-related disorders</b>
	<b>Coded Elsewhere:</b> Aortic aneurysm syndrome, Loeys-Dietz type (BD50.Z) Ectopia lentis syndrome (LA12.Y)
<b>LD28.00</b>	Congenital contractual arachnodactyly Congenital contractual arachnodactyly (CCA, Beals syndrome) is a connective tissue disorder characterised by multiple flexion contractures, arachnodactyly, severe kyphoscoliosis, abnormal pinnae and muscular hypoplasia. Although the clinical features can be similar to Marfan syndrome (MFS), multiple joint contractures (especially of the elbow, knee, and finger joints), and crumpled ears in the absence of significant aortic root dilatation are characteristic of Beals syndrome and rarely found in MFS.
<b>LD28.01</b>	Marfan syndrome Marfan syndrome is a systemic disease of connective tissue characterised by a variable combination of cardiovascular, musculo-skeletal, ophthalmic and pulmonary manifestations. Cardiovascular involvement is characterised by 1) progressive dilation of the aorta accompanied by an increased risk of aortic dissection, which affects prognosis and 2) mitral insufficiency. Skeletal involvement is often the first sign of the disease and can include dolichostenomelia, large size, arachnodactyly, joint hypermobility, scoliotic deformations, acetabulum protrusion, thoracic deformity, dolichocephaly of the anteroposterior axis, micrognathism or malar hypoplasia. Ophthalmic involvement results in axile myopia, which can lead to retinal detachment and lens displacement.
<b>LD28.0Y</b>	Other specified Marfan syndrome or Marfan-related disorders
<b>LD28.0Z</b>	Marfan syndrome or Marfan-related disorders, unspecified

<b>LD28.1</b>	<b>Ehlers-Danlos syndrome</b> Ehlers-Danlos syndrome (EDS) is a heterogeneous group of inherited disorders of connective tissue, principally collagen, that range in severity from mild joint hypermobility to life-threatening fragility of soft tissue and vasculature.
<b>LD28.10</b>	Ehlers-Danlos syndrome, classical type Ehlers-Danlos syndrome, classic type is a type of Ehlers-Danlos syndromes (EDS), a heterogeneous group of hereditary connective tissue diseases characterised by joint hyperlaxity, cutaneous hyperelasticity and tissue fragility, and is characterised by the following major clinical diagnostic criteria: hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity.
<b>LD28.1Y</b>	Other specified types of Ehlers-Danlos syndrome
<b>LD28.2</b>	<b>Genetically-determined cutis laxa</b>
<b>LD28.Y</b>	<b>Other specified syndromes with connective tissue involvement as a major feature</b>
<b>LD28.Z</b>	<b>Syndromes with connective tissue involvement as a major feature, unspecified</b>
<b>LD29</b>	<p><b>Syndromes with obesity as a major feature</b></p> <p><b>Exclusions:</b> WAGR syndrome (LD2A) Fragile X syndrome (LD55)</p> <p><b>Coded Elsewhere:</b> Prader-Willi syndrome (LD90.3) Alström syndrome (LD2H.Y) Cohen syndrome (LD90.Y) Sotos syndrome (LD2C) Weaver syndrome (LD2C) Beckwith-Wiedemann syndrome (LD2C)</p>
<b>LD2A</b>	<p><b>Malformative disorders of sex development</b></p> <p>Any condition caused by failure of the genitals to correctly develop during the antenatal period.</p> <p><b>Exclusions:</b> pseudohermaphroditism: female, with adrenocortical disorder (5A71)</p> <p><b>Coded Elsewhere:</b> Chimaera 46, XX, 46, XY (LD56) 46,XX disorders of sex development induced by androgens of maternal origin (5A71.1) Congenital adrenal hyperplasia (5A71.01)</p>
<b>LD2A.0</b>	<b>Ovotesticular disorder of sex development</b> Ovotesticular disorder of sex development, formerly called true hermaphroditism, is a rare cause of genital ambiguity characterised by the presence of ovarian and testicular tissue in an individual, leading to development of both male and female structures.

<b>LD2A.1</b>	<b>46,XY gonadal dysgenesis</b> This is any congenital developmental disorder of the reproductive system characterised by a progressive loss of primordial germ cells on the developing gonads of an embryo.
<b>LD2A.2</b>	<b>Testicular agenesis</b> A rare 46,XY disorder of gonadal development characterized by congenital complete absence of testicular tissue in an individual with an otherwise male phenotype and normal karyotype. In addition, a small penis is a frequent finding in anorchid patients. Typical hormonal characteristics are elevated basal levels of gonadotropins (especially FSH (follicle-stimulating hormone), low concentration of testosterone, and lack of increase of plasma testosterone in response to hCG (human chorionic gonadotropin) administration. The GnRH (gonadotropin-releasing hormone) stimulation test induces a prolonged increase in FSH and LH (luteinizing hormone) levels.
<b>LD2A.3</b>	<b>46,XY disorder of sex development due to a defect in testosterone metabolism</b> <b><i>Inclusions:</i></b> Congenital adrenal hyperplasia (5A71.01) <b><i>Coded Elsewhere:</i></b> Smith-Lemli-Opitz syndrome (5C52.10)
<b>LD2A.4</b>	<b>46,XY disorder of sex development due to androgen resistance</b> Androgen insensitivity syndrome (AIS) is a disorder of sex development (DSD) characterised by the presence of female external genitalia, ambiguous genitalia or variable defects in virilization in a 46,XY individual with absent or partial responsiveness to age-appropriate levels of androgens. It comprises two clinical subgroups: complete AIS (CAIS) and partial AIS (PAIS).
<b>LD2A.Y</b>	<b>Other specified malformative disorders of sex development</b>
<b>LD2A.Z</b>	<b>Malformative disorders of sex development, unspecified</b>
<b>LD2B</b>	<b>Syndromes with premature ageing appearance as a major feature</b> A heterogeneous group of hereditary syndromes in which affected individuals do or appear to age at an accelerated rate. <b><i>Inclusions:</i></b> Progeroid syndromes <b><i>Exclusions:</i></b> Xeroderma pigmentosum (LD27.1) Cutis laxa (EE41.0) <b><i>Coded Elsewhere:</i></b> Ehlers-Danlos syndrome, progeroid type (LD28.1Y) Autosomal recessive cutis laxa, type 3 (LD28.2) Bloom syndrome (4A01.31) Ataxia-telangiectasia (4A01.31) Mandibuloacral dysplasia (LD27.6Z)

**LD2C****Overgrowth syndromes**

- Exclusions:** Sturge-Weber syndrome (LD23)  
Diabetic embryopathy (KB60.1)  
Enchondromatosis (2E83)  
Maffucci syndrome (LD2F.1)

**Coded Elsewhere:** Perlman syndrome (2C90.Y)

**LD2D****Phakomatoses or hamartoneoplastic syndromes**

- Exclusions:** Ataxia-telangiectasia (4A01.31)  
familial dysautonomia [Riley-Day] (8C21.1)  
Rendu-Osler-Weber disease (LA90.00)  
Proteus syndrome (LD2C)  
Sturge-Weber syndrome (LD23)  
Enchondromatosis (2E83)  
Maffucci syndrome (LD2F.1)  
Angio-osteohypertrophic syndrome (LD26.60)

**Coded Elsewhere:** NAME syndrome (2F01)

- Von Hippel-Lindau disease (5A75)  
Focal dermal hypoplasia (LD27.0Y)  
Epidermal naevus syndrome (LC02)  
Lumbosacral dermal melanocytosis (LC10)  
Naevus of Ota (LC10)  
Naevus of Ito (LC10)  
Dermal melanocyte hamartoma (LC10)  
Hereditary leiomyomatosis and renal cell cancer (2C90.Y)

**LD2D.0****Peutz-Jeghers syndrome**

Peutz-Jeghers syndrome (PJS) is an autosomal dominant inherited disorder characterised by intestinal hamartomatous polyps in association with a distinct pattern of skin and mucosal macular melanin deposition. Patients have an increased risk of developing intestinal cancer.

**LD2D.1****Neurofibromatoses**

The neurofibromatoses (NF) are related genetic disorders which affect bone, soft tissue, skin and nervous system. In NF type 1 neurofibromas develop in the skin and elsewhere: these can cause problems as a result of their visibility in the skin, compression of vital internal structures or from malignant degeneration. Neuromas of the acoustic nerve are the predominant problem in NF type 2.

<b>LD2D.10</b>	Neurofibromatosis type 1 Neurofibromatosis type 1 (NF1) is an inherited, multi-system, neurocutaneous disorder that predisposes to the development of benign and malignant tumours. Two of the following criteria are required to diagnose NF1: six or more café au lait patches, neurofibromas, i.e. peripheral nerve sheath tumours manifesting as cutaneous, sub-cutaneous or plexiform lesions, skin-fold freckling, two or more iris Lisch nodules, an optic pathway glioma, a specific bony dysplasia (thinning of the long bone cortex, sphenoid wing dysplasia), an affected first-degree relative.
	<b>Inclusions:</b> von Recklinghausen disease
<b>LD2D.11</b>	Neurofibromatosis type 2 Neurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the development of multiple schwannomas and meningiomas.
<b>LD2D.12</b>	Neurofibromatosis type 3
<b>LD2D.1Y</b>	Other specified neurofibromatoses
<b>LD2D.1Z</b>	Neurofibromatosis, unspecified
<b>LD2D.2</b>	<b>Tuberous sclerosis</b> A disease caused by a dominant mutation of 9q34 (TSC1) or 16p13 (TSC2). This disease may present with facial angiofibromas, Koenen tumours, fibrous plaques on the forehead and scalp, renal angiomyolipomas, subependymal nodules, multiple cortical tubers or retinal hamartoma, epilepsy, or mental retardation.
	<b>Inclusions:</b> Bourneville disease
	<b>Coded Elsewhere:</b> Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis (LD2F.1Y)
<b>LD2D.3</b>	<b>Gardner syndrome</b> Gardner syndrome develops adenomatous polyps throughout the gastrointestinal tract, accompanied by extracolonic manifestations, including periampullary adenomas, papillary carcinoma of the thyroid, hepatoblastoma, osteomas of the mandible and skull, epidermal cysts, and desmoid tumours. Gardner syndrome is a term used to refer to patients in whom these extraintestinal features are unusually prominent.
<b>LD2D.4</b>	<b>Gorlin syndrome</b> Gorlin syndrome, also known as naevoid basal cell carcinoma syndrome (NBCCS), is a hereditary condition characterised by a wide range of developmental abnormalities (odontogenic keratocysts of the jaws, hyperkeratosis of palms and soles, skeletal abnormalities, intracranial ectopic calcifications, and facial dysmorphisms) and a predisposition to develop malignant neoplasms (such as multiple basal cell carcinomas or medulloblastoma), and benign neoplasms in the jaw, heart, or ovaries.
	<b>Inclusions:</b> Naevoid basal cell carcinoma syndrome
<b>LD2D.Y</b>	<b>Other specified phakomatoses or hamartoneoplastic syndromes</b>
<b>LD2D.Z</b>	<b>Phakomatoses or hamartoneoplastic syndromes, unspecified</b>

**LD2E****Syndromes with structural anomalies due to inborn errors of metabolism**

- Coded Elsewhere:** Disorders of cholesterol synthesis (5C52.10)  
Pyruvate dehydrogenase complex deficiency (5C53.02)  
Inborn errors of glycosylation or other specified protein modification (5C54)  
Fabry disease (5C56.01)  
Mucolipidosis (5C56.20)  
Oligosaccharidosis (5C56.21)  
Mucopolysaccharidosis (5C56.3)  
Pseudo-Zellweger syndrome (5C57.Y)  
Hypophosphatasia (5C64.3)  
Classical homocystinuria (5C50.B)  
Encephalopathy due to sulfite oxidase deficiency (5C50.B)  
Mucosulfatidosis (5C56.0Y)  
Zellweger syndrome (5C57.0)  
Infantile Refsum disease (5C57.1)  
Menkes disease (5C64.0Y)

**LD2F****Syndromes with multiple structural anomalies, without predominant body system involvement**

- Coded Elsewhere:** Congenital rubella syndrome (KA62.8)  
Congenital cytomegalovirus infection (KA62.3)  
Perinatal Herpes simplex infection (KA62.A)  
Congenital Epstein-Barr virus infection (KA62.1)  
Congenital parvovirus syndrome (KA62.7)  
Congenital enterovirus infection (KA62.5)  
Congenital toxoplasmosis (KA64.0)  
Congenital Zika virus infection (KA62.0)  
Congenital Varicella Zoster virus infection (KA62.2)  
Embryofetopathy due to maternal phenylketonuria (5C50.02)

**LD2F.0****Toxic or drug-related embryofetopathies**

- Coded Elsewhere:** Uterovaginal malformation due to diethylstilbestrol syndrome (LB44.6)

<b>LD2F.00</b>	Fetal alcohol syndrome  Fetal alcohol syndrome is a malformation syndrome caused by maternal consumption of alcohol during pregnancy. It is characterised by prenatal and/or postnatal growth deficiency (weight and/or height <10th percentile); a unique cluster of minor facial anomalies (short palpebral fissures, flat and smooth philtrum, and thin upper lip) that presents across all ethnic groups is identifiable at birth, and does not diminish with age. Affected children present severe central nervous system abnormalities including: microcephaly, cognitive and behavioural impairment (intellectual disability, deficit in general cognition, learning and language, executive function, visual-spatial processing, memory, and attention).  <b>Coded Elsewhere:</b> Neurodevelopmental syndrome due to prenatal alcohol exposure (6A0Y)
<b>LD2F.01</b>	Fetal hydantoin syndrome  Fetal hydantoin syndrome is a fetopathy likely to occur when a pregnant woman takes the anticonvulsant drug phenytoin (diphenylhydantoin) for epileptic seizures. In utero exposure to this drug may result in a characteristic dysmorphic syndrome in the newborn, including low-set hair, short neck with pterygium colli, small nose, deep nasal bridge, epicanthus, hypertelorism, large mouth, malformed ears, hypoplastic distal phalanges of the fingers and toes and finger-like thumbs. These dysmorphic features are often associated with growth retardation and delayed psychomotor development. The mechanism underlying these anomalies has been shown to depend on maternal genetic characteristics, i.e. on maternal capacity to detoxify intermediate metabolites of phenytoin.
<b>LD2F.02</b>	Embryofetopathy due to oral anticoagulant therapy  A condition caused by exposure of the embryo or fetus to anticoagulants during the antenatal period. This disease may present with optic nerve anomaly, optic atrophy, anomaly of the papilla, blindness, or choanal atresia.
<b>LD2F.03</b>	Fetal Valproate Spectrum Disorder  Fetal valproate spectrum disorder (FVSD) and Fetal valproate syndrome (FVS) describe the range of signs and symptoms which occur as a consequence of exposure to sodium valproate or valproic acid in the womb. A wide range of physical anomalies occur at increased frequency, including spina bifida, major and minor limb abnormalities, oral clefting, cardiac defects, hypospadias, and joint laxity. A characteristic pattern of facial dysmorphism is frequently present, especially notable in early childhood. Neurodevelopmental problems including reduced IQ, poorer language and motor development, increased rates of autistic spectrum disorder and attention deficit hyperactivity disorder are observed in up to 40% of those exposed. Vision problems such as myopia and astigmatism are also common. Risks are dose dependent and the impact on the brain may be seen at lower doses than those required for physical development alterations.
<b>LD2F.0Y</b>	Other specified toxic or drug-related embryofetopathies
<b>LD2F.0Z</b>	Toxic or drug-related embryofetopathies, unspecified

**LD2F.1**

**Syndromes with multiple structural anomalies, not of environmental origin**

**Coded Elsewhere:** Fraser syndrome (LD2H.0)

Waardenburg-Shah syndrome (LD2H.3)

Oculocerebrorenal syndrome (5C60.0)

Albinism - black lock - cell migration disorder of the neurocytes  
of the gut - sensorineural deafness (LD2H.Y)

Bardet-Biedl syndrome (5A61.0)

Blepharocheilodontic syndrome (LD27.0Y)

Cat-eye syndrome (LD41.P)

Cataract - intellectual deficit - hypogonadism (5A61.0)

CHARGE syndrome (5A61.0)

Coffin-Siris syndrome (LD27.0Y)

Dubowitz syndrome (LD27.0Y)

Ectodermal dysplasia - ectrodactyly - macular dystrophy  
(LD27.0Y)

Ectrodactyly - ectodermal dysplasia - cleft lip or palate  
(LD27.0Y)

Ectrodactyly - ectodermal dysplasia without clefting (LD27.0Y)

Hirschsprung disease - deafness - polydactyly (LD2H.Y)

Limb-mammary syndrome (LD27.0Y)

Marshall syndrome (LD27.0Y)

MODY 5 syndrome (5A13.6)

Nijmegen breakage syndrome-like disorder (4A01.31)

Papillorenal syndrome (LA13.7Y)

Perrault syndrome (LD2H.Y)

Phocomelia - ectrodactyly - deafness - sinus arrhythmia  
(LD2H.Y)

Shwachman-Diamond syndrome (3A70.0)

Smith-Magenis syndrome (LD44.H1)

Split hand - split foot - deafness (LD2H.Y)

Triple A syndrome (5A74.Y)

Waardenburg syndrome (EC23.2Y)

WAGR syndrome (LD2A.Y)

Williams-Beuren syndrome (LD44.70)

Gorham-Stout disease (FB86.2)

Alagille syndrome (LB20.0Y)

Deafness – onychodystrophy (LD27.0Y)

Autosomal recessive cutis laxa, type 3 (LD28.2)

Macrocephaly – alopecia – cutis laxa – scoliosis syndrome  
(LD28.2)

SCARF syndrome (LD28.2)

Lethal restrictive dermopathy (EE6Y)  
Encephalocranioscutaneous lipomatosis (EF02.1)  
Dahlberg-Borer-Newcomer syndrome (LD27.0Y)

- LD2F.10** Prune belly syndrome  
A syndrome characterised by cryptorchidism, urinary tract defects, and poor development of the abdominal muscles causing the skin on the abdomen to wrinkle.
- LD2F.11** VATER association  
VACTERL/VATER is an association of congenital malformations typically characterised by the presence of at least three of the following: vertebral defects, anal atresia, cardiac defects, tracheo-oesophageal fistula, renal anomalies, and limb abnormalities.
- LD2F.12** Sirenomelia  
Sirenomelia is a rare lethal malformation characterised by severe anomalies of the caudal part of the fetus that include a single lower limb, with various degrees of involvement ranging from single to separate femurs in the same skin shaft, presence of two feet (sympode mermaid) or one foot (monopode mermaid), to absence of both feet (ectromelic mermaid). Urogenital anomalies are also present and include bilateral renal agenesis, absence of outflow tract and absence of external genitalia. Imperforate anus and sacro-coccygeal agenesis have also been reported. Together these malformations comprise the extreme form of the caudal regression sequence.
- LD2F.13** Meckel-Gruber syndrome  
Meckel syndrome (MKS) is a monogenic disease characterised by a combination of renal cysts and variably associated features, including developmental anomalies of the central nervous system (usually occipital encephalocele), hepatic ductal dysplasia and cysts, and polydactyly, and a lethal course, with death occurring in the perinatal period.
- LD2F.14** MURCS association  
MURCS association, which stands for Müllerian duct aplasia (MU), congenital renal dysplasia (R), cervical somite anomalies (CS), is the atypical (or type II) form of Mayer-Rokitansky-Küster-Hauser syndrome, characterised by utero-vaginal atresia in otherwise normal females as well associated kidney and skeletal abnormalities and hearing problems.
- LD2F.15** Noonan syndrome  
Noonan Syndrome is characterised by short stature, facial dysmorphism and congenital heart defects. The main facial features of NS are hypertelorism with down-slanting palpebral fissures, ptosis and low-set posteriorly rotated ears with a thickened helix. The cardiovascular defects most commonly associated with this condition are pulmonary stenosis and hypertrophic cardiomyopathy. Other associated features are webbed neck, chest deformity, mild intellectual deficit, cryptorchidism, poor feeding in infancy, bleeding tendency and lymphatic dysplasia. The syndrome is transmitted as an autosomal dominant trait.

- LD2F.16** Otomandibular dysplasia  
Any condition characterised by malformation of facial bones and muscles. These conditions may present with eyes that slant downward, sparse eyelashes, eyelid coloboma, hearing loss, underdeveloped or absent vertebrae, or cleft palate.
- LD2F.1Y** Other specified syndromes with multiple structural anomalies, not of environmental origin
- LD2F.1Z** Syndromes with multiple structural anomalies, not of environmental origin, unspecified
- LD2F.Y** **Other specified syndromes with multiple structural anomalies, without predominant body system involvement**
- LD2F.Z** **Syndromes with multiple structural anomalies, without predominant body system involvement, unspecified**
- LD2G** **Conjoined twins**  
A condition characterised as twins that are physically united at some part or parts of their bodies at the time of birth.

**LD2H**

## **Syndromic genetic deafness**

**Coded Elsewhere:** CATCH 22 phenotype (LD44.N0)

Pendred syndrome (5A00.02)

Generalised resistance to thyroid hormone (5A05)

CHARGE syndrome (5A61.0)

Deafness - opticoacoustic nerve atrophy - dementia (5C53.2Y)

Ectodermal dysplasia - sensorineural deafness (LD27.0Y)

Hypoparathyroidism - deafness - renal disease (LD27.0Y)

Renal tubular acidosis - deafness (GB90.44)

Stapes ankylosis with broad thumbs and toes (LD2F.1Y)

Stickler syndrome (LD2F.1Y)

Thiamine-responsive megaloblastic anaemia syndrome  
(5C63.Y)

Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (8C73.Y)

Norrie disease (LD21.Y)

Fechtner syndrome (3B64.01)

Spondyloepiphyseal dysplasia, MacDermot type (LD24.3)

Oral-facial-digital syndrome type 1 (LD25.00)

Oral-facial-digital syndrome type 2 (LD25.00)

Oral-facial-digital syndrome type 3 (LD25.00)

Oral-facial-digital syndrome type 4 (LD25.00)

Oral-facial-digital syndrome type 6 (LD25.00)

Oral-facial-digital syndrome type 8 (LD25.00)

Otopalatodigital syndrome (LD25.1)

Kearns-Sayre syndrome (9C82.0)

Multiple synostoses syndrome (LD26.3)

Arthrogryposis-like hand anomaly - sensorineural deafness  
(LD26.4Y)

Cockayne syndrome (LD2B)

Keratitis – ichthyosis – deafness syndrome (LD27.2)

Connexin palmoplantar keratoderma with sensorineural  
deafness (EC20.30)

Deafness – enamel hypoplasia – nail defects (LD27.0Y)

Tietz hypomelanosis – deafness syndrome (EC23.2Y)

LEOPARD syndrome (LD2F.1Y)

Cutis verticis gyrata - retinitis pigmentosa - sensorineural  
deafness (LD27.Y)

Deafness, lymphoedema and leukaemia syndrome (BD93.0)

Long QT syndrome with hearing impairment (BC65.0)

Infantile Bartter syndrome with deafness (GB90.43)

<b>LD2H.0</b>	<b>Fraser syndrome</b>
	Fraser syndrome is a rare syndrome characterised by cryptophthalmos and syndactyly and associated with a wide variety of other anomalies including: middle and outer ear malformations; high-arched palate; cleavage along the midplane of nares and tongue; hypertelorism; laryngeal stenosis; wide separation of symphysis pubis; displacement of umbilicus and nipples; absent or multicystic kidneys; bicornuate uterus, malformed Fallopian tubes, fusion of labia and enlargement of clitoris in girls; and undescended testes and small penis with hypospadias in boys.
<b>LD2H.1</b>	<b>Neuropathy with hearing impairment</b>
	Neuropathy with hearing impairment is characterised by the association of sensorineural hearing impairment and peripheral demyelinating and predominantly sensory neuropathy.
<b>LD2H.2</b>	<b>Progressive deafness with stapes fixation</b>
<b>LD2H.3</b>	<b>Waardenburg-Shah syndrome</b>
	In this syndrome the phenotype includes not only the classical features of Waardenburg syndrome but also Hirschsprung disease. It may be caused by mutations in SOX10, EDN3 or EDNRB genes.
<b>LD2H.4</b>	<b>Usher syndrome</b>
	Usher syndrome is the most common cause of hereditary combined deafness-blindness, and is characterised by the association of sensorineural deafness (usually congenital) with retinitis pigmentosa and progressive vision loss.
<b>LD2H.Y</b>	<b>Other specified syndromic genetic deafness</b>
<b>LD2H.Z</b>	<b>Syndromic genetic deafness, unspecified</b>
<b>LD2Y</b>	<b>Other specified multiple developmental anomalies or syndromes</b>
<b>LD2Z</b>	<b>Multiple developmental anomalies or syndromes, unspecified</b>

Chromosomal anomalies, excluding gene mutations (LD40-LD7Z)

Any disease caused by alteration of the number or structure of chromosomes.

<b>LD40</b>	<b>Complete trisomies of the autosomes</b>
	Any disease caused by the presence of one extra autosome, for a total of three. Confirmation is through observation of a supernumerary autosome by karyotyping.

<b>LD40.0</b>	<b>Complete trisomy 21</b>
	Trisomy 21 is a chromosomal abnormality, characterised by the presence of a third (partial or total) copy of chromosome 21, which clinical manifestations include variable intellectual deficiency, muscular hypotonia and joint laxity, often associated with facial dysmorphism and variable malformations (essentially heart and digestive) and a risk of complications (epilepsy, leukemia, auto-immune and endocrine pathologies, earlier aging and Alzheimer disease).
	<b>Inclusions:</b> Down syndrome
	<b>Coded Elsewhere:</b> Keratoconus in Down syndrome (9A78.50)
<b>LD40.1</b>	<b>Complete trisomy 13</b>
	Trisomy 13 is a chromosomal anomaly caused by the presence of an extra chromosome 13 and is characterised by brain malformations (holoprosencephaly), facial dysmorphism, ocular anomalies, postaxial polydactyly, visceral malformations (cardiopathy) and severe psychomotor retardation.
	<b>Inclusions:</b> Patau syndrome
<b>LD40.2</b>	<b>Complete trisomy 18</b>
	Trisomy 18 is a chromosomal abnormality associated with the presence of an extra chromosome 18 and characterised by growth delay, dolichocephaly, a characteristic facies, limb anomalies and visceral malformations.
<b>LD40.Y</b>	<b>Other specified complete trisomies of the autosomes</b>
<b>LD40.Z</b>	<b>Complete trisomies of the autosomes, unspecified</b>
<b>LD41</b>	<b>Duplications of the autosomes</b>
<b>LD41.0</b>	<b>Duplications of chromosome 1</b>
<b>LD41.00</b>	Duplications of the long arm of chromosome 1
<b>LD41.01</b>	Duplications of the short arm of chromosome 1
<b>LD41.0Y</b>	Other specified duplications of chromosome 1
<b>LD41.0Z</b>	Duplications of chromosome 1, unspecified
<b>LD41.1</b>	<b>Duplications of chromosome 2</b>
<b>LD41.10</b>	Duplications of the long arm of chromosome 2
<b>LD41.11</b>	Duplications of the short arm of chromosome 2
<b>LD41.1Y</b>	Other specified duplications of chromosome 2
<b>LD41.1Z</b>	Duplications of chromosome 2, unspecified
<b>LD41.2</b>	<b>Duplications of chromosome 3</b>
<b>LD41.20</b>	Duplications of the long arm of chromosome 3
<b>LD41.21</b>	Duplications of the short arm of chromosome 3
<b>LD41.2Y</b>	Other specified duplications of chromosome 3

<b>LD41.2Z</b>	Duplications of chromosome 3, unspecified
<b>LD41.3</b>	<b>Duplications of chromosome 4</b>
<b>LD41.30</b>	Duplications of the long arm of chromosome 4
<b>LD41.31</b>	Duplications of the short arm of chromosome 4
<b>LD41.3Y</b>	Other specified duplications of chromosome 4
<b>LD41.3Z</b>	Duplications of chromosome 4, unspecified
<b>LD41.4</b>	<b>Duplications of chromosome 5</b>
<b>LD41.40</b>	Duplications of the long arm of chromosome 5
<b>LD41.41</b>	Duplications of the short arm of chromosome 5
<b>LD41.4Y</b>	Other specified duplications of chromosome 5
<b>LD41.4Z</b>	Duplications of chromosome 5, unspecified
<b>LD41.5</b>	<b>Duplications of chromosome 6</b>
<b>LD41.50</b>	Duplications of the long arm of chromosome 6
<b>LD41.51</b>	Duplications of the short arm of chromosome 6
<b>LD41.5Y</b>	Other specified duplications of chromosome 6
<b>LD41.5Z</b>	Duplications of chromosome 6, unspecified
<b>LD41.6</b>	<b>Duplications of chromosome 7</b>
<b>LD41.60</b>	Duplications of the long arm of chromosome 7
<b>LD41.61</b>	Duplications of the short arm of chromosome 7
<b>LD41.6Y</b>	Other specified duplications of chromosome 7
<b>LD41.6Z</b>	Duplications of chromosome 7, unspecified
<b>LD41.7</b>	<b>Duplications of chromosome 8</b>
<b>LD41.70</b>	Duplications of the long arm of chromosome 8
<b>LD41.71</b>	Duplications of the short arm of chromosome 8
<b>LD41.7Y</b>	Other specified duplications of chromosome 8
<b>LD41.7Z</b>	Duplications of chromosome 8, unspecified
<b>LD41.8</b>	<b>Duplications of chromosome 9</b>
<b>LD41.80</b>	Duplications of the long arm of chromosome 9
<b>LD41.81</b>	Duplications of the short arm of chromosome 9
<b>LD41.8Y</b>	Other specified duplications of chromosome 9

<b>LD41.8Z</b>	Duplications of chromosome 9, unspecified
<b>LD41.9</b>	<b>Duplications of chromosome 10</b>
<b>LD41.90</b>	Duplications of the long arm of chromosome 10
<b>LD41.91</b>	Duplications of the short arm of chromosome 10
<b>LD41.9Y</b>	Other specified duplications of chromosome 10
<b>LD41.9Z</b>	Duplications of chromosome 10, unspecified
<b>LD41.A</b>	<b>Duplications of chromosome 11</b>
<b>LD41.B</b>	<b>Duplications of chromosome 12</b>
<b>LD41.B0</b>	Duplications of the long arm of chromosome 12
<b>LD41.B1</b>	Duplications of the short arm of chromosome 12
<b>LD41.BY</b>	Other specified duplications of chromosome 12
<b>LD41.BZ</b>	Duplications of chromosome 12, unspecified
<b>LD41.C</b>	<b>Duplications of chromosome 13</b>
<b>LD41.D</b>	<b>Duplications of chromosome 14</b>
<b>LD41.E</b>	<b>Duplications of chromosome 15</b>
<b>LD41.F</b>	<b>Duplications of chromosome 16</b>
<b>LD41.F0</b>	Duplications of the long arm of chromosome 16
<b>LD41.F1</b>	Duplications of the short arm of chromosome 16
<b>LD41.FY</b>	Other specified duplications of chromosome 16
<b>LD41.FZ</b>	Duplications of chromosome 16, unspecified
<b>LD41.G</b>	<b>Duplications of chromosome 17</b>
<b>LD41.G0</b>	Duplications of the long arm of chromosome 17
<b>LD41.G1</b>	Duplications of the short arm of chromosome 17
<b>LD41.GY</b>	Other specified duplications of chromosome 17
<b>LD41.GZ</b>	Duplications of chromosome 17, unspecified
<b>LD41.H</b>	<b>Duplications of chromosome 18</b>
<b>LD41.H0</b>	Duplications of the long arm of chromosome 18
<b>LD41.H1</b>	Duplications of the short arm of chromosome 18
<b>LD41.HY</b>	Other specified duplications of chromosome 18
<b>LD41.HZ</b>	Duplications of chromosome 18, unspecified

<b>LD41.J</b>	<b>Duplications of chromosome 19</b>
<b>LD41.J0</b>	Duplications of the long arm of chromosome 19
<b>LD41.J1</b>	Duplications of the short arm of chromosome 19
<b>LD41.JY</b>	Other specified duplications of chromosome 19
<b>LD41.JZ</b>	Duplications of chromosome 19, unspecified
<b>LD41.K</b>	<b>Duplications of chromosome 20</b>
<b>LD41.K0</b>	Duplications of the long arm of chromosome 20
<b>LD41.K1</b>	Duplications of the short arm of chromosome 20
<b>LD41.KY</b>	Other specified duplications of chromosome 20
<b>LD41.KZ</b>	Duplications of chromosome 20, unspecified
<b>LD41.L</b>	<b>Duplications of chromosome 21</b>
<b>LD41.M</b>	<b>Duplications of chromosome 22</b>
<b>LD41.N</b>	<b>Extra ring or dicentric chromosomes</b>
<b>LD41.P</b>	<b>Duplications with other complex rearrangements</b>
<b>LD41.Q</b>	<b>Extra marker chromosomes</b>
<b>LD41.Y</b>	<b>Other specified duplications of the autosomes</b>
<b>LD41.Z</b>	<b>Duplications of the autosomes, unspecified</b>
<b>LD42</b>	<b>Polyploidies</b>
	Any disease caused by one or more additional sets of chromosomes. Non-mosaic versions of these diseases are characterised by gross fetal malformation or death of the fetus. Confirmation is through observation of supernumerary sets of chromosomes by karyotyping.
<b>LD42.0</b>	<b>Triploidy</b>
	A disease caused by one additional set of chromosomes, for a total of 69 chromosomes. Triploidy can present with albuminuria, oedema, or hypertension in the mother. The fetus may present with microcephaly and a placenta that is enlarged and filled with cysts in the case of extra maternally inherited chromosomes, while extra paternally inherited chromosomes cause severe growth problems, an enlarged head, and a small placenta that does not have cysts. Non-mosaic triploidy is highly lethal, and is rarely observed in live births. Confirmation is through observation of an additional set of chromosomes by karyotyping.

<b>LD42.1</b>	<b>Tetraploidy</b>
	A disease caused by two additional sets of chromosomes, for a total of 92 chromosomes. This disease commonly results in spontaneous abortion during the first trimester. Live births of tetraploidy individuals are very rare. These cases are characterised by facial dysmorphism, severely delayed growth and developmental delay. Confirmation is through observation of two additional sets of chromosomes by karyotyping.
<b>LD42.Y</b>	<b>Other specified polyploidies</b>
<b>LD42.Z</b>	<b>Polyploidies, unspecified</b>
<b>LD43</b>	<b>Complete monosomies of the autosomes</b>
<b>LD43.0</b>	<b>Complete monosomy of autosome</b>
<b>LD43.1</b>	<b>Mosaic monosomy of autosome</b>
	Any disease caused by embryonic fusion or loss of an autosome early in embryonic development, resulting in a subset of cells in the body having only one of a pair of autosomes.
<b>LD43.Y</b>	<b>Other specified complete monosomies of the autosomes</b>
<b>LD43.Z</b>	<b>Complete monosomies of the autosomes, unspecified</b>
<b>LD44</b>	<b>Deletions of the autosomes</b>
<b>LD44.1</b>	<b>Deletions of chromosome 1</b>
<b>LD44.10</b>	Deletions of the long arm of chromosome 1
<b>LD44.11</b>	Deletions of the short arm of chromosome 1
<b>LD44.1Y</b>	Other specified deletions of chromosome 1
<b>LD44.1Z</b>	Deletions of chromosome 1, unspecified
<b>LD44.2</b>	<b>Deletions of chromosome 2</b>
<b>LD44.20</b>	Deletions of the long arm of chromosome 2
<b>LD44.21</b>	Deletions of the short arm of chromosome 2
<b>LD44.2Y</b>	Other specified deletions of chromosome 2
<b>LD44.2Z</b>	Deletions of chromosome 2, unspecified
<b>LD44.3</b>	<b>Deletions of chromosome 3</b>
<b>LD44.30</b>	Deletions of the long arm of chromosome 3
<b>LD44.31</b>	Deletions of the short arm of chromosome 3
<b>LD44.3Y</b>	Other specified deletions of chromosome 3
<b>LD44.3Z</b>	Deletions of chromosome 3, unspecified
<b>LD44.4</b>	<b>Deletions of chromosome 4</b>

<b>LD44.40</b>	Deletions of the long arm of chromosome 4
<b>LD44.41</b>	Deletions of the short arm of chromosome 4
<b>LD44.4Y</b>	Other specified deletions of chromosome 4
<b>LD44.4Z</b>	Deletions of chromosome 4, unspecified
<b>LD44.5</b>	<b>Deletions of chromosome 5</b>
<b>LD44.50</b>	Deletions of the long arm of chromosome 5
<b>LD44.51</b>	Deletions of the short arm of chromosome 5
<b>LD44.5Y</b>	Other specified deletions of chromosome 5
<b>LD44.5Z</b>	Deletions of chromosome 5, unspecified
<b>LD44.6</b>	<b>Deletions of chromosome 6</b>
<b>LD44.60</b>	Deletions of the long arm of chromosome 6
<b>LD44.61</b>	Deletions of the short arm of chromosome 6
<b>LD44.6Y</b>	Other specified deletions of chromosome 6
<b>LD44.6Z</b>	Deletions of chromosome 6, unspecified
<b>LD44.7</b>	<b>Deletions of chromosome 7</b>
<b>LD44.70</b>	Deletions of the long arm of chromosome 7
<b>LD44.71</b>	Deletions of the short arm of chromosome 7
<b>LD44.7Y</b>	Other specified deletions of chromosome 7
<b>LD44.7Z</b>	Deletions of chromosome 7, unspecified
<b>LD44.8</b>	<b>Deletions of chromosome 8</b>
<b>LD44.80</b>	Deletions of the long arm of chromosome 8 <b>Coded Elsewhere:</b> Langer-Giedion syndrome (LD24.80)
<b>LD44.81</b>	Deletions of the short arm of chromosome 8
<b>LD44.8Y</b>	Other specified deletions of chromosome 8
<b>LD44.8Z</b>	Deletions of chromosome 8, unspecified
<b>LD44.9</b>	<b>Deletions of chromosome 9</b>
<b>LD44.90</b>	Deletions of the long arm of chromosome 9
<b>LD44.91</b>	Deletions of the short arm of chromosome 9
<b>LD44.9Y</b>	Other specified deletions of chromosome 9
<b>LD44.9Z</b>	Deletions of chromosome 9, unspecified

<b>LD44.A</b>	<b>Deletions of chromosome 10</b>
<b>LD44.A0</b>	Deletions of the long arm of chromosome 10
<b>LD44.A1</b>	Deletions of the short arm of chromosome 10
<b>LD44.AY</b>	Other specified deletions of chromosome 10
<b>LD44.AZ</b>	Deletions of chromosome 10, unspecified
<b>LD44.B</b>	<b>Deletions of chromosome 11</b>
<b>LD44.B0</b>	Deletions of the long arm of chromosome 11
<b>LD44.B1</b>	Deletions of the short arm of chromosome 11 These deletions may give rise to the Paris-Trousseau syndrome, a very rare disorder in which intellectual deficit, cardiac malformations and facial abnormalities are associated with thrombocytopenia and dysmegakaryopoiesis.
	<b>Coded Elsewhere:</b> WAGR syndrome (LD2A.Y)
<b>LD44.BY</b>	Other specified deletions of chromosome 11
<b>LD44.BZ</b>	Deletions of chromosome 11, unspecified
<b>LD44.C</b>	<b>Deletions of chromosome 12</b>
<b>LD44.C0</b>	Deletions of the long arm of chromosome 12
<b>LD44.C1</b>	Deletions of the short arm of chromosome 12
<b>LD44.CY</b>	Other specified deletions of chromosome 12
<b>LD44.CZ</b>	Deletions of chromosome 12, unspecified
<b>LD44.D</b>	<b>Deletions of chromosome 13</b>
<b>LD44.E</b>	<b>Deletions of chromosome 14</b>
<b>LD44.F</b>	<b>Deletions of chromosome 15</b>
<b>LD44.G</b>	<b>Deletions of chromosome 16</b>
<b>LD44.G0</b>	Deletions of the long arm of chromosome 16
<b>LD44.G1</b>	Deletions of the short arm of chromosome 16 <b>Coded Elsewhere:</b> Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis (LD2F.1Y) Alpha thalassaemia - intellectual deficit syndrome (3A50.1)
<b>LD44.GY</b>	Other specified deletions of chromosome 16
<b>LD44.GZ</b>	Deletions of chromosome 16, unspecified
<b>LD44.H</b>	<b>Deletions of chromosome 17</b>
<b>LD44.H0</b>	Deletions of the long arm of chromosome 17

<b>LD44.H1</b>	Deletions of the short arm of chromosome 17  <b>Coded Elsewhere:</b> Miller-Dieker syndrome (LD20.1)
<b>LD44.HY</b>	Other specified deletions of chromosome 17
<b>LD44.HZ</b>	Deletions of chromosome 17, unspecified
<b>LD44.J</b>	<b>Deletions of chromosome 18</b>
<b>LD44.J0</b>	Deletions of the long arm of chromosome 18
<b>LD44.J1</b>	Deletions of the short arm of chromosome 18
<b>LD44.JY</b>	Other specified deletions of chromosome 18
<b>LD44.JZ</b>	Deletions of chromosome 18, unspecified
<b>LD44.K</b>	<b>Deletions of chromosome 19</b>
<b>LD44.K0</b>	Deletions of the long arm of chromosome 19
<b>LD44.K1</b>	Deletions of the short arm of chromosome 19
<b>LD44.KY</b>	Other specified deletions of chromosome 19
<b>LD44.KZ</b>	Deletions of chromosome 19, unspecified
<b>LD44.L</b>	<b>Deletions of chromosome 20</b>
<b>LD44.L0</b>	Deletions of the long arm of chromosome 20
<b>LD44.L1</b>	Deletions of the short arm of chromosome 20
<b>LD44.LY</b>	Other specified deletions of chromosome 20
<b>LD44.LZ</b>	Deletions of chromosome 20, unspecified
<b>LD44.M</b>	<b>Deletions of chromosome 21</b>
<b>LD44.N</b>	<b>Deletions of chromosome 22</b>
<b>LD44.N0</b>	CATCH 22 phenotype  Monosomy 22q11 (DiGeorge Velocardiofacial syndrome, DGS/VCF) syndrome is a chromosomal anomaly characterised by the association of several variable malformations: hypoplastic thymus and parathyroid glands, congenital conotruncal heart defects, a subtle but characteristic facial dysmorphism, cleft palate or velar insufficiency, and learning difficulties.
	<b>Inclusions:</b> Pharyngeal pouch syndrome DiGeorge syndrome Velocardiofacial syndrome
<b>LD44.NY</b>	Other specified deletions of chromosome 22
<b>LD44.NZ</b>	Deletions of chromosome 22, unspecified
<b>LD44.P</b>	<b>Deletions with other complex rearrangements</b>

<b>LD44.Y</b>	<b>Other specified deletions of the autosomes</b>
<b>LD44.Z</b>	<b>Deletions of the autosomes, unspecified</b>
<b>LD45</b>	<p><b>Uniparental disomies</b></p> <p>Any disease caused by the inheritance of two homologous copies of a chromosome from one parent, and none from the other parent. Confirmation is by observation of identical chromosomes pairs by genetic testing.</p>
<b>LD45.0</b>	<p><b>Uniparental disomies of maternal origin</b></p> <p>Any disease characterised by the inheritance of two homologous copies of a chromosome from the mother, and none from the father. Confirmation is by observation of identical chromosome pairs, and matching to a maternal chromosome, by genetic testing.</p>
<b>LD45.1</b>	<p><b>Uniparental disomies of paternal origin</b></p> <p>Any disease caused by the inheritance of two homologous copies of a chromosome from the father, and none from the mother. Confirmation is by observation of identical chromosome pairs, and matching to a paternal chromosome, by genetic testing.</p>
<b>LD45.Y</b>	<b>Other specified uniparental disomies</b>
<b>LD45.Z</b>	<b>Uniparental disomies, unspecified</b>
<b>LD46</b>	<p><b>Imprinting errors</b></p>
<b>LD46.0</b>	<b>Maternal imprinting error</b>
<b>LD46.1</b>	<b>Paternal imprinting error</b>
<b>LD46.Y</b>	<b>Other specified imprinting errors</b>
<b>LD46.Z</b>	<b>Imprinting errors, unspecified</b>
<b>LD47</b>	<p><b>Balanced rearrangements or structural rearrangements</b></p> <p>A condition caused by translocation or other structural rearrangement of genomic material between chromosomes demonstrating no net gain or loss of genomic material, in an individual displaying no phenotype. Confirmation is through observation of a balanced event by genetic testing.</p>
<b>LD47.0</b>	<p><b>Balanced translocation and insertion in normal individual</b></p> <p>A condition caused by translocation of genetic material between chromosomes with no net gain or loss of genetic material, in an individual demonstrating no abnormalities. Confirmation is through observation of a balanced translocation and insertion by genetic testing.</p>
<b>LD47.1</b>	<p><b>Chromosome inversion in normal individual</b></p> <p>Any disease caused by inversion of genetic material on a chromosome, in an individual demonstrating no abnormalities. Confirmation is through observation of a chromosomal inversion by genetic testing.</p>

<b>LD47.2</b>	<b>Balanced autosomal rearrangement in abnormal individual</b> Any disease caused by alteration of autosome structure with no net gain or loss of genetic material, in an individual demonstrating abnormalities. Confirmation is through observation of a balanced chromosomal rearrangement by genetic testing.
<b>LD47.3</b>	<b>Balanced sex or autosomal rearrangement in abnormal individual</b> Any disease caused by alteration of chromosomal structure with no net gain or loss of genetic material, in an individual demonstrating abnormalities. Confirmation is through observation of a balanced chromosomal rearrangement by genetic testing.
<b>LD47.4</b>	<b>Autosomal fragile site</b> Any disease caused by presence of a fragile site on an autosome. These diseases may present as asymptomatic. Confirmation is through observation of a fragile site by genetic testing.
<b>LD47.Y</b>	<b>Other specified balanced rearrangements or structural rearrangements</b>
<b>LD47.Z</b>	<b>Balanced rearrangements or structural rearrangements, unspecified</b>

#### Sex chromosome anomalies (LD50-LD5Z)

Any disease caused by change in the number or structure of the X or Y chromosome. Confirmation is by observation of a chromosomal anomaly by genetic testing.

<b>LD50</b>	<b>Number anomalies of chromosome X</b>
<b>LD50.0</b>	<b>Turner syndrome</b> Karyotype missing one X chromosome (45,X0 or 45,X0/46,XX mosaicism); gonads: ovaries (streak); phenotype female with short stature, amenorrhea (hypergonadotropic hypogonadism), absence of sexual development, webbed neck, low set ears, posterior hairline, widely-spaced nipples, short fourth metacarpals, and increased carrying angle at the elbow (cubitus valgus). Often associated with renal, cardiac and ocular abnormalities. <i>Inclusions:</i> Monosomy X <i>Exclusions:</i> Noonan syndrome (LD2F.15)
<b>LD50.00</b>	Karyotype 45, X A disease affecting females, caused by absence of one of the two X chromosomes. This disease may present with short stature, extra folds of skin on the neck, a low hairline at the back of the neck, puffiness or swelling of the hands and feet, skeletal abnormalities, ovarian hypofunction or premature ovarian failure, kidney problems, or heart defects. Confirmation is through observation of only one X chromosome by karyotyping.

- LD50.01** Karyotype 46, X iso Xq  
A disease affecting females, caused by one of the two X chromosomes consisting of two q arms, which are structurally identical and contain the same genes. This disease may present with short stature, extra folds of skin on the neck, a low hairline at the back of the neck, puffiness or swelling of the hands and feet, skeletal abnormalities, ovarian hypofunction or premature ovarian failure, kidney problems, or heart defects. This disease may be differentiated from classical Turner Syndrome by a near complete lack of gonadal development, resulting in a lack of menstruation or breast development. Confirmation is through observation of an iso Xq chromosome by karyotyping.
- LD50.02** Karyotype 46, X with abnormal sex chromosome, except iso Xq
- LD50.03** Mosaicism, 45, X, 46, XX or XY  
A disease caused by embryonic fusion, or by the loss of one of the sex chromosomes from a cell early in embryonic development; Gonadal status: normal or variable abnormalities of sexual anatomy, maturation or function. Phenotype: normal, or abnormal sexual development.
- LD50.04** Mosaicism, 45, X or other cell line with abnormal sex chromosome  
A disease caused by embryonic fusion or the structural mutation of a sex chromosome early in embryonic development, resulting in a subset of cells in the body having one normal copy of the X chromosome and one abnormal sex chromosome. This disease may present with short stature, sexual organ dysfunction, or may be asymptomatic.
- LD50.1** **Karyotype 47,XXX**  
Trisomy X is a sex chromosome anomaly with a variable phenotype caused by the presence of an extra X chromosome in females (47,XXX instead of 46,XX). Most individuals are only mildly affected or asymptomatic, the most common physical features including tall stature, epicanthal folds, hypotonia and clinodactyly, with seizures, renal and genitourinary abnormalities, and premature ovarian failure being also associated findings.
- LD50.2** **Mosaicism, lines with various numbers of X chromosomes**  
A disease caused by embryonic fusion or gain or loss of X chromosomes early in embryonic development, resulting in a subset of cells in the body having an abnormal number of X chromosomes. This disease may present with abnormal height, genitourinary abnormalities, or may be asymptomatic.
- LD50.3** **Klinefelter syndrome**  
Klinefelter syndrome defines a group of chromosomal disorders in which there is at least one extra X chromosome compared with the normal 46,XY male karyotype. The effects on physical features and on physical and cognitive development increase with the number of extra X's, and each extra X is associated with an intelligence quotient (IQ) decrease of approximately 15-16 points, with language most affected, particularly expressive language skills.

<b>LD50.30</b>	Klinefelter syndrome with karyotype 47,XXY, regular Karyotype 47 XXY; gonads: testes (hypogonadism) small and firm with decreased spermatogenesis ; phenotype male with associated congenital abnormalities (decreased virilization due to decreased testosterone production, long arms and legs, short trunk, psychosocial problems).
<b>LD50.31</b>	Klinefelter syndrome, male with more than two X chromosomes A disease affecting males, caused by the presence of more than two X chromosomes in each cell. This disease is characterised by impaired sexual development, intellectual disability, distinctive facial features, skeletal abnormalities, poor coordination, and severe problems with speech. This disease may be differentiated from classic Klinefelter syndrome by increased severity of symptoms. Confirmation is through observation of more than two X chromosomes by karyotyping.
<b>LD50.3Y</b>	Other specified Klinefelter syndrome
<b>LD50.3Z</b>	Klinefelter syndrome, unspecified
<b>LD50.Y</b>	<b>Other specified number anomalies of chromosome X</b>
<b>LD50.Z</b>	<b>Number anomalies of chromosome X, unspecified</b>
<b>LD51</b>	<b>Structural anomalies of chromosome X, excluding Turner syndrome</b>
<b>LD52</b>	<b>Number anomalies of chromosome Y</b>
<b>LD52.0</b>	<b>Male with 46,XX karyotype</b> A disease affecting males, characterised by hypergonadotropic hypogonadism, testosterone deficiency, and infertility. This condition may also present with hypospadias. This disease may be associated with abnormal crossing over of the sex chromosomes during meiosis in the father, resulting in the SRY gene being present on one or both copies of the X chromosome.
<b>LD52.1</b>	<b>Male with double or multiple Y</b> A condition affecting males, caused by the presence of supernumerary Y chromosomes. This condition is asymptomatic. Confirmation is through observation of supernumerary Y chromosomes by karyotyping.
<b>LD52.Y</b>	<b>Other specified number anomalies of chromosome Y</b>
<b>LD52.Z</b>	<b>Number anomalies of chromosome Y, unspecified</b>
<b>LD53</b>	<b>Structural anomalies of chromosome Y</b> <b>Coded Elsewhere:</b> Chromosome Y deletion (5A81.1)
<b>LD54</b>	<b>Male with sex chromosome mosaicism</b> Any disease affecting males, caused by embryonic fusion or gain or loss of a sex chromosome early in embryonic development, resulting in a subset of cells in the body having an abnormal number of sex chromosomes. These diseases may present with deficiencies in testosterone, abnormalities of sexual development, or infertility.

**LD55****Fragile X chromosome**

Fragile X syndrome is a rare genetic disease associated with mild to severe intellectual deficit that may be associated with behavioural disorders and characteristic physical features.

*Inclusions:*                   Fragile X syndrome

**LD56****Chimaera 46, XX, 46, XY**

A disease caused by XX and XY embryonic fusion or two distinct loss events of a sex chromosome from an XXY embryo early in development. This results in a subset of cells in the body having an XX karyotype, while other cells demonstrate an XY karyotype. This disease may present with abnormal genital development.

**LD56.0****Androgenetic chimaera****LD56.1****Gynogenetic chimaera****LD56.Y****Other specified chimaera 46, XX, 46, XY****LD56.Z****Chimaera 46, XX, 46, XY, unspecified****LD5Y****Other specified sex chromosome anomalies****LD5Z****Sex chromosome anomalies, unspecified****LD7Y****Other specified chromosomal anomalies, excluding gene mutations****LD7Z****Chromosomal anomalies, excluding gene mutations, unspecified**

**Conditions with disorders of intellectual development as a relevant clinical feature**

**Coded Elsewhere:** Lesch-Nyhan syndrome (5C55.01)

Hydrocephalus with stenosis of the aqueduct of Sylvius  
(LA04.0)

Pelizaeus-Merzbacher disease (8A44.0)

Hereditary sensory and autonomic neuropathy type IV  
(8C21.2)

Joubert syndrome (LD20.00)

Phenylketonuria (5C50.0)

Tyrosinaemia type 2 (5C50.12)

Carbamoylphosphate synthetase deficiency (5C50.A1)

Carnosinaemia (5C50.F1)

Homocarnosinosis (5C50.F2)

Syndromes with lissencephaly as a major feature (LD20.1)

Sjögren-Larsson syndrome (5C52.03)

Polymicrogyria (LA05.50)

Porencephaly (LA05.60)

Pyruvate dehydrogenase complex deficiency (5C53.02)

Brain-lung-thyroid syndrome (CB04.5)

Metachromatic leukodystrophy (5C56.02)

Neuronal ceroid lipofuscinosis (5C56.1)

Mucopolysaccharidosis type 2 (5C56.31)

Mucopolysaccharidosis type 6 (5C56.33)

Oculocerebrorenal syndrome (5C60.0)

CATCH 22 phenotype (LD44.N0)

Langer-Giedion syndrome (LD24.80)

Crigler-Najjar syndrome (5C58.00)

Fragile X chromosome (LD55)

Incontinentia pigmenti (LD27.00)

Tuberous sclerosis (LD2D.2)

Noonan syndrome (LD2F.15)

Congenital rubella syndrome (KA62.8)

Congenital cytomegalovirus infection (KA62.3)

Complete trisomy 21 (LD40.0)

Klinefelter syndrome, male with more than two X chromosomes (LD50.31)

Intellectual disability – enteropathy – deafness – neuropathy – ichthyosis – keratoderma syndrome (LD2H.Y)

Microcephaly - deafness - intellectual disability (LD2H.Y)

Schizophrenia - intellectual disability - deafness - retinitis (LD2H.Y)

Corneal anaesthesia - deafness - intellectual disability  
(LD2H.Y)  
Ataxia - deafness - intellectual disability syndrome (LD2H.Y)  
Retinitis pigmentosa - intellectual disability - deafness -  
hypogenitalism (LD2H.Y)

- LD90.0 Angelman syndrome**  
Angelman syndrome is a neurogenetic disorder characterised by severe intellectual deficit and distinct facial dysmorphic (microcephaly, macrostomia, maxillary hypoplasia, prognathia), behavioural (outbursts of laughter with hand flapping, a happy demeanour, hyperactivity without aggression, short attention span, excitability and sleeping problems with decreased need to sleep, increased sensitivity to heat, attraction to and fascination with water), and neurological features (a puppet-like gait, ataxia and epileptic seizures).
- LD90.1 Early-onset parkinsonism - intellectual deficit**  
Early-onset parkinsonism with intellectual deficit is a basal ganglia disorder characterised by parkinsonian-type symptoms (postural changes, tremor, rigidity), megalencephaly and variable intellectual deficit. Other signs are frontal bossing, persistent frontal lobe reflexes, strabismus and seizures.
- LD90.2 Pelizaeus-Merzbacher-like disease**  
Pelizaeus-Merzbacher-like disease (PMLD) is an autosomal recessive leukodystrophy sharing identical clinical and radiological features as X-linked Pelizaeus-Merzbacher disease (PMD).
- LD90.3 Prader-Willi syndrome**  
Prader-Willi syndrome is a rare genetic disorder characterised by hypothalamic-pituitary abnormalities with severe hypotonia during the neonatal period and first two years of life and the onset of hyperphagia with a risk of morbid obesity during infancy and adulthood, learning difficulties and behavioural problems or severe psychiatric problems.
- LD90.4 Rett syndrome**  
A condition in which apparently normal early development is followed by partial or complete loss of speech and of skills in locomotion and use of hands, together with deceleration in head growth, usually with an onset between seven and 24 months of age. Loss of purposive hand movements, hand-wringing stereotypies, and hyperventilation are characteristic. Social and play development are arrested but social interest tends to be maintained. Trunk ataxia and apraxia start to develop by age four years and choreoathetoid movements frequently follow. Severe mental retardation almost invariably results.
- LD90.Y Other specified conditions with disorders of intellectual development as a relevant clinical feature**
- LD90.Z Conditions with disorders of intellectual development as a relevant clinical feature, unspecified**
- LD9Y Other specified developmental anomalies**
- LD9Z Developmental anomalies, unspecified**

# CHAPTER 21

---

## Symptoms, signs or clinical findings, not elsewhere classified

This chapter has 311 four-character categories.

Code range starts with MA00

Clinical findings include those found using physical, laboratory and imaging techniques.

Diseases can manifest in many ways and in different body systems. Such specific manifestations may be a reason for treatment or encounter, with or without identifying or addressing the underlying condition.

Categories in this chapter include the less well-defined conditions and symptoms that, without the necessary study of the case to establish a final diagnosis, could be designated 'not otherwise specified', 'unknown aetiology' or 'transient'.

The conditions and signs or symptoms included in this chapter consist of:

- cases for which no more specific diagnosis can be made even after all the facts bearing on the case have been investigated
- signs or symptoms existing at the time of initial encounter that proved to be transient and whose causes could not be determined;
- provisional diagnoses in a patient who failed to return for further investigation or care;
- cases referred elsewhere for investigation or treatment before the diagnosis was made;
- cases in which a more precise diagnosis was not available for any other reason;
- certain symptoms, for which supplementary information is provided, that represent important problems in medical care in their own right.

These categories should be used in conjunction with a code from another chapter that identifies the underlying condition.

**Exclusions:** Certain conditions originating in the perinatal period (Chapter 19)

Clinical findings on antenatal screening of mother (JA66)

This chapter contains the following top level blocks:

- Symptoms of blood, blood-forming organs, or the immune system
- Symptoms, signs or clinical findings of blood, blood-forming organs, or the immune system
- Symptoms, signs or clinical findings of endocrine, nutritional or metabolic diseases
- Symptoms, signs or clinical findings of speech or voice
- Mental or behavioural symptoms, signs or clinical findings
- Symptoms, signs or clinical findings of the nervous system
- Symptoms, signs or clinical findings of the visual system
- Symptoms, signs or clinical findings of ear or mastoid process
- Symptoms, signs or clinical findings of the circulatory system

- Symptoms, signs or clinical findings of the respiratory system
- Symptoms, signs or clinical findings of the digestive system or abdomen
- Symptoms, signs or clinical findings involving the skin
- Symptoms, signs or clinical findings of the musculoskeletal system
- Symptoms, signs or clinical findings of the genitourinary system
- General symptoms, signs or clinical findings
- Ill-defined and unknown causes of mortality

Symptoms of blood, blood-forming organs, or the immune system (MA00-MA0Y)

**Coded Elsewhere:** Fear of haematological disease (MG24.2)

**MA00 Symptom or complaint of the blood**

**MA01 Enlarged lymph nodes**

Enlarged lymph node is called lymphadenopathy which means the abnormal enlargement of lymph nodes.

**Inclusions:** Lymphadenopathy

**Exclusions:** Chronic lymphadenitis (BD90.2)

Nonspecific mesenteric lymphadenitis (BD90.1)

lymphadenitis NOS (BD90)

**MA01.0 Localised lymph node enlargement**

**MA01.1 Generalised lymph node enlargement**

**Exclusions:** Human immunodeficiency virus disease associated with generalised lymphadenopathy (1C62.0)

**MA01.Z Enlarged lymph nodes, unspecified**

**MA0Y Other specified symptoms of blood, blood-forming organs, or the immune system**

Symptoms, signs or clinical findings of blood, blood-forming organs, or the immune system (MA10-MA3Y)

Clinical findings in blood, blood-forming organs, or the immune system (MA10-MA1Y)

**Exclusions:** abnormalities of coagulation (3B10-3B4Z)

abnormalities of lipids (5C80-5C8Z)

Thrombocytopenia (3B64)

Abnormal haematological finding on antenatal screening of mother (JA66.0)

Haemorrhagic or haematological disorders of fetus or newborn (KA80-KA8Z)

**MA10 Abnormal serum enzyme levels**

<b>MA10.0</b>	<b>Elevation of levels of transaminase or lactic acid dehydrogenase</b>
<b>MA10.1</b>	<b>Abnormal levels of other specified serum enzymes</b>
<b>MA10.2</b>	<b>Abnormal level of unspecified serum enzyme</b>
<b>MA11</b>	<b>Clinical findings of hormones in blood, blood-forming organs, or the immune system</b>
<b>MA12</b>	<b>Clinical findings of drugs, medicaments and biological substances in blood, blood-forming organs, or the immune system</b>
<b>MA12.0</b>	<b>Finding of opiate drug in blood</b>
<b>MA12.1</b>	<b>Finding of cocaine in blood</b>
<b>MA12.2</b>	<b>Finding of hallucinogen in blood</b>
<b>MA12.3</b>	<b>Finding of psychotropic drug in blood</b>
<b>MA12.4</b>	<b>Finding of steroid agent in blood</b>
<b>MA12.Y</b>	<b>Other specified clinical findings of drugs, medicaments and biological substances in blood, blood-forming organs, or the immune system</b>
<b>MA13</b>	<b>Clinical findings of substances chiefly nonmedicinal as to source in blood, blood-forming organs, or the immune system</b>
<b>MA13.0</b>	<b>Finding of abnormal level of heavy metals in blood</b>
<b>MA13.00</b>	Abnormal level of lead in blood Abnormal level of lead in blood in those who have been exposed to lead and who require management.  <b>Exclusions:</b> Harmful effects of or exposure to noxious substances, Substances chiefly nonmedicinal as to source, Metals (NE61)
<b>MA13.0Y</b>	Finding of abnormal level of other specified heavy metals in blood
<b>MA13.1</b>	<b>Finding of alcohol in blood</b>
<b>MA13.Y</b>	<b>Abnormal level of other specified substances chiefly nonmedicinal as to source in blood, blood-forming organs and the immune system</b>
<b>MA14</b>	<b>Immunological findings in blood, blood-forming organs, or the immune system</b>
<b>MA14.0</b>	<b>Laboratory evidence of human immunodeficiency virus</b>  <b>Exclusions:</b> Human immunodeficiency disease complicating pregnancy, childbirth or the puerperium (JB63.7)  Human immunodeficiency virus disease (1C60-1C62.Z)  Asymptomatic human immunodeficiency virus infection (1C62.0)
<b>MA14.1</b>	<b>Certain specified immunological findings</b>

<b>MA14.10</b>	Abnormal reaction to tuberculin test
<b>MA14.11</b>	Anticitrullinated protein antibody negative
<b>MA14.12</b>	Anticitrullinated protein antibody positive
<b>MA14.13</b>	Anti-nuclear antibody negative
<b>MA14.14</b>	Anti-nuclear antibody positive
<b>MA14.15</b>	Elevated C-reactive protein
<b>MA14.16</b>	False-positive serological test for syphilis <i>Inclusions:</i> False-positive Wassermann reaction
<b>MA14.17</b>	Human leukocyte antigen negative
<b>MA14.18</b>	Human leukocyte antigen positive <i>Inclusions:</i> HLA B-27
<b>MA14.19</b>	Neural autoantibody negative
<b>MA14.1A</b>	Neural autoantibody positive
<b>MA14.1B</b>	Prostate specific antigen positive
<b>MA14.1C</b>	Raised antibody titre <i>Exclusions:</i> isoimmunization, in pregnancy affecting fetus or newborn (KA84)
<b>MA14.1D</b>	Rheumatoid factor negative
<b>MA14.1E</b>	Rheumatoid factor positive
<b>MA14.Y</b>	<b>Other specified immunological findings in blood, blood-forming organs, or the immune system</b>
<b>MA15</b>	<b>Microbiological findings in blood, blood-forming organs, or the immune system</b>
<b>MA15.0</b>	<b>Bacteraemia</b> The presence of bacteria in the blood. A positive blood culture without signs of infection. <i>Exclusions:</i> Bacterial infection of unspecified site (1C41) Sepsis (1G40-1G41)
<b>MA15.1</b>	<b>Fungaemia</b>
<b>MA15.Y</b>	<b>Other specified microbiological findings in blood, blood-forming organs, or the immune system</b>
<b>MA16</b>	<b>Cytological findings in blood, blood-forming organs, or the immune system</b>

<b>MA16.0</b>	<b>Abnormality of red blood cells</b>
	<b><i>Exclusions:</i></b>
	Polycythaemia neonatorum (KA8A)
	polycythaemia: NOS (3A80-3A8Z)
	polycythaemia: benign (familial) (3A80.0)
	anaemias (3A00-3A9Z)
	Polycythaemia vera (2A20.4)
	Acquired polycythaemia (3A81)
<b>MA16.00</b>	Haemolysis, not elsewhere classified
	<b><i>Exclusions:</i></b>
	Postpartum coagulation defects (JA43.3)
	Delayed or excessive haemorrhage following abortion, ectopic or molar pregnancy (JA05.1)
	Intrapartum haemorrhage with coagulation defect (JA42.0)
	HELLP syndrome (JA24.2)
	Neonatal haemolysis due to systemic bacterial infection with or without concomitant diffuse intravascular coagulation (KA84.5)
<b>MA16.0Y</b>	Other specified abnormality of red blood cells
<b>MA16.0Z</b>	Abnormality of red blood cells, unspecified
<b>MA16.1</b>	<b>Abnormality of white blood cells</b>
	<b><i>Exclusions:</i></b>
	Neutrophilia (4B00.1)
<b>MA16.10</b>	Decreased white blood cell count
<b>MA16.11</b>	Elevated white blood cell count
<b>MA16.1Z</b>	Abnormality of white blood cells, unspecified
<b>MA16.Y</b>	<b>Other specified cytological findings in blood, blood-forming organs, or the immune system</b>
<b>MA16.Z</b>	<b>Cytological findings in blood, blood-forming organs, or the immune system, unspecified</b>
<b>MA17</b>	<b>Histological findings in blood, blood-forming organs, or the immune system</b>

<b>MA18</b>	<b>Certain clinical findings of blood chemistry</b>
	<p><b>Exclusions:</b> specific findings indicating disorder of: carbohydrate metabolism (5C51)</p> <p>specific findings indicating disorder of: amino-acid metabolism (5C50)</p> <p>specific findings indicating disorder of: lipid metabolism (5C52)</p> <p>asymptomatic hyperuricaemia (5C55)</p> <p>abnormality of fluid, electrolyte or acid-base balance (5C70-5C7Z)</p> <p>Neonatal hypoglycaemia (KB60.4)</p>
<b>MA18.0</b>	<b>Elevated blood glucose level</b>
	<p><b>Exclusions:</b> Diabetes mellitus in pregnancy (JA63)</p> <p>Syndrome of infant of mother with gestational diabetes (KB60.0)</p> <p>Postprocedural hypoinsulinaemia (5D41)</p> <p>Syndrome of infant of a diabetic mother, type 1 or 2, nongestational, insulin dependent (KB60.1)</p> <p>Neonatal diabetes mellitus (KB60.2)</p>
	<b>Coded Elsewhere:</b> Neonatal hyperglycaemia (KB60.3)
<b>MA18.00</b>	Abnormal glucose tolerance test Greater than normal levels of glucose found in laboratory examination of the blood to check how the body breaks down (metabolizes) blood sugar. Positive findings may indicate diabetes or Cushing diseases, among other things.
<b>MA18.0Y</b>	Other specified elevated blood glucose level
<b>MA18.0Z</b>	Elevated blood glucose level, unspecified
<b>MA18.1</b>	<b>Abnormal level of blood mineral</b>
	<p><b>Inclusions:</b> Abnormal blood level of mineral NEC</p> <p><b>Exclusions:</b> nutritional mineral deficiency (5B5K)</p> <p>Neonatal hypomagnesaemia (KB61.0)</p>
<b>MA18.2</b>	<b>Abnormal arterial blood-gas level</b>
<b>MA18.3</b>	<b>Abnormal coagulation profile</b>
<b>MA18.4</b>	<b>Low haemoglobin</b>
	<p><b>Exclusions:</b> Low affinity haemoglobin (3A51.8)</p>
<b>MA18.Y</b>	<b>Other specified abnormal findings of blood chemistry</b>
<b>MA18.Z</b>	<b>Abnormal findings of blood chemistry, unspecified</b>

<b>MA19</b>	<b>Certain abnormalities of plasma proteins</b>
	<b><i>Exclusions:</i></b> Disorders of plasma-protein metabolism, not elsewhere classified (5D00-5D0Y)
<b>MA19.0</b>	<b>Abnormality of albumin</b>
<b>MA19.1</b>	<b>Abnormality of alphafetoprotein</b>
<b>MA19.2</b>	<b>Abnormality of globulin</b>
<b>MA19.Y</b>	<b>Abnormalities of other specified plasma proteins</b>
<b>MA19.Z</b>	<b>Abnormalities of unspecified plasma proteins</b>
<b>MA1A</b>	<b>Elevated erythrocyte sedimentation rate or abnormality of plasma viscosity</b>
<b>MA1A.0</b>	<b>Elevated erythrocyte sedimentation rate</b>
<b>MA1A.1</b>	<b>Abnormal plasma viscosity</b>
<b>MA1Y</b>	<b>Other specified clinical findings in blood, blood-forming organs, or the immune system</b>
<hr/>	
<b>MA3Y</b>	<b>Other specified symptoms, signs or clinical findings of blood, blood-forming organs, or the immune system</b>
	Symptoms, signs or clinical findings of endocrine, nutritional or metabolic diseases (MA50-MA6Y)
	<b><i>Coded Elsewhere:</i></b> Symptoms of endocrine, nutritional or metabolic diseases
	Results of function studies of the endocrine, nutritional or metabolic diseases (MA50-MA51)
<b>MA50</b>	<b>Abnormal results of thyroid function studies</b>
<b>MA51</b>	<b>Abnormal results of other endocrine function studies</b>
	<b><i>Exclusions:</i></b> Abnormal glucose tolerance test (MA18.00)
<hr/>	
<b>MA6Y</b>	<b>Other specified symptoms, signs or clinical findings of endocrine, nutritional or metabolic diseases</b>

## Symptoms, signs or clinical findings of speech or voice (MA80-MB0Y)

Symptoms or signs involving speech or voice (MA80-MA8Y)

**Coded Elsewhere:** Echolalia (MB23.9)

**MA80**

### **Speech disturbances**

Speech disturbances, not classified elsewhere include dysphasia and aphasia, dysarthria and anarthria, and other speech disturbances.

**Exclusions:** Developmental speech or language disorders (6A01)

Autism spectrum disorder (6A02)

Speech dysfluency (MA81)

**Coded Elsewhere:** Mutism (MB23.D)

**MA80.0**

### **Aphasia**

**Exclusions:** Developmental speech or language disorders (6A01)

**MA80.1**

### **Dysphasia**

A cognitive disorder marked by an impaired ability to comprehend or express language in its written or spoken form. This condition is caused by diseases which affect the language areas of the dominant hemisphere. Clinical features are used to classify the various subtypes of this condition.

**Exclusions:** progressive isolated aphasia (8E40-8E4Y)

Developmental speech or language disorders (6A01)

**MA80.2**

### **Dysarthria**

**Exclusions:** Developmental speech or language disorders (6A01)

**MA80.20**

Anarthria

**MA80.2Y**

Other specified dysarthria

**MA80.2Z**

Dysarthria, unspecified

**MA80.Y**

### **Other specified speech disturbances**

**MA80.Z**

### **Speech disturbances, unspecified**

**MA81**

### **Speech dysfluency**

Speech dysfluency is characterised by the frequent or pervasive disruption of the rhythmic flow of speech that arises subsequent to the developmental period (i.e., adult onset) and is outside the limits of normal variation and results in reduced intelligibility and significantly affects communication. It can involve repetitions of sounds, syllables or words, prolongations, word breaks, blockage of production, excessive use of interjections, and rapid short bursts of speech.

***Inclusions:***

- Developmental language disorder (6A01.2)
- Developmental speech or language disorders (6A01)
- Developmental speech fluency disorder (6A01.1)
- Dysarthria (MA80.2)
- Selective mutism (6B06)
- childhood onset stammering (6A01.1)
- childhood onset stuttering (6A01.1)
- childhood onset cluttering (6A01.1)
- childhood-onset speech fluency disorder (6A01.1)

**MA82**

### **Voice disturbances**

Voice disturbances include dysphonia, aphonia, hypernasality and hyponasality, and other voice disturbances.

**MA82.0**

#### **Aphonia**

Aphonia is the inability to produce voice. It is considered more severe than dysphonia. Like dysphonia, aphonia can be caused by voice strain or overuse, injury, by structural laryngeal anomalies or by dystonic neurological disorders.

***Inclusions:***

- Loss of voice

***Exclusions:***

- Dissociative disorders (6B60-6B6Z)

**MA82.1**

#### **Dysphonia**

Difficulty and/or pain in phonation or speaking.

***Exclusions:***

- Developmental speech or language disorders (6A01)
- Developmental speech fluency disorder (6A01.1)

**MA82.10**

Hoarseness

**MA82.1Y**

Other specified dysphonia

**MA82.1Z**

Dysphonia, unspecified

**MA82.2**

#### **Nasality**

Nasality (or resonance) refers to the quality of the voice that is determined by the balance of sound vibration in the oral, nasal, and pharyngeal cavities during speech. Abnormal resonance can occur when there is obstruction in one of the cavities, causing hyponasality, or when there is velopharyngeal dysfunction, causing hypernasality. This category should only be assigned when hyponasality or hypernasality is outside the limits of normal variation and results in reduced intelligibility and significantly affects communication.

<b>MA82.Y</b>	<b>Other specified voice disturbances</b>
<b>MA82.Z</b>	<b>Voice disturbances, unspecified</b>
<b>MA8Y</b>	<b>Other specified symptoms or signs involving speech or voice</b>

---

<b>MB0Y</b>	<b>Other specified symptoms, signs or clinical findings of speech or voice</b>
-------------	--

Mental or behavioural symptoms, signs or clinical findings (MB20-MB2Y)

<b>MB20</b>	<b>Symptoms, signs or clinical findings involving consciousness</b>
Symptoms, signs, and clinical findings indicative of a disturbance in the state or quality of awareness of oneself and the environment, alertness, or clarity of the wakeful state.	

<b>Exclusions:</b>	newborn uremic coma (KC01)
	Delirium (6D70)
	Psychomotor retardation (MB23.N)

<b>MB20.0</b>	<b>Stupor</b>
Total or nearly total lack of spontaneous movement and marked decrease in reactivity to environment.	
<b>Inclusions:</b> Semicoma	
<b>Exclusions:</b> Catatonia (6A40-6A4Z)	
Delirium (6D70)	

<b>MB20.1</b>	<b>Coma</b>
Acute state lasting more than one hour and usually less than a month. The comatose patient is unresponsive, lying with their eyes closed and cannot be aroused even by vigorous and noxious stimuli. Motor responses to noxious stimulation are limited to reflexive behaviour. Etiologies include but are not limited to traumatic, anoxic, infectious, neoplastic, vascular, inflammatory and metabolic brain injuries.	

**Coding Note:** Code also the causing condition

<b>Exclusions:</b>	Diabetic coma (5A23)
	Hepatic coma (DB99.5)
	Neonatal coma (KB03)
	Nondiabetic hypoglycaemic coma (5A41)
	chronic uremic coma (GB61)

<b>MB20.2</b>	<b>Clouding of consciousness</b> An impairment in the clarity of consciousness characterised by impaired ability to comprehend aspects of the environment or the self in relation to the environment, inattention, and abnormalities in thought processes, comprehension. It is typically accompanied by subjective experience of mental clouding described as feeling 'foggy'. Clouding of consciousness is a common form of cognitive disturbance in Delirium, but it is not synonymous with Delirium because Delirium includes additional diagnostic requirements.
	<b><i>Exclusions:</i></b> Delirium (6D70)
<b>MB20.Y</b>	<b>Other specified symptoms, signs or clinical findings involving consciousness</b>
<b>MB21</b>	<b>Symptoms, signs or clinical findings involving cognition</b> Symptoms, signs, and clinical findings indicative of a disturbance in mental abilities and processes related to attention, memory, judgment, reasoning, problem solving, decision making, or comprehension, or the integration of these functions. <b><i>Coded Elsewhere:</i></b> Symbolic dysfunctions (MB4B)
<b>MB21.0</b>	<b>Age-associated cognitive decline</b> A normative (non-pathological) deterioration of higher cortical functions such as thinking, reasoning, comprehension, calculation, learning, language, and judgment.
<b>MB21.1</b>	<b>Amnesia</b> An inability to recall past experiences, especially where recall is to be expected. <b><i>Exclusions:</i></b> Dissociative disorders (6B60-6B6Z)
<b>MB21.10</b>	<b>Anterograde amnesia</b> An inability to recall past experiences, especially where recall is to be expected, occurring after an event (psychological or physical) presumed to be responsible for the amnesia.
<b>MB21.11</b>	<b>Retrograde amnesia</b> An inability to recall past experiences, especially where recall is to be expected, preceding an event (psychological or physical) presumed to be responsible for the amnesia.
<b>MB21.12</b>	<b>Transient global amnesia</b> A time-limited episode (lasting up to two days) of short-term memory loss without other signs or symptoms of neurological impairment.
<b>MB21.1Y</b>	<b>Other specified amnesia</b>
<b>MB21.1Z</b>	<b>Amnesia, unspecified</b>
<b>MB21.2</b>	<b>Anosognosia</b> A lack of awareness or failure to recognize one's own illness, symptoms, or functional deficits, considered to be an aspect of the illness.

<b>MB21.3</b>	<b>Confabulation</b> The filling of memory gaps with fabricated, distorted, or misinterpreted memories about oneself or the world, without the conscious intention to deceive.
<b>MB21.4</b>	<b>Disorientation</b> Impairment in or loss of awareness of the position of the self in relation to place, time, situation, or other persons. In severe cases, the sense of personal identity may also be lost.
<b>MB21.5</b>	<b>Distractibility</b> Difficulty focusing on tasks; attention is easily diverted by extraneous stimuli.
<b>MB21.6</b>	<b>Impaired abstract thinking</b> The inability to use concepts and to make and understand generalizations, such as the identifying the properties or pattern shared by a variety of specific items or events.
<b>MB21.7</b>	<b>Impaired executive functioning</b> Impairment in higher-level cognitive abilities, such as planning, sequencing, concept formation, abstracting, and decision-making.
<b>MB21.8</b>	<b>Impaired judgment</b> Deficit in the capacity to make sound, reasoned, and responsible decisions.
<b>MB21.9</b>	<b>Perseveration</b> Persistent repetition of previously used words, phrases, or details that are not responsive to the demands of the situation.
<b>MB21.A</b>	<b>Poor concentration</b> Difficulty focusing attention and sustaining the mental energy necessary to accomplish a task or goal.
<b>MB21.B</b>	<b>Racing thoughts</b> Subjective perception of accelerated thought processes.
<b>MB21.Y</b>	<b>Other specified symptoms and signs involving cognition</b>
<b>MB21.Z</b>	<b>Symptoms and signs involving cognition, unspecified</b>
<b>MB22</b>	<b>Symptoms or signs involving motivation or energy</b> Symptoms and signs involving motivation (the process that initiates, guides, and maintains goal-oriented behaviours) or energy (the strength and vitality required for sustained physical or mental activity). <b>Coded Elsewhere:</b> Fatigue (MG22)
<b>MB22.0</b>	<b>Avolition</b> A general lack of drive, or lack of motivation to pursue meaningful goals (e.g., as evidenced by limited participation in work, school, or socializing with others).

<b>MB22.1</b>	<b>Decreased libido</b> Decreased sexual desire or sexual activity compared with the patient's usual levels of sexual interest and functioning.
<b>MB22.2</b>	<b>Demoralization</b> Loss of confidence in one's ability to cope, with associated feelings of helplessness, hopelessness, and discouragement.
<b>MB22.3</b>	<b>Hopelessness</b> Little or no belief in a positive future.
<b>MB22.4</b>	<b>Increased energy</b> Increased physical or mental resources for activity, typically characterised by increased capacity for work and greater efficiency in responding to stimuli.
<b>MB22.5</b>	<b>Increased goal-directed activity</b> Increased planning of and participation in multiple activities (e.g. sexual, occupational, political, religious), compared to the individual's typical level of activity.
<b>MB22.6</b>	<b>Increased libido</b> Increased sexual desire or sexual activity compared with the patient's usual levels of sexual interest and functioning.
<b>MB22.7</b>	<b>Tiredness</b> Feeling of reduced alertness and an accompanying decrease in mental acuity, in some cases resulting in an impulse or tendency to fall asleep.
<b>MB22.Y</b>	<b>Other specified symptoms and signs involving motivation or energy</b>
<b>MB22.Z</b>	<b>Symptoms or signs involving motivation or energy, unspecified</b>
<b>MB23</b>	<b>Symptoms or signs involving appearance or behaviour</b> <b>Coded Elsewhere:</b> Speech dysfluency (MA81)
<b>MB23.0</b>	<b>Aggressive behaviour</b> Actions intended to threaten or hurt another person or to damage property that may be physical, verbal, or symbolic (e.g., acting against the other person's interests). Aggressive behaviour may be appropriate and self-protective, or inappropriate, hostile, and destructive.
<b>MB23.1</b>	<b>Antisocial behaviour</b> Behaviour in which the basic rights of others or major age-appropriate societal norms, rules, or laws, are violated.
<b>MB23.2</b>	<b>Avoidance behaviour</b> The act of keeping away from circumstances, situations, or stimuli that cause anxiety or other negative emotions in the individual.
<b>MB23.3</b>	<b>Bradyphrenia</b> Slowness of thoughts or fatigability of initiative

<b>MB23.4</b>	<b>Compulsions</b> Repetitive behaviours or rituals (e.g., washing, checking) or mental acts (e.g., repeating words silently) that the individual feels driven to perform in response to an obsession, according to rigid rules, or to achieve a sense of 'completeness'.  <b>Exclusions:</b> Obsessive-compulsive disorder (6B20)
<b>MB23.5</b>	<b>Coprolalia</b> Involuntary swearing or the involuntary utterance of obscene words or socially inappropriate and derogatory remarks, often in Tourette syndrome.  <b>Exclusions:</b> Tourette syndrome (8A05.00)
<b>MB23.6</b>	<b>Disorganized behaviour</b> Behaviour including posture, gait, and other activity that is unpredictable or not goal-directed (e.g., shouting at strangers on the street).
<b>MB23.7</b>	<b>Disheveled appearance</b> Untidy or unkempt appearance reflecting a lack of attention to one or more aspects of hygiene, grooming, or dress.
<b>MB23.8</b>	<b>Disruptive behaviour</b> Behaviour that causes disorder and turmoil in others or one's environment (e.g., angry outbursts, arguments, disobedience).  <b>Exclusions:</b> Disruptive behaviour or dissocial disorders (6C90-6C9Z)
<b>MB23.9</b>	<b>Echolalia</b> The automatic repetition of vocalizations, words, or phrases uttered by another person, which may be immediate or delayed (e.g., repetition of phrases earlier heard on television), without meaningful communicative function. Echolalia is a common feature of communication abnormalities in Autism spectrum disorder, but may also occur in other Mental, behavioural or neurodevelopmental disorders and certain neurological conditions, among children with severe visual impairment, and occasionally in typically developing children. Echolalia does not include repetition as a normal feature of language acquisition in early childhood development.  <b>Exclusions:</b> Autism spectrum disorder (6A02) Developmental language disorder (6A01.2)
<b>MB23.A</b>	<b>Excessive crying of child, adolescent, or adult</b> Episodes of crying for several hours a day for more than several days a week for several weeks in an otherwise healthy child, adolescent, or adult.
<b>MB23.C</b>	<b>Increased sociability</b> Decrease or loss of normal social inhibitions manifested in increased impulses to be with and talk to other people, including overfamiliarity, compared to the individual's typical level of activity.
<b>MB23.D</b>	<b>Mutism</b> A lack of verbal output that may be generalised or restricted to specific situations.  <b>Coded Elsewhere:</b> Akinetic mutism (MB21.Y)

<b>MB23.E</b>	<b>Non-suicidal self-injury</b> Intentional self-inflicted injury to the body, most commonly cutting, scraping, burning, biting, or hitting, with the expectation that the injury will lead to only minor physical harm.
<b>MB23.F</b>	<b>Odd or peculiar appearance</b> Grooming, clothing, or other aspects of personal appearance that are eccentric, unusual, or peculiar, and inconsistent with cultural or subcultural norms.
<b>MB23.G</b>	<b>Odd or peculiar behaviour</b> Behaviour including posture and gait that is eccentric, unusual, or peculiar, and is inconsistent with cultural or subcultural norms.
<b>MB23.H</b>	<b>Panic attack</b> A discrete episode of intense fear or apprehension accompanied by the rapid and concurrent onset of a number of characteristic symptoms. These symptoms may include, but are not limited to, palpitations or increased heart rate, sweating, trembling, sensations of shortness of breath, feelings of choking, chest pain, nausea or abdominal distress, feelings of dizziness or lightheadedness, chills or hot flushes, tingling or lack of sensation in extremities (i.e., paresthesias), depersonalization or derealization, fear of losing control or going mad, and fear of imminent death. Panic attacks can appear out of the blue or can be triggered by particular situations.  <b>Exclusions:</b> Panic disorder (6B01) recurrent panic attacks (6B01)
<b>MB23.J</b>	<b>Poor personal hygiene</b> Unwillingness or inability to maintain a level of personal cleanliness that is in keeping with the standards of the person's culture, society, or setting, such as not washing or brushing one's teeth.
<b>MB23.K</b>	<b>Poverty of speech</b> A general lack of the unprompted content and elaboration normally seen in speech that is attributed to poverty of thought. It is one of the negative symptoms of Schizophrenia.
<b>MB23.L</b>	<b>Pressured speech</b> Speech in which the person feels undue pressure to get the words out. The person's speech is usually rapid, loud, and emphatic and may be difficult or impossible to interrupt. Frequently, the person talks without any social stimulation and may continue to talk even though no one is listening.  <b>Exclusions:</b> Schizophrenia or other primary psychotic disorders (6A20-6A2Z)  Bipolar or related disorders (6A60-6A6Z)
<b>MB23.M</b>	<b>Psychomotor agitation</b> Excessive motor activity, usually manifested by purposeless behaviours such as fidgeting, shifting, fiddling, inability to sit or stand still, wringing of the hands, etc.

<b>MB23.N</b>	<b>Psychomotor retardation</b> A visible generalised slowing of movements and speech.  <b>Exclusions:</b> Stupor (MB20.0)
<b>MB23.Q</b>	<b>Social withdrawal</b> Retreat from relationships and other social interactions
<b>MB23.R</b>	<b>Suicide attempt</b> A specific episode of self-harming behaviour undertaken with the conscious intention of ending one's life.
<b>MB23.S</b>	<b>Suicidal behaviour</b> Concrete actions, such as buying a gun or stockpiling medication, that are taken in preparation for fulfilling a wish to end one's life but that do not constitute an actual suicide attempt.
<b>MB23.Y</b>	<b>Other specified symptoms and signs involving appearance and behaviour</b>
<b>MB23.Z</b>	<b>Symptoms and signs involving appearance and behaviour, unspecified</b>
<b>MB24</b>	<b>Symptoms or signs involving mood or affect</b> Symptoms and signs involving the regulation and expression of emotions or feeling states.
<b>MB24.0</b>	<b>Ambivalence</b> Conflicting ideas, wishes, or feelings toward a person, thing or situation that are distressing and may create difficulties in making decisions.
<b>MB24.1</b>	<b>Anger</b> An emotional state related to one's psychological interpretation of having been threatened that may range in intensity from mild irritation to intense fury and rage.
<b>MB24.2</b>	<b>Anhedonia</b> Inability to experience pleasure from normally pleasurable activities.
<b>MB24.3</b>	<b>Anxiety</b> Apprehensiveness or anticipation of future danger or misfortune accompanied by a feeling of worry, distress, or somatic symptoms of tension. The focus of anticipated danger may be internal or external.  <b>Inclusions:</b> Nervous tension
<b>MB24.4</b>	<b>Apathy</b> A reduction or lack of feeling, emotion, interest, or concern; a state of indifference.
<b>MB24.5</b>	<b>Depressed mood</b> Negative affective state characterised by low mood, sadness, emptiness, hopelessness, or dejection  <b>Exclusions:</b> Mood disorders (6A60-6A8Z)  Low self-esteem (MB28.9)

<b>MB24.6</b>	<b>Disturbance of affect</b> A disturbance in the expression or outward manifestation of mood.
<b>MB24.60</b>	Constricted affect A marked reduction in the expressive range and intensity of affect, but less than is observed in Blunted affect.
<b>MB24.61</b>	Blunted affect A severe reduction in the expressive range and intensity of affect, but less than is observed in Flat affect.
<b>MB24.62</b>	Flat affect Absence or near absence of any sign of affective expression.
<b>MB24.63</b>	Labile affect Marked variability in emotional expression, with repeated, rapid, and abrupt shifts.
<b>MB24.64</b>	Inappropriate affect Affective expression that is discordant with the content of the person's speech or ideation, or incompatible with the demands of a particular situation.
<b>MB24.6Y</b>	Other specified disturbance of affect
<b>MB24.6Z</b>	Disturbance of affect, unspecified
<b>MB24.7</b>	<b>Dysphoria</b> An unpleasant mood state, which can include feelings of depression, anxiety, discontent, irritability, and unhappiness
<b>MB24.8</b>	<b>Elevated mood</b> A positive mood state typically characterised by increased energy and self-esteem which may be out of proportion to the individual's life circumstances.
<b>MB24.9</b>	<b>Euphoria</b> An exaggerated feeling of physical and emotional well-being and vitality.
<b>MB24.A</b>	<b>Fear</b> An emotional response to perceived imminent threat or danger associated with urges to flee or fight.
<b>MB24.B</b>	<b>Feelings of guilt</b> Remorse related to past events or one's past actions (or inaction), thoughts, or desires.
<b>MB24.C</b>	<b>Irritability</b> A mood state characterised by being easily annoyed and provoked to anger, out of proportion to the circumstances.

<b>MB24.D</b>	<b>Leaden paralysis</b> A feeling that one's arms or legs are as heavy as lead, associated with a form of depression that also commonly includes overeating and oversleeping.
<b>MB24.E</b>	<b>Mental rumination</b> Mental preoccupation with negative events, personal characteristics, or failures.
<b>MB24.F</b>	<b>Restlessness</b> A feeling of being unable to keep still.
<b>MB24.G</b>	<b>Tantrum</b> An emotional outburst, usually among children or those in emotional distress, that is typically characterised by stubbornness, crying, screaming, defiance, anger, a resistance to attempts at pacification, and in some cases hitting or other violent behaviour.
<b>MB24.H</b>	<b>Worry</b> Unpleasant thoughts that are difficult to control, related to anticipated potential negative events.
<b>MB24.Y</b>	<b>Other specified symptoms and signs involving mood or affect</b>
<b>MB24.Z</b>	<b>Symptoms and signs involving mood or affect, unspecified</b>
<b>MB25</b>	<b>Symptoms or signs involving form of thought</b> Symptoms and signs involving the logical sequence and coherence of thought, typically manifest in speech, including thought disorder (circumstantiality, tangentiality, disorganised thinking and incoherence), flight of ideas, neologisms, and thought blocking.
<b>MB25.0</b>	<b>Symptoms and signs of thought disorder</b> Disturbances in the associative thought process typically manifest in speech or writing that range from circumstantiality to incoherence. These may be indicative of Schizophrenia and other primary psychotic disorders but can also occur in other mental disorders (e.g., Delirium).
<b>MB25.00</b>	<b>Circumstantiality</b> A relatively mild disturbance in the associative thought process typically manifest in speech or writing characterised by delay in getting to the point because of the interpolation of unnecessary details and irrelevant parenthetical remarks.
<b>MB25.01</b>	<b>Tangentiality</b> A disturbance in the associative thought process typically manifest in speech in which the person tends to digress readily from the topic under discussion to other topics through associations without ever returning to the original topic.

<b>MB25.02</b>	Disorganised thinking A disturbance in the associative thought process typically manifested in speech in which the person shifts suddenly from one topic to another that is unrelated or minimally related to the first. The individual gives no indication of being aware of the disconnectedness or illogicality of their thinking.
<b>MB25.03</b>	Incoherence Speech or thinking that is so disorganized that it is essentially incomprehensible to others.
<b>MB25.0Y</b>	Other specified symptoms and signs of thought disorder
<b>MB25.0Z</b>	Symptoms and signs of thought disorder, unspecified
<b>MB25.1</b>	<p><b>Flight of ideas</b> A nearly continuous flow of thoughts, usually manifested in speech, with rapid changes from topic to topic that are often based on understandable associations, distracting stimuli, or plays on words. In severe cases, the changes may be so rapid that speech is disorganized and incoherent.</p>
<b>MB25.2</b>	<p><b>Neologisms</b> The invention of new words that have meaning only to the person using them. May also include the use of existing words in ways that are inconsistent with their common meaning.</p>
<b>MB25.3</b>	<p><b>Thought blocking</b> A phenomenon usually manifested by the person's speech being suddenly interrupted by silences, experienced as a quick and total emptying of the mind.</p>
<b>MB25.Y</b>	Other specified symptoms and signs of form of thought
<b>MB25.Z</b>	Symptoms and signs of form of thought, unspecified
<b>MB26</b>	<p><b>Symptoms or signs involving content of thought</b> Symptoms and signs involving content of thought include delusions, experiences of influence, passivity, and control, grandiosity, homicidal ideation, identity disturbance, obsessions, overvalued ideas, paranoid ideation, referential thinking, suspiciousness, and suicidal ideation.</p>
<b>MB26.0</b>	<p><b>Delusion</b> A belief that is demonstrably untrue or not shared by others, usually based on incorrect inference about external reality. The belief is firmly held with conviction and is not, or is only briefly, susceptible to modification by experience or evidence that contradicts it. The belief is not ordinarily accepted by other members or the person's culture or subculture (i.e., it is not an article of religious faith).</p>
<b>MB26.00</b>	<p>Bizarre delusion A delusion that involves a phenomenon that would be regarded as physically impossible within the person's cultural context.</p>

<b>MB26.01</b>	Delusion of being controlled A delusion that involves an external force or person controlling one's feelings, impulses, thoughts, or behaviour.
	<b><i>Exclusions:</i></b> Experiences of influence, passivity, and control (MB26.1)
<b>MB26.02</b>	Delusion of guilt A delusion involving exaggerated or inappropriate responsibility, need for punishment or retribution, or disproportionate consequences of one's actions, such as that a minor error in the past will lead to disaster, that the person has committed a sin or horrible crime and should be punished severely, or that the person is responsible for a horrible outcome with which there can be no possible connection.
<b>MB26.03</b>	Delusion of reference A delusion that events, objects, or other people in the person's immediate environment have a particular and unusual personal significance, usually of a negative or pejorative nature.
<b>MB26.04</b>	Erotomaniac delusion A delusion that another person, usually of higher status, is in love with the individual.
<b>MB26.05</b>	Grandiose delusion A delusion of inflated worth, power, knowledge, identity, or special relationship to a deity or famous person.
	<b><i>Exclusions:</i></b> Grandiosity (MB26.2)
<b>MB26.06</b>	Jealous delusion A delusion that one's sexual partner is unfaithful.
<b>MB26.07</b>	Persecutory delusion A delusion in which the central theme is that one (or someone to whom one is close) is being attacked, mocked, harassed, cheated, conspired against, or persecuted.
<b>MB26.08</b>	Religious delusion A delusion involving religious or spiritual themes or subject matter that other members of the person's religious group do not accept as possible.
<b>MB26.09</b>	Somatic delusion A delusion involving the functioning or appearance of one's body, including of having a serious disease.
	<b><i>Coded Elsewhere:</i></b> Olfactory reference disorder (6B22)
<b>MB26.0A</b>	Nihilistic delusion A delusion that the self, part of the self, part of the body, other persons, or the whole world has ceased to exist.

<b>MB26.0B</b>	Misidentification delusion A delusion that people in one's environment, which may include family members and loved ones, are imposters or actors or are otherwise not who they seem to be.
<b>MB26.0C</b>	Delusion of impoverishment A delusional conviction that one is currently destitute or soon will be, or that one does not have the necessary financial resources to live on, in spite of evidence to the contrary.
<b>MB26.0Y</b>	Other specified delusion
<b>MB26.0Z</b>	Delusion, unspecified
<b>MB26.1</b>	<b>Experiences of influence, passivity, and control</b> The experience that one's feelings, impulses, thoughts, bodily functions, or behaviour are under the control of another person or other external force instead of under one's own control. These experiences may or may not be accompanied by a delusional belief that provides an explanation for the subjective experience. <b>Exclusions:</b> Delusion of being controlled (MB26.01)
<b>MB26.10</b>	Thought broadcasting The experience that one's thoughts are accessible by others so that others know what one is thinking.
<b>MB26.11</b>	Thought insertion The experience that certain thoughts are being placed in one's mind by others.
<b>MB26.12</b>	Thought withdrawal The experience that one's thoughts are being removed by an outside person or force.
<b>MB26.1Y</b>	Other specified experiences of influence, passivity, and control
<b>MB26.1Z</b>	Experiences of influence, passivity, and control, unspecified
<b>MB26.2</b>	<b>Grandiosity</b> Exaggerated self-esteem or an unrealistic belief in one's superiority, importance, capacities, or identity. <b>Exclusions:</b> Grandiose delusion (MB26.05)
<b>MB26.3</b>	<b>Homicidal ideation</b> Thoughts, ideas, or ruminations about killing another person, which range from vague ideas of revenge to detailed and fully formulated plans but do not include actual homicidal attempts.
<b>MB26.4</b>	<b>Identity disturbance</b> Distortion or inconsistency in the sense or view of sameness and historical continuity of one's self.

<b>MB26.5</b>	<b>Obsessions</b> Repetitive and persistent thoughts (e.g., of contamination), images (e.g., of violent scenes), or impulses/urges (e.g., to stab someone) that are experienced as intrusive, unwanted, and are commonly associated with anxiety.
<b>MB26.6</b>	<b>Overvalued ideas</b> Unreasonable and sustained beliefs that are maintained with less than delusional intensity (i.e., the person is able to acknowledge the possibility that the belief may not be true). An alternative use of this term is to refer to conventional or plausible thoughts (e.g., religious concepts, political ideas, or excessively idealistic beliefs) that are held with such a level of intensity so that the person's life is taken up by them.  <b>Exclusions:</b> Delusion (MB26.0) Grandiosity (MB26.2) Paranoid ideation (MB26.7) Referential thinking (MB26.8)
<b>MB26.7</b>	<b>Paranoid ideation</b> Ideation, not held with delusional intensity, involving suspiciousness or beliefs of being harassed, persecuted, or unfairly treated by others.  <b>Exclusions:</b> Persecutory delusion (MB26.07)
<b>MB26.8</b>	<b>Referential thinking</b> Ideation, not held with delusional intensity, that random or coincidental events are of particular and unusual significance to the person.  <b>Exclusions:</b> Delusion of reference (MB26.03)
<b>MB26.9</b>	<b>Suspiciousness</b> The behaviour of others is viewed with anxiety, mistrust, or hostility and perceived as potentially threatening.
<b>MB26.A</b>	<b>Suicidal ideation</b> Thoughts, ideas, or ruminations about the possibility of ending one's life, ranging from thinking that one would be better off dead to formulation of elaborate plans.  <b>Exclusions:</b> Suicide attempt (MB23.R) Personal history of self-harm (QC4B)
<b>MB26.Y</b>	<b>Other specified symptoms or signs involving content of thought</b>
<b>MB26.Z</b>	<b>Symptoms or signs involving content of thought, unspecified</b>
<b>MB27</b>	<b>Symptoms or signs involving perceptual disturbance</b> Symptoms and signs involving a disruption in sensory perception, including depersonalization, derealization, and hallucinations in any modality.  <b>Exclusions:</b> disturbances of skin sensation (MB40.5)

<b>MB27.0</b>	<b>Depersonalisation</b> Experiencing the self as strange or unreal, or feeling detached from, or as though one were an outside observer of, one's thoughts, feelings, sensations, body, or actions. Depersonalization may take the form of emotional and/or physical numbing, a sense of watching oneself from a distance or 'being in a play', or perceptual alterations (e.g., a distorted sense of time).
<b>MB27.1</b>	<b>Derealisation</b> Experiencing other persons, objects, or the world as strange or unreal (e.g., dreamlike, distant, foggy, lifeless, colourless, or visually distorted) or feeling detached from one's surroundings.
<b>MB27.2</b>	<b>Hallucinations</b> Sensory perceptions of any modality occurring in the absence of the appropriate (external) stimulus. The person may or may not have insight into the unreal nature of the perception.
<b>MB27.20</b>	Auditory hallucinations Hallucinations involving the perception of sound, most frequently of voices but sometimes of clicks or other noises, that are not restricted to the period of awakening or the onset of sleep.
<b>MB27.21</b>	Gustatory hallucinations Hallucinations of taste in the absence of an actual external stimulus.
<b>MB27.22</b>	Hypnopompic hallucinations Hallucinations that occur during the period of awakening, most commonly of the visual, tactile or auditory modality.
<b>MB27.23</b>	Hypnagogic hallucinations Hallucinations that occur at the onset of sleep, most commonly of the visual, tactile or auditory modality.
<b>MB27.24</b>	Olfactory hallucinations Hallucinations involving the perception of odour (e.g., of burning rubber, decaying fish, orange peel) in the absence of an actual external stimulus.
<b>MB27.25</b>	Somatic hallucinations Hallucinations involving the perception of an unusual physical state or event within the body, such as an electrical impulse running down one's arms or an object inside one's chest.
<b>MB27.26</b>	Tactile hallucinations Hallucinations involving the perception of being touched (e.g., feeling like bugs are crawling on the skin, pins being stuck into one's finger) that are not restricted to the period of awakening or the onset of sleep.

<b>MB27.27</b>	Visual hallucinations Hallucinations involving sight in the absence of an actual visual stimulus that are not restricted to the period of awakening or the onset of sleep. Visual hallucinations may involve formed images, such as of people, or of unformed images, such as flashes of light. Visual hallucinations must be distinguished from illusions, which are visual misperceptions of real external stimuli.
	<b>Coded Elsewhere:</b> Visual release hallucinations (9D56)
<b>MB27.2Y</b>	Other specified hallucinations
<b>MB27.2Z</b>	Hallucinations, unspecified
<b>MB27.3</b>	<b>Disturbance of body image</b> Excessively negative, distorted, or inaccurate perception of one's own body or parts of it.
<b>MB27.4</b>	<b>Illusions</b> A misinterpretation of a true sensation (e.g., hearing voices in the sound of running water, the perception of figures in shadows).  <b>Exclusions:</b> Visual illusions (9D54)
<b>MB27.Y</b>	<b>Other specified symptoms and signs of perceptual disturbance</b>
<b>MB27.Z</b>	<b>Symptoms and signs of perceptual disturbance, unspecified</b>
<b>MB28</b>	<b>Symptoms or signs related to personality features</b> Symptoms and signs involving the characteristics or qualities possessed by a person that uniquely influence his or her cognition, motivations, and behaviours in various situations.
<b>MB28.0</b>	<b>Attention seeking</b> A tendency to engage in behaviour designed to attract notice and to make oneself the focus of others' attention.
<b>MB28.1</b>	<b>Callousness</b> Lack of concern for the feelings or problems of others; a lack of guilt or remorse about the negative or harmful effects of one's actions on others.
<b>MB28.2</b>	<b>Eccentricity</b> A tendency toward appearance or behaviour that is odd, unusual, peculiar, or unconventional, and is inconsistent with cultural or subcultural norms.
<b>MB28.3</b>	<b>Entitlement</b> The belief that one is inherently deserving of privileges or special treatment.
<b>MB28.4</b>	<b>Hostility</b> A tendency to experience persistent or frequent angry feelings, especially in response to minor slights and insults, and to adopt an unfriendly or threatening attitude in interactions with others.

<b>MB28.5</b>	<b>Impulsivity</b> A tendency to act on the spur of the moment in response to immediate stimuli, characterised by lack of deliberation and failure to consider risks and consequences before acting. Impulsivity may reflect a desire for immediate rewards or an inability to delay gratification.
<b>MB28.6</b>	<b>Indecisiveness</b> A tendency to have difficulty making decisions or committing to a course of action.
<b>MB28.7</b>	<b>Irresponsibility</b> A pattern of disregard for and failure to honour obligations or commitments; a lack of respect for and follow-through on agreements or promises; carelessness with others' property.
<b>MB28.8</b>	<b>Low frustration tolerance</b> Diminished ability to regulate one's emotions and behaviour in response to frustrating circumstances.
<b>MB28.9</b>	<b>Low self-esteem</b> Low appraisal of one's self-worth.
<b>MB28.A</b>	<b>Negative affectivity</b> A tendency to experience a broad range of distressing emotions, e.g. anxiety, anger, irritability, depression, and other negative emotional states, often in response to even relatively minor actual or perceived stressors.  <i>Inclusions:</i> negative emotionality proneness to negative emotional states
<b>MB28.B</b>	<b>Negativism</b> A tendency to oppose or resist suggestions or advice, or to resist stubbornly for no apparent reason.
<b>MB28.C</b>	<b>Perfectionism</b> An inclination to demand flawlessness of oneself or others and setting excessively high standards.
<b>MB28.D</b>	<b>Pessimism</b> An inclination to emphasize adverse aspects, conditions, and possibilities, or to expect the worst possible outcome.
<b>MB28.E</b>	<b>Recklessness</b> A tendency to engage in behaviour that potentially endangers a person's physical health, safety, or life.
<b>MB28.F</b>	<b>Sensation seeking</b> An inclination to search for experiences and feelings that are varied, novel, complex, and intense.

<b>MB28.G</b>	<b>Stubbornness</b> A steadfast adherence to an opinion, purpose, or course of action in spite of reason, arguments, or persuasion.
<b>MB28.H</b>	<b>Submissiveness</b> A tendency to adapt one's behaviour to the actual or perceived interests and desires of others even when doing so is antithetical to one's own interests, needs, or desires.
<b>MB28.Y</b>	<b>Other specified symptoms and signs related to personality features</b>
<b>MB28.Z</b>	<b>Symptoms and signs related to personality features, unspecified</b>
<b>MB29</b>	<b>Symptoms or signs involving eating and related behaviour</b> <p>Symptoms and signs related to disturbances in the regulation or form of eating behaviour that are not developmentally appropriate or culturally sanctioned, including avoidant or restrictive eating, binge eating, decreased appetite, eating of non-nutritive substances, increased appetite, purging behaviour, and rumination-regurgitation.</p> <p><b>Coded Elsewhere:</b> Decreased appetite (MG43.8)</p> <ul style="list-style-type: none"> <li>Excessive weight gain (MG43.6)</li> <li>Excessive weight loss (MG43.5)</li> <li>Increased appetite (MG43.9)</li> <li>Overeating (MG43.1)</li> </ul>
<b>MB29.0</b>	<b>Avoidant or restrictive eating</b> <p>Acceptance of only a limited diet, which may be defined in terms of a specific dietary composition or sensory features of food, that is inconsistent with cultural or subcultural norms.</p> <p><b>Exclusions:</b> Avoidant-restrictive food intake disorder (6B83)</p>
<b>MB29.1</b>	<b>Binge eating</b> <p>An episode in which an individual eats notably more than usual and feels that she or he is unable to stop or limit the amount or type of food eaten.</p> <p><b>Exclusions:</b> Bulimia Nervosa (6B81) Binge eating disorder (6B82)</p>
<b>MB29.2</b>	<b>Eating of non-nutritive substances</b> <p>Consumption of non-food objects and materials (e.g., clay, soil, chalk, plaster, plastic, metal and paper) or raw food ingredients (e.g., large quantities of salt or corn flour).</p> <p><b>Exclusions:</b> Pica (6B84)</p>

<b>MB29.3</b>	<b>Purging behaviour</b> Behaviour aimed at the removal of ingested food from the body with the specific intention to lose weight or prevent weight gain (e.g., self-induced vomiting, laxative abuse, or the use of enemas).
	<b><i>Exclusions:</i></b> Bulimia Nervosa (6B81) Anorexia Nervosa (6B80)
<b>MB29.4</b>	<b>Rumination-regurgitation</b> Rechewing of previously swallowed food that has been brought back to the mouth through regurgitation, which may then be reswallowed or spat out.
	<b><i>Exclusions:</i></b> Rumination-regurgitation disorder (6B85) Bulimia Nervosa (6B81) Anorexia Nervosa (6B80)
<b>MB29.Y</b>	<b>Other specified symptoms and signs involving eating and related behaviour</b>
<b>MB29.Z</b>	<b>Symptoms and signs involving eating and related behaviour, unspecified</b>
<b>MB2A</b>	<b>Symptoms or signs involving elimination</b> Symptoms and signs involving the behavioural components of defecation (soiling, faecal elimination) and urination.
<b>MB2A.0</b>	<b>Soiling</b> The passage of faeces in clothing, bed, or other inappropriate places in an individual who has reached a developmental age where faecal continence is ordinarily expected.
	<b><i>Exclusions:</i></b> Encopresis (6C01)
<b>MB2A.1</b>	<b>Wetting</b> The voiding of urine into clothes or bed, which may occur during the day or night in an individual who has reached a developmental age where urinary continence is ordinarily expected.
	<b><i>Exclusions:</i></b> Enuresis (6C00)
<b>MB2A.Y</b>	<b>Other specified symptoms and signs involving elimination</b>
<b>MB2A.Z</b>	<b>Symptoms and signs involving elimination, unspecified</b>
<b>MB2Y</b>	<b>Other specified mental or behavioural symptoms, signs or clinical findings</b>

## Symptoms, signs or clinical findings of the nervous system (MB40-MB9Y)

Symptoms or signs involving the nervous system (MB40-MB6Y)

**Coded Elsewhere:** Fear of neurological disease (MG24.9)

Symptom or complaint of a body part (ME86)

Age-associated cognitive decline (MB21.0)

Speech disturbances (MA80)

Types of seizures (8A68)

Fear of cancer of neurological system (MG24.0Y)

**MB40**

### **Sensation disturbance**

**MB40.0** **Asomatognosia**

**MB40.1** **Allodynia**

Pain due to a normally non-painful stimulus

**MB40.2** **Anacusis**

**MB40.3** **Anaesthesia of skin**

Partial or complete loss of sensation affecting the skin, most commonly affecting a circumscribed area and resulting from sensory nerve damage as from injury or leprosy.

**Inclusions:** Numbness of skin

**MB40.4** **Tingling fingers or feet or toes**

**MB40.5** **Hyperaesthesia**

Increased sensibility to stimuli of sense

**MB40.6** **Dysesthesia**

**MB40.7** **Acroparaesthesia**

Severe pain in the extremities

**MB40.8** **Analgesia**

**MB40.9** **Neurological neglect syndrome**

**MB40.Y** **Other specified sensation disturbance**

**MB40.Z** **Sensation disturbance, unspecified**

**MB41**

### **Disturbances of smell and taste**

Disturbances of smell and taste include anosmia, parosmia, parageusia, and other disturbances of smell and taste.

**MB41.0** **Anosmia**

**MB41.1** **Parosmia**

<b>MB41.2</b>	<b>Dysgeusia</b> A disorder characterised by an alteration of the sense of taste
	<b>Inclusions:</b> cacogeusia ageusia
<b>MB41.3</b>	<b>Hyposmia</b> Decreased ability to smell
<b>MB41.Y</b>	<b>Other specified disturbances of smell and taste</b>
<b>MB41.Z</b>	<b>Disturbances of smell and taste, unspecified</b>
<b>MB42</b>	<b>Phonophobia</b> Hypersensitivity to sounds
<b>MB43</b>	<b>Dyssomnia</b> Difficulties to fall asleep, or to remain sleeping
<b>MB44</b>	<b>Abnormalities of gait and mobility</b> Abnormalities of gait and mobility include ataxic gait, paralytic gait, difficulty in walking, immobility, and other abnormalities of gait and mobility.
	<b>Inclusions:</b> Immobility syndrome (FB32.3) Ataxia, unspecified (MB45.0) Hereditary ataxia (8A03.1) ataxia, locomotor (syphilitic) (1A62.01)
<b>MB44.0</b>	<b>Ataxic gait</b>
	<b>Inclusions:</b> Staggering gait
<b>MB44.1</b>	<b>Paralytic gait</b> A collection of gait abnormalities due to affected motor control, sensory feedback, and muscle strength.
	<b>Inclusions:</b> Spastic gait
<b>MB44.2</b>	<b>Difficulty in walking</b>
<b>MB44.3</b>	<b>Immobility</b>
	<b>Inclusions:</b> Bedfast Chairfast
	<b>Exclusions:</b> Catatonia (6A40-6A4Z) Psychomotor retardation (5C50.B)
<b>MB44.Y</b>	<b>Other specified abnormalities of gait and mobility</b>
<b>MB44.Z</b>	<b>Abnormalities of gait and mobility, unspecified</b>

**MB45****Lack of coordination**

Other lack of coordination is a lack of coordination other than abnormal involuntary movements and abnormalities of gait and mobility.

- Exclusions:**
- Vertigo (MB48.0)
  - Hereditary ataxia (8A03.1)
  - Ataxic gait (MB44.0)

**MB45.0 Ataxia, unspecified****MB45.1 Automatism**

Repetitive unconscious gestures such as lip smacking, chewing or swallowing

**MB45.2 Atonia**

Loss of muscle tone

**MB45.3 Head drop****MB45.4 Intention tremor**

Cerebellar tremor characterised by a broad course and low frequency

**MB45.Y Other specified lack of coordination****MB45.Z Lack of coordination, unspecified****MB46****Abnormal involuntary movements**

Abnormal involuntary movements include abnormal head movements, tremor, cramp, spasm, fasciculation, and other abnormal involuntary movements

- Exclusions:**
- Movement disorders (8A00-8A0Z)
  - Stereotyped movement disorder (6A06)
  - Tic disorders (8A05)
  - Essential tremor or related tremors (8A04.1)
  - Intention tremor (MB45.4)

**Coded Elsewhere:** Tremor due to certain specified central nervous system diseases (8A04.33)

**MB46.0 Asterixis****MB46.1 Abnormal head movements****MB46.2 Athetosis**

Twisting and writhing movements

**MB46.3 Drop attack**

A sudden spontaneous fall while standing and recovery within seconds or minutes

**MB46.4 Titubation**

Head tremor of cerebellar origin

**MB46.5 Shuddering**

<b>MB46.Y</b>	<b>Other specified abnormal involuntary movements</b>
<b>MB46.Z</b>	<b>Abnormal involuntary movements, unspecified</b>
<b>MB47</b>	<b>Abnormality of tonus and reflex</b>
<b>MB47.0</b>	<b>Abnormal reflex</b>
	<b><i>Exclusions:</i></b> vasovagal reaction or syncope (MG45) hyperactive gag reflex (CA00-CA0Z) abnormal pupillary reflex (LA11.62)
<b>MB47.1</b>	<b>Abnormal posture</b>
<b>MB47.2</b>	<b>Clonus</b> A series of involuntary muscle contractions and relaxations
<b>MB47.3</b>	<b>Cramp or spasm</b>
	<b><i>Exclusions:</i></b> Infantile spasms (8A62.0) carpopedal spasm (MB47.D)
<b>MB47.4</b>	<b>Dystonia</b> Sustained muscle contraction, involuntary movements that can lead to fixed abnormal postures
<b>MB47.5</b>	<b>Fasciculation</b>
<b>MB47.6</b>	<b>Meningismus</b>
<b>MB47.7</b>	<b>Muscle fibrillation</b> An involuntary muscle contraction and relaxation in a muscle fiber
<b>MB47.8</b>	<b>Muscular hypertonia</b> <b>Coded Elsewhere:</b> Congenital hypertonia (KB08.1)
<b>MB47.9</b>	<b>Myotonia</b> Slow relaxation of the muscles after voluntary contraction
<b>MB47.A</b>	<b>Ophthalmoparesis</b> Paresis of one or more extraocular muscles
<b>MB47.B</b>	<b>Opisthotonos</b> Arching position of the body due spasm of the axial muscles along the spinal column

<b>MB47.C</b>	<b>Tendency to fall</b>
	<p><b>Inclusions:</b> Tendency to fall because of old age or other unclear health problems</p> <p><b>Exclusions:</b> falls causing injury (Chapter 22) Dizziness and giddiness (MB48) Syncope and collapse (MG45) Difficulty in walking (MB44.2) accidents (Chapter 23)</p>
<b>MB47.D</b>	<b>Tetany</b>
	<p><b>Exclusions:</b> Parathyroid tetany (5A50) post-thyroidectomy tetany (5D42)</p> <p><b>Coded Elsewhere:</b> Neonatal tetany without calcium or magnesium deficiency (KB61.1)</p>
<b>MB47.Y</b>	<b>Other specified abnormality of tonus and reflex</b>
<b>MB47.Z</b>	<b>Abnormality of tonus and reflex, unspecified</b>
<b>MB48</b>	<b>Dizziness and giddiness</b> An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.
	<p><b>Exclusions:</b> Vertiginous syndromes (AB31.7)</p>
<b>MB48.0</b>	<b>Vertigo</b>
	<p><b>Coded Elsewhere:</b> Other peripheral vertigo (AB34.1) Epidemic vertigo (1C8Y)</p>
<b>MB48.00</b>	Vertigo of central origin Central vertigo is usually a result of an abnormal processing of the vestibular sensory input by the central nervous system due to either a disruption of central integrators (i.e. brain stem, cerebellum) or a sensory information mismatch (i.e. from the cortex). Lesions that affect the vestibular nerve or root entry zone (i.e. cerebellopontine angle [CPA] lesions) result in imbalance by affecting primary vestibular sensory information
	<p><b>Inclusions:</b> Central positional nystagmus</p>
<b>MB48.0Y</b>	Other specified vertigo
<b>MB48.0Z</b>	Vertigo, unspecified
<b>MB48.1</b>	<b>Disorder of equilibrium</b>
<b>MB48.2</b>	<b>Exertional dizziness</b>
<b>MB48.3</b>	<b>Light-headedness</b>
<b>MB48.4</b>	<b>Presyncope</b>

<b>MB48.Y</b>	<b>Other specified dizziness and giddiness</b>
<b>MB48.Z</b>	<b>Dizziness and giddiness, unspecified</b>
<b>MB49</b>	<p><b>Aura</b>  Reversible visual and/or sensory symptoms prior to a seizure (few seconds) or migraine with aura (20 minutes)</p>
<b>MB4A</b>	<b>Apraxia</b>
<b>MB4B</b>	<p><b>Symbolic dysfunctions</b></p> <p><b>Exclusions:</b> Developmental learning disorder (6A03)</p> <p><b>Coded Elsewhere:</b> Echolalia (MB23.9)</p>
<b>MB4B.0</b>	<p><b>Dyslexia and alexia</b>  Dyslexia and alexia refer to the loss, usually in adulthood, of a previous ability to read fluently and to accurately comprehend written material that is inconsistent with general level of intellectual functioning and is acquired after the developmental period in individuals who had previously attained these skills, such as due to a stroke or other brain injury.</p> <p><b>Exclusions:</b> Developmental learning disorder (6A03)</p> <p><b>Coded Elsewhere:</b> Alexia (9D92)</p>
<b>MB4B.1</b>	<p><b>Agnosia</b>  Agnosia refers to the inability to recognize objects, shapes, people, sounds, or smells, which occurs despite otherwise normal functioning of the specific sense and is not accounted for by memory impairment.</p>
<b>MB4B.2</b>	<p><b>Acalculia</b>  Acalculia refers to the loss, usually in adulthood, of a previous ability to perform simple mathematical calculations that is inconsistent with general level of intellectual functioning and is acquired after the developmental period in individuals who had previously attained these skills, such as due to a stroke or other brain injury.</p> <p><b>Exclusions:</b> Developmental learning disorder (6A03)</p>
<b>MB4B.3</b>	<p><b>Agraphia</b>  Agraphia refers to the loss, usually in adulthood, of a previous ability to write that is inconsistent with general level of intellectual functioning and is acquired after the developmental period in individuals who had previously attained these skills, such as due to a stroke or other brain injury.</p> <p><b>Exclusions:</b> Developmental learning disorder (6A03)</p>
<b>MB4B.4</b>	<p><b>Anomia</b>  Acquired difficulty in retrieving previously used vocabulary, particularly nouns and verbs.</p>

<b>MB4B.5</b>	<b>Dyscalculia</b> Dyscalculia refers to acquired difficulty with performing simple mathematical calculations that is inconsistent with general level of intellectual functioning, with onset after the developmental period in individuals who had previously attained these skills, such as due to a stroke or other brain injury.
	<b><i>Exclusions:</i></b> Developmental learning disorder (6A03)
<b>MB4B.Y</b>	<b>Other specified symbolic dysfunctions</b>
<b>MB4B.Z</b>	<b>Symbolic dysfunctions, unspecified</b>
<b>MB4C</b>	<b>Gerstmann syndrome</b> Gerstmann syndrome is a very rare neurological disorder characterised by the specific association of acalculia, finger agnosia, left-right disorientation, and agraphia, which is supposed to be secondary to a focal subcortical white matter damage in the parietal lobe.
	<b><i>Exclusions:</i></b> Gerstmann-Straussler-Scheinker syndrome (8E02.1)
<b>MB4D</b>	<b>Headache, not elsewhere classified</b> Headache with characteristic features suggesting that it is a unique diagnostic entity, a finding or complaint, but not fulfilling criteria for any of the headache disorders described above.
	<b><i>Exclusions:</i></b> Trigeminal neuralgia (8B82.0) Atypical facial pain (8A85) Acute headache, not elsewhere classified (MG31.1) Chronic secondary headache or orofacial pain (MG30.6)

## Paralytic symptoms (MB50-MB5Z)

	<b>Coding Note:</b> For primary coding, the following categories are to be used only when the relevant paralytic syndrome (complete) (incomplete) is reported without further specification, or is stated to be old or longstanding but of unspecified cause.
<b>MB50</b>	<b>Tetraplegia</b>
	<b>Coding Note:</b> Code also the causing condition
	<b><i>Inclusions:</i></b> Quadriplegia
<b>MB50.0</b>	<b>Flaccid tetraplegia</b> This is a severe or complete loss of motor function in all four limbs with limp and relaxed muscles.
	<b>Coding Note:</b> Code also the causing condition
<b>MB50.1</b>	<b>Spastic tetraplegia</b> This is a severe or complete loss of motor function in all four limbs with involuntary contractions.
	<b>Coding Note:</b> Code also the causing condition

**MB50.Z** **Tetraplegia, unspecified**

**Coding Note:** Code also the causing condition

**MB51** **Diplegia of upper extremities**

This is a loss of motor control in both arms.

**Coding Note:** Code also the causing condition

**Inclusions:** paralysis of both upper limbs  
Paralysis of both arms

**MB51.0** **Flaccid diplegia of upper extremities**

**MB51.1** **Spastic diplegia of upper extremities**

**MB51.Z** **Diplegia of upper extremities, unspecified**

**Coding Note:** Code also the causing condition

**MB52** **Diplegia of lower extremities**

**Coding Note:** Code also the causing condition

**MB53** **Hemiplegia**

This is a severe or complete loss of motor function on one side of the body.

**Coding Note:** Code also the causing condition

**Exclusions:** congenital cerebral palsy (8D20-8D2Z)  
spastic hemiplegic cerebral palsy (8D20.0)

**MB53.0** **Alternating hemiplegia**

**Coding Note:** Code also the causing condition

**MB53.1** **Flaccid hemiplegia**

This is a severe or complete loss of motor function on one side of the body with limp and relaxed muscles.

**Coding Note:** Code also the causing condition

**MB53.2** **Spastic hemiplegia**

This is a severe or complete loss of motor function on one side of the body with involuntary contractions.

**Coding Note:** Code also the causing condition

**MB53.Z** **Hemiplegia, unspecified**

**Coding Note:** Code also the causing condition

**MB54** **Monoplegia of upper extremity**

This is a loss of motor control in one arm.

**Coding Note:** Code also the causing condition

**Inclusions:** paralysis of upper limb  
Paralysis of arm

<b>MB54.0</b>	<b>Flaccid monoplegia of upper extremity</b>
<b>Coding Note:</b>	Code also the causing condition
<b>MB54.1</b>	<b>Spastic monoplegia of upper extremity</b>
<b>Coding Note:</b>	Code also the causing condition
<b>MB54.Z</b>	<b>Monoplegia of upper extremity, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>MB55</b>	<b>Monoplegia of lower extremity</b>
	This is a loss of motor control in one leg.
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b>
	paralysis of lower limb
	Paralysis of leg
<b>MB55.0</b>	<b>Flaccid monoplegia of lower extremity</b>
<b>Coding Note:</b>	Code also the causing condition
<b>MB55.1</b>	<b>Spastic monoplegia of lower extremity</b>
<b>Coding Note:</b>	Code also the causing condition
<b>MB55.Z</b>	<b>Monoplegia of lower extremity, unspecified</b>
<b>Coding Note:</b>	Code also the causing condition
<b>MB56</b>	<b>Paraplegia</b>
<b>Coding Note:</b>	Code also the causing condition
<b>MB57</b>	<b>Functional level of injury of spinal cord</b>
<b>Coding Note:</b>	These codes are not to be used alone. Code first injury or condition.
<b>MB57.0</b>	<b>Functional level of injury of cervical spinal cord</b>
<b>Coding Note:</b>	These codes are not to be used alone. Code first injury or condition.
<b>MB57.1</b>	<b>Functional level of injury of thoracic spinal cord</b>
<b>Coding Note:</b>	These codes are not to be used alone. Code first injury or condition.
<b>MB57.2</b>	<b>Functional level of injury of lumbar spinal cord</b>
<b>Coding Note:</b>	These codes are not to be used alone. Code first injury or condition.
<b>MB57.3</b>	<b>Functional level of injury of spinal cord, sacrum</b>
<b>Coding Note:</b>	These codes are not to be used alone. Code first injury or condition.
<b>MB57.Y</b>	<b>Other specified functional level of injury of spinal cord</b>
<b>Coding Note:</b>	These codes are not to be used alone. Code first injury or condition.
<b>MB57.Z</b>	<b>Functional level of injury of spinal cord, unspecified</b>
<b>Coding Note:</b>	These codes are not to be used alone. Code first injury or condition.

**MB5Y****Other specified paralytic symptoms****Coding Note:**

For primary coding, the following categories are to be used only when the relevant paralytic syndrome (complete) (incomplete) is reported without further specification, or is stated to be old or longstanding but of unspecified cause.

**MB5Z****Paralytic symptoms, unspecified****Coding Note:**

For primary coding, the following categories are to be used only when the relevant paralytic syndrome (complete) (incomplete) is reported without further specification, or is stated to be old or longstanding but of unspecified cause.

**MB60****Sleepalking****MB6Y****Other specified symptoms or signs involving the nervous system**

Clinical findings in the nervous system (MB70-MB7Y)

**MB70****Clinical findings in cerebrospinal fluid****MB70.0****Abnormal level of enzymes in cerebrospinal fluid****MB70.1****Abnormal level of hormones in cerebrospinal fluid****MB70.2****Abnormal level of drugs, medicaments and biological substances in cerebrospinal fluid****MB70.3****Abnormal level of substances chiefly nonmedicinal as to source in cerebrospinal fluid****MB70.4****Abnormal immunological findings in cerebrospinal fluid****MB70.5****Abnormal microbiological findings in cerebrospinal fluid****MB70.6****Abnormal cytological findings in cerebrospinal fluid****MB70.7****Abnormal histological findings in cerebrospinal fluid****MB70.8****Other abnormal findings in cerebrospinal fluid****MB70.Y****Other specified clinical findings in cerebrospinal fluid****MB70.Z****Clinical findings in cerebrospinal fluid, unspecified****MB71****Clinical findings on diagnostic imaging of central nervous system**

Clinical findings on diagnostic imaging of central nervous system is findings on diagnostic imaging of the brain or the spinal cord which don't appear in normal status of the body. Diagnostic imaging refers to technologies that doctors use to look inside body for clues about a medical condition. X-rays, CT scans, nuclear medicine scans, MRI scans and ultrasound are all types of diagnostic imaging.

**MB71.0****Intracranial space-occupying lesion****MB71.Y****Other specified clinical findings on diagnostic imaging of central nervous system****MB71.Z****Clinical findings on diagnostic imaging of central nervous system, unspecified**

**MB72**

**Results of function studies of the nervous system**

**MB7Y**

**Other specified clinical findings in the nervous system**

**MB9Y**

**Other specified symptoms, signs or clinical findings of the nervous system**

Symptoms, signs or clinical findings of the visual system (MC10-MC2Y)

Symptoms or signs involving the visual system (MC10-MC1Y)

**Coded Elsewhere:** Fear of eye disease (MG24.4)

Ophthalmoparesis (MB47.A)

**MC10**

**Eye appearance abnormal**

**MC11**

**Eye sensation abnormal**

**MC12**

**Chronic enlargement of lacrimal gland**

**MC13**

**Epiphora**

This is overflow of tears onto the face. A clinical sign or condition that constitutes insufficient tear film drainage from the eyes in that tears will drain down the face rather than through the nasolacrimal system.

**MC14**

**Eye discharge**

**MC15**

**Red eye**

**MC16**

**Pallor conjunctiva**

**MC17**

**Icteric sclera**

**MC18**

**Ocular pain**

**Exclusions:** Chronic primary headache or orofacial pain (MG30.03)

Chronic secondary headache or orofacial pain (MG30.6)

**MC19**

**Quadrantanopia**

**MC1A**

**Visual floaters**

Floater are dark spots or shapes that seem to float in front of the retinal image.

**MC1B**

**Symptom or complaint of the eyelid**

**MC1C**

**Symptom or complaint of glasses**

**MC1D**

**Symptom or complaint of contact lens**

**MC1Y**

**Other specified symptoms or signs involving the visual system**

**MC20**

**Clinical findings of the visual system**

<b>MC20.0</b>	<b>Staphyloma</b> This is an abnormal protrusion of the uveal tissue through a weak point in the eyeball. The protrusion is generally black in colour, due to the inner layers of the eye. It occurs due to weakening of outer layer of eye (cornea or sclera) by an inflammatory or degenerative condition. It may be of 5 types, depending on the location on the eye ball (bulbus oculi).
<b>MC20.1</b>	<b>Small drusen of the macula</b>
<b>MC20.2</b>	<b>Hypopyon</b> Hypopyon is inflammatory cells in the anterior chamber of eye. It is a leukocytic exudate, seen in the anterior chamber, usually accompanied by redness of the conjunctiva and the underlying episclera. It is a sign of inflammation of the anterior uvea and iris, i.e. iritis, which is a form of anterior uveitis. The exudate settles at the bottom due to gravity.
<b>MC20.Y</b>	<b>Other specified clinical findings of the visual system</b>
<b>MC21</b>	<b>Impairment of electrophysiological functions</b>
<b>MC21.0</b>	<b>Profound impairment of electrooculogram</b>
<b>MC21.1</b>	<b>Normal electroretinogram</b> An Electro-Retinogram records retinal action potentials in response to various visual stimuli.
<b>MC21.Y</b>	<b>Other specified impairment of electrophysiological functions</b>
<b>MC21.Z</b>	<b>Impairment of electrophysiological functions, unspecified</b>
<b>MC2Y</b>	<b>Other specified symptoms, signs or clinical findings of the visual system</b>

Symptoms, signs or clinical findings of ear or mastoid process (MC40-MC6Y)

Symptoms or signs involving the ear or mastoid process (MC40-MC4Y)

**Coded Elsewhere:** Otalgia or effusion of ear (AB70)

**MC40** **Plugged feeling ear**

**MC41** **Tinnitus**

A nonspecific symptom of hearing disorder characterised by the sensation of buzzing, ringing, clicking, pulsations, and other noises in the ear in the absence of appropriate corresponding external stimuli and in the absence of what the examiner can hear with a stethoscope.

**MC4Y** **Other specified symptoms or signs involving the ear or mastoid process**

---

MC6Y	<b>Other specified symptoms, signs or clinical findings of ear or mastoid process</b>
------	---

## Symptoms, signs or clinical findings of the circulatory system (MC80-MC9Y)

Symptoms or signs involving the circulatory system (MC80-MC8Y)

**Coded Elsewhere:** Ankle oedema (MG29.00)

Fear of cardiovascular disease (MG24.7)

Fear of heart disease (MG24.5)

Fear of hypertension (MG24.6)

MC80	<b>Abnormal blood-pressure reading, without diagnosis</b>
Abnormal blood-pressure reading, without diagnosis is a reading of blood pressure which is higher than normal blood pressure or lower than normal blood pressure, without diagnosis.	

**MC80.0      Elevated blood-pressure reading, without diagnosis of hypertension**

**Coding Note:** This category is to be used to record an episode of elevated blood pressure in a patient in whom no formal diagnosis of hypertension has been made, or as an isolated incidental finding.

**MC80.00      White coat hypertension**

Persistently elevated office blood pressure readings with persistently normal out-of-the-office readings.

**MC80.01      Combined diastolic and systolic elevated blood pressure reading without diagnosis of hypertension**

**MC80.02      Diastolic elevated blood pressure reading without diagnosis of hypertension**

**MC80.03      Systolic elevated blood pressure reading without diagnosis of hypertension**

**MC80.0Y      Other specified elevated blood-pressure reading, without diagnosis of hypertension**

**Coding Note:** This category is to be used to record an episode of elevated blood pressure in a patient in whom no formal diagnosis of hypertension has been made, or as an isolated incidental finding.

**MC80.0Z      Elevated blood-pressure reading, without diagnosis of hypertension, unspecified**

**Coding Note:** This category is to be used to record an episode of elevated blood pressure in a patient in whom no formal diagnosis of hypertension has been made, or as an isolated incidental finding.

**MC80.1      Nonspecific low blood-pressure reading**

**Exclusions:** Maternal hypotension syndrome (JA65.6)  
Orthostatic hypotension (BA21)

**MC80.Y      Other specified abnormal blood-pressure reading, without diagnosis**

**MC80.Z**      **Abnormal blood-pressure reading, without diagnosis, unspecified**

**MC81**

**Abnormalities of heart beat**

Abnormalities of heart beat is arrhythmia which is any disorder of the heart rate or rhythm. It means that the heart beats too quickly, too slowly or with an irregular pattern.

**Exclusions:**      specified arrhythmias (BC60-BC9Z)

Cardiovascular disorders present in the perinatal or neonatal period (KB40-KB4Z)

**MC81.0**      **Tachycardia, unspecified**

**MC81.1**      **Bradycardia, unspecified**

**MC81.2**      **Palpitations**

**Inclusions:**      Awareness of heart beat

**MC81.3**      **Paroxysmal tachycardia**

**Exclusions:**      complicating, abortion or ectopic or molar pregnancy (JA05)

**Coded Elsewhere:** Re-entry ventricular arrhythmia (BC71.2)

**MC81.4**      **Pulseless electrical activity, not elsewhere classified**

**MC81.Y**      **Other specified abnormalities of heart beat**

**MC81.Z**      **Abnormalities of heart beat, unspecified**

**MC82**

**Cardiac arrest**

A sudden, sometimes temporary, cessation of heart function resulting in hemodynamic collapse.

**Exclusions:**      complicating abortion or ectopic or molar pregnancy (JA05)

Cardiogenic shock (MG40.0)

**MC82.0**      **Ventricular tachycardia and fibrillation cardiac arrest**

Discoordinated or rapid ventricular depolarization resulting in hemodynamic collapse.

**MC82.1**      **Bradycardic cardiac arrest**

Slow escape rhythm associated with hemodynamic collapse.

**MC82.2**      **Asystolic cardiac arrest**

Absence of electrical activity of the heart resulting in hemodynamic collapse.

**MC82.3**      **Cardiac arrest with pulseless electrical activity**

Electrical activation of the heart without mechanical activation resulting in hemodynamic collapse.

**MC82.4**      **Cardiopulmonary arrest**

**MC82.Z**      **Cardiac arrest, unspecified**

**MC83**

**Cardiac murmurs and other cardiac sounds**

Cardiac murmurs are blowing, whooshing, or rasping sounds heard during a heartbeat. Other cardiac sounds are sounds heard from heart other than cardiac murmurs.

**Exclusions:** Cardiovascular disorders present in the perinatal or neonatal period (KB40-KB4Z)

**MC83.0**

**Benign and innocent cardiac murmurs**

**Coded Elsewhere:** Benign or innocent cardiac murmurs in newborn (KB47)

**MC83.1**

**Other cardiac sounds**

**MC83.Z**

**Cardiac murmurs and sounds, unspecified**

**MC84**

**Cardiovascular pain**

**Exclusions:** Chronic secondary visceral pain (MG30.4)

**MC85**

**Gangrene**

Gangrene, not elsewhere classified is the death of tissues in the body which happens when a part of the body loses its blood supply.

**Exclusions:** Pyoderma gangrenosum (EB21)

Gas gangrene (1C16)

Polymicrobial necrotising fasciitis (1B71.1)

**MC86**

**Precordial pain**

**Exclusions:** Chronic secondary visceral pain (MG30.4)

**MC87**

**Pressure or tightness of heart**

**MC88**

**Prominent veins**

**MC8Y**

**Other specified symptoms or signs involving the circulatory system**

**MC90**

**Clinical findings on diagnostic imaging of heart or coronary circulation**

**Exclusions:** Long QT syndrome (BC65.0)

**MC91**

**Results of function studies of the circulatory system**

**Exclusions:** Long QT syndrome (BC65.0)

**MC9Y**

**Other specified symptoms, signs or clinical findings of the circulatory system**

## Symptoms, signs or clinical findings of the respiratory system (MD10-MD6Y)

### Symptoms or signs involving the respiratory system (MD10-MD3Y)

**Coded Elsewhere:** Fear of respiratory disease (MG24.A)

Acute life threatening episode (MG44.Y)

#### MD10

##### **Abnormal sputum**

This category includes the abnormalities of quantity, colour and odor in sputum which may suggest an aetiology. Patients with chronic bronchitis typically expectorate small quantities of mucoid yellow material. A foul or fetid odor should suggest infection from anaerobic organisms, usually in cases of lung abscess. Occasionally, greatly excessive amounts of sputum or "bronchorrhoea" is associated with bronchioloalveolar carcinoma.

**Exclusions:** blood-stained sputum (MD22)

#### MD11

##### **Abnormalities of breathing**

Abnormalities of breathing includes dyspnoea, stridor, wheezing, periodic breathing, hyperventilation, mouth breathing, hiccup, sneezing, and other abnormalities of breathing.

**Exclusions:** Respiratory distress of newborn (KB23)

Respiratory failure of newborn (KB2D)

Respiratory arrest (MD33)

Adult acute respiratory distress syndrome (CB00)

#### MD11.0

##### **Apnoea**

**Exclusions:** Apnoea of newborn (KB2A)

Sleep-related breathing disorders (7A40-7A4Z)

#### MD11.1

##### **Asphyxia**

Asphyxia is a life-threatening condition in which oxygen is prevented from reaching the tissues by obstruction of or damage to any part of the respiratory system. More generally the term indicates all the conditions generating impaired or impeded breathing.

**Exclusions:** asphyxia due to foreign body in respiratory tract (ND72)

asphyxia due to carbon monoxide (NE61)

asphyxia due to traumatic (Chapter 22)

**Coded Elsewhere:** Intrauterine hypoxia (KB20)

Birth asphyxia (KB21)

#### MD11.2

##### **Ataxic breathing**

An irregular breathing pattern that usually progresses to complete apnoea.

#### MD11.3

##### **Breath holding**

- MD11.4 Sleep related Cheyne-Stokes respiration**  
Periodic breathing, a variant of Cheyne-Stokes respiration, is characterised by regular, recurrent cycles of changing tidal volumes in which the lowest tidal volume is less than half the maximal tidal volume in that cycle. It is the most frequent abnormal respiratory pattern directly related to stroke rather than underlying systemic disease, occurring in approximately 25 percent of patients. Periodic breathing may be more common among patients with subarachnoid haemorrhage.
- Exclusions:** Central sleep apnea with Cheyne-Stokes breathing (7A40.3)
- MD11.5 Dyspnoea**  
Dyspnoea is used to describe perceptions of difficulty or distress related to breathing and is recognised as symptomatic of disease when it occurs under inappropriate circumstances. Dyspnoea is a presenting complaint of patients with a wide variety of medical diseases by multiple mechanisms.  
Dyspnoea is considered acute when it lasts from hours up to 3 weeks, subacute from 3 weeks up to 8 weeks, and chronic dyspnoea lasts more than 8 weeks.
- Exclusions:** Transient tachypnoea of newborn (KB23.1)
- MD11.6 Hiccough**  
Hiccough are repeated involuntary spasms of the diaphragm followed by sudden closure of the glottis, which checks the inflow of air and causes the characteristic sound. Transient episodes are very common. Persistent (> 2 days) and intractable (> 1 mo) Hiccough are uncommon but quite distressing.
- MD11.7 Hyperventilation**  
Hyperventilation refers to an increase in the rate of alveolar ventilation that is excessive for the rate of metabolic carbon dioxide production, resulting in a decrease in arterial PCO<sub>2</sub> to below the normal range of 37 to 43 mm Hg. Hyperventilation should be distinguished from tachypnoea, an increase in respiratory frequency, and from hyperpnea, an increase in minute volume of ventilation.
- MD11.8 Mouth breathing**  
Breathing through mouth. Nasal obstruction may also necessitate mouth breathing, which itself can precipitate obstructive apnoea. Breathing through the mouth may also increase risk for OSA by its effect on the tongue. The tongue forms the anterior wall of the oropharynx; both the supine posture and opening of the mouth tend to displace it posteriorly and encourage airway closure.
- Exclusions:** Dry mouth (DA02.1)
- MD11.80 Stertor**  
Stertor is a heavy snoring or gasping sound on inspiration occurring in coma or deep sleep that may be caused by partial obstruction of airway, choanal stenosis, enlarged tonsils and/or adenoids, and redundant upper airway tissues.
- MD11.8Y Other specified mouth breathing**
- MD11.8Z Mouth breathing, unspecified**
- MD11.9 Nasal congestion**

**MD11.A** **Sneezing**  
Sneezing is one of the most fundamental airway reflexes, which is characterised by a deep preparatory inspiration followed by an abrupt increase in subglottic pressure reflecting a forceful, active expiration rather similar to coughing. Chemical or physical stimuli to the nasal mucosa may initiate potent respiratory and cardiovascular reflexes via stimulation of trigeminal nerves. Mild stimuli result in sneezing and nasal hypersecretion. These reflex responses protect the lower airways from inhalation of physical and chemical irritants.

**MD11.B** **Stridor**  
Stridor or a low-pitched, focal inspiratory wheeze usually heard over the neck is a manifestation of upper airway obstruction and should result in an expedited evaluation of the patient as it can precede complete upper airway obstruction and respiratory failure.

**Exclusions:** laryngismus (stridulus) (CA0H.4)  
congenital laryngeal stridor (KB20-KB2Z)

**MD11.C** **Wheezing**  
Continuous adventitious sounds that are high-pitched are called wheezes. Wheezes originate in airways narrowed by spasm, thickening of the mucosa, or luminal obstruction.

**MD11.D** **Yawning**

**MD11.Y** **Other specified abnormalities of breathing**

**MD11.Z** **Abnormalities of breathing, unspecified**

**MD12** **Cough**  
Cough is an important natural defensive mechanism and protective reflex for clearing the upper and lower airways of excessive secretions such as mucus and inhaled particles. Cough is a common symptom of most respiratory disorders and may be indicative of trivial to very serious airway or lung pathology.

**Exclusions:** cough with haemorrhage (MD22)

## Haemorrhage from respiratory passages (MD20-MD2Z)

Haemorrhage from respiratory passages is the bleeding from upper respiratory tract or lower respiratory tract. The major passages and structures of the upper respiratory tract include the nose or nostrils, nasal cavity, mouth, pharynx, and larynx. The major passages and structures of the lower respiratory tract include the trachea and within the lungs, the bronchi, bronchioles, and alveoli.

**Exclusions:** Pulmonary haemorrhage originating in the perinatal period (KB28)

**MD20** **Epistaxis**

Bleeding from the nose

**Inclusions:** Nosebleed  
Haemorrhage from nose

**Coded Elsewhere:** Neonatal epistaxis (KA83.A)

**MD21**

### **Haemorrhage from throat**

Haemorrhage from throat is the bleeding from throat. Throat is a tube that carries food to oesophagus and air to windpipe and larynx.

**Exclusions:** Haemoptysis (MD22)

**MD22**

### **Haemoptysis**

Expectoration or spitting of blood originating from any part of the respiratory tract, usually from haemorrhage in the lung parenchyma and the bronchial arteries.

**Inclusions:** Blood-stained sputum

Cough with haemorrhage

**MD23**

### **Haemorrhage from other sites in respiratory passages**

**Exclusions:** Pulmonary haemorrhage originating in the perinatal period (KB28)

**Coded Elsewhere:** Neonatal haemorrhage originating in trachea or pulmonary parenchyma (KA83.7)

**MD24**

### **Acute idiopathic pulmonary haemorrhage in infants over 28 days of age**

**Exclusions:** Von Willebrand disease (3B12)

**MD2Z**

### **Haemorrhage from respiratory passages, unspecified**

**MD30**

### **Pain in throat or chest**

Pain in throat and chest means having pain sensation in throat or chest. Throat is a tube that carries food to oesophagus and air to windpipe and larynx. The technical name for throat is pharynx.

**Exclusions:** Cervical spine pain (ME84.0)  
acute sore throat NOS (CA02)  
pain in breast (GB23.5)  
Epidemic myalgia (1D83)  
Dysphagia (MD93)  
Chronic primary chest pain syndrome (MG30.00)  
Chronic primary visceral pain (MG30.00)  
Chronic secondary visceral pain (MG30.4)

**Coded Elsewhere:** Pain in throat (MD36.0)

Precordial pain (MC86)

Musculoskeletal chest pain (ME81)

<b>MD30.0</b>	<b>Chest pain on breathing</b>
	Pleuritic chest pain is a type of pain that is caused by problems with the thin layers of tissue that surround the lungs (called the “pleura”). This type of pain feels like a sharp, stabbing chest pain, and it gets worse when you breathe in. Pleuritic chest pain can be caused by the following problems: pneumothorax, pleural effusion, pleuritis, empyema, pericarditis.
	<b>Inclusions:</b> Painful respiration
	<b>Exclusions:</b> Pleurisy (MD31)
	Chronic primary visceral pain (MG30.00)
	Chronic secondary visceral pain (MG30.4)
<b>MD30.1</b>	<b>Other chest pain</b>
	<b>Exclusions:</b> Chronic primary visceral pain (MG30.00)
	Chronic secondary visceral pain (MG30.4)
<b>MD30.Z</b>	<b>Chest pain, unspecified</b>
<b>MD31</b>	<b>Pleurisy</b>
	Pleurisy or Pleuritis is the medical term for inflammation of the pleura. The most common cause of pleuritis is infection, but it can also be caused by lupus, rheumatoid arthritis, and certain medicines. Pleurisy or pleuritis usually accumulates exudative pleural effusions.
	<b>Exclusions:</b> pleurisy with effusion (CB27)
<b>MD32</b>	<b>Rules</b>
<b>MD33</b>	<b>Respiratory arrest</b>
	Arrest of spontaneous breathing.
	<b>Coded Elsewhere:</b> Respiratory arrest of newborn (KB2E)
<b>MD34</b>	<b>Symptom or complaint of the nose</b>
<b>MD35</b>	<b>Symptom or complaint of the sinus</b>
<b>MD36</b>	<b>Symptom or complaint of the throat</b>
<b>MD36.0</b>	<b>Pain in throat</b>
	Pain in throat means having pain sensation in throat. Throat is a tube that carries food to oesophagus and air to windpipe and larynx.
	<b>Exclusions:</b> Chronic primary visceral pain (MG30.00)
	Chronic secondary visceral pain (MG30.4)
<b>MD36.Y</b>	<b>Other specified symptom or complaint of the throat</b>
<b>MD36.Z</b>	<b>Symptom or complaint of the throat, unspecified</b>
<b>MD3Y</b>	<b>Other specified symptoms or signs involving the respiratory system</b>

Clinical findings in the respiratory system (MD40-MD4Y)

<b>MD40</b>	<b>Clinical findings in specimens from respiratory organs and thorax</b> <b>Exclusions:</b> Haemoptysis (MD22)
<b>MD40.0</b>	<b>Abnormal level of enzymes in specimens from respiratory organs and thorax</b>
<b>MD40.1</b>	<b>Abnormal level of hormones in specimens from respiratory organs and thorax</b>
<b>MD40.2</b>	<b>Abnormal level of drugs, medicaments and biological substances in specimens from respiratory organs and thorax</b>
<b>MD40.3</b>	<b>Abnormal level of substances chiefly nonmedicinal as to source in specimens from respiratory organs and thorax</b>
<b>MD40.4</b>	<b>Abnormal immunological findings in specimens from respiratory organs and thorax</b>
<b>MD40.5</b>	<b>Abnormal microbiological findings in specimens from respiratory organs and thorax</b>
<b>MD40.50</b>	Positive culture from nose
<b>MD40.51</b>	Positive sputum culture
<b>MD40.52</b>	Positive throat culture
<b>MD40.5Y</b>	Other specified abnormal microbiological findings in specimens from respiratory organs and thorax
<b>MD40.5Z</b>	Abnormal microbiological findings in specimens from respiratory organs and thorax, unspecified
<b>MD40.6</b>	<b>Abnormal cytological findings in specimens from respiratory organs and thorax</b>
<b>MD40.7</b>	<b>Abnormal histological findings in specimens from respiratory organs and thorax</b>
<b>MD40.Y</b>	<b>Other specified clinical findings in specimens from respiratory organs and thorax</b>
<b>MD41</b>	<b>Clinical findings on diagnostic imaging of lung</b> Clinical findings on diagnostic imaging of lung is findings on diagnostic imaging of the lung which don't appear in normal status of the body. Diagnostic imaging refers to technologies that doctors use to look inside body for clues about a medical condition. X-rays, CT scans, nuclear medicine scans, MRI scans and ultrasound are all types of diagnostic imaging.
<b>MD42</b>	<b>Results of function studies of the respiratory system</b>
<b>MD4Y</b>	<b>Other specified clinical findings in the respiratory system</b>
<b>MD6Y</b>	<b>Other specified symptoms, signs or clinical findings of the respiratory system</b>

## Symptoms, signs or clinical findings of the digestive system or abdomen (MD80-ME4Y)

Symptoms or signs involving the digestive system or abdomen (MD80-ME1Y)

- Exclusions:**
- pylorospasm congenital or infantile (LB13.0)
  - Intestinal obstruction of newborn (KB87)
  - gastrointestinal haemorrhage newborn (KA83.1)
  - Symptoms, signs or clinical findings involving the male genital system (MF40-MF4Y)
  - Symptoms, signs or clinical findings involving the urinary system (MF50-MF5Y)
  - Symptoms, signs or clinical findings involving the female genital system (MF30-MF3Y)

**Coded Elsewhere:** Fear of digestive disease (MG24.3)

<b>MD80</b>	<b>Symptoms or signs of the orofacial complex</b>
<b>MD80.0</b>	<b>Symptom or complaint of the teeth or gum</b>
<b>MD80.1</b>	<b>Symptom or complaint of the mouth, tongue or lip</b>
<b>MD80.Y</b>	<b>Other specified symptoms or signs of the orofacial complex</b>
<b>MD81</b>	<b>Abdominal or pelvic pain</b>
	Pain, an unpleasant distress sensation occurring in varying degrees of severity, received by nerve ending in the abdominal and pelvic region.
	<b>Exclusions:</b>
	Spinal pain (ME84)
	Flatulence and related conditions (ME08)
	renal colic (MF56)
	Chronic primary visceral pain (MG30.00)
	Chronic secondary visceral pain (MG30.4)
<b>MD81.0</b>	<b>Abdominal tenderness</b>
<b>MD81.1</b>	<b>Localised abdominal pain</b>
	<b>Exclusions:</b>
	Chronic primary visceral pain (MG30.00)
	Chronic secondary visceral pain (MG30.4)
<b>MD81.10</b>	Pain localised to upper abdomen
	Pain, an unpleasant distress sensation, which is localised to upper part of abdomen.
	<b>Inclusions:</b>
	Epigastric pain
	<b>Exclusions:</b>
	Functional dyspepsia (DD90.3)
	Chronic primary visceral pain (MG30.00)
	Chronic secondary visceral pain (MG30.4)

- MD81.11** Pelvic or perineal pain  
 Pain, an unpleasant distress sensation, which occurs in the pelvic and perineal region.
- Exclusions:**
- Female pelvic pain associated with genital organs or menstrual cycle (GA34)
  - Chronic primary bladder pain syndrome (MG30.00)
  - Bladder pain (MF52)
  - Sexual pain-penetration disorder (HA20)
  - Chronic primary visceral pain (MG30.00)
  - Chronic secondary visceral pain (MG30.4)
- Coded Elsewhere:** Perineal pain (GA34.01)  
 Pelvic floor tension myalgia (GA34.0Y)
- MD81.12** Pain localised to other parts of lower abdomen  
 Pain, an unpleasant distress sensation, which is localised to other part of lower abdomen than the pelvic or perineal region.
- Exclusions:**
- Pelvic or perineal pain (MD81.11)
  - Chronic primary visceral pain (MG30.00)
  - Chronic secondary visceral pain (MG30.4)
- MD81.1Z** Localised abdominal pain, unspecified
- MD81.2** **Generalised abdominal pain**  
 Pain, an unpleasant distress sensation occurring in varying degrees of severity, or cramps, spasmodic contraction causing severe pain in the abdominal area in general.
- Exclusions:**
- Chronic primary visceral pain (MG30.00)
  - Chronic secondary visceral pain (MG30.4)
- MD81.3** **Acute abdomen**  
 A clinical syndrome with acute abdominal pain that is severe, and rapid onset. Acute abdomen may be caused by a variety of disorders, injuries, or diseases
- MD81.4** **Other and unspecified abdominal pain**
- Exclusions:**
- Infantile colic (DD93.1)
  - Chronic primary abdominal pain syndrome (MG30.00)
  - Chronic primary visceral pain (MG30.00)
  - Chronic secondary visceral pain (MG30.4)
- MD82** **Intra-abdominal or pelvic swelling, mass or lump**  
 This refers to the presence of abdominal or pelvic wall swelling, mass or tumour in the abdominal and pelvic regions. These mass or tumours can be recognised by visual examination and/or palpation.
- Exclusions:**
- Abdominal distension (ME01)
  - Ascites (ME04)

## Symptoms related to the upper gastrointestinal tract (MD90-MD9Y)

Clinical symptoms presumed to be arising from disorders/diseases of upper GI tract.

**Coded Elsewhere:** Haematemesis (ME24.A5)

### MD90

#### Nausea or vomiting

Nausea is the feeling of having an urge to vomit. Vomiting is forcing the contents of the stomach up through the oesophagus and out of the mouth.

- Exclusions:**
- haematemesis neonatal (KB8A)
  - Functional nausea or vomiting (DD90.4)
  - psychogenic vomiting (8A80.4)

### MD90.0

#### Nausea

### MD90.1

#### Vomiting

- Coded Elsewhere:**
- Vomiting following gastrointestinal surgery (DE10)
  - Excessive vomiting in pregnancy (JA60)
  - Vomiting in newborn (KD3C)

### MD91

#### Belching

The liberation of gas in the upper gastrointestinal tract via the oesophagus through the mouth.

- Exclusions:**
- Functional belching disorders (DD90.5)

### MD92

#### Dyspepsia

A condition characterised by upper abdominal symptoms that suggest indigestion (painful, difficult, or disturbed digestion), which may include pain or discomfort of upper abdomen, bloating, feeling of fullness with very little intake of food, nausea and vomiting, heartburn, loss of appetite.

- Exclusions:**
- Functional dyspepsia (DD90.3)

### MD93

#### Dysphagia

Difficulty in swallowing which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the pharynx and upper oesophageal sphincter; and oesophageal dysphagia due to malfunction of the oesophagus.

- Inclusions:**
- Difficulty in swallowing

- Exclusions:**
- Functional swallowing disorder (DD90.1)

### MD94

#### Halitosis

Halitosis is an oral health condition in which one's mouth emits a foul odour. There are many causes of halitosis such as poor oral hygiene, tobacco and/or alcohol, and possibly a medical condition such as respiratory and digestive tract disorders.

**MD95**

### **Heartburn**

Substernal pain or burning sensation, usually associated with regurgitation of gastric juice into the oesophagus.

- Exclusions:**
- Functional dyspepsia (DD90.3)
  - Pain in throat or chest (MD30)
  - Functional heartburn (DD90.2)

**MD9Y**

### **Other specified symptoms related to the upper gastrointestinal tract**

Symptoms related to the lower gastrointestinal tract or abdomen (ME00-ME0Y)

**Exclusions:** Abdominal or pelvic pain (MD81)

**Coded Elsewhere:** Haematochezia (ME24.A3)

- Haemorrhage of anus and rectum (ME24.A1)
- Meconium ileus without perforation (KB87.2)
- Melaena (ME24.A4)

**ME00**

### **Abdominal compartment syndrome**

Abdominal compartment syndrome is a condition of organ dysfunction caused by increased intra-abdominal pressure (intra-abdominal hypertension), possibly due to intra-abdominal haemorrhage, retroperitoneal haematoma, or intestinal oedema, often occurred after surgical intervention or trauma, or often associated with septic condition. The importance of this clinical entity was recognised recently in the end of the 20th Century. Usually the abdominal distension due to primary ischaemic bowel injury was excluded from this clinical entity.

**ME01**

### **Abdominal distension**

This is a condition in which the abdomen feels full and tight because of swelling of the abdomen, usually due to an increased amount of intestinal gas, but occurs sometimes when fluid, substances or mass are accumulating or expanding in the abdomen.

**ME02**

### **Abdominal rigidity**

Abdominal rigidity is stiffness of the muscles in the belly area, which can be felt when touched or pressed.

**Exclusions:** that with severe abdominal pain (MD81.3)

**ME03**

### **Abnormal bowel sounds**

Bowel sounds are caused by the products of digestion as they move through the lower gastrointestinal tract, usually heard on auscultation. Abnormal bowel sounds are reduced or increased bowel sounds which provide valuable information about the disorders of bowel movement.

**ME03.0** **Hyperactive bowel sounds**

**ME03.1** **Absent bowel sounds**

**ME03.Z** **Abnormal bowel sounds, unspecified**

**ME04**

**Ascites**

Accumulation or retention of free fluid in the abdominal peritoneal cavity between the tissues lining the abdomen and abdominal organs. The fluid may be serous, haemorrhagic, or the result of inflammation or tumour metastasis to the peritoneum.

**ME04.0**

**Fluid in peritoneal cavity**

**Exclusions:** Malignant ascites (2D91)

**ME04.Y**

**Other specified ascites**

**ME04.Z**

**Ascites, unspecified**

**ME05**

**Change in bowel habit**

Bowel habits are the time, size, amount, consistency and frequency of bowel movements throughout the day. A change in bowel habits is any alteration in regular bowel habits.

**Exclusions:** Functional diarrhoea (DD91.2)

**ME05.0**

**Constipation**

Constipation is an acute or chronic condition in which bowel movements occur less often than usual or consist of hard, dry stools that are often painful or difficult to pass. Here constipation other than specifically described elsewhere, such as in motility disorders of intestine or in functional bowel diseases, is described.

**Inclusions:** faecal impaction

**Exclusions:** Functional constipation (DD91.1)

Functional constipation of infants, toddlers or children (DD93)

Atonic constipation (DD91.1)

Slow transit constipation (DB32.1)

Neurogenic constipation (DD91.1)

Spastic constipation (DD91.1)

**ME05.1**

**Diarrhoea**

Diarrhoea is an acute or chronic condition in which there is an increased frequency or decreased consistency of bowel movements, usually with excessive and frequent evacuation of watery faeces. Here diarrhoea other than specifically described elsewhere, such as in motility disorders of intestine or in functional bowel diseases, is described.

**Inclusions:** frequent/loose bowel movements

watery stools

**Exclusions:** Melaena (ME24.A4)

Change in faeces or bowel movements (ME00-ME0Y)

Functional diarrhoea (DD91.2)

infectious diarrhoea (1A00-1A40.Z)

**Coded Elsewhere:** Noninfectious neonatal diarrhoea (KB8C)

**ME05.Z**

**Other and unspecified change in bowel habit**

<b>ME06</b>	<b>Chronic enteritis of uncertain aetiology</b>
	<b><i>Exclusions:</i></b> Gastroenteritis or colitis of infectious origin (1A00-1A40.Z)
<b>ME07</b>	<b>Faecal incontinence</b>
	Failure of voluntary control of the anal sphincters, with involuntary passage of faeces and flatus.
	<b><i>Exclusions:</i></b> Functional faecal incontinence (DD92.0) Nonretentive faecal incontinence in children (DD93) nonorganic encopresis (6C01)
<b>ME07.0</b>	<b>Faecal smearing</b>
<b>ME07.1</b>	<b>Incomplete defaecation</b>
	<b><i>Exclusions:</i></b> Constipation (ME05.0)
<b>ME07.2</b>	<b>Faecal urgency</b>
<b>ME07.Y</b>	<b>Other specified faecal incontinence</b>
<b>ME07.Z</b>	<b>Faecal incontinence, unspecified</b>
<b>ME08</b>	<b>Flatulence and related conditions</b>
	Production or presence of gas in the gastrointestinal tract which may be expelled through the anus and other conditions associated with the production or presence of gas in the GI tract.
<b>ME09</b>	<b>Rectal tenesmus</b>
	A symptom, where there is a feeling of constantly needing to pass stools, despite an empty colon.
<b>ME0A</b>	<b>Visible peristalsis</b>
	The wavelike increased peristaltic motions of the intestines by which contents are forced onward toward the opening in such a way that they become visible through the abdominal walls by visual examination.
<b>ME0B</b>	<b>Problems with defaecation, not otherwise specified</b>
	<b><i>Exclusions:</i></b> Incomplete defaecation (ME07.1) Functional constipation (DD91.1) Functional defaecation disorders (DD92.2)
<b>ME0Y</b>	<b>Other specified symptoms related to the lower gastrointestinal tract or abdomen</b>
<b>ME10</b>	<b>Abnormalities related to hepatobiliary system</b>
<b>ME10.0</b>	<b>Hepatomegaly or splenomegaly</b>
	Hepatomegaly is swelling of the liver beyond its normal size and splenomegaly is an enlargement of the spleen beyond its normal size.
<b>ME10.00</b>	Hepatomegaly, not elsewhere classified

<b>ME10.01</b>	Splenomegaly, not elsewhere classified This refers to swelling of the spleen beyond its normal size, not elsewhere described.
	<b>Exclusions:</b> Hypersplenism (3B81.B)
<b>ME10.02</b>	Hepatomegaly with splenomegaly This refers to swelling of the liver and spleen beyond its normal size, not elsewhere described.
<b>ME10.1</b>	<b>Unspecified jaundice</b> A clinical manifestation of hyperbilirubinemia of unspecified origin, characterised by the yellowish staining of the skin; mucus membranes and sclera.
	<b>Exclusions:</b> neonatal jaundice (KA87)
<b>ME1Y</b>	<b>Other specified symptoms or signs involving the digestive system or abdomen</b>

Clinical findings in the digestive system (ME20-ME2Y)

<b>ME20</b>	<b>Clinical findings in specimens from digestive organs or abdominal cavity</b>  <b>Exclusions:</b> Other faecal abnormalities (ME00-ME0Y)
<b>ME20.0</b>	<b>Abnormal level of enzymes in specimens from digestive organs or abdominal cavity</b>
<b>ME20.1</b>	<b>Abnormal level of hormones in specimens from digestive organs or abdominal cavity</b>
<b>ME20.2</b>	<b>Abnormal level of drugs, medicaments or biological substances in specimens from digestive organs of abdominal cavity</b>
<b>ME20.3</b>	<b>Abnormal level of substances chiefly nonmedicinal as to source in specimens from digestive organs and abdominal cavity</b>
<b>ME20.4</b>	<b>Abnormal immunological findings in specimens from digestive organs and abdominal cavity</b>
<b>ME20.5</b>	<b>Abnormal microbiological findings in specimens from digestive organs and abdominal cavity</b>
<b>ME20.6</b>	<b>Abnormal cytological findings in specimens from digestive organs and abdominal cavity</b>
<b>ME20.7</b>	<b>Abnormal histological findings in specimens from digestive organs and abdominal cavity</b>
<b>ME20.Y</b>	<b>Other specified clinical findings in specimens from digestive organs or abdominal cavity</b>
<b>ME20.Z</b>	<b>Clinical findings in specimens from digestive organs or abdominal cavity, unspecified</b>
<b>ME21</b>	<b>Clinical findings on diagnostic imaging of liver or biliary tract</b>

<b>ME22</b>	<b>Clinical findings on diagnostic imaging of digestive tract</b>
<b>ME23</b>	<b>Results of function studies of the digestive system</b>
<b>ME24</b>	<b>Clinical manifestations of the digestive system</b>
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.0</b>	<p><b>Digestive system abscess</b></p> <p>This is a clinical form of sign indicating the presence of abscess in digestive system. This category will be used for postcoordination codes as complications of underlying illness.</p>
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.1</b>	<p><b>Digestive system fistula</b></p> <p>This is a clinical form of sign indicating the presence of fistula in the digestive tract. This category will be used for postcoordination codes as complications of underlying illness.</p>
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.2</b>	<p><b>Digestive system obstruction</b></p> <p>This is a clinical form of a sign indicating obstruction of digestive tract. This category will be used for postcoordination codes as complications of underlying illness.</p>
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.3</b>	<p><b>Digestive system perforation</b></p> <p>This is a clinical form of sign indicating perforation of digestive tract. This category will be used for postcoordination codes as complications of underlying illness.</p>
<b>Coding Note:</b>	Code also the causing condition
	<p><b>Coded Elsewhere:</b> Prenatal gastric perforation (KB82)</p> <p>Postnatal gastric perforation (KB83)</p> <p>Postnatal intestinal perforation (KB86)</p> <p>Prenatal intrauterine intestinal perforation (KB85)</p>
<b>ME24.30</b>	<p>Perforation of small intestine</p> <p>Small intestinal perforation is a complete penetration of the wall of small intestine, often resulting in the leakage of small intestinal contents into the abdominal cavity.</p>
	<p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Primary ulcer of small intestine (DA94.0)</li> <li>Diverticulitis of small intestine (DC70)</li> <li>perforation due to Crohn disease (DD70.1)</li> <li>perforation due to obstruction (DA91)</li> <li>perforation due to malignant neoplasm ()</li> </ul>
	<p><b>Coded Elsewhere:</b> Postnatal isolated ileal perforation (KB84)</p> <p>Injury of small intestine (NB91.7)</p> <p>Laceration of small intestine (NB91.71)</p>

<b>ME24.31</b>	Perforation of large intestine Perforation of large intestine is a complete penetration of the colonic wall, often resulting in the leakage of luminal contents into the abdominal cavity. Perforation of large intestine results in the potential for bacterial contamination of the abdominal cavity and peritonitis.
	<b>Exclusions:</b> Diverticular disease of large intestine (DC80-DC82.Z) Ulcerative colitis (DD71) Crohn disease (DD70) Neoplasms of the large intestine ()
	<b>Coded Elsewhere:</b> Injury of colon (NB91.8)
<b>ME24.35</b>	Perforation of gallbladder or bile ducts This is perforation in the small organ that aids mainly in fat digestion and concentrates bile produced by the liver and in any of a number of long tube-like structures that carry bile.
	<b>Inclusions:</b> Rupture of cystic duct or gallbladder Rupture of gallbladder or bile duct
<b>ME24.3Y</b>	Digestive system perforation of other specified site
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.3Z</b>	Digestive system perforation of unspecified site
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.4</b>	<b>Digestive system stenosis</b> This is a clinical form of sign indicating stenosis of digestive tract. This category will be used for postcoordination codes as complications of underlying illness.
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.5</b>	<b>Digestive system ulcer</b>
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.6</b>	<b>Digestive system dilatation</b> This is a clinical form of sign indicating the excess dilatation of lumen in the digestive tract. This category will be used for postcoordination codes as complications of underlying illness.
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.7</b>	<b>Digestive system incarceration</b> This is a clinical form of sign indicating the presence of incarceration in the digestive tract. This category is to be used for postcoordination codes particularly in case of haemorrhoids and hernia as complications of underlying illness.
<b>Coding Note:</b>	Code also the causing condition

<b>ME24.8</b>	<b>Digestive system strangulation or gangrene</b> This is a clinical form of sign indicating the presence of strangulation and/or gangrene in the digestive tract. This category is to be used for postcoordination codes particularly in case of mechanical bowel obstruction and hernia as complications of underlying illness.
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.9</b>	<b>Gastrointestinal bleeding</b>
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.90</b>	Acute gastrointestinal bleeding, not elsewhere classified
<b>ME24.91</b>	Chronic gastrointestinal bleeding, not elsewhere classified
<b>ME24.9Z</b>	Gastrointestinal bleeding, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>ME24.A</b>	<b>Other digestive system haemorrhage, not elsewhere classified</b>
	<b>Coded Elsewhere:</b> Neonatal bleeding originating in the mouth, nose or pharynx (KA83.0)
	Neonatal bleeding originating in the oesophagus, stomach, small or large intestine (KA83.1)
<b>ME24.A0</b>	Obscure gastrointestinal bleeding Obscure gastrointestinal bleeding (OGIB) is defined as gastrointestinal bleeding with no source identified at upper and lower endoscopy. Despite a thorough endoscopic examination, the origin of the blood loss remains unexplained and observed for further bleeding.
<b>ME24.A1</b>	Haemorrhage of anus and rectum Bleeding from anus and anal canal. The bleeding due to specific diseases classified elsewhere (haemorrhoid, cancer, infection etc) is excluded from here. <b>Coded Elsewhere:</b> Neonatal rectal haemorrhage (KA83.2)
<b>ME24.A2</b>	Oesophageal haemorrhage
<b>ME24.A3</b>	Haematochezia Haematochezia is the passage of fresh blood through the anus, usually in or with stools (contrast with melena). Haematochezia is commonly associated with lower gastrointestinal bleeding.
<b>ME24.A4</b>	Melaena It is bloody stools that indicate bleeding from vascular system in the digestive tract. It is also described as black, tarry, and foul-smelling stools or red/maroon-coloured stools that contain degraded blood.
	<b>Exclusions:</b> occult blood in faeces (ME00-ME0Y)

<b>ME24.A5</b>	Haematemesis Vomiting of blood that is either fresh bright red, or older "coffee-ground" in character. Vomiting blood is a regurgitation of blood through the upper gastrointestinal tract and it generally indicates bleeding of the upper gastrointestinal tract.
	<b>Coded Elsewhere:</b> Neonatal haematemesis or melaena due to swallowed maternal blood (KB8A)
<b>ME24.A6</b>	Positive occult blood in stool Positive tests (positive stool) determined by faecal occult blood testing (FOBT), which aims to detect subtle blood loss in the gastrointestinal tract. Positive occult blood in stool may suggest gastrointestinal bleeding and warrant further investigation, especially for malignancy.
<b>ME24.Y</b>	<b>Other specified clinical manifestations of the digestive system</b>

**Coding Note:** Code also the causing condition

**ME2Y      Other specified clinical findings in the digestive system**

---

**ME4Y      Other specified symptoms, signs or clinical findings of the digestive system or abdomen**

Symptoms, signs or clinical findings involving the skin (ME60-ME6Y)

Symptoms or signs involving the skin (ME60-ME6Y)

This category allows the capture of imprecise data where a more specific diagnosis cannot be made or to supplement information about a specific diagnosis.

<b>ME60</b>	<b>Skin lesion of uncertain or unspecified nature</b> To be used where there is either significant uncertainty or alternatively no information as to the nature of a circumscribed skin lesion. This is of particular importance with regard to whether or not the lesion may be malignant.
<b>ME60.0</b>	<b>Skin lesion of uncertain nature</b> This denotes the presence of a skin lesion but uncertainty as to its nature. No inference as to whether the lesion might be of serious significance (e.g. suspected skin cancer) is made.
<b>ME60.1</b>	<b>Pigmented skin lesion of uncertain nature</b> This denotes the presence of a pigmented skin lesion but uncertainty as to its nature. No inference as to whether the lesion might be of serious significance (e.g. suspected skin cancer) is made.
<b>ME60.2</b>	<b>Ulcer of skin of uncertain nature</b> This denotes the presence of a skin ulcer but uncertainty as to its nature. No inference as to whether the ulcer might be of serious significance (e.g. suspected skin cancer) is made.

- ME60.3** **Keratosis of skin of uncertain or unspecified nature**
- ME60.Z** **Skin lesion of unspecified nature**
- ME61** **Subcutaneous swelling, mass or lump of uncertain or unspecified nature**  
One or more localised subcutaneous soft tissue masses of undetermined or unspecified nature
- Exclusions:** localized adiposity (5B80.1)  
mass and lump: breast (MF30)  
enlarged lymph nodes (MA01)  
mass and lump: intra-abdominal or pelvic (MD82)  
oedema (MG29)  
swelling (of): intra-abdominal or pelvic (MD82)  
swelling (of): joint (FA36)
- ME62** **Acute skin eruption of uncertain or unspecified nature**  
A provisional diagnosis for an acute skin eruption of less than six weeks' duration of unknown, uncertain or unspecified nature.
- Exclusions:** Drug eruptions (EH60-EH6Z)
- ME62.0** **Acute erythematous skin eruption**  
A provisional diagnosis for a skin eruption of unknown or uncertain nature which arises abruptly and consists predominantly of diffuse cutaneous erythema. A classical cause is scarlet fever but reactions to other bacterial toxins, drugs and certain foods or acute graft-versus-host disease may present with a similar picture.
- ME62.1** **Acute purpuric skin eruption**  
A provisional diagnosis for a skin eruption of unknown or uncertain nature which arises abruptly and consists predominantly of disseminated purpura. Potential causes are numerous and include thrombocytopenia, coagulopathies, vasculitides and sepsis.
- ME62.2** **Acute urticarial skin eruption**  
A provisional diagnosis for a skin eruption of unknown or uncertain nature which arises abruptly and consists of urticaria-like papules and plaques. Drugs are a common precipitant.
- ME62.3** **Acute maculopapular skin eruption**  
A provisional diagnosis for a skin eruption of unknown or uncertain nature which arises abruptly and consists of multiple macules and papules. Viral infections and drugs are common precipitants.

- ME62.4 Acute papular skin eruption**  
A provisional diagnosis for a skin eruption of unknown or uncertain nature which arises abruptly and consists of multiple skin papules. A wide variety of infectious and inflammatory skin disorders may present in this way. Examples include guttate psoriasis, lichen planus, pityriasis lichenoides, insect bites, scabies and secondary syphilis.
- ME62.5 Acute exudative skin eruption**  
A provisional diagnosis for a skin eruption of unknown or uncertain nature which arises abruptly and in which exudation and crusting are prominent features. Common causes are infected eczema, acute allergic contact dermatitis and impetigo.
- ME62.6 Acute blistering skin eruption**  
A provisional diagnosis for an acute blistering skin eruption of unknown or uncertain nature. Examples include vesicular dermatitis of the hands and feet (pompholyx), acute phototoxic reactions, especially to contact with plants (phytophotodermatitis), sunburn and immunobullous disorders such as bullous pemphigoid.
- ME62.7 Acute desquamating skin eruption**  
A provisional diagnosis for a skin eruption of unknown or uncertain nature which arises abruptly and in which desquamation (shedding of skin scales) is a prominent feature. This is seen characteristically in the later stages of many acute viral exanthemata but may also be seen in drug reactions and in unstable and erythrodermic psoriasis.
- ME62.8 Acute discoid or annular skin eruption**  
A provisional diagnosis for a skin eruption of unknown or uncertain nature which arises abruptly and consists of multiple circular or ring-shaped patches and plaques. Although infection due to dermatophyte infection (tinea or ringworm) can produce this pattern, many other skin disorders may have a discoid or annular configuration: these are frequently misdiagnosed as tinea. Common examples include atopic eczema, nummular dermatitis and psoriasis.
- ME62.9 Acute excoriation of skin**  
A provisional diagnosis for a skin eruption of unknown or uncertain nature which arises abruptly and consists of multiple excoriations. In the majority of cases the excoriation is secondary to intense pruritus arising either from an underlying systemic disorder such as cholestatic jaundice or from a pruritic skin disease such as eczema. In some cases, however, psychogenic factors may be responsible.
- ME62.Y Other specified acute skin eruption of uncertain or unspecified nature**
- ME63 Chronic skin disorder of uncertain or unspecified nature**  
A provisional diagnosis for a chronic skin disorder (of at least six weeks' duration) of unknown, uncertain or unspecified nature.

- ME63.0      Chronic erythematous skin disorder**  
A provisional diagnosis for a chronic skin disorder of unknown or uncertain nature in which widespread confluent erythema is the predominant feature. Examples include generalised atopic eczema, erythrodermic psoriasis, pityriasis rubra pilaris and Sézary syndrome.
- ME63.1      Chronic urticarial skin disorder**  
A provisional diagnosis for a rash consisting of persistent urticated papules and plaques for which a more precise diagnosis has not been or cannot be made. Diagnoses which should be considered include immunobullous disorders, urticarial vasculitis and drug reactions.
- ME63.2      Chronic papular skin disorder**  
A provisional diagnosis for a chronic skin disorder of unknown, uncertain or unspecified nature and characterised by the presence of multiple skin papules.
- ME63.3      Chronic blistering skin disorder**  
A provisional diagnosis for a chronic blistering skin disorder of unknown or uncertain nature. Examples include chronic vesicular dermatitis of the hands and feet, epidermolysis bullosa and immunobullous disorders such as bullous pemphigoid.
- ME63.4      Chronic scaling or hyperkeratotic skin disorder**  
A provisional diagnosis for a chronic skin disorder of unknown or uncertain nature in which scaling and hyperkeratosis are prominent features. Examples include psoriasis, ichthyoses, small plaque parapsoriasis and mycosis fungoides.
- ME63.5      Chronic lichenified skin disorder**  
A provisional diagnosis for a chronic skin disorder of unknown or uncertain nature in which lichenification is the prominent feature. Examples include chronic eczema, lichen simplex and lichen planus.
- ME63.6      Chronic discoid or annular skin disorder**  
A provisional diagnosis for a chronic skin disorder of unknown or uncertain nature consisting of multiple circular or ring-shaped patches and plaques. Although infection due to dermatophyte infection (tinea or ringworm) can produce this pattern, many other skin disorders may have a discoid or annular configuration: these are frequently misdiagnosed as tinea. Common examples include atopic eczema, nummular dermatitis and psoriasis.
- ME63.7      Chronic excoriation of skin**  
A provisional diagnosis for a chronic skin disorder of unknown or uncertain nature characterised by the presence of multiple excoriations. In some cases the excoriation is secondary to intense pruritus arising either from an underlying systemic disorder such as uraemia or from a pruritic skin disease such as eczema. In many cases, however, psychogenic factors may be responsible.

**ME64**

**Non-specific cutaneous vascular signs**

Changes perceptible in the skin as a result of alterations in blood composition, blood flow or blood vessel integrity. They may be due to local factors or may indicate underlying disorders such as anaemia, hypovolaemia, fever, hypoxia or defective clotting.

**ME64.0**

**Erythema**

Redness of skin due to the presence of increased amounts of oxygenated haemoglobin within dilated skin capillaries. It may be due to localised or generalised inflammatory processes but may result from increased cutaneous blood flow following exertion or associated with pyrexia.

**ME64.1**

**Cyanosis**

A blue-purple discolouration of the skin due to the presence of increased amounts of deoxygenated blood in skin blood vessels.

**Exclusions:** acrocyanosis (EG00)

cyanotic attacks of newborn (KB2C)

**ME64.2**

**Pallor**

Paleness of the skin such as may ensue from severe anaemia or from hypovolaemic shock.

**ME64.3**

**Petechiae**

Petechiae result from focal leakage of blood from dermal capillaries into the adjacent dermal connective tissue. They present as multiple pin-point non-blanching red or purple macules. The many underlying causes range from the innocuous (e.g. coughing or straining) to life-threatening conditions (e.g. meningococcal septicaemia).

**Coded Elsewhere:** Neonatal cutaneous haemorrhage (KA83.8)

**ME64.4**

**Flushing**

Paroxysmal vasodilatation of skin capillaries.

**ME65**

**Disturbances of skin sensation of unspecified aetiology**

A group of cutaneous symptoms for which it is frequently impossible to identify a precise cause.

**Coded Elsewhere:** Anaesthesia of skin (MB40.3)

Tactile hallucinations (MB27.26)

**ME65.0**

**Burning of skin**

A burning sensation in the skin which usually arises without obvious explanation.

**ME65.1**

**Itching of skin**

The sensation of itch in the skin. For persistent itch of unknown cause the term "Pruritus of unknown cause" should be used.

**ME65.2**

**Pain or tenderness of skin**

**Exclusions:** Chronic pain (MG30)

<b>ME65.3</b>	<b>Stinging of skin</b> An unpleasant sensation such as may be provoked by stinging nettles but which can be set off in some individuals by a wide variety of topical preparations or stimuli which are otherwise well tolerated by most people.
<b>ME65.4</b>	<b>Tingling of skin</b> A prickling sensation in the skin which may result from external factors such as rain falling on the skin or may be due to transient or permanent peripheral nerve damage.
<b>ME65.Y</b>	<b>Other specified disturbance of skin sensation</b>
<b>ME66</b>	<b>Miscellaneous non-specific skin-related symptoms and signs</b> Other specified skin changes which cannot be more precisely defined. <b>Coded Elsewhere:</b> Abnormal skin pigmentation (ED64)
<b>ME66.0</b>	<b>Abnormal sensitivity to light or UV radiation of uncertain or unspecified nature</b> <b>Inclusions:</b> Photosensitivity
<b>ME66.1</b>	<b>Changes in skin texture</b> Alterations in skin texture of unspecified cause.
<b>ME66.2</b>	<b>Excess and redundant skin</b> A condition which typically occurs in formerly grossly obese individuals following massive weight loss, as following bariatric surgery or severe calorie restriction.
<b>ME66.3</b>	<b>Symptom or complaint relating to hair or scalp</b> A very non-specific term to indicate an actual or perceived problem affecting the hair or the scalp which cannot be more precisely coded elsewhere.
<b>ME66.4</b>	<b>Symptom or complaint relating to nails</b> A very non-specific term to indicate an actual or perceived problem affecting the finger- or toenails which cannot be more precisely coded elsewhere.
<b>ME66.5</b>	<b>Complaint of abnormal sweating</b> Complaint that sweating is abnormal (most commonly that it is increased) without sufficient evidence to make a specific diagnosis.
<b>ME66.6</b>	<b>Rash</b> A non-specific term indicating the presence of an acquired skin disturbance to be used only when no more precise information is available. <b>Exclusions:</b> Acute skin eruption of uncertain or unspecified nature (ME62) Chronic skin disorder of uncertain or unspecified nature (ME63)

<b>ME66.60</b>	Rash localised A very non-specific term to denote a localised acquired visible alteration of the skin from normal in situations where a more precise description or diagnosis cannot be made. If a diagnosis cannot be made then a choice from the classes Acute skin eruption of uncertain or unspecified nature and Chronic skin disorder of uncertain or unspecified nature is preferred.
	<b><i>Exclusions:</i></b> Drug eruptions (EH60-EH6Z)
<b>ME66.61</b>	Rash generalised A very non-specific term to denote a widespread acquired visible alteration of the skin from normal in situations where a more precise description or diagnosis cannot be made. If a diagnosis cannot be made then a choice from the classes Acute skin eruption of uncertain or unspecified nature and Chronic skin disorder of uncertain or unspecified nature is preferred.
	<b><i>Exclusions:</i></b> Drug eruptions (EH60-EH6Z)
<b>ME66.6Y</b>	Other specified rash
<b>ME66.6Z</b>	Rash, unspecified
<b>ME66.Y</b>	<b>Other specified skin changes</b>
<b>ME67</b>	<b>Skin disorder of uncertain or unspecified nature</b> A category to enable the presence of a skin disorder to be recorded without making assumptions as to the precise nature of the disorder in question.
<b>ME6Y</b>	<b>Other specified symptoms or signs involving the skin</b>

### Symptoms, signs or clinical findings of the musculoskeletal system (ME80-MF1Y)

Symptoms or signs of the musculoskeletal system (ME80-ME8Y)

**Coded Elsewhere:** Abnormality of tonus and reflex (MB47)

- Constitutional tall stature (5B12)
- Fear of musculoskeletal disease (MG24.8)
- Myalgia (FB56.2)
- Osteonecrosis (FB81)
- Osteophyte (FA37.0)
- Short stature, not elsewhere classified (5B11)

### **ME80** **Clicking hip**

***Exclusions:*** Structural developmental anomalies of pelvic girdle (LB74)

**ME81**

**Musculoskeletal chest pain**

- Exclusions:**
- Other chest pain (MD30.1)
  - Costochondritis (FB82)
  - Tietze syndrome (FB82)
  - Chronic primary musculoskeletal pain (MG30.02)
  - Chronic secondary musculoskeletal pain (MG30.3)

**ME81.0**

**Intercostal pain**

- Exclusions:**
- Chronic primary musculoskeletal pain (MG30.02)
  - Chronic secondary musculoskeletal pain (MG30.3)

**ME81.Y**

**Other specified musculoskeletal chest pain**

**ME81.Z**

**Musculoskeletal chest pain, unspecified**

**ME82**

**Pain in joint**

Arthralgia secondary to inflammation, cartilage degeneration, crystal deposition, infection, and trauma not detailed in or used in conjunction with other condition.

- Exclusions:**
- Chronic primary musculoskeletal pain (MG30.02)
  - Chronic secondary musculoskeletal pain (MG30.3)

**ME83**

**Rheumatism, unspecified**

This is a group of disorders marked by inflammation or pain in the connective tissue structures of the body and is considered unspecified.

- Exclusions:**
- Chronic primary musculoskeletal pain (MG30.02)
  - Chronic secondary musculoskeletal pain (MG30.3)

**ME84**

**Spinal pain**

This is a condition characterised by pain felt in the back that usually originates from the muscles, nerves, bones, joints or other structures in the spine.

- Exclusions:**
- Symptom or complaint of the back (ME86.2)
  - Chronic secondary musculoskeletal pain (MG30.3)
  - Chronic neuropathic pain (MG30.5)

**ME84.0**

**Cervical spine pain**

This is a condition which is usually characterised by pain or discomfort in the neck region and can be caused by numerous spinal problems. It may be a feature of virtually every disorder and disease that occurs above the shoulder blades.

**Coding Note:**

Code also the causing condition

**Inclusions:**

cervicalgia

**Exclusions:**

cervical disc degeneration (FA80)

Chronic primary cervical pain (MG30.02)

Chronic secondary musculoskeletal pain (MG30.3)

Chronic neuropathic pain (MG30.5)

<b>ME84.1</b>	<b>Thoracic spine pain</b>
	This is a group of conditions characterised by pain perceived anywhere in the region bounded superiorly by a transverse line through the tip of the spinous process of T1, inferiorly by a transverse line through the tip of the spinous process of T12, and laterally by vertical lines tangential to the most lateral margins of the erector spinae muscles.
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b>
	Chronic primary thoracic pain (MG30.02)
	Chronic secondary musculoskeletal pain (MG30.3)
	Chronic neuropathic pain (MG30.5)
<b>ME84.2</b>	<b>Low back pain</b>
	This is a condition which is defined as pain and discomfort, localised below the costal margin and above the inferior gluteal folds, with or without leg pain.
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b>
	Lumbago NOS
	Loin pain
	<b>Exclusions:</b>
	Degenerative condition of spine (FA80-FA8Z)
	Chronic primary low back pain (MG30.02)
	Chronic secondary musculoskeletal pain (MG30.3)
	Chronic neuropathic pain (MG30.5)
<b>ME84.20</b>	Lumbago with sciatica
	<b>Exclusions:</b>
	that due to intervertebral disc disorder (FA80-FA8Z)
	Chronic primary musculoskeletal pain (MG30.02)
	Chronic secondary musculoskeletal pain (MG30.3)
	Chronic neuropathic pain (MG30.5)
<b>ME84.2Y</b>	Other specified low back pain
<b>Coding Note:</b>	Code also the causing condition
<b>ME84.2Z</b>	Low back pain, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>ME84.3</b>	<b>Sciatica</b>
	<b>Exclusions:</b>
	Degenerative condition of spine (FA80-FA8Z)
	Lesion of sciatic nerve (8C11.0)
	Lumbago with sciatica (ME84.20)
	Chronic neuropathic pain (MG30.5)
<b>ME84.Z</b>	<b>Spinal pain, unspecified</b>

<b>ME85</b>	<b>Stiffness of joint</b> Lack of range of motion of a joint secondary to pain, disease process or congenital malformation not detailed in or used in conjunction with other codes.
<b>ME86</b>	<b>Symptom or complaint of a body part</b>
<b>ME86.0</b>	<b>Symptom or complaint of the ankle</b>
	<b><i>Exclusions:</i></b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.1</b>	<b>Symptom or complaint of the arm</b>
	<b><i>Exclusions:</i></b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.2</b>	<b>Symptom or complaint of the back</b>
	<b><i>Exclusions:</i></b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.20</b>	Back syndrome without radiating pain <b><i>Exclusions:</i></b> Spondylolysis (FA81) Spondylolisthesis (FA84) Atlanto-axial instability or subluxation (LB73.22) Subluxation complex (ME93) Torticollis (FA71) Spinal enthesitis (FA92.00) Axial spondyloarthritis (FA92.0) Myelopathy (8B42) Spondylopathies (FB00-FB0Z) Intervertebral disc degeneration (FA80) Localised central endplate defect (FA85.10) Spinal instabilities (FB10) Strain or sprain of lumbar spine (NB53.5) Chronic primary musculoskeletal pain (MG30.02)
<b>ME86.21</b>	Back syndrome with radiating pain <b><i>Exclusions:</i></b> Spondylolysis (FA81) Low back pain (ME84.2) Sciatica (ME84.3) Intervertebral disc degeneration (FA80) Chronic primary musculoskeletal pain (MG30.02)
<b>ME86.22</b>	Symptom or complaint of the low back <b><i>Exclusions:</i></b> Chronic primary musculoskeletal pain (MG30.02)

<b>ME86.2Y</b>	Other specified symptom or complaint of the back
<b>ME86.2Z</b>	Symptom or complaint of the back, unspecified
<b>ME86.3</b>	<b>Symptom or complaint of the chest</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.4</b>	<b>Symptom or complaint of the elbow</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.5</b>	<b>Symptom or complaint of the flank or axilla</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.6</b>	<b>Symptom or complaint of the foot or toe</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.7</b>	<b>Symptom or complaint of the hand or finger</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.8</b>	<b>Symptom or complaint of the hip</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.9</b>	<b>Symptom or complaint of the jaw</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.A</b>	<b>Symptom or complaint of the knee</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.B</b>	<b>Symptom or complaint of the leg or thigh</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.C</b>	<b>Symptom or complaint of the neck</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.D</b>	<b>Symptom or complaint of the shoulder</b>
	<b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)

<b>ME86.D0</b>	Shoulder syndrome A shoulder syndrome is defined by shoulder pain with one or more of the following problems: limitations of movement, local tenderness, crepitus or periarticular calcification in imaging.
	<b>Exclusions:</b> Arthropathies (FA00-FA5Z) Shoulder lesions (FB53) Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.DY</b>	Other specified symptom or complaint of the shoulder
<b>ME86.DZ</b>	Symptom or complaint of the shoulder, unspecified
<b>ME86.E</b>	<b>Symptom or complaint of the wrist</b> <b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.F</b>	<b>Symptom or complaint of joint, not otherwise specified</b> <b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.G</b>	<b>Symptom or complaint of muscle, not otherwise specified</b> <b>Exclusions:</b> Chronic primary musculoskeletal pain (MG30.02) Chronic secondary musculoskeletal pain (MG30.3)
<b>ME86.Y</b>	<b>Problem of other specified body part</b>
<b>ME86.Z</b>	<b>Problem of unspecified body part</b>
<b>ME8Y</b>	<b>Other specified symptoms or signs of the musculoskeletal system</b>

Clinical findings in the musculoskeletal system (ME90-ME9Y)

<b>ME90</b>	<b>Clinical findings on diagnostic imaging of skull and head</b> <b>Exclusions:</b> Intracranial space-occupying lesion (MB71.0)
<b>ME91</b>	<b>Clinical findings on diagnostic imaging of limbs</b>
<b>ME92</b>	<b>Clinical findings on diagnostic imaging of other parts of musculoskeletal system</b> <b>Exclusions:</b> Clinical findings on diagnostic imaging of skull and head (ME90)
<b>ME92.0</b>	<b>Wedging of vertebra</b>
<b>ME92.1</b>	<b>Bony erosion</b>
<b>ME92.Y</b>	<b>Other specified clinical findings on diagnostic imaging of other parts of musculoskeletal system</b>

**ME92.Z** Clinical findings on diagnostic imaging of other parts of musculoskeletal system, unspecified

**ME93** Biomechanical lesions, not elsewhere classified

**Coding Note:** This category should not be used if the condition can be classified elsewhere.

**ME93.0** Segmental and somatic dysfunction

**ME93.1** Subluxation stenosis of neural canal

**ME93.2** Osseous stenosis of neural canal

**ME93.3** Connective tissue stenosis of neural canal

**ME93.4** Intervertebral disc stenosis of neural canal

**ME93.40** Intervertebral disc stenosis of neural canal, head region

**ME93.41** Intervertebral disc stenosis of neural canal, cervical region

**ME93.42** Intervertebral disc stenosis of neural canal, thoracic region

**ME93.43** Intervertebral disc stenosis of neural canal, lumbar region

**ME93.44** Intervertebral disc stenosis of neural canal, sacral region

**ME93.45** Intervertebral disc stenosis of neural canal, pelvic region

**ME93.46** Intervertebral disc stenosis of neural canal, lower extremity

**ME93.47** Intervertebral disc stenosis of neural canal, upper extremity

**ME93.48** Intervertebral disc stenosis of neural canal, rib cage

**ME93.4Y** Other specified intervertebral disc stenosis of neural canal

**ME93.4Z** Intervertebral disc stenosis of neural canal, unspecified

**ME93.5** Osseous and subluxation stenosis of intervertebral foramina

**ME93.6** Connective tissue and disc stenosis of intervertebral foramina

**ME93.Y** Other specified biomechanical lesions, not elsewhere classified

**Coding Note:** This category should not be used if the condition can be classified elsewhere.

**ME93.Z** Biomechanical lesions, unspecified

**Coding Note:** This category should not be used if the condition can be classified elsewhere.

**ME9Y** Other specified clinical findings in the musculoskeletal system

---

**MF1Y** Other specified symptoms, signs or clinical findings of the musculoskeletal system

## Symptoms, signs or clinical findings of the genitourinary system (MF30-MG0Y)

Symptoms, signs or clinical findings involving the female genital system (MF30-MF3Y)

**Coded Elsewhere:** Fear of complications of pregnancy (MG24.D)

Fear of female genital or breast disease (MG24.F)

Fear of sexually transmitted disease female (MG24.E)

Menstrual cycle bleeding disorders (GA20)

Breast engorgement of newborn (KC41.0)

**MF30      Breast lump or mass female**

**MF31      Breast or lactation symptom or complaint**

**MF32      Menopausal symptom or complaint**

**Coded Elsewhere:** Postmenopausal atrophic vaginitis (GA30.2)

Menopausal hot flush (GA30.4)

**MF33      Premenstrual symptom or complaint**

A symptom of premenstrual syndrome affecting females that is idiopathic. This symptom is characterised by cyclic emotional, physical, or behavioural symptoms such as mood alterations, psychological changes, fluid retention, neurologic changes, gastrointestinal changes, pelvic heaviness, or dermatological changes affecting women in the luteal phase of the menstrual cycle that interfere with an individual's lifestyle.

**MF34      Pregnancy symptom or complaint**

**MF35      Postpartum symptom or complaint**

**MF36      Other symptom or complaint of vagina**

**MF37      Symptom or complaint of female nipple**

**MF38      Symptom or complaint of female pelvis**

**MF39      Symptom or complaint of the vulva**

**MF3A      Vaginal discharge**

**MF3Y      Other specified symptoms, signs or clinical findings involving the female genital system**

Symptoms, signs or clinical findings involving the male genital system (MF40-MF4Y)

**Coded Elsewhere:** Fear of genital disease male (MG24.H)

Fear of sexually transmitted disease male (MG24.G)

Male infertility (GB04)

Fear of sexual dysfunction male (MG24.Y)

**MF40**

**Problems of male genital organs**

A group of disorders associated with the male genital organs occurring in diseases more specifically classified elsewhere.

**MF40.0 Symptom or complaint of the penis**

**MF40.00** Pain in penis

**Exclusions:** Chronic secondary visceral pain (MG30.4)

Chronic primary visceral pain (MG30.00)

**MF40.0Y** Other specified symptom or complaint of the penis

**MF40.0Z** Symptom or complaint of the penis, unspecified

**MF40.1 Problems of the prostate**

A group of disorders associated with the prostate occurring in diseases more specifically classified elsewhere.

**MF40.2 Symptom or complaint of the scrotum or testis**

**Coded Elsewhere:** Pain in scrotum (GB0Y)

**MF40.20** Acute scrotal pain

**Exclusions:** Torsion of testis (GB01.0)

Torsion of epididymis (GB01.1)

Torsion of hydatids (GB01.2)

Orchitis (GB02)

**MF40.21** Testicular pain

**Exclusions:** Chronic primary visceral pain (MG30.00)

Chronic secondary visceral pain (MG30.4)

**MF40.2Y** Other specified symptom or complaint of the scrotum or testis

**MF40.2Z** Symptom or complaint of the scrotum or testis, unspecified

**MF40.3 Retrograde ejaculation**

Retrograde Ejaculation is a condition in which semen that is normally ejaculated via the urethra is redirected to the urinary bladder. Retrograde Ejaculation is typically accompanied by subjective orgasm, though the man may notice that release of semen is limited or absent. Retrograde Ejaculation most commonly occurs as a complication of transurethral prostatic resection, but may also be caused by other surgery of the pelvic area, nervous system dysfunction, or use of pharmacological agents. Confirmation is by identification of spermatozoa in a urine sample.

<b>MF40.Y</b>	<b>Other specified problems of male genital organs</b>
<b>MF40.Z</b>	<b>Problems of male genital organs, unspecified</b>
<b>MF41</b>	<b>Symptom or complaint of male sexual function</b>
<b>MF42</b>	<b>Retractile testis migrans</b>
	A retractile testicle is one that may move back and forth between the scrotum and the groin. For most boys, the problem resolves sometime before or during puberty.
<b>MF4Y</b>	<b>Other specified symptoms, signs or clinical findings involving the male genital system</b>

Symptoms, signs or clinical findings involving the urinary system (MF50-MF5Y)

**Coded Elsewhere:** Fear of urinary disease (MG24.C)

<b>MF50</b>	<b>Abnormal micturition</b>
<b>MF50.0</b>	<b>Frequent micturition</b> Needing to urinate more often than normal.  <b>Exclusions:</b> Pollakiuria (MF50.1)
<b>MF50.1</b>	<b>Pollakiuria</b>
<b>MF50.2</b>	<b>Urinary incontinence</b> Any condition of the urinary system, caused by determinants arising during the antenatal period or after birth, leading to loss of voluntary control or support of the urethra. These conditions are characterised by involuntary leakage of large amounts of urine, in association with uninhibited contractions of the detrusor muscle and the inability to control urination.  <b>Exclusions:</b> haematuria: recurrent and persistent (GB40-GB4Z) haematuria with specified morphological lesion (GB40-GB4Z) proteinuria NOS (MF96) haematuria NOS (MF50.4) Diurnal enuresis (6C00.1) Enuresis (6C00) Nocturnal and diurnal enuresis (6C00.2) Nocturnal enuresis (6C00.0)
<b>MF50.20</b>	Stress incontinence Urinary incontinence due to diminished urethral pressure in straining or coughing.

**Coding Note:** Code also the causing condition

**Exclusions:** Stress incontinence associated with pelvic organ prolapse (GC40.50)

<b>MF50.21</b>	Urge Incontinence This is a form of urinary incontinence characterised by the involuntary loss of urine occurring for no apparent reason while feeling urinary urgency, a sudden need or urge to urinate.  <b>Exclusions:</b> Urge incontinence associated with pelvic organ prolapse (GC40.51)
<b>MF50.22</b>	Mixed incontinence
<b>MF50.23</b>	Functional urinary incontinence Urinary incontinence due to cognitive impairment, or severe physical disability or immobility  <b>Exclusions:</b> Stress incontinence (MF50.20)
<b>MF50.24</b>	Reflex incontinence Urinary incontinence that accompanies detrusor hyperreflexia
<b>MF50.2Y</b>	Other specified urinary incontinence
<b>MF50.2Z</b>	Urinary incontinence, unspecified
<b>MF50.3</b>	<b>Retention of urine</b> Incomplete emptying of the bladder
<b>MF50.4</b>	<b>Haematuria</b>  <b>Exclusions:</b> recurrent or persistent haematuria (GB40-GB4Z)
<b>MF50.40</b>	Macroscopic haematuria
<b>MF50.41</b>	Microscopic haematuria
<b>MF50.4Z</b>	Haematuria, unspecified
<b>MF50.5</b>	<b>Extravasation of urine</b>
<b>MF50.6</b>	<b>Other difficulties with micturition</b>
<b>MF50.60</b>	Hesitancy of micturition Difficulty in beginning the flow of urine or maintaining a urinary stream
<b>MF50.61</b>	Poor urinary stream A reduced, slow or weak stream of urine
<b>MF50.62</b>	Splitting of urinary stream A condition where the urine stream splits into two or more different directions
<b>MF50.63</b>	Urgency of urination A sudden and strong urge to urinate along with discomfort in the bladder
<b>MF50.64</b>	Feeling of incomplete bladder emptying A sensation that the bladder is not empty after voiding.

**MF50.65** Straining to void  
The need to strain or push in order to empty the bladder

**MF50.6Y** Other specified difficulties with micturition

**MF50.6Z** Difficulties with micturition, unspecified

**MF50.7** **Dysuria**  
painful urination

**Inclusions:** Strangury

**MF50.8** **Vesical tenesmus**  
ineffective and painful straining for urination

**MF50.Y** **Other specified abnormal micturition**

**MF50.Z** **Abnormal micturition, unspecified**

### **MF51** **Anuria or oliguria**

Anuria means nonpassage of urine, in practice is defined as passage of less than 50 millilitres of urine in a day. Oliguria is the low output of urine. It is clinically classified as an output below 300-500ml/day.

**Exclusions:** Maternal care for other conditions predominantly related to pregnancy (JA65)

### **MF52** **Bladder pain**

Complaint of suprapubic or retropubic pain, pressure, or discomfort, related to the bladder, and usually increasing with bladder filling. It may persist or be relieved after voiding.

**Exclusions:** Chronic primary bladder pain syndrome (MG30.00)  
Chronic primary visceral pain (MG30.00)  
Chronic secondary visceral pain (MG30.4)

### **MF53** **Extrarenal uraemia**

**Inclusions:** Prerenal uraemia

### **MF54** **Macroscopic changes of size of the kidney**

Any condition characterised by alterations in the size of the kidney, observable by the unaided eye.

<b>MF54.0</b>	<b>Smooth contracted kidney</b> A condition of the kidney, caused by an overgrowth of abnormal fibrous tissue and ischaemic atrophy. This condition is characterised by a small, granular, and smooth kidney.
	<b><i>Exclusions:</i></b> Small kidney (MF54.2) diffuse sclerosing glomerulonephritis (GB61) contracted kidney due to hypertension (BA02) hypertensive nephrosclerosis (arteriolar)(arteriosclerotic) (BA02)
<b>MF54.1</b>	<b>Irregularly contracted kidney</b> A kidney with deep cortical indentations or scars large enough to be perceived or examined by the naked eye
<b>MF54.2</b>	<b>Small kidney</b> A condition characterised by a kidney smaller in size and weight than the average (less than 11 centimetres long, 5-7.5 centimetres wide, 2.5 centimetres thick, and weighing less than 120 grams).
<b>MF54.Y</b>	<b>Other specified macroscopic changes of size of the kidney</b>
<b>MF54.Z</b>	<b>Macroscopic changes of size of the kidney, unspecified</b>
<b>MF55</b>	<b>Polyuria</b> Polyuria is a condition defined as excessive or abnormally large production or passage of urine.
<b>MF56</b>	<b>Renal colic</b> A severe paroxysmal pain in the flank radiating to the groin, scrotum or labia, caused by blockage of the renal pelvis or ureter most commonly by a renal stone. May be associated with nausea and vomiting.
<b>MF57</b>	<b>Symptom or complaint of bladder</b>
<b>MF58</b>	<b>Urethral discharge</b> <b><i>Inclusions:</i></b> Urethrorrhoea Penile discharge
<b>MF59</b>	<b>Urinary symptom or complaint</b>
<b>MF5Y</b>	<b>Other specified symptoms, signs or clinical findings involving the urinary system</b>

Clinical findings in specimens from female genital organs (MF60-MF6Z)

**Exclusions:** Low grade squamous intraepithelial lesion of vulva (GA13.1)

Carcinoma in situ of other or unspecified genital organs (2E67)

Low grade squamous intraepithelial lesion of cervix uteri (GA15.7)

**MF60** **Abnormal level of enzymes in specimens from female genital organs**

**MF61** **Abnormal level of hormones in specimens from female genital organs**

**MF62** **Abnormal level of drugs, medicaments and biological substances in specimens from female genital organs**

**MF63** **Abnormal level of substances chiefly nonmedicinal as to source in specimens from female genital organs**

**MF64** **Abnormal immunological findings in specimens from female genital organs**

**MF65** **Abnormal microbiological findings in specimens from female genital organs**

**MF66** **Abnormal cytological findings in specimens from female genital organs**

**MF66.0** **Abnormal cervix smear**

**MF66.Y** **Other specified abnormal cytological findings in specimens from female genital organs**

**MF66.Z** **Abnormal cytological findings in specimens from female genital organs, unspecified**

**MF67** **Abnormal histological findings in specimens from female genital organs**

**MF68** **Abnormal chromosomal findings in specimens from female genital organs**

**MF6Y** **Other specified clinical findings in specimens from female genital organs**

**MF6Z** **Clinical findings in specimens from female genital organs, unspecified**

Clinical findings in specimens from male genital organs (MF70-MF7Z)

**Exclusions:** Oligospermia (GB04)

Azoospermia (GB04.0)

**MF70** **Abnormal level of enzymes in specimens from male genital organs**

**MF71** **Abnormal level of hormones in specimens from male genital organs**

**MF72** **Abnormal level of drugs, medicaments and biological substances in specimens from male genital organs**

- MF73**      **Abnormal level of substances chiefly nonmedicinal as to source in specimens from male genital organs**
- MF74**      **Abnormal immunological findings in specimens from male genital organs**
- MF75**      **Abnormal microbiological findings in specimens from male genital organs**  
**Exclusions:**      Prostate specific antigen positive (MA14.1B)
- MF76**      **Abnormal cytological findings in specimens from male genital organs**
- MF77**      **Abnormal histological findings in specimens from male genital organs**
- MF78**      **Abnormal chromosomal findings in specimens from male genital organs**
- MF7Y**      **Other specified clinical findings in specimens from male genital organs**
- MF7Z**      **Clinical findings in specimens from male genital organs, unspecified**

Clinical findings in specimens from the urinary system (MF80-MF8Z)

- MF80**      **Diffuse mesangial sclerosis**  
Diffuse mesangial sclerosis is a histological appearance which is characterised by diffuse thickening of basement membrane and massive enlargement of mesangial areas leading to contraction and sclerosis of the glomerular capillary tuft. It may be seen in children with early onset steroid resistant nephrotic syndrome due to a variety of genetic abnormalities, either as an isolated renal disease or as part of a multi-organ syndrome.
- MF81**      **Fibronectin glomerulopathy**  
Fibronectin glomerulopathy is a rare hereditary kidney disease in which fibronectin (FN1) deposits are seen in the mesangium and subendothelial space. The clinical picture is characterised by proteinuria, type IV renal tubular acidosis, microscopic haematuria and hypertension that may lead to end-stage renal failure in the second to sixth decade of life. This disease may be associated with mutations in the FN1 gene.
- MF82**      **Lipoprotein glomerulopathy**  
Characteristic lipoprotein thrombi are found in the glomerulus in this genetically determined disease mainly found in East Asia.
- MF83**      **Diabetic glomerular changes**  
Diabetic glomerulosclerosis involves diffuse thickening of the basement membrane progressing to diffuse mesangial expansion (diffuse diabetic glomerulosclerosis) with in some cases matrix occupying the capillary lumen to form Kimmelstiel Wilson nodules (nodular glomerulosclerosis)

**Coding Note:** Code also the causing condition

**MF84**

### **Pauci-immune proliferative glomerulonephritis**

A focal and segmental necrotising glomerulonephritis with no immune deposits (“pauci-immune”). Typical of glomerular involvement in anti-neutrophil cytoplasmic antibody (ANCA) mediated vasculitis – microscopic polyangiitis and Wegener’s granulomatosis. Most but not all patients have circulation ANCA when there is active disease.

**MF85**

### **Anti-glomerular basement membrane antibody mediated disease**

Anti-GBM mediated glomerulonephritis is an aggressive focal and segmental proliferative glomerular disease characterised by linear staining of the glomerular basement membrane for immunoglobulins, particularly IgG and IgM. Crescentic change is often associated and circulating anti-bodies to glomerular basement membrane are found in active disease. The renal syndrome is often acute nephritis with rapid renal functional decline (rapidly progressive nephritis) and if associated with respiratory involvement (haemoptysis, respiratory failure) the couple is termed “Goodpasture's syndrome”.

**Inclusions:** Goodpasture syndrome

**MF8Y**

### **Other specified clinical findings in specimens from the urinary system**

**MF8Z**

### **Clinical findings in specimens from the urinary system, unspecified**

Clinical findings on examination of urine, without diagnosis (MF90-MF9Y)

**Coding Note:** This category is to be assigned when no underlying or determining condition is identified.

**Exclusions:** Specific findings indicating disorder of amino-acid metabolism (5C50)  
Specific findings indicating disorder of carbohydrate metabolism (5C51)  
Clinical findings on antenatal screening of mother (JA66)

**MF90**

### **Acetonuria**

Acetonuria is a medical condition in which acetone is present in the urine.

**Inclusions:** Ketonuria

**MF91**

### **Bilirubinuria**

Bilirubinuria means the presence of any bile pigment in the urine.

**MF92**

### **Chyluria**

Chyluria, also called chylous urine, is a medical condition involving the presence of chyle in the urine stream, which results in urine appearing milky white.

**Exclusions:** Filarial chyluria (1F66)

**MF93**

### **Glycosuria**

**Coded Elsewhere:** Renal glycosuria (GB90.45)

**MF94****Haemoglobinuria**

The presence of free haemoglobin in the urine, indicating haemolysis of erythrocytes within the vascular system. After saturating the haemoglobin-binding proteins (haptoglobins), free haemoglobin begins to appear in the urine.

**Exclusions:** Marchiafava-Micheli syndrome (3A21.0)

**MF95****Myoglobinuria**

Myoglobinuria is the presence of myoglobin in the urine usually as result of rhabdomyolysis. Any process that interferes with the storage or use of energy by muscle cells can lead to myoglobinuria. When excreted into the urine, myoglobin can precipitate, causing tubular obstruction and acute kidney injury. The most common causes of myoglobinuria in adults are trauma, alcohol and drug abuse, usually in relation to muscle necrosis from prolonged immobilization and pressure by the body weight. Prolonged ethanol consumption and seizure activity, similar to excessive physical activity, can produce an imbalance between muscle energy consumption and production, resulting in muscle destruction.

**MF96****Proteinuria**

Excessive serum proteins in the urine, such as in renal disease when albumin is the main protein, but also may be due to other proteins such as immunoglobulin light chains in plasma cell dyscrasia such as multiple myeloma.

**Exclusions:** Persistent proteinuria or albuminuria (GB42)

**Coded Elsewhere:** Gestational proteinuria without hypertension (JA22.0)

Gestational oedema with proteinuria without hypertension  
(JA22.2)

**MF96.0****Orthostatic proteinuria**

A condition characterised by an elevated protein excretion while in the upright position and normal protein excretion in a supine or recumbent position.

**MF96.1****Bence Jones proteinuria**

A condition characterised by the presence of a monoclonal globulin protein or immunoglobulin light chain (Bence Jones protein) in the urine. Originally detected by precipitating at 56 and dissolving again at 100 degrees centigrade (Henry Bence Jones 1813-1873) they are now detected by urinary electrophoresis or light chain assay.

**MF96.Y****Other specified proteinuria****MF96.Z****Proteinuria, unspecified****MF97****Pyuria**

Pyuria is a urinary condition that is characterized by an elevated number of white blood cells in the urine. Doctors define a high number as at least 10 white blood cells per cubic millimeter ( $\text{mm}^3$ ) of centrifuged urine. Pyuria can cause the urine to look cloudy or as if it contains pus.

**MF98****Abnormal levels of serum electrolytes in the urine**

**Coded Elsewhere:** Hyperphosphaturia (GB90.48)

<b>MF98.0</b>	<b>Hypercalciuria</b>
<b>MF98.1</b>	<b>Hyperkaluria</b>
<b>MF98.2</b>	<b>Hypermagnesuria</b>
<b>MF98.3</b>	<b>Hypocalciuria</b>
<b>MF98.4</b>	<b>Hypokaluria</b>
<b>MF98.5</b>	<b>Hypomagnesuria</b>
<b>MF98.6</b>	<b>Hypophosphaturia</b>
<b>MF98.Y</b>	<b>Other specified abnormal levels of serum electrolytes in the urine</b>
<b>MF98.Z</b>	<b>Abnormal levels of serum electrolytes in the urine, unspecified</b>

**MF99      Elevated urine levels of drugs, medicaments and biological substances**

Elevated urine levels of drugs, medicaments and biological substances mean that the levels of drugs, medicaments, and biological substances have elevated on the urine examination.

**MF9A      Abnormal urine levels of substances chiefly nonmedicinal as to source**

**MF9B      Abnormal findings on microbiological examination of urine**

**MF9C      Abnormal findings on cytological and histological examination of urine**

**MF9Y      Other specified clinical findings on examination of urine, without diagnosis**

**Coding Note:** This category is to be assigned when no underlying or determining condition is identified.

**MG00      Clinical findings on diagnostic imaging of breast**

Clinical findings on diagnostic imaging of breast is findings on diagnostic imaging of the breast which don't appear in normal status of the body. Diagnostic imaging refers to technologies that doctors use to look inside body for clues about a medical condition. X-rays, CT scans, nuclear medicine scans, MRI scans and ultrasound are all types of diagnostic imaging.

**MG01      Clinical findings on diagnostic imaging of urinary organs**

**Inclusions:**      hypertrophy of kidney (GB90)

**MG02      Results of kidney function studies**

**Inclusions:**      Abnormal renal function test

**MG0Y      Other specified symptoms, signs or clinical findings of the genitourinary system**

## General symptoms, signs or clinical findings (MG20-MG9Y)

### General symptoms (MG20-MG4Y)

**Coded Elsewhere:** Enlarged lymph nodes (MA01)

Symptom or complaint of a body part (ME86)

**MG20**

#### **Cachexia**

Cachexia is a pathological generalised loss of body mass with reduction of the storage fat deposits, structural fat and musculature that can be accompanied by gradual loss of function of organs.

**Inclusions:** Human immunodeficiency virus disease associated with wasting syndrome (1C62.3)

Malignant neoplasms of ill-defined or unspecified primary sites (2D40-2D4Z)

nutritional marasmus (5B51)

**MG20.0**

#### **Malignant cachexia**

**MG20.Z**

#### **Cachexia, unspecified**

**MG21**

#### **Chills**

**MG22**

#### **Fatigue**

A feeling of exhaustion, lethargy, or decreased energy, usually experienced as a weakening or depletion of one's physical or mental resource and characterised by a decreased capacity for work and reduced efficiency in responding to stimuli. Fatigue is normal following a period of exertion, mental or physical, but sometimes may occur in the absence of such exertion as a symptom of health conditions.

**Inclusions:** General physical deterioration

Lethargy

**Exclusions:** Combat fatigue (QE84)

Exhaustion due to exposure (NF07.2)

heat exhaustion (NF01)

Bodily distress disorder (6C20)

Depressive disorders (6A70-6A7Z)

Sleep-wake disorders (Chapter 07)

Bipolar or related disorders (6A60-6A6Z)

senile fatigue (MG2A)

Chronic fatigue syndrome (8E49)

Myalgic encephalomyelitis (8E49)

Postviral fatigue syndrome (8E49)

pregnancy-related exhaustion and fatigue (JA65)

**MG23**

#### **Fear of death or dying**

<b>MG24</b>	<b>Fear of disease</b>
	<p><b>Exclusions:</b> Bodily distress disorder (6C20) Hypochondriasis (6B23)</p>
	<p><b>Coded Elsewhere:</b> Fear of ear disease (MC4Y) Fear of skin disease (ME66.Y) Fear of sexual dysfunction female (MF3Y)</p>
<b>MG24.0</b>	<b>Fear of cancer</b>
<b>MG24.00</b>	<p>Fear of cancer of digestive system This refers to worrying about having a cancer of the digestive system.</p>
<b>MG24.01</b>	Fear of breast cancer female
<b>MG24.02</b>	Fear of genital cancer male
<b>MG24.0Y</b>	Other specified fear of cancer
<b>MG24.0Z</b>	Fear of cancer, unspecified
<b>MG24.1</b>	<b>Fear of human immunodeficiency virus</b>
<b>MG24.2</b>	<b>Fear of haematological disease</b> <i>Coded Elsewhere:</i> Fear of haematological cancer (MG24.0Y)
<b>MG24.3</b>	<p><b>Fear of digestive disease</b> This is a health anxiety and refers to worrying about having a digestive disease. <i>Coded Elsewhere:</i> Fear of cancer of digestive system (MG24.00)</p>
<b>MG24.4</b>	<b>Fear of eye disease</b>
<b>MG24.5</b>	<b>Fear of heart disease</b>
<b>MG24.6</b>	<b>Fear of hypertension</b>
<b>MG24.7</b>	<b>Fear of cardiovascular disease</b>
<b>MG24.8</b>	<p><b>Fear of musculoskeletal disease</b> <i>Coded Elsewhere:</i> Fear of cancer musculoskeletal (MG24.0Y)</p>
<b>MG24.9</b>	<p><b>Fear of neurological disease</b> <i>Coded Elsewhere:</i> Fear of cancer of neurological system (MG24.0Y)</p>
<b>MG24.A</b>	<p><b>Fear of respiratory disease</b> <i>Coded Elsewhere:</i> Fear of cancer of respiratory system (MG24.0Y)</p>
<b>MG24.B</b>	<p><b>Fear of endocrine, metabolic or nutritional disease</b> <i>Coded Elsewhere:</i> Fear of cancer of endocrine system (MG24.0Y)</p>
<b>MG24.C</b>	<p><b>Fear of urinary disease</b> <i>Coded Elsewhere:</i> Fear of cancer of urinary system (MG24.0Y)</p>

<b>MG24.D</b>	<b>Fear of complications of pregnancy</b>
<b>MG24.E</b>	<b>Fear of sexually transmitted disease female</b>
<b>MG24.F</b>	<b>Fear of female genital or breast disease</b> <i>Coded Elsewhere:</i> Fear of breast cancer female (MG24.01) Fear of genital cancer female (MG24.0Y)
<b>MG24.G</b>	<b>Fear of sexually transmitted disease male</b>
<b>MG24.H</b>	<b>Fear of genital disease male</b> <i>Coded Elsewhere:</i> Fear of genital cancer male (MG24.02)
<b>MG24.J</b>	<b>Fear of mental disorder</b>
<b>MG24.Y</b>	<b>Fear of other specified disease</b>
<b>MG24.Z</b>	<b>Fear of disease, unspecified</b>
<b>MG25</b>	<b>Feeling ill</b> <i>Inclusions:</i> malaise
<b>MG26</b>	<b>Fever of other or unknown origin</b> An abnormal elevation of body temperature of unknown origin, often as a result of a pathologic process.  <i>Exclusions:</i> fever of unknown origin in newborn (KD10-KD1Z) Malignant hyperthermia due to anaesthesia (NE86) <i>Coded Elsewhere:</i> Pyrexia of unknown origin following delivery (JB40.4) Pyrexia during labour, not elsewhere classified (JB0D.2) Fever of newborn (KD11)
<b>MG27</b>	<b>Haemorrhage, not elsewhere classified</b> Bleeding or escape of blood from a vessel.  <i>Exclusions:</i> Obstetric haemorrhage (JA40-JA4Z) Haemorrhage or haematoma complicating a procedure, not elsewhere classified (NE81.0) Fetal blood loss (KA80) Certain specified neonatal haemorrhages (KA83)
<b>MG28</b>	<b>Hypothermia, not associated with low environmental temperature</b> <i>Exclusions:</i> hypothermia NOS (NF02) hypothermia low environmental temperature (NF02) <i>Coded Elsewhere:</i> Hypothermia of newborn (KD12)

**MG29**

**Oedema**

Abnormal fluid accumulation in tissues or body cavities not coded elsewhere.

**Exclusions:** oedema of pharynx (CA00-CA0Z)

oedema of nasopharynx (CA00-CA0Z)

Pulmonary oedema (CB01)

Ascites (ME04)

hydrops fetalis NOS (KC41.1)

angioneurotic oedema (EB04)

Cerebral oedema due to birth injury (KA40.1)

hereditary oedema (4A00.14)

Oedema of larynx (CA0H.3)

malnutrition (5B50-5B7Z)

hydrothorax (CB27)

**Coded Elsewhere:** Gestational oedema without hypertension (JA22.1)

Gestational oedema with proteinuria without hypertension  
(JA22.2)

**MG29.0**

**Localised oedema**

**Coded Elsewhere:** Swollen tongue (MD80.1)

**MG29.00**

Ankle oedema

**MG29.01**

Oedema of legs

**MG29.02**

Pitting of lip

**MG29.0Y**

Other specified localised oedema

**MG29.1**

**Generalised oedema**

**MG29.10**

Oedema due to increased capillary pressure

Increased capillary pressure increases the leakage of fluid from the vascular compartment to the interstitial tissues, resulting in oedema. Causes include impaired or obstructed venous return (fluid overload, venous thrombosis, right heart failure, venous compression from tumour tissue), increased blood flow (physiological response to heat exposure, arteriovenous malformations, disturbed cutaneous vasomotor control due to drug or autonomic neuropathy), or reduced plasma oncotic pressure due to hypoproteinaemia.

**Coded Elsewhere:** Fluid overload with oedema (5C78)

**MG29.1Y**

Other specified generalised oedema

**MG29.2**

**Infectious oedema**

**MG29.3**

Pitting oedema

**MG29.Z**

Oedema, unspecified

**MG2A**

**Ageing associated decline in intrinsic capacity**

**Inclusions:** senescence without mention of psychosis

**Exclusions:** Senile dementia (6D80-6D8Z)

**Pain (MG30-MG3Z)**

**Inclusions:** pain not referable to any one organ or body region

**Exclusions:** Headache disorders (8A80-8A8Z)

Abdominal or pelvic pain (MD81)

Breast pain (GB23.5)

Pain in joint (ME82)

Pain in eye (MC18)

Ear pain (AB70.2)

Pain in chest (MD30)

Pelvic or perineal pain (MD81.11)

Pain in shoulder (ME82)

Spinal pain (ME84)

Pain in tooth, toothache (DA0A)

Renal colic (MF56)

Pain in throat (MD36.0)

Low back pain (ME84.2)

Pain in limb (FB56.4)

Pain disorders (8E43)

**MG30**

**Chronic pain**

Pain is an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage. Chronic pain is pain that persists or recurs for longer than 3 months. Chronic pain is multifactorial: biological, psychological and social factors contribute to the pain syndrome.

**Coding Note:** This code should be used if a pain condition persists or recurs for longer than 3 months.

**Exclusions:** Acute pain (MG31)

<b>MG30.0</b>	<b>Chronic primary pain</b> Chronic primary pain is chronic pain in one or more anatomical regions that is characterised by significant emotional distress (anxiety, anger/frustration or depressed mood) or functional disability (interference in daily life activities and reduced participation in social roles). Chronic primary pain is multifactorial: biological, psychological and social factors contribute to the pain syndrome. The diagnosis is appropriate independently of identified biological or psychological contributors unless another diagnosis would better account for the presenting symptoms.
<b>Coding Note:</b>	Other chronic pain diagnoses to be considered are chronic cancer-related pain, chronic postsurgical or posttraumatic pain, chronic neuropathic pain, chronic secondary headache or orofacial pain, chronic secondary visceral pain and chronic secondary musculoskeletal pain.
<b>Exclusions:</b>	Acute pain (MG31)
<b>Coded Elsewhere:</b>	Painful bruising syndrome (ED02)

  

<b>MG30.00</b>	Chronic primary visceral pain Chronic primary visceral pain is chronic pain localized in the thoracic, abdominal or pelvic region, and is associated with significant emotional distress or functional disability. The distinct anatomical location is compatible with typical referral pain patterns from specific internal organs. The symptoms are not better explained by a diagnosis of chronic secondary visceral pain. Chronic primary visceral pain is multifactorial: biological, psychological and social factors contribute to the pain syndrome. The diagnosis is appropriate independently of identified biological or psychological contributors unless another diagnosis would better account for the presenting symptoms.
<b>Exclusions:</b>	Chronic abdominal pain NOS (MD81.4)
<b>Coded Elsewhere:</b>	Penoscrotodynia (EC92.0) Vulvodynia (GA34.02) Irritable bowel syndrome (DD91.0) Functional gallbladder disorder (DD94) Functional sphincter of Oddi disorder (DD95) Functional abdominal pain in children (DD93.Y) Functional biliary sphincter of Oddi disorder (DD95) Functional pancreatic sphincter of Oddi disorder (DD95) Abdominal pain-related functional GI disorders in children (DD93.Y) Vulval dysaesthesia syndrome (GA34.02)

<b>MG30.01</b>	Chronic widespread pain  Chronic widespread pain (CWP) is diffuse pain in at least 4 of 5 body regions and is associated with significant emotional distress (anxiety, anger/frustration or depressed mood) or functional disability (interference in daily life activities and reduced participation in social roles). CWP is multifactorial: biological, psychological and social factors contribute to the pain syndrome. The diagnosis is appropriate when the pain is not directly attributable to a nociceptive process in these regions and there are features consistent with nociceptive pain and identified psychological and social contributors.
	<b><i>Exclusions:</i></b> Acute pain (MG31)
<b>MG30.02</b>	Chronic primary musculoskeletal pain  Chronic primary musculoskeletal pain is chronic pain in the muscles, bones, joints or tendons that is characterised by significant emotional distress (anxiety, anger/frustration or depressed mood) or functional disability (interference in daily life activities and reduced participation in social roles). Chronic primary musculoskeletal pain is multifactorial: biological, psychological and social factors contribute to the pain syndrome. The diagnosis is appropriate independently of identified biological or psychological contributors unless another diagnosis would better account for the presenting symptoms. Other chronic musculoskeletal pain diagnoses to be considered are those listed under chronic secondary musculoskeletal pain.
	<b><i>Exclusions:</i></b> Acute pain (MG31)
<b>MG30.03</b>	Chronic primary headache or orofacial pain  Chronic primary headache or orofacial pain is defined as headache or orofacial pain that occurs on at least 50% of the days during at least 3 months. It is characterised by significant emotional distress (anxiety, anger/frustration or depressed mood) or functional disability (interference in daily life activities, reduced participation in social roles). Chronic primary headache or orofacial pain is multifactorial: biological, psychological and social factors contribute to the pain syndrome. The diagnosis is appropriate independently of identified biological or psychological contributors unless another diagnosis would better account for the presenting symptoms. The duration of pain per day is at least 2 hours.
	<b><i>Exclusions:</i></b> Headache disorders (8A80-8A8Z)  <b><i>Coded Elsewhere:</i></b> Chronic migraine (8A80.2) Burning mouth syndrome (DA0F.0) Chronic tension-type headache (8A81.2) Chronic cluster headache (8A82) Hemicrania continua (8A82)

<b>MG30.04</b>	Complex regional pain syndrome  Complex regional pain syndrome (CRPS) is a chronic pain condition in an extremity with a variable course over time. It is characterized by continuing regional pain (not in a specific nerve territory or dermatome), usually with distal predominance or distal-to-proximal gradient. It typically arises after tissue trauma and is seemingly disproportionate in magnitude or duration to the usual course of pain after such tissue trauma.  CRPS is characterized by signs indicating autonomic and neuro-inflammatory changes in the affected body region varying between patients and over time. Often, CRPS is accompanied by significant emotional distress or functional disability. CRPS is multifactorial.
<b>MG30.0Y</b>	Other specified chronic primary pain
<b>Coding Note:</b>	Other chronic pain diagnoses to be considered are chronic cancer-related pain, chronic postsurgical or posttraumatic pain, chronic neuropathic pain, chronic secondary headache or orofacial pain, chronic secondary visceral pain and chronic secondary musculoskeletal pain.
<b>MG30.0Z</b>	Chronic primary pain, unspecified
<b>Coding Note:</b>	Other chronic pain diagnoses to be considered are chronic cancer-related pain, chronic postsurgical or posttraumatic pain, chronic neuropathic pain, chronic secondary headache or orofacial pain, chronic secondary visceral pain and chronic secondary musculoskeletal pain.
<b>MG30.1</b>	<b>Chronic cancer related pain</b>  Chronic cancer-related pain is pain caused by the primary cancer itself or metastases (chronic cancer pain) or its treatment (chronic post-cancer treatment pain). It is distinct from pain caused by co-morbid disease [1-3]. It should be highly probable that the pain is due to cancer or its treatment; if its genesis is vague, consider using codes in the section of Primary pain.
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.10</b>	Chronic cancer pain  Chronic cancer pain is chronic pain caused by the primary cancer or metastases. It should be highly probable that the pain is due to cancer; if its genesis is vague, consider using codes in the section of chronic primary pain.
<b>Coding Note:</b>	Code also the causing condition

<b>MG30.11</b>	<p>Chronic post cancer treatment pain</p> <p>Chronic post-cancer treatment pain is pain caused by any treatment given to treat the primary tumour or metastases. The most common forms are:</p> <ul style="list-style-type: none"> <li>(i) Chronic painful chemotherapy-induced polyneuropathy (CIPN): chronic peripheral neuropathic pain caused by oral or intravenous chemotherapy.</li> <li>(ii) Chronic post-radiotherapy pain: chronic pain caused by delayed local damage to the nervous system in the field of radiotherapy. It is distinct from pain caused by tumour recurrence or co-morbid disease.</li> </ul> <p>Other treatments include surgery and hormonal therapy.</p> <p><b>Diagnostic Criteria</b></p> <p>Conditions A to C are fulfilled:</p> <p>A. Chronic pain (persistent or recurrent for longer than 3 months) is present and characterised by all of the following:</p> <ul style="list-style-type: none"> <li>A1 History of treatment with neurotoxic chemotherapy or radiotherapy or any treatment given to treat the primary tumour or metastases</li> <li>A2 It is likely that the pain is caused by the cancer treatment.</li> </ul> <p>B. One of the following applies:</p> <ul style="list-style-type: none"> <li>B1 An active or recurrent tumour or metastases have been specifically excluded on radiological investigation.</li> <li>B2 If an active or a recurrent tumor or metastases are present, the pain is not better accounted for by them.</li> </ul> <p>C. The pain is not better accounted for by another diagnosis of chronic pain.</p> <p><b>Coding Note:</b> Code also the causing condition</p>
<b>MG30.1Y</b>	Other specified chronic cancer related pain
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.1Z</b>	Chronic cancer related pain, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.2</b>	<p><b>Chronic postsurgical or post traumatic pain</b></p> <p>Chronic postsurgical or post traumatic pain is pain developing or increasing in intensity after a surgical procedure or a tissue injury (involving any trauma including burns) and persisting beyond the healing process, i.e. at least 3 months after surgery or tissue trauma. The pain is either localized to the surgical field or area of injury, projected to the innervation territory of a nerve situated in this area, or referred to a dermatome (after surgery/injury to deep somatic or visceral tissues). Other causes of pain including infection, malignancy etc. need to be excluded as well as pain continuing from a pre-existing pain problem.</p> <p><b>Coding Note:</b> The postsurgical or posttraumatic aetiology of the pain should be highly probable; if it is vague, consider using codes in the section of chronic primary pain.</p> <p><b>Coded Elsewhere:</b> Complex regional pain syndrome (MG30.04)</p>

<b>MG30.20</b>	Chronic post traumatic pain  Chronic post traumatic pain is pain developing or increasing in intensity after a tissue injury (involving any trauma including burns) and persisting beyond the healing process, i.e. at least 3 months after the tissue trauma. The pain is either localized to the area of injury, projected to the innervation territory of a nerve situated in this area, or referred to a dermatome (after surgery/injury to deep somatic or visceral tissues). Other causes of pain including infection, malignancy etc. need to be excluded as well as pain continuing from a pre-existing pain problem.
<b>Coding Note:</b>	The posttraumatic aetiology of the pain should be highly probable; if it is vague, consider using codes in the section of chronic primary pain.
<b>Coded Elsewhere:</b>	Chronic central neuropathic pain associated with spinal cord injury (MG30.50)
	Chronic central neuropathic pain associated with brain injury (MG30.50)
	Chronic neuropathic pain after peripheral nerve injury (MG30.51)
	Complex regional pain syndrome type II (MG30.04)
<b>MG30.21</b>	Chronic postsurgical pain  Chronic postsurgical pain is chronic pain developing or increasing in intensity after a surgical procedure and persisting beyond the healing process, i.e. at least 3 months after surgery. The pain is either localised to the surgical field, projected to the innervation territory of a nerve situated in this area, or referred to a dermatome (after surgery/injury to deep somatic or visceral tissues). Other causes of pain including infection, malignancy etc. need to be excluded as well as pain continuing from a pre-existing pain problem. Dependent on type of surgery, chronic postsurgical pain often may be neuropathic pain.
<b>Coding Note:</b>	The postsurgical aetiology of the pain should be highly probable; if it is vague, consider using codes in the section of chronic primary pain.
<b>MG30.2Y</b>	Other specified chronic postsurgical or post traumatic pain
<b>Coding Note:</b>	The postsurgical or posttraumatic aetiology of the pain should be highly probable; if it is vague, consider using codes in the section of chronic primary pain.
<b>MG30.2Z</b>	Chronic postsurgical or post traumatic pain, unspecified
<b>Coding Note:</b>	The postsurgical or posttraumatic aetiology of the pain should be highly probable; if it is vague, consider using codes in the section of chronic primary pain.

<b>MG30.3</b>	<p><b>Chronic secondary musculoskeletal pain</b></p> <p>Chronic secondary musculoskeletal pain is chronic pain arising from bone(s), joint(s), muscle(s), vertebral column, tendon(s) or related soft tissue(s). It is a heterogeneous group of chronic pain conditions originating in persistent nociception in joint, bone, muscle, vertebral column, tendons and related soft tissues, with local and systemic aetiologies, but also related to deep somatic lesions. The pain may be spontaneous or movement-induced.</p>
<b>Coding Note:</b>	<p>If the pain is related to visceral lesions, it should be considered whether a diagnosis of chronic visceral pain is appropriate;</p> <p>if it is related to neuropathic mechanisms, it should be coded under chronic neuropathic pain;</p> <p>and if the pain mechanisms are non-specific, chronic musculoskeletal pain should be coded under chronic primary pain.</p>
<b>Exclusions:</b>	<p>Acute pain (MG31)</p> <p>Chronic neuropathic pain (MG30.5)</p> <p>Chronic primary pain (MG30.0)</p> <p>Chronic secondary visceral pain (MG30.4)</p>
<b>MG30.30</b>	<p>Chronic secondary musculoskeletal pain from persistent inflammation</p> <p>Chronic secondary musculoskeletal pain from persistent inflammation is chronic pain due to inflammatory mechanisms in joint(s), bone(s), tendon(s), muscle(s), soft tissue(s) or vertebral column. The pain may be spontaneous or movement-induced. It is characterised by clinical features of inflammation, including increased sensitivity of the part to stimuli.</p>
<b>Coding Note:</b>	<p>Code also the causing condition</p>
<b>MG30.31</b>	<p>Chronic secondary musculoskeletal pain associated with structural changes</p> <p>Chronic secondary musculoskeletal pain associated with structural changes is chronic pain of unknown mechanism(s) that is attributable to anatomical changes in joint(s), bone(s) or tendon(s). The structural change needs to be inferred from clinical examination and/or demonstrable on imaging. The pain may be spontaneous or movement-induced. It is characterised by clinical features such as swelling, allodynia or restricted movement.</p> <p>Diagnostic Criteria:</p> <p>Conditions A to D are fulfilled:</p> <p>A) Chronic pain (persistent or recurrent for longer than 3 months) in joint(s), bone(s), or tendon(s) is present. The pain may be spontaneous or movement induced.</p> <p>B) At least one of the following fulfilled:</p> <p>B1) Swelling is present.</p> <p>B2) Allodynia over the part is present.</p> <p>C) The structural change is inferred from clinical examination or imaging.</p> <p>D) The pain is not better accounted for by another diagnosis of chronic pain.</p>
<b>Coding Note:</b>	<p>Code also the causing condition</p>
	<p><b>Coded Elsewhere:</b> Chronic pain after musculoskeletal injury (MG30.20)</p>

<b>MG30.32</b>	Chronic secondary musculoskeletal pain due to disease of the nervous system Chronic secondary musculoskeletal pain due to diseases of the nervous system is chronic pain localized in joint(s), bone(s), tendon(s) or muscle(s) that is related to peripheral or central neurological disorders classified elsewhere. It includes pain due to altered motor function and altered sensory function. Altered biomechanical function due to the neurological disease is responsible for the activation of nociceptors in musculoskeletal tissue. The pain may be spontaneous or movement-induced.
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.3Y</b>	Other specified chronic secondary musculoskeletal pain
<b>Coding Note:</b>	If the pain is related to visceral lesions, it should be considered whether a diagnosis of chronic visceral pain is appropriate; if it is related to neuropathic mechanisms, it should be coded under chronic neuropathic pain; and if the pain mechanisms are non-specific, chronic musculoskeletal pain should be coded under chronic primary pain.
<b>MG30.3Z</b>	Chronic secondary musculoskeletal pain, unspecified
<b>Coding Note:</b>	If the pain is related to visceral lesions, it should be considered whether a diagnosis of chronic visceral pain is appropriate; if it is related to neuropathic mechanisms, it should be coded under chronic neuropathic pain; and if the pain mechanisms are non-specific, chronic musculoskeletal pain should be coded under chronic primary pain.
<b>MG30.4</b>	<b>Chronic secondary visceral pain</b> Chronic visceral pain is persistent or recurrent pain originating from internal organs of the head/neck region and of the thoracic, abdominal and pelvic cavities. The visceral etiology of the pain should be highly probable; if it is vague, consider using codes in the section of Chronic Primary Pain.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Neuropathic pain (8E43.0)
	<b>Coded Elsewhere:</b> Chronic visceral cancer pain (MG30.10)
<b>MG30.40</b>	Chronic visceral pain from mechanical factors Chronic visceral pain from mechanical factors is chronic pain deriving from a) the obstruction of hollow viscera as a consequence of internal migrating obstacles (e.g., stones) or stenosis, with dilation above the obstacle/stenosis or b) from the traction of ligaments and vessels of internal organs or the external compression of internal organs.
<b>Coding Note:</b>	Code also the causing condition

<b>MG30.41</b>	Chronic visceral pain from vascular mechanisms Chronic visceral pain from vascular mechanisms is chronic visceral pain due to alterations of arterial and/or venous blood vessels to/from viscera of the head/neck region, thoracic, abdominal and pelvic cavities or pain conditions of the vascular system producing pain in other locations.
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.42</b>	Chronic visceral pain from persistent inflammation Chronic visceral pain from persistent inflammation is chronic pain due to longlasting inflammation of internal organs of the head/neck region and of the thoracic, abdominal, or pelvic cavities.
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.4Y</b>	Other specified chronic secondary visceral pain
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.4Z</b>	Chronic secondary visceral pain, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.5</b>	<p><b>Chronic neuropathic pain</b></p> <p>Chronic neuropathic pain is chronic pain caused by a lesion or disease of the somatosensory nervous system. The pain may be spontaneous or evoked, as an increased response to a painful stimulus (hyperalgesia) or a painful response to a normally nonpainful stimulus (allodynia). The diagnosis of chronic neuropathic pain requires a history of nervous system injury or disease and a neuroanatomically plausible distribution of the pain. Negative (for example, decreased or loss of sensation) and positive sensory symptoms or signs (for example, allodynia or hyperalgesia) indicating the involvement of the somatosensory nervous system must be compatible with the innervation territory of the affected nervous structure.</p>
<b>Coding Note:</b>	Code also the causing condition
	<b>Coded Elsewhere:</b> Chronic neuropathic orofacial pain (MG30.62)
	Chronic neuropathic cancer pain (MG30.10)
<b>MG30.50</b>	Chronic central neuropathic pain
	Chronic central neuropathic pain is chronic pain caused by a lesion or disease of the central somatosensory nervous system. The pain may be spontaneous or evoked, as an increased response to a painful stimulus (hyperalgesia) or a painful response to a normally nonpainful stimulus (allodynia). The diagnosis of central neuropathic pain requires a history of central nervous system injury or disease and a neuroanatomically plausible distribution of the pain. Negative (e.g., decreased or loss of sensation) and positive sensory symptoms or signs (e.g., allodynia or hyperalgesia) indicating the involvement of the central somatosensory nervous system must be compatible with the innervation territory of the affected nervous structure.
<b>Coding Note:</b>	Code also the causing condition

<b>MG30.51</b>	Chronic peripheral neuropathic pain Chronic peripheral neuropathic pain is chronic pain caused by a lesion or disease of the peripheral somatosensory nervous system. The pain may be spontaneous or evoked, as an increased response to a painful stimulus (hyperalgesia) or a painful response to a normally nonpainful stimulus (allodynia). The diagnosis of peripheral neuropathic pain requires a history of peripheral nervous system injury or disease and a neuroanatomically plausible distribution of the pain. Negative (e.g., decreased or loss of sensation) and positive sensory symptoms or signs (e.g., allodynia or hyperalgesia) indicating the involvement of the peripheral somatosensory nervous system must be compatible with the innervation territory of the affected nervous structure.
<b>Coding Note:</b>	Code also the causing condition
<b>Coded Elsewhere:</b>	Postherpetic neuralgia (1E91.5)  Chronic painful radiation-induced neuropathy (MG30.11) Postzoster glossopharyngeal neuralgia (1E91.5) Postzoster trigeminal neuralgia (1E91.5)
<b>MG30.5Y</b>	Other specified chronic neuropathic pain
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.5Z</b>	Chronic neuropathic pain, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.6</b>	<b>Chronic secondary headache or orofacial pain</b> Chronic secondary headache and orofacial pain comprises all headache and orofacial pain disorders that have underlying causes and occur on at least 50% of the days during at least three months. The duration of pain per day is at least 2 hours.  <b>Coding Note:</b> If the aetiology is vague, consider using codes in the section of chronic primary pain.  <b>Exclusions:</b> Acute pain in the face, not elsewhere classified (MG31.0) Acute headache, not elsewhere classified (MG31.1)
<b>MG30.61</b>	Chronic dental pain Chronic dental pain is chronic pain that is caused by a disorder involving the teeth or associated tissues (pulpal, periodontal or gingival pain) and that occurs for two hours or more per day on at least 50% of the days during at least three months. The typical causative factor will be caries or trauma to a tooth or teeth or associated tissues. In addition to clinical examination, imaging (intraoral x-rays, CT scans etc.) may facilitate the correct diagnosis. If the aetiology is vague, consider using codes in the section of chronic primary pain.  <b>Coding Note:</b> Code also the causing condition

<b>MG30.62</b>	<p>Chronic neuropathic orofacial pain</p> <p>Chronic neuropathic orofacial pain is chronic pain in the orofacial region that is caused by a lesion or disease of the peripheral somatosensory nervous system. It occurs for two hours or more per day (or several shorter attacks per day occur) on at least 50% of the days during at least three months. The diagnosis of chronic neuropathic orofacial pain requires a history of peripheral nervous system injury or disease and a neuroanatomically plausible distribution of the pain. Negative and positive sensory symptoms or signs must be compatible with the innervation territory of the affected nervous structure.</p>
<b>Coding Note:</b>	Code also the causing condition
<b>Coded Elsewhere:</b>	Tolosa-Hunt syndrome (8A85)
	Other cranial neuralgia or other centrally mediated facial pain (8A85)
	Combined hyperactive dysfunction syndrome of the cranial nerves (8A85)
	Supraorbital neuralgia (8A85)
	Occipital neuralgia (8A85)
	Postzoster glossopharyngeal neuralgia (1E91.5)
	Postzoster trigeminal neuralgia (1E91.5)
<b>MG30.63</b>	<p>Headache or orofacial pain associated with chronic secondary temporomandibular disorders</p> <p>Chronic secondary temporomandibular disorder pain is chronic pain in the temporomandibular joint(s) or masseter or temporalis muscle(s) associated with persistent inflammation (due to e.g. infection, crystal deposition or autoimmune disorders), structural changes (such as osteoarthritis or spondylosis), injury, or diseases of the nervous system. It occurs on at least 50% of the days during at least three months. The duration of pain per day is at least 2 hours. If the etiology is vague, consider using codes in the section of chronic primary pain.</p>
<b>Coding Note:</b>	Code also the causing condition
<b>MG30.64</b>	<p>Chronic headache or orofacial pain associated with disorders of homoeostasis or their nonpharmacological treatment</p> <p>Chronic headache or orofacial pain associated with disorders of homeostasis or their nonpharmacological treatment is caused by disorders of homoeostasis or the nonpharmacological treatment thereof, and has a duration of more than three months. The pain occurs on at least 50% of the days during at least three months. The duration of pain per day is at least 2 hours.</p>
<b>MG30.65</b>	<p>Chronic headache or orofacial pain associated with cranial or cervical vascular disorder</p> <p>Chronic headache or orofacial pain associated with cranial or cervical vascular disorder is caused by vascular cervical or cranial disorders, and has a duration of more than three months. The pain occurs on at least 50% of the days during at least three months. The duration of pain per day is at least 2 hours.</p>

<b>MG30.66</b>	Chronic headache or orofacial pain associated with non-vascular intracranial disorder  Chronic headache or orofacial pain associated with non-vascular intracranial disorder is caused by non-vascular intracranial disorders, and has a duration of more than three months. The pain occurs on at least 50% of the days during at least three months. The duration of pain per day is at least 2 hours.
<b>MG30.67</b>	Chronic headache associated with a substance or its withdrawal  Chronic headache associated with a substance or its withdrawal is caused by use of, exposure to or withdrawal from a substance, and has a duration of more than three months. The pain occurs on at least 50% of the days during at least three months. The duration of pain per day is at least 2 hours.  <b><i>Exclusions:</i></b> Medication-overuse headache (8A84)
<b>MG30.6Y</b>	Other specified chronic secondary headache or orofacial pain
<b>Coding Note:</b>	If the aetiology is vague, consider using codes in the section of chronic primary pain.
<b>MG30.6Z</b>	Chronic secondary headache or orofacial pain, unspecified
<b>Coding Note:</b>	If the aetiology is vague, consider using codes in the section of chronic primary pain.
<b>MG30.Y</b>	<b>Other specified chronic pain</b>
<b>Coding Note:</b>	This code should be used if a pain condition persists or recurs for longer than 3 months.
<b>MG30.Z</b>	<b>Chronic pain, unspecified</b>
<b>Coding Note:</b>	This code should be used if a pain condition persists or recurs for longer than 3 months.
<b>MG31</b>	<b>Acute pain</b> Pain with a duration of less than 3 months.  This code should be used only when there is no further specification of site.
<b>MG31.0</b>	<b>Acute pain in the face, not elsewhere classified</b>
<b>MG31.1</b>	<b>Acute headache, not elsewhere classified</b>
<b>MG31.2</b>	<b>Acute postoperative pain, not elsewhere classified</b> Pain at the intervention site or caused by an intervention.
<b>MG31.Y</b>	<b>Other specified acute pain</b>
<b>MG31.Z</b>	<b>Acute pain, unspecified</b>
<b>MG3Z</b>	<b>Pain, unspecified</b>

**MG40**

### **Shock**

Shock is a life-threatening medical condition that occurs due to inadequate substrate for aerobic cellular respiration. In the early stages this is generally an inadequate tissue level of oxygen. Shock, not elsewhere classified is a shock that isn't classified elsewhere.

**Exclusions:** Traumatic shock, not elsewhere classified (NF0A.4)

Toxic shock syndrome (1C45)

lightening shock (NF08.0)

electric shock (NF08.4)

Psychic shock (QE84)

Anaphylactic shock NOS (4A84)

Anaphylaxis due to allergic reaction to food (4A84.0)

anaphylactic shock due to serum (NE80.3)

**Coded Elsewhere:** Sepsis with septic shock (1G41)

Shock following abortion, ectopic or molar pregnancy (JA05.3)

Shock during or following labour or delivery (JB0D.1)

**MG40.0**

### **Cardiogenic shock**

**Exclusions:** Cardiogenic shock, unrelated to mechanical complications, as current complication following acute myocardial infarction (BA60.9)

**MG40.1**

### **Hypovolaemic shock**

**Exclusions:** traumatic hypovolemic shock (NF0A.4)

**MG40.Y**

### **Other specified shock**

**MG40.Z**

### **Shock, unspecified**

**MG41**

### **Sleep disturbance, not elsewhere classified**

**Exclusions:** Sleep-wake disorders (Chapter 07)

**MG42**

### **Somnolence, not elsewhere classified**

**Inclusions:** Drowsiness

**Exclusions:** Sleep-wake disorders (Chapter 07)

**MG43**

### **Symptoms and signs concerning food and fluid intake**

Symptoms and signs concerning food and fluid intake include anorexia, polydipsia, polyphagia, feeding difficulties and mismanagement, abnormal weight loss, abnormal weight gain, insufficient intake of food and water due to self neglect and other symptoms and signs concerning food and fluid intake.

**Exclusions:** Feeding or eating disorders (6B80-6B8Z)

malnutrition (5B50-5B7Z)

<b>MG43.0</b>	<b>Polydipsia</b>
	<i>Inclusions:</i> Excessive thirst
<b>MG43.1</b>	<b>Overeating</b>
	The consumption of excess food in relation to energy and nutritional requirements.
	<i>Inclusions:</i> Excessive eating
	<i>Exclusions:</i> Bipolar or related disorders (6A60-6A6Z)
	Depressive disorders (6A70-6A7Z)
	Feeding or eating disorders (6B80-6B8Z)
<b>MG43.2</b>	<b>Abulia</b>
	Abulia is state of poverty of behaviour and speech output, lack of initiative, loss of emotional responses, psychomotor slowing, and prolonged speech latency.
<b>MG43.3</b>	<b>Feeding difficulties</b>
	<i>Exclusions:</i> Feeding problems of newborn (KD32)
	Feeding or eating disorders (6B80-6B8Z)
	Anorexia Nervosa (6B80)
	Bulimia Nervosa (6B81)
	Binge eating disorder (6B82)
	Avoidant-restrictive food intake disorder (6B83)
	Pica (6B84)
	Rumination-regurgitation disorder (6B85)
	Cyclic vomiting syndrome (8A80.4)
<b>MG43.30</b>	Feeding problem of infant
	<i>Exclusions:</i> Feeding problems of newborn (KD32)
	Avoidant-restrictive food intake disorder (6B83)
<b>MG43.31</b>	Feeding problem of child
	<i>Exclusions:</i> Feeding or eating disorders (6B80-6B8Z)
	Anorexia Nervosa (6B80)
	Avoidant-restrictive food intake disorder (6B83)
	Pica (6B84)
	Rumination-regurgitation disorder (6B85)
	Binge eating disorder (6B82)
	Bulimia Nervosa (6B81)
	Cyclic vomiting syndrome in children (DD93)

<b>MG43.32</b>	Feeding problem of adult
	<b>Exclusions:</b>
	Anorexia Nervosa (6B80)
	Bulimia Nervosa (6B81)
	Binge eating disorder (6B82)
	Avoidant-restrictive food intake disorder (6B83)
	Pica (6B84)
	Rumination-regurgitation disorder (6B85)
	Feeding or eating disorders (6B80-6B8Z)
	Cyclic vomiting syndrome (8A80.4)
<b>MG43.3Z</b>	Feeding difficulties, unspecified
<b>MG43.4</b>	<b>Insufficient intake of food and water due to self neglect</b>
	<b>Exclusions:</b>
	starvation due to privation of food (PD27)
	thirst due to privation of water (PD28)
	Anorexia Nervosa (6B80)
	Avoidant-restrictive food intake disorder (6B83)
	Bulimia Nervosa (6B81)
	Feeding or eating disorders (6B80-6B8Z)
<b>MG43.40</b>	Refusal of food, not elsewhere classified
	<b>Exclusions:</b>
	Intentional self-harm by lack of food (PD27)
	Anorexia (MG43.7)
<b>MG43.41</b>	Refusal of fluid, not elsewhere classified
	<b>Exclusions:</b>
	Intentional self-harm by lack of water (PD28)
	Dehydration (5C70.0)
<b>MG43.4Y</b>	Other specified insufficient intake of food and water due to self neglect
<b>MG43.4Z</b>	Insufficient intake of food and water due to self neglect, unspecified
<b>MG43.5</b>	<b>Excessive weight loss</b>
	A reduction of total body mass, due to loss of fluid, body fat or adipose tissue, or lean (muscle) mass that is sufficient in quantity or rate to create risk to the individual's health.
<b>MG43.6</b>	<b>Excessive weight gain</b>
	An increase in total body mass, due to increase in fluid, fat or adipose tissue, or lean (muscle) mass that is outside the expected range for normal growth and development and is sufficient in quantity or rate to create risk to the individual's health.
	<b>Exclusions:</b>
	Obesity (5B81)
	<b>Coded Elsewhere:</b> Excessive weight gain in pregnancy (JA65.2)

<b>MG43.7</b>	<b>Anorexia</b> Anorexia is a pathological lack or loss of appetite.
	<b>Inclusions:</b> Loss of appetite
	<b>Exclusions:</b> loss of appetite of nonorganic origin (6B80-6B8Z) anorexia nervosa (6B80) Decreased appetite (MG43.8)
<b>MG43.8</b>	<b>Decreased appetite</b> Intermittent or persistent decreased motivation or desire to eat food as compared to what is typical for the individual.
<b>MG43.9</b>	<b>Increased appetite</b> Intermittent or persistent increased motivation or desire to eat food as compared to what is typical for the individual.
<b>MG43.Y</b>	<b>Other specified symptoms and signs concerning food and fluid intake</b>
<b>MG44</b>	<b>Symptoms peculiar to infancy</b>
<b>MG44.0</b>	<b>Excessive crying of infant</b> <b>Inclusions:</b> Irritable infant <b>Exclusions:</b> neonatal cerebral irritability (KB03)
<b>MG44.1</b>	<b>Lack of expected normal physiological development</b> Lack of expected normal physiological development includes delayed milestone of development and other lack of expected normal physiological development including gross and fine motor development, language, social milestones. <b>Exclusions:</b> Delayed puberty (5A91) Disorders of intellectual development (6A00)
<b>MG44.10</b>	Delayed milestone <b>Inclusions:</b> Delayed attainment of expected physiological developmental stage
<b>MG44.11</b>	Failure to thrive in infant or child When an infant or child's current weight or rate of weight gain is significantly below that of other children of similar age and gender. <b>Exclusions:</b> Failure to thrive in newborn (KD32.4) Anorexia Nervosa (6B80) Avoidant-restrictive food intake disorder (6B83) Cachexia (MG20)

<b>MG44.12</b>	<p>Short stature of child Short stature is when a child is significantly shorter than children of the same age and gender</p> <p><b>Exclusions:</b>      Short stature due to growth hormone resistance (5A61.0)                           Short stature, not elsewhere classified (5B11)</p>
<b>MG44.13</b>	<p>Constitutional delay of growth and puberty Delayed development concerning maturation of bones and their growth at prepubertal and pubertal ages of children. Occurs with or without short stature below the third percentile of body height. Height velocity is usually temporarily below the mean. Bone age is always delayed. Puberty starts late, but spontaneously. Other causes of delayed growth (with or without short stature below the third percentile of body height) or of delayed puberty must be excluded.</p> <p><b>Exclusions:</b>      Short stature, not elsewhere classified (5B11)                           Short stature due to growth hormone resistance (5A61.0)</p>
<b>MG44.14</b>	<p>Familial short stature Short stature of a child or adolescent (below 3rd percentile) with one or both parents with an adult height below 3rd percentile. Combination with constitutional delay of growth and puberty may occur.</p> <p><b>Exclusions:</b>      Short stature, not elsewhere classified (5B11)                           Short stature due to growth hormone resistance (5A61.0)</p>
<b>MG44.1Y</b>	Other specified lack of expected normal physiological development
<b>MG44.1Z</b>	Lack of expected normal physiological development, unspecified
<b>MG44.Y</b>	<b>Other specified symptoms peculiar to infancy</b>
<b>MG44.Z</b>	<b>Symptoms peculiar to infancy, unspecified</b>

**MG45****Syncope and collapse**

Syncope is also called fainting, temporary loss of consciousness. Syncope and collapse is temporary loss of consciousness with a fall down.

**Inclusions:** Fainting

Blackout

**Exclusions:** Heat syncope (NF01.1)

carotid sinus syncope (8D88)

Shock during or following labour or delivery (JB0D.1)

unconsciousness NOS (MB20.1)

Cardiogenic shock (MG40.0)

Shock following abortion, ectopic or molar pregnancy (JA05.3)

shock: NOS (MG40)

Orthostatic hypotension (BA21)

neurogenic orthostatic hypotension (8D87.0)

**Coded Elsewhere:** Reflex syncope (8D89.0)

Syncope due to autonomic failure (8D89.1)

**MG45.0****Cardiac syncope****MG45.Y****Other specified syncope and collapse****MG45.Z****Syncope and collapse, unspecified****MG46****Systemic inflammatory response syndrome of noninfectious origin**

**Coding Note:**

Code also the underlying condition.

**Exclusions:** Systemic inflammatory response syndrome of infectious origin  
(Chapter 01)

**MG47****Toxicosis not further specified**

**Exclusions:** Harmful effects of substances (NE60-NE6Z)

**MG48****Unknown and unspecified causes of morbidity**

**Inclusions:** Undiagnosed disease, not specified as to the site or system involved

**MG49****Hangover**

**Exclusions:** Alcohol withdrawal (6C40.4)

**MG4A****Multi organ failure**

Failure of function of more than one organ or organ system, not otherwise specified

**Coding Note:**

Code also the causing condition

**MG4Y****Other specified general symptoms**

Finding of microorganism resistant to antimicrobial drugs (MG50-MG5Z)

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG50**

**Finding of gram negative bacteria resistant to antimicrobial drugs**

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG50.0**

**Antibiotic resistant Acinetobacter baumannii**

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG50.00**

Tetracycline resistant Acinetobacter baumannii

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG50.01**

Aminoglycoside resistant Acinetobacter baumannii

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG50.02**

Carbapenem resistant Acinetobacter baumannii

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG50.03**

Polymyxin resistant Acinetobacter baumannii

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG50.0Y**

Acinetobacter resistant to other antibiotic

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG50.0Z**

Acinetobacter resistant to unspecified antibiotic

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

<b>MG50.1</b>	<b>Antibiotic resistant Campylobacter</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.10</b>	Fluoroquinolone resistant Campylobacter
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.1Y</b>	Other specified antibiotic resistant Campylobacter
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.1Z</b>	Campylobacter resistant to unspecified antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.2</b>	<b>Antibiotic resistant Escherichia coli</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.20</b>	Sulfonamide or trimethoprim resistant Escherichia coli
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.21</b>	Fluoroquinolone resistant Escherichia coli
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.22</b>	Third generation cephalosporin resistant Escherichia coli
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

<b>MG50.23</b>	Fourth-generation cephalosporins resistant Escherichia coli
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.24</b>	Carbapenem resistant Escherichia coli
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.25</b>	Polymyxin resistant Escherichia coli
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.26</b>	Penicillin resistant Escherichia coli
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.27</b>	Extended spectrum beta-lactamase producing Escherichia coli
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.2Y</b>	Escherichia coli resistant to other antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.  In case of multiple resistances, code each one separately if listed below.
<b>MG50.2Z</b>	Escherichia coli resistant to unspecified antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.  In case of multiple resistances, code each one separately if listed below.
<b>MG50.3</b>	<b>Antibiotic resistant Haemophilus influenzae</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.  In case of multiple resistances, code each one separately if listed below.

<b>MG50.30</b>	Ampicillin resistant Haemophilus influenzae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.3Y</b>	Other specified antibiotic resistant Haemophilus influenzae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.3Z</b>	Antibiotic resistant Haemophilus influenzae, unspecified
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.4</b>	<b>Antibiotic resistant Helicobacter pylori</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.40</b>	Clarithromycin resistant Helicobacter pylori
<b>MG50.4Y</b>	Other specified antibiotic resistant Helicobacter pylori
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.4Z</b>	Antibiotic resistant Helicobacter pylori, unspecified
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.5</b>	<b>Antibiotic resistant Klebsiella pneumoniae</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.50</b>	Sulfonamide or trimethoprim resistant Klebsiella pneumoniae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

<b>MG50.51</b>	Fluoroquinolone resistant Klebsiella pneumoniae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.52</b>	Third-generation cephalosporin resistant Klebsiella pneumoniae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.53</b>	Fourth-generation cephalosporin resistant Klebsiella pneumoniae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.54</b>	Carbapenem resistant Klebsiella pneumoniae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.55</b>	Polymyxin resistant Klebsiella pneumoniae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.56</b>	Extended-spectrum beta-lactamase producing Klebsiella pneumoniae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.5Y</b>	Klebsiella pneumoniae resistant to other antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.  In case of multiple resistances, code each one separately if listed below.
<b>MG50.5Z</b>	Klebsiella pneumoniae resistant to unspecified antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.  In case of multiple resistances, code each one separately if listed below.

<b>MG50.6</b>	<b>Antibiotic resistant Neisseria gonorrhoeae</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.60</b>	Third generation cephalosporin resistant Neisseria gonorrhoeae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.61</b>	Macrolide resistant Neisseria gonorrhoeae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.62</b>	Aminocyclitol resistant Neisseria gonorrhoeae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.63</b>	Fluoroquinolone resistant Neisseria gonorrhoeae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.64</b>	Aminoglycoside resistant Neisseria gonorrhoeae
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.6Y</b>	Neisseria gonorrhoeae resistant to other antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.6Z</b>	Neisseria gonorrhoeae resistant to unspecified antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.

<b>MG50.7</b>	<b>Antibiotic resistant Neisseria meningitidis</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.70</b>	Penicillin resistant Neisseria meningitidis
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.7Y</b>	Other specified antibiotic resistant Neisseria meningitidis
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.7Z</b>	Antibiotic resistant Neisseria meningitidis, unspecified
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.8</b>	<b>Antibiotic resistant Pseudomonas aeruginosa</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.80</b>	Carbapenem-resistant Pseudomonas aeruginosa
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.81</b>	Polymyxin-resistant Pseudomonas aeruginosa
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.8Y</b>	Pseudomonas aeruginosa resistant to other antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.

<b>MG50.8Z</b>	Pseudomonas aeruginosa resistant to unspecified antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.9</b>	<b>Antibiotic resistant Salmonella</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.90</b>	Fluoroquinolone resistant Salmonella
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.91</b>	Third generation cephalosporin resistant Salmonella
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.92</b>	Carbapenem resistant Salmonella
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.9Y</b>	Salmonella resistant to other antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.9Z</b>	Salmonella resistant to unspecified antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.A</b>	<b>Antibiotic resistant Shigella</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.

<b>MG50.A0</b>	Carbapenem resistant Shigella
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.A1</b>	Fluoroquinolone resistant Shigella
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.A2</b>	Third-generation cephalosporins resistant Shigella
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.A3</b>	Macrolides resistant Shigella
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.AY</b>	Shigella resistant to other antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.AZ</b>	Shigella resistant to unspecified antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.B</b>	<b>Antibiotic resistant Vibrio</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.B0</b>	Fluoroquinolone resistant Vibrio
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

<b>MG50.BY</b>	Vibrio resistant to other antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.BZ</b>	Vibrio resistant to unspecified antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.C</b>	<b>Other antibiotic resistant Enterobacterales</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.C0</b>	Other carbapenem resistant Enterobacterales
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.C1</b>	Other third-generation cephalosporin resistant Enterobacterales
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.CY</b>	Other specified other antibiotic resistant Enterobacterales
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG50.CZ</b>	Other antibiotic resistant Enterobacterales, unspecified
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.

<b>MG50.Y</b>	<b>Other specified finding of gram negative bacteria resistant to antimicrobial drugs</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG50.Z</b>	<b>Finding of gram negative bacteria resistant to antimicrobial drugs, unspecified</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG51</b>	<b>Finding of gram positive bacteria resistant to antimicrobial drugs</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG51.0</b>	<b>Antibiotic resistant <i>Staphylococcus aureus</i></b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.  In case of multiple resistances, code each one separately if listed below.
<b>MG51.00</b>	Methicillin resistant <i>Staphylococcus aureus</i>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG51.01</b>	Vancomycin resistant <i>Staphylococcus aureus</i>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG51.02</b>	Penicillinase-stable beta lactams resistant <i>Staphylococcus aureus</i>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG51.0Y</b>	Other specified antibiotic resistant <i>Staphylococcus aureus</i>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.  In case of multiple resistances, code each one separately if listed below.

<b>MG51.0Z</b>	Antibiotic resistant <i>Staphylococcus aureus</i> , unspecified
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG51.1</b>	<b>Antibiotic resistant <i>Streptococcus pneumoniae</i></b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG51.10</b>	Penicillin resistant <i>Streptococcus pneumoniae</i>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG51.11</b>	Sulfonamide and trimethoprim resistant <i>Streptococcus pneumoniae</i>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG51.12</b>	Third-generation cephalosporins resistant <i>Streptococcus pneumoniae</i>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG51.1Y</b>	<i>Streptococcus pneumoniae</i> resistant to other antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG51.1Z</b>	<i>Streptococcus pneumoniae</i> resistant to unspecified antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG51.2</b>	<b>Antibiotic resistant <i>Enterococcus</i></b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.

<b>MG51.20</b>	Vancomycin resistant Enterococcus
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG51.2Y</b>	Enterococcus resistant to other antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG51.2Z</b>	Enteroccus resistant to unspecified antibiotic
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG51.Y</b>	<b>Other specified finding of gram positive bacteria resistant to antimicrobial drugs</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG51.Z</b>	<b>Finding of gram positive bacteria resistant to antimicrobial drugs, unspecified</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG52</b>	<b>Finding of bacteria, neither gram negative nor positive, resistant to antimicrobial drugs</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG52.0</b>	<b>Antibiotic resistant Mycobacterium</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG52.00</b>	Multi-drug resistant Mycobacterium tuberculosis
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

<b>MG52.01</b>	Antibiotic resistant non-tuberculous Mycobacterium
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG52.02</b>	Extensively drug-resistant mycobacterium tuberculosis
	Extensively drug-resistant tuberculous mycobacteria are resistant to at least four of the core anti-TB drugs. XDR-TB mycobacteria are resistant to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance, in addition to resistance to any of the fluoroquinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-line drugs (amikacin, capreomycin or kanamycin).
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG52.0Y</b>	Other specified antibiotic resistant Mycobacterium
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG52.0Z</b>	Antibiotic resistant Mycobacterium, unspecified
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
	In case of multiple resistances, code each one separately if listed below.
<b>MG52.Y</b>	<b>Other specified finding of bacteria, neither gram negative nor positive, resistant to antimicrobial drugs</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG52.Z</b>	<b>Finding of bacteria, neither gram negative nor positive, resistant to antimicrobial drugs, unspecified</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG53</b>	<b>Finding of virus resistant to antimicrobial drugs</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

<b>MG53.0</b>	<b>Antiretroviral therapy resistant Human immunodeficiency virus</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG53.Y</b>	<b>Other specified finding of virus resistant to antimicrobial drugs</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG53.Z</b>	<b>Finding of virus resistant to antimicrobial drugs, unspecified</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG54</b>	<b>Finding of fungus resistant to antimicrobial drugs</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG55</b>	<b>Finding of parasite resistant to antimicrobial drugs</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG55.0</b>	<b>Artemisinin resistant Plasmodium falciparum</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG55.Y</b>	<b>Other specified finding of parasite resistant to antimicrobial drugs</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.
<b>MG55.Z</b>	<b>Finding of parasite resistant to antimicrobial drugs, unspecified</b>
<b>Coding Note:</b>	These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG56      Finding of microorganism resistant to other multiple antimicrobial drugs**

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG5Y      Finding of other microorganism resistant to antimicrobial drugs**

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

**MG5Z      Finding of microorganism resistant to antimicrobial drugs, unspecified**

**Coding Note:** These categories should never be used in primary coding. The codes are provided for use as supplementary or additional codes when it is desired to identify the resistance, non-responsiveness and refractive properties of a condition to antimicrobials.

Clinical findings in specimens from other specified organs, systems and tissues (MG60-MG6Y)

**Coded Elsewhere:** Meconium staining (KD38)

**MG60      Abnormal level of enzymes in specimens from other organs, systems and tissues**

**MG61      Abnormal level of hormones in specimens from other organs, systems and tissues**

**MG62      Abnormal level of drugs, medicaments and biological substances in specimens from other organs, systems and tissues**

**MG63      Abnormal level of substances chiefly nonmedicinal as to source in specimens from other organs, systems and tissues**

**MG64      Abnormal immunological findings in specimens from other organs, systems and tissues**

**MG65      Abnormal microbiological findings in specimens from other organs, systems and tissues**

**MG66      Abnormal cytological findings in specimens from other organs, systems and tissues**

**MG67      Abnormal histological findings in specimens from other organs, systems and tissues**

**MG6Y      Other specified clinical findings in specimens from other specified organs, systems and tissues**

Abnormal results, not elsewhere classified (MG70-MG7Z)

**MG70      Abnormal diagnostic imaging results not elsewhere classified**

<b>MG71</b>	<b>Abnormal laboratory results, not elsewhere classified</b>
<b>MG71.0</b>	<b>Abnormal findings on neonatal screening</b>
<b>MG71.Y</b>	<b>Other specified abnormal laboratory results, not elsewhere classified</b>
<b>MG71.Z</b>	<b>Abnormal laboratory results, not elsewhere classified, unspecified</b>
<b>MG72</b>	<b>Abnormal results of function studies of other organs and systems</b>
<b>MG7Y</b>	<b>Other specified abnormal results, not elsewhere classified</b>
<b>MG7Z</b>	<b>Abnormal results, not elsewhere classified, unspecified</b>

---

<b>MG9Y</b>	<b>Other specified general symptoms, signs or clinical findings</b>
-------------	---

### III-defined and unknown causes of mortality (MH10-MH15)

**Exclusions:** Fetal death, cause not specified (KD3B)  
Obstetric death of unspecified cause (JB60)

<b>MH10</b>	<b>Brain death</b>
	Persistent apnoeic coma due to irreversible cessation brainstem, cerebellar and cortical activity as seen clinically by no eye opening or eye movement to noxious stimuli, no motor and verbal response, no brain stem and spinal reflexes corneal, cough, vestibuloocular and respiratory, and no cerebral electrical activity as seen by EEG, no cerebral blood flow as seen by cerebral angiogram (conventional, MR, CT, Doppler) and no metabolic activity evidenced by SPECT or PET lasting for more than 24 hours due to irreversible diffuse lesion of the brain not due to hypothermia, sedative drug, neuromuscular blocker overdose or metabolic abnormality without evidence of peripheral circulatory shock.

<b>MH11</b>	<b>Sudden infant death syndrome</b>
	Sudden infant death syndrome is the abrupt and unexplained death of an apparently healthy infant under one year of age, remaining unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of the clinical history.

<b>MH11.0</b>	<b>Sudden infant death syndrome with mention of autopsy</b>
<b>MH11.1</b>	<b>Sudden infant death syndrome without autopsy</b>
<b>MH11.Z</b>	<b>Sudden infant death syndrome, unspecified</b>
<b>MH12</b>	<b>Other sudden death, cause unknown</b>
	<b>Exclusions:</b> Sudden infant death syndrome (MH11)
<b>MH12.0</b>	<b>Instantaneous death</b>
	<b>Inclusions:</b> Sudden unexplained death in adult

MH12.1	<b>Death occurring less than 24 hours from onset of symptoms, not otherwise explained</b>
	<i>Inclusions:</i>
	Death known not to be violent or instantaneous for which no cause can be discovered
	Death without sign of disease
MH12.Y	<b>Other specified sudden death, cause unknown</b>
MH13	<b>Unattended death</b>
	<i>Inclusions:</i>
	Found dead
MH14	<b>Other ill-defined and unspecified causes of mortality</b>
	<i>Inclusions:</i>
	Unknown cause of mortality
MH15	<b>Sudden unexpected death in epilepsy</b>
	Sudden unexpected death in epilepsy (SUDEP) is a category of death in people with epilepsy that occurs under benign circumstances and in the absence of known structural causes of death (i.e. not due to drowning, injury, intoxication and other internal or external factors). Evidence of a preceding seizure may be present or not. A “definite SUDEP” is confirmed if a postmortem examination does not reveal an alternative cause of death. If such examination lacks, but potentially lethal alternative causes are excluded and all other criteria are met, the death is labelled as “probable SUDEP”. The term “possible SUDEP” is used in cases with competing causes of death or when data are insufficient to reasonably allow their classification. The term “SUDEP plus” applies when a patient also suffered from other diseases that may have contributed to the death, but there are no clues that the alternative condition has truly caused it. Cases in which cardiopulmonary resuscitation prevented the death are called “near-SUDEP”.

---

MH2Y	<b>Other specified symptoms, signs or clinical findings, not elsewhere classified</b>
------	---

# **CHAPTER 22**

---

## **Injury, poisoning or certain other consequences of external causes**

This chapter has 236 four-character categories.

Code range starts with NA00

In the ICD, injury means physical or physiological bodily harm resulting from interaction of the body with energy (mechanical, thermal, electrical, chemical or radiant, or due to extreme pressure) in an amount, or at a rate of transfer, that exceeds physical or physiological tolerance. Injury can also result from lack of vital elements, such as oxygen. Poisoning by and toxic effects of substances are included, as is damage of or due to implanted devices.

Injury usually has rapid onset in response to a well-defined event (e.g. a car crash, striking the ground after falling, drinking a strongly alkaline liquid, an overdose of a medication, a burn sustained during a surgical procedure). These events are often referred to as external causes of injury. The injurious energy can, however, originate from the injured person and/or from his or her immediate environment (e.g. a person running on a hot day sustains heat exhaustion), and injury can be caused by the injured person (i.e. intentional self-harm).

Injury includes manifestations that are evident immediately after onset, which may persist or not, and manifestations that first become evident at a later date.

<b><i>Exclusions:</i></b>	Stress fracture, not elsewhere classified (FB80.A)
	Pathological fracture (FB80.B)
	Certain specified obstetric trauma (JB0A)
	Malunion of fracture (FB80.7)
	Birth injury (KA40-KA4Z)
	Nonunion of fracture (FB80.8)

This chapter contains the following top level blocks:

- Injuries to the head
- Injuries to the neck
- Injuries to the thorax
- Injuries to the abdomen, lower back, lumbar spine or pelvis
- Injuries to the shoulder or upper arm
- Injuries to the elbow or forearm
- Injuries to the wrist or hand
- Injuries to the hip or thigh
- Injuries to the knee or lower leg
- Injuries to the ankle or foot
- Injuries involving multiple body regions

- Injuries to unspecified part of trunk, limb or body region
- Effects of foreign body entering through natural orifice
- Burns
- Frostbite
- Harmful effects of substances
- Injury or harm arising from surgical or medical care, not elsewhere classified
- Other or unspecified effects of external causes

## Injuries to the head (NA00-NA0Z)

**Coding Note:** This Block includes the following:

- injuries of face [any part]
- injuries of gum
- injuries of jaw
- injuries of oral cavity
- injuries of palate
- injuries of perioral area
- injuries of scalp
- injuries of temporomandibular joint area
- injuries of tongue
- injuries of tooth

**Exclusions:** Foreign body in ear (ND71)

Foreign body in mouth (ND73.0)

Foreign body in larynx (ND72.3)

Foreign body in pharynx (ND72.2)

Foreign body in nostril (ND72.1)

Burns (ND90-NE2Z)

Frostbite (NE40-NE4Z)

Foreign body on external eye (ND70)

**Coded Elsewhere:** Epilepsy due to injuries to the head (8A60.5)

Birth injury to face (KA43.3)

**NA00**

### Superficial injury of head

Damage inflicted on the surface or shallow tissues of the head as the direct or indirect result of an external force, with or without disruption of structural continuity.

**Exclusions:** Injury of eye or orbit (NA06)

cerebral contusion (diffuse) focal (NA07.4)

**NA00.0**

### Superficial injury of scalp

**Coded Elsewhere:** Birth injury to scalp (KA42)

<b>NA00.00</b>	Abrasions of scalp
<b>NA00.01</b>	Contusions of scalp  <b>Coded Elsewhere:</b> Bruising of scalp due to birth injury (KA42.0)
<b>NA00.02</b>	Superficial foreign body in scalp
<b>NA00.0Y</b>	Other specified superficial injury of scalp
<b>NA00.0Z</b>	Superficial injury of scalp, type unspecified
<b>NA00.1</b>	<b>Superficial injury of eyelid or periocular area</b>
<b>NA00.10</b>	Abrasions of eyelid or periocular area
<b>NA00.11</b>	Contusions of eyelid or periocular area  <b>Inclusions:</b> black eye  <b>Exclusions:</b> Contusion of eyeball or orbital tissues (NA06.9)
<b>NA00.1Y</b>	Other specified superficial injury of eyelid or periocular area
<b>NA00.1Z</b>	Superficial injury of eyelid or periocular area, unspecified
<b>NA00.2</b>	<b>Superficial injury of ear</b> Damage inflicted on the surface or shallow tissues of the ear as the direct or indirect result of an external force, with or without disruption of structural continuity.
<b>NA00.3</b>	<b>Superficial injury of nose</b>
<b>NA00.4</b>	<b>Superficial injury of lip or oral cavity</b>
<b>NA00.5</b>	<b>Multiple superficial injuries of head</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
<b>NA00.6</b>	<b>Abrasions of other or unspecified sites of head</b>
<b>NA00.7</b>	<b>Contusions of other or unspecified sites of head</b>
<b>NA00.Y</b>	<b>Superficial injury of other specified part of head</b>
<b>NA00.Z</b>	<b>Superficial injury of unspecified part of head</b>
<b>NA01</b>	<b>Open wound of head</b>  <b>Exclusions:</b> Decapitation (NA63) Traumatic amputation of part of head (NA09) Injury of eye or orbit (NA06)  <b>Coded Elsewhere:</b> Open wound of eyelid or periocular area (NA06.04)
<b>NA01.2</b>	<b>Laceration without foreign body of head</b>  <b>Inclusions:</b> laceration of skin of head

- NA01.3**      **Laceration with foreign body of head**
- NA01.4**      **Puncture wound without foreign body of head**
- NA01.5**      **Puncture wound with foreign body of head**
- NA01.6**      **Open bite of head**
- NA01.7**      **Multiple open wounds of head**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

- NA01.Y**      **Other specified open wound of head**

- NA01.Z**      **Open wound of head, unspecified**

## **NA02      Fracture of skull or facial bones**

**Coded Elsewhere:** Fracture of skull due to birth injury (KA45.0)

Birth injury to facial bones (KA45.2)

- NA02.0**      **Fracture of vault of skull**

- NA02.00**      Fracture of squama of frontal bone of skull

- NA02.01**      Fracture of parietal bone of skull

- NA02.02**      Fracture of squama of temporal bone of skull

- NA02.03**      Fracture of squama of occipital bone of skull

- NA02.0Z**      Fracture of vault of skull, unspecified

## **NA02.1      Fracture of base of skull**

Fractures which extend through the base of the skull, usually involving the petrous bone.

**Exclusions:**      Fracture of orbital floor (NA02.21)

fracture of orbit NOS (NA02.2)

- NA02.10**      Fracture of anterior fossa of base of skull

- NA02.11**      Fracture of middle fossa of base of skull

- NA02.12**      Fracture of posterior fossa of base of skull

- NA02.13**      Fracture of sinus of ethmoid bone of skull

- NA02.14**      Fracture of frontal sinus of skull

- NA02.15**      Fracture of sphenoid bone of skull

- NA02.16**      Fracture of occipital condyle of skull, type I

- NA02.17**      Fracture of occipital condyle of skull, type II

- NA02.18**      Fracture of occipital condyle of skull, type III

<b>NA02.19</b>	Fracture of other part of occipital bone of skull
<b>NA02.1A</b>	Other fractures of base of skull
<b>NA02.1Z</b>	Fracture of base of skull, unspecified
<b>NA02.2</b>	<b>Orbital fracture</b>
<b>NA02.20</b>	Fracture of orbital roof
<b>NA02.21</b>	Fracture of orbital floor
	<b><i>Inclusions:</i></b> Fracture of orbital roof (NA02.20)
<b>NA02.2Y</b>	Other specified orbital fracture
<b>NA02.2Z</b>	Orbital fracture, unspecified
<b>NA02.3</b>	<b>Fracture of nasal bones</b>
	<b><i>Coded Elsewhere:</i></b> Nasal bone fracture due to birth injury (KA45.21)
<b>NA02.4</b>	<b>Fracture of maxilla</b>
<b>NA02.40</b>	Le Fort fracture type I
<b>NA02.41</b>	Le Fort fracture type II
<b>NA02.42</b>	Le Fort fracture type III
<b>NA02.4Y</b>	Other specified fracture of maxilla
<b>NA02.4Z</b>	Fracture of maxilla, unspecified
<b>NA02.5</b>	<b>Fracture of zygoma</b>
	<b><i>Inclusions:</i></b> Fracture of malar
<b>NA02.7</b>	<b>Fracture of mandible</b>
	Fracture of the largest and strongest bone of the face constituting the lower jaw.
	<b><i>Coded Elsewhere:</i></b> Mandibular bone fracture due to birth injury (KA45.20)

**NA02.70** Fracture of condylar process of mandible  
Condylar process fractures are defined as fractures running above or posterior to a line confined by the sigmoid notch line and the masseteric notch line. The mandibular condylar process comprises three fracture levels and is subdivided into the head region, the condylar neck, and the condylar base. Fractures of the condylar head show typical fracture lines either within the lateral pole zone, which may lead to loss of vertical height, or medially to the pole zone, with the latter ones usually not compromising the vertical condyle to disc and fossa relation. Fractures of the condylar neck and base can be differentiated according to radiologically based rules with regard to the proportion of the fracture line above and below the level of the sigmoid notch, and are basically subdivided according to the presence or absence of displacement or dislocation. Further parameters for definition are presence or absence of fragmentation, sideward displacement (medially or laterally), angulation of the superior main fragment and fracture-site geometry (e.g. straight or oblique, interfragmentary interdigitation)

**Exclusions:** Fracture of ramus of mandible (NA02.73)  
Fracture of subcondylar process of mandible (NA02.71)

**NA02.71** Fracture of subcondylar process of mandible

**NA02.72** Fracture of coronoid process of mandible

**NA02.73** Fracture of ramus of mandible

**NA02.74** Fracture of angle of mandible

**NA02.75** Fracture of alveolar margin of mandible

**NA02.76** Fracture of symphysis of mandible

**NA02.7Y** Other specified fracture of mandible

**NA02.7Z** Fracture of mandible, unspecified

**NA02.8** **Multiple fractures involving skull or facial bones**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**NA02.Y** **Fracture of other specified skull or facial bones**

**NA02.Z** **Fracture of skull and facial bones, part unspecified**

**NA03** **Dislocation or strain or sprain of joints or ligaments of head**

**NA03.0** **Dislocation of jaw**

Displacement of the mandible, the largest and strongest bone of the face constituting the lower jaw. Dislocation of the temporomandibular joint is a painful condition that occurs when the mandibular condyle becomes fixed in the anterosuperior aspect of the articular eminence.

TMJ dislocation is due to either trauma or, more commonly, excessive opening of the mandible. Spasm of the masseter, temporalis, and internal pterygoid muscles results in trismus, preventing return of the condyle to the temporal fossa.

**Exclusions:** disc displacement (internal derangement of the TMJ) (DA0E.8)

<b>NA03.1</b>	<b>Dislocation of septal cartilage of nose</b>
<b>NA03.3</b>	<b>Strain or sprain of jaw</b> A collective term for muscle and ligament injuries of the tissues associated with the mandible without dislocation or fracture; a joint injury in which some of the fibers of a supporting ligament are ruptured but the continuity of the ligament remains intact. A strain is an overstretching or overexertion of some part of the musculature.
<b>NA03.Y</b>	<b>Dislocation or sprain of other specified joints or ligaments of head</b>
<b>NA03.Z</b>	<b>Dislocation or strain or sprain of joints or ligaments of head, unspecified</b>
<b>NA04</b>	<b>Injury of cranial nerves</b>
	<b>Coded Elsewhere:</b> Birth injury to cranial nerves (KA44.0)
<b>NA04.0</b>	<b>Injury of olfactory nerve</b>
<b>NA04.1</b>	<b>Injury of optic nerve or pathways</b>
<b>NA04.10</b>	Injury of optic nerve, unilateral <b>Coded Elsewhere:</b> Traumatic optic neuropathy (9C40.7)
<b>NA04.11</b>	Injury of optic nerve, bilateral <b>Coded Elsewhere:</b> Traumatic optic neuropathy (9C40.7)
<b>NA04.12</b>	Injury of optic chiasm
<b>NA04.13</b>	Injury of optic tract or pathways, unilateral
<b>NA04.14</b>	Injury of optic tract or pathways, bilateral
<b>NA04.15</b>	Injury of visual cortex, unilateral
<b>NA04.16</b>	Injury of visual cortex, bilateral
<b>NA04.1Y</b>	Other specified injury of optic nerve or pathways
<b>NA04.1Z</b>	Injury of optic nerve or pathways, unspecified
<b>NA04.2</b>	<b>Injury of oculomotor nerve</b>
<b>NA04.3</b>	<b>Injury of trochlear nerve</b>
<b>NA04.4</b>	<b>Injury of trigeminal nerve</b>
<b>NA04.5</b>	<b>Injury of abducent nerve</b>
<b>NA04.6</b>	<b>Injury of facial nerve</b> <b>Coded Elsewhere:</b> Birth injury to facial nerve (KA44.00)
<b>NA04.7</b>	<b>Injury of acoustic nerve</b>
<b>NA04.8</b>	<b>Injury of glossopharyngeal nerve</b>
<b>NA04.9</b>	<b>Injury of vagus nerve</b>

**NA04.A**      **Injury of accessory nerve**

**NA04.B**      **Injury of hypoglossal nerve**

**NA04.Z**      **Injury of cranial nerves, unspecified**

**NA05**      **Injury of blood vessels of head**

**NA05.0**      **Injury of intracranial vessels of head**

**NA05.1**      **Injury of extracranial vessels of head**

**NA05.Z**      **Injury of blood vessels of head, unspecified**

**NA06**      **Injury of eye or orbit**

**Exclusions:**      Orbital fracture (NA02.2)  
                        Injury of optic nerve, unilateral (NA04.10)  
                        Injury of oculomotor nerve (NA04.2)  
                        superficial injury of eyelid (NA00.1)

**Coded Elsewhere:** Birth injury to eye (KA41)

**NA06.0**      **Eyelid trauma**

**Coded Elsewhere:** Contusion of eyelid or periocular area (NA00.11)  
                        Chemical burn of eyelid and periocular area (NE00)

**NA06.00**      **Eyelid avulsion**  
  
This is an injury in which a body structure is forcibly detached from its normal point of insertion by either trauma or surgery. The term most commonly refers to a surface trauma where all layers of the skin have been torn away, exposing the underlying structures (i.e. subcutaneous tissue, muscle, tendons, or bone). This is similar to an abrasion but more severe, where the eyelid can be partially or fully detached from the body.

**NA06.01**      Haematoma of eyelid

**NA06.02**      Oedema of eyelid

**NA06.03**      Retained foreign body in eyelid

**NA06.04**      Open wound of eyelid or periocular area

**NA06.0Y**      Other specified eyelid trauma

**NA06.0Z**      Eyelid trauma, unspecified

**NA06.1**      **Penetrating wound of orbit with or without foreign body**

**Exclusions:**      Retained foreign body following penetrating wound of orbit (NA06.2)

<b>NA06.2</b>	<b>Retained foreign body following penetrating wound of orbit</b>
	<b><i>Exclusions:</i></b> Penetrating wound of orbit with or without foreign body (NA06.1) Traumatic injury to eyeball (NA06.8)
<b>NA06.3</b>	<b>Traumatic orbital haemorrhage</b> This is the loss of blood or blood escaping from the circulatory system, of the cavity or socket of the skull in which the eye and its appendages are situated.
<b>NA06.4</b>	<b>Injury of conjunctiva or corneal abrasion without mention of foreign body</b>
	<b><i>Exclusions:</i></b> Foreign body in cornea (ND70.0) Foreign body in conjunctival sac (ND70.1)
<b>NA06.5</b>	<b>Trauma to the iris sphincter</b> This refers to trauma to the muscle in the part of the eye called the iris. It encircles the pupil of the iris, appropriate to its function as a constrictor of the pupil.
<b>NA06.6</b>	<b>Traumatic injuries of the retina</b> This refers to traumatic injuries of the light-sensitive layer of tissue, lining the inner surface of the eye. The optics of the eye create an image of the visual world on the retina, which serves much the same function as the film in a camera.
<b>NA06.60</b>	Traumatic macular hole <b><i>Exclusions:</i></b> Non-traumatic macular hole (9B75.1)
<b>NA06.61</b>	Choroidal rupture
<b>NA06.62</b>	Commotio retinae
<b>NA06.63</b>	Optic nerve avulsion
<b>NA06.6Y</b>	Other specified traumatic injuries of the retina
<b>NA06.6Z</b>	Traumatic injuries of the retina, unspecified
<b>NA06.7</b>	<b>Traumatic retinal haemorrhage</b>
<b>NA06.8</b>	<b>Traumatic injury to eyeball</b> <b><i>Coded Elsewhere:</i></b> Chemical burn with resulting rupture or destruction of eyeball (NE00)
<b>NA06.80</b>	Retained intraocular magnetic foreign body, unilateral <b><i>Inclusions:</i></b> old magnetic foreign body in eyeball
<b>NA06.81</b>	Retained intraocular nonmagnetic foreign body, unilateral
<b>NA06.82</b>	Closed eyeball trauma, unilateral
<b>NA06.83</b>	Closed eyeball trauma, bilateral
<b>NA06.84</b>	Penetrating wound of eyeball without foreign body, unilateral

<b>NA06.85</b>	Avulsion of eye, unilateral  <b>Inclusions:</b> Traumatic enucleation
<b>NA06.86</b>	Avulsion of eye, bilateral
<b>NA06.87</b>	Ocular laceration or rupture with prolapse or loss of intraocular tissue, unilateral Forcible or traumatic tearing or breaking of the eyeball with protrusion or loss of the tissues and fluids located within the eyeball.
<b>NA06.88</b>	Ocular laceration or rupture with prolapse or loss of intraocular tissue, bilateral
<b>NA06.89</b>	Penetrating injury of eyeball, bilateral
<b>NA06.8A</b>	Perforating injury of eyeball, bilateral
<b>NA06.8B</b>	Retained intraocular magnetic foreign body, bilateral
<b>NA06.8C</b>	Retained intraocular nonmagnetic foreign body, bilateral
<b>NA06.8D</b>	Ocular laceration without prolapse or loss of intraocular tissue, unilateral
<b>NA06.8E</b>	Ocular laceration without prolapse or loss of intraocular tissue, bilateral
<b>NA06.8Y</b>	Other specified traumatic injury to eyeball
<b>NA06.8Z</b>	Traumatic injury to eyeball, unspecified
<b>NA06.9</b>	<b>Contusion of eyeball or orbital tissues</b> Injuries to the eyeball and surrounding tissue resulting in haemorrhage, usually manifested in the skin.  <b>Exclusions:</b> black eye (NA00.11) Contusion of eyelid or periocular area (NA00.11)
<b>NA06.A</b>	<b>Injury of lens</b>  <b>Coded Elsewhere:</b> Contusion of lens (NA06.9) Retained magnetic foreign body in lens, unilateral (NA06.80) Retained nonmagnetic foreign body in lens, unilateral (NA06.81) Ocular laceration or rupture with hernia of lens, unilateral (NA06.87) Penetrating injury of lens without foreign body, unilateral (NA06.84) Penetrating wound of lens with foreign body, unilateral (NA06.8Y)
<b>NA06.Y</b>	<b>Other specified injury of eye or orbit</b>
<b>NA06.Z</b>	<b>Injury of eye or orbit, unspecified</b>

<b>NA07</b>	<b>Intracranial injury</b>
	Damage inflicted on the tissues of the brain as the direct or indirect result of an external force, with or without disruption of structural continuity.
	<b>Coded Elsewhere:</b> Intracranial laceration or haemorrhage due to birth injury (KA40.0)
	Epilepsy due to injuries to the head (8A60.5)
<b>NA07.0</b>	<b>Concussion</b>
	Loss or diminution of consciousness due to injury.
<b>Coding Note:</b>	Code also the causing condition
	<b>Inclusions:</b> Commotio cerebri
<b>NA07.00</b>	Concussion with incomplete loss of consciousness with amnesia
<b>NA07.01</b>	Concussion with incomplete loss of consciousness without amnesia
<b>NA07.02</b>	Concussion with loss of consciousness, short duration of less than 30 minutes
<b>NA07.03</b>	Concussion with loss of consciousness, short duration of 30 minutes to less than one hour
<b>NA07.04</b>	Concussion with loss of consciousness, short duration of one hour to less than 6 hours
<b>NA07.05</b>	Concussion with loss of consciousness, intermediate duration of 6 hours to less than 24 hours
<b>NA07.06</b>	Concussion with loss of consciousness, persisting longer than 24 hours or until discharge or latest assessment
<b>NA07.07</b>	Concussion with loss of consciousness, persisting until death
<b>NA07.08</b>	Concussion with loss of consciousness, duration unspecified or unknown due to effects of therapy
<b>NA07.09</b>	Concussion with loss of consciousness, duration unspecified or unknown due to lack of information
<b>NA07.Y</b>	Other specified concussion
<b>Coding Note:</b>	Code also the causing condition
<b>NA07.0Z</b>	Concussion, unspecified
<b>Coding Note:</b>	Code also the causing condition
<b>NA07.1</b>	<b>Traumatic intracerebral haemorrhage</b>
	<b>Inclusions:</b> traumatic intracerebral haematoma
<b>NA07.2</b>	<b>Traumatic cerebral oedema</b>
	<b>Coded Elsewhere:</b> Cerebral oedema due to birth injury (KA40.1)
<b>NA07.20</b>	Diffuse traumatic cerebral oedema
<b>NA07.21</b>	Focal traumatic cerebral oedema

<b>NA07.2Y</b>	Other specified traumatic cerebral oedema
<b>NA07.2Z</b>	Traumatic cerebral oedema, unspecified
<b>NA07.3</b>	<b>Diffuse brain injury</b>
	<b>Coded Elsewhere:</b> Cerebral contusion due to birth injury (KA40.07)
<b>NA07.30</b>	Diffuse injury of cerebrum
<b>NA07.31</b>	Diffuse injury of cerebellum
	<b>Coded Elsewhere:</b> Cerebellar contusion due to birth injury (KA40.06)
<b>NA07.32</b>	Diffuse injury of brainstem
	<b>Coded Elsewhere:</b> Birth injury to brainstem (KA40.3)
<b>NA07.33</b>	Diffuse injury of multiple parts of brain
<b>NA07.3Y</b>	Other specified diffuse brain injury
<b>NA07.3Z</b>	Unspecified diffuse traumatic brain injury
<b>NA07.4</b>	<b>Focal brain injury</b>
<b>NA07.40</b>	Focal non-haemorrhagic contusion of cerebrum
<b>NA07.41</b>	Focal haemorrhagic contusion of cerebrum
<b>NA07.42</b>	Focal laceration of cerebrum
<b>NA07.43</b>	Multiple focal injuries of cerebrum
<b>NA07.44</b>	Focal non-haemorrhagic contusion of cerebellum
<b>NA07.45</b>	Focal haematoma or haemorrhage of cerebellum
<b>NA07.46</b>	Focal laceration of cerebellum
<b>NA07.47</b>	Multiple focal injuries of cerebellum
<b>NA07.48</b>	Focal non-haemorrhagic contusion of brainstem
<b>NA07.49</b>	Focal haematoma or haemorrhage of brainstem
<b>NA07.4A</b>	Contusion of temporal lobe
<b>NA07.4B</b>	Focal laceration of brainstem
<b>NA07.4C</b>	Focal brain contusion
<b>NA07.4D</b>	Focal brain laceration
<b>NA07.4E</b>	Contusion of parietal lobe
<b>NA07.4F</b>	Contusion of occipital lobe
<b>NA07.4Z</b>	Unspecified focal traumatic brain injury

- NA07.5                    Traumatic epidural haemorrhage**  
**Coded Elsewhere:** Extradural or epidural haemorrhage due to birth injury (KA40.08)
- NA07.6                    Traumatic subdural haemorrhage**  
**Exclusions:** Nontraumatic subdural haemorrhage (8B02)  
**Coded Elsewhere:** Subdural haemorrhage due to birth injury (KA40.00)
- NA07.60                  Acute traumatic subdural haemorrhage**
- NA07.61                  Chronic traumatic subdural haemorrhage**  
**Inclusions:** chronic subdural haematoma
- NA07.6Z                  Traumatic subdural haemorrhage, unspecified whether acute or chronic**
- NA07.7                    Traumatic subarachnoid haemorrhage**  
**Coded Elsewhere:** Subarachnoid haemorrhage due to birth injury (KA40.04)
- NA07.8                    Traumatic haemorrhage in brain tissue**
- NA07.80                  Traumatic haemorrhage in cerebrum white matter**
- NA07.81                  Traumatic haemorrhage in thalamus or basal ganglia**
- NA07.82                  Traumatic haemorrhage in cerebellum**
- NA07.83                  Traumatic haemorrhage in brainstem without specification whether primary or secondary**
- NA07.84                  Traumatic haemorrhage in brainstem, primary**
- NA07.85                  Traumatic haemorrhage in brainstem, secondary**
- NA07.86                  Multiple traumatic haemorrhages**
- NA07.8Y                  Other specified traumatic haemorrhage in brain tissue**
- NA07.8Z                  Traumatic haemorrhage in brain tissue, unspecified**
- NA07.Y                    Other specified intracranial injury**
- NA07.Z                    Intracranial injury, unspecified**
- NA08                      Crushing injury of head**  
Damage inflicted on the tissues of the head as the direct or indirect result of a crushing external force.
- NA08.0                    Crushing injury of brain**
- NA08.1                    Crushing injury of face**
- NA08.2                    Crushing injury of skull**  
**Exclusions:** with crushing injury of brain (NA08.0)
- NA08.3                    Crushed scalp**

<b>NA08.Y</b>	<b>Other specified crushing injury of head</b>
<b>NA08.Z</b>	<b>Crushing injury of head, unspecified</b>
<b>NA09</b>	<b>Traumatic amputation of part of head</b>
	<b><i>Exclusions:</i></b> Decapitation (NA63)
<b>NA09.0</b>	<b>Avulsion of scalp</b>
<b>NA09.1</b>	<b>Traumatic amputation of ear</b>
<b>NA09.10</b>	Traumatic amputation of ear, complete
<b>NA09.11</b>	Traumatic amputation of ear, partial
<b>NA09.1Z</b>	Traumatic amputation of ear, unspecified
<b>NA09.2</b>	<b>Traumatic amputation of nose</b>
<b>NA09.20</b>	Traumatic amputation of nose, complete
<b>NA09.21</b>	Traumatic amputation of nose, partial
<b>NA09.2Z</b>	Traumatic amputation of nose, unspecified
<b>NA09.3</b>	<b>Traumatic amputation of lip</b>
<b>NA09.Y</b>	<b>Other specified traumatic amputation of part of head</b>
<b>NA09.Z</b>	<b>Traumatic amputation of part of head, unspecified</b>
<b>NA0A</b>	<b>Certain specified injuries of head</b>
	<b><i>Coded Elsewhere:</i></b> Cephalohaematoma due to birth injury (KA42.1)
	Decapitation (NA63)
<b>NA0A.0</b>	<b>Complex wounds to the head</b>
	<b><i>Exclusions:</i></b> Decapitation (NA63)
<b>NA0A.00</b>	Complex wounds to the head with retained external material
<b>NA0A.01</b>	Complex wounds to the head with intracranial haemorrhage
<b>NA0A.02</b>	Complex wounds to the head with through and through perforation
<b>NA0A.03</b>	Complex wounds to the head with avulsive loss of part of skull and cranial contents
<b>NA0A.0Y</b>	Other specified complex wounds to the head
<b>NA0A.0Z</b>	Complex wounds to the head, unspecified
<b>NA0A.1</b>	<b>Injury of muscle, fascia or tendon of head</b>
<b>NA0A.10</b>	Strain or sprain of muscle, fascia or tendon of head
<b>NA0A.11</b>	Laceration of muscle, fascia or tendon of head
<b>NA0A.1Y</b>	Other specified injury of muscle, fascia or tendon of head

- NA0A.1Z** Injury of muscle, fascia or tendon of head, unspecified
- NA0A.2** **Traumatic rupture of ear drum**
- NA0A.3** **Multiple injuries of head**
- Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
- NA0A.Y** **Other specified injuries of head**
- NA0B** **Injury of the auricle**
- Exclusions:** Haematoma of auricle (NA00.2)  
Superficial injury of ear auricle (NA00.2)
- NA0C** **Injury of middle or inner ear**
- NA0D** **Injury of teeth or supporting structures**
- Damage inflicted on the surface of the tooth as the direct or indirect result of an external force, with disruption of continuity of the tooth substance, and/or impairment of the tooth-supporting structures (periodontium).
- Exclusions:** Abfraction (DA08.13)  
Dental caries (DA08.0)  
Excessive attrition of teeth (DA08.10)  
Abrasion of teeth (DA08.11)  
Erosion of teeth (DA08.12)  
Chronic dental injuries (DA08.2)  
Nontraumatic fracture of tooth (DA08.3)  
Certain specified disorders of teeth or supporting structures (DA0A)
- NA0D.0** **Injury of hard dental tissues and pulp**
- NA0D.00** Enamel infraction  
An incomplete fracture (crack) of the enamel without loss of tooth substance.
- NA0D.01** Enamel fracture  
Uncomplicated crown fracture. A fracture with loss of tooth substance confined to the enamel.
- NA0D.02** Enamel-dentin fracture  
Uncomplicated crown fracture. A fracture with loss of tooth substance confined to enamel and dentin, but not involving the pulp.
- NA0D.03** Complicated crown fracture  
A fracture involving enamel and dentin, and exposing the pulp.

- NA0D.04** Uncomplicated crown-root fracture  
A fracture involving enamel, dentin and cementum, but not exposing the pulp.
- NA0D.05** Complicated crown-root fracture  
A fracture involving enamel, dentin and cementum, and exposing the pulp.
- NA0D.06** Root fracture  
A fracture involving dentin, cementum and the pulp.
- NA0D.0Y** Other specified injury of hard dental tissues and pulp
- NA0D.0Z** Injury of hard dental tissues and pulp, unspecified
- NA0D.1** **Injury of periodontal tissues**
- NA0D.10** Concussion of periodontal tissue  
An injury to the tooth-supporting structures without abnormal loosening or displacement of the tooth. There is marked reaction to percussion.
- NA0D.11** Subluxation of tooth  
An injury to the tooth-supporting structures with abnormal loosening, but without displacement of the tooth.
- NA0D.12** Extrusive luxation of tooth  
Peripheral dislocation, partial avulsion. Partial displacement of the tooth out of its socket.
- NA0D.13** Lateral luxation of tooth  
Displacement of the tooth in a direction other than axially. This is accompanied by comminution or fracture of the alveolar socket.
- NA0D.14** Intrusive luxation of tooth  
Central dislocation. Displacement of the tooth into the alveolar bone. This injury is accompanied by comminution or fracture of the alveolar socket.
- NA0D.15** Avulsion of tooth  
Exarticulation. Complete displacement of the tooth out of its socket.
- NA0D.1Y** Other specified injury of periodontal tissues
- NA0D.1Z** Injury of periodontal tissues, unspecified
- NA0D.Y** **Other specified injury of teeth or supporting structures**
- NA0D.Z** **Injury of teeth or supporting structures, unspecified**

**NA0Z      Injuries to the head, unspecified**

**Coding Note:** This Block includes the following:

- injuries of face [any part]
- injuries of gum
- injuries of jaw
- injuries of oral cavity
- injuries of palate
- injuries of periocular area
- injuries of scalp
- injuries of temporomandibular joint area
- injuries of tongue
- injuries of tooth

**Injuries to the neck (NA20-NA6Z)**

**Coding Note:** This Block includes the following:

- injuries of nape
- injuries of supraclavicular region
- injuries of throat

**Exclusions:**      injury of spinal cord NOS (ND51)

                  Frostbite (NE40-NE4Z)

                  injury of trunk NOS (ND50-ND5Z)

                  fracture of spine NOS (ND50)

                  effects of foreign body in: larynx (ND72.3)

                  effects of foreign body in: oesophagus (ND73.1)

                  effects of foreign body in: pharynx (ND72.2)

                  effects of foreign body in: trachea (ND72.4)

                  burns and corrosions (ND90)

**NA20****Superficial injury of neck**

**Coded Elsewhere:** Sequelae of superficial injury or open wound of neck or trunk (NF2Y)

**NA20.0      Abrasion of throat**

**NA20.1      Contusion of throat**

**NA20.2      Other or unspecified superficial injuries of throat**

**NA20.3      Multiple superficial injuries of neck**

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

<b>NA20.Y</b>	<b>Other specified superficial injury of neck</b>
<b>NA20.Z</b>	<b>Superficial injury of neck, unspecified</b>
<b>NA21</b>	<b>Open wound of neck</b>
	<b><i>Inclusions:</i></b> Decapitation (NA63)
<b>NA21.0</b>	<b>Laceration without foreign body of neck</b>
	<b><i>Inclusions:</i></b> laceration of skin of neck
<b>NA21.1</b>	<b>Laceration with foreign body of neck</b>
<b>NA21.2</b>	<b>Puncture wound without foreign body of neck</b>
<b>NA21.3</b>	<b>Puncture wound with foreign body of neck</b>
<b>NA21.4</b>	<b>Open bite of neck</b>
<b>NA21.5</b>	<b>Multiple open wounds of neck</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NA21.Y</b>	<b>Other specified open wound of neck</b>
<b>NA21.Z</b>	<b>Open wound of neck, unspecified</b>
<b>NA22</b>	<b>Fracture of neck</b>
	<b><i>Inclusions:</i></b>
	fracture of cervical neural arch
	fracture of cervical spine
	fracture of cervical spinous process
	fracture of cervical transverse process
	fracture of cervical vertebra
	fracture of cervical vertebral arch
<b>NA22.0</b>	<b>Fracture of first cervical vertebra</b>
<b>NA22.00</b>	Fracture of first cervical vertebra, burst fracture
<b>NA22.01</b>	Fracture of posterior arch of first cervical vertebra
<b>NA22.02</b>	Fracture of lateral mass of first cervical vertebra
<b>NA22.03</b>	Other fracture of first cervical vertebra
<b>NA22.0Z</b>	Fracture of first cervical vertebra, unspecified
<b>NA22.1</b>	<b>Fracture of second cervical vertebra</b>
<b>NA22.10</b>	Traumatic spondylolisthesis of second cervical vertebra, type III
<b>NA22.11</b>	Other traumatic spondylolisthesis of second cervical vertebra
<b>NA22.12</b>	Fracture of odontoid process

<b>NA22.13</b>	Other fracture of second cervical vertebra
<b>NA22.1Z</b>	Fracture of second cervical vertebra, unspecified
<b>NA22.2</b>	<b>Fracture of other specified cervical vertebra</b>
<b>NA22.3</b>	<b>Multiple fractures of cervical spine</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NA22.Z</b>	<b>Fracture of neck, unspecified</b>
<b>NA23</b>	<b>Dislocation or strain or sprain of joints or ligaments at neck level</b>
<b>NA23.0</b>	<b>Traumatic rupture of cervical intervertebral disc</b>
<b>NA23.1</b>	<b>Dislocation of cervical vertebra</b> Displacement of one or more bones of the cervical spine
<b>NA23.10</b>	Cranio-cervical dissociation
<b>NA23.11</b>	Atlanto-axial dislocation
<b>NA23.12</b>	Dislocation of other specified cervical vertebra
<b>NA23.1Z</b>	Dislocation of cervical vertebra, unspecified
<b>NA23.2</b>	<b>Dislocation of other or unspecified parts of neck</b>
<b>NA23.3</b>	<b>Multiple dislocations of neck</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NA23.4</b>	<b>Strain or sprain of cervical spine</b> A collective term for muscle and ligament injuries of the tissues associated with the cervical spine without dislocation or fracture; a joint injury in which some of the fibers of a supporting ligament are ruptured but the continuity of the ligament remains intact. A strain is an overstretching or overexertion of some part of the musculature.
	<b>Inclusions:</b> Whiplash injury
<b>NA23.40</b>	Acute whiplash associated disorder with complaint of neck pain, stiffness or tenderness only
	<b>Exclusions:</b> Chronic whiplash injury associated pain (MG30.20)
<b>NA23.41</b>	Acute whiplash associated disorder with complaint of neck pain with musculoskeletal signs
	<b>Exclusions:</b> Chronic whiplash injury associated pain (MG30.20)
<b>NA23.42</b>	Acute whiplash associated disorder with complaint of neck pain with neurological signs
	<b>Exclusions:</b> Chronic whiplash injury associated pain (MG30.20)
<b>NA23.4Y</b>	Other specified strain or sprain of cervical spine

<b>NA23.4Z</b>	Strain or sprain of cervical spine, unspecified
<b>NA23.5</b>	<b>Strain or sprain of thyroid region</b>
<b>NA23.Y</b>	<b>Other specified dislocation or strain or sprain of joints or ligaments at neck level</b>
<b>NA23.Z</b>	<b>Dislocation or strain or sprain of joints or ligaments at neck level, unspecified</b>

Injury of nerves or spinal cord at neck level (NA30-NA4Z)

Injury of spinal cord at neck level (NA30-NA3Z)

<b>NA30</b>	<b>Concussion or oedema of cervical spinal cord</b>
<b>NA31</b>	<b>Certain specified injuries of cervical spinal cord</b>
<b>NA31.0</b>	<b>Complete lesion of cervical spinal cord</b>
<b>NA31.1</b>	<b>Central cord syndrome of cervical spinal cord</b>
<b>NA31.2</b>	<b>Anterior cord syndrome of cervical spinal cord</b>
<b>NA31.3</b>	<b>Posterior cord syndrome of cervical spinal cord</b>
<b>NA31.4</b>	<b>Brown-Sequard syndrome of cervical spinal cord</b>
<b>NA31.5</b>	<b>Other incomplete cord syndrome of cervical spinal cord</b>
<b>NA3Z</b>	<b>Injury of cervical spinal cord, unspecified</b>

Injury of nerves at neck level (NA40-NA4Z)

<b>NA40</b>	<b>Injury of nerve root of cervical spine</b>
<b>NA41</b>	<b>Injury of brachial plexus</b>
	<b>Coded Elsewhere:</b> Brachial plexus palsy in newborn (KA44.1)
<b>NA41.0</b>	<b>Injury of brachial plexus cord</b>
<b>NA41.1</b>	<b>Injury of brachial plexus division</b>
<b>NA41.2</b>	<b>Injury of brachial plexus trunk</b>
<b>NA41.Y</b>	<b>Other specified injury of brachial plexus</b>
<b>NA41.Z</b>	<b>Injury of brachial plexus, unspecified</b>
<b>NA42</b>	<b>Injury of peripheral nerves of neck</b>
<b>NA42.0</b>	<b>Injury of supraclavicular nerve</b>
<b>NA42.1</b>	<b>Injury to anterior cutaneous nerve of neck</b>
<b>NA42.Y</b>	<b>Injury of other specified peripheral nerves of neck</b>

<b>NA42.Z</b>	<b>Injury of peripheral nerves of neck, unspecified</b>
<b>NA43</b>	<b>Injury of cervical sympathetic nerves</b>
<b>NA44</b>	<b>Injury of phrenic nerve</b> <i>Coded Elsewhere:</i> Phrenic nerve paralysis due to birth injury (KA44.2)
<b>NA4Y</b>	<b>Injury of other specified nerves at neck level</b>
<b>NA4Z</b>	<b>Injury of nerves at neck level, unspecified</b>
<b>NA60</b>	<b>Injury of blood vessels at neck level</b>
<b>NA60.0</b>	<b>Injury of carotid artery</b>
<b>NA60.00</b>	Laceration of carotid artery, minor  <i>Inclusions:</i> incomplete transection of carotid artery laceration of carotid artery NOS superficial laceration of carotid artery
<b>NA60.01</b>	Laceration of carotid artery, major  <i>Inclusions:</i> complete transection of carotid artery traumatic rupture of carotid artery
<b>NA60.0Y</b>	Other specified injury of carotid artery
<b>NA60.0Z</b>	Injury of carotid artery, unspecified
<b>NA60.1</b>	<b>Injury of vertebral artery</b>
<b>NA60.10</b>	Laceration of vertebral artery, minor  <i>Inclusions:</i> incomplete transection of vertebral artery laceration of vertebral artery NOS superficial laceration of vertebral artery
<b>NA60.11</b>	Laceration of vertebral artery, major  <i>Inclusions:</i> complete transection of vertebral artery traumatic rupture of vertebral artery
<b>NA60.1Y</b>	Other specified injury of vertebral artery
<b>NA60.1Z</b>	Injury of vertebral artery, unspecified
<b>NA60.2</b>	<b>Injury of external jugular vein</b>
<b>NA60.20</b>	Laceration of external jugular vein, minor  <i>Inclusions:</i> incomplete transection of external jugular vein laceration of external jugular vein NOS superficial laceration of external jugular vein

<b>NA60.21</b>	Laceration of external jugular vein, major
	<i>Inclusions:</i>
	complete transection of external jugular vein
	traumatic rupture of external jugular vein
<b>NA60.2Y</b>	Other specified injury of external jugular vein
<b>NA60.2Z</b>	Injury of external jugular vein, unspecified
<b>NA60.3</b>	<b>Injury of internal jugular vein</b>
<b>NA60.30</b>	Laceration of internal jugular vein, minor
	<i>Inclusions:</i>
	incomplete transection of internal jugular vein
	laceration of internal jugular vein NOS
	superficial laceration of internal jugular vein
<b>NA60.31</b>	Laceration of internal jugular vein, major
	<i>Inclusions:</i>
	complete transection of internal jugular vein
	traumatic rupture of internal jugular vein
<b>NA60.3Y</b>	Other specified injury of internal jugular vein
<b>NA60.3Z</b>	Injury of internal jugular vein, unspecified
<b>NA60.4</b>	<b>Injury of multiple blood vessels at neck level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NA60.Y</b>	<b>Injury of other specified blood vessels at neck level</b>
<b>NA60.Z</b>	<b>Injury of blood vessels at neck level, unspecified</b>
<b>NA61</b>	<b>Injury of muscle, fascia or tendon at neck level</b>
<b>NA61.0</b>	<b>Strain or sprain of muscle, fascia or tendon at neck level</b>
<b>NA61.1</b>	<b>Laceration of muscle, fascia or tendon at neck level</b>
<b>NA61.Y</b>	<b>Other specified injury of muscle, fascia or tendon at neck level</b>
<b>NA61.Z</b>	<b>Injury of muscle, fascia or tendon at neck level, unspecified</b>
<b>NA62</b>	<b>Crushing injury of neck</b>
<b>NA62.0</b>	<b>Crushing injury of larynx or trachea</b>
<b>NA62.Y</b>	<b>Crushing injury of other specified site of neck</b>
<b>NA62.Z</b>	<b>Crushing injury of neck, unspecified</b>
<b>NA63</b>	<b>Traumatic amputation at neck level</b>

**NA64**

### **Multiple injuries of neck**

**Coding Note:**

Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

**NA6Y**

### **Other specified injuries to the neck**

**Coding Note:**

This Block includes the following:

- injuries of nape
- injuries of supraclavicular region
- injuries of throat

**NA6Z**

### **Injuries to the neck, unspecified**

**Coding Note:**

This Block includes the following:

- injuries of nape
- injuries of supraclavicular region
- injuries of throat

## **Injuries to the thorax (NA80-NB3Z)**

**Exclusions:**

- injuries of spinal cord NOS (ND51)
- injuries of shoulder (NC10-NC1Z)
- Injuries of trunk NOS (ND51)
- insect bite or sting, venomous (NE61)
- fracture of spine NOS (ND50)
- injuries of clavicle (NC10-NC1Z)
- injuries of scapular region (NC10-NC1Z)
- Frostbite (NE40-NE4Z)
- injuries of axilla (NC10-NC1Z)
- effects of foreign body in lung (ND72)
- effects of foreign body in bronchus (ND72.5)
- Foreign body in trachea (ND72.4)
- Foreign body in oesophagus (ND73.1)
- Burns (ND90-NE2Z)

**Coded Elsewhere:** Birth injury of thorax (KA45.3)

**NA80**

### **Superficial injury of thorax**

Damage inflicted on the surface or shallow tissues of the thorax as the direct or indirect result of an external force, with or without disruption of structural continuity.

**Coded Elsewhere:** Sequelae of superficial injury or open wound of neck or trunk (NF2Y)

<b>NA80.0</b>	<b>Abrasion of breast</b>
<b>NA80.1</b>	<b>Contusion of breast</b>
<b>NA80.2</b>	<b>Other or unspecified superficial injuries of breast</b>
<b>NA80.3</b>	<b>Other superficial injuries of front wall of thorax</b>
<b>NA80.4</b>	<b>Other superficial injuries of back wall of thorax</b>
<b>NA80.5</b>	<b>Abrasion of thorax</b>
<b>NA80.6</b>	<b>Contusion of thorax</b>
<b>NA80.7</b>	<b>Multiple superficial injuries of thorax</b>

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

<b>NA80.Y</b>	<b>Other specified superficial injury of thorax</b>
<b>NA80.Z</b>	<b>Superficial injury of thorax, unspecified</b>

### **NA81 Open wound of thorax**

**Inclusions:** open wound thoracic wall NOS

**Exclusions:** Traumatic pneumothorax (NB32.0)

Traumatic haemothorax (NB32.1)

Traumatic haemopneumothorax (NB32.2)

<b>NA81.0</b>	<b>Laceration without foreign body of thorax</b>
	<b>Inclusions:</b> laceration of skin of thorax

<b>NA81.1</b>	<b>Laceration with foreign body of thorax</b>
---------------	---

<b>NA81.2</b>	<b>Puncture wound without foreign body of thorax</b>
---------------	--

<b>NA81.3</b>	<b>Puncture wound with foreign body of thorax</b>
---------------	---

<b>NA81.4</b>	<b>Open bite of thorax</b>
---------------	----------------------------

<b>NA81.5</b>	<b>Multiple open wounds of thoracic wall</b>
---------------	--

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

<b>NA81.Y</b>	<b>Other specified open wound of thorax</b>
<b>NA81.Z</b>	<b>Open wound of thorax, unspecified</b>

### **NA82 Fracture of rib, sternum or thoracic spine**

**Exclusions:** Fracture of scapula (NC12.1)

Fracture of clavicle (NC12.0)

<b>NA82.0</b>	<b>Fracture of thoracic vertebra</b>
---------------	--------------------------------------

<b>NA82.1</b>	<b>Multiple fractures of thoracic spine</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NA82.2</b>	<b>Fracture of sternum</b>
<b>NA82.3</b>	<b>Fracture of rib</b>
<b>NA82.30</b>	Fracture of rib, posterior or posterior and lateral
<b>NA82.3Y</b>	Other specified fracture of rib
<b>NA82.3Z</b>	Fracture of rib, unspecified
<b>NA82.4</b>	<b>Multiple fractures of ribs</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NA82.5</b>	<b>Flail chest</b>
<b>NA82.Y</b>	<b>Other specified fracture of rib, sternum or thoracic spine</b>
<b>NA82.Z</b>	<b>Fracture of rib, sternum or thoracic spine, unspecified</b>
<b>NA83</b>	<b>Dislocation or strain or sprain of joints or ligaments of thorax</b>
	<b>Exclusions:</b> Intervertebral disc degeneration of thoracic spine with prolapsed disc (FA80.5)
<b>NA83.0</b>	<b>Traumatic rupture of thoracic intervertebral disc</b>
<b>NA83.1</b>	<b>Dislocation of thoracic vertebra</b>
<b>NA83.2</b>	<b>Dislocation of other or unspecified parts of thorax</b>
<b>NA83.3</b>	<b>Strain or sprain of ligaments of thoracic spine</b>
<b>NA83.4</b>	<b>Strain or sprain of ribs or sternum</b>
<b>NA83.40</b>	Strain or sprain of sternum
<b>NA83.41</b>	Strain or sprain of sterno-clavicular joint or ligament
<b>NA83.42</b>	Strain or sprain of chondro-sternal joint Aberrant biomechanical functions of the joints between the ribs and the sternum, which may be as a result of local disease, systemic disease, postural strain or trauma.
<b>NA83.4Y</b>	Strain or sprain of other specified site of ribs or sternum
<b>NA83.4Z</b>	Strain or sprain of ribs or sternum, unspecified
<b>NA83.Y</b>	<b>Other specified dislocation or strain or sprain of joints or ligaments of thorax</b>
<b>NA83.Z</b>	<b>Dislocation or strain or sprain of joints or ligaments of thorax, unspecified</b>

Injury of nerves or spinal cord at thorax level (NA90-NB2Z)

**Exclusions:** Injury of brachial plexus (NA41)

Injury of spinal cord at thorax level (NA90-NA9Z)

<b>NA90</b>	<b>Concussion or oedema of thoracic spinal cord</b>
<b>NA91</b>	<b>Certain specified injuries of thoracic spinal cord</b>
<b>NA91.0</b>	<b>Complete lesion of thoracic spinal cord</b>
<b>NA91.1</b>	<b>Central cord syndrome of thoracic spinal cord</b>
<b>NA91.2</b>	<b>Anterior cord syndrome of thoracic spinal cord</b>
<b>NA91.3</b>	<b>Posterior cord syndrome of thoracic spinal cord</b>
<b>NA91.4</b>	<b>Brown-Séquard syndrome of thoracic spinal cord</b>
<b>NA91.5</b>	<b>Other incomplete cord syndrome of thoracic spinal cord</b>
<b>NA9Z</b>	<b>Injury of thoracic spinal cord, unspecified</b>

Injury of nerves at thorax level (NB00-NB0Y)

<b>NB00</b>	<b>Injury of nerve root of thoracic spine</b>
<b>NB01</b>	<b>Injury of peripheral nerves of thorax</b>
<b>NB02</b>	<b>Injury of thoracic sympathetic nerves</b>
<b>NB0Y</b>	<b>Injury of other specified nerves at thorax level</b>
<b>NB2Y</b>	<b>Other specified injury of nerves or spinal cord at thorax level</b>
<b>NB2Z</b>	<b>Injury of nerves or spinal cord at thorax level, unspecified</b>
<b>NB30</b>	<b>Injury of blood vessels of thorax</b>
<b>NB30.0</b>	<b>Injury of thoracic aorta</b>
<b>NB30.00</b>	Minor laceration of thoracic aorta  <b>Inclusions:</b> incomplete transection of thoracic aorta laceration of thoracic aorta NOS superficial laceration of thoracic aorta
<b>NB30.01</b>	Major laceration of thoracic aorta  <b>Inclusions:</b> complete transection of thoracic aorta traumatic rupture of thoracic aorta
<b>NB30.0Y</b>	Other specified injury of thoracic aorta
<b>NB30.0Z</b>	Injury of thoracic aorta, unspecified

<b>NB30.1</b>	<b>Injury of innominate or subclavian artery</b>
<b>NB30.10</b>	Minor laceration of innominate or subclavian artery  <i>Inclusions:</i> incomplete transection of innominate or subclavian artery laceration of innominate or subclavian artery NOS superficial laceration of innominate or subclavian artery
<b>NB30.11</b>	Major laceration of innominate or subclavian artery  <i>Inclusions:</i> complete transection of innominate or subclavian artery traumatic rupture of innominate or subclavian artery
<b>NB30.1Y</b>	Other specified injury of innominate or subclavian artery
<b>NB30.1Z</b>	Injury of innominate or subclavian artery, unspecified
<b>NB30.2</b>	<b>Injury of superior vena cava</b>
<b>NB30.20</b>	Minor laceration of superior vena cava  <i>Inclusions:</i> incomplete transection of superior vena cava laceration of superior vena cava NOS superficial laceration of superior vena cava
<b>NB30.21</b>	Major laceration of superior vena cava  <i>Inclusions:</i> complete transection of superior vena cava traumatic rupture of superior vena cava
<b>NB30.2Y</b>	Other specified injury of superior vena cava
<b>NB30.2Z</b>	Injury of superior vena cava, unspecified
<b>NB30.3</b>	<b>Injury of innominate or subclavian vein</b>
<b>NB30.30</b>	Minor laceration of innominate or subclavian vein  <i>Inclusions:</i> incomplete transection of innominate or subclavian vein laceration of innominate or subclavian vein NOS superficial laceration of innominate or subclavian vein
<b>NB30.31</b>	Major laceration of innominate or subclavian vein  <i>Inclusions:</i> complete transection of innominate or subclavian vein traumatic rupture of innominate or subclavian vein
<b>NB30.3Y</b>	Other specified injury of innominate or subclavian vein
<b>NB30.3Z</b>	Injury of innominate or subclavian vein, unspecified
<b>NB30.4</b>	<b>Injury of pulmonary blood vessels</b>

<b>NB30.40</b>	Minor laceration of pulmonary blood vessels
	<b>Inclusions:</b>
	incomplete transection of pulmonary blood vessels
	laceration of pulmonary blood vessels NOS
	superficial laceration of pulmonary blood vessels
<b>NB30.41</b>	Major laceration of pulmonary blood vessels
	<b>Inclusions:</b>
	complete transection of pulmonary blood vessels
	traumatic rupture of pulmonary blood vessels
<b>NB30.4Y</b>	Other specified injury of pulmonary blood vessels
<b>NB30.4Z</b>	Injury of pulmonary blood vessels, unspecified
<b>NB30.5</b>	<b>Injury of intercostal blood vessels</b>
<b>NB30.50</b>	Laceration of intercostal blood vessels
<b>NB30.5Y</b>	Other specified injury of intercostal blood vessels
<b>NB30.5Z</b>	Injury of intercostal blood vessels, unspecified
<b>NB30.6</b>	<b>Injury of multiple blood vessels of thorax</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NB30.Y</b>	<b>Injury of other specified blood vessels of thorax</b>
<b>NB30.Z</b>	<b>Injury of unspecified blood vessels of thorax</b>
<b>NB31</b>	<b>Injury of heart</b>
<b>NB31.0</b>	<b>Injury of heart with haemopericardium</b>
<b>NB31.00</b>	Contusion of heart with haemopericardium
<b>NB31.01</b>	Minor laceration of heart with haemopericardium
	<b>Inclusions:</b>
	laceration of heart without penetration of heart chamber
<b>NB31.02</b>	Moderate laceration of heart with haemopericardium
	<b>Inclusions:</b>
	laceration of heart with penetration of heart chamber
<b>NB31.03</b>	Major laceration of heart with haemopericardium
	<b>Inclusions:</b>
	laceration of heart with penetration of multiple heart chambers
<b>NB31.0Y</b>	Other specified injury of heart with haemopericardium
<b>NB31.0Z</b>	Injury of heart with haemopericardium, unspecified
<b>NB31.1</b>	<b>Injury of heart without haemopericardium</b>
<b>NB31.10</b>	Contusion of heart without haemopericardium
<b>NB31.11</b>	Laceration of heart without haemopericardium
<b>NB31.1Y</b>	Other specified injury of heart without haemopericardium

<b>NB31.1Z</b>	Injury of heart without haemopericardium, unspecified
<b>NB31.2</b>	<b>Injury of heart, unspecified without open wound into thoracic cavity</b>
<b>NB31.3</b>	<b>Injury of heart, unspecified with open wound into thoracic cavity</b>
<b>NB31.4</b>	<b>Injury of heart valve</b>
<b>NB31.40</b>	Injury to mitral valve
<b>NB31.4Y</b>	Injury of other specified heart valve
<b>NB31.4Z</b>	Injury of heart valve, unspecified
<b>NB31.Y</b>	<b>Other specified injury of heart</b>
<b>NB31.Z</b>	<b>Injury of heart, unspecified</b>

**NB32      Injury of other or unspecified intrathoracic organs**

***Exclusions:***      injury of cervical oesophagus (NA20-NA6Z)

                        injury of trachea (cervical) (NA20-NA6Z)

***Coded Elsewhere:*** Oesophagitis due to external causes (DA24.2)

                        Injury of oesophagus (DA20.3Y)

<b>NB32.0</b>	<b>Traumatic pneumothorax</b>
<b>NB32.1</b>	<b>Traumatic haemothorax</b>
<b>NB32.2</b>	<b>Traumatic haemopneumothorax</b>
<b>NB32.3</b>	<b>Certain injuries of lung</b>
<b>NB32.30</b>	Contusion of lung
<b>NB32.31</b>	Laceration of lung
<b>NB32.32</b>	Inhalation injury of lung
<b>NB32.33</b>	Primary blast injury of lung
<b>NB32.3Y</b>	Other injury of lung
<b>NB32.3Z</b>	Injury of lung, unspecified
<b>NB32.4</b>	<b>Injury of bronchus</b>
<b>NB32.40</b>	Contusion of bronchus
<b>NB32.41</b>	Minor laceration of bronchus

***Inclusions:***      laceration of bronchus less than 1 cm  
                        laceration of bronchus NOS

<b>NB32.42</b>	Moderate laceration of bronchus
	<b>Inclusions:</b> laceration of bronchus 1 to 3 cm
	<b>Exclusions:</b> Multiple moderate lacerations of bronchus (NB32.43)
<b>NB32.43</b>	Major laceration of bronchus
	<b>Inclusions:</b> laceration of bronchus greater than 3 cm
	massive laceration of bronchus
	multiple moderate lacerations of bronchus
	stellate laceration of bronchus
<b>NB32.4Y</b>	Other specified injury of bronchus
<b>NB32.4Z</b>	Injury of bronchus, unspecified
<b>NB32.5</b>	<b>Injury of thoracic trachea</b>
	<b>Coded Elsewhere:</b> Tracheal haemorrhage of newborn due to airway trauma (KB2G)
<b>NB32.50</b>	Contusion of thoracic trachea
<b>NB32.51</b>	Minor laceration of thoracic trachea
	<b>Inclusions:</b> laceration of thoracic trachea less than 1 cm
	laceration of thoracic trachea NOS
<b>NB32.52</b>	Moderate laceration of thoracic trachea
	<b>Inclusions:</b> laceration of thoracic trachea 1 to 3 cm
	<b>Exclusions:</b> Multiple moderate lacerations of thoracic trachea (NB32.53)
<b>NB32.53</b>	Major laceration of thoracic trachea
	<b>Inclusions:</b> laceration of thoracic trachea greater than 3 cm
	massive laceration of thoracic trachea
	multiple moderate lacerations of thoracic trachea
	stellate laceration of thoracic trachea
<b>NB32.5Y</b>	Other specified injury of thoracic trachea
<b>NB32.5Z</b>	Injury of thoracic trachea, unspecified
<b>NB32.6</b>	<b>Injury of pleura</b>
<b>NB32.60</b>	Laceration of pleura
<b>NB32.6Y</b>	Other specified injury of pleura
<b>NB32.6Z</b>	Injury of pleura, unspecified

<b>NB32.7</b>	<b>Multiple injuries of intrathoracic organs</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
<b>NB32.Y</b>	<b>Other specified injury of other or unspecified intrathoracic organs</b>
<b>NB32.Z</b>	<b>Unspecified injury of unspecified intrathoracic organs</b>
<b>NB33</b>	<b>Crushing injury of thorax or traumatic amputation of part of thorax</b>
<b>NB33.0</b>	<b>Crushed chest</b>
	<b>Exclusions:</b> Flail chest (NA82.5)
<b>NB33.1</b>	<b>Traumatic amputation of breast</b>
<b>NB33.10</b>	Traumatic amputation of part of breast
<b>NB33.11</b>	Traumatic amputation of entire breast
<b>NB33.1Z</b>	Traumatic amputation of breast, unspecified
<b>NB33.2</b>	<b>Traumatic amputation of other or unspecified part of thorax</b>
	<b>Exclusions:</b> transection of thorax (ND35)
<b>NB34</b>	<b>Injury of muscle, fascia or tendon at thorax level</b>
<b>NB34.0</b>	<b>Strain or sprain of muscle, fascia or tendon at thorax level</b>
<b>NB34.1</b>	<b>Laceration of muscle, fascia or tendon at thorax level</b>
<b>NB34.Y</b>	<b>Other specified injury of muscle, fascia or tendon at thorax level</b>
<b>NB34.Z</b>	<b>Injury of muscle, fascia or tendon at thorax level, unspecified</b>
<b>NB35</b>	<b>Multiple injuries of thorax</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
<b>NB3Y</b>	<b>Other specified injuries to the thorax</b>
<b>NB3Z</b>	<b>Injuries to the thorax, unspecified</b>

## Injuries to the abdomen, lower back, lumbar spine or pelvis (NB50-NB9Z)

**Exclusions:**

- insect bite or sting, venomous (NE61)
- Foreign body in anus or rectum (ND73.5)
- Foreign body in genitourinary tract (ND74)
- Burns (ND90-NE2Z)
- Foreign body in colon (ND73.4)
- Fracture of spine, level unspecified (ND50)
- injuries of trunk NOS (ND51)
- injuries of spinal cord NOS (ND51)
- Frostbite (NE40-NE4Z)
- Foreign body in stomach (ND73.2)
- Foreign body in small intestine (ND73.3)

### NB50

#### **Superficial injury of abdomen, lower back or pelvis**

Damage inflicted on the surface or shallow tissues of the abdomen, lower back and pelvis as the direct or indirect result of an external force, with or without disruption of structural continuity.

**Exclusions:** superficial injury of hip (NC70)

**Coded Elsewhere:** Sequelae of superficial injury or open wound of neck or trunk (NF2Y)

<b>NB50.0</b>	<b>Abrasions of lower back or pelvis</b>
<b>NB50.1</b>	<b>Contusions of lower back or pelvis</b>
<b>NB50.2</b>	<b>Abrasions of abdominal wall</b>
<b>NB50.3</b>	<b>Contusions of abdominal wall</b>
<b>NB50.4</b>	<b>Abrasions of external genital organs</b> <b>Coded Elsewhere:</b> Birth injury to external genitalia (KA43.1)
<b>NB50.5</b>	<b>Contusions of external genital organs</b> <b>Coded Elsewhere:</b> Birth injury to external genitalia (KA43.1)
<b>NB50.6</b>	<b>Multiple superficial injuries of abdomen, lower back or pelvis</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NB50.Y</b>	<b>Other specified superficial injury of abdomen, lower back or pelvis</b>
<b>NB50.Z</b>	<b>Superficial injury of abdomen, lower back or pelvis, unspecified</b>
<b>NB51</b>	<b>Open wound of abdomen, lower back or pelvis</b>
	<b>Exclusions:</b>
	open wound of hip (NC71)
	traumatic amputation of part of abdomen, lower back and pelvis (NB93)

<b>NB51.0</b>	<b>Laceration without foreign body of abdomen, lower back or pelvis</b>
	<b>Inclusions:</b> laceration of skin of abdomen, lower back or pelvis
<b>NB51.1</b>	<b>Laceration with foreign body of abdomen, lower back or pelvis</b>
<b>NB51.2</b>	<b>Puncture wound without foreign body of abdomen, lower back or pelvis</b>
<b>NB51.3</b>	<b>Puncture wound with foreign body of abdomen, lower back or pelvis</b>
<b>NB51.4</b>	<b>Open bite of abdomen, lower back or pelvis</b>
<b>NB51.5</b>	<b>Multiple open wounds of abdomen, lower back or pelvis</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NB51.Y</b>	<b>Other specified open wound of abdomen, lower back or pelvis</b>
<b>NB51.Z</b>	<b>Open wound of abdomen, lower back or pelvis, unspecified</b>
<b>NB52</b>	<b>Fracture of lumbar spine or pelvis</b>
	Broken bone in the lumbar spine or pelvis.
	<b>Exclusions:</b> fracture of hip NOS (NC72.2)
<b>NB52.0</b>	<b>Fracture of lumbar vertebra</b>
<b>NB52.1</b>	<b>Fracture of pelvic bone without disruption of posterior arch of pelvic ring</b>
<b>NB52.10</b>	Fracture of sacrum without disruption of pelvic ring
<b>NB52.11</b>	Fracture of coccyx
<b>NB52.12</b>	Fracture of ilium without disruption of pelvic ring
<b>NB52.13</b>	Fracture of acetabulum without disruption of pelvic ring
<b>NB52.14</b>	Fracture of pubis without disruption of pelvic ring
<b>NB52.15</b>	Fracture of ischium without disruption of pelvic ring
<b>NB52.1Y</b>	Fracture of other specified pelvic bone without disruption of posterior arch of pelvic ring
<b>NB52.1Z</b>	Fracture of unspecified pelvic bone without disruption of posterior arch of pelvic ring
<b>NB52.2</b>	<b>Fracture of the pelvic ring with incomplete disruption of posterior arch</b>
<b>NB52.3</b>	<b>Fracture of pelvic ring with complete disruption of posterior arch</b>
<b>NB52.4</b>	<b>Multiple fractures of lumbar spine or pelvis</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NB52.Y</b>	<b>Other specified fracture of lumbar spine or pelvis</b>
<b>NB52.Z</b>	<b>Fracture of lumbar spine or pelvis, unspecified</b>

<b>NB53</b>	<b>Dislocation or strain or sprain of joints or ligaments of lumbar spine or pelvis</b>
	<b>Exclusions:</b> Dislocation or strain or sprain of joint or ligaments of hip (NC73)
	Obstetric damage to pelvic joints or ligaments (JB0A.7)
<b>NB53.0</b>	<b>Traumatic rupture of lumbar intervertebral disc</b>
<b>NB53.1</b>	<b>Dislocation of lumbar vertebra</b>
<b>NB53.2</b>	<b>Dislocation of sacroiliac or sacrococcygeal joint without disruption of pelvic ring</b>
<b>NB53.3</b>	<b>Dislocation of other or unspecified parts of lumbar spine or pelvis without disruption of pelvic ring</b>
<b>NB53.4</b>	<b>Traumatic rupture of symphysis pubis without disruption of pelvic ring</b>
<b>NB53.5</b>	<b>Strain or sprain of lumbar spine</b> A collective term for muscle and ligament injuries of the tissues associated with the lumbar spine without dislocation or fracture; a joint injury in which some of the fibers of a supporting ligament are ruptured but the continuity of the ligament remains intact. A strain is an overstretching or overexertion of some part of the musculature.
<b>NB53.6</b>	<b>Strain or sprain of sacroiliac joint</b> Aberrant biomechanical functions of the joints between the ilia and the sacrum, which may be as a result of local disease, systemic disease, postural strain or trauma.
<b>NB53.Y</b>	<b>Other specified dislocation or strain or sprain of joints or ligaments of lumbar spine or pelvis</b>
<b>NB53.Z</b>	<b>Dislocation or strain or sprain of joints or ligaments of lumbar spine or pelvis, unspecified</b>

Injury of nerves or lumbar spinal cord at abdomen, lower back or pelvis level (NB60-NB7Z)

Injury of spinal cord at abdomen, lower back or pelvis level (NB60-NB6Z)

<b>NB60</b>	<b>Concussion or oedema of lumbar spinal cord</b>
<b>NB61</b>	<b>Concussion or oedema of sacral spinal cord</b>
<b>NB62</b>	<b>Certain specified injuries of lumbar spinal cord</b>
<b>NB62.0</b>	<b>Complete lesion of lumbar spinal cord</b>
<b>NB62.1</b>	<b>Central cord syndrome of lumbar spinal cord</b>
<b>NB62.2</b>	<b>Anterior cord syndrome of lumbar spinal cord</b>
<b>NB62.3</b>	<b>Posterior cord syndrome of lumbar spinal cord</b>

<b>NB62.4</b>	<b>Brown-Sequard syndrome of lumbar spinal cord</b>
<b>NB62.5</b>	<b>Other incomplete cord syndrome of lumbar spinal cord</b>
<b>NB62.6</b>	<b>Puncture wound or laceration of dura mater of lumbar spinal cord</b>
<b>NB63</b>	<b>Certain specified injuries of sacral spinal cord</b>
<b>NB63.0</b>	<b>Complete injury of sacral spinal cord</b>
<b>NB63.1</b>	<b>Incomplete injury of sacral spinal cord</b>
<b>NB63.Z</b>	<b>Injury of sacral spinal cord, unspecified</b>
<b>NB6Z</b>	<b>Injury of spinal cord at abdomen, lower back or pelvis level, unspecified</b>

Injury of nerves at abdomen, lower back or pelvis level (NB70-NB7Z)

<b>NB70</b>	<b>Injury of nerve root of lumbar spine</b>
<b>NB71</b>	<b>Injury of nerve root of sacral spine</b>
<b>NB72</b>	<b>Injury of cauda equina</b>
<b>NB73</b>	<b>Injury of lumbosacral plexus</b>
<b>NB74</b>	<b>Injury of lumbar, sacral or pelvic sympathetic nerves</b>
<b>NB75</b>	<b>Injury of peripheral nerve of abdomen, lower back or pelvis</b>
<b>NB7Y</b>	<b>Other specified injury of nerves at abdomen, lower back or pelvis level</b>
<b>NB7Z</b>	<b>Injury of nerves at abdomen, lower back or pelvis level, unspecified</b>
<b>NB90</b>	<b>Injury of blood vessels at abdomen, lower back or pelvis level</b>
<b>NB90.0</b>	<b>Injury of abdominal aorta</b> <i>Exclusions:</i> injury aorta NOS (NB30.0)
<b>NB90.00</b>	Minor laceration of abdominal aorta <i>Inclusions:</i> incomplete transection of abdominal aorta laceration of abdominal aorta NOS superficial laceration of abdominal aorta
<b>NB90.01</b>	Major laceration of abdominal aorta <i>Inclusions:</i> complete transection of abdominal aorta traumatic rupture of abdominal aorta
<b>NB90.0Y</b>	Other specified injury of abdominal aorta
<b>NB90.0Z</b>	Injury of abdominal aorta, unspecified

<b>NB90.1</b>	<b>Injury of inferior vena cava</b>
	<b><i>Exclusions:</i></b> injury vena cava NOS (NB30.2)
<b>NB90.10</b>	Minor laceration of inferior vena cava
	<b><i>Inclusions:</i></b> incomplete transection of inferior vena cava laceration of inferior vena cava NOS superficial laceration of inferior vena cava
<b>NB90.11</b>	Major laceration of inferior vena cava
	<b><i>Inclusions:</i></b> complete transection of inferior vena cava traumatic rupture of inferior vena cava
<b>NB90.1Y</b>	Other specified injury of inferior vena cava
<b>NB90.1Z</b>	Injury of inferior vena cava, unspecified
<b>NB90.2</b>	<b>Injury of coeliac artery</b>
<b>NB90.20</b>	Minor laceration of coeliac artery
	<b><i>Inclusions:</i></b> incomplete transection of coeliac artery laceration of coeliac artery NOS superficial laceration of celiac artery
<b>NB90.21</b>	Major laceration of coeliac artery
	<b><i>Inclusions:</i></b> complete transection of coeliac artery traumatic rupture of coeliac artery
<b>NB90.2Y</b>	Other specified injury of coeliac artery
<b>NB90.2Z</b>	Injury of coeliac artery, unspecified
<b>NB90.3</b>	<b>Injury of mesenteric artery</b>
<b>NB90.30</b>	Minor laceration mesenteric artery
	<b><i>Inclusions:</i></b> incomplete transection of mesenteric artery laceration of mesenteric artery NOS superficial laceration of mesenteric artery
<b>NB90.31</b>	Major laceration of mesenteric artery
	<b><i>Inclusions:</i></b> complete transection of mesenteric artery traumatic rupture of mesenteric artery
<b>NB90.3Y</b>	Other specified injury of mesenteric artery
<b>NB90.3Z</b>	Injury of mesenteric artery, unspecified
<b>NB90.4</b>	<b>Injury of portal or splenic vein</b>

<b>NB90.40</b>	Minor laceration of portal or splenic vein  <b>Inclusions:</b> incomplete transection of portal or splenic vein laceration of portal or splenic vein NOS superficial laceration of portal or splenic vein
<b>NB90.41</b>	Major laceration of portal or splenic vein  <b>Inclusions:</b> complete transection of portal or splenic vein traumatic rupture of portal or splenic vein
<b>NB90.4Y</b>	Other specified injury of portal or splenic vein
<b>NB90.4Z</b>	Injury of portal or splenic vein, unspecified
<b>NB90.5</b>	<b>Injury of renal blood vessels</b>
<b>NB90.50</b>	Minor laceration of renal blood vessels  <b>Inclusions:</b> incomplete transection of renal blood vessels superficial laceration of renal blood vessels laceration of renal blood vessels NOS
<b>NB90.51</b>	Major laceration of renal blood vessels  <b>Inclusions:</b> complete transection of renal blood vessels traumatic rupture of renal blood vessels
<b>NB90.5Y</b>	Other specified injury of renal blood vessels
<b>NB90.5Z</b>	Injury of renal blood vessels, unspecified
<b>NB90.6</b>	<b>Injury of iliac blood vessels</b>
<b>NB90.60</b>	Minor laceration of iliac blood vessels  <b>Inclusions:</b> incomplete transection of iliac blood vessels laceration of iliac blood vessels NOS superficial laceration of iliac blood vessels
<b>NB90.61</b>	Major laceration of iliac blood vessels  <b>Inclusions:</b> complete transection of iliac blood vessels traumatic rupture of iliac blood vessels
<b>NB90.6Y</b>	Other specified injury of iliac blood vessels
<b>NB90.6Z</b>	Injury of iliac blood vessels, unspecified
<b>NB90.7</b>	<b>Injury of multiple blood vessels at abdomen, lower back or pelvis level</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NB90.Y</b>	<b>Injury of other specified blood vessels at abdomen, lower back or pelvis level</b>
<b>NB90.Z</b>	<b>Injury of unspecified blood vessel at abdomen, lower back or pelvis level</b>

<b>NB91</b>	<b>Injury of intra-abdominal organs</b>
	<b>Coded Elsewhere:</b> Adrenal haemorrhage due to birth injury (KA46.2)
<b>NB91.0</b>	<b>Injury of spleen</b>
	<b>Coded Elsewhere:</b> Birth injury to spleen (KA46.1)
<b>NB91.00</b>	Contusion of spleen, minor  <b>Inclusions:</b> contusion of spleen less than 2 cm
<b>NB91.01</b>	Contusion of spleen, major  <b>Inclusions:</b> contusion of spleen greater than 2 cm
<b>NB91.02</b>	Laceration of spleen, minor  <b>Inclusions:</b> laceration of spleen less than 1 cm
<b>NB91.03</b>	Laceration of spleen, moderate  <b>Inclusions:</b> laceration of spleen 1 to 3 cm  <b>Exclusions:</b> Multiple moderate lacerations of spleen (NB91.04)
<b>NB91.04</b>	Laceration of spleen, major  <b>Inclusions:</b> laceration of spleen greater than 3 cm massive laceration of spleen multiple moderate lacerations of spleen stellate laceration of spleen  <b>Exclusions:</b> Avulsion of spleen (NB91.05)
<b>NB91.05</b>	Avulsion of spleen
<b>NB91.0Y</b>	Other specified injury of spleen
<b>NB91.0Z</b>	Injury of spleen, unspecified
<b>NB91.1</b>	<b>Injury of liver</b>  Damage inflicted on the liver as the direct or indirect result of an external force, with or without disruption of structural continuity.  <b>Coded Elsewhere:</b> Birth injury to liver (KA46.0)
<b>NB91.10</b>	Contusion of liver
<b>NB91.11</b>	Laceration of liver, minor  <b>Inclusions:</b> laceration of liver involving capsule only, or, without significant involvement of hepatic parenchyma [i.e., less than 1 cm deep]

<b>NB91.12</b>	Laceration of liver, moderate
	<b>Inclusions:</b> laceration of liver involving parenchyma but without major disruption of parenchyma [i.e., less than 10 cm long and less than 3 cm deep]
	<b>Exclusions:</b> Multiple moderate lacerations of liver, with or without haematoma (NB91.13)
<b>NB91.13</b>	Laceration of liver, major
	<b>Inclusions:</b> laceration of liver with significant disruption of hepatic parenchyma [i.e., greater than 10 cm long and 3 cm deep] multiple moderate lacerations of liver, with or without haematoma stellate laceration of liver
<b>NB91.14</b>	Injury of hepatic duct
<b>NB91.1Y</b>	Other specified injury of liver
<b>NB91.1Z</b>	Injury of liver, unspecified
<b>NB91.2</b>	<b>Injury of gallbladder</b>
	<b>Coded Elsewhere:</b> Common bile duct trauma (NB91.3)
<b>NB91.3</b>	<b>Injury of bile duct</b>
<b>NB91.4</b>	<b>Injury of pancreas</b>
<b>NB91.40</b>	Contusion of pancreas
<b>NB91.41</b>	Laceration of pancreas, minor
	<b>Inclusions:</b> laceration of pancreas less than 1 cm laceration of pancreas NOS superficial capsular laceration of pancreas
<b>NB91.42</b>	Laceration of pancreas, moderate
	<b>Inclusions:</b> laceration of pancreas 1 to 3 cm
	<b>Exclusions:</b> Multiple moderate lacerations of pancreas (NB91.43)
<b>NB91.43</b>	Laceration of pancreas, major
	<b>Inclusions:</b> laceration of pancreas greater than 3 cm multiple moderate lacerations of pancreas massive laceration of pancreas stellate laceration of pancreas
<b>NB91.4Y</b>	Other specified injury of pancreas
<b>NB91.4Z</b>	Injury of pancreas, unspecified
<b>NB91.5</b>	<b>Injury of stomach</b>

<b>NB91.50</b>	Contusion of stomach
<b>NB91.51</b>	Laceration of stomach without perforation
<b>NB91.52</b>	Laceration of stomach with perforation, avulsion or massive damage
<b>NB91.53</b>	Ingestion injury of stomach without perforation  <i>Exclusions:</i> Chemical burn or corrosion of stomach (NE02)
<b>NB91.54</b>	Ingestion injury of stomach with perforation  <i>Exclusions:</i> Chemical burn or corrosion of stomach (NE02)
<b>NB91.5Y</b>	Other specified injury of stomach
<b>NB91.5Z</b>	Injury of stomach, unspecified
<b>NB91.6</b>	<b>Injury of duodenum</b>
<b>NB91.60</b>	Contusion of duodenum
<b>NB91.61</b>	Laceration of duodenum
<b>NB91.62</b>	Primary blast injury of duodenum
<b>NB91.63</b>	Perforation of duodenum  Perforation of duodenum is a penetration of the wall of the duodenum, resulting in luminal contents in duodenum flowing into the abdominal cavity or retroperitoneal wall.  <i>Inclusions:</i> Perforation of duodenum due to injury
<b>NB91.6Y</b>	Other specified injury of duodenum
<b>NB91.6Z</b>	Injury of duodenum, unspecified
<b>NB91.7</b>	<b>Injury of small intestine</b>
	<i>Inclusions:</i> Iatrogenic injury of small intestine
	<i>Exclusions:</i> Injury of duodenum (NB91.6)
<b>NB91.70</b>	Contusion of small intestine  An injury to small intestine resulting from a blow in which the subsurface tissue is injured and often internally bled but the skin is not broken.  <i>Exclusions:</i> Contusion of duodenum (NB91.60)
<b>NB91.71</b>	Laceration of small intestine  A tear or wound of small intestine.  <i>Exclusions:</i> Laceration of duodenum (NB91.61)
<b>NB91.72</b>	Primary blast injury of small intestine  An injury to small intestine resulting from direct or indirect exposure to explosion. Primary injuries are caused by high-order explosives or shock waves  <i>Exclusions:</i> Primary blast injury of duodenum (NB91.62)

<b>NB91.7Y</b>	Other specified injury of small intestine
<b>NB91.7Z</b>	Injury of small intestine, unspecified
<b>NB91.8</b>	<b>Injury of colon</b>
<b>NB91.80</b>	Contusion of colon  An injury to large intestine resulting from a blow in which the subsurface tissue is injured and often internally bled but the skin is not broken.
<b>NB91.81</b>	Laceration of colon  A tear or wound of large intestine.
<b>NB91.82</b>	Primary blast injury of colon  An injury to large intestine resulting from direct or indirect exposure to explosion. Primary injuries are caused by high-order explosives or shock waves.
<b>NB91.8Y</b>	Other specified injury of colon
<b>NB91.8Z</b>	Injury of colon, unspecified
<b>NB91.9</b>	<b>Injury of rectum</b>
<b>NB91.90</b>	Contusion of rectum
<b>NB91.91</b>	Laceration of rectum
<b>NB91.92</b>	Primary blast injury of rectum
<b>NB91.9Y</b>	Other specified injury of rectum
<b>NB91.9Z</b>	Injury of rectum, unspecified
<b>NB91.A</b>	<b>Injury of mesentery</b>
<b>NB91.B</b>	<b>Injury of multiple intra-abdominal organs</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
<b>NB91.Y</b>	<b>Injury of other specified intra-abdominal organs</b>
<b>NB91.Z</b>	<b>Injury of intra-abdominal organs, unspecified</b>
<b>NB92</b>	<b>Injury of urinary or pelvic organs</b>
	<b>Exclusions:</b> peritoneum and retroperitoneum (NB91)
	<b>Coded Elsewhere:</b> Female Genital Mutilation (GC51)
	Sequelae of injury of intra-abdominal or pelvic organs (NB91.Y)
<b>NB92.0</b>	<b>Injury of kidney</b>

<b>NB92.00</b>	Contusion of kidney, minor  <i>Inclusions:</i> contusion of kidney less than 2 cm contusion of kidney NOS
<b>NB92.01</b>	Contusion of kidney, major  <i>Inclusions:</i> contusion of kidney greater than 2 cm
<b>NB92.02</b>	Laceration of kidney, minor  <i>Inclusions:</i> laceration of kidney less than 1 cm laceration of kidney NOS
<b>NB92.03</b>	Laceration of kidney, moderate  <i>Inclusions:</i> laceration of kidney 1 to 3 cm  <i>Exclusions:</i> Multiple moderate lacerations of kidney (NB92.04)
<b>NB92.04</b>	Laceration of kidney, major  <i>Inclusions:</i> avulsion of kidney laceration of kidney greater than 3 cm massive laceration of kidney stellate laceration of kidney multiple moderate lacerations of kidney
<b>NB92.0Y</b>	Other specified injury of kidney
<b>NB92.0Z</b>	Injury of kidney, unspecified
<b>NB92.1</b>	<b>Injury of ureter</b>
<b>NB92.10</b>	Contusion of ureter
<b>NB92.11</b>	Laceration of ureter
<b>NB92.1Y</b>	Other specified injury of ureter
<b>NB92.1Z</b>	Injury of ureter, unspecified
<b>NB92.2</b>	<b>Injury of bladder</b>  <i>Exclusions:</i> Obstetric injury to bladder (JB0A.6)
<b>NB92.20</b>	Contusion of bladder
<b>NB92.21</b>	Laceration of bladder
<b>NB92.2Y</b>	Other specified injury of bladder
<b>NB92.2Z</b>	Injury of bladder, unspecified
<b>NB92.3</b>	<b>Injury of urethra</b>
<b>NB92.30</b>	Contusion of urethra
<b>NB92.31</b>	Laceration of urethra

<b>NB92.3Y</b>	Other specified injury of urethra
<b>NB92.3Z</b>	Injury of urethra, unspecified
<b>NB92.4</b>	<b>Injury of ovary</b>
<b>NB92.40</b>	Contusion of ovary
<b>NB92.41</b>	Laceration of ovary
<b>NB92.4Y</b>	Other specified injury of ovary
<b>NB92.4Z</b>	Injury of ovary, unspecified
<b>NB92.5</b>	<b>Injury of fallopian tube</b>
<b>NB92.6</b>	<b>Injury of uterus</b>
<b>NB92.7</b>	<b>Injury of urinary tract</b>
<b>NB92.8</b>	<b>Injury of multiple pelvic organs</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
<b>NB92.Y</b>	<b>Injury of other specified pelvic organs</b>
<b>NB92.Z</b>	<b>Injury of urinary or pelvic organs, unspecified</b>
<b>NB93</b>	<b>Crushing injury or traumatic amputation of part of abdomen, lower back or pelvis</b>
<b>NB93.0</b>	<b>Crushing injury of external genital organs</b>
	<b>Coded Elsewhere:</b> Birth injury to external genitalia (KA43.1)
<b>NB93.00</b>	Crushing injury of penis
<b>NB93.01</b>	Crushing injury of testes or scrotum
<b>NB93.02</b>	Crushing injury of vulva
<b>NB93.0Z</b>	Crushing injury of external genital organs, unspecified
<b>NB93.1</b>	<b>Crushing injury of other or unspecified parts of abdomen, lower back or pelvis</b>
<b>NB93.2</b>	<b>Traumatic amputation of external genital organs</b>
<b>NB93.20</b>	Traumatic amputation of entire penis
	<b>Inclusions:</b> Traumatic amputation of penis
<b>NB93.21</b>	Traumatic amputation of part of penis
<b>NB93.22</b>	Traumatic amputation of entire testes or scrotum
<b>NB93.23</b>	Traumatic amputation of part of testes or scrotum

<b>NB93.24</b>	Traumatic amputation of entire vulva  <b>Inclusions:</b> Traumatic amputation of vulva <b>Exclusions:</b> Female Genital Mutilation (GC51)
<b>NB93.25</b>	Traumatic amputation of part of vulva  <b>Exclusions:</b> Female Genital Mutilation (GC51)
<b>NB93.2Z</b>	Traumatic amputation of external genital organs, unspecified
<b>NB93.3</b>	<b>Traumatic amputation of other or unspecified parts of abdomen, lower back or pelvis</b>  <b>Exclusions:</b> transection of abdomen (ND35)
<b>NB94</b>	<b>Injury of muscle, fascia or tendon of abdomen, lower back or pelvis</b>
<b>NB94.0</b>	<b>Strain or sprain of muscle, fascia or tendon of abdomen</b>
<b>NB94.1</b>	<b>Strain or sprain of muscle, fascia or tendon of lower back</b>
<b>NB94.2</b>	<b>Strain or sprain of muscle, fascia or tendon of pelvis</b>
<b>NB94.3</b>	<b>Laceration of muscle, fascia or tendon of abdomen</b>
<b>NB94.4</b>	<b>Laceration of muscle, fascia or tendon of lower back</b>
<b>NB94.5</b>	<b>Laceration of muscle, fascia or tendon of pelvis</b>
<b>NB94.Y</b>	<b>Other specified injury of muscle, fascia or tendon of abdomen, lower back or pelvis</b>
<b>NB94.Z</b>	<b>Injury of muscle, fascia or tendon of abdomen, lower back or pelvis, unspecified</b>
<b>NB95</b>	<b>Injury of intra-abdominal organ with pelvic organ</b>  <b>Coded Elsewhere:</b> Sequelae of injury of intra-abdominal or pelvic organs (NB91.Y)
<b>NB96</b>	<b>Other multiple injuries of abdomen, lower back or pelvis</b>  <b>Coding Note:</b> Assign additional codes for the specific injuries.
<b>NB97</b>	<b>Certain specified injuries of abdomen, lower back or pelvis</b>
<b>NB97.0</b>	<b>Retroperitoneal haemorrhage or haematoma</b>
<b>NB97.1</b>	<b>Fractured penis</b>
<b>NB98</b>	<b>Injury to female genital organ without further specification</b>  <b>Exclusions:</b> Crushing injury of external genital organs (NB93.0)
<b>NB99</b>	<b>Injury to male genital organ without further specification</b>  <b>Exclusions:</b> Crushing injury of external genital organs (NB93.0)
<b>NB9Y</b>	<b>Other specified injuries to the abdomen, lower back, lumbar spine or pelvis</b>

<b>NB9Z</b>	<b>Injuries to the abdomen, lower back, lumbar spine or pelvis, unspecified</b>
-------------	---

### Injuries to the shoulder or upper arm (NC10-NC1Z)

- Exclusions:**
- Burns (ND90-NE2Z)
  - Other injuries of arm, level unspecified (ND53)
  - Frostbite (NE40-NE4Z)
  - Insect bite or sting, venomous (NE61)
  - Injuries to the elbow or forearm (NC30-NC3Z)

#### **NC10 Superficial injury of shoulder or upper arm**

- NC10.0 Abrasion of shoulder or upper arm**
- NC10.1 Contusion of shoulder or upper arm**
- NC10.2 Multiple superficial injuries of shoulder or upper arm**

**Coding Note:** Assign additional codes for the specific injuries.

- NC10.Y Other specified superficial injury of shoulder or upper arm**

- NC10.Z Superficial injury of shoulder or upper arm, unspecified**

#### **NC11 Open wound of shoulder or upper arm**

**Exclusions:** Traumatic amputation of shoulder or upper arm (NC18)

- NC11.0 Laceration without foreign body of shoulder or upper arm**
- Inclusions:** laceration of skin of shoulder or upper arm
- NC11.1 Laceration with foreign body of shoulder or upper arm**
- NC11.2 Puncture wound without foreign body of shoulder or upper arm**
- NC11.3 Puncture wound with foreign body of shoulder or upper arm**
- NC11.4 Open bite of shoulder or upper arm**
- NC11.5 Multiple open wounds of shoulder or upper arm**

**Coding Note:** Assign additional codes for the specific injuries.

- NC11.Y Other specified open wound of shoulder or upper arm**

- NC11.Z Open wound of shoulder or upper arm, unspecified**

#### **NC12 Fracture of shoulder or upper arm**

- NC12.0 Fracture of clavicle**

A break in one or both of the clavicles.

**Coded Elsewhere:** Fracture of clavicle due to birth injury (KA45.5)

<b>NC12.00</b>	Fracture of sternal end of clavicle
<b>NC12.01</b>	Fracture of shaft of clavicle
<b>NC12.02</b>	Fracture of acromial end of clavicle
<b>NC12.03</b>	Multiple fractures of clavicle, alone
<b>NC12.0Y</b>	Other specified fracture of clavicle
<b>NC12.0Z</b>	Fracture of clavicle, unspecified
<b>NC12.1</b>	<b>Fracture of scapula</b> A break in one or both of the scapulae.
<b>NC12.10</b>	Multiple fractures of scapula
<b>NC12.1Y</b>	Other specified fracture of scapula
<b>NC12.1Z</b>	Fracture of scapula, unspecified
<b>NC12.2</b>	<b>Fracture of upper end of humerus</b>
<b>NC12.20</b>	Fracture of upper end of humerus, head
<b>NC12.21</b>	Fracture of surgical neck of humerus
<b>NC12.22</b>	Fracture of anatomical neck of humerus
<b>NC12.23</b>	Fracture of greater tuberosity of humerus
<b>NC12.24</b>	Fracture of lesser tuberosity of humerus
<b>NC12.2Z</b>	Fracture of upper end of humerus, unspecified site
<b>NC12.3</b>	<b>Fracture of shaft of humerus</b>
<b>NC12.4</b>	<b>Fracture of lower end of humerus</b> <i>Inclusions:</i> fracture of articular process of humerus <i>Exclusions:</i> fracture of elbow NOS (NC32.0)
<b>NC12.40</b>	Supracondylar fracture of humerus
<b>NC12.41</b>	Fracture of lateral epicondyle of humerus
<b>NC12.42</b>	Fracture of medial epicondyle of humerus
<b>NC12.43</b>	Fracture of lateral condyle of humerus
<b>NC12.44</b>	Fracture of medial condyle of humerus
<b>NC12.4Y</b>	Other specified fracture of lower end of humerus
<b>NC12.4Z</b>	Fracture of lower end of humerus, unspecified
<b>NC12.5</b>	<b>Multiple fractures of clavicle, scapula or humerus</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

NC12.7	<b>Fracture of shoulder girdle, part unspecified</b>
NC12.Z	<b>Fracture of shoulder or upper arm, unspecified</b>
<b>NC13</b>	<b>Dislocation or strain or sprain of joints or ligaments of shoulder girdle</b>
NC13.0	<b>Dislocation of shoulder joint</b> Displacement of the humerus from the scapula.
NC13.1	<b>Dislocation of acromioclavicular joint</b>
NC13.2	<b>Dislocation of sternoclavicular joint</b>
NC13.3	<b>Dislocation of scapula</b>
NC13.4	<b>Dislocation of other or unspecified parts of shoulder girdle</b>
NC13.5	<b>Strain or sprain of shoulder joint</b> A collective term for muscle and ligament injuries of the tissues associated with the shoulder joint without dislocation or fracture; a joint injury in which some of the fibers of a supporting ligament are ruptured but the continuity of the ligament remains intact. A strain is an overstretching or overexertion of some part of the musculature.
NC13.6	<b>Strain or sprain of acromioclavicular joint</b>
NC13.7	<b>Strain or sprain of sternoclavicular joint</b> Aberrant biomechanical functions of the joints between the clavicle and the sternum, which may be as a result of local disease, systemic disease or trauma.
NC13.8	<b>Strain or sprain of other or unspecified parts of shoulder girdle</b>
NC13.Y	<b>Dislocation or sprain of other specified joints and ligaments of shoulder girdle</b>
NC13.Z	<b>Dislocation or strain or sprain of joints or ligaments of shoulder girdle, unspecified</b>
<b>NC14</b>	<b>Injury of nerves at shoulder or upper arm level</b>
	<b><i>Exclusions:</i></b> Injury of brachial plexus (NA41)
NC14.0	<b>Injury of ulnar nerve at upper arm level</b>
	<b><i>Exclusions:</i></b> ulnar nerve NOS (NC34.0)
NC14.1	<b>Injury of median nerve at upper arm level</b>
	<b><i>Exclusions:</i></b> median nerve NOS (NC34.1)
NC14.2	<b>Injury of radial nerve at upper arm level</b>
	<b><i>Exclusions:</i></b> radial nerve NOS (NC34.2)
NC14.3	<b>Injury of axillary nerve</b>
NC14.4	<b>Injury of musculocutaneous nerve</b>

**NC14.5      Injury of cutaneous sensory nerve at shoulder or upper arm level**

**NC14.6      Injury of multiple nerves at shoulder or upper arm level**

**Coding Note:** Assign additional codes for the specific injuries.

**NC14.Y      Injury of other specified nerves at shoulder or upper arm level**

**NC14.Z      Injury of unspecified nerve at shoulder or upper arm level**

**NC15      Injury of blood vessels at shoulder or upper arm level**

**Exclusions:**     injury of subclavian artery (NB30.1)  
                      injury of subclavian vein (NB30.3)

**NC15.0      Injury of axillary artery**

**NC15.00     Laceration of axillary artery**

**NC15.0Y     Other specified injury of axillary artery**

**NC15.0Z     Injury of axillary artery, unspecified**

**NC15.1      Injury of brachial artery**

**NC15.10     Laceration of brachial artery**

**NC15.1Y     Other specified injury of brachial artery**

**NC15.1Z     Injury of brachial artery, unspecified**

**NC15.2      Injury of axillary or brachial vein**

**NC15.20     Laceration of axillary or brachial vein**

**NC15.2Y     Other specified injury of axillary or brachial vein**

**NC15.2Z     Injury of axillary or brachial vein, unspecified**

**NC15.3      Injury of superficial vein at shoulder or upper arm level**

**NC15.30     Laceration of superficial vein at shoulder or upper arm level**

**NC15.3Y     Other specified injury of superficial vein at shoulder or upper arm level**

**NC15.3Z     Injury of superficial vein at shoulder or upper arm level, unspecified**

**NC15.4      Injury of multiple blood vessels at shoulder or upper arm level**

**Coding Note:** Assign additional codes for the specific injuries.

**NC15.Y      Injury of other specified blood vessels at shoulder or upper arm level**

**NC15.Z      Injury of unspecified blood vessel at shoulder or upper arm level**

**NC16      Injury of muscle, fascia, tendon or bursa at shoulder or upper arm level**

**Exclusions:**     injury of muscle and tendon at or below elbow (NC36)

**NC16.0      Injury of muscle or tendon of the rotator cuff of shoulder**

<b>NC16.00</b>	Strain or sprain of muscle or tendon of the rotator cuff of shoulder
<b>NC16.01</b>	Laceration of muscle or tendon of the rotator cuff of shoulder
<b>NC16.0Y</b>	Other specified injury of muscle or tendon of the rotator cuff of shoulder
<b>NC16.0Z</b>	Injury of muscle or tendon of the rotator cuff of shoulder, unspecified
<b>NC16.1</b>	<b>Injury of muscle, fascia or tendon of long head of biceps</b>
<b>NC16.10</b>	Strain or sprain of muscle, fascia or tendon of long head of biceps
<b>NC16.11</b>	Laceration of muscle, fascia or tendon of long head of biceps
<b>NC16.1Y</b>	Other specified injury of muscle, fascia or tendon of long head of biceps
<b>NC16.1Z</b>	Injury of muscle, fascia or tendon of long head of biceps, unspecified
<b>NC16.2</b>	<b>Injury of muscle, fascia or tendon of other parts of biceps</b>
<b>NC16.20</b>	Strain or sprain of muscle, fascia or tendon of other parts of biceps
<b>NC16.21</b>	Laceration of muscle, fascia or tendon of other parts of biceps
<b>NC16.2Y</b>	Other specified injury of muscle, fascia or tendon of other parts of biceps
<b>NC16.2Z</b>	Injury of muscle, fascia or tendon of other parts of biceps, unspecified
<b>NC16.3</b>	<b>Injury of muscle, fascia or tendon of triceps</b>
<b>NC16.30</b>	Strain or sprain of muscle, fascia or tendon of triceps
<b>NC16.31</b>	Laceration of muscle, fascia or tendon of triceps
<b>NC16.3Y</b>	Other specified injury of muscle, fascia or tendon of triceps
<b>NC16.3Z</b>	Injury of muscle, fascia or tendon of triceps, unspecified
<b>NC16.4</b>	<b>Injury of multiple muscles or tendons at shoulder or upper arm level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC16.40</b>	Strain or sprain of multiple muscles or tendons at shoulder or upper arm level
<b>NC16.41</b>	Laceration of multiple muscles or tendons at shoulder or upper arm level
<b>NC16.4Y</b>	Other specified injury of multiple muscles or tendons at shoulder or upper arm level
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC16.4Z</b>	Injury of multiple muscles or tendons at shoulder or upper arm level, unspecified
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC16.5</b>	<b>Injury of bursa of shoulder</b>
<b>NC16.Y</b>	<b>Injury of other specified muscle, fascia, tendon or bursa at shoulder or upper arm level</b>
<b>NC16.Z</b>	<b>Injury of unspecified muscle, fascia or tendon at shoulder or upper arm level</b>

<b>NC17</b>	<b>Crushing injury of shoulder or upper arm</b>
	<b>Exclusions:</b> Crushing injury of elbow (NC37.0)
<b>NC18</b>	<b>Traumatic amputation of shoulder or upper arm</b>
	<b>Exclusions:</b> traumatic amputation of arm, level unspecified (ND53) traumatic amputation at elbow level (NC38)
<b>NC18.0</b>	<b>Traumatic amputation at right shoulder joint</b>
<b>NC18.1</b>	<b>Traumatic amputation at left shoulder joint</b>
<b>NC18.2</b>	<b>Traumatic amputation at shoulder joint, bilateral</b>
<b>NC18.3</b>	<b>Traumatic amputation at level between right shoulder and elbow</b>
<b>NC18.4</b>	<b>Traumatic amputation at level between left shoulder and elbow</b>
<b>NC18.5</b>	<b>Traumatic amputation at level between shoulder and elbow, bilateral</b>
<b>NC18.Z</b>	<b>Traumatic amputation of shoulder or upper arm, unspecified</b>
<b>NC19</b>	<b>Multiple injuries of shoulder or upper arm</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
<b>NC1Y</b>	<b>Other specified injuries to the shoulder or upper arm</b>
<b>NC1Z</b>	<b>Injuries to the shoulder or upper arm, unspecified</b>
<b>Injuries to the elbow or forearm (NC30-NC3Z)</b>	
<b>Exclusions:</b>	Injuries to the wrist or hand (NC50-NC5Z) Insect bite or sting, venomous (NE61) Burns (ND90-NE2Z) Frostbite (NE40-NE4Z) Other injuries of arm, level unspecified (ND53)
<b>NC30</b>	<b>Superficial injury of forearm</b>
	<b>Exclusions:</b> Superficial injury of wrist or hand (NC51)
<b>NC30.0</b>	<b>Abrasions of elbow</b>
<b>NC30.1</b>	<b>Contusion of elbow</b>
<b>NC30.2</b>	<b>Abrasions of other or unspecified parts of forearm</b>
<b>NC30.3</b>	<b>Contusion of other or unspecified parts of forearm</b>

<b>NC30.4</b>	<b>Multiple superficial injuries of forearm</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
<b>NC30.Y</b>	<b>Other specified superficial injury of forearm</b>
<b>NC30.Z</b>	<b>Superficial injury of forearm, unspecified</b>
<b>NC31</b>	<b>Open wound of forearm</b>
	<b>Exclusions:</b> Open wound of wrist or hand (NC52) Traumatic amputation of forearm (NC38)
<b>NC31.0</b>	<b>Laceration without foreign body of forearm</b>
	<b>Inclusions:</b> laceration of skin of forearm
<b>NC31.1</b>	<b>Laceration with foreign body of forearm</b>
<b>NC31.2</b>	<b>Puncture wound without foreign body of forearm</b>
<b>NC31.3</b>	<b>Puncture wound with foreign body of forearm</b>
<b>NC31.4</b>	<b>Open bite of forearm</b>
<b>NC31.5</b>	<b>Multiple open wounds of forearm</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC31.Y</b>	<b>Other specified open wound of forearm</b>
<b>NC31.Z</b>	<b>Open wound of forearm, unspecified</b>
<b>NC32</b>	<b>Fracture of forearm</b>
	A break in one or both of the radius and/or ulna.
	<b>Exclusions:</b> Fracture at wrist or hand level (NC53)
<b>NC32.0</b>	<b>Fracture of upper end of ulna</b>
	<b>Exclusions:</b> supracondylar elbow fracture (NC12.4)
<b>NC32.1</b>	<b>Fracture of upper end of radius</b>
<b>NC32.2</b>	<b>Fracture of shaft of ulna</b>
<b>NC32.3</b>	<b>Fracture of shaft of radius</b>
<b>NC32.4</b>	<b>Fracture of shafts of both ulna and radius</b>
<b>NC32.5</b>	<b>Fracture of lower end of radius</b>
<b>NC32.50</b>	Fracture of lower end of radius, dorsal tilt
<b>NC32.51</b>	Fracture of lower end of radius, volar tilt
<b>NC32.5Y</b>	Other specified fracture of lower end of radius

- NC32.5Z** Fracture of lower end of radius, unspecified
- NC32.6** Fracture of lower end of both ulna and radius
- NC32.7** Multiple fractures of forearm
- Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**Exclusions:** Fracture of shafts of both ulna and radius (NC32.4)  
Fracture of lower end of both ulna and radius (NC32.6)

- NC32.Y** Fracture of other specified parts of forearm

- NC32.Z** Fracture of forearm, unspecified

**NC33 Dislocation or strain or sprain of joints or ligaments of elbow**

A collective term for muscle and ligament injuries of the tissues associated with, or displacement of the bones of, the elbow.

- NC33.0** Dislocation of radial head

**Inclusions:** Radiohumeral joint

**Exclusions:** Monteggia fracture-dislocation (NC32.0)

- NC33.1** Dislocation of elbow

- NC33.2** Traumatic rupture of radial collateral ligament

- NC33.3** Traumatic rupture of ulnar collateral ligament

- NC33.4** Strain or sprain of elbow

A collective term for muscle and ligament injuries of the tissues associated with the elbow without dislocation or fracture; a joint injury in which some of the fibers of a supporting ligament are ruptured but the continuity of the ligament remains intact. A strain is an overstretching or overexertion of some part of the musculature.

- NC33.Y** Dislocation or sprain of other specified joints or ligaments of elbow

- NC33.Z** Dislocation or strain or sprain of joints or ligaments of elbow, unspecified

**NC34 Injury of nerves at forearm level**

**Exclusions:** Injury of nerves at wrist or hand level (NC55)

- NC34.0** Injury of ulnar nerve at forearm level

- NC34.1** Injury of median nerve at forearm level

- NC34.2** Injury of radial nerve at forearm level

- NC34.3** Injury of cutaneous sensory nerve at forearm level

- NC34.4** Injury of multiple nerves at forearm level

**Coding Note:** Assign additional codes for the specific injuries.

- NC34.Y** Injury of other specified nerves at forearm level

<b>NC34.Z</b>	<b>Injury of unspecified nerve at forearm level</b>
<b>NC35</b>	<b>Injury of blood vessels at forearm level</b>
	<b>Exclusions:</b> Injury of blood vessels at wrist or hand level (NC56) injury of brachial vessels (NC15.2)
<b>NC35.0</b>	<b>Injury of ulnar artery at forearm level</b>
<b>NC35.00</b>	Laceration of ulnar artery at forearm level
<b>NC35.0Y</b>	Other specified injury of ulnar artery at forearm level
<b>NC35.0Z</b>	Injury of ulnar artery at forearm level, unspecified
<b>NC35.1</b>	<b>Injury of radial artery at forearm level</b>
<b>NC35.10</b>	Laceration of radial artery at forearm level
<b>NC35.1Y</b>	Other specified injury of radial artery at forearm level
<b>NC35.1Z</b>	Injury of radial artery at forearm level, unspecified
<b>NC35.2</b>	<b>Injury of vein at forearm level</b>
<b>NC35.20</b>	Laceration of vein at forearm level
<b>NC35.2Y</b>	Other specified injury of vein at forearm level
<b>NC35.2Z</b>	Injury of vein at forearm level, unspecified
<b>NC35.3</b>	<b>Injury of multiple blood vessels at forearm level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC35.Y</b>	<b>Injury of other specified blood vessels at forearm level</b>
<b>NC35.Z</b>	<b>Injury of unspecified blood vessel at forearm level</b>
<b>NC36</b>	<b>Injury of muscle, fascia, tendon or bursa at forearm level</b>
	<b>Exclusions:</b> injury of muscle and tendon at or below wrist (NC57)
<b>NC36.0</b>	<b>Injury of flexor muscle, fascia or tendon of thumb at forearm level</b>
<b>NC36.00</b>	Strain or sprain of flexor muscle, fascia or tendon of thumb at forearm level
<b>NC36.01</b>	Laceration of flexor muscle, fascia or tendon of thumb at forearm level
<b>NC36.0Y</b>	Other specified injury of flexor muscle, fascia or tendon of thumb at forearm level
<b>NC36.0Z</b>	Injury of flexor muscle, fascia or tendon of thumb at forearm level, unspecified
<b>NC36.1</b>	<b>Injury of long flexor muscle, fascia or tendon of other finger at forearm level</b>
<b>NC36.10</b>	Strain or sprain of long flexor muscle, fascia or tendon of other finger at forearm level
<b>NC36.11</b>	Laceration of long flexor muscle, fascia or tendon of other finger at forearm level

<b>NC36.1Y</b>	Other specified injury of long flexor muscle, fascia or tendon of other finger at forearm level
<b>NC36.1Z</b>	Injury of long flexor muscle, fascia or tendon of other finger at forearm level, unspecified
<b>NC36.2</b>	<b>Injury of other flexor muscle, fascia or tendon at forearm level</b>
<b>NC36.20</b>	Strain or sprain of other flexor muscle, fascia or tendon at forearm level
<b>NC36.21</b>	Laceration of other flexor muscle, fascia or tendon at forearm level
<b>NC36.2Y</b>	Other specified injury of other flexor muscle, fascia or tendon at forearm level
<b>NC36.2Z</b>	Injury of other flexor muscle, fascia or tendon at forearm level, unspecified
<b>NC36.3</b>	<b>Injury of extensor or abductor muscles or tendons of thumb at forearm level</b>
<b>NC36.30</b>	Strain or sprain of extensor or abductor muscles or tendons of thumb at forearm level
<b>NC36.31</b>	Laceration of extensor or abductor muscles or tendons of thumb at forearm level
<b>NC36.3Y</b>	Other specified injury of extensor or abductor muscles or tendons of thumb at forearm level
<b>NC36.3Z</b>	Injury of extensor or abductor muscles or tendons of thumb at forearm level, unspecified
<b>NC36.4</b>	<b>Injury of extensor muscle, fascia or tendon of other finger at forearm level</b>
<b>NC36.40</b>	Strain or sprain of extensor muscle, fascia or tendon of other finger at forearm level
<b>NC36.41</b>	Laceration of extensor muscle, fascia or tendon of other finger at forearm level
<b>NC36.4Y</b>	Other specified injury of extensor muscle, fascia or tendon of other finger at forearm level
<b>NC36.4Z</b>	Injury of extensor muscle, fascia or tendon of other finger at forearm level, unspecified
<b>NC36.5</b>	<b>Injury of other extensor muscle, fascia or tendon at forearm level</b>
<b>NC36.50</b>	Strain or sprain of other extensor muscle, fascia or tendon at forearm level
<b>NC36.51</b>	Laceration of other extensor muscle, fascia or tendon at forearm level
<b>NC36.5Y</b>	Other specified injury of other extensor muscle, fascia or tendon at forearm level
<b>NC36.5Z</b>	Injury of other extensor muscle, fascia or tendon at forearm level, unspecified
<b>NC36.6</b>	<b>Injury of multiple muscles or tendons at forearm level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC36.7</b>	<b>Injury of bursa of elbow</b>
<b>NC36.Y</b>	<b>Injury of other specified muscle, fascia, tendon or bursa at forearm level</b>
<b>NC36.Z</b>	<b>Injury of unspecified muscle, fascia, tendon or bursa at forearm level</b>

<b>NC37</b>	<b>Crushing injury of forearm</b>
	<b><i>Exclusions:</i></b> Crushing injury of wrist or hand (NC58)
<b>NC37.0</b>	<b>Crushing injury of elbow</b>
<b>NC37.Y</b>	<b>Crushing injury of other specified part of forearm</b>
<b>NC37.Z</b>	<b>Crushing injury of forearm, unspecified</b>
<b>NC38</b>	<b>Traumatic amputation of forearm</b>
	<b><i>Exclusions:</i></b> Traumatic amputation of wrist or hand (NC59)
<b>NC38.0</b>	<b>Traumatic amputation at right elbow level</b>
<b>NC38.1</b>	<b>Traumatic amputation at left elbow level</b>
<b>NC38.2</b>	<b>Traumatic amputation at elbow level, bilateral</b>
<b>NC38.3</b>	<b>Traumatic amputation at level between right elbow and wrist</b>
<b>NC38.4</b>	<b>Traumatic amputation at level between left elbow and wrist</b>
<b>NC38.5</b>	<b>Traumatic amputation between elbow and wrist, bilateral</b>
<b>NC38.Z</b>	<b>Traumatic amputation of forearm, unspecified</b>
<b>NC39</b>	<b>Multiple injuries of forearm</b>
<b><i>Coding Note:</i></b>	Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
<b>NC3Y</b>	<b>Other specified injuries to the elbow or forearm</b>
<b>NC3Z</b>	<b>Injuries to the elbow or forearm, unspecified</b>

### Injuries to the wrist or hand (NC50-NC5Z)

***Exclusions:***      Burns (ND90-NE2Z)  
                           Frostbite (NE40-NE4Z)  
                           Other injuries of arm, level unspecified (ND53)  
                           Insect bite or sting, venomous (NE61)

<b>NC50</b>	<b>Injury to fingernail</b>
<b>NC51</b>	<b>Superficial injury of wrist or hand</b>
<b>NC51.0</b>	<b>Superficial injury of finger or thumb</b>
<b>NC51.00</b>	Abrasions of finger or thumb
<b>NC51.01</b>	Contusions of finger or thumb
<b>NC51.0Y</b>	Other specified superficial injury of finger or thumb

- NC51.0Z** Superficial injury of finger or thumb, unspecified
- NC51.1** **Superficial injury of other parts of wrist or hand**
- Exclusions:** Superficial injury of finger or thumb (NC51.0)
- NC51.10** Contusion of other parts of wrist or hand
- NC51.11** Nonvenomous insect bite of other parts of wrist or hand
- NC51.1Y** Other specified superficial injury of other parts of wrist or hand
- NC51.1Z** Superficial injury of other parts of wrist or hand, unspecified
- NC51.2** **Multiple superficial injuries of wrist or hand**

**Coding Note:** Assign additional codes for the specific injuries.

- NC52** **Open wound of wrist or hand**
- Exclusions:** Traumatic amputation of wrist or hand (NC59)
- NC52.0** **Open wound of finger or thumb**
- Exclusions:** Traumatic amputation of other single finger (NC59.1)
- NC52.00** Laceration without foreign body of finger or thumb
- NC52.01** Laceration with foreign body of finger or thumb
- NC52.02** Puncture wound without foreign body of finger or thumb
- NC52.03** Puncture wound with foreign body of finger or thumb
- NC52.04** Open bite of finger or thumb
- NC52.0Y** Other specified open wound of finger or thumb
- NC52.0Z** Open wound of finger or thumb, unspecified
- NC52.1** **Open wound of other parts of wrist or hand**
- NC52.10** Laceration without foreign body of other parts of wrist or hand
- Inclusions:** laceration of skin of wrist or hand
- NC52.11** Laceration with foreign body of other parts of wrist or hand
- NC52.12** Puncture wound with foreign body of other parts of wrist or hand
- NC52.13** Puncture wound without foreign body of other parts of wrist or hand
- NC52.14** Open bite of other parts of wrist or hand
- NC52.1Y** Other specified open wound of other parts of wrist or hand
- NC52.1Z** Open wound of other parts of wrist or hand, unspecified
- NC52.2** **Multiple open wounds of wrist or hand**

**Coding Note:** Assign additional codes for the specific injuries.

<b>NC53</b>	<b>Fracture at wrist or hand level</b>
	A break in one of the bones of the wrist or hand.
	<b>Exclusions:</b> fracture of distal parts of ulna and radius (NC32.6)
<b>NC53.0</b>	<b>Fracture of scaphoid bone of hand</b>
<b>NC53.1</b>	<b>Fracture of other carpal bone</b>
	A break in one or more of the carpal bones of the wrist
<b>NC53.2</b>	<b>Fracture of first metacarpal bone</b>
	A break in the first metacarpal bone, that which is part of the thumb.
<b>NC53.3</b>	<b>Fracture of other metacarpal bone</b>
<b>NC53.30</b>	Fracture of shaft of other metacarpal bone
<b>NC53.31</b>	Fracture of neck of other metacarpal bone
<b>NC53.3Y</b>	Fracture of other specified part of other metacarpal bone
<b>NC53.3Z</b>	Fracture of other metacarpal bone, unspecified
<b>NC53.4</b>	<b>Multiple fractures of metacarpal bones</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NC53.5</b>	<b>Fracture of thumb bone</b>
	<b>Exclusions:</b> Fracture of first metacarpal bone (NC53.2)
<b>NC53.6</b>	<b>Fracture of other finger bone</b>
	A break in one or more of the phalanges
<b>NC53.60</b>	Fracture of index finger
<b>NC53.61</b>	Fracture of middle finger
<b>NC53.62</b>	Fracture of ring finger
<b>NC53.63</b>	Fracture of little finger
<b>NC53.6Y</b>	Other specified fracture of other finger bone
<b>NC53.6Z</b>	Fracture of other finger bone, unspecified
<b>NC53.7</b>	<b>Multiple fractures of fingers</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NC53.Y</b>	<b>Fracture at other specified part of wrist or hand level</b>
<b>NC53.Z</b>	<b>Fracture at wrist or hand level, unspecified</b>
<b>NC54</b>	<b>Dislocation or strain or sprain of joints or ligaments at wrist or hand level</b>

<b>NC54.0</b>	<b>Dislocation of wrist</b> Displacement of one or more of the bones of the wrist
<b>NC54.00</b>	Dislocation of distal radioulnar joint
<b>NC54.01</b>	Dislocation of radiocarpal joint
<b>NC54.02</b>	Dislocation of midcarpal joint
<b>NC54.03</b>	Dislocation of carpometacarpal joint of thumb
<b>NC54.04</b>	Dislocation of other carpometacarpal joint
<b>NC54.05</b>	Dislocation of metacarpal bone, proximal end
<b>NC54.0Y</b>	Dislocation of other specified part of wrist
<b>NC54.0Z</b>	Dislocation of wrist, unspecified
<b>NC54.1</b>	<b>Dislocation of thumb</b>
<b>NC54.10</b>	Dislocation of metacarpophalangeal joint of thumb
<b>NC54.11</b>	Dislocation of interphalangeal joint of thumb
<b>NC54.1Y</b>	Dislocation of other specified part of thumb
<b>NC54.1Z</b>	Dislocation of thumb, unspecified
<b>NC54.2</b>	<b>Dislocation of finger</b> Displacement of one or more of the phalanges
	<i>Inclusions:</i> Dislocation of phalanx, hand
<b>NC54.20</b>	Dislocation of metacarpophalangeal joint of finger
<b>NC54.21</b>	Dislocation of interphalangeal joint of finger
<b>NC54.2Y</b>	Dislocation of other specified part of finger
<b>NC54.2Z</b>	Dislocation of finger, unspecified
<b>NC54.3</b>	<b>Multiple dislocations of fingers</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NC54.4</b>	<b>Traumatic rupture of ligament of wrist or carpus</b>
<b>NC54.40</b>	Traumatic rupture of scapholunate ligament
<b>NC54.41</b>	Traumatic rupture of radiocarpal ligament
<b>NC54.42</b>	Traumatic rupture of ulnocarpal ligament
<b>NC54.43</b>	Traumatic rupture of lunotriquetral ligament
<b>NC54.4Y</b>	Traumatic rupture of other specified ligament of wrist or carpus
<b>NC54.4Z</b>	Traumatic rupture of ligament of wrist or carpus, unspecified

<b>NC54.5</b>	<b>Traumatic rupture of ligament of finger at metacarpophalangeal or interphalangeal joint</b>
<b>NC54.50</b>	Traumatic rupture of collateral ligament of finger at metacarpophalangeal or interphalangeal joint
<b>NC54.51</b>	Traumatic rupture of palmar ligament of finger at metacarpophalangeal or interphalangeal joint
<b>NC54.52</b>	Traumatic rupture of volar plate of finger at metacarpophalangeal or interphalangeal joint
<b>NC54.53</b>	Traumatic rupture of other ligament of finger at metacarpophalangeal or interphalangeal joint
<b>NC54.5Z</b>	Traumatic rupture of ligament of finger at metacarpophalangeal or interphalangeal joint, unspecified
<b>NC54.6</b>	<b>Strain or sprain of wrist</b>
	A collective term for muscle and ligament injuries of the tissues associated with the wrist without dislocation or fracture; a joint injury in which some of the fibers of a supporting ligament are ruptured but the continuity of the ligament remains intact. A strain is an overstretching or overexertion of some part of the musculature.
<b>NC54.60</b>	Strain or sprain of carpal joint
<b>NC54.61</b>	Strain or sprain of radiocarpal joint
<b>NC54.62</b>	Strain or sprain of carpometacarpal joint
<b>NC54.6Y</b>	Sprain of other specified part of wrist
<b>NC54.6Z</b>	Strain or sprain of wrist, unspecified
<b>NC54.7</b>	<b>Strain or sprain of thumb</b>
<b>NC54.70</b>	Strain or sprain of metacarpophalangeal joint of thumb
<b>NC54.71</b>	Strain or sprain of interphalangeal joint of thumb
<b>NC54.7Y</b>	Sprain or strain of other specified part of thumb
<b>NC54.7Z</b>	Strain or sprain of thumb, unspecified
<b>NC54.8</b>	<b>Strain or sprain of finger</b>
<b>NC54.80</b>	Strain or sprain of metacarpophalangeal joint of finger
<b>NC54.81</b>	Strain or sprain of interphalangeal joint of finger
<b>NC54.8Y</b>	Sprain of other specified part of finger
<b>NC54.8Z</b>	Strain or sprain of finger, unspecified
<b>NC54.Y</b>	<b>Dislocation or sprain of other specified joints or ligaments at wrist or hand level</b>
<b>NC54.Z</b>	<b>Dislocation or strain or sprain of joints or ligaments at wrist or hand level, unspecified</b>

<b>NC55</b>	<b>Injury of nerves at wrist or hand level</b>
NC55.0	<b>Injury of ulnar nerve at wrist or hand level</b>
NC55.1	<b>Injury of median nerve at wrist or hand level</b>
NC55.2	<b>Injury of radial nerve at wrist or hand level</b>
NC55.3	<b>Injury of multiple nerves at wrist or hand level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
NC55.Y	<b>Injury of other specified nerves at wrist or hand level</b>
NC55.Z	<b>Injury of unspecified nerve at wrist or hand level</b>
<b>NC56</b>	<b>Injury of blood vessels at wrist or hand level</b>
NC56.0	<b>Injury of ulnar artery at wrist or hand level</b>
NC56.00	Laceration of ulnar artery at wrist or hand level
NC56.01	Contusion of ulnar artery at wrist or hand level
NC56.0Y	Other specified injury of ulnar artery at wrist or hand level
NC56.0Z	Injury of ulnar artery at wrist or hand level, unspecified
NC56.1	<b>Injury of radial artery at wrist or hand level</b>
NC56.10	Laceration of radial artery at wrist or hand level
NC56.11	Contusion of radial artery at wrist or hand level
NC56.1Y	Other specified injury of radial artery at wrist or hand level
NC56.1Z	Injury of radial artery at wrist or hand level, unspecified
NC56.2	<b>Injury of superficial palmar arch</b>
NC56.20	Laceration of superficial palmar arch
NC56.21	Contusion of superficial palmar arch
NC56.2Y	Other specified injury of superficial palmar arch
NC56.2Z	Injury of superficial palmar arch, unspecified
NC56.3	<b>Injury of deep palmar arch</b>
NC56.30	Laceration of deep palmar arch
NC56.31	Contusion of deep palmar arch
NC56.3Y	Other specified injury of deep palmar arch
NC56.3Z	Injury of deep palmar arch, unspecified
NC56.4	<b>Injury of blood vessel of thumb</b>

<b>NC56.40</b>	Laceration of blood vessel of thumb
<b>NC56.41</b>	Contusion of blood vessel of thumb
<b>NC56.4Y</b>	Other specified injury of blood vessel of thumb
<b>NC56.4Z</b>	Injury of blood vessel of thumb, unspecified
<b>NC56.5</b>	<b>Injury of blood vessel of other finger</b>
<b>NC56.50</b>	Laceration of blood vessel of other finger
<b>NC56.51</b>	Contusion of blood vessel of other finger
<b>NC56.5Y</b>	Other specified injury of blood vessel of other finger
<b>NC56.5Z</b>	Injury of blood vessel of other finger, unspecified
<b>NC56.6</b>	<b>Injury of multiple blood vessels at wrist or hand level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC56.60</b>	Laceration of multiple blood vessels at wrist or hand level
<b>NC56.61</b>	Contusion of multiple blood vessels at wrist or hand level
<b>NC56.6Y</b>	Other specified injury of multiple blood vessels at wrist or hand level
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC56.6Z</b>	Injury of multiple blood vessels at wrist or hand level, unspecified
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC56.Y</b>	<b>Injury of other specified blood vessels at wrist and hand level</b>
<b>NC56.Z</b>	<b>Injury of unspecified blood vessel at wrist or hand level</b>
<b>NC57</b>	<b>Injury of muscle, fascia or tendon at wrist or hand level</b>
<b>NC57.0</b>	<b>Injury of long flexor muscle, fascia or tendon of thumb at wrist or hand level</b>
<b>NC57.00</b>	Strain or sprain of long flexor muscle, fascia or tendon of thumb at wrist or hand level
<b>NC57.01</b>	Laceration of long flexor muscle, fascia or tendon of thumb at wrist or hand level
<b>NC57.0Y</b>	Other specified injury of long flexor muscle, fascia or tendon of thumb at wrist or hand level
<b>NC57.0Z</b>	Injury of long flexor muscle, fascia or tendon of thumb at wrist or hand level, unspecified
<b>NC57.1</b>	<b>Injury of flexor muscle, fascia or tendon of other finger at wrist or hand level</b>
<b>NC57.10</b>	Strain or sprain of flexor muscle, fascia or tendon of other finger at wrist or hand level
<b>NC57.11</b>	Laceration of flexor muscle, fascia or tendon of other finger at wrist or hand level

<b>NC57.1Y</b>	Other specified injury of flexor muscle, fascia or tendon of other finger at wrist or hand level
<b>NC57.1Z</b>	Injury of flexor muscle, fascia or tendon of other finger at wrist or hand level, unspecified
<b>NC57.2</b>	<b>Injury of extensor muscle, fascia or tendon of thumb at wrist or hand level</b>
<b>NC57.20</b>	Strain or sprain of extensor muscle, fascia or tendon of thumb at wrist or hand level
<b>NC57.21</b>	Laceration of extensor muscle, fascia or tendon of thumb at wrist or hand level
<b>NC57.2Y</b>	Other specified injury of extensor muscle, fascia or tendon of thumb at wrist or hand level
<b>NC57.2Z</b>	Injury of extensor muscle, fascia or tendon of thumb at wrist or hand level, unspecified
<b>NC57.3</b>	<b>Injury of extensor muscle, fascia or tendon of other finger at wrist or hand level</b>
<b>NC57.30</b>	Strain or sprain of extensor muscle, fascia or tendon of other finger at wrist or hand level
<b>NC57.31</b>	Laceration of extensor muscle, fascia or tendon of other finger at wrist or hand level
<b>NC57.3Y</b>	Other specified injury of extensor muscle, fascia or tendon of other finger at wrist or hand level
<b>NC57.3Z</b>	Injury of extensor muscle, fascia or tendon of other finger at wrist or hand level, unspecified
<b>NC57.4</b>	<b>Injury of intrinsic muscle, fascia or tendon of thumb at wrist or hand level</b>
<b>NC57.40</b>	Strain or sprain of intrinsic muscle, fascia or tendon of thumb at wrist or hand level
<b>NC57.41</b>	Laceration of intrinsic muscle, fascia or tendon of thumb at wrist or hand level
<b>NC57.4Y</b>	Other specified injury of intrinsic muscle, fascia or tendon of thumb at wrist or hand level
<b>NC57.4Z</b>	Injury of intrinsic muscle, fascia or tendon of thumb at wrist or hand level, unspecified
<b>NC57.5</b>	<b>Injury of intrinsic muscle, fascia or tendon of other finger at wrist or hand level</b>
<b>NC57.50</b>	Strain or sprain of intrinsic muscle, fascia or tendon of other finger at wrist or hand level
<b>NC57.51</b>	Laceration of intrinsic muscle, fascia or tendon of other finger at wrist or hand level
<b>NC57.5Y</b>	Other specified injury of intrinsic muscle, fascia or tendon of other finger at wrist or hand level
<b>NC57.5Z</b>	Injury of intrinsic muscle, fascia or tendon of other finger at wrist or hand level, unspecified

<b>NC57.6</b>	<b>Injury of multiple flexor muscles or tendons at wrist or hand level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC57.7</b>	<b>Injury of multiple extensor muscles or tendons at wrist or hand level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC57.Y</b>	<b>Injury of other specified muscle, fascia or tendon at wrist or hand level</b>
<b>NC57.Z</b>	<b>Injury of unspecified muscle, fascia or tendon at wrist or hand level</b>
<b>NC58</b>	<b>Crushing injury of wrist or hand</b>
<b>NC58.0</b>	<b>Crushing injury of thumb</b>
<b>NC58.1</b>	<b>Crushing injury of other finger</b>
<b>NC58.2</b>	<b>Crushing injury of hand</b>
<b>NC58.3</b>	<b>Crushing injury of wrist</b>
<b>NC58.Y</b>	<b>Crushing injury of other specified part of wrist or hand</b>
<b>NC58.Z</b>	<b>Crushing injury of wrist or hand, unspecified</b>
<b>NC59</b>	<b>Traumatic amputation of wrist or hand</b>
<b>NC59.0</b>	<b>Traumatic amputation of thumb</b>
	<b><i>Exclusions:</i></b> avulsion of fingernail (NC50)
<b>NC59.00</b>	Traumatic amputation at or near base of right thumb
<b>NC59.01</b>	Traumatic amputation at or near base of left thumb
<b>NC59.02</b>	Traumatic amputation at or near base of thumb, bilateral
<b>NC59.0Y</b>	Other specified traumatic amputation of thumb
<b>NC59.0Z</b>	Traumatic amputation of thumb, unspecified
<b>NC59.1</b>	<b>Traumatic amputation of other single finger</b>
	<b><i>Exclusions:</i></b> avulsion of fingernail (NC50)
<b>NC59.2</b>	<b>Traumatic amputation of two or more fingers alone</b>
	<b><i>Exclusions:</i></b> avulsion of fingernail (NC50)
<b>NC59.20</b>	Traumatic amputation of two or more fingers at or near base, right hand
<b>NC59.21</b>	Traumatic amputation of two or more fingers at or near base, left hand
<b>NC59.22</b>	Traumatic amputation of two or more fingers alone at or near base, bilateral
<b>NC59.2Y</b>	Other specified traumatic amputation of two or more fingers alone
<b>NC59.2Z</b>	Traumatic amputation of two or more fingers alone, unspecified
<b>NC59.3</b>	<b>Combined traumatic amputation of finger with other parts of wrist or hand</b>

**NC59.4**      **Traumatic amputation of hand at metacarpal level**

**NC59.Z**      **Traumatic amputation of wrist or hand, unspecified**

**NC5A**      **Multiple injuries of wrist or hand**

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

**NC5A.0**      **Injury of multiple sites of hand**

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

**NC5A.1**      **Injury of multiple sites of wrist**

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

**NC5A.Y**      **Other specified multiple injuries of wrist or hand**

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

**NC5A.Z**      **Multiple injuries of wrist or hand, unspecified**

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

**NC5Y**      **Other specified injuries to the wrist or hand**

**NC5Z**      **Injuries to the wrist or hand, unspecified**

## Injuries to the hip or thigh (NC70-NC7Z)

**Exclusions:**      Frostbite (NE40-NE4Z)

                          Burns (ND90-NE2Z)

                          Insect bite or sting, venomous (NE61)

                          Other injuries of leg, level unspecified (ND55)

**NC70**      **Superficial injury of hip or thigh**

**NC70.0**      **Abrasions of hip**

**NC70.1**      **Contusion of hip**

**NC70.2**      **Abrasions of thigh**

- NC70.3**      **Contusion of thigh**  
**NC70.4**      **Multiple superficial injuries of hip or thigh**  
**Coding Note:** Assign additional codes for the specific injuries.  
**NC70.Y**      **Other specified superficial injury of hip or thigh**  
**NC70.Z**      **Superficial injury of hip or thigh, unspecified**

- NC71**      **Open wound of hip or thigh**  
**Exclusions:**      Traumatic amputation of hip or thigh (NC78)  
**NC71.0**      **Laceration without foreign body of hip or thigh**  
**Inclusions:**      laceration of skin of hip or thigh  
**NC71.1**      **Laceration with foreign body of hip or thigh**  
**NC71.2**      **Puncture wound without foreign body of hip or thigh**  
**NC71.3**      **Puncture wound with foreign body of hip or thigh**  
**NC71.4**      **Open bite of hip or thigh**  
**NC71.5**      **Multiple open wounds of hip or thigh**  
**Coding Note:** Assign additional codes for the specific injuries.

- NC71.Y**      **Other specified open wound of hip or thigh**  
**NC71.Z**      **Open wound of hip or thigh, unspecified**

- NC72**      **Fracture of femur**  
A break in the femur, longest and largest bone of the skeleton, situated between the hip and the knee.
- NC72.0**      **Fracture of head of femur**  
**NC72.1**      **Fracture of upper epiphysis of femur**  
**NC72.2**      **Fracture of neck of femur**  
**NC72.20**      Fracture of neck of femur, subcapital  
**NC72.21**      Fracture of neck of femur, mid-cervical  
**NC72.22**      Fracture of base of neck of femur  
**NC72.23**      Intracapsular fracture of femur  
**NC72.2Y**      Other specified fracture of neck of femur  
**NC72.2Z**      Fracture of neck of femur, unspecified  
**NC72.3**      **Fracture of trochanteric section of femur**  
**Inclusions:**      Trochanteric fracture  
**NC72.30**      Intertrochanteric fracture of femur

<b>NC72.31</b>	Petrochanteric fracture of femur
<b>NC72.3Y</b>	Fracture of other specified trochanteric section of femur
<b>NC72.3Z</b>	Fracture of unspecified trochanteric section of femur
<b>NC72.4</b>	<b>Subtrochanteric fracture of femur</b>
<b>NC72.5</b>	<b>Fracture of shaft of femur</b>
<b>NC72.6</b>	<b>Fracture of lower end of femur</b>
<b>NC72.60</b>	Fracture of lower end of femur not extending into joint, simple
<b>NC72.61</b>	Fracture of lower end of femur not extending into joint, wedge
<b>NC72.62</b>	Fracture of lower end of femur not extending into joint, complex
<b>NC72.63</b>	Fracture of lower end of femur extending into joint, lateral condyle
<b>NC72.64</b>	Fracture of lower end of femur extending into joint, medial condyle
<b>NC72.65</b>	Fracture of lower end of femur extending into joint, frontal
<b>NC72.66</b>	Fracture of lower end of femur extending into joint, complete articular
<b>NC72.6Y</b>	Other specified fracture of lower end of femur
<b>NC72.6Z</b>	Fracture of lower end of femur, unspecified
<b>NC72.7</b>	<b>Multiple fractures of femur</b>

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

<b>NC72.8</b>	<b>Fractures of other parts of femur</b>
<b>NC72.Y</b>	<b>Other specified fracture of femur</b>
<b>NC72.Z</b>	<b>Fracture of femur, unspecified</b>

### **NC73 Dislocation or strain or sprain of joint or ligaments of hip**

A collective term for muscle and ligament injuries of the tissues associated with, or displacement of the bones of, the hip.

<b>NC73.0</b>	<b>Dislocation of hip</b>
<b>NC73.00</b>	Posterior dislocation of hip
<b>NC73.01</b>	Obturator dislocation of hip
<b>NC73.02</b>	Other anterior dislocation of hip
<b>NC73.03</b>	Central dislocation of hip
<b>NC73.0Y</b>	Other specified dislocation of hip
<b>NC73.0Z</b>	Dislocation of hip, unspecified

<b>NC73.1</b>	<b>Strain or sprain of hip</b> A collective term for muscle and ligament injuries of the tissues associated with the hip without dislocation or fracture; a joint injury in which some of the fibers of a supporting ligament are ruptured but the continuity of the ligament remains intact. A strain is an overstretching or overexertion of some part of the musculature.
<b>NC73.10</b>	Iliofemoral ligament strain or sprain of hip
<b>NC73.11</b>	Ischiocapsular ligament strain or sprain of hip
<b>NC73.1Y</b>	Other specified strain or sprain of hip
<b>NC73.1Z</b>	Strain or sprain of hip, unspecified
<b>NC74</b>	<b>Injury of nerves at hip or thigh level</b>
<b>NC74.0</b>	<b>Injury of sciatic nerve at hip or thigh level</b>
<b>NC74.1</b>	<b>Injury of femoral nerve at hip or thigh level</b>
<b>NC74.2</b>	<b>Injury of cutaneous sensory nerve at hip or thigh level</b>
<b>NC74.3</b>	<b>Injury of multiple nerves at hip or thigh level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC74.Y</b>	<b>Injury of other specified nerves at hip or thigh level</b>
<b>NC74.Z</b>	<b>Injury of unspecified nerve at hip or thigh level</b>
<b>NC75</b>	<b>Injury of blood vessels at hip or thigh level</b>
	<b>Exclusions:</b> Injury of popliteal artery (NC95.0)
<b>NC75.0</b>	<b>Injury of femoral artery</b>
<b>NC75.00</b>	Laceration of femoral artery, minor <b>Inclusions:</b> incomplete transection of femoral artery laceration of femoral artery NOS superficial laceration of femoral artery
<b>NC75.01</b>	Laceration of femoral artery, major <b>Inclusions:</b> complete transection of femoral artery traumatic rupture of femoral artery
<b>NC75.0Y</b>	Other specified injury of femoral artery
<b>NC75.0Z</b>	Injury of femoral artery, unspecified
<b>NC75.1</b>	<b>Injury of femoral vein at hip or thigh level</b>
<b>NC75.10</b>	Laceration of femoral vein at hip or thigh level, minor <b>Inclusions:</b> incomplete transection of femoral vein at hip or thigh level laceration of femoral vein at hip or thigh level NOS superficial laceration of femoral vein at hip or thigh level

<b>NC75.11</b>	Laceration of femoral vein at hip or thigh level, major  <b>Inclusions:</b> complete transection of femoral vein at hip or thigh level traumatic rupture of femoral vein at hip and thigh level
<b>NC75.1Y</b>	Other specified injury of femoral vein at hip or thigh level
<b>NC75.1Z</b>	Injury of femoral vein at hip or thigh level, unspecified
<b>NC75.2</b>	<b>Injury of greater saphenous vein at hip or thigh level</b>  <b>Exclusions:</b> Injury of greater saphenous vein at lower leg level (NC95.4)
<b>NC75.20</b>	Laceration of greater saphenous vein at hip or thigh level, minor  <b>Inclusions:</b> incomplete transection of greater saphenous vein at hip or thigh level laceration of greater saphenous vein at hip or thigh level NOS superficial laceration of greater saphenous vein at hip or thigh level
<b>NC75.21</b>	Laceration of greater saphenous vein at hip or thigh level, major  <b>Inclusions:</b> complete transection of greater saphenous vein at hip or thigh level traumatic rupture of greater saphenous vein at hip or thigh level
<b>NC75.2Y</b>	Other specified injury of greater saphenous vein at hip or thigh level
<b>NC75.2Z</b>	Injury of greater saphenous vein at hip or thigh level, unspecified
<b>NC75.3</b>	<b>Injury of multiple blood vessels at hip or thigh level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC75.Y</b>	<b>Injury of other specified blood vessels at hip and thigh level</b>
<b>NC75.Z</b>	<b>Injury of unspecified blood vessel at hip or thigh level</b>
<b>NC76</b>	<b>Injury of muscle, fascia, tendon or bursa at hip or thigh level</b>
<b>NC76.0</b>	<b>Injury of muscle, fascia or tendon of hip</b>
<b>NC76.00</b>	Strain or sprain of muscle, fascia or tendon of hip
<b>NC76.01</b>	Laceration of muscle, fascia or tendon of hip
<b>NC76.0Y</b>	Other specified injury of muscle, fascia or tendon of hip
<b>NC76.0Z</b>	Injury of muscle, fascia or tendon of hip, unspecified
<b>NC76.1</b>	<b>Injury of quadriceps muscle or tendon</b>
<b>NC76.10</b>	Strain or sprain of quadriceps muscle or tendon
<b>NC76.11</b>	Laceration of quadriceps muscle or tendon
<b>NC76.1Y</b>	Other specified injury of quadriceps muscle or tendon

<b>NC76.1Z</b>	Injury of quadriceps muscle or tendon, unspecified
<b>NC76.2</b>	<b>Injury of adductor muscle, fascia or tendon of thigh</b>
<b>NC76.20</b>	Strain or sprain of adductor muscle, fascia or tendon of thigh
<b>NC76.21</b>	Laceration of adductor muscle, fascia or tendon of thigh
<b>NC76.2Y</b>	Other specified injury of adductor muscle, fascia or tendon of thigh
<b>NC76.2Z</b>	Injury of adductor muscle, fascia or tendon of thigh, unspecified
<b>NC76.3</b>	<b>Injury of muscle, fascia or tendon of the posterior muscle group at thigh level</b>
<b>NC76.30</b>	Strain or sprain of muscle, fascia or tendon of the posterior muscle group at thigh level
<b>NC76.31</b>	Laceration of muscle, fascia or tendon of the posterior muscle group at thigh level
<b>NC76.3Y</b>	Other specified injury of muscle, fascia or tendon of the posterior muscle group at thigh level
<b>NC76.3Z</b>	Injury of muscle, fascia or tendon of the posterior muscle group at thigh level, unspecified
<b>NC76.4</b>	<b>Injury of multiple muscles or tendons at hip or thigh level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC76.40</b>	Injury of bursa of hip
<b>NC76.4Y</b>	Other specified injury of multiple muscles or tendons at hip or thigh level
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC76.4Z</b>	Injury of multiple muscles or tendons at hip or thigh level, unspecified
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC76.Y</b>	<b>Injury of other specified muscle, fascia, tendon or bursa at hip or thigh level</b>
<b>NC76.Z</b>	<b>Injury of unspecified muscle, fascia, tendon or bursa at hip or thigh level</b>
<b>NC77</b>	<b>Crushing injury of hip or thigh</b>
<b>NC77.0</b>	<b>Crushing injury of hip</b>
<b>NC77.1</b>	<b>Crushing injury of thigh</b>
<b>NC77.2</b>	<b>Crushing injury of hip with thigh</b>
<b>NC77.Z</b>	<b>Crushing injury of hip or thigh, unspecified</b>
<b>NC78</b>	<b>Traumatic amputation of hip or thigh</b>
<b>Exclusions:</b>	traumatic amputation of leg, level unspecified (ND55)
<b>NC78.0</b>	<b>Traumatic amputation at right hip joint</b>
<b>NC78.1</b>	<b>Traumatic amputation at left hip joint</b>

- NC78.2      **Traumatic amputation at hip joint, bilateral**
- NC78.3      **Traumatic amputation at level between right hip and knee**
- NC78.4      **Traumatic amputation at level between left hip and knee**
- NC78.5      **Traumatic amputation at level between hip and knee, bilateral**
- NC78.Z      **Traumatic amputation of hip or thigh, unspecified**

**NC79      Multiple injuries of hip or thigh**

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

- NC7Y      Other specified injuries to the hip or thigh**

- NC7Z      Injuries to the hip or thigh, unspecified**

### Injuries to the knee or lower leg (NC90-NC9Z)

- Exclusions:**
- Burns (ND90-NE2Z)
  - Frostbite (NE40-NE4Z)
  - Insect bite or sting, venomous (NE61)
  - Other injuries of leg, level unspecified (ND55)
  - Injuries to the ankle or foot (ND10-ND1Z)

**NC90      Superficial injury of knee or lower leg**

- Exclusions:**      Superficial injury of ankle or foot (ND11)

- NC90.0      **Abrasions of knee**
- NC90.1      **Contusion of knee**
- NC90.2      **Abrasions of other or unspecified parts of lower leg**
- NC90.3      **Contusion of other or unspecified parts of lower leg**
- NC90.4      **Multiple superficial injuries of lower leg**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

- NC90.Y      Other specified superficial injury of knee or lower leg**

- NC90.Z      Superficial injury of knee or lower leg, unspecified**

**NC91      Open wound of knee or lower leg**

- Exclusions:**
- Traumatic amputation of lower leg (NC98)
  - Open wound of ankle or foot (ND12)

<b>NC91.0</b>	<b>Laceration without foreign body of lower leg</b>
	<b>Inclusions:</b> laceration of skin of lower leg Laceration without foreign body of knee
<b>NC91.1</b>	<b>Laceration with foreign body of lower leg</b>
<b>NC91.2</b>	<b>Puncture wound without foreign body of lower leg</b>
<b>NC91.3</b>	<b>Puncture wound with foreign body of lower leg</b>
<b>NC91.4</b>	<b>Open bite of lower leg</b>
<b>NC91.5</b>	<b>Multiple open wounds of lower leg</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NC91.Y</b>	<b>Other specified open wound of knee or lower leg</b>
<b>NC91.Z</b>	<b>Open wound of knee or lower leg, unspecified</b>
<b>NC92</b>	<b>Fracture of lower leg, including ankle</b>
	<b>Exclusions:</b> Fracture of foot, except ankle (ND13)
<b>NC92.0</b>	<b>Fracture of patella</b> A break in the patellar bone (kneecap)
<b>NC92.1</b>	<b>Fracture of upper end of tibia</b>
<b>NC92.10</b>	Avulsion of cruciate ligament insertion
<b>NC92.11</b>	Avulsion of tibial tuberosity
<b>NC92.12</b>	Metaphyseal fracture of upper end of tibia
<b>NC92.13</b>	Fracture of upper end of tibia, lateral condyle
<b>NC92.14</b>	Fracture of upper end of tibia, medial condyle
<b>NC92.1Y</b>	Other specified fracture of upper end of tibia
<b>NC92.1Z</b>	Fracture of upper end of tibia, unspecified
<b>NC92.2</b>	<b>Fracture of shaft of tibia</b>
<b>NC92.3</b>	<b>Fracture of lower end of tibia</b> <b>Exclusions:</b> Fracture of medial malleolus (NC92.5)
<b>NC92.4</b>	<b>Fracture of fibula</b> <b>Exclusions:</b> Fracture of lateral malleolus (NC92.6)
<b>NC92.40</b>	Avulsion of fibular head
<b>NC92.4Y</b>	Other specified fracture of fibula
<b>NC92.4Z</b>	Fracture of fibula, unspecified

<b>NC92.5</b>	<b>Fracture of medial malleolus</b> A fracture of the medial malleolus, the bony landmark located on the distal end of the tibia
<b>NC92.6</b>	<b>Fracture of lateral malleolus</b>
<b>NC92.7</b>	<b>Complex fractures of ankle</b>
<b>NC92.70</b>	Fracture, avulsion or collateral ligament rupture of lateral malleolus below syndesmosis with fracture, avulsion or collateral ligament rupture of medial malleolus
<b>NC92.71</b>	Fracture, avulsion or collateral ligament rupture of lateral malleolus below syndesmosis with fracture, avulsion or collateral ligament rupture of medial malleolus and fracture of posterior margin of distal tibia
<b>NC92.72</b>	Fracture of lateral malleolus at syndesmosis with fracture, avulsion or collateral ligament rupture of medial malleolus
<b>NC92.73</b>	Fracture of lateral malleolus at syndesmosis with fracture, avulsion or collateral ligament rupture of medial malleolus and fracture of posterior margin of distal tibia
<b>NC92.74</b>	Fracture, avulsion or collateral ligament rupture of medial malleolus with fracture of fibula above syndesmosis
<b>NC92.75</b>	Fracture, avulsion or collateral ligament rupture of medial malleolus with fracture of fibula above syndesmosis and fracture of posterior margin of distal tibia
<b>NC92.76</b>	Bimalleolar fracture of ankle, not otherwise specified
<b>NC92.77</b>	Trimalleolar fracture of ankle, not otherwise specified
<b>NC92.7Y</b>	Other specified complex fractures of ankle
<b>NC92.7Z</b>	Complex fractures of ankle, unspecified
<b>NC92.8</b>	<b>Multiple fractures of lower leg</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NC92.Y</b>	<b>Fracture of other specified part of lower leg, including ankle</b>
<b>NC92.Z</b>	<b>Fracture of lower leg, including ankle, unspecified</b>
<b>NC93</b>	<b>Dislocation or strain or sprain of joints or ligaments of knee</b>
	<b>Exclusions:</b>
	dislocation of knee recurrent (FA34.2)
	Internal derangement of knee (FA33)
	derangement of patella (FA32)
	dislocation of knee old (FA34.2)
<b>NC93.0</b>	<b>Acute internal damage of knee</b>
<b>NC93.1</b>	<b>Dislocation of patella</b> Displacement of the patella from the femoral groove.

<b>NC93.10</b>	Lateral dislocation of patella
<b>NC93.1Y</b>	Other specified dislocation of patella
<b>NC93.1Z</b>	Dislocation of patella, unspecified
<b>NC93.2</b>	<b>Dislocation of knee</b>
<b>NC93.20</b>	Anterior dislocation of proximal end of tibia
<b>NC93.21</b>	Posterior dislocation of proximal end of tibia
<b>NC93.22</b>	Medial dislocation of proximal end of tibia
<b>NC93.23</b>	Lateral dislocation of proximal end of tibia
<b>NC93.2Y</b>	Other specified dislocation of knee
<b>NC93.2Z</b>	Dislocation of knee, unspecified
<b>NC93.3</b>	<b>Tear of meniscus, current</b>
	<b><i>Exclusions:</i></b> old bucket-handle tear (FA33)
<b>NC93.30</b>	Tear of medial meniscus
<b>NC93.31</b>	Tear of lateral meniscus
<b>NC93.3Y</b>	Other specified tear of meniscus, current
<b>NC93.3Z</b>	Tear of meniscus, current, unspecified
<b>NC93.4</b>	<b>Tear of articular cartilage of knee</b>
<b>NC93.5</b>	<b>Strain or sprain involving fibular or tibial collateral ligament of knee</b>
<b>NC93.50</b>	Strain or sprain of medial collateral ligament of knee, excluding rupture
<b>NC93.51</b>	Strain or sprain of lateral collateral ligament of knee, excluding rupture
<b>NC93.52</b>	Rupture of medial collateral ligament of knee
<b>NC93.53</b>	Rupture of lateral collateral ligament of knee
<b>NC93.5Y</b>	Other specified strain or sprain involving fibular or tibial collateral ligament of knee
<b>NC93.5Z</b>	Strain or sprain involving fibular or tibial collateral ligament of knee, unspecified
<b>NC93.6</b>	<b>Strain or sprain involving anterior or posterior cruciate ligament of knee</b>
<b>NC93.60</b>	Strain or sprain of anterior cruciate ligament of knee, excluding rupture
<b>NC93.61</b>	Strain or sprain of posterior cruciate ligament of knee, excluding rupture
<b>NC93.62</b>	Rupture of anterior cruciate ligament
<b>NC93.63</b>	Rupture of posterior cruciate ligament
<b>NC93.6Y</b>	Other specified strain or sprain involving anterior or posterior cruciate ligament of knee

<b>NC93.6Z</b>	Strain or sprain involving anterior or posterior cruciate ligament of knee, unspecified
<b>NC93.7</b>	<b>Strain or sprain of other or unspecified parts of knee</b> A collective term for muscle and ligament injuries of other and unspecified tissues associated with the knee without dislocation or fracture; a joint injury in which some of the fibers of a supporting ligament are ruptured but the continuity of the ligament remains intact. A strain is an overstretching or overexertion of some part of the musculature.
	<b>Exclusions:</b> sprain of patellar ligament (NC76.1)
<b>NC93.8</b>	<b>Injury to multiple structures of knee</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
<b>NC93.Y</b>	<b>Other specified dislocation or strain or sprain of joints or ligaments of knee</b>
<b>NC93.Z</b>	<b>Dislocation or strain or sprain of joints or ligaments of knee, unspecified</b>
<b>NC94</b>	<b>Injury of nerves at lower leg level</b>
	<b>Exclusions:</b> Injury of nerves at ankle or foot level (ND15)
<b>NC94.0</b>	<b>Injury of tibial nerve at lower leg level</b>
<b>NC94.1</b>	<b>Injury of peroneal nerve at lower leg level</b>
<b>NC94.2</b>	<b>Injury of cutaneous sensory nerve at lower leg level</b>
<b>NC94.3</b>	<b>Injury of multiple nerves at lower leg level</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NC94.Y</b>	<b>Injury of other specified nerves at lower leg level</b>
<b>NC94.Z</b>	<b>Injury of unspecified nerve at lower leg level</b>
<b>NC95</b>	<b>Injury of blood vessels at lower leg level</b>
	<b>Exclusions:</b> Injury of blood vessels at ankle or foot level (ND16)
<b>NC95.0</b>	<b>Injury of popliteal artery</b>
<b>NC95.00</b>	Laceration of popliteal artery
<b>NC95.0Y</b>	Other specified injury of popliteal artery
<b>NC95.0Z</b>	Injury of popliteal artery, unspecified
<b>NC95.1</b>	<b>Injury of anterior tibial artery</b>
<b>NC95.10</b>	Laceration of anterior tibial artery
<b>NC95.1Y</b>	Other specified injury of anterior tibial artery
<b>NC95.1Z</b>	Injury of anterior tibial artery, unspecified

<b>NC95.2</b>	<b>Injury of posterior tibial artery</b>
<b>NC95.20</b>	Laceration of posterior tibial artery
<b>NC95.2Y</b>	Other specified injury of posterior tibial artery
<b>NC95.2Z</b>	Injury of posterior tibial artery, unspecified
<b>NC95.3</b>	<b>Injury of peroneal artery</b>
<b>NC95.30</b>	Laceration of peroneal artery
<b>NC95.3Y</b>	Other specified injury of peroneal artery
<b>NC95.3Z</b>	Injury of peroneal artery, unspecified
<b>NC95.4</b>	<b>Injury of greater saphenous vein at lower leg level</b>
<b>NC95.40</b>	Laceration of greater saphenous vein at lower leg level
<b>NC95.4Y</b>	Other specified injury of greater saphenous vein at lower leg level
<b>NC95.4Z</b>	Injury of greater saphenous vein at lower leg level, unspecified
<b>NC95.5</b>	<b>Injury of lesser saphenous vein at lower leg level</b>
<b>NC95.50</b>	Laceration of lesser saphenous vein at lower leg level
<b>NC95.5Y</b>	Other specified injury of lesser saphenous vein at lower leg level
<b>NC95.5Z</b>	Injury of lesser saphenous vein at lower leg level, unspecified
<b>NC95.6</b>	<b>Injury of popliteal vein</b>
<b>NC95.60</b>	Laceration of popliteal vein
<b>NC95.6Y</b>	Other specified injury of popliteal vein
<b>NC95.6Z</b>	Injury of popliteal vein, unspecified
<b>NC95.7</b>	<b>Injury of multiple blood vessels at lower leg level</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>NC95.Y</b>	<b>Injury of other specified blood vessels at lower leg level</b>
<b>NC95.Z</b>	<b>Injury of unspecified blood vessel at lower leg level</b>
<b>NC96</b>	<b>Injury of muscle, fascia, tendon or bursa at lower leg level</b>
	<b>Exclusions:</b> Injury of muscle, fascia or tendon at ankle or foot level (ND17) injury of patellar ligament (tendon) (NC76.1)
<b>NC96.0</b>	<b>Injury of Achilles tendon</b>
<b>NC96.00</b>	Strain or sprain of Achilles tendon
<b>NC96.01</b>	Laceration of Achilles tendon

<b>NC96.02</b>	Rupture of Achilles tendon
<b>NC96.0Y</b>	Other specified injury of Achilles tendon
<b>NC96.0Z</b>	Injury of Achilles tendon, unspecified
<b>NC96.1</b>	<b>Injury of other muscle, fascia or tendon of posterior muscle group at lower leg level</b>
<b>NC96.10</b>	Strain or sprain of other muscle, fascia or tendon of posterior muscle group at lower leg level
<b>NC96.11</b>	Laceration of other muscle, fascia or tendon of posterior muscle group at lower leg level
<b>NC96.1Y</b>	Other specified injury of other muscle, fascia or tendon of posterior muscle group at lower leg level
<b>NC96.1Z</b>	Injury of other muscle, fascia or tendon of posterior muscle group at lower leg level, unspecified
<b>NC96.2</b>	<b>Injury of muscle, fascia or tendon of anterior muscle group at lower leg level</b>
<b>NC96.20</b>	Strain or sprain of muscle, fascia or tendon of anterior muscle group at lower leg level
<b>NC96.21</b>	Laceration of muscle, fascia or tendon of anterior muscle group at lower leg level
<b>NC96.2Y</b>	Other specified injury of muscle, fascia or tendon of anterior muscle group at lower leg level
<b>NC96.2Z</b>	Injury of muscle, fascia or tendon of anterior muscle group at lower leg level, unspecified
<b>NC96.3</b>	<b>Injury of muscle, fascia or tendon of peroneal muscle group at lower leg level</b>
<b>NC96.30</b>	Strain or sprain of muscle, fascia or tendon of peroneal muscle group at lower leg level
<b>NC96.31</b>	Laceration of muscle, fascia or tendon of peroneal muscle group at lower leg level
<b>NC96.3Y</b>	Other specified injury of muscle, fascia or tendon of peroneal muscle group at lower leg level
<b>NC96.3Z</b>	Injury of muscle, fascia or tendon of peroneal muscle group at lower leg level, unspecified
<b>NC96.4</b>	<b>Injury of multiple muscles, fasciae or tendons at lower leg level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>NC96.5</b>	<b>Injury of bursa of knee</b>
<b>NC96.Y</b>	<b>Injury of other specified muscle, fascia, tendon or bursa at lower leg level</b>
<b>NC96.Z</b>	<b>Injury of unspecified muscle, fascia, tendon or bursa at lower leg level</b>
<b>NC97</b>	<b>Crushing injury of lower leg</b>
	<b>Exclusions:</b> Crushing injury of ankle or foot (ND18)

**NC97.0**      **Crushing injury of knee**

**NC97.Y**      **Crushing injury of other specified part of lower leg**

**NC97.Z**      **Crushing injury of lower leg, unspecified**

**NC98**      **Traumatic amputation of lower leg**

**Exclusions:**      Traumatic amputation of ankle or foot (ND19)  
                          traumatic amputation of leg, level unspecified (ND55)

**NC98.0**      **Traumatic amputation of right lower leg at knee level**

**NC98.1**      **Traumatic amputation of left lower leg at knee level**

**NC98.2**      **Traumatic amputation at knee level, bilateral**

**NC98.3**      **Traumatic amputation at level between right knee and ankle**

**NC98.4**      **Traumatic amputation at level between left knee and ankle**

**NC98.5**      **Traumatic amputation at level between knee and ankle, bilateral**

**NC98.Y**      **Other specified traumatic amputation of lower leg**

**NC98.Z**      **Traumatic amputation of lower leg, unspecified**

**NC99**      **Multiple injuries of lower leg**

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

**NC9Y**      **Other specified injuries to the knee or lower leg**

**NC9Z**      **Injuries to the knee or lower leg, unspecified**

**Injuries to the ankle or foot (ND10-ND1Z)**

**Exclusions:**      fracture of ankle and malleolus (NC92.5)  
                          Other injuries of leg, level unspecified (ND55)  
                          Frostbite (NE40-NE4Z)  
                          Burns (ND90-NE2Z)  
                          Insect bite or sting, venomous (NE61)

**ND10**      **Injury to toenail**

**ND11**      **Superficial injury of ankle or foot**

**ND11.0**      **Abrasions of ankle**

**ND11.1**      **Contusion of ankle**

**ND11.2**      **Nonthermal blister of ankle**

<b>ND11.3</b>	<b>Nonvenomous insect bite of ankle</b>
<b>ND11.4</b>	<b>Superficial foreign body in ankle</b>
<b>ND11.40</b>	Splinter in ankle
<b>ND11.4Y</b>	Other specified superficial foreign body in ankle
<b>ND11.4Z</b>	Superficial foreign body in ankle, unspecified
<b>ND11.5</b>	<b>Abrasions of toe</b>
<b>ND11.6</b>	<b>Contusion of toe</b>
<b>ND11.7</b>	<b>Abrasions of other or unspecified parts of foot</b>
<b>ND11.8</b>	<b>Contusions of other or unspecified parts of foot</b>
<b>ND11.9</b>	<b>Nonthermal blister of other or unspecified parts of foot</b>
<b>ND11.A</b>	<b>Nonvenomous insect bite of other or unspecified parts of foot</b>
<b>ND11.B</b>	<b>Superficial foreign body in other or unspecified parts of foot</b>
<b>ND11.B0</b>	Splinter in other or unspecified parts of foot
<b>ND11.BY</b>	Other specified superficial foreign body in other or unspecified parts of foot
<b>ND11.BZ</b>	Superficial foreign body in other or unspecified parts of foot, unspecified
<b>ND11.C</b>	<b>Multiple superficial injuries of ankle or foot</b>

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**ND11.Y** Other specified superficial injury of ankle or foot

**ND11.Z** Superficial injury of ankle or foot, unspecified

## **ND12 Open wound of ankle or foot**

**Exclusions:** Traumatic amputation of ankle or foot (ND19)

**ND12.0 Laceration without foreign body of ankle or foot**

**Inclusions:** laceration of skin of ankle or foot

**ND12.1 Laceration with foreign body of ankle or foot**

**ND12.2 Puncture wound with foreign body of ankle or foot**

**ND12.3 Puncture wound without foreign body of ankle or foot**

**ND12.4 Open bite of ankle or foot**

**ND12.5 Multiple open wounds of ankle or foot**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**ND12.6 Open wound of toe**

<b>ND12.60</b>	Laceration without foreign body of toe  <b><i>Exclusions:</i></b> Injury to toenail (ND10)
<b>ND12.61</b>	Laceration with foreign body of toe
<b>ND12.62</b>	Puncture wound without foreign body of toe
<b>ND12.63</b>	Puncture wound with foreign body of toe
<b>ND12.64</b>	Open bite of toe
<b>ND12.6Y</b>	Other specified open wound of toe
<b>ND12.6Z</b>	Open wound of toe, unspecified
<b>ND12.Y</b>	<b>Other specified open wound of ankle or foot</b>
<b>ND12.Z</b>	<b>Open wound of ankle or foot, unspecified</b>
<b>ND13</b>	<b>Fracture of foot, except ankle</b>
	<b><i>Exclusions:</i></b> Fracture of medial malleolus (NC92.5) Fracture of lower leg, including ankle (NC92) Fracture of lateral malleolus (NC92.6)
<b>ND13.0</b>	<b>Fracture of calcaneus</b>
<b>ND13.1</b>	<b>Fracture of talus</b>  <b><i>Inclusions:</i></b> Fracture of astragalus
<b>ND13.2</b>	<b>Fracture of unspecified tarsal bone</b>
<b>ND13.3</b>	<b>Fracture of metatarsal bone</b> A break in one or more of the metatarsal bones of the foot  <b><i>Exclusions:</i></b> march fracture (FB80.A)
<b>ND13.4</b>	<b>Fracture of great toe</b>
<b>ND13.5</b>	<b>Fracture of other toe</b>
<b>ND13.6</b>	<b>Multiple fractures of foot</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>ND13.7</b>	<b>Fracture of cuboid bone</b>
<b>ND13.8</b>	<b>Fracture of lateral cuneiform</b>
<b>ND13.9</b>	<b>Fracture of intermediate cuneiform</b>
<b>ND13.A</b>	<b>Fracture of medial cuneiform</b>
<b>ND13.B</b>	<b>Fracture of navicular of foot</b>
<b>ND13.Y</b>	<b>Fracture of other specified part of foot, except ankle</b>

<b>ND13.Z</b>	<b>Fracture of foot, except ankle, unspecified</b>
<b>ND14</b>	<b>Dislocation or strain or sprain of joints or ligaments at ankle or foot level</b>
<b>ND14.0</b>	<b>Dislocation of ankle joint</b> Displacement of one or more bones of the ankle, including the tarsals <i>Inclusions:</i> Dislocation of astragalus Dislocation of talus
<b>ND14.1</b>	<b>Dislocation of great toe</b>
<b>ND14.10</b>	Dislocation of metatarsophalangeal joint of great toe
<b>ND14.11</b>	Dislocation of interphalangeal joint of great toe
<b>ND14.1Z</b>	Dislocation of great toe, unspecified
<b>ND14.2</b>	<b>Dislocation of other toe</b>
<b>ND14.20</b>	Dislocation of metatarsophalangeal joint of lesser toe
<b>ND14.21</b>	Dislocation of interphalangeal joints of lesser toe
<b>ND14.2Y</b>	Dislocation of other specified toe
<b>ND14.2Z</b>	Dislocation of other toe, unspecified
<b>ND14.3</b>	<b>Dislocation of tarsal joint</b>
<b>ND14.4</b>	<b>Dislocation of tarsometatarsal joint</b>
<b>ND14.5</b>	<b>Rupture of ligaments at ankle or foot level</b>
<b>ND14.6</b>	<b>Dislocation of other or unspecified parts of foot</b>
<b>ND14.7</b>	<b>Strain or sprain of ankle</b> <i>Exclusions:</i> Injury of Achilles tendon (NC96.0)
<b>ND14.70</b>	Strain or sprain of calcaneofibular ligament
<b>ND14.71</b>	Strain or sprain of deltoid ligament
<b>ND14.72</b>	Strain or sprain of tibiofibular ligament
<b>ND14.73</b>	Strain or sprain of other ligament of ankle
<b>ND14.7Z</b>	Strain or sprain of ankle, unspecified
<b>ND14.8</b>	<b>Strain or sprain of other toe</b> <i>Exclusions:</i> Strain or sprain of great toe (ND14.9)
<b>ND14.80</b>	Strain or sprain of metatarsophalangeal joint of lesser toe
<b>ND14.81</b>	Strain or sprain of interphalangeal joints of lesser toe
<b>ND14.8Y</b>	Strain or sprain of other specified toe

<b>ND14.8Z</b>	Strain or sprain of other toe, unspecified
<b>ND14.9</b>	<b>Strain or sprain of great toe</b>
<b>ND14.90</b>	Strain or sprain of metatarsophalangeal joint of great toe
<b>ND14.91</b>	Strain or sprain of interphalangeal joint of great toe
<b>ND14.9Z</b>	Strain or sprain of great toe, unspecified
<b>ND14.A</b>	<b>Strain or sprain of other or unspecified parts of foot</b>
<b>ND14.Y</b>	<b>Other specified dislocation or strain or sprain of joints or ligaments at ankle or foot level</b>
<b>ND14.Z</b>	<b>Dislocation or strain or sprain of joints or ligaments at ankle or foot level, unspecified</b>

**ND15      Injury of nerves at ankle or foot level**

<b>ND15.0</b>	<b>Injury of lateral plantar nerve</b>
<b>ND15.1</b>	<b>Injury of medial plantar nerve</b>
<b>ND15.2</b>	<b>Injury of deep peroneal nerve at ankle or foot level</b>
<b>ND15.3</b>	<b>Injury of cutaneous sensory nerve at ankle or foot level</b>
<b>ND15.4</b>	<b>Injury of multiple nerves at ankle or foot level</b>

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

<b>ND15.Y</b>	<b>Injury of other specified nerves at ankle and foot level</b>
<b>ND15.Z</b>	<b>Injury of unspecified nerve at ankle or foot level</b>

**ND16      Injury of blood vessels at ankle or foot level**

**Exclusions:**      Injury of posterior tibial artery (NC95.2)

<b>ND16.0</b>	<b>Injury of dorsal artery of foot</b>
<b>ND16.00</b>	Laceration of dorsal artery of foot
<b>ND16.0Y</b>	Other specified injury of dorsal artery of foot
<b>ND16.0Z</b>	Injury of dorsal artery of foot, unspecified
<b>ND16.1</b>	<b>Injury of plantar artery of foot</b>
<b>ND16.10</b>	Laceration of plantar artery of foot
<b>ND16.1Y</b>	Other specified injury of plantar artery of foot
<b>ND16.1Z</b>	Injury of plantar artery of foot, unspecified
<b>ND16.2</b>	<b>Injury of dorsal vein of foot</b>

<b>ND16.20</b>	Laceration of dorsal vein of foot
<b>ND16.2Y</b>	Other specified injury of dorsal vein of foot
<b>ND16.2Z</b>	Injury of dorsal vein of foot, unspecified
<b>ND16.3</b>	<b>Injury of multiple blood vessels at ankle or foot level</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>ND16.Y</b>	<b>Injury of other specified blood vessels at ankle and foot level</b>
<b>ND16.Z</b>	<b>Injury of unspecified blood vessel at ankle or foot level</b>
<b>ND17</b>	<b>Injury of muscle, fascia or tendon at ankle or foot level</b>
	Damage inflicted on the muscular or tendinous tissues of the ankle or foot as the direct or indirect result of an external force, with or without disruption of structural continuity.
	<b>Exclusions:</b> Injury of Achilles tendon (NC96.0)
<b>ND17.0</b>	<b>Injury of muscle, fascia or tendon of long flexor muscle of toe at ankle or foot level</b>
<b>ND17.00</b>	Strain or sprain of muscle, fascia or tendon of long flexor muscle of toe at ankle or foot level
<b>ND17.01</b>	Laceration of muscle, fascia or tendon of long flexor muscle of toe at ankle or foot level
<b>ND17.0Y</b>	Other specified injury of muscle, fascia or tendon of long flexor muscle of toe at ankle or foot level
<b>ND17.0Z</b>	Injury of muscle, fascia or tendon of long flexor muscle of toe at ankle or foot level, unspecified
<b>ND17.1</b>	<b>Injury of muscle, fascia or tendon of long extensor muscle of toe at ankle or foot level</b>
<b>ND17.10</b>	Strain or sprain of muscle, fascia or tendon of long extensor muscle of toe at ankle or foot level
<b>ND17.11</b>	Laceration of muscle, fascia or tendon of long extensor muscle of toe at ankle or foot level
<b>ND17.1Y</b>	Other specified injury of muscle, fascia or tendon of long extensor muscle of toe at ankle or foot level
<b>ND17.1Z</b>	Injury of muscle, fascia or tendon of long extensor muscle of toe at ankle or foot level, unspecified
<b>ND17.2</b>	<b>Injury of intrinsic muscle, fascia or tendon at ankle or foot level</b>
<b>ND17.20</b>	Strain or sprain of intrinsic muscle, fascia or tendon at ankle or foot level
<b>ND17.21</b>	Laceration of intrinsic muscle, fascia or tendon at ankle or foot level
<b>ND17.2Y</b>	Other specified injury of intrinsic muscle, fascia or tendon at ankle or foot level

<b>ND17.2Z</b>	Injury of intrinsic muscle, fascia or tendon at ankle or foot level, unspecified
<b>ND17.3</b>	<b>Injury of multiple muscles or tendons at ankle or foot level</b>
<b>Coding Note:</b>	Assign additional codes for the specific injuries.
<b>ND17.Y</b>	<b>Injury of other specified muscle, fascia or tendon at ankle or foot level</b>
<b>ND17.Z</b>	<b>Injury of unspecified muscle, fascia or tendon at ankle or foot level</b>
<b>ND18</b>	<b>Crushing injury of ankle or foot</b>
<b>ND18.0</b>	<b>Crushing injury of ankle</b>
<b>ND18.1</b>	<b>Crushing injury of toe</b>
<b>ND18.2</b>	<b>Crushing injury of other parts of ankle or foot</b>
<b>ND18.Z</b>	<b>Crushing injury of ankle or foot, unspecified</b>
<b>ND19</b>	<b>Traumatic amputation of ankle or foot</b>
<b>ND19.0</b>	<b>Traumatic amputation of right foot at ankle level</b>
<b>ND19.1</b>	<b>Traumatic amputation of left foot at ankle level</b>
<b>ND19.2</b>	<b>Traumatic amputation of foot at ankle level, bilateral</b>
<b>ND19.3</b>	<b>Traumatic amputation of right foot at metatarsal level</b>
<b>ND19.4</b>	<b>Traumatic amputation of left foot at metatarsal level</b>
<b>ND19.5</b>	<b>Traumatic amputation of foot at metatarsal level, bilateral</b>
<b>ND19.6</b>	<b>Traumatic amputation of one toe</b> <i>Exclusions:</i> avulsion of toenail (ND10)
<b>ND19.7</b>	<b>Traumatic amputation of two or more toes</b> <i>Exclusions:</i> avulsion of toenail (ND10)
<b>ND19.8</b>	<b>Traumatic amputation of other parts of foot</b> <i>Inclusions:</i> Combined traumatic amputation of toe(s) and other parts of foot
<b>ND19.Z</b>	<b>Traumatic amputation of ankle or foot, unspecified</b>
<b>ND1A</b>	<b>Multiple injuries of ankle or foot</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.
<b>ND1Y</b>	<b>Other specified injuries to the ankle or foot</b>
<b>ND1Z</b>	<b>Injuries to the ankle or foot, unspecified</b>

## Injuries involving multiple body regions (ND30-ND37)

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**Exclusions:**

- Frostbite (NE40-NE4Z)
- Sunburn (EJ40)
- Burns (ND90-NE2Z)

### ND30

#### **Superficial injuries involving multiple body regions**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

### ND31

#### **Open wounds involving multiple body regions**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**Exclusions:** Traumatic amputations involving multiple body regions (ND35)

### ND32

#### **Fractures involving multiple body regions**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**Coded Elsewhere:** Fractures involving multiple body regions due to birth injury (KA45.Y)

### ND33

#### **Dislocations, strains or sprains involving multiple body regions**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

### ND34

#### **Crushing injuries involving multiple body regions**

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

### ND35

#### **Traumatic amputations involving multiple body regions**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**Inclusions:** avulsion involving multiple body regions

**Exclusions:** traumatic amputation of leg NOS (ND55)

traumatic amputation of arm NOS (ND53)

Open wounds involving multiple body regions (ND31)

Decapitation (NA63)

traumatic amputation of: trunk NOS (NB33)

### ND36

#### **Other injuries involving multiple body regions, not elsewhere classified**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**ND37****Unspecified multiple injuries**

**Coding Note:** Each injury should be coded separately. This code should be used alone only when the detail of the specific injuries is unknown, or it is not possible to code each injury. This code may also be used in postcoordination to identify cases of complex trauma.

**Exclusions:**      injury NOS (ND56)

**Injuries to unspecified part of trunk, limb or body region (ND50-ND5Z)**

**Exclusions:**      Injuries involving multiple body regions (ND30-ND37)

    Insect bite or sting, venomous (NE61)

    Burns (ND90-NE2Z)

    Frostbite (NE40-NE4Z)

**ND50****Fracture of spine, level unspecified**

**Exclusions:**      multiple fractures of spine, level unspecified (ND32)

**Coded Elsewhere:** Fracture, dislocation or subluxation of spine due to birth injury  
(KA45.4)

**ND51****Other injuries of spine or trunk, level unspecified**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**Exclusions:**      multiple internal injuries of trunk (ND36)  
                        crushing injury of trunk NOS (ND34)  
                        transection of trunk (ND35)

**ND51.0              Dislocation or strain or sprain of unspecified joint or ligament of trunk**

**Coded Elsewhere:** Fracture, dislocation or subluxation of spine due to birth injury  
(KA45.4)

**ND51.1              Injury of unspecified nerve, spinal nerve root or plexus of trunk**

**ND51.2              Injury of spinal cord, level unspecified**

**Coded Elsewhere:** Birth injury to spine or spinal cord (KA40.2)

**ND51.3              Injury of unspecified muscle, fascia or tendon of trunk**

**ND51.4              Crushing injury of spine or trunk, level unspecified**

**ND51.Y              Other specified injuries of spine or trunk, level unspecified**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**ND51.Z              Unspecified injuries of spine or trunk, level unspecified**

**Coding Note:** Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

<b>ND52</b>	<b>Fracture of arm, level unspecified</b>
	<b><i>Exclusions:</i></b> Fractures involving multiple regions of one arm (ND32)
<b>ND53</b>	<b>Other injuries of arm, level unspecified</b>
	<b><i>Exclusions:</i></b> crushing injury of arm NOS (ND34) Fracture of arm, level unspecified (ND52) Injuries involving multiple body regions (ND30-ND37)
<b>ND53.0</b>	<b>Crushing injury of arm, level unspecified</b>
<b>ND53.Y</b>	<b>Other specified injuries of arm, level unspecified</b>
<b>ND54</b>	<b>Fracture of leg, level unspecified</b>
	<b><i>Exclusions:</i></b> Fractures involving multiple regions of one leg (ND32)
<b>ND55</b>	<b>Other injuries of leg, level unspecified</b>
	<b><i>Exclusions:</i></b> Fracture of leg, level unspecified (ND54) Injuries involving multiple body regions (ND30-ND37)
<b>ND56</b>	<b>Injury of unspecified body region</b>
	Damage inflicted on the body in an unspecified area as the direct or indirect result of an external force, with or without disruption of structural continuity.
	<b><i>Exclusions:</i></b> Injuries involving multiple body regions (ND30-ND37) multiple injuries NOS (ND37)
<b>ND56.0</b>	<b>Superficial injury of unspecified body region</b>
	<b><i>Exclusions:</i></b> multiple superficial injuries NOS (ND30)
	<b><i>Coded Elsewhere:</i></b> Haematoma of surgical wound of skin (NE81.00) Superficial incisional site infection (NE81.20)
<b>ND56.1</b>	<b>Open wound of unspecified body region</b>
	<b><i>Exclusions:</i></b> Traumatic amputations involving multiple body regions (ND35) Open wounds involving multiple body regions (ND31) traumatic amputation NOS (ND56.8)
<b>ND56.2</b>	<b>Fracture of unspecified body region</b>
	<b><i>Exclusions:</i></b> multiple fractures NOS (ND32)
<b>ND56.3</b>	<b>Dislocation or strain or sprain of unspecified body region</b>
	<b><i>Exclusions:</i></b> multiple dislocations, sprains and strains NOS (ND33)
<b>ND56.4</b>	<b>Injury of nerve of unspecified body region</b>
	<b><i>Exclusions:</i></b> multiple injuries of nerves NOS (ND36)
<b>ND56.5</b>	<b>Injury of blood vessel of unspecified body region</b>
	<b><i>Exclusions:</i></b> multiple injuries of blood vessels NOS (ND36)

<b>ND56.6</b>	<b>Injury of muscles or tendons of unspecified body region</b>
	<b><i>Exclusions:</i></b> multiple injuries of tendons and muscles NOS (ND36)
<b>ND56.7</b>	<b>Crushing injury of unspecified body region</b>
<b>ND56.8</b>	<b>Traumatic amputation of unspecified body region</b>
	<b><i>Exclusions:</i></b> multiple: crushing injuries NOS (ND34) multiple traumatic amputations NOS (ND35)
<b>ND56.9</b>	<b>Injury complicating pregnancy</b>
<b>ND56.Y</b>	<b>Other specified injury of unspecified body region</b>
<b>ND56.Z</b>	<b>Unspecified injury to unspecified part of trunk, limb or body region</b>
<b>ND57</b>	<b>Secondary effect of trauma</b>
	<b><i>Inclusions:</i></b> deformity NOS scarring resulting from previous injury old amputation
	<b><i>Exclusions:</i></b> Post traumatic stress disorder (6B40) Post traumatic wound infection, not elsewhere classified (NF0A.3)
<b>ND5Y</b>	<b>Other specified injuries to unspecified part of trunk, limb or body region</b>
<b>ND5Z</b>	<b>Injuries to unspecified part of trunk, limb or body region, unspecified</b>

#### Effects of foreign body entering through natural orifice (ND70-ND7Z)

	<b><i>Exclusions:</i></b> foreign body accidentally left in operation wound (PL11.3) Residual foreign body in soft tissue (FB56.1)
<b>ND70</b>	<b>Foreign body on external eye</b>
	<b><i>Exclusions:</i></b> Retained foreign body following penetrating wound of orbit (NA06.2) Retained foreign body in eyelid (NA06.03)
<b>ND70.0</b>	<b>Foreign body in cornea</b>
<b>ND70.1</b>	<b>Foreign body in conjunctival sac</b>
<b>ND70.2</b>	<b>Foreign body in multiple parts of external eye</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>ND70.Y</b>	<b>Foreign body in other specified part of external eye</b>
<b>ND70.Z</b>	<b>Foreign body on external eye, unspecified</b>

<b>ND71</b>	<b>Foreign body in ear</b> Objects that inadvertently enter the ear from the environment.
<b>ND72</b>	<b>Foreign body in respiratory tract</b>
<b>ND72.0</b>	<b>Foreign body in nasal sinus</b>
<b>ND72.1</b>	<b>Foreign body in nostril</b>
<b>ND72.2</b>	<b>Foreign body in pharynx</b> Objects that inadvertently enter the pharynx from the environment.
<b>ND72.20</b>	Asphyxia on mucous in nasopharynx
<b>ND72.2Y</b>	Other specified foreign body in pharynx
<b>ND72.2Z</b>	Foreign body in pharynx, unspecified
<b>ND72.3</b>	<b>Foreign body in larynx</b>
<b>ND72.4</b>	<b>Foreign body in trachea</b>
<b>ND72.5</b>	<b>Foreign body in bronchus</b>
<b>ND72.6</b>	<b>Foreign body in multiple parts of respiratory tract</b>
<b>Coding Note:</b>	Each injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.
<b>ND72.Y</b>	<b>Foreign body in other parts of respiratory tract</b>
<b>ND72.Z</b>	<b>Foreign body in unspecified part of respiratory tract</b>
<b>ND73</b>	<b>Foreign body in alimentary tract</b>
	<i>Inclusions:</i> foreign body in digestive system NOS
	<i>Exclusions:</i> Foreign body in pharynx (ND72.2)
<b>ND73.0</b>	<b>Foreign body in mouth</b>
<b>ND73.1</b>	<b>Foreign body in oesophagus</b> Mechanical impaction or retention of foreign body in the oesophagus
<b>ND73.2</b>	<b>Foreign body in stomach</b> Mechanical impaction or retention of foreign body in the stomach.
<b>ND73.20</b>	Trichobezoar A hair ball which is formed from ingested hairs in the stomach which may cause bowel obstruction.
<b>ND73.2Y</b>	Other specified foreign body in stomach
<b>ND73.2Z</b>	Foreign body in stomach, unspecified
<b>ND73.3</b>	<b>Foreign body in small intestine</b> Mechanical impaction or retention of foreign body in the small intestine.

- ND73.4**      **Foreign body in colon**
- ND73.5**      **Foreign body in anus or rectum**
- ND73.Y**      **Foreign body in other specified part of alimentary tract**
- ND73.Z**      **Foreign body in alimentary tract, unspecified**
- ND74**      **Foreign body in genitourinary tract**
- Exclusions:*      Presence of contraceptive device (QB51.C)
- ND74.0**      **Foreign body in urethra**
- ND74.1**      **Foreign body in bladder**
- ND74.2**      **Foreign body in vulva or vagina**
- ND74.3**      **Foreign body in uterus, any part**
- ND74.Y**      **Foreign body in other specified part of genitourinary tract**
- ND74.Z**      **Foreign body in genitourinary tract, unspecified**
- ND7Z**      **Effects of foreign body entering through natural orifice, unspecified**

## Burns (ND90-NE2Z)

A burn is an injury to the tissues caused by a pathological flux of energy which causes cellular destruction and irreversible denaturation of proteins and is primarily caused by thermal or other acute trauma.

**Coding Note:** Code also the size of burn as the percentage of total body surface area burned to any depth, and the percentage with full-thickness or deep full thickness burns.

**Inclusions:**

- internal chemical burn or corrosion
- external chemical burn or corrosion
- burns from hot objects
- burns from friction
- burns from hot air and hot gases
- burns from lightning

**Exclusions:**

- Sunburn (EJ40)
- Adverse cutaneous effects of therapeutic ionizing irradiation (EL60-EL63)
- Adverse effects of phototherapy (Chapter 14)
- Photosensitivity due to drug (EH75)
- Phototoxic reactions to skin contact with photoactive agents (EK20-EK2Z)
- Neonatal phototherapy burn (KC50)

### Burns of external body surface, specified by site (ND90-ND9Z)

**Coding Note:** Code also the size of burn as the percentage of total body surface area burned to any depth, and the percentage with full-thickness or deep full thickness burns.

#### **ND90**

##### **Burn of head or neck except face**

Injury to the tissues of the head and neck caused by contact with, for example, heat, steam, chemicals, or electricity.

**Exclusions:**

- Burn of eye or ocular adnexa (NE00)
- Burn of mouth or pharynx (NE02)

**ND90.0**      **Burn of head or neck except face, epidermal burn**

**ND90.1**      **Burn of head or neck except face, superficial partial thickness burn**

**ND90.2**      **Burn of head or neck except face, deep partial thickness burn**

**ND90.3**      **Burn of head and neck except face, full thickness burn**

**ND90.4**      **Burn of head or neck except face, deep full thickness or complex burn**

**ND90.Z**      **Burn of head and neck except face, depth of burn unspecified**

#### **ND91**

##### **Burn of face except eye or ocular adnexa**

**ND91.0**      **Burn of face except eye or ocular adnexa, epidermal burn**

**ND91.1**      **Burn of face except eye or ocular adnexa, superficial partial thickness burn**

<b>ND91.2</b>	<b>Burn of face except eye or ocular adnexa, deep partial thickness burn</b>
<b>ND91.3</b>	<b>Burn of face except eye or ocular adnexa, full thickness burn</b>
<b>ND91.4</b>	<b>Burn of face except eye or ocular adnexa, deep full thickness or complex burn</b>
<b>ND91.Z</b>	<b>Burn of face except eye, depth of burn unspecified</b>
<b>ND92</b>	<b>Burn of trunk except perineum or genitalia</b> Injury to the tissues of the trunk caused by contact with, for example, heat, steam, chemicals, or electricity.  <i>Exclusions:</i> burn and corrosion of scapular region (ND94) burn and corrosion of axilla (ND94)
<b>ND92.0</b>	<b>Burn of trunk except perineum or genitalia, epidermal burn</b>
<b>ND92.00</b>	Burn of breast, epidermal burn
<b>ND92.01</b>	Burn of chest wall, epidermal burn
<b>ND92.02</b>	Burn of abdominal wall, epidermal burn
<b>ND92.03</b>	Burn of back, any part, epidermal burn
<b>ND92.0Y</b>	Other specified burn of trunk except perineum or genitalia, epidermal burn
<b>ND92.0Z</b>	Burn of trunk except perineum or genitalia, epidermal burn, unspecified
<b>ND92.1</b>	<b>Burn of trunk except perineum or genitalia, superficial partial thickness burn</b>
<b>ND92.2</b>	<b>Burn of trunk except perineum or genitalia, deep partial thickness burn</b>
<b>ND92.3</b>	<b>Burn of trunk except perineum or genitalia, full thickness burn</b>
<b>ND92.4</b>	<b>Burn of trunk except perineum or genitalia, deep full thickness or complex burn</b>
<b>ND92.Z</b>	<b>Burn of trunk except perineum and genitalia, depth of burn unspecified</b>
<b>ND93</b>	<b>Burn of perineum or genitalia</b>
<b>ND93.0</b>	<b>Burn of perineum or genitalia, epidermal burn</b>
<b>ND93.1</b>	<b>Burn of perineum or genitalia, superficial partial thickness burn</b>
<b>ND93.2</b>	<b>Burn of perineum or genitalia, deep partial thickness burn</b>
<b>ND93.3</b>	<b>Burn of perineum or genitalia, full thickness burn</b>
<b>ND93.4</b>	<b>Burn of perineum or genitalia, deep full thickness or complex burn</b>
<b>ND93.Z</b>	<b>Burn of perineum and genitalia, depth of burn unspecified</b>

**ND94**

**Burn of shoulder or arm, except wrist or hand**

Injury to the tissues of the shoulder and arm (except wrist and hand) caused by contact with, for example, heat, steam, chemicals, or electricity.

**Exclusions:**      burn and corrosion of interscapular region (ND92)

    Burn of wrist or hand (ND95)

**ND94.0**

**Burn of shoulder or arm, except wrist or hand, epidermal burn**

**ND94.1**

**Burn of shoulder or arm, except wrist or hand, superficial partial thickness burn**

**ND94.10**

Burn of forearm and elbow, superficial partial thickness burn

**ND94.1Y**

Other specified burn of shoulder or arm, except wrist or hand, superficial partial thickness burn

**ND94.1Z**

Burn of shoulder or arm, except wrist or hand, superficial partial thickness burn, unspecified

**ND94.2**

**Burn of shoulder or arm, except wrist or hand, deep partial thickness burn**

**ND94.20**

Burn of forearm or elbow, deep partial thickness burn

**ND94.2Y**

Other specified burn of shoulder or arm, except wrist or hand, deep partial thickness burn

**ND94.2Z**

Burn of shoulder or arm, except wrist or hand, deep partial thickness burn, unspecified

**ND94.3**

**Burn of shoulder or arm, except wrist or hand, full thickness burn**

**ND94.4**

**Burn of shoulder or arm, except wrist or hand, deep full thickness or complex burn**

**ND94.Z**

**Burn of shoulder and arm except wrist and hand, depth of burn unspecified**

**ND95**

**Burn of wrist or hand**

Injury to the tissues of the wrist and hand caused by contact with, for example, heat, steam, chemicals, or electricity.

**ND95.0**

**Burn of wrist or hand, epidermal burn**

**ND95.1**

**Burn of wrist or hand, superficial partial thickness burn**

**ND95.2**

**Burn of wrist or hand, deep partial thickness burn**

**ND95.3**

**Burn of wrist or hand, full thickness burn**

**ND95.4**

**Burn of wrist or hand, deep full thickness or complex burn**

**ND95.Z**

**Burn of wrist and hand, depth of burn unspecified**

**ND96**

**Burn of hip or leg, except ankle or foot**

Injury to the tissues of the hip and leg (except ankle and foot) caused by contact with, for example, heat, steam, chemicals, or electricity.

**Exclusions:**      Burn of ankle or foot (ND97)

<b>ND96.0</b>	<b>Burn of hip or leg, except ankle or foot, epidermal burn</b>
<b>ND96.1</b>	<b>Burn of hip or leg, except ankle or foot, superficial partial thickness burn</b>
<b>ND96.2</b>	<b>Burn of hip or leg, except ankle or foot, deep partial thickness burn</b>
<b>ND96.3</b>	<b>Burn of hip or leg, except ankle or foot, full thickness burn</b>
<b>ND96.4</b>	<b>Burn of hip or leg, except ankle or foot, deep full thickness or complex burn</b>
<b>ND96.Z</b>	<b>Burn of hip and leg except ankle and foot, depth of burn unspecified</b>
<b>ND97</b>	<b>Burn of ankle or foot</b> Injury to the tissues of the ankle and foot caused by contact with, for example, heat, steam, chemicals, or electricity.
<b>ND97.0</b>	<b>Burn of ankle or foot, epidermal burn</b>
<b>ND97.1</b>	<b>Burn of ankle or foot, superficial partial thickness burn</b>
<b>ND97.2</b>	<b>Burn of ankle or foot, deep partial thickness burn</b>
<b>ND97.3</b>	<b>Burn of ankle or foot, full thickness burn</b>
<b>ND97.4</b>	<b>Burn of ankle or foot, deep full thickness or complex burn</b>
<b>ND97.Z</b>	<b>Burn of ankle and foot, depth of burn unspecified</b>
<b>ND99</b>	<b>Acute skin injury due to skin contact with corrosive substance</b>
<b>ND99.1</b>	<b>Chemical burn due to skin contact with corrosive substance</b> A chemical skin burn is an acute, severe irritant reaction to skin contact with corrosive or caustic substances sufficient to cause cell necrosis. The corrosive potential of substances depends on their chemical properties, concentration and pH, and on the duration and type of skin contact. Occlusion has an additive effect.
<b>ND9Y</b>	<b>Burns of external body surface, other specified site</b>
<b>Coding Note:</b>	Code also the size of burn as the percentage of total body surface area burned to any depth, and the percentage with full-thickness or deep full thickness burns.
<b>ND9Z</b>	<b>Burns of external body surface, unspecified site</b>
<b>Coding Note:</b>	Code also the size of burn as the percentage of total body surface area burned to any depth, and the percentage with full-thickness or deep full thickness burns.

#### Burns of eye or internal organs (NE00-NE0Z)

Injury confined to the tissues of the eye and internal organs caused by contact with, for example, heat, steam, chemicals, or electricity.

<b>NE00</b>	<b>Burn of eye or ocular adnexa</b>
	Injury confined to the tissues of the eye and adnexa caused by contact with, for example, heat, steam, chemicals, or electricity.

**NE01**

### **Burn of respiratory tract**

Injury to the tissues of the respiratory tract caused by contact with, for example, heat, steam, chemicals, or electricity.

**NE02**

### **Burn of other internal organs**

Injury to other internal organs caused by contact with, for example, heat, steam, chemicals, or electricity.

**NE0Z**

### **Burns of unspecified internal organ**

Burns of multiple or unspecified body regions (NE10-NE11)

Injury to the tissues of the multiple and unspecified body regions caused by contact with, for example, heat, steam, chemicals, or electricity.

**Coding Note:** Each burn should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**NE10**

### **Burns of multiple body regions**

**Coding Note:** Each burn should be coded separately. This code should be used only when the detail of the specific burn is unknown, or it is not possible to code each burn.

**NE11**

### **Burn of unspecified body region**

---

**NE2Z**

### **Burns, unspecified**

**Coding Note:** Code also the size of burn as the percentage of total body surface area burned to any depth, and the percentage with full-thickness or deep full thickness burns.

Frostbite (NE40-NE4Z)

Frostbite is injury from ice formation within tissues resulting from contact with cold air, liquids or metals. It is most commonly due to excessive exposure of skin to sub-zero environmental temperatures. The risk of injury is exacerbated by wind. The most commonly affected sites are fingers, toes, ears, nose, cheeks and chin with injury limited to skin and soft tissues. Full thickness skin necrosis and injury to deeper structures including muscles and bone may occur with prolonged exposure to cold.

**Exclusions:** Hypothermia (NF02)

**NE40**

### **Superficial frostbite**

Frostbite in which injury is confined to the skin, where there may be epidermal blistering and sloughing but no significant tissue necrosis.

**Inclusions:** frostbite with partial-thickness skin loss

**Exclusions:** Superficial frostbite involving multiple body regions (NE42)

**NE41**

### **Frostbite with tissue necrosis**

Frostbite with localised tissue necrosis of skin and deeper tissues

**Exclusions:** Frostbite with tissue necrosis involving multiple body regions (NE42)

**NE42**

**Frostbite involving multiple body regions**

Frostbite is damage to tissues as the result of exposure to low environmental temperatures.

**Coding Note:**

Each frostbite injury should be coded separately. This code should be used only when the detail of the specific injuries is unknown, or it is not possible to code each injury.

**NE4Z**

**Frostbite, unspecified**

## Harmful effects of substances (NE60-NE6Z)

**Coding Note:** When a specified harmful effect of a substance or substances is known, code to the specific condition.

**NE60**

**Harmful effects of drugs, medicaments or biological substances, not elsewhere classified**

**Coding Note:** When a specified harmful effect of a substance or substances is known, code to the specific condition.

**Exclusions:** Alcohol intoxication (6C40.3)

pathological drug intoxication (6C40-6C5Z)

hypersensitivity reaction to correctly administered drug  
(4A80-4A8Z)

Reactions or intoxications due to drugs administered to fetus  
or newborn (KD34)

**NE61**

**Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified**

**Coding Note:** When a specified harmful effect of a substance or substances is known, code to the specific condition.

**Exclusions:** corrosions (ND90-NE2Z)

Bacterial foodborne intoxications (1A10-1A1Z)

**NE6Z**

**Harmful effects of unspecified substance**

**Coding Note:** When a specified harmful effect of a substance or substances is known, code to the specific condition.

Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)

- Exclusions:**
- Attention to artificial openings (QB62)
  - adverse effects of drugs and medicaments (NE60)
  - Fitting or adjustment of external prosthetic device (QB31.0)
  - burns and corrosions from local applications and irradiation (ND90-NE2Z)
  - poisoning and toxic effects of drugs and chemicals (NE60)
  - Colostomy malfunction (DE12.0)
  - Disorders of fluid, electrolyte or acid-base balance (5C70-5C7Z)
  - Other functional disturbances following cardiac surgery (BE11)
  - Dumping syndrome (DE11)
  - Postmastectomy lymphoedema syndrome (BE1B.0)
  - Postsurgical blind-loop syndrome (DE13)

- Coded Elsewhere:**
- Complications of intrauterine procedures, not elsewhere classified (KD39)
  - Complications of anaesthesia during pregnancy (JA67)
  - Complications of anaesthesia during labour or delivery (JB0C)
  - Complications of anaesthesia during the puerperium (JB43)

<b>NE80</b>	<b>Injury or harm arising following infusion, transfusion or therapeutic injection, not elsewhere classified</b>
	<b>Exclusions:</b>
	bone-marrow transplant rejection (NE84)
	toxic endophthalmitis (9C21)
<b>NE80.0</b>	<b>Air embolism following infusion, transfusion or therapeutic injection</b>
<b>NE80.1</b>	<b>ABO incompatibility reaction</b>
	<b>Inclusions:</b>
	Reaction to blood-group incompatibility in infusion or transfusion
<b>NE80.2</b>	<b>Rh incompatibility reaction</b>
	<b>Inclusions:</b>
	Reaction due to Rh factor in infusion or transfusion
<b>NE80.3</b>	<b>Other serum reactions</b>
	<b>Exclusions:</b>
	serum hepatitis (1E50.1)
	<b>Coded Elsewhere:</b>
	Serum sickness vasculitis (4A44.Y)
	Anaphylactic shock due to serum (4A84.Y)
<b>NE80.Y</b>	<b>Other specified injury or harm arising following infusion, transfusion or therapeutic injection, not elsewhere classified</b>
<b>NE80.Z</b>	<b>Injury or harm arising following infusion, transfusion or therapeutic injection, not elsewhere classified, unspecified</b>

<b>NE81</b>	<p><b>Injury or harm arising from a procedure, not elsewhere classified</b></p> <p>Any complication attributable to a medical, surgical or other clinical procedure which cannot be more precisely coded elsewhere in the classification.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified (NE60)</li> <li>Failure or rejection of transplanted organs or tissues (NE84)</li> <li>Injury or harm arising following infusion, transfusion or therapeutic injection, not elsewhere classified (NE80)</li> </ul>
<b>NE81.0</b>	<p><b>Haemorrhage or haematoma complicating a procedure, not elsewhere classified</b></p> <p><b>Inclusions:</b> Haemorrhage at any site resulting from a procedure</p> <p><b>Coded Elsewhere:</b> Haematoma of obstetric wound (JB44.2)</p>
<b>NE81.00</b>	<p>Haematoma of surgical wound of skin</p> <p>Collection of blood within skin and soft tissues following surgical wound of skin usually resulting from defective haemostasis</p>
<b>NE81.01</b>	Haemorrhage and haematoma of eye or ocular adnexa complicating a procedure
<b>NE81.0Z</b>	Haemorrhage or haematoma of other or unspecified site complicating a procedure, not elsewhere classified
<b>NE81.1</b>	<p><b>Disruption of operation wound, not elsewhere classified</b></p> <p><b>Inclusions:</b></p> <ul style="list-style-type: none"> <li>Dehiscence of operation wound</li> <li>Rupture of operation wound</li> </ul> <p><b>Exclusions:</b> Postsurgical anastomosis leak (NE81.3)</p> <p><b>Coded Elsewhere:</b> Disruption of caesarean section wound (JB44.0)</p> <p>Disruption of perineal obstetric wound (JB44.1)</p>
<b>NE81.2</b>	<p><b>Surgical site infection</b></p> <p><b>Coded Elsewhere:</b> Infection of obstetric surgical wound (JB40.1)</p>
<b>NE81.20</b>	<p>Superficial incisional site infection</p> <p>A surgical site infection involving only skin and subcutaneous tissue of the incision.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Streptococcal cellulitis of skin (1B70.1)</li> <li>Staphylococcal cellulitis of skin (1B70.2)</li> </ul>
<b>NE81.21</b>	<p>Deep incisional site infection</p> <p>A surgical site infection involving deep soft tissues of the incision (e.g. fascia and muscle layers).</p>
<b>NE81.22</b>	<p>Organ or organ space surgical site infection</p> <p>A surgical site infection that involves any part of the body deeper than the fascial or muscle layers, that is opened or manipulated during the operative procedure.</p>
<b>NE81.2Y</b>	Other specified surgical site infection
<b>NE81.2Z</b>	Surgical site infection, unspecified

<b>NE81.3</b>	<b>Postsurgical leak</b>
	<p><b>Exclusions:</b> Malfunction or complication of external stoma of digestive organs (DE12)</p> <p>Tracheostomy malfunction (CB60)</p>
<b>NE81.Y</b>	<b>Other specified injury or harm arising from a procedure, not elsewhere classified</b>
<b>NE81.Z</b>	<b>Injury or harm arising from a procedure, not elsewhere classified, unspecified</b>
<b>NE82</b>	<b>Dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified</b>
	<p><b>Coded Elsewhere:</b> Pacemaker or implantable cardioverter defibrillator battery at end of battery life (BC91)</p>
<b>NE82.0</b>	<b>Pacemaker or implantable cardioverter defibrillator complication</b>
	An event or occurrence related to a pacemaker or an implantable cardioverter defibrillator (ICD) or one of its components that is associated with a healthcare intervention, is a departure from the desired course of events, and may cause, or be associated with, a suboptimal outcome.
<b>NE82.00</b>	<p>Pacemaker or implantable cardioverter defibrillator pocket erosion</p> <p>Any breakdown of the implant site or skin overlying pacemaker or an implantable cardioverter defibrillator (ICD) pocket.</p>
<b>NE82.01</b>	<p>Pacemaker or implantable cardioverter defibrillator pocket muscle stimulation</p> <p>Inappropriate muscular stimulation in or near a pacemaker or implantable cardioverter defibrillator (ICD) generator pocket that cannot be managed with device reprogramming and results in patient discomfort or need for reoperation.</p>
<b>NE82.02</b>	Pacemaker or implantable cardioverter defibrillator phrenic nerve stimulation
<b>NE82.03</b>	<p>Pacing-induced cardiomyopathy</p> <p>Pacing-induced cardiomyopathy is ventricular dilation, dysfunction (systolic and/or diastolic) and dyskinesia associated with chronic ventricular pacing in the absence of other causes of cardiomyopathy.</p>
<b>NE82.0Y</b>	Other specified pacemaker or implantable cardioverter defibrillator complication
<b>NE82.0Z</b>	Pacemaker or implantable cardioverter defibrillator complication, unspecified
<b>NE82.1</b>	<b>Pacemaker or implantable cardioverter defibrillator dysfunction</b>
	Any abnormality of pacemaker or implantable cardioverter defibrillator (ICD) device function.
<b>NE82.10</b>	<p>Inappropriate implantable cardioverter defibrillator shock</p> <p>One or more implantable cardioverter defibrillator (ICD) high energy discharges delivered in response to an event other than an appropriately sensed ventricular arrhythmia meeting criteria for therapy. Examples of such events include artefactual sensing (e.g., T-wave oversensing or noise), supraventricular arrhythmias (e.g., atrial fibrillation or flutter, supraventricular tachycardia (SVT)) and sinus tachycardia.</p>

**NE82.11** Pacemaker syndrome  
Cardiovascular signs or symptoms following pacemaker implantation due to suboptimal atrioventricular synchrony, regardless of the pacing mode

**NE82.12** Pacemaker generator dysfunction  
Pacemaker pulse generator malfunction for any reason except routine battery exhaustion.

**NE82.1Y** Other specified pacemaker or implantable cardioverter defibrillator dysfunction

**NE82.1Z** Pacemaker or implantable cardioverter defibrillator dysfunction, unspecified

**NE82.2** **Pacemaker or implantable cardioverter defibrillator lead complication**

**NE82.20** Pacemaker or implantable cardioverter defibrillator lead fracture

**NE82.21** Pacemaker or implantable cardioverter defibrillator lead dislodgement

**NE82.22** Pacemaker or implantable cardioverter defibrillator lead insulation break

**NE82.2Y** Other specified pacemaker or implantable cardioverter defibrillator lead complication

**NE82.2Z** Pacemaker or implantable cardioverter defibrillator lead complication, unspecified

**NE82.3** **Pacemaker or implantable cardioverter defibrillator lead dysfunction**

**NE82.Y** **Other specified dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified**

**NE82.Z** **Dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified, unspecified**

**NE83** **Injury or harm arising from other device, implant or graft, not elsewhere classified**

**Coded Elsewhere:** Wear of articular bearing surface of joint prosthesis (FA35)  
Postsurgical osteolysis (FC01.8)  
Cardiac conduit failure (BE14.B)  
Systemic-to-pulmonary arterial shunt obstruction (BE14.B)  
Systemic-to-pulmonary arterial shunt failure (BE14.B)

**NE83.0** **Destruction or cartilage wear of joint with hemiarthroplasty**

**NE83.1** **Infection arising from device, implant or graft, not elsewhere classified**

**Coding Note:** This code should not be used if the type of infection is specified

**Coded Elsewhere:** Infection due to pacemaker or implantable cardioverter defibrillator (NE82.0Y)

**NE83.Y** **Other specified injury or harm arising from other device, implant or graft, not elsewhere classified**

**NE84** **Failure or rejection of transplanted organs or tissues**

**NE85** **Complications peculiar to reattachment or amputation**

<b>NE85.0</b>	<b>Complications of reattached upper extremity</b>
<b>NE85.1</b>	<b>Complications of reattached lower extremity</b>
<b>NE85.2</b>	<b>Complications of other reattached body part</b>
<b>NE85.3</b>	<b>Neuroma of amputation stump</b>
<b>NE85.4</b>	<b>Infection of amputation stump</b>
<b>NE85.5</b>	<b>Necrosis of amputation stump</b>
<b>NE85.6</b>	<b>Other or unspecified complications of amputation stump</b>

**Exclusions:** Phantom limb syndrome (8E43.00)

#### **NE86**

##### **Malignant hyperthermia due to anaesthesia**

A condition caused by hypermetabolism in response to certain anaesthetic drugs. This condition is characterised by hyperthermia, tachycardia, tachypnoea, increased carbon dioxide production, increased oxygen consumption, acidosis, muscle rigidity, and rhabdomyolysis. This condition may be associated with genetic mutation.

#### **NE87**

##### **Failed or difficult intubation**

Intubation complicated by patient anatomy or physiology which complicates, prolongs or prevents intubation.

Complication is defined as saturations falling more than 20% below baseline, significant damage to lips, teeth or tongue, or regurgitation and aspiration of gastric contents. Prolongation is defined as either intubation using special techniques (fibroscopic intubation) or three or more attempts at intubation using direct laryngoscopy or videolaryngoscopy when performed by a fully trained and expert anesthetist. Failure is defined as the abandonment of the attempt at intubation.

**Exclusions:** Failed or difficult intubation during pregnancy (JA67.5)  
Failed or difficult intubation during labour or delivery (JB0C.7)  
Failed or difficult intubation during the puerperium (JB43.5)

#### **NE88**

##### **Drug toxicity associated with harm in surgical or medical care, not elsewhere classified**

#### **NE89**

##### **Awareness under general anaesthesia**

The experience by patients whose expectation was oblivion under general anaesthesia of awareness of their surroundings. This may include some or all of the following sensations: visual, auditory, tactile (including presence of a tracheal tube or airway device, manipulation), motion, pain and paralysis.

**Exclusions:** Awareness of heartbeat (MC81.2)

#### **NE8Y**

##### **Other specified injury or harm arising from surgical or medical care, not elsewhere classified**

#### **NE8Z**

##### **Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified**

## Other or unspecified effects of external causes (NF00-NF0Z)

**Coded Elsewhere:** Anaphylaxis (4A84)

**NF00**

### Effects of radiation, not elsewhere classified

- Inclusions:** Sunburn (EJ40)  
Burns (ND90-NE2Z)  
specified adverse effects of radiation, such as leukaemia (2A20-2B3Z)  
Radiation gastritis (DA42.81)  
Acute pulmonary manifestations due to radiation (CA82.0)  
Radiation duodenitis (DA51.53)  
Radiation oesophagitis (DA24.22)  
Radiation-induced colitis (DB33.41)

**NF01**

### Effects of heat

Adverse effects resulting from a failure to maintain normal body core temperature on exposure to excessive heat. Vigorous exercise, insulation by clothing (e.g. protective clothing) or an inability to sweat normally (e.g. genetic hypohidrosis or autonomic neuropathy) may be contributory factors.

- Inclusions:** heat prostration NOS  
**Exclusions:** Sunburn (EJ40)  
Burns (ND90-NE2Z)  
Malignant hyperthermia due to anaesthesia (NE86)  
Dermatoses provoked by heat or electricity (EJ10-EJ1Y)

**NF01.0**

### Heat stroke

Elevation of core body temperature above 40.6 degrees centigrade due to environmental heat exposure and a failure of thermoregulation. This is a potentially fatal disorder, particularly in infants and children.

- Exclusions:** Exertional heat stroke (NF06.0)

**Coded Elsewhere:** Environmental hyperthermia of newborn (KD10)

**NF01.1**

### Heat syncope

Fainting attributable to exposure to heat

- Inclusions:** Heat collapse

**NF01.2**

### Heat exhaustion due to fluid depletion

A failure of thermoregulatory sweating on exposure to heat as a result of water deprivation and/or inadequate replacement of fluids lost through sweating or by other means (e.g. severe diarrhoea). If untreated this may progress to heat stroke.

- Inclusions:** Heat prostration due to water depletion

**NF01.3**

### Heat fatigue, transient

**NF01.Y**

### Other specified effects of heat

NF01.Z	<b>Effects of heat, unspecified</b>
NF02	<p><b>Hypothermia</b></p> <p><b>Inclusions:</b> Accidental hypothermia</p> <p><b>Exclusions:</b> Hypothermia, not associated with low environmental temperature (MG28)</p> <p>Frostbite (NE40-NE4Z)</p> <p><b>Coded Elsewhere:</b> Hypothermia of newborn (KD12)</p>
NF03	<p><b>Other effects of reduced temperature</b></p> <p><b>Exclusions:</b> Frostbite (NE40-NE4Z)</p> <p>Hypothermia (NF02)</p>
NF03.0	<p><b>Chilblains</b></p> <p>Chilblains are the result of cold-induced damage principally to the microvasculature of acral skin in susceptible individuals. They are commonest in the winter months in cold, damp climates. They present as itchy or painful red-purple macules, papules or plaques, most commonly affecting the fingers and toes, though other body extremities including the heels, nose and ears can be involved. Because of insulation from core body temperature, other areas, especially the lateral thighs, may be involved in areas where there is a thick layer of subcutaneous fat.</p>
NF03.1	<p><b>Immersion hand or foot</b></p> <p>Injury to the skin and soft tissues of the feet and, less commonly, the hands due to prolonged exposure to non-freezing cold and wet conditions. Originally reported in soldiers as trench foot during World War I, it is now more commonly seen in the homeless either because of vagrancy or as the result of conflict. Affected extremities are initially cold, numb, swollen and pulseless; this is followed by a period of intense hyperaemia and pain which then gives way to increased sweating and cold sensitivity.</p>
NF03.Y	<b>Other specified effects of reduced temperature</b>
NF03.Z	<b>Unspecified effects of reduced temperature</b>
NF04	<b>Effects of air pressure or water pressure</b>
NF04.0	<p><b>Otitic barotrauma</b></p> <p><b>Inclusions:</b> Aero-otitis media</p>
NF04.1	<p><b>Sinus barotrauma</b></p> <p><b>Inclusions:</b> Aerosinusitis</p> <p>Effects of change in ambient atmospheric pressure on sinuses</p>
NF04.2	<p><b>Caisson disease</b></p> <p><b>Inclusions:</b> Compressed-air disease</p> <p><b>Exclusions:</b> Osteonecrosis due to trauma (FB81.3)</p>
NF04.3	<b>Effects of high-pressure fluids</b>

<b>NF04.Y</b>	<b>Other specified effects of air pressure or water pressure</b>
<b>NF04.Z</b>	<b>Effects of air pressure or water pressure, unspecified</b>
<b>NF05</b>	<b>Asphyxiation</b>
	<p><b><i>Inclusions:</i></b> Respiratory distress of newborn (KB23)            Adult acute respiratory distress syndrome (CB00)            asphyxia from carbon monoxide (NE61)            asphyxia from inhalation of food or foreign body (ND72)</p>
<b>NF06</b>	<b>Effects of strenuous physical exercise</b>
<b>NF06.0</b>	<b>Exertional heat stroke</b>
<b>NF06.1</b>	<b>Post exercise postural hypotension</b>
<b>NF06.2</b>	<b>Post exertional dehydration</b>
<b>NF06.3</b>	<b>Exercise muscle cramp</b>
<b>NF06.Y</b>	<b>Other specified effects of strenuous physical exercise</b>
<b>NF06.Z</b>	<b>Effects of strenuous physical exercise, unspecified</b>
<b>NF07</b>	<b>Effects of other deprivation</b>
<b>NF07.0</b>	<b>Effects of hunger</b>
	<p><b><i>Inclusions:</i></b> Deprivation of food            Starvation</p>
<b>NF07.1</b>	<b>Effects of thirst</b>
	<p><b><i>Inclusions:</i></b> Deprivation of water</p>
<b>NF07.2</b>	<b>Exhaustion due to exposure</b>
<b>NF07.Y</b>	<b>Other specified effects of deprivation</b>
<b>NF07.Z</b>	<b>Effects of other deprivation, unspecified</b>
<b>NF08</b>	<b>Effects of certain specified external causes</b>
	<p><b><i>Inclusions:</i></b> electric burns (ND90-NE2Z)            Adverse effects, not elsewhere classified (NF09)</p>
<b>NF08.0</b>	<b>Effects of lightning</b>
<b>NF08.1</b>	<b>Drowning or nonfatal submersion</b>
	<p><b><i>Inclusions:</i></b> Immersion</p>
<b>NF08.2</b>	<b>Effects of vibration</b>
	<p><b><i>Coded Elsewhere:</i></b> Vibratory angioedema (EB01.Y)</p>

**NF08.20** Hand and arm vibration syndrome  
Hand Transmitted Vibration is mechanical vibration arising from powered processes or tools which enters the body at the fingers or the palm of the hands. As a consequence of this exposure some people develop a secondary Raynaud's phenomenon and / or peripheral sensory neuropathy affecting the hands.

**Exclusions:** Carpal tunnel syndrome (8C10.0)

**NF08.2Y** Other specified effects of vibration

**NF08.2Z** Effects of vibration, unspecified

**NF08.3** Motion sickness

**NF08.4** Effects of electric current

## **NF09**

### **Adverse effects, not elsewhere classified**

Adverse effects which cannot be attributed to any more specific cause and thus excluding but not limited to injury, allergy, hypersensitivity, toxic effects and complications of surgical and medical care.

**Exclusions:** Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)

Anaphylaxis (4A84)

anaphylactic shock due to serum (NE80.3)

Allergic or hypersensitivity disorders involving skin or mucous membranes (4A82)

Allergic or hypersensitivity disorders involving the gastrointestinal tract (4A83)

Allergic or hypersensitivity disorders involving the respiratory tract (4A80)

anaphylactic shock due to adverse food reaction (4A84.0)

Harmful effects of substances (NE60-NE6Z)

## **NF0A**

### **Certain early complications of trauma, not elsewhere classified**

**Exclusions:** Injury or harm arising from surgical or medical care, not elsewhere classified (NE80-NE8Z)

Respiratory distress of newborn (KB23)

Adult acute respiratory distress syndrome (CB00)

**NF0A.0** Air embolism, traumatic, not elsewhere classified

**Exclusions:** air embolism complicating abortion or ectopic or molar pregnancy (JA05.2)

air embolism complicating pregnancy, childbirth and the puerperium (JB42.0)

<b>NF0A.1</b>	<b>Fat embolism, traumatic, not elsewhere classified</b>
	<p><b><i>Exclusions:</i></b></p> <p style="margin-left: 20px;">fat embolism complicating abortion or ectopic or molar pregnancy (JA05.2)</p> <p style="margin-left: 20px;">fat embolism complicating: pregnancy, childbirth and the puerperium (JB42)</p>
<b>NF0A.2</b>	<b>Traumatic secondary or recurrent haemorrhage, not elsewhere classified</b>
<b>NF0A.3</b>	<b>Post traumatic wound infection, not elsewhere classified</b> Infection of skin and soft tissue secondary to trauma
<b>NF0A.4</b>	<b>Traumatic shock, not elsewhere classified</b>
	<p><b><i>Exclusions:</i></b></p> <p style="margin-left: 20px;">obstetric shock (JB0D.1)</p> <p style="margin-left: 20px;">nontraumatic shock NEC (MG40)</p> <p style="margin-left: 20px;">Shock following abortion, ectopic or molar pregnancy (JA05.3)</p> <p style="margin-left: 20px;">lightening shock (NF08.0)</p> <p style="margin-left: 20px;">electric shock (NF08.4)</p> <p style="margin-left: 20px;">anaphylactic shock NOS (4A84)</p> <p style="margin-left: 20px;">shock anaphylactic: due to: correct medicinal substance properly administered (4A84.1)</p> <p style="margin-left: 20px;">shock: anaphylactic: due to adverse food reaction (4A84.0)</p> <p style="margin-left: 20px;">anaphylactic due to serum (NE80.3)</p>
<b>NF0A.5</b>	<b>Traumatic anuria, not elsewhere classified</b>
	<p><b><i>Inclusions:</i></b></p> <p style="margin-left: 20px;">Crush syndrome</p> <p style="margin-left: 20px;">Renal failure following crushing</p>
<b>NF0A.6</b>	<b>Traumatic ischaemia of muscle, not elsewhere classified</b>
	<p><b><i>Inclusions:</i></b></p> <p style="margin-left: 20px;">Traumatic compartment syndrome</p> <p><b><i>Exclusions:</i></b></p> <p style="margin-left: 20px;">anterior tibial syndrome (FB54)</p>
<b>NF0A.7</b>	<b>Traumatic subcutaneous emphysema, not elsewhere classified</b>
	<p><b><i>Exclusions:</i></b></p> <p style="margin-left: 20px;">emphysema (subcutaneous) resulting from a procedure (NE81)</p>
<b>NF0A.Y</b>	<b>Other early complication of trauma, not elsewhere classified</b>
<b>NF0A.Z</b>	<b>Early complications of trauma, not elsewhere classified</b>
<b>NF0Y</b>	<b>Other specified effects of external causes</b>
<b>NF0Z</b>	<b>Unspecified effects of external causes</b>
<b>NF2Y</b>	<b>Other specified injury, poisoning or certain other consequences of external causes</b>
<b>NF2Z</b>	<b>Unspecified injury, poisoning or certain other consequences of external causes</b>

# CHAPTER 23

---

## External causes of morbidity or mortality

This chapter has 568 four-character categories.

Code range starts with PA00

The WHO definition of an 'injury' is: 'Injuries are caused by acute exposure to physical agents such as mechanical energy, heat, electricity, chemicals, and ionizing radiation interacting with the body in amounts or at rates that exceed the threshold of human tolerance. In some cases, (for example, drowning and frostbite), injuries result from the sudden lack of essential agents such as oxygen or heat. Injuries may be categorized in a number of ways. However, for most analytical purposes and for identifying intervention opportunities, it is especially useful to categorize injuries according to whether or not they were deliberately inflicted and by whom. Commonly used categories are:

- unintentional (i.e. accidental)
- intentional (i.e. deliberate):
- interpersonal (e.g. assault and homicide)
- self-harm (e.g. abuse of drugs and alcohol, self-mutilation, suicide)
- legal intervention (e.g. action by police or other law enforcement personnel)
- war, civil insurrection and disturbances (e.g. demonstrations and riots)
- undetermined intent

Regarding the collection of events that cause injuries, a set of definitions apply. See section 'Definition related to transport accidents'.

This chapter contains the following top level blocks:

- Unintentional causes
- Intentional self-harm
- Assault
- Undetermined intent
- Exposure to extreme forces of nature
- Maltreatment
- Legal intervention
- Armed conflict
- Causes of healthcare related harm or injury

Unintentional causes (PA00-PB6Z)

Unintentional transport injury event (PA00-PA5Z)

[Definitions in relation to transport injury events]  
(<https://icdcdn.who.int/icd11referenceguide/en/html/index.html#descriptions-related-to-transport-injury-events>)

**Unintentional land transport road traffic injury event (PA00-PA0Z)**

- PA00**      Unintentional land transport traffic event injuring a pedestrian
- PA01**      Unintentional land transport traffic event injuring the user of a pedestrian conveyance
- PA02**      Unintentional land transport traffic event injuring a pedal cyclist
- PA03**      Unintentional land transport traffic event injuring a motor cyclist
  - Exclusions:**      Unintentional land transport traffic event injuring an occupant of a low powered passenger vehicle (PA09)
- PA04**      Unintentional land transport traffic event injuring a car occupant
- PA05**      Unintentional land transport traffic event injuring an occupant of a bus or coach
- PA06**      Unintentional land transport traffic event injuring an occupant of a light goods vehicle
- PA07**      Unintentional land transport traffic event injuring an occupant of a heavy goods vehicle
- PA08**      Unintentional land transport traffic event injuring an occupant of a streetcar or tram
- PA09**      Unintentional land transport traffic event injuring an occupant of a low powered passenger vehicle
- PA0A**      Unintentional land transport traffic event injuring a user of a special vehicle mainly used in agriculture
- PA0B**      Unintentional land transport traffic event injuring a user of a special vehicle mainly used on industrial premises
- PA0C**      Unintentional land transport traffic event injuring a user of a special construction vehicle
- PA0D**      Unintentional land transport traffic event injuring a user of an all-terrain vehicle
- PA0E**      Unintentional land transport traffic event injuring a rider of an animal
- PA0F**      Unintentional land transport traffic event injuring an occupant of an animal-drawn vehicle
- PA0Y**      Unintentional land transport traffic event injuring a user of other specified land transport
- PA0Z**      Unintentional land transport traffic event injuring a user of unspecified land transport

Unintentional land transport off-road nontraffic injury event (PA10-PA1Z)

- PA10** Unintentional land transport nontraffic event injuring a pedestrian
- PA11** Unintentional land transport nontraffic event injuring the user of a pedestrian conveyance
- PA12** Unintentional land transport nontraffic event injuring a pedal cyclist
- PA13** Unintentional land transport nontraffic event injuring a motor cyclist
- PA14** Unintentional land transport nontraffic event injuring a car occupant
- PA15** Unintentional land transport nontraffic event injuring an occupant of a bus or coach
- PA16** Unintentional land transport nontraffic event injuring an occupant of a light goods vehicle
- PA17** Unintentional land transport nontraffic event injuring an occupant of a heavy goods vehicle
- PA18** Unintentional land transport nontraffic event injuring an occupant of a streetcar or tram
- PA19** Unintentional land transport nontraffic event injuring an occupant of a low powered passenger vehicle
- PA1A** Unintentional land transport nontraffic event injuring a user of a special vehicle mainly used in agriculture
- PA1B** Unintentional land transport nontraffic event injuring a user of a special vehicle mainly used on industrial premises
- PA1C** Unintentional land transport nontraffic event injuring a user of a special construction vehicle
- PA1D** Unintentional land transport nontraffic event injuring a user of an all-terrain vehicle
- PA1E** Unintentional land transport nontraffic event injuring a rider of an animal
- PA1F** Unintentional land transport nontraffic event injuring an occupant of an animal-drawn vehicle
- PA1Y** Unintentional land transport nontraffic event injuring a user of other specified land transport
- PA1Z** Unintentional land transport nontraffic event injuring a user of unknown or unspecified land transport

Unintentional land transport injury event unknown whether road traffic or off-road nontraffic (PA20-PA2Z)

- PA20** Unintentional land transport event unknown whether traffic or nontraffic injuring a pedestrian
- PA21** Unintentional land transport event unknown whether traffic or nontraffic injuring the user of a pedestrian conveyance
- PA22** Unintentional land transport event unknown whether traffic or nontraffic injuring a pedal cyclist
- PA23** Unintentional land transport event unknown whether traffic or nontraffic injuring a motor cyclist
- PA24** Unintentional land transport event unknown whether traffic or nontraffic injuring a car occupant
- PA25** Unintentional land transport event unknown whether traffic or nontraffic injuring an occupant of a bus or coach
- PA26** Unintentional land transport event unknown whether traffic or nontraffic injuring an occupant of a light goods vehicle
- PA27** Unintentional land transport event unknown whether traffic or nontraffic injuring an occupant of a heavy goods vehicle
- PA28** Unintentional land transport event unknown whether traffic or nontraffic injuring an occupant of a streetcar or tram
- PA29** Unintentional land transport event unknown whether traffic or nontraffic injuring an occupant of a low powered passenger vehicle
- PA2A** Unintentional land transport event unknown whether traffic or nontraffic injuring an occupant of a special vehicle mainly used in agriculture
- PA2B** Unintentional land transport event unknown whether traffic or nontraffic injuring an occupant of a special vehicle mainly used on industrial premises
- PA2C** Unintentional land transport event unknown whether traffic or nontraffic injuring an occupant of a special construction vehicle
- PA2D** Unintentional land transport event unknown whether traffic or nontraffic injuring an occupant of an all-terrain vehicle
- PA2E** Unintentional land transport event unknown whether traffic or nontraffic injuring a rider of an animal
- PA2F** Unintentional land transport event unknown whether traffic or nontraffic injuring an occupant of an animal-drawn vehicle
- PA2Y** Unintentional land transport injury event unknown whether traffic or nontraffic injuring a user of other specified transport

**PA2Z** Unintentional land transport injury event unknown whether traffic or nontraffic injuring a user of unspecified transport

Unintentional railway transport injury event (PA30-PA3Z)

**PA30** Unintentional railway transport injury event with collision or derailment

**PA31** Unintentional railway transport injury event without collision or derailment

**PA3Z** Unintentional railway transport injury event of unspecified type

Unintentional water transport injury event (PA40-PA4Z)

**PA40** Unintentional water transport injury event with water vessel not damaged, disabled or destroyed

**PA40.0** Unintentional water transport injury event with water vessel not damaged, disabled or destroyed, causing submersion or drowning

**PA40.1** Unintentional water transport injury event with water vessel not damaged, disabled or destroyed, causing other injury

**PA40.Z** Unintentional water transport injury event with water vessel not damaged, disabled or destroyed, causing unspecified injury

**PA41** Unintentional water transport injury event with water vessel damaged, disabled or destroyed

**PA41.0** Unintentional water transport injury event with water vessel damaged, disabled or destroyed, causing submersion or drowning

*Inclusions:* drowning and submersion due to boat sinking

*Exclusions:* Unintentional water transport injury event with water vessel not damaged, disabled or destroyed, causing submersion or drowning (PA40.0)

**PA41.Z** Unintentional water transport injury event with water vessel damaged, disabled or destroyed, causing unspecified injury

**PA4Z** Unintentional water transport injury event with damage to water vessel unspecified

**PA50** Unintentional air or space transport injury event

**PA50.0** Unintentional air or space transport injury event with aircraft or spacecraft not damaged, disabled or destroyed

**PA50.1** Unintentional air or space transport injury event with aircraft or spacecraft damaged, disabled or destroyed

**PA50.Z** Unintentional air or space transport injury event, unspecified

**PA5Y** Other specified unintentional transport injury event

**PA5Z**

**Unintentional transport injury event, unspecified**

Unintentional fall (PA60-PA6Z)

- Exclusions:**
- Fall in health care (PL14.E)
  - Tendency to fall (MB47.C)
  - Unintentional land transport traffic event injuring a rider of an animal (PA0E)
  - Fall from animal (PA1E)
  - Fall from burning building or structure (PB10)
  - Fall into fire (PB10-PB1Z)
  - Unintentional immersion, submersion or falling into water (PA90-PA9Z)
  - Fall into or from machinery (PB50-PB5B)
  - Fall from railway train or railway vehicle (PA31)

**PA60**

**Unintentional fall on the same level or from less than 1 metre**

- Exclusions:**
- Fall in health care (PL14.E)
  - Fall while in hospital (PL14.E)
  - Fall from hospital bed (PL14.E)

**PA61**

**Unintentional fall from a height of 1 metre or more**

- Exclusions:**
- Fall in health care (PL14.E)
  - Fall from animal (PA1E)

**PA6Z**

**Unintentional fall from unspecified height**

Unintentional contact with person, animal or plant (PA70-PA7Z)

**PA70**

**Unintentionally struck, kicked, or bumped by person**

**PA71**

**Unintentionally struck, kicked, or bumped by animal**

**PA72**

**Unintentionally stepped on or crushed by person**

**PA73**

**Unintentionally stepped on or crushed by animal**

**PA74**

**Unintentionally bitten by person**

**PA75**

**Unintentionally bitten by animal**

**PA76**

**Unintentionally scratched or clawed by person**

**PA77**

**Unintentionally scratched or clawed by animal**

**PA78**

**Unintentionally stung or envenomated by animal**

**PA79**

**Unintentionally injured by contact with plant**

<b>PA7Y</b>	<b>Other specified type of unintentional contact with person, animal or plant</b>
<b>PA7Z</b>	<b>Unintentional contact with person, animal or plant, type unspecified</b>

Unintentional exposure to object, not elsewhere classified (PA80-PA8Z)

**Exclusions:** Intentional self-harm by exposure to object, not elsewhere classified (PC50-PC5Z)

Assault by exposure to object not elsewhere classified (PE20-PE4Z)

Unintentional contact with person, animal or plant (PA70-PA7Z)

<b>PA80</b>	<b>Unintentionally struck by projectile from firearm</b>
-------------	--

**PA80.0** **Unintentionally struck by projectile from handgun**

**Inclusions:** gun for single hand use

**PA80.1** **Unintentionally struck by projectile from rifle, shotgun or larger firearm**

**PA80.2** **Unintentional exposure to other and unspecified firearm**

**Inclusions:** shot NOS

<b>PA81</b>	<b>Unintentionally struck by moving object</b>
-------------	--

<b>PA82</b>	<b>Unintentional striking against stationary object</b>
-------------	---

<b>PA83</b>	<b>Unintentionally cut or pierced by sharp object</b>
-------------	---

**PA83.0** Unintentionally cut or pierced by knife, sword, or dagger

**PA83.1** Unintentionally cut or pierced by sharp glass

**PA83.2** Unintentionally cut or pierced by other or unspecified sharp object

<b>PA84</b>	<b>Unintentionally struck by blunt object</b>
-------------	---

<b>PA85</b>	<b>Unintentionally caught, crushed, jammed or pinched between objects</b>
-------------	---

<b>PA8Y</b>	<b>Unintentional exposure to other specified object, not elsewhere classified</b>
-------------	---

<b>PA8Z</b>	<b>Unintentional exposure to object, unspecified</b>
-------------	--

Unintentional immersion, submersion or falling into water (PA90-PA9Z)

<b>PA90</b>	<b>Unintentional drowning or submersion, while in body of water</b>
-------------	---

<b>PA91</b>	<b>Unintentional drowning or submersion, following fall into body of water</b>
-------------	--

<b>PA92</b>	<b>Unintentional injury other than drowning following fall into body of water</b>
-------------	---

**PA9Z**      **Unintentional immersion, submersion or falling into water, unspecified**

Unintentional threat to breathing (PB00-PB0Z)

- PB00**      **Unintentional threat to breathing by suffocation from object covering mouth or nose**
- PB01**      **Unintentional threat to breathing by hanging**
- PB02**      **Unintentional threat to breathing by strangulation**
- PB03**      **Unintentional threat to breathing by external compression of airways or chest**
  - Exclusions:***      Unintentional threat to breathing by hanging (PB01)  
                          Unintentional threat to breathing by strangulation (PB02)
- PB04**      **Unintentional threat to breathing by inhalation or ingestion of gastric contents**
- PB05**      **Unintentional threat to breathing by inhalation or ingestion of liquids**
- PB06**      **Unintentional threat to breathing by inhalation or ingestion of food**
- PB07**      **Unintentional threat to breathing by inhalation or ingestion of other objects or materials**
- PB08**      **Unintentional threat to breathing from low oxygen environment**
- PB0Y**      **Unintentional threat to breathing by other specified means**
- PB0Z**      **Unintentional threat to breathing by unspecified means**

Unintentional exposure to thermal mechanism (PB10-PB1Z)

- PB10**      **Unintentional exposure to uncontrolled fire**
- PB11**      **Unintentional exposure to controlled fire**
- PB12**      **Unintentional exposure to ignition or melting of material**
- PB13**      **Unintentional contact with hot object or liquid**
- PB14**      **Unintentional exposure to steam, hot vapour, air or gases**
- PB15**      **Unintentional exposure to excessive heat**
- PB16**      **Unintentional exposure to excessive cold**
- PB1Y**      **Unintentional exposure to other specified thermal mechanism**
- PB1Z**      **Unintentional exposure to unspecified thermal mechanism**

Unintentional exposure to or harmful effects of substances (PB20-PB36)

Unintentional harmful effects of and exposure to noxious substances that occur outside of a therapeutic use context.

**Exclusions:** Substances associated with injury or harm in therapeutic use (PL00-PL0Z)

Unintentional exposure to or harmful effects of drugs, medicaments or biological substances (PB20-PB29)

**Exclusions:** Substances associated with injury or harm in therapeutic use (PL00-PL0Z)

**PB20      Unintentional exposure to or harmful effects of opioids or related analgesics**

**Inclusions:** accidental overdose of opioids or related analgesics

**Exclusions:** Substances associated with injury or harm in therapeutic use  
(PL00-PL0Z)

**PB21      Unintentional exposure to or harmful effects of sedative hypnotic drugs or other CNS depressants**

**Inclusions:** accidental overdose by sedative hypnotic drugs or other CNS depressants

**Exclusions:** Substances associated with injury or harm in therapeutic use  
(PL00-PL0Z)

**PB22      Unintentional exposure to or harmful effects of psychostimulants**

**Inclusions:** accidental overdose of psychostimulants

**Exclusions:** Substances associated with injury or harm in therapeutic use  
(PL00-PL0Z)

**PB23      Unintentional exposure to or harmful effects of cannabinoids or hallucinogens**

**Inclusions:** accidental overdose of cannabinoids or hallucinogens

**Exclusions:** Substances associated with injury or harm in therapeutic use  
(PL00-PL0Z)

**PB24      Unintentional exposure to or harmful effects of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs**

**Inclusions:** accidental overdose of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

**Exclusions:** Substances associated with injury or harm in therapeutic use  
(PL00-PL0Z)

**PB25      Unintentional exposure to or harmful effects of antidepressants**

**Inclusions:** accidental overdose of antidepressants

**Exclusions:** Substances associated with injury or harm in therapeutic use  
(PL00-PL0Z)

**PB26** **Unintentional exposure to or harmful effects of antipsychotics**

***Inclusions:*** accidental overdose of antipsychotics

***Exclusions:*** Substances associated with injury or harm in therapeutic use  
(PL00-PL0Z)

**PB27** **Unintentional exposure to or harmful effects of antiepileptics or antiparkinsonism drugs**

***Inclusions:*** accidental overdose of antiepileptics or antiparkinsonism drugs

***Exclusions:*** Substances associated with injury or harm in therapeutic use  
(PL00-PL0Z)

**PB28** **Unintentional exposure to or harmful effects of other or unspecified drug, medicament or biological substance**

**PB29** **Unintentional exposure to or harmful effects of multiple drugs, medicaments or biological substances**

***Inclusions:*** accidental overdose of multiple drugs, medicaments or biological substances

Unintentional exposure to or harmful effects of substances chiefly nonmedicinal as to source (PB30-PB36)

- PB30 Unintentional exposure to or harmful effects of alcohols
- PB31 Unintentional exposure to or harmful effects of organic solvents
- PB32 Unintentional exposure to or harmful effects of carbon monoxide
- PB33 Unintentional exposure to or harmful effects of pesticides
- PB34 Unintentional exposure to or harmful effects of corrosive substances
- PB35 Unintentional exposure to or harmful effects of halogen derivatives of aliphatic or aromatic hydrocarbons
- PB36 Unintentional exposure to or harmful effects of other or unspecified substances chiefly nonmedicinal as to source

#### Unintentional exposure to other mechanism (PB50-PB5B)

- PB50** Unintentional exposure to foreign body in orifice
- PB51** Unintentional exposure to electric current
- PB52** Unintentional exposure to sunlight
- PB53** Unintentional exposure to radiation
- PB54** Unintentional exposure to high or low air pressure or changes in air pressure

<b>PB55</b>	<b>Unintentional exposure to explosion</b>
<b>PB55.0</b>	<b>Unintentional exposure to chemical explosion</b>
<b>PB55.1</b>	<b>Unintentional exposure to explosion or rupture of pressurised materials or object</b>
<b>PB55.Y</b>	<b>Other specified unintentional exposure to explosion</b>
<b>PB55.Z</b>	<b>Unintentional exposure to explosion, unspecified</b>
<b>PB56</b>	<b>Unintentional exposure to physical overexertion</b>
<b>PB57</b>	<b>Unintentional lack of food</b>
<b>PB58</b>	<b>Unintentional lack of water</b>
<b>PB59</b>	<b>Unintentional other specified privation</b>
<b>PB5A</b>	<b>Unintentional abandonment</b>
<b>PB5B</b>	<b>Unintentional neglect</b>
<hr/>	
<b>PB6Y</b>	<b>Other unintentional cause of morbidity or mortality</b>
<b>PB6Z</b>	<b>Unspecified unintentional cause of morbidity or mortality</b>

### Intentional self-harm (PB80-PD3Z)

Intentional self-harm by transport injury event (PB80-PC2Z)

<b>PB80</b>	<b>Intentional self-harm by land transport road traffic injury event</b>
<b>PB81</b>	<b>Intentional self-harm by land transport off-road nontraffic injury event</b>
<b>PB82</b>	<b>Intentional self-harm by land transport injury event unknown whether traffic or nontraffic</b>
<b>PB83</b>	<b>Intentional self-harm by railway transport injury event</b>

Intentional self-harm by water transport injury event (PB90-PB9Z)

<b>PB90</b>	<b>Intentional self-harm by water transport injury event with water vessel damaged, disabled or destroyed</b>
<b>PB91</b>	<b>Intentional self-harm by water transport injury event with water vessel not damaged, disabled or destroyed</b>
<b>PB91.0</b>	<b>Intentional self-harm by water transport injury event with water vessel not damaged, disabled or destroyed causing submersion or drowning</b>

- PB91.1      Intentional self-harm by water transport injury event with water vessel not damaged, disabled or destroyed causing other injury
- PB91.Z      Intentional self-harm by water transport injury event with water vessel not damaged, disabled or destroyed, unspecified
- PB9Z**      **Intentional self-harm by water transport injury event with damage to water vessel unspecified**

Intentional self-harm by air or space transport injury event (PC00-PC0Z)

- PC00**      **Intentional self-harm by air or space transport injury event with aircraft or spacecraft damaged, disabled or destroyed**
- PC01**      **Intentional self-harm by air or space transport injury event with aircraft or spacecraft not damaged, disabled or destroyed**
- PC0Z**      **Intentional self-harm by air or space transport injury event with damage to aircraft or spacecraft unspecified**
- PC2Y**      **Intentional self-harm by other specified transport injury event**
- PC2Z**      **Intentional self-harm by transport injury event, unspecified**

Intentional self-harm by fall or jump (PC30-PC3Z)

- Inclusions:*      intentional fall from one level to another
- PC30**      **Intentional self-harm by fall or jump on same level or from less than 1 metre**
  - PC31**      **Intentional self-harm by fall or jump from a height of 1 metre or more**
  - PC3Y**      **Other specified intentional self-harm by fall or jump**
  - PC3Z**      **Intentional self-harm by fall or jump, unspecified**

Intentional self-harm by contact with person, animal or plant (PC40-PC4Z)

- PC40**      **Intentional self-harm by being struck, kicked, or bumped by person**
- PC41**      **Intentional self-harm by being struck, kicked, or bumped by animal**
- PC42**      **Intentional self-harm by being stepped on or crushed by person**
- PC43**      **Intentional self-harm by being stepped on or crushed by animal**
- PC44**      **Intentional self-harm by being bitten by animal**
- PC45**      **Intentional self-harm by being scratched or clawed by person**
- PC46**      **Intentional self-harm by being scratched or clawed by animal**
- PC47**      **Intentional self-harm by being stung or envenomated by animal**

<b>PC48</b>	<b>Intentional self-harm by contact with plant</b>
<b>PC4Y</b>	<b>Other specified type of intentional self-harm by contact with person, animal or plant</b>
<b>PC4Z</b>	<b>Intentional self-harm by contact with person, animal or plant, type unspecified</b>
Intentional self-harm by exposure to object, not elsewhere classified (PC50-PC5Z)	
<b>PC50</b>	<b>Intentional self-harm by being struck by projectile from firearm</b>
<b>PC50.0</b>	<b>Intentional self-harm by projectile from handgun</b>
<b>PC50.1</b>	<b>Intentional self-harm by projectile from rifle, shotgun or larger firearm</b>
<b>PC50.Y</b>	<b>Other specified intentional self-harm by being struck by projectile from firearm</b>
<b>PC50.Z</b>	<b>Intentional self-harm by being struck by projectile from firearm, unspecified</b>
<b>PC51</b>	<b>Intentional self-harm by being struck by moving object, not elsewhere classified</b>
<b>PC52</b>	<b>Intentional self-harm by striking against stationary object</b>
<b>PC53</b>	<b>Intentional self-harm by being cut or pierced by sharp object</b>
<b>PC53.0</b>	<b>Intentional self-harm by being cut or pierced by knife, sword or dagger</b>
<b>PC53.1</b>	<b>Intentional self-harm by being cut or pierced by sharp glass</b>
<b>PC53.Y</b>	<b>Other specified intentional self-harm by being cut or pierced by sharp object</b>
<b>PC53.Z</b>	<b>Intentional self-harm by being cut or pierced by sharp object, unspecified</b>
<b>PC54</b>	<b>Intentional self-harm by being struck by blunt object</b>
<b>PC55</b>	<b>Intentional self-harm by being caught, crushed, jammed or pinched between objects</b>
<b>PC5Y</b>	<b>Intentional self harm by contact with other specified type of weapon</b>
<b>PC5Z</b>	<b>Intentional self harm by contact with weapon, type unspecified</b>

Intentional self-harm by immersion, submersion or falling into water (PC60-PC6Z)

<b>PC60</b>	<b>Intentional self-harm by drowning or submersion while in body of water</b>
<b>PC61</b>	<b>Intentional self-harm by drowning or submersion following fall into body of water</b>
<b>PC62</b>	<b>Intentional self-harm by injury other than drowning while in body of water</b>

**PC63** Intentional self-harm by injury other than drowning following fall into body of water

**PC6Z** Intentional self-harm by immersion, submersion or falling into water, unspecified

Intentional self-harm by threat to breathing (PC70-PC7Z)

**PC70** Intentional self-harm by threat to breathing by suffocation from object covering mouth or nose

**PC71** Intentional self-harm by threat to breathing by hanging

**PC72** Intentional self-harm by threat to breathing by strangulation

**PC73** Intentional self-harm by threat to breathing by external compression of airways or chest

**Exclusions:** Intentional self-harm by threat to breathing by hanging (PC71)  
Intentional self-harm by threat to breathing by strangulation (PC72)

**PC74** Intentional self-harm by inhalation or ingestion of gastric contents

**PC75** Intentional self-harm by threat to breathing by inhalation or ingestion of liquids

**PC76** Intentional self-harm by threat to breathing by inhalation or ingestion of food

**PC77** Intentional self-harm by threat to breathing by inhalation or ingestion of other objects or materials

**PC78** Intentional self-harm by threat to breathing from low oxygen environment

**PC7Y** Other specified intentional self-harm by threat to breathing

**PC7Z** Intentional self-harm by threat to breathing, unspecified

Intentional self-harm by exposure to thermal mechanism (PC80-PC8Z)

**PC80** Intentional self-harm by exposure to controlled fire

**PC81** Intentional self-harm by exposure to uncontrolled fire

**PC82** Intentional self-harm by exposure to ignition or melting of material

**PC83** Intentional self-harm by contact with hot object or liquid

**PC84** Intentional self-harm by exposure to steam, hot vapour, air or gases

**PC85** Intentional self-harm by exposure to excessive heat

**PC86** Intentional self-harm by exposure to excessive cold

- PC8Y**      **Intentional self-harm by exposure to other specified thermal mechanism**
- PC8Z**      **Intentional self-harm by exposure to unspecified thermal mechanism**

Intentional self-harm by exposure to or harmful effects of substances (PC90-PD05)

Intentional self harm by harmful effects of and exposure to noxious substances that occur outside of a therapeutic use context.

Use additional extension code, if desired, to identify substance.

**Exclusions:**      Substances associated with injury or harm with therapeutic intent (PL00-PL0Z)

Intentional self-harm by exposure to or harmful effects of drugs, medicaments or biological substances (PC90-PC99)

- PC90**      **Intentional self-harm by exposure to or harmful effects of opioids or related analgesics**
- PC91**      **Intentional self-harm by exposure to or harmful effects of sedative hypnotic drugs or other CNS depressants**
- PC92**      **Intentional self-harm by exposure to or harmful effects of psychostimulants**
- PC93**      **Intentional self-harm by exposure to or harmful effects of cannabinoids or hallucinogens**
- PC94**      **Intentional self-harm by exposure to or harmful effects of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs**
- PC95**      **Intentional self-harm by exposure to or harmful effects of antidepressants**
- PC96**      **Intentional self-harm by exposure to or harmful effects of antipsychotics**
- PC97**      **Intentional self-harm by exposure to or harmful effects of antiepileptics or antiparkinsonism drugs**
- PC98**      **Intentional self-harm by exposure to other and unspecified drug, medicament and biological substance**
- PC99**      **Intentional self-harm by exposure to or harmful effects of multiple drugs, medicaments or biological substances**

Intentional self-harm by exposure to or harmful effects of substances chiefly nonmedicinal as to source (PD00-PD05)

- PD00**      **Intentional self-harm by exposure to or harmful effects of alcohols**

- PD01** Intentional self-harm by exposure to or harmful effects of organic solvents
- PD02** Intentional self-harm by exposure to or harmful effects of carbon monoxide
- PD03** Intentional self-harm by exposure to or harmful effects of pesticides
- PD04** Intentional self-harm by exposure to or harmful effects of corrosive substances
- PD05** Intentional self-harm by exposure to or harmful effects of other or unspecified substances chiefly nonmedicinal as to source

Intentional self-harm by exposure to other mechanism (PD20-PD29)

- PD20** Intentional self-harm by foreign body in orifice
- PD21** Intentional self-harm by exposure to electric current
- PD22** Intentional self-harm by exposure to sunlight
- PD23** Intentional self-harm by exposure to radiation
- PD24** Intentional self-harm by exposure to high or low air pressure or changes in air pressure
- PD25** Intentional self-harm by explosion or rupture of pressurised materials or object
- PD26** Intentional self-harm by physical overexertion
- PD27** Intentional self-harm by lack of food
- PD28** Intentional self-harm by lack of water
- PD29** Intentional self-harm by other specified privation

- 
- PD3Y** Other specified intentional self-harm
  - PD3Z** Intentional self-harm, unspecified

Assault (PD50-PF2Z)

Assault by transport events (PD50-PD9Z)

- PD50** Assault by land transport road traffic injury event
- PD51** Assault by land transport off-road nontraffic injury event
- PD52** Assault by land transport injury event unknown whether road traffic or off-road nontraffic

**PD53**      **Assault by railway transport injury event**

Assault by water transport injury event (PD60-PD6Z)

- PD60**      **Assault by water transport injury event with water vessel damaged, disabled or destroyed**
- PD60.0**      **Assault by water transport injury event with water vessel damaged, disabled or destroyed, causing submersion or drowning**
- PD60.1**      **Assault by water transport injury event with water vessel damaged, disabled or destroyed, causing other injury**
- PD60.Z**      **Assault by water transport injury event with water vessel damaged, disabled or destroyed, causing unspecified injury**
- PD61**      **Assault by water transport injury event with water vessel not damaged, disabled or destroyed**
- PD61.0**      **Assault by water transport injury event with water vessel not damaged, disabled or destroyed, causing submersion or drowning**
- PD61.1**      **Assault by water transport injury event with water vessel not damaged, disabled or destroyed, causing other injury**
- PD61.Y**      **Assault by water transport injury event with water vessel not damaged, disabled or destroyed, causing unspecified injury**
- PD61.Z**      **Assault by water transport injury event with water vessel not damaged, disabled or destroyed, unspecified**
- PD6Z**      **Assault by water transport injury event with damage to water vessel unspecified**

Assault by air or space transport injury event (PD70-PD7Z)

- PD70**      **Assault by air or space transport injury event with aircraft or spacecraft damaged, disabled or destroyed**
- PD71**      **Assault by air or space transport injury event with aircraft or spacecraft not damaged, disabled or destroyed**
- PD7Z**      **Assault by air or space transport injury event with damage to aircraft or spacecraft unspecified**
- PD9Y**      **Other specified assault by transport injury event**
- PD9Z**      **Assault by transport injury event, unspecified**

Assault by causing a fall or jump (PE00-PE0Z)

- PE00**      **Assault by causing a fall or jump on same level or from less than 1 metre**

**PE01**      **Assault by causing a fall or jump from a height of 1 metre or more**

**PE0Z**      **Assault by causing a fall or jump from unspecified height**

Assault by contact with person, animal or plant (PE10-PE1Z)

**PE10**      **Assault by being struck, kicked or bumped by person**

**PE11**      **Assault by being struck, kicked or bumped by animal**

**PE12**      **Assault by being crushed or stepped on by person**

**PE13**      **Assault by being crushed or stepped on by animal**

**PE14**      **Assault by being bitten by person**

**PE15**      **Assault by being bitten by animal**

**PE16**      **Assault by being scratched or clawed by person**

**PE17**      **Assault by being scratched or clawed by animal**

**PE18**      **Assault by being stung or envenomated by animal**

**PE19**      **Assault by contact with plant**

**PE1Y**      **Other specified type of assault by contact with person, animal or plant**

**PE1Z**      **Assault by contact with person, animal or plant, type unspecified**

Assault by exposure to object not elsewhere classified (PE20-PE4Z)

**PE20**      **Assault by projectile from firearm**

**PE20.0**      **Assault by projectile from handgun**

**PE20.1**      **Assault by projectile from rifle, shotgun or larger firearm**

**PE20.Y**      **Assault by being struck by projectile from other specified firearm**

**PE20.Z**      **Assault by being struck by projectile from unspecified firearm**

**PE21**      **Assault by being struck by moving object, not elsewhere classified**

**PE22**      **Assault by striking against stationary object**

Assault by being cut or pierced by sharp object (PE30-PE3Z)

**Inclusions:**      assault by being stabbed NOS

**PE30**      **Assault by being cut or pierced by knife, sword, or dagger**

**PE31**      **Assault by being cut or pierced by sharp glass**

**PE3Z**      **Assault by being cut or pierced by other or unspecified sharp object**

- PE40      Assault by being struck by blunt object**
- PE41      Assault by being caught, crushed, jammed or pinched between objects**
- PE4Y      Assault by contact with other specified object, not elsewhere classified**
- PE4Z      Assault by exposure to unspecified object, not elsewhere classified**

Assault by immersion, submersion or falling into water (PE50-PE52)

- PE50      Assault by drowning or submersion, while in body of water**
- PE51      Assault by drowning or submersion following fall into body of water**
- PE52      Assault by injury other than drowning while in body of water**
- PE53      Assault by injury other than drowning following fall into body of water**
- PE5Y      Other specified assault by immersion, submersion or falling into water**
- PE5Z      Assault by immersion, submersion or falling into water, unspecified**

## Assault by threat to breathing (PE60-PE6Z)

- PE60      Assault by threat to breathing, suffocation from object covering mouth or nose**
- PE61      Assault by threat to breathing by hanging**
- PE62      Assault by threat to breathing by strangulation**
- PE63      Assault by threat to breathing by external compression of airways or chest**
  - Exclusions:***      Assault by threat to breathing by hanging (PE61)
  - Assault by threat to breathing by strangulation (PE62)
- PE64      Assault by threat to breathing by inhalation or ingestion of liquids**
- PE65      Assault by threat to breathing by inhalation or ingestion of food**
- PE66      Assault by threat to breathing by inhalation or ingestion of other objects or materials**
- PE67      Assault by threat to breathing by low oxygen environment**
- PE6Y      Other specified assault by threat to breathing**
- PE6Z      Assault by threat to breathing, unspecified**

## Assault by exposure to thermal mechanism (PE70-PE7Z)

**PE70**      **Assault by exposure to uncontrolled fire**

<b>PE71</b>	<b>Assault by exposure to controlled fire</b>
<b>PE72</b>	<b>Assault by exposure to ignition or melting of materials</b>
<b>PE73</b>	<b>Assault by contact with hot object or liquid</b>
<b>PE74</b>	<b>Assault by contact with steam, hot vapour, air or gases</b>
<b>PE75</b>	<b>Assault by exposure to excessive heat</b>
<b>PE76</b>	<b>Assault by exposure to excessive cold</b>
<b>PE7Y</b>	<b>Assault by exposure to other specified thermal mechanism</b>
<b>PE7Z</b>	<b>Assault by exposure to unspecified thermal mechanism</b>

Assault by exposure to or harmful effects of substances (PE80-PE95)

Assault by harmful effects of and exposure to noxious substances that occur outside of a therapeutic use context.

Use additional extension code, if desired, to identify substance.

**Exclusions:** Substances associated with injury or harm in therapeutic use (PL00-PL0Z)

Assault by exposure to or harmful effects of drugs, medicaments or biological substances (PE80-PE8Z)

**Inclusions:**

- homicidal poisoning by (any) biological substance
- homicidal poisoning by (any) drug
- homicidal poisoning by (any) medicament

<b>PE80</b>	<b>Assault by exposure to or harmful effects of opioids or related analgesics</b>
<b>PE81</b>	<b>Assault by exposure to or harmful effects of sedative, hypnotic drugs or other CNS depressants</b>
<b>PE82</b>	<b>Assault by exposure to or harmful effects of psychostimulants</b>
<b>PE83</b>	<b>Assault by exposure to or harmful effects of cannabinoids or hallucinogens</b>
<b>PE84</b>	<b>Assault by exposure to or harmful effects of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs</b>
<b>PE85</b>	<b>Assault by exposure to or harmful effects of antidepressants</b>
<b>PE86</b>	<b>Assault by exposure to or harmful effects of antipsychotics</b>
<b>PE87</b>	<b>Assault by exposure to or harmful effects of antiepileptics or antiparkinsonism drugs</b>

- PE88**      **Assault by exposure to or harmful effects of other or unspecified drug, medicament or biological substance**
- PE89**      **Assault by exposure to or harmful effects of multiple drugs, medicaments or biological substances**
- PE8Y**      **Other specified assault by exposure to or harmful effects of drugs, medicaments or biological substances**
- PE8Z**      **Assault by exposure to or harmful effects of drugs, medicaments or biological substances, unspecified**

Assault by exposure to or harmful effects of substances chiefly nonmedicinal as to source (PE90-PE95)

- PE90**      **Assault by exposure to or harmful effects of alcohols**
- PE91**      **Assault by exposure to or harmful effects of organic solvents**
- PE92**      **Assault by exposure to or harmful effects of carbon monoxide**
- PE93**      **Assault by exposure to or harmful effects of pesticides**
- PE94**      **Assault by exposure to or harmful effects of corrosive substances**
- PE95**      **Assault by exposure to or harmful effects of other or unspecified substances chiefly nonmedicinal as to source**

Assault by exposure to other mechanism (PF10-PF1B)

- PF10**      **Assault by foreign body in orifice or eye**
- PF11**      **Assault by exposure to electric current**
- PF12**      **Assault by exposure to sunlight**
- PF13**      **Assault by exposure to radiation**
- PF14**      **Assault by exposure to high or low air pressure or changes in air pressure**
- PF15**      **Assault by exposure to explosion**
- PF15.0**      **Assault by exposure to chemical explosion**
- PF15.1**      **Assault by explosion or rupture of materials or object**
- PF15.Y**      **Other specified assault by exposure to explosion**
- PF15.Z**      **Assault by exposure to explosion, unspecified**
- PF16**      **Assault by physical overexertion**
- PF17**      **Assault by lack of food**

<b>PF18</b>	<b>Assault by lack of water</b>
<b>PF19</b>	<b>Assault by other specified privation</b>
<b>PF1A</b>	<b>Assault by abandonment</b>
<b>PF1B</b>	<b>Assault by neglect</b>
<hr/>	
<b>PF2Y</b>	<b>Other specified assault</b>
<b>PF2Z</b>	<b>Assault, unspecified</b>

### Undetermined intent (PF40-PH8Z)

Transport injury event of undetermined intent (PF40-PG4Z)

Land transport road traffic injury event of undetermined intent (PF40-PF4Z)

<b>PF40</b>	<b>Land transport traffic injury event of undetermined intent injuring a pedestrian</b>
<b>PF41</b>	<b>Land transport traffic injury event of undetermined intent injuring the user of a pedestrian conveyance</b>
<b>PF42</b>	<b>Land transport traffic injury event of undetermined intent injuring a pedal cyclist</b>
<b>PF43</b>	<b>Land transport traffic injury event of undetermined intent injuring a motor cyclist</b>
<b>PF44</b>	<b>Land transport traffic injury event of undetermined intent injuring a car occupant</b>
<b>PF45</b>	<b>Land transport traffic injury event of undetermined intent injuring a bus or coach occupant</b>
<b>PF46</b>	<b>Land transport traffic injury event of undetermined intent injuring an occupant of light goods vehicle</b>
<b>PF47</b>	<b>Land transport traffic injury event of undetermined intent injuring an occupant of heavy goods vehicle</b>
<b>PF48</b>	<b>Land transport traffic injury event of undetermined intent injuring an occupant of a streetcar or tram</b>
<b>PF49</b>	<b>Land transport traffic injury event of undetermined intent injuring an occupant of a low powered passenger vehicle</b>
<b>PF4A</b>	<b>Land transport traffic injury event of undetermined intent injuring a user of a special vehicle mainly used in agriculture</b>

- PF4B** Land transport traffic injury event of undetermined intent injuring a user of a special vehicle mainly used on industrial premises
- PF4C** Land transport traffic injury event of undetermined intent injuring a user of a special construction vehicle
- PF4D** Land transport traffic injury event of undetermined intent injuring a user of an all-terrain vehicle
- PF4E** Land transport traffic injury event of undetermined intent injuring a rider of an animal
- PF4F** Land transport traffic injury event of undetermined intent injuring an occupant of an animal-drawn vehicle
- PF4Y** Land transport traffic injury event of undetermined intent injuring a user of other specified land transport
- PF4Z** Land transport traffic injury event of undetermined intent injuring a user of unknown or unspecified land transport

Land transport off-road nontraffic injury event of undetermined intent (PF50-PF5Z)

- PF50** Land transport nontraffic injury event of undetermined intent injuring a pedestrian
- PF51** Land transport nontraffic injury event of undetermined intent injuring the user of a pedestrian conveyance
- PF52** Land transport nontraffic injury event of undetermined intent injuring a pedal cyclist
- PF53** Land transport nontraffic injury event of undetermined intent injuring a motor cyclist
- PF54** Land transport nontraffic injury event of undetermined intent injuring a car occupant
- PF55** Land transport nontraffic injury event of undetermined intent injuring a bus or coach occupant
- PF56** Land transport nontraffic injury event of undetermined intent injuring an occupant of light goods vehicle
- PF57** Land transport nontraffic injury event of undetermined intent injuring an occupant of heavy goods vehicle
- PF58** Land transport nontraffic injury event of undetermined intent injuring an occupant of a streetcar or tram
- PF59** Land transport nontraffic injury event of undetermined intent injuring an occupant of a low powered passenger vehicle
- PF5A** Land transport nontraffic injury event of undetermined intent injuring a user of a special vehicle mainly used in agriculture

- PF5B** Land transport nontraffic injury event of undetermined intent injuring a user of a special vehicle mainly used on industrial premises
- PF5C** Land transport nontraffic injury event of undetermined intent injuring a user of a special construction vehicle
- PF5D** Land transport nontraffic injury event of undetermined intent injuring a user of an all-terrain vehicle
- PF5E** Land transport nontraffic injury event of undetermined intent injuring a rider of an animal
- PF5F** Land transport nontraffic injury event of undetermined intent injuring an occupant of an animal-drawn vehicle
- PF5Y** Land transport nontraffic injury event of undetermined intent injuring a user of other specified land transport
- PF5Z** Land transport nontraffic injury event of undetermined intent injuring a user of unknown or unspecified land transport

Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic (PF60-PF6Z)

- PF60** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a pedestrian
- PF61** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring the user of a pedestrian conveyance
- PF62** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a pedal cyclist
- PF63** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a motor cyclist
- PF64** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a car occupant
- PF65** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a bus or coach occupant
- PF66** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring an occupant of light goods vehicle
- PF67** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring an occupant of heavy goods vehicle
- PF68** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring an occupant of a streetcar or tram

- PF69** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring an occupant of a low powered passenger vehicle
- PF6A** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a user of a special vehicle mainly used in agriculture
- PF6B** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a user of a special vehicle mainly used on industrial premises
- PF6C** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a user of a special construction vehicle
- PF6D** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a user of an all-terrain vehicle
- PF6E** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a rider of an animal
- PF6F** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring an occupant of an animal-drawn vehicle
- PF6Y** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a user of an other specified vehicle
- PF6Z** Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic injuring a user of an unknown or unspecified vehicle

#### Railway transport injury event of undetermined intent (PF70-PF7Z)

- PF70** Railway transport injury event of undetermined intent with collision or derailment
- PF71** Railway transport injury event of undetermined intent without collision or derailment
- PF7Z** Railway transport injury event of undetermined intent of unspecified type

#### Water transport injury event of undetermined intent (PF80-PG1Z)

Water transport injury event of undetermined intent with water vessel damaged, disabled or destroyed (PF80-PF8Z)

- PF80** Water transport injury event of undetermined intent with water vessel damaged, disabled or destroyed causing submersion or drowning

**PF8Y** **Water transport injury event of undetermined intent with water vessel damaged, disabled or destroyed causing other injury**

**PF8Z** **Water transport injury event of undetermined intent with water vessel damaged, disabled or destroyed causing unspecified injury**

Water transport injury event of undetermined intent with water vessel not damaged, disabled or destroyed (PF90-PF9Z)

**PF90** **Water transport injury event of undetermined intent with water vessel not damaged, disabled or destroyed causing submersion or drowning**

**PF9Y** **Water transport injury event of undetermined intent with water vessel not damaged, disabled or destroyed causing other injury**

**PF9Z** **Water transport injury event of undetermined intent with water vessel not damaged, disabled or destroyed causing unspecified injury**

---

**PG1Z** **Water transport injury event of undetermined intent, damage to water vessel unspecified**

Air or space transport injury event of undetermined intent (PG20-PG2Z)

**PG20** **Air or space transport injury event of undetermined intent with aircraft or spacecraft damaged, disabled or destroyed**

**PG21** **Air or space transport injury event of undetermined intent with aircraft or spacecraft not damaged, disabled or destroyed**

**PG2Z** **Air or space transport event injury of undetermined intent, damage to aircraft or spacecraft unspecified**

---

**PG4Y** **Other specified transport injury event of undetermined intent**

**PG4Z** **Unspecified transport injury event of undetermined intent**

Fall or jump with undetermined intent (PG50-PG5Z)

**PG50** **Fall or jump of undetermined intent on the same level or from less than 1 metre**

**PG51** **Fall or jump of undetermined intent from a height of 1 metre or more**

**PG5Z** **Fall or jump of undetermined intent, height unspecified**

Contact with person, animal or plant with undetermined intent (PG60-PG6Z)

**PG60** **Struck, kicked, or bumped with undetermined intent by person**

<b>PG61</b>	<b>Struck, kicked, or bumped with undetermined intent by animal</b>
<b>PG62</b>	<b>Stepped on or crushed with undetermined intent by person</b>
<b>PG63</b>	<b>Stepped on or crushed with undetermined intent by animal</b>
<b>PG64</b>	<b>Bitten with undetermined intent by person</b>
<b>PG65</b>	<b>Bitten with undetermined intent by animal</b>
<b>PG66</b>	<b>Scratched or clawed with undetermined intent by person</b>
<b>PG67</b>	<b>Scratched or clawed with undetermined intent by animal</b>
<b>PG68</b>	<b>Stung or envenomated with undetermined intent by animal</b>
<b>PG69</b>	<b>Contact with plant of undetermined intent</b>
<b>PG6Y</b>	<b>Other specified type of contact with person, animal or plant of undetermined intent</b>
<b>PG6Z</b>	<b>Unspecified type of contact with person, animal or plant of undetermined intent</b>

Contact with object, not elsewhere classified with undetermined intent (PG70-PH0Z)

Struck by projectile from firearm of undetermined intent (PG70-PG7Z)

<b>PG70</b>	<b>Struck by projectile from handgun of undetermined intent</b>
<b>PG71</b>	<b>Struck by projectile from rifle, shotgun or larger firearm of undetermined intent</b>
<b>PG7Z</b>	<b>Struck by projectile from other and unspecified firearm with unknown intent</b>
<b>PG80</b>	<b>Struck by moving object, not elsewhere classified of undetermined intent</b>
<b>PG81</b>	<b>Striking against stationary object of undetermined intent</b>

Cut or pierced by sharp object of undetermined intent (PG90-PG9Z)

<b>PG90</b>	<b>Cut or pierced by knife, sword or dagger of undetermined intent</b>
<b>PG91</b>	<b>Cut or pierced by sharp glass of undetermined intent</b>
<b>PG9Z</b>	<b>Cut or pierced by other or unspecified sharp object, undetermined intent</b>
<b>PH00</b>	<b>Struck by blunt object with undetermined intent</b>

- PH01** Caught, crushed, jammed or pinched between objects with undetermined intent
  - PH0Y** Contact with other specified object, not elsewhere classified with undetermined intent
  - PH0Z** Exposure to unspecified object, not elsewhere classified, undetermined intent
- Immersion, submersion or falling into water with undetermined intent (PH10-PH1Z)
- PH10** Drowning or submersion while in body of water with undetermined intent
  - PH11** Drowning or submersion following fall into body of water with undetermined intent
  - PH12** Injury other than drowning while in body of water with undetermined intent
  - PH13** Injury other than drowning following fall into body of water with undetermined intent
  - PH1Z** Immersion, submersion or falling into water with undetermined intent, unspecified

Threat to breathing with undetermined intent (PH20-PH2Z)

- PH20** Threat to breathing by suffocation from object covering mouth or nose with undetermined intent
- PH21** Threat to breathing by hanging with undetermined intent
- PH22** Threat to breathing by strangulation with undetermined intent
- PH23** Threat to breathing by external compression of airways or chest with undetermined intent
 

**Exclusions:**

  - Threat to breathing by hanging with undetermined intent (PH21)
  - Threat to breathing by strangulation with undetermined intent (PH22)
- PH24** Threat to breathing by inhalation or ingestion of liquids with undetermined intent
- PH25** Threat to breathing by inhalation or ingestion of food with undetermined intent
- PH26** Threat to breathing by inhalation or ingestion of other objects or materials with undetermined intent
- PH27** Threat to breathing by low oxygen environment with undetermined intent

**PH2Y**      Other specified threat to breathing with undetermined intent

**PH2Z**      Threat to breathing with undetermined intent, unspecified

Exposure to thermal mechanism with undetermined intent (PH30-PH3Z)

**PH30**      Exposure to uncontrolled fire with undetermined intent

**PH31**      Exposure to controlled fire with undetermined intent

**PH32**      Exposure to ignition or melting of materials with undetermined intent

**PH33**      Contact with hot object or liquid with undetermined intent

**PH34**      Contact with steam, hot vapour, air or gases with undetermined intent

**PH35**      Exposure to excessive heat with undetermined intent

**PH36**      Exposure to excessive cold with undetermined intent

**PH3Y**      Exposure to other specified thermal mechanism with undetermined intent

**PH3Z**      Exposure to unspecified thermal mechanism with undetermined intent

Exposure to or harmful effects of substances, undetermined intent (PH40-PH56)

Undetermined intent of harmful effects of and exposure to noxious substances that occur outside of a therapeutic use context.

**Exclusions:**      Substances associated with injury or harm in therapeutic use (PL00-PL0Z)

Exposure to or harmful effects of undetermined intent of drugs, medicaments or biological substances (PH40-PH49)

**PH40**      Exposure to or harmful effects of undetermined intent of opioids or related analgesics

**PH41**      Exposure to or harmful effects of undetermined intent of sedative hypnotic drugs or other CNS depressants

**PH42**      Exposure to or harmful effects of undetermined intent of psychostimulants

**PH43**      Exposure to or harmful effects of undetermined intent of cannabinoids or hallucinogens

**PH44**      Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

**PH45**      Exposure to or harmful effects of undetermined intent of antidepressants

- PH46**      **Exposure to or harmful effects of undetermined intent of antipsychotics**
- PH47**      **Exposure to or harmful effects of undetermined intent of antiepileptics or antiparkinsonism drugs**
- PH47.0**      **Harmful effects of or exposure to mixed antiepileptics, not elsewhere classified, undetermined intent**
- PH47.Z**      **Undetermined intent: Harmful effects of and exposure to noxious substances: Drugs, medicaments or biological substances: Unspecified antiepileptics or antiparkinsonism drugs**
- PH48**      **Exposure to or harmful effects of undetermined intent of other or unspecified drugs, medicaments or biological substances**
- PH49**      **Exposure to or harmful effects of undetermined intent of multiple drugs, medicaments or biological substances**

Exposure to or harmful effects of undetermined intent of substances chiefly nonmedicinal as to source (PH50-PH56)

- PH50**      **Exposure to or harmful effects of undetermined intent of alcohols**
- PH51**      **Exposure to or harmful effects of undetermined intent of organic solvents**
- PH52**      **Exposure to or harmful effects of undetermined intent of carbon monoxide**
- PH53**      **Exposure to or harmful effects of undetermined intent of pesticides**
- PH54**      **Exposure to or harmful effects of undetermined intent of corrosive substances**
- PH55**      **Exposure to or harmful effects of undetermined intent of halogen derivatives of aliphatic or aromatic hydrocarbons**
- PH56**      **Exposure to or harmful effects of undetermined intent of other or unspecified substances chiefly nonmedicinal as to source**

Exposure to other mechanism with undetermined intent (PH70-PH7B)

- PH70**      **Exposure to foreign body in orifice or eye with undetermined intent**
- PH71**      **Exposure to electric current with undetermined intent**
- PH72**      **Exposure to sunlight with undetermined intent**
- PH73**      **Exposure to radiation with undetermined intent**
- PH74**      **Exposure to high or low air pressure or changes in air pressure with undetermined intent**

<b>PH75</b>	<b>Exposure to explosion with undetermined intent</b>
<b>PH75.0</b>	<b>Exposure to chemical explosion with undetermined intent</b>
<b>PH75.1</b>	<b>Exposure to explosion or rupture of pressurised materials or object with undetermined intent</b>
<b>PH75.Y</b>	<b>Other specified exposure to explosion with undetermined intent</b>
<b>PH75.Z</b>	<b>Exposure to explosion with undetermined intent, unspecified</b>
<b>PH76</b>	<b>Physical overexertion with undetermined intent</b>
<b>PH77</b>	<b>Lack of food with undetermined intent</b>
<b>PH78</b>	<b>Lack of water with undetermined intent</b>
<b>PH79</b>	<b>Other specified privation with undetermined intent</b>
<b>PH7A</b>	<b>Abandonment with undetermined intent</b>
<b>PH7B</b>	<b>Neglect with undetermined intent</b>
<hr/>	
<b>PH8Y</b>	<b>Other specified injury event of undetermined intent</b>
<b>PH8Z</b>	<b>Unspecified injury event of undetermined intent</b>

**Exposure to extreme forces of nature (PJ00-PJ0Z)**

<b>PJ00</b>	<b>Victim of lightning</b>
<b>PJ01</b>	<b>Victim of earthquake</b>
<b>PJ02</b>	<b>Victim of cataclysmic earth movements caused by earthquake</b>
<b>PJ03</b>	<b>Victim of tsunami</b>
<b>PJ04</b>	<b>Victim of volcanic eruption</b>
<b>PJ05</b>	<b>Victim of avalanche, landslide or other earth movements</b>
<b>PJ06</b>	<b>Victim of cataclysmic storm</b>
<b>PJ07</b>	<b>Victim of flood</b>
<b>PJ0Y</b>	<b>Exposure to other specified forces of nature</b>
<b>PJ0Z</b>	<b>Exposure to unspecified forces of nature</b>

## Maltreatment (PJ20-PJ2Z)

Non-accidental acts of physical force, forced or coerced sexual acts, verbal or symbolic acts, or significant caregiving omissions that result in harm or have a reasonable potential for harm. These categories are applied to the victim of the maltreatment, not the perpetrator.

**PJ20**

### **Physical maltreatment**

Non-accidental acts of physical force that result, or have reasonable potential to result, in physical harm or that evoke significant fear. The category is applied to the victim of the maltreatment, not the perpetrator.

**PJ21**

### **Sexual maltreatment**

In adults, forced or coerced sexual acts or sexual acts with someone who is unable to consent; in children, sexual acts involving a child that are intended to provide sexual gratification to an adult. The category is applied to the victim of the maltreatment, not the perpetrator.

**PJ22**

### **Psychological maltreatment**

Non-accidental verbal or symbolic acts that result in significant psychological harm. The category is applied to the victim of the maltreatment, not the perpetrator.

**PJ2Y**

### **Other specified maltreatment**

**PJ2Z**

### **Maltreatment, unspecified**

## Legal intervention (PJ40-PJ4Z)

**Coding Note:** Injuries inflicted by the police or other law-enforcing agents, including military on duty, in the course of arresting or attempting to arrest lawbreakers, suppressing disturbances, maintaining order, or other legal action.

**PJ40**

### **Legal intervention involving projectile from firearm**

**Inclusions:** Legal intervention involving rifle pellet or rubber bullet

**PJ41**

### **Legal intervention involving other projectile**

**PJ42**

### **Legal intervention involving blunt object**

**Inclusions:** Hit, struck by blunt object during legal intervention

**PJ43**

### **Legal intervention involving sharp object**

**Inclusions:** Cut during legal intervention

**PJ44**

### **Legal intervention involving electric weapon**

**PJ45**

### **Legal intervention involving explosive**

**PJ46**

### **Legal intervention involving gas**

**PJ47**

### **Legal intervention involving application of physical force**

**PJ4Y**

**Legal intervention involving other means**

**Coding Note:** Injuries inflicted by the police or other law-enforcing agents, including military on duty, in the course of arresting or attempting to arrest lawbreakers, suppressing disturbances, maintaining order, or other legal action.

**PJ4Z**

**Legal intervention involving unspecified means**

**Coding Note:** Injuries inflicted by the police or other law-enforcing agents, including military on duty, in the course of arresting or attempting to arrest lawbreakers, suppressing disturbances, maintaining order, or other legal action.

## Armed conflict (PJ60-PK6Z)

Explosion of marine weapons during armed conflict (PJ60-PJ6Z)

**PJ60**

**Explosion of depth-charge or marine mine during armed conflict**

**PJ61**

**Explosion of torpedo during armed conflict**

**PJ62**

**Explosion of sea-based artillery shell during armed conflict**

**PJ6Y**

**Explosion of other marine weapons during armed conflict**

**PJ6Z**

**Explosion of unspecified marine weapon**

Attack on or destruction of aircraft during armed conflict (PJ70-PJ7Z)

**PJ70**

**Attack on or destruction of aircraft during armed conflict due to enemy fire or explosives**

**PJ71**

**Attack on or destruction of aircraft during armed conflict due to collision with other aircraft**

**PJ7Y**

**Other destruction of aircraft during armed conflict**

**PJ7Z**

**Unspecified destruction of aircraft during armed conflict**

Other explosions or fragments during armed conflict (PJ80-PJ8Z)

**Exclusions:** Attack on or destruction of aircraft during armed conflict due to enemy fire or explosives (PJ70)

Use of nuclear weapons during armed conflict (PK10-PK1Z)

Injury event occurring after cessation of armed conflict (PK40-PK4Z)

**PJ80**

**Explosion of missile during armed conflict**

**PJ81**

**Explosion of aerial bomb during armed conflict**

**PJ82**

**Explosion of munitions or weapons during armed conflict**

**PJ83**

**Explosion of improvised explosive device during armed conflict**

- PJ8Y**      Other explosion or fragments during armed conflict
- PJ8Z**      Unspecified explosion or fragments during armed conflict

Fires, conflagrations or hot substances during armed conflict (PJ90-PJ9Z)

- PJ90**      Use of gasoline bomb during armed conflict
- PJ91**      Use of flamethrower during armed conflict
- PJ92**      Use of incendiary bullets during armed conflict
- PJ9Y**      Other specified fires, conflagrations or hot substances during armed conflict
- PJ9Z**      Unspecified fire, conflagration or hot substance during armed conflict

Firearm discharge or other forms of conventional warfare during armed conflict (PK00-PK0Z)

- PK00**      Use of rubber bullets during armed conflict
- PK01**      Use of firearm pellets during armed conflict
- PK02**      Other firearms discharge during armed conflict
- PK03**      Other weapons use during armed conflict
- PK04**      Unarmed combat during armed conflict
- PK0Z**      Other and unspecified forms of conventional weapons use during armed conflict

Use of nuclear weapons during armed conflict (PK10-PK1Z)

- PK10**      Thermal or blast effects of nuclear weapon during armed conflict
- PK11**      Nuclear radiation effects of nuclear weapon during armed conflict
- PK1Z**      Other and unspecified effect of nuclear weapon during armed conflict

Use of biological weapons during armed conflict (PK20-PK2Z)

- PK20**      Use of weaponised micro-organisms during armed conflict
- PK2Y**      Use of other specified biological weapons during armed conflict
- PK2Z**      Use of unspecified biological weapons during armed conflict

Chemical weapons or other forms of unconventional warfare during armed conflict (PK30-PK3Z)

- PK30**      Use of chemical weapons during armed conflict

<b>PK31</b>	<b>Use of lasers or other energetic beams or fields during armed conflict</b>
<b>PK32</b>	<b>Use of electric weapons during armed conflict</b>
<b>PK33</b>	<b>Use of autonomous or semi-autonomous machines as weapons during armed conflict</b>
<b>PK3Z</b>	<b>Other and unspecified forms of unconventional warfare during armed conflict</b>

Injury event occurring after cessation of armed conflict (PK40-PK4Z)

<b>PK40</b>	<b>Explosion of mine after cessation of armed conflict</b>
<b>PK41</b>	<b>Explosion of bomb after cessation of armed conflict</b>
<b>PK4Z</b>	<b>Other and unspecified event after cessation of armed conflict</b>

---

<b>PK6Y</b>	<b>Other specified weapon or attack during armed conflict</b>
<b>PK6Z</b>	<b>Unspecified weapon or attack during armed conflict</b>

Causes of healthcare related harm or injury (PK80-PL14.Z)

Surgical or other medical procedures associated with injury or harm in diagnostic or therapeutic use (PK80-PK8Z)

**Coding Note:** Code first the injury or harm caused by the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK80</b>	<b>Medical or surgical procedure associated with injury or harm in therapeutic use</b>
-------------	--

**Coding Note:** Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

**Exclusions:** Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK80.0</b>	<b>Neurological procedure associated with injury or harm in therapeutic use</b>
---------------	---

**Coding Note:** Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

**Exclusions:** Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK80.00</b>	Neurological procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.01</b>	Neurological procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.02</b>	Neurological procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.0Y</b>	Neurological procedure associated with injury or harm, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.0Z</b>	Neurological procedure associated with injury or harm, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.1</b>	<b>Cardiac procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.10</b>	Cardiac procedure for repair of congenital anomaly associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.11</b>	Cardiac procedure for repair of congenital anomaly associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK80.12</b>	Cardiac procedure for repair of congenital anomaly associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.13</b>	Cardiac procedure for repair of congenital anomaly associated with injury or harm, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.14</b>	Other cardiac procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.15</b>	Other cardiac procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.16</b>	Other cardiac procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.17</b>	Other cardiac procedure associated with injury or harm, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm caused by the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.1Y</b>	Unspecified type of cardiac procedure associated with injury or harm in therapeutic use, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK80.1Z</b>	Unspecified type of cardiac procedure associated with injury or harm in therapeutic use, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.2</b>	<b>Thoracic procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<p><b>Exclusions:</b> Cardiac procedure associated with injury or harm in therapeutic use (PK80.1)</p> <p>Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)</p>
<b>PK80.20</b>	Thoracic procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<p><b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)</p>
<b>PK80.21</b>	Thoracic procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<p><b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)</p>
<b>PK80.22</b>	Thoracic procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<p><b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)</p>
<b>PK80.2Y</b>	Thoracic procedure associated with injury or harm, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.2Z</b>	Thoracic procedure associated with injury or harm, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK80.3</b>	<b>Gastrointestinal, abdominal, or abdominal wall procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.30</b>	Gastrointestinal, abdominal, or abdominal wall procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.31</b>	Gastrointestinal, abdominal, or abdominal wall procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.32</b>	Gastrointestinal, abdominal, or abdominal wall procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.3Y</b>	Gastrointestinal, abdominal, or abdominal wall procedure associated with injury or harm in therapeutic use, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.3Z</b>	Gastrointestinal, abdominal, or abdominal wall procedure associated with injury or harm in therapeutic use, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.4</b>	<b>Endocrine procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK80.40</b>	Endocrine procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.41</b>	Endocrine procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.42</b>	Endocrine procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.4Y</b>	Endocrine procedure associated with injury or harm in therapeutic use, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.4Z</b>	Endocrine procedure associated with injury or harm in therapeutic use, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.5</b>	<b>Gynaecological or breast procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
	Procedures related to abortion (PK80.7)
<b>PK80.50</b>	Gynaecological or breast procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK80.51</b>	Gynaecological or breast procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.52</b>	Gynaecological or breast procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.53</b>	Gynaecological or breast procedure associated with injury or harm in therapeutic use, per orifice approach
<b>PK80.5Y</b>	Gynaecological or breast procedure associated with injury or harm in therapeutic use, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.5Z</b>	Gynaecological or breast procedure associated with injury or harm in therapeutic use, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.6</b>	<b>Urological procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.60</b>	Urological procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.61</b>	Urological procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK80.62</b>	Urological procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.6Y</b>	Urological procedure associated with injury or harm, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.6Z</b>	Urological procedure associated with injury or harm, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.7</b>	<b>Obstetric procedure associated with injury or harm in therapeutic use</b> Surgical procedure on the pregnant woman for conditions associated with pregnancy, labour, or the puerperium
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.70</b>	Caesarean section or other obstetric procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.71</b>	Obstetric procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.72</b>	Obstetric procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK80.73</b>	Obstetric procedure associated with injury or harm in therapeutic use, per orifice approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.7Y</b>	Caesarean section or other obstetric procedure associated with injury or harm, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.7Z</b>	Caesarean section or other obstetric procedure associated with injury or harm, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.8</b>	<b>Musculoskeletal procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.80</b>	Musculoskeletal procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.81</b>	Musculoskeletal procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
	<b>Coded Elsewhere:</b> Bone marrow aspiration or biopsy associated with injury or harm in therapeutic use (PK81.4)
<b>PK80.82</b>	Musculoskeletal procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.8Y</b>	Musculoskeletal procedure associated with injury or harm in therapeutic use, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK80.8Z</b>	Musculoskeletal procedure associated with injury or harm in therapeutic use, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.9</b>	<b>Vascular procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.90</b>	Vascular procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.91</b>	Vascular procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.92</b>	Vascular procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.9Y</b>	Vascular procedure associated with injury or harm, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.9Z</b>	Vascular procedure associated with injury or harm, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.A</b>	<b>Ear, nose, oral, or throat procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK80.A0</b>	Ear, nose, oral, or throat procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.A1</b>	Ear, nose, oral, or throat procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.A2</b>	Ear, nose, oral, or throat procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.AY</b>	Ear, nose, oral, or throat procedure associated with injury or harm in therapeutic use, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.AZ</b>	Ear, nose, oral, or throat procedure associated with injury or harm in therapeutic use, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.B</b>	<b>Dental procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.B0</b>	Dental procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK80.B1</b>	Dental procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.B2</b>	Dental procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.BY</b>	Dental procedure associated with injury or harm, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.BZ</b>	Dental procedure associated with injury or harm, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.C</b>	<b>Skin or integument procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.C0</b>	Skin or integument procedure associated with injury or harm, open approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.C1</b>	Skin or integument procedure associated with injury or harm, percutaneous approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK80.C2</b>	Skin or integument procedure associated with injury or harm, endoscopic approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK80.CY</b>	Skin or integument procedure associated with injury or harm in therapeutic use, other specified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.CZ</b>	Skin or integument procedure associated with injury or harm in therapeutic use, unspecified approach
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK80.D</b>	<b>Ophthalmic procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK81</b>	<b>Certain medical procedures associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>Coded Elsewhere:</b>	Skin complications of BCG immunisation (EA51)
<b>PK81.0</b>	<b>Ventilation associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.1</b>	<b>Extracorporeal life support procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK81.2</b>	<b>Aspiration or drainage of body cavity or fluid collection associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.3</b>	<b>Acupuncture or related therapies associated with injury or harm in therapeutic use</b>
	Injury or harm associated with insertion of needles into certain points of the body for treatment.
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.30</b>	Acupuncture cupping associated with injury or harm in therapeutic use
<b>PK81.3Y</b>	Other specified acupuncture or related therapies associated with injury or harm in therapeutic use
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK81.3Z</b>	Acupuncture or related therapies associated with injury or harm in therapeutic use, unspecified
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK81.4</b>	<b>Bone marrow aspiration or biopsy associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.5</b>	<b>Biopsy procedure, not elsewhere classified, associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Bone marrow aspiration or biopsy associated with injury or harm in therapeutic use (PK81.4)
	Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK81.6</b>	<b>Dialysis associated with injury or harm in therapeutic use</b> Replacing kidney function, a procedure to filter blood, including haemodialysis and peritoneal dialysis.
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.7</b>	<b>Injection or infusion for therapeutic or diagnostic purposes associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.8</b>	<b>Insertion of tube associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.9</b>	<b>Joint aspiration associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first injury or harm associated with procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.A</b>	<b>Lumbar puncture associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first injury or harm associated with procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.B</b>	<b>Manipulative therapies associated with injury or harm in therapeutic use</b> Manipulation and/or movement of one or more parts of the human body for correction and treatment.
<b>Coding Note:</b>	Code first injury or harm associated with procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

<b>PK81.C</b>	<b>Radiation therapy associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first injury or harm associated with procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.D</b>	<b>Other specified medical procedure associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first injury or harm associated with procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.E</b>	<b>Cardiopulmonary resuscitation associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first injury or harm associated with procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)
<b>PK81.F</b>	<b>Needle stick associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first injury or harm associated with procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK8Y</b>	<b>Other specified surgical or other medical procedures associated with injury or harm in diagnostic or therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm caused by the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK8Z</b>	<b>Surgical or other medical procedures associated with injury or harm in diagnostic or therapeutic use, unspecified</b>
<b>Coding Note:</b>	Code first the injury or harm caused by the procedure. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

Surgical or other medical devices, implants or grafts associated with injury or harm in therapeutic use (PK90-PK9C.4)

Medical devices could be associated with injury or harm in therapeutic use through different mechanisms: failure, malfunction, dislodgement, misconnection, removal, unclean/unsterile, use error, inappropriate for related task, poor presentation or packaging, lack of presentation

**Coding Note:** Code first injury or harm associated with device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

**Exclusions:** medical devices associated with adverse incidents due to external causes classified elsewhere (PL12)

**PK90**

### **Anaesthesia devices associated with injury or harm**

**Coding Note:** Code first injury or harm associated with device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

**Exclusions:** Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

**PK90.0** **Anaesthesia devices associated with injury or harm, diagnostic or monitoring devices**

An anaesthesia device was involved in an incident that occurred in a diagnostic or monitoring task

**Coding Note:** Code first injury or harm associated with device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

**Exclusions:** Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

**PK90.1** **Anaesthesia devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices**

An anaesthesia device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task

**Coding Note:** Code first injury or harm associated with device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

**Exclusions:** Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

**PK90.2** **Anaesthesia devices associated with injury or harm, prosthetic or other implants, materials or accessory devices**

Anaesthesia related prosthetic and other implants, materials and accessory devices were involved in an adverse related incident

**Coding Note:** Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK90.3</b>	<b>Anaesthesiology devices associated with injury or harm, surgical instruments, materials or devices</b> Anaesthesiology related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK90.4</b>	<b>Anaesthesiology devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK90.Y</b>	<b>Other specified anaesthesiology devices associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK90.Z</b>	<b>Anaesthesiology devices associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first injury or harm associated with device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK91</b>	<b>Cardiovascular devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK91.0</b>	<b>Cardiovascular devices associated with injury or harm, diagnostic or monitoring devices</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
	<b>Coded Elsewhere:</b> Cardiovascular devices associated with injury or harm, central venous catheter (PK91.15)
<b>PK91.1</b>	<b>Cardiovascular devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
	<b>Coded Elsewhere:</b> Extracorporeal life support procedure associated with injury or harm in therapeutic use (PK81.1)

<b>PK91.10</b>	Cardiovascular devices associated with injury or harm, pacemaker
<b>Coding Note:</b>	Code first injury or harm associated with the device.
<b>Exclusions:</b>	Pacemaker or implantable cardioverter defibrillator battery at end of battery life (BC91)  Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.11</b>	Cardiovascular devices associated with injury or harm, implantable defibrillator
<b>Coding Note:</b>	Code first injury or harm associated with the device.
<b>Exclusions:</b>	Pacemaker or implantable cardioverter defibrillator battery at end of battery life (BC91)  Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.12</b>	Cardiovascular devices associated with injury or harm, left ventricular assist devices
<b>Coding Note:</b>	Code first injury or harm associated with the device.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.13</b>	Cardiovascular devices associated with injury or harm, intra-aortic balloon pump
<b>Coding Note:</b>	Code first injury or harm associated with the device.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.14</b>	Cardiovascular devices associated with injury or harm, IVC filter
<b>Coding Note:</b>	Code first injury or harm associated with the device.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.15</b>	Cardiovascular devices associated with injury or harm, central venous catheter
<b>Coding Note:</b>	Code first injury or harm associated with the device.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.16</b>	Cardiovascular devices associated with injury or harm: peripheral venous catheter
<b>Coding Note:</b>	Code first injury or harm associated with the device.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

<b>PK91.1Y</b>	Other specified cardiovascular devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK91.1Z</b>	Cardiovascular devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices, unspecified
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK91.2</b>	<b>Cardiovascular devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b>  A cardiovascular prosthetic or other implant, or cardiovascular material or an accessory device was associated with an adverse incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Ventricular assist devices (PK91.1Z)  Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.20</b>	Cardiovascular devices associated with injury or harm, grafts
<b>Coding Note:</b>	Code first injury or harm associated with the device.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.21</b>	Cardiovascular devices associated with injury or harm, stents
<b>Coding Note:</b>	Code first injury or harm associated with the device.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.22</b>	Cardiovascular devices associated with injury or harm, mechanical or bioprosthetic valves
<b>Coding Note:</b>	Code first injury or harm associated with the device.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.2Y</b>	Other specified cardiovascular devices associated with injury or harm, prosthetic or other implants, materials or accessory devices
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK91.2Z</b>	Cardiovascular devices associated with injury or harm, prosthetic or other implants, materials or accessory devices, unspecified
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK91.3</b>	<b>Cardiovascular devices associated with injury or harm, surgical instruments, materials or devices</b> A cardiovascular surgical instrument, material or device (including sutures) was associated with an adverse incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.4</b>	<b>Cardiovascular devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK91.Y</b>	<b>Other specified cardiovascular devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK91.Z</b>	<b>Cardiovascular devices, implants or grafts associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK92</b>	<b>Otorhinolaryngological devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK92.0</b>	<b>Otorhinolaryngological devices associated with injury or harm, diagnostic or monitoring devices</b> An otorhinolaryngological device was involved in an incident that occurred in a diagnostic or monitoring task
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

<b>PK92.1</b>	<b>Otorhinolaryngological devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b> An otorhinolaryngological device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK92.2</b>	<b>Otorhinolaryngological devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b> Otorhinolaryngological related prosthetic and other implants, materials and accessory devices were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK92.3</b>	<b>Otorhinolaryngological devices associated with injury or harm, surgical instruments, materials or devices</b> Otorhinolaryngological related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK92.4</b>	<b>Otorhinolaryngological devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK92.Y</b>	<b>Other specified otorhinolaryngological devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK92.Z</b>	<b>Otorhinolaryngological devices, implants or grafts associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK93</b>	<b>Gastroenterology or urology devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK93.0</b>	<b>Gastroenterology or urology devices associated with injury or harm, diagnostic or monitoring devices</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK93.1</b>	<b>Gastroenterology or urology devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b>
	A gastroenterology or urology device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK93.10</b>	Gastroenterology or urology devices associated with injury or harm, urinary catheter
<b>Coding Note:</b>	Code first injury or harm associated with the device.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK93.1Y</b>	Other specified gastroenterology or urology devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK93.1Z</b>	Gastroenterology or urology devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices, unspecified
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK93.2</b>	<b>Gastroenterology or urology devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

<b>PK93.3</b>	<b>Gastroenterology or urology devices associated with injury or harm, surgical instruments, materials or devices</b>
	Gastroenterology or urology related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK93.4</b>	<b>Gastroenterology or urology devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK93.Y</b>	<b>Other specified gastroenterology or urology devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK93.Z</b>	<b>Gastroenterology or urology devices, implants or grafts associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK94</b>	<b>General hospital or personal use devices associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK94.0</b>	<b>General hospital or personal use devices associated with injury or harm, diagnostic or monitoring devices</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

<b>PK94.1</b>	<b>General hospital or personal use devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b> A general hospital and personal-use device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK94.2</b>	<b>General hospital or personal use devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b> General hospital and personal-use related prosthetic and other implants, materials and accessory devices were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK94.3</b>	<b>General hospital or personal use devices associated with injury or harm, surgical instruments, materials or devices</b> General hospital and personal-use related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK94.4</b>	<b>General hospital or personal use devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK94.Y</b>	<b>Other specified general hospital or personal use devices associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK94.Z</b>	<b>General hospital or personal use devices associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK95</b>	<b>Neurological devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK95.0</b>	<b>Neurological devices associated with injury or harm, diagnostic or monitoring devices</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK95.1</b>	<b>Neurological devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK95.2</b>	<b>Neurological devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b> Neurological related prosthetic and other implants, materials and accessory devices were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK95.20</b>	Neurological devices associated with injury or harm, ventricular shunt
<b>Coding Note:</b>	Code first injury or harm associated with the device.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK95.2Y</b>	Other specified neurological devices associated with injury or harm, prosthetic or other implants, materials or accessory devices
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK95.2Z</b>	Neurological devices associated with injury or harm, prosthetic or other implants, materials or accessory devices, unspecified
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK95.3</b>	<b>Neurological devices associated with injury or harm, surgical instruments, materials or devices</b>
	Neurological related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK95.4</b>	<b>Neurological devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK95.Y</b>	<b>Other specified neurological devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK95.Z</b>	<b>Neurological devices, implants or grafts associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK96</b>	<b>Obstetric or gynaecological devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK96.0</b>	<b>Obstetric or gynaecological devices associated with injury or harm, diagnostic or monitoring devices</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

<b>PK96.1</b>	<b>Obstetric or gynaecological devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b>
	An obstetric or gynaecological device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK96.2</b>	<b>Obstetric or gynaecological devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK96.3</b>	<b>Obstetric or gynaecological devices associated with injury or harm, surgical instruments, materials or devices</b>
	Obstetric or gynaecological related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK96.4</b>	<b>Obstetric or gynaecological devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK96.Y</b>	<b>Other specified obstetric or gynaecological devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK96.Z</b>	<b>Obstetric or gynaecological devices, implants or grafts associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK97</b>	<b>Ophthalmic devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK97.0</b>	<b>Ophthalmic devices associated with injury or harm, diagnostic or monitoring devices</b>
	An ophthalmic device was involved in an incident that occurred in a diagnostic or monitoring task
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK97.1</b>	<b>Ophthalmic devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b>
	An ophthalmic device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK97.2</b>	<b>Ophthalmic devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b>
	Ophthalmic related prosthetic and other implants, materials and accessory devices were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK97.3</b>	<b>Ophthalmic devices associated with injury or harm, surgical instruments, materials or devices</b>
	Ophthalmic related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

<b>PK97.4</b>	<b>Ophthalmic devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK97.Y</b>	<b>Other specified ophthalmic devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK97.Z</b>	<b>Ophthalmic devices, implants or grafts associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK98</b>	<b>Radiological devices associated with injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK98.0</b>	<b>Radiological devices associated with injury or harm, diagnostic or monitoring devices</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK98.1</b>	<b>Radiological devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b>
	A radiological device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK98.2</b>	<b>Radiological devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b>
	Radiological related prosthetic and other implants, materials and accessory devices were involved in an adverse related incident
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

<b>PK98.3</b>	<b>Radiological devices associated with injury or harm, surgical instruments, materials or devices</b> Radiological related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK98.4</b>	<b>Radiological devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK98.Y</b>	<b>Other specified radiological devices associated with injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK98.Z</b>	<b>Radiological devices associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK99</b>	<b>Orthopaedic devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK99.0</b>	<b>Orthopaedic devices associated with injury or harm, diagnostic or monitoring devices</b> An orthopaedic device was involved in an incident that occurred in a diagnostic or monitoring task
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK99.1</b>	<b>Orthopaedic devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b> An orthopaedic device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

<b>PK99.2</b>	<b>Orthopaedic devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b> Orthopaedic related prosthetic and other implants, materials and accessory devices were involved in an adverse related incident
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Wear of articular bearing surface of joint prosthesis (FA35) Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK99.3</b>	<b>Orthopaedic devices associated with injury or harm, surgical instruments, materials or devices</b> Orthopaedic related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK99.4</b>	<b>Orthopaedic devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK99.Y</b>	<b>Other specified orthopaedic devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK99.Z</b>	<b>Orthopaedic devices, implants or grafts associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK9A</b>	<b>Physical medicine devices associated with injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

<b>PK9A.0</b>	<b>Physical medicine devices associated with injury or harm, diagnostic or monitoring devices</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9A.1</b>	<b>Physical medicine devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b>
	A physical medicine device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK9A.2</b>	<b>Physical medicine devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b>
	Physical medicine related prosthetic and other implants, materials and accessory devices were involved in an adverse related incident (e.g., infection following use of unclean acupuncture needles)
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9A.20</b>	Communication system devices associated with adverse incidents
<b>PK9A.21</b>	Communication system devices associated with adverse incidents in a physical medicine care environment
<b>PK9A.22</b>	Environmental control system devices associated with adverse incidents
<b>PK9A.23</b>	Mobility aids associated with adverse incidents
<b>PK9A.24</b>	Orthotic devices associated with adverse incidents
<b>PK9A.2Y</b>	Other specified physical medicine devices associated with injury or harm, prosthetic or other implants, materials or accessory devices
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK9A.2Z</b>	Physical medicine devices associated with injury or harm, prosthetic or other implants, materials or accessory devices, unspecified
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK9A.3</b>	<b>Physical medicine devices associated with injury or harm, surgical instruments, materials or devices</b> Physical medicine related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident.
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9A.4</b>	<b>Physical medicine devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9A.Y</b>	<b>Other specified physical medicine devices associated with injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK9A.Z</b>	<b>Physical medicine devices associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK9B</b>	<b>General or plastic surgery devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9B.0</b>	<b>General or plastic surgery devices associated with injury or harm, diagnostic or monitoring devices</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

<b>PK9B.1</b>	<b>General or plastic surgery devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b> A general- or plastic-surgery device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9B.2</b>	<b>General or plastic surgery devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b> General- or plastic-surgery related prosthetic and other implants, materials and accessory devices were involved in an adverse related incident
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9B.3</b>	<b>General or plastic surgery devices associated with injury or harm, surgical instruments, materials or devices</b> General- or plastic-surgery related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK9B.4</b>	<b>General or plastic surgery devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9B.Y</b>	<b>Other specified general or plastic surgery devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK9B.Z</b>	<b>General or plastic surgery devices, implants or grafts associated with injury or harm, unspecified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK9C</b>	<b>Other or unspecified medical devices, implants or grafts associated with injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK9C.0</b>	<b>Other or unspecified medical devices associated with injury or harm, diagnostic or monitoring devices</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9C.1</b>	<b>Other or unspecified medical devices associated with injury or harm, therapeutic, nonsurgical or rehabilitative devices</b>
	An other or unspecified medical device was involved in an adverse incident that occurred in a therapeutic (nonsurgical) and rehabilitative task
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9C.2</b>	<b>Other or unspecified medical devices associated with injury or harm, prosthetic or other implants, materials or accessory devices</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9C.3</b>	<b>Other or unspecified medical devices associated with injury or harm, surgical instruments, materials or devices</b>
	Other or unspecified medical related surgical instruments like materials and devices (including sutures) were involved in an adverse related incident
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
	<b>Exclusions:</b> Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
<b>PK9C.30</b>	Mechanical complication of nonabsorbable surgical material, not otherwise specified
<b>PK9C.31</b>	Mechanical complication of permanent sutures
<b>PK9C.3Y</b>	Other specified other or unspecified medical devices associated with injury or harm, surgical instruments, materials or devices
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PK9C.3Z</b>	Other or unspecified medical devices associated with injury or harm, surgical instruments, materials or devices, unspecified
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PK9C.4</b>	<b>Other or unspecified medical devices associated with injury or harm, miscellaneous devices, not elsewhere classified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)
Substances associated with injury or harm in therapeutic use (PL00-PL0Z)	
Situations where a substance (drug or medicament) causes harm, in the context of intentional use for therapeutic purposes	
<b>Coding Note:</b>	Code first the injury or harm associated with the substance. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	accidents in the technique of administration of drugs, medicaments and biological substances in medical and surgical procedures (PL13)
<b>PL00</b>	<b>Drugs, medicaments or biological substances associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the substance. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>Exclusions:</b>	Circumstances associated with exposure to a drug, medicament or biological substance influencing the episode of care without injury or harm (QA70-QA7Z)
<b>PL01</b>	<b>Complementary or traditional medicines associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the complementary or traditional medicine. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PL01.0</b>	<b>Complementary or traditional medicines associated with injury or harm in therapeutic use, Herbal Preparations or Formulas</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the complementary or traditional medicine. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PL01.1</b>	<b>Complementary or traditional medicines associated with injury or harm in therapeutic use, Dietary Supplements, Vitamins or Minerals</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the complementary or traditional medicine. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PL01.2</b>	<b>Complementary or traditional medicines associated with injury or harm in therapeutic use, Complementary or Traditional Medicines, not elsewhere classified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the complementary or traditional medicine. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.

<b>PL01.Y</b>	<b>Other specified complementary or traditional medicines associated with injury or harm in therapeutic use</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the complementary or traditional medicine. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PL01.Z</b>	<b>Complementary or traditional medicines associated with injury or harm in therapeutic use, unspecified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the complementary or traditional medicine. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PL0Z</b>	<b>Substances associated with injury or harm in therapeutic use, unspecified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the substance. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PL10</b>	<b>Other health care related causes of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care. Code also the mode or mechanism that explains the main way the cause leads to injury or harm.
<b>PL11</b>	<b>Mode of injury or harm associated with a surgical or other medical procedure</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the cause of harm which identifies the procedure or intervention.
	<b>Exclusions:</b> Mode of injury or harm associated with exposure to a drug, medicament or biological substance (PL13)
<b>PL11.0</b>	<b>Cut, puncture or tear, as mode of injury or harm</b>
	The cut or puncture occurs when a solid organ or blood vessel or nerve is unintentionally lacerated or otherwise damaged during a surgical or medical procedure. The cut or puncture must not be required for the successful completion of the procedure. A perforation occurs when a hollow viscous, such as the bowel or urinary bladder, is injured during a surgical procedure such that the contents of the viscous leak into the surrounding tissues or space.
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure or intervention. Code also the cause of harm which identifies the procedure or intervention.
<b>PL11.1</b>	<b>Burn arising during procedure, as mode of injury or harm</b>
	A burn occurs when tissue is damaged by heat, electricity or fire. It can occur, for example, as the direct result of cautery equipment, warming efforts, or because of a fire.
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure or intervention. Code also the cause of harm which identifies the procedure or intervention.
	<b>Exclusions:</b> Burn from ionising radiation (PB53)

<b>PL11.2</b>	<b>Embolisation, as mode of injury or harm</b> An embolisation occurs when a solid object within the venous or arterial circulation propagates to a distal location and becomes lodged there.
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure or intervention. Code also the cause of harm which identifies the procedure or intervention.
	<b>Exclusions:</b> Obstruction of device, as mode of injury or harm (PL12.3) Embolisation without injury or harm (QA50)
<b>PL11.20</b>	Air embolism, as mode of injury
<b>PL11.2Y</b>	Other specified embolisation, as mode of injury or harm
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure or intervention. Code also the cause of harm which identifies the procedure or intervention.
<b>PL11.2Z</b>	Embolisation, as mode of injury or harm, unspecified
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure or intervention. Code also the cause of harm which identifies the procedure or intervention.
<b>PL11.3</b>	<b>Foreign body accidentally left in body, as mode of injury or harm</b> A foreign body is any solid material not normally found in the human body. It is accidentally left in the body if there was no specific intention to keep it in the body, either because it was indicated for medical purposes or because it was unsafe to retrieve.
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure or intervention. Code also the cause of harm which identifies the procedure or intervention.
	<b>Exclusions:</b> Foreign body accidentally left in body without injury or harm (QA51)
<b>PL11.4</b>	<b>Failure of sterile precautions, as mode of injury or harm</b> An infection occurred because standard procedures designed to minimize the risk of hospital acquired infection were not followed or were insufficient.
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure or intervention. Code also the cause of harm which identifies the procedure or intervention.
	<b>Exclusions:</b> Failure of sterile precautions without injury or harm (QA52)
<b>PL11.5</b>	<b>Procedure undertaken at wrong site or wrong side, as mode of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure or intervention. Code also the cause of harm which identifies the procedure or intervention.
	<b>Exclusions:</b> Patient received diagnostic test or treatment intended for another patient (PL14.C)
<b>PL11.6</b>	<b>Pressure, as mode of injury or harm</b> Includes factors such as: body positioning, retractors, or other instruments causing tissue damage through direct pressure
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure or intervention. Code also the cause of harm which identifies the procedure or intervention.
	<b>Exclusions:</b> Pressure as potential mode of injury without injury or harm (QA53)

<b>PL11.Y</b>	<b>Other specified mode of injury or harm associated with a surgical or other medical procedure</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the cause of harm which identifies the procedure or intervention.
<b>PL11.Z</b>	<b>Unspecified mode of injury or harm associated with a surgical or other medical procedure</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the procedure. Code also the cause of harm which identifies the procedure or intervention.
<b>PL12</b>	<b>Mode of injury or harm associated with a surgical or other medical device, implant or graft</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the cause of harm which identifies the type of device.
<b>PL12.0</b>	<b>Structural device failure, as mode of injury or harm</b> Harm arising due to mechanical or material device failure not related to the installation of the device.
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the cause of harm which identifies the type of device.
	<b>Exclusions:</b> Wear of articular bearing surface of joint prosthesis (FA35) Combination or interaction of operator error and device failure, as mode of injury or harm (PL12.6) Structural device failure without injury or harm (QA60)
<b>PL12.1</b>	<b>Functional device failure, as mode of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the cause of harm which identifies the type of device.
	<b>Exclusions:</b> Pacemaker or implantable cardioverter defibrillator dysfunction (NE82.1) Pacemaker or implantable cardioverter defibrillator battery at end of battery life (BC91) Combination or interaction of operator error and device failure, as mode of injury or harm (PL12.6) Functional device failure without injury or harm (QA61)
<b>PL12.2</b>	<b>Perforation or protrusion by device, as mode of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the cause of harm which identifies the type of device.
	<b>Exclusions:</b> Cut, puncture or tear, as mode of injury or harm (PL11.0)
<b>PL12.3</b>	<b>Obstruction of device, as mode of injury or harm</b> Obstruction associated with prosthetic devices, grafts or implants
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the cause of harm which identifies the type of device.
	<b>Exclusions:</b> Obstruction of device without injury or harm (QA63)

<b>PL12.4</b>	<b>Dislodgement, misconnection or de-attachment, as mode of injury or harm</b> Harm arising from loss of connection of device
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the cause of harm which identifies the type of device.
	<b>Exclusions:</b> Wear of articular bearing surface of joint prosthesis (FA35) Pacemaker or implantable cardioverter defibrillator lead complication (NE82.2) Dislodgement, misconnection or de-attachment of a surgical or medical device without injury or harm (QA62)
<b>PL12.5</b>	<b>Operator error, as mode of injury or harm</b> Harm arising due to process or procedural issues associated with the use and/or maintenance of a device not related to device failure.
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the cause of harm which identifies the type of device.
	<b>Exclusions:</b> Combination or interaction of operator error and device failure, as mode of injury or harm (PL12.6) Operator error without injury or harm (QA64)
<b>PL12.6</b>	<b>Combination or interaction of operator error and device failure, as mode of injury or harm</b> Harm arising due to a combination of device failure and process/procedural error in device use or maintenance.
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the cause of harm which identifies the type of device.
	<b>Exclusions:</b> Operator error, as mode of injury or harm (PL12.5) Structural device failure, as mode of injury or harm (PL12.0) Functional device failure, as mode of injury or harm (PL12.1) Combination or interaction of operator error and device failure without injury or harm (QA65)
<b>PL12.Y</b>	<b>Other specified mode of injury or harm associated with a surgical or other medical device, implant or graft</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the cause of harm which identifies the type of device.
<b>PL12.Z</b>	<b>Mode of injury or harm associated with a surgical or other medical device, implant or graft, unspecified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the device. Code also the cause of harm which identifies the type of device.
<b>PL13</b>	<b>Mode of injury or harm associated with exposure to a drug, medicament or biological substance</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.

<b>PL13.0</b>	<b>Overdose of substance, as mode of injury or harm</b>
	Incorrect dose - too high
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>Inclusions:</b>	<p>overdose of prescribed drug</p> <p>medication error leading to excess level or effect of prescribed drug</p>
<b>Exclusions:</b>	<p>Overdose of substance without injury or harm (QA70)</p> <p>Unintentional exposure to or harmful effects of drugs, medicaments or biological substances (PB20-PB29)</p> <p>Intentional self-harm by exposure to or harmful effects of drugs, medicaments or biological substances (PC90-PC99)</p> <p>Assault by exposure to or harmful effects of drugs, medicaments or biological substances (PE80-PE8Z)</p> <p>Exposure to or harmful effects of undetermined intent of drugs, medicaments or biological substances (PH40-PH49)</p>
<b>PL13.1</b>	<b>Underdosing, as mode of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>PL13.2</b>	<b>Drug-related injury or harm in the context of correct administration or dosage, as mode of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>PL13.3</b>	<b>Incorrect substance, as mode of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>PL13.5</b>	<b>Incorrect administration of drug or medicament, as mode of injury</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
	<b>Exclusions:</b> Overdose of substance, as mode of injury or harm (PL13.0)
<b>PL13.50</b>	Incorrect route of drug or medicament, as mode of injury
	<b>Exclusions:</b> Overdose of substance, as mode of injury or harm (PL13.0)
<b>PL13.51</b>	Incorrect rate of drug or medicament, as mode of injury
	<b>Exclusions:</b> Overdose of substance, as mode of injury or harm (PL13.0)
<b>PL13.52</b>	Incorrect timing of drug or medicament, as mode of injury
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance.
	<b>Exclusions:</b> Problem with delayed treatment (PL14.B)
	Overdose of substance, as mode of injury or harm (PL13.0)

<b>PL13.53</b>	Incorrect duration of drug or medicament, as mode of injury
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance.
<b>Exclusions:</b>	Overdose of substance, as mode of injury or harm (PL13.0) Underdosing, as mode of injury or harm (PL13.1)
<b>PL13.5Y</b>	Other specified incorrect administration of drug or medicament, as mode of injury
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>PL13.5Z</b>	Incorrect administration of drug or medicament, as mode of injury, unspecified
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>PL13.6</b>	<b>Medication or substance that is known to be an allergen, as mode of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>PL13.7</b>	<b>Medication or substance that is known to be contraindicated for the patient, as mode of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
	<b>Exclusions:</b> Medication or substance that is known to be an allergen, as mode of injury or harm (PL13.6)
<b>PL13.8</b>	<b>Expired or deteriorated medication or substance, as mode of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>PL13.9</b>	<b>Drug or substance interactions, as mode of injury or harm</b> Medication or substance that is known to interact with another medication or substance that the patient is taking or is expected to take. Code also all involved substances.
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>PL13.A</b>	<b>Inappropriate stoppage or discontinuation of drug, as mode of injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>PL13.Y</b>	<b>Other specified mode of injury or harm associated with exposure to a drug, medicament or biological substance</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.
<b>PL13.Z</b>	<b>Mode of injury or harm associated with exposure to a drug, medicament or biological substance, unspecified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with the drug, medicament or substance. Code also the cause of harm which identifies the substance.

<b>PL14</b>	<b>Mode of injury or harm associated with other health care related causes</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>Exclusions:</b>	Mode of injury or harm associated with a surgical or other medical device, implant or graft (PL12) Mode of injury or harm associated with a surgical or other medical procedure (PL11) Mode of injury or harm associated with exposure to a drug, medicament or biological substance (PL13)
<b>PL14.0</b>	<b>Non-administration of necessary drug</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>Exclusions:</b>	Underdosing, as mode of injury or harm (PL13.1)
<b>PL14.1</b>	<b>Non provision of necessary procedure</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>Exclusions:</b>	Delayed treatment (PL14.B)
<b>PL14.2</b>	<b>Problem associated with physical transfer of patient</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.3</b>	<b>Mismatched blood used in transfusion</b>
	Mismatched blood was used in transfusion and led to injury.
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.4</b>	<b>Other problem associated with transfusion</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.5</b>	<b>Problem associated with physical restraints</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.6</b>	<b>Problem associated with isolation protocol</b>
	Isolation of patient for infection cause injury to occur
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)

<b>PL14.7</b>	<b>Problem associated with clinical documentation</b> Clinical documentation error or omission led to injury of patient
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.8</b>	<b>Problem associated with clinical software</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.9</b>	<b>Incorrect diagnosis</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.A</b>	<b>Delayed diagnosis</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.B</b>	<b>Delayed treatment</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
	<b>Exclusions:</b> Incorrect timing of drug or medicament, as mode of injury (PL13.0)
	Non provision of necessary procedure (PL14.1)
<b>PL14.C</b>	<b>Patient received diagnostic test or treatment intended for another patient</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
	<b>Exclusions:</b> Procedure undertaken at wrong site or wrong side, as mode of injury or harm (PL11.5)
<b>PL14.D</b>	<b>Problem associated with transitions of care, hand offs, or handovers</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.E</b>	<b>Fall in health care</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.Y</b>	<b>Other specified aspects of care associated with injury or harm</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)
<b>PL14.Z</b>	<b>Mode of injury or harm associated with other health care related causes, unspecified</b>
<b>Coding Note:</b>	Code first the injury or harm associated with other health care interventions. Code also the cause of harm (i.e. PL10 Other health care related causes of injury or harm)

---

**PL2Y      Other specified external causes of morbidity or mortality**

**PL2Z      External causes of morbidity or mortality, unspecified**

# CHAPTER 24

---

## Factors influencing health status or contact with health services

This chapter has 334 four-character categories.

Code range starts with QA00

Categories in this chapter are provided for occasions when circumstances other than a disease, injury or external cause classifiable elsewhere are recorded as "diagnoses" or "problems". This can arise in two main ways:

1. When a person who may or may not be sick encounters the health services for some specific purpose, such as to receive limited care or service for a current condition, to donate an organ or tissue, to receive prophylactic vaccination or to discuss a problem which is in itself not a disease or injury.
2. When some circumstance or problem is present which influences the person's health status but is not in itself a current illness or injury. Such circumstance or problem may be elicited during population surveys, when the person may or may not be currently sick, or be recorded as additional information to be borne in mind when the person is receiving care for some illness or injury.

This chapter contains the following top level blocks:

- Reasons for contact with the health services
- Factors influencing health status

Reasons for contact with the health services (QA00-QD3Z)

**Coded Elsewhere:** Gender incongruence (HA60-HA6Z)

Contact with health services for purposes of examination or investigation (QA00-QA0Z)

**Exclusions:** examinations related to pregnancy and reproduction (QA20-QA4Z)

Clinical findings in blood, blood-forming organs, or the immune system  
(MA10-MA1Y)

**QA00**

**General examination or investigation of persons without complaint or reported diagnosis**

**Exclusions:**

- Special screening examination for infectious diseases (QA08)
- Examination or encounter for administrative purposes (QA01)
- Special screening examination for neoplasms (QA09)
- Special screening examination for other diseases or disorders (QA0A)

<b>QA00.0</b>	<b>General adult medical examination</b> Encounter for periodic examination (annual) (physical) and any associated laboratory and radiologic examinations on adult.
	<b><i>Exclusions:</i></b> Routine child health examination (QA00.1) Routine general health check-up of defined subpopulation (QA03) Routine newborn health examination (QA00.2) Symptoms, signs or clinical findings, not elsewhere classified (Chapter 21)
<b>QA00.1</b>	<b>Routine child health examination</b> Routine health check for child over 28 days of age through 19 years of age.
	<b><i>Exclusions:</i></b> Health supervision or care of abandoned infant (QC22) Health supervision or care of other healthy infant or child (QC20-QC2Z)
<b>QA00.2</b>	<b>Routine newborn health examination</b> Health examination for infant under 29 days of age
	<b><i>Exclusions:</i></b> Routine child health examination (QA00.1)
<b>QA00.3</b>	<b>General mental examination</b> <b><i>Exclusions:</i></b> examination requested for medicolegal reasons (QA04)
<b>QA00.4</b>	<b>Examination of potential donor of organ or tissue</b>
<b>QA00.5</b>	<b>Examination for normal comparison or control in clinical research programme</b>
<b>QA00.6</b>	<b>Examination of eyes or vision</b> <b><i>Exclusions:</i></b> Examination for driving license (QA01.4)
<b>QA00.61</b>	Normal Visual Field
<b>QA00.62</b>	No vision impairment
<b>QA00.6Y</b>	Other specified examination of eyes or vision
<b>QA00.6Z</b>	Examination of eyes or vision, unspecified
<b>QA00.7</b>	<b>Examination of ears and hearing</b>
<b>QA00.8</b>	<b>Dental examination</b>
<b>QA00.9</b>	<b>Gynaecological examination</b> <b><i>Exclusions:</i></b> routine examination for contraceptive maintenance (QA21.5) Pregnancy examination or test (QA40)
<b>QA00.A</b>	<b>Skin or other sensitisation tests</b>

<b>QA00.B</b>	<b>Radiological examination</b>
	<b><i>Exclusions:</i></b> Special screening examination for neoplasm of breast (QA09.3)
<b>QA00.C</b>	<b>Laboratory examination</b>
<b>QA00.D</b>	<b>Encounter for blood typing</b>
<b>QA00.E</b>	<b>Encounter for antibody response examination</b>
	<b><i>Exclusions:</i></b> Skin or other sensitisation tests (QA00.A)
<b>QA00.Y</b>	<b>Other specified general examination or investigation of persons without complaint or reported diagnosis</b>
<b>QA00.Z</b>	<b>General examination or investigation of persons without complaint or reported diagnosis, unspecified</b>
<b>QA01</b>	<b>Examination or encounter for administrative purposes</b>
<b>QA01.0</b>	<b>Examination for admission to educational institution</b>
<b>QA01.1</b>	<b>Pre-employment examination</b>
	<b><i>Exclusions:</i></b> Occupational health examination (QA03.0)
<b>QA01.2</b>	<b>Examination for admission to residential institutions</b>
	<b><i>Exclusions:</i></b> Routine general health check-up of inhabitants of institutions (QA03.1)
<b>QA01.3</b>	<b>Examination for recruitment to armed forces</b>
	<b><i>Exclusions:</i></b> Routine general health check-up of armed forces (QA03.2)
<b>QA01.4</b>	<b>Examination for driving license</b>
<b>QA01.5</b>	<b>Examination for participation in sport</b>
	<b><i>Exclusions:</i></b> Blood-alcohol or blood-drug test (QA04.0)
	Routine general health check-up of sports teams (QA03.3)
<b>QA01.6</b>	<b>Examination for insurance purposes</b>
<b>QA01.7</b>	<b>Issue of medical certificate</b>
	<b><i>Exclusions:</i></b> General adult medical examination (QA00.0)
<b>QA01.8</b>	<b>Encounter for adoption services</b> Encounter to provide pre or post-adoption services to assist prospective adoptive parents in making an informed decision prior to adoption or to address the medical history and current health of the child and provide parental guidance
<b>QA01.Y</b>	<b>Other specified examination or encounter for administrative purposes</b>
<b>QA01.Z</b>	<b>Examination or encounter for administrative purposes, unspecified</b>

**QA02****Medical observation or evaluation for suspected diseases or conditions, ruled out**

Persons without signs or symptoms or a diagnosis when suspected of having an abnormal condition which requires study, but who, after examination and observation, show no need for further treatment or medical care because suspected condition has been ruled out.

**Coding Note:**

Includes persons who present some symptoms or evidence of an abnormal condition which requires study, but who, after examination and observation, show no need for further treatment or medical care

**Exclusions:** Person with feared complaint in whom no diagnosis is made (QA1C)

**QA02.0****Observation for suspected tuberculosis, ruled out**

Cases presenting with signs susceptible to be due to Tuberculosis, but where after observation and examination it was confirmed that this was not Tuberculosis - and no other disease had been identified that could explain the symptoms.

**QA02.1****Observation for suspected Dengue, ruled out****QA02.2****Observation for suspected malignant neoplasm, ruled out**

**Exclusions:** Special screening examination for neoplasms (QA09)

**QA02.3****Observation for suspected mental or behavioural disorders, ruled out****QA02.4****Observation for suspected nervous system disorder, ruled out****QA02.5****Observation for suspected toxic effect from ingested substance, ruled out**

**Inclusions:** observation for suspected adverse effect from drug  
observation for suspected poisoning

**QA02.6****Observation and evaluation of newborn for suspected condition, ruled out****QA02.7****Observation for suspected suicide ideation or attempt, ruled out****QA02.8****Observation for suspected allergy or hypersensitivity, ruled out**

Observation for a suspected allergy or hypersensitivity, not confirmed or no evidence found at the time of evaluation.

**QA02.Y****Medical observation or evaluation for other suspected diseases or conditions, ruled out****Coding Note:**

Includes persons who present some symptoms or evidence of an abnormal condition which requires study, but who, after examination and observation, show no need for further treatment or medical care

**QA03****Routine general health check-up of defined subpopulation**

**Exclusions:** Examination or encounter for administrative purposes (QA01)

**QA03.0****Occupational health examination**

**Exclusions:** Pre-employment examination (QA01.1)

<b>QA03.1</b>	<b>Routine general health check-up of inhabitants of institutions</b>
	<b><i>Exclusions:</i></b> Examination or encounter for administrative purposes (QA01)
<b>QA03.2</b>	<b>Routine general health check-up of armed forces</b>
	<b><i>Exclusions:</i></b> Examination for recruitment to armed forces (QA01.3)
<b>QA03.3</b>	<b>Routine general health check-up of sports teams</b>
	<b><i>Exclusions:</i></b> Examination for participation in sport (QA01.5) Blood-alcohol or blood-drug test (QA04.0)
<b>QA03.Y</b>	<b>Other specified routine general health check-up of defined subpopulation</b>
<b>QA03.Z</b>	<b>Routine general health check-up of defined subpopulation, unspecified</b>
<b>QA04</b>	<b>Examination or observation for reasons other than suspected diseases or conditions or administrative purposes</b>
<b>QA04.0</b>	<b>Blood-alcohol or blood-drug test</b>
	<b><i>Exclusions:</i></b> Finding of alcohol in blood (MA13.1) presence of drugs in blood (MA12)
<b>QA04.1</b>	<b>Alcohol and drug testing other than by blood</b>
<b>QA04.2</b>	<b>Examination or observation following transport accident</b>
	<b><i>Exclusions:</i></b> Examination or observation following work accident (QA04.3)
<b>QA04.3</b>	<b>Examination or observation following work accident</b>
<b>QA04.4</b>	<b>Examination or observation following accident other than work or transport</b>
<b>QA04.5</b>	<b>Examination or observation for suspected maltreatment</b>
<b>QA04.50</b>	Examination or observation for suspected physical maltreatment Observation and evaluation for suspected or alleged physical abuse which, after study, is ruled out.
<b>QA04.51</b>	Examination or observation for suspected sexual maltreatment Observation and evaluation for suspected or alleged sexual abuse or rape which, after study is ruled out.
<b>QA04.52</b>	Examination or observation for suspected psychological maltreatment Observation and evaluation for suspected or alleged psychological abuse which, after study, is ruled out.
<b>QA04.53</b>	Examination or observation for suspected neglect or abandonment Observation and evaluation for suspected or alleged neglect or abandonment which, after study, is ruled out.
<b>QA04.5Y</b>	Other specified examination or observation for suspected maltreatment
<b>QA04.5Z</b>	Examination or observation for suspected maltreatment, unspecified

QA04.6	<b>General mental examination, requested by authority</b>
QA04.7	<b>Examination for medicolegal reasons</b>
QA04.Y	<b>Other specified examination or observation for reasons other than suspected diseases or conditions or administrative purposes</b>
QA04.Z	<b>Examination or observation for reasons other than suspected diseases or conditions or administrative purposes, unspecified</b>
<b>QA05</b>	<b>Person consulting for explanation of investigation findings</b>
<b>QA06</b>	<b>Follow-up examination after treatment for malignant neoplasms</b> <p><i>Inclusions:</i> medical surveillance following treatment for malignant neoplasms</p> <p><i>Exclusions:</i> follow-up medical care and convalescence (QB70-QB7Z) Attention to surgical dressings, drains or sutures (QB85)</p>
<b>QA07</b>	<b>Follow-up examination after treatment for conditions other than malignant neoplasms</b> <p><i>Inclusions:</i> medical surveillance following treatment for conditions other than malignant neoplasms</p> <p><i>Exclusions:</i> Fitting, adjustment or management of devices (QB30-QB3Z) Surveillance of contraceptive device (QA21.6) Follow-up examination after treatment for malignant neoplasms (QA06) Convalescence (QB70-QB7Z)</p>
QA07.0	<b>Follow-up examination after organ transplant</b>
QA07.Y	<b>Other specified follow-up examination after treatment for conditions other than malignant neoplasms</b>
QA07.Z	<b>Follow-up examination after treatment for conditions other than malignant neoplasms, unspecified</b>
<b>QA08</b>	<b>Special screening examination for infectious diseases</b> <p>A reason for encounter to screen for an infection with a bacterial, viral, fungal, or parasitic source.</p>
QA08.0	<b>Special screening examination for intestinal infectious diseases</b>
QA08.1	<b>Special screening examination for respiratory tuberculosis</b>
QA08.2	<b>Special screening examination for other bacterial diseases</b>
QA08.3	<b>Special screening examination for infections with a predominantly sexual mode of transmission</b>
QA08.4	<b>Special screening examination for human immunodeficiency virus</b>

<b>QA08.5</b>	<b>Special screening examination for other viral diseases</b>
	<b><i>Exclusions:</i></b> Viral intestinal infections (1A20-1A2Z)
	Special screening examination for infections with a predominantly sexual mode of transmission (QA08.3)
	Special screening examination for human immunodeficiency virus (QA08.4)
<b>QA08.6</b>	<b>Special screening examination for other protozoal diseases or helminthiases</b>
	<b><i>Exclusions:</i></b> Protozoal intestinal infections (1A30-1A3Z)
<b>QA08.Y</b>	<b>Special screening examination for other specified infectious diseases</b>
<b>QA08.Z</b>	<b>Special screening examination for unspecified infectious diseases</b>
<b>QA09</b>	<b>Special screening examination for neoplasms</b>
<b>QA09.0</b>	<b>Special screening examination for neoplasm of stomach</b>
<b>QA09.1</b>	<b>Special screening examination for neoplasm of intestinal tract</b>
<b>QA09.2</b>	<b>Special screening examination for neoplasm of respiratory organs</b>
<b>QA09.3</b>	<b>Special screening examination for neoplasm of breast</b>
	<b><i>Exclusions:</i></b> routine mammogram (QA00.B)
<b>QA09.4</b>	<b>Special screening examination for neoplasm of cervix</b>
	<b><i>Exclusions:</i></b> Gynaecological examination (QA00.9)
<b>QA09.5</b>	<b>Special screening examination for neoplasm of prostate</b>
	<b><i>Exclusions:</i></b> Prostate specific antigen positive (MA14.1B)
<b>QA09.6</b>	<b>Special screening examination for neoplasm of bladder</b>
<b>QA09.7</b>	<b>Special screening examination for neoplasm of skin</b> Attendance for special screening for skin cancer including whole skin surface photographic or dermoscopic documentation of patients with multiple melanocytic naevi or naevoid basal cell carcinoma syndrome.
<b>QA09.Y</b>	<b>Other specified special screening examination for neoplasms</b>
<b>QA09.Z</b>	<b>Special screening for neoplasm of unspecified site</b>
<b>QA0A</b>	<b>Special screening examination for other diseases or disorders</b>
<b>QA0A.0</b>	<b>Special screening examination for diseases of the blood or blood-forming organs or certain disorders involving the immune mechanism</b>
<b>QA0A.1</b>	<b>Special screening examination for endocrine and metabolic disorder</b>
<b>QA0A.10</b>	Special screening examination for diabetes mellitus
<b>QA0A.1Y</b>	Other specified special screening examination for endocrine and metabolic disorder

- QA0A.1Z** Special screening examination for endocrine and metabolic disorder, unspecified
- QA0A.2** Special screening examination for nutritional disorders
- QA0A.3** Special screening examination for mental or behavioural disorders
- QA0A.4** Special screening examination for certain developmental disorders in childhood
- Exclusions:** routine development testing of infant or child (QA00.1)
- QA0A.5** Special screening examination for eye or ear disorders
- QA0A.6** Special screening examination for cardiovascular disorders
- QA0A.7** Special screening examination for allergic and hypersensitivity conditions
- QA0A.Y** Special screening for diseases and disorders not elsewhere classified
- QA0A.Z** Special screening examination for other diseases or disorders, unspecified

**QA0B** **Preprocedural examination**

Evaluation and testing for assessment and proactive management of risks of perioperative morbidity and mortality and implements measurements to minimize risks.

**QA0Y** **Other examination or investigation**

**QA0Z** **Examination or investigation, unspecified**

Contact with health services for counselling (QA10-QA1Z)

- Exclusions:** Mental, behavioural or neurodevelopmental disorders (Chapter 06)  
Contact with health services for menopausal counselling (QA4B)  
Contact with health services for preconception counselling (QA33)  
Contact with health services for fertility preservation counselling (QA34)

**Coded Elsewhere:** Contact with health services for genetic counselling (QA31)

**QA10** **Contact with health services for dietary counselling or surveillance**

**QA11** **Contact with health services for alcohol use counselling or surveillance**

- Exclusions:** Alcohol rehabilitation (QB95.2)  
Disorders due to use of alcohol (6C40)

**QA12** **Contact with health services for drug use counselling or surveillance**

- Exclusions:** Drug rehabilitation (QB95.3)  
Disorders due to substance use or addictive behaviours (6C40-6C5Z)

<b>QA13</b>	<b>Contact with health services for tobacco use counselling</b>
	<b>Exclusions:</b> Tobacco rehabilitation (QB95.8) Disorders due to use of nicotine (6C4A)
<b>QA14</b>	<b>Contact with health services for human immunodeficiency virus counselling</b>
	Human immunodeficiency virus counselling can be defined as accessible HIV counselling services that meet the needs of clients and providers in an equitable and acceptable manner, within the resources available and in line with national guidelines. Counselling should increase knowledge of HIV prevention and help the client to focus on solutions to risk reduction.
<b>QA15</b>	<b>Counselling related to sexuality</b>
	<b>Exclusions:</b> Contact with health services for contraceptive management (QA21)  Conditions related to sexual health (Chapter 17)  Contact with health services for procreative management (QA30-QA3Z)
<b>QA15.0</b>	<b>Counselling related to sexual attitudes</b>
<b>QA15.1</b>	<b>Counselling related to sexual behaviour and orientation or sexual relationships of the person</b>
<b>QA15.2</b>	<b>Counselling related to sexual behaviour and orientation or sexual relationships of third party</b>
<b>QA15.3</b>	<b>Counselling related to combined sexual attitudes, sexual behaviour and sexual relationships</b>
<b>QA15.Y</b>	<b>Other specified counselling related to sexuality</b>
<b>QA15.Z</b>	<b>Counselling related to sexuality, unspecified</b>
<b>QA16</b>	<b>Individual psychological or behavioural counselling</b>
<b>QA17</b>	<b>Marital or couples counselling</b>
<b>QA18</b>	<b>Family counselling</b>
<b>QA19</b>	<b>Group counselling</b>
<b>QA1A</b>	<b>Discussion of issues surrounding impending death</b>
<b>QA1B</b>	<b>Concern about or fear of medical treatment</b>
<b>QA1C</b>	<b>Person with feared complaint in whom no diagnosis is made</b>
	<b>Exclusions:</b> Medical observation or evaluation for suspected diseases or conditions, ruled out (QA02)
<b>QA1Y</b>	<b>Contact with health services for other specified counselling</b>
<b>QA1Z</b>	<b>Contact with health services for unspecified counselling</b>

Contact with health services for reasons associated with reproduction (QA20-QA4Z)

**Coded Elsewhere:** Contact with health services for concerns about body image related to pregnancy (QD31)

Contact with health services for preimplantation genetic diagnosis (QA3Y)

Contact with health services for preimplantation genetic screening (QA3Y)

**QA20**

**Contact with health services for concerns about pregnancy**

**QA21**

**Contact with health services for contraceptive management**

**QA21.0**

**Contact with health services for postcoital contraception**

**QA21.1**

**Contact with health services for general counselling or advice on contraception**

**QA21.2**

**Contact with health services for insertion of contraceptive device**

**QA21.3**

**Contact with health services for sterilisation**

**QA21.4**

**Contact with health services for menstrual extraction**

**QA21.5**

**Surveillance of contraceptive drugs**

**QA21.6**

**Surveillance of contraceptive device**

**QA21.60**

Retained intrauterine device without injury or harm in non-pregnant uterus

**QA21.6Y**

Other specified surveillance of contraceptive device

**QA21.6Z**

Surveillance of contraceptive device, unspecified

**QA21.Y**

**Other specified contact with health services for contraceptive management**

**QA21.Z**

**Contact with health services for contraceptive management, unspecified**

Contact with health services for procreative management (QA30-QA3Z)

**Exclusions:** complications associated with artificial fertilization (GA32)

**QA30**

**Contact with health services for medically assisted reproduction**

Medically Assisted Reproduction (MAR): reproduction brought about through ovulation induction, controlled ovarian stimulation, ovulation triggering, ART procedures, and intrauterine, intracervical, and intravaginal insemination with semen of husband/partner or donor.

**QA30.0**

**Contact with health services for assisted insemination**

Artificial insemination is a treatment for infertility that involves directly inserting sperm into a woman's uterus.

**QA30.00**

Contact with health services for gamete intrafallopian transfer

**QA30.01**

Contact with health services for procreative management by artificial insemination

- QA30.02** Contact with health services for medically assisted sperm insemination  
Noncoital insemination by intrauterine, intracervical, or intravaginal route using sperm from either a woman's partner or a sperm donor.
- QA30.0Y** Contact with health services for other specified assisted insemination
- QA30.0Z** Contact with health services for unspecified assisted insemination
- QA30.1** **Contact with health services for assisted reproductive technology**  
All treatments or procedures that include the in vitro handling of both human oocytes and sperm or embryos, for the purpose of establishing a pregnancy. This includes, but is not limited to, in vitro fertilization and embryo transfer, gamete intrafallopian transfer, zygote intrafallopian transfer, tubal embryo transfer, gamete and embryo cryopreservation, oocyte and embryo donation, and gestational surrogacy. ART does not include assisted insemination (artificial insemination) using sperm from either a woman's partner or a sperm donor.
- QA30.10** Contact with health services for in vitro fertilisation
- QA30.11** Contact with health services for egg retrieval  
Ovarian follicular aspiration performed with the aim to retrieve oocytes.
- QA30.12** Contact with health services for embryo transfer  
The procedure in which one or more embryos are placed in the uterus or Fallopian tube.
- QA30.13** Contact with health services for ovum implantation
- QA30.14** Contact with health services for harvesting ovum for in vitro fertilisation
- QA30.15** Contact with health services for harvesting or implantation of ova
- QA30.1Y** Contact with health services for other specified assisted reproductive technology
- QA30.1Z** Contact with health services for unspecified assisted reproductive technology
- QA30.2** **Contact with health services for other assisted fertilisation methods**
- QA30.20** Contact with health services for controlled ovarian stimulation for assisted reproductive technology  
Medical treatment in which women are stimulated to induce the development of multiple ovarian follicles to obtain multiple oocytes at follicular aspiration.
- QA30.21** Contact with health services for controlled ovarian stimulation for non-assisted reproductive technology cycles  
Pharmacological treatment for women with normal ovulatory cycles in which the ovaries are stimulated to ovulate more than one oocyte.
- QA30.22** Contact with health services for ovulation induction  
Ovulation Induction (OI): Pharmacological treatment for women with anovulation or oligo-ovulation to result in normal ovulatory cycles.
- QA30.2Y** Contact with health services for other specified assisted fertilisation methods

- QA30.2Z** Contact with health services for unspecified assisted fertilisation methods
- QA30.Y** Other specified contact with health services for medically assisted reproduction
- QA30.Z** Contact with health services for medically assisted reproduction, unspecified
- QA31** Contact with health services for genetic counselling
- QA32** Contact with health services for tuboplasty or vasoplasty after previous sterilisation
- QA33** Contact with health services for preconception counselling  
A reason for encounter to counsel an individual's queries or complaints regarding conception.
- QA34** Contact with health services for fertility preservation counselling  
A reason for encounter to counsel an individual's queries or complaints regarding fertility preservation.
- QA35** Contact with health services by gestational carrier  
A female who is carrying a pregnancy and who has agreed to give the neonate to the intended parents after childbirth. Gametes may be harvested from the intended parent(s) or from a third party.
- QA3Y** Contact with health services for other specified procreative management
- QA3Z** Contact with health services for procreative management, unspecified
- QA40** Pregnancy examination or test
- QA41** Pregnant state
- QA42** Supervision of normal pregnancy
- QA42.0** Supervision of normal first pregnancy
- QA42.Y** Supervision of other specified normal pregnancy
- QA42.Z** Supervision of normal pregnancy, unspecified
- QA43** Supervision of high-risk pregnancy
- QA43.0** Supervision of pregnancy with history of infertility
- QA43.1** Supervision of pregnancy with history of abortive outcome  
*Exclusions:* Recurrent pregnancy loss (GA33)  
Pregnancy care of habitual aborter (JA65.4)
- QA43.2** Supervision of pregnancy with other poor reproductive or obstetric history
- QA43.3** Supervision of pregnancy with history of insufficient antenatal care
- QA43.30** Concealed pregnancy

- QA43.3Y** Other specified supervision of pregnancy with history of insufficient antenatal care
- QA43.3Z** Supervision of pregnancy with history of insufficient antenatal care, unspecified
- QA43.4** **Supervision of elderly primigravida**
- QA43.5** **Supervision of very young primigravida**
- QA43.6** **Supervision of high-risk pregnancy due to social problems**
- QA43.Y** **Other specified supervision of high-risk pregnancy**
- QA43.Z** **Supervision of high-risk pregnancy, unspecified**

**QA44** **Expectant parent pre-birth visit**

Encounter for the provision of prenatal counselling to prospective parents where there is no identified fetal condition/anomaly or consultative services when referred by another physician due to an identified fetal condition/anomaly.

**QA45** **Antenatal screening**

Antenatal screening is a way of assessing whether the unborn baby could develop or has developed an abnormality or other condition during pregnancy.

**Exclusions:** routine prenatal care (QA42)  
Clinical findings on antenatal screening of mother (JA66)

- QA45.0** **Antenatal screening for chromosomal anomalies**
- QA45.1** **Antenatal screening due to raised alphafetoprotein level**
- QA45.Y** **Other specified antenatal screening**
- QA45.Z** **Antenatal screening, unspecified**

**QA46** **Outcome of delivery**

**Coding Note:** This category is intended for use as an additional code to identify the outcome of delivery on the mother's record.

**QA46.0** **Single live birth**  
Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.

**QA46.1** **Single stillbirth**  
Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.  
Stillbirths are distinct from cases of induced abortion.  
When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.

- QA46.2      Twins, both liveborn**  
Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.
- QA46.3      Twins, one liveborn and one stillborn**  
Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.  
Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.  
Stillbirths are distinct from cases of induced abortion.  
When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.
- QA46.4      Twins, both stillborn**  
Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.  
Stillbirths are distinct from cases of induced abortion.  
When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.
- QA46.5      Triplets, all liveborn**  
Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.
- QA46.6      Triplets, some liveborn**  
Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.  
Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.  
Stillbirths are distinct from cases of induced abortion.  
When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.

- QA46.7      Triplets, all stillborn**
- Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.
- Stillbirths are distinct from cases of induced abortion.
- When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.
- QA46.8      Quadruplets, all liveborn**
- Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.
- QA46.9      Quadruplets, some liveborn**
- Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.
- Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.
- Stillbirths are distinct from cases of induced abortion.
- When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.
- QA46.A      Quadruplets, all stillborn**
- Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.
- Stillbirths are distinct from cases of induced abortion.
- When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.
- QA46.B      Quintuplets, all liveborn**
- Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.

- QA46.C      Quintuplets, some liveborn**
- Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.
- Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.
- Stillbirths are distinct from cases of induced abortion.
- When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.
- QA46.D      Quintuplets, all stillborn**
- Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.
- Stillbirths are distinct from cases of induced abortion.
- When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.
- QA46.E      Sextuplets, all liveborn**
- Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.
- QA46.F      Sextuplets, some liveborn**
- Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.
- Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.
- Stillbirths are distinct from cases of induced abortion.
- When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.
- QA46.G      Sextuplets, all stillborn**
- Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.
- Stillbirths are distinct from cases of induced abortion.
- When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.

<b>QA46.H</b>	<b>Other multiple births, all liveborn</b> Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.
<b>QA46.J</b>	<b>Other multiple births, some liveborn</b> Live birth is the complete expulsion or extraction from a woman of a fetus, irrespective of the duration of the pregnancy, which, after such separation, shows signs of life.  Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.  Stillbirths are distinct from cases of induced abortion.  When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.
<b>QA46.K</b>	<b>Other multiple births, all stillborn</b> Stillbirth is the complete expulsion or extraction from a woman of a fetus, following its death prior to the complete expulsion or extraction, at 22 or more completed weeks of gestation.  Stillbirths are distinct from cases of induced abortion.  When information on gestational age is unavailable use birthweight 500 grams and more as the criteria.
<b>QA46.Z</b>	<b>Outcome of delivery, unspecified</b> <b>Coding Note:</b> This category is intended for use as an additional code to identify the outcome of delivery on the mother's record.
<b>QA47</b>	<b>Liveborn infants according to place of birth</b>
<b>QA47.0</b>	<b>Singleton, born in hospital</b>
<b>QA47.00</b>	Single liveborn infant, delivered vaginally
<b>QA47.01</b>	Single liveborn infant, delivered by caesarean
<b>QA47.0Y</b>	Other specified singleton, born in hospital
<b>QA47.0Z</b>	Singleton, born in hospital, unspecified
<b>QA47.1</b>	<b>Singleton, born outside hospital</b>
<b>QA47.2</b>	<b>Singleton, unspecified as to place of birth</b>
<b>QA47.3</b>	<b>Twin, born in hospital</b>
<b>QA47.30</b>	Twin liveborn infant, delivered vaginally
<b>QA47.31</b>	Twin liveborn infant, delivered by caesarean
<b>QA47.3Y</b>	Other specified twin, born in hospital

<b>QA47.3Z</b>	Twin, born in hospital, unspecified
<b>QA47.4</b>	<b>Twin, born outside hospital</b>
<b>QA47.5</b>	<b>Twin, unspecified as to place of birth</b>
<b>QA47.6</b>	<b>Multiple other than twins, born in hospital</b>
<b>QA47.60</b>	Multiple other than twins, delivered vaginally
<b>QA47.61</b>	Multiple other than twins, delivered by caesarean section
<b>QA47.6Y</b>	Other specified multiple other than twins, born in hospital
<b>QA47.6Z</b>	Multiple other than twins, born in hospital, unspecified
<b>QA47.7</b>	<b>Multiple other than twins, born outside hospital</b>
<b>QA47.8</b>	<b>Other multiple, unspecified as to place of birth</b>
<b>QA47.Z</b>	<b>Liveborn infants according to place of birth, unspecified</b>
<b>QA48</b>	<b>Postpartum care or examination</b>
<b>QA48.0</b>	<b>Care or examination immediately after delivery</b>
	<i><b>Exclusions:</b></i> Complications predominantly related to the puerperium (JB40-JB4Z)
<b>QA48.1</b>	<b>Care or examination of lactating mother</b>
	<i><b>Exclusions:</b></i> Certain specified disorders of breast or lactation associated with childbirth (JB46)
<b>QA48.2</b>	<b>Routine postpartum follow-up</b>
<b>QA48.Y</b>	<b>Other specified postpartum care or examination</b>
<b>QA48.Z</b>	<b>Postpartum care or examination, unspecified</b>
<b>QA49</b>	<b>Problems related to unwanted pregnancy</b>
	<i><b>Exclusions:</b></i> Supervision of high-risk pregnancy due to social problems (QA43.6)
<b>QA4A</b>	<b>Problems related to multiparity</b>
	<i><b>Exclusions:</b></i> Supervision of pregnancy with grand multiparity (QA43)
<b>QA4B</b>	<b>Contact with health services for menopausal counselling</b>
	A reason for encounter to counsel an individual's queries or complaints regarding menopause.
<b>QA4Y</b>	<b>Other specified contact with health services for reasons associated with reproduction</b>
<b>QA4Z</b>	<b>Contact with health services for reasons associated with reproduction, unspecified</b>

Health care related circumstances influencing the episode of care without injury or harm  
(QA50-QB0Z)

Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm (QA50-QA5Z)

**Exclusions:** Mode of injury or harm associated with a surgical or other medical procedure  
(PL11)

**QA50**

**Embolisation without injury or harm**

An embolisation without documented injury or harm occurs when a solid object within the venous or arterial circulation propagates to a distal location and becomes lodged there.

**Exclusions:** Embolisation, as mode of injury or harm (PL11.2)

**QA51**

**Foreign body accidentally left in body without injury or harm**

A foreign body is any solid material not normally found in the human body. It is accidentally left in the body if there was no specific intention to keep it in the body.

**Exclusions:** Foreign body accidentally left in body, as mode of injury or harm (PL11.3)

**QA52**

**Failure of sterile precautions without injury or harm**

Standard procedures designed to minimize the risk of hospital acquired infection were not followed or were insufficient, without documented injury or harm.

**Exclusions:** Failure of sterile precautions, as mode of injury or harm  
(PL11.4)

**QA53**

**Pressure as potential mode of injury without injury or harm**

Pressure as a potential mode of injury, includes factors such as: body positioning, retractors, or other instruments with direct pressure, without documented injury or harm.

**Exclusions:** Pressure, as mode of injury or harm (PL11.6)

**QA5Y**

**Other specified circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm**

**QA5Z**

**Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm, unspecified**

Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm (QA60-QA6Z)

**Exclusions:** Mode of injury or harm associated with a surgical or other medical device, implant or graft (PL12)

**QA60**

**Structural device failure without injury or harm**

Mechanical or material device failure not related to the installation of the device without any documented injury or harm.

**Exclusions:** Dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified (NE82)

Structural device failure, as mode of injury or harm (PL12.0)

**QA61**

**Functional device failure without injury or harm**

A device not working or operating correctly, or that has stopped functioning after a period of function, but without documented injury or harm to the patient.

**Exclusions:** Retained intrauterine device without injury or harm in non-pregnant uterus (QA21.60)

Retained intrauterine contraceptive device in pregnancy (JA65.5)

Breakage of device without documented injury or harm (QA60)

Functional device failure, as mode of injury or harm (PL12.1)

**QA62**

**Dislodgement, misconnection or de-attachment of a surgical or medical device without injury or harm**

A device that has moved out of place, become disconnected, loosened or unstable, but without documented injury or harm.

**Exclusions:** Dislodgement, misconnection or de-attachment, as mode of injury or harm (PL12.4)

**QA63**

**Obstruction of device without injury or harm**

A device that has become obstructed or blocked but without any documented injury or harm.

**Exclusions:** Obstruction of device, as mode of injury or harm (PL12.3)

**QA64**

**Operator error without injury or harm**

Incorrect, or improper maintenance or installation of device without documented injury or harm due to operator error.

**Exclusions:** Operator error, as mode of injury or harm (PL12.5)

**QA65**

**Combination or interaction of operator error and device failure without injury or harm**

Combination of device failure (structural or functional) and process/procedural error (poor training, maintenance, incorrect installation) in device use or maintenance without documented injury or harm.

**Exclusions:** Combination or interaction of operator error and device failure, as mode of injury or harm (PL12.6)

**QA6Y**

**Other specified circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm**

**QA6Z**

**Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm, unspecified**

Circumstances associated with exposure to a drug, medicament or biological substance influencing the episode of care without injury or harm (QA70-QA7Z)

**Exclusions:** Mode of injury or harm associated with exposure to a drug, medicament or biological substance (PL13)

**QA70**

**Overdose of substance without injury or harm**

Overdose of a substance occurs when a patient is given more of a prescribed drug or other substance than is intended. Can be the result of inaccurate measurement of drug, including oral administration. No injury or harm occurred as a result.

**Exclusions:** Overdose of substance, as mode of injury or harm (PL13.0)

**QA71**

**Underdosing without injury or harm**

Under-dosing occurs when a patient takes less of a medication than is prescribed by the provider or the manufacturer's instructions without documented injury or harm. This can be the result of inaccurate measurement of a drug, including oral administration. No injury or harm occurred as a result.

**Exclusions:** Underdosing, as mode of injury or harm (PL13.1)

**QA72**

**Incorrect substance without injury or harm**

Incorrect substance administration occurs when a substance is given which was not the intended or prescribed drug and does not result in injury or harm.

**Exclusions:** Incorrect substance, as mode of injury or harm (PL13.3)

**QA73**

**Incorrect route of administration without injury or harm**

Incorrect or wrong route of administration without documented injury or harm.

**Exclusions:** Incorrect route of drug or medicament, as mode of injury (PL13.50)

**QA74**

**Unspecified appropriateness of dosing or administration without injury or harm**

Unspecified administration of dosage or route without documented injury or harm.

**Exclusions:** Delayed treatment without injury or harm (QA8B)

**QA75**

**Incorrect duration of administration or course of therapy without injury or harm**

Incorrect duration of administration or course of therapy including extended period of time or too brief in duration without documented injury or harm.

**Exclusions:** Incorrect duration of drug or medicament, as mode of injury (PL13.53)

**QA76**

**Medication or substance that is known to be an allergen without injury or harm**

Medication that has previously been identified as an allergen to the patient is administered, but does not result in injury or harm.

**Exclusions:** Medication or substance that is known to be an allergen, as mode of injury or harm (PL13.6)

**QA77**

**Medication or substance that is known to be contraindicated for the patient without injury or harm**

Prescription or non-prescription drug or other substance that has a medical reason for why it should not be used that is administered and does not result in injury or harm.

**Exclusions:** Medication or substance that is known to be an allergen without injury or harm (QA76)

Medication or substance that is known to be contraindicated for the patient, as mode of injury or harm (PL13.7)

**QA78**

**Expired or deteriorated medication or substance without injury or harm**

Administration of a medication that has passed the manufacturer's expiration date. Administration of a medication which has become impaired or inferior in quality, functioning, or condition. No injury or harm occurred as a result.

**Exclusions:** Expired or deteriorated medication or substance, as mode of injury or harm (PL13.8)

**QA79**

**Drug or substance interactions without injury or harm**

A drug interaction is a situation in which a substance affects the activity of another drug when both are administered together. Includes increased effectiveness, decreased effectiveness or a new effect that is not produced from either drug on its own. No injury or harm occurred as a result.

**Exclusions:** Drug or substance interactions, as mode of injury or harm (PL13.9)

**QA7A**

**Inappropriate stoppage or discontinuation of drug without injury or harm**

Drug administration cancelled before prescribed or patient stopped taking drug without provider instructions. No injury or harm occurred as a result.

**Exclusions:** Inappropriate stoppage or discontinuation of drug, as mode of injury or harm (PL13.A)

**QA7Y**

**Other specified circumstances associated with exposure to a drug, medicament or biological substance influencing the episode of care without injury or harm**

**QA7Z**

**Circumstances associated with exposure to a drug, medicament or biological substance influencing the episode of care without injury or harm, unspecified**

Circumstances associated with other aspects of care influencing the episode of care without injury or harm (QA80-QA8Z)

**QA80**

**Non-administration of necessary drug without injury or harm**

Prescribed drug not given. Missed dose, drug not started, drug delayed resulting in missed dose, but no documented injury or harm resulted.

**Exclusions:**

Delayed treatment without injury or harm (QA8B)

Non-administration of necessary drug (PL14.0)

**QA81**

**Non-provision of necessary procedure without injury or harm**

Medically ordered procedure not performed in the episode of care (interrupted, cancelled).

**Exclusions:**

Delayed treatment without injury or harm (QA8B)

Non provision of necessary procedure (PL14.1)

**QA82**

**Problem associated with physical transfer of patient without injury or harm**

Fall, bump, slip, entanglement, drop of patient during movement with healthcare personnel, without documented injury or harm

**Exclusions:**

Problem associated with physical transfer of patient (PL14.2)

**QA83**

**Mismatched blood used in transfusion without injury or harm**

Blood product (e.g. packed red blood cells, platelets, plasma) improperly matched with patient; wrong blood product administered to patient without documented injury or harm.

**Exclusions:**

Mismatched blood used in transfusion (PL14.3)

**QA84**

**Other problem with transfusion without injury or harm**

Transfusion interruption or delay (e.g. took too long to administer – clotted or had to be discarded); transfusion line issues: cracked, leaked a substantial amount of blood so that insufficient amount reached patient; large amount of air infused without documented injury or harm.

**Exclusions:**

Other problem associated with transfusion (PL14.4)

**QA85**

**Problem with physical restraints without injury or harm**

Restraints not attached properly and not effective (e.g. restraints came undone); restraint broken; restraint too tight but problem identified before injury occurred

**Exclusions:**

Problem associated with physical restraints (PL14.5)

**QA86**

**Problem with isolation protocol without injury or harm**

Patient not monitored as frequently as required or ordered; or patient mistakenly or inappropriately put on isolation; or isolation technique broken and contamination possible by patient, health provider, or visitor. No injury or harm resulted.

**Exclusions:**

Problem associated with isolation protocol (PL14.6)

**QA87**

**Problem with clinical documentation without injury or harm**

Documentation on wrong patient; incomplete documentation; incorrect documentation identified as inconsistent with other source, but without documented injury or harm to the patient.

**Exclusions:** Problem associated with clinical documentation (PL14.7)

**QA88**

**Problem with clinical software without injury or harm**

Software malfunction causing interruption in processing of patient orders, laboratory or other diagnostic results, data entry, electronic communication, or data output, but without documented injury or harm.

**Exclusions:** Problem associated with clinical software (PL14.8)

**QA89**

**Incorrect diagnosis without injury or harm**

Diagnosis changed after further study and as a result, treatment was incorrect; misdiagnosis; conflicting diagnoses

**Exclusions:** Incorrect diagnosis (PL14.9)

**QA8A**

**Delayed diagnosis without injury or harm**

Diagnosis not established in a timely manner; symptoms but no diagnosis were documented. In this situation, no documented injury or harm resulted.

**Exclusions:** Delayed diagnosis (PL14.A)

**QA8B**

**Delayed treatment without injury or harm**

Delayed commencement of therapy (e.g. drug therapy, physical therapy, occupational therapy, radiation therapy, surgery, psychological or psychiatric therapy, dressing change, irrigation, etc.).

delayed surgery or procedure

delayed administration of drug or medicament

**Exclusions:** Delayed treatment (PL14.B)

**QA8C**

**Problem with transitions of care, hand offs, or handovers without injury or harm**

Miscommunication, errors, or no communication when changing setting of care from one patient care unit, department, or institution to another

**Exclusions:** Problem associated with transitions of care, hand offs, or handovers (PL14.D)

**QA8D**

**Patient received diagnostic test or treatment intended for another patient without injury or harm**

Patient order for testing or treatment performed on wrong patient (e.g. lab test, diagnostic imaging test, physical or psychological therapy, dressing change, irrigation, etc.).

Patient received drug or medicament meant for another patient, but no harm resulted.

**Exclusions:** Patient received diagnostic test or treatment intended for another patient (PL14.C)

- QA8E** **Fall in health care without injury or harm**  
**Exclusions:** Fall in health care with injury or harm (PL14.E)
- QA8F** **Needle stick without injury or harm**  
**Exclusions:** Needle stick associated with injury or harm in therapeutic use (PK81.F)
- QA8Y** **Other specified circumstances associated with other aspects of care influencing the episode of care without injury or harm**
- QA8Z** **Circumstances associated with other aspects of care influencing the episode of care without injury or harm, unspecified**
- QB0Y** **Other specified health care related circumstances influencing the episode of care without injury or harm**
- QB0Z** **Health care related circumstances influencing the episode of care without injury or harm, unspecified**

Factors related to medical facilities and other health care (QB10-QB1Z)

- QB10** **Medical services not available in home**  
**Exclusions:** Difficulty or need for assistance with activities (QF20-QF2Z)
- QB11** **Person awaiting admission to adequate facility elsewhere**
- QB12** **Waiting period for investigation or treatment other than awaiting admission to adequate facility elsewhere**
- QB12.0** **Organ transplant candidate**
- QB12.Y** **Other specified waiting period for investigation or treatment other than awaiting admission to adequate facility elsewhere**
- QB12.Z** **Waiting period for investigation or treatment other than awaiting admission to adequate facility elsewhere, unspecified**
- QB13** **Unavailability or inaccessibility of helping agencies other than health care facilities**
- QB14** **Unavailability or inaccessibility of health care facilities**  
**Exclusions:** bed unavailable (QB11)
- QB15** **Medical services not available in current medical facility**
- QB16** **Respite care**  
 Provision of temporary health-care facilities to a person normally cared for at home.
- QB1Y** **Other specified factors related to medical facilities and other health care**
- QB1Z** **Factors related to medical facilities and other health care, unspecified**

Donors of organs or tissues (QB20-QB2Z)

**Exclusions:** Examination of potential donor of organ or tissue (QA00.4)

**Coded Elsewhere:** Stem cell donor (QB20)

**QB20**

**Blood donor**

Blood donor is a human being who is a source of blood for the purpose of transfusion.

**QB21**

**Bone marrow donor**

Bone marrow donor is a human being who is a source of bone marrow for the purpose of transplantation.

**QB22**

**Kidney donor**

Kidney donor is a human being, who is a source of a kidney for the purpose of transplantation.

**QB23**

**Cornea donor**

Cornea donor is a human being, who is a source of a cornea for the purpose of transplantation.

**QB24**

**Liver donor**

Liver donor is a human being, who is a source of a liver for the purpose of transplantation.

**QB25**

**Heart donor**

Heart donor is a human being, who is a source of a heart for the purpose of transplantation.

**QB2Y**

**Donors of other specified organs or tissues**

**QB2Z**

**Donors of organs or tissues, unspecified**

Fitting, adjustment or management of devices (QB30-QB3Z)

**Exclusions:** Contact with health services for issue of repeat prescription (QB92)

Presence of devices other than cardiac or vascular implants (QB51)

malfunction or other complications of device (NE80-NE8Z)

**QB30**

**Adjustment or management of implanted devices**

**QB30.0**

**Adjustment or management of implanted hearing device**

**QB30.00**

Adjustment or management of bone conduction device

**QB30.01**

Adjustment or management of cochlear device

**QB30.0Y**

Adjustment or management of other implanted hearing device

**QB30.0Z**

Adjustment or management of implanted hearing device, unspecified

**QB30.1**

**Adjustment or management of infusion pump**

<b>QB30.2</b>	<b>Adjustment or management of cardiac devices</b>
	<b><i>Exclusions:</i></b> Dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified (NE82)
<b>QB30.20</b>	Adjustment or management of cardiac pacemaker
	<b><i>Exclusions:</i></b> Dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified (NE82)
<b>QB30.21</b>	Adjustment or management of cardiac resynchronization therapy defibrillator
	<b><i>Exclusions:</i></b> Dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified (NE82)
<b>QB30.22</b>	Adjustment or management of cardiac resynchronization therapy pacemaker
	<b><i>Exclusions:</i></b> Dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified (NE82)
<b>QB30.23</b>	Adjustment or management of cardioverter-defibrillator
	<b><i>Exclusions:</i></b> Dysfunction or complication of pacemaker, pacemaker lead or implantable cardioverter defibrillator, not elsewhere classified (NE82)
<b>QB30.2Y</b>	Other specified adjustment or management of cardiac devices
<b>QB30.2Z</b>	Adjustment or management of cardiac devices, unspecified
<b>QB30.3</b>	<b>Adjustment or management of vascular access device</b>
<b>QB30.4</b>	<b>Adjustment or management of implanted gastric device</b>
<b>QB30.5</b>	<b>Fitting or adjustment of urinary device</b>
<b>QB30.6</b>	<b>Adjustment or management of breast implant</b>
<b>QB30.7</b>	<b>Adjustment or removal of myringotomy stent or tube</b>
<b>QB30.8</b>	<b>Adjustment and management of a neurostimulator</b>
<b>QB30.9</b>	<b>Fitting or adjustment of cerebrospinal fluid drainage device</b>
<b>QB30.A</b>	<b>Fitting or adjustment of neuropacemaker</b>
<b>QB30.Y</b>	<b>Fitting, adjustment or management of other specified implanted devices</b>
<b>QB30.Z</b>	<b>Adjustment or management of implanted devices, unspecified</b>

<b>QB31</b>	<b>Fitting, adjustment or management of external devices</b>
	<b>Coded Elsewhere:</b> Fitting or adjustment of urinary device (QB30.5)
	Adjustment and management of a neurostimulator (QB30.8)
	Fitting or adjustment of cerebrospinal fluid drainage device (QB30.9)
	Fitting or adjustment of neuromodulator (QB30.A)
	Fitting or adjustment of devices related to nervous system or special senses (QB30.Z)
<b>QB31.0</b>	<b>Fitting or adjustment of external prosthetic device</b>
	<b>Exclusions:</b> presence of prosthetic device (QB50-QB5Z)
<b>QB31.00</b>	Fitting or adjustment of artificial arm
<b>QB31.01</b>	Fitting or adjustment of artificial leg
<b>QB31.02</b>	Fitting or adjustment of artificial eye
<b>QB31.03</b>	Fitting or adjustment of external breast prosthesis
<b>QB31.0Y</b>	Other specified fitting or adjustment of external prosthetic device
<b>QB31.0Z</b>	Fitting or adjustment of external prosthetic device, unspecified
<b>QB31.1</b>	<b>Fitting or adjustment of orthopaedic device</b>
<b>QB31.2</b>	<b>Fitting or adjustment of orthodontic device</b>
<b>QB31.3</b>	<b>Fitting or adjustment of dental prosthetic device</b>
<b>QB31.4</b>	<b>Fitting or adjustment of hearing aid</b>
<b>QB31.5</b>	<b>Fitting or adjustment of spectacles or contact lenses</b>
<b>QB31.Y</b>	<b>Fitting, adjustment or management of other specified external devices</b>
<b>QB31.Z</b>	<b>Fitting, adjustment or management of external devices, unspecified</b>
<b>QB3Z</b>	<b>Fitting, adjustment or management of devices, unspecified</b>

Dependence on enabling machines or devices (QB40-QB4Z)

<b>QB40</b>	<b>Dependence on aspirator</b>
<b>QB41</b>	<b>Dependence on respirator</b>
<b>QB42</b>	<b>Dependence on renal dialysis</b>
	<b>Inclusions:</b> renal dialysis status
	<b>Exclusions:</b> dialysis preparation, treatment or session (QB94)
<b>QB43</b>	<b>Dependence on artificial heart</b>
<b>QB44</b>	<b>Dependence on wheelchair</b>

**QB4Y**      **Dependence on other specified machine or device**

**QB4Z**      **Dependence on unspecified machine or device**

Presence of device, implants or grafts (QB50-QB5Z)

**QB50**      **Presence of cardiac or vascular implants or grafts**

**QB50.0**      **Presence of electronic cardiac devices**

*Exclusions:*      Adjustment or management of cardiac devices (QB30.2)

**QB50.00**      Presence of cardiac pacemaker

**QB50.01**      Presence of cardiac resynchronization therapy defibrillator

**QB50.02**      Presence of cardiac resynchronization therapy pacemaker

**QB50.03**      Presence of cardioverter-defibrillator

**QB50.0Y**      Other specified presence of electronic cardiac devices

**QB50.0Z**      Presence of electronic cardiac devices, unspecified

**QB50.1**      **Presence of aortocoronary bypass graft**

**QB50.2**      **Presence of prosthetic heart valve**

**QB50.3**      **Presence of xenogenic heart valve**

**QB50.4**      **Presence of coronary angioplasty implant or graft**

**QB50.Y**      **Presence of other specified cardiac or vascular implants or grafts**

**QB50.Z**      **Presence of unspecified cardiac or vascular implants or grafts**

**QB51**      **Presence of devices other than cardiac or vascular implants**

*Exclusions:*      Fitting, adjustment or management of devices (QB30-QB3Z)

**QB51.0**      **Presence of a neurostimulator**

**QB51.1**      **Presence of urogenital implants**

**QB51.2**      **Presence of intraocular lens**

**QB51.3**      **Presence of otological or audiological implants**

**QB51.4**      **Presence of artificial larynx**

**QB51.5**      **Presence of endocrine implants**

*Inclusions:*      presence of insulin pump

**QB51.6**      **Presence of tooth-root or mandibular implants**

**QB51.7**      **Presence of orthopaedic joint implants**

**QB51.8**      **Presence of artificial eye**

<b>QB51.9</b>	<b>Presence of artificial limb</b>
<b>QB51.A</b>	<b>Presence of dental prosthetic device</b>
<b>QB51.B</b>	<b>Presence of external hearing-aid</b>
<b>QB51.C</b>	<b>Presence of contraceptive device</b>
	<b><i>Exclusions:</i></b> Contact with health services for insertion of contraceptive device (QA21.2)
	Surveillance of contraceptive device (QA21.6)
<b>QB51.D</b>	<b>Presence of cerebrospinal fluid drainage device</b>
<b>QB51.Y</b>	<b>Presence of other specified devices other than cardiac or vascular implants</b>
<b>QB5Z</b>	<b>Presence of unspecified device</b>

Surgical or postsurgical states (QB60-QB6Z)

***Exclusions:*** Convalescence (QB70-QB7Z)

***Coded Elsewhere:*** After-cataract (9B10.22)

Presence of intraocular lens (QB51.2)

Presence of cataract surgery (9B1Z)

<b>QB60</b>	<b>Presence of arthrodesis</b>
-------------	--------------------------------

<b>QB61</b>	<b>Presence of artificial opening</b>
-------------	---------------------------------------

***Exclusions:*** Malfunction or complication of external stoma of urinary tract (GC74)

Attention to artificial openings (QB62)

Tracheostomy malfunction (CB60)

Malfunction or complication of external stoma of digestive organs (DE12)

<b>QB61.0</b>	<b>Presence of tracheostomy</b>
---------------	---------------------------------

<b>QB61.1</b>	<b>Presence of thoracostomy</b>
---------------	---------------------------------

<b>QB61.2</b>	<b>Presence of gastrostomy</b>
---------------	--------------------------------

<b>QB61.3</b>	<b>Presence of enterostomy</b>
---------------	--------------------------------

<b>QB61.30</b>	Presence of ileostomy
----------------	-----------------------

<b>QB61.3Y</b>	Other specified presence of enterostomy
----------------	---

<b>QB61.3Z</b>	Presence of enterostomy, unspecified
----------------	--------------------------------------

<b>QB61.4</b>	<b>Presence of colostomy</b>
---------------	------------------------------

<b>QB61.5</b>	<b>Presence of cystostomy</b>
---------------	-------------------------------

<b>QB61.6</b>	<b>Presence of nephrostomy</b>
---------------	--------------------------------

<b>QB61.7</b>	<b>Presence of ureterostomy</b>
<b>QB61.8</b>	<b>Presence of urethrostomy</b>
<b>QB61.Y</b>	<b>Presence of other artificial opening</b>
<b>QB61.Z</b>	<b>Presence of artificial opening, unspecified</b>
<b>QB62</b>	<b>Attention to artificial openings</b>
	<p><b>Inclusions:</b> fitting and adjustment of prosthetic and other devices (QB30-QB3Z)</p> <p>complications of external stoma (CB60)</p> <p>artificial opening status only, without need for care (QB61)</p> <p>Malfunction or complication of external stoma of digestive organs (DE12)</p> <p>Malfunction or complication of external stoma of urinary tract (GC74)</p>
<b>QB62.0</b>	<b>Attention to tracheostomy</b>
<b>QB62.1</b>	<b>Attention to gastrostomy</b>
<b>QB62.2</b>	<b>Attention to ileostomy</b>
<b>QB62.3</b>	<b>Attention to colostomy</b>
<b>QB62.4</b>	<b>Attention to cystostomy</b>
<b>QB62.5</b>	<b>Attention to artificial vagina</b>
<b>QB62.6</b>	<b>Attention to nephrostomy</b>
<b>QB62.7</b>	<b>Attention to ureterostomy</b>
<b>QB62.8</b>	<b>Attention to urethrostomy</b>
<b>QB62.Y</b>	<b>Attention to other artificial openings</b>
<b>QB62.Z</b>	<b>Attention to artificial openings, unspecified</b>
<b>QB63</b>	<b>Presence of transplanted organ or tissue</b>
	<p><b>Inclusions:</b> organ or tissue replaced by heterogenous or homogenous transplant</p> <p><b>Exclusions:</b> Failure or rejection of transplanted organs or tissues (NE84)</p> <p>Presence of cardiac or vascular implants or grafts (QB50)</p> <p>Presence of xenogenic heart valve (QB50.3)</p>
<b>QB63.0</b>	<b>Presence of transplanted kidney</b>
	<p><b>Inclusions:</b> kidney transplant status</p>
<b>QB63.1</b>	<b>Presence of transplanted heart</b>
	<p><b>Exclusions:</b> Presence of heart-valve replacement other than prosthetic or xenogenic (QB50)</p>

<b>QB63.2</b>	<b>Presence of transplanted lung</b>
<b>QB63.3</b>	<b>Presence of transplanted liver</b>
<b>QB63.4</b>	<b>Presence of transplanted skin</b>
<b>QB63.5</b>	<b>Presence of transplanted bone</b>
<b>QB63.6</b>	<b>Presence of transplanted bone marrow</b>
<b>QB63.7</b>	<b>Presence of transfused blood</b>
<b>QB63.8</b>	<b>Presence of transplanted stem cell</b>
<b>QB63.9</b>	<b>Presence of transplanted cornea</b>
<b>QB63.Y</b>	<b>Presence of other transplanted organ or tissue</b>
<b>QB63.Z</b>	<b>Presence of transplanted organ or tissue, unspecified</b>
<b>QB6Y</b>	<b>Other specified surgical or postsurgical states</b>
<b>QB6Z</b>	<b>Surgical or postsurgical states, unspecified</b>

**Convalescence (QB70-QB7Z)**

Convalescence is the period in which the body recovers from a serious illness, injury or surgery.

<b>QB70</b>	<b>Convalescence following chemotherapy</b>
<b>QB71</b>	<b>Convalescence following psychotherapy</b>
<b>QB72</b>	<b>Convalescence following treatment of fracture</b>
<b>QB73</b>	<b>Convalescence following combined treatment</b> Convalescence following any combination of rehabilitation treatments including cardiac rehabilitation, alcohol rehabilitation, drug rehabilitation, psychotherapy, and physical therapy
<b>QB7Y</b>	<b>Other specified convalescence</b>
<b>QB7Z</b>	<b>Convalescence, unspecified</b>

**Contact with health services for specific surgical interventions (QB80-QB8Z)**

**Coding Note:** Codes in this category are intended for use to indicate a reason for care when no specific diagnosis has been documented. They may be used for patients who have already been treated for a disease or injury, but who are receiving follow-up or prophylactic care, convalescent care, or care to consolidate the treatment, to deal with residual states, to ensure that the condition has not recurred, or to prevent recurrence.

**Exclusions:** follow-up examination for medical surveillance after treatment (QA00-QA0Z)

<b>QB80</b>	<b>Contact with health services for prophylactic surgery</b>
-------------	--

<b>QB80.0</b>	<b>Contact with health services for prophylactic surgery for risk-factors related to malignant neoplasms</b>
<b>QB80.Y</b>	<b>Other specified contact with health services for prophylactic surgery</b>
<b>QB80.Z</b>	<b>Contact with health services for prophylactic surgery, unspecified</b>
<b>QB81</b>	<b>Contact with health services for plastic surgery for unacceptable cosmetic appearance other than hair transplant</b>
	<i><b>Exclusions:</b></i> plastic and reconstructive surgery following healed injury or operation (QB83)
<b>QB82</b>	<b>Contact with health services for routine or ritual circumcision</b>
<b>QB83</b>	<b>Follow-up care involving plastic surgery</b>
	<i><b>Inclusions:</b></i> plastic and reconstructive surgery following healed injury or operation repair of scarred tissue
<b>QB84</b>	<b>Follow-up care involving removal of fracture plate or other internal fixation device</b>
	<i><b>Exclusions:</b></i> removal of external fixation device (QB80-QB8Z)
<b>QB85</b>	<b>Attention to surgical dressings, drains or sutures</b>
<b>QB86</b>	<b>Contact with health services for hair transplant</b>
<b>QB8Y</b>	<b>Contact with health services for other specified surgical interventions</b>
<b>Coding Note:</b>	Codes in this category are intended for use to indicate a reason for care when no specific diagnosis has been documented. They may be used for patients who have already been treated for a disease or injury, but who are receiving follow-up or prophylactic care, convalescent care, or care to consolidate the treatment, to deal with residual states, to ensure that the condition has not recurred, or to prevent recurrence.
<b>QB8Z</b>	<b>Contact with health services for specific surgical interventions, unspecified</b>
<b>Coding Note:</b>	Codes in this category are intended for use to indicate a reason for care when no specific diagnosis has been documented. They may be used for patients who have already been treated for a disease or injury, but who are receiving follow-up or prophylactic care, convalescent care, or care to consolidate the treatment, to deal with residual states, to ensure that the condition has not recurred, or to prevent recurrence.

Contact with health services for nonsurgical interventions not involving devices (QB90-QB9Z)

<b>QB90</b>	<b>Contact with health services for ear piercing</b>
<b>QB91</b>	<b>Contact with health services for piercing of body site other than ear</b>

**QB92****Contact with health services for issue of repeat prescription**

- Exclusions:** Issue of medical certificate (QA01.7)  
repeat prescription for contraceptive (QA21.5)

**QB93****Contact with health services for orthodontic care****QB94****Care involving dialysis**

Care involving dialysis includes the preparation and maintenance of the patient and carer(s) on dialysis whether extracorporeal or peritoneal dialysis. This includes, but is not confined to: education, counselling, assessment and management of comorbidities, prevention and management of infections (particularly blood borne) and psychosocial assessment and support.

- Inclusions:** dialysis preparation and treatment

- Exclusions:** renal dialysis status (QB42)

**QB94.0****Preparatory care for dialysis**

Preparatory care for dialysis may include the assessment, education and counselling of the patient and carer(s) to facilitate psychosocial adjustment, choice of dialysis modality (including site – home, satellite, hospital) and timing of commencement, identification and management of social and physical barriers to dialysis or specific modalities. This may include preparation of the patient for dialysis access modalities including creation of fistula and/or insertion of dialysis catheter.

**QB94.1****Care involving extracorporeal dialysis****QB94.2****Care involving peritoneal dialysis****QB94.Y****Care involving other specified dialysis****QB94.Z****Care involving dialysis, unspecified****QB95****Care involving use of rehabilitation procedures**

- Exclusions:** Contact with health services for counselling (QA10-QA1Z)

**QB95.0****Cardiac rehabilitation**

Cardiac rehabilitation is a medically supervised program that helps improve the health and well-being of people who have heart problems.

Cardiac rehabilitation aims to reverse limitations experienced by patients who have suffered the adverse pathophysiologic and psychological consequences of cardiac events.

**QB95.1****Physical rehabilitation**

- Exclusions:** Cardiac rehabilitation (QB95.0)

**QB95.2****Alcohol rehabilitation**

Alcohol rehabilitation is defined as the process that begins when alcohol users come into contact with a health provider or service, and continues through a succession of specific interventions until the highest attainable level of health and well-being is reached.

<b>QB95.3</b>	<b>Drug rehabilitation</b> Drug rehabilitation is defined as the process that begins when drug users come into contact with a health provider or service, and continues through a succession of specific interventions until the highest attainable level of health and well-being is reached.
	<b><i>Exclusions:</i></b> Tobacco rehabilitation (QB95.8)
<b>QB95.4</b>	<b>Psychotherapy</b>
<b>QB95.5</b>	<b>Speech therapy</b>
<b>QB95.6</b>	<b>Orthoptic training</b>
<b>QB95.7</b>	<b>Occupational therapy or vocational rehabilitation</b>
<b>QB95.8</b>	<b>Tobacco rehabilitation</b>
<b>QB95.Y</b>	<b>Care involving use of other specified rehabilitation procedures</b>
<b>QB95.Z</b>	<b>Care involving use of rehabilitation procedures, unspecified</b>
<b>QB96</b>	<b>Radiotherapy session</b>
<b>QB97</b>	<b>Chemotherapy session for neoplasm</b>
<b>QB98</b>	<b>Blood transfusion without reported diagnosis</b>
<b>QB99</b>	<b>Apheresis</b>
<b>QB9A</b>	<b>Preparatory care for subsequent treatment</b> <b><i>Exclusions:</i></b> Preparatory care for dialysis (QB94.0)
<b>QB9B</b>	<b>Palliative care</b> Palliative care is an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment, and treatment of pain and other problems – physical, psychosocial and spiritual.
<b>QB9C</b>	<b>Allergen immunotherapy</b> Allergen immunotherapy (AIT) is the stimulation of the immune system with the administration of gradually increasing doses of the substance/allergen to which the patient is allergic. AIT is indicated in the treatment of many allergic conditions, such as allergic rhinitis, allergic asthma, allergic conjunctivitis, IgE-mediated food allergies among others.
<b>QB9Y</b>	<b>Other specified contact with health services for nonsurgical interventions not involving devices</b>
<b>QB9Z</b>	<b>Contact with health services for nonsurgical interventions not involving devices, unspecified</b>

Contact with health services related to immunizations or certain other prophylactic measures  
(QC00-QC0Z)

**QC00**

**Need for immunization against single bacterial diseases**

**Exclusions:** Need for immunization against combinations of infectious diseases (QC03)

Immunization not carried out (QC04)

**QC00.0**

**Need for immunization against cholera alone**

**QC00.1**

**Need for immunization against typhoid-paratyphoid alone**

**QC00.2**

**Need for immunization against tuberculosis**

**QC00.3**

**Need for immunization against plague**

**QC00.4**

**Need for immunization against tularaemia**

**QC00.5**

**Need for immunization against tetanus alone**

**QC00.6**

**Need for immunization against diphtheria alone**

**QC00.7**

**Need for immunization against pertussis alone**

**QC00.Y**

**Other specified need for immunization against single bacterial diseases**

**QC00.Z**

**Need for immunization against single bacterial diseases, unspecified**

**QC01**

**Need for immunization against certain single viral diseases**

**Exclusions:** Need for immunization against combinations of infectious diseases (QC03)

Immunization not carried out (QC04)

**QC01.0**

**Need for immunization against poliomyelitis**

**QC01.1**

**Need for immunization against arthropod-borne viral encephalitis**

**QC01.2**

**Need for immunization against rabies**

**QC01.3**

**Need for immunization against yellow fever**

**QC01.4**

**Need for immunization against measles alone**

**QC01.5**

**Need for immunization against rubella alone**

**QC01.6**

**Need for immunization against viral hepatitis**

**QC01.7**

**Need for immunization against mumps alone**

**QC01.8**

**Need for immunization against influenza**

**QC01.9**

**Need for immunization against COVID-19**

**Exclusions:** Immunization not carried out (QC04)

**QC01.Y**

**Other specified need for immunization against certain single viral diseases**

**QC01.Z**

**Need for immunization against certain single viral diseases, unspecified**

<b>QC02</b>	<b>Need for immunization against certain specified single infectious diseases</b>
	<p><b><i>Exclusions:</i></b>      Need for immunization against combinations of infectious diseases (QC03)</p> <p>                            Immunization not carried out (QC04)</p>
<b>QC02.0</b>	<b>Need for immunization against leishmaniasis</b>
<b>QC02.Y</b>	<b>Other specified need for immunization against certain specified single infectious diseases</b>
<b>QC02.Z</b>	<b>Need for immunization against certain specified single infectious diseases, unspecified</b>
<b>QC03</b>	<b>Need for immunization against combinations of infectious diseases</b>
	<p><b><i>Exclusions:</i></b>      Immunization not carried out (QC04)</p>
<b>QC03.0</b>	<b>Need for immunization against cholera with typhoid-paratyphoid</b>
<b>QC03.1</b>	<b>Need for immunization against diphtheria-tetanus-pertussis, combined</b>
<b>QC03.2</b>	<b>Need for immunization against diphtheria-tetanus-pertussis with typhoid-paratyphoid</b>
<b>QC03.3</b>	<b>Need for immunization against diphtheria-tetanus-pertussis with poliomyelitis</b>
<b>QC03.4</b>	<b>Need for immunization against measles-mumps-rubella</b>
<b>QC03.Y</b>	<b>Other specified need for immunization against combinations of infectious diseases</b>
<b>QC03.Z</b>	<b>Need for immunization against combinations of infectious diseases, unspecified</b>
<b>QC04</b>	<b>Immunization not carried out</b>
<b>QC04.0</b>	<b>Immunization not carried out due to patient having had the disease</b>
<b>QC04.1</b>	<b>Immunization not carried out because of acute illness</b>
<b>QC04.2</b>	<b>Immunization not carried out because of chronic illness or condition of patient</b>
<b>QC04.3</b>	<b>Immunization not carried out because of immune-compromised state of patient</b>
<b>QC04.4</b>	<b>Immunization not carried out because of patient allergy to vaccine or component</b>
<b>QC04.5</b>	<b>Immunization not carried out because of patient refusal</b>
<b>QC04.6</b>	<b>Immunization not carried out because of caregiver refusal</b>
<b>QC04.7</b>	<b>Immunization not carried out due to lack of availability</b>
<b>QC04.Y</b>	<b>Immunization not carried out for other reasons</b>
<b>QC04.Z</b>	<b>Immunization not carried out for unspecified reason</b>

<b>QC05</b>	<b>Need for certain specified other prophylactic measures</b>
	<b>Exclusions:</b> Contact with health services for prophylactic surgery (QB80) Allergen immunotherapy (QB9C)
<b>QC05.0</b>	<b>Isolation</b>
	Isolation is the 'separation, for the period of communicability, of infected persons from others in such places and under such conditions as to prevent or limit the direct or indirect transmission of the infectious agent from those infected to those who are susceptible to infection or who may spread agent to others'. Isolation measures can be undertaken in hospitals or homes, as well as in alternative facilities.
<b>QC05.1</b>	<b>Prophylactic immunotherapy</b>
<b>QC05.Y</b>	<b>Other specified prophylactic measures</b>
<b>QC05.Z</b>	<b>Prophylactic measures, unspecified</b>
<b>QC06</b>	<b>Underimmunization status</b>
<b>QC0Y</b>	<b>Other specified contact with health services related to immunizations or certain other prophylactic measures</b>
<b>QC0Z</b>	<b>Contact with health services related to immunizations or certain other prophylactic measures, unspecified</b>

Interventions not carried out (QC10-QC1Z)

**Exclusions:** Immunization not carried out (QC04)  
Non provision of necessary procedure associated with injury or harm (PL14.1)  
Non-provision of necessary procedure without injury or harm (QA81)

<b>QC10</b>	<b>Procedure not carried out because of contraindication</b>
<b>QC11</b>	<b>Procedure not carried out because of patient's decision for reasons of belief or group pressure</b>
<b>QC12</b>	<b>Procedure not carried out because of patient's decision for reasons other than belief or group pressure</b>
<b>QC1Y</b>	<b>Intervention not carried out for other reasons</b>
<b>QC1Z</b>	<b>Intervention not carried out, unspecified reason</b>

Contact with health services associated with the health of others (QC20-QC2Z)

<b>QC20</b>	<b>Person consulting on behalf of another person</b>
	<b>Exclusions:</b> anxiety (normal) about sick person in family (QE50)
<b>QC20.0</b>	<b>Partner illness problem</b>
<b>QC20.1</b>	<b>Illness problem with child</b>

<b>QC20.Y</b>	<b>Other specified person consulting on behalf of another person</b>
<b>QC20.Z</b>	<b>Person consulting on behalf of another person, unspecified</b>
<b>QC21</b>	<b>Healthy person accompanying sick person</b>
<b>QC22</b>	<b>Health supervision or care of abandoned infant</b>
<b>QC2Y</b>	<b>Other specified contact with health services associated with the health of others</b>
<b>QC2Z</b>	<b>Contact with health services associated with the health of others, unspecified</b>
<b>QC30</b>	<p><b>Malingering</b></p> <p>Malingering is the feigning, intentional production or significant exaggeration of physical or psychological symptoms, or intentional misattribution of genuine symptoms to an unrelated event or series of events when this is specifically motivated by external incentives or rewards such as escaping duty or work; mitigating punishment; obtaining medications or drugs; or receiving unmerited recompense such as disability compensation or personal injury damages award</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>peregrinating patient (6D50)</li> <li>Factitious disorders (6D50-6D5Z)</li> <li>Bodily distress disorder (6C20)</li> <li>Factitious disorder imposed on another (6D51)</li> <li>Factitious disorder imposed on self (6D50)</li> <li>Hypochondriasis (6B23)</li> </ul>

Personal or family history or late effect of prior health problems (QC40-QC8Z)

<b>Exclusions:</b>	follow-up examination (QA00-QA0Z)
	Maternal care for known or suspected fetal abnormality or damage (JA85)
	Convalescence (QB70-QB7Z)
	Special screening examination for infectious diseases (QA08)
	Mental, behavioural or neurodevelopmental disorders (Chapter 06)
	Special screening examination for neoplasms (QA09)
	Special screening examination for other diseases or disorders (QA0A)
	Occupational exposure to risk-factors (QD84)

Personal history of health problems (QC40-QC4Z)

<b>Exclusions:</b>	Problems associated with health behaviours (QE10-QE2Z)
<b>QC40</b>	<b>Personal history of malignant neoplasm</b>
<b>Exclusions:</b>	Convalescence (QB70-QB7Z)

<b>QC40.0</b>	<b>Personal history of malignant neoplasm of digestive organs</b>
<b>QC40.1</b>	<b>Personal history of malignant neoplasm of trachea, bronchus or lung</b>
<b>QC40.2</b>	<b>Personal history of malignant neoplasm of respiratory or intrathoracic organs other than the digestive organs, trachea, bronchus or lung</b>
<b>QC40.3</b>	<b>Personal history of malignant neoplasm of breast</b>
<b>QC40.4</b>	<b>Personal history of malignant neoplasm of genital organs</b>
<b>QC40.5</b>	<b>Personal history of malignant neoplasm of urinary tract</b>
<b>QC40.6</b>	<b>Personal history of leukaemia</b>
<b>QC40.7</b>	<b>Personal history of other malignant neoplasms of lymphoid, haematopoietic or related tissues</b>
<b>QC40.Y</b>	<b>Personal history of malignant neoplasm of other specified site</b>
<b>QC40.Z</b>	<b>Personal history of malignant neoplasm of unspecified site</b>
<b>QC41</b>	<b>Personal history of non-malignant neoplasms</b>
	<i>Exclusions:</i> Personal history of malignant neoplasm (QC40)
<b>QC42</b>	<b>Personal history of infectious or parasitic diseases</b>
<b>QC42.0</b>	<b>Personal history of COVID-19</b>
<b>QC42.Y</b>	<b>Other specified personal history of infectious or parasitic diseases</b>
<b>QC42.Z</b>	<b>Personal history of infectious or parasitic diseases, unspecified</b>
<b>QC43</b>	<b>Personal history of diseases of the blood or blood-forming organs</b>
<b>QC44</b>	<b>Personal history of diseases of the immune system</b>
<b>QC44.0</b>	<b>Personal history of anaphylaxis</b>
<b>QC44.1</b>	<b>Personal history of food-induced allergy or hypersensitivity</b>
<b>QC44.2</b>	<b>Personal history of allergy to drugs, medicaments or biological substances</b>
<b>QC44.3</b>	<b>Personal history of allergy, other than to drugs or biological substances</b>
	<i>Exclusions:</i> Personal history of allergy to drugs, medicaments or biological substances (QC44.2)
<b>QC44.Y</b>	<b>Other specified personal history of diseases of the immune system</b>
<b>QC44.Z</b>	<b>Personal history of diseases of the immune system, unspecified</b>
<b>QC45</b>	<b>Personal history of endocrine, nutritional or metabolic diseases</b>
<b>QC46</b>	<b>Personal history of mental or behavioural disorder</b>

<b>QC47</b>	<b>Personal history of diseases of the nervous system or sense organs</b>
	<b>Exclusions:</b> Personal history of allergy or hypersensitivity involving the eye and adnexa (QC44)
<b>QC48</b>	<b>Personal history of medical treatment</b>
<b>QC48.0</b>	<b>Personal history of long-term use of anticoagulants</b>
<b>QC48.Y</b>	<b>Other specified personal history of medical treatment</b>
<b>QC48.Z</b>	<b>Personal history of medical treatment, unspecified</b>
<b>QC49</b>	<b>Personal history of noncompliance with medical treatment or regimen</b>
<b>QC4A</b>	<b>Personal history of poor personal hygiene</b>
<b>QC4B</b>	<b>Personal history of self-harm</b>
<b>QC4Y</b>	<b>Personal history of other specified health problems</b>
<b>QC4Z</b>	<b>Personal history of health problems, unspecified</b>
<b>QC50</b>	<b>Late effect of prior health problem, not elsewhere classified</b>
	Code used to indicate that a prior health problem is now associated with a late effect causing current symptoms or conditions. This concept excludes prior health problems that are NOT causing a current symptom or condition.
<b>Coding Note:</b>	Code also the causing condition
	<b>Exclusions:</b> Personal history of health problems (QC40-QC4Z)
	<b>Coded Elsewhere:</b> Sequelae of complication of pregnancy, childbirth or the puerperium (JB65)
	Sequelae of tuberculosis (1G80)
	Sequelae of poliomyelitis (1G83)
	Sequelae of leprosy (1G82)
	Sequelae of diphtheria (1G85)
	Sequelae of trachoma (1G81)
	Sequelae of viral encephalitis (1G84)

### Family history of health problems (QC60-QC6Z)

<b>QC60</b>	<b>Family history of infectious diseases</b>
<b>QC61</b>	<b>Family history of malignant neoplasm</b>
<b>QC61.0</b>	<b>Family history of malignant neoplasm of digestive organs</b>
<b>QC61.1</b>	<b>Family history of malignant neoplasm of trachea, bronchus or lung</b>
<b>QC61.2</b>	<b>Family history of malignant neoplasm of respiratory or intrathoracic organs other than digestive organs, trachea, bronchus or lung</b>
<b>QC61.3</b>	<b>Family history of malignant neoplasm of breast</b>

QC61.4	<b>Family history of malignant neoplasm of genital organs</b>
QC61.5	<b>Family history of malignant neoplasm of urinary tract</b>
QC61.6	<b>Family history of leukaemia</b>
QC61.7	<b>Family history of malignant neoplasms of lymphoid, haematopoietic or related tissues</b>
QC61.Y	<b>Other specified family history of malignant neoplasm</b>
QC61.Z	<b>Family history of malignant neoplasm, unspecified</b>
<b>QC62</b>	<b>Family history of diseases of the blood or blood-forming organs</b>
<b>QC63</b>	<b>Family history of disorders involving the immune mechanism</b>
<b>QC64</b>	<b>Family history of endocrine, nutritional or metabolic diseases</b>
QC64.0	<b>Family history of diabetes mellitus</b>
QC64.Y	<b>Other specified family history of endocrine, nutritional or metabolic diseases</b>
QC64.Z	<b>Family history of endocrine, nutritional or metabolic diseases, unspecified</b>
<b>QC65</b>	<b>Family history of mental or behavioural disorder</b>
<b>QC66</b>	<b>Family history of eye or ear disorders</b>
<b>QC67</b>	<b>Family history of ischaemic heart disease or other diseases of the circulatory system</b>
<b>QC68</b>	<b>Family history of consanguinity</b>
<b>QC69</b>	<b>Family history of stroke</b>
<b>QC6Y</b>	<b>Family history of other specified health problems</b>
<b>QC6Z</b>	<b>Family history of health problems, unspecified</b>
<b>QC8Y</b>	<b>Other specified personal or family history or late effect of prior health problems</b>
<b>QC8Z</b>	<b>Personal or family history or late effect of prior health problems, unspecified</b>

Risk factors associated with infectious or certain other conditions (QC90-QD2Z)

<b>QC90</b>	<b>Contact with or exposure to communicable diseases</b>
QC90.0	<b>Contact with or exposure to intestinal infectious diseases</b>
QC90.00	Exposure to cholera
QC90.0Y	Other specified contact with or exposure to intestinal infectious diseases
QC90.0Z	Contact with or exposure to intestinal infectious diseases, unspecified

## Carrier of infectious disease agent (QD00-QD0Z)

**Coded Elsewhere:** Carrier of viral hepatitis (obsolete concept) (1E51.Y)

QD00	<b>Carrier of salmonella typhi</b>
QD01	<b>Carrier of intestinal infectious agents</b>
QD01.0	<b>Asymptomatic enteric carriage of Entamoeba</b>
QD01.Y	<b>Other specified carrier of intestinal infectious agents</b>
QD01.Z	<b>Carrier of intestinal infectious agents, unspecified</b>
QD02	<b>Carrier of corynebacterium diphtheriae</b>
QD03	<b>Carrier of infectious agents with a predominantly sexual mode of transmission</b>
QD04	<b>Asymptomatic colonization of the skin by virulent or therapy resistant bacteria</b>  The presence on the skin of bacteria which may pose an elevated risk of disease either to the carrier or to others as a result of therapy resistance or increased virulence.  <b><i>Exclusions:</i></b> Certain skin disorders attributable to bacterial infection (EA40-EA5Z)
QD0Y	<b>Carrier of other specified infectious disease agent</b>
QD0Z	<b>Carrier of infectious disease agent, unspecified</b>
QD2Y	<b>Other specified health status associated with infectious or certain specified conditions</b>

**QD2Z**      **Unspecified health status associated with infectious or certain specified conditions**

Concern about body appearance (QD30-QD3Z)

*Exclusions:*      Body dysmorphic disorder (6B21)

**QD30**      **Concern about breast appearance**

*Exclusions:*      Body dysmorphic disorder (6B21)

**QD31**      **Contact with health services for concerns about body image related to pregnancy**

**QD3Y**      **Other specified concern about body appearance**

**QD3Z**      **Concern about body appearance, unspecified**

Factors influencing health status (QD50-QF2Z)

Problems associated with finances (QD50-QD5Z)

**QD50**      **Poverty**

**QD51**      **Low income**

**QD5Y**      **Other specified problems associated with finances**

**QD5Z**      **Problems associated with finances, unspecified**

Problems associated with drinking water or nutrition (QD60-QD6Z)

**QD60**      **Problems associated with inadequate drinking-water**

*Exclusions:*      Effects of thirst (NF07.1)

**QD61**      **Inadequate food**

*Exclusions:*      Effects of hunger (NF07.0)

Problems with inappropriate diet or eating habits (QE23)

malnutrition (5B50-5B7Z)

**QD6Z**      **Problems associated with drinking water or nutrition, unspecified**

Problems associated with the environment (QD70-QD7Z)

**QD70**      **Problems associated with the natural environment or human-made changes to the environment**

*Exclusions:*      Occupational exposure to risk-factors (QD84)

**Coded Elsewhere:** Problems associated with inadequate drinking-water (QD60)

<b>QD70.0</b>	<b>Problems associated with exposure to noise</b>
<b>QD70.1</b>	<b>Problems associated with exposure to air pollution</b>
	<b><i>Exclusions:</i></b> Problems associated with exposure to tobacco smoke (QD70.5)
<b>QD70.2</b>	<b>Problems associated with exposure to water pollution</b>
	<b><i>Exclusions:</i></b> Problems associated with inadequate drinking-water (QD60)
<b>QD70.3</b>	<b>Problems associated with exposure to soil pollution</b>
<b>QD70.4</b>	<b>Problems associated with exposure to radiation</b>
<b>QD70.5</b>	<b>Problems associated with exposure to tobacco smoke</b>
	<b><i>Exclusions:</i></b> Tobacco use (QE13)
	Personal history of psychoactive substance abuse (QC46)
	Disorders due to use of nicotine (6C4A)
	<b><i>Coded Elsewhere:</i></b> Exposure to tobacco smoke in the perinatal period (KD37)
<b>QD70.6</b>	<b>Problems associated with inadequate access to electricity</b>
	Inadequate power that may restrict healthy living.
<b>QD70.Z</b>	<b>Problems associated with the natural environment or human-made changes to the environment, unspecified</b>
<b>QD71</b>	<b>Problems associated with housing</b>
	<b><i>Exclusions:</i></b> Problems associated with inadequate drinking-water (QD60)
<b>QD71.0</b>	<b>Homelessness</b>
<b>QD71.1</b>	<b>Inadequate housing</b>
	<b><i>Exclusions:</i></b> Problems associated with the natural environment or human-made changes to the environment (QD70)
<b>QD71.2</b>	<b>Problems related to living in residential institution</b>
	<b><i>Exclusions:</i></b> Institutional upbringing (QE94)
<b>QD71.Z</b>	<b>Problems associated with housing, unspecified</b>
<b>QD7Y</b>	<b>Other specified problems associated with the environment</b>
<b>QD7Z</b>	<b>Problems associated with the environment, unspecified</b>

Problems associated with employment or unemployment (QD80-QD8Z)

***Exclusions:*** problems related to housing and economic circumstances (QD71)

***Coded Elsewhere:*** Problem associated with relationships with people at work (QE50.2)

**QD80** **Problem associated with unemployment**

**QD81** **Problem associated with change of job**

<b>QD82</b>	<b>Problem associated with threat of job loss</b>
<b>QD83</b>	<b>Problem with employment conditions</b>
<b>QD83.0</b>	<b>Problem associated with uncongenial work</b>
<b>QD83.1</b>	<b>Problem associated with stressful work schedule</b>
<b>QD83.Y</b>	<b>Other specified problem with employment conditions</b>
<b>QD83.Z</b>	<b>Problem with employment conditions, unspecified</b>
<b>QD84</b>	<b>Occupational exposure to risk-factors</b>
<b>QD84.0</b>	<b>Occupational exposure to dust</b> Occupational exposure to dust is exposure to dust during work, at the work location, or from the work location. The primary route of exposure is inhalation.  Dusts are technically defined as dry particle aerosols produced by mechanical processes such as breaking, grinding, and pulverizing. Dusts may be of biological or nonbiological origin.
<b>QD84.1</b>	<b>Occupational exposure to toxic agents in agriculture</b>
<b>QD84.2</b>	<b>Occupational exposure to toxic agents in industries other than agriculture</b>
<b>QD84.3</b>	<b>Occupational exposure to vibration</b>
<b>QD84.4</b>	<b>Occupational exposure to ergonomic risk</b>
<b>QD84.Y</b>	<b>Other specified occupational exposure to risk-factors</b>
<b>QD84.Z</b>	<b>Occupational exposure to risk-factors, unspecified</b>
<b>QD85</b>	<b>Burnout</b> Burnout is a syndrome conceptualized as resulting from chronic workplace stress that has not been successfully managed. It is characterised by three dimensions: 1) feelings of energy depletion or exhaustion; 2) increased mental distance from one's job, or feelings of negativism or cynicism related to one's job; and 3) a sense of ineffectiveness and lack of accomplishment. Burn-out refers specifically to phenomena in the occupational context and should not be applied to describe experiences in other areas of life.  <b>Exclusions:</b> Adjustment disorder (6B43) Disorders specifically associated with stress (6B40-6B4Z) Anxiety or fear-related disorders (6B00-6B0Z) Mood disorders (6A60-6A8Z)
<b>QD8Y</b>	<b>Other specified problems associated with employment or unemployment</b>
<b>QD8Z</b>	<b>Problems associated with employment or unemployment, unspecified</b>

Problems associated with education (QD90-QD9Z)

**Exclusions:** factors associated with psychological development (Chapter 06)

**Coded Elsewhere:** Relationships with teachers or classmates (QE50.1)

**QD90** **Problem associated with illiteracy or low-level literacy**

**QD91** **Problem associated with education unavailable or unattainable**

**QD92** **Problem with educational progress**

**Exclusions:** Disorders of intellectual development (6A00)

**QD9Y** **Other specified problems associated with education**

**QD9Z** **Problems associated with education, unspecified**

Problems associated with social or cultural environment (QE00-QE0Z)

**Coded Elsewhere:** Acute stress reaction (QE84)

**QE00** **Acculturation difficulty**

Problems resulting from the inability to adjust to a different culture or environment.

**Exclusions:** Disorders specifically associated with stress (6B40-6B4Z)

**QE01** **Stress, not elsewhere classified**

**Exclusions:** Problems associated with employment or unemployment (QD80-QD8Z)

**QE02** **Social role conflict**

**QE03** **Social exclusion or rejection**

Exclusion and rejection on the basis of personal characteristics such as physical appearance, sexual orientation, gender identity and expression, illness or behaviour.

**Exclusions:** Target of perceived adverse discrimination or persecution (QE04)

**QE04** **Target of perceived adverse discrimination or persecution**

Persecution or discrimination, perceived as reality by an individual or real, on the basis of membership in some group (such as defined by skin colour, religion, ethnic origin, sexual orientation, gender identity and expression, etc.) rather than personal characteristics

**Exclusions:** Social exclusion or rejection (QE03)

**QE0Y** **Other specified problems associated with social or cultural environment**

**QE0Z** **Problems associated with social or cultural environment, unspecified**

## Problems associated with health behaviours (QE10-QE2Z)

**Exclusions:** Difficulty or need for assistance with general life tasks or life management (QF21)

### Hazardous substance use (QE10-QE1Z)

Hazardous substance use is a pattern of psychoactive substance use that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of substance use, from the amount used on a given occasion, from risky behaviours associated with substance use or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of the substance or to longer-term cumulative effects on physical or mental health or functioning. Hazardous substance use has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of substance use often persists in spite of awareness of increased risk of harm to the user or to others.

**Exclusions:** Disorders due to substance use (6C40-6C4Z)

**QE10**

#### **Hazardous alcohol use**

A pattern of alcohol use that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of alcohol use, from the amount used on a given occasion, or from risky behaviours associated with alcohol use or the context of use, or from a combination of these. The risk may be related to short-term effects of alcohol or to longer-term cumulative effects on physical or mental health or functioning. Hazardous alcohol use has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of alcohol use often persists in spite of awareness of increased risk of harm to the user or to others.

**Exclusions:** Disorders due to use of alcohol (6C40)

**QE11**

#### **Hazardous drug use**

A pattern of use of psychoactive substance(s) other than nicotine or alcohol that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of substance use, from the amount used on a given occasion, from risky behaviours associated with substance use or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of the substance or to longer-term cumulative effects on physical or mental health or functioning. Hazardous drug use has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of drug use often persists in spite of awareness of increased risk of harm to the user or to others.

**Exclusions:** Disorders due to substance use (6C40-6C4Z)

- QE11.0 Hazardous use of opioids**  
A pattern of opioid use that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of opioid use, from the amount used on a given occasion, from risky behaviours associated with opioid use or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of opioids or to longer-term cumulative effects on physical or mental health or functioning. Hazardous use of opioids has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of opioid use often persists in spite of awareness of increased risk of harm to the user or to others.
- Exclusions:*** Disorders due to use of opioids (6C43)
- QE11.1 Hazardous use of cannabis**  
A pattern of cannabis use that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of cannabis use, from the amount used on a given occasion, from risky behaviours associated with cannabis use or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of cannabis or to longer-term cumulative effects on physical or mental health or functioning. Hazardous use of cannabis has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of cannabis use often persists in spite of awareness of increased risk of harm to the user or to others.
- Exclusions:*** Disorders due to use of cannabis (6C41)
- QE11.2 Hazardous use of sedatives, hypnotics or anxiolytics**  
A pattern of use of sedatives, hypnotics or anxiolytics that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of use of sedatives, hypnotics or anxiolytics, from the amount used on a given occasion, from risky behaviours associated with use of sedatives, hypnotics or anxiolytics or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of sedatives, hypnotics or anxiolytics or to longer-term cumulative effects on physical or mental health or functioning. Hazardous use of sedatives, hypnotics or anxiolytics has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of use of sedatives, hypnotics or anxiolytics often persists in spite of awareness of increased risk of harm to the user or to others.
- Exclusions:*** Disorders due to use of sedatives, hypnotics or anxiolytics (6C44)

**QE11.3**

**Hazardous use of cocaine**

A pattern of cocaine use that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of cocaine use, from the amount used on a given occasion, from risky behaviours associated with cocaine use or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of cocaine or to longer-term cumulative effects on physical or mental health or functioning. Hazardous use of cocaine has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of cocaine use often persists in spite of awareness of increased risk of harm to the user or to others.

**Exclusions:** Disorders due to use of cocaine (6C45)

**QE11.4**

**Hazardous use of stimulants including amphetamines or methamphetamine**

A pattern of use of stimulants including amphetamines and methamphetamine that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of use of stimulants including amphetamines and methamphetamine, from the amount used on a given occasion, from risky behaviours associated with use of stimulants including amphetamines and methamphetamine or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of stimulants including amphetamines and methamphetamine or to longer-term cumulative effects on physical or mental health or functioning. Hazardous use of stimulants including amphetamines and methamphetamine has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of use of stimulants including amphetamines and methamphetamine often persists in spite of awareness of increased risk of harm to the user or to others.

**Exclusions:** Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone (6C46)

**QE11.5**

**Hazardous use of caffeine**

A pattern of caffeine use that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of caffeine use, from the amount used on a given occasion, from risky behaviours associated with caffeine use or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of caffeine or to longer-term cumulative effects on physical or mental health or functioning. Hazardous use of caffeine has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of caffeine use often persists in spite of awareness of increased risk of harm to the user or to others.

**Exclusions:** Disorders due to use of caffeine (6C48)

**QE11.6**

**Hazardous use of MDMA or related drugs**

A pattern of use of MDMA (3,4-methylenedioxymethamphetamine) or related drugs that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of use of MDMA or related drugs, from the amount used on a given occasion, from risky behaviours associated with use of MDMA or related drugs or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of MDMA or related drugs or to longer-term cumulative effects on physical or mental health or functioning. Hazardous use of MDMA or related drugs has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of use of MDMA or related drugs often persists in spite of awareness of increased risk of harm to the user or to others.

**Exclusions:** Disorders due to use of MDMA or related drugs, including MDA (6C4C)

**QE11.7**

**Hazardous use of dissociative drugs including ketamine or PCP**

A pattern of use of dissociative drugs including ketamine and PCP (phencyclidine) that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of use of dissociative drugs including ketamine and PCP, from the amount used on a given occasion, from risky behaviours associated with use of dissociative drugs including ketamine and PCP or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of dissociative drugs including ketamine and PCP or to longer-term cumulative effects on physical or mental health or functioning. Hazardous use of dissociative drugs including ketamine and PCP has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of use of dissociative drugs including ketamine and PCP often persists in spite of awareness of increased risk of harm to the user or to others.

**Exclusions:** Disorders due to use of dissociative drugs including ketamine and phencyclidine [PCP] (6C4D)

**QE11.8**

**Hazardous use of other specified psychoactive substances**

A pattern of use of other specified psychoactive substances that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of use of the substance, from the amount used on a given occasion, from risky behaviours associated with use of the substance or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of the specified substance or to longer-term cumulative effects on physical or mental health or functioning. Hazardous use of other specified psychoactive substances has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of substance use often persists in spite of awareness of increased risk of harm to the user or to others.

**Exclusions:** Disorders due to use of other specified psychoactive substances, including medications (6C4E)

<b>QE11.9</b>	<b>Hazardous use of unknown or unspecified psychoactive substances</b> A pattern of use of unknown or unspecified psychoactive substances that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. The increased risk may be from the frequency of use of the substance, from the amount used on a given occasion, from risky behaviours associated with use of the substance or the context of use, from a harmful route of administration, or from a combination of these. The risk may be related to short-term effects of the unknown or unspecified substance or to longer-term cumulative effects on physical or mental health or functioning. Hazardous use of unknown or unspecified psychoactive substances has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of substance use often persists in spite of awareness of increased risk of harm to the user or to others.
	<b><i>Exclusions:</i></b> Disorders due to use of unknown or unspecified psychoactive substances (6C4G)
<b>QE11.Y</b>	<b>Other specified hazardous drug use</b>
<b>QE11.Z</b>	<b>Hazardous drug use, unspecified</b>
<b>QE12</b>	<b>Hazardous nicotine use</b> A pattern of nicotine use that appreciably increases the risk of harmful physical or mental health consequences to the user or to others to an extent that warrants attention and advice from health professionals. Most often nicotine is consumed in the form of tobacco, but there are also other forms of nicotine delivery (e.g., nicotine vapour). Hazardous nicotine use has not yet reached the level of having caused harm to physical or mental health of the user or others around the user. The pattern of nicotine use often persists in spite of awareness of increased risk of harm to the user or to others. This category is not intended to include the use of nicotine replacement therapies under medical supervision when these are used as part of attempts to stop or reduce smoking.
	<b><i>Exclusions:</i></b> Tobacco use (QE13) Disorders due to use of nicotine (6C4A)
<b>QE13</b>	<b>Tobacco use</b>
	<b><i>Exclusions:</i></b> Disorders due to use of nicotine (6C4A) Use of Nicotine in non-tobacco forms (QE12)
<b>QE1Y</b>	<b>Other specified hazardous substance use</b>
<b>QE1Z</b>	<b>Hazardous substance use, unspecified</b>
<b>QE20</b>	<b>Lack of physical exercise</b>

**QE21****Hazardous gambling or betting**

Hazardous gambling and betting refers to a pattern of gambling or betting that appreciably increases the risk of harmful physical or mental health consequences to the individual or to others around the individual. The increased risk may be from the frequency of gambling or betting, the amount of time spent on these activities, the context of gambling or betting, the neglect of other activities and priorities, risky behaviours associated with gambling or betting or its context, the adverse consequences of gambling or betting, or from the combination of these factors. The pattern of gambling or betting often persists in spite of awareness of increased risk of harm to the individual or to others. This category may be used when the pattern of gambling or betting warrants attention and advice from health professionals but does not meet the diagnostic requirements for Gambling Disorder.

**Exclusions:**      Gambling disorder (6C50)

**QE22****Hazardous gaming**

Hazardous gaming refers to a pattern of gaming, either online or offline, that appreciably increases the risk of harmful physical or mental health consequences to the individual or to others around the individual. The increased risk may be from the frequency of gaming, the amount of time spent on these activities, the neglect of other activities and priorities, risky behaviours associated with gaming or its context, the adverse consequences of gaming, or from the combination of these factors. The pattern of gaming often persists in spite of awareness of increased risk of harm to the individual or to others. This category may be used when the pattern of gaming behaviour warrants attention and advice from health professionals but does not meet the diagnostic requirements for Gaming Disorder.

**Exclusions:**      Gaming disorder (6C51)

**QE23****Problems with inappropriate diet or eating habits**

**Exclusions:**      malnutrition and other nutritional deficiencies (5B50-5C3Z)  
                        Inadequate food (QD61)  
                        Feeding or eating disorders (6B80-6B8Z)

**QE24****Problems with hygiene behaviours****QE25****Problems with oral health behaviours****QE26****Problem with sun exposure behaviour****QE27****Problem with behaviours related to psychological health or wellbeing****QE28****Problem with health literacy****QE2Y****Problems with other specified health-related behaviours****QE2Z****Problem with health-related behaviours, unspecified**

Problems associated with social insurance or welfare (QE30-QE3Z)

**QE30****Insufficient social insurance support**

QE30.0	<b>Insufficient social insurance support, aged</b>
QE30.1	<b>Insufficient social insurance support, disability</b>
QE30.2	<b>Insufficient social insurance support, unemployment</b>
QE30.3	<b>Insufficient social insurance support, family support</b>
QE30.Z	<b>Insufficient social insurance support, unspecified</b>
<b>QE31</b>	<b>Insufficient social welfare support</b>
QE31.0	<b>Insufficient social welfare support, child protection</b>
QE31.1	<b>Insufficient social welfare support, protection against domestic violence</b>
QE31.2	<b>Insufficient social welfare support, protection against homelessness</b>
QE31.3	<b>Insufficient social welfare support, post prison services</b>
QE31.Z	<b>Insufficient social welfare support, unspecified</b>
<b>QE3Y</b>	<b>Other specified problems associated with social insurance or welfare</b>
<b>QE3Z</b>	<b>Problems associated with social insurance or welfare, unspecified</b>

Problems associated with the justice system (QE40-QE4Z)

<b>QE40</b>	<b>Problem associated with conviction in civil or criminal proceedings without imprisonment</b>
<b>QE41</b>	<b>Problem associated with imprisonment and other incarceration</b>
<b>QE42</b>	<b>Problem associated with release from prison</b>
<b>QE4Y</b>	<b>Other specified problems associated with the justice system</b>
<b>QE4Z</b>	<b>Problems associated with the justice system, unspecified</b>

Problems associated with relationships (QE50-QE5Z)

<b>QE50</b>	<b>Problem associated with interpersonal interactions</b>
QE50.0	<b>Problem associated with relationship with friend</b>
QE50.1	<b>Relationships with teachers or classmates</b>
QE50.10	Dissatisfaction with school environment
QE50.1Y	Other specified relationships with teachers or classmates
QE50.1Z	Relationships with teachers or classmates, unspecified
QE50.2	<b>Problem associated with relationships with people at work</b>
QE50.3	<b>Relationships with neighbours, tenant or landlord</b>

<b>QE50.4</b>	<b>Relationship with parents, in-laws or other family members</b>
	<p><b><i>Exclusions:</i></b> Caregiver-child relationship problem (QE52.0)            Problems associated with upbringing (QE90-QE9Z)            Problem associated with interactions with spouse or partner (QE51)</p>
<b>QE50.5</b>	<b>Discord with counsellors</b>
<b>QE50.6</b>	<b>Inadequate social skills</b>
	<p><b><i>Exclusions:</i></b> Mental, behavioural or neurodevelopmental disorders (Chapter 06)</p>
<b>QE50.7</b>	<b>Personality difficulty</b>
	<p>Personality difficulty refers to pronounced personality characteristics that may affect treatment or health services but do not rise to the level of severity to merit a diagnosis of Personality disorder. Personality difficulty is characterised by long-standing difficulties (e.g., at least 2 years), in the individual's way of experiencing and thinking about the self, others and the world. In contrast to Personality disorders, these difficulties are manifested in cognitive and emotional experience and expression only intermittently (e.g., during times of stress) or at low intensity. The difficulties are associated with some problems in functioning but these are insufficiently severe to cause notable disruption in social, occupational, and interpersonal relationships and may be limited to specific relationships or situations.</p>
	<p><b><i>Exclusions:</i></b> Personality disorder (6D10)</p>
<b>QE50.Y</b>	<b>Other specified problem associated with interpersonal interactions</b>
<b>QE51</b>	<b>Problem associated with interactions with spouse or partner</b>
<b>QE51.0</b>	<b>Relationship distress with spouse or partner</b> Substantial and sustained dissatisfaction with a spouse or intimate partner associated with significant disturbance in functioning.
<b>QE51.1</b>	<b>History of spouse or partner violence</b> Non-accidental acts of physical force, forced or coerced sexual acts, verbal or symbolic acts, or significant caregiving omissions that result in harm to a spouse or intimate partner or that have a reasonable potential for harm.
<b>QE51.Y</b>	<b>Other specified problem associated with interactions with spouse or partner</b>
<b>QE51.Z</b>	<b>Problem associated with interactions with spouse or partner, unspecified</b>
<b>QE52</b>	<b>Problem associated with interpersonal interactions in childhood</b>
<b>QE52.0</b>	<b>Caregiver-child relationship problem</b> Substantial and sustained dissatisfaction within a caregiver-child relationship, including a parental relationship, associated with significant disturbance in functioning.

<b>QE52.1</b>	<b>Loss of love relationship in childhood</b>
	Loss of an emotionally close relationship, such as of a parent, a sibling, a very special friend or a loved pet, by death or permanent departure or rejection.
<b>QE52.Y</b>	<b>Other specified problem associated with interpersonal interactions in childhood</b>
<b>QE52.Z</b>	<b>Problem associated with interpersonal interactions in childhood, unspecified</b>
<b>QE5Y</b>	<b>Other specified problems associated with relationships</b>
<b>QE5Z</b>	<b>Problems associated with relationships, unspecified</b>

Problems associated with absence, loss or death of others (QE60-QE6Z)

<b>QE60</b>	<b>Absence of family member</b>
<b>QE61</b>	<b>Disappearance or death of family member</b>
	<i>Exclusions:</i> Prolonged grief disorder (6B42)
<b>QE61.0</b>	<b>Loss or death of child</b>
	<i>Exclusions:</i> Prolonged grief disorder (6B42)
<b>QE61.Y</b>	<b>Disappearance or death of other family member</b>
<b>QE62</b>	<b>Uncomplicated bereavement</b>
<b>QE6Y</b>	<b>Other specified problems associated with absence, loss or death of others</b>
<b>QE6Z</b>	<b>Problems associated with absence, loss or death of others, unspecified</b>
<b>QE70</b>	<b>Problems related to primary support group, including family circumstances</b>
	<i>Exclusions:</i> Problems associated with upbringing (QE90-QE9Z) Problems associated with harmful or traumatic events (QE80-QE8Z)
<b>QE70.0</b>	<b>Inadequate family support</b>
<b>QE70.1</b>	<b>Disruption of family by separation or divorce</b>
<b>QE70.2</b>	<b>Dependent relative needing care at home</b>
<b>QE70.Z</b>	<b>Problems related to primary support group, including family circumstances, unspecified</b>

Problems associated with harmful or traumatic events (QE80-QE8Z)

**Exclusions:** Disorders specifically associated with stress (6B40-6B4Z)

**Coded Elsewhere:** Personal history of psychological trauma, not elsewhere classified (QC4Y)

Personal history of physical trauma other than self-harm (QC4Y)

**QE80**

**Victim of crime or terrorism**

**QE81**

**Exposure to disaster, war or other hostilities**

**Exclusions:** Target of perceived adverse discrimination or persecution (QE04)

**QE82**

**Personal history of maltreatment**

Personal history of non-accidental acts of physical force, forced or coerced sexual acts, verbal or symbolic acts, or significant caregiving omissions that result in harm or have a reasonable potential for harm. These categories are applied to the victim of the maltreatment, not the perpetrator.

**Exclusions:** History of spouse or partner violence (QE51.1)

**QE82.0**

**Personal history of physical abuse**

Personal history of non-accidental acts of physical force that result, or have reasonable potential to result, in physical harm or that evoke significant fear. This category is applied to the victim of the maltreatment, not the perpetrator.

**Exclusions:** History of spouse or partner violence, physical (QE51.1)

**QE82.1**

**Personal history of sexual abuse**

Personal history of forced or coerced sexual acts, sexual acts with someone who is unable to consent, or sexual acts involving a child that are intended to provide sexual gratification to an adult. This category is applied to the victim of the maltreatment, not the perpetrator.

**Exclusions:** History of spouse or partner violence, sexual (QE51.1)

**QE82.2**

**Personal history of psychological abuse**

Personal history of non-accidental verbal or symbolic act that results in significant psychological harm. This category is applied to the victim of the maltreatment, not the perpetrator.

**Exclusions:** History of spouse or partner violence, psychological (QE51.1)

**QE82.3**

**Personal history of neglect**

Personal history of egregious acts or omissions by a caregiver that deprive a child of needed age-appropriate care or an adult who is incapable of self-care and that result, or have reasonable potential to result, in physical or psychological harm. This category is applied to the victim of the neglect, not the perpetrator.

**QE82.Y**

**Other specified personal history of maltreatment**

**QE82.Z**

**Personal history of maltreatment, unspecified**

**QE83**

**Personal frightening experience in childhood**

**QE84**

### **Acute stress reaction**

Acute stress reaction refers to the development of transient emotional, somatic, cognitive, or behavioural symptoms as a result of exposure to an event or situation (either short- or long-lasting) of an extremely threatening or horrific nature (e.g., natural or human-made disasters, combat, serious accidents, sexual violence, assault). Symptoms may include autonomic signs of anxiety (e.g., tachycardia, sweating, flushing), being in a daze, confusion, sadness, anxiety, anger, despair, overactivity, inactivity, social withdrawal, or stupor. The response to the stressor is considered to be normal given the severity of the stressor, and usually begins to subside within a few days after the event or following removal from the threatening situation.

**Inclusions:** acute crisis reaction

acute reaction to stress

**Exclusions:** Post traumatic stress disorder (6B40)

**QE8Y**

### **Other specified problems associated with harmful or traumatic events**

**QE8Z**

### **Problems associated with harmful or traumatic events, unspecified**

Problems associated with upbringing (QE90-QE9Z)

**QE90**

### **Inadequate parental supervision or control**

Lack of parental knowledge of what the child is doing or where the child is; poor control; lack of concern, understanding or comprehension or lack of attempted intervention when the child is in risky situations.

**QE91**

### **Parental overprotection**

**QE92**

### **Altered pattern of family relationships in childhood**

Departure of a family member or arrival of a new person into a family resulting in adverse change in child's relationships. May include new relationship or marriage by a parent, death or illness of a parent, illness or birth of a sibling.

**QE93**

### **Removal from home in childhood**

**QE94**

### **Institutional upbringing**

Group foster care in which parenting responsibilities are largely taken over by some form of institution (such as residential nursery, orphanage, or children's home), or therapeutic care over a prolonged period in which the child is in a hospital, convalescent home or the like, without at least one parent living with the child.

**QE95**

### **Inappropriate parental pressure or other abnormal qualities of upbringing**

Parents forcing the child to be different from the local norm, either sex-inappropriate (e.g. dressing a boy in girl's clothes), age-inappropriate (e.g. forcing a child to take on responsibilities above her or his own age) or otherwise inappropriate (e.g. pressing the child to engage in unwanted or too difficult activities).

**QE96**

**Events resulting in loss of self-esteem in childhood**

Events resulting in a negative self-reappraisal by the child such as failure in tasks with high personal investment; disclosure or discovery of a shameful or stigmatizing personal or family event; or other humiliating experiences.

**QE9Y**

**Other specified problems associated with upbringing**

**QE9Z**

**Problems associated with upbringing, unspecified**

Acquired absence of body structure (QF00-QF0Z)

**QF00**

**Acquired absence of limb**

- Inclusions:** postoperative loss of limb  
post traumatic loss of limb
- Exclusions:** Other acquired deformities of limbs (FA31)  
Congenital absence of thigh or lower leg with foot present (LB9A.3)  
Congenital absence of both lower leg and foot (LB9A.7)  
Congenital absence of upper arm or forearm with hand present (LB99.4)

**QF01**

**Acquired absence of organs**

- Exclusions:** postoperative absence of endocrine glands (5D40-5D46)  
postoperative absence of spleen (3B81.1)

**QF01.0**

**Acquired absence of breast**

**Coded Elsewhere:** Traumatic amputation of breast (NB33.1)

**QF01.1**

**Acquired absence of genital organs**

**Coded Elsewhere:** Aetiological considerations associated with a medical condition, injury, or the effects of surgery or radiation treatment (HA40.0)

**QF01.10**

Acquired absence of female genital organs

**Coded Elsewhere:** Traumatic amputation of entire vulva (NB93.24)

- Traumatic amputation of part of vulva (NB93.25)  
Female Genital Mutilation (GC51)

**QF01.11**

Acquired absence of male genital organs

**Coded Elsewhere:** Traumatic amputation of entire penis (NB93.20)

- Traumatic amputation of part of penis (NB93.21)  
Traumatic amputation of entire testes or scrotum (NB93.22)  
Traumatic amputation of part of testes or scrotum (NB93.23)

**QF01.Y**

**Other specified acquired absence of organs**

**QF01.Z**

**Acquired absence of organs, unspecified**

<b>QF0Y</b>	<b>Other specified acquired absence of body structure</b>
<b>QF0Z</b>	<b>Acquired absence of body structure, unspecified</b>
<b>QF10</b>	<b>Limited function or disability of body organ or system</b>
<i>Exclusions:</i>	Difficulty or need for assistance with activities (QF20-QF2Z)

Difficulty or need for assistance with activities (QF20-QF2Z)

Identifies activities for which the person needs assistance or has such difficulty with, that it affects their need for health services or their treatment.

*Exclusions:* Dependence on enabling machines or devices (QB40-QB4Z)

**QF20** **Difficulty or need for assistance with learning**

**QF21** **Difficulty or need for assistance with general life tasks or life management**

*Inclusions:* difficulty with carrying out tasks and daily routine

**QF22** **Difficulty or need for assistance with communication**

**QF23** **Difficulty or need for assistance with mobility**

*Exclusions:* Abnormalities of gait and mobility (MB44)

**QF24** **Difficulty or need for assistance with self-care**

**QF25** **Difficulty or need for assistance with relationships**

**QF26** **Difficulty or need for assistance with household tasks**

**QF27** **Difficulty or need for assistance at home and no other household member able to render care**

**QF28** **Difficulty or need for assistance with work activities**

**QF29** **Difficulty or need for assistance with major areas of life**

**QF2A** **Difficulty or need for assistance with community participation**

**QF2B** **Need for continuous supervision**

*Exclusions:* Difficulty or need for assistance at home and no other household member able to render care (QF27)

**QF2Y** **Difficulty or need for assistance with other specified activity**

**QF2Z** **Difficulty or need for assistance with unspecified activity**

---

**QF4Y** **Other specified factors influencing health status or contact with health services**

**QF4Z**

**Factors influencing health status or contact with health services,  
unspecified**

# CHAPTER 25

---

## Codes for special purposes

This chapter has 17 four-character categories.

Code range starts with RA00

This chapter contains the following top level blocks:

- International provisional assignment of new diseases of uncertain aetiology and emergency use
- National provisional assignment of new diseases of uncertain aetiology

International provisional assignment of new diseases of uncertain aetiology and emergency use (RA00-RA09)

**RA00      Conditions of uncertain aetiology and emergency use**

**RA00.0      Vaping related disorder**

Disorder resulting from inhaling a vaporized solution (aerosol) which frequently contains flavourants, usually dissolved into Propylene Glycol or Glycerin, or both, and may or may not contain doses of nicotine, and other substances and additives with the use of electronic nicotine delivery systems (ENDS) or electronic non-nicotine delivery systems (ENNDS).

In the affected individual, infections as cause of the damage are unlikely or should have been excluded.

Relevant findings include proof of presence of pulmonary infiltrate, such as opacities, on plain film chest radiograph or ground-glass opacities on chest CT.

**RA01      COVID-19**

As definition may evolve, the URL for the Global surveillance document will be added as the short description

**RA01.0      COVID-19, virus identified**

**Coding Note:** Use this code when infection with the COVID-19 virus (SARS-CoV-2) has been confirmed by laboratory testing irrespective of severity of clinical signs or symptoms.

**Inclusions:**      Coronavirus disease 2019

COVID-19 NOS

**Exclusions:**      Coronavirus infection, unspecified site (1D92)

Middle East respiratory syndrome (1D64)

Severe acute respiratory syndrome (1D65)

<b>RA01.1</b>	<b>COVID-19, virus not identified</b>
<b>Coding Note:</b>	Use this code when COVID-19 is diagnosed clinically or epidemiologically but laboratory testing is inconclusive or not available.
	<b>Exclusions:</b>
	COVID-19, virus identified (RA01.0)
	Coronavirus infection, unspecified site (1D92)
	Special screening examination for other viral diseases (QA08.5)
	suspected but ruled out by negative laboratory results (QA02)
	confirmed by laboratory testing (RA01.0)

**RA02**

### **Post COVID-19 condition**

Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms, and that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also others, and generally have an impact on everyday functioning. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time.

<b>Coding Note:</b>	This optional code serves to allow the establishment of a link with COVID-19. This code is not to be used in cases that still are presenting COVID-19.
---------------------	--

**RA03**

### **Multisystem inflammatory syndrome associated with COVID-19**

<b>Exclusions:</b>	Kawasaki syndrome (4A44.5)
	Mucocutaneous lymph node syndrome (4A44.5)

**RA04**

### **International emergency code 05**

**RA05**

### **International emergency code 06**

**RA06**

### **International emergency code 07**

**RA07**

### **International emergency code 08**

**RA08**

### **International emergency code 09**

**RA09**

### **International emergency code 10**

National provisional assignment of new diseases of uncertain aetiology (RA20-RA26)

**RA20**

### **National emergency code 01**

**RA21**

### **National emergency code 02**

**RA22**

### **National emergency code 03**

**RA23**

### **National emergency code 04**

**RA24**

### **National emergency code 05**

**RA25      National emergency code 06**

**RA26      National emergency code 07**

# CHAPTER 26

---

## Supplementary Chapter Traditional Medicine Conditions

This chapter has 468 four-character categories.

Code range starts with SA00

This chapter contains the following top level blocks:

- Module I

Module I (SA00-SJ1Z)

Traditional medicine disorders (TM1) (SA00-SE5Z)

Organ system disorders (TM1) (SA00-SB2Z)

Liver system disorders (TM1) (SA00-SA0Z)

**SA00 Hypochondrium pain disorder (TM1)**

**SA01 Jaundice disorder (TM1)**

*Inclusions:*      Acute jaundice  
                      Yang jaundice  
                      Yin jaundice

**SA02 Liver distension disorder (TM1)**

**SA03 Tympanites disorder (TM1)**

**SA04 Liver abscess disorder (TM1)**

**SA05 Gallbladder distension disorder (TM1)**

**SA0Y Other specified liver system disorders (TM1)**

**SA0Z Liver system disorders (TM1), unspecified**

## Heart system disorders (TM1) (SA10-SA4Z)

### Palpitation disorders (TM1) (SA10-SA1Z)

- SA10** **Inducible palpitation disorder (TM1)**  
*Inclusions:* Fright palpitation disorder (TM1)
- SA11** **Spontaneous palpitation disorder (TM1)**  
*Inclusions:* Fearful throbbing disorder (TM1)
- SA1Y** **Other specified palpitation disorders (TM1)**
- SA1Z** **Palpitation disorders (TM1), unspecified**

### Chest impediment disorders (TM1) (SA20-SA2Z)

- Inclusions:* Heart pain disorder (TM1)  
Chest impediment disorder (TM1)
- SA20** **True heart pain disorder (TM1)**
- SA2Y** **Other specified chest impediment disorders (TM1)**
- SA2Z** **Chest impediment disorders (TM1), unspecified**
- 
- SA4Y** **Other specified heart system disorders (TM1)**
- SA4Z** **Heart system disorders (TM1), unspecified**

### Spleen system disorders (TM1) (SA50-SA5Z)

- SA50** **Dysphagia disorder (TM1)**  
*Inclusions:* Choke disorder (TM1)
- SA51** **Stomach ache disorder (TM1)**
- SA52** **Epigastric distension disorder (TM1)**
- SA53** **Epigastric upset disorder (TM1)**
- SA54** **Food retention disorder (TM1)**
- SA55** **Diarrhea disorder (TM1)**
- SA56** **Dysentery disorder (TM1)**
- SA57** **Constipation disorder (TM1)**

- SA58**      **Abdominal pain disorder (TM1)**  
*Exclusions:*      Lower abdominal colic disorder (TM1)
- SA59**      **Intestinal abscess disorder (TM1)**
- SA5Y**      **Other specified spleen system disorders (TM1)**
- SA5Z**      **Spleen system disorders (TM1), unspecified**

Lung system disorders (TM1) (SA60-SA8Z)

- SA60**      **Common cold disorder (TM1)**  
*Exclusions:*      Seasonal cold disorder (TM1)

Cough disorders (TM1) (SA70-SA7Z)

- SA70**      **Cough with dyspnea disorder (TM1)**  
*Exclusions:*      Panting disorder (TM1)  
                        Dyspnea disorder (TM1)
- SA7Y**      **Other specified cough disorders (TM1)**
- SA7Z**      **Cough disorders (TM1), unspecified**
- SA80**      **Dyspnea disorder (TM1)**  
*Exclusions:*      Cough with dyspnea disorder (TM1)
- SA81**      **Wheezing disorder (TM1)**
- SA82**      **Lung distension disorder (TM1)**
- SA83**      **Pleural fluid retention disorder (TM1)**
- SA84**      **Lung heat disorder (TM1)**
- SA85**      **Lung withering disorder (TM1)**
- SA86**      **Chest bind disorder (TM1)**
- SA8Y**      **Other specified lung system disorders (TM1)**
- SA8Z**      **Lung system disorders (TM1), unspecified**

Kidney system disorders (TM1) (SA90-SB0Z)

- Strangury disorders (TM1) (SA90-SA9Z)
- SA90**      **Stony stranguria disorder (TM1)**

<b>SA91</b>	<b>Heat stranguria disorder (TM1)</b>
<b>SA9Y</b>	<b>Other specified strangury disorders (TM1)</b>
<b>SA9Z</b>	<b>Strangury disorders (TM1), unspecified</b>
<b>SB00</b>	<b>Kidney stagnation disorder (TM1)</b>
<b>SB01</b>	<b>Flooding urine disorder (TM1)</b>
<b>SB02</b>	<b>Enuresis disorder (TM1)</b>
<b>SB03</b>	<b>Turbid urine disorder (TM1)</b>
<b>SB04</b>	<b>Dribbling urinary block disorder (TM1)</b>
<b>SB05</b>	<b>Block and repulsion disorder (TM1)</b>
<b>SB06</b>	<b>Edema disorders (TM1)</b>
<b>SB06.0</b>	<b>Kidney edema disorder (TM1)</b>
<b>SB06.1</b>	<b>Wind edema disorder (TM1)</b>
<b>SB06.Y</b>	<b>Other specified edema disorders (TM1)</b>
<b>SB06.Z</b>	<b>Edema disorders (TM1), unspecified</b>
<b>SB07</b>	<b>Lower abdominal colic disorder (TM1)</b>
	<i>Inclusions:</i> Hernia (TM1)
	<i>Exclusions:</i> Abdominal pain disorder (TM1)
<b>SB08</b>	<b>Premature ejaculation disorder (TM1)</b>
<b>SB09</b>	<b>Involuntary ejaculation disorder (TM1)</b>
<b>SB0A</b>	<b>Persistent erection disorder (TM1)</b>
<b>SB0B</b>	<b>Impotence disorder (TM1)</b>
<b>SB0C</b>	<b>Male infertility disorder (TM1)</b>
<b>SB0Y</b>	<b>Other specified kidney system disorders (TM1)</b>
<b>SB0Z</b>	<b>Kidney system disorders (TM1), unspecified</b>
<hr/>	
<b>SB2Y</b>	<b>Other specified organ system disorders (TM1)</b>
<b>SB2Z</b>	<b>Organ system disorders (TM1), unspecified</b>

Other body system disorders (TM1) (SB30-SD6Z)

Skin and mucosa system disorders (TM1) (SB30-SB7Z)

**SB30**      **Dampness sore disorder (TM1)**

**SB31**      **Impetigo disorder (TM1)**

Furuncle disorders (TM1) (SB40-SB4Z)

**SB40**      **Septicemic furunculosis disorder (TM1)**

**SB4Y**      **Other specified furuncle disorders (TM1)**

**SB4Z**      **Furuncle disorders (TM1), unspecified**

**SB50**      **Bed sore disorder (TM1)**

Abscess disorders (TM1) (SB60-SB6Z)

**SB60**      **Deep multiple abscess disorder (TM1)**

**SB61**      **Anal abscess disorder (TM1)**

**SB6Y**      **Other specified abscess disorders (TM1)**

**SB6Z**      **Abscess disorders (TM1), unspecified**

**SB70**      **Headed carbuncle disorder (TM1)**

**SB71**      **Foot dampness itch disorder (TM1)**

**SB72**      **Tinea circinate disorder (TM1)**

**SB73**      **Dry skin disorder (TM1)**

**SB74**      **Gangrene disorder (TM1)**

**SB75**      **Wart disorder (TM1)**

**SB76**      **Hand dampness itch disorder (TM1)**

**SB77**      **Erysipelas disorder (TM1)**

**SB78**      **Cellulitis disorder (TM1)**

**SB79**      **Thrush disorder (TM1)**

**SB7A**      **Herpes zoster disorder (TM1)**

**SB7B**      **Interior haemorrhoid disorder (TM1)**

**SB7C**      **Fissured anus disorder (TM1)**

**SB7Y**      **Other specified skin and mucosa system disorders (TM1)**

**SB7Z**      **Skin and mucosa system disorders (TM1), unspecified**

Female reproductive system disorders (TM1) (including childbirth) (SB80-SC4Z)

Menstruation associated disorders (TM1) (SB80-SB9Z)

Menstruation cycle disorders (TM1) (SB80-SB8Z)

**SB80**      **Advanced menstruation disorder (TM1)**

**SB81**      **Delayed menstruation disorder (TM1)**

**SB82**      **Irregular menstruation disorders (TM1)**

**SB8Y**      **Other specified menstruation cycle disorders (TM1)**

**SB8Z**      **Menstruation cycle disorders (TM1), unspecified**

**SB90**      **Menorrhagia disorder (TM1)**

**SB91**      **Decreased menstruation disorder (TM1)**

**SB92**      **Prolonged menstruation disorder (TM1)**

**SB93**      **Metrorrhagia disorder (TM1)**

**SB94**      **Amenorrhea disorder (TM1)**

**SB95**      **Menopausal disorder (TM1)**

**SB96**      **Dysmenorrhea disorder (TM1)**

**SB9Y**      **Other specified menstruation associated disorders (TM1)**

**SB9Z**      **Menstruation associated disorders (TM1), unspecified**

Pregnancy associated disorders (TM1) (SC00-SC0Z)

**SC00**      **Morning sickness disorder (TM1)**

**SC01**      **Unstable fetus disorder (TM1)**

**SC02**      **Bladder pressure disorder (TM1)**

**Inclusions:**      Shifted colic disorder (TM1)  
                          Shifted bladder disorder (TM1)  
                          Bladder colic disorder (TM1)

**SC03**      **Eclampsia disorder (TM1)**

<b>SC04</b>	<b>Floating sensation pregnancy disorder (TM1)</b>
<b>SC0Y</b>	<b>Other specified pregnancy associated disorders (TM1)</b>
<b>SC0Z</b>	<b>Pregnancy associated disorders (TM1), unspecified</b>

Puerperium associated disorders (TM1) (SC10-SC1Z)

<b>SC10</b>	<b>Puerperal abdominal pain disorder (TM1)</b>
<b>SC11</b>	<b>Puerperal wind disorder (TM1)</b>
<b>SC12</b>	<b>Hypogalactia disorder (TM1)</b>
<b>SC13</b>	<b>Postpartum lochiorrhea disorder (TM1)</b>
<b>SC1Y</b>	<b>Other specified puerperium associated disorders (TM1)</b>
<b>SC1Z</b>	<b>Puerperium associated disorders (TM1), unspecified</b>

Other female reproductive system associated disorders (TM1) (SC20-SC2Z)

<b>SC20</b>	<b>Leukorrhea disorder (TM1)</b>
<b>SC21</b>	<b>Vaginal flatus disorder (TM1)</b>
<b>SC22</b>	<b>Infertility disorder (TM1)</b> <i>Inclusions:</i> Female sterility disorder (TM1) <i>Exclusions:</i> Male Infertility disorder (TM1)
<b>SC23</b>	<b>Uterine mass disorder (TM1)</b>
<b>SC24</b>	<b>Breast lump disorder (TM1)</b>
<b>SC2Y</b>	<b>Other specified other female reproductive system associated disorders (TM1)</b>
<b>SC2Z</b>	<b>Other female reproductive system associated disorders (TM1), unspecified</b>

---

<b>SC4Y</b>	<b>Other specified female reproductive system disorders (TM1) (including childbirth)</b>
<b>SC4Z</b>	<b>Female reproductive system disorders (TM1) (including childbirth), unspecified</b>

## Bone, joint and muscle system disorders (TM1) (SC50-SC6Z)

### Joint impediment disorders (TM1) (SC50-SC5Z)

<b>SC50</b>	<b>Cold impediment disorder (TM1)</b>
<b>SC51</b>	<b>Wind impediment disorder (TM1)</b>
<b>SC52</b>	<b>Dampness impediment disorder (TM1)</b>
<b>SC5Y</b>	<b>Other specified joint impediment disorders (TM1)</b>
<b>SC5Z</b>	<b>Joint impediment disorders (TM1), unspecified</b>
<b>SC60</b>	<b>Muscle spasm disorder (TM1)</b>
<b>SC61</b>	<b>Lumbago disorder (TM1)</b>
<b>SC62</b>	<b>Numbness disorder (TM1)</b>
<b>SC63</b>	<b>Wilting disorder (TM1)</b>
<b>SC6Y</b>	<b>Other specified bone, joint and muscle system disorders (TM1)</b>
<b>SC6Z</b>	<b>Bone, joint and muscle system disorders (TM1), unspecified</b>

### Eye, ear, nose and throat system disorders (TM1) (SC70-SC9Z)

<b>SC70</b>	<b>Night blindness disorder (TM1)</b>
<b>SC71</b>	<b>Wind glaucoma disorder (TM1)</b>
<b>SC72</b>	<b>Inflammatory eyelid disorder (TM1)</b>
<b>SC73</b>	<b>Non-inflammatory eyelid disorder (TM1)</b>
<b>SC74</b>	<b>Corneal opacity disorder (TM1)</b>
<b>SC75</b>	<b>Tinnitus disorder (TM1)</b>

*Exclusions:* Cerebral tinnitus disorder (TM1)

### Deafness disorders (TM1) (SC80-SC8Z)

<b>SC80</b>	<b>Sudden deafness disorder (TM1)</b>
<b>SC81</b>	<b>Gradual deafness disorder (TM1)</b>
<b>SC8Y</b>	<b>Other specified deafness disorders (TM1)</b>
<b>SC8Z</b>	<b>Deafness disorders (TM1), unspecified</b>
<b>SC90</b>	<b>Allergic rhinitis disorder (TM1)</b>

<b>SC91</b>	<b>Nasal sinusitis disorder (TM1)</b>
<b>SC92</b>	<b>Hoarseness disorder (TM1)</b>
<b>SC93</b>	<b>Tonsillitis disorder (TM1)</b>
<b>SC9Y</b>	<b>Other specified eye, ear, nose and throat system disorders (TM1)</b>
<b>SC9Z</b>	<b>Eye, ear, nose and throat system disorders (TM1), unspecified</b>

Brain system disorders (TM1) (SD00-SD4Z)

<b>SD00</b>	<b>Facial paralysis disorder (TM1)</b>
-------------	--

Headache disorders (TM1) (SD10-SD1Z)

<b>SD10</b>	<b>Migraine disorder (TM1)</b>
<b>SD11</b>	<b>Head wind disorder (TM1)</b>
<b>SD1Y</b>	<b>Other specified headache disorders (TM1)</b>
<b>SD1Z</b>	<b>Headache disorders (TM1), unspecified</b>
<b>SD20</b>	<b>Convulsion disorder (TM1)</b>
	<i>Inclusions:</i> Postpartum convulsion disorder (TM1)
<b>SD21</b>	<b>Cerebral tinnitus disorder (TM1)</b>
	<i>Exclusions:</i> Tinnitus disorder (TM1)
<b>SD22</b>	<b>Vertigo disorder (TM1)</b>
<b>SD23</b>	<b>Forgetfulness disorder (TM1)</b>
<b>SD24</b>	<b>Frequent protrusion of tongue disorder (TM1)</b>

Wind stroke disorders (TM1) (SD30-SD3Z)

<b>SD30</b>	<b>Prodrome of wind stroke disorder (TM1)</b>
	<i>Inclusions:</i> Onset of wind stroke (TM1)
	<i>Exclusions:</i> Sequela of wind stroke disorder (TM1)
<b>SD31</b>	<b>Sequela of wind stroke disorder (TM1)</b>
	<i>Exclusions:</i> Prodrome of wind stroke disorder (TM1)
<b>SD3Y</b>	<b>Other specified wind stroke disorders (TM1)</b>
<b>SD3Z</b>	<b>Wind stroke disorders (TM1), unspecified</b>

<b>SD40</b>	<b>Syncope disorder (TM1)</b>
	<i>Inclusions:</i>
	Qi syncope disorder (TM1)
	Blood syncope disorder (TM1)
	Phlegm syncope disorder (TM1)
	Hunger syncope disorder (TM1)
	Cold syncope disorder (TM1)
	<i>Exclusions:</i>
	wasting thirst related syncope disorder (TM1)
<b>SD4Y</b>	<b>Other specified brain system disorders (TM1)</b>
<b>SD4Z</b>	<b>Brain system disorders (TM1), unspecified</b>

---

<b>SD6Y</b>	<b>Other specified other body system disorders (TM1)</b>
<b>SD6Z</b>	<b>Other body system disorders (TM1), unspecified</b>

Qi, blood and fluid disorders (TM1) (SD70-SD7Z)

<b>SD70</b>	<b>Qi goiter disorder (TM1)</b>
<b>SD71</b>	<b>Wasting thirst disorder (TM1)</b>
<b>SD72</b>	<b>Consumptive disorder (TM1)</b>
<b>SD7Y</b>	<b>Other specified qi, blood and fluid disorders (TM1)</b>
<b>SD7Z</b>	<b>Qi, blood and fluid disorders (TM1), unspecified</b>

Mental and emotional disorders (TM1) (SD80-SD8Z)

<b>SD80</b>	<b>Lily disorder (TM1)</b>
	<i>Exclusions:</i>
	Hysteria disorder (TM1)
	Insomnia disorders (TM1)
<b>SD81</b>	<b>Manic disorder (TM1)</b>
<b>SD82</b>	<b>Depression disorder (TM1)</b>
	<i>Inclusions:</i>
	Postpartum depression disorder (TM1)
	Pregnancy depression disorder (TM1)
<b>SD83</b>	<b>Uneasiness disorder (TM1)</b>
	<i>Exclusions:</i>
	Depression disorder(TM1)
	Lily disorder(TM1)
<b>SD84</b>	<b>Insomnia disorder (TM1)</b>
<b>SD85</b>	<b>Somnolence disorder (TM1)</b>

<b>SD86</b>	<b>Dementia disorder (TM1)</b>
	<i>Inclusions:</i> Aged dementia disorders (TM1)
	<i>Exclusions:</i> Amnesia disorder (TM1)
<b>SD87</b>	<b>Repressed fire disorder (TM1)</b>
<b>SD8Y</b>	<b>Other specified mental and emotional disorders (TM1)</b>
<b>SD8Z</b>	<b>Mental and emotional disorders (TM1), unspecified</b>

External contraction disorders (TM1) (SD90-SE2Z)

<b>SD90</b>	<b>Seasonal cold disorder (TM1)</b>
	<i>Exclusions:</i> Common cold disorder (TM1)
<b>SD91</b>	<b>Fatigue consumption disorder (TM1)</b>
	<i>Exclusions:</i> Flowing phlegm disorder (TM1)
<b>SD92</b>	<b>Severe vomiting and diarrhoea disorder (TM1)</b>
	<i>Exclusions:</i> Diarrhea disorder (TM1)
	Cholera
<b>SD93</b>	<b>Alternating fever and chills disorder (TM1)</b>
	<i>Exclusions:</i> Malaria
<b>SD94</b>	<b>Parasitic disorder (TM1)</b>
<b>SD95</b>	<b>Flowing phlegm disorder (TM1)</b>
	<i>Inclusions:</i> Bone and joint tuberculosis disorder (TM1)

Warmth disorders (TM1) (SE00-SE0Z)

<b>SE00</b>	<b>Summer-heat disorder (TM1)</b>
<b>SE01</b>	<b>Spring warmth disorder (TM1)</b>
<b>SE02</b>	<b>Dampness and warmth disorder (TM1)</b>
<b>SE0Y</b>	<b>Other specified warmth disorders (TM1)</b>
<b>SE0Z</b>	<b>Warmth disorders (TM1), unspecified</b>
<b>SE2Y</b>	<b>Other specified external contraction disorders (TM1)</b>
<b>SE2Z</b>	<b>External contraction disorders (TM1), unspecified</b>

**Childhood and adolescence associated disorders (TM1) (SE30-SE3Z)**

<b>SE30</b>	<b>Developmental delay disorder (TM1)</b>
<b>SE31</b>	<b>Growth fever disorder (TM1)</b>
<b>SE32</b>	<b>Growth pain disorder (TM1)</b>
<b>SE33</b>	<b>Acute convulsion disorder (TM1)</b>
<b>SE34</b>	<b>Recurrent convulsion disorder (TM1)</b>
<b>SE35</b>	<b>Fright seizure disorder (TM1)</b>
<b>SE36</b>	<b>Night crying disorder (TM1)</b>
<b>SE37</b>	<b>Infantile malnutrition disorder (TM1)</b>
<b>SE38</b>	<b>Dribbling disorder (TM1)</b>
<b>SE39</b>	<b>Diaper dermatitis disorder (TM1)</b>
<b>SE3A</b>	<b>Infant stiffness disorder (TM1)</b>
<b>SE3B</b>	<b>Infant limpness disorder (TM1)</b>
<b>SE3Y</b>	<b>Other specified childhood and adolescence associated disorders (TM1)</b>
<b>SE3Z</b>	<b>Childhood and adolescence associated disorders (TM1), unspecified</b>

---

<b>SE5Y</b>	<b>Other specified traditional medicine disorders (TM1)</b>
<b>SE5Z</b>	<b>Traditional medicine disorders (TM1), unspecified</b>

**Traditional medicine patterns (TM1) (SE70-SJ1Z)**

**Principle-based patterns (TM1) (SE70-SE7Z)**

<b>SE70</b>	<b>Yang pattern (TM1)</b>
<b>SE71</b>	<b>Yin pattern (TM1)</b>
<b>SE72</b>	<b>Heat pattern (TM1)</b>
<b>SE73</b>	<b>Cold pattern (TM1)</b>
<b>SE74</b>	<b>Excess pattern (TM1)</b>
<b>SE75</b>	<b>Deficiency pattern (TM1)</b>
<b>SE76</b>	<b>Exterior pattern (TM1)</b>

<b>SE77</b>	<b>Interior pattern (TM1)</b>
<b>SE78</b>	<b>Moderate (Heat/Cold) pattern (TM1)</b>
<b>SE79</b>	<b>Medium (Excess/Deficiency) pattern (TM1)</b>
<b>SE7A</b>	<b>Tangled cold and heat pattern (TM1)</b>
<b>SE7Y</b>	<b>Other specified principle-based patterns (TM1)</b>
<b>SE7Z</b>	<b>Principle-based patterns (TM1), unspecified</b>

Environmental factor patterns (TM1) (SE80-SE8Z)

<b>SE80</b>	<b>Wind factor pattern (TM1)</b>
<b>SE81</b>	<b>Cold factor pattern (TM1)</b>
<b>SE82</b>	<b>Dampness factor pattern (TM1)</b>
<b>SE83</b>	<b>Dryness factor pattern (TM1)</b>
<b>SE84</b>	<b>Fire-heat factor pattern (TM1)</b>
<b>SE85</b>	<b>Summer-heat factor pattern (TM1)</b>
<b>SE86</b>	<b>Pestilent factor pattern (TM1)</b>
<b>SE8Y</b>	<b>Other specified environmental factor patterns (TM1)</b>
<b>SE8Z</b>	<b>Environmental factor patterns (TM1), unspecified</b>

Body constituents patterns (TM1) (SE90-SF4Z)

Qi patterns (TM1) (SE90-SE9Z)

*Exclusions:* Qi phase patterns (TM1)

<b>SE90</b>	<b>Qi deficiency pattern (TM1)</b>
-------------	------------------------------------

*Inclusions:* Qi decrease pattern (TM1)

<b>SE91</b>	<b>Qi stagnation pattern (TM1)</b>
<b>SE92</b>	<b>Qi uprising pattern (TM1)</b>
<b>SE93</b>	<b>Qi sinking pattern (TM1)</b>
<b>SE94</b>	<b>Qi collapse pattern (TM1)</b>
<b>SE9Y</b>	<b>Other specified qi patterns (TM1)</b>
<b>SE9Z</b>	<b>Qi patterns (TM1), unspecified</b>

## Blood patterns (TM1) (SF00-SF0Z)

<b>SF00</b>	<b>Blood deficiency pattern (TM1)</b>
	<i>Inclusions:</i> Blood decrease patterns (TM1)
<b>SF01</b>	<b>Blood stasis pattern (TM1)</b>
<b>SF02</b>	<b>Blood heat pattern (TM1)</b>
	<i>Exclusions:</i> Blood cold pattern (TM)
<b>SF03</b>	<b>Blood cold pattern (TM1)</b>
	<i>Exclusions:</i> Qi patterns (TM1)
	Blood heat pattern (TM1)
<b>SF04</b>	<b>Blood dryness pattern (TM1)</b>
	<i>Exclusions:</i> Qi patterns (TM1)
	Blood heat pattern (TM1)
<b>SF0Y</b>	<b>Other specified blood patterns (TM1)</b>
<b>SF0Z</b>	<b>Blood patterns (TM1), unspecified</b>

## Fluid patterns (TM1) (SF10-SF1Z)

<b>SF10</b>	<b>Fluid deficiency pattern (TM1)</b>
	<i>Exclusions:</i> Essence deficiency pattern (TM1)
<b>SF11</b>	<b>Fluid disturbance pattern (TM1)</b>
	<i>Inclusions:</i> Fluid retention pattern (TM1)
<b>SF12</b>	<b>Dry-phlegm pattern (TM1)</b>
<b>SF13</b>	<b>Damp phlegm pattern (TM1)</b>
<b>SF14</b>	<b>Phlegm-fire harassing the heart system pattern (TM1)</b>
<b>SF15</b>	<b>Wind-phlegm pattern (TM1)</b>
<b>SF1Y</b>	<b>Other specified fluid patterns (TM1)</b>
<b>SF1Z</b>	<b>Fluid patterns (TM1), unspecified</b>

## Essence patterns (TM1) (SF20-SF2Z)

<b>SF20</b>	<b>Essence deficiency pattern (TM1)</b>
<b>SF2Y</b>	<b>Other specified essence patterns (TM1)</b>

**SF2Z**      **Essence patterns (TM1), unspecified**

---

**SF4Y**      **Other specified body constituents patterns (TM1)**

**SF4Z**      **Body constituents patterns (TM1), unspecified**

Organ system patterns (TM1) (SF50-SG1Z)

Liver system patterns (TM1) (SF50-SF5Z)

**SF50**      **Liver yin deficiency pattern (TM1)**

**SF51**      **Liver yang deficiency pattern (TM1)**

**SF52**      **Liver yang ascendant hyperactivity pattern (TM1)**

**SF53**      **Liver qi deficiency pattern (TM1)**

**SF54**      **Liver blood deficiency pattern (TM1)**

**SF55**      **Liver depression and blood stasis pattern (TM1)**

**SF56**      **Liver wind stirring the interior pattern (TM1)**

**SF57**      **Liver qi stagnation pattern (TM1)**

**SF58**      **Liver fire flaming upward pattern (TM1)**

**SF59**      **Liver heat stirring wind pattern (TM1)**

**SF5A**      **Liver-gallbladder dampness-heat pattern (TM1)**

**SF5B**      **Liver meridian dampness-heat pattern (TM1)**

**SF5C**      **Liver meridian cold stagnation pattern (TM1)**

**SF5D**      **Gallbladder qi deficiency pattern (TM1)**

**SF5E**      **Gallbladder depression with phlegm harassment pattern (TM1)**

**SF5F**      **Gallbladder heat pattern (TM1)**

**SF5G**      **Gallbladder cold pattern (TM1)**

**SF5H**      **Liver and kidney yin deficiency pattern (TM1)**

**SF5J**      **Disharmony of liver and spleen systems pattern (TM1)**

**SF5K**      **Disharmony of liver and stomach systems pattern (TM1)**

**SF5L**      **Liver fire invading the stomach system pattern (TM1)**

**SF5M**      **Liver fire invading the lung system pattern (TM1)**

**SF5Y** Other specified liver system patterns (TM1)

**SF5Z** Liver system patterns (TM1), unspecified

Heart system patterns (TM1) (SF60-SF6Z)

**SF60** Heart qi deficiency pattern (TM1)

**SF61** Heart blood deficiency pattern (TM1)

**SF62** Dual deficiency of heart qi and blood pattern (TM1)

**SF63** Heart meridian obstruction pattern (TM1)

**SF64** Heart yin deficiency pattern (TM1)

**SF65** Deficiency of heart qi and yin pattern (TM1)

**SF66** Heart yang deficiency pattern (TM1)

**SF67** Heart yang collapse pattern (TM1)

**SF68** Heart fire flaming upward pattern (TM1)

**SF69** Fire harassing heart spirit pattern (TM1)

**SF6A** Water qi intimidating the heart system pattern (TM1)

**SF6B** Heart spirit restlessness pattern (TM1)

**SF6C** Anxiety damaging the spirit pattern (TM1)

**SF6D** Small intestine qi stagnation pattern (TM1)

**SF6E** Small intestine excess heat pattern (TM1)

**SF6F** Small intestine deficiency cold pattern (TM1)

**SF6G** Heart and liver blood deficiency pattern (TM1)

**SF6H** Heart and gallbladder qi deficiency pattern (TM1)

**SF6J** Heart and spleen systems deficiency pattern (TM1)

**SF6K** Heart and lung qi deficiency pattern (TM1)

**SF6L** Heart and kidney systems disharmony pattern (TM1)

**SF6M** Heart and kidney yang deficiency pattern (TM1)

**SF6Y** Other specified heart system patterns (TM1)

**SF6Z** Heart system patterns (TM1), unspecified

## Spleen system patterns (TM1) (SF70-SF7Z)

<b>SF70</b>	<b>Spleen qi deficiency pattern (TM1)</b>
<b>SF71</b>	<b>Spleen qi sinking pattern (TM1)</b>
<b>SF72</b>	<b>Spleen deficiency with qi stagnation pattern (TM1)</b>
<b>SF73</b>	<b>Spleen deficiency with food retention pattern (TM1)</b>
<b>SF74</b>	<b>Spleen failing to control the blood pattern (TM1)</b>
<b>SF75</b>	<b>Spleen deficiency and blood depletion pattern (TM1)</b>
<b>SF76</b>	<b>Spleen yin deficiency pattern (TM1)</b>
<b>SF77</b>	<b>Spleen yang deficiency pattern (TM1)</b>
<b>SF78</b>	<b>Dampness-heat encumbering the spleen system pattern (TM1)</b>
<b>SF79</b>	<b>Spleen deficiency with dampness accumulation pattern (TM1)</b>
<b>SF7A</b>	<b>Spleen deficiency with water flooding pattern (TM1)</b>
<b>SF7B</b>	<b>Cold-dampness encumbering the spleen system pattern (TM1)</b>
<b>SF7C</b>	<b>Stomach qi deficiency pattern (TM1)</b>
<b>SF7D</b>	<b>Stomach qi uprising pattern (TM1)</b>
<b>SF7E</b>	<b>Stomach yin deficiency pattern (TM1)</b> <i>Inclusions:</i> Stomach deficiency and heat pattern (TM1)
<b>SF7F</b>	<b>Stomach heat pattern (TM1)</b>
<b>SF7G</b>	<b>Dampness in the intestines pattern (TM1)</b>
<b>SF7H</b>	<b>Cold invading the stomach system pattern (TM1)</b>
<b>SF7J</b>	<b>Intestine cold stagnation pattern (TM1)</b>
<b>SF7K</b>	<b>Anxiety damaging the spleen system pattern (TM1)</b>
<b>SF7L</b>	<b>Lung and spleen deficiency pattern (TM1)</b>
<b>SF7M</b>	<b>Spleen and kidney yang deficiency pattern (TM1)</b>
<b>SF7Y</b>	<b>Other specified spleen system patterns (TM1)</b>
<b>SF7Z</b>	<b>Spleen system patterns (TM1), unspecified</b>

## Lung system patterns (TM1) (SF80-SF8Z)

<b>SF80</b>	<b>Lung qi deficiency pattern (TM1)</b>
-------------	---

<b>SF81</b>	<b>Lung yin deficiency pattern (TM1)</b>
<b>SF82</b>	<b>Lung and kidney yin deficiency pattern (TM1)</b>
<b>SF83</b>	<b>Lung qi and yin deficiency pattern (TM1)</b>
<b>SF84</b>	<b>Lung yang deficiency pattern (TM1)</b>
<b>SF85</b>	<b>Cold phlegm obstructing the lung pattern (TM1)</b>
<b>SF86</b>	<b>Turbid phlegm accumulation in the lung pattern (TM1)</b>
<b>SF87</b>	<b>Exterior cold with lung heat pattern (TM1)</b>
<b>SF88</b>	<b>Intense congestion of lung heat pattern (TM1)</b>
<b>SF89</b>	<b>Phlegm heat obstructing the lung pattern (TM1)</b>
<b>SF8A</b>	<b>Wind-heat invading the lung pattern (TM1)</b>
<b>SF8B</b>	<b>Lung heat transmitting into the intestine pattern (TM1)</b>
<b>SF8C</b>	<b>Wind-cold fettering the lung pattern (TM1)</b>
<b>SF8D</b>	<b>Dryness invading the lung pattern (TM1)</b>
<b>SF8E</b>	<b>Lung dryness with intestinal obstruction pattern (TM1)</b>
<b>SF8F</b>	<b>Large intestine excess heat pattern (TM1)</b>
<b>SF8G</b>	<b>Large intestine dampness heat pattern (TM1)</b>
<b>SF8H</b>	<b>Large intestine fluid deficiency pattern (TM1)</b>
<b>SF8J</b>	<b>Large intestine deficiency cold pattern (TM1)</b>
<b>SF8Y</b>	<b>Other specified lung system patterns (TM1)</b>
<b>SF8Z</b>	<b>Lung system patterns (TM1), unspecified</b>

### Kidney system patterns (TM1) (SF90-SF9Z)

<b>SF90</b>	<b>Kidney qi deficiency pattern (TM1)</b>
	<i>Inclusions:</i> Kidney qi depletion pattern (TM1)
<b>SF91</b>	<b>Kidney failing to receive qi pattern (TM1)</b>
<b>SF92</b>	<b>Kidney qi deficiency with water retention pattern (TM1)</b>
<b>SF93</b>	<b>Kidney yin deficiency pattern (TM1)</b>
<b>SF94</b>	<b>Kidney yin and yang deficiency pattern (TM1)</b>
<b>SF95</b>	<b>Kidney deficiency with marrow depletion pattern (TM1)</b>

<b>SF96</b>	<b>Kidney essence deficiency pattern (TM1)</b>
<b>SF97</b>	<b>Kidney yang deficiency pattern (TM1)</b>
	<i>Inclusions:</i> Life-gate fire depletion pattern (TM1) Primordial yang deficiency pattern (TM1)
<b>SF98</b>	<b>Fear damaging the kidney system pattern (TM1)</b>
<b>SF99</b>	<b>Blood and heat accumulation in the uterus pattern (TM1)</b>
<b>SF9A</b>	<b>Phlegm obstructing the uterus pattern (TM1)</b>
<b>SF9B</b>	<b>Dampness-heat in the uterus pattern (TM1)</b>
<b>SF9C</b>	<b>Cold stagnation in the uterus pattern (TM1)</b>
<b>SF9D</b>	<b>Uterine deficiency cold pattern (TM1)</b>
<b>SF9E</b>	<b>Blood accumulation in the bladder pattern (TM1)</b>
<b>SF9F</b>	<b>Bladder heat accumulation pattern (TM1)</b>
<b>SF9G</b>	<b>Bladder dampness-heat pattern (TM1)</b>
<b>SF9H</b>	<b>Bladder water accumulation pattern (TM1)</b>
<b>SF9J</b>	<b>Bladder deficiency cold pattern (TM1)</b>
<b>SF9Y</b>	<b>Other specified kidney system patterns (TM1)</b>
<b>SF9Z</b>	<b>Kidney system patterns (TM1), unspecified</b>

---

<b>SG1Y</b>	<b>Other specified organ system patterns (TM1)</b>
<b>SG1Z</b>	<b>Organ system patterns (TM1), unspecified</b>

Meridian and collateral patterns (TM1) (SG20-SG5Z)

Main Meridian Patterns (TM1) (SG20-SG2Z)

<b>SG20</b>	<b>Lung meridian pattern (TM1)</b>
<b>SG21</b>	<b>Large intestine meridian pattern (TM1)</b>
<b>SG22</b>	<b>Stomach meridian pattern (TM1)</b>
<b>SG23</b>	<b>Spleen meridian pattern (TM1)</b>
<b>SG24</b>	<b>Heart meridian pattern (TM1)</b>
<b>SG25</b>	<b>Small intestine meridian pattern (TM1)</b>

<b>SG26</b>	<b>Bladder meridian pattern (TM1)</b>
<b>SG27</b>	<b>Kidney meridian pattern (TM1)</b>
<b>SG28</b>	<b>Pericardium meridian pattern (TM1)</b>
<b>SG29</b>	<b>Triple energizer meridian pattern (TM1)</b>
<b>SG2A</b>	<b>Gallbladder meridian pattern (TM1)</b>
<b>SG2B</b>	<b>Liver meridian pattern (TM1)</b>
<b>SG2Y</b>	<b>Other specified main Meridian Patterns (TM1)</b>
<b>SG2Z</b>	<b>Main Meridian Patterns (TM1), unspecified</b>

#### Extra Meridian Patterns (TM1) (SG30-SG3Z)

<b>SG30</b>	<b>Governor vessel pattern (TM1)</b>
<b>SG31</b>	<b>Conception vessel pattern (TM1)</b>
<b>SG32</b>	<b>Yin heel vessel pattern (TM1)</b>
<b>SG33</b>	<b>Yang heel vessel pattern (TM1)</b>
<b>SG34</b>	<b>Yin link vessel pattern (TM1)</b>
<b>SG35</b>	<b>Yang link vessel pattern (TM1)</b>
<b>SG36</b>	<b>Thoroughfare vessel pattern (TM1)</b>
<b>SG37</b>	<b>Belt vessel pattern (TM1)</b>
<b>SG3Y</b>	<b>Other specified extra Meridian Patterns (TM1)</b>
<b>SG3Z</b>	<b>Extra Meridian Patterns (TM1), unspecified</b>

---

<b>SG5Y</b>	<b>Other specified meridian and collateral patterns (TM1)</b>
<b>SG5Z</b>	<b>Meridian and collateral patterns (TM1), unspecified</b>

#### Six stage patterns (TM1) (SG60-SG6Z)

<b>SG60</b>	<b>Early yang stage pattern (TM1)</b>
<b>SG61</b>	<b>Middle yang stage pattern (TM1)</b>
<b>SG62</b>	<b>Late yang stage pattern (TM1)</b>
<b>SG63</b>	<b>Early yin stage pattern (TM1)</b>
<b>SG64</b>	<b>Middle yin stage pattern (TM1)</b>

<b>SG65</b>	<b>Late yin stage pattern (TM1)</b>
<b>SG6Y</b>	<b>Other specified six stage patterns (TM1)</b>
<b>SG6Z</b>	<b>Six stage patterns (TM1), unspecified</b>

Triple energizer stage patterns (TM1) (SG70-SG7Z)

<b>SG70</b>	<b>Upper energizer stage patterns (TM1)</b>
<b>SG71</b>	<b>Middle energizer stage patterns (TM1)</b>
<b>SG72</b>	<b>Lower energizer stage patterns (TM1)</b>
<b>SG7Y</b>	<b>Other specified triple energizer stage patterns (TM1)</b>
<b>SG7Z</b>	<b>Triple energizer stage patterns (TM1), unspecified</b>

Four phase patterns (TM1) (SG80-SH3Z)

Defense phase patterns (TM1) (SG80-SG8Z)

<b>SG80</b>	<b>Dampness obstructing the defense yang pattern (TM1)</b>
<b>SG81</b>	<b>Heat attacking the lung defense pattern (TM1)</b>
<b>SG8Y</b>	<b>Other specified defense phase patterns (TM1)</b>
<b>SG8Z</b>	<b>Defense phase patterns (TM1), unspecified</b>

Qi phase patterns (TM1) (SG90-SG9Z)

<b>SG90</b>	<b>Heat entering the qi phase pattern (TM1)</b>
<b>SG91</b>	<b>Qi phase dampness and heat pattern (TM1)</b>
<b>SG92</b>	<b>Dampness obstructing the qi phase pattern (TM1)</b>
<b>SG9Y</b>	<b>Other specified qi phase patterns (TM1)</b>
<b>SG9Z</b>	<b>Qi phase patterns (TM1), unspecified</b>

Nutrient phase patterns (TM1) (SH00-SH0Z)

<b>SH00</b>	<b>Nutrient qi and defense qi disharmony pattern (TM1)</b>
<b>SH01</b>	<b>Heat in the nutrient phase pattern(TM1)</b>
<b>SH02</b>	<b>Heat entering the nutrient and blood phase pattern (TM1)</b>

**SH0Y** Other specified nutrient phase patterns (TM1)

**SH0Z** Nutrient phase patterns (TM1), unspecified

Blood phase patterns (TM1) (SH10-SH1Z)

**SH10** Blood phase pattern (TM1)

**SH11** Heat entering the blood phase pattern(TM1)

**SH1Y** Other specified blood phase patterns (TM1)

**SH1Z** Blood phase patterns (TM1), unspecified

---

**SH3Y** Other specified four phase patterns (TM1)

**SH3Z** Four phase patterns (TM1), unspecified

Four constitution medicine patterns (TM1) (SH40-SH9Z)

Large yang type patterns (TM1) (SH40-SH4Z)

**SH40** Large yang type exterior origin lower back pattern (TM1)

**SH41** Large yang type interior origin small intestine pattern (TM1)

**SH42** Large yang type exterior interior combined pattern (TM1)

**SH4Y** Other specified large yang type patterns (TM1)

**SH4Z** Large yang type patterns (TM1), unspecified

Small yang type patterns (TM1) (SH50-SH5Z)

**SH50** Small yang type lesser yang wind damage pattern (TM1)

**SH51** Small yang type yin depletion pattern (TM1)

**SH52** Small yang type chest heat congested pattern (TM1)

**SH53** Small yang type yin deficit pattern (TM1)

**SH54** Small yang type exterior interior combined pattern (TM1)

**SH5Y** Other specified small yang type patterns (TM1)

**SH5Z** Small yang type patterns (TM1), unspecified

**Large yin type patterns (TM1) (SH60-SH6Z)**

<b>SH60</b>	<b>Large yin type supraspinal exterior pattern (TM1)</b>
<b>SH61</b>	<b>Large yin type esophagus cold pattern (TM1)</b>
<b>SH62</b>	<b>Large yin type liver heat pattern (TM1)</b>
<b>SH63</b>	<b>Large yin type dryness heat pattern (TM1)</b>
<b>SH64</b>	<b>Large yin type exterior Interior combined pattern (TM1)</b>
<b>SH6Y</b>	<b>Other specified large yin type patterns (TM1)</b>
<b>SH6Z</b>	<b>Large yin type patterns (TM1), unspecified</b>

**Small yin type patterns(TM1) (SH70-SH7Z)**

<b>SH70</b>	<b>Small yin type congestive hyperpsychotic pattern (TM1)</b>
<b>SH71</b>	<b>Small yin type yang depletion pattern (TM1)</b>
<b>SH72</b>	<b>Small yin type greater yin pattern (TM1)</b>
<b>SH73</b>	<b>Small yin type lesser yin pattern (TM1)</b>
<b>SH74</b>	<b>Small yin type exterior interior combined pattern (TM1)</b>
<b>SH7Y</b>	<b>Other specified small yin type patterns(TM1)</b>
<b>SH7Z</b>	<b>Small yin type patterns(TM1), unspecified</b>

---

<b>SH9Y</b>	<b>Other specified four constitution medicine patterns (TM1)</b>
<b>SH9Z</b>	<b>Four constitution medicine patterns (TM1), unspecified</b>

---

<b>SJ1Y</b>	<b>Other specified traditional medicine patterns (TM1)</b>
<b>SJ1Z</b>	<b>Traditional medicine patterns (TM1), unspecified</b>

# **CHAPTER V**

---

## **Supplementary section for functioning assessment**

This chapter has 120 four-character categories.

Code range starts with VD00

The section allows for creating functioning profiles and overall functioning scores of individuals, which are suitable to describe and quantify the level of functioning associated with a health condition.

To guide functioning assessment, the section includes two ICF-based instruments developed by WHO: the WHO Disability Assessment Schedule (WHODAS 2.0 36-item version), and the Model Disability Survey (MDS).

The section is complemented by a generic set of functioning categories of high explanatory power derived from the ICF Annex 9.

This chapter contains the following top level blocks:

- WHODAS 2.0 36-item version
- Brief Model Disability Survey
- Generic functioning domains

### **WHODAS 2.0 36-item version**

This subsection includes the domains and questions for use with the WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) 36 item version. The WHODAS 2.0 captures an individual's level of functioning in six major life domains of the "activity and participation" dimension: cognition, mobility, self-care, getting along, life activities and participation in society. For all domains, the WHODAS 2.0 36-item version provides domain-specific and overall summary score of functioning. The table below provides the classification of severity of the functioning problem, based on the response received to the question related to the relevant functioning category. For coding, the relevant additional digit is added after the decimal point to the code of the relevant functioning category.

<b>additional digit</b>	<b>Level of functioning problem</b>
-------------------------	-------------------------------------

.0	None (no problem)
.1	Mild
.2	Moderate
.3	Severe
.4	Extreme or cannot do

## Cognition [WHODAS]

**VD00**

### **Attention functions [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in concentrating on doing something for ten minutes?

**VD01**

### **Memory functions [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in remembering to do important things?

**VD02**

### **Solving problems [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in analysing and finding solutions to problems in day to day life?

**VD03**

### **Basic learning [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in learning a new task, for example, learning how to get a new place?

**VD04**

### **Communicating with - receiving - spoken messages [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in generally understanding what people say?

**VD05**

### **Conversation [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in starting and maintaining a conversation?

## Mobility [WHODAS]

**VD10**

### **Maintaining a standing position [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in standing for long periods such as 30 minutes?

**VD11**

### **Changing body position - standing [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in standing up from sitting down?

**VD12**

### **Moving around within the home [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in moving around inside your home?

**VD13**

### **Moving around outside the home and other buildings [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in getting out of your home?

**VD14**

**Walking [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in walking a long distance such as a kilometre (or equivalent)?

Self-care [WHODAS]

**VD20**

**Washing oneself [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in washing your whole body?

**VD21**

**Dressing [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in getting dressed?

**VD22**

**Eating [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in eating?

**VD23**

**Carrying out daily routine [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in staying by yourself for a few days?

Getting along [WHODAS]

**VD30**

**Relating with strangers [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in dealing with people you do not know?

**VD31**

**Informal relationship with friends - maintaining [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in maintaining a friendship?

**VD32**

**Family relationships [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in getting along with people who are close to you?

**VD33**

**Informal relationship with friends - making new friends [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in making new friends?

**VD34**

**Intimate relationships [WHODAS]**

Because of your health condition, in the past 30 days, how much difficulty did you have in sexual activities?

Life activities [WHODAS]

- VD40** **Taking care of household responsibilities [WHODAS]**  
Because of your health condition, in the past 30 days, how much difficulty did you have in taking care of your household responsibilities?
- VD41** **Doing most important household tasks [WHODAS]**  
Because of your health condition, in the past 30 days, how much difficulty did you have in doing most important household tasks well?
- VD42** **Doing housework [WHODAS]**
- VD42.0** **Getting all needed housework done [WHODAS]**  
Because of your health condition, in the past 30 days, how much difficulty did you have in getting all the household work done that you need to do?
- VD42.1** **Getting household work done quickly [WHODAS]**  
Because of your health condition, in the past 30 days, how much difficulty did you have in getting your household work done as quickly as needed?
- VD42.Y** **Other specified doing housework [WHODAS]**
- VD42.Z** **Doing housework [WHODAS], unspecified**
- VD43** **Remunerative employment [WHODAS]**
- VD43.0** **Difficulties in daily work or school [WHODAS]**  
Because of your health condition, in the past 30 days, how much difficulty did you have in your day to day work/school?
- VD43.1** **Doing most important work or school task [WHODAS]**  
Because of your health condition, in the past 30 days, how much difficulty did you have in doing your most important work/school tasks well?
- VD43.2** **Getting all needed work or school work done [WHODAS]**  
Because of your health condition, in the past 30 days, how much difficulty did you have in getting all the work done that you need to do?
- VD43.3** **Getting remunerative work or school work done quickly [WHODAS]**  
Because of your health condition, in the past 30 days, how much difficulty did you have in getting your work done as quickly as needed?
- VD43.Y** **Other specified remunerative employment [WHODAS]**
- VD43.Z** **Remunerative employment [WHODAS], unspecified**

Participation and impact of health problems [WHODAS]

**VD50**

**Recreation and leisure [WHODAS]**

In the past 30 days, how much of a problem did you have in joining in community activities (for example: festivities, religious or other activities) in the same way as anyone else can?

**VD51**

**Problems by barriers [WHODAS]**

In the past 30 days, how much of a problem did you have because of barriers or hindrances in the world around you?

**VD52**

**Human rights [WHODAS]**

In the past 30 days, how much of a problem did you have living with dignity because of the attitudes and actions of others?

**VD53**

**Time spent on health condition [WHODAS]**

In the past 30 days, how much time did you spend on your health condition, or its consequences?

**VD54**

**Emotional effect of health condition [WHODAS]**

In the past 30 days, how much have you been emotionally affected by your health condition?

**VD55**

**Health drain on financial resources [WHODAS]**

In the past 30 days, how much has your health been a drain on the financial resources of you or your family?

**VD56**

**Health problems causing family problems [WHODAS]**

In the past 30 days, how much of a problem did your family have because of your health problems?

**VD57**

**Problems in relaxation or pleasure [WHODAS]**

In the past 30 days, how much of a problem did you have in doing things by yourself for relaxation or pleasure?

## Brief Model Disability Survey

This subsection includes the domains and questions for use with the WHO Model Disability Survey (MDS) brief version. The brief MDS includes body functions as well as activities and participation categories. The brief MDS allows to generate an overall summary score of functioning.

**VE00**

**Seeing and related functions [BMDS]**

How much difficulty do you have seeing things at a distance [without glasses]?

**VE01**

**Hearing and vestibular functions [BMDS]**

How much difficulty do you have hearing [without hearing aids]?

Mental functions [BMDS]

- VE10      Energy and drive functions [BMDS]**
- VE11      Sleep functions [BMDS]**
- VE12      Emotional functions [BMDS]**
- VE13      Attention functions [BMDS]**
- VE14      Memory functions [BMDS]**

Sensory functions and pain [BMDS]

- VE20      Sensation of pain [BMDS]**

## Generic functioning domains

This subsection contains a generic set of functioning categories of high explanatory power derived from the ICF Annex 9.

Mental functions

This chapter is about the functions of the brain: both global mental functions, such as consciousness, energy and drive, and specific mental functions, such as memory, language and calculation mental functions.

- VV00      Energy and drive functions**

General mental functions of physiological and psychological mechanisms that cause the individual to move towards satisfying specific needs and general goals in a persistent manner.

**Exclusions:**      Consciousness functions (VV00-VV0Z)  
                          Emotional functions (VV04)  
                          Psychomotor functions (VV00-VV0Z)  
                          Sleep functions (VV01)  
                          Temperament and personality functions (VV00-VV0Z)

- VV01      Sleep functions**

General mental functions of periodic, reversible and selective physical and mental disengagement from one's immediate environment accompanied by characteristic physiological changes.

**Exclusions:**      Attention functions (VV02)  
                          Consciousness functions (VV00-VV0Z)  
                          Energy and drive functions (VV00)  
                          Psychomotor functions (VV00-VV0Z)

VV02

### Attention functions

Specific mental functions of focusing on an external stimulus or internal experience for the required period of time.

**Exclusions:** Consciousness functions (VV00-VV0Z)

Energy and drive functions (VV00)

Memory functions (VV03)

Perceptual functions (VV00-VV0Z)

Psychomotor functions (VV00-VV0Z)

Sleep functions (VV01)

VV03

### Memory functions

Specific mental functions of registering and storing information and retrieving it as needed.

**Inclusions:** immediate memory

recent memory

remote memory

memory span

remembering

**Exclusions:** Attention functions (VV02)

Calculation functions (VV00-VV0Z)

Consciousness functions (VV00-VV0Z)

Higher-level cognitive functions (VV00-VV0Z)

intellectual functioning (VV00-VV0Z)

Mental functions of language (VV00-VV0Z)

Orientation functions (VV00-VV0Z)

Perceptual functions (VV00-VV0Z)

Thought functions (VV00-VV0Z)

**VV04**

**Emotional functions**

Specific mental functions related to the feeling and affective components of the processes of the mind.

**Inclusions:**      affect

sadness

tension

lability of emotion

flattening of affect

**Exclusions:**      Energy and drive functions (VV00)

Temperament and personality functions (VV00-VV0Z)

**VV0Y**

**Other specified mental functions**

**VV0Z**

**Mental functions, unspecified**

Sensory functions and pain

This chapter is about the functions of the senses, seeing, hearing, tasting and so on, as well as the sensation of pain.

**VV10**

**Seeing and related functions**

**VV11**

**Hearing and vestibular functions**

**VV12**

**Sensation of pain**

Sensation of unpleasant feeling indicating potential or actual damage to some body structure.

**Inclusions:**      aching pain

burning pain

dull pain

sensations of generalized or localized pain

stabbing pain

**VV1Y**

**Other specified sensory functions and pain**

**VV1Z**

**Sensory functions and pain, unspecified**

Voice and speech functions

This chapter is about the functions of producing sounds and speech.

**VV20**

**Voice functions**

Functions of the production of various sounds by the passage of air through the larynx.

**Exclusions:**

Alternative vocalization functions (VV20-VV2Z)

Articulation functions (VV20-VV2Z)

Mental functions of language (VV00-VV0Z)

**VV2Y**

**Other specified voice and speech functions**

**VV2Z**

**Voice and speech functions, unspecified**

Functions of the cardiovascular, haematological, immunological and respiratory systems

This chapter is about the functions involved in the cardiovascular system (functions of the heart and blood vessels), the haematological and immunological systems (functions of blood production and immunity), and the respiratory system (functions of respiration and exercise tolerance).

**VV30**

**Exercise tolerance functions**

Functions related to respiratory and cardiovascular capacity as required for enduring physical exertion.

**Exclusions:**

additional respiratory functions (VV30-VV3Z)

Functions of the cardiovascular system (VV30-VV3Z)

Haematological system functions (VV30-VV3Z)

Respiration functions (VV30-VV3Z)

Respiratory muscle functions (VV30-VV3Z)

**VV3Y**

**Other specified functions of the cardiovascular, haematological, immunological and respiratory systems**

**VV3Z**

**Functions of the cardiovascular, haematological, immunological and respiratory systems, unspecified**

Functions of the digestive, metabolic and endocrine systems

This chapter is about the functions of ingestion, digestion and elimination, as well as functions involved in metabolism and the endocrine glands.

**VV40**

**Functions related to the digestive system**

**VV4Y**

**Other specified functions of the digestive, metabolic and endocrine systems**

**VV4Z**

**Functions of the digestive, metabolic and endocrine systems, unspecified**

Genitourinary and reproductive functions

This chapter is about the functions of urination and the reproductive functions, including sexual and procreative functions.

**VV50**

**Urination functions**

Functions of discharge of urine from the urinary bladder.

**Exclusions:**      Sensations associated with urinary functions (VV50-VV5Z)

Urinary excretory functions (VV50-VV5Z)

**VV51**

**Sexual functions**

Mental and physical functions related to the sexual act, including the arousal, preparatory, orgasmic and resolution stages.

**Exclusions:**      Procreation functions (VV50-VV5Z)

Sensations associated with genital and reproductive functions (VV50-VV5Z)

**VV5Y**

**Other specified genitourinary and reproductive functions**

**VV5Z**

**Genitourinary and reproductive functions, unspecified**

Neuromusculoskeletal and movement-related functions

This chapter is about the functions of movement and mobility, including functions of joints, bones, reflexes and muscles.

**VV60**

**Mobility of joint functions**

Functions of the range and ease of movement of a joint.

**Exclusions:**      Control of voluntary movement functions (VV60-VV6Z)

Stability of joint functions (VV60-VV6Z)

**VV61**

**Muscle power functions**

Functions related to the force generated by the contraction of a muscle or muscle groups.

**Exclusions:**      Functions of structures adjoining the eye (VV10)

Muscle endurance functions (VV60-VV6Z)

Muscle tone functions (VV60-VV6Z)

**VV6Y**

**Other specified neuromusculoskeletal and movement-related functions**

**VV6Z**

**Neuromusculoskeletal and movement-related functions, unspecified**

Functions of the skin and related structures

This chapter is about the functions of skin, nails and hair.

**VV70 Functions of the skin**

**VV7Y Other specified functions of the skin and related structures**

**VV7Z Functions of the skin and related structures, unspecified**

Learning and applying knowledge

This chapter is about learning, applying the knowledge that is learned, thinking, solving problems, and making decisions.

**VV80 Basic learning**

**VV81 Solving problems**

Finding solutions to questions or situations by identifying and analysing issues, developing options and solutions, evaluating potential effects of solutions, and executing a chosen solution, such as in resolving a dispute between two people.

**Exclusions:** Making decisions (VV80-VV8Z)

Thinking (VV80-VV8Z)

**VV8Y Other specified learning and applying knowledge**

**VV8Z Learning and applying knowledge, unspecified**

General tasks and demands

This chapter is about general aspects of carrying out single or multiple tasks, organizing routines and handling stress. These items can be used in conjunction with more specific tasks or actions to identify the underlying features of the execution of tasks under different circumstances.

**VV90 Carrying out daily routine**

Carrying out simple or complex and coordinated actions in order to plan, manage and complete the requirements of day-to-day procedures or duties, such as budgeting time and making plans for separate activities throughout the day.

**Exclusions:** Undertaking multiple tasks (VV90-VV9Z)

**VV91 Handling stress and other psychological demands**

Carrying out simple or complex and coordinated actions to manage and control the psychological demands required to carry out tasks demanding significant responsibilities and involving stress, distraction, or crises, such as taking exams, driving a vehicle during heavy traffic, finishing a task within a time-limit or taking responsibility for a group of individuals.

**VV9Y Other specified general tasks and demands**

**VV9Z General tasks and demands, unspecified**

## Communication

This chapter is about general and specific features of communicating by language, signs and symbols, including receiving and producing messages, carrying on conversations, and using communication devices and techniques.

**VW00**

### **Communicating with - receiving - spoken messages**

Comprehending literal and implied meanings of messages in spoken language, such as understanding that a statement asserts a fact or is an idiomatic expression.

**VW01**

### **Conversation**

Starting, sustaining and ending an interchange of thoughts and ideas, carried out by means of spoken, written, signed or other forms of language, with one or more people one knows or who are strangers, in formal or casual settings.

**VW0Y**

### **Other specified communication**

**VW0Z**

### **Communication, unspecified**

## Mobility

This chapter is about moving by changing body position or location or by transferring from one place to another, by carrying, moving or manipulating objects, by walking, running or climbing, and by using various forms of transportation.

**VW10**

### **Maintaining a standing position**

Staying in a standing position for some time such as when standing in a queue.

**Inclusions:**

staying in a standing position or hard surfaces

staying in a standing position on a slope

staying in a standing position on slippery surfaces

**VW11**

### **Transferring oneself**

Moving from one surface to another, such as sliding along a bench or moving from a bed to a chair, without changing body position.

**Exclusions:**

Changing basic body position (VW10-VW1Z)

**VW12**

### **Carrying, moving and handling objects**

**VW13**

### **Walking**

Moving along a surface on foot, step by step, so that one foot is always on the ground, such as when strolling, sauntering, walking forwards, backwards, or sideways.

**Exclusions:**

Moving around (VW10-VW1Z)

Transferring oneself (VW11)

**VW14**

### **Moving around within the home**

Walking and moving around in one's home, within a room, between rooms, and around the whole residence or living area.

- Inclusions:**
- moving from floor to floor
  - moving on an attached balcony
  - moving in a restricted area such as a courtyard, porch or garden

**VW15**

### **Moving around using equipment**

Moving the whole body from place to place, on any surface or space, by using specific devices designed to facilitate moving or create other ways of moving around, such as with skates, skis, or scuba equipment, or moving down the street in a self-propelled wheelchair or a walker.

- Exclusions:**
- Driving (VW10-VW1Z)
  - Moving around (VW10-VW1Z)
  - Transferring oneself (VW11)
  - Using transportation (VW16)
  - Walking (VW13)

**VW16**

### **Using transportation**

Using transportation to move around as a passenger, such as being driven in a car, bus, rickshaw, jitney, pram or stroller, wheelchair, animal-powered vehicle, private or public taxi, train, tram, subway, boat or aircraft and using humans for transportation.

- Exclusions:**
- Driving (VW10-VW1Z)
  - Moving around using equipment (VW15)

**VW1Y**

### **Other specified mobility**

**VW1Z**

### **Mobility, unspecified**

## **Self-care**

This chapter is about caring for oneself, washing and drying oneself, caring for one's body and body parts, dressing, eating and drinking, and looking after one's health.

**VW20**

### **Washing oneself**

Washing and drying one's whole body, or body parts, using water and appropriate cleaning and drying materials or methods, such as bathing, showering, washing hands and feet, face and hair, and drying with a towel.

- Exclusions:**
- Caring for body parts (VW21)
  - Toileting (VW22)

**VW21**

### **Caring for body parts**

Looking after those parts of the body, such as skin, face, teeth, scalp, nails and genitals, that require more than washing and drying.

**Exclusions:**      Toileting (VW22)

Washing oneself (VW20)

**VW22**

### **Toileting**

Planning and carrying out the elimination of human waste (menstruation, urination and defecation), and clean oneself afterwards.

**Exclusions:**      Caring for body parts (VW21)

Dressing (VW23)

Moving around within the home (VW14)

Walking (VW13)

Washing oneself (VW20)

**VW23**

### **Dressing**

Carrying out the coordinated actions and tasks of putting on and taking off clothes and footwear in sequence and in keeping with climatic and social conditions, such as by putting on, adjusting and removing shirts, skirts, blouses, pants, undergarments, saris, kimono, tights, hats, gloves, coats, shoes, boots, sandals and slippers.

**VW24**

### **Eating**

Carrying out the coordinated tasks and actions of eating food that has been served, bringing it to the mouth and consuming it in culturally acceptable ways, cutting or breaking food into pieces, opening containers and packets, using eating implements, having meals, feasting or dining.

**Exclusions:**      Drinking (VW20-VW2Z)

Preparing meals (VW30)

**VW25**

### **Looking after one's health**

Ensuring physical comfort, health and physical and mental well-being, such as by maintaining a balanced diet, and an appropriate level of physical activity, keeping warm or cool, avoiding harms to health, following safe sex practices, such as using condoms, getting immunizations and regular physical examinations.

**VW2Y**

### **Other specified self-care**

**VW2Z**

### **Self-care, unspecified**

## Domestic life

This chapter is about carrying out domestic and everyday actions and tasks. Areas of domestic life include caring for one's belongings and space, acquiring food, clothing and other necessities, household cleaning and repairing, caring for personal and other household objects, and assisting others.

VW30

### Preparing meals

Planning, organizing, cooking and serving simple and complex meals for oneself and others, such as by making a menu, selecting edible food and drink, getting together ingredients for preparing meals, cooking with heat and preparing cold foods and drinks, and serving the food.

**Exclusions:**

- Acquisition of goods and services (VW30-VW3Z)
- Caring for household objects (VW30-VW3Z)
- caring for others (VW32)
- Doing housework (VW31)
- Drinking (VW20-VW2Z)
- Eating (VW24)

VW31

### Doing housework

Managing a household by cleaning the house, washing clothes, using household appliances, storing food and disposing of garbage, such as by sweeping, mopping, washing counters, walls and other surfaces; collecting and disposing of household garbage; tidying rooms, closets and drawers; collecting, washing, drying, folding and ironing clothes; cleaning footwear; using brooms, brushes and vacuum cleaners; using washing machines, dryers and irons.

**Exclusions:**

- Acquiring a place to live (VW30-VW3Z)
- Acquisition of goods and services (VW30-VW3Z)
- Caring for household objects (VW30-VW3Z)
- caring for others (VW32)
- Preparing meals (VW30)

VW32

### Assisting others

Assisting household members and others with their learning, communicating, self-care, movement, within the house or outside; being concerned about the well-being of household members and others.

**Exclusions:**

- Remunerative employment (VW50)

VW3Y

### Other specified domestic life

VW3Z

### Domestic life, unspecified

## Interpersonal interactions and relationships

This chapter is about carrying out the actions and tasks required for basic and complex interactions with people (strangers, friends, relatives, family members and lovers) in a contextually and socially appropriate manner.

**VW40**

### **Basic interpersonal interactions**

Interacting with people in a contextually and socially appropriate manner, such as by showing consideration and esteem when appropriate, or responding to the feelings of others.

**VW41**

### **Relating with strangers**

Engaging in temporary contacts and links with strangers for specific purposes, such as asking for directions or making a purchase.

Engaging in temporary contacts and links with strangers for specific purposes, such as when asking for information, directions or making a purchase.

**VW42**

### **Intimate relationships**

Creating and maintaining close or romantic relationships between individuals, such as husband and wife, lovers or sexual partners.

**VW4Y**

### **Other specified interpersonal interactions and relationships**

**VW4Z**

### **Interpersonal interactions and relationships, unspecified**

## Major life areas

This chapter is about carrying out the tasks and actions required to engage in education, work and employment and to conduct economic transactions.

**VW50**

### **Remunerative employment**

Engaging in all aspects of work, as an occupation, trade, profession or other form of employment, for payment, as an employee, full or part time, or self-employed, such as seeking employment and getting a job, doing the required tasks of the job, attending work on time as required, supervising other workers or being supervised, and performing required tasks alone or in groups.

**VW5Y**

### **Other specified major life areas**

**VW5Z**

### **Major life areas, unspecified**

## Community, social and civic life

This chapter is about the actions and tasks required to engage in organized social life outside the family, in community, social and civic areas of life.

**VW60**

### **Recreation and leisure**

Engaging in any form of play, recreational or leisure pursuit, such as informal or organized play and sports, programmes of physical fitness, relaxation, amusement or diversion, going to art galleries, museums, cinemas or theatres; engaging in crafts or hobbies, reading or singing for enjoyment, playing musical instruments; sightseeings, tourism and travelling for pleasure.

**Exclusions:** Political life and citizenship (VW60-VW6Z)

Religion and spirituality (VW60-VW6Z)

remunerative and non-remunerative work ( and )  
(VW50-VW5Z)

Riding animals for transportation (VW10-VW1Z)

Reading (VV80-VV8Z)

Singing (VW00-VW0Z)

**VW61**

### **Human rights**

Enjoying all nationally and internationally recognized rights that are accorded to people by virtue of their humanity alone, such as human rights as recognized by the United Nations Universal Declaration of Human Rights (1948), the United Nations Convention on the Rights of the Child (1989), the United Nations Standard Rules for the Equalization of Opportunities for Persons with Disabilities (1993), and the United Nations Convention on the Rights of Persons with Disabilities (2006); the right to self-determination or autonomy; and the right to control over one's destiny.

**Exclusions:** Political life and citizenship (VW60-VW6Z)

**VW6Y**

### **Other specified community, social and civic life**

**VW6Z**

### **Community, social and civic life, unspecified**

---

**VW8Y**

### **Other specified generic functioning domains**

**VW8Z**

### **Generic functioning domains, unspecified**

# CHAPTER X

---

## Extension Codes

This chapter has 6928 four-character categories.

Code range starts with XS8H

Extension codes should never be used in primary classification coding or tabulation.

- They are provided for use as supplementary or additional codes when desired to identify more detail in statistical categories classified elsewhere.
- Extension codes may be used alone in other contexts.

**Coded Elsewhere:** Extension codes of particular relevance to skin diseases

This chapter contains the following top level blocks:

- Severity Scale Value
- Temporality
- Aetiology
- Topology Scale Value
- Anatomy and topography
- Histopathology
- Dimensions of injury
- Dimensions of external causes
- Consciousness
- Substances
- Diagnosis code descriptors
- Capacity or context
- Health Devices, Equipment and Supplies
- Extension codes of particular relevance to skin diseases

## Severity Scale Value

Generic Severity Scale Value

**Coded Elsewhere:** Basic 3-Value Severity Scale Value: Mild-Moderate-Severe

Clinical Severity Scale Value: Stage 1-2-3-4

Clinical Severity Scale Value: Stage 1-2-2a-2b-3-4

### Mild Moderate Severe Scale Value

<b>XS8H</b>	<b>None</b>
<b>XS5W</b>	<b>Mild</b>
<b>XS0T</b>	<b>Moderate</b>
<b>XS25</b>	<b>Severe</b>
<b>XS2R</b>	<b>Profound</b>

*Inclusions:* Complete

### Clinical Staging Scale Value

<b>XS7A</b>	<b>Stage 1</b>
<b>XS5S</b>	<b>Stage 2</b>
<b>XS4D</b>	<b>Stage 2a</b>
<b>XS6D</b>	<b>Stage 2b</b>
<b>XS00</b>	<b>Stage 3</b>
<b>XS3T</b>	<b>Stage 3a</b>
<b>XS90</b>	<b>Stage 3b</b>
<b>XS6G</b>	<b>Stage 4</b>
<b>XS9N</b>	<b>Stage 5</b>
<b>XS88</b>	<b>Stage 6</b>
<b>XS52</b>	<b>Stage 7</b>
<b>XS0G</b>	<b>Stage 8</b>
<b>XS2C</b>	<b>Stage 9</b>
<b>XS2X</b>	<b>Stage 10</b>

### Grading Scale Value

<b>XS24</b>	<b>Grade 0</b>
<b>XS6P</b>	<b>Grade 1</b>
<b>XS31</b>	<b>Grade 2</b>
<b>XS6F</b>	<b>Grade 3</b>
<b>XS0K</b>	<b>Grade 4</b>
<b>XS87</b>	<b>Grade 5</b>
<b>XS9M</b>	<b>Grade 6</b>
<b>XS5M</b>	<b>Grade 7</b>
<b>XS7F</b>	<b>Grade 8</b>
<b>XS8J</b>	<b>Grade 9</b>
<b>XS57</b>	<b>Grade 10</b>

### Phase Scale Value

<b>XS4A</b>	<b>Phase 0</b>
<b>XS3K</b>	<b>Phase 1</b>
<b>XS4M</b>	<b>Phase 2</b>
<b>XS8V</b>	<b>Phase 3</b>
<b>XS21</b>	<b>Phase 4</b>
<b>XS8Z</b>	<b>Phase 5</b>
<b>XS41</b>	<b>Phase 6</b>
<b>XS73</b>	<b>Phase 7</b>
<b>XS9Z</b>	<b>Phase 8</b>
<b>XS83</b>	<b>Phase 9</b>
<b>XS47</b>	<b>Phase 10</b>

### Problem Scale Value

<b>XS5C</b>	<b>0 No problem</b>
<b>XS6Y</b>	<b>1 Mild problem</b>
<b>XS8T</b>	<b>2 Moderate problem</b>

<b>XS9D</b>	<b>3 Severe problem</b>
<b>XS91</b>	<b>4 Complete problem</b>
<b>XS5P</b>	<b>9 Not applicable</b>

Disease Specific Severity Scale Value

Tumour spread simplified Scale Value

<b>XS0J</b>	<b>A Remission / Free of disease</b>
<b>XS05</b>	<b>B Local Disease</b>
<b>XS0E</b>	<b>Local limited</b>
<b>XS67</b>	<b>Locally advanced</b>
<b>XS9S</b>	<b>C Regional disease</b>
<b>XS4Z</b>	<b>D Distant disease</b>

Tumour spread staging Scale Value

<b>XS76</b>	<b>Stage 0</b>
<b>XS1G</b>	<b>Stage I</b>
<b>XS4P</b>	<b>Stage II</b>
<b>XS6H</b>	<b>Stage III</b>
<b>XS9R</b>	<b>Stage IV</b>

Histological Grading Scale Value

<b>XS56</b>	<b>Grade I</b>
	Well differentiated
<b>XS58</b>	<b>Grade II</b>
	Moderately differentiated
<b>XS7Z</b>	<b>Grade III</b>
	Poorly differentiated
<b>XS7M</b>	<b>Grade IV</b>
	Undifferentiated

**XS7H** **Undetermined grade**  
Grade cannot be assessed

#### NYHA Functional Classification: Class I-IV

- XS3A** **NYHA Class I - No limitation of physical activity**  
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnoea (shortness of breath).
- XS6B** **NYHA Class II - Slight limitation of physical activity**  
Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnoea (shortness of breath).
- XS9T** **NYHA Class III - Marked limitation of physical activity**  
Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation or dyspnoea.
- XS9F** **NYHA Class IV - Unable to carry on any physical activity without discomfort**  
Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

#### Chronic Obstructive Lung Disease Criteria: GOLD 1-4

- XS80** **GOLD 1 - mild:  $FEV1 \geq 80\% \text{ predicted}$**
- XS7U** **GOLD 2 - moderate:  $50\% \leq FEV1 < 80\% \text{ predicted}$**
- XS8K** **GOLD 3 - severe:  $30\% \leq FEV1 < 50\% \text{ predicted}$**
- XS50** **GOLD 4 - very severe:  $FEV1 < 30\% \text{ predicted}$**

#### Peripheral arterial disease (PAD) Severity Classification by Fontaine

- XS1Y** **Stage I: Asymptomatic, incomplete blood vessel obstruction**
- XS5L** **Stage II: Mild claudication pain in limb**
- XS5V** **Stage IIA: Claudication at a distance > 200 metres**
- XS6C** **Stage IIB: Claudication at a distance < 200 metres**
- XS9L** **Stage III: Rest pain, mostly in the feet**
- XS2J** **Stage IV: Necrosis and/or gangrene of the limb**

#### Endometriosis Severity Scale Value

- XS3V** **No endometriosis**

**XS5N**      **Filmy endometriosis**

**XS55**      **Dense endometriosis**

Vocal Cord Paralysis Severity Scale Value

**XS1H**      **Incomplete vocal cord paralysis**

**XS66**      **Partial vocal cord paralysis**

**XS7K**      **Complete vocal cord paralysis**

Sepsis Severity Scale Value

**XS5E**      **Mild sepsis**

**XS65**      **Severe sepsis**

**XS26**      **Septic shock**

Peripheral arterial disease (PAD) Severity Classification by Rutherford

**XS1T**      **Grade 0 Category 0: Asymptomatic -no hemodynamically significant occlusive disease**

Objective criteria: Normal treadmill or reactive hyperemia test

**XS0Q**      **Grade 0 Category 1: Mild claudication**

Objective criteria: Completes treadmill exercise; ankle pressure (AP) after exercise > 50 mm Hg but at least 20 mm Hg lower than resting value

**XS2W**      **Grade I Category 2: Moderate claudication**

Objective criteria: Between categories 1 and 3

**XS51**      **Grade I Category 3: Severe claudication**

Objective criteria: Cannot complete standard treadmill exercise, and ankle pressure (AP) after exercise < 50 mm Hg

**XS8M**      **Grade II Category 4: Ischaemic rest pain**

Objective criteria: Resting ankle pressure (AP) < 40 mm Hg, flat or barely pulsatile ankle or metatarsal pulse volume recording (PVR); toe pressure (TP) < 30 mm Hg

**XS6U**      **Grade III Category 5: Minor tissue loss - nonhealing ulcer, focal gangrene with diffuse pedal ischaemia**

Objective criteria: Resting ankle pressure (AP) < 60 mm Hg, ankle or metatarsal pulse volume recording (PVR) flat or barely pulsatile; toe pressure (TP) < 40 mm Hg

**XS0U**

**Grade III Category 6: Major tissue loss - extending above transmetatarsal (TM) level, functional foot no longer salvageable**

Objective criteria: Same as category 5.

## Pain Severity Scale Value

The chronic pain severity scale value is a compound measure comprised of pain intensity, pain-related distress, and pain-related interference. Each of this measures is a patient rating.

### Pain intensity

Pain intensity is defined as the strength of the subjective pain experience ("how much does the pain hurt?"). The patient should be asked to rate the average pain intensity for the last week on an 11-point numerical rating scale (ranging from 0 'no pain' to 10 'worst pain imaginable') or a 100 mm visual rating scale.

**XS5B**

**No pain**

Pain intensity rating NRS: 0

**XS5D**

**Mild pain**

Pain intensity rating NRS: 1-3

**XS9Q**

**Moderate pain**

Pain intensity rating NRS: 4-6

**XS2E**

**Severe pain**

Pain intensity rating NRS: 7-10

### Pain-related distress

Pain-related distress is defined as the multifactorial unpleasant emotional experience of a cognitive, behavioral, emotional, social, or spiritual nature due to the chronic pain ("how distressed are you by the pain?"). The patient should be asked to rate the average pain-related distress they experienced in the last week on an 11-point numerical rating scale (ranging from 0 'no pain-related distress' to 10 'extreme pain-related distress') or a 100mm visual rating scale.

**XS1J**

**No distress**

Pain-related distress rating NRS: 0

**XS3R**

**Mild distress**

Pain-related distress rating NRS: 1-3

**XS7C**

**Moderate distress**

Pain-related distress rating NRS: 4-6

**XS7N**

**Severe distress**

Pain-related distress rating NRS: 7-10

#### Pain-related interference

Pain-related interference is a measure for how much the pain interferes with daily activities and participation ("how much does the pain interfere with your life?"). The patient should be asked to rate the average pain-related interference they experienced in the last week on an 11-point numerical rating scale (ranging from 0 'no interference' to 10 'unable to carry on activities') or a 100mm visual rating scale.

<b>XS71</b>	<b>No pain-related interference</b> Pain-related interference rating NRS: 0
<b>XS5R</b>	<b>Mild pain-related interference</b> Pain-related interference rating NRS: 1-3
<b>XS2L</b>	<b>Moderate pain-related interference</b> Pain-related interference rating NRS: 4-6
<b>XS2U</b>	<b>Severe pain-related interference</b> Pain-related interference rating NRS: 7-10

#### Presence of psychosocial factors Scale Value

Use this extension code to code the presence or absence of problematic emotional (e.g., anger, fear), cognitive (e.g., excessive worry, catastrophizing), behavioral (e.g., avoidance) or social factors (eg, work, relationships) that accompany a given health condition (e.g., chronic pain). The code for the presence of psychosocial factors is appropriate when there is positive evidence that psychological or social factors contribute to the cause, the maintenance or the exacerbation of the health condition, or associated disability, or when the health condition results in negative psychobehavioral consequences (eg, demoralisation, hopelessness, avoidance, withdrawal). Assigning this extension code does not require a judgement regarding aetiological contributions or causal priorities.

<b>XS7G</b>	<b>Psychosocial factors present</b>
<b>XS8B</b>	<b>No psychosocial factors present</b>

#### Adult Nutritional Status Scale Value

<b>XS11</b>	<b>Underweight BMI Below 18.5 kg/m<sup>2</sup></b>
<b>XS43</b>	<b>Normal weight BMI 18.5–24.9 kg/m<sup>2</sup></b>
<b>XS7R</b>	<b>Pre-obesity BMI 25.0–29.9 kg/m<sup>2</sup></b>
<b>XS3Y</b>	<b>Obesity class I BMI 30.0–34.9 kg/m<sup>2</sup></b>
<b>XS6N</b>	<b>Obesity class II BMI 35.0–39.9 kg/m<sup>2</sup></b>
<b>XS2B</b>	<b>Obesity class III BMI greater than or equal to 40 kg/m<sup>2</sup></b>

## Coronary atherosclerosis Severity Scale Value

- XS2V      Single vessel disease**
- XS8U      Multiple vessel disease**

## Anaphylaxis Severity Scale Value

- XS09      Anaphylaxis grade 1**  
Anaphylaxis grade 1 is considered when there is a single organ system involved.
- XS59      Anaphylaxis grade 2**  
Anaphylaxis grade 2 is considered in cases of more than one organ system involvement; but not life-threatening.
- XS2Y      Anaphylaxis grade 3**  
Anaphylaxis grade 3 is considered in life-threatening cases with more than one organ system involved.
- XS85      Anaphylaxis grade 4**  
Anaphylaxis grade 4 is considered in life-threatening cases with cardiac arrest.

## Temporality

### Course of the Condition

### Pattern, Activity, or Clinical Status

#### Intermittent-Persistent Scale Value

- XT5G      Intermittent**
- XT6Z      Persistent**
- XT5T      Persistent with overlaid attacks**
- XT3B      Asymptomatic**
- XT1T      Subclinical**
- XT98      Active**
- XT7X      Episodic**
- XT4M      Prodromal**
- XT44      Recurrent**
- XT4D      Relapse**

**XT9C      Cause of late effect**  
A condition that results in a late effect.

## Course

**Coded Elsewhere:** Acute-Chronic Scale Value

Acute-Subacute-Chronic Scale Value

**XT5R      Acute**  
**XT1L      Subacute**  
**XT8W      Chronic**

## Onset

**XT2Q      Early onset**  
**XT46      Immediate onset**  
**XT3R      Late onset**  
**XT64      Delayed onset**  
**XT3Z      Rapid onset**  
Rapid or sudden onset of a condition/illness that requires more immediate and/or aggressive treatment  
**XT42      Gradual onset**

## Time in Life

**XT0S      Pregnancy**  
For the mother, the period of time between fertilization and parturition.  
**XT4Z      Postpartum**  
**XT1G      Puerperium**  
For the mother, the period of time that lasts from birth through the 42nd day of life for the child.  
**XT77      Antenatal - WHO Standard**  
For the fetus, the period of time between fertilization and parturition.  
**XT5L      Antenatal - Aus. Standard**  
**XT5P      Antenatal - Can. Standard**  
**XT04      Antenatal - Ger. Standard**

<b>XT9S</b>	<b>Antenatal - US Standard</b>
<b>XT16</b>	<b>Neonatal</b> The period of time from birth through the 28th day of life.
<b>XT6P</b>	<b>Early Neonatal</b> The period of time from birth through the seventh day of life.
<b>XT30</b>	<b>Late Neonatal</b> The period of time from the eighth through the 28th day of life.
<b>XT3N</b>	<b>Perinatal</b> The period of time between 22 weeks after fertilization and 7 days after parturition.
<b>XT2C</b>	<b>Infancy</b> The period of time between 29 and 365 days of life.
<b>XT4X</b>	<b>Child under 5</b> The period of time from the start of the 1st year of life through the end of the 4th.
<b>XT50</b>	<b>Child over 5</b> The period of time from the start of the 5th year of life through the end of the 14th
<b>XT9V</b>	<b>Middle Childhood</b> The period of time from the start of the 5th year of life through the end of the 10th.
<b>XT7Q</b>	<b>Early Adolescence</b> The period of time from the start of the 11th year of life through the end of the 14th
<b>XT7M</b>	<b>Adolescent</b> The period of time from the start of the 15th year of life through the end of the 19th.
<b>XT4T</b>	<b>Middle Adolescence</b> The period of time from the start of the 15th year of life through the end of the 17th.
<b>XT9X</b>	<b>Late Adolescence</b> The period of time from the start of the 18th year of life through the end of the 19th.
<b>XT15</b>	<b>Young Adult</b> The period of time from the start of the 20th year of life through the end of the 24th.
<b>XT6S</b>	<b>Adult</b> The period of time from the start of the 25th year of life through the end of the 64th.
<b>XT19</b>	<b>Early Geriatric</b> The period of time from the start of the 65th year of life through the end of the 84th year

**XT13****Late Geriatric**

The period of time from the start of the 85th year through the end of life.

**Duration of pregnancy**

Use as additional code, if desired, for cases of Abortive outcome of pregnancy, Threatened abortion, Fetal death in utero, Premature rupture of membranes (before 37 completed weeks of gestation), False labour before 37 completed weeks of gestation (threatened premature labour) and Preterm labour (early onset of labour).

**XT3X****Duration of pregnancy less than 5 completed weeks****XT09****Duration of pregnancy 5-13 completed weeks****XT65****Duration of pregnancy 14-19 completed weeks****XT5N****Duration of pregnancy 20-21 completed weeks****XT0T****Duration of pregnancy 20-25 completed weeks****XT4J****Duration of pregnancy 26-33 completed weeks****XT84****Duration of pregnancy 34-36 completed weeks****XT6G****Duration of pregnancy more than 36 completed weeks****XT6K****Unspecified duration of pregnancy**

Duration of pregnancy not specified

**Aetiology****Coded Elsewhere:** Allergens**Causality****XB8M****Congenital****XB8D****Iatrogenic****XB5F****Idiopathic****XB1Y****Familial****XB25****Nosocomial****Inclusions:** Hospital-acquired**XB4Q****Environmental****Occupational relevance****XB17****Occupation as primary factor**

<b>XB5G</b>	<b>Occupation as cofactor</b>
<b>XB80</b>	<b>Not occupation-related</b>
<b>XB5W</b>	<b>Life-style</b>
<b>XB22</b>	<b>Community acquired</b>
<b>XT9T</b>	<b>Ageing-related</b> Ageing-related means "caused by biological processes which persistently lead to the loss of organism's adaptation and progress in older ages"
<b>XB2G</b>	<b>Post traumatic</b>
<b>XB4S</b>	<b>Genetic</b>
<b>XB7K</b>	<b>Hereditary</b>
<b>XB7S</b>	<b>Non-hereditary</b>

#### Infectious Agents

<b>XN74M</b>	<b>Bacteria</b>
<b>XN5PZ</b>	<b>Gram Negative Bacteria</b>
<b>XN25B</b>	Acinetobacter
<b>XN8LS</b>	Acinetobacter baumannii
<b>XN5YN</b>	Acinetobacter junii
<b>XN0DS</b>	Acinetobacter nosocomialis
<b>XN2QH</b>	Acinetobacter pittii
<b>XN048</b>	Anaplasma
<b>XN1MH</b>	Anaplasma phagocytophilum
<b>XN3NJ</b>	Bartonella
<b>XN0W4</b>	Bartonella bacilliformis
<b>XN3F6</b>	Bartonella clarridgeiae
<b>XN5J5</b>	Bartonella elizabethae
<b>XN5SH</b>	Bartonella grahamii
<b>XN862</b>	Bartonella henselae
<b>XN302</b>	Bartonella koehlerae
<b>XN14D</b>	Bartonella quintana
<b>XN43H</b>	Bartonella rochalimae

<b>XN6KD</b>	Bartonella vinsonii
<b>XN94Y</b>	Bartonella washoensis
<b>XN9W3</b>	Bordetella
<b>XN173</b>	Bordetella bronchiseptica
<b>XN23B</b>	Bordetella pertussis
<b>XN7LQ</b>	Bordetella parapertussis
<b>XN22N</b>	Brucella
<b>XN7A8</b>	Brucella abortus
<b>XN84J</b>	Brucella canis
<b>XN7ZW</b>	Brucella melitensis
<b>XN3UP</b>	Brucella suis
<b>XN01M</b>	Burkholderia
<b>XN351</b>	Burkholderia gladioli
<b>XN6Y3</b>	Burkholderia mallei
<b>XN3LD</b>	Burkholderia pseudomallei
<b>XN335</b>	Burkholderia cepacia complex
<b>XN06D</b>	Burkholderia stabilis
<b>XN0ZW</b>	Burkholderia anthina
<b>XN15B</b>	Burkholderia contaminans
<b>XN7US</b>	Campylobacter
<b>XN0BA</b>	Campylobacter coli
<b>XN3EN</b>	Campylobacter fetus
<b>XN4Q5</b>	Campylobacter jejuni
<b>XN27H</b>	Chlamydia
<b>XN9EE</b>	Chlamydia pneumoniae
<b>XN4S7</b>	Chlamydia psittaci
<b>XN4Q4</b>	Chlamydia trachomatis
<b>XN0FZ</b>	Citrobacter
<b>XN0M3</b>	Citrobacter freundii
<b>XN5H6</b>	Coxiella

<b>XN0QS</b>	<i>Coxiella burnetii</i>
<b>XN9M7</b>	<i>Ehrlichia</i>
<b>XN293</b>	<i>Ehrlichia canis</i>
<b>XN4GW</b>	<i>Ehrlichia chaffeensis</i>
<b>XN2YH</b>	<i>Ehrlichia ewingii</i>
<b>XN1VF</b>	<i>Eikenella</i>
<b>XN9W5</b>	<i>Enterobacter</i>
<b>XN3YM</b>	<i>Enterobacter cloacae</i>
<b>XN4WC</b>	<i>Escherichia</i>
<b>XN6P4</b>	<i>Escherichia coli</i>
<b>XN88S</b>	<i>Enteroinvasive Escherichia coli</i>
<b>XN2U0</b>	<i>Enteropathogenic Escherichia coli</i>
<b>XN81Z</b>	<i>Enterotoxigenic Escherichia coli</i>
<b>XN108</b>	<i>Shiga toxin-producing Escherichia coli</i>
<b>XN5NF</b>	<i>Enterohaemorrhagic Escherichia coli</i>
<b>XN55V</b>	<i>Enteroaggregative Escherichia coli</i>
<b>XN6MP</b>	<i>Escherichia hermannii</i>
<b>XN2S7</b>	<i>Pseudescherichia vulneris</i>
<b>XN94G</b>	<i>Francisella</i>
<b>XN6HJ</b>	<i>Francisella philomiragia</i>
<b>XN0BX</b>	<i>Francisella tularensis</i>
<b>XN4ZY</b>	<i>Francisella novicida</i>
<b>XN4LF</b>	<i>Fusobacterium</i>
<b>XN7B1</b>	<i>Fusobacterium necrophorum</i>
<b>XN5MA</b>	<i>Fusobacterium novum</i>
<b>XN4P8</b>	<i>Fusobacterium nucleatum</i>
<b>XN911</b>	<i>Fusobacterium polymorphum</i>
<b>XN2HK</b>	<i>Haemophilus</i>
<b>XN6MB</b>	<i>Haemophilus ducreyi</i>
<b>XN1P6</b>	<i>Haemophilus influenzae</i>

<b>XN1BX</b>	Haemophilus influenzae aegyptius
<b>XN0FG</b>	Haemophilus influenzae type B
<b>XN6XR</b>	Helicobacter
<b>XN0YS</b>	Helicobacter bilis
<b>XN0TD</b>	Helicobacter bizzozeronii
<b>XN42L</b>	Helicobacter canis
<b>XN354</b>	Helicobacter cinaedi
<b>XN6JN</b>	Helicobacter felis
<b>XN9X3</b>	Helicobacter ganmani
<b>XN8PN</b>	Helicobacter hepaticus
<b>XN3DY</b>	Helicobacter pylori
<b>XN9D7</b>	Helicobacter salomonis
<b>XN079</b>	Helicobacter suis
<b>XN620</b>	Klebsiella
<b>XN027</b>	Klebsiella granulomatis
<b>XN7WL</b>	Klebsiella oxytoca
<b>XN741</b>	Klebsiella pneumoniae
<b>XN7EJ</b>	Kingella kingae
<b>XN3SZ</b>	Legionella
<b>XN14Z</b>	Legionella longbeachae
<b>XN9YS</b>	Legionella pneumophila
<b>XN9RA</b>	Leptospira
<b>XN1R8</b>	Leptospira alexanderi
<b>XN7D2</b>	Leptospira borgpetersenii
<b>XN9K9</b>	Leptospira broomii
<b>XN5HC</b>	Leptospira fainei
<b>XN20F</b>	Leptospira inadai
<b>XN78P</b>	Leptospira interrogans
<b>XN110</b>	Leptospira kirschneri
<b>XN481</b>	Leptospira kmetyi

<b>XN6NU</b>	Leptospira licerasiae
<b>XN4KP</b>	Leptospira noguchii
<b>XN01X</b>	Leptospira santarosai
<b>XN4FL</b>	Leptospira species
<b>XN4E7</b>	Leptospira weilii
<b>XN77E</b>	Leptospira wolffii
<b>XN5UB</b>	Leptospira genomospecies 1 (alstonii)
<b>XN2JD</b>	Leptotrichia
<b>XN734</b>	Leptotrichia buccalis
<b>XN4GY</b>	Leptotrichia goodfellowii
<b>XN0SF</b>	Leptotrichia hofstadii
<b>XN4SA</b>	Leptotrichia hongkongensis
<b>XN7NF</b>	Leptotrichia shahii
<b>XN6QY</b>	Leptotrichia trevisanii
<b>XN5SN</b>	Leptotrichia wadei
<b>XN90V</b>	Moraxella
<b>XN8G6</b>	Morganella
<b>XN1W2</b>	Mycoplasma
<b>XN3NR</b>	Mycoplasma fermentans
<b>XN9UG</b>	Mycoplasma genitalium
<b>XN674</b>	Mycoplasma hyorhinis
<b>XN3AD</b>	Mycoplasma penetrans
<b>XN4NV</b>	Mycoplasma pneumoniae
<i>Inclusions:</i> Pleuro-pneumonia-like-organism [PPLO]	
<b>XN69X</b>	Neisseria
<b>XN59Y</b>	Neisseria gonorrhoeae
<b>XN1DV</b>	Neisseria meningitidis
<b>XN3CR</b>	Neisseria meningitidis serogroup A
<b>XN8FU</b>	Neisseria meningitidis serogroup B
<b>XN7EM</b>	Neisseria meningitidis serogroup C

<b>XN03X</b>	<i>Neisseria meningitidis</i> serogroup W
<b>XN0C2</b>	<i>Neisseria meningitidis</i> serogroup X
<b>XN5H0</b>	<i>Neisseria meningitidis</i> serogroup Y
<b>XN8ST</b>	<i>Neorickettsia</i>
<b>XN7C8</b>	<i>Neorickettsia sennetsu</i>
<b>XN3U2</b>	<i>Pasteurella</i>
<b>XN30D</b>	<i>Pasteurella multocida</i>
<b>XN1ZM</b>	<i>Pleisiomonas</i>
<b>XN3BS</b>	<i>Proteus</i>
<b>XN9ZF</b>	<i>Proteus mirabilis</i>
<b>XN9DS</b>	<i>Proteus morganii</i>
<b>XN7PE</b>	<i>Proteus penneri</i>
<b>XN118</b>	<i>Proteus vulgaris</i>
<b>XN7R2</b>	<i>Providencia</i>
<b>XN2PG</b>	<i>Providencia rettgeri</i>
<b>XN022</b>	<i>Pseudomonas</i>
<b>XN5L6</b>	<i>Pseudomonas aeruginosa</i>
<b>XN3JP</b>	<i>Pseudomonas oryzihabitans</i>
<b>XN52E</b>	<i>Pseudomonas mallei</i>
<b>XN8J7</b>	<i>Pseudomonas plecoglossicida</i>
<b>XN8AA</b>	<i>Pseudomonas pseudomallei</i>
<b>XN4YH</b>	<i>Rickettsia</i>
<b>XN9YP</b>	<i>Rickettsia africae</i>
<b>XN7WV</b>	<i>Rickettsia akari</i>
<b>XN23V</b>	<i>Rickettsia australis</i>
<b>XN8U4</b>	<i>Rickettsia conorii</i>
<b>XN6W8</b>	<i>Rickettsia felis</i>
<b>XN9NE</b>	<i>Rickettsia helvetica</i>
<b>XN5NY</b>	<i>Rickettsia hoogstraalii</i>
<b>XN3XV</b>	<i>Rickettsia japonica</i>

<b>XN8SY</b>	Rickettsia prowazekii
<b>XN33Q</b>	Rickettsia rickettsii
<b>XN1N6</b>	Rickettsia sibirica
<b>XN2AR</b>	Rickettsia typhi
<b>XN0QE</b>	Salmonellae
<b>XN5VC</b>	Salmonella enterica spp.
<b>XN0UV</b>	Salmonella Paratyphi
<b>XN1K5</b>	Salmonella paratyphi A
<b>XN322</b>	Salmonella paratyphi B
<b>XN5TR</b>	Salmonella paratyphi C
<b>XN4AM</b>	Salmonella Typhi
<b>XN7U5</b>	Salmonella Panama
<b>XN97K</b>	Salmonella Weltevreden
<b>XN13V</b>	Salmonella Wandsworth
<b>XN3DF</b>	Salmonella Virchow
<b>XN4QY</b>	Salmonella Give
<b>XN3AE</b>	Salmonella Gaminara
<b>XN0N5</b>	Salmonella Agona
<b>XN5SM</b>	Salmonella Kiambu
<b>XN3TU</b>	Salmonella Thompson
<b>XN15L</b>	Salmonella Typhimurium
<b>XN8SF</b>	Salmonella Saintpaul
<b>XN2MU</b>	Salmonella Stanley
<b>XN0LX</b>	Salmonella Strathcona
<b>XN5WE</b>	Salmonella Senftenberg
<b>XN291</b>	Salmonella Tennessee
<b>XN87G</b>	Salmonella Newport
<b>XN5TM</b>	Salmonella Hartford
<b>XN1QX</b>	Salmonella Oranienburg
<b>XN2SZ</b>	Salmonella Poona

<b>XN36N</b>	Salmonella Kedougou
<b>XN5LV</b>	Salmonella Litchfield
<b>XN4LH</b>	Salmonella Mbandaka
<b>XN1FK</b>	Salmonella Montevideo
<b>XN3UH</b>	Salmonella Mikawasima
<b>XN7QM</b>	Salmonella Concord
<b>XN8RF</b>	Salmonella Cubana
<b>XN39C</b>	Salmonella Infantis
<b>XN6JL</b>	Salmonella Havana
<b>XN1W7</b>	Salmonella Enteritidis
<b>XN0Q7</b>	Salmonella Bareilly
<b>XN4MS</b>	Salmonella Braenderup
<b>XN3KA</b>	Salmonella Brandenburg
<b>XN0NU</b>	Salmonella Choleraesuis
<b>XN910</b>	Salmonella Bredeney
<b>XN52S</b>	Salmonella Nchanga
<b>XN8F6</b>	Salmonella Lille
<b>XN7EC</b>	Salmonella Sandiego
<b>XN2DJ</b>	Salmonella enterica subspecies enterica serovar 4,5,12:i:-
<b>XN7PN</b>	Salmonella enterica subspecies enterica serovar 4,[5],12:i:-
<b>XN2DW</b>	Salmonella bongori spp
<b>XN71D</b>	Serratia spp
<b>XN2V6</b>	Serratia marcescens
<b>XN7HG</b>	Shigella spp
<b>XN7Y2</b>	Shigella flexneri
<b>XN8RN</b>	Shigella boydii
<b>XN285</b>	Shigella dysenteriae
<b>XN9M9</b>	Shigella sonnei
<b>XN23Z</b>	Spirillum
<b>XN0J7</b>	Spirillum minus

<b>XN78V</b>	<i>Spirillum pulli</i>
<b>XN17K</b>	<i>Spirillum volutans</i>
<b>XN96A</b>	<i>Spirillum winogradskyi</i>
<b>XN708</b>	<i>Streptobacillus</i>
<b>XN91U</b>	<i>Streptobacillus moniliformis</i>
<b>XN1L0</b>	<i>Stenotrophomonas</i>
<b>XN0AD</b>	<i>Stenotrophomonas maltophilia</i>
<b>XN36C</b>	<i>Treponema</i>
<b>XN76V</b>	<i>Treponema carateum</i>
<b>XN711</b>	<i>Treponema pallidum</i>
<b>XN6AL</b>	<i>Treponema pallidum carateum</i>
<b>XN35Z</b>	<i>Treponema pallidum endemicum</i>
<b>XN030</b>	<i>Treponema pallidum pallidum</i>
<b>XN46P</b>	<i>Treponema pallidum pertenue</i>
<b>XN1R2</b>	<i>Ureaplasma</i>
<b>XN8RL</b>	<i>Vibrio</i>
<b>XN7N1</b>	<i>Vibrio cholerae</i>
<b>XN8P1</b>	<i>Vibrio cholerae O1, biovar cholerae</i>
<b>XN62R</b>	<i>Vibrio cholerae O1, biovar eltor</i>
<b>XN8KD</b>	<i>Vibrio cholerae O139</i>
<b>XN1AA</b>	<i>Vibrio parahaemolyticus</i>
<b>XN44G</b>	<i>Vibrio vulnificus</i>
<b>XN4QG</b>	<i>Yersinia</i>
<b>XN91V</b>	<i>Yersinia enterocolitica</i>
<b>XN6QS</b>	<i>Yersinia pestis</i>
<b>XN6K8</b>	<i>Yersinia pseudotuberculosis</i>
<b>XN65H</b>	<i>Bacteroides</i>
<b>XN2R7</b>	<i>Bacteroides fragilis</i>
<b>XN9EB</b>	<i>Cronobacter</i>
<b>XN2YF</b>	<i>Cronobacter sakazakii</i>

<b>XN9AS</b>	Brevundimonas
<b>XN8W4</b>	Brevundimonas diminuta
<b>XN2F0</b>	Brevundimonas vesicularis
<b>XN1J7</b>	Aeromonas
<b>XN40Z</b>	Aeromonas hydrophila
<b>XN0XY</b>	Aeromonas caviae
<b>XN4X0</b>	Herbaspirillum
<b>XN7QA</b>	Herbaspirillum huttiense
<b>XN706</b>	Elizabethkingia
<b>XN6BA</b>	Elizabethkingia anophelis
<b>XN6C4</b>	Elizabethkingia meningoseptica
<b>XN15X</b>	Ralstonia
<b>XN6AH</b>	Ralstonia picketti
<b>XN694</b>	Ralstonia mannitololytica
<b>XN9VM</b>	Ralstonia insidiosa
<b>XN3NY</b>	Raoultella
<b>XN0MD</b>	Raoultella ornithinolytica
<b>XN6PA</b>	Orientia
<b>XN675</b>	Orientia tsutsugamushi
<b>XN2QM</b>	<b>Gram Positive Bacteria</b>
<b>XN3G0</b>	Actinomyces
<b>XN0GV</b>	Actinomyces gerencseriae
<b>XN15T</b>	Actinomyces israelii
<b>XN8HN</b>	Actinomyces species
<b>XN8EK</b>	Actinomycetales
<b>XN8P7</b>	Actinomadura
<b>XN9ZE</b>	Bacillus
<b>XN94F</b>	Bacillus anthracis
<b>XN8PY</b>	Bacillus cereus
<b>XN33F</b>	Bifidobacterium

<b>XN0PT</b>	<i>Bifidobacterium dentium</i>
<b>XN198</b>	<i>Clostridium</i>
<b>XN2JN</b>	<i>Clostridium botulinum</i>
<b>XN7J5</b>	<i>Clostridium perfringens</i>
<b>XN4LP</b>	<i>Clostridium sordellii</i>
<b>XN5NQ</b>	<i>Clostridium tetani</i>
<b>XN3NT</b>	<i>Corynebacterium</i>
<b>XN9N1</b>	<i>Corynebacterium diphtheriae</i>
<b>XN78S</b>	<i>Corynebacterium minutissimum</i>
<b>XN752</b>	<i>Corynebacterium striatum</i>
<b>XN3MP</b>	<i>Corynebacterium tenuis</i>
<b>XN1F7</b>	<i>Enterococcus</i>
<b>XN2H4</b>	<i>Enterococcus faecalis</i>
<b>XN51E</b>	<i>Enterococcus faecium</i>
<b>XN0DT</b>	<i>Enterococcus avium</i>
<b>XN3XY</b>	<i>Enterococcus casseliflavus</i>
<b>XN724</b>	<i>Enterococcus durans</i>
<b>XN8BQ</b>	<i>Enterococcus gallinarum</i>
<b>XN4ZZ</b>	<i>Enterococcus mundtii</i>
<b>XN3QK</b>	<i>Enterococcus raffinosus</i>
<b>XN494</b>	<i>Erysipelothrix</i>
<b>XN4FJ</b>	<i>Erysipelothrix rhusiopathiae</i>
<b>XN4D1</b>	<i>Listeria</i>
<b>XN39H</b>	<i>Listeria ivanovii</i>
<b>XN602</b>	<i>Listeria monocytogenes</i>
<b>XN20K</b>	<i>Nocardia</i>
<b>XN2BK</b>	<i>Nocardia asteroides</i>
<b>XN1LG</b>	<i>Nocardia brasiliensis</i>
<b>XN5M7</b>	<i>Propionibacterium</i>
<b>XN27L</b>	<i>Propionibacterium propionicus</i>

<b>XN9ZG</b>	Staphylococcus
<b>XN6BM</b>	Staphylococcus aureus
<b>XN4B5</b>	Panton-Valentine Leukocidin-producing Staphylococcus aureus
<b>XN0PR</b>	Staphylococcus auricularis
<b>XN0H1</b>	Staphylococcus capitis
<b>XN99G</b>	Staphylococcus caprae
<b>XN95B</b>	Staphylococcus cohnii
<b>XN8KJ</b>	Staphylococcus epidermidis
<b>XN2GD</b>	Staphylococcus haemolyticus
<b>XN09P</b>	Staphylococcus leei
<b>XN4N7</b>	Staphylococcus lugdunensis
<b>XN8WC</b>	Staphylococcus pasteurii
<b>XN6FH</b>	Staphylococcus pettenkoferi
<b>XN9X8</b>	Staphylococcus schleiferi
<b>XN2HN</b>	Staphylococcus sciuri
<b>XN7RE</b>	Staphylococcus simulans
<b>XN4C9</b>	Staphylococcus warneri
<b>XN7TQ</b>	Staphylococcus xylosus
<b>XN567</b>	Staphylococcus hominis
<b>XN3NM</b>	Streptococcus
<b>XN1V3</b>	Alpha-hemolytic Streptococcus
<b>XN3PW</b>	Streptococcus pneumoniae This is a Gram-positive, alpha-hemolytic, aerotolerant anaerobic member of the genus Streptococcus. This diagnosis is as the cause of diseases classified to other chapters.
<b>XN9LA</b>	Streptococcus viridans
<b>XN1AF</b>	Beta-haemolytic Streptococcus
<b>XN2NS</b>	Gamma-haemolytic Streptococcus
<b>XN6LP</b>	Streptococcus, group A Streptococcus is a genus of spherical Gram-positive bacteria belonging to the phylum Firmicutes and the lactic acid bacteria group.
<b>XN7YG</b>	Streptococcus pyogenes

<b>XN2M1</b>	Streptococcus, group B Streptococcus is a genus of spherical Gram-positive bacteria belonging to the phylum Firmicutes and the lactic acid bacteria group.
<b>XN0KC</b>	Streptococcus agalactiae
<b>XN518</b>	Group C Streptococcus
<b>XN0TY</b>	Streptococcus zooepidemicus
<b>XN5KC</b>	Streptococcus, group D Streptococcus is a genus of spherical Gram-positive bacteria belonging to the phylum Firmicutes and the lactic acid bacteria group.
<b>XN6KJ</b>	Streptococcus bovis
<b>XN625</b>	Streptococcus equinus
<b>XN8BJ</b>	Group E Streptococcus
<b>XN6BB</b>	Group F Streptococcus
<b>XN84N</b>	Group G Streptococcus
<b>XN8UN</b>	Streptococcus dysgalactiae
<b>XN40Y</b>	Group H Streptococcus
<b>XN39R</b>	Streptococcus anginosus
<b>XN3L7</b>	Streptococcus canis
<b>XN0FR</b>	Streptococcus constellatus
<b>XN4PA</b>	Streptococcus iniae
<b>XN67P</b>	Streptococcus intermedius
<b>XN5BP</b>	Streptococcus mitis
<b>XN2RH</b>	Streptococcus mutans
<b>XN4B2</b>	Streptococcus oralis
<b>XN18T</b>	Streptococcus parasanguinis
<b>XN58W</b>	Streptococcus peroris
<b>XN6KE</b>	Streptococcus pseudopneumoniae
<b>XN5DB</b>	Streptococcus ratti
<b>XN3BQ</b>	Streptococcus salivarius
<b>XN9FP</b>	Streptococcus sanguinis
<b>XN0XM</b>	Streptococcus sobrinus
<b>XN5SE</b>	Streptococcus suis

<b>XN4LM</b>	Streptococcus thermophilus
<b>XN1TV</b>	Streptococcus uberis
<b>XN0Z2</b>	Streptococcus vestibularis
<b>XN7PP</b>	Tropheryma
<b>XN5P4</b>	Tropheryma whipplei
<b>XN0SE</b>	Clostridioides difficile
<b>XN87X</b>	<b>Bacteria, neither Gram Negative nor Gram Positive</b>
<b>XN2DX</b>	Borrelia
<b>XN7GL</b>	Borrelia afzelii
<b>XN13C</b>	Borrelia burgdorferi
<b>XN4VZ</b>	Borrelia garinii
<b>XN3PD</b>	Borrelia hermsii
<b>XN2P3</b>	Borrelia miyamotoi
<b>XN6VH</b>	Borrelia parkeri
<b>XN5R4</b>	Borrelia recurrentis
<b>XN140</b>	Borrelia vincentii
<b>XN2NR</b>	Mycobacterium
<b>XN6YB</b>	Mycobacterium africanum
<b>XN8AB</b>	Mycobacterium bovis
<b>XN8N3</b>	Mycobacterium canetti
<b>XN4MR</b>	Mycobacterium caprae
<b>XN9H9</b>	Mycobacterium colombiense
<b>XN8FC</b>	Mycobacterium indicus pranii
<b>XN5TS</b>	Mycobacterium leprae
<b>XN3T2</b>	Mycobacterium microti
<b>XN7H2</b>	Mycobacterium pinnipedii
<b>XN1N2</b>	Mycobacterium tuberculosis
<b>XN96Q</b>	Non-tuberculous mycobacterium
<b>XN3L9</b>	Mycobacterium kansasii
<b>XN5C1</b>	Mycobacterium malmoense

<b>XN53D</b>	Mycobacterium xenopi
<b>XN6PL</b>	Mycobacterium asiaticum
<b>XN4MW</b>	Mycobacterium simiae
<b>XN975</b>	Mycobacterium szulgai
<b>XN74T</b>	Mycobacterium scrofulaceum
<b>XN7YR</b>	Mycobacterium haemophilum
<b>XN8ZX</b>	Mycobacterium fortuitum
<b>XN8RB</b>	Mycobacterium marinum
<b>XN9M0</b>	Mycobacterium ulcerans
<b>XN3D3</b>	Mycobacterium chelonei
<b>XN97H</b>	Mycobacterium avium complex
<b>XN5LZ</b>	Mycobacterium avium
<b>XN8FF</b>	Mycobacterium avium hominissuis
<b>XN5NW</b>	Mycobacterium avium paratuberculosis
<b>XN145</b>	Mycobacterium avium silvaticum
<b>XN3ZQ</b>	Mycobacterium intracellulare
<b>XN077</b>	Mycobacterium chimaera
<b>XN4TQ</b>	Mycobacterium abscessus complex
<b>XN7V4</b>	Mycobacterium abscessus subsp. abscessus
<b>XN5SW</b>	Mycobacterium abscessus subsp. massiliense
<b>XN017</b>	Mycobacterium abscessus subsp. bolletii
<b>XN44M</b>	Mycobacterium chelonae

**XN3BH**      **Virus**

**XN000**      **Adenovirus**

Adenovirus infections most commonly cause illness of the respiratory system; however, depending on the infecting serotype, they may also cause various other illnesses and presentations.

<b>XN0R0</b>	Atadenovirus
<b>XN05K</b>	Aviadenovirus
<b>XN728</b>	Ichtadenovirus
<b>XN93P</b>	Mastadenovirus

<b>XN13L</b>	Siadenovirus
<b>XN6ME</b>	<b>Alphavirus</b>
<b>XN0SK</b>	Aura virus
<b>XN434</b>	Babanki virus
<b>XN5KQ</b>	Barmah Forest virus
<b>XN6XS</b>	Bebaru virus
<b>XN0UF</b>	Cabassou virus
<b>XN4ZB</b>	Chikungunya virus
<b>XN78T</b>	Eastern equine encephalitis virus
<b>XN26A</b>	Everglades virus
<b>XN87D</b>	Kyzylagach virus
<b>XN5ZC</b>	Mayaro virus
<b>XN1VS</b>	Middleburg virus
<b>XN34P</b>	Mosso das Pedras virus
<b>XN7PD</b>	Mucambo virus
<b>XN0H9</b>	Ndumu virus
<b>XN9WS</b>	Ockelbo virus
<b>XN6AD</b>	o'nyong nyong virus
<b>XN240</b>	Paramana virus
<b>XN3YZ</b>	Pixuna virus
<b>XN79Q</b>	Río Negro virus
<b>XN49A</b>	Ross River virus
<b>XN4D3</b>	Salmon pancreatic disease virus
<b>XN3D4</b>	Semliki Forest virus
<b>XN0D6</b>	Sindbis virus
<b>XN132</b>	Sleeping Disease virus
<b>XN5MK</b>	Southern elephant seal virus
<b>XN4ER</b>	Tonate virus
<b>XN2B3</b>	Trocara virus
<b>XN445</b>	Venezuelan equine encephalitis virus

<b>XN8PC</b>	Whataroa virus
<b>XN2CK</b>	Western equine encephalitis virus
<b>XN1BE</b>	<b>Arbovirus</b>
<b>XN5VQ</b>	La Crosse virus
<b>XN8AC</b>	<b>Arenavirus</b>
<b>XN2WG</b>	Chapare virus
<b>XN56K</b>	Guanarito virus
<b>XN2ZL</b>	Junín virus
<b>XN0CU</b>	Lassa virus
<b>XN77P</b>	Lujo virus
<b>XN4ZL</b>	Lymphocytic choriomeningitis virus
<b>XN45B</b>	Machupo virus
<b>XN55S</b>	Sabiá virus
<b>XN5VM</b>	<b>Bornavirus</b>
<b>XN395</b>	Borna disease virus 1
<b>XN125</b>	variegated squirrel bornavirus 1
<b>XN7S5</b>	<b>Bunyavirus</b>
<b>XN9UC</b>	Amur virus
<b>XN17V</b>	Crimean-Congo haemorrhagic fever virus
<b>XN16H</b>	Dobrava virus
<b>XN2QZ</b>	gōu virus
<b>XN3GW</b>	Hantaan virus
<b>XN8UR</b>	Kurkino virus
<b>XN8AF</b>	Muju virus
<b>XN4S8</b>	Orthobunyavirus
<b>XN09U</b>	Cristoli virus
<b>XN4U2</b>	Oropouche orthobunyavirus
<b>XN28L</b>	Puumala virus
<b>XN9PD</b>	Saaremaa virus
<b>XN3PV</b>	Seoul virus

<b>XN95V</b>	Sochi virus
<b>XN0E0</b>	Soochong virus
<b>XN9G5</b>	Tula virus
<b>XN2VY</b>	Anajatuba virus
<b>XN4AP</b>	Andes virus
<b>XN2C8</b>	Araucária virus
<b>XN2WJ</b>	bayou virus
<b>XN0A0</b>	Bermejo virus
<b>XN66E</b>	Black Creek Canal virus
<b>XN8LW</b>	Blue River virus
<b>XN18Y</b>	Castelo dos Sonhos virus
<b>XN6XF</b>	El Moro Canyon virus
<b>XN8G9</b>	Juquitiba virus
<b>XN6P0</b>	Laguna Negra virus
<b>XN2CJ</b>	Lechiguanas virus
<b>XN2BW</b>	Maciel virus
<b>XN3WK</b>	Monongahela virus
<b>XN5SF</b>	Muleshoe virus
<b>XN9VX</b>	New York virus
<b>XN9BY</b>	Orán virus
<b>XN5JV</b>	Paranoá virus
<b>XN65X</b>	Pergamino virus
<b>XN2VC</b>	Río Mamoré virus
<b>XN7R1</b>	sin nombre virus
<b>XN057</b>	Tunari virus
<b>XN8AQ</b>	Araraquara virus
<b>XN5VU</b>	Phlebovirus
<b>XN2YW</b>	Punta Toro virus
<b>XN7AS</b>	Rift Valley fever phlebovirus
<b>XN72W</b>	Sicilian phlebovirus

<b>XN7FG</b>	Naples phlebovirus
<b>XN3V9</b>	Toscana phlebovirus
<b>XN3BT</b>	Dabie bandavirus
<b>XN9RK</b>	<b>Calicivirus</b>
<b>XN4EB</b>	Lagovirus
<b>XN8L1</b>	Nebovirus
<b>XN3Y2</b>	Norovirus
<b>XN9EH</b>	Sapovirus
<b>XN0R6</b>	Vesivirus
<b>XN83D</b>	<b>Coronavirus</b>
	These are species in the genera of virus belonging to the subfamily Coronavirinae in the family Coronaviridae. Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. This diagnosis is as the cause of diseases classified to other chapters.
<b>XN0UA</b>	Human coronavirus 229E
<b>XN9KN</b>	Human coronavirus HKU1
<b>XN7CX</b>	Human coronavirus OC43
<b>XN3BD</b>	Middle East respiratory syndrome coronavirus
<b>XN5V7</b>	Pipistrellus bat coronavirus HKU5
<b>XN1N9</b>	Rousettus bat coronavirus HKU9
<b>XN1V8</b>	Severe Acute Respiratory Syndrome coronavirus
<b>XN1GJ</b>	Tylonycteris bat coronavirus HKU4
<b>XN109</b>	SARS-CoV-2
<b>XN0HL</b>	SARS-CoV-2 Alpha
<b>XN4Q7</b>	SARS-CoV-2 Beta
<b>XN5BQ</b>	SARS-CoV-2 Gamma
<b>XN8V6</b>	SARS-CoV-2 Delta
<b>XN1GK</b>	SARS-CoV-2 Epsilon
<b>XN3ZE</b>	SARS-CoV-2 Zeta
<b>XN2V4</b>	SARS-CoV-2 Eta
<b>XN4Q1</b>	SARS-CoV-2 Theta
<b>XN3UD</b>	SARS-CoV-2 Iota

<b>XN9LB</b>	SARS-CoV-2 Kappa
<b>XN6AM</b>	SARS-CoV-2 Lambda
<b>XN39J</b>	SARS-CoV-2 Mu
<b>XN161</b>	SARS-CoV-2 Omicron
<b>XN8Z4</b>	BA.5
<b>XN4UD</b>	BQ.1
<b>XN51Y</b>	XBB
<b>XN72A</b>	XBB.1.5
<b>XN201</b>	XBB.1.16
<b>XN8RW</b>	EG.5
<b>XN031</b>	BA2.86
<b>XN3QV</b>	BA.1
<b>XN53K</b>	BA.2
<b>XN2P0</b>	<b>Enterovirus</b> These are a genus of positive-sense single-stranded RNA viruses associated with several human and mammalian diseases. This diagnosis is as the cause of diseases classified to other chapters.
<b>XN3MC</b>	Coxsackievirus
<b>XN2TU</b>	Echovirus
<b>XN3M0</b>	Poliovirus
<b>XN6KZ</b>	Wild poliovirus type 1
<b>XN9CF</b>	Wild poliovirus type 2
<b>XN97R</b>	Wild poliovirus type 3
<b>XN2T1</b>	Circulating vaccine-derived poliovirus type 1
<b>XN1XN</b>	Circulating vaccine-derived poliovirus type 2
<b>XN7UU</b>	Circulating vaccine-derived poliovirus type 3
<b>XN19Z</b>	Rhinovirus
<b>XN6R5</b>	<b>Filovirus</b>
<b>XN2LW</b>	Genus Ebolavirus
<b>XN1EN</b>	Ebola virus
<b>XN8JT</b>	Bundibugyo virus

<b>XN9QG</b>	Reston virus
<b>XN13U</b>	Sudan virus
<b>XN8TT</b>	Taï Forest virus
<b>XN12Y</b>	Bombali virus
<b>XN4XZ</b>	Genus Marburgvirus
<b>XN3F2</b>	Marburg virus
<b>XN5M2</b>	Ravn virus
<b>XN0AC</b>	<b>Flavivirus</b>
<b>XN4CA</b>	Dengue virus
<b>XN22Z</b>	Dengue virus 1
<b>XN4RL</b>	Dengue virus 2
<b>XN9XQ</b>	Dengue virus 3
<b>XN2EQ</b>	Dengue virus 4
<b>XN9ZK</b>	Japanese encephalitis virus
<b>XN5QW</b>	Saint Louis encephalitis virus
<b>XN0L1</b>	Tick-borne encephalitis virus
<b>XN1MT</b>	Tick-borne encephalitis virus-European subtype
<b>XN8WB</b>	Tick-borne encephalitis virus-Far Eastern subtype
<b>XN4LG</b>	Tick-borne encephalitis virus-Siberian subtype
<b>XN4E1</b>	West Nile virus
<b>XN9S3</b>	Yellow fever virus
<b>XN1H2</b>	Zika virus Zika virus (ZIKV) is a flavivirus from the Flaviviridae family and Spondweni serocomplex. The virus was first identified in 1947 in the Zika forest in Uganda in the rhesus macaque population. There are two main lineages of ZIKV, the African lineage and the Asian lineage.
<b>XN7C2</b>	Rocio virus
<b>XN7W2</b>	Alkhurma hemorrhagic fever virus
<b>XN2JR</b>	Kyasanur Forest disease virus
<b>XN41M</b>	<b>Hepatitis virus</b>
<b>XN5XD</b>	GB virus C
<b>XN40D</b>	Hepatitis A virus

<b>XN0GA</b>	Hepatitis B virus
<b>XN1EZ</b>	Hepatitis C virus
<b>XN99N</b>	Hepatitis D virus
<b>XN7TG</b>	Hepatitis E virus
<b>XN6BW</b>	Hepatitis F virus
<b>XN7V1</b>	<b>Human herpesvirus</b>
<b>XN6DH</b>	Ictalurivirus
<b>XN9QL</b>	Pityriasis Rosea virus
<b>XN465</b>	Alphaherpesvirinae
<b>XN42C</b>	Mardivirus
<b>XN41T</b>	Herpes simplex virus-1
<b>XN5V1</b>	Herpes simplex virus-2
<b>XN0TA</b>	Varicella zoster virus
<b>XN4P4</b>	Iltovirus
<b>XN8TA</b>	Betaherpesvirinae
<b>XN3SQ</b>	Cytomegalovirus
<b>XN5FN</b>	Muromegalovirus
<b>XN1GF</b>	Roseolavirus
<b>XN9NM</b>	Roseolavirus A
<b>XN8AM</b>	Roseolavirus B
<b>XN2VN</b>	Gammaherpesvirinae
<b>XN0R2</b>	Epstein-Barr virus
<b>XN7NE</b>	Rhadinovirus
<b>XN487</b>	<b>Human immunodeficiency virus</b>
<b>XN8LD</b>	Human immunodeficiency virus type 1
<b>XN71W</b>	Human immunodeficiency virus type 2
<b>XN8JY</b>	<b>Human papillomavirus</b> This is an ancient taxonomic family of non-enveloped DNA viruses, collectively known as papillomaviruses. This diagnosis is the cause of diseases classified to other chapters.
<b>XN2KP</b>	Human papillomavirus 45

<b>XN6LA</b>	Human papillomavirus 1
<b>XN2FC</b>	Human papillomavirus 2
<b>XN7DE</b>	Human papillomavirus 6
<b>XN7T9</b>	Human papillomavirus 11
<b>XN2NK</b>	Human papillomavirus 16
<b>XN97Y</b>	Human papillomavirus 18
<b>XN3HA</b>	Human papillomavirus 31
<b>XN1WJ</b>	<b>Human T-cell lymphotropic virus</b>
<b>XN5SG</b>	<b>Influenza virus</b>
<b>XN8WJ</b>	Influenza A virus
<b>XN297</b>	Influenza A H1N1 virus
<b>XN4TT</b>	Influenza A H5N1 virus
<b>XN7JR</b>	Influenza A H5N6 virus
<b>XN35G</b>	Influenza A H7N9 virus
<b>XN2J2</b>	Influenza A H1 virus
<b>XN9Z9</b>	Influenza A H1N1v virus
<b>XN3VG</b>	Influenza A H1N2v virus
<b>XN9SG</b>	Influenza A H1N1 pdm2009 virus
<b>XN3UJ</b>	Influenza A H1pdm09N2 2:6 reassortant influenza virus
<b>XN02Z</b>	Swine influenza A H1N1 virus
<b>XN16M</b>	Influenza A H1N2 variant
<b>XN79W</b>	Influenza A H2N2 virus
<b>XN8WA</b>	Influenza A H3 virus
<b>XN6WE</b>	Influenza A H3N2 virus
<b>XN476</b>	Swine influenza A H3N2 virus
<b>XN3UU</b>	Influenza A H3N2 Panama/2007/99 virus
<b>XN9HE</b>	Influenza A H3N2 Moscow/10/99 virus
<b>XN9FE</b>	Influenza A H3N2v virus
<b>XN81W</b>	Equine influenza A H3N8 virus
<b>XN6MR</b>	Influenza A H5 virus

<b>XN5DQ</b>	Influenza A H5N2 virus
<b>XN6MY</b>	Influenza A H5N8 virus
<b>XN0AS</b>	Influenza A H6N1 virus
<b>XN9GE</b>	Influenza A H7N2 virus
<b>XN2SA</b>	Influenza A H7N2 variant
<b>XN8Q3</b>	Influenza A H7N3 virus
<b>XN5WA</b>	Influenza A H7N4 virus
<b>XN8YT</b>	Influenza A H7N7 virus
<b>XN71C</b>	Influenza A H9 virus
<b>XN412</b>	Influenza A H9N2 virus
<b>XN5SY</b>	Influenza A H10N3 virus
<b>XN66Y</b>	Influenza A H10N7 virus
<b>XN0MW</b>	Influenza A H10N8 virus
<b>XN8SG</b>	Influenza B virus
<b>XN8U3</b>	Influenza C virus
<b>XN67Q</b>	Influenza D virus
<b>XN33B</b>	<b>Lyssavirus</b>
<b>XN796</b>	Rabies virus
<b>XN8R7</b>	<b>Orthopolyomavirus</b>
<b>XN7UP</b>	John Cunningham virus
<b>XN82V</b>	<b>Paramyxovirus</b>
<b>XN98T</b>	Henipavirus
<b>XN5PM</b>	Cedar Virus
<b>XN53N</b>	Hendra virus
<b>XN931</b>	Nipah virus
<b>XN513</b>	Human metapneumovirus
<b>XN186</b>	Measles virus
<b>XN22H</b>	Mumps virus
<b>XN6CR</b>	Parainfluenza virus
<b>XN4QJ</b>	Rubulavirus

<b>XN7X8</b>	<b>Parvovirus</b>
	This belongs to the Poxviridae family. Like all members of that family, they are oval, relatively large, double-stranded DNA viruses. Parapoxviruses have a unique spiral coat that distinguishes them from other poxviruses. This diagnosis is as the cause of diseases classified to other chapters.
<b>XN8PS</b>	Erythrovirus
<b>XN447</b>	Bocaparvovirus
<b>XN8W9</b>	<b>Pneumovirus</b>
<b>XN275</b>	Human respiratory syncytial virus This is a virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. This diagnosis is the cause of diseases classified to other chapters.
<b>XN9WH</b>	<b>Polyomavirus</b>
<b>XN0TQ</b>	BK polyoma virus
<b>XN7UC</b>	<b>Poxvirus</b>
<b>XN32K</b>	Orthopoxvirus
<b>XN3Y3</b>	Buffalopox virus
<b>XN0AU</b>	Cowpox virus
<b>XN2GM</b>	Monkeypox virus
<b>XN4L3</b>	Monkeypox virus Clade I Based on the virus genome sequence there are two clades/variants of the Monkeypox virus recognised; Clade I and Clade II.
<b>XN1BH</b>	Monkeypox virus Clade II Based on the virus genome sequence there are two clades/variants of the Monkeypox virus, also known as variants, recognised; Clade I and Clade II. Additionally, it was agreed that the Clade II consists of two subclades; Clade IIa and Clade IIb, with the latter referring primarily to the group of variants largely circulating in the 2022 global outbreak.
<b>XN00B</b>	Monkeypox virus Clade IIa Clade IIa and Clade IIb are two recognised subclades of the Monkeypox virus Clade II.
<b>XN7VR</b>	Monkeypox virus Clade IIb Clade IIa and Clade IIb are two recognised subclades of the Monkeypox virus Clade II. Clade IIb refers to a group of variants largely circulating in the 2022 global outbreak.
<b>XN4Q0</b>	Variola virus

<b>XN06N</b>	Vaccinia virus
<b>XN1M0</b>	Parapox virus
<b>XN7JF</b>	bovine papular stomatitis virus
<b>XN8E5</b>	Orf virus
<b>XN8JR</b>	pseudocowpox virus
<b>XN0CV</b>	Yatapox virus
<b>XN0K5</b>	tanapox virus
<b>XN81C</b>	yaba monkey tumour virus
<b>XN5G8</b>	Molluscipoxvirus
<b>XN7YE</b>	Molluscum contagiosum virus
<b>XN22T</b>	<b>Reovirus</b> Reovirus is a nonenveloped double-stranded RNA virus. This virus was initially not known to be related to any specific disease, and so was named Respiratory Enteric Orphan virus. However, some members of the reovirus family have been shown to cause mild illnesses such as diarrhea.
<b>XN6FR</b>	<b>Retrovirus</b> This is an RNA virus that replicates in a host cell. First it uses its own reverse transcriptase enzyme to produce DNA from its RNA genome, reverse of the usual pattern, thus retro (backwards).
<b>XN2R0</b>	Alpharetrovirus
<b>XN0TH</b>	Betaretrovirus
<b>XN787</b>	Deltaretrovirus
<b>XN6HX</b>	Epsilonretrovirus
<b>XN4K8</b>	Gammaretrovirus
<b>XN5R7</b>	Lentivirus
<b>XN6JB</b>	Oncovirus
<b>XN6N7</b>	<b>Rotavirus</b>
<b>XN6TN</b>	Rotavirus A
<b>XN55H</b>	Rotavirus B
<b>XN0F5</b>	Rotavirus C
<b>XN29P</b>	Rotavirus D
<b>XN71N</b>	Rotavirus E
<b>XN2F7</b>	<b>Rubivirus</b>

<b>XN2WE</b>	Rubella virus
<b>XN7R4</b>	<b>Astrovirus</b>
<b>XN6T9</b>	<b>Vesiculovirus</b>
<b>XN2BR</b>	Chandipura virus
<b>XN9XS</b>	Vesicular stomatitis virus
<b>XN8AY</b>	<b>Fungi</b>
<b>XN0WC</b>	<b>Aspergillus</b>
<b>XN6Q9</b>	Aspergillus clavatus
<b>XN6B8</b>	Aspergillus flavus
<b>XN5Z7</b>	Aspergillus fumigatus
<b>XN25K</b>	Aspergillus terreus
	The Aspergillus terreus is found in a wide variety of habitats, soil, compost, or dust, and the spectrum of diseases caused covers allergic bronchopulmonary aspergillosis, Aspergillus bronchitis and/or tracheobronchitis, and invasive and disseminated aspergillosis.
<b>XN7Q2</b>	Aspergillus niger
<b>XN4XX</b>	<b>Basidiobolus</b>
<b>XN4RM</b>	Basidiobolus ranarum
<b>XN08A</b>	<b>Blastomyces</b>
<b>XN14F</b>	Blastomyces dermatitidis
<b>XN3CL</b>	<b>Candida</b>
<b>XN31P</b>	Candida albicans
<b>XN72N</b>	Candida auris
<b>XN0RY</b>	Candida haemulonii
<b>XN066</b>	<b>Chromomycosis</b>
<b>XN106</b>	<b>Chrysosporium</b>
<b>XN8W1</b>	Chrysosporium parvum
<b>XN7Q9</b>	<b>Coccidioides</b>
<b>XN53F</b>	Coccidioides immitis
<b>XN5TT</b>	Coccidioides posadasii
<b>XN62A</b>	<b>Conidiobolus</b>
<b>XN3KM</b>	Conidiobolus coronatus

<b>XN4AQ</b>	Conidiobolus incongruus
<b>XN69C</b>	<b>Cryptococcus</b>
<b>XN0LE</b>	<i>Cryptococcus gattii</i>
<b>XN3EH</b>	<i>Cryptococcus neoformans</i>
<b>XN7WW</b>	<b>Dermatophyte fungi</b>
<b>XN655</b>	Anthropophilic dermatophytes
<b>XN2T0</b>	<i>Epidermophyton floccosum</i>
<b>XN3YF</b>	<i>Microsporum audouinii</i>
<b>XN2R2</b>	<i>Microsporum ferrugineum</i>
<b>XN8M6</b>	<i>Trichophyton concentricum</i>
<b>XN628</b>	<i>Trichophyton gourvilii</i>
<b>XN8BW</b>	<i>Trichophyton interdigitale</i>
<b>XN96H</b>	<i>Trichophyton megninii</i>
<b>XN2JF</b>	<i>Trichophyton rubrum</i>
<b>XN53A</b>	<i>Trichophyton schoenleinii</i>
<b>XN135</b>	<i>Trichophyton soudanense</i>
<b>XN1K6</b>	<i>Trichophyton tonsurans</i>
<b>XN31R</b>	<i>Trichophyton violaceum</i>
<b>XN8BF</b>	<i>Trichophyton yaoundei</i>
<b>XN2SY</b>	Zoophilic dermatophytes
<b>XN5ER</b>	<i>Microsporum canis</i>
<b>XN6NM</b>	<i>Microsporum equinum</i>
<b>XN5GR</b>	<i>Microsporum gallinae</i>
<b>XN3WX</b>	<i>Microsporum nanum</i>
<b>XN7JK</b>	<i>Microsporum persicolor</i>
<b>XN3YG</b>	<i>Trichophyton equinum</i>
<b>XN4DQ</b>	<i>Trichophyton mentagrophytes</i>
<b>XN4H4</b>	<i>Trichophyton simii</i>
<b>XN69S</b>	<i>Trichophyton verrucosum</i>
<b>XN1Z2</b>	Geophilic dermatophytes

<b>XN2VZ</b>	Microsporum gypseum
<b>XN7TP</b>	Microsporum praecox
<b>XN3AG</b>	<b>Geotrichum</b>
<b>XN0ES</b>	Geotrichum candidum
<b>XN9LU</b>	<b>Histoplasma</b>
<b>XN8VH</b>	Histoplasma capsulatum
<b>XN7YN</b>	Histoplasma duboisii
<b>XN119</b>	<b>Hortaea</b>
<b>XN0EF</b>	Hortaea werneckii
<b>XN3CM</b>	<b>Lacazia</b>
<b>XN3NU</b>	Lacazia loboi
<b>XN9ZX</b>	<b>Loboa</b>
<b>XN43L</b>	<b>Malassezia</b>
<b>XN25C</b>	Malassezia furfur
<b>XN0TE</b>	Malassezia globosa fungus
<b>XN9ZV</b>	<b>Microsporidia</b>
<b>XN1NU</b>	<b>Mucor</b>
<b>XN6QM</b>	Rhizopus
<b>XN9KP</b>	Rhizopus arrhizus
<b>XN7RH</b>	<b>Paracoccidioides</b>
<b>XN5UX</b>	Paracoccidioides brasiliensis
<b>XN79A</b>	<b>Talaromyces</b> A new fungal genus formerly part of Penicillium
<b>XN1ZF</b>	Penicillium
<b>XN7JJ</b>	Penicillium notatum
<b>XN0LD</b>	Talaromyces marneffei The fungus formerly known as Penicillium marneffei
<b>XN4YW</b>	<b>Piedraia</b>
<b>XN6H7</b>	Piedraia hortae
<b>XN5XK</b>	<b>Pneumocystidomycetes</b>
<b>XN3NS</b>	<b>Pseudallescheria</b>

XN6BV	Pseudallescheria boydii
XN720	<b>Rhinosporidium</b>
XN18W	Rhinosporidium seeberi
XN200	<b>Sporothrix</b>
XN6GM	Sporothrix schenckii
XN766	<b>Trichosporon</b>
XN0X5	<b>Fusarium</b>
XN55Z	Fusarium sporotrichioides
XN7KH	Fusarium incarnatum-equiseti
XN1FQ	Fusarium chlamydosporum
XN5KR	Fusarium dimerum
XN6XG	Fusarium fujikuroi
XN3HT	Fusarium oxysporum
XN0E6	Fusarium solani
XN16V	<b>Alternaria alternata</b>
XN8XY	<b>Cladosporium herbarum</b>
XN7TH	<b>Epicoccum purpurascens</b>
XN79P	<b>Mucor racemosus</b>
XN6EG	<b>Phoma</b>
XN4FM	<b>Stemphylium botryosum</b>
XN93N	<b>Curvularia lunata</b>
XN0W9	<b>Exserohilum</b>
XN26M	Exserohilum rostratum
XN9SM	Exserohilum longirostratum
XN9LC	Exserohilum mcginnisii
XN4XH	<b>Sarocladium</b>
XN8VN	Sarocladium kiliense
XN7ZD	Sarocladium strictum
XN9S1	<b>Parasites</b>

## **Helminths**

<b>XN9CG</b>	<b>Ancylostoma</b>
<b>XN5V8</b>	<b>Ancylostoma duodenal</b>
<b>XN7A5</b>	<b>Angiostrongylus</b>
<b>XN2UG</b>	<b>Angiostrongylus cantonensis</b>
<b>XN23C</b>	<b>Angiostrongylus costaricensis</b>
<b>XN574</b>	<b>Anisakis</b>
<b>XN9HA</b>	<b>Anisakis marina</b>
<b>XN9PQ</b>	<b>Ascaris</b>
<b>XN97M</b>	<b>Ascaris lumbricoides</b>
<b>XN0JL</b>	<b>Brugia</b>
<b>XN5RM</b>	<b>Brugia malayi</b>
<b>XN80F</b>	<b>Brugia timori</b>
<b>XN8T0</b>	<b>Capillaria</b>
<b>XN9DT</b>	<b>Capillaria philippinensis</b>
<b>XN9GC</b>	<b>Clonorchis</b>
<b>XN5SV</b>	<b>Clonorchis sinensis</b>
<b>XN3QD</b>	<b>Dicrocoelium</b>
<b>XN6EF</b>	<b>Diphyllobothrium</b>
<b>XN67S</b>	<b>Diphyllobothrium latum</b>
<b>XN7UT</b>	<b>Diphyllobothrium species</b>
<b>XN570</b>	<b>Dipylidium</b>
<b>XN20Y</b>	<b>Dipylidium caninum</b>
<b>XN15W</b>	<b>Dirofilaria</b>
<b>XN3BX</b>	<b>Dirofilaria immitis</b>
<b>XN7JS</b>	<b>Dirofilaria repens</b>
<b>XN7A6</b>	<b>Dracunculus</b>
<b>XN9Q5</b>	<b>Dracunculus medinensis</b>
<b>XN84K</b>	<b>Echinococcus</b>
<b>XN1H0</b>	<b>Echinococcus granulosus</b>

XN0K1	<b>Echinococcus multilocularis</b>
XN6TQ	<b>Echinococcus oligarthrus</b>
XN9LQ	<b>Echinococcus vogeli</b>
<b>XN801</b>	<b>Echinostoma</b>
<b>XN1DG</b>	<b>Enterobius</b>
XN4AR	<b>Enterobius vermicularis</b>
<b>XN1H3</b>	<b>Fasciola</b>
XN90A	<b>Fasciola gigantica</b>
XN7X9	<b>Fasciola hepatica</b>
<b>XN35Y</b>	<b>Fasciolopsis</b>
XN024	<b>Fasciolopsis buski</b>
<b>XN0H2</b>	<b>Gnathostoma</b>
XN8DD	<b>Gnathostoma hispidum</b>
XN8GS	<b>Gnathostoma spinigerum</b>
<b>XN23M</b>	<b>Heterophyes</b>
<b>XN69Y</b>	<b>Hookworm</b>
<b>XN629</b>	<b>Hymenolepis</b>
XN9S5	<b>Hymenolepis nana</b>
<b>XN8ZQ</b>	<b>Loa</b>
XN1QQ	<b>Loa loa</b>
<b>XN5Z0</b>	<b>Mansonella</b>
XN6PZ	<b>Mansonella ozzardi</b>
XN8AX	<b>Mansonella perstans</b>
XN0JQ	<b>Mansonella streptocerca</b>
<b>XN123</b>	<b>Metagonimus</b>
<b>XN3E8</b>	<b>Nanophyetus</b>
<b>XN9T3</b>	<b>Necator</b>
XN8K8	<b>Necator americanus</b>
<b>XN7L5</b>	<b>Oesophagostomum</b>
XN0NZ	<b>Oesophagostomum bifurcum</b>

XN9R1	<b>Onchocerca</b>
XN8T4	<b>Onchocerca volvulus</b>
XN91W	<b>Opisthorchis</b>
XN27A	<b>Paragonimus</b>
XN0A6	<b>Paragonimus westermani</b>
XN9NR	<b>Phylum Nemata</b>
XN78L	<b>Schistosoma</b>
XN86N	<b>Schistosoma haematobium</b>
XN90N	<b>Schistosoma matthei</b>
XN9FK	<b>Schistosoma intercalatum</b>
XN1ZJ	<b>Schistosoma japonicum</b>
XN8HD	<b>Schistosoma mansoni</b>
XN9T7	<b>Schistosoma mekongi</b>
XN5B9	<b>Sparganum</b>
XN89M	<b>Spirometra</b>
XN07X	<b>Strongyloides</b>
XN1KQ	<b>Strongyloides stercoralis</b>
XN5RB	<b>Syngamus</b>
XN04L	<b>Syngamus trachea</b>
XN0D8	<b>Taenia</b>
XN871	<b>Taenia saginata</b>
XN8XE	<b>Taenia solium</b>
XN8DL	<b>Ternidens</b>
XN2L3	<b>Toxocara</b>
XN7MR	<b>Toxocara canis</b>
XN54C	<b>Toxocara cati</b>
XN597	<b>Trichinella</b>
XN34A	<b>Trichinella spiralis</b>
XN025	<b>Trichostrongylus</b>
XN4K7	<b>Trichostrongylus colubriformis</b>

<b>XN4MM</b>	<b>Trichuris</b>
<b>XN6UA</b>	<b>Trichuris trichiura</b>
<b>XN0H3</b>	<b>Wuchereria</b>
<b>XN3V2</b>	<b>Wuchereria bancrofti</b>
<b>XN2DD</b>	<b>Halicephalobus</b>
<b>XN10L</b>	<b>Halicephalobus gingivalis</b>

## Protozoa

<b>XN0HM</b>	<b>Acanthamoeba</b>
<b>XN7S2</b>	<b>Amoeba</b>
<b>XN9YX</b>	<b>Babesia</b>
<b>XN7ZS</b>	<b>Balantidium</b>
<b>XN3H4</b>	<b>Balantidium coli</b>
<b>XN6UY</b>	<b>Blastocystis</b>
<b>XN1M7</b>	<b>Blastocystis hominis</b>
<b>XN1XA</b>	<b>Coccidia</b> subclass of microscopic, spore-forming, single-celled obligate intracellular parasites belonging to the apicomplexan class Conoidasida
<b>XN8LE</b>	<b>Cryptosporidium</b>
<b>XN0NC</b>	<b>Cryptosporidium canis</b>
<b>XN5SZ</b>	<b>Cryptosporidium felis</b>
<b>XN4ZT</b>	<b>Cryptosporidium hominis</b>
<b>XN4VU</b>	<b>Cryptosporidium meleagridis</b>
<b>XN4MN</b>	<b>Cryptosporidium muris</b>
<b>XN9BP</b>	<b>Cryptosporidium parvum</b>
<b>XN7VL</b>	<b>Cyclospora</b>
<b>XN4BR</b>	<b>Cyclospora cayetanensis</b>
<b>XN3S1</b>	<b>Entamoeba</b>
<b>XN82F</b>	<b>Entamoeba histolytica</b>
<b>XN6H5</b>	<b>Giardia</b>
<b>XN94Z</b>	<b>Giardia lamblia</b>

XN4Y2	<b>Isospora</b>
XN9ZT	<b>Isospora belli</b>
XN8JE	<b>Leishmania</b>
XN87Z	<b>Leishmania aethiopica</b>
XN6DJ	<b>Leishmania brasiliensis</b>
XN1M5	<b>Leishmania donovani infantum</b>
XN3HN	<b>Leishmania chagasi</b>
XN7EU	<b>Leishmania major</b>
XN1EE	<b>Leishmania mexicana</b>
XN95N	<b>Leishmania tropica</b>
XN1M1	<b>Naegleria</b>
XN6EV	<b>Naegleria fowleri</b>
XN5FW	<b>Plasmodium</b>
XN69B	<b>Plasmodium falciparum</b>
XN7K1	<b>Plasmodium malariae</b>
XN5WD	<b>Plasmodium ovale</b>
XN217	<b>Plasmodium vivax</b>
XN93K	<b>Plasmodium knowlesi</b>
XN12A	<b>Plasmodium cynomolgi</b>
XN92F	<b>Sarcocystis</b>
XN7HC	<b>Toxoplasma</b>
XN896	<b>Toxoplasma gondii</b>
XN316	<b>Trichomonas</b>
XN7YM	<b>Trichomonas vaginalis</b>
XN9H4	<b>Trypanosoma</b>
XN0C1	<b>Trypanosoma brucei</b>
XN7TC	<b>Trypanosoma brucei gambiense</b>
XN5C7	<b>Trypanosoma brucei rhodesiense</b>
XN56V	<b>Trypanosoma cruzi</b>
XN7XH	<b>Dientamoeba</b>

XN86U	<b>Dientamoeba fragilis</b>
XN30L	<b>Retortamonas</b>
XN9K3	<b>Retortamonas intestinalis</b>
XN4BE	<b>Chilomastix</b>
XN0UD	<b>Chilomastix mesnili</b>

### Lice and Mites

XN4RB	<b>Demodex</b>
XN9EL	<b>Dermanyssus</b>
XN59U	<b>Vandellia cirrhosa</b>
XN857	<b>Infestation by beetle</b>
XN00Z	<b>Insect larva</b>
XN2K0	<b>Leech</b>
XN9MA	<b>Linguatula serrata</b>
XN0ZB	<b>Liponyssoides</b>
XN0D5	<b>Pediculus</b>
XN84U	<b>Phthirus</b>
XN3E3	<b>Sarcoptes</b>
XN5YU	<b>Sarcoptes scabiei var. hominis</b>
XN7Z8	<b>Trombicula</b>
XN6VS	<b>Tunga</b>
XN2GY	<b>Porocephalidae</b>
XN8CT	<b>Screwworm</b>
XN4JW	New World screwworm
XN8TR	Old World screwworm

### Other Pathogens

XN7AM	<b>Prion</b>
XN42T	<b>Prototheca</b>
XN47C	<b>Pythium</b>

## Topology Scale Value

### Relational

XK7V	<b>Anterior</b>
XK8L	<b>Posterior</b>
XK9H	<b>Medial</b>
XK09	<b>Lateral</b>
XK5N	<b>Superior</b>
XK4H	<b>Inferior</b>
XK4M	<b>Ventral</b>
XK87	<b>Dorsal</b>
XK6J	<b>Proximal</b>
XK6C	<b>Distal</b>
XK3Z	<b>Ipsilateral</b>
XK3Y	<b>Contralateral</b>
XK2H	<b>External</b>
XK49	<b>Internal</b>
XK7F	<b>Superficial</b>
XK16	<b>Deep</b>

### Distribution

XK2J	<b>Complete distribution</b>
XK6P	<b>Consolidated distribution</b>
XK31	<b>Diffuse distribution</b>
XK5A	<b>Disseminated distribution</b>
XK37	<b>Focal distribution</b>
XK63	<b>Generalised distribution</b>
XK06	<b>Incomplete distribution</b>
XK0V	<b>Intertriginous distribution</b>
XK5F	<b>Linear distribution</b>

<b>XK9A</b>	<b>Localised distribution</b>
<b>XK36</b>	<b>Segmental distribution</b>
<b>XK7Z</b>	<b>Systematised distribution</b>

Laterality

<b>XK9J</b>	<b>Bilateral</b>
<b>XK8G</b>	<b>Left</b>
<b>XK9K</b>	<b>Right</b>
<b>XK70</b>	<b>Unilateral, unspecified</b>

Regional

<b>XK62</b>	<b>Brachial</b>
<b>XK07</b>	<b>Caudal</b>
<b>XK2K</b>	<b>Cranial</b>
<b>XK0P</b>	<b>Infratentorial</b>
<b>XK18</b>	<b>Supratentorial</b>

Anatomy and topography

Functional anatomy

Haematopoietic system

<b>XA8EC5</b>	<b>Blood</b>
<b>XA8UK8</b>	<b>Blood cells</b>
<b>XM8QV9</b>	Erythrocytes
<b>XA32R4</b>	Leucocytes
<b>XA2WC0</b>	Granulocytes
<b>XA8C44</b>	Neutrophils
<b>XA5G96</b>	Basophils
<b>XA0V82</b>	Eosinophils
<b>XA46Q2</b>	Monocytes

<b>XA9DP6</b>	Macrophages
<b>XA8YQ2</b>	Lymphocytes Lymphocytes include natural killer cells (which function in cell-mediated, cytotoxic innate immunity), T cells (for cell-mediated, cytotoxic adaptive immunity), and B cells (for humoral, antibody-driven adaptive immunity).
<b>XA10B5</b>	Platelets
<b>XA7UR0</b>	<b>Plasma</b>
<b>XA3JX0</b>	Platelet-rich plasma Platelet-rich plasma consists of two elements: plasma (the liquid portion of blood) and platelets (a type of blood cells that play an important role in healing throughout the body).
<b>XA9XK1</b>	<b>Bone marrow</b>
<b>XA5869</b>	<b>Haematopoietic stem cells</b>
<b>XA3K78</b>	<b>Common myeloid progenitor</b>
<b>XA8LY0</b>	Erythroblast
<b>XA6385</b>	Myeloblast
<b>XA3EA5</b>	Megakaryoblast
<b>XA0TJ1</b>	<b>Lymphoblast</b>

## Immune system

### Lymphoid organs

Organs involved in immune regulation

<b>XA8373</b>	<b>Thymus</b> <i>Inclusions:</i> Thymus gland
<b>XA2PK9</b>	<b>Connective and other soft tissues of thymus</b>
<b>XA7FU9</b>	<b>Spleen</b>
<b>XA1EM4</b>	<b>Lingual tonsil</b>
<b>XA8US7</b>	<b>Waldeyer ring</b>
<b>XA3V90</b>	<b>Palatine tonsil</b>
<b>XA33X2</b>	<b>Lymph nodes</b>
<b>XA9U65</b>	<b>Lymph nodes of head, face and neck</b>
<b>XA6H69</b>	Occipital lymph node

<b>XA7YF1</b>	Auricular lymph node
<b>XA91C5</b>	Posterior auricular lymph node
<b>XA56J5</b>	Preauricular lymph node
<b>XA0W17</b>	Parotid lymph node
<b>XA1Q47</b>	Subparotid lymph node
<b>XA85E1</b>	Superficial parotid lymph node
<b>XA07P4</b>	Deep parotid lymph node
	<b>Coded Elsewhere:</b> Preauricular lymph node (XA56J5)
<b>XA2U89</b>	Facial lymph node
<b>XA1SG7</b>	Buccinator lymph node
<b>XA8DW7</b>	Mandibular lymph node
<b>XA2S79</b>	Deep facial lymph node
<b>XA1DV2</b>	Lingual lymph node
<b>XA8027</b>	Sublingual lymph node
<b>XA42P9</b>	Submental lymph node
<b>XA9E80</b>	Submandibular lymph node
<b>XA4759</b>	Anterior cervical lymph node
	<b>Coded Elsewhere:</b> Anterior jugular node (XA6YX2)
<b>XA9PW0</b>	Deep cervical lymph node
<b>XA2RE9</b>	Prelaryngeal lymph node
<b>XA4LC1</b>	Pretracheal lymph node
<b>XA7W32</b>	Paratracheal lymph node
<b>XA08L8</b>	Retropharyngeal lymph node
<b>XA60D1</b>	Jugular lymph node
<b>XA6YX2</b>	Anterior jugular node
<b>XA6HG6</b>	Jugulodigastric lymph node
<b>XA5A75</b>	Jugulo-omohyoid lymph node
<b>XA5XT7</b>	Cervical lymph node
<b>XA4R20</b>	Inferior cervical lymph node
<b>XA1W79</b>	Lateral cervical lymph node

<b>XA6AC0</b>	Superior deep cervical lymph node <b>Coded Elsewhere:</b> Jugulodigastric lymph node (XA6HG6)
<b>XA3S48</b>	Inferior deep cervical lymph node <b>Coded Elsewhere:</b> Jugulo-omohyoid lymph node (XA5A75)
<b>XA7N00</b>	Superficial cervical lymph node
<b>XA00M7</b>	Supraclavicular lymph node
<b>XA9WH0</b>	<b>Intrathoracic lymph nodes</b>
<b>XA41B8</b>	Tracheobronchial lymph node
<b>XA96Z0</b>	Bronchopulmonary lymph node
<b>XA5MW1</b>	Hilar lymph node
<b>XA9QW9</b>	Pulmonary lymph node
<b>XA3194</b>	Tracheal lymph node
<b>XA2JX0</b>	Superior tracheobronchial lymph node
<b>XA1PA1</b>	Inferior tracheobronchial lymph node
<b>XA61B8</b>	Mediastinal lymph node
<b>XA5HA3</b>	Anterior mediastinal visceral lymph node
<b>XA7571</b>	Posterior mediastinal visceral lymph node
<b>XA8VY5</b>	Oesophageal lymph node
<b>XA8E34</b>	Intercostal lymph node
<b>XA2CH0</b>	Parasternal lymph node
<b>XA1478</b>	Superior diaphragmatic lymph node
<b>XA4P97</b>	Innominate lymph node
<b>XA05C1</b>	<b>Intra-abdominal lymph nodes</b>
<b>XA59Q1</b>	Lumbar lymph node
<b>XA25W0</b>	Aortic lymph node
<b>XA4WV3</b>	Preaortic lymph node
<b>XA38T7</b>	Coeliac lymph node
<b>XA1HL1</b>	Gastric lymph node
<b>XA1FW5</b>	Inferior gastric lymph node
<b>XA1T01</b>	Upper superior gastric lymph node
<b>XA3F65</b>	Superior gastric lymph node

<b>XA3ET7</b>	Lower superior gastric lymph node
<b>XA4WL5</b>	Paracardial superior gastric lymph node
<b>XA2AX1</b>	Pyloric lymph node
<b>XA1RP0</b>	Subpyloric lymph node
<b>XA11U1</b>	Hepatic lymph node
<b>XA35G1</b>	Common duct lymph node
<b>XA71D7</b>	Cystic lymph node
<b>XA7ZP7</b>	Pancreaticosplenic lymph node
<b>XA6W89</b>	Pancreaticoduodenal lymph node
<b>XA9PJ7</b>	Splenic lymph node
<b>XA8X72</b>	Splenic hilar lymph node
<b>XA7T42</b>	Pancreatic lymph node
<b>XA2P83</b>	Peripancreatic lymph node
<b>XA8Y29</b>	Inferior mesenteric lymph node
<b>XA6ZA5</b>	Pararectal inferior mesenteric lymph node
<b>XA37Y9</b>	Superior mesenteric lymph node
<b>XA26J2</b>	Mesenteric lymph node
<b>XA69J6</b>	Ileocolic lymph node
<b>XA66B8</b>	Ileal ileocolic lymph node
<b>XA8W06</b>	Anterior ileocolic lymph node
<b>XA7JE2</b>	Posterior ileocolic lymph node
<b>XA73R0</b>	Right colic ileocolic lymph node
<b>XA09W7</b>	Colic lymph node
<b>XA4F32</b>	Midcolic lymph node
<b>XA8JH9</b>	Epicolic lymph node
<b>XA9JM2</b>	Paracolic lymph node
<b>XA7PM1</b>	Intermediate colic lymph node
<b>XA3TX6</b>	Preterminal colic lymph node

<b>XA6KK3</b>	Lateral aortic lymph node
	<b>Coded Elsewhere:</b> Common iliac lymph node (XA1MS6)
	External iliac lymph node (XA8M66)
	Internal iliac lymph node (XA0TJ6)
<b>XA9T50</b>	Epigastric lymph node
	<b>Coded Elsewhere:</b> Inferior epigastric lymph node (XA5VA3)
<b>XA53K4</b>	Iliac circumflex lymph node
<b>XA0TK3</b>	Retroaortic lymph node
<b>XA3TG4</b>	Intestinal lymph node
<b>XA0KH9</b>	Retroperitoneal lymph node
<b>XA7DX9</b>	Suprarenal lymph node
<b>XA2YR9</b>	Porta hepatis lymph node
<b>XA5HU6</b>	<b>Pelvic lymph nodes</b>
<b>XA50T5</b>	Iliac lymph node
<b>XA1MS6</b>	Common iliac lymph node
<b>XA0TJ6</b>	Internal iliac lymph node
<b>XA8M66</b>	External iliac lymph node
<b>XA9Z71</b>	Obturator lymph node
<b>XA4J45</b>	Suprainguinal lymph node
<b>XA24Q3</b>	Sacral lymph node
<b>XA1EN9</b>	Lateral sacral lymph node
<b>XA86R4</b>	Median sacral lymph node
<b>XA32C4</b>	Presymphysial lymph node
<b>XA5VA3</b>	Inferior epigastric lymph node
<b>XA9TN5</b>	Female genital lymph node
<b>XA3QA5</b>	Parametrial lymph node
<b>XA5M72</b>	Uterine paracervical lymph node
<b>XA7TQ3</b>	<b>Lymph nodes of upper extremity</b>
<b>XA90B2</b>	Axillary lymph node
<b>XA63L4</b>	Pectoral lymph node
<b>XA6NK2</b>	Lateral axillary lymph node

<b>XA9R12</b>	Subscapular lymph node
<b>XA8HY4</b>	Central axillary lymph node
<b>XA1N88</b>	Subclavicular axillary lymph node
<b>XA9CD6</b>	Subclavian lymphatic trunk
<b>XA2UJ4</b>	Intermediate lymph node
<b>XA3H20</b>	Cubital lymph node
<b>XA5183</b>	Epitrochlear lymph node
<b>XA0MR2</b>	Infraclavicular lymph node
<b>XA86X1</b>	<b>Lymph nodes of lower extremity</b>
<b>XA7N26</b>	Inguinal lymph node
<b>XA1114</b>	Superficial inguinal lymph node
<b>XA4RT0</b>	Subinguinal lymph node
<b>XA30V5</b>	Superficial subinguinal lymph node
<b>XA6EE2</b>	Deep subinguinal lymph nodes
<b>XA5130</b>	Femoral lymph node
<b>XA4AU1</b>	Lymph node of Cloquet
<b>XA4W98</b>	Popliteal lymph node
<b>XA2PP2</b>	Tibial lymph node
<b>XA3X71</b>	Anterior tibial lymph node
<b>XA4T07</b>	<b>Lymph nodes of multiple regions</b>
<b>XA0GJ0</b>	<b>Mononuclear phagocyte system</b>

## Endocrine system

**Coded Elsewhere:** Ovary (XA1QK0)

Testis (XA4947)

**XA1CN1** Hypothalamus

**XA1EU3** Pineal gland

**XA8J35** Pituitary gland

**Coded Elsewhere:** Pituitary fossa (XA9N34)

**XA9787** Rathke pouch

<b>XA5309</b>	Craniopharyngeal duct Craniopharyngeal duct is a bony channel that connects the floor of the sella turcica, along the midline, to the nasopharynx.
<b>XA8RK3</b>	<b>Thyroid gland</b> <i>Coded Elsewhere:</i> Thyroglossal duct (XA0SH3)
<b>XA8LV3</b>	<b>Left lobe of thyroid gland</b>
<b>XA9L72</b>	<b>Right lobe of thyroid gland</b>
<b>XA4NE5</b>	<b>Isthmus of thyroid gland</b>
<b>XA5109</b>	<b>Pyramidal lobe of thyroid gland</b>
<b>XA1342</b>	<b>Parathyroid gland</b>
<b>XA45E6</b>	<b>Pancreatic islets</b>
<b>XA0NE9</b>	<b>Adrenal gland</b> <i>Coded Elsewhere:</i> Adrenal vein (XA6TQ3) Inferior adrenal artery (XA9QC3)
<b>XA8956</b>	<b>Adrenal cortex</b>
<b>XA6SS0</b>	<b>Adrenal medulla</b>

## Nervous system

<b>XA3JU6</b>	<b>Central nervous system</b>
<b>XA0AK4</b>	<b>Meninges</b>
<b>XA6HA2</b>	Cerebral meninges
<b>XA9M51</b>	Cranial dura mater
<b>XA6WL2</b>	Cranial arachnoid
<b>XA2T81</b>	Cranial pia mater
<b>XA7N98</b>	Tentorium cerebelli
<b>XA09H1</b>	Falx without further specification
<b>XA1FV7</b>	Falx cerebri
<b>XA33G9</b>	Falx cerebelli
<b>XA5AH0</b>	Spinal meninges
<b>XA8R98</b>	Spinal dura mater
<b>XA0382</b>	Spinal arachnoid

<b>XA8SH5</b>	Spinal pia mater
<b>XA04B5</b>	Dura mater
<b>XA3D30</b>	Arachnoid mater
<b>XA6AF5</b>	Pia mater
<b>XA9738</b>	<b>Brain</b> <i>Coded Elsewhere:</i> Cranial fossa (XA0KU6)
<b>XA1M33</b>	Cerebrum <i>Coded Elsewhere:</i> Hypothalamus (XA1CN1)
<b>XA8GR3</b>	Cerebral hemisphere
<b>XA2NT0</b>	Frontal Lobe
<b>XA3RD9</b>	Frontal pole
<b>XA97T4</b>	Temporal lobe
<b>XA7BD1</b>	Hippocampus
<b>XA7J78</b>	Uncus
<b>XA1XY9</b>	Amygdala
<b>XA92Y6</b>	Parietal Lobe
<b>XA89Y2</b>	Occipital lobe
<b>XA5TY2</b>	Brodmann area
<b>XA0B59</b>	Occipital pole
<b>XA64R0</b>	Cerebral cortex
<b>XA7L93</b>	Thalamus
<b>XA4T82</b>	Basal ganglia
<b>XA64F9</b>	Corpus striatum
<b>XA8W72</b>	Lentiform nucleus
<b>XA80J3</b>	Globus pallidus
<b>XA8KA5</b>	Putamen
<b>XA7TX5</b>	Caudate nucleus
<b>XA00D6</b>	Clastrum
<b>XA5TX3</b>	Optic chiasm
<b>XA63Y1</b>	Optic tract
<b>XA5CF8</b>	Visual cortex

<b>XA1ZN9</b>	Cerebral white matter
<b>XA0XP7</b>	Insula
<b>XA5JN6</b>	Internal capsule
<b>XA84G1</b>	Operculum
<b>XA4F88</b>	Pallium
<b>XA0Z39</b>	Rhinencephalon
<b>XA5N14</b>	Cerebral lobe  <i>Coded Elsewhere:</i> Occipital lobe (XA89Y2) Parietal Lobe (XA92Y6) Temporal lobe (XA97T4) Frontal Lobe (XA2NT0)
<b>XA73A8</b>	Supratentorial region of brain
<b>XA1CW2</b>	Cerebellum
<b>XA4SL2</b>	Cerebellar hemisphere
<b>XA7E38</b>	Cerebellar tonsil
<b>XA8E64</b>	Cerebellar vermis
<b>XA5694</b>	Superior vermis
<b>XA70Y8</b>	Inferior vermis
<b>XA8733</b>	Limbic system
<b>XA26E8</b>	Cerebral ventricle
<b>XA45Y8</b>	Lateral ventricle of the brain
<b>XA1XM1</b>	Choroid plexus of lateral ventricle
<b>XA1H64</b>	Third ventricle of the brain
<b>XA53A3</b>	Choroid plexus of third ventricle
<b>XA83T2</b>	Cerebral aqueduct
<b>XA1804</b>	Fourth ventricle of the brain
<b>XA1B86</b>	Choroid plexus of fourth ventricle
<b>XA9KX2</b>	Choroid plexus  <i>Coded Elsewhere:</i> Choroid plexus of lateral ventricle (XA1XM1) Choroid plexus of third ventricle (XA53A3) Choroid plexus of fourth ventricle (XA1B86)
<b>XA6J38</b>	Ependyma

<b>XA8AT9</b>	Brainstem The brainstem is the structure that connects the cerebrum of the brain to the spinal cord and cerebellum. It is composed of three sections in descending order: the midbrain, pons, and medulla oblongata.
	<b>Coded Elsewhere:</b> Choroid plexus of fourth ventricle (XA1B86)
	Fourth ventricle of the brain (XA1804)
<b>XA17J6</b>	Medulla oblongata
<b>XA5KS6</b>	Midbrain The midbrain (also known as the mesencephalon) is the most superior of the three regions of the brainstem.
<b>XA1AA8</b>	Cerebral peduncle
<b>XA9CM4</b>	Pons
<b>XA34M4</b>	Reticular formation
<b>XA5KN2</b>	Olives
<b>XA5097</b>	Pyramid
<b>XA1GA1</b>	Infratentorial region of brain
<b>XA08F7</b>	Intracranial site, not elsewhere classified
<b>XA0V83</b>	<b>Spinal cord</b>
<b>XA1SP1</b>	Cervical spinal cord <i>Inclusions:</i> Cervical cord
<b>XA2K06</b>	C1 level
<b>XA7852</b>	C2 level
<b>XA3JF5</b>	C3 level
<b>XA2MQ3</b>	C4 level
<b>XA3JA6</b>	C5 level
<b>XA4LT0</b>	C6 level
<b>XA3NV2</b>	C7 level
<b>XA8965</b>	C8 level
<b>XA6Z51</b>	Thoracic spinal cord <i>Inclusions:</i> Thoracic cord
<b>XA17G6</b>	T1 level
<b>XA6GU9</b>	T2 level
<b>XA7U15</b>	T3 level

<b>XA5UF4</b>	T4 level
<b>XA0D58</b>	T5 level
<b>XA5Q83</b>	T6 level
<b>XA79E1</b>	T7 level
<b>XA0N76</b>	T8 level
<b>XA5T86</b>	T9 level
<b>XA4QU1</b>	T10 level
<b>XA9DV3</b>	T11 level
<b>XA6FB9</b>	T12 level
<b>XA8PP5</b>	Lumbar spinal cord  <i>Inclusions:</i> Lumbar cord
<b>XA6TL5</b>	L1 level
<b>XA8X63</b>	L2 level
<b>XA57M0</b>	L3 level
<b>XA1ZV5</b>	L4 level
<b>XA86M5</b>	L5 level
<b>XA85J0</b>	Sacral spinal cord  <i>Inclusions:</i> Sacral cord
<b>XA3407</b>	S1 level
<b>XA8EL3</b>	S2 level
<b>XA1VA6</b>	S3 level
<b>XA2EF6</b>	S4 level
<b>XA4L09</b>	S5 level
<b>XA5QM0</b>	Medullary cavity
<b>XA2FQ1</b>	Conus medullaris
<b>XA8EK9</b>	<b>Cranial Nerve</b>
<b>XA5QD6</b>	Olfactory nerve
<b>XA1E00</b>	Optic nerve  <i>Coded Elsewhere:</i> Optic chiasm (XA5TX3) Optic tract (XA63Y1)
<b>XA7488</b>	Oculomotor nerve

<b>XA0GK2</b>	Trochlear nerve
<b>XA72G0</b>	Trigeminal nerve
<b>XA95Y8</b>	Trigeminal nerve, ophthalmic branch
<b>XA5BP8</b>	Ethmoidal nerve
<b>XA8482</b>	External nasal nerve
<b>XA7F46</b>	Frontal nerve
<b>XA31J6</b>	Supraorbital nerve
<b>XA95V8</b>	Supratrochlear nerve
<b>XA16M4</b>	Lacrimal nerve
<b>XA5WM9</b>	Nasociliary nerve
<b>XA8KJ5</b>	Trigeminal nerve, maxillary branch
<b>XA4E11</b>	Inferior palpebral nerve
<b>XA3G43</b>	Infraorbital nerve
<b>XA9G70</b>	Middle meningeal nerve
<b>XA0S35</b>	Nasopalatine nerve
<b>XA9LR9</b>	Nerve of pterygoid canal
<b>XA7P00</b>	Palatine nerve
<b>XA5Q86</b>	Pharyngeal nerve
<b>XA3W58</b>	Sphenopalatine nerves
<b>XA6AE9</b>	Superior labial nerve
<b>XA4DJ9</b>	Zygomatic nerve
<b>XA62X3</b>	Zygomaticofacial nerve
<b>XA9MM8</b>	Zygomaticotemporal nerve
<b>XA1F17</b>	Trigeminal nerve, mandibular branch
<b>XA5DA8</b>	Auriculotemporal nerve
<b>XA7UK9</b>	Buccal nerve
<b>XA52H1</b>	Deep temporal nerve
<b>XA3VT0</b>	Inferior alveolar nerve
<b>XA9FV5</b>	Mylohyoid nerve
<b>XA3114</b>	Lateral pterygoid nerve

<b>XA5CT7</b>	Lingual nerve
<b>XA5NQ5</b>	Masseteric nerve
<b>XA1RH8</b>	Medial pterygoid nerve
<b>XA6ZD8</b>	Mental nerve
<b>XA4GX3</b>	Abducens nerve
<b>XA64Y7</b>	Facial nerve
<b>XA7F87</b>	Posterior auricular nerve
<b>XA1VA9</b>	Temporal branch of the facial nerve
<b>XA7JD7</b>	Zygomatic branch of the facial nerve
<b>XA3A57</b>	Buccal branch of the facial nerve
<b>XA1TY5</b>	Marginal mandibular branch of the facial nerve
<b>XA5241</b>	Cervical branch of the facial nerve
<b>XA1ZH3</b>	Digastric branch of the facial nerve
<b>XA36Y9</b>	Stylohyoid branch of the facial nerve
<b>XA2BL2</b>	Chorda tympani
<b>XA69Y7</b>	Nerve to the stapedius
<b>XA6LY7</b>	Vestibulocochlear nerve
<b>XA1QU6</b>	Cochlear nerve
<b>XA1AL7</b>	Vestibular nerve
<b>XA8RW1</b>	Glossopharyngeal nerve
<b>XA5QA5</b>	Pharyngeal branches of glossopharyngeal nerve
<b>XA6VN1</b>	Vagus nerve <b>Coded Elsewhere:</b> Right recurrent laryngeal nerve (XA1BR5)
<b>XA0P44</b>	Auricular branch of vagus nerve
<b>XA9LV7</b>	Pharyngeal plexus
<b>XA8F53</b>	Pharyngeal branch of vagus nerve
<b>XA2HA5</b>	Superior laryngeal nerve
<b>XA9LP4</b>	External laryngeal nerve
<b>XA6UK8</b>	Internal laryngeal nerve
<b>XA3524</b>	Left recurrent laryngeal nerve

<b>XA2KY5</b>	Pulmonary branches of vagus nerve
<b>XA2M45</b>	Accessory nerve
<b>XA3YX3</b>	Hypoglossal nerve
<b>XA48Z8</b>	Petrosus ganglion
<b>XA4Q30</b>	Tympanic nerve
<b>XA9CT5</b>	Deep petrosal nerve
<b>XA4W18</b>	Greater petrosal nerve
<b>XA1SG6</b>	Ciliary ganglion
<b>XA3VY1</b>	Long ciliary nerves
<b>XA2260</b>	Otic ganglion
<b>XA0ER1</b>	Pterygopalatine ganglion
<b>XA74N6</b>	Submandibular ganglion
<b>XA1630</b>	<b>Peripheral nervous system</b>
<b>XA65L3</b>	<b>Spinal nerve</b>
<b>XA1YC9</b>	Cervical spinal nerve
<b>XA9DY6</b>	First cervical spinal nerve
<b>XA1LR0</b>	Second cervical spinal nerve
<b>XA7LF0</b>	Third cervical spinal nerve
<b>XA1QX0</b>	Fourth cervical spinal nerve
<b>XA06Q1</b>	Fifth cervical spinal nerve
<b>XA26W5</b>	Sixth cervical spinal nerve
<b>XA4WT3</b>	Seventh cervical spinal nerve
<b>XA3XK7</b>	Eighth cervical spinal nerve
<b>XA6KS1</b>	Thoracic spinal nerve
<b>XA2QF3</b>	First thoracic spinal nerve
<b>XA1K85</b>	Second thoracic spinal nerve
<b>XA0DY5</b>	Third thoracic spinal nerve
<b>XA7BM1</b>	Fourth thoracic spinal nerve
<b>XA48M5</b>	Fifth thoracic spinal nerve
<b>XA4GT3</b>	Sixth thoracic spinal nerve

<b>XA0RA9</b>	Seventh thoracic spinal nerve
<b>XA2VJ9</b>	Eighth thoracic spinal nerve
<b>XA64N5</b>	Ninth thoracic spinal nerve
<b>XA5AZ7</b>	Tenth thoracic spinal nerve
<b>XA6369</b>	Eleventh thoracic spinal nerve
<b>XA7QX3</b>	Twelfth thoracic spinal nerve
<b>XA44R0</b>	Lumbar spinal nerve
<b>XA1471</b>	First lumbar spinal nerve
<b>XA0VF5</b>	Second lumbar spinal nerve
<b>XA9178</b>	Third lumbar spinal nerve
<b>XA6N66</b>	Fourth lumbar spinal nerve
<b>XA7VL6</b>	Fifth lumbar spinal nerve
<b>XA17Y2</b>	Sacral spinal nerve
<b>XA2E82</b>	First sacral spinal nerve
<b>XA9V46</b>	Second sacral spinal nerve
<b>XA74E6</b>	Third sacral spinal nerve
<b>XA25F0</b>	Fourth sacral spinal nerve
<b>XA73B4</b>	Fifth sacral spinal nerve
<b>XA4CU7</b>	Dorsal spinal nerve
<b>XA7TS7</b>	Ventral spinal nerve
<b>XA6EC2</b>	<b>Spinal nerve root</b>
<b>XA3UZ3</b>	Cervical nerve root
<b>XA53S6</b>	First cervical nerve root
<b>XA15A2</b>	Second cervical nerve root
<b>XA2MT0</b>	Third cervical nerve root
<b>XA36V3</b>	Fourth cervical nerve root
<b>XA87U1</b>	Fifth cervical nerve root
<b>XA8YT7</b>	Sixth cervical nerve root
<b>XA5BL9</b>	Seventh cervical nerve root
<b>XA0245</b>	Eighth cervical nerve root

<b>XA5SU4</b>	Thoracic nerve root
<b>XA22C5</b>	First thoracic nerve root
<b>XA8933</b>	Second thoracic nerve root
<b>XA2EK5</b>	Third thoracic nerve root
<b>XA6NV1</b>	Fourth thoracic nerve root
<b>XA8DN4</b>	Fifth thoracic nerve root
<b>XA1AB6</b>	Sixth thoracic nerve root
<b>XA1VM6</b>	Seventh thoracic nerve root
<b>XA2UY4</b>	Eighth thoracic nerve root
<b>XA8QS1</b>	Ninth thoracic nerve root
<b>XA2VK2</b>	Tenth thoracic nerve root
<b>XA61G0</b>	Eleventh thoracic nerve root
<b>XA76V2</b>	Twelfth thoracic nerve root
<b>XA4T95</b>	Lumbar nerve root
<b>XA8VX2</b>	First lumbar nerve root
<b>XA9BK9</b>	Second lumbar nerve root
<b>XA4N03</b>	Third lumbar nerve root
<b>XA2ZQ7</b>	Fourth lumbar nerve root
<b>XA5W91</b>	Fifth lumbar nerve root
<b>XA9F62</b>	Sacral nerve root
<b>XA4HY7</b>	First sacral nerve root
<b>XA4PP9</b>	Second sacral nerve root
<b>XA32J7</b>	Third sacral nerve root
<b>XA0WH3</b>	Fourth sacral nerve root
<b>XA7BN5</b>	Fifth sacral nerve root
<b>XA9J98</b>	Dorsal nerve root ganglion
<b>XA1TP8</b>	Dorsal nerve root
<b>XA8G34</b>	Ventral nerve root ganglion
<b>XA1V70</b>	Ventral nerve root
<b>XA64F0</b>	<b>Spinal nerve plexus</b>

<b>XA6LU7</b>	Cervical plexus
<b>XA22K9</b>	Brachial plexus
<b>XA1UT5</b>	Posterior cord of brachial plexus
<b>XA9PG2</b>	Lateral cord of brachial plexus
<b>XA7UA9</b>	Medial cord of brachial plexus
<b>XA8YS2</b>	Lumbosacral plexus
<b>XA1E79</b>	Lumbar plexus
<b>XA1JE5</b>	Presacral plexus
<b>XA0929</b>	Sacral plexus
<b>XA5186</b>	Patellar plexus
<b>XA3SK8</b>	Splanchnic plexus
<b>XA2G95</b>	Uterovaginal plexus
<b>XA1KP5</b>	Vesical nervous plexus
<b>XA06U6</b>	<b>Peripheral nerve</b>
<b>XA20S2</b>	Inferior cervical ganglion
<b>XA0Z50</b>	Suboccipital nerve
<b>XA4WK4</b>	Greater auricular nerve
<b>XA6BB0</b>	Greater occipital nerve
<b>XA3ND8</b>	Lesser occipital nerve
<b>XA18D0</b>	Third occipital nerve
<b>XA8T30</b>	Iliohypogastric nerve
<b>XA5Q50</b>	Ilioinguinal nerve
<b>XA8CZ0</b>	Inferior anal nerves
<b>XA8U35</b>	Lumbar splanchnic nerve
<b>XA8ML2</b>	Middle cardiac nerve
<b>XA11K1</b>	Posterior branch of spinal nerve
<b>XA9AN9</b>	Posterior superior alveolar nerve
<b>XA7ZD7</b>	Proper palmar digital nerves of median nerve
<b>XA0SA1</b>	Sacral splanchnic nerves
<b>XA1SM8</b>	Semilunar ganglion

<b>XA07F8</b>	Short ciliary nerves
<b>XA1AC5</b>	Superior cardiac nerve
<b>XA6BG1</b>	Superior cervical ganglion
<b>XA6YL5</b>	Superior ganglion
<b>XA25F4</b>	Transverse cervical nerve
<b>XA9ZM0</b>	Phrenic nerve
<b>XA6W14</b>	Sympathetic trunk
<b>XA7HH4</b>	Common fibular nerve
<b>XA3QB5</b>	Deep fibular nerve
<b>XA11D4</b>	Femoral nerve
<b>XA9JZ4</b>	Genitofemoral nerve
<b>XA60R4</b>	Gluteal nerve
<b>XA1GU3</b>	Inferior gluteal nerve
<b>XA4834</b>	Lateral femoral cutaneous nerve
<b>XA9958</b>	Lateral plantar nerve
<b>XA5UE9</b>	Lumbar nerve
<b>XA8307</b>	Lumboinguinal nerve
<b>XA76D3</b>	Lumbosacral trunk
<b>XA9AF5</b>	Medial plantar nerve
<b>XA7S27</b>	Nerve to quadratus femoris
<b>XA3906</b>	Plantar nerve
<b>XA83P9</b>	Posterior cutaneous nerve of thigh
<b>XA9EW1</b>	Saphenous nerve
<b>XA9KK8</b>	Sciatic nerve
<b>XA2125</b>	Superficial fibular nerve
<b>XA9AC5</b>	Superior gluteal nerve
<b>XA4HR8</b>	Sural nerve
<b>XA7534</b>	Tibial nerve
<b>XA9JU0</b>	Anococcygeal nerve
<b>XA84W1</b>	Cauda equina

<b>XA5C62</b>	Coccygeal nerve
<b>XA76C3</b>	Dorsal nerve of clitoris
<b>XA8CC3</b>	Dorsal nerve of the penis
<b>XA99Q6</b>	Genital branch of genitofemoral nerve
<b>XA0W10</b>	Perineal nerve
<b>XA7NU3</b>	Posterior scrotal nerve
<b>XA6WU3</b>	Pudendal nerve
<b>XA55J8</b>	Accessory obturator nerve
<b>XA9RP3</b>	Dorsal scapular nerve
<b>XA9TB4</b>	Inferior cardiac nerve
<b>XA5HJ3</b>	Intercostal nerve
<b>XA2F71</b>	Intercostobrachial nerve
<b>XA5A06</b>	Lateral pectoral nerve
<b>XA0A05</b>	Long thoracic nerve
<b>XA9XA5</b>	Lower subscapular nerve
<b>XA49V5</b>	Medial pectoral nerve
<b>XA1BR5</b>	Right recurrent laryngeal nerve
<b>XA3RU6</b>	Subcostal nerve
<b>XA5318</b>	Supraclavicular nerves
<b>XA8QY6</b>	Suprascapular nerve
<b>XA2R06</b>	Thoracic splanchnic nerve
<b>XA0462</b>	Thoraco-abdominal nerve
<b>XA2542</b>	Thoracodorsal nerve
<b>XA5KR0</b>	Upper subscapular nerve
<b>XA1ZC4</b>	Axillary nerve
<b>XA1LW6</b>	Common palmar digital nerves of median nerve
<b>XA5179</b>	Deep branch of the radial nerve
<b>XA37M8</b>	Digital nerve
<b>XA1TY7</b>	Dorsal branch of ulnar nerve
<b>XA6166</b>	Lateral cutaneous nerve of forearm

<b>XA9HJ5</b>	Medial cutaneous nerve
<b>XA7K97</b>	Medial cutaneous nerve of arm
<b>XA26F7</b>	Medial cutaneous nerve of forearm
<b>XA3P46</b>	Muscular branches of the radial nerve
<b>XA89K2</b>	Palmar branch of the median nerve
<b>XA7FU0</b>	Palmar branch of ulnar nerve
<b>XA0KL7</b>	Posterior cutaneous nerve of forearm
<b>XA2XU7</b>	Posterior cutaneous nerve of arm
<b>XA2E94</b>	Superficial branch of the radial nerve
<b>XA6B07</b>	Superior lateral cutaneous nerve of arm
<b>XA2M04</b>	Ansa cervicalis
<b>XA6RQ4</b>	Anterior interosseous nerve
<b>XA6PJ8</b>	Anterior superior alveolar nerve
<b>XA54B9</b>	Bulbar nuclei
<b>XA89R1</b>	Celiac ganglion
<b>XA8QL3</b>	Diagonal band of Broca
<b>XA66H0</b>	Geniculate ganglion
<b>XA6B81</b>	Intermediate cutaneous nerve
<b>XA8AU6</b>	Jugular ganglion
<b>XA1Z01</b>	Long root of the ciliary ganglion
<b>XA9RD0</b>	Middle cervical ganglion
<b>XA5QF4</b>	Musculocutaneous nerve
<b>XA96Q6</b>	Nerve of the cervical region
<b>XA1HC7</b>	Nerve to obturator internus
<b>XA8PE3</b>	Nerve to the piriformis
<b>XA4XD7</b>	Nerve to the subclavius
<b>XA0869</b>	Nervus intermedius
<b>XA2KG8</b>	Nervus spinosus
<b>XA5NY4</b>	Nodose ganglion
<b>XA4548</b>	Obturator nerve

<b>XA9519</b>	Paraganglion <i>Coded Elsewhere:</i> Carotid body (XA0F61)
<b>XA0VA6</b>	Aortic body
<b>XA6Y08</b>	Coccygeal glomus
<b>XA17K2</b>	Glomus jugulare
<b>XA8S02</b>	Para-aortic body
<b>XA1GM8</b>	Pelvic splanchnic nerve
<b>XA6GZ8</b>	Perforating cutaneous nerve
<b>XA4A74</b>	Perineal branches of posterior femoral cutaneous nerve
<b>XA7718</b>	<b>Autonomic nervous system</b>
<b>XA2BH4</b>	<b>Nerves of the autonomic nervous system</b> <i>Coded Elsewhere:</i> Infraorbital nerve (XA3G43)
	Splanchnic plexus (XA3SK8)
	Uterovaginal plexus (XA2G95)
	Vesical nervous plexus (XA1KP5)
<b>XA3XN8</b>	Aortic plexus
<b>XA2G56</b>	Auerbach plexus
<b>XA9QM5</b>	Cardiac plexus
<b>XA3FS7</b>	Cavernous plexus
<b>XA4U92</b>	Coeliac plexus
<b>XA2Y82</b>	Gastric plexus
<b>XA4YZ0</b>	Hepatic plexus
<b>XA05T1</b>	Inferior hypogastric plexus
<b>XA8QG3</b>	Inferior mesenteric plexus
<b>XA5JN1</b>	Internal carotid plexus
<b>XA8Z10</b>	Meissner plexus
<b>XA7K49</b>	Oesophageal plexus
<b>XA9PB2</b>	Ovarian plexus
<b>XA0C44</b>	Pancreatic plexus
<b>XA9ME3</b>	Phrenic plexus
<b>XA16Y3</b>	Prostatic plexus

<b>XA9411</b>	Pudendal plexus
<b>XA82M9</b>	Renal plexus
<b>XA4V38</b>	Splenic plexus
<b>XA33C1</b>	Superior hypogastric plexus
<b>XA3DJ3</b>	Superior mesenteric plexus
<b>XA4G22</b>	Superior rectal plexus
<b>XA6MY2</b>	Suprarenal plexus
<b>XA7EA2</b>	<b>Parasympathetic nervous system</b>
<b>XA93B4</b>	<b>Sympathetic nervous system</b>

Nerve

**Coded Elsewhere:** Peripheral nerve (XA06U6)

- Accessory obturator nerve (XA55J8)
- Auricular branch of vagus nerve (XA0P44)
- Anococcygeal nerve (XA9JU0)
- Ansa cervicalis (XA2M04)
- Anterior interosseous nerve (XA6RQ4)
- Anterior superior alveolar nerve (XA6PJ8)
- Aortic plexus (XA3XN8)
- Auerbach plexus (XA2G56)
- Auriculotemporal nerve (XA5DA8)
- Axillary nerve (XA1ZC4)
- Buccal nerve (XA7UK9)
- Bulbar nuclei (XA54B9)
- Cardiac plexus (XA9QM5)
- Cauda equina (XA84W1)
- Cavernous plexus (XA3FS7)
- Celiac ganglion (XA89R1)
- Chorda tympani (XA2BL2)
- Ciliary ganglion (XA1SG6)
- Coccygeal nerve (XA5C62)
- Cochlear nerve (XA1QU6)
- Common palmar digital nerves of median nerve (XA1LW6)
- Common fibular nerve (XA7HH4)
- Conus medullaris (XA2FQ1)
- Cranial Nerve (XA8EK9)
- Deep branch of the radial nerve (XA5179)
- Deep fibular nerve (XA3QB5)
- Deep petrosal nerve (XA9CT5)
- Deep temporal nerve (XA52H1)
- Diagonal band of Broca (XA8QL3)
- Digital nerve (XA37M8)
- Dorsal branch of ulnar nerve (XA1TY7)
- Dorsal nerve of clitoris (XA76C3)
- Dorsal nerve of the penis (XA8CC3)
- Dorsal scapular nerve (XA9RP3)
- Oesophageal plexus (XA7K49)
- Ethmoidal nerve (XA5BP8)
- External laryngeal nerve (XA9LP4)
- Femoral nerve (XA11D4)

Frontal nerve (XA7F46)  
Gastric plexus (XA2Y82)  
Geniculate ganglion (XA66H0)  
Genital branch of genitofemoral nerve (XA99Q6)  
Genitofemoral nerve (XA9JZ4)  
Gluteal nerve (XA60R4)  
Greater auricular nerve (XA4WK4)  
Greater occipital nerve (XA6BB0)  
Greater petrosal nerve (XA4W18)  
Hepatic plexus (XA4YZ0)  
Iliohypogastric nerve (XA8T30)  
Ilioinguinal nerve (XA5Q50)  
Inferior alveolar nerve (XA3VT0)  
Inferior anal nerves (XA8CZ0)  
Inferior cardiac nerve (XA9TB4)  
Inferior cervical ganglion (XA20S2)  
Inferior gluteal nerve (XA1GU3)  
Inferior hypogastric plexus (XA05T1)  
Inferior mesenteric plexus (XA8QG3)  
Inferior palpebral nerve (XA4E11)  
Infraorbital nerve (XA3G43)  
Intercostal nerve (XA5HJ3)  
Intercostobrachial nerve (XA2F71)  
Intermediate cutaneous nerve (XA6B81)  
Internal carotid plexus (XA5JN1)  
Internal laryngeal nerve (XA6UK8)  
Jugular ganglion (XA8AU6)  
Lacrimal nerve (XA16M4)  
Lateral cord of brachial plexus (XA9PG2)  
Lateral cutaneous nerve of forearm (XA6166)  
Lateral femoral cutaneous nerve (XA4834)  
Lateral pectoral nerve (XA5A06)  
Lateral plantar nerve (XA9958)  
Lateral pterygoid nerve (XA3114)  
Left recurrent laryngeal nerve (XA3524)  
Lesser occipital nerve (XA3ND8)  
Lingual nerve (XA5CT7)  
Long ciliary nerves (XA3VY1)  
Long root of the ciliary ganglion (XA1Z01)  
Long thoracic nerve (XA0A05)

Lower subscapular nerve (XA9XA5)  
Lumbar nerve (XA5UE9)  
Lumbar splanchnic nerve (XA8U35)  
Lumboinguinal nerve (XA8307)  
Lumbosacral trunk (XA76D3)  
Trigeminal nerve, mandibular branch (XA1F17)  
Masseteric nerve (XA5NQ5)  
Trigeminal nerve, maxillary branch (XA8KJ5)  
Medial cord of brachial plexus (XA7UA9)  
Medial cutaneous nerve of arm (XA7K97)  
Medial cutaneous nerve of forearm (XA26F7)  
Medial cutaneous nerve (XA9HJ5)  
Medial pectoral nerve (XA49V5)  
Medial plantar nerve (XA9AF5)  
Medial pterygoid nerve (XA1RH8)  
Meissner plexus (XA8Z10)  
Mental nerve (XA6ZD8)  
Middle cardiac nerve (XA8ML2)  
Middle cervical ganglion (XA9RD0)  
Middle meningeal nerve (XA9G70)  
Muscular branches of the radial nerve (XA3P46)  
Musculocutaneous nerve (XA5QF4)  
Mylohyoid nerve (XA9FV5)  
Nasociliary nerve (XA5WM9)  
Nasopalatine nerve (XA0S35)  
Nerve of pterygoid canal (XA9LR9)  
Nerve of the cervical region (XA96Q6)  
Spinal nerve plexus (XA64F0)  
Spinal nerve root (XA6EC2)  
Nerve to obturator internus (XA1HC7)  
Nerve to quadratus femoris (XA7S27)  
Nerve to the piriformis (XA8PE3)  
Nerve to the stapedius (XA69Y7)  
Nerve to the subclavius (XA4XD7)  
Nervus intermedius (XA0869)  
Nervus spinosus (XA2KG8)  
Nodose ganglion (XA5NY4)  
Obturator nerve (XA4548)  
Trigeminal nerve, ophthalmic branch (XA95Y8)  
Otic ganglion (XA2260)

Ovarian plexus (XA9PB2)  
Palatine nerve (XA7P00)  
Palmar branch of the median nerve (XA89K2)  
Palmar branch of ulnar nerve (XA7FU0)  
Pancreatic plexus (XA0C44)  
Paraganglion (XA9519)  
Patellar plexus (XA5186)  
Pelvic splanchnic nerve (XA1GM8)  
Perforating cutaneous nerve (XA6GZ8)  
Perineal branches of posterior femoral cutaneous nerve (XA4A74)  
Perineal nerve (XA0W10)  
Petrous ganglion (XA48Z8)  
Pharyngeal nerve (XA5Q86)  
Phrenic nerve (XA9ZM0)  
Phrenic plexus (XA9ME3)  
Plantar nerve (XA3906)  
Posterior auricular nerve (XA7F87)  
Posterior branch of spinal nerve (XA11K1)  
Posterior cord of brachial plexus (XA1UT5)  
Posterior cutaneous nerve of arm (XA2XU7)  
Posterior cutaneous nerve of forearm (XA0KL7)  
Posterior cutaneous nerve of thigh (XA83P9)  
Posterior scrotal nerve (XA7NU3)  
Posterior superior alveolar nerve (XA9AN9)  
Proper palmar digital nerves of median nerve (XA7ZD7)  
Prostatic plexus (XA16Y3)  
Pterygopalatine ganglion (XA0ER1)  
Pudendal nerve (XA6WU3)  
Pudendal plexus (XA9411)  
Renal plexus (XA82M9)  
Right recurrent laryngeal nerve (XA1BR5)  
Sacral splanchnic nerves (XA0SA1)  
Saphenous nerve (XA9EW1)  
Sciatic nerve (XA9KK8)  
Semilunar ganglion (XA1SM8)  
Short ciliary nerves (XA07F8)  
Sphenopalatine nerves (XA3W58)  
Spinal nerve (XA65L3)  
Splenic plexus (XA4V38)  
Subcostal nerve (XA3RU6)

Submandibular ganglion (XA74N6)  
Suboccipital nerve (XA0Z50)  
Superficial branch of the radial nerve (XA2E94)  
Superficial fibular nerve (XA2I25)  
Superior cardiac nerve (XA1AC5)  
Superior cervical ganglion (XA6BG1)  
Superior ganglion (XA6YL5)  
Superior gluteal nerve (XA9AC5)  
Superior hypogastric plexus (XA33C1)  
Superior labial nerve (XA6AE9)  
Superior laryngeal nerve (XA2HA5)  
Superior lateral cutaneous nerve of arm (XA6B07)  
Superior mesenteric plexus (XA3DJ3)  
Superior rectal plexus (XA4G22)  
Supraclavicular nerves (XA5318)  
Suprarenal plexus (XA6MY2)  
Suprascapular nerve (XA8QY6)  
Supratrochlear nerve (XA95V8)  
Sural nerve (XA4HR8)  
Sympathetic trunk (XA6W14)  
Third occipital nerve (XA18D0)  
Thoracic splanchnic nerve (XA2R06)  
Thoraco-abdominal nerve (XA0462)  
Thoracodorsal nerve (XA2542)  
Tibial nerve (XA7534)  
Transverse cervical nerve (XA25F4)  
Tympanic nerve (XA4Q30)  
Upper subscapular nerve (XA5KR0)  
Vestibular nerve (XA1AL7)  
Zygomatic nerve (XA4DJ9)  
Zygomaticofacial nerve (XA62X3)  
Zygomaticotemporal nerve (XA9MM8)

**XA3PR2**      **Nerve ganglia**

**XA2B55**      **Infraorbital plexus**

**XA0GB0**      **Median nerve**

**XA3M58**      **Nerve of the Thorax**

## Number of Nerves

XA2330	<b>Multiple Nerves</b>
XA7MX8	<b>Single Nerve</b>
XA8BJ3	<b>Radial nerve</b>
XA2AS2	<b>Ulnar nerve</b>
XA4M27	<b>Ventral ramus</b>

## Visual system

XA7D89	<b>Eye</b> <i>Coded Elsewhere:</i> Lacrimal gland (XA75Y9)
XA17K1	<b>Eyelid and ocular surface</b> <i>Coded Elsewhere:</i> Cornea (XA4C02)
XA3RB1	Eyelids
XA9K79	Upper eyelid
XA53T1	Upper eyelid margin <i>Coded Elsewhere:</i> Superior lacrimal punctum (XA2VR4)
XA4649	Superior palpebral sulcus
XA0JV9	Lower eyelid
XA4AX5	Lower eyelid margin <i>Coded Elsewhere:</i> Inferior lacrimal punctum (XA99D0)
XA0403	Lateral canthus
XA2GQ3	Medial canthus
XA8PS3	Conjunctiva
XA3X70	Palpebral conjunctiva
XA6EZ4	Conjunctival fornices
XA4H06	Superior conjunctival fornix
XA3KE6	Inferior conjunctival fornix
XA6V06	Bulbar conjunctiva
XA0M40	<b>Eyeball</b> <i>Coded Elsewhere:</i> Anterior chamber of the eye (XA4MZ4) Posterior chamber of the eye (XA0N58)

<b>XA2AF4</b>	Sclera
<b>XA4C02</b>	Cornea
<b>XA1DA5</b>	Limbus of cornea
<b>XA4MT3</b>	Uvea
<b>XA03X9</b>	Ciliary body
<b>XA9SH1</b>	Ciliary muscle
<b>XA1S43</b>	Ciliary processes
<b>XA96A7</b>	Choroid
	<b><i>Coded Elsewhere:</i></b> Crystalline lens (XA13U9)
<b>XA3GW7</b>	Iris
<b>XA0B15</b>	Pupil
<b>XA0571</b>	Pupillary membrane
<b>XA13U9</b>	Crystalline lens
<b>XA6U53</b>	Suspensory ligament of lens
<b>XA8WV8</b>	Retina
<b>XA9V06</b>	Macula lutea
<b>XA2U02</b>	Fovea
<b>XA4A75</b>	Optic disc
<b>XA4YS8</b>	Peripheral retina
<b>XA0BB2</b>	<b>Chamber of eye</b>
<b>XA0N58</b>	Posterior chamber of the eye
<b>XA4HU2</b>	Vitreous humor
<b>XA4MZ4</b>	Anterior chamber of the eye
<b>XA3518</b>	Aqueous humour
<b>XA1TF9</b>	<b>Eye fluid</b>
	<b><i>Coded Elsewhere:</i></b> Aqueous humour (XA3518)
	Vitreous humor (XA4HU2)
<b>XA0096</b>	<b>Lacrimal apparatus</b>
<b>XA75Y9</b>	<b>Lacrimal gland</b>
	<b><i>Coded Elsewhere:</i></b> Nasolacrimal duct (XA5SW9)
	Lacrimal sac (XA0096)

<b>XA2PA4</b>	Lacrimal gland ducts
<b>XA9D80</b>	<b>Meibomian gland</b>
<b>XA8EM9</b>	<b>Lacrimal puncta</b>
<b>XA2VR4</b>	Superior lacrimal punctum
<b>XA99D0</b>	Inferior lacrimal punctum
<b>XA6C35</b>	<b>Lacrimal canaliculi</b>
<b>XA5SW9</b>	<b>Nasolacrimal duct</b>
<b>XA2WJ9</b>	<b>Orbit</b>
	<i>Coded Elsewhere:</i> Orbital bone (XA8E69)
<b>XA9WT4</b>	<b>Connective and other soft tissue of orbit</b>
	<i>Coded Elsewhere:</i> Lateral palpebral artery (XA00Q9)
	Superior rectus muscle (XA51R1)
	Superior oblique muscle (XA2X27)
	Medial rectus muscle (XA95N1)
	Inferior rectus muscle (XA1X67)
	Inferior oblique muscle (XA4N79)
	Lateral rectus muscle (XA3282)
	Levator palpebrae superioris muscle (XA2R46)
<b>XA8GT2</b>	Nasofrontal vein
<b>XA7LQ0</b>	Supraorbital vein

## Auditory system

<b>XA01U5</b>	<b>Ear</b>
<b>XA57R3</b>	<b>Inner Ear</b>
<b>XA3MS6</b>	Semicircular canals
<b>XA0JV0</b>	Cochlea
<b>XA6ZY7</b>	Internal Acoustic Meatus
<b>XA0L54</b>	Labyrinth
<b>XA44P4</b>	Auditory vestibule
<b>XA0G74</b>	<b>Middle Ear</b>
	<i>Coded Elsewhere:</i> Bones of middle ear (XA6EQ1)
<b>XA7XY6</b>	Eustachian tube
<b>XA16S6</b>	Oval window

<b>XA9RH9</b>	Mastoid antrum
<b>XA3KB2</b>	Tympanic cavity
<b>XA3UT7</b>	Connective and other soft tissues of middle ear
<b>XA08X4</b>	Tympanic membrane
<b>XA6ZY6</b>	<b>External Ear</b> The external portion of the ear comprising the pinna (auricle) and the external auditory canal.
<b>XA4E71</b>	Pinna
<b>XA6B58</b>	Helix of pinna
<b>XA9A86</b>	Crus of helix
<b>XA9M10</b>	Apex of helix
<b>XA7AB8</b>	Spine of helix
<b>XA1BZ8</b>	Tail of helix
<b>XA7V14</b>	Antihelix
<b>XA96Q7</b>	Crura of antihelix
<b>XA5LW2</b>	Scaphoid fossa of pinna
<b>XA8W55</b>	Concha of pinna
<b>XA5KM5</b>	Cymba conchae
<b>XA8D58</b>	Conchal bowl of pinna
<b>XA3RC6</b>	Triangular fossa of pinna The concavity bounded by the superior and inferior crura of the antihelix and the ascending portion of the helix of the external ear
<b>XA2N71</b>	Tragus of pinna
<b>XA5VK5</b>	Intertragic notch of pinna
<b>XA0TW7</b>	Earlobe
<b>XA7RR9</b>	Antitragus of pinna
<b>XA3S47</b>	Posterior surface of pinna
<b>XA6NU1</b>	Antihelical fossa
<b>XA6KW8</b>	Eminence of concha
<b>XA0H47</b>	Eminence of scapha
<b>XA8VK6</b>	Eminence of triangular fossa
<b>XA4DV9</b>	Retroauricular sulcus

<b>XA3UC1</b>	External auditory canal The tubular skin-lined canal which focuses sound from the external environment onto the ear-drum  <b>Coded Elsewhere:</b> Tympanic membrane (XA08X4)
<b>XA5GS5</b>	External auditory meatus The entrance to the external auditory canal
<b>XA5K66</b>	Ceruminal gland
<b>XA9E26</b>	Skin of auricle

## Circulatory system

<b>XA4PM9</b>	<b>Cardiovascular system</b>
<b>XA5999</b>	<b>Arteries</b>
<b>XA4TS7</b>	Artery of head, face, and neck
<b>XA2B10</b>	Anterior communicating artery
<b>XA2QF4</b>	Anterior ethmoidal artery
<b>XA53D3</b>	Nasal branches of the anterior ethmoidal artery
<b>XA00K1</b>	Anterior meningeal artery
<b>XA1GU9</b>	Anterior superior alveolar artery
<b>XA2505</b>	Artery of pterygoid canal
<b>XA9AD7</b>	Carotid artery
<b>XA0F61</b>	Carotid body
<b>XA1V84</b>	Common carotid artery
<b>XA78C0</b>	Internal carotid artery
<b>XA1CW5</b>	Ophthalmic artery
<b>XA9EK2</b>	External carotid artery
<b>XA5SN3</b>	Cerebellar artery
<b>XA13S2</b>	Cerebral artery
<b>XA1VB0</b>	Anterior cerebral artery
<b>XA2K99</b>	Basilar artery
<b>XA3185</b>	Pontine branches of the basilar artery
<b>XA2JH8</b>	Middle cerebral artery
<b>XA4WT4</b>	Anterolateral central artery

<b>XA7C50</b>	Posterior cerebral artery
<b>XA2UK9</b>	Costocervical trunk
<b>XA7SK1</b>	Deep auricular artery
<b>XA1NY7</b>	Deep cervical artery
<b>XA18D8</b>	Dorsal nasal artery
<b>XA56R8</b>	Dorsal nasal artery to the root of nose
<b>XA0PF0</b>	Dorsal nasal artery to the dorsum of the nose
<b>XA4QF0</b>	External striate of the anterolateral central artery
<b>XA3FL3</b>	Facial artery
<b>XA7YP8</b>	Ascending palatine artery
<b>XA4UT8</b>	Superior labial artery
<b>XA2ZM0</b>	Inferior labial artery
<b>XA36S6</b>	Angular artery
<b>XA9QG7</b>	Cervical artery
<b>XA85T4</b>	Deep branch of the submental artery
<b>XA83M8</b>	Glandular branches of the cervical artery
<b>XA2626</b>	Greater palatine artery
<b>XA4H29</b>	Hyoid artery
<b>XA4VH9</b>	Inferior palpebral arch artery
<b>XA5VX8</b>	Internal striate of the anterolateral central artery
<b>XA85W7</b>	Intracranial artery
<b>XA16L7</b>	Lateral branch of the posterior inferior cerebellar artery
<b>XA3N26</b>	Lateral nasal branch of the facial artery
<b>XA5Z38</b>	Lesser palatine artery
<b>XA5TR9</b>	Lingual branch of the inferior alveolar artery
<b>XA18M5</b>	Maxillary artery
<b>XA49F5</b>	First portion of the maxillary artery
<b>XA0BD0</b>	Deep temporal artery (anterior and posterior)
<b>XA7SV5</b>	Inferior alveolar artery
<b>XA3W87</b>	Incisor branch of the Inferior alveolar artery

<b>XA7AG7</b>	Mental branch of the Inferior alveolar artery
<b>XA49F4</b>	Masseteric artery
<b>XA55G2</b>	Descending palatine artery
<b>XA9XM3</b>	Pharyngeal artery
<b>XA3WA5</b>	Posterior superior alveolar artery
<b>XA0LK0</b>	Buccal artery
<b>XA9MM1</b>	Anterior tympanic artery
<b>XA8YX3</b>	Accessory meningeal artery
<b>XA5RM1</b>	Middle meningeal artery
<b>XA2WS5</b>	Lingual artery
<b>XA9EU7</b>	Occipital artery
<b>XA13U3</b>	Posterior auricular artery
<b>XA0SB1</b>	Superficial temporal artery
<b>XA7WG0</b>	Frontal branch of the superficial temporal artery
<b>XA7K29</b>	Superior thyroid artery
<b>XA0FT7</b>	Cricothyroid artery
<b>XA2V10</b>	Inferior thyroid artery
<b>XA77C5</b>	Sternocleidomastoid artery
<b>XA00E5</b>	Ascending pharyngeal artery
<b>XA53A8</b>	Right common carotid artery
<b>XA6X36</b>	Middle temporal artery
<b>XA3TE9</b>	Mylohyoid branch of the inferior alveolar artery
<b>XA6XV2</b>	Parietal branch of the superficial temporal artery
<b>XA7U73</b>	Posterior communicating artery
<b>XA5881</b>	Posterior ethmoidal artery
<b>XA7561</b>	Nasal branches of the posterior ethmoidal artery
<b>XA7945</b>	Meningeal branch of the posterior ethmoidal artery
<b>XA8RM9</b>	Posterior inferior cerebellar artery
<b>XA9VV0</b>	Posterior lateral nasal branches of the sphenopalatine artery
<b>XA8FA1</b>	Posterior meningeal artery

<b>XA4Q78</b>	Posterior septal branches of the sphenopalatine artery
<b>XA1K74</b>	Pterygoid branches
<b>XA1BZ0</b>	Sphenopalatine artery, terminal branch
<b>XA90T0</b>	Submental artery of the cervical artery
<b>XA6FR0</b>	Superficial branch of the submental artery
<b>XA0898</b>	Superficial branch of the transverse cervical artery
<b>XA82P9</b>	Superficial petrosal branch of the anterior and posterior meningeal artery
<b>XA7423</b>	Superior cerebellar artery
<b>XA9GU1</b>	Superior laryngeal artery
<b>XA50Q9</b>	Superior tympanic artery
<b>XA6W31</b>	Supratrochlear artery
<b>XA65G3</b>	Temporal branches of the anterior and posterior meningeal artery
<b>XA9XH0</b>	Thyrocervical trunk
<b>XA2E78</b>	Tonsillar branch of the cervical artery
<b>XA6142</b>	Transverse cervical artery
<b>XA9M59</b>	Transverse facial artery
<b>XA5D86</b>	Twig to the upper part of lacrimal sac of the dorsal nasal artery
<b>XA1XP6</b>	Vertebral artery
<b>XA3NW4</b>	Meningeal branches of vertebral artery
<b>XA6TE8</b>	Ascending branch of the vertebral artery
<b>XA3R20</b>	Descending branch of the vertebral artery
<b>XA1C15</b>	Supraorbital artery
<b>XA6503</b>	Superficial branch of the supraorbital artery
<b>XA8BL5</b>	Deep branch of the supraorbital artery
<b>XA34H5</b>	Orbital branches of the anterior and posterior meningeal artery
<b>XA5C33</b>	Infraorbital artery
<b>XA05E9</b>	Orbital branches of the infraorbital artery
<b>XA9RA2</b>	Long posterior ciliary artery
<b>XA04E2</b>	Short posterior ciliary artery
<b>XA94Y6</b>	Anterior ciliary artery

<b>XA5RB0</b>	Central retinal artery
<b>XA22D8</b>	Circulus arteriosus major artery
<b>XA8T70</b>	Circulus arteriosus minor artery
<b>XA5P69</b>	Lacrimal artery
<b>XA00Q9</b>	Lateral palpebral artery
<b>XA8VA1</b>	Medial palpebral artery
<b>XA35L5</b>	Superior palpebral arch artery
<b>XA1Q49</b>	Zygomatic branches of the lacrimal artery
<b>XA4KE1</b>	Branches to gingiva
<b>XA9UT1</b>	Artery of thorax <b>Coded Elsewhere:</b> Arteries of heart (XA42G7)
<b>XA4TH8</b>	Branches to diaphragm of the musculophrenic artery
<b>XA1PX4</b>	Branches to lower part of the pericardium of the musculophrenic artery
<b>XA2KA0</b>	Brachiocephalic trunk
<b>XA3M86</b>	Deep branch of dorsal scapular artery
<b>XA7KK5</b>	Intercostal artery
<b>XA0T62</b>	Intercostal branches of the musculophrenic artery
<b>XA9S49</b>	Internal thoracic artery
<b>XA4XE2</b>	Mediastinal artery
<b>XA3DE1</b>	Lateral thoracic artery
<b>XA09J9</b>	Pulmonary artery
<b>XA1EE3</b>	Lower (3rd to 11th) posterior intercostal artery
<b>XA0QG6</b>	Lower branches of the space anastomoses of the six anterior intercostal branches of the internal thoracic artery
<b>XA7EC2</b>	Musculophrenic artery
<b>XA1190</b>	Perforating branches of the internal thoracic artery
<b>XA0WT1</b>	Posterior intercostal artery
<b>XA14K0</b>	Six anterior intercostal branches of the internal thoracic artery
<b>XA6UQ6</b>	Sternal branches of the internal thoracic artery
<b>XA3311</b>	Subcostal artery
<b>XA9J15</b>	Superior phrenic artery

<b>XA8M67</b>	Superior thoracic artery
<b>XA7TT5</b>	Supreme intercostal artery
<b>XA79X5</b>	Thoracoacromial artery
<b>XA99C2</b>	Upper branches of the six anterior intercostal branches of the internal thoracic artery
<b>XA8ES3</b>	Oesophageal artery
<b>XA8K52</b>	Aorta of thorax
<b>XA75Z8</b>	Arch of the aorta  <b>Coded Elsewhere:</b> Aortic body (XA0VA6)
<b>XA01A6</b>	Ascending aorta
<b>XA5H34</b>	Descending aorta
<b>XA6E07</b>	Bronchial artery
<b>XA5D68</b>	Subclavian artery
<b>XA9JK8</b>	Artery of abdomen  <b>Coded Elsewhere:</b> Abdominal aorta (XA5Z66)
<b>XA7TZ1</b>	Anterior suprarenal artery
<b>XA82R7</b>	Ascending branch of the left colic artery
<b>XA8BY2</b>	Branches to abdominal muscles of the musculophrenic artery
<b>XA8577</b>	Coeliac artery
<b>XA26R6</b>	Common hepatic artery
<b>XA0JE4</b>	Cystic artery
<b>XA6NY6</b>	Descending branch of the left colic artery
<b>XA1VJ7</b>	Descending vasa recta
<b>XA1QB0</b>	Dorsal pancreatic artery
<b>XA0NN4</b>	Gastroduodenal artery
<b>XA5AP2</b>	Hepatic artery
<b>XA2LQ8</b>	Hepatic branch of the left gastric artery
<b>XA2Z43</b>	Ileocolic artery
<b>XA3F13</b>	Inferior epigastric artery
<b>XA2N15</b>	Inferior mesenteric artery
<b>XA6358</b>	Inferior pancreaticoduodenal artery

<b>XA2LL9</b>	Inferior phrenic artery
<b>XA68L7</b>	Intestinal artery
<b>XA6WR7</b>	Left colic artery
<b>XA0LL0</b>	Left gastric artery
<b>XA9AQ6</b>	Left gastro-omental artery
<b>XA4UK9</b>	Lumbar artery
<b>XA6CA5</b>	Mesenteric artery
<b>XA1Z62</b>	Middle colic artery
<b>XA1GQ7</b>	Middle suprarenal artery
<b>XA00T1</b>	Posterior suprarenal artery
<b>XA8C72</b>	Proper hepatic artery
<b>XA69V9</b>	Renal artery
<b>XA6GC2</b>	Right colic artery
<b>XA9HE0</b>	Right gastric artery
<b>XA8V02</b>	Right gastro-omental artery
<b>XA02A2</b>	Sigmoid artery
<b>XA0R02</b>	Splenic artery
<b>XA2870</b>	Superior pancreaticoduodenal artery
<b>XA51U4</b>	Terminal branches of the proper hepatic artery
<b>XA0VZ0</b>	Umbilical artery
<b>XA3VR0</b>	Superior mesenteric artery
<b>XA4GP1</b>	Artery of pelvis
<b>XA5PV1</b>	Artery of bulb of penis
<b>XA30X9</b>	Artery of bulb of vestibule
<b>XA4XP0</b>	Deep artery of clitoris
<b>XA7AM0</b>	Deep artery of penis
<b>XA14N2</b>	Deep branch of the superior gluteal artery
<b>XA4AP3</b>	Deep external pudendal artery
<b>XA27B8</b>	Deferential artery
<b>XA4FK8</b>	Dorsal artery of clitoris

<b>XA4X54</b>	Dorsal artery of penis
<b>XA5GV0</b>	Iliac branch of the iliolumbar artery
<b>XA7D46</b>	Iliolumbar artery
<b>XA3XS2</b>	Inferior branch of the lateral sacral artery
<b>XA0G82</b>	Inferior gluteal artery
<b>XA2QX3</b>	Inferior vesical artery
<b>XA7FK7</b>	Internal pudendal artery
<b>XA5Y50</b>	Lateral sacral artery
<b>XA82V4</b>	Median sacral artery
<b>XA8X93</b>	Middle rectal artery
<b>XA69V8</b>	Obturator artery
<b>XA1MF5</b>	Ovarian artery in females
<b>XA5MN1</b>	Perineal artery
<b>XA34Z7</b>	Posterior labial branches of the internal pudendal artery
<b>XA2025</b>	Posterior scrotal branches of the internal pudendal artery
<b>XA2TT0</b>	Superficial branch of the superior gluteal artery
<b>XA0AZ8</b>	Superior branch of the lateral sacral artery
<b>XA26E6</b>	Superior gluteal artery
<b>XA1426</b>	Superior vesical artery
<b>XA0UK9</b>	Testicular artery in males
<b>XA85K8</b>	Urethral artery
<b>XA0610</b>	Uterine artery
<b>XA47A2</b>	Vaginal artery
<b>XA83D6</b>	Iliac artery
<b>XA6PZ8</b>	Common iliac artery
<b>XA9MJ1</b>	Deep circumflex iliac artery
<b>XA4HL2</b>	Internal iliac artery
<b>XA53T4</b>	External iliac artery
<b>XA9QC3</b>	Inferior adrenal artery

<b>XA81N7</b>	Artery of upper extremity  <b>Coded Elsewhere:</b> Subclavian artery (XA5D68)
<b>XA0H14</b>	Anterior humeral circumflex artery
<b>XA7U09</b>	Anterior ulnar recurrent artery
<b>XA2PP8</b>	Anterior interosseous artery
<b>XA8ZA6</b>	Ascending branches of the Inferior ulnar collateral artery
<b>XA38W3</b>	Axillary artery
<b>XA1138</b>	Brachial artery
<b>XA5RC6</b>	Branch to volar carpal network of the anterior interosseous artery
<b>XA91T8</b>	Branches to the deltoid muscle of the Profunda brachii artery
<b>XA4RU3</b>	Common interosseous artery
<b>XA3M37</b>	Deep palmar arch
<b>XA1ES5</b>	Descending branches of the Inferior ulnar collateral artery
<b>XA2UT9</b>	First dorsal metacarpal artery
<b>XA9F90</b>	Inferior ulnar collateral artery
<b>XA9179</b>	Interosseous recurrent artery
<b>XA2722</b>	Medial collateral artery
<b>XA8LL2</b>	Muscular branches of the anterior interosseous artery
<b>XA0GZ0</b>	Palmar carpal arch
<b>XA2F13</b>	Palmar carpal branch of radial artery
<b>XA51P8</b>	Posterior interosseous artery
<b>XA8JY7</b>	Posterior ulnar recurrent artery
<b>XA05L5</b>	Princeps pollicis artery
<b>XA2PP0</b>	Profunda brachii artery
<b>XA8RG5</b>	Radial artery
<b>XA9W25</b>	Radial branches at the wrist of the radial artery
<b>XA91J7</b>	Radial branches in the hand of the radial artery
<b>XA3SL1</b>	Radial branches in the forearm of the radial artery
<b>XA3PZ4</b>	Radial collateral artery
<b>XA3H61</b>	Radial recurrent artery

<b>XA62C1</b>	Radialis indicis of the radial artery
<b>XA5AG1</b>	Superficial palmar arch
<b>XA5BG5</b>	Superficial palmar branch of the radial artery
<b>XA0JA6</b>	Superior ulnar collateral artery
<b>XA23B7</b>	Ulnar artery
<b>XA90B4</b>	Volar carpal network
<b>XA1VB5</b>	Deep volar branch of ulnar artery
<b>XA9ZJ6</b>	Dorsal carpal arch
<b>XA44C1</b>	Dorsal carpal branch of radial artery
<b>XA7M90</b>	Dorsal carpal network
<b>XA2YJ5</b>	Subscapular artery
<b>XA0882</b>	Posterior humeral circumflex artery
<b>XA8DW5</b>	Artery of lower extremity
<b>XA61E8</b>	Acetabular branch
<b>XA91J1</b>	Anterior lateral malleolar artery
<b>XA4K68</b>	Anterior medial malleolar artery
<b>XA6CN3</b>	Anterior tibial artery
<b>XA7BL5</b>	Anterior tibial recurrent artery
<b>XA5BU3</b>	Ascending branch of the lateral femoral circumflex artery
<b>XA0DB6</b>	Ascending branch of the medial femoral circumflex artery
<b>XA42R8</b>	Branch of the medial inferior genicular artery to popliteus
<b>XA7WF1</b>	Branch of the medial superior genicular artery to vastus medialis
<b>XA2DD1</b>	Branch of the medial superior genicular artery to surface of the femur and the knee-joint
<b>XA4VS8</b>	Communicating branch of the fibular artery to the anterior tibial artery
<b>XA7DF6</b>	Deep branch of the descending branch of the Medial femoral circumflex artery
<b>XA19F5</b>	Deep branch of the lateral superior genicular artery
<b>XA3KL5</b>	Deep femoral artery
<b>XA3SV6</b>	Descending branch of the lateral femoral circumflex artery
<b>XA15J8</b>	Descending branch of the Medial femoral circumflex artery
<b>XA3CV5</b>	Descending genicular artery

<b>XA41L4</b>	Dorsalis pedis artery
<b>XA2JF3</b>	Femoral artery
<b>XA9GM6</b>	Fibular artery
<b>XA2GU0</b>	First perforating artery
<b>XA9EP9</b>	Lateral femoral circumflex artery
<b>XA4B67</b>	Lateral inferior genicular artery
<b>XA6920</b>	Medial femoral circumflex artery
<b>XA1QB3</b>	Medial inferior genicular artery
<b>XA7PN1</b>	Medial plantar artery
<b>XA5LB1</b>	Middle genicular artery
<b>XA0PT7</b>	Muscular branches of the anterior tibial artery
<b>XA9TP5</b>	Musculo-articular branch of the Descending genicular artery
<b>XA0GA4</b>	Perforating artery
<b>XA1YF2</b>	Perforating branch of the fibular artery to the posterior tibial artery
<b>XA44K1</b>	Popliteal artery
<b>XA6LK2</b>	Posterior tibial artery
<b>XA33D9</b>	Posterior tibial recurrent artery
<b>XA09P5</b>	Saphenous branch of the Descending genicular artery
<b>XA2Z59</b>	Second perforating artery
<b>XA7W56</b>	Superficial branch of the descending branch of the Medial femoral circumflex artery
<b>XA5687</b>	Superficial branch of the lateral superior genicular artery
<b>XA08Q7</b>	Sural artery
<b>XA8J55</b>	Third or fourth perforating artery
<b>XA4XR2</b>	Transverse branch of the lateral femoral circumflex artery
<b>XA6QR6</b>	Lateral plantar artery
<b>XA8YC8</b>	Common femoral artery
<b>XA5PP5</b>	Superficial femoral artery
<b>XA9PU5</b>	Afferent arteriole of the interlobular artery

<b>XA6Y34</b>	Aorta
	<b>Coded Elsewhere:</b> Ascending aorta (XA01A6)
	Arch of the aorta (XA75Z8)
	Descending aorta (XA5H34)
<b>XA9NQ2</b>	Thoracoabdominal aorta
	<b>Coded Elsewhere:</b> Aorta of thorax (XA8K52)
<b>XA5Z66</b>	Abdominal aorta
<b>XA5EX6</b>	Suprarenal abdominal aorta
<b>XA2LN9</b>	Infrarenal abdominal aorta
<b>XA5J49</b>	<b>Veins</b>
<b>XA59M2</b>	Vein of head, face, and neck
<b>XA9TJ8</b>	Cortical vein
<b>XA8ZU5</b>	Basal vein
<b>XA37J7</b>	Alveolar vein
<b>XA8ZS9</b>	Angular vein
<b>XA6HG4</b>	Temporal vein
<b>XA1GE4</b>	Deep anterior temporal vein
<b>XA8SD6</b>	Middle temporal vein
<b>XA30B2</b>	Deep posterior temporal vein
<b>XA2NX9</b>	Superficial temporal vein
<b>XA6SL1</b>	Basilar plexus
<b>XA5SG1</b>	Buccinator vein
<b>XA91N0</b>	Cerebellar vein
<b>XA93W0</b>	Inferior cerebellar vein
<b>XA2Z35</b>	Superior cerebellar vein
<b>XA2LX2</b>	Cerebral vein
<b>XA6DC3</b>	Internal cerebral vein
<b>XA1MX7</b>	Deep middle cerebral vein
	<b>Inclusions:</b> deep sylvian vein
<b>XA0U80</b>	Inferior cerebral vein
<b>XA43H1</b>	Middle cerebral vein

<b>XA4WV6</b>	Superficial middle cerebral vein
<b>XA0E47</b>	Superior cerebral vein
<b>XA7VW1</b>	Small anterior cerebral vein
<b>XA18W3</b>	Great cerebral vein
<b>XA49Y4</b>	Choroid vein
<b>XA7C08</b>	Cricothyroid vein
<b>XA9U81</b>	Deep cervical vein
<b>XA2QB0</b>	Diploic vein
<b>XA6VQ5</b>	Frontal diploic vein
<b>XA6694</b>	Anterior temporal diploic vein
<b>XA5AY0</b>	Posterior temporal diploic vein
<b>XA2HM1</b>	Occipital diploic vein
<b>XA12G2</b>	Emissary vein of the foramen of Vesalius
<b>XA14M4</b>	Emissary vein
<b>XA6BA1</b>	Condylloid emissary vein
<b>XA4K04</b>	Occipital emissary vein
<b>XA8C81</b>	Mastoid emissary vein
<b>XA0T02</b>	Parietal emissary vein
<b>XA74U9</b>	Frontal vein
<b>XA0CA3</b>	Frontal venous lacunae
<b>XA3DS7</b>	Great anastomotic vein of Trolard
<b>XA9GT2</b>	Inferior striate vein
<b>XA4ZZ3</b>	Maxillary vein
<b>XA23C4</b>	Laryngeal vein
<b>XA2JH6</b>	Inferior laryngeal vein
<b>XA3XZ1</b>	Superior laryngeal vein
<b>XA8Z61</b>	Masseteric vein
<b>XA8NY9</b>	Lingual vein
<b>XA4105</b>	Meningeal vein
<b>XA8D07</b>	Anterior meningeal vein

<b>XA5600</b>	Middle meningeal vein
<b>XA73V2</b>	Posterior meningeal vein
<b>XA01E7</b>	Occipital vein
<b>XA7AS3</b>	Occipital venous lacunae
<b>XA0X91</b>	Ophthalmic vein
<b>XA6C95</b>	Superior ophthalmic vein
<b>XA8M04</b>	Inferior ophthalmic vein
<b>XA1SM5</b>	Palatine vein
<b>XA4HX4</b>	Parietal venous lacunae
<b>XA91G2</b>	Parotid vein
<b>XA98C1</b>	Pharyngeal vein
<b>XA2NF3</b>	Posterior anastomotic vein of Labbé
<b>XA0QP2</b>	Pterygoid venous plexus
<b>XA0M51</b>	Sphenopalatine vein
<b>XA4XY4</b>	Stylocervical vein
<b>XA7K99</b>	Sublingual vein
<b>XA7ZY4</b>	Submaxillary vein
<b>XA1LD6</b>	Submental vein
<b>XA8680</b>	Terminal vein
	<b><i>Inclusions:</i></b> superior thalamostriate vein
<b>XA7F45</b>	Tracheal vein
<b>XA6945</b>	Transverse cervical vein
<b>XA22T9</b>	Vein from the tympanic cavity
<b>XA21F0</b>	Vein of the ala nasi
<b>XA9914</b>	Vein of the pterygoid canal
<b>XA1RH4</b>	Vena comitans of the hypoglossal nerve
<b>XA1K34</b>	Venous jugular arch
<b>XA1VJ8</b>	Venous Sinuses
<b>XA5WN3</b>	Cavernous sinus
<b>XA4NJ4</b>	Confluence of the sinuses

<b>XA6ZV2</b>	Inferior petrosal sinus
<b>XA9ED6</b>	Inferior sagittal sinus
<b>XA2SC7</b>	Occipital sinus
<b>XA4041</b>	Sigmoid sinus
<b>XA03D2</b>	Straight sinus
<b>XA81R3</b>	Superior sagittal sinus
<b>XA1YP1</b>	Superior petrosal sinus
<b>XA4289</b>	Transverse sinus
<b>XA5255</b>	Sphenoparietal sinus
<b>XA3U52</b>	Intercavernous sinus
<b>XA8P44</b>	Anterior intercavernous sinus
<b>XA7QE4</b>	Posterior intercavernous sinus
<b>XA9JS4</b>	Circular sinus
<b>XA6UW5</b>	Petrosquamous sinus
<b>XA6HK7</b>	Sinus of the dura mater
<b>XA5UX2</b>	Cranial venous sinus <i>Inclusions:</i> cerebral venous sinus
<b>XA9VA8</b>	Thyroid vein
<b>XA2KJ8</b>	Inferior thyroid vein
<b>XA2DN0</b>	Middle thyroid vein
<b>XA9BZ3</b>	Superior thyroid vein
<b>XA9SD5</b>	Palpebral vein
<b>XA9K84</b>	Inferior palpebral vein
<b>XA9T11</b>	Superior palpebral vein
<b>XA0Z20</b>	Lateral palpebral vein
<b>XA52V8</b>	Labial vein
<b>XA5DP6</b>	Inferior labial vein
<b>XA4AG1</b>	Superior labial vein
<b>XA97T8</b>	Auricular vein
<b>XA46F3</b>	Anterior auricular vein

<b>XA67N9</b>	Posterior auricular vein
<b>XA0BP3</b>	Facial vein
<b>XA7WC0</b>	Anterior facial vein
<b>XA2681</b>	Deep facial vein
<b>XA3LQ0</b>	Common facial vein
<b>XA4NP1</b>	Posterior facial vein
<b>XA5GY9</b>	Transverse facial vein
<b>XA4582</b>	Jugular vein
<b>XA9U48</b>	Anterior jugular vein
<b>XA46B9</b>	Internal jugular vein
<b>XA99S7</b>	External jugular vein
<b>XA31W7</b>	Posterior external jugular vein
<b>XA9XW7</b>	Orbital vein
<b>XA73J2</b>	Vein of the pericranium
<b>XA0ET2</b>	Anterior vertebral vein
<b>XA1LU7</b>	Deep temporal vein
<b>XA2L55</b>	Extraspinal vein
<b>XA5YM5</b>	Internal auditory vein
<b>XA5TG4</b>	Pterygoid plexus
<b>XA1VP6</b>	Pterygoid vein
<b>XA1RV1</b>	Superior sagittal vein
<b>XA7QR6</b>	Vertebral vein
<b>XA0BP6</b>	Anterior vertebral venous plexus
<b>XA8CT1</b>	Vein of thorax <b>Coded Elsewhere:</b> Pulmonary vein (XA8FY4)
<b>XA6DM9</b>	Accessory hemiazygos vein
<b>XA7AN5</b>	Azygos vein
<b>XA57F8</b>	Brachiocephalic vein
<b>XA1GY9</b>	Bronchial vein
<b>XA9NE2</b>	Diaphragmatic vein

<b>XA3VU3</b>	Oesophageal vein
<b>XA4GF1</b>	Hemiazygos vein
<b>XA27D1</b>	Innominata vein
<b>XA9HG3</b>	Intercostal vein
<b>XA6JE5</b>	Mediastinal vein
<b>XA6YT2</b>	Subclavian vein
<b>XA3568</b>	Subcostal vein
<b>XA4VD1</b>	Superior epigastric vein
<b>XA5WA4</b>	Superior vena cava
<b>XA4DR2</b>	Superior intercostal vein <i>Inclusions:</i> highest intercostal vein
<b>XA3V69</b>	Internal mammary vein <i>Inclusions:</i> internal thoracic vein
<b>XA2DL5</b>	Transverse scapular vein
<b>XA8WJ4</b>	Subscapular vein
<b>XA2YF2</b>	Thymic vein
<b>XA0RA8</b>	Vein of abdomen
<b>XA4DQ4</b>	Ascending lumbar vein
<b>XA9PF5</b>	Caput medusae vein
<b>XA1MQ4</b>	Cystic Vein
<b>XA95M2</b>	Ileocolic vein
<b>XA7UV5</b>	Inferior vena cava
<b>XA2UD7</b>	Hepatic Vein
<b>XA52L9</b>	Lumbar vein
<b>XA3X37</b>	Pancreatic vein
<b>XA4XM0</b>	Pancreaticoduodenal vein
<b>XA0N54</b>	Paraumbilical Vein
<b>XA1E17</b>	Portal Vein
<b>XA5JV6</b>	Rectal venous plexus
<b>XA0J33</b>	Splenic vein
<b>XA46Q0</b>	Thoracoepigastric vein

<b>XA2DK6</b>	Colic vein
<b>XA2UN4</b>	Right colic vein
<b>XA49E0</b>	Middle colic vein
<b>XA2WF1</b>	Left colic vein
<b>XA5T10</b>	Rectal vein
	<i>Inclusions:</i> hemorrhoidal vein
<b>XA6NJ4</b>	Middle rectal vein
	<i>Inclusions:</i> middle hemorrhoidal vein
<b>XA80L8</b>	Inferior rectal vein
	<i>Inclusions:</i> inferior hemorrhoidal vein
<b>XA30C9</b>	Superior hemorrhoidal vein
<b>XA34F0</b>	Perineal hemorrhoidal vein
<b>XA1EK8</b>	Phrenic vein
<b>XA27Y3</b>	Superior phrenic vein
<b>XA0EZ6</b>	Inferior phrenic vein
<b>XA5KA1</b>	Mesenteric vein
<b>XA4DA7</b>	Superior mesenteric vein
<b>XA4EK2</b>	Inferior mesenteric vein
<b>XA04Q7</b>	Epigastric vein
<b>XA8WC0</b>	Superficial epigastric vein
<b>XA30F2</b>	Inferior epigastric vein
<b>XA1C53</b>	Veins of stomach
<b>XA7CB3</b>	Gastric vein
<b>XA73S8</b>	Left gastric vein
	<i>Inclusions:</i> coronary vein
<b>XA23Q4</b>	Right gastric vein
	<i>Inclusions:</i> pyloric vein
<b>XA5QC9</b>	Short gastric vein
<b>XA2R35</b>	Gastroepiploic vein
<b>XA55H2</b>	Intestinal vein
<b>XA26H2</b>	Vein of pelvis

<b>XA3200</b>	Renal vein
<b>XA6YL8</b>	Corpus cavernosum penis
<b>XA03F7</b>	Deep dorsal vein of the penis
<b>XA9X28</b>	Iliolumbar vein
<b>XA7U63</b>	Deep vein of the penis
<b>XA5AH6</b>	Obturator vein
<b>XA4PC3</b>	Ovarian Vein
<b>XA05M3</b>	Pampiniform plexus
<b>XA1W18</b>	Perineal vein
<b>XA8WY0</b>	Prostatic vein
<b>XA0GG0</b>	Pubic vein
<b>XA8HY5</b>	Sigmoid vein
<b>XA4TQ4</b>	Superficial dorsal vein of the penis
<b>XA2WW4</b>	Suprarenal vein
<b>XA7AB3</b>	Uterine plexus
<b>XA8M77</b>	Uterine vein
<b>XA1MK5</b>	Vaginal vein
<b>XA0DB7</b>	Vesical plexus
<b>XA7GN4</b>	Vesical vein
<b>XA9GG9</b>	Vulval vein
<b>XA8GA3</b>	Gluteal vein
<b>XA3HW8</b>	Inferior gluteal vein
<b>XA47S7</b>	Superior gluteal vein
<b>XA03Q4</b>	Iliac vein
<b>XA3EG0</b>	Internal iliac vein
	<i>Inclusions:</i> hypogastric vein
<b>XA49T5</b>	External iliac vein
<b>XA7W40</b>	Common iliac vein
<b>XA3H93</b>	Deep iliac circumflex vein
<b>XA71Q4</b>	Sacral vein

<b>XA4PJ8</b>	Lateral sacral vein
<b>XA9Z04</b>	Middle sacral vein
<b>XA5KK7</b>	Spermatic Vein
<b>XA3F81</b>	Pudendal vein
<b>XA7XD2</b>	Internal pudendal vein
<b>XA6NF9</b>	Superficial external pudendal vein
<b>XA1ET7</b>	Deep external pudendal vein
<b>XA6TQ3</b>	Adrenal vein
<b>XA9WN7</b>	Vein of upper extremity
<b>XA0QT1</b>	Accessory cephalic vein
<b>XA3EY8</b>	Axillary vein
<b>XA6JD7</b>	Basilic vein
<b>XA43Q5</b>	Brachial vein
<b>XA4YQ8</b>	Cephalic vein
<b>XA7FD2</b>	Common volar digital vein
<b>XA7902</b>	Deep volar venous arch
<b>XA6NS3</b>	Dorsal interosseous vein
<b>XA9886</b>	Dorsal metacarpal vein
<b>XA4A41</b>	Lateral thoracic vein
<b>XA3TW9</b>	Median antebrachial vein
<b>XA1YZ7</b>	Median basilic vein <i>Inclusions:</i> median cubital vein
<b>XA3GZ6</b>	Proper volar digital vein
<b>XA32L8</b>	Radial vein
<b>XA7HM9</b>	Superficial volar venous arch
<b>XA8CK3</b>	Ulnar vein
<b>XA2Y72</b>	Volar digital vein <i>Inclusions:</i> palmar digital vein
<b>XA2C08</b>	Volar interosseous vein
<b>XA13N1</b>	Volar metacarpal vein
<b>XA76A3</b>	Vein of lower extremity

<b>XA8WJ3</b>	Accessory saphenous vein
<b>XA4CQ8</b>	Anterior tibial vein
<b>XA23R2</b>	Common digital vein
<b>XA3E41</b>	Deep Femoral Vein
<b>XA8RN9</b>	Deep plantar venous arch
<b>XA3QX9</b>	Femoral vein
<b>XA59H1</b>	Great saphenous vein
<b>XA74K2</b>	Lateral femoral circumflex vein
<b>XA4L08</b>	Lateral marginal vein
<b>XA0L88</b>	Lateral plantar vein
<b>XA8PZ9</b>	Medial femoral circumflex vein
<b>XA1XM3</b>	Medial marginal vein
<b>XA85B7</b>	Medial plantar vein
<b>XA7ND7</b>	Metatarsal vein
<b>XA4EV7</b>	Plantar cutaneous venous arch
<b>XA8657</b>	Plantar digital vein
<b>XA08Q1</b>	Popliteal vein
<b>XA5D60</b>	Posterior tibial vein
<b>XA2073</b>	Small saphenous vein
<b>XA8HR9</b>	Superficial iliac circumflex vein
<b>XA4930</b>	Peroneal vein
<b>XA8LE8</b>	Anterior femoral cutaneous vein
<b>XA60H0</b>	Vena cava
<b>Coded Elsewhere:</b> Inferior vena cava (XA7UV5)	
Superior vena cava (XA5WA4)	

<b>XA21T7</b>	<b>Blood Vessels</b>
<b>XA6943</b>	Blood vessel of the finger
<b>XA7SM4</b>	Blood vessel of the thumb
<b>XA6Y60</b>	Blood vessels at wrist or hand level
<b>XA08R7</b>	Blood vessel of the kidney
<b>XA5K61</b>	Blood vessel of the lung

<b>XA9AN5</b>	Blood vessel of the neck
<b>XA8N71</b>	Blood vessel of the thorax
<b>XA7P54</b>	Blood vessel of hip
<b>XA9M17</b>	Blood vessels at lower leg level
<b>XA2769</b>	Capillary, not elsewhere classified
<b>XA5TF7</b>	Cerebral vasculature
<b>XA4H19</b>	Intracranial blood vessels, not elsewhere classified
<b>XA1SX5</b>	Extracranial blood vessels, not elsewhere classified
<b>XA6H07</b>	<b>Heart</b>
	<b>Coded Elsewhere:</b> Chordae tendineae (XA01T0)
<b>XA6548</b>	Left atrium
<b>XA7V72</b>	Mitral valve
<b>XA3GE9</b>	Cusps of mitral valve
<b>XA69W6</b>	Chordae tendineae of mitral valve
<b>XA78X5</b>	Interatrial septum
<b>XA6T92</b>	Right atrium
<b>XA6FF2</b>	Tricuspid valve
<b>XA19H9</b>	Cusps of tricuspid valve
<b>XA4LY3</b>	Chordae tendineae of tricuspid valve
<b>XA8FJ7</b>	Left ventricle
<b>XA19J4</b>	Aortic valve
<b>XA2QK7</b>	Cusps of aortic valve
<b>XA7S34</b>	Left ventricular papillary muscles
<b>XA5651</b>	Interventricular septum
<b>XA9HH8</b>	Right ventricle
<b>XA5Y16</b>	Right ventricular papillary muscles
<b>XA6WC4</b>	Pulmonary valve
<b>XA1403</b>	Cusps of pulmonary valve
<b>XA3B03</b>	Coronary arteries
<b>XA0F62</b>	Left main coronary artery

<b>XA9FX9</b>	Left circumflex artery
<b>XA7NQ7</b>	Left anterior descending coronary artery
<b>XA2N78</b>	Diagonal branches of left anterior descending coronary artery Diagonal branches of the left anterior descending coronary artery supply blood flow to the anterior and anterolateral walls of the left ventricle. There are usually denoted as D1, D2, D3, etc. There are termed "diagonal" due to them branching from their parent vessel at acute angles. They extend over the left ventricle in a diagonal fashion toward the acute margin and the cardiac apex. They often run parallel to one another and are variable in number (often 2 to 9).
<b>XA20E5</b>	D1 - first diagonal branch
<b>XA86J1</b>	D2 - second diagonal branch
<b>XA5SR3</b>	D3 - third diagonal branch
<b>XA1SH6</b>	Left obtuse marginal artery
<b>XA3QP2</b>	Ramus intermedius artery
<b>XA5LW8</b>	Septal artery
<b>XA2QX7</b>	Right coronary artery
<b>XA1LL7</b>	Right acute marginal artery
<b>XA81T7</b>	Posterior interventricular artery
<b>XA8PS0</b>	Posterolateral artery
<b>XA7TB5</b>	Sinoatrial nodal artery
<b>XA9FK9</b>	Cardiac veins
<b>XA6YW4</b>	Oblique vein of the left atrium
<b>XA0HP7</b>	Left marginal vein of heart
<b>XA38Z5</b>	Great cardiac vein
<b>XA8HT6</b>	Posterior vein of the left ventricle
<b>XA3UN3</b>	Middle cardiac vein
<b>XA6QD7</b>	Small cardiac vein
<b>XA16E4</b>	Coronary sinus
<b>XA4TZ2</b>	Anterior cardiac veins
<b>XA9498</b>	Smallest cardiac vein
<b>XA2KE8</b>	Right marginal vein of heart
<b>XA4366</b>	Pericardial vein

<b>XA10E0</b>	Chamber of the heart
<b>XA91S4</b>	Cardiac atrium  <b>Coded Elsewhere:</b> Left atrium (XA6548) Right atrium (XA6T92)
<b>XA7XU8</b>	Cardiac ventricle  <b>Coded Elsewhere:</b> Left ventricle (XA8FJ7) Right ventricle (XA9HH8)
<b>XA3113</b>	Connective and other soft tissue of heart  <b>Coded Elsewhere:</b> Myocardium (XA8SK6) Heart valve (XA0QB6) Cardiac veins (XA9FK9)
<b>XA42G7</b>	Arteries of heart  <b>Coded Elsewhere:</b> Coronary arteries (XA3B03)
<b>XA9X98</b>	Pericardiophrenic artery
<b>XA2XU0</b>	Pericardium
<b>XA8RK9</b>	Parietal pericardium
<b>XA48H9</b>	Pericardial cavity
<b>XA37Q8</b>	Epicardium
<b>XA3227</b>	Endocardium
<b>XA81Z5</b>	Cardiac septum  <b>Coded Elsewhere:</b> Interatrial septum (XA78X5) Interventricular septum (XA5651)
<b>XA2DC8</b>	Papillary muscle
<b>XA6CK2</b>	Heart wall
<b>XA7RE3</b>	Anterior wall of heart
<b>XA5W05</b>	Anterolateral wall of heart
<b>XA2RT9</b>	Anteroseptal wall of heart
<b>XA4U99</b>	Anteroapical wall of heart
<b>XA3RM8</b>	Inferior wall of heart
<b>XA61Y9</b>	Inferolateral wall of heart
<b>XA2H88</b>	Inferoposterior wall of heart
<b>XA8ZQ8</b>	Apical-lateral wall of heart

<b>XA6GR4</b>	Basal-lateral wall of heart
<b>XA1HH6</b>	High lateral wall of heart
<b>XA3XS7</b>	Lateral wall of heart
<b>XA01U7</b>	True posterior wall of heart
<b>XA7D76</b>	Posterobasal wall of heart
<b>XA4RC1</b>	Posterolateral wall of heart
<b>XA60V2</b>	Posteroseptal wall of heart
<b>XA83Q5</b>	Septal wall of heart
<b>XA79Z5</b>	Cardiac electrical conducting system
<b>XA1UE3</b>	Sinoatrial node
<b>XA4359</b>	Atrioventricular node
<b>XA7J11</b>	Bundle of His
<b>XA0QB6</b>	Heart valve <i>Coded Elsewhere:</i> Mitral valve (XA7V72) Tricuspid valve (XA6FF2) Aortic valve (XA19J4) Pulmonary valve (XA6WC4)
<b>XA8SK6</b>	Myocardium

#### Lymphatic system

*Coded Elsewhere:* Lymph nodes (XA33X2)

<b>XA10P2</b>	<b>Lymphatic system of the head and neck</b> <i>Coded Elsewhere:</i> Lymph nodes of head, face and neck (XA9U65)
<b>XA0LH6</b>	<b>Jugular lymphatic trunk</b>
<b>XA6TY4</b>	<b>Lymphatic vessel of the pinna</b>
<b>XA02Y8</b>	<b>Lymphatic vessel of the external acoustic meatus</b>
<b>XA1EC8</b>	<b>Lymphatic vessel of the face</b>
<b>XA0167</b>	<b>Lymphatic vessel of the palatine tonsil</b>
<b>XA4QZ6</b>	<b>Lymphatic vessel of the scalp</b>
<b>XA9FT5</b>	<b>Lymphatic vessel of the tongue</b>
<b>XA1G40</b>	<b>Lymphatic vessels of the skin and muscles of the neck</b>

<b>XA23Z9</b>	<b>Lymphatic system of the upper extremity</b>
	<i>Coded Elsewhere:</i> Lymph nodes of upper extremity (XA7TQ3)
<b>XA05S0</b>	<b>Deep lymphatic vessel</b>
<b>XA6D43</b>	<b>Dorsal interosseous lymphatic vessel</b>
<b>XA7FS7</b>	<b>Median lymphatic vessel</b>
<b>XA3HQ3</b>	<b>Radial lymphatic vessel</b>
<b>XA12G8</b>	<b>Superficial lymphatic vessel</b>
<b>XA4UB1</b>	<b>Ulnar lymphatic vessel</b>
<b>XA5SZ5</b>	<b>Volar lymphatic vessel</b>
<b>XA52C3</b>	<b>Lymphatic system of the thorax</b>
	<i>Coded Elsewhere:</i> Subclavian lymphatic trunk (XA9CD6)
	Intrathoracic lymph nodes (XA9WH0)
<b>XA94Z9</b>	<b>Bronchomediastinal trunk</b>
<b>XA7474</b>	<b>Cisterna chyli lymph sac</b>
<b>XA1VK9</b>	<b>Deep lymphatic vessel of the thoracic wall</b>
<b>XA9D98</b>	<b>Intestinal lymphatic trunk</b>
<b>XA8JF4</b>	<b>Jugular lymph sac</b>
<b>XA1SQ2</b>	<b>Lymph Sac</b>
<b>XA8YM1</b>	<b>Lymphatic vessel of the diaphragm</b>
<b>XA4RC7</b>	<b>Lymphatic vessel of the breast</b>
<b>XA3SY2</b>	<b>Lymphatic vessel of the thoracic viscera</b>
<b>XA55B8</b>	<b>Lymphatic vessel of the heart</b>
<b>XA3EB8</b>	<b>Lymphatic vessel of the lungs</b>
<b>XA8QZ0</b>	<b>Lymphatic vessel of the oesophagus</b>
<b>XA6J62</b>	<b>Lymphatic vessel of the pericardium</b>
<b>XA4QL2</b>	<b>Lymphatic vessel of the pleura</b>
<b>XA3JF4</b>	<b>Lymphatic vessel of the thymus</b>
<b>XA4J10</b>	<b>Posterior lymph sac</b>
<b>XA8MX8</b>	<b>Retroperitoneal lymph sac</b>
<b>XA3ER1</b>	<b>Right lymphatic duct</b>
<b>XA3TX9</b>	<b>Superficial lymphatic vessel of the thoracic wall</b>

XA8A74	<b>Thoracic duct</b>
XA81G2	<b>Lymphatic system of the abdomen</b>
	<i>Coded Elsewhere:</i> Intra-abdominal lymph nodes (XA05C1)
XA07V7	<b>Intestinal lumbar trunk</b>
XA6R71	<b>Lumbar lymphatic trunk</b>
XA9XL5	<b>Lymphatic vessel of the caecum</b>
XA1BU5	<b>Lymphatic vessel of the colon</b>
XA92E5	<b>Lymphatic vessel of the duodenum</b>
XA6VD0	<b>Lymphatic vessel of the gallbladder</b>
XA55Y5	<b>Lymphatic vessel of the ileum</b>
XA4CQ1	<b>Lymphatic vessel of the jejunum</b>
XA3610	<b>Lymphatic vessel of the kidney</b>
XA0WY9	<b>Lymphatic vessel of the liver</b>
XA9YZ4	<b>Lymphatic vessel of the pancreas</b>
XA5LE6	<b>Lymphatic vessel of the spleen</b>
XA1599	<b>Lymphatic vessel of the stomach</b>
XA3RD0	<b>Lymphatic vessel of the subdiaphragmatic portion of the digestive tube</b>
XA21T8	<b>Lymphatic vessel of the suprarenal lymph node</b>
XA29U5	<b>Lymphatic vessel of the vermiform process</b>
XA6709	<b>Lymphatic system of the pelvis and perineum</b>
XA9H16	<b>Anterior vesical lymphatic vessel of the bladder</b>
XA28F6	<b>Lateral vesical lymphatic vessel of the bladder</b>
XA4LM3	<b>Lymphatic vessel of the anal canal</b>
XA5C29	<b>Lymphatic vessel of the anus</b>
XA1UK6	<b>Lymphatic vessel of the bladder</b>
XA16J8	<b>Lymphatic vessel of the ductus deferens</b>
XA4229	<b>Lymphatic vessel of the ovary</b>
XA1SS8	<b>Lymphatic vessel of the prostate</b>
XA6DH7	<b>Lymphatic vessel of the rectum</b>
XA2XZ6	<b>Lymphatic vessel of the reproductive organs</b>

<b>XA1UA0</b>	Lymphatic vessel of the testes
<b>XA6324</b>	Lymphatic vessel of the ureter
<b>XA6HM6</b>	Lymphatic vessel of the urethra
<b>XA7JY4</b>	Lymphatic vessel of the urinary organ
<b>XA5755</b>	Lymphatic vessel of the uterine tube
<b>XA9PA3</b>	Lymphatic vessel of the uterus
<b>XA1ZK1</b>	Lymphatic vessel of the vagina
<b>XA0GB7</b>	Lymphatic vessel of the seminal vesicles
<b>XA0Z86</b>	<b>Lymphatic system of the lower extremity</b>
	<i>Coded Elsewhere:</i> Lymph nodes of lower extremity (XA86X1)
<b>XA6UC7</b>	Anterior tibial lymphatic trunk

## Respiratory system

<b>XA8Z63</b>	<b>Upper respiratory tract</b>
	<i>Coded Elsewhere:</i> Nostril (XA1B05)
	Middle Ear (XA0G74)
	Hypopharynx (XA2J67)
<b>XA43C9</b>	<b>Nasal cavity</b>
	<i>Coded Elsewhere:</i> Nostril (XA1B05)
<b>XA53X2</b>	Nasal vestibule
<b>XA8D47</b>	Nasal septum
<b>XA8817</b>	Nasal turbinate
<b>XA7WQ4</b>	Nasal cartilage
<b>XA4CN5</b>	Nasal mucosa
<b>XA6YH7</b>	Connective, subcutaneous and other soft tissues of nasal cavity
<b>XA3HQ4</b>	nasal arch vein
<b>XA3523</b>	<b>Accessory sinuses</b>
<b>XA1R64</b>	Maxillary sinus
<b>XA58F6</b>	Ethmoid sinus
<b>XA91G8</b>	Frontal sinus
<b>XA4U67</b>	Sphenoid sinus

<b>XA9AZ1</b>	<b>Nasopharynx</b>
<b>XA0659</b>	Superior wall of nasopharynx
<b>XA21P9</b>	Anterior wall of nasopharynx
<b>XA4BR4</b>	Posterior wall of nasopharynx
<b>XA5AS8</b>	Adenoid
<b>XA7PX5</b>	Lateral wall of nasopharynx
<b>XA7W35</b>	Pharyngeal recess
<b>XA9P89</b>	Retropharyngeal recess
<b>XA6QY3</b>	Parapharyngeal recess
<b>XA2RH5</b>	<b>Larynx</b>
<b>XA1PB3</b>	Supraglottic larynx
<b>XA9ZY9</b>	Epiglottis
<b>XA4DV7</b>	Anterior surface of epiglottis
<b>XA8U54</b>	Posterior surface of epiglottis
<b>XA9907</b>	Aryepiglottic fold
<b>XA8N50</b>	Laryngeal aspect of aryepiglottic fold
<b>XA7AE7</b>	Glottis
<b>XA3299</b>	Vocal cord
<b>XA25B1</b>	Subglottic larynx
<b>XA0NK8</b>	Laryngeal cartilage
<b>XA0AF3</b>	Arytenoid cartilage
<b>XA7S05</b>	Cricoid cartilage
<b>XA2383</b>	Cricoarytenoid articulation
<b>XA73G2</b>	Cricothyroid articulation
<b>XA7SZ3</b>	Cuneiform cartilage
<b>XA2716</b>	Thyroid cartilage
<b>XA07R2</b>	<b>Lower respiratory tract</b>
<b>XA26H1</b>	Trachea
<b>XA7SG3</b>	Cervical trachea
<b>XA4RN3</b>	Thoracic trachea

<b>XA57M6</b>	Lung
<b>XA9TC5</b>	Main bronchus
	<b>Coded Elsewhere:</b> Carina (XA4JA0)
	Hilum of left lung (XA6VA2)
	Hilum of right lung (XA29Y4)
<b>XA3L52</b>	Right main bronchus
<b>XA5FV2</b>	Left main bronchus
<b>XA4JA0</b>	Carina
<b>XA7EZ3</b>	Right lung
<b>XA29Y4</b>	Hilum of right lung
<b>XA8Z30</b>	Right upper lobe bronchus
<b>XA41Z3</b>	Right lower lobe bronchus
<b>XA1QM3</b>	Right middle lobe bronchus
<b>XA2UD3</b>	Left lung
<b>XA6VA2</b>	Hilum of left lung
<b>XA6F58</b>	Left upper lobe bronchus
<b>XA4565</b>	Lingula of lung
<b>XA2XH5</b>	Left lower lobe bronchus
	<b>Coded Elsewhere:</b> Right pulmonary vein (XA86L0)
	Left pulmonary vein (XA1WN5)
<b>XA90M2</b>	Lobe of lung
<b>XA9HN5</b>	Upper lobe of lung
<b>XA1N36</b>	Middle lobe of lung
<b>XA7L34</b>	Lower lobe of lung
<b>XA37W0</b>	Upper lobe, bronchus
<b>XA1K94</b>	Middle lobe, bronchus
<b>XA8JM5</b>	Lower lobe, bronchus
<b>XA2PV7</b>	Connective and other soft tissues of lung
	<b>Coded Elsewhere:</b> Lobe of lung (XA90M2)

<b>XA61M6</b>	Bronchus  <b>Coded Elsewhere:</b> Upper lobe, bronchus (XA37W0) Middle lobe, bronchus (XA1K94) Lower lobe, bronchus (XA8JM5) Main bronchus (XA9TC5)
<b>XA8Z62</b>	Lung parenchyma
<b>XA5437</b>	Bronchioles
<b>XA5772</b>	Alveoli
<b>XA4646</b>	Pulmonary vasculature  <b>Coded Elsewhere:</b> Pulmonary artery (XA09J9)
<b>XA8FY4</b>	Pulmonary vein
<b>XA1WN5</b>	Left pulmonary vein
<b>XA9941</b>	Left superior pulmonary vein
<b>XA8TW3</b>	Left inferior pulmonary vein
<b>XA86L0</b>	Right pulmonary vein
<b>XA05T2</b>	Right superior pulmonary vein
<b>XA41F3</b>	Right inferior pulmonary vein
<b>XA4530</b>	Accessory right pulmonary vein
<b>XA1SF4</b>	Common left sided trunk of pulmonary veins
<b>XA0F36</b>	Pulmonary capillaries
<b>XA5TT2</b>	Pleura
<b>XA1B59</b>	Visceral pleura
<b>XA7RC6</b>	Parietal pleura
<b>XA4U64</b>	Artery of lung  <b>Coded Elsewhere:</b> Afferent arteriole of the interlobular artery (XA9PU5)
<b>XA2AT1</b>	Efferent arteriole of the interlobular artery
<b>XA6WT9</b>	Interlobar artery
<b>XA2S57</b>	Interlobular artery
<b>XA3713</b>	Pulmonary trunk

## Digestive system

<b>XA8182</b>	<b>Mouth</b>
	<b>Coded Elsewhere:</b> Palatine tonsil (XA3V90)
<b>XA5TW5</b>	<b>Vestibule of mouth</b>
<b>XA9072</b>	Labial mucosa of upper lip <b>Inclusions:</b> Mucosa of upper lip
<b>XA72W2</b>	Labial mucosa of lower lip <b>Inclusions:</b> Mucosa of lower lip
<b>XA8WB3</b>	Buccal mucosa
<b>XA0S17</b>	Retromolar region
<b>XA44M8</b>	Labial sulcus
<b>XA2151</b>	Superior labial sulcus
<b>XA52Q7</b>	Inferior labial sulcus
<b>XA6A73</b>	Buccal sulcus
<b>XA6WJ3</b>	Superolateral buccal sulcus
<b>XA5MG3</b>	Inferolateral buccal sulcus
<b>XA54T3</b>	<b>Gingivae</b>
<b>XA6743</b>	Upper gingiva
<b>XA2C94</b>	Upper alveolar mucosa
<b>XA7DA0</b>	Upper alveolar ridge mucosa
<b>XA9303</b>	Lower gingiva
<b>XA96F2</b>	Lower alveolar mucosa
<b>XA8C21</b>	Lower alveolar ridge mucosa
<b>XA3SP9</b>	Alveolar mucosa <b>Coded Elsewhere:</b> Lower alveolar mucosa (XA96F2) Upper alveolar mucosa (XA2C94)
<b>XA6CZ2</b>	<b>Teeth</b>
<b>XA4GG3</b>	Permanent dentition
<b>XA5306</b>	Upper right 3rd molar
<b>XA0BR9</b>	Upper right 2nd molar
<b>XA0TL3</b>	Upper right 1st molar

<b>XA45K9</b>	Upper right 2nd bicuspid
<b>XA64J5</b>	Upper right 1st bicuspid
<b>XA0LE1</b>	Upper right canine
<b>XA3QH3</b>	Upper right lateral incisor
<b>XA43X2</b>	Upper right central incisor
<b>XA8328</b>	Upper left 3rd molar
<b>XA1YK1</b>	Upper left 2nd molar
<b>XA2GW7</b>	Upper left 1st molar
<b>XA5Z15</b>	Upper left 2nd bicuspid
<b>XA3EF6</b>	Upper left 1st bicuspid
<b>XA2LF2</b>	Upper left canine
<b>XA0MG2</b>	Upper left lateral incisor
<b>XA9P69</b>	Upper left central incisor
<b>XA8YF6</b>	Lower right 3rd molar
<b>XA5CA4</b>	Lower right 2nd molar
<b>XA5M57</b>	Lower right 1st molar
<b>XA26X2</b>	Lower right 2nd bicuspid
<b>XA47C4</b>	Lower right 1st bicuspid
<b>XA95A1</b>	Lower right canine
<b>XA8660</b>	Lower right lateral incisor
<b>XA5NT8</b>	Lower right central incisor
<b>XA0XB1</b>	Lower left 3rd molar
<b>XA8YV5</b>	Lower left 2nd molar
<b>XA6R23</b>	Lower left 1st molar
<b>XA80S2</b>	Lower left 2nd bicuspid
<b>XA1SQ7</b>	Lower left 1st bicuspid
<b>XA8P88</b>	Lower left canine
<b>XA4B13</b>	Lower left lateral incisor
<b>XA7B54</b>	Lower left central incisor
<b>XA7675</b>	Deciduous dentition

<b>XA2GE5</b>	Upper right 2nd molar, deciduous
<b>XA7ZT9</b>	Upper right 1st molar, deciduous
<b>XA06P0</b>	Upper right canine, deciduous
<b>XA2XZ5</b>	Upper right lateral incisor, deciduous
<b>XA3BG3</b>	Upper right central incisor, deciduous
<b>XA2BD4</b>	Upper left 2nd molar, deciduous
<b>XA85K7</b>	Upper left 1st molar, deciduous
<b>XA98V8</b>	Upper left canine, deciduous
<b>XA9QP7</b>	Upper left lateral incisor, deciduous
<b>XA4ZQ5</b>	Upper left central incisor, deciduous
<b>XA6F50</b>	Lower right 2nd molar, deciduous
<b>XA36B2</b>	Lower right 1st molar, deciduous
<b>XA8KQ7</b>	Lower right canine, deciduous
<b>XA1W31</b>	Lower right lateral incisor, deciduous
<b>XA6TB6</b>	Lower right central incisor, deciduous
<b>XA8NE2</b>	Lower left 2nd molar, deciduous
<b>XA55D8</b>	Lower left 1st molar, deciduous
<b>XA8QV7</b>	Lower left canine, deciduous
<b>XA8MH6</b>	Lower left lateral incisor, deciduous
<b>XA2RW5</b>	Lower left central incisor, deciduous
<b>XA1PT3</b>	Parts of tooth
<b>XA5B71</b>	Pulp
<b>XA6FX3</b>	Dentin
<b>XA5R09</b>	Enamel
<b>XA4KC7</b>	Cementum
<b>XA2CA1</b>	Periapical tissue
<b>XA2US1</b>	Surfaces of the teeth
<b>XA5ML5</b>	Distal surface of tooth
<b>XA4UP2</b>	Labial surface of tooth
<b>XA6DE2</b>	Buccal surface of tooth

<b>XA3W20</b>	Incisal surface of tooth
<b>XA8M68</b>	Lingual surface of tooth
<b>XA5Z48</b>	Mesial surface of tooth
<b>XA5DM8</b>	Occlusal surface of tooth
<b>XA3HD5</b>	Proximal surface of tooth
<b>XA1WN1</b>	<b>Oral cavity</b>
<b>XA7ZA6</b>	Palate
<b>XA4527</b>	Hard palate
<b>XA8HL5</b>	Soft palate
<b>XA2993</b>	Uvula
<b>XA00H5</b>	Palatal mucosa
<b>XA1T19</b>	Tongue
<b>XA8Q87</b>	Body of tongue
	<i>Inclusions:</i> Anterior tongue
	<b>Coded Elsewhere:</b> Dorsal surface of body of tongue (XA8YB9)
<b>XA65E9</b>	Midline of tongue
<b>XA8SX3</b>	Junctional zone of tongue
<b>XA25G3</b>	Base of tongue
	<b>Coded Elsewhere:</b> Dorsal surface of base of tongue (XA0HQ3)
<b>XA2B11</b>	Posterior of tongue
<b>XA1V27</b>	Dorsal surface of tongue
<b>XA8YB9</b>	Dorsal surface of body of tongue
<b>XA0HQ3</b>	Dorsal surface of base of tongue
<b>XA9RP1</b>	Other and unspecified parts of tongue
<b>XA8FK4</b>	Ventral surface of tongue
	<b>Coded Elsewhere:</b> Lingual tonsil (XA1EM4)
<b>XA9YA2</b>	Lingual frenulum
<b>XA4DB6</b>	Border of tongue
<b>XA49C6</b>	Lateral margin of tongue
<b>XA1WZ8</b>	Tip of tongue
<b>XA8EY7</b>	Floor of mouth

<b>XA69M6</b>	Alveololingual sulcus
<b>XA8CF9</b>	Mucosa of floor of mouth
<b>XA29D3</b>	Tonsillar region
<b>XA9A13</b>	Glossopalatine arch
<b>XA2JB0</b>	Anterior tonsillar pillar
<b>XA46Z4</b>	Tonsillar fossa
	<b>Coded Elsewhere:</b> Palatine tonsil (XA3V90)
<b>XA3021</b>	Pharyngopalatine arch
<b>XA0X58</b>	Posterior tonsillar pillar
<b>XA15G1</b>	Palatine arch
<b>XA6NQ7</b>	<b>Oral mucosa</b>
	<b>Coded Elsewhere:</b> Labial mucosa of upper lip (XA9072)
	Labial mucosa of lower lip (XA72W2)
	Buccal mucosa (XA8WB3)
	Alveolar mucosa (XA3SP9)
	Lower alveolar ridge mucosa (XA8C21)
	Upper alveolar ridge mucosa (XA7DA0)
	Palatal mucosa (XA00H5)
	Mucosa of floor of mouth (XA8CF9)
	Alveolar ridge mucosa (XA54T3)
<b>XA2KN0</b>	<b>Other and unspecified parts of mouth</b>
<b>XA5T23</b>	<b>Salivary gland apparatus</b>
<b>XA07S5</b>	<b>Parotid gland</b>
	<b>Coded Elsewhere:</b> Parotid gland duct (XA44X8)
<b>XA9Q61</b>	<b>Submandibular gland</b>
	<b>Inclusions:</b> Submandibular salivary gland
<b>XA0CS1</b>	Left submandibular gland
	<b>Inclusions:</b> Left submaxillary salivary gland
<b>XA8GQ5</b>	Right submandibular gland
	<b>Inclusions:</b> Right submaxillary salivary gland
<b>XA7GY0</b>	Submandibular gland duct

<b>XA51Q9</b>	<b>Sublingual gland</b>
	<i>Inclusions:</i> Sublingual salivary gland
	<i>Coded Elsewhere:</i> Sublingual gland duct (XA1J93)
<b>XA30Q1</b>	<b>Minor salivary gland</b>
<b>XA5CM1</b>	<b>Salivary duct</b>
	<i>Coded Elsewhere:</i> Submandibular gland duct (XA7GY0)
<b>XA44X8</b>	Parotid gland duct
<b>XA1J93</b>	Sublingual gland duct
<b>XA93V5</b>	<b>Pharynx</b>
	<i>Coded Elsewhere:</i> Nasopharynx (XA9AZ1)
<b>XA4J67</b>	<b>Oropharynx</b>
	<i>Coded Elsewhere:</i> Anterior surface of epiglottis (XA4DV7)
<b>XA8RX5</b>	Lateral wall of oropharynx
<b>XA8659</b>	Posterior wall of oropharynx
<b>XA88V4</b>	Vallecula
<b>XA60Q5</b>	Branchial cleft
<b>XA2J67</b>	<b>Hypopharynx</b>
	<i>Coded Elsewhere:</i> Aryepiglottic fold (XA9907)
<b>XA3MZ0</b>	Piriform recess
<b>XA4NZ9</b>	Postcricoid region
<b>XA0XK1</b>	Hypopharyngeal wall
<b>XA9607</b>	<b>Gastrointestinal tract</b>
<b>XA0828</b>	<b>Oesophagus</b>
<b>XA1180</b>	Upper third of oesophagus
<b>XA2BY3</b>	Middle third of oesophagus
<b>XA9CB6</b>	Lower third of oesophagus
<b>XA0N03</b>	Cervical oesophagus
<b>XA8JT3</b>	Thoracic oesophagus
<b>XA0TN5</b>	Abdominal oesophagus
<b>XA4YW8</b>	Overlapping sites of oesophagus
<b>XA7SR6</b>	<b>Cardiooesophageal junction</b>

<b>XA7MC7</b>	<b>Stomach</b>
	<b>Coded Elsewhere:</b> Veins of stomach (XA1C53)
<b>XA2828</b>	Gastric cardia
<b>XA7UE1</b>	Gastric corpus
<b>XA56K7</b>	Gastric fundus
<b>XA6P89</b>	Gastric pylorus
<b>XA4EC5</b>	Pyloric antrum
<b>XA7WQ5</b>	Greater curvature of stomach
<b>XA4ML9</b>	Lesser curvature of stomach
<b>XA6452</b>	<b>Small intestine</b>
<b>XA9780</b>	Duodenum
<b>XA8UM1</b>	Jejunum
<b>XA0QT6</b>	Ileum
<b>XA1B13</b>	<b>Large intestine</b>
<b>XA6J68</b>	Caecum
<b>XA03U9</b>	Colon
<b>XA3AL5</b>	Ascending colon
<b>XA95L3</b>	Hepatic flexure of colon
<b>XA49U1</b>	Transverse colon
<b>XA1PY9</b>	Splenic flexure of colon
<b>XA2G13</b>	Descending colon
<b>XA8YJ9</b>	Sigmoid colon
<b>XA33J5</b>	Rectosigmoid junction
<b>XA7177</b>	Descending colon and splenic flexure of colon
<b>XA25P9</b>	Ascending colon and right flexure of colon
<b>XA4KU2</b>	Rectum
<b>XA0D34</b>	Anus
<b>XA39S6</b>	Anal Canal
	<b>Coded Elsewhere:</b> Sphincter ani muscle (XA3ML6)
<b>XA8QB7</b>	Cloacogenic zone
<b>XA28R6</b>	<b>Upper gastrointestinal tract, not elsewhere classified</b>

**XA8PW4      Appendix****XA0W19      Hepatobiliary system****XA5DY0**      Liver**XA5766**      Left lobe of liver**XA2KG6**      Right lobe of liver**XA3278**      Caudate lobe of liver**XA13D3**      Quadrate lobe of liver**XA0KT3      Biliary tract****XA4415**      Hepatic bile ducts**XA89K4**      Left hepatic duct**XA6M95**      Right hepatic duct**XA96K1**      Common hepatic duct**XA0077**      Cystic duct**XA8KL9**      Gallbladder**XA6R80**      Common bile duct**XA6WA8**      Sphincter of Oddi**XA7QA8**      Ampulla of Vater**XA9HM5**      Extrahepatic bile duct**Coded Elsewhere:** Common bile duct (XA6R80)

Cystic duct (XA0077)

Sphincter of Oddi (XA6WA8)

**XA3QC5      Pancreas****Coded Elsewhere:** Pancreatic islets (XA45E6)**XA1412**      Head of pancreas**XA8LA4**      Neck of pancreas**XA6ZE4**      Body of pancreas**XA0CX6**      Tail of pancreas**XA1XL7**      Pancreatic duct**XA8WC8**      Duct of Santorini**XA3789**      Duct of Wirsung**XA0KZ0      Peritoneum**

<b>XA6S21</b>	<b>Retroperitoneum</b>
<b>XA43V8</b>	<b>Mesentery</b>
<b>XA6DF7</b>	<b>Omentum</b>
<b>XA46W1</b>	<b>Mesoappendix</b>
<b>XA4QM7</b>	<b>Mesocolon</b>
<b>XA5PF4</b>	<b>Pelvic peritoneum</b>

### Integumentary system

<b>XA0364</b>	<b>Skin</b>
<b>XA3JN1</b>	<b>Epidermis</b>
<b>XA5P21</b>	Stratum corneum
<b>XA3G02</b>	Stratum lucidum
<b>XA4W90</b>	Stratum granulosum
<b>XA8AM6</b>	Stratum spinosum
<b>XA9QS1</b>	Stratum basale
<b>XA8JE9</b>	Epidermal basement membrane
<b>XA8113</b>	<b>Epidermal appendages</b>
<b>XA0XC8</b>	Hair follicle
<b>XA2MW3</b>	Hair bulb
<b>XA6666</b>	Sebaceous gland
<b>XA7487</b>	Apocrine sweat gland
<b>XA6DT2</b>	Hair shaft
<b>XA8T72</b>	Hair <i>Coded Elsewhere:</i> Hair follicle (XA0XC8)
<b>XA5Y68</b>	Scalp hair
<b>XA78D2</b>	Eyebrow hairs
<b>XA1RK2</b>	Eyelashes
<b>XA9N28</b>	Beard hair
<b>XA1WH2</b>	Body hair
<b>XA12U4</b>	Pubic hair
<b>XA4S72</b>	Nail apparatus

<b>XA4KT3</b>	Nail matrix
<b>XA5LM0</b>	Germinal matrix
<b>XA0060</b>	Sterile matrix
<b>XA6Q52</b>	Nail  <i>Coded Elsewhere:</i> Toenail (XA9E36) Fingernails (XA0EH9) Nail matrix (XA4KT3)
<b>XA5US0</b>	Perionychium
<b>XA1ES4</b>	Eponychium
<b>XA0NS1</b>	Hyponychium
<b>XA63U7</b>	Eccrine gland
<b>XA6PJ1</b>	Acrosyringium
<b>XA7P52</b>	Eccrine sweat duct
<b>XA5VA9</b>	Eccrine sweat coil
<b>XA1QT7</b>	<b>Dermis</b>
<b>XA4LG9</b>	Papillary dermis
<b>XA2Q30</b>	Reticular dermis
<b>XA2013</b>	<b>Hypodermis</b>
<b>XA5CS6</b>	Subcutaneous fat

## Musculoskeletal system

### Bones

<b>XA4S38</b>	<b>Axial skeleton</b>
<b>XA4RY5</b>	<b>Bones of the head</b>
<b>XA1RZ4</b>	Cranial Bones
<b>XA0E94</b>	Base of the skull
<b>XA2BH0</b>	Calvarium
<b>XA0KU6</b>	Cranial fossa
<b>XA7B66</b>	Anterior fossa
<b>XA8Y22</b>	Middle fossa
<b>XA5U78</b>	Posterior fossa

<b>XA2SR4</b>	Ethmoid bone
<b>XA6ZM9</b>	Frontal bone
<b>XA5JA2</b>	Occipital bone
<b>XA4RS9</b>	Occipital condyle
<b>XA33W1</b>	Occiput
<b>XA2J87</b>	Parietal bone
<b>XA63R0</b>	Sphenoid bone  <b>Coded Elsewhere:</b> Craniopharyngeal duct (XA5309)
<b>XA9N34</b>	Pituitary fossa
<b>XA2P19</b>	Temporal bone
<b>XA1E15</b>	Petrosus bone
<b>XA68N3</b>	Mastoid
<b>XA8E69</b>	Orbital bone
<b>XA9XW3</b>	Orbital roof
<b>XA7MW9</b>	Orbital floor
<b>XA3Y16</b>	Facial bones
<b>XA5CQ0</b>	Hyoid bone
<b>XA6UV6</b>	Inferior nasal conchae
<b>XA9GZ6</b>	Lacrimal bone
<b>XA4319</b>	Palatine bone
<b>XA14T2</b>	Vomer bone
<b>XA8N32</b>	Zygomatic bone
<b>XA51B7</b>	Mandible  <b>Coded Elsewhere:</b> Temporomandibular joint (XA2SM2)
<b>XA3B77</b>	Alveolar border of body of mandible
<b>XA0M61</b>	Angle of mandible
<b>XA98M7</b>	Condylar process of the mandible
<b>XA7919</b>	Subcondylar process of mandible
<b>XA24B3</b>	Coronoid process of the mandible
<b>XA5969</b>	Ramus of mandible
<b>XA8JR9</b>	Symphysis of mandible

<b>XA0NC8</b>	Inferior maxilla
<b>XA7VK5</b>	Maxilla
<b>XA8E16</b>	Nasal bone
<b>XA88P5</b>	Jaw, unspecified
<b>XA6EQ1</b>	Bones of middle ear
<b>XA4D04</b>	Incus
<b>XA5DS8</b>	Malleus
<b>XA3WA4</b>	Stapes
<b>XA5J55</b>	<b>Vertebral column</b>
<b>XA7MS2</b>	Vertebra
<b>XA9ZW8</b>	Cervical vertebra
<b>XA2XE8</b>	Atlas
<b>XA0KQ4</b>	Posterior arch of first cervical vertebra
<b>XA1304</b>	Lateral mass of first cervical vertebra
<b>XA17N0</b>	Axis
<b>XA5W02</b>	Odontoid process
<b>XA2W05</b>	Third cervical vertebra
<b>XA51V4</b>	Arch of third cervical vertebra
<b>XA4UV1</b>	Body of third cervical vertebra
<b>XA8CG0</b>	Processes of third cervical vertebra
<b>XA3RE9</b>	Fourth cervical vertebra
<b>XA24X7</b>	Arch of fourth cervical vertebra
<b>XA3GT0</b>	Body of fourth cervical vertebra
<b>XA75V3</b>	Processes of fourth cervical vertebra
<b>XA9C12</b>	Fifth cervical vertebra
<b>XA1PJ5</b>	Arch of fifth cervical vertebra
<b>XA1BS2</b>	Body of fifth cervical vertebra
<b>XA2FY7</b>	Processes of fifth cervical vertebra
<b>XA5S79</b>	Sixth cervical vertebra
<b>XA8W16</b>	Arch of sixth cervical vertebra

<b>XA9Q12</b>	Body of sixth cervical vertebra
<b>XA60Z0</b>	Processes of sixth cervical vertebra
<b>XA34U8</b>	Seventh cervical vertebra
<b>XA05M5</b>	Arch of seventh cervical vertebra
<b>XA1JS3</b>	Body of seventh cervical vertebra
<b>XA91D7</b>	Processes of seventh cervical vertebra
<b>XA6E88</b>	Thoracic vertebra
<b>XA3F93</b>	First thoracic vertebra
<b>XA7UP5</b>	Arch of first thoracic vertebra
<b>XA8PH0</b>	Body of first thoracic vertebra
<b>XA1AX4</b>	Processes of first thoracic vertebra
<b>XA8QS0</b>	Second thoracic vertebra
<b>XA2VV9</b>	Arch of second thoracic vertebra
<b>XA3Z42</b>	Body of second thoracic vertebra
<b>XA6T61</b>	Processes of second thoracic vertebra
<b>XA1Z15</b>	Third thoracic vertebra
<b>XA2SM3</b>	Arch of third thoracic vertebra
<b>XA35A0</b>	Body of third thoracic vertebra
<b>XA41U9</b>	Processes of third thoracic vertebra
<b>XA0C31</b>	Fourth thoracic vertebra
<b>XA22W3</b>	Arch of fourth thoracic vertebra
<b>XA3J42</b>	Body of fourth thoracic vertebra
<b>XA1WL4</b>	Processes of fourth thoracic vertebra
<b>XA3PH5</b>	Fifth thoracic vertebra
<b>XA28A7</b>	Arch of fifth thoracic vertebra
<b>XA8W59</b>	Body of fifth thoracic vertebra
<b>XA0449</b>	Processes of fifth thoracic vertebra
<b>XA45S2</b>	Sixth thoracic vertebra
<b>XA29X2</b>	Arch of sixth thoracic vertebra
<b>XA0YY2</b>	Body of sixth thoracic vertebra

<b>XA1R53</b>	Processes of sixth thoracic vertebra
<b>XA59Y3</b>	Seventh thoracic vertebra
<b>XA54G1</b>	Arch of seventh thoracic vertebra
<b>XA62Y3</b>	Body of seventh thoracic vertebra
<b>XA1CQ7</b>	Processes of seventh thoracic vertebra
<b>XA8NQ5</b>	Eighth thoracic vertebra
<b>XA3PL7</b>	Arch of eighth thoracic vertebra
<b>XA5JX9</b>	Body of eighth thoracic vertebra
<b>XA1SD8</b>	Processes of eighth thoracic vertebra
<b>XA3E70</b>	Ninth thoracic vertebra
<b>XA9N69</b>	Arch of ninth thoracic vertebra
<b>XA2X21</b>	Body of ninth thoracic vertebra
<b>XA5SW1</b>	Processes of ninth thoracic vertebra
<b>XA0AV7</b>	Tenth thoracic vertebra
<b>XA7LF7</b>	Arch of tenth thoracic vertebra
<b>XA6VP6</b>	Body of tenth thoracic vertebra
<b>XA7122</b>	Processes of tenth thoracic vertebra
<b>XA7T69</b>	Eleventh thoracic vertebra
<b>XA98R9</b>	Arch of eleventh thoracic vertebra
<b>XA91J0</b>	Body of eleventh thoracic vertebra
<b>XA92Q6</b>	Processes of eleventh thoracic vertebra
<b>XA69W5</b>	Twelfth thoracic vertebra
<b>XA15N3</b>	Arch of twelfth thoracic vertebra
<b>XA1401</b>	Body of twelfth thoracic vertebra
<b>XA2D62</b>	Processes of twelfth thoracic vertebra
<b>XA0D60</b>	Lumbar vertebra
<b>XA3291</b>	First lumbar vertebra
<b>XA8AX7</b>	Arch of first lumbar vertebra
<b>XA9E61</b>	Body of first lumbar vertebra
<b>XA4U01</b>	Processes of first lumbar vertebra

<b>XA2GH9</b>	Second lumbar vertebra
<b>XA24M1</b>	Arch of second lumbar vertebra
<b>XA5079</b>	Body of second lumbar vertebra
<b>XA52T1</b>	Processes of second lumbar vertebra
<b>XA3N97</b>	Third lumbar vertebra
<b>XA3G24</b>	Arch of third lumbar vertebra
<b>XA0TL0</b>	Body of third lumbar vertebra
<b>XA80X7</b>	Processes of third lumbar vertebra
<b>XA9A53</b>	Fourth lumbar vertebra
<b>XA7CH7</b>	Arch of fourth lumbar vertebra
<b>XA4145</b>	Body of fourth lumbar vertebra
<b>XA38A4</b>	Processes of fourth lumbar vertebra
<b>XA9641</b>	Fifth lumbar vertebra
<b>XA2JV2</b>	Arch of fifth lumbar vertebra
<b>XA5886</b>	Body of fifth lumbar vertebra
<b>XA4PS3</b>	Processes of fifth lumbar vertebra
<b>XA14W3</b>	Sacrum
<b>XA4V28</b>	Coccyx
<b>XA02R1</b>	Intervertebral disc or space
<b>XA8D30</b>	Cervical discs or space
<b>XA9Z06</b>	Cervical intervertebral disc or space C1-C2
<b>XA18M2</b>	Cervical intervertebral disc or space C2-C3
<b>XA94K2</b>	Cervical intervertebral disc or space C3-C4
<b>XA3623</b>	Cervical intervertebral disc or space C4-C5
<b>XA1X49</b>	Cervical intervertebral disc or space C5-C6
<b>XA16L1</b>	Cervical intervertebral disc or space C6-C7
<b>XA2SG0</b>	Cervicothoracic disc or space C7-T1
<b>XA1N54</b>	Thoracic discs or space
<b>XA4722</b>	Thoracic intervertebral disc or space T1-T2
<b>XA6KQ8</b>	Thoracic intervertebral disc or space T2-T3

<b>XA6CX2</b>	Thoracic intervertebral disc or space T3-T4
<b>XA0NE8</b>	Thoracic intervertebral disc or space T4-T5
<b>XA7PD1</b>	Thoracic intervertebral disc or space T5-T6
<b>XA4TP2</b>	Thoracic intervertebral disc or space T6-T7
<b>XA7117</b>	Thoracic intervertebral disc or space T7-T8
<b>XA9PW9</b>	Thoracic intervertebral disc or space T8-T9
<b>XA8E13</b>	Thoracic intervertebral disc or space T9-T10
<b>XA6HY9</b>	Thoracic intervertebral disc or space T10-T11
<b>XA5LG2</b>	Thoracic intervertebral disc or space T11-T12
<b>XA97A4</b>	Thoracolumbar intervertebral disc or space T12-L1
<b>XA54S5</b>	Lumbar discs or space
<b>XA7RD5</b>	Lumbar intervertebral disc or space L1-L2
<b>XA8DG2</b>	Lumbar intervertebral disc or space L2-L3
<b>XA1F44</b>	Lumbar intervertebral disc or space L3-L4
<b>XA2N96</b>	Lumbar intervertebral disc or space L4-L5
<b>XA54R2</b>	Lumbosacral intervertebral disc or space L5-S1
<b>XA2Y58</b>	Intervertebral disc
<b>XA8WM9</b>	Nucleus pulposus
<b>XA10M1</b>	Annulus fibrosus
<b>XA5VB6</b>	<b>Bones of the thorax</b>
<b>XA5TK7</b>	Rib
<b>XA98Q1</b>	First rib
<b>XA7XY2</b>	Second rib
<b>XA2U21</b>	Third rib
<b>XA4SQ6</b>	Fourth rib
<b>XA31L8</b>	Fifth rib
<b>XA63Z2</b>	Sixth rib
<b>XA2WC3</b>	Seventh rib
<b>XA9WQ3</b>	Eighth rib
<b>XA31V8</b>	Ninth rib

<b>XA54R4</b>	Tenth rib
<b>XA3VH4</b>	Eleventh rib
<b>XA6W52</b>	Twelfth rib
<b>XA6NB3</b>	Sternum
<b>XA3M45</b>	Body of sternum
<b>XA0K13</b>	Manubrium
<b>XA2RB7</b>	Xiphoid
<b>XA4N47</b>	<b>Bones of the pelvis</b>
	<i>Coded Elsewhere:</i> Sacrum (XA14W3)
	Coccyx (XA4V28)
<b>XA8Y23</b>	Pelvis
<b>XA5FT5</b>	Ilium
<b>XA4743</b>	Iliac crest
<b>XA5L47</b>	Ischium
<b>XA82W3</b>	Pubis
<b>XA1XZ3</b>	Superior pubic ramus
<b>XA4VB9</b>	Inferior pubic ramus
<b>XA6Z32</b>	Acetabulum
<b>XA4TM1</b>	<b>Peripheral skeleton</b>
<b>XA7R53</b>	<b>Bones of the upper extremity</b>
<b>XA2AL0</b>	Bones of the shoulder girdle
<b>XA6384</b>	Clavicle
<b>XA76N8</b>	Sternal end of clavicle
<b>XA4PT6</b>	Shaft of the clavicle
<b>XA09P2</b>	Acromial end of clavicle
<b>XA53X6</b>	Scapula
<b>XA2HS8</b>	Neck of the scapula
<b>XA1216</b>	Glenoid cavity of the scapula
<b>XA2Y48</b>	Coracoid process of the scapula
<b>XA3664</b>	Acromion
<b>XA2XL4</b>	Humerus

<b>XA4VY5</b>	Head of the humerus
<b>XA0XN0</b>	Anatomical neck of the humerus
<b>XA6FR2</b>	Surgical neck of the humerus
<b>XA7144</b>	Greater tuberosity of the humerus
<b>XA72X2</b>	Lesser tuberosity of the humerus
<b>XA4RN8</b>	Shaft of the humerus
<b>XA3RE0</b>	Condyle of the humerus
<b>XA11M8</b>	Capitulum of humerus
<b>XA9LK4</b>	Trochlea of humerus
<b>XA6EF8</b>	Lateral epicondyle of the humerus
<b>XA4097</b>	Medial epicondyle of the humerus
<b>XA3WG1</b>	Radius
<b>XA2N25</b>	Radial head
<b>XA0ZF7</b>	Radial neck
<b>XA35U4</b>	Shaft of radius
<b>XA6YE5</b>	Radial groove
<b>XA3MH2</b>	Styloid process of radius
<b>XA4X32</b>	Lower end of radius not otherwise specified
<b>XA76U7</b>	Upper end of radius not otherwise specified
<b>XA5007</b>	Ulna
<b>XA0NS5</b>	Coronoid process of the ulna
<b>XA0725</b>	Lower end of ulna not otherwise specified
<b>XA5VA1</b>	Olecranon process of the ulna
<b>XA8U33</b>	Shaft of the ulna
<b>XA05C5</b>	Styloid process of the ulna
<b>XA6SV9</b>	Upper end of ulna not otherwise specified
<b>XA09H2</b>	Carpal bones
<b>XA7480</b>	Scaphoid bone
<b>XA8E71</b>	Distal pole of scaphoid
<b>XA1GV4</b>	Distal third of the scaphoid bone

<b>XA3ZG5</b>	Middle third of the scaphoid bone
<b>XA5ZE5</b>	Proximal third of the scaphoid bone
<b>XA30C8</b>	Lunate bone
<b>XA4A64</b>	Triquetrum bone
<b>XA8SZ6</b>	Pisiform bone
<b>XA7XM2</b>	Trapezium bone
<b>XA9DH2</b>	Trapezoid bone
<b>XA06T2</b>	Capitate bone
<b>XA8488</b>	Hamate bone
<b>XA97A0</b>	Hook of hamate
<b>XA0GJ4</b>	Carpal tunnel
<b>XA22M5</b>	Base of other carpal bone
<b>XA9640</b>	Neck of other carpal bone
<b>XA5TX9</b>	Shaft of other carpal bone
<b>XA3YX4</b>	Metacarpal bone
<b>XA58X4</b>	First metacarpal
<b>XA12D2</b>	Head of the first metacarpal bone
<b>XA8J87</b>	Neck of the first metacarpal bone
<b>XA5N95</b>	Shaft of the first metacarpal bone
<b>XA2P67</b>	Base of the first metacarpal bone
<b>XA5HE0</b>	Second metacarpal
<b>XA93C5</b>	Head of the second metacarpal bone
<b>XA8KU0</b>	Neck of the second metacarpal bone
<b>XA4RC8</b>	Shaft of the second metacarpal bone
<b>XA37V2</b>	Base of the second metacarpal bone
<b>XA7J93</b>	Third metacarpal
<b>XA6442</b>	Head of the third metacarpal bone
<b>XA50H4</b>	Neck of the third metacarpal bone
<b>XA8BP2</b>	Shaft of the third metacarpal bone
<b>XA8NK6</b>	Base of the third metacarpal bone

<b>XA9KB7</b>	Fourth metacarpal
<b>XA8X42</b>	Head of the fourth metacarpal bone
<b>XA9NT7</b>	Neck of the fourth metacarpal bone
<b>XA4CP7</b>	Shaft of the fourth metacarpal bone
<b>XA3ZF8</b>	Base of the fourth metacarpal bone
<b>XA88S1</b>	Fifth metacarpal
<b>XA3Z46</b>	Head of the fifth metacarpal bone
<b>XA16Y6</b>	Neck of the fifth metacarpal bone
<b>XA92G8</b>	Shaft of the fifth metacarpal bone
<b>XA65Y7</b>	Base of the fifth metacarpal bone
<b>XA3PA7</b>	Phalanx of the hand
<b>XA0HH1</b>	Proximal phalanx of the hand
<b>XA25U2</b>	Proximal phalanx of index finger
<b>XA6ET0</b>	Proximal phalanx of middle finger
<b>XA9MR0</b>	Proximal phalanx of ring finger
<b>XA73Q6</b>	Proximal phalanx of little finger
<b>XA0903</b>	Proximal phalanx of thumb
<b>XA89G7</b>	Middle phalanx of hand
<b>XA3JL6</b>	Middle phalanx of index finger
<b>XA5910</b>	Middle phalanx of middle finger
<b>XA8N14</b>	Middle phalanx of ring finger
<b>XA6HX0</b>	Middle phalanx of little finger
<b>XA7LS3</b>	Distal phalanx of the hand
<b>XA54X0</b>	Distal phalanx of index finger
<b>XA8NR0</b>	Distal phalanx of middle finger
<b>XA51S6</b>	Distal phalanx of ring finger
<b>XA32G6</b>	Distal phalanx of little finger
<b>XA70H5</b>	Distal phalanx of thumb
<b>XA5D87</b>	Bone of finger, not elsewhere classified
<b>XA95Q5</b>	Bone of thumb, not elsewhere classified

<b>XA2T04</b>	<b>Bones of the lower extremity</b>
<b>XA6BA0</b>	Femur
<b>XA96S5</b>	Femoral head
<b>XA1673</b>	Femoral neck
<b>XA32G0</b>	Trochanter
<b>XA1VJ3</b>	Greater trochanter of femur
<b>XA9TD9</b>	Lesser trochanter of femur
<b>XA9JB2</b>	Intertrochanteric crest of femur
<b>XA4AF2</b>	Femoral shaft
<b>XA6UG0</b>	Femoral condyle
<b>XA2BJ0</b>	Femoral epiphysis
<b>XA00N4</b>	Petrochanter
<b>XA5EL8</b>	Subtrochanteric line of femur
<b>XA4T36</b>	Patella
<b>XA44U1</b>	Tibia
<b>XA5RE8</b>	Tibial condyle
<b>XA87A0</b>	Lateral condyle of tibia
<b>XA7Y69</b>	Medial condyle of tibia
<b>XA3DL5</b>	Tibial tuberosity
<b>XA66B3</b>	Tibial shaft
<b>XA2EN5</b>	Tibial spine
<b>XA1HS9</b>	Medial malleolus
<b>XA3450</b>	Posterior malleolus
<b>XA3KT5</b>	Fibula
<b>XA0K77</b>	Fibular head
<b>XA5G97</b>	Fibular shaft
<b>XA4UL1</b>	Lateral malleolus
<b>XA7NN4</b>	Tarsal bone
<b>XA5LU2</b>	Calcaneus
<b>XA57V1</b>	Anterior process of calcaneus

<b>XA62P4</b>	Tuberosity of calcaneus
<b>XA1LF4</b>	Talus
<b>XA1N98</b>	Dome of the talus
<b>XA6L02</b>	Neck of the talus
<b>XA3MT9</b>	Posterior process of the talus
<b>XA84E6</b>	Navicular bone
<b>XA4J74</b>	Medial cuneiform bone
<b>XA4046</b>	Intermediate cuneiform bone
<b>XA8462</b>	Lateral cuneiform bone
<b>XA0LW4</b>	Cuboid bone
<b>XA43L9</b>	Bone of ankle
<b>XA6UL8</b>	Tarsal canal
<b>XA6VH2</b>	Metatarsal bone
<b>XA39M2</b>	Phalanx of the foot
<b>XA6U96</b>	Proximal phalanx of the toe
<b>XA8KC3</b>	Proximal phalanx of great toe
<b>XA0AQ0</b>	Proximal phalanx of second toe
<b>XA11P1</b>	Proximal phalanx of third toe
<b>XA8CX6</b>	Proximal phalanx of fourth toe
<b>XA8PK1</b>	Proximal phalanx of fifth toe
<b>XA8539</b>	Middle phalanx of toe
<b>XA1UN2</b>	Middle phalanx of second toe
<b>XA9YP5</b>	Middle phalanx of third toe
<b>XA2SX4</b>	Middle phalanx of fourth toe
<b>XA90F0</b>	Middle phalanx of fifth toe
<b>XA4352</b>	Distal phalanx of the toe
<b>XA2AC2</b>	Distal phalanx of great toe
<b>XA3QM7</b>	Distal phalanx of second toe
<b>XA38Q1</b>	Distal phalanx of third toe
<b>XA8XV0</b>	Distal phalanx of fourth toe

**XA6ED4** Distal phalanx of fifth toe

Joints and ligaments

<b>XA7948</b>	<b>Joints and ligaments of the head and neck</b>
<b>XA6UT2</b>	<b>Joints of the head</b>
<b>XA65F2</b>	Atlantooccipital joint
<b>XA7EM1</b>	Atlantoaxial joint
<b>XA2SM2</b>	Temporomandibular joint
<b>XA1LE7</b>	<b>Ligaments of the head and neck</b>
<b>XA68Z9</b>	Anterior atlantoaxial ligament
<b>XA4XK9</b>	Anterior atlantooccipital ligament
<b>XA9F16</b>	Anterior longitudinal ligament
<b>XA3K95</b>	Apical odontoid ligament
<b>XA3XV5</b>	Articular capsules
<b>XA3ZW3</b>	Interarticular ligament
<b>XA9M15</b>	Interspinal ligament
<b>XA9NZ1</b>	Intertransverse ligament
<b>XA5180</b>	Intervertebral fibrocartilage ligament
<b>XA97L7</b>	Lateral atlantooccipital ligament
<b>XA72L3</b>	Ligamenta flava
<b>XA6RG7</b>	Ligamentum nuchae
<b>XA3J99</b>	Occipitoaxial ligament
<b>XA1CC5</b>	Posterior atlantoaxial ligament
<b>XA80K5</b>	Posterior atlantooccipital ligament
<b>XA8E20</b>	Posterior longitudinal ligament
<b>XA4FR7</b>	Sphenomandibular ligament
<b>XA4WM3</b>	Stylomandibular ligament
<b>XA7WU3</b>	Supraspinal ligament
<b>XA4WJ7</b>	Temporomandibular ligament
<b>XA8389</b>	Transverse ligament of the atlas
<b>XA33F9</b>	Thyrohyoid ligament

<b>XA9XG3</b>	Cricoarytenoid ligament
<b>XA6B16</b>	Cricopharyngeal ligament
<b>XA3BV9</b>	Cricotracheal ligament
<b>XA3JR5</b>	Hyoepiglottic ligament
<b>XA4051</b>	Cricothyroid ligament
<b>XA56S4</b>	Thyroepiglottic ligament
<b>XA4KB2</b>	Vestibular ligament
<b>XA6928</b>	Vocal ligament
<b>XA2EL4</b>	<b>Joints and ligaments of the thorax</b>
<b>XA2NG8</b>	<b>Joints of the thorax</b>
<b>XA83N6</b>	Sternocostal joint
<b>XA30Q4</b>	Costochondral joint
<b>XA0892</b>	Costovertebral joint
<b>XA7AR2</b>	Costotransverse joint
<b>XA0ZE4</b>	Facet joint
<b>XA2UN9</b>	<b>Ligaments of the thorax</b>
<b>XA70E9</b>	Anterior costotransverse ligament
<b>XA0QM2</b>	Anterior intersternal ligament
<b>XA8V32</b>	Anterior ligament of the spine
<b>XA5G44</b>	Costotransverse ligament
<b>XA2S05</b>	Costoxiphoid ligament
<b>XA4356</b>	Iliolumbar ligament
<b>XA70A1</b>	Interarticular sternocostal ligament
<b>XA8D15</b>	Interchondral ligament
<b>XA6ZD7</b>	Ligament of the neck of the rib
<b>XA81P3</b>	Ligament of the tubercle of the rib
<b>XA4A37</b>	Posterior costotransverse ligament
<b>XA8B33</b>	Lumbocostal ligament
<b>XA26A7</b>	Posterior intersternal ligament
<b>XA8RC0</b>	Radiate ligament

<b>XA43Z7</b>	Radiate sternocostal ligament
<b>XA6KC7</b>	<b>Joints and ligaments of the pelvis and perineum</b>
<b>XA1TL5</b>	<b>Joints of the pelvis</b>
<b>XA5A04</b>	Lumbosacral joint
<b>XA70B6</b>	Sacrococcygeal joint
<b>XA3T32</b>	Sacroiliac joint
<b>XA9TF3</b>	<b>Ligaments of the pelvis and perineum</b>
<b>XA5S21</b>	Anterior pubic ligament
<b>XA10C4</b>	Anterior sacroiliac ligament
<b>XA9621</b>	Arcuate pubic ligament
<b>XA0EJ9</b>	Broad ligament of the uterus
<b>XA6VF6</b>	Mesovarium
<b>XA9TX2</b>	Parovarian region
<b>XA6CV1</b>	Mesosalpinx
<b>XA3AN2</b>	Mesometrium
<b>XA46Z2</b>	Interarticular ligament of the pelvis
<b>XA02T6</b>	Interosseous sacroiliac ligament
<b>XA1NT7</b>	Ligamentum teres of the Liver
<b>XA92G5</b>	Posterior pubic ligament
<b>XA6RS4</b>	Posterior sacroiliac ligament
<b>XA69U0</b>	Long posterior sacroiliac ligament
<b>XA9HV6</b>	Short posterior sacroiliac ligament
<b>XA1UP6</b>	Pubic symphysis
<b>XA23X3</b>	Round ligament of uterus
<b>XA8GZ2</b>	Sacrococcygeal ligament
<b>XA2MA4</b>	Anterior sacrococcygeal ligament
<b>XA4B16</b>	Lateral sacrococcygeal ligament
<b>XA2U92</b>	Posterior sacrococcygeal ligament
<b>XA8J68</b>	Sacrospinous ligament
<b>XA6396</b>	Sacrotuberous ligament

<b>XA68K7</b>	Superior pubic ligament
<b>XA4T57</b>	Uterine ligament
<b>XA2NB2</b>	Uterosacral ligament
<b>XA4XC0</b>	<b>Joints and ligaments of the upper extremity</b>
<b>XA4U90</b>	<b>Joints of the upper extremity</b>
<b>XA05J7</b>	Shoulder joint
<b>XA49P8</b>	Glenohumeral joint
<b>XA69U6</b>	Acromioclavicular joint
<b>XA0CH1</b>	Sternoclavicular joint
<b>XA69H4</b>	Elbow joint
<b>XA3G42</b>	Proximal radioulnar joint
<b>XA46J3</b>	Humeroulnar joint
<b>XA53P1</b>	Humeroradial joint
<b>XA64C3</b>	Wrist joint
<b>XA78S6</b>	Distal radioulnar joint
<b>XA0P38</b>	Radiocarpal joint
<b>XA62V5</b>	Joints of the hand
<b>XA3MB4</b>	Carpal joint
<b>XA0E90</b>	Intercarpal joint
<b>XA4AS7</b>	Midcarpal joint
<b>XA0JX0</b>	Carpometacarpal joint
<b>XA9DN6</b>	Intermetacarpal joint
<b>XA86T5</b>	Metacarpophalangeal joint
<b>XA3M83</b>	First metacarpophalangeal joint
<b>XA9YH1</b>	Second metacarpophalangeal joint
<b>XA6HB0</b>	Third metacarpophalangeal joint
<b>XA7XA8</b>	Fourth metacarpophalangeal joint
<b>XA7KA0</b>	Fifth metacarpophalangeal joint
<b>XA9291</b>	Interphalangeal joint of the hand
<b>XA6L43</b>	Interphalangeal joint of the thumb

<b>XA1307</b>	Proximal interphalangeal joint of finger
<b>XA1DN6</b>	Proximal interphalangeal joint of index finger
<b>XA3NW6</b>	Proximal interphalangeal joint of middle finger
<b>XA0BF5</b>	Proximal interphalangeal joint of ring finger
<b>XA4175</b>	Proximal interphalangeal joint of little finger
<b>XA4U75</b>	Distal interphalangeal joint of finger
<b>XA6KB0</b>	Distal interphalangeal joint of index finger
<b>XA15C8</b>	Distal interphalangeal joint of middle finger
<b>XA0LT5</b>	Distal interphalangeal joint of ring finger
<b>XA1928</b>	Distal interphalangeal joint of little finger
<b>XA4BC2</b>	<b>Ligaments of the upper extremity</b>
<b>XA93X9</b>	Ligament of the shoulder
<b>XA2H23</b>	Acromioclavicular ligament
<b>XA49Z7</b>	Inferior acromioclavicular ligament
<b>XA8RC9</b>	Superior acromioclavicular ligament
<b>XA01C8</b>	Anterior ligament of the shoulder
<b>XA2JQ3</b>	Anterior sternoclavicular ligament
<b>XA8MA3</b>	Coracoacromial ligament
<b>XA9WP5</b>	Coracoclavicular ligament
<b>XA4PU7</b>	Conoid ligament
<b>XA5SJ7</b>	Trapezoid ligament
<b>XA5EW9</b>	Coracohumeral ligament
<b>XA1PK9</b>	Costoclavicular ligament
<b>XA8H81</b>	Glenohumeral ligament
<b>XA5Z24</b>	Glenoidal labrum ligament
<b>XA84L3</b>	Interclavicular ligament
<b>XA3PT9</b>	Posterior sternoclavicular ligament
<b>XA6EG3</b>	Rotator cuff capsule
<b>XA6EE7</b>	Spinoglenoid ligament
<b>XA5MU7</b>	Suprascapular ligament

<b>XA9C92</b>	Transverse humeral ligament
<b>XA5Y12</b>	Ligament of the elbow
<b>XA0JJ8</b>	Annular ligament
<b>XA4S76</b>	Ligament of Struthers
<b>XA16Y4</b>	Posterior ligament of elbow
<b>XA8B40</b>	Quadratus ligament
<b>XA9WJ8</b>	Radial collateral ligament
<b>XA9220</b>	Ulnar collateral ligament
<b>XA6SA0</b>	Interosseous membrane of forearm
<b>XA9Y28</b>	Ligament of the wrist and hand <b>Coded Elsewhere:</b> Radial collateral ligament (XA9WJ8)
<b>XA9MY7</b>	Collateral carpal ligament
<b>XA0K88</b>	Collateral metacarpophalangeal ligament
<b>XA20K5</b>	Dorsal carpometacarpal ligament
<b>XA0PE4</b>	Dorsal intercarpal ligament
<b>XA0WZ1</b>	Dorsal intermetacarpal ligament
<b>XA2PN5</b>	Dorsal metacarpophalangeal ligament
<b>XA7Q52</b>	Dorsal radiocarpal ligament
<b>XA52E8</b>	Interosseous ligament
<b>XA10U4</b>	Palmar aponeurosis
<b>XA1Z72</b>	Pisohamate ligament
<b>XA3VJ3</b>	Pisometacarpal ligament
<b>XA0PY0</b>	Radio-ulnar ligament
<b>XA4396</b>	Dorsal radio-ulnar ligament
<b>XA2940</b>	Volar radio-ulnar ligament
<b>XA3SZ9</b>	Transverse metacarpal ligament
<b>XA3K32</b>	Ulnocarpal ligament
<b>XA1PU7</b>	Volar carpometacarpal ligament
<b>XA47N4</b>	Volar intercarpal ligaments
<b>XA1LF5</b>	Volar intermetacarpal ligament

<b>XA3VN5</b>	Volar metacarpophalangeal ligament
<b>XA0492</b>	Volar radiocarpal ligament
<b>XA5ST4</b>	<b>Joints and ligaments of the lower extremity</b>
<b>XA7L41</b>	<b>Joints of lower extremity</b>
<b>XA4XS4</b>	Hip joint
<b>XA8RL1</b>	Knee joint
<b>XA0LC4</b>	Tibiofemoral joint
<b>XA0VJ4</b>	Patellofemoral joint
<b>XA0LG3</b>	Proximal tibiofibular joint
<b>XA8VV2</b>	Semilunar cartilage
	<b>Coded Elsewhere:</b> Lateral meniscus of knee joint (XA6HQ4)
	Medial meniscus of knee joint (XA7LB6)
<b>XA27P3</b>	Ankle joint
<b>XA8MM7</b>	Talocrural joint
<b>XA2K81</b>	Distal tibiofibular joint
<b>XA7SZ8</b>	Subtalar joint
<b>XA22T0</b>	Joint of the foot
<b>XA2YS1</b>	Intertarsal joint
	<b>Coded Elsewhere:</b> Subtalar joint (XA7SZ8)
<b>XA4JJ1</b>	Calcaneocuboid joint
<b>XA0WY5</b>	Talocalcaneonavicular joint
<b>XA6NT7</b>	Cuneonavicular joint
<b>XA1N77</b>	Cuboideonavicular joint
<b>XA9SD1</b>	Intercuneiform joint
<b>XA2FA3</b>	Cuneocuboid joint
<b>XA2MY1</b>	Tarsometatarsal joint
<b>XA6FF3</b>	Intermetatarsal joint
<b>XA8XU1</b>	Metatarsophalangeal joint
<b>XA7NJ7</b>	First metatarsophalangeal joint
<b>XA58K5</b>	Second metatarsophalangeal joint
<b>XA2792</b>	Third metatarsophalangeal joint

<b>XA7QC6</b>	Fourth metatarsophalangeal joint
<b>XA5A23</b>	Fifth metatarsophalangeal joint
<b>XA04T7</b>	Interphalangeal joint of the foot
<b>XA87P9</b>	Interphalangeal joint of great toe
<b>XA5573</b>	Proximal interphalangeal joint of the foot
<b>XA56K9</b>	Proximal interphalangeal joint of second toe
<b>XA2QY2</b>	Proximal interphalangeal joint of third toe
<b>XA2R87</b>	Proximal interphalangeal joint of fourth toe
<b>XA1LM0</b>	Proximal interphalangeal joint of fifth toe
<b>XA0RK3</b>	Distal interphalangeal joint of the foot
<b>XA8UM5</b>	Distal interphalangeal joint of second toe
<b>XA43F0</b>	Distal interphalangeal joint of third toe
<b>XA8NU9</b>	Distal interphalangeal joint of fourth toe
<b>XA39U1</b>	Distal interphalangeal joint of fifth toe
<b>XA9Z55</b>	Transverse tarsal joint
<b>XA7U26</b>	<b>Ligaments of the lower extremity</b>
<b>XA1A66</b>	Ligament of the hip
<b>XA1F23</b>	Iliofemoral ligament
<b>XA6KC6</b>	Iliotibial ligament
<b>XA6TZ6</b>	Iliotrochanteric ligament
<b>XA5HX9</b>	Ischiocapsular ligament
<b>XA13S4</b>	Ligamentum teres femoris
<b>XA3GE8</b>	Pubofemoral ligament
<b>XA9J44</b>	Transverse acetabular ligament
<b>XA8P38</b>	Ligament of the knee
<b>XA0ZC8</b>	Anterior cruciate ligament
<b>XA04S7</b>	Coronary ligament
<b>XA4YJ0</b>	Fibular collateral ligament
<b>XA6HQ4</b>	Lateral meniscus of knee joint
<b>XA87R6</b>	Oblique popliteal ligament

<b>XA3772</b>	Patellar ligament
<b>XA4635</b>	Posterior cruciate ligament
<b>XA7LD2</b>	Tibial collateral ligament
<b>XA71L7</b>	Transverse ligament of the knee
<b>XA7LB6</b>	Medial meniscus of knee joint
<b>XA2F70</b>	Ligament of the ankle or foot
<b>XA93X1</b>	Anterior inferior ligament
<b>XA84J2</b>	Anterior talofibular ligament
<b>XA1259</b>	Anterior tibiofibular ligament
<b>XA5EY2</b>	Bifurcated ligament
<b>XA3154</b>	Calcaneofibular ligament
<b>XA59Z4</b>	Collateral ligament of the foot
<b>XA2314</b>	Cuneometatarsal ligament
<b>XA9YS6</b>	Deltoid ligament
<b>XA42X4</b>	Dorsal calcaneocuboid ligament
<b>XA6Q67</b>	Dorsal cuboideonavicular ligament
<b>XA3TS2</b>	Dorsal intermetatarsal ligament
<b>XA8NU3</b>	Dorsal naviculocuneiform ligament
<b>XA86X4</b>	Dorsal talonavicular ligament
<b>XA9E13</b>	Dorsal tarsometatarsal ligament
<b>XA2FV7</b>	Inferior transverse ligament of ankle
<b>XA16V1</b>	Intercuneiform ligament
<b>XA7075</b>	Dorsal intercuneiform ligament
<b>XA5HQ7</b>	Plantar intercuneiform ligament
<b>XA4XJ2</b>	Interosseous talocalcaneal ligament
<b>XA6NS2</b>	Long plantar ligament
<b>XA59U6</b>	Plantar accessory ligament
<b>XA87B0</b>	Plantar aponeurosis
<b>XA4N86</b>	Plantar calcaneocuboid ligament
<b>XA5KN3</b>	Plantar calcaneonavicular ligament

<b>XA2NX5</b>	Plantar cuboideonavicular ligament
<b>XA18T4</b>	Plantar intermetatarsal ligament
<b>XA1747</b>	Plantar naviculocuneiform ligament
<b>XA71L9</b>	Plantar tarsometatarsal ligament
<b>XA2D55</b>	Posterior inferior ligament
<b>XA93E6</b>	Posterior talofibular ligament
<b>XA6RA3</b>	Posterior tibiofibular ligament
<b>XA6546</b>	Talocalcaneal ligament
<b>XA93N5</b>	Anterior talocalcaneal ligament
<b>XA4VX8</b>	Lateral talocalcaneal ligament
<b>XA09E2</b>	Medial talocalcaneal ligament
<b>XA60T4</b>	Posterior talocalcaneal ligament
<b>XA5BX0</b>	Transverse metatarsal ligament

**XA2P74      Ligaments and joints of multiple sites**

Number of joints

<b>XA4EJ6</b>	<b>Multiple Joints</b>
<b>XA1CK9</b>	<b>Oligoarticular</b>
<b>XA3FU7</b>	<b>Polyarticular</b>
<b>XA02P3</b>	Multiple large joints only Large joints include ankle joint, knee joint, hip joint, elbow joint and shoulder joint.
<b>XA2SK7</b>	Multiple small joints only Small joints include toe joints, finger joints and wrist joint.
<b>XA3BZ3</b>	Both large and small joints
<b>XA5X22</b>	Large joints only with cervical spine or temporomandibular involvement
<b>XA4BF0</b>	<b>Monoarticular</b>

Number of Ligaments

<b>XA5XD5</b>	<b>Multiple ligaments</b>
<b>XA5NN2</b>	<b>Single ligament</b>

Cartilage

XA8YS7	Elastic cartilage
XA8VH7	Fibrous cartilage
XA2686	Hyaline cartilage
XA3NV3	Articular cartilage
XA6958	Costal cartilage

Muscles

XA2JQ8	<b>Muscles of the head and neck</b>
XA2SJ6	Alaeque nasi muscle
XA2QF2	Anterior auricularis muscle
XA3SS4	Aryepiglotticus muscle
XA8GG0	Buccinator muscle
XA0UH6	Constrictor of pharynx - inferior muscle
XA3S80	Constrictor of pharynx - middle muscle
XA9568	Constrictor of pharynx - superior muscle
XA01U4	Corrugator supercilii muscle
XA7W64	Cricothyroid muscle
XA04G0	Depressor anguli oris muscle
XA60C8	Depressor labii inferioris muscle
XA2967	Digastric muscle
XA09D1	Frontalis muscle
XA50R5	Genioglossus muscle
XA5YU7	Geniohyoid muscle
XA5DX5	Hyoglossus muscle
XA3PY5	Hyoid muscle
XA4N79	Inferior oblique muscle
XA1X67	Inferior rectus muscle
XA31C3	Intrinsic muscles of tongue
XA5WQ9	Lateral cricoarytenoid muscle
XA8ZB7	Lateral pterygoid muscle

XA3282	Lateral rectus muscle
XA75X0	Levator anguli oris muscle
XA1490	Levator labii superioris muscle
XA2R46	Levator palpebrae superioris muscle
XA5LP4	Levator veli palatini muscle
XA6YE6	Longus capitis muscle
XA8EM8	Longus colli muscle
XA2VD8	Masseter muscle
XA2DX4	Medial pterygoid muscle
XA95N1	Medial rectus muscle
XA0U25	Mentalis muscle
XA8AR7	Musculus uvulae muscle
XA83A9	Mylohyoid muscle
XA0Y41	Nasalis muscle
XA59J0	Oblique arytenoid muscle
XA8L72	Oblique auricularis muscle
XA6LS5	Obliquus capitis inferior muscle
XA0X13	Obliquus capitis superior muscle
XA4RN7	Omohyoid muscle
XA0ZM1	Orbicularis oculi muscle
XA55R2	Orbicularis oris muscle
XA2U72	Palatoglossus muscle
XA1PG4	Palatopharyngeus muscle
XA17T6	Platysma muscle
XA8C48	Posterior auricularis muscle
XA9RS8	Posterior cricoarytenoid muscle
XA6648	Procerus muscle
XA16A4	Rectus capitis anterior muscle
XA0JK2	Rectus capitis lateralis muscle
XA20Q8	Rectus capitis posterior major muscle

XA80F2	Rectus capitis posterior minor muscle
XA49A7	Risorius muscle
XA81P5	Salpingopharyngeus muscle
XA0JF1	Scalenus anterior muscle
XA6S71	Scalenus medius muscle
XA3TF5	Scalenus minimus muscle
XA35K5	Scalenus posterior muscle
XA58T9	Splenius capitis muscle
XA6095	Splenius cervicis muscle
XA8D61	Stapedius muscle
XA2H61	Sternocleidomastoid muscle
XA5QR5	Sternohyoid muscle
XA9H91	Sternothyroid muscle
XA5L15	Styloglossus muscle
XA1TY3	Stylohyoid muscle
XA9AM5	Stylopharyngeus muscle
XA8SW4	Superior auricularis muscle
XA2X27	Superior oblique muscle
XA51R1	Superior rectus muscle
XA01H9	Temporalis muscle
XA1CQ1	Temporoparietalis muscle
XA42R7	Tensor tympani muscle
XA7LF2	Tensor veli palatini muscle
XA8352	Thyroarytenoid muscle
XA2ZL4	Thyroepiglotticus muscle
XA87S0	Thyrohyoid muscle
XA3856	Transverse arytenoid muscle
XA9AU8	Transverse auricularis muscle
XA0M12	Vocalis muscle
XA37U4	Zygomaticus major muscle

<b>XA2AP2</b>	<b>Zygomaticus minor muscle</b>
<b>XA19W0</b>	<b>Muscle of the thorax</b>
<b>XA2JL0</b>	<b>Diaphragm</b>
<b>XA6RW0</b>	<b>External intercostal muscle</b>
<b>XA3P12</b>	<b>Innermost intercostal muscle</b>
<b>XA1256</b>	<b>Internal intercostal muscle</b>
<b>XA7NL0</b>	<b>Levator costarum muscle</b>
<b>XA1QH6</b>	<b>Pectoralis major muscle</b>
<b>XA0SB2</b>	<b>Pectoralis minor muscle</b>
<b>XA7QL8</b>	<b>Serratus anterior muscle</b>
<b>XA44Y8</b>	<b>Subcostalis muscle</b>
<b>XA3G64</b>	<b>Transversus thoracis muscle</b>
<b>XA8PG5</b>	<b>Muscle of the abdomen</b>
<b>XA3TW8</b>	<b>External oblique abdominis muscle</b>
<b>XA9B36</b>	<b>Internal oblique abdominis muscle</b>
<b>XA43E9</b>	<b>Psoas major muscle</b>
<b>XA7DA1</b>	<b>Psoas minor muscle</b>
<b>XA6AY9</b>	<b>Pyramidalis muscle</b>
<b>XA1GP3</b>	<b>Quadratus lumborum muscle</b>
<b>XA1N65</b>	<b>Rectus abdominis muscle</b>
<b>XA9FR3</b>	<b>Transversus abdominis muscle</b>
<b>XA8Z76</b>	<b>Muscle of the back</b>
<b>XA19S9</b>	<b>Iliocostalis muscle</b>
<b>XA8YU1</b>	<b>Interspinales muscle</b>
<b>XA02Z7</b>	<b>Intertransversarii muscle</b>
<b>XA9AG9</b>	<b>Latissimus dorsi muscle</b>
<b>XA00C1</b>	<b>Levator scapulae muscle</b>
<b>XA6MB7</b>	<b>Longissimus muscle</b>
<b>XA8512</b>	<b>Multifidus muscle</b>
<b>XA25S1</b>	<b>Rhomboid major muscle</b>

XA5GH5	Rhomboid minor muscle
XA76Q0	Rotatores muscle
XA60Q0	Semispinalis muscle
XA4A47	Serratus posterior inferior muscle
XA15B6	Serratus posterior superior muscle
XA0U57	Spinalis muscle
XA7RM2	Teres major muscle
XA86Q8	Trapezius muscle
<b>XA2J71</b>	<b>Muscles of the pelvis and perineum</b>
XA2E07	Bulbospongiosus muscle
XA5FZ1	Cremaster muscle
XA8HG2	Dartos muscle
XA2LG6	Deep transverse perinei muscle
XA3YC6	Iliococcygeus muscle
XA73H8	Ischiocavernosus muscle
XA9T66	Levator ani-coccygeus muscle
XA3HP4	Pubococcygeus muscle
XA7MM8	Puborectalis muscle
XA4RK4	Pubovaginalis muscle
XA3ML6	Sphincter ani muscle
XA8FT0	Sphincter urethrae muscle
XA56U7	Superficial transverse perinei muscle
<b>XA4Z20</b>	<b>Muscles of the upper extremity</b>
XA90T3	Abductor digiti minimi muscle (hand)
XA0Z05	Abductor pollicis brevis muscle
XA7PS1	Abductor pollicis longus muscle
XA54Z7	Adductor pollicis muscle
XA2583	Anconeus muscle
XA0GV5	Articularis cubiti muscle
XA1KL5	Biceps brachii muscle

XA0481	Long head of the biceps brachii muscle
XA3J17	Short head of the biceps brachii muscle
XA6CR7	<b>Brachialis muscle</b>
XA2ZN1	<b>Brachioradialis muscle</b>
XA0TQ5	<b>Coracobrachialis muscle</b>
XA3VN0	<b>Deltoid muscle</b>
XA4U40	<b>Extensor carpi radialis brevis</b>
XA8824	<b>Extensor carpi radialis longus muscle</b>
XA9304	<b>Extensor carpi ulnaris muscle</b>
XA0T60	<b>Extensor digiti minimi muscle (hand)</b>
XA7QU8	<b>Extensor digitorum muscle (hand)</b>
XA1AV6	<b>Extensor indicis muscle</b>
XA4V20	<b>Extensor pollicis brevis muscle</b>
XA0CS4	<b>Extensor pollicis longus muscle</b>
XA0S07	<b>Flexor carpi radialis muscle</b>
XA4HV9	<b>Flexor carpi ulnaris muscle</b>
XA3UK3	<b>Flexor digiti minimi brevis muscle (hand)</b>
XA4Z43	<b>Flexor digitorum profundus muscle</b>
XA1NW3	<b>Flexor digitorum superficialis muscle</b>
XA5QD0	<b>Flexor pollicis brevis muscle</b>
XA3GQ7	<b>Flexor pollicis longus muscle</b>
XA6463	<b>Interossei of the hand muscle</b>
XA2QW3	Dorsal interossei of the hand muscle
XA5055	Palmar interossei of the hand muscle
XA9B77	<b>Lumbricals of hand muscle</b>
XA4RW9	<b>Opponens digiti minimi muscle (hand)</b>
XA0Q73	<b>Opponens pollicis muscle</b>
XA9KL5	<b>Palmaris brevis muscle</b>
XA6P76	<b>Palmaris longus muscle</b>
XA91W0	<b>Pronator quadratus muscle</b>

XA58Z6	Pronator teres muscle
XA3DL4	Rotator cuff muscle
XA7E49	Infraspinatus muscle
XA1QF1	Subscapularis muscle
XA74P3	Supraspinatus muscle
XA3CP1	Teres minor muscle
XA90Z6	Supinator muscle
XA2EB2	Triceps brachii muscle
<b>XA47J0</b>	<b>Muscles of the lower extremity</b>
XA0W07	Abductor digiti minimi muscle (foot)
XA7119	Abductor hallucis muscle
XA8GU7	Adductor brevis muscle
XA0FW7	Adductor hallucis muscle
XA01U3	Adductor longus muscle
XA8HR3	Adductor magnus muscle
XA0DE1	Articularis genu muscle
XA3CB9	Biceps femoris muscle
XA7FZ1	Extensor digitorum brevis muscle (foot)
XA24U7	Extensor digitorum longus muscle (foot)
XA3T27	Extensor hallucis brevis muscle
XA7R67	Extensor hallucis longus muscle
XA20W3	Flexor digiti minimi brevis muscle (foot)
XA97C3	Flexor digitorum brevis muscle
XA23Q3	Flexor digitorum longus muscle (foot)
XA3MB7	Flexor hallucis brevis muscle
XA7E33	Flexor hallucis longus muscle
XA1PK6	Gastrocnemius muscle
XA7PN8	Gemellus inferior muscle
XA0472	Gemellus superior muscle
XA1HH2	Gracilis muscle

XA0200	Iliacus muscle
XA15P6	Interossei - dorsal of foot muscle
XA8TS8	Interossei - plantar of foot muscle
XA7PN0	Lumbricals of foot muscle
XA7Y24	Obturator externus muscle
XA11E8	Obturator internus muscle
XA9E00	Pectineus muscle
XA26M7	Peroneus brevis muscle
XA3P60	Peroneus longus muscle
XA9D52	Peroneus tertius muscle
XA7XS8	Piriformis muscle
XA7W96	Plantaris muscle
XA8CL8	Popliteus muscle
XA41G3	Quadratus plantae muscle
XA1BT5	Quadriceps femoris muscle
XA5447	Rectus femoris muscle
XA5CE3	Sartorius muscle
XA5AM5	Semimembranosus muscle
XA2EK1	Semitendinosus muscle
XA5B83	Soleus muscle
XA02U9	Tibialis anterior muscle
XA3VR3	Tibialis posterior muscle
XA33F6	Vastus intermedius muscle
XA00Z6	Vastus lateralis muscle
XA9RD2	Vastus medialis muscle
XA48F2	Gluteus maximus muscle
XA5VJ8	Gluteus medius muscle
XA7BY4	Gluteus minimus muscle
XA11U3	Tensor fasciae lata muscle

Tendons

<b>XA3PP9</b>	<b>Tendons of the head and neck</b>
<b>XA46A9</b>	<b>Alaeque nasi tendon</b>
<b>XA6J99</b>	<b>Aryepiglotticus tendon</b>
<b>XA8XC7</b>	<b>Auricularis tendon</b>
<b>XA3163</b>	<b>Buccinator tendon</b>
<b>XA6L11</b>	<b>Corrugator supercilii tendon</b>
<b>XA01X1</b>	<b>Cricothyroid tendon</b>
<b>XA28X5</b>	<b>Depressor anguli oris tendon</b>
<b>XA6WZ3</b>	<b>Depressor labii inferioris tendon</b>
<b>XA5S69</b>	<b>Digastric tendon</b>
<b>XA5CP4</b>	<b>Frontalis tendon</b>
<b>XA6BT8</b>	<b>Genioglossus tendon</b>
<b>XA9L90</b>	<b>Geniohyoid tendon</b>
<b>XA8N10</b>	<b>Hyoglossus tendon</b>
<b>XA7EE6</b>	<b>Hyoid tendon</b>
<b>XA3ZA2</b>	<b>Inferior oblique tendon</b>
<b>XA7HT8</b>	<b>Inferior rectus tendon</b>
<b>XA1394</b>	<b>Lateral cricoarytenoid tendon</b>
<b>XA6PK4</b>	<b>Lateral pterygoid tendon</b>
<b>XA3LT8</b>	<b>Lateral rectus tendon</b>
<b>XA7653</b>	<b>Levator anguli oris tendon</b>
<b>XA0YK7</b>	<b>Levator labii superioris tendon</b>
<b>XA61C9</b>	<b>Levator palpebrae superioris tendon</b>
<b>XA7VD7</b>	<b>Levator veli palatini tendon</b>
<b>XA1FR7</b>	<b>Longus capitis tendon</b>
<b>XA0UD3</b>	<b>Longus colli tendon</b>
<b>XA1FB3</b>	<b>Masseter tendon</b>
<b>XA8F95</b>	<b>Medial pterygoid tendon</b>
<b>XA6SG3</b>	<b>Medial rectus tendon</b>

XA7JW2	Mentalis tendon
XA7ZZ8	Mylohyoid tendon
XA7NU6	Nasalis tendon
XA5Q22	Oblique arytenoid tendon
XA8AT8	Obliquus capitis inferior tendon
XA39M0	Obliquus capitis superior tendon
XA2JY6	Omohyoid tendon
XA65X4	Orbicularis oculi tendon
XA0W74	Orbicularis oris tendon
XA6SX4	Palatoglossus tendon
XA6LA2	Palatopharyngeus tendon
XA4758	Platysma tendon
XA0AE2	Posterior cricoarytenoid ligament
XA5HD8	Procerus tendon
XA8CQ6	Rectus capitis anterior tendon
XA4RG2	Rectus capitis lateralis tendon
XA6WL6	Rectus capitis posterior major tendon
XA1XH8	Rectus capitis posterior minor tendon
XA9450	Risorius tendon
XA0SH8	Salpingopharyngeus tendon
XA3XC1	Scalene tendon
XA45L1	scalenus anterior tendon
XA7XV7	scalenus medius tendon
XA7NL5	scalenus minimus tendon
XA9HH7	scalenus posterior tendon
XA39C9	Splenius capitis tendon
XA2HL1	Splenius cervicis tendon
XA8W69	Stapedius tendon
XA70V9	Sternocleidomastoid tendon
XA6S11	Sternohyoid tendon

XA4VX2	Sternothyroid tendon
XA90J0	Styloglossus tendon
XA20E0	Stylohyoid tendon
XA7GV2	Stylopharyngeus tendon
XA5ES8	Superior oblique tendon
XA3ZN4	Superior rectus tendon
XA7D16	Temporalis tendon
XA8BT2	Temporoparietalis tendon
XA5956	Tensor tympani tendon
XA2W44	Tensor veli palatini tendon
XA4ME3	Thyroarytenoid tendon
XA0CT5	Thyroepiglotticus tendon
XA9YC3	Transverse arytenoid tendon
XA4CN7	Vocalis tendon
XA0XQ7	Zygomaticus major tendon
XA0SZ1	Zygomaticus minor tendon
XA3SA1	Tendons of the thorax
XA01T0	Chordae tendineae
XA9N29	Diaphragm tendon
XA5WL5	Intercostals external tendon
XA8FV0	Intercostals innermost tendon
XA92E2	Intercostals internal tendon
XA5R18	Levatores costarum tendon
XA3C70	Pectoralis major tendon
XA40K0	Pectoralis minor tendon
XA91D0	Serratus anterior tendon
XA7J14	Serratus posterior inferior tendon
XA0MH0	Serratus posterior superior tendon
XA8WS6	Subcostalis tendon
XA3XC9	Tendon of Todaro

<b>XA1HX3</b>	<b>Transversus thoracis tendon</b>
<b>XA4797</b>	<b>Tendons of the abdomen</b>
<b>XA0101</b>	<b>External oblique abdominis tendon</b>
<b>XA45G1</b>	<b>Internal oblique abdominis tendon</b>
<b>XA3045</b>	<b>Psoas major tendon</b>
<b>XA7V41</b>	<b>Psoas minor tendon</b>
<b>XA49W5</b>	<b>Pyramidalis tendon</b>
<b>XA34K5</b>	<b>Quadratus lumborum tendon</b>
<b>XA1HT1</b>	<b>Rectus abdominis tendon</b>
<b>XA0V25</b>	<b>Transversus abdominis tendon</b>
<b>XA9Z26</b>	<b>Tendons of the back</b>
<b>XA48X7</b>	<b>Iliocostalis tendon</b>
<b>XA2MX3</b>	<b>Infraspinatus tendon</b>
<b>XA2E69</b>	<b>Interspinales tendon</b>
<b>XA8UU5</b>	<b>Intertransversarii tendon</b>
<b>XA8467</b>	<b>Latissimus dorsi tendon</b>
<b>XA3TD7</b>	<b>Longissimus tendon</b>
<b>XA33T4</b>	<b>Multifidus tendon</b>
<b>XA3P63</b>	<b>Rhomboid major tendon</b>
<b>XA8918</b>	<b>Rhomboid minor tendon</b>
<b>XA16J2</b>	<b>Rotatores tendon</b>
<b>XA3D42</b>	<b>Semispinalis tendon</b>
<b>XA28J9</b>	<b>Spinalis tendon</b>
<b>XA09K4</b>	<b>Teres major tendon</b>
<b>XA42P8</b>	<b>Teres minor tendon</b>
<b>XA9PV0</b>	<b>Trapezius tendon</b>
<b>XA1SN1</b>	<b>Tendons of the pelvis and perineum</b>
<b>XA15H4</b>	<b>Bulbospongiosus tendon</b>
<b>XA45X9</b>	<b>Coccygeus tendon</b>
<b>XA4755</b>	<b>Cremaster tendon</b>

XA2BV5	Dartos tendon
XA2TD5	Deep transverse perinei tendon
XA6QW7	Iliococcygeus tendon
XA7YP5	Ischiocavernosus tendon
XA5JV1	Pubococcygeus tendon
XA66F5	Puborectalis tendon
XA32R3	Pubovaginalis tendon
<b>XA0WU6</b>	<b>Tendons of the upper extremity</b>
XA5AY5	Abductor digiti minimi tendon
XA7YE1	Abductor pollicis brevis tendon
XA0UY5	Abductor pollicis longus tendon
XA9749	Adductor pollicis tendon
XA4HK3	Anconeus tendon
XA8AM4	Biceps brachii tendon
XA2UD9	Long head of biceps brachii tendon
XA0FB1	Short head of biceps brachii tendon
XA9G06	Brachialis tendon
XA3YY6	Brachioradialis tendon
XA83R8	Coracobrachialis tendon
XA0942	Deltoid tendon
XA24P4	Dorsal Interosseous tendon
XA18F0	Extensor carpi radialis brevis tendon
XA1T90	Extensor carpi radialis longus tendon
XA4PY2	Extensor carpi ulnaris tendon
XA4WU2	Extensor digiti minimi tendon
XA5H06	Extensor digitorum tendon
XA4EE2	Extensor indicis tendon
XA5KN6	Extensor pollicis brevis tendon
XA4CG6	Extensor pollicis longus tendon
XA8U10	Extensor tendon

XA8H50	<b>Flexor carpi radialis tendon</b>
XA5CE2	<b>Flexor carpi ulnaris tendon</b>
XA23D8	<b>Flexor digiti minimi tendon</b>
XA0GQ6	<b>Flexor digitorum profundus tendon</b>
XA9526	<b>Flexor digitorum superficialis tendon</b>
XA9Q34	<b>Flexor digitorum tendon</b>
XA1Q82	<b>Flexor pollicis brevis tendon</b>
XA92F7	<b>Flexor pollicis longus tendon</b>
XA5YQ2	<b>Flexor tendon</b>
XA4M25	<b>Interossei tendon</b>
XA1X89	<b>Levator scapulae tendon</b>
XA8TQ1	<b>Lumbrical tendon</b>
XA9KM7	<b>Opponens digiti minimi tendon</b>
XA3W45	<b>Opponens pollicis tendon</b>
XA82E6	<b>Palmar interosseous tendon</b>
XA7B73	<b>Palmaris brevis tendon</b>
XA41L1	<b>Palmaris longus tendon</b>
XA41Z5	<b>Pronator quadratus tendon</b>
XA7EK5	<b>Pronator teres tendon</b>
XA7V30	<b>Subclavius tendon</b>
XA54N6	<b>Subscapularis tendon</b>
XA5EJ6	<b>Supinator tendon</b>
XA5VZ4	<b>Supraspinatus tendon</b>
XA5RS6	<b>Triceps brachii tendon</b>
<b>XA5L93</b>	<b>Tendons of the lower extremity</b>
XA5ZK0	<b>Abductor digiti minimi (foot) tendon</b>
XA14Z8	<b>Abductor hallucis tendon</b>
XA8BK1	<b>Achilles tendon</b>
XA4HF0	<b>Adductor brevis tendon</b>
XA8B14	<b>Adductor hallucis tendon</b>

XA1TK8	Adductor longus tendon
XA8746	Adductor magnus tendon
XA9381	Anterior ligament of the lower extremity
XA7MT0	Articularis genu tendon
XA1MF8	Biceps femoris tendon
XA86H9	Dorsal interossei of foot tendon
XA6230	Extensor digitorum brevis (foot) tendon
XA1ZF4	Extensor digitorum longus (foot) tendon
XA4NZ0	Extensor hallucis brevis tendon
XA5L26	Extensor hallucis longus tendon
XA8X38	Flexor digiti minimi brevis (foot) tendon
XA8GD0	Flexor digitorum brevis tendon
XA3MK8	Flexor digitorum longus (foot) tendon
XA00Z8	Flexor hallucis brevis tendon
XA1MF0	Flexor hallucis longus tendon
XA5LZ0	Gastrocnemius tendon
XA2HX4	Gemellus inferior tendon
XA5M18	Gemellus superior tendon
XA1JL3	Gluteus maximus tendon
XA1387	Gluteus medius tendon
XA4HK9	Gluteus minimus tendon
XA12U3	Gracilis tendon
XA8FT1	Iliacus tendon
XA5DE3	Lumbrical of foot tendon
XA3EE9	Obturator externus tendon
XA2469	Obturator internus tendon
XA07E4	Pectineus tendon
XA3AN0	Peroneus brevis tendon
XA7VY0	Peroneus longus tendon
XA3D16	Peroneus tertius tendon

XA3EU4	Piriformis tendon
XA7L19	Plantar interossei of foot tendon
XA6BZ6	Plantaris tendon
XA4V24	Popliteus tendon
XA1L44	Quadratus plantae tendon
XA9420	Quadriceps femoris tendon
XA4ZG0	Rectus femoris tendon
XA0981	Sartorius tendon
XA4AL5	Semimembranosus tendon
XA7DY9	Semitendinosus tendon
XA7E05	Soleus tendon
XA33Q1	Tensor fasciae lata tendon
XA8SN1	Tibialis anterior tendon
XA7FR7	Tibialis posterior tendon
XA8ST5	Vastus intermedius tendon
XA8CQ5	Vastus lateralis tendon
XA6RK3	Vastus medialis tendon
XA2C51	Enthesis
XA16K5	Bursa
XA12U7	Bursa olecrani
XA7P88	Bursa praepatellaris

## Genitourinary system

### Urinary system

XA6KU8	Kidney
XA5EP6	Renal capsule
XA35W4	Renal cortex
XA91E4	Renal medulla
XA9Q52	Renal pyramid
XA21J4	Renal pelvis

<b>XA0AC1</b>	Renal calyces
<b>XA6N83</b>	Major calyx
<b>XA8XL0</b>	Minor calyx
<b>XA7NQ9</b>	Ureteropelvic junction
<b>XA4UD2</b>	<b>Renal hilum</b>
<b>XA40R2</b>	<b>Glomerulus</b>
<b>XA8AN8</b>	Nephron
<b>XA2364</b>	Renal tubule
<b>XA7156</b>	<b>Ureter</b>
	<i>Coded Elsewhere:</i> Ureteropelvic junction (XA7NQ9)
<b>XA9L57</b>	<b>Ureterovesical orifice</b>
<b>XA77K2</b>	<b>Urinary bladder</b>
	<i>Coded Elsewhere:</i> Urachus (XA1NC2)
	Ureterovesical orifice (XA9L57)
<b>XA2PT2</b>	<b>Dome of bladder</b>
<b>XA0R03</b>	<b>Bladder wall</b>
	<i>Coded Elsewhere:</i> Trigone of bladder (XA6KF2)
<b>XA3JA5</b>	Lateral wall of bladder
<b>XA4UM5</b>	Anterior wall of bladder
<b>XA2562</b>	Posterior wall of bladder
<b>XA6SR9</b>	Superior wall of bladder
<b>XA6KF2</b>	<b>Trigone of bladder</b>
<b>XA4P63</b>	Ureteric orifice
<b>XA8KN5</b>	Internal urethral orifice
<b>XA0VZ5</b>	<b>Bladder neck</b>
<b>XA5TA5</b>	<b>Urethra</b>
<b>XA33M0</b>	<b>Internal urethral sphincter</b>
<b>XA75T3</b>	<b>Membranous urethra</b>
<b>XA7869</b>	<b>Prostatic urethra</b>
<b>XA4DF2</b>	<b>External urethral sphincter</b>
<b>XA8EW9</b>	<b>Penile urethra</b>

<b>XA4NU9</b>	<b>External urethral meatus</b>
<b>XA4V93</b>	<b>Urinary tract, not elsewhere classified</b>
<b>XA34X0</b>	<b>Lower urinary tract</b>
<b>XA6RS6</b>	<b>Upper urinary tract</b>

Reproductive system

<b>XA75A2</b>	<b>Male genital organs</b>
	<b>Coded Elsewhere:</b> Urethra (XA5TA5)
<b>XA7QV2</b>	<b>Penis</b>
<b>XA0970</b>	Root of penis
<b>XA9A26</b>	Body of penis
<b>XA03Y8</b>	Dorsal surface of penis
<b>XA3D56</b>	Ventral surface of penis
<b>XA0MH6</b>	Glans penis
<b>XA3Q76</b>	Penile urethral meatus
<b>XA3KB3</b>	Paraurethral gland
<b>XA71S4</b>	Prepuce
<b>XA2BL8</b>	Outer surface of prepuce
<b>XA1CP6</b>	Mucosal surface of prepuce
<b>XA54U4</b>	Coronal sulcus of penis
<b>XA7V24</b>	Frenulum of penis
<b>XA4947</b>	<b>Testis</b>
<b>XA1FS5</b>	Tunica vaginalis
<b>XA07W9</b>	Tunica albuginea
<b>XA9636</b>	Seminiferous tubules
<b>XA13Z7</b>	Descended testis
<b>XA14M8</b>	Testicular appendage
<b>XA4D25</b>	<b>Epididymis</b>
<b>XA9235</b>	<b>Spermatic cord</b>
	<b>Coded Elsewhere:</b> Pampiniform plexus (XA05M3)
<b>XA8PQ1</b>	Vas deferens

<b>XA0MJ1</b>	Seminal vesicle
<b>XA63E5</b>	Prostate gland
<b>XA2GU7</b>	<b>Female genital organs</b>
	<b>Coded Elsewhere:</b> Placenta (XA90F8)
<b>XA78U5</b>	<b>Vulva</b>
	<b>Coded Elsewhere:</b> Mons pubis (XA10Z0)
<b>XA11L9</b>	Labia of vulva
<b>XA59G9</b>	Labium majus
<b>XA0MU9</b>	Labium minus
	<b>Coded Elsewhere:</b> Posterior fourchette of vulva (XA0565)
<b>XA4851</b>	Clitoris
<b>XA3C45</b>	Clitoral hood
<b>XA1A52</b>	Vulval vestibule
	<b>Coded Elsewhere:</b> External urethral meatus (XA4NU9)
<b>XA27K9</b>	Bartholin gland
<b>XA0565</b>	Posterior fourchette of vulva
<b>XA1LK7</b>	<b>Vagina</b>
<b>XA4AH3</b>	Vaginal introitus
<b>XA3A69</b>	Hymen
<b>XA9BM1</b>	Gartner duct
<b>XA46V2</b>	Vaginal vault
<b>XA99N3</b>	<b>Uterus</b>
<b>XA3V49</b>	Fundus of uterus
<b>XA5229</b>	Corpus uteri
	<b>Coded Elsewhere:</b> Amnion (XA8XR0)
	Isthmus uteri (XA7F09)
	Fundus of uterus (XA3V49)
<b>XA8QA8</b>	Endometrium
<b>XA9DM0</b>	Endometrial gland
<b>XA3FR4</b>	Endometrial stroma
<b>XA2LU5</b>	Myometrium

<b>XA9HG1</b>	Parametrium  <b>Coded Elsewhere:</b> Uterine ligament (XA4T57) Uterosacral ligament (XA2NB2)
<b>XA3QZ2</b>	Uterine cavity
<b>XA7F09</b>	Isthmus uteri
<b>XA5WW1</b>	Cervix uteri
<b>XA3Z33</b>	Internal os
<b>XA7Z73</b>	Cervical canal
<b>XA0KR7</b>	Connective and other soft tissues of uterus
<b>XA1QK0</b>	Ovary
<b>XA6FA5</b>	Cortex of ovary
<b>XA44X6</b>	Medulla of ovary
<b>XA7E69</b>	<b>Uterine adnexa</b>  <b>Coded Elsewhere:</b> Broad ligament of the uterus (XA0EJ9) Round ligament of uterus (XA23X3) Parametrium (XA9HG1) Ovary (XA1QK0)
<b>XA3EF0</b>	Fallopian tube
<b>XA1MQ5</b>	<b>Embryological structures</b>
<b>XA7A99</b>	<b>Developmental tissue</b>
<b>XA7TJ5</b>	Ectoderm
<b>XA3HM5</b>	Endoderm
<b>XA3D33</b>	Mesoderm
<b>XA3NA0</b>	<b>Embryo</b>
<b>XA23B0</b>	<b>Fetus</b>
<b>XA85H6</b>	<b>Fetal membranes</b>
<b>XA7MU1</b>	Amniotic sac
<b>XA8XR0</b>	Amnion
<b>XA66R5</b>	Chorion
<b>XA33K4</b>	Amniotic fluid
<b>XA9YJ5</b>	Allantois
<b>XA0SH3</b>	<b>Thyroglossal duct</b>

<b>XA1NC2</b>	<b>Urachus</b>
<b>XA3L42</b>	<b>Umbilical cord</b>
<b>XA90F8</b>	<b>Placenta</b>
	<b>Coded Elsewhere:</b> Fetal membranes (XA85H6)

Surface topography

<b>XA1RS6</b>	<b>Head and neck</b>
<b>XA20Q1</b>	<b>Head</b>
	<b>Coded Elsewhere:</b> External Ear (XA6ZY6)
	Mouth (XA8182)
<b>XA6CW5</b>	Scalp
<b>XA0WK0</b>	Frontal scalp
<b>XA0WG9</b>	Frontal scalp margin
<b>XA9DZ0</b>	Temporal scalp
<b>XA26C1</b>	Temporal scalp margin
<b>XA4W34</b>	Parietal scalp
<b>XA7JE5</b>	Occipital scalp
<b>XA3EK3</b>	Occipital scalp margin
<b>XA5BY6</b>	Vertex of scalp
<b>XA6AL1</b>	Scalp margin
	<b>Coded Elsewhere:</b> Frontal scalp margin (XA0WG9)
	Occipital scalp margin (XA3EK3)
	Temporal scalp margin (XA26C1)
<b>XA93S9</b>	Parietal scalp margin
<b>XA86S4</b>	Face
<b>XA6TR8</b>	Forehead
<b>XA9SG2</b>	Central forehead
<b>XA1UW4</b>	Paramedian forehead That part of the forehead between the central and lateral forehead extending up from the superior border of the eyebrow to the frontal scalp margin.
<b>XA1Z38</b>	Lateral forehead
<b>XA90D8</b>	Glabella

<b>XA9T94</b>	Temple
<b>XA29E7</b>	Orbital region
	<b>Coded Elsewhere:</b> Eyelid and ocular surface (XA17K1)
	Orbit (XA2WJ9)
<b>XA0SB3</b>	Periorbital region
<b>XA5WP1</b>	Supraorbital region
<b>XA1LZ5</b>	Eyebrow
<b>XA6TV2</b>	Infraorbital region
<b>XA7MK8</b>	Cheek
<b>XA5KE9</b>	Upper cheek
<b>XA0M67</b>	Malar region
<b>XA57N0</b>	Malar eminence
<b>XA6C41</b>	Central cheek
<b>XA3ZL3</b>	Paranasal region
<b>XA7207</b>	Lower cheek
<b>XA0SU2</b>	Preauricular region
<b>XA8KA2</b>	Mandibular region
<b>XA3H13</b>	Nose
	<b>Coded Elsewhere:</b> Skin of nose (XA04T9)
<b>XA0LR7</b>	Root of nose
<b>XA5YP3</b>	Dorsum of nose
<b>XA3057</b>	Supratip of nose
<b>XA9JN5</b>	Lateral side wall of nose
<b>XA56T3</b>	Tip of nose
<b>XA3ZG3</b>	Infratip lobule of nose
<b>XA32Q9</b>	Ala nasi
<b>XA5ED7</b>	Alar groove
<b>XA7LG9</b>	Alar rim
<b>XA2TK5</b>	Side wall of ala nasi
<b>XA1B05</b>	Nostril
<b>XA4S17</b>	Columella

<b>XA9YZ7</b>	Sill of nostril
<b>XA5A87</b>	Oral region
<b>XA1A48</b>	Perioral region
<b>XA8JD4</b>	Lip
<b>XA7VQ4</b>	Upper lip
	<b>Coded Elsewhere:</b> Labial mucosa of upper lip (XA9072)
<b>XA0K68</b>	External upper lip
<b>XA5LY8</b>	Philtrum
<b>XA5163</b>	Nasolabial fold
<b>XA8RK1</b>	Vermilion border of upper lip
<b>XA75S0</b>	Vermilion of upper lip
<b>XA1EF8</b>	Labial commissure
<b>XA15W6</b>	Lower lip
	<b>Coded Elsewhere:</b> Labial mucosa of lower lip (XA72W2)
<b>XA5VD0</b>	External lower lip
<b>XA9TK2</b>	Vermilion border of lower lip
<b>XA7H02</b>	Vermilion of lower lip
<b>XA1BP2</b>	Inner aspect of lip
<b>XA3141</b>	Frenulum of lip
<b>XA3K27</b>	External lip
<b>XA2C62</b>	Chin
<b>XA04T9</b>	Skin of nose
<b>XA7AA6</b>	<b>Neck</b>
<b>XA4QS6</b>	Front of neck
<b>XA1NS6</b>	Anterior triangle of neck
<b>XA5TZ1</b>	Submental region
<b>XA0MP5</b>	Submandibular region
<b>XA8RA2</b>	Suprasternal notch
<b>XA9DQ5</b>	Supraclavicular region
<b>XA2ZF0</b>	Side of neck
<b>XA45K8</b>	Posterior triangle of neck

<b>XA1M78</b>	Nape of neck
<b>XA3FR3</b>	<b>Trunk</b>
<b>XA4QH7</b>	<b>Upper trunk</b>
	<b>Coded Elsewhere:</b> Axilla (XA17J1)
<b>XA5D93</b>	Thorax
<b>XA55T2</b>	Chest wall
<b>XA00R3</b>	Anterior thoracic region
<b>XA8ML7</b>	Upper anterior thoracic region
<b>XA4MN6</b>	Clavicular region
<b>XA6M63</b>	Infraclavicular region
<b>XA5MS8</b>	Presternal region
<b>XA7GU3</b>	Lower anterior thoracic region
<b>XA7884</b>	Lateral thoracic region
<b>XA9RL9</b>	Upper lateral thoracic region
<b>XA0XL3</b>	Anterolateral upper thoracic region
<b>XA5C28</b>	Posterolateral upper thoracic region
<b>XA9MN4</b>	Lower lateral thoracic region
<b>XA3266</b>	Anterolateral lower thoracic region
<b>XA7MS4</b>	Posterolateral lower thoracic region
<b>XA10L7</b>	Upper back
<b>XA3PG8</b>	Suprascapular region
<b>XA3WD7</b>	Scapular region
<b>XA9LN5</b>	Interscapular region
<b>XA8NK1</b>	Infrascapular region
<b>XA6RF2</b>	Lower thoracic paraspinal region
<b>XA8EK1</b>	Skin of thorax
<b>XA12C1</b>	Breast
<b>XA1NS5</b>	Upper half of breast
<b>XA3LS6</b>	Upper inner quadrant of breast
<b>XA2Q54</b>	Upper outer quadrant of breast

<b>XA3PG5</b>	Axillary tail of breast
<b>XA0US1</b>	Central portion of breast
<b>XA2JK3</b>	Areola
<b>XA85A1</b>	Lactiferous ducts
<b>XA5MC5</b>	Nipple
<b>XA3UY3</b>	Lower half of breast
<b>XA0VX8</b>	Lower inner quadrant of breast
<b>XA94U2</b>	Lower outer quadrant of breast
<b>XA9CM2</b>	Lateral half of breast
	<b>Coded Elsewhere:</b> Upper outer quadrant of breast (XA2Q54)
	Lower outer quadrant of breast (XA94U2)
<b>XA3JH6</b>	Medial half of breast
	<b>Coded Elsewhere:</b> Upper inner quadrant of breast (XA3LS6)
	Lower inner quadrant of breast (XA0VX8)
<b>XA0T50</b>	Inframammary flexure
<b>XA6CY1</b>	<b>Lower trunk</b>
<b>XA6GV0</b>	Abdomen
	<b>Coded Elsewhere:</b> Umbilical cord (XA3L42)
<b>XA0U66</b>	Upper abdomen
<b>XA8ZL8</b>	Epigastrium
<b>XA3TD4</b>	Hypochondrium
<b>XA1LM1</b>	Perumbilical region
<b>XA3MT8</b>	Umbilicus
<b>XA1DN2</b>	Lateral lumbar region
<b>XA4TC0</b>	Lower abdomen
<b>XA6N20</b>	Hypogastrium
<b>XA0NH8</b>	Iliac region

<b>XA3KX0</b>	Abdominal wall  <b>Coded Elsewhere:</b> Iliac region (XA0NH8) Lateral lumbar region (XA1DN2) Perumbilical region (XA1LM1) Suprapubic area (XA0LF4) Epigastrium (XA8ZL8) Hypochondrium (XA3TD4)
<b>XA4SN6</b>	Anterior abdominal wall
<b>XA25R8</b>	Lumbosacral region
<b>XA6ZR2</b>	Mid back
<b>XA7ZW8</b>	Lumbar paraspinal region
<b>XA8FK6</b>	Posterior lumbar region
<b>XA9ET2</b>	Lower back
<b>XA6DS1</b>	Coccygeal area
<b>XA2UC8</b>	Sacral region
<b>XA4L23</b>	Sacrococcygeal region
<b>XA2P90</b>	<b>Back</b>  <b>Coded Elsewhere:</b> Upper back (XA10L7) Mid back (XA6ZR2) Lower back (XA9ET2)
<b>XA8HA7</b>	<b>Anogenital region</b>
<b>XA5FG3</b>	Genital region
<b>XA9PG6</b>	Female external genitalia  <b>Coded Elsewhere:</b> Vulva (XA78U5)
<b>XA1AK8</b>	Male external genitalia  <b>Coded Elsewhere:</b> Penis (XA7QV2)
<b>XA8MT4</b>	Scrotum
<b>XA9PX3</b>	Perigenital region
<b>XA0LF4</b>	Suprapubic area
<b>XA10Z0</b>	Mons pubis
<b>XA2XG2</b>	Inguinocrural fold
<b>XA00B4</b>	Inguinal canal

<b>XA4B34</b>	Perianal region <i>Coded Elsewhere:</i> Anus (XA0D34)
<b>XA53N9</b>	Perineum
<b>XA2F27</b>	Intergluteal cleft
<b>XA6AS2</b>	<b>Extremities</b>
<b>XA4BA8</b>	<b>Upper extremity</b>
<b>XA2ND5</b>	Shoulder
<b>XA3PZ3</b>	Anterior surface of shoulder
<b>XA5BU5</b>	Apex of shoulder
<b>XA34G7</b>	Posterior surface of shoulder
<b>XA17J1</b>	Axilla
<b>XA41A1</b>	Anterior axillary fold
<b>XA86E8</b>	Apex of axilla
<b>XA2RY5</b>	Posterior axillary fold
<b>XA6809</b>	Upper arm
<b>XA22Q1</b>	Anterior surface of upper arm
<b>XA2W33</b>	Lateral surface of upper arm
<b>XA5TK8</b>	Posterior surface of upper arm
<b>XA3J41</b>	Medial surface of upper arm
<b>XA9FF8</b>	Elbow
<b>XA9NE6</b>	Antecubital fossa
<b>XA6599</b>	Lateral condylar surface of elbow
<b>XA3RT8</b>	Elbow tip
<b>XA4983</b>	Medial condylar surface of elbow
<b>XA7WB0</b>	Forearm
<b>XA8ZL6</b>	Volar surface of forearm
<b>XA1VA2</b>	Lateral surface of forearm
<b>XA8WH0</b>	Dorsal surface of forearm
<b>XA2Q46</b>	Medial surface of forearm
<b>XA2J63</b>	Wrist

<b>XA6AR5</b>	Volar surface of wrist
<b>XA3LK1</b>	Radial border of wrist
<b>XA0SH5</b>	Dorsal surface of wrist
<b>XA0J47</b>	Ulnar border of wrist
<b>XA5R12</b>	Hand
<b>XA30Z6</b>	Dorsum of hand
<b>XA3T43</b>	Knuckles
	<b>Coded Elsewhere:</b> First metacarpophalangeal joint (XA3M83)
	Second metacarpophalangeal joint (XA9YH1)
	Third metacarpophalangeal joint (XA6HB0)
	Fourth metacarpophalangeal joint (XA7XA8)
	Fifth metacarpophalangeal joint (XA7KA0)
<b>XA65Z3</b>	Interdigital web space of hand
<b>XA1BR6</b>	First interdigital web space of hand
<b>XA5PY9</b>	Second interdigital web space of hand
<b>XA4012</b>	Third interdigital web space of hand
<b>XA3WG2</b>	Fourth interdigital web space of hand
<b>XA3NY8</b>	Palm of hand
<b>XA3FJ0</b>	Proximal palm
<b>XA2JN4</b>	Thenar eminence
<b>XA5TQ4</b>	Hypothenar eminence
<b>XA50E4</b>	Central palm
<b>XA00D7</b>	Distal palm
<b>XA2593</b>	Fingers and thumb
	<b>Coded Elsewhere:</b> Knuckles (XA3T43)
<b>XA8DJ6</b>	Thumb
	<b>Coded Elsewhere:</b> Proximal phalanx of thumb (XA0903)
	Interphalangeal joint of the thumb (XA6L43)
	Distal phalanx of thumb (XA70H5)
<b>XA0RL8</b>	Perionychium of thumb
<b>XA13E9</b>	Proximal nailfold of thumb
<b>XA20L7</b>	Eponychium of thumb

<b>XA4GD7</b>	Lateral nailfold of thumb
<b>XA63L0</b>	Hyponychium of thumb
<b>XA5PD5</b>	Thumbnail
<b>XA6DM1</b>	Lunula of thumb
<b>XA9N39</b>	Nail bed of thumb
<b>XA5V24</b>	Nail plate of thumb
<b>XA5ZV0</b>	Pad of thumb
<b>XA76N2</b>	Dorsum of thumb
<b>XA6NZ0</b>	Index finger
<b>Coded Elsewhere:</b> Proximal phalanx of index finger (XA25U2)	
	Proximal interphalangeal joint of index finger (XA1DN6)
	Middle phalanx of index finger (XA3JL6)
	Distal interphalangeal joint of index finger (XA6KB0)
	Distal phalanx of index finger (XA54X0)
<b>XA6YH1</b>	Perionychium of index finger
<b>XA90K8</b>	Eponychium of index finger
<b>XA2UG0</b>	Hyponychium of index finger
<b>XA40D9</b>	Index fingernail
<b>XA1GS3</b>	Lunula of index finger
<b>XA1SB3</b>	Nail bed of index finger
<b>XA2XE0</b>	Nail plate of index finger
<b>XA6TA9</b>	Pad of index finger
<b>XA0Y38</b>	Middle finger
<b>Coded Elsewhere:</b> Proximal phalanx of middle finger (XA6ET0)	
	Proximal interphalangeal joint of middle finger (XA3NW6)
	Middle phalanx of middle finger (XA5910)
	Distal interphalangeal joint of middle finger (XA15C8)
	Distal phalanx of middle finger (XA8NR0)
<b>XA1FY2</b>	Perionychium of middle finger
<b>XA8YE5</b>	Proximal nail fold of middle finger
<b>XA13L6</b>	Eponychium of middle finger
<b>XA2N38</b>	Lateral nail fold of middle finger
<b>XA8KX8</b>	Hyponychium of middle finger

<b>XA9YZ9</b>	Middle fingernail
<b>XA8VS0</b>	Lunula of middle finger
<b>XA2A53</b>	Nail bed of middle finger
<b>XA10T8</b>	Nail plate of middle finger
<b>XA79X0</b>	Pad of middle finger
<b>XA06X8</b>	Ring finger
<b>Coded Elsewhere:</b> Proximal phalanx of ring finger (XA9MR0)	
	Proximal interphalangeal joint of ring finger (XA0BF5)
	Middle phalanx of ring finger (XA8N14)
	Distal interphalangeal joint of ring finger (XA0LT5)
	Distal phalanx of ring finger (XA51S6)
<b>XA7K11</b>	Perionychium of ring finger
<b>XA1F61</b>	Proximal nail fold of ring finger
<b>XA8L06</b>	Eponychium of ring finger
<b>XA3HG9</b>	Lateral nail fold of ring finger
<b>XA1W89</b>	Hyponychium of ring finger
<b>XA6Y59</b>	Ring fingernail
<b>XA4P58</b>	Lunula of ring finger
<b>XA3MW5</b>	Nail bed of ring finger
<b>XA3PS0</b>	Nail plate of ring finger
<b>XA6C72</b>	Pad of ring finger
<b>XA5EN3</b>	Little finger
<b>Coded Elsewhere:</b> Proximal phalanx of little finger (XA73Q6)	
	Proximal interphalangeal joint of little finger (XA4175)
	Middle phalanx of little finger (XA6HX0)
	Distal interphalangeal joint of little finger (XA1928)
	Distal phalanx of little finger (XA32G6)
<b>XA89P0</b>	Perionychium of little finger
<b>XA4KU5</b>	Proximal nail fold of little finger
<b>XA2AV8</b>	Eponychium of little finger
<b>XA3LC5</b>	Lateral nail fold of little finger
<b>XA1C10</b>	Hyponychium of little finger
<b>XA4WN3</b>	Pad of little finger

<b>XA29K9</b>	Little fingernail
<b>XA3R66</b>	Lunula of little finger
<b>XA6HB9</b>	Nail bed of little finger
<b>XA4A79</b>	Nail plate of little finger
<b>XA4HZ3</b>	Side of finger
<b>XA7GT9</b>	Tips of fingers
<b>XA41X5</b>	Tip of index finger
<b>XA9Y99</b>	Tip of middle finger
<b>XA91S7</b>	Tip of ring finger
<b>XA8QW7</b>	Tip of little finger
<b>XA0EH9</b>	Fingernails  <i>Coded Elsewhere:</i> Index fingernail (XA40D9) Middle fingernail (XA9YZ9) Ring fingernail (XA6Y59) Little fingernail (XA29K9) Thumbnail (XA5PD5)
<b>XA66R9</b>	Skin of elbow
<b>XA45A6</b>	<b>Lower extremity</b>
<b>XA3VA7</b>	Buttock  <i>Coded Elsewhere:</i> Intergluteal cleft (XA2F27)
<b>XA5UE3</b>	Gluteal fold
<b>XA5S78</b>	Thigh
<b>XA98B3</b>	Anterior surface of thigh
<b>XA8RH9</b>	Lateral surface of thigh
<b>XA4TQ2</b>	Trochanteric region
<b>XA0183</b>	Posterior surface of thigh
<b>XA1YQ6</b>	Medial surface of thigh
<b>XA9ZB4</b>	Upper medial surface of thigh
<b>XA8KL5</b>	Knee
<b>XA9L17</b>	Patellar region
<b>XA77E9</b>	Lateral surface of knee
<b>XA9S09</b>	Medial surface of knee

<b>XA4DM3</b>	Popliteal fossa
<b>XA3YG1</b>	Lower leg
<b>XA33X4</b>	Anterior surface of lower leg
<b>XA4K86</b>	Calf
<b>XA4RR4</b>	Lateral surface of lower leg
<b>XA0LQ2</b>	Posterior surface of lower leg
<b>XA15P0</b>	Medial surface of lower leg
<b>XA5U49</b>	Distal lower leg
<b>XA90X0</b>	Proximal lower leg
<b>XA67V4</b>	Ankle
<b>XA2V14</b>	Anterior surface of ankle
<b>XA7AM4</b>	Lateral surface of ankle
	<b><i>Coded Elsewhere:</i></b> Lateral malleolus (XA4UL1)
<b>XA1D83</b>	Lateral supramalleolar region
<b>XA41K4</b>	Lateral retromalleolar region
<b>XA7P78</b>	Medial surface of ankle
	<b><i>Coded Elsewhere:</i></b> Medial malleolus (XA1HS9)
<b>XA87M9</b>	Medial supramalleolar region
<b>XA1SM7</b>	Medial retromalleolar region
<b>XA6AP4</b>	Posterior surface of ankle
<b>XA47V8</b>	Foot
<b>XA99M7</b>	Hindfoot
<b>XA5HK0</b>	Heel
<b>XA5ZE2</b>	Posterior surface of heel
<b>XA1QH8</b>	Medial surface of heel
<b>XA3R99</b>	Lateral surface of heel
<b>XA2N02</b>	Plantar surface of heel
<b>XA5151</b>	Midfoot
<b>XA02P2</b>	Dorsal surface of midfoot
<b>XA5YL1</b>	Forefoot
	<b><i>Coded Elsewhere:</i></b> Metatarsophalangeal joint (XA8XU1)

<b>XA81Z3</b>	Dorsal surface of forefoot
<b>XA1FL5</b>	Interdigital web space of foot
<b>XA81N1</b>	First interdigital web space of foot
<b>XA8HC5</b>	Second interdigital web space of foot
<b>XA9LB9</b>	Third interdigital web space of foot
<b>XA2A07</b>	Fourth interdigital web space of foot
<b>XA6KE9</b>	Plantar surface of forefoot
<b>XA6V29</b>	First metatarsal head region
<b>XA2P22</b>	Second metatarsal head region
<b>XA0HX4</b>	Third metatarsal head region
<b>XA86J0</b>	Fourth metatarsal head region
<b>XA05N7</b>	Fifth metatarsal head region
<b>XA8BE2</b>	Dorsum of foot  <i>Coded Elsewhere:</i> Dorsal surface of forefoot (XA81Z3) Dorsal surface of midfoot (XA02P2)
<b>XA1XM4</b>	Sole of foot  <i>Coded Elsewhere:</i> Plantar surface of heel (XA2N02)
<b>XA9Y82</b>	Lateral border of foot
<b>XA3WM8</b>	Medial border of foot
<b>XA3T29</b>	Arch of foot
<b>XA4LC9</b>	Toes
<b>XA2RP7</b>	Great toe  <i>Coded Elsewhere:</i> Proximal phalanx of great toe (XA8KC3) Interphalangeal joint of great toe (XA87P9) Distal phalanx of great toe (XA2AC2)
<b>XA4774</b>	Perionychium of great toe
<b>XA8L19</b>	Proximal nail fold of great toe
<b>XA7WP9</b>	Eponychium of great toe
<b>XA7GD8</b>	Lateral nail fold of great toe
<b>XA2F64</b>	Hyponychium of great toe
<b>XA1RE3</b>	Great toenail

<b>XA64R9</b>	Lunula of great toe
<b>XA0HX8</b>	Nail bed of great toe
<b>XA47T1</b>	Nail plate of great toe
<b>XA6VJ2</b>	Pad of great toe
<b>XA8ZZ3</b>	Second toe
	<b>Coded Elsewhere:</b> Proximal phalanx of second toe (XA0AQ0)
	Proximal interphalangeal joint of second toe (XA56K9)
	Middle phalanx of second toe (XA1UN2)
	Distal interphalangeal joint of second toe (XA8UM5)
	Distal phalanx of second toe (XA3QM7)
<b>XA5446</b>	Perionychium of second toe
<b>XA1ED1</b>	Proximal nail fold of second toe
<b>XA0SL7</b>	Eponychium of second toe
<b>XA7003</b>	Lateral nail fold of second toe
<b>XA2ZJ7</b>	Hyponychium of second toe
<b>XA7GG3</b>	Second toenail
<b>XA9439</b>	Lunula of second toe
<b>XA7B22</b>	Nail bed of second toe
<b>XA1WQ6</b>	Nail plate of second toe
<b>XA3626</b>	Pad of second toe
<b>XA0SP3</b>	Third toe
	<b>Coded Elsewhere:</b> Proximal phalanx of third toe (XA11P1)
	Proximal interphalangeal joint of third toe (XA2QY2)
	Middle phalanx of third toe (XA9YP5)
	Distal interphalangeal joint of third toe (XA43F0)
	Distal phalanx of third toe (XA38Q1)
<b>XA3UC8</b>	Perionychium of third toe
<b>XA2484</b>	Proximal nail fold of third toe
<b>XA8DQ2</b>	Eponychium of third toe
<b>XA1MM3</b>	Lateral nail fold of third toe
<b>XA2H72</b>	Hyponychium of third toe
<b>XA5JP9</b>	Pad of third toe
<b>XA3D73</b>	Third toenail

<b>XA9UL1</b>	Lunula of third toe
<b>XA6189</b>	Nail bed of third toe
<b>XA3LW9</b>	Nail plate of third toe
<b>XA4KK7</b>	Fourth toe
	<b>Coded Elsewhere:</b> Proximal phalanx of fourth toe (XA8CX6)
	Proximal interphalangeal joint of fourth toe (XA2R87)
	Middle phalanx of fourth toe (XA2SX4)
	Distal interphalangeal joint of fourth toe (XA8NU9)
	Distal phalanx of fourth toe (XA8XV0)
<b>XA40R3</b>	Perionychium of fourth toe
<b>XA2Y79</b>	Proximal nail fold of fourth toe
<b>XA0XZ8</b>	Eponychium of fourth toe
<b>XA0PV4</b>	Lateral nail fold of fourth toe
<b>XA4ZB3</b>	Hyponychium of fourth toe
<b>XA9316</b>	Pad of fourth toe
<b>XA6TS5</b>	Fourth toenail
<b>XA2PD3</b>	Lunula of fourth toe
<b>XA65U3</b>	Nail bed of fourth toe
<b>XA8F87</b>	Nail plate of fourth toe
<b>XA42W4</b>	Fifth toe
	<b>Coded Elsewhere:</b> Proximal phalanx of fifth toe (XA8PK1)
	Proximal interphalangeal joint of fifth toe (XA1LM0)
	Middle phalanx of fifth toe (XA90F0)
	Distal interphalangeal joint of fifth toe (XA39U1)
	Distal phalanx of fifth toe (XA6ED4)
<b>XA1AV3</b>	Perionychium of fifth toe
<b>XA43K6</b>	Proximal nail fold of fifth toe
<b>XA2W24</b>	Eponychium of fifth toe
<b>XA38J0</b>	Lateral nail fold of fifth toe
<b>XA0DD8</b>	Hyponychium of fifth toe
<b>XA3C43</b>	Pad of fifth toe
<b>XA3VM6</b>	Fifth toenail
<b>XA1PK7</b>	Lunula of fifth toe

<b>XA9L52</b>	Nail bed of fifth toe
<b>XA4U10</b>	Nail plate of fifth toe
<b>XA9LJ5</b>	Plantar surface of toe
<b>XA7J49</b>	Dorsal surface of toe
<b>XA14Y9</b>	Side of toe
<b>XA9E36</b>	Toenail
	<b>Coded Elsewhere:</b> Great toenail (XA1RE3)
	Second toenail (XA7GG3)
	Third toenail (XA3D73)
	Fourth toenail (XA6TS5)
	Fifth toenail (XA3VM6)

Partonomic view

**Coded Elsewhere:** Body Organ

Surface topography (XA1RS6-XA9E36)

## Walls in the Body

**Coded Elsewhere:** Abdominal wall (XA3KX0)  
 Bladder wall (XA0R03)  
 Cardiac septum (XA81Z5)  
 Chest wall (XA55T2)  
 Nasal septum (XA8D47)  
 Orbital roof (XA9XW3)  
 Orbital floor (XA7MW9)

**XA4UM2** **Alveolar wall**

**XA5UL3** **Cell wall**

**XA3JR1** **Intestinal Wall**

**XA37C7** **Oral floor**

**XA9KX3** **Parietal wall**

**XA5CW9** **Pelvic floor**

**XA29C1** **Pelvic wall**

**XA60B5** **Rectovaginal septum**

**XA37K5** **Rectovesical septum**

**XA1DP8** **Uterine wall**

**XA57Q2**      **Vaginal wall**

## Body Tissues

	<b>Coded Elsewhere:</b> Bone marrow (XA9XK1)
	Cartilage (XA8YS7-XA6958)
	Developmental tissue (XA7A99)
<b>XA06R8</b>	<b>Body fluid</b>
	<b>Coded Elsewhere:</b> Amniotic fluid (XA33K4)
<b>XA1N55</b>	<b>Cerebrospinal fluid</b>
<b>XA08M4</b>	<b>Interstitial fluid</b>
<b>XA2L90</b>	<b>Serous fluid</b>
<b>XA0518</b>	<b>Synovial fluid</b>
<b>XA0UK0</b>	<b>Bone tissue</b>
<b>XA7YJ2</b>	<b>Collagen fibres</b>
<b>XA5A05</b>	<b>Connective tissue</b>
	<b>Coded Elsewhere:</b> Blood (XA8EC5)
<b>XA6R65</b>	<b>Adipose tissue</b>
<b>XA0FR0</b>	<b>Fascia</b>
<b>XA51U1</b>	<b>Loose connective tissue</b>
<b>XA53R0</b>	<b>Perichondrium</b>
<b>XA7YP0</b>	<b>Periodontium</b>
<b>XA6FQ2</b>	<b>Periosteum</b>
<b>XA3G85</b>	<b>Synovium</b>
<b>XA8SZ4</b>	<b>Lymphatic tissue</b>
<b>XA97C4</b>	<b>Soft tissue, not elsewhere classified</b>
<b>XA5P05</b>	Soft tissue of limb, not elsewhere classified
<b>XA56S9</b>	<b>Epithelium</b>
	<b>Coded Elsewhere:</b> Epidermis (XA3JN1)
<b>XA0PT3</b>	<b>Mucosa</b>
<b>XA0182</b>	<b>Mesothelium</b>
<b>XA1922</b>	<b>Gamete</b>

<b>XA95A3</b>	<b>Female gamete</b>
<b>XA2470</b>	<b>Male gamete</b>
<b>XA39T1</b>	<b>Muscle tissue</b>
<b>XA6283</b>	<b>Cardiac muscle</b>
<b>XA0DD5</b>	<b>Skeletal muscle</b>
<b>XA0JY3</b>	<b>Smooth muscle</b>
<b>XA5B23</b>	<b>Nervous Tissue</b>
<b>XA1J91</b>	<b>Neuroglia</b>
<b>XA1413</b>	<b>Neuron</b>
<b>XA5BW5</b>	Interneuron
<b>XA5DJ5</b>	Motor Neuron
<b>XA2LT7</b>	Sensory Neuron

## Body Cavities

**Coded Elsewhere:** Chamber of the heart (XA10E0)

- Medullary cavity (XA5QM0)
- Nasal cavity (XA43C9)
- Oral cavity (XA1WN1)
- Accessory sinuses (XA3523)
- Parapharyngeal recess (XA6QY3)
- Pharyngeal recess (XA7W35)
- Retropharyngeal recess (XA9P89)
- Tympanic cavity (XA3KB2)
- Uterine cavity (XA3QZ2)

**XA1ZV6** **Cranial cavity**

**Coded Elsewhere:** Cerebral ventricle (XA26E8)

**XA1XM6** **Subarachnoid space**

**XA1FQ8** **Subdural space**

**XA9QA7** **Dorsal body cavity**

**XA1GB6** **Perineural space**

**XA2N82** **Ventral body cavity**

**XA34B0** **Abdominopelvic cavity**

**Coded Elsewhere:** Peritoneum (XA0KZ0)

<b>XA9M74</b>	Abdominal cavity
<b>XA25Q2</b>	Pelvic cavity  <b>Coded Elsewhere:</b> Pelvic wall (XA29C1) Rectovaginal septum (XA60B5)
<b>XA9CK0</b>	Ischiorectal fossa
<b>XA53A7</b>	Presacral region
<b>XA2EG4</b>	Perirectal region
<b>XA0GN7</b>	Inguinal region
<b>XA7WA2</b>	<b>Mediastinum</b>
<b>XA5UF8</b>	Anterior mediastinum
<b>XA99Z0</b>	Middle mediastinum
<b>XA1FD0</b>	Posterior mediastinum
<b>XA8607</b>	Connective and other soft tissues of mediastinum  <b>Coded Elsewhere:</b> Mediastinal vein (XA6JE5)
<b>XA8YW7</b>	<b>Vertebral cavity</b>
<b>XA8SS8</b>	Epidural space
<b>XA4LQ4</b>	Intramedullary space
<b>XA1XJ5</b>	<b>Thoracic cavity</b>  <b>Coded Elsewhere:</b> Pericardial cavity (XA48H9)
<b>XA3LX5</b>	Pleural cavity
<b>XA2RT1</b>	Precordium

## Histopathology

**Coded Elsewhere:** Neoplasms, NOS  
Histopathology by behaviour

Acinar cell neoplasms

Acinar cell neoplasms, benign

<b>XH96Q1</b>	<b>Acinar cell adenoma</b>
<b>Inclusions:</b>	Acinar adenoma Acinic cell adenoma

Acinar cell neoplasms, malignant

- XH3PG9      Acinar cell carcinoma**
- XH99S4      Acinar cell cystadenocarcinoma**
- XH9B93      Mixed acinar-ductal carcinoma**
- XH0F68      Acinar adenocarcinoma of the lung**

Acinar cell neoplasms, uncertain whether benign or malignant

- XH2SK9      Acinar cell tumour**

Adenomas and adenocarcinomas

Adenomas, benign

- XH9574      Acidophil adenoma**
- XH3DV3      Adenoma, NOS**
- XH1CV4      Adenomatous polyposis coli**
  - Inclusions:*      Familial polyposis coli
  - Adenomatosis, NOS
- XH1YP0      Adrenal cortical adenoma, clear cell**
- XH2CT2      Adrenal cortical adenoma, compact cell**
- XH60N5      Adrenal cortical adenoma, glomerulosa cell**
- XH2VZ8      Adrenal cortical adenoma, mixed cell**
- XH2FJ6      Adrenal cortical adenoma, pigmented**
  - Inclusions:*      Black adenoma
  - Pigmented adenoma
- XH9356      Alveolar adenoma**
- XH60D1      Basal cell adenoma**
- XH3AH8      Basophil adenoma**
  - Inclusions:*      Mucoid cell adenoma
- XH6KR6      Bile duct adenoma**
  - Inclusions:*      Cholangioma
- XH0778      Bile duct cystadenoma**

<b>XH7BS0</b>	<b>Biliary intraepithelial neoplasia, low grade</b>
<b>XH5YG5</b>	<b>Biliary papillomatosis</b>
<b>XH1TD7</b>	<b>Canalicular adenoma</b>
<b>XH6WK1</b>	<b>Chief cell adenoma</b>
<b>XH7475</b>	<b>Chromophobe adenoma</b>
<b>XH9JJ4</b>	<b>Clear cell adenofibroma</b> <i>Inclusions:</i> Clear cell cystadenofibroma
<b>XH8R87</b>	<b>Clear cell adenoma</b>
<b>XH6J91</b>	<b>Cylindroma of skin</b>
<b>XH5GN1</b>	<b>Eccrine dermal cylindroma</b>
<b>XH6685</b>	<b>Embryonal adenoma</b>
<b>XH3K13</b>	<b>Oesophageal glandular dysplasia (intraepithelial neoplasia), low grade</b>
<b>XH83X4</b>	<b>Flat adenoma</b>
<b>XH0LM0</b>	<b>Follicular adenoma</b> <i>Inclusions:</i> Follicular adenoma, NOS
<b>XH5SM2</b>	<b>Follicular adenoma, oxyphilic cell</b>
<b>XH6AF9</b>	<b>Glandular intraepithelial neoplasia, low grade</b> <i>Inclusions:</i> Glandular intraepithelial neoplasia, grade I Glandular intraepithelial neoplasia, grade II
<b>XH3BK2</b>	<b>Glandular papilloma</b>
<b>XH6PG8</b>	<b>Hurthle cell adenoma</b>
<b>XH5X53</b>	<b>Hurthle cell tumour</b>
<b>XH6M13</b>	<b>Juxtaglomerular tumour</b> <i>Inclusions:</i> Reninoma
<b>XH0W31</b>	<b>Lactating adenoma</b>
<b>XH8P28</b>	<b>Lipoadenoma</b> <i>Inclusions:</i> Adenolipoma
<b>XH68V1</b>	<b>Liver cell adenoma</b> <i>Inclusions:</i> Hepatoma, benign Hepatocellular adenoma

<b>XH19E3</b>	<b>Macrofollicular adenoma</b>
	<i>Inclusions:</i> Colloid adenoma
<b>XH0JC7</b>	<b>Metanephric adenoma</b>
<b>XH3DH3</b>	<b>Microcystic adenoma</b>
<b>XH5LD9</b>	<b>Mixed acidophil-basophil adenoma</b>
<b>XH0WV8</b>	<b>Mixed adenomatous and hyperplastic polyp</b>
<b>XH1XU4</b>	<b>Mixed cell adenoma</b>
<b>XH2CQ8</b>	<b>Monomorphic adenoma</b>
<b>XH6CZ4</b>	<b>Multiple adenomatous polyps</b>
<b>XH9Z86</b>	<b>Oxyphilic adenoma</b>
	<i>Inclusions:</i> Oncocytic adenoma Oncocytoma
<b>XH0BF2</b>	<b>Pancreatobiliary neoplasm, non-invasive</b>
	<i>Inclusions:</i> Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia
<b>XH6GG6</b>	<b>Pancreatic microadenoma</b>
<b>XH1BH4</b>	<b>Papillomatosis, glandular</b>
<b>XH6EJ4</b>	<b>Papillotubular adenoma</b>
	<i>Inclusions:</i> Tubulo-papillary adenoma
<b>XH1QS0</b>	<b>Lactotroph adenoma</b>
<b>XH5903</b>	<b>Serrated adenoma</b>
	<i>Inclusions:</i> Traditional serrated adenoma Serrated adenoma, NOS
<b>XH9G87</b>	<b>Trabecular adenoma</b>
<b>XH8T50</b>	<b>Turban tumour</b>
<b>XH0731</b>	<b>Villous papilloma</b>
<b>XH8UC1</b>	<b>Water-clear cell adenoma</b>
<b>XH28X1</b>	<b>Cylindroma of breast</b>
<b>XH8MU5</b>	<b>Adenomatous polyp, NOS</b>
	<i>Inclusions:</i> Polypoid adenoma

<b>XH7SY6</b>	<b>Tubular adenoma, NOS</b>
<b>XH2F06</b>	<b>Sessile serrated adenoma</b>
<b>XH63V9</b>	<b>Sessile serrated polyp</b>
<b>XH9PD9</b>	<b>Traditional sessile serrated adenoma</b>
<b>XH5QL3</b>	<b>Atypical adenomatous hyperplasia</b>
<b>XH09B0</b>	<b>Papillary adenoma, NOS</b>
<b>XH90D6</b>	<b>Villous adenoma, NOS</b>
<b>XH10B0</b>	<b>Tubulovillous adenoma, NOS</b> <i>Inclusions:</i> Villoglandular adenoma
<b>XH94U0</b>	<b>Pituitary adenoma, NOS</b>
<b>XH26P7</b>	<b>Spindle cell oncocytoma</b>
<b>XH52F6</b>	<b>Adrenal cortical adenoma, NOS</b>
<b>XH6ZD0</b>	<b>Endometrioid adenoma, NOS</b> <i>Inclusions:</i> Endometrioid cystadenoma, NOS
<b>XH1CX5</b>	<b>Endometrioid adenofibroma, NOS</b> <i>Inclusions:</i> Endometrioid cystadenofibroma, NOS
<b>XH2H83</b>	<b>Microfollicular adenoma, NOS</b> <i>Inclusions:</i> Fetal adenoma
<b>XH7DU3</b>	<b>Adenoma, intestinal type</b>
<b>XH1Q16</b>	<b>Pancreatic neuroendocrine microadenoma</b>
<b>XH8NK5</b>	<b>Oncocytic papillary cystadenoma</b>
<b>XH8Y40</b>	<b>Null cell adenoma</b>
<b>XH1JL3</b>	<b>Plurihormonal adenoma</b>
<b>XH50K4</b>	<b>Gonadotroph adenoma</b>
<b>XH4HE3</b>	<b>Somatotroph adenoma</b>
<b>XH0MY4</b>	<b>Thyrotroph adenoma</b>
<b>XH5RH2</b>	<b>Pituitary adenoma, ectopic</b>
<b>XH1C58</b>	<b>Corticotroph adenoma</b>
<b>XH7743</b>	<b>Bronchiolar adenoma / Ciliated muconodular papillary tumour</b>

## Adenocarcinomas in situ

- XH2L30 Adenocarcinoma in situ, NOS**
- XH4J07 Adenocarcinoma in situ in adenomatous polyp**
- XH3770 Adenocarcinoma in situ in tubulovillous adenoma**
- XH8TV2 Adenocarcinoma in situ in villous adenoma**
- XH5U91 Biliary intraepithelial neoplasia, high grade**  
*Inclusions:* Biliary intraepithelial neoplasia, grade 3 (BillN-3)
- XH7Y32 Cribriform carcinoma in situ**  
*Inclusions:* Ductal carcinoma in situ, cribriform type
- XH0557 Ductal carcinoma in situ, solid type**  
*Inclusions:* Intraductal carcinoma, solid type
- XH36M5 Oesophageal glandular dysplasia (intraepithelial neoplasia), high grade**  
*Inclusions:* Oesophageal intraepithelial neoplasia, high grade
- XH5161 Flat intraepithelial glandular neoplasia, high grade**  
*Inclusions:* Flat intraepithelial neoplasia (dysplasia), high grade
- XH28N7 Glandular intraepithelial neoplasia, high grade**  
*Inclusions:* Flat intraepithelial neoplasia, high grade  
Glandular intraepithelial neoplasia, grade III
- XH26M2 Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia**  
*Inclusions:* Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia  
Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia
- XH5C49 Prostatic intraepithelial neoplasia, grade III**  
*Inclusions:* PIN III  
Prostatic intraepithelial neoplasia, high grade
- XH1FR9 Adenocarcinoma in situ of lung, non-mucinous**
- XH6BU6 Adenocarcinoma in situ of lung, mucinous**
- XH4Z68 Endometrioid intraepithelial neoplasia**  
*Inclusions:* Atypical hyperplasia of the endometrium

**Adenocarcinomas, malignant**

<b>XH2QZ6</b>	<b>Acidophil carcinoma</b>
	<i>Inclusions:</i> Eosinophil adenocarcinoma Acidophil adenocarcinoma Eosinophil carcinoma
<b>XH5LA4</b>	<b>Adenocarcinoid tumour</b>
<b>XH74S1</b>	<b>Adenocarcinoma, NOS</b>
<b>XH7QZ0</b>	<b>Adenocarcinoma in adenomatous polyp</b>
	<i>Inclusions:</i> Adenocarcinoma in tubular adenoma Adenocarcinoma in polypoid adenoma Carcinoma in adenomatous polyp Adenocarcinoma in a polyp, NOS Carcinoma in a polyp, NOS
<b>XH2ZH8</b>	<b>Adenocarcinoma in adenomatous polyposis coli</b>
<b>XH9YR3</b>	<b>Adenocarcinoma in multiple adenomatous polyps</b>
<b>XH7QB1</b>	<b>Adenocarcinoma in tubulovillous adenoma</b>
<b>XH6DA5</b>	<b>Adenocarcinoma in villous adenoma</b>
<b>XH5RE1</b>	<b>Adenocarcinoma of anal glands</b>
	<i>Inclusions:</i> Adenocarcinoma of anal ducts
<b>XH2ZQ0</b>	<b>Adenocarcinoma with mixed subtypes</b>
	<i>Inclusions:</i> Adenocarcinoma combined with other types of carcinoma
<b>XH0349</b>	<b>Adenocarcinoma, intestinal type</b>
<b>XH8B45</b>	<b>Solid carcinoma, NOS</b>
<b>XH8DS0</b>	<b>Neuroendocrine tumour, NOS</b>
<b>XH8LX8</b>	<b>Neuroendocrine carcinoma, low grade</b>
<b>XH55D7</b>	<b>Neuroendocrine carcinoma, well-differentiated</b>
<b>XH9LV8</b>	<b>Neuroendocrine tumor, grade 1</b>
<b>XH7NM1</b>	<b>Enterochromaffin cell carcinoid</b>
<b>XH0U20</b>	<b>Neuroendocrine carcinoma, NOS</b>
<b>XH7F73</b>	<b>Neuroendocrine carcinoma, moderately differentiated</b>

XH24W2	<b>Lepidic adenocarcinoma</b>
	<i>Inclusions:</i>
	Bronchiolar carcinoma
	Bronchiolar adenocarcinoma
	Alveolar cell carcinoma
	Bronchiolo-alveolar carcinoma, NOS
	Bronchiolo-alveolar adenocarcinoma, NOS
XH3QM0	<b>Minimally invasive adenocarcinoma, Non-mucinous</b>
XH4302	<b>Adenoid cystic carcinoma</b>
	<i>Inclusions:</i>
	Adenocarcinoma, cylindroid
	Adenocystic carcinoma
	Cylindroma, NOS
XH2098	<b>Minimally invasive adenocarcinoma, Mucinous</b>
XH6LV9	<b>Papillary adenocarcinoma, NOS</b>
XH95U1	<b>Villoglandular carcinoma</b>
XH6QG3	<b>Micropapillary carcinoma, NOS</b>
XH4MW7	<b>Micropapillary adenocarcinoma</b>
XH7KL6	<b>Pituitary carcinoma, NOS</b>
XH6L02	<b>Clear cell adenocarcinoma, NOS</b>
XH5085	<b>Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome-associated renal cell carcinoma</b>
XH1442	<b>MiT Family translocation carcinomas</b>
XH8EN1	<b>Succinate dehydrogenase deficient renal cell carcinoma</b>
XH07X3	<b>Alveolar adenocarcinoma</b>
	<i>Inclusions:</i>
	Alveolar carcinoma
XH05V6	<b>Renal cell carcinoma, NOS</b>
	<i>Inclusions:</i>
	Renal cell adenocarcinoma
XH3Z08	<b>Renal cell carcinoma, unclassified</b>
	<i>Inclusions:</i>
	Hypernephroma
XH0RU3	<b>Acquired cystic disease associated renal cell carcinoma</b>
XH7K79	<b>Tubulocystic renal cell carcinoma</b>
XH1VB1	<b>Hybrid oncocytic chromophobe tumour</b>
XH3Z50	<b>Follicular carcinoma, NOS</b>

XH9508	<b>Endometrioid adenocarcinoma, ciliated cell variant</b>
XH0718	<b>Endometrioid adenocarcinoma, secretory variant</b>
XH4KH2	<b>Adrenal cortical carcinoma</b> <i>Inclusions:</i> Adrenal cortical adenocarcinoma
XH0SD2	<b>Endometrioid adenocarcinoma, NOS</b> <i>Inclusions:</i> Endometrioid carcinoma, NOS
XH51K1	<b>Neuroendocrine tumour, grade 2</b>
XH09B7	<b>Endometrioid cystadenocarcinoma</b>
XH6KR7	<b>Endometrioid adenofibroma, malignant</b> <i>Inclusions:</i> Endometrioid cystadenofibroma, malignant
XH0GS9	<b>Adenocarcinoma, endocervical type</b> <i>Inclusions:</i> Adenocarcinoma, endocervical type, NOS
XH8SF8	<b>Islet cell adenomatosis</b>
XH43E4	<b>Perihilar cholangiocarcinoma</b>
XH4BY1	<b>Islet cell adenoma</b>
XH3CU4	<b>Villoglandular variant of endometrioid adenocarcinoma</b>
XH5QV8	<b>Pituitary blastoma</b>
XH0Y80	<b>Follicular carcinoma, encapsulated, angioinvasive</b>
XH46F1	<b>Clear cell renal cell carcinoma, NOS</b>
XH9SA7	<b>Basal cell adenocarcinoma</b>
XH85C2	<b>Endolymphatic sac tumor</b>
XH4PB1	<b>Acinar adenocarcinoma of prostate</b>
XH8E54	<b>Mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN)</b>
XH5QW8	<b>Neuroendocrine tumour, grade 3</b>
XH1NL5	<b>Nesidioblastoma</b>
XH5XB7	<b>Islet cell carcinoma</b>
XH2ST7	<b>Islet cell tumor, NOS</b>
XH4SH8	<b>Insulinoma, NOS</b>
XH93H8	<b>Gastrinoma</b>
XH7JQ0	<b>Parathyroid carcinoma</b>

XH9LV7	<b>Basophil carcinoma</b>
	<i>Inclusions:</i> Mucoid cell adenocarcinoma Basophil adenocarcinoma
XH7152	<b>Glucagon-like peptide-producing tumour</b>
XH7LW9	<b>L-cell tumour</b>
XH9ZS8	<b>Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumour</b>
XH4NQ8	<b>Glucagonoma</b>
XH2PF0	<b>Enteroglucagonoma</b>
XH72E5	<b>Vipoma</b>
XH5VH0	<b>Somatostatinoma</b>
XH41P2	<b>Endocrine tumour, functioning, NOS</b>
XH7AG8	<b>ACTH-producing tumour</b>
XH60V1	<b>Medullary thyroid carcinoma</b>
XH3BU6	<b>Bile duct cystadenocarcinoma</b>
XH2MW1	<b>Medullary carcinoma with amyloid stroma</b>
	<i>Inclusions:</i> C cell carcinoma Parafollicular cell carcinoma
XH8VU6	<b>Poorly differentiated thyroid carcinoma</b>
XH4NH4	<b>Pituitary neuroendocrine tumour</b>
XH2ZA2	<b>Bronchial adenoma, carcinoid</b>
XH5TR7	<b>Adenocarcinoma of lung, mixed mucinous and non-mucinous</b>
XH7GY6	<b>Adenocarcinoma of lung, mucinous</b>
XH2035	<b>Bronchiolo-alveolar carcinoma, non-mucinous</b>
	<i>Inclusions:</i> Bronchiolo-alveolar carcinoma, Clara cell Bronchiolo-alveolar carcinoma, type II pneumocyte
XH6LF9	<b>Carcinoma simplex</b>
XH0XL5	<b>Carcinoma, diffuse type</b>
	<i>Inclusions:</i> Adenocarcinoma, diffuse type

XH7M15	<b>Cholangiocarcinoma</b>
	<i>Inclusions:</i> Bile duct adenocarcinoma Bile duct carcinoma
XH7SS7	<b>Chromophobe carcinoma</b>
	<i>Inclusions:</i> Chromophobe adenocarcinoma
XH2Q13	<b>Clear cell adenocarcinofibroma</b>
	<i>Inclusions:</i> Clear cell cystadenocarcinofibroma
XH6YS0	<b>Clear cell adenocarcinoma, mesonephroid</b>
XH4SQ4	<b>Collecting duct carcinoma</b>
	<i>Inclusions:</i> Bellini duct carcinoma Renal carcinoma, collecting duct type
XH7QJ6	<b>Combined hepatocellular carcinoma and cholangiocarcinoma</b>
	<i>Inclusions:</i> Hepatocholangiocarcinoma Mixed hepatocellular and bile duct carcinoma
XH4KK0	<b>Cyst-associated renal cell carcinoma</b>
XH0LH8	<b>Enterochromaffin-like cell tumour</b>
XH5P16	<b>Fetal adenocarcinoma</b>
XH7TE3	<b>Follicular adenocarcinoma, moderately differentiated</b>
	<i>Inclusions:</i> Follicular carcinoma, moderately differentiated
XH0VD1	<b>Follicular adenocarcinoma, trabecular</b>
	<i>Inclusions:</i> Follicular carcinoma, trabecular
XH8FK7	<b>Follicular adenocarcinoma, well differentiated</b>
	<i>Inclusions:</i> Follicular carcinoma, well differentiated
XH3DN7	<b>Follicular carcinoma, minimally invasive</b>
XH90N9	<b>Follicular carcinoma, oxyphilic cell</b>
XH3XT5	<b>Glycogen-rich carcinoma</b>
	<i>Inclusions:</i> Glycogen-rich clear cell carcinoma
XH4262	<b>Goblet cell carcinoid</b>
	<i>Inclusions:</i> Mucinous carcinoid
XH2EH4	<b>Granular cell carcinoma</b>
	<i>Inclusions:</i> Granular cell adenocarcinoma
XH4T58	<b>Hepatocellular carcinoma, clear cell type</b>

XH9Q35	<b>Hepatocellular carcinoma, fibrolamellar</b>
XH0G90	<b>Hepatocellular carcinoma, pleomorphic type</b>
XH5761	<b>Hepatocellular carcinoma, scirrhous</b> <i>Inclusions:</i> Sclerosing hepatic carcinoma
XH3T17	<b>Hepatocellular carcinoma, spindle cell variant</b> <i>Inclusions:</i> Hepatocellular carcinoma, sarcomatoid
XH6YH5	<b>Hurthle cell adenocarcinoma</b>
XH8MQ3	<b>Hurthle cell carcinoma</b>
XH8WM4	<b>Linitis plastica</b>
XH6TK0	<b>Lipid-rich carcinoma</b>
XH81N8	<b>Merkel cell carcinoma</b> <i>Inclusions:</i> Primary cutaneous neuroendocrine carcinoma
XH7019	<b>Mixed acidophil-basophil carcinoma</b>
XH8EZ3	<b>Mixed acinar-endocrine carcinoma</b>
XH74Y9	<b>Mixed acinar-endocrine-ductal carcinoma</b>
XH6H10	<b>Mixed adenoneuroendocrine carcinoma</b> <i>Inclusions:</i> Combined carcinoid and adenocarcinoma Composite carcinoid Combined/mixed carcinoid and adenocarcinoma MANEC Mixed carcinoid-adenocarcinoma
XH2AM6	<b>Mixed cell adenocarcinoma</b>
XH7CY5	<b>Mixed ductal-endocrine carcinoma</b>
XH6UP4	<b>Mixed endocrine and exocrine adenocarcinoma</b>
XH7DG7	<b>Mixed medullary-follicular carcinoma</b>
XH3340	<b>Mixed medullary-papillary carcinoma</b>
XH9LZ7	<b>Mixed pancreatic endocrine and exocrine tumour, malignant</b>
XH1108	<b>Nonencapsulated sclerosing carcinoma</b> <i>Inclusions:</i> Nonencapsulated sclerosing adenocarcinoma

XH09D6	<b>Oxyphilic adenocarcinoma</b>
	<i>Inclusions:</i> Oncocytic adenocarcinoma Oncocytic carcinoma
XH3614	<b>Islet cell adenocarcinoma</b>
XH3709	<b>Pancreatic neuroendocrine tumor, nonfunctioning</b>
XH6XY9	<b>Pancreatobiliary-type carcinoma</b>
	<i>Inclusions:</i> Adenocarcinoma, pancreatobiliary type
XH1ND9	<b>Papillary carcinoma of thyroid</b>
XH85E5	<b>Papillary carcinoma, columnar cell</b>
	<i>Inclusions:</i> Papillary carcinoma, tall cell
XH0426	<b>Papillary carcinoma, diffuse sclerosing</b>
XH0Q59	<b>Papillary carcinoma, encapsulated, of thyroid</b>
XH29M4	<b>Papillary carcinoma, follicular variant</b>
	<i>Inclusions:</i> Papillary adenocarcinoma, follicular variant Papillary and follicular adenocarcinoma Papillary and follicular carcinoma
XH5YT2	<b>Papillary carcinoma, oncocytic variant</b>
XH2AW7	<b>Papillary microcarcinoma</b>
XH1D07	<b>Papillary renal cell carcinoma</b>
XH4Q20	<b>Papillotubular adenocarcinoma</b>
	<i>Inclusions:</i> Tubulopapillary adenocarcinoma
XH1JZ0	<b>Parietal cell carcinoma</b>
	<i>Inclusions:</i> Parietal cell adenocarcinoma
XH6153	<b>Renal cell carcinoma, chromophobe type</b>
	<i>Inclusions:</i> Chromophobe cell renal carcinoma
XH9DH7	<b>Renal cell carcinoma, sarcomatoid</b>
	<i>Inclusions:</i> Renal cell carcinoma, spindle cell
XH4FS4	<b>Scirrhous adenocarcinoma</b>
	<i>Inclusions:</i> Carcinoma with productive fibrosis Scirrhous carcinoma
XH34G3	<b>Solid carcinoma with mucin formation</b>
XH0JE3	<b>Superficial spreading adenocarcinoma</b>

<b>XH7EX3</b>	<b>Trabecular adenocarcinoma</b>
	<i>Inclusions:</i> Trabecular carcinoma
<b>XH4TA4</b>	<b>Tubular adenocarcinoma</b>
	<i>Inclusions:</i> Tubular carcinoma
<b>XH1Z69</b>	<b>Typical carcinoid</b>
<b>XH22Z8</b>	<b>Carcinoma of Skene, Cowper and Littré Glands</b>
<b>XH0X20</b>	<b>Villous adenocarcinoma</b>
<b>XH0A57</b>	<b>Water-clear cell adenocarcinoma</b>
	<i>Inclusions:</i> Water-clear cell carcinoma
<b>XH8UE4</b>	<b>Adenocarcinoma, metastatic, NOS</b>
<b>XH4ZC3</b>	<b>Basal cell carcinoma of the prostate</b>
<b>XH4W48</b>	<b>Hepatocellular carcinoma, NOS</b>
	<i>Inclusions:</i> Liver cell carcinoma
	Hepatoma, malignant
	Hepatocarcinoma
	Hepatoma, NOS
<b>XH81Q9</b>	<b>Bronchial adenoma, cylindroid</b>
<b>XH92Y9</b>	<b>Thymic carcinoma with adenoid cystic carcinoma-like features</b>
<b>XH1YZ3</b>	<b>Cribiform carcinoma, NOS</b>
	<i>Inclusions:</i> Ductal carcinoma, cribiform type
<b>XH4YG1</b>	<b>Cribiform comedo-type carcinoma</b>
	<i>Inclusions:</i> Adenocarcinoma, cribiform comedo-type
<b>XH74B2</b>	<b>Serrated adenocarcinoma</b>

Adenomas and adenocarcinomas, uncertain whether benign or malignant

**Coded Elsewhere:** ACTH-producing tumour (XH7AG8)

Enteroglucagonoma (XH2PF0)

L-cell tumour (XH7LW9)

Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumour (XH9ZS8)

Glucagonoma (XH4NQ8)

Gastrinoma (XH93H8)

Vipoma (XH72E5)

Somatostatinoma (XH5VH0)

Endocrine tumour, functioning, NOS (XH41P2)

Glucagon-like peptide-producing tumour (XH7152)

**XH6770**

**Apudoma**

**XH6VL9**

**Atypical adenoma**

*Inclusions:* Bronchial adenoma, NOS

**XH3T38**

**Atypical follicular adenoma**

**XH0S86**

**Clear cell adenofibroma of borderline malignancy**

*Inclusions:* Clear cell cystadenofibroma of borderline malignancy

**XH5DQ2**

**Endometrioid adenoma, borderline malignancy**

*Inclusions:* Endometrioid cystadenoma, borderline malignancy  
Endometrioid tumour, borderline

**XH76W6**

**Multiple endocrine adenomas**

*Inclusions:* Endocrine adenomatosis

**XH8468**

**Pulmonary adenomatosis**

**XH54H3**

**Hypernephroid tumour**

**XH7PR9**

**Multilocular cystic renal neoplasm of low malignant potential**

**XH9DS4**

**Endometrioid adenofibroma, borderline malignancy**

*Inclusions:* Endometrioid cystadenofibroma, borderline malignancy

**XH4JG0**

**Tubular carcinoid**

**XH4XL2**

**Aggressive papillary tumour**

**XH9PN4**

**Well differentiated tumor of uncertain malignant potential**

**XH6SY0**

**Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)**

**XH1Y66**

**Hyalinizing trabecular tumour**

<b>XH27W5</b>	<b>Follicular tumor of uncertain malignant potential</b>
<b>XH9T60</b>	<b>Clear cell papillary renal cell carcinoma</b>
<b>XH6CZ3</b>	<b>Clear cell borderline tumour</b>

Adnexal and skin appendage neoplasms

Adnexal and skin appendage neoplasms, benign

<b>XH6YZ9</b>	<b>Apocrine adenoma</b>
<b>XH0AQ8</b>	<b>Clear cell hidradenoma</b>
<b>XH46Z2</b>	<b>Eccrine acrospiroma</b>
<b>XH42Z3</b>	<b>Eccrine papillary adenoma</b>
<b>XH25Z9</b>	<b>Eccrine poroma</b>
<b>XH3AM1</b>	<b>Spiradenoma, NOS</b>
	<i>Inclusions:</i> Eccrine spiradenoma
<b>XH4YU8</b>	<b>Follicular fibroma</b>
	<i>Inclusions:</i> Fibrofolliculoma
	Perifollicular fibroma
	Trichodiscoma
<b>XH7NR3</b>	<b>Hidrocystoma</b>
<b>XH4MV7</b>	<b>Hidradenoma, NOS</b>
<b>XH4DX4</b>	<b>Papillary hidradenoma</b>
	<i>Inclusions:</i> Hidradenoma papilliferum
<b>XH1PY0</b>	<b>Syringocystadenoma papilliferum</b>
<b>XH96Q5</b>	<b>Skin appendage adenoma</b>
<b>XH3U61</b>	<b>Sweat gland adenoma</b>
	<i>Inclusions:</i> Syringadenoma, NOS
<b>XH06Y5</b>	<b>Syringofibroadenoma</b>
<b>XH6325</b>	<b>Syringoma, NOS</b>
<b>XH9GB7</b>	<b>Syringomatous tumour of nipple</b>
	<i>Inclusions:</i> Infiltrating syringomatous adenoma of nipple
	Syringomatous adenoma of nipple

<b>XH1NC5</b>	<b>Sebaceous adenoma</b>
<b>XH0SH5</b>	<b>Sebaceous epithelioma</b>
<b>XH7AL8</b>	<b>Ceruminous adenoma</b>
<b>XH8R55</b>	<b>Spindle cell predominant trichodiscoma</b>
<b>XH1A80</b>	<b>Apocrine poroma</b>
<b>XH8N28</b>	<b>Poroma, NOS</b>
<b>XH0QL4</b>	<b>Sebaceoma</b>

Adnexal and skin appendage neoplasms, in situ

<b>XH7WE6</b>	<b>Porocarcinoma in situ</b>
---------------	------------------------------

Adnexal and skin appendage neoplasms, malignant

<b>XH9L77</b>	<b>Apocrine adenocarcinoma</b>
	<i>Inclusions:</i> Apocrine carcinoma
<b>XH6FB5</b>	<b>Digital papillary adenocarcinoma</b>
<b>XH7VK4</b>	<b>Porocarcinoma, NOS</b>
<b>XH58E1</b>	<b>Malignant eccrine spiradenoma</b>
<b>XH7NK9</b>	<b>Hidradenocarcinoma</b>
<b>XH17P2</b>	<b>Microcystic adnexal carcinoma</b>
<b>XH89V4</b>	<b>Adnexal adenocarcinoma, NOS</b>
<b>XH5LY3</b>	<b>Sweat gland adenocarcinoma</b>
	<i>Inclusions:</i> Sweat gland carcinoma
<b>XH4VR2</b>	<b>Sebaceous carcinoma</b>
<b>XH8NE4</b>	<b>Eccrine adenocarcinoma</b>
<b>XH6Z69</b>	<b>Ceruminous adenocarcinoma</b>
	<i>Inclusions:</i> Ceruminous carcinoma
<b>XH9C82</b>	<b>Malignant neoplasm arising from pre-existing spiradenoma</b>
<b>XH2ZK9</b>	<b>Malignant neoplasm arising from pre-existing cylindroma</b>
<b>XH9NW9</b>	<b>Malignant neoplasm arising from pre-existing spiradenocylindroma</b>
<b>XH65F9</b>	<b>Sialadenoma papilliferum</b>

**XH0BE5      Syringocystadenocarcinoma papilliferum**

Adnexal and skin appendage neoplasms, uncertain whether benign or malignant

**XH8BW1      Sweat gland tumour, NOS**

Basal cell neoplasms

Basal cell neoplasms, benign

**XH1PG0      Intraepidermal epithelioma of Jadassohn**

**XH5AU2      Trichilemmoma**

**XH6QT9      Trichoepithelioma**

*Inclusions:*      Epithelioma adenoides cysticum

**XH0U05      Trichofolliculoma**

**XH5L76      Pilar tumour**

**XH9E37      Pilomatrixoma, NOS**

*Inclusions:*      Calcifying epithelioma of Malherbe

Pilomatrixoma, NOS

**XH05Z3      Trichogermanoma**

**XH7CM2      Melanocytic matricoma**

**XH3EY8      Pilar sheath acanthoma**

**XH0489      Tumor of follicular infundibulum**

**XH2K97      Trichoblastoma**

Basal cell neoplasms, malignant

**XH70J2      Adenoid basal carcinoma**

**XH45F3      Basal cell carcinoma, fibroepithelial**

*Inclusions:*      Fibroepithelioma, NOS

Fibroepithelial basal cell carcinoma, Pinkus type

Fibroepithelioma of Pinkus type

**XH4GJ2      Basal cell carcinoma, micronodular**

**XH2CR0      Basal cell carcinoma, nodular**

<b>XH2615</b>	<b>Basal cell carcinoma, NOS</b>
	<i>Inclusions:</i> Rodent ulcer Basal cell epithelioma
<b>XH4C18</b>	<b>Basosquamous carcinoma</b>
	<i>Inclusions:</i> Mixed basal-squamous cell carcinoma
<b>XH5VK4</b>	<b>Infiltrating basal cell carcinoma, NOS</b>
<b>XH0T12</b>	<b>Infiltrating basal cell carcinoma, non-sclerosing</b>
<b>XH67Y4</b>	<b>Infiltrating basal cell carcinoma, sclerosing</b>
	<i>Inclusions:</i> Basal cell carcinoma, desmoplastic type Basal cell carcinoma, morpheic
<b>XH9E93</b>	<b>Metatypical carcinoma</b>
<b>XH5NL6</b>	<b>Superficial basal cell carcinoma</b>
	<i>Inclusions:</i> Multicentric basal cell carcinoma
<b>XH2HE7</b>	<b>Pigmented basal cell carcinoma</b>
<b>XH9K96</b>	<b>Trichilemmocarcinoma</b>
	<i>Inclusions:</i> Trichilemmal carcinoma
<b>XH9G49</b>	<b>Pilomatrical carcinoma</b>
	<i>Inclusions:</i> Matrical carcinoma Pilomatrixoma, malignant Pilomatrixoma, malignant Pilomatrix carcinoma
<b>XH6S67</b>	<b>Basal cell carcinoma with adnexal differentiation</b>
<b>XH3DL9</b>	<b>Trichoblastic carcinoma</b>
<b>XH8324</b>	<b>Trichoblastic carcinosarcoma</b>
<b>XH1JH6</b>	<b>Basal cell carcinoma, sarcomatoid</b>

Basal cell neoplasms, uncertain whether benign or malignant

<b>XH8189</b>	<b>Basal cell tumour</b>
<b>XH7WJ7</b>	<b>Proliferating trichilemmal cyst</b>

Blood vessel tumours

**Coded Elsewhere:** Haemangiopericytic meningioma (XH7050)

Blood vessel tumours, benign

**XH3U29 Capillary haemangioma**

**XH1GU2 Cavernous haemangioma**

**XH10T4 Epithelioid haemangioma**

A benign neoplasm most commonly affecting the skin and characterised by local proliferation of vascular channels. Affected individuals typically present with a cluster of small, translucent nodules on the head and neck, particularly around the ear or the hairline. The neoplasm may rarely arise in oral mucosa or in internal organs.

**XH0LN3 Haemangioendothelioma, benign**

**XH0553 Intramuscular haemangioma**

*Inclusions:* Intramuscular angioma

**XH2HR3 Racemose haemangioma**

**XH4NS3 Venous haemangioma**

**XH5AW4 Haemangioma, NOS**

*Inclusions:* Chorioangioma

Angioma, NOS

**XH37N4 Myointimoma**

**XH1JJ2 Angiofibroma, NOS**

**XH23S6 Verrucous keratotic haemangioma**

**XH4E06 Cellular angiofibroma**

**XH73S9 Giant cell angiofibroma**

**XH2EX4 Acquired tufted haemangioma**

**XH4KP7 Angiokeratoma**

**XH8SM9 Cutaneous epithelioid angiomyomatoid nodule**

**XH8KN7 Atypical vascular lesion**

**XH9Q71 Cherry hemangioma**

**XH88L5 Sinusoidal hemangioma**

**XH9UU3 Microvenular hemangioma**

XH9NB0	<b>Glomeruloid hemangioma</b>
XH6RP8	<b>Spindle cell hemangioma</b>
XH27G6	<b>Congenital hemangioma, NOS</b>
XH6RC4	<b>Congenital hemangioma, rapidly involuting</b>
XH5427	<b>Congenital hemangioma, non-involuting</b>
XH8PD3	<b>Hobnail hemangioma</b>
XH4LY5	<b>Lobular capillary hemangioma</b>

Blood vessel tumours, malignant

XH4E71	<b>Haemangioendothelioma, malignant</b>
XH6264	<b>Hemangiosarcoma</b>
XH36A5	<b>Kaposi sarcoma</b>
XH6FJ5	<b>Kupffer cell sarcoma</b>
XH3C78	<b>Intravascular bronchial alveolar tumour</b>
XH36H7	<b>Intimal sarcoma</b>
XH9GF8	<b>Epithelioid haemangioendothelioma, NOS</b>

Blood vessel tumours, uncertain whether benign or malignant

**Coded Elsewhere:** Haemangiopericytic meningioma (XH7050)

XH4SY7	<b>Papillary intralymphatic angioendothelioma</b>
XH6PA4	<b>Kaposiform haemangioendothelioma</b>
XH2PS0	<b>Spindle cell haemangioendothelioma</b>
	<i>Inclusions:</i> Spindle cell angioendothelioma
XH26F6	<b>Pseudomyogenic (epithelioid sarcoma-like) haemangioendothelioma</b>
XH64U8	<b>Retiform haemangioendothelioma</b>
XH8D24	<b>Composite haemangioendothelioma</b>
XH2L98	<b>Haemangioendothelioma, NOS</b>
	<i>Inclusions:</i> Angioendothelioma
XH6810	<b>Haemangioblastoma</b>
	<i>Inclusions:</i> Angioblastoma

Complex epithelial neoplasms

Complex epithelial neoplasms, benign

- XH9ZB2 Adenolymphoma**  
*Inclusions:* Papillary cystadenoma lymphomatosum
- XH1TX5 Mixed squamous cell and glandular papilloma**
- XH7J33 Lymphadenoma**

Complex epithelial neoplasms, malignant

- XH2PY4 Adenocarcinoma with squamous metaplasia**  
*Inclusions:* Adenoacanthoma
- XH7873 Adenosquamous carcinoma**  
*Inclusions:* Mixed adenocarcinoma and epidermoid carcinoma  
Mixed adenocarcinoma and squamous cell carcinoma
- XH9JP2 Epithelial-myoepithelial carcinoma**
- XH7247 Adenocarcinoma with cartilaginous and osseous metaplasia**
- XH2QL8 Adenocarcinoma with spindle cell metaplasia**
- XH6G98 Fibromatosis-like metaplastic carcinoma**
- XH4GA3 Adenocarcinoma with apocrine metaplasia**  
*Inclusions:* Carcinoma with apocrine metaplasia
- XH4T39 Adenocarcinoma with neuroendocrine differentiation**
- XH0RD4 Metaplastic carcinoma, NOS**
- XH7MV6 Hepatoid adenocarcinoma**  
*Inclusions:* Hepatoid carcinoma
- XH95Y6 Squamoid eccrine ductal carcinoma**
- XH8XD1 Endometrioid carcinoma with squamous differentiation**

Complex mixed and stromal neoplasms

Complex mixed and stromal neoplasms, benign

- XH4ZH4 Adenomyoma**
- XH7ZB1 Atypical polypoid adenomyoma**

<b>XH6YS4</b>	<b>Benign cystic nephroma</b>
<b>XH70N8</b>	<b>Chondroid syringoma</b>
<b>XH8C13</b>	<b>Endometrial stromal nodule</b>
<b>XH3SR2</b>	<b>Ossifying renal tumour</b>
<b>XH2KC1</b>	<b>Pleomorphic adenoma</b>
	<i>Inclusions:</i> Mixed tumour, NOS
	Mixed tumour, salivary gland type, NOS
<b>XH3470</b>	<b>Renomedullary interstitial cell tumour</b>
<b>XH2E97</b>	<b>Stromal tumour, benign</b>
<b>XH0533</b>	<b>Mixed epithelial and stromal tumour</b>
<b>XH7TJ0</b>	<b>Paediatric cystic nephroma</b>
<b>XH5QU1</b>	<b>Adenomyoepithelioma, NOS</b>
<b>XH2V57</b>	<b>Adenomyoepithelioma, benign</b>
<b>XH9T96</b>	<b>Phosphaturic mesenchymal tumour, benign</b>
	<i>Inclusions:</i> Phosphaturic mesenchymal tumour, NOS
<b>XH3UD9</b>	<b>Pulmonary hamartoma</b>
<b>XH3CQ8</b>	<b>Myoepithelioma</b>
<b>XH7AA3</b>	<b>Mesenchymoma, benign</b>
<b>XH1SP3</b>	<b>Adult cystic nephroma</b>
<b>XH2P15</b>	<b>Mesenchymal hamartoma</b>
<b>XH1WZ6</b>	<b>Ectomesenchymal chondromyxoid tumour</b>

Complex mixed and stromal neoplasms, malignant

<b>XH5544</b>	<b>Adenosarcoma</b>
<b>XH1YV7</b>	<b>Carcinofibroma</b>
<b>XH42V2</b>	<b>Carcinoma ex pleomorphic adenoma</b>
<b>XH2RK1</b>	<b>Carcinosarcoma, embryonal</b>
<b>XH2CV3</b>	<b>Endometrial stromal sarcoma, high grade</b>
	<i>Inclusions:</i> Endometrioid stromal sarcoma, high grade

XH1S94	<b>Endometrial stromal sarcoma, low grade</b>
	<i>Inclusions:</i>
	Stromal endometriosis
	Endometrial stromatosis
	Endolymphatic stromal myosis
	Endometrioid stromal sarcoma, low grade
	Stromal myosis, NOS
XH9HQ1	<b>Gastrointestinal stromal tumour</b>
XH2WE3	<b>Hepatoblastoma</b>
	A disease caused by abnormal proliferation of liver precursor cells. This disease is characterised by a solid, well circumscribed mass, which may contain a stromal component that may be undifferentiated or develop into bone or cartilage.
	<i>Inclusions:</i>
	Embryonal hepatoma
	Hepatoblastoma, NOS
XH0765	<b>Clear cell sarcoma of kidney</b>
XH64D5	<b>Malignant chondroid syringoma</b>
XH9M31	<b>Malignant cystic nephroma</b>
	<i>Inclusions:</i>
	Malignant multilocular cystic nephroma
XH3RF3	<b>Rhabdoid tumor, NOS</b>
XH0Y65	<b>Mesodermal mixed tumour</b>
XH7ZJ9	<b>Mullerian mixed tumour</b>
XH27L5	<b>Pancreatoblastoma</b>
XH2FY9	<b>Pleuropulmonary blastoma</b>
XH5VH1	<b>Pulmonary blastoma</b>
	<i>Inclusions:</i>
	Pneumoblastoma
XH1TK5	<b>Endometrial stromal sarcoma, NOS</b>
	<i>Inclusions:</i>
	Endometrial sarcoma, NOS
XH49Y5	<b>Stromal sarcoma, NOS</b>
XH0V86	<b>Mixed tumour, malignant, NOS</b>
XH5QN3	<b>Nephroblastoma, NOS</b>
	<i>Inclusions:</i>
	Nephroma, NOS
XH0H07	<b>Hepatoblastoma, epithelioid</b>
XH33R5	<b>Hepatoblastoma, mixed epithelial-mesenchymal</b>
XH2W45	<b>Carcinosarcoma, NOS</b>

<b>XH7TL5</b>	<b>Adenomyoepithelioma with carcinoma</b>
	<i>Inclusions:</i> Malignant adenomyoepithelioma
<b>XH3B27</b>	<b>Phosphaturic mesenchymal tumour, malignant</b>
<b>XH43E6</b>	<b>Myoepithelial carcinoma</b>
<b>XH9N95</b>	<b>Mesenchymoma, malignant</b>
	<i>Inclusions:</i> Mixed mesenchymal sarcoma
<b>XH42Q2</b>	<b>Embryonal sarcoma</b>
<b>XH4VQ1</b>	<b>Gastroblastoma</b>
<b>XH5CT2</b>	<b>Gastrointestinal autonomic nerve tumour</b>
<b>XH0712</b>	<b>Gastrointestinal pacemaker cell tumour</b>

Complex mixed and stromal neoplasms, uncertain whether benign or malignant

**Coded Elsewhere:** Gastrointestinal autonomic nerve tumour (XH5CT2)  
Gastrointestinal pacemaker cell tumour (XH0712)

<b>XH1JB4</b>	<b>Cystic partially differentiated nephroblastoma</b>
<b>XH10F1</b>	<b>Mesoblastic nephroma</b>
<b>XH0G00</b>	<b>Sialoblastoma</b>
<b>XH6R49</b>	<b>Stromal tumour, NOS</b>
<b>XH4N88</b>	<b>Metanephric stromal tumour</b>
<b>XH8747</b>	<b>Stromal tumour of uncertain malignant potential</b>
<b>XH8X78</b>	<b>Calcifying nested stromal-epithelial tumor</b>
<b>XH2AD1</b>	<b>Mesenchymoma, NOS</b>
<b>XH5LL8</b>	<b>Primitive non-neural granular cell tumor</b>

Cystic, mucinous and serous neoplasms

Cystic, mucinous and serous neoplasms, benign

<b>XH6ZU1</b>	<b>Clear cell cystadenoma</b>
<b>XH55F1</b>	<b>Cystic tumour of atrio-ventricular node</b>
<b>XH5232</b>	<b>Intraductal papillary-mucinous adenoma</b>
<b>XH4070</b>	<b>Intraductal papillary-mucinous tumour with intermediate dysplasia</b>

<b>XH8MD2</b>	<b>Intraductal papillary-mucinous tumour with low grade dysplasia</b>
	<i>Inclusions:</i> Intraductal papillary-mucinous neoplasm with low grade dysplasia
<b>XH8ML6</b>	<b>Intraductal papillary-mucinous tumour with moderate dysplasia</b>
	<i>Inclusions:</i> Intraductal papillary-mucinous neoplasm with moderate dysplasia
<b>XH0556</b>	<b>Serous microcystic adenoma</b>
<b>XH38C4</b>	<b>Serous surface papilloma</b>
<b>XH5RJ2</b>	<b>Cystadenoma, NOS</b>
	<i>Inclusions:</i> Cystoma, NOS
<b>XH8TJ0</b>	<b>Serous cystadenoma, NOS</b>
<b>XH0FM6</b>	<b>Papillary cystadenoma, NOS</b>
<b>XH6H73</b>	<b>Mucinous cystadenoma, NOS</b>
<b>XH8XL1</b>	<b>Mucinous cystic neoplasm with intermediate-grade dysplasia</b>
<b>XH6NK7</b>	<b>Mucinous cystic neoplasm with low-grade intraepithelial neoplasia</b>
<b>XH7K36</b>	<b>Mucinous cystic tumour with intermediate dysplasia</b>
<b>XH7834</b>	<b>Mucinous cystic tumour with moderate dysplasia</b>
<b>XH0EK3</b>	<b>Mucinous cystic neoplasm with low-grade dysplasia</b>
<b>XH8EW6</b>	<b>Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia</b>
<b>XH9BE7</b>	<b>Seromucinous cystadenoma</b>
<b>XH2M29</b>	<b>Mucinous adenoma</b>
<b>XH5RX2</b>	<b>Mucous gland adenoma</b>
<b>XH9MS1</b>	<b>Papillary cystadenofibroma</b>

Cystic, mucinous and serous neoplasms, in situ

<b>XH5E08</b>	<b>Intraductal papillary-mucinous carcinoma, non-invasive</b>
<b>XH3MB3</b>	<b>Intraductal papillary mucinous neoplasm with high grade dysplasia</b>
<b>XH06M2</b>	<b>Mucinous cystadenocarcinoma, non-invasive</b>
<b>XH81P3</b>	<b>Mucinous cystic neoplasm with high-grade dysplasia</b>
<b>XH8PZ6</b>	<b>Serous intraepithelial carcinoma</b>

<b>XH9DM1</b>	<b>Serous borderline tumour, micropapillary variant</b>
<b>XH8NV8</b>	<b>Serous tubal intraepithelial carcinoma (STIC)</b>
<b>XH1YW4</b>	<b>Serous endometrial intraepithelial carcinoma</b>

Cystic, mucinous and serous neoplasms, malignant

<b>XH5WU3</b>	<b>Intraductal papillary-mucinous carcinoma, invasive</b>
<b>XH2SE1</b>	<b>Intraductal papillary mucinous neoplasm with an associated invasive carcinoma</b>
<b>XH0572</b>	<b>Micropapillary serous carcinoma</b>
<b>XH5P21</b>	<b>Solid pseudopapillary carcinoma</b>
<b>XH0219</b>	<b>Cystadenocarcinoma, NOS</b>
<b>XH7A08</b>	<b>Serous carcinoma, NOS</b>
<b>XH6JU6</b>	<b>Papillary cystadenocarcinoma, NOS</b> <i>Inclusions:</i> Papillocystic adenocarcinoma
<b>XH12V5</b>	<b>Low grade serous carcinoma</b>
<b>XH24N6</b>	<b>High grade serous carcinoma</b>
<b>XH1390</b>	<b>Mucinous cystadenocarcinoma, NOS</b>
<b>XH1K19</b>	<b>Mucinous cystic tumour with an associated invasive carcinoma</b>
<b>XH4186</b>	<b>Seromucinous carcinoma</b>
<b>XH1S75</b>	<b>Mucinous adenocarcinoma</b>
<b>XH4U83</b>	<b>Pseudomyxoma peritonei with unknown primary site</b>
<b>XH5EQ2</b>	<b>Mucinous tubular and spindle cell carcinoma</b>
<b>XH83J5</b>	<b>Pseudomyxoma peritonei</b>
<b>XH4KC5</b>	<b>Mucinous carcinoma, gastric type</b>
<b>XH56K0</b>	<b>Metastatic signet ring cell carcinoma</b>
<b>XH5AF5</b>	<b>Mucin-producing adenocarcinoma</b> <i>Inclusions:</i> Mucin-secreting carcinoma Mucin-secreting adenocarcinoma Mucin-producing carcinoma
<b>XH4546</b>	<b>Signet ring cell carcinoma</b>
<b>XH2KK0</b>	<b>Poorly cohesive carcinoma</b>

<b>XH3RD4</b>	<b>Krukenberg tumour</b>
<b>XH0XE5</b>	<b>Signet ring cell/histiocytoid carcinoma</b>
<b>XH3AE9</b>	<b>Solid pseudopapillary neoplasm of pancreas</b>

Cystic, mucinous and serous neoplasms, uncertain whether benign or malignant

<b>XH2FF0</b>	<b>Mucinous cystic tumour of borderline malignancy</b>
<b>XH1P30</b>	<b>Papillary cystadenoma, borderline malignancy</b>
<b>XH0RB9</b>	<b>Seromucinous borderline tumour</b> <i>Inclusions:</i> Seromucinous tumour, atypical proliferative
<b>XH3ZK9</b>	<b>Serous borderline tumour, NOS</b>
<b>XH3FD4</b>	<b>Solid pseudopapillary tumor of ovary</b> <i>Inclusions:</i> Solid and papillary epithelial neoplasm
<b>XH7BB4</b>	<b>Low grade appendiceal mucinous neoplasm</b>

Ductal and lobular neoplasms

Ductal and lobular neoplasms, benign

<b>XH6RX1</b>	<b>Intracystic papillary neoplasm with low grade intraepithelial neoplasia</b> <i>Inclusions:</i> Intraductal papillary neoplasm with intermediate grade neoplasia Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia Intraglandular papillary neoplasm with low grade intraepithelial neoplasia
<b>XH5ZH7</b>	<b>Intraductal papillary neoplasm with low grade intraepithelial neoplasia</b>
<b>XH4LZ4</b>	<b>Intraductal papilloma</b> <i>Inclusions:</i> Duct adenoma, NOS Ductal papilloma
<b>XH7QS7</b>	<b>Intraductal tubular-papillary neoplasm, low grade</b>
<b>XH6HK2</b>	<b>Intraductal papillary neoplasm, NOS</b>
<b>XH60S7</b>	<b>Intraductal papilloma with atypical ductal hyperplasia</b>
<b>XH7GN3</b>	<b>Adenoma of nipple</b> <i>Inclusions:</i> Subareolar duct papillomatosis

XH9F80	<b>Intracystic papillary adenoma</b>
	<i>Inclusions:</i> Intracystic papilloma
XH4JD3	<b>Intraductal papillomatosis, NOS</b>
	<i>Inclusions:</i> Diffuse intraductal papillomatosis
	Ductal and lobular neoplasms, in situ
XH8P86	<b>Comedocarcinoma, noninfiltrating</b>
	<i>Inclusions:</i> DCIS, comedo type Ductal carcinoma in situ, comedo type
XH6AH7	<b>Intraductal papillary neoplasm with high grade intraepithelial neoplasia</b>
	<i>Inclusions:</i> Intraductal papillary neoplasm with high grade dysplasia Intracystic papillary neoplasm with high grade intraepithelial neoplasia
XH9VG0	<b>Noninfiltrating intraductal papillary adenocarcinoma</b>
	<i>Inclusions:</i> DCIS, papillary Ductal carcinoma in situ, papillary Noninfiltrating intraductal papillary carcinoma Intraductal papillary carcinoma, NOS Intraductal papillary adenocarcinoma, NOS
XH1H31	<b>Intraductal carcinoma, noninfiltrating, NOS</b>
XH4V32	<b>Ductal carcinoma in situ, NOS</b>
XH11S9	<b>Intraductal papilloma with DCIS</b>
XH64S7	<b>Intraductal tubular-papillary neoplasm, high grade</b>
XH9XV2	<b>Noninfiltrating intracystic carcinoma</b>
	<i>Inclusions:</i> Encysted papillary carcinoma Intracystic papillary carcinoma Intracystic carcinoma, NOS Intracystic papillary adenocarcinoma
XH0134	<b>Solid papillary carcinoma in situ</b>
XH39X8	<b>Intraductal carcinoma, clinging, high grade</b>
XH9SL6	<b>Cystic hypersecretory carcinoma, intraductal</b>
XH0GQ3	<b>Intraductal micropapillary carcinoma</b>
	<i>Inclusions:</i> Ductal carcinoma in situ, micropapillary

<b>XH2HB2</b>	<b>Lobular carcinoma in situ, pleomorphic</b>
	<i>Inclusions:</i> LCIS, pleomorphic
<b>XH6EH0</b>	<b>Lobular carcinoma in situ, NOS</b>
<b>XH7XE0</b>	<b>Intraductal carcinoma and lobular carcinoma in situ</b>
<b>XH3PE9</b>	<b>Intraductal tubulopapillary neoplasm</b>
<b>XH8010</b>	<b>Endocrine mucin-producing sweat gland carcinoma in situ</b>
<b>XH4US4</b>	<b>Intraductal papilloma with lobular carcinoma in situ</b>

Ductal and lobular neoplasms, malignant

<b>XH44J4</b>	<b>Secretory carcinoma</b>
<b>XH7KH3</b>	<b>Infiltrating duct carcinoma, NOS</b>
	<i>Inclusions:</i> Invasive breast carcinoma of no special type
	Duct adenocarcinoma, NOS
	Duct carcinoma, NOS
	Ductal carcinoma, NOS
	Duct cell carcinoma
	Infiltrating duct adenocarcinoma
<b>XH9FX2</b>	<b>Adenocarcinoma of mammary gland type</b>
<b>XH1N58</b>	<b>Comedocarcinoma, NOS</b>
<b>XH8MA7</b>	<b>Intraductal papillary adenocarcinoma with invasion</b>
	<i>Inclusions:</i> Infiltrating papillary adenocarcinoma
	Infiltrating and papillary adenocarcinoma
<b>XH8KR8</b>	<b>Papillary carcinoma of the breast</b>
<b>XH90W1</b>	<b>Intraductal papillary neoplasm with associated invasive carcinoma</b>
	<i>Inclusions:</i> Intracystic papillary neoplasm with associated invasive carcinoma
<b>XH0GT6</b>	<b>Encapsulated papillary carcinoma with invasion</b>
	<i>Inclusions:</i> Encysted papillary carcinoma with invasion
	Intracystic papillary carcinoma with invasion
<b>XH9C56</b>	<b>Invasive micropapillary carcinoma of breast</b>
	<i>Inclusions:</i> Micropapillary carcinoma of breast
<b>XH1XB5</b>	<b>Solid papillary carcinoma with invasion</b>
<b>XH2YP5</b>	<b>Medullary carcinoma, NOS</b>

<b>XH9B99</b>	<b>Medullary-like carcinoma</b>
<b>XH2XR3</b>	<b>Lobular carcinoma, NOS</b>
	<p><i>Inclusions:</i>      Infiltrating lobular carcinoma, NOS            Lobular adenocarcinoma</p>
<b>XH9620</b>	<b>Medullary adenocarcinoma</b>
<b>XH6KZ1</b>	<b>Atypical medullary carcinoma</b>
<b>XH6PY4</b>	<b>Duct carcinoma, desmoplastic type</b>
<b>XH55H7</b>	<b>Medullary carcinoma with lymphoid stroma</b>
<b>XH3RK9</b>	<b>Tubulolobular carcinoma</b>
<b>XH0408</b>	<b>Infiltrating ductular carcinoma</b>
<b>XH8RN5</b>	<b>Infiltrating duct and lobular carcinoma</b>
	<p><i>Inclusions:</i>      Lobular and ductal carcinoma</p>
<b>XH9Z29</b>	<b>Intraductal and lobular carcinoma</b>
<b>XH6MH3</b>	<b>Infiltrating duct and lobular carcinoma in situ</b>
<b>XH9551</b>	<b>Infiltrating lobular carcinoma and ductal carcinoma in situ</b>
<b>XH8CS0</b>	<b>Infiltrating duct mixed with other types of carcinoma</b>
<b>XH9GX4</b>	<b>Infiltrating duct and colloid carcinoma</b>
<b>XH2ST9</b>	<b>Infiltrating duct and cribriform carcinoma</b>
<b>XH3969</b>	<b>Infiltrating duct and mucinous carcinoma</b>
<b>XH1ND7</b>	<b>Infiltrating duct and tubular carcinoma</b>
<b>XH3CB4</b>	<b>Infiltrating lobular mixed with other types of carcinoma</b>
<b>XH5SD5</b>	<b>Polymorphous adenocarcinoma</b>
<b>XH9G73</b>	<b>Inflammatory carcinoma</b>
	<p><i>Inclusions:</i>      Inflammatory adenocarcinoma</p>
<b>XH3E21</b>	<b>Paget disease, mammary</b>
	<p><i>Inclusions:</i>      Paget disease of breast</p>
<b>XH47A6</b>	<b>Paget disease and infiltrating duct carcinoma of breast</b>
<b>XH70F8</b>	<b>Paget disease, extramammary</b>
<b>XH0C76</b>	<b>Paget disease and intraductal carcinoma of breast</b>
<b>XH32K6</b>	<b>Basal-like carcinoma of breast</b>

<b>XH4ZU9</b>	<b>Adenocarcinoma of anogenital mammary-like glands</b>
<b>XH5KW8</b>	<b>Carcinoma of male breast</b>
<b>XH4EK4</b>	<b>Endocrine mucin-producing sweat gland carcinoma</b>
<b>XH9HB7</b>	<b>Lobular carcinoma, pleomorphic</b>
<b>XH1146</b>	<b>Juvenile carcinoma of breast</b>
<b>XH8TH6</b>	<b>Cystic hypersecretory carcinoma</b> Code change from 8508/3 to 8500/2 in ICD-O3 2016

#### Epithelial neoplasms, NOS

##### Epithelial neoplasms, benign

<b>XH9HV0</b>	<b>Epithelial tumour, benign</b>
<b>XH1TD2</b>	<b>Tumourlet, benign</b>
<b>XH65S3</b>	<b>Epithelioma, benign</b>
<b>XH0M86</b>	<b>Focal nodular hyperplasia</b>

##### Epithelial neoplasms, in situ

<b>XH5NV6</b>	<b>Carcinoma in situ, NOS</b>
<i>Inclusions:</i>	Intraepithelial carcinoma, NOS

##### Epithelial neoplasms, malignant

<b>XH56X7</b>	<b>Carcinoma with osteoclast-like giant cells</b>
<b>XH63D2</b>	<b>Carcinoma, NOS</b>
<i>Inclusions:</i>	Epithelial tumour, malignant
<b>XH3XZ6</b>	<b>Giant cell and spindle cell carcinoma</b>
<b>XH1JZ2</b>	<b>Giant cell carcinoma</b>
<b>XH00N7</b>	<b>Glassy cell carcinoma</b>
<b>XH4QU2</b>	<b>Large cell carcinoma with rhabdoid phenotype</b>
<b>XH0NL5</b>	<b>Large cell neuroendocrine carcinoma</b>
<b>XH35G0</b>	<b>Pleomorphic carcinoma</b>
<b>XH92T7</b>	<b>Polygonal cell carcinoma</b>

<b>XH35M3</b>	<b>Pseudosarcomatous carcinoma</b>
	<i>Inclusions:</i> Sarcomatoid carcinoma
<b>XH1YN3</b>	<b>Carcinoma, metastatic, NOS</b>
<b>XH8D74</b>	<b>Carcinomatosis</b>
<b>XH4P61</b>	<b>Epithelioma, malignant</b>
	<i>Inclusions:</i> Epithelioma, NOS
<b>XH45J4</b>	<b>Large cell carcinoma, NOS</b>
<b>XH1YY4</b>	<b>Carcinoma, undifferentiated, NOS</b>
<b>XH57U9</b>	<b>Carcinoma, anaplastic, NOS</b>
<b>XH2855</b>	<b>Nuclear protein in testis (NUT) associated carcinoma</b>
	<i>Inclusions:</i> NUT midline carcinoma
	NUT carcinoma
<b>XH3RZ4</b>	<b>Spindle cell carcinoma, NOS</b>
<b>XH0YB0</b>	<b>Small cell carcinoma, NOS</b>
	<i>Inclusions:</i> Round cell carcinoma
	Reserve cell carcinoma
<b>XH9SY0</b>	<b>Small cell neuroendocrine carcinoma</b>
	<i>Inclusions:</i> Small cell carcinoma, pulmonary type
<b>XH28J9</b>	<b>Oat cell carcinoma</b>
<b>XH3T00</b>	<b>Small cell carcinoma, fusiform cell</b>
<b>XH6GK0</b>	<b>Small cell carcinoma, intermediate cell</b>
<b>XH8ZR8</b>	<b>Small cell carcinoma, hypercalcaemic type</b>
<b>XH7YE3</b>	<b>Combined small cell carcinoma</b>
	<i>Inclusions:</i> Mixed small cell carcinoma
<b>XH0793</b>	<b>Combined small cell-adenocarcinoma</b>
<b>XH6FK9</b>	<b>Combined small cell-large cell carcinoma</b>
<b>XH9ZD2</b>	<b>Combined small cell-squamous cell carcinoma</b>
<b>XH1DU4</b>	<b>Non-small cell carcinoma</b>
<b>XH26N1</b>	<b>Heterotopia-associated carcinoma</b>
<b>XH90B3</b>	<b>Combined large cell neuroendocrine carcinoma</b>
<b>XH98Z7</b>	<b>Anaplastic undifferentiated carcinoma</b>

<b>XH5R16</b>	<b>Dedifferentiated carcinoma</b>
<b>XH2BS4</b>	<b>Squamous carcinoma with osteoclast-like giant cells</b>
<b>XH2224</b>	<b>Undifferentiated carcinoma with osteoclast-like giant cells</b>

Epithelial neoplasms, uncertain whether benign or malignant

<b>XH1N44</b>	<b>Tumourlet, NOS</b>
---------------	-----------------------

Fibroepithelial neoplasms

Fibroepithelial neoplasms, benign

<b>XH5DX3</b>	<b>Brenner tumour, NOS</b>
<b>XH4MA6</b>	<b>Intracanalicular fibroadenoma</b>
<b>XH7JU0</b>	<b>Papillary adenofibroma</b>
<b>XH0N11</b>	<b>Pericanalicular fibroadenoma</b>
<b>XH9HE2</b>	<b>Fibroadenoma, NOS</b>
<b>XH91Y8</b>	<b>Adenofibroma, NOS</b>
<b>XH5S99</b>	<b>Cystadenofibroma, NOS</b>
<b>XH5ZB5</b>	<b>Serous adenofibroma, NOS</b>
<b>XH6RL8</b>	<b>Serous cystadenofibroma, NOS</b>
<b>XH1VJ0</b>	<b>Seromucinous adenofibroma</b>
<b>XH59X8</b>	<b>Mucinous adenofibroma, NOS</b>
<b>XH9SM7</b>	<b>Mucinous cystadenofibroma, NOS</b>
<b>XH50P7</b>	<b>Phyllodes tumour, benign</b>
	<i>Inclusions:</i> Cystosarcoma phyllodes, benign
<b>XH4RU1</b>	<b>Giant fibroadenoma</b>
<b>XH70H4</b>	<b>Juvenile fibroadenoma</b>
<b>XH5853</b>	<b>Lipofibroadenoma</b>
<b>XH7ZU2</b>	<b>Metanephric adenofibroma</b>

Fibroepithelial neoplasms, malignant

- XH6NJ7      **Brenner tumour, malignant**
- XH7284      **Mucinous adenocarcinofibroma**  
*Inclusions:*      Malignant mucinous adenofibroma
- XH75P5      **Periductal stromal tumour, low grade**
- XH9JC2      **Serous adenocarcinofibroma**  
*Inclusions:*      Malignant serous adenofibroma
- XH6PQ0      **Serous cystadenocarcinofibroma**  
*Inclusions:*      Malignant serous cystadenofibroma
- XH0WW5      **Mucinous cystadenocarcinofibroma**  
*Inclusions:*      Malignant mucinous cystadenofibroma
- XH8HJ7      **Phyllodes tumour, malignant**  
*Inclusions:*      Cystosarcoma phyllodes, malignant

Fibroepithelial neoplasms, uncertain whether benign or malignant

- XH2CH8      **Brenner tumour, borderline malignancy**  
*Inclusions:*      Borderline Brenner tumour  
                    Brenner tumour, atypical proliferative
- XH7AR7      **Mucinous adenofibroma of borderline malignancy**
- XH2YZ1      **Mucinous cystadenofibroma of borderline malignancy**
- XH5NK4      **Phyllodes tumour, borderline**  
*Inclusions:*      Cystosarcoma phyllodes, NOS
- XH07C7      **Serous adenofibroma of borderline malignancy**
- XH2M30      **Serous cystadenofibroma of borderline malignancy**

Fibromatous neoplasms

Fibromatous neoplasms, benign

- XH8A47      **Angiomyofibroblastoma**

<b>XH06N0</b>	<b>Benign fibrous histiocytoma</b>
	<i>Inclusions:</i>
	Fibroxanthoma, NOS
	Xanthofibroma
	Fibrous histiocytoma, NOS
	Benign fibrous histiocytoma, NOS
<b>XH3BQ8</b>	<b>Elastofibroma</b>
<b>XH2MW3</b>	<b>Fascial fibroma</b>
<b>XH5XQ3</b>	<b>Fibromyxoma</b>
	<i>Inclusions:</i>
	Myxoid fibroma
	Myxofibroma, NOS
	Fibromyxoma, NOS
<b>XH3NQ0</b>	<b>Myofibroblastoma</b>
<b>XH0953</b>	<b>Myofibroma</b>
<b>XH7FV0</b>	<b>Periosteal fibroma</b>
<b>XH8E66</b>	<b>Fibroma, NOS</b>
<b>XH2ZF3</b>	<b>Desmoplastic fibroblastoma</b>
<b>XH7GT0</b>	<b>Gardner fibroma</b>
<b>XH0XH6</b>	<b>Nuchal fibroma</b>
<b>XH2WT6</b>	<b>Plexiform fibromyxoma</b>
<b>XH0WB3</b>	<b>Fibroma of tendon sheath</b>
<b>XH8Q71</b>	<b>Solitary fibrous tumour/Haemangiopericytoma, grade 1</b>
<b>XH7TH6</b>	<b>Calcifying fibrous tumour</b>
<b>XH5LM1</b>	<b>Nodular fasciitis</b>
<b>XH1UJ5</b>	<b>Histiocytoma, NOS</b>
<b>XH8B90</b>	<b>Dermatofibroma, NOS</b>
	<i>Inclusions:</i>
	Subepidermal nodular fibrosis
	Dermatofibroma lenticulare
	Cutaneous histiocytoma, NOS
<b>XH7436</b>	<b>Sclerosing pneumocytoma</b>
<b>XH5DP4</b>	<b>Deep histiocytoma</b>
<b>XH9VG1</b>	<b>Juvenile histiocytoma</b>

XH33Q1	<b>Reticulohistiocytoma</b>
XH8ZE3	<b>Calcifying aponeurotic fibroma</b>
XH2874	<b>Collagenous fibroma</b>
XH3665	<b>Plaque-like CD34 positive dermal fibroma</b>
XH8173	<b>Acral fibromyxoma</b>
XH5JG7	<b>Sclerotic fibroma</b>
XH6JX7	<b>Proliferative fasciitis</b>
XH87F9	<b>Proliferative myositis</b>
XH15M9	<b>Epithelioid fibrous histiocytoma</b>
XH1BV2	<b>Pleomorphic fibroma</b>
XH18K3	<b>Dermatomyofibroma</b>
XH2HE9	<b>Myopericytoma</b>
XH5FY2	<b>Fibrous dysplasia</b>

Fibromatous neoplasms, malignant

XH8EV4	<b>Fascial fibrosarcoma</b>
XH6LT0	<b>Fibromyxosarcoma</b>
XH7BC6	<b>Infantile fibrosarcoma</b>
	<i>Inclusions:</i> Congenital fibrosarcoma
XH3406	<b>Periosteal fibrosarcoma</b>
XH56W2	<b>Periosteal sarcoma, NOS</b>
XH1HP3	<b>Solitary fibrous tumour, malignant</b>
XH4EP1	<b>Fibrosarcoma, NOS</b>
XH1DA3	<b>Solitary fibrous tumour/Haemangiopericytoma, grade 3</b>
XH2668	<b>Myofibroblastic sarcoma</b>
XH0947	<b>Malignant fibrous histiocytoma</b>
XH8WH0	<b>Myxofibrosarcoma</b>
XH9V92	<b>Dermatofibrosarcoma protuberans, fibrosarcomatous</b>

Fibromatous neoplasms, uncertain whether benign or malignant

XH6116	<b>Abdominal fibromatosis</b>
	<i>Inclusions:</i> Abdominal desmoid Mesenteric fibromatosis Retroperitoneal fibromatosis
XH13Z3	<b>Aggressive fibromatosis</b>
	<i>Inclusions:</i> Invasive fibroma Extra-abdominal desmoid Desmoid tumour, NOS Desmoid, NOS
XH1RM7	<b>Atypical fibrous histiocytoma</b>
	<i>Inclusions:</i> Atypical fibroxanthoma
XH9HH5	<b>Cellular fibroma</b>
XH5MH2	<b>Congenital generalised fibromatosis</b>
	<i>Inclusions:</i> Infantile myofibromatosis
XH85R1	<b>Myofibroblastic tumour, peribronchial</b>
XH1N00	<b>Myofibromatosis</b>
XH2D15	<b>Myxoinflammatory fibroblastic sarcoma</b>
XH0TA8	<b>Atypical myxoinflammatory fibroblastic tumour</b>
XH9526	<b>Haemosiderotic fibrolipomatous tumour</b>
XH75J5	<b>Palmar/plantar type fibromatosis</b>
XH7E62	<b>Solitary fibrous tumour, NOS</b>
XH1EH1	<b>Solitary fibrous tumour/Haemangiopericytoma, grade 2</b>
XH66Z0	<b>Myofibroblastic tumour, NOS</b>
XH6YK5	<b>Desmoplastic fibroma</b>
XH4QZ8	<b>Dermatofibrosarcoma protuberans, NOS</b>
XH5CT4	<b>Pigmented dermatofibrosarcoma protuberans</b>
XH9AV8	<b>Giant cell fibroblastoma</b>
XH4GL1	<b>Plexiform fibrohistiocytic tumour</b>
XH9362	<b>Angiomatoid fibrous histiocytoma</b>
XH7050	<b>Haemangiopericytic meningioma</b>

## Germ cell neoplasms

### Germ cell neoplasms, benign

- XH3GV5** **Teratoma, benign**
- XH9F67** **Dermoid cyst, NOS**  
*Inclusions:* Dermoid, NOS
- XH52Q4** **Teratoma, prepubertal type**  
*Inclusions:* Teratoma, mature, prepubertal type
- XH22M4** **Struma ovarii, NOS**

### Germ cell neoplasms, in situ

- XH8AD3** **Intratubular malignant germ cells**  
*Inclusions:* Germ cell neoplasia in situ  
Intratubular germ cell neoplasia

### Germ cell neoplasms, malignant

- XH24E0** **Dysgerminoma**
- XH0A34** **Germ cell tumour, nonseminomatous**
- XH1E13** **Germinoma**
- XH7SG5** **Hepatoid yolk sac tumour**
- XH0N49** **Immature teratoma, malignant**
- XH2PP9** **Malignant teratoma, undifferentiated**  
*Inclusions:* Malignant teratoma, anaplastic
- XH9Z28** **Polyembryoma**  
*Inclusions:* Embryonal carcinoma, polyembryonal type
- XH6YQ4** **Seminoma, anaplastic**  
*Inclusions:* Seminoma with high mitotic index
- XH80D1** **Spermatocytic seminoma**  
*Inclusions:* Spermatocytic tumour  
Spermatocytoma
- XH56W1** **Teratocarcinoma**  
*Inclusions:* Mixed embryonal carcinoma and teratoma

<b>XH09W7</b>	<b>Yolk sac tumour</b>
	<i>Inclusions:</i> Orchioblastoma Embryonal carcinoma, infantile Yolk sac tumor, NOS
<b>XH9FM4</b>	<b>Seminoma, NOS</b>
<b>XH8MB9</b>	<b>Embryonal carcinoma, NOS</b>
	<i>Inclusions:</i> Embryonal adenocarcinoma
<b>XH15X1</b>	<b>Yolk sac tumour, post pubertal type</b>
<b>XH7YZ9</b>	<b>Teratoma, malignant, NOS</b>
	<i>Inclusions:</i> Embryonal teratoma Teratoblastoma, malignant
<b>XH43T4</b>	<b>Malignant teratoma, intermediate</b>
<b>XH33E8</b>	<b>Teratoma with malignant transformation</b>
	<i>Inclusions:</i> Dermoid cyst with malignant transformation Teratoma with somatic-type malignancies
<b>XH2PS1</b>	<b>Mixed germ cell tumour</b>
<b>XH9QP9</b>	<b>Germ cell tumour with associated haematological malignancy</b>
<b>XH5U02</b>	<b>Mixed teratoma and seminoma</b>
<b>XH5PU7</b>	<b>Struma ovarii, malignant</b>
<b>XH1P78</b>	<b>Teratocarcinosarcoma</b>

Germ cell neoplasms, uncertain whether benign or malignant

<b>XH0K61</b>	<b>Gonadoblastoma</b>
	<i>Inclusions:</i> Gonocytoma
<b>XH83G5</b>	<b>Teratoma, NOS</b>
	<i>Inclusions:</i> Solid teratoma
<b>XH4NU1</b>	<b>Germ cell tumour, regressed</b>
<b>XH5MG2</b>	<b>Immature teratoma of the lung</b>
<b>XH2KP9</b>	<b>Immature teratoma of the thymus</b>
<b>XH2XW3</b>	<b>Strumal carcinoid</b>
	<i>Inclusions:</i> Struma ovarii and carcinoid
<b>XH5PC3</b>	<b>Immature teratoma of thyroid</b>

Giant cell tumours

Giant cell tumours, benign

- XH6911      **Tenosynovial giant cell tumour, localised**  
*Inclusions:*      Fibrous histiocytoma of tendon sheath
- XH0HZ1      **Tenosynovial giant cell tumour, NOS**

Giant cell tumours, malignant

- XH0492      **Giant cell tumour of bone, malignant**  
*Inclusions:*      Giant cell sarcoma of bone  
                          Osteoclastoma, malignant
- XH84X1      **Malignant giant cell tumour of soft parts**

Giant cell tumours, uncertain whether benign or malignant

- XH4TC2      **Giant cell tumour of bone, NOS**  
*Inclusions:*      Osteoclastoma, NOS
- XH81M1      **Giant cell tumour of soft parts, NOS**
- XH52J9      **Tenosynovial giant cell tumour, diffuse**  
*Inclusions:*      Pigmented villonodular synovitis
- XH5AQ9      **Malignant tenosynovial giant cell tumour**

Gliomas

**Coded Elsewhere:** CNS embryonal tumor with rhabdoid features (XH3AV2)

Gliomas, benign

- XH0RF9      **Choroid plexus papilloma, NOS**
- XH0H76      **Dysembryoplastic neuroepithelial tumour**
- XH1Q28      **Sellar ependymoma**

Gliomas, malignant

**Coded Elsewhere:** CNS embryonal tumor with rhabdoid features (XH3AV2)

- XH1DC5      **Astroblastoma**

<b>XH96C7</b>	<b>Astrocytoma, anaplastic</b>
	<i>Inclusions:</i> Astrocytoma, anaplastic, NOS
<b>XH1S63</b>	<b>Astrocytoma, low grade</b>
<b>XH54D9</b>	<b>Cellular ependymoma</b>
<b>XH3M77</b>	<b>Choroid plexus carcinoma</b>
	<i>Inclusions:</i> Choroid plexus papilloma, malignant
	Choroid plexus papilloma, anaplastic
<b>XH6E51</b>	<b>Clear cell ependymoma</b>
<b>XH8W32</b>	<b>Diffuse astrocytoma</b>
	<i>Inclusions:</i> Diffuse astrocytoma, NOS
<b>XH6UY7</b>	<b>Diffuse astrocytoma, low grade</b>
<b>XH6922</b>	<b>Ependymoma, anaplastic</b>
	<i>Inclusions:</i> Ependymoblastoma
<b>XH6C35</b>	<b>Fibrillary astrocytoma</b>
	<i>Inclusions:</i> Fibrous astrocytoma
<b>XH5Y81</b>	<b>Gemistocytic astrocytoma</b>
	<i>Inclusions:</i> Gemistocytoma
	Gemistocytic astrocytoma, NOS
<b>XH4RQ3</b>	<b>Glioma, malignant</b>
	<i>Inclusions:</i> Glioma, NOS
<b>XH6ZH4</b>	<b>Gliomatosis cerebri</b>
<b>XH9RC8</b>	<b>Gliosarcoma</b>
	<i>Inclusions:</i> Glioblastoma with sarcomatous component
<b>XH6F49</b>	<b>Oligoastrocytoma, NOS</b>
<b>XH9J28</b>	<b>Papillary ependymoma</b>
<b>XH99U2</b>	<b>Pleomorphic xanthoastrocytoma</b>
	<i>Inclusions:</i> Pleomorphic xanthoastrocytoma, NOS
<b>XH6UV4</b>	<b>Protoplasmic astrocytoma</b>
<b>XH4BJ4</b>	<b>Tanycytic ependymoma</b>
<b>XH7692</b>	<b>Diffuse midline glioma, H3 K27M-mutant</b>
<b>XH9YU2</b>	<b>Diffuse intrinsic pontine glioma, H3 K27M-mutant</b>

<b>XH1511</b>	<b>Ependymoma, NOS</b>
	<i>Inclusions:</i> Epithelial ependymoma
<b>XH2AY7</b>	<b>Ependymoma, RELA fusion-positive</b>
<b>XH6PH6</b>	<b>Astrocytoma, NOS</b>
	<i>Inclusions:</i> Astroglioma Astrocytic glioma
<b>XH36Y8</b>	<b>Cystic astrocytoma</b>
<b>XH2HK4</b>	<b>Diffuse astrocytoma, IDH-mutant</b>
<b>XH7HQ6</b>	<b>Astrocytoma, anaplastic, IDH-mutant</b>
<b>XH83Y5</b>	<b>Polar spongioblastoma</b>
	<i>Inclusions:</i> Spongioblastoma polare Primitive polar spongioblastoma
<b>XH8BK8</b>	<b>Anaplastic pleomorphic xanthoastrocytoma</b>
<b>XH7F82</b>	<b>Glioblastoma, NOS</b>
<b>XH5571</b>	<b>Glioblastoma, IDH-wild type</b>
<b>XH0MB1</b>	<b>Glioblastoma, primary, NOS</b>
	<i>Inclusions:</i> Spongioblastoma multiforme Glioblastoma multiforme
<b>XH3N49</b>	<b>Diffuse midline glioma, NOS</b>
<b>XH61Y5</b>	<b>Diffuse intrinsic pontine glioma</b>
<b>XH4FN3</b>	<b>Glioblastoma, IDH mutant</b>
	<i>Inclusions:</i> Glioblastoma, secondary, IDH-mutant
<b>XH17J4</b>	<b>Glioblastoma, secondary, NOS</b>
<b>XH7W59</b>	<b>Oligodendrogloma, NOS</b>
<b>XH7K31</b>	<b>Oligodendrogloma, IDH-mutant and 1p/19q co deleted</b>
<b>XH9QF3</b>	<b>Oligodendrogloma, anaplastic, IDH mutant and 1p/19q co deleted</b>
<b>XH7CX7</b>	<b>Oligodendroblastoma</b>
<b>XH8P29</b>	<b>Medulloblastoma, NOS</b>
<b>XH9M38</b>	<b>Medulloblastoma, SHH-activated and TP53-wild type</b>
<b>XH8844</b>	<b>Oligodendrogloma, anaplastic</b>
	<i>Inclusions:</i> Oligodendrogloma, anaplastic, NOS

XH4B47	<b>Melanotic medulloblastoma</b>
XH6JN6	<b>Medulloblastoma with extensive nodularity</b>
XH85M7	<b>Medulloblastoma, SHH activated, NOS</b>
XH8SH6	<b>CNS embryonal tumour, NOS</b>
XH89C3	<b>Central primitive neuroectodermal tumour</b> <i>Inclusions:</i> CPNET Central primitive neuroectodermal tumor,NOS
XH3EX1	<b>Medulloblastoma, WNT-activated, classic</b>
XH5163	<b>Medulloblastoma, WNT-activated, Large cell type</b>
XH2FW8	<b>Medulloblastoma, WNT-activated, Anaplastic type</b>
XH1SH4	<b>Medulloblastoma, SHH-activated and TP53-mutant</b>
XH87Q5	<b>Medulloblastoma, non-WNT/non-SHH</b>
XH51C5	<b>Embryonal tumours with multilayered rosettes with C19MC alteration</b>
XH0KZ2	<b>Embryonal tumour with multilayered rosettes, NOS</b>
XH5538	<b>Cerebellar sarcoma, NOS</b>
XH8R14	<b>Medullomyoblastoma</b>
XH7Y86	<b>Supratentorial PNET</b>
XH5PR7	<b>Large cell medulloblastoma</b>
XH0H95	<b>Anaplastic medulloblastoma</b>
XH8UC5	<b>Giant cell glioblastoma</b> <i>Inclusions:</i> Monstrocellular sarcoma
XH0RY1	<b>Classic medulloblastoma</b>
XH7PN5	<b>Desmoplastic nodular medulloblastoma</b>
XH3904	<b>Papillary tumour of the pineal region</b>
XH2C49	<b>Diffuse astrocytoma, IDH-wildtype</b>
XH2BA5	<b>Epithelioid glioblastoma</b>
XH0ZP6	<b>Medulloblastoma, WNT-activated, NOS</b>
XH5XD3	<b>Medulloblastoma, group 3</b>
XH25R4	<b>Medulloblastoma, group 4</b>
XH39Z7	<b>Astrocytoma, anaplastic, IDH-wildtype</b>

XH17F8	<b>Diffuse low-grade glioma, MAPK pathway-altered</b>
XH2SS9	<b>Diffuse hemispheric glioma, H3 G34-mutant</b>
XH4Q01	<b>Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype</b>
XH4ZM8	<b>Infant-type hemispheric glioma</b>
XH12D2	<b>Pilocytic astrocytoma</b>
XH29Q5	<b>Pilomyxoid astrocytoma</b>

Gliomas, uncertain whether benign or malignant

XH41C5	<b>Angiocentric glioma</b>
XH3Y57	<b>Atypical choroid plexus papilloma</b>
XH7M44	<b>Desmoplastic infantile astrocytoma</b>
XH6TQ7	<b>Desmoplastic infantile ganglioglioma</b>
XH0B58	<b>Gliofibroma</b>
XH6738	<b>Mixed subependymoma-ependymoma</b>
XH15U1	<b>Myxopapillary ependymoma</b>
XH1L48	<b>Subependymal giant cell astrocytoma</b>
XH8FZ9	<b>Subependymoma</b> <i>Inclusions:</i> Subependymal glioma Subependymal astrocytoma, NOS
XH59V4	<b>Pituicytoma</b>
XH9HV1	<b>Chordoid glioma</b>
XH4101	<b>Chordoid glioma of third ventricle</b>

Granular cell tumours and alveolar soft part sarcomas

Granular cell tumours and alveolar soft part sarcomas, benign

XH09A9	<b>Granular cell tumour, NOS</b>
	<i>Inclusions:</i> Granular cell myoblastoma, NOS
XH2XW8	<b>Granular cell tumour of the sellar region</b>

Granular cell tumours and alveolar soft part sarcomas, malignant

**XH8V95 Alveolar soft part sarcoma**

**XH90D3 Granular cell tumour, malignant**

*Inclusions:* Granular cell myoblastoma, malignant

Lipomatous neoplasms

Lipomatous neoplasms, benign

**XH2SJ1 Fibrolipoma**

**XH0PH8 Fibromyxolipoma**

*Inclusions:* Myxolipoma

**XH7TB0 Infiltrating angiolipoma**

**XH5GN5 Infiltrating lipoma**

**XH3TE0 Intramuscular lipoma**

**XH30M7 Pleomorphic lipoma**

**XH4E98 Spindle cell lipoma**

**XH1PL8 Lipoma, NOS**

**XH4G31 Thymolipoma**

**XH3C77 Angiolipoma, NOS**

**XH4VB4 Angiomyolipoma**

**XH7WX8 Chondroid lipoma**

**XH17C5 Myelolipoma**

**XH1054 Hibernoma**

*Inclusions:* Fetal fat cell lipoma

**XH8L55 Lipoblastomatosis**

*Inclusions:* Fetal lipoma, NOS

Fetal lipomatosis

Lipoblastoma

Lipomatous neoplasms, malignant

**XH1C03 Dedifferentiated liposarcoma**

XH6R46	<b>Fibroblastic liposarcoma</b>
XH7PE7	<b>Inflammatory liposarcoma</b>
XH7Y61	<b>Liposarcoma, well differentiated</b>
	<i>Inclusions:</i> Lipoma-like liposarcoma Liposarcoma, differentiated Liposarcoma, well differentiated, NOS
XH8VG3	<b>Mixed liposarcoma</b>
XH3EL0	<b>Myxoid liposarcoma</b>
	<i>Inclusions:</i> Myxoliposarcoma Round cell liposarcoma
XH25R1	<b>Pleomorphic liposarcoma</b>
XH8D43	<b>Sclerosing liposarcoma</b>
XH2J05	<b>Liposarcoma, NOS</b>
	<i>Inclusions:</i> Fibroliposarcoma

Lipomatous neoplasms, uncertain whether benign or malignant

XH0RW4	<b>Atypical lipomatous tumour</b>
XH4QB6	<b>Lipofibromatosis</b>
XH0QR3	<b>Angiomyolipoma, Epithelioid</b>

Lymphatic vessel tumours

Lymphatic vessel tumours, benign

XH9MR8	<b>Lymphangioma, NOS</b>
	<i>Inclusions:</i> Lymphangioendothelioma, NOS
XH6LF7	<b>Capillary lymphangioma</b>
XH2EU7	<b>Cavernous lymphangioma</b>
XH8G00	<b>Cystic lymphangioma</b>
	<i>Inclusions:</i> Cystic hygroma Hygroma, NOS
XH2DS9	<b>Lymphangiomyoma</b>
XH62A3	<b>Haemolymphangioma</b>

Lymphatic vessel tumours, malignant

**XH10U6 Lymphangiosarcoma**

*Inclusions:* Lymphangioendothelioma, malignant  
Lymphangioendothelial sarcoma

Lymphatic vessel tumours, uncertain whether benign or malignant

**XH10K6 Lymphangiomyomatosis**

*Inclusions:* Lymphangioleiomyomatosis

Meningiomas

Meningiomas, benign

**XH5ZC7 Fibrous meningioma**

*Inclusions:* Fibroblastic meningioma

**XH0R11 Lymphoplasmacyte-rich meningioma**

**XH11P5 Meningioma, NOS**

**XH40T5 Meningothelial meningioma**

*Inclusions:* Syncytial meningioma  
Endotheliomatous meningioma

**XH7N06 Metaplastic meningioma**

**XH1F70 Microcystic meningioma**

**XH6Z51 Secretory meningioma**

**XH3L73 Haemangioblastic meningioma**

*Inclusions:* Angioblastic meningioma

**XH4ZM7 Psammomatous meningioma**

**XH6L68 Angiomatous meningioma**

**XH4EX5 Transitional meningioma**

*Inclusions:* Mixed meningioma

Meningiomas, malignant

**XH0324 Meningioma, malignant**

*Inclusions:* Meningothelial sarcoma  
Meningioma, anaplastic  
Meningeal sarcoma  
Leptomeningeal sarcoma

**XH2NY9 Papillary meningioma**

**XH6QS9 Rhabdoid meningioma**

**XH5976 Meningeal sarcomatosis**

Meningiomas, uncertain whether benign or malignant

**XH71V9 Clear cell meningioma**

**XH2LS4 Chordoid meningioma**

**XH1PF6 Atypical meningioma**

Mesonephromas

Mesonephromas, benign

**XH3SX7 Adenoma of rete ovarii**

**XH5AH3 Mesonephroma, benign**

*Inclusions:* Mesonephric adenoma  
Wolffian duct adenoma

Mesonephromas, malignant

**XH71B5 Adenocarcinoma of rete ovarii**

**XH5WG5 Mesonephroma, malignant**

Mesonephromas, uncertain whether benign or malignant

**XH2WJ5 Wolffian tumour**

Mesothelial neoplasms

Mesothelial neoplasms, benign

- XH2VV6 Fibrous mesothelioma, benign**
- XH1SS1 Mesothelioma, benign**
- XH0KC4 Epithelioid mesothelioma, benign**
- XH67N8 Well differentiated papillary mesothelioma**
  - Inclusions:* Mesothelial papilloma
- XH8U12 Peritoneal inclusion cysts**
- XH6BY3 Adenomatoid tumour, NOS**

Mesothelial neoplasms, malignant

- XH54S8 Fibrous mesothelioma, malignant**
  - Inclusions:* Fibrous mesothelioma, NOS
  - Desmoplastic mesothelioma
  - Sarcomatoid mesothelioma
  - Spindled mesothelioma
- XH0XV0 Mesothelioma, malignant**
  - Inclusions:* Mesothelioma, NOS
- XH1DX8 Mesothelioma, biphasic, malignant**
  - Inclusions:* Mesothelioma, biphasic, NOS
- XH0VP5 Epithelioid mesothelioma, malignant**
  - Inclusions:* Epithelioid mesothelioma, NOS

Mesothelial neoplasms, uncertain whether benign or malignant

- XH85T6 Well differentiated papillary mesothelioma of the pleura**

Miscellaneous bone tumours

Miscellaneous bone tumours, benign

- XH6M86 Ossifying fibroma**
  - Inclusions:* Fibro-osteoma
  - Osteofibroma

**XH23E0 Aneurysmal bone cyst**

Miscellaneous bone tumours, malignant

**XH8F52 Adamantinoma of long bones**

*Inclusions:* Tibial adamantinoma

Miscellaneous tumours

Miscellaneous tumours, benign

**XH6C72 Melanotic neuroectodermal tumour**

*Inclusions:* Melanotic progonoma  
Melanoameloblastoma

**XH7MT7 Benign notochordal cell tumour**

**XH0S20 Parachordoma**

Miscellaneous tumours, malignant

**XH2S71 Mixed pineal tumour**

*Inclusions:* Mixed pineocytoma-pineoblastoma

**XH1S48 Pineal parenchymal tumour of intermediate differentiation**

**XH1ZH1 Pineoblastoma**

Pineoblastomas are a rare, malignant type of supratentorial primitive neuroectodermal tumour, found mainly in children (less than 10% of cases are reported in adults), located in the pineal region of the brain but that can metastasize along the neuroaxis. As they are the most aggressive of the pineal parenchymal tumours, they are usually associated with a poor prognosis.

**XH3D20 Transitional pineal tumour**

**XH7K24 Neuroectodermal tumour, NOS**

**XH6P76 Peripheral primitive neuroectodermal tumour**

**XH9GH0 Chordoma, NOS**

**XH8KJ8 Ewing sarcoma**

**XH0FH0 Askin tumour**

**XH17D8 Chondroid chordoma**

**XH7303 Dedifferentiated chordoma**

Miscellaneous tumours, uncertain whether benign or malignant

- XH1AZ2      Craniopharyngioma**
- XH15X9      Craniopharyngioma, adamantinomatous**
- XH2BF0      Craniopharyngioma, papillary**
- XH8QA9      Pinealoma**
- XH1K94      Pineocytoma**

Mucoepidermoid neoplasms

Mucoepidermoid neoplasms, malignant

- XH1J36      Mucoepidermoid carcinoma**

Mucoepidermoid neoplasms, uncertain whether benign or malignant

- XH80V3      Mucoepidermoid tumour**

Myomatous neoplasms

Myomatous neoplasms, benign

- XH7CL0      Angiomyoma**  
*Inclusions:*      Vascular leiomyoma  
                          Angioleiomyoma
- XH9824      Bizarre leiomyoma**  
*Inclusions:*      Atypical leiomyoma  
                          Pleomorphic leiomyoma  
                          Symplastic leiomyoma
- XH9662      Cellular leiomyoma**
- XH8S79      Epithelioid leiomyoma**  
*Inclusions:*      Leiomyoblastoma
- XH4729      Fetal rhabdomyoma**
- XH4FS5      Lipoleiomyoma**
- XH1CZ1      Myoma**
- XH4EP9      Plexiform leiomyoma**

XH4CY6	<b>Leiomyoma, NOS</b>
XH9CC7	<b>Myxoid leiomyoma</b>
XH8WG9	<b>Rhabdomyoma, NOS</b>
XH4BG5	<b>Adult cellular rhabdomyoma</b>
XH2736	<b>Glycogenic rhabdomyoma</b>
XH5AF2	<b>Genital rhabdomyoma</b>
XH8B88	<b>Leiomyoma, apoplectic</b>
XH5Z76	<b>Leiomyoma, hydropic</b>
XH5G84	<b>Cotyledonoid leiomyoma</b>
XH6GV7	<b>Myolipoma</b>

Myomatous neoplasms, malignant

XH27W3	<b>Angiomyosarcoma</b>
XH13Z5	<b>Epithelioid leiomyosarcoma</b>
XH7ED4	<b>Leiomyosarcoma, NOS</b>
XH08B3	<b>Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma</b>
XH6YL0	<b>Mixed type rhabdomyosarcoma</b>
XH8H07	<b>Myosarcoma</b>
XH3122	<b>Myxoid leiomyosarcoma</b>
XH5SX9	<b>Pleomorphic rhabdomyosarcoma, NOS</b>
	<i>Inclusions:</i> Rhabdomyosarcoma, pleomorphic type
XH4VB5	<b>Pleomorphic rhabdomyosarcoma, adult type</b>
XH0GA1	<b>Rhabdomyosarcoma, NOS</b>
	<i>Inclusions:</i> Rhabdosarcoma
XH83G1	<b>Embryonal rhabdomyosarcoma, NOS</b>
	<i>Inclusions:</i> Rhabdomyosarcoma, embryonal type
XH4749	<b>Embryonal rhabdomyosarcoma, pleomorphic</b>
XH7V57	<b>Sarcoma botryoides</b>
	<i>Inclusions:</i> Botryoid sarcoma

**XH7NM2** **Spindle cell rhabdomyosarcoma**  
*Inclusions:* Rhabdomyosarcoma, spindle cell/sclerosing type  
Sclerosing rhabdomyosarcoma

**XH7099** **Alveolar rhabdomyosarcoma**

**XH0S12** **Ectomesenchymoma**

Myomatous neoplasms, uncertain whether benign or malignant

**XH60C2** **Intravascular leiomyomatosis**

*Inclusions:* Intravenous leiomyomatosis

**XH2L80** **Leiomyomatosis, NOS**

**XH1EX8** **Metastasizing leiomyoma**

**XH1EN1** **Smooth muscle tumour of uncertain malignant potential**

**XH00B4** **Smooth muscle tumour, NOS**

**XH8MR2** **Leiomyomatosis, peritonealis disseminata**

**XH22N2** **Leiomyosarcoma, cutaneous**

Myxomatous neoplasms

Myxomatous neoplasms, benign

**XH6Q84** **Myxoma, NOS**

**XH9HK9** **Angiomyxoma**

**XH1DA7** **Ossifying fibromyxoid tumour**

*Inclusions:* Ossifying fibromyxoid tumour, NOS

**XH4V74** **Deep angiomyxoma**

**XH58A9** **Superficial angiomyxoma**

Myxomatous neoplasms, malignant

**XH4V76** **Low grade fibromyxoid sarcoma**

**XH4BT2** **Sclerosing epithelioid fibrosarcoma**

**XH3TB0** **Ossifying fibromyxoid tumour, malignant**

**XH51Y9** **Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation**

**XH5WF6      Myxosarcoma**

Nerve sheath tumours

Nerve sheath tumours, benign

- XH5T39      Acoustic neuroma**
- XH0U07      Ancient schwannoma**
- XH8WW8      Cellular schwannoma**
- XH75P8      Degenerated schwannoma**
- XH2GD5      Melanotic neurofibroma**
- XH87J5      Neurofibroma, NOS**
- XH2MJ4      Plexiform neurofibroma**  
*Inclusions:*      Plexiform neuroma
- XH9XT2      Plexiform schwannoma**
- XH9MN2      Psammomatous schwannoma**
- XH98Z3      Schwannoma, NOS**  
*Inclusions:*      Neurinoma  
                        Neurilemoma, NOS
- XH27Y1      Nerve sheath tumour, NOS**
- XH01G0      Hybrid nerve sheath tumour**
- XH4UE6      Neuroma, NOS**
- XH90Y8      Solitary circumscribed neuroma**
- XH0XF7      Perineurioma, NOS**
- XH3L35      Nerve sheath myxoma**
- XH9QH2      Soft tissue perineurioma**
- XH4BQ8      Intraneuronal perineurioma**
- XH1UZ6      Cellular neurothekeoma**
- XH9J01      Benign Triton tumour**

Nerve sheath tumours, malignant

XH2XP8	<b>Malignant peripheral nerve sheath tumour</b>
	<i>Inclusions:</i> Neurosarcoma
	Neurogenic sarcoma
	Neurofibrosarcoma
	MPNST, NOS
	Malignant peripheral nerve sheath tumor, NOS
XH5C30	<b>Melanotic MPNST</b>
XH3NT0	<b>Melanotic psammomatous MPNST</b>
XH8HF5	<b>MPNST with glandular differentiation</b>
XH7HR8	<b>MPNST with mesenchymal differentiation</b>
XH3W53	<b>MPNST with perineurial differentiation</b>
XH4V81	<b>Malignant peripheral nerve sheath tumour, epithelioid</b>
	<i>Inclusions:</i> Epithelioid MPNST
XH88C2	<b>Neurileoma, malignant</b>
	<i>Inclusions:</i> Malignant schwannoma, NOS
XH2VV8	<b>Malignant peripheral nerve sheath tumour with rhabdomyoblastic differentiation</b>
	<i>Inclusions:</i> MPNST with rhabdomyoblastic differentiation
	Malignant schwannoma with rhabdomyoblastic differentiation
XH31C8	<b>Perineurioma, malignant</b>
	<i>Inclusions:</i> Perineural MPNST

Nerve sheath tumours, uncertain whether benign or malignant

XH2637	<b>Melanotic schwannoma</b>
Neuroepitheliomatous neoplasms	
	Neuroepitheliomatous neoplasms, benign
XH6K00	<b>Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)</b>
XH6KA6	<b>Gangliocytoma</b>
	<i>Inclusions:</i> Gangliocytoma, NOS
XH03L9	<b>Ganglioneuroma</b>

<b>XH6LR5</b>	<b>Ganglioneuromatosis</b>
<b>XH28W9</b>	<b>Medulloepithelioma, benign</b>
	<i>Inclusions:</i> Diktyoma, benign
<b>XH8NQ6</b>	<b>Pacinian tumour</b>
<b>XH5AV1</b>	<b>Retinocytoma</b>
<b>XH5NR7</b>	<b>Teratoid medulloepithelioma, benign</b>

Neuroepitheliomatous neoplasms, malignant

<b>XH7ZQ4</b>	<b>Atypical teratoid/rhabdoid tumour</b>
<b>XH2GG3</b>	<b>Ganglioglioma, anaplastic</b>
<b>XH77W7</b>	<b>Ganglioneuroblastoma</b>
<b>XH0RB7</b>	<b>Ganglioneuroblastoma, intermixed</b>
<b>XH6JM6</b>	<b>Retinoblastoma, differentiated</b>
<b>XH49K9</b>	<b>Spongioneuroblastoma</b>
<b>XH0AM8</b>	<b>Teratoid medulloepithelioma</b>
	<i>Inclusions:</i> Teratoid medulloepithelioma, NOS
<b>XH70S0</b>	<b>CNS ganglioneuroblastoma</b>
<b>XH85Z0</b>	<b>Neuroblastoma, NOS</b>
	<i>Inclusions:</i> Sympathicoblastoma CNS neuroblastoma Central neuroblastoma
<b>XH2WK5</b>	<b>Medulloepithelioma, NOS</b>
	<i>Inclusions:</i> Diktyoma, malignant
<b>XH9FP2</b>	<b>Neuroepithelioma, NOS</b>
<b>XH8WC7</b>	<b>Retinoblastoma, NOS</b>
<b>XH7KP6</b>	<b>Retinoblastoma, undifferentiated</b>
<b>XH1YZ7</b>	<b>Retinoblastoma, diffuse</b>
<b>XH09A4</b>	<b>Olfactory neurogenic tumour</b>
<b>XH7QE0</b>	<b>Olfactory neurocytoma</b>
	<i>Inclusions:</i> Esthesioneurocytoma

<b>XH2Y49</b>	<b>Olfactory neuroepithelioma</b>
	<i>Inclusions:</i> Esthesioneuroepithelioma
<b>XH50L1</b>	<b>Olfactory neuroblastoma</b>
	<i>Inclusions:</i> Esthesioneuroblastoma

Neuroepitheliomatous neoplasms, uncertain whether benign or malignant

<b>XH0C11</b>	<b>Central neurocytoma</b>
	<i>Inclusions:</i> Neurocytoma, NOS
<b>XH2GB0</b>	<b>Cerebellar liponeurocytoma</b>
	<i>Inclusions:</i> Neurolipocytoma Medullocytoma Lipomatous medulloblastoma
<b>XH5FJ3</b>	<b>Ganglioglioma, NOS</b>
	<i>Inclusions:</i> Neuroastrocytoma Glioneuroma
<b>XH2HS1</b>	<b>Extraventricular neurocytoma</b>
<b>XH3XU4</b>	<b>Papillary glioneuronal tumour</b>
<b>XH2JU8</b>	<b>Rosette-forming glioneuronal tumour</b>
<b>XH2F27</b>	<b>Retinoblastoma, spontaneously regressed</b>

Nevi and melanomas

Nevi and melanomas, benign

<b>XH8RN4</b>	<b>Balloon cell naevus</b>
<b>XH27A6</b>	<b>Compound naevus</b>
	<i>Inclusions:</i> Dermal and epidermal naevus
<b>XH8WP0</b>	<b>Inflamed juvenile conjunctival naevus</b>
<b>XH6DN3</b>	<b>Diffuse melanocytosis</b>
<b>XH9035</b>	<b>Dysplastic naevus</b>
<b>XH2HG8</b>	<b>Epithelioid and spindle cell naevus</b>
<b>XH8ZB4</b>	<b>Hairy naevus</b>

<b>XH5971</b>	<b>Halo naevus</b>
	<i>Inclusions:</i> Regressing naevus
<b>XH2MQ5</b>	<b>Dermal naevus</b>
<b>XH1BE4</b>	<b>Magnocellular naevus</b>
<b>XH8CU4</b>	<b>Neuronevus</b>
<b>XH0XH2</b>	<b>Nonpigmented naevus</b>
	<i>Inclusions:</i> Achromic naevus
<b>XH4L78</b>	<b>Pigmented naevus, NOS</b>
<b>XH02Z5</b>	<b>Melanocytoma, NOS</b>
<b>XH8974</b>	<b>Meningeal melanocytosis</b>
<b>XH1M79</b>	<b>Junctional naevus, NOS</b>
	<i>Inclusions:</i> Intraepidermal naevus
	Junction naevus
<b>XH9QV1</b>	<b>Spindle cell naevus, NOS</b>
<b>XH7QJ7</b>	<b>Blue nevus, NOS</b>
	<i>Inclusions:</i> Jadassohn blue nevus
<b>XH2P88</b>	<b>Pigmented spindle cell naevus of Reed</b>
<b>XH79G6</b>	<b>Epithelioid cell naevus</b>
<b>XH3X84</b>	<b>Cellular blue naevus</b>
<b>XH40S8</b>	<b>Naevus spilus</b>
<b>XH81Y1</b>	<b>Deep penetrating naevus</b>
<b>XH0DU8</b>	<b>Combined naevus</b>
<b>XH5EL4</b>	<b>Genital naevus</b>
<b>XH8FS8</b>	<b>Conjunctival naevus</b>
<b>XH9QC8</b>	<b>Lentiginous melanocytic naevus</b>
<b>XH88L0</b>	<b>Simple lentigo</b>
<b>XH9DB2</b>	<b>Acral naevus</b>
<b>XH8NP4</b>	<b>Meyerson naevus</b>
<b>XH5YN0</b>	<b>Congenital melanocytic naevus, NOS</b>
<b>XH9WF4</b>	<b>Spitz naevus, atypical</b>

Nevi and melanomas, in situ

**XH9KY6      Lentigo maligna**

*Inclusions:*      Hutchinson melanotic freckle, NOS

**XH3XX3      Melanoma in situ**

**XH41F9      Precancerous melanosis, NOS**

Nevi and melanomas, malignant

**XH9L11      Acral melanoma**

**XH3TK1      Amelanotic melanoma**

**XH8TE3      Balloon cell melanoma**

**XH1P36      Desmoplastic melanoma, amelanotic**

**XH1Z15      Desmoplastic melanoma, NOS**

*Inclusions:*      Desmoplastic melanoma, malignant

**XH9NL4      Lentigo maligna melanoma**

*Inclusions:*      Malignant melanoma in Hutchinson melanotic freckle

**XH5L25      Malignant melanoma arising in giant congenital naevus**

**XH23B1      Malignant melanoma in junctional naevus**

**XH7L76      Malignant melanoma in precancerous melanosis**

**XH6XP3      Malignant melanoma, regressing**

**XH1BP7      Meningeal melanomatosis**

**XH5QP3      Mucosal lentiginous melanoma**

**XH5F94      Neurotropic melanoma, malignant**

**XH4QG5      Nodular melanoma**

**XH08X7      Superficial spreading melanoma**

**XH4846      Malignant melanoma, NOS**

*Inclusions:*      Melanoma, NOS

**XH25M1      Spindle cell melanoma, NOS**

**XH8HA2      Mixed epithelioid and spindle cell melanoma**

**XH0QL5      Epithelioid cell melanoma**

**XH5KW3      Spindle cell melanoma, type A**

<b>XH5YE7</b>	<b>Spindle cell melanoma, type B</b>
<b>XH1G74</b>	<b>Blue naevus, malignant</b>
<b>XH7JW1</b>	<b>Low cumulative sun damage melanoma</b>
<b>XH8DS3</b>	<b>Malignant Spitz tumour</b>
<b>XH3DN1</b>	<b>Melanoma, meningeal</b>
<b>XH8681</b>	<b>Nevoid melanoma</b>

Nevi and melanomas, uncertain whether benign or malignant

<b>XH2C28</b>	<b>Giant pigmented naevus, NOS</b>
<b>XH1XJ3</b>	<b>Intermediate and giant congenital naevus</b>
<b>XH2RY7</b>	<b>Meningeal melanocytoma</b>
<b>XH6AH3</b>	<b>Proliferative dermal lesion in congenital naevus</b>
<b>XH4VD0</b>	<b>Pigmented epithelioid melanocytoma</b>

Odontogenic tumours

Odontogenic tumours, benign

<b>XH2SD0</b>	<b>Adenomatoid odontogenic tumour</b>
	<i>Inclusions:</i> Adenoameloblastoma
<b>XH44W7</b>	<b>Ameloblastic fibro-odontoma</b>
	<i>Inclusions:</i> Fibroameloblastic odontoma
<b>XH0964</b>	<b>Ameloblastic fibrodentinoma</b>
	<i>Inclusions:</i> Dentinoma
<b>XH3R33</b>	<b>Calcifying odontogenic cyst</b>
<b>XH5Y46</b>	<b>Cementifying fibroma</b>
<b>XH52T0</b>	<b>Cemento-ossifying fibroma</b>
<b>XH4VL1</b>	<b>Cementoblastoma, benign</b>
<b>XH1MT3</b>	<b>Odontogenic fibroma, NOS</b>
	<i>Inclusions:</i> Central odontogenic fibroma
<b>XH7H47</b>	<b>Complex odontoma</b>
<b>XH57B1</b>	<b>Compound odontoma</b>

<b>XH6W94</b>	<b>Gigantiform cementoma</b>
	<i>Inclusions:</i> Florid osseous dysplasia
<b>XH06N8</b>	<b>Odontoameloblastoma</b>
<b>XH12N4</b>	<b>Dentinogenic ghost cell tumour</b>
<b>XH48L4</b>	<b>Odontogenic myxoma</b>
	<i>Inclusions:</i> Odontogenic myxofibroma
<b>XH43L1</b>	<b>Odontogenic tumour, benign</b>
<b>XH4PV9</b>	<b>Squamous odontogenic tumour</b>
<b>XH8FX0</b>	<b>Cementoma, NOS</b>
	<i>Inclusions:</i> Periapical cemental dysplasia
	Periapical cemento-osseous dysplasia
<b>XH4QJ8</b>	<b>Odontoma, NOS</b>
<b>XH1SV4</b>	<b>Ameloblastoma, NOS</b>
	<i>Inclusions:</i> Adamantinoma, NOS
<b>XH2M31</b>	<b>Peripheral odontogenic fibroma</b>
<b>XH06Y3</b>	<b>Ameloblastic fibroma</b>
<b>XH4PT4</b>	<b>Calcifying epithelial odontogenic tumour</b>
<b>XH39C5</b>	<b>Sinonasal ameloblastoma</b>
<b>XH5ZZ6</b>	<b>Ameloblastoma, unicystic type</b>
<b>XH4KQ4</b>	<b>Ameloblastoma, extraosseous/peripheral type</b>

### Odontogenic tumours, malignant

<b>XH1MW0</b>	<b>Ameloblastic odontosarcoma</b>
	<i>Inclusions:</i> Ameloblastic fibrodentinosarcoma
	Ameloblastic fibro-odontosarcoma
<b>XH96J9</b>	<b>Ameloblastoma, metastasizing</b>
<b>XH4M89</b>	<b>Odontogenic tumour, malignant</b>
	<i>Inclusions:</i> Primary intraosseous carcinoma
	Odontogenic sarcoma
	Odontogenic carcinoma
	Ameloblastic carcinoma

<b>XH0XD5</b>	<b>Ameloblastic fibrosarcoma</b>
	<i>Inclusions:</i>
	Ameloblastic sarcoma
	Odontogenic fibrosarcoma
<b>XH4LP1</b>	<b>Odontogenic carcinosarcoma</b>
<b>XH2BX2</b>	<b>Ghost cell odontogenic carcinoma</b>
<b>XH5DZ4</b>	<b>Clear cell odontogenic carcinoma</b>

Odontogenic tumours, uncertain whether benign or malignant

<b>XH1P03</b>	<b>Odontogenic tumour, NOS</b>
---------------	--------------------------------

Osseous and chondromatous neoplasms

Osseous and chondromatous neoplasms, benign

<b>XH9SY5</b>	<b>Enchondroma</b>
<b>XH5Y87</b>	<b>Osteochondroma</b>
	<i>Inclusions:</i>
	Osteocartilaginous exostosis
	Ecchondroma
	Cartilaginous exostosis
<b>XH4818</b>	<b>Osteoma, NOS</b>
<b>XH61J9</b>	<b>Osteoid osteoma, NOS</b>
<b>XH4316</b>	<b>Osteoblastoma, NOS</b>
	<i>Inclusions:</i>
	Giant osteoid osteoma
<b>XH6KR3</b>	<b>Osteochondromyxoma</b>
<b>XH23J5</b>	<b>Bizarre parosteal osteochondromatous proliferation</b>
<b>XH0NS4</b>	<b>Chondroma, NOS</b>
<b>XH49G1</b>	<b>Juxtacortical chondroma</b>
<b>XH3BC3</b>	<b>Periosteal chondroma</b>
<b>XH89S0</b>	<b>Chondromyxoid fibroma</b>
<b>XH1XL9</b>	<b>Subungual exostosis</b>

**Osseous and chondromatous neoplasms, malignant**

<b>XH1Y90</b>	<b>Central osteosarcoma</b>
	<i>Inclusions:</i> Medullary osteosarcoma Conventional central osteosarcoma Central osteosarcoma, NOS
<b>XH3T03</b>	<b>Chondroblastic osteosarcoma</b>
<b>XH23T4</b>	<b>Fibroblastic osteosarcoma</b>
	<i>Inclusions:</i> Osteofibrosarcoma
<b>XH29N8</b>	<b>Fibrochondrosarcoma</b>
<b>XH6TL0</b>	<b>High grade surface osteosarcoma</b>
<b>XH9LS2</b>	<b>Intracortical osteosarcoma</b>
<b>XH9119</b>	<b>Intraosseous well differentiated osteosarcoma</b>
	<i>Inclusions:</i> Intraosseous low grade osteosarcoma
<b>XH06W9</b>	<b>Osteosarcoma in Paget disease of bone</b>
	<i>Inclusions:</i> Secondary osteosarcoma
<b>XH8HG5</b>	<b>Parosteal osteosarcoma</b>
	<i>Inclusions:</i> Juxtacortical osteosarcoma
<b>XH48A9</b>	<b>Periosteal osteosarcoma</b>
<b>XH4EZ4</b>	<b>Small cell osteosarcoma</b>
	<i>Inclusions:</i> Round cell osteosarcoma
<b>XH5CL5</b>	<b>Telangiectatic osteosarcoma</b>
<b>XH1XF3</b>	<b>Osteosarcoma, NOS</b>
	<i>Inclusions:</i> Osteochondrosarcoma Osteoblastic sarcoma Osteogenic sarcoma, NOS
<b>XH2CD6</b>	<b>Osteosarcoma, extraskeletal</b>
<b>XH7N84</b>	<b>Low grade central osteosarcoma</b>
<b>XH8J23</b>	<b>Chondrosarcoma, NOS</b>
<b>XH6LT5</b>	<b>Chondrosarcoma, grade 2</b>
<b>XH0Y34</b>	<b>Chondrosarcoma, grade 3</b>
<b>XH5FH4</b>	<b>Juxtacortical chondrosarcoma</b>

<b>XH1S32</b>	<b>Periosteal chondrosarcoma</b>
<b>XH6W00</b>	<b>Chondroblastoma, malignant</b>
<b>XH9344</b>	<b>Myxoid chondrosarcoma</b>
<b>XH8X47</b>	<b>Mesenchymal chondrosarcoma</b>
<b>XH7XB9</b>	<b>Clear cell chondrosarcoma</b>
<b>XH6E77</b>	<b>Dedifferentiated chondrosarcoma</b>

Osseous and chondromatous neoplasms, uncertain whether benign or malignant

<b>XH2RD1</b>	<b>Aggressive osteoblastoma</b>
<b>XH70W8</b>	<b>Osteochondromatosis, NOS</b>
	<i>Inclusions:</i> Ecchondrosis
<b>XH5BT0</b>	<b>Chondromatosis, NOS</b>
<b>XH0FY0</b>	<b>Atypical cartilaginous tumour</b>
	<i>Inclusions:</i> Chondrosarcoma, grade 1
<b>XH4NK2</b>	<b>Chondroblastoma, NOS</b>

Paragangliomas and glomus tumours

Paragangliomas and glomus tumours, benign

**Coded Elsewhere:** Pheochromocytoma, NOS (XH3854)

<b>XH2012</b>	<b>Gangliocytic paraganglioma</b>
<b>XH47J2</b>	<b>Glomus tumour, NOS</b>
<b>XH4CC6</b>	<b>Perivascular epithelioid tumour, benign</b>
<b>XH3RX1</b>	<b>Glomangioma</b>
<b>XH2702</b>	<b>Glomangiomyoma</b>

Paragangliomas and glomus tumours, malignant

<b>XH9WD1</b>	<b>Perivascular epithelioid tumour, malignant</b>
<b>XH1UN6</b>	<b>Extra-adrenal paraganglioma</b>
<b>XH8GG7</b>	<b>Nonchromaffin paraganglioma</b>

<b>XH05Y1</b>	<b>Glomangiosarcoma</b>
	<i>Inclusions:</i> Glomoid sarcoma
<b>XH21E6</b>	<b>Glomus tumour, malignant</b>
<b>XH9YX6</b>	<b>Middle ear paraganglioma</b>
<b>XH5521</b>	<b>Laryngeal paraganglioma</b>
<b>XH1493</b>	<b>Vagal paraganglioma</b>
<b>XH3JF3</b>	<b>Composite paraganglioma</b>
<b>XH9K97</b>	<b>Composite pheochromocytoma</b>
<b>XH0EW6</b>	<b>Paraganglioma, NOS</b>
<b>XH4G21</b>	<b>Sympathetic paraganglioma</b>
<b>XH5LK3</b>	<b>Parasympathetic paraganglioma</b>
<b>XH7YU4</b>	<b>Aortic body tumour</b>
<b>XH3FS7</b>	<b>Carotid body paraganglioma</b>
<b>XH20B4</b>	<b>Chemodectoma</b>
<b>XH3854</b>	<b>Pheochromocytoma, NOS</b>

Paragangliomas and glomus tumours, uncertain whether benign or malignant

**Coded Elsewhere:** Aortic body tumour (XH7YU4)  
 Carotid body paraganglioma (XH3FS7)  
 Chemodectoma (XH20B4)  
 Paraganglioma, NOS (XH0EW6)  
 Parasympathetic paraganglioma (XH5LK3)  
 Sympathetic paraganglioma (XH4G21)

<b>XH7CP7</b>	<b>Glomangiomatosis</b>
<b>XH5D10</b>	<b>Glomus tumor of uncertain malignant potential</b>

Soft tissue tumours and sarcomas, NOS

Soft tissue tumours and sarcomas, NOS, benign

<b>XH67T7</b>	<b>Soft tissue tumour, benign</b>
---------------	-----------------------------------

Soft tissue tumours and sarcomas, NOS, malignant

XH4UM7	<b>Sarcoma, NOS</b>
	<i>Inclusions:</i> Soft tissue sarcoma
XH7Y17	<b>Sarcomatosis, NOS</b>
XH7AN8	<b>Spindle cell sarcoma</b>
XH73J4	<b>Giant cell sarcoma</b>
XH85G7	<b>Small cell sarcoma</b>
XH4F96	<b>Epithelioid sarcoma</b>
XH6HY6	<b>Undifferentiated sarcoma</b>
XH5SN6	<b>Desmoplastic small round cell tumour</b>
XH7XH3	<b>Pleomorphic dermal sarcoma</b>
XH92Y0	<b>Epithelioid sarcoma, undifferentiated</b>

Soft tissue tumours and sarcomas, NOS, uncertain whether benign or malignant

XH2193	<b>Pleomorphic hyalinizing angiectatic tumour</b>
XH52J1	<b>GLI1-altered epithelioid soft tissue tumor</b>

Specialized gonadal neoplasms

Specialized gonadal neoplasms, benign

XH7H87	<b>Androblastoma, benign</b>
	<i>Inclusions:</i> Arrhenoblastoma, benign
XH6NZ8	<b>Sclerosing stromal tumour</b>
XH0BG7	<b>Sertoli cell tumour with lipid storage</b>
	<i>Inclusions:</i> Folliculome lipidique
	Tubular androblastoma with lipid storage
XH7E53	<b>Sertoli-Leydig cell tumour, well differentiated</b>
XH0Z30	<b>Thecoma, luteinized</b>
XH3C14	<b>Sex cord-stromal tumour, benign</b>
XH69N5	<b>Signet-ring stromal tumour</b>
XH35B3	<b>Microcystic stromal tumour</b>

<b>XH34A0</b>	<b>Thecoma, NOS</b>
<b>XH40J2</b>	<b>Luteoma, NOS</b>
	<i>Inclusions:</i> Luteinoma
<b>XH2U25</b>	<b>Granulosa cell tumour of the testis, juvenile</b>
<b>XH5XQ2</b>	<b>Leydig cell tumour of the ovary, NOS</b>
	Change of term was Leydig cell, benign. Leydig cell NOS was 8650/1
<b>XH9LH4</b>	<b>Hilus cell tumour</b>
<b>XH9XY1</b>	<b>Lipid cell tumour of ovary</b>
<b>XH1PE9</b>	<b>Masculinovblastoma</b>
<b>XH9RV1</b>	<b>Adrenal rest tumour</b>

Specialized gonadal neoplasms, malignant

<b>XH44E8</b>	<b>Androblastoma, malignant</b>
	<i>Inclusions:</i> Arrhenoblastoma, malignant
<b>XH1QG7</b>	<b>Granulosa cell carcinoma</b>
<b>XH97Z8</b>	<b>Granulosa cell tumour, sarcomatoid</b>
<b>XH29E0</b>	<b>Sertoli-Leydig cell tumour, poorly differentiated</b>
<b>XH3BT2</b>	<b>Sertoli-Leydig cell tumour, poorly differentiated, with heterologous elements</b>
<b>XH4KB9</b>	<b>Sertoli-Leydig cell tumour, sarcomatoid</b>
<b>XH1JS6</b>	<b>Thecoma, malignant</b>
<b>XH0GA5</b>	<b>Adult granulosa cell tumor of ovary</b>
<b>XH7DV5</b>	<b>Granulosa cell tumour, adult type</b>
<b>XH9G68</b>	<b>Leydig cell tumour, malignant</b>
<b>XH4L39</b>	<b>Steroid cell tumour, malignant</b>
<b>XH7051</b>	<b>Sertoli cell carcinoma</b>

Specialized gonadal neoplasms, uncertain whether benign or malignant

<b>XH2KH2</b>	<b>Granulosa cell tumour, juvenile</b>
<b>XH37K7</b>	<b>Granulosa cell-theca cell tumour</b>
	<i>Inclusions:</i> Theca cell-granulosa cell tumour

XH0Q64	<b>Gynandroblastoma</b>
XH9E02	<b>Large cell calcifying Sertoli cell tumour</b>
XH0UP7	<b>Sertoli-Leydig cell tumour of intermediate differentiation</b> <i>Inclusions:</i> Sertoli-Leydig cell tumour, moderately differentiated Sertoli-Leydig cell tumor of intermediate differentiation, NOS
XH6FQ9	<b>Sertoli-Leydig cell tumour, NOS</b>
XH8U56	<b>Sertoli-Leydig cell tumour, intermediate differentiation, with heterologous elements</b>
XH6XB6	<b>Sertoli-Leydig cell tumour, retiform</b>
XH3PN1	<b>Sertoli-Leydig cell tumour, retiform, with heterologous elements</b>
XH5BV8	<b>Sex cord tumour with annular tubules</b>
XH5PC7	<b>Sex cord-gonadal stromal tumour, incompletely differentiated</b>
XH19F9	<b>Sex cord-gonadal stromal tumour, mixed forms</b> <i>Inclusions:</i> Sex cord-gonadal stromal tumour, mixed
XH9G57	<b>Sex cord-gonadal stromal tumour, NOS</b> <i>Inclusions:</i> Sex cord-stromal tumour, NOS
XH8033	<b>Stromal tumour with minor sex cord elements</b>
XH8CW8	<b>Uterine tumour resembling ovarian sex cord tumour</b>
XH0667	<b>Sex cord-stromal tumour, unclassified</b>
XH0U48	<b>Mixed germ cell-sex cord-stromal tumour, NOS</b>
XH27A8	<b>Mixed germ cell-sex cord-stromal tumour, unclassified</b>
XH5BN5	<b>Adult granulosa cell tumour of testis</b>
XH0GT2	<b>Androblastoma, NOS</b> <i>Inclusions:</i> Arrhenoblastoma, NOS
XH4H24	<b>Sertoli cell tumour, NOS</b> <i>Inclusions:</i> Testicular adenoma Pick tubular adenoma Tubular androblastoma, NOS Sertoli cell adenoma
XH7RD2	<b>Intratubular large cell hyalinizing Sertoli cell neoplasia</b>
XH51L7	<b>Leydig cell tumour of the testis, NOS</b> Change of behaviour, See 8650/0

Squamous cell neoplasms

Squamous cell neoplasms, benign

- XH17Q9      **Papilloma, NOS**
- XH7YQ5      **Squamous cell papilloma, inverted**
- XH50T2      **Squamous cell papilloma, NOS**  
*Inclusions:*      Squamous papilloma  
                          Keratotic papilloma
- XH4611      **Squamous intraepithelial neoplasia, low grade**
- XH50N3      **Squamous papillomatosis**  
*Inclusions:*      Papillomatosis, NOS
- XH2Y10      **Verrucous papilloma**
- XH9S34      **Anal intraepithelial neoplasia, low grade**
- XH1W63      **Cervical intraepithelial neoplasia, low grade**
- XH3Y37      **Oesophageal squamous intraepithelial neoplasia (dysplasia), low grade**
- XH0S03      **Benign keratosis, NOS**
- XH63L8      **Lichen planus-like keratosis**
- XH7AQ2      **Large cell acanthoma**
- XH36H6      **Actinic keratosis**
- XH8MN8      **PUVA keratosis**
- XH5NG4      **Arsenical keratosis**
- XH13L5      **Clear cell acanthoma**
- XH65S7      **Warty dyskeratoma**
- XH0949      **Seborrhoeic keratosis**
- XH7B58      **Solar lentigo**

Squamous cell neoplasms, in situ

- XH2NM8      **Bowen disease**  
*Inclusions:*      Intraepidermal squamous cell carcinoma, Bowen type
- XH9CL8      **Differentiated VIN**

<b>XH6824</b>	<b>Differentiated PeIN</b>
<b>XH4JA4</b>	<b>Papillary carcinoma in situ</b>
<b>XH8YK9</b>	<b>Papillary squamous cell carcinoma, non-invasive</b>
	<i>Inclusions:</i> Papillary squamous cell carcinoma in situ
<b>XH1U36</b>	<b>Squamous cell carcinoma in situ with questionable stromal invasion</b>
	<i>Inclusions:</i> Epidermoid carcinoma in situ with questionable stromal invasion
<b>XH7WM7</b>	<b>Squamous cell carcinoma in situ, NOS</b>
	<i>Inclusions:</i> Intraepithelial squamous cell carcinoma Intraepidermal carcinoma, NOS Epidermoid carcinoma in situ, NOS
<b>XH3EA2</b>	<b>Squamous intraepithelial neoplasia, high grade</b>
<b>XH7SX5</b>	<b>Anal intraepithelial neoplasia, grade III</b>
	<i>Inclusions:</i> AIN III
<b>XH62N8</b>	<b>Cervical intraepithelial neoplasia, grade III</b>
<b>XH9ND8</b>	<b>Oesophageal squamous intraepithelial neoplasia (dysplasia), high grade</b>
<b>XH6F63</b>	<b>Vaginal intraepithelial neoplasia, grade III</b>
	<i>Inclusions:</i> VAIN III
<b>XH5FT2</b>	<b>Vulvar intraepithelial neoplasia, grade III</b>
	<i>Inclusions:</i> VIN III
<b>XH2H04</b>	<b>Queyrat erythroplasia</b>
<b>XH6RW7</b>	<b>Differentiated intraepithelial neoplasia</b>

Squamous cell neoplasms, malignant

<b>XH3GS1</b>	<b>Basaloid squamous cell carcinoma</b>
<b>XH0UU4</b>	<b>Papillary carcinoma, NOS</b>
<b>XH6S97</b>	<b>Papillary squamous cell carcinoma</b>
	<i>Inclusions:</i> Papillary epidermoid carcinoma
<b>XH7LH0</b>	<b>Squamous cell carcinoma, adenoid</b>
	<i>Inclusions:</i> Squamous cell carcinoma, acantholytic Squamous cell carcinoma, pseudoglandular

<b>XH9DC1</b>	<b>Squamous cell carcinoma, clear cell type</b>
<b>XH4CR9</b>	<b>Squamous cell carcinoma, keratinizing, NOS</b>
	<i>Inclusions:</i> Squamous cell carcinoma, large cell, keratinizing Epidermoid carcinoma, keratinizing
<b>XH84Q4</b>	<b>Squamous cell carcinoma, metastatic, NOS</b>
<b>XH90Y3</b>	<b>Squamous cell carcinoma, microinvasive</b>
<b>XH0945</b>	<b>Squamous cell carcinoma, NOS</b>
<b>XH2435</b>	<b>Squamous cell carcinoma, small cell, nonkeratinizing</b>
	<i>Inclusions:</i> Epidermoid carcinoma, small cell, nonkeratinizing
<b>XH6D80</b>	<b>Squamous cell carcinoma, spindle cell</b>
	<i>Inclusions:</i> Epidermoid carcinoma, spindle cell Squamous cell carcinoma, sarcomatoid
<b>XH5PM0</b>	<b>Verrucous carcinoma, NOS</b>
	<i>Inclusions:</i> Verrucous squamous cell carcinoma Verrucous epidermoid carcinoma
<b>XH7UR7</b>	<b>Warty carcinoma</b>
	<i>Inclusions:</i> Condylomatous carcinoma
<b>XH6705</b>	<b>Squamous cell carcinoma, large cell, nonkeratinizing, NOS</b>
	<i>Inclusions:</i> Squamous cell carcinoma, nonkeratinizing, NOS Epidermoid carcinoma, large cell, nonkeratinizing
<b>XH2JN3</b>	<b>Squamous cell carcinoma with horn formation</b>
<b>XH1E40</b>	<b>Lymphoepithelial carcinoma</b>
	<i>Inclusions:</i> Lymphoepithelioma-like carcinoma Lymphoepithelioma
<b>XH4GV2</b>	<b>Schmincke tumour</b>
<b>XH0Z16</b>	<b>Pseudovascular squamous cell carcinoma</b>
<b>XH24M0</b>	<b>Papillary-basaloid carcinoma</b>
<b>XH0EJ7</b>	<b>Squamous cell carcinoma, HPV positive</b>
<b>XH2137</b>	<b>Squamous cell carcinoma, HPV negative</b>
<b>XH6FU0</b>	<b>Warty-basaloid carcinoma</b>
<b>XH9XR8</b>	<b>Keratoacanthoma</b>

Synovial-like neoplasms

Synovial-like neoplasms, benign

**XH2AW8      Synovioma, benign**

Synovial-like neoplasms, malignant

**XH9B22      Synovial sarcoma, NOS**

*Inclusions:*      Synovioma, NOS  
                         Synovioma, malignant

**XH77N6      Clear cell sarcoma, NOS**

**XH9346      Synovial sarcoma, spindle cell**

*Inclusions:*      Synovial sarcoma, monophasic fibrous

**XH06L8      Synovial sarcoma, epithelioid cell**

**XH1J28      Synovial sarcoma, biphasic**

**XH3797      Biphenotypic sinonasal sarcoma**

**XH5854      Malignant melanoma of soft parts**

A soft tissue sarcoma of young adults with melanocytic differentiation, typically involving tendons and aponeuroses. This tumour is unrelated to paediatric lesions currently known as clear cell sarcoma of the kidney.

Thymic epithelial neoplasms

Thymic epithelial neoplasms, benign

**XH9QW0      Microscopic thymoma**

**XH4341      Thymoma, benign**

**XH0707      Ectopic hamartomatous thymoma**

Thymic epithelial neoplasms, malignant

**XH6WN9      Thymoma, type A**

*Inclusions:*      Thymoma, medullary  
                         Thymoma, spindle cell

**XH0JH0      Thymoma, type AB**

*Inclusions:*      Thymoma, mixed type

<b>XH66U8</b>	<b>Thymoma, type B1</b>
	<i>Inclusions:</i>
	Thymoma, predominantly cortical
	Thymoma, organoid
	Thymoma, lymphocyte-rich
	Thymoma, lymphocytic
<b>XH2G89</b>	<b>Thymoma, type B2</b>
	<i>Inclusions:</i>
	Thymoma, cortical
<b>XH4EW9</b>	<b>Thymoma, type B3</b>
	<i>Inclusions:</i>
	Thymoma, atypical
	Thymoma, epithelial
	Well differentiated thymic carcinoma
<b>XH3734</b>	<b>Thymoma, NOS</b>
<b>XH1GA4</b>	<b>Intrapulmonary thymoma</b>
<b>XH6QN6</b>	<b>Sclerosing thymoma</b>
<b>XH3DX0</b>	<b>Metaplastic thymoma</b>
<b>XH6AK2</b>	<b>Thymic carcinoma, NOS</b>
	<i>Inclusions:</i>
	Thymoma, type C
<b>XH6ZG8</b>	<b>Spindle epithelial tumour with thymus-like element</b>
	<i>Inclusions:</i>
	SETTLE
<b>XH33N4</b>	<b>Intrathyroid thymic carcinoma</b>
	<i>Inclusions:</i>
	Carcinoma showing thymus-like differentiation
	CASTLE
	Carcinoma showing thymus-like element

Thymic epithelial neoplasms, uncertain whether benign or malignant

<b>XH56K5</b>	<b>Micronodular thymoma with lymphoid stroma</b>
---------------	--

Transitional cell papillomas and carcinomas

Transitional cell papillomas and carcinomas, benign

<b>XH0TP8</b>	<b>Sinonasal papilloma, exophytic</b>
---------------	---------------------------------------

<b>XH3HQ8</b>	<b>Transitional papilloma, inverted, NOS</b>
---------------	--

Change from 8121/1 to 8121/0 in ICD-O3 2016

**XH5A08      Urothelial papilloma, inverted**

**XH5M82      Urothelial papilloma, NOS**

Transitional cell papillomas and carcinomas, in situ

**XH12F0      Papillary urothelial carcinoma, non-invasive**

**XH5GH8      Urothelial carcinoma in situ**

Transitional cell papillomas and carcinomas, malignant

**XH4UA2      Cylindrical cell carcinoma**

**XH35M0      Schneiderian carcinoma**

**XH8EH1      Transitional cell carcinoma, NOS**

*Inclusions:*      Urothelial carcinoma, NOS

**XH7TL4      Transitional carcinoma**

**XH5P27      Urothelial carcinoma, sarcomatoid**

*Inclusions:*      Transitional cell carcinoma, sarcomatoid

Urothelial carcinoma, spindle cell

Transitional cell carcinoma, spindle cell

**XH0NZ4      Papillary urothelial carcinoma**

**XH08S6      Transitional cell carcinoma, micropapillary**

**XH3UJ1      Cloacogenic carcinoma**

**XH2V80      Basaloid carcinoma**

**XH4W76      Urothelial carcinoma, micropapillary**

Transitional cell papillomas and carcinomas, uncertain whether benign or malignant

**Coded Elsewhere:** Urothelial papilloma, NOS (XH5M82)

**XH7R01      Cylindrical cell papilloma**

**XH4PB5      Schneiderian papilloma, inverted**

**XH5UU5      Papillary urothelial neoplasm of low malignant potential**

**XH8FH7      Sinonasal papilloma, inverted**

**XH8CD4      Sinonasal papilloma, oncocytic**

Trophoblastic neoplasms

Trophoblastic neoplasms, benign

**XH8CX2      Hydatidiform mole, NOS**

*Inclusions:*      Complete hydatidiform mole  
                          Hydatid mole

**XH5325      Partial hydatidiform mole**

Trophoblastic neoplasms, malignant

**XH3WM1      Choriocarcinoma combined with other germ cell elements**

*Inclusions:*      Choriocarcinoma combined with embryonal carcinoma  
                          Choriocarcinoma combined with teratoma

**XH0774      Malignant teratoma, trophoblastic**

**XH8PK7      Choriocarcinoma, NOS**

*Inclusions:*      Chorioepithelioma  
                          Chorionepithelioma

**XH8FW3      Trophoblastic tumour, epithelioid**

Trophoblastic neoplasms, uncertain whether benign or malignant

**XH46G2      Invasive hydatidiform mole**

**XH1RM5      Placental site trophoblastic tumour**

Myelodysplastic syndromes

Myelodysplastic syndromes, malignant

**XH2N45      Myelodysplastic syndrome with single lineage dysplasia**

**XH5B21      Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia**

**XH79X8      Myelodysplastic syndrome with excess blasts**

**XH1D20      Refractory anaemia with excess blasts in transformation**

*Inclusions:*      RAEB-T

**XH5DA2      Myelodysplastic syndrome with multilineage dysplasia**

**XH3T02      Myelodysplastic syndrome with isolated del (5q)**

<b>XH0L58</b>	<b>Therapy-related myelodysplastic syndrome, NOS</b>
	<i>Inclusions:</i>
	Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related
	Therapy-related myelodysplastic syndrome, alkylating agent related
<b>XH7PK9</b>	<b>Myelodysplastic syndrome, NOS</b>
	<i>Inclusions:</i>
	Preleukemic syndrome
	Myelodysplastic syndrome, unclassifiable
<b>XH8BA8</b>	<b>Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia</b>

Other haematologic disorders

Other haematologic disorders, malignant

**Coded Elsewhere:** Polymorphic post transplant lymphoproliferative disorder (XH74K1)

<b>XH3EJ1</b>	<b>Myeloproliferative neoplasm, unclassifiable</b>
<b>XH28M3</b>	<b>Myelodysplastic/myeloproliferative neoplasm, unclassifiable</b>

Other haematologic disorders, uncertain whether benign or malignant

<b>XH2LK2</b>	<b>Lymphoproliferative disorder, NOS</b>
	<i>Inclusions:</i>
	Lymphoproliferative disease, NOS
<b>XH2R75</b>	<b>Post transplant lymphoproliferative disorder, NOS</b>
	<i>Inclusions:</i>
	PTLD, NOS
<b>XH74K1</b>	<b>Polymorphic post transplant lymphoproliferative disorder</b>

Chronic myeloproliferative disorders

Chronic myeloproliferative disorders, malignant

<b>XH0453</b>	<b>Polycythaemia vera</b>
	<i>Inclusions:</i>
	Chronic erythremia
<b>XH5HH7</b>	<b>Myeloproliferative neoplasm, NOS</b>
	<i>Inclusions:</i>
	Myeloproliferative disease, NOS
	Chronic myeloproliferative disorder
	Chronic myeloproliferative disease, NOS

<b>XH7GG7</b>	<b>Primary myelofibrosis</b>
	<i>Inclusions:</i>
	Myelosclerosis with myeloid metaplasia
	Myelofibrosis with myeloid metaplasia
	Myelofibrosis as a result of myeloproliferative disease
	Megakaryocytic myelosclerosis
	Chronic idiopathic myelofibrosis
	Agnogenic myeloid metaplasia
<b>XH4ZM5</b>	<b>Essential thrombocythemia</b>
	<i>Inclusions:</i>
	Idiopathic thrombocythemia
<b>XH5NQ7</b>	<b>Chronic neutrophilic leukaemia</b>
<b>XH51D2</b>	<b>Chronic eosinophilic leukaemia</b>
<b>XH07H5</b>	<b>Myeloid and lymphoid neoplasms with PDGFRA rearrangement</b>
<b>XH6QD4</b>	<b>Myeloid neoplasms with PDGFRB rearrangement</b>
<b>XH1WR8</b>	<b>Myeloid and lymphoid neoplasms with FGFR1 abnormalities</b>
<b>XH2WB4</b>	<b>Myeloid or lymphoid neoplasm with PCM1-JAK2</b>

## Leukaemias

leukaemias, NOS, malignant

<b>XH4S92</b>	<b>Leukaemia, NOS</b>
<b>XH29P0</b>	<b>Aleukemic leukaemia, NOS</b>
<b>XH80C3</b>	<b>Chronic leukaemia, NOS</b>
<b>XH6QV5</b>	<b>Subacute leukaemia, NOS</b>
<b>XH1B20</b>	<b>Acute leukaemia, NOS</b>
<b>XH37U0</b>	<b>Acute biphenotypic leukaemia</b>
<b>XH2H98</b>	<b>Acute bilineal leukaemia</b>
<b>XH3VV7</b>	<b>Acute mixed lineage leukaemia</b>
<b>XH97B7</b>	<b>Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1</b>
<b>XH2S51</b>	<b>Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged</b>
<b>XH1928</b>	<b>Mixed phenotype acute leukaemia, B/myeloid, NOS</b>
<b>XH4YB5</b>	<b>Mixed phenotype acute leukaemia, T/myeloid, NOS</b>

**Lymphoid leukaemias, malignant**

- XH81V3      **B lymphoblastic leukaemia/lymphoma, NOS**
- XH73L9      **B lymphoblastic leukaemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1**
- XH8GG0      **B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged**
- XH4KA2      **B lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)**
- XH24C7      **B lymphoblastic leukaemia/lymphoma with hyperdiploidy**
- XH2MD9      **B lymphoblastic leukaemia/lymphoma with hypodiploidy (Hypodiploid ALL)**
- XH4ZL2      **B lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32); IL3-IGH**
- XH3GU8      **B lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)**
- XH7Q12      **Lymphoid leukaemia, NOS**
- XH1GQ1      **Lymphatic leukaemia, NOS**
- XH7PW5      **Lymphocytic leukaemia, NOS**
- XH4KS4      **Aleukemic lymphoid leukaemia**
- XH5BA6      **Lymphosarcoma cell leukaemia**
- XH8GQ0      **Subacute lymphoid leukaemia**  
*Inclusions:*      Subacute lymphocytic Leukaemia  
                        Subacute lymphatic Leukaemia
- XH15T2      **B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma**
- XH6TE2      **Adult T-cell leukaemia/lymphoma (HTLV-1 positive)**  
*Inclusions:*      Adult T-cell lymphoma
- XH6687      **T-cell large granular lymphocytic leukaemia**  
*Inclusions:*      T-cell large granular lymphocytosis  
                        Large granular lymphocytosis, NOS
- XH5EN4      **Chronic lymphoproliferative disorder of NK cells**
- XH8TD6      **Prolymphocytic leukaemia, NOS**
- XH95H2      **Prolymphocytic leukaemia, B-cell type**
- XH0DU4      **Prolymphocytic leukaemia, T-cell type**

XH5J37	<b>Precursor cell lymphoblastic leukaemia, NOS</b>
	<i>Inclusions:</i> FAB L2 FAB L1
XH7T28	<b>Precursor T-cell lymphoblastic leukaemia</b>
XH50W7	<b>T lymphoblastic leukaemia/lymphoma</b>
XH1D04	<b>B lymphoblastic leukemia/lymphoma, BCR-ABL1-like</b>
XH0KD4	<b>B lymphoblastic leukemia/lymphoma with iAMP21</b>
XH8F29	<b>Early T-cell precursor acute lymphoblastic leukemia</b>
Myeloid leukaemias, malignant	
XH43N4	<b>Acute erythroid leukemia</b>
XH7S21	<b>Myeloid leukaemia, NOS</b>
XH7LG8	<b>Aleukemic myeloid leukaemia</b>
XH5DV4	<b>Aleukemic monocytic leukaemia</b>
XH0E35	<b>Chronic monocytic leukaemia</b>
XH6JX2	<b>Eosinophilic leukaemia</b>
XH5JT8	<b>Monocytic leukaemia, NOS</b>
XH1S60	<b>Subacute monocytic leukaemia</b>
XH7DF6	<b>Subacute myeloid leukaemia</b>
XH8AA5	<b>Acute myeloid leukaemia, NOS</b>
XH4M02	<b>Acute myeloid leukemia with biallelic mutation of CEBPA</b>
XH74W8	<b>Acute myeloid leukaemia with mutated NPM1</b>
XH4XG8	<b>Chronic myeloid leukaemia, NOS</b>
XH9Y46	<b>Acute myeloid leukaemia with t(6;9)(p23;q34); DEK-NUP214</b>
XH1A50	<b>Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)</b>
	<i>Inclusions:</i> FAB M3
XH78Y4	<b>Acute myelomonocytic leukaemia</b>
XH2KE3	<b>Acute myeloid leukaemia with inv(3)(q21;q26.2) or t(3.3)(q21;q26.2); RPN1-EVI1</b>
XH7MR1	<b>Acute basophilic leukaemia</b>

<b>XH3PA4</b>	<b>Acute myeloid leukaemia with abnormal marrow eosinophils</b>
	<i>Inclusions:</i> FAB M4Eo
<b>XH90G0</b>	<b>Acute myeloid leukaemia, minimal differentiation</b>
	<i>Inclusions:</i> FAB M0
<b>XH5AH8</b>	<b>Acute myeloid leukaemia without maturation</b>
	<i>Inclusions:</i> FAB M1
<b>XH1XJ9</b>	<b>Acute myeloid leukaemia with maturation</b>
	<i>Inclusions:</i> FAB M2, NOS
<b>XH2AB7</b>	<b>Chronic myelogenous leukaemia, BCR/ABL positive</b>
<b>XH21X5</b>	<b>Atypical chronic myeloid leukaemia, BCR/ABL negative</b>
<b>XH26U9</b>	<b>Atypical chronic myeloid leukaemia, Philadelphia chromosome (Ph1) negative</b>
<b>XH9NE2</b>	<b>Acute monocytic leukaemia</b>
	<i>Inclusions:</i> FAB M5
<b>XH1K97</b>	<b>Acute monoblastic and monocytic leukaemia</b>
<b>XH64R4</b>	<b>Acute myeloid leukaemia with myelodysplasia-related changes</b>
<b>XH3CX5</b>	<b>Acute myeloid leukaemia, t(8;21)(q22;q22)</b>
	<i>Inclusions:</i> FAB M2, AML1(CBF-alpha)/ETO
	FAB M2, t(8;21)(q22;q22)
<b>XH1E41</b>	<b>Acute myeloid leukaemia, 11q23 abnormalities</b>
<b>XH6AQ7</b>	<b>Myeloid leukaemia associated with Down Syndrome</b>
<b>XH4750</b>	<b>Acute megakaryoblastic leukaemia</b>
	<i>Inclusions:</i> FAB M7
<b>XH16K4</b>	<b>Acute myeloid leukaemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1</b>
<b>XH7045</b>	<b>Therapy related myeloid neoplasm</b>
<b>XH6Z50</b>	<b>Therapy-related acute myeloid leukaemia, alkylating agent related</b>
<b>XH4EJ0</b>	<b>Therapy-related acute myeloid leukaemia, epipodophyllotoxin-related</b>
<b>XH3L40</b>	<b>Myeloid sarcoma</b>
	<i>Inclusions:</i> Granulocytic sarcoma
	Chloroma

<b>XH1075</b>	<b>Acute panmyelosis with myelofibrosis</b>
<i>Inclusions:</i>	Acute myelosclerosis, NOS Acute panmyelosis, NOS Acute myelofibrosis Malignant myelosclerosis
<b>XH6FZ7</b>	<b>Acute myeloid leukemia with BCR-ABL1</b>
<b>XH1EK4</b>	<b>Acute myeloid leukemia with mutated RUNX1</b>

Myeloid leukaemias, uncertain whether benign or malignant

<b>XH67W4</b>	<b>Transient abnormal myelopoiesis</b>
---------------	--

Other leukaemias, malignant

<b>XH86N4</b>	<b>Chronic myelomonocytic leukaemia, NOS</b>
<b>XH0FC4</b>	<b>Chronic myelomonocytic leukaemia, Type I</b>
<b>XH7HJ7</b>	<b>Chronic myelomonocytic leukaemia, Type II</b>
<b>XH4QZ1</b>	<b>Juvenile myelomonocytic leukaemia</b>
<b>XH9MA0</b>	<b>Aggressive NK-cell leukaemia</b>
<b>XH5J10</b>	<b>Hairy cell leukaemia</b>
<i>Inclusions:</i>	Leukemic reticuloendotheliosis Hairy cell leukemia, NOS

Hodgkin and non-Hodgkin lymphomas

Malignant lymphomas, NOS or diffuse

<b>XH5FJ5</b>	<b>Malignant lymphoma, NOS</b>
<i>Inclusions:</i>	Lymphoma, NOS Microglioma
<b>XH50P3</b>	<b>Malignant lymphoma, non-Hodgkin, NOS</b>
<i>Inclusions:</i>	Non-Hodgkin lymphoma, NOS
<b>XH5RG7</b>	<b>B cell lymphoma, NOS</b>
<b>XH9MU1</b>	<b>Lymphosarcoma, NOS</b>
<i>Inclusions:</i>	Lymphosarcoma, diffuse
<b>XH8226</b>	<b>Malignant lymphoma, diffuse, NOS</b>

<b>XH5WX8</b>	<b>Malignant lymphoma, non-cleaved cell, NOS</b>
<b>XH51A9</b>	<b>Reticulum cell sarcoma, NOS</b>
	<i>Inclusions:</i> Reticulosarcoma, NOS Reticulum cell sarcoma, diffuse Reticulosarcoma, diffuse
<b>XH9E18</b>	<b>Hairy cell leukaemia variant</b>
<b>XH1SK1</b>	<b>Malignant lymphoma, lymphocytic, intermediate differentiation, nodular</b>
<b>XH06Q4</b>	<b>Malignant lymphoma, lymphocytic, poorly differentiated, diffuse</b>
	<i>Inclusions:</i> Malignant lymphoma, cleaved cell, NOS Malignant lymphoma, small cleaved cell, NOS
<b>XH9PT6</b>	<b>Malignant lymphoma, small cell, noncleaved, diffuse</b>
	<i>Inclusions:</i> Malignant lymphoma, undifferentiated cell type, NOS Malignant lymphoma, undifferentiated cell, non-Burkitt
<b>XH2TN1</b>	<b>Malignant lymphoma, small cleaved cell, diffuse</b>
<b>XH75T5</b>	<b>Splenic B-cell lymphoma/leukaemia, unclassifiable</b>
<b>XH99V9</b>	<b>Splenic diffuse red pulp small B-cell lymphoma</b>
<b>XH3BP6</b>	<b>Composite Hodgkin and non-Hodgkin lymphoma</b>
<b>XH04Y1</b>	<b>B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma</b>
<b>XH1FZ7</b>	<b>Primary cutaneous follicle centre lymphoma</b>
<b>XH73D5</b>	<b>Monoclonal B-cell lymphocytosis, NOS</b>
<b>XH5M35</b>	<b>Monoclonal B-cell lymphocytosis, non-CLL type</b>

## Hodgkin lymphoma

<b>XH94F7</b>	<b>Hodgkin lymphoma, NOS</b>
	<i>Inclusions:</i> Hodgkin disease, NOS Malignant lymphoma, Hodgkin
<b>XH22K3</b>	<b>Classical Hodgkin lymphoma post-transplant lymphoproliferative disease</b>
<b>XH8CB2</b>	<b>Hodgkin lymphoma, lymphocyte-rich</b>
	<i>Inclusions:</i> Classical Hodgkin lymphoma, lymphocyte-rich

<b>XH7KX4</b>	<b>Hodgkin disease, lymphocyte predominance, NOS</b>
	<i>Inclusions:</i> Hodgkin disease, lymphocyte predominance, diffuse Hodgkin disease, lymphocytic-histiocytic predominance
<b>XH9NJ5</b>	<b>Hodgkin lymphoma, mixed cellularity, NOS</b>
	<i>Inclusions:</i> Classical Hodgkin lymphoma, mixed cellularity, NOS
<b>XH7RN9</b>	<b>Hodgkin lymphoma, lymphocyte depletion, NOS</b>
	<i>Inclusions:</i> Classical Hodgkin lymphoma, lymphocyte depletion, NOS
<b>XH7299</b>	<b>Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis</b>
	<i>Inclusions:</i> Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis
<b>XH4E19</b>	<b>Hodgkin lymphoma, lymphocyte depletion, reticular</b>
	<i>Inclusions:</i> Classical Hodgkin lymphoma, lymphocyte depletion, reticular
<b>XH2FG7</b>	<b>Hodgkin lymphoma, nodular lymphocyte predominant</b>
	<i>Inclusions:</i> Hodgkin paragranuloma, nodular Hodgkin paragranuloma, NOS Hodgkin lymphoma, lymphocyte predominance, nodular
<b>XH13B0</b>	<b>Hodgkin granuloma</b>
<b>XH11Y2</b>	<b>Hodgkin sarcoma</b>
<b>XH6SC5</b>	<b>Hodgkin lymphoma, nodular sclerosis, NOS</b>
	<i>Inclusions:</i> Classical Hodgkin lymphoma, nodular sclerosis, NOS Hodgkin disease, nodular sclerosis, NOS
<b>XH51K7</b>	<b>Hodgkin lymphoma, nodular sclerosis, cellular phase</b>
	<i>Inclusions:</i> Classical Hodgkin lymphoma, nodular sclerosis, cellular phase
<b>XH62T3</b>	<b>Hodgkin lymphoma, nodular sclerosis, grade 1</b>
	<i>Inclusions:</i> Classical Hodgkin lymphoma, nodular sclerosis, grade 1 Hodgkin disease, nodular sclerosis, lymphocyte predominance Hodgkin disease, nodular sclerosis, mixed cellularity
<b>XH8K28</b>	<b>Hodgkin lymphoma, nodular sclerosis, grade 2</b>
	<i>Inclusions:</i> Classical Hodgkin lymphoma, nodular sclerosis, grade 2 Hodgkin disease, nodular sclerosis, lymphocyte depletion Hodgkin disease, nodular sclerosis, syncytial variant

## Non-Hodgkin lymphomas

XH3FE9	<b>Mature B-cell lymphomas</b>
	<i>Coded Elsewhere:</i> Intravascular large B-cell lymphoma (XH50S7)
XH0QZ9	<b>Lymphoplasmacytic lymphoma</b>
XH43K4	<b>Immunocytoma</b>
XH9TT4	<b>Malignant lymphoma, plasmacytoid</b>
XH3KQ3	<b>Plasmacytic lymphoma</b>
XH1VV1	<b>Mantle cell lymphoma</b>
XH1J80	<b>Malignant lymphoma, mixed small and large cell, diffuse</b>
	<i>Inclusions:</i> Malignant lymphoma, centroblastic-centrocytic, NOS
	Malignant lymphoma, centroblastic-centrocytic, diffuse
	Malignant lymphoma, mixed cell type, diffuse
	Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse
XH2LN1	<b>Primary effusion lymphoma</b>
XH8U09	<b>Mediastinal large B-cell lymphoma</b>
	<i>Inclusions:</i> Thymic large B-cell lymphoma
XH9B17	<b>Diffuse large B-cell lymphoma, NOS</b>
XH0RM6	Fibrin-associated EBV+ diffuse large B-cell lymphoma
XH1VQ1	<b>Malignant lymphoma, centroblastic, NOS</b>
XH9JY8	<b>Malignant lymphoma, centroblastic, diffuse</b>
XH78W3	<b>Anaplastic large B-cell lymphoma</b>
XH9L43	<b>B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma</b>
XH3N15	<b>Diffuse large B-cell lymphoma associated with chronic inflammation</b>
XH1QK0	<b>EBV positive diffuse large B-cell lymphoma</b>
XH8657	<b>Primary cutaneous DLBCL, leg type</b>
XH2MP0	<b>Primary diffuse large B-cell lymphoma of CNS</b>
XH2WM7	<b>High grade B-cell lymphoma, NOS</b>
XH23Z3	<b>High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements</b>
XH86B5	<b>Vitreoretinal lymphoma</b>

<b>XH7Z25</b>	<b>Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS</b>
	<i>Inclusions:</i>
	Malignant lymphoma, immunoblastic, NOS
	Immunoblastic sarcoma
	Malignant lymphoma, large cell, immunoblastic
<b>XH4KA9</b>	<b>Burkitt lymphoma, NOS</b>
<b>XH0H23</b>	<b>Burkitt-like lymphoma</b>
<b>XH8NN2</b>	<b>Burkitt-like lymphoma with 11q aberration</b>
<b>XH6B12</b>	Burkitt cell leukaemia
<b>XH0WP6</b>	<b>T-cell/histiocyte rich large B-cell lymphoma</b>
<b>XH0MV1</b>	<b>Splenic marginal zone B-cell lymphoma</b>
	<i>Inclusions:</i>
	Splenic marginal zone lymphoma, NOS
	Splenic lymphoma with villous lymphocytes
<b>XH0LK1</b>	<b>Follicular lymphoma, NOS</b>
	<i>Inclusions:</i>
	Malignant lymphoma, centroblastic-centrocytic, follicular
	Malignant lymphoma, nodular, NOS
	Malignant lymphoma, lymphocytic, nodular, NOS
	Malignant lymphoma, follicular, NOS
<b>XH9RH9</b>	<b>Follicular lymphoma, pediatric type</b>
<b>XH79L3</b>	<b>Follicular lymphoma, grade 2</b>
	<i>Inclusions:</i>
	Malignant lymphoma, mixed cell type, follicular
	Malignant lymphoma, mixed cell type, nodular
	Malignant lymphoma, mixed lymphocytic-histiocytic, nodular
	Malignant lymphoma, mixed small cleaved and large cell, follicular
<b>XH6Y69</b>	<b>Follicular lymphoma, grade 1</b>
	<i>Inclusions:</i>
	Follicular lymphoma, small cleaved cell
	Malignant lymphoma, lymphocytic, poorly differentiated, nodular
	Malignant lymphoma, small cleaved cell, follicular
<b>XH9L76</b>	<b>Follicular lymphoma, duodenal type</b>

<b>XH6RN1</b>	<b>Follicular lymphoma, grade 3</b>
	<i>Inclusions:</i>
	Malignant lymphoma, large cell, follicular, NOS
	Malignant lymphoma, noncleaved cell, follicular, NOS
	Follicular lymphoma, grade 3A
	Follicular lymphoma, grade 3B
	Malignant lymphoma, centroblastic, follicular
	Malignant lymphoma, histiocytic, nodular
	Malignant lymphoma, large cell, noncleaved, follicular
	Malignant lymphoma, large cleaved cell, follicular
	Malignant lymphoma, lymphocytic, well differentiated, nodular
<b>XH6SU8</b>	<b>Large B-cell lymphoma with IRF4 rearrangement</b>
<b>XH1X21</b>	<b>Marginal zone B-cell lymphoma, NOS</b>
<b>XH1V99</b>	<b>Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue</b>
<b>XH6JB5</b>	<b>Primary choroidal lymphoma</b>
<b>XH8EM2</b>	<b>In situ mantle cell neoplasia</b>
<b>XH3SG2</b>	<b>EBV positive mucocutaneous ulcer</b>
<b>XH4L38</b>	<b>In situ follicular neoplasia</b>
<b>XH3400</b>	<b>Mature T- and NK-cell lymphomas</b>
<b>XH8R56</b>	<b>Mycosis fungoides</b>
	<i>Inclusions:</i>
	Pagetoid reticulosis
<b>XH0EH1</b>	<b>Granulomatous slack skin</b>
<b>XH8HN3</b>	<b>Sezary syndrome</b>
	<i>Inclusions:</i>
	Sezary disease
<b>XH3HJ2</b>	<b>Mature T-cell lymphoma, NOS</b>
	<i>Inclusions:</i>
	T-zone lymphoma
	Peripheral T-cell lymphoma, pleomorphic small cell
	Peripheral T-cell lymphoma, pleomorphic medium and large cell
	Peripheral T-cell lymphoma, large cell
	T-cell lymphoma, NOS
	Peripheral T-cell lymphoma, NOS
<b>XH92G2</b>	<b>Lymphoepithelioid lymphoma</b>
	<i>Inclusions:</i>
	Lennert lymphoma
<b>XH14S3</b>	<b>Follicular T-cell lymphoma</b>
<b>XH6SR1</b>	<b>Nodal peripheral T-cell lymphoma with T follicular helper phenotype</b>

<b>XH1J86</b>	<b>Angioimmunoblastic T-cell lymphoma</b>
	<i>Inclusions:</i> Angioimmunoblastic lymphoma
<b>XH3NV1</b>	<b>Subcutaneous panniculitis-like T-cell lymphoma</b>
<b>XH1951</b>	<b>Cutaneous T-cell lymphoma, NOS</b>
	<i>Inclusions:</i> Cutaneous lymphoma, NOS
<b>XH2513</b>	<b>Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma</b>
<b>XH7S84</b>	<b>Primary cutaneous acral CD8 positive T-cell lymphoma</b>
<b>XH7EZ9</b>	<b>Anaplastic large cell lymphoma, T cell and Null cell type</b>
<b>XH1LC0</b>	<b>Anaplastic large cell lymphoma, NOS</b>
<b>XH9484</b>	<b>Anaplastic large cell lymphoma, ALK positive</b>
<b>XH8D49</b>	<b>Hepatosplenic T-cell lymphoma</b>
	<i>Inclusions:</i> Hepatosplenic gamma-delta cell lymphoma
<b>XH9FT0</b>	<b>Intestinal T-cell lymphoma</b>
	<i>Inclusions:</i> Enteropathy associated T-cell lymphoma
	Enteropathy type intestinal T-cell lymphoma
<b>XH1AG7</b>	<b>Monomorphic epitheliotropic intestinal T-cell lymphoma</b>
<b>XH5SC3</b>	<b>Primary cutaneous anaplastic large cell lymphoma</b>
	<i>Inclusions:</i> Primary cutaneous CD30 positive large T-cell lymphoma
<b>XH0353</b>	<b>Primary mucosal CD30+ T-cell lymphoproliferative disorder</b>
<b>XH5LU6</b>	<b>NK/T-cell lymphoma, nasal and nasal-type</b>
	<i>Inclusions:</i>
	T/NK-cell lymphoma
	Malignant midline reticulosis
	Polymorphic reticulosis
	Extranodal NK/T-cell lymphoma, nasal type
	Angiocentric T-cell lymphoma
	Malignant reticulosis, NOS
<b>XH0B02</b>	<b>Indolent T-cell lymphoproliferative disorder of gastrointestinal tract</b>
<b>XH3QE7</b>	<b>Primary cutaneous CD4 positive small/medium T-cell lymphoproliferative disorder</b>
<b>XH7EL2</b>	<b>Primary cutaneous CD4-positive small/medium T-cell lymphoma</b>
<b>XH50S7</b>	<b>Intravascular large B-cell lymphoma</b>
<b>XH9T74</b>	<b>Anaplastic large cell lymphoma, ALK negative</b>
<b>XH05D8</b>	<b>Breast implant-associated anaplastic large cell lymphoma</b>

XH40C0	<b>Primary cutaneous CD30+ T-cell lymphoproliferative disorder</b>
<b>XH2216</b>	<b>Precursor cell lymphoblastic lymphoma</b>
XH6TZ4	<b>Systemic EBV positive T-cell lymphoproliferative disease of childhood</b>
XH84A5	<b>Primary cutaneous gamma/delta T-cell lymphoma</b>
XH14N1	<b>Precursor cell lymphoblastic lymphoma, NOS</b>
	<i>Inclusions:</i> Malignant lymphoma, lymphoblastic, NOS
	Lymphoblastoma
	Malignant lymphoma, convoluted cell
XH42X4	<b>Blastic NK-cell lymphoma</b>
XH1DB1	<b>Blastic plasmacytoid dendritic cell neoplasm</b>
XH0AK5	<b>Hydroa vacciniforme-like lymphoproliferative disorder</b>

Immunoproliferative diseases

Immunoproliferative diseases, malignant

<b>XH4KF3</b>	<b>Immunoproliferative disease, NOS</b>
<b>XH8GW4</b>	<b>Waldenstrom macroglobulinemia</b>
<b>XH7RJ1</b>	<b>Heavy chain disease, NOS</b>
<b>XH1Y65</b>	<b>Alpha heavy chain disease</b>
<b>XH1EA7</b>	<b>Gamma heavy chain disease</b>
	<i>Inclusions:</i> Franklin disease
<b>XH2JK2</b>	<b>Mu heavy chain disease</b>
<b>XH3SS7</b>	<b>Immunoproliferative small intestinal disease</b>
	<i>Inclusions:</i> Mediterranean lymphoma
<b>XH71D5</b>	<b>Lymphomatoid granulomatosis, grade 3</b>

Immunoproliferative diseases, uncertain whether benign or malignant

<b>XH1NV1</b>	<b>Monoclonal gammopathy of undetermined significance</b>
<b>XH3U73</b>	<b>Angiocentric immunoproliferative lesion</b>
<b>XH4P09</b>	<b>Lymphomatoid granulomatosis</b>
	<i>Inclusions:</i> Lymphomatoid granulomatosis, NOS

<b>XH2A53</b>	<b>Angioimmunoblastic lymphadenopathy (AIL)</b>
	<i>Inclusions:</i> Immunoblastic lymphadenopathy (IBL)
<b>XH0HS7</b>	<b>T-gamma lymphoproliferative disease</b>
<b>XH2WA6</b>	<b>Immunoglobulin deposition disease</b>
<b>XH4F97</b>	<b>Lymphomatoid granulomatosis, grade 1</b>
<b>XH7BG6</b>	<b>Lymphomatoid granulomatosis, grade 2</b>
<b>XH16T1</b>	<b>IgM monoclonal gammopathy of undetermined significance</b>

Plasma cell tumours

<b>XH4BL1</b>	<b>Plasmacytoma, NOS</b>
	<i>Inclusions:</i> Plasmacytoma of bone Solitary myeloma Solitary plasmacytoma
<b>XH4XA9</b>	<b>Plasma cell myeloma</b>
<b>XH7GC9</b>	<b>Plasma cell leukaemia</b>
<b>XH0N40</b>	<b>Plasmacytoma, extramedullary</b>
	<i>Inclusions:</i> Extraosseous plasmacytoma
<b>XH6YR5</b>	<b>Plasmablastic lymphoma</b>
<b>XH1EB9</b>	<b>ALK positive large B-cell lymphoma</b>
<b>XH5HJ5</b>	<b>Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease</b>

Mast cell tumours

Mast cell tumours, malignant

<b>XH6A72</b>	<b>Mast cell sarcoma</b>
	<i>Inclusions:</i> Malignant mastocytoma
<b>XH2992</b>	<b>Malignant mastocytosis</b>
	<i>Inclusions:</i> Systemic tissue mast cell disease
<b>XH10N1</b>	<b>Aggressive systemic mastocytosis</b>
<b>XH1H01</b>	<b>Systemic mastocytosis with AHNMD</b>

<b>XH5191</b>	<b>Systemic mastocytosis with associated haematological clonal non-mast cell disorder</b>
<b>XH5ER6</b>	<b>Mast cell leukaemia</b>
<b>XH1VJ3</b>	<b>Erdheim-Chester disease</b>

Mast cell tumours, uncertain whether benign or malignant

<b>XH1J17</b>	<b>Mastocytoma, NOS</b>
<b>XH74F2</b>	<b>Cutaneous mastocytosis</b>
	<i>Inclusions:</i> Cutaneous mastocytosis, NOS
<b>XH2RG8</b>	<b>Diffuse cutaneous mastocytosis</b>
<b>XH8VS0</b>	<b>Urticaria pigmentosa</b>
<b>XH2Y59</b>	<b>Indolent systemic mastocytosis</b>
<b>XH2RL8</b>	<b>Solitary mastocytoma of skin</b>

Neoplasms of histiocytes and accessory lymphoid cells

**Coded Elsewhere:** Erdheim-Chester disease (XH1VJ3)

Neoplasms of histiocytes and accessory lymphoid cells, malignant

**Coded Elsewhere:** Langerhans cell histiocytosis (XH1J18)

<b>XH2WJ3</b>	<b>Malignant histiocytosis</b>
<b>XH7PV7</b>	<b>Histiocytic medullary reticulosis</b>
<b>XH4XT4</b>	<b>Acute progressive histiocytosis X</b>
<b>XH8VV4</b>	<b>Histiocytosis X, NOS</b>
<b>XH86U0</b>	<b>Hand-Schuller-Christian disease</b>
<b>XH60Q1</b>	<b>Letterer-Siwe disease</b>
<b>XH0YE1</b>	<b>Nonlipid reticuloendotheliosis</b>
<b>XH40U7</b>	<b>Langerhans cell histiocytosis, disseminated</b>
	<i>Inclusions:</i> Langerhans cell granulomatosis
<b>XH4JD4</b>	<b>Histiocytic sarcoma</b>
<b>XH46Q0</b>	<b>True histiocytic lymphoma</b>
<b>XH8J76</b>	<b>Langerhans cell sarcoma</b>

<b>XH7UM7</b>	<b>Interdigitating dendritic cell sarcoma</b>
	<i>Inclusions:</i> Interdigitating cell sarcoma
<b>XH8Q19</b>	<b>Dendritic cell sarcoma, NOS</b>
<b>XH3ZM0</b>	<b>Indeterminate dendritic cell tumour</b>
<b>XH1JT6</b>	<b>Follicular dendritic cell sarcoma</b>
<b>XH6ZR5</b>	<b>Follicular dendritic cell tumour</b>
<b>XH0124</b>	<b>Fibroblastic reticular cell tumour</b>
<b>XH75E6</b>	<b>Eosinophilic granuloma</b>

Neoplasms of histiocytes and accessory lymphoid cells, uncertain whether benign or malignant

*Coded Elsewhere:* Erdheim-Chester disease (XH1VJ3)

<b>XH0RF4</b>	<b>Langerhans cell histiocytosis, monostotic</b>
<b>XH2PY9</b>	<b>Langerhans cell histiocytosis, polyostotic</b>
<b>XH1J18</b>	<b>Langerhans cell histiocytosis</b>

### Dimensions of injury

A grouping for dimensions of injury that are supplementary to the fully specified injury chapter codes, i.e. concepts that can not, or are likely to not be able to be used as a standalone code in mortality or morbidity-coded data.

#### Dimensions of Burns

Burns classified according to extent of body surface involved

<b>XJ4PF</b>	<b>Burns involving less than 10% of body surface</b>
<b>XJ4NH</b>	<b>Burns involving less than 5% of body surface</b>
<b>XJ7TR</b>	<b>Burns involving 5-9% of body surface</b>
<b>XJ257</b>	<b>Burns involving 10-19% of body surface</b>
<b>XJ5GA</b>	<b>Burns involving 20-29% of body surface</b>
<b>XJ7ZW</b>	<b>Burns involving 30-39% of body surface</b>
<b>XJ3R2</b>	<b>Burns involving 40-49% of body surface</b>
<b>XJ19C</b>	<b>Burns involving 50-59% of body surface</b>

<b>XJ4B7</b>	<b>Burns involving 60-69% of body surface</b>
<b>XJ7F7</b>	<b>Burns involving 70-79% of body surface</b>
<b>XJ1HD</b>	<b>Burns involving 80-89% of body surface</b>
<b>XJ9JX</b>	<b>Burns involving 90% or more of body surface</b>

Extent of body surface with full thickness or deep full thickness burn

<b>XJ31W</b>	<b>Full thickness or deep full thickness burn involving less than 10% of body surface</b>
<b>XJ243</b>	<b>Full thickness or deep full thickness burn involving less than 5% of body surface</b>
<b>XJ4FJ</b>	<b>Full thickness or deep full thickness burn involving 5-9% of body surface</b>
<b>XJ82Z</b>	<b>Full thickness or deep full thickness burn involving 10-19% of body surface</b>
<b>XJ3XZ</b>	<b>Full thickness or deep full thickness burn involving 20-29% of body surface</b>
<b>XJ1NG</b>	<b>Full thickness or deep full thickness burn involving 30-39% of body surface</b>
<b>XJ4CR</b>	<b>Full thickness or deep full thickness burn involving 40-49% of body surface</b>
<b>XJ9MY</b>	<b>Full thickness or deep full thickness burn involving 50-59% of body surface</b>
<b>XJ8E0</b>	<b>Full thickness or deep full thickness burn involving 60-69% of body surface</b>
<b>XJ68M</b>	<b>Full thickness or deep full thickness burn involving 70-79% of body surface</b>
<b>XJ9UE</b>	<b>Full thickness or deep full thickness burn involving 80-89% of body surface</b>
<b>XJ3MB</b>	<b>Full thickness or deep full thickness burn involving 90% or more of body surface</b>

Outcome of deep full thickness or complex burn

Whether a deep full thickness or complex burn has resulted in the loss of a limb.

<b>XJ71T</b>	<b>Deep full thickness or complex burn with no loss of limb</b>
--------------	---

- XJ6NX** **Deep full thickness or complex burn with loss of digit**  
Loss of digit or digits (toes or fingers including thumbs) either by surgical amputation necessitated by the burn, or through complete physical destruction as a result of a burn.
- XJ36Y** **Deep full thickness or complex burn with loss of limb**  
Loss of limb or limbs (arms or legs) either by surgical amputation necessitated by the burn, or through complete physical destruction as a result of a burn.

Joint involvement in fracture

- XJ5GS** **Fracture extends into joint**  
Fracture involves articular surface or surfaces.
- XJ5L7** **Fracture extends into joint and a portion of the articular part remains attached to the main part of the bone**  
*Inclusions:* partial articular fractures
- XJ92H** **Fracture extends into joint and the entire articular part is detached from the main part of the bone**
- XJ5VJ** **Fracture does not extend into joint**  
Fractures that do not involve an articular surface.

Open fracture or closed fracture

- XJ44E** **Closed fracture**
- XJ7YM** **Open fracture**

Fracture types

- XJ36W** **Avulsion fracture**
- XJ2EL** **Bucket handle or corner fracture**
- XJ76E** **Buckle fracture**
- XJ7ZH** **Burst fracture**
- XJ1Z6** **Comminuted fracture**
- XJ1PP** **Compound fracture**
- XJ778** **Compression fracture**
- XJ9UB** **Depressed fracture**
- XJ69V** **Dislocated fracture**
- XJ8PQ** **Displaced fracture**

XJ0QE	Elevated fracture
XJ5N9	Fissured fracture
XJ45W	Greenstick fracture
XJ7AT	Impacted fracture
XJ4PE	Infected fracture
XJ392	Linear fracture
XJ6RL	Longitudinal fracture
XJ4CX	Missile fracture
XJ4FU	Osteochondral fracture
XJ3HH	Physeal fracture
XJ64N	Puncture fracture
XJ909	Simple fracture
XJ9XQ	Slipped epiphysis fracture
XJ967	Spiral fracture
XJ5V7	Transverse fracture
XJ6NA	Wedge fracture
XJ8QL	Fracture with foreign body

Types of superficial injuries

XJ652	Abrasions
XJ8JK	Blister, nonthermal
XJ9NV	Contusion
XJ4D1	External constriction
XJ69A	Insect bite, nonvenomous
XJ06K	Superficial foreign body
XJ3U1	Superficial splinter
XJ1C6	Superficial haematoma

## Dimensions of external causes

Additional aspects of mechanism

<b>XE72E</b>	<b>Exposure to injurious transport event</b>
<b>XE9S7</b>	<b>Exposure to land transport injury event</b>
<b>XE9EE</b>	Exposure to land transport on-road injury event
<b>XE8TM</b>	Exposure to land transport off-road injury event
<b>XE3S3</b>	<b>Exposure to railway transport injury event</b>
<b>XE85L</b>	<b>Exposure to water transport injury event</b>
<b>XE5XH</b>	<b>Exposure to air or space transport injury event</b>
<b>XE3Y8</b>	<b>Exposure to fall</b>
<b>XE8J4</b>	<b>Exposure to fall on the same level or from less than 1 metre</b>
<b>XE3QG</b>	<b>Exposure to fall from a height of 1 metre or more</b>
<b>XE4U1</b>	<b>Exposure to person, animal or plant</b>
<b>XE1TU</b>	<b>Exposure to being struck, kicked, or bumped</b>
<b>XE0VW</b>	<b>Exposure to being stepped on or crushed</b>
<b>XE359</b>	<b>Exposure to being bitten</b>
<b>XE9PG</b>	<b>Exposure to being scratched or clawed</b>
<b>XE972</b>	<b>Exposure to being stung or envenomated</b>
<b>XE214</b>	<b>Exposure to object, not elsewhere classified</b>
<b>XE2YW</b>	<b>Exposure to being struck by projectile from firearm</b>
<b>XE4UV</b>	<b>Exposure to being struck by moving object</b>
<b>XE6LQ</b>	<b>Exposure to being struck against stationary object</b>
<b>XE20S</b>	<b>Exposure to being cut or pierced by sharp object</b>
<b>XE59C</b>	<b>Exposure to being struck by blunt object</b>
<b>XE4FE</b>	<b>Exposure to being caught, crushed, jammed or pinched between objects</b>
<b>XE64Q</b>	<b>Exposure to immersion, submersion or falling into water</b>
<b>XE72F</b>	<b>Exposure to drowning or submersion, while in body of water</b>
<b>XE1AF</b>	<b>Exposure to drowning or submersion, following fall into body of water</b>
<b>XE8NX</b>	<b>Exposure to threat to breathing</b>

XE9N2	Exposure to threat to breathing by suffocation from object covering mouth or nose
XE9LA	Exposure to threat to breathing by hanging
XE17S	Exposure to threat to breathing by strangulation
XE2NR	Exposure to threat to breathing by external compression of airways or chest
XE33X	Exposure to threat to breathing by inhalation or ingestion of gastric contents
XE2PV	Exposure to threat to breathing by inhalation or ingestion of liquids
XE5QH	Exposure to threat to breathing by inhalation or ingestion of food
XE9RJ	Exposure to threat to breathing by inhalation or ingestion of other objects or materials
XE2DJ	Exposure to threat to breathing from low oxygen environment
<b>XE6JM</b>	<b>Exposure to thermal mechanism</b>
XE0S0	Exposure to uncontrolled fire
XE5WP	Exposure to controlled fire
XE9T8	Exposure to ignition, or melting of material
XE494	Exposure to hot object or liquid
XE515	Exposure to steam, hot vapour, air or gases
XE00Z	Exposure to excessive heat
XE4AY	Exposure to excessive cold
<b>XE3SH</b>	<b>Exposure to or harmful effects of substances</b>
XE13E	Poisoning or toxic effect of exposure to substance
XE1SS	Corrosion due to exposure to substance

#### Exposure to other mechanism

<b>XE202</b>	Foreign body in orifice
<b>XE8A0</b>	Exposure to electric current
<b>XE8DS</b>	Exposure to sunlight
<b>XE60C</b>	Exposure to radiation
XE82Y	Exposure to welding light
XE436	Exposure to other visible and ultraviolet light of man-made sources
XE500	Exposure to ultraviolet radiation

<b>XE6JQ</b>	<b>Exposure to other non-ionizing radiation</b>
<b>XE6VK</b>	Exposure to microwave radiation
<b>XE9G0</b>	Exposure to infrared radiation
<b>XE5PJ</b>	<b>Exposure to ionizing radiation</b>
<b>XE5DF</b>	<b>Exposure to high or low air pressure or changes in air pressure</b>
<b>XE4ZB</b>	<b>Exposure to changes in air pressure</b>
<b>XE07M</b>	<b>Exposure to high air pressure</b>
<b>XE67J</b>	<b>Exposure to low air pressure</b>
<b>XE9Y8</b>	<b>Exposure to explosion</b>
<b>XE22U</b>	<b>Exposure to chemical explosion</b>
<b>XE27P</b>	<b>Exposure to explosion or rupture of pressurised materials or object</b>
<b>XE7Y1</b>	<b>Exposure to noise</b>
<b>XE3RX</b>	<b>Exposure to vibration</b>
<b>XE7BT</b>	<b>Exposure to suction</b>
<b>XE7SS</b>	<b>Lack of food</b>
<b>XE3WS</b>	<b>Lack of water</b>
<b>XE4TW</b>	<b>Exposure to physical overexertion</b>
<b>XE67Q</b>	<b>Exposure to other specified privation</b>
<b>XE42R</b>	<b>Abandonment</b>
<b>XE00G</b>	<b>Neglect</b>

Activity when injured

<b>XE545</b>	<b>Paid work</b>
<b>XE7NW</b>	<b>Travelling to or from paid work</b>
<b>XE9Q2</b>	<b>Travelling in the course of paid work</b>
<b>XE2QJ</b>	<b>Repetitive forceful work</b>
<b>XE88E</b>	<b>Extended periods of work in a kneeling position</b>
<b>XE714</b>	<b>Extended periods of work in a squatting position</b>
<b>XE8VF</b>	<b>Unpaid work</b>
<b>XE1C6</b>	<b>Travelling to or from unpaid work</b>

<b>XE3RL</b>	<b>Travelling in the course of unpaid work</b>
<b>XE9ME</b>	<b>Unpaid cleaning, cooking or maintenance at own place of residence</b>
<b>XE729</b>	<b>Educational activity</b>
<b>XE3HD</b>	<b>Physical education class, school sports</b>
	<i>Exclusions:</i> Sports, recreation or leisure activity (XE5UF-XE5C9)
<b>XE4SM</b>	<b>Travelling to or from educational activity</b>

Sports, recreation or leisure activity

<b>XE5UF</b>	<b>Organised sports and exercise during leisure time</b>
	<i>Exclusions:</i> Physical education class, school sports (XE3HD)
	Travelling to or from paid work (XE7NW)
	Leisure or play (XE617)
<b>XE617</b>	<b>Leisure or play</b>
	<i>Exclusions:</i> Unpaid work (XE8VF)
<b>XE5C9</b>	<b>Other specified sports and exercise during leisure time</b>
	<i>Exclusions:</i> Organised sports and exercise during leisure time (XE5UF)
	Leisure or play (XE617)
	Travelling to or from paid work (XE7NW)
	Physical education class, school sports (XE3HD)

Being taken care of

<b>XE245</b>	<b>Being taken care of by health care professional</b>
<b>XE2EZ</b>	<b>Being taken care of by non health care person</b>
	<i>Exclusions:</i> Leisure or play (XE617)
<b>XE643</b>	<b>Being taken care of by a person, not specified as a health care professional or non health care person</b>
	<i>Exclusions:</i> Leisure or play (XE617)

Aspects of place of injury occurrence

## Type of place

<b>XE266</b>	<b>Home</b>
	<b><i>Exclusions:</i></b> Residential institution (XE9DC) Prison (XE30E) Sidewalk (XE53A) Building under construction (XE11T) Demolition site (XE0Z7) Nursing home (XE498)
<b>XE9XY</b>	<b>Detached house</b>
<b>XE9P0</b>	<b>Terrace house or row house</b>
<b>XE7DU</b>	<b>Apartment or flat</b>
<b>XE7F8</b>	<b>Farmhouse</b>
<b>XE1LE</b>	<b>Residential caravan, mobile home, houseboat or motor home</b>
<b>XE3ZC</b>	<b>Hut</b>
<b>XE6X4</b>	<b>Boarding house or hotel</b>
<b>XE9DC</b>	<b>Residential institution</b>
<b>XE8PL</b>	<b>Home for the elderly</b>
	<b><i>Exclusions:</i></b> Nursing home (XE498)
<b>XE498</b>	<b>Nursing home</b>
	<b><i>Exclusions:</i></b> Home for the elderly (XE8PL)
<b>XE30E</b>	<b>Prison</b>
<b>XE8BC</b>	<b>Shelter for battered women and their children</b>
<b>XE138</b>	<b>Military institution</b>
	<b><i>Exclusions:</i></b> Hospital (XE28K) Prison (XE30E)
<b>XE9VC</b>	<b>Medical service area</b>
	<b><i>Exclusions:</i></b> Residential institution (XE9DC) Building under construction (XE11T)
<b>XE28K</b>	<b>Hospital</b>
	<b><i>Exclusions:</i></b> Nursing home (XE498)
<b>XE8DZ</b>	<b>Outpatient clinic or health centre</b>

<b>XE86F</b>	<b>Health professionals' office</b>
<b>XE9ZD</b>	<b>Hospice</b>
<b>XE6TU</b>	<b>School or educational area</b>
	<i>Exclusions:</i> Building under construction (XE11T)
<b>XE3JM</b>	<b>Child centre or day care centre</b>
<b>XE9LH</b>	<b>Preschool or kindergarten</b>
<b>XE1ZF</b>	<b>Primary school</b>
<b>XE3CZ</b>	<b>Secondary school</b>
<b>XE9BK</b>	<b>College or university</b>
<b>XE1JM</b>	<b>Adult education institution</b>
<b>XE7K0</b>	<b>Sports and athletics area</b>
	<i>Exclusions:</i> Home (XE266)
<b>XE9WC</b>	<b>Outdoor sporting grounds</b>
<b>XE1CY</b>	<b>Indoor sporting hall</b>
	<i>Exclusions:</i> Outdoor sporting grounds (XE9WC)
<b>XE3YG</b>	<b>Public swimming centre</b>
<b>XE8BN</b>	<b>Racetrack or racecourse</b>
<b>XE2LU</b>	<b>Equestrian facility</b>
<b>XE7QG</b>	<b>Skating rink or ice palace</b>
	<i>Exclusions:</i> Roadway (XE6NQ) Area of still water (XE0ZP) Sidewalk (XE53A)
<b>XE7WU</b>	<b>Skiing or snowboarding area</b>
<b>XE5NE</b>	<b>Public highway, street or road</b>
<b>XE6NQ</b>	<b>Roadway</b>
<b>XE53A</b>	<b>Sidewalk</b>
	<i>Exclusions:</i> Home (XE266)
<b>XE4U4</b>	<b>Cycleway</b>
<b>XE5KY</b>	<b>Transport area other than highway, street or road</b>
<b>XE3NV</b>	<b>Parking area</b>
<b>XE4N9</b>	<b>Public transport area or facility</b>

<b>XE7T4</b>	<b>Industrial or construction area</b>
<b>XE11T</b>	<b>Building under construction</b>
<b>XE0Z7</b>	<b>Demolition site</b>
<b>XE3U5</b>	<b>Factory or plant</b>
	<i>Exclusions:</i> Home (XE266)
<b>XE0Y1</b>	<b>Mine or quarry</b>
<b>XE7GD</b>	<b>Oil or gas extraction facility</b>
<b>XE7MT</b>	<b>Shipyard</b>
<b>XE8Q1</b>	<b>Power station</b>
<b>XE9CS</b>	<b>Farm or other place of primary production</b>
	<i>Exclusions:</i> Home (XE266)
<b>XE1ES</b>	<b>Area for growing crops, market gardening, horticulture</b>
	<i>Exclusions:</i> Area for growing crops combined with raising and care of animals (XE9C6)
<b>XE54N</b>	<b>Area for raising or care of animals</b>
<b>XE9WB</b>	<b>Animal stables</b>
<b>XE9C6</b>	<b>Area for growing crops combined with raising and care of animals</b>
<b>XE1WL</b>	<b>Place for socialising and consumption of alcoholic drinks</b>
<b>XE03P</b>	<b>Bar, pub, saloon or other commercial place primarily for provision of alcoholic drinks</b>
<b>XE7Y2</b>	<b>Nightclub, restaurant or other commercial place for socialising and recreation</b>
<b>XE7GY</b>	<b>Recreational area, cultural area, or public building</b>
<b>XE0AJ</b>	<b>Public playground</b>
	<i>Exclusions:</i> Home (XE266)
<b>XE35Q</b>	<b>Amusement park or theme park</b>
<b>XE5C2</b>	<b>Public park</b>
	<i>Exclusions:</i> Countryside (XE5JL)
<b>XE774</b>	<b>Non-cultural public building</b>
	<i>Exclusions:</i> Prison (XE30E)
<b>XE4TG</b>	<b>Holiday park or campground</b>
<b>XE0ES</b>	<b>Public religious place</b>
<b>XE48U</b>	<b>Commercial area (non-recreational)</b>

<b>XE319</b>	<b>Shop or store</b>
<b>XE058</b>	<b>Café or fast food outlet</b>
<b>XE543</b>	<b>Commercial garage</b>
	<b><i>Exclusions:</i></b> Home (XE266)
	Parking area (XE3NV)
<b>XE58T</b>	<b>Office building</b>
	<b><i>Exclusions:</i></b> Health professionals' office (XE86F)
<b>XE5JL</b>	<b>Countryside</b>
<b>XE0ZP</b>	<b>Area of still water</b>
	<b><i>Exclusions:</i></b> Beach, shore or bank of a body of water (XE010)
	Large area of water (XE93X)
<b>XE17F</b>	<b>Stream of water</b>
	<b><i>Exclusions:</i></b> Beach, shore or bank of a body of water (XE010)
<b>XE93X</b>	<b>Large area of water</b>
	<b><i>Exclusions:</i></b> Area of still water (XE0ZP)
	Beach, shore or bank of a body of water (XE010)
<b>XE5TX</b>	<b>Marsh or swamp</b>
	<b><i>Exclusions:</i></b> Beach, shore or bank of a body of water (XE010)
<b>XE010</b>	<b>Beach, shore or bank of a body of water</b>
<b>XE6AV</b>	<b>Forest</b>
<b>XE601</b>	<b>Desert</b>
<b>XE2BE</b>	<b>Out-of-hospital</b>
<b>XE36S</b>	<b>In-hospital</b>

#### Part of place

<b>XE2XM</b>	<b>Part of building or grounds, bathroom, toilet</b>
<b>XE4XM</b>	<b>Part of building or grounds, kitchen</b>
<b>XE1M5</b>	<b>Part of building or grounds, living room</b>
<b>XE8RZ</b>	<b>Part of building or grounds, bedroom</b>
<b>XE45Z</b>	<b>Part of building or grounds, playroom or family room</b>
<b>XE051</b>	<b>Part of building or grounds, office or home office</b>
<b>XE115</b>	<b>Part of building or grounds, classroom</b>

XE70Z	Part of building or grounds, canteen or cafeteria
XE4U5	Part of building or grounds, balcony
XE2NQ	Part of building or grounds, stairs
XE9L8	Part of building or grounds, elevator
XE6ZJ	Part of building or grounds, corridor
XE3R6	Part of building or grounds, lobby
XE3DE	Part of building or grounds, garden or yard
	<i>Exclusions:</i> Part of building or grounds, tennis court (XE7DE) Part of building or grounds, swimming pool (XE4PW)
XE2Q4	Part of building or grounds, garage
XE65J	Part of building or grounds, driveway
XE4PW	Part of building or grounds, swimming pool
XE7DE	Part of building or grounds, tennis court
XE9DN	Part of building or grounds, other specified sporting facility
XE8SG	Part of building or grounds, playground
XE5RE	Part of building or grounds, private road
XE5MW	Part of building or grounds, private parking area
XE6ZY	Part of building or grounds, other specified indoor part of building or grounds
XE06N	Part of building or grounds, other specified outdoor part of building or grounds

Objects, living things or substances involved in causing injury

**Coded Elsewhere:** Health Devices, Equipment and Supplies (XD7FF9-XD6UU3)  
Substances (XM1349-XM7XM0)

## Land vehicle or means of land transport

<b>XE81T</b>	<b>Person-powered means of transport</b>
<b>XE38Y</b>	<b>Transport vehicle drawn or pushed by person</b>
<b>XE94Q</b>	<b>Pedal cycle</b>
<b>XE1MP</b>	<b>Animal-powered means of transport</b>
<b>XE0ZZ</b>	<b>Animal being ridden</b>

XE1CF	Animal-drawn vehicle
<b>XE3ZP</b>	<b>Motorised two- or three-wheeled vehicle</b>
XE0TY	Motorcycle
XE9N6	Moped, scooter
XE9AX	Three-wheeled motor vehicle or scooter
<b>XE3GH</b>	<b>Light transport vehicle with four or more wheels</b>
XE50Z	Passenger car
XE4BF	Light truck, Sports Utility Vehicle (SUV), utility van, 4x4 vehicle, jeep, pick-up truck
XE6DC	Minibus
<b>XE4NR</b>	<b>Heavy transport vehicle with four or more wheels</b>
XE60G	Bus, coach
XE8XB	Tractor-trailer, articulated lorry, 18-wheeler, rig
XE5A8	Heavy truck, not elsewhere classified
XE5KW	Trailer or horse-float
<b>XE0ZK</b>	<b>Rail vehicle</b>
XE40X	Streetcar, tram, electric car, car trolley
XE9Q3	Train
XE3P6	Funicular, monorail, or other similar rail vehicle
<b>XE0YD</b>	<b>Parts or components of land vehicle or means of land transport</b>
XE954	Vehicle doors, not elsewhere classified
XE226	Vehicle seat belts, deploying air bags
XE8UK	Tyre (tire) or battery (attached or unattached)
XE8CT	Vehicle window or windshield
XE1LF	Interior of vehicle
XE5D5	Engine of vehicle
<b>XE3C0</b>	<b>Certain specified land vehicle or means of land transport</b>
XE8KJ	Cable car, ski chair lift, ski lift with gondola
XE8C8	Motorized wheelchair
XE4D7	Small-sized motorized vehicles for children
XE3FP	Motor home

Mobile machinery or special purpose vehicle

<b>XE7X0</b>	<b>Mobile machinery or special purpose vehicle mainly used in agriculture</b>
XE9HQ	Ride-on lawn mower
XE0S2	Tractor
XE0YP	Harvesting machine
XE7SF	Auger, post hole digger
XE0LF	Equipment towed or powered by tractors, not elsewhere classified
<b>XE0M8</b>	<b>Mobile machinery or special purpose vehicle mainly used in industry</b>
XE21P	Forklift or lift truck
XE8TB	Mobile crane
XE6VY	Battery-powered airport passenger vehicle
XE13Q	Logging car
XE6B4	Coal-car in mine
XE1BG	Tram, truck, or tub in mine or quarry
<b>XE1GE</b>	<b>Mobile machinery or special purpose vehicle mainly used in construction</b>
XE4MS	Grader
XE69J	Front-end loader, bulldozer
XE6XP	Excavator, digger, mechanical shovel
XE3GR	Road roller
<b>XE381</b>	<b>Certain specified mobile machinery or special purpose vehicle</b>
XE80A	Ambulance
XE5BQ	Fire truck, fire engine
XE387	Race car
XE2LT	Snowmobile, ski-scooter
XE6R9	Special all-terrain vehicle or off-road vehicle

Watercraft or means of water transport

<b>XE70T</b>	<b>Powered watercraft or means of water transport</b>
XE7NQ	Merchant ship, cargo ship, oil tanker

XE3HS	<b>Passenger ship, passenger liner, ocean liner</b>
XE801	<b>Fishing boat, trawler</b>
XE69F	<b>Ferry used for short trips across closed waters</b>
XE3WZ	<b>Motorised yacht, motorboat, powered boat, personal powered watercraft</b>
XE304	<b>Houseboat</b>
XE5ZR	<b>Hovercraft</b>
XE3PW	<b>Airboat</b>
XE4UQ	<b>Submarine or related craft</b>
<b>XE29V</b>	<b>Unpowered watercraft or means of water transport</b>
XE9SF	<b>Sailboat, unpowered yacht</b>
XE8BZ	<b>Canoe, kayak, row boat, pirogue, piragua</b>
XE3CC	<b>Wave board, surfboard, paddle ski</b>
XE3LU	<b>Windsurfer</b>
<b>XE5G3</b>	<b>Part or component of powered or unpowered watercraft</b>

Aircraft or means of air transport

<b>XE9LQ</b>	<b>Powered aircraft or means of air transport</b>
XE4LN	<b>Helicopter</b>
XE8RL	<b>Airship, blimp</b>
XE0WR	<b>Ultralight powered aircraft</b>
XE7MP	<b>Private fixed-wing powered aircraft</b>
XE7FK	<b>Commercial fixed-wing powered aircraft</b>
XE6FD	<b>Military fixed-wing powered aircraft</b>
XE346	<b>Spacecraft</b>
<b>XE4QU</b>	<b>Unpowered aircraft or means of air transport</b>
XE96T	<b>Passenger balloon, unpowered</b>
XE627	<b>Parachute</b>
XE3VU	<b>Hang-glider</b>
XE2KU	<b>Glider</b>
<b>XE79E</b>	<b>Part or component of powered or unpowered aircraft</b>

<b>XE5HA</b>	<b>Furniture or furnishing</b>
<b>XE8PK</b>	<b>Bed, bedding or bedding accessories</b>
<b>XE86G</b>	Bunk bed
<b>XE7QQ</b>	Special bed, orthopaedic bed, or stretcher
<b>XE27V</b>	Hammock
<b>XE0TM</b>	Mattress, sleeping mat
<b>XE2DR</b>	Other specified bed
<b>XE6R1</b>	Pillow, cushion
<b>XE38G</b>	Bed rails
<b>XE769</b>	<b>Chair or sofa</b>
<b>XE33K</b>	Upholstered chair or sofa
<b>XE853</b>	Hard chair or bench
<b>XE5NL</b>	Rocking or gliding chair
<b>XE1NC</b>	Folding chair
<b>XE7FS</b>	Revolving chair
<b>XE484</b>	Stool
<b>XE61B</b>	Commode chair
<b>XE2F3</b>	<b>Table, stand, cupboard, shelf or partition</b>
<b>XE002</b>	Rack, bookshelf
<b>XE3BY</b>	Cabinet, cupboard, side board, chest of drawers, tall boy, dresser
<b>XE1DK</b>	Dining room or kitchen table
<b>XE6E5</b>	Coffee table
<b>XE2C9</b>	Night table, end table
<b>XE2AM</b>	Desk, workbench
<b>XE3TY</b>	Television table, stand, cupboard
<b>XE6EN</b>	Folding table
<b>XE4B1</b>	Room divider or partition
<b>XE7MK</b>	<b>Decoration, decorating item</b>
<b>XE3WK</b>	Rug, mat, loose carpet
<b>XE003</b>	Draperies, curtains

<b>XE92A</b>	Roller or venetian blind or indoor shutter
<b>XE3EA</b>	Window covering hardware
<b>XE962</b>	Mirror or mirror glass
<b>XE05Q</b>	Portrait, picture, picture frame, or other wall hanging or similar decoration
<b>XE1FR</b>	Christmas tree
<b>XE4CE</b>	Holiday decorations
<b>XE8RW</b>	<b>Infant or child product</b>
<b>XE1AW</b>	<b>Baby or child article</b>
<b>XE0CS</b>	Baby pram, buggy, pusher, stroller, carriage
<b>XE4JE</b>	Baby walker
<b>XE8U9</b>	Baby exerciser, jumper, or portable swing for home use
<b>XE39K</b>	High chair, booster seat
<b>XE52H</b>	Baby or child car seat
<b>XE9MB</b>	Potty chair, training seat
<b>XE8RG</b>	Cot, crib, baby bed
<b>XE5QK</b>	Playpen, travel yard
<b>XE12N</b>	Baby gate or barrier
<b>XE34A</b>	Baby carrier, back pack type
<b>XE8HU</b>	Pedal cycle baby carrier
<b>XE8VC</b>	Baby baths or bathinettes
<b>XE49V</b>	Baby or child changing table
<b>XE9R1</b>	Baby or child pacifier, dummy
<b>XE1JQ</b>	Baby bottle or nipple
<b>XE7HA</b>	Diaper, nappy
<b>XE5E9</b>	Diaper fastener
<b>XE3Y2</b>	<b>Toy</b>
<b>XE0GX</b>	Child's tricycle or other ride-on toy
<b>XE959</b>	Toy vehicle
<b>XE93L</b>	Toy gun or related accessory
<b>XE8ZY</b>	Other toy weapon or projectile toy

<b>XE1DG</b>	Toy - art, craft, or kit
<b>XE9DY</b>	Board game or accessory or piece
<b>XE887</b>	Toy sports equipment
<b>XE1HM</b>	Ball, general, other than sport specific
<b>XE5FF</b>	Infant or child product, flying toy
<b>XE30M</b>	Infant or child product, doll, doll accessory or part, stuffed toy
<b>XE5E1</b>	Infant or child product, toy balloon
<b>XE4HX</b>	Infant or child product, inflatable toy
<b>XE2KV</b>	Infant or child product, marble, bead
<b>XE1X0</b>	Infant or child product, play tent, tunnel, or other enclosure
<b>XE7UT</b>	Infant or child product, toy box or chest
<b>XE6JS</b>	<b>Playground equipment</b>
<b>XE7YQ</b>	Tree house, play house
<b>XE8H2</b>	Playground equipment, flying fox
<b>XE27W</b>	Playground equipment, monkey bar
<b>XE8K7</b>	Other playground climbing apparatus
<b>XE0R1</b>	Playground equipment, slide, sliding board
<b>XE5W3</b>	Playground equipment, swing, swing set
<b>XE9AU</b>	Playground equipment, seesaw, teeter totter
<b>XE59P</b>	Powered amusement rides
<b>XE14C</b>	<b>Appliance mainly used in household</b>
<b>XE68B</b>	<b>Cooking or kitchen appliance</b>
<b>XE3WY</b>	Electric kettle
<b>XE3FW</b>	Electric frying pan, deep fryer
<b>XE03R</b>	Electric bread making machine
<b>XE6DV</b>	Food processor, blender, juicer
<b>XE02T</b>	Powered knife
<b>XE5LB</b>	Electric toaster, toaster oven
<b>XE7D9</b>	Microwave oven
<b>XE6PT</b>	Stove, oven, cooktop

<b>XE464</b>	Pressurised kerosene or paraffin cooking stove
<b>XE0U0</b>	Coal pot
<b>XE5YC</b>	Chulo stove
<b>XE6A4</b>	Barbeque, outdoor cookers or griller, outdoor clay oven
<b>XE0U1</b>	Dishwasher
<b>XE3JZ</b>	Refrigerator, freezer appliance
<b>XE87D</b>	<b>Cleaning or laundering appliance or tool</b>
<b>XE4FB</b>	Washing machine
<b>XE0Y0</b>	Clothes dryer
<b>XE2VW</b>	Clothes iron, press
<b>XE06L</b>	Clothesline, clothes drying rack, clotheshorse
<b>XE9H2</b>	Unpowered cleaning tool
<b>XE5PE</b>	Vacuum cleaner
<b>XE7Z3</b>	Powered cleaning tool, not elsewhere classified
<b>XE4KD</b>	<b>Lighting appliance</b>
<b>XE3QJ</b>	Free-standing gas, oil, or kerosene lamp
<b>XE926</b>	Electric lamp
<b>XE5GA</b>	Other specified lamp or lamp component
<b>XE1D7</b>	Battery-operated torch
<b>XE01B</b>	Candle, candlestick
<b>XE84K</b>	<b>Heating or cooling appliance</b>
<b>XE5VR</b>	Fan
<b>XE1ZZ</b>	Electric or gas radiator, heater
<b>XE0KQ</b>	Kerosene heater
<b>XE9WK</b>	<b>Sewing appliance or equipment</b>
<b>XE0PW</b>	Sewing machine
<b>XE204</b>	Scissors
<b>XE8D1</b>	Pin, needle
<b>XE80T</b>	<b>Entertainment appliance</b>
<b>XE6SR</b>	Television

<b>XE1PK</b>	Video recorder, decoder player
<b>XE5Y8</b>	Video camera, camera, digital camera or accessory
<b>XE59W</b>	Sound equipment
<b>XE2MS</b>	<b>Cord of household appliance, extension cord</b>

Utensil or container

<b>XE4G0</b>	<b>Cooking or food processing utensil</b>
<b>XE7VX</b>	<b>Non-electric kettle</b>
<b>XE8WH</b>	<b>Knife, not elsewhere classified</b>
<b>XE9LY</b>	<b>Cooking pot, pan</b>
<b>XE50Y</b>	<b>Pressure cooker</b>
<b>XE5CG</b>	<b>Cutlery, food preparation utensil</b>
<b>XE9W8</b>	<b>Crockery, kitchen container</b>
<b>XE532</b>	<b>Drinking glass, cup made from glass or china</b>
<b>XE9Q8</b>	<b>Plate, bowl, dish made from glass or china</b>
<b>XE6LK</b>	<b>Glass bottle or jar</b>
<b>XE5G7</b>	<b>Container made from plastic, wood, or clay</b>
<b>XE8EL</b>	<b>Cleaning utensil or container</b>
<b>XE383</b>	<b>Bucket, pail</b>
<b>XE4WL</b>	<b>Food storage or related utensil or container</b>
<b>XE1GJ</b>	<b>Tinned container, tin can</b>
<b>XE5N6</b>	<b>Box or carton containing food or drink</b>
<b>XE8JZ</b>	<b>Grocery or shopping trolley or cart</b>
<b>XE31H</b>	<b>Certain specified utensil or container</b>
<b>XE3SR</b>	<b>Rubbish bin, trash can, dumpster</b>
<b>XE0GP</b>	<b>Heavy container, box, package, not elsewhere classified</b>
<b>XE80G</b>	<b>Bag, sack, not elsewhere classified</b>

Item mainly for personal use

<b>XE12D</b>	<b>Clothes, foot wear, or related products</b>
<b>XE42F</b>	<b>Belt, braces, suspenders, sash</b>

<b>XE06P</b>	<b>Button</b>
<b>XE8H8</b>	<b>Other specified clothes fastener</b>
<b>XE1KG</b>	<b>Shoe, sandal, slipper, boot</b>
<b>XE0MQ</b>	<b>Shoelace, shoe buckle</b>
<b>XE6A6</b>	<b>Shirt, blouse, t-shirt, trousers, slacks, jacket, coat, outerwear</b>
<b>XE4AP</b>	<b>Nightclothes, pyjamas, nightwear, underwear, undergarment, lingerie</b>
<b>XE91F</b>	<b>Clothing accessory or personal decoration item</b>
<b>XE79Y</b>	<b>Wristwatch, jewellery</b>
<b>XE9WV</b>	<b>Personal grooming utensil</b>
<b>XE7FF</b>	<b>Hair dryer, curling iron, curler</b>
<b>XE2CA</b>	<b>Comb, hairbrush</b>
<b>XE22C</b>	<b>Razor, razor blade</b>
<b>XE39S</b>	<b>Electric shaver</b>
<b>XE1RS</b>	<b>Electric toothbrush</b>
<b>XE88G</b>	<b>Other toothbrush</b>
<b>XE45T</b>	<b>Toiletries, cosmetics, or related product</b>
	<i>Coded Elsewhere:</i> Nail polish remover (XM0ES5)
<b>XE5U0</b>	<b>Cleaning agent for contact lenses</b>
<b>XE5CY</b>	<b>Dental care products</b>
<b>XE94F</b>	<b>Cotton swab, cotton bud, Q-tip®</b>
<b>XE1H5</b>	<b>Soap</b>
<b>XE1B1</b>	<b>Deodorants</b>
<b>XE5DV</b>	<b>Perfume, cologne</b>
<b>XE8PE</b>	<b>Hair colouring preparation</b>
<b>XE1T3</b>	<b>Hair removal preparation, depilatory</b>
<b>XE8EH</b>	<b>Other hair care product</b>
<b>XE3EV</b>	<b>Nail polish</b>
<b>XE7DF</b>	<b>Body or facial cream or lotion</b>
<b>XE8W8</b>	<b>Body powder, talc</b>
<b>XE79N</b>	<b>Cosmetics, not elsewhere classified</b>

XE8NY	Suntan or sunscreen products, self-tan products
XE4KX	Essential oils, oils used in aromatherapy
<b>XE3AM</b>	<b>Communication or related utensil or accessory</b>
XE2A3	Telephone, mobile phone, cellular phone
XE9K5	Personal computer or related accessory
XE38S	Fax machine and other related equipment
XE5V8	Typewriter correction fluid
XE38A	Pen, pencil
XE1RG	Other stationery item
<b>XE58R</b>	<b>Arts and crafts supplies</b>
XE0NW	Artist paint
XE2EN	Chalk, crayon
XE6E6	Glazes
XE8ZP	Canvas
<b>XE0X7</b>	<b>Personal aid</b>
XE5EM	Eyewear
XE293	Wheelchair
XE90Y	Cane, walker, walking stick, walking frame
XE5W4	Prosthesis
XE6ZS	Rubber bathtub mat
<b>XE7P9</b>	<b>Tobacco or related product</b>
XE01N	Cigarette, cigar, pipe
XE4U8	Lighter, match
XE0Q7	Aids to quit smoking
<b>XE2H2</b>	<b>Certain specified personal use item</b>
XE1NP	Vaporizer, humidifier
XE1PV	Oil burner
XE7S6	Condom, or other contraceptive device
XE9GS	Sex aids
XE030	Alarm clock, clock

<b>XE9R0</b>	<b>Umbrella</b>
<b>XE3T5</b>	<b>Coins</b>
<b>XE6N6</b>	<b>Hand-held fan</b>

Equipment mainly used in sports or recreational activity

<b>XE5BJ</b>	<b>Ball used in sport</b>
<b>XE9X9</b>	<b>Soft ball</b>
<b>XE7M5</b>	<b>Puck, hard ball</b>
<b>XE68L</b>	<b>Hand-held sports equipment</b>
<b>XE3H8</b>	<b>Spear, javelin, not elsewhere classified</b>
<b>XE9CT</b>	<b>Bow, arrow, crossbow bolt, crossbow, not elsewhere classified</b>
<b>XE557</b>	<b>Other specified sports projectile</b>
<b>XE23P</b>	<b>Bat, hockey stick</b>
<b>XE9MP</b>	<b>Racquet</b>
<b>XE1HX</b>	<b>Ice pick</b>
<b>XE0AQ</b>	<b>Equipment or structure for playing sports or exercise</b>
<b>XE2EM</b>	<b>Net for sports or exercise</b>
<b>XE9R3</b>	<b>Rugby pole, net pole, goal post</b>
<b>XE6HE</b>	<b>Trampoline for playing sports or exercise</b>
<b>XE8C0</b>	<b>Gymnastic equipment</b>
<b>XE76Q</b>	<b>Sports mat for playing sports or exercise</b>
<b>XE9TW</b>	<b>Diving board, platform</b>
<b>XE1EH</b>	<b>Exercise, fitness equipment - movable</b>
<b>XE6G9</b>	<b>Exercise, fitness equipment - fixed</b>
<b>XE70Q</b>	<b>Equipment with wheels or designed for movement, mainly for use in sports or recreational activity</b>
<b>XE38Q</b>	<b>Roller skates, rollerski, in-line skates, roller blades</b>
<b>XE7TJ</b>	<b>Skateboard</b>
<b>XE06X</b>	<b>Folding scooter</b>
<b>XE9XZ</b>	<b>Waterski</b>
<b>XE5W5</b>	<b>Snow ski</b>

<b>XE6DZ</b>	<b>Snow board</b>
<b>XE2AY</b>	<b>Ice skate</b>
<b>XE0AR</b>	<b>Sled, toboggan, sleigh, snow disk, snow tube</b>
	<b><i>Exclusions:</i></b> Snowmobile, ski-scooter (XE2LT)
<b>XE9TA</b>	<b>Underwater diving equipment</b>
<b>XE1WX</b>	<b>Aqualung</b>
<b>XE85D</b>	<b>Diving belt, weight</b>
<b>XE8X8</b>	<b>Wetsuit</b>
<b>XE3NW</b>	<b>Goggle or mask, flipper or fin, snorkel</b>
<b>XE8FX</b>	<b>Certain specified equipment for sports or recreational activity</b>
<b>XE92X</b>	<b>Personal protective equipment (PPE) designed for use in sports</b>
<b>XE0P3</b>	<b>Tool, machine, apparatus mainly used for work-related activity</b>
<b>XE6TZ</b>	<b>Machinery or fixed plant</b>
<b>XE43P</b>	Cutting or slicing machinery or fixed plant
<b>XE0VT</b>	Crushing or pressing machinery or fixed plant
<b>XE1WC</b>	Heating or cooking machinery or fixed plant
<b>XE76C</b>	Refrigeration machinery or fixed plant
	<b><i>Exclusions:</i></b> Ducted air-conditioning unit or related fitting (XE9HH)
<b>XE14G</b>	Lifting machinery
<b>XE77A</b>	Hoist machinery
<b>XE3BT</b>	Crane machinery or fixed plant
<b>XE9U1</b>	Elevated work platform
<b>XE6T6</b>	Conveyors
<b>XE99N</b>	Mains - gas, water, sewerage, steam, hot water, electricity
	<b><i>Exclusions:</i></b> Fittings or pipes for gas, steam or hot water (XE7UU)
<b>XE8FD</b>	Shearing plant
<b>XE6VH</b>	Dairy or milking plant
<b>XE6AF</b>	Press
<b>XE0JX</b>	Garbage compactor
<b>XE02Q</b>	Threshing machine
<b>XE8KN</b>	Chaff-cutter, fodder-cutter

<b>XE5WX</b>	<b>Powered hand tool or equipment</b>
<b>XE88U</b>	Drill
<b>XE8MJ</b>	Chainsaw
<b>XE66P</b>	Other power saw
<b>XE0TD</b>	Welder, welding equipment
<b>XE3E3</b>	Nail gun, stud driver
<b>XE3UP</b>	Grinder, buffer, polisher, sander
<b>XE8T6</b>	Powered garden tool
<b>XE89A</b>	Powered push lawn mower
<b>XE0N1</b>	Industrial vacuum cleaner
<b>XE16F</b>	<b>Unpowered hand tool or equipment</b>
<b>XE8P1</b>	Unpowered push lawnmower
<b>XE0VV</b>	Hammer, mallet
<b>XE56E</b>	Chopping tool
<b>XE9CU</b>	Cutting tool
<b>XE9GT</b>	Digging or tilling tool
<b>XE3KL</b>	Lifting tool
<b>XE7VR</b>	Nail, screw, tack
<b>XE3W7</b>	Fishhook used for work-related activity
<b>XE8KL</b>	Rat or mouse trap used for work-related activity
<b>XE9N7</b>	<b>Pressure-based equipment</b>
<b>XE5VQ</b>	Gas cylinder
<b>XE974</b>	Pressurised hose, pipe
<b>XE3RZ</b>	<b>Certain unpowered equipment</b>
<b>XE9P7</b>	Ladder, movable step
<b>XE7RK</b>	Scaffolding
<b>XE5F6</b>	Helmet
<b>XE67K</b>	Earplugs
<b>XE2PS</b>	Welding mask
<b>XE7RJ</b>	Personal protective equipment, not elsewhere classified

<b>XE7HB</b>	Fire extinguisher
<b>XE505</b>	<b>Mechanical power transmission device</b>

## Weapon

<b>XE4BU</b>	<b>Sharp object</b>
<b>XE3KV</b>	<b>Spear, javelin designed as weapon</b>
<b>XE9PM</b>	<b>Arrow or bolt designed as weapon</b>
<b>XE174</b>	<b>Knife designed as weapon</b>
<b>XE598</b>	<b>Sword, dagger, bayonet, machete, panga, cutlass</b>
<b>XE04A</b>	<b>Firearm or related item</b>
<b>XE4KC</b>	<b>Bullet, pellet</b>
<b>XE72J</b>	<b>Hand gun</b>
<b>XE0Q9</b>	<b>Rifle</b>
<b>XE32H</b>	<b>Shotgun</b>
<b>XE6YZ</b>	<b>Air gun</b>
<b>XE1XM</b>	<b>Certain specified weapon</b>
<b>XE61H</b>	<b>Club, cudgel, rod, knobkierie</b>
<b>XE9F9</b>	<b>Electrical prod, stun gun</b>
<b>XE203</b>	<b>Capicum spray, mace, pepper spray</b>

## Person, animal or plant

<b>XE3C1</b>	<b>Plant</b>
<b>XE9CV</b>	<b>Tree, plant</b>
<b>XE2ZX</b>	<b>Leaves, flowers</b>
<b>XE4DN</b>	<b>Mushroom, toadstool, fungus</b>
<b>XE8XA</b>	<b>Plant seed</b>
<b>XE4KB</b>	<b>Fruit from plant</b>
<b>XE8SV</b>	<b>Plant thorn</b>
<b>XE50M</b>	<b>Branch or stick, separate from branch or tree</b>
<b>XE2PR</b>	<b>Venomous or toxic plant, not elsewhere classified</b>
<b>XE6L5</b>	<b>Bird</b>

XE99A	Ostrich, emu
XE69N	Parrot, parakeet, cockatoo
XE1Q3	Raven, crow, magpie
<b>XE6UV</b>	<b>Insect, invertebrate</b>
XE4D9	Bee
XE6LT	Wasp
XE322	Hornet <i>Coded Elsewhere:</i> Hornet venom (XM31U2)
XE7WQ	Yellow hornet
XE7TV	Whitefaced hornet
XE4YS	Ant
XE75L	Spider
XE2EP	Scorpion
XE779	Tick
XE11M	Centipede, millipede
XM6QA5	Cochineal <i>Coded Elsewhere:</i> Cochineal extract (XM3K54)
<b>XE813</b>	<b>Land mammal</b>
XE33Q	Dog
XE0W5	Dog dander
XE3GM	Dog epithelium
XE4V0	Cat
XE896	Cat dander
XE8X3	Rat, guinea pig, mouse
XE3UD	Pig, wild boar
XE25P	Sheep, goat
XE257	Cow, bull, bovine animals
XE1LR	Beef
XE5NG	Cow dander
XE5VC	Horse, pony, donkey, mule, ass
XE7NS	Baboon, monkey, chimpanzee, gorilla

XE4TZ	<b>Marsupials</b>
XE1MH	<b>Deer, moose, antelope, zebra, wildebeest</b>
XE37L	<b>Hippopotamus</b>
XE82S	<b>Lion, puma, panther, cougar, mountain lion, tiger</b>
XE7UA	<b>Bear, grizzly bear, polar bear</b>
XE2Q6	<b>Elephant</b>
XE96F	<b>Buffalo, bison, African buffalo</b>
XE08V	<b>Hamster epithelium</b>
XE09T	<b>Horse dander</b>
XE7CQ	<b>Mouse epithelium</b>
XE43Q	<b>Mouse urine proteins</b>
XE7TQ	<b>Rabbit epithelium</b>
XE9BL	<b>Pork</b>
XE6T4	<b>Blue mussel</b>
XE6WA	<b>Scallop</b>
XE5ZB	<b>Guinea pig epithelium</b>
<b>XE2AH</b>	<b>Marine animal</b>
XE765	<b>Shark</b>
XE71F	<b>Other fishes</b>
XE48L	<b>Sea snake</b>
XE3UQ	<b>Marine mammal</b>
XE8BW	<b>Jellyfish</b>
XE40R	<b>Nematocysts</b>
XE75E	<b>Coral</b>
XE6ZA	<b>Sea urchin</b>
XE45C	<b>Sea anemone</b>
XE43L	<b>Sea cucumber</b>
<b>XE1PT</b>	<b>Reptile or amphibian</b>
XE44L	<b>Non-venomous snake</b>
XE9H6	<b>Venomous snake</b>

<b>XE9X2</b>	Cobra
<b>XE5N3</b>	Fer de lance
<b>XE2RM</b>	Rattlesnake
<b>XE8LD</b>	Viper
<b>XE2UZ</b>	Krait
<b>XE11V</b>	<b>Snake, unspecified whether venomous or not</b>
<b>XE6A7</b>	<b>Lizard, gecko, goanna</b>
<b>XE65X</b>	Gila monster
<b>XE4YK</b>	Frog, toad
<b>XE4FD</b>	<b>Crocodile, alligator</b>
<b>XE653</b>	<b>Person</b>
<b>XE70B</b>	<b>Person, self</b>
<b>XE0TZ</b>	<b>Crowd of people</b>

Building, building component, or related fitting

<b>XE1P6</b>	<b>Building fitting</b>
<b>XE766</b>	<b>Flush toilet</b>
<b>XE429</b>	<b>Pit latrine</b>
<b>XE2C6</b>	<b>Bathtub, spabath, shower cubicle</b>
<b>XE78X</b>	Bathtub
<b>XE5T1</b>	spabath
<b>XE5RW</b>	shower cubicle
<b>XE31Q</b>	Shower
<b>XE8P0</b>	<b>Fitted counter, counter-top, kitchen top</b>
<b>XE2AC</b>	<b>Door, window, or related fitting or feature</b>
<b>XE68A</b>	<b>Door, door sill</b>
<b>XE4YT</b>	<b>Glass door</b>
<b>XE4NX</b>	<b>Security door or gate, fly gate</b>
<b>XE6FE</b>	<b>Bars on windows</b>
<b>XE4BD</b>	<b>Window</b>

XE5B1	<b>Exterior window shutters</b>
<b>XE7SG</b>	<b>Floor or related fitting or feature</b>
XE0SK	<b>Floor - carpeted</b>
XE19Z	<b>Floor - tile, brick, concrete</b>
XE6M6	<b>Floor - wood</b>
XE6ZE	<b>Floor - mud, clay, animal dung</b>
<b>XE4ZE</b>	<b>Wall or related fitting or feature</b>
XE19W	<b>Fireplace</b>
XE1B2	<b>Built-in barbecue</b>
XE0WS	<b>Wall - brick, concrete, tile</b>
XE7CH	<b>Wall - wood</b>
XE3GJ	<b>Wall - mud, clay, animal dung</b>
<b>XE3PF</b>	<b>Certain specified building, building component, or fitting</b>
XE39L	<b>In-ground swimming pool</b>
XE4PB	<b>Above-ground swimming pool, external spa, or hot tub</b>
XE5PL	<b>Above-ground swimming pool</b>
XE3PX	<b>external spa</b>
XE8AX	<b>external hot tub</b>
XE7FP	<b>Fence, gate</b>
XE3BP	<b>Fence</b>
XE3GT	<b>Gate</b>
XE9QW	<b>Moving ramp, escalator</b>
XE0KF	<b>Moving ramp</b>
XE73T	<b>Escalator</b>
XE8PC	<b>Lift, elevator</b>
XE3HC	<b>Stairs, steps</b>
XE2VG	<b>Handrail, railing, banister</b>
XE6T1	<b>Electrical transmission line in or around building</b>
XE7UU	<b>Fittings or pipes for gas, steam or hot water</b>
XE171	<b>Fittings or pipes for gas</b>

<b>XE2BH</b>	Fittings or pipes for steam
<b>XE48P</b>	Fittings or pipes for hot water
<b>XE871</b>	<b>Electrical fixture</b>
<b>XE9HH</b>	<b>Ducted air-conditioning unit or related fitting</b>

Ground surface or surface conformation

<b>XE58F</b>	<b>Ground surface</b>
<b>XE1AK</b>	<b>Cliff</b>
<b>XE94G</b>	<b>Slope, ramp</b>
<b>XE3EC</b>	<b>Trench, ditch, pit</b>
<b>XE5Y0</b>	<b>Sewer grate</b>
<b>XE2G4</b>	<b>Open drain, channel</b>
<b>XE7K9</b>	<b>Body of water</b>
<b>XE9TJ</b>	<b>Body of water, man-made well, dug well for underground water</b>
<b>XE40U</b>	<b>Body of water, water reservoir</b>
<b>XE64D</b>	<b>Body of water, puddle</b>
<b>XE285</b>	<b>Body of water, dam, lake</b>
<b>XE1CZ</b>	<b>Body of water, river, stream</b>
<b>XE57J</b>	<b>Body of water, swamp, marsh, estuary</b>
<b>XE636</b>	<b>Body of water, beach, seashore</b>
<b>XE5N4</b>	<b>Body of water, open sea</b>
<b>XE0CX</b>	<b>Body of water, flood water</b>
<b>XE2QX</b>	<b>Body of water, canal or irrigation channel</b>
<b>XE7CY</b>	<b>Certain specified surface conformation</b>
<b>XE45P</b>	<b>Sloping surface, not elsewhere classified</b>
<b>XE9CC</b>	<b>Even surface, not elsewhere classified</b>
<b>XE1DA</b>	<b>Uneven surface, not elsewhere classified</b>

Material, not elsewhere classified

<b>XE4BY</b>	<b>Natural material</b>
<b>XE3LV</b>	<b>Snow, ice</b>

XE233	Natural grass
XE83R	Rock, stone, not elsewhere classified
XE2JN	Wood - timber, board, splinter, not elsewhere classified
XE9D4	Gravel, soil, sand, not elsewhere classified
XE36E	Hay, straw
XE410	Grain in bulk
<b>XE4Y6</b>	<b>Manufactured or industrial material</b>
XE59G	Artificial grass
XE6MG	Brick, concrete, concrete block
XE983	Molten metal
XE1FP	Metal - sheet, part, piece etc.
XE1LM	China, ceramics - sheet, part, piece
XE57U	Molten glass
XE4KU	Glass - sheet, piece, shard
XE7K4	Plastic
XE63Q	Paper, cardboard
XE7CA	Bitumen
<b>XE16B</b>	<b>Material not mentioned elsewhere</b>
XE5XN	Textiles
<b>XE3NR</b>	<b>Fire, flame or smoke causing injury</b>
XE9DT	Fire, flame causing injury
XE7PM	Burning oil
XE73M	Other burning liquid
XE3K6	Burning gas, not elsewhere classified
XE27S	Controlled fire, flame in building or structure
XE7W8	Controlled fire, flame, not in building or structure
XE87S	Uncontrolled fire, flame in building or structure
XE7V9	Uncontrolled fire, flame not in building or structure
XE4F3	<b>Smoke causing injury</b>

<b>XE63H</b>	<b>Hot object or substance, not elsewhere classified</b>
	<b>Exclusions:</b> Food, drink (XE3FD-XE6SF)
	Fire, flame or smoke causing injury (XE3NR)
<b>XE4VA</b>	<b>Hot liquid</b>
<b>XE396</b>	Hot tap water
<b>XE4WG</b>	Boiling water other than tap water
<b>XE3BS</b>	<b>Hot air or gas</b>
<b>XE77R</b>	Steam, hot vapour

Food, drink

<b>XE3FD</b>	<b>Food, drink, or related product</b>
	<b>Coded Elsewhere:</b> Alcohol beverage (XM1A61)
<b>XE5VU</b>	<b>Hot cooking oil or fat</b>
<b>XE3KH</b>	<b>Hot solid food</b>
<b>XE36T</b>	<b>Hot drink</b>
<b>XE3VM</b>	<b>Cold solid food</b>
<b>XE6SF</b>	<b>Cold drink - non-alcoholic</b>
<b>XE4QT</b>	<b>Law enforcement equipment</b>
	<b>Exclusions:</b> Weapon (XE4BU-XE203)
<b>XE8YS</b>	<b>Handcuffs</b>
<b>XE5TH</b>	<b>Public use item</b>
<b>XE6KX</b>	<b>Fire hydrant</b>
<b>XE0MT</b>	<b>Telephone pole, Stobie pole</b>
<b>XE35R</b>	<b>High-tension overhead power line</b>
<b>XE63M</b>	<b>Camping equipment</b>
<b>XE14D</b>	<b>Tent</b>
<b>XE11D</b>	<b>Fastening, binding, or securing item, not elsewhere classified</b>
<b>XE4H9</b>	<b>Rope, string, or twine</b>
<b>XE3U7</b>	<b>Barbed wire</b>
<b>XE1PL</b>	<b>Other wire</b>
<b>XE18Y</b>	<b>Chain</b>

<b>XE3WL</b>	<b>Explosive material or flammable object, not elsewhere classified</b>
XE6KQ	Fireworks
XE59Q	Explosive
<b>XE908</b>	<b>Certain other specified object or living thing involved in causing injury</b>
XE2JA	High-pressure jet
XE5DQ	Laser light and equipment
XE9AP	Laser pointer
XE6UH	Sharp object, not elsewhere classified
XE9GE	Blunt object, not elsewhere classified
XE98K	Motor, engine, not elsewhere classified
XE8AE	Dry cell battery
XE8H0	Disc battery
XE72W	Battery, not elsewhere classified
XE146	Animal cage
XE12Z	Gastric content
XE8FT	Excrement, human or animal
XE08P	Blood, carcass, body, bone, not elsewhere classified, human or animal
XE2DW	Plastic bag
XE2AU	Garbage, litter, trash
XE2VX	Environmental pollution, not elsewhere classified
<b>XE6QS</b>	<b>Medical or surgical device not in therapeutic use</b>

Alcohol use in injury event

<b>XE47R</b>	<b>Alcohol use, no information available</b>
<b>XE08X</b>	<b>Alcohol use, no suspicion or evidence of alcohol use by any person involved in the injury event</b>
<b>XE1G3</b>	<b>Alcohol use, suspicion or evidence of alcohol use by the injured person</b>
<b>XE15H</b>	<b>Alcohol use, suspicion or evidence of alcohol use by other persons involved in the injury event</b>
<b>XE3JF</b>	<b>Alcohol use, suspicion or evidence of alcohol use by both the injured person and other persons involved in the injury event</b>

Psychoactive drug use in injury event

- |              |  |
|--------------|--|
| <b>XE43G</b> | <b>Psychoactive drug use, no information available</b>   |
| <b>XE5TU</b> | <b>Psychoactive drug use, no suspicion or evidence of psychoactive drug use by any person involved in the injury event</b>                             |
| <b>XE5VY</b> | <b>Psychoactive drug use, suspicion or evidence of psychoactive drug use by the injured person</b>   |
| <b>XE8GW</b> | <b>Psychoactive drug use, suspicion or evidence of psychoactive drug use by other persons involved in the injury event</b>                             |
| <b>XE28E</b> | <b>Psychoactive drug use, suspicion or evidence of psychoactive drug use by both the injured person and other persons involved in the injury event</b> |

Aspects of transport injury events

#### Mode of transport of person injured in transport event

Collective term for forms of transportation. Includes types of vehicle; walking and other aspects of being a pedestrian (e.g. lying on a road); and using a pedestrian conveyance.

- |              |   |
|--------------|---|
| <b>XE88K</b> | <b>Pedestrian as mode of transport of person injured in transport event</b><br>A pedestrian is any person involved in a transport crash who was not in or on a vehicle or pedestrian conveyance at the time.  |
| <b>XE645</b> | <b>Person on foot injured in transport related event</b>  |
| <b>XE0HE</b> | <b>Person on foot standing, walking or running at the time of the crash</b>   |
| <b>XE7ZY</b> | <b>Pedestrian conveyance as mode of transport of person injured in transport event</b><br>A device which is designed primarily for, or being used at the time primarily for, conveying the person and is not a transport vehicle.                                   |
| <b>XE0TE</b> | <b>Mobility scooter as mode of transport of person injured in transport related event</b><br>A mobility scooter is a pedestrian conveyance which is a motorised mobility aid, designed for outdoor or indoor/outdoor use to convey one person in a seated position. |
| <b>XE80N</b> | <b>Motorised wheelchair as mode of transport of person injured in transport related event</b>   |
| <b>XE08H</b> | <b>Ice skates as mode of transport of person injured in transport related event</b>   |
| <b>XE0FX</b> | <b>Skis as mode of transport of person injured in transport related event</b>   |
| <b>XE3JS</b> | <b>Snowboard as mode of transport of person injured in transport related event</b>  |
| <b>XE036</b> | <b>Sled as mode of transport of person injured in transport related event</b>   |

XE96G	<b>Skateboard as mode of transport of person injured in transport related event</b>
XE2PW	<b>Roller skates as mode of transport of person injured in transport related event</b>
XE4HS	<b>Scooter as mode of transport of person injured in transport related event</b>
XE7RL	<b>Baby carriage as mode of transport of person injured in transport related event</b>
XE1BH	<b>Perambulator as mode of transport of person injured in transport related event</b>
XE9SV	<b>Push chair as mode of transport of person injured in transport related event</b>
XE7KT	<b>Stroller as mode of transport of person injured in transport related event</b>
<b>XE71D</b>	<b>Pedal cycle as mode of transport of person injured in transport related event</b>  A pedal-cycle is any land transport vehicle propelled by the muscular energy of the person(s) on that vehicle usually by means of a pedal system but sometimes by lever(s) or handle(s). Includes vehicles with two wheels (the usual number) or more.
XE2BW	<b>Trailer or sidecar attached to a pedal cycle as mode of transport of person injured in transport related event</b>
XE6R4	<b>Cycle rickshaw or tri-shaw as mode of transport of person injured in transport related event</b>
<b>XE7NK</b>	<b>Motorcycle as mode of transport of person injured in transport related event</b>  A motorcycle is a land transport motor vehicle with one or two riding saddles, usually with two-wheels in-line. A sidecar or trailer is considered part of the motorcycle.  <i>Inclusions:</i> Includes vehicles with one wheel at the rear and two closely-spaced steerable wheels at the front and motorised tricycles (one wheel at the front) if registered as motorcycles
XE2J1	<b>Moped as mode of transport of person injured in transport related event</b>
XE39A	<b>Underbone motorcycle as mode of transport of person injured in transport related event</b>
XE9BU	<b>Motor scooter as mode of transport of person injured in transport related event</b>
XE9RC	<b>Motorised bicycle as mode of transport of injured person in transport related event</b>  <i>Exclusions:</i> Low-powered passenger vehicle as mode of transport of person injured in transport event (XE5WB)
XE1ZG	<b>Ag bike as mode of transport of person injured in transport related event</b>

**XE2W4****Car as mode of transport of person injured in transport related event**

A land transport motor vehicle designed primarily to seat no more than 9 persons, including the driver, designed primarily for on-road use or so as to be registrable for on-road use. A trailer or caravan being towed by a car is considered a part of the car. Usually has four wheels.

**XE0V3****4x4 vehicle as mode of transport of person injured in transport related event**

**Exclusions:** Minibus or passenger van as mode of transport of person injured in transport related event (XE6PF)

Light transport vehicle with four or more wheels used in sport and leisure activities as mode of transport of person injured in transport related event (XE2TP)

**XE2TP**

**Light transport vehicle with four or more wheels used in sport and leisure activities as mode of transport of person injured in transport related event**

**XE9K7**

**Microcar as mode of transport of person injured in transport related event**

**XE62M**

**Motor car as mode of transport of person injured in transport related event**

**XE85J**

**Station wagon as mode of transport of person injured in transport related event**

**XE7LL**

**Minivan as mode of transport of person injured in transport related event**

**XE1CK**

**Jeep as mode of transport of person injured in transport related event**

**XE5X0**

**Sport utility vehicle as mode of transport of person injured in transport related event**

**XE2RA****Bus or coach as mode of transport of person injured in transport related event**

A passenger motor vehicle designed to carry 10 or more persons (including the driver). Buses may be designed to accommodate standing passengers and/or seated passengers.

**XE9JB****Light goods vehicle as mode of transport of person injured in transport related event**

A light goods vehicle is a four- or six-wheeled motor vehicle designed primarily for carrying property on roads, weighing less than the local limit for classification as a heavy goods vehicle (usually less than 3500 kg), and not requiring a special driver's licence.

**XE6PF**

**Minibus or passenger van as mode of transport of person injured in transport related event**

**Exclusions:** Light transport vehicle with four or more wheels used in sport and leisure activities as mode of transport of person injured in transport related event (XE2TP)

4x4 vehicle as mode of transport of person injured in transport related event (XE0V3)

XE165	<b>Pick-up truck, goods or work van, ambulance, motor home as mode of transport of person injured in transport related event</b>
	<b><i>Exclusions:</i></b> 4x4 vehicle as mode of transport of person injured in transport related event (XE0V3)
	Minibus or passenger van as mode of transport of person injured in transport related event (XE6PF)
<b>XE1PH</b>	<b>Heavy goods vehicle as mode of transport of person injured in transport related event</b>
	A heavy goods vehicle is a motor vehicle designed primarily for carrying property on roads, meeting local criteria for classification as a heavy goods vehicle in terms of curbside weight (usually above 3500 kg), and usually requiring a special driver's licence.
XE10A	<b>Trucks, lorries, and other heavy goods vehicle as mode of transport of person injured in transport related event</b>
	<b><i>Exclusions:</i></b> Pick-up truck, goods or work van, ambulance, motor home as mode of transport of person injured in transport related event (XE165)
XE1VN	<b>Fire brigade pump vehicle as mode of transport of person injured in transport related event</b>
XE7XM	<b>Road tractor with or without semi-trailer as mode of transport of person injured in transport related event</b>
XE5ET	<b>Truck with trailer as mode of transport of person injured in transport related event</b>
<b>XE41E</b>	<b>Streetcar or tram as mode of transport of person injured in transport related event</b>
	A streetcar or tram is a device running on rails and operated entirely or partly on roads. Streetcars and trams are used primarily for transporting persons, usually in urban and suburban places. A trailer being towed by a streetcar or tram is considered a part of the streetcar.
<b>XE5WB</b>	<b>Low-powered passenger vehicle as mode of transport of person injured in transport event</b>
	(1) A land transport motor vehicle with three wheels (usually one in front and two behind), designed primarily for on-road use. Globally, most commonly used as taxis. Design, construction, type of motor and registration/licensing requirements vary widely. (2) A low-powered quadricycle or other low-powered four-wheeled passenger vehicle that is not a car.
XE8DK	<b>Tuk-tuk as mode of transport of person injured in transport related event</b>
XE1DF	<b>Mototaxi as mode of transport of person injured in transport related event</b>
XE4SA	<b>Auto rickshaw three-wheeler as mode of transport of person injured in transport related event</b>

<b>XE35C</b>	<b>Special vehicle mainly used in agriculture as mode of transport of person injured in transport related event</b> A motor vehicle designed specifically for use in farming and agriculture (horticulture), for example to work the land, tend and harvest crops and transport materials on the farm.
<b>XE3WV</b>	<b>Self-propelled agricultural machine as mode of transport of person injured in transport related event</b>
<b>XE3QK</b>	<b>Harvester as mode of transport of person injured in transport related event</b>
<b>XE872</b>	<b>Agricultural tractor as mode of transport of person injured in transport related event</b> A motor vehicle designed primarily to provide mechanical power for use in farming and agriculture (horticulture).
<b>XE885</b>	<b>Special vehicle mainly used on industrial premises as mode of transport of person injured in transport related event</b> A motor vehicle designed primarily for use within the buildings and premises of industrial or commercial establishments.
<b>XE31K</b>	<b>Fork lift truck as mode of transport of person injured in transport related event</b>
<b>XE312</b>	<b>Special construction vehicle as mode of transport of person injured in transport related event</b> A motor vehicle designed specifically for use in the construction (or demolition) of roads, buildings and other structures or associated earth-moving.
<b>XE5RK</b>	<b>Special all-terrain vehicle as mode of transport of person injured in transport related event</b> A vehicle designed primarily for off-road use with capability to traverse a wide range of types of terrain by means of wheels, tracks, support on a cushion of air or other form of support/traction.
<b>XE63N</b>	<b>Snowmobile as mode of transport of person injured in transport related event</b>
<b>XE5U7</b>	<b>Hovercraft operating on land or swamp as mode of transport of person injured in transport related event</b>
<b>XE4MT</b>	<b>Amphibious vehicle on land as mode of transport of person injured in transport related event</b>
<b>XE3SA</b>	<b>Quad bike as mode of transport of person injured in transport related event</b>
<b>XE940</b>	<b>Animal being ridden as mode of transport of person injured in transport related event</b> A person riding on an animal of any type. Includes person directing or attempting to direct the animal and any other person riding on it.
<b>XE1ZJ</b>	<b>Horse as mode of transport of person injured in transport related event</b> A person riding on a horse of any type.

<b>XE4ZZ</b>	<b>Animal drawn vehicle as mode of transport of person injured in transport related event</b> A vehicle on wheels (cart, dray, carriage) or runners (sled) the motive power for which is provided by one or more animals.
<b>XE8YD</b>	<b>Railway vehicle as mode of transport of person injured in transport related event</b> A vehicle, or a coupled set of vehicles (a train), designed for traffic on a railway.
<b>XE1KN</b>	<b>Railway train as mode of transport of person injured in transport related event</b>
<b>XE3NY</b>	<b>Funicular or monorail as mode of transport of person injured in transport related event</b>
<b>XE27K</b>	<b>Watercraft as mode of transport of person injured in transport related event</b> A watercraft is any device for transporting passengers or goods on or in water.
<b>XE4FF</b>	<b>Submarine as mode of transport of person injured in transport related event</b>
<b>XE3QY</b>	<b>Merchant ship as mode of transport of person injured in transport related event</b>
<b>XE9YQ</b>	<b>Passenger ship as mode of transport of person injured in transport related event</b>
<b>XE9PA</b>	<b>Fishing boat or trawler as mode of transport of person injured in transport related event</b>
<b>XE0L4</b>	<b>Sailboat or unpowered yacht as mode of transport of person injured in transport related event</b> <b>Exclusions:</b> Other specified unpowered watercraft as mode of transport of person injured in transport related event (XE36L)
<b>XE4AK</b>	<b>Hovercraft and amphibious vehicles when in or above a body of water as mode of transport of person injured in transport related event</b>
<b>XE5WL</b>	<b>Other specified powered or motorised watercraft as mode of transport of person injured in transport related event</b>
<b>XE36L</b>	<b>Other specified unpowered watercraft as mode of transport of person injured in transport related event</b>
<b>XE1JR</b>	<b>Aircraft as mode of transport of person injured in transport related event</b> Device for transporting passengers or goods in the air by means of buoyancy in air or aerodynamic lift
<b>XE3J3</b>	<b>Balloons and other lighter than air devices as mode of transport of person injured in transport related event</b>
<b>XE2UU</b>	<b>Powered aircraft as mode of transport of person injured in transport related event</b>
<b>XE6SQ</b>	<b>Unpowered aircraft as mode of transport of person injured in transport related event</b>

XE4VS	<b>Parachute used in descent from damaged aircraft as mode of transport of person injured in transport related event</b>
XE08L	<b>Parachute used in descent from undamaged aircraft as mode of transport of person injured in transport related event</b>
XE33H	<b>Glider as mode of transport of person injured in transport related event</b>
XE48X	<b>Helicopter as mode of transport of person injured in transport related event</b>
<b>XE0VS</b>	<b>Spacecraft as mode of transport of person injured in transport related event</b> Device designed for transporting passengers or goods to, from and in places with very low atmospheric pressure.
XE82G	<b>Devices or parts of devices designed for ascent from and landing on earth or the surface of other bodies as mode of transport of person injured in transport related event</b>

#### Vehicle user role of person injured in transport event

<b>XE42A</b>	<b>Vehicle driver injured in transport related event</b>  A driver is an occupant of a transport vehicle who is operating or intending to operate it. Includes rider operating a motorcycle or bicycle, and a rider directing or attempting to direct a ridden animal. An autonomous or remotely-controlled vehicle has no driver.  <b>Exclusions:</b> Person boarding or alighting a vehicle injured in transport related event (XE9Y1)
<b>XE8ZW</b>	<b>Person driving a motor vehicle injured in transport related event</b>
<b>XE65U</b>	<b>Person riding, operating or controlling a motorcycle or pedal cycle injured in transport related event</b>
<b>XE3WH</b>	<b>Person responsible to resume manual control of a vehicle under autonomous or partly autonomous control injured in transport related event</b>
<b>XE8SZ</b>	<b>Person with control of steering and braking in the case of a tandem bicycle or similar vehicle injured in transport related event</b>
<b>XE302</b>	<b>Person directing or attempting to direct an animal injured in transport related event</b>
<b>XE1LZ</b>	<b>Vehicle passenger injured in transport related event</b>  A passenger is any occupant of a transport vehicle, other than the driver, in a position designed for the carriage of people.  <b>Exclusions:</b> Person boarding or alighting a vehicle injured in transport related event (XE9Y1)  Person on outside of vehicle or in load space injured in transport related event (XE166)
<b>XE5X3</b>	<b>Vehicle occupant not otherwise specified</b>
<b>XE3FA</b>	<b>Occupant of position provided for patient in an ambulance</b>

XE9FE	<b>Occupants of wheelchair or mobility scooter located in a position in a motor vehicle provided for carrying such devices</b>
XE9CP	<b>Occupants of area in a bus provided for standing</b>
<b>XE9Y1</b>	<b>Person boarding or alighting a vehicle injured in transport related event</b>  A person boarding [attempting to board] a transport vehicle, or alighting [attempting to alight] from a transport vehicle.
XE76V	<b>Person getting into or out of a vehicle injured in transport related event</b>
XE6LC	<b>Person boarding or alighting from a bus, tram, streetcar or railway vehicle injured in transport related event</b>
<b>XE166</b>	<b>Person on outside of vehicle or in load space injured in transport related event</b>  Any person being transported by a vehicle but not occupying the space normally reserved for the driver or passengers.
XE7FA	<b>Person being transported by a vehicle and occupying space intended for the transport of goods or cargo injured in transport related event</b>
XE4CZ	<b>Person being transported by a vehicle and occupying space on the roof injured in transport related event</b>
XE9X1	<b>Person being transported by a vehicle and occupying space on a running board injured in transport related event</b>
XE7PL	<b>Person being transported by a vehicle and occupying space outside the cabin holding onto the vehicle injured in transport related event</b>
<b>XE6R5</b>	<b>Rider of an animal injured in transport event</b>  A person being transported by and upon an animal, whether controlling the animal or being transported as a passenger.

### Counterpart in land transport crash

The vehicle[s] or other object[s], if any, with which the vehicle conveying the injured person collided in the event that resulted in the injury.

<b>XE6K0</b>	<b>Pedestrian as counterpart in land transport crash</b>  A pedestrian is any person involved in a transport crash who was not in or on a vehicle or pedestrian conveyance at the time.
XE57K	<b>Person on foot as counterpart in land transport crash</b>
XE2ZK	<b>Person using a pedestrian conveyance as counterpart in land transport crash</b>
<b>XE3NU</b>	<b>Pedestrian conveyance as counterpart in land transport crash</b>  A device which is designed primarily for, or being used at the time primarily for, conveying the person and is not a transport vehicle.

<b>XE93R</b>	<b>Mobility scooter as counterpart in land transport crash</b> A pedestrian conveyance which is a motorised mobility aid, designed for outdoor or indoor/outdoor use to convey one person in a seated position.
<b>XE3XF</b>	<b>Wheelchair as counterpart in land transport crash</b>
<b>XE1TJ</b>	<b>Ice skates as counterpart in land transport crash</b>
<b>XE5XW</b>	<b>Skis as counterpart in land transport crash</b>
<b>XE4NZ</b>	<b>Snowboard as counterpart in land transport crash</b>
<b>XE5D9</b>	<b>Sled as counterpart in land transport crash</b>
<b>XE5H4</b>	<b>Skateboard as counterpart in land transport crash</b>
<b>XE9J0</b>	<b>Roller skates as counterpart in land transport crash</b>
<b>XE28X</b>	<b>Scooter as counterpart in land transport crash</b>
<b>XE5SX</b>	<b>Baby carriage as counterpart in land transport crash</b>
<b>XE1ZX</b>	Perambulator as counterpart in land transport crash
<b>XE168</b>	<b>Push chair as counterpart in land transport crash</b>
<b>XE2JL</b>	<b>Stroller as counterpart in land transport crash</b>
<b>XE7ZZ</b>	<b>Pedal cycle as counterpart in land transport crash</b> A pedal-cycle is any land transport vehicle propelled by the muscular energy of the person(s) on that vehicle usually by means of a pedal system but sometimes by lever(s) or handle(s). Includes vehicles with two wheels (the usual number) or more.
<b>XE5GG</b>	<b>Trailer or sidecar attached to a pedal cycle as counterpart in land transport crash</b>
<b>XE2PY</b>	<b>Cycle rickshaw or tri-shaw as counterpart in land transport crash</b>
<b>XE8XQ</b>	<b>Motorcycle as counterpart in land transport crash</b> A motorcycle is a land transport motor vehicle with one or two riding saddles, usually with two-wheels in-line. A sidecar or trailer is considered part of the motorcycle.
<b>XE1SA</b>	<b>Motorised bicycle as counterpart in land transport crash</b> <b>Exclusions:</b> Low powered passenger vehicle as counterpart in land transport crash (XE90S)
<b>XE0V4</b>	<b>Moped as counterpart in land transport crash</b>
<b>XE4C1</b>	<b>Underbone motorcycle as counterpart in land transport crash</b>
<b>XE9FR</b>	<b>Motor scooter as counterpart in land transport crash</b>
<b>XE59J</b>	<b>Ag-bike as counterpart in land transport crash</b>

<b>XE0JH</b>	<b>Car as counterpart in land transport crash</b> A land transport motor vehicle designed primarily to seat no more than 9 persons, including the driver, designed primarily for on-road use or so as to be registrable for on-road use. A trailer or caravan being towed by a car is considered a part of the car. Usually four wheels.
<b>XE0LP</b>	<b>Motorcar as counterpart in land transport crash</b>
<b>XE0HH</b>	<b>Station wagon as counterpart in land transport crash</b>
<b>XE0ZR</b>	Microcar as counterpart in land transport crash
<b>XE0T7</b>	<b>Minivan as counterpart in land transport crash</b> <i>Exclusions:</i> Minibus or passenger van as counterpart in land transport crash (XE0ZL) Light transport vehicle with four or more wheels used in sport and leisure activities as counterpart in land transport crash (XE0MB)
<b>XE38X</b>	<b>4x4 as counterpart in land transport crash</b>
<b>XE6G7</b>	<b>Sport utility vehicle as counterpart in land transport crash</b>
<b>XE3BW</b>	<b>Jeep as counterpart in land transport crash</b>
<b>XE5LJ</b>	<b>Bus or coach as counterpart in land transport crash</b> A passenger motor vehicle designed to carry 10 or more persons (including the driver). Buses may be designed to accommodate standing passengers and/or seated passengers. <i>Exclusions:</i> Minibus or passenger van as counterpart in land transport crash (XE0ZL)
<b>XE6UN</b>	<b>Light goods vehicle as counterpart in land transport crash</b> A light goods vehicle is a four- or six-wheeled motor vehicle designed primarily for carrying property on roads, weighing less than the local limit for classification as a heavy goods vehicle (usually less 3500 kg), and not requiring a special driver's licence.
<b>XE0ZL</b>	<b>Minibus or passenger van as counterpart in land transport crash</b> <i>Exclusions:</i> Light transport vehicle with four or more wheels used in sport and leisure activities as counterpart in land transport crash (XE0MB) Minivan as counterpart in land transport crash (XE0T7) Bus or coach as counterpart in land transport crash (XE5LJ)
<b>XE4DB</b>	<b>Pick-up truck, goods or work van, ambulance or motor home as counterpart in land transport crash</b> <i>Exclusions:</i> Minivan as counterpart in land transport crash (XE0T7) Minibus or passenger van as counterpart in land transport crash (XE0ZL)

<b>XE0MB</b>	<b>Light transport vehicle with four or more wheels used in sport and leisure activities as counterpart in land transport crash</b>
<b>XE854</b>	<b>Heavy goods vehicle as counterpart in land transport crash</b> A heavy goods vehicle is a motor vehicle designed primarily for carrying property on roads, meeting local criteria for classification as a heavy goods vehicle in terms of curbside weight (usually above 3500 kg), and usually requiring a special driver's licence.
<b>XE590</b>	<b>Trucks, lorries, and other heavy goods vehicles as counterpart in land transport crash</b> <b>Exclusions:</b> Pick-up truck, goods or work van, ambulance or motor home as counterpart in land transport crash (XE4DB)
<b>XE4Q6</b>	<b>Truck with trailer as counterpart in land transport crash</b>
<b>XE45E</b>	<b>Road tractor with or without semi-trailer as counterpart in land transport crash</b>
<b>XE3M3</b>	<b>Fire brigade pump vehicle as counterpart in land transport crash</b>
<b>XE8UX</b>	<b>Streetcar or tram as counterpart in land transport crash</b> A streetcar or tram is a device running on rails and operated entirely or partly on roads. Streetcars and trams are used primarily for transporting persons, usually in urban and suburban places. A trailer being towed by a streetcar or tram is considered a part of the streetcar.
<b>XE90S</b>	<b>Low powered passenger vehicle as counterpart in land transport crash</b> (1) A land transport motor vehicle with three wheels (usually one in front and two behind), designed primarily for on-road use. Globally, most commonly used as taxis. Design, construction, type of motor and registration/licensing requirements vary widely. (2) A low-powered quadricycle or other low-powered four-wheeled passenger vehicle that is not a car.
<b>XE9VV</b>	<b>Tuk-tuk as counterpart in land transport crash</b>
<b>XE9ML</b>	<b>Mototaxi as counterpart in land transport crash</b>
<b>XE73V</b>	<b>Auto rickshaw three-wheeler as counterpart in land transport crash</b>
<b>XE9HB</b>	<b>Special vehicle mainly used in agriculture as counterpart in land transport crash</b> A motor vehicle designed specifically for use in farming and agriculture (horticulture), for example to work the land, tend and harvest crops and transport materials on the farm.
<b>XE9HZ</b>	<b>Self-propelled agricultural machine as counterpart in land transport crash</b>
<b>XE6W7</b>	<b>Harvester as counterpart in land transport crash</b>
<b>XE9GD</b>	<b>Agricultural tractor as counterpart in land transport crash</b>

<b>XE9DQ</b>	<b>Special vehicle mainly used on industrial premises as counterpart in land transport crash</b> A motor vehicle designed primarily for use within the buildings and premises of industrial or commercial establishments.
<b>XE1U3</b>	<b>Fork lift truck as counterpart in land transport crash</b>
<b>XE1YW</b>	<b>Special construction vehicle as counterpart in land transport crash</b> A motor vehicle designed specifically for use in the construction (or demolition) of roads, buildings and other structures or associated earth-moving.
<b>XE23Q</b>	<b>Special all-terrain vehicle as counterpart in land transport crash</b> A vehicle designed primarily for off-road use with capability to traverse a wide range of types of terrain by means of wheels, tracks, support on a cushion of air or other form of support/traction.
<b>XE60L</b>	<b>Snowmobile as counterpart in land transport crash</b>
<b>XE28S</b>	<b>Hovercraft operating on land or swamp as counterpart in land transport crash</b>
<b>XE8AH</b>	<b>Amphibious vehicle on land as counterpart in land transport crash</b>
<b>XE9KN</b>	<b>Quad bike as counterpart in land transport crash</b>
<b>XE6QK</b>	<b>Animal as counterpart in land transport crash</b> Any animal struck in a transport crash.
<b>XE7A0</b>	<b>Unattended animal as counterpart in land transport crash</b>
<b>XE22V</b>	<b>Animal being herded as counterpart in land transport crash</b>
<b>XE756</b>	<b>Animal being ridden as counterpart in land transport crash</b>
<b>XE6X8</b>	<b>Animal drawn vehicle as counterpart in land transport crash</b> A vehicle on wheels (cart, dray, carriage) or runners (sled) the motive power for which is provided by one or more animals.
<b>XE6DQ</b>	<b>Railway vehicle as counterpart in land transport crash</b> A vehicle, or a coupled set of vehicles (a train), designed for traffic on a railway.
<b>XE320</b>	<b>Railway train as counterpart in land transport crash</b>
<b>XE1W8</b>	<b>Funicular or monorail as counterpart in land transport crash</b> <b>Exclusions:</b> Other specified mechanism with no counterpart (XE5XB)
<b>XE98X</b>	<b>Fixed or stationary object as counterpart in land transport crash</b> Any object, structure or land conformation struck by a vehicle involved in a transport crash other than a transport vehicle in use, or a pedestrian, or a pedestrian conveyance in use.
<b>XE3KY</b>	<b>Vehicle parked at the side of a road or in a parking lot as counterpart in land transport crash</b>

<b>XE1RC</b>	<b>Small loose object as counterpart in land transport crash</b>
<b>XE9KG</b>	<b>Small or light fixed object as counterpart in land transport crash</b>
<b>XE43C</b>	<b>Large or heavy fixed object as counterpart in land transport crash</b>

#### Other mechanisms of transport injury without counterpart

<b>XE0JJ</b>	<b>Fall in mode of transport without counterpart</b>
<b>XE3M5</b>	<b>Fall from mode of transport without counterpart</b> Transport-related injurious event in which injury was sustained when the person fell from his/her mode of transport and did not involve a crash with a counterpart.
<b>XE64P</b>	<b>Fall from horse without counterpart</b>
<b>XE20L</b>	<b>Fall from motor vehicle without counterpart</b>
<b>XE7JA</b>	<b>Fall from motorcycle without counterpart</b>
<b>XE2K7</b>	<b>Fall from pedal cycle without counterpart</b>
<b>XE929</b>	<b>Fall from pedestrian conveyance without counterpart</b>
<b>XE5XB</b>	<b>Other specified mechanism with no counterpart</b> Transport-related injurious event in which a injury was sustained in an event that did not involve a crash with a counterpart or fall from the mode of transport.
<b>XE5FP</b>	<b>Sudden movement of vehicle, without collision, resulting in injury</b>
<b>XE9K8</b>	<b>Vehicle overturned without counterpart</b>
<b>XE5YL</b>	<b>Vehicle out of control without mention of collision with another vehicle or fixed object</b>

#### Aspects of sports injury events

##### Type of sport or exercise activity

<b>XE3GK</b>	<b>Team ball sports</b>
<b>XE9UG</b>	<b>Type of sport or exercise activity, basketball</b>
<b>XE3T2</b>	<b>Type of sport or exercise activity, football - American tackle</b>
<b>XE31W</b>	<b>Type of sport or exercise activity, football - American touch or flag</b>
<b>XE72L</b>	<b>Type of sport or exercise activity, football - Australian rules</b>
<b>XE3BA</b>	<b>Type of sport or exercise activity, football not otherwise specified</b>
<b>XE7D6</b>	<b>Type of sport or exercise activity, handball - team</b>
<b>XE510</b>	<b>Type of sport or exercise activity, netball</b>

XE9RW	Type of sport or exercise activity, rugby union
XE5XZ	Type of sport or exercise activity, rugby league
XE1XR	Type of sport or exercise activity, rugby not otherwise specified
XE5EU	Type of sport or exercise activity, soccer - outdoor
XE0TN	Type of sport or exercise activity, soccer - indoor
XE8WP	Type of sport or exercise activity, soccer not otherwise specified
XE79M	Type of sport or exercise activity, volleyball
XE0JP	Type of sport or exercise activity, wallyball
<b>XE2BF</b>	<b>Team bat or stick sports</b>
XE84M	Type of sport or exercise activity, baseball
XE5M7	Type of sport or exercise activity, cricket
XE2UD	Type of sport or exercise activity, ice hockey
XE6B7	Type of sport or exercise activity, hockey - street or ball
XE8HB	Type of sport or exercise activity, field hockey
XE9N5	Type of sport or exercise activity, floor hockey
XE02P	Type of sport or exercise activity, hockey not otherwise specified
XE8M1	Type of sport or exercise activity, ringette
XE63E	Type of sport or exercise activity, softball
XE5WM	Type of sport or exercise activity, t-ball
<b>XE2BG</b>	<b>Team water sports</b>
XE8KM	Type of sport or exercise activity, rescue and resuscitation
XE6Y2	Type of sport or exercise activity, synchronized swimming <i>Exclusions:</i> Individual water sports (XE6W9)
XE323	Type of sport or exercise activity, underwater hockey
XE2YS	Type of sport or exercise activity, water polo
<b>XE85T</b>	<b>Boating sports</b>
XE1LG	Type of sport or exercise activity, canoeing
XE7BZ	Type of sport or exercise activity, jet skiing
XE99V	Type of sport or exercise activity, kayaking or white-water rafting
XE4LT	Type of sport or exercise activity, power boat racing

XE4XV	Type of sport or exercise activity, rowing or sculling
XE0XD	Type of sport or exercise activity, surf boating
XE0G3	Type of sport or exercise activity, yachting or sailing
<b>XE6W9</b>	<b>Individual water sports</b>
XE3R2	Type of sport or exercise activity, platform diving
	<i>Exclusions:</i> Type of sport or exercise activity, cliff diving (XE5RZ)
XE7S0	Type of sport or exercise activity, springboard diving
XE5UC	type of sport/exercise activity, diving - unspecified
XE5FN	Type of sport or exercise activity, fishing
XE1TE	Type of sport or exercise activity, scuba diving
XE1ZK	Type of sport or exercise activity, snorkelling
XE48G	Type of sport or exercise activity, surfing or boogie boarding
	<i>Exclusions:</i> Type of sport or exercise activity, wind surfing (XE7PV)
XE84Q	Type of sport or exercise activity, surf life saving
XE1FN	Type of sport or exercise activity, competitive swimming
	<i>Exclusions:</i> Type of sport or exercise activity, recreational swimming (XE6P1)
XE167	Type of sport or exercise activity, water skiing
XE92F	Type of sport or exercise activity, water tubing
XE7PV	Type of sport or exercise activity, wind surfing
XE5RZ	Type of sport or exercise activity, cliff diving
XE6P1	Type of sport or exercise activity, recreational swimming
<b>XE9DF</b>	<b>Ice or snow sports</b>
XE225	Type of sport or exercise activity, bobsledding
XE7J1	Type of sport or exercise activity, curling
XE1SZ	Type of sport or exercise activity, ice skating or ice dancing
	<i>Exclusions:</i> Type of sport or exercise activity, speed skating (XE6RE)
XE9KF	Type of sport or exercise activity, luge
XE7E1	Type of sport or exercise activity, ski patrolling
XE9X7	Type of sport or exercise activity, skiing - alpine or downhill
XE8CR	Type of sport or exercise activity, skiing - Nordic cross country

XE8UF	Type of sport or exercise activity, freestyle skiing
XE471	Type of sport or exercise activity, snow ski jumping
XE240	Type of sport or exercise activity, snowmobiling
XE7J0	Type of sport or exercise activity, snow boarding
XE6RE	Type of sport or exercise activity, speed skating
XE8G0	Type of sport or exercise activity, tobogganing
<b>XE3L1</b>	<b>Individual athletic activities</b>
XE286	Type of sport or exercise activity, aerobic or callisthenics
XE5KC	Type of sport or exercise activity, jogging or running
	<i>Exclusions:</i> Type of sport or exercise activity, walking (XE2TV)
XE05C	Type of sport or exercise activity, tai chi
XE1SW	Type of sport or exercise activity, track and field - racing over obstacles or hurdles
XE02A	Type of sport or exercise activity, track and field - sprinting (1-400 metres)
XE2RC	Type of sport or exercise activity, track and field - running middle distances (401-1,500 metres)
XE4Y7	Type of sport or exercise activity, track and field - running long distances (greater than 1,500 metres)
XE1X1	Type of sport or exercise activity, track and field - high jump
XE10W	Type of sport or exercise activity, track and field - long jump
XE8YM	Type of sport or exercise activity, track and field - pole vault
XE5X4	Type of sport or exercise activity, track and field - triple jump
XE4C5	Type of sport or exercise activity, track and field - discus
XE037	Type of sport or exercise activity, track and field - javelin
XE1FT	Type of sport or exercise activity, track and field - hammer throw
XE3M7	Type of sport or exercise activity, track and field - shot putt
XE2TV	Type of sport or exercise activity, walking
XE7F9	Type of sport or exercise activity, yoga or Pilates
XE9V7	Type of sport or exercise activity, stationary aerobic exercise with equipment
<b>XE4HZ</b>	<b>Acrobatic sports</b>
XE2T9	Type of sport or exercise activity, cheerleading
XE65D	Type of sport or exercise activity, gymnastics - balance beam

XE5WY	Type of sport or exercise activity, gymnastics - floor exercise or tumbling
XE69D	Type of sport or exercise activity, gymnastics - high bar
XE6R6	Type of sport or exercise activity, gymnastics - parallel bars
XE4YF	Type of sport or exercise activity, gymnastics - rhythmic with or without props
XE8WK	Type of sport or exercise activity, gymnastics - rings
XE802	Type of sport or exercise activity, gymnastics - side horse or pommel horse
XE8V7	Type of sport or exercise activity, gymnastics - trampoline or mini-trampoline
XE5KU	Type of sport or exercise activity, gymnastics - uneven parallel bars
XE7PU	Type of sport or exercise activity, gymnastics - vault
<b>XE9SK</b>	<b>Aesthetic activities</b>
XE6H2	Type of sport or exercise activity, dancing
XE0R2	Type of sport or exercise activity, marching
<b>XE0KE</b>	<b>Racquet sports</b>
XE3SV	Type of sport or exercise activity, badminton
XE5Z7	Type of sport or exercise activity, racquetball
XE629	Type of sport or exercise activity, squash
XE5JM	Type of sport or exercise activity, table tennis or ping-pong
XE97B	Type of sport or exercise activity, tennis
<b>XE2NY</b>	<b>Target or precision sports</b>
XE0KA	Type of sport or exercise activity, archery
XE760	Type of sport or exercise activity, bocce, boules or petanque
XE5XX	Type of sport or exercise activity, billiards, pool or snooker
XE5VJ	Type of sport or exercise activity, lawn bowling
XE8AU	Type of sport or exercise activity, croquet
XE7NG	Type of sport or exercise activity, darts
XE416	Type of sport or exercise activity, golf
XE6YY	Type of sport or exercise activity, ten-pin bowling
XE08Q	Type of sport or exercise activity, firearm shooting
<i><b>Exclusions:</b></i> Type of sport or exercise activity, paintball gun shooting (XE1N9)	

XE0HX	Type of sport or exercise activity, bb or pellet gun shooting
XE1N9	Type of sport or exercise activity, paintball gun shooting
<b>XE3E4</b>	<b>Combative sports</b>
XE7K5	Type of sport or exercise activity, aikido
XE8AB	Type of sport or exercise activity, boxing
XE4E3	Type of sport or exercise activity, fencing
XE6B1	Type of sport or exercise activity, judo
XE0U2	Type of sport or exercise activity, jujitsu
XE567	Type of sport or exercise activity, karate
XE8WT	Type of sport or exercise activity, kendo
XE0Y9	Type of sport or exercise activity, kick-boxing
XE5QV	Type of sport or exercise activity, kung fu
XE7RA	Type of sport or exercise activity, tae kwon do
XE0CG	Type of sport or exercise activity, freestyle wrestling
XE8M6	Type of sport or exercise activity, Greco-Roman wrestling
XE4QQ	Type of sport or exercise activity, professional wrestling - entertainment style
XE75J	Type of sport or exercise activity, self defence training
<b>XE1EU</b>	<b>Power sports</b>
XE7QE	Type of sport or exercise activity, power lifting
XE6RQ	Type of sport or exercise activity, Olympic weightlifting
XE0N6	Type of sport or exercise activity, strength training or body building
XE3PG	Type of sport or exercise activity, timber-related sports
<b>XE42Q</b>	<b>Equestrian activities</b>
XE6DF	Type of sport or exercise activity, equestrian dressage
XE75K	Type of sport or exercise activity, endurance riding
XE8JM	Type of sport or exercise activity, equestrian eventing
XE0BK	Type of sport or exercise activity, mustering or stock work
XE6PK	Type of sport or exercise activity, equestrian polo or polocrosse
XE4GZ	Type of sport or exercise activity, pony club
XE0P4	Type of sport or exercise activity, horse racing

XE56X	Type of sport or exercise activity, rodeo
XE7X5	Type of sport or exercise activity, show jumping
XE7MC	Type of sport or exercise activity, equestrian steeplechase
XE1LH	Type of sport or exercise activity, trail or general horseback riding
XE2LJ	Type of sport or exercise activity, equestrian trotting or harness
<b>XE3T3</b>	<b>Adventure sports</b>
XE08U	Type of sport or exercise activity, abseiling or rappelling
XE5BS	Type of sport or exercise activity, hiking
XE79W	Type of sport or exercise activity, mountaineering
XE8WG	Type of sport or exercise activity, orienteering or rogaining
XE2J8	Type of sport or exercise activity, river rafting
XE6Z2	Type of sport or exercise activity, rock climbing
XE74G	Type of sport or exercise activity, bungee jumping
<b>XE85A</b>	<b>Wheeled motor sports</b>
XE7HV	Type of sport or exercise activity, riding an all-terrain vehicle (ATV)
XE1R5	Type of sport or exercise activity, motorcycling
XE26F	Type of sport or exercise activity, motor car racing
XE46F	Type of sport or exercise activity, go-carting or carting
XE1MM	Type of sport or exercise activity, motorised scootering
<b>XE4DA</b>	<b>Wheeled non-motored sports</b>
XE5UJ	Type of sport or exercise activity, BMX cycling
XE4SS	Type of sport or exercise activity, mountain cycling
XE87G	Type of sport or exercise activity, road cycling
XE8U6	Type of sport or exercise activity, track or velodrome cycling
XE7MG	Type of sport or exercise activity, cycling not otherwise specified
XE5V9	type of sport/exercise activity, in-line skating/rollerblading
XE2DY	Type of sport or exercise activity, roller skating
XE1AS	Type of sport or exercise activity, skate boarding
XE6X9	Type of sport or exercise activity, scootering
XE72X	Type of sport or exercise activity, spinning or stationary bike riding

XE78K	Type of sport or exercise activity, street luge
<b>XE7BS</b>	<b>Multidiscipline sports</b>
XE3BK	Type of sport or exercise activity, biathlon - cross-country skiing event
XE05T	Type of sport or exercise activity, biathlon - shooting event
XE7ZX	Type of sport or exercise activity, biathlon - unspecified event
XE5PT	Type of sport or exercise activity, decathlon - 100 metre event
XE7ND	Type of sport or exercise activity, decathlon - 400 metre event
XE9AM	Type of sport or exercise activity, decathlon - 1,500 metre event
XE5C1	Type of sport or exercise activity, decathlon - 110 metre hurdles event
XE6CK	Type of sport or exercise activity, decathlon - long jump event
XE331	Type of sport or exercise activity, decathlon - high jump event
XE6GN	Type of sport or exercise activity, decathlon - shot put event
XE11Q	Type of sport or exercise activity, decathlon - discus event
XE37C	Type of sport or exercise activity, decathlon - javelin event
XE7LJ	Type of sport or exercise activity, decathlon - pole vault event
XE48E	Type of sport or exercise activity, decathlon - unspecified event
XE4LW	Type of sport or exercise activity, heptathlon - 200 metre event
XE9EF	Type of sport or exercise activity, heptathlon - 100 metre hurdles event
XE90J	Type of sport or exercise activity, heptathlon - high jump event
XE8WE	Type of sport or exercise activity, heptathlon - long jump event
XE7TG	Type of sport or exercise activity, heptathlon - javelin event
XE294	Type of sport or exercise activity, heptathlon - shot putt event
XE4CW	Type of sport or exercise activity, heptathlon - 800 metre event
XE1JE	Type of sport or exercise activity, heptathlon - unspecified event
XE3GA	Type of sport or exercise activity, modern pentathlon - shooting event
XE758	Type of sport or exercise activity, modern pentathlon - fencing event
XE7GA	Type of sport or exercise activity, modern pentathlon - swimming event
XE8KQ	Type of sport or exercise activity, modern pentathlon - equestrian event
XE84E	Type of sport or exercise activity, modern pentathlon - running event
XE2B4	Type of sport or exercise activity, modern pentathlon - unspecified event

XE2XU	Type of sport or exercise activity, triathlon - cycling event
XE0J9	Type of sport or exercise activity, triathlon - running event
XE8ZK	Type of sport or exercise activity, triathlon - swimming event
XE01T	Type of sport or exercise activity, triathlon - unspecified event
<b>XE03W</b>	<b>Aero (non-motored) sports</b>
XE34L	Type of sport or exercise activity, aerobatics
XE88Y	Type of sport or exercise activity, gliding
XE3VS	Type of sport or exercise activity, hang gliding
XE0JU	type of sport/exercise activity, parachuting/sky diving
XE06C	Type of sport or exercise activity, paragliding or parasailing
XE99S	Type of sport or exercise activity, hot air ballooning
<b>XE68C</b>	<b>Other school-related recreational activities</b>
XE49T	Type of sport or exercise activity, school physical education class
XE67P	Type of sport or exercise activity, school free play

#### Phase of sport or exercise activity

<b>XE9ET</b>	<b>Phase of sport or exercise activity - Training or practice</b>
XE1U5	<b>Phase of activity, sport-specific or skill-specific practice</b>
	<b><i>Exclusions:</i></b> Phase of activity, scrimmaging (XE07B)
XE07B	<b>Phase of activity, scrimmaging</b>
XE0BT	<b>Phase of activity, strength and conditioning or weight training</b>
	<b><i>Exclusions:</i></b> Phase of activity, cardiovascular training (XE945)
XE945	<b>Phase of activity, cardiovascular training</b>
	<b><i>Exclusions:</i></b> Phase of activity, strength and conditioning or weight training (XE0BT)
XE583	<b>Phase of activity, not otherwise specified training or practice</b>
<b>XE8MZ</b>	<b>Phase of activity, pre-event</b>
<b>XE2D1</b>	<b>Phase of activity, warm-up</b>
<b>XE5TJ</b>	<b>Phase of sport or exercise activity - Competition or participation</b>
XE66C	<b>Phase of activity, competition or participation, first 25% of expected event duration</b>

<b>XE0QY</b>	<b>Phase of activity, competition or participation, middle 50% of expected event duration</b>
<b>XE2CG</b>	<b>Phase of activity, competition or participation, last 25% of expected event duration</b>
<b>XE20Y</b>	<b>Phase of activity, competition or participation, events whose time course can not be anticipated</b>
<b>XE4ZN</b>	<b>Phase of activity, competition or participation, unspecified stage of the event</b>
<b>XE1P9</b>	<b>Phase of activity, cool down</b>
<b>XE2BD</b>	<b>Phase of activity, post-event</b>
<b>XE49R</b>	<b>Phase of activity, recreational participation</b>
<b>XE0QV</b>	<b>Phase of activity, other specified phase of activity</b>
<b>XE8ZT</b>	<b>Unspecified phase of activity</b>

Personal countermeasures in sport or exercise

<b>XE4K4</b>	<b>Personal countermeasures, no protective devices used</b>
<b>XE8Z8</b>	<b>Personal countermeasures, braces, guards or orthoses</b>
<b>XE75U</b>	<b>Personal countermeasures, rigid taping of joint</b>
<b>XE9TY</b>	<b>Personal countermeasures, padding of joint, bony prominence, or muscle</b>
<b>XE10N</b>	<b>Personal countermeasures, thermal devices</b>
<b>XE0LS</b>	<b>Personal countermeasures, splints</b>
<b>XE16J</b>	<b>Personal countermeasures, jock strap or protective cup</b>
<b>XE4RU</b>	<b>Personal countermeasures, gloves</b>
<b>XE49L</b>	<b>Personal countermeasures, mouth guard</b>
<b>XE338</b>	<b>Personal countermeasures, eye goggles or protective glasses</b>
<b>XE2ZG</b>	<b>Personal countermeasures, helmet</b>
<b>XE3RM</b>	<b>Personal countermeasures, face mask or shield</b>
<b>XE7K8</b>	<b>Personal countermeasures, foot wear</b>
<b>XE26E</b>	<b>Personal countermeasures, personal flotation device</b>

Environmental countermeasures in sport or exercise

<b>XE3U8</b>	<b>Environmental countermeasures, no protective devices used</b>
--------------	--

<b>XE0DA</b>	<b>Environmental countermeasures, protective padding on competition surface</b>
<b>XE0W0</b>	<b>Environmental countermeasures, padded goal posts, or corner markers</b>
<b>XE8UC</b>	<b>Environmental countermeasures, barrier between area of activity and spectators or surrounds</b>
<b>XE0LL</b>	<b>Environmental countermeasures, safety restraints or vehicle restraints</b>

Aspects of occupational injury events

### Economic activity

<b>XE7J2</b>	<b>Economic activity, agriculture, hunting, or forestry</b>
	<i>Exclusions:</i> Economic activity, health or social work (XE0G4)
<b>XE227</b>	<b>Economic activity, fishing</b>
<b>XE45Q</b>	<b>Economic activity, mining, quarrying, or extraction</b>
<b>XE13G</b>	<b>Economic activity, manufacturing</b>
<b>XE6WE</b>	<b>Economic activity, electricity, gas, or water supply</b>
<b>XE0SE</b>	<b>Economic activity, construction</b>
<b>XE139</b>	<b>Economic activity, wholesale or retail trade</b>
<b>XE6J4</b>	<b>Economic activity, repair of motor vehicles, motorcycles, or personal and household goods</b>
<b>XE4JS</b>	<b>Economic activity, hotels or restaurants</b>
<b>XE5JN</b>	<b>Economic activity, transport, storage, or communications</b>
<b>XE8A7</b>	<b>Economic activity, financial intermediation</b>
<b>XE3YF</b>	<b>Economic activity, real estate, renting, or business activities</b>
<b>XE3K1</b>	<b>Economic activity, public administration, defence, or compulsory social security</b>
<b>XE54F</b>	<b>Economic activity, providing education</b>
<b>XE0G4</b>	<b>Economic activity, health or social work</b>
<b>XE7X1</b>	<b>Economic activity, other community, social, or personal service activities</b>
<b>XE2PM</b>	<b>Economic activity, private households with employed persons</b>
<b>XE6N7</b>	<b>Economic activity, extra-territorial organisations or bodies</b>

## Occupation

XE3TU	<b>Occupation - legislators, senior officials, managers</b>
XE59Y	<b>Occupation - professionals</b>
XE558	<b>Occupation - technicians or associate professionals</b>
XE17U	<b>Occupation - clerks, secretaries</b>
XE1CA	<b>Occupation - service workers, shop and market sales workers</b>
XE6TG	<b>Occupation - skilled agriculture or fishery workers</b>
XE0VC	<b>Occupation - craft or related trades workers</b>
XE37Y	<b>Occupation - plant/machine operators or assemblers</b>
XE4EE	<b>Occupation - elementary occupations</b>
XE5G8	<b>Occupation - armed forces</b>

Aspects of assault and maltreatment

## Perpetrator-victim relationship

XE454	<b>Spouse or partner</b>
XE041	<b>Perpetrator-victim relationship, legal spouse</b> <i>Exclusions:</i> Perpetrator-victim relationship, Ex-spouse (XE6Q9)
XE8JN	<b>Perpetrator-victim relationship, cohabiting partner</b>
XE8GZ	<b>Perpetrator-victim relationship, noncohabiting partner</b> <i>Exclusions:</i> Perpetrator-victim relationship, date (XE7GT)
XE6Q9	<b>Perpetrator-victim relationship, Ex-spouse</b>
XE8TC	<b>Perpetrator-victim relationship, Ex-partner</b>
XE8AA	<b>Parent</b> <i>Exclusions:</i> Perpetrator-victim relationship, foster parent (XE4BZ)
XE8QX	<b>Perpetrator-victim relationship, father or mother</b> <i>Exclusions:</i> Perpetrator-victim relationship, step-parent (XE9FD)
XE9FD	<b>Perpetrator-victim relationship, step-parent</b>
XE5WN	<b>Other relative</b>
XE9JY	<b>Perpetrator-victim relationship, full sibling</b>
XE9RK	<b>perpetrator-victim relationship, partial or half sibling</b>

XE4KJ	<b>Perpetrator-victim relationship, step-sibling</b>
XE9S0	<b>Perpetrator-victim relationship, grandparent</b>
XE10C	<b>Perpetrator-victim relationship, offspring</b>
XE8EU	<b>Perpetrator-victim relationship, other blood relative</b>
XE8FS	<b>Perpetrator-victim relationship, in-laws</b>
<b>XE4BG</b>	<b>Unrelated care giver</b>
XE4BZ	<b>Perpetrator-victim relationship, foster parent</b>
XE670	<b>Perpetrator-victim relationship, care giver in institution</b>
XE02B	<b>Perpetrator-victim relationship, health care provider</b>
<b>XE270</b>	<b>Acquaintance or friend</b>
XE1X5	<b>Perpetrator-victim relationship, parent's partner</b>
	<i><b>Exclusions:</b></i> Perpetrator-victim relationship, step-parent (XE9FD)
XE7GT	<b>Perpetrator-victim relationship, date</b>
XE6WK	<b>Perpetrator-victim relationship, roommate</b>
	<i><b>Exclusions:</b></i> Stranger (XE4WS)
XE6P9	<b>Perpetrator-victim relationship, business relation</b>
XE32X	<b>Perpetrator-victim relationship, neighbour</b>
XE80F	<b>Perpetrator-victim relationship, institutional co-member</b>
XE5MH	<b>Perpetrator-victim relationship, friend not otherwise specified</b>
XE39B	<b>Perpetrator-victim relationship, acquaintance not otherwise specified</b>
<b>XE2HC</b>	<b>Official or legal authority</b>
XE6AM	<b>Perpetrator-victim relationship, official or legal authority, military</b>
	<i><b>Exclusions:</b></i> Perpetrator-victim relationship, official or legal authority, police (XE2Z7)
	Perpetrator-victim relationship, national or official authority not otherwise specified (XE5ZT)
XE2Z7	<b>Perpetrator-victim relationship, official or legal authority, police</b>
	<i><b>Exclusions:</b></i> Perpetrator-victim relationship, official or legal authority, military (XE6AM)
	Perpetrator-victim relationship, security group not otherwise specified (XE8PB)
	Perpetrator-victim relationship, national or official authority not otherwise specified (XE5ZT)

<b>XE5ZT</b>	<b>Perpetrator-victim relationship, national or official authority not otherwise specified</b>
<b>XE8PB</b>	<b>Perpetrator-victim relationship, security group not otherwise specified</b>
<b>XE59K</b>	<b>Perpetrator-victim relationship, official or legal authority, civilian authority</b>
	<b><i>Exclusions:</i></b> Perpetrator-victim relationship, security group not otherwise specified (XE8PB)
<b>XE4WS</b>	<b>Stranger</b>
<b>XE0CA</b>	<b>Perpetrator-victim relationship, stranger in vigilante group</b>
<b>XE7XG</b>	<b>Perpetrator-victim relationship, stranger in mob</b>
<b>XE2XY</b>	<b>Perpetrator-victim relationship, stranger not otherwise specified</b>
<b>XE0H2</b>	<b>Perpetrator-victim relationship, prisoner or detainee</b>
<b>XE3FJ</b>	<b>Perpetrator-victim relationship, person executing a felony or crime</b>
<b>XE388</b>	<b>Perpetrator-victim relationship, person interceding in a crime</b>

#### Gender of perpetrator

<b>XE5YG</b>	<b>Gender of perpetrator, male</b>
<b>XE56C</b>	<b>Gender of perpetrator, female</b>
<b>XE9SL</b>	<b>Gender of perpetrator, unknown</b>
<b>XE6W8</b>	<b>Gender of perpetrator, other</b>

#### Context of assault and maltreatment

<b>XE0UM</b>	<b>Altercation</b>
	<b><i>Exclusions:</i></b> Drug-related incident (XE933)
<b>XE591</b>	<b>About family issues</b>
<b>XE2RR</b>	Context of assault, altercation about family issues, children
<b>XE37R</b>	Context of assault, altercation about family issues, in-laws
<b>XE1B3</b>	Context of assault, altercation about family issues, dowry issues
<b>XE1F9</b>	Context of assault, altercation about family issues, family honour
<b>XE9SP</b>	<b>About personal issues</b>
<b>XE1XB</b>	Context of assault, altercation about current love relationship
<b>XE3YH</b>	Context of assault, altercation about terminating a love relationship

<b>XE6DB</b>	Context of assault, altercation about sex  <b><i>Exclusions:</i></b> Context of assault, sexual assault (XE213)
<b>XE4H5</b>	<b>About personally-held views</b>
<b>XE03X</b>	Context of assault, altercation about personally-held views regarding politics
<b>XE860</b>	Context of assault, altercation about personally-held views regarding religious or spiritual matters
<b>XE1RW</b>	Context of assault, altercation about personally-held views regarding cultural issues
<b>XE6YL</b>	Context of assault, altercation about personally-held views regarding racial or ethnic issues
<b>XE1Q8</b>	Context of assault, altercation about personally-held views regarding issues of gender or sexual orientation
<b>XE0Z5</b>	<b>About business or financial issues</b>
<b>XE4ML</b>	Context of assault, altercation about loss of employment
<b>XE00W</b>	Context of assault, altercation about other financial losses related to employment or business  <b><i>Exclusions:</i></b> Drug-related incident (XE933)
<b>XE05L</b>	Context of assault, other employment disputes
<b>XE62S</b>	Context of assault, altercation about money or property
<b>XE6VD</b>	<b>About sports and other leisure</b>
<b>XE81U</b>	Context of assault, altercation about gambling
<b>XE47F</b>	Context of assault, altercation about sports  <b><i>Exclusions:</i></b> Context of assault, altercation about gambling (XE81U)
<b>XE8NL</b>	<b>Context of assault, altercation about traffic</b>
<b>XE4XA</b>	<b>Context of assault, malicious misconduct</b>
<b>XE4P2</b>	<b>Context of assault, bullying, intimidation</b>
<b>XE3KE</b>	<b>Context of assault, altercation about past altercation</b>
<b>XE91G</b>	<b>Illegal acquisition or attempted illegal acquisition of money or property</b>  <b><i>Exclusions:</i></b> Drug-related incident (XE933) Context of assault, kidnapping (XE1N7)
<b>XE0LR</b>	<b>Context of assault, burglary</b>
<b>XE6PL</b>	<b>Robbery</b>
<b>XE6YM</b>	Context of assault, unarmed robbery
<b>XE989</b>	Context of assault, armed robbery

<b>XE933</b>	<b>Drug-related incident</b>
XE5AY	<b>Context of assault, selling drugs or drug business</b>
XE0Z6	<b>Context of assault, argument over possession, use, or cost of drugs</b>
XE1GC	<b>Context of assault, failure to pay a drug debt</b>
XE1LL	<b>Context of assault, probable drug involvement, but no positive evidence</b>
<b>XE213</b>	<b>Context of assault, sexual assault</b>
XE6U2	<b>Context of assault, rape or attempted rape</b>
XE85Q	<b>Context of assault, sodomy or attempted sodomy</b>
XE29Q	<b>Context of assault, touching or fondling of genitals</b>
XE18N	<b>Context of assault, oral sex</b>
<b>XE8DB</b>	<b>Gang-related incident</b>
XE3QM	<b>Context of assault, gang initiation</b>
XE2A5	<b>Context of assault, gang rivalry</b>
<b>XE3V7</b>	<b>Other criminal activity</b>
XE2QF	<b>Context of assault, blackmail</b>
XE1N7	<b>Context of assault, kidnapping</b>
XE0NB	<b>Context of assault, contract injuring or killing</b>
XE5A7	<b>Context of assault, drive-by shooting</b>
<b>XE5QX</b>	<b>Other specified context of assault</b>
XE6FN	<b>Context of assault, retaliation or revenge</b>
XE3G0	<b>Context of assault, mercy killing or euthanasia</b>
XE90G	<b>Context of assault, neglect</b>
XE580	<b>Context of assault, torture</b>
XE92U	<b>Context of assault, additional context, mistaken identity</b>

Aspects of intentional self-harm events

Proximal risk-factors for intentional self-harm

<b>XE17Z</b>	<b>Conflict in relationship with family member, partner, or friend</b>
XE9SZ	<b>Proximal risk factors for intentional self-harm, Conflict in relationship with spouse, partner, boy/girlfriend</b>

XE6QA	<b>Proximal risk factors for intentional self-harm, Conflict in relationship with parent</b>
XE1A1	<b>Proximal risk factors for intentional self-harm, Conflict in relationship with offspring</b>
<b>XE3GP</b>	<b>Death of a relative, partner, or friend</b>
XE19R	<b>Proximal risk factors for intentional self-harm, Suicide of a relative, partner or friend</b>
XE8T3	<b>Proximal risk factors for intentional self-harm, Other manner of death of a relative, partner or friend</b>
XE2FT	<b>Proximal risk factors for intentional self-harm, Unspecified manner of death of a relative, partner or friend</b>
<b>XE97R</b>	<b>Physical problem</b>
XE5CU	<b>Proximal risk factors for intentional self-harm, HIV or AIDS</b>
XE3AG	<b>Proximal risk factors for intentional self-harm, Unwanted pregnancy</b>
<b>XE6XD</b>	<b>Mental condition</b>
XE2Q7	<b>Proximal risk factors for intentional self-harm, Substance abuse</b>
XE79G	<b>Proximal risk factors for intentional self-harm, Postpartum depression</b>
<b>XE3U9</b>	<b>Income-related or financial problem</b>
XE70C	<b>Proximal risk factors for intentional self-harm, Work-related</b>
XE4UX	<b>Proximal risk factors for intentional self-harm, Dowry</b>
<b>XE5J3</b>	<b>Abuse</b>
XE8HX	<b>Proximal risk factors for intentional self-harm, Sexual abuse</b>
XE8ND	<b>Proximal risk factors for intentional self-harm, Physical abuse</b>
XE2RX	<b>Proximal risk factors for intentional self-harm, Neglect</b>
<b>XE31V</b>	<b>Proximal risk factors for intentional self-harm, Legal system encounters</b>
<b>XE8MK</b>	<b>Proximal risk factors for intentional self-harm, School-related problem</b>
<b>XE98Q</b>	<b>Proximal risk factors for intentional self-harm, Religious belief or affiliation</b>
<b>XE6TW</b>	<b>Proximal risk factors for intentional self-harm, Cultural issue</b>

Previous non-fatal intentional self harm

**XE76W**      **Previous suicide attempt, No**

**XE3YR Previous suicide attempt, Yes**

Intention to die aspect of self-harm

**Inclusions:**

- parasuicide (incomplete suicide attempt)
- self-mutilation
- suicide

**XE97V Intentional self-harm, person intended to die**

Intentional self-harm with intent to cause the death of the person.

**XE5D6 Intentional self-harm, person did not intend to die**

Self-injury, self-harm, cutting or self-mutilation undertaken intentionally for reasons other than to bring about the death of the person.

**XE2SF Intentional self-harm, not known or not determined if person intended to die**

Information that a competent person (e.g. psychiatrist, coroner) had concluded that it could not be determined whether the intentional self-harm was done with intent to die. No information or insufficient information was available.

Aspects of armed conflict

Type of armed conflict

**XE2RB Type of conflict, civil war or guerrilla operation**

**XE324 Type of conflict, war**

**XE4RJ Type of conflict, declared terrorism**

**XE0EG Type of conflict, civil insurrection**

**XE7HW Type of conflict, postconflict incident**

Role of injured person in armed conflict

**XE42H Military personnel**

**XE2WZ Civilian**

**XE3P0 Role of injured person in armed conflict unknown**

Type of legal intervention

**XE52B Potential arrest situation**

**XE9JF Type of legal intervention, potential arrest related traffic pursuit**

XE25D	Type of legal intervention, potential arrest related investigation of a suspicious person or incident
XE3XD	Type of legal intervention, potential arrest related execution of an arrest
<b>XE8Z9</b>	<b>Response to a disturbance call</b>
XE84H	Type of legal intervention, response to a disturbance call because of a family dispute
XE8WD	Type of legal intervention, response to a disturbance call because of a person behaving aberrantly
XE3FV	Type of legal intervention, response to other specified disturbance call
XE439	Type of legal intervention, response to unspecified disturbance call
<b>XE8M2</b>	<b>Type of legal intervention, ambush situation</b>
<b>XE1DD</b>	<b>Type of legal intervention, civil disorder</b>
<b>XE0RZ</b>	<b>Type of legal intervention, handling, transporting, or custody of prisoner</b>
<b>XE7AT</b>	<b>Type of legal intervention, execution of a legal sentence</b>

Aspects of incidents related to devices

Problem related to the interaction between the patient and the device.

<b>XE4HK</b>	<b>Patient device interaction problem</b>
<b>XE6GS</b>	<b>Patient-device incompatibility</b>
<b>XE7ZE</b>	Biocompatibility Problem associated with undesirable local or systemic effects due to exposure to medical device materials or leachates from those materials by a patient who has an implant or is receiving treatment with a device made from them.
<b>XE2CL</b>	Device appears to trigger rejection The device appears to elicit undesired response in the patient to the presence of an implanted or invasive device, without inherent device failure, e.g. fibrous encapsulation, or inflammation of the tissue around the device, or extrusion of the device
<b>XE584</b>	Inadequacy of device shape or size The physical size or shape of the device was inadequate with regard to the patient's anatomy.
<b>XE7JV</b>	<b>Osseointegration problem</b> Problem associated with interconnection between the bone tissue and the implanted device.

<b>XE94Z</b>	Failure to osseointegrate Problem associated with the failure to see direct anchorage of an implant by the formation of bony tissue around the implant without the growth of fibrous tissue at the bone-implant interface.
<b>XE0Z9</b>	Loss of osseointegration Problem associated with weakened integration of the device at the bone-implant interface due to loss of fibrous and/or bony tissue and leading to compromised anchorage of the device
<b>XE2K9</b>	<b>Loosening of implant not related to bone-ingrowth</b> Problem associated with the loss of direct anchorage of an implanted device over time or due to an injury.
<b>XE0VD</b>	<b>Migration or expulsion of device</b> Problem with an implanted or invasive device moving within the body, or being completely expelled from the body.
<b>XE763</b>	Migration of device Problem with all or part of an implanted or invasive device moving from its intended location within the body.
<b>XE1FH</b>	Expulsion of device Problem with all or part of an implanted or invasive device being completely expelled from its intended location within the body.
<b>XE7Q8</b>	<b>Manufacturing, packaging or shipping problem</b> Problem associated with any deviations from the documented specifications of the device that relate to nonconformity during manufacture to the design of an item or to specified manufacturing, packaging or shipping processes (out of box problem).
<b>XE5Y1</b>	<b>Product quality problem</b>
<b>XE4UR</b>	Dull or blunt Problem associated with a device not being as sharp as intended or expected.
<b>XE46G</b>	Nonstandard device Problem associated with the device that does not meet the specifications or requirements for which it was manufactured (e.g. materials, parts, manufacturing process).
<b>XE1K1</b>	<b>Defective component</b>
<b>XE9CD</b>	<b>Defective device</b>
<b>XE12L</b>	<b>Device damaged prior to use</b>
<b>XE8RY</b>	<b>Packaging problem</b> Problem associated with the materials used to construct the cover or outer wrapping of the device.

<b>XE01Z</b>	Difficult to open or remove packaging material Problem associated with difficulty for users to operate the device, specifically as it relates to the opening or removal of the outer wrapping.
<b>XE5YH</b>	Incomplete or missing packaging Problem associated with the nonconformance to the device specifications due to incomplete or missing packaging that may compromise the device operation as intended.
<b>XE4VM</b>	Unsealed device packaging Problem associated with the loss of packaging seal.
<b>XE2AN</b>	Tear, rip or hole in device packaging Problem associated with packaging damage (tear, rip or hole) prior to the use of the device.
<b>XE151</b>	<b>Device misassembled during manufacturing or shipping</b>
<b>XE9R8</b>	Component misassembled A device found to have one or more components incorrectly assembled when delivered to the user facility.
<b>XE89V</b>	Component missing A device component(s) found to be missing when delivered to the user facility.
<b>XE8ZA</b>	<b>Shipping damage or problem</b> Problem associated with shipping damage or problem prior to the use of the device.
<b>XE78P</b>	Delivered as unsterile product Problem associated with a device being received in such a manner to indicate that its sterility has been compromised (e.g. sterile packaging breached, visible contaminant present)
<b>XE52X</b>	<b>Chemical problem</b> Problem associated with any from the documented specifications of the device that relate to any chemical characterization, i.e., element, compound, or mixture.
<b>XE9AC</b>	<b>Device emits odour</b> Problem associated with an unexpected or inappropriate smell released by the device.
<b>XE3E0</b>	<b>Device ingredient or reagent problem</b> Problem associated with any deviations from the documented specifications of the device that relate to any ingredient or reagent characterization.
<b>XE4BC</b>	Clumping in device or device ingredient Problem associated with the aggregation of particles into irregular masses.

<b>XE49W</b>	Coagulation in device or device ingredient Problem associated with the undesired characterization of congealing, solidifying, thickening, curdling.
<b>XE4VP</b>	Precipitate in device or device ingredient Problem associated with the separation of solid particles from a liquid as the result of a chemical or physical change.
<b>XE8Z6</b>	Cross reactivity Problem associated with the degree to which an antibody or antigen participates in cross reactions.
<b>XE0VB</b>	Particulates Substances that consist of separate particles that are introduced by the device during use.
<b>XE0K7</b>	High pH pH higher than expected and / or anticipated.
<b>XE657</b>	Low pH pH lower than expected and / or anticipated.
<b>XE6E7</b>	<b>Improper chemical reaction</b>
<b>XE4LP</b>	<b>Material integrity problem</b> Problem associated with any deviations from the documented specifications of the device that relate to the limited durability of all material used to construct device.
<b>XE8D2</b>	<b>Break</b> Problem associated with undesired damage or breakage of those materials used in the device construction.
<b>XE1M6</b>	<b>Fracture of device</b> Problem associated with a partial or full-thickness crack in the device materials.
<b>XE9DU</b>	<b>Loss of or failure to bond</b> Problem associated with lack or loss of adherence between materials intended to be joined together by an adhesive.
<b>XE2ET</b>	<b>Material fragmentation</b> Problem associated with small pieces of the device breaking off unexpectedly.
<b>XE82N</b>	<b>Solder joint fracture</b> Problem associated with undesired damage or breakage in a solder joint of materials used in the device construction.
<b>XE638</b>	<b>Burst container or vessel</b> Problem associated with the pressure inside a vessel or container rising to such a degree that the container ruptures.

<b>XE5EZ</b>	<b>Explosion</b> Problem associated with the violent bursting due to the sudden expansion of air, gas or fluid.
<b>XE38M</b>	<b>Crack</b> Problem associated with an undesired partial separation and/or a visible opening along the length or width in the materials that are used in the device construction.
<b>XE0HB</b>	<b>Degraded</b> Problem associated with a undesired change in the chemical structure, physical properties, or appearance in the materials that are used in the device construction.
<b>XE8J3</b>	<b>Calcified</b> Problem associated with buildup of calcium salts on the device.
<b>XE228</b>	<b>Corroded</b> Problem associated with the chemical or electrochemical reaction between materials, usually a metal and its environment that produces a deterioration of the metal and its properties.
<b>XE1WE</b>	<b>Material erosion</b> Problem associated with a progressive loss of a material from a solid surface.
<b>XE9F6</b>	<b>Pitted</b> Problem associated with the corrosion of a material's surface, confined to a point or small area that takes the form of cavities.
<b>XE0YK</b>	<b>Flaked</b> Problem associated with the detachment of small pieces of the coating film of a material.
<b>XE3VG</b>	<b>Peeled or delaminated</b> Peeling or delamination of composite materials, including coatings, that occurs when layers are separated as a result of stress or impact and resulting in loss of mechanical toughness.
<b>XE975</b>	<b>Naturally worn</b> Problem associated with material damage to a surface, usually involving progressive loss or displacement of material, due to relative motion between that surface and a contacting substance or substances.
<b>XE9JW</b>	<b>Unraveled material</b> Problem due to the undesired unravelling of material (e.g. disentangled, unwound etc.).
<b>XE1LJ</b>	<b>Material deformation</b> Problem associated with an undesired material change in shape or property caused by external forces.

<b>XE0JB</b>	Deformation due to compressive stress Problem associated with an undesired bulge, bend, bow, kink, or wavy condition observed in the device material resulting from compressive stresses.
<b>XE5NT</b>	Dent in material Problem associated with a undesired change in shape, characterised by the presence of a slight hollow (dent) in the device surface.
<b>XE0ZV</b>	Failure to fold Problem associated with an undesired material change in physical property, characterised by failure to fold.
<b>XE06Q</b>	Failure to unfold or unwrap Problem associated with the comprising materials' deformation in that device fails to open its wrapping or open/extend in a certain manner i.e. balloon or lens.
<b>XE37M</b>	Material frayed Problem associated with the comprising materials having damaged edges.
<b>XE8PS</b>	Material invagination Problem associated with an undesired material change in shape, characterised by the infolding of one part within another part of a structure.
<b>XE4Z7</b>	Material too rigid or stiff Problem associated with an undesired material change in physical property, characterised by rigidity (it resists deformation in response to an applied force).
<b>XE9WH</b>	Material too soft or flexible Problem associated with any device material that results in the material's inability to maintain the desired shape or support function.
<b>XE47S</b>	Material twisted or bent Problem associated with deformations that lead to twisting or bending of the device.
<b>XE8ZQ</b>	Melted Problem associated with a solid device being transformed into a molten or liquid state.
<b>XE5D0</b>	Stretched Problem associated with an increase or elongation in a materials' dimension.
<b>XE2G9</b>	<b>Material discoloured</b> Problem associated with an undesired streak, pattern and/or a noticeable change in color from the rest of the materials used in the device construction.
<b>XE0RF</b>	<b>Material disintegration</b> Problem associated with material breaking into small particles.

<b>XE585</b>	<b>Material opacification</b> Problem associated with an undesirableopaqueness or cloudiness.
<b>XE9AR</b>	<b>Material perforation</b> Material constituting device is perforated possibly compromising the device's intended purpose.
<b>XE0X4</b>	Material puncture or hole Device material(s) punctured leading to undesired holes/openings.
<b>XE72S</b>	<b>Material protrusion or extrusion</b> Problem associated with undesired physical appearance of device material, specifically when material extends beyond or above device surface.
<b>XE6G0</b>	<b>Material rupture</b> Problem associated with perforations that lead to bursting of the device.
<b>XE6K7</b>	<b>Material separation</b> Problem associated with an undesired disassociation or breaking apart of the device.
<b>XE4FP</b>	<b>Material split, cut or torn</b> Problem associated with materials composing the device being split, cut or torn due to external forces (e.g. wrenching or laceration) or internal forces (e.g. exceeding the tensile stress limits belonging to the materials used in the device construction).
<b>XE609</b>	<b>Scratched material</b> Problem associated with an undesirable shallow cut or narrow groove in the surface of the device materials.
<b>XE2GF</b>	<b>Mechanical problem</b> Problems associated with mechanical actions or defects, including moving parts or subassemblies, etc.
<b>XE2CM</b>	<b>Detachment of device or device component</b> Problem associated with the separation of the device from its physical construct, integrity, or chassis.
<b>XE634</b>	<b>Device damaged by another device</b> Problem associated with one device causing harm to another device.
<b>XE7NX</b>	<b>Ejection problem</b>
<b>XE0VZ</b>	Failure to eject Problem associated with the inability to remove or discharge the device from the location of use.
<b>XE1PM</b>	Unintended ejection Problem associated with unexpected discharge of the device from expected location includes but not limited to the device such as clip applicers, film cartridge, staples.

<b>XE944</b>	<b>Leak or splash</b>
<b>XE2ZY</b>	Fluid leak Escape (Release, Discharge) of fluid through an unintended location - often accompanied by a loss of pressure and/or output.
<b>XE0RV</b>	Gas leak Problem associated with the unintended escape of a gas from the container in which it is housed.
<b>XE53W</b>	Gel leak Escape (Release, Discharge) of gel through an unintended location - as in leakage of ultrasound gel. Escape or release of gel from containment structures - as in gel filled implant leak.
<b>XE0B1</b>	Radiation leak Escape of radiation (energy in the form of waves or subatomic particles, especially those that cause ionization) through containment structures, leading to unintended exposure.
<b>XE2JE</b>	Perivalvular leak Problem associated with the escape of blood around a heart valve, particularly around its leaflets.
<b>XE1RJ</b>	<b>Firing problem</b>
<b>XE666</b>	Failure to fire Problem associated with failure of the device to discharge its load (e.g. surgical stapler failed to partially or completely deploy its staples).
<b>XE5P4</b>	Misfire Problem associated with a therapy or algorithm not being delivered or executed at the expected time.
<b>XE88N</b>	<b>Mechanical jam</b> The motion of the device is prevented or restricted.
<b>XE279</b>	<b>Mechanics altered</b> Problem associated with a device mechanical functioning of machinery, moving parts or tools of device being changed or modified.
<b>XE7KY</b>	Failure to align Problem associated with a circuit, equipment, or system whereby its functions fail to be properly synchronized or its relative positions properly oriented.
<b>XE0XR</b>	Failure to cut Inability of the device to make an incision, pierce or open as intended.

<b>XE23L</b>	Failure to cycle Problem associated with the device failing to complete a series of processes or events.
<b>XE289</b>	Failure to form staple Problem associated with the device failing to connect tissue with a stapling device due to the staples not forming correctly.
<b>XE4F9</b>	<b>Noise, audible</b> Problem associated with any unintended sound which emanates from the device (for example, squeaking from two parts rubbing together or buzzing sounds from electrical components).
<b>XE635</b>	<b>Physical resistance or sticking</b> Problem associated with the lack of movement in the device due parts sticking or seizing.
<b>XE306</b>	<b>Retraction problem</b> Problem associated with drawing back the device to an intended location.
<b>XE79Q</b>	<b>Structural problem</b> Problem associated with the basic physical construction or physical make-up of the device.
<b>XE8H1</b>	Structural collapse Problem associated with the buckling or crushing of material from external forces.
<b>XE3VF</b>	Sharp edges The device has undesirable sharp edges which can cause harm or damage.
<b>XE8ZX</b>	Difficult to fold or unfold Problem associated with the use of the device in terms of user experiencing difficulty to close or to spread out/extend length of the device, even if the operation is being performed according to labeled instructions for use.
<b>XE2EV</b>	Difficult to open or close Problem associated with the use of the device in terms of user experiencing difficulty opening and closing the device, even if the operation is being performed according to labeled instructions for use.
<b>XE3UJ</b>	Incomplete coaptation Problem associated with the heart valve leaflet not closing properly.
<b>XE8ZZ</b>	<b>Unintended movement</b> Problem associated with an undesired movement of the device, which may be related to malfunction of the device, misdiagnosis, or mistreatment.
<b>XE6KT</b>	Device dislodged or dislocated Problems associated with the device not remaining in an expected location.

<b>XE78C</b>	Device tipped over Problem associated with the inability of the device to stay in an upright position.
<b>XE5JJ</b>	Device fell Problem associated with the device or a component unexpectedly being dropped or moving down from an intended place.
<b>XE1Q1</b>	Device slipped Problem associated with the device moving or sliding from the intended position.
<b>XE0QZ</b>	Unintended collision of device Problem associated with the device impacting with another object.
<b>XE1Y1</b>	Unintended system motion Problem associated with any motion of the system or components that was not initiated by the user.
<b>XE5CH</b>	Unstable device Problem associated with the mechanical stability of the device.
<b>XE76A</b>	Vibration of device Problem associated with the undesirable mechanical oscillation.
<b>XE941</b>	<p><b>Optical problem</b></p> <p>Problem associated with transmission of visible light affecting the quality of the image transmitted or otherwise affecting the intended application of the visible light path.</p>
<b>XE5CX</b>	<p><b>Misfocusing</b></p> <p>The problem relates to the poor focusing of the object or the focus is on the wrong object or in the wrong area.</p>
<b>XE4W1</b>	<p><b>Optical decentration</b></p> <p>Problem associated with being off-center of optical lenses.</p>
<b>XE1VT</b>	<p><b>Optical discolouration</b></p> <p>Problem associated with an undesired change of color.</p>
<b>XE4BE</b>	<p><b>Optical distortion</b></p> <p>Problem associated with an optical defect in an image-forming system whereby the image is not the shape of an ideal image of the object.</p>
<b>XE93N</b>	<p><b>Optical obstruction</b></p> <p>Problem associated with the blocking of optical devices, e.g. visual pathways.</p>
<b>XE28Y</b>	<p><b>Output problem</b></p> <p>Problem associated with any deviation from the documented specifications of the device that relate to the end result, data, or test results provided by the device.</p>

<b>XE8NW</b>	<b>Audible prompt or feedback</b> Problem with any deviation from the documented specifications of the device that relate to audible feedback, e.g. voice prompts or beeps, but not safety-related alarms which are covered under "Protective measures problem".
<b>XE0WU</b>	Inappropriate audible prompt or feedback Problem with audible messages which do not guide a device user to the correct action.
<b>XE487</b>	Inaudible or unclear audible prompt or feedback Problem associated with audible prompts which cannot be heard clearly.
<b>XE8MP</b>	No audible prompt or feedback Problem associated with the device ceasing to provide audible prompts.
<b>XE2S2</b>	<b>Display or visual feedback problem</b> Problem with any deviation from the documented specifications of the device that relate to visual feedback, e.g. the display of information, images on a screen, or output from the device.
<b>XE4TX</b>	Device displays incorrect message Problem associated with providing incorrect display information.
<b>XE2NW</b>	Display difficult to read Problem associated with legibility of the display, compromising for instance the reading/interpretation of patient parameters or test results. Legibility problems can be due to color, size of font, display screen contrast or other factors.
<b>XE2ES</b>	Erratic or intermittent display A device does not consistently display the same message, result, reading, or image. E.g. the display might flicker, switch between readings or messages, or go completely blank for brief periods of time.
<b>XE7T8</b>	Image display error or artifact Problem with image display leading to corrupted images or readouts/measurement indications.
<b>XE2V3</b>	Image orientation incorrect Problem associated with an incorrect image orientation on the device display.
<b>XE5Q5</b>	No display or image Problem associated with the absence of display or image.
<b>XE4FQ</b>	No visual prompts or feedback Problem associated with the device ceasing to provide visual feedback.
<b>XE5XP</b>	Poor quality image Inadequate quality of an image or any visual representation displayed by the device, or output from the device.

<b>XE1C5</b>	Visual prompts will not clear Problem with visual messages which continue to be displayed on / by the device after the appropriate action has been taken.
<b>XE7Z4</b>	<b>Tactile prompts or feedback</b> Problem with any deviation from the documented specifications of the device that relate to tactile feedback, e.g. device vibrational prompt.
<b>XE6CE</b>	Inappropriate tactile prompt or feedback Problem with tactile feedback which does not guide a device user to the correct action.
<b>XE963</b>	No tactile prompts or feedback Problem associated with the device ceasing to provide tactile feedback.
<b>XE0KH</b>	<b>Energy output problem</b> Problem with the device's intended output of energy.
<b>XE7ST</b>	Energy spectrum incorrect Problem associated with the energy output from the device not being in the expected part of the spectrum.
<b>XE5PU</b>	Failure to deliver energy Problem associated with the failure of the device to deliver any energy.
<b>XE538</b>	Intermittent energy output Problem associated with the energy output from the device being inconsistent over time.
<b>XE81P</b>	Output above specifications Device output is exceeding the documented specifications of the device.
<b>XE8XC</b>	Output below specifications Device output is below the documented specifications of the device.
<b>XE2MC</b>	Therapeutic or diagnostic output failure Problem associated with the failure of the device to deliver the output required for treatment or identification of a disease.
<b>XE1US</b>	Therapy delivered to incorrect body area Problem associated with the device causing unintended therapeutic action to an area of the body other than the intended area.
<b>XE1ED</b>	<b>Radiation output problem</b> Problem with the device's intended output of radiation.
<b>XE5F0</b>	Radiation output failure Problem associated with the absence of radiation output from radiological or diagnostic devices.

<b>XE0JA</b>	Radiation overexposure Problem associated with excessive radiation emitted from radiological or diagnostic devices.
<b>XE74E</b>	Radiation underexposure Problem associated with too little radiation emitted from radiological or diagnostic devices.
<b>XE6UD</b>	Unexpected or unintended radiation output Device-emitted radiation when it was not supposed to. This applies to devices which are intended to emit radiation, and the radiation being emitted from the correct part of the device, but at an incorrect time.  Use "radiation leak" if the device emits radiation which should never have been emitted, or from a location from which it should never be emitted.
	<b><i>Exclusions:</i></b> Radiation leak (XE0B1)
<b>XE68Z</b>	<b>Gas output problem</b> Problem associated with gas output.
<b>XE7E5</b>	<b>No device output</b> Problem associated with no measurement outcome, value or data obtained from the device.
<b>XE4BB</b>	<b>Incorrect, inadequate or imprecise result or readings</b> Problem associated with a nonconforming end result, data, or test results provided by the device to its performance specifications.
<b>XE7TS</b>	Signal artifact Problem associated with impurities or interference in a signal (e.g. ECG artifact).
<b>XE3MS</b>	Failure to obtain sample The device does not collect or transfer the sample.
<b>XE2E8</b>	False negative result Problem associated with the device incorrectly reporting that something has not been detected and may mislead the operator into not taking certain actions when action should be taken.
<b>XE9K2</b>	False positive result Problem associated with the device incorrectly reporting that something has been detected and may mislead the operator to take certain actions.
<b>XE3XG</b>	Incorrect measurement Measurement obtained from or provided by the device is obviously incorrect.
<b>XE5E8</b>	Nonreproducible results Device results cannot be reliably reproduced.

<b>XE9D6</b>	High readings Reading provided by the device is too high or higher than expected.
<b>XE5KE</b>	Low readings Reading provided by the device is too low or lower than expected.
<b>XE485</b>	High test results Test results provided by the device are too high or higher than expected.
<b>XE8EM</b>	Low test results Test results provided by the device are too low or lower than expected.
<b>XE8YH</b>	Unable to obtain readings The device does not provide or display a valid reading.
<b>XE56S</b>	Missing test results Problem associated with the results of a test or measurement not appearing.
<b>XE3YZ</b>	<b>Unexpected therapeutic results</b> Problem associated with the use of the device for therapeutic purposes.
<b>XE16C</b>	<b>Electrical or electronic property problem</b> Problem associated with a failure of the electrical circuitry of the device.
<b>XE57L</b>	<b>Capturing problem</b> Problem associated with the inability of the device to achieve successful depolarization and contraction of a cardiac chamber caused by a pacemaker output pulse.
<b>XE0UH</b>	Failure to capture Problem associated with the failure to achieve effective and consistent depolarization of the heart resulting from the electrical stimulus of the pacemaker.
<b>XE18Z</b>	High capture threshold Problem with the amount of output energy needed to cause cardiac depolarization being higher than expected/desired.
<b>XE1T0</b>	Intermittent capture Problem associated with the ineffective and inconsistent depolarization of the heart.
<b>XE350</b>	Unstable capture threshold Problem with the amount of output energy needed to cause cardiac depolarization being unstable.
<b>XE4QC</b>	<b>Continuous firing</b> Problem associated with the excessive production of electrical impulses over a period.

<b>XE4HP</b>	<b>Arcing</b> Problem associated with electrical current flowing through a gap between two conductive surfaces, typically resulting in a visible flash of light.
<b>XE4X8</b>	Arcing at paddles Problem associated with electrical current flowing through a gap between paddles (conductive surfaces), typically resulting in a visible flash of light.
<b>XE7KZ</b>	Arcing of electrodes Problem associated with electrical current flowing through a gap between electrodes (conductive surfaces), typically resulting in a visible flash of light.
<b>XE2SR</b>	<b>Sparking</b> Problem associated with a flash of light related to an electrical discharge into a normally non conductive medium, such as air. Not associated with a discharge between two conductive surfaces.
<b>XE16Z</b>	<b>Battery problem</b> Problem associated with the internal power of the device (e.g. battery, transformer, fuel cell or other power sources).
<b>XE2MD</b>	Battery problem with high impedance Problem related to increased battery internal impedance.
<b>XE41Q</b>	Battery problem with low impedance Problem related to decreased battery internal impedance.
<b>XE548</b>	Failure to run on battery Problem associated with the device failing to operate when not connected to a fixed power source.
<b>XE5U8</b>	Premature discharge of battery Battery discharging earlier than expected.
<b>XE5ER</b>	<b>Charging problem</b> Problem associated with the inability of the device to successfully charge an electrical source.
<b>XE6QY</b>	Aborted charge Problem associated with the premature ending of the charging process (e.g. of a battery or other charge storage device).
<b>XE67U</b>	Delayed charge time Problem associated with an unexpected amount of time required to charge the device (e.g. a delay in starting charging or a longer than expected charge time).
<b>XE5PM</b>	Failure to charge Problem associated with inability to initiate the appropriate charging process (e.g. of a battery or other charge storage device)

<b>XE8DT</b>	<b>Failure to discharge</b> Problem associated with the failure of a battery or other charge storage device to appropriately discharge as intended. Does not apply to defibrillation.
<b>XE2B3</b>	<b>Power problem</b> Problem associated with the energy to operate the device.
<b>XE1DB</b>	Complete loss of power Problem associated with the lack of power to run the device.
<b>XE2A6</b>	Intermittent loss of power Problem associated with an intermittent disruption to the power to run the device.
<b>XE38R</b>	Failure to power up Problem associated with the inability of the device to turn on related to energy delivered to the device.
<b>XE7Z7</b>	Unintended power up Problem associated with the device turning on when not intended.
<b>XE0Q2</b>	<b>Device sensing problem</b> Problem associated with the device features that are designed to respond to a physical stimulus (temperature, illumination, motion, cardiac rhythms) and that do not transmit a resulting signal for interpretation or measurement.
<b>XE6SM</b>	Decreased sensitivity Problem with the device being less sensitive to an input than intended or expected.
<b>XE7QR</b>	Increased sensitivity Problem with the device being more sensitive to an input than intended or expected.
<b>XE8H3</b>	Failure to analyze signal Problem with the device not analyzing a signal.
<b>XE0K3</b>	Failure to select signal Problem associated with the failure of the device to select the appropriate input signal.
<b>XE6H7</b>	High sensing threshold Problem associated with the amount of input required by the device to detect a signal being higher than expected/desired.
<b>XE2P7</b>	Low sensing threshold Problem associated with the amount of an input required by the device to detect a signal being lower than expected/desired.
<b>XE9TK</b>	Loss of threshold Problem associated with the loss of the minimum amount of energy, voltage, or current needed to consistently stimulate the heart muscle.

<b>XE210</b>	Failure to sense Problem associated with the failure of the device designed to respond to a physical stimulus (as temperature, illumination, motion) to transmit a resulting signal for interpretation or measurement.
<b>XE02C</b>	Over-sensing Problem related to failure of the device to properly filter cardiac signals resulting in inappropriate device response.
<b>XE73Q</b>	Under-sensing Problem related to failure of the device to properly detect intrinsic cardiac activity and respond appropriately.
<b>XE69X</b>	Sensing intermittently Problem with the device receiving an incoming signal on an intermittent basis when expected to be continuous.
<b>XE28F</b>	Incorrect interpretation of signal Problem with the device inappropriately analyzing a signal.
<b>XE22D</b>	<b>Failure to conduct</b> Problem associated with the inability of the device to allow a current of electricity to pass or to conduct electricity continuously along an electrical path.
<b>XE8S0</b>	<b>Interrogation problem</b> Problems associated with the device's ability to respond to signals from a system designed to interrogate its status.
<b>XE9HR</b>	Difficult to interrogate Problem associated with difficulty of a transponder system to trigger a response.
<b>XE3PE</b>	Failure to interrogate Problem associated with the device failure to appropriately respond to signals from a system designed to interrogate its status.
<b>XE8HJ</b>	<b>Pacing problem</b> Problem associated with the inability of the device to generate a therapeutic simulated heart beat via electrical impulses.
<b>XE19S</b>	Failure to convert rhythm Failure of the device therapy or set of therapies to terminate the harmful cardiac rhythm that the therapy is meant to terminate.
<b>XE47M</b>	Inaccurate synchronization Problem associated with an error due to imperfect timing of two operations, e.g. signal transmission time.

<b>XE2LL</b>	Inappropriate waveform Failure of the device to generate a correctly-shaped pacing output, e.g., a waveform that is too wide.
<b>XE9A9</b>	No pacing Problem associated with the device ceasing to deliver paces.
<b>XE281</b>	Pacemaker found in back-up mode A device with a pacing function found in back-up Mode. This may be an appropriate fail-safe action (e.g. end of battery life), or be caused by device-malfunction or due to operator error.
<b>XE13R</b>	Pacing asynchronously Problem associated with a pacing transmission process such that between any two significant instants in the same group, there is always an integral number of unit intervals. Between two significant instants located in different groups, there are not always an integral number of unit intervals.
<b>XE10M</b>	Pacing inadequately Pacing voltage or pulse width is less than desired.
<b>XE1SU</b>	Pacing intermittently Problem associated with the failure of pacing device for a limited period of time, following which the item recovers its ability to perform its required function without being subjected to any external corrective action. Note: such a failure is often recurrent.
<b>XE99K</b>	Pocket stimulation Problem associated with a pocket of skin in which the pulse generator is housed.
<b>XE440</b>	<b>Defibrillation problem</b> Problem associated with the inability of the device to provide an appropriate or successful electrical shock.
<b>XE12S</b>	Failure to deliver shock Problem associated with the failure of the device to deliver electrical energy intended to change an electrical rhythm.
<b>XE6T0</b>	Inappropriate shock Problem associated with the inappropriate delivery of an electrical energy.
<b>XE8BU</b>	Intermittent shock Problem associated with the failure to deliver shock for a limited period of time, following which the item recovers its ability to perform its required function without being subjected to any external corrective action. Note: such a failure is often recurrent.
<b>XE739</b>	<b>Unintended electrical shock</b> The device delivers unintended electrical shock.

<b>XE9QT</b>	<b>Grounding malfunction</b> Problem associated with the inability to connect conductors of an electronic system for the purpose of controlling or impeding ground currents and voltages.
<b>XE3S7</b>	<b>Electrical overstress</b> Problem associated with an electrical activity that exceeded the specified threshold limit of the internal integrated circuitry.
<b>XE268</b>	<b>Electro-static discharge</b> Problem associated with the discharge of electricity between two bodies previously electrically charged.
<b>XE20P</b>	<b>Failure to shut off</b> Problem associated with the device not powering off when a shutdown was requested.
<b>XE7JN</b>	<b>Unexpected shutdown</b> Problem associated with the device unexpectedly powering down.
<b>XE4PR</b>	<b>Electromagnetic compatibility problem</b> Problem associated with the ability of a system to function in its electromagnetic environment without introducing intolerable disturbances to anything in its environment.
<b>XE5FA</b>	<b>Circuit failure</b> Problem associated with a failure of the internal network paths or electrical circuitry (i.e. electrical components, circuit boards, wiring)
<b>XE6ZB</b>	<b>Impedance problem</b> Problem associated with electrical impedance levels between device and patient connections.
<b>XE55U</b>	<b>Calibration problem</b> Problem associated with the operation of the device, related to its accuracy, and associated with the calibration of the device.
<b>XE6GR</b>	<b>Failure to calibrate</b> Problem associated with the failure of the device to perform a self-calibration procedure or process designed to assure the accuracy and proper performance of the device.
<b>XE8MT</b>	<b>Failure to recalibrate</b> Problem associated with the failure of the device which is unable to regain a standard level of accuracy when performing a calibration procedure or process designed to assure the accuracy and proper performance of the device.
<b>XE7H5</b>	<b>Imprecision</b> Problem associated with the device providing imprecise measurements when compared to a reference standard.

<b>XE1WU</b>	<b>Overcorrection</b> Problem associated with an adjustment that surpasses a set of criteria.
<b>XE586</b>	<b>Temperature problem</b> Problem associated with the device producing unintended temperatures
<b>XE9C7</b>	<b>Excessive cooling</b> Problem associated with the device producing temperatures that are lower than specified.
<b>XE77H</b>	<b>Excessive heating</b> Problem associated with the device having a warming or heating function, producing excessive heat.
<b>XE200</b>	<b>Insufficient cooling</b> Problem associated with the device insufficiently cooled in device active (working) or/and non-active (nonworking) state.
<b>XE2A4</b>	<b>Insufficient heating</b> Problem associated with the device or its components producing temperatures that are not as high as what is specified.
<b>XE14Q</b>	<b>Overheating of device</b> Problem associated with the device producing high temperatures, such that its operation is compromised or harm is caused (e.g. overheating that produces melting of components or automatic shutdown).
<b>XE6DP</b>	<b>Thermal decomposition of device</b> Problems associated with a discoloration or destruction as a result of thermal decomposition of the device.
<b>XE5T3</b>	<b>Fire</b> Problem associated with the combustion of the device with a steady flame.
<b>XE03F</b>	<b>Flare or flash</b> Problem associated with device-related burn with an unsteady flame.
<b>XE5H5</b>	<b>Smoke</b> Problem associated with a cloud of vapor or gas generated from the device, generally associated after a fire or a burn.
<b>XE85E</b>	<b>Computer software problem</b> Problem associated with written programs, codes, and/or software system that affects device performance or communication with another device.
<b>XE6PS</b>	<b>Application network problem</b> Problem associated with the deviations from documented system specifications that affects overall system performance and/or the performance of an individual device connected to that system.

<b>XE8HP</b>	<b>Application program problem</b> Problem associated with the requirement for software to fulfill its function within an intended use or application.
<b>XE5YA</b>	Application program freezes, or becomes nonfunctional Problem associated with freezing and becoming nonfunctional of an application program.
<b>XE46R</b>	Application program problem, dose calculation error Problem associated with the written program code or application software used by the device to calculate specific measurements or quantities managed by the device.
<b>XE09U</b>	Application program problem, medication error Event in which the device software results in errors of medication preparation or administration.
<b>XE2BJ</b>	Application program problem, parameter calculation error Problem associated with the written program code or application software used by the device to calculate parameters other than those related to dose or power.
<b>XE6SW</b>	Application program problem, power calculation error Problem associated with the written program code or application software used by the device for calculations related to device power.
<b>XE2CW</b>	Application program version or upgrade problem Problem associated with installing updates to a software system that affects the device performance or communication with another device.
<b>XE5CT</b>	Problem with software installation Problem associated with installing the device software in a manner that allows full functioning of the device. Source of installation could be manufacturer or user.
<b>XE842</b>	Unintended application program shutdown Problem associated with an unintended shutdown by malfunction of the application program.
<b>XE1HG</b>	<b>Program or algorithm execution problem</b> Problem associated with execution problems relating to program or algorithm.
<b>XE87N</b>	Delayed program or algorithm execution Problem associated with delayed execution relating to program or algorithm.
<b>XE1WW</b>	Intermittent program or algorithm execution Problem associated with intermittent execution relating to program or algorithm.
<b>XE0UN</b>	Program or algorithm execution failure Problem associated with the failure of a program or algorithm to execute. Sudden/unexpected interruption to a program's execution.

<b>XE4Z0</b>	<b>Computer operating system problem</b> Problem associated with software, firmware, and/or hardware elements that control the execution of computer programs and provide such services as computer resource allocation, job control, input/output control, and file management in a computer system.
<b>XE5F1</b>	Operating system becomes nonfunctional Problem associated with malfunction of the computer operating system as opposed to an application software problem.
<b>XE6VL</b>	Operating system version or upgrade problem Problem associated with replacing an older operating system to an up-to-date operating system.
<b>XE5EP</b>	<b>Computer system security problem</b> Problem associated with unauthorized access to or modification of a software system resulting in a loss of confidentiality, integrity, or availability of written program code, application software, or data or entire device.
<b>XE9XK</b>	Application security problem Problem associated with the acquisition of computer programming codes that can replicate and spread from one computer system to another thereby leading to damaged software, hardware and data.
<b>XE15X</b>	Unauthorized access to computer system Problem associated with an access that was not permitted to the computer system that may lead to modification of program, corruption of data, or a break in network security. This concept is closely associated with computer integrity which is the degree to which a system or component prevents unauthorized access to, or modification of, computer programs or data.
<b>XE2ZM</b>	<b>Data back-up problem</b> Problems relating to a system, component, file, procedure, or person available to replace or help restore a primary item in the event of a failure or externally caused disaster.
<b>XE72G</b>	Failure to back up Problem associated with the inability to back up or to retrieve a backed-up version (corrupted file) of device data or system files.
<b>XE8PZ</b>	Failure to convert to back-up Problem associated with a failure to transition from a primary system, component, file, procedure to a backup in response to a failure in the primary item.
<b>XE99Y</b>	<b>Data problem</b> Event in which data (charting, orders, results) is not correctly stored, transferred, updated, or displayed.

<b>XE992</b>	<p><b>Loss of data</b></p> <p>Event in which data is unintentionally permanently or temporarily lost, deleted, corrupted, or overwritten.</p>
<b>XE7BE</b>	<p><b>Patient data problem</b></p> <p>Event in which data is accessed by the healthcare provider and either the wrong patient or the wrong data is retrieved despite correct inquiry procedures.</p>
<b>XE048</b>	<p><b>Date or time related software problem</b></p> <p>Problem associated with programming of calendar dates and/or time as a factor in the operation of the device.</p>
<b>XE3UR</b>	<p><b>Connection problem</b></p> <p>Problem associated with linking of the device and/or the functional units set up to provide means for a transfer of liquid, gas, electricity or data.</p>
<b>XE9D0</b>	<p><b>Blocked connection</b></p> <p>Problem associated with linking of the device whereby their functional units set up to provide means for a transfer of fluid, gas, or data is prevented or impeded.</p>
<b>XE74X</b>	<p><b>Decoupling</b></p> <p>Problem associated with the device being unassociated in such a way that fluid, gas, power or signal information may not be transferred from one to another.</p>
<b>XE5WZ</b>	<p><b>Disconnection</b></p> <p>Problem associated with the linking of the device having a sufficient open space to prevent gas, liquid or electrical current flow between connectors.</p>
<b>XE9HJ</b>	<p><b>Failure to disconnect</b></p> <p>Problem associated with the linking of the device whereby termination of the transfer of liquid, gas, electricity, or information cannot be accomplished, or linking components do not come apart, or disconnect, when expected.</p>
<b>XE3G6</b>	<p><b>Loose or intermittent connection</b></p> <p>Problem associated with the connection of the device being loose or intermittent.</p>
<b>XE0WB</b>	<p><b>Misconnection</b></p> <p>Problem associated with the connection of the device being improper or not in accordance with device specification, requirements or intended uses.</p>
<b>XE4C0</b>	<p><b>Incomplete or inadequate connection</b></p> <p>Problem associated with a partial linking of the device whereby device may appear to be connected however only a partial, intermittent or no transfer of liquid, gas, electricity, or information can be accomplished.</p>
<b>XE0P9</b>	<p><b>Fitting problem</b></p> <p>Problem associated with the connection of the device whereby channels, switching systems, and other functional units set up to provide means for a transfer of liquid, gas, electricity, or information do not match or fit.</p>

<b>XE0JD</b>	<b>Communication or transmission problem</b> Problem associated with the device sending or receiving signals or data. This includes transmission among internal components of the device to which the device is intended to communicate.
<b>XE3EG</b>	<b>Failure to read input signal</b> Problem associated with a failure of the device to read a signal for interpretation or measurement.
<b>XE0V5</b>	<b>Failure to transmit record</b> Problem associated with a failure of the device to transmit a record for interpretation or measurement.
<b>XE4JX</b>	<b>Intermittent communication failure</b> Inconsistent or lack of intended communication of data among internal components or with other external devices.
<b>XE5H8</b>	<b>Telemetry discrepancy</b> Problem associated with variability of the transmission of telemetry signals.
<b>XE4YY</b>	<b>Wireless communication problem</b> Problems with the RF wireless technology characteristics and performance (e.g., frequency, output power, range, reception), wireless quality of service, wireless coexistence, security of wireless signals and data, and electromagnetic compatibility.
<b>XE7NV</b>	<b>Infusion or flow problem</b> Problem associated with the device failing to deliver liquids or gases as intended (e.g. delivering drugs at incorrect rate, problems with drawing fluid from a system).
<b>XE4VT</b>	<b>Deflation problem</b> Problem associated with the inability of the device to release its contents.
<b>XE6YH</b>	<b>Excess flow or over-infusion</b> Problem associated with a delivery overdose of therapeutic agents, such as drugs or fluids being delivered into a device or a patient.
<b>XE49K</b>	<b>Filling problem</b> Problem associated with the method or amount of time associated with the delivery of a fluid. Time to delivery or amount of delivered entity may be affected.
<b>XE3T4</b>	Inability to auto-fill Complete failure to fill as part of an automated process. For insufficient filling use "Short Fill". For excessive filling use "Overfill". For inconsistent filling use "Volume Accuracy Problem".

<b>XE97E</b>	<p>Overfill Excessive filling of a device</p> <p><b>Exclusions:</b>      Insufficient filling (XE8RE)                         Inconsistent filling (XE1QQ)</p>
<b>XE8RE</b>	<p>Short fill Insufficient filling of a device.</p> <p><b>Exclusions:</b>      Complete failure to fill (XE3T4)                         Inconsistent filling (XE1QQ)</p>
<b>XE1QQ</b>	<p>Volume accuracy problem Inconsistent filling of a device. This describes a problem which is observed to vary between overfilling and under filling, and may be intermittent.</p> <p><b>Exclusions:</b>      Consistent overfilling (XE97E)                         Consistent short filling (XE8RE)</p>
<b>XE2YK</b>	<p><b>Filtration problem</b> Problem associated with the process of passing a substance through a porous medium, e.g., a blood clot filter for the removal of suspended matter.</p>
<b>XE3VH</b>	<p>Inadequate filtration process Problem associated with the filter failing to remove items or substances which should have been removed.</p>
<b>XE4UN</b>	<p>Inadequate ultra filtration Problem associated with the transfer of fluid between the blood and dialysate through the dialysis membrane due to a pressure gradient (trans-membrane pressure) existing between the blood and dialysate compartments.</p>
<b>XE1H4</b>	<p><b>Improper flow or infusion</b> Problem associated with the regulation and delivery of therapeutic agents (e.g. air, gas, drugs or fluids into a device or a patient under positive pressure).</p>
<b>XE9RA</b>	<p>Backflow Continuous flow of fluid (e.g. liquid, gas) against the intended flow direction.</p>
<b>XE447</b>	<p>Free or unrestricted flow Problem associated with uncontrolled flow of infusion of air, gas or fluids.</p>
<b>XE628</b>	<p>Gradient increase Problem associated with the increased rate of change in temperature, pressure, or other variables as a function of distance, time, etc.</p>
<b>XE667</b>	<p>Inaccurate delivery Delivery at endpoint not as intended; either too low or too high.</p>

<b>XE44F</b>	Inaccurate flow rate Problem associated with fluctuations in the flow volume delivered per time, even if end volume is correct, and delivered in the correct total time.
<b>XE2DM</b>	Intermittent infusion Problem associated with the infusion not being stable, characterised by intermittent stoppages to the flow.
<b>XE09Q</b>	Reflux with device Problem associated with partial backflow, compromising the device's flow output.
<b>XE8AY</b>	Restricted flow rate Problem associated with flow rate. Flow volume delivered over time is not reaching intended flow rate.
<b>XE1V7</b>	Tidal volume fluctuations Problem associated with the amount of gas that is inspired and expired during one respiratory cycle.
<b>XE5GY</b>	<b>Inflation problem</b> Problem associated with the inability of the device to expand or enlarge with the intended inflation agent (e.g. saline or air).
<b>XE1S7</b>	<b>Insufficient flow or under infusion</b> Problem associated with an insufficient dose of therapeutic agents, e.g., drugs or fluids being delivered into a patient under positive pressure.
<b>XE1Y3</b>	<b>No flow</b> Problem arising from the device failing to deliver the specified liquid or gas.
<b>XE94H</b>	Failure to deliver flow Failure (=complete nonperformance) with regard to the intended function of delivery.
<b>XE1JK</b>	Failure to infuse Failure (=complete nonperformance) with regard to the intended function of infusion.
<b>XE8L2</b>	Inability to irrigate Failure (=complete nonperformance) with regard to the intended function of irrigation.
<b>XE3GX</b>	<b>Obstruction of flow</b> Problem related to an obstruction or blockage within the device component (e.g. tube, opening, pipe) that results in restriction of flow.
<b>XE3QL</b>	Complete blockage Problem related to an obstruction or blockage within the device component (e.g. tube, opening, pipe) that results in no flow.

<b>XE2JF</b>	<b>Partial blockage</b> Problem related to an obstruction or blockage within the device component (e.g. tube, opening, pipe) that results in a reduction of the flow rate.
<b>XE6BM</b>	<b>Difficult to flush</b> The device is difficult to flush, possibly indicating an obstruction within device.
<b>XE8Z5</b>	<b>Pressure problem</b> Problem associated with the application of a force either internal or external to device that compromises the flow of fluid or gas.
<b>XE3XR</b>	<b>Decrease in pressure</b> Unintended decrease in pressure, compromising the device's intended function.
<b>XE6S6</b>	<b>Increase in pressure of device</b> Unintended increase in pressure, compromising the device's intended function.
<b>XE94J</b>	<b>No pressure</b> Unintended complete loss of pressure, compromising the device's intended function.
<b>XE6Z5</b>	<b>Pumping problem</b> Problem associated with pump performance deviating from specifications in a way to compromise flow or infusion.
<b>XE64X</b>	<b>Decreased pump speed</b> Unintended decrease in pump speed and hence, probably, flow rate, compromising the intended function of the device.
<b>XE7BN</b>	<b>Increased pump speed</b> Unintended increase in pump speed and hence, probably, flow rate, compromising the intended function of the device.
<b>XE5R0</b>	<b>Failure to pump</b> Problem associated with the device which fails to start pumping.
<b>XE0TF</b>	<b>Pumping stopped</b> Unexpected or unintended cessation of pump.
<b>XE69E</b>	<b>Suction problem</b> Problem associated with suction equipment, which may be a manual, electrical, vacuum or pressure source operated to evacuate and remove undesired substances (air, gas, fluid, or particulates) via tubing and collection bag.
<b>XE3Y3</b>	<b>Decrease in suction</b> Problem associated with the removal of fluid or gas from a body cavity due to decreased suction.

<b>XE35T</b>	Increase in suction Problem associated with the removal of excess fluid or gas from a body cavity due to increased suction.
<b>XE5FE</b>	Suction failure Problem associated with the complete inability to provide suction.
<b>XE0B4</b>	<b>Priming problem</b> Problem associated with the preparation of the device to begin pumping.
<b>XE3KR</b>	Failure to prime Problem associated with the device failing to begin the priming process (i.e. the process of preparation of device for the delivery of fluids).
<b>XE63F</b>	Incomplete or inadequate priming Problem associated with not adequately preparing the device.
<b>XE4GH</b>	<b>Activation, positioning or separation problem</b> Problem associated with any deviations from the documented specifications of the device that relate to the sequence of events for activation, positioning or separation of device. NOTE 1 “Deployment” is synonymous with “activation”.
<b>XE76U</b>	<b>Activation problem</b> Problem associated with the activation of the device.
<b>XE48N</b>	Activation failure or expansion failures Problem associated with the device failing to be activated including expansion.
<b>XE9Y0</b>	Difficult or delayed activation Problem associated with delayed or difficult activation of the device.
<b>XE6E9</b>	Premature activation Problem associated with early and unexpected activation of the device.
<b>XE5VT</b>	Self-activation or keying Problem associated with the unintended activation of the device, or the device having been unexpectedly turned on during use.
<b>XE2J9</b>	<b>Positioning problem</b> Problem associated with the movement of the device to an intended location.
<b>XE41N</b>	Positioning failure Problem associated with the inability of the device to be positioned in a specified location.
<b>XE8P2</b>	Malposition of device Problem associated with the device being positioned in a location other than intended or specified.

<b>XE74U</b>	Difficult or delayed positioning Problem associated with users experiencing difficulty or delay to position the device to a specified location.
<b>XE4CG</b>	Failure to advance Problem associated with failure to move the device to an intended location.
<b>XE9NU</b>	Difficult to advance Problem associated with difficulty moving the device to an intended location (e.g. difficulty in advancing guide wire).
<b>XE2JZ</b>	Difficult to insert Problem associated with problems introducing or inserting the device, even if the user is operating the device in accordance with the instructions for use or labeling.
<b>XE0HC</b>	Difficult to remove Problem associated with the use of the device in terms of user experiencing difficulty to take out or get rid of the device, even if the user is operating device in accordance with the instructions for use or labeling.
<b>XE9MQ</b>	Entrapment of device Problem associated with the device caught within patient vasculature, tissue, or other device.
<b>XE1KB</b>	<b>Separation problem</b> Problem associated with the detachment or separation of the device.
<b>XE9BM</b>	Separation failure Problem associated with the device or one of its components failing to detach or separate as intended.
<b>XE6U9</b>	Difficult or delayed separation Problem associated with users experiencing difficulty or delay with detachment or separation of the device.
<b>XE1TT</b>	Premature separation of device Problem associated with an early and unexpected detachment or separation of the device from the system.
<b>XE1XC</b>	<b>Protective measures problem</b> Problem associated with any deviations from the documented specifications of the device that relate to the implemented and inherited design features specific to devices used for reducing risks to patient or caregiver or maintaining risks within specified levels.
<b>XE98H</b>	<b>Device alarm system</b> Problem associated with the alarm system of the device.

<b>XE5JP</b>	Alarm not visible The device does not display an alarm message when required.
<b>XE6DH</b>	No audible alarm The device fails to emit an audible alarm.
<b>XE2RK</b>	Low audible alarm The audible device alarm cannot be heard clearly.
<b>XE3QU</b>	Delayed alarm The device alarm system operates with delay.
<b>XE2K0</b>	False alarm Problem associated with the device providing incorrect alarm warning or alert to user.
<b>XE3UE</b>	Defective alarm The device alarm does not operate as expected and/or in agreement with device's specifications.
<b>XE78D</b>	<b>Fail-safe problem</b> Problem associated with the feature that prevents the unsafe use of the device.
<b>XE659</b>	Fail-safe did not activate Problem associated with the device fail-safe mechanism, which did not function or function in a non effective way, compromising safe use of the device.
<b>XE6VE</b>	No fail-safe mechanism The device does not have a fail-safe mechanism, although such mechanism would be required for its appropriate and/or safe functioning.
<b>XE3V3</b>	<b>Failure of device to self-test</b> Problem associated with the device failing to perform an internal self-diagnostic process to ensure normal operation during or prior to use.
<b>XE16Y</b>	<b>Failure to auto stop</b> Problem associated with the inability of device to turn itself off when the device is not in an operable condition.
<b>XE4KE</b>	<b>Reset problem</b> Problem associated with setting a variable, register, or other storage location back to a prescribed state.
<b>XE59S</b>	Failure to reset Problem associated with the device failing to set a variable, register, or other storage location back to a prescribed state.

<b>XE0HZ</b>	Failure to zero Problem associated with the device failing to set a variable, register, or other storage location back to zero.
<b>XE2T4</b>	Inappropriate or unexpected reset Problem associated with the device setting a variable, register, or other storage location to an inappropriate or unexpected state.
<b>XE1H0</b>	<b>Premature indicator activation</b> Problems with the activation of a protective measure indicator earlier than expected.
<b>XE6KH</b>	Premature elective replacement indicator Problems with the early or unexpected activation of the elective replacement indicator.
<b>XE6ND</b>	Premature end-of-life indicator Problem with the early or unexpected activation of the end-of-life indicator.
<b>XE4PS</b>	<b>Shielding failure</b> Problem associated with the device inability to act as a barrier for absorption of radiation energy in X-rays, gamma rays, etc.
<b>XE452</b>	<b>Compatibility problem</b> Problem associated with compatibility between device, patients or substances (medication, body fluid, etc.)
<b>XE02E</b>	<b>Component or accessory incompatibility</b> Problem associated with the incompatibility of any device while being operated in the same use environment thereby leading to a dysfunction between the devices.
<b>XE7N5</b>	Accessory incompatible An accessory required for the intended purpose of the device appears incompatible with the device, thus compromising the intended function of the device.
<b>XE1UE</b>	Component incompatible A component required for the proper functioning of the device is not compatible with other components or subassemblies of the device, thus compromising the intended function of the device.
<b>XE8KS</b>	<b>Device-device incompatibility</b> Problem associated with the incompatibility of two or more devices while being operated in the same use environment thereby leading to a dysfunction of more than one device.
<b>XE0HJ</b>	<b>Measurement system incompatibility</b> Problem associated with the incompatibility of the measurement systems between and/or within device systems that are inherent to the individual device thereby leading to miscalculated or mismatched measurements from those devices, e.g., international metric system versus U.S. measurement system.

<b>XE4UP</b>	<b>Unintended compatibility</b> Problem associated with the ability of two or more devices which are intended to be incompatible but are able to work or fit together.
<b>XE4XW</b>	<b>Contamination or decontamination problem</b> Problem associated with the presence of any unexpected foreign substance found in the device, on its surface or in the package materials, which may affect performance or intended use of the device, or problem that compromises effective decontamination of the device.
<b>XE9L2</b>	<b>Contamination during use</b>
<b>XE9H4</b>	Biofilm coating in device Problem associated with the undesired introduction of a biofilm coating into or onto the device.
<b>XE2AR</b>	Contamination of device ingredient or reagent Problem associated with the undesired introduction of impurities either chemical or microbiological in nature, or of foreign matter into or onto the device ingredient or reagent.
<b>XE4VF</b>	Device contamination with body fluid Problem associated with the undesired presence of body fluid in/on the device, which is not part of the documented device specifications and requirements.
<b>XE9AH</b>	Device contamination with chemical or other material Problem associated with contamination of the device with chemical substance or other non biologic material.
<b>XE97G</b>	Microbial contamination of device Problem associated with undesired microbial contamination of the device.
<b>XE450</b>	<b>Device contaminated during manufacture or shipping</b>
<b>XE5LK</b>	<b>Device reprocessing problem</b>
<b>XE3MN</b>	Failure to clean adequately Problem associated with the failure of the device or operator to remove any visible soil, foreign material or organism deposits on the external surfaces, crevices, and joints of the device.
<b>XE4A4</b>	Failure to disinfect Failure to properly disinfect the device when reprocessing it.
<b>XE0VE</b>	Flushing problem Failure to properly disinfect the device when reprocessing it.
<b>XE2LR</b>	Problem with sterilisation Device was not sterilized properly during reprocessing.

<b>XE0HG</b>	Residue after decontamination Problem associated with the decontamination process not adequately removing unwanted visible soil, foreign material, or organism deposits.
<b>XE6K5</b>	<b>Environmental compatibility problem</b> Problem associated with the surrounding conditions in which the device is being used such as temperature, noise, lighting, ventilation, or other external factors such as power supply.
<b>XE027</b>	<b>Ambient noise problem</b> Problem associated with any undesired acoustic energy or vibration that tends to interfere with the operation of the device.
<b>XE5R1</b>	<b>Ambient temperature problem</b> Problem associated with compromised device performance at the ambient temperature or the storage at an inappropriate ambient temperature.
<b>XE50X</b>	<b>Fumes or vapours as environmental compatibility problem</b> Problem associated with the visibility, odor, or toxicity of an ambient vapor or gas.
<b>XE011</b>	<b>Fungus in device environment</b> Problem associated with the visibility of molds, mildews, yeasts, and/or mushrooms in the immediate environment in which the device is being used.
<b>XE8HD</b>	<b>Moisture or humidity problem</b> Problem associated with an unsatisfactory humidity level in the storage or use environment which affects the device performance.
<b>XE7KA</b>	<b>Ventilation problem in device environment</b> Problem associated with the circulation of fresh air in the immediate atmosphere in which the device is being used.
<b>XE5NF</b>	<b>Device unsafe to use in environment</b> Problem associated with environmental condition that results in the unsafe use of the device. (E.g. electromagnetic fields, noise, vibration, microbiological contamination etc.)
<b>XE55E</b>	<b>Environmental particulates</b> Problem associated with fine solids or liquid particles such as dust, smoke, fume, and/or mist suspended in the immediate atmosphere in which the device is being used.
<b>XE6V9</b>	<b>Medical gas supply problem</b> Problem associated with the facility-supplied medical gases such as medical air, oxygen, nitrous oxide, and nitrogen.
<b>XE5ZE</b>	<b>Electrical power problem</b> Problem associated with the quality of the facility-supplied power.

<b>XE2H3</b>	<b>Installation related problem</b> Problem associated with unsatisfactory installation, configuration, and/or setup of a specific device.
<b>XE36N</b>	<b>Misassembled during installation</b> Problem associated with the use of the device characterised by incorrect assembly of device components, parts or constituents.
<b>XE3J4</b>	<b>Labelling, instructions for use or training problem</b> Problem associated with device markings / labelling, instructions for use, training and maintenance documentation or guidelines.
<b>XE23E</b>	<b>Device markings or labelling problem</b> Problem associated with the written, printed or graphic material accompanying or affixed to the device or any of its packaging. This includes verbal instructions relating to identification, technical description, and usage provided by the device manufacturers. Problems can include but are not limited to this material being unclear, missing, worn out, incorrect or inaccurate.
<b>XE25T</b>	<b>Lack of maintenance documentation or guidelines</b> Problem associated with user facility not receiving adequate service documentation, guidelines, or recommendations to perform preventative and corrective maintenance and performance assurance checks.
<b>XE13S</b>	<b>Inadequate instructions for healthcare professional</b> Problem associated with inaccuracies in any written, printed, or graphic matter that is affixed to the device or its packaging with any matter that accompanies the device including verbal instructions related to identification, technical description and use of device provided by the device manufacturers that is intended for healthcare professionals.
<b>XE17P</b>	<b>Inadequate instructions for non-healthcare professional</b> Problem associated with users being unclear and not able to follow any written, printed, or graphic matter that is affixed to device or its packaging with any matter that accompanies the device including verbal instructions related to identification, technical description and use of the device provided by the device manufacturers that vary from the standard of medical care in a given environment.
<b>XE22G</b>	<b>Inadequate or insufficient training</b> Problem associated with facility not providing satisfactory initial and/or periodic user training covering operation of the device.
<b>XE5DG</b>	<b>Human-device interface problem</b> Problem associated with an act or omission of an act that has a different result than that intended by the manufacturer or expected by the operator.
<b>XE1C2</b>	<b>Device difficult to set up or prepare</b> Problem associated with the use of the device in terms of user experiencing difficulty in preparing device for use, even if the operation is being performed according to labeled instructions for use.

<b>XE3B8</b>	<b>Device difficult to program or calibrate</b> The device is difficult to program, calibrate or set to desired state, even by appropriately trained user/operator.
<b>XE2N3</b>	<b>Device difficult to maintain</b> Problem associated with the user's ability to service the device according to the manufacturer specifications relating to the device routine maintenance, i.e., periodic inspection, failure detection, repair, and care of the device to sustain or restore acceptable operating conditions.
<b>XE35S</b>	<b>Inadequate user interface</b> Problem associated with the means by which the operator and the equipment communicate or interact.
<b>XE0AG</b>	<b>Use of device problem</b> Problem associated with failure to process, service, or operate the device according to the manufacturer's recommendations or recognised best practices.
<b>XE6PE</b>	<b>Device handling problem</b> Handling of the device not in accordance with specification, prior to use on the patient.
<b>XE7S3</b>	<b>Use of incorrect control settings</b> Problem associated with the use of the device in terms of inappropriate and false control setting for the device's specified operation and/or intended use.
<b>XE2XZ</b>	<b>Improper or incorrect procedure or method</b> Problem associated with the use of the device in terms of nonconforming to that device's intended use, specifications, procedure and process or service instructions and information provided by the device manufacturers.
<b>XE7VD</b>	<b>Off-label use</b> Problem associated with the device which has been used for an unapproved indication or for an unapproved intended use.
<b>XE61V</b>	<b>Misassembled</b> Problem associated with incorrect assembly of the device or constituents after being put into use.
<b>XE3GL</b>	<b>Adverse event without identified device or use problem</b> An adverse event (e.g. patient harm) appears to have occurred, but there does not appear to have been a problem with the device or the way it was used.
<b>XE3DN</b>	<b>No apparent adverse event</b> A report has been received but the description provided does not appear to relate to an adverse event.  This code allows a report to be recorded for administration purposes, even if it doesn't meet the requirements for adverse event reporting.

**XE1W0****Appropriate term or code not available for aspects of incidents related to devices**

The device problem is not adequately described by any other term.

Note: this code must not be used unless there is no other feasible code. The preferred term should be documented when submitting an adverse event report. This information will be used to determine if a new term should be added to the code table.

Investigation conclusion of events related to devices

**XE1UR****Cause traced to device design****XE7NC****Cause traced to component failure****XE2TX****Cause traced to manufacturing****XE18E****Cause traced to transport or storage****XE7NN****Cause traced to infrastructure****XE1WV****Cause traced to environment****XE5AS****Cause traced to maintenance****XE5UX****Cause traced to training****XE674****Cause traced to labeling****XE5BM****Cause cannot be traced to device****XE6LX****Cause traced to user****XE0QB****Known inherent risk of device****XE8UG****Falsified device****XE51D****No problem with device detected****XE2SY****Cause of problem with device not established****XE0T3****Conclusion not yet available regarding problem with device**

Findings of investigations related to devices

**XE0WX****Biological problem with device identified**

Problems relating to, caused by or affecting biological processes or living organisms.

**XE5T0****Biocompatibility problem with device identified**

The device causes cellular or tissue responses that elicit an undesirable local or systemic effect in the recipient or beneficiary of that therapy. (See ISO 10993)

<b>XE4YZ</b>	<b>Biological contamination of device</b> The undesirable presence of living organisms such as bacteria, fungi, or viruses or their products (enzymes or toxins).
<b>XE7B7</b>	<b>Material or material leachate pyrogenic problem with device identified</b> The undesirable presence of pyrogens or fever-producing organisms caused by materials that permeate through the device.
<b>XE2RY</b>	<b>Cytotoxicity problem with device identified</b> The device was found to have an undesirable level of toxicity to living cells.
<b>XE2PA</b>	<b>Genotoxicity problem with device identified</b> The device's ability to cause damage to genetic material (e.g. leading to malignant tumors). (See ISO 10993)
<b>XE7AM</b>	<b>Hematological problem with device identified</b> The device affects or impacts the blood or its components. (See ISO 10993 all parts)
<b>XE1Y9</b>	<b>Unintended presence of allergens in device identified</b> Unintended or unexpected presence of allergens in the device. <b>Exclusions:</b> Presence of allergen expected but not adequately labelled (XE1YT)
<b>XE2XW</b>	<b>Reproductive toxicity problem with device identified</b> The device affects reproductive function, embryo development (teratogenicity), and prenatal and early postnatal development. (ISO 10993 part 3)
<b>XE4CB</b>	<b>Electrical problem with device identified</b> Events associated with an electrically powered device where an electrical malfunction results in a device problem (e.g. electrical circuitry, contact or component failed) even if the problem is intermittent.
<b>XE1YA</b>	<b>Electrical or electronic component problem with device identified</b> The performance of an electrical or electronic component was found to be inadequate.
<b>XE53K</b>	<b>Hardware timing problem with device identified</b> Problem that results from improper sequential activation of components.
<b>XE546</b>	<b>Impedance problem with device identified</b> Problems due to insufficient or excessive resistance to current flow either by the device or circuit.
<b>XE1TX</b>	<b>Insulation problem with device identified</b> Problems due to inadequate or incorrect electrical insulation material.

<b>XE4PP</b>	<b>Open circuit in device</b> Problem due to an electrical circuit that does not conduct current because a switch is open, a wire is broken, etc.
<b>XE2V6</b>	<b>Current leakage problem of device identified</b> Problems related to leakage currents which may cause electric shock. These currents usually flow through the protective ground conductor. In its absence, these currents could flow from the device to the ground via the human body.
<b>XE0KB</b>	<b>Power source problem identified in device</b> Problems related to the source that provides electrical power to the device.
<b>XE4ZM</b>	<b>Energy storage system problem in device</b> Problems related to the energy storage system (e.g. the rechargeable battery, charging system, or capacitor) and includes problems such as premature power source depletion and battery explosions.
<b>XE2WJ</b>	<b>Loss of power to device</b> A device that experienced problems due to a loss in the power supply.
<b>XE7RB</b>	<b>Power fluctuation in device</b> The device failed due to fluctuations within the power supply (e.g. transient power, power spike, power dip, or power sequencing).
<b>XE7AB</b>	<b>Short circuit of device</b> Problems due to an unintentionally low-resistance connection between two points in an electric circuit, resulting in either excessive current flow that often causes damage or in a new shorter circuit that draws current away from the original pathways and components.
<b>XE8KR</b>	<b>Signal loss of device</b> Problems due to the loss or weakening of an electrical signal or signals.
<b>XE6AQ</b>	<b>Electromagnetic compatibility problem with device identified</b> Device-to-device or device-environment problem resulting from electromagnetic disturbances.
<b>XE6BD</b>	<b>Conducted interference with device</b> Problems related to electromagnetic interference (EMI) by physical contact with conductors (e.g. wires, resistors, terminals) as opposed to radiated EMI which is caused by induction (without physical contact of the conductors).
<b>XE8P9</b>	<b>Electrostatic discharge of device</b> Problems due to sudden and momentary bursts of electrical current flowing between two objects at different electrical potentials.
<b>XE2ME</b>	<b>Inadequate immunity of device</b> Problems related to immunity or capabilities to resist electromagnetic interference (EMI).

<b>XE8TZ</b>	<b>Unintended emission of device</b> Problems due to unintended emission of electromagnetic energy by the device.
<b>XE1LT</b>	<b>Radiofrequency interference with device identified</b> Problems due to radiofrequency interference. RFI is a disturbance that affects an electrical circuit due to either electromagnetic conduction or electromagnetic radiation emitted from an external source.
<b>XE02N</b>	<b>Interoperability problem with device identified</b> Problems with the mechanical, electrical, or communication interface between two or more separate devices.
<b>XE6C8</b>	<b>Communications problem with device identified</b> Devices that do not send or receive adequate signals (this speaks to the interoperability between devices).
<b>XE22K</b>	Wired communication problem with device identified Communications problems between devices within a wired system.
<b>XE1PD</b>	Wireless communication problem with device identified Communications problems between devices within a wireless system.
<b>XE5NA</b>	Network communication problem with device identified Communications problems between devices within a network system.
<b>XE1SP</b>	<b>Incompatible component or accessory of device identified</b> A device that malfunctions due to a component(s)/accessory that does not operate correctly and according to the device's specifications.
<b>XE1YT</b>	<b>Labeling and instructions for use or maintenance of device problem identified</b> Insufficient, inadequate, or incorrect information provided on a device's label or documentation regarding e.g. its intended use, directions for use, and characteristics of the device, including its maintenance.
<b>XE3PV</b>	<b>Inadequate labelling or instructions for use of device identified</b> Inadequate information on the labels or in the instructions for use e.g. steps that are difficult to follow or that are missing.
<b>XE4MR</b>	<b>Incorrect labelling or instructions for use of device identified</b> Missing, incorrect, or inappropriate information on the labels e.g. mislabeled contents or device labeling characteristics or package contents.
<b>XE7Y7</b>	<b>Inadequate or incorrect instructions for maintenance of device identified</b> Inadequate or incorrect information in the instructions for maintenance.
<b>XE3RW</b>	<b>Material or chemical problem with device identified</b> Problems with the device materials or how its materials react to other elements either within the device or within the environment.

<b>XE2H0</b>	<b>Degradation problem identified with device</b> Problems that occur when the device becomes worn, weakened, corroded, or broken down due to processes such as aging, permeation, and corrosion.
<b>XE2WT</b>	<b>Inappropriate material identified in device</b> Problems that occur due to the presence of a material that should not be present or part of the device.
<b>XE60T</b>	<b>Inadequate physicochemical properties identified in device</b> Problems that occur due to the physicochemical properties.
<b>XE4EB</b>	<b>Incompatible material identified in device</b> Problems that occur due to the incompatibility of materials that co-exist simultaneously as part of the device.
<b>XE25Z</b>	<b>Reactivity problem identified with device</b> Problems that occur due to the reactivity of materials (e.g. over-react or under-react).
<b>XE6U0</b>	<b>Tolerance stack-up identified in device</b> Problems that result from a combination of specification variances of the components.
<b>XE640</b>	<b>Mechanical problem with device identified</b> Problems that result from internal or external forces including fluids, other objects, or environmental or physiologic influences.
<b>XE8RU</b>	<b>Device migration identified</b> A device that has moved from its original location due to external forces (e.g. stent or lead movement).
<b>XE3HZ</b>	<b>Friction problem identified with device</b> Problems caused by its surface coming in contact with another surface or fluid.
<b>XE1P8</b>	<b>Leakage or seal problem identified with device</b> Problems caused by inadequate/broken seal within the device.
<b>XE6UT</b>	<b>Lubrication problem identified with device</b> Problems that occurred because of the presence of either too much or too little lubricant where required (e.g. connectors, leading to failure mechanisms such as corrosion).
<b>XE69Q</b>	<b>Stiffness problem identified with device</b> Problems caused by either excessive or inadequate physical force exerted on it by another object resulting in problems e.g. wear, bending, deformation, fracture, fatigue.

<b>XE8V5</b>	<b>Stress problem with device identified</b> Problems caused by either excessive or inadequate physical force exerted on it by another object resulting in problems e.g. wear, bending, deformation, fracture, fatigue.
<b>XE0WG</b>	Deformation problem with device identified Problems caused by changes in the shape or size of the device due to an applied force. This can be a result of tensile forces, compressive forces, shear, bending, tensile (pulling), or torsion.
<b>XE3Y4</b>	Fatigue problem with device identified Problems due to the weakening or breakdown of its material when subjected to stress or a series of repeated stresses.
<b>XE1ZP</b>	Fracture problem with device identified Problems caused by the separation of a component, object, or material into two or more pieces including shear.
<b>XE1UJ</b>	Mechanical shock problem with device identified Problems caused by the sudden violent blow or collision to the whole device (e.g. by dropping).
<b>XE1H3</b>	Vibration problem with device identified Problems caused by the constant rhythmic motion of the device, or something in the environment to which the device is exposed.
<b>XE1ZQ</b>	Wear problem with device identified Problems due to the premature or expected erosion of its material by use, deterioration, or change.
<b>XE1EJ</b>	<b>Incorrect dimension of device identified</b> Problems caused by incorrect physical dimensions of the device or one of its parts
<b>XE4KN</b>	<b>Optical problem with device identified</b> Problems related to the optical properties of a device.
<b>XE42B</b>	<b>Optical transmission problem identified with device</b> Problems with the device's ability to pass light energy.
<b>XE8XT</b>	<b>Light source problem identified with device</b> Problems with the optical properties of a device such as diopter, glare, and irradiance or glistening.
<b>XE05W</b>	<b>Clinical imaging problem with device identified</b> Problems that occur with devices used for radiographic or imaging procedures e.g. CT scanners, magnetic resonance imaging.

<b>XE15N</b>	<b>Gradient induced field problem with device identified</b> Problems that result from the gradient-induced fields generated during radiologic procedures e.g. magnetic resonance imaging.
<b>XE1HK</b>	<b>Image artifact identified in device</b> The unacceptable distortion of an image due to signal loss that may occur during a radiologic procedure such as magnetic resonance imaging.
<b>XE6YW</b>	<b>Magnetically-induced movement of device identified</b> Problems due to unintended or excessive movement created by the application of magnetic fields.
<b>XE9Y9</b>	<b>Radiofrequency induced overheating of device identified</b> Problems due to unintended radiofrequency-induced temperature increase that can occur in the vicinity of the device.
<b>XE6TE</b>	<b>Software problem with device identified</b> Problems related to the device software.
<b>XE77W</b>	<b>Configuration issue of device identified</b> Problems due to change control or incorrect version, including regional requirements.
<b>XE6DT</b>	<b>Design error of device identified</b> The device had faulty (incomplete or incorrect) software design.
<b>XE006</b>	<b>Data compression error in device identified</b> Data was lost or corrupted during the operation of reducing storage space or communication bandwidth.
<b>XE62E</b>	<b>Incorrect algorithm in device identified</b> The device software was found to implement an incorrect sequence of steps for a specific computation.
<b>XE1X4</b>	<b>Incorrect data definition in device identified</b> The device software was found to contain errors in specifying or manipulating data items.
<b>XE2FL</b>	<b>Interface design error of device identified</b> The device software was found to contain errors in the user interface (including usability problems) or the interfaces with other systems.
<b>XE85U</b>	<b>Non-functional defect in device identified</b> The device software contained software errors that did not impact its operation.
<b>XE3RD</b>	<b>Software timing problem in device identified</b> Problem that results from the incorrect sequencing or activation of software modules.

<b>XE9JR</b>	<b>Software maintenance problem identified with device</b> The device software was not maintained/updated properly.
<b>XE688</b>	<b>Software installation problem identified with device</b> The device software was not installed as per the specifications or failed to properly install.
<b>XE4SV</b>	<b>Software requirement error with device identified</b> The software requirements for the device are either incomplete, inadequate, or in conflict.
<b>XE51Q</b>	<b>Software runtime error in device identified</b> The device software failed during operation as a result of a coding error.
<b>XE9W2</b>	<b>Software security vulnerability of device identified</b> The device software failed to provide adequate authorization, access control, protection and accountability features.
<b>XE1KR</b>	<b>Erroneous data transfer in device identified</b> The device software fails to transfer the expected data within a system or to another device.
<b>XE2A7</b>	<b>Data storage or loss of data problem in device identified</b> Storage of data was unsuccessful in total or in part.
<b>XE8XM</b>	<b>Thermal problem with device identified</b> Problems related to the temperature of the device.  <b>Exclusions:</b> Problems related to environmental temperature identified (XE3AL)
<b>XE62G</b>	<b>Overheating of device problem identified</b> The device was found to become hotter than expected during operation. This applies to devices which are not intended to deliver heat.  Use "Excessive heating identified" for devices which are intended to deliver heat during operation.  <b>Exclusions:</b> Overheating of devices intended to deliver heat during operation (XE9HT)
<b>XE9HT</b>	<b>Excessive heating of device problem identified</b> The device delivered more heat than intended or expected during operation.  This applies to devices which are intended to deliver heat.  Use "Overheating problem identified" for devices which are not intended to deliver heat during operation.  <b>Exclusions:</b> Overheating of device not intended to deliver heat during operation (XE62G)
<b>XE7A1</b>	<b>Inadequate cooling of device problem identified</b> The device did not sufficiently cool the patient or another device during operation.

<b>XE5HU</b>	<b>Protective system problem with device identified</b> Problems related to the system(s) designed to prevent or warn about unsafe operation of the device.
<b>XE0WJ</b>	<b>Fail-safe problem with device identified</b> A system intended to prevent unsafe operation of the device did not operate correctly.
<b>XE4JQ</b>	<b>Alarm system problem with device identified</b> A system intended to warn of a potentially unsafe condition did not operate correctly.
<b>XE7ZT</b>	<b>Problem of device to self-test identified</b> Malfunction of the device's self-test system.
<b>XE1JG</b>	<b>Problem of device to auto stop identified</b> An auto stop function of a device did not operate correctly.
<b>XE9AV</b>	<b>Reset problem with device identified</b> The device does not reset properly.
<b>XE2FY</b>	<b>Premature indicator activation problem identified</b> A system intended to indicate the device status was triggered prematurely.
<b>XE3BG</b>	<b>Shielding problem with device identified</b> Inadequate shielding of/by the device.
<b>XE0M6</b>	<b>Missing or inadequate safety measures of device identified</b> Safety measures are inadequately applied or missing.
<b>XE82X</b>	<b>Operational problem with device identified</b> Problems that occur during the performance, use, or functioning of the device.
<b>XE5RS</b>	<b>Device incorrectly reprocessed</b> Problems associated with the failure to properly and adequately reprocess the device.
<b>XE2RQ</b>	Device incorrectly cleaned during reprocessing identified The cleaning procedure is not followed correctly or used inappropriate cleaning materials.
<b>XE63T</b>	Device incorrectly disinfected or sterilised during reprocessing identified The disinfection or sterilization process was incorrect or the wrong products for disinfection or sterilization were used.
<b>XE0TU</b>	Device incorrectly assembled during reprocessing identified Incorrect assembly of the device following reprocessing.

<b>XE15Q</b>	<b>Failure to calibrate problem identified</b> A device that cannot calibrate (establish the relationship between a measuring device and the units of measure) to ensure accurate readings.
<b>XE3W1</b>	<b>Device difficult to operate problem identified</b> Problems including set-up, operation, and disassembly of equipment. Not including reprocessing.
<b>XE2QD</b>	<b>Incorrect interpretation of results or data problem identified</b> Problems resulting from the incorrect interpretation by the user of the results or data provided by the device.
<b>XE2YD</b>	<b>Patient sample problem with device identified</b> Problems that occurred due to endogenous or exogenous interferent in the sample, or unexpected variation in the target analyte/marker.
<b>XE8DL</b>	<b>New or unknown interferent problem with device identified</b> New or unknown endogenous or exogenous interferent (sample) identified.
<b>XE9C0</b>	<b>Known interferent problem with device identified</b> Known interferent in the sample identified.
<b>XE83B</b>	<b>Pre-analytical handling problem with device identified</b> Incorrect pre-analytical handling of patient's sample by the user.
<b>XE3AL</b>	<b>Environment problem with device identified</b> Problems that occurred due to factors within the environment e.g. dust, dirt, humidity, temperature.
<b>XE5K2</b>	<b>Environmental temperature problem with device identified</b> Device performance was affected by the temperature, or changes in temperature, of the environment in which it was used.
<b>XE9HK</b>	<b>Dust or dirt problem with device identified</b> A device that experienced problems due to ingress, or coating, of dust or dirt.
<b>XE2VF</b>	<b>Contamination of environment by device identified</b> Operation of the device results in contamination of the nearby environment e.g. dust, dirt, smoke, heat or biological material.
<b>XE6QW</b>	<b>Environmental pressure problem with device identified</b> Device performance was affected by the pressure, or changes in pressure, of the environment in which it was used.
<b>XE5SF</b>	<b>Ambient light problem with device identified</b> Device performance was affected by ambient light.  This term applies to the direct effects of ambient light on the device, and to the user's ability to operate the device (e.g. to read device output).

XE4V1	<b>Environmental humidity problem with device identified</b> Device performance was affected by the humidity, or changes in humidity, of the environment in which it was used.
XE205	<b>Manufacturing process problem with device identified</b> Problems with a device that can be traced to a problem in the manufacturing and/or production process.
XE3NF	<b>Assembly problem with device identified</b> Problems that occurred because the device was assembled incorrectly.
XE00F	<b>Sterilization problem with device identified</b> Problems that occurred during terminal sterilization by the manufacturer.
XE1PG	<b>Installation problem with device identified</b> A device that malfunctions because it was incorrectly installed, set up, or configured (E.g. misconfiguration of an "automatic" defibrillator to "semi-automatic", thereby leading to failure).
XE843	<b>Maintenance of manufacturing machinery problem with device identified</b> Problems caused by failure to maintain manufacturing equipment used to produce the device.
XE278	<b>Packaging problem with device identified</b> Problems that occurred because of the device packaging.
XE9F7	Packaging of device compromised problem identified Problems that occurred because of a compromised packaging of the device (e.g. broken or incomplete seal).
XE0KG	Packaging materials of device problem identified Problems that occurred because the composition or type of packaging materials was inappropriate for the device.
XE8S1	Packaging of device contains unintended material problem identified Problems that occurred because unintended material was packaged with the device.
XE8TA	Packaging contains incorrect device problem identified Problems that occurred because the packaging contained an incorrect device.
XE6LZ	<b>Maintenance problem with device identified</b> A device malfunction or problem that occurs after production because the device was not properly maintained according to the instructions (e.g. maintenance may be performed by user facility, distributor, or service provider).
XE9VK	<b>Transport or storage problem with device identified</b> Problems caused by transport or storage conditions.

<b>XE32G</b>	<b>Storage of device problem identified</b> Problems that result from storing the device in an uncontrolled or improper environment (e.g. moisture sensitive devices stored in a humid environment).
<b>XE41R</b>	<b>No device problem found</b> The device either functioned as intended or a problem was not found.
<b>XE587</b>	<b>No findings available</b> Use when no investigation can be performed and therefore no results will be obtained.
<b>XE3PA</b>	<b>Results pending completion of investigation</b> Investigation is ongoing and results are not yet available. Do not use this code if the investigation is complete.
<b>XE3WR</b>	<b>Appropriate term or code for investigation of device not available</b> Problems not adequately described by any other term.  Note: This code must not be used unless there is no other feasible code. The preferred term should be documented when submitting an adverse event report. This information will be used to determine if a new term should be added to the code table.
 <b>Cause investigation and type of investigation</b> For describing what was investigated and what kind of investigation was conducted to specify the root cause of the adverse event.	
<b>XE9HD</b>	<b>Testing of actual or suspected device</b> The investigation employed relevant empirical testing of the actual device suspected in the reported adverse event in order to establish their functional and other properties and to identify possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.
<b>XE7XH</b>	<b>Testing of device from same lot or batch retained by manufacturer</b> The investigation employed relevant empirical testing of the device of the same lot or batch as that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. Testing was performed using the device retained by the manufacturer (i.e. was not shipped). Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.
<b>XE4S0</b>	<b>Testing of device from same lot batch returned from user</b> The investigation employed relevant empirical testing of the device of the same lot or batch as that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. The device was returned from the user. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.

**XE2ZR****Testing of device from other lot/batch retained by manufacturer**

The investigation employed relevant empirical testing of the device of another lot or batch than that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. This includes devices without a lot/batch designation. Testing was performed using the device retained by the manufacturer (i.e. was not shipped). Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.

**XE4X1****Testing of device from other lot/batch returned from user**

The investigation employed relevant empirical testing of the device of another lot or batch than that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. This includes devices without a lot/batch designation. The device was returned from the user. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the technical file. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.

**XE1XT****Testing of model variant**

The investigation employed relevant empirical testing of a model variant of the device involved in the reported adverse event in order to support the identification of possible causes for the adverse event through plausibility reasoning. A model variant is not identical to the actual device, but shares relevant characteristics with the device involved. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.

**XE8XV****Testing of raw or starting materials**

The investigation employed relevant empirical testing of the materials used in construction of the device involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.

**XE6FS****Testing of patient sample or reference material using manufacturer's device**

The investigation employed relevant empirical testing of a patient sample or reference material using the device (usually an IVD) involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.

**XE9MY****Testing of patient sample or reference material using reference method**

The investigation employed relevant empirical testing of a patient sample or reference material using an appropriate reference method to the device (usually an IVD) involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.

**XE89L****Testing of patient sample or reference material using competitor's device**

The investigation employed relevant empirical testing of a patient sample or reference material using a competitor's device that is comparable to the device (usually an IVD) involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.

**XE8UH****Historical data analysis**

The investigation involved the analysis of historical adverse events data of the actual device involved in the adverse event and/or of products from the same and/or different batches/ lots.

**XE8BM****Trend analysis**

The investigation involved trend analysis of adverse event of the actual device involved in the adverse event and/or of products from the same and/or different batches/ lots. It should be noted that trend analysis typically is not considered sufficient as a stand-alone method, but should be used in conjunction with other investigation methods for providing for instance complementary information.

**XE7GK****Communication or interviews**

The investigation involved communication/interviews (either interpersonal or through technical means, e.g. phone, e-mail) with persons close to the adverse event, e.g. healthcare professionals (doctors, nurses etc.), the affected patient(s) or other users including, where appropriate, relatives or others engaged in caring for the affected patient.

**XE4KV****Analysis of production records**

The investigation involved the analysis of relevant production records in view of supporting the identification of possible causes for the adverse event.

**XE59M****Analysis of data provided by user or third party**

The investigation involved the analysis of relevant data provided by the user (e.g. healthcare professional, patient, clinical engineer) or a third party (e.g. testing facility) in view of supporting the identification of possible causes for the adverse event.

**XE8FB****Device not manufactured by reporting manufacturer**

Further information was obtained which established that the manufacturer of the device involved was not the one to which it was initially attributed.

**XE970****Device not returned**

The actual device involved in the adverse event was not returned for testing despite requests by manufacturer.

**XE18W****Device discarded**

The actual device involved in the adverse event had been already discarded and thus irretrievably lost for testing.

**XE5AN**

**Incomplete device returned**

The device was returned incompletely, lacking parts, components or accessories that would be required for appropriate testing and analysis of root causes.

**XE53L**

**Device not accessible for testing**

The actual device involved in the adverse event is not readily accessible for testing (e.g. remains implanted in patient).

**XE6Q2**

**Type of investigation not yet determined**

Details to determine the type of investigation are not yet available, but are being sought. Do not use this code if the investigation is complete.

**XE3TW**

**Insufficient information available**

The information available relating to the reported event is not sufficient to identify either the manufacturer, the device, or other essential information. This term indicates that no further investigation is possible. Do not use this code if further information is being sought, instead use "Type of investigation not yet determined".

**Medical device component**

Terms/codes for describing the parts and components which were involved in, or affected by, the medical device adverse event/incident.

**Biological and chemical medical device component**

Component whose mode of action involves a biological process (e.g. test strip which acts on antibodies) and chemical reaction or transformation (e.g. activated charcoal absorber).

**XE8XD**

**Absorber component of medical device**

A component or material designed to take in or attenuate a substance.

**XE6Z7**

**Cautery tip component of medical device**

A component designed to coagulate and seal blood vessels or to destroy tissue with heat or electric current.

**XE7JR**

**Device ingredient or reagent component of medical device**

A consumable material that is added to a device and is used to make a finished product or becomes part of a finished product.

**XE8HT**

**Gas scavenging component of medical device**

A component designed to remove certain gases from a gas stream or environment.

**XE4VK**

**Monomer liquid component of medical device**

The liquid that reacts with the polymer powder to form adhesive, resin, or cement.

**XE68H**

**Test strip component of medical device**

A piece of chemically treated medium designed to react in the presence of specific amounts of a trigger substance.

**XE7WP**

**Polymer powder component of medical device**

The powder that reacts with the monomer liquid to form adhesive, resin, or cement.

**Electrical and magnetic medical device component**

Components which relate to the force of magnetism or such as microchips and transistors which control and direct electric currents. Also includes components involved in the representation, storage, or transmission of information by electronic systems.

**XE321**

**Antenna component of medical device**

A component designed to transmit or receive electromagnetic signals.

**XE3WM**

**Battery component of medical device**

A component designed to produce an electric current through chemical reaction.

**XE80Z**

**Battery charger component of medical device**

A device designed to restore the capacity of a battery.

**XE7JQ**

**Cable, electrical component of medical device**

A long, thin, multistranded electrical wire designed to carry signals or power over a distance.

**XE77B**

**Cable grip component of medical device**

Component used for tensioning, pulling or stringing of wires and cables.

**XE2BS**

**Cable sleeve component of medical device**

Component used to protect cables and wires from abrasion, moisture and the elements.

**XE2WY**

**Circuit board component of medical device**

A non-conducting board with conductive tracks and electronic components forming a circuit.

**XE5BT**

**Circuit breaker component of medical device**

A component designed to open an electrical circuit when it becomes overloaded.

**XE2ZE**

**Computer hardware component of medical device**

The physical components from which a computer is constructed (electronic circuits and input/output devices).

**XE3Q8**

**Computer processor component of medical device**

Component that carries out the instructions of a computer program by performing the basic arithmetic, logic, controlling, and input/output operations specified by the instructions.

**XE1JS**

**Memory or storage component of medical device**

Any component that can hold data in machine-readable format.

<b>XE2YC</b>	<b>Network interface component of medical device</b> Point of interconnection between a computer and other computer that are linked each other.
<b>XE8UU</b>	<b>Computer software component of medical device</b> A collection of data or computer instructions that tell the computer how to work.
<b>XE59Z</b>	<b>Computer software driver component of medical device</b> A computer interface designed to control the interaction between a CPU and a peripheral device.
<b>XE2JQ</b>	<b>Software interface component of medical device</b> Languages, codes and messages that programs use to communicate with each other and to the hardware.
<b>XE8V6</b>	<b>User interface component of medical device</b> A computer program that controls the interaction between a user and a system.
<b>XE7P0</b>	<b>Cooling module component of medical device</b> A component designed to lower the temperature of a device or system.
<b>XE8UV</b>	<b>Device programmer component of medical device</b> A piece of hardware for transferring data onto programmable integrated circuits.
<b>XE033</b>	<b>Device reader component of medical device</b> A piece of hardware used to read the memory and the properties of a device.
<b>XE6UE</b>	<b>Discrete electrical component of medical device</b> An electrical component which is just one circuit, either passive or active, that is not an integrated circuit.
<b>XE845</b>	<b>Electrical capacitor component of medical device</b> An electrical component designed to store an electric charge.
<b>XE38E</b>	<b>Electrical fuse component of medical device</b> An electrical component designed to stop the flow of current when an overload condition exists.
<b>XE1UQ</b>	<b>Electrical inductor component of medical device</b> A component designed to introduce electromotive force to a circuit, usually a coil surrounding a wire.
<b>XE2AJ</b>	<b>Electrical resistor component of medical device</b> An electronic component that opposes the flow of current.
<b>XE4VJ</b>	<b>Electrical solenoid component of medical device</b> An electronic component consisting of a coil surrounding a movable iron core that is designed to act as a switch or relay.

XE018	<b>Electrical transducer component of medical device</b> An electrical component that converts one form of energy into another.
XE27R	<b>Electrical semiconductor component of medical device</b> A type of electronic component, including transistors and diodes, that make use of the variable conductivity of certain materials.
XE9ZW	<b>Integrated circuit chip component of medical device</b> A microelectronic circuit that incorporates many interconnected transistors and other components.
XE8GY	<b>Display component of medical device</b> A component designed to present information visually. <b>Exclusions:</b> Touchscreen component of medical device (XE9ZJ)
XE4YD	<b>Display indicator component of medical device</b> A component designed to show an operating condition of a system or to attract attention.
XE2JV	<b>Display screen component of medical device</b> A panel or area on an electronic device where images and data are displayed.
XE59E	<b>Electrical lead or wire component of medical device</b> A coated or uncoated wire used to connect two locations electronically. Not to be used for patient connection.
XE5U9	<b>Electrode component of medical device</b> A small piece of metal or other conductive substance that is used to take an electric current to or from a source of power, a piece of equipment. Not to be used for patient connection.
XE561	<b>Ground strap or wire component of medical device</b> A wire cable or strap designed to carry current safely away from an electronic device under fault condition
XE753	<b>Wiring harness component of medical device</b> A collection of grouped wires or cables designed to connect to a specific device.
XE6S4	<b>Electrical mixer component of medical device</b> An electronic component designed to blend signals.
XE0Y5	<b>Electrical port component of medical device</b> An electronic circuit that acts as a connection to another device or component.
XE2PX	<b>Emitter component of medical device</b> The electron source electrode in a transistor or any source in a system.

XE5GC	<b>Headphone or headset component of medical device</b> A component that covers the ear through which you can listen without other people hearing. Some headphones come with a microphone which is used to communicate with other people or the device.
XE9TB	<b>Heater component of medical device</b> A piece of equipment used to raise the temperature of air, gas or water or an object.
XE713	<b>Hub component of medical device</b> An electronic component designed as a central connection for other devices or components.
XE8JV	<b>Inverter component of medical device</b> An electrical component that converts direct current to alternating current.
XE4BN	<b>Magnet component of medical device</b> A component that attracts iron and produces a magnetic field.
XE7YS	<b>Oscillator component of medical device</b> An electronic component designed to produce a wave signal.
XE525	<b>Patient lead component of medical device</b> An insulated electrical cable designed to connect to an electrical device to a patient.
XE7F1	<b>Lead conductor component of medical device</b> A cable designed to conduct electricity from the device to the lead.
XE25C	<b>Patient electrode component of medical device</b> An electrical conductor that is designed to make contact with a patient including defibrillator paddles.
XE4XJ	<b>Power cord component of medical device</b> A flexible cable designed to connect an electrical device to a power outlet.
XE4Q4	<b>Power supply component of medical device</b> Component designed to supply electrical power to devices.
XE7EJ	<b>Pressure transducer probe component of medical device</b> A probe component designed to convert a change in pressure into a varying electrical signal.
XE062	<b>Printer component of medical device</b> An electronic component that is designed to transfer text or images to paper or other substrate.
XE2KA	<b>Receiver component of medical device</b> An electronic component designed to capture an incoming electromagnetic signal and convert it to an audible or visual signal.

<b>XE6SG</b>	<b>Receiver stimulator unit component of medical device</b> As part of a cochlear implant, an implanted component designed to receive signal from the external component and then decode the signal and transmit it to the brain.
<b>XE4TH</b>	<b>Scanner component of medical device</b> An electronic component that generates a digital representation of an image for data input to a computer; or a receiver designed to search for a signal within a specified frequency range.
<b>XE0ST</b>	<b>Speaker or sounder component of medical device</b> A component designed to convert electrical signals to sounds that can be heard.
<b>XE5R5</b>	<b>Switch or relay component of medical device</b> A mechanical or electronic component designed to break or change the connections in a circuit (e.g. button).
<b>XE1EF</b>	<b>Power switch component of medical device</b> A switch designed to regulate the power to a device.
<b>XE4QR</b>	<b>Relay component of medical device</b> A electronic component designed to break or change the connections in a circuit.
<b>XE884</b>	<b>Telemetry component of medical device</b> Component designed to transmit and receive data from a remote source using telecommunications methods.
<b>XE30P</b>	<b>Temperature compensator component of medical device</b> A component designed to compensate the temperature of one system in response to temperature changes in another system or the environment.
<b>XE56F</b>	<b>Thermostat component of medical device</b> A component designed to regulate temperature by controlling the starting and stopping of a heating/cooling system.
<b>XE256</b>	<b>Transformer component of medical device</b> A component that either steps up or steps down an alternating electrical current to an output that is suitable for another electrical device or component.
<b>XE579</b>	<b>Transmitter component of medical device</b> A component to propagate electromagnetic waves.
<b>XE5A0</b>	<b>User input device component of medical device</b> A component that uses a movable handle to create two-axis input to a computer.
<b>XE9TZ</b>	<b>Joystick component of medical device</b> A control component that uses a movable handle to create two-axis input to a computer.

<b>XE6CN</b>	<b>Keyboard or keypad component of medical device</b> A component consisting of mechanical keys that are pressed to create input to a computer.
<b>XE9FY</b>	<b>Microphone component of medical device</b> A component designed to convert sound to an electrical signal.
<b>XE9ZJ</b>	<b>Touchscreen component of medical device</b> A control component that operates the device following pressing the display on the screen.

## Measurement medical device component

Component capable of measuring something in order to obtain a result.

<b>XE37A</b>	<b>Analyzer component of medical device</b> Any component designed to perform an analysis.
<b>XE0A7</b>	<b>Oxygen analyzer component of medical device</b> A component designed to measure the concentration of oxygen in a gas mixture.
<b>XE6E8</b>	<b>Aperture component of medical device</b> An instrument designed to measure the size of an opening or one used to increase the diameter of an opening.
<b>XE34X</b>	<b>Calibrator component of medical device</b> A standard or reference material used to set the operating parameters of an instrument.
<b>XE06B</b>	<b>Clock component of medical device</b> A component designed to indicate the time of day.
<b>XE9NB</b>	<b>Counter component of medical device</b> A component designed to keep track of the number of times something happens.
<b>XE20X</b>	<b>Curvette component of medical device</b> A clear container designed to interface with an optical sensor in order to obtain an optical measurement of a contained substance.
<b>XE00B</b>	<b>Gauges or meters component of medical device</b> A component designed to give a visual indication of the condition of a system.
<b>XE1WJ</b>	<b>Flowmeter component of medical device</b> A component designed to measure the flow rate of a fluid.
<b>XE6V2</b>	<b>Manometer component of medical device</b> A component designed to measure pressure.

XE019	<b>Thermometer component of medical device</b> A component designed to measure temperature.
XE8RD	<b>Marker component of medical device</b> A visual indicator of position, place or route, including radiopaque markers.
XE7MS	<b>Pipette component of medical device</b> A measuring component, traditionally including a graduated tube, designed for the accurate transfer of liquid volumes.
XE5UB	<b>Pointer component of medical device</b> An indicator component designed to show a position on a scale.
XE2MH	<b>Scale component of medical device</b> A component designed for weighing or an indicator component with a graduated sequence of divisions.
XE8GP	<b>Sensor component of medical device</b> A component designed to respond to a stimulus by generating a signal that can be measured or interpreted.
XE5Q2	<b>Bubble sensor component of medical device</b> A component designed to signal the presence of bubbles in a system.
XE5ZD	<b>Oxygen sensor component of medical device</b> A sensor designed to respond to the presence or level of oxygen in a space or environment.
XE9G5	<b>Photodetector component of medical device</b> A component designed to detect light.
XE5WR	<b>Pressure sensor component of medical device</b> A sensor designed to respond to the level of pressure in a space or pressing on a surface.
XE7Q4	<b>Sensor probe component of medical device</b> A component designed to reach into a location for sensing. Should be used when the problem involves the probe, not the sensor.
XE3W9	<b>Temperature sensor component of medical device</b> A sensor designed to respond to the temperature of a space, surface, or environment.
XE3R3	<b>Timer component of medical device</b> A component designed to measure a time interval.

## Mechanical medical device component

Component of a device when it is working, often using power from an engine or from electricity.

**XE3UX**

### **Access port component of medical device**

A component designed for the introduction or removal of medical equipment or any substance.

**XE0WZ**

### **Actuator component of medical device**

A component which moves or controls a mechanism or system.

**XE0SV**

### **Adaptor component of medical device**

A component designed to make different pieces of apparatus compatible.

**XE6D6**

### **Air eliminator component of medical device**

A component designed to remove air from a space or fluid.

**XE4F2**

### **Anchor component of medical device**

A component designed to fix the device or a portion of the device in place.

**XE94Y**

### **Applicator component of medical device**

A component designed to transfer a substance to a surface.

**XE968**

### **Automatic injection system component of medical device**

A system designed to pump a gas or liquid into a space or environment without outside intervention.

**XE7E4**

### **Bag component of medical device**

A flexible container, often with a single opening.

**XE0HN**

### **Ball component of medical device**

Any component that is spherical in shape.

**XE5AV**

### **Balloon component of medical device**

A sac designed to be inflated and deflated.

**XE1G8**

### **Bearings component of medical device**

A point of contact between moving parts designed for support or to reduce friction.

**XE0Y2**

### **Potting component of medical device**

The resin, glue or other substance used to seal other components together.

**XE46S**

### **Probe component of medical device**

A component designed to reach into a location for manipulating or for measuring.

XE23M	<b>Processor component of medical device</b> A component designed for preparing or treating a material. Should not be used for computer processors.
	<b>Exclusions:</b> Computer processor component of medical device (XE3Q8)
XE9DJ	<b>Pulley component of medical device</b> A component which changes the direction of a force (e.g. belt or chain).
XE0K1	<b>Pump component of medical device</b> A component designed to facilitate the movement of a fluid.
XE8RF	<b>Pusher component of medical device</b> A component designed to advance something by pushing it.
XE76K	<b>Ratchet component of medical device</b> A part that allows or forces another part's movement in a single direction.
XE4JZ	<b>Rail component of medical device</b> A bar designed for support, attachment, guidance, or protection from falling.
XE0KN	<b>Side rail component of medical device</b> A supportive or protective rail attached to the side of something.
XE6YN	<b>Regulator component of medical device</b> A component designed to control a process or condition.
XE65T	<b>Reservoir component of medical device</b> A vessel designed to store a fluid.
XE1XK	<b>Bellows component of medical device</b> A component that expands and contracts to draw in air through a valve or orifice and expels it through a tube.
XE7DG	<b>Ring component of medical device</b> A circular band-shaped component.
XE017	<b>Rod or shaft component of medical device</b> A long cylindrical bar used to transmit motion or connect other components.
XE4BJ	<b>Seal component of medical device</b> A component designed to prevent passage of material through a joint or opening.
XE7N2	<b>Shock absorber component of medical device</b> A mechanical component designed to dampen or attenuate a force.
XE7ZG	<b>Sleeve component of medical device</b> A cylindrical fitting that slides over another part of a device or other object.

XE6VJ	<b>Slide component of medical device</b> A flat rectangular piece of glass on which specimens can be mounted for microscopic study.
XE740	<b>Socket component of medical device</b> A component designed as an opening into which something else fits.
XE4DU	<b>Spacer component of medical device</b> A component designed to position objects further apart.
XE7QZ	<b>Spring component of medical device</b> An elastic component designed to bend under a load and then return to its shape when unloaded.
XE4K0	<b>Stand component of medical device</b> A support component designed to hold an object.
XE9CF	<b>Belt component of medical device</b> A component consisting of a narrow band of material moving over shafts or pulleys.
XE82E	<b>Steering wire component of medical device</b> A wire designed to enable a device to be maneuvered.
XE7UE	<b>Stent component of medical device</b> Tubular support placed inside a blood vessel, canal, or duct to aid healing or relieve an obstruction.
XE8M4	<b>Stopcock component of medical device</b> A rotating component designed to act like a tap for regulating the flow of a fluid, and to completely stop the flow when closed fully.
XE00C	<b>Stopper component of medical device</b> Component designed to close an opening.
XE4E4	<b>Strain relief component of medical device</b> A structure designed to function with a connector to prevent damage to a hose or cable from excess flexing.
XE3GN	<b>Stylet component of medical device</b> A thin metal wire designed to be passed through a needle, catheter, or cannula to stiffen it or clear it of debris.
XE05P	<b>Syringe component of medical device</b> A component designed as a rigid cylinder with a plunger at one end and a delivery opening at the other.

<b>XE3ED</b>	<b>Table component of medical device</b> A component having a smooth flat surface that is usually supported by one or more vertical legs.
<b>XE06W</b>	<b>Tip component of medical device</b> Pointed or rounded end of an object.
<b>XE6GE</b>	<b>Tool component of medical device</b> A component that is delivered with a device to support its assembly or operation, and is not part of the device. Use only in the case there are no other terms to describe the component.
<b>XE7G4</b>	<b>Bottle component of medical device</b> A rigid or semi-rigid container used to store liquid.
<b>XE0UG</b>	<b>Translational motion component of medical device</b> A rotating part which is intended to transfer rotational movement or motion to another type of movement (e.g. excenters).
<b>XE2FM</b>	<b>Trap component of medical device</b> A component designed to capture or remove bubbles or fluid.
<b>XE4M3</b>	<b>Trocars component of medical device</b> A sharp, pointed rod designed to pierce the wall of a body cavity to withdraw fluid or allow placement of a catheter or other device.
<b>XE8TY</b>	<b>Tube component of medical device</b> A long hollow cylinder, either rigid or flexible, for holding or transporting liquids or gasses.
<b>XE2PZ</b>	<b>Capillary tube component of medical device</b> A narrow tube in which a liquid flows up against gravity.
<b>XE01P</b>	<b>Valve component of medical device</b> A mechanical component designed to control the flow of a fluid or gas.
<b>XE3YJ</b>	<b>Control valve component of medical device</b> A valve designed to regulate the flow of a fluid or gas.
<b>XE229</b>	<b>Luer valve component of medical device</b> A valve that incorporates a Luer fitting.
<b>XE2LS</b>	<b>One-way valve component of medical device</b> A valve designed to allow flow in only one direction.
<b>XE6MT</b>	<b>Vaporiser component of medical device</b> A component for gasifying liquids such as drugs.

<b>XE0FP</b>	<b>Vibrator component of medical device</b> A mechanical component designed to create a vibratory motion.
<b>XE83A</b>	<b>Washer component of medical device</b> A flattened disk used as a mechanical seal between objects.
<b>XE1PW</b>	<b>Weld component of medical device</b> Any joining connection that is the result of welding 2 or more parts.
<b>XE6HA</b>	<b>Wheel component of medical device</b> A mechanical component consisting of a spoked, circular rim or solid disk designed to rotate on an axle or shaft.
<b>XE0C3</b>	<b>Breathing circuit component of medical device</b> In an anesthesia machine, the pathway by which a gaseous anesthetic agent and oxygen are delivered to the patient and carbon dioxide is removed. The circuit can be open or closed.
<b>XE99Z</b>	<b>Window component of medical device</b> A transparent panel in a device designed for visual inspection or to let light pass.
<b>XE2Q3</b>	<b>Shutter component of medical device</b> Aperture that controls or blocks light or radiation passing through.
<b>XE5YT</b>	<b>Brush component of medical device</b> A component consisting of hairs or bristles set into a handle or holder.
<b>XE0AX</b>	<b>Brushing component of medical device</b> A cylindrical metal sleeve designed to reduce the friction of a rotating shaft.
<b>XE4NU</b>	<b>Cable, mechanical structural component of medical device</b> A long, thin, multistranded rope or metallic wire to hold the subject.
<b>XE2UB</b>	<b>Cannula component of medical device</b> A rigid or semi-rigid tube inserted into the body.
<b>XE9FK</b>	<b>Cannula hub component of medical device</b> A metal or plastic component that connects to the cannula.
<b>XE44H</b>	<b>Cap component of medical device</b> A component designed to close an opening of a container or device.
<b>XE00E</b>	<b>Carrier component of medical device</b> A component designed to facilitate the support, movement, or transport of another device or object.
<b>XE3K0</b>	<b>Caster component of medical device</b> A pivoting roller or wheel designed to attach to an object to make it movable.

XE088	<b>Catheter component of medical device</b> A flexible tube inserted into the body designed to permit injection or withdrawal of fluids or to keep passage open.
XE8NS	<b>Catheter hub component of medical device</b> A small metal or plastic component that connects to the catheter.
XE1TF	<b>Cell component of medical device</b> A component that is designed as a container to collect and/or transfer materials, reagents or specimens.
XE65A	<b>Chain component of medical device</b> Assembly of interconnected links, typically made of metal used for connecting other components.
XE6N0	<b>Chamber component of medical device</b> A component designed as a reservoir/storage.
XE4BK	<b>Chassis or frame component of medical device</b> A supporting frame designed to hold other components or devices such as the internal frame of an electronic device.
XE5CL	<b>Clutch component of medical device</b> A component that engages and disengages power transmission.
XE3C8	<b>Coating material component of medical device</b> A layer of material covering the surface of a device.
XE1S0	<b>Coil component of medical device</b> A structure consisting of something wrapped in a continuous series of loops.
XE8AQ	<b>Helifix coil component of medical device</b> A coil designed to allow a Helifix pacing electrode to be placed in the endocardium.
XE0YX	<b>Collimator component of medical device</b> A diaphragm or system of diaphragms made of an absorbing material, designed to define and restrict the dimensions and direction of a beam of radiation.
XE7YF	<b>Concentrator component of medical device</b> A component designed to increase the weight per unit volume of a substance.
XE5TK	<b>Cone component of medical device</b> A three-dimensional part that tapers smoothly from a flat circular shape at one end to a point at the other end.
XE7EE	<b>Connector or coupler component of medical device</b> A component designed to serve as a link between parts allowing easy disconnection and reconnection when necessary.

<b>XE4T6</b>	<b>Connector pin component of medical device</b> A projecting part of a device that allows it to be secured through an opening.
<b>XE83L</b>	<b>Controller component of medical device</b> A component designed to control or regulate the operation of another device.
<b>XE46J</b>	<b>Compressor component of medical device</b> A component that increases the pressure of air or gas.
<b>XE1S2</b>	<b>Cover component of medical device</b> An object designed to conceal, enclose, or protect something.
<b>XE8LZ</b>	<b>Cuff component of medical device</b> A bandlike structure that encircles a body part or another component or device.
<b>XE8YR</b>	<b>Cup component of medical device</b> Part or design of a device with a concave hemispherical shape.
<b>XE8T8</b>	<b>Cusp and leaflet component of medical device</b> A thin blade-like component, typically used as part of a one-way valve.
<b>XE3LB</b>	<b>Cutter or blade component of medical device</b> A component designed for slicing or cutting.
<b>XE9WL</b>	<b>Cylinder component of medical device</b> A three-dimensional part with flat circular ends and long straight sides.
<b>XE3CX</b>	<b>Device collapser component of medical device</b> A component designed to fold or collapse something.
<b>XE8J5</b>	<b>Device deployer component of medical device</b> A component designed to install something or distribute something in a systematic way.
<b>XE1KD</b>	<b>Diaphragm component of medical device</b> A component consisting of a flexible sheet or partition.
<b>XE85G</b>	<b>Dome component of medical device</b> Part or design of a device with a convex hemispherical shape.
<b>XE5K4</b>	<b>Ejector component of medical device</b> A mechanism that pushes a device or component out.
<b>XE1VC</b>	<b>Equipment pole component of medical device</b> A structural component designed to hang medical equipment.
<b>XE8ZU</b>	<b>Extender component of medical device</b> A component designed to lengthen a structure.

<b>XE026</b>	<b>Fabric component of medical device</b> Cloth produced from textile fibers.
<b>XE8VD</b>	<b>Fan or blower component of medical device</b> A component designed to create an air current through the rotation of a planar surface.
<b>XE5DL</b>	<b>Fastner component of medical device</b> A component designed to hold items in place.
<b>XE1A5</b>	<b>Adhesive fastner component of medical device</b> Any substance that affixes 2 or more surfaces together. This may be supplied separately, or attached to another item such as tape.
<b>XE4V8</b>	<b>Bolt fastner component of medical device</b> A cylindrical connector element which may have a thread/nut connection to form a fastener.
<b>XE4PG</b>	<b>Clamp fastner component of medical device</b> A component designed to mechanically hold items firmly together.
<b>XE3VN</b>	<b>Clip fastner component of medical device</b> A small component designed to hold and attach items together.
<b>XE9KR</b>	<b>Fixation wire fastner component of medical device</b> A metal strand designed for structural or other purpose.
<b>XE6R2</b>	<b>Latch fastner component of medical device</b> A fastening component for a mobile part usually consisting of a bar that is retained in a slot.
<b>XE7GP</b>	<b>Nail fastner component of medical device</b> A pin-shaped fastener with a sharp point at one end and usually flat on the other end.
<b>XE0F0</b>	<b>Nut fastner component of medical device</b> A threaded fastener designed to engage a bolt.
<b>XE6A2</b>	<b>Pin fastner component of medical device</b> A small, slender separate component which is designed to secure another object.
<b>XE059</b>	<b>Prong fastner component of medical device</b> A projecting pointed part of a device, usually one designed to attach a device to something else.
<b>XE33C</b>	<b>Retainer fastner component of medical device</b> A physical component designed to hold items in place.

<b>XE9MM</b>	<b>Rivet fastner component of medical device</b> A fastening component resembling a heavy pin, having a head on one end and designed to have the other end flattened after passing through the parts to be connected.
<b>XE3NX</b>	<b>Screw fastner component of medical device</b> A fastening component with a tapered threaded shaft and a head designed to engage with a driving tool.
<b>XE2HY</b>	<b>Staple fastner component of medical device</b> A fastening component consisting of a bent wire designed to pierce and hold two or more surfaces together.
<b>XE0NL</b>	<b>Suture thread fastner component of medical device</b> A monofilament or multifilament material used surgically to close a wound, join tissues, or fasten components of a device (e.g. fabric to wire stent frame).
<b>XE8MX</b>	<b>Tape for fixation component of medical device</b> A long, thin, flat, flexible material often used for binding or fastening.
<b>XE15J</b>	<b>Fiber component of medical device</b> Any component made from a long, slender material.
<b>XE65M</b>	<b>Filter component of medical device</b> A component designed to remove something from whatever passes through it.
<b>XE10F</b>	<b>Flange component of medical device</b> A protruding edge designed to strengthen or stabilize a device or facilitate its attachment to a surface.
<b>XE4PC</b>	<b>Foil component of medical device</b> A thin, flexible sheet of metal.
<b>XE3HQ</b>	<b>Gas exchanger component of medical device</b> Component that is used to transfer gasses between two or more locations.
<b>XE3QZ</b>	<b>Gasket component of medical device</b> A preformed material designed to form a seal between connecting surfaces.
<b>XE5M6</b>	<b>Gears component of medical device</b> A toothed wheel designed to mesh with another toothed object and transmit motion.
<b>XE0RK</b>	<b>Generator component of medical device</b> A component designed to produce electricity, vapor or gas.
<b>XE1ND</b>	<b>Guide component of medical device</b> A component designed to help direct the passage of another object.

XE64H	<b>Guidewire component of medical device</b> A flexible wire designed to help position medical devices within the body.
XE11W	<b>Handpiece component of medical device</b> A part of a device designed to be used while held in the hand.
XE37B	<b>Header component of medical device</b> The connection point between the leads and the generator.
XE2AL	<b>Sewing ring component of medical device</b> A ring of supportive material designed to provide a stable surface for attachment to surrounding tissues.
XE12Q	<b>Heat exchanger component of medical device</b> A component designed to transfer heat between fluids and/or gases across a barrier or to the environment.
XE5ZS	<b>Hinge component of medical device</b> A component designed to join two objects and allow them to swing relative to one another.
XE4FZ	<b>Holder component of medical device</b> A component designed to hold another object.
XE3A4	<b>Hose component of medical device</b> A flexible tube designed to carry a fluid or gas.
XE5S9	<b>Housing component of medical device</b> A rigid casing that encloses and protects a piece of equipment.
XE0YE	<b>Humidifier component of medical device</b> A component used to increase moisture in a gas.
XE1TK	<b>Hydraulic system component of medical device</b> A system designed to use fluid pressure to bring about movement.
XE4NN	<b>Impeller component of medical device</b> The rotating component of a centrifugal pump, compressor, or other machine designed to move a fluid by rotation.
XE3WA	<b>Inserter component of medical device</b> A component whose function is to facilitate the insertion of a particular device.
XE1Y2	<b>Insulation component of medical device</b> A material designed to reduce the transmission of heat, sound, or electricity.
XE7JF	<b>Isolator component of medical device</b> Any material or structure designed to limit the interaction between two components.

<b>XE7N3</b>	<b>Jaw component of medical device</b> A component designed to use opposing parts to close on and hold an object.
<b>XE7GQ</b>	<b>Joint component of medical device</b> A component designed as the junction between objects; it may be flexible or rigid.
<b>XE3AW</b>	<b>Knob component of medical device</b> A rounded lump or ball used for adjusting or controlling.
<b>XE6R7</b>	<b>Label component of medical device</b> Any written, printed, or graphic matter upon a device to identify its nature, ownership, or other characteristics of the device.
<b>XE1VQ</b>	<b>Leaflet component of medical device</b> A device consisting of two thin blades hinged in the center; typically designed to control flow of fluids.
<b>XE5XR</b>	<b>Lever component of medical device</b> A rigid bar that rotates around a fixed point.
<b>XE08E</b>	<b>Foot pedal component of medical device</b> A lever designed to be operated with the foot.
<b>XE80W</b>	<b>Liner component of medical device</b> A component placed inside the walls of a cavity or container for protection or insulation.
<b>XE17E</b>	<b>Magazine or cassette component of medical device</b> A compartment in a device designed to house a consumable material for feeding into a mechanism.
<b>XE87E</b>	<b>Manifold component of medical device</b> A compartment in a device designed to house a consumable material for feeding into a mechanism.
<b>XE26U</b>	<b>Mask component of medical device</b> A flexible, form-shaped component designed to be placed over the nose and/or mouth.
<b>XE74K</b>	<b>Mechanical mixer component of medical device</b> A mechanical component designed to blend materials.
<b>XE9VQ</b>	<b>Membrane component of medical device</b> A component that is made from or resembles a thin flexible sheet of material acting as a boundary or separating two chambers.
<b>XE8R6</b>	<b>Mesh component of medical device</b> Component made of overlapping strands forming a fine net-like structure.

XE0R5	<b>Motor component of medical device</b> A machine that converts any form of energy to produce or impart motion (kinetic energy).
XE8X1	<b>Mount component of medical device</b> A structural component designed to facilitate the attachment of one object to another.
XE4BH	<b>Needle component of medical device</b> A component with a long, slender, pointed shape.
XE78G	<b>Nozzle component of medical device</b> A component designed to regulate and direct the flow of a fluid or gas.
XE7C4	<b>Packaging component of medical device</b> The outer wrapping around a device which serves to contain, identify, and protect it prior to use.
XE5AR	<b>Pad component of medical device</b> Typically a soft, cushion-like material used to prevent injury or damage to a person or device. Can also be made of an absorbent material to absorb liquid.
XE080	<b>Panel component of medical device</b> A rigid sheet that forms a surface of a device or component.
XE965	<b>Plate component of medical device</b> A thin, flat sheet or strip used to join, strengthen or to form parts of another structure.
XE09R	<b>Plug component of medical device</b> A component designed to seat into an opening in a device or other object.
XE9R2	<b>Plunger component of medical device</b> A component of a machine, tool or device that pushes or thrusts another object, liquid or gas.
XE25A	<b>Post component of medical device</b> An upright piece that is fixed firmly that supports, place or aligns other parts.

## Optical medical device component

Component which involves or relates to vision, light, or images.

XE120	<b>Camera component of medical device</b> An apparatus for taking photographs, generally consisting of a lightproof enclosure having an aperture with a shuttered lens through which the image of an object is focused and recorded on a photosensitive film or plate.
-------	---

<b>XE5CR</b>	<b>Film component of medical device</b> A photographic material designed to capture an image upon exposure to electromagnetic radiation.
<b>XE7NH</b>	<b>Imager component of medical device</b> A component designed to create or record a visual representation.
<b>XE6GJ</b>	<b>Laser component of medical device</b> A component designed to emit a monochromatic beam of coherent light.
<b>XE6QH</b>	<b>Light emitting diode component of medical device</b> A type of diode designed to emit light when a current passes through it.
<b>XE616</b>	<b>Lenses component of medical device</b> An electric or optical component designed to focus (concentrate) or disperse electromagnetic radiation.
<b>XE5LN</b>	<b>Light source component of medical device</b> A component that produces visible light.
<b>XE5G9</b>	<b>Bulb component of medical device</b> A component designed to produce light or heat.
<b>XE9EM</b>	<b>Mirror component of medical device</b> A component consisting of a polished surface designed to reflect light.
<b>XE7A6</b>	<b>Optical fiber component of medical device</b> A component made with thin glass fibers as a conduit for transmission of light.

## Safety medical device component

Safety related component

<b>XE28G</b>	<b>Alarm component of medical device</b> A component designed to signal the occurrence of a particular event.
<b>XE5DW</b>	<b>Alarm component of medical device, audible</b> A component designed to signal the occurrence of a particular event by making a sound.
<b>XE3WT</b>	<b>Alarm component of medical device, visual</b> A component designed to signal the occurrence of a particular event in a way that can be seen.
<b>XE2N6</b>	<b>Emergency button or switch component of medical device</b> A button and circuits designed to force the shutdown of a machine or device.

<b>XE37H</b>	<b>Fail-safe system component of medical device</b> A component designed to prevent malfunction, unsafe, or unauthorized operation of a device or system.
<b>XE51V</b>	<b>Locking mechanism component of medical device</b> A fastening component designed to hold, close, or secure.
<b>XE8RN</b>	<b>Protector or shield component of medical device</b> A component designed to prevent harm or protect against damage to other components.
<b>XE0ZU</b>	<b>Safety interlock component of medical device</b> A mechanical or electronic component designed to prevent undesired actions due to the changing state of a device, typically to prevent harm to an operator or damage to the device itself.
<b>XE4HV</b>	<b>Needle stick prevention mechanism</b> A mechanism integrated into a device to prevent needle stick injuries.
<b>XE58K</b>	<b>Safety valve component of medical device</b> A valve designed to automatically open in order to maintain the pressure in a system below a specified pressure.

## Other component of medical device

Terms not yet classified. If these terms get moved to other categories, this category can be deleted.  
(Previously the device category.)

<b>XE27U</b>	<b>Part, component or sub-assembly term not applicable</b> The device does not have distinct parts, components, or sub-assemblies, or it would not be appropriate to link the reported incident to a single part, component, or sub-assembly. Use this term if the problem involves or affects the overall device rather than a specific component.
<b>XE8NG</b>	<b>Appropriate term or code not available for medical device component</b> The parts, components, or sub-assemblies are not adequately described by any other term. Note: this code must not be used unless there is no other feasible code. The preferred term should be documented when submitting an adverse event report. This information will be used to determine if a new term should be added to the code table.

## Consciousness

### Glasgow Coma Scale Eye opening score

<b>XC3W</b>	<b>One or both eyes are open spontaneously</b>
-------------	--

- XC5L**      One or both eyes open to verbal stimulation
- XC3H**      One or both eyes open to painful or noxious stimulation
- XC87**      No eye opening even with painful or noxious stimulation

Glasgow Coma Scale Motor score

- XC4L**      Obeys commands
- XC6J**      Localizes response to painful or noxious stimulation
- XC8Q**      Withdrawal response to painful or noxious stimulation
- XC8W**      Abnormal flexion response to painful or noxious stimulation
- XC8H**      Extension response to painful or noxious stimulation
- XC34**      No motion even with painful or noxious stimulation

Glasgow Coma Scale Verbal score

- XC2X**      Oriented, normal speech
- XC4Y**      Confused, disoriented speech
- XC4A**      Language utterances
- XC7U**      Non-language utterances (incomprehensible sounds) to painful or noxious stimulation
- XC8U**      No verbal output even with painful or noxious stimulation

Pupil reaction score

- XC5Y**      Neither pupil reacts
- XC16**      One pupil reacts
- XC5K**      Both pupils react
- XC85**      Data not available

## Substances

**Coded Elsewhere:** Allergens

### Medicaments

Agents primarily affecting the gastrointestinal system

**XM1349      Antacids**

**Coded Elsewhere:** Magnesium oxide (XM7G33)

**XM7GM7      Magnesium compounds**

**Coded Elsewhere:** Magnesium peroxide (XM3CD3)

**XM39M3**      Magnesium hydroxide

**XM35X7**      Aluminium, aluminium magnesium silicate

**XM3JP8      Aluminium compounds**

**XM9N47**      Algeldrate

**XM2VU8**      Aluminium, aluminium phosphate

**XM4NY5**      Aloglutamol

**XM7DC3**      Aluminium, aluminium glycinate

**XM9PG0**      Dihydroxyaluminum sodium carbonate

**XM38T8**      Aluminum hydroxide (gel)

**XM0SA0      Calcium compounds**

**XM9003**      Calcium carbonate

**XM8EF6**      Calcium silicate

**XM0D52      Combinations and complexes of aluminium, calcium and magnesium compounds**

**XM5R16**      Magaldrate

**XM8J56**      Almagate

**XM3EB6**      Hydrotalcite

**XM9Y49**      Almasilate

Gastric acid secretion suppressants

Histamine H2-receptor antagonists

**XM9YL4      Cimetidine**

<b>XM6441</b>	<b>Famotidine</b>
<b>XM9ZP3</b>	<b>Nizatidine</b>
<b>XM6WY8</b>	<b>Ranitidine</b>
<b>XM0SH0</b>	<b>Roxatidine</b>
<b>XM08A8</b>	<b>Niperotidine</b>
<b>XM1ZT1</b>	<b>Ranitidine bismuth citrate</b>
<b>XM0Q37</b>	<b>Lafutidine</b>
<b>XM2WX5</b>	<b>Proton pump inhibitors</b>
<b>XM8X45</b>	<b>Omeprazole</b>
<b>XM86M3</b>	<b>Pantoprazole</b>
<b>XM39X4</b>	<b>Lansoprazole</b>
<b>XM3M01</b>	<b>Rabeprazole</b>
<b>XM8YE1</b>	<b>Esomeprazole</b>
<b>XM5RA0</b>	<b>Dexlansoprazole</b>
<b>XM1J18</b>	<b>Dexrabeprazole</b>
<b>XM3MK2</b>	<b>Tegoprazan</b>
<b>XM4ML1</b>	<b>Prostaglandins</b>
<b>XM28N9</b>	<b>Misoprostol</b>
<b>XM4GD1</b>	<b>Enprostil</b>
<b>XM1CF2</b>	<b>Alprostadil</b>
<b>XM3Q43</b>	<b>Dinoprost</b>
<b>XM5VF9</b>	<b>Dinoprostone</b>
<b>XM2L11</b>	<b>Gemeprost</b>
<b>XM8XM0</b>	<b>Carboprost</b>
<b>XM9BJ7</b>	<b>Sulprostone</b>

Other drugs for peptic ulcer and gastro-oesophageal reflux disease

<b>XM2H82</b>	<b>Carbenoxolone</b>
<b>XM0044</b>	<b>Sucralfate</b>
<b>XM6690</b>	<b>Pirenzepine</b>

<b>XM6WX3</b>	<b>Proglumide</b>
<b>XM0HB8</b>	<b>Gefarnate</b>
<b>XM2689</b>	<b>Sulglicotide</b>
<b>XM4H50</b>	<b>Alginic acid</b>
<b>XM2891</b>	<b>Rebamipide</b>
<b>XM1F15</b>	<b>Methiosulfonium chloride</b>
<b>XM1BG6</b>	<b>Bismuth subcitrate</b>
<b>XM1LT9</b>	<b>Acetoxolone</b>
<b>XM9SW3</b>	<b>Zolimidine</b>
<b>XM1Y11</b>	<b>Troxipide</b>
<b>XM84X1</b>	<b>Bismuthyl subnitrate</b>
<b>XM1364</b>	<b>Fixed Combinations for Helicobacter pylori eradication</b>

Drugs for functional gastrointestinal disorders

<b>XM4S40</b>	<b>Serotonin receptor antagonists</b>
	<b>Coded Elsewhere:</b> Dronabinol (XM1W83)
	Nabilone (XM3UF9)
<b>XM7423</b>	<b>Ondansetron</b>
<b>XM8123</b>	<b>Granisetron</b>
<b>XM3X37</b>	<b>Cilansetron</b>
<b>XM2493</b>	<b>Diisopromine</b>
<b>XM30Q8</b>	<b>Chlorbenzoxamine</b>
<b>XM2GC8</b>	<b>Pinaverium</b>
<b>XM3CZ9</b>	<b>Fenoverine</b>
<b>XM5RS2</b>	<b>Alverine</b>
<b>XM27M9</b>	<b>Isometheptene</b>
<b>XM6UH6</b>	<b>Migalstat</b>
<b>XM49K4</b>	<b>Fenpiprane</b>
<b>XM7F16</b>	<b>Idanpramine</b>
<b>XM8N97</b>	<b>Proxazole</b>

<b>XM2SK3</b>	<b>Trepibutone</b>
<b>XM3R36</b>	<b>Caroverine</b>
<b>XM66E5</b>	<b>Phloroglucinol</b>
<b>XM7ZC5</b>	<b>Trimethyldiphenylpropylamine</b>
<b>XM9K48</b>	<b>Valethamate bromide</b>

Antidiarrhoeal drugs

<b>XM6Q06</b>	<b>Aluminium, aluminium tannate</b>
<b>XM62S7</b>	<b>Amylopectin</b>
<b>XM8A95</b>	<b>Antidiarrhoeal drug absorbent</b>
<b>XM6V74</b>	<b>Attapulgite</b>
<b>XM4SG9</b>	<b>Bacillus subtilis</b>
<b>XM98L3</b>	<b>Bismuth salts subcarbonate</b>
<b>XM5U61</b>	<b>Bismuth salts</b>
<b>XM3962</b>	<b>Carbo medicinalis</b>
<b>XM0S42</b>	<b>Charcoal</b>
<b>XM46T5</b>	<b>Charcoal activated</b>
<b>XM2269</b>	<b>Charcoal medicinal (activated)</b>
<b>XM8D61</b>	<b>Charcoal medicinal antidiarrhoeal</b>
<b>XM8ET0</b>	<b>Difenoxin</b>
<b>XM15K3</b>	<b>Fetoxilate</b>
<b>XM3ZU0</b>	<b>Intestinal motility control drug</b>
<b>XM7CN8</b>	<b>Kaolin</b>
<b>XM2GB1</b>	<b>Kaolin light</b>
<b>XM1N12</b>	<b>Lactobacillus acidophilus compound</b>
<b>XM0EB5</b>	<b>Lactobacillus acidophilus</b>
<b>XM0QG1</b>	<b>Lactobacillus bifidus, lyophilized</b>
<b>XM1TF2</b>	<b>Lactobacillus bulgaricus</b>
<b>XM4KH7</b>	<b>Lactobacillus sporogenes</b>

<b>XM48X2</b>	<b>Lignin hemicellulose</b>
<b>XM8683</b>	<b>Lomotil</b>
<b>XM2UP7</b>	<b>Miyari bacteria</b>
<b>XM2HR7</b>	<b>Pectin</b>
<b>XM4X08</b>	<b>Saccharomyces boulardii</b>

Digestants

<b>XM2663</b>	<b>Anise oil</b>
<b>XM8A26</b>	<b>Antiflatulent</b>
<b>XM0090</b>	<b>Betaine</b>
<b>XM0TD5</b>	<b>Bile salts</b>
<b>XM5TC9</b>	<b>Carminative</b>
<b>XM5QD3</b>	<b>Cholagogues</b>
<b>XM6RN6</b>	<b>Choleretic</b>
<b>XM5CH0</b>	<b>Cytochrome C</b>
<b>XM00U8</b>	<b>Dehydrocholic acid</b>
<b>XM0365</b>	<b>Dill</b>
<b>XM4RK4</b>	<b>Elastase</b>
<b>XM5H83</b>	<b>Enzyme intestinal</b>
<b>XM2Q01</b>	<b>Florantyrone</b>
<b>XM5BH7</b>	<b>Gastric enzymes</b>
<b>XM63F8</b>	<b>Gentian</b>
<b>XM1TN8</b>	<b>Ginger</b>
<b>XM0994</b>	<b>Glutamic acid</b>
<b>XM15D5</b>	<b>Hydrochloric acid medicinal (digestant)</b>
<b>XM2702</b>	<b>Ox bile extract</b>
<b>XM6HM1</b>	<b>Pancreatin</b>
<b>XM9Z07</b>	<b>Pancrelipase</b>
<b>XM6DW4</b>	<b>Papain</b>

<b>XM72V4</b>	<b>Papain digestant</b>
<b>XM1XP0</b>	<b>Peppermint (oil)</b>
<b>XM17U7</b>	<b>Pepsin digestant</b>
<b>XM7L34</b>	<b>Phenylpropanol</b>
<b>XM4U70</b>	<b>Tilactase</b>

Antinauseants, antiemetics and emetics

**Coded Elsewhere:** Serotonin receptor antagonists (XM4S40)

<b>XM4H25</b>	<b>Cerium oxalate</b>
<b>XM3ME7</b>	<b>Copper emetic</b>
<b>XM9FG8</b>	<b>Copper sulfate medicinal emetic</b>
<b>XM2WE8</b>	<b>Mustard black</b>
<b>XM5SW7</b>	<b>Chlorobutanol</b>
<b>XM8SN3</b>	<b>Trimethobenzamide</b>
<b>XM46N1</b>	<b>Metopimazine</b>
<b>XM1DC1</b>	<b>Aprepitant</b>
<b>XM2633</b>	<b>Casopitant</b>
<b>XM41Y6</b>	<b>Rolapitant</b>
<b>XM2170</b>	<b>Pipamazine</b>
<b>XM9FU8</b>	<b>Pyrathiazine</b>

Other agents primarily affecting gastrointestinal system

<b>XM3KJ5</b>	<b>Ammonium sulfonate resin</b>
<b>XM4KK2</b>	<b>Bacillus lactobacillus</b>
<b>XM4663</b>	<b>Carrageenan</b>
<b>XM8NM7</b>	<b>Charcoal medicinal poison control</b>
<b>XM4GA5</b>	<b>Charcoal medicinal specified use other than for diarrhoea</b>
<b>XM7ER1</b>	<b>Dimethyl polysiloxane</b>
<b>XM30A7</b>	<b>Gastrointestinal drug biological</b>
<b>XM0KJ8</b>	<b>Gastrointestinal drug specified</b>

<b>XM7L13</b>	<b>Glucurolactone</b>
<b>XM9Q94</b>	<b>Hepatic secretion stimulant</b>
<b>XM7EV4</b>	<b>Intestinal motility control drug biological</b>
<b>XM9S11</b>	<b>Ion exchange resin anion</b>
<b>XM1AX0</b>	<b>Ion exchange resin intestinal</b>
<b>XM0UP4</b>	<b>Liquorice extract</b>
<b>XM8UW6</b>	<b>Mesalazine</b>
<b>XM0TN5</b>	<b>Olsalazine</b>
<b>XM73P5</b>	<b>Pancreatic digestive secretion stimulant</b>
<b>XM0EK0</b>	<b>Polysilane</b>
<b>XM2K96</b>	<b>Sodium alginate</b>
<b>XM7M46</b>	<b>Sodium amylosulfate</b>
<b>XM7AL9</b>	<b>Sulfated amylopectin</b>

Other antacids and anti-gastric-secretion drugs

**Coded Elsewhere:** Sodium bicarbonate (XM4XZ4)

<b>XM6347</b>	<b>Alexitol sodium</b>
<b>XM8YP0</b>	<b>Aluminium, aluminium carbonate (gel, basic)</b>
<b>XM3Q55</b>	<b>Aluminium, aluminium chlorhydroxide-complex</b>
<b>XM9DS4</b>	<b>Aluminium, aluminium hydroxide-magnesium carb. gel</b>
<b>XM8FL6</b>	<b>Aluminium, aluminium silicate</b>
<b>XM0BM4</b>	<b>Aluminium, aluminium sodium silicate</b>
<b>XM37S3</b>	<b>Antacid</b>
<b>XM5XT4</b>	<b>Anti-gastric-secretion drug</b>
<b>XM9KD3</b>	<b>Benexate</b>
<b>XM1F19</b>	<b>Bismuth salts aluminate</b>
<b>XM5R07</b>	<b>Burimamide</b>
<b>XM7Y04</b>	<b>Cetraxate</b>
<b>XM1WQ5</b>	<b>Chalk, precipitated</b>
<b>XM1622</b>	<b>Dihydroxyaluminum aminoacetate</b>

<b>XM9BS9</b>	<b>Dimethicone</b>
<b>XM6YR9</b>	<b>Magnesia magma</b>
<b>XM7V20</b>	<b>Magnesium carbonate</b>
<b>XM8L43</b>	<b>Magnesium trisilicate</b>
<b>XM1EN3</b>	<b>Methylpolysiloxane</b>
<b>XM9414</b>	<b>Metiamide</b>
<b>XM7SH2</b>	<b>Milk of magnesia</b>
<b>XM01K0</b>	<b>Ornoprostil</b>
<b>XM7K87</b>	<b>Pepstatin</b>
<b>XM7W08</b>	<b>Potassium glucaldrate</b>
<b>XM7Z18</b>	<b>Rolaids</b>
<b>XM87Z0</b>	<b>Rosaproston</b>
<b>XM64X9</b>	<b>Simaldrate</b>
<b>XM38C5</b>	<b>Simethicone</b>
<b>XM0QL9</b>	<b>Soda bicarb</b>
<b>XM43U8</b>	<b>Sodium glucaldrate</b>
<b>XM7M59</b>	<b>Sodium polyhydroxyaluminium monocarbonate</b>
<b>XM38H3</b>	<b>Triple carbonate</b>
<b>XM5QM5</b>	<b>Vitamin ulceroprotectant</b>

#### Other laxatives

<b>XM8K92</b>	<b>Agar</b>
<b>XM5FL6</b>	<b>Arachis oil cathartic</b>
<b>XM5993</b>	<b>Atonia drug, intestinal</b>
<b>XM9281</b>	<b>Bran (wheat)</b>
<b>XM21B3</b>	<b>Bulk filler cathartic</b>
<b>XM0ML8</b>	<b>Calcium dioctyl sulfosuccinate</b>
<b>XM0HS3</b>	<b>Carboxymethyl-cellulose</b>
<b>XM3EV1</b>	<b>Carmellose</b>

<b>XM99E9</b>	<b>Cathartic bulk</b>
<b>XM4DA2</b>	<b>Cathartic emollient</b>
<b>XM2Y48</b>	<b>Cathartic mucilage</b>
<b>XM3000</b>	<b>Cellulose cathartic</b>
<b>XM22V5</b>	<b>Cellulose hydroxyethyl</b>
<b>XM6ZN5</b>	<b>Dioctyl sulfosuccinate (calcium) (sodium)</b>
<b>XM2UB3</b>	<b>Ethylhydroxycellulose</b>
<b>XM6CL0</b>	<b>Fecal softener</b>
<b>XM1RJ7</b>	<b>Fiber, dietary</b>
<b>XM4A22</b>	<b>Ispagula husk</b>
<b>XM1J98</b>	<b>Karaya (gum)</b>
<b>XM5CR2</b>	<b>Konsyl</b>
<b>XM2J55</b>	<b>Metamucil</b>
<b>XM0X73</b>	<b>Methylcellulose laxative</b>
<b>XM5VW0</b>	<b>Mucilage, plant</b>
<b>XM1VV2</b>	<b>Olive oil (medicinal)</b>
<b>XM3CM0</b>	<b>Peach kernel oil (emulsion)</b>
<b>XM85Z3</b>	<b>Peanut oil (emulsion)</b>
<b>XM4PD5</b>	<b>Phosphate laxative</b>
<b>XM95P7</b>	<b>Poloxamer</b>
<b>XM9PF1</b>	<b>Polycarbophil</b>
<b>XM4YU2</b>	<b>Psyllium hydrophilic mucilloid</b>
<b>XM0ZU4</b>	<b>Soap enema</b>
<b>XM6J59</b>	<b>Sodium dioctyl sulfosuccinate</b>
<b>XM3DH4</b>	<b>Tartrate, laxative</b>

Saline and osmotic laxatives

<b>XM69K0</b>	<b>Cathartic saline</b>
<b>XM40M7</b>	<b>Epsom salt</b>

<b>XM4WX6</b>	<b>Laxative osmotic</b>
<b>XM5NK8</b>	<b>Laxative saline</b>
<b>XM06D3</b>	<b>Potassium bisulfate</b>

Drugs for constipation

### Laxatives

<b>XM9P20</b>	<b>Aloes</b>
<b>XM6UQ2</b>	<b>Aloin</b>
<b>XM9N98</b>	<b>Bryonia</b>
<b>XM9YN3</b>	<b>Carter's Little Pills</b>
<b>XM2632</b>	<b>Cathartic anthacene derivative</b>
<b>XM3W96</b>	<b>Cathartic contact</b>
<b>XM53Q7</b>	<b>Cathartic irritant</b>
<b>XM6LH5</b>	<b>Cathartic vegetable</b>
<b>XM0JN3</b>	<b>Colocynth</b>
<b>XM4217</b>	<b>Croton (oil)</b>
<b>XM4C29</b>	<b>Dianthone</b>
<b>XM8PF5</b>	<b>Dihydroxyanthraquinone</b>
<b>XM77A6</b>	<b>Dulcolax</b>
<b>XM9KZ8</b>	<b>Elaterium</b>
<b>XM6CR4</b>	<b>Ex-Lax (phenolphthalein)</b>
<b>XM7XD6</b>	<b>Frangula</b>
<b>XM6L10</b>	<b>Frangula extract</b>
<b>XM1L58</b>	<b>Gamboge</b>
<b>XM1RP5</b>	<b>Hinkle's pills</b>
<b>XM6XG3</b>	<b>Jalap</b>
<b>XM9DZ3</b>	<b>Mineral oil emulsion</b>
<b>XM4CS7</b>	<b>Phenisatin</b>
<b>XM5042</b>	<b>Potassium sulfate</b>

<b>XM14Q1</b>	<b>Rhubarb dry extract</b>
<b>XM40D1</b>	<b>Rhubarb tincture, compound</b>
<b>XM38T6</b>	<b>Scammony</b>
<b>XM91P4</b>	<b>Sennoside A+B</b>
<b>XM9ML9</b>	<b>Sodium phosphate dibasic</b>
<b>XM38A9</b>	<b>Sodium phosphate monobasic</b>
<b>XM7XV5</b>	<b>Squirting cucumber (cathartic)</b>
<b>XM8WQ0</b>	<b>Sulisatin</b>
<b>XM69R3</b>	<b>Yellow phenolphthalein</b>
<b>XM1NY1</b>	<b>Softeners or emollients</b>
<b>XM8UE2</b>	<b>Liquid paraffin</b>
<b>XM59Z2</b>	<b>Docusate sodium</b>
<b>XM5CM0</b>	<b>Contact laxatives</b>
<b>XM5E72</b>	<b>Oxyphenisatine</b>
<b>XM14G1</b>	<b>Bisacodyl</b>
<b>XM86Q2</b>	<b>Dantron</b>
<b>XM30Q0</b>	<b>Phenolphthalein</b>
<b>XM7G77</b>	<b>Castor oil</b>
<b>XM9LC4</b>	<b>Senna glycosides</b>
<b>XM8YN7</b>	<b>Sodium picosulfate</b>
<b>XM00W5</b>	<b>Bisoxatin</b>
<b>XM8N88</b>	<b>Cascara</b>
<b>XM42M0</b>	<b>Bulk-forming laxatives</b>
<b>XM9JR8</b>	<b>Sterculia</b>
<b>XM3VP9</b>	<b>Linseed</b>
<b>XM5DN2</b>	<b>Methylcellulose</b>
<b>XM3JB5</b>	<b>Ispaghula</b>
<b>XM0LV6</b>	<b>Ethulose</b>
<b>XM4SJ2</b>	<b>Triticum (wheat fibre)</b>
<b>XM5BR4</b>	<b>Polycarbophil calcium</b>

<b>XM2806</b>	<b>Osmotically acting laxatives</b>
	<i>Coded Elsewhere:</i> Mannitol (XM5BJ8)
<b>XM7G33</b>	<b>Magnesium oxide</b>
<b>XM6EC7</b>	<b>Magnesium sulfate</b>
<b>XM3CD3</b>	<b>Magnesium peroxide</b>
<b>XM7W31</b>	<b>Lactulose</b>
<b>XM6AX9</b>	<b>Sodium sulfate</b>
<b>XM6FQ8</b>	<b>Macrogol</b>
<b>XM9YJ1</b>	<b>Sorbitol</b>
<b>XM4RE1</b>	<b>Lactitol</b>
<b>XM7RN6</b>	<b>Pentaerithryl</b>
<b>XM5348</b>	<b>Glycerol</b>
<b>XM7DT2</b>	<b>Carbon dioxide producing drugs</b>
<b>XM4U05</b>	<b>Lubiprostone</b>
<b>XM3086</b>	<b>Linaclootide</b>
<b>XM2396</b>	<b>Prucalopride</b>
<b>XM2SC1</b>	<b>Tegaserod</b>
<b>XM78V7</b>	<b>Plecanatide</b>
<b>XM6DL1</b>	<b>Oil</b>

Propulsives

<b>XM3XX3</b>	<b>Metoclopramide</b>
<b>XM3346</b>	<b>Cisapride</b>
<b>XM3GF5</b>	<b>Domperidone</b>
<b>XM2Q19</b>	<b>Bromopride</b>
<b>XM6AH6</b>	<b>Alizapride</b>
<b>XM4GL7</b>	<b>Clebopride</b>
<b>XM2KJ6</b>	<b>Itopride</b>
<b>XM1W04</b>	<b>Cinitapride</b>
<b>XM6ZM7</b>	<b>Mosapride</b>

Antipropulsives

**XM8136      Eluxadoline**

Agents primarily affecting blood constituents and immune system

**Coded Elsewhere:** Estrogens and progestogens (XM9N33-XM0SU9)

Gonadotropin releasing hormones and analogues (XM32E8-XM3S25)

Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified  
(XM6W81-XM5XB7)

Antineoplastic agents

**XM09D9      Alkylating agents**

**XM06G0      Nitrogen mustard analogues**

**XM7SY9      Cyclophosphamide**

**XM5TX7      Chlorambucil**

**XM2VC7      Melphalan**

**XM9W18      Chlormethine**

**XM7FY4      Ifosfamide**

**XM4EP0      Trofosfamide**

**XM4NR8      Prednimustine**

**XM45K9      Bendamustine**

**XM0DA1      Melphalan flufenamide**

**XM3WS2      Alkyl sulfonates**

**XM7WX6      Busulfan**

**XM9CR4      Treosulfan**

**XM4TU0      Mannosulfan**

**XM66A3      Ethylene imines**

**XM8QS9      Thiotepa**

**XM2RU1      Triaziquone**

**XM8A50      Carboquone**

**XM9708      Nitrosoureas**

**XM82H4      Carmustine**

**XM2G49      Lomustine**

<b>XM0VS7</b>	Semustine
<b>XM5GB0</b>	Streptozocin
<b>XM1KF0</b>	Nimustine
<b>XM9KU3</b>	Uramustine
<b>XM5RH5</b>	Fotemustine
<b>XM64P5</b>	Ranimustine
<b>XM4KL3</b>	<b>Etoeglucid</b>
<b>XM31W0</b>	<b>Mitobronitol</b>
<b>XM0MB5</b>	<b>Pipobroman</b>
<b>XM3VF4</b>	<b>Temozolomide</b>
<b>XM32Y8</b>	<b>Dacarbazine</b>
<b>XM7Y28</b>	<b>Bis(chloromethyl) ether</b>

#### Antineoplastic antimetabolites

<b>XM4DQ8</b>	<b>Folic acid analogues</b>
<b>XM7KT0</b>	<b>Methotrexate</b>
<b>XM1SK9</b>	<b>Mercaptopurine</b>
<b>XM3FP5</b>	<b>Tioguanine</b>
<b>XM5NF9</b>	<b>Raltitrexed</b>
<b>XM16W8</b>	<b>Pemetrexed</b>
<b>XM06R0</b>	<b>Pralatrexate</b>
<b>XM71S1</b>	<b>Purine analogues</b>
<b>XM3ZN1</b>	<b>Cytarabine</b>
<b>XM55V5</b>	<b>Fluorouracil</b>
<b>XM10L4</b>	<b>Tegafur</b>
<b>XM6CQ5</b>	<b>Carmofur</b>
<b>XM92X1</b>	<b>Azacitidine</b>
<b>XM1055</b>	<b>Cladribine</b>
<b>XM9RH9</b>	<b>Fludarabine</b>
<b>XM2YA3</b>	<b>Clofarabine</b>

<b>XM6079</b>	<b>Nelarabine</b>
<b>XM9584</b>	<b>Pyrimidine analogues</b>
	<i>Coded Elsewhere:</i> Floxuridine (XM8NR1)
<b>XM0YN9</b>	<b>Trifluridine, combinations</b>
<b>XM8GX9</b>	<b>Gemcitabine</b>
<b>XM40Y4</b>	<b>Capecitabine</b>
<b>XM1458</b>	<b>Decitabine</b>
<b>XM7GE5</b>	<b>Aminopterin sodium</b>
<b>XM3264</b>	<b>Antibiotic anticancer</b>
<b>XM8T13</b>	<b>Antimetabolite</b>
<b>XM9D05</b>	<b>Antineoplastic antibiotics</b>
<b>XM4TR6</b>	<b>Azaribine</b>
<b>XM3HR8</b>	<b>Broxuridine</b>
<b>XM3A97</b>	<b>Chloropurine</b>
<b>XM1BL2</b>	<b>Doxifluridine</b>
<b>XM5ZK1</b>	<b>Enocitabine</b>
<b>XM2SL0</b>	<b>Folic acid antagonist</b>
<b>XM0KZ3</b>	<b>Mopidamol</b>
<b>XM2FK2</b>	<b>Pyrimidine antagonist</b>

#### Antineoplastic natural products and derivatives

<b>XM6137</b>	<b>Vinca alkaloids and analogues</b>
<b>XM0BG8</b>	<b>Vinblastine</b>
<b>XM82R6</b>	<b>Vincristine</b>
<b>XM59U2</b>	<b>Vindesine</b>
<b>XM1Y07</b>	<b>Vinorelbine</b>
<b>XM9QY3</b>	<b>Vinflunine</b>
<b>XM9DS3</b>	<b>Vintafolide</b>
<b>XM3SH7</b>	<b>Podophyllotoxin derivatives</b>
<b>XM9VL7</b>	<b>Etoposide</b>

<b>XM4565</b>	<b>Teniposide</b>
<b>XM05L1</b>	<b>Taxanes</b>
<b>XM5TC8</b>	<b>Paclitaxel</b>
<b>XM5U86</b>	<b>Docetaxel</b>
<b>XM9NR6</b>	<b>Paclitaxel poliglumex</b>
<b>XM50E3</b>	<b>Cabazitaxel</b>
<b>XM6F82</b>	<b>Actinomycin C</b>
<b>XM7K70</b>	<b>Demecolcine</b>
<b>XM3F90</b>	<b>Trabectedin</b>
<b>XM4DQ7</b>	<b>Cytotoxic antibiotics and related substances</b>
<b>XM5GC9</b>	<b>Anthracyclines and related substances</b>
<b>XM7JU8</b>	Doxorubicin
<b>XM0031</b>	Daunorubicin
<b>XM6LT8</b>	Epirubicin
<b>XM1VB7</b>	Aclarubicin
<b>XM9R95</b>	Zorubicin
<b>XM3PF9</b>	Idarubicin
<b>XM26H0</b>	Mitoxantrone
<b>XM4AY9</b>	Pirarubicin
<b>XM9CA4</b>	Valrubicin
<b>XM3J03</b>	Amrubicin
<b>XM8ZP9</b>	Pixantrone
<b>XM0VU1</b>	<b>Bleomycin</b>
<b>XM3JL4</b>	<b>Plicamycin</b>
<b>XM21Z8</b>	<b>Mitomycin</b>
<b>XM65P2</b>	<b>Ixabepilone</b>
<b>XM4RQ4</b>	<b>Fibroblast growth factor receptor tyrosine kinase inhibitors</b>

#### Monoclonal antibodies

<b>XM52L2</b>	<b>Edrecolomab</b>
---------------	--------------------

<b>XM3AY3</b>	<b>Rituximab</b>
<b>XM2FU8</b>	<b>Trastuzumab</b>
<b>XM1WL2</b>	<b>Gemtuzumab ozogamicin</b>
<b>XM3VL3</b>	<b>Cetuximab</b>
<b>XM5ST9</b>	<b>Bevacizumab</b>
<b>XM1GA2</b>	<b>Panitumumab</b>
<b>XM9P40</b>	<b>Catumaxomab</b>
<b>XM2KB4</b>	<b>Ofatumumab</b>
<b>XM5JH7</b>	<b>Ipilimumab</b>
<b>XM5VT7</b>	<b>Brentuximab vedotin</b>
<b>XM6618</b>	<b>Pertuzumab</b>
<b>XM6H29</b>	<b>Trastuzumab emtansine</b>
<b>XM6ES5</b>	<b>Obinutuzumab</b>
<b>XM74W8</b>	<b>Dinutuximab</b>
<b>XM6M26</b>	<b>Nivolumab</b>
<b>XM8UG5</b>	<b>Pembrolizumab</b>
<b>XM9BU9</b>	<b>Blinatumomab</b>
<b>XM6Y05</b>	<b>Ramucirumab</b>
<b>XM5WX4</b>	<b>Necitumumab</b>
<b>XM10Z6</b>	<b>Elotuzumab</b>
<b>XM4ES5</b>	<b>Daratumumab</b>
<b>XM3JP4</b>	<b>Mogamulizumab</b>
<b>XM8648</b>	<b>Inotuzumab ozogamicin</b>
<b>XM3DU2</b>	<b>Olaratumab</b>
<b>XM7NY5</b>	<b>Durvalumab</b>
<b>XM6PT2</b>	<b>Ermekumab</b>
<b>XM2065</b>	<b>Avelumab</b>
<b>XM8SU2</b>	<b>Atezolizumab</b>
<b>XM9Z80</b>	<b>Cemiplimab</b>

<b>XM5WX2</b>	<b>Alemtuzumab</b>
<b>XM8LF5</b>	<b>Erenumab</b>
<b>XM4XM4</b>	<b>Galcanezumab</b>
<b>XM47L7</b>	<b>Fremanezumab</b>
<b>XM46X2</b>	<b>Ubrogepant</b>
<b>XM1D23</b>	<b>Eptinezumab</b>
<b>XM8C95</b>	<b>Rimegepant</b>
<b>XM4W34</b>	<b>Atogepant</b>
<b>XM3T47</b>	<b>Sensitizers used in photodynamic or radiation therapy</b>
<b>XM8EW4</b>	<b>Porfimer sodium</b>
<b>XM5GF8</b>	<b>Methyl aminolevulinate</b>
<b>XM40J3</b>	<b>Aminolevulinic acid</b>
<b>XM04X3</b>	<b>Temoporfin</b>
<b>XM2BE2</b>	<b>Efaproxiral</b>
<b>XM1ER6</b>	<b>Padeliporfin</b>

### Other antineoplastic drugs

**Coded Elsewhere:** Celecoxib (XM63D2)

<b>XM40B7</b>	<b>Platinum compounds</b>
<b>XM05M0</b>	<b>Cisplatin</b>
<b>XM6Z30</b>	<b>Carboplatin</b>
<b>XM2LX1</b>	<b>Oxaliplatin</b>
<b>XM86Z5</b>	<b>Satraplatin</b>
<b>XM0FB2</b>	<b>Polyplatinnen</b>
<b>XM1MP7</b>	<b>Procarbazine</b>
<b>XM8307</b>	<b>Amsacrine</b>
<b>XM4LJ7</b>	<b>Asparaginase</b>
<b>XM9YD3</b>	<b>Altretamine</b>
<b>XM7SD2</b>	<b>Hydroxycarbamide</b>
<b>XM3R45</b>	<b>Lonidamine</b>

<b>XM9JX7</b>	<b>Estramustine</b>
<b>XM9DB5</b>	<b>Tretinoin</b>
<b>XM9T72</b>	<b>Pentostatin</b>
<b>XM2Q11</b>	<b>Mitoguazone</b>
<b>XM7PT2</b>	<b>Venetoclax</b>
<b>XM1NF7</b>	<b>Vosaroxin</b>
<b>XM1DL2</b>	<b>Niraparib</b>
<b>XM2G84</b>	<b>Rucaparib</b>
<b>XM0569</b>	<b>Etirinotecan pegol</b>
<b>XM8UF4</b>	<b>Plitidepsin</b>
<b>XM8QL8</b>	<b>Epacadostat</b>
<b>XM8NP2</b>	<b>Enasidenib</b>
<b>XM5QR0</b>	<b>Talazoparib</b>
<b>XM44N1</b>	<b>Copanlisib</b>
<b>XM10P3</b>	<b>Mitotane</b>
<b>XM56L5</b>	<b>Ivosidenib</b>
<b>XM6038</b>	<b>Glasdegib</b>
<b>XM7FX3</b>	<b>Entinostat</b>
<b>XM3BC1</b>	<b>Alpelisib</b>
<b>XM1840</b>	<b>Selinexor</b>
<b>XM4MB0</b>	<b>Tagraxofusp</b>
<b>XM7RN1</b>	<b>Belotecan</b>
<b>XM5A01</b>	<b>Holmium-166</b> Holmium-166 (166Ho) is an isotope for the internal radiation therapy of hepatic malignancies.
<b>XM2HS5</b>	<b>Arsenic trioxide</b>
<b>XM3ST0</b>	<b>Alkylating drug antimyeloproliferative</b>
<b>XM9DP5</b>	<b>Alkylating drug lymphatic</b>
<b>XM6AB6</b>	<b>Alkylating drug</b>
<b>XM0JA8</b>	<b>Hexalen</b>

<b>XM07W3</b>	<b>Antramycin</b>
<b>XM9F82</b>	<b>Anticancer agents</b>
<b>XM3MH4</b>	<b>Antimitotic agent</b>
<b>XM6Q44</b>	<b>Antineoplastic without further specification</b>
<b>XM0V25</b>	<b>Antineoplastic alkaloidal</b>
<b>XM4DV2</b>	<b>Antineoplastic combination</b>
<b>XM1Q78</b>	<b>Azaserine</b>
<b>XM0TE5</b>	<b>Azatepa</b>
<b>XM7WD3</b>	<b>Benzcarbimine</b>
<b>XM3WB5</b>	<b>Cactinomycin</b>
<b>XM7RS5</b>	<b>Cancer chemotherapy drug regimen</b>
<b>XM6Z55</b>	<b>Chlorhexamide</b>
<b>XM3ZJ5</b>	<b>Chromic phosphate 32P</b>
<b>XM5VY1</b>	<b>Chromomycin A3</b>
<b>XM6ZM0</b>	<b>Corynebacterium parvum</b>
<b>XM8C02</b>	<b>Cycloleucin</b>
<b>XM7L47</b>	<b>Dactinomycin</b>
<b>XM0HK3</b>	<b>Elliptinium acetate</b>
<b>XM32L4</b>	<b>FAC (fluorouracil + doxorubicin + cyclophosphamide)</b>
<b>XM8NR1</b>	<b>Floxuridine</b>
<b>XM9FT7</b>	<b>Hormone cancer therapy</b>
<b>XM5UH8</b>	<b>Imidazole-4-carboxamide</b>
<b>XM2D46</b>	<b>Inproquone</b>
<b>XM5DL7</b>	<b>Iproplatin</b>
<b>XM8C52</b>	<b>M-vac</b>
<b>XM8XQ7</b>	<b>Mannomustine</b>
<b>XM33V8</b>	<b>Matulane</b>
<b>XM1NW0</b>	<b>Metoprime</b>
<b>XM6VK8</b>	<b>Mitolactol</b>

<b>XM3A89</b>	<b>Mitopodozide</b>
<b>XM3L39</b>	<b>MOPP (mechloreth-amine + vincristine + prednisone + procarbazine)</b>
<b>XM4582</b>	<b>Mustard (emetic)</b>
<b>XM6MP1</b>	<b>Myelobromal</b>
<b>XM5C25</b>	<b>Myleran</b>
<b>XM5MX5</b>	<b>Olivomycin</b>
<b>XM9TL3</b>	<b>Oncovin</b>
<b>XM7TK6</b>	<b>Paroxypropione</b>
<b>XM7040</b>	<b>Peplomycin</b>
<b>XM7NL0</b>	<b>Phenyl hydrazine antineoplastic</b>
<b>XM03S1</b>	<b>Phenylalanine mustard</b>
<b>XM7S82</b>	<b>Porfiromycin</b>
<b>XM6QJ7</b>	<b>Pteroyltriglutamate</b>
<b>XM2CG3</b>	<b>Razoxane</b>
<b>XM9TR7</b>	<b>Rufocromomycin</b>
<b>XM4ZA6</b>	<b>Sarcolysin</b>
<b>XM1TG4</b>	<b>Sarkomycin</b>
<b>XM5FB8</b>	<b>Tauromustine</b>
<b>XM0L32</b>	<b>TEPA</b>
<b>XM3SV7</b>	<b>Trichlormethine</b>
<b>XM5FH3</b>	<b>Trichlorotriethylamine</b>
<b>XM7TR9</b>	<b>Triethanomelamine</b>
<b>XM9T22</b>	<b>Triethylenemelamine</b>
<b>XM6NM1</b>	<b>Triethylenephosphoramide</b>
<b>XM5GV6</b>	<b>Triethylenethiophosphoramide</b>
<b>XM4J62</b>	<b>Trimustine</b>
<b>XM6A19</b>	<b>Uracil mustard</b>
<b>XM9AV3</b>	<b>Urethane</b>
<b>XM1DU5</b>	<b>Zinostatin</b>

<b>XM4KU8</b>	<b>Masoprocol</b>
<b>XM7ST9</b>	<b>Topotecan</b>
<b>XM3ZR1</b>	<b>Tiazofurine</b>
<b>XM0992</b>	<b>Irinotecan</b>
<b>XM8200</b>	<b>Alitretinoin</b>
<b>XM6AL6</b>	<b>Pegaspargase</b>
<b>XM3NJ7</b>	<b>Bexarotene</b>
<b>XM6027</b>	<b>Denileukin diftitox</b>
<b>XM5Z86</b>	<b>Bortezomib</b>
<b>XM2PZ5</b>	<b>Anagrelide</b>
<b>XM1NQ8</b>	<b>Oblimersen</b>
<b>XM3VC2</b>	<b>Sitimagene ceradenovec</b>
<b>XM7R04</b>	<b>Vorinostat</b>
<b>XM91S2</b>	<b>Romidepsin</b>
<b>XM3RX2</b>	<b>Omacetaxine mepesuccinate</b>
<b>XM3BC3</b>	<b>Eribulin</b>
<b>XM96L9</b>	<b>Panobinostat</b>
<b>XM0N96</b>	<b>Vismodegib</b>
<b>XM4XD1</b>	<b>Aflibercept</b>
<b>XM0A07</b>	<b>Carfilzomib</b>
<b>XM7202</b>	<b>Olaparib</b>
<b>XM8F40</b>	<b>Idelalisib</b>
<b>XM9E27</b>	<b>Sonidegib</b>
<b>XM0Y26</b>	<b>Belinostat</b>
<b>XM3753</b>	<b>Ixazomib</b>
<b>XM1BM0</b>	<b>Talimogene laherparepvec</b>
<b>XM1CT6</b>	<b>Protein kinase inhibitors</b>
<b>XM5W30</b>	<b>Imatinib</b>
<b>XM3A37</b>	<b>Gefitinib</b>

<b>XM3420</b>	<b>Erlotinib</b>
<b>XM1982</b>	<b>Sunitinib</b>
<b>XM4A57</b>	<b>Sorafenib</b>
<b>XM50U1</b>	<b>Dasatinib</b>
<b>XM1FM4</b>	<b>Lapatinib</b>
<b>XM6BP0</b>	<b>Nilotinib</b>
<b>XM93U4</b>	<b>Temsirolimus</b>
<b>XM69S5</b>	<b>Everolimus</b>
<b>XM4FT3</b>	<b>Pazopanib</b>
<b>XM3W52</b>	<b>Vandetanib</b>
<b>XM7917</b>	<b>Afatinib</b>
<b>XM60L5</b>	<b>Bosutinib</b>
<b>XM55B8</b>	<b>Vemurafenib</b>
<b>XM2U80</b>	<b>Crizotinib</b>
<b>XM6JL9</b>	<b>Axitinib</b>
<b>XM0853</b>	<b>Ruxolitinib</b>
<b>XM0SL6</b>	<b>Ridaforolimus</b>
<b>XM0601</b>	<b>Regorafenib</b>
<b>XM0JZ7</b>	<b>Masitinib</b>
<b>XM1HB8</b>	<b>Dabrafenib</b>
<b>XM70G2</b>	<b>Ponatinib</b>
<b>XM7VJ9</b>	<b>Trametinib</b>
<b>XM4TL0</b>	<b>Cabozantinib</b>
<b>XM0C70</b>	<b>Ibrutinib</b>
<b>XM14D3</b>	<b>Ceritinib</b>
<b>XM7ZH9</b>	<b>Lenvatinib</b>
<b>XM4EA3</b>	<b>Nintedanib</b>
<b>XM2QS0</b>	<b>Cediranib</b>
<b>XM4K70</b>	<b>Palbociclib</b>
<b>XM8B31</b>	<b>Tivozanib</b>

<b>XM8YD2</b>	<b>Osimertinib</b>
<b>XM4JL2</b>	<b>Alectinib</b>
<b>XM21J7</b>	<b>Rociletinib</b>
<b>XM6K99</b>	<b>Cobimetinib</b>
<b>XM5Y46</b>	<b>Midostaurin</b>
<b>XM0J75</b>	<b>Olmertinib</b>
<b>XM3YP5</b>	<b>Binimetinib</b>
<b>XM2RL4</b>	<b>Ribociclib</b>
<b>XM2DD8</b>	<b>Brigatinib</b>
<b>XM59V9</b>	<b>Lorlatinib</b>
<b>XM5MT6</b>	<b>Neratinib</b>
<b>XM5RQ2</b>	<b>Encorafenib</b>
<b>XM15D6</b>	<b>Dacomitinib</b>
<b>XM9L11</b>	<b>Icotinib</b>
<b>XM8E34</b>	<b>Abemaciclib</b>
<b>XM09W7</b>	<b>Acalabrutinib</b>
<b>XM1L31</b>	<b>Quizartinib</b>
<b>XM2LF4</b>	<b>Larotrectinib</b>
<b>XM4BT2</b>	<b>Gilteritinib</b>
<b>XM16Z9</b>	<b>Entrectinib</b>
<b>XM28Z0</b>	<b>Fedratinib</b>
<b>XM7168</b>	<b>Asciminib</b>
<b>XM7380</b>	<b>Pacritinib</b>
<b>XM9U75</b>	<b>Infigratinib</b>
<b>XM9XE8</b>	<b>Futibatinib</b>
<b>XM74A3</b>	<b>Selpercatinib</b>
<b>XM1UG8</b>	<b>Pralsetinib</b>
<b>XM1JG6</b>	<b>Monoclonal antibodies and antibody drug conjugates</b>
<b>XM6TQ6</b>	<b>Clusters of differentiation 20 inhibitors</b>
<b>XM0NB9</b>	<b>Clusters of differentiation 22 inhibitors</b>

<b>XM4F67</b>	<b>Clusters of differentiation 38 inhibitors</b>
<b>XM6DT1</b>	<b>Human epidermal growth factor receptor 2 inhibitors</b>
<b>XM3ZP2</b>	<b>Epidermal growth factor receptor inhibitors</b>
<b>XM9KZ5</b>	Trastuzumab duocarmazine
<b>XM9ND9</b>	<b>Programmed cell death protein 1/death ligand 1 inhibitors</b>
<b>XM3Q80</b>	Tislelizumab
<b>XM2KA7</b>	Retifanlimab
<b>XM0AN7</b>	Oportuzumab monatox
<b>XM5Q93</b>	Sacituzumab govitecan
<b>XM0550</b>	Amivantamab
<b>XM1GS6</b>	<b>Vascular endothelial growth factor inhibitors</b>
<b>XM4ZA4</b>	<b>Other monoclonal antibodies and antibody drug conjugates</b>
<b>XM0PX7</b>	Pamiparib
<b>XM4WB3</b>	Tazemetostat
<b>XM78S9</b>	Sotorasib
<b>XM7SW9</b>	Belzutifan

Immunostimulants

<b>XM9VN3</b>	<b>Colony stimulating factors</b>
<b>XM93Q2</b>	<b>Filgrastim</b>
<b>XM2M96</b>	<b>Molgramostim</b>
<b>XM38N5</b>	<b>Sargramostim</b>
<b>XM7UB4</b>	<b>Lenograstim</b>
<b>XM17W1</b>	<b>Ancestim</b>
<b>XM4TX7</b>	<b>Pegfilgrastim</b>
<b>XM1G49</b>	<b>Lipegfilgrastim</b>
<b>XM7670</b>	<b>Balugrastim</b>
<b>XM9RV6</b>	<b>Empegfilgrastim</b>
<b>XM8VY9</b>	<b>Pegteograstim</b>
<b>XM1KX1</b>	<b>Interferon alfa-2a</b>
<b>XM58E0</b>	<b>Interferons</b>

<b>XM1GZ3</b>	<b>Interferon alfa</b>
<b>XM3CU5</b>	<b>Interferon beta</b>
<b>XM3KQ4</b>	<b>Interferon gamma</b>
<b>XM6QT3</b>	<b>Interferon alfa-2b</b>
<b>XM6D22</b>	<b>Interferon beta-1a</b>
<b>XM0CS1</b>	<b>Interferon beta-1b</b>
<b>XM0C05</b>	<b>Interferon alfacon-1</b>
<b>XM5L32</b>	<b>Peginterferon alfacon-2</b>
<b>XM70P0</b>	<b>Peginterferon alfa-2b</b>
<b>XM1RW9</b>	<b>Peginterferon alfa-2a</b>
<b>XM1HG5</b>	<b>Albinterferon alfa-2b</b>
<b>XM3XV8</b>	<b>Peginterferon beta-1a</b>
<b>XM41L0</b>	<b>Cepeginterferon alfa-2b</b>
<b>XM24N9</b>	<b>Ropeginterferon alfa-2b</b>
<b>XM2Q27</b>	<b>Interleukins</b>
<b>XM4MJ0</b>	<b>Interferon alfa-n1</b>
<b>XM0RF4</b>	<b>Aldesleukin</b>
<b>XM4PY0</b>	<b>Orelvekin</b>
<b>XM3SM5</b>	<b>Netakimab</b>
<b>XM8615</b>	<b>Bimekizumab</b>
<b>XM4YW3</b>	<b>Spesolimab</b>
<b>XM7N26</b>	<b>Thymopentin</b>
<b>XM6GW5</b>	<b>Lentinan</b>
<b>XM48E5</b>	<b>Roquinimex</b>
<b>XM9D28</b>	<b>Pegademase</b>
<b>XM30D0</b>	<b>Pidotimod</b>
<b>XM1R32</b>	<b>Poly I:C</b>
<b>XM4J95</b>	<b>Poly ICLC</b>
<b>XM9D43</b>	<b>Immunocyanin</b>
<b>XM94J4</b>	<b>Tasonermin</b>

<b>XM99P5</b>	<b>Melanoma vaccine</b>
<b>XM4PM9</b>	<b>Glatiramer acetate</b>
<b>XM5KS2</b>	<b>Histamine dihydrochloride</b>
<b>XM97M6</b>	<b>Mifamurtide</b>
<b>XM19S3</b>	<b>Plerixafor</b>
<b>XM2ZJ6</b>	<b>Sipuleucel-T</b>
<b>XM4ZS8</b>	<b>Cridanimod</b>
<b>XM9BT1</b>	<b>Dasiprotimut-T</b>
<b>XM3R87</b>	<b>Elapogademase</b>

Immunosuppressive agents

**Coded Elsewhere:** Methotrexate (XM7KT0)

<b>XM5140</b>	<b>Selective immunosuppressants</b>
<b>XM9RY3</b>	<b>Muromonab-CD3</b>
<b>XM3TG8</b>	<b>Antilymphocyte immunoglobulin (horse)</b>
<b>XM2Q51</b>	<b>Antithymocyte immunoglobulin (rabbit)</b>
<b>XM57B1</b>	<b>Mycophenolic acid</b>
<b>XM76R4</b>	<b>Sirolimus</b>
<b>XM5M04</b>	<b>Leflunomide</b>
<b>XM1PY3</b>	<b>Alefacept</b>
<b>XM75G0</b>	<b>Gusperimus</b>
<b>XM8CX4</b>	<b>Efalizumab</b>
<b>XM4RN7</b>	<b>Abetimus</b>
<b>XM9YN4</b>	<b>Natalizumab</b>
<b>XM45M8</b>	<b>Abatacept</b>
<b>XM3KK5</b>	<b>Eculizumab</b>
<b>XM9M75</b>	<b>Belimumab</b>
<b>XM9K56</b>	<b>Fingolimod</b>
<b>XM4FP8</b>	<b>Belatacept</b>
<b>XM7U27</b>	<b>Tofacitinib</b>

XM1835	Teriflunomide
XM9UD1	Apremilast
XM5MC2	Vedolizumab
XM7BS8	Begelomab
XM2B74	Ocrelizumab
XM1SM6	Baricitinib
XM0700	Ozanimod
XM3F23	Emapalumab
XM09N4	Imlifidase
XM6N55	Siponimod
XM31G3	Ravulizumab
XM0V48	Upadacitinib
XM6QJ6	Belumosudil
XM3RJ6	Peficitinib
XM69Y4	Ponesimod
XM1PC0	Anifrolumab
XM8AR9	Teprotumumab
XM8913	Pegcetacoplan
XM6PD2	Sutimlimab
XM93Q8	Deucravacitinib
<b>XM9PG4</b>	<b>Tumour necrosis factor alpha inhibitors</b>
XM0FU1	Etanercept
XM3MX3	Infliximab
XM31F7	Afelimomab
XM9DS9	Adalimumab
XM9QW1	Certolizumab pegol
XM97H7	Golimumab
XM0PE5	Opinercept
<b>XM5ZL1</b>	<b>Interleukin inhibitors</b>
XM3CD8	Daclizumab

<b>XM6FT1</b>	<b>Basiliximab</b>
<b>XM3CP6</b>	<b>Anakinra</b>
<b>XM4YD0</b>	<b>Rilonacept</b>
<b>XM1BA7</b>	<b>Ustekinumab</b>
<b>XM2FV1</b>	<b>Tocilizumab</b>
<b>XM67R0</b>	<b>Canakinumab</b>
<b>XM5JM2</b>	<b>Briakinumab</b>
<b>XM0NF8</b>	<b>Secukinumab</b>
<b>XM9D29</b>	<b>Siltuximab</b>
<b>XM6601</b>	<b>Brodalumab</b>
<b>XM7AB4</b>	<b>Ixekizumab</b>
<b>XM45G5</b>	<b>Sarilumab</b>
<b>XM7N41</b>	<b>Sirukumab</b>
<b>XM2L20</b>	<b>Guselkumab</b>
<b>XM9VJ6</b>	<b>Tildrakizumab</b>
<b>XM70N9</b>	<b>Risankizumab</b>
<b>XM3CM4</b>	<b>Calcineurin inhibitors</b>
<b>XM28J8</b>	<b>Ciclosporin</b>
<b>XM1661</b>	<b>Tacrolimus</b>
<b>XM0Z09</b>	<b>Voclosporin</b>
<b>XM1079</b>	<b>Immunosuppressive drug</b>
<b>XM99R8</b>	<b>Azathioprine</b>
<b>XM6B78</b>	<b>Thalidomide</b>
<b>XM5Q10</b>	<b>Lenalidomide</b>
<b>XM7952</b>	<b>Pirfenidone</b>
<b>XM6S50</b>	<b>Pomalidomide</b>
<b>XM2EM8</b>	<b>Dimethyl fumarate</b>
<b>XM0LG0</b>	<b>Darvadstrocel</b>
<b>XM8X05</b>	<b>Mepolizumab</b>
<b>XM9UK4</b>	<b>Diroximel fumarate</b>

Anticoagulants and antithrombotics

<b>XM7S34</b>	<b>Vitamin K antagonists</b>
<b>XM8RN0</b>	<b>Dicoumarol</b>
<b>XM79U8</b>	<b>Phenindione</b>
<b>XM86W0</b>	<b>Warfarin</b>
<b>XM4E47</b>	<b>Phenprocoumon</b>
<b>XM6QR1</b>	<b>Acenocoumarol</b>
<b>XM5XY7</b>	<b>Ethyl biscoumacetate</b>
<b>XM2567</b>	<b>Diphenadione</b>
<b>XM6550</b>	<b>Tioclomarol</b>
<b>XM4GN9</b>	<b>Fluindione</b>
<b>XM3508</b>	<b>Clorindione</b>
<b>XM2YP8</b>	<b>Heparin and heparin derivatives</b>
<b>XM1MN3</b>	<b>Heparin</b>
<b>XM12N6</b>	<b>Antithrombin III</b>
<b>XM3DU0</b>	<b>Dalteparin</b>
<b>XM8ZP5</b>	<b>Enoxaparin</b>
<b>XM5727</b>	<b>Nadroparin</b>
<b>XM9V60</b>	<b>Parnaparin</b>
<b>XM9JC4</b>	<b>Reviparin</b>
<b>XM2YJ7</b>	<b>Danaparoid</b>
<b>XM3SS4</b>	<b>Tinzaparin</b>
<b>XM3E38</b>	<b>Sulodexide</b>
<b>XM7QG7</b>	<b>Bemiparin</b>

Platelet aggregation inhibitors

*Exclusions:* Heparin and heparin derivatives (XM2YP8)

<b>XM9J84</b>	<b>Dipyridamole</b>
<b>XM51R2</b>	<b>Epoprostenol</b>
<b>XM5G01</b>	<b>Indobufen</b>
<b>XM5A15</b>	<b>Ticlopidine</b>

<b>XM00R9</b>	<b>Iloprost</b>
<b>XM5PR9</b>	<b>Triflusal</b>
<b>XM5K56</b>	<b>Ditazole</b>
<b>XM8NM5</b>	<b>Cloricromen</b>
<b>XM09W2</b>	<b>Picotamide</b>
<b>XM7CM7</b>	<b>Clopidogrel</b>
<b>XM39C9</b>	<b>Abciximab</b>
<b>XM2924</b>	<b>Eptifibatide</b>
<b>XM0DS1</b>	<b>Tirofiban</b>
<b>XM8Y64</b>	<b>Beraprost</b>
<b>XM5057</b>	<b>Treprostинil</b>
<b>XM8LN2</b>	<b>Prasugrel</b>
<b>XM92L1</b>	<b>Cilostazol</b>
<b>XM1HH4</b>	<b>Ticagrelor</b>
<b>XM3126</b>	<b>Cangrelor</b>
<b>XM3835</b>	<b>Vorapaxar</b>
<b>XM5MZ5</b>	<b>Selexipag</b>
<b>XM17B1</b>	<b>Anticoagulant and antithrombotic enzymes</b>
<b>XM1AV3</b>	<b>Streptokinase</b>
<b>XM9A41</b>	<b>Alteplase</b>
<b>XM1P81</b>	<b>Anistreplase</b>
<b>XM1QH1</b>	<b>Urokinase</b>
<b>XM77L2</b>	<b>Brinase</b>
<b>XM3YU3</b>	<b>Ancrod</b>
<b>XM5PV9</b>	<b>Direct thrombin inhibitors</b>
<b>XM84G2</b>	<b>Desirudin</b>
<b>XM2HU1</b>	<b>Lepirudin</b>
<b>XM7Y21</b>	<b>Argatroban</b>
<b>XM1D58</b>	<b>Melagatran</b>

<b>XM2QF7</b>	<b>Ximelagatran</b>
<b>XM1WF7</b>	<b>Bivalirudin</b>
<b>XM16E4</b>	<b>Dabigatran etexilate</b>
<b>XM4SD9</b>	<b>Direct factor Xa inhibitors</b>
<b>XM48G2</b>	<b>Rivaroxaban</b>
<b>XM3Y33</b>	<b>Apixaban</b>
<b>XM2SN5</b>	<b>Edoxaban</b>
<b>XM1AM0</b>	<b>Other antithrombotic agents</b>
<b>XM2JQ1</b>	<b>Defibrotide</b>
<b>XM2XP4</b>	<b>Dermatan sulfate</b>
<b>XM31P2</b>	<b>Fondaparinux</b>

### Anticoagulants

<b>XM02P8</b>	<b>Anisindione</b>
<b>XM54A7</b>	<b>Bromindione</b>
<b>XM9E78</b>	<b>Coumarin</b>
<b>XM0SY0</b>	<b>Coumetarol</b>
<b>XM0PM7</b>	<b>Drotrecogin alfa</b>
<b>XM9313</b>	<b>Enoxaparin sodium</b>
<b>XM7AL6</b>	<b>Ethyldene dicoumarol</b>
<b>XM4S57</b>	<b>Heparin sodium</b>
<b>XM5YT5</b>	<b>Heparin-fraction</b>
<b>XM5LC3</b>	<b>Heparinoid (systemic)</b>
<b>XM38V8</b>	<b>Indandione (derivatives)</b>
<b>XM4Z97</b>	<b>Indendione (derivatives)</b>
<b>XM5796</b>	<b>Panwarfin</b>
<b>XM04M3</b>	<b>Prothrombin synthesis inhibitor</b>
<b>XM8J87</b>	<b>Xigris</b>
<b>XM7EQ6</b>	<b>Zovant</b>

Other fibrinolysis-affecting drugs

<b>XM4Z15</b>	<b>Amino acids</b>
	<b>Coded Elsewhere:</b> Ornithine (XM1GT0)
<b>XM0ES3</b>	<b>Arginine hydrochloride</b>
<b>XM2NR2</b>	<b>Alanyl glutamine</b>
<b>XM44Y2</b>	<b>Lysine</b>
<b>XM8KJ7</b>	<b>Tyrosine</b>
<b>XM4PP7</b>	<b>Phenylalanine</b>
<b>XM4H38</b>	<b>Leucine</b>
<b>XM2K61</b>	<b>Cysteine</b>
<b>XM6VX4</b>	<b>Alanine</b>
<b>XM4BG8</b>	<b>Aminocaproic acid</b>
<b>XM8GE2</b>	<b>Tranexamic acid</b>
<b>XM41G3</b>	<b>Aminomethylbenzoic acid</b>
<b>XM3QV9</b>	<b>Fibrinolysis inhibitor</b>
<b>XM6Y53</b>	<b>Aprotinin</b>
<b>XM0UH4</b>	<b>Antifibrinolytic drug</b>
<b>XM7XD3</b>	<b>Epsilon amino-caproic acid</b>
<b>XM8X82</b>	<b>Hemostatic drug, systemic</b>
<b>XM9PF3</b>	<b>Alfa1 antitrypsin</b>
<b>XM9QH4</b>	<b>Camostat</b>

Anticoagulant antagonists, vitamin K and other coagulants

<b>XM6DJ4</b>	<b>Vitamin K</b>
<b>XM1KN2</b>	<b>Menadione</b>
<b>XM1VC9</b>	<b>Etamsylate</b>
<b>XM0M37</b>	<b>Acetomenaphthone</b>
<b>XM5LG4</b>	<b>Anticoagulant Antagonist</b>
<b>XM0D26</b>	<b>Antihemophilic globulin concentrate</b>
<b>XM2KH0</b>	<b>Antihemophilic plasma, dried</b>

<b>XM0RA5</b>	<b>Antiheparin drug</b>
<b>XM4Z99</b>	<b>Coagulant</b>
<b>XM3RB9</b>	<b>Cotarnine</b>
<b>XM8MM4</b>	<b>Cytozyme</b>
<b>XM5WF6</b>	<b>Gelfoam</b>
<b>XM35E4</b>	<b>Heparin action reverser</b>
<b>XM9CA7</b>	<b>Hexadimethrine (bromide)</b>
<b>XM3AJ3</b>	<b>Menadiol</b>
<b>XM2JG9</b>	<b>Menadiol sodium sulfate</b>
<b>XM7MA9</b>	<b>Menadione sodium bisulfite</b>
<b>XM8912</b>	<b>Menaquinone</b>
<b>XM55W0</b>	<b>Menatetrenone</b>
<b>XM4U16</b>	<b>Protamine sulfate</b>
<b>XM0SY7</b>	<b>Prothrombin activator</b>
<b>XM8RT8</b>	<b>Russel's viper venin</b>
<b>XM6QQ2</b>	<b>Snake venom or bite hemocoagulase</b>
<b>XM0HF1</b>	<b>Thromboplastin</b>
<b>XM3W89</b>	<b>Vitamin K1</b>
<b>XM1YD0</b>	<b>Vitamin K2</b>
<b>XM5UU0</b>	<b>Carbazochrome</b>
<b>XM6RT1</b>	<b>Carbazochrome sodium sulfonate</b>
<b>XM7KW2</b>	<b>Batroxobin</b>
<b>XM96S9</b>	<b>Romiplostim</b>
<b>XM95R8</b>	<b>Eltrombopag</b>

Natural blood and blood products

<b>XM9766</b>	<b>Coagulation factor VIII</b>
<b>XM3GR1</b>	<b>Thrombin</b>
<b>XM04N3</b>	<b>Blood plasma</b>

<b>XM5WD4</b>	<b>Albumin bovine</b>
<b>XM1YW8</b>	<b>Albumin human serum salt-poor</b>
<b>XM7150</b>	<b>Albumin human serum</b>
<b>XM2NV9</b>	<b>Blood (derivatives) (natural) (plasma) (whole)</b>
<b>XM1GJ9</b>	<b>Blood dried</b>
<b>XM5GG5</b>	<b>Blood fraction</b>
<b>XM9TT2</b>	<b>EPO</b>
<b>XM6BM2</b>	<b>Epoetin alpha</b>
<b>XM79U3</b>	<b>Erythropoietin human</b>
<b>XM3TM8</b>	<b>Factor I (fibrinogen)</b>
<b>XM3ZZ2</b>	<b>Factor III (thromboplastin)</b>
<b>XM44Z6</b>	<b>Coagulation factor IX</b>
<b>XM9JK6</b>	<b>Fibrin</b>
<b>XM6HF0</b>	<b>Human albumin</b>
<b>XM0XT3</b>	<b>Natural blood (product)</b>
<b>XM3YQ9</b>	<b>Normal serum albumin, salt-poor (human)</b>
<b>XM8TU6</b>	<b>Whole blood (human)</b>
<b>XM1596</b>	<b>Blood substitutes and plasma protein fractions</b>
<b>XM84Y1</b>	<b>Other plasma protein fractions</b>
<b>XM0CQ3</b>	<b>Gelatin agents</b>
<b>XM4NU0</b>	<b>Gelatin (intravenous)</b>
<b>XM99H6</b>	<b>Polygeline</b>
<b>XM8BW6</b>	<b>Hemoglobin crosfumaril</b>
<b>XM4MK5</b>	<b>Hemoglobin raffimer</b>
<b>XM6W72</b>	<b>Hemoglobin glutamer</b>
<b>XM3CZ0</b>	<b>Dextran</b>
<b>XM1H99</b>	<b>Plasma protein fraction, human</b>
<b>XM6KC5</b>	<b>Albumin</b>
<b>XM8H48</b>	<b>Hydroxyethylstarch</b>

<b>XM6YJ2</b>	<b>Oxypolygelatin</b>
<b>XM8UH8</b>	<b>Polyvinylpyrrolidone</b>
<b>XM8K98</b>	<b>Hematin</b>
<b>XM3P96</b>	<b>Factor VIII inhibitor bypassing activity</b>
<b>XM58W5</b>	<b>Coagulation factor VII</b>
<b>XM1UV6</b>	<b>Coagulation factor XIII</b>
<b>XM0A85</b>	<b>Coagulation factor VIIa</b>
<b>XM25U1</b>	<b>Von Willebrand factor</b>
<b>XM4S88</b>	<b>Catrideracog</b>
<b>XM2RZ4</b>	<b>Coagulation factor X</b>
<b>XM6B13</b>	<b>Susoctocog alfa</b>
<b>XM7KC2</b>	<b>Thrombocytes</b>
<b>XM6GB5</b>	<b>Stem cells from umbilical cord blood</b>
<b>XM7JU3</b>	<b>Serum complement (inhibitor)</b>
<b>XM08V1</b>	<b>Serum hemolytic complement</b>
<b>XM8VX7</b>	<b>Epoetin beta</b>
<b>XM26D5</b>	<b>Red blood cells, packed</b>

Iron and its compounds

**Coded Elsewhere:** Ferric citrate (XM8NS1)

<b>XM8ZX9</b>	<b>Calcium ferrous citrate</b>
<b>XM6S51</b>	<b>Dextriferron</b>
<b>XM5DJ4</b>	<b>Ferric chloride</b>
<b>XM60G9</b>	<b>Ferric hydroxide colloidal</b>
<b>XM9W49</b>	<b>Ferric hydroxide polymaltose</b>
<b>XM2C90</b>	<b>Ferric pyrophosphate</b>
<b>XM55G4</b>	<b>Ferritin</b>
<b>XM8GJ1</b>	<b>Ferrocholate</b>
<b>XM3SU9</b>	<b>Ferrodextrane</b>
<b>XM1018</b>	<b>Ferropolimaler</b>

<b>XM7EW8</b>	<b>Ferrous fumerate, gluconate, lactate, salt, sulfate (medicinal)</b>
<b>XM2LA7</b>	<b>Ferrous phosphate</b>
<b>XM8L47</b>	<b>Ferrous salt</b>
<b>XM8Z42</b>	<b>Iron (compounds) (medicinal)</b>
<b>XM6FS8</b>	<b>Iron ammonium</b>
<b>XM7PP8</b>	<b>Iron dextran injection</b>
<b>XM54R9</b>	<b>Iron salts</b>
<b>XM3EH2</b>	<b>Iron sorbitol citric acid complex</b>
<b>XM8KK0</b>	<b>Isomaltose, ferric complex</b>
<b>XM77C5</b>	<b>Jectofer</b>
<b>XM1Y67</b>	<b>Polyferose</b>
<b>XM5SE8</b>	<b>Sodium iron edetate</b>
<b>XM85E8</b>	<b>Saccharated iron oxide</b>
<b>XM5HE0</b>	<b>Sodium feredetate</b>
<b>XM7E86</b>	<b>Ferrous glycine sulfate</b>
<b>XM04C6</b>	<b>Ferrous fumarate</b>
<b>XM3N76</b>	<b>Ferrous gluconate</b>
<b>XM2865</b>	<b>Ferrous carbonate</b>
<b>XM6UB4</b>	<b>Ferrous chloride</b>
<b>XM8SK2</b>	<b>Ferrous succinate</b>
<b>XM3SQ1</b>	<b>Ferrous sulfate</b>
<b>XM0FD3</b>	<b>Ferrous tartrate</b>
<b>XM8638</b>	<b>Ferrous aspartate</b>
<b>XM0S20</b>	<b>Ferrous ascorbate</b>
<b>XM1BG1</b>	<b>Ferrous iodine</b>
<b>XM7FV2</b>	<b>Ferric sodium citrate</b>
<b>XM4HF0</b>	<b>Ferric hydroxide</b>
<b>XM5AW9</b>	<b>Ferric oxide polymaltose complexes</b>
<b>XM6CK7</b>	<b>Chondroitin sulfate-iron complex</b>

<b>XM5L86</b>	<b>Ferric acetyl transferrin</b>
<b>XM8NX7</b>	<b>Ferric proteinsuccinylate</b>
<b>XM4J31</b>	<b>Ferric maltol</b>
<b>XM0216</b>	<b>Ferrous amino acid complex</b>
<b>XM6435</b>	<b>Sodium dipantoyl ferrate</b>

Vitamin B12, folic acid and other anti-megaloblastic-anaemia preparations

<b>XM7CP9</b>	<b>Hydroxocobalamin</b>
<b>XM7R82</b>	<b>Folic acid</b>
<b>XM2AT9</b>	<b>Mecobalamin</b>
<b>XM2RU3</b>	<b>Cobalamine</b>
<b>XM9KD4</b>	<b>Cyanocobalamin</b>
<b>XM20E6</b>	<b>Hematinic preparation</b>
<b>XM16W1</b>	<b>Leucovorin (factor)</b>
<b>XM9130</b>	<b>Erythropoietin</b>
<b>XM09N3</b>	<b>Cyanocobalamin tannin complex</b>
<b>XM2NR4</b>	<b>Cobamamide</b>
<b>XM7M42</b>	<b>Darbepoetin alfa</b>
<b>XM66M0</b>	<b>Methoxy polyethylene glycol-epoetin beta</b>
<b>XM9D96</b>	<b>Peginesatide</b>
<b>XM27M4</b>	<b>Daprodustat</b>
<b>XM59J5</b>	<b>Vadadustat</b>

Enzymes

<b>XM6Y81</b>	<b>Alidase</b>
<b>XM0KX8</b>	<b>Alpha amylase</b>
<b>XM7NZ6</b>	<b>Chymotrypsin</b>
<b>XM8P48</b>	<b>Cocarboxylase</b>
<b>XM1819</b>	<b>Deoxyribonuclease</b>
<b>XM3HF5</b>	<b>Diffusin</b>

<b>XM3TF2</b>	<b>Enzyme fibrolytic</b>
<b>XM5GS9</b>	<b>Enzyme thrombolytic</b>
<b>XM0543</b>	<b>Hyaluronidase</b>
<b>XM2P48</b>	<b>Pancreatic dornase</b>
<b>XM9J86</b>	<b>Penicillinase</b>
<b>XM52N4</b>	<b>Pronase</b>
<b>XM94J1</b>	<b>Serrapeptase</b>
<b>XM93U7</b>	<b>Streptodornase</b>
<b>XM8183</b>	<b>Sutilains</b>
<b>XM40V6</b>	<b>Trypsin</b>
<b>XM6RN7</b>	<b>Reteplase</b>
<b>XM04S7</b>	<b>Saruplase</b>
<b>XM8K47</b>	<b>Drotrecogin alfa (activated)</b>
<b>XM5ZA2</b>	<b>Tenecteplase</b>
<b>XM35D2</b>	<b>Protein C</b>
<b>XM32Y3</b>	<b>Fibrinolysin and desoxyribonuclease</b>
<b>XM4XM2</b>	<b>Fibrinolysin</b>
<b>XM9PZ9</b>	<b>Tissue plasminogen activator</b>

Drugs used in hereditary angioedema

<b>XM9AX4</b>	<b>C1-inhibitor, plasma derived</b>
<b>XM7TQ2</b>	<b>Icatibant</b>
<b>XM9192</b>	<b>Ecallantide</b>
<b>XM7M63</b>	<b>Conestat alfa</b>
<b>XM2UN9</b>	<b>Berotralstat</b>

Local hemostatics

<b>XM3RF2</b>	<b>Absorbable gelatin sponge</b>
<b>XM6EK6</b>	<b>Oxidized cellulose</b>
<b>XM1MS7</b>	<b>Tetragalacturonic acid hydroxymethyl ester</b>

**XM6BS8 Adrenalone**

**XM1JS6 Calcium alginate**

Other haematological agents

**XM8F45 Voxelotor**

Agents affecting genitourinary system, sex and anabolic hormones

**Coded Elsewhere:** Labour repressants

Drugs used in erectile dysfunction

Acidifiers

Oxytocic drugs (XM0Q45-XM6MR2)

Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified  
(XM6W81-XM5XB7)

Other gynaecologicals

**XM8R05 Atosiban**

**XM5EY9 Flibanserin**

**XM19G4 Agni casti fructus**

**XM6DH4 Cimicifugae rhizoma**

Intrauterine and intravaginal contraceptives

**XM92Y5 Plastic intrauterine contraceptive device**

**XM0B44 Plastic intrauterine contraceptive device with copper**

**XM7P32 Plastic intrauterine contraceptive device with progestogen**

**XM2AH3 Vaginal ring with progestogen and estrogen**

Estrogens and progestogens

**XM9N33 Progestogens and estrogens, fixed combinations**

**XM65V3 Levonorgestrel with ethinylestradiol**

**XM4BC7 Gestodene and ethinylestradiol**

**XM5PH2 Norgestimate and ethinylestradiol**

**XM01B4 Norelgestromin and ethinylestradiol**

**XM0QV1 Nomegestrol and estradiol**

XM3727	Chlormadinone and ethinylestradiol
XM4AD5	Quingestanol and ethinylestradiol
XM9ZQ5	Lynestrenol and ethinylestradiol
XM3344	Megestrol and ethinylestradiol
XM7D82	Norethisterone with ethinylestradiol
XM6EU8	Medroxyprogesterone and ethynodiol diacetate
XM6Y16	Desogestrel and ethinylestradiol
XM3L86	Drospirenone and ethinylestradiol
XM5KE9	Dienogest and ethinylestradiol
XM3WW4	Ethinylestradiol, ethynodiol with levonorgestrel
XM7M76	Ethinylestradiol, ethynodiol with norethisterone
XM8HJ8	Ethynodiol with mestranol diacetate
<b>XM0ZZ0</b>	<b>Progestogens and estrogens, sequential preparations</b>
<b>XM70N0</b>	<b>Estrogens</b>
XM51S9	Diethylstilbestrol
XM7YR1	Epimestrol
XM4EH0	Estriol
XM1058	Chlorotrianisene
XM8YK8	Estrone
XM56M0	Estrogen conjugated
XM6UC0	Dienoestrol
XM4T41	Methallenestrol
XM3YX8	Polyestradiol phosphate
XM03K8	Fosfestrol
XM7FC3	Promestriene
XM7ST1	Moxestrol
XM70N6	Tibolone
XM1SV5	Ethynodiol diacetate
XM7CP4	Estrogen
<b>XM9HA7</b>	<b>Progestogens</b>

XM2HB5	Medroxyprogesterone acetate (depot)
XM1KX5	Gestonorone caproate
XM6U53	Levonorgestrel
XM1DX1	Quingestanol
XM8Y77	Lynestrenol
XM7KS3	Megestrol
XM7LY6	Norethisterone
XM7ZG5	Desogestrel
XM7XY6	Drospirenone
XM0R79	Hydroxyprogesterone
XM3799	Progesterone
XM71X5	Dydrogesterone
XM4HQ9	Medrogestone
XM2LR3	Nomegestrol
XM6SD5	Demegestone
XM5FK8	Chlormadinone
XM71B5	Promegestone
XM0U58	Dienogest
XM77R9	Allylestrenol
XM0TH1	Ethisterone
XM6TX3	Ethynodiol
XM37T7	Methylestrenolone
XM94C4	Etonogestrel
XM31C0	Norgestrienone
XM6CL2	Anhydrohydroxy-progesterone
XM0W29	Antineoplastic combination estrogen
XM76F9	Conjugated estrogenic substances
XM4DR7	Delalutin
XM49U4	Dimestrol
XM5RK3	Dimethisterone

<b>XM1P34</b>	<b>Epiestriol</b>
<b>XM39W0</b>	<b>Estradiol benzoate</b>
<b>XM2GR3</b>	<b>Estrogen with progesterone</b>
<b>XM6133</b>	<b>Estropipate</b>
<b>XM7JV9</b>	<b>Gonadal tissue extract female</b>
<b>XM8WE5</b>	<b>Hexestrol</b>
<b>XM4NZ9</b>	<b>Hydroxyestrone</b>
<b>XM5A00</b>	<b>Hydroxyprogesterone caproate</b>
<b>XM3AK8</b>	<b>Mestranol</b>
<b>XM1SH1</b>	<b>Norethynodrel</b>
<b>XM1B43</b>	<b>Normethandrone</b>
<b>XM3MJ7</b>	<b>Ovarian hormone</b>
<b>XM26R0</b>	<b>Ovarian stimulant</b>
<b>XM8AV0</b>	<b>Oxendolone</b>
<b>XM1K26</b>	<b>Pregnandiol</b>
<b>XM8FT3</b>	<b>Progesterone</b>
<b>XM9HS1</b>	<b>Quinestradol</b>
<b>XM3HH8</b>	<b>Quinestrol</b>
<b>XM0SU9</b>	<b>Steroid antineoplastic, hormone estrogen</b>

Estrogen receptor modulators

<b>XM74M2</b>	<b>Clomiphene</b>
<b>XM1ZT8</b>	<b>Ormeloxifene</b>
<b>XM7P20</b>	<b>Cyclofenil</b>
<b>XM2CF9</b>	<b>Raloxifene</b>
<b>XM8818</b>	<b>Bazedoxifene</b>
<b>XM4JW0</b>	<b>Lasofoxifene</b>
<b>XM8HF1</b>	<b>Ospemifene</b>

Progesterone receptor modulators

**XM4RW1**      **Mifepristone**

**XM04R5**      **Ulipristal**

Androgens and anabolic congeners

**XM8VE0**      **Stanozolol**

**XM24D1**      **Methandrostenolone**

**XM0E55**      **Mestanolone**

**XM1E21**      **Oxymesterone**

**XM7WQ1**      **Oxymetholone**

**XM8788**      **Quinbolone**

**XM5Q72**      **Prasterone**

**XM6327**      **Oxandrolone**

**XM5115**      **Norethandrolone**

**XM29P0**      **Fluoxymesterone**

**XM4TC8**      **Methyltestosterone**

**XM3HM6**      **Testosterone**

**XM3QK3**      **Mesterolone**

**XM3478**      **Androstalone**

**XM3BT9**      **Anabolic steroid**

**XM65R6**      **Androgen**

**XM5CT6**      **Androgen-estrogen mixture**

**XM89R1**      **Androsterone**

**XM7LM1**      **Antineoplastic steroid**

**XM0T50**      **Calusterone**

**XM1SV6**      **Congener, anabolic**

**XM1RM3**      **Dromostanolone**

**XM81H5**      **Durabolin**

**XM76Q0**      **Epitiostanol**

**XM3UJ6**      **Estradiol with testosterone**

<b>XM7X01</b>	<b>Gonadal tissue extract male</b>
<b>XM6R95</b>	<b>Macrolide anabolic drug</b>
<b>XM21D8</b>	<b>Mepitiostane</b>
<b>XM2GQ1</b>	<b>Metenolone</b>
<b>XM6966</b>	<b>Methandriol</b>
<b>XM8HC6</b>	<b>Methyl androstanolone</b>
<b>XM8NZ0</b>	<b>Nandrolone</b>
<b>XM3KV3</b>	<b>Steroid androgenic</b>
<b>XM1KA5</b>	<b>Steroid antineoplastic, hormone</b>
<b>XM5T49</b>	<b>Testolactone</b>
<b>XM50S2</b>	<b>Zeranol</b>
<b>XM54A1</b>	<b>Ethylestrenol</b>
<b>XM6RN8</b>	<b>Oxabolone cipionate</b>
<b>XM11B1</b>	<b>Drugs for urinary frequency and incontinence</b>

Other urologicals

**Coded Elsewhere:** Magnesium hydroxide (XM39M3)

<b>XM1TG5</b>	<b>Phenyl salicylate</b>
<b>XM5549</b>	<b>Acetohydroxamic acid</b>
<b>XM2VJ5</b>	<b>Phenazopyridine</b>
<b>XM1JS5</b>	<b>Dimethyl sulfoxide</b>
<b>XM8GM2</b>	<b>Pentosan polysulfate sodium</b>
<b>XM2D76</b>	<b>Tiopronin</b>
<b>XM6VX1</b>	<b>Succinimide</b>
<b>XM8BX6</b>	<b>Dapoxetine</b>

Drugs used in benign prostatic hypertrophy

**Coded Elsewhere:** Alfuzosin (XM1C94)

Tamsulosin (XM3F82)

Terazosin (XM9LH2)

Mepartinicin (XM40Q3)

Finasteride (XM8P68)

Dutasteride (XM01Y3)

Silodosin (XM1FQ5)

**XM3WK8      Prunus africanae cortex**

**XM5B91      Sabalis serrulatae fructus**

**XM2Y08      Fexapotide**

Hormones and their synthetic substitutes and antagonists, not elsewhere classified

**Coded Elsewhere:** Mineralocorticoids (XM44R0-XM9X54)

Anterior pituitary [adenohypophyseal] hormones and analogues

**XM5Y80      Adrenocorticotrophic hormone**

**XM7XJ1      Corticotropin**

**XM4B77      Tetracosactide**

**XM7309      Anterior pituitary hormone**

**XM1EM4      Cosyntropin**

**XM4MB2      Follicle-stimulating hormone, human**

**XM1027      FSH**

**XM1NX7      Human growth hormone (HGH)**

**XM86N5      Luteinizing hormone**

**XM92R5      Menotropins**

**XM4QA7      Pergonal**

**XM0Y82      Pituitary extracts anterior**

**XM77Q1      Prolactin**

**XM9NW5      Seractide**

**XM3LZ6      Somatotropin**

**XM52T6      Tetracosactrin**

<b>XM4WS0</b>	<b>Thyrotrophin</b>
<b>XM7J71</b>	<b>Thyrotropic hormone</b>
<b>XM8HC4</b>	<b>Urofollitropin</b>
<b>XM03E8</b>	<b>Somatropin and somatropin agonists</b>
<b>XM96L8</b>	<b>Somatrem</b>
<b>XM30J6</b>	<b>Sermorelin</b>
<b>XM3038</b>	<b>Mecasermin</b>
<b>XM5CS4</b>	<b>Pegvisomant</b>
<b>XM9BW0</b>	<b>Mecasermin rinfabate</b>
<b>XM9109</b>	<b>Tesamorelin</b>
<b>XM9WW0</b>	<b>Somatrogon</b>
<b>XM49L1</b>	<b>Chorionic gonadotrophin</b>
<b>XM2J59</b>	<b>Human menopausal gonadotrophin</b>
<b>XM5ZL8</b>	<b>Serum gonadotrophin</b>
<b>XM4K30</b>	<b>Follitropin alfa</b>
<b>XM6EZ5</b>	<b>Follitropin beta</b>
<b>XM8TP5</b>	<b>Lutropin alfa</b>
<b>XM6HX4</b>	<b>Choriogonadotropin alfa</b>
<b>XM5M71</b>	<b>Corifollitropin alfa</b>
<b>XM0RZ5</b>	<b>Follitropin delta</b>
<b>XM26R5</b>	<b>Thyrotropin alfa</b>

Posterior pituitary hormones and analogues

<b>XM9EQ9</b>	<b>Enterogastrone</b>
<b>XM3MT8</b>	<b>Felypressin</b>
<b>XM6X07</b>	<b>Gonadal tissue extract</b>
<b>XM10K7</b>	<b>Gonadotropin</b>
<b>XM3GP5</b>	<b>Leuprorelin</b>
<b>XM7399</b>	<b>Melanocyte-stimulating hormone</b>
<b>XM00P3</b>	<b>Pituitary extracts (posterior)</b>

<b>XM0J12</b>	<b>Placental hormone</b>
<b>XM5714</b>	<b>Posterior pituitary hormone</b>
<b>XM7LM2</b>	<b>Thymus extract</b>
<b>XM1Y33</b>	<b>Vasopressor drugs</b>
<b>XM25M7</b>	<b>Vasopressin and analogues</b>
<b>XM6A76</b>	<b>Vasopressin</b>
<b>XM77T2</b>	<b>Desmopressin</b>
<b>XM3GU1</b>	<b>Lypressin</b>
<b>XM4E12</b>	<b>Terlipressin</b>
<b>XM3LP5</b>	<b>Ornipressin</b>
<b>XM1DB3</b>	<b>Oxytocin and analogues</b>
<b>XM9SN0</b>	<b>Oxytocin</b>
<b>XM41G8</b>	<b>Demoxytocin</b>
<b>XM4ZX0</b>	<b>Carbetocin</b>

Hypothalamic hormones and analogues

Gonadotropin releasing hormones and analogues

<b>XM32E8</b>	<b>Buserelin</b>
<b>XM8CG4</b>	<b>Goserelin</b>
<b>XM2TU9</b>	<b>Gonadorelin</b>
<b>XM4VT6</b>	<b>Nafarelin</b>
<b>XM78X7</b>	<b>Histrelin</b>
<b>XM3S25</b>	<b>Leuprorelin</b>
<b>XM9XC3</b>	<b>Somatostatin and analogues</b>
<b>XM5L29</b>	<b>Somatostatin</b>
<b>XM01Z4</b>	<b>Octreotide</b>
<b>XM7GZ3</b>	<b>Lanreotide</b>
<b>XM28Z2</b>	<b>Vapreotide</b>
<b>XM3AN9</b>	<b>Pasireotide</b>

Prolactin inhibitors

**Coded Elsewhere:** Bromocriptine (XM5QR9)

**XM4S44 Cabergoline**

**XM7828 Metergoline**

**XM96P1 Quinagolide**

**XM3MG0 Terguride**

Glucocorticoids and synthetic analogues

**XM51K6 Adrenal (extract, cortex or medulla) (glucocorticoids) (hormones)  
(mineralocorticoids)**

**XM6SU0 Betamethasone**

**XM0XB5 Clocortolone**

**XM4AF4 Cloprednol**

**XM3R56 Compound E (cortisone)**

**XM4HH6 Compound F (hydrocortisone)**

**XM6FJ6 Cortate**

**XM6TY3 Corticosteroid**

**XM5AE3 Cortisone**

**XM17S1 Cortivazol**

**XM25L1 Cortone**

**XM5CF7 Deflazacort**

**XM72R5 Dexamethasone**

**XM48E4 Fluorinated corticosteroids**

**XM2GK4 Fluprednisolone**

**XM4Z52 Glucocorticoids**

**XM0XY8 Hormone adrenal cortical steroids**

**XM2UL5 Kenacort**

**XM5V41 Meprednisone**

**XM4RH1 Paramethasone**

**XM5AM2 Percorten**

<b>XM6JJ4</b>	<b>Prednisolone</b>
<b>XM39W4</b>	<b>Prednisone</b>
<b>XM3YJ1</b>	<b>Prednylidene</b>
<b>XM8JY6</b>	<b>Steroid</b>
<b>XM5FR6</b>	<b>Fluocortolone</b>
<b>XM4J30</b>	<b>Triamcinolone</b>
<b>XM21H0</b>	<b>Hydrocortisone</b>
<b>XM3UP9</b>	<b>Budesonide</b>
<b>XM9VX0</b>	<b>Flunisolide</b>
<b>XM8PN0</b>	<b>Mometasone</b>
<b>XM5PW9</b>	<b>Fluticasone</b>
<b>XM3FX7</b>	<b>Methylprednisolone</b>
<b>XM3SM4</b>	<b>Rimexolone</b>
<b>XM3293</b>	<b>Beclometasone</b>
<b>XM4TY1</b>	<b>Ciclesonide</b>
<b>XM1XF3</b>	<b>Fluticasone furoate</b>

Anticorticosteroids

<b>XM7DQ5</b>	<b>Trilostane</b>
<b>XM8676</b>	<b>Osilodrostat</b>

Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified

<b>XM6W81</b>	<b>Gonadotrophin-releasing hormone antagonists</b>
<b>XM5JS1</b>	<b>Ganirelix</b>
<b>XM8Z22</b>	<b>Cetrorelix</b>
<b>XM5064</b>	<b>Elagolix</b>
<b>XM5ZS9</b>	<b>Abarelix</b>
<b>XM8292</b>	<b>Degarelix</b>
<b>XM3NR0</b>	<b>Linzagolix</b>
<b>XM10A6</b>	<b>Antiestrogen</b>

<b>XM2UX2</b>	<b>Tamoxifen</b>
<b>XM1312</b>	<b>Toremifene</b>
<b>XM2ZV3</b>	<b>Fulvestrant</b>
<b>XM7JF4</b>	<b>Antiandrogen</b>
<b>XM3G31</b>	<b>Flutamide</b>
<b>XM9AL0</b>	<b>Nilutamide</b>
<b>XM5FE9</b>	<b>Bicalutamide</b>
<b>XM7BF6</b>	<b>Enzalutamide</b>
<b>XM6Q81</b>	<b>Apalutamide</b>
<b>XM3FZ0</b>	<b>Darolutamide</b>
<b>XM9X91</b>	<b>Aromatase inhibitors</b>
<b>XM7D25</b>	<b>Aminoglutethimide</b>
<b>XM14P8</b>	<b>Formestane</b>
<b>XM4Z64</b>	<b>Anastrozole</b>
<b>XM2J37</b>	<b>Letrozole</b>
<b>XM6976</b>	<b>Vorozole</b>
<b>XM2VT0</b>	<b>Exemestane</b>
<b>XM8MB2</b>	<b>Antigonadotrophin</b>
<b>XM3C58</b>	<b>Cyproterone</b>
<b>XM0FW7</b>	<b>Danazol</b>
<b>XM9QT3</b>	<b>Nafoxidine</b>
<b>XM0P47</b>	<b>Taleranol</b>
<b>XM40Q3</b>	<b>Mepartircin</b>
<b>XM3028</b>	<b>Testosterone-5-alpha reductase inhibitors</b>
<b>XM8P68</b>	<b>Finasteride</b>
<b>XM01Y3</b>	<b>Dutasteride</b>
<b>XM7E94</b>	<b>Gestrinone</b>
<b>XM1517</b>	<b>Abiraterone</b>
<b>XM5XB7</b>	<b>Relugolix</b>

Thyroid hormones and substitutes

XM68B8	Detrothyronine
XM2YU4	Dextrothyroxine
XM27J7	Dextrothyroxine sodium
XM5M40	Euthroid
XM93X7	Hormone thyroid
XM10Z7	Levoid
XM5G81	Levothyroxine
XM2WC1	Levothyroxine sodium
XM2XB6	Liothyronine
XM0P56	Liotrix
XM9RU3	Prolloid
XM65J7	Sodium L-triiodothyronine
XM66B8	Thyroglobulin
XM5685	Thyroxine
XM4H64	Tiratricol
XM5590	Titroid
XM47Z3	Liothyronine sodium
XM8CX3	Thyroid gland preparations

Antithyroid drugs

XM1H03	Benzylthiouracil
XM35K1	Carbimazole
XM6Y24	Diiodotyrosine
XM8492	Iodine 131 therapeutic
XM6VL9	Iodine for thyroid conditions (antithyroid)
XM7TM9	Iothiouracil
XM38T7	Methimazole
XM54P6	Methylthiouracil
XM6V39	Potassium perchlorate antithyroid

<b>XM9LL4</b>	<b>Potassium perchlorate medicinal</b>
<b>XM5DE7</b>	<b>Propylthiouracil</b>
<b>XM8X98</b>	<b>Thiouracil (benzyl) (methyl) (propyl)</b>
<b>XM3G29</b>	<b>Thiourea</b>
<b>XM2MJ8</b>	<b>Dibromotyrosine</b>

Iodine therapy

<b>XM8AS5</b>	<b>Sodium iodide</b>
<b>XM9N95</b>	<b>Glucagon</b>

Parathyroid hormones and analogues

<b>XM7GD6</b>	<b>Parathyroid gland extract</b>
<b>XM59Z3</b>	<b>Teriparatide</b>
<b>XM4RN4</b>	<b>Parathyroid hormone</b>

Antiparathyroid agents

<b>XM0S16</b>	<b>Calcitonin preparations</b>
<b>XM74V3</b>	<b>Calcitonin, salmon synthetic</b>
<b>XM28Z6</b>	<b>Calcitonin, pork natural</b>
<b>XM32U7</b>	<b>Calcitonin, human synthetic</b>
<b>XM6US3</b>	<b>Elcatonin</b>
<b>XM40P9</b>	<b>Cinacalcet</b>
<b>XM9LS5</b>	<b>Paricalcitol</b>
<b>XM48A9</b>	<b>Doxercalciferol</b>
<b>XM0NY4</b>	<b>Etelcalcetide</b>

Insulin and antidiabetic drugs

<b>XM21C9</b>	<b>Insulin human</b>
<b>XM8S35</b>	<b>Antidiabetic</b>
<b>XM9AX5</b>	<b>Antidiabetic biguanide and sulfonyl combined</b>
<b>XM5DC4</b>	<b>Biguanides</b>

<b>XM4K79</b>	<b>Phenformin</b>
<b>XM0JN5</b>	<b>Metformin</b>
<b>XM6EJ2</b>	<b>Buformin</b>
<b>XM0S91</b>	<b>Proguanil</b>
<b>XM0EG5</b>	<b>Cycloguanil embonate</b>
<b>XM5SK7</b>	<b>Antidiabetic combined</b>
<b>XM11C9</b>	<b>Sulfonylureas</b>
<b>XM8S18</b>	<b>Chlorpropamide</b>
<b>XM1RV6</b>	<b>Tolbutamide</b>
<b>XM8E97</b>	<b>Glibornuride</b>
<b>XM8YD0</b>	<b>Tolazamide</b>
<b>XM8ZU0</b>	<b>Carbutamide</b>
<b>XM3TQ4</b>	<b>Glipizide</b>
<b>XM8597</b>	<b>Gliquidone</b>
<b>XM2G21</b>	<b>Gliclazide</b>
<b>XM65J8</b>	<b>Glisoxepide</b>
<b>XM60R0</b>	<b>Acetohexamide</b>
<b>XM5N48</b>	<b>Metahexamide</b>
<b>XM5N74</b>	<b>Glimepiride</b>
<b>XM6932</b>	<b>Biguanide derivatives, oral</b>
<b>XM06A4</b>	<b>Glimidine</b>
<b>XM2584</b>	<b>Glisolamide</b>
<b>XM4SE3</b>	<b>Globin zinc insulin</b>
<b>XM6JN8</b>	<b>Glyburide</b>
<b>XM0K09</b>	<b>Glycopyramide</b>
<b>XM6861</b>	<b>Glycyclamide</b>
<b>XM88E8</b>	<b>Glymidine sodium</b>
<b>XM4M26</b>	<b>Hormone antidiabetic agents</b>
<b>XM5MV9</b>	<b>Iletin</b>
<b>XM4C63</b>	<b>Insular tissue extract</b>

<b>XM2JC7</b>	<b>Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)</b>
<b>XM3RW5</b>	<b>Insulin defalan</b>
<b>XM16M5</b>	<b>Biphasic insulin injection</b>
<b>XM1DZ9</b>	<b>Insulin injection, soluble</b>
<b>XM9728</b>	<b>Insulin intermediate acting</b>
<b>XM54Q2</b>	<b>Insulin protamine zinc</b>
<b>XM0KT2</b>	<b>Insulin slow acting</b>
<b>XM7VD3</b>	<b>Protamine zinc insulin injection</b>
<b>XM0US2</b>	<b>Insulin zinc suspension (amorphous) (crystalline)</b>
<b>XM73L8</b>	<b>Isophane insulin</b>
<b>XM9AZ3</b>	<b>Lente iletin (insulin)</b>
<b>XM8502</b>	<b>Neutral insulin injection</b>
<b>XM8VX4</b>	<b>NPH iletin (insulin)</b>
<b>XM3J06</b>	<b>Protamine sulfate zinc insulin</b>
<b>XM8QQ1</b>	<b>PZI</b>
<b>XM73P6</b>	<b>Sulfonylurea derivatives, oral</b>
<b>XM99F8</b>	<b>Insulins and analogues</b>
<b>XM2WY1</b>	<b>Alpha glucosidase inhibitors</b>
<b>XM9JV9</b>	<b>Acarbose</b>
<b>XM9EX0</b>	<b>Miglitol</b>
<b>XM4QD6</b>	<b>Voglibose</b>

### Sulfonamides (heterocyclic)

<b>XM19U1</b>	<b>Acedapsone</b>
<b>XM91Z9</b>	<b>Acesulfamethoxypyridazine</b>
<b>XM1RU4</b>	<b>Acetilsulfamethoxypyridazine</b>
<b>XM7WC8</b>	<b>Diaphenylsulfone</b>
<b>XM96M6</b>	<b>Disulfanilamide</b>
<b>XM3GA0</b>	<b>Neoprontosil</b>

<b>XM1RY1</b>	<b>Phthalylsulfathiazole</b>
<b>XM55D8</b>	<b>Prontosil</b>
<b>XM85A7</b>	<b>Succinylsulfathiazole</b>
<b>XM69G3</b>	<b>Sulfachlorpyridazine</b>
<b>XM5C46</b>	<b>Sulfacitine</b>
<b>XM57L7</b>	<b>Sulfadoxine</b>
<b>XM03X3</b>	<b>Sulfaethidole</b>
<b>XM0F36</b>	<b>Sulfaguanidine</b>
<b>XM6N26</b>	<b>Sulfaloxate</b>
<b>XM57M8</b>	<b>Sulfaloxic acid</b>
<b>XM8UP5</b>	<b>Sulfameter</b>
<b>XM5X85</b>	<b>Sulfamethylthiazole</b>
<b>XM6D90</b>	<b>Sulfamonomethoxine</b>
<b>XM2187</b>	<b>Sulfaphenylthiazole</b>
<b>XM8QW8</b>	<b>Sulfaproxyline</b>
<b>XM2XQ2</b>	<b>Sulfasalazine</b>
<b>XM9MJ3</b>	<b>Sulfasuxidine</b>
<b>XM2Y59</b>	<b>Sulfasymazine</b>
<b>XM6BM7</b>	<b>Sulfisomidine</b>
<b>XM7Z85</b>	<b>Trisulfapyrimidines</b>
<b>XM5EH1</b>	<b>Glymidine</b>
<b>XM4UA3</b>	<b>Thiazolidinediones</b>
<b>XM0NQ7</b>	<b>Troglitazone</b>
<b>XM27D8</b>	<b>Rosiglitazone</b>
<b>XM0TX6</b>	<b>Pioglitazone</b>
<b>XM9SM6</b>	<b>Dipeptidyl peptidase 4 inhibitors</b>
<b>XM4M71</b>	<b>Sitagliptin</b>
<b>XM9867</b>	<b>Vildagliptin</b>
<b>XM5QH2</b>	<b>Saxagliptin</b>

<b>XM1044</b>	<b>Alogliptin</b>
<b>XM9X94</b>	<b>Linagliptin</b>
<b>XM5T11</b>	<b>Gemigliptin</b>
<b>XM5SF9</b>	<b>Evogliptin</b>
<b>XM4MK4</b>	<b>Glucagon-like peptide-1 analogues</b>
<b>XM06C6</b>	<b>Exenatide</b>
<b>XM0EQ7</b>	<b>Liraglutide</b>
<b>XM3U71</b>	<b>Lixisenatide</b>
<b>XM2516</b>	<b>Albiglutide</b>
<b>XM1FT0</b>	<b>Dulaglutide</b>
<b>XM9KJ3</b>	<b>Semaglutide</b>
<b>XM0FD1</b>	<b>Meglitinide</b>
<b>XM9V31</b>	<b>Repaglinide</b>
<b>XM5Z74</b>	<b>Nateglinide</b>
<b>XM7967</b>	<b>Mitiglinide</b>
<b>XM9EK1</b>	<b>Other blood glucose lowering drugs</b>
	<i>Coded Elsewhere:</i> Benfluorex (XM9UB7)
<b>XM62R6</b>	<b>Pramlintide</b>
<b>XM7VJ0</b>	<b>Teduglutide</b>
<b>XM0615</b>	<b>Sodium-glucose co-transporter 2 inhibitors</b>
<b>XM97T4</b>	<b>Dapagliflozin</b>
<b>XM1NP2</b>	<b>Canagliflozin</b>
<b>XM9RW3</b>	<b>Empagliflozin</b>
<b>XM66V1</b>	<b>Ertugliflozin</b>
<b>XM8Y84</b>	<b>Ipragliflozin</b>
<b>XM7947</b>	<b>Sotagliflozin</b>
<b>XM29C4</b>	<b>Insulin (beef)</b>
<b>XM8YE2</b>	<b>Insulin (pork)</b>
<b>XM6NY5</b>	<b>Insulin lispro</b>
<b>XM0HQ0</b>	<b>Insulin aspart</b>

<b>XM7WH3</b>	<b>Insulin glulisine</b>
<b>XM96W1</b>	<b>Insulin detemir</b>
<b>XM6R62</b>	<b>Insulin degludec</b>
<b>XM65E7</b>	<b>Tolrestat</b>
<b>XM93G5</b>	<b>Imeglimin</b>
<b>XM5374</b>	<b>Cholecystokinin</b>

Agents affecting bones, joints and other connective tissue, not elsewhere classified

Bisphosphonates

<b>XM7171</b>	<b>Clodronic acid</b>
<b>XM6UW3</b>	<b>Etidronic acid</b>
<b>XM55G3</b>	<b>Pamidronic acid</b>
<b>XM94M8</b>	<b>Alendronic acid</b>
<b>XM2M01</b>	<b>Tiludronic acid</b>
<b>XM93D5</b>	<b>Ibandronic acid</b>
<b>XM5CM8</b>	<b>Risedronic acid</b>
<b>XM5908</b>	<b>Zoledronic acid</b>

Bone morphogenetic proteins

<b>XM5GF1</b>	<b>Dibotermin alfa</b>
<b>XM8NB9</b>	<b>Eptotermin alfa</b>
<b>XM94X8</b>	<b>Collagen</b>

Enzymes affecting bones, joints and other connective tissue, not elsewhere classified

<b>XM2UE2</b>	<b>Chymopapain</b>
<b>XM6F64</b>	<b>Bromelains</b>
<b>XM0NQ8</b>	<b>Collagenase clostridium histolyticum</b>
<b>XM4GT8</b>	<b>Ipriflavone</b>
<b>XM5AP2</b>	<b>Aluminium chlorhydrate</b>
<b>XM6U91</b>	<b>Strontium ranelate</b>

<b>XM2P79</b>	<b>Denosumab</b>
<b>XM4MQ4</b>	<b>Burosumab</b>
<b>XM7AJ2</b>	<b>Romosozumab</b>
<b>XM6EQ0</b>	<b>Hyaluronic acid</b>
<b>XM2SL6</b>	<b>Chondrocytes, autologous</b>
<b>XM99J5</b>	<b>Vosoritide</b>

Agents primarily affecting water and nutrition-balance and metabolism

Drugs affecting uric acid metabolism and other antigout preparations

*Coded Elsewhere:* Colchicine (XM3Q99)

<b>XM2ZB4</b>	<b>Preparations inhibiting uric acid production</b>
<b>XM9589</b>	<b>Allopurinol</b>
<b>XM47Z2</b>	<b>Tisopurine</b>
<b>XM0K04</b>	<b>Febuxostat</b>
<b>XM7F05</b>	<b>Preparations increasing uric acid excretion</b>
<b>XM0WT0</b>	<b>Probenecid</b>
<b>XM7K05</b>	<b>Sulfinpyrazone</b>
<b>XM9DK8</b>	<b>Benzbromarone</b>
<b>XM3WF1</b>	<b>Isobromindione</b>
<b>XM95H8</b>	<b>Lesinurad</b>
<b>XM2D08</b>	<b>Atophan</b>
<b>XM3WA0</b>	<b>Cinchophen</b>
<b>XM0M93</b>	<b>Ethebenecid</b>
<b>XM5VG7</b>	<b>Neocinchophen</b>
<b>XM6FA5</b>	<b>Oxipurinol</b>
<b>XM3JP7</b>	<b>Phenoquin</b>
<b>XM9DH5</b>	<b>Spindle inactivator</b>
<b>XM56G7</b>	<b>Urate oxidase</b>
<b>XM95S3</b>	<b>Uric acid metabolism drug</b>

**XM6953      Uricosuric agent**

**XM9TL4      Pegloticase**

Mineral salts and supplements, not elsewhere classified

**Coded Elsewhere:** Iron and its compounds (XM8ZX9-XM6435)

**XM8KC2      Calcium**

**Coded Elsewhere:** Calcium compounds (XM0SA0)

Calcium carbonate (XM9003)

Calcium chloride (XM9VN8)

**XM1AY1      Calcium phosphate**

**XM7ND2      Calcium glubionate**

**XM3EU2      Calcium gluconate**

**XM46G3      Calcium lactate**

**XM0VY0      Calcium acetate**

**XM4N33      Calcium lactate gluconate**

**XM9WA2      Calcium glycerylphosphate**

**XM4X88      Calcium citrate lysine complex**

**XM08S9      Calcium glucoheptonate**

**XM7G46      Calcium pangamate**

**XM5TW4      Calcium acetate anhydrous**

**XM4S97      Calcium citrate**

**XM6AK3      Calcium laevulate**

**XM8AM9      Calcium bromolactobionate**

**XM9566      Calcium salts**

**XM8278      Potassium**

**Coded Elsewhere:** Potassium chloride (XM0U09)

**XM7D96      Potassium citrate**

**XM46S4      Potassium bitartrate**

**XM56J9      Potassium bicarbonate**

**XM2P49      Potassium gluconate**

**XM0H50      Potassium salts**

<b>XM1ZS4</b>	<b>Sodium</b>
	<i>Coded Elsewhere:</i> Sodium chloride (XM0X22)
<b>XM0VG1</b>	<b>Sodium acid phosphate</b>
<b>XM6R29</b>	<b>Sodium biphosphate</b>
<b>XM8ZD6</b>	<b>Sodium cyclamate</b>
<b>XM9KZ3</b>	<b>Sodium hydrogen carbonate</b>
<b>XM7L15</b>	<b>Sodium magnesium citrate</b>
<b>XM3H90</b>	<b>Sodium salt</b>
<b>XM1U95</b>	<b>Zinc</b>
<b>XM3E63</b>	<b>Zinc chloride nonmedicinal</b>
<b>XM52P2</b>	<b>Zinc chromate</b>
<b>XM93K2</b>	<b>Zinc oxide nonmedicinal</b>
<b>XM6D77</b>	<b>Zinc phosphide</b>
<b>XM82L3</b>	<b>Zinc sulfate nonmedicinal</b>
<b>XM27E8</b>	<b>Zinc pesticide, not elsewhere classified</b>
<b>XM68Z2</b>	<b>Zinc sulfate</b>
<b>XM5WL8</b>	<b>Zinc gluconate</b>
<b>XM0418</b>	<b>Zinc protein complex</b>
<b>XM3R55</b>	<b>Zinc acetate</b>
<b>XM5TD2</b>	<b>Magnesium</b>
	<i>Coded Elsewhere:</i> Magnesium oxide (XM7G33)
	Magnesium sulfate (XM6EC7)
<b>XM7KF0</b>	<b>Magnesium citrate</b>
<b>XM1AU1</b>	<b>Magnesium gluconate</b>
<b>XM2U66</b>	<b>Magnesium aspartate</b>
<b>XM3U21</b>	<b>Magnesium lactate</b>
<b>XM8W21</b>	<b>Magnesium levulinate</b>
<b>XM9GU6</b>	<b>Magnesium pidolate</b>
<b>XM8P82</b>	<b>Magnesium orotate</b>
<b>XM5VT1</b>	<b>Magnesium silicofluoride</b>
<b>XM1VS5</b>	<b>Fluoride</b>

XM1F39	Sodium fluoride
XM82S0	Sodium monofluorophosphate
XM47M7	Selenium
XM4HH9	Selenium fumes
XM5RR4	Sodium selenate
XM7809	Sodium selenite
XM6777	Acetic acid irrigating solution
XM7KG7	Aminoacetic acid (derivatives)
XM6DF0	Carbacrylamine (resin)
XM1619	Dialysis solution (intraperitoneal)
XM6YF0	Electrolytic agent
XM6598	Glucose with sodium chloride
XM02Y3	Glycerol intravenous
XM7NQ3	Glycine
XM8UU5	Lactated potassic saline
XM5FN3	Mineral salt
XM6P40	Polyaminostyrene resins
XM3UT8	Potassic saline injection (lactated)
XM11X8	Ringer solution (lactate)
XM6XG7	Sodium free salt
XM7JQ2	Travert
XM1DP8	Water balance drug
XM5N49	Water distilled
XM9V59	Water purified
XM8323	Cobalt medicinal (trace) (chloride)
XM5DN1	Copper medicinal (trace)
XM3046	Dietary supplements rich in vitamins and antioxidants
XM7113	Liver extract
XM9GC7	Liver fraction 1

**XM25P4** Liver hydrolysate

**XM09R3** Cod-liver oil

**XM9FC4** Yeast

**XM2W18** Yeast dried

**XM40J4** Ready-to-use therapeutic food

Ready-to-use therapeutic food (RUTF) are energy dense, micronutrient enhanced, soft or crushable foods used in therapeutic feeding for children from the age of 6 months without adding water. Typically, RUTF consists of four food ingredients (milk powder, peanut paste, vegetable oil and sugar) and multiple micronutrients to provide a complete complement of vitamins and minerals.

Electrolytic, caloric and water-balance agents

*Coded Elsewhere:* Amino acids (XM4Z15)

**XM0N15** Solutions producing osmotic diuresis

**XM5BJ8** Mannitol

**XM4HL5** Carbamide

**XM62S0** Antikaluretic

**XM51Y8** Caloric agent

**XM7BR0** Dextrose

**XM7UQ5** Electrolyte balance drug

**XM9SL7** Electrolyte solutions

*Coded Elsewhere:* Magnesium sulfate (XM6EC7)

Hydrochloric acid (XM6F61)

**XM0U09** Potassium chloride

**XM4XZ4** Sodium bicarbonate

**XM0X22** Sodium chloride

**XM9VN8** Calcium chloride

**XM1W37** Ammonium chloride

**XM76C9** Sodium phosphate

**XM7F36** Sodium acetate

**XM6NV5** Magnesium phosphate

**XM03Q8** Magnesium chloride

**XM40H8** Zinc chloride

XM83Z9	Sodium glycerophosphate
XM3T43	Potassium lactate
XM99L3	Cardioplegia solutions
XM45S7	Potassium acetate
XM3US9	Compound solution of sodium lactate
XM7E16	Gluconic acid
XM2S34	Glycerophosphate
XM61E9	Sodium citrate
XM5Y58	Hartmann's solution
XM0KH7	Invert sugar
XM9XU2	Levulose
XM39B5	Oral rehydration salts
XM39C1	Peritoneal dialysis solution
XM03B7	Potassium-removing resin
XM5KE7	Potassium-retaining drug
XM3UA2	Replacement solution
XM4EK0	Sodium removing resins
XM9Y86	Sucrose
XM6JX1	Carnitine
XM5S14	Electrolytes
XM9QW3	Trometamol
XM7345	Ademethionine
XM1P36	Glutamine
XM85F8	Mercaptamine
XM0977	Carglumic acid
XM9GM1	Fat emulsions
XM4YU3	Carbohydrates
XM55C2	Protein hydrolysates

## Diuretics

	<b>Coded Elsewhere:</b> Carbonic-anhydrase inhibitors
	Equisetum diuretic (XM0EC2)
<b>XM5W29</b>	<b>Aminometradine</b>
<b>XM2E81</b>	<b>Amisometradine</b>
<b>XM8U06</b>	<b>Anhydron</b>
<b>XM8TM1</b>	<b>Benzothiadiazides</b>
<b>XM0JW3</b>	<b>Benzylhydrochlorothiazide</b>
<b>XM3ER5</b>	<b>Carbonic acid gas anhydrase inhibitor</b>
<b>XM80T6</b>	<b>Chlorazanil</b>
<b>XM6946</b>	<b>Chlormerodrin</b>
<b>XM4JM8</b>	<b>Diupres</b>
<b>XM4D06</b>	<b>Diuretic</b>
<b>XM68T7</b>	<b>Diuretic benzothiadiazine</b>
<b>XM8B36</b>	<b>Diuretic carbonic acid anhydrase inhibitors</b>
<b>XM1N83</b>	<b>Diuretic furfuryl</b>
<b>XM6VW0</b>	<b>Diuretic mercurial</b>
<b>XM43Q2</b>	<b>Diuretic saluretic</b>
<b>XM3558</b>	<b>Diuretic sulfonamide</b>
<b>XM58W3</b>	<b>Diuretic thiazide</b>
<b>XM04R3</b>	<b>Diurgin</b>
<b>XM5L31</b>	<b>Flumethiazide</b>
<b>XM8T28</b>	<b>Hydromox</b>
<b>XM8HM6</b>	<b>Meralluride</b>
<b>XM5R34</b>	<b>Merbaphen</b>
<b>XM1SB8</b>	<b>Mercaptomerin</b>
<b>XM3PF7</b>	<b>Mercumatilin</b>
<b>XM3L13</b>	<b>Mercurophylline</b>
<b>XM4B84</b>	<b>Osmotic diuretics</b>
<b>XM6BR0</b>	<b>Purine diuretics</b>

<b>XM7660</b>	<b>Regroton</b>
<b>XM01E9</b>	<b>Salicylate theobromine calcium</b>
<b>XM9409</b>	<b>Saluretic</b>
<b>XM7J43</b>	<b>Sodium mersalate</b>
<b>XM9VJ2</b>	<b>Thiomercaptomerin</b>
<b>XM1177</b>	<b>Thiomerin</b>
<b>XM0YS2</b>	<b>Tiamizide</b>
<b>XM3YV1</b>	<b>Tripamide</b>
<b>XM93H5</b>	<b>Xanthine diuretics</b>
<b>XM3K70</b>	<b>Low-ceiling diuretics</b>

**Coded Elsewhere:** Theobromine (XM4L37)

#### Benzothiadiazine derivatives

<b>XM5FV5</b>	<b>Altizide</b>
<b>XM64R7</b>	<b>Bendroflumethiazide</b>
<b>XM7Q17</b>	<b>Benzthiazide</b>
<b>XM83Q3</b>	<b>Butizide</b>
<b>XM3PJ4</b>	<b>Chlorothiazide</b>
<b>XM4SP9</b>	<b>Cyclopenthiazide</b>
<b>XM1PM4</b>	<b>Cyclothiazide</b>
<b>XM71N6</b>	<b>Disulfamide</b>
<b>XM8532</b>	<b>Epitizide</b>
<b>XM6910</b>	<b>Hydrochlorothiazide</b>
<b>XM2671</b>	<b>Hydroflumethiazide</b>
<b>XM3EW9</b>	<b>Mebutizide</b>
<b>XM9T97</b>	<b>Methyclothiazide</b>
<b>XM1DC4</b>	<b>Penflutizide</b>
<b>XM7NZ7</b>	<b>Polythiazide</b>
<b>XM26G2</b>	<b>Teclothiazide</b>

<b>XM1L59</b>	<b>Trichlormethiazide</b>
<b>XM4AF6</b>	<b>Mersalyl</b>
<b>XM0G11</b>	<b>Cicletanine</b>
<b>XM6U69</b>	<b>Low-ceiling diuretic sulfonamides</b>
<b>XM3WN8</b>	<b>Quinethazone</b>
<b>XM7A66</b>	<b>Clopamide</b>
<b>XM51L8</b>	<b>Chlortalidone</b>
<b>XM1DG9</b>	<b>Mefruside</b>
<b>XM0EZ6</b>	<b>Clofenamide</b>
<b>XM7G39</b>	<b>Metolazone</b>
<b>XM3GK5</b>	<b>Meticrane</b>
<b>XM4U11</b>	<b>Xipamide</b>
<b>XM49L3</b>	<b>Indapamide</b>
<b>XM8GT1</b>	<b>Clorexolone</b>
<b>XM6CD1</b>	<b>Fenquizone</b>
<b>XM3L93</b>	<b>Aldosterone antagonists and other potassium-sparing agents</b>

#### Mineralocorticoids antagonists

<b>XM94A6</b>	<b>Aldosterone</b>
<b>XM6QK1</b>	<b>Canrenoic acid</b>
<b>XM1ML2</b>	<b>Canrenone</b>
<b>XM0TH6</b>	<b>Eplerenone</b>
<b>XM0ET8</b>	<b>Potassium canrenoate</b>
<b>XM1JS8</b>	<b>Spironolactone</b>
<b>XM8ZW7</b>	<b>Finerenone</b>
<b>XM1SM2</b>	<b>Amiloride</b>
<b>XM5SJ5</b>	<b>Triamterene</b>

#### Loop [high-ceiling] diuretics

<b>XM8CG7</b>	<b>Diuretic loop (high-ceiling)</b>
---------------	-------------------------------------

<b>XM79L6</b>	<b>Ethacrynone sodium</b>
<b>XM2LW1</b>	<b>Etacrynic acid</b>
<b>XM1H00</b>	<b>Etozolin</b>
<b>XM06E2</b>	<b>Lasix</b>
<b>XM2C78</b>	<b>Lyovac Sodium Edecrin</b>
<b>XM9KF7</b>	<b>Tienilic acid</b>
<b>XM6M47</b>	<b>Muzolimine</b>
<b>XM2W24</b>	<b>Loop [high-ceiling] diuretic sulfonamides</b>
<b>XM8UE3</b>	<b>Furosemide</b>
<b>XM6MV2</b>	<b>Bumetanide</b>
<b>XM9ML2</b>	<b>Piretanide</b>
<b>XM4DR4</b>	<b>Torasemide</b>
<b>XM7VU2</b>	<b>Vasopressin antagonists</b>
<b>XM9LF5</b>	<b>Tolvaptan</b>
<b>XM25L2</b>	<b>Conivaptan</b>

Mineralocorticoids

<b>XM44R0</b>	<b>Antagonist Aldosterone</b>
<b>XM8CC8</b>	<b>Corticosteroid mineral</b>
<b>XM4HZ4</b>	<b>Salt-retaining mineralocorticoid</b>
<b>XM9SX2</b>	<b>Deoxycortone</b>
<b>XM6PJ9</b>	<b>Desoxycorticosteroid</b>
<b>XM9HZ6</b>	<b>Desoxycortone</b>
<b>XM6JQ6</b>	<b>Fludrocortisone</b>
<b>XM9X54</b>	<b>Mineralocorticosteroid</b>

Vitamins and antioxidants

**Coded Elsewhere:** Menadione (XM1KN2)

<b>XM5G71</b>	<b>Vitamin D</b>
<b>XM75Z5</b>	<b>Ergocalciferol</b>

<b>XM37C2</b>	<b>Dihydrotachysterol</b>
<b>XM3NT7</b>	<b>Alfacalcidol</b>
<b>XM85V3</b>	<b>Calcitriol</b>
<b>XM11C6</b>	<b>Cholecalciferol</b>
<b>XM8SM6</b>	<b>Calcifediol</b>
<b>XM4H09</b>	<b>B complex vitamins and derivates</b>
	<b>Coded Elsewhere:</b> Cyanocobalamin (XM9KD4)
	Cyanocobalamin tannin complex (XM09N3)
	Cobamamide (XM2NR4)
	Mecobalamin (XM2AT9)
	Folic acid (XM7R82)
<b>XM5HF5</b>	<b>Benfotiamine</b>
<b>XM4PS9</b>	<b>Nicotinamide</b>
<b>XM8V93</b>	<b>Riboflavin</b>
<b>XM9RX3</b>	<b>Biotin</b>
<b>XM4GD2</b>	<b>Pyridoxal phosphate</b>
<b>XM41P5</b>	<b>Dexpanthenol</b>
<b>XM7398</b>	<b>Calcium pantothenate</b>
<b>XM50T4</b>	<b>Thiamine</b>
<b>XM42G9</b>	<b>sulbutiamine</b>
<b>XM2SV4</b>	<b>Vitamin B-complex, plain</b>
<b>XM0Y25</b>	<b>Potassium aminobenzoate</b>
<b>XM3UQ2</b>	<b>Acetiamine</b>
<b>XM3HE8</b>	<b>Bisbentiamine</b>
<b>XM5LG0</b>	<b>Bisbutiamine</b>
<b>XM8SY7</b>	<b>Cetotiamine</b>
<b>XM20C9</b>	<b>Fursultiamine</b>
<b>XM9609</b>	<b>Octotiamine</b>
<b>XM72U8</b>	<b>Panthenol</b>
<b>XM7D01</b>	<b>Prosultiamine</b>
<b>XM5MM0</b>	<b>Pyridoxine</b>

<b>XM7XY8</b>	<b>Ascorbic acid</b>
<b>XM1PU6</b>	<b>Tocopherol</b>
<b>XM5TU4</b>	<b>Vitamin E</b>
<b>XM9CG5</b>	<b>Thioctic acid</b>
<b>XM1SD9</b>	<b>Octyl gallate</b>
<b>XM88X6</b>	<b>Sodium metabisulfite</b>
<b>XM4BD4</b>	<b>Chlorophyll</b>
<b>XM31S0</b>	<b>Thioctamide</b>
<b>XM2EM5</b>	<b>Pangamic acid</b>
<b>XM7E89</b>	<b>Betacarotene</b>
<b>XM4BT6</b>	<b>Retinol</b>

Enzymes and digestants

**Coded Elsewhere:** Tilactase (XM4U70)

<b>XM7KX6</b>	<b>Chenodeoxycholic acid</b>
<b>XM8MG9</b>	<b>Ursodeoxycholic acid</b>
<b>XM37T5</b>	<b>Cholic acid</b>
<b>XM1F53</b>	<b>Diastase</b>
<b>XM5888</b>	<b>Multienzymes</b>
<b>XM2VN0</b>	<b>Protease</b>
<b>XM3UE5</b>	<b>Pepsin</b>
<b>XM6F61</b>	<b>Hydrochloric acid</b>
<b>XM6QZ3</b>	<b>Hydrochloric acid vapor</b>
<b>XM3RH9</b>	<b>Citric acid</b>
<b>XM96V4</b>	<b>Alglucerase</b>
<b>XM51F9</b>	<b>Obeticholic acid</b>
<b>XM3UT3</b>	<b>Glutamic acid hydrochloride</b>
<b>XM7Y97</b>	<b>Betaine hydrochloride</b>
<b>XM7EN2</b>	<b>Imiglucerase</b>
<b>XM3EW0</b>	<b>Agalsidase alfa</b>

<b>XM1CJ9</b>	<b>Agalsidase beta</b>
<b>XM4PC4</b>	<b>Laronidase</b>
<b>XM69V4</b>	<b>Sacrosidase</b>
<b>XM3EE9</b>	<b>Alglucosidase alfa</b>
<b>XM11U1</b>	<b>Galsulfase</b>
<b>XM3Z98</b>	<b>Idursulfase</b>
<b>XM8J61</b>	<b>Velaglucerase alfa</b>
<b>XM8HN5</b>	<b>Taliglucerase alfa</b>
<b>XM7QH6</b>	<b>Elosulfase alfa</b>
<b>XM5U98</b>	<b>Asfotase alfa</b>
<b>XM6UN5</b>	<b>Sebelipase alfa</b>
<b>XM5U91</b>	<b>Velmanase alfa</b>
<b>XM98F5</b>	<b>Idursulfase beta</b>
<b>XM9L40</b>	<b>Cerliponase alfa</b>
<b>XM3FP4</b>	<b>Vestronidase alfa</b>
<b>XM8F43</b>	<b>Pegvaliase</b>
<b>XM30U5</b>	<b>Pegunigalsidase alfa</b>
<b>XM56M4</b>	<b>Atidarsagene autotemcel</b>
<b>XM9F01</b>	<b>Avalglucosidase alfa</b>

Agents in bile and liver therapy

<b>XM4HD8</b>	<b>Arginine glutamate</b>
<b>XM5RS5</b>	<b>Silymarin</b>
<b>XM6T01</b>	<b>Epomediol</b>
<b>XM1GT0</b>	<b>Ornithine</b>
<b>XM1R31</b>	<b>Nicotinyl methylamide</b>
<b>XM03F0</b>	<b>Piprozolin</b>
<b>XM0HT0</b>	<b>Hymecromone</b>
<b>XM2EM9</b>	<b>Cyclobutyrol</b>

<b>XM0413</b>	<b>Citiolone</b>
<b>XM0F81</b>	<b>Tidiacic arginine</b>
<b>XM7600</b>	<b>Anethole trithione</b>
<b>XM8B34</b>	<b>Sodium dehydrocholate</b>
<b>XM56J1</b>	<b>Monoctanooin</b>
<b>XM44G8</b>	<b>Orazamide</b>
<b>XM3E24</b>	<b>Tidiacic</b>
<b>XM3VV1</b>	<b>Maralixibat chloride</b>
<b>XM30B2</b>	<b>Odevixibat</b>

Antibesity preparations

<b>XM9UB7</b>	<b>Benfluorex</b>
<b>XM2AF4</b>	<b>Centrally acting antibesity products</b>
<b>XM5VK3</b>	<b>Phentermine</b>
<b>XM5TZ8</b>	<b>Fenfluramine</b>
<b>XM84W9</b>	<b>Amfepramone</b>
<b>XM5WS4</b>	<b>Dexfenfluramine</b>
<b>XM25W6</b>	<b>Mazindol</b>
<b>XM8K95</b>	<b>Cathine</b>
<b>XM2NX7</b>	<b>Clobenzorex</b>
<b>XM3DL8</b>	<b>Mefenorex</b>
<b>XM7830</b>	<b>Etilamfetamine</b>
<b>XM13P5</b>	<b>Sibutramine</b>
<b>XM4NN9</b>	<b>Lorcaserin</b>
<b>XM54E8</b>	<b>Aminorex</b>
<b>XM4DD3</b>	<b>Benzphetamine</b>
<b>XM16Q1</b>	<b>Chlorphentermine</b>
<b>XM3AJ4</b>	<b>Cloforex</b>
<b>XM8H60</b>	<b>Clortermine</b>
<b>XM5FP0</b>	<b>Diethylpropion</b>

<b>XM1145</b>	<b>Fenproporex</b>
<b>XM4PR1</b>	<b>Phenbutrazate</b>
<b>XM6AJ3</b>	<b>Phendimetrazine</b>
<b>XM73T8</b>	<b>Phenmetrazine</b>
<b>XM5DN4</b>	<b>Setmelanotide</b>
<b>XM0NL0</b>	<b>Orlistat</b>
<b>XM7GX4</b>	<b>Rimonabant</b>
<b>XM2520</b>	<b>Amfetamine and amfetamine derivatives</b>
<b>XM48Z9</b>	<b>Amfetamine</b>
<b>XM2154</b>	<b>Fencamfamin</b>
<b>XM8N26</b>	<b>Fenetylline</b>
<b>XM4SD7</b>	<b>Lisdexamfetamine</b>
<b>XM0462</b>	<b>Solriamfetol</b>

Drugs used to treat enzyme deficiencies and disorders of aminoacid, glycolipid and glycoprotein metabolism

<b>XM5SC6</b>	<b>Sodium phenylbutyrate</b>
<b>XM1843</b>	<b>Nitisinone</b>
<b>XM19C6</b>	<b>Miglustat</b>
<b>XM6ZV0</b>	<b>Sapropterin</b>
<b>XM4F44</b>	<b>Glycerol phenylbutyrate</b>
<b>XM0K95</b>	<b>Eliglustat</b>
<b>XM2QP5</b>	<b>Sodium benzoate</b>
<b>XM6QN8</b>	<b>Migalastat</b>
<b>XM53N4</b>	<b>Choline chloride</b>
<b>XM3KK0</b>	<b>Choline dihydrogen citrate</b>
<b>XM7291</b>	<b>Inositol</b>
<b>XM9J35</b>	<b>Adenine</b>
<b>XM3CJ7</b>	<b>Flavine adenine dinucleotide</b>
<b>XM7ZH6</b>	<b>Fosdenopterin</b>

**XM4L78      Lonafarnib**

Agents primarily affecting the cardiovascular system

**Coded Elsewhere:** Beta blocking agents

Agents acting on the renin-angiotensin system

**XM4MG6      Imidapril**

**XM72L5      Angiotensin-converting-enzyme inhibitors**

**XM3FH7      Renin-inhibitors**

**XM9N15      Zofenopril**

**XM8091      Spirapril**

**XM2A48      Ramipril**

**XM3DU1      Quinapril**

**XM58G7      Perindopril**

**XM7TF8      Lisinopril**

**XM4Z53      Fosinopril**

**XM5609      Enalaprilat**

**XM6X56      Enalapril**

**XM1AZ4      Cilazapril**

**XM6P97      Captopril**

**XM0HG1      Benazepril**

**XM7169      Angiotensin II antagonists**

**XM7DY0      Losartan**

**XM2F90      Eprosartan**

**XM29M2      Valsartan**

**XM1935      Irbesartan**

**XM0T42      Tasosartan**

**XM4168      Candesartan**

**XM2P63      Telmisartan**

**XM1B39      Olmesartan medoxomil**

**XM5GC5      Azilsartan**

<b>XM2T51</b>	Fimasartan
<b>XM3YY8</b>	Alacepril
<b>XM3F15</b>	Trandolapril
<b>XM3DT0</b>	Delapril
<b>XM6DX1</b>	Moexipril
<b>XM25N5</b>	Temocapril

Antihyperlipidemic and antiarteriosclerotic drugs

<b>XM5SK2</b>	<b>HMG CoA reductase inhibitors</b>
<b>XM7AU9</b>	Simvastatin
<b>XM7SM7</b>	Pravastatin
<b>XM72M6</b>	Lovastatin
<b>XM5UF1</b>	Fluvastatin
<b>XM2WF6</b>	Atorvastatin
<b>XM0M94</b>	Cerivastatin
<b>XM6NK5</b>	Rosuvastatin
<b>XM8420</b>	Pitavastatin
<b>XM1KP1</b>	<b>Fibrates</b>
<b>XM19J9</b>	Clofibrate
<b>XM3F75</b>	Bezafibrate
<b>XM7929</b>	Aluminium clofibrate
<b>XM01S9</b>	Gemfibrozil
<b>XM73E0</b>	Fenofibrate
<b>XM6MW5</b>	Simfibrate
<b>XM39Z8</b>	Ronifibrate
<b>XM9HU7</b>	Ciprofibrate
<b>XM4390</b>	Etofibrate
<b>XM93U8</b>	Clofibrate
<b>XM9554</b>	Choline fenofibrate
<b>XM1W44</b>	<b>Bile acid sequestrants</b>
<b>XM0HQ4</b>	Colestyramine

<b>XM0KK8</b>	<b>Colestipol</b>
<b>XM5RQ3</b>	<b>Colextran</b>
<b>XM6MC3</b>	<b>Colesevelam</b>
<b>XM0563</b>	<b>Nicotinic acid and derivatives</b>
	<i>Coded Elsewhere:</i> Nicotinyl alcohol (XM0274)
	Nicofuranose (XM5TA2)
	Niacin (XM3PK2)
<b>XM5QD1</b>	<b>Inositol nicotinate</b>
<b>XM48Y3</b>	<b>Ciclonicate</b>
<b>XM6QT0</b>	<b>Acipimox</b>
<b>XM2KX4</b>	<b>Oxiniacic acid</b>
<b>XM3N68</b>	<b>Antiarteriosclerotic drug</b>
<b>XM2EA3</b>	<b>Anticholesterolemic drug</b>
<b>XM3108</b>	<b>Antihyperlipidemic drug</b>
<b>XM4FN5</b>	<b>Antilipemic drug</b>
<b>XM2GM2</b>	<b>b-benzalbutyramide</b>
<b>XM4KW6</b>	<b>b-sitosterol (s)</b>
<b>XM6BA8</b>	<b>Benzalbutyramide</b>
<b>XM4WS4</b>	<b>Benzyl nicotinate</b>
<b>XM43X4</b>	<b>Binifibrate</b>
<b>XM35X4</b>	<b>Cholesterol-lowering agents</b>
<b>XM8FB5</b>	<b>Cholestyramine (resin)</b>
<b>XM2LR7</b>	<b>Clinofibrate</b>
<b>XM6DX0</b>	<b>Clofibrlic acid</b>
<b>XM2R17</b>	<b>Cyamopsis tetragono-loba</b>
<b>XM8K49</b>	<b>Detaxtran</b>
<b>XM8FC2</b>	<b>Ethylparachlorophen-oxyisobutyrate</b>
<b>XM0TN1</b>	<b>Etiroxate</b>
<b>XM6B07</b>	<b>Etofylline clofibrate</b>
<b>XM6DW9</b>	<b>Guar gum (medicinal)</b>

<b>XM4E46</b>	<b>Halofenate</b>
<b>XM2WA3</b>	<b>Ion exchange resin cholestyramine</b>
<b>XM0H99</b>	<b>Linoleic acid</b>
<b>XM5VN6</b>	<b>Linolenic acid</b>
<b>XM0KD7</b>	<b>Mesoglycan</b>
<b>XM45F6</b>	<b>Oleic acid</b>
<b>XM68L2</b>	<b>Pirozadil</b>
<b>XM1Q10</b>	<b>Polidexide sulfate</b>
<b>XM4UK3</b>	<b>Probucol</b>
<b>XM2YX6</b>	<b>Safflower oil</b>
<b>XM5F26</b>	<b>Sitosterols</b>
<b>XM2LX5</b>	<b>Soysterol</b>
<b>XM3C43</b>	<b>Sunflower seed oil</b>
<b>XM95B1</b>	<b>Triparanol</b>
<b>XM3PL9</b>	<b>Unsaturated fatty acid</b>
<b>XM2KC4</b>	<b>Omega-3-triglycerides</b>
<b>XM2AL6</b>	<b>Tiadenol</b>
<b>XM44B6</b>	<b>Meglutol</b>
<b>XM10P8</b>	<b>Magnesium pyridoxal 5-phosphate glutamate</b>
<b>XM9HP8</b>	<b>Policosanol</b>
<b>XM5BK7</b>	<b>Ezetimibe</b>
<b>XM52K4</b>	<b>Alipogene tiparvovec</b>
<b>XM7049</b>	<b>Mipomersen</b>
<b>XM3RL5</b>	<b>Lomitapide</b>
<b>XM9F64</b>	<b>Evolocumab</b>
<b>XM1LB0</b>	<b>Alirocumab</b>
<b>XM2KT4</b>	<b>Evinacumab</b>
<b>XM4RG7</b>	<b>Volanesorsen</b>

Calcium-channel blockers

<b>XM8BT9</b>	<b>Selective calcium-channel blockers</b>
<b>XM3D74</b>	<b>Dihydropyridine derivatives</b>
<b>XM1BZ0</b>	Felodipine
<b>XM1SC0</b>	Isradipine
<b>XM3L32</b>	Nicardipine
<b>XM3N90</b>	Nifedipine
<b>XM5TX8</b>	Nimodipine
<b>XM5W45</b>	Nisoldipine
<b>XM17Z8</b>	Nitrendipine
<b>XM2QH8</b>	Lacidipine
<b>XM68M5</b>	Amlodipine
<b>XM6PC3</b>	Nilvadipine
<b>XM3GA2</b>	Manidipine
<b>XM84M5</b>	Barnidipine
<b>XM3MV9</b>	Lercanidipine
<b>XM3TF3</b>	Cilnidipine
<b>XM8EW6</b>	Benidipine
<b>XM5GS7</b>	Clevidipine
<b>XM91L4</b>	Levamlodipine
<b>XM2XU6</b>	<b>Phenylalkylamine derivatives - selective</b>
<b>XM5GX3</b>	Verapamil
<b>XM2WH6</b>	Gallopamil
<b>XM6GX5</b>	Mibepradil
<b>XM5K59</b>	Diltiazem
<b>XM1EL1</b>	Tiapamil
<b>XM3BC0</b>	Oxodipine
<b>XM2JS2</b>	<b>Non-selective calcium-channel blockers</b>
<b>XM6T88</b>	<b>Phenylalkylamine derivatives - non-selective</b>
<b>XM1LR8</b>	Bepridil

<b>XM5BR3</b>	Fendiline
<b>XM3NU8</b>	<b>Lidoflazine</b>
<b>XM0T83</b>	<b>Moxonidine hydrochloride</b>

Cardiac stimulants

**Coded Elsewhere:** Alpha- and beta-adrenoreceptor agonists (XM36U7)

Strophanthin-k (XM9QZ9)

Strophanthus gratus plant (XM9834)

<b>XM5JS3</b>	<b>Cardiac glycosides</b>
---------------	---------------------------

<b>XM2EL5</b>	<b>Digitalis glycosides</b>
---------------	-----------------------------

<b>XM0QK0</b>	Acetyldigitoxin
---------------	-----------------

<b>XM1640</b>	Acetyldigoxin
---------------	---------------

<b>XM2GT4</b>	Digitalis leaves
---------------	------------------

<b>XM8VJ6</b>	Digoxin
---------------	---------

<b>XM13W9</b>	Digitoxin
---------------	-----------

<b>XM8036</b>	Lanatoside C
---------------	--------------

<b>XM8XH2</b>	Deslanoside
---------------	-------------

<b>XM37V6</b>	Metildigoxin
---------------	--------------

<b>XM2505</b>	Gitoformate
---------------	-------------

<b>XM71V6</b>	<b>Scilla glycosides</b>
---------------	--------------------------

<b>XM1EG1</b>	Proscillarin
---------------	--------------

<b>XM6GX1</b>	<b>Strophanthus glycosides</b>
---------------	--------------------------------

<b>XM30Z9</b>	Cymarin
---------------	---------

<b>XM9YU9</b>	g-Strophanthin
---------------	----------------

<b>XM3WU3</b>	Peruvoside
---------------	------------

<b>XM2PQ4</b>	<b>Phosphodiesterase inhibitors</b>
---------------	-------------------------------------

<b>XM0QD0</b>	Amrinone
---------------	----------

<b>XM6JT4</b>	Milrinone
---------------	-----------

<b>XM2H68</b>	Enoximone
---------------	-----------

<b>XM4BC1</b>	Bucladesine
---------------	-------------

<b>XM1K71</b>	<b>Predominantly alpha-adrenoreceptor and dopamine receptor agonists</b> <b>Coded Elsewhere:</b> Dopamine agonists (XM5QR9-XM50V4)
<b>XM9NM4</b>	<b>Dopamine</b>
<b>XM2A75</b>	<b>Norfenefrine</b>
<b>XM5HS9</b>	<b>Oxedrine</b>
<b>XM6L38</b>	<b>Metaraminol</b>
<b>XM2CG2</b>	<b>Methoxamine</b>
<b>XM4B54</b>	<b>Gepefrine</b>
<b>XM1641</b>	<b>Ibopamine</b>
<b>XM6LP2</b>	<b>Dimetofrine</b>
<b>XM4ZY2</b>	<b>Dopexamine</b>
<b>XM79K5</b>	<b>Midodrine</b>
<b>XM91X4</b>	<b>Fenoldopam</b>
<b>XM2BX9</b>	<b>Cafedrine</b>
<b>XM1CS6</b>	<b>Theodrenaline</b>
<b>XM9QY5</b>	<b>Dexmedetomidine</b>
<b>XM38P3</b>	<b>Amidefrine mesilate</b>
<b>XM7AV8</b>	<b>Fenoxyazoline</b>
<b>XM0H59</b>	<b>Indanazoline</b>
<b>XM5J98</b>	<b>Metizoline</b>
<b>XM3Q12</b>	<b>Naphazoline</b>
<b>XM4KH5</b>	<b>Oxymetazoline</b>
<b>XM4435</b>	<b>Propylhexedrine</b>
<b>XM1RJ9</b>	<b>Tramazoline</b>
<b>XM8706</b>	<b>Tuaminoheptane</b>
<b>XM0240</b>	<b>Tymazoline</b>
<b>XM8US0</b>	<b>Xylocastazoline</b>

Predominantly beta-adrenoreceptor agonists

<b>XM96M5</b>	<b>Agonist predominantly beta-adrenoreceptor</b>
<b>XM10L5</b>	<b>Angiotensin</b>

<b>XM3D85</b>	<b>Beclomethasone</b>
<b>XM4E14</b>	<b>Dobutamine</b>
<b>XM18Q9</b>	<b>Prenalterol</b>
<b>XM5HL3</b>	<b>Racepinephrine</b>
<b>XM1CS3</b>	<b>Ritodrine</b>
<b>XM1X48</b>	<b>Selective beta-2-adrenoceptor agonists</b>
<b>XM8MA0</b>	<b>Salbutamol</b>
<b>XM6NE3</b>	<b>Terbutaline</b>
<b>XM2HS2</b>	<b>Fenoterol</b>
<b>XM3NS3</b>	<b>Clenbuterol</b>
<b>XM7MM4</b>	<b>Reprotoanol</b>
<b>XM2YD0</b>	<b>Procaterol</b>
<b>XM15R7</b>	<b>Bitolterol</b>
<b>XM2U16</b>	<b>Bambuterol</b>
<b>XM51C1</b>	<b>Indacaterol</b>
<b>XM1QR3</b>	<b>Olodaterol</b>
<b>XM05Y4</b>	<b>Broxaterol</b>
<b>XM4ZB3</b>	<b>Carbuterol</b>
<b>XM22C3</b>	<b>Rimiterol</b>
<b>XM1GA5</b>	<b>Hexoprenaline</b>
<b>XM8ZC3</b>	<b>Isoetarine</b>
<b>XM1QR7</b>	<b>Pirbuterol</b>
<b>XM3GQ2</b>	<b>Tretoquinol</b>
<b>XM2YE0</b>	<b>Tulobuterol</b>
<b>XM6B34</b>	<b>Salmeterol</b>
<b>XM27W7</b>	<b>Clorprenaline</b>
<b>XM4YX5</b>	<b>Etafedrine</b>
<b>XM55D7</b>	<b>Ibutterol</b>
<b>XM6EU7</b>	<b>Levalbuterol</b>
<b>XM0QJ7</b>	<b>Formoterol</b>

<b>XM6KG3</b>	<b>Isoprenaline</b>
<b>XM6AG0</b>	<b>Orciprenaline</b>
<b>XM78W6</b>	<b>Methoxyphenamine</b>
<b>XM9TS0</b>	<b>Octopamine</b>
<b>XM17S3</b>	<b>Arbutamine</b>
<b>XM0FE9</b>	<b>Protokylol</b>
<b>XM7YK1</b>	<b>Alpha acetyldigoxin</b>
<b>XM0SY1</b>	<b>b-acetyldigoxin</b>
<b>XM91S1</b>	<b>Cardiotonic (glycoside)</b>
<b>XM1W74</b>	<b>Cerberin</b>
<b>XM5NG4</b>	<b>Ch'an su</b>
<b>XM11U7</b>	<b>Convallaria glycosides</b>
<b>XM4Q19</b>	<b>Crataegus extract</b>
<b>XM7RY5</b>	<b>Digitalin (e)</b>
<b>XM2SP4</b>	<b>Digitalis lanata</b>
<b>XM3Y64</b>	<b>Digitalis purpurea</b>
<b>XM0V98</b>	<b>Digitoxose</b>
<b>XM0DG3</b>	<b>Gitalin</b>
<b>XM8K74</b>	<b>Gitaloxin</b>
<b>XM7KP5</b>	<b>Lanatosides</b>
<b>XM2X57</b>	<b>Meproscillarin</b>
<b>XM6AA6</b>	<b>Oleandrin</b>
<b>XM0N63</b>	<b>Ouabain (e)</b>
<b>XM02F5</b>	<b>Pengitoxin</b>
<b>XM77L9</b>	<b>Squill</b>
<b>XM2AW9</b>	<b>Strophanthin</b>
<b>XM0EP6</b>	<b>Angiotensinamide</b>
<b>XM45U9</b>	<b>Xamoterol</b>
<b>XM88B5</b>	<b>Levosimendan</b>

**XM11H1      Angiotensin II**

Antiarrhythmics

**XM2FU1      Antiarrhythmics, class Ia****XM8AL5**      Quinidine**XM4MK3**      Procainamide**XM8B35**      Disopyramide**XM9ZC0**      Sparteine**XM5CS7**      Ajmaline**XM18V8**      Lorajmine**XM0D87**      Hydroquinidine**XM6FW1**      Prajmaline**XM7844      Antiarrhythmics, class Ib****XM2BR1**      Lidocaine**XM93V0**      Lidocaine regional**XM4RU4**      Lidocaine spinal**XM3XK1**      Mexiletine**XM1V81**      Tocainide**XM37J0**      Aprindine**XM0NC9      Antiarrhythmics, class Ic****XM9R82**      Propafenone**XM1E38**      Flecainide**XM04P2**      Lorcainide**XM6TZ8**      Encainide**XM23Q8**      Ethacizine**XM1AP6      Antiarrhythmics, class III****XM3ZJ7**      Amiodarone**XM3ZG2**      Bretylium tosilate**XM56N7**      Bunaftine**XM1143**      Dofetilide

<b>XM8AA1</b>	Ibutilide
<b>XM8QN8</b>	Tedisamil
<b>XM8K75</b>	Dronedarone
<b>XM5JW0</b>	<b>Other antiarrhythmics, class I and III</b>
<b>XM1SV2</b>	Cibenzoline
<b>XM6KX7</b>	Moracizine
<b>XM6602</b>	Vernakalant
<b>XM0KK7</b>	<b>Antidysrhythmic</b>
<b>XM9ZL3</b>	<b>Cardiac depressants</b>
<b>XM2W76</b>	<b>Cardiac rhythm regulator specified</b>
<b>XM88L7</b>	<b>Cardiac rhythm regulator</b>
<b>XM0Y13</b>	Pilsicainide
<b>XM64X0</b>	Prajmalium bitartrate
<b>XM1NG6</b>	Quinaglute
<b>XM7MH8</b>	Tiracizine

Other antihypertensive drugs

<b>XM4X84</b>	<b>Centrally acting antiadrenergic agents</b>
<b>XM67X4</b>	Rauwolfia alkaloids
<b>XM9SB3</b>	Rescinnamine
<b>XM7424</b>	Deserpidine
<b>XM0ND0</b>	Methoserpidine
<b>XM2764</b>	Reserpine
<b>XM39Z4</b>	Rauwolfia alkaloids, whole root
<b>XM64M5</b>	Bietaserpine
<b>XM9G49</b>	<b>Methyldopa</b>
<b>XM54Y3</b>	Methyldopa, levorotatory
<b>XM9ZV9</b>	Methyldopa, racemic
<b>XM2298</b>	<b>Imidazoline receptor agonists</b>
<b>XM6GV8</b>	Clonidine

**XM5KP4** Guanfacine

**XM9SU8** Tolonidine

**XM4NH5** Moxonidine

**XM6AB8** Rilmenidine

**XM7NT3 Ganglion-blocking antiadrenergic agents**

*Coded Elsewhere:* Trimethaphan (XM4BZ9)

Mecamylamine (XM13Z0)

**XM8SX7 Peripherally acting antiadrenergic agents**

*Coded Elsewhere:* Alpha-adrenoreceptor antagonists (XM45W7-XM1FQ5)

**XM3EN5 Guanidine derivatives**

**XM8LD0** Betanidine

**XM3QD6** Guanethidine

**XM3952** Guanoxan

**XM4L51** Debrisoquine

**XM4189** Guanoclor

**XM4L63** Guanoxabenz

**XM6N54** Guanzodine

**XM9M92** Ripasudil

**XM1AF9 Agents affecting arteriolar smooth muscle**

*Coded Elsewhere:* Minoxidil (XM46T4)

Pinacidil (XM9PA9)

**XM7XR3 Thiazide derivatives**

**XM8YG1** Diazoxide

**XM9021 Hydrazinophthalazine derivatives**

**XM2FP9** Dihydralazine

**XM8D89** Hydralazine

**XM1KN9** Endralazine

**XM33U1** Cadralazine

**XM8V56 Antihypertensives for pulmonary arterial hypertension**

**XM4KA3** Bosentan

**XM8HR5** Ambrisentan

<b>XM7WR2</b>	Sitaxentan
<b>XM21T1</b>	Macitentan
<b>XM8BU0</b>	Riociguat
<b>XM4NN7</b>	<b>Alkavervir</b>
<b>XM28Y3</b>	<b>Alseroxylon</b>
<b>XM6T97</b>	<b>Amiquinsin</b>
<b>XM3WP0</b>	<b>Antagonist serotonin</b>
<b>XM2PT6</b>	<b>Antihypertensive drug</b>
<b>XM0CY8</b>	<b>Apresoline</b>
<b>XM4FW8</b>	<b>Benazepril hydrochloride</b>
<b>XM5E71</b>	<b>Budralazine</b>
<b>XM9W04</b>	<b>Cryptenamine (tannates)</b>
<b>XM1TT7</b>	<b>DHE 45</b>
<b>XM24X9</b>	<b>Dihydrazine</b>
<b>XM7NV2</b>	<b>Guanabenz</b>
<b>XM5ET8</b>	<b>Guanacline</b>
<b>XM5JL6</b>	<b>Guanadrel</b>
<b>XM7TE8</b>	<b>Guanoctine</b>
<b>XM1LN2</b>	<b>Harmonyl</b>
<b>XM4EP4</b>	<b>Hypotensive drug</b>
<b>XM7W35</b>	<b>Methyldopate</b>
<b>XM1F18</b>	<b>Metirosine</b>
<b>XM7HA8</b>	<b>Moderil</b>
<b>XM1U35</b>	<b>Pargyline</b>
<b>XM1GS9</b>	<b>Protoveratrine (s) (A) (B)</b>
<b>XM01D4</b>	<b>Raudixin</b>
<b>XM74W2</b>	<b>Rautina</b>
<b>XM5FH0</b>	<b>Rautotal</b>
<b>XM5PW7</b>	<b>Rauwoldin</b>

<b>XM00F2</b>	<b>Saralasin</b>
<b>XM6E07</b>	<b>Serpasil</b>
<b>XM2W66</b>	<b>Sodium nitroprusside</b>
<b>XM8AK5</b>	<b>Syrosingopine</b>
<b>XM3HS0</b>	<b>Teprotide</b>
<b>XM5T36</b>	<b>Todralazine</b>
<b>XM48R9</b>	<b>Veratrine</b>
<b>XM8BQ9</b>	<b>Veratrum</b>
<b>XM0YY0</b>	<b>Ketanserin</b>

Vasodilators used in cardiac diseases

<b>XM2856</b>	<b>Organic nitrates</b>
<b>XM8LK8</b>	<b>Glyceryl trinitrate</b>
<b>XM7KD0</b>	<b>Pentaerythrityl tetranitrate</b>
<b>XM0DY4</b>	<b>Propatylnitrate</b>
<b>XM3077</b>	<b>Isosorbide dinitrate</b>
<b>XM55H8</b>	<b>Trolnitrate</b>
<b>XM8SP5</b>	<b>Eritrityl tetranitrate</b>
<b>XM5KH9</b>	<b>Tenitramine</b>
<b>XM9UE1</b>	<b>Methylpropylpropanediol dinitrate</b>
<b>XM01Q8</b>	<b>Isosorbide</b>
<b>XM6801</b>	<b>Amikhelline</b>
<b>XM5QW3</b>	<b>Bendazol</b>
<b>XM3K91</b>	<b>Benziodarone</b>
<b>XM38C7</b>	<b>Carbocromen</b>
<b>XM38U6</b>	<b>Coronary vasodilator</b>
<b>XM0SG8</b>	<b>Cromonar</b>
<b>XM0MW9</b>	<b>Diisopropylamine</b>
<b>XM1E15</b>	<b>Dilazep</b>
<b>XM8Q26</b>	<b>Dimoxylene</b>

XM5M47	<b>Efloxate</b>
XM3ZB0	<b>Etafenone</b>
XM3E93	<b>Fenalcomine</b>
XM6QE9	<b>Fluorosol</b>
XM8Y13	<b>Heptaminol</b>
XM4A49	<b>Hexadiline</b>
XM5MP5	<b>Hexobendine</b>
XM5B68	<b>Isoamyl nitrite</b>
XM5BS6	<b>Itramin tosilate</b>
XM9PV4	<b>Khellin</b>
XM39T6	<b>Khelloside</b>
XM30P9	<b>Mannitol hexanitrate</b>
XM5720	<b>Molsidomine</b>
XM7HW6	<b>Nicorandil</b>
XM5YX5	<b>Nitrite, amyl (medicinal) (vapor)</b>
XM4J35	<b>Nitrous ether spirit</b>
XM1VC4	<b>Octyl nitrite</b>
XM0A82	<b>Organonitrate</b>
XM5YA6	<b>Oxyfedrine</b>
XM2N57	<b>Pentaerythritol</b>
XM3VX9	<b>Pentrinat</b>
XM7F31	<b>Perhexiline</b>
XM7FE6	<b>Piridoxilate</b>
XM4K89	<b>Prenylamine</b>
XM2BJ0	<b>Sweet niter spirit</b>
XM24R2	<b>Trapidil</b>
XM5770	<b>Triethanolamine trinitrate (biphosphate)</b>
XM8YZ8	<b>Trinitrine</b>
XM23M8	<b>Flosequinan</b>

<b>XM6V17</b>	<b>Imolamine</b>
<b>XM0UA6</b>	<b>Cinepazet</b>
<b>XM30L8</b>	<b>Cloridarol</b>
<b>XM5AY1</b>	<b>Linsidomine</b>
<b>XM2460</b>	<b>Nesiritide</b>
<b>XM1M18</b>	<b>Serelaxin</b>
<b>XM2VG8</b>	<b>Regadenoson</b>
<b>XM1HP8</b>	<b>Meldonium</b>

Peripheral vasodilators

**Coded Elsewhere:** Nicotinic acid and derivatives (XM0563)

<b>XM6G82</b>	<b>Tadalafil</b>
<b>XM9AZ1</b>	<b>Vardenafil</b>
<b>XM65A3</b>	<b>Sildenafil</b>
<b>XM7DC4</b>	<b>Aluminium nicotinate</b>
<b>XM1269</b>	<b>Azapetine</b>
<b>XM3GB4</b>	<b>Bencyclane</b>
<b>XM3FH5</b>	<b>Brovincamine</b>
<b>XM3B71</b>	<b>Buflomedil</b>
<b>XM6XW8</b>	<b>Butalamine</b>
<b>XM1UQ0</b>	<b>Cetiedil</b>
<b>XM7LH3</b>	<b>Cinepazide</b>
<b>XM16K3</b>	<b>Cyclandelate</b>
<b>XM9Q04</b>	<b>Dihydroergocornine</b>
<b>XM7K86</b>	<b>Dihydroergokryptine</b>
<b>XM3WW1</b>	<b>Dihydroergotoxine</b>
<b>XM9CH9</b>	<b>Etofylline</b>
<b>XM8317</b>	<b>Heprionate</b>
<b>XM2LT4</b>	<b>Hydromethylpyridine</b>
<b>XM86J1</b>	<b>Ifenprodil</b>

<b>XM8MZ0</b>	<b>Kallidinogenase</b>
<b>XM5TC7</b>	<b>Kallikrein</b>
<b>XM6F75</b>	<b>Lipo-alprostadiol</b>
<b>XM46T4</b>	<b>Minoxidil</b>
<b>XM8YE5</b>	<b>Moxislyte</b>
<b>XM3J93</b>	<b>Naftidrofuryl</b>
<b>XM3PK2</b>	<b>Niacin</b>
<b>XM2GA2</b>	<b>Nicametate</b>
<b>XM5TA2</b>	<b>Nicotofuranose</b>
<b>XM0274</b>	<b>Nicotinyl alcohol</b>
<b>XM6B85</b>	<b>Nyldrin</b>
<b>XM12T2</b>	<b>Phenoxybenzamine</b>
<b>XM67M9</b>	<b>Prostaglandin E1</b>
<b>XM1B47</b>	<b>Raubasine</b>
<b>XM9761</b>	<b>Suloctidil</b>
<b>XM07V4</b>	<b>Tetranicotinoyl fructose</b>
<b>XM4074</b>	<b>Thurfyl nicotinate</b>
<b>XM79S2</b>	<b>Thymoxamine</b>
<b>XM1UM9</b>	<b>Vasodilan</b>
<b>XM3LG1</b>	<b>Vinburnine</b>
<b>XM51E4</b>	<b>Viquidil</b>
<b>XM0122</b>	<b>Xanthinol nicotinate</b>
<b>XM0BT5</b>	<b>2-amino-1-phenylethanol derivatives</b>
<b>XM5RH0</b>	<b>Isoxsuprine</b>
<b>XM0HU4</b>	<b>Bamethan</b>
<b>XM0B82</b>	<b>Imidazoline derivatives</b>
<b>XM5NP2</b>	<b>Phentolamine</b>
<b>XM3BY1</b>	<b>Tolazoline</b>
<b>XM5NF4</b>	<b>Purine derivatives</b>

<b>XM5RL7</b>	<b>Pentifylline</b>
<b>XM91G7</b>	<b>Xantinol nicotinate</b>
<b>XM8BD1</b>	<b>Pentoxifylline</b>
<b>XM0JV4</b>	<b>Etofylline nicotinate</b>
<b>XM9PA9</b>	<b>Pinacidil</b>
<b>XM3VH9</b>	<b>Vincamine</b>
<b>XM68C7</b>	<b>Visnadine</b>
<b>XM0XY6</b>	<b>Ergot alkaloids</b>
<b>XM0U65</b>	<b>Ergoloid mesylates</b>
<b>XM5TD8</b>	<b>Nicergoline</b>
<b>XM0TP6</b>	<b>Dihydroergocristine (mesilate)</b>
<b>XM93Q7</b>	<b>Methylergometrine</b>
<b>XM3LX6</b>	<b>Ergometrine</b>
<b>XM5P25</b>	<b>Ergotamine</b>
<b>XM4G36</b>	<b>Methysergide</b>
<b>XM4E49</b>	<b>Lisuride</b>
<b>XM4CT2</b>	<b>fasudil</b>
<b>XM5021</b>	<b>Yohimbine</b>
<b>XM1WB2</b>	<b>Avanafil</b>
<b>XM4914</b>	<b>Udenafil</b>

Other agents primarily affecting the cardiovascular system

**Coded Elsewhere:** Aconitine (XM2WR7)

- Aconitum ferox plant (XM3VB6)
- Aconitum plant (XM99Y1)
- Prostaglandins (XM4ML1)

<b>XM20Z9</b>	<b>Adrenochrome semicarbazone (mono)</b>
<b>XM7NH6</b>	<b>Adrenochrome derivative</b>
<b>XM8ZY5</b>	<b>Aurantiin</b>
<b>XM6YS0</b>	<b>Benzopyrone</b>
<b>XM3LU4</b>	<b>Calcium dobesilate</b>

<b>XM53V8</b>	<b>Chlorisondamine chloride</b>
<b>XM1H36</b>	<b>Escin</b>
<b>XM8AB2</b>	<b>Ethoxazorutoside</b>
<b>XM6BM1</b>	<b>Flavodic acid</b>
<b>XM0WZ5</b>	<b>Hesperidin</b>
<b>XM63M1</b>	<b>Leucocianidol</b>
<b>XM4U20</b>	<b>Metescufylline</b>
<b>XM6102</b>	<b>Phenopyrazone</b>
<b>XM6EY7</b>	<b>Pholedrine</b>
<b>XM62Q1</b>	<b>Adenosine</b>
<b>XM3PB7</b>	<b>Trimetazidine</b>
<b>XM5FW1</b>	<b>Camphora</b>
<b>XM7F77</b>	<b>Crataegus glycosides</b>
<b>XM6619</b>	<b>Creatinolfosfate</b>
<b>XM8R77</b>	<b>Fosfocreatine</b>
<b>XM2PV3</b>	<b>Fructose 1,6-diphosphate</b>
<b>XM4MP2</b>	<b>Ubidecarenone</b>
<b>XM2UJ1</b>	<b>Acadesine</b>
<b>XM09Q3</b>	<b>Ivabradine</b>
<b>XM9DF5</b>	<b>Ranolazine</b>
<b>XM2DH5</b>	<b>Tiazotic acid</b>

#### Vasoprotectives

<b>XM50P4</b>	<b>Capillary stabilising agents</b>
<b>XM41G5</b>	<b>Bioflavonoids</b>
<b>XM5734</b>	<b>Rutoside</b>
<b>XM6UE1</b>	<b>Diosmin</b>
<b>XM71U2</b>	<b>Troxerutin</b>
<b>XM7EF1</b>	<b>monoxerutin</b>
<b>XM2SA0</b>	<b>hidrosmin</b>

<b>XM6N03</b>	<b>Tribenoside</b>
<b>XM1PT0</b>	<b>Naftazone</b>
<b>XM0MJ2</b>	<b>Hippocastani semen</b>
<b>XM93T6</b>	<b>Esculin</b>

Agents used in antivaricose therapy

<b>XM0NL5</b>	<b>Antivaricose drug</b>
<b>XM57B0</b>	<b>Dextrose concentrated solution, intravenous</b>
<b>XM1ME2</b>	<b>Ethanolamine oleate</b>
<b>XM6C05</b>	<b>Phenol in oil injection</b>
<b>XM9854</b>	<b>Sclerosing agent</b>
<b>XM3846</b>	<b>Sodium morrhuate</b>
<b>XM52L8</b>	<b>Sodium psylliate</b>
<b>XM2N32</b>	<b>Sodium tetradecyl sulfate</b>
<b>XM1LV9</b>	<b>Varicose reduction drug</b>
<b>XM3FL1</b>	<b>Venous sclerosing drug</b>
<b>XM4J29</b>	<b>Zinc antivaricose</b>
<b>XM3WS8</b>	<b>Monoethanolamine</b>
<b>XM4DD8</b>	<b>Polidocanol</b>
<b>XM81W1</b>	<b>Sotradecol</b>

Drugs primarily affecting the autonomic nervous system

Adrenergic agonists

**Coded Elsewhere:** Predominantly alpha-adrenoreceptor and dopamine receptor agonists (XM1K71)  
Predominantly beta-adrenoreceptor agonists (XM96M5-XM0FE9)

<b>XM36U7</b>	<b>Alpha- and beta-adrenoreceptor agonists</b>
<b>XM9187</b>	<b>Etilefrine</b>
<b>XM6RQ3</b>	<b>Mephentermine</b>
<b>XM3273</b>	<b>Epinephrine</b>
<b>XM10F0</b>	<b>Amezinium metilsulfate</b>

XM5H72	Ephedrine
XM7B75	Droxidopa
XM9K94	Ethylnorepinephrine
XM1H52	Cinnamedrine
<b>XM3LR7</b>	<b>Predominantly alpha-adrenoreceptor agonists</b>
XM39Y4	Thenyldiamine
XM2V55	Phenyltoloxamine
XM7D21	Paredrine
XM81D8	Norepinephrine
XM7RF2	Moxastine
XM8TK4	Methaphenilene
XM4TB9	Levocabastine (hydrochloride)
XM2305	Homochlorcyclizine
XM59T1	Embramine
XM8ZH9	Dimenhydrinate
XM29D4	Difenidol
XM62B0	Dibenzheptropine
XM8Y26	Cyclopentamine
XM0Y33	Clemizole
XM4PH8	Chlorothen
XM66X7	Chlor-Trimeton
XM0AN5	Cetoxime
XM88Z7	Bisulepin (hydrochloride)
XM35M7	Benzquinamide
XM25T0	Apraclonidine (hydrochloride)
XM0W81	Antistine
XM6XN3	Phenylpropanolamine
XM6ZQ3	Phenylephrine
XM0CL2	Pseudoephedrine

Adrenergic antagonists

Alpha-adrenoreceptor antagonists

XM45W7	Prazosin
XM3L37	Indoramin
XM58X5	Doxazosin
XM30L7	Urapidil
XM2L44	Alpha adrenergic blocking drug
XM6MJ9	Bunazosin
XM4UW6	Dibenamine
XM70W7	Dibenzylidine
XM3Y81	Hydergine
XM81R1	Priscol, Priscoline
XM3F82	Tamsulosin
XM9LH2	Terazosin
XM1C94	Alfuzosin
XM7D19	Trimazosin
XM1FQ5	Silodosin

Beta-adrenoreceptor antagonists

XM7R98	Beta-adrenoreceptor antagonists, non selective
XM2YK6	Alprenolol
XM0M15	Oxprenolol
XM2SH3	Pindolol
XM3HA9	Propranolol
XM1KQ9	Timolol
XM5BT4	Sotalol
XM69F3	Nadolol
XM89L8	Mepindolol
XM1AJ9	Carteolol

XM6489	Tertatolol
XM79L8	Bopindolol
XM9RX1	Bupranolol
XM17Y6	Penbutolol
XM2M62	Cloranolol
<b>XM9MF0</b>	<b>Beta-adrenoreceptor antagonists, selective</b>
XM9VG1	Practolol
XM8L21	Metoprolol
XM0M62	Atenolol
XM0V36	Acebutolol
XM7U87	Betaxolol
XM0HY3	Bevantolol
XM8QC9	Bisoprolol
XM54E1	Celiprolol
XM4AB1	Esmolol
XM1T80	Epanolol
XM7115	S-atenolol
XM0995	Nebivolol
XM3156	Talinolol
XM44F9	Landiolol
<b>XM5S93</b>	<b>Beta adrenergic blocking agent, heart</b>
<b>XM8026</b>	<b>Bunitrolol</b>
<b>XM3N87</b>	<b>Carazolol</b>
<b>XM7V19</b>	<b>Indenolol</b>
<b>XM91L7</b>	<b>Pronetalol</b>
<b>XM77W2</b>	<b>Tolamolol</b>
<b>XM77E7</b>	<b>Alpha and beta blocking agents, antagonists</b>
XM8ER3	Labetalol
XM80G6	Carvedilol
XM0TY3	Medroxalol

Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics

<b>XM9FY5</b>	<b>Agents predominantly used for gastrointestinal disorders</b>
<b>XM8921</b>	<b>Synthetic anticholinergics, esters with tertiary amino group</b>
<b>XM5D56</b>	Oxyphencyclimine
<b>XM5RM7</b>	Camylofin
<b>XM90R8</b>	Mebeverine
<b>XM0EL4</b>	Trimebutine
<b>XM7GS6</b>	Rociverine
<b>XM0CE0</b>	Dicycloverine
<b>XM24K8</b>	Piperidolate
<b>XM1LM4</b>	Oxyphenonium
<b>XM05C6</b>	Propantheline
<b>XM8YF7</b>	Otilonium bromide
<b>XM5WL4</b>	Methantheline
<b>XM6XN4</b>	Isopropamide
<b>XM1WN2</b>	Hexocyclium
<b>XM7EV5</b>	Poldine
<b>XM7W33</b>	Mepenzolate
<b>XM6FV2</b>	Pipenzolate
<b>XM63B0</b>	Bevonium
<b>XM4SN3</b>	Dihexyverine
<b>XM2043</b>	Difemerine
<b>XM26J4</b>	<b>Synthetic anticholinergics, quaternary ammonium compounds</b>
<b>XM2WF7</b>	(2-benzhydryloxyethyl)diethyl-methylammonium iodide
<b>XM2LU4</b>	Tiemonium iodide
<b>XM6X69</b>	Prifinium bromide
<b>XM51J2</b>	Timepidium bromide
<b>XM7XV6</b>	Benzilone
<b>XM4LY7</b>	Tridihexethyl
<b>XM0D83</b>	Fenpiverinium

<b>XM7W64</b>	<b>Synthetic antispasmodics, amides with tertiary amines</b>
<b>XM4VE1</b>	Dimethylaminopropionylphenothiazine
<b>XM5LN3</b>	Nicofetamide
<b>XM36J3</b>	Tiopramide
<b>XM7FH3</b>	<b>Papaverine and derivatives</b>
<b>XM8X70</b>	Papaverine
<b>XM13K8</b>	Drotaverine
<b>XM1V30</b>	Moxaverine
<b>XM6089</b>	<b>Belladonna alkaloids and derivatives</b>
<b>XM7Y01</b>	Atropine
<b>XM11J9</b>	Hyoscyamine
<b>XM4P67</b>	Methylatropine
<b>XM0PN2</b>	Cimetropium bromide
<b>XM1642</b>	Homatropine methylbromide
<b>XM1MW1</b>	Scopolamine
<b>XM0QS6</b>	Butylscopolamine
<b>XM3068</b>	Methylscopolamine
<b>XM08K5</b>	Fentonium
<b>XM1JA8</b>	<b>Agents predominantly used for urinary frequency and incontinence</b>
	<b>Coded Elsewhere:</b> Flavoxate (XM0CH2)
	Emepronium (XM6190)
	Meladrazine (XM0M49)
	Oxybutynin (XM0LB8)
	Terodilime (XM4DW3)
	Propiverine (XM9FU4)
	Tolterodine (XM82U8)
	Solifenacin (XM2Z66)
	Trospium (XM7V08)
	Darifenacin (XM1N89)
	Fesoterodine (XM4265)
	Mirabegron (XM5L72)
	Desfesoterodine (XM5QR7)
<b>XM6WD2</b>	<b>Anticholinergics predominantly used for Parkinson disease</b>

<b>XM8U00</b>	<b>Tertiary amines</b>
<b>XM4RV4</b>	Metixene
<b>XM9W98</b>	Trihexyphenidyl
<b>XM65C9</b>	Biperiden
<b>XM9AG2</b>	Procyclidine
<b>XM8VR6</b>	Profenamine
<b>XM1H88</b>	Dexetimide
<b>XM64K1</b>	Phenglutarimide
<b>XM8T72</b>	Bornaprine
<b>XM4YL9</b>	Tropatepine
<b>XM3FW6</b>	Mazaticol
<b>XM0HT8</b>	Diethazine
<b>XM3B14</b>	<b>Ethers chemically close to antihistamines</b>
<b>XM7U62</b>	Orphenadrine
<b>XM8UB6</b>	Etanautine
<b>XM72C6</b>	<b>Ethers of tropine or tropine derivatives</b>
<b>XM8ZR2</b>	Benzatropine
<b>XM2789</b>	Etybenzatropine
<b>XM0CR7</b>	<b>Emepronium bromide</b>
<b>XM1Q67</b>	<b>Adiphenine</b>
<b>XM0DF0</b>	<b>Ambutonium bromide</b>
<b>XM0TL7</b>	<b>Aminopentamide</b>
<b>XM1Q22</b>	<b>Amprotropine</b>
<b>XM3HR2</b>	<b>Aniscoropine</b>
<b>XM0B31</b>	<b>Anticholinergic</b>
<b>XM5BE4</b>	<b>Antimuscarinic</b>
<b>XM66R0</b>	<b>Artane</b>
<b>XM7LZ6</b>	<b>Atropine derivative</b>
<b>XM5098</b>	<b>Belladonna alkaloids</b>
<b>XM6RQ9</b>	<b>Belladonna extract</b>

<b>XM2YW9</b>	<b>Belladonna herb</b>
<b>XM29D7</b>	<b>Benactyzine</b>
<b>XM3NJ0</b>	<b>Benaprizine</b>
<b>XM54W7</b>	<b>Benzilonium bromide</b>
<b>XM8NZ1</b>	<b>Benztropine anticholinergic</b>
<b>XM5ML2</b>	<b>Butropium bromide</b>
<b>XM1T59</b>	<b>Butyl scopolamine bromide</b>
<b>XM9633</b>	<b>Caramiphen</b>
<b>XM8JS6</b>	<b>Carpronium chloride</b>
<b>XM2619</b>	<b>Clidinium bromide</b>
<b>XM8KY2</b>	<b>Clorotepine</b>
<b>XM2HD0</b>	<b>Cogentin</b>
<b>XM0VC2</b>	<b>Cyclodrine</b>
<b>XM7VB2</b>	<b>Cyclopentolate</b>
<b>XM93T2</b>	<b>Cycrimine</b>
<b>XM4CZ8</b>	<b>Dibutoline sulfate</b>
<b>XM89R5</b>	<b>Diphemanil</b>
<b>XM1M52</b>	<b>Duboisine</b>
<b>XM3A08</b>	<b>Dyphylline</b>
<b>XM17M9</b>	<b>Ethaverine</b>
<b>XM62B7</b>	<b>Etomidoline</b>
<b>XM1VS4</b>	<b>Euphthalmine</b>
<b>XM6L51</b>	<b>Extrapyramidal antagonist</b>
<b>XM3L41</b>	<b>Flopropione</b>
<b>XM8WX2</b>	<b>Hexasonium iodide</b>
<b>XM7832</b>	<b>Homatropine</b>
<b>XM1EF8</b>	<b>Hyoscyamus</b>
<b>XM4FB2</b>	<b>Hyoscyamus dry extract</b>
<b>XM4QH8</b>	<b>Isopropamide iodide</b>

XM5ED5	<b>Levsin</b>
XM0WK8	<b>Mepenzolate bromide</b>
XM1FH6	<b>Mepiperphenidol</b>
XM39X0	<b>Methanthelinium bromide</b>
XM0E13	<b>Methscopolamine bromide</b>
XM3KR9	<b>Methylatropine nitrate</b>
XM14X3	<b>Methylbenactyzium bromide</b>
XM5F96	<b>Milverine</b>
XM3YV6	<b>Muscle affecting agents relaxants smooth</b>
XM4U03	<b>Octatropine methyl-bromide</b>
XM5YT3	<b>Oxapium iodide</b>
XM3A77	<b>Parasympatholytic</b>
XM8U27	<b>Penthienate</b>
XM6MG0	<b>Pipethanate</b>
XM7711	<b>Pramiverine</b>
XM3CK8	<b>Profenil</b>
XM7VK4	<b>Propantheline bromide</b>
XM1JN1	<b>Quaternary ammonium parasympatholytic</b>
XM3UE6	<b>Scopolia extract</b>
XM31L2	<b>Smooth muscle relaxant</b>
XM7PY1	<b>Spacoline</b>
XM14Z1	<b>Spasmolytic anticholinergics</b>
XM6RA6	<b>Spasmolytic autonomic</b>
XM9NH9	<b>Spasmolytic quaternary ammonium</b>
XM0GS2	<b>Thiphenamil</b>
XM9WW9	<b>Tiemonium</b>
XM8346	<b>Tigloidine</b>
XM2595	<b>Tiquizium bromide</b>
XM8YD7	<b>Toquizine</b>

XM64P0	Triampyzine
XM2TJ3	Tricyclamol chloride
XM17K9	Tridihexethyl iodide
XM5S52	Trimeprazine (tartrate)
XM2M46	Triperiden
XM4YB7	Tritiozine
XM2973	Tropacine
XM4466	Tropicamide
XM8F25	Trospium chloride
XM1CE8	Anticholinergics predominantly used for obstructive airway diseases
XM54K2	Ipratropium bromide
XM55K5	Oxitropium bromide
XM42V2	Glycopyrronium bromide
XM6LS6	Stramonium
XM9HA8	Tiotropium bromide
XM2PE9	Aclidinium bromide
XM3MF8	Umeclidinium bromide
XM8BL4	Reverfenacin
XM4DL3	Flutropium bromide
XM9FU4	Propiverine
XM82U8	Tolterodine
XM2Z66	Solifenacin
XM7V08	Trospium
XM1N89	Darifenacin
XM4265	Fesoterodine
XM5L72	Mirabegron
XM5QR7	Desfesoterodine
XM6190	Emepronium
XM0CH2	Flavoxate

**XM0M49** **Meladrazine**

**XM0LB8** **Oxybutynin**

**XM4DW3** **Terodilime**

Parasympathomimetics [cholinergics]

**XM4AJ3** **Aceclidine**

**XM1EC3** **Acetylcholine chloride**

**XM3GM3** **Acetylcholine derivative**

Anticholinesterase agents

**XM4PZ3** **Ambenonium**

**XM8KF3** **Anticholinesterase**

**XM87V2** **Anticholinesterase organophosphorus**

**XM9D92** **Anticholinesterase reversible**

**XM4VC4** **Cholinergic organophosphorus**

**XM1L81** **DFP**

**XM1389** **Diflos**

**XM86K6** **Difluorophate**

**XM0UQ3** **Diisopropylfluorophosphonate**

**XM5YK5** **Distigmine bromide**

**XM6565** **Edrophonium chloride**

**XM99M6** **Galantamine**

**XM1NE7** **Isofluorophate**

**XM40R6** **Neomycin with neostigmine**

**XM3671** **Neostigmine bromide**

**XM3YR0** **Prostigmin**

**XM41N9** **Pyridostigmine bromide**

**XM4LN1** **Tacrine**

**XM62U1** **Donepezil**

**XM0NP3** **Rivastigmine**

XM3B88	Ipidacrine
XM8C30	Neostigmine
XM4NE1	Pyridostigmine
XM7494	Arecoline
XM0000	Benzpyrinium bromide
XM0MZ4	Bethanechol chloride
XM4LE7	Cholinergic (drug)
XM4ZZ7	Cholinergic muscle tone enhancer
XM6VJ2	Cholinergic trimethyl ammonium propanediol
XM8JX6	Parasympathomimetic drug
XM0RX5	Pilocarpine
XM5EY0	Pilocarpus extract (jaborandi)
XM9223	Choline esters
XM4AT9	Carbachol
XM9XA2	Bethanechol
XM63Q0	Choline alfoscerate
XM31K4	Cevimeline
XM6PN9	Varenicline
XM7HS1	Cytisinicline
XM4C58	Amifampridine

#### Ganglionic blocking drugs

XM90S5	Hexamethonium bromide
XM13Z0	Mecamylamine
XM8JB8	Pemipidine
XM68K9	Pentamethonium bromide
XM2A33	Pentolinium tartrate
XM3YS6	Quaternary ammonium ganglion blocking
XM6JW6	Tetraethylammonium chloride

<b>XM9MS2</b>	<b>Tetrylammonium chloride</b>
<b>XM3YZ9</b>	<b>Trimetaphan camsilate</b>
<b>XM4BZ9</b>	<b>Trimethaphan</b>
<b>XM9BT3</b>	<b>Trimethidinium</b>

## Drugs used in addictive disorders

**Coded Elsewhere:** Naltrexone (XM2M16)  
 Methadone (XM7XP1)  
 Buprenorphine (XM9Z94)  
 Diamorphine (XM05B3)  
 Nalmefene (XM4PD9)  
 Varenicline (XM6PN9)  
 Cytisinicline (XM7HS1)

<b>XM51D2</b>	<b>Disulfiram</b>
<b>XM2FC3</b>	<b>Calcium carbimide</b>
<b>XM6BN2</b>	<b>Nicotine</b>
<b>XM9T01</b>	<b>Acamprosate</b>

## Antivertigo and motion sickness preparations

**Coded Elsewhere:** Antinauseants, antiemetics and emetics (XM4H25-XM9FU8)  
 Antihistamines (XM4J58)

<b>XM14C0</b>	<b>Betahistine</b>
<b>XM7CE7</b>	<b>Cinnarizine</b>
<b>XM52G4</b>	<b>Flunarizine</b>
<b>XM2U21</b>	<b>Acetylleucine</b>

## Agents primarily acting on smooth and skeletal muscles and the respiratory system

**Coded Elsewhere:** Labour repressants

### Oxytocic drugs

**Coded Elsewhere:** Prostaglandins (XM4ML1)  
 Ergot alkaloids (XM0XY6)

<b>XM0Q45</b>	<b>Ergot derivative</b>
<b>XM77J5</b>	<b>Ergot prepared</b>

<b>XM5NB5</b>	<b>Ergotocine</b>
<b>XM4534</b>	<b>Hormone oxytocic</b>
<b>XM8BU6</b>	<b>Muscle affecting agents oxytocic</b>
<b>XM5606</b>	<b>Prostaglandin F2 alpha</b>
<b>XM7F20</b>	<b>Tocosamine</b>
<b>XM6MR2</b>	<b>Vetrabutine</b>

Muscle relaxants

<b>XM8SY4</b>	<b>Muscle relaxants, peripherally acting</b>
<b>XM23H5</b>	<b>Alcuronium</b>
<b>XM7139</b>	<b>Tubocurarine</b>
<b>XM2RT6</b>	<b>Dimethyltubocurarine</b>
<b>XM0L61</b>	<b>Hexafluronium</b>
<b>XM87E3</b>	<b>Fazadinium bromide</b>
<b>XM2SB5</b>	<b>Mivacurium chloride</b>
<b>XM0FZ0</b>	<b>Atracurium</b>
<b>XM0Q59</b>	<b>Pipecuronium bromide</b>
<b>XM2811</b>	<b>Doxacurium chloride</b>
<b>XM4R62</b>	<b>Rocuronium bromide</b>
<b>XM0SQ7</b>	<b>Cisatracurium</b>
<b>XM9M51</b>	<b>Botulinum toxin</b>
<b>XM9YY8</b>	<b>Muscle relaxants, centrally acting</b>
<b>XM5AB5</b>	<b>Carbamic acid esters</b>
<b>XM8DV7</b>	<b>Phenprobamate</b>
<b>XM2DC7</b>	<b>Carisoprodol</b>
<b>XM7AC3</b>	<b>Methocarbamol</b>
<b>XM3KM3</b>	<b>Styramate</b>
<b>XM2339</b>	<b>Febarbamate</b>
<b>XM09D8</b>	<b>Oxazol, thiazine, and triazine derivatives</b>
<b>XM8MD5</b>	<b>Chlormezanone</b>

<b>XM7Q44</b>	Chlorzoxazone
<b>XM7ZQ9</b>	Zoxazolamine
<b>XM5PZ1</b>	Metaxalone
<b>XM09Y8</b>	<b>Suxamethonium</b>
<b>XM5CB4</b>	<b>Pancuronium</b>
<b>XM9416</b>	<b>Gallamine</b>
<b>XM7S28</b>	<b>Vecuronium</b>
<b>XM6X03</b>	<b>Orphenadrine citrate</b>
<b>XM5US2</b>	<b>Baclofen</b>
<b>XM1BK1</b>	<b>Tizanidine</b>
<b>XM26R3</b>	<b>Pridinol</b>
<b>XM4MA5</b>	<b>Tolperisone</b>
<b>XM1HD7</b>	<b>Mephenesin</b>
<b>XM2RH8</b>	<b>Tetrazepam</b>
<b>XM7LP5</b>	<b>Cyclobenzaprine</b>
<b>XM52Y2</b>	<b>Thiocolchicoside</b>
<b>XM9UU4</b>	<b>Eperisone</b>
<b>XM7995</b>	<b>Fenyramidol</b>
<b>XM0W80</b>	<b>Afloqualone</b>
<b>XM3V06</b>	<b>Aclatonium napadisilate</b>
<b>XM9RW1</b>	<b>Anesthesia muscle relaxation</b>
<b>XM5GC4</b>	<b>Atracurium besilate</b>
<b>XM8PU1</b>	<b>Carbolonium (bromide)</b>
<b>XM7DG2</b>	<b>Decamethonium bromide</b>
<b>XM6XS1</b>	<b>Dimethyltubocurarinium chloride</b>
<b>XM8A87</b>	<b>Flaxedil</b>
<b>XM9QC2</b>	<b>Hexafluorenium bromide</b>
<b>XM9WH2</b>	<b>Hexanuorenium</b>
<b>XM82Z5</b>	<b>Hexcarbacholine bromide</b>
<b>XM3676</b>	<b>Laudexium</b>

<b>XM3RJ7</b>	<b>Methocarbamol skeletal muscle relaxant</b>
<b>XM4W78</b>	<b>Muscle affecting agents relaxants skeletal</b>
<b>XM3SC6</b>	<b>Myoneural blocking agents</b>
<b>XM2UG5</b>	<b>Neuromuscular blocking drug</b>
<b>XM8QC2</b>	<b>Skeletal muscle relaxants</b>
<b>XM91M0</b>	<b>Spasmolytic skeletal muscle</b>
<b>XM7142</b>	<b>Suxethonium chloride</b>
<b>XM9502</b>	<b>Woorali</b>
<b>XM5ZN8</b>	<b>Dantrolene</b>

Other drugs acting on muscles

<b>XM82K6</b>	<b>Botox</b>
<b>XM0WW2</b>	<b>Bruceine</b>
<b>XM7E87</b>	<b>Hydrastine</b>
<b>XM7C89</b>	<b>Lututrin</b>
<b>XM20G5</b>	<b>Strychnine medicinal</b>
<b>XM8NV1</b>	<b>Duchenne muscular dystrophy therapy</b>
<b>XM1CL7</b>	<b>Ataluren</b>
<b>XM7H79</b>	<b>Drisapersen</b>
<b>XM0BM1</b>	<b>Eteplirsen</b>
<b>XM6TG6</b>	<b>Hydroquinine</b>
<b>XM0TQ8</b>	<b>Aceneuramic acid</b>
<b>XM90G7</b>	<b>Nusinersen</b>
<b>XM0U21</b>	<b>Viltolarsen</b>
<b>XM4VE2</b>	<b>Casimersen</b>

**XM9P78****Drugs for obstructive airway diseases**

**Coded Elsewhere:** Glucocorticoids and synthetic analogues (XM51K6-XM1XF3)

Budesonide (XM3UP9)

Flunisolide (XM9VX0)

Betamethasone (XM6SU0)

Fluticasone (XM5PW9)

Triamcinolone (XM4J30)

Mometasone (XM8PN0)

Predominantly beta-adrenoreceptor agonists (XM96M5-XM0FE9)

Selective beta-2-adrenoceptor agonists (XM1X48)

Anticholinergics predominantly used for obstructive airway diseases (XM1CE8)

**XM3R34**      **Cromoglicic acid****XM4TP3**      **Nedocromil****XM0B09**      **Antileukotrienes****XM9BZ0**      Zafirlukast**XM1C43**      Pranlukast**XM10P5**      Montelukast**XM12R0**      Ibudilast**XM4U85**      **Monoclonal antibodies used in airway diseases**

**Coded Elsewhere:** Mepolizumab (XM8X05)

**XM4LH9**      Omalizumab**XM6VB5**      Reslizumab**XM0KT0**      Benralizumab**XM82N7**      **Amlexanox**

Aminophylline, theophylline and other xanthines

**XM5SD1**      **Acefylline piperazine****XM1719**      **Acepifylline****XM6493**      **Ambuphylline****XM5XJ1**      **Aminophylline****XM5Y44**      **Bamifylline****XM1QL3**      **Bufyline**

<b>XM31P6</b>	<b>Enprofylline</b>
<b>XM1W21</b>	<b>Etamiphylline</b>
<b>XM3ZP6</b>	<b>Levoproxyphylline</b>
<b>XM81W0</b>	<b>Oxtriphylline</b>
<b>XM5YJ3</b>	<b>Proxyphylline</b>
<b>XM4L37</b>	<b>Theobromine</b>
<b>XM1FP4</b>	<b>Theophylline</b>
<b>XM07L0</b>	<b>Theophylline aminobenzoic acid</b>
<b>XM07F4</b>	<b>Theophylline piperazine p-amino-benzoate</b>
<b>XM9608</b>	<b>Doxofylline</b>
<b>XM7X44</b>	<b>Mepyramine theophyllinacetate</b>
<b>XM42T9</b>	<b>Fenspiride</b>
<b>XM40T5</b>	<b>Eprozinoil</b>
<b>XM8DS8</b>	<b>Seratrodast</b>
<b>XM53U2</b>	<b>Roflumilast</b>
<b>XM5Y33</b>	<b>Tranilast</b>
<b>XM2351</b>	<b>Bufrolin</b>
<b>XM9Y50</b>	<b>Tezepelumab</b>

Expectorants and mucolytics

**Coded Elsewhere:** Acetylcysteine (XM7372)

- Mesna (XM1JB5)
- Mannitol (XM5BJ8)
- Potassium iodide (XM1260)

<b>XM6JV7</b>	<b>Ambroxol</b>
<b>XM4A47</b>	<b>Ammonium chloride expectorant</b>
<b>XM8CT0</b>	<b>Bromhexine</b>
<b>XM9FP2</b>	<b>Calcium iodide</b>
<b>XM3XU8</b>	<b>Carbocisteine</b>
<b>XM2NU9</b>	<b>Cough mixture (syrup)</b>
<b>XM1MJ1</b>	<b>Cough mixture expectorants</b>

<b>XM81Q9</b>	<b>Creosote</b>
<b>XM4C87</b>	<b>Creosote syrup</b>
<b>XM68U4</b>	<b>Deglycyrrhizinized extract of liquorice</b>
<b>XM1KM0</b>	<b>Domiodol</b>
<b>XM28N4</b>	<b>Dornase</b>
<b>XM71N5</b>	<b>Eprazinone</b>
<b>XM7QX2</b>	<b>Glyceryl guaiacolate</b>
<b>XM86G0</b>	<b>Glycyrrhiza extract</b>
<b>XM3CL2</b>	<b>Glycyrrhizic acid</b>
<b>XM8EW0</b>	<b>Glycyrrhizinate potassium</b>
<b>XM0G60</b>	<b>Guaiacol derivatives</b>
<b>XM48K1</b>	<b>Guaimesal</b>
<b>XM8GY5</b>	<b>Guaiphenesin</b>
<b>XM31Y1</b>	<b>Hydriodic acid</b>
<b>XM3E62</b>	<b>Iodide potassium (expectorant)</b>
<b>XM60L0</b>	<b>Iodinated glycerol</b>
<b>XM8BL3</b>	<b>Ipecacuanha</b>
<b>XM2K57</b>	<b>Letosteine</b>
<b>XM9Q09</b>	<b>Liquorice</b>
<b>XM6MB5</b>	<b>Mecysteine</b>
<b>XM4DQ1</b>	<b>Mucolytic drug</b>
<b>XM4KG8</b>	<b>Organidin</b>
<b>XM8A78</b>	<b>Quillaja extract</b>
<b>XM44A1</b>	<b>Respiratory drug expectorant</b>
<b>XM4Y94</b>	<b>S-Carboxymethyl-cysteine</b>
<b>XM1Y62</b>	<b>Senega</b>
<b>XM92P8</b>	<b>Soberrol</b>
<b>XM06E7</b>	<b>Sodium dibunate</b>
<b>XM2BM5</b>	<b>Sputum viscosity-lowering drug</b>

<b>XM7BF1</b>	<b>Stepronin</b>
<b>XM1PU5</b>	<b>Sulfogaiacol</b>
<b>XM6JE5</b>	<b>Superinone</b>
<b>XM1CP3</b>	<b>Tenoglicin</b>
<b>XM0ES0</b>	<b>Terpin hydrate (cis)</b>
<b>XM1F74</b>	<b>Tyloxapol</b>
<b>XM1KG9</b>	<b>Antimony pentasulfide</b>
<b>XM61F4</b>	<b>Dornase alfa</b>
<b>XM48C4</b>	<b>Althaeae radix</b>
<b>XM8983</b>	<b>Guaiacolsulfonate</b>
<b>XM5QU8</b>	<b>Levooverbenone</b>
<b>XM48W4</b>	<b>Hederae helicis folium</b>
<b>XM7Q79</b>	<b>Cineole</b>
<b>XM66E3</b>	<b>Neltenexine</b>
<b>XM7Y66</b>	<b>Erdosteine</b>

#### Antitussives

**Coded Elsewhere:** Codeine, codeine derivatives and other opioids used in cough suppression (XM4587)

<b>XM6NJ7</b>	<b>Benproperine</b>
<b>XM8G23</b>	<b>Benzonatate</b>
<b>XM1U36</b>	<b>Bibenzonium bromide</b>
<b>XM8WM3</b>	<b>Butamirate</b>
<b>XM4D27</b>	<b>Clobutinol</b>
<b>XM9DL9</b>	<b>Chlophedianol</b>
<b>XM80M9</b>	<b>Cloperastine</b>
<b>XM9KL2</b>	<b>Dimethoxanate</b>
<b>XM6995</b>	<b>Droplopizine</b>
<b>XM61F3</b>	<b>Ethyl dibunate</b>
<b>XM0SA9</b>	<b>Fedrilate</b>

<b>XM5BB1</b>	<b>Fominoben</b>
<b>XM8300</b>	<b>Isoaminile</b>
<b>XM97D0</b>	<b>Levodropropizine</b>
<b>XM3WX2</b>	<b>Methorate</b>
<b>XM2ET3</b>	<b>Oxeladin</b>
<b>XM9FU3</b>	<b>Oxolamine</b>
<b>XM4331</b>	<b>Pentoxyverine</b>
<b>XM7G25</b>	<b>Picoperine</b>
<b>XM84C4</b>	<b>Pipazetate</b>
<b>XM0HR9</b>	<b>Piperidione</b>
<b>XM8JR1</b>	<b>Prenoxdiazine</b>
<b>XM9KN8</b>	<b>Zipeprol</b>
<b>XM6SJ0</b>	<b>Dibunate</b>
<b>XM1G75</b>	<b>Meprotixol</b>
<b>XM2W89</b>	<b>Morclofone</b>
<b>XM7UA5</b>	<b>Nepinalone</b>
<b>XM06F9</b>	<b>Butetamate</b>
<b>XM4SL3</b>	<b>Gefapixant</b>
<b>XM4J58</b>	<b>Antihistamines</b>
<b>XM2JE5</b>	<b>First-generation antihistamine</b>
<b>XM8MV2</b>	Aminoalkyl ethers
<b>XM1TL5</b>	Bromazine
<b>XM6KY0</b>	Diphenhydramine
<b>XM3DL4</b>	Clemastine
<b>XM4QD7</b>	Chlorphenoxamine
<b>XM7GV4</b>	Diphenylpyraline
<b>XM9KZ9</b>	Carbinoxamine
<b>XM77K6</b>	Doxylamine
<b>XM7180</b>	Piprinhydrinate

<b>XM3FN3</b>	Rotoxamine
<b>XM5YE8</b>	Substituted alkylamines
<b>XM5PK9</b>	Brompheniramine
<b>XM6CF9</b>	Dexchlorpheniramine
<b>XM74S1</b>	Dimetindene
<b>XM9VG3</b>	Chlorpheniramine
<b>XM4UU4</b>	Pheniramine
<b>XM1107</b>	Dexbrompheniramine
<b>XM4AA0</b>	Talastine
<b>XM9MB0</b>	Substituted ethylene diamines
<b>XM54R1</b>	Pyrilamine
<b>XM9CM1</b>	Chloropyramine
<b>XM0N55</b>	Tripeleannamine
<b>XM7TD1</b>	Methapyrilene
<b>XM6NM2</b>	Thonzylamine
<b>XM4NS9</b>	Histapyrrodine
<b>XM52P9</b>	Phenothiazine derivatives
<b>XM1N75</b>	Alimemazine
<b>XM0605</b>	Promethazine
<b>XM9QY1</b>	Thiethylperazine
<b>XM5E89</b>	Methdilazine
<b>XM5EB9</b>	Mequitazine
<b>XM5DB5</b>	Oxomemazine
<b>XM4Z91</b>	Isothipendyl
<b>XM5QG6</b>	Hydroxyethylpromethazine
<b>XM29Q8</b>	Thiazinam
<b>XM9NA0</b>	Piperazine derivatives of first-generation antihistaminic agents
<b>XM8GH2</b>	Buclizine
<b>XM0S26</b>	Cyclizine
<b>XM9SK3</b>	Chlorcyclizine

<b>XM1A78</b>	Meclozine
<b>XM6AV1</b>	Oxatomide
<b>XM0QD9</b>	Cetirizine
<b>XM07V7</b>	Piperazine
<b>XM1VF1</b>	Diethylcarbamazine
<b>XM5AC9</b>	Levocetirizine
<b>XM4GX4</b>	Bamipine
<b>XM11C5</b>	Cyproheptadine
<b>XM9BD4</b>	Phenindamine
<b>XM5Q41</b>	Antazolin
<b>XM8RT2</b>	Triprolidine
<b>XM6Z93</b>	Azatadine
<b>XM4280</b>	Mebhydrolin
<b>XM7ZS2</b>	Thenalidine
<b>XM0404</b>	Pipoxizine
<b>XM5463</b>	Setastine
<b>XM3B95</b>	<b>Second-generation antihistamine</b>
<b>XM6G21</b>	Piperazine derivatives of second-generation antihistaminic agents
<b>XM7S59</b>	Astemizole
<b>XM2S36</b>	Terfenadine
<b>XM4PE5</b>	Loratadine
<b>XM4F63</b>	Ketotifen
<b>XM4GA2</b>	Acrivastine
<b>XM9VB8</b>	Azelastine
<b>XM9EU0</b>	Ebastine
<b>XM7J45</b>	Mizolastine
<b>XM1586</b>	Fexofenadine
<b>XM2656</b>	Desloratadine
<b>XM3E25</b>	Rupatadine
<b>XM1WZ8</b>	Bilastine

<b>XM3YG8</b>	Quifenadine
<b>XM57C9</b>	Pyrrobutamine
<b>XM8ZS4</b>	Deptropine
<b>XM0J21</b>	Tritoqualine
<b>XM70F3</b>	Pimethixene
<b>XM5BJ5</b>	Epinastine
<b>XM40P7</b>	Sequifenadine
<b>XM9L77</b>	Doxantrazole

Respiratory stimulants

*Coded Elsewhere:* Picrotoxin (XM6KR6)

<b>XM0AP5</b>	Almitrine
<b>XM9QA2</b>	Amiphenazole
<b>XM0WB3</b>	Bemegride
<b>XM5T65</b>	Bicuculline
<b>XM7BN2</b>	<b>Central nervous system stimulants analeptics</b>
<b>XM6938</b>	<b>Central nervous system stimulants opiate antagonists</b>
<b>XM3465</b>	Crotethamide with cropropamide
<b>XM0A24</b>	Dimefline
<b>XM2ZT4</b>	Dimorpholamine
<b>XM3FP9</b>	Doxapram
<b>XM6D72</b>	Etamivan
<b>XM6YR1</b>	Leptazol
<b>XM4CU0</b>	Lobeline
<b>XM0001</b>	Nikethamide
<b>XM0Q86</b>	Pentetrazol
<b>XM5VY2</b>	Pimeclone
<b>XM4901</b>	Prethcamide
<b>XM1D17</b>	Mepixanox
<b>XM04S2</b>	<b>Other respiratory system products</b>

<b>XM4HQ2</b>	<b>Nitric oxide</b>
<b>XM3CW0</b>	<b>Ivacaftor</b>
<b>XM15G5</b>	<b>Ivacaftor and lumacaftor</b>
<b>XM2QZ5</b>	<b>Ivacaftor and tezacaftor</b>

## Systemic antibiotics, anti-infectives and antiparasitics

Systemic antibiotics and antibacterials

**Coded Elsewhere:** Antifungal antibiotics (XM7S10)

<b>XM0MG9</b>	<b>Amphenicols</b>
<b>XM2TE7</b>	<b>Chloramphenicol</b>
<b>XM40F4</b>	<b>Thiamphenicol</b>

### Penicillins

<b>XM1JY8</b>	<b>Adicillin</b>
<b>XM1LV7</b>	<b>Ancillin</b>
<b>XM0JT4</b>	<b>Apalcillin</b>
<b>XM46K9</b>	<b>Bacampicillin</b>
<b>XM94E1</b>	<b>Benethamine penicillin</b>
<b>XM2SP1</b>	<b>Carfecillin</b>
<b>XM9MK4</b>	<b>Cephalosporins N (adicillin)</b>
<b>XM4YY1</b>	<b>Clemizole penicillin</b>
<b>XM2361</b>	<b>Ciclacillin</b>
<b>XM9VG2</b>	<b>Hydrabamine penicillin</b>
<b>XM7LA4</b>	<b>Imipenem</b>
<b>XM0V84</b>	<b>Isoxazolyl penicillin</b>
<b>XM00H2</b>	<b>Methoxybenzyl penicillin</b>
<b>XM9XB6</b>	<b>Penethamate</b>
<b>XM7Q57</b>	<b>Penicillin (any)</b>
<b>XM71L1</b>	<b>Phenbenicillin</b>
<b>XM3UP8</b>	<b>Xantocillin</b>

<b>XM3173</b>	<b>Penicillins with extended spectrum</b>
<b>XM5MY7</b>	<b>Ampicillin</b>
<b>XM7CR7</b>	<b>Pivampicillin</b>
<b>XM3D58</b>	<b>Carbenicillin</b>
<b>XM7CM1</b>	<b>Amoxicillin</b>
<b>XM7J83</b>	<b>Carindacillin</b>
<b>XM31J4</b>	<b>Epicillin</b>
<b>XM9LR3</b>	<b>Pivmecillinam</b>
<b>XM8820</b>	<b>Azlocillin</b>
<b>XM1Z93</b>	<b>Mezlocillin</b>
<b>XM5562</b>	<b>Mecillinam</b>
<b>XM3MP9</b>	<b>Piperacillin</b>
<b>XM4D90</b>	<b>Ticarcillin</b>
<b>XM1HX8</b>	<b>Metampicillin</b>
<b>XM3Z13</b>	<b>Talampicillin</b>
<b>XM3S35</b>	<b>Sulbenicillin</b>
<b>XM1QC3</b>	<b>Temocillin</b>
<b>XM9HP3</b>	<b>Hetacillin</b>
<b>XM70P4</b>	<b>Aspoxicillin</b>
<b>XM9FQ5</b>	<b>Beta-lactamase sensitive penicillins</b>
<b>XM83S8</b>	<b>Benzylpenicillin</b>
<b>XM9B11</b>	<b>Phenoxyethylpenicillin</b>
<b>XM5MN2</b>	<b>Propicillin</b>
<b>XM4EZ4</b>	<b>Azidocillin</b>
<b>XM9NF6</b>	<b>Phenetocillin</b>
<b>XM16L6</b>	<b>Penamecillin</b>
<b>XM5N44</b>	<b>Clometocillin</b>
<b>XM4E82</b>	<b>Benzathine benzylpenicillin</b>
<b>XM4HD6</b>	<b>Procaine benzylpenicillin</b>
<b>XM6MK0</b>	<b>Benzathine phenoxyethylpenicillin</b>

<b>XM9QY0</b>	<b>Beta-lactamase resistant penicillins</b>
<b>XM5SF7</b>	<b>Dicloxacillin</b>
<b>XM6L30</b>	<b>Cloxacillin</b>
<b>XM0PP7</b>	<b>Methicillin</b>
<b>XM2UY3</b>	<b>Oxacillin</b>
<b>XM6AV2</b>	<b>Flucloxacillin</b>
<b>XM8HL9</b>	<b>Nafcillin</b>
<b>XM6QQ6</b>	<b>Combinations of penicillins</b>
<b>XM0RU1</b>	<b>Sultamicillin</b>
<b>XM3DN8</b>	<b>Ampicillin and beta-lactamase inhibitor</b>
<b>XM7UP4</b>	<b>Amoxicillin and beta-lactamase inhibitor</b>
<b>XM1FZ0</b>	<b>Ticarcillin and beta-lactamase inhibitor</b>
<b>XM0LH3</b>	<b>Piperacillin and beta-lactamase inhibitor</b>
<b>XM9XT2</b>	<b>Beta-lactamase inhibitors</b>
<b>XM3Y87</b>	<b>Sulbactam</b>
<b>XM2D37</b>	<b>Tazobactam</b>

**Cephalosporins and other beta-lactam antibiotics**

<b>XM3WK4</b>	<b>Antibiotic b-lactam</b>
<b>XM7TD6</b>	<b>Antibiotic cephalosporin (group)</b>
<b>XM5J74</b>	<b>Cefaloglycin</b>
<b>XM8J52</b>	<b>Cefamycin antibiotic</b>
<b>XM01V2</b>	<b>Cefpimizole</b>
<b>XM45T3</b>	<b>Cefteram</b>
<b>XM0C25</b>	<b>Cefuzonam</b>
<b>XM4HC8</b>	<b>Cephalosporins</b>
<b>XM67G9</b>	<b>Cephalothin</b>
<b>XM2K88</b>	<b>Clavulanic acid</b>
<b>XM9BE0</b>	<b>First-generation cephalosporins</b>
<b>XM9Z22</b>	<b>Cefalexin</b>

<b>XM7GR3</b>	<b>Cefaloridine</b>
<b>XM0BY6</b>	<b>Cefazolin</b>
<b>XM11S1</b>	<b>Cefadroxil</b>
<b>XM1EQ8</b>	<b>Cefazedone</b>
<b>XM8UF3</b>	<b>Cefatrizine</b>
<b>XM6DE1</b>	<b>Cefapirin</b>
<b>XM8X72</b>	<b>Cefradine</b>
<b>XM7DR9</b>	<b>Cefacetile</b>
<b>XM75P2</b>	<b>Cefroxadine</b>
<b>XM2L78</b>	<b>Ceftezole</b>
<b>XM4DG8</b>	<b>Second-generation cephalosporins</b>
<b>XM26N9</b>	<b>Cefoxitin</b>
<b>XM7VY3</b>	<b>Cefuroxime</b>
<b>XM8839</b>	<b>Cefamandole</b>
<b>XM1ZJ9</b>	<b>Cefaclor</b>
<b>XM5QJ0</b>	<b>Cefotetan</b>
<b>XM3M14</b>	<b>Cefonicid</b>
<b>XM3V37</b>	<b>Cefotiam</b>
<b>XM8S59</b>	<b>Cefmetazole</b>
<b>XM3QK7</b>	<b>Ceforanide</b>
<b>XM27Z3</b>	<b>Cefminox</b>
<b>XM14Q0</b>	<b>Cefbuperazone</b>
<b>XM83K2</b>	<b>Flomoxef</b>
<b>XM6KH0</b>	<b>Loracarbef</b>
<b>XM4CP3</b>	<b>Cefprozil</b>
<b>XM3FN8</b>	<b>Third-generation cephalosporins</b>
<b>XM7CZ4</b>	<b>Cefotaxime</b>
<b>XM94G4</b>	<b>Ceftazidime</b>
<b>XM9732</b>	<b>Cefsulodin</b>
<b>XM3P83</b>	<b>Ceftriaxone</b>

<b>XM6FL0</b>	<b>Cefmenoxime</b>
<b>XM0B94</b>	<b>Latamoxef</b>
<b>XM1064</b>	<b>Ceftizoxime</b>
<b>XM4Q77</b>	<b>Cefixime</b>
<b>XM8YC6</b>	<b>Cefetamet</b>
<b>XM9YD6</b>	<b>Cefpiramide</b>
<b>XM5425</b>	<b>Cefoperazone</b>
<b>XM12J5</b>	<b>Cefodizime</b>
<b>XM85Q0</b>	<b>Cefpodoxime</b>
<b>XM2D98</b>	<b>Ceftibuten</b>
<b>XM2141</b>	<b>Cefdinir</b>
<b>XM2SP6</b>	<b>Cefditoren</b>
<b>XM0H82</b>	<b>Cefcapene</b>
<b>XM9RH3</b>	<b>Cefotaxime and beta-lactamase inhibitor</b>
<b>XM8EN5</b>	<b>Ceftazidime and beta-lactamase inhibitor</b>
<b>XM4UZ8</b>	<b>Cefoperazone and beta-lactamase inhibitor</b>
<b>XM19K3</b>	<b>Ceftriaxone and beta-lactamase inhibitor</b>
<b>XM60V7</b>	<b>Fourth-generation cephalosporins</b>
<b>XM1HW5</b>	<b>Cefepime</b>
<b>XM0MR4</b>	<b>Cefpirome</b>
<b>XM1BL5</b>	<b>Cefozopran</b>
<b>XM3XC6</b>	<b>Monobactams</b>
<b>XM3DB8</b>	<b>Aztreonam</b>
<b>XM9FE9</b>	<b>Carumonam</b>
<b>XM1JU9</b>	<b>Carbapenems</b>
<b>XM82S6</b>	<b>Meropenem</b>
<b>XM50J4</b>	<b>Ertapenem</b>
<b>XM27D0</b>	<b>Doripenem</b>
<b>XM1Q21</b>	<b>Biapenem</b>
<b>XM12K6</b>	<b>Imipenem and cilastatin</b>

<b>XM02N8</b>	Panipenem
<b>XM1N97</b>	Faropenem
<b>XM5261</b>	Betamipron
<b>XM3QS2</b>	Ceftobiprole medocaril
<b>XM2LW5</b>	Ceftaroline fosamil
<b>XM7RT0</b>	Ceftolozane and beta-lactamase inhibitor
<b>XM8SY8</b>	Sulfonamides and trimethoprim derivatives
<b>XM3MG7</b>	Trimethoprim derivatives
<b>XM7NY9</b>	Trimethoprim
<b>XM8162</b>	Short-acting sulfonamides
<b>XM0XY9</b>	Sulfamethizole
<b>XM72R1</b>	Sulfapyridine
<b>XM3G53</b>	Sulfathiazole
<b>XM72K1</b>	Sulfanilamide
<b>XM9TQ5</b>	Sulfisoxazole
<b>XM06K1</b>	Intermediate-acting sulfonamides
<b>XM1AM5</b>	Sulphamethoxazole
<b>XM12D1</b>	Sulfadiazine
<b>XM43U3</b>	Sulfamoxole
<b>XM4J39</b>	Long-acting sulfonamides
<b>XM3ER6</b>	Sulfadimethoxine
<b>XM8LL9</b>	Sulfalene
<b>XM7XJ2</b>	Sulfamethoxypyridazine
<b>XM92E0</b>	Sulfaperin
<b>XM7R74</b>	Sulfamerazine
<b>XM1G41</b>	Sulfaphenazole
<b>XM0ZN8</b>	Sulfamazone
<b>XM95D0</b>	Sulfametomidine
<b>XM3EU7</b>	Sulfonamides and trimethoprim derivatives, fixed combinations
<b>XM22Y8</b>	Trimethoprim with sulfamethoxazole

<b>XM18A9</b>	Sulfadiazine and trimethoprim
<b>XM87N2</b>	Sulfametrole and trimethoprim
<b>XM4008</b>	Sulfamoxole and trimethoprim
<b>XM4WW1</b>	Sulfadimidine and trimethoprim
<b>XM1UR3</b>	Sulfadiazine and tetroxoprim
<b>XM3Y04</b>	Sulfamerazine and trimethoprim
<b>XM4YB5</b>	<b>Brodimoprim</b>
<b>XM98X3</b>	<b>Iclaprim</b>
<b>XM4L44</b>	<b>Sulfathiourea</b>

#### Macrolides

<b>XM1329</b>	<b>Azithromycin</b>
<b>XM36F7</b>	<b>Erythromycin</b>
<b>XM2YT6</b>	<b>Josamycin</b>
<b>XM06K0</b>	<b>Kitasamycin</b>
<b>XM80A1</b>	<b>Midecamycin</b>
<b>XM3CC3</b>	<b>Miocamycin</b>
<b>XM8HR9</b>	<b>Oleandomycin</b>
<b>XM8UC1</b>	<b>Rokitamycin</b>
<b>XM98M0</b>	<b>Roxithromycin</b>
<b>XM1K16</b>	<b>Spiramycin</b>
<b>XM2WF8</b>	<b>Troleandomycin</b>
<b>XM1VG4</b>	<b>Clarithromycin</b>
<b>XM0EH3</b>	<b>Dirithromycin</b>
<b>XM2J45</b>	<b>Flurithromycin</b>
<b>XM5TV4</b>	<b>Telithromycin</b>
<b>XM2LU0</b>	<b>Solithromycin</b>
<b>XM4094</b>	<b>Ansamycin</b>
<b>XM7E36</b>	<b>Lincosamides</b>
<b>XM8158</b>	<b>Clindamycin</b>

<b>XM53Q9</b>	<b>Lincomycin</b>
<b>XM69N7</b>	<b>Streptogramins</b>
<b>XM48W5</b>	<b>Pristinamycin</b>
<b>XM4NJ6</b>	<b>Quinupristin</b>
<b>XM2YS9</b>	<b>Dalfopristin</b>

### Aminoglycosides

<b>XM3X89</b>	<b>Amikacin</b>
<b>XM4LV0</b>	<b>Antibiotic aminoglycoside</b>
<b>XM7WC2</b>	<b>Antitubercular antibiotics</b>
<b>XM4BG6</b>	<b>Astromicin</b>
<b>XM4PT0</b>	<b>Bekanamycin</b>
<b>XM45U4</b>	<b>Dibekacin</b>
<b>XM8KT1</b>	<b>Dihydrostreptomycin</b>
<b>XM0PH0</b>	<b>Framycetin</b>
<b>XM3YS5</b>	<b>Gentamicin</b>
<b>XM6YS3</b>	<b>Isepamicin</b>
<b>XM0C03</b>	<b>Kanamycin</b>
<b>XM9VS3</b>	<b>Micronomicin</b>
<b>XM2YC8</b>	<b>Neomycin (derivatives)</b>
<b>XM1W69</b>	<b>Netilmicin</b>
<b>XM1QQ2</b>	<b>Novobiocin</b>
<b>XM1696</b>	<b>Paromomycin</b>
<b>XM58T2</b>	<b>Ribostamycin</b>
<b>XM4GS3</b>	<b>Sisomicin</b>
<b>XM6T34</b>	<b>Streptomycin</b>
<b>XM32G0</b>	<b>Streptomycin derivative</b>
<b>XM7N64</b>	<b>Streptoduocin</b>
<b>XM4YK6</b>	<b>Streptonivicin</b>

<b>XM40X6</b>	<b>Streptovarycin</b>
<b>XM6G20</b>	<b>Tobramycin</b>
<b>XM79T7</b>	<b>Arbekacin</b>
<b>XM1KN3</b>	<b>Plazomicin</b>
<b>XM7YK9</b>	<b>Quinolones and derivatives</b>
<b>XM3HL2</b>	<b>Fluoroquinolones</b>
<b>XM8072</b>	Ofloxacin
<b>XM77G2</b>	Ciprofloxacin
<b>XM1Z91</b>	Pefloxacin
<b>XM7SH9</b>	Enoxacin
<b>XM85E7</b>	Norfloxacin
<b>XM2GR2</b>	Fleroxacin
<b>XM98Z1</b>	Temafloxacin
<b>XM3JX8</b>	Lomefloxacin
<b>XM6MR3</b>	Sparfloxacin
<b>XM7BN7</b>	Rufloxacin
<b>XM6RS6</b>	Grepafloxacin
<b>XM7KX7</b>	Levofloxacin
<b>XM6YH9</b>	Trovafloxacin
<b>XM8147</b>	Moxifloxacin
<b>XM5HN4</b>	Gemifloxacin
<b>XM17A4</b>	Gatifloxacin
<b>XM3NU2</b>	Prulifloxacin
<b>XM3Z59</b>	Pazufloxacin
<b>XM1QZ5</b>	Garenoxacin
<b>XM5MK4</b>	Sitaflloxacin
<b>XM3S71</b>	Tosufloxacin
<b>XM9CC7</b>	Delaflloxacin
<b>XM8SV4</b>	<b>Rosoxacin</b>
<b>XM82P4</b>	<b>Nalidixic acid</b>

<b>XM1298</b>	<b>Piromidic acid</b>
<b>XM61M8</b>	<b>Pipemidic acid</b>
<b>XM3GX9</b>	<b>Combinations of antibacterials</b>
<b>XM5CX9</b>	<b>Sulfonamides, combinations with other antibacterials</b>
	<b><i>Exclusions:</i></b> Trimethoprim (XM7NY9)
<b>XM39C8</b>	<b>Penicillins, combinations with other antibacterials</b>
<b>XM9162</b>	<b>Cefuroxime and metronidazole</b>
<b>XM3E19</b>	<b>Spiramycin and metronidazole</b>
<b>XM8TH8</b>	<b>Levofloxacin and ornidazole</b>
<b>XM3DB6</b>	<b>Cefepime and amikacin</b>
<b>XM5QC3</b>	<b>Azithromycin, fluconazole and secnidazole</b>
<b>XM1CM9</b>	<b>Tetracycline and oleandomycin</b>
<b>XM2CJ8</b>	<b>Ofloxacin and ornidazole</b>
<b>XM9T47</b>	<b>Ciprofloxacin and metronidazole</b>
<b>XM36B5</b>	<b>Ciprofloxacin and tinidazole</b>
<b>XM51W6</b>	<b>Ciprofloxacin and ornidazole</b>
<b>XM31E8</b>	<b>Norfloxacin and tinidazole</b>
<b>XM8S33</b>	<b>Glycopeptides</b>
<b>XM9YD1</b>	<b>Vancomycin</b>
<b>XM2004</b>	<b>Teicoplanin</b>
<b>XM8WT1</b>	<b>Telavancin</b>
<b>XM4F99</b>	<b>Dalbavancin</b>
<b>XM9LJ3</b>	<b>Oritavancin</b>
<b>XM2CE2</b>	<b>Nitrofuran derivatives</b>
<b>XM09K7</b>	<b>Nitrofurantoin</b>
<b>XM1QV5</b>	<b>Nifurtoinol</b>
<b>XM9F49</b>	<b>Nifurtimox</b>
<b>XM8FX2</b>	<b>Furazidin</b>
<b>XM08Z2</b>	<b>Furazolidone</b>
<b>XM3DZ3</b>	<b>Polymyxins</b>

<b>XM6510</b>	<b>Colistin</b>
<b>XM0NQ2</b>	<b>Polymyxin B</b>
<b>XM8MH4</b>	<b>Polymyxin</b>

#### Other antibacterials

<b>XM5183</b>	<b>Aerosporin</b>
<b>XM5PV6</b>	<b>Albamycin</b>
<b>XM4E54</b>	<b>Amphomycin</b>
<b>XM2H40</b>	<b>Anti-infective antibiotics specified</b>
<b>XM41T2</b>	<b>Antibiotic intestinal</b>
<b>XM0MJ1</b>	<b>Antibiotic polypeptide</b>
<b>XM7SQ4</b>	<b>Antibiotic specified</b>
<b>XM2EH2</b>	<b>Betamicin</b>
<b>XM0D75</b>	<b>Carbomycin</b>
<b>XM74K5</b>	<b>Enviomycin</b>
<b>XM0HU8</b>	<b>Fosfomycin</b>
<b>XM5UL0</b>	<b>Fusafungine</b>
<b>XM6AH3</b>	<b>Fusidic acid</b>
<b>XM14K4</b>	<b>Neosporin</b>
<b>XM19A7</b>	<b>Ristocetin</b>
<b>XM0BX1</b>	<b>Sodium fusidate</b>
<b>XM4F54</b>	<b>Sulfomyxin</b>
<b>XM6HE3</b>	<b>Viomycin</b>
<b>XM2A60</b>	<b>Virginiamycin</b>
<b>XM71G5</b>	<b>Xibornol</b>
<b>XM2TG1</b>	<b>Spectinomycin</b>
<b>XM02L5</b>	<b>Methenamine (mandelate)</b>
<b>XM3HJ6</b>	<b>Mandelic acid</b>
<b>XM33S9</b>	<b>Nitroxoline</b>

<b>XM11V4</b>	<b>Clofoctol</b>
<b>XM9WV9</b>	<b>Linezolid</b>
<b>XM2NL4</b>	<b>Daptomycin</b>
<b>XM20R8</b>	<b>Bacitracin</b>
<b>XM9GT9</b>	<b>Tedizolid</b>
<b>XM9QK9</b>	<b>Lefamulin</b>

## Tetracyclines

<b>XM8124</b>	<b>Antibiotic tetracycline (group)</b>
<b>XM7FD5</b>	<b>Chlormethylenecycline</b>
<b>XM1JT2</b>	<b>Chlortetracycline</b>
<b>XM0WY0</b>	<b>Clomocycline</b>
<b>XM9219</b>	<b>Demeclocycline</b>
<b>XM17F8</b>	<b>Demethylchlortetracycline</b>
<b>XM7KG3</b>	<b>Demethyltetracycline</b>
<b>XM7J58</b>	<b>Doxycycline</b>
<b>XM4492</b>	<b>Guamecycline</b>
<b>XM47D7</b>	<b>Lymecycline</b>
<b>XM9KD5</b>	<b>Meclocycline</b>
<b>XM4CA1</b>	<b>Metacycline</b>
<b>XM5TY0</b>	<b>Minocycline</b>
<b>XM8DQ8</b>	<b>Oxytetracycline</b>
<b>XM3D34</b>	<b>Penimepicycline</b>
<b>XM45X2</b>	<b>Rolitetracycline</b>
<b>XM0BP1</b>	<b>Tetracycline</b>
<b>XM74B7</b>	<b>Tigecycline</b>

## Antimycobacterials

<b>XM8781</b>	<b>Aminosalicylic acid and derivatives</b>
<b>XM1X82</b>	<b>Aminosalicylic acid</b>

XM6TY4	Sodium aminosalicylate
XM7FE7	Calcium aminosalicylate
<b>XM3BE3</b>	<b>Thiocarbamide derivatives</b>
XM1GT1	Protonamide
XM86N7	Ethionamide
<b>XM8Q31</b>	<b>Drugs for treatment of lepra</b>
XM3122	Clofazimine
XM73W4	Dapsone
XM34C6	Clascoterone
<b>XM6QT5</b>	<b>Aminosalylum</b>
<b>XM4TV0</b>	<b>Anti-infective antimycobacterial</b>
<b>XM5K63</b>	<b>Antimycobacterial drug combination</b>
<b>XM6DX3</b>	<b>Antituberculars</b>
<b>XM18Y4</b>	<b>Benzoylpas calcium</b>
<b>XM3307</b>	<b>Bromosalicylhydroxamic acid</b>
<b>XM2754</b>	<b>Calcium benzamidosalicylate</b>
<b>XM7TM4</b>	<b>Chaulmosulfone</b>
<b>XM95S8</b>	<b>Cyanacetyl hydrazide</b>
<b>XM4N96</b>	<b>Ethambutol</b>
<b>XM64N2</b>	<b>Ethyl chaulmoograte</b>
<b>XM23G7</b>	<b>Fenamisal</b>
<b>XM4RF4</b>	<b>Glucosulfone sodium</b>
<b>XM7945</b>	<b>Glyconiazide</b>
<b>XM5FH2</b>	<b>Isoniazid</b>
<b>XM2ZK2</b>	<b>Isonicotinic acid hydrazide</b>
<b>XM3XE5</b>	<b>Methaniazide</b>
<b>XM8UX1</b>	<b>Morinamide</b>
<b>XM6LM1</b>	<b>Morphazinamide</b>
<b>XM2QH1</b>	<b>Pasiniazid</b>

<b>XM4Q32</b>	<b>Pentylsalicylamide</b>
<b>XM3UQ6</b>	<b>Potassium aminosalicylate</b>
<b>XM8DJ8</b>	<b>Promacetin</b>
<b>XM8CP2</b>	<b>Promin</b>
<b>XM4611</b>	<b>Pyrazinamide</b>
<b>XM4GU0</b>	<b>Rimifon</b>
<b>XM7SC9</b>	<b>Salinazid</b>
<b>XM3070</b>	<b>Acetosulfone sodium</b>
<b>XM06Z9</b>	<b>Solasulfone</b>
<b>XM3SD9</b>	<b>Sulfonazide</b>
<b>XM3SN8</b>	<b>Sulfones</b>
<b>XM72Q4</b>	<b>Aldesulfone sodium</b>
<b>XM9TD0</b>	<b>Terizidone</b>
<b>XM99P0</b>	<b>Thiambutosine</b>
<b>XM0AR8</b>	<b>Thioacetazone</b>
<b>XM5MQ5</b>	<b>Thioacetazone with isoniazid</b>
<b>XM62H2</b>	<b>Tiocarlide</b>
<b>XM60U0</b>	<b>Bedaquiline</b>
<b>XM1FD5</b>	<b>Delamanid</b>
<b>XM7AQ6</b>	<b>Antimycobacterial antibiotic</b>
<b>XM63V4</b>	<b>Cycloserine</b>
<b>XM0R30</b>	<b>Rifampicin</b>
<b>XM7HL1</b>	<b>Rifamycin</b>
<b>XM5QH8</b>	<b>Rifabutin</b>
<b>XM8MQ4</b>	<b>Rifapentine</b>
<b>XM0892</b>	<b>Capreomycin</b>
<b>XM2LE1</b>	<b>Rifaximin</b>
<b>XM38J6</b>	<b>Rifamide</b>

Antifungal agents

<b>XM2SD6</b>	<b>Imidazole derivatives</b>
<b>XM9UH0</b>	<b>Miconazole</b>
<b>XM9795</b>	<b>Ketoconazole</b>
<b>XM4GT1</b>	<b>Triazole and tetrazole derivatives</b>
<b>XM97S6</b>	<b>Fluconazole</b>
<b>XM5XD2</b>	<b>Itraconazole</b>
<b>XM70R4</b>	<b>Voriconazole</b>
<b>XM1VE3</b>	<b>Posaconazole</b>
<b>XM69J7</b>	<b>Oteseconazole</b>
<b>XM8YE6</b>	<b>Griseofulvin</b>
<b>XM32L5</b>	<b>Nystatin</b>
<b>XM2H01</b>	<b>Pimaricin</b>
<b>XM3BU7</b>	<b>Flucytosine</b>
<b>XM7HQ1</b>	<b>Terbinafine</b>
<b>XM0K47</b>	<b>Caspofungin</b>
<b>XM1F82</b>	<b>Micafungin</b>
<b>XM0HG4</b>	<b>Anidulafungin</b>
<b>XM7S10</b>	<b>Antifungal antibiotics</b>
<b>XM5TR4</b>	<b>Amphotericin B</b>
<b>XM9CM4</b>	<b>Hachimycin</b>

Antiviral drugs

<b>XM56B8</b>	<b>Nucleosides and nucleotides</b>
<b>XM3MC4</b>	<b>Aciclovir</b>
<b>XM30N1</b>	<b>Vidarabine</b>
<b>XM1M61</b>	<b>Ganciclovir</b>
<b>XM2GP5</b>	<b>Idoxuridine</b>
<b>XM3RL1</b>	<b>Famciclovir</b>
<b>XM4GK4</b>	<b>Valaciclovir</b>

<b>XM6HE0</b>	<b>Cidofovir</b>
<b>XM3AF7</b>	<b>Penciclovir</b>
<b>XM2RU2</b>	<b>Valganciclovir</b>
<b>XM5L76</b>	<b>Brivudine</b>
<b>XM1ES0</b>	<b>Remdesivir</b>
<b>XM4CD1</b>	<b>Brincidofovir</b>
<b>XM7QR0</b>	<b>Cyclic amines</b>
<b>XM2TS5</b>	<b>Rimantadine</b>
<b>XM7GR8</b>	<b>Tromantadine</b>
<b>XM90G3</b>	<b>Phosphonic acid derivatives</b>
<b>XM5XQ9</b>	<b>Foscarnet</b>
<b>XM8Z26</b>	<b>Fosfonet</b>
<b>XM8GK2</b>	<b>Protease inhibitors</b>
<b>XM7YP4</b>	<b>Saquinavir</b>
<b>XM1VT6</b>	<b>Indinavir</b>
<b>XM56L1</b>	<b>Ritonavir</b>
<b>XM6175</b>	<b>Nelfinavir</b>
<b>XM6WJ3</b>	<b>Amprenavir</b>
<b>XM2AR2</b>	<b>Fosamprenavir</b>
<b>XM2U50</b>	<b>Atazanavir</b>
<b>XM8QH1</b>	<b>Tipranavir</b>
<b>XM63Q8</b>	<b>Darunavir</b>
<b>XM3EZ0</b>	<b>Nucleoside and nucleotide reverse transcriptase inhibitors</b>
<b>XM9C07</b>	<b>Zidovudine</b>
<b>XM7XQ2</b>	<b>Zalcitabine</b>
<b>XM8Z78</b>	<b>Didanosine</b>
<b>XM7RM1</b>	<b>Stavudine</b>
<b>XM5471</b>	<b>Lamivudine</b>
<b>XM35P4</b>	<b>Abacavir</b>
<b>XM67N3</b>	<b>Tenofovir disoproxil</b>

<b>XM96H1</b>	<b>Adefovir</b>
<b>XM2L06</b>	<b>Emtricitabine</b>
<b>XM0Z52</b>	<b>Entecavir</b>
<b>XM2P85</b>	<b>Telbivudine</b>
<b>XM9K66</b>	<b>Clevudine</b>
<b>XM06Z6</b>	<b>Tenofovir alafenamide</b>
<b>XM5PT4</b>	<b>Non-nucleoside reverse transcriptase inhibitors</b>
<b>XM10T5</b>	<b>Nevirapine</b>
<b>XM0LC3</b>	<b>Delavirdine</b>
<b>XM1DX2</b>	<b>Efavirenz</b>
<b>XM7N44</b>	<b>Etravirine</b>
<b>XM1KD4</b>	<b>Rilpivirine</b>
<b>XM6DT0</b>	<b>Neuraminidase inhibitors</b>
<b>XM0JN4</b>	<b>Zanamivir</b>
<b>XM6823</b>	<b>Oseltamivir</b>
<b>XM0AQ6</b>	<b>Peramivir</b>
<b>XM6M67</b>	<b>Laninamivir</b>
<b>XM9DH8</b>	<b>Antivirals for treatment of hepatitis C infections</b>
<b>XM8YT1</b>	<b>Ribavirin</b>
<b>XM2WF9</b>	<b>Telaprevir</b>
<b>XM07W4</b>	<b>Boceprevir</b>
<b>XM1QK4</b>	<b>Faldaprevir</b>
<b>XM9FF9</b>	<b>Simeprevir</b>
<b>XM6LF8</b>	<b>Asunaprevir</b>
<b>XM41F6</b>	<b>Daclatasvir</b>
<b>XM0ZZ5</b>	<b>Sofosbuvir</b>
<b>XM34X5</b>	<b>Dasabuvir</b>
<b>XM5HK2</b>	<b>Elbasvir</b>
<b>XM9WK5</b>	<b>Grazoprevir</b>
<b>XM6ZX2</b>	<b>Coblopasvir</b>

<b>XM3SJ3</b>	<b>Antivirals for treatment of hepatitis C infections, combinations</b>
<b>XM5CA7</b>	<b>Sofosbuvir and Ledipasvir</b>
<b>XM4R75</b>	<b>Dasabuvir, Ombitasvir, Paritaprevir and Ritonavir</b>
<b>XM70P2</b>	<b>Ombitasvir, Paritaprevir and Ritonavir</b>
<b>XM7VS7</b>	<b>Elbasvir and Grazoprevir</b>
<b>XM3K33</b>	<b>Sofosbuvir and Velpatasvir</b>
<b>XM14S9</b>	<b>Sofosbuvir, Velpatasvir and Voxilaprevir</b>
<b>XM1NF4</b>	<b>Glecaprevir and Pibrentasvir</b>
<b>XM10G0</b>	<b>Daclatasvir, Asunaprevir and Beclabuvir</b>
<b>XM3U67</b>	<b>Antivirals for treatment of human immunodeficiency virus infections, combinations</b>
<b>XM5UM7</b>	<b>Zidovudine and Lamivudine</b>
<b>XM41D4</b>	<b>Lamivudine and Abacavir</b>
<b>XM75H2</b>	<b>Tenofovir disoproxil and Emtricitabine</b>
<b>XM2F89</b>	<b>Zidovudine, Lamivudine and Abacavir</b>
<b>XM0SL5</b>	<b>Zidovudine, Lamivudine and Nevirapine</b>
<b>XM7RZ6</b>	<b>Emtricitabine, Tenofovir disoproxil and Efavirenz</b>
<b>XM99U8</b>	<b>Stavudine, Lamivudine and Nevirapine</b>
<b>XM1KH0</b>	<b>Emtricitabine, Tenofovir disoproxil and Rilpivirine</b>
<b>XM99Q5</b>	<b>Emtricitabine, Tenofovir disoproxil, Elvitegravir and Cobicistat</b>
<b>XM3EH7</b>	<b>Lopinavir</b>
<b>XM9NL2</b>	<b>Lamivudine, Tenofovir disoproxil and Efavirenz</b>
<b>XM50Z0</b>	<b>Lamivudine and Tenofovir disoproxil</b>
<b>XM2UU9</b>	<b>Lamivudine, Abacavir and Dolutegravir</b>
<b>XM1FA4</b>	<b>Darunavir and Cobicistat</b>
<b>XM4KM0</b>	<b>Atazanavir and Cobicistat</b>
<b>XM0229</b>	<b>Lamivudine and Raltegravir</b>
<b>XM8RF0</b>	<b>Emtricitabine and Tenofovir alafenamide</b>
<b>XM4JT2</b>	<b>Emtricitabine, Tenofovir alafenamide, Elvitegravir and Cobicistat</b>
<b>XM08B7</b>	<b>Emtricitabine, Tenofovir alafenamide and Rilpivirine</b>
<b>XM0UN9</b>	<b>Emtricitabine, Tenofovir alafenamide and Bictegravir</b>

<b>XM4C60</b>	<b>Dolutegravir and Rilpivirine</b>
<b>XM7T33</b>	<b>Emtricitabine, Tenofovir alafenamide, Darunavir and Cobicistat</b>
<b>XM4TF3</b>	<b>Atazanavir and Ritonavir</b>
<b>XM5FB9</b>	<b>Lamivudine, Tenofovir disoproxil and Doravirine</b>
<b>XM9CE4</b>	<b>Lamivudine and Dolutegravir</b>
<b>XM8ZN1</b>	<b>Darunavir and Ritonavir</b>
<b>XM8QY9</b>	<b>Lamivudine, Tenofovir disoproxil and Dolutegravir</b>
<b>XM63K0</b>	<b>Anti-infective antiviral</b>
<b>XM7SG2</b>	<b>Dideoxyinosine</b>
<b>XM9VL0</b>	<b>Foscarnet sodium</b>
<b>XM6CJ2</b>	<b>Fosfonet sodium</b>
<b>XM1R42</b>	<b>Ibacicabine</b>
<b>XM6SP8</b>	<b>Metisazone</b>
<b>XM5GV1</b>	<b>Moroxydine</b>
<b>XM6WB2</b>	<b>Trifluridine</b>
<b>XM60K5</b>	<b>Lysozyme</b>
<b>XM8AQ1</b>	<b>Inosine pranobex</b>
<b>XM23V6</b>	<b>Pleconaril</b>
<b>XM1EQ6</b>	<b>Enfuvirtide</b>
<b>XM82D3</b>	<b>Raltegravir</b>
<b>XM3FG0</b>	<b>Maraviroc</b>
<b>XM7HJ6</b>	<b>Maribavir</b>
<b>XM7WY9</b>	<b>Elvitegravir</b>
<b>XM6K45</b>	<b>Dolutegravir</b>
<b>XM3S98</b>	<b>Umifenovir</b>
<b>XM8CN1</b>	<b>Enisamium iodide</b>
<b>XM01X3</b>	<b>Letermovir</b>
<b>XM1UC2</b>	<b>Tilorone</b>
<b>XM90X2</b>	<b>Pentanedioic acid imidazolyl ethanamide</b>

<b>XM2KW1</b>	<b>Ibalizumab</b>
<b>XM7FP8</b>	<b>Tecovirimat</b>
<b>XM9A16</b>	<b>Baloxavir marboxil</b>
<b>XM1QY5</b>	<b>Amenamevir</b>
<b>XM2L29</b>	<b>Favipiravir</b>
<b>XM1KL9</b>	<b>Cobicistat</b>
<b>XM85A9</b>	<b>Lenacapavir</b>

Antivenin, antivenom (sera), Immunoglobulin

<b>XM6MB2</b>	<b>AHLG</b>
<b>XM9CH0</b>	<b>Anti-human lymphocytic globulin</b>
<b>XM9L34</b>	<b>Antidiphtheria serum</b>
<b>XM9D37</b>	<b>Antiscorpion sera</b>
<b>XM5CP2</b>	<b>Antitoxin</b>
<b>XM81Z0</b>	<b>Antitoxin gas gangrene</b>
<b>XM5TW5</b>	<b>Antivenin, antivenom (sera)</b>
<b>XM2T48</b>	<b>Antivenin, antivenom crotaline</b>
<b>XM6D91</b>	<b>Antivenin, antivenom spider bite</b>
<b>XM4XP6</b>	<b>Black widow spider antivenin</b>
<b>XM7VG2</b>	<b>Gamimune</b>
<b>XM6Z81</b>	<b>Gamma globulin</b>
<b>XM7MC6</b>	<b>Gamulin</b>
<b>XM1AG2</b>	<b>Glandular extract (medicinal)</b>
<b>XM8MQ7</b>	<b>Globulin antilymphocytic</b>
<b>XM6UW5</b>	<b>Globulin antirhesus</b>
<b>XM3LT2</b>	<b>Globulin antivenin</b>
<b>XM9XP6</b>	<b>Globulin antiviral</b>
<b>XM5443</b>	<b>Homo-tet</b>
<b>XM3KZ0</b>	<b>Horse anti-human lymphocytic serum</b>

<b>XM7BR5</b>	<b>Human immune serum</b>
<b>XM42S1</b>	<b>Hypertussis</b>
<b>XM5DZ4</b>	<b>Pegademase, bovine</b>
<b>XM67L1</b>	<b>RhoGAM</b>
<b>XM77D4</b>	<b>Serum anti-Rh</b>
<b>XM3HE6</b>	<b>Serum antbotulinus</b>
<b>XM9V23</b>	<b>Serum anticytotoxic</b>
<b>XM7HP0</b>	<b>Serum antimeningococcus</b>
<b>XM5F14</b>	<b>Serum antitetanic</b>
<b>XM8MX1</b>	<b>Serum antitoxic</b>
<b>XM9QJ7</b>	<b>Serum convalescent</b>
<b>XM0SJ2</b>	<b>Serum protective</b>
<b>XM5CC6</b>	<b>Spider antivenin</b>
<b>XM2042</b>	<b>Tetanus toxoid or vaccine antitoxin</b>
<b>XM2GK5</b>	<b>Tetanus toxoid or vaccine immune globulin (human)</b>
<b>XM8Y67</b>	<b>Vaccine antineoplastic</b>
<b>XM6VF9</b>	<b>Immune sera</b>
<b>XM2MN8</b>	<b>Diphtheria antitoxin</b>
<b>XM18X1</b>	<b>Tetanus antitoxin</b>
<b>XM5083</b>	<b>Antirabies hyperimmune serum</b>
<b>XM18Y9</b>	<b>Snake venom antiserum</b>
<b>XM0AD6</b>	<b>Botulinum antitoxin</b>
<b>XM1FR6</b>	<b>Gas-gangrene sera</b>
<b>XM1RS8</b>	<b>Immunoglobulins</b>
<b>XM0AQ7</b>	<b>Immunoglobulins, normal human</b>
<b>XM26U5</b>	<b>Immunoglobulins, normal human, intravenous</b>
<b>XM3H32</b>	<b>Immunoglobulins, normal human, extravascular</b>
<b>XM5YM7</b>	<b>Specific immunoglobulins</b>
<b>XM4361</b>	<b>Anti-D (rh) immunoglobulin</b>

<b>XM8824</b>	Tetanus immunoglobulin
<b>XM6JK2</b>	Hepatitis B immunoglobulin
<b>XM5R25</b>	Rabies immunoglobulin
<b>XM8Q08</b>	Vaccinia immunoglobulin
<b>XM3FU2</b>	Pertussis immunoglobulin
<b>XM8Z30</b>	Mumps immunoglobulin
<b>XM7X82</b>	Varicella zoster immunoglobulin
<b>XM3ZS8</b>	Rubella immunoglobulin
<b>XM1V63</b>	Staphylococcus immunoglobulin
<b>XM7NM9</b>	Cytomegalovirus immunoglobulin
<b>XM4YT6</b>	Diphtheria immunoglobulin
<b>XM7LD1</b>	Hepatitis A immunoglobulin
<b>XM5NX5</b>	Encephalitis, tick borne immunoglobulin
<b>XM1GU6</b>	Measles immunoglobulin
<b>XM45N8</b>	Palivizumab
<b>XM0QB1</b>	Motavizumab
<b>XM0U74</b>	Raxibacumab
<b>XM8Y60</b>	Anthrax immunoglobulin
<b>XM6GD5</b>	Bezlotoxumab
<b>XM54X9</b>	Obiltoxaximab
<b>XM1BS2</b>	<b>Immunoglobulin not elsewhere classified</b>
<b>XM3NK9</b>	<b>Antiviral monoclonal antibodies</b>
<b>XM78P5</b>	Tixagevimab
<b>XM1CT9</b>	Cilgavimab

#### Vaccines

<b>XM3KV2</b>	<b>Bacterial vaccines</b>
<b>XM29K4</b>	<b>Cholera vaccines</b>
<b>XM3Z26</b>	Cholera, inactivated, whole cell vaccines
<b>XM72A0</b>	Cholera, live attenuated vaccines
<b>XM1FT6</b>	Cholera, combinations with typhoid vaccine, inactivated, whole cell vaccines

<b>XM11V3</b>	<b>Haemophilus influenzae B vaccines</b>
	<b>Coded Elsewhere:</b> Diphtheria, hemophilus influenzae B, pertussis, poliomyelitis, tetanus vaccines (XM1LX9)
	Hemophilus influenzae B and poliomyelitis vaccines (XM01H1)
	Hemophilus influenzae B and hepatitis B vaccines (XM32L7)
	Diphtheria, hemophilus influenzae B, pertussis, tetanus, hepatitis B vaccines (XM7JP3)
	Diphtheria, hemophilus influenzae B, pertussis, tetanus- hepatitis B, meningococcus A + C vaccines (XM5XP9)
	Diphtheria tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM21E6)
	Diphtheria, hepatitis B, tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM84S1)
<b>XM6RG9</b>	Hib, purified antigen conjugated vaccines
<b>XM7F70</b>	Hib, combinations with toxoids vaccines
<b>XM81F7</b>	Hib, combinations with pertussis and toxoids vaccines
<b>XM0X86</b>	Hib, combinations with meningococcus C, conjugated vaccines
<b>XM2WV4</b>	<b>Meningococcal vaccines</b>
<b>XM92B2</b>	Meningococcal monovalent purified polysaccharides antigen vaccines
<b>XM5LC2</b>	Meningococcal polyvalent purified polysaccharides antigen vaccines
<b>XM3T39</b>	Meningococcus A, C, bivalent purified polysaccharides antigen vaccines
	<b>Coded Elsewhere:</b> Diphtheria, hemophilus influenzae B, pertussis, tetanus- hepatitis B, meningococcus A + C vaccines (XM5XP9)
<b>XM2AR0</b>	Meningococcus A, C, Y, W-135, tetravalent purified polysaccharides antigen vaccines
<b>XM2EH7</b>	Meningococcus A, C, Y, W-135, tetravalent purified polysaccharides antigen conjugated vaccines
<b>XM18Y8</b>	Meningococcus C, purified polysaccharides antigen conjugated vaccines
<b>XM2280</b>	Meningococcus A, purified polysaccharides antigen conjugated vaccines
<b>XM9GJ1</b>	Meningococcus B, outer membrane vesicle vaccines
<b>XM1X81</b>	Meningococcus B, multicomponent vaccines
<b>XM37L5</b>	Meningococcus A, purified polysaccharides antigen vaccines

<b>XM43M9</b>	<b>Pertussis vaccines</b>
	<b>Coded Elsewhere:</b> Tetanus, diphtheria, acellular pertussis vaccines (XM31Q8)
	Diphtheria vaccines combination including pertussis (XM46V1)
	Diphtheria, pertussis, poliomyelitis, tetanus vaccines (XM09Q7)
	Diphtheria, hepatitis B, pertussis, tetanus vaccines (XM41N3)
	Diphtheria, hemophilus influenzae B, pertussis, poliomyelitis, tetanus vaccines (XM1LX9)
	Diphtheria, hemophilus influenzae B, pertussis, tetanus, hepatitis B vaccines (XM7JP3)
	Diphtheria, pertussis, poliomyelitis, tetanus, hepatitis B vaccines (XM0LT9)
	Diphtheria, hemophilus influenzae B, pertussis, tetanus- hepatitis B, meningococcus A + C vaccines (XM5XP9)
	Diphtheria tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM21E6)
	Diphtheria, hepatitis B, tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM84S1)
	Diphtheria, tetanus, acellular pertussis, inactivated polio virus vaccines (XM9JP8)
<b>XM45L8</b>	Pertussis, inactivated, whole cell vaccines
<b>XM62J1</b>	Pertussis, purified antigen vaccines
<b>XM2TK2</b>	Pertussis, inactivated, whole cell, combinations with toxoids vaccines
<b>XM4082</b>	Pertussis, purified antigen, combinations with toxoids vaccines
<b>XM2CV8</b>	Vaccines pertussis with diphtheria
<b>XM9EM7</b>	<b>Pneumococcal vaccines</b>
<b>XM9G97</b>	Pneumococcal conjugate (13-valent) vaccines
<b>XM2249</b>	Pneumococcal polysaccharide 23-valent vaccines
<b>XM91D7</b>	Pneumococcus, purified polysaccharides antigen vaccines
<b>XM96S7</b>	Pneumococcus, purified polysaccharides antigen conjugated vaccines
<b>XM4R39</b>	Pneumococcus purified polysaccharides antigen and Haemophilus influenzae, conjugated vaccines

<b>XM5L44</b>	<b>Tetanus vaccines</b>
	<b>Coded Elsewhere:</b> Diphtheria, poliomyelitis, tetanus vaccines (XM8AW1)
	Diphtheria, pertussis, poliomyelitis, tetanus vaccines (XM09Q7)
	Diphtheria, rubella, tetanus vaccines (XM9744)
	Diphtheria, hepatitis B, pertussis, tetanus vaccines (XM41N3)
	Diphtheria, hemophilus influenzae B, pertussis, poliomyelitis, tetanus vaccines (XM1LX9)
	Diphtheria, hepatitis B, tetanus vaccines (XM3G68)
	Diphtheria, hemophilus influenzae B, pertussis, tetanus, hepatitis B vaccines (XM7JP3)
	Diphtheria, pertussis, poliomyelitis, tetanus, hepatitis B vaccines (XM0LT9)
	Diphtheria, hemophilus influenzae B, pertussis, tetanus- hepatitis B, meningococcus A + C vaccines (XM5XP9)
	Diphtheria tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM21E6)
	Diphtheria, hepatitis B, tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM84S1)
	Diphtheria, tetanus, acellular pertussis, inactivated polio virus vaccines (XM9JP8)
<b>XM29H5</b>	Tetanus toxoid vaccines
<b>XM1G86</b>	Tetanus toxoid, combinations with diphtheria toxoid vaccines
<b>XM9AK2</b>	Tetanus toxoid, combinations with tetanus immunoglobulin vaccines
<b>XM31Q8</b>	Tetanus, diphtheria, acellular pertussis vaccines
<b>XM1PB8</b>	Triple vaccines DPT
<b>XM9ZL9</b>	Pertussis vaccines (with diphtheria toxoid) (with tetanus toxoid)
<b>XM9YH9</b>	Diphtheria toxoid with tetanus toxoid with pertussis component vaccines
<b>XM32Q5</b>	Tetanus and diphtheria vaccines
<b>XM4039</b>	Vaccines diphtheria with tetanus
<b>XM8XH5</b>	Tetanus toxoid or vaccines toxoid with diphtheria toxoid
<b>XM8BU8</b>	<b>Typhoid vaccines</b>
	<b>Coded Elsewhere:</b> Typhoid, hepatitis A vaccines (XM3JA6)
<b>XM33K4</b>	Typhoid, oral, live attenuated vaccines
<b>XM89G3</b>	Typhoid, inactivated, whole cell vaccines
<b>XM3SF6</b>	Typhoid, purified polysaccharide antigen vaccines
<b>XM9UB1</b>	Typhoid-paratyphoid vaccines

<b>XM3VD2</b>	Vaccines TAB
<b>XM95H3</b>	Paratyphoid vaccines
<b>XM8ZX8</b>	<b>Plague vaccines</b>
<b>XM3796</b>	Plague, inactivated, whole cell vaccines
<b>XM9SW5</b>	<b>Vaccines bacterial with other bacterial component</b>
<b>XM91J8</b>	<b>Vaccines rickettsial</b>
<b>XM3JJ2</b>	Typhus (exanthematicus) vaccines
<b>XM2NU8</b>	Typhus exanthematicus, inactivated, whole cell vaccines
<b>XM4F19</b>	Vaccines rickettsial with bacterial component
<b>XM0E84</b>	Rocky Mountain spotted fever vaccines
<b>XM5926</b>	<b>Vaccines bacterial mixed, not elsewhere classified</b>
<b>XM8NU9</b>	<b>Anthrax vaccines</b>
<b>XM2C05</b>	Anthrax antigen vaccines
<b>XM7PB3</b>	<b>Brucellosis vaccines</b>
<b>XM7RX8</b>	Brucella antigen vaccines

<b>XM8AW3</b>	<b>Diphtheria vaccines</b>
	<b>Coded Elsewhere:</b> Tetanus, diphtheria, acellular pertussis vaccines (XM31Q8)
	Tetanus and diphtheria vaccines (XM32Q5)
	Vaccines pertussis with diphtheria (XM2CV8)
	Diphtheria, poliomyelitis, tetanus vaccines (XM8AW1)
	Diphtheria, pertussis, poliomyelitis, tetanus vaccines (XM09Q7)
	Diphtheria, rubella, tetanus vaccines (XM9744)
	Diphtheria, hepatitis B, pertussis, tetanus vaccines (XM41N3)
	Diphtheria, hemophilus influenzae B, pertussis, poliomyelitis, tetanus vaccines (XM1LX9)
	Diphtheria, hepatitis B, tetanus vaccines (XM3G68)
	Diphtheria, hemophilus influenzae B, pertussis, tetanus, hepatitis B vaccines (XM7JP3)
	Diphtheria, pertussis, poliomyelitis, tetanus, hepatitis B vaccines (XM0LT9)
	Diphtheria, hemophilus influenzae B, pertussis, tetanus- hepatitis B, meningococcus A + C vaccines (XM5XP9)
	Diphtheria tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM21E6)
	Diphtheria, hepatitis B, tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM84S1)
	Diphtheria, tetanus, acellular pertussis, inactivated polio virus vaccines (XM9JP8)
<b>XM86V7</b>	Diphtheria toxoid vaccines
<b>XM46V1</b>	Diphtheria vaccines combination including pertussis
<b>XM39K8</b>	Diphtheria vaccines combination without pertussis
<b>XM8YP9</b>	Diphtheria vaccines combination
<b>XM4639</b>	<b>Tuberculosis vaccines</b>
<b>XM8142</b>	Tuberculosis, live attenuated vaccines
<b>XM61M7</b>	<b>Viral vaccines</b>

<b>XM68M6</b>	<b>COVID-19 vaccines</b>
	<p>These codes have been assigned based on the landscape documents that have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.</p>
<b>XM1NL1</b>	COVID-19 vaccines, inactivated virus
	<p>These codes have been assigned based on the landscape documents that have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.</p>
<b>XM7HT3</b>	CoronaVac® Inactivated COVID-19 (VERO CELL) vaccine
<b>XM8866</b>	Covilo  <b><i>Exclusions:</i></b> Inactivated SARS-CoV-2 vaccine (XM1FB4)
<b>XM9TQ1</b>	KCONVAC  <b><i>Exclusions:</i></b> Inactivated SARS-CoV-2 vaccine (XM1FB4)
<b>XM1G90</b>	Covaxin
<b>XM85P5</b>	Covi-Vac
<b>XM9FQ7</b>	Hayat-Vax
<b>XM97N6</b>	QazVac

<b>XM2YG8</b>	COVIran Barekat
<b>XM0K39</b>	Covidful
<b>XM0J98</b>	FAKHRAVAC (MIVAC)
<b>XM1FB4</b>	Inactivated SARS-CoV-2 vaccine
<b>XM86F7</b>	Turkovac
<b>XM42N8</b>	VLA2001
<b>XM5DF6</b>	COVID-19 vaccines, live attenuated virus
	These codes have been assigned based on the landscape documents that have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents
<b>XM9QW8</b>	COVID-19 vaccines, non-replicating viral vector
	These codes have been assigned based on the landscape documents that have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
<b>XM4YL8</b>	COVID-19 Vaccine AstraZeneca - Vaxzevria
	Viral vector vaccine using as a vector the modified chimpanzee adenovirus ChAdOx1.

<b>XM97T2</b>	Covishield® Viral vector vaccine using as a vector the modified chimpanzee adenovirus ChAdOx1.
<b>XM6QV1</b>	COVID-19 Vaccine Janssen Viral vector vaccine based on a modified human adenovirus 26.
<b>XM1AG7</b>	Convidecia
<b>XM5QM6</b>	Sputnik-Light
<b>XM4T09</b>	Convidecia Air
<b>XM2LP0</b>	Convidecia Air XBB1.5.
<b>XM6Z24</b>	Gam-COVID-Vac (intranasal)
<b>XM4PM4</b>	Gam-COVID-Vac-M
<b>XM5309</b>	iNCOVACC
<b>XM4N49</b>	Jcovden
<b>XM37C0</b>	Sputnik-V
<b>XM0CX4</b>	COVID-19 vaccines, replicating viral vector  These codes have been assigned based on the landscape documents that have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
<b>XM5BL0</b>	DeINS1-2019-nCoV-RBD-OPT1

<b>XM5JC5</b>	COVID-19 vaccines, virus protein subunit These codes have been assigned based on the landscape documents that have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
<b>XM3CT4</b>	Zifivax
<b>XM8T18</b>	Abdala
<b>XM3PG0</b>	Soberana-02
<b>XM4EC8</b>	MVC COVID-19
<b>XM6SZ8</b>	EpiVacCorona
<b>XM0RV9</b>	Soberana Plus
<b>XM3SK8</b>	Aurora-CoV
<b>XM9P21</b>	SpikoGen
<b>XM9T65</b>	NUVAXOVID
<b>XM9N08</b>	Razi COV PARS
<b>XM6790</b>	Bimervax
<b>XM8R60</b>	Bivalent Omicron
<b>XM63N7</b>	Corbevax
<b>XM2NP9</b>	Coviccine
<b>XM0E93</b>	Coviccine Trivalent (XBB.1.5+BA.5+Delta)
<b>XM85Q5</b>	Covovax
<b>XM85Q8</b>	EuCorVac-19
<b>XM7E37</b>	Indovac
<b>XM7P85</b>	Noora
<b>XM2FM2</b>	NUVAXOVID XBB1.5.

<b>XM97Q5</b>	PastoCovac
<b>XM8BU1</b>	PastoCovac Plus
<b>XM9P29</b>	Recombinant SARS-CoV-2 Vaccine (CHO Cell)
<b>XM5YS2</b>	SARS-COV-2 Bivalent
<b>XM8ME2</b>	SCB-2019
<b>XM71X6</b>	SCTV01C
<b>XM62V8</b>	SKYcovione
<b>XM8267</b>	Tetraivalent SCTV01E
<b>XM6WB0</b>	V-01
<b>XM9ZB6</b>	Vidprevlyn Beta
<b>XM1J92</b>	COVID-19 vaccines, virus like particle  These codes have been assigned based on the landscape documents that have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents
<b>XM0BS6</b>	Covifenz

<b>XM6AT1</b>	COVID-19 vaccines, DNA based  These codes have been assigned based on the landscape documents that have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
<b>XM52P3</b>	ZyCov-D
<b>XM0GQ8</b>	COVID-19 vaccines, RNA based  These codes have been assigned based on the landscape documents that have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
<b>XM8NQ0</b>	Comirnaty®  A nucleoside-modified messenger RNA (modified nucleosides or by synthetic nucleoside analogues).
<b>XM3DT5</b>	COVID-19 Vaccine Moderna - Spikevax  A nucleoside-modified messenger RNA (modified nucleosides or by synthetic nucleoside analogues).
<b>XM5E97</b>	AWcorna
<b>XM1CQ8</b>	Comirnaty Bivalent Original/Omicron BA.1
<b>XM5U85</b>	Comirnaty Bivalent Original/Omicron BA.4/BA.5

<b>XM7U45</b>	Comirnaty XBB.1.5.
<b>XM6HM3</b>	Daichirona
<b>XM15E9</b>	Duentai
<b>XM2708</b>	Duentai Bivalent (XBB.1.5+BQ.1)
<b>XM3X29</b>	Gemcovac-19
<b>XM8FH6</b>	Gemcovac-OM
<b>XM6FF0</b>	KOSTAIVE
<b>XM0QH5</b>	COVID-19 Vaccine Moderna - Spikevax Bivalent Original/Omicron BA.1
<b>XM3984</b>	COVID-19 Vaccine Moderna - Spikevax Bivalent Original/Omicron BA.4/BA.5
<b>XM21B8</b>	COVID-19 Vaccine Moderna - Spikevax XBB1.5.
<b>XM38G7</b>	<b>Dengue vaccines</b>
<b>XM7P50</b>	<b>Ebola vaccines</b>
<b>XM0RC1</b>	<b>Encephalitis vaccines</b>
<b>XM8MP6</b>	Encephalitis, tick borne, inactivated, whole virus
<b>XM0LB5</b>	Encephalitis, Japanese, inactivated, whole virus
<b>XM47S0</b>	Encephalitis, Japanese, live attenuated
<b>XM1LR5</b>	<b>Influenza vaccines</b>
<b>XM8857</b>	Influenza vaccines, inactivated, whole virus
<b>XM5V64</b>	Influenza vaccines, live attenuated
<b>XM8MP2</b>	Influenza vaccines, inactivated, split virus or surface antigen
<b>XM9E16</b>	Influenza vaccines, virus like particle
<b>XM33X8</b>	Influenza, purified antigen
<b>XM6LL6</b>	<b>Hepatitis vaccines</b>
	<b>Coded Elsewhere:</b> Diphtheria, hepatitis B, pertussis, tetanus vaccines (XM41N3)

<b>XM9V38</b>	Hepatitis B, purified antigen  <b>Coded Elsewhere:</b> Diphtheria, hepatitis B, tetanus vaccines (XM3G68) Hemophilus influenzae B and hepatitis B vaccines (XM32L7) Diphtheria, hemophilus influenzae B, pertussis, tetanus, hepatitis B vaccines (XM7JP3) Diphtheria, pertussis, poliomyelitis, tetanus, hepatitis B vaccines (XM0LT9) Diphtheria, hemophilus influenzae B, pertussis, tetanus- hepatitis B, meningococcus A + C vaccines (XM5XP9) Diphtheria, hepatitis B, tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM84S1)
<b>XM2A12</b>	Hepatitis A, inactivated, whole virus  <b>Coded Elsewhere:</b> Typhoid, hepatitis A vaccines (XM3JA6)
<b>XM03Y7</b>	Combinations hepatitis vaccines
<b>XM28X5</b>	<b>Measles vaccines</b>
<b>XM8L15</b>	Measles, live attenuated
<b>XM9439</b>	Measles, combinations with mumps, live attenuated
<b>XM8TF3</b>	Measles, combinations with mumps and rubella, live attenuated
<b>XM21H2</b>	Measles, combinations with rubella, live attenuated
<b>XM4AJ8</b>	Measles, combinations with mumps, rubella and varicella, live attenuated
<b>XM1131</b>	<b>Mumps vaccines</b>
<b>XM2340</b>	Mumps, live attenuated
<b>XM0N50</b>	<b>Poliomyelitis vaccines</b>  <b>Coded Elsewhere:</b> Diphtheria, poliomyelitis, tetanus vaccines (XM8AW1) Diphtheria, pertussis, poliomyelitis, tetanus vaccines (XM09Q7) Hemophilus influenzae B and poliomyelitis vaccines (XM01H1) Diphtheria, hemophilus influenzae B, pertussis, poliomyelitis, tetanus vaccines (XM1LX9) Diphtheria, pertussis, poliomyelitis, tetanus, hepatitis B vaccines (XM0LT9) Diphtheria tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM21E6) Diphtheria, hepatitis B, tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines (XM84S1) Diphtheria, tetanus, acellular pertussis, inactivated polio virus vaccines (XM9JP8)
<b>XM4KG4</b>	Orimune

<b>XM1Y59</b>	Vaccine sabin oral
<b>XM2KH7</b>	Diplovax
<b>XM0VX8</b>	Poliomyelitis oral, monovalent live attenuated
<b>XM0KZ1</b>	Poliomyelitis oral, trivalent, live attenuated
<b>XM79H3</b>	Poliomyelitis oral, bivalent, live attenuated
<b>XM5V19</b>	Poliomyelitis, trivalent, inactivated, whole virus
<b>XM1CE0</b>	<b>Rotavirus diarrhoea vaccines</b>
<b>XM4GV0</b>	Rota virus, live attenuated
<b>XM4VG1</b>	Rota virus, pentavalent, live, reassorted
<b>XM7PP1</b>	<b>Rubella vaccines</b> <i>Coded Elsewhere:</i> Diphtheria, rubella, tetanus vaccines (XM9744)
<b>XM9PS9</b>	Rubella, live attenuated
<b>XM3B09</b>	Rubella, combinations with mumps, live attenuated
<b>XM8DG3</b>	<b>Varicella zoster vaccines</b>
<b>XM0NS8</b>	Varicella, live attenuated
<b>XM1SS1</b>	Zoster, live attenuated
<b>XM9QP0</b>	<b>Papillomavirus vaccines</b>
<b>XM1821</b>	Papillomavirus (human types 6,11,16,18)
<b>XM9BT4</b>	Papillomavirus (human types 16,18)
<b>XM5CE9</b>	Papillomavirus (human types 6,11,16,18,31,33,45,52,58)
<b>XM95R0</b>	<b>Smallpox vaccine</b>
<b>XM6T09</b>	<b>Rabies vaccines</b>
<b>XM7BE8</b>	Rabies, inactivated, whole virus
<b>XM02Y0</b>	<b>Respiratory syncytial virus vaccines</b>
<b>XM69P6</b>	Synagis
<b>XM0N24</b>	<b>Yellow fever vaccines</b>
<b>XM3418</b>	Yellow fever, live attenuated
<b>XM7C66</b>	<b>Bacterial and viral vaccines, combined</b>
<b>XM8AW1</b>	Diphtheria, poliomyelitis, tetanus vaccines
<b>XM09Q7</b>	Diphtheria, pertussis, poliomyelitis, tetanus vaccines

<b>XM9744</b>	<b>Diphtheria, rubella, tetanus vaccines</b>
<b>XM41N3</b>	<b>Diphtheria, hepatitis B, pertussis, tetanus vaccines</b>
<b>XM1LX9</b>	<b>Diphtheria, hemophilus influenzae B, pertussis, poliomyelitis, tetanus vaccines</b>
<b>XM3G68</b>	<b>Diphtheria, hepatitis B, tetanus vaccines</b>
<b>XM32L7</b>	<b>Hemophilus influenzae B and hepatitis B vaccines</b>
<b>XM3JA6</b>	<b>Typhoid, hepatitis A vaccines</b>
<b>XM7JP3</b>	<b>Diphtheria, hemophilus influenzae B, pertussis, tetanus, hepatitis B vaccines</b>
<b>XM0LT9</b>	<b>Diphtheria, pertussis, poliomyelitis, tetanus, hepatitis B vaccines</b>
<b>XM5XP9</b>	<b>Diphtheria, hemophilus influenzae B, pertussis, tetanus-hepatitis B, meningococcus A + C vaccines</b>
<b>XM21E6</b>	<b>Diphtheria tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines</b>
<b>XM84S1</b>	<b>Diphtheria, hepatitis B, tetanus, acellular pertussis, inactivated polio virus, haemophilus Influenzae type B vaccines</b>
<b>XM9JP8</b>	<b>Diphtheria, tetanus, acellular pertussis, inactivated polio virus vaccines</b>
<b>XM01H1</b>	<b>Hemophilus influenzae B and poliomyelitis vaccines</b>

Other specified systemic anti-infectives and antiparasitics

**Coded Elsewhere:** Quinolones and derivatives (XM7YK9)

<b>XM5YM6</b>	<b>Metronidazole</b>
<b>XM7Z72</b>	<b>Tinidazole</b>
<b>XM6BF7</b>	<b>Trimetrexate</b>
<b>XM3Y85</b>	<b>Acetarsol</b>
<b>XM0067</b>	<b>Pentamidine</b>
<b>XM11F5</b>	<b>Suramin sodium</b>
<b>XM9CB1</b>	<b>Atovaquone</b>
<b>XM71Y7</b>	<b>Miltefosine</b>

Antiprotozoal drugs

**Coded Elsewhere:** Nitrofuran derivatives (XM2CE2)

<b>XM21E9</b>	<b>Hydroxyquinoline derivatives</b>
<b>XM5MW6</b>	<b>Broxyquinoline</b>

<b>XM1V59</b>	<b>Clioquinol</b>
<b>XM56H5</b>	<b>Chlorquinaldol</b>
<b>XM1KS8</b>	<b>Tilbroquinol</b>
<b>XM0V89</b>	<b>Tiliquinol</b>

Antimalarials and drugs acting on other blood protozoa

**Coded Elsewhere:** Biguanides (XM5DC4)

<b>XM6M61</b>	<b>8-Aminoquinoline drugs</b>
<b>XM0NC8</b>	<b>Amopyroquin</b>
<b>XM37R2</b>	<b>Anti-infective antimalarial</b>
<b>XM0VE8</b>	<b>Anti-infective antiprotozoal blood</b>
<b>XM1914</b>	<b>Antimalarial</b>
<b>XM5WN6</b>	<b>Antimalarial prophylactic</b>
<b>XM5Q32</b>	<b>Antimalarial pyrimidine derivative</b>
<b>XM7LP3</b>	<b>Antiprotozoal drug blood</b>
<b>XM0KE4</b>	<b>Chlorproguanil</b>
<b>XM38E0</b>	<b>Cinchona</b>
<b>XM9V39</b>	<b>Cinchonine alkaloids</b>
<b>XM9511</b>	<b>Daraprim</b>
<b>XM23A5</b>	<b>Guanatol</b>
<b>XM3T26</b>	<b>Halofantrine</b>
<b>XM17W0</b>	<b>Isopentaquine</b>
<b>XM50J2</b>	<b>Mefloquine</b>
<b>XM08Q1</b>	<b>Pamaquine (naphthoate)</b>
<b>XM0346</b>	<b>Pentaquine</b>
<b>XM0XQ2</b>	<b>Pyrimethamine</b>
<b>XM90Z4</b>	<b>Pyrimethamine with sulfadoxine</b>
<b>XM10R3</b>	<b>Quinacrine</b>
<b>XM8RC3</b>	<b>Quinine</b>
<b>XM0RU7</b>	<b>Quinocide</b>

<b>XM9Z81</b>	<b>Schizontocide (blood) (tissue)</b>
<b>XM50C8</b>	<b>Aminoquinolines</b>
<b>XM6ZE6</b>	<b>Chloroquine</b>
<b>XM9YB2</b>	<b>Hydroxychloroquine</b>
<b>XM9F55</b>	<b>Primaquine</b>
<b>XM3GB3</b>	<b>Amodiaquine</b>
<b>XM5EL4</b>	<b>Tafenoquine</b>
<b>XM5SP0</b>	<b>Artemisinin and derivatives, plain</b>
<b>XM1ED1</b>	<b>Artemisinin</b>
<b>XM7D52</b>	<b>Artemether</b>
<b>XM7Q22</b>	<b>Artesunate</b>
<b>XM37K1</b>	<b>Artemotil</b>
<b>XM9ND1</b>	<b>Artenimol</b>
<b>XM3B54</b>	<b>Arterolane and Piperaquine</b>
<b>XM8H63</b>	<b>Naphthoquine</b>
<b>XM6TH1</b>	<b>Artemether and Lumefantrine</b> Artemisinin-based combination of artemether + lumefantrine used for the prophylaxis and treatment of uncomplicated falciparum malaria.
<b>XM8MB3</b>	<b>Acterol</b>
<b>XM0FS7</b>	<b>Aminitroxole</b>
<b>XM4GE4</b>	<b>Anti-infective antiprotozoal</b>
<b>XM4W96</b>	<b>Antimony dimercaptosuccinate</b>
<b>XM9GG8</b>	<b>Antimony sodium dimercaptosuccinate</b>
<b>XM4393</b>	<b>Antiprotozoal drug</b>
<b>XM2HL1</b>	<b>Antitrichomonial drug</b>
<b>XM83L5</b>	<b>Bialamicol</b>
<b>XM8E05</b>	<b>Carbarsone</b>
<b>XM8DJ7</b>	<b>DHE</b>
<b>XM1RE2</b>	<b>Glaucarubin</b>
<b>XM1LB9</b>	<b>Hydroxystilbamidine</b>

<b>XM5NQ7</b>	<b>Melarsonyl potassium</b>
<b>XM4UC9</b>	<b>Melarsoprol</b>
<b>XM1HA1</b>	<b>Misonidazole</b>
<b>XM3WL0</b>	<b>Ornidazole</b>
<b>XM3E43</b>	<b>Oxphenarsine</b>
<b>XM45H6</b>	<b>Stibogluconate</b>
<b>XM0CL7</b>	<b>Stilbamidine isetionate</b>
<b>XM05U5</b>	<b>Teclozan</b>
<b>XM6XS3</b>	<b>Trichomonacides</b>
<b>XM5R30</b>	<b>Tryparsamide</b>
<b>XM7BM9</b>	<b>Nitroimidazole derivatives</b>
<b>XM4HZ1</b>	<b>Azanidazole</b>
<b>XM5LH9</b>	<b>Nimorazole</b>
<b>XM98K0</b>	<b>Secnidazole</b>
<b>XM0JG6</b>	<b>Benznidazole</b>
<b>XM61Z9</b>	<b>Propenidazole</b>
<b>XM5VX1</b>	<b>Fexinidazole</b>
<b>XM4RW6</b>	<b>Dichloroacetamide derivatives</b>
<b>XM7AM3</b>	<b>Diloxanide</b>
<b>XM9H76</b>	<b>Clefamide</b>
<b>XM3PL8</b>	<b>Etofamide</b>
<b>XM4787</b>	<b>Arsenic compounds</b>
<b>XM09B5</b>	<b>Arsthinol</b>
<b>XM0A09</b>	<b>Difetarsone</b>
<b>XM6V40</b>	<b>Glycobiarsol</b>
<b>XM64G7</b>	<b>Antimony compounds</b>
<b>XM2TP0</b>	<b>Meglumine antimonate</b>
<b>XM2284</b>	<b>Sodium stibogluconate</b>

Other agents against amoebiasis and other protozoal diseases

XM3E78	Akritoin
XM8LB8	Anti-infective arsenical
XM44A9	Anti-infective heavy metals
XM8CX5	Antimony anti-infectives
XM69W3	Antimony potassium tartrate (sodium)
XM2AH2	Antimony tartrated
XM1Z32	Antiparasitic drug specified
XM0L93	Arsphenamine (silver)
XM12U8	Bismuth salts anti-infectives
XM7A39	Bismuth salts subsalicylate
XM8SJ3	Bithionol
XM7PV2	Chiniofon
XM6DH1	Cinoxacin
XM0402	Croconazole
XM1YN6	Dichlorhydroxyquinoline
XM59A1	Disinfectant intestinal
XM4923	Flumequine
XM7BY8	Flunidazole
XM4XE9	Fluorocytosine
XM6UT2	Hexetidine
XM74Y8	Idobismitol
XM80M5	Iodoquinol
XM7T64	Lead anti-infectives
XM0FS9	Mapharsen
XM0RW4	Mercury, mercurial, mercuric, mercurous anti-infective systemic
XM08P3	Neoarsphenamine
XM0M05	Neosilversalvarsan
XM39N3	Nifuratel

<b>XM70Q8</b>	<b>Oxolinic acid</b>
<b>XM10R8</b>	<b>Potassium antimony tartrate</b>
<b>XM8WV6</b>	<b>Quiniobine</b>
<b>XM8U22</b>	<b>Quinoline (derivatives)</b>
<b>XM3VB9</b>	<b>Salvarsan 606 (neosilver) (silver)</b>
<b>XM6260</b>	<b>Silver salvarsan</b>
<b>XM3DB2</b>	<b>Sodium cacodylate anti-infective</b>
<b>XM9L57</b>	<b>Stovarsal</b>
<b>XM80F6</b>	<b>Sulfarsphenamine</b>
<b>XM96Q1</b>	<b>Tartar emetic</b>
<b>XM6A32</b>	<b>Tartrated antimony (anti-infective)</b>
<b>XM9KU4</b>	<b>Thiobismol</b>
<b>XM9UP9</b>	<b>Thiocarbarsone</b>
<b>XM5VM3</b>	<b>Tin anti-infectives</b>
<b>XM2SB0</b>	<b>Urinary anti-infective</b>
<b>XM2HD6</b>	<b>Emetine</b>
<b>XM5GF4</b>	<b>Phanquinone</b>
<b>XM9VB9</b>	<b>Mepacrine</b>
<b>XM5RX3</b>	<b>Tenonitroxazole</b>
<b>XM28N6</b>	<b>Dehydroemetine</b>
<b>XM5WJ8</b>	<b>Fumagillin</b>
<b>XM84S6</b>	<b>Nitazoxanide</b>
<b>XM9JL2</b>	<b>Eflornithine</b>

#### Anthelmintics

<b>XM2NT3</b>	<b>Alantolactone</b>
<b>XM1PP4</b>	<b>Amphotalide</b>
<b>XM8LU8</b>	<b>Anthiolimine</b>
<b>XM95R7</b>	<b>Anti-infective anthelmintic</b>

<b>XM43K9</b>	<b>Antifilarial drug</b>
<b>XM4EC0</b>	<b>Antihelmintics</b>
<b>XM9637</b>	<b>Antihookworm drug</b>
<b>XM16G5</b>	<b>Antinematode drug</b>
<b>XM2078</b>	<b>Antiplatyhelmintic drug</b>
<b>XM60W7</b>	<b>Antischistosomal drug</b>
<b>XM6500</b>	<b>Antitapeworm drug</b>
<b>XM5273</b>	<b>Antiwhipworm drug</b>
<b>XM7QL4</b>	<b>Ascaridole</b>
<b>XM9GK4</b>	<b>Aspidium (oleoresin)</b>
<b>XM3JR4</b>	<b>Benzimidazole derivatives</b>
<b>XM3GX0</b>	<b>Mebendazole</b>
<b>XM0CU8</b>	<b>Tiabendazole</b>
<b>XM79J1</b>	<b>Albendazole</b>
<b>XM8RG6</b>	<b>Flubendazole</b>
<b>XM5XC2</b>	<b>Fenbendazole</b>
<b>XM7982</b>	<b>Ciclobendazole</b>
<b>XM3667</b>	<b>Bephenium</b>
<b>XM6FY4</b>	<b>Bithionol anthelminthic</b>
<b>XM5L27</b>	<b>Bitoscanate</b>
<b>XM4WY5</b>	<b>Chenopodium</b>
<b>XM0ZD3</b>	<b>Dichlorophen</b>
<b>XM8C12</b>	<b>Dithiazanine iodide</b>
<b>XM2RX7</b>	<b>Filix mas</b>
<b>XM05F2</b>	<b>Ivermectin</b>
<b>XM5W42</b>	<b>Levamisole</b>
<b>XM9Z70</b>	<b>Lucanthone</b>
<b>XM4SZ4</b>	<b>Male fern extract</b>
<b>XM2034</b>	<b>Niclosamide</b>

<b>XM2WY0</b>	<b>Niridazole</b>
<b>XM7NR1</b>	<b>Nitrothiazol</b>
<b>XM5JZ6</b>	<b>Oxamniquine</b>
<b>XM9FH0</b>	<b>Pelletierine tannate</b>
<b>XM5ZH0</b>	<b>Perchloroethylene medicinal</b>
<b>XM3T27</b>	<b>Pinkroot</b>
<b>XM8205</b>	<b>Praziquantel</b>
<b>XM7SZ5</b>	<b>Pumpkin seed extract</b>
<b>XM5PX0</b>	<b>Pyrvinium</b>
<b>XM9KL1</b>	<b>Santonin</b>
<b>XM3FE9</b>	<b>Spigelia (root)</b>
<b>XM5VV1</b>	<b>Stibophen</b>
<b>XM4GA8</b>	<b>Teroxalene</b>
<b>XM7PN4</b>	<b>Tetrachloroethylene medicinal</b>
<b>XM93X2</b>	<b>Tetramisole</b>
<b>XM2621</b>	<b>Urea stibamine</b>
<b>XM5C18</b>	<b>Veroxil</b>
<b>XM3AT4</b>	<b>Viprynum</b>
<b>XM4555</b>	<b>Wormseed, American</b>
<b>XM6U56</b>	<b>Tetrahydropyrimidine derivatives</b>
<b>XM90N4</b>	<b>Pyrantel</b>
<b>XM05V2</b>	<b>Oxantel</b>
<b>XM9H59</b>	<b>Metrifonate</b>
<b>XM7VW8</b>	<b>Triclabendazole</b>
<b>XM7F99</b>	<b>Moxidectin</b>
<b>XM0399</b>	<b>Desaspardin</b>

Neuroprotective agents, not elsewhere classified

<b>XM9DZ4</b>	<b>Tetrabenazine</b>
---------------	----------------------

<b>XM3BR4</b>	<b>Memantine</b>
<b>XM1CG4</b>	<b>Ginkgo folium</b>
<b>XM9VG8</b>	<b>Tirilazad</b>
<b>XM9Z74</b>	<b>Riluzole</b>
<b>XM4ER7</b>	<b>Xaliproden</b>
<b>XM5PS1</b>	<b>Fampridine</b>
<b>XM2AL2</b>	<b>Tafamidis</b>
<b>XM1LU9</b>	<b>Laquinimod</b>
<b>XM3QR7</b>	<b>Pitolisant</b>
<b>XM3FT2</b>	<b>Patisiran</b>
<b>XM1KZ8</b>	<b>Edaravone</b>
<b>XM7DT3</b>	<b>Inotersen</b>
<b>XM8MX8</b>	<b>Valbenazine</b>
<b>XM87M0</b>	<b>Aducanumab</b>
<b>XM5UK9</b>	<b>Deutetrabenazine</b>
<b>XM4F26</b>	<b>Arimoclomol</b>

Analgesics, antipyretics and anti-inflammatory drugs

<b>XM4KS4</b>	<b>Nonsteroidal anti-inflammatory and antirheumatic agents</b>
<b>XM7W23</b>	<b>Butylpyrazolidines</b>
<b>XM8HN0</b>	<b>Phenylbutazone</b>
<b>XM8P27</b>	<b>Mofebutazone</b>
<b>XM12M5</b>	<b>Oxyphenbutazone</b>
<b>XM8X86</b>	<b>Clofezone</b>
<b>XM4H41</b>	<b>Kebuzone</b>
<b>XM74U4</b>	<b>Acetic acid derivatives and related substances</b>
<b>XM7497</b>	<b>Indometacin</b>
<b>XM24W2</b>	<b>Sulindac</b>
<b>XM97N5</b>	<b>Tolmetin</b>
<b>XM92G8</b>	<b>Zomepirac</b>

<b>XM2AU1</b>	Diclofenac
<b>XM2186</b>	Etodolac
<b>XM8M52</b>	Ketorolac
<b>XM6KJ8</b>	Bumadizone
<b>XM12Q6</b>	Lonazolac
<b>XM2AX1</b>	Fentiazac
<b>XM3458</b>	Acemetacin
<b>XM7K80</b>	Difenpiramide
<b>XM7CA3</b>	Oxametacin
<b>XM2P51</b>	Proglumetacin
<b>XM5W40</b>	Aceclofenac
<b>XM7AB1</b>	Bufexamac
<b>XM9S89</b>	Alclofenac
<b>XM8G95</b>	Ibufenac
<b>XM0UL8</b>	<b>Oxicams</b>
<b>XM9MD6</b>	Piroxicam
<b>XM7WP9</b>	Droxicam
<b>XM3X14</b>	Lornoxicam
<b>XM1XY0</b>	Meloxicam
<b>XM83U4</b>	Isoxicam
<b>XM1867</b>	Tenoxicam
<b>XM2S54</b>	<b>Propionic acid derivatives</b>
<b>XM2RR6</b>	Ibuprofen
<b>XM1KL8</b>	Naproxen
<b>XM63J5</b>	Ketoprofen
<b>XM7BS7</b>	Fenoprofen
<b>XM2N63</b>	Suprofen
<b>XM8VP8</b>	Flurbiprofen
<b>XM0WQ1</b>	Tiaprofenic acid
<b>XM9694</b>	Oxaprozin

<b>XM1918</b>	Ibuproxam
<b>XM4W51</b>	Fenbufen
<b>XM7F06</b>	Benoxyprofen
<b>XM4KX7</b>	Pirprofen
<b>XM3G14</b>	Indoprofen
<b>XM32V2</b>	Dexibuprofen
<b>XM4FK3</b>	Flunoxaprofen
<b>XM1W06</b>	Alminoprofen
<b>XM1ZF2</b>	Dexketoprofen
<b>XM9ES5</b>	Naproxinod
<b>XM8GM3</b>	Carprofen
<b>XM9DC7</b>	<b>Fenamates</b>
<b>XM6Q83</b>	Mefenamic acid
<b>XM31G8</b>	Flufenamic acid
<b>XM3W40</b>	Meclofenamic acid
<b>XM9WQ9</b>	Tolfenamic acid
<b>XM16D6</b>	<b>Coxibs</b>
<b>XM63D2</b>	Celecoxib
<b>XM70K9</b>	Rofecoxib
<b>XM4SK9</b>	Valdecoxib
<b>XM96Q4</b>	Parecoxib
<b>XM2W58</b>	Etoricoxib
<b>XM0BC7</b>	Lumiracoxib
<b>XM1N20</b>	Polmacoxib
<b>XM7AM9</b>	<b>Glafenine</b>
<b>XM3WB0</b>	<b>Floctafenine</b>
<b>XM8WS4</b>	<b>Nabumetone</b>
<b>XM6SW5</b>	<b>Azapropazone</b>
<b>XM6SR1</b>	<b>Glucosamine</b>
<b>XM73Q0</b>	<b>Benzydamine</b>

<b>XM8GX7</b>	<b>Proquazone</b>
<b>XM5C49</b>	<b>Nimesulide</b>
<b>XM37T1</b>	<b>Feprazone</b>
<b>XM4KV5</b>	<b>Niflumic acid</b>
<b>XM5Z51</b>	<b>Glucosaminoglycan polysulfate</b>
<b>XM9Z19</b>	<b>Orgotein</b>
<b>XM51H0</b>	<b>Diacerein</b>
<b>XM1019</b>	<b>Morniflumate</b>
<b>XM7Z95</b>	<b>Tenidap</b>
<b>XM4L54</b>	<b>Oxaceprol</b>
<b>XM9352</b>	<b>Chondroitin sulfate</b>
<b>XM0H27</b>	<b>Avocado and soyabean oil, unsaponifiables</b>
<b>XM9C36</b>	<b>Ethoxazene</b>
<b>XM85Z4</b>	<b>Fenflumizol</b>

Specific antirheumatic agents

<b>XM46B3</b>	<b>Analgesic antirheumatic</b>
<b>XM8DE1</b>	<b>Antiphlogistic</b>
<b>XM95N2</b>	<b>Antirheumatic</b>
<b>XM8526</b>	<b>Aurothioglycanide</b>
<b>XM4XH9</b>	<b>Farnesil</b>
<b>XM4DJ6</b>	<b>Sodium aurothiosulfate</b>
<b>XM3LE3</b>	<b>Gold preparations</b>
<b>XM9ZC2</b>	<b>Sodium aurothiomalate</b>
<b>XM5HT1</b>	<b>Auranofin</b>
<b>XM1MX1</b>	<b>Aurothioglucose</b>
<b>XM28Y9</b>	<b>Aurotioprol</b>
<b>XM8CF5</b>	<b>Sodium aurotiosulfate</b>
<b>XM0VQ7</b>	<b>Bucillamine</b>
<b>XM5L52</b>	<b>Oxycinchophen</b>

**XM1QA0      Penicillamine**

Acetylsalicylic acid and other salicylates

**XM4G06      Acetylsalicylic acid**

**XM0XT0      Carbaspirin**

**XM0GX7      Choline salicylate**

**XM72N6      Fiorinal**

**XM6PW4      Sodium salicylate**

**XM4WV7      Salicylamide**

**XM68K3      Salsalate**

**XM5UX6      Diflunisal**

**XM2JA1      Aloxiprin**

**XM3ZP5      Ethenzamide**

**XM49Y6      Morpholine salicylate**

**XM9TC0      Dipirocetyl**

**XM1UA7      Benorilate**

**XM2CV1      Potassium salicylate**

**XM1DD2      Guacetisal**

**XM4TV1      Carbasalate calcium**

**XM5UF9      Imidazole salicylate**

**XM8F16      Calcium salicylate**

**XM5X48      Carbethyl salicylate**

**XM6M40      Magnesium salicylate**

**XM8FA6      Sodium thiosalicylate**

Pyrazolone derivatives

**XM7045      Aminophenazone**

**XM7840      Analgesic pyrazole**

**XM22E9      Antipyrine**

**XM60M2      Coal tar medicinal analgesics**

<b>XM4T98</b>	<b>Dipyrone</b>
<b>XM2FJ5</b>	<b>Isopropylaminophenazone</b>
<b>XM8762</b>	<b>Myochrysin (e)</b>
<b>XM4YB4</b>	<b>Nifenazone</b>
<b>XM53Q3</b>	<b>Noramidopyrine</b>
<b>XM6GV7</b>	<b>Propyphenazone</b>
<b>XM5H28</b>	<b>Pyrazole (derivatives)</b>
<b>XM5L33</b>	<b>Pyrazolone analgesic</b>
<b>XM0K68</b>	<b>Ramifenazone</b>
<b>XM1SG0</b>	<b>Sulfamidopyrine</b>
<b>XM9CV5</b>	<b>Suxibuzone</b>

Paracetamol (acetaminophen) and 4-aminophenol derivatives

<b>XM5DJ7</b>	<b>Acetaminophen</b>
<b>XM75Y5</b>	<b>Para-aminophenol derivatives</b>
<b>XM43A6</b>	<b>Phenacetin</b>
<b>XM7HP8</b>	<b>Bucetin</b>
<b>XM8QF6</b>	<b>Propacetamol</b>
<b>XM24R8</b>	<b>Acetaminosalol</b>
<b>XM45S5</b>	<b>Acetanilide</b>
<b>XM4T97</b>	<b>Bromo-seltzer</b>

Other nonopioid analgesics and antipyretics, not elsewhere classified

<b>XM2XD8</b>	<b>Acetylphenylhydrazine</b>
<b>XM3J63</b>	<b>Clonixin</b>
<b>XM1LX8</b>	<b>Cropropamide</b>
<b>XM0LT4</b>	<b>Crotethamide</b>
<b>XM0M53</b>	<b>Cyclopyrabital</b>
<b>XM3YJ4</b>	<b>Darvon</b>
<b>XM7K04</b>	<b>Diclonixin</b>

<b>XM2PY3</b>	<b>Doloxene</b>
<b>XM7SA1</b>	<b>Emorfazone</b>
<b>XM9455</b>	<b>Etomide</b>
<b>XM5YR6</b>	<b>Fluradoline</b>
<b>XM7983</b>	<b>Jamaica dogwood (bark)</b>
<b>XM6233</b>	<b>Lefetamine</b>
<b>XM03M0</b>	<b>Methopholine</b>
<b>XM4WT5</b>	<b>Nefopam</b>
<b>XM8QV3</b>	<b>Perisoxal</b>
<b>XM0D38</b>	<b>Phenicarbazide</b>
<b>XM2DH4</b>	<b>Phenyramidol</b>
<b>XM0X95</b>	<b>Piroxicam beta-cyclodextrin complex</b>
<b>XM63V3</b>	<b>Piscidia (bark) (erythrina)</b>
<b>XM49C9</b>	<b>Pyrabital</b>
<b>XM3WM4</b>	<b>Pyridium</b>
<b>XM4PW4</b>	<b>Rimazolium metilsulfate</b>
<b>XM3375</b>	<b>Tiaramide</b>
<b>XM9YA8</b>	<b>Tinordidine</b>
<b>XM0794</b>	<b>Zactane</b>
<b>XM3P63</b>	<b>Methoxyflurane</b>
<b>XM6Z00</b>	<b>Rimazolium</b>
<b>XM5WQ7</b>	<b>Flupirtine</b>
<b>XM5XN0</b>	<b>Ziconotide</b>
<b>XM70Q6</b>	<b>Tanezumab</b>
<b>XM6HK1</b>	<b>Antimigraine drugs</b>
	<i>Coded Elsewhere:</i> Ergot alkaloids (XM0XY6)
	Monoclonal antibodies (XM52L2-XM4W34)
	Clonidine (XM6GV8)
<b>XM6FB9</b>	<b>Triptans</b>
<b>XM9AV2</b>	Sumatriptan

<b>XM8BC6</b>	Naratriptan
<b>XM06P8</b>	Zolmitriptan
<b>XM6W13</b>	Rizatriptan
<b>XM92S7</b>	Almotriptan
<b>XM7YU2</b>	Eletriptan
<b>XM4WN0</b>	Frovatriptan
<b>XM7P17</b>	Lasmiditan
<b>XM81Q8</b>	<b>Dimetotiazine</b>
<b>XM7N03</b>	<b>Oxetorone</b>
<b>XM4WH4</b>	<b>Pizotifen</b>
<b>XM2G27</b>	<b>Iprazochrome</b>

#### Antiepileptics and antiparkinsonism drugs

**XM63D6      Antiepileptics**

*Coded Elsewhere:* Barbiturates and derivatives (XM4YG0)

#### Hydantoin derivatives

**XM52B4      Albutoin**

**XM9QF8      Amino(diphenylhydantoin) valeric acid**

**XM55H4      Anticonvulsant hydantoin**

**XM08H9      Dilantin**

**XM45R0      Epanutin**

**XM8MV0      Ethotoxin**

**XM4A36      Mephenytoin**

**XM02E9      Metetoin**

**XM0RY4      Phenytoin**

**XM4DR6      Oxazolidine derivatives**

**XM7N89      Paramethadione**

**XM31H5      Trimethadione**

**XM9993      Ethadione**

<b>XM1535</b>	Aloxdone
<b>XM4521</b>	<b>Fatty acid derivatives</b>
<b>XM29Q3</b>	Valproic acid
<b>XM71X1</b>	Valpromide
<b>XM5G31</b>	Vigabatrin
<b>XM2HC7</b>	Progabide
<b>XM5ZT1</b>	Aminobutyric acid
<b>XM8HQ0</b>	Tiagabine
<b>XM3C23</b>	<b>Succinimide derivatives</b>
<b>XM1K85</b>	Ethosuximide
<b>XM9E68</b>	Phensuximide
<b>XM2KZ3</b>	Mesuximide
<b>XM6421</b>	Morsuximide
<b>XM9GA9</b>	<b>Other antiepileptics</b>
<b>XM1RS9</b>	Sultiame
<b>XM7BQ9</b>	Phenacemide
<b>XM4RJ7</b>	Pheneturide
<b>XM6KR2</b>	Beclamide
<b>XM6FN4</b>	Lamotrigine
<b>XM15W2</b>	Felbamate
<b>XM2103</b>	Topiramate
<b>XM0J96</b>	Gabapentin
<b>XM9326</b>	Levetiracetam
<b>XM0SP9</b>	Zonisamide
<b>XM0AK1</b>	Pregabalin
<b>XM34S0</b>	Stiripentol
<b>XM30R8</b>	Lacosamide
<b>XM7PP9</b>	Carisbamate
<b>XM1P90</b>	Retigabine
<b>XM46J5</b>	Perampanel

<b>XM78C3</b>	Brivaracetam
<b>XM7QW2</b>	Ganaxolone
<b>XM70W8</b>	<b>Carboxamide derivatives</b>
<b>XM3D95</b>	Carbamazepine
<b>XM69D6</b>	Oxcarbazepine
<b>XM6BU4</b>	Rufinamide
<b>XM5HL7</b>	Eslicarbazepine
<b>XM2909</b>	<b>Clonazepam</b>

**XM9G63      Antiparkinson drugs**

**Coded Elsewhere:** Anticholinergics predominantly used for Parkinson disease (XM6WD2)

Muscle relaxants, centrally acting (XM9YY8)

Lisuride (XM4E49)

<b>XM5Y20</b>	<b>Dopaminergic agents</b>
<b>XM1Z60</b>	Carbidopa
<b>XM7SN1</b>	Dopa and dopa derivatives
<b>XM2WU7</b>	Levodopa
<b>XM7RF5</b>	Difluoromethyldopa
<b>XM3MW1</b>	Levodopa with carbidopa
<b>XM7ZB9</b>	Levodopa and decarboxylase inhibitor
<b>XM3PK3</b>	Levodopa, Decarboxylase inhibitor and COMT inhibitor
<b>XM1JZ7</b>	Melevodopa
<b>XM0D22</b>	Melevodopa and Decarboxylase inhibitor
<b>XM6R13</b>	Etilevodopa and Decarboxylase inhibitor

### Dopamine agonists

**Coded Elsewhere:** Cabergoline (XM4S44)

<b>XM5QR9</b>	<b>Bromocriptine</b>
<b>XM1GL7</b>	<b>Pergolide</b>
<b>XM5PE4</b>	<b>Apomorphine</b>
<b>XM2QX7</b>	<b>Piribedil</b>
<b>XM5DT8</b>	<b>Dihydroergocryptine mesylate</b>

<b>XM9D35</b>	<b>Ropinirole</b>
<b>XM5YJ4</b>	<b>Pramipexole</b>
<b>XM7B98</b>	<b>Rotigotine</b>
<b>XM50V4</b>	<b>Mesulergine</b>
<b>XM9GG4</b>	Monoamine oxidase B inhibitors
<b>XM8FH5</b>	Selegiline
<b>XM6XW7</b>	Rasagiline
<b>XM8H59</b>	Safinamide
<b>XM2H09</b>	Amantadine
<b>XM0BA4</b>	Tolcapone
<b>XM07G6</b>	Entacapone
<b>XM0K96</b>	Budipine
<b>XM6TZ5</b>	Opicapone

## Antipsychotics [neuroleptics]

Phenothiazine antipsychotics and neuroleptics  
antipsychotics and neuroleptics

<b>XM7KE0</b>	<b>Carphenazine</b>
<b>XM83L8</b>	<b>Compazine</b>
<b>XM7WF8</b>	<b>Dioxopromethazine</b>
<b>XM5EP8</b>	<b>Ethyl aminophenothiazine</b>
<b>XM9C32</b>	<b>Isopromethazine</b>
<b>XM2WD3</b>	<b>Mellaril</b>
<b>XM2VU6</b>	<b>Mepazine</b>
<b>XM8ZW1</b>	<b>Methoxypromazine</b>
<b>XM4TX5</b>	<b>Metofenazate</b>
<b>XM52V9</b>	<b>Phenothiazine (psychotropic)</b>
<b>XM0F82</b>	<b>Piperacetazine</b>
<b>XM6GY2</b>	<b>Propylaminopheno-thiazine</b>

<b>XM2XX6</b>	<b>Sparine</b>
<b>XM5JH1</b>	<b>Stelazine</b>
<b>XM9Q32</b>	<b>Stemetil</b>
<b>XM5Z28</b>	<b>Sulforidazine</b>
<b>XM6YW4</b>	<b>Thiazinamium metilsulfate</b>
<b>XM87F3</b>	<b>Tindal</b>
<b>XM0EE9</b>	<b>Tranquilizer dimethylamine</b>
<b>XM9B27</b>	<b>Tranquilizer ethylamine</b>
<b>XM1QV8</b>	<b>Tranquilizer phenothiazine</b>
<b>XM7057</b>	<b>Tranquilizer piperazine</b>
<b>XM5KD3</b>	<b>Tranquilizer piperidine</b>
<b>XM3Z20</b>	<b>Tranquilizer propylamine</b>
<b>XM4SG0</b>	<b>Phenothiazines with aliphatic side-chain</b>
<b>XM4U75</b>	<b>Chlorpromazine</b>
<b>XM61Z1</b>	<b>Levomepromazine</b>
<b>XM3CL7</b>	<b>Promazine</b>
<b>XM8LW2</b>	<b>Acepromazine</b>
<b>XM1TZ3</b>	<b>Triflupromazine</b>
<b>XM3AU5</b>	<b>Cyamemazine</b>
<b>XM6WY7</b>	<b>Chlorproethazine</b>
<b>XM1YC7</b>	<b>Phenothiazines with piperazine structure</b>
<b>XM75P4</b>	<b>Dixyrazine</b>
<b>XM6Z10</b>	<b>Fluphenazine</b>
<b>XM5Z27</b>	<b>Perphenazine</b>
<b>XM84U4</b>	<b>Prochlorperazine</b>
<b>XM0PU2</b>	<b>Thiopropazate</b>
<b>XM18F5</b>	<b>Trifluoperazine</b>
<b>XM3EY1</b>	<b>Acetophenazine</b>
<b>XM1V98</b>	<b>Thioproperazine</b>
<b>XM5JD6</b>	<b>Butaperazine</b>

<b>XM0TU3</b>	<b>Perazine</b>
<b>XM9HH5</b>	<b>Phenothiazines with piperidine structure</b>
<b>XM5664</b>	<b>Periciazine</b>
<b>XM4DG6</b>	<b>Thioridazine</b>
<b>XM6447</b>	<b>Mesoridazine</b>
<b>XM0168</b>	<b>Pipotiazine</b>

Butyrophenone derivatives

<b>XM12B1</b>	<b>Benperidol</b>
<b>XM4QG3</b>	<b>Bromperidol</b>
<b>XM2HT3</b>	<b>Butyrophenone(-based tranquilizers)</b>
<b>XM6FV0</b>	<b>Droperidol</b>
<b>XM0FM0</b>	<b>Fluanisone</b>
<b>XM9580</b>	<b>Haloperidol</b>
<b>XM6E81</b>	<b>Lenperone</b>
<b>XM26W9</b>	<b>Melperone</b>
<b>XM7DW6</b>	<b>Moperone</b>
<b>XM5AB4</b>	<b>Pipamperone</b>
<b>XM1UG0</b>	<b>Spiperone</b>
<b>XM7RP6</b>	<b>Timiperone</b>
<b>XM5NL7</b>	<b>Tranquilizer butyrophenone</b>
<b>XM4U52</b>	<b>Trifluperidol</b>
<b>XM9NX2</b>	<b>Lumateperone</b>
<b>XM1QY7</b>	<b>Indole derivatives</b>
<b>XM84W2</b>	<b>Oxypertine</b>
<b>XM61G1</b>	<b>Molindone</b>
<b>XM69Z2</b>	<b>Sertindole</b>
<b>XM8YM0</b>	<b>Ziprasidone</b>
<b>XM9EW5</b>	<b>Lurasidone</b>
<b>XM8X87</b>	<b>Thioxanthene derivatives</b>

XM4EY8	Flupentixol
XM87S1	Clopenthixol
XM2H35	Chlorprothixene
XM6B79	Tiotixene
XM3MW6	Zuclopenthixol
<b>XM2NF9</b>	<b>Diphenylbutylpiperidine derivatives</b>
XM0Q81	Fluspirilene
XM1FB1	Pimozide
XM5SZ6	Penfluridol
<b>XM12F2</b>	<b>Diazepines, oxazepines, thiazepines and oxepines</b>
XM8FG8	Loxapine
XM8UG6	Clozapine
XM6GK7	Olanzapine
XM4G70	Quetiapine
XM90C7	Asenapine
XM9DC4	Clotiapine
XM9Q20	Veralipride
XM0624	Levosulpiride
<b>XM1W79</b>	<b>Benzamides</b>
XM7Z05	Sulpiride
XM9G21	Sultopride
XM8KD4	Tiapride
XM3WA3	Remoxipride
XM1DG3	Amisulpride

Lithium

<b>XM0W09</b>	<b>Lithium gluconate</b>
<b>XM5C35</b>	<b>Lithium salts (carbonate)</b>

Other antipsychotics and neuroleptics

<b>XM4GQ2</b>	<b>Amperozide</b>
---------------	-------------------

<b>XM3JM5</b>	<b>Amphenidone</b>
<b>XM7AA5</b>	<b>Antipsychotic drug specified</b>
<b>XM23M7</b>	<b>Azacyclonol</b>
<b>XM56Y5</b>	<b>Benzperidine</b>
<b>XM9VY2</b>	<b>Benzperidol</b>
<b>XM3KB9</b>	<b>Enpiprazole</b>
<b>XM9097</b>	<b>Hydroxyphenamate</b>
<b>XM7EB1</b>	<b>Mebutamate</b>
<b>XM88L2</b>	<b>Mosapramine</b>
<b>XM7B44</b>	<b>Nemonapride</b>
<b>XM5F36</b>	<b>Oxanamide</b>
<b>XM9799</b>	<b>Phenaglycodol</b>
<b>XM3BH3</b>	<b>Prothipendyl</b>
<b>XM7L04</b>	<b>Raclopride</b>
<b>XM7KX5</b>	<b>Setoperone</b>
<b>XM6YS4</b>	<b>Spirilene</b>
<b>XM0ES8</b>	<b>Tranquilizer carbamate</b>
<b>XM7Z64</b>	<b>Tranquilizer hydroxyzine</b>
<b>XM3ES1</b>	<b>Tranquilizer specified</b>
<b>XM0GN3</b>	<b>Tranquilizer thioxanthene</b>
<b>XM06W2</b>	<b>Tybamate</b>
<b>XM4EU4</b>	<b>Zotepine</b>
<b>XM1Z15</b>	<b>Risperidone</b>
<b>XM67P4</b>	<b>Aripiprazole</b>
<b>XM7H28</b>	<b>Paliperidone</b>
<b>XM0FR9</b>	<b>Iloperidone</b>
<b>XM1SS2</b>	<b>Cariprazine</b>
<b>XM8504</b>	<b>Brexpiprazole</b>
<b>XM0715</b>	<b>Pimavanserin</b>

## Antidepressants

Monoamine oxidase-inhibitor, non-selective

XM3533	<b>Amiflamine</b>
XM8CW9	<b>Antidepressant monoamine oxidase inhibitor</b>
XM9VZ7	<b>Clorgiline</b>
XM2WY9	<b>Iproclozide</b>
XM6DW5	<b>Iproniazid</b>
XM4T23	<b>Isocarboxazid</b>
XM2K50	<b>Mebanazine</b>
XM2GX9	<b>Monoamine oxidase inhibitor hydrazine</b>
XM6944	<b>Monoamine oxidase inhibitor</b>
XM0158	<b>Nialamide</b>
XM3KZ3	<b>Parnate</b>
XM4S21	<b>Phenelzine</b>
XM4A50	<b>Pheniprazine</b>
XM96M0	<b>Safrazine</b>
XM1023	<b>Tranylcypromine</b>

Selective serotonin reuptake inhibitors

XM2NP3	<b>Antidepressant selective serotonin reuptake inhibitor</b>
XM6WT9	<b>Citalopram</b>
XM24M0	<b>Femoxetine</b>
XM7LE6	<b>Fluoxetine</b>
XM64L1	<b>Fluvoxamine</b>
XM5R26	<b>Indalpine</b>
XM3PJ6	<b>Paroxetine</b>
XM6WB9	<b>Zimeldine</b>
XM5TZ9	<b>Sertraline</b>
XM7ZN2	<b>Alaproclate</b>

<b>XM4MF4</b>	<b>Etoperidone</b>
<b>XM7PX8</b>	<b>Escitalopram</b>
<b>XM0HR7</b>	<b>Cianopramine</b>

Serotonin-norepinephrine reuptake inhibitors

<b>XM0PE4</b>	<b>Antidepressant selective serotonin norepinephrine reuptake inhibitor</b>
<b>XM8D31</b>	<b>Antidepressant triazolopyridine</b>
<b>XM10Q5</b>	<b>Duloxetine</b>
<b>XM3KS5</b>	<b>Desvenlafaxine</b>
<b>XM6J21</b>	<b>Milnacipran</b>
<b>XM17Z4</b>	<b>Levomilnacipran</b>
<b>XM36V6</b>	<b>Venlafaxine</b>

Other antidepressants

<b>XM03J9</b>	<b>Bifemelane</b>
<b>XM03E6</b>	<b>Bupropion</b>
<b>XM7U12</b>	<b>Diclofensine</b>
<b>XM78C1</b>	<b>Other specified antidepressant</b>
<b>XM0T46</b>	<b>Mianserin</b>
<b>XM5QV7</b>	<b>Minaprine</b>
<b>XM6X89</b>	<b>Nomifensine</b>
<b>XM6AP8</b>	<b>Oxitriptan</b>
<b>XM4WM9</b>	<b>Prazitone</b>
<b>XM0ST5</b>	<b>Thiazesim</b>
<b>XM5DV5</b>	<b>Tianeptine</b>
<b>XM5L45</b>	<b>Viloxazine</b>
<b>XM62E7</b>	<b>Trazodone</b>
<b>XM0B23</b>	<b>Mirtazapine</b>
<b>XM54Q7</b>	<b>Tryptophan</b>
<b>XM85H1</b>	<b>Nefazodone</b>

<b>XM4ML8</b>	<b>Oxaflozane</b>
<b>XM80H8</b>	<b>Medifoxamine</b>
<b>XM4ZF1</b>	<b>Pivagabine</b>
<b>XM70H2</b>	<b>Reboxetine</b>
<b>XM5KP8</b>	<b>Gepirone</b>
<b>XM5F11</b>	<b>Agomelatine</b>
<b>XM7T91</b>	<b>Vilazodone</b>
<b>XM4230</b>	<b>Hyperici herba</b>
<b>XM0EP0</b>	<b>Vortioxetine</b>
<b>XM8FB6</b>	<b>Serotonin</b>
<b>XM0227</b>	<b>Metapramine</b>
<b>XM9KG1</b>	<b>Non-selective monoamine reuptake inhibitors</b>
<b>XM6FC9</b>	<b>Desipramine</b>
<b>XM6PZ9</b>	<b>Imipramine</b>
<b>XM76Z6</b>	<b>Clomipramine</b>
<b>XM37K4</b>	<b>Opipramol</b>
<b>XM9WZ5</b>	<b>Trimipramine</b>
<b>XM7T42</b>	<b>Lofepramine</b>
<b>XM6H22</b>	<b>Dibenzepin</b>
<b>XM7BL0</b>	<b>Amitriptyline</b>
<b>XM79G5</b>	<b>Nortriptyline</b>
<b>XM2WA4</b>	<b>Protriptyline</b>
<b>XM1LC7</b>	<b>Doxepin</b>
<b>XM24M7</b>	<b>Iprindole</b>
<b>XM1575</b>	<b>Melitracen</b>
<b>XM8QA6</b>	<b>Butriptyline</b>
<b>XM2T20</b>	<b>Dosulepin</b>
<b>XM8TQ9</b>	<b>Amoxapine</b>
<b>XM1190</b>	<b>Amineptine</b>
<b>XM41L8</b>	<b>Maprotiline</b>

<b>XM34S5</b>	<b>Quinupramine</b>
<b>XM4SZ9</b>	<b>Imipramine oxide</b>
<b>XM3MV6</b>	<b>Dimetacrine</b>
<b>XM5RG3</b>	<b>Oxaprotiline</b>
<b>XM7GY1</b>	<b>Noxiptiline</b>
<b>XM1UL5</b>	<b>Monoamine oxidase A inhibitors</b>
<b>XM14X9</b>	<b>Moclobemide</b>
<b>XM1TG1</b>	<b>Toloxatone</b>

### Cannabinoids & hallucinogens

<b>XM2PL7</b>	<b>Cannabinoids</b>
<b>XM3UF9</b>	<b>Nabilone</b>
<b>XM4HM2</b>	<b>Tetrahydrocannabinol</b>
<b>XM5B55</b>	<b>Cannabidiol</b>
<b>XM1W83</b>	<b>Dronabinol</b>
<b>XM4SV9</b>	<b>Hallucinogens</b>
<b>XM5JH5</b>	<b>Psilocin</b> active constituent of the psilocybe genus of mushrooms
<b>XM7642</b>	<b>Psilocybin</b> active constituent of the psilocybe genus of mushrooms
<b>XM0T53</b>	<b>Mescaline</b> active constituent of peyote cactus ( <i>Lophophora williamsii</i> )
<b>XM78V1</b>	<b>Aeruginascin</b> an active constituent of the mushroom <i>Inocybe aeruginascens</i> .
<b>XM9WX3</b>	<b>Bufofenine</b>
<b>XM9T61</b>	<b>N,N-Dimethyltryptamine</b> active constituent of the Amerindian brew Ayahuasca
<b>XM9CL3</b>	<b>Lysergic acid amide</b> active constituent of morning glory and Hawaiian baby woodrose seeds
<b>XM5M84</b>	<b>Phencyclidine</b>
<b>XM50E4</b>	<b>Muscimol</b> active constituent of <i>Amanita muscaria</i>

<b>XM1PJ8</b>	<b>Ibotenic acid</b> active constituent of Amanita muscaria
<b>XM5SB5</b>	<b>Salvinorin A</b> active constituent of Salvia divinorum, the sage of the diviners

**Methylenedioxymethamphetamine**

<b>XM3C53</b>	<b>Amfetaminil</b>
<b>XM3E65</b>	<b>Benzedrine (amphetamine)</b>
<b>XM1NA8</b>	<b>Central nervous system stimulants amphetamines</b>
<b>XM1WW4</b>	<b>Dexedrine</b>
<b>XM6LD5</b>	<b>Dextroamphetamine</b>
<b>XM07Y4</b>	<b>Ecstasy</b>
<b>XM5B49</b>	<b>Methamphetamine</b>
<b>XM3WD9</b>	<b>Methedrine</b>
<b>XM3Q37</b>	<b>Methylamphetamine</b>
<b>XM9932</b>	<b>Psychostimulant caffeine</b>
<b>XM6RB6</b>	<b>Psychostimulant amphetamine</b>
<b>XM6V10</b>	<b>Tenamfetamine</b>
<b>XM12M9</b>	<b>Psychostimulants, ADHD and nootropic agents</b>
<b>XM7LR7</b>	<b>Centrally acting sympathomimetics</b>
<b>XM1NX2</b>	Methylphenidate
<b>XM52S5</b>	Pemoline
<b>XM75Z6</b>	Modafinil
<b>XM5921</b>	Fenozolone
<b>XM9DQ5</b>	Atomoxetine
<b>XM5288</b>	Dexmethylphenidate
<b>XM3ZW9</b>	Armodafinil
<b>XM9FY1</b>	Etryptamine
<b>XM3K58</b>	Levopropylhexedrine
<b>XM2XU4</b>	<b>Xanthine derivatives</b>

<b>XM0NG8</b>	Caffeine
<b>XM3Y68</b>	Propentofylline
<b>XM1SE2</b>	<b>Meclofenoxate</b>
<b>XM8QG2</b>	<b>Nizofenone</b>
<b>XM84X9</b>	<b>Prolintane</b>
<b>XM8EX0</b>	<b>Pipradrol</b>
<b>XM8029</b>	<b>Vinpocetine</b>
<b>XM37E2</b>	<b>Tipepidine</b>
<b>XM1LB1</b>	<b>Pyritinol</b>
<b>XM5207</b>	<b>Piracetam</b>
<b>XM3HZ4</b>	<b>Deanol</b>
<b>XM2AB6</b>	<b>Fipexide</b>
<b>XM5TT1</b>	<b>Citicoline</b>
<b>XM5N75</b>	<b>Oxiracetam</b>
<b>XM6EM2</b>	<b>Pirisudanol</b>
<b>XM1MZ1</b>	<b>Linopirdine</b>
<b>XM0Z60</b>	<b>Aniracetam</b>
<b>XM77H2</b>	<b>Acetyl-L-carnitine</b>
<b>XM5CY6</b>	<b>Idebenone</b>
<b>XM59Z4</b>	<b>Pramiracetam</b>
<b>XM3WZ9</b>	<b>Adrafinil</b>
<b>XM94C0</b>	<b>Mebicar</b>
<b>XM3J14</b>	<b>Phenibut</b>
<b>XM45U3</b>	<b>Deanol aceglumate</b>

Other psychodysleptics [hallucinogens]

<b>XM9DQ3</b>	<b>Diethyltryptamine (DET)</b>
<b>XM6LV4</b>	<b>Dimethyl tryptamine</b>
<b>XM9438</b>	<b>Hawaiian Woodrose seeds</b>
<b>XM52J2</b>	<b>Heavenly Blue (morning glory)</b>

<b>XM79N5</b>	<b>Magic mushroom</b>
<b>XM0169</b>	<b>Mescal buttons</b>
<b>XM32H5</b>	<b>Morning glory seeds</b>
<b>XM4B51</b>	<b>Pearly Gates (morning glory seeds)</b>
<b>XM0QA2</b>	<b>Peyote</b>
<b>XM0075</b>	<b>Yohimbic acid</b>

Synthetic cannabinoids

<b>XM8E16</b>	<b>Cannabinol</b>
---------------	-------------------

Unspecified psychodysleptics [hallucinogens]

<b>XM0XQ5</b>	<b>Central nervous system depressants hallucinogenics</b>
<b>XM31A7</b>	<b>Psychodysleptic drug</b>
<b>XM3Z58</b>	<b>Psychotomimetic agents</b>
<b>XM8X97</b>	<b>Hallucinogen</b>
<b>XM7DW4</b>	<b>Megahallucinogen</b>

Opioids

Opioids or related analgesics and agents affecting opioid receptors

<b>XM05B3</b>	<b>Diamorphine</b>
<b>XM69R4</b>	<b>Morphine, morphine derivatives and metabolites</b>
<b>XM39E2</b>	<b>14-hydroxydihydro-morphinone</b>
<b>XM5CY8</b>	<b>Acemorphan</b>
<b>XM0E25</b>	<b>Benzomorphan</b>
<b>XM8YM7</b>	<b>Benzyl morphine</b>
<b>XM0BB1</b>	<b>Blue velvet</b>
<b>XM45R8</b>	<b>Desomorphine</b>
<b>XM4T95</b>	<b>Dihydromorphine</b>
<b>XM3473</b>	<b>Hydromorphinol</b>
<b>XM8SD7</b>	<b>Hydromorphone</b>

<b>XM78E0</b>	<b>Metopon</b>
<b>XM7VL7</b>	<b>Morpholinylethylmorphine</b>
<b>XM7W06</b>	<b>Nicomorphine</b>
<b>XM9BE3</b>	<b>Normorphine</b>
<b>XM64M0</b>	<b>Oxymorphone</b>
<b>XM1KZ5</b>	<b>Morphine</b>
<b>XM0P98</b>	<b>Benzylmorphine</b>
<b>XM7ZJ1</b>	<b>Myrophine</b>
<b>XM4ES0</b>	<b>Opium</b>
<b>XM2T93</b>	<b>Opium alkaloids (total)</b>
<b>XM69X3</b>	<b>Opium alkaloids standardized powdered</b>
<b>XM91H1</b>	<b>Opium alkaloids tincture (camphorated)</b>
<b>XM1EE2</b>	<b>Laudanum</b>
<b>XM1YK2</b>	<b>Papaveretum</b>
<b>XM1LB8</b>	<b>Paregoric</b>
<b>XM4SL9</b>	<b>Oxycodone</b>
<b>XM79K2</b>	<b>Acetyldihydrocodeinone</b>
<b>XM7HX3</b>	<b>Eucodal</b>
<b>XM9UH3</b>	<b>Nalfurafine</b>
<b>XM4587</b>	<b>Codeine, codeine derivatives and other opioids used in cough suppression</b>
<b>XM3DS6</b>	<b>Acetyldihydrocodeine</b>
<b>XM05R0</b>	<b>Antitussive codeine mixture</b>
<b>XM3YP8</b>	<b>Cliradon</b>
<b>XM4046</b>	<b>Desocodeine</b>
<b>XM06K5</b>	<b>Dihydrocodeine</b>
<b>XM77C9</b>	<b>Dihydroisocodeine</b>
<b>XM9UN6</b>	<b>Hycodan</b>
<b>XM0YG5</b>	<b>Hydroxydihydrocodeinone</b>
<b>XM07U7</b>	<b>Percodan</b>
<b>XM5NP7</b>	<b>Piminodine</b>

<b>XM3WN9</b>	<b>Ethylmorphine</b>
<b>XM8E09</b>	<b>Hydrocodone</b>
<b>XM6RX7</b>	<b>Noscapine</b>
<b>XM4QV7</b>	<b>Pholcodine</b>
<b>XM9UV0</b>	<b>Dextromethorphan</b>
<b>XM2358</b>	<b>Thebacon</b>
<b>XM7V96</b>	<b>Dimemorfan</b>
<b>XM5PZ4</b>	<b>Normethadone</b>
<b>XM1ZY9</b>	<b>Methadone, methadone derivatives and other drugs used to treat opioid addictive disorders</b>
<b>XM7XP1</b>	<b>Methadone</b>
<b>XM9RG7</b>	<b>Levo-iso-methadone</b>
<b>XM4MV8</b>	<b>Opioid anaesthetics</b> <i>Coded Elsewhere:</i> Phenoperidine (XM0K66)
<b>XM4G88</b>	<b>Alfentanil</b>
<b>XM1EF3</b>	<b>Sufentanil</b>
<b>XM7YQ6</b>	<b>Anileridine</b>
<b>XM0YQ0</b>	<b>Remifentanil</b>

### Opioid receptor antagonists

<b>XM7TT0</b>	<b>Antagonist narcotic analgesic</b>
<b>XM0850</b>	<b>Cyclazocine</b>
<b>XM65J2</b>	<b>Levallorphan</b>
<b>XM4HP3</b>	<b>Morphine antagonist</b>
<b>XM14T9</b>	<b>Naloxone</b>
<b>XM2M16</b>	<b>Naltrexone</b>
<b>XM9BM4</b>	<b>Narcotic antagonist</b>
<b>XM5DJ2</b>	<b>Opiate antagonists</b>
<b>XM3TK0</b>	<b>Methylnaltrexone bromide</b>
<b>XM4GP3</b>	<b>Alvimopan</b>
<b>XM93Z3</b>	<b>Naloxegol</b>

<b>XM6KY8</b>	<b>Opioid antagonist</b>
<b>XM4S22</b>	<b>Other opioid analgesics, natural, synthetic and semi-synthetic</b>
	<b>Coded Elsewhere:</b> Dihydrocodeine (XM06K5)
	Piminodine (XM5NP7)
	Hydrocodone (XM8E09)
<b>XM30T6</b>	<b>Prodine</b>
<b>XM9907</b>	<b>Antitussive opiate</b>
<b>XM6C31</b>	<b>Cough mixture containing opiates</b>
<b>XM8ZF5</b>	<b>Dextrorphan</b>
<b>XM1K75</b>	<b>Difenclozazine</b>
<b>XM1HE9</b>	<b>Dilaudid</b>
<b>XM9SW6</b>	<b>Dipipanone</b>
<b>XM81P5</b>	<b>Dromoran</b>
<b>XM4EW3</b>	<b>Eptazocine</b>
<b>XM6CK0</b>	<b>Ethoheptazine</b>
<b>XM35C1</b>	<b>Heptalgin</b>
<b>XM5F21</b>	<b>Levo-dromoran</b>
<b>XM4P40</b>	<b>Levopropoxyphene</b>
<b>XM1R71</b>	<b>Levorphanol</b>
<b>XM0GS3</b>	<b>Meperidine</b>
<b>XM8PP7</b>	<b>Narcotic synthetic</b>
<b>XM8MP5</b>	<b>Nisentil</b>
<b>XM7S23</b>	<b>Opioid</b>
<b>XM04Z5</b>	<b>Phenadoxone</b>
<b>XM2542</b>	<b>Phenazocine</b>
<b>XM9B34</b>	<b>Phenomorphan</b>
<b>XM72D5</b>	<b>Pipadone</b>
<b>XM39L3</b>	<b>Profadol</b>
<b>XM9AZ5</b>	<b>Promedol</b>
<b>XM3E08</b>	<b>Propoxyphene</b>
<b>XM6625</b>	<b>Racemoramide</b>

<b>XM8804</b>	<b>Thebaine</b>
<b>XM09H6</b>	<b>Tilidine</b>
<b>XM7KC0</b>	<b>Tramadol</b>
<b>XM5UK3</b>	<b>Viminol</b>
<b>XM9Y28</b>	<b>Diphenoxylate</b>
<b>XM86N4</b>	<b>Loperamide</b>
<b>XM9NL3</b>	<b>Phenylpiperidine derivatives</b>
<b>XM9HP7</b>	Ketobemidone
<b>XM76M8</b>	Fentanyl
<b>XM8286</b>	<b>Diphenylpropylamine derivatives</b>
<b>XM3246</b>	Dextromoramide
<b>XM55Z5</b>	Piritramide
<b>XM8GB8</b>	Dextropropoxyphene
<b>XM5GN5</b>	Bezitramide
<b>XM1QE0</b>	<b>Benzomorphan derivatives</b>
<b>XM9K14</b>	Pentazocine
<b>XM09R6</b>	<b>Morphinan derivatives</b>
<b>XM1682</b>	Butorphanol
<b>XM4P05</b>	Nalbuphine
<b>XM9Z94</b>	<b>Buprenorphine</b>
<b>XM02X7</b>	<b>Etorphine</b>
<b>XM3PK7</b>	<b>Acetorphine</b>
<b>XM0K66</b>	<b>Phenoperidine</b>
<b>XM40T9</b>	<b>Meptazinol</b>
<b>XM0GU8</b>	<b>Drotebanol</b>
<b>XM7VK6</b>	<b>Loperamide oxide</b>
<b>XM13Q9</b>	<b>Dezocine</b>
<b>XM25Z3</b>	<b>Tapentadol</b>
<b>XM1G85</b>	<b>Oliceridine</b>
<b>XM4PD9</b>	<b>Nalmefene</b>

**XM4M74 Difelikefalin**

## Psychostimulants

**Coded Elsewhere:** Cocaine (XM7UN8)

Opioid receptor antagonists (XM7TT0-XM6KY8)

Cathinone

Main active agent in Khat

**XM0VG7 Catha (edulis) (tea)**

**XM0238 Khat**

Other specified amphetamines

Unspecified psychostimulant drug

**XM3GQ0 Central nervous system stimulants, not elsewhere classified**

**XM0854 Cerebral stimulants psychotherapeutic**

**XM93X4 Cerebral stimulants**

**XM7125 Stimulant central nervous system psychotherapeutic**

## Sedative hypnotic drugs and other central nervous system depressants

Anaesthetics and therapeutic gases

### General anaesthetics

**Coded Elsewhere:** Phencyclidine (XM5M84)

**XM8T75 Inhaled anaesthetics**

**XM4VX3 Ethers**

**XM3J00 Diethyl ether**

**XM7UB3 Vinyl ether**

**XM0TE1 Halogenated hydrocarbons**

**XM2FH0 Halothane**

**XM7MX5 Chloroform**

**XM1GP5 Chloroform vapor**

<b>XM35M6</b>	Enflurane
<b>XM1E91</b>	Trichloroethylene anaesthetic gas
<b>XM9HY9</b>	Isoflurane
<b>XM0ZA2</b>	<b>Anaesthesia endotracheal</b>
<b>XM05Z8</b>	<b>Anaesthetic gaseous</b>
<b>XM8V73</b>	<b>Anaesthetic halogenated hydrocarbon derivatives</b>
<b>XM5UK1</b>	<b>Central nervous system depressants anaesthetic gases</b>
<b>XM42D4</b>	<b>Chloroform anaesthetic</b>
<b>XM2DK4</b>	<b>Chloroform water, concentrated</b>
<b>XM9TE3</b>	<b>Divinyl ether</b>
<b>XM3EA4</b>	<b>Ethyl bromide anaesthetic</b>
<b>XM2D90</b>	<b>Ethyl chloride anaesthetic</b>
<b>XM6WF0</b>	<b>Ethylene anaesthetic</b>
<b>XM9K99</b>	<b>Fluroxene</b>
<b>XM73B5</b>	<b>Nitrous oxide</b>
<b>XM9NP2</b>	<b>Trifluoroethyl vinyl ether</b>
<b>XM7Q24</b>	<b>Vinesthene</b>
<b>XM1C44</b>	<b>Desflurane</b>
<b>XM07G7</b>	<b>Sevoflurane</b>
<b>XM8X62</b>	<b>Xenon</b>
<b>XM7D47</b>	<b>Intravenous anaesthetics</b>
	<b>Coded Elsewhere:</b> Barbiturates and derivatives (XM4YG0)
	Opioid anaesthetics (XM4MV8)
<b>XM14F2</b>	<b>Alphadolone</b>
<b>XM4PF7</b>	<b>Alfaxalone</b>
<b>XM59B1</b>	<b>Barbiturate anaesthetic, intravenous</b>
<b>XM9CB4</b>	<b>Brevital sodium</b>
<b>XM6LE6</b>	<b>Buthalitone sodium</b>
<b>XM5K69</b>	<b>Butyl thiobarbital sodium</b>
<b>XM9SR9</b>	<b>Central nervous system depressants anaesthetic, intravenous</b>
<b>XM5MB2</b>	<b>Etomidate</b>

<b>XM93E9</b>	<b>Evipal sodium</b>
<b>XM5ZF4</b>	<b>Sernyl</b>
<b>XM4XN0</b>	<b>Thialbarbital</b>
<b>XM66H8</b>	<b>Thiamylal</b>
<b>XM8UK0</b>	<b>Thiamylal sodium</b>
<b>XM4NL3</b>	<b>Thiobarbital sodium</b>
<b>XM1QW9</b>	<b>Thiobarbiturate anaesthetic</b>
<b>XM72F2</b>	<b>Thiobutabarbital sodium</b>
<b>XM7JR4</b>	<b>Methohexital</b>
<b>XM08U4</b>	<b>Hexobarbital</b>
<b>XM0EL8</b>	<b>Thiopental sodium</b>
<b>XM7C11</b>	<b>Ketamine</b>
<b>XM4BS0</b>	<b>Propanidid</b>
<b>XM1903</b>	<b>Propofol</b>
<b>XM2W08</b>	<b>Esketamine</b>
<b>XM7T11</b>	<b>Cyclopropane</b>
<b>XM9MS5</b>	<b>Gammahydroxybutyrate</b>
<b>XM5C03</b>	<b>Hexobarbital rectal</b>
<b>XM20X3</b>	<b>Minaxolone</b>
<b>XM2MR8</b>	<b>Tiletamine</b>
<b>XM8DR0</b>	<b>Tribromoethanol, rectal</b>
<b>XM7Y85</b>	<b>Local anaesthetics</b>
	<i>Coded Elsewhere:</i> Cocaine topical anesthetic (XM0BC6)
<b>XM1FJ6</b>	<b>Amylocaine, regional</b>
<b>XM1H49</b>	<b>Amylocaine, regional infiltration</b>
<b>XM7CH6</b>	<b>Amylocaine, regional nerve block</b>
<b>XM37J6</b>	<b>Amylocaine, regional spinal</b>
<b>XM5JY6</b>	<b>Amylocaine, regional topical</b>
<b>XM5R82</b>	<b>Anaesthesia, caudal</b>
<b>XM8MY3</b>	<b>Anaesthesia, epidural</b>

<b>XM25C7</b>	<b>Anaesthesia, mucosal</b>
<b>XM0D14</b>	<b>Anesthesia rectal local</b>
<b>XM0FJ3</b>	<b>Anesthesia regional</b>
<b>XM0LM0</b>	<b>Anaesthetic infiltration</b>
<b>XM7EC3</b>	<b>Anaesthetic spinal</b>
<b>XM8E23</b>	<b>Anesthetic topical</b>
<b>XM3S41</b>	<b>Anaesthetic with local muscle relaxant</b>
<b>XM5ZK7</b>	<b>Aptocaine</b>
<b>XM52S4</b>	<b>Articaine</b>
<b>XM4YN0</b>	<b>Benzamine</b>
<b>XM8KD9</b>	<b>Benzocaine</b>
<b>XM1604</b>	<b>Botoxycaine</b>
<b>XM5YL1</b>	<b>Bupivacaine</b>
<b>XM7WQ7</b>	<b>Bupivacaine infiltration</b>
<b>XM4216</b>	<b>Bupivacaine nerve block</b>
<b>XM46M2</b>	<b>Bupivacaine spinal</b>
<b>XM3781</b>	<b>Butacaine</b>
<b>XM7MD5</b>	<b>Butamben</b>
<b>XM9VA7</b>	<b>Butanilicaine</b>
<b>XM0HA0</b>	<b>Butyl aminobenzoate</b>
<b>XM5NW5</b>	<b>Butyn</b>
<b>XM2YU2</b>	<b>Carbocaine infiltration</b>
<b>XM8C65</b>	<b>Carbocaine nerve block</b>
<b>XM2DT1</b>	<b>Carbocaine topical</b>
<b>XM6HZ0</b>	<b>Chloroprocaine</b>
<b>XM8XD3</b>	<b>Chloroprocaine infiltration</b>
<b>XM0GC2</b>	<b>Chloroprocaine nerve block</b>
<b>XM94U2</b>	<b>Chloroprocaine spinal</b>
<b>XM0L28</b>	<b>Cinchocaine</b>
<b>XM5Y10</b>	<b>Cinchocaine topical</b>

<b>XM7FD6</b>	<b>Cyclaine</b>
<b>XM41W7</b>	<b>Cyclomethycaine</b>
<b>XM3BB4</b>	<b>Dimethocaine</b>
<b>XM8UZ3</b>	<b>Diperodon</b>
<b>XM23R3</b>	<b>Dorsacaine</b>
<b>XM5601</b>	<b>Dyclone</b>
<b>XM3QB4</b>	<b>Dyclonine</b>
<b>XM20M0</b>	<b>Endocaine</b>
<b>XM0P92</b>	<b>EPAB</b>
<b>XM2H77</b>	<b>Ethocaine infiltration</b>
<b>XM6585</b>	<b>Ethocaine nerve block</b>
<b>XM7217</b>	<b>Ethocaine spinal</b>
<b>XM1WJ3</b>	<b>Ethyl aminobenzoate</b>
<b>XM87H9</b>	<b>Ethyl chloride local anaesthetic</b>
<b>XM8X57</b>	<b>Etidocaine</b>
<b>XM8013</b>	Etidocaine infiltration
<b>XM8RU6</b>	Etidocaine nerve block
<b>XM2F20</b>	<b>Eucaine</b>
<b>XM76M6</b>	<b>Hexylcaine</b>
<b>XM5863</b>	<b>Leucinocaine</b>
<b>XM1MK4</b>	<b>Mepivacaine</b>
<b>XM0EH7</b>	Mepivacaine epidural
<b>XM9DE9</b>	<b>Meprylcaine</b>
<b>XM7CG8</b>	<b>Metabutethamine</b>
<b>XM68T6</b>	<b>Nesacaine</b>
<b>XM6AA0</b>	Nesacaine infiltration
<b>XM4148</b>	Nesacaine nerve block
<b>XM38C9</b>	<b>Novocain infiltration</b>
<b>XM6R58</b>	<b>Novocain topical</b>
<b>XM6NN7</b>	<b>Nupercaine, spinal</b>

<b>XM8739</b>	<b>Nupercaine topical</b>
<b>XM0QU2</b>	<b>Orthocaine</b>
<b>XM5HP0</b>	<b>Oxetacaine</b>
<b>XM6V01</b>	<b>Oxethazine</b>
<b>XM6RN9</b>	<b>Oxybuprocaine</b>
<b>XM7H65</b>	<b>Percaine, spinal</b>
<b>XM7EK6</b>	<b>Percaine topical</b>
<b>XM6Z26</b>	<b>Phenacaine</b>
<b>XM2ZH3</b>	<b>Piperocaine</b>
<b>XM7UW6</b>	<b>Piperocaine infiltration</b>
<b>XM8J09</b>	<b>Piperocaine nerve block</b>
<b>XM40M8</b>	<b>Piperocaine topical</b>
<b>XM8AE6</b>	<b>Pitkin's solution</b>
<b>XM2X66</b>	<b>Prilocaine</b>
<b>XM9NH0</b>	<b>Prilocaine infiltration</b>
<b>XM85Q7</b>	<b>Prilocaine nerve block</b>
<b>XM4EE1</b>	<b>Prilocaine regional</b>
<b>XM5L66</b>	<b>Procaine</b>
<b>XM05Z5</b>	<b>Procaine nerve block</b>
<b>XM1CG3</b>	<b>Procaine regional</b>
<b>XM8KS3</b>	<b>Procaine spinal</b>
<b>XM97J9</b>	<b>Proparacaine</b>
<b>XM72A2</b>	<b>Propoxycaaine</b>
<b>XM9BY7</b>	<b>Propoxycaaine infiltration</b>
<b>XM2DT4</b>	<b>Propoxycaaine nerve block</b>
<b>XM0BG4</b>	<b>Propoxycaaine topical</b>
<b>XM87E0</b>	<b>Quotane</b>
<b>XM2MX6</b>	<b>Stovaine</b>
<b>XM79W4</b>	<b>Stovaine infiltration</b>
<b>XM08B5</b>	<b>Stovaine nerve block</b>

<b>XM9657</b>	Stovaine spinal
<b>XM3MW8</b>	Stovaine topical
<b>XM6392</b>	<b>Surfacaine</b>
<b>XM1HW1</b>	<b>Tetracaine</b>
<b>XM32E4</b>	Tetracaine nerve block
<b>XM9H96</b>	Tetracaine regional
<b>XM9CQ9</b>	Tetracaine spinal
<b>XM3QD1</b>	<b>Trimecaine</b>
<b>XM2FR2</b>	<b>Tronothane</b>
<b>XM7771</b>	<b>Xylocaine infiltration</b>
<b>XM18M2</b>	<b>Xylocaine nerve block</b>
<b>XM5K48</b>	<b>Xylocaine spinal</b>
<b>XM5G11</b>	<b>Xylocaine topical</b>

Sedative-hypnotic and anxiolytic drugs

### Benzodiazepines

<b>XM1030</b>	<b>Alprazolam</b>
<b>XM4R58</b>	<b>Bentazepam</b>
<b>XM2GL0</b>	<b>Benzodiapin</b>
<b>XM9JC7</b>	<b>Bromazepam</b>
<b>XM2S43</b>	<b>Brotizolam</b>
<b>XM5133</b>	<b>Camazepam</b>
<b>XM9S41</b>	<b>Carpipramine</b>
<b>XM1J81</b>	<b>Central nervous system depressants benzodiazepines</b>
<b>XM5JC4</b>	<b>Chlordiazepoxide</b>
<b>XM43U0</b>	<b>Clobazam</b>
<b>XM3C29</b>	<b>Dipotassium clorazepate</b>
<b>XM0A75</b>	<b>Clotiazepam</b>
<b>XM5M11</b>	<b>Cloxazolam</b>

<b>XM0GD3</b>	<b>Delorazepam</b>
<b>XM8P99</b>	<b>Diazepam</b>
<b>XM9YX9</b>	<b>Estazolam</b>
<b>XM54N1</b>	<b>Ethyl loflazepate</b>
<b>XM9DN9</b>	<b>Etizolam</b>
<b>XM8NC2</b>	<b>Fludiazepam</b>
<b>XM9W71</b>	<b>Flunitrazepam</b>
<b>XM73H1</b>	<b>Flurazepam</b>
<b>XM68Z6</b>	<b>Flutazolam</b>
<b>XM81V7</b>	<b>Flutoprazepam</b>
<b>XM3FR2</b>	<b>Halazepam</b>
<b>XM86G3</b>	<b>Haloxazolam</b>
<b>XM5WE7</b>	<b>Ketazolam</b>
<b>XM6KW2</b>	<b>Loprazolam</b>
<b>XM85H7</b>	<b>Lorazepam</b>
<b>XM1EE3</b>	<b>Lormetazepam</b>
<b>XM9KN4</b>	<b>Medazepam</b>
<b>XM7QC1</b>	<b>Mexazolam</b>
<b>XM9PG6</b>	<b>Midazolam</b>
<b>XM8TH1</b>	<b>Nimetazepam</b>
<b>XM4TR7</b>	<b>Nitrazepam</b>
<b>XM4FQ9</b>	<b>Nordazepam</b>
<b>XM1A29</b>	<b>Oxazepam</b>
<b>XM62U2</b>	<b>Oxazolam</b>
<b>XM3LR9</b>	<b>Perlapine</b>
<b>XM0GW7</b>	<b>Pinazepam</b>
<b>XM4M86</b>	<b>Prazepam</b>
<b>XM42F4</b>	<b>Quazepam</b>
<b>XM3215</b>	<b>Temazepam</b>

<b>XM79N8</b>	<b>Tofisopam</b>
<b>XM9X46</b>	<b>Tranquilizer benzodiazepine</b>
<b>XM0G58</b>	<b>Tranxene</b>
<b>XM1VC3</b>	<b>Triazolam</b>
<b>XM1YU1</b>	<b>Valium</b>
<b>XM36R8</b>	<b>Potassium clorazepate</b>
<b>XM94Z2</b>	<b>Adinazolam</b>
<b>XM66N4</b>	<b>Doxefazepam</b>
<b>XM4BU2</b>	<b>Cinolazepam</b>
<b>XM8CM3</b>	<b>Diphenylmethane derivatives</b>
<b>XM8CV8</b>	<b>Hydroxyzine</b>
<b>XM70L1</b>	<b>Captodiame</b>
<b>XM96H3</b>	<b>Carbamates</b>
<b>XM3MX1</b>	<b>Meprobamate</b>
<b>XM8G67</b>	<b>Emylcamate</b>
<b>XM3XU7</b>	<b>Aldehydes and derivatives</b>
<b>XM8AH5</b>	<b>Chloral hydrate</b>
<b>XM8D85</b>	<b>Chloraladol</b>

### Paraldehyde

<b>XM0ZC2</b>	<b>Paracetaldehyde</b>
<b>XM46J8</b>	<b>Acetylglycinamide chloral hydrate</b>
<b>XM9V32</b>	<b>Dichloralphenazone</b>
<b>XM0V58</b>	<b>Cinnamaldehyde</b>
<b>XM37U9</b>	<b>Hexyl cinnamal</b>
<b>XM5TZ2</b>	<b>Amyl cinnamal</b>
<b>XM9J50</b>	<b>Butylchloral hydrate</b>
<b>XM6R00</b>	<b>Piperidinedione derivatives</b>
<b>XM5S80</b>	<b>Glutethimide</b>
<b>XM2MN1</b>	<b>Methyprylon</b>

<b>XM2MC9</b>	<b>Pyrithyldione</b>
<b>XM4YG0</b>	<b>Barbiturates and derivatives</b>
	<i>Coded Elsewhere:</i> Methohexital (XM7JR4)
	Hexobarbital (XM08U4)
	Thiopental sodium (XM0EL8)
<b>XM3Z73</b>	<b>Narcobarbital</b>
<b>XM01Z3</b>	<b>Pentobarbital</b>
<b>XM01F5</b>	<b>Amobarbital</b>
<b>XM8TB8</b>	<b>Butobarbital</b>
<b>XM2B90</b>	<b>Barbital</b>
<b>XM6QG0</b>	<b>Secobarbital</b>
<b>XM28V1</b>	<b>Talbutal</b>
<b>XM6NX3</b>	<b>Vinylbital</b>
<b>XM9VX7</b>	<b>Vinbarbital</b>
<b>XM89L9</b>	<b>Cyclobarbital</b>
<b>XM7ZK9</b>	<b>Heptobarbital</b>
<b>XM8FN0</b>	<b>Allobarbital</b>
<b>XM8C15</b>	<b>Proxibarbal</b>
<b>XM60H4</b>	<b>Methylphenobarbital</b>
<b>XM2605</b>	<b>Phenobarbital</b>
<b>XM5J41</b>	<b>Primidone</b>
<b>XM45T7</b>	<b>Barbexacalone</b>
<b>XM64T5</b>	<b>Metharbital</b>
<b>XM1ZM1</b>	<b>Reposal</b>
<b>XM1WN6</b>	<b>Etallobarbital</b>
<b>XM8YV1</b>	<b>Aprobarbital</b>
<b>XM50Q3</b>	<b>Brallobarbital</b>
<b>XM3UQ5</b>	<b>Butalbital</b>
<b>XM6XH1</b>	<b>Butallylonal</b>
<b>XM4C65</b>	<b>Difebarbamate</b>
<b>XM8DQ9</b>	<b>Methobarbital, methobarbitone</b>

XM3YG4	Nealbarbital
XM6F85	Probarbital
XM37N4	Propallylonal
XM81J9	Secbutabarbital
XM4843	Z-drugs
XM8LM1	Zopiclone
XM8188	Zolpidem
XM0UU3	zaleplon
XM4DP1	Eszopiclone
XM0GA0	Melatonin receptor agonists
XM7R38	Melatonin
XM4Y11	Ramelteon
XM0DX1	Tasimelteon

#### Bromine compounds

XM93J2	Bromide salts
XM5V35	Acecarbromal
XM3260	Bromisoval
XM7XH5	Bromoform
XM68H5	Carbromal

#### Other sedatives, hypnotics and antianxiety drugs

**Coded Elsewhere:** Scopolamine (XM1MW1)

XM4JD8	Acetylpheneturide
XM0Y74	Allylisopropylacetylurea
XM2MT0	Allyltribromide
XM0FX2	Ammonium bromide
XM2P06	Anticonvulsant hypnotic
XM4LR0	Anticonvulsant pyrimidinedione
XM80V1	Anticonvulsant specified

<b>XM2851</b>	<b>Apronal</b>
<b>XM8WF0</b>	<b>Avomine</b>
<b>XM34M8</b>	<b>Beta-Chlor</b>
<b>XM2S35</b>	<b>Bromal (hydrate)</b>
<b>XM16D8</b>	<b>Bromine compounds (medicinal)</b>
<b>XM0JD2</b>	<b>Bromine sedative</b>
<b>XM14P7</b>	<b>Bromisovalum</b>
<b>XM0L99</b>	<b>Bromural</b>
<b>XM7Q19</b>	<b>Calcium bromide</b>
<b>XM44G1</b>	<b>Bromides</b>
<b>XM6Z70</b>	<b>Central nervous system depressants chloral hydrate</b>
<b>XM4A26</b>	<b>Central nervous system depressants hypnotics specified</b>
<b>XM0MP0</b>	<b>Central nervous system depressants paraldehyde</b>
<b>XM2PX1</b>	<b>Chloral derivative</b>
<b>XM5HQ1</b>	<b>Chloralamide</b>
<b>XM1XU2</b>	<b>Chloretone</b>
<b>XM7N56</b>	<b>Chlorhexadol</b>
<b>XM7GE6</b>	<b>Clomethiazole</b>
<b>XM58S5</b>	<b>Croton chloral</b>
<b>XM1L51</b>	<b>Diethylsulfone-diethylmethane</b>
<b>XM5P16</b>	<b>Divalproex</b>
<b>XM2ML0</b>	<b>Doriden</b>
<b>XM0YS0</b>	<b>Dormison</b>
<b>XM76A5</b>	<b>Ectylurea</b>
<b>XM4SW2</b>	<b>Ethchlorvynol</b>
<b>XM8HM5</b>	<b>Ethinamate</b>
<b>XM0959</b>	<b>Etifoxine</b>
<b>XM5084</b>	<b>Hexapropymate</b>
<b>XM3GR8</b>	<b>Hypnotic drug specified</b>

XM1H40	Lactuca ( <i>virosa</i> ) (extract)
XM7EA2	Lactucarium
XM2447	Lettuce opium
XM1SJ9	Levanil
XM9S20	Levoprome
XM3C52	Methaqualone
XM8UW8	Methyl sulfonal
XM79Y3	Methylpentynol
XM9L86	Niaprazine
XM67F2	Noludar
XM41Z4	Periclor
XM7865	Petrichloral
XM8U36	Phenergan
XM3YQ0	Potassium bromide
XM23J2	Propionaldehyde (medicinal)
XM5KU5	Quaalude
XM5YQ4	Sedative mixed
XM53R6	Sedormid
XM5BF2	Serenesil
XM8SU3	Sodium bromide
XM9F88	Sodium valproate
XM4ZG6	Somnos
XM1BT3	Sopor
XM2N03	Soporific drug specified type
XM81Z5	Sulfonal
XM9QV2	Sulfonethylmethane
XM4YF8	Sulfonmethane
XM8296	Tetronal
XM6WP4	Tranquilizer with hypnotic or sedative

<b>XM9XF5</b>	<b>Tribromacetaldehyde</b>
<b>XM1DU6</b>	<b>Trichloroethanol</b>
<b>XM4236</b>	<b>Trichloroethyl phosphate</b>
<b>XM68E8</b>	<b>Triclofos</b>
<b>XM2334</b>	<b>Trional</b>
<b>XM16S3</b>	<b>Triple bromides</b>
<b>XM3PP3</b>	<b>Valerian root</b>
<b>XM0MV0</b>	<b>Valerian tincture</b>
<b>XM1WZ4</b>	<b>Valmid</b>
<b>XM2TP4</b>	<b>Valnoctamide</b>
<b>XM2AQ9</b>	<b>Welldorm</b>
<b>XM1ZF1</b>	<b>Buspirone</b>
<b>XM01J5</b>	<b>Mephenoxalone</b>
<b>XM9TL2</b>	<b>Propiomazine</b>
<b>XM15N4</b>	<b>Sodium oxybate</b>
<b>XM3EH5</b>	<b>Benzoctamine</b>
<b>XM9727</b>	<b>Gedocarnil</b>
<b>XM5928</b>	<b>Fabomotizole</b>
<b>XM4DF5</b>	<b>Lavandulae aetheroleum</b>
<b>XM8488</b>	<b>Valeriana radix</b>
<b>XM2HN6</b>	<b>Suvorexant</b>
<b>XM2AY7</b>	<b>Dipiperonylamoethanol</b>
<b>XM9235</b>	<b>Lemborexant</b>
<b>XM1VL2</b>	<b>Hexethal (sodium)</b>
<b>XM7MG1</b>	<b>Mephebarital</b>
<b>XM0217</b>	<b>Methitural</b>
<b>XM2XY6</b>	<b>4-Aminobutyric acid</b>

## Other and unspecified drugs, medicaments and biological substances

### Antidotes

**Coded Elsewhere:** Ipecacuanha (XM8BL3)  
Penicillamine (XM1QA0)  
Naloxone (XM14T9)  
Ethanol (XM8ZW3)  
Potassium Permanganate medicinal (XM0XP0)  
Physostigmine (XM4605)  
Hydroxocobalamin (XM7CP9)  
Phentolamine (XM5NP2)

<b>XM3XY4</b>	<b>Alcohol deterrent</b>
<b>XM2XV6</b>	<b>Antabuse</b>
<b>XM1S43</b>	<b>Antidote</b>
<b>XM65Y8</b>	<b>Chelating agent</b>
<b>XM68U2</b>	<b>Cholinesterase reactivator</b>
<b>XM81B1</b>	<b>Cysteamine</b>
<b>XM9M46</b>	<b>Detoxifying agent</b>
<b>XM0ZM0</b>	<b>Disodium edetate</b>
<b>XM1V56</b>	<b>EDTA</b>
<b>XM0FL5</b>	<b>Phytic acid, nonasodium</b>
<b>XM7SW5</b>	<b>Glutathione</b>
<b>XM1YY3</b>	<b>Methylthioninium chloride</b>
<b>XM7Z31</b>	<b>Nitrefazole</b>
<b>XM7HV6</b>	<b>Obidoxime chloride</b>
<b>XM2ZD4</b>	<b>Pralidoxime</b>
<b>XM6TE9</b>	<b>Potassium ferric hexacyanoferrate (medicinal)</b>
<b>XM7K47</b>	<b>Pralidoxime iodide</b>
<b>XM6BZ5</b>	<b>Pralidoxime chloride</b>
<b>XM8P25</b>	<b>Prussian blue therapeutic</b>
<b>XM6DU2</b>	<b>Pyridine aldoxime methiodide</b>
<b>XM6043</b>	<b>Pyridine aldoxime methyl chloride</b>

<b>XM3810</b>	<b>Sodium nitrite</b>
<b>XM7LV6</b>	<b>Sodium phytate</b>
<b>XM6NW5</b>	<b>Thiosulfate</b>
<b>XM2KC9</b>	<b>Sodium versenate</b>
<b>XM99S5</b>	<b>Tetraethylthiuram disulfide</b>
<b>XM6GP9</b>	<b>Trientine</b>
<b>XM2U68</b>	<b>Trisodium hydrogen edetate</b>
<b>XM7KV3</b>	<b>Versenate</b>
<b>XM4UW9</b>	<b>Nalorphine</b>
<b>XM89R9</b>	<b>Dimercaprol</b>
<b>XM1260</b>	<b>Potassium iodide</b>
<b>XM7372</b>	<b>Acetylcysteine</b>
<b>XM5MC0</b>	<b>Methionine</b>
<b>XM28B1</b>	<b>Uridine triacetate</b>
<b>XM0588</b>	<b>Edetates</b>
<b>XM5VJ5</b>	<b>Prednisolone and Promethazine</b>
<b>XM8ET8</b>	<b>Obidoxime</b>
<b>XM2GR4</b>	<b>Protamine</b>
<b>XM4JM7</b>	<b>Copper sulfate</b>
<b>XM9AD6</b>	<b>Digitalis antitoxin</b>
<b>XM2UQ5</b>	<b>Flumazenil</b>
<b>XM2H17</b>	<b>4-dimethylaminophenol</b>
<b>XM8ZA0</b>	<b>Cholinesterase</b>
<b>XM62Q3</b>	<b>Prussian blue</b>
<b>XM7LQ9</b>	<b>Fomepizole</b>
<b>XM9NQ8</b>	<b>Sugammadex</b>
<b>XM0666</b>	<b>Idarucizumab</b>
<b>XM01C9</b>	<b>Andexanet alfa</b>

Iron chelating agents

**XM5A41 Deferoxamine**

**XM03A5 Deferiprone**

**XM12X8 Deferasirox**

Drugs for treatment of hyperkalaemia, hypercalcaemia and hyperphosphataemia

**Coded Elsewhere:** Calcium acetate (XM0VY0)

**XM3B07 Polystyrene sulfonate**

**XM8NS1 Ferric citrate**

**XM1AY3 Sodium phosphate cellulose**

**XM6Q80 Sevelamer**

**XM22K8 Lanthanum carbonate**

**XM4MP9 Calcium acetate and Magnesium carbonate**

**XM9188 Sucroferric oxyhydroxide**

**XM4C26 Colestilan**

Detoxifying agents for antineoplastic treatment

**XM1JB5 Mesna**

**XM7BJ9 Calcium folinate**

**XM45R5 Dexrazoxane**

**XM2852 Calcium levofolinate**

**XM5GF2 Amifostine**

**XM61A6 Sodium folinate**

**XM4NB1 Rasburicase**

**XM8J47 Palifermin**

**XM8L87 Glucarpidase**

**XM1EU2 Sodium levofolinate**

**XM0MC0 Arginine and Lysine**

**XM7PK0 Trilaciclib**

Protectives against UV-radiation for systemic use

**Coded Elsewhere:** Betacarotene (XM7E89)

**XM0LA6 Afamelanotide**

**XM8337 Canthaxanthin**

Antipsoriatics for systemic use

**XM3GF4 Retinoids**

**XM0Z07 Etretinate**

**XM2M63 Acitretin**

**XM4RP3 Tioxysalen**

**XM47G3 Methoxsalen**

**XM1G69 Bergapten**

**XM7WA3 Fumaric acid**

Vitamin A derivative and other anti-acne preparations for systemic use

**XM98J9 Isotretinoin**

**XM9FP6 Ichtaisol**

Agents used in diagnostic tests, not elsewhere classified

**Coded Elsewhere:** Gonadorelin (XM2TU9)

Carbon monoxide (XM1X11)

**XM4CF3 Coccidioidin**

**XM1V31 Congo red**

**XM34X2 Evans blue**

**XM5618 Fluorescein**

**XM3Y60 Histoplasmin**

**XM2818 Indocyanine green**

**XM3WZ1 Lymphogranuloma venereum antigen**

**XM1VN8 Mumps skin test antigen**

**XM3Q40 Penicilloyl polylysine**

**XM36R6 Sodium metrizoate**

<b>XM1QL6</b>	<b>Sulfonphthalein, sulfonphthol</b>
<b>XM8478</b>	<b>Sulkowitch's reagent</b>
<b>XM4DA3</b>	<b>Toxin, diphtheria (Schick Test)</b>
<b>XM0EK6</b>	<b>Tuberculin, purified protein derivative (PPD)</b>
<b>XM6XX8</b>	<b>Glucose</b>

Tests for bile duct patency

<b>XM53M3</b>	<b>Sincalide</b>
<b>XM0D92</b>	<b>Ceruletide</b>

Tests for pituitary function

<b>XM5GR6</b>	<b>Metyrapone</b>
<b>XM7E13</b>	<b>Somatorelin</b>
<b>XM1UJ0</b>	<b>Corticorelin</b>
<b>XM5AM6</b>	<b>Macimorelin</b>
<b>XM60V4</b>	<b>Tests for liver functional capacity</b>

<b>XM9ZW8</b>	<b>Galactose</b>
<b>XM1XE0</b>	<b>Sulfobromophthalein</b>
<b>XM0N95</b>	<b>Methacetin (13C)</b>
<b>XM90L9</b>	<b>Iprofenin</b>
<b>XM3114</b>	<b>Lidofenin</b>
<b>XM2PX0</b>	<b>Rose bengal sodium (131i)</b>

<b>XM9H30</b>	<b>Tests for gastric secretion</b>
	<b>Coded Elsewhere:</b> Methylthioninium chloride (XM1YY3)

<b>XM44K8</b>	<b>Cation exchange resin</b>
<b>XM1MP2</b>	<b>Betazole</b>
<b>XM1286</b>	<b>Histamine phosphate</b>
<b>XM9AU1</b>	<b>Pentagastrin</b>
<b>XM1Q27</b>	<b>Caffeine and Sodium benzoate</b>
<b>XM1F97</b>	<b>Azuresin</b>

<b>XM4E68</b>	<b>Tests for renal function and ureteral injuries</b>
<b>XM9RK1</b>	<b>Indigo carmine</b>
<b>XM3G67</b>	<b>Alsactide</b>
<b>XM27H8</b>	<b>Aminohippuric acid</b>
<b>XM87Y9</b>	<b>Sodium para-aminohippurate</b>
<b>XM2JZ2</b>	<b>Inulin and other polyfructosans</b>
<b>XM7M20</b>	<b>Phenolsulfonphthalein</b>
<b>XM0N07</b>	<b>Tests for thyroid function</b>
<b>XM7R30</b>	<b>Protirelin</b>
<b>XM76Z9</b>	<b>Tests for pancreatic function</b>
<b>XM3L99</b>	<b>Secretin</b>
<b>XM7A79</b>	<b>Bentiromide</b>
<b>XM6014</b>	<b>Pancreozymin-cholecystokinin</b>
<b>XM24K5</b>	<b>Selenomethionine (75Se)</b>
<b>XM8B05</b>	<b>Edrophonium</b>
<b>XM3YJ9</b>	<b>Methacholine</b>
<b>XM5K20</b>	<b>Fructose</b>
<b>XM9258</b>	<b>Vitamin A concentrates</b>
<b>XM7PF6</b>	<b>Tuberculin</b>
<b>XM9QZ5</b>	<b>13C-urea</b>
<b>XM0UW4</b>	<b>Hexaminolevulinate</b>
<b>XM02S2</b>	<b>Patent blue</b>
<b>XM9Y95</b>	<b>Bromophenol blue reagent</b>
<b>XM5PT0</b>	<b>Diacetyl monoxime</b>
<b>XM8M78</b>	<b>Guaiac reagent</b>
<b>XM3385</b>	<b>Oxalic acid ammonium salt</b>
<b>XM74W0</b>	<b>Phenaphthazine reagent</b>

Medical gases

**Coded Elsewhere:** Helium (XM0JJ6)

<b>XM4SZ3</b>	<b>Oxygen</b>
<b>XM6NZ1</b>	<b>Carbon dioxide medicinal</b>
<b>XM3K31</b>	<b>Nitrogen</b>
<b>XM7EZ9</b>	<b>Medical air</b>

Contrast media

<b>XM2S71</b>	<b>X-ray contrast media, iodinated</b>
<b>XM7YS2</b>	<b>Watersoluble, nephrotropic, high osmolar X-ray contrast media</b>
<b>XM7PH4</b>	Metrizoic acid
<b>XM6583</b>	Iodamide
<b>XM8XV8</b>	Iotalamic acid
<b>XM34M9</b>	Ioxitalamic acid
<b>XM50Y6</b>	Acetrizoic acid
<b>XM7ZV2</b>	Locarmic acid
<b>XM2DC4</b>	Diodone
<b>XM8KK9</b>	Diatrizoic acid
<b>XM50U3</b>	Ioglicic acid
<b>XM9C52</b>	Methiodal
<b>XM4AG5</b>	<b>Watersoluble, nephrotropic, low osmolar X-ray contrast media</b>
<b>XM3WB6</b>	Metrizamide
<b>XM3R65</b>	Iohexol
<b>XM5EP5</b>	Ioxaglic acid
<b>XM8C50</b>	Iopamidol
<b>XM4UK7</b>	Iopromide
<b>XM8VT7</b>	Lotrolan
<b>XM5LW4</b>	Lototoxic acid
<b>XM6227</b>	Iopentol
<b>XM8NA7</b>	Iodixanol
<b>XM75B4</b>	Iomeprol

<b>XM79B6</b>	Iobitridol
<b>XM6VV1</b>	loxilan
<b>XM0KA6</b>	<b>Watersoluble, hepatotropic X-ray contrast media</b>
<b>XM2VE6</b>	Iodoxamic acid
<b>XM8411</b>	loglycamic acid
<b>XM7QU5</b>	Adipiodone
<b>XM1QH8</b>	Iobenzamic acid
<b>XM2NU7</b>	Iopanoic acid
<b>XM8PW2</b>	Iocetamic acid
<b>XM4ZU7</b>	Sodium iopodate
<b>XM8WD0</b>	Tyropanoic acid
<b>XM6TF5</b>	Calcium iopodate
<b>XM0LK3</b>	<b>Non-watersoluble X-ray contrast media</b>
<b>XM1AX3</b>	Iopydol
<b>XM1YV8</b>	Propylidone
<b>XM1R87</b>	Iofendylate
<b>XM6SE3</b>	Ethyl esters of iodised fatty acids
<b>XM6XU2</b>	Diatrizoate
<b>XM8QZ2</b>	Iodophthalein sodium

X-ray contrast media, non-iodinated

<b>XM0L44</b>	<b>Amidotrizoate</b>
<b>XM80W7</b>	<b>Bunamiodyl</b>
<b>XM5NA9</b>	<b>Iodipamide</b>
<b>XM4E01</b>	<b>Iodohippuric acid</b>
<b>XM9402</b>	<b>Iophenoic acid</b>
<b>XM7S30</b>	<b>Iopodic acid</b>
<b>XM4R74</b>	<b>Iotroxate</b>
<b>XM44B9</b>	<b>Ioxaglate</b>
<b>XM5N73</b>	<b>Methiodal sodium</b>

<b>XM96Q8</b>	<b>Phenobutiodil</b>
<b>XM3E15</b>	<b>Thorium dioxide suspension</b>
<b>XM90A9</b>	<b>Tyropanoate</b>
<b>XM2MR0</b>	<b>Barium sulfate with suspending agents</b>
<b>XM1FW7</b>	<b>Barium sulfate without suspending agents</b>
<b>XM05Z9</b>	<b>Magnetic resonance imaging contrast media</b>
<b>XM2LS2</b>	<b>Paramagnetic contrast media</b>
<b>XM7CY5</b>	Gadopentetic acid
<b>XM4UX1</b>	Gadoteric acid
<b>XM1564</b>	Gadodiamide
<b>XM0FN2</b>	Gadoteridol
<b>XM73Z5</b>	Mangafodipir
<b>XM3BF7</b>	Gadoversetamide
<b>XM29E1</b>	Ferric ammonium citrate
<b>XM0XE4</b>	Gadobenic acid
<b>XM3VG2</b>	Gadobutrol
<b>XM7W85</b>	Gadoxetic acid
<b>XM6GF6</b>	Gadofosveset
<b>XM8966</b>	<b>Superparamagnetic contrast media</b>
<b>XM33C2</b>	ferumoxsil
<b>XM84N5</b>	ferristene
<b>XM2945</b>	iron oxide, nanoparticles
<b>XM2666</b>	<b>Perflubron</b>
<b>XM5TN4</b>	<b>Ultrasound contrast media</b>
<b>XM40N1</b>	<b>Microspheres of human albumin</b>
<b>XM3PF3</b>	<b>Microparticles of galactose</b>
<b>XM7S16</b>	<b>Perflenapent</b>
<b>XM4VR4</b>	<b>Microspheres of phospholipids</b>
<b>XM8169</b>	<b>Sulfur hexafluoride</b>
<b>XM8G80</b>	<b>Perflubutane polymer microspheres</b>

**XM9320 Diagnostic radiopharmaceuticals**

**Coded Elsewhere:** Sodium fluoride (XM1F39)  
Thallium (XM63C5)  
Chromium (XM9YJ8)  
Selenium (XM47M7)

**XM8ZM1 Technetium (99mTc) compounds**

**XM5VK7** Sodium pertechnetate Tc99m

**XM9YB1 Iodine (123I) compounds**

**XM2R88 sodium iodide (131i)**

**XM6941 Rubidium chloride Rb82**

**XM3GL6 Gallium citrate**

**XM8SB4** Gallium (67Ga) citrate

**XM3WK3 Fludeoxyglucose (18F)**

**XM4ML0 Iodocholesterol (131I)**

**XM6Z69 Xenon (127Xe) gas**

**XM6EQ3 Xenon (133xe)**

**XM39A6 Sodium iodide (124I)**

**XM9F18 Maternal antibodies**

**XM3HU5 ferric (59Fe) citrate**

**XM1899 Sodium iodide (123I)**

**XM9063 Sodium iodohippurate (123I)**

**XM60X3 lobenguane (131I)**

**XM1QL4 lobenguane (123I)**

**XM6UT0 Fluoroethyl-L-tyrosine (18F)**

**XM80F7 Fluoroestradiol (18F)**

**XM5G08 Fluciclovine (18F)**

**XM3LK2 Fluorodopa (18F)**

**XM1N90 Fluoromethylcholine (18F)**

**XM5XR7 Fluoroethylcholine (18F)**

**XM5EC5 Gallium (68Ga) edotreotide**

**XM7VT3 Cobalt (57Co) cyanocobalamin**

<b>XM8YZ3</b>	<b>Cobalt (58Co) cyanocobalamin</b>
<b>XM5FA9</b>	<b>Tauroselcholic acid</b>
<b>XM42A5</b>	<b>Selenium (75Se) norcholesterol</b>
<b>XM2MJ2</b>	<b>Iodinated (131I) human serum albumin</b>
<b>XM2YP2</b>	<b>Iodine 125</b>
<b>XM8YZ7</b>	<b>Iodine 131</b>
<b>XM0RB0</b>	<b>Sodium iodohippurate (131I)</b>
<b>XM15W7</b>	<b>Sodium iothalamate (125I)</b>
<b>XM5674</b>	<b>Ammonia (13N)</b>
<b>XM05N6</b>	<b>Gallium (68Ga) gozetotide</b>
<b>XM45C8</b>	<b>Therapeutic radiopharmaceuticals</b>
	<b>Coded Elsewhere:</b> Iobenguane (131I) (XM60X3)
	Phosphoric acid (XM0270)
	Cyanogen chloride (XM1293)
	Chromic phosphate 32P (XM3ZJ5)
	Gold preparations (XM3LE3)
<b>XM6RC9</b>	<b>Sodium iodide I-131 therapeutic</b>
<b>XM01S1</b>	<b>Isoaminile (citrate)</b>
<b>XM9XW5</b>	<b>Antimonic sulfide</b>
<b>XM8Z31</b>	<b>Yttrium (90Y) ferrihydroxide colloid</b>
<b>XM0JJ4</b>	<b>Samarium (153Sm) hydroxyapatite colloid</b>
<b>XM56F9</b>	<b>Dysprosium (165Dy) colloid</b>
<b>XM10B1</b>	<b>Yttrium (90Y) citrate colloid</b>
<b>XM3MD6</b>	<b>Erbium (169Er) citrate colloid</b>
<b>XM5ZE8</b>	<b>Amylene dichloride</b>
<b>XM1WG6</b>	<b>Ethiodized oil (131 I)</b>
<b>XM7MV3</b>	<b>Iodine (131I) omburtamab</b>

Topical agents primarily affecting skin and mucous membrane and ophthalmological, otorhinolaryngological and dental drugs

Antipruritics

XM32B6	<b>b-eucaine</b>
XM79Q0	<b>Benzamine lactate</b>
XM8MM9	<b>Coal tar</b>
XM96H7	<b>Ether-soluble tar distillate</b>
XM6PP6	<b>Juniper tar</b>
XM8YS8	<b>Phenol medicinal</b>
XM96T6	<b>Phenolic preparation</b>
XM8485	<b>Pramoxine</b>
XM6A20	<b>Quinisocaine</b>
XM8W74	<b>Tar distillate</b>
XM8WM2	<b>Tar ointment</b>
XM4543	<b>Tolpropamine</b>
XM2833	<b>Mepyramine topical</b>
XM29P8	<b>Diphenhydramine methylbromide</b>
XM9UN5	<b>Thonzylamine topical</b>
XM7JY5	<b>Thenalidine topical</b>
XM6WM2	<b>Promethazine topical</b>

Camphor

Emollients, demulcents and protectants

*Coded Elsewhere:* Nutmeg oil (XM6FE5)

XM4B01	<b>Acetic acid with sodium acetate (ointment)</b>
XM7MV6	<b>Acrylic resin</b>
XM8U60	<b>Allylthiourea</b>
XM06X6	<b>Aluminium, aluminum ointment (surgical) (topical)</b>
XM1S82	<b>Aminobenzoic acid (-p)</b>

<b>XM3VB3</b>	<b>Arachis oil</b>
<b>XM8SU9</b>	<b>Barrier cream</b>
<b>XM5L08</b>	<b>Bentonite</b>
<b>XM7D95</b>	<b>Benzophenones</b>
<b>XM6F99</b>	<b>Benzophenone-3</b>
<b>XM4DT5</b>	<b>Benzophenone-4</b>
<b>XM08U7</b>	<b>Betula oil</b>
<b>XM7K00</b>	<b>Calamine (lotion)</b>
<b>XM2EP3</b>	<b>Cellulose nitrates (topical)</b>
<b>XM9ZA9</b>	<b>Chlordiethyl benzamide</b>
<b>XM88R8</b>	<b>Cold cream</b>
<b>XM7033</b>	<b>Corn starch</b>
<b>XM38M3</b>	<b>Cornhusker's lotion</b>
<b>XM8P34</b>	<b>Cottonseed oil</b>
<b>XM5PK1</b>	<b>Demulcent (external)</b>
<b>XM0XB3</b>	<b>Diethyl toluamide medicinal</b>
<b>XM9U76</b>	<b>Dimethyl phthalate</b>
<b>XM8KY4</b>	<b>Flaxseed (medicinal)</b>
<b>XM6694</b>	<b>Homosalate</b>
<b>XM8M74</b>	<b>Hydrophilic lotion</b>
<b>XM8WH4</b>	<b>Lanolin</b>
<b>XM4HE0</b>	<b>Lanolin alcohol</b>
<b>XM7TK2</b>	<b>Mecrilate</b>
<b>XM7VP7</b>	<b>Melanizing agents</b>
<b>XM8EY7</b>	<b>Mexenone</b>
<b>XM9TZ7</b>	<b>Mineral oil topical</b>
<b>XM3214</b>	<b>Octafonium chloride</b>
<b>XM66S8</b>	<b>Oil wintergreen (bitter)</b>
<b>XM9CQ4</b>	<b>Methoxsalen topical</b>

<b>XM0VT0</b>	<b>Padimate</b>
<b>XM9AG3</b>	<b>Para-aminobenzoic acid</b>
<b>XM1U48</b>	<b>Peanut oil topical</b>
<b>XM8PB6</b>	<b>Petrolatum</b>
<b>XM8J96</b>	<b>Plaster dressing</b>
<b>XM9V04</b>	<b>Plastic dressing</b>
<b>XM2BL7</b>	<b>Polyethylene adhesive</b>
<b>XM6J14</b>	<b>Protectant, skin</b>
<b>XM9VE3</b>	<b>Pyroxylin</b>
<b>XM8293</b>	<b>Rose water ointment</b>
<b>XM06Y2</b>	<b>Silicone medicinal</b>
<b>XM9410</b>	<b>Topical sunscreen</b> Preparations, usually in the form of lotions, creams or gels, applied to the skin to protect it from ultraviolet radiation.
<b>XM4YA6</b>	<b>Sulisobenzene</b>
<b>XM7YQ8</b>	<b>Sweet oil (birch)</b>
<b>XM3599</b>	<b>Talcum</b>
<b>XM3MF9</b>	<b>Thiosinamine</b>
<b>XM7Q94</b>	<b>Titanium dioxide</b>
<b>XM6WX7</b>	<b>Titanium oxide</b>
<b>XM5E39</b>	<b>Ultraviolet light protectants</b>
<b>XM4D35</b>	<b>2-(4-Diethylamino-2-hydroxybenzoyl)-benzoic acid hexylester</b>
<b>XM8A13</b>	<b>Methylene-bis-benzotriazolyltetramethylbutylphenol</b>
<b>XM6UT3</b>	<b>Phenylbenzimidazol-5-sulfonic acid</b>
<b>XM65Q8</b>	<b>2,4,6-Trianilino-p-(carbo-2-ethylhexyl-1-oxi)-1,3,5-triazine</b>
<b>XM5PP3</b>	<b>Unna's boot</b>
<b>XM8H46</b>	<b>Zinc gelatin</b>
<b>XM7RG9</b>	<b>Zinc oxide</b>
<b>XM4NT3</b>	<b>Zinc stearate</b>
<b>XM8YJ6</b>	<b>Colophonium</b>

<b>XM1LY7</b>	<b>Sorbitan sesquioleate</b>
<b>XM2M34</b>	<b>Octinoxate</b>
<b>XM2F87</b>	<b>Hyaluronic acid topical</b>
<b>XM90Q0</b>	<b>Cetomacrogol</b>
<b>XM8N69</b>	<b>Etofenamate</b>

Fluoride preparations

<b>XM85Z1</b>	<b>Fluoride medicinal dental use</b>
<b>XM9RB7</b>	<b>Stannous fluoride</b>

Iodine (antiseptic)

<b>XM60N7</b>	<b>Bismuth salts formic iodide</b>
<b>XM0DJ3</b>	<b>Cadexomer</b>
<b>XM12P7</b>	<b>Diiodohydroxypropane</b>
<b>XM8UZ7</b>	<b>Diiodohydroxyquin topical</b>
<b>XM0809</b>	<b>Iodide</b>
<b>XM8C24</b>	<b>Iodide mercury (ointment)</b>
<b>XM3Q63</b>	<b>Iodide methylate</b>
<b>XM6TG8</b>	<b>Iodochlorhydroxyquin topical</b>
<b>XM3X72</b>	<b>Iodoform</b>
<b>XM58X1</b>	<b>Potassium iodate</b>
<b>XM24J7</b>	<b>Povidone iodine</b>

Keratolytics, keratoplastics, and other hair treatment drugs and preparations

**Coded Elsewhere:** p-Phenylenediamine (XM0AK0)

<b>XM9ZS1</b>	<b>Allantoin</b>
<b>XM7H25</b>	<b>Alum (medicinal)</b>
<b>XM2GV6</b>	<b>Ammonium ichthiosulfonate</b>
<b>XM8RR9</b>	<b>Ammonium persulfate</b>
<b>XM8HL4</b>	<b>Anthralin</b>

<b>XM8SX1</b>	<b>Antiseborrheics</b>
<b>XM8GU1</b>	<b>Butantrone</b>
<b>XM4FV2</b>	<b>Cade oil</b>
<b>XM2ST0</b>	<b>Cadmium sulfide (medicinal)</b>
<b>XM9TT3</b>	<b>Capsicum</b>
<b>XM4AW0</b>	<b>Carbon dioxide snow</b>
<b>XM01Q7</b>	<b>Chlorothymol</b>
<b>XM92H5</b>	<b>Chloroxine</b>
<b>XM7HY4</b>	<b>Chrysarobin</b>
<b>XM3P37</b>	<b>Coal tar medicinal (ointment)</b>
<b>XM3LD7</b>	<b>Collagenase topical</b>
<b>XM7PM1</b>	<b>Corn cures</b>
<b>XM5W78</b>	<b>Depilatory</b>
<b>XM95C8</b>	<b>Diachylon plaster</b>
<b>XM64V2</b>	<b>Dimethyl sulfoxide medicinal</b>
<b>XM26P0</b>	<b>Dimethylamine sulfate</b>
<b>XM8RS8</b>	<b>Dithranol</b>
<b>XM17Y7</b>	<b>Enzyme proteolytic</b>
<b>XM3JC8</b>	<b>Ethyl chloride local</b>
<b>XM4P92</b>	<b>Ethyl fumarate</b>
<b>XM7WC9</b>	<b>Euresol</b>
<b>XM7VL9</b>	<b>Hair dye</b>
<b>XM8GV4</b>	<b>Hemostyptic</b>
<b>XM7KM8</b>	<b>Isopropyl alcohol medicinal</b>
<b>XM6ES1</b>	<b>Keratolytic drug anthracene</b>
<b>XM23V5</b>	<b>Keratolytic drug</b>
<b>XM4KL1</b>	<b>Keratoplastic</b>
<b>XM76E0</b>	<b>Lassar's paste</b>
<b>XM1VX5</b>	<b>Methyl nicotinate</b>

<b>XM8N27</b>	<b>Monobenzone</b>
<b>XM6YQ8</b>	<b>Pyrithione zinc</b>
<b>XM4549</b>	<b>Resorcin, resorcinol medicinal</b>
<b>XM5DQ2</b>	<b>Rubefacient</b>
<b>XM68B5</b>	<b>Salicylic acid</b>
<b>XM02N6</b>	<b>Savin (oil)</b>
<b>XM4CB3</b>	<b>Selenium disulfide</b>
<b>XM43T8</b>	<b>Selenium sulfide</b>
<b>XM1UK4</b>	<b>Selsun</b>
<b>XM3E07</b>	<b>Silver nitrate toughened (keratolytic)</b>
<b>XM1FW6</b>	<b>Sulfur compounds not elsewhere classified (medicinal)</b>
<b>XM6ZA6</b>	<b>Sulfur keratolytic ointment</b>
<b>XM1W96</b>	<b>Thioglycolate</b>
<b>XM7GY2</b>	<b>Tioxolone</b>
<b>XM4ZP4</b>	<b>Triacetoxyanthracene</b>
<b>XM6U21</b>	<b>Trichloroacetic acid medicinal</b>
<b>XM2V83</b>	<b>Vleminckx's solution</b>
<b>XM6T99</b>	<b>White lotion (keratolytic)</b>
<b>XM25J6</b>	<b>Xenysalate</b>
<b>XM7AM5</b>	<b>Glyceryl monothioglycolate</b>
<b>XM5L79</b>	<b>p-Toluenediamine</b>

Ophthalmological drugs and preparations

**Coded Elsewhere:** Bendazac (XM0P54)

- Neomycin topical (XM7D13)
- Inosine (XM8BH0)
- Nitrofurazone (XM71W2)
- Povidone iodine (XM24J7)
- Resorcin, resorcinol medicinal (XM4549)
- Neomycin ophthalmic preparation (XM7D13)

**XM75W8 Adrenal ophthalmic preparation**

<b>XM6H73</b>	<b>Ammonium acid tartrate</b>
<b>XM6G79</b>	<b>Anti-infective ophthalmic preparation</b>
<b>XM5568</b>	<b>Anticholinesterase reversible ophthalmological</b>
<b>XM5T83</b>	<b>Befunolol</b>
<b>XM6NB7</b>	<b>Bibrocathol</b>
<b>XM32H1</b>	<b>Chymotrypsin ophthalmic preparation</b>
<b>XM6E41</b>	<b>Colistin sulfate (eye preparation)</b>
<b>XM1WZ1</b>	<b>Contact lens solution</b>
<b>XM3X79</b>	<b>Copper sulfate cupric medicinal eye</b>
<b>XM3918</b>	<b>Cycloplegic drug</b>
<b>XM8S71</b>	<b>Demecarium bromide</b>
<b>XM1X30</b>	<b>Dendrid</b>
<b>XM0L12</b>	<b>Dipivefrine</b>
<b>XM17P1</b>	<b>Echothiophate</b>
<b>XM7K14</b>	<b>Ecothiopate iodide</b>
<b>XM09W6</b>	<b>Edoxudine</b>
<b>XM8PJ6</b>	<b>Eucatropine</b>
<b>XM45L3</b>	<b>Fluorphenylalanine</b>
<b>XM1783</b>	<b>Herplex</b>
<b>XM9EN3</b>	<b>Hydroxyamphetamine</b>
<b>XM9E72</b>	<b>Hypromellose</b>
<b>XM0PE3</b>	<b>Lachesine</b>
<b>XM8098</b>	<b>Levobunolol</b>
<b>XM4QZ9</b>	<b>Methylparaben (ophthalmic)</b>
<b>XM0YH4</b>	<b>Metipranolol</b>
<b>XM2JE0</b>	<b>Miotic drug</b>
<b>XM4DY8</b>	<b>Mycitracin ophthalmic preparation</b>
<b>XM5PU9</b>	<b>Mydriatic drug</b>
<b>XM28C3</b>	<b>Neosporin ophthalmic preparation</b>

<b>XM4PY4</b>	<b>Phospholine</b>
<b>XM4605</b>	<b>Physostigmine</b>
<b>XM9N59</b>	<b>Polymyxin E sulfate (eye preparation)</b>
<b>XM2WK3</b>	<b>Propylparaben (ophthalmic)</b>
<b>XM56H1</b>	<b>Silver protein</b>
<b>XM7AV0</b>	<b>Sodium borate cleanser eye</b>
<b>XM6Q18</b>	<b>Stoxil</b>
<b>XM8A14</b>	<b>Sulfisoxazole ophthalmic preparation</b>
<b>XM9PG5</b>	<b>Sulfonamide eye</b>
<b>XM61C9</b>	<b>Tear solution</b>
<b>XM5RC2</b>	<b>Tetrahydrozoline</b>
<b>XM31C8</b>	<b>Visine</b>
<b>XM9X81</b>	<b>Acetazolamide</b>
<b>XM4LU1</b>	<b>Dichlorphenamide</b>
<b>XM4DH5</b>	<b>Ethoxzolamide</b>
<b>XM8P33</b>	<b>Methazolamide</b>
<b>XM3ZJ4</b>	<b>Pemirolast</b>
<b>XM2JR8</b>	<b>Picloxydine</b>
<b>XM6JB1</b>	<b>Fluostigmine</b>
<b>XM3BT0</b>	<b>Dorzolamide</b>
<b>XM9GB8</b>	<b>Brinzolamide</b>
<b>XM5130</b>	<b>Latanoprost</b>
<b>XM5ZG4</b>	<b>Unoprostone</b>
<b>XM6E95</b>	<b>Bimatoprost</b>
<b>XM9BS0</b>	<b>Travoprost</b>
<b>XM3UC8</b>	<b>Tafluprost</b>
<b>XM6PD6</b>	<b>Dapiprazole</b>
<b>XM8469</b>	<b>Netarsudil</b>
<b>XM0GK6</b>	<b>Pegaptanib</b>

<b>XM95Y7</b>	<b>Ranibizumab</b>
<b>XM42E0</b>	<b>Iodoheparinate</b>
<b>XM67C4</b>	<b>Lifitegrast</b>
<b>XM57P1</b>	<b>Cenegermin</b>
<b>XM2RM5</b>	<b>Ocriplasmin</b>
<b>XM0YQ8</b>	<b>Autologous limbal stem cells</b>
<b>XM2GK8</b>	<b>Artificial tears and other indifferent preparations</b>
<b>XM3PF8</b>	<b>Anecortave</b>
<b>XM7CE4</b>	<b>Guaiazulen</b>
<b>XM0ST2</b>	<b>Olopatadine</b>
<b>XM49V8</b>	<b>Azidamfenicol</b>
<b>XM3G39</b>	<b>Sulfadicramide</b>
<b>XM13T1</b>	<b>Sulfafenazol</b>
<b>XM4F24</b>	<b>Interferon ophthalmic preparation</b>
<b>XM0C71</b>	<b>Fomivirsen</b>
<b>XM1A96</b>	<b>Besifloxacin</b>
<b>XM7415</b>	<b>Mercury compounds</b>
<b>XM9KL6</b>	<b>Loteprednol</b>
<b>XM6GF5</b>	<b>Formocortal</b>
<b>XM9166</b>	<b>Pranoprofen</b>
<b>XM4GZ0</b>	<b>Nepafenac</b>
<b>XM0QS2</b>	<b>Bromfenac</b>
<b>XM14H0</b>	<b>Brimonidine ophthalmic preparation</b>
<b>XM9KS5</b>	<b>Acetylcholine ophthalmic preparation</b>
<b>XM32J7</b>	<b>Levocabastine</b>
<b>XM9L65</b>	<b>Lodoxamide</b>
<b>XM1CM1</b>	<b>Emedastine</b>
<b>XM4JE3</b>	<b>Alcaftadine</b>
<b>XM7SY2</b>	<b>Sodium chloride, hypertonic (ophthalmic)</b>

<b>XM2LQ4</b>	<b>Sodium edetate ophthalmic preparation</b>
<b>XM3ZG3</b>	<b>Ciclosporin ophthalmic preparation</b>
<b>XM7UH0</b>	<b>Nandrolone ophthalmic preparation</b>
<b>XM3XE4</b>	<b>Apraclonidine</b>
<b>XM2Y24</b>	<b>Verteporfin</b>
<b>XM63C9</b>	<b>Spaglumic acid</b>

Other dental drugs, topically applied

<b>XM3YZ7</b>	<b>Dentifrice</b>
<b>XM1JW3</b>	<b>Dressing, live pulp</b>
<b>XM0PR1</b>	<b>Eucalyptus oil</b>
<b>XM3XP7</b>	<b>Oil cloves</b>
<b>XM8PE1</b>	<b>Pulp devitalizing paste</b>
<b>XM9023</b>	<b>Acetylsalicylic acid topical</b>
<b>XM7K59</b>	<b>Olaflur</b>
<b>XM5GY2</b>	<b>Sodium monofluorophosphate topical</b>

Other local antifungal, anti-infective and anti-inflammatory drugs

**Coded Elsewhere:** Flurandrenolide (XM5086)

<b>XM53X2</b>	<b>Tetracycline topical</b>
<b>XM2FL0</b>	<b>Acriflavinium chloride</b>
<b>XM8K50</b>	<b>Acrinol</b>
<b>XM5PD0</b>	<b>Acrisorcin</b>
<b>XM7696</b>	<b>Adrenal topical</b>
<b>XM9B70</b>	<b>Aerosporin topical</b>
<b>XM2ET5</b>	<b>Alclometasone</b>
<b>XM3NX2</b>	<b>Alkonium (bromide)</b>
<b>XM7TF6</b>	<b>Allethrin</b>
<b>XM0CC9</b>	<b>Aluminium acetate solution</b>
<b>XM6JG7</b>	<b>Aluminium sulfate</b>

<b>XM18N0</b>	<b>Glutaraldehyde medicinal</b>
<b>XM7XA4</b>	<b>Glyceryl triacetate topical</b>
<b>XM7Y78</b>	<b>Gramicidin</b>
<b>XM5UQ0</b>	<b>Halcinolone</b>
<b>XM9Q64</b>	<b>Halethazole</b>
<b>XM0C80</b>	<b>Haloprogin</b>
<b>XM3KW0</b>	<b>Halquinols</b>
<b>XM6XH7</b>	<b>HCH medicinal</b>
<b>XM8UW4</b>	<b>Hedaquinium</b>
<b>XM95K6</b>	<b>Hexachlorophene</b>
<b>XM6RK6</b>	<b>Aminoacridine</b>
<b>XM7RK5</b>	<b>Hexamidine</b>
<b>XM19W1</b>	<b>Hydrargaphen</b>
<b>XM0JC1</b>	<b>Hydrargyri amino-chloridum</b>
<b>XM4AG2</b>	<b>Hydrogen peroxide</b>
<b>XM6E35</b>	<b>Hydroxytoluene medicinal</b>
<b>XM02H1</b>	<b>Hypochlorite</b>
<b>XM3PT9</b>	<b>Ichthammol</b>
<b>XM6BF8</b>	<b>Isoconazole</b>
<b>XM07S0</b>	<b>Kwell anti-infective (topical)</b>
<b>XM3U48</b>	<b>Laurolinium</b>
<b>XM7CU1</b>	<b>Amphotericin B topical</b>
<b>XM8C45</b>	<b>Lidex</b>
<b>XM8E58</b>	<b>Lindane medicinal</b>
<b>XM7CM3</b>	<b>Locorten</b>
<b>XM5MZ8</b>	<b>Mafenide</b>
<b>XM6QD7</b>	<b>Malathion (medicinal)</b>
<b>XM6L15</b>	<b>Medrysone</b>
<b>XM53R5</b>	<b>Melaleuca alternifolia oil</b>

<b>XM35K3</b>	<b>Merbromin</b>
<b>XM7FY5</b>	<b>Mercaptobenzothiazole salts</b>
<b>XM1B13</b>	<b>Mercurochrome</b>
<b>XM8GN4</b>	<b>Anti-infective bismuth, local</b>
<b>XM2J64</b>	<b>Mercury ammoniated</b>
<b>XM9Z76</b>	<b>Mercury anti-infective topical</b>
<b>XM10V3</b>	<b>Mercury chloride (ammoniated)</b>
<b>XM6Q50</b>	<b>Mercury oxide, yellow</b>
<b>XM9613</b>	<b>Merthiolate</b>
<b>XM2JH4</b>	<b>Mesulfen</b>
<b>XM2M00</b>	<b>Metactesylacetate</b>
<b>XM0XV0</b>	<b>Methyl paraben</b>
<b>XM1910</b>	<b>Methyl prednisolone topical</b>
<b>XM5HR1</b>	<b>Methylbenzethonium chloride</b>
<b>XM1JC6</b>	<b>Antifungal disinfectant, local</b>
<b>XM7C91</b>	<b>Methylrosaniline</b>
<b>XM2793</b>	<b>Methylrosanilinium chloride</b>
<b>XM0ZY9</b>	<b>Micatin</b>
<b>XM9A06</b>	<b>Monistat</b>
<b>XM23B6</b>	<b>Mupirocin</b>
<b>XM43U9</b>	<b>Mycifradin topical</b>
<b>XM14D6</b>	<b>Myralact</b>
<b>XM1HX1</b>	<b>Naftifine</b>
<b>XM2BK7</b>	<b>Natamycin</b>
<b>XM7D13</b>	<b>Neomycin topical</b>
<b>XM44R8</b>	<b>Argyrol</b>
<b>XM51P6</b>	<b>Neomycin with bacitracin</b>
<b>XM6YS1</b>	<b>Neosporin topical</b>
<b>XM5BH2</b>	<b>Nilstat topical</b>

<b>XM71W2</b>	<b>Nitrofurazone</b>
<b>XM4T72</b>	<b>Nitromersol</b>
<b>XM2HP9</b>	<b>Nitrozone</b>
<b>XM1102</b>	<b>Noxytiolin</b>
<b>XM70Z6</b>	<b>Orthoboric acid</b>
<b>XM63S9</b>	<b>Oxiconazole</b>
<b>XM8610</b>	<b>Oxychlorosene</b>
<b>XM7VP9</b>	<b>Asiaticoside</b>
<b>XM7N08</b>	<b>Oxylone</b>
<b>XM9LG4</b>	<b>Parachlorophenol (camphorated)</b>
<b>XM12F4</b>	<b>Paramethasone acetate</b>
<b>XM0MS1</b>	<b>Peruvian balsam</b>
<b>XM70C4</b>	<b>Phenoctide</b>
<b>XM6L76</b>	<b>Phenol</b>
<b>XM4H85</b>	<b>Phenothrin</b>
<b>XM9D74</b>	<b>Phenoxyethanol</b>
<b>XM3R68</b>	<b>Phenylmercuric acetate</b>
<b>XM89P9</b>	<b>Phenylmercuric borate</b>
<b>XM0295</b>	<b>Chlortetracycline topical</b>
<b>XM0K18</b>	<b>Phenylmercuric nitrate</b>
<b>XM3DV8</b>	<b>Piketoprofen</b>
<b>XM7B69</b>	<b>Polymyxin B topical</b>
<b>XM0J95</b>	<b>Polynoxylin</b>
<b>XM2G74</b>	<b>Polyoxymethyleneurea</b>
<b>XM0XP0</b>	<b>Potassium Permanganate medicinal</b>
<b>XM6YA5</b>	<b>Proflavine</b>
<b>XM35Q1</b>	<b>Propamidine</b>
<b>XM4TA7</b>	<b>Propiolactone</b>
<b>XM3DH9</b>	<b>Propion gel</b>

<b>XM6SG3</b>	<b>Azelaic acid</b>
<b>XM77H8</b>	<b>Propionate (calcium) (sodium)</b>
<b>XM03K3</b>	<b>Pyrethrum extract</b>
<b>XM2A13</b>	<b>Pyrogallic acid</b>
<b>XM8BE0</b>	<b>Pyrogallol</b>
<b>XM97F8</b>	<b>Quaternary ammonium anti-infective</b>
<b>XM2SR9</b>	<b>Retinoic acid</b>
<b>XM9773</b>	<b>Salicylhydroxamic acid</b>
<b>XM5GX7</b>	<b>Sodium hypochlorite medicinal (anti-infective) (external)</b>
<b>XM5372</b>	<b>Sodium hyposulfite</b>
<b>XM7Z80</b>	<b>Sodium perborate medicinal</b>
<b>XM4PL5</b>	<b>Bacimycin</b>
<b>XM7EV2</b>	<b>Sodium propionate</b>
<b>XM1VV3</b>	<b>Sporostacin</b>
<b>XM38S1</b>	<b>Staphisagria or stavesacre (pediculicide)</b>
<b>XM8HC5</b>	<b>Steroid topical</b>
<b>XM2237</b>	<b>Sulbentine</b>
<b>XM2CH0</b>	<b>Sulfacetamide</b>
<b>XM06Y3</b>	<b>Sulfiram</b>
<b>XM4XY4</b>	<b>Sulfur ointment</b>
<b>XM9ST9</b>	<b>Synalar</b>
<b>XM33Y9</b>	<b>Terconazole</b>
<b>XM00V5</b>	<b>Bacitracin zinc</b>
<b>XM2GG6</b>	<b>Tetramethylthiuram medicinal</b>
<b>XM9ZY9</b>	<b>Thimerosal</b>
<b>XM7W47</b>	<b>Thymol</b>
<b>XM3C36</b>	<b>Ticlatone</b>
<b>XM9HG1</b>	<b>Tioconazole</b>
<b>XM9SF6</b>	<b>Tolciclate</b>

<b>XM23C3</b>	<b>Tolnaftate</b>
<b>XM6848</b>	<b>Triacetin</b>
<b>XM4873</b>	<b>Triamcinolone hexacetonide</b>
<b>XM5KU0</b>	<b>Triclobisonium chloride</b>
<b>XM6Y48</b>	<b>Bacitracin zinc with neomycin</b>
<b>XM74T6</b>	<b>Triclocarban</b>
<b>XM5WW5</b>	<b>Triclosan</b>
<b>XM93J3</b>	<b>Tridesilon</b>
<b>XM84C7</b>	<b>Undecenoic acid</b>
<b>XM5GQ1</b>	<b>Undecylium</b>
<b>XM1TP6</b>	<b>Undecylenic acid (derivatives)</b>
<b>XM81Z1</b>	<b>Urea peroxide</b>
<b>XM2VU7</b>	<b>Valisone</b>
<b>XM0GR5</b>	<b>Vioform topical</b>
<b>XM2B18</b>	<b>Zinc anti-infectives</b>
<b>XM7E88</b>	<b>Basic fuchsin</b>
<b>XM6KL1</b>	<b>Zinc peroxide</b>
<b>XM8SM1</b>	<b>Zinc sulfate topical</b>
<b>XM5L28</b>	<b>Zinc undecylenate</b>
<b>XM71H0</b>	<b>Cloponone</b>
<b>XM0BF3</b>	<b>Acriflavine</b>
<b>XM1KZ4</b>	<b>Nifuraldezone</b>
<b>XM4DT4</b>	<b>Tibezonium iodide</b>
<b>XM5U34</b>	<b>Eosin</b>
<b>XM24W5</b>	<b>Propanol</b>
<b>XM5DR7</b>	<b>Isopropanol</b>
<b>XM2ZR2</b>	<b>Benisone</b>
<b>XM2Q40</b>	<b>Pecilocin</b>
<b>XM6UW2</b>	<b>Pyrrolnitrin</b>

<b>XM8S89</b>	<b>Polihexanide</b>
<b>XM0SV3</b>	<b>Policresulen</b>
<b>XM80T0</b>	<b>Biphenylool</b>
<b>XM68P2</b>	<b>Didecyldimethylammonium chloride</b>
<b>XM5LX3</b>	<b>Mercury, metallic</b>
<b>XM53J8</b>	<b>Decamethoxine</b>
<b>XM2UH3</b>	<b>Euflavine</b>
<b>XM7KH0</b>	<b>Sodium chlorite</b>
<b>XM2VS1</b>	<b>Benzalkonium chloride</b>
<b>XM7022</b>	<b>Nadifloxacin</b>
<b>XM8BY6</b>	<b>Clindamycin topical</b>
<b>XM6AC5</b>	<b>Chlormidazole</b>
<b>XM2NB3</b>	<b>Sulconazole</b>
<b>XM8B91</b>	<b>Bifonazole</b>
<b>XM4J78</b>	<b>Fenticonazole</b>
<b>XM0072</b>	<b>Omoconazole</b>
<b>XM9U15</b>	<b>Sertaconazole</b>
<b>XM49Z6</b>	<b>Flutrimazole</b>
<b>XM5XM5</b>	<b>Eberconazole</b>
<b>XM1QH3</b>	<b>Benzethonium chloride</b>
<b>XM6H72</b>	<b>Luliconazole</b>
<b>XM7CT0</b>	<b>Bromochlorosalicylanilide</b>
<b>XM89W5</b>	<b>Tribromometaresol</b>
<b>XM8JJ2</b>	<b>2-(4-chlorphenoxy)-ethanol</b>
<b>XM67B0</b>	<b>Ethyl hydroxybenzoate</b>
<b>XM6474</b>	<b>Amorolfine</b>
<b>XM2L70</b>	<b>Butenafine</b>
<b>XM3PR6</b>	<b>Tavaborole</b>
<b>XM20T9</b>	<b>Efinaconazole</b>

<b>XM0CH6</b>	<b>Imiquimod</b>
<b>XM7SQ2</b>	<b>Benzoic acid with salicylic acid</b>
<b>XM8BH0</b>	<b>Inosine</b>
<b>XM4BA3</b>	<b>Docosanol</b>
<b>XM2CA6</b>	<b>Sinecatechins</b>
<b>XM0N01</b>	<b>Mercuric iodide</b>
<b>XM4796</b>	<b>Benzododecinium</b>
<b>XM2PS8</b>	<b>Aluminium acetotartrate</b>
<b>XM0P54</b>	<b>Bendazac</b>
<b>XM3J77</b>	<b>Bioallethrin</b>
<b>XM7MQ0</b>	<b>Copper oleinate</b>
<b>XM73B3</b>	<b>Decamethrin</b>
<b>XM9JZ6</b>	<b>Benzoic acid</b>
<b>XM4KG9</b>	<b>Dibutylsuccinate</b>
<b>XM84S5</b>	<b>Dibutylphthalate</b>
<b>XM1BB3</b>	<b>Dimethylcarbate</b>
<b>XM74X3</b>	<b>Dimethylphthalate</b>
<b>XM4UE1</b>	<b>Ethacridine lactate</b>
<b>XM2Y03</b>	<b>Etohexadiol</b>
<b>XM8XZ0</b>	<b>Felbinac</b>
<b>XM6XJ9</b>	<b>Oxyquinoline</b>
<b>XM4PX0</b>	<b>Potassium polysulfide</b>
<b>XM9R96</b>	<b>Quassia</b>
<b>XM63Y9</b>	<b>Benzoxonium chloride</b>
<b>XM0GR6</b>	<b>Tyrothricin</b>
<b>XM0FD5</b>	<b>Fidaxomicin</b>
<b>XM1071</b>	<b>Nifuroxazide</b>
<b>XM5BH0</b>	<b>Nifurzide</b>
<b>XM7MF9</b>	<b>Balsalazide</b>

<b>XM0JJ7</b>	<b>Dimeticone topical</b>
<b>XM6XD8</b>	<b>Streptomycin topical</b>
<b>XM4KV4</b>	<b>Acetic acid medicinal</b>
<b>XM7014</b>	<b>Terbinafine topical</b>
<b>XM0K16</b>	<b>Iodoxuridine topical</b>
<b>XM43M3</b>	<b>Benzoyl peroxide</b>
<b>XM9X60</b>	<b>Penciclovir topical</b>
<b>XM3SK7</b>	<b>Famciclovir topical</b>
<b>XM7A63</b>	<b>Ganciclovir topical</b>
<b>XM1P27</b>	<b>Lomefloxacin topical</b>
<b>XM3CL3</b>	<b>Levofloxacin topical</b>
<b>XM92Q3</b>	<b>Gatifloxacin topical</b>
<b>XM6VX8</b>	<b>Moxifloxacin topical</b>
<b>XM1HU5</b>	<b>Loxoprofen</b>
<b>XM8TB9</b>	<b>Abametapir</b>
<b>XM7QG0</b>	<b>Benzyl benzoate</b>
<b>XM0GX2</b>	<b>Benzyl Benzoic acid</b>
<b>XM9208</b>	<b>BHC (medicinal)</b>
<b>XM7S48</b>	<b>Bismuth salts glycolylarsenate</b>
<b>XM5RT8</b>	<b>Boric acid</b>
<b>XM84D8</b>	<b>Bromosalicylchloranitide</b>
<b>XM0YT9</b>	<b>Buclosamide</b>
<b>XM6862</b>	<b>Butoconazole (nitrate)</b>
<b>XM7VA5</b>	<b>Calomel</b>
<b>XM2AV1</b>	<b>Candididin</b>
<b>XM2V43</b>	<b>Carbamide peroxide</b>
<b>XM2ZX1</b>	<b>Carbol fuchsin</b>
<b>XM6C04</b>	<b>Carfusin</b>
<b>XM9H69</b>	<b>Castellani's paint</b>

<b>XM5ZY9</b>	<b>Ceepryn</b>
<b>XM9432</b>	<b>Cetalkonium chloride</b>
<b>XM1BP8</b>	<b>Cethexonium chloride</b>
<b>XM62D0</b>	<b>Cetrimide</b>
<b>XM6ZW9</b>	<b>Cetrimonium bromide</b>
<b>XM94W4</b>	<b>Cetylpyridinium chloride</b>
<b>XM7CX5</b>	<b>Chamomile</b>
<b>XM8HU1</b>	<b>Chloramine T</b>
<b>XM72P5</b>	<b>Chloramphenicol topical</b>
<b>XM7DZ3</b>	<b>Chlorhexidine</b>
<b>XM2ZT2</b>	<b>Chlorhydroxyquinolin</b>
<b>XM5D99</b>	<b>Chlorinated lime and boric acid solution</b>
<b>XM0HL8</b>	<b>Chlorinated soda solution</b>
<b>XM8FE7</b>	<b>Chlorocresol</b>
<b>XM3XC5</b>	<b>Chloroxylenol</b>
<b>XM93C6</b>	<b>Chlorphenesin topical (antifungal)</b>
<b>XM2CN0</b>	<b>Chlorquinol</b>
<b>XM0852</b>	<b>Ciclopirox (olamine)</b>
<b>XM6MJ1</b>	<b>Clobetasone</b>
<b>XM2WP5</b>	<b>Clodantoin</b>
<b>XM8TG2</b>	<b>Clofenotane</b>
<b>XM8W85</b>	<b>Clotrimazole</b>
<b>XM6BT6</b>	<b>Cloxiquine</b>
<b>XM4M83</b>	<b>Copper gluconate</b>
<b>XM42L5</b>	<b>Creosol (compound)</b>
<b>XM35M5</b>	<b>Creosote (coal tar) (beechwood)</b>
<b>XM7ZK1</b>	<b>Cresol (s)</b>
<b>XM0WM0</b>	<b>Cresol and soap solution</b>
<b>XM4YB3</b>	<b>Cresyl acetate</b>

<b>XM0348</b>	<b>Cresylic acid</b>
<b>XM3726</b>	<b>Crotamiton</b>
<b>XM7YY8</b>	<b>Dakin's solution</b>
<b>XM8CF0</b>	<b>Dequalinium chloride</b>
<b>XM6LZ1</b>	<b>Desonide</b>
<b>XM0PQ7</b>	<b>Dettol</b>
<b>XM1RR7</b>	<b>Dibromopropamidine isethionate</b>
<b>XM0UE0</b>	<b>Dibromopropamidine</b>
<b>XM06U7</b>	<b>Dicophane</b>
<b>XM2355</b>	<b>Diethyltoluamide</b>
<b>XM4A13</b>	<b>Dimazole</b>
<b>XM42D3</b>	<b>Dixanthogen</b>
<b>XM3JL3</b>	<b>Dodicin</b>
<b>XM7YF5</b>	<b>Dofamium chloride</b>
<b>XM3TY6</b>	<b>Domiphen bromide</b>
<b>XM5XH3</b>	<b>Econazole</b>
<b>XM8E88</b>	<b>Erythromycin topical</b>
<b>XM5QE6</b>	<b>Ethacridine</b>
<b>XM09B1</b>	<b>Ethylene oxide medicinal</b>
<b>XM91H3</b>	<b>Eurax</b>
<b>XM2258</b>	<b>Exalamide</b>
<b>XM9K22</b>	<b>Fenticlor</b>
<b>XM2E99</b>	<b>Fluocinonide</b>
<b>XM67C1</b>	<b>Flurobate</b>
<b>XM6AZ9</b>	<b>Furazolium chloride</b>
<b>XM5JA4</b>	<b>Gamma-benzene hexachloride (medicinal)</b>
<b>XM0XR4</b>	<b>Gentamicin topical</b>

Other local astringents and local detergents

**Coded Elsewhere:** Acetic acid medicinal (XM4KV4)

<b>XM3P38</b>	<b>Aluminium acetate</b>
<b>XM7FE1</b>	<b>Aluminium chloride</b>
<b>XM2D21</b>	<b>Aluminium diacetate</b>
<b>XM2399</b>	<b>Aluminium subacetate</b>
<b>XM38V9</b>	<b>Antihemorrhoidal preparation</b>
<b>XM1KT1</b>	<b>Detergent external medication</b>
<b>XM16X4</b>	<b>Dial (soap)</b>
<b>XM2KD7</b>	<b>Duponol (C) (EP)</b>
<b>XM3Y82</b>	<b>Green soap</b>
<b>XM2273</b>	<b>Lauryl sulfoacetate</b>
<b>XM8P35</b>	<b>Lead acetate</b>
<b>XM3E94</b>	<b>Polyethanolamine alkyl sulfate</b>
<b>XM2P20</b>	<b>Soap medicinal, soft</b>
<b>XM6EW6</b>	<b>Soap superfatted</b>
<b>XM1X23</b>	<b>Sodium lauryl (sulfate)</b>
<b>XM1484</b>	<b>Tannic acid medicinal (astringent)</b>
<b>XM7KD1</b>	<b>Thiram medicinal</b>
<b>XM19Y0</b>	<b>Vegetable extract, astringent</b>
<b>XM4S15</b>	<b>Witch hazel</b>
<b>XM4KJ0</b>	<b>Antiperspirant</b>
<b>XM20Y8</b>	<b>Hamamelis</b>
<b>XM1DT0</b>	<b>Iproheptine</b>
<b>XM9RY1</b>	<b>Lowila</b>
<b>XM1AY0</b>	<b>Septisol</b>
<b>XM3DK8</b>	<b>Sulfatostearate</b>

Other topical agents

<b>XM9R98</b>	<b>Benoquin</b>
---------------	-----------------

<b>XM4597</b>	<b>Cantharides</b>
<b>XM8JB2</b>	<b>Cell stimulants and proliferants</b>
<b>XM4JD6</b>	<b>Charcoal medicinal topical</b>
<b>XM6GG8</b>	<b>Chloresium</b>
<b>XM9YX8</b>	<b>Dextromoramide topical</b>
<b>XM1KB4</b>	<b>Elaste</b>
<b>XM0M69</b>	<b>Enzyme depolymerizing</b>
<b>XM5VL6</b>	<b>Gelfilm</b>
<b>XM1FF8</b>	<b>Heet</b>
<b>XM6P44</b>	<b>Lactic acid</b>
<b>XM2D09</b>	<b>Lytta (vitatta)</b>
<b>XM54L7</b>	<b>Nonoxinol</b>
<b>XM4M68</b>	<b>Nonylphenoxy (polyethoxy-ethanol)</b>
<b>XM2TV0</b>	<b>Octoxinol-9</b>
<b>XM7DL5</b>	<b>Panthenol topical</b>
<b>XM8865</b>	<b>Podophyllotoxin</b>
<b>XM3403</b>	<b>Preparation H</b>
<b>XM0VK2</b>	<b>Santyl</b>
<b>XM4AZ3</b>	<b>Scarlet red</b>
<b>XM6Z04</b>	<b>Sodium borate therapeutic</b>
<b>XM8EC8</b>	<b>Spermicide</b>
<b>XM0M54</b>	<b>Tosylchloramide sodium</b>
<b>XM8WU4</b>	<b>Urea topical</b>
<b>XM0M02</b>	<b>Becaplermin</b>
<b>XM4QZ6</b>	<b>Gamolenic acid</b>
<b>XM14C4</b>	<b>Capsaicin</b>
<b>XM5DL8</b>	<b>Zucapsaicin</b>
<b>XM7ZQ6</b>	<b>Organo-heparinoid</b>
<b>XM1485</b>	<b>Sodium apolate</b>

<b>XM3711</b>	<b>Tacalcitol</b>
<b>XM6BQ3</b>	<b>Tazarotene</b>
<b>XM3GL1</b>	<b>Dextranomer</b>
<b>XM7618</b>	<b>Crilanomer</b>
<b>XM1JG0</b>	<b>Enoxolone</b>
<b>XM0W31</b>	<b>Trolamine</b>
<b>XM1W34</b>	<b>Betulae cortex</b>
<b>XM1NP5</b>	<b>Ingenol mebutate</b>
<b>XM60N1</b>	<b>Selenium compounds</b>
<b>XM4HG0</b>	<b>Metandienone topical</b>
<b>XM5DF2</b>	<b>Pimecrolimus</b>
<b>XM1015</b>	<b>Dupilumab</b>
<b>XM1A95</b>	<b>Brimonidine</b>
<b>XM8HP9</b>	<b>Deoxycholic acid</b>
<b>XM2TT0</b>	<b>Calcipotriol</b>
<b>XM41S0</b>	<b>Aluminium oxide</b>
<b>XM8ZR0</b>	<b>Cadmium compounds (medicinal)</b>
<b>XM9MC0</b>	<b>Lithium succinate</b>
<b>XM0RJ6</b>	<b>Mequinol</b>
<b>XM7XL9</b>	<b>Albumin tannate</b>
<b>XM87L7</b>	<b>Diosmectite</b>
<b>XM0XA0</b>	<b>Ceratonia</b>
<b>XM3AJ8</b>	<b>Crospovidone</b>
<b>XM86M9</b>	<b>Racecadotril</b>
<b>XM33M4</b>	<b>Trafermin</b>
<b>XM0A16</b>	<b>Abrocitinib</b>

Otorhinolaryngological drugs and preparations

**Coded Elsewhere:** Spaglumic acid (XM63C9)

    Neomycin topical (XM7D13)  
    Nitrofurazone (XM71W2)  
    Benzethonium chloride (XM1QH3)  
    Levocabastine (XM32J7)  
    Oxyquinoline (XM6XJ9)  
    Olopatadine (XM0ST2)  
    Neomycin ENT agent (XM7D13)

<b>XM7BG3</b>	<b>Alkaline antiseptic solution (aromatic)</b>
<b>XM7CJ4</b>	<b>Ambazole</b>
<b>XM9SX0</b>	<b>Amylmetacresol</b>
<b>XM59F4</b>	<b>Biclotymol</b>
<b>XM51P8</b>	<b>Bisdequalinium (salts) (diacetate)</b>
<b>XM0LW6</b>	<b>Chloromycetin otic solution</b>
<b>XM2954</b>	<b>Copper sulfate cupric medicinal ear</b>
<b>XM6270</b>	<b>Corbadrine</b>
<b>XM96Z5</b>	<b>Dichlorobenzyl alcohol</b>
<b>XM37H6</b>	<b>Glycerol borax</b>
<b>XM4UQ0</b>	<b>Levonordefrin</b>
<b>XM9EQ5</b>	<b>Neosporin ENT agent</b>
<b>XM4RA5</b>	<b>Nose preparations</b>
<b>XM8YH0</b>	<b>Thenoic acid</b>
<b>XM9VY0</b>	<b>Zinc chloride (mouthwash)</b>
<b>XM83Z7</b>	<b>Acetic acid ENT agent</b>
<b>XM0G17</b>	<b>Ritiometan</b>
<b>XM3RP3</b>	<b>Myristyl-benzalkonium</b>
<b>XM8XE9</b>	<b>Antazoline topical</b>
<b>XM9FX7</b>	<b>Calcium hexamine thiocyanate</b>
<b>XM3NR8</b>	<b>Octenidine</b>
<b>XM0M82</b>	<b>Phenazone topical</b>

<b>XM5HX7</b>	<b>Podophyllin</b>
<b>XM4L14</b>	<b>Podophyllum (resin)</b>
Topical corticosteroid preparations	
<b>XM35S7</b>	<b>Amcinonide</b>
<b>XM8WS1</b>	<b>Triamcinolone topical</b>
<b>XM46G7</b>	<b>Betamethasone topical</b>
<b>XM4FN3</b>	<b>Clobetasol</b>
<b>XM57Z7</b>	<b>Corticosteroid topical</b>
<b>XM5PM3</b>	<b>Desoximetasone</b>
<b>XM6TE1</b>	<b>Dexamethasone topical</b>
<b>XM8V58</b>	<b>Diflorasone</b>
<b>XM4XD6</b>	<b>Diflucortolone</b>
<b>XM4TV8</b>	<b>Fluclorolone acetonide</b>
<b>XM0WP2</b>	<b>Fludrocortisone topical</b>
<b>XM84F4</b>	<b>Fludroxcortide</b>
<b>XM6LQ2</b>	<b>Flumethasone</b>
<b>XM3EM1</b>	<b>Fluocortin (butyl)</b>
<b>XM7MM0</b>	<b>Fluorometholone</b>
<b>XM52K8</b>	<b>Fluprednidene</b>
<b>XM5086</b>	<b>Flurandrenolide</b>
<b>XM0ZX1</b>	<b>Halcinonide</b>
<b>XM8TL4</b>	<b>Halometasone</b>
<b>XM8KB5</b>	<b>Hydrocortisone aceponate</b>
<b>XM6JE7</b>	<b>Hydrocortisone topical</b>
<b>XM0ME0</b>	<b>Prednicarbate</b>
<b>XM1B59</b>	<b>Prednisolone steaglate</b>
<b>XM09Z4</b>	<b>Prednisolone topical</b>
<b>XM4Y24</b>	<b>Hydrocortisone butyrate</b>

<b>XM55S3</b>	<b>Flumetasone</b>
<b>XM41T8</b>	<b>Fluperolone</b>
<b>XM5ZS6</b>	<b>Buteprate</b>
<b>XM64R0</b>	<b>Ulobetasol</b>
<b>XM6DT9</b>	<b>Difluprednate</b>
<b>XM5EY3</b>	<b>Methylprednisolone aceponate</b>
<b>XM4HA4</b>	<b>Fluocinolone acetonide</b>
<b>XM1068</b>	<b>Fluclorolone</b>
<b>XM9DE4</b>	<b>Ciclesonide topical</b>
<b>XM8963</b>	<b>Tixocortol pivalate</b>
<b>XM5PA8</b>	<b>Ufenamate</b>
<b>XM3VA9</b>	<b>Chlorphenesin</b>
<b>XM2NU3</b>	<b>Idrocilamide</b>
<b>XM6H69</b>	<b>Methyl salicylate</b>

Retinoids topical

<b>XM10R5</b>	<b>Adapalene</b>
<b>XM6KD7</b>	<b>Motretinide</b>
<b>XM7C94</b>	<b>Tretinoin topical</b>
<b>XM6PV8</b>	<b>Retinol topical</b>
<b>XM2PQ2</b>	<b>Isotretinoin topical</b>
<b>XM01G3</b>	<b>Silver</b>
<b>XM0CN1</b>	<b>Silver anti-infectives</b>
<b>XM3QX7</b>	<b>Silver colloidal</b> <i>Coded Elsewhere:</i> Silver nitrate ophthalmic preparation (XM2U36)
<b>XM2U36</b>	<b>Silver nitrate ophthalmic preparation</b>
<b>XM9R64</b>	<b>Silver sulfadiazine</b>
<b>XM6RF0</b>	<b>Silver nitrate</b>

Substances, chiefly nonmedicinal

**Exclusions:** Allergens ()

Medicaments (XM1349-XM6RF0)

**XM5LS4 Acrylamide**

**XM1SE1 Agrochemical**

**XM10X3 Fertilizer**

**Coded Elsewhere:** Sodium nitrate (XM7FZ2)

**XM4NU1 Ammonium nitrate**

**XM0AR7 Guano**

**XM7046 Magnesium thiosulfate**

**XM7D46 Pesticide**

**Coded Elsewhere:** Aluminium phosphide (XM3TB8)

Azobenzene (XM1UP9)

Calcium cyanide (XM42L1)

Chloropicrin (XM3U53)

Dinitrocyclohexylphenol (XM95M5)

Dinitrophenol (XM73Y7)

Fluoride nonmedicinal (XM10Z2)

Hydrogen cyanide (XM8WA4)

Mercuric oxide nonmedicinal (XM5X38)

Phosphine (XM3G46)

Sodium arsenite (XM7Y18)

Antimony pesticide, not elsewhere classified (XM81B2)

Arsenic pesticide, not elsewhere classified (XM4GU5)

Cadmium pesticide, not elsewhere classified (XM1TW0)

Copper pesticide, not elsewhere classified (XM3757)

Cyanide pesticide, not elsewhere classified (XM77X3)

Mercury pesticide, not elsewhere classified (XM7UW8)

Petroleum pesticide, not elsewhere classified (XM8AA6)

Phenol pesticide, not elsewhere classified (XM5YF7)

Plant derived pesticide, not elsewhere classified (XM8PU3)

Zinc pesticide, not elsewhere classified (XM27E8)

**XM6PM8 Dibromochloropropane**

**XM61U9 Dichloropropene**

**XM4G15 Ethylene oxide**

<b>XM83G4</b>	Fungicide  <b>Coded Elsewhere:</b> Borate nonmedicinal (XM8X28) Copper acetate (XM5U84) Copper hydroxide (XM0EX6) Copper oxide (XM0Y98) Copper oxychloride (XM48K0) Copper sulfate nonmedicinal (XM6859) Diphenylamine (XM2732) Ethyl mercuric chloride (XM8JX9) Formaldehyde (XM0TV9) Mercuric chloride nonmedicinal (XM9524) Methyl isothiocyanate (XM4QN2) Oxine-copper (XM98Z3) Phenylmercury acetate (XM2Z22) Verdigris (XM30V1)
<b>XM0MT5</b>	Auramine
<b>XM44B4</b>	Benzimidazole
<b>XM9F10</b>	Carbendazim
<b>XM2WG5</b>	Benomyl
<b>XM0ZM1</b>	Fuberidazole
<b>XM7ZN0</b>	Thiabendazole nonmedicinal
<b>XM7E92</b>	Thiophanate-methyl
<b>XM9051</b>	Blasticidin-S
<b>XM6TA8</b>	Bordeaux mixture
<b>XM3F05</b>	Captafol
<b>XM9BL0</b>	Captan
<b>XM75T2</b>	Chlorothalonil
<b>XM21E5</b>	Cycloheximide
<b>XM8E94</b>	Dichlone
<b>XM3365</b>	Difenoconazole
<b>XM5KQ8</b>	Dithiocarbamate
<b>XM3TR4</b>	Edifenphos
<b>XM04K8</b>	Folpet
<b>XM40T8</b>	Glutaral nonmedicinal

<b>XM4AW6</b>	Hexachlorobenzene
<b>XM0HQ1</b>	Tetramethylthiuram disulfide
<b>XM3JA8</b>	Zineb
<b>XM0P16</b>	Octylisothiazolinone
<b>XM6J29</b>	Herbicide  <i>Coded Elsewhere:</i> Acrolein (XM4HP5) Allyl Alcohol (XM51N7) Sodium chlorate (XM0345)
<b>XM3FE7</b>	Ammonium sulfamate
<b>XM2RT5</b>	Bromoxynil
<b>XM62D4</b>	Chloroacetic acid
<b>XM3KU8</b>	Dalapon
<b>XM3MM5</b>	Dicamba
<b>XM5DH1</b>	Dichlobenil
<b>XM9CD8</b>	2,4-Dichlorophenoxyacetic acid
<b>XM23C2</b>	Dinoseb
<b>XM60K0</b>	Dinoseb acetate
<b>XM62Q7</b>	Dinoterb
<b>XM1M07</b>	Diquat
<b>XM5TV1</b>	Diuron
<b>XM6KX6</b>	Endothall
<b>XM50V7</b>	Glyphosate
<b>XM88B4</b>	MCPA
<b>XM6T93</b>	MCPA-thioethyl
<b>XM0CJ6</b>	Mecoprop
<b>XM0QY2</b>	Mecoprop-P
<b>XM0TQ1</b>	Monuron
<b>XM4SL8</b>	Paraquat
<b>XM8J05</b>	Propachlor
<b>XM66Q3</b>	Propanil
<b>XM48M2</b>	Simazine

<b>XM7KH8</b>	Sodium cacodylate herbicide
<b>XM0MH9</b>	Triazine derivative herbicide, not elsewhere classified
<b>XM7ML8</b>	Triazole
<b>XM9MT5</b>	2,4,5-Trichlorophenoxyacetic acid
<b>XM4PA4</b>	Carbamate herbicide, not elsewhere classified
<b>XM3K66</b>	Insecticide
	<b>Coded Elsewhere:</b> Azadirachta plant (XM17F2)
	Cinnamomum camphora plant (XM6YA3)
	Copper arsenic complex (XM8SC0)
	Derris elliptica plant (XM3KT4)
	Dimethyl phthalate nonmedicinal (XM34N7)
	Kerosene (XM2Q78)
	Lead arsenate (XM8LC6)
	Pyrethrin nonmedicinal (XM5HR7)
	Sabadilla insecticide (XM4BY7)
	Sodium selenate (XM5RR4)
<b>XM0231</b>	Carbamate insecticide
<b>XM0HS9</b>	Aldicarb
<b>XM0ZT6</b>	Butocarboxim
<b>XM4DS5</b>	Butoxycarboxim
<b>XM9G20</b>	Carbaryl
<b>XM1KX0</b>	Naphthol
<b>XM7A68</b>	Carbofuran
<b>XM8FU1</b>	Ethiofencarb
<b>XM9HR4</b>	Furathiocarb
<b>XM9Y05</b>	Methiocarb
<b>XM2CU6</b>	Methomyl
<b>XM0DL6</b>	Oxamyl
<b>XM79F9</b>	Propoxur
<b>XM3358</b>	Thiofanox
<b>XM7LT1</b>	Cryolite
<b>XM12C2</b>	DEET
<b>XM4NG6</b>	Diflubenzuron

<b>XM5S01</b>	Naphthalene  <b>Coded Elsewhere:</b> Naphthol (XM1KX0)
<b>XM3AD4</b>	Nicotine insecticide
<b>XM41B3</b>	Organochlorine insecticide  <b>Coded Elsewhere:</b> Carbon tetrachloride (XM3CP7)  Chlorex (XM77V1) Chlorinated naphthalene (XM1YR6) Hexachlorocyclohexane (XM8PE4) Methoxychlor (XM0MD1)
<b>XM5Y08</b>	Aldrin
<b>XM12L2</b>	Chlordane
<b>XM7JD5</b>	Chlorobenzilate
<b>XM9EL1</b>	DDT
<b>XM1UT2</b>	DDE - [dichlorodiphenyldichloroethylene]
<b>XM3XK2</b>	Paradichlorobenzene
<b>XM2CK5</b>	Dicofol
<b>XM5U23</b>	Dieldrin
<b>XM5C19</b>	Endosulfan
<b>XM6ZU9</b>	Endrin
<b>XM2JS5</b>	Heptachlor
<b>XM5642</b>	Isobenzan
<b>XM4H89</b>	Kelevan
<b>XM16G7</b>	Lindane
<b>XM07J5</b>	Lindane vapor
<b>XM5NU4</b>	Mirex
<b>XM32P2</b>	Pentachlorophenol
<b>XM4FV5</b>	Strobane
<b>XM91D0</b>	Toxaphene
<b>XM7154</b>	Organophosphate insecticide
<b>XM7RX0</b>	Azinphos-ethyl
<b>XM7H46</b>	Azinphos-methyl
<b>XM2JZ1</b>	Cadusafos

<b>XM8AZ4</b>	Carbophenothion
<b>XM3DK0</b>	Chlorethoxyfos
<b>XM20D7</b>	Chlorfenvinphos
<b>XM4RG9</b>	Chlormephos
<b>XM3QX6</b>	Chlorpyrifos
<b>XM5566</b>	Chlorthion
<b>XM2MP2</b>	Chlorthiophos
<b>XM8WL8</b>	Coumaphos
<b>XM6L87</b>	Demephion
<b>XM4WK8</b>	Demephion-O
<b>XM8KA9</b>	Demephion-S
<b>XM5F29</b>	Demeton
<b>XM4724</b>	Demeton-O
<b>XM8LS8</b>	Demeton-O-methyl
<b>XM6UD3</b>	Demeton-S
<b>XM8ZM3</b>	Demeton-S-methyl
<b>XM6AY4</b>	Diazinon
<b>XM26D3</b>	Dicaphthon
<b>XM03V8</b>	Dichlorvos
<b>XM5UL4</b>	Dicrotophos
<b>XM5Q52</b>	Dimefox
<b>XM58G9</b>	Dimethoate
<b>XM56E1</b>	Dimetilan
<b>XM3494</b>	Dioxathion
<b>XM9SP5</b>	Disulfoton
<b>XM5BC5</b>	EPN
<b>XM7X81</b>	Ethion
<b>XM9F71</b>	Ethoprophos
<b>XM7818</b>	Famphur
<b>XM7SU5</b>	Fenthion

<b>XM5KA2</b>	Fluorophosphate insecticide
<b>XM7TZ6</b>	Heptenophos
<b>XM5G36</b>	Hexaethyl tetraphosphate
<b>XM5JS5</b>	Isoxathion
<b>XM6A89</b>	Leptophos
<b>XM0G23</b>	Malathion insecticide
<b>XM5406</b>	Mecarbam
<b>XM9R34</b>	Mephosfolan
<b>XM56W1</b>	Methamidophos
<b>XM83J2</b>	Methidathion
<b>XM8ZT2</b>	Mevinphos
<b>XM4197</b>	Mipafox
<b>XM27J3</b>	Monocrotophos
<b>XM0US9</b>	Naled
<b>XM2D86</b>	Omethoate
<b>XM48D2</b>	Oxydemeton-methyl
<b>XM7LW0</b>	Paraoxon
<b>XM14N6</b>	Parathion
<b>XM1YY0</b>	Parathion-methyl
<b>XM20V2</b>	Phorate
<b>XM2324</b>	Phosfolan
<b>XM3QY4</b>	Phosphamidon
<b>XM6YG2</b>	Propetamphos
<b>XM7GK7</b>	Prothoate
<b>XM7UW2</b>	Quinalphos
<b>XM0TB4</b>	Schradan
<b>XM1E56</b>	Sulfotep
<b>XM7LH6</b>	Tebupirimfos
<b>XM6P90</b>	TEPP
<b>XM2QB5</b>	Terbufos

<b>XM72Q5</b>	Thiometon
<b>XM4T49</b>	Thionazin
<b>XM2AH6</b>	Triazophos
<b>XM13H5</b>	Trichloronate
<b>XM9FN4</b>	Vamidothion
<b>XM5EB8</b>	Phenothiazine insecticide
<b>XM4AP8</b>	Pyrethroid insecticide
<b>XM27C9</b>	Allethrin insecticide
<b>XM79U4</b>	Bifenthrin
<b>XM7YT2</b>	Cyfluthrin
<b>XM8HR7</b>	Cyhalothrin
<b>XM1MQ5</b>	Cypermethrin
<b>XM3Y88</b>	Cyphenothrin
<b>XM3BQ7</b>	Deltamethrin
<b>XM76R8</b>	Esfenvalerate
<b>XM1Z58</b>	Fenpropathrin
<b>XM9JZ0</b>	Fenvalerate
<b>XM6H26</b>	Flucythrinate
<b>XM7461</b>	Permethrin
<b>XM4AC0</b>	Prallethrin
<b>XM5QE0</b>	Tefluthrin
<b>XM1MW0</b>	Tetramethrin
<b>XM2H33</b>	Tralomethrin
<b>XM1S21</b>	Rotenone
<b>XM95F1</b>	Metaldehyde
<b>XM0NK1</b>	Methyl bromide
<b>XM6FE7</b>	Piperonyl butoxide

<b>XM2KK3</b>	Rodenticide  <b>Coded Elsewhere:</b> Barium carbonate (XM3709) Scilliroside (XM0SG7) Sodium cyanide (XM1AZ9) Strychnine rodenticide (XM9JS2) Thallium sulfate (XM9YD2) Zinc phosphide (XM6D77)
<b>XM8UV3</b>	Alpha chlorhydrin
<b>XM4X40</b>	Alpha naphthylthiourea
<b>XM7138</b>	Brodifacoum
<b>XM7RU0</b>	Bromadiolone
<b>XM3QV7</b>	Bromethalin
<b>XM1GN8</b>	Chloralose
<b>XM1FD8</b>	Chlorophacinone
<b>XM0DK0</b>	Coumatetralyl
<b>XM3KE1</b>	Crimidine
<b>XM9VL9</b>	Difenacoum
<b>XM6DL4</b>	Difethialone
<b>XM4J38</b>	Diphacinone
<b>XM7HA0</b>	Flocoumafen
<b>XM7P90</b>	Fluoroacetamide
<b>XM2WD6</b>	Norbormide
<b>XM4116</b>	Pindone
<b>XM8QH8</b>	Pyriminil
<b>XM9LE1</b>	Sodium fluoroacetate
<b>XM8LJ0</b>	Warfarin rodenticide
<b>XM6BS1</b>	Tetradifon
<b>XM6372</b>	Acaricide, not elsewhere classified
<b>XM8V89</b>	Fumigant, not elsewhere classified
<b>XM0ZQ8</b>	Molluscicide, not elsewhere classified
<b>XM5E09</b>	Organochlorine pesticide, not elsewhere classified
<b>XM8HA3</b>	Seed disinfectant, not elsewhere classified

<b>XM86Y5</b>	Sulfur pesticide, not elsewhere classified
<b>XM0J68</b>	Thiocarbamate pesticides, not elsewhere classified
<b>XM86L9</b>	Wood preservative, not elsewhere classified
<b>XM55D5</b>	Copper oleate
<b>XM6U34</b>	<b>Alcohol</b> <i>Coded Elsewhere:</i> Diacetone alcohol (XM9F73)
<b>XM9BA5</b>	<b>Alcohol vapor</b>
<b>XM51N7</b>	<b>Allyl Alcohol</b>
<b>XM6K71</b>	<b>Bay rum</b>
<b>XM0AD5</b>	<b>Benzyl alcohol nonmedicinal</b>
<b>XM7VB3</b>	<b>Cinnamyl alcohol</b>
<b>XM3XS0</b>	<b>Cyclohexanol</b>
<b>XM8ZW3</b>	<b>Ethanol</b>
<b>XM1A61</b>	Alcohol beverage
<b>XM8HG4</b>	Absolute alcohol
<b>XM3094</b>	Denatured alcohol
<b>XM6DN6</b>	Ethanol disinfectant
<b>XM8RP6</b>	Ethanol motor fuel <i>Coded Elsewhere:</i> Gasohol (XM52C5)
<b>XM2VC0</b>	<b>Ethyl methylcarbinol</b>
<b>XM48D0</b>	<b>Fusel alcohol</b>
<b>XM88C8</b>	<b>Amyl alcohol</b>
<b>XM5JW4</b>	<b>Amylene hydrate</b>
<b>XM49S0</b>	<b>Butyl alcohol</b>
<b>XM6HQ5</b>	<b>Diethyl carbinol</b>
<b>XM5SH0</b>	<b>Isoamyl alcohol</b>
<b>XM5RS7</b>	<b>Propyl alcohol</b>
<b>XM5M32</b>	<b>Trimethylcarbinol</b>
<b>XM6C11</b>	<b>Hexahydrocresol</b>
<b>XM4BN8</b>	<b>Hydroabietyl alcohol</b>
<b>XM5531</b>	<b>Isopropyl alcohol</b>

<b>XM8YA1</b>	Isopropyl rubbing alcohol
<b>XM80Q0</b>	<b>Jamaica ginger</b>
<b>XM7KD9</b>	<b>Methanol</b> <b>Coded Elsewhere:</b> Denatured alcohol (XM3094)
<b>XM0ZA4</b>	Methanol motor fuel
<b>XM6VD7</b>	<b>Antifreeze, not elsewhere classified</b>
<b>XM7XX5</b>	<b>Canned heat, not elsewhere classified</b>
<b>XM4S45</b>	<b>Geraniol</b>
<b>XM7UN9</b>	<b>Hydroxycitronellal</b>
<b>XM9TZ4</b>	<b>Algal toxin</b>
<b>XM6F50</b>	<b>Cyanotoxin</b>
<b>XM38M2</b>	Microcystin
<b>XM9RM0</b>	<b>Amyl propionate</b>

Animal toxin, venom, or poison

<b>XM26J2</b>	<b>Amphibian toxin</b>
<b>XM0KH6</b>	<b>Frog toxin</b>
<b>XM0CW7</b>	Bruno's casque headed frog venom
<b>XM8QW3</b>	Greening's frog venom
<b>XM7JP5</b>	Poison dart frog poison
<b>XM4BD8</b>	Golden poison frog poison
<b>XM6K27</b>	Anthony's poison arrow frog poison
<b>XM7JV0</b>	Strawberry poison dart frog poison
<b>XM9TX1</b>	Kokoe poison frog poison
<b>XM2698</b>	Black legged poison frog poison
<b>XM7P83</b>	<b>Salamander toxin</b>
<b>XM93N2</b>	Newt toxin
<b>XM7YQ1</b>	<b>Toad toxin</b>
<b>XM8YT6</b>	Colorado River toad toxin
<b>XM54D9</b>	Marine toad toxin
<b>XM7930</b>	<b>Arthropod venom</b>

<b>XM12G1</b>	<b>Arachnid venom</b>
<b>XM9DM8</b>	Scorpion venom
<b>XM0HC0</b>	Asian black scorpion venom
<b>XM8F59</b>	Black emperor scorpion venom
<b>XM52D7</b>	Giant forest scorpion venom
<b>XM72V7</b>	Australian forest scorpion venom
<b>XM10T2</b>	Australian urodacus scorpion venom
<b>XM48S4</b>	Australian black rock scorpion venom
<b>XM10R0</b>	Australian desert scorpion venom
<b>XM0YV3</b>	Australian marbled scorpion venom
<b>XM3HL0</b>	Bark scorpion venom
<b>XM2HW7</b>	Brazilian yellow scorpion venom
<b>XM12P5</b>	Chinese scorpion venom
<b>XM5QE7</b>	Common yellow scorpion venom
<b>XM0E23</b>	Death stalker scorpion venom
<b>XM95A6</b>	Fattail scorpion venom
<b>XM91Z5</b>	Flat rock scorpion venom
<b>XM67X5</b>	Indian red scorpion venom
<b>XM11L8</b>	Lesser Asian scorpion venom
<b>XM1WF9</b>	Transvaal thick tailed scorpion venom
<b>XM8XC7</b>	Yellow creeping leg scorpion venom
<b>XM6NN5</b>	Spider venom
<b>XM2RM6</b>	Brown recluse spider venom
<b>XM6SD4</b>	False widow spider venom
<b>XM3KD6</b>	Funnel web spider venom
<b>XM57S7</b>	Hobo spider venom
<b>XM0C68</b>	Jumping spider venom
<b>XM1LF5</b>	Mouse spider venom
<b>XM6QH2</b>	Six eyed sand spider venom
<b>XM8095</b>	Tarantula spider venom

<b>XM8FT7</b>	Wandering spider venom
<b>XM7JS2</b>	Widow spider venom
<b>XM7M21</b>	Black widow spider venom
<b>XM9Z42</b>	Brown widow spider venom
<b>XM1TF6</b>	Redback spider venom
<b>XM2JA0</b>	Red widow spider venom
<b>XM2WM2</b>	Wolf spider venom
<b>XM3UW9</b>	Yellow sac spider venom
<b>XM94S4</b>	Tick venom
<b>XM7WR0</b>	American dog tick venom
<b>XM51Y1</b>	Australian paralysis tick venom
<b>XM3J29</b>	Brown dog tick venom
<b>XM77E1</b>	Deer tick venom
<b>XM5RS1</b>	Lone star tick venom
<b>XM8YN1</b>	Spinose ear tick venom
<b>XM6TD6</b>	<b>Centipede venom</b>
<b>XM5LB1</b>	Amazonian giant centipede venom
<b>XM52L4</b>	Australian giant centipede venom
<b>XM9FP1</b>	Texas redheaded centipede venom
<b>XM2WU4</b>	Vietnamese centipede venom
<b>XM50Y9</b>	<b>Insect venom</b>
<b>XM3Y95</b>	Ant venom
<b>XM4CP1</b>	Bull ant venom
<b>XM02L8</b>	Bullet ant venom
<b>XM3UK8</b>	Fire ant venom
<b>XM1547</b>	Harvester ant venom
<b>XM5ZS2</b>	Jack jumper ant venom
<b>XM13H7</b>	Bee venom
<b>XM1GA3</b>	Africanized honey bee venom
<b>XM0NK4</b>	Bumblebee venom

<b>XM42T0</b>	Honey bee venom
<b>XM1142</b>	Caterpillar venom
<b>XM2T44</b>	Cup moth caterpillar venom
<b>XM57P9</b>	Puss caterpillar venom
<b>XM7D92</b>	Horsefly venom
<b>XM2YA4</b>	Wasp venom
<b>XM6D92</b>	Yellow jacket venom
<b>XM1PF5</b>	Paper wasp venom
<b>XM31U2</b>	Hornet venom
<b>XM7CC3</b>	Asian giant hornet venom
<b>XM4C00</b>	<b>Millipede toxin</b>
<b>XM0HS8</b>	<b>Bird toxin</b>
<b>XM5V29</b>	<b>Ifrita bird toxin</b>
<b>XM5Y38</b>	<b>Pitohui bird toxin</b>
<b>XM35H6</b>	<b>Mammal toxin</b>
<b>XM27R8</b>	<b>Platypus venom</b>
<b>XM8EC2</b>	<b>Shrew venom</b>
<b>XM9R52</b>	<b>Slow loris venom</b>
<b>XM67Y0</b>	<b>Solenodon venom</b>
<b>XM6NB8</b>	<b>Vampire bat venom</b>
<b>XM2P96</b>	<b>Marine and freshwater animal toxins</b>
<b>XM99J1</b>	<b>Marine and freshwater animal venom</b>
<b>XM2GR5</b>	Blue ringed octopus venom
<b>XM56D3</b>	Brittle star venom
<b>XM0CW4</b>	Coral venom
<b>XM65N5</b>	Fire coral venom
<b>XM0R26</b>	Soft coral venom
<b>XM05Z4</b>	Fish venom
<b>XM0UJ4</b>	Cobbler fish venom
<b>XM6643</b>	Dogfish shark venom

<b>XM3DB5</b>	Ghost shark venom
<b>XM5FP5</b>	Goblinfish venom
<b>XM4CL4</b>	Lionfish venom
<b>XM17D1</b>	Rabbitfish venom
<b>XM5V26</b>	Scorpionfish venom
<b>XM73V9</b>	Stargazer fish venom
<b>XM7P10</b>	Stingray venom
<b>XM8P00</b>	Stonefish venom
<b>XM83T2</b>	Striped blenny fish venom
<b>XM0784</b>	Striped eel catfish venom
<b>XM33N5</b>	Toadfish venom
<b>XM0U57</b>	Waspfish venom
<b>XM1VW1</b>	Weeverfish venom
<b>XM9YA3</b>	Jellyfish venom
<b>XM4057</b>	Box jellyfish venom
<b>XM0ZB2</b>	Irukandji jellyfish venom
<b>XM87R6</b>	Sea wasp venom
<b>XM6PY9</b>	Lion's mane jellyfish venom
<b>XM8EA9</b>	Sea nettle venom
<b>XM6S92</b>	Portuguese man o war venom
<b>XM41L4</b>	Sea anemone venom
<b>XM2HU5</b>	Sea cucumber venom
<b>XM2M75</b>	Sea urchin venom
<b>XM48L3</b>	Snail venom
<b>XM7A02</b>	Starfish venom
<b>XM3X53</b>	Crown of thorns starfish venom
<b>XM3BZ7</b>	<b>Seafood poison</b>
<b>XM1KF5</b>	Crab seafood poison
<b>XM7V29</b>	Fish seafood poison Poisoning with fish toxin (nonbacterial) eaten as seafood.
<b>XM1DD9</b>	Ciguatera fish seafood poison

<b>XM7N43</b>	Greenland shark seafood poison
<b>XM33K2</b>	Puffer fish seafood poison
<b>XM74Y6</b>	Scombroid fish seafood poison
<b>XM40D3</b>	Toadfish seafood poison
<b>XM5QW5</b>	Sea cucumber seafood poison
<b>XM51R6</b>	Sea snail seafood poison
<b>XM7VB5</b>	Shellfish seafood poison
<b>XM3XQ0</b>	Oyster seafood poison
<b>XM3S96</b>	Clam seafood poison
<b>XM3KC2</b>	Scallop seafood poison
<b>XM41B9</b>	Mussel seafood poison
<b>XM7DB8</b>	Turtle seafood poison
<b>XM2YA1</b>	Box turtle seafood poison
<b>XM1C12</b>	Green sea turtle seafood poison
<b>XM0RH0</b>	Hawksbill sea turtle seafood poison

**XM2X61      Reptile venom**

<b>XM4RP9</b>	Lizard venom
<b>XM5HY6</b>	Beaded lizard venom
<b>XM7HD4</b>	Gila monster lizard venom
<b>XM4KN1</b>	<b>Snake venom</b>
<b>XM6UB3</b>	Sea snake venom
<b>XM8DS9</b>	Terrestrial snake venom
<b>XM9034</b>	Adder snake venom
	<b>Coded Elsewhere:</b> Asp viper snake venom (XM5UK6)
<b>XM4R63</b>	Puff adder snake venom
<b>XM8DE0</b>	Death adder snake venom
<b>XM2J41</b>	European adder snake venom
<b>XM6CL7</b>	American copperhead snake venom
<b>XM5UK6</b>	Asp viper snake venom
<b>XM3DZ2</b>	Australasian black snake venom

<b>XM9E44</b>	Mulga snake venom
<b>XM5MD7</b>	Australian brown snake venom
<b>XM2UN5</b>	Common brown snake venom
<b>XM1FY9</b>	Australian copperhead snake venom
<b>XM0RN4</b>	Boomslang snake venom
<b>XM26Z0</b>	Bush viper snake venom
<b>XM2650</b>	Bushmaster snake venom
<b>XM6HP1</b>	Carpet viper snake venom
<b>XM1R49</b>	Cobra snake venom
<b>XM45D4</b>	Chinese cobra snake venom
<b>XM4760</b>	Egyptian cobra snake venom
<b>XM6052</b>	Indian cobra snake venom
<b>XM0W24</b>	King cobra snake venom
<b>XM1UH2</b>	Northern Philippine cobra snake venom
<b>XM5F28</b>	Spitting cobra snake venom
<b><i>Coded Elsewhere:</i></b> Northern Philippine cobra snake venom (XM1UH2)	
<b>XM7LZ0</b>	Black necked spitting cobra snake venom
<b>XM69M0</b>	Javan spitting cobra snake venom
<b>XM6U92</b>	Mozambique spitting cobra venom
<b>XM2B16</b>	Red spitting cobra snake venom
<b>XM7BF9</b>	West African brown spitting cobra venom
<b>XM7P11</b>	Tree cobra snake venom
<b>XM4WV8</b>	Coral snake venom
<b>XM2PM7</b>	Harlequin coralsnake venom
<b>XM0EN5</b>	Texas coralsnake venom
<b>XM5A72</b>	Desert viper snake venom
<b>XM2RJ2</b>	Gaboon viper snake venom
<b>XM6LU5</b>	Horned viper snake venom
<b>XM7WL0</b>	Hump nosed pit viper snake venom
<b>XM7TD0</b>	Krait snake venom

<b>XM2RD0</b>	Banded krait snake venom
<b>XM5J22</b>	Indian krait snake venom
<b>XM78S0</b>	Malayan krait snake venom
<b>XM7JF1</b>	Lancehead snake venom
<b>XM2267</b>	Common lancehead snake venom
<b>XM9Y58</b>	Fer de lance snake venom
<b>XM40A2</b>	Levant viper snake venom
<b>XM9JL4</b>	Mamba snake venom
<b>XM2SH0</b>	Black mamba snake venom
<b>XM1RM0</b>	Eastern green mamba snake venom
<b>XM8E53</b>	Jameson's mamba snake venom
<b>XM1GY6</b>	Western green mamba snake venom
<b>XM81Z8</b>	Mole viper snake venom
<b>XM3G20</b>	Moorish viper snake venom
<b>XM2A66</b>	Ottoman viper snake venom
<b>XM88F6</b>	Palestine viper snake venom
<b>XM1504</b>	Rattlesnake venom
<b>XM3RE1</b>	Eastern diamondback rattlesnake venom
<b>XM1RY2</b>	Mojave rattlesnake venom
<b>XM8MU5</b>	Prairie rattlesnake venom
<b>XM2P01</b>	Timber rattlesnake venom
<b>XM5JD1</b>	Western diamondback rattlesnake venom
<b>XM8JD0</b>	Russell viper snake venom
<b>XM4SM0</b>	Taipan snake venom
<b>XM5T51</b>	Coastal taipan snake venom
<b>XM7NG4</b>	Inland taipan snake venom
<b>XM7XU4</b>	Western ranges taipan snake venom
<b>XM23U8</b>	Tiger snake venom
<b>XM59V3</b>	Water mocassin snake venom
<b>XM7FH1</b>	<b>Tetrodotoxin</b>

**XM7S46      Carbon disulfide**

Corrosive substance

<b>XM34D2</b>	<b>Acetic anhydride</b>
<b>XM4HP5</b>	<b>Acrolein</b>
<b>XM2MJ1</b>	<b>Acrolein gas</b>
<b>XM3GN3</b>	<b>Aziridine</b>
<b>XM9WX0</b>	<b>Benzidine</b>
<b>XM6PB5</b>	<b>Corrosive acid</b> <i>Coded Elsewhere:</i> Hydrochloric acid (XM6F61)
<b>XM6HP3</b>	<b>Formic acid</b>
<b>XM6SY2</b>	Formic acid vapor
<b>XM3C02</b>	<b>Hydrazoic acid</b>
<b>XM0VA0</b>	<b>Hydrogen fluoride</b>
<b>XM34T7</b>	Hydrogen fluoride vapor
<b>XM5NZ1</b>	<b>Nitric acid</b>
<b>XM5CC8</b>	Nitric acid vapor
<b>XM5WU5</b>	<b>Nitrohydrochloric acid</b>
<b>XM2WH3</b>	<b>Nitrous acid</b>
<b>XM6QY4</b>	Nitrous acid fumes
<b>XM5JW8</b>	<b>Orthotolidine</b>
<b>XM22A0</b>	<b>Osmic acid</b>
<b>XM07R4</b>	Osmic acid fumes
<b>XM4AK6</b>	<b>Oxalic acid</b>
<b>XM03N8</b>	Potassium oxalate
<b>XM6CB1</b>	Sodium oxalate
<b>XM0270</b>	<b>Phosphoric acid</b>
<b>XM0KV1</b>	<b>Picric acid</b>
<b>XM8724</b>	<b>Sulfuric acid</b>
<b>XM9SC9</b>	<b>Trichloroacetic acid</b>

<b>XM2R89</b>	<b>Corrosive alkali</b>
<b>XM4TP4</b>	<b>Ammonia</b>
<b>XM2KS4</b>	<b>Ammonia liquid</b>
<b>XM51W3</b>	<b>Ammonium carbonate</b>
<b>XM8X28</b>	<b>Borate nonmedicinal</b>
<b>XM4Q76</b>	<b>Sodium borate cleanser</b>
<b>XM25T4</b>	<b>Sodium perborate nonmedicinal</b>
<b>XM4AF1</b>	<b>Calcium hydroxide</b>
<b>XM50U9</b>	<b>Calcium hypochlorite</b>
<b>XM87X9</b>	<b>Calcium oxide</b>
<b>XM8586</b>	<b>Caustic hydroxide</b>
<b>XM5N47</b>	<b>Potassium hydroxide</b>
<b>XM4SW1</b>	<b>Sodium hydroxide</b>
<b>XM8WC7</b>	<b>Potassium carbonate</b>
<b>XM9370</b>	<b>Sodium carbonate</b>
<b>XM0KW1</b>	<b>Sodium hypochlorite</b>
<b>XM6KZ0</b>	<b>Sodium hypochlorite vapor</b>
<b>XM8F93</b>	<b>Triethanolamine</b>
<b>XM9JC6</b>	<b>Alkaline disinfectant, not elsewhere classified</b>
<b>XM71L2</b>	<b>Dimethyl sulfate</b>
<b>XM8TX4</b>	<b>Dimethyl sulfate fumes</b>
<b>XM10Z2</b>	<b>Fluoride nonmedicinal</b>
<b>XM48A5</b>	<b>Sulfuryl fluoride</b>
<b>XM8LE5</b>	<b>Hydrazine</b>
<b>XM0WH6</b>	<b>Methyl hydrazine</b>
<b>XM7BT1</b>	<b>Methyl iodide</b>
<b>XM92T1</b>	<b>Phenol, nonmedicinal</b>
<b>XM3FK8</b>	<b>Aminophenol</b>
<b>XM9JR4</b>	<b>Methyl aminophenol</b>
<b>XM2PP7</b>	<b>Butylated hydroxytoluene</b>

XM7645	Nitrophenol
XM0HB7	Phenol disinfectant, not elsewhere classified
XM5YF7	Phenol pesticide, not elsewhere classified
XM9814	Liquor cresolis compositus
XM5380	Phthalic anhydride
XM49E4	Silver nitrate nonmedicinal
XM9GW2	Sodium bisulfate
XM0345	Sodium chlorate
XM5M78	Sodium oxide
XM4XF6	Sodium peroxide
XM8FM5	Sodium silicate
XM6826	Thioglycolic acid
XM85F7	Corrosive aromatics, not elsewhere classified
XM1ZR1	Corrosive cleaning product, not elsewhere classified
XM2A78	Bleach, not elsewhere classified
XM6AU8	Drain cleaner, not elsewhere classified
XM57L3	Corrosive cleaning product fumes, not elsewhere classified
XM05Q8	Oxidizing agent, not elsewhere classified
XM3HX8	Cyanide <i>Coded Elsewhere:</i> Bromobenzylcyanide (XM9FN5) Mercuric cyanide nonmedicinal (XM39J4)
XM23N0	Acrylonitrile
XM9R22	Aliphatic thiocyanates
XM42L1	Calcium cyanide
XM1ZE4	Cyanogen
XM1293	Cyanogen chloride
XM8WA4	Hydrogen cyanide
XM0YF6	Isocyanate
XM4QN2	Methyl isothiocyanate
XM1VD7	Potassium cyanide

<b>XM2Q39</b>	<b>Potassium ferric hexacyanoferrate nonmedicinal</b>
<b>XM1AZ9</b>	<b>Sodium cyanide</b>
<b>XM36N4</b>	<b>Toluene diisocyanate</b>
<b>XM77X3</b>	<b>Cyanide pesticide, not elsewhere classified</b>
<b>XM4VA2</b>	<b>Dichloroformoxine</b>
<b>XM14Q4</b>	<b>Ethyldene diacetate</b>

## Explosive chemical

**Coded Elsewhere:** Ammonium nitrate (XM4NU1)

- Picric acid (XM0KV1)
- Tetryl (XM9ZV3)
- TNT (XM1X35)
- Trinitrobenzol (XM4B36)

<b>XM5NJ3</b>	<b>Cordite</b>
<b>XM1926</b>	<b>Cordite vapor</b>
<b>XM4PQ8</b>	<b>Nitrocellulose</b>
	<b>Coded Elsewhere:</b> Nitrocellulose lacquer (XM8B47)
<b>XM8T02</b>	<b>Nitroglycerin nonmedicinal</b>
<b>XM5VU2</b>	<b>Nitroglycerin nonmedicinal fumes</b>
<b>XM9YX2</b>	<b>Dynamite</b>
<b>XM7Q61</b>	<b>Dynamite fumes</b>
<b>XM7GP0</b>	<b>Nitronaphthalene</b>
<b>XM7EN6</b>	<b>Potassium chlorate</b>
<b>XM8SN2</b>	<b>Fiberglass</b>

## Gas, fumes or vapour

- Coded Elsewhere:** Acetaldehyde vapor (XM5Q94)  
Acetylene tetrachloride vapor (XM4YD3)  
Acridine vapor (XM2QW2)  
Acrolein gas (XM2MJ1)  
Alcohol vapor (XM9BA5)  
Ammonia (XM4TP4)  
Amyl acetate vapor (XM1JM2)  
Aniline vapor (XM0061)  
Brake fluid vapor (XM8TE5)  
Boron trifluoride (XM5AP1)  
Carbon tetrachloride vapor (XM0386)  
Chlorinated naphthalene vapor (XM9P39)  
Chlorodinitrobenzene vapor (XM5VH9)  
Chloroethylene (XM6YR0)  
Chloroform vapor (XM1GP5)  
Chloronitrobenzene vapor (XM5S30)  
Chloropicrin (XM3U53)  
Cordite vapor (XM1926)  
Cyanogen (XM1ZE4)  
Decaborane fumes (XM74T0)  
Dichloromethane vapor (XM7EF6)  
Dimethyl sulfate fumes (XM8TX4)  
Dinitrobenzene vapor (XM54Q3)  
Dynamite fumes (XM7Q61)  
Ethyl ether nonmedicinal (XM0N40)  
Ethylene chlorohydrin vapor (XM5HK4)  
Ethylene dichloride vapor (XM8QX0)  
Ethylene oxide (XM4G15)  
Formic acid vapor (XM6SY2)  
Freon (XM9813)  
Hydrochloric acid vapor (XM6QZ3)  
Hydrogen cyanide (XM8WA4)  
Hydrogen fluoride vapor (XM34T7)  
Hydroquinone vapor (XM1N69)  
Lindane vapor (XM07J5)  
Methyl bromide (XM0NK1)  
Methyl sulfate fumes (XM5Y11)  
Mineral spirits fumes (XM2E62)

Nitric acid vapor (XM5CC8)  
Nitroaniline vapor (XM8M07)  
Nitrobenzene vapor (XM2VA4)  
Nitrotoluene vapor (XM5F24)  
Nitrous acid fumes (XM6QY4)  
Osmic acid fumes (XM07R4)  
Pyridine vapor (XM7TE7)  
Selenium fumes (XM4HH9)  
Sodium hypochlorite vapor (XM6KZ0)  
Tar fumes (XM5LE8)  
Tetrachloroethane vapor (XM4N54)  
Tetrachloroethylene vapor (XM86D7)  
Trichloroethylene vapor (XM7YS9)  
Toluidine vapor (XM7S87)  
Corrosive cleaning product fumes, not elsewhere classified (XM57L3)  
Paint fumes, not elsewhere classified (XM1XL9)

<b>XM3GS6</b>	<b>Bromine vapor</b>
<b>XM8XZ6</b>	<b>Carbon dioxide</b>
<b>XM1X11</b>	<b>Carbon monoxide</b>
<b>XM8MR4</b>	<b>Blast furnace gas</b>
<b>XM7SP6</b>	<b>Carbon monoxide from engine exhaust gas</b>
<b>XM7R97</b>	Carbon monoxide from engine driven electrical generator
<b>XM2LM9</b>	Carbon monoxide from motor vehicle exhaust
<b>XM4QD5</b>	<b>Carbon monoxide from incomplete combustion of charcoal</b>
<b>XM2EK4</b>	<b>Carbon monoxide from incomplete combustion of coal</b>
<b>XM7NG7</b>	<b>Carbon monoxide from incomplete combustion of coke</b>
<b>XM9675</b>	<b>Carbon monoxide from incomplete combustion of fuel gas</b>
<b>XM1MB6</b>	Carbon monoxide from incomplete combustion of acetylene
<b>XM5TT8</b>	Carbon monoxide from incomplete combustion of coal gas
<b>XM1JF3</b>	Carbon monoxide from incomplete combustion of producer gas
<b>XM3ES0</b>	Carbon monoxide from incomplete combustion of utility gas
<b>XM5XY1</b>	Carbon monoxide from incomplete combustion of liquefied petroleum gas
<b>XM45F2</b>	Carbon monoxide from incomplete combustion of butane
<b>XM3UB7</b>	Carbon monoxide from incomplete combustion of propane

<b>XM6708</b>	Carbon monoxide from incomplete combustion of utility natural gas
<b>XM9ZV7</b>	Carbon monoxide from incomplete combustion of water gas
<b>XM8WR8</b>	<b>Carbon monoxide from incomplete combustion of wood</b>
<b>XM0GT6</b>	<b>Chlorine</b>
<b>XM3KE4</b>	<b>Cyanic acid</b>
<b>XM8Z33</b>	<b>Diazomethane</b>
<b>XM70H1</b>	<b>Diborane</b>
<b>XM6UG7</b>	<b>Dichloroethyl sulfide</b>
<b>XM0YQ4</b>	<b>Ethidium chloride</b>
<b>XM1947</b>	<b>Ethylene</b>
<b>XM5EU1</b>	<b>Ferrovanadium</b>
<b>XM9SB2</b>	<b>Fluorine</b>
<b>XM0TV9</b>	<b>Formaldehyde</b>
<b>XM0JJ6</b>	<b>Helium</b>
<b>XM5LN6</b>	<b>Hydrocarbon gas</b>
<b>XM3FZ1</b>	<b>Acetylene</b>
<b>XM8GS7</b>	<b>Coal gas</b>
<b>XM53K7</b>	<b>Liquefied petroleum gas</b>
<b>XM76Q9</b>	Propane
<b>XM4653</b>	Butane
<b>XM6BD0</b>	<b>Natural gas</b>
<b>XM56Q2</b>	Methane
<b>XM6993</b>	<b>Producer gas</b>
<b>XM4X82</b>	<b>Water gas</b>
<b>XM8ZY7</b>	<b>Hydrogen</b>
<b>XM7FL0</b>	<b>Hydrogen sulfide</b>
<b>XM74J0</b>	<b>Iodine vapor</b>
<b>XM2JX3</b>	<b>Lacrimogenic gas</b>
<b>XM9FN5</b>	<b>Bromobenzylcyanide</b>
<b>XM2N89</b>	<b>Chloroacetone</b>

<b>XM7J14</b>	<b>Chloroacetophenone</b>
<b>XM41V6</b>	<b>Ethyl iodoacetate</b>
<b>XM3RL0</b>	<b>Mace lacrimogenic gas</b>
<b>XM6RK9</b>	<b>Methyl chloroformate</b>
<b>XM29D2</b>	<b>Methyl chloride</b>
<b>XM4FU5</b>	<b>Methyl mercaptan</b>
<b>XM16X6</b>	<b>Mustard gas</b>
<b>XM69M3</b>	<b>Nitrogen oxide</b> <i>Coded Elsewhere:</i> Nitrogen (XM3K31)
<b>XM05F4</b>	<b>Nitrogen dioxide</b>
<b>XM1418</b>	<b>Nonchlorofluorocarbon refrigerant gas</b>
<b>XM54H2</b>	<b>Ozone</b>
<b>XM91W5</b>	<b>Phosgene</b>
<b>XM3D40</b>	<b>Polyester fumes</b>
<b>XM1663</b>	<b>Polytetrafluoroethylene</b>
<b>XM8242</b>	<b>Propylene</b>
<b>XM2598</b>	<b>Sulfur oxides</b>
<b>XM0Z74</b>	<b>Sulfur dioxide</b>
<b>XM3NH9</b>	<b>Aerosol spray, not elsewhere classified</b>
<b>XM1D37</b>	<b>Firedamp, not elsewhere classified</b>
<b>XM61G0</b>	<b>Nerve gas, not elsewhere classified</b>
<b>XM60X6</b>	<b>Oil fumes, not elsewhere classified</b>
<b>XM1EM9</b>	<b>Sewer gas, not elsewhere classified</b>
<b>XM6QK6</b>	<b>Smog, not elsewhere classified</b>
<b>XM9N00</b>	<b>Smoke, not elsewhere classified</b>
<b>XM0G86</b>	<b>Sternutator gas, not elsewhere classified</b>

Halogen derivative of aliphatic and aromatic hydrocarbons

*Coded Elsewhere:* Chloroform (XM7MX5)

<b>XM2X70</b>	<b>Acetyl bromide</b>
---------------	-----------------------

<b>XM7594</b>	<b>Acetyl chloride</b>
<b>XM2W36</b>	<b>Acetylene tetrachloride</b>
<b>XM4YD3</b>	<b>Acetylene tetrachloride vapor</b>
<b>XM45Q9</b>	<b>Amyl chloride</b>
<b>XM3CP7</b>	<b>Carbon tetrachloride</b>
<b>XM0386</b>	<b>Carbon tetrachloride vapor</b>
<b>XM77V1</b>	<b>Chlorex</b>
<b>XM1363</b>	<b>Chlorinated camphene</b>
<b>XM4XU4</b>	<b>Chlorinated hydrocarbons, not elsewhere classified</b>
<b>XM1YR6</b>	<b>Chlorinated naphthalene</b>
<b>XM9P39</b>	<b>Chlorinated naphthalene vapor</b>
<b>XM0WL1</b>	<b>Chloroaniline</b>
<b>XM6LC4</b>	<b>Chlorobenzene</b>
<b>XM0KE3</b>	<b>Chlorobromomethane</b>
<b>XM6QB9</b>	<b>Chlorodinitrobenzene</b>
<b>XM5VH9</b>	<b>Chlorodinitrobenzene vapor</b>
<b>XM8D04</b>	<b>Chlorodiphenyl</b>
<b>XM6YR0</b>	<b>Chloroethylene</b>
<b>XM2HX1</b>	<b>Chlorofluorocarbons</b>
<b>XM9813</b>	<b>Freon</b>
<b>XM3QE2</b>	<b>Dichlorodifluoromethane</b>
<b>XM7FF5</b>	<b>Trichlorofluoromethane</b>
<b>XM8G05</b>	<b>Chloronitrobenzene</b>
<b>XM5S30</b>	<b>Chloronitrobenzene vapor</b>
<b>XM84K8</b>	<b>Chlorophenol</b>
<b>XM3U53</b>	<b>Chloropicrin</b>
<b>XM9GK3</b>	<b>Dibromoethane</b>
<b>XM55X0</b>	<b>Dichlorobenzene</b>
	<b>Coded Elsewhere:</b> Paradichlorobenzene (XM3XK2)

<b>XM1AF0</b>	<b>Dichloroethane</b>
<b>XM8G49</b>	<b>Dichloroethylene</b>
<b>XM7JZ1</b>	<b>Acetylene dichloride</b>
<b>XM3DX7</b>	<b>Vinylidene chloride</b>
<b>XM73T7</b>	<b>Dichloromethane</b>
<b>XM7EF6</b>	<b>Dichloromethane vapor</b>
<b>XM9Y80</b>	<b>Dioxin</b>
<b>XM45K4</b>	<b>Ethyl chloride</b>
<b>XM9B31</b>	<b>Ethylene chlorohydrin</b>
<b>XM5HK4</b>	<b>Ethylene chlorohydrin vapor</b>
<b>XM4Z80</b>	<b>Ethylene dichloride</b>
<b>XM8QX0</b>	<b>Ethylene dichloride vapor</b>
<b>XM8PE4</b>	<b>Hexachlorocyclohexane</b>
<b>XM0MD1</b>	<b>Methoxychlor</b>
<b>XM42E8</b>	<b>Orthodichlorobenzene</b>
<b>XM5JU8</b>	<b>Pentachloroethane</b>
<b>XM59S9</b>	<b>Polybrominated biphenyl</b>
<b>XM77J7</b>	<b>Polychlorinated biphenyl</b>
<b>XM4D89</b>	<b>Tetrachloroethane</b>
<b>XM4N54</b>	<b>Tetrachloroethane vapor</b>
<b>XM3DA8</b>	<b>Tetrachloroethylene</b>
<b>XM86D7</b>	<b>Tetrachloroethylene vapor</b>
<b>XM9R55</b>	<b>Trichloroethane</b>
<b>XM1992</b>	<b>1,1,2 trichloroethane</b>
<b>XM3NB3</b>	<b>Trichloroethylene</b>
<b>XM7YS9</b>	<b>Trichloroethylene vapor</b>
<b>XM58Q9</b>	<b>Trichloropropene</b>

## Inorganic substance

**Coded Elsewhere:** Sodium peroxide (XM4XF6)

Sodium silicate (XM8FM5)

**XM2KQ2**

### Arsenic

**Coded Elsewhere:** Arsenic trioxide (XM2HS5)

**XM00Z1**

**Arsine**

**XM0DR1**

**Cacodyl**

**XM6C50**

**Cacodylic acid**

**XM1BL4**

**Chlorovinyldichloroarsine**

**XM8SC0**

**Copper arsenic complex**

**XM9YA9**

**Diphenylchlorarsine**

**XM1AE2**

**Ethyl dichloroarsine**

**XM8LC6**

**Lead arsenate**

**XM3M96**

**Lead arsenite**

**XM4TW8**

**Potassium arsenite**

**XM32L9**

**Realgar**

**XM7H00**

**Sodium arsenate**

**XM7Y18**

**Sodium arsenite**

**XM4GU5**

**Arsenic pesticide, not elsewhere classified**

**XM53B3**

### Asbestos

**XM8SU1**

**Barium nonmedicinal**

**XM3709**

**Barium carbonate**

**XM5DL6**

**Barium chloride**

**XM38G1**

**Barium sulfite**

**XM8QL6**

**Borane complex**

**XM2BF4**

**Boron**

**XM3FZ9**

**Boron hydride**

**XM5AP1**

**Boron trifluoride**

**XM0XT5**

**Calcium dichromate**

**XM4QG2**

**Chloramine**

**XM5JW5**

**Decaborane**

<b>XM74T0</b>	<b>Decaborane fumes</b>
<b>XM97M0</b>	<b>Hydrogen chloride</b>
<b>XM3FY4</b>	<b>Manganese</b>
<b>XM9ZR0</b>	<b>Manganese dioxide</b>
<b>XM1FQ3</b>	<b>Permanganate</b>
<b>XM3VC7</b>	<b>Potassium permanganate nonmedicinal</b>
<b>XM2AZ6</b>	<b>Phosphorus</b>
<b>XM3G46</b>	<b>Phosphine</b>
<b>XM0LP4</b>	<b>Yellow phosphorus</b>
<b>XM95X4</b>	<b>Potassium perchlorate nonmedicinal</b>
<b>XM2SG3</b>	<b>Potassium Fluoride</b>
<b>XM2G85</b>	<b>Potassium nitrate</b>
<b>XM5XL5</b>	<b>Sodium bichromate</b>
<b>XM9EQ8</b>	<b>Sodium chromate</b>
<b>XM7FZ2</b>	<b>Sodium nitrate</b>
<b>XM3M65</b>	<b>Erionite</b>

## Metal

<b>Coded Elsewhere:</b>	Selenium (XM47M7)
	Magnesium (XM5TD2)
	Zinc (XM1U95)
<b>XM68C9</b>	<b>Alum nonmedicinal</b>
<b>XM9CV4</b>	<b>Alum ammonium</b>
<b>XM5GN1</b>	<b>Alum potassium</b>
<b>XM7JJ2</b>	<b>Aluminium nonmedicinal</b>
<b>XM3TB8</b>	<b>Aluminium phosphide</b>
<b>XM5HW4</b>	<b>Antimony</b>
	<b>Coded Elsewhere:</b> Antimony pentasulfide (XM1KG9)
<b>XM2AE9</b>	<b>Antimony hydride</b>
<b>XM81B2</b>	<b>Antimony pesticide, not elsewhere classified</b>
<b>XM4QG7</b>	<b>Beryllium</b>

<b>XM0TX8</b>	<b>Bismuth nonmedicinal</b>
<b>XM4DZ8</b>	<b>Brass</b>
<b>XM0V73</b>	<b>Cadmium</b>
<b>XM3S39</b>	<b>Cadmium carbonate</b>
<b>XM3YF2</b>	<b>Cadmium chloride</b>
<b>XM4YU7</b>	<b>Cadmium selenide</b>
<b>XM9217</b>	<b>Cadmium succinate</b>
<b>XM0TH7</b>	<b>Cadmium sulfate</b>
<b>XM5YV2</b>	<b>Cadmium sulfide nonmedicinal</b>
<b>XM1TW0</b>	<b>Cadmium pesticide, not elsewhere classified</b>
<b>XM9YJ8</b>	<b>Chromium</b>
	<i>Coded Elsewhere:</i> Lead chromate (XM91V9)
<b>XM95L9</b>	<b>Chromic acid</b>
<b>XM79V9</b>	<b>Chromyl chloride</b>
<b>XM0QY9</b>	<b>Potassium dichromate</b>
<b>XM34P0</b>	<b>Chromium VI compounds</b>
<b>XM1NV2</b>	<b>Cobalt</b>
<b>XM5KH2</b>	<b>Copper</b>
	<i>Coded Elsewhere:</i> Copper arsenic complex (XM8SC0)
<b>XM5U84</b>	<b>Copper acetate</b>
<b>XM0EX6</b>	<b>Copper hydroxide</b>
<b>XM0Y98</b>	<b>Copper oxide</b>
<b>XM48K0</b>	<b>Copper oxychloride</b>
<b>XM6859</b>	<b>Copper sulfate nonmedicinal</b>
<b>XM98Z3</b>	<b>Oxine-copper</b>
<b>XM30V1</b>	<b>Verdigris</b>
<b>XM3757</b>	<b>Copper pesticide, not elsewhere classified</b>
<b>XM8U54</b>	<b>Iron nonmedicinal</b>
<b>XM0ZH6</b>	<b>Lead</b>
	<i>Coded Elsewhere:</i> Lead arsenate (XM8LC6)
	Lead arsenite (XM3M96)

XM5071	<b>Lead acetate nonmedicinal</b>
XM17Q5	<b>Lead alkyl</b>
XM2PV9	<b>Lead antimonate</b>
XM9WK6	<b>Lead azide</b>
XM3Y96	<b>Lead carbonate</b>
XM91V9	<b>Lead chromate</b>
XM59W8	<b>Lead dioxide</b>
XM4EW1	<b>Lead iodide</b>
XM7LD9	<b>Lead monoxide</b>
XM2R16	<b>Lead oxide</b>
XM3ZU1	<b>Lead sulfide</b>
XM0891	<b>Lead paint, not elsewhere classified</b>
<b>XM4AM4</b>	<b>Lithium nonmedicinal</b>
<b>XM1FG4</b>	<b>Mercury</b>
XM8JX9	<b>Ethyl mercuric chloride</b>
XM90P2	<b>Methoxyethyl mercuric chloride</b>
XM9524	<b>Mercuric chloride nonmedicinal</b>
XM39J4	<b>Mercuric cyanide nonmedicinal</b>
XM5X38	<b>Mercuric oxide nonmedicinal</b>
XM8HV3	<b>Mercuric sulfate nonmedicinal</b>
XM4WJ1	<b>Mercury fulminate</b>
XM3W50	<b>Mercury thiocyanate</b>
XM5DJ5	<b>Methyl mercury</b>
XM2Z22	<b>Phenylmercury acetate</b>
XM7UW8	<b>Mercury pesticide, not elsewhere classified</b>
<b>XM4E11</b>	<b>Nickel</b>
XM9P91	<b>Nickel carbonyl</b>
XM7K88	<b>Nickel sulphate</b>
XM5F09	<b>Nickelocene</b>
<b>XM9359</b>	<b>Silver nonmedicinal</b>

<b>XM0XQ4</b>	<b>Tellurium</b>
<b>XM63C5</b>	<b>Thallium</b>
<b>XM9YD2</b>	<b>Thallium sulfate</b>
<b>XM1NS5</b>	<b>Tin</b>
<b>XM9KC4</b>	<b>Tin chloride</b>
<b>XM0K92</b>	<b>Tin oxide</b>
<b>XM7B62</b>	<b>Titanium</b>
<b>XM4WJ2</b>	<b>Titanium tetrachloride</b>
<b>XM89Q2</b>	<b>Titanocene</b>
<b>XM0907</b>	<b>Vanadium</b>
<b>XM7UJ7</b>	<b>Amalgam</b>
<b>XM0FY1</b>	<b>Palladium chloride</b>
<b>XM6NP0</b>	<b>Metal, not elsewhere classified</b>
<b>XM3AW0</b>	<b>Hard metal dust</b>
<b>XM1UC6</b>	<b>Osmium</b>
<b>XM0JD9</b>	<b>Tungsten</b>
<b>XM5H13</b>	<b>Methyl acrylate</b>
<b>XM34R5</b>	<b>Monosodium glutamate</b>
<b>XM5490</b>	<b>Mycotoxin</b>
<b>XM7U84</b>	<b>Aflatoxin</b>
<b>XM0232</b>	<b>Citreoviridin</b>
<b>XM4UE5</b>	<b>Citrinin</b>
<b>XM3NK1</b>	<b>Cyclopiazonic acid</b>
<b>XM3G74</b>	<b>Fusarium toxin</b>
<b>XM2BE5</b>	<b>Ergot alkaloid mycotoxin</b>
<b>XM9C09</b>	<b>Fumonisin</b>
<b>XM9GV7</b>	<b>Moniliformin</b>
<b>XM6X33</b>	<b>Trichothecenes</b>
<b>XM4E53</b>	<b>Zearalenone</b>
<b>XM9F85</b>	<b>3-Nitropropionic acid</b>

<b>XM5WG7</b>	Ochratoxin
<b>XM9C47</b>	Patulin
<b>XM28H1</b>	Penitrem
<b>XM77Q2</b>	Satratoxin
<b>XM6VH6</b>	Sterigmatocystin
<b>XM1PM8</b>	Tenuazonic acid
<b>XM6PE4</b>	Naphthylamine

Organic solvent

<b>XM50A4</b>	Acetal
<b>XM4LM8</b>	Acetaldehyde
<b>XM5Q94</b>	Acetaldehyde vapor
<b>XM6QH4</b>	Acetic acid ester
<b>XM2KF5</b>	Amyl acetate
<b>XM1JM2</b>	Amyl acetate vapor
<b>XM5AK0</b>	Benzyl acetate
<b>XM3RG6</b>	Butyl acetate
<b>XM3AP0</b>	Cyclohexyl acetate
<b>XM00H9</b>	Ethyl acetate
<b>XM3MD8</b>	Isobutyl acetate
<b>XM1EQ5</b>	Isopropyl acetate
<b>XM27U4</b>	Methyl cyclohexyl acetate
<b>XM6XW9</b>	Acetonitrile
<b>XM5HX1</b>	Amyl formate
<b>XM0QY7</b>	Benzene
<b>XM2738</b>	Benzene homologue <i>Coded Elsewhere:</i> Acetophenone (XM0AM0)
<b>XM4214</b>	Butyltoluene
<b>XM01R0</b>	Hexylresorcinol
<b>XM50B6</b>	Hydroquinone

<b>XM1N69</b>	Hydroquinone vapor
<b>XM00E9</b>	Toluene
<b>XM0D44</b>	Xylene
<b>XM3TU9</b>	<b>Benzene vapor</b>
<b>XM9UH2</b>	<b>Diphenylmethane</b>
<b>XM83H3</b>	<b>Nitroderivative or aminoderivative of benzene or benzene homologue</b> <i>Coded Elsewhere:</i> Picric acid (XM0KV1)
<b>XM76E2</b>	Aniline
<b>XM0061</b>	Aniline vapor
<b>XM3R71</b>	Anisidine
<b>XM1UP9</b>	Azobenzene
<b>XM1ZR2</b>	Dinitro-ortho-cresol
<b>XM76A0</b>	Dichlorobenzidine
<b>XM11G0</b>	Dinitrobenzene
<b>XM54Q3</b>	Dinitrobenzene vapor
<b>XM95M5</b>	Dinitrocyclohexylphenol
<b>XM73Y7</b>	Dinitrophenol
<b>XM2732</b>	Diphenylamine
<b>XM0179</b>	Nitroaniline
<b>XM8M07</b>	Nitroaniline vapor
<b>XM2W93</b>	Nitrobenzene
<b>XM2VA4</b>	Nitrobenzene vapor
<b>XM6GM2</b>	Nitrobiphenyl
<b>XM1MY0</b>	Nitrosodimethylamine
<b>XM6EB1</b>	Nitrotoluene
<b>XM5F24</b>	Nitrotoluene vapor
<b>XM1E24</b>	Phenylenediamine
<b>XM54V0</b>	N-isopropyl-N'-phenyl-p-paraphenylenediamine
<b>XM0AK0</b>	p-Phenylenediamine
<b>XM9BN0</b>	Phenylhydrazine

<b>XM9ZV3</b>	Tetryl
<b>XM1X35</b>	TNT
<b>XM67F1</b>	Toluylenediamine
<b>XM4B36</b>	Trinitrobenzol
<b>XM6ZJ9</b>	<b>Resorcin nonmedicinal</b>
<b>XM5V50</b>	Styrene
<b>XM0M80</b>	<b>Butyl butyrate</b>
<b>XM3XT7</b>	<b>Butyl formate</b>
<b>XM59Y7</b>	<b>Butyl lactate</b>
<b>XM3NC8</b>	<b>Butyl propionate</b>
<b>XM4DT3</b>	<b>Decahydronaphthalene</b>
<b>XM8R64</b>	<b>Dialkyl carbonate</b>
<b>XM77E6</b>	Ethyl carbonate
<b>XM7CR8</b>	Methyl carbonate
<b>XM38Z7</b>	<b>Dichlorhydrin</b>
<b>XM7MB5</b>	<b>Dimethylformamide</b>
<b>XM2XU7</b>	<b>Dioxane</b>
<b>XM1LN6</b>	<b>Dipentene</b>
<b>XM5L21</b>	<b>Epichlorhydrin</b>
<b>XM29X5</b>	<b>Ethyl benzoate</b>
<b>XM0N40</b>	<b>Ethyl ether nonmedicinal</b>
<b>XM5YV7</b>	<b>Phenylglycidylether</b>
<b>XM6FX9</b>	<b>Ethyl formate</b>
<b>XM7TN8</b>	<b>Ethyl hydroxyisobutyrate</b>
<b>XM3NZ9</b>	<b>Ethyl lactate</b>
<b>XM6FQ2</b>	<b>Ethyl oxybutyrate</b>
<b>XM7QX9</b>	<b>Furfural</b>
<b>XM4QR6</b>	<b>Hexahydrobenzene</b>
<b>XM2D79</b>	<b>Isophorone</b>

<b>XM4XC6</b>	<b>Isophoronediisocyanate</b>
<b>XM58V1</b>	<b>Isophoronediamine</b>
<b>XM38W0</b>	<b>Isopropyl ether</b>
<b>XM9UX0</b>	<b>Ketones</b>
	<i>Coded Elsewhere:</i> Chloroacetone (XM2N89)
<b>XM7U59</b>	<b>Acetone</b>
<b>XM0ES5</b>	<b>Nail polish remover</b>
<b>XM0AM0</b>	<b>Acetophenone</b>
<b>XM1L02</b>	<b>Cyclohexanone</b>
<b>XM9F73</b>	<b>Diacetone alcohol</b>
<b>XM7KB7</b>	<b>Hexanone</b>
<b>XM5E65</b>	<b>Hydroxymethylpentanone</b>
<b>XM12H2</b>	<b>Methyl acetate</b>
<b>XM9LD3</b>	<b>Methyl acetone</b>
<b>XM5H65</b>	<b>Methyl isobutyl ketone</b>
<b>XM5LH2</b>	<b>N-Hexane and Methyl n-butyl ketone solvent</b>
<b>XM4GN3</b>	<b>Benzoquinone</b>
<b>XM6UK4</b>	<b>Methyl benzoate</b>
<b>XM4513</b>	<b>Methyl cyclohexane</b>
<b>XM91A0</b>	<b>Methyl cyclohexanone</b>
<b>XM5BM9</b>	<b>Methyl sulfate</b>
<b>XM5Y11</b>	<b>Methyl sulfate fumes</b>
<b>XM5CA9</b>	<b>Nitropropane</b>
<b>XM0TB3</b>	<b>Petroleum</b>
<b>XM7MJ9</b>	<b>Petroleum product</b>
<b>XM27Z5</b>	<b>Automobile fuel</b>
<b>XM7CM2</b>	<b>Automobile fuel vapor</b>
<b>XM4RN1</b>	<b>Gas oil</b>
<b>XM9A95</b>	<b>Diesel fuel</b>
<b>XM8WE9</b>	<b>Gasoline</b>

<b>XM52C5</b>	Gasohol
<b>XM0FK9</b>	Gasoline vapor
<b>XM81T5</b>	Coal tar fumes
<b>XM6U93</b>	Coal tar naphtha
<b>XM2CE3</b>	Coal tar nonmedicinal
<b>XM16M2</b>	Pitch
<b>XM7WM1</b>	Anthracene
<b>XM2Q78</b>	Kerosene
<b>XM3QU8</b>	Kerosine vapor
<b>XM3SU8</b>	Mineral oil nonmedicinal
<b>XM4NT9</b>	Lubricating oil
<b>XM7CX7</b>	Mineral spirits
<b>XM2E62</b>	Mineral spirits fumes
<b>XM8PX9</b>	Paraffin wax
<b>XM3ZG5</b>	Petrolatum nonmedicinal
<b>XM9WJ0</b>	Solid petroleum <b>Coded Elsewhere:</b> Bitumen (XE7CA)
<b>XM4C94</b>	Tar
<b>XM5LE8</b>	Tar fumes
<b>XM8AA6</b>	Petroleum pesticide, not elsewhere classified
<b>XM0B41</b>	<b>Petroleum vapor</b>
<b>XM02T2</b>	<b>Phosphate solvent</b>
<b>XM5FS3</b>	<b>Tricresyl phosphate</b>
<b>XM2NF0</b>	<b>Pyridine</b>
<b>XM7TE7</b>	<b>Pyridine vapor</b>
<b>XM5XP8</b>	<b>Tetrahydrofuran</b>
<b>XM2GY2</b>	<b>Tetralin</b>
<b>XM0W28</b>	<b>Organic solvents, not elsewhere classified</b>
<b>XM3U55</b>	<b>Glue</b>
<b>XM0R56</b>	<b>Lighter fluid</b>

<b>XM9B14</b>	<b>Paint stripper</b>
<b>XM0KG9</b>	<b>Polishing compound</b>
<b>XM39J1</b>	<b>Car polish</b>
<b>XM1545</b>	<b>Floor polish</b>
<b>XM2BC0</b>	<b>Furniture polish</b>
<b>XM1J33</b>	<b>Metal polish</b>
<b>XM5J78</b>	<b>Silver polish</b>
<b>XM1P52</b>	<b>Porcelain polish</b>
<b>XM3JF2</b>	<b>Polyester resin hardener</b>
<b>XM3EF0</b>	<b>Polyester resin hardener fumes</b>
<b>XM1762</b>	<b>Ethylene glycol</b>
<b>XM0WA9</b>	<b>Ethylene glycol dinitrate</b>
<b>XM8BF5</b>	<b>Ethylene glycol monobutyl ether</b>
<b>XM4E62</b>	<b>Ethylene glycol monoethyl ether</b>
<b>XM0C04</b>	<b>Ethylene glycol monomethyl ether</b>
<b>XM55M8</b>	<b>Diethylene glycol</b>
<b>XM3834</b>	<b>Diethylene glycol monoacetate</b>
<b>XM1A56</b>	<b>Diethylene glycol monobutyl ether</b>
<b>XM8XU3</b>	<b>Diethylene glycol monoethyl ether</b>
<b>XM99B7</b>	<b>Brake fluid, not elsewhere classified</b>
<b>XM8TE5</b>	<b>Brake fluid vapor</b>

## Paint or dye

**Coded Elsewhere:** Aniline (XM76E2)  
Auramine (XM0MT5)  
Cadmium selenide (XM4YU7)  
Cadmium sulfide nonmedicinal (XM5YV2)  
Copper arsenic complex (XM8SC0)  
Dinitrophenol (XM73Y7)  
Lead antimonate (XM2PV9)  
Lead carbonate (XM3Y96)  
Lead chromate (XM91V9)  
Lead iodide (XM4EW1)  
Lead monoxide (XM7LD9)  
Lead oxide (XM2R16)  
Tellurium (XM0XQ4)  
Lead paint, not elsewhere classified (XM0891)

<b>XM9UE9</b>	<b>Acridine</b>
<b>XM2QW2</b>	<b>Acridine vapor</b>
<b>XM4UG8</b>	<b>Disperse dye</b>
<b>XM5C83</b>	<b>Lacquer</b>
<b>XM8B47</b>	<b>Nitrocellulose lacquer</b>
<b>XM2FV2</b>	<b>Prussian blue nonmedicinal</b>
<b>XM9WW6</b>	<b>Whitewash</b>
<b>XM6HZ8</b>	<b>Ink, not elsewhere classified</b>
<b>XM1XL9</b>	<b>Paint fumes, not elsewhere classified</b>
<b>XM8H37</b>	<b>Dye, not elsewhere classified</b>
<b>XM3K54</b>	<b>Cochineal extract</b>
<b>XM7U05</b>	<b>Paratertiary butylphenol formaldehyde resin</b>
<b>XM5B21</b>	<b>Phthalate</b>
<b>XM75C9</b>	<b>Diethylhexyl phthalate</b>
<b>XM34N7</b>	<b>Dimethyl phthalate nonmedicinal</b>
<b>XM9HC2</b>	<b>Di-n-butyl phthalate</b>
<b>XM74S8</b>	<b>Poisonous mushroom</b>
<b>XM0366</b>	<b>Agaricus xanthodermus mushroom</b>

<b>XM7P94</b>	<b>Amanita mushroom</b>
<b>XM82H0</b>	Amanita bisporigera mushroom
<b>XM5911</b>	Amanita hygrophoroides mushroom
<b>XM91N3</b>	Amanita muscaria mushroom
<b>XM8MF4</b>	Amanita ocreata mushroom
<b>XM6HP7</b>	Amanita phalloides mushroom
<b>XM4NS6</b>	Amanita pantherina mushroom
<b>XM23X2</b>	Amanita pseudopurpurea hongo mushroom
<b>XM2HH5</b>	Amanita suballiacea mushroom
<b>XM3VN8</b>	Amanita smithiana mushroom
<b>XM5039</b>	Amanita tenuifolia mushroom
<b>XM0G40</b>	Amanita verna mushroom
<b>XM1DV5</b>	Amanita virosa mushroom
<b>XM2FU2</b>	<b>Clitocybe mushroom</b>
<b>XM2BD5</b>	Clitocybe rivulosa mushroom
<b>XM9BX0</b>	<b>Conocybe filaris mushroom</b>
<b>XM4CB0</b>	<b>Cortinarius mushroom</b>
<b>XM85A8</b>	Cortinarius rubellus mushroom
<b>XM9TZ1</b>	Cortinarius orellanus mushroom
<b>XM2BB9</b>	Cortinarius speciosissimus mushroom
<b>XM1LD8</b>	<b>Galerina mushroom</b>
<b>XM6W91</b>	Galerina fasciculata mushroom
<b>XM7NR0</b>	Galerina marginata mushroom
<b>XM24L3</b>	Galerina sulcipes mushroom
<b>XM78T5</b>	Galerina venenata mushroom
<b>XM0M17</b>	<b>Gyromitra mushroom</b>
<b>XM0BM0</b>	Gyromitra ambigua mushroom
<b>XM76X5</b>	Gyromitra esculenta mushroom
<b>XM3LC5</b>	Gyromitra infula mushroom
<b>XM1PK2</b>	<b>Hapalopilus rutilans mushroom</b>

<b>XM87D0</b>	<b>Hebeloma crustuliniforme mushroom</b>
<b>XM9B73</b>	<b>Inocybe mushroom</b>
<b>XM2BC2</b>	<b>Lepiota mushroom</b>
<b>XM7K06</b>	<b>Lepiota brunneoincarnata mushroom</b>
<b>XM4L76</b>	<b>Lepiota brunneolilacea mushroom</b>
<b>XM0FJ0</b>	<b>Lepiota chlorophyllum mushroom</b>
<b>XM6882</b>	<b>Lepiota fulvella mushroom</b>
<b>XM1UJ5</b>	<b>Lepiota helveola mushroom</b>
<b>XM8R10</b>	<b>Lepiota josserandii mushroom</b>
<b>XM95E9</b>	<b>Omphalotus mushroom</b>
<b>XM8VV0</b>	<b>Omphalotus nidiformis mushroom</b>
<b>XM7RG5</b>	<b>Omphalotus illudens mushroom</b>
<b>XM1M89</b>	<b>Panaeolus mushroom</b>
<b>XM3NJ2</b>	<b>Panaeolus papilionaceus mushroom</b>
<b>XM0B62</b>	<b>Panaeolus sphinctrinus mushroom</b>
<b>XM27Y3</b>	<b>Panaeolus subbalteatus mushroom</b>
<b>XM44P3</b>	<b>Pleurocybella porrigens mushroom</b>
<b>XM3CK7</b>	<b>Podostroma cornu-damae mushroom</b>
<b>XM4321</b>	<b>Psilocybe semilanceata mushroom</b>
<b>XM36C7</b>	<b>Russula subnigricans mushroom</b>
<b>XM0QR2</b>	<b>Tricholoma equestre mushroom</b>
<b>XM9KE6</b>	<b>Silicone</b>
<b>XM3DP9</b>	<b>Silicon dioxide</b>

Substance of plant origin

**Coded Elsewhere:** Rotenone (XM1S21)

<b>XM98Y1</b>	<b>Abrus precatorius plant</b>
<b>XM99Y1</b>	<b>Aconitum plant</b>
<b>XM2WR7</b>	<b>Aconitine</b>
<b>XM3VB6</b>	<b>Aconitum ferox plant</b>
<b>XM7BA0</b>	<b>Actaea plant</b>

XM3QE1	<b>Actaea spicata</b>
XM55K4	<b>Aethusa cynapium plant</b>
XM3AF3	<b>Anamirta cocculus plant</b>
XM6KR6	<b>Picrotoxin</b>
XM8SE2	<b>Antiaris toxicaria plant</b>
XM2X16	<b>Arum maculatum plant</b>
XM1EY0	<b>Atropa belladonna plant</b>
XM17F2	<b>Azadirachta plant</b>
XM5W16	<b>Bergamot oil</b>
XM1GJ1	<b>Bitter almond</b>
XM4XS8	<b>Diallyl disulfide</b>
XM6A31	<b>Sesquiterpene lactones</b>
XM4W45	<b>Citronellol</b>
XM9CQ1	<b>Citral</b>
XM6CP3	<b>Eugenol</b>
XM9CZ8	<b>Evernia prunastri extract</b>
XM5AM5	<b>Isoeugenol</b>
XM88U7	<b>Abietic acid</b>
XM9L39	<b>Turpentine oil</b>
XM3B42	<b>Atranorin</b>
XM4BW2	<b>Blighia sapida plant</b>
XM6635	<b>Evernic acid</b>
XM26G6	<b>Usnic acid</b>
XM3XH8	<b>Grains and flours</b>
XM21W4	<b>Plant or herbal extracted compounds</b>
XM7CA8	<b>Folium stramoniae</b>
XM1D48	<b>Ephedra</b>
XM82G2	<b>Benzoin (tincture)</b>
XM9GX9	<b>Menthol</b>

<b>XM8UA9</b>	<b>Cianidanol</b>
<b>XM4Y73</b>	<b>Gelsemine</b>
<b>XM2YX0</b>	<b>Palm kernel oil</b>
<b>XM1PQ5</b>	<b>Tragacanth</b>
<b>XM8VJ2</b>	<b>Datura stramonium plant</b>
<b>XM8MB5</b>	<b>Rubber</b>
<b>XM0XN7</b>	<b>Cotton plant</b>
<b>XM1KF1</b>	<b>Sisal</b>
<b>XM2BX6</b>	<b>Brucea javanica plant</b>
<b>XM9B82</b>	<b>Caladium plant</b>
<b>XM1021</b>	<b>Caladium bicolor</b>
<b>XM0BS2</b>	<b>Caladium seguimum</b>
<b>XM9S25</b>	<b>Cannabis (natural; phytocannabinoids)</b>
<b>XM08L6</b>	<b>Afghanistan black</b>
<b>XM5WR8</b>	<b>Indian hemp</b>
<b>XM3R78</b>	<b>Lebanese red</b>
<b>XM8PV1</b>	<b>Marijuana</b>
<b>XM0WA6</b>	<b>Celastrus scandens plant</b>
<b>XM5L03</b>	<b>Cerbera plant</b> <i>Coded Elsewhere:</i> Cerberin (XM1W74)
<b>XM2KR7</b>	<b>Cerbera odollam plant</b>
<b>XM1FN8</b>	<b>Cerbera manghas plant</b>
<b>XM8AZ9</b>	<b>Cerbera venenifera plant</b>
<b>XM9DJ3</b>	<b>Chelidonium majus plant</b>
<b>XM49V0</b>	<b>Chrysanthemum cinerariifolium plant</b>
<b>XM5HR7</b>	<b>Pyrethrin nonmedicinal</b>
<b>XM6709</b>	<b>Cicuta maculata plant</b>
<b>XM1S86</b>	<b>Cicutoxin</b>
<b>XM6YA3</b>	<b>Cinnamomum camphora plant</b>
<b>XM5804</b>	<b>Clematis plant</b>

XM5D25	Clematis vitalba plant
XM9KW2	Coffee
XM7TP8	Colchicum plant
XM3Q99	Colchicine
XM9Z51	Conium maculatum plant
XM3FY5	Coniine
XM9T69	Convallaria majalis plant
XM72P9	Cyclamen plant
XM56R9	Cyclamen europaeum plant
XM5174	Cyclamen persicum plant
XM5ZF9	Cytisus laburnum plant
XM2YN7	Cytisus scoparius plant
XM4TF9	Daphne plant
XM8YH8	Delphinium plant
XM3KT4	Derris elliptica plant
XM46Y1	Digitalis purpurea plant
XM1LE7	Erythroxylum coca lam plant
XM7UN8	Cocaine
XM0BC6	Cocaine topical anesthetic
XM0XS0	Equisetum plant
XM0EC2	Equisetum diuretic
XM4TJ7	Euphorbia plant
XM91T0	Gaultheria procumbens plant
XM5P41	Gaultheria procumbens plant oil
XM1VX3	Gelsemium sempervirens plant
XM66Z7	Gloriosa superba plant
XM5EL7	Gratiola officinalis plant
XM3QP5	Helleborus niger plant
XM0SF4	Helleborus viridis plant

<b>XM4UC8</b>	<b>Hyoscyamus niger plant</b>
<b>XM3EA9</b>	<b>Ilex plant</b>
<b>XM7ED8</b>	<b>Jatropha plant</b>
<b>XM8QC3</b>	<b>Jatropha curcas plant</b>
<b>XM7CZ8</b>	<b>Jatropha gossypiifolia plant</b>
<b>XM2C70</b>	<b>Jatropha hastata plant</b>
<b>XM4R06</b>	<b>Jatropha macrorhiza plant</b>
<b>XM84E3</b>	<b>Jatropha multifida plant</b>
<b>XM04B0</b>	<b>Jatropha podagraria plant</b>
<b>XM7762</b>	<b>Latex</b>
<b>XM5EH9</b>	<b>Lathyrus sativus plant</b>
<b>XM5F38</b>	<b>Ligustrum plant</b>
<b>XM1WT1</b>	<b>Ligustrum lucidum plant</b>
<b>XM4CK0</b>	<b>Ligustrum sinense plant</b>
<b>XM23X8</b>	<b>Ligustrum vulgare plant</b>
<b>XM2BQ5</b>	<b>Lobelia plant</b>
<b>XM76G6</b>	<b>Lolium temulentum plant</b>
<b>XM6LL4</b>	<b>Manihot esculenta plant</b>
<b>XM1TB2</b>	<b>Melia azedarach plant</b>
<b>XM3M91</b>	<b>Myristica fragrans plant</b>
<b>XM6FE5</b>	<b>Nutmeg oil</b>
<b>XM31J1</b>	<b>Myristicin</b>
<b>XM14Y1</b>	<b>Myrsine africana plant</b>
<b>XM3XT1</b>	<b>Nerium oleander plant</b>
<b>XM2VY1</b>	<b>Nicotiana plant</b>
<b>XM88J8</b>	<b>Tobacco</b> <i>Coded Elsewhere:</i> Nicotine (XM6BN2)
<b>XM33X3</b>	<b>Nux vomica plant</b>
<b>XM7134</b>	<b>Brucine</b>
<b>XM5421</b>	<b>Strychnine</b>

<b>XM9JS2</b>	Strychnine rodenticide
<b>XM7JG0</b>	<b>Physostigma venenosum plant</b>
<b>XM61M4</b>	<b>Phytolacca decandra plant</b>
<b>XM19G9</b>	<b>Pine oil</b>
<b>XM1XZ4</b>	<b>Piper cubeba plant</b>
<b>XM21J6</b>	<b>Poison oak plant</b>
<b>XM4882</b>	<b>Poison sumak plant</b>
<b>XM95D5</b>	<b>Primula plant</b>
<b>XM9HN7</b>	<b>Primula obconica plant</b>
<b>XM07P7</b>	Primin
<b>XM4TX6</b>	<b>Primula officinalis plant</b>
<b>XM19S7</b>	<b>Primula veris plant</b>
<b>XM3QL7</b>	<b>Prunus plant</b>
<b>XM01R5</b>	Amygdalin
<b>XM0PX4</b>	<b>Apricot kernel</b>
<b>XM5MK6</b>	<b>Cherry kernel</b>
<b>XM7B39</b>	<b>Peach kernel</b>
<b>XM52C3</b>	<b>Plum kernel</b>
<b>XM6Z57</b>	<b>Psoralea corylifolia plant</b>
<b>XM1MV4</b>	<b>Psoralen nonmedicinal</b>
<b>XM03C0</b>	<b>Pulsatilla plant</b>
<b>XM3PV6</b>	<b>Pyrrolizidine alkaloids</b>
<b>XM0NB5</b>	<b>Ranunculus plant</b>
<b>XM0PR3</b>	<b>Ricinus communis plant</b>
<b>XM2VG9</b>	Ricin
<b>XM4AC2</b>	<b>Ruta graveolens plant</b>
<b>XM7BE0</b>	<b>Sambucus plant</b>
<b>XM9W70</b>	<b>Sanguinaria canadensis plant</b>
<b>XM0EH6</b>	<b>Schoenocaulon officinale plant</b>

XM4BY7	Sabadilla insecticide
XM8YX9	Senecio vulgaris plant
XM4TE3	Solanum plant
XM56G1	Solanum dulcamara plant
XM1AE1	Solanum nigrum plant
XM0QV6	Solanum pseudocapsicum plant
XM9588	Solanine
XM4UE4	Spartium junceum plant
XM9834	Strophanthus gratus plant
XM9QZ9	Strophanthin-k
XM58G8	Tanacetum plant
XM7EL5	Tartaric acid
XM5YT6	Taxus plant
XM6WF4	Thevetia peruviana plant
XM40N4	Toxicodendron radicans plant
XM46N0	Urginea maritima plant
XM0SG7	Scilliroside
XM84R4	Urtica plant
XM5KR7	Veratrum plant
XM86L8	Veratrum album plant
XM9Z08	Veratrum viride plant
XM43H5	Wisteria plant
XM29R2	Wisteria floribunda plant
XM8ZH3	Wisteria sinensis plant
XM6076	Zygadenus plant
XM8PU3	Plant derived pesticide, not elsewhere classified
XM98M9	Poisonous plant berries, not elsewhere classified
XM7MT6	Poisonous plant flowers, not elsewhere classified
XM6LL5	Poisonous plant fruits, not elsewhere classified

<b>XM2BH3</b>	<b>Poisonous plant leaves, not elsewhere classified</b>
<b>XM0GB3</b>	<b>Poisonous plant roots, not elsewhere classified</b>
<b>XM2CE0</b>	<b>Poisonous plant sap, not elsewhere classified</b>
<b>XM7JK8</b>	<b>Poisonous plant seeds, not elsewhere classified</b>
<b>XM7KY1</b>	<b>Poisonous plant stem, not elsewhere classified</b>
<b>XM56V2</b>	<b>Poisonous plant thorns, not elsewhere classified</b>
<b>XM5NH2</b>	<b>Substance of marine plant origin, not elsewhere classified</b>
<b>XM8A62</b>	<b>Plant protein</b>
<b>XM7A46</b>	<b>American beech wood dust</b>
<b>XM4M03</b>	<b>Oak wood dust</b>
<b>XM6VG6</b>	<b>European ash wood dust</b>
<b>XM1K52</b>	<b>Apple</b>
<b>XM07U6</b>	<b>Banana</b>
<b>XM77D3</b>	<b>Grape</b>
<b>XM4TY6</b>	<b>Kiwifruit</b>
<b>XM6AW1</b>	<b>Mango</b>
<b>XM0DF7</b>	<b>Melon</b>
<b>XM2Q13</b>	<b>Olive</b>
<b>XM2XN1</b>	<b>Orange</b>
<b>XM9UT8</b>	<b>Paprika</b>
<b>XM7S13</b>	<b>Cabbage</b>
<b>XM5J64</b>	<b>Grapefruit</b>
<b>XM5733</b>	<b>Black pepper</b>
<b>XM9BG0</b>	<b>Green bean</b>
<b>XM25M2</b>	<b>Spinach</b>
<b>XM3EW6</b>	<b>Mexican firebush</b>
<b>XM3XQ1</b>	<b>Rice</b>
<b>XM9135</b>	<b>Pecan or hickory nut</b>
<b>XM5S85</b>	<b>Peach</b>
<b>XM4GG6</b>	<b>Pear</b>

<b>XM5ZK9</b>	<b>Strawberry</b>
<b>XM6E89</b>	<b>Pineapple</b>
<b>XM9MB5</b>	<b>Barley</b>
<b>XM47Z9</b>	<b>Bahia grass</b>
<b>XM5ZN2</b>	<b>Bermuda grass</b>
<b>XM13D1</b>	<b>Buckwheat</b>
<b>XM3GC8</b>	<b>Corn</b>
<b>XM56U7</b>	<b>Gluten</b>
<b>XM9898</b>	<b>Japanese hop</b>
<b>XM39Y3</b>	<b>Johnson grass</b>
<b>XM0D79</b>	<b>Kentucky blue grass</b>
<b>XM8X04</b>	<b>Oat</b>
<b>XM6JA2</b>	<b>Rye</b>
<b>XM01D6</b>	<b>Perennial rye grass</b>
<b>XM8M82</b>	<b>Cultivated rye</b>
<b>XM4BW3</b>	<b>Salt grass</b>
<b>XM13U2</b>	<b>Sweet vernal grass</b>
<b>XM94M9</b>	<b>Timothy</b>
<b>XM63G5</b>	<b>Avocado</b>
<b>XM1E00</b>	<b>Baker yeast</b>
<b>XM9S46</b>	<b>Carrot</b>
<b>XM1PN2</b>	<b>Celery</b>
<b>XM5TW0</b>	<b>Cocksfoot</b>
<b>XM9SJ1</b>	<b>Cocoa</b>
<b>XM9DZ5</b>	<b>Common pigweed</b>
<b>XM5V61</b>	<b>Common ragweed</b>
<b>XM3KE2</b>	<b>English plantain</b>
<b>XM40Y5</b>	<b>Garlic</b>
<b>XM4GX7</b>	<b>Goosefoot</b>
<b>XM1X29</b>	<b>Giant ragweed</b>

<b>XM45L6</b>	<b>Lentils</b>
<b>XM6798</b>	<b>Lettuce</b>
<b>XM0L96</b>	<b>Mugwort</b>
<b>XM7GY3</b>	<b>Mustard</b>
<b>XM8F26</b>	<b>Nettle</b>
<b>XM9KB5</b>	<b>Onion</b>
<b>XM56E2</b>	<b>Pea</b>
<b>XM9J59</b>	<b>Potato</b>
<b>XM3VS0</b>	<b>Rough pigweed</b>
<b>XM72E8</b>	<b>Sheep sorrel</b>
<b>XM3TW1</b>	<b>Soybean</b>
<b>XM72C5</b>	<b>Tomato</b>
<b>XM3LL8</b>	<b>Wall pellitory</b>
<b>XM42C5</b>	<b>Western ragweed</b>
<b>XM0GA2</b>	<b>White bean</b>
<b>XM9S45</b>	<b>Wormwood</b>
<b>XM60Q8</b>	<b>Almond</b>
<b>XM1304</b>	<b>American beech</b>
<b>XM5TH6</b>	<b>Arizona cypress</b>
<b>XM3ES3</b>	<b>Brazil nut</b>
<b>XM9GG3</b>	<b>Cedar elm</b>
<b>XM36B2</b>	<b>Coastal maple</b>
<b>XM6MF9</b>	<b>Coconut</b>
<b>XM9JG2</b>	<b>Cottonwood</b>
<b>XM2044</b>	<b>English walnut pollen</b>
<b>XM2EQ3</b>	<b>Cashew nut</b>
<b>XM7QD6</b>	<b>Grey alder</b>
<b>XM7L19</b>	<b>Hazelnut</b>
<b>XM4WW3</b>	<b>Italian cypress</b>
<b>XM3940</b>	<b>Japanese cedar</b>

<b>XM8QG1</b>	<b>Japanese cypress</b>
<b>XM9AZ7</b>	<b>Macadamia</b>
<b>XM0QL5</b>	<b>Mesquite</b>
<b>XM7G21</b>	<b>Mountain juniper</b>
<b>XM8K37</b>	<b>Paper mulberry</b>
<b>XM6Q82</b>	<b>Peanut</b>
<b>XM1QN3</b>	<b>Pecan or hickory tree</b>
<b>XM7833</b>	<b>Pine nut</b>
<b>XM2B46</b>	<b>Pistachio</b>
<b>XM34T8</b>	<b>Red maple</b>
<b>XM03B3</b>	<b>Red mulberry</b>
<b>XM1L09</b>	<b>Sesame seed</b>
<b>XM30J5</b>	<b>Silver birch</b>
<b>XM3DB3</b>	<b>Walnut</b>
<b>XM5VB3</b>	<b>Wattle</b>
<b>XM3ZG1</b>	<b>Western white pine</b>
<b>XM3DL1</b>	<b>White ash</b>
<b>XM3VX2</b>	<b>White birch</b>
<b>XM6V15</b>	<b>White hickory</b>
<b>XM5AD4</b>	<b>White mulberry</b>
<b>XM4YR5</b>	<b>Willow</b>
<b>XM8SV5</b>	<b>Red top grass</b>
<b>XM6SX5</b>	<b>Pacific squid</b>
<b>XM7AS2</b>	<b>Lemon</b>
<b>XM2YD2</b>	<b>Sunflower seed</b>
<b>XM2XV2</b>	<b>Chick pea</b>
<b>XM1FG7</b>	<b>Sweet gum</b>
<b>XM1A07</b>	<b>Gum-tree</b>
<b>XM0885</b>	<b>Cherry</b>

Substance of human origin

**Coded Elsewhere:** Blood plasma (XM04N3)

**XM0RZ0 Human seminal plasma**

**XM7FG4 Toluidine**

**XM7S87 Toluidine vapor**

**XM5NA2 Triorthocresyl phosphate**

**XM90U0 Triphenyl phosphate**

**XM3FJ3 Vinyl acetate**

**XM6A87 Vinyl bromide**

Adhesive, not elsewhere classified

**XM23X0 Epoxy resin, not elsewhere classified**

**XM9MV5 Butylglycidylether**

Chemical compounds not elsewhere classified

**XM87D3 Chromium sesquioxide**

**XM83G3 Borate buffer**

**XM1FY5 Cyclamate**

**XM7CN5 Saccharin**

**XM5567 Sodium propyl hydroxybenzoate**

**XM16M4 Sodium barbiturate**

**XM6DJ2 Iminostilbene**

Chemicals used as process regulators

Includes: Accelerators, activators, oxidation agents, reducing agent

**XM45E1 N-Cyclohexylbenzothiazyl sulphenamide**

**XM90X8 Dibenzothiazyl disulphide**

**XM2RH1 Dipentamethylenethiuram disulphide**

**XM3BY9 Tetramethylthiuram monosulphide**

**XM1A88 Morpholinylmercaptobenzothiazole**

Cleaning agent, not elsewhere classified

<b>XM0XA8</b>	<b>Detergent nonmedicinal, not elsewhere classified</b>
<b>XM7DD6</b>	<b>Disinfectant, not elsewhere classified</b>
<b>XM5151</b>	<b>Scouring powder, not elsewhere classified</b>
<b>XM8VR0</b>	<b>Shampoo, not elsewhere classified</b>
<b>XM8B44</b>	<b>Soap, not elsewhere classified</b>
<b>XM5FV8</b>	<b>Window cleaning fluid, not elsewhere classified</b>

Food additives not elsewhere classified

<b>XM6PY1</b>	<b>Paratertiary butylphenol</b>
<b>XM6000</b>	<b>6-Methylcoumarin</b>

Organic compounds not elsewhere classified

<b>XM2EK8</b>	<b>4,4'-Diaminodiphenyl methane</b>
<b>XM7N15</b>	<b>Hydroxyisohexyl 3-cyclohexene carboxaldehyde</b>
<b>XM2TV3</b>	<b>Farnesol</b>
<b>XM3MM6</b>	<b>Bisphenol A-glycidyl methacrylate</b>
<b>XM0BY4</b>	<b>2-Hydroxyethylmethacrylate</b>
<b>XM90H5</b>	<b>Diurethane dimethacrylate</b>
<b>XM49C3</b>	<b>Methyl methacrylate</b>
<b>XM58E5</b>	<b>Diethanolamine</b>
<b>XM0L39</b>	<b>Diethylenetriamine</b>
<b>XM2TA7</b>	<b>Hexamethylenetetramine</b>
<b>XM7QN7</b>	<b>Triethylenetetramine</b>
<b>XM1GH9</b>	<b>Bisphenol A</b>
<b>XM7AX9</b>	<b>Cresylglycidylether</b>
<b>XM1AH4</b>	<b>2-Bromo-2-nitropropane-1,3-diol</b>
<b>XM3TN8</b>	<b>Mercaptobenzothiazole</b> <i>Coded Elsewhere:</i> Mercaptobenzothiazole salts (XM7FY5)
<b>XM2ZT3</b>	<b>Ethylhexyl methoxycinnamate</b>

<b>XM63U8</b>	<b>Octocrylene</b>
<b>XM3YZ8</b>	<b>Octyltriazone</b>
<b>XM8VV3</b>	<b>Aminoethylisothiourium</b>
<b>XM7W63</b>	<b>Sodium cacodylate (nonmedicinal)</b>
<b>XM6GU7</b>	<b>Butylated hydroxyanisole</b>
<b>XM2YA2</b>	<b>Coenzyme A</b>
<b>XM4S70</b>	<b>Cogalactoisomerase</b>
<b>XM1X04</b>	<b>Lactose (as excipient)</b>
<b>XM82Y6</b>	<b>Methylethyl cellulose</b>
<b>XM39E8</b>	<b>Pentane</b>

Preservative nonmedicinal, not elsewhere classified

<b>XM2RB2</b>	<b>Benzisothiazolinone</b>
<b>XM6XV7</b>	<b>Methylene-bis(methyloxazolidine)</b>
<b>XM88M1</b>	<b>DMDM hydantoin</b>
<b>XM8DV5</b>	<b>Methylchloroisothiazolinone and methylisothiazolinone (3:1)</b>
<b>XM87J0</b>	<b>Methylisothiazolinone</b>
<b>XM9NB7</b>	<b>Methyldibromo glutaronitrile and phenoxyethanol</b>
<b>XM04A1</b>	<b>Methyl parahydroxybenzoate</b>
<b>XM1CG8</b>	<b>Ethyl parahydroxybenzoate</b>
<b>XM0XV1</b>	<b>Propyl parahydroxybenzoate</b>
<b>XM38K5</b>	<b>Butyl parahydroxybenzoate</b>
<b>XM51H6</b>	<b>Diazolidinyl urea</b>
<b>XM5TQ9</b>	<b>Imidazolidinyl urea</b>
<b>XM0562</b>	<b>Fentichlor</b>
<b>XM6F66</b>	<b>Soldering fluid, not elsewhere classified</b>

Substance eaten as food, nonbacterial, not elsewhere classified

<b>XM44A4</b>	<b>Bone meal</b>
<b>XM77G6</b>	<b>Fungus eaten in food, not elsewhere classified</b>

<b>XM00E5</b>	<b>Claviceps purpurea</b>
<b>XM4L77</b>	<b>Noxious meat, non bacterial, not elsewhere classified</b>
<b>XM3825</b>	<b>Animal protein</b>

Fowl or egg

<b>XM9Y41</b>	<b>Chicken</b>
<b>XM4500</b>	<b>Chicken feather</b>
<b>XM66A9</b>	<b>Cockatiel droppings</b>
<b>XM9LW5</b>	<b>Cockatiel feather</b>
<b>XM9JZ2</b>	<b>Cockatiel serum</b>
<b>XM6AD6</b>	<b>Egg white</b>
<b>XM2E06</b>	<b>Whole egg</b>
<b>XM9CD1</b>	<b>Egg yolk</b>
<b>XM2PB2</b>	<b>Goose feather</b>
<b>XM3LH5</b>	<b>Duck feather</b>

Fish or seafood

<b>XM95M8</b>	<b>Fish</b>
<b>XM6BL6</b>	<b>Codfish</b>
<b>XM8Q65</b>	<b>Salmon</b>
<b>XM3QU9</b>	<b>Tuna</b>
<b>XM31E6</b>	<b>Halibut</b>
<b>XM8Y82</b>	<b>Sardine</b>
<b>XM64N8</b>	<b>Trout</b>
<b>XM5MB3</b>	<b>Crab</b>
<b>XM9JT3</b>	<b>Lobster</b>
<b>XM7E84</b>	<b>Shrimp</b>
<b>XM55Z4</b>	<b>Oyster</b>
<b>XM66P3</b>	<b>Octopus</b>

Insect or arthropod

XM6ZC1	<b>Blomia tropicalis</b>
XM5AK3	<b>American house dust mite</b>
XM8BV4	<b>Dermatophagoides pteronyssinus</b>
XM99T8	<b>Mite dust</b>
XM0B91	<b>Mosquito</b>
XM95T4	<b>Aedes</b>
XM7VF0	<b>Anopheles</b>
XM0ZZ8	<b>Culex</b>
XM3WD1	<b>Moth</b>
XM0K01	<b>Cockroach</b>
XM27E1	<b>American cockroach</b>

Milk or dairy

XM8RU4	<b>Milk</b>
XM6RB2	<b>Cow milk</b>
XM4Y68	<b>Goat milk</b>
XM4JV9	<b>Cheese</b>
XM5GA5	<b>Cheese cheddar type</b>
XM3FK1	<b>Cheese mold type</b>

Synthetic fragrances not elsewhere classified

XM5T39	<b>Ethylenediamine dihydrochloride</b>
XM15W5	<b>Varnish, not elsewhere classified</b>
XM6MC4	<b>Soot, not elsewhere classified</b>
XM4VX8	<b>Aromatic amine</b>
XM6ZV1	<b>Antiseptic, not elsewhere classified</b>
XM60L2	<b>Beta-naphthylamine</b>
XM76S9	<b>House dust</b>
XM7XM0	<b>Wheat dust</b>

## Diagnosis code descriptors

### Discharge diagnosis types

- |             |  |
|-------------|--|
| <b>XY0Y</b> | <b>Main condition</b>  |
|             | Reason for encounter or admission after study at the end of the episode. |
| <b>XY7B</b> | <b>Main resource condition</b>   |
| <b>XY6E</b> | <b>Initial reason for encounter or admission</b>                         |

### Diagnosis timing

- |             |  |
|-------------|--|
| <b>XY6M</b> | <b>Present on admission</b>                            |
| <b>XY69</b> | <b>Developed after admission</b>                       |
| <b>XY85</b> | <b>Uncertain timing of onset relative to admission</b> |

### Diagnosis timing in relation to surgical procedure

- |             |                       |
|-------------|-----------------------|
| <b>XY9U</b> | <b>Preoperative</b>   |
| <b>XY9N</b> | <b>Intraoperative</b> |
| <b>XY7V</b> | <b>Postoperative</b>  |

### Diagnosis method of confirmation

- |             |  |
|-------------|--|
| <b>XY3B</b> | <b>Diagnosis confirmed by laboratory examination</b> |
| <b>XY0E</b> | <b>Diagnosis confirmed by serology</b>               |
| <b>XY9Q</b> | <b>Diagnosis confirmed by histology</b>              |
| <b>XY8K</b> | <b>Diagnosis confirmed by genetics</b>               |
| <b>XY9R</b> | <b>Diagnosis confirmed by imaging</b>                |
| <b>XY19</b> | <b>Diagnosis confirmed by microscopy</b>             |
| <b>XY0K</b> | <b>Diagnosis confirmed by culture</b>                |

### Diagnosis certainty

- |             |                               |
|-------------|-------------------------------|
| <b>XY7Z</b> | <b>Provisional diagnosis</b>  |
| <b>XY75</b> | <b>Differential diagnosis</b> |

Obstetrical diagnosis timing

- XY3K      Delivered with or without mention of antepartum condition**
- XY8Q      Delivered, with mention of postpartum condition**
- XY8U      Antepartum condition or complication**
- XY9P      Postpartum condition or complication**
- XY9S      Unspecified as to episode of care, or not applicable**

Encounter descriptors

- XY18      Initial encounter**
- XY8S      Subsequent encounter**

Capacity or context

- XX2QG9      Condition of the fetus and newborn reported in the context of the mother**  
This code is intended to flag that an additional code from the perinatal section is used to identify the outcome of delivery on the mother's record.

Biological sex

- XX2V25      Female**
- XX2UQ8      Male**
- XX45B7      Intersex**
- XX2PX3      Biological sex not specified**

Health Devices, Equipment and Supplies

Devices for administration, collecting and picking

Hematology and hemotransfusion devices

Cardiocirculatory devices

- XD7FF9      Central venous catheters**
- XD4ZY0      Stethoscopes**
- XD8DB0      Stethoscopes, Binaural**

**XD04L8            Stethoscopes, MRI**

Disinfectants, antiseptics and proteolytics for medical devices (D. Lgs. 46/97)

Dialysis devices

<b>XD8V84</b>	<b>Dialysis filters</b>
<b>XD8DD4</b>	<b>Haemodialysis, hemofiltration, haemodiafiltration filters</b>
<b>XD2KJ5</b>	Dialyzers - UHF < 18 ml/h/mmHg
<b>XD2N29</b>	Dialyzers - UHF < 18 ml/h/mmHg, cellulose membranes
<b>XD6QR4</b>	Dialyzers - UHF < 18 ml/h/mmHg, substituted cellulose membranes
<b>XD5S48</b>	Dialyzers - UHF < 18 ml/h/mmHg, synthetic membranes
<b>XD2DL2</b>	Dialyzers - UHF < 18 ml/h/mmHg - others
<b>XD4WX5</b>	Dialyzers - UHF = 18 - 35 ml/h/mmHg
<b>XD9RP1</b>	Dialyzers - UHF = 18 - 35 ml/h/mmHg, cellulose membranes
<b>XD0XB0</b>	Dialyzers - UHF = 18 - 35 ml/h/mmHg, substituted cellulose membranes
<b>XD2KD5</b>	Dialyzers - UHF = 18 - 35 ml/h/mmHg, synthetic membranes
<b>XD7ZP1</b>	Dialyzers - UHF = 18 - 35 ml/h/mmHg - others
<b>XD1904</b>	Dialyzers - UHF > 35 ml/h/mmHg
<b>XD2T66</b>	Dialyzers - UHF > 35 ml/h/mmHg, cellulose membranes
<b>XD4S95</b>	Dialyzers - UHF > 35 ml/h/mmHg, substituted cellulose membranes
<b>XD4379</b>	Dialyzers - UHF > 35 ml/h/mmHg, synthetic membranes
<b>XD8UZ1</b>	Dialyzers - UHF > 35 ml/h/mmHg - others
<b>XD8VS0</b>	Dialyzers for special hemodiafiltration and other therapies
<b>XD1V74</b>	<b>Hemoperfusion filters</b>
<b>XD27T5</b>	Hemoperfusion carbon filters
<b>XD2RV2</b>	Hemoperfusion resin filters
<b>XD9GN2</b>	Hemoperfusion filters - others
<b>XD5TA3</b>	<b>Absorption filters and columns</b>
<b>XD8NE7</b>	Immunoabsorption filters and columns
<b>XD0TG6</b>	Immunoabsorption filters
<b>XD6RX5</b>	Immunoabsorption columns

<b>XD3RD1</b>	Endotoxin removal filters and columns
<b>XD5SV0</b>	Endotoxin removal filters
<b>XD6KC0</b>	Endotoxin removal columns
<b>XD5DX9</b>	<b>Haemodialysis filters - others</b>
<b>XD6F86</b>	<b>Dialysis lines</b>
<b>XD12J0</b>	<b>Dialysis lines - haemodialysis-haemofiltration-haemodiafiltration</b>
<b>XD5BR1</b>	Artero-venous dialysis lines, one needle
<b>XD0B51</b>	Artero-venous dialysis lines, two needles
<b>XD5ED6</b>	Reinfusion dialysis lines
<b>XD8QE4</b>	Artero-venous dialysis lines - accessories
<b>XD0270</b>	Artero-venous dialysis lines - others
<b>XD65W3</b>	<b>Peritoneal dialysis lines</b>
<b>XD51F1</b>	Permanent peritoneal dialysis lines
<b>XD65K8</b>	Permanent peritoneal dialysis lines, one bag (CAPD)
<b>XD6QD1</b>	Permanent peritoneal dialysis lines, two bags (CAPD)
<b>XD0DE3</b>	Permanent peritoneal dialysis lines - others
<b>XD8H28</b>	Temporary peritoneal dialysis lines
<b>XD6606</b>	Temporary peritoneal dialysis lines, gravimetric (APD)
<b>XD89M1</b>	Temporary peritoneal dialysis lines, with pump (APD)
<b>XD2M70</b>	Temporary peritoneal dialysis lines - others
<b>XD4SJ0</b>	Peritoneal dialysis lines - accessories
<b>XD2WX9</b>	Peritoneal dialysis lines - others
<b>XD0ZQ3</b>	<b>Dialysis lines - others</b>
<b>XD83M2</b>	<b>Dialysis sets</b>
<b>XD0KV9</b>	<b>Haemofiltration-haemodiafiltration sets</b>
<b>XD0R67</b>	<b>Biofiltration sets</b>
<b>XD6TC6</b>	<b>Haemodialysis sets</b>
<b>XD80S8</b>	<b>Dialysis, washing/filling sets</b>
<b>XD2QE7</b>	<b>Hemoperfusion sets</b>
<b>XD7QD7</b>	<b>Continuous dialysis sets</b>

<b>XD5KR3</b>	Ultrafiltration sets
<b>XD9Z50</b>	Dialysis sets - others
<b>XD5C20</b>	<b>Dialysates</b>
<b>XD62N1</b>	<b>Dialysates, acid solutions</b>
<b>XD3V66</b>	Dialysates, acid solutions, non-sterile
<b>XD1KF2</b>	Dialysates, acid solutions, sterile
<b>XD0UL9</b>	<b>Dialysates, basic solutions</b>
<b>XD2JY9</b>	Dialysates, basic solutions, powder
<b>XD5240</b>	Dialysates, basic solutions, liquid
<b>XD6LX2</b>	<b>Dialysates, without acetate buffer</b>
<b>XD9594</b>	Dialysates, without acetate buffer - AFB
<b>XD6W13</b>	Dialysates, without acetate buffer - other treatments
<b>XD7157</b>	<b>Dialysis procedures, salts</b>
<b>XD67E6</b>	<b>Dialysates - others</b>
<b>XD8VC9</b>	<b>Dialysis devices - various</b>
<b>XD18U5</b>	<b>Peritoneal dialysis devices (not in other groups)</b>
<b>XD7RE0</b>	Peritoneal dialysis, catheters
<b>XD47T0</b>	Peritoneal dialysis - others
<b>XD8689</b>	<b>Vascular access devices (only for haemodialysis)</b>
<b>XD9YY6</b>	Temporary haemodialysis, catheters
<b>XD3AU4</b>	Permanent haemodialysis, catheters
<b>XD3297</b>	Vascular access devices (only for haemodialysis) - others
<b>XD2EM7</b>	<b>Dialysis, adaptors</b>
<b>XD8Q72</b>	Haemodialysis, adaptors
<b>XD39M3</b>	Peritoneal dialysis, adaptors
<b>XD25C5</b>	<b>Dialysate tanks, collection and reinfusion</b>
<b>XD6LH4</b>	Dialysate tanks, collection
<b>XD6MC0</b>	Haemodialysate tanks, collection
<b>XD22A9</b>	Peritoneal dialysate tanks, collection
<b>XD1ZR7</b>	Dialysate tanks, reinfusion

<b>XD8A37</b>	<b>Extracorporeal dialysis devices</b>
<b>XD9KW0</b>	<b>Dialysis devices - other accessories</b>
<b>XD46Z0</b>	<b>Dialysis devices - others</b>

Gastrointestinal devices

<b>XD53A5</b>	<b>Naso-gastric tube</b>
---------------	--------------------------

Suture devices

Active-implantable devices

Endotherapy and electrosurgical devices

Reusable surgical instruments

Devices for generic and specialistic medication

Devices for nervous and medullary systems

Implantable prosthetic devices and osteosynthesis devices

Dental, ophthalmologic and ear, nose and throat devices

Respiratory and anaesthesia devices

<b>XD9246</b>	<b>Nasopharyngeal tubes</b>
<b>XD2M69</b>	<b>Airway guedel tubes</b>
<b>XD78N3</b>	<b>Laryngeal masks</b>
<b>XD0T92</b>	<b>Endotracheal tubes, without cuff</b>
<b>XD37X2</b>	<b>Endotracheal tubes, with cuff</b>
<b>XD3UM6</b>	<b>Endotracheal tubes - accessories</b>
<b>XD2MG6</b>	<b>Tracheolaryngostomy cannulas and kits, with cuff</b>
<b>XD7EB1</b>	<b>Bipap/CPAP circuits</b>
<b>XD5GF6</b>	<b>Respiratory masks and balloons, single-use and reusable</b>

<b>XD3W67</b>	Air/oxygen masks and nasal cannulas
<b>XD0VQ3</b>	Air/oxygen masks
<b>XD5RM4</b>	Venturi masks
<b>XD61Z5</b>	Air/oxygen nasal cannulas
<b>XD5AL4</b>	Oxygen administration tubings
<b>XD51T0</b>	<b>Hand-operated ventilation balloons</b>
<b>XD9AF0</b>	<b>Ventilation filters, antibacterial and antiviral, moisturizer</b>
<b>XD35D5</b>	<b>Respiratory suction, probes and systems</b>
<b>XD76M0</b>	<b>Humidifying systems, oxygen administration</b>

Sterilization devices

Protection devices and incontinence aids (D. Lgs. 46/97)

<b>XD3ZH8</b>	<b>Examination / treatment gloves, nitrile</b>
<b>XD3LV8</b>	<b>Surgical drapes</b>
<b>XD4E80</b>	<b>Surgical gowns, standard</b>
<b>XD9LJ2</b>	<b>Standard surgical face masks</b>

Medical devices, urogenital apparatus

<b>XD1ZP3</b>	<b>Urological catheters, self-retained</b>
---------------	--

Medical devices - various

<b>XD2AJ4</b>	<b>Electronic thermometers and end caps</b>
<b>XD97L1</b>	<b>Clinical trays and bowls</b>

In vitro diagnostic devices (D. Lgs. 332/2000)

<b>XD5GV0</b>	<b>C-REACTIVE PROTEIN</b>
<b>XD9YL7</b>	<b>Transport media</b>
<b>XD9S44</b>	<b>Coronavirus-NA Reagents</b>
<b>XD9N16</b>	<b>Coronavirus (diagnostic)</b>
<b>XD7M68</b>	<b>Other Virology - RT &amp; POC</b>

<b>XD1C76</b>	<b>Reagents for DNA and/or RNA extraction and preparation : bacteria and/or virus</b>
<b>XD6EG0</b>	<b>Blood gas portable analysers</b>
<b>XD80L4</b>	<b>Samples transport containers - other</b>

Supports or technical aids for disabled persons

Medical equipment and related accessories and materials

<b>XD6EX8</b>	<b>Ultrasound Scanners</b>
<b>XD89G9</b>	<b>Ultrasound Scanners, Mobile</b>
<b>XD7FU9</b>	<b>Ultrasound Scanners, Portable</b>
<b>XD4T57</b>	<b>Ultrasound Scanners, Hand-held</b>
<b>XD8DR8</b>	<b>Bulk steam sterilizing units</b>
<b>XD0U91</b>	<b>Laryngoscopes</b>
<b>XD3JX1</b>	<b>Videolaryngoscopes</b>
<b>XD7EC8</b>	<b>Continuous positive airway pressure units (CPAP)</b>
<b>XD60Z6</b>	<b>Transportable ventilators</b>
<b>XD3SM4</b>	<b>Intensive care ventilators</b>
<b>XD4KU3</b>	<b>Portable multi-parameter patient monitors</b>
<b>XD66D8</b>	<b>Pulse Oximeters</b>
<b>XD8QN4</b>	<b>Pulse Oximeters, Tabletop</b>
<b>XD4U89</b>	<b>Pulse Oximeters, Hand-held</b>
<b>XD5QV8</b>	<b>Pulse Oximeters, Spot-check</b>
<b>XD8QY1</b>	<b>Infusion Pumps</b>
<b>XD4CT3</b>	<b>Infusion Pumps, Volumetric</b>
<b>XD52M6</b>	<b>Infusion Pumps, Volumetric, Nuclear Magnetic Resonance</b>
<b>XD8DH3</b>	<b>Infusion Pumps, Enteral nutrition</b>
<b>XD36Q1</b>	<b>Infusion Pumps, Syringe</b>
<b>XD1N14</b>	<b>Infusion Pumps, Syringe, Nuclear Magnetic Resonance</b>
<b>XD80Z7</b>	<b>Medical/medicinal gas systems and relative accessories</b>
<b>XD4U38</b>	<b>General purpose electrocardiographs</b>

**XD6UU3**

**Oxygen Concentrators**